of 414104
the 384599
and 330160
in 266063
to 155079
a 154454
with 126256
for 89622
is 89381
that 79804
by 65585
The 59579
was 58444
were 49119
as 47951
are 43446
patients 41089
or 36471
on 35968
an 35453
from 33187
be 30146
at 27730
In 25929
this 25644
have 25627
we 25533
We 24544
which 22186
not 21513
gene 21294
cell 20857
been 19407
protein 18976
has 18580
expression 18405
treatment 17882
cells 17637
these 16053
clinical 16024
associated 15794
also 15414
but 15357
may 15200
human 15130
disease 14713
A 14434
between 14265
DNA 14240
study 13353
can 12872
This 12808
mutations 12784
results 12102
its 12071
both 11728
than 11520
genes 11487
cancer 11465
other 11417
role 11073
syndrome 11013
after 10976
two 10933
= 10639
using 10588
their 10572
data 10395
had 10376
found 10077
activity 9988
during 9883
increased 9850
analysis 9630
more 9615
levels 9465
These 9454
most 9140
studies 8917
all 8908
proteins 8872
used 8561
risk 8511
it 8494
identified 8452
mutation 8446
including 8439
1 8266
such 8174
2 8142
significantly 8041
compared 8010
effects 7942
novel 7905
one 7737
no 7663
into 7620
© 7617
well 7609
tumor 7545
function 7506
new 7491
factor 7487
showed 7449
different 7403
show 7207
high 7111
significant 7107
present 7053
binding 6997
RNA 6984
type 6984
only 6882
transcription 6874
cells. 6707
important 6706
response 6679
genetic 6664
first 6656
potential 6629
However, 6625
therapy 6611
All 6582
development 6429
effect 6419
who 6395
receptor 6394
growth 6345
complex 6279
group 6247
To 6188
suggest 6155
use 6102
through 5984
patient 5951
Our 5813
specific 5795
within 5774
our 5741
cardiac 5731
known 5679
3 5669
multiple 5596
molecular 5575
observed 5565
three 5497
control 5458
primary 5454
normal 5432
Copyright 5399
kinase 5397
evidence 5350
number 5273
common 5222
target 5143
cases 5125
reported 5119
histone 5085
involved 5067
higher 5037
reduced 5036
could 5028
model 4968
patients. 4957
inhibitor 4952
those 4910
characterized 4905
disease. 4889
when 4877
findings 4822
several 4816
report 4774
functional 4768
factors 4727
caused 4717
activation 4709
revealed 4683
severe 4665
survival 4642
cause 4573
major 4539
efficacy 4475
association 4474
shown 4473
therapeutic 4459
further 4425
brain 4410
increase 4408
inhibition 4392
demonstrated 4376
regulation 4375
family 4373
treated 4356
mechanism 4328
chromatin 4325
among 4323
mice 4305
sequence 4304
drug 4297
early 4257
signaling 4244
rights 4213
phase 4206
mouse 4202
due 4196
some 4192
It 4189
reserved. 4183
without 4159
rate 4130
against 4124
similar 4117
inhibitors 4082
induced 4079
breast 4076
Elsevier 4057
II 4044
provide 4017
mechanisms 3988
changes 3988
presence 3985
there 3985
system 3981
required 3978
cellular 3951
based 3941
diagnosis 3936
highly 3930
expressed 3921
genomic 3914
case 3890
chronic 3879
previously 3857
low 3836
decreased 3832
small 3824
mg 3815
effective 3799
many 3790
related 3783
did 3777
chromosome 3761
pathway 3737
review 3727
methylation 3707
blood 3698
while 3697
heart 3694
acid 3686
Here, 3679
single 3666
time 3653
regulatory 3651
identify 3637
cells, 3635
years 3608
disorder 3607
acute 3600
over 3591
performed 3589
large 3587
demonstrate 3582
domain 3567
regions 3553
nuclear 3528
sites 3524
active 3499
developed 3486
either 3476
4 3463
interaction 3453
mRNA 3452
combination 3433
will 3429
genome 3419
< 3419
each 3416
level 3413
dose 3398
age 3394
they 3393
should 3388
transcriptional 3378
available 3373
loss 3371
Although 3370
form 3364
tissue 3344
region 3311
under 3307
total 3306
lower 3291
adverse 3282
trials 3273
events 3268
vitro 3255
features 3227
bone 3225
study, 3209
mitochondrial 3185
essential 3169
key 3157
via 3154
thyroid 3154
syndrome. 3146
suggesting 3142
positive 3140
replication 3133
Inc. 3132
whether 3112
four 3110
Here 3095
whereas 3093
formation 3086
symptoms 3079
placebo 3079
safety 3076
mutant 3064
months 3062
There 3060
various 3051
children 3050
cancer. 3032
conserved 3027
95% 2982
patients, 2936
following 2929
6 2926
5 2924
tumors 2909
muscle 2882
women 2878
detected 2859
investigated 2839
reduction 2826
P 2826
oral 2822
determine 2816
trial 2813
serum 2810
stem 2807
indicate 2798
structure 2797
test 2782
rare 2767
sequencing 2767
about 2753
affected 2750
addition, 2750
phosphorylation 2742
received 2734
critical 2733
enzyme 2724
current 2713
recently 2709
site 2705
10 2702
membrane 2695
included 2691
any 2689
sequences 2670
Furthermore, 2661
vivo 2650
recent 2640
less 2634
plasma 2631
death 2626
(P 2607
same 2605
possible 2601
evaluated 2597
method 2596
Patients 2561
assessed 2553
autosomal 2543
interactions 2542
approach 2532
12 2527
direct 2524
leading 2501
mean 2499
ventricular 2477
antibody 2474
functions 2473
least 2467
likely 2453
stress 2452
polymerase 2452
result 2449
overall 2447
central 2443
I 2443
might 2441
disease, 2439
distinct 2434
outcome 2434
play 2428
being 2420
differences 2411
respectively. 2404
biological 2393
repair 2389
drugs 2388
versus 2383
phenotype 2382
elements 2377
promoter 2374
lung 2370
ratio 2366
very 2364
however, 2350
infection 2348
genes. 2346
resulting 2341
because 2338
confirmed 2330
mammalian 2322
describe 2318
suggests 2314
treatment. 2310
agents 2308
weeks 2308
include 2299
support 2296
variants 2294
resistance 2294
per 2291
negative 2276
and/or 2273
isolated 2261
score 2259
models 2258
improved 2253
hormone 2250
(n 2237
often 2234
groups 2228
provides 2209
prostate 2208
additional 2204
remains 2203
how 2203
ability 2202
described 2200
studied 2187
monoclonal 2186
amino 2183
calcium 2183
dominant 2177
determined 2174
followed 2167
frequency 2163
liver 2163
analyzed 2162
incidence 2160
resulted 2160
Published 2153
information 2151
CI 2150
selective 2149
samples 2148
responsible 2141
individuals 2141
syndrome, 2135
addition 2134
Thus, 2133
Using 2130
identification 2129
skin 2129
thus 2127
cardiovascular 2123
congenital 2119
therapy. 2111
stroke 2107
activity. 2105
roles 2104
variant 2103
progression 2103
inhibited 2098
structural 2095
absence 2093
T 2089
deficiency 2089
considered 2082
where 2080
examined 2079
independent 2076
For 2067
evaluate 2066
pathways 2063
disorders 2061
immune 2059
up 2057
inflammatory 2056
understanding 2054
long 2052
plays 2050
developmental 2047
apoptosis 2046
screening 2044
exon 2042
combined 2039
rates 2038
types 2037
analyses 2036
subjects 2035
causes 2028
deletion 2022
Moreover, 2018
lines 2014
proliferation 2011
process 2010
regulates 1992
healthy 1991
genes, 1986
adult 1977
five 1962
renal 1956
investigate 1956
days 1956
decrease 1954
gene. 1954
peripheral 1938
controls 1934
methods 1931
does 1922
action 1910
differentiation 1909
before 1909
detection 1903
diagnosed 1902
management 1901
virus 1898
containing 1897
B 1892
although 1892
encoding 1883
assess 1882
regulated 1881
better 1875
expression. 1873
alternative 1873
peptide 1864
diseases 1861
yeast 1854
production 1851
basis 1850
underlying 1842
study. 1837
8 1834
complete 1830
III 1827
damage 1826
measured 1825
targeting 1823
wild-type 1822
cerebral 1822
greater 1820
sensitivity 1817
recurrent 1816
secondary 1815
body 1814
range 1811
correlated 1810
status 1808
improve 1808
ovarian 1802
degradation 1801
if 1800
still 1797
targets 1797
across 1795
change 1795
obtained 1794
tested 1794
currently 1790
contribute 1787
population 1786
directly 1783
failure 1783
An 1782
out 1780
unique 1780
forms 1775
regulate 1771
pathogenesis 1769
part 1769
elevated 1768
gene, 1767
Ltd. 1767
consistent 1765
median 1763
randomized 1762
clinically 1759
baseline 1758
enhanced 1757
lead 1755
standard 1749
useful 1744
recessive 1741
20 1738
antibodies 1736
function. 1734
epigenetic 1730
domains 1726
led 1724
advanced 1723
mass 1723
cycle 1723
proteins. 1722
mice. 1722
concentrations 1720
(p 1719
No 1719
impact 1717
One 1714
onset 1713
p53 1713
pattern 1707
class 1703
targeted 1699
As 1695
pain 1685
mediated 1684
suggested 1682
given 1680
seen 1679
approximately 1677
release 1676
implicated 1669
testing 1665
relative 1664
exposure 1663
presented 1655
± 1654
increases 1653
induction 1653
diagnostic 1651
occurred 1649
Two 1644
short 1643
motor 1643
doses 1630
indicating 1627
previous 1624
difference 1624
particularly 1621
male 1619
+/- 1617
At 1613
15 1613
end 1613
research 1611
intracellular 1610
then 1609
responses 1605
controlled 1605
myocardial 1603
even 1603
C 1600
systemic 1595
long-term 1593
set 1592
Mutations 1590
splicing 1588
patterns 1582
established 1582
diabetes 1578
administration 1571
especially 1569
frequently 1567
quality 1564
development. 1561
limited 1559
point 1558
left 1555
need 1554
rat 1552
leads 1551
species 1546
After 1543
agent 1542
components 1540
conditions 1540
linked 1536
distribution 1533
chromosomal 1533
defined 1533
tissues 1531
do 1524
Ca(2+) 1524
upon 1521
proteins, 1520
markers 1519
initial 1519
predicted 1518
second 1518
activated 1517
indicated 1513
Clinical 1510
inhibits 1508
30 1505
7 1502
assay 1501
rapid 1500
component 1499
would 1497
improvement 1496
tyrosine 1495
mortality 1495
cohort 1493
Recent 1492
increasing 1492
protein, 1492
vs. 1491
synthesis 1491
maintenance 1491
general 1490
aim 1490
majority 1489
RNAs 1488
correlation 1487
glucose 1487
regulator 1486
induce 1482
complexes 1482
specifically 1480
outcomes 1479
nervous 1476
located 1474
abnormalities 1473
receptors 1473
pulmonary 1471
daily 1470
affect 1468
stable 1468
inherited 1466
derived 1465
neurological 1463
order 1460
iron 1460
strong 1457
American 1456
anemia 1456
Treatment 1449
processes 1446
health 1446
tool 1445
occurs 1444
potent 1444
profile 1438
properties 1437
(95% 1436
accumulation 1435
overexpression 1433
metabolic 1432
fetal 1431
occur 1430
embryonic 1430
metastatic 1429
lack 1424
malignant 1424
silencing 1424
allele 1421
approved 1421
nucleotide 1421
scores 1420
female 1419
involving 1418
six 1417
Both 1411
Among 1410
value 1408
prevalence 1404
neuronal 1404
imaging 1397
medical 1395
strongly 1394
appears 1394
familial 1393
individual 1393
24 1393
administered 1392
reduce 1391
experimental 1391
conducted 1389
confidence 1389
relationship 1388
carcinoma 1387
channel 1385
Drosophila 1383
few 1383
care 1378
chain 1376
main 1370
9 1369
characteristics 1369
able 1366
promising 1366
mutations. 1363
skeletal 1362
transcripts 1360
evaluation 1360
Alzheimer's 1360
signal 1359
relevant 1357
pediatric 1356
spectrum 1355
Therefore, 1351
families 1351
cognitive 1349
2012 1346
Of 1344
fusion 1341
weight 1338
induces 1338
benefit 1337
progressive 1337
candidate 1336
marker 1335
poor 1333
now 1332
generated 1328
mutants 1328
Finally, 1327
here 1325
propose 1324
dysfunction 1322
animal 1321
epithelial 1320
influence 1320
heterozygous 1320
viral 1319
members 1318
endogenous 1317
2013 1316
chemotherapy 1314
potentially 1313
variety 1311
specificity 1310
frequent 1309
history 1306
size 1303
inhibitor, 1303
regulating 1301
abnormal 1300
RA 1297
analysis. 1297
represent 1295
inhibit 1295
produced 1292
binds 1292
vs 1291
neurons 1286
bacterial 1282
contrast, 1281
follow-up 1280
ischemic 1277
according 1275
p 1274
vascular 1272
global 1272
achieved 1271
involvement 1266
free 1266
insulin 1266
develop 1264
localization 1260
pathway. 1259
residues 1258
prior 1258
subunit 1258
- 1252
severity 1250
coding 1248
them 1248
values 1247
life 1246
genome-wide 1246
By 1245
week 1245
day 1245
defects 1241
side 1241
approaches 1238
requires 1238
strategy 1237
oxidative 1237
plus 1236
surgical 1234
alterations 1233
receiving 1232
prognostic 1231
therefore 1230
published 1227
altered 1227
partial 1226
prevention 1226
downstream 1225
mild 1225
yet 1224
11 1224
diseases. 1220
concentration 1217
lesions 1217
noncoding 1213
pressure 1213
literature 1211
activity, 1211
shows 1210
generation 1209
100 1205
extracellular 1204
sclerosis 1204
proposed 1203
somatic 1203
diverse 1202
genomes 1200
14 1199
impaired 1195
comparison 1191
cytoplasmic 1191
quantitative 1189
physical 1189
dependent 1188
find 1186
work 1183
importance 1182
spinal 1182
commonly 1177
subsequent 1175
rats 1174
developing 1173
enhancer 1172
sensitive 1172
de 1172
injury 1171
unknown. 1170
database 1170
young 1167
underwent 1160
X-linked 1160
molecules 1158
state 1156
interval 1155
future 1154
transcript 1154
inhibitory 1152
processing 1151
reaction 1151
mainly 1150
rheumatoid 1149
selected 1147
moderate 1145
assessment 1144
promotes 1144
nerve 1143
coronary 1143
H3 1143
discuss 1142
2011 1142
fully 1141
remain 1140
enzymes 1139
predict 1138
protein. 1137
respectively, 1136
levels. 1136
modification 1135
metabolism 1134
structures 1134
usually 1133
crucial 1133
every 1132
50 1131
surgery 1129
lysine 1128
criteria 1125
therapies 1123
generally 1122
predictive 1122
stage 1122
applied 1120
particular 1117
activities 1114
surface 1114
AD 1114
While 1113
performance 1113
putative 1112
prevent 1111
characteristic 1110
contains 1110
missense 1110
Phase 1108
physiological 1107
newly 1106
efficient 1101
suppressor 1101
called 1101
When 1099
strategies 1098
so 1096
sleep 1096
largely 1094
2014 1093
modifications 1093
little 1091
reveal 1089
group. 1089
lipid 1089
bladder 1089
neural 1087
necessary 1086
On 1083
alpha 1083
18 1083
maternal 1083
matrix 1082
hypothesis 1082
differential 1081
core 1080
locus 1080
local 1078
period 1078
exhibited 1077
alone 1075
duration 1075
CpG 1074
experiments 1072
vitamin 1071
transmembrane 1070
leukemia 1069
and, 1068
whose 1067
sample 1067
causing 1065
stimulation 1065
kidney 1064
biomarkers 1061
tumors. 1060
assembly 1060
along 1056
toxicity 1056
susceptibility 1054
1, 1054
pathological 1053
prediction 1053
cancer, 1052
affinity 1052
Most 1052
together 1051
bind 1050
autophagy 1050
represents 1049
origin 1049
CI, 1048
biochemical 1047
vivo. 1047
muscular 1042
controls. 1041
X 1040
facial 1039
late 1038
loci 1037
relatively 1035
application 1034
parameters 1033
16 1029
treatments 1029
affecting 1028
reticulum 1028
h 1027
variable 1026
Despite 1026
network 1025
wide 1024
detect 1023
years, 1023
recognition 1023
statistically 1022
Wiley 1022
thereby 1021
search 1021
assays 1021
encodes 1020
arthritis 1019
provided 1017
reports 1015
since 1014
promote 1014
studies. 1014
population. 1013
eukaryotic 1012
cases. 1010
appear 1009
compounds 1009
CTCF 1009
times 1007
cleavage 1007
analysis, 1006
EGFR 1003
mutation. 1002
pregnancy 1002
contain 1001
years. 1000
With 999
substrate 998
characterization 998
chromosomes 998
studies, 997
initiation 995
13 995
index 995
mutated 995
vaccine 994
widely 993
modified 992
Several 992
typical 991
respiratory 991
act 989
Because 989
primarily 988
adults 987
best 986
remained 985
miRNAs 984
data. 983
reverse 982
autoimmune 981
inflammation 980
Fanconi 979
invasive 978
treatment, 978
made 975
condition 974
designed 974
having 973
N-terminal 972
series 971
transport 971
localized 969
lysosomal 969
FA 969
expression, 968
endothelial 965
serious 963
cancers 961
cortical 961
grade 960
intravenous 960
Interestingly, 959
discovery 958
splice 958
terms 954
host 954
length 953
good 953
complex. 953
poorly 952
regarding 952
function, 952
conclude 951
atrial 951
subset 949
despite 949
rapidly 948
Society 947
sufficient 947
pathogenic 947
sudden 947
marked 945
enhancers 944
accompanied 943
interacts 943
sporadic 942
system. 942
non-coding 940
mutations, 940
> 940
certain 940
selection 939
Scale 939
melanoma 938
line 937
groups. 937
natural 937
Recently, 936
unknown 936
hepatic 935
months. 935
another 934
base 934
year 934
carried 933
depression 933
comprehensive 931
become 930
article 929
Human 928
recombinant 926
receive 925
throughout 923
inactivation 921
recruitment 921
rather 920
longer 920
position 920
light 920
randomized, 920
Parkinson's 919
needed 918
molecule 918
complications 917
contrast 915
fibroblasts 915
systems 914
prenatal 913
death. 913
conventional 913
tumour 911
transition 911
expressing 910
Analysis 910
translocation 907
strains 907
trial. 906
exhibit 904
partially 903
exons 902
tools 902
novo 902
germline 902
contributes 901
C-terminal 901
delayed 901
miRNA 899
estimated 897
disorders. 897
knowledge 896
diabetic 895
much 894
course 893
finding 892
marrow 890
25 889
murine 888
transgenic 888
right 887
hereditary 886
profiles 886
+ 886
showing 885
whole 885
promoters 885
defect 885
variation 884
repeat 884
antigen 884
Alu 884
knockdown 882
distal 881
significance 881
They 881
volume 881
help 880
epilepsy 879
treat 878
signs 878
EZH2 878
PCR 876
syndromes 875
acids 875
catalytic 875
prognosis 874
reducing 871
indicates 870
cardiomyopathy 870
infections 870
seven 869
laboratory 869
intestinal 868
B. 868
examine 867
conclusion, 867
C. 867
includes 867
21 867
pancreatic 866
University 865
bodies 864
like 864
reveals 861
urinary 861
Based 860
enriched 860
uptake 860
hair 860
nucleosome 858
phenotypes 857
mg/kg 857
factors, 856
Three 856
group, 856
eight 856
alleles 855
objective 855
deletions 854
Expression 853
last 853
assigned 853
% 853
cases, 852
telomerase 852
thought 852
resistant 852
feature 852
During 851
stability 850
evolutionary 849
circadian 849
involves 849
depletion 849
isoforms 848
extensive 847
2, 846
age, 845
open 844
Ca2+ 844
proteasome 844
occurrence 843
tests 842
recovery 842
RET 841
placebo-controlled 841
2010 839
migration 838
venous 838
polymorphism 837
Cancer 835
phenotypic 834
energy 833
corresponding 831
randomly 831
prospective 831
neurodegenerative 831
neonatal 831
content 830
remodeling 829
affects 829
gastrointestinal 828
methyltransferase 828
polymorphisms 826
cultured 826
mice, 826
facilitate 825
area 825
trials. 824
men 824
2015 824
member 823
reduces 821
compare 821
compound 820
suppressed 819
seems 818
situ 818
prolonged 818
animals 818
authors 817
infants 817
measures 817
red 817
suppression 816
inhibiting 816
glioma 816
density 815
populations 815
MS 815
homozygous 815
twice 813
encoded 812
therapy, 812
interact 811
mental 811
implications 810
require 810
Further 810
safe 810
glioblastoma 810
allows 809
tolerated 807
transporter 807
spontaneous 806
coli 806
recurrence 804
hours 804
gastric 804
bound 803
evolution 802
magnetic 801
intervention 800
conditions. 798
3' 798
expected 796
adhesion 796
translation 796
infection. 796
capacity 794
extent 794
investigation 793
17 793
channels 793
produce 793
accuracy 793
resonance 793
colorectal 792
manner. 792
transient 792
22 791
basal 791
understand 790
repression 789
undergoing 789
differentiation. 788
beta 787
completely 787
data, 786
European 785
complex, 785
D 783
survival. 782
tissues. 782
probably 781
ubiquitin 781
beneficial 781
cohesin 781
Molecular 780
phosphorylated 780
plant 780
understood. 779
examination 779
aimed 779
development, 778
homologous 778
degree 778
T3 778
generate 777
focus 777
Chinese 776
pharmacological 776
vitro. 774
hematopoietic 774
until 773
identified. 772
acts 772
effectiveness 772
lacking 772
stages 771
insights 771
older 771
transcribed 771
that, 770
treating 770
disorder. 769
Since 769
heterogeneous 767
validated 767
event 767
invasion 766
peptides 766
occurring 764
dynamic 764
40 763
postoperative 763
average 762
double-blind, 762
effects. 761
aberrant 761
mediate 761
refractory 760
product 760
& 760
preclinical 759
regression 759
strain 759
New 758
enrolled 758
associations 757
apoptosis. 757
warfarin 756
et 755
precursor 754
highest 754
upstream 753
motif 752
collected 751
clear 751
classification 750
aged 749
lateral 749
mTOR 749
appropriate 748
artery 748
acquired 746
focal 746
oxygen 745
larger 744
Saccharomyces 744
regulators 743
around 742
participants 742
step 741
design 740
humans 740
proportion 738
allow 738
head 736
independently 735
myeloid 734
purpose 734
identifying 734
bowel 733
neuropathy 733
nucleus 732
define 732
topoisomerase 732
genotype 732
smoking 732
fluid 731
providing 731
50% 730
epidermal 730
fraction 729
systematic 728
characterize 727
almost 725
genetically 725
environmental 725
deficient 725
phenotype. 724
completed 724
factors. 723
SR 723
Type 722
activation. 721
Western 721
predominantly 720
weeks. 720
must 720
antagonist 720
cholesterol 719
phosphatase 719
Hirschsprung 717
replacement 717
genome. 716
apoptotic 715
necrosis 714
antisense 714
BRAF 713
display 712
infected 712
presenting 712
levels, 712
substantial 712
reference 712
organization 711
culture 710
enhance 710
diseases, 710
manifestations 709
statistical 709
pituitary 708
signals 707
recognized 706
formed 706
toward 706
serve 705
element 704
Genetic 703
once 703
isoform 703
response. 702
cluster 702
effectively 701
failure. 701
link 700
placebo. 698
points 698
observed. 698
hearing 698
Association 696
radiation 696
monitoring 695
amount 695
bleeding 695
context 693
intermediate 693
account 693
carriers 693
sustained 692
comparable 692
copy 692
program 692
products 691
interest 691
purified 690
60 690
signalling 689
causative 689
double 688
possibility 688
numerous 686
means 686
basic 686
hybridization 685
S. 685
measure 685
actin 684
block 684
fluorescence 684
B.V. 683
establish 683
elongation 682
sodium 680
bilateral 680
confirm 679
Drug 678
third 677
impairment 677
maximum 677
intrinsic 676
whom 676
sister 676
comparative 675
pathways. 675
proximal 675
200 675
cerebrospinal 675
collagen 674
inhibitors. 674
lines. 673
Additionally, 673
aortic 673
percentage 673
sarcoplasmic 673
HuR 673
US 670
Japanese 670
successfully 669
scale 669
together, 668
signaling. 668
minimal 668
DNA. 664
Results 664
dual 664
Escherichia 664
explore 662
activating 662
retrospective 662
areas 662
Lewy 662
deacetylase 662
advances 661
defective 661
respect 660
premature 660
mutation, 660
T-cell 657
anxiety 657
reactive 656
model. 655
possibly 655
demonstrates 654
flow 654
markedly 653
symptomatic 652
biomarker 651
observations 651
regions. 651
suspected 651
sites. 650
minor 650
nine 649
technology 648
ligand 648
appeared 648
differentially 648
Taken 648
Data 648
toxin 648
screened 647
techniques 647
pathway, 646
axonal 646
substitution 645
transcription. 645
focused 645
improves 645
carrying 645
benign 644
package 644
existing 643
unclear. 643
experience 641
acetylation 641
numbers 639
failed 639
activate 637
reporter 637
exposed 637
termed 637
blocks 636
preventing 636
upper 636
entire 636
codon 636
cytokine 635
manner 634
residue 634
protective 634
computational 633
metastasis 633
aspects 631
transfer 631
express 630
emerging 630
classified 630
idiopathic 630
differ 628
2016 628
sarcoma 626
superior 625
oncogenic 624
kinases 624
fibrosis 624
Pol 624
myeloma 624
behavior 623
screen 623
cutaneous 622
successful 621
dynamics 621
3, 620
arrest 620
explain 619
profiling 619
controlling 619
Inhibition 618
heat 617
disruption 616
functionally 616
protocol 616
inhibitors, 616
Some 616
decreases 616
unrelated 616
full 615
formation. 614
absent 614
platelet 614
closely 612
real-time 612
sex 612
enhances 612
maintain 612
wall 612
exercise 612
near 610
cDNA 610
erythroid 610
presentation 609
recommended 608
technique 608
tumors, 607
modulate 606
experienced 606
linear 606
secretion 605
Many 605
n 605
estrogen 604
adjacent 603
remission 603
adjuvant 603
homeostasis 603
tract 603
symptoms. 603
clusters 602
classical 601
start 601
depends 601
oxidase 601
rats. 600
More 599
problem 598
correlate 598
regimen 598
benefits 598
motifs 598
23 598
disorders, 598
process. 597
synthetic 597
solid 597
referred 597
reported. 597
activator 596
reviewed 596
resolution 596
algorithm 596
continuous 595
heterochromatin 595
apparent 594
stimulated 593
past 593
genomes. 593
capable 592
prevented 592
Marfan 592
transmission 591
vertebrate 591
regulation. 591
deep 591
atypical 591
mitochondria 591
discovered 590
review, 589
Identification 589
tolerability 589
paper 589
insight 588
seizures 588
triad 588
(OR 588
United 587
options 587
time, 586
predicting 586
directed 586
simple 586
staining 585
system, 585
cytokines 584
miR-21 584
telomere 584
nature 583
progression-free 583
gliomas 583
mode 582
field 582
recombination 582
substrates 581
detailed 581
reactions 581
imatinib 581
make 580
progression. 580
amplification 580
models. 580
Oxford 580
strand 579
option 579
internal 578
hospital 578
displayed 577
broad 577
resection 577
fever 577
ribosomal 577
malaria 577
children. 576
negatively 576
consecutive 576
maintained 574
anterior 574
R 574
repeats 573
Compared 573
Group 573
model, 573
nor 572
ongoing 572
infusion 572
lymphoma 572
19 571
later 571
agents. 571
people 571
what 571
DNA-binding 571
fibrillation 571
comparing 570
close 570
white 570
recruited 570
events. 569
differentiated 569
undergo 569
International 569
analysed 568
CYLD 568
fat 567
enrichment 567
making 567
difficult 567
supports 567
behavioral 567
towards 566
Other 566
28 565
conditions, 565
mRNAs 564
correlates 564
signature 564
orally 564
procedure 563
arterial 563
coupled 563
robust 563
source 563
phylogenetic 563
Importantly, 562
great 562
Health 562
biology 562
dystrophy 562
typically 561
alter 561
high-risk 561
modulation 560
brain. 560
diffuse 560
surgery. 559
mature 558
cannot 556
HSCR 554
persistent 553
accurate 553
atrophy 553
humans. 553
upregulated 552
lesion 552
childhood 552
editing 552
promoting 551
share 551
upregulation 551
efficiently 551
stroke. 551
inactive 551
us 550
disability 550
stress. 550
dopamine 550
dilated 550
linkage 549
family. 549
processes. 549
phenomenon 549
subsequently 548
QT 548
proliferation, 547
constitutive 547
48 545
matched 544
identical 544
proper 544
noted 543
mediates 543
gain 542
protection 542
trial, 542
already 542
intact 542
Multiple 542
cerevisiae 542
5' 542
generalized 541
P. 541
Plasmodium 541
CSF 541
analyze 540
chemical 540
injection 540
amyloid 540
half 539
address 539
drugs. 539
training 539
MRI 539
consists 539
web 539
bacteria 539
mapping 538
supporting 538
scoring 537
functions. 537
fibroblast 537
arrhythmias 537
groups, 537
inclusion 537
mutational 536
optimal 536
sets 535
domain. 535
his 535
consisting 535
terminal 534
subunits 534
vivo, 533
blocked 533
particular, 533
composition 532
concomitant 532
degradation. 532
fragment 532
hypothesized 531
symptom 531
27 531
contribution 530
Overall, 530
trials, 530
expansion 530
months, 530
wild 530
period. 530
helicase 530
improvements 529
depressive 529
PLN 529
syndrome: 528
abundance 528
hypertension 528
aggressive 527
V 527
serotonin 527
tissue. 526
methylated 526
reliable 525
species. 525
Muenke 525
cancers. 524
secreted 524
mostly 524
spectrometry 524
optic 524
abundant 522
response, 522
allowing 522
intracranial 522
selectively 521
symptoms, 521
diet 521
odds 521
3D 521
toxic 520
colon 519
homology 519
ocular 519
region. 519
observation 519
visual 519
risk. 518
achieve 517
1) 517
endocrine 517
taken 515
enzymatic 514
highlight 514
Four 514
randomised 514
Only 513
food 513
polymorphic 513
E. 513
interacting 512
termination 512
knockout 511
far 511
glutamate 511
utility 510
26 510
IV 510
prevents 510
ratios 510
normally 510
inheritance 509
growth. 509
sites, 508
preferentially 508
attenuated 508
cerebellar 508
level. 507
presents 507
relation 507
Disease 507
circulating 506
documented 505
diabetes. 505
Gene 504
location 504
birth 504
demonstrating 503
features, 503
agents, 503
clearance 503
John 503
composed 503
hypertrophic 503
rise 502
proven 502
term 502
pregnant 502
blot 501
electron 501
Periodicals, 501
DNA, 501
HIV-1 501
final 500
pathology 500
removal 499
progress 499
immunoprecipitation 499
zebrafish 499
meta-analysis 499
diagnosis. 498
results. 498
earlier 498
FISH 498
organ 498
injury. 498
alpha-synuclein 498
parallel 497
NF-κB 497
assay. 497
ER 497
alignment 497
pluripotent 496
consensus 496
fragments 496
peak 494
delivery 494
widespread 493
approval 493
continued 493
0 493
Functional 493
Arabidopsis 493
diversity 492
efficiency 492
routine 492
variability 491
morbidity 490
panel 490
dose-dependent 490
isolates 490
subarachnoid 490
latter 489
classes 489
( 489
min 489
Protein 488
high-throughput 488
cytotoxic 488
fluorescent 488
G 488
loop 487
effect. 487
synaptic 487
her 487
instability 487
Administration 486
tumours 486
antitumor 486
calculated 486
chromatid 486
relevance 485
questionnaire 485
cost 485
males 484
full-length 483
favorable 483
Given 483
consequences 483
temporal 482
disorder, 482
patient's 481
memory 481
taking 481
anomalies 481
90 480
improving 479
elderly 479
biopsy 479
problems 479
circular 479
measurements 478
clearly 478
infarction 477
Chronic 477
insertion 477
mutagenesis 477
placebo, 477
Wiley-Liss, 476
inner 476
infantile 476
child 476
interferon 475
view 475
days. 475
Food 474
lipoprotein 474
PD 474
restricted 473
discussed. 473
classic 473
nearly 473
extended 473
background 473
date, 472
apoptosis, 472
GBM 472
overexpressed 471
ranging 471
old 471
emerged 470
elucidate 470
mesenchymal 470
Authors. 470
arm 469
timing 469
innate 469
native 469
protease 469
SNPs 469
A. 468
way 467
transcription, 467
none 467
cohesion 467
tomography 466
types. 465
blocking 465
(1) 465
finger 465
topical 465
bilirubin 465
integrated 464
synthesized 464
activates 464
offer 464
neurons. 464
dysfunction. 464
tuberculosis 464
heterogeneity 463
soluble 463
initially 463
Primary 462
progenitor 462
regions, 461
first-line 461
giant 461
maintaining 461
time. 461
sequences. 461
empagliflozin 461
subtypes 460
frequencies 460
cardiomyocytes 460
microarray 459
From 459
MRSA 459
psoriasis 459
(2) 458
describes 458
Notch 458
dementia 458
mechanical 457
Wnt 457
pharmacokinetic 457
mitotic 457
sequenced 457
remaining 456
age. 456
dysplasia 456
identifies 455
respond 455
subject 455
samples. 455
except 455
zinc 455
National 455
living 455
Sotos 455
families. 454
promoted 454
protein-coding 454
subcellular 454
joint 454
pathophysiology 454
family, 453
mechanistic 453
fatigue 453
life. 453
pharmacokinetics 452
Press. 452
enables 452
social 452
ultrasound 451
inducing 451
growing 451
(the 451
constitute 451
suitable 450
differentiation, 450
neurologic 450
eye 450
stromal 449
determining 449
years) 449
mortality. 449
recorded 449
retardation 449
introduced 448
positively 448
tachycardia 448
gamma-secretase 448
cultures 447
detectable 447
easily 447
(mean 447
Studies 447
fatal 447
reversed 446
prevalent 446
squamous 446
valve 446
loss-of-function 445
dosage 445
offers 445
tau 445
fission 445
craniosynostosis 445
seizure 444
spatial 444
EMT 444
fatty 444
dehydrogenase 444
outcome. 443
applications 443
malformations 443
ryanodine 443
array 442
respectively). 442
ulcerative 442
degrees 442
sign 442
variations 441
dosing 441
Median 441
shared 441
month 441
adaptive 441
S 441
asthma 441
valuable 440
setting 440
practice 440
anticancer 440
HIV 440
metabolites 440
viability 439
attention 439
percent 439
hundred 439
control. 439
initiated 439
CNS 439
random 439
ubiquitination 439
Study 438
failure, 438
unusual 438
tandem 438
BRCA1 438
etiology 437
genome, 437
outer 437
vector 437
marks 437
tofacitinib 437
combining 436
specimens 436
posterior 436
ALK 436
microRNAs 435
determination 435
reversal 435
Ewing 435
effects, 434
survival, 434
overlapping 434
mechanisms. 434
damage. 434
allowed 434
women. 434
question 434
lymph 433
interactions. 433
rarely 433
mm 433
others 432
activation, 432
states 432
precise 432
choice 432
powerful 432
increasingly 431
conformation 431
JNK 431
fracture 430
acting 430
complement 430
ion 430
E3 430
medication 430
hypertrophy 430
considerable 429
2009 429
subjects. 429
movement 429
individuals. 429
ataxia 429
reflect 428
E-cadherin 428
woman 428
repetitive 428
added 428
H19 428
factor, 427
cytotoxicity 427
monotherapy 427
Stroke 427
pylori 427
annotation 426
0.05). 426
establishment 426
probe 426
kb 426
greatly 426
shift 426
M. 426
p38 425
cytosolic 425
amounts 425
relationships 425
availability 425
effector 425
retinal 425
contained 425
rapamycin 425
PTPN22 425
evaluating 424
existence 424
0.001). 424
involve 424
hemorrhage 424
NADPH 424
mapped 423
vitro, 423
exogenous 423
hand 423
next 423
extremely 423
MC1R 423
drugs, 422
Charcot-Marie-Tooth 422
supported 421
gel 421
reversible 421
therapies. 421
episodes 421
untreated 421
mTORC1 421
requiring 420
proliferation. 420
Gaucher 420
aneurysmal 420
complementary 419
prominent 419
mechanism. 419
associates 419
medulloblastoma 419
shape 419
microRNA 418
Its 418
alone. 418
suffering 418
restriction 418
Together, 417
origins 417
dendritic 416
died 416
II, 416
2) 416
non-invasive 416
hemoglobin 416
Such 415
CI: 415
suppresses 415
TRH 415
36 414
searched 414
accelerated 414
shock 414
macrophages 413
trend 413
predictor 413
Current 413
employed 413
cervical 413
degeneration 412
II. 412
antagonists 411
tissue-specific 411
High 411
androgen 411
patient. 411
Medical 411
occupancy 411
cytogenetic 411
guide 411
level, 410
chemotherapy. 410
mixed 410
namely 410
proteomic 410
Mutation 410
tissues, 409
resource 409
downregulation 409
BRCA 409
challenge 408
Early 408
reductions 408
budding 408
access 407
trisomy 407
Crohn's 407
HRC 407
apremilast 407
45 406
subcutaneous 406
validation 406
guidelines 406
senescence 406
water 406
imprinted 406
tail 406
sensory 406
believed 405
metabolism. 405
diagnosis, 405
literature. 405
humans, 405
Aβ 405
population, 404
divided 403
overlap 403
Syndrome 403
(a 402
postnatal 402
post-translational 402
hypermethylation 402
checkpoint 402
restored 402
falciparum 402
explored 401
potassium 401
repressor 401
Hox 401
SUMOylation 401
hand, 400
interventions 400
If 400
harboring 400
Previous 399
Cell 399
lethal 399
candidates 399
pivotal 399
32 399
correct 399
Five 399
diastolic 399
architecture 399
networks 398
separate 398
above 398
decline 398
links 398
neither 397
risks 397
integrity 397
triggered 396
bp 396
MM 396
measurement 396
multivariate 395
short-term 395
consistently 395
outcomes. 395
Novel 395
spread 395
myopathy 395
excision 395
software 395
humanized 394
dietary 394
populations. 394
canonical 394
respectively 394
hypersensitivity 394
map 394
complication 394
replication. 394
organisms 394
machinery 393
extension 393
excessive 393
ischemia 393
adjusted 393
statin 393
nuclei 393
vaccination 393
unit 393
ligase 392
Akt 392
perform 392
costs 392
deleterious 392
maturation 392
fundamental 392
300 392
siRNA 392
granules 392
plants 392
subgroup 391
complexes. 391
brain, 391
influenza 391
species, 391
formation, 390
public 390
cytoplasm 390
Society. 390
transplantation 390
estimate 390
neuron 390
phospholamban 390
databases 390
abolished 389
transduction 389
(e.g., 389
topology 389
transporters 389
systems. 388
35 388
limb 388
mellitus 388
up-regulated 387
detecting 387
medications 387
personality 387
events, 386
domain, 386
library 386
radiotherapy 386
chimeric 386
cardiomyopathy. 386
breath 386
studied. 385
modeling 385
encode 385
review. 385
weeks, 385
community 385
nucleosomes 385
admitted 385
infectious 385
DMD 385
microscopy 384
cycles 384
Mowat-Wilson 383
hormones 383
characterised 383
STAT3 383
genotypes 383
signaling, 382
goal 382
relapse 382
females 382
ATP 381
endoplasmic 381
sought 381
Thyroid 381
FBN1 381
beyond 380
translational 380
million 380
neck 380
storage 380
urine 380
hypothyroidism 380
stimulate 379
serine 379
results, 379
growth, 379
largest 379
promise 379
subjected 379
dabigatran 379
x 378
pathways, 378
concept 378
biosynthesis 378
repeated 378
overcome 378
enhancement 378
ultraconserved 378
dystrophin 378
controls, 377
ligands 377
influenced 377
pilot 377
2. 377
incontinence 377
(e.g. 376
attributed 376
overview 376
features. 376
maximal 376
transmitted 376
RyR2 376
domains. 375
Consistent 375
therefore, 375
exhibits 375
uses 375
Genome 375
hearts 375
agonist 375
immediately 375
OR 375
duplication 375
NF1 375
infection, 374
methods. 374
intensive 374
edema 374
pairs 374
asymptomatic 373
severely 373
cortex 373
H. 373
named 372
lncRNAs 372
discussed 372
fact 372
Six 372
neutropenia 372
antibody, 372
melanoma. 372
31 372
CT 372
contractile 372
intellectual 372
performed. 371
homolog 371
morphology 371
similarity 371
29 371
preliminary 370
Research 370
elevation 370
viruses 370
Histone 370
intron 369
inhibitor. 369
extracted 369
transfected 368
sequences, 368
connective 368
encephalopathy 368
antiviral 368
B-cell 368
clock 368
findings, 367
90% 367
lupus 367
elements. 367
predicts 366
curve 366
high-grade 366
lines, 366
FDA 366
modulates 366
traditional 366
glial 366
region, 366
interference 366
depleted 366
sequencing. 366
thalidomide 366
exclusively 365
Their 365
example, 365
intensity 365
levodopa 365
lost 365
ALS 365
suppress 364
date 364
endpoint 364
January 364
lesions. 364
TRIM37 364
integrin 363
advantage 363
shorter 363
20% 363
Evaluation 363
H4 363
morphological 363
decision 363
statins 363
incorporation 362
pain. 362
example 362
angiogenesis 362
HDAC 362
membranes 361
facilitates 361
smaller 361
mediating 361
large-scale 361
methyl 361
site. 361
conservation 360
lymphocytes 360
probability 360
concerning 360
WT 360
barrier 360
methylation. 360
(range 360
yeast. 360
collection 359
excess 359
brown 359
contact 359
siltuximab 359
cis-regulatory 358
programmed 358
Xa 358
100% 357
microtubule 357
introduction 357
adipose 357
flanking 357
contributing 357
amyotrophic 357
modafinil 357
proved 356
70 356
X-ray 356
enable 356
interfering 356
Pendred 356
lineage 355
described. 355
rearrangements 355
delay 355
investigated. 355
promoter. 355
germ 355
procedures 355
death, 355
up-regulation 354
predictions 354
dramatically 354
trastuzumab 354
double-blind 354
anticoagulant 354
blockade 353
framework 353
400 353
systolic 353
organic 353
antioxidant 353
RNA-binding 353
skipping 353
toxicity. 353
though 353
sclerosis. 353
deposition 352
solution 352
abnormalities. 352
(median 351
substantially 351
method. 351
force 351
expanded 351
temozolomide 351
pooled 351
capture 351
datasets 351
positions 351
RLS 351
52 350
nonsense 350
NSCLC 350
Index 350
younger 349
modulating 349
regimens 349
done 349
ES 349
conversion 348
carcinoma. 348
countries 348
metastasis. 348
coverage 348
starting 348
nasal 348
pathogenesis. 347
membrane. 347
investigations 347
metastases 347
exact 347
randomised, 347
summarize 347
phenotype, 347
mg, 347
E 346
indication 346
depending 346
Over 346
correlations 346
he 346
slow 346
Down 346
registered 346
≥ 346
responses. 346
autism 346
embryos 346
4, 345
alteration 345
carcinomas 345
man 345
syndromes. 345
diminished 345
structure. 345
trigger 345
PARP 345
success 344
protein-protein 344
use. 344
oncogene 344
rescue 344
slightly 344
NSD1 344
hepatocyte 344
structure, 343
fewer 343
questions 343
segment 343
unaffected 343
corpus 343
synthesis. 342
open-label 342
consequence 342
(c) 342
evident 342
intervals 342
athletes 342
implemented 342
(in 342
biogenesis 342
computed 341
orteronel 341
safety, 341
approach, 341
5% 341
LDL 341
behalf 341
repressive 341
influences 340
integration 340
Oral 340
challenges 340
donor 340
simultaneously 340
dopaminergic 340
balance 340
absolute 340
liquid 340
case-control 340
ratio, 340
TH 340
disease: 339
metformin 339
Serum 339
histological 339
external 339
distributed 339
satellite 339
manifestation 338
deaths 338
1. 338
(i.e., 338
null 338
antibiotic 338
protect 338
cranial 338
island 338
persons 338
NF-kappaB 338
extracts 338
exist 337
30% 337
special 337
150 337
parental 337
Similar 337
stimulates 336
stress, 336
actions 336
headache 336
tuberous 336
Zika 336
receptor, 335
phosphate 335
ATPase 335
susceptible 335
exists 334
coupling 334
carry 334
comparisons 334
downregulated 334
articles 334
reviews 334
progesterone 334
BCR-ABL 334
ChIP-seq 334
sexual 334
G6PD 334
cancers, 333
comprising 333
predominant 333
predictors 333
fast 333
Assessment 333
maps 333
deficiency. 333
users 333
Rif1 333
RG7112 333
decreasing 332
combinations 332
selectivity 332
A, 332
principal 332
75 332
bortezomib 332
smooth 331
cytochrome 331
Overexpression 331
Ctf4 331
explained 330
agreement 330
ablation 330
psychiatric 330
protects 330
intake 330
apparently 330
control, 329
feedback 329
production. 329
HeLa 329
representing 329
code 329
TP53 329
rivaroxaban 329
2D:4D 329
seem 328
arthritis. 328
summarizes 328
Ras 328
meningioma 328
appearance 328
SERCA 328
makes 327
outside 327
80 327
heavy 327
al. 327
evolutionarily 327
weak 327
antigens 327
adults. 327
excluded 327
three-dimensional 327
complementation 327
Bacillus 327
AF 327
give 326
generating 326
unclear 326
deficits 326
truncated 326
(r 326
Mean 326
chaperone 326
found. 325
patients' 325
2017 325
programs 325
Author(s) 325
binding. 325
HCV 325
progression, 324
North 324
input 324
reuptake 324
Further, 323
cord 323
non-small 323
scientific 323
sympathetic 323
ROS 323
attractive 323
moderate-to-severe 323
inflammation, 322
resistance. 322
brainstem 322
complicated 321
switch 321
observational 321
women, 321
processes, 321
condition. 321
OS 321
adrenal 321
Effects 321
international 321
colitis 321
ectopic 320
myocytes 320
producing 320
original 320
laser 320
gestational 320
assessing 320
parasite 320
obtain 319
bias 319
became 319
adequate 319
respective 319
Efficacy 319
scaffold 319
forming 319
transformation 319
migraine 319
next-generation 319
boy 319
sequence. 319
elimination 319
aureus 319
prognosis. 318
burden 318
kinetics 318
abnormalities, 318
metabolism, 318
hedgehog 318
tumorigenesis 318
patient, 318
animals. 318
postmenopausal 317
CONCLUSIONS: 317
carrier 317
pregnancy. 317
Author 317
implementation 316
assays. 316
medium 316
Research. 316
multicenter 316
distance 316
constitutively 316
metabolite 316
measuring 316
high-dose 316
Mycobacterium 316
aims 315
weekly 315
segments 315
10% 315
inflammation. 315
variables 315
double-strand 315
biologic 315
hypophosphatemic 315
syndromic 314
steps 314
hallmark 314
quantification 314
anti-inflammatory 314
please 314
regeneration 314
identity 313
Cochrane 313
cycle. 313
arise 313
survey 313
paired 313
ranged 313
Genomic 313
UCEs 313
visualization 313
positioning 313
albinism 313
interval, 312
models, 312
introduce 312
weakness 312
December 312
life-threatening 312
neuroprotective 312
inhibition. 312
doxorubicin 312
psoriatic 312
loss, 311
Collectively, 311
portion 311
middle 311
met 311
receptors, 311
abdominal 311
dramatic 311
long-range 311
algorithms 311
sclerostin 311
underlie 310
distinguish 310
Conversely, 310
power 310
likelihood 310
dysregulation 310
fungal 310
just 309
80% 309
surgery, 309
opposite 309
foot 309
surveillance 309
learning 309
leukemia. 309
foci 309
released 308
drive 308
aid 308
trafficking 308
cloned 308
(i) 308
genomes, 308
minutes 308
MDM2 308
HGF 308
freely 308
status, 307
synovial 307
Following 307
requirement 307
phase. 307
SERCA2a 307
root 307
unable 307
back 307
subgroups 307
thickness 307
test. 307
α-synuclein 307
fork 307
phenotypes. 306
monitored 306
regional 306
prospectively 306
Press 306
72 305
pain, 305
immunohistochemistry 305
determinant 305
setting. 305
transcriptome 305
raised 305
associate 305
histones 305
(ii) 305
epilepsy, 305
aggregation 305
delivered 305
autophagy. 305
AMPK 305
vortioxetine 305
tissue, 304
evaluated. 304
reviewed. 304
identified, 304
down-regulation 304
aging 304
(also 304
Chromatin 304
DUX4 304
biopsies 304
AD. 304
granule 304
synthase 304
Sons 304
CML 304
repair. 304
meningitis 304
infant 303
place 303
indirect 303
avoid 303
highlights 303
specialized 302
suppressing 302
pharmacologic 302
changed 302
supplementation 302
schizophrenia 302
39 302
centromeric 302
equivalent 301
strength 301
aptamers 301
craniofacial 301
efficacious 301
Increased 301
Staphylococcus 301
preoperative 301
proliferative 300
below 300
produces 300
juvenile 300
nascent 300
Depression 300
genetics 299
determined. 299
IL-6 299
sequential 299
acceptable 299
microbial 299
rate, 298
crystal 298
neuromuscular 298
Transcription 298
down 298
interstitial 298
master 298
hot 298
locus. 298
enhancing 297
limit 297
varying 297
radical 297
systematically 297
excellent 297
2014. 297
conjunction 296
MAPK 296
Each 296
distant 296
extensively 296
Ewing's 296
Indian 296
selenium 296
polyadenylation 296
cavernous 296
TFIIS 296
sensorineural 295
conformational 295
take 295
summary, 295
adenosine 295
neuropathic 295
× 295
incorporated 295
deafness 295
unstable 295
TREM2 295
similarly 294
accurately 294
efforts 294
37 294
xenograft 294
nucleotides 294
(1 294
5, 294
[95% 294
PCSK9 294
elements, 294
breaks 294
Duchenne 294
vasospasm 294
material 293
obesity 293
ring 293
responded 293
Notably, 293
hemolytic 293
logistic 293
stability. 293
2015. 293
studying 292
complexity 292
(3) 292
organs 292
criteria. 292
vectors 292
causal 292
neuroblastoma 292
concurrent 292
lamin 292
poly(A) 292
brush 292
airway 291
recommendations 291
cystic 291
standardized 291
copper 291
children, 291
half-life 291
BRCA2 291
segregation 290
utilized 290
pathologic 290
always 290
simultaneous 290
proinflammatory 290
Indeed, 290
prescribed 290
open-label, 290
live 289
acid, 289
heart. 289
approach. 289
constructed 289
LV 289
islands 289
residual 289
Loss 289
FGFR3 289
CaMKII 289
regard 288
palmoplantar 288
suggestive 288
(10 288
Aurora 288
ustekinumab 288
analyses. 287
driven 287
introns 287
efficacy, 287
beginning 287
stabilization 287
6, 287
division 287
assay, 287
labeling 287
methyltransferases 287
antibiotics 287
rickets 287
varied 286
fatigue, 286
serves 286
Cardiac 286
interleukin 286
virulence 286
period, 286
GC 286
anticoagulants 286
reached 285
included. 285
drug. 285
oligonucleotide 285
cessation 285
(odds 285
thermal 285
Hsp90 285
DNMT1 285
inheritance. 284
surrounding 284
receptor. 284
usage 284
test, 284
reprogramming 284
, 284
cytosine 284
technologies 284
mg/day 284
vaginal 284
practice. 283
biomedical 283
proteomics 283
tightly 283
retrospectively 283
number, 283
ClinicalTrials.gov 283
processed 282
limitations 282
clones 282
esophageal 282
detected. 282
early-onset 282
L-type 282
chromatography 282
chromatin. 282
antidepressant 282
gland 281
33 281
RT-PCR 281
samples, 281
fourth 281
Secondary 281
Acute 281
yielded 281
skin, 281
method, 281
terminus 281
focuses 280
g 280
turn 280
loading 280
Global 280
subtype 280
(FA) 280
sedation 280
H2A.Z 280
status. 279
25% 279
Additional 279
available. 279
cyclin 279
knowledge, 279
constant 279
dysfunction, 279
profound 279
practical 278
loci. 278
synergistic 278
differentiate 278
structures. 278
post-transcriptional 278
illness 278
remarkable 278
cascade 278
real 278
ultimately 278
analyzing 278
proteome 278
obstructive 278
functioning 278
42 278
Christianson 278
undertaken 277
traits 276
factor. 276
K 276
muscles 276
targets. 276
consider 276
participate 276
Grade 276
Effect 276
adenocarcinoma 276
traumatic 276
organisms. 276
isolation 276
circRNAs 276
transforming 275
signatures 275
known. 275
locally 275
mediator 275
parkinsonism 275
unilateral 275
mucosal 275
ASD 275
c-Jun 275
incomplete 274
assays, 274
eligible 274
(hazard 274
0.01). 274
plaque 274
extract 274
clustering 274
TDP-43 274
OATP1B1 274
worse 273
compatible 273
HR 273
heart, 273
functions, 273
emergency 273
SGLT2 273
anemia. 273
rare, 272
500 272
state. 272
receptors. 272
telomeres 272
Tumor 272
kinase, 272
small-molecule 272
revealing 272
Bioinformatics 272
hippocampal 272
needs 272
yield 272
inducible 272
insufficiency 272
arginine 272
discharge 272
methods, 272
legs 272
NOD1 272
contributed 271
days, 271
issues 271
junction 271
withdrawal 271
true 271
triggers 271
belonging 271
SUMO 271
meiotic 271
follow 270
analyzed. 270
51 270
indications 270
distinctive 270
score, 270
Case 270
eczema 270
families, 269
malformation 269
validate 269
genomics 269
TSH 269
list 269
research. 269
paternal 269
testing. 269
pelvic 269
irradiation 269
consumption 269
MAOA 269
enzymes. 268
States 268
challenging 268
regular 268
vesicles 268
40% 268
silico 268
centromere 268
tolerance 268
tamoxifen 268
size, 267
splicing. 267
Evidence 267
consisted 267
pronounced 267
moderately 267
ten 267
placebo-controlled, 267
allelic 266
proteolytic 266
version 266
malignancies. 266
activities. 266
treatments. 266
becoming 266
triadin 266
bacterium 266
adaptation 266
sometimes 266
homeostasis. 266
count 266
damage, 266
chains 266
macrophage 265
node 265
J 265
myocardium 265
enzymes, 265
proximity 265
ERK 265
competitive 265
Factor 265
CD 265
substitutions 265
hepatitis 265
examined. 264
docking 264
(AD) 264
critically 264
units 264
MAP 264
July 264
unexpected 264
physicians 264
counts 264
(including 264
FUS 264
mitochondria. 264
bypass 264
70% 263
Similarly, 263
I, 263
immunoglobulin 263
clarify 263
feasibility 263
purification 263
alters 263
nicotine 263
herpes 263
chromodomain 263
transcripts. 262
experimentally 262
fold 262
lymphoid 262
cardiomyocyte 262
needed. 262
African 262
fibrosis. 262
apixaban 262
0.001) 261
tumor. 261
250 261
however 261
cysteine 261
65 261
pre-mRNA 261
C, 261
created 261
alfa 261
beta-barrel 261
pseudomallei 261
multiplex 260
luminal 260
quantified 260
platform 260
lymphocyte 260
stimulation. 260
overload 260
pathogen 260
depression, 260
parents 259
34 259
prepared 259
cell. 259
properties. 259
College 259
: 259
sources 259
PTEN 259
SD 259
defects, 259
immunity 259
Diamond-Blackfan 259
meningococcal 259
propofol 259
Direct 258
loss. 258
messenger 258
down-regulated 258
cost-effectiveness 258
changes. 258
description 258
work, 258
speech 258
partly 258
discrete 258
phosphorylates 258
automated 258
HCC 258
silencing. 258
spindle 258
linker 258
precursors 258
prion 258
erectile 258
CPVT 258
axis 257
PSA 257
readily 257
temperature 257
evolved 257
digestion 257
oxide 257
disrupted 257
estimates 257
thrombin 257
resistance, 257
XK 257
avanafil 257
reads 256
concerns 256
rate. 256
repressed 256
endpoints 256
toxicities 256
methylation, 256
pathogens 256
motility 256
correction 256
telomeric 256
pembrolizumab 256
exchange 255
exert 255
advantages 255
Significant 255
never 255
dental 255
B1 255
prophylaxis 255
depend 254
neoplastic 254
findings. 254
recently, 254
bases 254
malignancies 254
arrhythmia 254
derivative 254
opportunity 254
ends 254
permanent 254
achieving 254
environment 254
dupilumab 254
imprinting 254
CRP 254
endothelin 254
flumazenil 254
confer 253
evolution. 253
replicative 253
deleted 253
generates 253
Huntington's 253
integral 253
vital 253
histologic 253
Hospital 253
ghrelin 253
baseline, 253
magnesium 253
yeast, 253
infections. 253
antibodies. 252
Comparison 252
turnover 252
38 252
haplotype 252
She 252
ribosome 252
MCM2-7 252
BACKGROUND: 251
contacts 251
becomes 251
wound 251
comprised 251
mitogen-activated 251
Therapy 251
similarities 251
Severe 251
accumulated 251
analog 251
spastic 251
potency 251
2016. 251
thousands 250
dorsal 250
Herein, 250
Cells 250
multiforme 250
sequence, 250
retained 250
plasmid 250
recognize 250
follow-up. 250
diabetes, 250
SET 250
anomaly 250
atopic 250
rDNA 250
H3K79 250
ferroportin 250
threshold 249
Adverse 249
hormonal 249
fused 249
fate 249
Caucasian 249
transfection 249
radiological 249
Regulation 249
constructs 249
Genome-wide 249
preterm 249
folding 249
dose, 249
faster 249
Supplementary 249
Plasma 248
RNAs. 248
box 248
Nevertheless, 248
HER2 248
onto 248
focusing 248
predisposition 248
hematologic 248
cross-sectional 248
life, 248
chest 248
cell-free 248
Activation 247
migration. 247
originally 247
60% 247
arrhythmias. 247
cyclic 247
structurally 247
fibers 247
hundreds 247
proton 247
deacetylation 247
striking 246
percutaneous 246
defects. 246
why 246
hypertension. 246
shortening 246
hepatocellular 246
Aft1 246
Tokuhashi 246
variants. 245
glycoprotein 245
RNA. 245
origin. 245
mechanisms, 245
countries. 245
mammals, 245
epileptic 245
impairs 245
ischaemic 245
reductase 245
anaplastic 245
space 245
replicate 245
dissociation 244
carcinogenesis 244
complications. 244
Currently, 244
IgG 244
dystonia 244
mobile 244
dexamethasone 244
hypertension, 244
pregnancies 244
verified 244
exome 244
words 244
SLE 244
text 244
vemurafenib 244
carmustine 244
regarded 243
participates 243
Low 243
western 243
arising 243
3) 243
adjustment 243
modest 243
emergence 243
genital 243
oxidation 243
possess 242
action. 242
adolescents 242
alcohol 242
displays 242
responsive 242
tests. 242
matter 242
injury, 242
Barth 242
neurons, 242
hypoxia 242
damaged 242
antagonist, 242
distributions 242
Philadelphia 242
determinants 241
actively 241
According 241
subsets 241
uncommon 241
rationale 241
silenced 241
investigation. 241
eosinophil 241
SIRT1 241
bearing 240
Seven 240
article, 240
scan 240
insufficient 240
Unlike 240
Laboratory 240
site, 240
working 240
triple 240
Due 240
started 240
cerevisiae. 240
compartment 240
leptin 240
endovascular 240
relapsed 240
Rac1 240
illustrate 239
U.S. 239
designated 239
discontinuation 239
electrical 239
eukaryotes. 239
placed 239
issue 239
concluded 239
gemcitabine 239
vaccines 239
autophagic 239
GATA-1 239
SPAG5 239
NEECHAM 239
pharmacodynamic 238
injected 238
spine 238
present, 238
He 238
chromosomes. 238
emission 238
Thus 238
separation 238
own 238
approaches. 238
profile. 238
retardation, 238
Outcome 238
psoriasis. 238
LSD1 238
K27M 238
varies 237
rates. 237
types, 237
Patient 237
Surprisingly, 237
annotations 237
Long-term 237
Use 237
artificial 237
human, 237
longitudinal 237
immunodeficiency 237
carcinogenesis. 237
opioid 237
syndromes, 236
Within 236
rich 236
Italian 236
fractures 236
report. 236
risk, 236
continue 236
liver, 236
hepatocytes 236
academic 236
arrhythmogenic 236
enabled 236
feeding 236
Weaver 236
replication, 236
centromeres 236
frame 236
aggregates 236
restless 236
RSV 236
macitentan 236
modulated 235
therapeutics 235
immunohistochemical 235
entry 235
Whereas 235
equal 235
mother 235
interesting 235
2000 235
represented 235
%) 235
47 235
defense 235
myelodysplastic 235
atxA 235
benzodiazepine 235
genotype-phenotype 234
mononuclear 234
vertebral 234
promoters. 234
RA. 234
chromosome. 234
pore 234
changes, 234
hypomethylation 234
(SR) 234
hypertensive 234
epilepsy. 234
glycogen 234
amplified 234
delirium 234
2013. 233
agent, 233
gut 233
II) 233
radiographic 233
engineered 233
1000 233
pH 233
FSHD 233
Pediatric 233
decay 233
helix 233
reproductive 233
type, 233
AML 233
update 232
use, 232
mammals. 232
pathophysiological 232
efficacy. 232
organism 232
reflux 232
fasting 232
Publishing 232
(Funded 232
apolipoprotein 232
export 232
viable 232
M3/6 232
RPS19 232
Accordingly, 231
degraded 231
hazard 231
part, 231
hematological 231
investigating 231
layer 231
kDa 231
facilitating 231
deficit 231
itself 231
tumorigenesis. 231
mark 231
cisplatin 231
everolimus 231
anthracis 231
relatives 230
clinicians 230
reach 230
parts 230
potently 230
phosphorylation. 230
possesses 230
this, 230
ejection 230
Upon 230
rescued 230
conditional 230
crosslinking 230
55 230
frameshift 230
annotated 229
accessible 229
accumulate 229
instead 229
effort 229
dermatitis 229
removed 229
(or 229
investigational 229
stroke, 229
VEGF 229
pump 229
rule 229
Brugada 229
penetrance 228
PFS 228
established. 228
patients) 228
rash 228
immunofluorescence 228
liver. 228
national 228
i.e. 228
exerts 228
reading 228
cryptic 228
recovered 228
triiodothyronine 228
rucaparib 228
Helicobacter 228
tyrosinase 228
enteric 227
genotyping 227
EGF 227
intergenic 227
bovine 227
management. 227
strategies. 227
interpretation 227
process, 227
optimized 227
ubiquitous 227
tolerated. 227
subclinical 227
green 227
periods 227
papillary 227
antimicrobial 227
mRNA. 227
attack 227
infarct 227
equally 227
ancestral 227
mammals 227
coronal 227
TR 227
CCSVI 227
McLeod 227
gender 226
anomalies, 226
used. 226
paradigm 226
syndrome) 226
seizures, 226
novel, 226
permeability 226
relaxation 226
extend 226
domains, 226
examples 226
B, 226
interphase 226
myosin 226
records 226
EDNRB 226
online. 226
sulfate 225
phosphorylation, 225
March 225
pool 225
information. 225
false 225
44 225
ages 225
Trial 225
probes 225
CNEs 225
intronic 224
simulations 224
understood 224
Eight 224
regardless 224
modulators 224
massive 224
depressed 224
corrected 224
tertiary 224
α 224
Rating 224
naturally 223
interplay 223
interfere 223
43 223
muscle. 223
limits 223
excretion 223
quantify 223
Safety 223
autoantibodies 223
May 223
online 223
Participants 223
stop 223
undergone 223
mismatch 223
epithelium 222
disrupt 222
muscle, 222
synthesis, 222
95 222
stimulating 222
administration. 222
stratified 222
acquisition 222
representative 222
partner 222
interactions, 222
MI 222
epidemiological 222
retention 222
microM 222
report, 222
acetylated 222
exposure. 222
clopidogrel 222
monoamine 222
T(3) 222
Polycomb 222
Parkinson 222
worldwide. 221
adalimumab 221
nucleus. 221
suffered 221
separated 221
J. 221
initiate 221
pro-inflammatory 221
MR 221
Database 221
epitope 221
imetelstat 221
eosinophilic 221
genotyped 221
TSC2 221
unipolar 221
analyses, 220
individuals, 220
presumably 220
osteoporosis 220
2007 220
PET 220
grown 220
filaments 220
delay, 220
mast 220
scanning 220
melanogaster 219
mineral 219
unlike 219
principle 219
Induction 219
create 219
acidic 219
autonomic 219
Women 219
synthetase 219
trait 219
Activity 219
MITF 219
L1 219
. 218
scales 218
Under 218
eventually 218
Growth 218
overexpressing 218
p53, 218
pair 218
Ca 218
intracerebral 218
site-specific 218
chromatin, 218
thrombosis 218
infections, 218
self-renewal 218
GTPase 218
DC 218
DBA 218
fields 218
ectopia 218
accounted 217
associating 217
Also, 217
year. 217
disease-causing 217
confirming 217
myocyte 217
phase, 217
impairment. 217
AG, 217
periodic 217
heterozygosity 217
complexes, 217
girl 217
sense 217
frontal 217
AtxA 217
PLB 217
variants, 216
mammary 216
KRAS 216
ensure 216
electrophoresis 216
Response 216
abnormality 216
she 216
Alzheimer 216
patients; 216
unlikely 216
RNA, 216
flexible 216
irreversible 216
inversely 216
latency 216
deficiency, 216
balanced 216
gained 216
stenosis 216
see 216
tomato 216
Gfi-1B 216
polypeptide 215
vary 215
is, 215
normalized 215
compartments 215
mood 215
eukaryotes, 215
lymphocytic 215
center 215
CF 215
CD38 215
TTFields 215
46 214
cumulative 214
admission 214
cytoskeletal 214
monitor 214
elusive. 214
clonal 214
Targeting 214
antibodies, 214
reason 214
secretory 214
Bax 214
cycle, 214
anemia, 214
inadequate 214
silent 214
peptidoglycan 214
oculocutaneous 214
high-resolution 213
Whether 213
stably 213
Blood 213
None 213
Role 213
3. 213
counseling 213
neutrophil 213
altering 213
meningiomas 213
adenomas 213
observe 213
SNP 213
fibroblasts. 212
performing 212
extreme 212
(RA) 212
attributable 212
restore 212
chemotherapy, 212
paraffin-embedded 212
rhythm 212
trimethylation 212
Candida 212
limiting 212
fragmentation 212
Chk2 212
TERT 212
giving 211
limited. 211
animals, 211
potential. 211
Ireland 211
lowest 211
preparation 211
contraction 211
pol 211
contractility 211
modulator 211
apnea 211
(range, 211
assessments 211
disability, 211
T. 211
vestibular 211
vancomycin 211
follicular 210
Prognostic 210
discusses 210
myeloma. 210
weight, 210
interface 210
manifested 210
thrombocytopenia 210
immunological 210
Hh 210
allele. 210
vein 210
modify 210
MWS 210
wafers 210
Schwann 209
them. 209
abrogated 209
concentrations. 209
2004 209
immediate 209
enhancers. 209
Karger 209
enzyme. 209
template 209
steady-state 209
enzyme, 209
0.5 208
available, 208
sequencing, 208
channels. 208
resting 208
failing 208
LINE-1 208
confers 208
analogue 208
intragenic 208
low-density 208
CRC 208
albumin 208
fail 207
lncRNA 207
Long 207
mouse, 207
dependence 207
Specific 207
mRNA, 207
them, 207
creatinine 207
exclusion 207
D4Z4 207
Sequence 207
discover 207
spanning 207
parent 207
cross-linking 207
harbor 207
DCM 207
plants. 207
disturbance 207
AS 207
dose. 207
import 207
well-known 207
pharmacophore 207
transformed 206
transcriptionally 206
assembled 206
IL-1β 206
platinum 206
condition, 206
alone, 206
Institute 206
0.05) 206
) 206
clinical, 206
ancient 206
whereby 206
requirements 206
predisposing 206
gradient 206
post 206
establishing 206
Between 206
these, 206
Knockdown 206
implantation 206
VPA 206
gliomas. 206
Ehlers-Danlos 206
explanation 205
binding, 205
neutral 205
concentrations, 205
degradation, 205
tendency 205
respectively) 205
Development 205
biliary 205
mg/m(2) 205
mobility 205
population-based 205
atrophy. 205
nitric 205
UK 205
reaction. 205
TF 205
(iii) 205
primer 205
glycemic 205
mitral 205
H3.3 205
server 205
antiangiogenic 205
furin 205
anomalies. 204
reciprocal 204
invasion. 204
M 204
volunteers 204
landscape 204
prednisone 204
quite 204
universal 204
whole-genome 204
normalization 204
passive 204
conjugated 204
HCM 204
H1N1 204
subacute 204
microcephaly, 204
ceritinib 204
modifier 203
migration, 203
molecules. 203
compression 203
belongs 203
immunotherapy 203
black 203
presented. 203
ethnic 203
psychological 203
41 203
polyposis 203
device 203
Pompe 203
arms 202
not. 202
extraction 202
labeled 202
newborn 202
loops 202
plasticity 202
bodies. 202
Through 202
definition 202
alteplase 202
12, 202
informed 202
800 202
comprise 202
healing 202
callosum 202
circRNA 202
color 202
measles 202
STOP-Bang 202
examining 201
dimer 201
mixture 201
biology. 201
(miRNAs) 201
sinus 201
entity 201
repair, 201
intervention. 201
embolism 201
effect, 201
Journal 201
coordinated 201
metal 201
occlusion 201
hemorrhage. 201
endometriosis 201
2.5 201
survivors 201
behaviour 201
multicenter, 201
Consequently, 201
sumoylation 201
fever, 201
encephalomyelitis 201
OSA 201
ZFHX1B 201
modes 200
RNA-seq 200
characteristics, 200
75% 200
relies 200
action, 200
MicroRNAs 200
technical 200
58 200
properties, 200
clinic 200
remodelling 200
language 200
proteasomal 200
discontinued 200
carpal 200
branch 200
relapsing 200
mellitus. 200
C-reactive 200
nM 200
fetuses 200
Fisher 200
patterns. 199
Risk 199
hydrogen 199
South 199
biologically 199
composite 199
congestive 199
pressure, 199
cycling 199
physically 199
locations 199
placental 199
injections 199
care. 199
neurodevelopmental 199
asymmetric 199
Bach1 199
daratumumab 199
malignancy 198
manner, 198
mediators 198
born 198
electronic 198
0.0001). 198
score. 198
h. 198
medicine 198
preserved 198
leak 198
analogs 198
GI 198
attenuates 198
stability, 198
untranslated 198
preferential 198
trimester 198
continues 198
myelin 198
transposon 198
idarucizumab 198
First, 197
infiltration 197
case, 197
medial 197
mortality, 197
prospective, 197
2006 197
copies 197
frontotemporal 197
MEN1 197
H3K27me3 197
nuclease 197
boundaries 197
publicly 197
Oncotype 197
depression. 197
locus, 196
deterioration 196
pure 196
subjects, 196
HD 196
systems, 196
regulation, 196
(MS) 196
solely 196
primitive 196
essentially 196
D. 196
caspase 196
selenoprotein 196
mepolizumab 196
agitation 196
proband 195
experiments, 195
gamma 195
incubation 195
primate 195
c 195
elicited 195
remarkably 195
otherwise 195
antiarrhythmic 195
Previously, 195
select 195
patch 195
British 195
lacks 195
coli. 195
paper, 195
validity 195
neoplasia 195
Nucleic 195
latent 195
apical 195
isotretinoin 195
interaction. 195
cation 195
currents 195
insertions 195
Atrial 195
alemtuzumab 195
Wernicke's 195
crest 194
immunoreactivity 194
spliced 194
apply 194
redox 194
outpatient 194
significant. 194
Preclinical 194
so-called 194
transgene 194
Y 194
production, 194
Selective 194
amplitude 194
propensity 194
adenoma 194
subependymal 194
keratin 194
partners 193
(HR 193
June 193
toxicity, 193
tubulin 193
attempts 193
restoration 193
Hence, 193
neuroectodermal 193
driver 193
lymphoblastic 193
attacks 193
Neurological 193
Fusarium 193
specificities 193
epigenomic 193
Xist 193
Aux/IAA 193
Centor 193
driving 192
network. 192
spreading 192
homologue 192
daily, 192
construct 192
preferred 192
fish 192
hydrophobic 192
Changes 192
read 192
I. 192
MET 192
distress 192
D1 192
iodide 192
RT 192
63 192
brief 192
CMT 192
thaliana 192
healthcare 192
Mendelian 191
vehicle 191
mutants. 191
transcripts, 191
expand 191
protected 191
stratification 191
borderline 191
assessed. 191
exchanger 191
modifications. 191
Transcriptional 191
face 191
8, 191
nutrient 191
mimic 191
orthologous 191
progenitors 191
von 191
decarboxylase 191
bodies, 191
Ihh 191
Hirschsprung's 190
Central 190
RNAi 190
chemotherapeutic 190
Total 190
Europe 190
vessels 190
Cellular 190
1), 190
closed 190
markers, 190
spontaneously 190
add-on 190
prophylactic 190
homozygosity 190
calsequestrin 190
differed 190
PI3K 190
Acids 190
cAMP 190
fixed 190
recommend 190
looping 190
oprozomib 190
sepsis 190
aberrations 189
replaced 189
embryo 189
molecules, 189
agent. 189
therapies, 189
(5 189
obvious 189
state, 189
stimuli 189
lowering 189
49 189
well. 189
Familial 189
deficiencies 189
posttranslational 189
gabapentin 189
covalent 189
cure 189
reperfusion 189
encountered 189
Nine 189
endemic 189
Different 188
noninvasive 188
mAb 188
reactivation 188
tolerability, 188
pluripotency 188
highlighted 188
glioblastoma. 188
employing 188
quantitatively 188
TNF-α 188
G1 188
1% 188
vertebrates 188
adjusting 188
mg) 188
eukaryotes 188
Epigenetic 188
perchlorate 188
carfilzomib 188
Guillain-Barré 188
angioplasty 188
Burkholderia 188
mdx 188
SLC40A1 188
years; 187
Experimental 187
(FISH) 187
cytometry 187
Heart 187
helpful 187
peritoneal 187
4. 187
culture. 187
divergent 187
troponin 187
convertase 187
hybrid 187
initiating 187
mutants, 187
glomerular 187
leg 187
MS. 187
bioprinting 187
PUVA 187
Mozart 187
pathology. 186
phosphatidylinositol 186
phases 186
fractions 186
56 186
Cox 186
drug, 186
October 186
disturbances 186
cell-cycle 186
UV 186
arrays 186
infarction. 186
Systemic 186
tremor 186
coagulation 186
matching 186
reliability 186
target. 186
atherosclerosis 186
derivatives 186
calls 186
cytoskeleton 186
oxidized 186
dinucleotide 186
superoxide 186
revised 186
prioritization 186
SAH 186
forward 185
Nuclear 185
belong 185
greatest 185
World 185
i.e., 185
slowly 185
techniques. 185
bile 185
localize 185
vast 185
ataxia, 185
carbon 185
years). 185
pregnancy, 185
follow-up, 185
worldwide 185
fibroblasts, 185
gait 185
efflux 185
combines 185
lysosomes 185
lineages 185
T4 185
tacrine 185
Waardenburg 184
extending 184
transcriptase 184
disease-modifying 184
accounts 184
options. 184
linking 184
emphasis 184
spleen 184
expressions 184
gives 184
kinetic 184
modules 184
kinase. 184
haploinsufficiency 184
ex 184
mining 184
bulk 184
bidirectional 184
air 184
accessibility 184
WS 184
elegans 183
RNAs, 183
gain-of-function 183
15% 183
conduction 183
details 183
progressed 183
type. 183
pretreatment 183
feasible 183
Diagnosis 183
Even 183
54 183
impair 183
tests, 183
natriuretic 183
Characterization 183
activators 183
chicken 183
episodic 183
erythrocyte 183
task 183
confirms 182
microenvironment 182
exception 182
carcinoma, 182
pharmaceutical 182
Management 182
vertebrates. 182
Ten 182
interactive 182
Sons, 182
actual 182
difficulties 182
physiology 182
modifying 182
rearrangement 182
evidenced 182
database. 182
researchers 182
glioma. 182
principles 182
rabbit 182
cloning 182
breakpoints 182
strands 182
CSC 182
synostosis 182
dry 182
nucleic 182
SGs 182
TSC 182
insomnia 182
5-HT2A 182
difficile 182
elucidated. 181
Trials 181
Williams 181
amiodarone 181
defining 181
neuroendocrine 181
output 181
rodent 181
mtDNA 181
obesity, 181
antiepileptic 181
subjective 181
single-stranded 181
[CI], 181
prokaryotic 181
neighboring 181
7, 181
insulator 181
forks 181
TBI 181
APOBEC3G 181
[18F]altanserin 181
ECM 180
cell-cell 180
stronger 180
hospitalized 180
responses, 180
N 180
Future 180
handling 180
confirmation 180
pre- 180
Brain 180
smokers 180
filament 180
inside 180
Northern 180
anthrax 180
lagging 180
paroxetine 180
paclitaxel 179
lesions, 179
electrophysiological 179
decisions 179
considered. 179
(with 179
cardiomyocytes. 179
wave 179
segmental 179
magnitude 179
publications 179
equilibrium 179
higher-order 179
Questionnaire 179
considerably 179
anaemia 179
tunnel 179
digit 179
HELLP 179
probands 178
cancer: 178
parameters. 178
luciferase 178
III, 178
required. 178
steroid 178
facilitated 178
shed 178
junctin 178
property 178
promoters, 178
offered 178
virtually 178
ear 178
lumbar 178
sex, 178
Another 178
TCR 178
microscopy. 177
destruction 177
immunosuppressive 177
concern 177
120 177
proliferating 177
pharmacokinetics, 177
stabilized 177
tumor, 177
additive 177
9, 177
experiments. 177
organized 177
53 177
assayed 177
rest 177
recognizes 177
vessel 177
2% 177
pleiotropic 177
April 177
Deletion 177
CHD1 177
nanism 177
Pfh1 177
lesser 176
usefulness 176
updated 176
history, 176
Quantitative 176
Breast 176
anatomical 176
reflected 176
seizures. 176
demonstration 176
RCTs 176
2008 176
decade 176
microtubules 176
H2A 176
cap 176
Bmi-1 176
takes 175
switching 175
economic 175
sensitivity, 175
Structural 175
mosaicism 175
(RR 175
gave 175
Score 175
TGF-β 175
1.5 175
orientation 175
hepcidin 175
disrupts 174
which, 174
project 174
Approximately 174
cysts 174
definitive 174
serial 174
metastases. 174
men. 174
(and 174
constitutes 174
encouraging 174
embedded 174
regenerative 174
bioinformatics 174
brains 174
images 174
opening 174
deviation 174
initiates 174
macrophages. 174
bacteria. 174
defined. 174
twins 174
topological 174
colitis. 174
well-tolerated 174
assembly. 174
PML 174
reflex 174
pontine 174
IL-5 174
SDHA 174
TORC1 174
probable 173
mRNAs. 173
obese 173
0.001), 173
markers. 173
age-related 173
correctly 173
adapted 173
Phosphorylation 173
carriers. 173
observed, 173
salivary 173
program. 173
significance. 173
modern 173
hydrolysis 173
karyotype 173
allogeneic 173
Cajal 173
TFs 173
Imatinib 173
anti-TNF 173
IFN 173
dural 173
subfamily 173
tRNA 173
line, 172
absorption 172
unchanged 172
accepted 172
Common 172
criteria, 172
release. 172
result, 172
L. 172
sp. 172
translation. 172
(N 172
overgrowth 172
biallelic 172
fibrillation. 172
minimally 172
hypoplasia 172
corneal 172
combinatorial 172
fitness 172
lamins 172
HDAC6 172
Mulibrey 172
contributions 171
single-nucleotide 171
differs 171
eliminated 171
importantly, 171
immunomodulatory 171
Cerebral 171
transformation. 171
took 171
System 171
notably 171
rehabilitation 171
Neither 171
(i.e. 171
module 171
postulated 171
neuropathy. 171
developed. 171
astrocytoma 171
catalyzes 171
plantar 171
allergic 170
RA, 170
September 170
1-year 170
year, 170
Xenopus 170
worsening 170
prolongation 170
arrested 170
nausea 170
comprises 170
recruit 170
hemodynamic 170
testing, 170
enabling 170
autistic 170
arthritis, 170
inverse 170
augmented 170
centers 170
historical 170
Basel. 170
cohort. 170
localizes 170
skin. 170
autophagy, 170
size. 170
MDS 170
lymphatic 170
PD-1 170
mossy 170
(EGFR) 169
patterns, 169
administration, 169
donors 169
diagnosing 169
emotional 169
castration-resistant 169
resolved 169
heme 169
Prader-Willi 169
scores. 169
tubular 169
excitatory 169
sorting 169
schizophrenia. 169
hydrocephalus 169
FANCA 169
OPS 169
Differential 168
far, 168
Is 168
CD4(+) 168
proportional 168
French 168
behavior. 168
imaging. 168
engineering 168
soft 168
applications. 168
spectrometry. 168
picture 168
participation 168
precision 168
owing 168
uveal 168
Prevention 168
libraries 168
normal. 168
reconstruction 168
Clostridium 168
attempt 168
Dravet 168
thiamine 168
OATP1B3 168
auxin 168
HSCR. 167
ganglion 167
utilizing 167
ELISA 167
gefitinib 167
newer 167
Biochemical 167
undifferentiated 167
sampling 167
all-cause 167
PubMed 167
suffer 167
date. 167
Children 167
H3K4 167
cardiolipin 167
IBD 167
taliglucerase 167
reported, 166
strongest 166
dimerization 166
analytical 166
communication 166
deregulated 166
oligonucleotides 166
parathyroid 166
cerebellum 166
c-Myc 166
characteristics. 166
displaying 166
positron 166
infarction, 166
profile, 166
heterozygotes 166
ATP-dependent 166
Subsequently, 166
participated 166
demographic 166
evolocumab 166
headache, 166
repress 166
organization. 166
Targeted 166
complications, 166
attachment 166
TMZ 166
fruit 166
Rac 166
divergence 166
miR-146a 166
simplex 165
neurofibromatosis 165
leukocyte 165
residues. 165
600 165
exhibiting 165
lobe 165
syndrome). 165
potentials 165
confocal 165
colonic 165
2005 165
recruits 165
craniosynostosis. 165
represses 165
inclusions 165
neurodegeneration 165
viroid 165
gray 165
hyperbilirubinemia 165
pridopidine 165
hypothesize 164
evolving 164
aspect 164
managed 164
persistence 164
changing 164
translocations 164
irrespective 164
epitopes 164
considering 164
present. 164
sole 164
interest. 164
iodine 164
cohesion. 164
palsy 164
CLL 164
thromboembolic 164
CRISPR 164
Permissions, 164
amitriptyline 164
orexin 164
sevoflurane 164
bath-PUVA 164
translated 163
adherence 163
excluded. 163
meaningful 163
anti-tumor 163
quickly 163
approaches, 163
integrating 163
preventive 163
modifications, 163
siblings 163
agonists 163
perhaps 163
disease) 163
proteases 163
fiber 163
user 163
categories 163
hypoxic 163
enhancers, 163
cardiomyopathy, 163
Academy 163
remodeling. 163
biases 163
particles 163
choroid 163
insect 163
hematoma 163
Glasgow 163
Vortioxetine 163
retrotransposition 163
NEMO 163
Specifically, 162
developmentally 162
splicing, 162
perspective 162
off 162
dystrophy. 162
cohorts 162
Comparative 162
prove 162
rational 162
wider 162
intense 162
patients: 162
encompassing 162
≤ 162
remove 162
occur. 162
hours. 162
NKX2-1 162
late-onset 162
adjunct 162
waves 162
non-small-cell 162
MLN4924 162
Neisseria 162
aptamer 162
golimumab 162
assumed 161
embryos. 161
junctions 161
exploring 161
triggering 161
consideration 161
general, 161
annual 161
AEs 161
avoided 161
defines 161
glutathione 161
controversial. 161
i.v. 161
(ES) 161
reflecting 161
SAS. 161
angiotensin 161
METHODS: 161
norepinephrine 161
Bcl-2 161
specificity, 161
unknown, 161
dataset 161
sonidegib 161
G2 161
processing. 161
Circular 161
AND 161
thalamic 161
mitochondria, 161
glycosylase 161
TAL1 161
SLN 161
variant, 160
GDNF 160
groups: 160
Detection 160
extra 160
exacerbation 160
ClinicalTrials.gov, 160
diphtheria 160
gap 160
diameter 160
rats, 160
2), 160
6-month 160
Verlag 160
MMP-9 160
behaviors 160
Janus 160
lactate 160
tend 160
visualize 160
calling 160
falls 160
clone 160
TGF-beta 160
severity. 160
aneurysm 160
(PD) 160
cis 160
tretinoin 160
chondrocyte 160
3-kinase 159
media 159
membrane, 159
Receptor 159
Quality 159
RESULTS: 159
p73 159
case. 159
surrogate 159
lithium 159
enough 159
H3K27 159
oseltamivir 159
treatment-related 159
DX 159
encephalitis 159
catalyzed 159
replisome 159
relapsing-remitting 159
APOBEC3 159
H3F3A 159
uncover 158
August 158
(2 158
cyclin-dependent 158
converted 158
Genes 158
CVD 158
KO 158
catecholaminergic 158
Like 158
neutrophils 158
onset. 158
journals.permissions@oup.com. 158
c-myc 158
NSCLC. 158
pigmentation 158
radial 158
nintedanib 158
infliximab 158
meiosis 158
Drp1 158
coilin 158
Okazaki 158
ethanol 158
autologous 158
citrullinated 158
amifostine 158
depth 157
Telomerase 157
hallmarks 157
hospitals 157
killing 157
2002 157
Mitochondrial 157
(as 157
gradually 157
sizes 157
myocytes. 157
aerobic 157
applying 157
arrest, 157
lowered 157
players 157
clustered 157
10, 157
ventilation 157
F. 157
2D 157
presynaptic 157
hippocampus 157
Asian 157
desmin 157
MLP 157
xenografts 156
nucleus, 156
sperm 156
TNF 156
deregulation 156
cross 156
Markov 156
ipilimumab 156
responsiveness 156
indicator 156
hematopoiesis 156
slower 156
second-line 156
I/II 156
increased. 156
(WT) 156
hairpin 156
PCR. 156
64 156
hypertrophy. 156
compensatory 156
P450 156
overt 156
endometrial 156
indices 156
image 156
double-stranded 156
operating 156
Mice 156
thus, 156
difficulty 156
tendon 156
distinguished 156
SG 156
NIH 156
optimization 156
Task 156
FCD 156
mimicking 155
developments 155
senescence. 155
testosterone 155
lineages. 155
tested. 155
specificity. 155
Renal 155
Small 155
chemokine 155
preference 155
skull 155
analogues 155
Subjects 155
fibronectin 155
reporting 155
imply 155
sera 155
nausea, 155
found, 155
stalled 155
erythematosus 155
70-gene 155
6S 155
scale. 155
secukinumab 155
HERG 155
telcagepant 155
desvenlafaxine 155
PTX3 155
asthma. 154
78 154
hence 154
diagnoses 154
melanocytes 154
pigment 154
zone 154
lists 154
detail 154
patients), 154
impacts 154
characterized. 154
nucleolar 154
precisely 154
filtration 154
Overall 154
trauma 154
demyelinating 154
intrathecal 154
CAG 154
NIPT 154
Dax1 154
swirl 154
competition 153
band 153
(which 153
Bone 153
intravenously 153
malignancies, 153
objectives 153
conjugates 153
ml 153
2014, 153
duplications 153
fetus 153
aromatic 153
notion 153
(at 153
mitosis 153
future. 153
Twelve 153
NT-proBNP 153
trained 153
loci, 153
protocols 153
pharmacodynamics 153
warranted. 153
applicable 153
neuroimaging 153
ELMO1 153
OCTAVE 153
invadopodia 152
ubiquitously 152
Caenorhabditis 152
(4) 152
structures, 152
suppressive 152
Vitamin 152
granular 152
uncontrolled 152
break 152
hospitalization 152
estimation 152
highlighting 152
hearts. 152
AD, 152
anxiety, 152
allocated 152
Binding 152
restores 152
transthyretin 152
antifungal 152
MCT8 152
DPP-4 152
cortex. 152
myelogenous 152
malaria, 152
Chl1 152
Center 152
regulon 152
Ubc9 152
clonidine 152
Idarucizumab 152
CUTs 152
TBR1 152
challenge. 151
79 151
adipocytes 151
scale, 151
advance 151
mechanism, 151
glands 151
methodology 151
integrate 151
over-expression 151
influencing 151
multisystem 151
broader 151
Remarkably, 151
saline 151
prone 151
H 151
disease-associated 151
outbreak 151
movements 151
blue 151
Analyses 151
TFEB 151
CD99 151
parasites 151
auditory 151
iatrogenic 151
syncope 151
immunization 151
serogroup 151
POEMS 151
eczema. 151
Apremilast 151
finally 150
abnormally 150
connected 150
understood, 150
myocardium. 150
myogenic 150
amenable 150
weakly 150
metastasis, 150
rely 150
stimulation, 150
h, 150
(SD) 150
popular 150
low-grade 150
well-characterized 150
bacteria, 150
SMN 150
cocaine 150
resveratrol 150
delta 150
tafazzin 150
ZEB2 150
Corynebacterium 150
Castleman 150
direction 149
completion 149
thyroxine 149
mimics 149
corticosteroids 149
al., 149
isoforms, 149
Orteronel 149
pausing 149
subtelomeric 149
resembling 149
hypothesis, 149
two-hybrid 149
outcome, 149
(3 149
inactivating 149
connection 149
Mammalian 149
neutralizing 149
(SGLT2) 149
albicans 149
(group 149
mosaic 149
computing 149
botulinum 149
(from 149
drug-induced 149
APP 149
microdeletion 149
crizotinib 149
cancer-related 148
age-matched 148
cost-effective 148
months; 148
examinations 148
p53. 148
experiment 148
participating 148
replicating 148
Masson 148
blocker 148
strains. 148
devastating 148
visceral 148
maintains 148
asked 148
malformations. 148
(such 148
manifestations. 148
Korean 148
phosphatases 148
epidural 148
evaluation. 148
CENP-A 148
H3K4me3 148
PCI 148
bupropion 148
Esrrb 148
dovitinib 148
angiogenic 147
β 147
histology 147
retroviral 147
macular 147
PK 147
inhibition, 147
PCa 147
too 147
Nanog 147
error 147
Ca(2+)-ATPase 147
utilize 147
3% 147
misfolded 147
epidemiology 147
Left 147
large, 147
nucleosomal 147
gold 147
microcephaly 147
transplant 147
idea 147
regeneration. 147
implying 147
rRNA 147
browser 147
OCT3 147
rates, 147
antipsychotic 147
Lambert-Eaton 147
Inn1 147
pulp 147
overdose 147
exosomes 146
substrates. 146
differentiating 146
adjunctive 146
utilization 146
studied, 146
Screening 146
missing 146
endosomal 146
sections 146
ischemia. 146
RR 146
heritable 146
purine 146
acids, 146
helps 146
broadly 146
β1 146
accounting 146
subtle 146
recycling 146
outcomes, 146
colony-stimulating 146
microsatellite 146
implicate 146
stabilizes 146
Initial 146
guanine 146
peaks 146
cytosol 146
strains, 146
CR 146
throat 146
gastroesophageal 146
nephrotic 146
CIDEC 146
adding 145
consist 145
circulation 145
blockers 145
trends 145
Surgical 145
HER-2 145
combine 145
manage 145
microscopic 145
0.01) 145
tolerated, 145
cleavage. 145
theory 145
(CI) 145
cerebrovascular 145
Recently 145
exposure, 145
deubiquitinating 145
polycomb 145
sildenafil 145
Dnmt1 145
wearing-off 145
Leishmania 145
Orpington 145
Statistical 144
antibody. 144
1.0 144
elicit 144
believe 144
infants. 144
targets, 144
medicine. 144
melanomas 144
accessory 144
s 144
catecholamine 144
mg/kg, 144
addressed 144
format 144
truncating 144
psychomotor 144
Japan 144
plasminogen 144
respectively; 144
creates 144
heterochromatic 144
Review 144
association. 144
GO 144
CRS 144
minimum 144
Depletion 144
microglia 144
lipids 144
procedure. 144
design, 144
Mediterranean 144
NET 144
analogous 144
monkeys 144
olaparib 144
Bioconductor 144
nicotinamide 144
CXCR4 144
apoE 144
Nod1 144
Mis18 144
Paget's 144
Autosomal 143
obstruction 143
transactivation 143
environment. 143
hyperplasia 143
ingestion 143
stage, 143
evidence-based 143
routinely 143
beta-catenin 143
61 143
time-dependent 143
inferior 143
MCF-7 143
respectively), 143
hemorrhagic 143
Second, 143
tag 143
transplantation. 143
instrument 143
easy 143
Understanding 143
pericentromeric 143
lymphoma. 143
angiogenesis. 143
alleles. 143
(GBM) 143
hands 143
TBI. 143
components. 143
graphical 143
Golgi 143
erythrocytes 143
capsule 143
massively 143
HPV 143
phosphodiesterase 143
TYR 143
interaction, 142
AACR. 142
concentrated 142
optimize 142
thin 142
gender, 142
adults, 142
Therapeutic 142
testis 142
body. 142
literature, 142
favor 142
disseminated 142
histopathological 142
glycosylation 142
miR-1 142
load 142
propranolol 142
nutritional 142
indicative 142
qualitative 142
minority 142
59 142
assist 142
H3K9 142
effectors 142
biosynthetic 142
anion 142
integrity. 142
repressing 142
resolution. 142
malaria. 142
tooth 142
striatal 142
Borrelia 142
firing 142
Rett 142
amyloidosis 142
SLC9A6 142
melanocytosis 142
common, 141
membranes. 141
osteoporosis. 141
closure 141
route 141
2001 141
doxycycline 141
stained 141
HF 141
posttranscriptional 141
assessment, 141
Severity 141
cerevisiae, 141
non 141
Information 141
investigators 141
anti-apoptotic 141
Fas 141
homeostasis, 141
digital 141
Reduced 141
entities 141
indeed 141
superficial 141
blood, 141
prefrontal 141
cm 141
tree 141
served 141
anticoagulation 141
recording 141
Hippel-Lindau 141
FOXP2 141
[Formula: 141
septin 141
STOP-BANG 141
dissection 140
Once 140
die 140
dominantly 140
sclerosing 140
17,20-lyase 140
vomiting 140
eliminate 140
inappropriate 140
volume, 140
fed 140
autosomal-dominant 140
examination, 140
members. 140
crossover 140
Complex 140
months). 140
Besides 140
UV-induced 140
index, 140
incident 140
personal 140
derive 140
undergoes 140
ataxia. 140
ill 140
N-type 140
p16 140
cortex, 140
dephosphorylation 140
monogenic 140
coefficient 140
non-canonical 140
English 140
eosinophils 140
matuzumab 140
gluten 140
explains 139
Spanish 139
Liver 139
narrow 139
calcitonin 139
decade, 139
meta-analysis. 139
.001). 139
effective, 139
promoter, 139
total, 139
networks. 139
(MRI) 139
alanine 139
chromosomes, 139
microglial 139
stress-induced 139
proteolysis 139
accuracy. 139
licensed 139
stent 139
organs. 139
months) 139
cohort, 139
computer 139
acceptor 139
breakpoint 139
urge 139
kinases, 139
Association. 139
bevacizumab 139
gross 139
organisms, 139
degenerative 139
(CML) 139
dogs 139
nemaline 139
cardiotoxicity 139
proto-oncogene 138
Emerging 138
commercial 138
kidney, 138
Extensive 138
parameters, 138
saturation 138
diseased 138
scored 138
62 138
autopsy 138
0.1 138
form, 138
sensitivity. 138
isolate 138
arteries 138
0, 138
intermittent 138
diagnose 138
described, 138
fidelity 138
department 138
GV1001 138
virus. 138
functionality 138
biogenesis. 138
regularly 138
graft 138
components, 138
2A 138
tight 138
Phospholamban 138
anastrozole 138
dengue 138
minoxidil 138
armodafinil 138
Kaplan-Meier 137
(by 137
2011. 137
programs. 137
inactivated 137
single-agent 137
96 137
careful 137
mitosis. 137
diarrhea, 137
orphan 137
enlarged 137
childhood. 137
p. 137
onset, 137
fashion. 137
design. 137
referral 137
questionnaires 137
multivariable 137
summary 137
atherosclerotic 137
radiotherapy. 137
AKT 137
epidemic 137
endocytosis 137
technique. 137
benralizumab 137
formalin 137
incorporating 137
Criteria 137
chaperone-mediated 137
Mb 137
GA 137
yellow 137
cell-mediated 137
West 137
thyroiditis 137
endonuclease 137
lenalidomide 137
MTHFR 137
others. 136
latest 136
acetylcholine 136
world. 136
lung, 136
adaptor 136
doses. 136
pattern. 136
4) 136
personalized 136
avoiding 136
compromised 136
sensor 136
WHO 136
localization. 136
window 136
rituximab 136
fertility 136
tumours. 136
mobilization 136
melanoma, 136
aneuploidy 136
angiogenesis, 136
virus, 136
suture 136
AA 136
68 136
antidepressants 136
conclusions 136
TS 136
influx 136
EEG 136
SCN5A 136
PCCA 136
CWD 136
deer 136
mirabegron 136
pharyngitis 136
milk 135
evolution, 135
bond 135
carefully 135
Fifteen 135
distribution, 135
2010. 135
plaques 135
degeneration. 135
formulation 135
screening. 135
manual 135
Instead, 135
capillary 135
only. 135
raise 135
operation 135
5-HT 135
augmentation 135
secretion. 135
intractable 135
techniques, 135
paediatric 135
Eleven 135
mucosa 135
cigarettes 135
HLA 135
How 135
dysplasia, 135
recurrence. 135
(100 135
cognition 135
boundary 135
atrophy, 135
perioperative 135
moyamoya 135
septins 135
lentis 135
aleglitazar 135
Koebner 135
fexinidazole 135
add 134
males, 134
span 134
multicentre, 134
18, 134
covered 134
reactivity 134
phenotypes, 134
profiles. 134
devoid 134
dilation 134
physician 134
codes 134
E2 134
Hedgehog 134
abuse 134
granted 134
unmethylated 134
swelling 134
preceding 134
role. 134
consanguineous 134
polymerases 134
decades 134
German 134
hypoglycemia 134
dense 134
tuberculosis. 134
East 134
chondrocytes 134
super-enhancers 134
Vif 134
glabrata 134
scarlet 134
bezlotoxumab 134
colony 133
occurred. 133
therapeutics. 133
velocity 133
(all 133
monkey 133
practice, 133
localization, 133
alveolar 133
perfusion 133
reliably 133
HO-1 133
tagged 133
supportive 133
selection. 133
reasons 133
severity, 133
(one 133
RNase 133
macrophages, 133
Control 133
perinatal 133
surfactant 133
cleft 133
antiplatelet 133
(mTOR) 133
incubated 133
pyramidal 133
semantic 133
Diabetes 133
accumulates 133
arrangement 133
alignments 133
themselves 133
bioavailable 133
replicated 133
PWS 133
canine 133
productivity 133
cilengitide 133
SPARC 133
Bartter 133
creating 132
turn, 132
implicating 132
assemble 132
men, 132
x-ray 132
Prediction 132
affected. 132
iPSCs 132
safety. 132
seemed 132
call 132
informative 132
manifest 132
founder 132
ECG 132
plasmids 132
min. 132
isoforms. 132
Exposure 132
yields 132
market 132
inactivation. 132
painful 132
effective. 132
presumed 132
corticosteroid 132
submitted 132
myopathy, 132
top 132
reaction, 132
R-loops 132
R-loop 132
develops 132
anti-cancer 132
Mutational 132
manifestations, 132
physiologic 132
antidiabetic 132
Sleep 132
(HDAC) 132
stabilizing 132
cartilage 132
noise 132
Mouse 132
relief 132
bleeding, 132
PTSD 132
elucidated 131
reactions, 131
hold 131
Controlled 131
disability. 131
ideal 131
chosen 131
evaluable 131
Epilepsy 131
Medicine 131
theoretical 131
fly 131
Interaction 131
degrade 131
(12 131
opportunities 131
EWS-FLI1 131
carries 131
scores, 131
acoustic 131
low-dose 131
olfactory 131
dementia, 131
end, 131
epithelial-mesenchymal 131
PKA 131
parameter 131
Aire 131
implanted 131
burgdorferi 131
performance. 131
Tuberous 131
state-of-the-art 131
exosome 131
echogenic 131
fibrillin-1 131
hyperbilirubinemia. 131
mouse. 130
exons. 130
alkaline 130
carcinomas. 130
polarity 130
dynamically 130
searches 130
15, 130
impairment, 130
disease-free 130
herein 130
transferred 130
collectively 130
slight 130
Single 130
uncovered 130
Cardiovascular 130
soil 130
strain. 130
ways 130
transport, 130
cigarette 130
populations, 130
Numerous 130
heterochromatin. 130
protein) 130
USA 130
hypothyroidism. 130
Baseline 130
virtual 130
(AD). 130
once-daily 130
it. 130
PRC2 130
screening, 130
second-generation 130
retinoic 130
Surgery 130
globular 130
Empagliflozin 130
Gram-negative 130
PLK2 130
COP9 130
lengths 129
drives 129
dominant-negative 129
carbohydrate 129
constraints 129
evidence, 129
discriminate 129
MEDLINE 129
imaging, 129
2011, 129
analyse 129
rare. 129
CONCLUSION: 129
erlotinib 129
document 129
resources 129
Chromosome 129
series. 129
reverses 129
motifs. 129
cold 129
diarrhea 129
blotting 129
valid 129
behind 129
parity 129
Muscle 129
origin, 129
2013, 129
hypothyroid 129
hERG 129
Sp1 129
GD 129
Non-invasive 129
HLA-B*5701 129
agenesis 129
VHL 129
signalosome 129
romosozumab 129
obtained. 128
Aberrant 128
2003 128
dysregulated 128
biomarkers. 128
warranted 128
Organization 128
Until 128
shares 128
performed, 128
inserted 128
lentiviral 128
categorized 128
ions 128
inotropic 128
nucleosomes. 128
EWS/FLI 128
clinic. 128
concordance 128
calculate 128
53BP1 128
piRNA 128
variance 128
methicillin-resistant 128
Transgenic 128
rice 128
ligament 128
Resveratrol 128
demethylase 128
Ezh2 128
MMR 128
polycystic 128
SUDEP 128
DMP1 128
implication 127
Congenital 127
attenuation 127
Altered 127
Potential 127
entered 127
originating 127
illustrates 127
nodes 127
Subsequent 127
febrile 127
dose-limiting 127
undetectable 127
safely 127
ciliary 127
CAD 127
CASQ2 127
compounds. 127
Complete 127
cultures. 127
severe, 127
favourable 127
predispose 127
transiently 127
interacted 127
Systematic 127
Anxiety 127
Bayesian 127
FANCD2 127
dispensable 127
(NSCLC) 127
16, 127
criterion 127
%), 127
Individuals 127
PPI 127
inability 127
inverted 127
antiretroviral 127
CTF4 127
transferrin 127
O 127
MDD 127
PCCB 127
Miller 127
gingival 127
IP 127
CHCHD10 127
evaluations 126
lacking. 126
amongst 126
multifunctional 126
extends 126
histologically 126
thoracic 126
measures. 126
heavily 126
BMD 126
low, 126
covalently 126
enzyme-linked 126
immunosorbent 126
information, 126
colocalization 126
recorded. 126
stabilize 126
subunit, 126
junctional 126
RyR 126
pig 126
reflects 126
lifestyle 126
NMR 126
valproic 126
conferred 126
ionizing 126
occasionally 126
twin 126
reconstituted 126
incorporate 126
sorafenib 126
Combination 126
TSA 126
neurosurgical 126
leukaemia 126
consciousness 126
Asia 126
directional 126
sports 126
annexin 126
PCC 126
rhesus 126
millions 126
meeting 126
filopodia 126
Abeta 126
endostatin 126
weeks' 125
cut-off 125
determines 125
integrins 125
tended 125
volunteers. 125
modalities 125
shortened 125
oncogenes 125
docetaxel 125
incremental 125
homologues 125
cleaved 125
v 125
line. 125
induction. 125
evoked 125
lumen 125
rabbits 125
Differences 125
measured. 125
innovative 125
repression. 125
insulin, 125
Levels 125
lymphoma, 125
high-performance 125
acids. 125
homogeneous 125
Physical 125
Oseltamivir 125
November 125
bleeding. 125
PS 125
BM 125
transferase 125
K562 125
ALS. 125
injuries 125
wasting 125
H4K20 125
TADs 125
transplanted 125
TRalpha1 125
CRMs 125
D2 125
butterfly 125
falciparum, 125
%, 124
world 124
unclear, 124
IL-6, 124
indirectly 124
meet 124
co-expression 124
chromosome, 124
behavior, 124
web-based 124
astrocytes 124
U1 124
ductal 124
move 124
progressively 124
mutually 124
discussion 124
presentation, 124
Combined 124
Europe, 124
proprotein 124
small, 124
modification. 124
(two 124
length, 124
sagittal 124
Pro250Arg 124
tasks 124
cyst 124
originated 124
GARS 124
first-in-class 124
multicentric 124
Rotor 124
vedolizumab 124
fifth 123
concentration-dependent 123
ortholog 123
separately 123
axial 123
compliance 123
awareness 123
Class 123
intention-to-treat 123
patients). 123
deliver 123
substantia 123
prerequisite 123
Drosophila. 123
suspicion 123
Catecholaminergic 123
machinery. 123
round 123
ribonucleoprotein 123
infusions 123
Doppler 123
Myocardial 123
deletions, 123
unless 123
replace 123
LOH 123
(30 123
possible. 123
mg/kg) 123
exonic 123
involved. 123
toxins 123
heterologous 123
ventral 123
acne 123
TSC1 123
postsynaptic 123
works 123
DSB 123
sclerosis, 123
BRCA1/2 123
(P<0.05). 123
Restless 123
mutagenic 123
RPE 123
microbiota 123
NXY-059 123
e-mail: 123
eliglustat 123
2017. 123
dyshidrotic 123
inheritance, 122
AUC 122
voice 122
schedule 122
reactions. 122
Lung 122
peptides, 122
exposures 122
tested, 122
emphasize 122
Diagnostic 122
General 122
6% 122
perforation 122
athletes. 122
LDL-C 122
SAM 122
reproducible 122
JAK 122
hTERT 122
scans 122
trichostatin 122
69 122
GTPases 122
range, 122
mesylate 122
TKIs 122
empirical 122
rupture 122
neuropsychiatric 122
database, 122
Little 122
(PLN) 122
heterodimer 122
shunt 122
allosteric 122
Metnase 122
chaperones 122
calcification 122
ascorbate 122
CFTR 122
detrusor 122
optogenetic 122
erythromycin 122
lipoidica 122
attempted 121
individually 121
subtypes. 121
Drosophila, 121
Intravenous 121
actually 121
preservation 121
guidance 121
fails 121
played 121
0.0001) 121
secretion, 121
centres 121
range. 121
84 121
antiproliferative 121
decreased. 121
16% 121
GFP 121
databases. 121
strictly 121
Australian 121
ischemia, 121
hypertrophy, 121
Proteins 121
2012. 121
arrest. 121
CC 121
proapoptotic 121
cortisol 121
Rankin 121
questionnaire. 121
females. 121
later. 121
OBJECTIVE: 121
triglyceride 121
CAGE 121
AIP 121
consequently 121
subunits, 121
Maternal 121
Sanger 121
lifespan 121
cotransporter 121
correspond 121
peroxisome 121
compartment. 121
record 121
Annexin 121
Disorders 121
coma 121
deposits 121
First 121
MECP2 121
streptococcal 121
antagonism 121
Psoriasis 121
methotrexate 121
Behçet's 121
Melkersson-Rosenthal 121
onartuzumab 121
(HSCR) 120
used, 120
milder 120
acid. 120
cell-based 120
dermal 120
release, 120
Major 120
prescription 120
PE 120
decades, 120
exclusive 120
tolerability. 120
66 120
elevations 120
Heterozygous 120
phenomenon. 120
detects 120
bisulfite 120
terminated 120
Hereditary 120
retardation. 120
occupied 120
JASPAR 120
(range: 120
Test 120
pathogenesis, 120
compared. 120
uncharacterized 120
evaluation, 120
PD. 120
lamina 120
CD44 120
glycolysis 120
conservative 120
abacavir 120
intraoperative 120
STAT1 120
overactive 120
alpha-glucosidase 120
SEA0400 120
deafness, 119
neurotrophic 119
tagging 119
Immunohistochemical 119
properly 119
3.0 119
differing 119
activities, 119
Survival 119
weakness, 119
breast, 119
(for 119
prescribing 119
experiencing 119
soon 119
daily. 119
explaining 119
escape 119
proof 119
Twenty 119
instability. 119
persisted 119
Somatic 119
members, 119
scheme 119
cooperate 119
Recurrent 119
ligation 119
performs 119
migraine. 119
Authors 119
molecularly 119
accompanying 119
durable 119
craniosynostosis, 119
offspring 119
foetal 119
HbA1c 119
behavioural 119
4% 119
cerebellum. 119
rating 119
Sequencing 119
sequestration 119
T1 119
Neu5Gc 119
dabigatran, 119
quiescent 119
NK 119
EDS 119
Salmonella 119
chordoma 119
dapivirine 119
lymphangiectasia 119
osteoblasts 118
involvement. 118
hip 118
monthly 118
establishes 118
day. 118
ones 118
integrates 118
neuropathy, 118
Co. 118
spectral 118
His 118
plasma. 118
run 118
values. 118
(OR) 118
outperforms 118
IL-4 118
player 118
goiter 118
throughput 118
helical 118
MSCs 118
neuropsychological 118
What 118
(SNPs) 118
retrieval 118
GDAP1 118
plexus 118
CV 118
dysmorphism 118
hidden 118
Japan. 118
GIST 118
Fabry 118
HPRT 118
osteomyelitis 118
nimotuzumab 118
nusinersen 118
prompted 117
later, 117
ago, 117
obesity. 117
osteoblast 117
(a) 117
2012, 117
exercise. 117
tube 117
curative 117
staining. 117
consequent 117
reasonable 117
forced 117
detection. 117
channels, 117
presentations 117
safe, 117
echocardiography 117
blinded 117
bioavailability 117
cytokinesis 117
Outcomes 117
distinguishing 117
intolerance 117
oocytes 117
antiapoptotic 117
keratinocytes 117
ICR 117
unicoronal 117
enlargement 117
Th17 117
neoadjuvant 117
pathologies 117
confined 117
catalytically 117
Browser 117
ixazomib 117
pleural 117
oxysporum 117
SMAD4 117
unconjugated 117
geographic 117
Lesch-Nyhan 117
BIOASQ 117
migalastat 117
H3.3K27M 117
DosR 117
Manta 117
males. 116
aganglionic 116
CaM 116
unfavorable 116
deprivation 116
States. 116
(50 116
1a 116
preparations 116
nude 116
conflicting 116
positive. 116
cell, 116
peptides. 116
coordination 116
ophthalmoplegia, 116
Jewish 116
harbored 116
globally 116
end-stage 116
high-density 116
home 116
primers 116
Randomized 116
adolescent 116
epidemiologic 116
breakage 116
repeats, 116
lymphocytes. 116
mutant, 116
acupuncture 116
nuclei. 116
indispensable 116
algorithm, 116
interpreted 116
alopecia 116
huge 116
(OS) 116
transverse 116
DA 116
February 116
inferred 116
arises 116
Abnormal 116
motifs, 116
Sry 116
TM 116
errors 116
miR-155 116
HCNEs 116
(CPVT) 116
SOX9 116
psammoma 116
enteropathy 116
mumps 116
insulin-like 115
machine 115
attenuate 115
ease 115
edema, 115
prostate-specific 115
challenged 115
vesicle 115
(ER) 115
monomeric 115
acetyltransferase 115
enrolled. 115
pressure. 115
homologs 115
85% 115
uremic 115
returned 115
cholesterol, 115
3.5 115
Short 115
(HR, 115
answer 115
conclusion 115
positioned 115
nucleoside 115
duplicated 115
volumes 115
get 115
definite 115
periodontal 115
common. 115
mouth 115
ABC 115
bolus 115
neddylation 115
executive 115
fever. 115
uranium 115
rhythms 115
Simpson 115
uveitis 115
gestation 114
Akt, 114
mM 114
urgent 114
myasthenic 114
About 114
category 114
preceded 114
Various 114
concomitantly 114
treatments, 114
3), 114
weighted 114
kallikrein 114
caspase-3 114
immunity. 114
potential, 114
Pharmacological 114
(Pol 114
Family 114
bromodomain 114
NO 114
A549 114
Higher 114
thrombocytopenia, 114
cofactor 114
Adult 114
areas. 114
Statins 114
12% 114
transitions 114
2-year 114
(adjusted 114
northern 114
morphogenesis 114
flexibility 114
57 114
removing 114
strategy. 114
research, 114
fungi 114
spectra 114
selenocysteine 114
FTD 114
plants, 114
microM) 114
Rapid 114
Cold 114
antidote 114
granulocyte 114
F 114
FEC 114
LQTS 114
Na(+) 114
glucocorticoid 114
post-operative 114
SAH. 114
SCN 114
Syk 114
coeliac 114
Tietz 114
pathology, 113
allele, 113
poorer 113
cetuximab 113
recombination. 113
superfamily 113
77 113
increased, 113
euthyroid 113
survived 113
health. 113
go 113
again 113
proportions 113
exploited 113
pairwise 113
disturbed 113
trace 113
contributor 113
hearts, 113
NPC 113
non-specific 113
concepts 113
blood-brain 113
Unexpectedly, 113
instability, 113
manipulation 113
BMI 113
beam 113
ethical 113
ovary 113
nested 113
RNA-Seq 113
hypermethylated 113
nonspecific 113
medulloblastoma. 113
Fluorescence 113
benchmark 113
chloride 113
sputum 113
wildtype 113
CS 113
KCNQ1 113
Blackwell 113
vertebrates, 113
exciting 113
proliferator-activated 113
plate 113
agonist, 113
Considering 113
normal, 113
melatonin 113
channel. 113
0.05 113
P-bodies 113
bioactive 113
MTX 113
jugular 113
4CMenB 113
pibrentasvir 113
tract. 112
HSCR, 112
stage. 112
approximate 112
ERK1/2 112
Federation 112
(miRNA) 112
tool, 112
Prostate 112
NOTCH1 112
envelope 112
scaffolds 112
iPS 112
products. 112
sample. 112
synapses 112
shifted 112
playing 112
mildly 112
hypersensitive 112
exerted 112
pretreated 112
Tissue 112
P1 112
delays 112
platelets 112
usual 112
exploratory 112
Thirteen 112
1.3 112
custom 112
Preliminary 112
unexplained 112
Enhancer 112
SLC26A4 112
previously. 112
FFPE 112
granules. 112
additionally 112
arrhythmias, 112
content, 112
codons 112
sponge 112
(TSC) 112
confusion 112
cilia 112
TIEG1 112
dynamin 112
AF. 112
stresses 112
monkeys. 112
MHC 112
conjoined 112
2015, 112
nocturnal 112
guided 111
92 111
(b) 111
inform 111
fall 111
transition. 111
signals. 111
(eg, 111
voltage-gated 111
Methylation 111
parasympathetic 111
salt 111
(4 111
dual-specificity 111
biology, 111
describing 111
6. 111
memory, 111
5q35 111
simvastatin 111
demonstrated. 111
(EMT) 111
neuroprotection 111
hospital. 111
radiation. 111
representation 111
Han 111
deacetylases 111
septal 111
programme 111
ipsilateral 111
Everolimus 111
Metabolic 111
(type 111
transcript. 111
loaded 111
COMT 111
simulated 111
anaerobic 111
cholinergic 111
responds 111
RNAP 111
avium 111
music 111
MFS 111
TNF-alpha 111
Thalidomide 111
open-source 111
platinum-resistant 111
Glucose-6-phosphate 111
MutT 111
Geobacter 111
Avanafil 111
melioidosis 111
SMARCB1/INI1 111
CURB65 111
hard 110
5-year 110
tobacco 110
name 110
hyperphosphorylated 110
surgically 110
substances 110
baseline. 110
such, 110
tailored 110
stored 110
defect. 110
recommended. 110
site-directed 110
aqueous 110
1.2 110
procedure, 110
thrombotic 110
peptide, 110
stages. 110
participants, 110
maturation, 110
ternary 110
construction 110
nm 110
alleles, 110
prolactinoma 110
cis-acting 110
stay 110
neonates 110
intrauterine 110
mothers 110
walk 110
Altogether, 110
calcineurin 110
Inhibitor 110
era 110
organelles 110
glucocerebrosidase 110
products, 110
protein-DNA 110
inference 110
SECIS 110
enter 110
ubiquitinated 110
neurodegeneration. 110
immobilized 110
IC(50) 110
amino-terminal 110
exit 110
paralogous 110
Harbor 110
colonization 110
bortezomib, 110
fossa 110
string 110
contralateral 110
polyneuropathy 110
ApoE 110
LIM 110
frataxin 110
Viliuisk 110
speculate 109
ligands, 109
coordinate 109
alternate 109
calculated. 109
transmission. 109
ineffective 109
bioinformatic 109
spite 109
weeks) 109
tools, 109
value. 109
content. 109
egg 109
ventricle 109
facultative 109
intestine 109
antihypertensive 109
perceived 109
0.3 109
relate 109
S-phase 109
H1 109
raises 109
EMT. 109
(OMIM 109
ascending 109
protocol. 109
Rag 109
neutropenia, 109
miRNAs, 109
CREST 109
Angelman 109
Knowledge 109
mutant. 109
Spring 109
Iron 109
24, 109
morphologic 109
Treg 109
teratogenic 109
SERMs 109
XII 109
5hmC 109
e.g. 108
ganglia 108
Combining 108
67 108
Examination 108
former 108
abilities 108
13, 108
assumption 108
ranges 108
LNH 108
1/2 108
univariate 108
sarcoma. 108
antigenic 108
assessment. 108
balloon 108
Life 108
140 108
neuroblastoma. 108
94 108
(P<0.001). 108
excreted 108
heterochromatin, 108
antibiotics. 108
gas 108
Southern 108
hypotheses 108
lysosome 108
lasting 108
dysmorphic 108
curves 108
deletion. 108
Though 108
leucine 108
Associated 108
photomorphogenesis 108
E7 108
accelerate 108
anabolic 108
tropical 108
GERD 108
anesthesia 108
technology, 108
filamentous 108
hyperkeratotic 108
TFIIB 108
edaravone 108
OSA. 108
OCA 108
TcdB 108
Malignant 107
osteosarcoma 107
Peripheral 107
μg 107
clinicopathological 107
duration, 107
(FDA) 107
Advances 107
specification 107
far. 107
Eligible 107
physiologically 107
briefly 107
Gy 107
fresh 107
topologically 107
channel, 107
0.001 107
ranolazine 107
modifiers 107
area. 107
creatine 107
adrenergic 107
SWI/SNF 107
kinases. 107
cystatin 107
A/S. 107
diet. 107
planned 107
consistency 107
situation 107
stature 107
delineate 107
harmful 107
clear. 107
Care 107
warrants 107
vacuolar 107
detrimental 107
steady 107
pattern, 107
eyes 107
subtilis 107
multifocal 107
obtaining 107
beta-galactosidase 107
neuropathological 107
ferritin 107
subunits. 107
oligomerization 107
mosquitoes 107
Purkinje 107
restrict 107
antimalarial 107
etexilate 107
HU 107
CNVs 107
transcription-coupled 107
polyglutamine 107
nucleases 107
SERT 107
GAN 107
PAH 107
immunohistochemically 107
SH3 107
word 107
FXR 107
Asf1 107
Ectopic 106
file 106
resorption 106
frequency, 106
uniformly 106
paraneoplastic 106
aware 106
drug-drug 106
intraperitoneal 106
necessity 106
(HR) 106
verify 106
APC 106
phospholipid 106
hypothalamic 106
neurite 106
biochemically 106
originate 106
mg/m2 106
mitomycin 106
recovery. 106
gliomas, 106
compute 106
drug-related 106
speed 106
program, 106
frequency. 106
(25 106
H3K36me3 106
HP1 106
Swedish 106
drug-resistant 106
drivers 106
episode 106
Scale, 106
R/Bioconductor 106
GBM. 106
S6K1 106
intermediates 106
Inhibitors 106
(ALS) 106
indicators 106
synonymous 106
axon 106
Hamilton 106
plain 106
OPA1 106
addiction 106
chemistry 106
NMD 106
Nox1 106
(DMD) 106
treprostinil 106
metaxin 106
teriflunomide 106
TSS 106
Emanuel 106
remodeling, 105
F-actin 105
substrates, 105
(lncRNAs) 105
adipocyte 105
Increasing 105
myasthenia 105
0.4 105
America 105
injection. 105
selection, 105
modality 105
thresholds 105
AT 105
developed, 105
implies 105
label 105
expanding 105
TAp73 105
(PCR) 105
length. 105
fusions 105
fine 105
examination. 105
elongation. 105
deletion, 105
129 105
applicability 105
sensitization 105
Those 105
septic 105
timely 105
hours, 105
event. 105
stature, 105
subtilisin/kexin 105
datasets, 105
FCM 105
Large 105
cells: 105
kindred 105
fractional 105
pedigree 105
night 105
[CI] 105
macroautophagy 105
Autophagy 105
multidrug 105
inputs 105
substrate. 105
QOL 105
FGFR 105
polypeptides 105
breakdown 105
simulation 105
hemorrhage, 105
85 105
pairing 105
PcG 105
discharges 105
glycyl-tRNA 105
Anemia 105
diagnostics 105
MD 105
rules 105
UCSC 105
miR-132 105
immune-mediated 105
dysarthria 105
sleepiness 105
parotid 105
parkinsonian 105
CGRP 105
BCNU 105
HOQ 105
PBT2 105
disulfide 104
threonine 104
ncRNAs 104
matrix. 104
Register 104
robustness 104
perspective. 104
aging. 104
responders 104
measurable 104
ChIP 104
ontology 104
points. 104
planning 104
selecting 104
parkinsonism, 104
imbalance 104
cirrhosis 104
interspersed 104
ambulatory 104
aggregated 104
A) 104
transitional 104
resides 104
tumours, 104
Sudden 104
estradiol 104
entirely 104
technique, 104
lesion. 104
sensing 104
resident 104
structured 104
CTCF, 104
Stress 104
Conserved 104
ALL 104
ng/ml 104
NCT 104
(ROS) 104
recipients 104
polyclonal 104
relapsed/refractory 104
HNSCC 104
files 104
SERM 104
barriers 104
Warburg 104
radius 104
myopathy. 104
HS 104
tick 104
itaconic 104
HOTAIR 104
Fbw7 104
Haspin 104
chocolate 104
mimotope 104
galunisertib 104
ozanimod 104
Blount's 104
incompletely 103
cytokines, 103
oligomers 103
comprehensively 103
Calcium 103
uterine 103
beta-adrenergic 103
organs, 103
5. 103
disease; 103
lacked 103
AP 103
Peptide 103
So 103
5) 103
Impact 103
involvement, 103
ultrastructural 103
reaching 103
adequately 103
signal-regulated 103
solutions 103
areas, 103
0.05), 103
instances 103
brain-lung-thyroid 103
inhaled 103
Apert 103
testicular 103
truncation 103
surface. 103
r 103
elective 103
impairments 103
transposable 103
wheat 103
fibrinogen 103
striatum 103
Spinal 103
axons 103
(CSF) 103
microvascular 103
participants. 103
diffusion 103
electrocardiogram 103
warfarin. 103
TB 103
haplotypes 103
multicentre 103
decitabine 103
nivolumab 103
mosquito 103
wafer 103
amoxicillin 103
(G6PD) 103
Tomita 103
hepaCAM 103
Noxo1 103
puffy 103
multifactorial 102
resemble 102
form. 102
one-third 102
medications, 102
all, 102
Elevated 102
65% 102
Retrospective 102
disclosed 102
necessarily 102
metastases, 102
oncoprotein 102
Age 102
adhesion, 102
cooperative 102
context. 102
lethality 102
Magnetic 102
elongating 102
starts 102
intended 102
TG 102
echocardiographic 102
inherent 102
endoscopic 102
active, 102
premenstrual 102
fair 102
0% 102
two-dimensional 102
medullary 102
X-chromosome 102
cytoplasm. 102
Canada, 102
adds 102
chance 102
killer 102
searching 102
generic 102
denaturing 102
short-read 102
grouped 102
fashion 102
post-traumatic 102
barrel 102
tails 102
coordinates 102
lifetime 102
chronically 102
Europe. 102
However 102
MEN 102
A-type 102
RASSF1A 102
propionic 102
KCNJ11 102
OI 102
PIL 102
ulcerans 102
tinea 102
pathogenetic 101
intercellular 101
membrane-bound 101
But 101
malignancy. 101
(an 101
Together 101
traditionally 101
xenografts. 101
vision 101
perspectives 101
Wistar 101
dementia. 101
thorough 101
father 101
G+C 101
nodular 101
caveolin-1 101
syndrome]. 101
prompt 101
Sixteen 101
Institutes 101
%). 101
BNP 101
PR 101
Prospective 101
passage 101
concentration, 101
ubiquitin-like 101
anoikis 101
sore 101
malformations, 101
PKC 101
stopped 101
PDS 101
carotid 101
glioma, 101
MS, 101
microdeletions 101
Rho 101
placebo). 101
empagliflozin, 101
transposons 101
catalyze 101
pXO1 101
anthracycline 101
Src 101
ultrasonography 101
directions 101
venlafaxine 101
pheochromocytoma 101
Therefore 101
DP 101
benefit. 100
AR 100
invasion, 100
extent, 100
marker, 100
costs. 100
evidence. 100
87 100
prolong 100
Discovery 100
settings 100
(8 100
triadin, 100
ET 100
nearby 100
comorbid 100
removes 100
N- 100
GmbH 100
holds 100
patient-derived 100
pneumonia 100
composition, 100
center. 100
argue 100
multidisciplinary 100
group) 100
strand. 100
5-methylcytosine 100
extracts. 100
peptide. 100
condensation 100
Syndrome. 100
exacerbations 100
helper 100
synergy 100
starvation 100
alternating 100
leukocytes 100
lymphocytes, 100
architecture. 100
radioactive 100
histidine-rich 100
unrecognized 100
blood. 100
reorganization 100
cardinal 100
interferes 100
D3 100
declined 100
connectivity 100
query 100
platinum-sensitive 100
HER2-positive 100
retrieve 100
Barr 100
transposase 100
Recognition 100
Ménière's 100
Aedes 100
EIF2AK2 100
probe-to-bone 100
lineage. 99
cognate 99
metalloproteinase 99
rank 99
antagonistic 99
AMP-activated 99
management, 99
2010, 99
transducer 99
morphology, 99
substituted 99
thereafter. 99
11, 99
workflow 99
processing, 99
integrative 99
raising 99
Strikingly, 99
Lennox-Gastaut 99
cells) 99
Prevalence 99
menopausal 99
explored. 99
mainstay 99
duplex 99
countries, 99
PCR, 99
TTR 99
S6 99
Biology, 99
pathogens. 99
patterning 99
rated 99
teaching 99
BiFC 99
field. 99
contents 99
exclude 99
problem. 99
ticks 99
survivin 99
sets. 99
γH2AX 99
cancer-associated 99
Huntington 99
LEMS 99
eteplirsen 99
FAK 99
erythropoiesis 99
melanin 99
acidemia 99
citrullination 99
Meis1 99
HIPEC 99
DBT 99
specified 98
expresses 98
joints 98
kappa 98
repertoire 98
Pain 98
specimen 98
resected 98
cynomolgus 98
125 98
survive 98
Addition 98
fibrosis, 98
methodological 98
Positive 98
digestive 98
resolve 98
AED 98
proteinuria 98
follows 98
zebrafish. 98
1.6 98
sufficiently 98
spots 98
commercially 98
(both 98
shRNA 98
interim 98
reduction. 98
ectodermal 98
tear 98
placement 98
known, 98
ameliorate 98
dog 98
pairs. 98
Z 98
position. 98
coiled-coil 98
Lyme 98
IGF-1 98
Stem 98
0.2 98
ABL 98
enzastaurin 98
MLL1 98
NFAT 98
Wells 98
G3BP2 98
C9ORF72 98
Krabbe 98
etiologic 97
kinds 97
abundantly 97
setting, 97
metalloproteinases 97
intriguing 97
late-stage 97
MTT 97
Issue 97
81 97
recruiting 97
hepatocytes, 97
hematopoiesis. 97
8% 97
130 97
expressed, 97
capacity. 97
primates 97
microscopy, 97
problems, 97
stimuli. 97
Progressive 97
De 97
Dutch 97
distribution. 97
EWS 97
3'-untranslated 97
translocation, 97
receptor-positive 97
(SD 97
affinity. 97
multimodal 97
dystrophy, 97
dependent. 97
maternally 97
trimethylated 97
ubiquitin-proteasome 97
Silencing 97
placebo; 97
CYP2C19 97
Biochemistry 97
Eukaryotic 97
well-defined 97
technology. 97
problems. 97
modelling 97
signs, 97
2.8 97
tools. 97
convenient 97
stimulatory 97
considerations 97
off-target 97
donors. 97
ophthalmic 97
oscillations 97
decompression 97
Hb 97
K201 97
transcranial 97
neurostimulation 97
ataxin-3 97
C12orf65 97
BORIS 97
ADAMTSL4 97
1.1 96
Distinct 96
cycles. 96
warrant 96
migratory 96
Reduction 96
mass. 96
IL-17 96
98 96
sequence-specific 96
summarized 96
unprecedented 96
examines 96
senescent 96
senescence, 96
1:1 96
crosstalk 96
nitrogen 96
phenotypically 96
continuously 96
kill 96
Monoclonal 96
plasma, 96
neurotransmitter 96
concentration. 96
autism. 96
LPS 96
(20 96
antagonists, 96
reduced. 96
2009. 96
tolerate 96
email: 96
Ultraconserved 96
one, 96
motif. 96
achieves 96
maturation. 96
pandemic 96
began 96
glucocorticoids 96
curated 96
optical 96
noted. 96
vesicular 96
Members 96
inversion 96
ultraviolet 96
earliest 96
adenine 96
track 96
miRNAs. 96
conduct 96
suppressors 96
(CMT) 96
inducers 96
GABAergic 96
dentin 96
synteny 96
aetiology 96
acetylation. 96
recapitulated 96
protein-coupled 96
coat 96
astrocytomas 96
proof-of-concept 96
meningitidis 96
biotinylation 96
benzodiazepines 96
beads 96
transposition 96
settings. 96
IR 96
metaphase 96
myotubularin 96
ICH 96
A-to-I 96
3'-end 96
gene-related 96
ILAE 96
(MWS) 96
FGF23 96
sarcoidosis 96
ROSIER 96
CSN 96
panencephalitis 96
arose 95
Comprehensive 95
trans 95
Chromosomal 95
MEK 95
dissemination 95
cross-talk 95
mRNAs, 95
Giant 95
manifesting 95
160 95
erythema 95
cutoff 95
Limited. 95
oral, 95
urea 95
antigens. 95
Eighteen 95
negative. 95
melanocyte 95
NCX 95
(7 95
1999 95
away 95
pervasive 95
MM. 95
cDNAs 95
resultant 95
unmet 95
etiological 95
1). 95
Registry 95
exploration 95
inpatient 95
interval: 95
000 95
uracil 95
Tumors 95
doses, 95
discordant 95
GC-rich 95
improved. 95
susceptibility. 95
raw 95
dark 95
characterizing 95
damaging 95
ALS-linked 95
high-fat 95
haemorrhage 95
helped 95
glyburide 95
demethylation 95
Chd1 95
morphogenetic 95
aromatase 95
MYC 95
dyskeratosis 95
peroxide 95
monosomy 95
lens 95
intrinsically 95
180 95
notable 95
cytokines. 95
82 95
follicle 95
printing 95
(MRSA) 95
epileptiform 95
gingivalis 95
A3G 95
Turcot 95
niraparib 95
Ebstein's 95
Nrd1 95
relating 94
deposited 94
clues 94
expert 94
resection, 94
reports, 94
collaboration 94
13% 94
depolarization 94
AMI 94
(6 94
examined, 94
angiography 94
macromolecular 94
alterations, 94
simply 94
complaints 94
Mass 94
discoveries 94
frozen 94
acutely 94
education 94
disabling 94
HT 94
heterogeneity. 94
mg. 94
alive 94
modification, 94
reminiscent 94
polymerization 94
seasonal 94
birth. 94
hypotonia 94
homeobox 94
recursive 94
translocation. 94
alpha, 94
newborns 94
GFR 94
wk 94
Scale. 94
Cytoplasmic 94
sphincter 94
Hsp70 94
ICD 94
stationary 94
adipocytes. 94
ever 94
HAX-1 94
dosing. 94
receiver 94
Willis-Ekbom 94
al.; 94
allergy 94
celiac 94
pestis 94
isradipine 94
chorion 94
tolcapone 94
Siltuximab 94
TNNI3K 94
Daratumumab 94
SINEUPs 94
pseudomallei. 94
dinutuximab 94
females, 93
aberrantly 93
acquire 93
unidentified 93
inefficient 93
(RA). 93
neoplasms 93
Notch1 93
IC50 93
pro-apoptotic 93
pharmacologically 93
poly(ADP-ribose) 93
origins. 93
muscles. 93
days) 93
application. 93
column 93
chapter 93
genus 93
pocket 93
pancreas 93
dialysis 93
one. 93
Hg 93
interventions. 93
self-reported 93
d 93
group). 93
Africa 93
hypoxia-inducible 93
cooperates 93
immunostaining 93
14, 93
neurotoxicity 93
dimeric 93
emphasizes 93
assisted 93
perception 93
fluctuations 93
hair, 93
Glioblastoma 93
12-month 93
cell-type-specific 93
procedures. 93
9) 93
infants, 93
Phylogenetic 93
MCM 93
indels 93
L 93
pombe 93
infer 93
reversing 93
Before 93
Dabigatran 93
Hi-C 93
Cas9 93
Australia 93
U 93
dystonia. 93
Dyke-Davidoff-Masson 93
MGMT 93
UVA 93
CRISPR/Cas9 93
cryptococcal 93
Lepidopteran 93
T790M 93
crizotinib-resistant 93
macroH2A1 93
IFNAR1 93
SMARCAL1 93
uc.189 93
Hepatic 92
service 92
surviving 92
Methods 92
histopathologic 92
fact, 92
NOTCH3 92
γ-secretase 92
event, 92
other. 92
generation. 92
datasets. 92
biophysical 92
asymmetry 92
SMA 92
11% 92
history. 92
PI 92
cavity 92
compares 92
medically 92
siRNA-mediated 92
cyclophosphamide 92
withdrawn 92
104 92
Postoperative 92
3-4 92
instruments 92
underway 92
deletions. 92
alternatively 92
ATM 92
Friedreich's 92
repeats. 92
unfolded 92
conjugation 92
chorionic 92
spatially 92
organelle 92
but, 92
(CT) 92
outline 92
unbiased 92
chloroplast 92
daily) 92
Cases 92
(RA), 92
initiation. 92
spectroscopy 92
fT3 92
palsy. 92
Trypanosoma 92
vulnerable 92
remote 92
serine/threonine 92
kinetochore 92
Schizosaccharomyces 92
motif, 92
ceftriaxone 92
bias. 92
expectancy 92
bring 92
glycolytic 92
respiration 92
Performance 92
morpholino 92
single-cell 92
95%CI 92
pregabalin 92
shortly 92
PD-L1 92
Klinefelter 92
DBS 92
Emery-Dreifuss 92
adiponectin 92
Dock180 92
HCl 92
GFI1B 92
Exploding 92
Melioidosis 92
glecaprevir 92
Germline 91
profiles, 91
alignments. 91
110 91
bone, 91
subcutaneously 91
density. 91
Generation 91
split 91
Disruption 91
radiotherapy, 91
drawn 91
culture, 91
7% 91
goals 91
others, 91
delivery. 91
(CNS) 91
infarcted 91
hemochromatosis 91
excitation-contraction 91
35% 91
spectrometric 91
releasing 91
Active 91
transport. 91
EZH2, 91
particle 91
risks. 91
dinucleotides 91
Carney's 91
pathophysiologic 91
fibrous 91
PA 91
daytime 91
automatically 91
21, 91
implantable 91
type-specific 91
retrieved 91
apart 91
aligned 91
p300 91
aggregate 91
covering 91
human. 91
GABA 91
Coma 91
Â© 91
CHD 91
miR-7 91
pose 91
rivaroxaban, 91
TAD 91
TRbeta1 91
NER 91
stomach 91
adhesive 91
Treating 91
Diabetic 91
flashes 91
PR-Set7 91
Gaucher's 91
transluminal 91
sterol 91
Gfi1b 91
rickets. 91
Flumazenil 91
contagiosum 91
underlies 90
interest, 90
ncRNA 90
(PFS) 90
return 90
prespecified 90
accordance 90
potentiated 90
dimers 90
projects 90
Individual 90
(SERCA) 90
55% 90
biosynthesis. 90
G2/M 90
A2 90
Currently 90
myoclonic 90
(approximately 90
Streptococcus 90
1,000 90
haemolytic 90
boys 90
controversial 90
birth, 90
health-related 90
myeloma, 90
years), 90
lungs 90
medulloblastoma, 90
Polymerase 90
ligation-dependent 90
change, 90
Oncology 90
responding 90
microtubule-associated 90
Suppression 90
defect, 90
P<0.001). 90
positional 90
out. 90
Disability 90
tuberculosis, 90
ALT 90
etanercept 90
traits. 90
SCD 90
publication 90
resolution, 90
discrimination 90
pathophysiology. 90
format, 90
Virus 90
mass, 90
superiority 90
presently 90
NETs 90
di- 90
acetylation, 90
myelination 90
arrhythmia. 90
paroxysmal 90
longevity 90
RLS. 90
Sclerosis 90
antisocial 90
t 90
body, 90
carboxyl-terminal 90
irradiated 90
granulomatous 90
metazoan 90
excluding 90
f. 90
fluid. 90
pigmentary 90
Ser-129 90
thrombolytic 90
H2AX 90
sarcoidosis. 90
polyps 90
SSPE 90
genesis 89
non-syndromic 89
look 89
expected, 89
phylogeny 89
monocytes 89
93 89
Prior 89
conducted. 89
location, 89
pharmacology 89
exercise, 89
dasatinib 89
albeit 89
Yamanaka 89
HIF-1α 89
protecting 89
low. 89
oligomeric 89
teleost 89
glucose, 89
(50%) 89
commonest 89
vicinity 89
Isolated 89
strategies, 89
recognition. 89
PI3K/Akt 89
isotope 89
infancy 89
8. 89
Relative 89
Study. 89
implicates 89
residues, 89
2.0 89
context, 89
etiology. 89
kindreds 89
UVB 89
USA. 89
infancy. 89
field, 89
0.02). 89
17% 89
aspirin 89
atherosclerosis. 89
division. 89
synthesize 89
accumulation. 89
confounding 89
progenitors. 89
paternally 89
stretch 89
1.9 89
incorporates 89
experiences 89
polyubiquitin 89
Red 89
Ca²⁺ 89
surprisingly 89
thromboembolism 89
CO2 89
contractions 89
Prenatal 89
stepwise 89
CTGF 89
acetate 89
subdural 89
Alemtuzumab 89
deiodinase 89
thalamotomy 89
COL5A1 89
VKORC1 89
dabrafenib 89
Robertsonian 89
intetumumab 89
Cidec 89
DGAT1 89
Decreased 88
series, 88
gland. 88
organization, 88
molecule. 88
rapid, 88
values, 88
thyrotropin 88
27% 88
88 88
repeatedly 88
established, 88
providers 88
mAbs 88
compounds, 88
immature 88
neighbouring 88
Key 88
derivative, 88
therapeutically 88
Dual 88
2a 88
recordings 88
both, 88
keep 88
Literature 88
kg(-1) 88
blunted 88
muscles, 88
predisposes 88
resembles 88
interface. 88
multiprotein 88
UC 88
mellitus, 88
renin 88
MM, 88
Likewise, 88
immunohistochemistry. 88
cancerous 88
encompasses 88
care, 88
cent 88
satisfaction 88
EORTC 88
Africa. 88
knock-out 88
recover 88
adenomas. 88
interleukin-6 88
cells; 88
reduced, 88
ratio. 88
versions 88
trait. 88
pendrin 88
Histological 88
preferences 88
salvage 88
supratentorial 88
sarco(endo)plasmic 88
hemispheric 88
epigenetically 88
controlled, 88
orbital 88
Intriguingly, 88
(15 88
experience. 88
replication-timing 88
10-year 88
Mdm2 88
science 88
diffraction 88
Aspergillus 88
minutes. 88
pyknons 88
Timothy 88
SPINK5 88
peroxisomal 88
PsA 88
anti-GQ1b 88
occludin 88
MOPD 88
PTPN22, 88
glucose-6-phosphate 88
BioCreative 88
afamelanotide 88
hidradenitis 88
erythrasma 88
LHON 88
TRPM2 88
colocalize 87
reduction, 87
co-transcriptional 87
dedicated 87
put 87
observations, 87
density, 87
knee 87
antagonist. 87
diverged 87
Unfortunately, 87
duration. 87
charge 87
States, 87
stimulus 87
tags 87
36% 87
electric 87
Regulatory 87
hyperactivity 87
nerves 87
Toll-like 87
cascade. 87
incidences 87
intramuscular 87
distances 87
sucrose 87
advent 87
3). 87
JAK2 87
vaccine. 87
blotting. 87
c-Met 87
vertical 87
Dupilumab 87
shifts 87
contiguous 87
(relative 87
Epstein-Barr 87
specific, 87
cover 87
medication. 87
palsy, 87
manifests 87
sensitivities 87
diploid 87
DSBs 87
user-friendly 87
catheter 87
m 87
240 87
IgA 87
G-CSF 87
miR-21, 87
RING 87
autoimmunity 87
subnuclear 87
vomiting, 87
76 87
H2B 87
bipolar 87
motility. 87
derepression 87
Status 87
μm 87
morphine 87
suvorexant 87
ketoacidosis 87
pre-RC 87
L-DOPA 87
Modafinil 87
gevokizumab 87
calciphylaxis 87
ligands. 86
differently 86
1.8 86
roles. 86
templates 86
switched 86
documented. 86
(11 86
Detailed 86
2.4 86
molecule, 86
chemically 86
synergistically 86
formerly 86
heterozygote 86
RNA-dependent 86
connecting 86
86% 86
adolescents. 86
kg 86
net 86
hour 86
cytoskeleton. 86
inhibitor-1 86
uptake. 86
infertility 86
variables. 86
ng 86
umbilical 86
lowers 86
(UCEs) 86
fragile 86
deamination 86
presentation. 86
segregation. 86
ligases 86
immunogenicity 86
Th1 86
person 86
asthma, 86
Area 86
83 86
psychosocial 86
cochlear 86
masses 86
performance, 86
Brown 86
coincide 86
somewhat 86
clusters, 86
scar 86
paralysis 86
(T3) 86
vegetative 86
mineralization 86
DNA-dependent 86
juice 86
resection. 86
nonhuman 86
Mfd 86
transfer. 86
mg/day) 86
glioblastomas 86
Endogenous 86
al 86
CYP2C9 86
disordered 86
A/C 86
psoriasis, 86
nebulin 86
apps 86
melanocortin 86
homocystinuria 86
EphA2 86
LYST 86
plasmepsin 86
Dovitinib 86
leishmaniasis 86
necrobiosis 86
itself. 85
phenomena 85
compact 85
fibers. 85
pre-clinical 85
stem-loop 85
Department 85
phage 85
corresponds 85
heterodimers 85
peroxidase 85
siRNAs 85
well-established 85
uncertain. 85
transduced 85
milestones 85
secrete 85
(MAPK) 85
Transfection 85
factor-1 85
reconstitution 85
KGaA, 85
multipotent 85
midline 85
Defects 85
hamster 85
31% 85
statistics 85
(aged 85
held 85
visits 85
aplastic 85
prolactin 85
disrupting 85
different. 85
centromeres. 85
(Aβ) 85
Infection 85
Her 85
Target 85
judged 85
refined 85
Web 85
N. 85
strain, 85
imatinib, 85
hydroxylase 85
in-frame 85
RNAPII 85
fungus 85
UGA 85
Amyotrophic 85
Replication 85
electrophoretic 85
uniform 85
extension. 85
MammaPrint 85
environments. 85
DE 85
Opa1 85
materials 85
warfarin, 85
elotuzumab 85
articular 85
Stat3 85
aorta 85
occluded 85
clinician 85
CABG 85
commotio 85
neurogenic 85
serological 85
TIA 85
DNMT3B 85
pupillary 85
PLA2G6 85
anti-Aβ 85
insomnia. 85
Y. 85
fascin 85
GAA 85
eRNAs 85
Hst 85
sotagliflozin 85
discovery. 84
unnecessary 84
exons, 84
Computational 84
12-week 84
lytic 84
achieved. 84
microsomal 84
(IC50 84
(> 84
annotate 84
standards 84
Ca(2 84
reticulum. 84
C2C12 84
fractionation 84
Identifying 84
Also 84
14% 84
exacerbated 84
Emergency 84
Transient 84
triglycerides 84
discontinuation. 84
mg/dL 84
placebo-treated 84
tension 84
450 84
converts 84
autonomous 84
Genetics 84
states. 84
smoke 84
cooperation 84
2009, 84
Mutant 84
documentation 84
fear 84
estimating 84
class, 84
came 84
DNase 84
Microbiology. 84
Cognitive 84
Testing 84
translation, 84
NE 84
prostacyclin 84
were: 84
Confusion 84
Pharmacokinetics 84
musculoskeletal 84
hypothalamus 84
dormancy 84
(CD) 84
annotations. 84
V. 84
zeste 84
alkylating 84
Carfilzomib 84
hybridization. 84
supranuclear 84
E6 84
islet 84
2nd 84
Abl 84
forces 84
here, 84
bapineuzumab 84
dystonia, 84
practices 84
piggyBac 84
myotubular 84
AMH 84
Mepolizumab 84
HLA-DRB1 84
macroH2A 84
MTH1 84
herpetiformis 84
HLA-B*1502 84
KCNQ2 84
STXBP1 84
peginesatide 84
SWR1 84
MNase 84
anti-EGFR 83
cassette 83
membranes, 83
brought 83
node-negative 83
set. 83
immunotherapy. 83
denosumab 83
bone. 83
femoral 83
fractures. 83
30, 83
pigmented 83
limbs 83
e.g., 83
positive, 83
7. 83
capability 83
demand 83
target, 83
sham 83
rat. 83
tiling 83
rescues 83
myoblasts 83
store 83
simplified 83
perfused 83
leaves 83
Structure 83
groove 83
lipopolysaccharide 83
viability, 83
protein-1 83
alterations. 83
begin 83
plausible 83
homocysteine 83
classification, 83
running 83
(where 83
21. 83
substance 83
Fourteen 83
authors' 83
screens 83
longest 83
Australia, 83
leukemic 83
termination. 83
know 83
1998 83
R. 83
variant. 83
dysfunctional 83
Pendred's 83
workers 83
Tay-Sachs 83
biogenesis, 83
machinery, 83
edema. 83
CD4 83
IL-10 83
pedigrees 83
deduced 83
dynamics. 83
Mortality 83
incontinence. 83
haemoglobin 83
restoring 83
hCG 83
high-affinity 83
PS1 83
Dnmt3a 83
augment 83
microenvironment. 83
indication. 83
apixaban, 83
gradual 83
false-positive 83
Day 83
Marfan's 83
tricyclic 83
measures, 83
point-of-care 83
IL-18 83
amygdala 83
marine 83
penumbra 83
JTV519 83
BMP 83
eRNA 83
nonmelanoma 83
Sclerostin 83
suppurativa 83
diphenylene 83
exploding 83
class. 82
aspartic 82
predictions. 82
RANKL 82
serous 82
generalised 82
recognised 82
improvement. 82
pointed 82
FRAX 82
captured 82
chick 82
Isolation 82
7.5 82
follows: 82
hope 82
1-2 82
creation 82
come 82
procedures, 82
inflammasome 82
unreported 82
proposed. 82
periphery 82
18% 82
tail. 82
portions 82
pipeline 82
dynamics, 82
genotoxic 82
margin 82
Atypical 82
regimen. 82
strict 82
visit 82
rectal 82
domain-containing 82
addressing 82
dosing, 82
leukemia, 82
eradication 82
cytidine 82
drastically 82
Clinic 82
paid 82
temporally 82
area, 82
hypothyroidism, 82
plan 82
section 82
programming 82
allele-specific 82
element. 82
versatile 82
motion 82
MSI 82
uniquely 82
poisoning 82
CD. 82
solitary 82
invariably 82
non-Hodgkin 82
CD4+ 82
MEFV 82
people. 82
antigen, 82
Advanced 82
sedimentation 82
PINK1 82
alleviate 82
Hho1p 82
cffDNA 82
tremor. 82
Dock2 82
curcumin 82
NFL 82
Palmini 82
ocrelizumab 82
NOX5 82
MenB 82
ATMIN 82
hypoplasia, 81
forms, 81
cytoprotective 81
medium. 81
EGFR, 81
hydrochloride 81
hampered 81
cathepsin 81
osteoclast 81
MicroRNA 81
regulators. 81
(age 81
gravis 81
bony 81
with, 81
uncertain 81
fate. 81
0.0001), 81
(RT) 81
p27 81
stores 81
cardiac-specific 81
charged 81
thyrotropin-releasing 81
lysines 81
Diseases 81
monocyte 81
cultures, 81
chromatids 81
expensive 81
(but 81
institution 81
syndrome), 81
stressed 81
residents 81
university 81
desired 81
Against 81
degrades 81
addresses 81
CHIP 81
childhood, 81
osteogenic 81
dilatation 81
software. 81
palate 81
guanosine 81
cases), 81
thrombosis, 81
peculiar 81
cohesion, 81
pathogenicity 81
orthologs 81
roots 81
Drugs 81
regulators, 81
marketed 81
concurrently 81
serotonergic 81
typing 81
conditioning 81
Pulmonary 81
SAGA 81
cordis 81
contamination 81
seed 81
Na,K-ATPase 81
claims 81
succinate 81
omega-conotoxin 81
electrophysiologic 81
CTR2 81
inhalational 81
Ustekinumab 81
MTM1 81
Tofacitinib 81
ERT 81
T-type 81
p50 81
Katayama 81
naloxone 81
selexipag 81
2-OH-dATP 81
HFNC 81
[(18) 81
Mirabegron 81
high-altitude 81
Tbr1 81
injured 80
phospholipase 80
Alternative 80
professionals 80
osteoporotic 80
fracture. 80
scaling 80
co-expressed 80
weaker 80
aberrations, 80
Serious 80
cardiomyocytes, 80
45% 80
K(+) 80
China. 80
Pharmacology 80
Follow-up 80
71 80
biopsy. 80
autosomal-recessive 80
transcription-associated 80
solution. 80
Yet, 80
slowing 80
Weinheim. 80
neurofibrillary 80
matrix, 80
purpura 80
coli, 80
intake. 80
(MS). 80
irregular 80
operative 80
tumorigenesis, 80
totally 80
minute 80
indistinguishable 80
irradiation. 80
hybrids 80
prime 80
Predicting 80
methyltransferases. 80
ameliorates 80
long-lasting 80
ESCs 80
uncomplicated 80
hypotonia, 80
22, 80
immunoblotting 80
cytoplasm, 80
competing 80
osteogenesis 80
limitation 80
colocalizes 80
Fatigue 80
general. 80
detail. 80
patient-specific 80
(NF1) 80
91 80
fibrotic 80
operate 80
learn 80
Exon 80
principally 80
hepatoma 80
problem, 80
congenita 80
ferric 80
IgM 80
epirubicin 80
malnutrition 80
keratinocyte 80
GRB 80
trauma, 80
NLRP3 80
polymer 80
relational 80
Disease. 80
GAD 80
prolymphocytic 80
reproducibility 80
SEGA 80
mismatches 80
MALAT1 80
annulus 80
Lupus 80
schistosomiasis 80
answering 80
SLEDAI 80
NBEAL2 80
piRNAs 80
gluten-free 80
thyrocyte 80
raxibacumab 80
ANGPTL3 80
EDN3 79
fairly 79
Epidermal 79
parasitic 79
compelling 79
Rheumatoid 79
experts 79
element, 79
Skin 79
similar, 79
way. 79
organismal 79
31, 79
(AEs) 79
classify 79
postmortem 79
(AF) 79
adopted 79
(LV) 79
Few 79
accumulating 79
configuration 79
ago 79
Expert 79
Mental 79
Academic 79
room 79
β-amyloid 79
HEK293 79
indications. 79
analyzed, 79
exercise-induced 79
dependency 79
Symptoms 79
measurements. 79
health, 79
managing 79
constrained 79
height 79
statins, 79
anticipated 79
assignment 79
FH 79
hypoxia, 79
lymphomas 79
G-quadruplex 79
co-localize 79
intramolecular 79
sensitized 79
mitosis, 79
IkappaB 79
CRD-BP 79
flu 79
oocyte 79
Argonaute 79
Linkage 79
CD56 79
0.02) 79
unit. 79
filled 79
palate, 79
biosynthesis, 79
vasogenic 79
necessary. 79
cohesins 79
beta-globin 79
permit 79
opicapone 79
cylindromatosis 79
SAHA 79
ERAD 79
deficits. 79
DITPA 79
A1c 79
sulfonylurea 79
fixation 79
naïve 79
repressors 79
Nucleotide 79
tablets 79
subcortical 79
26S 79
persists 79
insoluble 79
new, 79
OF 79
cyclosporin 79
CML. 79
IL-17A 79
pallidal 79
V600E 79
vasospasm, 79
Cyk3 79
retrotransposition. 79
PTHrP 79
Ficolin-3 79
VE 79
veins 79
stridor 79
GALC 79
presenteeism 79
interdigital 79
Ebola 79
NSD-1015 79
OC 78
3.6 78
EMBASE 78
interventional 78
biomarkers, 78
hypothetical 78
induction, 78
face, 78
sinusoidal 78
sharing 78
(IQR 78
BID 78
thymidine 78
suboptimal 78
retain 78
voltage 78
triphosphate 78
drinking 78
Biol. 78
coordinately 78
masked 78
prognosis, 78
pharmacotherapy 78
carcinogenesis, 78
folate 78
2). 78
services 78
lipid-lowering 78
(PCSK9) 78
Antibodies 78
HepG2 78
radioactivity 78
BRAF(V600E) 78
regression. 78
prediction. 78
21% 78
Cancer. 78
sleep, 78
age- 78
daughter 78
81% 78
CMA 78
cargo 78
grow 78
Rights 78
Reserved. 78
Karnofsky 78
headache. 78
EAE 78
transcription-polymerase 78
globin 78
alongside 78
Motor 78
1st 78
BACKGROUND 78
Ashkenazi 78
UTR 78
option. 78
leaf 78
droplets 78
0.01, 78
CGI 78
ischemia/reperfusion 78
MDA-MB-231 78
cancer-specific 78
ubiquitylation 78
ST 78
hippocampus. 78
suicidal 78
transported 78
Myc 78
TAZ 78
registry 78
ED 78
NRT 78
ESCC 78
parkin 78
Bcr-Abl 78
answers 78
(WS) 78
proangiogenic 78
anti-IL-5 78
Skeletal 78
infectivity 78
H3K27ac 78
dyskinesia 78
lymphedema 78
Tsix 78
bullosa 78
CDI 78
BWT 78
TREAT-NMD 78
Vedolizumab 78
ATRX 78
iodonium 78
EPAS1 78
elucidation 77
bronchial 77
αvβ3 77
inhibitor) 77
morbidity. 77
Factors 77
treated. 77
transduction. 77
.001) 77
5.5 77
day, 77
unaffected. 77
suited 77
positivity 77
Involvement 77
amplification. 77
dispersed 77
are, 77
computationally 77
building 77
laboratories 77
filaments. 77
6) 77
parkinsonism. 77
Apart 77
Facioscapulohumeral 77
both. 77
isoproterenol 77
antibiotics, 77
qualitatively 77
K+ 77
transporters. 77
IL-1beta 77
Developmental 77
IL-1 77
remission. 77
TGFβ 77
TGFbeta 77
Conventional 77
delay. 77
lipoproteins 77
Homozygous 77
67% 77
Formation 77
lie 77
PURPOSE: 77
partners. 77
law 77
Arg 77
rodents 77
assembly, 77
IκB 77
signalling. 77
recommendation 77
endocytic 77
dermatitis. 77
directs 77
28-day 77
102 77
coordinating 77
platelet-derived 77
RASFs 77
Inventory 77
mTORC2 77
patent 77
KP4 77
ESC 77
two-step 77
corepressor 77
archaeal 77
units. 77
SMN1 77
number. 77
reperfusion. 77
opportunistic 77
southern 77
nicotinic 77
consequences. 77
escalation 77
alcoholic 77
nurses 77
ospemifene 77
4.5 77
BCR 77
bruxism 77
SCN1A 77
HOT 77
Nod2 77
LRES 77
CUT 77
imperfecta 77
TCGA 77
[The 76
Biological 76
conditioned 76
electrostatic 76
attached 76
PBMC 76
III. 76
2-fold 76
Foundation 76
0.6 76
other, 76
closer 76
obligate 76
administered. 76
dividing 76
antigen. 76
Imaging 76
efficiency. 76
Successful 76
grades 76
Consortium 76
cytotoxicity. 76
iPSC 76
opposing 76
teams 76
accessed 76
predefined 76
repolarization 76
coactivator 76
expands 76
0.8 76
hydrophilic 76
Autism 76
eating 76
arteries. 76
AP-1 76
phosphoinositide 76
trypsin 76
43% 76
sparse 76
illness. 76
Sixty 76
ratings 76
(up 76
p21 76
clinics 76
29% 76
promotion 76
neuroma 76
ascertained 76
multicellular 76
reversion 76
Immunohistochemistry 76
etoposide 76
neurofilament 76
Nonetheless, 76
persist 76
seen. 76
deeper 76
inconsistent 76
preimplantation 76
polymerase, 76
memory. 76
antenatal 76
vulvar 76
eosinophilia 76
bones 76
colocalized 76
radiologic 76
rigorous 76
densely 76
architectures 76
CREB 76
angle 76
hoc 76
perinuclear 76
dosages 76
Pathological 76
lies 76
evaluated, 76
(iv) 76
titers 76
interval. 76
tick-borne 76
Topical 76
investigation, 76
compartments. 76
urgently 76
33% 76
Yeast 76
resections 76
p53-MDM2 76
multidrug-resistant 76
Local 76
operated 76
Parkin 76
Disorder 76
breakthrough 76
Contrary 76
America. 76
DS 76
Castleman's 76
LEKTI 76
ziconotide 76
GINS 76
hypothermia 76
OAB 76
PP1 76
incontinentia 76
(ALK) 76
ATF4 76
carboxymaltose 76
Oculocutaneous 76
diabeticorum 76
MELD 76
forms. 75
3.1 75
housekeeping 75
Next, 75
89 75
satisfactory 75
2-3 75
acid) 75
(four 75
inward 75
Possible 75
embryonal 75
tryptic 75
community. 75
serving 75
supply 75
Inheritance 75
(SERCA2a) 75
Application 75
detection, 75
guinea 75
loops. 75
analgesic 75
accumulation, 75
Nrf2 75
tangles 75
kidney. 75
meal 75
patient-reported 75
registries 75
stiffness 75
4-week 75
placebo) 75
96% 75
methionine 75
scattered 75
origins, 75
E, 75
degron 75
births 75
Runx2 75
Apoptosis 75
(AS) 75
prevention. 75
high-quality 75
partitioning 75
retaining 75
Pseudomonas 75
early-stage 75
TKI 75
RCC 75
nephropathy 75
eligibility 75
ancestor 75
sativa 75
AM 75
selenoproteins 75
ALS, 75
Science 75
sibling 75
taxonomic 75
(CaMKII) 75
disease-related 75
nM) 75
bridge 75
century 75
Associations 75
MIM 75
97 75
neutralize 75
reports. 75
I/R 75
shuttle 75
elucidating 75
insufficiency. 75
incurable 75
high-level 75
dissect 75
alpha1 75
reabsorption 75
coexpression 75
ensuring 75
gains 75
power-law-like 75
TNFα 75
hemodialysis 75
foreign 75
GCS 75
Essential 75
islands, 75
complement-dependent 75
solanezumab 75
IL-12 75
avian 75
7SL 75
mug 75
(vitamin 75
knife 75
alisertib 75
Allan-Herndon-Dudley 75
DIPG 75
MED12 75
heparin 74
contemporary 74
22% 74
signals, 74
73 74
Dysregulation 74
scenarios 74
osteoporosis, 74
billion 74
hypothesis. 74
105 74
TRUNCATED 74
WORDS) 74
(grade 74
selective, 74
prostatic 74
orthotopic 74
corresponded 74
Efficient 74
lineage-specific 74
shotgun 74
Normal 74
substrate, 74
ANG 74
arranged 74
4.0 74
Kinase 74
Inflammation 74
turned 74
besides 74
died. 74
surface, 74
BMJ 74
thrombolysis 74
elite 74
consent 74
website 74
biased 74
extant 74
98% 74
geographical 74
Pharmaceuticals 74
harbouring 74
paradox 74
perturbed 74
V, 74
points, 74
Lys 74
modifies 74
oligomer 74
44% 74
deafness. 74
guideline 74
trafficking, 74
B2 74
nodules 74
expressed. 74
ZEB1 74
occupies 74
bimolecular 74
apparatus 74
relieve 74
background. 74
trapping 74
melanogaster. 74
delineated 74
fusion. 74
(SNP) 74
segregated 74
lipids, 74
pharmacokinetics. 74
old, 74
Failure 74
chart 74
sensation 74
runs 74
lectin 74
programmes 74
Rivaroxaban 74
low-risk 74
Illumina 74
hosts 74
antibody-dependent 74
GM1 74
erythropoietin 74
remission, 74
universally 74
disease). 74
task. 74
muscle-specific 74
domestic 74
p40 74
DENV 74
Wernicke 74
BTBR 74
DOT1L 74
IRG1 74
phones 74
flecainide 74
(MC1R) 74
spp. 74
varespladib 74
MetS 74
urodynamic 74
arbitrary 74
NfL 74
(CCSVI) 74
Macitentan 74
K.448 74
bath 74
RNA-RNA 74
adhesin 74
CA-MRSA 74
OCA1 74
Ohdo 74
female, 73
lineages, 73
polymorphism, 73
stroma 73
μM 73
Brucella 73
log-rank 73
monotherapy. 73
decisions. 73
3-year 73
probabilistic 73
cohorts. 73
64% 73
thick 73
dermatological 73
infect 73
solubility 73
combination. 73
(13 73
That 73
colonies 73
transform 73
helping 73
proteomes 73
software, 73
built 73
mutations: 73
ACE 73
Special 73
sources. 73
subtypes, 73
Modulation 73
anchoring 73
Canadian 73
guidelines. 73
(JNK) 73
existed 73
WILEY-VCH 73
108 73
thrombocytopenic 73
slices 73
menstrual 73
evaluates 73
premenopausal 73
cognitive-behavioral 73
mild-to-moderate 73
(P<0.001 73
T-UCRs 73
manageable 73
primordial 73
fingers 73
actomyosin 73
smoking. 73
Eastern 73
penetration 73
IKK 73
exceptionally 73
Met 73
pre-treatment 73
illness, 73
paralleled 73
Craniosynostosis 73
sodium-glucose 73
subgroups. 73
monitoring. 73
EC 73
dystrophic 73
coexisting 73
thrombosis. 73
heterodimeric 73
glycosylated 73
octreotide 73
thyrotoxicosis 73
entacapone 73
KN-93 73
foramen 73
conscious 73
slowed 73
acuity 73
visible 73
DH 73
binary 73
retrotransposons 73
nucleolus 73
transporter, 73
LRRK2 73
sclerosis: 73
plakoglobin 73
diet, 73
aminotransferase 73
sparing 73
porcine 73
prothrombin 73
carriers, 73
B-type 73
preexisting 73
pigs 73
admission, 73
snRNA 73
leakage 73
sheep 73
drainage 73
anesthetic 73
proteasome. 73
palatal 73
quantity 73
anti 73
continuum 73
India. 73
cataracts 73
ROCKET 73
interfaces 73
16S 73
disorder: 73
electrocardiographic 73
adenocarcinoma. 73
angiogenin 73
NHE6 73
ulcers 73
CSL 73
PTC 73
oxaliplatin 73
centrosome 73
A3 73
Gliadel 73
macitentan, 73
stiff-man 73
protein-losing 73
pharmacogenetic 72
engagement 72
paracrine 72
proline 72
Thirty 72
Does 72
concentration-time 72
Out 72
sensitize 72
platinum-based 72
Multivariate 72
specimens. 72
disappeared 72
individualized 72
Immune 72
2008. 72
syntenic 72
classification. 72
unbalanced 72
tolerable 72
Program 72
organize 72
platforms 72
build 72
formalin-fixed 72
correlating 72
54% 72
weight. 72
now, 72
association, 72
(FSHD) 72
compromise 72
duodenal 72
(MM) 72
attenuating 72
possessed 72
gaining 72
2.6 72
endurance 72
RhoA 72
Blockade 72
long, 72
(defined 72
colon, 72
only, 72
methodologies 72
tone 72
insensitive 72
dose-escalation 72
bona 72
fide 72
smoking, 72
necrotic 72
pass 72
radiation-induced 72
propagation 72
carcinomas, 72
fibrocytes 72
Then, 72
TFBS 72
non-redundant 72
phosphoprotein 72
MEDLINE, 72
microg 72
ng/mL 72
investigates 72
fragments. 72
counselling 72
arrhythmia, 72
learned 72
10) 72
Insulin 72
relapse-free 72
zolpidem 72
papers 72
nucleosome-free 72
alleviated 72
(PARP) 72
nucleosomes, 72
whilst 72
cristae 72
PLN-R14Del 72
analysed. 72
checkpoint. 72
trabecular 72
And 72
viability. 72
chronic, 72
palindromic 72
kilogram 72
noncanonical 72
COPD 72
78% 72
1b 72
pegylated 72
antigens, 72
non-smokers 72
knock-in 72
spinocerebellar 72
decapping 72
unwanted 72
deltaEF1 72
Gulf 72
nimodipine 72
CPVT. 72
Netherton 72
alpha-NAGA 72
pravastatin 72
molindone 72
elbow 72
DOPA 72
Stupp 72
CHS 72
noncompaction 72
FCGR2A 72
PBC 72
I-1 72
KCNQ3 72
RADT 72
Down's 71
zero 71
embryogenesis 71
unexpectedly 71
IV, 71
qRT-PCR 71
hormone, 71
D, 71
fit 71
middle-aged 71
[HR] 71
possibilities 71
convert 71
instrumental 71
disease-specific 71
28% 71
Project 71
proteins: 71
23% 71
repository 71
horizontal 71
cascades 71
nigra 71
network, 71
course, 71
index. 71
quaternary 71
IL-8, 71
implant 71
radiation, 71
ultimate 71
exaggerated 71
Hemolytic 71
Neonatal 71
laparoscopic 71
nociceptive 71
convergent 71
items 71
3.2 71
mutation-positive 71
ester 71
Sonic 71
interstrand 71
familiar 71
cell-derived 71
Australia. 71
supernumerary 71
packaging 71
gestation. 71
epithelium. 71
Imetelstat 71
feet 71
parietal 71
aqueduct 71
Brazilian 71
Urinary 71
medium, 71
ichthyosis 71
similar. 71
lysosomes. 71
integrity, 71
isolates. 71
microorganisms 71
levothyroxine 71
rash, 71
intervals. 71
vulnerability 71
states, 71
CTCF-cohesin 71
cooperatively 71
Animal 71
HSP 71
SMN2 71
hemizygous 71
sequelae 71
Recombinant 71
zinc-finger 71
transporters, 71
circle 71
BPD 71
debate 71
classes. 71
files. 71
iris 71
Modified 71
HDACs 71
aspartyl 71
humoral 71
bud 71
OP 71
Rheumatology 71
Cilengitide 71
hypereosinophilic 71
midazolam 71
oculomotor 71
SRY 71
T-ALL 71
zyxin 71
ZIKV 71
p100 71
SnoN 71
NDRG1 71
dynein-2 71
ALK-positive 71
gastroduodenal 71
DF 71
Schimke 71
King-Kopetzky 71
cell-specific 70
antagonizes 70
IV. 70
layers 70
ENCODE 70
dose-dependently 70
Not 70
axis. 70
difference, 70
Ongoing 70
off-label 70
progressing 70
4.6 70
87% 70
opens 70
governing 70
adenocarcinomas 70
antineoplastic 70
competent 70
in-depth 70
clamp 70
conductance 70
Science. 70
recessively 70
kind 70
Ca(2+)-binding 70
predictable 70
metabolites, 70
shock. 70
bundles 70
infusion, 70
opposed 70
Restoration 70
decreased, 70
rheumatic 70
Third, 70
Blocking 70
Finnish 70
counterparts. 70
undertook 70
· 70
endosomes 70
permission 70
mood, 70
Ovarian 70
team 70
Findings 70
dimension 70
oestrogen 70
differences. 70
relapses 70
conformation. 70
FIPA 70
hydrocarbon 70
destabilizes 70
Cooperative 70
overcoming 70
COX-2 70
count, 70
twelve 70
mg/kg/day 70
nonsyndromic 70
(FGFR3) 70
utero 70
Zealand 70
homozygotes 70
underscore 70
carboplatin 70
8-week 70
42% 70
change. 70
(PD). 70
(RR) 70
BDNF 70
embryo. 70
article. 70
opinion 70
ribosomes 70
mannose 70
6-phosphate 70
microM, 70
vildagliptin 70
uptake, 70
Dynamic 70
T3, 70
aneurysms 70
Apixaban 70
∼ 70
unusually 70
databases, 70
sarcolipin 70
Seventeen 70
Inflammatory 70
SERCA2 70
1500 70
circuit 70
SNX27 70
Willebrand 70
Oxidative 70
polymorphisms, 70
HbVar 70
bundling 70
appearing 70
NRAS 70
α-syn 70
overdose. 70
dysplasia. 70
arrhythmic 70
GRBs 70
transporting 70
fostamatinib 70
p21WAF1 70
colour 70
Mug 70
pigmenti 70
CPU 70
marijuana 70
SLC38A9 70
Alteplase 70
stationary-phase 70
NELF 70
lomustine 70
pictilisib 70
GA-sequences 70
BBCAnalyzer 70
74 69
protrusions 69
catalog 69
important. 69
(mRNA) 69
Mechanisms 69
generation, 69
2007, 69
gaps 69
PC 69
ligand, 69
Canada 69
verapamil 69
Na+ 69
portal 69
potent, 69
aging, 69
therapy: 69
constipation 69
treatment; 69
render 69
disappearance 69
IHC 69
PC-3 69
adopt 69
(three 69
viewed 69
antagonize 69
overexpression. 69
whole-exome 69
schizophrenia, 69
Less 69
week. 69
dysphoric 69
exceeded 69
recommendations. 69
Foundation. 69
hypercholesterolemia 69
randomisation 69
cholesterol. 69
snoRNA 69
sugar 69
ATR 69
(HCM) 69
mTOR, 69
c-Src 69
pre-existing 69
affected, 69
NKX2.1 69
subunit. 69
breaks. 69
monotherapy, 69
VA 69
fragmentation, 69
vorinostat 69
Cohesin 69
hotspots 69
coincided 69
immunogenic 69
triphosphatase 69
cytosol, 69
metabolically 69
sialic 69
medications. 69
pathologically 69
occupy 69
sets, 69
uncertainty 69
ependymomas 69
medulloblastomas 69
pathologies. 69
carboxylase 69
93% 69
rhythmic 69
DMD. 69
Patau 69
tracks 69
Model 69
Fibroblast 69
amniocentesis 69
situs 69
flushing 69
Sec 69
hydrocephalus. 69
HCNE 69
nickel 69
viroids 69
isochore 69
interneurons 69
tocilizumab 69
G3BP1 69
phototoxic 69
Heyde 69
H2A.W 69
Pta1 69
immuno-osseous 69
strep 69
halys 69
counseling. 68
Certain 68
spliceosome 68
tends 68
lysates 68
Library 68
CRPC 68
Up 68
pharmacodynamics, 68
38% 68
tumorigenic 68
transgenes 68
foundation 68
sound 68
Standard 68
synapse 68
transcriptome. 68
Spectrum 68
contractility, 68
HF. 68
kept 68
marks. 68
transients 68
polar 68
environments 68
24-hour 68
cytometry. 68
constituent 68
Network 68
downregulate 68
cleaving 68
biotinylated 68
signature. 68
Intensive 68
EB 68
catecholamines 68
signal. 68
refers 68
12. 68
made. 68
modestly 68
enormous 68
appearance, 68
percentages 68
Part 68
staff 68
53% 68
Mechanism 68
elastic 68
116 68
H3K9me2 68
antiparallel 68
microarrays 68
mg/m(2), 68
ischemia-reperfusion 68
MLPA 68
vesicles. 68
spatiotemporal 68
homeostatic 68
clonogenic 68
shortness 68
component. 68
recall 68
Daily 68
genotype. 68
hypoxia. 68
first, 68
orders 68
PubMed, 68
parallel, 68
thickening 68
disequilibrium 68
atomic 68
hyperactive 68
trap 68
Absence 68
surveyed 68
reside 68
Lack 68
T2DM 68
co-immunoprecipitation 68
PD, 68
M1 68
spacing 68
chromodomains 68
gallbladder 68
synthesizing 68
gland, 68
disposition 68
dynamin-related 68
imported 68
assign 68
GTP 68
Regarding 68
wherein 68
glycine 68
cardioprotective 68
implants 68
disassembly 68
permits 68
Maintenance 68
tachycardia. 68
eyes, 68
pulse 68
analgesia 68
Bilateral 68
high. 68
sent 68
3T3-L1 68
XX 68
cofactors 68
NS3 68
WNV 68
metabolites. 68
Effectiveness 68
anaesthesia 68
iodothyronine 68
sleep. 68
League 68
LSD1-kd 68
Gfi1 68
(MTHFR) 68
biofilm 68
scavenger 68
Creutzfeldt-Jakob 68
ChR2 68
DMRs 68
GDM 68
BD 68
PP2A 68
Sjögren's 68
lacritin 68
subsurface 68
CD55 68
LDLR 68
PCDH10 68
FtsZ 68
plasmepsins 68
methylenetetrahydrofolate 68
CCA 67
factor-α 67
invasiveness 67
morphogenesis. 67
1.4 67
pertinent 67
professional 67
afterdepolarizations 67
subdivided 67
Classification 67
identifiable 67
morphology. 67
centrally 67
(40 67
Company 67
HR, 67
reprogrammed 67
basis. 67
regards 67
Ontology 67
BP 67
blind 67
flies 67
telangiectasia 67
Barthel 67
Impaired 67
unchanged. 67
lumenal 67
LC-MS/MS 67
contractility. 67
Intestinal 67
immunity, 67
dysfunctions 67
skills 67
factor-alpha 67
light. 67
avenues 67
candidates. 67
LOX 67
sarcoma, 67
cleave 67
genetic, 67
courses 67
factor-beta 67
Headache 67
issues. 67
implications. 67
h) 67
2.2 67
ezetimibe 67
preserve 67
thymine 67
absorbed 67
keeping 67
Arabidopsis. 67
concerted 67
relationship. 67
prematurely 67
targeting. 67
nanoparticles 67
cAMP-dependent 67
prostaglandin 67
merits 67
T2 67
adulthood. 67
urogenital 67
predisposed 67
digested 67
Furthermore 67
recruited. 67
prodrug 67
redistribution 67
neutropenia. 67
Time 67
variable, 67
metabolized 67
99 67
species-specific 67
compaction 67
Adults 67
Accumulating 67
utilizes 67
Function 67
prokaryotes 67
Tarlov 67
treatment-emergent 67
botulism 67
DNMT 67
Th2 67
presenilin 67
b 67
homogeneity 67
Male 67
(total 67
PLN, 67
non-synonymous 67
downregulates 67
indexing 67
autoinflammatory 67
prevalence, 67
solve 67
detachment 67
renders 67
amiloride 67
excitation 67
occipital 67
uncoupling 67
Physiological 67
db/db 67
fluids 67
discovery, 67
verbal 67
scheduled 67
algorithm. 67
TNFalpha 67
achondroplasia 67
educational 67
SCLC 67
breathing 67
Turkish 67
AU-rich 67
KIT 67
(14 67
pregnancies. 67
DEX 67
GATA1 67
erythropoiesis. 67
anhedonia 67
insomnia, 67
pheochromocytomas 67
QTc 67
Moebius 67
TMBs 67
2016, 67
apoE4 67
falciform 67
lentis. 67
enlimomab 67
0.9 66
tip 66
guiding 66
elicits 66
Sprague-Dawley 66
depended 66
comparison. 66
ameliorating 66
inclusion. 66
minimize 66
needle 66
Medicines 66
Agency 66
92% 66
Report 66
perturbation 66
dose- 66
staining, 66
internalization 66
division, 66
visualized 66
coverage. 66
astrocytes. 66
deposition. 66
sessions 66
Promoter 66
bioremediation 66
N-terminus 66
ileal 66
106 66
reserved 66
exist. 66
perturbations 66
inactivation, 66
upregulate 66
stopping 66
pneumoniae 66
girls 66
absolutely 66
licence) 66
comorbidities 66
10,000 66
Investigation 66
(primary 66
UCE 66
NBS1 66
fragility 66
terminator 66
leaving 66
subpopulation 66
predominance 66
calcium-binding 66
auricular 66
successive 66
vaccination. 66
translocated 66
fibrils 66
spectrum. 66
thyroglobulin 66
frequent, 66
continuing 66
polymorphism. 66
aplasia 66
carboxy-terminal 66
Deficiency 66
septum 66
gene: 66
glucose-lowering 66
months), 66
Recurrence 66
Sensitivity 66
affective 66
(RCTs) 66
H3K9me3 66
adaptations 66
infarcts 66
dead 66
biopsies. 66
cytogenetics 66
migrating 66
sacral 66
trough 66
formulations 66
consciousness. 66
Natural 66
hypoplastic 66
tryptophan 66
Consistently, 66
HPL-2 66
Downregulation 66
hamartoma 66
compartmentalization 66
hotspot 66
(CRP) 66
exist, 66
Rats 66
noninferior 66
Next 66
hydrocephalus, 66
cyclase 66
ms 66
forks. 66
approval. 66
mycobacterial 66
pericarditis 66
Hospital, 66
Lastly, 66
check 66
cortactin 66
titin 66
ruled 66
FOUR 66
callosum, 66
purifying 66
cytokinesis. 66
Variant 66
83% 66
postoperatively. 66
CONCLUSIONS 66
implements 66
19% 66
Li-Fraumeni 66
intraepithelial 66
encephalopathy. 66
RBC 66
CBT 66
T3R 66
ILK 66
volatile 66
optogenetics 66
RhD 66
Bloom 66
NOD2 66
anti-CCP 66
palpebrarum 66
fractal 66
U(VI) 66
DENdb 66
DECKO 66
palivizumab 66
TIRR 66
Tibetans 66
RET, 65
carboxyl 65
potentiate 65
manually 65
Exogenous 65
calcified 65
inducer 65
multinucleated 65
discriminating 65
Twenty-one 65
Respiratory 65
experience, 65
Improvement 65
State 65
regimens. 65
monitoring, 65
product, 65
man. 65
haemodynamic 65
contrary, 65
unaltered 65
days). 65
C-terminus 65
oncology 65
antitumour 65
PB 65
sickle 65
modular 65
(CRC) 65
moving 65
(25%) 65
location. 65
acrocentric 65
gating 65
ivabradine 65
or, 65
worsened 65
0.03) 65
offering 65
preserving 65
globus 65
trans-acting 65
detected, 65
extremity 65
(RyR2) 65
71% 65
Utilizing 65
options, 65
Multiplex 65
to, 65
EWS/FLI1 65
deemed 65
tumor-specific 65
Committee 65
well, 65
proteasome, 65
Endovascular 65
recognizing 65
favorably 65
(either 65
hydroxyurea 65
RNA-DNA 65
apo 65
distantly 65
intention 65
group; 65
EMT, 65
(siRNA) 65
ICU 65
nuclei, 65
Inactivation 65
naive 65
C) 65
RT-PCR. 65
immunoreactive 65
cause. 65
MRI. 65
side-effects 65
engaged 65
cues 65
diary 65
Coronary 65
ABCB1 65
high, 65
applications, 65
tremendous 65
dose-response 65
aspiration 65
Ig 65
temperatures 65
crystals 65
electrophoresis. 65
86 65
Transforming 65
41% 65
attributes 65
genes: 65
endothelium 65
technological 65
monomers 65
(ECM) 65
oil 65
assembles 65
HMG 65
assemblies 65
drop 65
NF-kappa 65
droplet 65
erythrocytes. 65
amplitudes 65
anti-Neu5Gc 65
Reversal 65
Interactions 65
blotting, 65
Ca-ATPase 65
altered. 65
Silver 65
organellar 65
lose 65
YAP 65
TA 65
diagnostics, 65
P-body 65
pharmacy 65
centronuclear 65
decision-making 65
(RLS), 65
PASI 65
communities 65
palmar 65
thalamus, 65
carbonic 65
megakaryocytic 65
Subacute 65
Suvorexant 65
MEF2 65
NGS 65
pemetrexed 65
L-dopa 65
dabigatran. 65
Per3 65
ARISTOTLE 65
betrixaban 65
Hydrocephalus 65
ACPA 65
Muller's 65
Nox5 65
rickets, 65
S1P 65
AdoMet 65
Pridopidine 65
spectrin 65
620W 65
vivax 65
selumetinib 65
NOX 65
petechiae 65
fimA 65
vanoxerine 65
Dinutuximab 65
Upc2p 65
Morgellons 65
amniotic 64
Dominant 64
previously, 64
converting 64
glutamic 64
EOC 64
serum, 64
avoidance 64
alternatives 64
cases) 64
rectifier 64
clearance. 64
clearance, 64
degeneration, 64
(median, 64
geometric 64
indications, 64
reprogramming. 64
misdiagnosed 64
benefits. 64
organizing 64
conformations 64
abrogates 64
consequence, 64
significant, 64
y 64
elongation, 64
elsewhere 64
mutagenesis, 64
hr 64
Crystal 64
devices 64
fibrillation, 64
fibres 64
kidneys 64
antagonized 64
TLR4 64
Proteasome 64
meningiomas. 64
elderly. 64
etc. 64
of, 64
TTP 64
Thieme 64
0.002) 64
perceptions 64
explanations 64
asymptomatic, 64
3-month 64
noncancerous 64
clinicopathologic 64
entity. 64
G9a 64
immunologic 64
Previously 64
Signaling 64
gonadotropin 64
abstracts 64
thyroid, 64
caudate 64
temperature, 64
numbers, 64
steroids 64
letrozole 64
cohorts, 64
attention. 64
occupational 64
Free 64
capacity, 64
cluster. 64
draw 64
message 64
straightforward 64
missed 64
thaliana. 64
Insights 64
quick 64
nonsense-mediated 64
eliminates 64
hitherto 64
stretches 64
non-selective 64
neuropathies 64
overcomes 64
symmetric 64
KRIT1 64
ages. 64
sitagliptin 64
Vascular 64
deleting 64
course. 64
Partial 64
minichromosomes 64
solved 64
engage 64
remainder 64
neurotoxic 64
license. 64
supplements 64
namely, 64
PDCD4 64
Animals 64
Lower 64
co-localization 64
detoxification 64
euchromatin 64
phylogenomic 64
conserved. 64
extrinsic 64
repaired 64
Cystic 64
match 64
two-thirds 64
DM 64
vasomotor 64
(PET) 64
nonvalvular 64
govern 64
thalassemia 64
DMD, 64
Graves' 64
tibial 64
UK. 64
RP 64
dimethylation 64
antirheumatic 64
RTT 64
HSCs 64
rabies 64
India 64
Costello 64
miR-223 64
aneuploidies 64
ratchet 64
RUNX3 64
virologic 64
BMPR1A 64
histatin 64
BACE1 64
pro-hepcidin 64
PIM2 64
molluscum 64
DST1 64
journals.permissions@oup.com 64
marginally 63
hypomorphic 63
chains. 63
osteoarthritis 63
10-fold 63
metformin, 63
miR-203 63
diurnal 63
FDA-approved 63
embryos, 63
carcinogenic 63
Cardiology 63
I) 63
synovium 63
(ie, 63
pancreatitis 63
radiolabeled 63
independence 63
contrary 63
average, 63
Induced 63
product. 63
collagen, 63
challenging. 63
loop. 63
Medline 63
prospects 63
Meanwhile, 63
destabilization 63
infusion. 63
GH 63
hormone. 63
dynein 63
outpatients 63
non-Hodgkin's 63
T, 63
47% 63
Clinically, 63
T-UCR 63
suicide 63
MIC2 63
arrhythmogenesis 63
(TFs) 63
9. 63
Snail 63
significantly. 63
Pregnancy 63
107 63
activator, 63
pruritus 63
patches 63
CMV 63
canagliflozin 63
implantation. 63
centre 63
distinguishes 63
outflow 63
Polymorphisms 63
fragments, 63
reserve 63
hippocampus, 63
VI 63
fibers, 63
densities 63
traps 63
cleaves 63
degrading 63
intoxication 63
Fisher's 63
neurotransmission 63
HDAC1 63
topic 63
invading 63
mild, 63
(MDS) 63
p62 63
descriptive 63
arteritis 63
connections 63
ROCK 63
postulate 63
U12-dependent 63
ones. 63
larval 63
displacement 63
bases, 63
parents. 63
BMAL1 63
epsilon 63
Zn 63
diving 63
character 63
ectasia 63
beta-amyloid 63
ASD. 63
Ultrasound 63
FGF 63
Shprintzen-Goldberg 63
NS5 63
Bickerstaff's 63
piRNA-mediated 63
8-oxo-dGTP 63
NadA 63
scurvy 63
Rucaparib 63
Septins 63
Molluscum 63
Mis16 63
inbred 62
Ret 62
irinotecan 62
fundamentally 62
(AMPK) 62
platform. 62
variation. 62
destruction. 62
redundant 62
androgens 62
(HD) 62
cycles, 62
amplification, 62
CD34(+) 62
69% 62
space. 62
ascertain 62
73% 62
medication, 62
mo 62
Republic 62
atrophic 62
urine. 62
proceeds 62
Plant 62
aspartate 62
attracted 62
phosphorylate 62
vimentin 62
talk 62
topiramate 62
Enhanced 62
accelerates 62
patency 62
irritable 62
comorbidity 62
provision 62
Danish 62
treat. 62
trees 62
Statistically 62
industry 62
homeodomain 62
mutagenesis. 62
sarcomere 62
replacement. 62
ear, 62
[A 62
rate-limiting 62
F-box 62
ensures 62
vaccine, 62
chorea 62
favour 62
MCF7 62
Cytogenetic 62
alpha- 62
Saethre-Chotzen 62
CKD 62
scaffolding 62
Regression 62
extremities 62
CTCF. 62
P2 62
exceeding 62
viruses. 62
thymus 62
HEK-293 62
Nerve 62
signs. 62
sterile 62
negligible 62
comparator 62
pyruvate 62
stroke: 62
emerge 62
cattle 62
Rb 62
scope 62
Genomicus 62
annualized 62
TGF-β1 62
Bacterial 62
HA 62
thermogenesis 62
ciRS-7 62
ascorbic 62
regulated. 62
dioxide 62
temperature. 62
addressed. 62
recombination, 62
architectural 62
SPRY 62
particles. 62
CTF18 62
circulation. 62
types: 62
LOD 62
Nucleosome 62
Germany, 62
actinic 62
SV40 62
VEGF-A 62
scattering 62
AADC 62
Cyclin 62
suprachiasmatic 62
Whole 62
mating 62
hair. 62
IDH1 62
tumoral 62
enalapril 62
epilepticus 62
ependymal 62
hemorrhage: 62
propionyl-CoA 62
p105 62
Tregs 62
postpartum 62
Chediak-Higashi 62
epidermolysis 62
hyperbilirubinemia, 62
(FBN1) 62
hemangioma 62
INSURE 62
Tpl2 62
ACVR1 62
pseudomallei, 62
Q-tip 62
aganglionosis 61
protection. 61
abortus 61
microRNA-21 61
neoplasm 61
SCC 61
109 61
CADASIL 61
ligase, 61
commitment 61
group), 61
©2014 61
TUNEL 61
pairs, 61
Antibody 61
24-h 61
rat, 61
unravel 61
bp, 61
hnRNP 61
shoulder 61
age-dependent 61
ionization 61
IL-8 61
hence, 61
behave 61
rendered 61
PP 61
Phenotypic 61
HDL 61
coming 61
(38%) 61
profiling, 61
Highly 61
CRC. 61
robustly 61
20, 61
expansions 61
Friedreich 61
HCM. 61
Main 61
tried 61
bivalent 61
suite 61
maintenance. 61
constituted 61
neuraminidase 61
C6 61
Proteomic 61
ADP 61
augments 61
here. 61
poor. 61
lasted 61
affinity, 61
RUNX1 61
organizer 61
CBP 61
Biologists 61
may, 61
RBPs 61
test). 61
prion-like 61
catechol-O-methyltransferase 61
hydrolases 61
concert 61
importance. 61
Children's 61
composition. 61
retrograde 61
plasticity. 61
(TH) 61
pole 61
trauma. 61
MMP 61
outbreaks 61
teeth 61
senescence-associated 61
mating-type 61
upregulates 61
early, 61
glutamatergic 61
images. 61
PTMs 61
ancestry 61
Fanconi's 61
Ltd 61
strikingly 61
IgG1 61
yr 61
eviction 61
3.3 61
Intracellular 61
Dermatology 61
encounter 61
X-rays 61
pharmacology, 61
chondrocytes. 61
registration 61
London 61
challenge, 61
anomalous 61
HFE 61
licensing 61
Impression 61
puncture 61
ageing 61
(PD-1) 61
mutator 61
CMG 61
beta-1a 61
fibrillar 61
Very 61
sedative 61
multicomponent 61
divalent 61
melanocytes. 61
MALAT-1 61
ROC 61
exemplary 61
polyadenylated 61
spongiform 61
PTA 61
KRT5 61
DEND 61
thrombophilia 61
Nusinersen 61
Propranolol 61
Mis18α 61
MethPed 61
COL1A1 61
Sustain 61
Twenty-two 60
OS. 60
Owing 60
osteoclastogenesis 60
Obesity 60
tibia 60
combination, 60
temporary 60
cured 60
simultaneously. 60
dismutase 60
burden, 60
progressive, 60
≥3 60
3'UTR 60
cleared 60
companion 60
include: 60
Nineteen 60
recognized. 60
counteracts 60
66% 60
CCCTC-binding 60
0.25 60
+) 60
Validation 60
phospholipids 60
uric 60
simple, 60
histones. 60
Gastrointestinal 60
quantities 60
constriction 60
armamentarium 60
second, 60
GLP-1 60
24% 60
role, 60
conferring 60
catabolism 60
overlaps 60
cardiovascular, 60
backbone 60
subtype, 60
(-/-) 60
tracts 60
quit 60
SUMO-1 60
Xi 60
mitogenic 60
Hepatocyte 60
border 60
delivering 60
membrane-associated 60
nt 60
CSCs 60
eczema, 60
-2 60
difficult, 60
Sodium 60
(BM) 60
complemented 60
ATP-binding 60
filters 60
1990 60
mersacidin 60
(200 60
arthritis: 60
(GWAS) 60
euchromatic 60
begun 60
flux 60
amiodarone-induced 60
extremities. 60
8) 60
1: 60
novel. 60
eye, 60
FUS/TLS 60
favored 60
adenovirus 60
deficits, 60
CHF 60
investigations. 60
progenitors, 60
protein: 60
Ventricular 60
(P=0.001). 60
papillomavirus 60
documents 60
susceptibility, 60
p65 60
phenomenon, 60
0.7 60
VC 60
short-lived 60
splenic 60
H(2)O(2) 60
poly 60
parenteral 60
FA, 60
eleven 60
sepsis. 60
(3D) 60
Ctf4, 60
hamartin 60
Activating 60
sixth 60
code. 60
debilitating 60
depletion. 60
TCA 60
Hot 60
RLS/WED 60
(EDNRB) 60
host. 60
deadenylation 60
zoster 60
Ph 60
electrode 60
CN 60
REM 60
operations 60
CCR4 60
Fetal 60
epigenome 60
isolates, 60
Kanzaki 60
Across 60
SGLT-2 60
suspension 60
proteasomes 60
SNORD116 60
prolamellar 60
Polo-like 60
sPLA2 60
microsporidia 60
RTS,S/AS01 60
β-barrel 60
TMB 60
(OSA) 60
huntingtin 60
CYP17A1 60
heterotachy 60
listening 60
G3BP1, 60
Kell 60
Brca2(Delta27/Delta27) 60
ADAR 60
Ng 60
HS. 60
oculo(dermal) 60
CLAST 60
WGS 60
Uc.160+ 60
Influence 59
stem/progenitor 59
variably 59
pointing 59
favoring 59
210 59
Rather, 59
Metformin 59
biphasic 59
sorted 59
TaqMan 59
calculating 59
2:1 59
MG 59
abiraterone 59
accomplished 59
Rare 59
D1, 59
fraction. 59
2.9 59
efficient, 59
A1 59
c-Myc, 59
collect 59
adenoviral 59
dissociated 59
afferent 59
subfamilies 59
protocol, 59
background, 59
characterizes 59
50%, 59
sum 59
TGFβ1 59
constellation 59
questionnaire, 59
test-retest 59
contractures 59
statins. 59
37% 59
SC 59
counteract 59
unfolding 59
1B 59
68% 59
--> 59
pericentric 59
.05). 59
ligase. 59
broad-spectrum 59
knock-down 59
abrogation 59
(OR, 59
trans-Golgi 59
IL-13 59
refine 59
2007. 59
instance, 59
tarsal 59
way, 59
choice. 59
lysis 59
IgE 59
mm, 59
CYP2C19*2 59
diet-induced 59
bactericidal 59
encephalopathy, 59
(NER) 59
erosion 59
hierarchical 59
(9 59
quality, 59
haematological 59
(ChIP-seq) 59
M2 59
interactome 59
classifications 59
Alterations 59
MDM2, 59
bp) 59
Affected 59
Pretreatment 59
naltrexone 59
stool 59
articles, 59
clones, 59
clusters. 59
amplify 59
SCF 59
IGF2 59
downloaded 59
fungi. 59
LGE 59
intermembrane 59
burning 59
framework. 59
download 59
fibrillary 59
analysing 59
quercetin 59
Enzyme 59
editing. 59
FA. 59
(MM), 59
bladder. 59
antibacterial 59
excitability 59
eye. 59
Lu 59
0.005) 59
neutralization 59
bonds 59
P/Q-type 59
Leiden 59
mathematical 59
BMI-1 59
Mac1p 59
BDV 59
HPLC 59
transfusion 59
fishes 59
vasospasm. 59
subtotal 59
Kupffer 59
imiglucerase 59
Selenium 59
arteriovenous 59
preeclampsia 59
KCND3 59
Ser96Ala 59
DARA 59
alkyltransferase 59
doxorubicin-induced 59
MRI-guided 59
NOXO1 59
BED 59
ergosterol 59
iaa 59
fremanezumab 59
births. 58
incidence, 58
marks, 58
static 58
ascites 58
acetylcholinesterase 58
(18 58
counterparts 58
paraneoplastica 58
testes 58
declines 58
sensitizes 58
injection, 58
specific. 58
advanced, 58
Update 58
oncogenesis 58
hepatocytes. 58
proteomics. 58
appropriately 58
illustrated 58
introns. 58
cotranscriptional 58
position, 58
recruitment, 58
fell 58
helices 58
denervation 58
IL-1β, 58
(ERK) 58
isoform-specific 58
joining 58
harbors 58
knockdown. 58
Pharmacokinetic 58
mandatory 58
locomotor 58
infrared 58
significantly, 58
implementing 58
neurotransmitters 58
Female 58
2006, 58
functioning, 58
Are 58
circumference 58
intolerant 58
63% 58
replaces 58
stable, 58
resolving 58
sliding 58
Laser 58
XIST 58
Gemcitabine 58
Objective 58
couples 58
signal, 58
caregivers 58
designs 58
livers 58
dimensions 58
long-acting 58
goiter, 58
sulphate 58
interested 58
IFAP 58
epidermis 58
Genotyping 58
pharmacogenetics 58
ongoing. 58
times. 58
synoviocytes 58
specify 58
Fifty 58
viruses, 58
colitis, 58
employ 58
1A 58
radioiodine 58
(5%) 58
Medicine. 58
tachycardia, 58
dogs. 58
TE 58
flanked 58
sitagliptin, 58
134 58
falciparum. 58
SLE. 58
shaping 58
neurotoxin 58
coded 58
worldwide, 58
Hidden 58
phylogenetically 58
smallest 58
admission. 58
TFs, 58
meningeal 58
luteal 58
172 58
non-compaction 58
vacuole 58
islets 58
compartment, 58
20S 58
relieved 58
2008, 58
100,000 58
trials; 58
25(OH)D 58
QALY 58
retinoids 58
alpha-actin 58
querying 58
sensorimotor 58
regurgitation 58
Fibrillation 58
Zinc 58
Naxos 58
82% 58
islands. 58
necrosis, 58
Death 58
monoubiquitination 58
EpCAM 58
treatment-naïve 58
easy-to-use 58
unresectable 58
TD 58
SUMO1 58
paralogs 58
NS 58
co-administration 58
paralog 58
subscale 58
vasculitis, 58
NovoTTF 58
myogenesis 58
PRPS1 58
aliskiren 58
anthrax. 58
(HRC) 58
Nox 58
Oatp1a/1b 58
MINOS 58
imiglucerase. 58
albinism. 58
blistering 58
daratumumab, 58
Raxibacumab 58
PHEX 58
ossificans 58
FOP 58
heterochromia 58
PC7 58
SYNTAX 58
rilotumumab 58
aux 58
(HSCR), 57
initiated. 57
associations. 57
penetrance. 57
ascribed 57
over-expressed 57
sustain 57
value, 57
amine 57
Resistance 57
evidences 57
127 57
(p<0.001). 57
abolishes 57
unpublished 57
graded 57
supplemented 57
Men 57
segments. 57
overproduction 57
excretion. 57
hormones. 57
summarized. 57
(VEGF) 57
desirable 57
limited, 57
emulsion 57
agreed 57
Accurate 57
Sox2, 57
efficiency, 57
support. 57
quantifying 57
align 57
Ranolazine 57
tremor, 57
dissociates 57
Physicians 57
profoundly 57
anxiety. 57
gonadal 57
Comparisons 57
discharged 57
0.01 57
uterus 57
filling 57
before, 57
meta-analyses 57
Online 57
etiology, 57
interestingly, 57
CG 57
3/4 57
isogenic 57
aryl 57
glutamine 57
XY 57
hyperacetylation 57
histone-to-protamine 57
immunotherapies 57
week, 57
situations 57
multisubunit 57
compensated 57
adherent 57
β-cell 57
Initially, 57
disc 57
trunk 57
conference 57
(mTORC1) 57
decade. 57
MIC 57
G. 57
unselected 57
labelling 57
neuropathology 57
EBV 57
Nicotinamide 57
TERRA 57
ChIP-Seq 57
anatomic 57
compensation 57
codon. 57
paraspeckle 57
directing 57
issues, 57
rings 57
another. 57
amantadine 57
conservation, 57
condensed 57
silencing, 57
tethering 57
karyotyping 57
single-strand 57
en 57
task, 57
(CS) 57
(MIM 57
Monoamine 57
peroxidation 57
question, 57
Dyskeratosis 57
regression, 57
EU 57
INR 57
accompanies 57
kilobases 57
FMF 57
confirmatory 57
nonselective 57
cotransporter-2 57
SGLT1 57
(TCR) 57
introducing 57
NEDD8 57
recalcitrant 57
EAAC1 57
stain 57
LVEF 57
hemisphere 57
TTX 57
terminals 57
default 57
vector. 57
bystander 57
storing 57
splenomegaly 57
22. 57
Infantile 57
14-3-3 57
nonexonic 57
PU.1 57
h-index 57
(CF) 57
pallidus 57
IVF 57
anhydrase 57
sleep-wake 57
CP-690,550 57
amyloid-beta 57
Yersinia 57
phone 57
biotin 57
Digit 57
sedation. 57
ICP 57
hypokalemic 57
FGFR1 57
UPC2 57
endometriomas 57
Bartter's 57
OTULIN 57
CROP 57
graminearum 57
TUC.338 57
hyperviscosity 57
JACUSA 57
Finkelstein's 57
nifurtimox 57
Tibetans. 57
histamine 56
man, 56
Deep 56
identification. 56
Upregulation 56
Real-time 56
prednisolone 56
AChE 56
optimum 56
recognizable 56
ovarian, 56
Week 56
archival 56
specimens, 56
exploiting 56
suppression. 56
advantageous 56
zebrafish, 56
junctions. 56
shaped 56
occurs. 56
(standard 56
so, 56
facioscapulohumeral 56
macrosatellite 56
permissive 56
decades. 56
that: 56
receptor-mediated 56
descriptions 56
medicinal 56
cytometric 56
ubiquitination, 56
meningioma. 56
lysyl 56
show, 56
distinction 56
inactivate 56
meningitis. 56
insufficiency, 56
gene-specific 56
assesses 56
acceptability 56
acceptance 56
maximally 56
Unique 56
groups; 56
S-adenosylmethionine 56
alpha-helical 56
filaments, 56
withdrew 56
Greater 56
enigmatic. 56
vaccinated 56
hyperphosphorylation 56
poses 56
pregnancies, 56
future, 56
CH 56
ganglia, 56
well-studied 56
25, 56
purpose, 56
processive 56
telomeres. 56
grading 56
art 56
marginal 56
community-dwelling 56
Acid 56
Electron 56
relapse. 56
Forty 56
glioblastoma, 56
Personality 56
II). 56
stochastic 56
generations. 56
Infants 56
comparisons. 56
substitute 56
codons. 56
(MAOA) 56
sharp 56
17, 56
Ki 56
sea 56
normalize 56
averaged 56
chamber 56
equivalence 56
deacetylation. 56
canal 56
methylation-specific 56
μM) 56
wing 56
Shh 56
anchored 56
sample, 56
RS 56
rolling 56
CGIs 56
0.03). 56
p<0.001). 56
Flow 56
atxA, 56
4.2 56
older. 56
unified 56
territories 56
predictions, 56
Union 56
enrollment 56
TRalpha 56
genetics, 56
Turner 56
lymphoblastoid 56
intricate 56
histocompatibility 56
falling 56
Rates 56
year-old 56
simulate 56
addiction. 56
transcriptomes 56
losses 56
CsA 56
anatomy 56
CL 56
Metastatic 56
Hippo 56
antipsychotics 56
dominated 56
interference. 56
compositional 56
permitted 56
formula 56
DCM. 56
mPTP 56
paragangliomas 56
tricuspid 56
gigaxonin 56
IFN-γ 56
amyloid-β 56
rod 56
War 56
(VHL) 56
cerebellum, 56
programs, 56
ovulation 56
granulosa 56
telephone 56
aseptic 56
Amifostine 56
DUX4, 56
Hsc70 56
pretest 56
Nod1/2 56
hypopigmentation 56
Eliglustat 56
endocrinopathy, 56
Tremor 56
Romosozumab 56
MPE-seq 56
tonsillectomy 56
Abf1 56
Heerfordt 56
Differentiation 55
trafficking. 55
contrasting 55
sarcomeric 55
devised 55
ventilatory 55
malignancy, 55
(15%) 55
delivery, 55
designing 55
schedules 55
negative, 55
-independent 55
Sox2 55
GB 55
Reverse 55
abundance. 55
mapping, 55
Genomes 55
strategy, 55
variation, 55
cone 55
roughly 55
Advancement 55
potentiation 55
(CVD) 55
initiation, 55
revascularization 55
Frequency 55
snRNP 55
FSHD. 55
probe. 55
57% 55
coupling. 55
suitability 55
blocker, 55
validating 55
tumorigenicity 55
293 55
long-standing 55
etiologies 55
computerized 55
training. 55
strenuous 55
York. 55
cell-type 55
possible, 55
symptomatology 55
dyspareunia 55
written 55
0.01), 55
overgrowth, 55
methyltransferase, 55
immunocytochemical 55
morphologically 55
single-dose 55
cross-links 55
predisposition. 55
1997 55
hindered 55
modeling. 55
dendrite 55
PTB 55
valacyclovir 55
policy 55
95%CI: 55
barrier. 55
immortalized 55
biologics 55
sutures 55
locus-specific 55
dimensional 55
albicans, 55
rendering 55
staging 55
radicals 55
counting 55
Radiation 55
EMBASE, 55
proteostasis 55
immunohistochemistry, 55
transcript, 55
ionic 55
scalable 55
AIT 55
compensate 55
stenosis, 55
50, 55
Immunofluorescence 55
microtubules. 55
short, 55
lymphoproliferative 55
BoNT 55
neuroaxonal 55
PARP-1 55
surfaces 55
β-catenin 55
productive 55
striatum, 55
SOD1 55
astrocyte 55
Assessing 55
VNTR 55
P<0.05). 55
(FA), 55
Programmed 55
emergent 55
adenylyl 55
(P<0.001) 55
alignment. 55
identification, 55
angiographic 55
liposomal 55
62% 55
NEDD8-activating 55
Trauma 55
glucuronide 55
intubation 55
eyes. 55
leukemias 55
introduces 55
Improvements 55
formin 55
impacted 55
virulent 55
CLOCK 55
X-inactivation 55
>10 55
(formerly 55
nursing 55
nifedipine 55
pupil 55
cyclophilin 55
hosts. 55
(MFS) 55
deadenylase 55
twitch 55
histories 55
EGLN1 55
Variants 55
Continuous 55
jaw 55
Amitriptyline 55
incontinence, 55
EMD 55
m6A 55
(SUMO) 55
contracture 55
B1) 55
GBA 55
anesthetized 55
IDH 55
JAK3 55
Elmo1 55
TIA-1 55
super 55
drm1 55
drm2 55
urgency 55
Tripolin 55
al, 55
dentate 55
CHEK2 55
MgSO4 55
guardian 55
sun 55
STARR-seq 55
NCPAP 55
Burrows-Wheeler 55
fasciitis 55
avanafil, 55
cccDNA 55
Benralizumab 55
Genetics. 54
penetrant 54
triple-negative 54
serum. 54
measure, 54
grade, 54
compatibility 54
teriparatide 54
cost, 54
(PSA) 54
conjugate 54
times, 54
applies 54
Delta 54
stresses. 54
52% 54
environment, 54
seek 54
specifically, 54
19, 54
couple 54
deadly 54
(10%) 54
specialist 54
symmetrical 54
subtype. 54
square 54
accurate, 54
endoscopy 54
supernatants 54
pg/ml, 54
MMP-2 54
quantitation 54
exploit 54
diacylglycerol 54
hemolysis 54
Spontaneous 54
difficult. 54
fat, 54
Exercise 54
females) 54
km23-1 54
elevate 54
plans 54
priority 54
97% 54
satisfied 54
threshold. 54
race 54
sport 54
117 54
intervention, 54
spot 54
small-cell 54
counts. 54
E1 54
laevis 54
Hypertrophic 54
replacing 54
Evolution 54
neonates. 54
swine 54
ossification 54
TSH, 54
immunoblot 54
bottom-up 54
maximize 54
Visual 54
generations 54
axillary 54
vessels. 54
lysosomes, 54
nutrients 54
HIF-1 54
step. 54
pyrimidine 54
toxicities. 54
21-day 54
thalidomide, 54
escalating 54
characterized, 54
recipients. 54
unconventional 54
CTCF-binding 54
Percutaneous 54
7) 54
maize 54
hyperthyroidism 54
Neurofibromatosis 54
tumor-suppressor 54
prototype 54
Evolutionary 54
Brooke-Spiegler 54
suppressor. 54
CMT2 54
mg/d 54
glucose. 54
entering 54
hypogonadism 54
CMT3 54
neurogenesis 54
protozoan 54
Delayed 54
76% 54
VT 54
HL-60 54
trigeminal 54
country 54
GBshape 54
(circRNAs) 54
cardiotoxic 54
Basal 54
two-stage 54
disturbances, 54
Bortezomib 54
exonuclease 54
conflict 54
PARP1 54
olaparib, 54
hydroxamic 54
RhoA, 54
prenatally 54
SAMHD1 54
microm 54
concordant 54
hemiatrophy 54
(MR) 54
hypospadias 54
non-inferiority 54
periods. 54
c-Abl 54
infrastructure 54
I(Na) 54
MDD. 54
isoform. 54
DeltaNp73 54
elastase 54
Becker 54
(PLB) 54
network-based 54
pharmacogenomics 54
DNAs 54
TFRs 54
urban 54
bodyweight 54
PCOS 54
cream 54
(SCN) 54
Ib 54
realistic 54
CTLA-4 54
hCtf4 54
vocal 54
uveitis, 54
Sleeping 54
Vsr 54
BAT 54
(GRBs) 54
filgotinib 54
hDPCs 54
(NIPT) 54
Majeed 54
RPL5 54
Stevens-Johnson 54
OATP1B1, 54
Psoriatic 54
ATAC-seq 54
mulibrey 54
apocynin 54
dens 54
eflornithine 54
Calciphylaxis 54
disease]. 53
structure-based 53
anchor 53
consortium 53
ranking 53
inhibited. 53
factor-κB 53
Science, 53
intake, 53
success. 53
golimumab, 53
embryogenesis. 53
precedes 53
lung. 53
tract, 53
Clinically 53
4.8 53
HER3 53
gram 53
trastuzumab, 53
advancement 53
transcriptase-polymerase 53
protocols. 53
cationic 53
cancer; 53
oriented 53
(days 53
Wild-type 53
folds 53
heterogeneity, 53
350 53
segregate 53
progresses 53
arm, 53
(TRH) 53
intestine, 53
sensitive, 53
characterization. 53
chemoattractant 53
PIK3CA 53
exponential 53
neuropathologic 53
DNA-damaging 53
segregating 53
Synthesis 53
historically 53
(high 53
IL-10, 53
sensations 53
Georg 53
co-localized 53
remnant 53
101 53
practitioners 53
analyzes 53
neurological, 53
forebrain 53
Light 53
marker. 53
(five 53
fecal 53
displaced 53
strand, 53
evolve 53
XCI 53
surrounded 53
day) 53
obsessive-compulsive 53
Kinetic 53
TGN 53
engraftment 53
recapitulate 53
26% 53
mother. 53
E-cadherin, 53
histidine 53
Canagliflozin 53
glycaemic 53
spent 53
inspection 53
convenience 53
genotypes. 53
(40%) 53
destabilized 53
wall. 53
methodology. 53
(AD), 53
analogs, 53
diplegia 53
descending 53
emotion 53
rising 53
organism. 53
cytological 53
ingested 53
peptidase-4 53
[OR] 53
CLL. 53
MMPs 53
equine 53
leukodystrophy 53
Forkhead 53
foci, 53
nonhomologous 53
dna 53
thaliana, 53
helicase, 53
epithelial-to-mesenchymal 53
shifting 53
Mechanistically, 53
edge 53
blindness 53
automatic 53
processivity 53
Japan, 53
graph 53
incision 53
Asians 53
theta 53
question. 53
result. 53
maxillary 53
(GD) 53
intercalation 53
ones, 53
pathogen. 53
contexts. 53
sweating 53
organomegaly, 53
ultrasonographic 53
oscillation 53
intent-to-treat 53
BBS 53
necrosis. 53
premalignant 53
Users 53
MEF-2 53
occupancy. 53
BCR/ABL 53
biopsy, 53
UPS 53
E-cadherin. 53
Fibronectin 53
insulating 53
Borna 53
replicates 53
otitis 53
(CGRP) 53
adoptive 53
oligodendrocyte 53
strands, 53
ovaries 53
Romano-Ward 53
KB-R7943 53
(cffDNA) 53
JAK1 53
FANTOM5 53
Viroids 53
pyogenes 53
fumarate 53
gossypii 53
plagiocephaly 53
Sir2 53
(2D:4D) 53
urethral 53
MAYP 53
travel 53
penile 53
aeruginosa 53
OATP1B3. 53
endometrioma 53
S19 53
AAK 53
cereal 53
HRQoL 53
Sm 53
cruzi 53
CJD 53
pneumonic 53
Migalastat 53
Zinn 53
MNase-seq 53
Upc2 53
tumor-normal 53
Heerfordt's 53
multiplicative 52
space, 52
acceleration 52
governs 52
OA 52
LT4 52
stages, 52
essential. 52
update. 52
sophisticated 52
antagonizing 52
duct 52
Notch-1 52
(risk 52
investigational, 52
Improved 52
layer. 52
California 52
(iPSCs) 52
84% 52
generated. 52
reagents 52
path 52
tomographic 52
demands 52
volume. 52
fulfilled 52
oesophageal 52
child. 52
kb) 52
Ca(2+), 52
silica 52
creatinine, 52
arsenic 52
46% 52
polarized 52
moiety 52
amelioration 52
revision 52
SB 52
SH-SY5Y 52
intensity, 52
Applying 52
enrich 52
aneuploidy. 52
t(11;22) 52
age: 52
expenditure 52
Stuttgart 52
diagnosed. 52
advice 52
neoplasms. 52
education, 52
interviews 52
theories 52
connect 52
financial 52
macrocephaly, 52
comparisons). 52
103 52
cytotoxicity, 52
scenario 52
Biallelic 52
importantly 52
intimately 52
27, 52
ubiquitination. 52
intratumoral 52
H3. 52
Africa, 52
Pfeiffer 52
well-recognized 52
discovered. 52
Hashimoto's 52
finding, 52
Samples 52
attained 52
Chiari 52
CKD, 52
syndromes: 52
CP 52
brings 52
OMIM 52
Valproic 52
175 52
multiforme. 52
conserved, 52
starvation. 52
mg/day, 52
enrolled, 52
bands 52
FLS 52
ability. 52
ordinary 52
cytomegalovirus 52
Monitoring 52
occasional 52
insulators 52
enhancer-promoter 52
fields. 52
tool. 52
thymic 52
transcriptome-wide 52
CLIP 52
polyacrylamide 52
nature. 52
lobar 52
activity) 52
phorbol 52
LDH 52
microM). 52
analog, 52
seeking 52
ankyrin 52
nematode 52
hypomethylated 52
MRG15 52
cytosol. 52
polymorphisms. 52
complexed 52
neutralized 52
ER-positive 52
ARVC 52
supplement 52
rigorously 52
Routine 52
autoimmunity. 52
STAT4 52
deal 52
compete 52
inferring 52
constipation, 52
tubules 52
15. 52
recurrence, 52
reproduce 52
therapy; 52
hyperactivation 52
impressive 52
outstanding 52
Rheb 52
ago. 52
sex-matched 52
gyrus 52
motile 52
(SERMs) 52
Beck 52
Trisomy 52
CCFDN 52
France, 52
SASP 52
pancreas, 52
orofacial 52
karyotypes 52
Author(s). 52
Edwards 52
helicase. 52
Double 52
assumptions 52
ecological 52
zoonotic 52
stereotactic 52
floor 52
Areas 52
brodalumab 52
PAH. 52
Diffuse 52
SS 52
vasculitis 52
Cutaneous 52
pharmacogenomic 52
Israeli 52
(JAK) 52
lacrimal 52
Ashbya 52
DSIF 52
Fe(III) 52
Magnesium 52
APOBEC3F 52
Filipino 52
Apolipoprotein 52
Clonidine 52
DUSPs 52
Selexipag 52
erythropoietic 52
lenvatinib 52
cardiotoxicity. 52
Tibetan 52
Serial 51
hormones, 51
Chemical 51
sheath 51
affinities 51
priming 51
Determination 51
myocytes, 51
precursors. 51
tartrate 51
possessing 51
Types 51
mechanism-based 51
counterpart 51
(RT-PCR) 51
schemes 51
LNCaP 51
overexpress 51
surprising 51
yielding 51
145 51
(47%) 51
(day 51
Stimulation 51
transplantation, 51
abundance, 51
excised 51
dying 51
phagocytosis 51
angina 51
relaxation. 51
dosed 51
ventricles 51
chromatography. 51
chromatographic 51
post-treatment 51
BC 51
spectroscopy, 51
truly 51
outgrowth 51
justify 51
agar 51
proliferate 51
Stable 51
erythematosus, 51
(24 51
lumbosacral 51
Effective 51
all. 51
cornerstone 51
115 51
clinicaltrials.gov 51
Amino 51
osseous 51
urine, 51
ORC 51
trinucleotide 51
maintenance, 51
Endocrine 51
circulatory 51
Randomized, 51
probes. 51
herpesvirus 51
governed 51
transactivator 51
windows 51
germinal 51
elongated 51
Adjuvant 51
(HGF) 51
ventilation. 51
myocarditis 51
obstetric 51
emphasizing 51
anti-proliferative 51
FGFR2 51
Thai 51
eliminating 51
circumstances 51
postural 51
Clinicians 51
deformity 51
glands. 51
leukopenia 51
PG 51
compound, 51
(GBM), 51
treated, 51
4), 51
migrate 51
SHR 51
looping. 51
sirtuin 51
(RNAPII) 51
gadolinium 51
rearrangements. 51
two, 51
infiltrating 51
Neurology 51
views 51
constitutional 51
17. 51
ACC 51
gain, 51
3-fold 51
reversibly 51
demyelination 51
identified: 51
increase, 51
metabolomics 51
(TBI) 51
originates 51
marking 51
Clr4 51
tachyarrhythmias 51
co-factors 51
stand-alone 51
threat 51
Nile 51
disparate 51
tongue 51
RAS 51
star 51
individual's 51
Lysine 51
worm 51
cyclosporine 51
lifespan. 51
anticoagulants. 51
AF, 51
harm 51
Transmembrane 51
119 51
μm) 51
UCEs. 51
TRbeta 51
beta1 51
→ 51
(PWS) 51
HIV-infected 51
cardiopulmonary 51
packed 51
attending 51
silence 51
adopts 51
interobserver 51
innovations 51
(RLS) 51
cucumber 51
geldanamycin 51
XLH 51
autoantibody 51
nucleation 51
scales. 51
LVNC 51
(MMR) 51
lay 51
Models 51
SCH 51
SNAG 51
histones, 51
burst 51
k 51
vaccines. 51
bosentan 51
Southeast 51
delamanid 51
Na(+)/Ca(2+) 51
paralysis, 51
vemurafenib. 51
β-globin 51
mg/L 51
RHC 51
SDHA. 51
carbamylation 51
Alus 51
IVIG 51
birds 51
homeo 51
α-tubulin 51
trait-associated 51
allopurinol 51
dronedarone 51
Ang 51
meningitis, 51
Leber's 51
megakaryocyte 51
VOCs 51
U4atac 51
A3B 51
Evans 51
glabrata. 51
UGT1A1, 51
ogt 51
necitumumab 51
SerH3 51
Scribble 51
Cucumis 51
LOXL2 51
maturated 51
(TYR) 51
JBP2 51
JGT 51
GABHS 51
autocrine 50
packaged 50
arisen 50
ID 50
Epithelial 50
profiled 50
4.3 50
Except 50
morbidity, 50
encourage 50
subpopulations 50
pertaining 50
laryngeal 50
entity, 50
nail 50
hypertrichosis 50
thereafter 50
(67%) 50
Jan 50
worst 50
coadministered 50
covers 50
ELISA. 50
transduction, 50
Klf4, 50
expansion. 50
private 50
Biology 50
chose 50
blockers, 50
biochemical, 50
inborn 50
Czech 50
interrupted 50
catalysis. 50
Mosby, 50
today 50
Measurement 50
Nearly 50
NF2 50
sciatic 50
LCM 50
observation, 50
absent. 50
recurrences 50
overweight 50
10. 50
work. 50
Migraine 50
Twenty-five 50
Americans 50
participant 50
H3K36 50
high-intensity 50
39% 50
problematic 50
Novartis 50
myeloproliferative 50
monomer 50
ribonuclease 50
adenomas, 50
adenomatous 50
smoked 50
classically 50
15) 50
112 50
month. 50
56% 50
(16%) 50
abortion 50
dizziness 50
lessons 50
episodes, 50
VAS 50
165 50
(2%) 50
exon-intron 50
co-transporter 50
(T2DM). 50
granules, 50
Maximum 50
delineation 50
glioblastomas. 50
Rags 50
(TFEB), 50
core. 50
gram-negative 50
MSC 50
DAT 50
temsirolimus 50
unexplored. 50
stage-specific 50
residing 50
(interquartile 50
aggregates. 50
ataxic 50
Cmax 50
minimizing 50
deubiquitination 50
(5) 50
transmission, 50
veterans 50
York 50
plot 50
nM, 50
glibenclamide 50
washout 50
(SLE) 50
Greek 50
uniparental 50
library. 50
extracts, 50
frog 50
cullin 50
telomeres, 50
chromo 50
reservoir 50
77% 50
(PRC2) 50
dimethylated 50
tablet 50
genera 50
antioxidants 50
surveys 50
scenarios. 50
operational 50
NC 50
bootstrap 50
LC3 50
clotting 50
cysteines 50
TMPDB 50
HSV 50
caspase-1 50
urothelial 50
34% 50
lesion, 50
impairing 50
CRM 50
multimeric 50
G-protein 50
multifaceted 50
cytoreductive 50
HoxA 50
(22 50
tetracycline 50
Topo 50
adhesions 50
SR. 50
ordered 50
Nox4 50
tender 50
(DCM) 50
trisomies 50
chromosome-positive 50
sub-Saharan 50
anxiolytic 50
X, 50
P19 50
RNA-based 50
MV 50
NB 50
AFT1 50
thoroughly 50
reproduction 50
Epidemiological 50
reagent 50
bulbar 50
Ischemic 50
depolarizations 50
(HIV-1) 50
Dermatitis 50
pineal 50
permissions, 50
anionic 50
Bidirectional 50
adoption 50
fulvestrant 50
Obstructive 50
Bladder 50
cholestasis 50
isochores 50
Dnmt3b 50
Arts 50
WDR34 50
toxigenic 50
S100A4 50
shark 50
RPS19, 50
pyloric 50
abscess 50
CD38, 50
22q11.2 50
craniospinal 50
HEXA 50
buprenorphine 50
Ambras 50
Nottingham 50
sternal 50
PDE5 50
DMT1 50
Borden 50
(LHON) 50
FaceBase 50
dialectical 50
penetrance, 49
male, 49
©2013 49
immunocompromised 49
beta, 49
2.7 49
basement 49
Splicing 49
implied 49
osteoclasts 49
calvarial 49
hazards 49
(A 49
PCR-based 49
fractures, 49
hormone-refractory 49
palliative 49
recurred 49
NOTCH 49
lip 49
follicles 49
America, 49
(TAK-700), 49
overexpression, 49
Bax, 49
multistep 49
Oct3/4, 49
definitions 49
dendrites 49
Neuropathy 49
unequivocal 49
(MI) 49
noticed 49
MI. 49
89% 49
childhood-onset 49
variability. 49
Manual 49
adeno-associated 49
calsequestrin, 49
striated 49
Chem. 49
current. 49
bundle 49
titration 49
2.1 49
consumption. 49
SMO 49
tumors: 49
min) 49
note, 49
ghrelin, 49
KG 49
labelled 49
acted 49
woman, 49
measure. 49
mono- 49
0. 49
siltuximab, 49
daily; 49
Neuronal 49
HCM, 49
cessation. 49
abstinence 49
poised 49
Amplification 49
it, 49
Pregnant 49
trimester. 49
330 49
tracheal 49
hydrogel 49
endogenously 49
interleukin-4 49
(28%) 49
reactivated 49
fluctuating 49
SDS-PAGE 49
spectrometry-based 49
intramembrane 49
destabilizing 49
sequelae. 49
deciphering 49
dermatitis, 49
aiming 49
arms. 49
activity-dependent 49
undiagnosed 49
persistently 49
Movement 49
supine 49
(eight 49
Expanded 49
twins. 49
begins 49
Mild 49
mutations) 49
intracytoplasmic 49
CSF. 49
CCM 49
nM). 49
fixed-dose 49
encompass 49
MRI, 49
spans 49
autoantibodies. 49
AGA 49
rigid 49
innervation 49
routes 49
Mitochondria 49
GTP-binding 49
Mechanistic 49
monozygotic 49
lethal, 49
sexually 49
KD 49
polymerase. 49
leukaemia. 49
HDACi 49
bortezomib. 49
operon 49
74% 49
blast 49
128 49
Olaparib 49
clarithromycin 49
indicated. 49
p52 49
2012), 49
Today, 49
activator-like 49
vulgaris 49
doxorubicin. 49
PSP 49
HD. 49
linearity 49
contacts. 49
idiosyncratic 49
updates 49
Bmal1 49
embolism. 49
(IBD) 49
printed 49
antidepressants. 49
48% 49
translocations. 49
lamellipodia 49
rs75932628-T 49
CLN3 49
calpain 49
Mac1 49
multiples 49
Snail1 49
THE 49
ET-1 49
Gfi-1 49
Tg 49
Canada. 49
micrococcal 49
noxious 49
transmissible 49
cilengitide, 49
lipophilic 49
HDAC3 49
cardioprotection 49
ER. 49
correcting 49
(mAb) 49
Malaria 49
titrated 49
glucosylceramide 49
SF-36 49
kallikreins 49
IRES 49
death-inducing 49
Monte 49
1,4-benzothiazepine 49
CpNpG 49
chromomethylase 49
KFERQ 49
NPC1 49
CCN1 49
5-hydroxymethylcytosine 49
NS5A 49
biodegradable 49
(TS) 49
Rad9 49
graphics 49
EIF2AK2-dependent 49
C5 49
Bertolotti's 49
RNU4ATAC 49
diffusional 49
RIP1 49
IVC 49
AlkA 49
silymarin 49
Peginesatide 49
Adalimumab 49
progressiva 49
S-II 49
nanopore 49
MEN2 48
polygenic 48
peptidase 48
Asthma 48
Akt. 48
author 48
adversely 48
wrist 48
lenalidomide, 48
occurrence, 48
approval, 48
Acrokeratosis 48
undertaken. 48
QRS 48
numerical 48
reversible, 48
(HER2) 48
HER-2/neu 48
practically 48
bioactivity 48
AML. 48
kit 48
map. 48
hardware 48
assuming 48
transcriptomic 48
thiol 48
undefined. 48
overload, 48
beta-blockers 48
randomization 48
0.005). 48
disturbance, 48
variables, 48
6th 48
reviewed, 48
heat-shock 48
(0.5 48
foods 48
agonists, 48
3.7 48
shock, 48
acetyltransferases 48
residue. 48
rarity 48
(NF-κB) 48
termini 48
needs. 48
microangiopathic 48
improved, 48
thrombocytopenia. 48
mL 48
Ghrelin 48
temporarily 48
B) 48
zygotic 48
endometriosis. 48
cut 48
users. 48
functioning. 48
mentioned 48
steps. 48
hydrolase 48
walking 48
Affymetrix 48
profiling. 48
MMC 48
suggestion 48
132 48
behaviour. 48
50%. 48
school 48
Classical 48
methyltransferases, 48
elephant 48
ras 48
GRN163L 48
inhibitors: 48
121 48
3rd 48
Loss-of-function 48
issue. 48
end. 48
strands. 48
stabilization. 48
SDS 48
isolating 48
morning 48
evening 48
brothers 48
Prolonged 48
autophagosomes 48
tensin 48
heterogeneous, 48
0.001, 48
genotype, 48
SNPs, 48
insert 48
TRF2 48
illuminate 48
gene) 48
Full 48
paraplegia 48
video 48
eggs 48
Alignment 48
SGs. 48
sequester 48
sex. 48
histology, 48
Genotype-phenotype 48
protracted 48
stimuli, 48
nasopharyngeal 48
SPECT 48
C57BL/6J 48
glycated 48
proposal 48
recognition, 48
retroviruses 48
demethylating 48
Institute. 48
obligatory 48
(DSBs) 48
Mapping 48
threatening 48
Hepatitis 48
testis, 48
COS-7 48
offspring. 48
RT-PCR, 48
supplementation. 48
characterise 48
C57BL/6 48
Roles 48
Telomere 48
Reactive 48
centers. 48
primates. 48
rearranged 48
clue 48
ATM, 48
0.83 48
license 48
tandemly 48
Second 48
CHL1 48
GREAT 48
Tool 48
underscores 48
non-homologous 48
RhoC, 48
Cdc42 48
eventual 48
LAM 48
MLN4924, 48
PPTP 48
formal 48
chemosensitivity 48
0.68 48
inception 48
mesenchyme 48
nexin 48
reconstruction. 48
S6K 48
Conditional 48
dysarthria, 48
administering 48
3: 48
attention, 48
leptomeningeal 48
insulin-dependent 48
Embolism 48
stenosis. 48
eyelid 48
autoregulation 48
curvature 48
spina 48
2005, 48
weekly, 48
block, 48
polyneuropathy, 48
cingulate 48
retinitis 48
Na+/H+ 48
country. 48
SUMOylated 48
anesthesia. 48
Gfi-1b 48
isozymes 48
MAC 48
(HDACs) 48
brucei 48
Carlo 48
nonreceptor 48
pharmacists 48
LD 48
cEDS 48
iE-DAP 48
MCV 48
Phthiriasis 48
APOBEC3B 48
Dracorhodin 48
erythropoiesis-stimulating 48
H2AZ 48
free-electron 48
Dot1 48
du 48
O6-alkylguanine-DNA 48
BSEP 48
SNVs 48
©2016 48
Bexsero 48
sign, 48
apoE3 48
webSDA 48
NSD 48
(OPS) 48
sSMC 48
Necrobiosis 48
diphtheriae 48
pet 48
musclin 48
Rrp6 48
volar 48
Linc-pint 48
annotatr 48
Zieve's 48
Neanderthal 48
descent 47
are: 47
unstimulated 47
intervening 47
e 47
Activated 47
Jurkat 47
Implications 47
marrow-derived 47
set, 47
controversy 47
neck, 47
prostate, 47
costs, 47
Bazex 47
neck. 47
saturated 47
lipase 47
Pharmaceutical 47
(28 47
Herceptin 47
androgen-independent 47
trastuzumab. 47
Alternatively, 47
buffer 47
observation. 47
0.002). 47
mg/kg. 47
parallels 47
Proteome 47
China 47
astrocytic 47
kinetics. 47
myotubes 47
genotypic 47
Wilson's 47
swelling, 47
overload. 47
diversity, 47
arms, 47
brother 47
JCN 47
measurement. 47
tolerance. 47
amino-acid 47
constants 47
(8%) 47
(88%) 47
SD) 47
longer-term 47
Dietary 47
chemokines 47
recruitment. 47
copy-number 47
sampled 47
carbamazepine 47
anchorage-independent 47
dipeptidyl 47
places 47
instances, 47
1.7 47
archaea 47
pull-down 47
histopathology 47
EM 47
fraction, 47
self-report 47
Lipid 47
2; 47
doxorubicin, 47
Thirty-two 47
750 47
MTD 47
FRDA 47
hyperplasia, 47
restrictive 47
2.3 47
applied. 47
5.0 47
Purified 47
neurites 47
Almost 47
clathrin 47
Examples 47
(6%) 47
single-gene 47
[corrected] 47
proteomes. 47
groundwater 47
photosynthetic 47
putatively 47
AKI 47
assume 47
merely 47
catabolic 47
aggregation. 47
lymphopenia 47
dizziness, 47
GWAS 47
discovering 47
Univariate 47
liver-specific 47
Echocardiography 47
gradients 47
disorders; 47
deviations 47
improvement, 47
neurodegeneration, 47
behaviors. 47
template. 47
moved 47
cord. 47
Ca(2+)/calmodulin-dependent 47
antagonists. 47
PMP22 47
study: 47
polyneuropathy. 47
progeny 47
hits 47
saxagliptin, 47
Embase, 47
circuitry 47
fragment, 47
GmbH. 47
CHD5 47
nodal 47
hydroxyl 47
branches 47
specialists 47
combat 47
basal-like 47
0.04). 47
old. 47
(DBA) 47
shortest 47
fibre 47
mucosa. 47
TET2 47
anti-myeloma 47
decay. 47
discovered, 47
NSCLC, 47
side-effect 47
TSC. 47
restart 47
point. 47
dictates 47
unannotated 47
innovation 47
home-based 47
prevention, 47
quality-adjusted 47
PDT 47
Jarid2 47
Dicer 47
solute 47
Traditional 47
histone-like 47
beta-myosin 47
nutrition 47
MDR 47
strokes 47
MSA 47
RF 47
iron. 47
reflexes 47
immobilization 47
postoperatively 47
client 47
glia 47
oldest 47
PD-1/PD-L1 47
ε4 47
medicine, 47
L-amino 47
collapse 47
frequent. 47
.0001). 47
CDK 47
dermatologic 47
endoderm 47
K-ras 47
CD52 47
permitting 47
Immunotherapy 47
prostatectomy 47
sedation, 47
bFGF 47
relied 47
secukinumab, 47
FANCC 47
m(6)A 47
DLB 47
tardive 47
extensor 47
osteopenia 47
WE 47
monocarboxylate 47
ATS 47
child's 47
giant-cell 47
JTV-519 47
squamous-cell 47
(SAH) 47
clipping 47
enhanceosome 47
TMD 47
miR-124a 47
Plk1 47
aegypti 47
Telcagepant 47
J/cm2 47
HGG 47
RAPIDR 47
ONX 47
0912 47
dracorhodin 47
LDB1 47
-7 47
phosphoribosyltransferase 47
trypan 47
metagenomic 47
MUL 47
cementum 47
ALDHbright 47
SNV 47
pentraxin 47
hypoglycin 47
Nab3 47
assortativity 47
KRT14 47
prioritize 46
infrequently 46
colon. 46
neurites. 46
ends. 46
135 46
tail, 46
crisis 46
Acquired 46
muscarinic 46
checked 46
multimodality 46
concerns. 46
renewed 46
nonsynonymous 46
neoplasia. 46
prolonging 46
myogenesis. 46
discussed, 46
achievable 46
cell-lines. 46
Gleason 46
humanised 46
280 46
toxin. 46
STAT3, 46
pluripotency. 46
revolutionized 46
facing 46
efficiencies 46
BLAST 46
HEK 46
CNS. 46
characterisation 46
0.004). 46
diseases: 46
emerges 46
intermolecular 46
alpha-MHC 46
diets 46
Experiments 46
(+/- 46
bacterium, 46
chromatin-remodeling 46
sides 46
male) 46
nerves. 46
min, 46
Bcl-2, 46
CNS, 46
MAPK, 46
AKT1 46
listed 46
anticonvulsant 46
i.p.) 46
measurements, 46
triad. 46
accelerating 46
consumed 46
donation 46
view, 46
Comparing 46
mesothelioma 46
speculated 46
5.2 46
coexistence 46
contraceptive 46
cognition, 46
(LDL-C) 46
(AMG 46
atherogenic 46
(LDL) 46
computer-generated 46
Asia, 46
translate 46
dyslipidemia, 46
methylase 46
Fewer 46
crosslinks 46
Existing 46
(LOH) 46
vice 46
quality. 46
capecitabine 46
Randomised 46
(PI3K) 46
ability, 46
Vaccination 46
virion 46
111 46
proposed, 46
electrodes 46
freshly 46
dye 46
rituximab, 46
0.02 46
syndactyly 46
Hearing 46
enlargement, 46
splice-site 46
scalp 46
P2Y12 46
Critical 46
lantibiotic 46
Incubation 46
insertional 46
perforation. 46
Nintedanib 46
banding 46
DCs 46
(TNF) 46
neuroticism 46
Medline, 46
equation 46
immunosuppression 46
whole-cell 46
reads, 46
plane 46
20) 46
internally 46
react 46
mislocalization 46
(ALS), 46
shuttling 46
regenerate 46
dopamine, 46
Point 46
M6P 46
genes) 46
progress. 46
Placebo 46
sequenced. 46
US. 46
vasculature 46
abnormality. 46
forensic 46
dangerous 46
polyamine 46
centromeres, 46
depletion, 46
sporadic, 46
DSM-IV 46
order. 46
training, 46
exercises 46
projection 46
dimethyl 46
heightened 46
DNA-repair 46
exacerbates 46
comparisons, 46
antidotes 46
pore-forming 46
WNT 46
mutual 46
anti-CD38 46
coated 46
expect 46
TRIM5alpha 46
conjugating 46
adducts 46
II/III 46
White 46
(MHC) 46
doing 46
p53-dependent 46
Latin 46
Exome 46
resequencing 46
Breath 46
SH2 46
pipeline. 46
Black 46
seropositivity 46
FoxO3a 46
paralysis. 46
casein 46
Antagonism 46
differentiation-related 46
smears 46
exhaled 46
limitations, 46
IRLS 46
(P<0.001), 46
clients 46
voltage-dependent 46
INa 46
SDs 46
formulated 46
epistatic 46
Fallot 46
DJ-1 46
ATP13A2 46
nucleotides. 46
5-HT1A 46
SSRIs 46
AA21004 46
decided 46
log 46
OCD 46
consolidation 46
risks, 46
BTBD9 46
TT 46
organophosphate 46
psychosis 46
intercourse 46
Ikaros 46
nanomolar 46
peptide-based 46
spanned 46
Delamanid 46
inversus 46
anxiety-depression 46
albinism, 46
imposed 46
BALB/c 46
(CNEs) 46
Source 46
(HCNEs) 46
disomy 46
Porphyromonas 46
pigmentation. 46
MWS. 46
endochondral 46
(Ihh) 46
Ubc9, 46
R788 46
NOD 46
fixed-length 46
MeCP2 46
hypoxanthine 46
afatinib 46
abuse. 46
idarucizumab. 46
RIFIN 46
sortilin 46
Ulcerative 46
mGluR5 46
Scrib 46
peel 46
SJS 46
Cidea 46
(PIL) 46
LITT 46
SII 46
TFIIS, 46
photoaging 46
Mast 46
Doege-Potter 46
Paget 46
BORSA 46
EDNRB, 45
expressivity 45
dysplastic 45
collagen. 45
P<0.001) 45
relates 45
healthy, 45
0.003). 45
short- 45
promising. 45
1980 45
cord, 45
lesional 45
dissociate 45
overlapped 45
atherosclerosis, 45
structure-activity 45
s.c. 45
HSP70 45
consuming 45
spectrometry, 45
). 45
committed 45
oocytes. 45
calcium, 45
Ser 45
leukoencephalopathy 45
nevertheless 45
interruption 45
extrapyramidal 45
evident. 45
belonged 45
junctin, 45
1-3 45
9% 45
32% 45
88% 45
(30%) 45
burden. 45
autophosphorylation 45
THP-1 45
(no 45
IL-5, 45
minus 45
occur, 45
emphasized 45
methylates 45
Beckwith-Wiedemann 45
nonsense, 45
Proprotein 45
farnesoid 45
desirable. 45
reproducibly 45
HCC. 45
cases; 45
related. 45
(Hh) 45
FMR1 45
repeating 45
hospitals. 45
anaphase 45
effusion 45
transient. 45
endocytosis. 45
compartments, 45
tens 45
capabilities 45
depletes 45
insult 45
invade 45
anal 45
cochlea 45
transversion 45
detergent 45
entries 45
ChIP-chip 45
(IFAP) 45
Missense 45
radiochemotherapy 45
regulator, 45
organelles. 45
chloroquine 45
factor) 45
chloroplasts 45
mg/day. 45
stated 45
suggested. 45
EWS-Fli1 45
Rad21 45
multicolor 45
technologies, 45
Modeling 45
pacing 45
0.1% 45
precipitated 45
differentiation-associated 45
genomics. 45
captures 45
Amiodarone 45
antithyroid 45
spasticity 45
CDKN2A 45
terminate 45
individual. 45
Survey 45
(PK) 45
glycoproteins 45
Cdt1 45
proficient 45
catalogue 45
Childhood 45
metformin. 45
durations 45
metrics 45
classes, 45
folded 45
bridging 45
phosphatase. 45
diminishes 45
yeasts 45
orchestrated 45
determined, 45
Proper 45
operates 45
H-Ras 45
myoblast 45
axis, 45
BMS 45
width, 45
propeller 45
roll, 45
twist 45
month, 45
interrogate 45
phospholamban, 45
citrate 45
SEMA3A 45
pools 45
steric 45
was, 45
capsid 45
restricts 45
caspases 45
Responses 45
genitourinary 45
hypoglycemia. 45
Events 45
clear, 45
considered, 45
Working 45
photodynamic 45
photosensitivity 45
media, 45
structure-function 45
700 45
terminating 45
RNA-mediated 45
localisation 45
extensions 45
crude 45
autism, 45
Infectious 45
A), 45
right-sided 45
trunk, 45
cytology 45
physicians. 45
weaning 45
microbiome 45
double-blinded, 45
(APP) 45
migraine, 45
pulses 45
MVIIC 45
HDAC2 45
Variation 45
communities. 45
kb, 45
imatinib. 45
unresponsive 45
SSRI 45
(nine 45
retrogene 45
Snail2 45
niche 45
typed 45
Merck 45
germline, 45
department. 45
CAP 45
TC 45
Erectile 45
C1 45
spermatids 45
bullous 45
Doose 45
myoclonic-astatic 45
neuroleptic 45
application, 45
keratinocytes. 45
narcolepsy 45
0.0001 45
adherence. 45
PGD 45
FANCG 45
periostin 45
TF-encoding 45
MT1 45
α1 45
VASP 45
HDV 45
annotations, 45
Neurology. 45
Mayo 45
computation 45
T24 45
OR, 45
tolterodine 45
MESH 45
(NSCLC). 45
kg-1 45
ProTalpha 45
R(2) 45
infantile-onset 45
PAD2 45
NT 45
α-granule 45
PSDRS 45
Ty1 45
Sororin 45
sclerostin, 45
CTLA4 45
HoxB 45
OTX2 45
SHAPE-Seq 45
cytoreduction 45
Guadeloupean 45
α-Gal 45
ChIP-exo 45
Hidradenitis 45
PIONEER 45
streptococci 45
operon-like 45
JBP1 45
melioidosis. 45
ZMapp 45
DAVFs 45
(2017). 45
Galunisertib 45
gestation, 44
der 44
hydrolyzes 44
matrices 44
TRAIL 44
interventions, 44
abolish 44
collections 44
safe. 44
contacted 44
antibody) 44
costly 44
calcium. 44
25-hydroxyvitamin 44
chordate 44
confirmed. 44
clearing 44
Any 44
physicochemical 44
medium-sized 44
arteries, 44
Beyond 44
©2011 44
HER 44
standardization 44
paraffin 44
(AML) 44
favors 44
melanocytes, 44
1200 44
exogenously 44
invertebrate 44
cascade, 44
beat 44
traffic 44
relaxation, 44
nonfatal 44
(90%) 44
124 44
introns, 44
FSHD1 44
100%, 44
conversely, 44
ventricle, 44
hemodynamics 44
(MAP) 44
organism, 44
children's 44
causes. 44
moreover, 44
ectopically 44
Tyr 44
isotopic 44
optimizing 44
basis, 44
tonic-clonic 44
25%, 44
caution 44
confused 44
caloric 44
recovery, 44
Britain 44
discriminated 44
fatigue. 44
obviously 44
ANP 44
prevailing 44
Web-based 44
Haploinsufficiency 44
(previously 44
atorvastatin 44
Middle 44
returning 44
Much 44
non-protein-coding 44
seemingly 44
hydrolysis. 44
mimetic 44
taste 44
fill 44
KSHV 44
prominently 44
Groups 44
Simultaneous 44
HGF-induced 44
pneumonia. 44
trophoblast 44
intravascular 44
sensors 44
cuff 44
mepolizumab, 44
contrasts 44
Consecutive 44
coverage, 44
synostosis, 44
nighttime 44
protease, 44
(TMZ) 44
recurring 44
misfolding 44
important, 44
retinoid 44
A., 44
nontoxic 44
2002. 44
Solid 44
hypotension 44
Inventory, 44
cited 44
%. 44
semi-quantitative 44
microscope 44
(RBPs) 44
centered 44
Hong 44
chain, 44
FUS, 44
interface, 44
Opicapone 44
dependent, 44
multidimensional 44
situated 44
consequently, 44
signalling, 44
receptor-associated 44
horn 44
occurs, 44
neurovascular 44
(IL-6) 44
(23 44
infertility. 44
carriage 44
meat 44
multigene 44
Significantly 44
metastatic, 44
PTM 44
BAC 44
(Ph) 44
Mediator 44
(21 44
handful 44
fragment. 44
swollen 44
place. 44
TAILORx 44
vitamins 44
benefits, 44
TNF-α, 44
.01) 44
heterozygotes, 44
5-azacytidine 44
27) 44
recessive, 44
miR-1, 44
repression, 44
Portuguese 44
capsular 44
CO(2) 44
NHL 44
DNA-protein 44
comes 44
bacteremia 44
compiled 44
emanating 44
(60 44
gelatin 44
0.0001, 44
diabetics 44
dropped 44
non-steroidal 44
sisters 44
(0.1 44
Removal 44
Asia. 44
long-QT 44
Conference 44
reperfusion, 44
intercalators 44
proteomics, 44
pathogens, 44
EGF-induced 44
charts 44
stiffness, 44
Focal 44
periodontitis 44
mixtures 44
scoliosis 44
Tafazzin 44
decline. 44
fungi, 44
phosphatidylserine 44
91% 44
points; 44
gender. 44
6-week 44
Subcutaneous 44
polymers 44
dose-ranging 44
vectors. 44
Autoantibodies 44
England 44
Room 44
movement, 44
hepatotoxicity 44
IM 44
Reference 44
quiescence 44
episodes. 44
MMSE 44
characters 44
neglected 44
beads. 44
(12%) 44
gliomas: 44
GIST. 44
crest-derived 44
Survivin 44
IBD. 44
relief. 44
hand. 44
RecG 44
anti-interleukin-5 44
BSCL2 44
KCNE1 44
necroptosis 44
(acute 44
HIF2alpha 44
R329W 44
eGFR 44
inhalation 44
tasimelteon 44
caffeine 44
headaches 44
diversification 44
subscore 44
fibrillin 44
Chs2 44
stone 44
SLE, 44
epitope. 44
(HD). 44
Meier-Gorlin 44
caudal 44
phycocyanin 44
lasers 44
(EDS) 44
carcinoid 44
euglycemic 44
ALK-rearranged 44
booster 44
FoxA 44
Leptin 44
UCNEs 44
Betrixaban 44
galactocerebrosidase 44
CD38-expressing 44
adalimumab, 44
Ada 44
azole 44
donovani 44
dispensing 44
INCA 44
Iatrogenic 44
UBC9 44
CSN6 44
Taliglucerase 44
Obeticholic 44
DHBV 44
Fexinidazole 44
Diseases. 43
micromolar 43
invariant 43
regimens, 43
polo-like 43
Available 43
penetrate 43
Prous 43
identity. 43
activated, 43
Notch3 43
helix-loop-helix 43
rounds 43
androgen-dependent 43
hyperglycemia, 43
laboratory. 43
(AR) 43
mind 43
2-week 43
Antisense 43
oncogene. 43
MLL 43
terminally 43
outlined 43
electrochemical 43
consumption, 43
se 43
storage. 43
small. 43
28, 43
Taiwanese 43
β-adrenergic 43
serotype 43
RyRs 43
finding. 43
abuse, 43
epinephrine 43
propranolol. 43
source. 43
co-activator 43
(68%) 43
Thirty-six 43
restrictions 43
Repeated 43
protection, 43
challenges. 43
DPP 43
Herein 43
152 43
ways. 43
appetite 43
postprandial 43
Controls 43
220 43
chances 43
aspects. 43
tracking 43
race, 43
196 43
Caucasians 43
systemically 43
BBB 43
weeks; 43
12-week, 43
Starting 43
methyltransferase. 43
trapped 43
cases). 43
glycolipid 43
t(11;22)(q24;q12) 43
ligand-dependent 43
checkpoints 43
myotonic 43
pause 43
triplet 43
Smoking 43
Child 43
cluster, 43
Strong 43
kappaB 43
abrogate 43
Smad 43
HGF/SF 43
promptly 43
fourteen 43
Wnt/β-catenin 43
(PKA) 43
corticosteroids. 43
limbs, 43
accommodate 43
diarrhoea 43
organification 43
Haplotype 43
corrects 43
step, 43
outputs 43
lot 43
objectively 43
voluntary 43
melanogaster, 43
photophobia 43
concentrate 43
tricarboxylic 43
anomaly. 43
Incidence 43
Igf2 43
embryogenesis, 43
diminish 43
atrioventricular 43
CREBBP 43
sporadically 43
rectus 43
purposes. 43
persons. 43
parallel-group 43
issue, 43
(80%) 43
transfer, 43
Cdk2 43
duplication. 43
linagliptin, 43
7-day 43
anti-angiogenic 43
Iran. 43
sick 43
Dr. 43
stringent 43
chains, 43
Pty 43
CTD 43
retrotransposon 43
(17%) 43
anti-arrhythmic 43
flavivirus 43
questions, 43
Profile 43
PTEN, 43
normotensive 43
coenzyme 43
concerned 43
micro 43
testis-specific 43
explores 43
(CMT2D) 43
non-functional 43
functional, 43
packing 43
shelterin 43
www.clinicaltrials.gov 43
injuries. 43
MicroRNA-21 43
PH 43
nodes, 43
retrovirus 43
anticoagulation. 43
extracranial 43
STAT4, 43
haematopoietic 43
biologists 43
HD, 43
A- 43
thymocytes 43
opened 43
outward 43
myocardium, 43
CTF8, 43
NHEJ 43
NMDA 43
methylating 43
Moyamoya 43
parametric 43
AIDS 43
pericardial 43
angiomyolipoma 43
grafting 43
Without 43
partners, 43
technologies. 43
algorithms, 43
Quest 43
dephosphorylate 43
authorities 43
coadministration 43
feeling 43
acid-induced 43
nevus 43
fetuses. 43
masking 43
polyubiquitination 43
exceed 43
diphosphate 43
surveillance, 43
motility, 43
respondents 43
TCE 43
respiration, 43
FOXO3a 43
reliable, 43
CK1 43
compared, 43
Dictyostelium 43
IIa 43
thalamus 43
dwarfism 43
cM 43
proto-oncogene, 43
PCD 43
beta-subunit 43
UPR 43
anti-PD-1 43
anti-PD-L1 43
counts, 43
terreus 43
mitophagy 43
Persistent 43
calculation 43
Melanoma 43
interspaced 43
MT1-MMP 43
skipping, 43
(SAH). 43
appraisal 43
E-box 43
2B 43
pheochromocytomas. 43
Von 43
3000 43
.). 43
Healthy 43
rural 43
(SLC9A6) 43
angioedema 43
OSA, 43
ELANE 43
Jervell 43
fatality 43
degranulation 43
drastic 43
TFBSshape 43
N-truncated 43
CNEs. 43
Enhancers 43
interleukins 43
ultrafast 43
Antigen 43
miR-9 43
co-regulated 43
unsuspected 43
A2A 43
S100 43
voiding 43
neutralizes 43
CRP1 43
IMD 43
nalmefene 43
SVM-based 43
SIRT2 43
avoids 43
rhabdoid 43
CgA 43
HuR. 43
HRC-KD 43
alignments, 43
chordomas 43
Geobacteraceae 43
desflurane 43
SJS/TEN 43
gallic 43
α-galactosidase 43
(CSN) 43
osimertinib 43
WS2 43
HIST1H3B 43
air, 43
TOP2B/TOP2A 43
tularensis 43
icr 43
Swirl 43
Milwaukee 43
EBS 43
adherens 42
UICC. 42
releases 42
proteinase 42
phosphatase, 42
(TSH) 42
fast, 42
classifier 42
144 42
ameliorated 42
Neural 42
semiquantitative 42
young, 42
bradycardia 42
Trastuzumab 42
conducting 42
reportedly 42
dose-related 42
(iPS) 42
Oct4, 42
factors: 42
mechanism(s) 42
spermatogenesis 42
redundancy 42
interconnected 42
Extracellular 42
Internal 42
Royal 42
hospitalizations 42
angiotensin-converting 42
adulthood 42
out, 42
furthermore 42
authentic 42
output, 42
adaptation. 42
pockets 42
yet. 42
discharge. 42
Tyrosine 42
MS/MS 42
frequently, 42
Massachusetts 42
Circulating 42
allograft 42
corroborated 42
Behavioral 42
Egyptian 42
Netherlands, 42
Correlations 42
athletes, 42
interviewed 42
Frequent 42
undefined 42
treatment: 42
58% 42
conformation, 42
G-rich 42
CGG 42
deaminase 42
adenoma. 42
students 42
household 42
divisions 42
tumor-infiltrating 42
(TKIs) 42
vaccination, 42
collecting 42
hyperkinetic 42
neurology 42
meiosis. 42
corticosteroids, 42
sutures. 42
Genet 42
malformation. 42
anti-diabetic 42
Stage 42
multiplexed 42
constituents 42
Protocol 42
grows 42
Histopathological 42
Ocular 42
autophagosome 42
fusion, 42
dipeptide 42
mg/kg). 42
monocyte-derived 42
Proliferation 42
(MD 42
cohesin. 42
linkages 42
(SCD) 42
secretes 42
cDNA. 42
limbs. 42
EMG 42
deformities 42
dissected 42
Ca2 42
featuring 42
parenchyma 42
Sporadic 42
postischemic 42
cysts. 42
debated 42
T2DM. 42
up-to-date 42
noninferiority 42
subgroup, 42
Recovery 42
Strategies 42
food. 42
claimed 42
α-Syn 42
remodel 42
GAGA 42
substitutions, 42
topologies 42
Chromodomain 42
asthmatic 42
anomaly, 42
obscure. 42
contrast-enhanced 42
underestimated 42
taurine 42
isolation, 42
Ltd.. 42
(TG) 42
adolescence 42
eastern 42
sporting 42
monomethylation 42
involved, 42
Purification 42
SUV39H1 42
annually 42
Diamond 42
pancytopenia 42
decipher 42
thromboembolism. 42
neurosurgeons 42
CO2-enhanced 42
underlines 42
oprozomib, 42
transmit 42
queries 42
nature, 42
modules, 42
locations. 42
octamer 42
Rmi1 42
tetramer 42
stranded 42
7-year-old 42
multisystemic 42
certainly 42
inexpensive 42
HIV. 42
epirubicin, 42
Anderson 42
variability, 42
note 42
strengthen 42
enters 42
unwinding 42
endosomes. 42
disease), 42
banana 42
failures 42
haemorrhage. 42
CYP3A4 42
seropositive 42
Annotation 42
scales, 42
Legs 42
awake 42
CDS 42
hypoventilation 42
CCHS 42
volunteers, 42
(growth 42
exosome. 42
0.70 42
syncytial 42
lineage, 42
employs 42
RESULTS 42
clade 42
masticatory 42
CaSR 42
FKBP12.6 42
Prophylactic 42
thought. 42
centric 42
immunoassay 42
tomography. 42
SUI 42
hypnotic 42
astrocytomas, 42
Iranian 42
tau, 42
RdRP 42
inorganic 42
anesthesia, 42
(HCV) 42
hyphae 42
H9c2 42
Bruton's 42
multigenic 42
oligodendrocytes 42
PBMCs 42
plague 42
portable 42
CXCR2 42
miR-133 42
flavination 42
third-generation 42
Mcm2-7 42
POR 42
amyloidosis. 42
lamp2a 42
promoter-proximal 42
oxalate 42
Sumoylation 42
Miller-Fisher 42
P53 42
UCA1 42
light-sensitive 42
Beauty 42
PD173074 42
pioneer 42
MCI 42
MutS 42
Incontinentia 42
Vemurafenib 42
neurogranin 42
phthiriasis 42
BRAF-mutant 42
delirium. 42
MTC 42
DEEP 42
ulcer 42
(ACTA1) 42
(ROSIER) 42
5mC 42
vaccinology 42
STOP 42
ada 42
alfa, 42
BART 42
Rac3 42
fU 42
cannulae 42
MRgFUS 42
ADCC 42
EAST 42
hyperlipoproteinemia 42
capsulitis 42
Fsp27 42
K27M-H3.3 42
REVIGO 42
GDF15 42
Kummell's 42
(Additional 42
Glecaprevir 42
Dupuytren's 42
plexuses 41
GDNF, 41
Integrin 41
lncRNAs. 41
marrow. 41
overnight 41
miR 41
paclitaxel, 41
relapse, 41
subgroup. 41
(The 41
spine, 41
medicines 41
supplementation, 41
thirds 41
heterogenous 41
vessels, 41
preparations. 41
diarrhea. 41
sensitizing 41
definitely 41
vectors, 41
subventricular 41
companies 41
retains 41
fertility. 41
(MS), 41
theoretically 41
placenta 41
POLG 41
ophthalmoplegia 41
(pol 41
transmural 41
current, 41
weights 41
end-diastolic 41
PR, 41
1993 41
Taiwan. 41
reticulum, 41
chromatography, 41
closest 41
HAT 41
(GI) 41
Scores 41
Improving 41
mechanistically 41
epidemiology, 41
Short-term 41
included, 41
Netherlands. 41
challenging, 41
0.04) 41
Independent 41
rose 41
prescriptions 41
support, 41
exon, 41
looked 41
injectable 41
123 41
Education 41
(T-UCRs) 41
HhaI 41
Dose 41
(AIP) 41
(MEN1) 41
TK 41
aggressiveness 41
counted 41
Ca(2+). 41
159 41
easier 41
mark, 41
distinct, 41
(1:1:1) 41
perirenal 41
tumor-associated 41
dehydrogenase, 41
imetelstat, 41
2004, 41
vault 41
coalition 41
synostosis. 41
complaint 41
FT3 41
complements 41
N-linked 41
compound. 41
separating 41
intensity. 41
wear 41
µM 41
industrial 41
pH, 41
potentiates 41
determination, 41
reasonably 41
rejection 41
head-to-head 41
diversity. 41
block. 41
Rubinstein-Taybi 41
positives 41
(22%) 41
ablative 41
Intracranial 41
strength, 41
sequesters 41
cross-linked 41
non-random 41
Twenty-three 41
regressions 41
recently. 41
K63-linked 41
ulnar 41
permeability. 41
0.5% 41
T4, 41
advancements 41
Pharmacophore 41
myriad 41
posttraumatic 41
articles. 41
thresholds. 41
nucleosome. 41
feature. 41
foci. 41
tumor-suppressive 41
unmodified 41
N-terminally 41
itself, 41
not, 41
disturbances. 41
neurochemical 41
aggression 41
(HCC) 41
MPTP 41
cooperativity 41
rodents. 41
regulon, 41
(ChIP) 41
(ROC) 41
demanding 41
hyperglycemia 41
anticoagulants, 41
epigenetics 41
architecture, 41
passed 41
nmol/L 41
Transcription-coupled 41
manufacturing 41
beige 41
(95 41
handle 41
try 41
HCT116 41
Head 41
signature, 41
duplicate 41
female. 41
[odds 41
Ultrastructural 41
amsacrine 41
potencies 41
(miRNAs), 41
RCAS 41
organelles, 41
annular 41
ESS 41
breast. 41
IL-2 41
electroencephalography 41
difficulties, 41
iPSC-derived 41
coherent 41
butyrate 41
Homozygosity 41
Exploratory 41
in-hospital 41
spores 41
R47H 41
SGs, 41
tuber 41
imbalances 41
cattle. 41
PR2 41
Commotio 41
III) 41
homoplasy 41
antifibrotic 41
edges 41
astrocytes, 41
PARN 41
IL-23 41
ankylosing 41
disabilities 41
oesophagitis 41
time- 41
administer 41
cytokine/chemokine 41
radiosensitivity 41
photon 41
SGS 41
rigidity 41
tenth 41
Anopheles 41
BMP-2 41
IgG4 41
NSAIDs 41
Ae. 41
Hsp20 41
words, 41
radiosurgery 41
GCA 41
nephritis 41
sevoflurane-induced 41
nitrous 41
LFS 41
Per2 41
lamp 41
hindbrain 41
lice 41
MCD 41
EIF2S1. 41
TMBHMM 41
dystonia-parkinsonism 41
sickness 41
(CWD) 41
β-MHC 41
RPL5, 41
Andexanet 41
idarucizumab, 41
G:C 41
aligning 41
2-aminobenzamide 41
Ala96 41
SLCO1B1 41
[(18)F]altanserin 41
thermolabile 41
tanezumab 41
NeuroBlate 41
EL 41
(SUDEP) 41
Davidson 41
actoxumab 41
hemangiomas 41
ribbon 41
AZD0530 41
HPG 41
neuropeptide 40
polarization 40
deficit. 40
in, 40
170 40
supplementary 40
figures 40
αvβ5 40
microRNAs, 40
(p<0.05). 40
bromide 40
S.A.U. 40
licensors. 40
reviewers 40
ustekinumab, 40
Besides, 40
embryo, 40
dependence. 40
hyperplastic 40
crossing 40
testes, 40
transaminase 40
withdrawal. 40
treatment) 40
3.4 40
Nanog, 40
contraction. 40
achievement 40
clarified. 40
hinge 40
(41%) 40
Ca(2+)-dependent 40
RyR1 40
filter 40
adapt 40
performances 40
Thyrotropin-releasing 40
unifying 40
beta-sheet 40
alkyl 40
blot, 40
arachnoid 40
antinociceptive 40
appreciated. 40
Puerto 40
lean 40
Body 40
desire 40
6.5 40
fasted 40
isoform, 40
days; 40
190 40
others; 40
tracer 40
2006. 40
obscure 40
habits 40
deserves 40
posttreatment 40
Limited 40
nationwide 40
virtue 40
2: 40
between-group 40
assignments 40
mg/dl 40
(EC 40
PN 40
whenever 40
6). 40
induced. 40
increases, 40
oocytes, 40
repeat-containing 40
discussing 40
missense, 40
2- 40
Brazil 40
transporter. 40
(< 40
expectations 40
(PA) 40
24h 40
appropriate. 40
megacolon, 40
plaques, 40
range: 40
powered 40
Scoring 40
chemoradiotherapy 40
gram-positive 40
provoked 40
5.6 40
RT. 40
RECIST 40
single-arm 40
8.5 40
reversible. 40
Microarray 40
matrix-degrading 40
APOE 40
caregivers' 40
(mainly 40
supposed 40
(MD) 40
Igh 40
compaction. 40
cardiomyopathy: 40
inversions 40
EP300 40
element-binding 40
perfect 40
HuR, 40
complexity. 40
neurofibromin 40
real-world 40
translating 40
manipulated 40
infiltrate 40
cognitive, 40
debated. 40
dose-proportional 40
136 40
went 40
timing. 40
deubiquitinase 40
Pathogenic 40
considers 40
calmodulin 40
parasites, 40
kinase) 40
microM), 40
Italy 40
1994 40
guidelines, 40
necessitating 40
observations. 40
drug's 40
old) 40
Gram 40
inadequately 40
Washington, 40
Seattle. 40
refinement 40
themselves. 40
zipper 40
Cdk1 40
Artery 40
clarified 40
world, 40
CMR 40
Leber 40
Glutamate 40
anemia: 40
perspective, 40
Parallel 40
sequenced, 40
α-helical 40
active. 40
epoxyketone-based 40
Membrane 40
end-joining 40
CNV 40
vehicle. 40
TRα1 40
pressures 40
FHC 40
VEGF, 40
narrowing 40
ESTs 40
Group. 40
ORR 40
operation. 40
pacemaker 40
abnormality, 40
arsenite, 40
(10%). 40
E4 40
100-fold 40
Accumulation 40
cost. 40
taxa 40
PDGFR 40
cell's 40
requested 40
HMM 40
USA) 40
LES 40
parents, 40
zones 40
[n 40
boost 40
Homo 40
genomics, 40
blocks. 40
YFV 40
USA, 40
titer 40
cancer]. 40
Hu 40
p16(INK4a) 40
IRSp53 40
Side 40
MPN 40
Regional 40
PBs 40
DCP2 40
(IR) 40
paralytic 40
(TKI) 40
mesylate, 40
49% 40
filtering 40
BTB 40
adapter 40
Fatal 40
SVM 40
sensu 40
snail 40
vertigo, 40
orthostatic 40
p24 40
microglia, 40
UK, 40
fibril 40
(RP) 40
algorithms. 40
rods 40
agalsidase 40
Independence 40
LBs 40
Dementia 40
(TB) 40
ruptured 40
(TGN) 40
interleukin-5 40
abrupt 40
leucine-stimulated 40
mismatched 40
alpha-N-acetylgalactosaminidase 40
lower-grade 40
MEF2C 40
Ubiquitin 40
migrated 40
aurora 40
dystonia-choreoathetosis 40
Weill-Marchesani 40
glaucoma 40
RPC 40
tackle 40
dataset, 40
Modifications 40
UGT1A1 40
metabolite, 40
Erythematosus 40
centralized 40
Bickerstaff 40
Eps8 40
wafers. 40
DKO 40
Teriflunomide 40
Rotor-syndrome 40
sylvatic 40
FHL1 40
H3K79me2 40
reticulum-associated 40
NDC1 40
alfalfa 40
CDK4 40
MoAbs 40
Ab-dependent 40
Fanca(-/-) 40
(HIPEC) 40
ABCD2 40
haspin 40
Nox1, 40
dbSUPER 40
SUMOylation. 40
cell-expressed 40
SUDEP. 40
Ferroportin 40
ackee 40
(CUTs) 40
oxacillin 40
nursemaid's 40
Carpal 40
Tabix 40
lumican 40
dominant, 39
bowel. 39
line-derived 39
lactation 39
ligand. 39
transcribed, 39
Cells. 39
blot. 39
post-transcriptionally 39
let-7a 39
transcription-PCR 39
bisphosphonates 39
Fc 39
then, 39
layer, 39
Chest 39
neoplasms, 39
coincides 39
-3 39
oxidases 39
Agents 39
Pharmaceuticals, 39
multiple-dose 39
unacceptable 39
Trial. 39
fashion, 39
(20%) 39
(0 39
survivin, 39
modeling, 39
NSCs 39
(GO) 39
launched 39
project. 39
comparatively 39
Societies. 39
connects 39
speech, 39
treatable 39
big 39
junctin. 39
chromatography-tandem 39
choline 39
H4. 39
12-year-old 39
biopsies, 39
side, 39
limitations. 39
ESFT 39
Inherited 39
expected. 39
gain. 39
Great 39
Ireland. 39
79% 39
discriminant 39
2004. 39
risk: 39
were, 39
142 39
non-significant 39
Symptom 39
plateau 39
lipids. 39
visit. 39
plethora 39
uc.388 39
decide 39
postdose 39
crosslinked 39
telomerase, 39
Carney 39
cTnC 39
mimicked 39
Mood 39
G1/S 39
sumoylation. 39
mammal 39
worked 39
constraint 39
translocate 39
unit, 39
morbid 39
Defective 39
(55%) 39
spermatids, 39
tumor-initiating 39
analogues, 39
substitutes 39
PIWI 39
(19%) 39
(72%) 39
inoculation 39
colony-forming 39
0.006). 39
investigated, 39
Kidney 39
count. 39
Service 39
(CYP) 39
(VPA) 39
starvation, 39
autoregulatory 39
deprivation. 39
mTOR. 39
material. 39
crystallographic 39
12.5 39
Tay 39
nodule 39
blockade. 39
(pooled 39
phenotype-genotype 39
wall, 39
thickness, 39
Ustilago 39
uninfected 39
browsing 39
choices 39
edited 39
survey. 39
rotation 39
Measure 39
flies, 39
PABP 39
TDP-43, 39
manipulations 39
reparative 39
serotonin, 39
indeed, 39
Yet 39
initiator 39
histology. 39
mosquitoes, 39
(Ki 39
tonic 39
IFN-beta 39
radiotracer 39
suggestions 39
keywords 39
saxagliptin 39
parallel-group, 39
(19 39
pioglitazone 39
Multivariable 39
moves 39
lincRNA 39
4H 39
poly(ADP-ribosyl)ation 39
Fluorescent 39
CHD7 39
CHD4 39
array. 39
FAD 39
invasiveness. 39
relationships. 39
alpha. 39
levodopa. 39
Twenty-four 39
ischaemia 39
211 39
male. 39
node-negative, 39
altitude 39
panic 39
SERCA. 39
GSH 39
supervised 39
Tetrahymena 39
spermatogenesis. 39
(miR-21) 39
Chlamydia 39
N-glycolylneuraminic 39
thromboplastin 39
acpA 39
participants) 39
5q 39
Introduction 39
caveolae 39
distances. 39
Cohesion 39
26, 39
propidium 39
DSBs. 39
post-natal 39
MADRS 39
Mfd, 39
choroidal 39
artery. 39
Days 39
75) 39
customized 39
(TF) 39
MLN4924. 39
(reduced 39
frailty 39
wt 39
rodents, 39
GRK2 39
CD40 39
activity; 39
CD99, 39
examinations. 39
0.03), 39
seriously 39
movements. 39
FOXO 39
felt 39
acyl 39
Km 39
(mostly 39
Pathways 39
assembling 39
30-day 39
Tamoxifen 39
paradoxical 39
myoclonus 39
(95%) 39
MSS 39
fibres. 39
SP 39
Juvenile 39
ibuprofen 39
ERAP2 39
SAH, 39
vaccines, 39
questions. 39
Interleukin-6 39
multiorgan 39
electrolyte 39
fulfilling 39
(available 39
α-Synuclein 39
Paroxetine 39
more. 39
(PAH). 39
9/Delta 39
vagus 39
(78%) 39
AB 39
head-on 39
interview 39
promising, 39
ulcers, 39
Lange-Nielsen 39
IR-induced 39
Colombian 39
primers. 39
base-pair 39
water. 39
Substitution 39
megakaryocytes 39
CBF 39
periportal 39
Nkx2-5 39
Tofacitinib, 39
High-throughput 39
traction 39
L-T3 39
MWS, 39
Complications 39
MBT 39
consciousness, 39
Arthritis 39
uracil-DNA 39
SNRPN 39
baricitinib 39
anti-CD20 39
transabdominal 39
sonography 39
lone 39
stenting 39
PTH 39
crizotinib. 39
anti-citrullinated 39
Epworth 39
ISMARA 39
INO80 39
jaundice. 39
high-affinity, 39
betrixaban, 39
Enterobacteriaceae 39
enrichments 39
pheochromocytoma. 39
anti-interleukin-6 39
Armodafinil 39
RPL11 39
tissue-targeting 39
hematomas 39
8-oxo-GTP 39
1858T 39
A:T 39
ephrinA1 39
necrolysis 39
rash. 39
fluconazole 39
OCA2 39
antipsychotic-induced 39
sAC 39
poly-ubiquitination 39
DV 39
CBZ-induced 39
bmi-1 39
θ 39
niraparib, 39
AmpA 39
hyperlipoproteinemia. 39
FSP27 39
(OCA) 39
crowned 39
hypoalbuminemia 39
Mcidas 39
UBCs 39
andexanet 39
ribociclib 39
MPE-Fe(II) 39
TcdA 39
hard-to-replicate 39
EEM 39
Rpb9 39
53BP1. 39
Halyomorpha 39
inconclusive. 38
multiple, 38
cholangiocarcinoma 38
6.0 38
elegans. 38
Invasive 38
cysteine-rich 38
spliceosomal 38
(ncRNAs) 38
convincing 38
178 38
Pharmacologic 38
mirror 38
therapy) 38
Vaughan 38
compilation 38
potentials. 38
-2, 38
coexpressed 38
multitude 38
ipilimumab, 38
Pooled 38
1.02 38
receptor-negative 38
nM. 38
anti-HER2 38
ErbB 38
palmitate 38
tumour. 38
AI 38
San 38
counteracting 38
non-human 38
haploid 38
infertility, 38
topics 38
Cx43 38
Na 38
remodelling. 38
comparably 38
preparation, 38
physical, 38
kindred. 38
Force 38
(amino 38
tails. 38
centrifugation 38
(30%), 38
c-jun 38
G(2)/M 38
light, 38
pathophysiology, 38
meningiomas, 38
rearrangements, 38
need. 38
biochemistry 38
oncogenesis. 38
circumvent 38
Korea. 38
Investigations 38
runners 38
IBS 38
PMDD 38
interindividual 38
cTnI 38
meaning 38
[OR 38
tall 38
(16 38
occurred, 38
collected. 38
microenvironment, 38
relevance. 38
151 38
(17 38
Sonidegib 38
branched 38
people, 38
M., 38
118 38
Post-translational 38
Sequential 38
adriamycin 38
hospitalization. 38
serologic 38
singleton 38
Late 38
renal, 38
inherited, 38
lavage 38
(24%) 38
elaborate 38
2-4 38
End 38
hypertelorism, 38
gene-environment 38
plates 38
Med 38
counter 38
4-5 38
mode. 38
fractions. 38
extracting 38
EST 38
globule 38
(CRS) 38
hypoplasia. 38
eyelashes 38
[CI]: 38
(KO) 38
pores 38
celecoxib 38
thalidomide. 38
patchy 38
Mesenchymal 38
SF 38
everolimus, 38
Basel 38
neuroinflammation 38
(to 38
classifying 38
insulation 38
(CTCF) 38
at-risk 38
synchronous 38
RBP 38
RNA-protein 38
editing, 38
transition, 38
heel 38
Microsatellite 38
insertion, 38
regenerating 38
Taking 38
demonstrated, 38
[Molecular 38
genuine 38
low-level 38
(2:1) 38
(1). 38
BI 38
diabetes: 38
A1C 38
P-glycoprotein 38
arousal 38
wakefulness 38
psychotropic 38
TIMP-1 38
pursued 38
Assay 38
fishes. 38
Vaccine 38
spermidine 38
progeroid 38
Centromere 38
CHARGE 38
catalyzing 38
diltiazem 38
spleen, 38
multispecific 38
aldosterone 38
fragmentation. 38
glycerol 38
neurophysiological 38
herbal 38
stimulator 38
0.18 38
pyrosequencing 38
SERCA, 38
SERCA2a. 38
catalase 38
probiotics 38
distributional 38
modeled 38
germ-line 38
Ki-67 38
heparins 38
employed. 38
plasmids, 38
mechanically 38
priori 38
fusions, 38
prosurvival 38
S-phase. 38
Enrichment 38
completed. 38
stoichiometry 38
firstly 38
irradiation, 38
urokinase 38
epithelioid 38
oscillator 38
anthracyclines 38
proving 38
blunt 38
orthologue 38
femur 38
13-cis-RA 38
p53-mediated 38
intercalate 38
derivatives. 38
rotational 38
base, 38
Electrophysiological 38
learning, 38
vesicles, 38
distributions. 38
platelets. 38
paucity 38
quest 38
quarter 38
fruits 38
ward 38
IIb 38
gangliosidosis 38
ganglioside 38
rough 38
microphthalmia 38
motor, 38
midbrain 38
BTHS 38
knock 38
mosaicism. 38
code, 38
withdrawal, 38
adjust 38
localised 38
ketone 38
price 38
hospital, 38
Bioprinting 38
variations, 38
incidence. 38
characteristically 38
avoided. 38
resolved. 38
adhesion. 38
nearest 38
nonredundant 38
DCP1 38
5'-to-3' 38
glycolysis, 38
Mcl-1 38
duloxetine 38
mouth, 38
SDHD, 38
SDHB, 38
SDHC, 38
syncope, 38
relieves 38
accumbens 38
operation, 38
Research, 38
variegation 38
slow-wave 38
medulla 38
IPF 38
neutrophils, 38
simplicity 38
aids 38
fight 38
UTRs 38
sequence-based 38
pull 38
broadens 38
AAV 38
Site-directed 38
phosphopeptide 38
PF 38
features: 38
8-methoxypsoralen 38
melanomas. 38
(maximum 38
SALL4 38
LSD1, 38
ADHD 38
nonsustained 38
bottleneck 38
adjudicated 38
CSD 38
lobes 38
inoperable 38
lymphangiogenesis 38
Rac1, 38
p15 38
methylator 38
potato 38
Macroautophagy 38
BS 38
coincident 38
RYR2 38
noteworthy 38
antimitotic 38
WMS 38
RMS 38
Varespladib 38
CA 38
miR-16 38
NF-SLN 38
UCB 38
enrichment, 38
O. 38
emerin 38
SE 38
Matuzumab 38
NS5B 38
BAM 38
23, 38
peptidylarginine 38
ocrelizumab, 38
prions 38
landmark 38
deaminases 38
APOBEC3A 38
Lubag 38
gfi1aa 38
APOBEC3G, 38
Rotor-type 38
jaundice 38
films 38
anti-MM 38
Malgaigne 38
Glyburide 38
T2D 38
hormone-related 38
loud 38
prophase 38
pertuzumab 38
Afamelanotide 38
sling 38
Gb 38
hyperthermic 38
Oncotype-DX 38
GBP 38
EBNA1 38
protons 38
Slc9a6 38
MRSA. 38
DAL 38
osteoanabolic 38
hepadnaviral 38
Apremilast, 38
Osteogenesis 38
ctcf 38
FBXW7-185aa 38
LINC-PINT 38
Quervain's 38
stink 38
relatives. 37
dominance 37
compromised. 37
resources. 37
shedding 37
terminus. 37
EGFR. 37
recipient 37
movement. 37
tubule 37
(excluding 37
OPG 37
discrepancies 37
Moreover 37
Peak 37
advancing 37
Osteoporosis 37
raloxifene 37
immunotherapeutic 37
consultation 37
marketing 37
grade. 37
erosions 37
dependence, 37
Brief 37
5.7 37
Fifty-three 37
obstacle 37
30) 37
twofold 37
MDA 37
paths 37
reproduced 37
advantages, 37
accompany 37
proteome. 37
categories. 37
annotation, 37
fine-tuning 37
Panx1 37
RV 37
8.1 37
Interstitial 37
shortening, 37
accumulations 37
imposes 37
signatures, 37
Supporting 37
myopathic 37
WBC 37
KCl 37
ms, 37
SERCA2a, 37
hypothalamus, 37
beta- 37
yr, 37
walls 37
LPS-induced 37
p38alpha 37
genome: 37
derivatives, 37
partner. 37
directly. 37
converge 37
cisplatin, 37
belief 37
complication. 37
syndrome; 37
low-fat 37
neurohormonal 37
necessary, 37
refer 37
headaches, 37
Practice 37
HL 37
169 37
marathon 37
Now 37
English-language 37
260 37
interference, 37
trimethylation. 37
Considerable 37
nasopharyngitis, 37
Identifier: 37
labile 37
(14%) 37
curve, 37
methodology, 37
H3, 37
T-cells 37
Pancreatic 37
precursors, 37
i) 37
minutes) 37
fetus. 37
departments 37
first-trimester 37
32, 37
blots 37
bear 37
radiographs 37
endolymphatic 37
insulin-independent 37
dapagliflozin 37
fractionated 37
spin 37
PSG 37
cardiorenal 37
iron, 37
package, 37
scarring 37
visualizing 37
fundus 37
PON1 37
Toxicity 37
(7%) 37
battery 37
glycan 37
suspect 37
3-week 37
IL6 37
fibroblast-like 37
11.5 37
(83%) 37
formalin-fixed, 37
Kaposi's 37
cycle-dependent 37
(BiFC) 37
(PPI) 37
ideas 37
coactivators 37
analogue, 37
Lin28 37
circularization 37
residue, 37
mutant-FUS 37
TAR 37
isomerase 37
physiology. 37
prototypical 37
socioeconomic 37
(COMT) 37
defined, 37
switches 37
Initiation 37
frames 37
duplication, 37
competes 37
GTPase-activating 37
HIF-1alpha 37
dephosphorylated 37
axons. 37
parenchymal 37
brains. 37
scintigraphy 37
chemistry, 37
DPP4i 37
reason, 37
impaired. 37
rifampicin 37
references 37
0.17 37
facilities 37
URL: 37
actions, 37
poisoning. 37
unstructured 37
ensemble 37
dispersion 37
cmt3 37
myelination. 37
loop, 37
174 37
neurotransmission. 37
oligodendroglial 37
melanomas, 37
Negative 37
(27%) 37
inositol 37
EAAT2 37
mimicry 37
folding. 37
4.7 37
mediators. 37
catalysis 37
neuropathies. 37
unsupervised 37
PCNA 37
preconditioning 37
Center. 37
regeneration, 37
LC3-II 37
required, 37
nonsteroidal 37
tripartite 37
DNMT3a 37
endothelin-3 37
simian 37
currents. 37
immunoprecipitated 37
Hz 37
C++ 37
162 37
intolerance. 37
(TR) 37
attacks. 37
immunoglobulins 37
children: 37
lymphangioleiomyomatosis 37
turnover. 37
1996 37
NAE 37
adduct 37
Neddylation 37
(37%) 37
appealing 37
94% 37
gene-expression 37
tamoxifen, 37
0.75 37
(CI), 37
larvae 37
Ablation 37
cytarabine 37
spectroscopy. 37
CA1 37
PDZ 37
forest 37
top-down 37
diagnostics. 37
FHOD1 37
actin-rich 37
interrupting 37
61% 37
Work 37
ESRD 37
adjustments 37
disorders: 37
forkhead 37
Neuropsychological 37
cell-autonomous 37
DNMT1, 37
Age, 37
events) 37
populated 37
(particularly 37
RLS, 37
hypersomnia 37
122 37
fibroblastic 37
hfq 37
non-neoplastic 37
curation 37
mice) 37
10), 37
acyclovir 37
MCT4 37
90%, 37
MDD, 37
conservation. 37
beta-MHC 37
bedside 37
(NMD) 37
bapineuzumab, 37
reversibility 37
invited 37
13) 37
oxytocin 37
putamen 37
effectors, 37
thousand 37
IFN-gamma 37
Williams-Beuren 37
Ser129 37
practitioner 37
US, 37
GISTs 37
well-differentiated 37
mesothelial 37
anoikis. 37
gnotobiotic 37
C2 37
appropriateness 37
(91%) 37
NACP/alpha-synuclein 37
ultrasonic 37
fertilization 37
Generalized 37
Disorders, 37
Nov 37
(RSV) 37
isoproterenol-induced 37
malnutrition. 37
deiodinases 37
GD. 37
intrahepatic 37
palpebral 37
mg: 37
(HCNEs), 37
bilayer 37
interpretation. 37
adult-onset 37
oedema 37
TALEN 37
CPC 37
NP 37
machineries 37
DNMT3L 37
MutL 37
planktonic 37
biofilms 37
V60L 37
ethics 37
dacarbazine 37
hyperprolactinemia 37
cyanobacteria 37
xanthine 37
GBS 37
miR-146a, 37
azathioprine 37
Lepidoptera 37
primrose 37
PiggyBac 37
prioritization. 37
H3K4me1 37
sellar 37
U.G 37
(MLP) 37
MASP-3 37
Set2 37
irritation 37
(HS) 37
odorant 37
azygous 37
ready-to-use 37
MeCP1 37
reversal. 37
glucuronidated 37
Piwi 37
narrowband 37
laryngospasm 37
Alisertib 37
AHDS 37
IHPS 37
ID4 37
tirilazad 37
Cdc48 37
Dabrafenib 37
subtilis. 37
phototherapy 37
user-understandable 37
Eph 37
TAS-102 37
(SMN) 37
space-occupying 37
Tretinoin 37
CD38+ 37
indel 37
MRP2, 37
UvrAB 37
adalimumab. 37
Niraparib 37
UBQLN2 37
oxidase, 37
HA-MRSA 37
25-aa 37
pri-miRNA 37
Vanoxerine 37
027 37
SMARCB1 37
libgapmis 37
ProADM 37
marmorated 37
obstruction. 36
3.9 36
Goldberg-Shprintzen 36
(EGF) 36
Good 36
4-fold 36
superfamily. 36
removal. 36
tables 36
K. 36
absorption, 36
(AUC) 36
cross-over 36
aforementioned 36
; 36
knowledge. 36
nodes. 36
blockers. 36
II), 36
arrival 36
serially 36
immunostained 36
(six 36
Signal 36
Selected 36
initiative 36
experiment. 36
cartilaginous 36
γ 36
repolarization. 36
(NCX) 36
cirrhosis. 36
4th 36
comparison, 36
wanted 36
dystrophy: 36
manipulate 36
solvent 36
coefficients 36
bromodomains 36
Histologically, 36
presented, 36
treatment-resistant 36
unresolved 36
freedom 36
100%. 36
oncoproteins 36
simulations. 36
circuits 36
adipocytes, 36
modalities. 36
2012). 36
endometriosis, 36
childbearing 36
up. 36
controversial, 36
NT-pro-BNP 36
143 36
comorbidities, 36
widened 36
overgrowth. 36
gestalt 36
vedolizumab, 36
overrepresented 36
481 36
pathobiology 36
intermediate. 36
sarcoma/peripheral 36
regulator. 36
(FRDA) 36
AID 36
correlation. 36
surprisingly, 36
G, 36
firm 36
attended 36
balancing 36
Telomeres 36
immortalization 36
Slug 36
beta-catenin, 36
FN 36
hospitalization, 36
hemisphere. 36
ultrastructure 36
on. 36
aggregation, 36
importance, 36
palbociclib 36
Features 36
wearing 36
registry. 36
low- 36
senses 36
cytometry, 36
thyroid-stimulating 36
Level 36
hypogonadism, 36
AHR 36
healing, 36
deaths. 36
H19/Igf2 36
Abnormalities 36
clones. 36
broaden 36
observed; 36
Paediatric 36
elusive, 36
repeat. 36
orchestrates 36
Sulfolobus 36
denoted 36
Whole-genome 36
Tudor 36
IH 36
feature, 36
neuroradiological 36
Krit1 36
malformation, 36
electromyography 36
Weight 36
hypoglycaemia 36
discontinued. 36
Matrix 36
Neutrophil 36
submit 36
Germany 36
axons, 36
(OI) 36
degenerate 36
van 36
L.) 36
capturing 36
Murine 36
Correlation 36
intraneuronal 36
intact. 36
allocation 36
Cost-effectiveness 36
Spain 36
poststroke 36
prolongs 36
IGF-I 36
rT3 36
MAO 36
following: 36
relocation 36
Arabidopsis, 36
mucosa, 36
pag 36
MDS. 36
Tet2 36
uni- 36
AG 36
non-tumor 36
Reversible 36
century. 36
Regions 36
killed 36
recurrent, 36
RAD51 36
single-molecule 36
elderly, 36
Cumulative 36
Aortic 36
mother, 36
sonographic 36
assistance 36
dexamethasone, 36
lymphomas. 36
potency. 36
Guidelines 36
(DUSP8) 36
suffix 36
IX 36
B-carotene 36
Acetylation 36
topoisomerases 36
representatives 36
Schizophrenia 36
oncogenes. 36
therapeutics, 36
proteases, 36
polyphenol 36
PI3K/AKT 36
insurance 36
Subclinical 36
longevity. 36
bedaquiline 36
persisting 36
FoxO 36
contracted 36
Circadian 36
embolism, 36
international, 36
Evaluating 36
formally 36
engineering. 36
1:1:1 36
down-regulates 36
(MWS), 36
(SCLC) 36
examinations, 36
page 36
FINDbase 36
displace 36
P-bodies. 36
exoribonuclease 36
transformation, 36
clozapine 36
NANOG 36
nucleotides, 36
Menzerath-Altmann 36
paused 36
lunar 36
IPF. 36
hemophilia 36
(1, 36
Dental 36
behaviors, 36
GM 36
GAP 36
obstacles 36
hepaticus 36
presumptive 36
MTMR2 36
positioning. 36
stratum 36
expiratory 36
(mepolizumab) 36
eosinophils, 36
phenotyping 36
KCNH2 36
syncopal 36
allodynia 36
controls). 36
(residues 36
COL5A2 36
(PBMCs) 36
alcoholics 36
lysine-specific 36
Gfi 36
grafts 36
thioredoxin 36
• 36
villus 36
Protection 36
insects 36
referring 36
fugu 36
Riedel 36
(DNMT1) 36
ABL1 36
RBCs 36
lipodystrophy 36
Treated 36
Snord116 36
(CPVT), 36
7.4 36
Cdc14 36
Tax 36
dislocation 36
MCM7 36
areflexia 36
Optogenetic 36
(SLN) 36
programmes. 36
super-enhancer 36
MUG 36
tissue-type 36
Paneth 36
prothymosin 36
plating 36
(SLEDAI) 36
teriflunomide, 36
chimpanzee 36
gfi1b 36
cannula 36
lobules, 36
Cy 36
(TIA) 36
osteomyelitis. 36
RPS24, 36
TCS 36
varsity 36
Fyn 36
ITL 36
Perry 36
hyperhomocysteinemia 36
Eteplirsen 36
covered: 36
ESR1 36
apoE2 36
CSN5 36
E-PASS 36
rotator 36
Jamaican 36
Mondor's 36
hemangioma. 36
VX-509 36
h19 36
Rap1p 36
Abf1p 36
auxin-inducible 36
ligamentum 36
teres 36
MR-pro-ADM 36
valaciclovir 36
20-fold 35
submucosal 35
192 35
BRAF, 35
TNBC 35
weakness. 35
(p<0.001) 35
2009), 35
Change 35
cholinesterase 35
settings, 35
arm. 35
docetaxel. 35
Newer 35
147 35
ethnically 35
PC12 35
dermatology 35
precede 35
proarrhythmic 35
pointes 35
chemotherapy-naive 35
p<0·0001). 35
(human 35
labels 35
nonessential 35
HSP90 35
FISH, 35
leukemogenesis. 35
(within 35
delivers 35
ranked 35
transcriptomics 35
constituting 35
retina 35
flow, 35
echocardiography, 35
CAD. 35
rigidity, 35
micromol/L 35
sibs 35
entitled: 35
(23%) 35
Viral 35
Junctin 35
devoted 35
turns 35
sequestering 35
electrospray 35
LC 35
M) 35
published. 35
center, 35
(ASD) 35
gastritis 35
contributors 35
disruption. 35
convergence 35
spectrum, 35
invaluable 35
pathognomonic 35
sarcoma-associated 35
sarcomas 35
Joint 35
cofactors, 35
IL-2, 35
IL-4, 35
balance. 35
session. 35
higher, 35
sedentary 35
circulation, 35
138 35
inflamed 35
evoke 35
Young 35
coping 35
long-distance 35
minutes, 35
5.3 35
gynecological 35
≥10 35
193 35
assignment. 35
rehabilitation. 35
faced 35
420 35
mmol/L) 35
AE 35
single, 35
assessable 35
Excellent 35
toxicities, 35
BCC 35
helicases 35
assessments. 35
Clinical, 35
definition, 35
substitution, 35
People 35
mg; 35
telomerase. 35
whereas, 35
bears 35
homologies 35
factor-induced 35
Epithelial-mesenchymal 35
rapamycin. 35
rapamycin, 35
restriction. 35
testis. 35
sorafenib, 35
machines 35
subpopulations. 35
melting 35
dysmorphism, 35
Distal 35
N-cadherin 35
prediction, 35
CDK4/6 35
Mexican 35
(PS) 35
undescribed 35
digestion. 35
sepsis, 35
subgroups, 35
Do 35
twenty 35
screen, 35
cross-resistance 35
borders 35
temozolomide. 35
(area 35
GBM, 35
Concomitant 35
bevacizumab, 35
traits, 35
resilience 35
plaques. 35
neocortical 35
Generally, 35
materials, 35
membranous 35
TTAGGG 35
PAR-CLIP 35
up, 35
codon, 35
women) 35
discriminatory 35
(except 35
component, 35
mitigate 35
profilin 35
insults 35
happiness 35
(PE) 35
7.0 35
Africans 35
g, 35
7.1 35
prolapse 35
perineal 35
aggravated 35
(DPP-4) 35
Spatial 35
alogliptin 35
satisfy 35
(difference 35
NYHA 35
elegans, 35
α-synuclein, 35
TATA 35
DRM 35
(GFP) 35
nucleoporin 35
arch 35
symmetry 35
dysgenesis 35
SMC 35
GCs 35
203 35
Flaviviridae 35
Oct3 35
Transport 35
antioxidant, 35
Deregulation 35
mediators, 35
droplets. 35
72% 35
validates 35
attain 35
effort. 35
CpGs 35
precordial 35
PLN. 35
intakes 35
133 35
Significantly, 35
(DC) 35
mucocutaneous 35
(DBA), 35
BACH1 35
185 35
libraries. 35
Abs 35
Amongst 35
non-valvular 35
host, 35
virulence. 35
atxA-null 35
intestine. 35
speckles 35
networks, 35
I(to) 35
RRM 35
intertwined 35
mg/m(2). 35
Anaplastic 35
0.05, 35
basolateral 35
accuracy, 35
Repair 35
ophthalmologic 35
ventricle. 35
lungs. 35
predictability 35
prodromal 35
comprehension 35
mg/m2, 35
search, 35
radioligand 35
(motif 35
aneuploidy, 35
99% 35
EWG 35
anorexia 35
22) 35
(IFN) 35
alkaloids 35
DOX 35
(PD), 35
Aptamers 35
HPV16 35
antithrombotic 35
destructive 35
medulloblastomas. 35
arrays. 35
thyroiditis. 35
exocrine 35
Chinese. 35
chondrocytes, 35
society. 35
term. 35
clocks 35
correspondence 35
determination. 35
(60%) 35
VTE 35
spherical 35
preference. 35
countless 35
Preoperative 35
high-frequency 35
given. 35
France 35
death-1 35
filopodial 35
genomewide 35
NCCM 35
boys. 35
5'-3' 35
(RNAi) 35
XRN1 35
function: 35
(PCI) 35
attacks, 35
disruptions 35
"reverse 35
BCR-ABL1 35
receptor) 35
454 35
(MDD). 35
5-HT7 35
formats 35
iterative 35
periphery. 35
(75%) 35
foundations 35
Axonal 35
infertile 35
(DBS) 35
mt 35
spark 35
toxicological 35
symptoms: 35
higher. 35
re-uptake 35
Dysphoric 35
compulsive 35
Centre 35
R3H 35
karyotype. 35
Extended 35
myo-inositol 35
polymerases. 35
eosinophils. 35
photosensitivity. 35
keratoconic 35
0.99 35
unbound 35
Solanezumab 35
capping 35
TDT 35
methyl-CpG-binding 35
erythroleukemia 35
V3 35
newborns. 35
ERK5 35
tofacitinib, 35
joints, 35
HPRT1 35
brucei. 35
constantly 35
Elmo1(-/-) 35
DNMT3b 35
sgRNA 35
thermogenic 35
spermatid 35
facet 35
DNMT1. 35
solving 35
~ 35
FA-D1 35
FANCD2, 35
tears 35
puffer 35
selected. 35
acidemia. 35
comatose 35
.001), 35
alphabet 35
F508 35
oat 35
interferon-beta 35
CAM 35
(GA) 35
apnea. 35
dreaming 35
HFD 35
CD44v 35
injections. 35
parasites. 35
NIHSS 35
Set1 35
visualization. 35
CARD4/NOD1 35
intraobserver 35
Kartagener 35
Kartagener's 35
ASSET 35
miR-375 35
x-linked 35
Next-generation 35
prolactinoma. 35
callers 35
(phase 35
amphioxus 35
tea 35
hexanucleotide 35
LPIN2 35
Kir6.2 35
Ixodes 35
Rickettsia 35
UL42 35
noggin 35
FeSulf 35
fasudil 35
pupils 35
PRD 35
(DIPG) 35
L-DOPA-induced 35
benserazide 35
PSP-like 35
angiodysplasia 35
ovale 35
cardiotoxicity, 35
PLX3397 35
COL1A2 35
Gabapentin 35
methadone 35
PrP 35
RAD1901 35
5p 35
cocoa 35
Morsier 35
Gomafu 35
perforation, 35
Ssu72 35
MET-positive 35
SOLO 35
Foxp1 35
obeticholic 35
ARG 35
lucinactant 35
NNS 35
Hy's 35
patisiran 35
text]-avoided 35
trismus 35
white-tailed 35
await 34
6.2 34
sex-linked 34
skewed 34
interfered 34
EGF, 34
(OS). 34
panitumumab 34
junctions, 34
0.004) 34
competitively 34
annotation. 34
at: 34
supernatant 34
(PBMC) 34
(qRT-PCR) 34
leave 34
miR-148a 34
T-score 34
(BMD) 34
acetate, 34
ng/ml, 34
segmentation 34
homolog, 34
lining 34
Form 34
efficiently. 34
erlotinib. 34
adenoid 34
(100%) 34
substantiated 34
indexes 34
(patient 34
(HF). 34
MI, 34
rhythm, 34
dilation, 34
diameter, 34
retinoblastoma 34
tips 34
transcribing 34
definition. 34
transcription-dependent 34
(encoding 34
Polish 34
diagnoses. 34
Netherlands 34
triadin. 34
relaxed 34
columns 34
feed 34
(27 34
co-activators 34
(23%), 34
24. 34
manuscript 34
(LPS) 34
osteomyelitis, 34
upregulating 34
sheds 34
oxygenase-1 34
IkappaBalpha 34
high-confidence 34
AEDs 34
anaphase. 34
up-regulating 34
signatures. 34
HUS 34
proteinuria, 34
glucagon-like 34
triglycerides, 34
SD, 34
categorical 34
occlusion. 34
3.8 34
item 34
velocities 34
completing 34
HRT 34
dormant 34
ORs 34
overall, 34
self-monitoring 34
Recruitment 34
(63%) 34
nasopharyngitis 34
on-treatment 34
Transcribed 34
microarrays. 34
hydrolytic 34
methyl-directed 34
cytogenetically 34
G4 34
going 34
lab 34
heterozygous, 34
disclose 34
segregates 34
nonfunctional 34
thirty 34
seeds 34
18. 34
Inc 34
monocytes, 34
granulocyte-macrophage 34
shorten 34
(IKK) 34
collective 34
Unit 34
Logistic 34
Birth 34
OBJECTIVES: 34
format. 34
chromatography/mass 34
function; 34
(150 34
(300 34
sutures, 34
cause, 34
KCNJ10 34
encountered. 34
enamel 34
Linear 34
dosage. 34
DES 34
Caucasians. 34
warning 34
(74%) 34
cues, 34
destabilize 34
folding, 34
glycol 34
lysosome-associated 34
polyubiquitinated 34
ramoplanin 34
smegmatis 34
broth 34
Venous 34
weeks). 34
(PR) 34
died, 34
IA 34
(2.5 34
(seven 34
filters. 34
cartilage. 34
therapeutical 34
facets 34
harms 34
suppression, 34
Integrated 34
resolves 34
intranuclear 34
Subcellular 34
acetyl 34
kills 34
autoimmunity, 34
normalizing 34
down-regulating 34
non-parametric 34
deviation, 34
spatio-temporal 34
avenue 34
Phenotype 34
probes, 34
5.4 34
re-expression 34
interference-mediated 34
counseling, 34
exonization 34
EADs 34
CMT. 34
flow. 34
tendons 34
T(4) 34
sacrificed 34
homogenates 34
obliteration 34
Later, 34
Symptomatic 34
5). 34
schedule. 34
criteria: 34
(CV) 34
tolerance, 34
HMG-CoA 34
recurrence-free 34
everyday 34
qPCR 34
alpha-synuclein. 34
teeth. 34
eukaryote 34
repeat, 34
Poly(ADP-ribose) 34
plasmon 34
interpret 34
Intrinsic 34
incompatible 34
Over-expression 34
guanylate 34
complicate 34
low-affinity 34
blindness. 34
periodicity 34
worm, 34
Adjuvant! 34
(P<0.05) 34
CMT2D 34
projections 34
fluorescently 34
buildup 34
H4K20me1 34
genome-scale 34
congenita. 34
Transmission 34
mg/kg), 34
Blackfan 34
Observation 34
time-lapse 34
anthracis, 34
(+) 34
probing 34
pathologies, 34
FANC 34
answers. 34
(CNVs) 34
T(1)AM 34
mm) 34
capped 34
blasts 34
156 34
(DSB) 34
CSB 34
3-methyladenine 34
regimen, 34
arsenite 34
keratoses 34
Isotretinoin 34
users, 34
teratogenicity 34
hit 34
decatenation 34
side. 34
methamphetamine 34
orchestrate 34
IS 34
silver 34
Quantification 34
Craniofacial 34
Pathway 34
51% 34
point, 34
(CKD) 34
dataset. 34
integrins, 34
availability. 34
Subgroup 34
causally 34
left-sided 34
Cardiolipin 34
fibrillation: 34
discontinuing 34
repositories 34
heme, 34
virions 34
TBI, 34
(ranging 34
hydrogels 34
geometry 34
sequentially 34
asexual 34
infancy, 34
correlations. 34
Norwegian 34
sized 34
beneficial, 34
DNA-damage 34
up-regulate 34
CD8(+) 34
Germany. 34
alpha-tropomyosin 34
cells). 34
BMI1 34
AURKA 34
3'-5' 34
Xrn1 34
nucleocytoplasmic 34
inulin 34
intraventricular 34
multikinase 34
STI571 34
first-generation 34
any, 34
2000, 34
(MDD) 34
encephalitis. 34
SDHA, 34
High-resolution 34
Google 34
NCBI 34
degree. 34
authorization 34
moderate, 34
walked 34
1995 34
BJU 34
Progression 34
Nature 34
streptozotocin 34
military 34
adaptors 34
CD8+ 34
doctors 34
sublingual 34
non-receptor 34
estimates. 34
on-demand 34
PE. 34
168 34
counteracted 34
(ESES). 34
CB 34
demise 34
XLMTM 34
surgeon 34
translocase 34
folic 34
epilepsies 34
T-wave 34
foot. 34
4.1 34
midbrain. 34
risperidone 34
KCNJ2 34
cardiomyocyte-like 34
microtubules, 34
polycistronic 34
worsen 34
Bach1, 34
commentary 34
text] 34
LDs 34
execution 34
Fibroblasts 34
Hck 34
SOX2 34
AL 34
UCP1 34
PUMA 34
ETV6 34
XI 34
jaundice, 34
melanocortin-1 34
10-mg 34
usage. 34
FAST 34
cMTs 34
fish. 34
summer 34
streptavidin 34
(TTFields) 34
S6Ks 34
mitogen 34
protochlorophyllide 34
DNM2 34
cm(3) 34
board 34
LAMP-2A 34
(Group 34
PR2-bias 34
CD44v6 34
uveitis. 34
LepChorionDB, 34
interneuron 34
PAP 34
Ptch 34
prostanoid 34
pre-replication 34
ECX 34
(NIHSS) 34
flibanserin 34
5-HT(2A) 34
progeria 34
pigmenti. 34
mibefradil 34
PAS 34
gadolinium-enhancing 34
sphingosine-1-phosphate 34
expose 34
machine-learning 34
5-azacytosine 34
SEA0400, 34
carbapenemases 34
direct-acting 34
mitofilin 34
metaproteomics 34
mole 34
SWD 34
RPS17, 34
Ham-D 34
MLN8237 34
Francisella 34
MutY 34
Niemann-Pick 34
Aicardi-Goutières 34
bioremediation. 34
EphrinB2 34
ocular, 34
gp210 34
ESCRT 34
osteotomy 34
arimoclomol 34
EP 34
des-acyl 34
β3 34
alectinib 34
hydroxymethylation 34
CRISPRi 34
oligonucleotide, 34
excursion 34
CTS 34
microbicide 34
transcranial-orbital 34
EHS 34
(K27M) 34
verubecestat 34
Ssu72, 34
677C-->T 34
Y' 34
citicoline 34
short-segment 33
heparin-binding 33
neoplasm. 33
Exosomes 33
0.02), 33
C/D 33
Denosumab 33
(especially 33
Healthcare 33
offset 33
Numb 33
CYP 33
29, 33
prednisone. 33
(33%). 33
FISH. 33
relying 33
down-regulate 33
needed, 33
resembled 33
(18%) 33
funding 33
proposes 33
16. 33
sarcolemma 33
inconsistencies 33
Maximal 33
Na+/Ca2+ 33
O2 33
truncate 33
can, 33
flat 33
SR, 33
diluted 33
pre-treated 33
versatility 33
subclass 33
restriction, 33
perspectives. 33
office 33
NH2-terminal 33
SA 33
elusive 33
optimally 33
toxicology 33
EYA3 33
NPY 33
C3 33
C4 33
compromising 33
hemolysis, 33
complicating 33
plasmapheresis 33
insulin. 33
6.8 33
hypothesised 33
half-lives 33
Finland. 33
glioma: 33
bones, 33
Dec 33
snoRNAs 33
(HCC). 33
Gel 33
abasic 33
230 33
Safety, 33
feces 33
3-5 33
solution, 33
actin, 33
HC 33
deacetylation, 33
Constitutive 33
imprint 33
ii) 33
13), 33
Angiogenesis 33
messages 33
threefold 33
non-motor 33
mutation; 33
Crown 33
situation. 33
Forest 33
immunotherapy, 33
sustaining 33
duplexes 33
(IC(50) 33
Hoechst 33
P250R 33
deformities, 33
11.1 33
goitre 33
osmotic 33
(FFPE) 33
measured, 33
(36 33
genotypes, 33
(HDACi) 33
orally, 33
(TSA) 33
Association, 33
land 33
9.5 33
(43%) 33
neurosurgery 33
stand 33
lifelong 33
autopsy. 33
caregiver 33
depleting 33
effectiveness, 33
erlotinib, 33
Library, 33
conflicts 33
regulated, 33
(exon 33
dsRNA 33
transitions. 33
Immunoprecipitation 33
amiodarone, 33
Base 33
age) 33
placing 33
(SECIS) 33
issued 33
154 33
dynamic, 33
(ALS). 33
(SGs), 33
fibrogenic 33
Interleukin 33
lived 33
U937 33
evident, 33
reconstructed 33
cylindromatosis, 33
adrenocortical 33
calmodulin-dependent 33
disease-relevant 33
hemorrhages 33
safer 33
separately. 33
reader 33
linagliptin 33
1.00 33
MMP-9, 33
concern. 33
Alpha-synuclein 33
MEFs 33
oxidoreductase 33
propagate 33
nucleoplasmic 33
pharyngeal 33
pest 33
Copy 33
extract. 33
agree 33
Groucho 33
lives 33
symptom. 33
defibrillator 33
g) 33
COUGER 33
anxious 33
Down-regulation 33
faces 33
consecutively 33
season 33
miR-138 33
alleviating 33
cytosines 33
sarcolemmal 33
cardiomyopathies 33
cycling. 33
tighter 33
experiment, 33
(usually 33
0.90 33
Localization 33
kidneys. 33
situations. 33
feeding. 33
type) 33
synergize 33
molar 33
condensation, 33
expansion, 33
reconcile 33
primates, 33
Haemophilus 33
crystallography 33
vomiting. 33
2003. 33
MALDI-TOF 33
HER2+ 33
PARPi 33
heteromeric 33
drainage. 33
transduce 33
flies. 33
cardioversion 33
diuretics 33
requirements. 33
CaMKII-dependent 33
vigorous 33
(LQTS) 33
Dual-specificity 33
on-line 33
Cluster 33
hypercalcemia 33
PpIX 33
malformed 33
babies 33
stroma. 33
Topoisomerase 33
termination, 33
bridges 33
knocked 33
spheroid 33
yr. 33
0.002), 33
Forty-two 33
FT4 33
elder 33
11) 33
proves 33
phosphatase-1 33
group: 33
older, 33
Plasmodium, 33
proteolysis. 33
deciding 33
ERα 33
peer-reviewed 33
seedlings 33
(90% 33
leader 33
related, 33
QTL 33
p16INK4a 33
formulate 33
indinavir, 33
filopodia. 33
matter, 33
metric 33
ESCC. 33
extents 33
hyphal 33
strips 33
TKIs. 33
CML, 33
traced 33
agonist. 33
haematoma 33
Kingdom 33
survivors. 33
Siberia 33
illnesses 33
(CNS). 33
spliceR 33
Population 33
fluoxetine 33
E2-2 33
latencies 33
Initially 33
nonresponders 33
Intervention 33
(45 33
48, 33
side-effects. 33
barely 33
deadenylases 33
melphalan 33
commensal 33
reuteri 33
effusion, 33
Cyld 33
LB 33
8-year-old 33
ambulation 33
LMNA 33
KVLQT1 33
Africans. 33
raptor 33
cohort: 33
TAL1-associated 33
neuroleptics 33
4-year 33
BIX-01294 33
CRISPR-Cas9 33
vitiligo, 33
NF449 33
polymerization, 33
BK 33
(more 33
mesenteric 33
R151C, 33
studies) 33
adenocarcinomas. 33
fission. 33
flap 33
Propionic 33
bundles. 33
J, 33
etioplasts 33
light-harvesting 33
embolization 33
water, 33
15q11-q13 33
Sarcolipin 33
microcephaly. 33
Elements 33
osteodysplastic 33
ung 33
TAM 33
natalizumab 33
mono-ubiquitination 33
Tn-seq 33
Gamma 33
IFT 33
anti-IL-17A 33
GPU-based 33
Vif-deficient 33
heroin 33
G-banding 33
XDP 33
CaV1.2 33
hydroxylation 33
IQGAP1 33
coproporphyrinuria, 33
near-absent 33
gene-finding 33
human-mouse 33
MARs 33
(NEB) 33
archaeological 33
SUR1 33
new-onset 33
rrm3 33
aclarubicin 33
CD38. 33
ChIRP-seq 33
Chagas 33
IGFBP7 33
Wnt/ß-catenin 33
high-flow 33
F]MH.MZ 33
FFI 33
MR-guided 33
chat 33
Wellens' 33
surgery-field 33
lingua 33
lossless 33
apocynin, 33
NSD-1015, 33
furin-dependent 33
striae 33
eumelanin 33
LedPred 33
(RPS19) 33
PTSD. 33
UBE3B 33
JPS 33
RG 33
circ-FBXW7 33
ERCC1-XPF 33
myenteric 32
Bardet-Biedl 32
cytokine, 32
adenylate 32
chemokines, 32
nonneoplastic 32
pave 32
(lncRNA) 32
Transcript 32
miR-100 32
paclitaxel. 32
gathered 32
junction. 32
Autoimmune 32
paramount 32
factor-kappaB 32
CRPC. 32
contaminated 32
Dishevelled 32
ganglionic 32
mucous 32
syndrome): 32
amiodarone. 32
digoxin 32
actions. 32
calcium-dependent 32
distributed, 32
(of 32
bifunctional 32
anti-human 32
acinar 32
enforced 32
cloning. 32
incorrect 32
deeply 32
brains, 32
vasculature. 32
fish, 32
fulfill 32
undesirable 32
untreated, 32
kidneys, 32
>50% 32
report]. 32
intrafamilial 32
vasculopathy 32
load, 32
alpha-myosin 32
seldom 32
pesticide 32
Gram-positive 32
Bacteria 32
impossible 32
(59%) 32
Concentrations 32
preponderance 32
gabapentin, 32
topiramate, 32
cofactor, 32
Helicase 32
gemcitabine. 32
infusions. 32
cortisol, 32
absorption. 32
p<0.001) 32
Colorectal 32
fibromyalgia. 32
peaked 32
percentile 32
MB 32
Observational 32
menopause. 32
difficulties. 32
Clinicaltrials.gov 32
Statin 32
(36%) 32
dyslipidemia 32
arthralgia, 32
leukemias. 32
uc.73 32
explants 32
Cys 32
neuroepithelioma 32
(CR) 32
promises 32
in-house 32
Elimination 32
Processing 32
RNA:DNA 32
bp. 32
Expansion 32
nonfunctioning 32
1; 32
inactive. 32
smokers. 32
H3S10P 32
(not 32
12) 32
chemoimmunotherapy 32
Oncogenic 32
conditionally 32
sequestered 32
(PI) 32
corroborate 32
deaths, 32
(52%) 32
cesarean 32
preeclampsia, 32
throat, 32
bird 32
959 32
geographically 32
prioritized 32
involuntary 32
synergism 32
Focused 32
reaches 32
methotrexate, 32
.05) 32
TWIST 32
FGFR3. 32
intra- 32
uncovers 32
deaf 32
Northeastern 32
extraction, 32
specialty 32
discrepancy 32
follicularis, 32
137 32
RPA 32
Lysosomal 32
nucleoid 32
aureus, 32
11.4 32
(400 32
B1, 32
(42%) 32
astrocytoma, 32
Twenty-nine 32
dyspnea 32
nausea. 32
quartile 32
TSC2, 32
interrogation 32
anthropometric 32
Computed 32
cores 32
unappreciated 32
exacerbate 32
stratify 32
Elucidation 32
infects 32
kDa) 32
AIRE 32
crosslink 32
preparation. 32
spasticity, 32
obtained, 32
Pearson 32
oxidation. 32
fatal, 32
span, 32
myofibroblast 32
(MMPs) 32
Repression 32
10(-6) 32
thanks 32
exactly 32
detail, 32
timing, 32
investigations, 32
face. 32
SMA. 32
complex: 32
fragmented 32
plasticity, 32
T-lymphocytes 32
3T3 32
pRb 32
arachidonic 32
mother's 32
leaky 32
Embase 32
who, 32
Otherwise, 32
(average 32
ab 32
Botulinum 32
hypogonadotropic 32
(TSA), 32
propagated 32
ISWI 32
polytene 32
H3K27me3, 32
Homologous 32
Defining 32
2005. 32
phyla 32
1970s 32
maze 32
scission 32
capsules 32
Italy, 32
accessibility, 32
node-positive 32
IGF 32
orientation. 32
(500 32
n-3 32
GlyRS 32
GARS, 32
savings 32
fascinating 32
recapitulates 32
Shwachman-Diamond 32
occult 32
(IP) 32
enzymatically 32
SIRT1, 32
1.4% 32
enrichment. 32
calibrated 32
Doses 32
anthracis. 32
topologies. 32
Caveolae 32
boundaries, 32
Triiodothyronine 32
B30.2 32
hubs 32
era. 32
D4 32
temperature-sensitive 32
leading-strand 32
RhoC 32
plots 32
hemoglobin, 32
Brazil. 32
bulky 32
prokaryotes. 32
dissection, 32
Idiopathic 32
8.7 32
paradigm. 32
TSC, 32
pCR 32
Ubiquitination 32
G(1) 32
well-designed 32
complementarity 32
(BMI) 32
relevant. 32
0.025% 32
rabbits. 32
16) 32
393 32
reactivate 32
stapled 32
schizophrenic 32
outgrowth. 32
transporter-1 32
Simulations 32
NHS 32
chimeras 32
Medulloblastoma 32
N-myc 32
ouabain 32
empty 32
preferable 32
archived 32
Syndrome, 32
infection: 32
dysarthria. 32
dystonic 32
glucosyltransferase 32
beta-gal 32
Synthetic 32
demographics 32
PS. 32
(ED) 32
vascularized 32
agonists. 32
single-copy 32
tetrodotoxin 32
electromyographic 32
(CCFDN) 32
boosting 32
mol 32
rs75932628 32
Therapeutics 32
Conclusion 32
JARID2 32
(trisomy 32
hydrops 32
soma 32
Dasatinib 32
Ph+ 32
Commission 32
XR 32
Thailand 32
cats 32
feasible, 32
endonucleolytic 32
rhythm. 32
antisera 32
(A) 32
(RPE) 32
dystrophin-associated 32
hyperacetylated 32
deployed 32
deployment 32
granuloma 32
(mean, 32
noise, 32
hematologic, 32
pyknons, 32
run-on 32
lambda 32
PDGFRA 32
DAOY 32
reporters 32
light-induced 32
(NHE6) 32
Klotho 32
Arnold-Chiari 32
mutagenicity 32
Reviews 32
Cyld(Delta 32
(26 32
Bypass 32
kg/m(2) 32
reviews, 32
vasculitis. 32
Berardinelli-Seip 32
ulceration 32
chemopreventive 32
topography-guided 32
grain 32
exosomal 32
p32 32
hiPSCs 32
(LQTS), 32
ptosis. 32
epidermis. 32
3'-UTR 32
bilirubin, 32
nuclear-encoded 32
Glioma 32
Rheumatology. 32
infliximab, 32
readthrough 32
(CASQ2) 32
headings 32
4q35 32
Irg1 32
calstabin2 32
ubiquitylated 32
weight) 32
seipin 32
Nivolumab 32
E1B 32
Ixazomib 32
myeloma: 32
PEG 32
antiestrogen 32
inactive, 32
FGFR3, 32
ammonia 32
mTORC2, 32
chemoprevention 32
implement 32
Intraoperative 32
suffers 32
S, 32
clock-controlled 32
heat-induced 32
CEP290 32
Super-enhancers 32
excise 32
alkylated 32
(FISH), 32
brain-specific 32
mRS 32
bacilli 32
postmitotic 32
activity-regulated 32
wounds 32
NS3/4A 32
11.0 32
telcagepant, 32
pack/day 32
Pembrolizumab 32
leucocyte 32
Hoffmann-La 32
CZP 32
RTS,S/AS01(E) 32
illicit 32
stabilizer 32
Cart1 32
Q 32
Cse4 32
Enterobacter 32
hypoxanthine-guanine 32
classifier, 32
polyps. 32
Nemaline 32
RESID 32
RPL11, 32
RPS24 32
ricinus 32
bites 32
G3BP2, 32
HRC(S96A) 32
ESET 32
EphB4 32
(CYLD) 32
stationary-phase-induced 32
Histatin 32
psychosine 32
mg/kg/wk 32
oligodeoxyribonucleotides 32
Logan 32
MT-A70 32
customizable 32
decompressive 32
Linux 32
TEMSO 32
ZNF335 32
coal 32
cri 32
(FOP) 32
iridum 32
Bexsero® 32
CIDEA 32
lichen 32
gorilla 32
IL-18BP 32
AFL 32
EXCEL 32
CNCs 32
oculocerebrofacial 32
pregenome 32
pollicis 32
ROF1 32
Ketoacidosis 32
libgapmis, 32
PSI 32
PNH 32
calciphylaxis. 32
fibrocyte 32
circ-ABCB10 32
famciclovir 32
births, 31
cetuximab, 31
AC 31
gut. 31
significance, 31
phagocytic 31
Inhibiting 31
proteases. 31
chromatin-associated 31
apoptosis-inducing 31
miR-132, 31
0.52 31
(29 31
126 31
alendronate 31
delaying 31
forearm 31
argues 31
ECG, 31
-4 31
endothelium. 31
Inc, 31
(TAK-700) 31
[HR], 31
8.3 31
Oncology. 31
Dose-limiting 31
likely, 31
competence 31
selectivity. 31
Specificity 31
PCa. 31
docetaxel, 31
qualities 31
6), 31
cell-like 31
Selection 31
output. 31
non-overlapping 31
roles, 31
Alpers 31
vasoconstriction 31
90-day 31
relations 31
ascertainment 31
pre-messenger 31
pubertal 31
DCIS 31
(SR). 31
RyR2, 31
sediments 31
probed 31
domain) 31
achalasia 31
stomach, 31
discomfort 31
assessments, 31
Estrogen 31
MAPKs 31
Metastasis 31
interferon-gamma 31
CRMP2 31
unique, 31
Depending 31
actinomycin 31
Compound 31
GSTM4 31
inactivity 31
standardised 31
7), 31
ANOVA 31
h). 31
receptor-interacting 31
237 31
hypermethylation, 31
amplifying 31
approached 31
questionnaires. 31
after, 31
players. 31
breastfeeding 31
Longitudinal 31
frameshift, 31
mild. 31
Evolocumab 31
rhabdomyolysis 31
bad 31
DLT 31
alopecia. 31
lymphoblasts 31
excessively 31
unanticipated 31
impede 31
agarose 31
16-year-old 31
infrequent 31
ears 31
choose 31
territory 31
influenza. 31
immunized 31
conception 31
contradictory 31
China, 31
BHC 31
(GRN163L), 31
wet 31
different, 31
shape, 31
Clin 31
feet, 31
petrous 31
trait, 31
Depressive 31
self 31
ABCB1, 31
Carriers 31
0.67, 31
mTORC1, 31
inevitably 31
intermediates. 31
Incorporation 31
staphylococcal 31
10). 31
(58%) 31
dose-finding 31
gather 31
mg). 31
Release 31
Open 31
tasks, 31
Toxic 31
Thirty-three 31
(CMV) 31
EWSR1 31
modules. 31
cohesin's 31
PPIs 31
scientists 31
(about 31
buccal 31
smear 31
U. 31
virally 31
Kong 31
Hypothyroidism 31
0.43 31
weighed 31
decoding 31
filtered 31
[SD] 31
Towards 31
pH. 31
autonomously 31
diameter. 31
CYLD, 31
PTCH 31
mosquitoes. 31
phosphorylating 31
ER-associated 31
irritability, 31
Bioinformatic 31
stains 31
(SERCA), 31
monitored. 31
semen 31
injury: 31
blinded, 31
1.8% 31
treatment-naive 31
cope 31
granulocytes 31
family: 31
(EMT). 31
dimers. 31
Detecting 31
(DH) 31
reorganization. 31
minichromosome 31
Co-immunoprecipitation 31
duplex. 31
atresia 31
well-documented 31
retrotransposons. 31
stressors 31
repairing 31
Pathology 31
preinitiation 31
Metazoan 31
brand 31
BRCA2, 31
somatically 31
Immediately 31
Borderline 31
phospholamban. 31
(GARS) 31
gene; 31
0.69 31
Hematopoietic 31
head, 31
10(6) 31
suppressors, 31
donors, 31
implications, 31
miR-21. 31
synthase, 31
immunosuppressant 31
229 31
UA 31
vacuoles 31
streptococcus 31
specially 31
antiinflammatory 31
Transcripts 31
Assuming 31
Xq28 31
cardiac, 31
disturb 31
lamina-associated 31
sub-nuclear 31
isometric 31
restricting 31
Old 31
unclassified 31
19S 31
CTF4, 31
establishment. 31
leukemia: 31
relapsed, 31
comet 31
UvrA 31
collateral 31
Fab 31
events; 31
stomatitis 31
retreatment 31
0.72 31
phylogeny. 31
adduct. 31
(ABC) 31
valvular 31
167 31
tamoxifen. 31
ng/mL. 31
hypercalciuria 31
telomere-binding 31
controversies 31
mitoxantrone 31
Lewis 31
Concomitantly, 31
immunogold 31
pulsed 31
wilt 31
Digital 31
Opioid 31
GSK-3 31
invadopodia. 31
upcoming 31
nucleoids 31
self-limiting 31
euthyroidism 31
(serum 31
today. 31
chiefly 31
C). 31
speakers 31
Reflux 31
hemiparesis, 31
cases]. 31
acyltransferase 31
noncarriers 31
job 31
Epidemiology 31
(ET) 31
tailor 31
NPV 31
ketogenic 31
multi-center 31
(SMD 31
sleepiness, 31
RCT 31
wake 31
donor. 31
Achondroplasia 31
neurturin 31
shallow 31
radiography 31
reinforce 31
shRNA-mediated 31
Meta-analysis 31
eubacterial 31
context-dependent 31
N-end 31
codeletion 31
skip 31
table 31
inulinase 31
CBS 31
cough, 31
leucine-rich 31
alpha-synuclein, 31
bcr-abl 31
endowed 31
increase. 31
(PCC) 31
SDHAF2, 31
Ghent 31
cardioverter-defibrillator 31
transcription-repair 31
Co-expression 31
microsomes 31
EDSS 31
deplete 31
aneurysm, 31
irritability 31
pheochromocytoma, 31
nerve, 31
(TSSs) 31
self-renewing 31
flank 31
AIS 31
sleeping 31
HIV-negative 31
CRD 31
implementation. 31
vertebra 31
encounters 31
end-organ 31
generalize 31
alpha-subunit 31
Wide 31
4E-BP1 31
malarial 31
exchanger, 31
rice, 31
post-mortem 31
Chinese, 31
glucocerebrosidase, 31
HIF1alpha 31
CoREST 31
(iPSC) 31
(MFS), 31
skeletal, 31
adult. 31
Assembly 31
Maf 31
R329Q 31
Predictive 31
5-aza-2'-deoxycytidine 31
dystrophin. 31
hiPSC-derived 31
Ryanodine 31
glands, 31
diaphragm 31
DNMT3A 31
mitochondrially 31
JTV519, 31
pseudoautosomal 31
centile 31
tolerant 31
CPAP 31
fluctuations. 31
beliefs 31
FoxOs 31
JIA 31
psoriasin 31
populate 31
alpha-glucosidase. 31
IKKβ 31
PLK 31
draining 31
[95 31
sweep 31
microdeletions. 31
bite 31
encapsulated 31
MER 31
LCP 31
H2A.Z. 31
TLR2 31
capitis 31
OBJECTIVE 31
IN 31
Jeune 31
DYNC2H1, 31
market. 31
Tet 31
Results. 31
captive 31
ctDNA 31
vibrational 31
IE 31
venography 31
CCSVI. 31
pro 31
piebaldism 31
KI 31
(ED). 31
disposition. 31
arboviruses 31
hypersensitivities. 31
conjugates) 31
edoxaban, 31
mosquito-borne 31
transperineal 31
mH2A1 31
Sjogren's 31
AAUAAA 31
EJ 31
messaging 31
thumb 31
basal-cell 31
femtosecond 31
MP 31
Pds5B 31
flumazenil. 31
Aleglitazar 31
Doxorubicin 31
Stent 31
Alagille 31
ferroportin, 31
miR-335 31
relaxin 31
daratumumab. 31
OikoBase 31
Delirium 31
nicastrin 31
employees 31
Ngb 31
nicastrin, 31
ALDH2 31
spondyloepiphyseal 31
zoster, 31
CARMEN 31
Revascularization 31
CONTACT: 31
(COP9) 31
Fibrodysplasia 31
ABCC 31
iron-regulatory 31
FIM 31
ADL 31
LIMT 31
DMT1-mutant 31
H3.3. 31
H3-K27M 31
lymphatics 31
Khib 31
hemangiomas. 31
hyperhomocysteinemia. 31
SKA2 31
ribotype 31
photoaged 31
TMEM132 31
Ozanimod 31
minutissimum 31
lycopersici 31
Dialectical 31
bug, 31
first- 30
SOX10, 30
(GDNF) 30
Pituitary 30
confluent 30
situ. 30
calculations 30
P<0.05) 30
internalized 30
DTC 30
shapes 30
myotube 30
dodecyl 30
Zebrafish 30
resorption. 30
IL-17, 30
feasible. 30
ptosis 30
preferably 30
life-long 30
anecdotal 30
Adherence 30
approvals 30
DVL1 30
Wnt/beta-catenin 30
minimized 30
torsades 30
(class 30
debate. 30
10%, 30
2C9 30
testosterone, 30
AACR 30
Inhibitory 30
retarded 30
Growing 30
hormone-dependent 30
immunodeficient 30
finally, 30
joined 30
pluripotency, 30
donor, 30
MITF, 30
choosing 30
bases. 30
collaborative 30
foster 30
projects. 30
retina. 30
(ATP) 30
localizations 30
ions, 30
Dysfunction 30
dysfunction: 30
subendocardial 30
bradycardia, 30
(ACE) 30
assessed, 30
disease? 30
criterion. 30
SMCHD1 30
B12 30
Roma 30
auxiliary 30
sparks 30
quantification. 30
Action 30
Mutagenesis 30
radiofrequency 30
regard, 30
facts 30
purity 30
localizing 30
concise 30
Nowadays, 30
Phosphorylated 30
macroscopic 30
DAX1 30
more, 30
bortezomib-based 30
Tunisian 30
cleavage, 30
leptin, 30
Leptin, 30
INTRODUCTION: 30
stents 30
5.9 30
Adolescent 30
laparoscopy 30
hypersensitivity. 30
(73%) 30
harvested 30
.01). 30
Berlin 30
wide. 30
1992 30
topic. 30
exceeds 30
Applications 30
CI) 30
identifier: 30
intolerance, 30
Along 30
(SAM) 30
methylate 30
proceed 30
Cloning 30
kb. 30
dealing 30
C9orf72 30
tracts. 30
hypotheses. 30
(FIPA) 30
L29Q 30
etc.). 30
spreads 30
astroglial 30
intraocular 30
pneumonitis 30
apparent. 30
clathrin-mediated 30
0.45 30
Atopic 30
shape. 30
CS. 30
fits 30
some, 30
witnessed 30
Therapies 30
growth-inhibitory 30
organification. 30
Presence 30
dilatation, 30
/ 30
Others 30
albicans. 30
including: 30
sulfur 30
self-organizing 30
PAD 30
Platelet 30
0.74 30
mTORC1. 30
chitin 30
subtilis, 30
particulate 30
-resistant 30
sunitinib 30
1-5 30
10.8 30
METHODS 30
anti-tumour 30
tiredness 30
(MSCs) 30
behaviour, 30
R, 30
geriatric 30
ChIA-PET 30
SCD. 30
(RF) 30
immunoprecipitation. 30
functionality. 30
cross-link 30
AIT, 30
Three-dimensional 30
N-glycosylation 30
Aggregation 30
removed, 30
challenges, 30
limbic 30
fitted 30
h), 30
electrophoresis, 30
archaeon 30
Accelerated 30
organisation 30
trichoepithelioma 30
limb. 30
(42 30
multiplicity 30
Government 30
capillaries 30
variable. 30
dysplasias 30
analogs. 30
classifies 30
hinder 30
(80 30
Distribution 30
Administration, 30
extent. 30
noradrenergic 30
awakening 30
antitumoral 30
France. 30
Å 30
nociception 30
hypogonadism. 30
GnRH 30
Toxoplasma 30
nuclear, 30
nerve. 30
misexpression 30
contraindicated 30
cardioverter 30
Impairment 30
sizes, 30
259 30
fine-tunes 30
serology 30
penumbra. 30
height, 30
173 30
21-gene 30
tri-iodothyronine 30
Depressed 30
sex-determining 30
intercalated 30
(age, 30
9), 30
probiotic 30
Lactobacillus 30
45-year-old 30
complex) 30
co-regulation 30
ad 30
immune-related 30
apixaban. 30
concentrates 30
advise 30
rivaroxaban. 30
Warfarin 30
(TM) 30
antiserum 30
timescale 30
virus-induced 30
LADs 30
late-replicating 30
locations, 30
grouping 30
(cohort 30
DT40 30
Sexual 30
TP53, 30
Excision 30
Coupled 30
before. 30
(HIV) 30
8.0 30
8), 30
K4 30
pancreas. 30
nmol 30
discordance 30
benefit, 30
system: 30
enChIP 30
dose-dependent, 30
HCG 30
10(-5) 30
lymphopenia, 30
R6/2 30
endosome 30
type-1 30
Translocation 30
Islands 30
Blue 30
immunostimulatory 30
Volatile 30
HSC 30
immediate-early 30
(STAT3) 30
microRNAs. 30
oncogene-induced 30
re-established 30
ng/mL, 30
TOR 30
starved 30
mix 30
60, 30
klotho 30
airways 30
psychotic 30
CRY1 30
ACS 30
omics 30
Basic 30
Dynamics 30
featured 30
SCA 30
abundances 30
willingness 30
respiration. 30
inspired 30
object 30
consideration. 30
hydrolyze 30
Amyloid 30
IIA 30
nystagmus, 30
Prominent 30
neurogenetic 30
cyclophilins 30
zebra 30
oncogene, 30
listing 30
Sustained 30
proline-rich 30
neighbor 30
prostatectomy. 30
uncovering 30
immunocompetent 30
RM 30
twice-daily 30
iNOS 30
ketamine 30
CpG-rich 30
HDAC6, 30
long-lived 30
valves 30
Promotes 30
synthetic, 30
p63 30
terminates 30
Endoplasmic 30
alemtuzumab, 30
X-chromosomal 30
intersection 30
Mobile 30
Boehringer 30
esophagus 30
i.v.) 30
intervals, 30
implantation, 30
cilia, 30
0.97 30
biomechanical 30
PAH, 30
compliance, 30
exported 30
(5mC) 30
(SLE). 30
exceptions 30
IGF-II 30
FEB 30
second-trimester 30
E2-conjugating 30
FSH 30
1.25 30
HES 30
interictal 30
spike 30
polysomnography 30
SCN5A, 30
Plantar 30
insulin-stimulated 30
uncorrected 30
AN 30
Man 30
waiting 30
Review. 30
HNC 30
CA9 30
striatum. 30
Careful 30
mmHg 30
selenoproteins, 30
ERG 30
GalNAcalpha1-O-Thr 30
glimepiride 30
spines 30
Ser16 30
intrathecally 30
co-administered 30
blurred 30
corticosterone 30
manipulating 30
CPCs 30
G1, 30
integrin-linked 30
CXCL12 30
NFκB 30
Hypermethylation 30
344 30
hemimethylated 30
ibrutinib 30
anti-obesity 30
ask 30
Nucleosomes 30
myosins 30
stones 30
SUMOylation, 30
ixazomib, 30
macroautophagy, 30
coiling 30
(OR: 30
(PP1), 30
footprinting 30
SDH 30
flash 30
chloroplasts. 30
LRSAM1 30
canakinumab 30
(SGLT-2) 30
talocalcaneal 30
permutation 30
Cohort 30
MFS. 30
c-MYC 30
peaking 30
plagiocephaly. 30
PsA, 30
quail 30
time-resolved 30
Sciences 30
phycoerythrin 30
isochores. 30
alpha-tubulin 30
enhancer-associated 30
hemostasis 30
asphyxiated 30
Simple 30
P<0.05 30
Cryptochrome 30
ciliopathy 30
vermis 30
Questionnaire. 30
(BCNU) 30
BRCA2. 30
optional 30
wood 30
HCP 30
lncRNAs, 30
(A3G) 30
(VE) 30
overdose, 30
Sleepiness 30
fistulas 30
Anoikis 30
detoxification-limiting 30
minichromosomes. 30
PDGFRB 30
investigator 30
KATP 30
RPS10 30
MDL 30
Xq26.3 30
+8 30
NGF 30
C1858T 30
monosymptomatic 30
PUBMED 30
"ideal" 30
DENV-2 30
EphB2 30
CBs 30
BOR 30
crown 30
DCTN1 30
Coilin 30
cryptogenic 30
GAS 30
enteropathy. 30
presenteeism. 30
PsA. 30
(MUL) 30
bronchiolitis 30
Sjogren 30
Thr3 30
PI3K-mTORC1 30
Thalamotomy 30
(fHbp), 30
Cistrome 30
'SDA 30
wiki 30
Noxa1 30
syndecan-3 30
Xpert 30
Siberia. 30
Bauer 30
Pro-hepcidin 30
(EHS) 30
HaploReg 30
hypolipidemia 30
PDS5B 30
PDE4 30
Fkh1 30
Kaufman 30
H3-H4 30
Grin2b 30
Ecm22 30
binaries 30
cervids 30
NLGN3 30
Studying 29
ultrasound, 29
compromises 29
correlations, 29
gene-gene 29
vagal 29
MoAb 29
gefitinib, 29
laminin 29
225 29
6.1 29
GENCODE 29
RNAs: 29
single- 29
decoy 29
28) 29
miR-152 29
Number 29
derivation 29
zoledronic 29
non-melanoma 29
lyase 29
payer 29
2002, 29
acrokeratosis 29
kg, 29
liposarcoma 29
lengthening 29
placebo: 29
0.67 29
shrinkage 29
(termed 29
(65%) 29
≥50% 29
chelator 29
Her2/neu 29
ligand-binding 29
(11%) 29
reprograms 29
(AP) 29
NSC 29
mapping. 29
conceived 29
293T 29
ring, 29
ammonium 29
think 29
Where 29
proband, 29
knocking 29
aquatic 29
Brd2 29
BET 29
buried 29
Hypertension 29
citalopram 29
Dermatologists. 29
augmenting 29
saliva 29
homogenous 29
session 29
PYY 29
J., 29
IAT 29
annually. 29
pitfalls 29
Can 29
7.3 29
coexist 29
demographics, 29
fibromyalgia 29
IC 29
intimate 29
RRs 29
impact. 29
diagnosed, 29
hospitals, 29
8.4 29
weekly. 29
effectiveness. 29
NSD1, 29
overlap. 29
attempting 29
PCSK9, 29
(PCSK9), 29
attitudes 29
Eventually, 29
Larger 29
ifosfamide 29
crossed 29
29-year-old 29
Liquid 29
FA(C) 29
reinforces 29
hybridized 29
kilobase 29
Occurrence 29
unequivocally 29
weakened 29
versa. 29
Snurf-Snrpn 29
dependently 29
macromolecules. 29
Src, 29
(ESCs) 29
Ki67 29
Soluble 29
6.3 29
6.9 29
resist 29
IL-13, 29
T-helper 29
discontinue 29
bicoronal 29
nucleotide-binding 29
closure. 29
Crouzon 29
(4%) 29
underway. 29
counselling. 29
thyroiditis, 29
confusion. 29
physiology, 29
monoallelic 29
label-free 29
bacterium. 29
[Clinical 29
surgery: 29
diffusely 29
3-year-old 29
starvation-induced 29
fosfomycin 29
glioblastoma: 29
(35 29
pazopanib 29
(OS), 29
sweat 29
conceptual 29
longstanding 29
tasks. 29
rearrangement. 29
imprinting, 29
(UTR) 29
crop 29
intensely 29
(NGS) 29
mg), 29
11.6 29
movements, 29
phases. 29
Cross-sectional 29
ALS-associated 29
aggregate, 29
nigra, 29
(designated 29
co-repressor 29
archaea, 29
Mycoplasma 29
metazoans 29
Slovak 29
inter- 29
melanocytic 29
ribonucleoproteins 29
parasite. 29
ICa 29
co-occurrence 29
trimeric 29
first-degree 29
asymptomatic. 29
Translational 29
perineurial 29
disk 29
beta-cell 29
subset. 29
(CLL) 29
recovering 29
reticular 29
MMP-3 29
faecal 29
antitoxin 29
manifestations: 29
monophyletic 29
floral 29
integrase 29
gondii 29
most, 29
18) 29
time-consuming 29
epithelia 29
laboratories. 29
veins. 29
flowering 29
intuitive 29
1.04 29
males) 29
monoaminergic 29
pro- 29
TGF-beta1 29
Bcl-2. 29
elevated, 29
twist, 29
globulin 29
acute, 29
circles 29
one-half 29
dollars 29
SSCP 29
train 29
Regular 29
post-synaptic 29
notably, 29
nerves, 29
contextual 29
synapsin 29
pigmentation, 29
DC. 29
person-years 29
AMI. 29
unambiguous 29
haemorrhagic 29
edoxaban 29
situations, 29
pXO2, 29
204 29
recurrently 29
(MDS). 29
derives 29
baby 29
overcame 29
enigmatic 29
acylation 29
lamina, 29
.01), 29
TRIM5α 29
genes; 29
Domain 29
delete 29
-1 29
frontline 29
gene-based 29
polymerases, 29
Ras-induced 29
combinations. 29
strand-specific 29
dissection. 29
gentamicin 29
azithromycin 29
institutional 29
Nedd8-activating 29
cullin-RING 29
panel, 29
suspicious 29
sarcoidosis, 29
practicing 29
ORFs 29
25OHD 29
stomach. 29
ALA 29
molecule-mediated 29
(PCR). 29
spacer 29
900 29
(less 29
GFAP 29
rectifying 29
execute 29
Green 29
lid 29
Panama 29
Notch, 29
stems 29
live-cell 29
NF1, 29
inflammatory, 29
Bristol-Myers 29
MDR-TB 29
Speech 29
FOXO1 29
adjustment. 29
Correction 29
alert 29
(EEG) 29
Facial 29
neurocognitive 29
schizoaffective 29
T1-weighted 29
SAT 29
adipogenesis. 29
Hg, 29
anticipate 29
discoideum 29
infused 29
fourth-generation 29
Single-cell 29
endpoints. 29
hardly 29
reflexes, 29
Thermal 29
opioids 29
Finger 29
researchers. 29
midface 29
dysfunction; 29
Shah-Waardenburg 29
WS4 29
endothelin-B 29
achieved, 29
2.6, 29
cis-trans 29
MA 29
5'-end 29
p16Ink4a 29
(P=0.02). 29
immunoaffinity 29
library, 29
Batten 29
ceramide 29
vector, 29
(EZH2) 29
21) 29
dissolution 29
Production 29
microbes 29
lidocaine 29
currents, 29
PCI. 29
normal) 29
"Reverse 29
mitophagy. 29
methylome 29
blastocyst 29
macroautophagy. 29
RNA-guided 29
(10%), 29
(34%) 29
mutation) 29
modulatory 29
(DS) 29
E1A 29
E2F 29
divide 29
pieces 29
repopulation 29
Publishers 29
remitting 29
caregivers. 29
(Abeta) 29
phylum 29
genome-wide, 29
calcific 29
individual, 29
readers 29
confusion, 29
spaces 29
now. 29
CSF, 29
(PTSD) 29
collaterals 29
adolescents, 29
poly(A)-binding 29
astrocytoma. 29
navigation 29
spliceosome, 29
myopathy: 29
claim 29
(WHO 29
antivirals 29
warranting 29
psoralen 29
linearly 29
Traumatic 29
Injury 29
212 29
Microscopic 29
HM 29
response) 29
(normal 29
Brazil, 29
PGE2 29
ABO 29
Athens 29
questionnaires, 29
equations 29
pumps 29
associated. 29
Heme 29
exporter 29
protein-based 29
tune 29
Hematology. 29
1p19q 29
PK/PD 29
etanercept, 29
Noncoding 29
sinusitis, 29
tibialis 29
non-linear 29
Hck. 29
knockouts 29
pipelines 29
landscape. 29
cranberry 29
Atg8 29
Rap1 29
Ophthalmic 29
words. 29
economically 29
fat. 29
conjunctival 29
flux. 29
orexigenic 29
operator 29
time-consuming, 29
evasion 29
bile. 29
favoured 29
utilised 29
miR-323-3p 29
actin-bundling 29
annealing 29
(specificity 29
affording 29
intraflagellar 29
Microsporidia 29
pigs. 29
PDAC 29
1-6 29
PRS-I 29
CDO 29
JBTS 29
FANCM 29
K(+)-depleted 29
erythematosus. 29
GDM. 29
non-CpG 29
standard. 29
IFT-B 29
Ceritinib 29
Methods. 29
phosphorodiamidate 29
hA3G 29
APOBEC3F, 29
CD, 29
server, 29
164 29
UvrB 29
GATA-1, 29
telemonitoring 29
Ca(V)1.2 29
insulin-producing 29
Bilirubin, 29
Abcc3, 29
Abcc3 29
liver-blood 29
CICR 29
SAMe 29
5'-triphosphate 29
Cocaine 29
thyrocytes 29
alcohol, 29
SPAN-100 29
CYP17 29
heterotachy, 29
topotecan, 29
Sri 29
MEC-17 29
twitcher 29
captopril 29
polC 29
Donohue 29
OATP1B3, 29
hepcidin. 29
R620W 29
trigonus 29
COSMIC 29
HD5 29
NOX1 29
SINEB2 29
Nox1. 29
Gitelman's 29
visualizes 29
Furin 29
Turner's 29
Cryptic 29
TRAMP 29
anti-GD2 29
001 29
Puffy 29
Wood's 29
smarcal1 29
CAR-T 29
IAA9 29
MARS 29
TCGA2BED 29
tezepelumab 29
Chocolate 29
RIblast 29
(SSPE) 29
Tinea 29
oxacillin-resistant 29
7.6 28
Taqman 28
lying 28
(EGFR), 28
0.54 28
MDCK 28
distinctly 28
explicitly 28
Transcriptome 28
κB 28
0.5, 28
studies: 28
Recommendations 28
Optimal 28
transitioned 28
probabilities 28
antibody-based 28
aerodigestive 28
III). 28
Fast 28
cholangitis 28
hairy 28
MAbs 28
mice; 28
necessitates 28
representations 28
screened. 28
Conclusions 28
Cytotoxicity 28
hESCs 28
differentiated, 28
0.13 28
encompassed 28
India, 28
ATP, 28
0.009). 28
Increases 28
deposition, 28
questioned 28
steatosis 28
Recessive 28
appreciable 28
neonate 28
amide 28
organophosphorus 28
energy. 28
BRG1 28
ileo-colonic 28
(7.5 28
interleukin-1 28
55-kDa 28
cascades. 28
described: 28
time-of-flight 28
benign, 28
ethosuximide, 28
Either 28
FLI1 28
TNF-induced 28
cure. 28
imperative 28
H, 28
intensities 28
hamsters 28
records. 28
Ninety 28
self-administered 28
recur 28
contraceptives 28
1.1, 28
entry, 28
contraception 28
(1%) 28
unaware 28
Internet 28
distress, 28
latter. 28
mmol/L 28
(SE) 28
183 28
precancerous 28
intermediate, 28
event-free 28
protooncogene 28
breakpoints. 28
builds 28
PRL 28
calcium-induced 28
P., 28
Acupuncture 28
Finally 28
141 28
centromere-specific 28
4/6 28
intradermal 28
screened, 28
Heat 28
Temozolomide 28
losing 28
up-regulates 28
morphogenic 28
Bcl-xL 28
XIAP 28
fivefold 28
agrees 28
España, 28
gait, 28
cotransfected 28
(57%) 28
nanoparticle 28
Dupilumab, 28
persistent, 28
Repeat 28
325 28
Sensorineural 28
immunocytochemistry. 28
substituting 28
phenocopies 28
Proteomics 28
CKD. 28
predictors. 28
wk. 28
whole-body 28
Report. 28
alopecia, 28
*2 28
ie, 28
Thirty-seven 28
EIAED 28
interior 28
discriminates 28
Enterococcus 28
Radiotherapy 28
(ClinicalTrials.gov 28
women; 28
underscoring 28
cartilage, 28
joints. 28
removed. 28
Inventory. 28
(protein 28
everolimus. 28
fine-needle 28
(12.5 28
epigenomics 28
ring. 28
reconstitute 28
strengths 28
(CREB) 28
Swiss 28
concept, 28
account. 28
0.05. 28
paraparesis 28
surgeons 28
interrater 28
ankle 28
hemiplegia 28
seen, 28
pelvis 28
IQ 28
retrospectively. 28
neurofibromas 28
backgrounds. 28
glycine-rich 28
Register. 28
heritability 28
0.33 28
opicapone, 28
lysosome. 28
fingerprints 28
NuRD 28
purposes 28
rarely, 28
c. 28
miniature 28
calcium/calmodulin-dependent 28
thapsigargin 28
CMT1 28
superimposed 28
boy. 28
1999. 28
Experience 28
authors. 28
nM), 28
ER, 28
VS 28
atherothrombotic 28
cardioembolic 28
horses 28
society 28
matter. 28
hydrolyzed 28
wealth 28
retroelements 28
rapidly, 28
stands 28
breaks, 28
littermates 28
plant, 28
supraventricular 28
0.87 28
thickness. 28
flaviviruses 28
Yellow 28
d-AMPH 28
synergizes 28
endometrium 28
disorganization 28
deleted, 28
(GBshape; 28
http://rohslab.cmb.usc.edu/GBshape/) 28
ursodeoxycholic 28
slope 28
Pharmacology. 28
(45%) 28
ACTH 28
(circRNA) 28
ultrasound. 28
R14del 28
(DCM). 28
fitness. 28
soy 28
myelinated 28
chromatin-modifying 28
MDS, 28
TERC 28
impairments. 28
crypt 28
embolic 28
scarce 28
plasmid, 28
orchestrating 28
factor), 28
structure-specific 28
proteasome-mediated 28
genes), 28
aberrations. 28
exchanges 28
D2, 28
aberration 28
carfilzomib, 28
microdomains 28
coiled 28
blockage 28
compartmentalized 28
experimentally. 28
Ctf18, 28
sister-chromatid 28
RF-C(Ctf18/Dcc1/Ctf8) 28
constituents. 28
nonrandomized 28
Non-small 28
HL60 28
MMD 28
clinics. 28
195 28
rereplication 28
Enforced 28
stores. 28
prudent 28
included: 28
arsenite-induced 28
reciprocally 28
chapter, 28
causality 28
turnover, 28
vulgaris. 28
5%, 28
provokes 28
Mus 28
NCI-60 28
gels 28
G-protein-coupled 28
eliminations 28
ambiguous 28
phosphoproteomics 28
ARC1779 28
vehicle-treated 28
(mtDNA) 28
request 28
advised 28
©2012 28
sweating, 28
college 28
CS1 28
provided. 28
(MDR) 28
Dysarthria 28
neurologists 28
quality-of-life 28
immunocytochemistry 28
0.96 28
formats. 28
metabolomic 28
scans, 28
Software 28
88%, 28
0.35 28
Technology 28
constructing 28
alginate 28
disturbance. 28
0.003) 28
gene-rich 28
GVIA 28
(LEMS) 28
pleiotropy 28
finite 28
formic 28
antigen-specific 28
beta-hydroxylase 28
animal, 28
livestock 28
transcriptome, 28
postnatally 28
(20% 28
(T-ALL) 28
niger 28
suddenly 28
[Ca2+]i 28
Holter 28
high-energy 28
effect" 28
fuel 28
directly, 28
front-line 28
outlook 28
mirtazapine 28
abiotic 28
incapable 28
cassettes 28
occurrences 28
ecology 28
(Arabidopsis 28
(NSCLC), 28
activators, 28
pneumonia, 28
CAMPATH-1H 28
senile 28
ZF 28
Bdf1 28
directions. 28
vibration 28
CD8 28
Kingdom. 28
thinking 28
thereafter, 28
psoriasis: 28
apremilast. 28
retrotransposons, 28
single-base 28
reacted 28
(DPI) 28
child, 28
discernible 28
fibrils. 28
BMI, 28
racial 28
tetrabenazine 28
TB. 28
hexamer 28
anti-interleukin 28
(administered 28
Epilepsy. 28
KvLQT1 28
U251 28
resveratrol-induced 28
post-surgical 28
paw 28
(mTOR), 28
DAS28 28
T3-dependent 28
well-tolerated, 28
Brownian 28
suramin 28
configurations 28
(MTX) 28
TALENs 28
state-dependent 28
exists. 28
afflicted 28
(ERT) 28
NF 28
k-mer 28
-5 28
nick 28
CPVT, 28
IgG4-related 28
resetting 28
crosses 28
Plants 28
overload-induced 28
apelin 28
Thr17 28
hypophysectomized 28
15q11q13 28
BAX 28
flushing, 28
service. 28
HbF 28
Hunt 28
inspected 28
dimer. 28
t-test 28
footprint 28
richer 28
DTS 28
over-expressing 28
Edition, 28
R406 28
defense. 28
encephalitis, 28
postmarketing 28
packages 28
extubation 28
front 28
RASFs. 28
Entrez 28
(RNA 28
clock. 28
Fascin 28
villous 28
aneuploidies. 28
Edema 28
Flecainide 28
phenomena. 28
text-mining 28
terms. 28
computes 28
nondividing 28
0.002 28
mismatch-specific 28
transversions 28
test; 28
(FTD) 28
Hutchinson-Gilford 28
cryptochrome 28
residency 28
Whole-exome 28
nitroprusside 28
sprouting 28
Reported 28
DAP3 28
tuberculin 28
wafers, 28
ficolin-3 28
pubis 28
Transcranial 28
Jup 28
aura 28
elegant 28
flutter 28
certolizumab 28
impediments 28
abatacept 28
R3R 28
R3C 28
UvrD 28
nodosum 28
exporter, 28
A3G, 28
Klinefelter's 28
HSV-1 28
streptokinase 28
RAF 28
detoxification-enhancing 28
Oatp1a/1b-deficient 28
HSCR-Waardenburg 28
Klebsiella 28
Firmicutes 28
metagenome 28
Polyadenylation 28
Behçet 28
anti-IL-6 28
(CNTO 28
referrals 28
androgenetic 28
spasm 28
Curcumin 28
17-hydroxylase 28
polyp 28
g/dL 28
MtuMutT1 28
Foxp3 28
CTLA4, 28
apnoea 28
DDK 28
"guardian 28
endotracheal 28
MTI 28
Rrm3p 28
RIP3 28
Tet1 28
protoporphyria 28
ATase 28
SV 28
dystromirs 28
monovalent 28
FBN1, 28
cannabis 28
commentary: 28
regorafenib 28
biosimilar 28
PrP(C) 28
RLP-C 28
statin-associated 28
deneddylation 28
suppurativa. 28
(DIPGs) 28
ASH 28
golimumab/standard 28
H4K20me2 28
Versus 28
Bupropion 28
transacylase 28
Unipolar 28
debarquement 28
melioidosis, 28
Verubecestat 28
RP-1127 28
(EL) 28
semaglutide 28
CDP-diglycerides 28
Pheochromocytoma 28
hypophosphatemia 28
LDL-R 28
photoaging. 28
XUTs 28
PRM1 28
(GRFs) 28
SIOD 28
SBQ 28
pharyngitis, 28
E-box-like 28
(SMR 28
A→I 28
OU, 28
R160W 28
DRPLA 28
low-penetrance 27
unsuccessful 27
Diverse 27
(HSCR, 27
KRAS, 27
docked 27
5-fold 27
lengths. 27
Exons 27
Twenty-six 27
ascites, 27
sustained-release 27
fracture, 27
Moderate 27
dasatinib, 27
estimated. 27
avoided, 27
polypeptide. 27
translocates 27
hands, 27
Antiarrhythmic 27
less, 27
cell-surface 27
considerations. 27
Randomisation 27
(25% 27
(47%), 27
2+ 27
PC3 27
Minimal 27
(PCa) 27
modalities, 27
organ. 27
MAb 27
3+ 27
EGFR-TKI 27
(FISH). 27
ERBB2 27
HER2/neu 27
0.03 27
protocols, 27
HMGA1 27
tyrosinase, 27
(PTMs) 27
gene's 27
digests 27
Spain, 27
purinergic 27
excretion, 27
aiding 27
Fifty-eight 27
Finding 27
identical. 27
BRCA1, 27
tetrameric 27
transients, 27
Accuracy 27
PE, 27
Brg1 27
simulations, 27
TFIID 27
(IBD). 27
poor, 27
caspase-3, 27
neuritic 27
published, 27
colleagues 27
expertise 27
impose 27
subclasses 27
analogues. 27
μM. 27
FK506 27
bed 27
appetite, 27
Coexpression 27
occlusion, 27
uterus. 27
covariates 27
satisfaction. 27
Important 27
treadmill 27
NH(2)-terminal 27
Social 27
≥2 27
only) 27
≥1 27
Automated 27
self-management 27
attrition 27
distress. 27
mark. 27
unanswered. 27
genetics. 27
outlines 27
52. 27
moieties 27
rhabdomyosarcoma, 27
neuroblastoma, 27
remissions 27
tumour, 27
smoothened 27
Periodic 27
Transcription-associated 27
pituitary. 27
M, 27
ineffective. 27
economical 27
maintained. 27
GM-CSF 27
Concurrent 27
inflammation-related 27
siRNA, 27
detached 27
Widespread 27
trimester, 27
Cytokine 27
lungs, 27
Probe 27
(MLPA) 27
TTF-1 27
clathrin-coated 27
forskolin 27
motivated 27
insertions, 27
Nell-1 27
BrdU 27
separation, 27
aqueduct, 27
phenylalanine 27
sac 27
glycopeptides 27
spectrometer 27
Analogue 27
T12 27
2-year-old 27
tortuosity 27
exists, 27
TLR 27
attenuation. 27
inconsistent. 27
217 27
0.69, 27
apparatus. 27
appearance. 27
perturbing 27
abbreviated 27
(CI): 27
(75 27
B). 27
institution. 27
Neuroticism 27
Small-molecule 27
mantle 27
1.27 27
(EBV) 27
enhancer-blocking 27
mid-S 27
signal-to-noise 27
tethered 27
capacities 27
energetic 27
aetiological 27
CREB-binding 27
RSTS 27
amplicons 27
7th 27
let-7 27
cross-linking. 27
diplegia. 27
hind 27
boys, 27
selenoproteins. 27
NLS 27
fibronectin, 27
sections. 27
half-life, 27
metazoans. 27
35-year-old 27
Aside 27
papules 27
enhancer. 27
synapses. 27
stellate 27
moth 27
AMP 27
NRG1 27
fluid, 27
Herpes 27
strokes, 27
Better 27
entitled 27
failure: 27
High-dose 27
explosive 27
(2). 27
Aim 27
preserved. 27
monoamines 27
autoantibodies, 27
testes. 27
germination 27
reverse-transcription 27
remodeler 27
epithelium, 27
preferences. 27
segment. 27
position-effect 27
dissecting 27
provoke 27
damage-induced 27
array-based 27
cementoblasts 27
Heterochromatin 27
instance 27
view. 27
202 27
concentric 27
Dengue 27
arguing 27
(TGF-beta) 27
Optic 27
1-associated 27
decrease, 27
sources, 27
UI 27
Gars 27
HMT 27
hyperpigmentation 27
Receiver 27
BRCA1-deficient 27
hyperglycemic 27
ICH. 27
really 27
prepare 27
AtxA. 27
IIB 27
temperatures. 27
lethal. 27
Relationship 27
dystrophies 27
Topologically 27
one-to-one 27
(C) 27
7.9 27
contexts, 27
repair-deficient 27
suberoylanilide 27
39-year-old 27
uninvolved 27
(via 27
nystagmus 27
mechanics 27
lobe. 27
stabilisation 27
circumferential 27
dozens 27
tuberin 27
ADH2 27
(on 27
(UC) 27
nmol/L) 27
confidently 27
modality. 27
(HF) 27
chain. 27
Public 27
community, 27
exacerbations. 27
Region 27
HoxD 27
isotretinoin. 27
shown, 27
marrow, 27
orientations 27
206 27
5-hydroxytryptamine 27
feeding, 27
pathogen, 27
inoculated 27
Inappropriate 27
invadopodia, 27
Hic-5 27
(EMT), 27
cytoskeleton, 27
abacavir. 27
(β 27
bathing 27
ethnicity 27
Bedaquiline 27
articulation 27
linguistic 27
St. 27
Psychiatric 27
3-methylglutaconic 27
well-conserved 27
bait 27
MBP 27
optimization. 27
(53%) 27
random-effects 27
monocytes. 27
nonstructural 27
chemicals 27
(GCS) 27
functionalities 27
ropinirole, 27
multi-step 27
PTTG1/Securin 27
13. 27
spikes 27
pedis 27
holding 27
truncal 27
(CI 27
Hsmar1 27
ends, 27
i 27
p38. 27
1996, 27
queries, 27
Browser. 27
junctate 27
regulations 27
Patients' 27
filopodium 27
tracks. 27
deformation 27
overrepresentation 27
Majority 27
(cell 27
NF1. 27
additional, 27
glycolysis. 27
Effect. 27
eradicate 27
Translation 27
Thailand. 27
melanoma: 27
gonads 27
interspecific 27
Newly 27
extraordinary 27
swabs 27
Intermediate 27
astrocytomas. 27
copper-sensing 27
Modification 27
reviewing 27
alemtuzumab. 27
reward 27
Solanezumab, 27
uncertain, 27
methicillin 27
inference. 27
plastid 27
taxa. 27
occurrence. 27
standard-of-care 27
negated 27
(NETs) 27
laboratory, 27
media. 27
well-described 27
probands, 27
WS. 27
(CSF). 27
Q10 27
has, 27
Treatment-related 27
Inclusion 27
gaze 27
psychiatry 27
eliciting 27
Promising 27
alphavbeta3 27
+1 27
μmol/L 27
Sweden 27
catheterization 27
calibration 27
Typical 27
(CD). 27
HDAC1, 27
Truncation 27
VIII 27
LH, 27
inhibin 27
end-points 27
sulfone 27
benralizumab, 27
(Doose 27
ictal 27
resveratrol. 27
EDS. 27
bariatric 27
splenium 27
under-represented 27
freezing 27
monophosphate 27
KBP 27
MT 27
Moroccan 27
micturition 27
RAM 27
copies, 27
CNE 27
(DMD). 27
Sciences. 27
infarctions 27
V600 27
S-adenosylhomocysteine 27
MEF-2a 27
upregulation. 27
inhibitor: 27
gamma-aminobutyric 27
transglutaminase 27
myelinating 27
sinusitis 27
depth, 27
BrS 27
S90L 27
Coadministration 27
transvection 27
pufferfish 27
warm 27
DCI 27
Hess 27
skipped 27
myeloperoxidase 27
Fork 27
primase 27
Mrc1 27
Adenosine 27
amyloidosis, 27
etexilate. 27
Ser/Thr 27
prophylaxis, 27
FTLD 27
restenosis 27
sumoylation, 27
miR-17-92 27
Required 27
Ribosomal 27
subviral 27
channelrhodopsin-2 27
discontinuous 27
VF 27
blunting 27
ZEB2, 27
zfhx1b 27
search. 27
UCEs, 27
C-PC 27
Arn3 27
carers 27
repairs 27
neuroblasts 27
BMSCs 27
spermatozoa 27
ChREBP 27
pulled 27
610 27
valsartan 27
DMN 27
film 27
(0.98 27
germline. 27
deiminase 27
Edaravone 27
plectin 27
Ocrelizumab 27
oedema. 27
(Xist) 27
Syndrome: 27
Prx2 27
Vif. 27
Unified 27
EDC 27
DeepCAGE 27
input, 27
misuse 27
prehospital 27
stenoses 27
amoxicillin, 27
IKBKG/NEMO 27
Gfi-1b, 27
ACF/WCRF 27
GATA-1/FOG-1 27
GATA-1/TAL-1 27
parasite, 27
acetone 27
arbovirus 27
midgut 27
competitor 27
hDlg 27
transvaginal 27
Dron 27
Therapeutics. 27
SKOV3 27
ER-α 27
δ(13)C 27
(ACR16) 27
RPS26 27
Idarucizumab, 27
miyamotoi 27
ACT-132577 27
covarion 27
bcr 27
FeCarb 27
leishmaniasis, 27
Rv1700 27
retrospective, 27
plans. 27
forelimb 27
CBTH 27
Intrathecal 27
DIPG, 27
(RBC) 27
erucism 27
Myelin 27
dyscrasia 27
UV-B 27
Daratumumab, 27
INSR 27
oats 27
50× 27
RNA-chromatin 27
hepatotoxicity. 27
Rfree 27
neuroglobin 27
transposase-accessible 27
HERS 27
resistant/refractory 27
Mef2c, 27
TFIIF 27
neuroacanthocytosis 27
Sost 27
XOMA 27
Grg 27
leishmaniasis. 27
Tourette 27
imaging-guided 27
Bexsero, 27
(MenB) 27
Diclofenac 27
antiobesity 27
Qsymia 27
LVX 27
METABRIC 27
PIEZO2 27
Harlequin 27
(CSN), 27
poxvirus 27
Thr341 27
(hemolysis, 27
fissured 27
fibrodysplasia 27
Plasmepsin 27
GKRS 27
doRiNA 27
Septo-optic 27
Holstein 27
fragility. 27
Waldmann's 27
cirrhotic 27
multiciliated 27
mFOLFOX6 27
sMET 27
Bath-PUVA 27
homocystinuria. 27
EP-DNN 27
TcdB, 27
Nephrotic 27
CDH3 27
SUTs 27
DILI 27
Stamey 27
Table 27
AR1b 27
SMiLE-seq 27
(DBT) 27
iLIR 27
CDP-choline 27
RET. 26
Integration 26
EGFR-positive 26
Instead 26
MCF10A 26
factor-like 26
μM, 26
nematodes 26
pre-mRNA. 26
rule, 26
lincRNAs 26
TRAIL-induced 26
MC3T3-E1 26
ovariectomized 26
daily). 26
Candidate 26
up- 26
B), 26
Tumour 26
Twenty-eight 26
inconclusive 26
oropharyngeal 26
vertebroplasty 26
(CRPC) 26
inhibitor; 26
Resource 26
nose 26
journal 26
TDM 26
IV) 26
independently. 26
catalyses 26
subsidiary 26
Simulation 26
Her2 26
HER2, 26
pancreatic, 26
gefitinib. 26
EV 26
4-6 26
enhancer, 26
one-step 26
atlas 26
ratios, 26
standards. 26
ATP. 26
cDNA, 26
10%. 26
renin-angiotensin-aldosterone 26
Ca2+-ATPase 26
Untreated 26
fulminant 26
ceroid 26
coincidence 26
symptomatology, 26
bringing 26
Heterogeneity 26
(CTD) 26
isolated. 26
youngest 26
EcoRI 26
calf 26
proband's 26
hypomethylation. 26
pyrosequencing. 26
[Ca(2+)] 26
anchors 26
precipitation 26
drawbacks 26
rabbits, 26
exchange. 26
activators. 26
IL-1beta, 26
JNK. 26
ALP 26
tau. 26
218 26
demarcate 26
matrix-assisted 26
Determining 26
α- 26
spine. 26
entities. 26
epilepsies, 26
mineralization, 26
extension, 26
infecting 26
acylated 26
increment 26
coimmunoprecipitation 26
http://group.bmj.com/group/rights-licensing/permissions. 26
eligible. 26
save 26
penultimate 26
Residual 26
misdiagnosis 26
levels) 26
(based 26
171 26
Depression, 26
QLQ-INFO25 26
psychometric 26
echocardiography. 26
0.92 26
0.97, 26
encouraged 26
Eligibility 26
SETD2 26
hoped 26
59% 26
arthralgia 26
Rationale 26
designation 26
hypercholesterolaemia 26
alirocumab 26
least-squares 26
PIWI-interacting 26
south 26
Askin 26
fresh-frozen 26
(estimated 26
bivariate 26
FAC 26
heteroduplex 26
Should 26
nonpathogenic 26
myofilament 26
Hum 26
courses. 26
quitting 26
responder 26
4-cell 26
3-Mb 26
ancestor. 26
Chemotherapy 26
oligonucleotides, 26
TGF-β-induced 26
iii) 26
caspase-8 26
co-treatment 26
(MI), 26
0.9% 26
activated. 26
HaCaT 26
(32%) 26
infant. 26
FRET 26
occasions, 26
γ-H2AX 26
oncology. 26
pruritus, 26
Biomarkers 26
reslizumab, 26
Pharmaceuticals; 26
inguinal 26
CGH 26
NELL-1 26
(A, 26
non-transcribed 26
anaemia, 26
146 26
atresia. 26
ear. 26
goitre. 26
pendrin, 26
goal, 26
accelerometer 26
open-access 26
position-specific 26
equipped 26
CYP2C19, 26
homozygote 26
single-center 26
43%, 26
Reporter 26
intensified 26
polymeric 26
aureus. 26
unstressed 26
Questionnaire, 26
(31 26
2001, 26
(PFS), 26
9.3 26
(MTD) 26
Progress 26
I-II 26
VEGFR 26
healing. 26
BAFF 26
mentally 26
Structured 26
Revised 26
speed, 26
mu 26
phosphorylated, 26
(GFR) 26
ews 26
analysed, 26
pair-wise 26
retroviruses. 26
Embryonic 26
reads. 26
SD. 26
hypomyelination, 26
step-up 26
3- 26
(CREST) 26
perturb 26
amygdala, 26
entacapone, 26
100, 26
Man-6-P 26
eluted 26
Cdc6 26
hierarchy 26
appendage 26
answered 26
5-10% 26
20-year-old 26
Products 26
preserves 26
centres, 26
CCM1 26
CAT 26
cosegregated 26
immunofluorescent 26
L-thyroxine 26
incidental 26
successful. 26
aetiology. 26
Alogliptin 26
max 26
magnitude. 26
inhibition) 26
surge 26
immunologically 26
ages, 26
Teaching 26
elucidated, 26
dysphagia 26
silencer 26
positions. 26
methylation-sensitive 26
YAC 26
chromodomain, 26
neurogenesis. 26
silencers 26
homologs, 26
methyl-lysine 26
member, 26
reconstructions 26
Sex 26
clonogenicity 26
robust, 26
TNM 26
impacting 26
hypotension. 26
half-life. 26
impulse 26
Flavivirus 26
OCT3. 26
cations. 26
CRT 26
Smad4 26
suppressor, 26
fractions, 26
peri-infarct 26
NF-kappaB. 26
Sept 26
volunteer 26
impaired, 26
sponge, 26
BY 26
288 26
seventh 26
Dilated 26
(PLN), 26
assigned, 26
Cr 26
flavonoids 26
(P<0.01). 26
SOD 26
14) 26
neuropathies, 26
homodimeric 26
CD133 26
images, 26
larvae. 26
(AML), 26
hygiene 26
shortening. 26
above-mentioned 26
PI3K/Akt/mTOR 26
interferon-γ 26
primed 26
(ROCKET 26
AtxA-dependent 26
(6) 26
carboxy 26
arteriopathy 26
submicroscopic 26
ExTopoDB 26
Morphological 26
cyclooxygenase 26
factories 26
T3. 26
defence 26
for, 26
215 26
constructed. 26
Eco1, 26
ties 26
Ctf18p, 26
Rfc2p, 26
Rfc3p, 26
Rfc4p, 26
Rfc5p. 26
olaparib. 26
≥18 26
Janssen 26
hypoglycemic 26
independent. 26
nontranscribed 26
bypassing 26
hemiparesis 26
haplotype, 26
thermodynamic 26
purify 26
angiomyolipomas 26
50) 26
Forty-five 26
(CABG) 26
conflicting. 26
CisMiner 26
Pattern 26
stoichiometric 26
X-1 26
achievements 26
arsenite. 26
(DUSPs) 26
0.76 26
Spain. 26
study). 26
acne. 26
craniofacial, 26
CTG 26
two-fold 26
export, 26
relationships, 26
genotoxicity 26
multi-drug 26
Acta 26
littermates. 26
progress, 26
tonsillar 26
supplied 26
Twist1 26
passenger 26
solubilized 26
FT(4) 26
drops 26
neprilysin 26
F, 26
causes, 26
antidepressants, 26
PNET 26
vimentin, 26
biomarker. 26
cross-reactivity 26
successful, 26
Laparoscopic 26
Barrett's 26
paranasal 26
Pathogenesis 26
cardiolipin, 26
Xq28. 26
adipogenic 26
algorithmic 26
unambiguously 26
lipolysis 26
Deciphering 26
chip 26
fuels 26
potentiating 26
introduced, 26
engineer 26
adhere 26
Pregabalin 26
posed 26
insects, 26
amyloidogenic 26
LEMS. 26
downregulating 26
ptosis, 26
nosocomial 26
IB 26
Hungarian 26
underpin 26
peptidyl-prolyl 26
doubling 26
pre-mRNAs 26
complete, 26
attraction 26
" 26
Cruz 26
theory, 26
substitution. 26
centrosomal 26
communities, 26
projects, 26
g/L 26
(GIST) 26
four-way 26
nothing 26
failed. 26
(p<0.0001). 26
flexible, 26
parent-of-origin 26
dilatation. 26
Gigaxonin 26
ways, 26
retention, 26
CD20 26
remyelination 26
(35%) 26
Rituximab 26
>60 26
Bapineuzumab 26
equivocal 26
City 26
Thereafter, 26
Parental 26
nivolumab, 26
(PD-L1) 26
0.08 26
numbness 26
BDV-infected 26
prophylaxis. 26
funded 26
(I) 26
endocrinological 26
observing 26
ICER 26
(change 26
Enzastaurin 26
inpatients 26
nominally 26
Costs 26
CVD, 26
perfectly 26
Thirty-one 26
magnesium, 26
physicians, 26
modes, 26
316 26
nevi 26
albino 26
DEPTOR. 26
Cerebrospinal 26
somnolence, 26
mg/dl, 26
venlafaxine, 26
reuptake. 26
module, 26
(WE) 26
hyperemesis 26
ophthalmoplegia. 26
Environmental 26
HIF1 26
Meis1, 26
cells' 26
callosum. 26
computations 26
Parkinsons 26
RHR 26
reductase, 26
vertigo 26
intracellularly 26
ray-finned 26
MCAO 26
bladder, 26
bradykinin 26
intraerythrocytic 26
cancer-testis 26
1p/19q 26
ACR20 26
MVIIA 26
hyperalgesia 26
Clonal 26
SYK 26
pulling 26
width 26
specifying 26
Rac1. 26
transcribes 26
BTK 26
Wilms' 26
dermis 26
5.1 26
NPCs 26
illumination 26
AS, 26
Illness 26
framework, 26
hydrochlorothiazide 26
segments, 26
Paris 26
hCMG 26
necrotizing 26
snRNA, 26
bilateral, 26
hypermutation 26
pre-mRNAs. 26
associations, 26
oncogenesis, 26
clot 26
X-inactivation. 26
midazolam, 26
deacetylated 26
neighborhood 26
Schistosoma 26
outlet 26
placement. 26
bigeminy 26
FXa 26
implicitly 26
ML 26
Metaxin 26
(PLK2) 26
serum-inducible 26
kingdom 26
GC-poor 26
Oryza 26
drove 26
intact, 26
mg/d, 26
QD 26
(TMB) 26
Drug-induced 26
(HPRT) 26
Leu(+) 26
oriC 26
2-hour 26
tinnitus 26
pyroptosis 26
dichlorphenamide 26
NOD2, 26
newest 26
Neuroimaging 26
aneurysms, 26
Deletions 26
A3F 26
s-Se 26
averted 26
beta-strands 26
UvrC 26
(PTA) 26
dexmedetomidine 26
commitment. 26
blight 26
(FXR) 26
monolithic 26
TIMP-2 26
NF-kappaB1 26
crops 26
Development. 26
(BWT) 26
matching. 26
WKY 26
modafinil, 26
unspecific 26
ACT-333679 26
throat. 26
Pentalogy 26
Desvenlafaxine 26
g/dl 26
EZH2:ECAD 26
cordless 26
FRAX® 26
mutY 26
triple-helical 26
(per-allele 26
Shapiro 26
H3/H4 26
JAG1 26
lovastatin 26
students. 26
HH 26
HSR 26
HVA 26
ADAM10 26
BRCA1-like 26
Arimoclomol 26
anti-TNF-α 26
IL-12, 26
NGB 26
dystrophin-positive 26
Guadeloupe 26
Sus1 26
ABCD(2) 26
fibrothecomas. 26
p38gamma 26
carbamazepine-induced 26
(SJS) 26
writing, 26
Aagenaes 26
outcomes; 26
tid, 26
DAT1 26
PHA-E 26
Plm 26
community-acquired 26
LncRNA 26
Sakha 26
hTfR1 26
allantoin 26
b/b 26
NRD 26
imperfecta. 26
libFLASM, 26
GemC1 26
Karak 26
TLR1 26
postdeployment 26
CENP-A. 26
duck 26
Paroxysmal 26
Mtr4 26
GMC 26
VLPP 26
Strelka, 26
csaunders@illumina.com 26
GenomeVIP 26
recount2 26
IHPS. 26
multi-omics 26
elk 26
(SERM) 26
SeqArray 26
Mc1r 26
emicizumab 26
TAB-delimited 26
aciclovir 26
Valacyclovir 26
SOX10 25
megacolon) 25
agenesis, 25
fates 25
pg/ml 25
breadth 25
Particularly, 25
plate. 25
osteoclasts. 25
Pathology. 25
osteoblastic 25
1.5, 25
Measurements 25
microarray, 25
ascites. 25
regimes 25
junction, 25
modulation. 25
cyclosporine, 25
denosumab, 25
refractory, 25
supplemental 25
ipilimumab. 25
women: 25
planar 25
located. 25
extremities, 25
woman. 25
neovascularization 25
proteolytically 25
Sod1 25
enrolling 25
[5%] 25
(DLT) 25
castration 25
prototypic 25
(IHC) 25
efforts. 25
scan. 25
activity: 25
2b 25
12.6 25
cultivated 25
sites; 25
Board 25
observable 25
symbol 25
Confocal 25
menopause, 25
(CAD) 25
CVD. 25
discontinuation, 25
WD 25
awaited. 25
argued 25
adolescence. 25
bilaterally 25
expectation 25
28. 25
Recursive 25
Reducing 25
retinopathy 25
asymmetrical 25
complained 25
done. 25
(RyR) 25
leak. 25
phosphatidylcholine 25
0.04 25
verapamil, 25
exploitation 25
BRD7 25
(ASD). 25
colonoscopy 25
UC. 25
sustains 25
Erk 25
LY294002 25
anticonvulsants 25
anti-epileptic 25
ETS 25
EWSAT1 25
Dipeptidyl 25
suspected. 25
uncommon. 25
intensively 25
damages 25
P<0.001 25
Smad2 25
(48%) 25
(30% 25
Visceral 25
compliance. 25
Epidemiologic 25
hospital-based 25
86%, 25
ATP-sensitive 25
complaining 25
Organ 25
reliability, 25
measurement, 25
information: 25
pro-brain 25
HRV 25
1.35 25
stressful 25
0.005 25
unlimited 25
participants' 25
NSD1. 25
map, 25
Design 25
specialised 25
coprimary 25
Living 25
drugs: 25
56%, 25
category. 25
HCT-116 25
ratios. 25
justified 25
myelofibrosis 25
MF 25
mechanisms: 25
adenoma, 25
(85%) 25
hyperplasia. 25
Height 25
aborted 25
spectroscopic 25
preventable 25
(control 25
249 25
Health, 25
H3K9me2, 25
Measures 25
macromolecules 25
NF-kappaB, 25
antigen-presenting 25
kinase-3beta 25
thickening, 25
surveillance. 25
noted, 25
Unusual 25
0.71 25
10th 25
intubated 25
Sertoli 25
extrusion 25
machines. 25
world's 25
Regeneron 25
(gene 25
MSX2 25
plasmid. 25
skull. 25
MYCN 25
spiral 25
siblings. 25
side-effects, 25
(BP) 25
lysate 25
MS-based 25
retinol 25
(TCA) 25
cell-to-cell 25
paper. 25
resumption 25
proxy 25
Patterns 25
Psychological 25
flexion 25
gender-matched 25
ventilated 25
benefited 25
vision. 25
clopidogrel. 25
MACE 25
monolayer 25
0.66 25
3-D 25
glycopeptide 25
mycobacteria. 25
well-being 25
predetermined 25
35%, 25
anorexia, 25
13.9 25
siblings, 25
subluxation 25
IFN-α 25
afforded 25
TOR-I 25
(EAE) 25
(RT-PCR). 25
[Detection 25
cohesin, 25
IGF2-H19 25
technically 25
stem-cell 25
CM 25
toes 25
corn 25
kDa. 25
noise. 25
absent, 25
jumping 25
Similarities 25
purification, 25
inclusions, 25
Q388stop 25
degenerating 25
inclusions. 25
se, 25
neurobiological 25
employment 25
one-way 25
nigra. 25
levodopa/carbidopa 25
elution 25
interpreting 25
NR0B1 25
protein's 25
Wolbachia 25
extrachromosomal 25
boxes 25
Z-curve 25
illustrating 25
pleomorphic 25
underline 25
I-III 25
Limitations 25
nsSNPs 25
148 25
exon. 25
scoliosis, 25
useful. 25
thyroidectomy 25
DPP-IV 25
α-glucosidase 25
criterion, 25
Collaborative 25
(HbA1c) 25
hepatobiliary 25
nonsignificant 25
databases: 25
dairy 25
autoantigens 25
integration. 25
divisions. 25
silences 25
canals 25
Neurochemistry. 25
sexes 25
Master 25
100-mg 25
(ICD) 25
TFs. 25
co-factor 25
arthropod 25
amphetamine 25
high-capacity 25
inactivates 25
organizes 25
38) 25
GLT1 25
consent, 25
448 25
245 25
BPD. 25
positioning, 25
oxidant 25
fuzzy 25
H3K56 25
sperm. 25
36, 25
past, 25
calcifications 25
DKC1 25
DBA. 25
controls) 25
neuron-specific 25
PERV 25
injections, 25
D) 25
pXO1-encoded 25
acpA, 25
(PRC2), 25
(AML). 25
Synergistic 25
redistributed 25
(TADs) 25
compacted 25
.0001), 25
Adaptive 25
HIV-1, 25
regions; 25
predominately 25
Pharmacodynamic 25
(UPR) 25
Csm3, 25
Mrc1, 25
ChIP-seq, 25
Copyright© 25
quantitated 25
biochemistry, 25
load. 25
differentiates 25
mg/kg; 25
DNA-PKcs 25
P-TEFb 25
TS. 25
unequal 25
NaCl 25
wk, 25
ECHO 25
bench 25
m(-2) 25
queried 25
stress-related 25
work-up 25
cordis. 25
making. 25
Ratio 25
lymphomas, 25
cross-species 25
phenylephrine 25
intercalator 25
(v) 25
Meningococcal 25
GT 25
phase) 25
aptamers. 25
Inc., 25
aptamers, 25
clinic, 25
phytoalexin 25
(known 25
188 25
reintegration 25
TRβ1 25
Beside 25
unadjusted 25
0.23 25
baseball 25
Abstracts 25
(DM) 25
stroke; 25
LDL-cholesterol 25
visited 25
clock, 25
recommends 25
triacylglycerol 25
unexplored 25
device. 25
0.15 25
enoxaparin. 25
HIF 25
Compounds 25
fabrication 25
Ospemifene 25
182 25
dopa 25
polysomnographic 25
looking 25
gene-modified 25
doubled 25
(XLH) 25
T21 25
Eighty 25
specifies 25
salient 25
country, 25
(ECG) 25
microinjection 25
(wt) 25
AS. 25
p53-null 25
Santa 25
barriers, 25
RSC 25
Ino80 25
superfamily, 25
Mahalanobis 25
integer 25
W 25
(PKC) 25
MFS, 25
DSS 25
nonrandom 25
(1.5 25
bodies) 25
varicella 25
levodopa, 25
loading. 25
two-compartment 25
Period 25
(BCR) 25
(CDK) 25
basophils 25
immunoprecipitation, 25
c-Kit 25
cocktail 25
infrequent, 25
imprinting. 25
Lamin 25
eubacteria. 25
marfanoid 25
girls, 25
PGC-1 25
personnel 25
swab 25
peroxisomes 25
due, 25
MBL 25
HRAS 25
RRMS 25
burdens 25
rupture, 25
anti-amyloid 25
BACE 25
Hazard 25
Rotterdam 25
phylogenies 25
SIP1 25
Ets1 25
Related 25
(ID) 25
reactivity. 25
IMS 25
Close 25
Achilles 25
sensory, 25
purines 25
home. 25
neuropeptides 25
WBS 25
tongue, 25
(9%) 25
Pacific 25
Pyknons 25
ACR 25
Secukinumab 25
nucleated 25
nodules, 25
RPGR 25
12.9 25
divergence. 25
dentritic 25
ED, 25
skull, 25
Autopsy 25
(PTC) 25
covariate 25
cytoplasmic, 25
slices. 25
ubiquitin-related 25
25) 25
Mismatch 25
Corticosteroids 25
MAE 25
LQTS. 25
92%, 25
UVA, 25
topographic 25
fifty 25
Index, 25
summaries 25
21st 25
(MECP2) 25
encephalopathies 25
fasting, 25
non-Jewish 25
nm) 25
(small 25
Arterial 25
breaking 25
chicken. 25
MICs 25
(GRBs). 25
teleosts 25
Cell-free 25
excitability, 25
window. 25
biosensor 25
Tyk2 25
T4. 25
mOCT3 25
[1, 25
toolkit 25
caspases-4 25
ELA2 25
MT2 25
Zyxin 25
(DNMTs) 25
MALAT1, 25
SQTS 25
δ 25
pedigree. 25
47, 25
BRAF(V600E)-positive 25
post-mitotic 25
acquiring 25
annotating 25
servers 25
Molindone 25
Burke-Fahn-Marsden 25
schemes, 25
isozymes. 25
cuticular 25
Sef 25
MAX 25
Fischer 25
Ctf4/AND-1 25
6-year-old 25
inosine 25
chlorophyll 25
Gy, 25
centriole 25
ACS. 25
sPLA2-IIA 25
Rif1, 25
grey 25
Determinants 25
w 25
0.88 25
BCa 25
genotyping, 25
Ag 25
(GBS) 25
dating 25
AO 25
miR-155, 25
pre-miRNA 25
v2 25
OAB, 25
Institutional 25
Antimicrobial 25
Ambulatory 25
Joubert 25
thermogenesis. 25
transgenesis 25
ducts 25
(PLK2, 25
SNK) 25
(eRNAs) 25
super-enhancers, 25
T.G 25
MC 25
NBS1. 25
(35) 25
Sympathetic 25
H1975 25
MEN1-associated 25
skew 25
Aliskiren 25
disabled 25
β-glucan 25
loads 25
©2015 25
(MCV) 25
nits 25
(GM-CSF), 25
mucociliary 25
retrotransposition, 25
Se 25
receipt 25
STAT3. 25
EIF2S1 25
STAT3-targeting 25
STAT3-EIF2AK2 25
(fatty 25
RyR2(R4496C+/-) 25
ARR 25
HSCs. 25
tumefaciens 25
immunodeficiency, 25
BirA 25
(i.v.) 25
ESKAPE 25
Acinetobacter 25
baumannii 25
constants, 25
KPC 25
pri-miRNAs 25
der(22) 25
ensuing 25
converged 25
PPV 25
dermatologists 25
lipin 25
stood 25
PDS/SLC26A4 25
afzelii 25
iMSCs 25
dose; 25
LEF/TCF 25
Diagnosing 25
Mycobacteria 25
Anhedonia 25
miR-675 25
dabrafenib, 25
G3BP 25
uranium-contaminated 25
medicarpin 25
Nimotuzumab 25
mutSL 25
trichome 25
GC. 25
distraction 25
minoxidil. 25
O6-alkylguanine 25
NG 25
ritonavir 25
OI. 25
Gd-PSP 25
nanism. 25
fibrothecomas 25
NEDD9 25
cathepsin-L 25
calling. 25
frataxin, 25
Gad1 25
sclerostin. 25
Gevokizumab 25
WED 25
degrader 25
MATS 25
Neisserial 25
TEN 25
RASA2 25
-7/7q- 25
GL-3 25
Micro-C 25
FimA 25
heat, 25
Legg-Calvé-Perthes 25
fasciitis. 25
E-PASS. 25
Gardner-Diamond 25
(OCA1) 25
H2A.Z-H2B 25
pharyngitis. 25
(CHAMP) 25
CHAMP 25
Gpr132 25
chordal 25
Teriparatide 25
subnucleosome-sized 25
apremilast, 25
PRDM12 25
IRVAN 25
ALF 25
itraconazole 25
hmU 25
NA12878 25
Manta, 25
split-read 25
CellBase 25
schimke 25
Euglycemic 25
PPFA 25
SNP2TFBS 25
EPB 25
HEAT 25
Quanadli 25
do. 24
NRAS, 24
EGF. 24
0.3% 24
Non-coding 24
sharply 24
osteoblasts. 24
(OA) 24
fatal. 24
intranasal 24
taxane 24
Fracture 24
adherence, 24
1- 24
0.60 24
segment, 24
transducers 24
proto-oncogenes 24
immunostaining. 24
acral 24
(SCC) 24
inserting 24
earlier. 24
futility 24
DU145 24
apoptosis-related 24
PSA, 24
ideally 24
hybridisation 24
</= 24
episomal 24
happens 24
(hESCs) 24
reprogramming, 24
Project. 24
gene-centric 24
assigning 24
Russian 24
exemplified 24
proteome, 24
resources, 24
danger 24
isoelectric 24
I(f) 24
beats 24
Langendorff 24
Neurologic 24
dyskinesia. 24
constructs, 24
array, 24
yearly 24
strength. 24
preparations, 24
<0.05). 24
locate 24
modifiers. 24
(5-HT) 24
Arthrobacter 24
draft 24
pseudo 24
K9 24
microscopically 24
(29%) 24
esophagitis 24
metalloproteinase-9 24
Apoptotic 24
phenomena, 24
highlighted. 24
precision, 24
(p. 24
carbamazepine, 24
dogs, 24
S-transferase 24
(without 24
0.19 24
rafts 24
pre-specified 24
randomization. 24
intra-arterial 24
surgeries 24
Bowel 24
complain 24
(P= 24
survivors, 24
NHL, 24
this. 24
postexercise 24
Substantial 24
(BNP) 24
CK 24
(HT) 24
Texas 24
reimbursement 24
Registry. 24
(P<.001). 24
moment 24
hernia, 24
Cardiology. 24
Regardless 24
personnel, 24
(most 24
age), 24
Panel 24
hypoxia-induced 24
transcribed-ultraconserved 24
lend 24
Sites 24
enzyme's 24
cyclophosphamide, 24
epitope, 24
(LDE225) 24
DNA/RNA 24
(ORC) 24
repeats) 24
nonfamilial 24
cessation, 24
steadily 24
smoker 24
H3K9me3, 24
maize, 24
meiosis, 24
Protective 24
5-fluorouracil 24
promiscuous 24
(r(2) 24
(77%) 24
pdm 24
4.5% 24
Influenza 24
Kingdom, 24
ectopy 24
thyroidal 24
CNC 24
seminal 24
normal-appearing 24
entities, 24
ophthalmological 24
(piRNAs) 24
realization 24
thyroid. 24
4-10 24
Temporal 24
filter-aided 24
cutting 24
storage, 24
microdissection 24
Morris 24
4). 24
multiforme: 24
Seizure 24
403 24
OS, 24
Chaperone-mediated 24
(CMA) 24
partnership 24
H., 24
(AA) 24
20%, 24
carboplatin, 24
CCL18 24
cognitively 24
sigma 24
Temsirolimus 24
Rapamycin 24
definitively 24
runx1 24
C- 24
athletic 24
cosmids 24
(39 24
steroids, 24
Lithium 24
longitudinally 24
disabilities. 24
in-vitro 24
acids), 24
mitigated 24
mislocalized 24
Ataxin-2 24
Insulin-like 24
CD117+ 24
each. 24
digest 24
increases. 24
archaea. 24
Diversity 24
asymmetry, 24
cHL 24
Tertiary 24
Thirty-four 24
mutations), 24
dictate 24
Ca2+/calmodulin-dependent 24
probands. 24
(CCM) 24
haemorrhage, 24
two. 24
perineural 24
157 24
remitted 24
preoperatively 24
margins 24
0.44, 24
type-2 24
hypoglycaemia, 24
Host 24
acuity, 24
pseudogenes 24
chimera 24
20th 24
coinciding 24
dentition, 24
perivascular 24
trademark 24
polarity, 24
meshwork 24
distance, 24
DNMTs 24
interphase. 24
Chd2 24
SLIDE 24
Rat 24
GATA 24
0.008) 24
Precise 24
acid-binding 24
swallowing 24
backgrounds 24
tentative 24
repressor, 24
occupying 24
1.01 24
(64%) 24
Fever 24
bidirectional, 24
sublethal 24
Cowden 24
needing 24
25%. 24
GBshape: 24
Tolerability 24
centre. 24
miRNA-mediated 24
CircRNAs 24
pentamer 24
football 24
synthetases 24
Appropriate 24
fertility, 24
tri-methylation 24
subdomains 24
subsets. 24
HCT 24
Premature 24
synergy. 24
aggregates, 24
AMPK, 24
intraperitoneally 24
enolase 24
(chromosome 24
myopathies 24
trachomatis 24
ancestry. 24
Humans 24
target-specific 24
multicopy 24
beta) 24
ASXL1 24
clinically. 24
ribonucleotide 24
scavenging 24
FACC 24
PIs 24
(MM). 24
immunoproteasome 24
GvHD 24
impeded 24
incorporation. 24
mineralization. 24
exclusion. 24
promyelocytic 24
Then 24
7.2 24
macaque 24
alpha/beta 24
labor 24
ATF4. 24
collapsed 24
S-phase, 24
fallopian 24
rucaparib, 24
followed-up 24
assumes 24
forks, 24
SpA 24
TLC 24
colchicine 24
pericarditis, 24
0.12 24
CRMs. 24
sports. 24
high- 24
scaffold. 24
0.80 24
0.16 24
drawing 24
embryotoxic 24
pinpoint 24
denaturation 24
frontier 24
chloramphenicol 24
ribonucleic 24
microM. 24
jejunal 24
polarization, 24
Known 24
Phosphatidylinositol 24
SHH 24
epithelia. 24
spreading, 24
rank, 24
created. 24
9.1 24
deoxynucleotidyl 24
tubers 24
0.11 24
IgG, 24
hypokinetic 24
Gastroesophageal 24
lactic 24
necropsy 24
substrate-binding 24
ROS. 24
metabolic, 24
Société 24
denotes 24
Typically, 24
summarizing 24
Search 24
>95% 24
Mitotic 24
summarization 24
separation. 24
LN 24
CTA 24
emotions 24
Hepcidin 24
hepcidin, 24
cigarettes, 24
sedated 24
grid 24
unique. 24
concerns, 24
apnea, 24
excitable 24
mV 24
42%, 24
nicardipine 24
50-year-old 24
isomerization 24
ssDNA 24
reconstruct 24
(UV) 24
Myc-induced 24
relevant, 24
references. 24
beta-thalassemia 24
(UCSC) 24
cytokinesis, 24
rule. 24
EGFRvIII 24
endocardial 24
girls. 24
overlapping, 24
Enzymatic 24
NSAID 24
1-2% 24
[Ca(2+)](i) 24
LKB1 24
nilotinib 24
Estimated 24
HEM-AP 24
administered, 24
CE 24
5-HT(1A) 24
visualizations 24
infestation 24
letters 24
A/T 24
branching 24
decision-making. 24
inevitable 24
unexpectedly, 24
IF 24
topography 24
Aft1p 24
barrier, 24
revolution 24
trimming 24
333 24
assemblers 24
2000. 24
impedes 24
ancestry, 24
preclude 24
(CN) 24
1991 24
MEN1. 24
calcium-sensing 24
Scopus 24
Frzb/sFRP3 24
minimizes 24
alpha-Synuclein 24
synucleinopathies. 24
fluoxetine, 24
Progesterone 24
Forty-four 24
men; 24
Endostatin 24
MMP-2, 24
pad 24
identically 24
5'-UTR 24
Ion 24
mutability 24
detachment. 24
Cyclic 24
nNOS 24
SLC9A6. 24
indels, 24
6-minute 24
package. 24
England. 24
typhlocolitis 24
jejuni 24
Meigs' 24
transfusions 24
mRNA-binding 24
alpha-syn 24
neocortex 24
Myotubularin 24
pneumoniae, 24
transient, 24
lethality. 24
H4, 24
H2A, 24
apex 24
480 24
ART 24
(mepolizumab, 24
α-chain 24
humanized, 24
Myoclonic 24
cognition. 24
Spearman 24
disappointing. 24
combined, 24
proprietary 24
hyperextensibility, 24
hypermobility 24
19) 24
attribute 24
homozygotes. 24
time-points 24
podocyte 24
(LSD1) 24
Gfi1b, 24
Transplantation 24
Loeys-Dietz 24
ARE 24
secretions 24
city 24
GRBs. 24
vemurafenib, 24
partition 24
non-muscle 24
(Syk) 24
cetuximab. 24
hub 24
contexts 24
co-receptor 24
radiology 24
IFNalpha 24
Nickel 24
lactose 24
HT, 24
PSTVd 24
Chlamydomonas 24
pups 24
nifedipine, 24
(112 24
hyperpigmentation, 24
XG 24
Insufficient 24
Isradipine 24
gossypii. 24
motion, 24
okadaic 24
ICH, 24
replisome. 24
And-1 24
flashes. 24
intensification 24
yeasts. 24
Replisome 24
further. 24
thylakoid 24
(GDAP1) 24
enhanceosome, 24
(study 24
annexins 24
heterotopic 24
angioplasty, 24
voided 24
nomenclature 24
Fostamatinib 24
Rule 24
dissipate 24
Sirt1 24
recovered. 24
nuchal 24
urgency, 24
resource, 24
sapiens 24
mansoni 24
topology. 24
AT2220 24
bloodstream 24
click 24
ASDs 24
Roche 24
threshold, 24
phosphodiesterase-5 24
Seckel 24
phycobiliprotein 24
TRalpha2 24
Polymorphic 24
3,N(4)-ethenocytosine 24
ALLO 24
3'-H3K4me3 24
GSK-3beta 24
Determine 24
neurocristopathies 24
c-fos 24
CARM1 24
EGFR-mutated 24
FGFR4 24
overlooked 24
focal, 24
GRF 24
Composite 24
(HGG) 24
wafer-treated 24
MER41 24
(CHS) 24
46,XX 24
participants: 24
DCP 24
ependymoma 24
collagenase 24
Sp3 24
KEYNOTE-006 24
nimodipine, 24
H3K79me 24
carbidopa 24
(AADC) 24
'wearing-off' 24
ET(A) 24
8/c-Jun 24
(MAPK8/JNK1) 24
PKR 24
Synaptic 24
TMBs. 24
gfi 24
Agrobacterium 24
.05), 24
BCL-2 24
gamma-globin 24
invadopodial 24
MP1 24
KSR-2 24
piRNAs. 24
Biology. 24
spp., 24
1b, 24
suppurative 24
ceftriaxone. 24
CPSS 24
9-month 24
anti-IL-1β 24
lipin-2 24
Mantoux 24
'dry 24
azurophil 24
Coherent 24
extra-gonadal 24
p185(BCR/ABL) 24
p210(BCR/ABL) 24
Ferric 24
GSK3beta 24
T15 24
(PTPN22) 24
Ednrb 24
NF-kappaB2 24
Cga 24
Set1A 24
isoflavonoid 24
atazanavir 24
aesthetic 24
telomestatin 24
(GALC) 24
NB-UV-B 24
Minoxidil 24
angiodysplasia. 24
daratumumab-dependent 24
modafinil. 24
varus 24
absenteeism, 24
GN 24
ADARs 24
gamma-Secretase 24
endostar 24
BRCA1/2, 24
Orco 24
MLS 24
SOST 24
Ohtahara 24
ULN 24
SLITRK1 24
medication-refractory 24
Oclacitinib 24
RPT 24
meningococci 24
PHYLUCE 24
Tec1 24
SDA 24
splenectomy 24
AbetaPP 24
Bexsero(®) 24
Zinn. 24
(LOX) 24
SAMS 24
PC7. 24
methylKit 24
clr4 24
IMRT, 24
HGG, 24
EH 24
(PIL), 24
lymphangiectasia. 24
7872 24
fiber-unipolar 24
Melioidosis, 24
diphosphatidylglycerol 24
phosphatidylglycerol 24
circRNAs. 24
1484-1490del 24
AVFs 24
CDKN1C 24
RGS12 24
reference-based 24
poems 24
2017, 24
RESTful 24
CTL019 24
zip 24
(FMF) 24
free-ranging 24
FullSSR 24
emm 24
americanum 24
XR-seq 24
unraveling 23
non-Mendelian 23
5000 23
neurocristopathy. 23
correlation, 23
gene(s) 23
231 23
guidance. 23
unspliced 23
dauer 23
identity, 23
candidates, 23
accession 23
(RANKL) 23
osteoclasts, 23
bone-forming 23
OVX 23
microarray. 23
μL 23
aliquots 23
let-7a, 23
covariates. 23
painless 23
internationally 23
Economic 23
(AE) 23
osteoclastic 23
antiresorptive 23
>30 23
glycoprotein, 23
(93%) 23
descriptions, 23
0.58 23
Large-scale 23
endpoint, 23
<50 23
ErbB2 23
i.p. 23
differences, 23
(after 23
added. 23
(33%) 23
Functionally, 23
layers. 23
overwhelming 23
layers, 23
functioned 23
Atlas 23
diagnostic, 23
conductive 23
damage-associated 23
non-fatal 23
Ivabradine 23
Half 23
Confirmation 23
decompensated 23
hemochromatosis, 23
decisions, 23
U2 23
(named 23
subretinal 23
material, 23
province 23
139 23
monomers, 23
myotubes. 23
sparks, 23
atrium 23
calsequestrin. 23
likewise 23
1.6% 23
phases, 23
phosphatidylethanolamine 23
μg/mL 23
(K(D) 23
ileocolonic 23
(ADHD) 23
yr) 23
data; 23
LPS-stimulated 23
metalloproteinase-2 23
malfunction 23
pathways: 23
GST 23
phosphatases. 23
Qualitative 23
amines 23
fifteen 23
EWS/FLI-1 23
osteolytic 23
Refractory 23
precipitating 23
transplants 23
elevated. 23
aspirin, 23
peptide-1 23
meals 23
%; 23
(49 23
intraarterial 23
fertilization, 23
(56%) 23
(IBS) 23
innervate 23
cultural 23
ratio) 23
Reductions 23
0.007), 23
recreational 23
meningioma, 23
194 23
Standardized 23
>90% 23
hypercholesterolemia. 23
submission 23
onartuzumab, 23
52-week 23
331 23
yet, 23
40%, 23
island. 23
precludes 23
2,000 23
option, 23
365 23
RNA/DNA 23
Cyclin-dependent 23
mutation-negative 23
N-domain 23
dichroism 23
replacement, 23
insignificant 23
blind, 23
(Xi) 23
adenocarcinoma, 23
ERK, 23
0.008). 23
Fibrosis 23
IIalpha 23
Immunoblotting 23
abortions 23
158 23
winter 23
(13)C 23
seminiferous 23
unanswered 23
self-renewal. 23
long-term, 23
nonclinical 23
days), 23
investigator's 23
pathomechanisms 23
midfacial 23
coined 23
narrowed 23
1.5% 23
receptor-positive, 23
syndrome" 23
in-gel 23
delayed. 23
non-diabetic 23
batch 23
10.5 23
chemoradiation 23
TFEB. 23
(TBI). 23
proatherogenic 23
Closterium 23
antibiotic, 23
cylindrical 23
antimycobacterial 23
pentose 23
9.6 23
KPS 23
deteriorated 23
8.6 23
late-life 23
Aging 23
power, 23
glucocorticoids. 23
cis-eQTLs 23
behaves 23
cooperating 23
CTCF-regulated 23
interchromatin 23
co-localizes 23
analysis: 23
stratification. 23
hormone) 23
continuation 23
Mann-Whitney 23
Proton 23
noticeable 23
cattle, 23
cloned, 23
autophagosomes. 23
zone. 23
regenerated 23
said 23
multipoint 23
control) 23
184 23
Pharmacokinetics, 23
residence 23
flight 23
2-D 23
recombinase 23
remodels 23
Species 23
another, 23
skipping. 23
autopsy, 23
TBC1D7 23
KN-93, 23
echovirus 23
10(5) 23
novo, 23
(70%) 23
matches 23
additions 23
alogliptin, 23
CLL, 23
underrepresented 23
apomorphine 23
regained 23
pace 23
MCS 23
serotypes 23
sandwich 23
myopia, 23
eruption 23
5), 23
deriving 23
lacZ 23
5'-flanking 23
(CHD) 23
non-CG 23
Genital 23
remodelling, 23
(PcG) 23
rather, 23
pombe. 23
scFv 23
Zea 23
further, 23
nonetheless 23
faithful 23
protein), 23
amplicon 23
318 23
Fungi, 23
d. 23
0.006), 23
g. 23
Altogether 23
chemotherapy-induced 23
(HPV) 23
legal 23
immunopositive 23
nucleosome-occupied 23
Forty-eight 23
immunoblotting. 23
executed 23
exudative 23
anaemia. 23
(ADP-ribose) 23
adapting 23
anti-Xa 23
postsurgical 23
extrapolation 23
sixfold 23
Immunologists, 23
over-represented 23
appreciated 23
disassembled 23
compositions 23
nucleoli 23
macaques 23
Vasa 23
artificially 23
mobilized 23
screen. 23
Smc3 23
thought, 23
cycle) 23
Cdc42, 23
glomeruli 23
II: 23
9.8 23
Comet 23
direct, 23
occlusions 23
fermentation 23
ciprofloxacin 23
intramuscularly 23
turning 23
steroidal 23
thrombolysis. 23
transcription-independent 23
TFIIS. 23
mg/m(2)) 23
MBC 23
Hematologic 23
(ORR) 23
weaknesses 23
1998. 23
(positive 23
discriminative 23
query, 23
neddylation, 23
RNAi-mediated 23
scenario, 23
relatives, 23
Profiling 23
(single 23
version, 23
completeness 23
Hand 23
5-ALA 23
abortions, 23
ribose 23
alkylation 23
moiety, 23
concludes 23
kbp 23
labeling. 23
genomes: 23
199 23
Commonly 23
better, 23
DNA-based 23
spore 23
combined. 23
numbers. 23
ob/ob 23
cilium 23
Invadopodia 23
stemness 23
interests 23
interpretable 23
nucleoprotein 23
categorize 23
glyceraldehyde-3-phosphate 23
p70 23
consequences, 23
(SEM 23
elotuzumab, 23
milestone 23
bronchitis 23
infective 23
insufficiently 23
LINX 23
institution, 23
titanium 23
GM1-gangliosidosis 23
electroclinical 23
smokers, 23
scarcity 23
lipidomics 23
built-in 23
spectra. 23
of: 23
reduced-nicotine 23
single-step 23
appreciation 23
[P 23
enacarbil, 23
asking 23
committee 23
chromatography-mass 23
Permanent 23
(TALENs) 23
heterozygotes. 23
founding 23
(WS4), 23
CCHS, 23
areflexia, 23
seconds 23
precipitate 23
elimination, 23
anaesthesia. 23
BCR-ABL, 23
Replicative 23
hemoglobinopathies. 23
broadened 23
11.1% 23
motif) 23
polymerization. 23
Dinucleotide 23
fields, 23
cyanobacterial 23
(98%) 23
DDX6 23
Firstly, 23
angiography. 23
7.8 23
guinea-pig 23
fold, 23
effect," 23
Leukemia 23
t(9;22) 23
ending 23
(incidence 23
5-20 23
Expressions 23
paired-end 23
Historically, 23
ubiquitin-binding 23
CRISPR-Cas 23
(G 23
cardioverter-defibrillators 23
night. 23
assaying 23
fingolimod 23
fludarabine, 23
Earlier 23
18S 23
karyotypes. 23
Suv39H1 23
unclassifiable 23
untreated. 23
(ICH) 23
constraint. 23
chaperone, 23
FKBP10 23
1-4 23
distal, 23
clinically, 23
phosphorus 23
arena 23
Tooth 23
27-year-old 23
peer 23
51, 23
Annual 23
facies, 23
insulin-induced 23
finds 23
(79%) 23
Significance 23
invertebrates 23
Epigenomic 23
domains: 23
trypanosome 23
spondylitis 23
amphibian 23
HIV-positive 23
inherited. 23
Bet 23
PDGF-BB 23
metastasis-associated 23
abdomen 23
workup 23
benzene 23
lots 23
pretreatment. 23
amorphous 23
ethnicity, 23
haloperidol 23
H3.1 23
Glucose 23
principle, 23
(DNA 23
treatment). 23
eosinophilia. 23
astatic 23
(12%), 23
tanning 23
RdRp 23
vehicle, 23
Lumbar 23
descent. 23
units, 23
HIF1alpha, 23
hallucinations 23
FBN1. 23
(NS) 23
extract, 23
strengthened 23
duration) 23
shark, 23
960 23
BRAF-V600E 23
Satellite 23
Gliomas 23
paradigms 23
genome-editing 23
ziconotide, 23
test) 23
SEGAs 23
arrhythmogenesis. 23
Questions 23
2]. 23
resistant. 23
SNAS 23
conclusive 23
Hashimoto 23
d-tubocurarine 23
(NPC) 23
copies. 23
Wiley-VCH 23
PAR1 23
vulva 23
simpler 23
channelopathy 23
cortices 23
V60L, 23
R151C 23
N88S 23
prevalence. 23
longer, 23
LIR 23
GABARAPL1 23
oscillation. 23
HRM 23
groin 23
expansions. 23
Behavior 23
caution. 23
Spinocerebellar 23
flashes, 23
gold-standard 23
FACT 23
P= 23
Regulator 23
immuno 23
strengthens 23
I(Y) 23
(stage 23
BA 23
mobility. 23
istradefylline 23
(CMA), 23
Ca-binding 23
digits 23
(2D:4D), 23
GRS 23
K48-linked 23
normal; 23
Cryptococcus 23
end-tidal 23
TNFα-induced 23
Focusing 23
methyltransferase) 23
Uganda. 23
omega-3 23
ERT. 23
longus 23
NIPD 23
multinational, 23
BVT 23
rule-based 23
ciliopathies. 23
(UCEs), 23
species-tree 23
SSc 23
AhR 23
PRP 23
hyperstimulation 23
Fe-S 23
flexibility. 23
1,600 23
tPA 23
rhythmicity 23
sGCβ1 23
(HuR) 23
etoposide, 23
Support 23
telaprevir 23
Desert 23
sonication 23
Surveillance 23
emerging. 23
DHAP 23
email 23
Children. 23
arteritis. 23
(59%), 23
(MIM# 23
dismal 23
Crizotinib 23
GPGPU 23
pegol 23
abatacept, 23
odorants 23
TMBBs 23
insertion. 23
CRMs, 23
FLCN 23
agonistic 23
IJV 23
macrothrombocytopenia 23
SEA 23
depigmented 23
unsaturated 23
CACNA1C 23
UniProt 23
Classic 23
FE(NO) 23
.03). 23
fibrinolytic 23
non-nucleoside 23
fungicidal 23
RG7112, 23
p.o. 23
ecarin 23
pVHL 23
obtains 23
antiphospholipid 23
(PPV) 23
Res; 23
(35%), 23
tadalafil 23
orteronel, 23
DHEA 23
H3.3, 23
[6 23
TRAF1/C5 23
hemosiderin 23
Celiac 23
cobimetinib 23
cobas 23
benzodiazepine-induced 23
flumazenil, 23
Pupil 23
Horner's 23
FBW7 23
G-CSFR 23
Chédiak-Higashi 23
mink 23
128-kd 23
ethanol-treated 23
G-quadruplexes 23
NB4 23
daratumumab-induced 23
SORL1 23
GDNFOS 23
Titin 23
(IL)-12 23
TKKQKTDEDD 23
PCa, 23
catch-up 23
1100delC 23
Fancf-deficient 23
Fanca 23
eteplirsen, 23
Guadeloupe, 23
DZCyt 23
Upf1p, 23
TIA. 23
cementum-like 23
Gata4, 23
F]altanserin 23
4C 23
AtHaspin 23
alectinib. 23
necrosome 23
+8, 23
Gro 23
Background 23
(TEMSO) 23
opinion: 23
DiGeorge 23
0·68, 23
ERAP1-ERAP2 23
aminopeptidases 23
CLCNKB 23
NMF 23
extraocular 23
Tyrosinase 23
H3K27M 23
(OCA1). 23
CENP-C 23
2-hydroxyisobutyrylation 23
CPF 23
plague, 23
(WGS) 23
cholangitis. 23
G2A 23
Smyd3 23
β3-adrenoceptor 23
PANTHER-PSEP 23
Arthritis. 23
(pre-RC) 23
coilin, 23
tularemia 23
neuroretinitis 23
Sld5 23
k-mers 23
NOMe-seq 23
Pore 23
Klu 23
napabucasin 23
Xrn1-sensitive 23
Call 23
dst1 23
SSE- 23
typhoid 23
5-nitroimidazole 23
Vanishing 23
Epidermolysis 23
sex-dependent 22
SPSS 22
trophic 22
biogenic 22
less. 22
histone-modification 22
exon/intron 22
snRNAs 22
integrin, 22
co-cultured 22
Investigative 22
ingestion. 22
gynecologic 22
Array 22
panel. 22
60. 22
Around 22
relieving 22
Neuromuscular 22
(PC) 22
EMA 22
Mineral 22
(mAbs) 22
ears, 22
MyoD 22
H2O2 22
0.87, 22
(54%) 22
Treatments 22
naked 22
(ELISA). 22
pathologists 22
Oct3/4 22
p73, 22
karyotype, 22
embryoid 22
Oct4 22
project, 22
326 22
propagating 22
broken 22
10.4 22
hospitalisation 22
angina, 22
beta-blocker 22
(87%) 22
effects; 22
presymptomatic 22
standing 22
(SMA) 22
2C 22
molecular, 22
atria 22
pesticides 22
Urine 22
biotechnological 22
anti-freeze 22
(KD) 22
moiety. 22
interquartile 22
pg/ml) 22
beneficial. 22
documented, 22
c-Jun, 22
CXC 22
alteration. 22
recorded, 22
pregabalin, 22
indication, 22
protein-2 22
ready 22
oncoprotein. 22
gammopathy 22
rest. 22
balance, 22
PYY, 22
activin 22
Often, 22
(0% 22
term, 22
Divergent 22
(QOL) 22
athlete 22
conducted, 22
Elucidating 22
Focus 22
stratifying 22
(81%) 22
Zealand, 22
hypercholesterolemia, 22
statin-treated 22
approved. 22
Program. 22
(HIF) 22
non-exonic 22
variously 22
26) 22
ncRNAs, 22
transcribed. 22
S-adenosyl-L-methionine 22
flipped 22
osteosarcoma, 22
(G-CSF) 22
checkpoint, 22
ICL 22
AT-rich 22
Native 22
non-denaturing 22
exhaustive 22
length-dependent 22
hypertrophied 22
acupressure 22
238 22
H4K20me3, 22
spermatogenesis, 22
(XCI) 22
(using 22
hypersensitivity, 22
alpha-chain 22
IKKalpha 22
immunofluorescence. 22
HGF-treated 22
observational, 22
La 22
A/H1N1 22
(Tamiflu) 22
aspirates 22
(50%), 22
placenta. 22
RTS 22
forehead, 22
-- 22
morphogenesis, 22
Uc.160+, 22
Infant 22
evaluations. 22
underlined 22
34-year-old 22
Syndrome) 22
efflux. 22
hypoglycemia, 22
0.024). 22
inherently 22
outperform 22
digestion, 22
proteins; 22
Observed 22
Thirty-eight 22
atrichia, 22
MBTPS2 22
avascular 22
(TLR) 22
thrombi 22
TMZ. 22
(11%), 22
cues. 22
polyethylene 22
because, 22
probe, 22
Progression-free 22
Vorinostat 22
indices. 22
eighteen 22
components: 22
attentional 22
213 22
5.8 22
(82%) 22
pragmatic 22
latently 22
RNAPII. 22
shortens 22
ubiquitin-mediated 22
disadvantages 22
arrays, 22
maydis 22
Switzerland 22
milieu 22
accuracies 22
(65 22
P-value 22
exceptional 22
synergic 22
device, 22
(NF1), 22
itching 22
subject. 22
cloned. 22
(SGs) 22
cords 22
translationally 22
43, 22
radicals, 22
twins, 22
monkeys, 22
360 22
5- 22
7-fold 22
bioavailability. 22
200, 22
proteins) 22
BCL11B 22
spaced 22
however. 22
dermatoses 22
tumour-suppressor 22
computer-aided 22
Hodgkin 22
(SMA). 22
Africans, 22
elevating 22
bypasses 22
(ERAD) 22
identical, 22
meningoencephalitis 22
explanted 22
(cerebral 22
hamartomatous 22
(T4) 22
gliptins 22
3.6% 22
mellitus: 22
model-based 22
Exclusion 22
DRS 22
CHF. 22
(NET) 22
multilocus 22
ISO 22
poison 22
review]. 22
enhancement. 22
flaccid 22
awaits 22
kD 22
demonstrable 22
gonadotropin-releasing 22
iliac 22
CHD8 22
CDY 22
isothermal 22
independent, 22
function(s) 22
reverted 22
(ATM) 22
mandibular 22
self-renewal, 22
bias, 22
out-of-hospital 22
discharge, 22
p<0.0001). 22
(HCM). 22
acknowledged 22
virus) 22
myogenesis, 22
phosphorylation-dependent 22
Average 22
pseudogene 22
Babesia 22
340 22
10- 22
(≤ 22
circRNA, 22
ND 22
desmosomal 22
186 22
son 22
A: 22
Melatonin 22
M-FISH 22
classifiers 22
(31%) 22
terminus, 22
TERT, 22
X-linked, 22
sub-type 22
validation, 22
age-adjusted 22
RECK 22
miR-126 22
homology-directed 22
hepatectomy 22
0.04), 22
degradative 22
mutations). 22
dioxide. 22
-10 22
confirmed, 22
pre 22
AA. 22
cosmid 22
(P=0.001) 22
consistent. 22
impediment 22
Synergism 22
combinations, 22
pomalidomide 22
continual 22
shear 22
virus-infected 22
partitioned 22
mere 22
discontinuations 22
(HNSCC). 22
CTF18, 22
Establishment 22
unperturbed 22
Analogous 22
translesion 22
0.03, 22
FEBS. 22
AMPA 22
store-operated 22
electrocardiography 22
(1.0 22
tertile 22
wedge 22
sodium, 22
panels. 22
Cockayne 22
time-course 22
occlusive 22
45,X 22
tapering 22
thickened 22
TSC2. 22
discussions 22
anthracycline-based 22
(FEC 22
grafting. 22
(CRMs) 22
purpose. 22
DLBCL 22
nucleophilic 22
Ca(2) 22
acidosis 22
want 22
High-risk 22
(rate 22
Specialised 22
nmol/l 22
community-based 22
indices, 22
Surgeons 22
FD 22
(3%), 22
confounders, 22
musculus 22
teratogen 22
Reports 22
HDM2 22
immunoblotting, 22
cleavable 22
producers 22
Serine 22
concatenated 22
wild-type, 22
logarithmic 22
water-soluble 22
formulation. 22
objects 22
frequently. 22
PLB, 22
GC-1 22
sildenafil, 22
albumin, 22
ganglia. 22
halt 22
>3 22
ambient 22
(delta 22
320 22
ci 22
gastro-oesophageal 22
authors, 22
beads, 22
70) 22
Decrease 22
repressors, 22
started. 22
realize 22
fingerprint 22
paves 22
cycloheximide 22
territories. 22
multiforme, 22
undertake 22
20-year 22
simplify 22
NLR 22
patch. 22
indigenous 22
engineering, 22
crisis. 22
1.50 22
rotigotine 22
A). 22
beta-glucosidase 22
nucleases. 22
APP, 22
explicit 22
collision 22
VI, 22
E.coli 22
BBS, 22
produced. 22
cells), 22
Immunization 22
ageing. 22
interchromosomal 22
VP-16 22
integration, 22
non-cell-autonomous 22
Thereby, 22
preferences, 22
retrieval, 22
communicating 22
(RT-PCR), 22
CD34+ 22
aorta, 22
P-bodies, 22
4%, 22
repolarisation 22
COX 22
GLUT1 22
stroma, 22
mPer2 22
Abelson 22
GNF-2 22
TKI, 22
inferences 22
granulocytic 22
injecting 22
Interferon 22
29%, 22
co-transporter-2 22
strand-bias 22
WT, 22
ECGs 22
apart. 22
wrong 22
Preventive 22
coagulation. 22
sensory-motor 22
endosomes, 22
p53-binding 22
P=0.005). 22
Termination 22
Learning 22
hepatosplenomegaly, 22
anti-Abeta 22
terms: 22
sixteen 22
hominoid 22
bHLH 22
paraganglioma, 22
pirfenidone 22
BAL 22
agonist) 22
Gastric 22
peroneal 22
dilute 22
infiltrates 22
NF-kB 22
elastin 22
FzE3 22
TSSs 22
Hypoxia 22
(DLB) 22
Double-Blind, 22
17-item 22
Wilcoxon 22
24) 22
logic 22
9.4 22
manufacturer 22
HHO1 22
interleukin-23 22
GISTs. 22
PA, 22
glioblastomas, 22
translocations, 22
integrins. 22
(cyclic 22
mg/dL, 22
exomes 22
mutation(s) 22
societal 22
colonized 22
delineating 22
upfront 22
entorhinal 22
hepatomegaly, 22
firmly 22
something 22
LM 22
KDEL 22
full-term 22
interferon-alpha 22
Parents 22
stretching 22
SS. 22
KCNQ1, 22
p16INK4 22
anti-inflammatory, 22
incision-induced 22
nociceptors 22
MTase 22
chicken, 22
autoradiographic 22
frequencies. 22
Wernicke-Korsakoff 22
alcoholism 22
(MRS) 22
pons 22
Jews 22
TRAP 22
N370S 22
FANCB 22
manifestation. 22
VEGF-C 22
Kazal-type 22
ontogeny 22
NRF2 22
(alpha-NAGA) 22
corporis 22
empagliflozin. 22
Method 22
HCL 22
AHI 22
myostatin 22
TERTp-mut 22
fostamatinib, 22
exquisitely 22
interrupt 22
insertion/deletion 22
ruffling 22
cytohesin 22
CD34 22
SGK1 22
(± 22
MAP1B 22
contact. 22
catastrophic 22
(greater 22
lamellipodial 22
TRAF 22
hypermethylation. 22
difference. 22
polypeptides. 22
Lymphoma 22
efficacious, 22
Tolerance 22
PABPN1 22
Just 22
syncope. 22
(low 22
mHealth 22
Initiative 22
pons, 22
R163Q 22
37) 22
4.4 22
contraindications 22
unveil 22
Sister 22
open, 22
thinning 22
ovaries, 22
DM2 22
elevation. 22
T-DNA 22
tumor-treating 22
Compliance 22
Ctf4. 22
Dia2 22
text]-time 22
independently, 22
PLBs 22
craniotomy 22
(C 22
prehypertrophic 22
CMA. 22
hepatic, 22
dimorphic 22
chi-square 22
sumoylated 22
cooling 22
NEC 22
Core 22
1995. 22
pombe, 22
MiR-223 22
(FGFR) 22
Reaction 22
ferrous 22
DUBm 22
LepChorionDB 22
experimentation 22
alga 22
newfound 22
shunting 22
keratins 22
His-Purkinje 22
transposons. 22
Treprostinil 22
triage 22
phycobiliproteins 22
hydroxyapatite 22
plk2 22
p-Ser-129 22
microsporidian 22
avoidance. 22
8-OH-DPAT 22
textual 22
Listening 22
p<0.001), 22
SHAM 22
PER2 22
SSI 22
microalbuminuria 22
judge 22
(AHR 22
first-ever 22
Lys-63-linked 22
hairpins 22
Physiology 22
amniocytes 22
menin 22
radiograph 22
Hh, 22
biofabrication 22
carcinomatosis 22
(600 22
relaxant 22
NICE 22
deviation) 22
palpable 22
Scale), 22
Prion 22
PADI4 22
SNPs. 22
scenario. 22
axonemal 22
dynein-1 22
ciliopathies, 22
crowding 22
crizotinib, 22
bronchiectasis 22
H3K79me3 22
post-partum 22
RNA-activated 22
polyinosinic:polycytidylic 22
2·5 22
merozoite 22
diphtheria, 22
Likelihood 22
cryopreserved 22
bipotent 22
Thrombotic 22
Smith-Waterman 22
phosphaturic 22
Piebaldism 22
SHP 22
ultra-conserved 22
(VOCs) 22
VOC 22
hypermobility, 22
ZO-1 22
extubation. 22
Hyperbilirubinemia 22
AzgA 22
(EDN3) 22
beans 22
palpitations 22
southeast 22
(PPTP) 22
Puckered 22
LY450139 22
SMM 22
Microbiology 22
Integrating 22
SPT 22
1a, 22
METLIN 22
post-herpetic 22
Siltuximab, 22
reasoning 22
efforts, 22
Arabic 22
(DEND) 22
pexophagy 22
borreliosis 22
ticks, 22
Septal 22
eliglustat, 22
GS 22
peroral 22
Gpp 22
Ehrlichia 22
MIT 22
hypophosphatemia, 22
beta-secretase 22
non-HLA 22
10(-5), 22
OLIG3/TNFAIP3 22
T-box 22
dementia-amyotrophic 22
1b. 22
RelB 22
ependymomas. 22
colour. 22
strand-biased 22
Klenow 22
protoporphyria. 22
anthrapyrazoles 22
DuP 22
T2C 22
α4β7 22
Ada-C 22
MAO-A 22
enumerated 22
SLC16A2 22
Selumetinib 22
Hyperthermic 22
Neuroglobin 22
eteplirsen-treated 22
bronchiolitis. 22
ASP 22
Lck 22
ALK-TKI 22
(5hmC) 22
(LRES) 22
non-synaptic 22
(POEMS) 22
capsulotomy 22
twinning 22
oclacitinib 22
BCG 22
H-binding 22
(NadA), 22
CAFE 22
Bioconductor. 22
Scurvy 22
off" 22
etoricoxib 22
D-resistant 22
fistula 22
harlequin 22
muciniphila 22
superoxide-producing 22
MiRduplexSVM 22
SEP 22
Dapivirine 22
cobalt-60 22
DENdb, 22
searching, 22
circling 22
hemisomes 22
Golimumab 22
Sen1 22
EHS. 22
odontoid 22
craniopharyngioma 22
DIPGs 22
non-brainstem 22
Fixed-length 22
ODM 22
Onartuzumab 22
emollients. 22
Mal 22
EL. 22
Eic1 22
CCAN/Mis6/Ctf19 22
cri-du-chat 22
(OAB). 22
IORT 22
Dna2 22
ectrodactyly, 22
CUTs. 22
IL-23, 22
DosT 22
anaphylaxis 22
RBM6 22
auxin-responsive 22
glecaprevir/pibrentasvir 22
extraluminal 22
substring 22
(p=0.000), 22
53BP1-TIRR 22
(BORSA) 22
Coding 21
homing 21
adopting 21
myofibroblasts 21
inappropriately 21
chemotactic 21
(EGFR). 21
analysis) 21
13-acetate 21
RANKL, 21
sham-operated 21
pyrophosphate 21
lacunar 21
EOC. 21
up-regulated, 21
miR-200b 21
gravis. 21
scanned 21
laterally 21
Postmenopausal 21
2010). 21
absorptiometry 21
specification. 21
relocalization 21
erythema, 21
esophagus, 21
113 21
tachyarrhythmias. 21
disproportionately 21
enzalutamide, 21
0.77, 21
Takeda 21
Visualization 21
antimetastatic 21
amplifications 21
speculation 21
MYC, 21
transfection. 21
phosphopeptides 21
subsets, 21
intent 21
continually 21
graft-versus-host 21
collection, 21
retina, 21
photoreceptor 21
myofibers 21
Thr 21
(13%) 21
mask 21
(26%) 21
IVA 21
success, 21
admissions 21
rings, 21
Adding 21
heads. 21
FSHD2 21
pictures 21
beating 21
caffeine-induced 21
L., 21
orthogonal 21
Tests 21
0.06 21
saprophytic 21
naphthalene, 21
15-year-old 21
children) 21
Histologic 21
(NO) 21
hyperthermia 21
ERK1/2, 21
(TK) 21
cyclized 21
chemoresistance 21
mediated, 21
Fusion 21
μM). 21
(HUS) 21
exchange, 21
dialysis. 21
Rico 21
vincristine, 21
Hospital. 21
bout 21
addition. 21
Multicenter 21
233 21
Ribosome 21
institutions 21
290 21
(ratio 21
Troponin 21
soccer 21
kinetics, 21
women's 21
1.07 21
219 21
confirmation. 21
motivation 21
argument 21
myalgia, 21
Treatment-emergent 21
complexities 21
(every 21
hyperlipidemia 21
preparative 21
hypermethylation-associated 21
(lincRNAs) 21
bacteriophage 21
4; 21
hybridization, 21
(CML). 21
DESIGN: 21
arresting 21
summarise 21
remnants 21
influx. 21
degree, 21
DCM, 21
Mol. 21
feel 21
on, 21
acupuncture. 21
conclusions. 21
histone, 21
(hTERT) 21
Aβ₂₅₋₃₅ 21
apoptosis; 21
deacetylase, 21
underpinning 21
frees 21
Cyr61 21
GATA-4 21
LY294002, 21
c-kit 21
UVB-induced 21
intubation, 21
alpha-fetoprotein 21
headaches. 21
rapidly. 21
experiences. 21
Denmark, 21
Mac 21
curves. 21
lamellar 21
transactivating 21
(VAS) 21
Random 21
punctate 21
subjects) 21
amenorrhea 21
dyshormonogenetic 21
inhibitors; 21
0.1, 21
dissolved 21
oxidize 21
disadvantage 21
Cardiorenal 21
lower. 21
free-living 21
upright 21
minimise 21
(CP) 21
disappeared. 21
noticed. 21
acronym 21
GG 21
Genotype 21
thrombus 21
coherence 21
2C19 21
70%, 21
Seizures 21
RTOG 21
RPA, 21
(62%) 21
LSDs. 21
GSK3 21
lantibiotics 21
Vancomycin 21
meta-analysis, 21
deficit, 21
(GBM). 21
escalated 21
CONCLUSION 21
(86%) 21
Diphtheria 21
hypotension, 21
Best 21
cataracts, 21
hairs 21
IL17A 21
2-5 21
bystanders 21
premorbid 21
(see 21
normative 21
3A4 21
4.9 21
participants), 21
I), 21
predominated 21
neurally 21
hydrochloride, 21
mesoderm 21
(3C) 21
DM1 21
instead, 21
compaction, 21
fluctuation 21
β, 21
RTS, 21
fungus, 21
patch-clamp 21
photoactivatable 21
Motif 21
(HSP) 21
CP. 21
Selenoproteins 21
codons, 21
have, 21
overexpressed, 21
particles, 21
(MEFs) 21
profibrotic 21
2-DE 21
glycans 21
ORF 21
harbour 21
synchronized 21
replicon 21
Dysregulated 21
etiopathogenesis 21
pubic 21
nevertheless, 21
variance, 21
prospects. 21
SMA, 21
(GAP) 21
neuropil 21
gallinaceum 21
VSMC 21
(1), 21
contractions. 21
sural 21
conceptually 21
PDCD10 21
T2-weighted 21
MRIs 21
platform, 21
(ELISA) 21
Hg) 21
TCs 21
ejaculation 21
PharmaGist 21
enrollment. 21
endopeptidases 21
prevented. 21
pregnancy; 21
smell 21
pg/mL 21
spiked 21
neurotoxins 21
neurotoxicity. 21
aa 21
polymerase-1 21
box, 21
centromere. 21
autoantigen 21
Chd7 21
2/3 21
bulb 21
chromodomain-containing 21
kDa, 21
chromodomain. 21
(HP1) 21
prefers 21
(Hemiptera: 21
engages 21
records, 21
tomography, 21
UNLABELLED: 21
left-right 21
candidate. 21
JIL-1 21
discounted 21
diagnoses, 21
multispecies 21
normoxic 21
reinforcing 21
fluids, 21
convulsions. 21
reliance 21
formations 21
Reintroduction 21
cavity. 21
lithium, 21
decline, 21
CART 21
diversion 21
RNA) 21
0.8% 21
analytic 21
inter-individual 21
(ARVC) 21
R14del+ 21
0.007). 21
CRP, 21
malondialdehyde 21
SH 21
sections, 21
sexes. 21
BZLF1 21
methylated. 21
materials. 21
PARN, 21
fludarabine 21
recognise 21
DC, 21
(52% 21
Ad-miR-21 21
acridine 21
μg/kg 21
acidification 21
heterophile 21
NOAC 21
Hitherto, 21
hours). 21
non-toxin 21
625 21
experimentally-characterized 21
ENS 21
3A 21
ligand-induced 21
endothelin-1 21
transit 21
sort 21
polynucleotide 21
second-generation, 21
non-histone 21
necessitate 21
skeleton 21
GUS 21
cloning, 21
Orthologous 21
influenzae 21
Budding 21
binomial 21
12.2 21
determinations 21
298 21
blocks, 21
grant 21
RTH 21
TCR. 21
(TCR), 21
(TS), 21
Hispanic 21
inexpensive, 21
mediastinal 21
rifampicin, 21
(PCR), 21
drainage, 21
constrictive 21
1998, 21
fibrin 21
TSC1/TSC2 21
Site 21
once-weekly 21
reasons. 21
DFS 21
ubiquitin-conjugating 21
Ca(2+)-ATPase, 21
12-lead 21
prolapse, 21
publications. 21
respect, 21
12-myristate 21
hypervariable 21
20%. 21
year) 21
Incremental 21
gained. 21
iv 21
uneventful 21
vegetable 21
MTBP 21
6-12 21
Empirical 21
Interest 21
Efforts 21
mutate 21
Sorting 21
recycling. 21
zeta 21
Kir2.1 21
function-related 21
implemented. 21
errors. 21
0.05% 21
gel. 21
equipment 21
vWF 21
RB 21
clarification 21
questionable 21
Abacavir 21
psychotherapy 21
fMRI 21
invaded 21
Tsc1 21
interleukin-2 21
(MoAbs) 21
emerge. 21
anti-tuberculosis 21
synthase. 21
microorganisms. 21
CagA 21
host's 21
calcification, 21
vaccinations 21
CD14 21
excluded, 21
direction, 21
speech. 21
beta-hexosaminidase 21
sinuses 21
BMAL1, 21
role(s) 21
patient-years; 21
(43% 21
smaller, 21
Toward 21
(PS), 21
(NPV) 21
explosion 21
Pfizer; 21
years); 21
pectin 21
ZFNs 21
nucleases, 21
minigene 21
convenient, 21
accord 21
(100%), 21
vision, 21
Lantibiotics 21
syndrome-associated 21
5q31 21
expectancy. 21
environments, 21
plasmids. 21
prompting 21
DDR 21
B-cells 21
century, 21
receptor-1 21
RNAi. 21
DADs 21
looped 21
EZH2. 21
correctable 21
fine-tuned 21
bifida 21
Republic. 21
contagious 21
Ultrasonography 21
therapy-resistant 21
insults. 21
contracting 21
0.73 21
hour, 21
L-lactate 21
secreting 21
HSCT 21
maculopapular 21
indolent 21
inhibitors) 21
dizziness. 21
HAM-D(17) 21
toxoplasmosis 21
extraembryonic 21
proceeded 21
CRISPR/Cas 21
destroy 21
tuning 21
blows 21
implicit 21
kingdoms 21
underdiagnosed 21
224 21
11-year-old 21
aPKC 21
53BP1, 21
status) 21
metals 21
purpura, 21
usability 21
MD. 21
moon 21
(MGMT) 21
immunization. 21
solanezumab, 21
Aβ42 21
delirium, 21
SCCmec 21
loosely 21
hominid 21
empirically 21
(SSRIs) 21
ASD, 21
ASDs. 21
switch, 21
breeds 21
sulphate, 21
grew 21
elsewhere. 21
paraganglioma. 21
exacerbations, 21
study; 21
purely 21
ligation. 21
interleukin-6, 21
(TSS) 21
interleukin-12 21
Rhythmic 21
54-year-old 21
plan. 21
Demographic 21
Arm 21
Components 21
OT 21
brain-derived 21
lincRNA-p21 21
worms 21
Register, 21
off, 21
kinesin 21
13.8 21
Hho1 21
poly(A)-specific 21
trypanosomes 21
pentapeptide 21
enrolled; 21
trended 21
U7 21
HMGCR 21
phytochemical 21
medical, 21
(92%), 21
MCO 21
microbiota. 21
Campylobacter 21
lumen. 21
laparotomy 21
nm), 21
(Glasgow 21
SCI 21
dichotomized 21
Tau 21
nm. 21
myoclonus, 21
SENP2 21
8-oxoguanine 21
polyposis. 21
κ 21
lamotrigine 21
DS. 21
(SS) 21
Ki-67, 21
translucency 21
"the 21
(Hsp) 21
jointly 21
agglutination 21
gravidarum 21
dysautonomia 21
Epigenetics 21
polyphenols 21
* 21
Canagliflozin. 21
SALL4-mediated 21
programme. 21
Attention 21
voltage-sensitive 21
leprosy 21
intron-exon 21
Autonomic 21
ICN 21
MLH1 21
ticks. 21
emphysema 21
treatment), 21
Exploring 21
(apo) 21
teleosts, 21
aCNEs 21
slow-twitch 21
AHS 21
convulsive 21
industry. 21
(MEF-2) 21
IL-6-induced 21
anti-rheumatic 21
dystrophinopathy 21
preventative 21
recoding 21
keratinocytes, 21
conformers 21
miR-34a, 21
alpha-actinin 21
SMAD2 21
INTERPRETATION: 21
diffusivity 21
spirochetes 21
untoward 21
Allergy 21
anesthetics 21
Elmo1, 21
engulfment 21
lamellipodia. 21
destined 21
Viroid 21
rod-like 21
TAP 21
Fourth, 21
diuretic 21
Access 21
Degradation 21
weight-loss 21
inheritable 21
ABI 21
NMSC 21
D84E, 21
(ER). 21
PWS. 21
RyR2. 21
Bortezomib, 21
GABARAP 21
17-AAG 21
oscillating 21
boundaries. 21
S100B 21
situation, 21
neurostimulation. 21
myosin-Ibeta 21
myosin-VI 21
myosin-VIIa 21
constrain 21
insulated 21
clonally 21
Mcm10 21
perception. 21
Cdc45 21
PHOX2B 21
5S 21
p.R120W 21
ganglioside-induced 21
(I 21
pain-free 21
on-off 21
Dopamine 21
hsp70 21
Δ(r-l) 21
gliosis 21
(CA) 21
239 21
USP25 21
(MCP-1) 21
phosphotyrosine 21
asymmetries 21
Isolates 21
gasdermin 21
Fe 21
personally 21
T(reg) 21
DdVASP 21
(1998) 21
elbow, 21
eyebrows, 21
microphthalmia, 21
leave-one-out 21
clustering. 21
(QOL). 21
(p-Ser-129). 21
TGF-beta1-induced 21
URA3 21
CSRP3 21
bromocriptine 21
glycosylases 21
SAINT 21
Ejection 21
prohormone 21
anthocyanin 21
dioxygenases 21
whorls 21
microsynteny 21
carnitine 21
"July 21
(CNEs). 21
Angiotensin 21
admixture 21
rice. 21
cGMP 21
microspheres 21
3p 21
thalamus. 21
oligomer, 21
glandular 21
M31, 21
TOM 21
non-peptide 21
AT1R 21
maritima 21
Typhi 21
ETV 21
ZNF 21
AGS 21
Phthirus 21
Histidine-rich 21
(I-1) 21
Nimodipine 21
GRADE 21
Uhl's 21
V2 21
(CAGE) 21
IFT172 21
Mainzer-Saldino 21
muscle-derived 21
solver 21
G-to-A 21
ACPAs 21
cFn 21
subthalamic 21
UPDRS 21
"on" 21
Stattic, 21
JSI-124 21
WP1066) 21
programmatic 21
polio 21
Nodal 21
BoNT/A 21
GDP 21
bovis 21
TDP43 21
mediated. 21
488 21
(FCS), 21
absorbing 21
(eteplirsen) 21
51. 21
EtCO2 21
PBF 21
TIMP 21
Ezh1 21
fidelity. 21
Propofol 21
S1P1 21
(piRNA) 21
Stellate 21
(0%) 21
Prochlorococcus 21
IKKbeta 21
preprotein 21
Bacteroides 21
Gradenigo's 21
15q 21
siltuximab. 21
dose-finding, 21
hemagglutinin 21
deamidation 21
wake-promoting 21
MWT, 21
RPS7, 21
PAX3 21
Cvt 21
CNSs 21
ET(B) 21
ET-1-induced 21
Finland 21
x-rays 21
CaMKIIdelta(C) 21
A3G/B 21
buffalo 21
8-oxo-GDP 21
endosomal/lysosomal 21
gliadin 21
miR-27a 21
TGFBR1 21
C58/J 21
depressive-like 21
ephrin-B2 21
SCF(Fbw7) 21
(eRNAs). 21
CQ 21
transected 21
fruit, 21
LR 21
Separation 21
unsuitable 21
5-mg 21
intetumumab, 21
enterocytes 21
arthropod-borne 21
kg⁻¹) 21
DnaE 21
O6-benzylguanine 21
Col 21
preauricular 21
GDF-10 21
5-HT(2C) 21
SLC6A2 21
(PsA) 21
SOL 21
shoot 21
GKT137831 21
052 21
(WED), 21
G6PD-deficient 21
(CJD) 21
teriflunomide. 21
(SERD) 21
PorA 21
pseudohyperphosphorylated 21
regioneR 21
http://www.bmj.com/company/products-services/rights-and-licensing/. 21
VZV 21
miR-539 21
Bora 21
bean 21
plexus-derived 21
fascia 21
Ser154 21
Osimertinib 21
Gitelman 21
microphthalmos 21
intracavernosal 21
oxidase. 21
PSC 21
DENdb: 21
1015 21
MRP/ABCC 21
chronic-plus-binge 21
rik1+ 21
distensae 21
x-CSI 21
p-CSI 21
3D-CRT 21
H3F3A, 21
melanocytosis. 21
Bioconductor: 21
fat-depleted 21
B.pseudomallei 21
zonular 21
peptide-aptamer 21
Behind 21
(MNase) 21
(PALACE 21
Fam118B 21
Allgrove 21
Rpb9, 21
FIRE 21
echinacea. 21
echinacea 21
Evans' 21
Anp32e 21
Rilotumumab 21
gammopathy, 21
(JPS) 21
Manta: 21
GPLv3 21
Palatal 21
Reb1p 21
STOP, 21
Conjoined 21
vara 21
CLIP-Seq 21
hyperprolactinaemia 21
seed-and-extension 21
RiVIERA 21
(D-MER) 21
PA2G4 21
miR-19b 21
extramammary 21
kindred, 20
ret 20
(referred 20
pro-survival 20
niche. 20
arrangements 20
examples, 20
Predicted 20
tRNAs 20
RAW 20
bone-resorbing 20
IL-6. 20
validation. 20
(AUC 20
0.40 20
antibody-mediated 20
(January 20
access. 20
estrogens 20
USA). 20
neuroblast 20
psoriasiform 20
lymphadenopathy. 20
carcinoma: 20
antiarrhythmics 20
Class-III 20
(active 20
0.70, 20
Androgen 20
tumor-bearing 20
cycle-related 20
anti-epidermal 20
ELISA, 20
endpoint. 20
mobility, 20
underpinnings 20
sparse. 20
ADC 20
C-HPP 20
confidence. 20
Ab 20
MALDI 20
ions. 20
volumes, 20
Ataxia 20
pay 20
destabilization, 20
undesired 20
(53%), 20
end-point 20
chronotropic 20
Signs 20
transferase, 20
presentations, 20
heterogeneous. 20
genome-wide. 20
generated, 20
Coupling 20
kindreds. 20
APC, 20
dilution 20
TRH. 20
meta 20
sediment 20
Strain 20
so. 20
male). 20
overall. 20
single-blind 20
temperatures, 20
(PI3K)/Akt 20
loops, 20
assignment, 20
steps, 20
Terminal 20
sonic 20
lacosamide 20
respiratory, 20
propeptide 20
chemoresistance. 20
join 20
aHUS 20
newborn. 20
complement, 20
YY 20
trials: 20
modes. 20
three, 20
rest, 20
donation. 20
actin-based 20
1.05 20
1.21 20
Odds 20
DRG 20
uterus, 20
diarrhoea, 20
speculative 20
instrument. 20
cTnT 20
NT-proBNP, 20
Absolute 20
menarche 20
menopause 20
microdeletion, 20
photographs 20
1.2% 20
hypercholesterolemic 20
investigators, 20
LDLC 20
rosuvastatin 20
338 20
flipping 20
1-hour 20
oncologists 20
girl, 20
(LC-MS/MS) 20
ATR, 20
by-products 20
nucleotide, 20
displacing 20
X. 20
11q13 20
contraction, 20
single-blind, 20
1.00, 20
gets 20
H3K4me2 20
latency. 20
Centromeres 20
anti-oxidant 20
proof-of-principle 20
system; 20
Rel 20
insensitivity 20
(before 20
265 20
conveys 20
0.20 20
0.47 20
unexposed 20
learnt 20
P=0.02). 20
cousins 20
bronchoalveolar 20
(13%). 20
thio-phosphoramidate 20
doublet 20
(DSBs). 20
counterparts, 20
α-subunit 20
instructed 20
allergen 20
asparagine 20
cytogenetics, 20
>20 20
HER2-negative 20
gene), 20
syndrome? 20
hypothyroid, 20
valine 20
picture. 20
risk-benefit 20
Orbitrap 20
formulas 20
molecule-1 20
sizes. 20
Dermatology, 20
163 20
response: 20
189 20
tumor-related 20
choice, 20
enzyme-inducing 20
acid-dependent 20
(GC) 20
metazoans, 20
analogy 20
(S. 20
ATCC 20
(56 20
12.4 20
bleed 20
steroids. 20
(target 20
exotoxin 20
(IV) 20
newly-diagnosed 20
hypomyelination 20
IL6, 20
1138 20
6-year 20
(SHR) 20
SMC3 20
organizational 20
Long-range 20
myofibrillar 20
defensins 20
toxin, 20
anti-thyroid 20
IMT 20
circumference, 20
plexus, 20
eIF2α 20
spared 20
healed 20
Upper 20
route. 20
mock 20
MPRs 20
neuroblastomas 20
trichoepitheliomas 20
G0/G1 20
synapse. 20
p21, 20
PMP22, 20
CCM3 20
CCM3/PDCD10 20
protein; 20
approaching 20
trade 20
caution, 20
credible 20
0.77 20
potency, 20
antihyperglycemic 20
Electronic 20
(weeks 20
strokes. 20
command 20
followed. 20
endopeptidase 20
multimers 20
pro-angiogenic 20
initio 20
outbreaks. 20
succeeded 20
hemifacial 20
(BBB) 20
mouth. 20
oligodendrocytes, 20
1993-2020, 20
GeneReviews 20
aminoacyl-tRNA 20
instructions 20
demethylation. 20
kinetochores 20
homotypic 20
targeting, 20
repositioning 20
faithfully 20
attach 20
Isw1 20
Mr 20
methylation-dependent 20
Matrigel 20
coloboma, 20
Posterior 20
explanation, 20
distortion 20
nucleate 20
five, 20
anterior-posterior 20
browsers 20
clades, 20
aggravation 20
(DE) 20
intramural 20
DCE 20
neuropharmacological 20
OCTs 20
intermediary 20
33258 20
sertraline 20
services. 20
PTEN. 20
DX, 20
Ki67, 20
levels; 20
(T(3)) 20
3,5,3'-triiodothyronine 20
impact, 20
guarantee 20
sponges. 20
miR-7, 20
(lncRNAs), 20
base-pairs 20
lymphoblast 20
electrocardiograms 20
pump. 20
catalase, 20
administrated 20
lag 20
preprocessing 20
Analyzing 20
demethylases 20
thermophila 20
clarified, 20
spermatocytes 20
C2H2 20
death; 20
condition; 20
chronological 20
(TERT) 20
models: 20
periodontitis, 20
adenovirus-mediated 20
RFS 20
Beclin 20
autophagy-related 20
myositis 20
TLRs 20
Autophagy, 20
resided 20
chlamydial 20
thromboprophylaxis 20
CO2. 20
stresses, 20
transducing 20
(NHL) 20
megacolon 20
pigmentosum 20
R-UMSCC-1 20
R-Cal33 20
MDR-1/P-gp 20
invaginations 20
deficiencies. 20
speckles. 20
(LADs). 20
unveiled 20
CNVs, 20
once, 20
constructs. 20
Inference 20
Singapore 20
II-dependent 20
multidomain 20
precocious 20
at, 20
high-fidelity 20
G1. 20
testable 20
(21%) 20
Ras, 20
mmol/L, 20
acetaminophen 20
men) 20
nonischemic 20
boy, 20
artery, 20
horse 20
mycobacteria 20
cough 20
pericarditis. 20
configuration. 20
trial; 20
621 20
64%, 20
stay, 20
requirements, 20
CPB 20
user. 20
graph-based 20
(NAE) 20
thioester 20
HIV-1. 20
intermediate-risk 20
dephosphorylates 20
AP-1. 20
chimeric, 20
2012) 20
0.92, 20
0.95; 20
audit 20
2.5% 20
checklist 20
miR-155-deficient 20
IFNγ 20
uncomfortable 20
all-trans-RA 20
0.81 20
contrasted 20
Retinoic 20
proteasomes. 20
inhibitor), 20
hollow 20
Raman 20
intercalative 20
heterocyclic 20
stacking 20
miR-34a 20
gradient. 20
Functions 20
PX 20
(CGIs) 20
compositionally 20
0.6% 20
neovascular 20
TrkC 20
NS). 20
extranodal 20
1600 20
food, 20
dosage, 20
10.3 20
peptic 20
mid 20
PDGF 20
H(2)O(2), 20
regurgitation, 20
2.4% 20
GM2 20
startle 20
intelligence 20
epileptogenic 20
clozapine. 20
1.73 20
attack, 20
(44%) 20
236 20
met, 20
dichotomous 20
misregulation 20
Tumours 20
cost-effective. 20
541 20
development: 20
untargeted 20
infiltrated 20
Colitis 20
(SDH) 20
oxidation, 20
ICC 20
intubation. 20
anatomy. 20
inductive 20
estrogenic 20
Vaginal 20
SERMs. 20
40, 20
benzodiazepines. 20
205 20
WS4. 20
abductor 20
posttranslationally 20
modified, 20
synthesised 20
anaesthesia, 20
parent. 20
boronic 20
bypassed 20
Ipilimumab 20
soleus 20
MEF-2, 20
deacetylating 20
containment 20
subsequences 20
each). 20
Engineering 20
Cardiomyocyte 20
T-ALL. 20
filamentation 20
spermatocytes. 20
inulinases 20
frameshifts 20
perfusion. 20
LQT2 20
intravenously. 20
multinational 20
), 20
mitophagy, 20
FACS 20
Myeloid 20
approved, 20
Hematology 20
halted 20
toxic, 20
Empagliflozin, 20
vortioxetine, 20
(MADRS) 20
2009). 20
Press, 20
atypically 20
mRNA-Seq 20
convey 20
miR-346 20
Carcinoma 20
pale 20
prokaryotes, 20
intrastrand 20
four-codon 20
violation 20
electrophysiology 20
Trimetazidine 20
Lon1 20
(GAN) 20
neurofilaments 20
deformities. 20
DS, 20
mfd 20
overproduced 20
timed 20
unassembled 20
Interference 20
densities. 20
asynchronous 20
K-Ras 20
cytolytic 20
Reconstitution 20
386 20
treatment-refractory 20
premedication 20
personality. 20
waist 20
0.07, 20
DR 20
increasing, 20
collagens 20
Posttranslational 20
thiols 20
war 20
herald 20
(OP) 20
sign. 20
antecedent 20
browser. 20
microglia. 20
glycation 20
(45% 20
(PR2) 20
exceedingly 20
popularity 20
opinions 20
complications: 20
volumetric 20
loading, 20
(ICER) 20
interpersonal 20
correlative 20
endostatin, 20
cornea 20
heparan 20
Antiangiogenic 20
12.3 20
(CT), 20
ongoing, 20
authorized 20
maximise 20
footprints 20
3'- 20
exonucleolytic 20
integrin-mediated 20
Pilot 20
cap-independent 20
N6-methyladenosine 20
anti-sense 20
protein-truncating 20
Cost 20
policies 20
HAE 20
Neutropenia 20
(ATCC 20
superhelical 20
ColE1 20
8-MOP 20
phototoxicity 20
5th 20
neuroprotectant 20
urea, 20
gyrus, 20
decision, 20
myotubularin-related 20
critical. 20
L2 20
vaccinia 20
insulin-resistant 20
plots. 20
(RNAP) 20
stalling 20
polyposis, 20
half-maximal 20
Andersen-Tawil 20
sunlight 20
falciparum-infected 20
paradox. 20
Hsp110 20
(95%CI 20
epistasis 20
312 20
alcoholics. 20
80-90% 20
(RTT) 20
serum-free 20
3-bp 20
megakaryocytic, 20
hallucinations, 20
fissures, 20
NS. 20
TSLP 20
Neuropathology. 20
permeability, 20
diseases]. 20
rostral 20
Schindler 20
2.9% 20
rifabutin 20
Orexin 20
circuits. 20
IIb, 20
first-order 20
PLB-KO 20
DOT1L, 20
subcomplex 20
NY-ESO-1 20
enhancer-binding 20
III-IV 20
homology, 20
Ziconotide 20
hOCT3 20
AML, 20
FANCA, 20
TG2 20
reservoirs 20
fusing 20
DAPK-1 20
IBD-associated 20
RIP 20
messengers 20
retrotransposed 20
pancuronium 20
VSMCs 20
p16, 20
Riociguat 20
sgRNAs 20
CD40, 20
idelalisib 20
Multicentric 20
prolongation, 20
Malat1 20
quiescence. 20
(46 20
disruptive 20
calculates 20
Galaxy 20
picture, 20
Seipin 20
FAA 20
neurobehavioral 20
BNIP1 20
SUMO-conjugating 20
tachycardia: 20
fimbriae 20
dyslipidaemia 20
GATE-16 20
Atg 20
nucleolus. 20
packages, 20
miR-30 20
gastroenterologists 20
biotin-dependent 20
PCC. 20
degraded, 20
RelA 20
p100. 20
Pheochromocytoma-paraganglioma 20
(SDH), 20
Arabian 20
accordingly. 20
AIs 20
Inn1, 20
ingression 20
MEK1 20
gestalt, 20
barley 20
motif-containing 20
catechol-O-methyl 20
ms) 20
recycle 20
urease 20
sirtuins 20
agitation. 20
246 20
single-locus 20
restriction-modification 20
sphenoid 20
neoformans 20
Database. 20
metalloenzyme 20
rs2910164 20
miR-34a* 20
NSCLCs 20
NuA4 20
PLMVd 20
moths 20
timescales. 20
cfDNA 20
ID, 20
gene/protein 20
RWR 20
fibrocytes. 20
microtia, 20
ATR-ATRIP 20
chitotriosidase 20
R-phycoerythrin 20
GMP 20
TPPP/p25 20
behaviours. 20
Smad3 20
Sox10 20
base-excision 20
hK3 20
alteplase, 20
NC. 20
concussion 20
TBC1D24 20
inputs, 20
CRY 20
pressor 20
TET 20
RyR(R4496C) 20
11q13, 20
p18 20
IHH 20
nephrectomy 20
Biofabrication 20
ethosuximide 20
sulfide 20
diclofenac 20
J/cm2. 20
OM 20
Aggressive 20
epilepsy: 20
default-mode 20
stalk 20
bloc 20
CysC 20
cirrhosis, 20
PAPP-A 20
(HOQ) 20
lymphopoietin 20
ipilimumab; 20
mimetics 20
parasitological 20
millimolar 20
unavailable. 20
Occupancy 20
>200 20
leveraging 20
experts, 20
workplace 20
collisions 20
μg/l 20
EIF2AK2. 20
cellula, 20
(STAT3), 20
(EIF2AK2), 20
(EIF2S1) 20
C3C 20
(TADs), 20
s.q. 20
Ragulator 20
ASCs 20
FGF23, 20
intertriginous 20
immunodeficiency. 20
gall 20
H2AZ. 20
UCNEbase 20
rewiring 20
AVI-4658 20
TB, 20
test: 20
limb, 20
SMAP1 20
RSS 20
Piwi-interacting 20
pipeline, 20
D556 20
(CICR) 20
MMT 20
estrogen-dependent 20
carbapenemase 20
mH2A 20
vertebrae 20
NA808 20
crack-cocaine 20
lupus. 20
ACTA1 20
Rtt109 20
SKOV3/TR 20
CAOV3/TR 20
non-stroke, 20
zebularine 20
finasteride 20
armodafinil, 20
lipin-1 20
Synergy 20
TPO 20
rosiglitazone 20
nanocrystals 20
crystallography. 20
animal-derived 20
WISP-1 20
post-meiotic 20
Rag-Ragulator 20
Transthyretin 20
p47phox 20
Deinococcus 20
SATB1 20
aggression, 20
semantically 20
infrastructure, 20
domain-binding 20
EphrinA1 20
RSK2 20
Set1B 20
hemochromatosis. 20
WIF-B 20
i.p.), 20
InSurE 20
Nasal 20
β-1,3-glucans 20
grasses 20
SOICR 20
(LDLR) 20
PLD 20
noises 20
lymphoma- 20
MM-derived 20
CD38-positive 20
Vemurafenib, 20
small-bowel 20
MutS1 20
microvillous 20
CMRglu 20
hydroxide 20
(CC) 20
(ChIRP), 20
absenteeism 20
bromfenac, 20
troglitazone, 20
PDC 20
(ATAC-seq), 20
1(V) 20
TRIM37. 20
CIITA 20
Anti-TNF 20
Fat 20
KGF 20
2q14.2 20
Mbp 20
exotic 20
Tacrine 20
ALAT 20
regorafenib, 20
(4CMenB) 20
fHbp 20
akinesia 20
SU(VAR)3-7 20
herd 20
1·68, 20
NCT. 20
CRB2 20
(apoE) 20
NDF 20
CSN1 20
CR-Csn8KO 20
peptide-trimming 20
non-truncating 20
(MITF) 20
plicata 20
PmV 20
Encounter 20
VE. 20
5-hydroxytryptophan 20
(CIDEC) 20
[rs 20
epsilon3 20
clr4+ 20
Combo 20
Pcf11 20
iMCD 20
Anticoagulant 20
glucosylated 20
PUVA-bath 20
GDC-0941 20
Pictilisib 20
UDCA 20
Xience 20
Koos 20
POLD3 20
minichromosomes, 20
ducks 20
Corpus 20
TcdB. 20
Apremilast: 20
cloud 20
needling 20
Cognard 20
exudates 20
IMAGe 20
Kiaa0319, 20
CAMUR 20
(NOMe-seq) 20
neuroligin-3 20
aNK 20
Upc2p, 20
calor, 20
https://github.com/Illumina/manta. 20
self-harm 20
Ribi 20
Java, 20
NHPX 20
(scores 20
mule 20
Alere 20
Genomiser 20
Amblyomma 20
dysphoria 20
HSD17B1 20
1A29 20
Citicoline 20
rs56721780:G>C 20
brucellosis 20
enhancer-like 19
aganglionosis, 19
Syndromic 19
Glial 19
amphiregulin 19
MAPK. 19
tractable 19
O-linked 19
glimpse 19
GenBank 19
Transwell 19
glycosaminoglycans 19
vascular, 19
cysts, 19
debulking 19
pyridostigmine 19
(AChE) 19
azathioprine. 19
sclerotic 19
Summary 19
horizon. 19
increasing. 19
PCP 19
Throughout 19
Minor 19
Later 19
antiarrhythmics, 19
TDM. 19
sotalol 19
(CADASIL) 19
livers, 19
NOTCH2 19
vasculature, 19
NAD(P)H 19
cell: 19
0.7, 19
Oct 19
herein. 19
(log-rank 19
Present 19
formulations. 19
Reprogramming 19
nestin 19
c-Myc. 19
reality 19
direction. 19
m/z 19
isotope-labeled 19
citations 19
Australasian 19
phosphorylase 19
renin-angiotensin 19
Attempts 19
Onset 19
supported. 19
CD45 19
element-1 19
TRN 19
Ca(v)1.2 19
construct. 19
Knocking 19
6- 19
intraluminal 19
run. 19
contaminants 19
aquifer 19
acetyl-lysine 19
ileum 19
advocated 19
categories: 19
baroreflex 19
factor-kappa 19
(TNF-α) 19
caspases, 19
(43 19
JNK2 19
interferons 19
simplifying 19
3-day 19
201 19
Meningiomas 19
probability. 19
market, 19
(chronic 19
enantiomer 19
conventionally 19
toxin-producing 19
EI 19
hunger 19
0.006) 19
meal. 19
hyperphagia 19
subject, 19
undertaking 19
melanosis 19
IBS. 19
constipation. 19
8.2 19
Hodgkin's 19
disclosure 19
items. 19
race. 19
BNP, 19
echocardiogram 19
competition. 19
(NT-proBNP) 19
subjects: 19
substantiate 19
0.58, 19
case). 19
register 19
Hormone 19
adiposity 19
FM 19
large. 19
peers 19
diaries 19
illnesses. 19
will, 19
Vertebrate 19
of) 19
(rather 19
(76%) 19
Lp(a) 19
(Spearman 19
(vs 19
niacin 19
harnessing 19
injection-site 19
biweekly 19
shown. 19
Sequence-specific 19
hydrolyzing 19
negligible. 19
M.HhaI 19
extraosseous 19
(FCM) 19
3,000 19
nonlinear 19
transplant, 19
R-loop-mediated 19
demonstrate, 19
aggressive, 19
immunohistochemical, 19
sarcomere. 19
desensitization 19
(HCM), 19
Steady-state 19
identified; 19
S., 19
Ca2+-dependent 19
Personal 19
H3S10 19
condensation. 19
marsupial 19
maturing 19
HSP70, 19
(GV1001) 19
stabilization, 19
anti-MET 19
(VEGF), 19
12). 19
KC 19
pregnancy: 19
CDC 19
Weeks 19
adjuvanted 19
confounders 19
A(H1N1)pdm09 19
Surfactant 19
PAX8 19
endocytosis, 19
≈ 19
vasodilator-stimulated 19
13-mer 19
exerting 19
α, 19
recommendation. 19
five. 19
craniosynostoses 19
Mol 19
hematopoiesis, 19
27.9 19
goiter. 19
pooling 19
launching 19
279 19
Promotion 19
canagliflozin. 19
misleading 19
buffers 19
unfractionated 19
shortcomings 19
LBP 19
unsuccessful. 19
furthermore, 19
nails, 19
hypogammaglobulinemia. 19
scalp. 19
responsiveness. 19
TMZ, 19
291 19
lysosome, 19
antioxidative 19
exocytosis 19
waste 19
Antibiotics 19
liberate 19
exponentially 19
vancomycin, 19
purposes, 19
faecium 19
Mutants 19
ml. 19
(4%), 19
(15%), 19
factorial 19
radiographically 19
mutation). 19
(41%), 19
loose 19
hypofractionated 19
orthopaedic 19
monocytic 19
Cortical 19
squares 19
rejection. 19
(RR), 19
linkages, 19
myopathies. 19
deterioration. 19
13-year-old 19
wheat. 19
proteinases 19
transforms 19
method). 19
carbonate 19
troublesome 19
category, 19
depressed. 19
[SD 19
Intelligence 19
8). 19
DHPLC 19
peroxynitrite 19
frame, 19
FUS. 19
polysomes 19
earlier, 19
sub-groups 19
0.36 19
DOPAC 19
spots. 19
forty 19
1996. 19
Origins 19
Cdc6, 19
cyanobacterium 19
perilesional 19
(ACC) 19
patterned 19
specimen. 19
Presenting 19
KN-93. 19
Beta 19
p21. 19
Intermittent 19
Cdc25C 19
multi-domain 19
insects. 19
parenchyma. 19
MCP-1 19
Low-dose 19
67-year-old 19
lipoprotein, 19
RMSD 19
HbA1c. 19
reflective 19
biotransformation 19
(62 19
(T2DM) 19
worth 19
isoleucine 19
299 19
coma. 19
amitriptyline, 19
awareness, 19
sera. 19
ECs 19
fold. 19
source, 19
solutions. 19
C-terminus, 19
inducibility 19
MET1 19
(DNMT) 19
CDKI 19
Trichostatin 19
neocentromere 19
centromere, 19
412 19
CHD1, 19
tri-methylated 19
ARK(S/T) 19
bioenergetic 19
DMR 19
27. 19
helix. 19
Swi6 19
segregation, 19
Dosage 19
PHD 19
°C 19
NCC 19
accessibility. 19
proteoglycan 19
413 19
duplications. 19
invasiveness, 19
HP1α 19
demethylase, 19
submicromolar 19
cardiogenic 19
upward 19
imaged 19
co-factors. 19
(typically 19
(NE), 19
4-(4-(dimethylamino)styryl)-N-methylpyridinium 19
stathmin 19
manners. 19
adipokines 19
induced, 19
bulb, 19
submitochondrial 19
fission, 19
siRNA. 19
(RLS). 19
breast/ovarian 19
Criteria. 19
3-phosphate 19
(41 19
Options 19
216 19
brain: 19
three- 19
ancestors. 19
NKA 19
sarcolemma, 19
Poland. 19
Superoxide 19
post- 19
Thirty-nine 19
SRC 19
trithorax 19
coreceptor 19
(H4K20me1) 19
Surveillance: 19
post-infarct 19
miR-29 19
Bmi1 19
mastectomy 19
ChIPnorm, 19
priority. 19
antidote, 19
Xa, 19
(rivaroxaban, 19
trial) 19
precautions 19
adjustment, 19
oligomerization. 19
factor(s) 19
air. 19
atxA-regulated 19
avirulent 19
Subunit 19
nicotine-replacement 19
improper 19
J) 19
chromosomally 19
cyclobutane 19
highly-selective, 19
PI, 19
tension, 19
CHO 19
Oikopleura 19
diameters 19
Susceptibility 19
Interacts 19
14-day 19
Antitumor 19
preanaphase 19
(NHEJ) 19
(SAHA) 19
satisfying 19
macrovascular 19
36-month 19
angiopathy 19
regurgitation. 19
biotechnology 19
granulomas 19
effusion. 19
Perioperative 19
liters 19
hemodynamics. 19
genome; 19
coregulated 19
Nedd8 19
ligases. 19
Cdt1, 19
p53(-/-) 19
Ser(16) 19
aetiologies 19
2001. 19
prognosis-signature 19
IMGT 19
libraries, 19
bridge, 19
H2 19
0.41 19
Hunter 19
hypercalciuria. 19
PNETs 19
45%, 19
non-malignant 19
telomere-associated 19
3.5% 19
(13-cis-retinoic 19
mg/kg/day, 19
equipotent 19
tretinoin. 19
emphasises 19
slows 19
Hair 19
447 19
cytarabine, 19
synthesized. 19
DNA-DNA 19
poisons 19
spermine 19
Sensitive 19
(HSV) 19
metabotropic 19
follow. 19
GC-AG 19
trees. 19
aptamers: 19
1990s, 19
Investigational 19
A431-III 19
Twist 19
PDGFRα 19
appropriate, 19
6.7 19
(ESS) 19
TFT 19
14.9 19
SILAC 19
(encoded 19
Relapsed 19
Coprimary 19
isoenzyme 19
co-infection 19
Digestive 19
iron-deficiency 19
1.15 19
manganese 19
stimulus. 19
5%. 19
Protease 19
ventriculomegaly 19
Takayasu 19
(MRI), 19
CK2 19
(interaction 19
CHADS2 19
adequacy 19
42, 19
unicellular 19
Investigating 19
ultra 19
Apixaban, 19
0.62 19
derangements 19
dialysis, 19
μM), 19
virions. 19
235 19
Outline 19
science, 19
ospemifene, 19
pramipexole 19
transdermal 19
immunofluorescence, 19
(ZFNs) 19
bending 19
car 19
achondroplasia. 19
achondroplasia, 19
dysplasias. 19
ACH 19
(HSCR). 19
minisequencing 19
VGCC 19
steroid-responsive 19
ACh 19
seizure, 19
syntaxin 19
bacterially 19
synthesized, 19
SETMAR 19
cisplatin-induced 19
cisplatin. 19
trans-activation 19
sustainable 19
nucleosome-depleted 19
prototypes 19
inflammation-induced 19
Image 19
XY, 19
Biomedical 19
0.003), 19
mesangial 19
disassembly, 19
docking. 19
stable. 19
LTP 19
(GBA) 19
Seventy 19
(sodium 19
TO 19
energy-rich 19
scheme, 19
short-acting 19
nilotinib, 19
entry. 19
CML) 19
durability 19
splenomegaly, 19
subsequently, 19
daunorubicin 19
tolerated; 19
5-HT1B 19
PFC 19
trazodone 19
venlafaxine. 19
A2, 19
rim 19
guides 19
intragenomic 19
trajectory 19
trimetazidine 19
ED. 19
thaliana) 19
seedling 19
Patched 19
(DS), 19
uvrA 19
Topology 19
disassembly. 19
cystathionine 19
FET3 19
thyronamines 19
hyperthyroidism, 19
(3%) 19
autoreactive 19
18-55 19
neurobiology 19
isocitrate 19
files, 19
baPWV 19
influential 19
Rate 19
tree, 19
principles. 19
vitreous 19
ADP-ribosylation 19
(TH), 19
transmitting 19
cHS4 19
perhaps, 19
waves, 19
ferritin. 19
(IPF) 19
FDA. 19
INPULSIS-1 19
PLB. 19
undetermined 19
poisoned 19
esters 19
anticholinergic 19
electroencephalographic 19
ISH 19
hyperactivity, 19
reflux, 19
MBSR 19
Fasting 19
males), 19
satisfactorily 19
hGH 19
(B) 19
dorsolateral 19
mm; 19
weeks), 19
15%. 19
ethanol-induced 19
E-selectin 19
revealed. 19
each) 19
BTX-A 19
prescribed. 19
alternatives. 19
vanishing 19
CCR4-NOT 19
Pab1p 19
(L1) 19
formalin-induced 19
(PAH) 19
variations. 19
RGD 19
atom 19
CTCs 19
pressures. 19
SDS. 19
methylation: 19
ingredient 19
mitigating 19
effusions 19
Group's 19
worthy 19
tauopathy 19
neuropathologically 19
dephosphorylating 19
second-order 19
discovers 19
plexus. 19
SU 19
retrieved. 19
ovaries. 19
insulin-sensitizing 19
K, 19
C-peptide 19
androstenedione 19
double-blinded 19
IL-5. 19
Workshop 19
0.009 19
(BSCL2) 19
LQTS, 19
minK 19
larger, 19
uncommon, 19
0.79 19
adipose-derived 19
analgesics 19
perfusate 19
KB-R7943, 19
-paradox 19
post-ischemic 19
vegetables, 19
Caribbean 19
plate, 19
THAL 19
autistic-like 19
RTT. 19
fasting. 19
tissue) 19
(M(r) 19
lipiodol 19
GATA1, 19
TAL1-mediated 19
unsatisfactory 19
olanzapine 19
arachnodactyly, 19
corneum 19
high-molecular-weight 19
N(ICD) 19
Suppressor 19
oxygenase 19
(NA) 19
beta-strand 19
triplex 19
attenuation, 19
Empagliflozin: 19
protein-ligand 19
oxygenation 19
(negative 19
DWI 19
hepatomegaly 19
(AHI) 19
Co-administration 19
text]. 19
rofecoxib 19
specification, 19
collagen-induced 19
24-week, 19
MTX. 19
Jak 19
analgesics, 19
β1-integrin 19
U87 19
(PB) 19
scaffold, 19
colitis-associated 19
deserts, 19
pool, 19
dUTP 19
5-15 19
ng/mL; 19
I(NCX) 19
MPS 19
J774 19
foods, 19
NPs 19
conversion, 19
Agonist 19
deacetylates 19
Engulfment 19
Dock2-dependent 19
AGS. 19
castrated 19
PABPC4 19
lipoprotein. 19
(ALL). 19
toolbox 19
Decitabine 19
(de 19
females: 19
pedigree, 19
Hammersmith 19
(TFs). 19
GeneSeqer 19
infections: 19
0.84 19
Myotonic 19
MYB 19
(statins) 19
pounds 19
similarities, 19
p50. 19
primase. 19
SCF(Dia2) 19
ISC 19
Maturation 19
Although, 19
depigmentation 19
enhanceosome. 19
(65%), 19
super-resolution 19
centrosomes 19
(CL) 19
coalition. 19
FgfR3 19
Coping 19
CMA, 19
numerous. 19
occupancies 19
cerevisiae) 19
Rictor 19
separates 19
peroxiredoxin 19
A/A 19
Spleen 19
impart 19
GQ1b 19
Xq28, 19
Cryptococcal 19
BIS 19
Sevoflurane 19
unsteady 19
synostotic 19
cautious 19
command-line 19
cones 19
Sgf11 19
fluorogenic 19
voltage- 19
(ChR2), 19
1996) 19
referenced 19
(RyRs) 19
Alanine 19
Rh 19
SG-inducing 19
Mowat 19
(Mowat-Wilson 19
rounded 19
diolamine 19
dopamine. 19
sex-related 19
Bethlem 19
(cEDS) 19
iron-responsive 19
Aft2 19
niches 19
thymine-DNA 19
mispairs 19
3:1 19
[1 19
Per1 19
nonnucleoside 19
bipartite 19
Cdc2 19
tacrolimus 19
introgression 19
I). 19
soft-tissue 19
involvement), 19
osteoblast-like 19
absence. 19
Calcitonin 19
(MK-0974) 19
ABCG2 19
pool. 19
(nt) 19
R-DHAP 19
CKD-EPI 19
RAPID 19
Acetazolamide 19
H2Bub1 19
pembrolizumab, 19
Lynch 19
PPARγ 19
anti-cyclic 19
(histidine-rich 19
DIND 19
(MCD) 19
asphyxiating 19
Fingolimod 19
pre-implantation 19
mPFC 19
PRDX2 19
PFV 19
Nothobranchius 19
ovary, 19
porins 19
msec, 19
ruling 19
groin, 19
immunoregulatory 19
completely. 19
forelock 19
vitiligo 19
FLVCR1 19
epididymal 19
fats 19
Swr1 19
aristaless 19
6-shogaol 19
frequency) 19
runs. 19
dwell 19
ICS 19
ratchet. 19
24-32 19
Thromboembolic 19
Calcineurin 19
cassava 19
YY1 19
enzymopathy 19
Exonic 19
dedifferentiated 19
DBA, 19
Arboviruses 19
utilization. 19
CHROMagar 19
Intracerebral 19
import, 19
APOOL 19
team. 19
(SLE), 19
discern 19
dextrose 19
concise, 19
per-protocol 19
CPT-11 19
PSD 19
biting 19
(AHDS), 19
Macitentan, 19
taxol 19
(MOPD 19
(XLMR) 19
ABCD 19
Pds5 19
β-glucosidase 19
GD1. 19
statin-induced 19
RKIP 19
-742 19
megabase 19
α/γ 19
aleglitazar, 19
Lacritin 19
osteonecrosis 19
Nudix 19
depression/anxiety 19
chordoma. 19
sacrococcygeal 19
Ufd1-Npl4 19
seronegative 19
Par6 19
(QA), 19
ontologies. 19
prowazekii 19
traverse 19
oriCs 19
Infliximab 19
hydroxylases 19
Aleutian 19
order: 19
DIPG. 19
VCAM-1 19
LHCII 19
(BACE1) 19
caterpillar 19
urticating 19
globoid 19
ultraconservation 19
naproxen 19
comets 19
2-substituted 19
2-hydroxydeoxyadenosine 19
α-melanocyte-stimulating 19
Vitiligo 19
MC1R. 19
globule, 19
Oligopaint 19
(PSP). 19
modafinil's 19
athetoid 19
Mct8 19
rifamycin 19
Cardiotoxicity 19
CCR1 19
P-cadherin 19
-adrenoceptor 19
4/group). 19
2-(1H)-pyrimidinone 19
NS-3 19
500-50,000 19
Upf1 19
nonsense-containing 19
Sup35p 19
macrolide 19
PS1, 19
radiometabolites 19
impulsive 19
DSIF, 19
Hex 19
SSC 19
MPE 19
Tet3 19
Kx 19
XK, 19
HER2(+) 19
globe 19
(Willis-Ekbom 19
PRNP 19
pazopanib. 19
Approval. 19
CD59 19
Uppsala 19
http://www.bmj.com/company/products-services/rights-and-licensing/ 19
sulfoxide 19
nipple-areola 19
implementations. 19
lorcaserin 19
cruzi. 19
ChIP-nexus 19
(SPAG5) 19
iii 19
automates 19
melanogenesis 19
nucleoli. 19
Methicillin-resistant 19
GeneOhm 19
penis 19
tenofovir 19
apoB 19
Iakut 19
(OCA1), 19
RADAR 19
MAPKAPK2 19
H4K20me3 19
(H3F3A 19
G34R/V 19
K36M 19
PIL. 19
(PTX3) 19
Pentraxin 19
Pap1 19
19K 19
J-binding 19
8-methoxypsoralen. 19
scalability 19
melastatin 19
BCPAP 19
Musclin 19
ULMCA 19
PEDLA 19
smyd3 19
mirabegron, 19
Pse-in-One 19
Fkh2 19
MCM-BP 19
3'-ends 19
(DosR) 19
MDR1, 19
MDA5 19
ICR. 19
snv 19
GRFs 19
mononucleosis 19
©2017 19
(Bases 19
CIGAR 19
Analyzer) 19
call. 19
elbow. 19
pSS 19
EML4-ALK 19
CURB65-A 19
RDT 19
OD, 19
Circ-Seq 19
scarlatinal 19
Atg8-family 19
UBQLN 19
gambiense 19
VL-10 19
GCA. 19
TCZ 19
compressor 19
NT4X 19
MAOA-L 19
(EBS) 19
(congenital 18
sigmoid 18
Mammary 18
RANTES 18
energies 18
0.0 18
wished 18
(lncRNAs). 18
learning. 18
Perl 18
isopeptide 18
co-culture 18
Neutralization 18
miR-200a 18
miR-200c 18
symptomatic, 18
azathioprine, 18
pain) 18
SRE 18
(bone 18
20-30% 18
resorption, 18
discs 18
beta-adrenoceptor 18
reached. 18
NOTCH1, 18
Elevation 18
0.75, 18
0.63 18
those, 18
(77 18
nonsteroidal, 18
advanced-stage 18
dehydroepiandrosterone 18
(20%). 18
high-LET 18
lentiviruses 18
xenografts, 18
successes 18
spread. 18
EL, 18
reactivity, 18
strong, 18
unlabeled 18
(69%) 18
recombinant, 18
reprogram 18
c-Myc) 18
iPSCs. 18
µM). 18
cancers; 18
glia. 18
8- 18
phosphoproteomic 18
identifier 18
Putative 18
workflows 18
In-depth 18
Sequencing, 18
platforms, 18
Pannexin1 18
emerged. 18
infiltration, 18
conformations. 18
Nervous 18
assists 18
whatever 18
[New 18
(increased 18
maladaptive 18
durations. 18
overactivity 18
20. 18
Arab 18
CD45, 18
alternative. 18
A1, 18
IBC. 18
RASSF1A, 18
Calsequestrin 18
structural, 18
leak, 18
buffering 18
μg/ml 18
Serotonin 18
(T3), 18
weak, 18
co-existent 18
concern, 18
ICI 18
(MMP-9) 18
Cerebellar 18
Codon 18
Raf 18
cleavages 18
feed-forward 18
truncations 18
advantages. 18
meningothelial 18
(AEDs) 18
AEDs, 18
functionalized 18
anti-convulsant 18
corroborating 18
PRAS40 18
M4 18
Complement 18
380 18
categories, 18
etiologies. 18
suppressed. 18
norepinephrine, 18
road 18
carrier. 18
gynaecological 18
endometrium, 18
[ 18
(74 18
QLQ-C30 18
EF 18
L, 18
Parameters 18
14), 18
ng/L 18
lactate, 18
1092 18
1.8, 18
neurosurgery. 18
1-, 18
histone-modifying 18
(H3K27) 18
Constitutional 18
80%, 18
145) 18
Amgen 18
329 18
dose: 18
p<0·0001) 18
Societies 18
neoplasia, 18
UCRs 18
electrophilic 18
accept 18
phosphodiester 18
AIMS: 18
(PN) 18
GD2, 18
c-myc, 18
sonidegib, 18
ligand-independent 18
proportionally 18
¹⁴C-sonidegib 18
ruxolitinib, 18
ATR-dependent 18
methods: 18
FXN 18
camptothecin 18
complexities, 18
304 18
(cTnC) 18
proband. 18
cardiomyopathic 18
mutations; 18
45, 18
assisting 18
hereby 18
habit 18
bead 18
2011). 18
pressing 18
12), 18
females). 18
Additionally 18
passing 18
parsimony 18
landscapes 18
H3K27me3. 18
deaths; 18
Combinations 18
epitopes. 18
HGF. 18
(GSK-3beta) 18
IAP 18
0.01); 18
caspase-9, 18
vigilant 18
(ICU) 18
0.79; 18
ended 18
[OR], 18
Sweden. 18
Z-score 18
ABCA3 18
(TD) 18
rationalized 18
vacuole. 18
resumed 18
optimization, 18
interleukin-13, 18
(P<0.001); 18
dupilumab, 18
Forced 18
microcornea, 18
bones. 18
goitre, 18
Malformations 18
low/negative 18
(≥ 18
Sample 18
for. 18
standardize 18
industrialized 18
variance. 18
inventory 18
Case-control 18
hypogammaglobulinemia 18
etc.) 18
Ichthyosis 18
delineated. 18
(2.9%) 18
mutated, 18
CES 18
bibliographic 18
Ancient 18
bioassay 18
Streptomyces 18
Infections 18
vancomycin-susceptible 18
(50% 18
10.7 18
isotretinoin, 18
mg/day), 18
HGG. 18
Gefitinib 18
Spearman's 18
(PTEN) 18
Twenty-seven 18
[hazard 18
0.99; 18
retraction 18
spasticity. 18
neurocutaneous 18
FOXP3 18
plasmacytoid 18
defense, 18
polymorphonuclear 18
downregulated. 18
synovium. 18
z 18
neuropathology. 18
Interview 18
documenting 18
DAT, 18
affect, 18
complaints. 18
covariates, 18
Sorafenib 18
statistic 18
RAD001 18
agencies 18
QTLs 18
mine 18
ZEB1, 18
cycle-regulated 18
intron. 18
partner, 18
Extreme 18
transgene. 18
best-characterized 18
reproduction. 18
immunomodulation 18
alternative, 18
aligns 18
real-life 18
390 18
(AM) 18
two-year 18
re-treatment 18
kinematic 18
angles 18
subjects' 18
spots, 18
immunochemical 18
1999, 18
Fused 18
FUS-positive 18
coupling, 18
reperfused 18
mesh 18
mood. 18
P=0.002) 18
Causes 18
Globally, 18
Hence 18
trypsin, 18
verification 18
Archaea 18
replicated. 18
90%) 18
Refined 18
culminate 18
IH. 18
Ca2+. 18
heterodimerization 18
CMT1A 18
deteriorate 18
Orphan 18
enterovirus 18
cell-matrix 18
G) 18
(DITPA) 18
DITPA, 18
supply. 18
CT, 18
microsurgical 18
1989 18
(R) 18
sulfonylureas, 18
1st, 18
detectable. 18
mmol/mol) 18
257 18
selectivity, 18
24-week 18
(64 18
T2DM, 18
predominating 18
uridine 18
improvements. 18
Endothelial 18
trimers 18
average. 18
birds, 18
as, 18
18-year-old 18
dentition 18
perturbs 18
(CT)n 18
positions, 18
atresia, 18
CoA 18
RNA-induced 18
presenilin-1 18
Neurospora 18
bonding 18
Prognosis 18
CRCs 18
ICDs 18
(CMR) 18
Contrast-enhanced 18
(VT) 18
(DA), 18
serotonin. 18
blood-cerebrospinal 18
MEK/ERK 18
trabeculae 18
SMAD 18
3B 18
mitofusin 18
degenerated 18
periods, 18
nonstop 18
xCT 18
glutamate, 18
excitotoxicity, 18
mortem 18
inhibitor-resistant 18
swimming 18
sponges 18
(BPD) 18
Allelic 18
0.004), 18
0.007) 18
postal 18
Arg(9) 18
cardiomyopathies. 18
(120 18
Student's 18
Post 18
WILEY 18
progressed, 18
WES 18
grip 18
instar 18
disjunction 18
downregulation. 18
Raji 18
4-year-old 18
anticipation 18
341 18
Addressing 18
intermediates, 18
10.0 18
burn 18
milliliter 18
(AF). 18
prosthetic 18
ignored. 18
Elderly 18
C402 18
CO2/bicarbonate 18
capsule, 18
cytisine 18
retention. 18
trimethylation, 18
0.0002). 18
L1CAM 18
µg 18
holoenzyme 18
substructure 18
isotonic 18
hexamers 18
TRIM 18
replacements 18
iteratively 18
Hamming 18
DBHS 18
bottlenecks 18
(DDR) 18
CHOP 18
Biologic 18
Sister-chromatid 18
travels 18
SW480 18
stopped. 18
tube, 18
RAD51. 18
serine-threonine 18
patient-years 18
(geometric 18
affords 18
alpha-amanitin 18
T7 18
equivalents 18
template, 18
hypergonadotropic 18
cardiologic 18
successfully. 18
predominate 18
Indirect 18
(under 18
10-year-old 18
lamina. 18
immunoglobulins. 18
ion-exchange 18
G-65 18
1988 18
1993, 18
fitting 18
Tsc2 18
fluorouracil 18
hybrids. 18
(5% 18
microg/kg 18
presence/absence 18
(EC(50) 18
MTOR 18
c-FLIP 18
PLN/HAX-1 18
Dephosphorylated 18
person. 18
anthracyclines, 18
targetable 18
poor-prognosis 18
GTPases. 18
availability, 18
(May 18
(85 18
0.57 18
1.24 18
0.09 18
review: 18
BMD, 18
40) 18
28%, 18
5-aminolevulinic 18
HoxB, 18
mice: 18
gonadotrophin 18
shelves 18
Mdm2, 18
RPL6 18
upregulation, 18
planar, 18
(vs. 18
penetrating 18
Last, 18
speciation 18
(CNS), 18
N-methyl-D-aspartate 18
1alpha 18
infiltration. 18
Luciferase 18
(Shh) 18
(IGF) 18
(39%) 18
multitargeted 18
medulloblastomas, 18
Exploiting 18
orthologues 18
autonomy, 18
refused 18
patient) 18
Element 18
comorbidity. 18
(3.1 18
nonthyroidal 18
ALL. 18
Potent 18
SLAMF7 18
Pharmacotherapy 18
nephropathy. 18
leukocytes, 18
physiological, 18
decidualized 18
peroxide, 18
deficiencies, 18
adulthood, 18
Anticoagulation 18
AF) 18
PT 18
valproate 18
Alone 18
(INR) 18
anisotropy 18
Ultimately, 18
reflection 18
estimation. 18
progeny. 18
extinction-based 18
Category 18
3-dimensional 18
theory. 18
SERMs, 18
agonist/antagonist 18
statement 18
dryness 18
pramipexole, 18
writing 18
diagnosis; 18
hydrolases. 18
efficient. 18
feelings 18
disproportionate 18
Hsp90. 18
or/and 18
(MEN 18
organogenesis 18
(codon 18
(94%) 18
protein). 18
Having 18
producer 18
permeabilization 18
(mild 18
calcineurin. 18
immunophilin 18
restrained 18
restored. 18
1997, 18
Introducing 18
mDia 18
Wiskott-Aldrich 18
F-actin, 18
proposing 18
monocot 18
setup 18
handling. 18
mutation: 18
pyrexia 18
1.10 18
Whilst 18
0.57, 18
Ultrasonographic 18
Secondly, 18
free, 18
beta-glucocerebrosidase 18
Diastolic 18
Rhythm 18
0.10 18
0.65 18
metastasis: 18
Cav-1 18
Allogeneic 18
synergetic 18
dermatofibrosarcoma 18
19th 18
SCT 18
schedules. 18
0%, 18
(55% 18
(Lu 18
Postgraduate 18
cat 18
SW620 18
Nanog-like 18
develop. 18
unscheduled 18
C), 18
Sci 18
oscillatory 18
competed 18
Forty-seven 18
best-studied 18
expression) 18
Enhancement 18
ESCRT-III 18
p53-induced 18
transcript) 18
Copper 18
N-Ras 18
Dissecting 18
centers, 18
T-PLL 18
(IVIG) 18
revolutionary 18
disease" 18
0.56 18
0.40, 18
0.95, 18
sampling. 18
taxa, 18
Registry, 18
modifiable 18
mothers, 18
CLBC 18
destroyed 18
protein-binding 18
rs9296249 18
Cell-based 18
Tandem 18
orientation, 18
small-vessel 18
bihemispheric 18
(difference, 18
ml; 18
interleukin-1β 18
poisonings 18
32-year-old 18
poisoning, 18
level: 18
sales 18
demyelination. 18
esterase 18
Muscular 18
14). 18
refractoriness 18
deviate 18
calendar 18
Diet 18
leaflet 18
vasopressin 18
amygdalar 18
provocative 18
calcitonin/CGRP 18
sFRP3 18
Nurses 18
multilayer 18
alcohol-induced 18
(treatment 18
noradrenaline 18
organizations. 18
(SUI) 18
cystectomy 18
antihistamines 18
Allele-specific 18
Hho1p, 18
functional. 18
gametogenesis 18
deadenylation. 18
Pop2p 18
eRF3 18
(6%). 18
vasculopathy. 18
harbours 18
insulinomas 18
HUVECs 18
(nNOS) 18
2010), 18
pigmentosa 18
allergy. 18
Utilities 18
ambrisentan 18
stays 18
(66%) 18
Microbial 18
arrived 18
deserve 18
LBs, 18
IUGR 18
CF. 18
wortmannin 18
EU, 18
sputum-culture 18
nonsurgical 18
Fourier 18
>50 18
Capture 18
sacroiliac 18
850 18
assurance 18
subfraction 18
Bovine 18
hexameric 18
backtracked 18
IL-5R 18
Preventing 18
GlaxoSmithKline 18
enrolment 18
allergens 18
placebo), 18
Immunology. 18
LGS 18
epilepsies. 18
HMN 18
neutrophils. 18
torsade 18
ether-a-go-go-related 18
Albinism 18
D1. 18
IR, 18
erythrocytes, 18
nondiabetic 18
rotations 18
-paradoxic 18
(calcium 18
(RR: 18
mm. 18
updated. 18
seizure. 18
diffusion-weighted 18
(CVD). 18
Pharmacogenetics 18
SNP, 18
deletion) 18
counterpart, 18
WR-1065 18
(LD) 18
megakaryopoiesis. 18
kg) 18
ca. 18
95%, 18
(SGS) 18
vertebrae, 18
Kazal-type-related 18
Urological 18
somatosensory 18
DTT 18
(T-ALL). 18
34, 18
CDK6, 18
(Kanzaki 18
angiokeratoma 18
mAb, 18
NRP 18
wakefulness-promoting 18
suvorexant. 18
17) 18
Cat 18
Spreading 18
waves. 18
occluding 18
antrum 18
ensured 18
CLINICAL 18
(ATPase) 18
co-occurred 18
IDH1/2 18
subject-derived 18
contraction-induced 18
edit 18
GVIA, 18
proviral 18
TALEN-mediated 18
Sickle 18
Pediatrics 18
arterioles 18
MMS 18
Id3 18
enterica 18
-9, 18
(SEGA) 18
≥30% 18
(SEGAs) 18
Neurosurgical 18
(130 18
Immunostaining 18
(ILK) 18
beta2 18
Tasimelteon 18
linkers 18
heterotrimeric 18
nephrotoxicity 18
IA, 18
CRISPR/Cas9-based 18
MCL 18
ouabain-induced 18
JTV 18
reperfusion-induced 18
5-Aza-2'-deoxycytidine 18
alcohol. 18
(X-linked 18
adolescence, 18
outperformed 18
Poisson 18
(BrS) 18
abolishing 18
PKP2 18
mesencephalic 18
TF's 18
R160W, 18
1.42 18
amyotrophy 18
14.0 18
FANCC, 18
CTF 18
uropathogenic 18
phagophore 18
(sensitivity, 18
aspirin. 18
LS 18
hematoma, 18
aneurysms. 18
Duration 18
pathogenicity. 18
heteropolymeric 18
MDS/AL 18
MYO7A 18
pericuticular 18
glaucoma. 18
0.016), 18
Fields 18
q3w 18
spread, 18
Urea 18
jackknife 18
C2-domain 18
Cdc45, 18
linear-time 18
abstracted 18
Irish 18
light-dependent 18
non-randomly 18
articulation. 18
Location 18
audiograms 18
APTT 18
neuralgia 18
p.R47H 18
low-frequency 18
sediments. 18
POCT 18
IL-27 18
SCCs 18
LeuRS 18
PIAS1 18
Score. 18
mucosa-associated 18
anti-ganglioside 18
Vector 18
INK4 18
0.007 18
Analysis. 18
DI 18
ASA 18
extubation, 18
283 18
STA 18
abducens 18
miR-223, 18
NF-κB-dependent 18
blood-derived 18
Gene, 18
Browser, 18
Clusters 18
DUB 18
hammerhead 18
travellers 18
(GAA) 18
interphase, 18
rectification 18
tetanic 18
AAV-mediated 18
digitalis 18
E-box-binding 18
Glis3 18
turtles 18
clade, 18
ORC1 18
patella 18
NF-κB, 18
heterotachy. 18
principles, 18
isochores, 18
genic 18
matricellular 18
cytomix 18
FRE2 18
mismatches, 18
lower, 18
Orally 18
(EDSS) 18
75%. 18
Ring 18
shunts 18
VFs 18
Chromogranin 18
prelingual 18
18.5% 18
CUGBP1 18
CPVT-associated 18
L858R 18
karyotyping. 18
0.46 18
PHQ-9 18
guanines 18
PEV 18
ligand-activated 18
RAAS 18
DnaA 18
trigeminovascular 18
porphyrin 18
zoster. 18
BRCA-related 18
Psammoma 18
IL-18. 18
accessing 18
hydrocephalus: 18
(HOQ), 18
)= 18
rs2535629 18
extinction 18
citrulline 18
rheumatologic 18
eyelashes. 18
0.38, 18
χ(2) 18
EPO 18
(32 18
palpitations, 18
MTA 18
DMTs 18
illegitimate 18
phenylethanolamine 18
RVLM 18
insulators, 18
bronchiectasis, 18
quadriceps 18
Vif, 18
unexpressed 18
AIH 18
(CsA) 18
1α, 18
35kDa 18
(EIF2S1/eIF2α) 18
2/protein 18
(EIF2AK2/PKR), 18
GMT 18
TADs. 18
eggshell 18
(SVMs) 18
BTMX 18
OMPs 18
outer-membrane 18
heterochromatin-mediated 18
psoralens 18
post-incision 18
hypoxemic 18
8.2% 18
Drs. 18
α-granules. 18
comorbidities. 18
Melanocytes 18
32), 18
LXXLL 18
activation- 18
Esrrb. 18
Esrrb-binding 18
(ERRE1, 18
Point-of-care 18
hypovitaminosis 18
rt-PA 18
kinetoplastid 18
varenicline 18
SAR 18
Americas. 18
histopathology. 18
strengths, 18
(17%), 18
sarcomatous 18
AATAAA 18
(GM) 18
two-point 18
Hemoglobin 18
(loss 18
Atf4 18
selexipag, 18
Cervical 18
RPS17 18
secretions. 18
5-aza-CdR 18
Pfam 18
garinii 18
lato 18
ACT-064992 18
capital 18
Function. 18
macromolecules, 18
Kolaczkowski 18
Hitherto 18
Tetralogy 18
HIV-1Δvif, 18
APOBEC3D, 18
LRP5 18
oppositely 18
mug, 18
osteocytes 18
hurdle 18
PADI4, 18
City, 18
FACIT-F 18
pingyangmycin 18
I-interacting 18
prereplicative 18
aganglionosis. 18
PCs 18
diencephalic 18
flexors. 18
NEP 18
Ori 18
PEST 18
Fbxw7 18
FBXW7 18
feet. 18
MethylCap-seq 18
vestitone 18
CHS1/LYST 18
antimalarials 18
B*5701 18
pipelines. 18
mg/l) 18
thyrocytes, 18
caspase-6 18
RNA•DNA 18
shadow 18
LIMEs 18
PfEMP1 18
(MC1R), 18
Nfia, 18
α-MSH 18
Sm-like 18
F14512 18
2'-hydroxyl 18
(DARA) 18
mAb-based 18
non-Type 18
VLP 18
hnRNP-A1 18
sequence-specific, 18
Presenteeism 18
Na+,K+ATPase 18
hNET-A457P 18
once-daily, 18
respectively.). 18
(6MWT). 18
ZCyt 18
eRF1 18
FSH, 18
RING-B-box-coiled-coil 18
peroxin 18
p38δ 18
barcodes 18
Impulsiveness 18
RF+ 18
BRD4 18
downloading 18
G230C 18
nerve-intact 18
pore. 18
MLL2 18
Fibrillin-1 18
HLA-SE 18
JEV 18
primaquine 18
G6PD. 18
Vim 18
PEGylated, 18
NKG2D 18
avelumab, 18
"wearing 18
Links 18
therapeutic-intervention 18
7q- 18
(Nottingham-oestrogen 18
Ch17q11.2 18
p=0·0010). 18
H5N1 18
rucaparib. 18
ApoE2 18
ERAP1 18
(Nox 18
gallbladders 18
Unipept 18
MRSA, 18
(Gardner-Diamond 18
9-mg 18
iodonium, 18
http://www.cbrc.kaust.edu.sa/dendb/. 18
pipelines, 18
84-aa 18
pre-pro-hormone 18
hepcidin-25 18
NIHSS, 18
ABR 18
(PIM2) 18
PICU 18
p.R489K 18
(DMT1) 18
microcytic 18
Hennekam 18
Recombination 18
unripe 18
Ackee 18
GAIT 18
onartuzumab. 18
PIB 18
soaked 18
(Double 18
Knockout), 18
(gRNAs) 18
gRNAs, 18
DECKO, 18
ape 18
photosensitive 18
HOXD10 18
VEGFR-3 18
Eluting 18
Bdnf 18
Romosozumab, 18
osteocyte 18
Cnp1(CENP-A) 18
rs7849 18
PSEP 18
MNase, 18
exotoxins, 18
MIBG 18
extra-adrenal 18
licensing. 18
coilin. 18
(TADs). 18
lagging-strand 18
nonhemorrhagic 18
subtilisin-kexin 18
BWS 18
ectrodactyly 18
Nrd1- 18
Nab3-directed 18
Retinol 18
Voice 18
(Hi-C) 18
galunisertib. 18
ND10 18
ERG2 18
Cdk8 18
Celsus 18
Igf2/H19 18
somatic, 18
VarScan, 18
s1p 18
ii 18
(К 18
Monospot 18
emanuel 18
brachyury, 18
STARs 18
593 18
Palivizumab 18
Trismus 18
mislabeling 18
high-threshold 18
Sjögren 18
Click-PEGylation 18
CURB 18
BPD, 18
lncRNA-RNA 18
LIRCPs 18
MLO-Y4 18
Crenezumab 18
multiagent, 18
QFP 18
(TRPM2) 18
androstenone 18
D294H 18
violence 18
Buss 18
Durkee 18
undulant 18
non-mendelian 17
EDN3, 17
transactivation. 17
mCRC 17
AR, 17
separable 17
folds, 17
organogenesis. 17
account, 17
predicted. 17
(FAK) 17
tartrate-resistant 17
acceleration, 17
TT4 17
let-7b, 17
MG. 17
physiopathological 17
cancer) 17
vertebral, 17
(CRPC). 17
pending 17
1990s. 17
DVL-1 17
49-year-old 17
acanthosis 17
(first 17
nose, 17
keratoderma 17
veins, 17
uncoupled 17
death: 17
pancreatitis, 17
Millennium 17
wholly 17
Longer 17
(BID) 17
Dose-dependent 17
CYP1A2, 17
2C8, 17
hypokalemia, 17
derivative. 17
trastuzumab-based 17
inhibited, 17
accrual 17
aspects, 17
ng/mL) 17
arrests 17
cytostatic 17
trajectories 17
vigorously 17
cell-associated 17
CD44, 17
feeder 17
tissue-derived 17
sex-specific 17
strategic 17
defenses 17
debris 17
pyroptotic 17
heterologously 17
appended 17
pathogenic. 17
Awareness 17
Physicians. 17
(AMI) 17
angioplasty. 17
24%, 17
study]. 17
(250 17
mg/kg/day) 17
intelligence, 17
Machado-Joseph 17
Excessive 17
noninvasive, 17
given, 17
palm 17
S2 17
slowly, 17
orthopedic 17
fetus, 17
severe. 17
kb). 17
pulsed-field 17
mmol 17
Na(+)-Ca(2+) 17
Hz) 17
amplifies 17
concentration; 17
pauses 17
diminished. 17
appropriately. 17
constant, 17
HILIC 17
(PC), 17
yolk 17
analytes 17
homodimer 17
module. 17
14-year-old 17
(LNH) 17
Asperger's 17
Colonic 17
Seventy-five 17
malabsorption, 17
language. 17
beyond. 17
spring 17
LPS. 17
factor-2 17
226 17
made, 17
phosphatases, 17
N-termini 17
streamlined 17
metalloprotease 17
base. 17
expression; 17
clonic 17
0.26 17
reexpression 17
triad, 17
declining 17
sessions. 17
consume 17
min). 17
commenced 17
Subjective 17
JNK, 17
km23 17
AIS. 17
13.5 17
Mechanical 17
fibromyalgia, 17
Endometriosis 17
11. 17
stenotic 17
example. 17
wish 17
(78 17
0.68, 17
sports, 17
tell 17
Hormonal 17
2.5, 17
1.0, 17
protective. 17
Delivery 17
Individualized 17
Trends 17
to: 17
visit, 17
girl. 17
fuses 17
macrocephaly 17
Intellectual 17
camptodactyly, 17
lipoproteins, 17
AMG 17
(P<0.0001). 17
ultracentrifugation 17
(higher 17
71%) 17
comparable. 17
Robust 17
non-syntenic 17
snoRNAs. 17
C-to-T 17
reagents. 17
EFTs 17
anatomically 17
rearrangement, 17
Multimodal 17
five-gene 17
(BCC), 17
complementing 17
Pif1 17
(R 17
incipient 17
skewing 17
paramagnetic 17
PRE 17
Cell. 17
velocity, 17
acupuncture, 17
youth 17
H3K79me3. 17
euchromatin, 17
latency, 17
pachytene 17
(1000 17
survival; 17
leukocytes. 17
ground 17
dictated 17
elevates 17
PI3K-Akt 17
pathway; 17
hours) 17
MET, 17
neuroprotection. 17
Bax. 17
MEK1/2 17
Centers 17
aminotransferase, 17
Markers 17
AFP 17
flu. 17
0.44 17
subsided 17
Frameshift 17
SFTPC 17
hypopituitarism 17
syndrome". 17
member. 17
nanoparticles. 17
bleomycin 17
early-phase 17
beta-agonists 17
suture. 17
cataract 17
craniosynostosis: 17
leukemias, 17
textbook 17
follicles. 17
incretin 17
unloading 17
relationship, 17
regimens: 17
power. 17
platforms. 17
(SDS) 17
summarises 17
proteinuria. 17
(physical 17
(EC) 17
ichthyosis, 17
46, 17
dermotrichic 17
hyperextensibility 17
CYP2C19*17 17
Cytochrome 17
(32%), 17
chemoradiotherapy. 17
nutrients. 17
microphthalmia-associated 17
Enhancing 17
V-ATPase 17
factor-1α 17
multivesicular 17
Properties 17
ampicillin 17
39, 17
hint 17
permeabilized 17
Sixty-five 17
(4%). 17
>5 17
PURPOSE 17
bromodeoxyuridine 17
197 17
Bevacizumab 17
8.9 17
(each 17
1,200 17
0.88, 17
(score 17
(RR, 17
micromol/L, 17
1.12 17
ancillary 17
(base 17
[RR] 17
G(2) 17
SA2 17
Covalent 17
mutated. 17
(refs 17
(family 17
Antifungal 17
Abstract 17
family). 17
photoreactive 17
knockdown, 17
upregulated, 17
sequence-dependent 17
delineates 17
HuR's 17
co-purified 17
RIT 17
CGA 17
normalised 17
0.91 17
tilt 17
rehabilitation, 17
café-au-lait 17
5-10 17
ribosomes. 17
efficiencies, 17
utilized. 17
71%, 17
submitted, 17
TAF15, 17
mutant-specific 17
formed, 17
(SGs). 17
stress-mediated 17
import. 17
(IL)-6 17
granulation 17
Secretion 17
cultivation 17
TGF-beta. 17
GATA-4, 17
microvessel 17
happiness. 17
Levodopa 17
Secreted 17
sequencing-based 17
organised 17
ACC, 17
details, 17
appendages 17
electrophysiology, 17
Calcium/calmodulin-dependent 17
KN-92 17
Injection 17
monophasic 17
cdk4 17
Medicinal 17
MPZ, 17
centres. 17
liability 17
ancestors 17
(IFN-beta) 17
thyromimetic 17
40-year-old 17
comparators 17
pancreatitis. 17
176 17
0.90) 17
(CIs) 17
FPG 17
mixed-effects 17
attainment 17
non-Japanese 17
designed, 17
glucose-induced 17
unmutated 17
amantadine, 17
stimulants 17
0.24 17
exposure-response 17
12.7 17
enrollment, 17
Tropical 17
NETosis 17
pseudogenes. 17
advances, 17
Botulism 17
alleviates 17
fly, 17
dimerization. 17
iab-7 17
(SCF) 17
ascertained. 17
80%. 17
NADH 17
helicases. 17
acetylate 17
protozoa 17
(Th2) 17
caspase-9 17
buds 17
LTR 17
inert 17
requisite 17
COOH-terminal 17
Intragenic 17
molars 17
remodeled 17
trimethyl 17
intragastric 17
requirement. 17
males; 17
unresolved. 17
VT. 17
(r2 17
5-HT, 17
Slc22a3) 17
Organic 17
TGF-beta-induced 17
(Drp1) 17
Drp1. 17
[1]. 17
perilipin 17
day). 17
endodermal 17
rules, 17
beta-lactam 17
(90 17
merit 17
penicillin 17
seamless 17
b) 17
(FT4) 17
hepatocarcinogenesis. 17
(Sry), 17
sponges, 17
metabolizing 17
Arrhythmogenic 17
ARVC. 17
PLN(R9C) 17
analyzed: 17
G526R 17
dHMN 17
detectably 17
partly, 17
TERC, 17
(often 17
congenita, 17
haploinsufficiency. 17
renewal 17
strengthening 17
TGFβRIII 17
miRNA, 17
activator. 17
Neuroendocrine 17
(NE) 17
ROS, 17
T-cells, 17
cell) 17
dampen 17
accidents 17
aPTT 17
instances. 17
reasons: 17
Concerns 17
AtxA, 17
Anthrax 17
ubiquitous, 17
8; 17
hypomethylating 17
Topological 17
neurocristopathy 17
(RET) 17
diepoxybutane 17
bioavailability, 17
anti-resorptive 17
mechanosensitive 17
epoxide 17
sensors, 17
(PR), 17
cotransfection 17
collectively, 17
10(-9) 17
clades 17
halting 17
Stone 17
p54nrb 17
body-surface 17
non-disjunction 17
down-stream 17
(combination 17
alpha1. 17
RhoB 17
enhanced, 17
Still, 17
photobleaching 17
puncta 17
possibility, 17
Johnson 17
m(2) 17
subcategories 17
histopathology, 17
SMS 17
<10 17
Intron 17
(pH 17
reset 17
K36 17
282 17
myeloblastic 17
equimolar 17
75%, 17
(0.75 17
6; 17
314 17
T3-treated 17
Fuzzy 17
spurious 17
noisy 17
four, 17
activations 17
CRL 17
(18)F-FDG 17
PET. 17
T/C 17
false-negative 17
recurrences. 17
M3/6. 17
Mitogen-activated 17
deactivation 17
plot. 17
(Triticum 17
falls. 17
0.96; 17
0.61, 17
optimal. 17
entails 17
microscope. 17
lipogenesis 17
clindamycin 17
department, 17
oil, 17
explant 17
export. 17
hydrogen-bonded, 17
ataxia-telangiectasia 17
pair. 17
methylene 17
proximity. 17
supercoiled 17
(VEGF). 17
miR-9, 17
YAC128 17
syngeneic 17
mg/g 17
apex. 17
RTN2B 17
Uptake 17
Multidrug 17
COS-1 17
inwardly 17
Coomassie 17
gel-based 17
conjugation. 17
first-in-human 17
biocontrol 17
dichotomy 17
Benz 17
Actin 17
filamin 17
Glucocorticoids 17
Americans. 17
anaphylactic 17
allergy, 17
low-T3 17
factors; 17
(Hsp90) 17
heat. 17
lenalidomide. 17
antitubercular 17
tuberculosis: 17
Tuberculosis 17
IHD 17
epidemics 17
ratio: 17
13C 17
neurologist 17
extraordinarily 17
aorta. 17
sinus, 17
tafazzin. 17
(TAZ) 17
occupancy, 17
lesson 17
proteasome-dependent 17
Vmax 17
J-ROCKET 17
numerically 17
≥75 17
1.44 17
Oral, 17
spotlight 17
(body 17
body) 17
Y-chromosome 17
non-commercial 17
CED 17
thromboembolism, 17
steatohepatitis 17
15.8 17
0.3, 17
(89%) 17
chondrogenic 17
modulus 17
0.00001), 17
narrative 17
QoL 17
legs, 17
incomplete. 17
be. 17
somnolence 17
nidulans 17
ZFN 17
confound 17
histories. 17
endonucleases 17
hsp90 17
207 17
Smith-Lemli-Opitz 17
24), 17
chromaffin 17
channelopathies 17
(PCD) 17
carboxylate 17
off. 17
18q. 17
microphthalmos, 17
mmHg, 17
Cyclosporin 17
costimulatory 17
aa) 17
linked. 17
currently, 17
ERM 17
autoinhibition 17
Rpd3 17
others.). 17
Triple 17
tenderness 17
PM 17
merging 17
drisapersen 17
diaphragmatic 17
surgeon, 17
deprivation, 17
piRNAs, 17
(SG) 17
repressors. 17
saline, 17
TKIs, 17
Imatinib, 17
tyrosine-kinase 17
24-month 17
Bcr-Abl, 17
clone, 17
leukemogenesis 17
biggest 17
farnesyl 17
arabinoside 17
Emergence 17
synergistic, 17
oedema, 17
alive. 17
convulsions 17
dsPIG 17
nonimprinted 17
(DMRs) 17
pedigrees. 17
Massive 17
lamins, 17
contacts, 17
same. 17
R403Q 17
166 17
0.009) 17
aneurysm. 17
searches. 17
autonomy 17
rejected 17
victims 17
oligomers, 17
promoter-driven 17
ARF 17
Mac1p. 17
oncogenes, 17
H-Ras, 17
0.29; 17
thoughts 17
rupture. 17
Aβ, 17
optimism 17
Neuropathological 17
L-T4 17
Adjusted 17
score) 17
X) 17
GC-skew 17
honey 17
administrative 17
E-boxes 17
archive 17
Desmin 17
G4.5 17
nonenzymatic 17
(MEK) 17
ahead 17
Sharp 17
Perturbation 17
father, 17
LCR 17
(starting 17
deficiency: 17
GWS 17
Veterans 17
impossible. 17
chromogranin 17
diabetes-induced 17
down-regulated. 17
insecticide 17
relaxants 17
flexor 17
(8%), 17
(BDV) 17
neurotropic 17
fellowship 17
(100% 17
Nocturnal 17
Mindfulness-based 17
Systolic 17
Cancer: 17
stressing 17
Raised 17
cold, 17
cardiology 17
visits. 17
hemiagenesis 17
hsFRP 17
(CSF), 17
A53T 17
somatodendritic 17
obsessive 17
bronchopulmonary 17
anonymously 17
dropout 17
clone. 17
(1996) 17
pea 17
specificities. 17
Regulated 17
TNFα, 17
ixekizumab 17
brodalumab, 17
symptom-free 17
FEV1 17
nominal 17
161 17
Ras-GTPase-activating 17
MPM 17
precluded 17
9.9 17
(measured 17
atheroprotective 17
beta-carotene 17
(TFRs) 17
(m6A) 17
CD40L 17
it's 17
TrkB 17
story 17
fostering 17
(IBD), 17
(NOD) 17
DPI 17
propria 17
extraintestinal 17
nonconsanguineous 17
xenograft-bearing 17
brownish 17
(CRD-BP) 17
isomer 17
0.85 17
GOS 17
motoneuron 17
complicates 17
repeatability 17
demented 17
(absolute 17
echogenicity 17
(38%), 17
(XLMTM) 17
haloperidol, 17
monoubiquitylation 17
H2B, 17
interpretation, 17
Top 17
gastrectomy 17
17-year-old 17
73-year-old 17
0.014). 17
Implementation 17
A-I 17
looks 17
foam 17
NusA 17
irreversibly 17
Eosinophilic 17
compendium 17
disorder; 17
difficult-to-treat 17
pharmacoresistant 17
LTG 17
shall 17
bifrontal 17
renamed 17
Persons 17
brevis 17
devices. 17
LQT1 17
positivity. 17
mm). 17
PrCa 17
Anterior 17
(Athens 17
-6 17
opiate 17
diazepam 17
p38-MAPK 17
repletion 17
flaviviruses, 17
70-kDa 17
Simplified 17
periaqueductal 17
française 17
unremarkable. 17
bilaterally. 17
generations, 17
G>A 17
Pharmacogenomics 17
85.2% 17
NGAL 17
LSD1-targeted 17
(hereafter 17
GAL4 17
shaft 17
homozygotes, 17
medulla, 17
ANK 17
Mastermind-like 17
Bach1. 17
(TNF-alpha) 17
diminishing 17
Congo 17
wake. 17
tetrapods 17
solid-state 17
(SERCA). 17
739 17
exposing 17
meropenem 17
3D7 17
screens. 17
bred 17
oligodendrogliomas, 17
(1966 17
(ACR20) 17
catheters 17
mexiletine 17
FANCD2. 17
FANCA. 17
endocytosed 17
globotriaosylceramide 17
PSCs 17
attract 17
unfavourable 17
BRC 17
Caspases 17
SIRS 17
noninfectious 17
DTI 17
adhesions. 17
verapamil. 17
NCX1 17
exchanger. 17
(Ca(2+)) 17
Listeria 17
(TNF-α), 17
HIC1 17
IL-11 17
48-year-old 17
imparts 17
hepatectomy. 17
NIH-3T3 17
factor-β 17
biomarker, 17
0.4% 17
Dnmt1. 17
34.3% 17
I(Ca) 17
preservation. 17
gingivalis, 17
(p<0.05, 17
RIN1 17
transients. 17
telemedicine 17
consultation. 17
decitabine-mediated 17
typing, 17
Ring1B 17
erythroid-specific 17
E2, 17
V1 17
2003, 17
(95%CI) 17
FA/BRCA 17
isradipine, 17
side-by-side 17
Center, 17
coastal 17
155 17
clustering, 17
Simvastatin 17
Aneurysmal 17
single-center, 17
aggravates 17
autoradiography 17
Test, 17
oligonucleotide-mediated 17
Netherlands) 17
teeth, 17
(64% 17
vein, 17
angiocrine 17
niche, 17
RPCs 17
Anastrozole 17
third-line 17
TPR 17
(88 17
RNAs' 17
photomorphogenesis. 17
kingdom. 17
divides 17
Supervised 17
promotor 17
(WHO) 17
maximizing 17
7-year 17
(ACS) 17
surfactant, 17
b.i.d. 17
intramembranous 17
(FGFR3 17
Autistic 17
l-dopa 17
inflammation: 17
Conclusion. 17
shifts, 17
Sin1 17
1.12, 17
Melbourne 17
g/dL; 17
(sensitivity 17
HG 17
panitumumab. 17
(R788) 17
Wistar-Kyoto 17
manually. 17
Older 17
GBS. 17
intra-strand 17
ranges. 17
Near 17
Siberia, 17
low-molecular-weight 17
CDH 17
anaesthetic 17
GQ 17
(TNFα), 17
Btk 17
Series 17
nonsynostotic 17
dysmorphology 17
wetting 17
incontinent 17
RNMT 17
375 17
(Katayama 17
travelers 17
(54.5%) 17
types/tissues. 17
interneurons, 17
frequencies, 17
coordinates, 17
5.2% 17
9p, 17
Pbp1 17
triangular 17
urethra 17
PKHD1 17
nine, 17
Replacement 17
Synechococcus 17
color, 17
wavelength 17
families: 17
-/- 17
HDAC6. 17
reductive 17
Assays 17
EGFR-expressing 17
3; 17
'bystander' 17
Importance 17
synthesizes 17
LOS 17
SOX3 17
intraatrial 17
glucocorticoid-induced 17
Horner 17
analysis; 17
mediation 17
Chk2-dependent 17
β-blocker 17
R4496C 17
MS-275 17
Men1(+/-) 17
hyperparathyroidism, 17
macules 17
plague. 17
Werner 17
(ORs) 17
Via 17
(CSCs) 17
(hDPCs) 17
error-prone 17
356 17
inotropy 17
firing. 17
Administration. 17
antimigraine 17
tetrazolium 17
(LVEF) 17
artifact 17
Seventy-eight 17
BTP 17
1.24; 17
infection-associated 17
Mtb 17
redness 17
allocation. 17
ON 17
hypersomnia. 17
(HLA) 17
(18)F-flutemetamol 17
curators. 17
FOR 17
ablate 17
(LDK378), 17
theca 17
UPCG 17
compressed 17
biomolecular 17
speeds 17
sphingosine 17
P398H 17
tolcapone, 17
leflunomide 17
tocilizumab, 17
sulfasalazine 17
microbiology 17
describes, 17
musk 17
Matthews 17
beta-barrels 17
Theatre 17
Explorer 17
archetypal 17
Reprints 17
permissions: 17
sagepub.co.uk/journalsPermissions.nav. 17
CCSVI, 17
mid-term 17
FSS 17
intersections, 17
GPS 17
(NEMO) 17
PU.1, 17
FXR(-/-) 17
MUTYH 17
H2Av 17
ALX1 17
invadopodium 17
cofilin 17
separations 17
MVD 17
infinite 17
base-case 17
Shoc2 17
5-aza-2'-deoxycytidine. 17
CD28 17
SBP2 17
regresses 17
histotype 17
Heparin 17
2:2:1 17
River 17
Transabdominal 17
UEBW 17
β-site 17
carbapenemase-producing 17
breakpoints, 17
IKKα 17
EGFR-TKIs. 17
schwannomas 17
isotype 17
core-like 17
Objective. 17
WB 17
(AMS) 17
behaviours 17
STUDY 17
(-)-OSU6162 17
envisaged 17
macrocytic 17
(38.1%) 17
RPL35A. 17
correction. 17
keratoses. 17
(P=0.01), 17
inspiratory 17
IPD 17
dysautonomia, 17
dabigatran-induced 17
Alfy 17
diffractive 17
tri-snRNP 17
(PTHrP) 17
tumour-specific 17
sororin 17
official 17
IBD, 17
(IDA) 17
transfusion. 17
(BD) 17
APOBEC3B, 17
nonathletes 17
odontoblasts 17
Leishmaniasis 17
(Galassi 17
TRβ 17
Brainstem 17
continuously. 17
triples 17
ovine 17
PTPN22.6 17
true-positive 17
P19CL6 17
ERAD. 17
trypanosomiasis, 17
revertants 17
PMC42-LA 17
Nematode 17
KIF1A 17
indexing, 17
answering, 17
α3 17
QOL, 17
bilharzial 17
MethylCap 17
CYLD(ex7/8) 17
MLL/SET1 17
FGENE 17
HLH 17
hemojuvelin 17
bullae 17
projected 17
HSRs 17
Wld(S) 17
L-DOPA. 17
Fas-FasL 17
FasL 17
refrigerator 17
Lonomia 17
ASIP 17
SLC45A2 17
dose-volume 17
HWE 17
gnathostome 17
bichir 17
48. 17
fencing 17
hyponatremia 17
tumor-preserving 17
Intetumumab 17
598 17
MITF. 17
GFD 17
altitude. 17
Prothymosin 17
impulsivity 17
oxidase-A 17
workers' 17
scars, 17
MSP-1 17
Lin(-)Sca-1(+) 17
diapedesis. 17
CSF-1 17
PAK2 17
Synapsin 17
β2 17
CK1epsilon 17
Upf1p 17
fibrothecomas, 17
fU:G 17
PDL 17
highly-expressed 17
HHHFNC 17
BMP4 17
[18F]altanserin-specific 17
5HT2 17
Adipokines 17
Bmi-1, 17
processor 17
rivastigmine 17
(5hmC), 17
3D-CISS 17
ENV 17
Blmtm3Brd 17
Lymphedema 17
Polyneuropathy, 17
SVR12 17
Mff 17
death-ligand 17
(NHBA) 17
nhba 17
hypervirulent 17
easing 17
INteractive 17
(INCA) 17
Bentham 17
Publishers; 17
epub@benthamscience.org. 17
UP-regulate 17
Uchl1 17
tubulopathy 17
CAR 17
PeakXus 17
Anderson-NeoACT: 17
STP 17
(CO-338, 17
PF-01367338) 17
HLP 17
apoE, 17
hyperlipoproteinemia, 17
arthrogryposis 17
p22phox 17
PAX3, 17
dystopia 17
gli 17
FOP. 17
GxxxG 17
protons, 17
Viliui 17
SUDEP, 17
doRiNA, 17
curating, 17
1015, 17
haemochromatosis 17
DFF45-like 17
Swi6p 17
reticuloendothelial 17
Inversion 17
Striae 17
protons. 17
libFLASM 17
(Waldmann's 17
DTA-HGGs. 17
HGGs 17
EPRS 17
dose-reduction 17
DECKO: 17
Single-oligo, 17
dual-CRISPR 17
hypobetalipoproteinemia 17
deer. 17
PBC. 17
(EXCEL) 17
RbAp48 17
M18BP1 17
Mis19 17
cry 17
PALACE 17
PFO 17
SH2, 17
CUTs, 17
(CUTs), 17
RPB9 17
0.2%/LR2412 17
CVE 17
aslncRNAs 17
tonsillectomy. 17
APL 17
gliding 17
NAP 17
trypanosomatid 17
hPer3 17
GARLIC 17
middle-aged, 17
rna 17
terra 17
addicts 17
x. 17
auxin-dependent 17
TIR1 17
ssmc 17
smarcb1 17
promoter-centered 17
palivizumab, 17
dispensing. 17
beta-hemolytic 17
Auxin 17
craniopagus 17
supination-flexion 17
MBV 17
Blount 17
ISS-N1 17
bombesin 17
Hyperprolactinaemia 17
subpallial 17
Sarcoidosis 17
(Avena 17
SSPE. 17
tick-associated 17
zoster-associated 17
HMOX2 17
cLADs 17
obstruction, 16
faulty 16
factor-binding 16
EGF-like 16
HB-EGF 16
0.50 16
pg/ml; 16
protocadherin 16
development; 16
trachea 16
Collagen 16
epithelia, 16
two-exon 16
5.6% 16
osteoclastogenesis. 16
semaphorin 16
4D 16
electromagnetic 16
foods. 16
OSC 16
bank 16
qRT-PCR. 16
28). 16
CA125 16
0.015). 16
post-intervention 16
events: 16
-2.5 16
weight-bearing 16
(World 16
bisphosphonate 16
senior 16
incurred 16
inhibitor). 16
effectively. 16
dermatosis 16
subclassified 16
(92%) 16
peroxide. 16
urologic 16
[6%] 16
unblinded 16
orteronel. 16
3+) 16
5'UTR 16
bioengineered 16
prostate. 16
Benign 16
assay) 16
kit. 16
androgen-responsive 16
integration-free 16
SOX2, 16
Klf4 16
stem-like 16
Myc, 16
picked 16
cohort). 16
colonies, 16
(C-HPP) 16
Project, 16
collaborations 16
Chr 16
Norway, 16
LC-MS 16
Neuroblastoma 16
unitary 16
chemotaxis, 16
Panx2 16
notion, 16
mtDNA. 16
characterised. 16
antianginal 16
post-myocardial 16
<70 16
Iva 16
quantified. 16
interval) 16
familial, 16
early. 16
1984 16
considerably. 16
slow. 16
Multidisciplinary 16
counselling, 16
60-year-old 16
4q. 16
(RyR), 16
myotubes, 16
atria. 16
miscellaneous 16
reliable. 16
force. 16
mM) 16
diltiazem, 16
utilization, 16
N-acetylglucosamine 16
multiply 16
(five), 16
(one), 16
UC, 16
secretin 16
mL/min 16
six, 16
Hg. 16
(ROS). 16
SA. 16
chemotaxis 16
AKT1E17K 16
pharmacotherapy, 16
Lacosamide 16
gastrointestinal, 16
p.o.) 16
Chimeric 16
(ESFT) 16
RNAseq 16
(R(2) 16
(TTP) 16
TTP, 16
microangiopathy 16
delayed, 16
associated, 16
cardiometabolic 16
(BMI), 16
(arm 16
intracerebroventricular 16
0.025) 16
Energy 16
bouts 16
5-min 16
(PP) 16
10); 16
9). 16
Pou5f1 16
SoxB1 16
lagged 16
microinjected 16
validity. 16
(EORTC 16
AIM: 16
0.37 16
0.07 16
players, 16
two-sided. 16
counties 16
menarche, 16
(standardized 16
1987 16
repertoire. 16
Nutrition 16
parity, 16
participation. 16
ossification. 16
geneticists 16
features; 16
dates 16
Feb 16
pursuit 16
paved 16
mg/dL. 16
run-in 16
influenza, 16
tunicate 16
tiny 16
Dcm 16
SAM. 16
Traditionally, 16
oligodeoxynucleotide 16
extraskeletal 16
Extending 16
(MTD), 16
(DLT), 16
gaps. 16
(MMC). 16
hybrids, 16
periodically 16
unfold 16
(GH) 16
Families 16
neurosurgery, 16
death) 16
2.1, 16
pharmacotherapies 16
Auricular 16
smoke. 16
student 16
(case 16
best. 16
silenced, 16
joins 16
group); 16
Ischemia 16
determinant-binding 16
cyclooxygenase-2 16
GSK-3beta, 16
hypoxia/reoxygenation 16
Akt1 16
adriamycin-induced 16
HGF/SF, 16
laboratory-confirmed 16
pregnant. 16
reverse-transcriptase 16
prospectively. 16
cardiomyopathy; 16
(between 16
hrs 16
case-fatality 16
612 16
clear-cut 16
Delineation 16
phenotypes: 16
Ligation-dependent 16
neurologic, 16
fuse 16
PRKAR1A 16
RFECS 16
TIC 16
nucleosides 16
TH2 16
indexes, 16
(indicating 16
taper 16
withdrawn, 16
Sanofi 16
Single-gene 16
(exons 16
Am 16
estimates, 16
cretinism 16
sexes, 16
canagliflozin, 16
CD99+/CD90+/CD45- 16
(FASP) 16
handling, 16
lysed 16
aided 16
trypsin. 16
8-hour 16
habitual 16
expectations, 16
p<0.01), 16
diary. 16
T-allele 16
(DES) 16
vasodilator 16
97%, 16
(VA) 16
efficacies 16
Monotherapy 16
instituted 16
(GD), 16
Seventy-one 16
temozolomide, 16
doses), 16
PATIENTS 16
(7%), 16
Salvage 16
mg/m2/day 16
Vomiting 16
single-arm, 16
hemispheres 16
5-year-old 16
Dendritic 16
stream 16
PMN 16
openness 16
subscales 16
(p<0.05) 16
pathway: 16
KIT, 16
neuro-endocrine 16
proceedings 16
(CENTRAL) 16
1.06 16
congenic 16
spleen. 16
FINDINGS: 16
ews/fli1 16
distance. 16
fli1 16
thorax 16
mirrored 16
insulation, 16
inter-chromosomal 16
V(H) 16
behaved 16
CTCF/cohesin 16
genomic, 16
IL-3 16
tethers 16
disorganized 16
adults: 16
CINAHL 16
ductus 16
disabilities, 16
agricultural 16
P4 16
polypeptide, 16
fluxes 16
crosslinking. 16
unveiling 16
(AIT) 16
PTU 16
11.9 16
swing 16
Manipulation 16
(54 16
Selenoprotein 16
inefficiently 16
clinicians, 16
(FTD). 16
C-terminally 16
Truncated 16
implanting 16
(containing 16
well-being. 16
opicapone. 16
OPC 16
microdialysis 16
favorable. 16
taken. 16
altogether 16
desorption 16
affinity-purified 16
(MPRs) 16
MFT 16
microdissected 16
figures. 16
multigenerational 16
ubiquitin-specific 16
multi-copy 16
blockade, 16
KN93 16
(LDH) 16
cyclins 16
CaMKII, 16
wasting. 16
pleocytosis 16
extraction. 16
6.9% 16
cavities 16
metaphase, 16
midbody 16
three-generation 16
(MCT8) 16
dilation. 16
(MI). 16
cm) 16
cyst. 16
relief, 16
4000 16
above. 16
manuscript. 16
sitagliptin. 16
'sitagliptin', 16
'saxagliptin', 16
'alogliptin', 16
Biomarker 16
2.5-fold 16
(versus 16
0.51 16
0.22 16
HbA(1c) 16
coma, 16
feasibility, 16
receptor-binding 16
toxoid 16
(only 16
hypodontia 16
commonly, 16
southeastern 16
Fab-7 16
methyltransferase2 16
unlinked 16
non-DNA 16
scleroderma 16
puberty 16
chromodomains, 16
MBD1 16
CTCF-dependent 16
CD2 16
Fission 16
discerning 16
co-immunoprecipitated 16
C., 16
arguments 16
Tf1 16
PRC1 16
slide 16
cheaper 16
Mature 16
(p<0.01). 16
KDM5B 16
(ESC) 16
ominous 16
Amiodarone, 16
etc., 16
C(max) 16
60%. 16
hyperenhancement 16
iodide. 16
24.1 16
(OCT3; 16
BCSFB 16
Nitric 16
lentivirus-mediated 16
TIEG1(-/-) 16
OPA1, 16
Aβ. 16
supramolecular 16
clonazepam 16
paroxetine, 16
FTC 16
participants). 16
ER+ 16
241 16
(RS) 16
a) 16
levels: 16
c) 16
micrograms 16
prolonged, 16
sponge; 16
(circular 16
miR-7). 16
circRNAs, 16
paranoid 16
0.017) 16
pentameric 16
TAC 16
Athletes 16
twice, 16
charging 16
PERIODICALS, 16
INC. 16
charges 16
neuropathy; 16
connection. 16
Kappa 16
Hybridization 16
NCI 16
NOP10, 16
variant(s) 16
(PTEN), 16
IP. 16
Rad51 16
ubiquitin-dependent 16
NBS1, 16
0.003 16
dystrophin, 16
μg/mL, 16
untested 16
recommendations, 16
uncontrollable 16
Irrespective 16
dabigatran) 16
phosphotransferase 16
plasmid-encoded 16
epitope-tagged 16
pXO1, 16
atxA+ 16
lef, 16
atxA. 16
Cross-talk 16
bicarbonate. 16
cap. 16
omega 16
Council 16
precursor. 16
discussion. 16
site: 16
anti-CS1 16
panobinostat 16
caveolar 16
sarcolemma. 16
quantum 16
excludes 16
subcomplexes 16
NBs 16
enriched. 16
conditions: 16
SIV 16
ancient, 16
constraints, 16
modularity 16
links. 16
labour 16
heterodimers. 16
GFP-tagged 16
non-treated 16
second-in-class 16
BIK 16
Scc2 16
fork. 16
RF-CCtf18/Dcc1/Ctf8, 16
polymerase-alpha-associated 16
DNA-polymerase-alpha-associated 16
TRF4, 16
RecQ 16
Wapl 16
establishment, 16
acetylation-independent 16
Annotations 16
550 16
(BRCA) 16
CTNNB1 16
tracing 16
advantage. 16
Relevant 16
UGE 16
panels, 16
296 16
steps: 16
T2, 16
till 16
heads 16
BER 16
subpathway 16
UvrB, 16
ATPases 16
335 16
12p 16
Leukocyte 16
Optimization 16
clofazimine 16
radiological, 16
exudate 16
relocated 16
homologue, 16
(DFS) 16
off-pump 16
publication, 16
Tree 16
(here 16
(TFBSs) 16
NAE∼Nedd8 16
37, 16
HAX-1, 16
(SERCA2a), 16
Emphasis 16
Thr(17) 16
recommending 16
unpredictable 16
harm. 16
JNK-interacting 16
520 16
ASK1 16
controversy. 16
1,25-dihydroxyvitamin 16
(1980 16
(79 16
falls, 16
residential 16
mounting 16
(enChIP) 16
Soon 16
acneiform 16
Discontinuation 16
transactivate 16
conotruncal 16
MDM2. 16
imaginal 16
E2F1 16
Assessments 16
third, 16
Structure-activity 16
Drug-related 16
amonafide 16
antileukemic 16
32) 16
m-AMSA 16
neuroinflammatory 16
microfluidic 16
Differentially 16
GLAST 16
resistance-associated 16
abilities. 16
PDZ-binding 16
synapse, 16
as: 16
useful, 16
Pfizer 16
Foc 16
sealed 16
threatens 16
agriculture 16
dubbed 16
grossly 16
Wnt, 16
glycoside 16
VHL, 16
cortactin, 16
period) 16
ablation. 16
suspected, 16
Europeans 16
Korea 16
palate. 16
progesterone, 16
Behavioural 16
55, 16
Elotuzumab 16
MDR-TB, 16
MDR-TB. 16
IDA 16
1.13 16
fibrinogen, 16
Presently, 16
dysarthric 16
questions: 16
hypo- 16
neuron, 16
dismutase. 16
(GERD) 16
heartburn 16
laparoscopically 16
acidosis, 16
glycosphingolipid 16
alpha-galactosidase 16
organelle. 16
Right 16
adipogenesis 16
adipogenesis, 16
CLIC1 16
attack. 16
non-major 16
(TTR) 16
maps. 16
membrane-spanning 16
Paradoxically, 16
coats 16
(±SD) 16
averages 16
life-year 16
cost-effectiveness, 16
21), 16
post-translationally 16
NAD(+) 16
erythropoiesis, 16
1.11 16
Antiviral 16
unprocessed 16
nicotine, 16
mg/day). 16
carcinogen 16
fail. 16
identify, 16
fabricated 16
printing, 16
multilayered 16
modulator, 16
ERβ 16
greater, 16
sleep-related 16
worsens 16
Supportive 16
interdisciplinary 16
bowing 16
audiometric 16
dried 16
chaperone. 16
Oncogene 16
triads 16
mV, 16
anticholinesterase 16
methylprednisolone 16
researches 16
refractive 16
neuropathy-Lom 16
834 16
cis/trans 16
quantifiable 16
transmits 16
looping, 16
Mariner 16
oxidases, 16
p15INK4b 16
(http://www.findbase.org) 16
CPM 16
emerged, 16
Employing 16
Abundance 16
Pervasive 16
temperate 16
40. 16
rindopepimut 16
woolly 16
NIR 16
(CTGF) 16
BNIP3L 16
nests 16
0.82 16
Deregulated 16
today, 16
(ARE) 16
EDC4 16
Pacman 16
RNP 16
7.7 16
ranolazine. 16
OXPHOS 16
Ba/F3 16
oridonin 16
BCR-ABL. 16
ABL-BCR 16
myelosuppression, 16
15%, 16
antidiabetes 16
Duloxetine 16
Pending 16
5-HT1A, 16
(reference) 16
≥4 16
(70 16
institute 16
tissue- 16
communication, 16
(called 16
ubiquitin, 16
double-edged 16
(clustered 16
Directional 16
G(s)alpha 16
Cleavage 16
0.02; 16
STZ 16
myoblasts. 16
undiagnosed. 16
inadvertently 16
ST-segment 16
skeleton. 16
NEFL 16
Alters 16
depolymerization 16
utility. 16
converging 16
Dissociation 16
aminopeptidase 16
oxytocinase 16
anti-CD52 16
risky 16
Remission 16
harvesting 16
ApoE4 16
hypothalamic-pituitary-thyroid 16
1992, 16
involucrin 16
gorillas 16
BH3 16
Especially 16
taxon 16
spur 16
substitutions. 16
SSRIs, 16
(SSRI) 16
(ASDs) 16
INTERNATIONAL. 16
desmin, 16
granulocytopenia, 16
beta-tubulin 16
Locus 16
hyperpnoea 16
displaces 16
curing 16
Registered 16
Ca(2+)-induced 16
organophosphate-induced 16
crises 16
(8) 16
BD, 16
Tools 16
mindfulness 16
debate, 16
dyspnea. 16
31-year-old 16
95, 16
self-administration 16
S129 16
alcoholism, 16
Sixty-seven 16
ng/ml) 16
proangiogenesis 16
evenly 16
Evidence-Based 16
hypothermia, 16
>1 16
terms, 16
epigenetics, 16
H5 16
Decay 16
SINE 16
Nf1 16
littermates, 16
(GISTs) 16
Cilengitide, 16
(RNA-Seq) 16
Ther 16
mmol/L), 16
microRNA, 16
demethylated 16
Macmillan 16
/H(+) 16
branching, 16
utilities 16
budgetary 16
(QALY) 16
solid-phase 16
instruments, 16
TOF 16
deacetylate 16
15-20 16
Merkel 16
caspase-dependent 16
(71%) 16
pelvis. 16
torsion 16
Dosing 16
LB-bearing 16
Colocalization 16
NAC 16
multiethnic 16
weighing 16
transfusions. 16
(0.5%) 16
redundant, 16
drug-susceptible 16
realized. 16
585 16
GPx 16
PCOS. 16
antral 16
fractionation, 16
PROTEOMICS 16
crucially 16
surface-exposed 16
antinuclear 16
scoring, 16
(ILAE) 16
clobazam 16
Activities 16
manner; 16
Anesthesia 16
ulcerated 16
(BCC) 16
blacks 16
appearances 16
antitumorigenic 16
Gy). 16
scarring. 16
57-year-old 16
Combined, 16
API 16
Marked 16
(WNV) 16
strain) 16
fruits, 16
GSK3B 16
Ex 16
underestimation 16
Questionnaire-Disability 16
CDAI 16
poverty 16
EtOH 16
African-American 16
ribonucleolytic 16
suffices 16
radio-chemotherapy. 16
exosomes, 16
corepressors 16
undifferentiated, 16
delusional 16
immunoperoxidase 16
first-choice 16
(CPVT). 16
Pluripotent 16
(ref. 16
aetiology, 16
ribs 16
TGFBR2 16
endocarditis 16
SPINK5, 16
autonomic, 16
amounted 16
locking 16
rationalize 16
Strains 16
Gag 16
AH 16
Variations 16
MSH6 16
non-replicating 16
SGLT2, 16
<60 16
mammal-teleost 16
"bystander" 16
dog, 16
(NIPD) 16
user-defined 16
mice). 16
TF. 16
hairy-cell 16
AdoHcy 16
fast-twitch 16
carp 16
prognostication 16
promoter-mutated 16
IDH, 16
janus 16
(DMARD) 16
inducible. 16
Site-specific 16
nociception. 16
innervation, 16
urological 16
Lmo2 16
RyR, 16
(Abeta), 16
typhimurium 16
pyrin 16
myoblasts, 16
hESC 16
TFCONES 16
TSSs, 16
variegated 16
(focal 16
sevoflurane. 16
phase-shifting 16
bundles, 16
palmitoylation 16
re-organization 16
Cetuximab 16
Elmo1-RNAi 16
DAC 16
CD30 16
multistage 16
CEV 16
(sgRNA) 16
AA, 16
registries. 16
NCTs 16
denticola 16
paraventricular 16
70kDa 16
LQT3 16
(PLN). 16
HF, 16
exclusive, 16
KGaA. 16
0-1 16
decitabine-induced 16
reactivates 16
cholestatic 16
references, 16
32-kDa 16
tumor: 16
RBCs, 16
http://bioconductor.org 16
single-end 16
modulation, 16
cardioverter-defibrillator. 16
SNARE 16
disease' 16
p43 16
Twinkle 16
colour, 16
UPS, 16
2-, 16
receptor- 16
C15orf2 16
(ER), 16
Shigella 16
SplicePredictor 16
nimodipine. 16
silicon 16
non-responders 16
non-cancer 16
cMT 16
Polycap 16
Valsalva 16
(TTX) 16
neuromuscular, 16
Yorkie 16
aSAH. 16
aSAH 16
volumes. 16
nanoscale 16
Corporation 16
internus 16
ventralis 16
neurostimulation, 16
palsy: 16
VIM 16
stereociliary 16
Ataxin-3 16
(SDHAF2 16
lentis, 16
metronomic 16
concept. 16
Tamoxifen, 16
sweats, 16
ΔF508 16
Alu-like 16
PORA 16
Q218E 16
(DNM2) 16
gross-total 16
dura 16
Cep135 16
ACS, 16
6.7% 16
(P244R) 16
Characteristic 16
spasms 16
feedforward 16
(Saccharomyces 16
studies; 16
f 16
OSCC 16
(MetS) 16
prothrombotic 16
HYAL-1 16
Services 16
high-cholesterol 16
(XLMTM), 16
basophilic 16
bootstrapping 16
Sequences 16
Russia 16
Adipose 16
adiponectin, 16
(S 16
ICP. 16
4p16, 16
(CD44v) 16
Overactive 16
worsened. 16
pseudopodia 16
domain). 16
Ubp8 16
viroid-like 16
Subviral 16
Glycogen 16
DX-88 16
(matrix 16
Tol2 16
calcification. 16
anticoagulants: 16
Malaysian 16
statistics. 16
heuristic 16
benchmark. 16
17.5 16
urokinase-type 16
neuroepithelial 16
laser, 16
intestinalis 16
lipofuscinosis 16
submodel 16
deacetylase. 16
(HDAC6) 16
improvements, 16
autocrine/paracrine 16
extravasation 16
ZFHX1B, 16
open-chromatin 16
Disorders. 16
gonadotroph 16
Necitumumab 16
committee. 16
(ECX) 16
scavenger, 16
Item 16
questions; 16
thereof. 16
Aβ42, 16
TH, 16
Dronedarone 16
Poly(A) 16
IFs 16
prevalent. 16
core/proximal 16
knockdowns 16
3a 16
myalgia 16
sweeps 16
phosphoribosyl 16
supplements, 16
ELAV 16
eotaxin 16
ubiquitin. 16
ABA 16
nucleolin 16
α-subunits 16
suggested, 16
TX 16
Sotos. 16
angiofibromas 16
Deubiquitinating 16
cytokine. 16
constitution 16
NPHP 16
Gli3 16
RNH1 16
bioink 16
Imageware 16
alginate-gelatin 16
bioprinted 16
GD2 16
semi-structured 16
non-clinical 16
6-10 16
PGE(2) 16
hyperalgesia. 16
telcagepant. 16
Holliday 16
survival: 16
toxicity; 16
depicted 16
36-year-old 16
90, 16
testing) 16
acetazolamide 16
CBTs 16
(NELF) 16
citrullination, 16
eyelids 16
conjunctivitis 16
TAC-FH 16
subtraction 16
Crude 16
peroxidation, 16
deaminated 16
3a. 16
(IL)-1β, 16
GR 16
CLOCK/BMAL1 16
EPC 16
Video 16
narcolepsy, 16
PTH. 16
(IFT) 16
ATD 16
daclizumab, 16
natalizumab, 16
Roche. 16
(99%) 16
painting 16
region-specific 16
animal. 16
circuit. 16
Background. 16
dyskinesias 16
p<0.01) 16
non-LTR 16
habitats 16
pmol/min 16
end-of-dose 16
organisation, 16
743 16
immunisation 16
saponin 16
BOCTOPUS 16
structure) 16
TMBpro 16
Ciona 16
uvrB 16
miR-106b 16
(CCSVI). 16
leprosum 16
SEA0400. 16
CCL2 16
FD. 16
lymphedema, 16
Farnesoid 16
(ASDs). 16
multi-organ 16
S-type 16
globally. 16
splice-switching 16
AS-like 16
"ERRE" 16
"Esrrb-responsive 16
element") 16
instruments. 16
dynamical 16
proinsulin 16
dMP1 16
90. 16
(UTRs) 16
recall, 16
oogenesis 16
Telomeric 16
metazoa. 16
neurturin, 16
nutlin 16
RG7112i 16
vector-borne 16
18.8 16
TAF10 16
faecium, 16
baumannii, 16
dashboard 16
LND 16
tigecycline 16
DICO 16
costunolide 16
sofosbuvir 16
abusers 16
MRS 16
mir-21 16
PMA-induced 16
inconsistency 16
non-enhancers. 16
ratio(allergy-glioma) 16
SQTS. 16
SCENAR 16
neuralgia. 16
Prognostication 16
endometriomata 16
(ACTA1), 16
(TPM3) 16
(face, 16
Suberoylanilide 16
POU5F1 16
RPL35A 16
5q- 16
matrine 16
p70S6K 16
PTCL 16
ABK 16
Linac 16
DHEA. 16
51G>A, 16
dosimetry 16
within-site 16
homotachous 16
R319W 16
Bengal 16
pentalogy 16
Milk 16
CGS 16
6-item 16
MDR1 16
Semantic 16
Hardell 16
Noggin 16
mH2A1.1 16
(week 16
protamines 16
calcium-independent 16
granulosus 16
K.448. 16
DIHPA 16
mg/100 16
vandetanib, 16
MTH1, 16
AgNP 16
SOS 16
week] 16
cleavage/polyadenylation 16
CCDC40 16
1858 16
HLA-DRB1, 16
EDS, 16
cereals 16
EDN-3 16
(OAB) 16
Investigators 16
revertants. 16
SMAR1 16
diuresis 16
SOLiD 16
ontologies, 16
DDX6, 16
Rf4T 16
TrkA 16
hypnosis 16
nurse-led 16
prolyl 16
hCdc4 16
(eRNAs), 16
(PBC) 16
chiral 16
CHS1 16
Ser(67) 16
prescription. 16
YqjH 16
dermis. 16
infrastructure. 16
bruising 16
galactosylceramide 16
(RHC) 16
tyrosinase-related 16
Tpl2(-/-) 16
364 16
condition-specific 16
(2-OH-dATP), 16
ADA 16
TARDBP 16
ABPP 16
ICRF-187 16
foveal 16
cellulitis 16
Platform 16
0.004; 16
DARA-treated 16
UM-9 16
FtsZ, 16
MEF-2A 16
mLST8 16
3'-end. 16
decapeptide 16
proTalpha 16
roX2 16
Patient-reported 16
micrograms/ml), 16
silica-induced 16
Na+,K(+)-ATPase 16
iodine-124 16
µM), 16
apicoplast 16
anti-malarial 16
trypanocidal 16
mefloquine 16
aerial 16
Gdf10 16
CTXG 16
WT1 16
Ngb-Tg 16
levodopa-resistant 16
parkinsonism-dementia 16
Upf3p 16
Nmd2p, 16
TIA, 16
(AlkA) 16
anticholinergics. 16
(71%), 16
(ADL) 16
(HFNC) 16
T68, 16
TSHR 16
saponins 16
hCDC4 16
anti-TNFα 16
H3T3ph 16
ALK-TKIs. 16
hepatotoxic 16
HPD 16
PBT2, 16
(ICR) 16
Behcet's 16
Dnmt3a. 16
Guided 16
Btbd9 16
Silymarin 16
(DBH) 16
desomorphine 16
cheaply 16
kernicterus 16
(FFI) 16
(Teriflunomide 16
rerandomized 16
beta-thalassaemia 16
fulvestrant, 16
neisserial 16
hSBA 16
MINDY-1 16
DUBs 16
Ub 16
embryopathy 16
workshops 16
(DAT1) 16
HTT 16
IT15 16
aducanumab 16
bezafibrate 16
migalastat. 16
ribotypes 16
SPAG5. 16
p<0·0001; 16
AG014699 16
ubiquilin 16
hallux 16
LUBAC 16
DOS 16
Adhesive 16
NOXA1 16
(HELLP) 16
Waardenburg's 16
tanezumab, 16
PMV 16
lineage; 16
MRSA-positive 16
(PDE5) 16
carriage. 16
GPs 16
psychogenic 16
(p<0·0001), 16
C(2)-ceramide 16
oAβ 16
Yakut 16
sacubitril/valsartan 16
l-tyrosine 16
convertases 16
fat-specific 16
OPS-1 16
septo-optic 16
MCAST 16
CEN 16
hemisome 16
ANA 16
ZFP36L1 16
(hERG) 16
"torsades 16
K897T 16
CF1 16
ointment 16
RBE 16
rosettes 16
(methionine 16
DIPGs. 16
GemC1/Lynkeas 16
oculodermal 16
iPLA2-VIA 16
(NLD) 16
diabeticorum. 16
triterpene 16
fiber-granule 16
PUVA-paint 16
(21.4 16
UVA), 16
PUVA-paint, 16
MdDS 16
MIRA-seq 16
ebolavirus 16
FVL 16
UDCA, 16
QTcF 16
DEEP-ENCODE 16
Mis14 16
Cri-du-chat 16
abemaciclib 16
MNase. 16
40.6% 16
(ORC), 16
ARHR 16
multi-thread 16
Adar 16
CEGA 16
Onyx 16
Pfh1. 16
Basset 16
DHX32 16
asf1 16
PCSK9-mediated 16
Law 16
(TBR1), 16
FOXP2, 16
Mcm 16
E(spl) 16
lncRNA#32 16
D4GDI 16
dormancy. 16
welding 16
inter-TAD 16
cephalopod 16
ATTR 16
subsampling 16
Rpb4 16
DSPS. 16
masitinib 16
IC1 16
Strelka 16
strelka 16
Colitis. 16
text], 16
(AID) 16
aurimucosum 16
pitted 16
siod 16
metadata 16
NCT01465763 16
NCT01458951 16
NCT01458574 16
cebocephaly 16
BQ, 16
Ustekinumab, 16
linearisation 16
tomatinase 16
BBCAnalyzer: 16
uniting 16
maneuvers 16
buprenorphine-naloxone 16
CellMaps 16
(gas 16
Osteomyelitis 16
osteomyelitis: 16
Lanka 16
testis-biased 16
Gore 16
chondromas 16
VCF 16
BCF 16
angiopathic 16
CD55. 16
chaffeensis 16
lossy 16
CTPA 16
NUB1L 16
agouti 16
15-20% 15
C>T 15
desmoplastic 15
panitumumab, 15
elaboration 15
PS2 15
Affinity 15
invertebrates, 15
parts, 15
475 15
graphs 15
poly-A 15
(OPG) 15
Osteosarcoma 15
264.7 15
RANK 15
RANKL. 15
Suppress 15
miR-145 15
0.31 15
mycophenolate 15
exacerbation, 15
contraindication 15
denosumab. 15
unresectable, 15
acid), 15
third-party 15
radiologist 15
We, 15
diltiazem. 15
linear, 15
frequency-dependent 15
coculture 15
others). 15
611 15
estimable) 15
[10%] 15
(12% 15
DLTs 15
(Grade 15
meets 15
ABY-025 15
incubation. 15
colorectal, 15
ganciclovir 15
BCL2 15
HER2-overexpressing 15
dose) 15
Fgf4 15
Artd1 15
75-year-old 15
Advisory 15
list, 15
male-specific 15
post-genomic 15
low-abundance 15
297 15
innervated 15
dihydropyridine 15
External 15
Post-mortem 15
TP 15
9.2 15
(CAD). 15
angina. 15
miR-133, 15
(combined 15
failure). 15
mo, 15
demyelination, 15
method) 15
(CTCF), 15
intron-containing 15
snRNPs 15
predilection 15
Extension 15
FSHD, 15
reevaluation 15
(WBC) 15
K., 15
decay, 15
neurotransmitters, 15
Greece. 15
Solution 15
(BRG1) 15
mM). 15
pocket. 15
Gut 15
refining 15
baroreceptor 15
(MAPKs) 15
ischemia-induced 15
iTRAQ 15
juxtaposed 15
anticoagulant, 15
Cultured 15
dysregulation. 15
lessen 15
SPA 15
indicated, 15
glucagon 15
(10% 15
7). 15
appetite. 15
ml) 15
immunoreactivity. 15
protein(s) 15
1.67, 15
temporomandibular 15
[adjusted 15
recognized, 15
occasions 15
provisional 15
high-sensitivity 15
speckle 15
pg 15
ECG. 15
1.15, 15
1400 15
interview. 15
gender-specific 15
productivity. 15
P<.001). 15
pain; 15
(Cohen's 15
414 15
analyses: 15
statin. 15
dyslipidemia. 15
trial: 15
ixekizumab, 15
cholesterol-lowering 15
Apo 15
randomized. 15
deciliter 15
treatments: 15
(TFBS) 15
Fifty-six 15
(AdoMet) 15
overlap, 15
(patients 15
[22%] 15
accelerator 15
319 15
FA-C 15
RNA: 15
(R-loops) 15
non-template 15
prolactinomas. 15
aryl-hydrocarbon 15
essential, 15
phosphomimetic 15
skinned 15
A8V 15
primes 15
affinities. 15
WT. 15
1.5-fold 15
enhanced. 15
monoxide 15
refute 15
1985 15
(H3K36me3), 15
dinucleotides, 15
H3-K9 15
Silent 15
(n=6), 15
protein-mediated 15
anti-VEGF 15
co-immunoprecipitate 15
(NF-kappaB) 15
SCF-type 15
anoikis, 15
c-MET 15
MAP2 15
Hemodynamic 15
ADR-induced 15
keratinocyte-derived 15
(H1N1) 15
247 15
14. 15
Estimates 15
302 15
0.97; 15
S.L. 15
"classical" 15
IMH 15
bioassay. 15
varieties 15
planes 15
management: 15
(CSC) 15
engraft 15
Eczema 15
airflow 15
flare 15
dysregulation, 15
metopic 15
forehead 15
co-transfected 15
lambdoid 15
bossing, 15
distinguishable 15
obscure, 15
euthyroid. 15
description. 15
possibility. 15
dapagliflozin, 15
(eGFR) 15
mL/min/1.73 15
Researchers 15
ppm 15
identifications 15
OCT 15
mixture, 15
dissimilatory 15
(CKD). 15
CRS. 15
lipocalin 15
sub-acute 15
CLBP 15
p<0.05). 15
behaviours, 15
177 15
atrichia 15
photophobia, 15
CYP2C9, 15
98%, 15
(8%). 15
(RPA) 15
RT, 15
triphosphatases 15
disruption, 15
biocompatible 15
cargo. 15
two-component 15
lantibiotics. 15
Structures 15
transglycosylation. 15
metabolome 15
single-institution 15
12.1 15
chemotherapies 15
(16.7%) 15
centralised 15
1-3, 15
interrelated 15
reflexes. 15
nowadays 15
resemblance 15
IL-1R 15
cascades, 15
conscientiousness 15
perceptual 15
Greece 15
40S 15
temsirolimus, 15
Octreotide 15
standard-dose 15
(lower 15
Pubmed 15
SHR. 15
colocalizing 15
(46%) 15
typing. 15
diffuse, 15
Lange 15
(KSHV) 15
subtelomere 15
overview. 15
SCD, 15
CBP. 15
(CBP) 15
(DHPLC) 15
Biotechnology 15
non-identical 15
Relatively 15
wheat, 15
scientifically 15
maydis. 15
(AGO) 15
protein-RNA 15
introduced. 15
apart, 15
hemiplegia, 15
age; 15
pelvis, 15
(MSI) 15
selenocysteines 15
collaborate 15
FTD, 15
calcium-responsive 15
paraspeckles. 15
disassemble 15
(NLS) 15
(TDP-43) 15
protrusions. 15
insult. 15
detergent-insoluble 15
Hedgehog, 15
Macrophage 15
441 15
MZ 15
hydrolases, 15
diverse, 15
hyperthermophilic 15
curve. 15
cylindromas, 15
cell-line 15
extracted. 15
heterozygosity, 15
wasting, 15
self-association 15
adrenocorticotropic 15
mini 15
ERK1 15
(DA) 15
GJB1, 15
(CMT2) 15
(types 15
CCM2, 15
silent, 15
alpha), 15
dermis, 15
compassionate 15
normalizes 15
28-year-old 15
sacrum 15
Vildagliptin 15
pharmacophoric 15
"ZincPharmer 15
Database" 15
H-bond 15
inhibitors), 15
baseline; 15
broadening 15
faeces 15
sub-populations 15
Zucker 15
sulfonylureas 15
underrepresentation 15
diverging 15
week; 15
(OR), 15
unpleasant 15
lncRNA, 15
botulism, 15
countermeasures 15
imperfect 15
hsp26 15
primers, 15
CMT, 15
phasing 15
Immunoblot 15
Cbx2 15
derepress 15
Origin 15
Immunocytochemical 15
Sci. 15
nontumor 15
PGC 15
NMR, 15
phosphoserine 15
Biophysical 15
engaging 15
nonphosphorylatable 15
SP600125 15
examined; 15
(equivalent 15
templates. 15
PIC 15
CRCs. 15
succeeding 15
fingers. 15
simultaneously, 15
internucleosomal 15
exploration. 15
flecainide, 15
facilitation 15
Endpoints 15
high-capacity, 15
GCs, 15
cations 15
BMP2 15
Inducible 15
Bim 15
NO, 15
supplies 15
lipolytic 15
fastest 15
OPA1. 15
Yme1 15
gatekeeper 15
AV 15
Ceftriaxone 15
BID. 15
g/d 15
neurotrophins 15
Administration-approved 15
disease): 15
handled 15
excitotoxicity 15
clinico-pathological 15
NN 15
(p≤0.001). 15
575 15
Ca-transport 15
annually, 15
Antioxidant 15
TNF. 15
PL 15
501 15
polyunsaturated 15
non-athletes 15
slides 15
analyzable 15
Finder 15
reference. 15
transfers 15
Agents/circumstances 15
avoid: 15
dyskerin 15
transplant. 15
(75% 15
hematoxylin 15
LVEDP 15
miR-494 15
Discovering 15
0.01; 15
large-cell 15
LPS-activated 15
LC3, 15
ChIPnorm 15
CD84 15
sera, 15
birds. 15
scarce. 15
antithrombin 15
trial). 15
enoxaparin 15
P-gp 15
sponsored 15
185-kb 15
Preferred 15
pRNA 15
height. 15
X-ray, 15
vorinostat. 15
bone-anabolic 15
RPMI-8226 15
basically 15
10(-7) 15
Hz, 15
hyperthyroid 15
avidity 15
macaques. 15
interesting, 15
TRIM50 15
SSB-1 15
FusionDB 15
neighbors 15
version. 15
horizontally 15
them: 15
– 15
NMD. 15
b-AP15 15
GRP78 15
(48 15
acetylates 15
happen 15
Chl1, 15
ontologies 15
enriching 15
0.21 15
BRCA-mutated 15
TMA 15
cediranib 15
(1:1) 15
(NIH) 15
Institute, 15
ionotropic 15
lumen, 15
(26% 15
252 15
incisions 15
Blockage 15
BRCC3, 15
AAA 15
angiography, 15
projectile 15
3p, 15
0.00 15
pastoris 15
IgG. 15
3.0, 15
evacuation 15
61%, 15
laid 15
chromatin-remodelling 15
chromodomains. 15
Rpd3S 15
Fifty-one 15
patients]. 15
lod 15
pump, 15
peri-operative 15
coregulation 15
co-occurring 15
Cullin 15
BH3-only 15
(UPS) 15
(EFS 15
SAMHD1, 15
(HAX-1) 15
coordinator 15
ischemia/reperfusion. 15
need, 15
(MammaPrint) 15
phosphates 15
c-Jun. 15
VH 15
aestivum 15
Interventions 15
0.71, 15
1.19 15
0.64, 15
cut-offs 15
0.50, 15
likelihoods 15
Espana. 15
protoporphyrin 15
Mir155 15
cheilitis 15
(11%). 15
socio-economic 15
embryotoxicity 15
VITA, 15
Culture 15
5.0% 15
micrognathia 15
E4. 15
injuries, 15
mitoxantrone, 15
II; 15
agents) 15
protein-associated 15
N-acyl 15
unprovoked 15
Drosha 15
sodium-dependent 15
homocysteine, 15
phosphatidic 15
256 15
corrections 15
cheap 15
HIV, 15
modulators. 15
herniation 15
Bak 15
theme 15
drivers, 15
histone. 15
mg/d. 15
Eighty-three 15
0.07). 15
AKI. 15
66.7% 15
curves, 15
likely. 15
taxonomy 15
mammosphere 15
depression-like 15
Rheb. 15
(FCD) 15
pericyte 15
Continued 15
migrants 15
outdoor 15
68%, 15
(NK) 15
awaited 15
anti-TB 15
2013) 15
pylori) 15
ITP 15
CagA-positive 15
erythrocytic 15
urticaria 15
microorganism 15
lacking, 15
atherogenesis. 15
non-inflammatory 15
phonation 15
aphasic 15
modelling. 15
GERD. 15
deficiency) 15
postictal 15
generalization 15
syndrome--a 15
aciduria. 15
GSK-3β 15
DNMT3B, 15
(HR: 15
NVAF 15
outcomes: 15
store, 15
DB 15
organism's 15
GTPase, 15
multi-protein 15
(P<0.05), 15
PAT 15
transcriptomics, 15
two- 15
sphingolipid 15
(25%). 15
Consensus 15
experts. 15
BHB 15
Standards 15
patch, 15
Zealand. 15
Score, 15
intraclass 15
infarctions, 15
0.83; 15
segmented 15
hyaluronic 15
Printing 15
affordable 15
vulvovaginal 15
(SERM), 15
evokes 15
flushes 15
179 15
RLS/WED. 15
well-tolerated. 15
(84%) 15
habitus 15
Msp 15
PCR-RFLP 15
PCR-SSCP 15
HSCR: 15
(CCHS), 15
(BBS), 15
cartilage-hair-hypoplasia 15
(CHH), 15
(SLO), 15
Goldberg-Sprintzsen 15
(GSS), 15
sylvius 15
70%. 15
endothelin-signalling 15
trios 15
depolarizing 15
mV) 15
blots. 15
antibody-positive 15
therapy-related 15
Early-onset 15
changes) 15
Competitive 15
Olympic 15
sporulation 15
h(-1) 15
fitness, 15
Chk1 15
beta-cells 15
addicted 15
CT-011 15
immunomodulating 15
junctate. 15
Real 15
BAH 15
vasoactive 15
barbed 15
H2A/H2B 15
ɛ4 15
2.09 15
'evolutionary 15
acquires 15
'genomic 15
Distance 15
relatedness 15
digenic 15
message. 15
CSCs, 15
CIN 15
hyaline 15
spontaneously. 15
87%, 15
(1.8 15
cities 15
Edc3 15
Cytokines 15
PV 15
ethanol. 15
juice, 15
Parkinsonism 15
phenotypical 15
anti-ischemic 15
Microtubules 15
Adhesion 15
thrombocytosis 15
22q11.2. 15
Second-generation 15
cures 15
phosphokinase 15
doses) 15
6%, 15
raphe 15
sequelae, 15
deceased 15
kits 15
expressions. 15
GBMs 15
Why 15
willing 15
enforces 15
constraints. 15
Proc 15
Natl 15
Acad 15
1.4, 15
intracardiac 15
OVE26 15
UCF-101 15
defibrillators 15
(when 15
Implantable 15
language, 15
1/X 15
events). 15
barriers. 15
disregulated 15
Pick's 15
License 15
SAC 15
transactivation, 15
dually 15
242 15
IL-17A, 15
426 15
hyperthyroidism. 15
preliminary, 15
stimulus, 15
premise 15
oligomers. 15
(Aβ), 15
abandoned 15
L-T(4) 15
1970, 15
0.80) 15
Corresponding 15
unreliable 15
precision. 15
GNU 15
meta-analyses, 15
Snail2, 15
UM-UC-3 15
disseminate 15
dissemination. 15
chaperones, 15
iron-deficient 15
seeing 15
heterotypic 15
CREB, 15
critical, 15
PET, 15
TMEM127 15
parathyroid, 15
IPF, 15
α-smooth 15
intratracheal 15
Histology 15
saline. 15
CASQ2, 15
(ryanodine 15
OPs 15
foot, 15
chlorpyrifos 15
intoxicated 15
filtering, 15
Proximity 15
intranasally 15
DCF 15
Reporting 15
installation 15
Fifty-nine 15
developers 15
(WS), 15
Range 15
life; 15
reported; 15
hearing, 15
frizzled 15
mg/L, 15
formulations, 15
Placebo-Controlled 15
fallen 15
anger 15
escaped 15
(PDT) 15
Corneal 15
deficiency). 15
efficacious. 15
substances. 15
Sin 15
HHO1p 15
Fungi 15
physician's 15
52, 15
anti-IL-17 15
reasons, 15
retinoblastoma, 15
classed 15
Integrins 15
transposon-free 15
sub-cellular 15
(IVS10-1G>A) 15
(NHE6). 15
(79%), 15
germ-free 15
Kl 15
sister, 15
morphologies 15
helix, 15
bifida. 15
discharges. 15
sarcoma: 15
0.021). 15
Ets 15
resected, 15
bottom 15
Meigs 15
both). 15
psychosis. 15
deoxyribonucleic 15
readings 15
pleckstrin 15
hyperintensities 15
benzhexol 15
CBC 15
isoniazid 15
procedure-related 15
ischemia: 15
Intact 15
hindering 15
efficiently, 15
totalis 15
abdomen, 15
Obstetricians 15
Clomifene 15
cumbersome 15
expense 15
determinants. 15
[HR 15
interleukin-5, 15
eosinophilia, 15
Anti-IL-5 15
electroencephalogram 15
felbamate 15
s. 15
small- 15
15), 15
shocks 15
home, 15
bupivacaine 15
343 15
(78%), 15
solar 15
KS 15
polyphenolic 15
resveratrol, 15
photorefractive 15
Adiponectin 15
Eli 15
fentanyl 15
(RdRP) 15
(DENV) 15
necroptosis. 15
BMI. 15
instant 15
non-alcoholic 15
42-year-old 15
20.6 15
chase 15
hypoxia-regulated 15
powder 15
tracked 15
PGM 15
monocytosis, 15
LSD1-CoREST 15
(MEL) 15
MEL 15
erythroid, 15
clozapine, 15
(85% 15
cardiomyopathies, 15
cloverleaf 15
deformity, 15
pectus 15
Dysplasia 15
lymphoepithelial 15
ATG 15
Conformational 15
panels 15
(n=12) 15
(ALT) 15
stress-inducible 15
NA 15
GalNAcalpha1-O-Ser 15
GalNAcalpha1-O-Ser:GalNAcalpha1-O-Thr 15
diffusum 15
0.025, 15
albuminuria 15
hypotheses, 15
deals 15
penumbra-like 15
(SDs) 15
Sarcoplasmic 15
Ala 15
http://rohslab.cmb.usc.edu/TFBSshape/), 15
quantitatively, 15
91%. 15
N-methyltransferase 15
AEs. 15
(IRES) 15
construction, 15
erythroblasts 15
blocker. 15
(OCT3) 15
anemia-afflicted 15
(PKC). 15
(HSCs) 15
consulted 15
Evidence-based 15
sulfonate 15
Id1 15
(CRC). 15
pyroptosis. 15
SCN, 15
hyperglycemia. 15
displacement, 15
regrowth 15
opening. 15
hESC-derived 15
abstract 15
Normally 15
sensibility 15
leveled 15
receptors) 15
endplate 15
Mg2+ 15
(DMRA) 15
2.1-4.4 15
0.0692 15
CHO-K1 15
0.304 15
body's 15
Rac. 15
Elmo2 15
ELMO1, 15
Dock180, 15
Testicular 15
non-methylated 15
avocado 15
Pospiviroidae 15
mg/L. 15
mg/l 15
reinhardtii 15
Success 15
number: 15
PABP1 15
(TS). 15
microsomes. 15
form) 15
initially, 15
(males: 15
209 15
provider 15
pseudouridine 15
hematuria 15
99) 15
Xga 15
thymocyte 15
task-specific 15
contigs 15
autosomic 15
p38, 15
SOR 15
Non-Small-Cell 15
dissections 15
Snord116del 15
NOXA 15
FANCE, 15
collapse. 15
Ca(v)3.2 15
Ca(v) 15
my 15
nurses. 15
validity, 15
haemophilia 15
11; 15
(35%). 15
homologues, 15
villages 15
polypill 15
dispensed 15
statin, 15
Ultrabithorax 15
starch 15
compression. 15
markets 15
TCD 15
Scale) 15
angular 15
nm, 15
Pallidal 15
deep-brain 15
inner-ear 15
HTLV-1 15
TTField 15
K516 15
disparities 15
uncharacterised 15
C2-domain, 15
CHS2 15
MEK2 15
polyhydramnios, 15
Mcm2 15
fixed-sized 15
(CCHS) 15
Downs 15
CBAVD 15
population: 15
Cdk 15
alu 15
inhabiting 15
Pchlide 15
(L.) 15
Belgian 15
17p 15
Stereotactic 15
cartwheel 15
Lp-PLA(2) 15
Diabetes. 15
adjustments. 15
1B1 15
landmarks 15
FGFR2, 15
(ages 15
supratherapeutic 15
ETD 15
Rif1. 15
sumatriptan 15
relay 15
testosterone. 15
County 15
cytologic 15
hydrolyses 15
brain) 15
R406, 15
Surgeons. 15
TLR4, 15
-induced 15
ophthalmoparesis, 15
GBS, 15
Parity 15
Ontario 15
(CI: 15
dreams 15
saved 15
(3%). 15
(IL) 15
plagiocephaly, 15
v6 15
5/6 15
statistically. 15
BT 15
implementations 15
mention 15
collection. 15
Sgf73 15
Plk1. 15
Universal 15
fecundity 15
uncertainty. 15
behaving 15
bonds. 15
slippage 15
abduction 15
model: 15
syndactyly. 15
SRY. 15
evolve. 15
Ecallantide 15
company 15
purified, 15
CALM1 15
intolerable 15
HPA 15
zfhz1b 15
ToppGene 15
cross-validation 15
names 15
one-stop 15
non-model 15
coalescent 15
inhabit 15
bolsters 15
patellar 15
decelerated 15
patellae 15
parkinsonism: 15
stimuli-induced 15
S100P 15
Hsp90, 15
biomass 15
allophycocyanin 15
BG 15
hybridizes 15
overlying 15
Encephalitozoon 15
non-sustained 15
(CTRL) 15
predictor. 15
downloadable 15
HMM_RA 15
quantifies 15
contents, 15
TGF-β2 15
HT29 15
deprived 15
Aft1, 15
Attenuated 15
sequencing; 15
(MUG) 15
MUG. 15
Intraperitoneal 15
ECX/matuzumab 15
oxidatively 15
NXY-059, 15
polyuria 15
Flibanserin 15
marmoset 15
Question 15
CC. 15
Allopurinol 15
NfH(SMI) 15
fluorescence-activated 15
plant. 15
DOORS 15
fetal-specific 15
methylated, 15
GGT 15
double-positive 15
MEST, 15
5-LOX 15
PAX6, 15
Fontan 15
(0.2 15
diuretics. 15
phosphoribosylpyrophosphate 15
complication, 15
UTR. 15
RCTs, 15
Ryr2 15
AN-7 15
Z-disc 15
adult, 15
drilling 15
hypercalcemia. 15
uncultured 15
Genome-scale 15
HBV 15
M31 15
noise-induced 15
GalR 15
triptans 15
nitroglycerin 15
4h 15
Photodynamic 15
Balloon 15
aspect, 15
Mitofusin 15
dexamethasone. 15
ara-C 15
Ara-C 15
(25%), 15
mineralized 15
(IL-1β) 15
0.93 15
factor-23 15
47,XXY 15
(Reliable 15
non-Invasive 15
package) 15
validated, 15
(HOQ). 15
streamline 15
6566 15
p21(CIP1) 15
248 15
Checkpoint 15
Evolution. 15
NOD1, 15
PGN 15
(EAE), 15
louse 15
constriction-induced 15
HL-1 15
HRC, 15
CA3 15
Palmini's 15
musculature 15
UCH-L1 15
narcolepsy. 15
classifier. 15
LINE1 15
hotspots. 15
glatiramer 15
S.L.U. 15
neuromyelitis 15
masked. 15
ceritinib. 15
druggable 15
inversus, 15
PC. 15
furzeri 15
RecA 15
proceed. 15
MRP 15
QSAR 15
mutants; 15
stabilises 15
Outer 15
porin 15
limitation, 15
elapsed 15
(IE) 15
VISTA 15
RagA 15
Philippines, 15
lubag 15
MAPKs. 15
azygos 15
257) 15
PALB2 15
non-pharmacologic 15
nucleotide-resolution 15
enucleated 15
hemostatic 15
CDK6. 15
(sgRNA). 15
(FGF23), 15
0.72; 15
Na+-Ca2+ 15
SLC49 15
telmisartan 15
APOBEC3G. 15
LoF 15
tagging/proteomics 15
lipoproteins. 15
668 15
semi-supervised 15
G406R 15
pterostilbene 15
Interphase 15
principle; 15
(i.m.) 15
beta), 15
repression; 15
Oct3/4-independent 15
dovitinib, 15
Th2-mediated 15
(13)CO(2) 15
uPA 15
(recombinant 15
KSR-1 15
oligomerization, 15
Mexico 15
verified. 15
insulin-secreting 15
60S 15
SAZN 15
CG9754 15
Aub 15
Fcy21p, 15
nmol/L), 15
RG7112-MDM2 15
(F 15
hosts, 15
DUSP 15
EBW 15
semagacestat 15
Turkey, 15
Sowah 15
ribavirin 15
river 15
Bacteroidetes 15
cancer). 15
(RIC) 15
living, 15
Abdominal 15
acetabular 15
childbirth. 15
fixator 15
GRO-sequencing 15
5p15.3 15
20q13.3 15
GSTP1 15
1q21 15
alignment, 15
lymphadenopathy 15
Mabthera 15
pEGFP-Stat3 15
one), 15
shifts. 15
Roman 15
dyserythropoietic 15
V59A 15
miRNA) 15
RPS26, 15
S19, 15
erythroblastopenia 15
B3) 15
nicotinamide, 15
body-mass 15
reduction), 15
immediate, 15
anterograde 15
granule-selective 15
-refractory 15
tick. 15
genospecies 15
pro-fibrotic 15
(ERA) 15
High-Risk 15
(CDI) 15
CACCC 15
decarboxylase. 15
IAA 15
stiff-person 15
document, 15
deletion), 15
300243), 15
50th 15
pigmentosum. 15
heterotachous 15
others), 15
during, 15
cyanotic 15
afatinib, 15
indeterminate 15
promoterome 15
BMI-1, 15
AMPK-α 15
Cby 15
PERV-specific 15
isochromosome 15
Hsp70.1 15
Dot1-like 15
estriol 15
meningococcus 15
Lenvatinib 15
phagosomal 15
8-oxo-dGDP 15
misincorporation 15
Npc1(-/-) 15
TNFAIP3 15
analeptic 15
Glc7 15
samples; 15
(HRQoL) 15
N1 15
answers, 15
QA 15
RDF 15
snippets 15
Central; 15
"exact" 15
paragraph-sized 15
(summaries). 15
answers; 15
(G3BP1) 15
Dystrophin-deficient 15
Amitriptyline-induced 15
mood-associated 15
Rifle, 15
sulfurreducens 15
syringe 15
ephrin-A1 15
EphA2, 15
beside 15
nonpolyadenylated 15
Alpha 15
RARβ(2) 15
Ash2L 15
(Medicago 15
colors 15
Cdk4 15
HJV, 15
ESCs, 15
nimotuzumab. 15
Craniospinal 15
Alu/SVA 15
P-P 15
Israel, 15
GLD 15
taurocholate 15
grass 15
var 15
RIFINs 15
osteotomies 15
CASP8 15
(HWE) 15
afamelanotide. 15
integrating, 15
pimelic 15
whole-blood 15
(Heyde 15
Insulators 15
myeloma-specific 15
intetumumab. 15
gluten-sensitive 15
mutS 15
wildlife 15
retromer 15
≤2 15
daunting 15
bioactivation 15
preeclampsia. 15
C677T 15
presenteeism, 15
imbalance, 15
MALT 15
Fi 15
Bilirubin 15
actopaxin 15
Erbin 15
Merlin 15
CaN 15
eteplirsen's 15
(n=2/group) 15
25; 15
biopsied, 15
Duration, 15
miR-206 15
Guadeloupe: 15
(Cytosine-C5) 15
AZA 15
(ITT) 15
event; 15
alpha2(V) 15
MK2 15
(muscle-liver-brain-eye 15
p38beta, 15
Morphologic 15
bone-like 15
sequence; 15
Hydroxyurea 15
bolus/infusion 15
(TSD) 15
ET. 15
scribble 15
culprit 15
metronidazole 15
antamanide 15
lithium. 15
p=0.056). 15
PCDH 15
ITT 15
cisternography 15
Canakinumab 15
rs3923809 15
LCS 15
Tacrine, 15
psychosocially 15
α-defensins 15
α-defensin 15
single-tablet 15
G-6-PD 15
FFI. 15
PrPSc 15
medication-resistant 15
IL-7, 15
PorA, 15
ST-269 15
nadA 15
RER 15
'codon 15
bias', 15
Nc 15
CAI, 15
6-OHDA-lesioned 15
wearing-off, 15
PTPRF 15
20q-, 15
D22S 15
Cri 15
granulosa-lutein 15
(99m)Tc-HYNIC-annexin 15
HTZ 15
GLA 15
Mumps 15
bespoke 15
Aph-1 15
APH-1 15
self-interacting 15
sPE 15
apoE-1Harrisburg 15
INTRODUCTION 15
Gordon 15
painful, 15
behavior-assessing 15
persons' 15
Noxa1, 15
nephrocalcinosis. 15
platelets) 15
bmp6 15
tongue. 15
intersections 15
treemaps 15
Tanezumab 15
PvPM4 15
mecA 15
erythromycin, 15
PDE 15
dapivirine, 15
Autoerythrocyte 15
(diphenylene 15
Toxocara 15
septins, 15
oxidase-like 15
Nav1.1 15
doRiNA: 15
ladasten 15
5-HTP 15
pro-peptide 15
pro-hepcidin, 15
macrophagic 15
Furin, 15
DFFA-like 15
EWAT 15
NIHSS. 15
woolsorters' 15
rik1 15
POI 15
(p.L129P) 15
hypochromic 15
activating, 15
Crowned 15
dosimetric 15
ependymomas, 15
CSI 15
beams 15
(DGAT1) 15
lysine-to-methionine 15
Ménière 15
generalisation 15
hypoproteinemia 15
primordium, 15
patterning/microphthalmia, 15
CDF2 15
glioma; 15
annulare 15
E62K 15
(ARISTOTLE) 15
views. 15
Pla 15
Budd-Chiari 15
hypoproteinemia, 15
bug 15
UBC 15
paint-PUVA 15
mimotopes 15
fluid-attenuated 15
Topaz1 15
Ssu72. 15
MUC1-G 15
SRY-negative 15
CD28(-) 15
ZMapp, 15
beta-synthase 15
Pds5B(-/-) 15
nerve-associated 15
(28.8% 15
SRS 15
G34R/V) 15
Mirabegron, 15
methidiumpropyl-EDTA 15
(MPE-seq), 15
withMPE-Fe(II) 15
Actoxumab 15
bezlotoxumab. 15
Ebstein 15
(DMP1) 15
hCINAP 15
DON 15
priapism 15
transarterial 15
0.46) 15
greatly, 15
Sotagliflozin 15
sotagliflozin, 15
pre-processing, 15
klu 15
Scuba 15
(LY317615) 15
TOT 15
Galunisertib, 15
DSPS 15
Jakinibs 15
smad4 15
LEPRE1 15
S1PR 15
RP101075 15
AUX/IAA 15
Erythrasma 15
Schimke-immuno-osseous 15
Filgotinib 15
ini1 15
(P=0.007); 15
16.6% 15
ustekinumab. 15
pasi 15
risankizumab 15
DREB/CBF 15
rapa 15
DKA 15
deer, 15
non-CAP-LRTI. 15
SERM, 15
pneumoconiosis 15
(PTB) 15
(RIF1) 15
D-MER. 15
Neglected 15
Enlimomab 15
herpes, 15
MCs 15
multifactorial, 14
long-segment 14
10(-4)). 14
crest, 14
proto-oncogene. 14
cytokines/chemokines, 14
STAT 14
forces. 14
precursor, 14
gonad 14
sulfate-polyacrylamide 14
completed, 14
non-protein 14
neurodevelopment. 14
MG-63 14
osteoprotegerin 14
osteoblasts, 14
microarchitecture 14
hypothalamic-pituitary 14
(EOC) 14
Obstetrics 14
miR-145, 14
0.05; 14
Pearson's 14
(HRs) 14
(55 14
PFS. 14
Myasthenia 14
SR-Pyr 14
Specialized 14
1966 14
neostigmine 14
30-month 14
deviated 14
Denosumab, 14
three-quarters 14
(FDA)-approved 14
pain: 14
nonvertebral 14
TAK 14
Transition 14
antagonist) 14
(tyrosine 14
Austrian 14
dishevelled 14
multi-gene 14
strikingly, 14
(65% 14
derangement 14
(Bazex 14
utmost 14
71-year-old 14
(LQT1) 14
IV), 14
drug-specific 14
recognising 14
Ligand 14
kappa, 14
hypertension: 14
amylase 14
292 14
15.2 14
2C19, 14
26), 14
toxins. 14
inclusion, 14
(0, 14
tendencies 14
(∼ 14
(% 14
EGFR/HER2 14
rapid. 14
bevacizumab. 14
in-situ 14
abnormal. 14
34) 14
retard 14
chimeras. 14
KLF4, 14
Kit 14
retrovirus-mediated 14
Postmortem 14
evidently 14
(chromatin 14
phosphoproteins 14
chromosome-centric 14
searches, 14
seeks 14
accomplish 14
Machine 14
cones, 14
permeable 14
HeLa, 14
Sensory 14
synthesises 14
characterizations 14
proofreading 14
beta-blockers, 14
0.001); 14
post-MI 14
HRR 14
pressure-volume 14
chelation 14
contracture. 14
sporadic. 14
perpetuation 14
uncouple 14
intronless 14
stalls 14
Elongation 14
Prescription 14
deterioration, 14
father. 14
(1%). 14
CDH1 14
amplitude, 14
Calsequestrin, 14
electrically 14
(1995) 14
gene-targeting 14
scan, 14
methanol 14
matrices. 14
13%. 14
pharmaceuticals 14
RSD 14
genus, 14
264 14
unraveled 14
identity) 14
BRD2 14
pocket, 14
K14 14
casual 14
opinion, 14
9%, 14
cultured, 14
non-IBD 14
crypts 14
Conditions 14
SA, 14
up-regulated. 14
(AP-1) 14
Fos 14
Jun 14
Labeling 14
isobaric 14
non-NF2 14
(AED) 14
polytherapy 14
complement-mediated 14
splenectomy. 14
C3, 14
glomerulonephritis 14
revolutionize 14
hemolytic-uremic 14
infarctions. 14
episode. 14
24.4 14
(TGFbeta) 14
absence, 14
tumorigenicity. 14
267 14
era, 14
dilemma 14
Histopathology 14
ignored 14
single-centre 14
rectosigmoid 14
Thoracic 14
(NHL), 14
sociodemographic 14
Taiwan 14
25). 14
cyclists 14
(45%), 14
37.5 14
1.23 14
1.09 14
patients? 14
Participation 14
(OCs) 14
&lt; 14
©2010 14
naturalistic 14
usage, 14
therapist 14
catastrophizing 14
face-to-face 14
Overgrowth 14
145), 14
PCSK9. 14
HDL-C 14
evolocumab, 14
anti-atherogenic 14
Long-Term 14
6.3% 14
LDL, 14
≥12 14
198 14
(UC). 14
20). 14
snoRNAs, 14
(ncRNA) 14
cytosine-C5 14
locked 14
ensued. 14
cytogenetics. 14
Surface 14
nosological 14
responded. 14
(38%, 14
interruptions 14
benefit-to-risk 14
continuously, 14
Blood, 14
LC-MS/MS, 14
MF. 14
4,5',8-trimethylpsoralen 14
FA-A 14
AGO1, 14
CTG.CAG 14
HI 14
hyperparathyroidism 14
hormone-secreting 14
CDKN1B 14
Grb2 14
protooncogene, 14
tumourigenesis. 14
regain 14
Diagnosed 14
ATPase, 14
D., 14
hinders 14
expired 14
self-efficacy 14
pack-years 14
Clinic, 14
chromocenters 14
disappearing 14
euchromatin. 14
shrinkage, 14
cell-penetrating 14
non-covalent 14
years: 14
IκBα 14
osteosarcoma. 14
EGFR-TKIs 14
c-Met, 14
anti-apoptosis 14
factor-stimulated 14
(BrdU) 14
outbreak. 14
myocarditis. 14
(2009) 14
261 14
kg), 14
neonates, 14
reassurance 14
second- 14
chills, 14
texts 14
641 14
commencement 14
Characteristics 14
birthweight 14
morbidly 14
Phenotypes 14
discrepant 14
improve, 14
(19%), 14
cargo, 14
designs. 14
maternal-fetal 14
1h 14
dehydrogenase. 14
clonogenicity, 14
(86% 14
frontal, 14
imbalances, 14
array-CGH 14
thumbs 14
transactivated 14
Balanced 14
TWIST, 14
Apert, 14
pancytopenia, 14
regions: 14
29.6 14
one-sided 14
elaborated 14
unassociated 14
Radiological 14
(Pendred 14
Forty-one 14
periplasmic 14
buffer, 14
(TTR), 14
(false 14
benchmarks 14
liberated 14
inadequate. 14
reinforcement 14
pre-test 14
getting 14
thigh 14
Conclusions. 14
syndrome-like 14
follicularis-alopecia-photophobia 14
33-year-old 14
subepithelial 14
legs. 14
uncle 14
Variability 14
non-carriers 14
VPA, 14
Morbidity 14
Younger 14
181 14
mTORC1-dependent 14
proteostasis. 14
471 14
prioritizing 14
Disruptions 14
Canonical 14
cell-wall 14
vancomycin. 14
Mersacidin 14
kanamycin 14
(57 14
XRT 14
surgery) 14
One-year 14
reassessment 14
Thirty-five 14
(complete 14
synovitis. 14
Searches 14
2.0; 14
metropolitan 14
midlife 14
diminution 14
personality, 14
Record 14
Mini-Mental 14
CNI 14
methodologically 14
0.84, 14
1.23, 14
websites 14
EAE, 14
Foxp3(+) 14
Germany) 14
ChIP-chip, 14
sites) 14
RAD21 14
preincubation 14
straightforward. 14
96-well 14
assumed. 14
smut 14
law, 14
imposing 14
RNPs 14
PAR-CLIP, 14
polyadenylation, 14
ribonucleoside 14
254 14
crosslinking, 14
fT4 14
Gait 14
ornithine 14
Gross 14
rater 14
session, 14
0.78 14
calcaneal 14
neurologically 14
y) 14
Wechsler 14
periventricular 14
10-meter 14
coarse 14
harboured 14
Selenocysteine 14
societies 14
deleterious. 14
RGG 14
aggregation-prone 14
actin-binding 14
(FTLD) 14
outweigh 14
intramyocardial 14
(MAOA-L) 14
levodopa-treated 14
dialysate 14
400, 14
column. 14
receptor-dependent 14
Two-dimensional 14
liposarcoma, 14
Springer-Verlag 14
evolved. 14
reliant 14
haloarchaeal 14
chromosome-specific 14
Methanococcus 14
appendages. 14
cylindromatosis. 14
CYLD. 14
64-year-old 14
TNFAIP3, 14
treatment]. 14
TSC1-TSC2 14
micromol/L) 14
Hearts 14
Single-nucleotide 14
MPZ 14
enteroviruses 14
subtle, 14
anaphase, 14
VII 14
novo. 14
3,5-diiodothyropropionic 14
332 14
6.6 14
(Tarlov) 14
sciatica 14
(MRI). 14
(any 14
opted 14
Linagliptin 14
biguanides, 14
(4, 14
vildagliptin, 14
co-stimulatory 14
HbA1c, 14
glycemia 14
sulfonylureas. 14
IGHV 14
Virtually 14
wks 14
neuroleptics, 14
Predictors 14
monomers. 14
MMP-1 14
knowledgebase 14
botulism. 14
Being 14
hypomyelinating 14
hypodontia, 14
POLR3A 14
Overview 14
boundary, 14
counterpart. 14
nonhistone 14
homeotic 14
palms 14
G(1)/S 14
-B 14
immunoblots 14
Connective 14
remodelers 14
SANT 14
Methylated 14
CDYL 14
Homeobox 14
H3K9. 14
CDs 14
calorimetry 14
CReMM 14
HP1, 14
chromatin-based 14
Proc. 14
Natl. 14
Acad. 14
Chk2. 14
plates. 14
whole. 14
Neurochemistry 14
transformants 14
methylations 14
Repressive 14
(H3K4me3) 14
642 14
phylum, 14
renally 14
(47 14
hospitalised 14
(YFV) 14
extraneuronal 14
battery. 14
sulfonic 14
neurotransmitters. 14
placenta, 14
Krüppel-like 14
suppressors. 14
stem, 14
carbonyl 14
unforeseen 14
crista 14
Seventy-two 14
CS, 14
glutamate. 14
motoneurons 14
Biliary 14
Neuroprotective 14
Lateral 14
assignments. 14
(ER)-positive 14
(HA) 14
0.61 14
OCT4-pg4 14
OCT4 14
miR-7-dependent 14
circRNA. 14
repressor. 14
Carotid 14
promoter-associated 14
(42%), 14
(prevalence 14
oxidizing 14
47%, 14
minerals 14
(P) 14
hr, 14
absorbance 14
Steady 14
CMT-causing 14
stack 14
minimization 14
utilized, 14
counting. 14
lethality, 14
G9a, 14
DCC 14
anogenital 14
December, 14
NHP2, 14
WRAP53 14
myeloablative 14
transfused 14
roots. 14
MiR-21 14
I/R-induced 14
pressure-overload-induced 14
ubiquitinates 14
undamaged 14
Bax/Bcl-2 14
Erasmus 14
U/L 14
0.03; 14
LPS, 14
endometriotic 14
explants. 14
(P>0.05). 14
(Neu5Gc) 14
(NOACs) 14
procoagulant 14
plasmas 14
VKAs 14
forward. 14
Rivaroxaban, 14
NOACs 14
dimer/monomer 14
sap 14
trans-activator 14
P2, 14
sigma(70)-dependent 14
CBP/p300 14
glutamine-rich 14
CADASIL. 14
Ezh2-deficient 14
Ezh2, 14
IPSS 14
276 14
crystallography, 14
Pakistani 14
(CDS) 14
monoubiquitinated 14
ethyl 14
vorinostat, 14
orally-administered 14
oprozomib; 14
daratumumab; 14
degrees, 14
(EM) 14
effectors. 14
MCA 14
degraded. 14
denucleation 14
baculovirus 14
preformed 14
attitude 14
3-iodothyronamine 14
C; 14
luminescence 14
Rhesus 14
host-pathogen 14
coil 14
Python 14
interactome. 14
gene-fusion 14
paraspeckles 14
connexin 14
unimpaired 14
July, 14
onward 14
orderly 14
Ctf18-RFC 14
hydroxyurea. 14
Eco1 14
dyspepsia 14
21.7% 14
16.4 14
0.86, 14
(NER), 14
receptor: 14
T₃ 14
fine-tune 14
homomeric 14
fixation. 14
insights. 14
18.2 14
381 14
without. 14
outpatients. 14
(3.2 14
calreticulin 14
NER, 14
Lesions 14
Rad26 14
UvrA, 14
intimal 14
infant, 14
throughput. 14
TIMP2 14
G/C 14
proliferated 14
Sharing 14
polypyrimidine 14
Pichia 14
8.8 14
Combinatorial 14
qualified 14
multiplication 14
leads. 14
coating 14
(TSC). 14
Eker 14
(RCC) 14
(LAM) 14
pharmacotherapeutic 14
HP1a, 14
cycles). 14
T) 14
postoperatively, 14
mining. 14
NEDD8-MLN4924 14
substrate-assisted 14
Nedd8-MLN4924 14
enzymes: 14
B., 14
HS-1 14
co-transfection 14
48%, 14
reject 14
20,000 14
PTH, 14
registers 14
(1946 14
(RaR 14
0.86; 14
0.96, 14
1.20; 14
persons, 14
(BMD), 14
nurse 14
30%, 14
innovation. 14
Española 14
(Treg) 14
Identified 14
CRISPR. 14
(FGF) 14
wash 14
AUCs 14
endothelium, 14
beneath 14
0.25, 14
values). 14
Actinomycin 14
binders 14
poisons. 14
extravascular 14
disturbing 14
monofunctional 14
6-fold 14
blinding 14
neurodevelopment 14
DNMT3A, 14
tauopathies. 14
L-[14C]cysteine 14
Michaelis 14
ASC 14
g/kg 14
dampening 14
head. 14
MARCKS 14
non-duplicated 14
adjuvants 14
Availability 14
mount 14
(MMP) 14
Mercedes 14
(AMPK), 14
MBs 14
formins 14
flavonoid 14
podosomes, 14
genomically 14
reasoned 14
mitochondrion 14
rotenone 14
0.011). 14
iopanoic 14
e-mail 14
(FT3) 14
beta1, 14
31) 14
Epistasis 14
70, 14
Final 14
Concentration-dependent 14
multi 14
endemic. 14
1.60 14
indirectly, 14
atherogenesis 14
(58 14
musical 14
Bengali 14
(9) 14
CsA-induced 14
dysphagia, 14
(GERD). 14
reflux. 14
proton-pump 14
infantile, 14
Substrate 14
mastoid 14
aspergillosis 14
hyperpneumatization 14
rhythms. 14
grounded 14
ROCKET-AF 14
warfarin-treated 14
HR: 14
pace. 14
TAG 14
micron 14
one's 14
(60%), 14
implementation, 14
11.3 14
0.39 14
(DSS) 14
ALI 14
AAH 14
234 14
(ROS), 14
C282Y 14
randomization, 14
craving 14
Females 14
discomfort, 14
expensive, 14
scale: 14
0.94 14
manufacturing, 14
patents 14
plastic 14
estrogen-induced 14
6.6% 14
clonidine, 14
PLMD 14
colonization. 14
FokI 14
10.2% 14
(due 14
inheriting 14
7.5% 14
gut, 14
often, 14
penetrant, 14
quantal 14
SCLC. 14
terminals. 14
(beta 14
69-year-old 14
lenses 14
calculation, 14
isolate. 14
Fifty-five 14
Cyclophilins 14
Ligase 14
p53-deficient 14
Fas, 14
disappointing 14
MEFs, 14
p16INK4a, 14
senescence-like 14
doxycycline. 14
(DCs) 14
characterization, 14
COOH 14
YAP/TAZ 14
latter, 14
bundled 14
Vps75 14
(R47H) 14
imputed 14
signatures: 14
correction, 14
lengthy 14
breed 14
cyanobacteria, 14
TPM1 14
Notch. 14
>2 14
SUZ12 14
respectively); 14
(EZH2), 14
HOX 14
(TMA) 14
karyotypic 14
born, 14
tetralogy 14
DCP1a 14
post-infection. 14
(P-bodies), 14
rhythmically 14
I(Na), 14
procedural 14
DOCA-salt 14
alternans 14
(that 14
Disturbed 14
4-fold. 14
Per 14
(TKI), 14
cellularity 14
<300 14
response; 14
chromosome) 14
dasatinib. 14
trying 14
stages: 14
Approval 14
oocyst 14
Silver-Russell 14
(maternal 14
paraganglioma 14
capture. 14
reversely 14
Ol-Nanog 14
normally. 14
conveyed 14
(Type 14
seamlessly 14
phages 14
Dicer, 14
codes. 14
sciences 14
develop, 14
dephosphorylation, 14
dyspnea, 14
survived. 14
ice 14
Andean 14
lon1 14
(T-ALL), 14
(FAD) 14
(APP). 14
CNM 14
unrepaired 14
CD95 14
alpha) 14
copper-responsive 14
N-Ras, 14
B- 14
cell-depleting 14
social, 14
remissions. 14
haemorrhage: 14
applicability. 14
CABG. 14
subspecies 14
rDNA, 14
chimpanzees 14
order, 14
(ASD), 14
mothers. 14
metaplasia 14
2%, 14
lambrolizumab 14
protein-bound 14
ICRs 14
Prader-Willi/Angelman 14
INS 14
shell 14
GlaxoSmithKline, 14
night-time 14
pediatricians 14
E2F3 14
deacetylases. 14
c-Myb 14
isolated, 14
aerosol 14
Pheochromocytomas 14
CNEE 14
Sildenafil 14
saturation, 14
nutrition, 14
intoxication. 14
insecticides, 14
Beginning 14
illness; 14
Tag 14
criteria; 14
TSS, 14
AP1, 14
Deviations 14
proteobacteria. 14
pyrimidines. 14
System. 14
Every 14
recording, 14
RMMA 14
1.3% 14
Measuring 14
Executive 14
Maryland 14
justifies 14
GHD 14
Tc 14
HSA 14
α-synuclein. 14
synucleinopathy 14
sertraline, 14
underestimate 14
Increase 14
Hepatocellular 14
vary, 14
intravaginal 14
continence 14
prosthesis 14
combinatorially 14
H1. 14
PARN. 14
CNOT7 14
(PASI 14
100). 14
TH17 14
GFP. 14
αvβ5. 14
HUVEC 14
(EMD 14
Lentiviral 14
enalapril, 14
0.56, 14
(m(6)A) 14
Viagra 14
362 14
exclusivity 14
instrument, 14
one-quarter 14
lock 14
vulgatus 14
microorganisms, 14
(OSA). 14
XIII 14
skills, 14
additively 14
FHIT 14
impetus 14
searched: 14
concentrations; 14
PSP, 14
(LB) 14
CLBs 14
Medicine, 14
frank 14
myofiber 14
Charcot-Marie 14
MTM1, 14
MTMR13 14
tetrabenazine, 14
Dystonia 14
(P=0.008). 14
errors, 14
undetectable. 14
abundant, 14
excellent. 14
joint. 14
(shRNA) 14
fermented 14
thawed 14
follicles, 14
week) 14
labeled, 14
Churg-Strauss 14
0.62; 14
late-phase 14
GEFS+ 14
(16%); 14
Nevertheless 14
subcutaneously. 14
ms. 14
symptomatic. 14
JLNS 14
Nigeria 14
hyperpigmented 14
SIRT1. 14
keratectomy 14
(TLRs) 14
MyD88 14
punctures 14
Nurses' 14
1955 14
apoptotic, 14
Intense 14
younger, 14
ESR 14
ambiguity 14
nonalcoholic 14
underpins 14
NTIS 14
Druze 14
enthusiasm 14
isoenzymes 14
sequencer 14
Dapagliflozin 14
AutoDock 14
amifostine. 14
cytoprotection 14
CD24 14
LD. 14
2006) 14
Lysine-specific 14
granulomonocytic, 14
expanded. 14
(PKA)-mediated 14
LSD1-mediated 14
307 14
KCNJ2, 14
(Tg) 14
(hiPSCs) 14
outgrowth, 14
rarely. 14
hK5 14
ex-vivo 14
Kazal 14
thrive 14
pmol/min/mg 14
Mastermind 14
HMOX1 14
alpha-globin 14
(Schindler/Kanzaki 14
capuramycin 14
duration; 14
Aurora-A 14
atoms 14
miscarriage 14
amplitude) 14
excitability. 14
entropic 14
twist) 14
UniPROBE. 14
compare, 14
steatosis, 14
dephosphorylation. 14
dabrafenib. 14
Brain. 14
ET-1, 14
HDAC5 14
PGAM-M 14
codeletion, 14
(ACR) 14
English, 14
biologics. 14
immunohistochemistry; 14
(DSBs), 14
PCA 14
small-molecule, 14
peptidyl 14
fanconi 14
heterozygote. 14
(Pol) 14
NEU3 14
5'-untranslated 14
vein. 14
TAT-TALEN 14
β-glucocerebrosidase 14
<30 14
scarred 14
costly, 14
caspase-4 14
gambiae 14
92) 14
Clearance 14
continuity 14
Cochran-Mantel-Haenszel 14
GATA4 14
PKC-beta 14
Ancora 14
labs 14
Systems 14
podoplanin 14
communicate 14
0.001; 14
antagonise 14
MT2, 14
darkness. 14
min), 14
valve. 14
polymers. 14
3b 14
Frequency, 14
non-infected 14
non-Watson-Crick 14
viroids. 14
Questionnaires 14
septicemia 14
Cre 14
lymphoma: 14
JTV519-treated 14
K(ATP) 14
anticipated. 14
Apelin 14
nitrotyrosine 14
videoconferencing 14
uncertainties 14
Quervain 14
B6, 14
Resection 14
plasma-cell 14
type-I 14
simulation, 14
detections 14
Mixed 14
Length 14
(OSA), 14
Expected 14
concealed 14
bioenergetics 14
mtTFA 14
T(3), 14
hormone-responsive 14
(95%CI: 14
Microdeletions 14
Drp1, 14
staurosporine 14
XRCC3 14
Saudi 14
non-canonical, 14
5'- 14
Cranberry 14
dyscrasia. 14
Stbd1 14
AgSwe1p 14
kinase), 14
CTGF. 14
CTGF, 14
blood-pressure-lowering 14
Disease: 14
skeleton, 14
edible 14
Marine 14
ultrasonography. 14
ribosomes, 14
kg. 14
neonatal-onset 14
2.7% 14
(GPi) 14
Wisconsin 14
dimerize. 14
(NF-kappa 14
(VHL), 14
hSDH5), 14
dislocated 14
nonsmall 14
non-dividing 14
capsule. 14
sufficiency 14
4-8 14
carbamylated 14
tags, 14
Episodic 14
permeation 14
2-7 14
Fulvestrant 14
arthralgias 14
Hof1 14
(RMS) 14
Rad53 14
AND-1 14
bounded 14
AMs 14
(A-to-I) 14
illumination. 14
organ-specific 14
B73 14
co-segregated 14
excels 14
convexity 14
Cep135/Bld10 14
microcephalic 14
(PCI). 14
CLR 14
fixation, 14
presenilins 14
sensitivity-inducing 14
1980s 14
Transitional 14
Memory 14
deterministic 14
neurotoxin, 14
areata 14
R-M 14
transferring 14
c-Ski/SnoN 14
Stain-Free 14
bid 14
Guillain-Barre 14
relapses. 14
(MFS). 14
neurologists. 14
haematopoiesis 14
PRC2, 14
5637 14
Nascent 14
hindlimb 14
responsible, 14
BAK 14
Anesthesiologists 14
midazolam. 14
PONV 14
longevity, 14
(16%), 14
reestablished 14
validations 14
(28%), 14
CD44v8-10 14
naevi 14
(M. 14
Life, 14
urodynamically 14
anticitrullinated 14
Alteration 14
CSF-1-induced 14
peach 14
fever: 14
Immediate 14
scuba 14
Genet. 14
empirically-derived 14
fear, 14
radionuclide 14
Hakim 14
resistant, 14
glucose-regulated 14
techniques: 14
Transposition 14
moderate-severe 14
(ZEB2) 14
(SIP1). 14
login 14
accessible. 14
text-based 14
Suite 14
cilia. 14
(MCI) 14
cholangiocyte 14
I2 14
University, 14
EP2 14
patellae, 14
oncological 14
CoCl2 14
C-phycocyanin 14
each, 14
algae 14
bright 14
Phospho-α-Syn 14
PLK2-mediated 14
(EDMD) 14
Approaches 14
scapuloperoneal 14
soma. 14
FSR 14
modules: 14
focus, 14
SHh 14
iron-sulfur 14
Trr 14
SE, 14
auto-regulatory 14
Prolactinoma 14
uracils 14
rediscovered 14
restraint 14
arrive 14
FANCB, 14
barbiturate 14
NFL, 14
T-tau, 14
Pressure 14
stress: 14
MSP 14
anergic 14
RRM1 14
nestin, 14
SSIs 14
[p 14
interneurons. 14
oligodeoxyribonucleotide 14
Cytosine 14
CNEs, 14
urochordates, 14
duplicates 14
Enalapril 14
ventilation, 14
doxorubicin-treated 14
breath, 14
methods) 14
preadipocytes 14
DM, 14
electrocardiogram, 14
HIF-1α, 14
Inhibitors. 14
hypopigmented 14
leiomyoma 14
cerebello-oculo-renal 14
(NPHP6) 14
Breaks 14
methacrylated 14
lacS 14
transitions, 14
cannabinoid 14
IHF 14
Thermotoga 14
two-sided 14
anti-migraine 14
photosensitizing 14
Knife 14
survivals 14
(Gliadel 14
52-year-old 14
inhibitor-1, 14
identifiers 14
Leigh 14
arm) 14
meningioangiomatosis 14
peri-implantitis 14
active-site 14
paravertebral 14
Opinion 14
Sick 14
Predictor 14
MID 14
Reading 14
Ficolin-1 14
(collectively 14
Lys(36) 14
Therapy. 14
anti-programmed 14
(NLR) 14
drawn. 14
hyperlipidemia, 14
deiminases 14
CID 14
non-smokers, 14
notified 14
hairs. 14
TAC-FH. 14
histidine-rich, 14
RyR1, 14
HRCBP 14
surgical, 14
(Naxos 14
rimmed 14
damage-inducing 14
foamy 14
hypersomnia, 14
downstream-regulated 14
# 14
2a, 14
See 14
curation, 14
contig 14
nephrolithiasis 14
IFT-A 14
(ATD; 14
Sensenbrenner 14
IFT-B-encoding 14
MZSDS. 14
ift172 14
myelosuppression 14
tabalumab 14
Biogen 14
blastocysts 14
hybrid, 14
Butterfly 14
G1202R 14
(G-CSF), 14
cdk5 14
GPU 14
TRIAC 14
PITX1 14
locomotion 14
H2A.Z, 14
(ACPA) 14
erosive 14
∼50% 14
∼1 14
(IR 14
II-transcribed 14
"off" 14
polymerized 14
(DP) 14
BACE-1 14
303 14
peroxidases 14
Tocilizumab 14
VE, 14
transFold 14
polydactyly 14
Pleiotropic 14
Treslin/TICRR 14
dyad 14
transportation 14
uvrC 14
Ramsay 14
venoplasty 14
impulses 14
Insufficiency 14
cerebro-spinal 14
ethically 14
erythro-megakaryocytic 14
leprosy, 14
1B) 14
(TOP2A) 14
rafts. 14
[Ca(2+)]i 14
stunted 14
86%), 14
amoxicillin. 14
WAT 14
49) 14
democracy 14
(Integrated 14
Analysis). 14
expression/chromatin 14
LMO2-C 14
patient; 14
(enrichment 14
(ASDs), 14
(estrogen-related 14
Dax1-interacting 14
FeNO 14
PAI-1 14
nm23 14
vaginosis 14
Thrombolysis 14
fibrinolysis 14
haemodynamically 14
signal-responsive 14
KSR 14
Originally 14
Menkes 14
HESX1 14
p105. 14
coproporphyrin 14
Abundant 14
piwi 14
(15-20%) 14
Nursing 14
proof-of-mechanism 14
overproduce 14
proliferation/apoptosis 14
(http://pptp.nchresearch.org/data.html). 14
µM, 14
Wilms, 14
Peg-IFNα 14
World. 14
flaviviruses. 14
Portugal, 14
Antibiotic 14
h-L 14
DUSP5 14
outlining 14
STARR-seq. 14
sciatica. 14
Oswestry 14
ER-negative 14
40.9%) 14
arteritis, 14
(ESCC). 14
miR-146b 14
symposium 14
miR-31 14
(pri-miRNA) 14
ligamentous 14
Miller-Dieker 14
1-42 14
(parts 14
SPAN-100-positive 14
(TPM3), 14
pregestational 14
Trichomonas 14
FLOWERING 14
SWD, 14
fiber-like 14
DPSCs 14
30.3% 14
red-cell 14
snoring 14
(sensitivity: 14
alisertib, 14
(MLN8237) 14
megabases 14
shorter, 14
count) 14
Turkey 14
(T2D) 14
cyclases 14
(Neu5Gc), 14
IAVs 14
Flk-1(+) 14
MRS. 14
P383L) 14
c-abl 14
imprecise 14
non-MHC 14
APOBEC3H 14
RyR2(R420Q) 14
histone-based 14
Grappa 14
dermcidin 14
hematoma. 14
months" 14
subthreshold 14
candidate-gene 14
PADI-4, 14
(TNF)-α, 14
LH6 14
PLE 14
trametinib 14
.02), 14
675 14
antimuscarinic 14
OAB. 14
genome" 14
headings. 14
indexer 14
NLM 14
NLM's 14
indexer. 14
SG-positive 14
Epidural 14
ephrins 14
EPHB6 14
simulating 14
reflex. 14
Noxious 14
unanesthetized 14
tropicamide 14
p100, 14
ALK2 14
PsycINFO, 14
PFM 14
prion-related 14
hemophagocytic 14
(LYST) 14
mink. 14
SPS1 14
FPN 14
IFNα 14
multi-purpose 14
Original 14
Tcf3 14
(PR 14
MutM, 14
Wallerian 14
Ninety-three 14
CD95-induced 14
candidiasis. 14
subluxation, 14
GALC-PS 14
alignment-free 14
nonsyntenic 14
exception, 14
TYR, 14
VLDL 14
(Tpl2) 14
hematotoxicity 14
(partial 14
vitiligo. 14
impurity 14
nonmotor 14
SMN. 14
nuisance 14
Elephant 14
H19/IGF2 14
PSP. 14
s(x) 14
non-varsity 14
panreactivity 14
myeloma]. 14
InterPro 14
dioica 14
Low-grade 14
angiosarcoma. 14
0.25% 14
DH, 14
SIRT1-∆Exon8 14
TRA2β 14
Gli2 14
co-evolves 14
immunoactive 14
sadness 14
Ogt 14
GC-->AT 14
C:G, 14
(TSS). 14
calls. 14
pro-inflammation 14
GA-rich 14
(Oncotype 14
DUF1618 14
disabling, 14
cixutumumab 14
selumetinib. 14
Microneedling 14
(P. 14
canis 14
calcium/calmodulin 14
ethanolic 14
DEXA 14
CSF1 14
all). 14
alkalosis 14
5-Aza-CdR 14
Trim37 14
(BMP) 14
ß-catenin 14
DF, 14
unrecognised 14
poly(adenosine 14
[ADP]-ribose) 14
barcoded 14
100907 14
Alu, 14
oligodendrogliomas 14
TSD 14
DISCORE 14
reptiles, 14
CTCFL 14
melo 14
αIISp 14
Thr11 14
Par-4 14
I-cell 14
INK4a/ARF 14
dynamic-programming 14
tympanograms 14
CRSP 14
Avsunviroidae 14
Sclerostin, 14
equalization 14
digestions, 14
MC, 14
homozygous, 14
lymphoedema 14
Be 14
veliparib, 14
pHGA 14
intermedius 14
MRgFUS. 14
DT 14
thalamotomy. 14
CARMEN, 14
TOWER 14
(PASI-75) 14
NOX2 14
antihormonal 14
avelumab-mediated 14
(ZIKV) 14
RNA-sequencing 14
pemphigus 14
INCA: 14
Win32 14
Hsp104 14
PrP(Sc) 14
Workshops 14
phentermine/topiramate 14
[SE 14
SINEUP 14
anthrax, 14
bioterrorism 14
CBMF 14
aprotinin 14
rheumatological 14
PROs 14
pitavastatin 14
Sperm-associated 14
unprotected 14
NTF 14
PS2, 14
Pen-2 14
NCT, 14
optineurin 14
multisutural 14
AOM 14
Slitrk1 14
(constitutive 14
COP10 14
chromDraw 14
pox 14
p47(phox) 14
p22(phox) 14
SNAI2 14
Mitf(Mi-wh) 14
/+ 14
intralesional 14
plasmepsins. 14
spa 14
Phosphodiesterase 14
(Bexsero®) 14
autoerythrocyte 14
APP(SW) 14
APP(LON) 14
3,4-diaminobenzoic 14
BV-2 14
Northeast 14
(Yakutian) 14
2015) 14
unilocular 14
CIDE 14
coloration 14
54. 14
(SLC40A1). 14
hyperferritinemia 14
macrophage-type 14
+/b 14
CBSs 14
3D-CRT, 14
INDEL 14
microphthalmia. 14
OCA1B 14
transsulcal 14
Swc4p 14
Siltuximab: 14
glucosylation 14
unintelligible 14
interpretation: 14
subdivisions 14
clouds 14
Plus 14
assassin 14
JBP2, 14
JBP1, 14
J-synthesis. 14
eczema? 14
plaque-type 14
clone-derivation 14
(MK-8931) 14
Pta1, 14
noncompaction. 14
Methylenetetrahydrofolate 14
MTHFR, 14
B-ALL. 14
PDS5 14
rilonacept 14
0.24; 14
ATR-16 14
genu 14
yippee, 14
MPE-seq, 14
ESTEEM 14
(pre-RC). 14
ARHR. 14
BWA-MT 14
Latent 14
chAB4 14
DAVF 14
TIMELESS 14
(IRVAN) 14
disoproxil 14
Asf1. 14
anti-silencing 14
Lucinactant 14
SRT 14
Auts2, 14
Nr4a2, 14
Sox5 14
XUTs, 14
Dbp2 14
inter-TADs 14
enzastaurin, 14
formant 14
interferonopathies 14
lomustine, 14
GFRAL 14
tenosynovitis 14
RIG-I 14
neparvovec 14
Challenges, 14
GenomeVIP's 14
buprenorphine, 14
Ozanimod, 14
Sphingosine-1-Phosphate 14
ozanimod, 14
ICHs 14
GRFs, 14
archaic 14
Trichophyton 14
erythrasma, 14
corynebacterium 14
recount 14
PARP1- 14
invitro 14
Circ-FBXW7 14
metacentric 14
subscale, 14
SBQ, 14
CancerSubtypes, 14
CancerSubtypes 14
computing, 14
exudates, 14
lycopersici. 14
Deriving 14
caller's 14
input- 14
Supplement_3. 14
"BBCAnalyzer". 14
(MP4 14
11571 14
HGNC, 14
UCSC, 14
miRBase). 14
hyperpronation 14
Fremanezumab 14
check-point 14
GRP 14
CT-falciform 14
(Odocoileus 14
Presepsin 14
Uc.160 14
Probe-to-bone 14
REDUCE 14
StereoGene 14
5-HT6 14
measles. 14
42-day 14
ExpansionHunter 14
Atg8-interacting 14
(Amblyomma 14
Emicizumab 14
gallstones 14
HAT. 14
GFF, 14
BED, 14
PSL, 14
SQL 14
retrieves 14
gzip 14
FTP/HTTP 14
calciphylaxis, 14
DIRAS3 14
Dinutuximab: 14
RGS6 14
R142H, 14
ASPD 14
anxious-depressive 14
H4S47C-anchored 14
complex; 13
C-->T 13
samples) 13
CVs 13
ECE1, 13
Hypoventilation 13
brain-related 13
hormone-induced 13
EC(50) 13
papilin 13
cassette, 13
fighting 13
6.4 13
Osteoprotegerin 13
(OC) 13
Semaphorin 13
bioequivalence 13
white, 13
dysregulations 13
miR-26a, 13
let-7i 13
twenty-one 13
pre-operative 13
(MG) 13
control), 13
cement 13
remain, 13
nomogram 13
Lifestyle 13
advisable 13
compression, 13
horizon 13
0.49 13
raloxifene, 13
realized 13
ofatumumab 13
58-year-old 13
keratotic 13
liposarcoma. 13
retroperitoneal 13
65-year-old 13
fingers, 13
68-year-old 13
class-I 13
Jagged1 13
septa 13
saw 13
clarifying 13
historic 13
cabazitaxel. 13
0.53 13
0.0001; 13
extra-cellular 13
Affibody 13
sublines 13
dearth 13
non-toxic 13
fostered 13
receptor-2 13
afford 13
micrometastatic 13
spindles, 13
retrieval. 13
Paraffin-embedded 13
DU 13
(AI) 13
accrued 13
microtubular 13
bcl-2 13
MIA 13
tumor) 13
mixed-lineage 13
reinitiation 13
feeder-free 13
delicate 13
NANOG, 13
1.14 13
dozen 13
Chromosome-centric 13
HPP 13
comprehensive, 13
microarrays, 13
antigen) 13
GFAP, 13
Homology 13
322 13
BEAUTIFUL 13
(HR), 13
HR. 13
contraindicated. 13
hepatitis, 13
obvious. 13
Leigh's 13
(author's 13
transl)]. 13
systems: 13
multimolecular 13
Retinal 13
fluorescein 13
97, 13
Triadin 13
caffeine, 13
depolarization-induced 13
KEKE 13
(SR), 13
ventricles, 13
analyte 13
recoveries 13
culminated 13
10(-8) 13
atrium. 13
mM, 13
left-handed 13
Peptides 13
achalasia. 13
(4.5%) 13
non-verbal 13
minimal. 13
lipopolysaccharide-induced 13
estrogen, 13
p38MAPK 13
scheme. 13
heating 13
tangles. 13
post-stroke 13
(HO-1) 13
(mitogen-activated 13
c-Fos 13
mode, 13
JAK/STAT 13
PI3K, 13
levetiracetam 13
saliva. 13
AED, 13
duloxetine, 13
Relation 13
assembled, 13
NFkappaB 13
arteriolar 13
diarrheal 13
contraceptives. 13
max) 13
cage 13
alpha-MSH 13
conducive 13
control: 13
finishing 13
dynactin 13
analysis). 13
maternal-to-zygotic 13
(31% 13
.003), 13
[range, 13
13%, 13
Designing 13
visually 13
vagina 13
doctor 13
PID 13
probability, 13
internet 13
Taiwan, 13
ml(-1), 13
12-24 13
purported 13
mug/L 13
workload 13
2,500 13
urea. 13
Pre- 13
LAD 13
(RRs) 13
0.06). 13
Bay 13
289 13
1.20 13
(ORs), 13
confounders. 13
Fibromyalgia 13
23) 13
Communication 13
single-blinded 13
acceptance, 13
writers 13
prognoses 13
23. 13
hoarse 13
(Q2W) 13
Q2W 13
coefficient, 13
ofatumumab, 13
Evolocumab, 13
transaminases 13
endorsed 13
kexin 13
(antisense 13
[5 13
36%, 13
atorvastatin, 13
henceforth 13
(snoRNAs), 13
ncRNAs. 13
Conservation 13
sulfhydryl 13
deoxycytidine 13
dihydrocytosine 13
ploidy 13
ICM 13
vincristine 13
cm3 13
mucositis 13
1:2 13
[32%] 13
Pre-treatment 13
unstable. 13
Fragile 13
Cell, 13
sporadically. 13
(MEN2) 13
Forty-three 13
TNNC1 13
19-year-old 13
(corresponding 13
SL 13
Ca2+-free 13
Tobacco 13
131 13
Eye 13
started, 13
Descriptive 13
education. 13
behind. 13
responsibility 13
exquisite 13
cell-types 13
di-, 13
production; 13
E3-ubiquitin 13
GV1001, 13
(n=6) 13
permuted 13
[8%] 13
(34 13
fluorodeoxyglucose 13
beta-Trcp 13
beta-catenin. 13
(nuclear 13
5-FU 13
(peak 13
factor-I 13
HGF, 13
abortion, 13
prematurity, 13
0.94). 13
pandemic. 13
SGA 13
6.4% 13
oseltamivir, 13
self-limited 13
dysgenesis. 13
NKX2.1, 13
SFTPB, 13
(NKX2-1/TITF1) 13
(CH), 13
(IRDS) 13
(BHC). 13
61%. 13
16th 13
transcutaneous 13
maps, 13
oncolytic 13
primary, 13
<4 13
micromol/L). 13
Biologics 13
polarized, 13
dupilumab. 13
hypotonia. 13
medially 13
OSE2 13
ears. 13
ray 13
NIH3T3 13
Msx2 13
designate 13
neuroblastomas, 13
investigator-assessed 13
conclusively 13
(PDS) 13
aqueducts 13
glycosuria 13
hyperglycaemia. 13
agents; 13
BP. 13
11-fold 13
spectrometer. 13
(OCT) 13
metrics. 13
bicarbonate 13
microgram 13
∼30% 13
nephropathy, 13
health-care 13
covariance 13
p<0.01). 13
Normalization 13
Caucasian, 13
374 13
desmosomes 13
ichthyosiform 13
sebaceous 13
150-mg 13
reaction-based 13
2C19*2 13
drug-eluting 13
RT/TMZ 13
14.6 13
13.6 13
1.49; 13
thrombopenia 13
rescuing 13
IBRO. 13
MTORC1 13
tuned 13
tetracycline-inducible 13
algal 13
(PG) 13
β-lactam 13
(2004) 13
lysis. 13
D-alanine 13
PFS-6 13
point) 13
12%, 13
permanently 13
institutions. 13
BEV 13
passages. 13
tangles, 13
socially 13
pre-morbid 13
backward 13
Discussion 13
(TTP), 13
immunosuppression, 13
(5), 13
Norway 13
eQTL 13
EAE. 13
synaptophysin 13
Gtl2 13
estrogen-regulated 13
Cornelia 13
NAD 13
repertoire, 13
Bimolecular 13
Protein-protein 13
tutorial 13
alleviation 13
myosin, 13
TPM1, 13
16p13.3 13
arteriosus 13
daughters. 13
planta 13
(PAR-CLIP) 13
(CLIP) 13
thyrotoxicosis. 13
TPOAb 13
propylthiouracil 13
continued. 13
(CGA) 13
swings 13
joint, 13
females; 13
0.30 13
Relationships 13
tone, 13
CP, 13
indexed 13
brachial 13
neurofibromas, 13
UAG 13
SeP 13
P, 13
Decisions 13
Calcium-responsive 13
sarcoma/translocated 13
PFN1 13
mutating 13
futsch 13
entrapped 13
attendant 13
STEMI 13
Potentially 13
formed. 13
153 13
causation 13
high-calorie 13
translates 13
mannose-6-phosphate 13
up-regulation. 13
Synechocystis 13
selected, 13
Cylindromatosis 13
neuron. 13
Cross 13
(SMA), 13
externalized 13
(CaM 13
CPEB 13
CaMKII. 13
ERK1/2. 13
normally, 13
calmodulin. 13
Fifty-seven 13
Resulting 13
Italy. 13
sister. 13
CCM2 13
Branchiostoma 13
thymus, 13
telophase, 13
observed: 13
SHBG 13
(PLB), 13
thyroidectomy, 13
gliptin 13
bromocriptine, 13
dutogliptin, 13
(3). 13
minimal, 13
[RR 13
neutrality 13
(overall 13
Amantadine 13
disability) 13
Children, 13
effects: 13
NETs, 13
odor 13
I: 13
(HC) 13
averaging 13
1.56 13
remedy 13
pre-synaptic 13
heated 13
ecotypes 13
ubiquitin/proteasome 13
capability. 13
beta-galactosidase, 13
lacO 13
lysine-methylated 13
homologue. 13
single-chain 13
No. 13
>40% 13
SPOCK1 13
pairs) 13
multimerization 13
Box 13
semicircular 13
non-responsive 13
removal, 13
abilities, 13
neurogenesis, 13
otoacoustic 13
F2 13
side-chain 13
Swi6/HP1 13
Congestive 13
velocity. 13
tachyarrhythmia 13
CE-CMR 13
ethidium 13
(ALL) 13
TIEG1, 13
HHT 13
Bcl-XL 13
Bcl-2/Bax 13
KLF10 13
papilloma 13
NFATc1 13
c, 13
fusion/fission 13
persistence. 13
88-kDa 13
cristae. 13
lipolysis. 13
protector 13
Methylation-specific 13
EAAT2, 13
2-related 13
2-h 13
(P<0.01) 13
season. 13
cis, 13
CDR1as) 13
Atherosclerosis 13
191 13
(13%), 13
(71 13
misrouted 13
C>G 13
(0.3 13
P<0.01). 13
(MDA) 13
502 13
LP 13
free-radical 13
sport. 13
whey 13
A; 13
unaffected, 13
over-express 13
utility, 13
observer 13
mono-, 13
glycosylphosphatidylinositol 13
(H3K27me3), 13
H4K20me3. 13
REST 13
Pivotal 13
precluding 13
cancer), 13
(MDS), 13
cytopenias 13
patient: 13
Dissection 13
(I/R) 13
eosin 13
ischaemia/reperfusion 13
fulfil 13
(PDCD4) 13
libitum 13
β-galactosidase 13
CR. 13
5; 13
0.012) 13
(mammalian 13
0.02, 13
N-acetylneuraminic 13
(ICH). 13
(FXa) 13
non-inferior 13
too. 13
though, 13
Bleeding 13
unphosphorylated 13
cotranscribed 13
Especially, 13
closing 13
doubles 13
gum 13
myelodysplasia 13
SIP1) 13
HU. 13
5TGM1 13
pits 13
epitopes, 13
CR, 13
~100 13
finger, 13
Species-specific 13
confidence, 13
cart 13
654 13
NONO 13
dimer, 13
Arsenic 13
(D) 13
Carfilzomib- 13
oprozomib-induced 13
ring-shaped 13
RF-C(Ctf18/Dcc1/Cft8), 13
RFC1-like 13
Ctf18p 13
RF-C, 13
RF-C 13
RF-C(CTF18) 13
(GREAT) 13
1-10 13
collaboratively 13
2-step 13
HR-related 13
betaPV 13
muscle-invasive 13
0.016). 13
Rho/ROCK 13
Sodium-glucose 13
Pharma 13
EU. 13
Agency. 13
(SGLT) 13
(TSH 13
(+/-SD) 13
Outpatient 13
FHC. 13
UV-damaged 13
dihydrofolate 13
Reversion 13
nicking 13
formaldehyde 13
deficient, 13
encountering 13
error-free 13
repair-proficient 13
neurofibromatosis, 13
neuroimaging, 13
transthoracic 13
17q25. 13
haplotype. 13
aphasia 13
adsorption 13
three. 13
lobe, 13
immunosuppression. 13
TNFRSF1A 13
breath. 13
bedside. 13
October, 13
tropisetron 13
on-pump 13
h(-1)) 13
18%, 13
devices, 13
operations. 13
preoperatively, 13
values: 13
retrieving 13
NAEβ 13
NF-κB. 13
cocultured 13
prognosis-signature. 13
0.023). 13
hippocampi. 13
AP-1, 13
reproducible, 13
pages 13
transgene, 13
polyA 13
Atlas. 13
trials) 13
0.94; 13
0.78; 13
pros 13
(COPD) 13
robust. 13
ideation 13
Author. 13
Postnatal 13
baby. 13
unavoidable 13
thirteen 13
57%, 13
histochemical 13
13-cis 13
(6), 13
noncovalent 13
Mdm2's 13
ways: 13
topotecan 13
incision. 13
isozyme 13
hydrodynamic 13
II-mediated 13
N-acetyl 13
in: 13
complex' 13
HT-29 13
gadd153 13
three-repeat 13
10-week-old 13
Density 13
saturable 13
jejunum 13
pigs, 13
(gene-unrelated 13
"orphan" 13
CGIs). 13
intron, 13
CBB 13
photocoagulation 13
cubense 13
banana, 13
percent) 13
synostosis: 13
Locally 13
kinase-3 13
podosomes 13
crisis, 13
thionamides 13
awaiting 13
Myocyte 13
DD 13
Sixty-one 13
Shortness 13
(IGF-1) 13
(T3). 13
patient-years, 13
small-scale 13
Tor 13
mural 13
(ITP) 13
cytotoxin-associated 13
anti-H. 13
immunoassay. 13
pylori. 13
Index. 13
Characterizing 13
cyclical 13
Chi-square 13
GERD, 13
promise, 13
standard, 13
comments 13
3.1% 13
efficiencies. 13
gangliosides 13
multimer 13
radiologically 13
tonsillitis 13
sided 13
Unilateral 13
ridge 13
cooccurrence 13
K27me3 13
Lys36 13
dose-adjusted 13
Asians, 13
rivaroxaban-treated 13
mg/day; 13
(Rivaroxaban 13
14.5 13
1.51 13
0.89, 13
1.01, 13
SPIKE 13
door 13
PLIN1 13
new-generation 13
resolutions 13
laser-induced 13
PS, 13
(PCA) 13
222 13
multi-dimensional 13
facile 13
cost-utility 13
meaningful. 13
high/low 13
(subcutaneous 13
HIF1A 13
RC 13
phenobarbital 13
This, 13
hemodialysis. 13
(Human 13
cue 13
Sedation 13
image-based 13
manufactured 13
Neck 13
antenna 13
hamper 13
suspended 13
Dimensional 13
macroporous 13
throughput, 13
dyspareunia. 13
predose 13
52-week, 13
zone, 13
risen 13
recipient. 13
(HADS). 13
outlined. 13
tubes 13
kyphosis 13
successively 13
corticospinal 13
syndromic. 13
51), 13
214 13
infinity 13
potentials, 13
node. 13
transmitter 13
diplopia, 13
transbronchial 13
SCLC, 13
FDG-PET 13
ribosomally 13
corrective 13
micropupil 13
ageing, 13
transposon, 13
TIR 13
VP-16. 13
essence, 13
tumour-suppressive 13
p21Cip1 13
(Hb) 13
legacy 13
chemical, 13
0.28 13
NK-cell 13
PD-1, 13
Asp 13
cDNAs. 13
(isoform 13
frame. 13
Rac, 13
oligopeptide 13
neocortex, 13
Rs75932628-T 13
samples). 13
illuminated 13
granzyme 13
(CHF), 13
Metabolism 13
intertrabecular 13
273 13
(3, 13
deposits, 13
Malformation 13
live-born 13
18), 13
Wales 13
Incidences 13
(over 13
NMD, 13
interdependence 13
GW182, 13
vanished 13
mitotically 13
SIFT, 13
non-neuronal 13
microbiological 13
three-fold 13
nigral 13
drosophila 13
pars 13
ubiquitin-protein 13
dyskinesias. 13
reentrant 13
failure) 13
sodium-calcium 13
(OXPHOS) 13
catabolism, 13
paradigm, 13
idea, 13
(t 13
STAT5 13
hTERT, 13
(PDGF) 13
protuberans 13
transcripts; 13
Ph-positive 13
(GIST). 13
rationally 13
Novartis) 13
was: 13
interferon, 13
20-25% 13
thrice 13
CCR 13
11.2 13
AA21004) 13
(NNT) 13
buspirone 13
(1:1:1:1) 13
BeadChip 13
imprinted. 13
Parametric 13
Imprinted 13
medaka 13
you 13
housed 13
chemistry. 13
746 13
littermate 13
streptozotocin-induced 13
favouring 13
N-acetylcysteine 13
resuscitated 13
resuscitation 13
nonpenetrating 13
chest, 13
sheep. 13
AtLon1 13
(GAN), 13
neuron-glia 13
Dynamin 13
Np73 13
gamma, 13
FRE1 13
K-Ras, 13
glycosylation, 13
tryptamine 13
Hypothyroid 13
Alemtuzumab, 13
253 13
mild-moderate 13
(OCD) 13
OCD, 13
bone-marrow 13
T- 13
CAMPATH-1H. 13
conditioning. 13
Passive 13
clearance) 13
Unfortunately 13
revert 13
Neuropathology 13
equations. 13
correlated. 13
organising 13
membership 13
methicillin-susceptible 13
saturation. 13
distributes 13
behavioral, 13
cadherin 13
AUTHORS. 13
Vimentin 13
Id2 13
(DRM) 13
25-30% 13
core, 13
scans. 13
bedtime 13
interrogated 13
mononucleosomal 13
multivalent 13
(61% 13
Uranium 13
525 13
(CNEEs), 13
FVC 13
INPULSIS-2. 13
61.5% 13
(240 13
GLUT4 13
(FKBP12.6) 13
-ATPase 13
IMS. 13
paresthesia, 13
noticeably 13
toe 13
2,4-D 13
complexity, 13
ligated 13
neonatally 13
oligodendroglioma 13
periphery, 13
76%. 13
varicella-zoster 13
rate) 13
trout 13
Chargaff' 13
deviations. 13
Scholar 13
self-perceived 13
resin 13
0.0% 13
postintervention 13
mindfulness-based 13
men's 13
attendance 13
justified. 13
(CAP) 13
controls), 13
function) 13
dysmorphisms 13
(ACTH) 13
NHSII 13
(TFs), 13
prices 13
substantive 13
PMS 13
18-45 13
30%. 13
consent. 13
retinopathy. 13
Simultaneously, 13
angiogenin, 13
(like 13
scoliosis. 13
Inuit 13
satisfaction, 13
Implication 13
Incontinence 13
chance. 13
arrange 13
GII 13
deadenylases. 13
Mn(2+) 13
catalysed 13
nucleotides) 13
mRNP 13
(44% 13
therapeutically. 13
ORF2 13
itch 13
heteroplasmic 13
freckling, 13
Gy) 13
hopes 13
K1 13
non-metastatic 13
CTC 13
nonmetastatic 13
curriculum 13
0.95 13
supplying 13
modest, 13
N(6)-methyladenosine 13
(CLL), 13
succeed 13
4-19 13
(QALYs) 13
QALYs 13
Definition 13
sildenafil. 13
(PAH), 13
Gender 13
9.2% 13
mono-associated 13
co-infected 13
Anti-inflammatory 13
(PF) 13
[Surgical 13
26-year-old 13
(HDAC1) 13
PML, 13
PDEF 13
CA-125 13
France) 13
MDR-1 13
Changing 13
myc 13
turns, 13
LILACS 13
scale) 13
duplications, 13
nephrotoxic 13
neurites, 13
hypothalamus. 13
medulla. 13
boutons 13
bowel, 13
parvovirus 13
(13) 13
0.05]. 13
MTMR2, 13
myotubularin. 13
(160 13
P=0.04). 13
minimum, 13
Situs 13
(HDL) 13
better. 13
clomiphene 13
0.011) 13
IVF/ICSI 13
oligomenorrhea 13
benchmarking 13
crucial, 13
workflows. 13
irreversible, 13
MSH2, 13
Service, 13
(version 13
depression) 13
(P=0.03). 13
moderate/severe 13
Presentation 13
fluticasone 13
reslizumab 13
medium-chain 13
Epilepsy, 13
KIF1B 13
bacteremia, 13
ANC 13
rhGM-CSF 13
school, 13
(JLNS) 13
Nigerian 13
Caucasians, 13
January, 13
surfaces. 13
p44/42 13
PDK1 13
DEPTOR 13
oxLDL-induced 13
NAD-dependent 13
trophozoite 13
SLACK 13
Incorporated. 13
ectasia. 13
PTK 13
mean, 13
thinner 13
biotherapeutic 13
analgesia, 13
ADRs 13
(glioblastoma 13
calcium-free 13
taurine. 13
EDTA 13
Canine 13
Study, 13
domain-like 13
desipramine 13
alpha-2 13
DMARD 13
cast 13
ENT 13
neuroinflammation. 13
him 13
immunosuppressed 13
RTT, 13
(miRNAs). 13
emerging, 13
UCP3 13
VKORC1, 13
Resolution 13
Jews, 13
valves. 13
Carolina 13
Angiogenin 13
angiogenin. 13
Invokana 13
(GD). 13
(GC), 13
glucocerebrosidase. 13
D409H 13
progressive. 13
elsewhere, 13
puzzling 13
Mutated 13
recipients, 13
saliva, 13
Sal-like 13
(SALL4)-mediated 13
LDB1, 13
(LSD1-kd) 13
granulopoiesis, 13
monopoiesis, 13
Extramedullary 13
reversion, 13
Hoxa9 13
HSC/progenitor 13
Gfi1b-negative 13
Gfi1b:GFP 13
RE1 13
ADHD. 13
Damage 13
SGS. 13
connective-tissue 13
long-chain 13
Netherton's 13
codon-optimized 13
epidermis, 13
microstructural 13
Mice. 13
Weak 13
major, 13
intrapulmonary 13
loses 13
CO, 13
MTB 13
Mycobacterial 13
tube. 13
0.044). 13
mmol/l, 13
IR. 13
anti-diabetes 13
no. 13
carboxylases 13
overexpressed. 13
fgf8 13
Teleost 13
transposon-based 13
97.3% 13
(US) 13
two-photon 13
hypotensive 13
Ser-16 13
pore, 13
(SERCA 13
remotely 13
Enrollment 13
BRAFV600E 13
DOT1L. 13
parasitemia 13
oxide, 13
myocyte-specific 13
rs2736100 13
(37 13
DMARDs 13
(CP-690,550) 13
scintillation 13
FANCL 13
10-15% 13
Catholic 13
Sindbis 13
integrin-dependent 13
protrusion 13
COX2 13
cardiomyogenesis 13
vicious 13
puncture, 13
(SYK) 13
megabase-sized 13
Prophylaxis 13
cardiomyogenic 13
sentinel 13
transdifferentiation 13
VIC 13
anastrozole. 13
SEGAs. 13
forces, 13
EPI 13
CaSRs 13
detailing 13
multi-functional 13
monocytogenes 13
subtractive 13
destabilization. 13
schizophrenia: 13
floxed 13
slit 13
hepatomegaly. 13
(EC50 13
delta, 13
d-tubocurarine, 13
vecuronium 13
epsilon, 13
waveform 13
GABAA 13
non-24-hour 13
mechanotransduction 13
radially 13
wraps 13
Microtubule 13
tyrosine-phosphorylated 13
TGCT 13
carcinogenesis; 13
NPC. 13
riociguat 13
sGC 13
survey, 13
Recommended 13
Lenalidomide 13
(AA), 13
unliganded 13
propranolol, 13
ischaemia. 13
upregulated. 13
thymosin 13
periodontitis. 13
vasoconstrictor 13
PABP4 13
site) 13
biofeedback 13
prefer 13
pre-initiation 13
machineries. 13
app 13
(autosomal 13
ROCK2 13
63-year-old 13
PGC-1alpha 13
Seipin/BSCL2 13
renal-cell 13
PVN 13
DRP1 13
leverage 13
FANCF, 13
isradipine. 13
synchrony 13
milieu. 13
80.5%, 13
paresthesias 13
dura, 13
losartan 13
Lagocephalus 13
Takifugu 13
snails 13
tetranucleotide 13
Vasospasm 13
transaminase. 13
Subarachnoid 13
Atorvastatin 13
269 13
triple-H 13
impression 13
viscous 13
intractable, 13
hypertonic 13
necklace 13
(rDNA) 13
(France). 13
brachydactyly, 13
glaucoma, 13
Alternating 13
intermediate-frequency 13
? 13
in-vivo 13
reclassification 13
hCtf4-CMG 13
And-1/Ctf4 13
Mcm10, 13
modulators, 13
(59%). 13
[Therapeutic 13
septa. 13
ARMS 13
hyperinsulinemic 13
supervision 13
text]-space 13
linear-space 13
(CFTR) 13
retroposition 13
etiolated 13
H3K9me2-containing 13
ZMET2 13
zero, 13
plotted 13
radiosurgical 13
resect 13
validated. 13
domain-specific 13
(sPLA2) 13
(6.1%) 13
2.45 13
craniectomy, 13
donepezil 13
demand. 13
synchronization 13
λ 13
1970s, 13
abortive 13
Means 13
CIs 13
Frontotemporal 13
Interim 13
(CRP), 13
CD44s 13
(HNSCC) 13
escalation. 13
70,000 13
Icaritin 13
JAK1/2 13
pSTAT3 13
myogenin 13
Pupillary 13
King 13
Memorial 13
plotting 13
Mtm1 13
HIV-1-infected 13
0.4) 13
"oncogene 13
sugammadex 13
Gsdma 13
Cu 13
(HFD) 13
BBE 13
miR-16, 13
(PCR)-based 13
miR-939 13
canthal 13
14.3 13
Scandinavian 13
Database, 13
4.5, 13
RF-positive 13
non-catalytic 13
Cap 13
401 13
Septin 13
Tsc1(-/-) 13
spectra, 13
ataxin-2 13
apple 13
Uganda, 13
hepatosplenomegaly 13
web, 13
annotators, 13
pHMMs 13
climacteric 13
Gaa(-/-) 13
Nonsense 13
optogenetics, 13
light-gated 13
(ChR2) 13
Sln-null 13
DPC 13
Repetitive 13
Forty-six 13
transversion, 13
incompatibility 13
MLPKO 13
beat-to-beat 13
(DADs) 13
tachycardias 13
9p 13
(TORC1) 13
narcotic 13
"Mowat-Wilson" 13
(SIP1) 13
Genitourinary 13
(ZFHX1B). 13
kernel 13
benchmarked 13
100%) 13
discord 13
(IFN)-γ, 13
m. 13
accentuated 13
ATRIP 13
co-chaperones 13
microg/ml) 13
recovered, 13
histograms 13
chromophoric 13
incomplete, 13
propositus 13
female) 13
regionally 13
(10(-8) 13
interactomes 13
sLe(x/a) 13
TGFbeta-induced 13
strabismus 13
Monomethylation 13
epicentres, 13
section. 13
(Mug). 13
gastric, 13
NXY 13
user's 13
(BAT) 13
monoubiquitination, 13
0-24 13
(NfL) 13
homovanillic 13
non-genomic 13
AMI, 13
P<0.05. 13
DRON 13
266 13
maspin 13
hereafter 13
Insect 13
stressors. 13
light-dark 13
Cry1 13
May, 13
phase-dependent 13
hemi-methylated 13
Coimmunoprecipitation 13
Dnmt3b, 13
micronutrients 13
Met1 13
PND 13
T3-induced 13
Pan-vertebrate 13
myeloid-derived 13
Baricitinib 13
parasagittal 13
Iraqi 13
1997). 13
Alu-mediated 13
mAb. 13
Tn-seq, 13
cream. 13
Dhh 13
dimensional(3D)bioprinting 13
trileaflet 13
organoids 13
controllable 13
high-transcription 13
BiotHER 13
trimethadione 13
don't 13
cPHB 13
zolmitriptan 13
J/cm2). 13
Carmustine 13
conformal 13
wafers) 13
FANCJ 13
pneumothorax, 13
TS, 13
Incidentally 13
IFN-STAT 13
encephalomyopathy, 13
Calcification 13
meningocytic 13
CAF1 13
54.7% 13
eGFRcys 13
mGFR 13
cost-effective, 13
45,X, 13
RAPIDR: 13
deletions/duplications 13
acetazolamide, 13
attend 13
emotional, 13
Pooling 13
ficolin-3-mediated 13
distributions, 13
Spt5 13
beta1. 13
GLT8D1. 13
Nod-like 13
Nod 13
Citrullination 13
tears. 13
blots, 13
triadic 13
digoxigenin-HCP 13
Wnt-signaling 13
Remodeling 13
Ib, 13
medium- 13
2A, 13
sMTC 13
Ltd, 13
(X 13
HPRT-deficient 13
Xite 13
single-unit 13
signalosome. 13
Peroxiredoxin 13
programming. 13
SYNDROME 13
inversus. 13
Pitx1 13
APOBEC3F. 13
25th 13
span. 13
inviable 13
benserazide, 13
Tolcapone 13
T47D 13
designed. 13
S/AS01 13
Mozambique. 13
isotopomers 13
DIC 13
β-barrels 13
supersecondary 13
self-consistency 13
PRED-TMBB 13
finder 13
=10 13
122), 13
disassembles 13
stabilising 13
CA-miRNAs 13
4EBP1. 13
Zamboni 13
insufficiency: 13
SIR. 13
congestion 13
Cerebro-Spinal 13
Atlas, 13
1956 13
asymptotic 13
hereditary, 13
NCX, 13
constructed, 13
SNP-induced 13
6-59 13
ninety-eight 13
(40%vs. 13
(84%vs. 13
WG 13
deamination. 13
CYBB 13
FOG-1 13
wireless 13
other's 13
Pax3 13
differently. 13
XII, 13
Cohesins 13
figure 13
Dax1. 13
Dax1, 13
label, 13
LI 13
Nox2, 13
pellucidum 13
25-hydroxy 13
Check 13
alteplase. 13
TIMI 13
isotypes 13
MORG1 13
SZ 13
receiver-operating 13
PRC2-Ezh1 13
immunoprecipitation-on-chip 13
SRF 13
speckles, 13
cysteine, 13
prevalent, 13
non-telomeric 13
Argonautes 13
hypoxanthine-adenine-guanine 13
SCs 13
aetiologically 13
bupropion, 13
bleeds 13
fissure 13
entomological 13
VAP 13
scheduling 13
WM 13
PDGFRB, 13
damage) 13
DWT 13
Transvaginal 13
Aβ40, 13
Gamma-secretase 13
patient-centered 13
dashboards 13
self-injurious 13
biomineralization 13
AMI-DBD 13
394 13
(controls). 13
cocaine-associated 13
IRS 13
FLAMSA-RIC 13
TAB2 13
TAB3 13
cadaver 13
Pathologic 13
metagenomics 13
Metagenomics 13
schwannomas. 13
schwannoma 13
LOH. 13
aporeceptor 13
Results: 13
affect. 13
Ca(v)α(2)δ-1 13
milliseconds 13
Archive 13
sweat, 13
I-II, 13
Seventy-nine 13
NEB 13
1q42. 13
s.c.) 13
diabetics, 13
inference, 13
(HHV-8) 13
tool-the 13
scale-for 13
Il2 13
AFP-producing 13
Sir3 13
USP22 13
compound-specific 13
alerts 13
Uganda 13
SWD. 13
nCPAP 13
hospital-acquired 13
ABCC8 13
V59M 13
pridopidine, 13
computers 13
3-aminobenzamide, 13
decarboxylase, 13
length) 13
Stridor 13
Rarely, 13
apnea-hypopnea 13
psychiatrist 13
Improves 13
insulin-mediated 13
phagocytophilum 13
ketoconazole 13
candidiasis 13
photosystem 13
MAD 13
Photosystem 13
PKG 13
IAV 13
T1DM 13
excellence 13
Heterotachy 13
sensitive: 13
Sororin. 13
Pds5A 13
imidazopyridine 13
FGIN-1-27 13
(GD1). 13
HIV-1Δvif 13
INTERPHONE 13
DEX-mediated 13
dentinogenesis 13
aleglitazar. 13
AleCardio 13
Tirilazad 13
fertilization. 13
Y-P30 13
alpha-fetoprotein, 13
Aarhus 13
six-month 13
10.9 13
DSS1 13
ESCs. 13
mutators 13
NUDT5 13
mutS, 13
death/MI 13
hUCB-MSCs 13
FcgR 13
rebleed 13
happened 13
ATRA 13
non-regulatory/non-mobile 13
Mef2c 13
retrotranslocation 13
verrucal 13
43) 13
0.20, 13
urochordate 13
low-pressure 13
sulfate-reducing 13
Thermococcus 13
NIK 13
goitres 13
BIU-87 13
(MethylCap-seq) 13
apoptosis-promoting 13
lymphohistiocytosis 13
TRHR 13
Pertuzumab 13
HSR. 13
PGx 13
A3F, 13
hsCRP 13
ICAM-1 13
(NCPAP) 13
lepidopterism 13
(Hst 13
insensitivity. 13
denture 13
osteopenia, 13
(Krabbe 13
LOGLD 13
Maurer's 13
TSG 13
EEG-fMRI. 13
VOCs. 13
2-hydroxy-dATP 13
Venereology. 13
arginine- 13
Lsm4 13
snRNPs, 13
antineutrophil 13
941 13
IgG1κ 13
subgrouping 13
herpetiformis. 13
alkyltransferases 13
regime, 13
shunting, 13
PolC 13
Nicastrin 13
CCNU 13
ethylating 13
ogt- 13
MTase-deficient 13
MAO-B 13
MAOA-uVNTR 13
p19ARF, 13
IVH. 13
hyperhomocysteinaemia 13
EGFR-specific 13
employers 13
particulates 13
ACP 13
Fancf 13
Hs578T 13
(Vif) 13
Gingival 13
15q11-13 13
anti-interleukin-17A 13
(PsA). 13
NCS 13
immunophilins 13
OTR 13
6MWT. 13
(p≤0.002). 13
sarcoglycans 13
Ambulation-evaluable 13
67.3 13
placebo/delayed 13
cytosine, 13
Crystallographic 13
Inter- 13
laxity 13
LR, 13
(GBP) 13
iCMs 13
Tbx5 13
High-flow 13
(17/20, 13
ori 13
F]altanserin. 13
granulomatosis 13
Québec, 13
fibrocytes, 13
Turcot's 13
Goiter 13
partner-specific 13
miR-296 13
SCRIB 13
Brassica 13
(TEN) 13
eruptions 13
Anti-proliferative 13
Ets-1 13
ALK-TKIs 13
non-B 13
β-secretase 13
MDSCs 13
HPO 13
mTORC1/STAT3/Notch1 13
IFNs 13
KCNQ 13
multi-core 13
DN 13
oxidase-mediated 13
ADP-ribose 13
catecholamine-synthesizing 13
maximising 13
risk-reducing 13
Poly(ADP-Ribose) 13
PARP1/2 13
tremor: 13
Prevention. 13
leiomyosarcoma, 13
14-mg 13
Vel- 13
Microcephaly 13
avelumab-IR700 13
(NadA) 13
(NadA). 13
NHBA 13
scurvy. 13
ecchymosis 13
"wearing-off" 13
nipple 13
BioCreAtIvE 13
naltrexone/bupropion 13
liraglutide 13
[0 13
-5/5q- 13
kcnj10 13
liposome 13
extracorporeal 13
rofecoxib, 13
high-income 13
(α-Gal 13
prevailed 13
meningitis-specific 13
(p70), 13
convulsion. 13
bleb 13
(Tamiflu), 13
Presenilin 13
XL 13
BCCIP, 13
RAD51L1), 13
EMSY, 13
apoE3, 13
dysbetalipoproteinemia 13
apoE2(158 13
phosphate-regulating 13
Foot 13
COP1 13
Int6 13
Met1-linked 13
smallpox 13
(PMA), 13
Nox1-catalyzed 13
Nox3 13
indian 13
FUNC 13
K02288 13
FOP, 13
SAMP8 13
iridum, 13
Plasmepsins 13
herds 13
antiretrovirals 13
YBOCS 13
N-degrons 13
(Gardner-Diamond) 13
Tenon's 13
Rosuvastatin 13
ISIS-SMNRx), 13
APPs 13
T1D 13
Yakutsk 13
Yakut-Evenk 13
septins. 13
octameric 13
prognosticate 13
(RBP 13
regulators). 13
browsed, 13
PicTar 13
(DOPA) 13
furin, 13
Alcoholic 13
OCA. 13
Q402 13
OCA4 13
hyperferritinemia, 13
Belgrade 13
(H4K20) 13
Calcific 13
'true 13
medulloblastoma/primitive 13
(H3F3A) 13
(eQTL) 13
Persisting 13
(pri-miRNAs) 13
difficult-to-access 13
Supratentorial 13
tox 13
diphtheria. 13
IgAN 13
anti-Bax 13
JBP2-stimulated 13
(UBCs) 13
UVA1 13
delayed-type 13
Sequences. 13
Neuro-Oncology. 13
TOP2B/RRM2 13
glue 13
EP-DNN, 13
osteoporosis; 13
Mis18, 13
Mis18BP1(KNL2) 13
cat-like 13
(MNase), 13
nucleosome-sized 13
(141-190 13
101-140 13
MNase-seq. 13
nucleosome-like 13
actoxumab-bezlotoxumab 13
phosphate-wasting 13
BWA 13
dADAR 13
Hub 13
Facilitate 13
Cofactors 13
Activation. 13
hyperactivation, 13
SSCprofiler 13
(EEM 13
T-Brain-1 13
Cdh8, 13
Mcm4/6/7 13
MethPed: 13
CAMUR: 13
Asp-261 13
Glu-262 13
NDRs 13
DosR, 13
acetaldehyde 13
Nonsense-Mediated 13
Anti-GD2 13
ECM22 13
ERG11 13
synesthesia 13
synesthetic 13
ERG11, 13
SUT1, 13
KEYNOTE-006, 13
GenomeVIP: 13
(GenomeVIP), 13
cloud- 13
GATK, 13
Pindel, 13
BreakDancer, 13
STRiP, 13
low-stretch 13
radiolucency 13
CONCLUSIONS</b>: 13
CNEEs 13
auxin. 13
dermatophytes 13
(butterfly 13
ReliableGenome 13
(RG) 13
(IHPS). 13
Mallampati 13
siG12D-LODER™ 13
(Solanum 13
SLC2A10 13
Consortium: 13
Nursemaid's 13
trismus. 13
flexibly 13
GLE 13
Mountain 13
Star 13
Ts65Dn 13
NPM-ALK 13
Avena 13
Ag/Ab 13
Uc.189 13
anti-regulated 13
Zieve 13
Sclerosing 13
PGB 13
MK-3415A 13
hemoglobinuria 13
Rucaparib: 13
Ubiquilins 13
(Stål), 13
BMSB 13
V/Q 13
-dimer 13
Enlimomab, 13
RS-sites 13
Tibetans, 13
KLF5 13
braziliensis 13
nystatin 13
sought. 12
tumor-derived 12
ADAMTS 12
secreted, 12
pericellular 12
coSI 12
Interleukin-1β 12
bond. 12
(RANKL), 12
Thyrotropin 12
miR-200b, 12
FIGO 12
0.48 12
collections. 12
(compared 12
PFS, 12
62, 12
History 12
bimodal 12
Benefits 12
gravis: 12
consensus. 12
MG, 12
interventions: 12
Vertebral 12
period). 12
peculiarities 12
childhood: 12
skeletally 12
osteoporosis: 12
applicable. 12
DXA 12
1980s, 12
outgroup 12
Dvl-1 12
widespread, 12
Up-regulation 12
revisited. 12
presentations. 12
migrans 12
toes, 12
53-year-old 12
neatly 12
hepatoblastoma 12
0.63; 12
0.83, 12
mineralocorticoid 12
[2%] 12
non-steroidal, 12
(40%), 12
prednisolone. 12
CYP17A1, 12
prednisone, 12
(SGPT), 12
Biodistribution 12
androgens, 12
(s.c.) 12
targeted. 12
immunoemulsion 12
(Herceptin) 12
immunocytochemistry, 12
groups) 12
Paclitaxel 12
cotreatment 12
expedite 12
iPSC-based 12
leukemogenic 12
hESCs. 12
teratoma 12
unfortunately, 12
Nanog. 12
seeded 12
project: 12
initiatives 12
therapeutic, 12
protein-encoding 12
Consortium, 12
configuration, 12
these. 12
ample 12
Sweden, 12
developments. 12
morphological, 12
(PET). 12
left-ventricular 12
30.3 12
hospitalizations, 12
>70 12
endpoint). 12
reassessed 12
end-systolic 12
recessive. 12
together. 12
cotranscriptionally 12
opposes 12
cis- 12
anterolateral 12
18.5 12
10-15 12
(LINE-1) 12
(<1 12
junctin-devoid 12
Age-dependent 12
(Ca(2+) 12
afterload 12
(Ca) 12
NMR. 12
(HILIC) 12
swallow 12
Endoscopic 12
pharmacotherapy. 12
efferent 12
apnoea, 12
mild-to-moderate, 12
(ERK1/2) 12
μmol/L) 12
MMPs, 12
(ALP) 12
thrombin, 12
rat: 12
286 12
Substrates 12
cutoffs 12
HBL-52 12
(p.Glu17Lys) 12
welcome 12
NFTs 12
Lysyl 12
chemotherapeutics 12
(NPY) 12
(AKI) 12
triad: 12
forms: 12
week), 12
NS) 12
breakfast 12
60-min 12
(GLP-1) 12
1-h 12
VO2max 12
wheel 12
(siRNAs) 12
1.29 12
1.67 12
(modified 12
recanalization 12
(62% 12
pain-related 12
8-11 12
multi-system 12
Irritable 12
Seventy-six 12
CFS, 12
Organisation 12
[median 12
velocities, 12
46), 12
catecholamines, 12
0.78, 12
0.93, 12
1.06). 12
contraceptives, 12
Diagnoses 12
sufferers 12
1-month 12
30). 12
website. 12
5-month 12
smartphone 12
Clarifying 12
cry. 12
therapies: 12
LDL-C. 12
(ten 12
CETP 12
<0.001). 12
≥100 12
Amgen; 12
(T-UCRs). 12
O-GlcNAcylation 12
decisively 12
nonmalignant 12
AdoHcy. 12
M.HhaI. 12
nonhematologic 12
myelomonocytic 12
exclusively, 12
(LDE225), 12
GLI1 12
Radioactivity 12
Unchanged 12
invigorated 12
unwinds 12
CGG-repeat 12
premutation 12
Immunoglobulin 12
SDS-PAGE. 12
exacerbating 12
McTnC(F27W) 12
consenting 12
16.8 12
individually, 12
[Role 12
dephosphorylated. 12
2-cell 12
maize. 12
H3K27me1 12
Su(var)3-9 12
SUVH2 12
Compilation 12
Kaposi 12
Sarcoma 12
Lys9 12
mitochondria-associated 12
PBS 12
clusterin 12
chemosensitivity. 12
regressed 12
FLIP 12
PI3 12
18-24 12
Ontario, 12
(4.6%) 12
295 12
Mothers 12
Gestational 12
(CH) 12
lingual 12
onset) 12
DSPC 12
"Brain-Lung-Thyroid 12
ILD 12
Demonstration 12
placentas 12
reporter, 12
Medicine/Blackwell 12
CSCs. 12
cell-permeable 12
exclusion, 12
TICs 12
EASI 12
55.7% 12
Injection-site 12
twice-weekly 12
inversions, 12
Identical 12
cosmetic 12
interestingly 12
Slc26a4 12
morphometric 12
Urogenital 12
inoculation, 12
hypoglycaemic 12
diuretics, 12
in-solution 12
(PSG) 12
amounts, 12
one-dimensional 12
biopsy-proven 12
inaccurate 12
6-day 12
CORE, 12
CORE 12
keratosis 12
Histopathologically, 12
18-month-old 12
(adenosine 12
14%, 12
22%, 12
LOF 12
Therapy, 12
(National 12
0.56; 12
(RTOG 12
-0.09 12
EORTC/NCIC 12
0.39, 12
(GTPases) 12
(proteostasis) 12
β-hexosaminidase 12
catabolism. 12
uncharacterized. 12
lysosome-to-nucleus 12
receptive 12
PGRN 12
RRAGs 12
(HIF-1) 12
phosphorylations 12
desmid 12
Gold 12
wall-membrane 12
megaterium 12
LY191145 12
Chatterjee, 12
tripeptide 12
30-fold 12
Health-related 12
HRQOL 12
4-month 12
(44 12
irinotecan, 12
[An 12
Analog 12
insidious 12
stools 12
pazopanib, 12
declared 12
photosensitivity, 12
dioxygenase 12
CD20+ 12
myofibroblast-like 12
Scopus, 12
E) 12
dimensions, 12
conscientiousness, 12
lives. 12
everolimus) 12
RR, 12
antimetabolites, 12
RI 12
cis-eQTL 12
(20/25) 12
3,4-dihydroxyphenylalanine 12
erg 12
gapdh 12
(80%). 12
V(D)J 12
RAD21, 12
rosette 12
orientation-dependent 12
gaps, 12
MYH7 12
goes 12
(RAAS) 12
Rab 12
endogenous, 12
Exploration 12
calcium-regulated 12
beta-strands. 12
ridge, 12
box. 12
miRTarCLIP 12
1-7 12
nt) 12
nuclear. 12
HITS-CLIP 12
Amiodarone-induced 12
dysfunctions. 12
Kong. 12
(mean: 12
(7.8 12
Dexamethasone 12
diplegia, 12
gait. 12
0.86 12
rotated 12
y, 12
walk, 12
mins 12
system) 12
Noonan 12
plexiform 12
(RFLP) 12
Denaturing 12
reticulocyte 12
postulated. 12
Neonates 12
submissions 12
co-aggregates 12
solubility; 12
sclerosis-linked 12
(FUS) 12
(APC) 12
hits, 12
PRMT1 12
FTLD, 12
Macrophages 12
TGF-beta-preprogrammed 12
adrenaline 12
COMT-opicapone 12
cofactors. 12
second. 12
microsatellites 12
homolog. 12
fire 12
Halobacterium 12
cylindromas 12
tropomyosin 12
Maspin 12
(CYLD), 12
patterning. 12
46-year-old 12
factor-kappaB, 12
predispositions 12
cure, 12
correlate, 12
kinase-dead 12
antennal 12
reorganized 12
p300, 12
E., 12
NE, 12
Chk2, 12
Threonine 12
titres 12
contract 12
disease-causative 12
gene-1, 12
Cavernous 12
1950s, 12
ICAM-1, 12
euthyroid, 12
laminectomy 12
managed. 12
root. 12
rarefaction 12
peripherally 12
roots, 12
Sitagliptin 12
Aromatic 12
thiazolidinediones, 12
States: 12
hydroxylated 12
-1.3 12
'vildagliptin', 12
'dutogliptin' 12
1.51, 12
leveraged 12
1.0% 12
saving 12
restoration, 12
benzodiazepines, 12
sensitive. 12
B: 12
veterinary 12
(MLST) 12
afflicting 12
climbing 12
laminar 12
Carrier 12
Immunoblots 12
Now, 12
(mouse 12
heat-inducible 12
Nicotiana 12
(2.1 12
ubiquitin-associated 12
assembly/disassembly 12
CENPA 12
(cmt3) 12
LTR-retrotransposons 12
4q 12
choanal 12
methyllysine 12
H19, 12
Cbx7 12
40-50 12
directionality 12
inserts 12
200,000 12
nucleosome-remodeling 12
(CHD4) 12
cis-element 12
regime 12
>100 12
Lmo4, 12
anchorage 12
retroviruses, 12
synapsis 12
altered, 12
promoter-bound 12
H3K4me3, 12
CRCs, 12
H3T3 12
protists 12
dronedarone, 12
death). 12
VT/VF 12
51) 12
family) 12
COUGER, 12
classification-based 12
non-structural 12
(5-HT). 12
synonymous: 12
guanidinoacetic 12
(TIEG1) 12
lymphopoiesis 12
BMP-6, 12
up-regulation, 12
gene-1 12
AKT, 12
(TGF)-β 12
outlier 12
Mfn2 12
50,000 12
elucidates 12
Mgm1 12
lipolysis, 12
dispersal 12
BMS. 12
10q 12
cocaine, 12
minocycline 12
excitotoxicity. 12
cystine 12
rationale, 12
stimulators 12
[12%]) 12
Values 12
HER2-enriched 12
hypometabolism 12
amenorrhea, 12
R1 12
Vietnam 12
disks 12
R9C 12
(R9C) 12
opportunities. 12
-42 12
Training 12
non-enzymatic 12
Strength 12
Res 12
meat, 12
repeated-measures 12
(GlyRS) 12
synthetase. 12
glycyl 12
(WES) 12
aminoacylation 12
FISH-probed 12
uneven 12
H3K36me3, 12
Knockout 12
inducers, 12
(TSA). 12
H3-K4 12
(DC), 12
ROS-mediated 12
(miR-21, 12
ERK-MAP 12
calorie 12
(TNF)-α 12
different: 12
V/propidium 12
BECN1 12
LC3. 12
TLR9 12
Huh-7 12
p53- 12
positive-strand 12
TEM 12
ChIPnorm: 12
K27-only 12
228 12
inflammation-mediated 12
humans: 12
antigen-antibody 12
Which 12
authorisation 12
compensates 12
titration, 12
institutions, 12
(37°C) 12
BMH 12
cya 12
lef 12
replicase 12
low-cost 12
Self-reported 12
unpaired 12
(MEN) 12
WNT8A 12
Multipoint 12
consanguinity 12
finely 12
(PIs) 12
rocilinostat. 12
(PIs), 12
(OBs), 12
caveolin 12
resurgence 12
vasodilation 12
endothelium-denuded 12
(CHO) 12
shutdown 12
BRG1, 12
hr. 12
Vietnamese 12
cryo-electron 12
SSB-4 12
proteins). 12
inflammasome. 12
gus 12
GPL 12
2004) 12
undiscovered 12
duplicated, 12
synchrotron 12
scene 12
Robinow 12
trioxide 12
combination-treated 12
pursuing 12
ctf18 12
dcc1 12
chromatids, 12
SRF, 12
XRCC2 12
26.2% 12
21.3 12
12.9% 12
Anticancer 12
Annexin-V 12
(TR 12
TRalpha1, 12
T(3). 12
GTPases, 12
GAC 12
tetramers 12
photoproducts 12
dimers, 12
Rad7 12
defective. 12
translocating 12
TCR, 12
(RNAP 12
morphant 12
Stanford 12
10(10) 12
mg/d) 12
Fox 12
(TSC1) 12
13th 12
Isw1b 12
peptide-binding 12
minimisation 12
Feasibility 12
75, 12
resectable 12
1986 12
5-HT3 12
q 12
single-stage 12
thirty-one 12
01 12
Basel, 12
cycles) 12
(40% 12
hours), 12
P=.001) 12
coronary-artery 12
meter 12
in-silico 12
bortezomib-induced 12
TRAIL, 12
ligases, 12
Vpx 12
unveils 12
(SERCA2) 12
deleterious, 12
tragic 12
ought 12
Gallen 12
II-III 12
cancer? 12
H:I 12
Test. 12
protein-damaging 12
5], 12
Polyglutamine 12
DSP 12
dog. 12
IU 12
(1950 12
1.08, 12
CENTRAL 12
0.89 12
1.11, 12
fall, 12
tries 12
Monthly 12
COPD. 12
criteria) 12
demographic, 12
Mini 12
Sociedad 12
251 12
keratoses, 12
Adjusting 12
preferred. 12
(present 12
teratogenicity. 12
(3), 12
ubiquitinate 12
knockin 12
Mdmx 12
L6 12
nucleoplasm 12
amsacrine, 12
subchronic 12
Catalytic 12
anthraquinone 12
did. 12
electronically 12
producers, 12
mitoxantrone. 12
tauopathy, 12
recapitulating 12
labeling, 12
(excitatory 12
L-[14C]cystine 12
(>90%) 12
Position 12
hEAAT2 12
Gly 12
(SNX27) 12
Kir3 12
taxonomy-related 12
house-keeping 12
CGIs, 12
AT-AC 12
0.02% 12
colloidal 12
micelles 12
targets; 12
thrombin. 12
ODNs 12
AMD. 12
R-aptamers 12
(1.4 12
Fourth 12
(PDGFR) 12
extensions, 12
tumor-promoting 12
biases. 12
states: 12
non-ionic 12
excess. 12
(CD), 12
immunoassays. 12
0.32, 12
187 12
xerostomia 12
Precursor 12
B-LBL 12
doubtful 12
inter 12
TSC1/2 12
angiomyolipoma. 12
Myeloma. 12
past. 12
(H. 12
School 12
(13)C-urea 12
atherothrombosis: 12
cardioembolism: 12
pylori, 12
Collaboration 12
ineligible 12
diseases; 12
Interesting 12
Hp 12
P<0.001), 12
circumstances. 12
neurologists, 12
FOXO1, 12
decidualization 12
(MSA) 12
hernia 12
Medical, 12
MN, 12
[Treatment 12
oncologic 12
interlinked 12
organomegaly 12
retinas 12
well-controlled 12
Morquio 12
hemiatrophy, 12
fronto-parietal 12
clinicoradiological 12
secondarily 12
25-year-old 12
tafazzin, 12
primate-specific 12
PSL 12
(free 12
male-to-female 12
CLOCK, 12
age-associated 12
DNMT3B. 12
kinase-1 12
nonmajor 12
eg, 12
use; 12
non-East 12
amlodipine. 12
non-CNS 12
year; 12
lower-risk 12
contents. 12
lipogenesis. 12
sciences. 12
S-adenosyl-l-methionine 12
1.52 12
lipidomic 12
tamoxifen-treated 12
0.14 12
4.3% 12
17). 12
ketones 12
short-chain 12
single-stranded, 12
SI 12
Immunodeficiency 12
ill-defined 12
cigarettes. 12
(RNC) 12
patches, 12
Framework 12
Notum 12
0.018), 12
(rho 12
(Modified 12
months' 12
electrodes. 12
viable, 12
tissue-selective 12
estrogen-receptor 12
bothersome 12
non-hormonal 12
meetings 12
Augmentation 12
fourfold 12
caveats 12
cellulose 12
mycorrhizal 12
impractical 12
secretases 12
xenografted 12
indefinite 12
nonsyndromic) 12
(HSAS). 12
(T21) 12
71), 12
Sequenom 12
Whole-cell 12
Sixty-six 12
gated 12
produced, 12
re-evaluation 12
impairment). 12
Consequently 12
Belgium 12
exhausted 12
practiced 12
calcineurin, 12
autoinhibitory 12
unregulated 12
selfish 12
topo 12
p16(INK4a). 12
Senescent 12
p19(ARF) 12
(http://globin.bx.psu.edu/hbvar) 12
abrogating 12
actin. 12
DRF 12
Iec1 12
504 12
(TREM2) 12
chromosomes) 12
dicot 12
practicable 12
legitimate 12
holistic 12
conversion. 12
Rindopepimut 12
1-8 12
weakens 12
Aims 12
2.18 12
phosphorothioate 12
XYY 12
(Down 12
(Patau 12
studied: 12
fetuses, 12
central, 12
UPF1, 12
exonuclease, 12
yield. 12
CoQ10 12
above, 12
1.9, 12
Ran 12
[Na(+)](i) 12
model) 12
bilayers 12
amplitude. 12
5%) 12
mutagen 12
especially, 12
Briefly, 12
232 12
PERIOD 12
multi-kinase 12
ultrasensitive 12
women). 12
(TKIs), 12
(P=0.022). 12
publications, 12
Articles 12
ABL, 12
undoubtedly 12
90%. 12
Overcoming 12
Novartis), 12
3-6 12
clonality 12
computer-assisted 12
Vortioxetine: 12
Sheehan 12
antidepressant-like 12
agonism 12
Montgomery-Asberg 12
duloxetine. 12
8-week, 12
Interpretation 12
emphasized. 12
over- 12
TMEM127, 12
Nodal, 12
YSL 12
unmasked 12
HH-GLI 12
spermatogenic 12
forth 12
Cas 12
stressors, 12
9-week 12
double-mutant 12
unloaded 12
epicardial 12
strip 12
30-40% 12
Mitral 12
defect). 12
favorable, 12
depresses 12
HE 12
(90%), 12
subtly 12
T>A 12
swellings 12
drugs; 12
p34 12
ruffles 12
Arc 12
bilayers. 12
TAp73, 12
PIR2 12
Slug, 12
alphaB-crystallin 12
Mac1p, 12
derepressed 12
thyronamine 12
6.5% 12
infusion-associated 12
York, 12
0.38 12
exposes 12
accumbens, 12
biological, 12
60%, 12
-negative 12
'amyloid 12
hypothesis' 12
Pre-clinical 12
meningoencephalitis. 12
(CHD), 12
sHT 12
than, 12
prescribe 12
homoplasy, 12
exemplify 12
Principal 12
mandible 12
genus. 12
reconstruction, 12
bee 12
bursts 12
263 12
Poland, 12
hopefully 12
L-ferritin 12
thereof, 12
restlessness, 12
hemoptysis 12
µg/L, 12
sounds 12
dust 12
Afghanistan 12
mysterious 12
exposures, 12
TREX1 12
PGL 12
nintedanib, 12
Ingelheim 12
Ingelheim; 12
Enrolment 12
(CaSR) 12
(STZ; 12
(CM) 12
CM. 12
intercostal 12
oximes 12
insecticides 12
methamidophos 12
accidental 12
virus-specific 12
columns. 12
Chargaff's 12
departments. 12
funding, 12
power-law 12
growing. 12
productivity, 12
RMMA, 12
clenching 12
comment 12
ProtecT 12
(RCT) 12
letter 12
neuroscience 12
microU/ml), 12
frizzled-related 12
Wnt3a 12
2q 12
receptor-related 12
linc-RoR 12
accordingly 12
Casein 12
PMDD. 12
pill 12
interrelationship 12
mg/m(2)/day 12
nitrosourea 12
aptamer, 12
MH 12
antibodies) 12
dapoxetine 12
nonoverlapping 12
portend 12
distorted 12
wild-type. 12
oligo(A) 12
Extracts 12
Ccr4-Not 12
(IL)-17 12
allodynia. 12
abolished. 12
cavities. 12
monomer. 12
compartmental 12
83.3% 12
noninvasively 12
alphavbeta5 12
U7snRNA 12
Denti 12
2006; 12
ramipril 12
tomato-based 12
by-product 12
notch 12
0.035). 12
ribozymes 12
treprostinil, 12
Medicare 12
insurers 12
149 12
drift 12
Resolving 12
(PK), 12
preemptive 12
mpk 12
(n=21) 12
(n=8) 12
post-infection 12
xenobiotics 12
CMI 12
activity), 12
magnum, 12
thrive, 12
Ectopically 12
EWSR1-FLI1 12
mesothelioma. 12
2B, 12
CRD-BP. 12
oncofetal 12
determinant. 12
photobinding 12
thrombophlebitis 12
(LBs) 12
(DLB). 12
LBs. 12
NT, 12
SLA 12
immunodominant 12
cytomegalovirus, 12
38-year-old 12
pigments 12
(3.8%) 12
(1.3 12
seconds. 12
ligating 12
(S) 12
myotubularins 12
MTM 12
heterogeneities 12
chlorpromazine, 12
improvement) 12
anticholinergics 12
SUS1 12
Sus1, 12
Sputum 12
22.7% 12
SAGA, 12
H3.1, 12
hypermodified 12
SIT 12
restitution 12
(49%), 12
proved. 12
Usually 12
irregularities 12
hemoglobin. 12
RNAP. 12
backtracking 12
3.7% 12
(TPI 12
leukotriene 12
polyarthritis 12
stomatitis, 12
doses; 12
epilepsy? 12
eminence 12
dHMN-V 12
unmyelinated 12
SCN. 12
I(Ks) 12
Complementary 12
ALM 12
16%, 12
worker 12
MDA-MB-231. 12
PRK 12
scars 12
phosphate. 12
>1.5 12
1.22 12
protocol) 12
consultant 12
MPO 12
Lilly 12
Co 12
cross-reactive 12
ADR 12
(70%), 12
serotonin-norepinephrine 12
latex 12
0.34) 12
medians 12
(DAS28) 12
thiamin 12
overlooked, 12
carbohydrates 12
HIV/AIDS 12
chief 12
phosphate, 12
osteoclast-mediated 12
dentine 12
laboratories, 12
genotype/phenotype 12
Specifically 12
(K)-specific 12
(LSD1/KDM1A) 12
LSD1-inhibitory 12
corepressors. 12
TAL1-LSD1 12
H89 12
(LSD1), 12
(CoREST), 12
(HDAC1), 12
p4.2 12
LSD1/HDAC1 12
(CBT) 12
risperidone, 12
syndactyly, 12
human-induced 12
subtype-specific 12
osteopenia. 12
high-pitched 12
abnormalities; 12
(LEKTI) 12
kallikrein-related 12
agitation, 12
autophagy) 12
distributed. 12
ventrolateral 12
short-range 12
NMB 12
HNPCC 12
Anaplasma 12
Redox 12
lac 12
(OMIM#104170) 12
(alpha-NAGA; 12
E.C.3.2.1.49), 12
alpha-NAGA. 12
Gal 12
microdilution 12
rebound 12
GABA(A) 12
antihyperglycaemics, 12
(3.3% 12
≥30 12
[IQR, 12
SBP 12
pair, 12
(PGD) 12
flows 12
concentrically 12
CSDs 12
s) 12
non-ischemic 12
electrode. 12
aftermath 12
experimentally, 12
transports 12
(PP1) 12
(T) 12
phosphoryl 12
(TAG) 12
(H3K79) 12
SET7/9 12
demethylation, 12
12.8 12
Concerning 12
Guarantors 12
COX-2, 12
Editing 12
basal, 12
(Z 12
corticosterone, 12
ventricles. 12
northeastern 12
Gene. 12
pro-invasive 12
disrupted. 12
(C-C 12
(HGF). 12
intracoronary 12
(Ang 12
7.0% 12
(TGF-β) 12
pro-tumorigenic 12
sensitively 12
C-type 12
UTRs, 12
34.2 12
Belgium, 12
maintained, 12
trans-membrane 12
plated 12
stiffness. 12
transferases 12
human-fugu 12
Unaffected 12
vastus 12
lateralis 12
enteritis 12
Implantation 12
Ilk 12
d-TC 12
agomelatine 12
force-bearing 12
Dock180-RNAi 12
AnkB 12
viroid, 12
PINK1/Parkin 12
(>10 12
microg/mL 12
sweet 12
MCL, 12
ECOG 12
clefts 12
anticonvulsants. 12
pacing, 12
18.4 12
LT 12
Treponema 12
glucose-stimulated 12
Enhances 12
(leptin, 12
choices. 12
barcode 12
eating, 12
providers. 12
pathogenesis; 12
pre-rRNA 12
orthologs, 12
21-kDa 12
formulation, 12
approximation 12
RNA-Seq, 12
circumstances, 12
BrS. 12
depict 12
malate 12
MC1R, 12
1.48 12
V92M, 12
longer. 12
15q11.2 12
downregulation, 12
domain-dependent 12
malignant, 12
(159 12
post-baseline 12
protein-like 12
APC/C 12
multinucleate 12
peroxisomes. 12
simvastatin, 12
flora 12
114 12
Andaman 12
DMPK 12
HBS1L-MYB 12
exit. 12
399 12
(death, 12
DINDs 12
kg). 12
1999), 12
antipsychotic-treated 12
Again, 12
ropionic 12
subunit) 12
anonymous 12
T428I 12
1527del3 12
Medtronic. 12
post-operatively 12
12; 12
VIIa 12
ataxin-3. 12
Université 12
ADAMTS10 12
crystalline 12
cataract, 12
kHz) 12
receptors). 12
conduits 12
reconstitutes 12
Including 12
deduce 12
P290R 12
(hCtf4) 12
(FPC), 12
ni 12
Inn1-Cyk3 12
reverting 12
M-Cdk1 12
vas 12
deferens 12
77%, 12
Cl(-) 12
phagosomes 12
cenocepacia 12
dark-grown 12
darkness 12
plants: 12
temperature-dependent 12
cis-aconitate 12
SUPERMAN 12
gamete 12
Phenotypical 12
predominance. 12
mesodermal 12
first-time 12
(DTS) 12
essentiality 12
centriolar 12
centrioles 12
ciliopathies 12
innovations, 12
CP110 12
dots 12
nm). 12
.08). 12
.04). 12
q.d. 12
normoglycaemic 12
beagle 12
FGFR-related 12
inserts, 12
c.749C>G 12
TMJ 12
condylar 12
expand. 12
elimination. 12
hydration 12
(PML) 12
topiramate. 12
varieties. 12
(GCA) 12
366 12
albumin. 12
expectancy, 12
Prx 12
54%, 12
PTX3, 12
miR-125b 12
Mcm5 12
CD44v, 12
Statistics 12
"hot 12
spot" 12
cetuximab-based 12
0.14, 12
Sharp-1 12
hypoxic-ischemic 12
urticarial 12
bisphosphonates, 12
disodium 12
R788, 12
Sixty-eight 12
PRO 12
error) 12
toll-like 12
areflexia. 12
vigilance 12
10.5% 12
reduced-intensity 12
268 12
var. 12
daughter, 12
infected, 12
undetected 12
1.7) 12
HER2. 12
kPa 12
(P=0.03) 12
rocuronium 12
portion. 12
Sirtuin 12
CDK-2 12
T-lymphocyte 12
(RASFs). 12
thereby, 12
miR-18a 12
anthropometry 12
Pro250Arg, 12
(NSCLCs) 12
1995), 12
cystometry 12
(20.6%) 12
completion, 12
terodiline 12
influenced. 12
psychologically 12
Taxonomy 12
(Chk2) 12
CRP1, 12
dDia2 12
schistosomiasis. 12
schistosomiasis, 12
sarcopenia 12
MoRFs 12
(LSD) 12
wire 12
alpha-glucosidase, 12
clamp, 12
halorhodopsin 12
epileptogenesis. 12
Optogenetics 12
viewers 12
SES 12
FOXM1 12
(uni- 12
thermogenesis, 12
ATP-driven 12
397 12
over-representation 12
RHD 12
S100A1 12
halts 12
flecainide. 12
clock-dependent 12
benefit-risk 12
gambling 12
ZEB2. 12
ours 12
disease-gene 12
melanogaster), 12
odontogenic 12
radiations 12
tree. 12
PGI(2) 12
22.5 12
shunts. 12
(tumor 12
vasodilatation 12
daughters 12
44, 12
phycobilisome 12
congruent 12
surprising, 12
citric 12
anti-motility 12
mesenchymal-epithelial 12
Conversion 12
overriding 12
iron-independent 12
MR, 12
(complex 12
inactive/poised 12
Pioneer 12
caesarean 12
Fertility 12
glycosylase. 12
G/U 12
(Ung) 12
G: 12
(development 12
STAIR 12
'core 12
erythropoietin, 12
abstracts, 12
10-14 12
skeletogenesis. 12
dizygotic 12
succumbed 12
fruitfly 12
Tob 12
nonteaching 12
teaching-intensive 12
(Dnmt1) 12
micronutrient 12
(similar 12
-deficient 12
TRbeta1-mediated 12
baffle 12
[enalapril] 12
anxiolytics 12
0.98 12
noradrenalin 12
antiquity 12
(CMTX5), 12
methodologic 12
GM-CSF, 12
Ink4a 12
Elavl1Mø 12
Alopecia 12
Lys-48-linked 12
rise. 12
Guideline 12
H2AX, 12
metastasis-related 12
ZEB1. 12
cm3. 12
Mlp84B 12
(2, 12
BIBW2992 12
FGFRs 12
5q35, 12
aCGH 12
prolactinomas 12
transplants. 12
Jews. 12
IKBKG 12
dpc 12
=3 12
(ChIP-chip) 12
hDPCs. 12
blends 12
depositing 12
Philadelphia, 12
morphogenetically 12
SaOS-2 12
alginate/gelatin 12
polyP·Ca(2+)-complex 12
tacrine-induced 12
aliskiren, 12
DNAs. 12
thermosensitive 12
5-hydroxymethyluracil 12
(i.d. 12
E(max) 12
(Gliadel) 12
diffusive 12
Gy), 12
non-FA 12
cough. 12
claims, 12
(MER41). 12
paraparesis, 12
(113 12
0.41, 12
50-60% 12
mCAF1 12
27.5 12
here: 12
normokalemic 12
ficolins 12
Rap1, 12
ITIH3 12
Apc 12
H8 12
clamps 12
muramyl 12
wait 12
Adoptive 12
blepharoconjunctivitis 12
Pthirus 12
palpebrarum, 12
SINEs 12
clazosentan, 12
Hemorrhage 12
scavengers 12
auras 12
b. 12
(Danio 12
BW 12
Ndrg1 12
(NDRG1), 12
Ndrg1-deficient 12
Added 12
REGISTRATION 12
Narcolepsy 12
radiotracers 12
(FANTOM3), 12
WITH 12
(MZSDS). 12
WD40 12
(IL)-17A 12
(4%; 12
3·0-4·4) 12
BirA-mediated 12
inactive-specific 12
Xist. 12
Optical 12
L1196M, 12
F1174C, 12
0·01). 12
speedups 12
list-mode 12
recommended, 12
2009); 12
Excellence 12
discoloration 12
Keratin 12
3D-QSAR 12
(3D 12
CCR3 12
catalyst 12
exceptions, 12
circumsporozoite 12
prospect 12
Modelling 12
send 12
OMPs, 12
0.54, 12
non-TMB 12
ANN- 12
well-annotated 12
208 12
BOMP 12
Ty3/gypsy 12
autosomes. 12
quadruple 12
uvrD 12
0.12, 12
miR-216a 12
RNF152 12
acid-sensitive 12
(hair 12
(XDP, 12
"Lubag" 12
(XDP) 12
IJ 12
MS) 12
confluence 12
(PTA). 12
semiautomated 12
Dexmedetomidine 12
'CCSVI' 12
world-wide 12
Gfi-1B. 12
Smad2/TIF1-gamma 12
RPS14, 12
del(5q) 12
got 12
worthwhile 12
α-granules 12
pooled, 12
CRS, 12
anoïkis 12
repolarization, 12
nA 12
genodermatosis 12
freckling 12
freckling. 12
equipoise 12
posts 12
95%-CI 12
cefdinir, 12
Malawi 12
monitors 12
verrucous 12
GATA-1/Gfi-1b 12
GATA-1/FOG-1/MeCP1 12
MRP2 12
break-induced 12
users' 12
(UCNEs). 12
FCS 12
callosal 12
PAK1 12
CDKL5, 12
274 12
(RTT), 12
Self-renewal 12
Oct3/4-centered 12
asthenia 12
IGR 12
d-dimer 12
macroprolactinomas 12
fittest 12
HSV-1. 12
Nox2 12
edition 12
reopen 12
kinase/extracellular 12
(LINE-1 12
(H3K27me3) 12
Cdx2 12
RelB, 12
re 12
ICV 12
brm-related 12
piNG-body 12
azgA 12
(GDNF 12
NTN 12
WTs 12
ultralong 12
MEN2A 12
small-interfering 12
(2g) 12
MDM2-amplified 12
YF 12
AstraZeneca 12
inoculum 12
Tract 12
(LND) 12
(Case 12
E(Z) 12
AdoMet, 12
beta-lactamase 12
beta-lactamases 12
cloacae 12
3'-terminal 12
clamping 12
DIM 12
boceprevir 12
symbiont 12
(cases) 12
62-year-old 12
cocaine. 12
15- 12
miR-122 12
mir-21, 12
(miR-21), 12
syndrome-related 12
Techniques 12
oxygen. 12
Metaproteomics 12
MS(2) 12
Vespucci 12
9p21.3 12
Gradenigo 12
paresthesia 12
P53-binding 12
hpl-2 12
(NM) 12
TPM3 12
Washington 12
(WKY) 12
Methyl 12
(siltuximab) 12
unconfirmed 12
[Effects 12
MCL-1, 12
CBR, 12
Sp 12
CDKN2A, 12
SIR 12
nocodazole 12
chromatography/isotope 12
neurotoxin-induced 12
Army 12
NARP 12
GRIPHON 12
Gain-of-function 12
CYP2D6 12
neurotoxins, 12
DBA: 12
hypoventilation, 12
ratings. 12
Dabigatran. 12
VLPs 12
glutathione, 12
histologies 12
ALCL 12
(MLN8237), 12
Immunological 12
voles 12
s.l. 12
mainland 12
TTV 12
macitentan. 12
ACT-132577, 12
Slow 12
rifampin 12
sickness, 12
snRNA. 12
PPAR 12
paraclinical 12
285 12
(http://www.treat-nmd.eu). 12
PET/CT 12
microcephalic, 12
normocephalic, 12
22year-old 12
p.Gln306X 12
Thornton 12
(G57S, 12
cub 12
(DF) 12
covariance. 12
(ECOG) 12
PPA, 12
tartrate. 12
QT/QTc 12
(UCB) 12
Knock-down 12
telephones 12
epidemiology. 12
prediabetes 12
receptor-α/γ 12
CBF. 12
Tear 12
tick, 12
arachnoidal 12
p<0.001, 12
K.545 12
(Tokuhashi 12
"died 12
GC-24 12
lenvatinib, 12
cabozantinib 12
non-vertebral 12
(NGF) 12
FbFPs 12
Intrinsically 12
radiodurans 12
MutT2 12
MtuMutT2 12
MsmMutT2 12
(GO). 12
diets. 12
CCDC39 12
PADI-4 12
anti-citrulline 12
RA-development 12
curcumin. 12
sulindac 12
(FA-A 12
Ser314 12
chordomas. 12
PLE. 12
Rad3-related 12
rif1Δ 12
late/dormant 12
oats. 12
SVIP 12
mut(+) 12
BRAF(V600K) 12
perisomatic 12
(CNEs), 12
Microbacterium 12
SEPW1 12
Benzodiazepine 12
Flumazenil, 12
MKS 12
malaise, 12
neuroinflammation, 12
multimer. 12
CAPRIN1 12
puncture. 12
(AGS) 12
predominates 12
simulator 12
THs 12
(1.7 12
Pfh1p 12
CBT-I 12
GSK3β 12
Genomewide 12
eIF2alpha 12
IOMT 12
IFR 12
hypopigmentation, 12
Disassembly 12
TRH, 12
HAMP 12
Thr(35) 12
hemangioblastoma 12
genotype: 12
PGX 12
MutSL 12
mispairing 12
crime 12
POD1-2, 12
RyR3 12
FasL, 12
apparatus, 12
hairpins, 12
berberine 12
cooked 12
bees 12
brown-tail 12
Lepidopterism 12
(cutaneous 12
transporter-encoding 12
DUR3 12
DUR31. 12
Dur 12
rif 12
caries 12
(VLDL) 12
h/mL 12
PCL 12
(4). 12
FENO 12
cyclohexane, 12
1,4-dimethyl-. 12
α-melanocyte 12
(FXN) 12
(Lsm) 12
(snRNP) 12
R162Q 12
H209/V6 12
(TRAP) 12
48-week 12
33589 12
CD38- 12
non-permissive 12
ZapA 12
Z-ring 12
BPI 12
(n=32), 12
59.4 12
herpetiformis, 12
louping 12
TRA2β4 12
cation-independent 12
CIMPR 12
colitis: 12
immunosuppressants, 12
INPH 12
exonuclease. 12
ProTα 12
Modafinil, 12
RCTs) 12
antipsychotic-associated 12
cognitive-enhancing 12
antianxiety 12
DmAGT 12
high-activity 12
5-hydroxyindoleacetic 12
Dentin 12
FAP 12
thrombophilia. 12
pregnancy-related 12
fibrillization. 12
DUF1471 12
T790M-specific-siRNAs 12
workforce 12
mSOD1 12
hyperbilirubinemia; 12
glucuronide, 12
3-glucuronide 12
pitavastatin, 12
CDCF, 12
OATP1B1/OATP1B3, 12
BSEP, 12
thyromimetics 12
Hospitals 12
vivax. 12
falciparum: 12
5-fluorocytosine. 12
PU 12
Btbd12 12
(18%), 12
anti-HIV 12
POTS. 12
POTS 12
phylogenies, 12
IGA 12
Dermatological 12
(PASI) 12
(NFAT) 12
problems; 12
rNGB 12
prasugrel 12
(BMD). 12
tauopathy. 12
acetogenins, 12
"armoured 12
ethics, 12
Stat92E 12
MAPKAPK2) 12
3rd, 12
open-reading 12
prelamin 12
mottled 12
OGG1 12
thymine, 12
IL-1alpha 12
genes--including 12
desaturation 12
709 12
BMPs 12
altanserin 12
FBP 12
χ(2 12
(T1D), 12
hyt/hyt 12
TSPO 12
KO) 12
([G] 12
[A]: 12
[GG] 12
[AA]: 12
RyR2-V2475F 12
TAD, 12
DXPas34 12
meristems, 12
Amanita 12
iron-binding 12
frataxin. 12
Micrococcal 12
(CRISPRi) 12
(CRISPRi), 12
disease-affected 12
activator-dependent 12
alkali 12
BFNC 12
KCNQ2, 12
Aβ:Zn 12
instead. 12
levofloxacin 12
Wise 12
rhinorrhoea. 12
KLK13 12
TNFRII 12
Marijuana 12
oxidase-dependent 12
once-monthly 12
A-catalyzed 12
revisited: 12
suppression-burst 12
antileishmanial 12
benzene-induced 12
(ORMA 12
SP790 12
Alzheimers 12
TNBS 12
beans. 12
haemolysis 12
Beutler 12
HRD 12
non-BRCA-mutated 12
poly-ADP-ribose 12
° 12
(ARR), 12
TOPIC 12
7-mg 12
≥2% 12
anti-doping 12
daratumumab-mediated 12
SMIM1 12
NOX4 12
NOX1, 12
Pediatrics. 12
6E3 12
Québec 12
Adhesin 12
MenB, 12
identified), 12
Pharmacists 12
Patients. 12
(Qsymia) 12
Nobel 12
Prize 12
SNP-A 12
MDS-RA 12
Chat 12
mycotoxin 12
abscesses 12
hesperetin 12
HMZ 12
Fabry's 12
ChIP-Nexus 12
meta-regression 12
Synchronization 12
progression-driving 12
KJ/mol 12
Pen-2. 12
PEN-2, 12
(NCT). 12
(TMD), 12
Aph1 12
hBora 12
pcr 12
ARIEL2 12
Meta-Analysis 12
Interdigital 12
cruciate 12
Csn6 12
CSN. 12
axillae 12
ward. 12
surgery-related 12
prevention/treatment. 12
triamcinolone 12
MediaWiki 12
Ser-154 12
Noxo1gamma 12
ClC-Kb 12
CPPD 12
(ZED) 12
(WS2A) 12
otic 12
Ihh. 12
PTH-related 12
(CTS) 12
velaglucerase 12
mirBase19.0 12
MiRduplexSVM. 12
Aph1B 12
GenoType 12
agars 12
MRSA-carrier 12
erythromycin. 12
Avanafil, 12
IIEF-EF 12
(MenB), 12
p27KIP1 12
'annulus 12
oculi 12
Experience. 12
sham-controlled, 12
paraquat-induced 12
(DPI), 12
N-vanillylnonanamide, 12
Kv 12
AGE-induced 12
O(2)(*-) 12
Viliuiski 12
sacubitril 12
decarboxylase) 12
3-hydroxybenzylhydrazine 12
hypophysial 12
PACE4, 12
preprohepcidin 12
CIDEC/Fsp27 12
CIDEC, 12
Validating 12
OPS-2 12
mcast 12
epsilon2 12
Cost-Effectiveness 12
Treatment, 12
c.386T>C 12
pointes" 12
Nrd1, 12
Nab3, 12
traseR, 12
wake-sleep 12
bendability 12
otologic 12
barcoding 12
Top1mt 12
hypoalbuminemia, 12
clubbing 12
lacteals 12
microphthalmic 12
OCA1A 12
rGBM. 12
TL 12
PLA2G6-associated 12
LedPred: 12
R/bioconductor 12
LedPred, 12
(Khib), 12
(Kac) 12
crotonylation 12
diphtheriae. 12
Stroke/National 12
Stomach 12
B-cell-targeted 12
interleukin-13 12
Lucifer 12
Jarid2(-/-) 12
UVA-dose 12
(smokers 12
24+/-17.7 12
(mean+/-SD) 12
67.6+/-51.3 12
25.7+/-16.3 12
68.5+/-49.3 12
(CR; 12
clearance), 12
(PR; 12
(NC; 12
clearance). 12
(Student 12
mal 12
sAPPβ 12
(MK-8931), 12
TOPAZ1 12
Angus 12
DSD 12
EBOV 12
PBC, 12
ursodiol 12
(FBN1), 12
medium-to-high-dose 12
Asthma. 12
EXCEL-like 12
death/MI/CVA 12
(diphosphatidylglycerol) 12
Q4W 12
Smyd5 12
Osteocrin 12
Ostn 12
rs1399685 12
MPE-Fe(II). 12
B-neutralizing 12
β-solenoid 12
diaphoresis 12
non-pheochromocytoma 12
(ciRS-7) 12
PfMCM2, 12
(MCM2-7) 12
ARHR, 12
DMP1. 12
HHRH 12
EULAR 12
TST 12
LTBI 12
RPS19R62W 12
graminearum. 12
Overlap 12
Alignments 12
stuttering 12
nephrotic-range 12
ncsDAVFs 12
Accessory 12
Preserve 12
(KOS) 12
TCRα 12
ATMIN. 12
achalasia, 12
yAsf1 12
CIA/ASF1 12
(CUTs). 12
type-9 12
MCM7-S121A 12
reference-free 12
multiclass 12
Ad12 12
Asp-Glu 12
ribbon, 12
metaSPAdes 12
tb 12
DosS 12
NB4-2 12
GA-sequence 12
d(GA)n 12
S.cerevisiae 12
2018 12
4330 12
Tonsillectomy 12
(LY2157299) 12
galunisertib, 12
viewed, 12
downloaded, 12
octopus 12
left- 12
ipilimumab-naïve 12
spt8Delta 12
dst1Delta 12
PsyGeNET 12
sleep-phase 12
AH8.1 12
DDX54 12
JPS. 12
eQTLs. 12
COL1A2, 12
(COL1A1 12
Bruck 12
igf2 12
large-data 12
PanCanAtlas 12
ICGC 12
Pilots, 12
CPTAC, 12
ICGC-TCGA 12
DREAM 12
[Puffy 12
<b>BACKGROUND</b>: 12
ICH-volume 12
ICHs. 12
JavaScript 12
Insulating 12
(440-731) 12
Tbf1p, 12
(GRFs). 12
Abf1, 12
monospot 12
oxydans 12
dermatophyte 12
a-like 12
SMARCAL1, 12
tisagenlecleucel, 12
Promote 12
IHPS, 12
Postn(-/-) 12
assortativity, 12
(GABHS) 12
zCry1a 12
briakinumab 12
ALK+ 12
SCF(TIR1)-mediated 12
lycopersicum) 12
SlIAA15 12
MARS, 12
TCGA2BED: 12
extracting, 12
extending, 12
high-throughout 12
Logic 12
Bentall's 12
wide-dynamic 12
(CGRP), 12
Aδ 12
trastuzumab-related 12
XXY 12
read, 12
bounded, 12
better-suited 12
JACUSA, 12
medium-to-high 12
Rocky 12
MPG 12
(CURB65-A 12
Limb-Enhancer 12
beneficence 12
chondroma, 12
pleura 12
FGF21 12
emm1 12
HEATR1 12
snoring, 12
D-MER 12
polyphagous 12
benznidazole 12
strain), 12
Tabix: 12
Python. 12
estradiol-synthesizing 12
ch14.18), 12
dinutuximab-containing 12
Proseek 12
MMP12 12
anti-ICAM 12
2298 12
cable-tie-based 12
epineurectomy 12
herpes. 12
pheomelanin 12
Melanocortin-1 12
V92M 12
melanoma-risk 12
hormonally 11
irinotecan. 11
(mCRC) 11
(AR), 11
Poor 11
MPNST 11
exosomes. 11
Acquisition 11
metalloproteases 11
widely, 11
gastrulation 11
procollagen 11
laminin, 11
sulfated 11
buoyant 11
snRNAs. 11
factor-related 11
Activator 11
TNFSF11 11
ovariectomy 11
(PPA) 11
arthritic 11
(54% 11
MiRNA 11
(51 11
valued 11
weaker, 11
pyridostigmine. 11
resection; 11
Maintaining 11
metastasize 11
racial/ethnic 11
Scientific 11
10-20% 11
Fortunately, 11
controls; 11
wingless 11
immunostaining, 11
hyperkeratosis. 11
larynx. 11
brittle 11
persisted. 11
porphyria 11
fast-inward 11
(TDM) 11
antisympathetic 11
IKs 11
catecholamines. 11
Notch1. 11
neovascularization. 11
organogenesis, 11
cell-fate 11
viz. 11
searching. 11
(137 11
358 11
boundary. 11
17.0 11
2D6 11
p35 11
no, 11
HER2-targeted 11
dominant. 11
progression; 11
Genomics 11
commercialized 11
Adenoid 11
1+ 11
infrequent. 11
prostatectomy, 11
(MAb) 11
construct, 11
chromogenic 11
receptors: 11
(68% 11
p27Kip1 11
dimerization, 11
therapeutic. 11
non-viral 11
aneuploid 11
transfecting 11
donor-derived 11
laying 11
two-part 11
standards, 11
reagents, 11
investigators. 11
consortium. 11
LC-MS/MS. 11
1%, 11
840 11
caspase-3. 11
calnexin 11
flounder 11
(17%). 11
mendelian 11
(p<0.0001), 11
CHF, 11
36). 11
LA 11
post-infarction 11
sibships 11
homo- 11
Spliceosome 11
co-transcriptionally, 11
U2AF65 11
FSHD-permissive 11
Hungary. 11
bigger 11
4q35. 11
IBC, 11
(p<0.0001 11
Junctin, 11
JCN-KO 11
[Ca(2+)], 11
Cardiomyocytes 11
relengthening 11
R., 11
270, 11
singly 11
glucocorticoids, 11
Vmax) 11
metabolize 11
microbe 11
(HAT) 11
topology, 11
K12 11
Seventy-four 11
dyslexia 11
(UC), 11
(5.4%) 11
expressive 11
cited. 11
studied; 11
non-pharmacological 11
Steroid 11
BSA 11
versa, 11
interferon-stimulated 11
MAPKs, 11
C/EBP 11
enriches 11
commit 11
degradomics 11
P6 11
aldehyde 11
Incorporating 11
p-ERK1/2 11
1989, 11
lamotrigine, 11
forthcoming 11
(3.9 11
oncoprotein, 11
optimizes 11
(EWS-FLI1) 11
midzone 11
Eighty-five 11
breakthroughs 11
peptidases 11
NKX2.2 11
EWS/FLI-regulated 11
EWS-FLI 11
gain- 11
C4, 11
complement. 11
Comparable 11
kg/m(2), 11
Ghrelin, 11
hunger, 11
post-exercise 11
se. 11
(muscle 11
golden 11
wound-healing 11
96), 11
counseled 11
physician. 11
(39.5 11
36.0 11
consult 11
retrogradely 11
dyes 11
(DRG) 11
transitory 11
immersion, 11
278 11
(ANP) 11
1.18, 11
(HRT) 11
1.58 11
meningioma: 11
population-based, 11
histopathologically 11
3.2, 11
advocacy 11
(H3K36) 11
Sotos-like 11
loss-of-function, 11
improves, 11
1974, 11
Truncating 11
~80%, 11
soft, 11
improve. 11
AREAS 11
reductions. 11
LDL-receptor 11
Achievement 11
myositis, 11
7.1% 11
advances. 11
ezetimibe, 11
property. 11
blocker) 11
micro-RNA 11
(SC) 11
Cholesterol 11
(420 11
cancer-derived 11
concomitantly, 11
5'-CpG 11
Dlx-2 11
round-cell 11
neuroepithelioma. 11
ESB 11
enolase, 11
myelin-associated 11
reacts 11
breakpoint. 11
Askin's 11
BOLT 11
Absorption, 11
15.4 11
Metabolites 11
subjects; 11
ICLs 11
cancer-susceptibility 11
bidirectionally 11
R-loops. 11
functions: 11
hyperparathyroidism. 11
>10% 11
tetratricopeptide 11
D145E 11
8-fold 11
complexes: 11
Trp 11
nonphosphorylated 11
A-dependent 11
cessation: 11
0.72, 11
adopted. 11
one-year 11
evolution: 11
Herpesvirus 11
(n=4) 11
(grades 11
μg) 11
[12%] 11
transcriptase. 11
transcriptase, 11
E3, 11
HGF/c-Met 11
(COX-2) 11
c-MET, 11
transcriptase-PCR 11
A431 11
3-kinase/Akt 11
influenza-like 11
Turkey. 11
non-pregnant 11
1.59 11
7.4% 11
Keith 11
pulmonary, 11
function--causes 11
56.1 11
pneumopathy 11
BHC, 11
24%). 11
(RDS) 11
RDS 11
(76%), 11
Docking 11
cholangiocarcinoma. 11
tourniquet 11
triple-stranded 11
triplexes 11
lesions) 11
Exacerbation 11
endotypes 11
parameter, 11
-3, 11
[From 11
ALP, 11
Craniosynostosis, 11
suture, 11
non-transformed 11
methylation-associated 11
(T-UCRs), 11
DNA-demethylating 11
leucopenia 11
endocochlear 11
sensory-neural 11
cochlea, 11
Vestibular 11
congenital, 11
thiazolidinediones. 11
embodies 11
22%. 11
High-grade 11
IIIB 11
Analytical 11
Preparation 11
gelatinase-associated 11
postures 11
worn 11
perceive 11
predictors, 11
waking 11
matrix-based 11
photophobia. 11
hyperkeratosis, 11
cryptorchidism, 11
cryptorchidism 11
keratoderma. 11
interphalangeal 11
hypohidrotic 11
hyperkeratosis 11
keratitis 11
vascularization, 11
vascularization 11
VerifyNow 11
600-mg 11
67%, 11
individualize 11
(C/T) 11
sub-family 11
other-AEDs 11
©AlphaMed 11
VA. 11
277 11
77.8% 11
proteolipid 11
all-trans-retinoic 11
evade 11
Smith 11
penicillin-binding 11
transglycosylation 11
lantibiotics, 11
10(4) 11
hand-foot 11
daily), 11
chemotherapies. 11
multi-targeted 11
(PFS). 11
unchanged, 11
adjuvant, 11
1120) 11
(various 11
exams 11
DCs. 11
(RASFs) 11
agreeableness 11
<0.001, 11
Psychiatry. 11
Broad 11
Five-Factor 11
visuospatial 11
Midlife 11
rigidity. 11
sirolimus 11
searched. 11
mL/min, 11
Genome-Wide 11
EWS-ERG 11
messages. 11
positivity, 11
Dlk1-Dio3 11
increased; 11
Cutting 11
CCCTC 11
CREs 11
PLAGL1 11
multicistronic 11
SMC3, 11
pro-B 11
illustrative 11
13-fold 11
fluorophore 11
hirsutism, 11
DNA) 11
KP4, 11
breeding 11
Killer 11
nontransgenic 11
sustenance 11
(2011) 11
RBPs. 11
multinodular 11
(67 11
compensation. 11
(weighted 11
(SD), 11
differ. 11
hyperextension 11
evaluations, 11
skills. 11
dorsiflexion 11
Controlling 11
heads, 11
externally 11
once. 11
(P<.05). 11
encephalopathy: 11
Stability 11
frame-shift 11
MPNSTs 11
10-12 11
clade. 11
normalization, 11
Ethical 11
granule-associated 11
SOD1, 11
glia, 11
dendrites. 11
osteopontin 11
neovascularization, 11
deposit 11
-50 11
monkey. 11
(10, 11
concentration) 11
s(-1) 11
(RISC) 11
delimited 11
BCL11B, 11
p14(ARF), 11
elements: 11
jannaschii 11
Archaea. 11
volcanii 11
Chromosomes 11
mtDNA, 11
distances, 11
mucinous 11
focally 11
pleomorphism 11
syndrome." 11
atrophy: 11
SMN2, 11
amount. 11
(mTORC1), 11
Calcium-induced 11
EAD 11
Biochem. 11
decrease. 11
influx, 11
suprabasal 11
heterodimerization. 11
reaction-restriction 11
baclofen, 11
(2% 11
EudraCT 11
GJB1 11
novelty 11
diffused 11
PeV 11
Adenovirus 11
Coxsackie 11
CCMs 11
domain-associated 11
hemorrhages, 11
invertebrates. 11
subjects), 11
TRs 11
slow-release 11
pellets 11
weights, 11
hamsters. 11
eNOS 11
caring 11
abnormal, 11
sensation, 11
Computerized 11
moderators 11
pharmacophores 11
(MCS). 11
choices, 11
appreciably 11
alogliptin. 11
DATA 11
(FPG) 11
2h 11
K(i) 11
fumarate, 11
KEGG 11
CRY1, 11
FDA-cleared 11
Survivors 11
outcome) 11
(VS) 11
anticonvulsants, 11
Hygiene. 11
0.019). 11
endothelium-dependent 11
AFM 11
1990, 11
immense 11
beef 11
detector 11
BoNTs 11
89%, 11
nineteenth 11
proportions. 11
PD-related 11
(polymerase 11
individuals) 11
puberty. 11
oligodontia 11
conception, 11
HS3 11
HSEs 11
distinguished. 11
interspecies 11
carrot 11
ddm1 11
alphoid 11
Cenpa 11
prometaphase 11
species) 11
fertile 11
(H3K9me2), 11
delays, 11
DNA: 11
CHD1. 11
olfaction 11
HP1-like 11
environmentally 11
Ring1b 11
CXXC 11
CD3 11
A/T-rich 11
CHROMOMETHYLASE3 11
singular 11
switching. 11
HP1. 11
variegation. 11
chromodomain-helicase-DNA-binding 11
IFN-γ. 11
Myosin 11
respects. 11
(Stål) 11
0.008), 11
chromatin-binding 11
(BAC) 11
bitumen 11
(25, 11
macro 11
clonogenicity. 11
MPP8 11
H1, 11
Restricted 11
(SMC) 11
promoter-specific 11
conceivable 11
Genomicus: 11
repositories. 11
phylogenomics 11
(http://www.genomicus.biologie.ens.fr/genomicus) 11
(Vertebrate, 11
iodinated 11
anti-anginal 11
hypertriglyceridemia 11
TBE 11
Pestivirus 11
(HCV). 11
methamphetamine. 11
OCT3-mediated 11
Differentiated 11
Creatine 11
TGF-β1, 11
connectivity, 11
depolarized 11
bodily 11
4.8% 11
grams 11
transporter-2 11
Assigning 11
15-year 11
B1. 11
pituitary-thyroid 11
ml-1, 11
confounded 11
intima-media 11
Clarification 11
Island 11
41) 11
Na/K-ATPase 11
idiopathic, 11
17.8 11
1-week 11
Quercetin 11
percent. 11
negate 11
(VC) 11
vegetables 11
(RE) 11
RE 11
Consumption 11
Rhodiola 11
(SOD) 11
volleyball 11
diets, 11
CMT2D. 11
cocrystal 11
(GARS). 11
tyrosyl-tRNA 11
scatter 11
axonopathy 11
(3-D) 11
representation. 11
compressive 11
monomethyl 11
12-O-tetradecanoylphorbol-13-acetate 11
(TPA), 11
reactivation. 11
H3-K27 11
NuA3 11
H4K20, 11
amounts. 11
(DKC1, 11
non-irradiated 11
30-year-old 11
608 11
(clinical 11
concentrating 11
(70% 11
PDCD4, 11
Ad-GFP 11
serum- 11
-133, 11
cardioprotection. 11
arrayed 11
hypoxia/reoxygenation-induced 11
phosphoprotein, 11
BRCA1. 11
p62/SQSTM1 11
(PH) 11
(46% 11
rapamycin) 11
TLR3 11
(MCAO) 11
DAPI 11
http://lcbb.epfl.ch/software.html. 11
(anti-TNF) 11
Neu5Gc. 11
14.8 11
NOACs. 11
organ, 11
apixaban) 11
authorities. 11
bicarbonate/CO2 11
AtxA-deficient 11
RNA-mRNA 11
CO2, 11
pXO2. 11
eag 11
primer-extension 11
731 11
wt. 11
bulge 11
TLS 11
methylcytosine 11
ExTopoDB: 11
Genotypes 11
(EDNRB), 11
NTN, 11
distension 11
sensing, 11
[7, 11
(1.5- 11
5-fold) 11
recordings. 11
bilayer. 11
Images 11
continues, 11
protectors 11
when, 11
10(7) 11
Bombyx 11
reside. 11
dioica, 11
early-replicating 11
partitions 11
disfavored 11
UCE-disrupting 11
Conflicting 11
.0001) 11
extensive, 11
NALP3 11
cow 11
TRIM5alpha, 11
VAS, 11
triplets 11
linked, 11
Rosetta 11
heterodimer. 11
unit-cell 11
heterodimer, 11
osteosclerotic 11
proteasome-independent 11
MCL1, 11
attenuate, 11
MCL1 11
hydrolysis-dependent 11
early-firing 11
Smc3. 11
links, 11
Tof1, 11
Wapl. 11
platinum-sensitive, 11
(66% 11
DIGE 11
PARPi, 11
RTH, 11
PTGS2 11
Amounts 11
read-out 11
Orai1 11
glomeruli, 11
ml/min/1.73 11
disposal 11
fT3, 11
All-cause 11
8%, 11
calcium-handling 11
CSB, 11
DNA; 11
masks 11
arguably 11
strands; 11
karyotyping, 11
Japanese, 11
D-loop 11
(aCGH) 11
0.005; 11
(MLS) 11
Etiology 11
goat 11
TM4 11
hilar 11
Minimum 11
micrograms/ml 11
tuberin, 11
Genetic, 11
Rapamycin, 11
21%, 11
PEComas 11
Snf2-related 11
61-year-old 11
378 11
1994; 11
(MBC). 11
thirty-six 11
bypass, 11
(4% 11
bypass. 11
subline 11
384-well 11
(CRLs) 11
quantitating 11
piece 11
0.114 11
PLN-binding 11
HS-1-associated 11
SERCA2. 11
mechanics. 11
confronted 11
(18%). 11
14.4 11
stress-activated 11
MKP7 11
PMA-stimulated 11
85.5% 11
numbering 11
complete. 11
Clustering 11
organizations, 11
unproven 11
fallers 11
0.82; 11
1.11; 11
cons 11
expenditure. 11
COPD, 11
.009). 11
(BMI 11
fluorescence. 11
inconsistently 11
Administered 11
routes. 11
intraoperatively 11
Jarid2. 11
TAL 11
enChIP-mass 11
(enChIP-MS) 11
(gRNA) 11
medicolegal 11
disturbs 11
irritation, 11
hamster, 11
topically 11
transplacental 11
dams 11
305 11
Experiment 11
study) 11
cataracts. 11
union 11
MDM2-mediated 11
finger. 11
dicentrine 11
Adriamycin 11
hematology, 11
intercalating 11
prohibiting 11
Top1 11
quinoline 11
folk 11
linker. 11
cervix 11
etoposide. 11
polycyclic 11
bioinformatics, 11
AMP-responsive 11
miR-128, 11
cards 11
row 11
ion. 11
cross-linking, 11
vitro: 11
stretches, 11
inter-CGI 11
Expressed 11
gels. 11
unstable, 11
<1 11
1D 11
range) 11
pRb. 11
clopidogrel, 11
pegaptanib 11
acid-based 11
coagulation, 11
infested 11
Race 11
(ACC). 11
Smoothened 11
p27(Kip1) 11
vinculin 11
drivers. 11
mitochondrion. 11
euthyroidism, 11
(P=0.007). 11
AIT. 11
(AIH) 11
Americans, 11
Evaluate 11
resampling 11
0.08, 11
(ESRD) 11
(1.2 11
neurophysiologic 11
degrees. 11
G1-S 11
CO 11
style 11
communication. 11
(n=20) 11
practised 11
amount, 11
cavitary 11
diseases), 11
Pylori 11
Larger, 11
C/C 11
subtypes: 11
ulceration. 11
teach 11
(SMR) 11
reduction) 11
globally, 11
Kruskal-Wallis 11
osteoarthritis. 11
fundoplication 11
MSA. 11
Consideration 11
(LES), 11
glycosphingolipids 11
[Three 11
Transduction 11
10-20 11
(Dyke-Davidoff-Masson 11
Included 11
Dyke 11
Asymmetry 11
Anesthetic 11
effusions, 11
monolysocardiolipin 11
SAT. 11
homoeostasis 11
Promoters 11
Polycomb-group 11
(ROCKET-AF) 11
AF). 11
(AF), 11
Bayer 11
upload 11
homopolymeric 11
organelle, 11
obesity-related 11
amnion 11
acquisition. 11
Innovative 11
(SCA) 11
S-cells 11
simplifies 11
(MS)-based 11
reclassified 11
(SE 11
1.09, 11
(TNFalpha) 11
dextran 11
(IL)-1β 11
RSV. 11
prelude 11
nicotine. 11
0.98; 11
Computer 11
porous 11
music. 11
printing. 11
biomaterial 11
grafts, 11
Single-dose 11
distinct. 11
augmentation, 11
evidence). 11
gabapentin. 11
EFNS. 11
300, 11
nidulans. 11
Zinc-finger 11
Effector 11
gene-corrected 11
famous 11
five-fold 11
29.8% 11
short-lasting 11
tracheostomy 11
25%; 11
dwarfism. 11
dominate 11
(FGFR3). 11
IPI-504 11
inhibition: 11
radicicol 11
under-representation 11
ligand) 11
paraplegia, 11
11.7 11
14.3% 11
-20 11
nicardipine, 11
P-type 11
bronchoscopic 11
prednisolone, 11
Biopsy 11
Bergmann 11
antimicrobials 11
nisin 11
determinants, 11
phospholipases 11
dehydration 11
untreatable 11
Hungary 11
peripheral, 11
limits. 11
practitioners. 11
athlete's 11
cardiological 11
1.95 11
Sports 11
spliceosome. 11
covariation 11
Inverted 11
(DOX) 11
Ras-Raf 11
server. 11
Titus 11
page. 11
reverse-phase 11
CT-011, 11
effect: 11
Dasatinib, 11
Targets 11
mDia1 11
depolymerizing 11
polarity. 11
addressed, 11
[3]. 11
(TREM) 11
(p.R47H) 11
783 11
delta-distance, 11
Profiles 11
scanned. 11
sequences; 11
genomes; 11
non-negative 11
[Expression 11
transcribe 11
CGP41251 11
JAK2V617F 11
(LFS) 11
.001, 11
amniocentesis. 11
(61 11
398 11
(4.8 11
521 11
1.7% 11
Xrn1, 11
Lsm 11
ARE-mediated 11
GW182 11
Pab 11
1801 11
hyperosmotic 11
(processing 11
trypanosomes. 11
(TRN) 11
ARE-containing 11
bar 11
NRRL 11
mg/ml) 11
heparin, 11
dissociation, 11
parkin. 11
Heritable 11
(late 11
kinase-MB 11
([Ca(2+)](i)) 11
forskolin, 11
Cigarette 11
Metabolism. 11
effect." 11
Autophagic 11
mPER2 11
SDF-1α 11
T315I 11
9q34 11
(TKIs). 11
(2%). 11
granulocytes, 11
Optimizing 11
mesylate. 11
adverse-event 11
although, 11
ATP-competitive 11
populations: 11
t(9;22)(q34;q11) 11
(IM) 11
Lundbeck 11
baseline) 11
treat, 11
societies. 11
5-HT1A-Rs 11
Postsynaptic 11
DSM-IV-TR 11
antidepressant, 11
2.8% 11
(n=145) 11
Venlafaxine 11
amines, 11
Paired-End 11
GitHub 11
diabetes) 11
parent-of-origin-specific 11
UM 11
Gal4 11
reuse 11
Pyrococcus 11
hypothesis-driven 11
wk) 11
10(-3) 11
electrophysiology. 11
His-tagged 11
COS 11
generalizable 11
annuloaortic 11
parameters: 11
diagnosis: 11
5'-AMP-activated 11
coding, 11
P<.001), 11
hockey 11
underappreciated 11
Euclidean 11
Ultrastructurally, 11
(IF) 11
immunoexpression 11
avidly 11
heterodimers, 11
gamma-secretase. 11
GTP-dependent 11
vesicle, 11
non-phosphorylatable 11
isoforms: 11
questioning 11
densities, 11
NQO1 11
sites: 11
Aft1p. 11
acquisition, 11
H- 11
(EpCAM) 11
crowded 11
CD52, 11
three-times 11
CD25 11
deconvolution 11
distressing 11
remains. 11
Obsessive 11
Functioning 11
T-PLL, 11
38%, 11
pretreated, 11
(SAH), 11
(IDH1 11
AN1792, 11
Abeta. 11
epsilon4 11
(6.6%) 11
stiffening 11
normality 11
phenomenon). 11
1950 11
Student 11
MSSA 11
phylogeny, 11
vastly 11
hominoids 11
phylogenies. 11
effort, 11
SSRIs. 11
Perinatal 11
newborn, 11
(PVR) 11
N-cadherin, 11
E47. 11
fibronectin. 11
tubulin, 11
A/C, 11
immunology 11
forefront 11
Embryo 11
maintenance) 11
insulators. 11
Sweden), 11
properly. 11
ASR 11
trans-histone 11
(histone 11
SWR-C 11
Htz1 11
pains, 11
(PTSD). 11
symptom, 11
deposits. 11
pituitary, 11
neoplasias, 11
Nintedanib: 11
FKBP10, 11
0.77; 11
exacerbation. 11
receptor-α 11
TIMP-1, 11
Dawley 11
ip) 11
Resveratrol, 11
Organophosphate-induced 11
(EMG) 11
workers, 11
sensomotor 11
exposition 11
Neuropsychiatric 11
toes. 11
cross-links. 11
epigenome, 11
(M) 11
transmissibility 11
immunization, 11
(IL-1beta), 11
factor-beta1 11
14-kDa 11
AP-2, 11
bibliometric 11
rankings 11
rankings. 11
directors 11
physicians' 11
planning, 11
acrylic 11
electromyography, 11
endocrine, 11
IFN-gamma, 11
mind. 11
Survey, 11
GP 11
LUTS 11
severity; 11
ignoring 11
kit, 11
microdeletion/microduplication 11
kainate 11
ceiling 11
(MDD), 11
psychiatry. 11
Problems 11
7.5, 11
extended-release 11
1983 11
interruption. 11
fluvoxamine 11
6.8) 11
Thalidomide, 11
(T), 11
(bFGF) 11
angiostatin, 11
Cathepsin 11
CHD. 11
orthotopically 11
2500 11
Peritoneal 11
matrices, 11
retinopathy, 11
antiangiogenesis 11
419 11
coast 11
References 11
compliant 11
1975 11
probability-based 11
pyknon 11
HML 11
Deadenylation 11
PUF 11
PUM 11
your 11
polyadenylation. 11
72%, 11
LINE 11
journey 11
genotyping. 11
neoplasms: 11
(PA), 11
strain-specific 11
DGS. 11
(MC) 11
cilengitide. 11
test), 11
rats) 11
correct, 11
government 11
lycopene 11
antioxidants. 11
Women's 11
creatinine. 11
<1.5 11
Tomato 11
0.004, 11
sd 11
3'-UTRs 11
context-specific 11
weakening 11
transfectant 11
lymphadenopathy, 11
arched 11
rods. 11
TPM2 11
nonverbal 11
walk. 11
bosentan, 11
Medicaid 11
cost-effectiveness. 11
Market 11
Hungary, 11
PAH-related 11
digesting 11
strains: 11
IL-2-/- 11
B6.129P2-IL-10(tm1Cgn) 11
(IL-10(-/-) 11
Metagenomic 11
piglet 11
IBD: 11
microflora 11
linkage. 11
decompression. 11
(MRIs) 11
fibrillin-1, 11
lip, 11
mg/dl). 11
Karyotype 11
(aa 11
X-ray. 11
fibroma 11
revisiting 11
proximity, 11
cornerstones 11
tranexamic 11
(BUN) 11
statistics, 11
step-wise 11
coefficient. 11
stem. 11
non-Abeta 11
nondemented 11
4-5% 11
(right 11
ultrasound: 11
(if 11
13.3 11
zero-flow 11
myotubularin, 11
pimozide 11
Tourette's 11
drowsiness 11
dyskinesia, 11
circumvents 11
Shortly 11
anti-oxidative 11
alloxan 11
TFG 11
[Effect 11
post-ER 11
(PCOS) 11
Anti-Müllerian 11
(AMH) 11
biguanide 11
Oil 11
NH2 11
stall 11
(GAD) 11
Diseases, 11
(generalized 11
Mepolizumab, 11
0.26, 11
ASM8). 11
esophagitis, 11
Interleukin-5 11
(mepolizumab 11
tenascin 11
atopy 11
Numbers 11
Allergic 11
Allergy, 11
progresses, 11
HSPB1 11
rhG-CSF 11
(locus 11
only), 11
9-year-old 11
albinos 11
Nigeria. 11
Squamous 11
amputation 11
50- 11
mTOR/DEPTOR 11
SIRT1-mediated 11
rosetting. 11
0.003, 11
high-fluence 11
keratometric 11
flattening 11
same-day, 11
transepithelial 11
D). 11
C-termini 11
hypermobility. 11
perfusing 11
edematous 11
Ca2+-containing 11
PCD. 11
minimized. 11
NET. 11
magnitudes 11
extra-articular 11
Journals, 11
obese, 11
p<0.001; 11
WE. 11
Wernicke&apos;s 11
(DWI) 11
Favorable 11
(CAD), 11
Epigenome 11
hyperhomocysteinemia, 11
MCT8, 11
Lebanese 11
>T 11
typified 11
African-Americans. 11
p<0.0001) 11
dosages. 11
molecules' 11
pmol 11
Pertinent 11
(Canagliflozin) 11
SGLT2. 11
min(-1) 11
0.002, 11
mmol/l 11
faster, 11
neuronopathic 11
point-mutated 11
444 11
7.8% 11
prodrug, 11
tissue-specific, 11
(MMC) 11
spontaneous, 11
podocytes 11
MiRNAs 11
SALL4-associated 11
(HSC), 11
TAL1-directed 11
kniase 11
TAL1-corepressor 11
dimeH3K4 11
groundwork 11
perikarya 11
(ATS) 11
KIAA1279 11
failed, 11
ribs, 11
Communicating 11
Marfanoid 11
low-set 11
planus, 11
dampened 11
compromised, 11
Enteric 11
Correlated 11
suggest, 11
anti-viral 11
nonpolyposis 11
(HPLC) 11
HO-1, 11
cycloheximide. 11
Bach1(-/-) 11
l 11
GalNAcalpha1-O-Ser/Thr. 11
(MAC) 11
coinfection 11
mycobacteria, 11
intracellulare 11
rhodopsin 11
suvorexant, 11
(Jardiance(®)), 11
(≤104 11
≥76 11
sulfonylurea. 11
100) 11
bioactivity. 11
Bystander 11
pax6.1/2, 11
rx3, 11
id1, 11
mirn9-1 11
mirn9-5 11
GRB, 11
similarity. 11
CVS 11
DYS14 11
(CSD) 11
CBF(LSF) 11
vasoconstrictive 11
SD-induced 11
rCBF 11
scrambled 11
reserve. 11
EC50 11
PLN/SERCA 11
TFBSshape: 11
object. 11
nonradioactive 11
MSTN 11
JAK-STAT 11
alpha-cardiac 11
-5, 11
down-regulated, 11
IDH-mutated 11
ACR70 11
cytokine-mediated 11
CTs 11
auto-immune 11
(MTX). 11
(4.1%) 11
tactile 11
indicators, 11
hindpaw. 11
hindpaw 11
Shared 11
T-ALL, 11
PTC. 11
Cotransfection 11
actin-dependent 11
DEP 11
programmable 11
designs, 11
functionality, 11
paralogues 11
disrupted, 11
nonapoptotic 11
Hermansky-Pudlak 11
spindle-like 11
β-catenin. 11
(mTOR). 11
decode 11
transferase-mediated 11
Ca(2+ 11
(FANTOM5) 11
Knowing 11
Interferon-gamma 11
oligodeoxynucleotides 11
(kb) 11
scaled 11
(alpha 11
ACD 11
rhinitis 11
proven. 11
TH1 11
G4-related 11
apart). 11
times) 11
(50-200 11
depress 11
irrelevant 11
Tasimelteon: 11
zyxin, 11
co-distributed 11
destroys 11
compensating 11
Dnmt1, 11
peritoneum 11
copied 11
citrus 11
exocortis 11
circular, 11
antigenomic 11
creatinine-based 11
rises 11
Harnessing 11
meta-analyses. 11
bubonic 11
0.34 11
preserved, 11
E7, 11
vivo; 11
genes' 11
apelin-13 11
LH 11
AII 11
PABPCs 11
PABPs 11
(FRET) 11
cyclase, 11
50%) 11
cGMP-dependent 11
posttreatment. 11
realized, 11
lends 11
Methyltransferase 11
news 11
Xg(a+) 11
ad-hoc 11
assumptions. 11
N3 11
(BrS), 11
inhabitants 11
ATG5 11
signaling: 11
PPARgamma 11
MDH 11
gene-regulation 11
DNA-associated 11
pooled-analysis 11
Null 11
ng/ml). 11
PWS, 11
pores, 11
SNORD115 11
UBE3A 11
(SNRPN) 11
RAS-induced 11
partially, 11
reshaping 11
APP/PS1 11
deformation, 11
(MPTP) 11
bioluminescence 11
voluntarily 11
(FAST) 11
diaries. 11
ketoprofen 11
Caspase 11
push 11
microns 11
diagrams 11
secure 11
surgeons. 11
mailed 11
surgery; 11
life-saving 11
cm), 11
flow-mediated 11
waters 11
Tetrodotoxin 11
nigroviridis 11
(CCTG)(n) 11
enteral 11
ictus 11
10-80 11
vasospasm-related 11
analytically 11
attention-deficit/hyperactivity 11
olanzapine, 11
stabilizers 11
Oriental 11
relevance, 11
Thrombocytopenia 11
GPi 11
myosins-Ibeta, 11
-VI, 11
-VIIa 11
stereocilia 11
-4, 11
NF-kappaB/Rel 11
(VHL 11
Descartes 11
c.91C 11
(p.Arg31X). 11
c.1753C 11
(p.Arg585Trp). 11
SDHA-related 11
(para)sympathetic 11
WMS. 11
NovoTTF™-100A 11
Chemotherapeutic 11
Slit 11
oxygen, 11
carbamylation, 11
cysteines. 11
(CMG) 11
Mcm2, 11
(RPC), 11
p180 11
Musculoskeletal 11
y. 11
Phox2b 11
ethnicity. 11
>250 11
cruciform 11
"young" 11
sCJD 11
plastids 11
barley, 11
(infliximab, 11
methylases 11
cytosines. 11
arabidopsis 11
Zmet2 11
(GST) 11
IRF-3 11
resections. 11
94%, 11
centrosome. 11
immotile 11
proteinaceous 11
whorl 11
varespladib, 11
sPLA(2) 11
(h) 11
SGLT-1, 11
(bilateral 11
eponymous 11
anteroposterior 11
(FGFR3-related 11
craniosynostosis): 11
FGFR1, 11
high-functioning 11
'off' 11
KFERQ-like 11
1.18 11
FS 11
stones, 11
triptans, 11
sumatriptan, 11
10.6 11
SUMO, 11
(mTORC2) 11
TNF-α-induced 11
rictor 11
R-L 11
2D/4D 11
spondylitis, 11
perturbation. 11
mg/dl. 11
organizations 11
NASH 11
rHuEPO 11
vulgaris, 11
20), 11
(E3) 11
circuits, 11
exam 11
MMS-induced 11
multilineage 11
(ISH), 11
270 11
ANRIL 11
p15(INK4B) 11
down. 11
(MTM1) 11
replicates. 11
TDR 11
leptin. 11
regress 11
Dreaming 11
TMD. 11
Testisin 11
CD6 11
(FOXO) 11
acyclovir, 11
TRAF6 11
synoviocytes. 11
(P<0.01), 11
rs3746444 11
CD44v3 11
Triton 11
CD44v5 11
staging, 11
human-specific 11
long-term. 11
cystometric 11
OMIA 11
(Online 11
periocular 11
washing 11
fascin, 11
reorganization, 11
crosslinkers 11
Eps8. 11
IRSp53-Eps8 11
Sgf11, 11
single-particle 11
SCA2 11
viroids, 11
ribozyme 11
Allied 11
isoflavone 11
Asymptomatic 11
(19.0%) 11
Periods 11
opsins, 11
practices. 11
questioned. 11
(T2) 11
650 11
Triad 11
hypothermia. 11
SLN. 11
Actuarial 11
villi 11
Performing 11
mucus 11
non-infarcted 11
restoration. 11
Prompt 11
measures: 11
endocavitary 11
Namely, 11
Beauty, 11
intra 11
BACs 11
tip, 11
Supernumerary 11
decisive 11
interpretability 11
plausibility 11
expandable 11
ducts. 11
(EP) 11
tablet. 11
m, 11
six-minute 11
interruptions, 11
GCase 11
resume 11
algae. 11
Spirulina 11
5.5, 11
fluorescence), 11
gene-dosage 11
microsporidians 11
cardioskeletal 11
(LMNA) 11
LMNA, 11
leucocytes 11
mg/ml 11
TAK1 11
HMMTOP 11
TMHMM 11
soybean 11
(MMPs), 11
invasive, 11
permease 11
assimilation 11
huntingtin. 11
re-evaluated 11
Smad-interacting 11
Myelination 11
knowing 11
Proinflammatory 11
17q 11
TP53. 11
tubal 11
XDG 11
(Gallinari, 11
Jiricny, 11
383, 11
735-738) 11
(epsilonC) 11
epsilonC.G 11
epsilonC. 11
chloroacetaldehyde. 11
glycosylases, 11
high-speed 11
hemorrhages. 11
manipulation. 11
fragility, 11
Scales 11
boxers 11
AD-like 11
SHAM, 11
EF% 11
2600 11
T(4), 11
57.1% 11
hydrated 11
Aiming 11
mCry-deficient 11
Clock 11
trainees 11
(LOS) 11
Nestin 11
NGF, 11
methionine. 11
DNMT1's 11
ten-fold 11
CpG-methylated 11
Angiotensin-converting 11
HFD-induced 11
(52%), 11
maximum-likelihood-based 11
phenotyping, 11
CMTX5 11
Gain 11
superactivity 11
disease-5 11
Phosphoribosylpyrophosphate 11
mixed. 11
chromium 11
>300 11
Hydrogen 11
azide 11
redistribute 11
PAI-2 11
p16(Ink4a) 11
L) 11
TJ 11
baricitinib, 11
Lys-48- 11
IP(3)R 11
exclusive. 11
agglutinated 11
quinidine 11
(catecholaminergic 11
deregulates 11
STS 11
11%, 11
contributory 11
Alu-Alu 11
angiofibromas, 11
ependymoma, 11
au 11
(Tn-seq) 11
resistin, 11
interleukin-10 11
Iroquois 11
restenosis, 11
acids) 11
reversions 11
C57Bl/6 11
amlodipine 11
LVA 11
MRPs 11
Extraction 11
[Analysis 11
640 11
AT1 11
H-NS 11
heat-stable 11
decondensed 11
elementary 11
olcegepant 11
moreover 11
preincubated 11
FANCA-mutant 11
BLM 11
pneumothorax 11
Fifty-two 11
CMT6 11
i. 11
R-CHOP 11
(ORR), 11
oval 11
(dry 11
biofilm. 11
MSCT 11
CodY 11
non-diabetics 11
similar; 11
hailed 11
18p. 11
registries, 11
coagulopathy 11
restrictions. 11
HypoPP 11
SD). 11
shunt. 11
HUI3 11
Difficulties 11
meta-analytic 11
BUR 11
Lys4 11
unimpeded 11
implicated. 11
kilogram) 11
0.90; 11
IL-1beta-dependent 11
NOD1/2(-/-) 11
NOD1(-/-), 11
allergen-specific 11
citrullination. 11
Sera 11
pubis. 11
overlays 11
Ca-cycling 11
stay. 11
phenytoin 11
Manager 11
6.5, 11
tetraiodothyroacetic 11
IB. 11
(IA 11
epigastric 11
epileptogenesis 11
parenchyma, 11
SRY-related 11
gate 11
TRIAL 11
oxysterol 11
(fingolimod, 11
(rituximab, 11
(AIN457) 11
statisticians 11
Xist, 11
eutherian 11
antisense-mediated 11
blastocysts, 11
blastocysts. 11
Prions 11
crizotinib; 11
metastases), 11
G1269A, 11
PRDX-2 11
cumulus 11
slow, 11
ToF 11
GIST, 11
(A3) 11
APOBEC 11
hA3 11
APOBEC3C 11
Deltavif 11
BPH 11
(ACPAs) 11
-0.52 11
1.38 11
convoluted 11
Primer 11
replication-dependent 11
annealed 11
wearing-off. 11
harmless 11
Ro 11
zona 11
visualization, 11
S-Se 11
supplementing 11
SelT 11
anakinra 11
commercial-scale 11
anti-CS 11
SAE 11
RTS,S 11
RTS,S/AS 11
co-morbidities 11
787 11
(TMBs) 11
Loop 11
E(z) 11
toxigenicity 11
hour. 11
mosquito, 11
hyperdynamic 11
AEG-1 11
GTPase-dependent 11
DSC3 11
Panay 11
'lubag' 11
chorea, 11
pulsatility 11
transfusion, 11
'liberation 11
0.018). 11
stenting) 11
(severe 11
IJVs 11
16; 11
(Gfi-1B) 11
reevaluated 11
Nbeal2(-/-) 11
Hypophosphatemic 11
chymase 11
reexamined 11
ladder 11
Feline 11
weight-for-height 11
42.3 11
alcohol-related 11
constellations 11
initio. 11
Ldb-1, 11
Eto-2, 11
GPA 11
PIAS3 11
acute-phase 11
ambulance 11
web-accessible 11
mining: 11
"functional 11
scoring" 11
comparability 11
TS1 11
capitalizing 11
Glu 11
actin-cortactin 11
(rDNA 11
S.cerevisiae. 11
Skipping 11
(AOs) 11
AONs 11
column, 11
Wapl, 11
sitting 11
(33%), 11
(TKI258) 11
Chromatograms 11
windows, 11
(abundance 11
air). 11
subtyping 11
(Chi-square 11
0.039) 11
re-emerging 11
enzootic 11
microduplication 11
glucokinase 11
Plasminogen 11
Handicap 11
(ICRs) 11
Dnmt3L 11
Transposable 11
encephalomyelitis. 11
MSL 11
Bioequivalence 11
Wood 11
6MWT 11
Alu-element 11
Meiotic 11
trypanosomiasis 11
Insertion 11
c-Rel, 11
hyperbilirubinemic 11
Co-transcriptional 11
(NPCs) 11
transposons, 11
symporter 11
favism 11
fava 11
fixed-effects 11
comparator. 11
EudraCT, 11
edoxaban. 11
ruler 11
Colombia, 11
FLI 11
BPE. 11
BPE 11
γ-Secretase 11
Semagacestat 11
refinement. 11
vehicles 11
hyperuricemia 11
large- 11
chimpanzee, 11
Citrobacter 11
carbapenem 11
ESBL 11
Enterobacteriaceae. 11
mitochondria-dependent 11
RBV 11
pressures, 11
berry 11
miR-130a, 11
MC-LR 11
mir-16, 11
(CCA). 11
million. 11
compress 11
SIRT6 11
disadvantages. 11
Third-generation 11
neo-adjuvant 11
Mitofilin/MINOS 11
quantitative, 11
ecosystem 11
microbiota, 11
Preimplantation 11
trophectoderm 11
QT(end) 11
KCNIP2 11
paraquat 11
DEEP: 11
90.2% 11
0.59, 11
CACNA2D1 11
cell-dependent 11
endometrioma. 11
reserve, 11
prematurity 11
Sixty-four 11
characterises 11
µg/ml, 11
g/dL) 11
[17 11
RUNX2 11
Fluorescein 11
palaeodietary 11
prehistoric 11
component; 11
location-based 11
alertness 11
Geometric 11
ACT-333679. 11
(GRIPHON 11
NCT01106014). 11
(Kir6.2) 11
Stroop 11
Trail-Making 11
Col5a2 11
Cancer-related 11
sun-damaged 11
Poststroke 11
PSD. 11
ellipticine 11
macroautophagic 11
(Ub) 11
stricto 11
ERA 11
Actelion 11
Denmark 11
ERAD, 11
≤50 11
PR; 11
negative) 11
electrons, 11
uraemic 11
17α-hydroxylase 11
Adrenal 11
Microcephalic 11
(snRNAs), 11
deletion). 11
²/¹² 11
incorrectly 11
Bayes 11
Waardenburg-Hirschsprung 11
(PP2A) 11
preloaded 11
alpidem, 11
nonbenzodiazepine 11
Afatinib 11
postpartum, 11
(BI) 11
imiglucerase, 11
Approach 11
10(-8)) 11
A3B, 11
cell/tissue 11
rheumatology 11
phagocytes 11
prediabetes. 11
Preceding 11
YEATS 11
lacritin, 11
pregnancy-associated 11
=5 11
Galassi 11
Parasympathetic 11
Sonata 11
MSCC 11
1.80 11
ClF 11
GAL1 11
(multiple 11
8-oxo-GTP, 11
8-oxo-7,8-dihydroguanine 11
mutL 11
(TX) 11
post-PCI. 11
RCTs. 11
R-to-W 11
NAN 11
-1123G 11
genotyped. 11
curcumin, 11
chitosan 11
fluoroscopy-guided 11
(PLE) 11
CD11b 11
transactions 11
dyspepsia, 11
(ERAD). 11
Misfolded 11
BRAF(V600)-mutant 11
surrogates 11
[SD, 11
proliferation-promoting 11
tetanus 11
tetramer. 11
gpt 11
FTD-ALS 11
BZD 11
flumazenil-treated 11
hydrate 11
CGIS 11
SPG30 11
FLX 11
preference, 11
T+ 11
tf/J 11
homo-multimer 11
hetero-multimer 11
G3BP1. 11
depths 11
dtxR 11
uraniireducens 11
ephrin-B3 11
class-specific 11
Sickness 11
epiphyseal 11
TMEV 11
Engl 11
(ER-α) 11
nucleoporins 11
ALADIN 11
FG 11
Homolog 11
TIA-1. 11
MeWo 11
Doxycycline 11
CHS. 11
SPS2 11
(ESCRT) 11
arginine-to-cysteine 11
HAMP, 11
(CsA), 11
(NADPH) 11
NAPDH 11
RA-treated 11
eIF4E 11
AHS, 11
emtricitabine, 11
(CSI) 11
microorganism. 11
operon) 11
hypermutable 11
Kit-positive 11
Inborn 11
corpuscular 11
II.5 11
(FasL) 11
IL-1beta-induced 11
β-Site 11
SB203580 11
48), 11
caterpillars 11
pine 11
(genus 11
Dur3p 11
Dur31p 11
β-1,3-glucan 11
histatin-5 11
candidacidal 11
miconazole 11
CGT 11
stevor 11
STEVOR 11
co-directional 11
flaps 11
Thaled® 11
Myeloma 11
8-11; 11
EGCG 11
video-EEG 11
tuberculosis) 11
Venereology 11
alpha-melanocyte 11
cytokinin 11
compromise, 11
(HDACs 11
PRMT5 11
smaller. 11
splits. 11
chromatin-interaction 11
baldness. 11
stenosis) 11
compressing 11
AGO1 11
surfing 11
10-mg/kg 11
Subscale 11
mean±SD 11
decrements 11
angiosarcoma 11
(INSR) 11
dapsone 11
farther 11
TIA1/TIAL1 11
Titin, 11
GATA4, 11
LST8 11
ISIS 11
alpha(4)beta(7) 11
hydrops. 11
sialoprotein 11
Inc.) 11
quadrivalent 11
(SNVs) 11
alpha-spectrin 11
Thrombophilia 11
superfused 11
DUF 11
CT: 11
transthyretin. 11
wrinkles, 11
SOD1(G93A) 11
OATP1B3-mediated 11
atazanavir, 11
amprenavir, 11
transaminase; 11
nelfinavir, 11
trovafloxacin, 11
brain-injured 11
msp-1 11
relic 11
Transcriptionally 11
fanca 11
(HIPEC). 11
Sema3A 11
Investigator's 11
adenotonsillectomy 11
post-injury 11
(AVI-4658). 11
annonacin 11
narcosis 11
postherpetic 11
PR-Set7. 11
COL5A2, 11
MUL, 11
prenatal-onset 11
nanism; 11
MUL) 11
mono-ubiquitinated 11
poly-ubiquitinated 11
Regulators 11
cementum, 11
Rfx1 11
Apnea 11
Fate. 11
Neurogranin 11
T68D 11
5-HT2AR 11
dexfenfluramine 11
Lt. 11
[18F]altanserin. 11
Wegener's 11
PTPN22-620W 11
T1D, 11
hPMS2 11
Regulates 11
Na(V)1.5 11
Am. 11
(CNVs). 11
IMR90 11
P-FAKSer732 11
violet 11
(H3T3ph) 11
(CPC) 11
hemolysis. 11
INK4A-ARF 11
Al 11
tympanometry 11
Failed 11
lariat 11
acanthocytosis. 11
hedgehog, 11
455 11
(LRES). 11
KLK 11
serious, 11
phenotypes; 11
(Nox) 11
(IL-1RI) 11
revisit 11
groucho 11
PCDH19 11
40.8% 11
virological 11
Hemicraniectomy 11
AGES-Reykjavik 11
WED, 11
cholestasis. 11
non-cirrhotic 11
M-protein 11
(PNMT) 11
hydroxylase, 11
ramifications 11
tables, 11
Dehydrogenase 11
CJD. 11
Containing 11
DeepBlue 11
resonance-guided 11
Moderate-to-Severe 11
cranium 11
synapses, 11
PEGylated 11
peginesatide, 11
SERD 11
REST/NRSF 11
Americas 11
(MenB). 11
4CMenB. 11
(IMD) 11
(NHBA), 11
metaphyseal 11
hypertrichosis. 11
http://www.bioinfo-hr.org/inca 11
tutorial. 11
sQTLseekeR 11
Contrave 11
Raxibacumab, 11
cocktails 11
DOTAP 11
VEGFR-TKI 11
ether-à-go-go-related 11
(NSAIDs) 11
funnel 11
Aseptic 11
protein-1β 11
(MIP-1β), 11
statins' 11
[1] 11
globe, 11
ducks, 11
Zanamivir 11
beta-peptide, 11
TMDs 11
modification: 11
IFNG 11
disaggregase 11
apoE4, 11
CVR 11
webSDA: 11
atomically 11
preventable. 11
Suppurativa 11
HOIP 11
high-delirium 11
orthopedic-field 11
(ADL), 11
alkalosis, 11
freckles 11
Ihh, 11
lips 11
switchover 11
tRNA, 11
MiRduplexSVM: 11
High-Performing 11
MiRNA-Duplex 11
Methodology. 11
miRBase, 11
ACVR1, 11
NOG 11
Ascher's 11
ligament. 11
85.0%) 11
(20/20, 11
100.0%) 11
(CA-MRSA) 11
(Sexual 11
[SEP] 11
(Bexsero) 11
noncomparative, 11
FHbp 11
(GKRS) 11
Gy. 11
Psychogenic 11
chiasm 11
strabismus, 11
(ISIS-SMN(Rx)) 11
LncRNAs 11
iodonium. 11
[diphenylene 11
oAβ, 11
panencephalitis. 11
(NSD-1015), 11
L-aromatic 11
MRP5 11
Arg100 11
PC5, 11
droplet-associated 11
hepatosteatosis 11
methylKit, 11
RADAR: 11
RADAR--a 11
(Drosophila 11
swi6 11
Cul4 11
Cut4 11
LINC01089 11
Metastasis; 11
LIMT), 11
fanc 11
fiber-to-fiber 11
sSMC. 11
traseR: 11
explosions 11
gliomas), 11
MBG 11
ANP32E 11
haem 11
Protein-Losing 11
lymphatics. 11
Microphthalmos 11
Hox-Pbx 11
BSs 11
Hox/Pbx-independent 11
cup 11
territory-specific 11
Meis1(-/-) 11
blurred. 11
coagulation/fibrinolysis 11
non-survivors 11
drawbacks. 11
Yaf9 11
PIE1 11
CENP-A, 11
Hypoglycin 11
(Kcr). 11
diphtheriae, 11
(U01NS076788). 11
terminator, 11
NFRs 11
RW 11
http://revigo.irb.hr/. 11
CYP2B6 11
patch-clamped 11
Biocytin, 11
ultrathin 11
Ependymomas 11
(DIPG), 11
Wnt9a/Prickle1/Fzd2 11
(8-MOP) 11
PUVA. 11
depots 11
burning, 11
MIF 11
Design. 11
(SUR1) 11
"gene 11
TSOACs 11
(LHON). 11
antiarrhythmic. 11
(NPLB) 11
organism-independent 11
(FBN1). 11
ChIPpeakAnno 11
arabinoside-based 11
M2-subtype 11
(RRM2) 11
(TOP2B) 11
TOP2B/TOP2 11
Pold3 11
mis18 11
Mis18β 11
Mis18BP1(KNL2), 11
(DHBV) 11
Neuroblastoma. 11
PacBio 11
PANTHER 11
difficile. 11
anti-TcdA 11
anti-TcdB 11
CC-10004 11
(5.3% 11
5.8%) 11
LR- 11
IE62 11
double-hexamer 11
hypophosphataemic 11
case]. 11
Bowtie 11
(http://bioinformatics.hitsz.edu.cn/Pse-in-One/), 11
t(13;22) 11
(coiled) 11
FHB 11
ADAMTS-13 11
(LOLA) 11
automatable 11
CNCs/UCEs, 11
(CEGA), 11
701 11
flood 11
Fkh2, 11
Integrity. 11
Swi1, 11
tularemia, 11
pre-computed 11
elvitegravir, 11
cobicistat, 11
SRT3025 11
subtilisin 11
T-Brain-1--A 11
(Cd44, 11
Cntn6, 11
Gpc6, 11
Ntng1) 11
laBCC 11
(TAD) 11
polymerase's 11
15-kDa 11
C-ribbon 11
histone-DNA 11
microdermabrasion 11
Klumpfuss 11
prioritisation 11
's 11
cediranib) 11
(HR=1.24, 11
STAR 11
C11 11
XLID 11
ipilimumab-naive 11
Q3W 11
(FRAX) 11
RPE65-mediated 11
Galen 11
DMR2 11
data-download 11
"download 11
analyze" 11
cloud-computing 11
Mashl 11
lapatinib 11
0.045; 11
sign), 11
partitioners. 11
Reb1 11
abf1 11
TIR1, 11
tir1 11
onychomycosis 11
tetracyclines 11
(SIOD), 11
t(11;22)(q23;q11) 11
LHON. 11
aOR 11
clival 11
TFNs 11
(AHI 11
NHT 11
LAPC 11
poly(ADP-ribosyl)ation. 11
Pore, 11
Miravirsen 11
CancerSubtypes: 11
Material. 11
Strep 11
centor 11
Aux/IAAs 11
radicis-lycopersici 11
CSV, 11
GTF, 11
JSON, 11
XML 11
Variation, 11
DNA-methylation, 11
DNA-seq, 11
miRNA-seq, 11
(V1,V2) 11
biospecimen 11
attribute-value 11
SMC1A 11
CGRP-mAb 11
(CGRP-mAbs) 11
region-to-annotation 11
varum 11
DAA-containing 11
Dlx1/2 11
libgapmis: 11
alignment; 11
seed-and-extend 11
prefix 11
read--the 11
seed--an 11
read--extend. 11
http://www.exelixis-lab.org/gapmis. 11
ATF4, 11
(RNA-DNA 11
RNA-RNA). 11
(MELD) 11
Gardnerella 11
HIV-1/2 11
(122/152, 11
80.3%, 11
(p=0.009), 11
72.4% 11
(specialized 11
osteomyelitis) 11
neurosarcoidosis 11
non-islet 11
normal-adjacent 11
'RIblast', 11
dysphoria, 11
mimic. 11
emphysematous 11
TCPO(2) 11
Diaskintest® 11
(Proseek 11
corr 11
phaeomelanin 11
Arg160Trp 11
D294H, 11
Tibetan-specific 11
Himalayan 11
Formalin 11
Brucellosis 11
DDIs 11
disaccharidase 10
sex-modified 10
heterogonous 10
AREG 10
myoepithelial 10
TGF-α 10
alpha-smooth 10
MFs 10
25.0 10
classes: 10
neuregulin 10
Exosomal 10
vitronectin 10
bridges, 10
protruding 10
proteoglycans 10
9277 10
neutrally 10
sequences-particularly 10
"first 10
Thousands 10
multi-exon 10
336 10
log-odds 10
327 10
bond, 10
osteocalcin 10
immunopathological 10
destruction, 10
TRAP-positive 10
orally. 10
downregulated, 10
miRNA. 10
(miRs) 10
III/IV 10
Germany). 10
exertion. 10
non-progressive 10
Acetylcholinesterase 10
mofetil 10
steroid-sparing 10
2010) 10
pedicle 10
SREs 10
calcitonin, 10
women), 10
hip, 10
4.1% 10
castrate-resistant 10
Federal 10
FDA's 10
strontium 10
Fully 10
FDA, 10
DVL-3 10
diverge 10
chordates, 10
Wnt-mediated 10
Bull 10
Occasionally, 10
nonlesional 10
coexistent 10
monitoring: 10
perhexiline. 10
safety) 10
[Current 10
(I-IV) 10
deactivating 10
(eg 10
Notch1, 10
Notch-related 10
0.66, 10
0.76, 10
[17%] 10
owned 10
orteronel-prednisone 10
(14% 10
Cycle 10
30.8 10
omeprazole, 10
Guidance 10
(+)-3c 10
androgenic 10
ng/dL) 10
Re-H 10
mystery 10
LNCaPdcc 10
xenograft. 10
C4-2 10
killing. 10
Definitive 10
us, 10
borne 10
dual-color 10
39), 10
participate. 10
20%). 10
IHC, 10
5-7 10
positive; 10
DHT 10
(CB) 10
20-30 10
KLF4 10
factors) 10
GCT 10
AF-iPS 10
3%, 10
Contribution 10
officially 10
Iran, 10
mobilizing 10
objective, 10
cores, 10
phagocytes. 10
(Panx1) 10
trans, 10
demand, 10
Beneficial 10
beta-blockers. 10
left. 10
disease's 10
Misregulation 10
interconnections 10
hese 10
Genetically 10
exceptions. 10
brother, 10
atypia 10
ADH/FEA, 10
TWIST1) 10
Sarco(endo)plasmic 10
Echocardiographic 10
unresolved, 10
[Ca(2+)](SR) 10
reversed-phase 10
Utilization 10
pesticides. 10
colorimetric 10
(12.4 10
xenobiotic 10
bromodomain. 10
ZA 10
cavity, 10
bromodomains, 10
four-helix 10
barium 10
colorectum, 10
endoscopy. 10
0.0003), 10
0.2). 10
macroscopically 10
enterocolitis 10
pathologists. 10
(controls) 10
(14.3%) 10
ileitis 10
adequate. 10
nongenomic 10
(E2) 10
attenuated. 10
IL-1β. 10
root, 10
aggregating 10
RANTES/CCL5 10
JNK2alpha2 10
383 10
desorption/ionization 10
undertaken, 10
helpful, 10
partial-onset 10
chemo- 10
t(11;22)(q24:q12) 10
engine 10
ES. 10
Mosaic 10
wondered 10
aspects]. 10
t(11; 10
PANC1 10
substitution) 10
assertion 10
NR0B1, 10
GGAA-microsatellite 10
GGAA-microsatellites 10
(aHUS) 10
thrombomodulin 10
aHUS. 10
acquired, 10
pneumoniae. 10
normalized. 10
typical, 10
infarcts. 10
washed 10
(effect 10
m(-2), 10
exercise) 10
CON 10
8-h 10
anti-metastatic 10
0-2 10
1.27, 10
laparoscopy, 10
abdomen. 10
24.9 10
3%. 10
CFS 10
Eindhoven 10
IN-PATSAT32 10
marathon. 10
p=0.003) 10
rugby 10
stunning 10
(97 10
29) 10
type). 10
geography 10
0.80, 10
influences. 10
menses. 10
strata. 10
Reproductive 10
CI). 10
pharmacological, 10
making, 10
decisional 10
answered. 10
36. 10
(n=18) 10
(12/48). 10
(4/48) 10
doughy 10
9: 10
1359 10
2.0% 10
statin-intolerant 10
transitioning 10
elected 10
apheresis 10
East, 10
Patients, 10
415 10
(n=55), 10
spurred 10
non-familial 10
(FH) 10
underdiagnosed. 10
lowering. 10
Anti-PCSK9 10
Co-primary 10
(AEs), 10
Receiving 10
hyperlipidemia. 10
limiting. 10
cross-transgenesis 10
tag, 10
S-adenosyl 10
Michael 10
neuroepithelioma, 10
poor-risk 10
72-hour 10
histogenesis 10
O13 10
Gynaecology 10
spasm, 10
µCi) 10
Absorbed 10
feces. 10
pathway(s) 10
link? 10
co-localise 10
Cushing 10
transsphenoidal 10
mutation-related 10
somatostatin 10
bind. 10
ATPase. 10
McTnC 10
NIQD 10
Rana 10
sham-controlled 10
cured, 10
'incorrect' 10
autumn 10
Meier 10
painless, 10
follow-up; 10
21.4% 10
12.5% 10
8-cell 10
SUV39H1, 10
HMTases 10
Xi. 10
HSPs 10
16-amino 10
(68 10
extra-telomeric 10
caps 10
(HSP70) 10
PI3K/Akt, 10
mg/m² 10
Telomerase, 10
granulocyte/macrophage 10
c-Src-phosphatidylinositol 10
3-kinase-AKT-mammalian 10
Proximal 10
3-kinase/AKT 10
transwell 10
(PI3K)/protein 10
antiapoptosis 10
PI3-K-Akt 10
factor/scatter 10
proliferate, 10
(N. 10
(AFP) 10
aggressively 10
whom, 10
mitigates 10
(SGA) 10
third-trimester 10
23-year-old 10
impending 10
352 10
included; 10
(POR, 10
1.00; 10
Kaiser 10
Permanente 10
(27% 10
Aged 10
25.0% 10
CH, 10
choreic 10
prevalently 10
SP-B 10
TTF1/NKX2.1 10
Clathrin 10
post-Golgi 10
syncytiotrophoblasts 10
reporters. 10
Förster 10
compartment-specific 10
hypoalgesic 10
States) 10
selects 10
N3'→P5' 10
properties; 10
distributive 10
imetelstat-mediated 10
imetelstat. 10
findings: 10
(P=0.002), 10
(SAR231893/REGN668), 10
medium-dose 10
LABAs 10
(44%), 10
0.28; 10
Baller-Gerold 10
stature. 10
homozygous. 10
"dark 10
matter" 10
pendrin. 10
Mondini 10
411 10
coils 10
region) 10
(proband 10
aqueduct. 10
FT4, 10
contraindications, 10
UTI 10
administration; 10
renoprotective 10
(PFS; 10
contaminating 10
whole, 10
Filter 10
ultrafiltration 10
Making 10
Paired 10
Pain. 10
walking, 10
walking. 10
Map 10
annotated, 10
original, 10
fistula. 10
etc.), 10
nails 10
analyzer 10
*4 10
(37%, 10
polymorphic, 10
(CYP2C19) 10
Temozolomide, 10
Deacetylase 10
(GB) 10
23.9 10
TMZ/RT 10
LEV 10
puts 10
native, 10
GRN 10
Hypoxia-inducible 10
chloroquine, 10
LAMP2A 10
crystals, 10
colchicine, 10
amoxicillin/clavulanic 10
Mode 10
HIL 10
inducibly 10
phosphoenolpyruvate 10
constant. 10
(22%). 10
46.5% 10
5.9, 10
Multidimensional 10
dose-dense 10
(22%), 10
Ninety-eight 10
B3 10
cycles; 10
(KPS) 10
favourably 10
tolerable, 10
CTCAE 10
100-200 10
1991, 10
hips 10
accordance, 10
heterogeneous; 10
cell-activating 10
CXCR4, 10
CXCR1 10
cellularity, 10
monocyte/macrophage 10
dementia; 10
Geriatric 10
Fifty-four 10
Conscientiousness 10
Openness 10
(DAT) 10
Costa 10
7%, 10
tumours: 10
Databases 10
1.03; 10
0.49; 10
rhabdomyosarcoma 10
ews/erg 10
(fusion 10
amplified, 10
CTCF-independent 10
cohesin-bound 10
Igkappa 10
Imprinting 10
Pcdh 10
(PPIs) 10
self-assembly 10
deleted. 10
interact, 10
sarcomeres 10
biventricular 10
RSTS. 10
angulation 10
Applied 10
(Aire) 10
germline-specific 10
PAR-CliP 10
coimmunoprecipitated 10
ultrasonography, 10
dysfunctions, 10
thyrotoxicosis, 10
groups). 10
continued, 10
recur. 10
videos 10
residents. 10
sessions, 10
(IMT) 10
Leg 10
contractures, 10
quotient 10
pulmonic 10
Dermal 10
markers; 10
bracket 10
Sepp1 10
bulb. 10
disulphide 10
merged 10
Mammals 10
collagen-rich 10
infarct. 10
Immunofluorescent 10
matters 10
(ANOVA) 10
3-OMD 10
s(-1)). 10
fingerprinting 10
LSD 10
(2D) 10
Correspondingly, 10
purification. 10
disparity 10
MK 10
Haloferax 10
asymmetry. 10
NRC-1 10
trichoepitheliomas, 10
9p21 10
cylindroma 10
patterning, 10
proliferative, 10
(SMN1) 10
(survival 10
Rheb-GAP 10
ATP- 10
>90 10
(CMT1), 10
15th 10
Krev1 10
coimmunoprecipitation, 10
Variable 10
enumeration 10
four), 10
vasodilatory 10
(TR), 10
d, 10
heart: 10
effect; 10
pellet 10
Wall 10
vasorelaxation 10
10(-4) 10
near-normal 10
Postoperatively, 10
verifying 10
(n=17) 10
ZincPharmer 10
countries-alogliptin, 10
saxagliptin. 10
distinctions 10
Interval 10
'linagliptin', 10
RESEARCH 10
[MD 10
0.63, 10
1.04, 10
(0.88, 10
pharmacokinetic, 10
1356 10
once-a-day 10
(A1C) 10
treatment-experienced 10
thiazolidinedione 10
Serbian 10
Oxygen 10
Scale-Revised 10
psychostimulants 10
psychoactive 10
5A 10
well-validated 10
Cranial 10
acuity. 10
MLST 10
farm 10
conformations, 10
bithorax 10
reintroduced 10
C5-MTase 10
scrutiny 10
leaves. 10
(UBA) 10
UBA 10
singlet 10
Skp2 10
PARP-2 10
SET-domain 10
protein-7 10
hematocrit 10
glomerulopathy 10
frogs, 10
cpSRP43. 10
chromatic 10
ortholog, 10
(CMT3) 10
(mortality 10
ablated 10
Interestingly 10
Collectively 10
lysates. 10
signal-regulating 10
(CHD5) 10
isolation. 10
1-like 10
pedigrees, 10
(H3K9me3) 10
Pf1 10
(TE) 10
SK-N-SH 10
Gas 10
transformant 10
myelination, 10
(CGH) 10
(P=0.04). 10
monomethylated 10
(H3K27me2 10
H3K27me3) 10
cementum. 10
MSI-H 10
modified. 10
reinforced 10
(http://www.dyogen.ens.fr/genomicus/) 10
Plants). 10
Causative 10
again. 10
la 10
flutter. 10
racemic 10
declined. 10
(5.5% 10
DA, 10
guanidinoacetate 10
BMP-6 10
TGF-beta, 10
(inhibitor 10
[Influence 10
TFAM 10
Excess 10
susceptibilities 10
TIEG2 10
MEFs. 10
p21(WAF1/CIP1) 10
Adenoviral 10
formations. 10
dynamin-like 10
Opa1. 10
15d-PGJ2 10
cristae, 10
cm). 10
ceftriaxone, 10
saline-treated 10
1040 10
modest. 10
(Trial 10
(TSH), 10
hormone-binding 10
estradiol, 10
thyroxine, 10
Finland, 10
pronounced. 10
rearrange 10
MAOB 10
SNP. 10
459 10
Arg(14) 10
Ca-handling 10
(nucleic 10
Leu-39 10
Ca(2+)-cycling 10
(PLN-R14Del) 10
questionable. 10
C: 10
drink 10
30-min 10
(SOD), 10
Supplementation 10
PUFA 10
counterbalanced 10
(ESR) 10
CMT-associated 10
appeared, 10
(GARS), 10
vector-mediated 10
attracting 10
interests. 10
color. 10
GPI 10
CD14, 10
3-deazaneplanocin 10
(K) 10
Trimethylated 10
Set9 10
(BMF), 10
nonmyeloablative 10
chimerism 10
intraoral 10
-320 10
1a. 10
etc 10
underlining 10
centrosomes, 10
b, 10
PH. 10
LC3B 10
additionally, 10
Atg5 10
β-amyloid, 10
decorated 10
ATG7 10
Rab7 10
0.004 10
(wild-type) 10
16.3 10
Practical 10
(NOAC) 10
NOA 10
fondaparinux, 10
[Pharmacologic 10
encouraging. 10
manufacturers 10
(international 10
Å. 10
operon. 10
pXO1. 10
cya, 10
pag, 10
atx4-null 10
Transposon-insertion 10
atxA-dependent 10
CO2- 10
bicarbonate-mediated 10
electroporation 10
slot-blot 10
translation-initiation 10
capB. 10
(protective 10
dual-function 10
leukaemic 10
14q 10
T-bet 10
(5%). 10
TMPDB: 10
intron/exon 10
Allele 10
5,000 10
(ET-1) 10
Novo 10
autoradiography. 10
crosslinks. 10
49, 10
methanesulfonate 10
ixazomib. 10
UMSCC-1 10
Cal33, 10
205- 10
64-fold 10
(8- 10
29-fold), 10
entinostat. 10
Bik, 10
Bik 10
MDR-1/P-gp. 10
reversin 10
drug(s) 10
Cav3 10
acid; 10
(HSV-1) 10
(PCH) 10
amine-associated 10
clamped 10
I(K1) 10
depressant 10
(0.4 10
15). 10
.005). 10
tropism 10
deranged 10
Muckle-Wells 10
orthologs. 10
dominance. 10
discard 10
(16%). 10
unfused 10
present-day 10
crystallized 10
branches. 10
CCAAT/enhancer-binding 10
8505C 10
1.75 10
pursue 10
including, 10
Ctf18 10
re-engage 10
Eco1. 10
ctf4Δ 10
chl1Δ 10
greater. 10
(γH2AX) 10
mg/mL 10
Ubc13 10
17.9 10
Diagnosis, 10
CD31 10
BT474 10
cotreated 10
(TRalpha1) 10
Omnibus 10
dimer-to-tetramer 10
serine, 10
accordingly, 10
kg/m(2). 10
FPG, 10
excursions 10
means, 10
13; 10
period; 10
cases: 10
(CASQ2), 10
CPDs 10
Elc1 10
NER. 10
UV-irradiated 10
NTS 10
moyamoya. 10
bFGF, 10
dysmorphism. 10
bicuspid 10
classification) 10
Scottish 10
intima 10
unknown; 10
heterozygosity. 10
minigene. 10
(SpA) 10
optimized. 10
amikacin 10
(MIC) 10
idiopathic. 10
FMF, 10
bi-allelic 10
24.8 10
(78% 10
Knudson's 10
beta. 10
multi-subunit 10
H3K9me2. 10
SET1 10
unilateral, 10
440 10
mg/m2) 10
100. 10
w, 10
CPB. 10
radioimmunoassay 10
itemset 10
limitations: 10
cullins 10
CLI 10
postinfection 10
virus-like 10
adsorbed 10
homogenates, 10
transfections 10
metastasis-free 10
EGAPP 10
Phosphatases 10
518 10
beta-arrestin 10
hVH5 10
Language 10
immunogenicity. 10
fractured 10
Frailty 10
male; 10
interrelation 10
nondepressed 10
self-rated 10
<18 10
categorised 10
(enChIP), 10
96%, 10
(12), 10
organotypic 10
13-cis-retinoic 10
pregnant, 10
entail 10
toxicant 10
9.1% 10
p53's 10
restrain 10
(MDM2), 10
Dose-response 10
cyclization 10
Amonafide 10
perinucleolar 10
(Topo 10
Epoxy 10
(m-AMSA) 10
DC3F/9-OHE 10
viscosity 10
guanine-cytosine 10
headgroup 10
hydrophobicity 10
passage. 10
(CAT) 10
dyes, 10
supercoils 10
prominent. 10
(10- 10
854 10
responders. 10
polyglutamine-induced 10
fetal, 10
miR-125b, 10
slices, 10
Immunogold 10
EAAC1. 10
0.06, 10
ASCT1 10
ezrin 10
astroglia 10
sperm, 10
(out 10
Sypro 10
dye, 10
pI 10
stains, 10
PAGE 10
antigenicity 10
HPV16-transformed 10
polymers, 10
Antiplatelet 10
U373-MAGI-CCR5 10
medicine: 10
(ISS) 10
spp.) 10
Live 10
pathogen-free 10
stock 10
analgesics. 10
antagonism. 10
(HSCs), 10
craniosynostoses, 10
"Mercedes 10
phenotype? 10
AMPK. 10
Gli1, 10
(TSC), 10
glycosides 10
talin 10
transformative 10
logical 10
starving 10
electron-dense 10
thyroidologists 10
FT(3) 10
include, 10
FR 10
(TRs) 10
TRbeta1, 10
HLA-B*5701, 10
(HSR) 10
(AKI). 10
0.52, 10
(2.8 10
origin; 10
Tricyclic 10
pre-B 10
CD43 10
mucin 10
CD74 10
fructose 10
subfamily. 10
Hamartin 10
pinpointed 10
back. 10
27%, 10
partnerships 10
warnings 10
(IS) 10
anti-Cag 10
emboli 10
1.33 10
interleukin-8 10
effectively, 10
articulation, 10
prosody 10
vowel 10
reading, 10
HMM-based 10
IGF-1, 10
substances, 10
decidua 10
nonerosive 10
underused 10
subtle. 10
erosions, 10
Sandhoff 10
subnormal 10
juvenile, 10
phospholipids, 10
PET-CT 10
murmur 10
heterogeneously 10
decompressed 10
(DDMS) 10
zones. 10
Interictal 10
hemisphere, 10
cerebrum 10
hemiatrophy. 10
Ipsilateral 10
supercomplex 10
Complexes 10
transcription) 10
demarcated 10
latency-associated 10
Phf19 10
(alpha, 10
conform 10
multisite 10
reproducing 10
(73 10
1.06; 10
gliclazide 10
stroke/systemic 10
Infarction 10
post-hoc 10
1.72, 10
SVD 10
Daily, 10
P<0.0001). 10
hour) 10
pools, 10
X-inactive 10
body: 10
metabolomics, 10
shift. 10
instrumentation 10
Distant 10
2%) 10
(CTA) 10
scenarios, 10
spare 10
62.5 10
forget 10
defensive 10
Metabolomics 10
succinic 10
stretch-induced 10
RC. 10
urate 10
stores, 10
title 10
mock-infected 10
Flavivirus, 10
(22.2 10
patches. 10
(NRT), 10
freshwater 10
UnResponsiveness) 10
integrated, 10
culturing 10
readout 10
inkjet 10
complex), 10
cell-laden 10
parabasal 10
t1/2 10
risk/benefit 10
dyspareunia, 10
estrogen. 10
VVA 10
woman's 10
dryness, 10
extrapolated 10
Polysomnography 10
alpha-2-delta 10
effect) 10
nonpharmacologic 10
opioids. 10
bruxism, 10
EFNS 10
opioids, 10
l-DOPA 10
Polysomnographic 10
polysaccharide 10
Cel12A 10
expansin 10
homology-based 10
nematodes, 10
hampers 10
microbicidal 10
gp91(phox) 10
Headaches 10
playground 10
haplotypes. 10
Epistatic 10
173), 10
H209 10
omega-agatoxin 10
immunoreaction 10
Probing 10
ultrasound-guided 10
cautiously 10
presume 10
Marinesco-Sjögren 10
18qter. 10
Accompanying 10
Nordic 10
1979 10
3.4; 10
prolines 10
endonuclease, 10
end-joining. 10
SC35 10
-9 10
immortalization. 10
(MEFs), 10
bystanders, 10
Oncogene-induced 10
transcriptomes. 10
Professor 10
thalassemias 10
entries, 10
automatically. 10
incorporated. 10
Humbug 10
insulin/IGF-1 10
noncatalytic 10
Inactivating 10
guidance, 10
microfilament 10
furrow 10
FH2 10
Rac-dependent 10
co-operate 10
octamers 10
lost. 10
Yang 10
signature', 10
species-type 10
eubacterium 10
(dinucleotide 10
Proteobacteria 10
(NCCM) 10
(LVNC) 10
desmoplakin 10
toddler 10
nanostructures 10
CCN 10
photoreceptors 10
PMF 10
(Edwards 10
anorectal 10
space-time 10
England, 10
0.06) 10
Authority 10
RNAi, 10
LSM1, 10
NS3. 10
cycloheximide, 10
g/l 10
Kluyveromyces 10
marxianus 10
bradykinesia, 10
Hsp70, 10
nigrostriatal 10
FDOPA 10
dopa-responsive 10
NCX1.1 10
2.8, 10
ranolazine, 10
ms; 10
opening, 10
paced 10
fueling 10
MM20 10
"Warburg 10
recycled 10
CL4 10
(Per) 10
SKBR3 10
ponatinib 10
responses; 10
Allosteric 10
10(9)/L, 10
(TA) 10
Oncology, 10
care: 10
fails, 10
mature, 10
1980s. 10
86%. 10
alive, 10
10773, 10
BI10773, 10
24-item 10
(SERT) 10
pindolol 10
(PFC) 10
(SERT 10
vortioxetine. 10
Montgomery-Åsberg 10
Extensible 10
children]. 10
<5 10
7q 10
(mRNAs) 10
FAK, 10
D3, 10
(Cdk) 10
configurations. 10
deregulate 10
microautophagy 10
incidentally 10
bacteriophages 10
Clustered 10
alpha-bases 10
gamma-bases 10
A+T 10
0.005), 10
genotype-specific 10
(0.25%) 10
mammals) 10
myosin. 10
L5 10
z-scores 10
endocarditis, 10
dihydroethidium 10
TGZ 10
STZ-induced 10
ineffectiveness 10
climate 10
GAN. 10
tubular-like 10
clearer 10
Pick 10
APP. 10
gamma-secretase, 10
uvrA, 10
(H(2)O(2)) 10
dynamin-2 10
ΔNp73 10
oogenesis, 10
(COX) 10
SHSY5Y 10
CTR2. 10
Mac1. 10
copper-dependent 10
salts 10
2A) 10
Trace 10
IL-7 10
infections; 10
lymphopenia. 10
culminating 10
p<0.0001), 10
Natalizumab, 10
leg, 10
5-day 10
purpura. 10
Lymphocyte 10
venom 10
10-day 10
lesions; 10
spliceR, 10
(HPA) 10
(T-PLL) 10
myth 10
phospho-tau 10
microhemorrhages 10
Amyloid-β 10
soluble, 10
Aβ(1-42) 10
anti-β-amyloid 10
Ala92 10
1980. 10
reoperation 10
hypercoagulable 10
effect' 10
outweighs 10
1988. 10
630 10
limit. 10
clades. 10
CC398 10
RD 10
homoplasy. 10
interview, 10
Fluoxetine 10
quiescent, 10
What's 10
Id 10
immunotherapies. 10
Merck's 10
Mono-allelic 10
(germline 10
homopolymer 10
Uppsala, 10
Stockholm, 10
duodenum. 10
erythropoietin. 10
EEG, 10
TV 10
2.7, 10
organophosphates 10
Searching 10
veterans. 10
symptoms; 10
hemorrhage; 10
(PCCs) 10
(PGLs) 10
NETs. 10
INPULSIS-2 10
disappointing, 10
lung-function 10
George's 10
1066 10
considerations, 10
rats; 10
Sprague 10
day(-1) 10
(SIRT) 10
syndrome'. 10
mandatory. 10
Weaning 10
acid-base 10
vinyl 10
kin 10
worse. 10
(polyneuropathy, 10
Electrophoretic 10
(7) 10
o 10
OL 10
Neurons 10
TNF-alpha, 10
neurosurgeons. 10
16.6 10
oncology, 10
Los 10
SB. 10
grinding 10
SB, 10
reflow 10
2.3% 10
minutes: 10
figures, 10
leaflets 10
WS, 10
OGTT 10
sibutramine 10
sample) 10
(7.0 10
0.4, 10
Albumin 10
alpha1-antitrypsin 10
(α-syn) 10
Menstrual 10
PRISM 10
(Clinical 10
scores) 10
warned 10
emotionally 10
Cycles 10
5-17 10
Tumors, 10
platelets, 10
angiostatin 10
Bonferroni 10
microg/ml 10
generally, 10
Quebec 10
Off-label 10
Conservative 10
Consultation 10
vardenafil, 10
24-48 10
2.6-fold 10
variable-length 10
Y., 10
bridged 10
Mg(2+) 10
(Schizosaccharomyces 10
dispensable. 10
residues) 10
Nocturnin 10
preparing 10
spondylitis. 10
RECENT 10
interleukin-17 10
(2-3 10
pruritic 10
targeted, 10
heteroplasmy 10
Recklinghausen 10
higher-grade 10
hit" 10
spermatozoa. 10
N-ras 10
picomolar 10
mentioned. 10
120, 10
41). 10
2008; 10
mutation-adapted 10
Correct 10
0.8) 10
(sd 10
random, 10
adenosines 10
FTO 10
cap, 10
CTL 10
CD1a+ 10
Survivin, 10
(c.1498 10
c>t, 10
p.R500X; 10
c.1710 10
g>a, 10
p.W570X). 10
iloprost, 10
(HAE) 10
Pharmacy 10
dimensions. 10
infants: 10
Marrow 10
SPF 10
IL-10(-/-) 10
tonsils 10
trisomy. 10
co-occur 10
small-for-date 10
inhibitor-based 10
12-48 10
accepted. 10
cytology, 10
shields 10
CRD-BP, 10
diffraction, 10
epithelial, 10
Veterinary 10
donation, 10
54.9 10
DLB, 10
threads 10
DLB. 10
compartmentalization, 10
N-terminal, 10
Proteinase 10
midbrain, 10
intra-uterine 10
(21%), 10
hyperechoic 10
reproducible. 10
(8.9%) 10
(6.3%) 10
(6.3%). 10
EPR 10
sarcopenia. 10
(two). 10
USP49 10
(MDR-TB) 10
commonly. 10
Two-year 10
ultra-high 10
Isoform 10
identities 10
pervasively 10
quantification, 10
Lys(4) 10
confounds 10
ejection, 10
quadrant 10
thoracoabdominal 10
exocytosis. 10
It's 10
achievement, 10
hyperinsulinism, 10
metformin-treated 10
CC, 10
tags. 10
thermolysin 10
S1 10
solubilization 10
3700 10
correspondingly 10
interviews, 10
ICD-10 10
Edition 10
65) 10
mepolizumab. 10
fasciitis, 10
CENTRAL, 10
function). 10
16-week 10
40%) 10
hyperferritinemia. 10
0.32 10
protean 10
redness, 10
(SB-240563), 10
maturational 10
(half-life 10
pg/mL) 10
encephalopathy]. 10
52%, 10
well; 10
seizure-free 10
Terminology 10
dHMN-V, 10
hands. 10
slowly. 10
44. 10
Inpatient 10
Single-strand 10
QTc, 10
mV. 10
BCC. 10
ulcer, 10
latitude 10
Delay 10
edge, 10
insulin- 10
Sirt1-independent 10
TSC1/2-deficient 10
oxLDL 10
nociceptors. 10
(TMZ), 10
nutrients, 10
Clonogenic 10
243 10
CXL 10
keratoconus 10
keratometry, 10
Pittsburgh 10
morphine. 10
analgesia. 10
repletion, 10
part. 10
425 10
nervosa 10
HAQ 10
Patient's 10
makeup 10
upgrade 10
pediatric, 10
Korsakoff's 10
alcoholism. 10
pollutants 10
therapy]. 10
genotype-guided 10
56, 10
angioplastic 10
(Study 10
Bedouin 10
homozygously 10
radioprotection 10
chemoembolization 10
exosome-like 10
podocytes. 10
trans-repressive 10
SALL4. 10
marrows, 10
EBF1, 10
hematopoietic-specific 10
ME 10
densitometry 10
ATS. 10
valve, 10
BMP, 10
non-tumorigenic 10
Radiographic 10
dramatically. 10
sheets 10
erythroderma, 10
Proteolytic 10
(LEKTI), 10
G1258A 10
trypsin-like 10
delusions 10
Fibrillar 10
(DTT) 10
livers. 10
MAML 10
MAML1.ICN.CSL.DNA 10
transduces 10
33, 10
swapping 10
-B, 10
testing; 10
(NO), 10
impeding 10
eucaryotic 10
wiring 10
E325K 10
47-year-old 10
curable 10
orexin-A 10
OX2R 10
(MK-4305) 10
wash-out 10
UTIs 10
30.6 10
phenol 10
-1.2 10
HypoGen 10
GRBs, 10
HCNE/target 10
Xenopus, 10
vertebrate, 10
fishes, 10
miscarriage. 10
damage: 10
wavefront 10
reproduces 10
PIDs 10
MCAO. 10
species-dependent 10
(PLB). 10
Thr17, 10
Ca-ATPase. 10
TM2-115 10
competitive, 10
perpetuate 10
homogenates. 10
Nkx2-5, 10
phosphoglycerate 10
undetermined. 10
infiltrative 10
(1p/19q 10
5.5) 10
HLA-DR 10
Event 10
35.9% 10
CP-690,550, 10
[90% 10
(SF-36) 10
TALE 10
β-thalassemia 10
harnessed 10
complementary, 10
Post-operative 10
diazepam, 10
FA-associated 10
0.029). 10
16.7, 10
hopping 10
Lhx2 10
neuroanatomical 10
situ, 10
hCSCs 10
reentry 10
factor-receptor 10
drawback 10
caspase-1, 10
cecal 10
hth 10
pseudoobscura, 10
terrestrial 10
(SCN). 10
haemopoietic 10
16.7% 10
convulsion 10
bronchitis, 10
mg/kg/day. 10
(ECM). 10
anti-correlated 10
Periostin 10
stemness, 10
calcium-release 10
keyword 10
(FSHD1) 10
(DUX4) 10
chickens 10
welfare 10
immune-responsive 10
stem-cell-derived 10
RCS 10
blindness, 10
Ni-rich 10
0.044), 10
asthenia, 10
high-power 10
physiopathology 10
hepatocyte-specific 10
nondepolarizing 10
vecuronium, 10
insurmountable 10
Hetlioz(®) 10
(tasimelteon) 10
Non-24-Hour 10
Sleep-Wake 10
(Non-24). 10
co-existing 10
mechanical, 10
trimer 10
dedicator 10
RhoG 10
531 10
attachment. 10
proteasomes, 10
(DUBs) 10
deubiquitinases 10
Lys-63 10
virus-associated 10
carcinogens 10
adenocarcinomas, 10
alpha-amanitin. 10
rolling-circle 10
ASBV-specific 10
NMDAR 10
CTEPH 10
curative. 10
(sGC) 10
dosing; 10
single-guide 10
defends 10
ibrutinib, 10
UI: 10
deliveries 10
carbamazepine. 10
S107 10
fluorescence, 10
modulator. 10
3.3% 10
59.6 10
intratumor 10
Early-stage 10
Gram-negative, 10
RNA-processing 10
(PABP) 10
CHL 10
heart-specific 10
hearing. 10
splicing: 10
Ca2+-calmodulin-dependent 10
site(s) 10
isoproterenol, 10
staff, 10
stress-dependent 10
operons 10
unidirectional 10
PKCδ, 10
melanoma-associated 10
enteroviral 10
apps. 10
35, 10
dermatology. 10
Windows. 10
shortage 10
ifosfamide, 10
MAbs, 10
CD99-H 10
Y) 10
minor, 10
synaptophysin, 10
NgM 10
derivatization 10
accurate. 10
gapped 10
polynomial 10
zhaohui.qin@emory.edu 10
expensive. 10
1992. 10
dome 10
(BS) 10
I-V 10
Tim44 10
UCP2 10
Injections 10
Transcription-factor 10
syndrome/spastic 10
Nivolumab, 10
pneumonitis. 10
C-X-C 10
ventromedial 10
(snoRNA) 10
GTP. 10
fibrogenic, 10
transformations 10
FA-D1. 10
(RYR2) 10
altogether. 10
s, 10
pond 10
uroepithelial 10
ftf 10
diary, 10
chymotrypsin-like 10
FDG-PET/CT 10
Atg4D 10
aegypti, 10
(11), 10
anaphase-promoting 10
hyphae. 10
peroxisomes, 10
homogeneously 10
Kras 10
followup 10
atenolol 10
anatomy, 10
Color 10
echocardiograms 10
doxycycline, 10
caught 10
re-examined 10
seas 10
21.7 10
S100B, 10
(n=5) 10
biomolecules. 10
34%, 10
32%, 10
Early-Onset 10
concerned. 10
propionyl 10
Alleles 10
E.coli, 10
acidemia, 10
carboxylation 10
Greenland. 10
site; 10
Neurostimulation 10
segmental, 10
BP-DBS 10
34.7 10
Palsy 10
tips, 10
belt 10
squeezed 10
with) 10
(rRNA) 10
(abnormal 10
cm. 10
Tumor-treating 10
low-intensity, 10
(TTFields). 10
kinase-independent 10
p300/CBP-associated 10
(PCAF) 10
transmittable 10
Carbamylation 10
k-nearest 10
phagocyte 10
endoreplication, 10
Ctf4p 10
1.0; 10
(24.6%) 10
thrombophlebitis, 10
1-mg 10
INN1 10
(MCM) 10
Cohesin-mediated 10
F508del 10
cepacia 10
Useful 10
insertions. 10
A-rich 10
spheres 10
PORB 10
porB-1 10
porC-1 10
quenching 10
foetus 10
pericarp 10
fruit. 10
Mo17 10
791 10
ganglioside-induced-differentiation-associated 10
(CMT4A) 10
(CMT2K 10
ARCMT2K). 10
axonal, 10
homology. 10
tissues; 10
Neurofilament 10
aldosterone, 10
hormone). 10
peaks. 10
scripts 10
0.0011). 10
(52 10
88.3% 10
flagella 10
elongate 10
346 10
Volumetric 10
taught 10
pro-atherogenic 10
IIA, 10
anion-transporting 10
sequences: 10
facet. 10
28.5% 10
cephalo-facial 10
pilot, 10
externalization 10
meanings 10
noncontrast 10
(AL) 10
scanner 10
ECV 10
immunoprecipitates 10
deacetylases, 10
carbonate, 10
headache: 10
(n=9) 10
TNF-α-mediated 10
unconditional 10
(n=59, 10
transrectal 10
Variables 10
573 10
4D), 10
(r) 10
bands. 10
immunoassays 10
specificity; 10
palindromes 10
AZD1480 10
(SB) 10
SCC. 10
computer-based 10
non-essential 10
(SUMO)-specific 10
3-10 10
TPN 10
antigen-dependent 10
R406. 10
Reperfusion 10
LDL. 10
diplopia 10
ophthalmoparesis 10
neurone 10
polyradiculoneuropathy 10
recombinations. 10
skews 10
HSCs, 10
proteostasis, 10
Labrador 10
ancestor, 10
Bangladeshi 10
1.4; 10
oncomiR 10
Scandinavica 10
dreamers 10
(myocardial 10
ml(-1) 10
FKHs 10
(2%), 10
miR-221/222 10
miR-223. 10
CC: 10
(FGFR2 10
canthi 10
craniosynostoses. 10
radiologic, 10
Particularly 10
(51% 10
modelled 10
7-methylguanosine 10
phosphatase) 10
incubating 10
sequestrants, 10
chemotaxis. 10
IRSp53, 10
VASP. 10
shortened, 10
Single-stranded 10
fever), 10
nonimmune 10
visiting 10
Annotated 10
(pHMMs), 10
cardiorespiratory 10
(AAG) 10
(Pompe 10
beats) 10
P545L 10
alpha-D-glucosidase 10
neuroscience, 10
ChR1/ChR2 10
Portugal. 10
Thanatophoric 10
referred. 10
could, 10
cffDNA. 10
bradykinin. 10
palpitations. 10
monomorphic 10
Tol2, 10
transgenesis. 10
(MWS; 10
retardation-multiple 10
MedSim 10
literature-based 10
dentigerous 10
Phylogenomics 10
mislead 10
MIP-1α 10
iloprost 10
yrs 10
precuneus 10
IKKα, 10
-oncogenic- 10
evinced 10
Calothrix 10
intestinalis. 10
isolates) 10
near-total 10
EDMD. 10
EDMD 10
humeroperoneal 10
Tendon 10
(VTE) 10
arginine. 10
cln3 10
(T 10
MET. 10
TGF-β2-mediated 10
TGF-beta1, 10
Raf/MAPK 10
Aft1. 10
Aft1/Aft2 10
RIM101 10
Repressor 10
decommissioning 10
Asn-140 10
Ser-23 10
(Saparbaev, 10
Laval, 10
8508-8513). 10
vsr 10
mug(+) 10
matuzumab. 10
OG 10
prognosis; 10
nimotuzumab, 10
(CR), 10
tailoring 10
trophoblasts 10
volunteers: 10
hypoactive 10
desire. 10
Disorder. 10
INDOC--a 10
microsome 10
BRCA. 10
(HR). 10
asphyxia. 10
allopurinol. 10
afterwards. 10
injury). 10
(NFL) 10
tau-negative 10
(P=0.04) 10
basin 10
FOG-2 10
+dp/dt 10
-dp/dt 10
analog. 10
RAW264.7 10
revisited 10
formation: 10
mCRY2 10
FBXL3 10
cocci 10
brain's 10
indicator, 10
Uhrf1 10
DMAP1 10
DSBs, 10
(cytosine 10
Volvox 10
transcapillary 10
microalbuminuric 10
TERalb 10
vertebrates: 10
PVP 10
BMD. 10
11.5% 10
LN, 10
(Oryza 10
continuum, 10
emerge, 10
oncoproteins, 10
U-rich 10
sheaths 10
Inositol 10
IP(3)Rs 10
brushes 10
(NHS) 10
fate, 10
large-scale, 10
Caco-2 10
provocation 10
Tachycardia 10
"leaky" 10
adrenergically 10
62%. 10
TTN 10
mirrors 10
EGFR-mutant 10
heparinized 10
0.23, 10
5q35.3 10
5q35.3, 10
inasmuch 10
p18, 10
99mTc-MIBI 10
SCA3 10
SAXS 10
saturating 10
(BER) 10
Toronto 10
Pigmenti 10
(Dhh), 10
Dramatic 10
providers' 10
3.4, 10
Su(var)3-9, 10
centromere-associated 10
(PEV) 10
mixtures]. 10
parameters; 10
printable 10
Bordeaux 10
hMSCs 10
TAM, 10
Specimens 10
mitoribosome 10
procaryotic 10
procaryotes 10
Condensation 10
HUbeta 10
CGRP-R 10
Asymmetric 10
RAMP1 10
photosensitizer 10
DISCUSSION: 10
protocol). 10
(±standard 10
Polifeprosan 10
3.85% 10
acquired. 10
abscess. 10
RISC 10
glycosylase, 10
plasmid-based 10
protein/extracellular 10
non-repetitive 10
g.21043 10
(c.282+2 10
T>A) 10
(IPI) 10
T1, 10
double, 10
PPNET 10
codY 10
creatinine-cystatin 10
≥65 10
rate: 10
obstetricians 10
072013: 10
CRAN 10
http://cran.r-project.org/web/packages/RAPIDR/index.html. 10
kitty.lo@ucl.ac.uk 10
company. 10
refusal 10
arrayCGH 10
(MPS)) 10
foresee 10
T21, 10
Probability 10
2007) 10
(0.65 10
parents' 10
Clinics 10
hypodense 10
FCN3 10
Cdk9 10
ipilimumab-refractory 10
dose-comparison 10
arise, 10
Nod1-deficient 10
meso-diaminopimelic 10
IL-1R1 10
Wt 10
RIP2 10
NGT 10
MMP9 10
MCP-1, 10
frightening 10
blepharitis. 10
phthirus 10
pilocarpine 10
blepharoconjunctivitis, 10
pubis, 10
Ca(2+)-release. 10
Ca(2+)-uptake 10
DNAm 10
875 10
0.10, 10
hours; 10
(NT) 10
62.0 10
3a, 10
Taylor 10
Marker 10
TDP1, 10
EPCs 10
(SQTS) 10
Trial: 10
where, 10
NO.: 10
grade) 10
neuroimmunological 10
campaign 10
scanning. 10
LINEs 10
(MTC) 10
resequenced 10
(V600E) 10
MAS 10
(IFT), 10
WDR60 10
TCTEX1D2 10
coimmunoprecipitates 10
(X-inactive 10
MeCP2. 10
(XCI), 10
IVP 10
vivo-derived 10
parthenogenetic 10
XIC 10
infectivity. 10
X-associated 10
(FMR1) 10
interactions; 10
I1171T, 10
S1206Y 10
Discov; 10
634 10
(hCG) 10
preconditioned 10
exploits 10
cardioversion, 10
bronchiectasis. 10
dystrophies. 10
DUX4-fl 10
GIT1 10
H3(K9) 10
SELECT 10
habitat 10
Anti-citrullinated 10
Peto 10
diet-fed 10
rnhA 10
R-loop. 10
Entacapone 10
post-marketing 10
agreement, 10
adjuncts 10
detach 10
Anatomical 10
ovary. 10
contacting 10
Dowling-Meara 10
In-hospital 10
infarction: 10
OPTN 10
hybridization) 10
cross-validated 10
<100 10
protease. 10
myxedematous 10
Clearly, 10
ctDNA. 10
hyperphosphorylation. 10
(SAEs) 10
AS01 10
ORs, 10
nucleolus, 10
unnoticed 10
physico-chemical 10
TMBs, 10
beta-contacts 10
propensities 10
alpha-helix 10
(CRMs). 10
non-regulatory 10
CRE 10
1%. 10
msec 10
Kufor-Rakeb 10
dystonia-parkinsonism. 10
centimorgans 10
perchlorate. 10
genistein 10
Surgery. 10
Indications 10
(CCSVI), 10
liberation 10
abroad 10
insufficiency" 10
follow-up) 10
scales: 10
times). 10
latitudes 10
arena. 10
TMS 10
FAVL 10
Rosen 10
Myerburg 10
Hmg20b 10
erythroblasts, 10
co-repressors 10
Gfi-1b(-/-) 10
(Revlimid) 10
Celgene 10
P-selectin 10
solutions, 10
SLC48 10
(FLVCR1), 10
FLVCR2 10
species; 10
CB1 10
eccrine 10
ISMARA: 10
transcriptions 10
pseudopodium 10
CdK9. 10
Ski 10
cholestasis, 10
O-GlcNAc 10
H2A.X 10
non-Hispanic 10
ubiquitylation, 10
sensors. 10
® 10
Hg; 10
(ORA), 10
relocalized 10
fibroblast, 10
methyl-CpG 10
(29%), 10
(TKI258), 10
Rabbits 10
delta(13)CO(2) 10
(13)C-methacetin 10
easy, 10
(88%), 10
Culex 10
Muller 10
Nox5. 10
3-7 10
pre-eclampsia 10
2.21, 10
MoM 10
Safe 10
CVADs 10
Thrombolytic 10
(ECT) 10
Raf-1 10
intervein 10
ERK-dependent 10
CpG-island 10
FOXA1 10
SelS 10
sheep, 10
G.A 10
AAI 10
(1.1) 10
awoke 10
boluses 10
co-transcriptionally 10
BRG1. 10
oogenesis. 10
transposition, 10
TART 10
Aubergine 10
AzgA, 10
5-fluorocytosine 10
variants/haplotypes 10
Neurturin) 10
CredI 10
betrixaban. 10
(compound 10
vials 10
Americas, 10
Vaccines 10
EGFR; 10
radioligands 10
6500 10
BOO. 10
BVM 10
H(2)O 10
open-ended 10
KPC, 10
Formalin-fixed 10
15; 10
database: 10
(Bertolotti's 10
(REM) 10
Fas-mediated 10
Bcl2 10
(PTK) 10
Plumbagin 10
daclatasvir 10
cocaine-related 10
miR-181b 10
3'-extended 10
consistency, 10
ZD 10
(FLAMSA) 10
CR1 10
IKK2 10
IKKgamma 10
violent 10
(125 10
rami 10
1857 10
nonoperative 10
(Malgaigne 10
deformed 10
metabonomic 10
Revolver 10
Hippocampal 10
short-QT 10
T618I 10
KCNJ2) 10
guaranteeing 10
MMTV 10
(53BP1) 10
Scale: 10
≤1, 10
SPAN-100-negative 10
vulval 10
gynaecologists 10
endometrioma, 10
NM 10
patient), 10
2q22, 10
lady 10
natal 10
forcing 10
vaginalis 10
(thalidomide 10
IL-6-treated 10
µg/ml) 10
stabilised 10
unicentric 10
DIAGNOSTIC 10
86) 10
ER]). 10
seven-item 10
+5) 10
fits) 10
[13 10
symptoms]) 10
89-97), 10
(77-89), 10
(85-95), 10
(83-93). 10
C/EBPβ 10
VprBP 10
TSA, 10
minoxidil, 10
<0.01). 10
SHT 10
.012). 10
Adjunct 10
paint 10
I(NaL) 10
PNDM. 10
start, 10
DUBs, 10
LCLs 10
anemia]. 10
Council; 10
(MAO-A) 10
L-dopa, 10
chin 10
overspill 10
specificity: 10
LIV1 10
mo. 10
AUEC2-12 10
(mitophagy) 10
lipolytica 10
non-native 10
(AAK) 10
(alisertib), 10
afzelii, 10
s.s. 10
Borr. 10
ERAs. 10
Renal, 10
congestion, 10
ACT-373898 10
Efficacy, 10
ACT-132577. 10
Actelion-1 10
[N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N'-propylaminosulfonamide], 10
ET(A)/ET(B) 10
(ET(A) 10
sarafotoxin 10
S6c-induced 10
(ET(B) 10
stenosis: 10
Colombia 10
Hrd1 10
(LFS), 10
beam, 10
Source. 10
(IR). 10
17A 10
liquid-liquid 10
T-cells. 10
GAD-65 10
TREAT-NMD. 10
TREAT-NMD, 10
Pitt–Hopkins 10
(TCF4), 10
(SLC9A6), 10
Mowat–Wilson 10
(ZEB2), 10
Kleefstra 10
(EHMT1), 10
FOXG1, 10
FHL1. 10
310300), 10
(XMPMA, 10
300696), 10
300695), 10
300717, 10
300718). 10
ALRV 10
likelihood-based 10
supplanted 10
Short-Form 10
Fallot). 10
metaphases 10
behaviorally 10
on-therapy 10
thrombocytosis. 10
μg/L, 10
.004) 10
iron), 10
TSAT 10
(stratified 10
eliglustat), 10
(non-treatment 10
related); 10
T-scores 10
-1.6 10
-0.9 10
VSP 10
MutL, 10
rs4149056 10
polyphasic 10
H3K27Me3 10
GSK3β, 10
preadipocytes, 10
SNRPN, 10
Parp-1-/- 10
H19. 10
compact, 10
DOT1L-mediated 10
oestriol 10
Swine 10
Mozart's 10
23425 10
50-60 10
IgG2 10
gateway 10
8-oxo-dGDP, 10
monophosphates. 10
MutT, 10
anhedonic 10
non-anhedonic 10
1.66, 10
emotions, 10
Nausea, 10
Phospholipid 10
apoptogenic 10
npc1(-/-) 10
T(eff) 10
HVMA 10
rs2476601 10
(rs2476601) 10
1989. 10
ACPA-status 10
CUR 10
A-induced 10
hypocretin-1 10
sickness) 10
cardiomyocyte-specific 10
(TNNI3K), 10
rif1Δ. 10
malabsorption 10
Ednrb(sl) 10
megacolon. 10
assistants 10
(ERAD), 10
BRAF-mutated 10
HC. 10
person-years, 10
(GWASs) 10
somatostatin-expressing 10
(2.6%), 10
benzodiazepine-positive 10
Neurobehavioral 10
intoxications 10
Palestinian 10
B9D1 10
hypermelatoninemia 10
ASD-like 10
amygdala. 10
pre-participation 10
U(IV) 10
cydA 10
Anaeromyxobacter 10
(1st 10
iduronate 10
ephrin 10
Themococcales 10
RIP3, 10
pupil, 10
nociceptors, 10
iris. 10
glycosylation. 10
holoprosencephaly. 10
telephone. 10
CUL1 10
nulliparous 10
Cyclophilin 10
Press; 10
(IEGs) 10
gp210, 10
(Skp1-Cullin1-F-box 10
p16(INK4a), 10
HMTase 10
GeneBuilder 10
reductase. 10
elicitor 10
LYST, 10
(CHS), 10
Lyst 10
SECp43 10
p16INK4A 10
p16INK4a. 10
3H-MeTRH 10
JxT 10
(HH) 10
noninflammatory 10
APS 10
dsDNA. 10
hAgo2 10
hemangioblastomas 10
abacavir, 10
evolved, 10
tenofovir-based 10
Antiretroviral 10
Hypersensitivity 10
multiforme) 10
boost, 10
myelitis, 10
Stiff-man 10
(mismatch 10
YB955 10
(MMR; 10
stationary-phase-associated 10
Edinburgh 10
tubastatin 10
sirtinol 10
acetaldehyde. 10
stabilized. 10
encapsidate 10
H9 10
L-Dopa 10
i.p.). 10
antinociception 10
NCPAP. 10
p70/p80 10
relaxin. 10
β-protein 10
telomestatin-treated 10
hygiene. 10
Argentina. 10
albicans; 10
CaDur3 10
CaDur31 10
Hsn-5 10
Globoid 10
(11% 10
depth. 10
rifin 10
Clinician 10
blond 10
inhibitor-induced 10
HCTZ 10
valsartan/HCTZ 10
SGD, 10
PAS, 10
low-GC, 10
(PLD) 10
Igf2, 10
orthodenticle 10
ULCs 10
"sick 10
Afamelanotide, 10
(α-MSH) 10
-positive 10
Transformation 10
assistance, 10
106), 10
o-aminobenzamide 10
(2-aminobenzamides) 10
TOP2 10
pursuits, 10
cartilaginous, 10
electroretinogram 10
Heyde's 10
sub-urethral 10
tape 10
putida. 10
learning-based 10
(ESCs), 10
microenvironment-mediated 10
CS-1 10
(elotuzumab) 10
(daratumumab) 10
(http://oikoarrays.biology.uiowa.edu/Oiko/), 10
adhesins 10
ftsZ 10
q3w. 10
AAC 10
Ser96 10
Ser2814 10
Spitz 10
60%; 10
fertilizers 10
IgA-AGA 10
radiodurans, 10
impacts, 10
grouse 10
HuR-interacting 10
M-line 10
myofibrillogenesis. 10
Z-line 10
A-band 10
Protor-1 10
PML. 10
Crohn 10
CDAI-100 10
41.8% 10
antidrug 10
NT. 10
proTα(100-109) 10
ProTalpha's 10
proTalpha(103-109) 10
proTalpha. 10
PANSS 10
alerting 10
(6.0%) 10
(ATase) 10
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea 10
lacl 10
alkyltransferase-proficient 10
(VNTR) 10
VNTR. 10
(Col 10
SCN1A, 10
vaccinating 10
(SNPs), 10
hMBF 10
residents' 10
Thromboembolism 10
thrombophilic 10
'aggregation-prone' 10
slings 10
CHEK2-1100delC 10
Productivity 10
hypertonia 10
anti-IGF-1R 10
>6 10
0.00) 10
NKT 10
saquinavir. 10
faldaprevir 10
eprotirome 10
berghei. 10
yoelii 10
GPIs 10
Cyclophosphamide 10
Fancm-deficient 10
Fancm(Delta2/Delta2) 10
BRCA-positive 10
CSF1R 10
CSF-1R 10
(CSF-1R) 10
aureus) 10
trivalent 10
TRPC6 10
immunohistochemical. 10
pAdEasy-rNGB-GFP 10
platelet-rich 10
(q)RT-PCR 10
UCMD 10
annonacin. 10
B-20 10
Zebularine 10
Armoured 10
haematoma, 10
mono-methylation 10
PCNEs 10
sup45 10
UPF3 10
sup112 10
CCAs 10
p-value 10
(ABCD2) 10
HS, 10
protrusio 10
(p38α, 10
cementoblasts, 10
3,100 10
DCR 10
polymerase-chain-reaction 10
mandated 10
FoxA. 10
oscillations. 10
Battery 10
Eut 10
SPPB 10
sonication, 10
GATA-1. 10
-1.9 10
Ng48-76 10
P-tau(181) 10
ketanserin 10
serotoninergic 10
hexosaminidase 10
Argentinean 10
498 10
Ca/calmodulin-dependent 10
(CaMKII)delta(C) 10
(ISO)-inducible 10
rs2056116 10
diabetics. 10
depots. 10
(P<0.01, 10
Sea 10
peels 10
Roxb. 10
streptozotocin-induced-diabetic 10
Phaseolus 10
2.8-fold 10
>10-fold 10
TRF2, 10
TRF2. 10
Rgnef 10
BY-2 10
sulphasalazine 10
nitrotyrosine, 10
enlargements 10
Bmi-1. 10
postconditioning 10
cadaveric 10
MT-A 10
(PS1) 10
PHF 10
1.1% 10
POLDIP3 10
17/2.8 10
(XK) 10
acanthocytosis 10
(BFNC) 10
IGE 10
rolandic 10
metals, 10
amylose 10
Anatomy 10
CCP 10
anti-MCV 10
misuse. 10
Cannabis 10
(IL-1 10
Gro/TLE1 10
ependymoma. 10
DNA-(cytosine 10
nulliparity 10
ENU 10
fractality 10
Macromolecular 10
microtubule-binding 10
Disease). 10
lessening 10
tacrine. 10
THA 10
LGRs 10
cancer-identified 10
tribal 10
haemolysis. 10
endemicity 10
hemizygous. 10
PDX 10
FEN1 10
E7449 10
46-74) 10
2-10) 10
(MRgFUS), 10
24.3 10
Quality-of-life 10
tcMRgFUS 10
siponimod 10
(RMS), 10
Oral) 10
treatment-by-subgroup 10
alfa. 10
Peginesatide, 10
NOX2, 10
Nox3, 10
PD-L1, 10
Infection. 10
NadR 10
rNadA 10
NFT 10
exanthematous 10
(SCAR) 10
Erythema 10
endosulfan 10
hyperventilation 10
(entacapone). 10
tolcapone. 10
tonsils. 10
1,25(OH)2D 10
40-bp 10
(HTT) 10
IT-15 10
CACNA1A 10
mosaically 10
haploinsufficiencies. 10
toxin-mediated 10
SUMO-conjugated 10
silkworm 10
ubiquitinated, 10
proteotoxic 10
(HS), 10
297) 10
ofloxacin 10
[18F]annexin 10
injection; 10
lipoproteinemia 10
LLT 10
orlistat 10
phentermine 10
Migalastat, 10
globotriaosylsphingosine 10
lyso-Gb3 10
Malawi, 10
cytokines/chemokines 10
Authors.Pediatrics 10
non-diabetics. 10
ABCA1 10
1.29; 10
Path2PPI 10
(METABRIC 10
[copy 10
aberration]: 10
1·18-1·92, 10
p=0·00010; 10
[transcript]: 10
1·40-2·01, 10
Nottingham-HES-breast 10
[protein]: 10
1·32-2·12, 10
(Uppsala: 10
1·62, 10
1·03-2·53, 10
p=0·036; 10
METABRIC: 10
1·27, 10
1·02-1·58, 10
p=0·034; 10
2·34, 10
1·24-4·42, 10
p=0·0090; 10
Nottingham-HES: 10
1·73, 10
1·23-2·46, 10
p=0·0020). 10
receptor-negative-ACT 10
0·37, 10
0·20-0·60, 10
Description 10
1918 10
endoproteolysis 10
gamma-secretase-mediated 10
UBC9, 10
SIM 10
PIAS 10
rgpB 10
cis-interactions 10
IFNG. 10
Wellens 10
apoE2, 10
Etiologies 10
bupropion. 10
(SDA) 10
docking' 10
association' 10
EGR-1 10
L12P 10
Cancer-specific 10
Csn8 10
Cardiomyocyte-restricted 10
CDD 10
HiSCR 10
RELEVANCE 10
arthroscopic 10
SSTAR 10
p47(phox), 10
Noxa1. 10
NoxA1 10
osimertinib, 10
alkalosis. 10
(5.8 10
Tietz/Waardenburg 10
heparinase 10
PTH/PTHrP 10
physeal 10
9months 10
procaryotes, 10
PM4 10
swabs. 10
(SEP3) 10
anatomica 10
Maria 10
prima 10
2-14 10
safety/tolerability 10
nusinersen: 10
2'-O-methoxyethyl 10
phosphorothioate-modified 10
equivalents) 10
Ionis 10
(Val717Ile) 10
(Val717Ile), 10
TLR4. 10
Dectin-1-reactive 10
AdN17Rac1 10
anti-LOXL2 10
simtuzumab, 10
syndrome)]. 10
Tomita, 10
API. 10
ABCC4 10
hexaploid 10
anti-mature 10
anti-pro 10
ethanol-fed 10
CIDEC. 10
FSP27/CIDEC 10
PPARgamma2 10
(FIM) 10
-.74, 10
(-.88, 10
-.45), 10
.0007] 10
-.81, 10
(-.92, 10
-.58), 10
.0002]. 10
methylKit: 10
automating 10
ALD 10
ABCE1 10
pellucidum. 10
(OCA2) 10
OCA1. 10
c.1205G 10
http://RNAedit.com). 10
(Homo 10
sapiens), 10
(Mus 10
musculus) 10
Scm3 10
cenH3 10
CDEII 10
wrists 10
PLN/QALY 10
€/QALYG) 10
golimumab. 10
Golimumab, 10
golimumab) 10
TSB 10
Saos-2 10
(PICU) 10
cut-off, 10
PIM 10
hyperferritinaemia. 10
mk/mk 10
Co-regulation 10
BBMV 10
ATR's 10
NRD-dependent 10
Tens 10
theorizing, 10
parasomnia 10
awaken 10
CRL4(Cdt2) 10
Suv4-20h 10
H3K56Ac 10
cytological, 10
dihydrate 10
Enhancer/Promoter 10
planus 10
EQ-5D, 10
SF-6D 10
DGAT 10
Midline 10
Mutation: 10
Alterations. 10
(H3K27M) 10
(K27M-H3.3) 10
HIST1H3B, 10
G34V/R-H3.3, 10
gains/amplifications 10
MYC/PVT1 10
K27M- 10
G34V-H3.3 10
(brainstem/cortex) 10
H3.3-mutation 10
27-to-methionine 10
mutations--a 10
G34 10
(EH) 10
Menière's 10
(PNH) 10
Mondor 10
bandaging 10
gastroenteropathy 10
Analysing 10
(LITT) 10
first-in-humans 10
(rGBM). 10
thermometry, 10
SWR1/SRCAP 10
AMS 10
HGA 10
non-R 10
GitHub: 10
https://github.com/aitgon/LedPred 10
http://bioconductor.org/packages/release/bioc/html/LedPred.html 10
Biotech, 10
Inc.), 10
>4 10
protein-depletion 10
NLD. 10
infliximab. 10
(amitriptyline: 10
topiramate: 10
sua7-1 10
interpret.REVIGO 10
YO28252 10
Glioblastoma: 10
rilotumumab, 10
(75%). 10
craving. 10
whitish 10
calretinin 10
darker 10
rhomboid 10
pseudomallei-specific 10
undisturbed 10
Derivative 10
Advantage 10
(glyburide 10
glyburide, 10
Sur1 10
v1.1. 10
pta1-Delta75 10
Ser5-P 10
CPF. 10
trabeculations, 10
Health-System 10
Pharmacists, 10
porphyrias 10
ZMapp. 10
scalability, 10
homocystinuria, 10
A1298C 10
CENTRIC 10
percentile: 10
AACRSee 10
GNE-317 10
GS2 10
Intercept 10
5-10-mg 10
(NPLB): 10
p.Arg62Cys 10
LMCAD 10
cross-cell 10
phosphatidylglycerol, 10
CPT2 10
post-deployment 10
pre-deployment; 10
abaloparatide, 10
romosozumab, 10
Resilience 10
Mis15, 10
(strong 10
RbAp46), 10
Mis17, 10
positioned. 10
K27M-mutant 10
Bezlotoxumab 10
bezlotoxumab, 10
colonocytes 10
(CROP) 10
phosphodiesterase-4 10
Phytologist 10
CircRNA 10
heterohexameric 10
ORC, 10
Hadoop 10
Pse-in-One: 10
ROBs 10
(CBs). 10
gene-enhancer 10
LOLA: 10
CEGA--a 10
http://cega.ezlab.org. 10
IgAN. 10
CIP-box 10
wall), 10
AVFs, 10
Pfh1-dependent 10
valbenazine 10
ASCIZ) 10
Abelson-related 10
22q11 10
aortitis 10
Elvitegravir/cobicistat/emtricitabine/tenofovir 10
~80.8 10
Transform-based 10
LARVA 10
Nab3. 10
sn/snoRNAs 10
NRD1 10
(SUTs) 10
Rrp47 10
Ess1 10
transcripts) 10
hPCSK9 10
LDLRs 10
hyperlipemia, 10
dyslexia, 10
Baiap2, 10
cascading 10
diagnoses/subgroups. 10
http://bioconductor.org/packages/MethPed/. 10
lncRNA. 10
microvesicles 10
two-metal-ion 10
computing. 10
Faucet 10
DNaseI-seq 10
Kmt5a 10
H4K20Me1 10
emollient 10
de-methylation 10
O(n) 10
shimmer 10
K29 10
PMEPA1 10
coligo 10
uploaded 10
hATTR 10
NCT01866319. 10
Rpb9. 10
(decernotinib) 10
(DSPS) 10
voretigene 10
rubor, 10
rubor 10
COL1A2) 10
CTCF--cohesin 10
paternal-specific 10
ICR' 10
cpg 10
wrist. 10
(RPC1063) 10
RP101988, 10
CellBase, 10
naïvely 10
unguium 10
"butterfly" 10
5q, 10
13q. 10
gbm 10
Lebers 10
non-negligible 10
interpolates 10
Rabl 10
hub. 10
STOP-BANG, 10
>: 10
CA19-9 10
siG12D-LODER 10
(SGOT), 10
GPL-2 10
(http://bioconductor.org/packages/CancerSubtypes/). 10
thuc.le@unisa.edu.au 10
jiuyong.li@unisa.edu.au. 10
miravirsen 10
Petechiae 10
Adds 10
Pharyngitis 10
pharyngotonsillitis 10
octave 10
tomato. 10
thoracopagus 10
MARS: 10
shifts) 10
integratively, 10
LCR/β-globin 10
benralizumab), 10
(lebrikizumab 10
tralokinumab), 10
(dupilumab), 10
(omalizumab), 10
anti-thymic 10
(tezepelumab) 10
MBD2; 10
(Match 10
VCF); 10
cross-sample 10
LAF 10
C-fiber 10
CpGs/regions, 10
GWAS-associated 10
(promoters, 10
27× 10
packages. 10
http://bioconductor.org/packages/annotatr/ 10
speech' 10
pangenotypic 10
glucosuria. 10
HTML5 10
displaying, 10
Rigler's 10
right-upper-quadrant 10
microfluidics-based 10
RRD 10
(CWD), 10
myofibroblastic 10
ALK, 10
(CURB65-A) 10
brivanib 10
DBT-based 10
residency. 10
residency, 10
Fen1 10
uantitative 10
T-UCRs. 10
non-maleficence, 10
beneficence, 10
lower-extremity 10
onycholysis 10
month). 10
Pso 10
membrane-less 10
RIblast: 10
Measles 10
(SSPE), 10
circ-Amotl1 10
CADD 10
Scarlet 10
emm12 10
STREPTOCOCCUS 10
pyrogenic 10
'SeqArray' 10
array-oriented 10
VCF, 10
feature-rich, 10
TGFβ/Activin 10
53BP1-dependent 10
RAP1-interacting 10
nuclear-soluble 10
centring 10
CHAPLE 10
JQ1 10
proteoforms 10
Lone 10
americanum) 10
americanum, 10
parkeri 10
halys, 10
Mentzer 10
g-HAT 10
fexinidazole, 10
phosphorescent 10
CTPE 10
http://samtools.sourceforge.net. 10
Ser312Gly 10
A-allele 10
(A/G 10
arteriolopathy 10
UBE2F 10
Sox6 10
postconsolidation 10
sponging 10
CDP-choline. 10
ZipFix(TM) 10
Pelota 10
navicular 10
EGLN1, 10
amnion, 10
impulsiveness 10
Lumican 10
Neanderthals 10
(CVs) 9
chemokine, 9
signal-related 9
TGFα 9
chemorefractory 9
Intrahepatic 9
simulation. 9
TGF-α, 9
exosome, 9
DLD-1 9
(AC) 9
post-embryonic 9
thrombospondin 9
Kunitz 9
polyA+ 9
micro- 9
RANKL/OPG 9
manuscript, 9
arthropathy 9
PPA 9
Levothyroxine 9
0.09). 9
miR-200 9
Individually, 9
(38 9
non-interventional 9
quasi-randomised 9
Fractures 9
skeletal-related 9
tyrosine-protein 9
1/3 9
risedronate, 9
docetaxel-based 9
therapy), 9
CRPC, 9
223 9
dollars. 9
willingness-to-pay 9
CA, 9
approval: 9
Dvl 9
somite 9
Dermatol 9
lobular 9
sotalol. 9
sublining 9
pathways), 9
progression: 9
2.08 9
4): 9
324 9
(Europe, 9
[4%]). 9
83%, 9
17,20-lyase, 9
Decreases 9
radioimmunotherapy 9
radio- 9
lentivirus 9
ErbB-2 9
(HER-2) 9
acyclic 9
(MAbs) 9
taxane. 9
(IHC 9
methodologies. 9
c-erbB-2 9
quantitate 9
Company. 9
Docetaxel 9
tumor-cell 9
immunotoxin 9
inhibition; 9
teratomas 9
(STAT) 9
Copyright: 9
donor's 9
OCT4, 9
Timely 9
prognostic, 9
Similarly 9
section, 9
QC 9
immunolabeled 9
437 9
Myopathy 9
Parkinsonism, 9
(15%, 9
bpm, 9
supply, 9
HCN2 9
subanalysis 9
sustained. 9
pre-defined 9
metoprolol 9
enforce 9
levodopa-induced 9
tiger 9
mg/L) 9
controller 9
Israel 9
Mb. 9
Accumulated 9
metastable 9
girdle 9
whereupon 9
brother. 9
IBC 9
(RyR1) 9
[Ca](i) 9
junctin-overexpressing 9
strips, 9
O., 9
Campbell, 9
(JCN), 9
spiking 9
sphingomyelin 9
isoprenaline 9
TC-1 9
bromodomains. 9
bromodomain-containing 9
vitro; 9
acetyllysine 9
Nasopharyngeal 9
(NPC). 9
(HATs) 9
chromatin-bound 9
confirmation, 9
Ileal 9
evidence; 9
monitoring; 9
Uncontrolled 9
(JNK). 9
E2. 9
necessitated 9
TIMPs 9
jellyfish 9
herb 9
Lethal 9
primer, 9
refolding 9
Ras. 9
high-content 9
proteolysis, 9
N-terminomics 9
annotates 9
polymer. 9
Salivary 9
clonazepam, 9
fusions. 9
sarcomas, 9
midzone. 9
down-regulation. 9
retroviral-mediated 9
eculizumab 9
Nephrology. 9
pneumococcal 9
etiologies, 9
irreversible. 9
Uremic 9
donations 9
rejection, 9
P=0.002). 9
POMC 9
[mean 9
ghrelin. 9
non-smoking 9
exercise; 9
unrestricted 9
satiety 9
(2000) 9
(2007) 9
km23-2 9
lactacystin, 9
RII 9
fixed-effect 9
miR-430. 9
.02). 9
cystitis 9
Pelvic 9
28.1 9
Rome 9
Relevance 9
abdominopelvic 9
(EM), 9
migraineurs 9
17.1 9
immediately, 9
0.55, 9
(LAD) 9
HT. 9
1.1-2.9), 9
0.74-1.67). 9
1.44). 9
definitive, 9
(PR). 9
post-menopausal 9
Subject 9
workplace. 9
acceptability, 9
usefulness. 9
methylation-related 9
leukemogenesis, 9
CREBBP, 9
lipoprotein(a) 9
40.2% 9
permissions 9
Breakthrough 9
SOC 9
(FH). 9
computerised 9
hyperlipidaemia 9
moderate-intensity 9
mg/dL; 9
spasms, 9
female; 9
tunicates, 9
Olfactores. 9
Bisulfite 9
Evf-2 9
(MTase) 9
(cytosine-5)-methyltransferase 9
Transfer 9
(ES), 9
diploid, 9
6-hour 9
old), 9
(VP-16) 9
locoregional 9
glycoproteins, 9
extensively, 9
But, 9
Hh-activated 9
(34%, 9
150) 9
MF, 9
strand-displacement 9
promoter-origins 9
recruited, 9
AIP-mutated 9
R16H 9
filament, 9
cardiomyopathy-linked 9
C-domain 9
A8V, 9
assays; 9
HCM-associated 9
EAP 9
(ST 9
re-evaluate 9
DB2 9
Nicotine 9
Start 9
Ser10 9
telophase. 9
chromocenter 9
HP1alpha 9
HP1beta 9
(transcriptionally 9
used; 9
anti-aging 9
(PBS) 9
tankyrase 9
CLU 9
region(s) 9
betaTrCP1 9
refs 9
IKKbeta, 9
EMT-related 9
circumvented 9
RL95-2 9
c-Src. 9
PI-3K/Akt 9
Fas-triggered 9
X-Linked 9
thicker 9
phosphatidylinositol-3'-OH 9
census 9
ST-T 9
pandemic, 9
(spontaneous 9
(PTB), 9
A(H1N1) 9
Ministry 9
liveborn 9
Preterm 9
844 9
doubt 9
Brain-lung-thyroid 9
(BLTS) 9
(NKX2-1/TTF1) 9
(BHC), 9
MLPA, 9
NKX2-1. 9
(2)H 9
12.4% 9
(L176V, 9
P202L, 9
Q210P), 9
(376-2A-->G), 9
14q13. 9
enhancer/promoter. 9
NKX2-1-P202L 9
PAX8-WT, 9
L176V 9
Q210P. 9
(IRDS 9
76%; 9
micrographs 9
eggs, 9
C7 9
spines. 9
Random-Forest 9
cell-types. 9
conjugate, 9
hTR 9
cease 9
(MMP-2) 9
Overexpressed 9
mammospheres 9
bleomycin-induced 9
hyperresponsiveness, 9
IL-4/IL-13 9
27%) 9
anti-IL-4 9
births) 9
sutural 9
Runx2, 9
transactivates 9
(FGFR2) 9
homozygosity. 9
Boston 9
aplasia. 9
(ncRNAs), 9
unplanned 9
[4%] 9
phenotype). 9
organification, 9
stria 9
Goitre 9
Sudanese 9
dealt 9
audiological 9
EVA, 9
CFU 9
7-10 9
goal. 9
micrometastases 9
Multiparameter 9
aspirates, 9
nonpelvic 9
unspecified 9
FASP 9
quadrupole 9
cryopreservation 9
surfactants 9
Microbiological 9
zymogen 9
(ST) 9
Registration 9
avoidance, 9
subjectively 9
18-65 9
MAIN 9
twice. 9
ANCOVA 9
0.73, 9
phyloFACTS 9
hemizygosity 9
follicularis 9
Expanding 9
hypohydrosis, 9
hairless 9
scalp, 9
scaly 9
coincidental 9
revascularization, 9
(PAD) 9
1.08 9
0.029) 9
0.026). 9
non-carriers. 9
Glioblastoma. 9
Treatment). 9
Sub-group 9
544 9
0.67; 9
0.54; 9
(EORTC) 9
(252 9
Cox-regression 9
crossroads 9
Modulating 9
(S6K1) 9
bafilomycin 9
kinase-dependent 9
sphingolipids 9
Lysosomes 9
late, 9
susceptible, 9
combating 9
G., 9
explanation. 9
antituberculosis 9
adaptable 9
cohort; 9
16.7 9
tolerated: 9
≥60 9
rechallenge 9
28.6% 9
Multicentre 9
chemo 9
MTD. 9
catheters. 9
(IA) 9
(PNET) 9
uncontrolled, 9
0.99). 9
TTD 9
distinctive, 9
trichothiodystrophy 9
Contemporary 9
IRAK1 9
(systemic 9
non-affected 9
MSCs, 9
MSCs. 9
(SF) 9
Hierarchical 9
1.13, 9
Extraversion 9
baseline). 9
extraversion, 9
sum, 9
plausible, 9
PsycINFO 9
Neuroticism-Extraversion-Openness 9
Immunosuppression 9
4E-binding 9
insulinoma 9
(CI). 9
0.99) 9
(pQTLs) 9
(QTL) 9
IL2 9
endorse 9
(reverse 9
EWS-Ets 9
ES/pPNETs. 9
Fli1 9
Adequate 9
Kcnq1/Kcnq1ot1 9
Contraction 9
(CREs) 9
CTCF-mediated 9
cohesin-binding 9
divergently 9
(PARPs) 9
SA2. 9
(GA), 9
SPT5 9
(4C) 9
enhancer/promoter 9
juxtapose 9
young. 9
cycling, 9
disarray 9
RAAS, 9
(RTS) 9
thumbs, 9
signifying 9
affection 9
fungus. 9
(dsRNA) 9
contention 9
polypeptides, 9
cleavage-stage 9
Medullary 9
Review, 9
immunopurified 9
Ago2 9
co-immunoprecipitation, 9
QKI 9
step-by-step 9
iCLIP 9
benign. 9
median: 9
quadriplegia 9
Bayley 9
picking 9
extended, 9
stance 9
separately, 9
mo) 9
y), 9
Congress 9
forty-five 9
4,000 9
read-through 9
trans. 9
8-10 9
abnormally, 9
crucibles 9
FUS) 9
Profilin 9
stressor 9
arrested. 9
non-classical 9
Deleterious 9
NOS 9
GFP-transgenic 9
scar, 9
Twin 9
371 9
(LOD 9
enzyme-inhibitor 9
37.6 9
dissociative 9
Man6-P 9
sugar, 9
derivatized 9
Ews/Fli-1 9
neuroblastoma-Ews/Fli-1 9
Microsatellites 9
Methanosarcina 9
orc/cdc6-associated 9
Haloarcula 9
endosymbionts 9
evolves 9
nitrate 9
Mb) 9
FC 9
pathway) 9
frameshift. 9
exonization. 9
racially 9
diminished, 9
glomeruli. 9
(IH) 9
zygote 9
ookinete 9
clofilium 9
2.58 9
determine: 9
T., 9
PMP22. 9
(PMP22) 9
MFN2, 9
CMT2. 9
21). 9
Chain 9
understanding. 9
Krit1B 9
Kritl 9
ossification, 9
ontogenesis 9
Monocarboxylate 9
Molecules 9
growth-promoting 9
(T(4)) 9
0.013) 9
succumb 9
70-year-old 9
standing. 9
offered. 9
containing, 9
website, 9
(MK- 9
0431), 9
Saxagliptin, 9
Melogliptin, 9
(BI-1356), 9
Dutogliptin, 9
Carmegliptin, 9
(A), 9
500, 9
(insulin, 9
Nesina® 9
co-morbidities. 9
neutral. 9
iv) 9
assistance. 9
Mantel-Haenszel 9
DESIGN 9
(AEs). 9
<7% 9
stereotyped 9
5-gene 9
awareness. 9
slope, 9
connections. 9
restored, 9
extradural 9
Crossover 9
0.24) 9
humans) 9
odors 9
foodborne 9
botulinum. 9
(qPCR) 9
(BoNT) 9
emergency. 9
liposomes 9
BTX 9
War. 9
feared 9
epidemic. 9
α-synuclein-induced 9
nematodes. 9
leukodystrophy. 9
astrogliosis 9
later-onset 9
sib 9
transcription), 9
defending 9
DNA-methyltransferase 9
flowers 9
prokaryote 9
pairing. 9
luteinizing 9
dosage-dependent 9
coprophila 9
ScoHET1 9
ScoHET2 9
SU(VAR) 9
position-dependent 9
(CHD). 9
(H3K9) 9
CNG 9
B-myb 9
(Rb) 9
C-terminus. 9
(H) 9
crest. 9
Wang, 9
(ORF) 9
551 9
CHD1L 9
talipes 9
equinovarus 9
Segregation 9
interfaces. 9
nucleoplasm. 9
2008). 9
silencing: 9
GC/MS 9
EGFP 9
mm(3), 9
HPL-1 9
weaken 9
microdissection. 9
TCTP 9
morphants 9
F1 9
(CRCs) 9
subdivision 9
>150 9
metazoa, 9
tachyarrhythmias, 9
benzofuran 9
fraction). 9
cine 9
COUGER--co-factors 9
uniquely-bound 9
page, 9
interface: 9
http://couger.oit.duke.edu. 9
globe. 9
aminergic 9
herbicide 9
escape. 9
(breast 9
NO. 9
(MTT) 9
TGF-β1. 9
compose 9
Opa1, 9
macrocephaly. 9
hypoglossal 9
causative. 9
proceeding 9
(CART) 9
adaptations. 9
(DHEAS) 9
5'-deiodinase 9
exercising 9
flight. 9
Sry) 9
bisulphite 9
(PKA), 9
recall. 9
Harvard 9
g), 9
GPx, 9
limits, 9
leaves, 9
(PL) 9
insufficient, 9
quercetin, 9
Rosea 9
glycine. 9
12-year 9
annotated. 9
GARS-associated 9
mutation-associated 9
posing 9
standalone 9
GPI-anchored 9
hermaphrodite 9
lysines, 9
H3-lysine 9
derepresses 9
BMF 9
(CBC) 9
fibrosis: 9
products; 9
Proliferative 9
1991. 9
.05); 9
287 9
suffice 9
parameter. 9
And, 9
(I/R)-induced 9
miR-208 9
miRs 9
PDCD4. 9
Lately, 9
anti-miR-21 9
angiogenesis-related 9
IL-1Ra 9
expressions, 9
(light 9
polymyositis 9
preischemic 9
(ds)RNA 9
CMAH 9
mass-spectrometry 9
proposals 9
VKA 9
also, 9
antidote. 9
encouraging, 9
rivaroxaban) 9
preferred, 9
drug). 9
pediatrics, 9
(aPTT) 9
phosphorylation/dephosphorylation 9
five- 9
CO2-induced 9
atxA4+ 9
Tn917-LTV3. 9
tcr-lacZ 9
(tcr 9
coregulated) 9
Tox+, 9
polyglutamate 9
acpA-null 9
encapsulation, 9
capB, 9
capC, 9
capA, 9
pXO1-located 9
antigen). 9
discriminator 9
stationary-phase-specific 9
Ezh2. 9
http://bioinformatics.biol.uoa.gr/ExTopoDB. 9
beta-stranded, 9
bioinformaticians 9
unexplained. 9
Ret. 9
Frequencies 9
immaturity 9
least, 9
pioneering 9
(MSC) 9
suction 9
Caveolin-1 9
how, 9
radioresistance. 9
Coilin, 9
prominent, 9
confine 9
(Hi-C), 9
Giemsa 9
"closed" 9
unaltered, 9
capsids 9
stomach-specific 9
3-kinase-dependent 9
overlay 9
TRIM67 9
vasa 9
Gustavus 9
Particular 9
bordering 9
VASA 9
clique 9
linkages. 9
COG 9
paralogy 9
STRING 9
display, 9
Evidently, 9
SFPQ 9
DRB 9
(NMD), 9
ATO 9
(96%) 9
Mrc1. 9
restarting 9
cohesion; 9
Eco1-independent 9
fork-associated 9
formula, 9
(81 9
radiotherapy-induced 9
15.7 9
34.0 9
(IC50) 9
PARP. 9
PARPi. 9
RAD51, 9
11). 9
A1C, 9
334 9
triiodothyronine, 9
442 9
281 9
(p<0.001), 9
(SLN), 9
developmental, 9
radiation-damaged 9
level; 9
GGR 9
repaired. 9
RAD26 9
Mfd. 9
postulates 9
6p 9
graying, 9
stroke-like 9
(ESTs) 9
U2-dependent 9
glycine, 9
clarithromycin, 9
ethambutol, 9
ethambutol 9
microbiologic 9
Toxicities 9
macrolides, 9
Recurrences 9
myopericarditis 9
TGFbeta. 9
omitted 9
Lymphangioleiomyomatosis 9
(9q34) 9
three-stranded 9
operable 9
M.D. 9
(fluorouracil 9
13.2 9
(same 9
70.5% 9
ALT, 9
Switzerland) 9
Pairwise 9
finished 9
both) 9
CPB, 9
open-heart 9
responsiveness, 9
justification 9
Top-Down 9
(CRMs), 9
TFBSs 9
Cullin-RING 9
(T24, 9
SCID 9
AlphaScreen 9
MLN4924-induced 9
DEPTOR, 9
three-step 9
K(D) 9
PKA-dependent 9
annum. 9
unexpected, 9
preparticipation 9
junior 9
Wolff-Parkinson-White 9
noncompetitive 9
MammaPrint(TM) 9
2/3, 9
Frozen 9
JNK-mediated 9
JNK-induced 9
[2, 9
inactivated. 9
MKP-3 9
anisomycin 9
neurones. 9
immunogenetics 9
vocabulary 9
IG 9
species), 9
IMGT/3Dstructure-DB 9
L.). 9
(RCTs). 9
1.71, 9
1.02, 9
registers. 9
0.73; 9
follow-ups 9
steep 9
eight, 9
PFS6 9
Specification 9
(Th17) 9
IRF-1 9
suicide, 9
(13), 9
irritation. 9
sacrificed, 9
monkey, 9
rabbit. 9
acetylsalicylic 9
interconversion 9
25,000 9
Intake 9
(1994) 9
gastrulation. 9
roof 9
frontonasal 9
(7), 9
(4), 9
HAUSP 9
p300. 9
cannot, 9
teniposide 9
kinetoplast 9
emodin 9
5-position 9
cyanomorpholinyldoxorubicin, 9
morpholinyldoxorubicin, 9
(0.35 9
unwound 9
arsenal 9
poisons, 9
dock 9
stauranthine 9
(even 9
1800 9
scrutiny. 9
14-mer 9
(2), 9
seizure-induced 9
miR-193a-5p 9
micro-RNAs 9
VGLUT1 9
perisynaptic 9
HEK(EAAC1) 9
MSG 9
piglets 9
EAAT1 9
(GRK2) 9
MRP4 9
β-Pix 9
Diacylglycerol 9
(NMDA) 9
discarding 9
amounting 9
1.40 9
immune-based 9
staining). 9
thromboxane 9
analyzer. 9
83%. 9
TR4 9
soil, 9
tropics 9
blindly 9
nalmefene, 9
1976 9
inadvertent 9
suboptimal. 9
pro-proliferative 9
neurotrophin-3 9
nestin-expressing 9
(MB) 9
Distinctive 9
miR-224, 9
Boyden 9
luteolin 9
capabilities. 9
reluctant 9
(log 9
thyroidologists. 9
(C, 9
Trained 9
hyperthyroid-like 9
TCE-containing 9
problematic. 9
0.027), 9
0.0002) 9
2.0, 9
NS), 9
ng/mL). 9
recovers 9
haemodialysis 9
(3.3 9
669 9
local, 9
neuraxis 9
TNBC. 9
cytokeratins 9
interferon-induced 9
lines: 9
S6K2 9
growth-related 9
sweating. 9
game 9
0.2) 9
Squibb 9
SHIP-1 9
Publications, 9
Shanghai 9
IS, 9
random-effect 9
IS. 9
colonization, 9
check-up 9
proven, 9
infection; 9
388 9
pts 9
controls: 9
dysarthria: 9
communicative 9
F0, 9
pitch 9
Cantonese 9
prosodic 9
FOXO4 9
OA. 9
International. 9
preadipocytes. 9
MN), 9
oligosaccharide 9
Structure-function 9
Immunoelectron 9
infrarenal 9
sinuses. 9
Davidoff 9
supercomplexes 9
glycerolipid 9
tapered 9
rearing 9
shut 9
Lys27. 9
transcription-PCR, 9
14.2 9
(rivaroxaban 9
anticoagulation, 9
embolism) 9
0.51; 9
<75 9
decision-analytic 9
noninterventional 9
(Signaling 9
Engine; 9
literature-referenced 9
ushered 9
Leishmania, 9
anaplerotic 9
morning. 9
reconsideration 9
(H3K27me3). 9
condenses 9
(BBF) 9
profound, 9
CA) 9
1997. 9
9.7% 9
0.55 9
1.31; 9
1.80; 9
(VTE). 9
peritonitis 9
consumer 9
21.9%). 9
BOLD 9
RNC 9
help, 9
Signalling 9
glycosaminoglycan 9
(Full 9
Department. 9
Proof 9
intricately 9
biomaterials 9
Deposition 9
spheroids 9
pre-processing 9
estrogen-like 9
postdose. 9
Fecal 9
individualized. 9
endometrium. 9
estrogens, 9
polysomnography, 9
pramipexole. 9
(2.1% 9
syndrome/Willis-Ekbom 9
non-dopaminergic 9
rotigotine, 9
consensus, 9
(RLS; 9
deficient. 9
polysaccharides 9
loosening 9
Nucleases 9
exchanging 9
Cre-LoxP 9
norms. 9
headache) 9
Hypochondroplasia 9
adults; 9
(FGFR3), 9
Dicoumarol 9
IIB, 9
haplotypes, 9
nontransmitted 9
NaB 9
Disease-causing 9
single-channel 9
stimulations 9
insidiously 9
channelopathies. 9
reappeared 9
antibodies: 9
CIDP 9
LEMS, 9
streptococci. 9
GTP, 9
lactis 9
ophthalmologists 9
Observations 9
Tour 9
medallists 9
Russia, 9
79, 9
cyclophilin. 9
cyclophilins. 9
chemostats 9
late-acting 9
5'-terminal 9
transposase. 9
helix-turn-helix 9
Transposons 9
transposon. 9
restart. 9
Nox1- 9
lymphomagenesis 9
Cdk2-/- 9
oxygen-induced 9
on-column 9
solvents 9
PD-L1. 9
anti-PD1 9
junctate, 9
AbetaH-J-J 9
mRNAs; 9
converges 9
Protein-Protein 9
Treatment. 9
polymerize 9
mDia2 9
Formin 9
generator 9
Diaphanous 9
autoinhibited 9
culminates 9
Diaphanous-related 9
microglia-mediated 9
(predicted 9
TREM2, 9
2.16 9
(DRAPs); 9
rho*XY 9
(stable 9
isotopes 9
β-myosin 9
describe, 9
NCI-H520 9
(bHLH) 9
A549, 9
NSCLCs. 9
.003). 9
carcinoids. 9
Geminin 9
RUNX1, 9
similarly, 9
myelofibrosis. 9
proportionality 9
AON 9
exon-skipping 9
VBP15 9
resource-intensive 9
collagens, 9
8000 9
amniocentesis, 9
girls) 9
(per 9
trisomic 9
terminations 9
Records 9
(fixed 9
<40 9
DDX3, 9
XRN1, 9
MVH 9
bodies), 9
bodies: 9
redundantly 9
3C 9
tristetraprolin 9
meanwhile 9
septum, 9
echocardiogram, 9
weaned 9
AM, 9
re-sequencing 9
sodium/calcium 9
goals, 9
sham+ranolazine, 9
DOCA-salt+ranolazine, 9
(LQT2) 9
bioenergetics, 9
0.04, 9
substantial. 9
dissemination, 9
Effect" 9
extrude 9
wherever 9
Effect". 9
Philadelphia-positive 9
CFC 9
imatinib-resistant 9
anti-leukemia 9
Raf/MEK/ERK 9
720 9
matinib 9
leukemia]. 9
nilotinib. 9
blastic 9
neoplasias 9
Cytoreductive 9
TK, 9
(r-metHuG-CSF) 9
http://www.clinicaltrials.gov 9
multi-modal 9
NNH 9
Serotonergic 9
33.3% 9
328) 9
9.9% 9
MDE 9
AA21004, 9
multi-panel 9
X). 9
non-imprinted 9
DAE 9
listed, 9
paragangliomas. 9
PCC/PGL 9
phosphorylated. 9
MARCH-7 9
CD133(+) 9
Cxcr4b 9
vacuole, 9
stress) 9
non-apoptotic 9
interdependent 9
fails. 9
abundant. 9
tRNAs. 9
favours 9
heavy-chain 9
x403 9
4%). 9
pCa 9
submaximal 9
Dural 9
stainings 9
lipotoxicity 9
nematode. 9
miRNA- 9
Verification 9
risk) 9
basketball 9
Rather 9
survivor 9
soccer, 9
cordis, 9
(commotio 9
dangers 9
Iceman's 9
digests. 9
modern-day 9
Lon 9
reintroduction 9
curly 9
Theoretically, 9
neuropathy: 9
kinky 9
treatment-limiting 9
carboxylase. 9
mfd, 9
nth, 9
umuDC 9
turbidity 9
scattering, 9
Commons 9
cytokinetic 9
sorting. 9
hijacking 9
TA, 9
TP73, 9
anticipated, 9
copper-depletion 9
copper-deficient 9
monoubiquitination. 9
farnesylation 9
feedback, 9
H-ras 9
H-ras, 9
RRMS. 9
Seventh 9
(interferon 9
Cambridge 9
recirculation 9
annualised 9
=1 9
(thyroid 9
stimulated. 9
coeruleus 9
hypothalamic-pituitary-adrenal 9
OCD. 9
FMC-A 9
pentostatin 9
respond. 9
reality? 9
solanezumab. 9
ARIA 9
CAA 9
Aβ40 9
abandoned. 9
eagerly 9
accident 9
Bapineuzumab, 9
Abeta, 9
0.61; 9
Study). 9
762 9
0.91, 9
cladistic 9
Third 9
eliminated, 9
anxiety-like 9
hypothalamo-pituitary 9
(LC) 9
Snail-mediated 9
JOURNAL 9
COMPILATION 9
provoking 9
Snail, 9
NMuMG 9
deltaEF1. 9
myometrial 9
(56% 9
(PWS), 9
insufficient. 9
overly 9
unrecognized, 9
rhythms, 9
structure-guided 9
Bromodomain 9
sweats 9
9.9, 9
milligram 9
incapacitating 9
districts 9
unintentional 9
thinking, 9
histogram 9
(CADASIL), 9
PCCs 9
Operating 9
pathologist 9
fibrogenesis 9
0.38; 9
18.6% 9
FVC, 9
SERCA-2 9
pesticides, 9
profuse 9
malathion 9
deliberate 9
charcoal 9
OPIDP 9
pinch 9
intentional 9
Late-onset 9
physiotherapy 9
'dying 9
back' 9
interosseus 9
intoxication, 9
fields: 9
abates 9
conditions; 9
(ChIA-PET) 9
Analyzer. 9
BDV. 9
nonpermissive 9
interleukin-1beta 9
BD. 9
c-fos, 9
PU.1. 9
ranks 9
Gastroenterology 9
restorative 9
audio-video 9
participated. 9
(RMMA) 9
acidification. 9
erosion, 9
wear, 9
Portable 9
short-burst, 9
Medication 9
Forty-nine 9
(assessed 9
healthier 9
PSA. 9
web-log 9
65.6 9
deletion/duplication 9
multivitamin 9
CPP 9
Overt 9
hemangiomas, 9
normal: 9
hybridizations 9
Repressing 9
Reciprocal 9
mdig 9
reconfiguration 9
orbitofrontal 9
worms, 9
PMDD, 9
conclusive. 9
Ovid 9
controlled-release 9
change: 9
Six-month 9
phase). 9
VAS-Mood 9
histaminergic 9
PDD 9
34%. 9
BSG 9
2-11 9
(6%), 9
signed-rank 9
PDT. 9
(USA). 9
HSPG2 9
15.3 9
dissatisfaction 9
full-text 9
Insomnia 9
desvenlafaxine, 9
pads 9
Penile 9
SUI. 9
exercises. 9
cystectomy. 9
trazodone, 9
insomnia: 9
multiplicities 9
energetically 9
structures; 9
genome-unique 9
domains" 9
Psoralen 9
Atomic 9
lifetime. 9
Zn(2+) 9
agents). 9
guselkumab 9
85%, 9
(100-300 9
injury-induced 9
hotspots, 9
neurofibromin, 9
PA. 9
FLR 9
121974), 9
80.0% 9
modality, 9
0.020). 9
Antisense-mediated 9
19: 9
U1-antisense 9
non-conserved 9
domain' 9
refill 9
possession 9
A1c, 9
servings/wk 9
interrogating 9
plant-specific 9
TRP2 9
HAART 9
fibres, 9
financed 9
Viagra, 9
Indicators 9
ecallantide 9
1.64 9
(PAP) 9
Immunology 9
karyotypes, 9
dysmorphisms, 9
HL. 9
voluminous 9
(CRD) 9
endoribonuclease 9
(Ovid) 9
(placebo, 9
E18.5 9
damaged. 9
technetium-99m 9
10(-8)). 9
nigro-striatal 9
nigro-amygdaloid 9
44-year-old 9
LB, 9
postnatally. 9
meconium 9
(CF). 9
PI(3)P 9
dimerize 9
stereotypy, 9
Tardive 9
dystonia: 9
(39% 9
Ubp8, 9
Complex. 9
phenocopied 9
mycolic 9
EXPERT 9
Occlusion 9
ICA 9
medically. 9
4.9% 9
fiber. 9
Da 9
Modest 9
misdiagnosis, 9
SENP1 9
heart-failure 9
SERCA2A 9
SUMO1. 9
Glutathione 9
[WBC 9
(SU) 9
hyperinsulinemia 9
cleavages, 9
trypsins 9
triplicate 9
digestions 9
artifacts 9
TRCF 9
UvrB. 9
psychopathology. 9
glucocorticoid-sparing 9
points) 9
Eosinophils 9
asthma: 9
receptor), 9
hyaluronan 9
reslizumab), 9
(benralizumab), 9
corticosteroid-sparing 9
EE 9
oesophagitis. 9
oesophagus, 9
Anti 9
system), 9
allergen-induced 9
(MAE) 9
rufinamide 9
aggression. 9
acetaminophen, 9
SMEI, 9
neuroradiologic 9
HSPB8 9
myelopathy 9
electrophysiological, 9
gangrene, 9
(LPS), 9
(Blood. 9
hematology 9
prolapse. 9
RWS 9
entropy 9
24). 9
lentiginous 9
subungual 9
expression: 9
13.8% 9
investigative 9
soles 9
TSC1/2. 9
LKB1, 9
restenosis. 9
grapes 9
wine, 9
microg/ml), 9
acid-stimulated 9
PNT1A 9
interleukin-1β. 9
AB, 9
excimer 9
myopia 9
astigmatism 9
Private 9
μm). 9
Inc.; 9
E(2) 9
(EDS), 9
pharmacies 9
Reactions 9
pediatrics. 9
repletion. 9
3-min 9
ruptures 9
small-angle 9
grains, 9
quintile 9
hurdles 9
S33005 9
non-Caucasian 9
LAC 9
genders 9
INherited 9
consortia. 9
non-profit 9
results; 9
mammillary 9
tectal 9
achalasic 9
draws 9
histochemistry 9
Thiamine 9
Mecp2 9
cataloging 9
ORM1 9
(CYP2C9) 9
HDA-based 9
glucocerebroside 9
Miglustat 9
32. 9
5.7% 9
(36%), 9
2.26% 9
CA9, 9
mosaicism, 9
biomolecules 9
uEVs 9
lectins 9
immunoelectron 9
Torrent 9
deacylases. 9
TAL1/SCL 9
hSET1 9
Contrasting 9
Andersen 9
hiPSC-ECs 9
procainamide 9
calcium- 9
conduit 9
Biol 9
micrognathia, 9
errors), 9
by: 9
Contact 9
thoracolumbar 9
Dermatology. 9
family]. 9
head-up 9
microsomes, 9
retards 9
anti-V3 9
59, 9
0.023) 9
heme-binding 9
MAF 9
Bach1-deficient 9
H(2)O(2). 9
crucial. 9
miR-196 9
stress-responsive 9
neointimal 9
homeostasis: 9
marriage. 9
transition) 9
Inner 9
50.0 9
(63%), 9
20-mg 9
OX2 9
orexin-2 9
[12%]). 9
495 9
(baseline: 9
chow 9
(T2DM), 9
qd 9
keywords. 9
acceptor, 9
transgenes, 9
tetrapod 9
Real-Time 9
Reliable 9
indications: 9
Neutrophils 9
(<3 9
penumbral 9
(CBF) 9
cats. 9
min; 9
glucose-related 9
662 9
excited 9
SERCA1a 9
lobes. 9
Italiana 9
caused, 9
MEK-ERK 9
berghei 9
(H3K4) 9
CTAs 9
MCF7, 9
Wnt5a 9
HB-EGF-induced 9
casq2 9
CArG 9
DTEF-1 9
MEF2D 9
(heart 9
TRE 9
bind, 9
(PK)/pharmacodynamic 9
tofacitinib. 9
Necrosis 9
JAK2, 9
MTX, 9
Jak3 9
(TALEN)-mediated 9
β-Thal 9
67%. 9
anti-nociceptive 9
voltage-clamp 9
15-fold 9
FA-BRCA 9
Flowcytometric 9
Anemia. 9
tests: 9
readthrough. 9
CLIC4 9
Indeed 9
glycolipids 9
alpha-Gal 9
maturity. 9
(TG2) 9
Disease-specific 9
done, 9
ETS-1 9
GEF 9
Aptamer 9
aptamer. 9
blebbing. 9
caspase, 9
caspase-8, 9
homothorax 9
Fugu 9
CSF3R 9
spermatozoa, 9
revival 9
evaluate, 9
wounding 9
Angiomyolipoma 9
mg/m 9
2-negative 9
Pharmaceuticals. 9
left). 9
ECM, 9
(ECM), 9
passages 9
diffusible 9
amplitudes, 9
2.3-fold 9
Ancora: 9
(Transcription 9
COnserved 9
ElementS) 9
gene-by-gene 9
(FSHD). 9
(epi)genetic 9
IRG1, 9
PBMCs. 9
orchestration 9
immune-deficient 9
(spanning 9
seeding 9
laminin-111 9
9%. 9
"systemic 9
irritant 9
(Immunoglobulin 9
eosinophils) 9
RTX 9
Wound 9
isoflurane 9
5%; 9
melatonergic 9
FAs 9
palmitoyl 9
subfamily, 9
co-expressing 9
ablating 9
Rac1-GTP 9
CCR7 9
Gi 9
lyse 9
radixin 9
homologue), 9
ELMO.Dock180 9
WASP-interacting 9
CrkII 9
(DNMT3B) 9
hepatocarcinogenesis 9
incorporation, 9
PICK1 9
hypertension; 9
microg/mL). 9
Newborn 9
516 9
RH 9
Ibrutinib 9
(GS-1101) 9
RyR2-mediated 9
Stabilization 9
FKBP12 9
multiple-channel 9
catecholamine-induced 9
CDDP 9
(K(ATP)) 9
Upregulated 9
polymicrobial 9
dimethylarginine 9
540 9
insertions/deletions 9
QT, 9
Q-T 9
Oligomeric 9
frequency-domain 9
gonad. 9
(decitabine) 9
CTLs 9
PCH 9
rfx6 9
(14.6%) 9
(94 9
non-pathogenic 9
CD99wt 9
Exact 9
round, 9
Cufflinks 9
heaviest 9
uniqueness 9
Grape 9
avalanche 9
revolutionizing 9
SDB 9
SCN5A. 9
PREP 9
neurones 9
Ssa1p 9
Lipids 9
interventricular 9
(3.0 9
PPARalpha 9
0.74; 9
centrifugation. 9
uncoordinated 9
High-occupancy 9
(HOT) 9
1.61 9
D84E 9
2.74 9
#182960) 9
V). 9
Mb, 9
nonneuronal 9
Melanoma. 9
0.88; 9
15q11-q13, 9
SNURF-SNRPN, 9
SNORD116, 9
widespread. 9
repeated, 9
Aβ-induced 9
photodamage 9
Glucocorticoid 9
radioresistant 9
BRCA1/2-negative 9
exercise-related 9
unifies 9
(RyR2). 9
http://bioinformatics.iastate.edu/bioinformatics2go/gs/download.html. 9
Ca(v)3.1 9
(33%; 9
hand-held 9
62%, 9
2.23 9
single-agent, 9
(37%), 9
(AIM) 9
AIM 9
paralogue, 9
COS7 9
An. 9
ascomycete 9
microtubule-based 9
SPB 9
collagens. 9
homologs. 9
Probiotics 9
sold 9
12.0 9
COMPARE 9
importing 9
LL 9
puffers 9
2000-2001. 9
subtropical 9
toxins, 9
Suspected 9
CCTG 9
intergenerational 9
AP-2 9
(aSAH). 9
15%; 9
(28% 9
(ICH), 9
embolization. 9
36) 9
ligature 9
9-12 9
prolactin. 9
1950s 9
nurses' 9
molindone, 9
(PCC), 9
(3' 9
predictably 9
dodecameric 9
(PCC, 9
branched-chain 9
mitochondrial, 9
videotaped 9
(VIM) 9
isozymes, 9
belt. 9
aminoglycoside 9
ejection. 9
p65. 9
CONTEXT: 9
(94% 9
HDL, 9
MCM2-7, 9
anastrozole, 9
letrozole, 9
(RFS) 9
ER(+) 9
(unless 9
RasGRF1 9
osteofibrous 9
[6]. 9
re-establish 9
(non-syndromic) 9
Nat. 9
(B. 9
protein- 9
III-bound 9
retroposing 9
human) 9
progenitor, 9
III-dependent 9
conserving 9
III-transcribed 9
pigment-protein 9
illumination, 9
structure: 9
Itaconic 9
CHROMOMETHYLASE 9
NEFL, 9
Leucine-rich 9
4A 9
Heterodimeric 9
DNA-bound 9
p50/p65 9
IRF1, 9
Graphical 9
CEP 9
ninefold 9
CEP135 9
Stepwise 9
HECT 9
HERC2 9
HERC2, 9
Sf9 9
VISTA-16 9
A(2) 9
TTT 9
(GMR 9
investigator. 9
Receptor3 9
phalanges 9
p.Pro250Arg 9
loss; 9
markings 9
FGFR3-related 9
others' 9
OFF 9
post-contrast 9
73-kDa 9
retardation; 9
(AFP), 9
beta-clip 9
hypermutation. 9
pausing, 9
(DSIF) 9
Ser2 9
lifespan, 9
struvite 9
divalproex 9
tearing 9
injection). 9
athymic 9
staging. 9
469 9
Weibull 9
Colombia. 9
secretagogue 9
MetS. 9
oligodendrocytes. 9
NMP22 9
4- 9
Standardization 9
Avoidance 9
Palindromic 9
EGFR-targeted 9
Bcl-xL, 9
PC-9 9
de-SUMOylation 9
myogenin. 9
enterocolitis. 9
MCM7, 9
Fostamatinib, 9
cell-driven 9
tolerogenic 9
ever-changing 9
(75%), 9
Cohesin, 9
A=T 9
(HSPC) 9
curative, 9
doxycycline-regulated 9
BLZ-211 9
oblique 9
Virulence 9
HMW 9
LMW 9
1.1; 9
EMs 9
BIM 9
Humanized 9
Ethics 9
propofol, 9
propofol. 9
1063 9
AMO 9
12-fold 9
chloroplastic 9
FKH 9
FoxO6 9
neocortex. 9
applied, 9
miR-146 9
IL-1beta. 9
Larsen 9
0.017). 9
rhumatologie. 9
SF. 9
MicroRNAs, 9
(Tregs) 9
FGFR1-3 9
skulls 9
CD44v2 9
B-CLL 9
(HA), 9
overwhelmingly 9
(SCC), 9
oxybutynin 9
micturitions/24 9
65, 9
same, 9
10K 9
Listing 9
JIA. 9
(n=1). 9
Semliki 9
(HOCOMOCO, 9
http://autosome.ru/HOCOMOCO/, 9
http://cbrc.kaust.edu.sa/hocomoco/) 9
hand-curated 9
S100A7 9
thereof 9
Per3, 9
Ca²⁺/calmodulin-dependent 9
cones. 9
rib 9
simplest 9
Viroids, 9
Characterisation 9
non-specific, 9
Chorion 9
unreviewed 9
http://bioinformatics.biol.uoa.gr/LepChorionDB. 9
cohosh, 9
dong 9
HFRDIS 9
(CAM) 9
AAG 9
DNJ 9
(0.2% 9
clears 9
WONOEP 9
traces 9
acoustic, 9
(PSA), 9
missed. 9
shunting. 9
gefitinib-induced 9
(SLN). 9
nonshivering 9
sarco/endoplasmic 9
force-frequency 9
double-knockout 9
ankylosis 9
cultured. 9
RhD-negative 9
True 9
vasodilator, 9
angioedema. 9
intravenously, 9
(PVT) 9
(BVT), 9
"ping 9
pong" 9
reciprocating 9
bigeminy. 9
shift, 9
PBL 9
underdiagnosed, 9
"syndromic 9
(ZFHX1B) 9
rules. 9
imputation 9
ENDEAVOUR 9
multi-factorial 9
vocabularies, 9
thymoma 9
studies). 9
Network-Based 9
timescales 9
(cAMP) 9
phospho-p38 9
Fibrocytes 9
EP4 9
ineffective, 9
patella, 9
incur 9
LIMP-2 9
Geldanamycin 9
quickly. 9
teratoid/rhabdoid 9
Hsc70-interacting 9
Smad1. 9
g/L, 9
39%, 9
urceolata 9
chloride, 9
EDMD, 9
electrocardiogram. 9
tendons, 9
MD, 9
(n=10). 9
(factor 9
LAMP-2 9
hyper- 9
CTRL 9
MetaTM 9
bayesian 9
Forward 9
TEs 9
Tubacin 9
tubacin. 9
tubacin, 9
Brainbow 9
PVR, 9
iron-regulated 9
-2.0 9
keeps 9
SIP-1) 9
underestimated. 9
hypospadias. 9
H3K27ac, 9
unrealized 9
microenvironments. 9
preovulatory 9
hyperprolactinaemia. 9
hyperprolactinemic 9
26.7 9
(LDs) 9
(n=12), 9
circularized 9
micromol/L. 9
NINDS 9
posed. 9
definitions, 9
anemia-BRCA 9
65%; 9
monitor. 9
(CONT). 9
15.5 9
counted. 9
CSF/serum 9
curative-intent 9
TRα 9
T3-mediated 9
amiodarone-like 9
(TRalpha1), 9
(SP) 9
TCC 9
ultrasound-based 9
billions 9
96.9% 9
NIFTY 9
DNase-Seq 9
nucleo-cytoplasmic 9
staggered 9
fixed, 9
propagates 9
(vi) 9
cell-lineage 9
405 9
Cry 9
(July 9
Mthfr 9
MG132 9
Embryos 9
(Dnmt) 9
human/zebrafish 9
pax6 9
HCNEs. 9
furosemide 9
LVESWS 9
thinning, 9
left-to-right 9
Discriminant 9
scale; 9
sweep. 9
Antagonistic 9
(likely 9
band, 9
low-resolution 9
(mutation 9
continuum: 9
(DFN2) 9
DFN2 9
Q10-150 9
Studio 9
ARE-binding 9
HDF 9
immunoprecipitations 9
buds. 9
saphenous 9
(CCI) 9
post-TBI 9
5'-D2 9
G/A 9
nanocrystals. 9
(SQTS), 9
8-year 9
channelopathies: 9
ICD. 9
Ryr2-R2474S 9
4/5 9
1-bp 9
pan-HDAC 9
Separate 9
factor-positive 9
Superior 9
mlp84B 9
titin, 9
N-RAP 9
integrator 9
β-Catenin 9
5q35.2-q35.3 9
(NSD1) 9
deletion-type 9
lipomas 9
18q 9
oneidensis 9
Asians. 9
2.98 9
hedgehog. 9
homologs: 9
3.5, 9
polycythemia 9
aphthous 9
ulcerations 9
(JBTS) 9
Cep290 9
operons, 9
blueprint. 9
exciting, 9
tyrosinases 9
suitable, 9
(TAM) 9
apurinic/apyrimidinic 9
(TAM): 9
Encouraging 9
amplified). 9
mibefradil, 9
CSE 9
amlodipine, 9
cm(2) 9
angiotensin-receptor 9
hydrochlorothiazide, 9
HU, 9
Hin 9
Centre, 9
TmHU 9
DHE 9
0.82, 9
migraine-associated 9
hydrogenation 9
spectrometers. 9
ABCG2, 9
BEN-MEN-1 9
Appraisal 9
radiochemotherapy. 9
2-month 9
1,3-bis(2-chloroethyl)-1-nitrosourea 9
Vivo 9
Gray 9
PACT 9
DGCR8 9
Giardia 9
labyrinth 9
dentatorubral-pallidoluysian 9
digestion; 9
HNSCC. 9
SLX4 9
network: 9
Hematol. 9
10.1 9
Primates, 9
Lagomorpha. 9
estimations 9
data.We 9
"negative 9
control" 9
cortex/precuneus 9
autosomaldominant, 9
CMT6. 9
CMT6, 9
C12orf65-related 9
paraparesis.We 9
c.413_417 9
delAACAA, 9
GGQ-containing 9
gemcitabine, 9
cyclophosphamide. 9
g/m2 9
(PBs) 9
papillae 9
tentorium 9
S-100 9
initiators 9
calculi 9
invested 9
dispersive 9
Infected 9
NLRC4 9
A+T-rich 9
harvest 9
Cystatin 9
m(2), 9
C-based 9
MDRD 9
Agreement 9
high-impact 9
non-ST-segment 9
NIPT. 9
Implementing 9
hypoPP, 9
acidosis. 9
Verbal 9
wide-ranging 9
magnum 9
schooling 9
might, 9
non-statistically 9
circulates 9
Heterozygosity 9
treatment-associated 9
fates. 9
unidentified, 9
mismatch-repair 9
intra-S 9
cycle; 9
iE-DAP-induced 9
Rip2 9
sheath. 9
(GDM). 9
ICAM1 9
NFKB 9
NLRP1 9
PAD4 9
Peptidylarginine 9
HCD 9
scrapie-infected 9
PADI4. 9
ball 9
infest 9
blepharoconjunctivitis. 9
palpebrarum: 9
transmitted. 9
hairs, 9
(AAV)-mediated 9
SR-mediated 9
chymotryptic 9
shores 9
assessors 9
.005) 9
0.025). 9
journals 9
ARVC, 9
(n=68). 9
0.22, 9
3.19, 9
mixing 9
tetrac 9
Ic, 9
Engel 9
(Ib 9
Ic) 9
IB). 9
Blumcke 9
0.8), 9
cytomegalic 9
1971 9
EEG. 9
rich, 9
Latency 9
understanding, 9
diversities. 9
Greyhound 9
(COPD). 9
denote 9
pacing-induced 9
traveled 9
rebleeding 9
6.7-fold 9
recalled 9
voxels 9
discount 9
Intraflagellar 9
(IFT-A) 9
(IFT-B), 9
1,467 9
optica 9
Idec 9
TSS. 9
autosomes 9
explored, 9
reinstatement 9
encephalopathies. 9
JAB1 9
A2/B1 9
intersect 9
(fluorescence 9
ceritinib, 9
crizotinib-treated 9
4(6); 9
662-73. 9
Ramalingam 9
Khuri, 9
621. 9
Prx-2 9
erythrocyte. 9
671 9
NVIDIA 9
workstation 9
(IQR) 9
40-50% 9
arises. 9
wounded 9
SEPP 9
good. 9
(PEG) 9
34%), 9
northeast 9
cold-induced 9
oriC-independent 9
DNA-RNA 9
proposed: 9
Orion 9
Entacapone, 9
raft 9
hybridization: 9
(7% 9
Hypo 9
drug-like 9
atoms. 9
Insight 9
thyroid: 9
close-knit 9
deiodinases, 9
self-amplifying 9
IL-15 9
paracetamol 9
deepCAGE, 9
ClinicalTrials.gov. 9
348 9
Technical 9
cyclopentadecanone 9
underscored 9
factor; 9
Time-lapse 9
(PDB) 9
graph-theoretic 9
Q(2) 9
TMH 9
optimisation 9
VDAC 9
(OM), 9
limb-specific 9
notochord 9
Zfhx1b 9
SNAP-25 9
dextromethorphan 9
breaths/min 9
crew 9
cytochemical 9
VP16 9
owat-Wilson 9
distally 9
UvrABC 9
pri-miR-216a 9
folliculin 9
LRS 9
raptor. 9
Nonrandom 9
(Alu 9
dystonia-parkinsonism) 9
dracorhodin. 9
MMP, 9
(AIF) 9
AIF 9
pro-apoptosis 9
MSQoL-54 9
(≥50% 9
Relapsing 9
sequencing). 9
(GFI1B) 9
(Gfi1b) 9
ISEH 9
Gfi1b(ko/ko) 9
protein-1, 9
1961, 9
GFI1B, 9
(GPS) 9
sgRNA:Cas9 9
protoplast 9
promise. 9
2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline 9
proarrhythmia 9
piebaldism. 9
spotting. 9
stakeholders 9
C57BL/6N 9
CCC 9
simplex, 9
Reciprocally, 9
GW4064 9
I-IV 9
Bile 9
sorafenib. 9
manipulation, 9
H2AX. 9
canonically 9
H1R 9
MDC1 9
MHR 9
textile 9
ORA, 9
ORA 9
(MT1-MMP) 9
sever 9
aspects: 9
(6-12% 9
Nop1p 9
crescent-shaped 9
circles. 9
(L-type) 9
1450 9
2:2 9
(AONs) 9
α-sarcoglycan, 9
β-dystroglycan 9
(BDG) 9
and--in 9
cases--neuronal 9
(DAPC). 9
MudPIT 9
nocodazole-induced 9
entangled 9
FOXG1 9
exclusively. 9
dovitinib. 9
(KI) 9
rebreathing 9
circumstantial 9
methacetin 9
instilled 9
Hg). 9
EGA 9
desktop 9
FT-IR 9
(74% 9
uPAR 9
parasellar 9
none. 9
frontoparietal 9
SoS 9
25-OHD 9
season, 9
300,000 9
(NINDS) 9
clearances 9
(MEK 9
Raf, 9
KSR2 9
GAB2 9
hydralazine 9
PRC2-Ezh2 9
H3K27me2/3 9
SAFB1 9
N-glycan 9
271 9
CD40LG 9
stimulator. 9
Bispectral 9
(8.3 9
Dubin-Johnson 9
Dubin-Johnson, 9
Gilbert-Meulengracht 9
hyperbilirubinaemia: 9
hyperbilirubinemia.Moreover, 9
PCR-amplified 9
(GRP94) 9
BRG1-associated 9
Vasa, 9
nuage 9
TSE 9
ARTN, 9
p44/p42 9
non-related 9
RG7112: 9
Small-Molecule 9
cytokine-1 9
apoptosis). 9
508 9
betrixaban), 9
arthroplasty 9
(2.4%) 9
billion, 9
Guinea, 9
dengue, 9
phenolic 9
World, 9
speculates 9
bounds 9
containers 9
aeruginosa, 9
0.87) 9
miss 9
forebrain, 9
MKPs 9
1.68 9
USA), 9
BWT, 9
(BWT), 9
enlargement. 9
myelodysplasia. 9
newborns, 9
GSMs 9
(APP), 9
6.1, 9
Affairs 9
PCPs 9
RIZ1 9
(Met) 9
AtHMT-1 9
kDa), 9
imipenem 9
metallo-beta-lactamases 9
detected: 9
enhancer-activity 9
ecdysone 9
MCB, 9
MCB 9
dissipates 9
DEA 9
myoclonus. 9
LDH-A 9
DIM. 9
IOA 9
tetA 9
cocaine-negative 9
miR-221 9
dose-dependently. 9
low-LET 9
(miR-21 9
mir-31, 9
miR-377 9
Sciences, 9
Notable 9
NOS2 9
U87MG 9
EGFR-regulated 9
hospitalizations. 9
alarming 9
33%, 9
heterotrimer 9
glucose-responsive 9
importin 9
emerges. 9
mitofilin, 9
OMM 9
symbionts 9
Alphaproteobacteria 9
specialists. 9
papers, 9
Fine 9
22q 9
LOH, 9
SOX9. 9
1-infected 9
matching, 9
A-tail 9
DEEP, 9
enhancer's 9
gametes. 9
(GRO-seq) 9
p.Ser755Thr 9
(KCNH2, 9
metabolizes 9
conceive 9
electrocoagulation 9
(skeletal 9
uveitic 9
all-grade 9
(tocilizumab). 9
RCC. 9
Test) 9
acetylation/deacetylation 9
GSTp 9
cAMP-responsive 9
TFIIIC 9
Cd8 9
tether 9
bexarotene 9
LOCUS 9
teratogen, 9
2.04; 9
14C 9
feed. 9
5/6Nx 9
texting 9
Literature. 9
(SWD) 9
multiple-dose, 9
(BFI), 9
user, 9
Trypan 9
non-prostanoid 9
vomiting) 9
phenylephrine. 9
MCT-PAH 9
EP(3) 9
(PNDM) 9
(DEND 9
C166F 9
viewing 9
A-68930 9
82.6% 9
mMS 9
mediodorsal 9
ation 9
methylation-free 9
normochromic 9
Aug 9
P=0.12) 9
51] 9
P=0.05). 9
voice. 9
cyanosis 9
Studies-Depression 9
Impression, 9
metabolite. 9
α-tubulin, 9
CYPs 9
hs-IL-6 9
anticoagulated 9
1·01 9
non-vitamin 9
dB 9
Zmax 9
(cM) 9
volume) 9
sibship 9
PD-associated 9
(PAS). 9
tattoo 9
Ehrlichia, 9
valaisiana 9
71.5% 9
Endothelin 9
(part 9
(renal 9
OVB 9
2-5% 9
germlineTP53 9
79). 9
(triple 9
(XFEL) 9
XFEL 9
low-energy 9
developed: 9
corticoid-synthesis 9
(DHEA), 9
EBSI, 9
Sp1, 9
Epitope 9
orthopaedics, 9
radioiodine-refractory, 9
it? 9
artefact 9
rRNA, 9
(CES-D) 9
HADS, 9
hardship 9
households 9
irides 9
nadir 9
Tiger 9
9q34, 9
abl-related 9
acidA 9
succinate), 9
50-mg/day 9
(HAM-D(17)) 9
DVS 9
short-term, 9
FCM. 9
(ferritin 9
12.2% 9
(FeSulf) 9
ENGAGE 9
eliglustat. 9
(NCT00358150). 9
(14.2%) 9
Femur 9
(Genz-112638), 9
~2 9
EPOF 9
VL 9
hCLCs 9
hypergravity 9
VSELs 9
c-kit+AT2+ 9
postsurgery 9
ECAD 9
SGHPL-5 9
placentas. 9
Wnt-dependent 9
wnt 9
PPAR-α/γ 9
fenofibrate 9
Arrhythmias 9
chromatin; 9
Dot1-dependent 9
Cyclosporine 9
DCD-1L 9
Ingestion 9
fenestration 9
Rauscher 9
46.0 9
L-T( 9
hypolipidemic 9
microtubule-destabilizing 9
(PTH) 9
rot 9
chemosensory 9
huntingtin, 9
eqFP611 9
8-oxo-G 9
8-oxo-dGMP 9
antimutator 9
dCTP 9
8-oxo-dGTP. 9
SN-38 9
Hepatotoxicity 9
mg/m2/day) 9
(MET) 9
2.18; 9
23.7% 9
enjoyment 9
Naltrexone 9
fluorouracil/calcium 9
11.8% 9
(NPC1) 9
NPC1(-/-) 9
HLA-DRB1*04 9
fatigue: 9
Curcuma 9
neuritis 9
FA-G 9
repurposed 9
(TIA-1 9
TNNI3K, 9
T-cell-mediated 9
melanoblast 9
shield 9
pyrexia, 9
(GSK2118436) 9
BJD 9
V600EBRAF 9
DDC 9
stress). 9
Snail1, 9
vertebrates). 9
plans, 9
p53(+/+) 9
equipment. 9
OTC 9
receives 9
subgenomic 9
ISG 9
G3BPs 9
(VR) 9
iron-reducing 9
Field 9
amendment 9
(HERG) 9
prowazekii, 9
prophage 9
BRAG1 9
sulfatase 9
EphA7 9
NB. 9
Eph/ephrin 9
ephrinA5 9
RRM3 9
dapiprazole-blocked 9
Dapiprazole 9
dilate 9
NF-kappaB-inducing 9
HES7 9
Comorbidities 9
fatigued 9
WLC 9
CB(1) 9
orientation-independent 9
anti-gp210 9
IFNAR1. 9
p19 9
methyl-specific 9
tumor/lung 9
MethylCap-seq. 9
Dvl. 9
apocrine 9
Ash2L/RbBP5 9
NSD3L 9
HDAC1/2 9
SPARC, 9
LYST/CHS1 9
Authors, 9
GST-I-1(T35A) 9
NCLK-phosphorylated 9
I-1. 9
NETosis. 9
22), 9
generalizability 9
reactions: 9
MIR22 9
ORI 9
case), 9
leu 9
(8-oxo-G) 9
(composed 9
YtkD, 9
YfhQ) 9
postadoption 9
CES-D 9
Tubulin 9
II-induced 9
Sir2-related 9
21.6 9
32.1% 9
retroelement 9
RBCs. 9
Scale; 9
dyskinetic 9
LID 9
ALAAD 9
"InSurE" 9
(CPAP) 9
(HT). 9
G-quadruplex-interactive 9
refrigerated 9
refrigeration 9
trifluridine 9
non-BRCA1-like 9
Erucism 9
Dermatologists 9
France: 9
nodosa 9
(ocular 9
azole-resistant 9
RMA 9
hypothesizes 9
galactosylsphingosine 9
GALC-GC 9
LRs 9
merozoites 9
var, 9
P.falciparum 9
periosteal 9
haired 9
E189D 9
LNM35 9
amino-acid-changing 9
Replication-associated 9
biased. 9
(SGD) 9
SGD 9
polC, 9
dnaE, 9
SGD. 9
deformity. 9
transplant-ineligible 9
Pharmacoeconomics 9
BZM 9
Catastrophic 9
well" 9
Erythropoietic 9
afamelanotide, 9
repigmentation 9
vir 9
activity-based 9
asymmetrically 9
delocalization 9
gantenerumab, 9
II-targeting 9
SHAPE-Seq, 9
mmA13CNS 9
Hox-gene 9
Visualizing 9
chorioretinopathy 9
(two-sided 9
prescriptions. 9
trans-obturator 9
2.2% 9
convenience, 9
dimensionality 9
CRISPR/Cas9. 9
CRISPR/Cas9-mediated 9
masculine 9
Varsity 9
athleticism. 9
104) 9
117). 9
fencers 9
lenalidomide) 9
DARA, 9
Met1Val 9
1260 9
11%; 9
Cronbach's 9
95) 9
MTG 9
Rabson-Mendenhall 9
MUPs 9
spitzoid 9
FFPE-FASP 9
affectivity 9
Ds 9
papulovesicular 9
TmL 9
2009; 9
biodiversity 9
SMRT 9
Me2SO. 9
Mannose-6-phosphate 9
endosome-to-TGN 9
36.4% 9
Vedolizumab, 9
calprotectin 9
(26.6%) 9
clonidine-treated 9
dementias) 9
Well-powered, 9
MATRICS 9
Approved 9
ogt+ 9
norepinephrine. 9
impulsivity, 9
(ASPD) 9
Cause 9
spike-in 9
B-lymphocytes 9
coverage) 9
warts 9
pre-exposure 9
unorthodox 9
Vel 9
(block 9
633 9
Unless 9
ATDC5 9
TMT 9
1.81 9
function(s). 9
r2 9
cagA+ 9
mumol 9
(AHDS) 9
>0.2 9
Nonclinical 9
UGT1A1. 9
MRP2. 9
IC50. 9
Cmax,free 9
Rfree, 9
glucuronidation/transport 9
indinavir. 9
nelfinavir 9
trovafloxacin. 9
FQ 9
acyl-CoA 9
Minab 9
drug: 9
BMP-3 9
FA-M 9
PC3PR 9
RhoGDI2 9
Rac1-dependent 9
15q11-q13. 9
15q. 9
PW71 9
-0.5 9
PLX3397, 9
5-point 9
etanercept. 9
≥50 9
IL-23/Th17 9
SEN 9
cyclophilin, 9
phyla. 9
Vezf1 9
Csnk1e 9
entrainment 9
(280-320 9
Foundation; 9
eteplirsen. 9
annonaceous 9
differed, 9
Pointe 9
à 9
(CINAHL), 9
M.HhaI, 9
5-methylcytosine, 9
armoured 9
pentobarbital 9
specialist. 9
Uncovering 9
TREX-2 9
moral 9
Nonsense-mediated 9
PsPD 9
(COL5A1) 9
Gynecological 9
cord-stromal 9
(Mulibrey 9
nanism) 9
Nanism. 9
MpgII 9
fU:A 9
Smad1 9
Ro52 9
ectasia, 9
p38beta 9
inducement 9
ligament, 9
DNA-Repair 9
94%. 9
[20%]) 9
Tbx5, 9
Shyper 9
409 9
curvature, 9
humidified 9
CPAP. 9
reintubation 9
NG2 9
ketanserin, 9
5-HT6, 9
intrasubject 9
(DV), 9
altanserinol 9
radiometabolites, 9
TOM20 9
metaxins 9
hSpt4 9
(pendrin) 9
KvLQT1, 9
Prime 9
Mth1 9
Rgt1 9
duplications), 9
dose-sensitive 9
indicating, 9
acid-inducible 9
Cucurbitaceae 9
STZ-induced-diabetic 9
(SJS), 9
TRF2-independent 9
extra-chromosomic 9
SiHa 9
Thr-3 9
BIR 9
5-aminosalicylic 9
NetDiseaseSNP 9
ghr-/- 9
Ink4a/Arf 9
Foxj3 9
c-miRNA 9
myomiRs 9
reconfigurable 9
swelling. 9
inducible, 9
amniotes, 9
(N6-adenosine)-methyltransferase 9
(Orco) 9
AF150(S) 9
38.5% 9
(LR) 9
Dbr1 9
(HDV) 9
acanthocytosis, 9
MLS. 9
RAP 9
clioquinol 9
PCDHGC3 9
EN1 9
SCTR 9
IIS 9
high-cost 9
LRP6. 9
CE-MRC 9
KLKs 9
MMEL1 9
marijuana. 9
resonances 9
H-protein 9
hosted 9
EphrinB1 9
(cytosine-5)-methyltransferases 9
C5)-methyltransferase. 9
R130A 9
geldanamycin, 9
infliximab) 9
inject 9
alphaviruses 9
HAMLET 9
B1s 9
primate-rodent 9
K-H 9
0.14; 9
Outpatients 9
SZ. 9
(J-POST) 9
discoid 9
DBH, 9
Treadmill 9
HD5. 9
BRCA-2 9
chemoprevention, 9
Sovaldi® 9
Glucose-6-Phosphate 9
PrPc 9
Hdc 9
Trk-like 9
talazoparib, 9
(MK-4827) 9
(MK4827) 9
treatments; 9
PARP-DNA 9
veliparib 9
thermometry 9
imminently 9
cediranib, 9
(n=1088) 9
epoetin 9
deter 9
Pruritus 9
beta-Thalassemia 9
alpha-Thalassemia 9
CD38-targeting 9
complement-inhibitory 9
NOX5-like 9
RAD1901, 9
steroid-based, 9
invisible 9
avelumab 9
forecast 9
NadA(Δ351-405) 9
CAFE: 9
(http://bioinfo.au.tsinghua.edu.cn/dbsuper/), 9
OXTR 9
genes). 9
advisory 9
∆ES 9
UchL1 9
raxibacumab, 9
IgG1lambda 9
GFP-AmpA 9
Eukaryotes. 9
-5/5q-, 9
hybridization]. 9
8.4%, 9
SKY 9
c-v 9
(n=79), 9
<85 9
Remnant 9
ATTRACT 9
(PROs) 9
HRV, 9
1959 9
anti-T2DM 9
"Insulin 9
(DM). 9
engagement, 9
transcriptomic, 9
(n=684), 9
(n=5439), 9
(Nottingham-HES; 9
n=1650), 9
1·50, 9
0·48-0·97, 9
p=0·031). 9
THY1 9
measles, 9
PS2. 9
Ubc9. 9
deSUMOylating 9
apoE. 9
Ldlr 9
apoE-2, 9
apoE-3 9
papilledema 9
(PHEX), 9
phosphoglycoprotein. 9
cross-binding 9
bone-renal 9
0.585 9
HONE1 9
azuki 9
distributor 9
mistaken 9
rust 9
CSN-dependent 9
isopeptidase 9
Ins-1 9
(CSN). 9
1,3,4-trisphosphate 9
auxin, 9
AtItpk-1 9
Legg-Perthes 9
ERAP 9
ERAP1, 9
ERAP1/2 9
cm(3). 9
Nox1; 9
betaPix 9
735 9
hypokalemia 9
NCCT 9
RMBase 9
Hemolysis, 9
[Hereditary 9
hypopigmentation. 9
Microphthalmia-associated 9
melanogenesis. 9
(Tassabehji 9
Nobukuni 9
united 9
Shh-N 9
Gli 9
ihh 9
oligosymptomatic 9
plicata. 9
eyelid, 9
60U/kg 9
2years. 9
diaphanous-related 9
snail. 9
anti-formin 9
dextral 9
sinistral 9
phenocopy, 9
chirality-randomizing 9
(pre-cilia) 9
eucaryotes. 9
MaturePred, 9
MiRPara, 9
MatureBayes, 9
MiRdup 9
Locator 9
miRNA*, 9
2nts 9
overhang 9
(FOP), 9
Computations 9
intercanthal 9
canthorum. 9
community-associated 9
patient-days 9
staphylococcus 9
erection 9
congestion. 9
Chile, 9
orbitotomy 9
retrobulbar 9
(HFMSE) 9
cohorts; 9
HFMSE 9
9-14 9
"Swedish" 9
(APP(SW)) 9
"London" 9
(APP(LON)) 9
apocynin. 9
Paraquat-induced 9
expeditions 9
neuropathologic, 9
SEPT14 9
(LOXL) 9
plan, 9
Tokuhashi, 9
63%. 9
Sacubitril/valsartan 9
afobazole 9
L-DOPA, 9
pseudouridines 9
prohepcidin 9
PPARα 9
multilocular 9
RQC 9
(3/5), 9
R402Q 9
melanin. 9
schizophrenia-associated 9
Gomafu, 9
clr4+, 9
swi6+ 9
H3K14 9
-2.0, 9
mg/200 9
Items 9
Bilirubin-induced 9
bilirubin-induced 9
bilirrubin 9
monozygosity 9
PICUs 9
SLC40A1) 9
HFE4 9
606069), 9
oxymatrine 9
escitalopram 9
(NRD) 9
traseR 9
50+ 9
(2.80%) 9
bang. 9
flashing 9
periodontoid 9
corticosteroid-resistant 9
TFIIB. 9
Rna15 9
sclerosus 9
Boyd 9
Nelder 9
toxicity) 9
Lys27Met 9
DIBG 9
tumorigenesis? 9
∼8-12 9
70-90 9
chondroblastomas 9
G34W/L 9
backdrop 9
tumor-adjacent 9
tinnitus, 9
dislocations. 9
hypermobile 9
libFLASM: 9
PIL; 9
non-polyadenylated 9
PTX3/sTWEAK 9
rGBM 9
40-mm 9
rigid, 9
gas-cooled, 9
side-firing 9
(Cleveland 9
Hospitals-Case 9
Center). 9
34-69 9
70-90). 9
2.6-19 9
cm(3)), 9
57%-90%), 9
conformality 9
1.00-2.04). 9
62-767 9
neurologically, 9
Steroid-responsive 9
NCT00747253 9
case-series 9
SWR1. 9
Swr1-Z 9
sclera 9
PLA2G6, 9
aitor.gonzalez@univ-amu.fr 9
79), 9
degrons 9
A/M 9
genitalia. 9
NLD 9
Kac 9
Kcr 9
immunodetection, 9
H4K8hib 9
H4K8ac-associated 9
H4K8hib-labeled 9
5-repeat 9
corynebacteria, 9
inclusive, 9
20-24). 9
(IL-18BP) 9
Ssl2 9
(Apixaban 9
Onartuzumab, 9
poxviruses 9
contagiosum, 9
marneral 9
cluster) 9
lobules 9
cortex-intrinsic 9
branchlets 9
Mossy 9
mHGG 9
glioma). 9
Dyshidrotic 9
Hyperkeratotic 9
APOB 9
rhomboid-like 9
uncouples 9
teenagers. 9
anthropogenic 9
GAMES-RP 9
(pseudo-normalization), 9
(P=0.035). 9
gasdermin-N 9
PAZ 9
(CPF) 9
Pti1, 9
Ysh1, 9
degron-mediated 9
track, 9
stapling 9
Ciraparantag 9
DOAC 9
(andexanet 9
TSOAC 9
DSCR1 9
campomelic 9
microfibrils 9
liver-infiltrating 9
EVD 9
ZMAb, 9
Ikaros-deleted 9
(GDC-0941) 9
hERG, 9
non-penetrance. 9
MFS1 9
CAPS 9
(ULMCA) 9
EXCEL, 9
semaglutide, 9
(SUDEP). 9
Temporary 9
(DNN)-based 9
RFECS. 9
outperforming 9
osteocytes, 9
weight-of-evidence 9
DNMT3A/3B 9
HJURP 9
Mis20 9
nucleosome-protected 9
[nucleotides 9
2700], 9
DHBV-positive 9
ducklings. 9
sequence-specifically 9
monochromatic 9
cmlc2, 9
vmhc, 9
Ribociclib 9
vivo? 9
(K27M 9
osteocrin 9
onabotulinumtoxinA 9
right- 9
preservation': 9
(ESTEEM 9
DLQI 9
Uhl 9
SLC34A3 9
BWA. 9
(IORT) 9
afterloading 9
endocurietherapy 9
RPL32, 9
RPL12, 9
(13;22) 9
vehicle-controlled 9
gems 9
deoxynivalenol 9
tomato, 9
Bd 9
flight-related 9
website: 9
Adar(5G1) 9
Hyperglycosylated 9
M694V 9
fistulas. 9
Pfh1-binding 9
occupancy) 9
H2A). 9
Pfh1-dependent. 9
Sterol 9
mSREBP1 9
KOS 9
PTKs. 9
tularensis, 9
tularemia. 9
HeFH 9
ASF1 9
hypotrichosis 9
nrd1 9
nab3 9
(NNS) 9
Nrd1-exosome-TRAMP 9
Pcsk9 9
IgG1-PA4 9
Drug-Induced 9
TRMOD 9
(N=504) 9
Ser-121 9
(phentermine 9
lncRNA-CIR 9
flanks. 9
cotransporters 9
Inhibitor, 9
Dormancy 9
photoaging, 9
GMCs 9
davunetide 9
non-JAK 9
emMAW, 9
external-memory 9
SUI, 9
urethrovesical 9
jitter 9
TGFB1 9
(LY2157299 9
PrPC 9
window, 9
Upc2, 9
Ecm22, 9
7-bp 9
UROBORUS 9
6-azauracil 9
PMLVI 9
subSeq 9
MKB 9
HLA-DR1 9
TLR7 9
endocrinopathy 9
MLMT 9
SMAD4, 9
bmpr1a 9
(CIP) 9
CRTAP, 9
BMP1 9
(ICR). 9
2-sided 9
bispecific 9
0.87), 9
6.5). 9
antinucleosomal 9
nns 9
k. 9
alphabet. 9
time-optimal 9
impetigo 9
pedis. 9
Gram's 9
(SIOD, 9
SMARCAL1. 9
Ubx 9
c.1129G>C, 9
p.Glu377Gln 9
(q23;q11). 9
(Emanuel 9
ReliableGenome: 9
concordance. 9
can/cannot 9
PARP1-CTCF 9
Macrolide 9
Tumorigenesis. 9
Aα-chain 9
telocentric 9
interior, 9
anti-mouse 9
Assortativity 9
ties. 9
(AHI/RDI 9
DORs 9
aims: 9
(FSS), 9
vegfd 9
EXPEDITION 9
Hypothesis. 9
petechial 9
sent. 9
85/100 9
86/100 9
84/100 9
RAT 9
gabhs 9
interleukin-12/23 9
il 9
Requires 9
auxin-sensitive 9
IAA19 9
(Aux/IAA) 9
Dicephalus 9
omphalopagus 9
shift) 9
widely-studied 9
facilitative 9
OCDM 9
p53-regulated 9
pronation 9
prebronchodilator 9
IL-5Rα 9
Ercc1 9
ICRs, 9
Tunnel 9
anti-CGRP 9
Trastuzumab-induced 9
annotatr: 9
https://github.com/rcavalcante/annotatr. 9
rcavalca@umich.edu. 9
physis 9
Nematoda 9
signeR 9
http://bioconductor.org/packages/signeR 9
SomaticSignatures 9
perforation? 9
Dlx1&2 9
(SMiLE-seq). 9
binders; 9
JACUSA: 9
(RRDs) 9
JACUSA's 9
RDD 9
(4.4%), 9
elk, 9
cervids. 9
SLEDAI-2K 9
ProADM-levels 9
3.8*LN[total 9
bilirubin] 9
9.6*LN[creatinine] 9
Beauchamp 9
inpatients? 9
(340-400 9
evidence), 9
vitritis 9
otalgia, 9
Work-up 9
hoxb3a 9
extrapleural 9
PEA 9
SSPE, 9
Genomiser, 9
SeqArray-a 9
storage-efficient 9
Benchmarks 9
(VCF), 9
(BCF, 9
VCF), 9
(BGT) 9
(SeqArray) 9
FGF13 9
(TIRR) 9
(H4K20me2). 9
(TIRR), 9
https://ilir.warwick.ac.uk 9
rhSCL 9
BRCA-Mutated 9
overwintering 9
trypanosomiasis: 9
Fexinidazole, 9
26-week 9
usnic 9
trichotomized 9
(VLS) 9
Fgf21 9
NEDDylation 9
ch14.18 9
(Unituxin™; 9
near-single-nucleotide 9
miR-1271. 9
miR-1271, 9
aHSCT 9
bedside-to-bench 9
Sirt1⁻/⁻ 9
CXCL7 9
BORG 9
penicillinase 9
RPS19-deficient 9
aciclovir. 9
(Valtrex), 9
OR7D4 9
Barrat 9
formalin. 9
KLF8 9
SMURF2 9
high-penetrance 8
family-based 8
beyond: 8
second-degree 8
liability. 8
decomposition 8
Van 8
Waals 8
PEPD 8
matched, 8
metalloproteinases. 8
v7 8
14,880 8
0.75. 8
Tgase-2 8
time-dependently 8
osteoclastogenesis, 8
IL-17. 8
milieu, 8
(OVX) 8
(LT4) 8
microRNA-203 8
(EOC). 8
non-cancerous 8
Gynecology 8
(miR-132, 8
SEOC 8
miR-20a, 8
chemotherapy-resistant 8
0.042). 8
53, 8
(p<.01). 8
Pyridostigmine 8
population) 8
Metastases 8
(EMA) 8
(FDA), 8
(shown 8
17,20 8
on-going 8
payers 8
heralded 8
clearer. 8
(trade 8
Xenopus. 8
paraneoplastica. 8
tonsil 8
violaceous 8
bizarre 8
rarer 8
females), 8
zinc. 8
recurrences, 8
agents]. 8
IKr 8
Beta-adrenergic 8
Notch2 8
ducts, 8
"younger" 8
0.00001). 8
eligibility. 8
784 8
(42% 8
200-400 8
met. 8
DDI 8
naphthylmethylimidazole 8
ng/dL. 8
biodistribution 8
radiolabel 8
site-specifically 8
androgen-sensitive 8
111In-trastuzumab 8
0.08). 8
p27, 8
ZD1839 8
IHC. 8
larger-scale 8
anti- 8
completion. 8
16), 8
receptor; 8
Francisco, 8
kinase-2 8
(OCT4, 8
PB. 8
(Oct3/4, 8
differentiate, 8
DNp73 8
own, 8
iPSCs, 8
AP+ 8
colonies. 8
SCF, 8
NSCs, 8
0.29 8
academia, 8
goals. 8
Y, 8
inflammasome, 8
poPanx1 8
β-blockers 8
(CHF). 8
pacing. 8
59%, 8
energetics 8
mg·kg(-1) 8
(RV) 8
IVA, 8
HCN4 8
intergroup 8
revascularization. 8
post-MI, 8
Hallervorden-Spatz 8
lipofuscinosis, 8
hyperintense 8
pallidus, 8
copper, 8
cotranscriptional, 8
CTCF-promoted 8
camptothecin, 8
leg. 8
Lifespan 8
CMS 8
[Genetic 8
CSQ 8
[(3)H]ryanodine 8
protein-tagged 8
ablation, 8
intra-sarcoplasmic 8
[Ca(2+)]. 8
TG. 8
hastening 8
mM), 8
26-kd 8
LC/MS 8
interferences 8
shapes. 8
SM 8
Uric 8
i.v.). 8
alpha-adrenergic 8
pig. 8
sugars 8
BD1 8
BD2 8
Bromodomains 8
conserves 8
P/CAF 8
forty-eight 8
Macroscopic 8
Ileo-colonic 8
(IL)-6, 8
Ileocolonoscopy 8
3-16; 8
disintegrative 8
(two), 8
routinely. 8
(88.5%) 8
pancreatico-biliary 8
catheter. 8
Resistant 8
elevation, 8
(JNK), 8
JNK2, 8
(ERK), 8
autophosphorylation. 8
363 8
JNKs 8
yield, 8
IL-1, 8
Grb2, 8
GTP-bound 8
Proteolysis 8
N-terminome 8
metalloproteinases, 8
p-ERK1/2, 8
SFRP1 8
391 8
atypical, 8
prescribed, 8
discontinued, 8
phenobarbital, 8
neuroactive 8
collapsing 8
anticonvulsive 8
first-in-class, 8
EWSAT1-mediated 8
A673 8
(FAP), 8
70%) 8
unmask 8
ofa 8
1997-2007 8
MCP 8
scleroderma, 8
nephrotoxicity, 8
adolescents: 8
Hunger 8
ergometer 8
Meals 8
PP. 8
particularly, 8
(TAP) 8
(RCT), 8
qualifying 8
surgeon. 8
endometriosis: 8
treatment? 8
24.5 8
p=0.001 8
surgically. 8
determine, 8
2.2, 8
complaints, 8
survivorship 8
received. 8
QLQ-INFO 8
Convergent 8
14.1 8
19.1 8
p=0.006). 8
pmol/L 8
Running 8
deflection 8
estrogen- 8
breastfeeding, 8
350,000 8
311 8
505 8
86.3% 8
1.39, 8
smoking) 8
sampling, 8
Interactive 8
(Archived 8
WebCite 8
catalyse 8
modeling: 8
(though 8
conspicuous 8
(n=7) 8
COVERED: 8
1,300 8
ch14.18, 8
Ninety-two 8
FH. 8
clinics, 8
fibrates, 8
reached, 8
(AHA) 8
(140 8
evolocumab. 8
triglycerides. 8
310 8
affirmed 8
(Olfactores) 8
'Olfactores 8
non-tumoral 8
Dlx-5/6 8
throw 8
Lowering 8
S-adenosylmethionine. 8
copying 8
monotonous 8
suspensions 8
Granulocyte 8
Consolidation 8
neuroectoderm 8
glycoconjugates 8
c-myb, 8
eleventh 8
(BOLT): 8
[13%] 8
actionable 8
escalations 8
(18% 8
exposure-dependent 8
kBq, 8
biweekly, 8
Metabolite 8
excreta 8
(1.20 8
56.9 8
splenomegaly. 8
JAK2. 8
Arrest 8
(FAC) 8
lymphoblasts. 8
R-loops, 8
Quite 8
R-loop, 8
duplex, 8
varied, 8
activation-induced 8
macroadenoma. 8
GNAS 8
(PRL)-secreting 8
macroadenomas 8
acromegaly 8
Eighty-eight 8
acromegaly. 8
co-chaperone 8
α-helix 8
separate, 8
TNNC1-encoded 8
pseudophosphorylation 8
force, 8
100%; 8
TF, 8
cTnC. 8
(1999) 8
GmbH, 8
best, 8
1.22, 8
consultations 8
53.8% 8
H3K27me2, 8
H3K9me 8
heterochromatin-specific 8
H4-K20 8
mystery, 8
XCI. 8
Clr4, 8
(HSPs) 8
A/B 8
IRI. 8
IRI 8
nitrogen, 8
vaccine-induced 8
restricted. 8
Clusterin 8
phosphoacceptor 8
U-0126 8
Cisplatin 8
PHA-665752 8
factor-dependent 8
MAP2, 8
phosphoinositide-3-kinase 8
pre-treatment. 8
kinase/Akt 8
HGF/SF. 8
KC, 8
SP1, 8
1996). 8
HGF- 8
fibronectin-induced 8
0.46% 8
pregnancy]. 8
38.3 8
providers, 8
unvaccinated 8
coagulopathy. 8
Health. 8
1.32; 8
Assess 8
889 8
<2 8
Adjustment 8
1.03, 8
(P=0.08), 8
(aCGH). 8
76.5 8
SFTPC, 8
SFTPB 8
Heterogeneous 8
immunopositivity 8
(CNC) 8
sunitinib, 8
5-fluorouracil, 8
(hTR) 8
processivity. 8
Oligonucleotide 8
ante 8
mycophenolic 8
omalizumab 8
Moderate-to-severe 8
dermatitis: 8
proactive 8
decompensation 8
hernia. 8
SOX6 8
brachycephaly, 8
proptosis, 8
FGFR, 8
IIIa 8
phalanges, 8
malignancies: 8
(instead 8
prominence 8
EVA 8
glucosuria 8
1.1%, 8
sulphonylureas 8
troublesome, 8
tofogliflozin 8
m2 8
(MPFC) 8
MPFC. 8
CD45-/CD90+/CD99+. 8
assigned. 8
phased 8
LysC 8
discovery-based 8
multiple-suture 8
categorization 8
garnered 8
Rehabilitation 8
sample: 8
recorded: 8
posture 8
schools 8
0.75; 8
0.71; 8
(p<0.01) 8
KPI 8
level) 8
overrepresented, 8
http://jaspar.genereg.net. 8
total) 8
IU/mL. 8
keratoderma, 8
follicular, 8
arrangement. 8
circumscribed 8
tortuous 8
Coexisting 8
CYP3A4, 8
(median: 8
intra-stent 8
seventy 8
Scheme 8
synergistic. 8
(P<.0001; 8
(NCIC) 8
CE.3 8
(48.3%) 8
[16.9%]) 8
0.24-0.63) 8
[44%]) 8
0.53-0.90) 8
polytherapy. 8
adapts 8
TFEB, 8
ceria 8
bacitracin 8
dramatically, 8
ramoplanin. 8
muraymycins 8
vancomycin-resistant 8
1992). 8
simulans 8
supernatant. 8
Susceptible 8
transcriptome: 8
(86 8
schedule) 8
evaluable) 8
(62%), 8
B2, 8
=2 8
AST 8
10.6% 8
31.9 8
radiosensitization 8
Side-effects 8
conjunctivitis. 8
(DT) 8
property, 8
tumors) 8
Atrophy 8
oriental 8
diagnostically 8
brisk 8
sulphur 8
CYP1A1 8
IRAK1/4 8
Co-culture 8
(FLS) 8
T-cell-dependent 8
HOXD9 8
agreeableness, 8
2.6; 8
Neuroticism, 8
knowledgeable 8
Premorbid 8
15.0 8
Vertical 8
substantially. 8
(everolimus) 8
Akt/PKB 8
post-transplant 8
algorithms; 8
whole-transcriptome 8
BCL2, 8
intercross 8
disproved 8
0.37; 8
CD99. 8
colocalize, 8
(DMR) 8
Runx1 8
loci: 8
post-fertilization 8
non-allelic 8
Paternal 8
biallelically 8
LANA 8
(ORF73), 8
vCyclin 8
(ORF72), 8
vFLIP 8
vGPCR 8
(ORF74). 8
SMC1, 8
Bcl11b 8
Arhgap6 8
CTCF- 8
CpG-islands 8
(Pcdh) 8
PPIs, 8
interact. 8
leads, 8
thickening. 8
modifiers, 8
(SCD). 8
signal-transduction 8
depolarize 8
Immunity 8
crystallization 8
alpha-helices 8
High-level 8
Lin28. 8
(NGS). 8
RNases 8
Fig. 8
(2.5%) 8
no-treatment 8
Spastic 8
angle) 8
guard 8
transversal 8
argininemia 8
OGS 8
test's 8
develops. 8
(1-minute 8
twenty-three 8
11-13 8
inframe 8
homogeneity. 8
age-appropriate 8
(ALS)-linked 8
(FUS/TLS 8
(fused 8
(L) 8
Fus 8
ubiquitin-positive 8
PY 8
two-hit 8
(iNOS) 8
Chemokines 8
economical, 8
income, 8
subsample 8
proximate 8
S-COMT 8
nitrocatechol 8
received, 8
levodopa/benserazide 8
entacapone. 8
pronounced, 8
long-lasting, 8
k(off) 8
purified. 8
MPR 8
Fractionation 8
Mannose 8
mixture. 8
glycoforms 8
dysregulates 8
(11;22) 8
peak, 8
Eukaryotes 8
dispensability 8
(MFT) 8
trichoepithelioma. 8
phenotype; 8
ACC. 8
Morphometric 8
(TEs), 8
TEs. 8
CYLD(C/S) 8
G-->A 8
atrophies 8
SMN, 8
manifestation, 8
acne, 8
ERK1, 8
p56(Lck) 8
PD98059 8
Ca++ 8
(calculated 8
repolarizing 8
oligonucleotide. 8
(KN-93) 8
89.2% 8
interferon. 8
(CCMs) 8
details. 8
downstream, 8
TAA 8
cavernomas, 8
(DITPA), 8
(T4, 8
thyroidectomies 8
cyst: 8
radicular 8
cyst, 8
followed, 8
metaanalysis 8
Completed 8
metaregression 8
(LAF237). 8
hits. 8
Log 8
(dipeptidyl 8
[DPP 8
IV] 8
glinides, 8
amylin 8
sequestrants. 8
gliptins. 8
pharmacokinetics/pharmacodynamics, 8
CYP3A4. 8
diabetes; 8
non-cardiovascular 8
272 8
Confidence 8
0.28, 8
0.00001], 8
0.81, 8
trails 8
(WMD 8
(vildagliptin, 8
interaction) 8
(CLL). 8
n=19) 8
>85% 8
secondary, 8
acetylcholine, 8
DOC 8
Placebo-controlled 8
disconnection 8
Weekly 8
MMP-9. 8
50-fold 8
MMP-1, 8
(TIMPs) 8
nonpregnant 8
neuroparalytic 8
(BoNTs) 8
horses, 8
carbamate 8
natively 8
polyamines 8
callosum; 8
(hypomyelination, 8
myelin, 8
(delayed 8
physician, 8
tRNA. 8
incisors. 8
myelin. 8
mesenchyme. 8
pairing-dependent 8
YY1. 8
1990). 8
CHG 8
DNMTs, 8
divisions, 8
Bub3, 8
persists. 8
BEL 8
fossa. 8
Cbx7, 8
CD1 8
apicidin 8
p53-independent 8
(C), 8
(NuRD) 8
pp32r1 8
charge-charge 8
NlElp3 8
methyl-binding 8
metallopeptidase 8
glass 8
1β 8
guarantees 8
crassa 8
gene-silencing 8
inefficient. 8
transcripts: 8
H1299 8
4.6% 8
(mono-, 8
Hertwig's 8
Cbx3 8
branchial 8
spreading. 8
paradoxically 8
CHD4, 8
researchers, 8
orders, 8
Argentina 8
(ICDs) 8
closely. 8
(ERP) 8
dromotropism 8
>25% 8
patchy, 8
cm, 8
Hepacivirus 8
(SLC22A3) 8
amphetamine. 8
41.5 8
resident-intruder 8
plus-maze 8
circuitries. 8
phosphocreatine 8
Transporters 8
CRT, 8
(OCT3/SLC22A3) 8
TIEG 8
TGF-β, 8
SMAD7 8
(GSH) 8
(OPA1) 8
Fis1 8
sublocalization 8
G2019S 8
esters, 8
hormone-sensitive 8
(PKA). 8
(BMS) 8
vera 8
Burning 8
numeric 8
(DTC) 8
hamartomas 8
(GFAP) 8
(SOD1) 8
Nrf2, 8
MND 8
g/24 8
duration: 8
µg/mL) 8
MINDACT 8
discussion, 8
mid-range 8
4500 8
<3 8
protein-3 8
30%), 8
fT4, 8
joggers 8
TBG 8
jogging 8
POU 8
(PDAC); 8
posttranscriptionally 8
degeneration-related 8
(MZ) 8
reared 8
0.0003) 8
(1.5%) 8
Adoption 8
amines. 8
increments 8
pentamer. 8
(unlike 8
ischemic, 8
0.4%), 8
G-T 8
116, 8
Double-blind 8
cautioned 8
trivial 8
24-hr 8
SOD, 8
TBARS 8
P<0.01), 8
demands. 8
8-OHdG 8
athletics 8
flavonoids, 8
IMC 8
record. 8
first. 8
Glycyl-tRNA 8
anticodon 8
unidentified. 8
anticodon-binding 8
(dSMA-V) 8
histological, 8
crystal, 8
dSMA-V. 8
(GlyRS). 8
insufficiencies 8
GARS. 8
ENU-induced 8
13%). 8
canoe 8
(H4K20me) 8
HDAC2, 8
pulldown 8
eyelashes, 8
CTC1, 8
(HCT) 8
supportive, 8
(has 8
methotrexate. 8
pancytopenia. 8
gradients. 8
pre-miR-21 8
I/R, 8
miRNA-21 8
miR-21) 8
miR-199a, 8
miR-21-mediated 8
(AMI). 8
H(2)O(2)-induced 8
Brca1 8
vacuoles, 8
Beclin-1 8
orange 8
(2.0 8
SQSTM1/p62 8
(UA) 8
MEF 8
IFN-γ, 8
(LC3) 8
non-RA 8
~30 8
27.2 8
agglutinate 8
(Neu5Gc). 8
monosaccharide 8
glycans. 8
haemostasis 8
non-activated 8
Prothrombin 8
complications; 8
(VKA) 8
Managing 8
life-threatening. 8
anti-factor 8
therapy? 8
PTS 8
AtxA: 8
-signalling. 8
(PTS). 8
PTS. 8
anthracis: 8
cassette. 8
stem-loops 8
σ 8
MDS/myeloproliferative 8
SF3B1 8
mutation), 8
http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/. 8
4:1 8
intestines 8
rs7804122 8
30-50% 8
EDNRB. 8
T>C 8
FA-like 8
(HU), 8
Cultures 8
wtih 8
carfilzomib. 8
lipopolysaccharide, 8
BrDU 8
formidable 8
organizers 8
(GC/MS). 8
compartments: 8
cataract. 8
lineage-committed 8
transition: 8
400-800 8
('replication 8
domains'), 8
sub-stratified 8
territories, 8
established: 8
30-minute 8
microvilli 8
DEAD-box 8
SOCS 8
Pyrin 8
Primate 8
incoming 8
predate 8
lentiviruses. 8
oocyte. 8
rosetta-stone 8
several) 8
remote, 8
Phydbac2 8
sub-network 8
lost, 8
post-genome 8
Crystallization 8
octamer-binding 8
paraspeckles, 8
rejoining 8
chemotherapeutics. 8
circumstantial. 8
NRSF, 8
GABP, 8
298; 8
CCDC6 8
ROS-induced 8
endometrioid 8
November, 8
0.9), 8
reinitiated. 8
antidepressive 8
PubMed. 8
non-tumorous 8
zymography 8
T4; 8
ammonia, 8
assemblies. 8
objectives. 8
bodyweight. 8
two-period, 8
723 8
(fT3) 8
sub-clinical 8
1.7; 8
Often 8
(GGR) 8
prototrophy 8
(suppressor 8
templates, 8
elc1 8
Swi2/Snf2 8
deamination, 8
MMD. 8
noting 8
classifications, 8
17q, 8
array-comparative 8
A9 8
(EST) 8
Two-point 8
(LOD) 8
atheromatous 8
mAbs, 8
attributes. 8
IgA, 8
ciprofloxacin, 8
C57 8
(7.9 8
masses. 8
[corrected]. 8
Azithromycin 8
bacteriological 8
irrigation 8
tuberculous 8
Mosaicism 8
0.08) 8
nodules. 8
lymphangioleiomyomatosis. 8
angiomyolipomas, 8
LAM, 8
TSC1, 8
(RC) 8
(16p13.3) 8
Isw1a, 8
Isw2, 8
HP1a 8
FEC-75 8
(pCR) 8
FEC(75) 8
ten-year 8
Epirubicin 8
.002). 8
leucopenia, 8
receive, 8
(epirubicin 8
P: 8
3.4% 8
5.3. 8
0.009), 8
2.67 8
387 8
(0.15 8
tackles 8
vasculogenesis. 8
Cul1-Nedd8. 8
Cul1-Nedd8 8
subdomain 8
(SIVmac) 8
turnaround 8
lipopolysaccharides 8
(TRAIL) 8
triphosphates 8
radiosensitizer 8
myocarditis, 8
prevented, 8
2005). 8
taxanes 8
JNK1β 8
JNK2α 8
515, 8
(JIPs), 8
esters. 8
SAPK 8
Naturally 8
MHC. 8
1970 8
FWA 8
occurrences. 8
alphacalcidol 8
glasses 8
0.74, 8
0.64 8
4051 8
0.91; 8
Reviewers 8
mortality) 8
Trials. 8
31%, 8
frailty. 8
mortality; 8
decrement 8
fluorescence-guided 8
requested. 8
contrast-enhancing 8
Neurosurgery 8
polycomb-mediated 8
enChIP, 8
tag(s), 8
(dCas9), 8
(SILAC) 8
(HoxA, 8
HoxC, 8
milder, 8
puberty, 8
suppose 8
(all-trans 8
RAMQ 8
deaths) 8
8609 8
32.7 8
far; 8
Describe 8
rabbit, 8
NOAEL 8
LOAEL 8
(0.05 8
31), 8
variance). 8
precardiac 8
isotype, 8
arches 8
distortions 8
3H-thymidine 8
mesenchyme, 8
40%). 8
CD-1 8
toxic. 8
(8), 8
monoubiquitin 8
Mdm2(C462A) 8
UV, 8
HDM2-p53 8
FK506-binding 8
alkaloid 8
repair-specific 8
DNA-topoisomerase 8
biophysical, 8
[e.g., 8
A-T 8
enzyme-mediated 8
epipodophyllotoxins 8
DC3F 8
Stauranthus 8
distamycin 8
regularity 8
4'-(9-acridinylamino)methanesulfon-m-anisidide 8
employed, 8
adriamycin, 8
PTBP2 8
3-nitropropionic 8
Dcp1 8
miR-222, 8
cochlea. 8
afferents 8
HEK(GLAST) 8
EAAT1. 8
Glt(Ph) 8
ecgltP. 8
Transporter 8
kainic 8
redirected 8
Ras-ERK 8
337 8
2DE 8
phosphoproteins. 8
scanning, 8
chemicals. 8
assays) 8
Aspirin 8
nmol/L). 8
expectations. 8
biotech 8
Pegaptanib 8
heralds 8
pharmaceuticals. 8
inoculation. 8
anti-fibrotic 8
Naltrexone, 8
hepatoprotective 8
percent). 8
VPA. 8
IGF2, 8
Sunitinib 8
tumor/metastasis 8
podosome 8
controlled. 8
driver-passenger 8
[8 8
thyrotoxic 8
Withdrawal 8
(NCX), 8
TR-beta1 8
alpha2 8
Bootstrap 8
concepts. 8
HFpEF 8
μL, 8
hemodialyzed 8
(0.7 8
lips, 8
zinc, 8
Pathophysiology 8
pCR. 8
telencephalic 8
recombinantly 8
(Ras 8
20-min 8
(SLAMF7), 8
79%, 8
co-cultures 8
gene-A 8
IgG) 8
fibrillation) 8
Non 8
confirmative 8
factor-alpha, 8
T/T 8
residence. 8
13C-urea 8
>15 8
Fibrinogen 8
fibrinogen. 8
seroprevalence 8
non-cardiac 8
immunoassay, 8
1.42; 8
3.53; 8
1.78 8
FAS 8
noncyclical 8
focussed 8
moderate. 8
(10), 8
restricted, 8
readmission 8
nonmedical 8
LINX(™) 8
(PPIs). 8
Health-Related 8
gangliosidoses 8
GSL 8
quadriparesis 8
counterbalance 8
neuraminidase, 8
microscopical 8
caliber 8
DDMS 8
hypothesise 8
zone" 8
partial, 8
21-year-old 8
utero. 8
ridge. 8
aciduria, 8
dissipation 8
TGA 8
(SAT) 8
age-specific 8
K27 8
LIF 8
CLIC3 8
SCS 8
epsilon), 8
41, 8
SLS 8
30-49 8
score: 8
Coagulation 8
(Efficacy 8
Fibrillation) 8
bleeding; 8
1.28, 8
3.72, 8
Hemorrhagic 8
quartiles 8
TI 8
http://www.cs.tau.ac.il/&~spike/) 8
straightforward, 8
interlocking 8
Cytosolic 8
Lys27 8
HBiX1 8
Probable 8
X-chromosomes 8
(1,2). 8
consolidate 8
dimorphism 8
chromosome-wide 8
chambers 8
Top-down 8
fluids. 8
Alkaline 8
(BC). 8
(81% 8
Surveillance, 8
Coverage 8
Diffusion 8
superiority). 8
Astrocytes 8
loadings 8
inflammasome-mediated 8
recycling, 8
microM; 8
NTPase 8
Etoposide 8
20.8 8
Abuse 8
mecamylamine 8
Ad 8
Setting 8
extinction. 8
Quit 8
Agitation 8
evaluation: 8
(GOS) 8
reflex, 8
toxicology. 8
jet-based 8
conveniently 8
optics 8
Ospemifene, 8
0.00001) 8
triphenylethylene 8
605 8
nonhormonal 8
30-mg 8
(IRLS) 8
"very 8
trials), 8
lifestyle, 8
Medications 8
(EFNS) 8
recommendation, 8
2012: 8
150, 8
responders, 8
conidial 8
nidulans, 8
walls. 8
colonize 8
momentum 8
designer 8
SP1 8
TALENs. 8
microsurgery, 8
observation; 8
57.0 8
(58.5%) 8
respondents, 8
convalescent 8
craniocervical 8
accident. 8
certainty 8
glycine-to-arginine 8
G380R 8
dicoumarol 8
3'UTR. 8
haplotypic 8
"Hirschsprung 8
haplotype" 8
endothelin-3, 8
10.7% 8
Ca(2+)-free 8
[Lambert-Eaton 8
(VGCC) 8
lobectomy 8
(LEMS), 8
electromyogram 8
CT-scan 8
possibly, 8
CT. 8
reacting 8
mediastinum 8
2q22-q23. 8
explorative 8
staphylococci 8
planosporicin 8
realizing 8
hydroxy 8
nonneurological 8
LF 8
(2.3 8
neutron 8
pleiotropy. 8
h(-1). 8
intrachromosomal 8
mariner 8
mobilize 8
Deleting 8
cell-autonomous, 8
(MEFs). 8
hyperproliferative 8
Inducing 8
p16. 8
show: 8
online, 8
7.3% 8
410 8
beta-hydroxylase, 8
junctates 8
(c)2001 8
Mst1/2 8
thin, 8
Filopodia 8
emanate 8
finger-like 8
accumulated. 8
equatorial 8
Cdc42. 8
Rho-dependent 8
bundling. 8
debris. 8
726 8
1107 8
1887 8
4061 8
"odds 8
ratios" 8
(thorough 8
shuffling). 8
values) 8
GpC 8
Rickettsia, 8
glutamyl 8
science. 8
GBMs. 8
EGFRvIII-specific 8
p.D84N 8
destroying 8
Msi1 8
PHC1 8
1.85 8
370 8
spleens 8
(ESCC) 8
Endometrial 8
sarcomas. 8
image, 8
3800 8
(alpha-fetoprotein, 8
argonaute 8
(TTP, 8
PBs. 8
exonucleases 8
XRN1. 8
Dcp2 8
depleted. 8
post-infection, 8
polysome 8
spermatogonia 8
MutPred, 8
hDIS3L2 8
(RNA-seq) 8
poliovirus 8
bonding. 8
attaining 8
consolidated 8
fructooligosaccharides 8
37.4 8
65%, 8
NSAIDs, 8
coxsackievirus 8
Parkin. 8
overflow 8
prolific 8
Linking 8
Ca2+i 8
APs 8
LVP 8
(mPTP) 8
Contractile 8
ATX-II 8
using, 8
Efficiency 8
reestablishment 8
"fuels" 8
Effect," 8
Effect." 8
themselves, 8
"The 8
(mPer) 8
mPER1 8
AMPK-dependent 8
PECAM-1 8
(Ph+) 8
accelerated-phase 8
AKIs 8
pan 8
ACA-AP 8
strata 8
Ph(+) 8
Gleevec 8
leukemia) 8
(CCR) 8
molecular-targeted 8
Blast 8
(Glivec, 8
chromosome). 8
short. 8
chronic-phase 8
tradition 8
true. 8
BMT 8
(imatinib 8
BMS-214662 8
Perspectives 8
juxtaposition 8
idarubicin 8
(STI571), 8
(vortioxetine 8
NNT 8
vilazodone 8
535 8
18-75 8
5mg 8
hyperhidrosis, 8
1960s 8
12-18 8
contamination. 8
(dsPIG) 8
(SINEs) 8
imprinted, 8
recombinations 8
Toolkit 8
KIF1B, 8
familial. 8
mxtx2, 8
hiPSCs. 8
A/C-positive 8
lamins. 8
scaffold-like 8
A/C. 8
(IVF) 8
enclosed 8
destination 8
animals: 8
synopsis 8
Compelling 8
invader 8
RNAi-like 8
PR1), 8
PR2). 8
tending 8
C-G 8
D), 8
pressure) 8
varies, 8
Perspective 8
accessible, 8
(FHC) 8
Arg403Gln 8
2.3, 8
QTd 8
MVP 8
assessed: 8
SDT 8
coactivator-1 8
troglitazone 8
ZDF 8
incubation, 8
Circ2Traits: 8
prognosticators 8
parts) 8
flawed. 8
Cordis 8
inflicted 8
Neuropathy. 8
Sural 8
neurofilaments. 8
CUL3 8
comfort 8
palmitoyltransferase 8
paralogue 8
(HSC) 8
(NSC) 8
Creative 8
executes 8
egress 8
best-known 8
disentangle 8
p73. 8
gametes 8
-8 8
Calpain 8
Med. 8
Storage 8
Ctr2p 8
(comprising 8
fruiting 8
KRas 8
dispense 8
HRAS, 8
functionally. 8
EpCAM. 8
stimulus-dependent 8
octopamine 8
T(0)AM 8
essence 8
(Treg 8
sclerosis; 8
(1% 8
(RRMS) 8
(97%) 8
B-cells, 8
≥6 8
435 8
demyelinated 8
registration, 8
(TRD). 8
NAcc-DBS 8
Modern 8
pleasure 8
transplants, 8
C228T 8
drugs' 8
Amyloid-beta 8
Immunotherapeutic 8
amyloid-related 8
out; 8
Braak 8
moieties. 8
Anti-Aβ 8
5-15% 8
lipoprotein-cholesterol 8
case-by-case 8
0.46, 8
nonvigorous 8
pertain 8
"A" 8
livestock. 8
(MSSA) 8
groupings 8
groupings. 8
characters. 8
systematics 8
taxonomically 8
valuable. 8
ecologically 8
Carnivora, 8
papionins. 8
rudolfensis 8
assumptions, 8
Size 8
Apis 8
phasic 8
(H3K9me2) 8
EpFosER 8
Desmin, 8
Prader 8
normalization. 8
insulator. 8
hallmarked 8
(>20%) 8
putamen. 8
routine. 8
hemoptysis. 8
Harcourt 8
neuropathy) 8
Rational 8
K(d) 8
Gcn5 8
line) 8
GWV 8
war. 8
event-related 8
psychosomatic 8
veteran 8
theater 8
Syndrome? 8
Strokes 8
77) 8
ectodomain 8
CADASIL, 8
gastroenteropancreatic 8
TOMORROW 8
(INPULSIS-1 8
INPULSIS-2) 8
3:2 8
44.8 8
1.15; 8
2.42; 8
63.2% 8
NCT01335464 8
(FVC) 8
-β 8
BB 8
PKC-α 8
FKBP12.6, 8
RyR2) 8
insecticides. 8
(OPIDP) 8
22-year-old 8
electrodiagnostic 8
creatinine; 8
symmetrical, 8
(EEG), 8
hyperreflexia, 8
immunopathology 8
obtained: 8
righting 8
(IFN-gamma) 8
infusion-related 8
metrics, 8
h-index, 8
without, 8
assistant 8
specialties 8
silicone 8
eroded 8
movement; 8
seconds, 8
lycopene, 8
Cortisol 8
TNF, 8
pages. 8
Developing 8
HADS 8
862 8
Respondents 8
parent-reported 8
(WS). 8
microg/mq, 8
[TSH 8
B/I) 8
0.6-2.2]. 8
Endocrinological 8
adrenocorticotropin 8
CRF, 8
desired. 8
cis. 8
Wang 8
declined, 8
blocked, 8
synuclein 8
(PMDD). 8
intermittent, 8
phobia 8
lability, 8
Impressions 8
obsessive- 8
psychiatrists 8
(CGI 8
KPS, 8
men). 8
57%. 8
hematological, 8
endostatin. 8
mice), 8
sight 8
(gestational 8
intravitreal 8
releasate 8
Aromatase 8
protamine 8
(2005) 8
aggressiveness. 8
(AIS) 8
Evolving 8
(until 8
readouts 8
youths 8
Switzerland. 8
hypnotics, 8
meeting. 8
accidents, 8
pyknons. 8
anions 8
HHO1, 8
YPL127C, 8
LPI17) 8
deadenylase. 8
5'-AMP 8
Ccr4p 8
HO 8
K(m) 8
Angel 8
(37% 8
L1) 8
L1s 8
capsaicin-induced 8
NF-1 8
(ss) 8
301 8
"two 8
p120 8
αv 8
detachment, 8
sevenfold 8
Arg-Gly-Asp 8
ανβ 8
(n=6). 8
cytokine-induced 8
5'ss 8
601-608, 8
Chapter 8
cosegregates 8
RP. 8
exon-specific 8
pricing 8
isoflavones 8
(ICAM-1) 8
summed 8
molecule-1, 8
50%), 8
gamma-carotene 8
opossum, 8
integrations 8
vivo-generated 8
arborization 8
sitaxentan 8
icatibant, 8
guideline-based 8
dollars, 8
inextricably 8
1993. 8
Cytomegalovirus 8
ganciclovir, 8
Nissle 8
(P<0·05). 8
virulence, 8
trinitrobenzene 8
valgus 8
elbows, 8
49,XXXXY 8
1q 8
ultimately, 8
Lys-382 8
Friend 8
PDGF-BB-mediated 8
SMAC 8
carcinoma; 8
(DSS), 8
Burkitt's 8
BL 8
CRC, 8
ascitic 8
differentiate. 8
severity). 8
Injuries 8
Instances 8
956-amino 8
hyperplasic 8
284 8
tangle 8
LBD 8
there, 8
37-year-old 8
(DLB), 8
CA2-3 8
anti-NAC 8
Pregnancies 8
CMV, 8
demise. 8
nonechogenic 8
Intrauterine 8
stillbirth. 8
PtdIns(3)P 8
PtdIns 8
aggravate 8
phosphoinositides 8
fractionation. 8
spermatids. 8
calcifications, 8
OPINION: 8
MS1 8
(PTM) 8
Set1, 8
dissociation. 8
tagging. 8
arrangement, 8
SUMO1-dependent 8
calcium-transporting 8
ATP2A2, 8
adeno-associated-virus-mediated 8
Transgene-mediated 8
things 8
methanolic 8
i.v., 8
69.2% 8
mg/kg/min 8
tendency. 8
returns 8
bilayer, 8
cryosections 8
code) 8
hyperinsulinemia, 8
Metformin, 8
0.041) 8
Seventy-three 8
37). 8
peptide-level 8
turtle 8
ACEI 8
overlooked. 8
Quantifying 8
deglycosylation 8
DinB 8
IV). 8
MLH1, 8
(GAD), 8
sociodemographic, 8
underrecognized 8
(P=0.02) 8
polymyositis, 8
debatable. 8
sputum, 8
0.30, 8
asthmatics 8
1:1:1:1 8
asthmatics, 8
hyper-eosinophilic 8
allergens. 8
impaction 8
adults) 8
(IL-5), 8
haematopoietin 8
hypereosinophilia 8
telangiectasia. 8
(<5 8
Multicenter, 8
0.006 8
APT 8
mepolizumab-treated 8
PGA 8
recordings) 8
month) 8
(MAE, 8
defined: 8
MAE. 8
RUF 8
Responder 8
deteriorating 8
e. 8
papers. 8
digitorum 8
extremity, 8
(N88S, 8
S90L) 8
fevers, 8
greatly. 8
perianal 8
drugs) 8
aligned. 8
HERG, 8
coexpressed. 8
(RWS), 8
KCNH2, 8
cRNA 8
KVLQT1, 8
domains; 8
consecutive, 8
irregular, 8
p70S6 8
SMC. 8
IL-6-mediated 8
blocked. 8
(2.5-10 8
anti-inflammation 8
EGTA. 8
Erythrocyte 8
malaria-endemic 8
non-O 8
-0.32 8
(flat 8
CDVA 8
sequential, 8
6.80 8
weekly) 8
to-date 8
gadolinium-enhanced 8
Villefranche 8
non-drug 8
SB203580, 8
-overload 8
ERK2 8
effluent 8
Aerobic 8
legumes, 8
chemotherapy-treated 8
NET), 8
GRR 8
alpha-1 8
5-HT2A, 8
milnacipran. 8
NE. 8
2-day 8
duties 8
followup, 8
FINDbase: 8
(FINDbase) 8
ETHNOS 8
querying, 8
thiamine, 8
pediatricians. 8
nutrition. 8
drinks 8
acetate. 8
described; 8
afterward. 8
inadequate, 8
commitment, 8
well-understood 8
thyroidectomized 8
pM) 8
0.7) 8
(VKORC1) 8
anticoagulant. 8
CYP4F2 8
(HRM) 8
milk. 8
contiguous, 8
neuronopathy 8
saposin 8
GC, 8
<0.05 8
(EC). 8
(Hypoxia 8
CA9) 8
(53.8%), 8
amifostine, 8
complicated, 8
eradicated 8
cc 8
(DEB) 8
DEB 8
adults). 8
AQP2 8
Glycosylation 8
MYEF2. 8
CoREST, 8
recent-onset 8
psychosis, 8
expressivity. 8
Patient-derived 8
pharmacogenomics, 8
biology: 8
stringently 8
LDS 8
habitus. 8
grafted 8
silencer. 8
desquamation 8
calcein 8
literatures 8
Atg7 8
dithiothreitol 8
DTT, 8
assembled. 8
Hairless, 8
initiated, 8
scrutinized 8
gp120 8
(37.5%) 8
84, 8
IgA1 8
HLA-A, 8
RNA). 8
indomethacin 8
1b) 8
heme-regulated 8
alpha-NAGAs 8
R329 8
GalNAcalpha1-O-Ser. 8
Alpha-N-acetylgalactosaminidase 8
(Schindler 8
(34.4%) 8
cases/100 8
Solitary 8
(MAC), 8
pks12 8
(-21.4 8
GPCR 8
(UGE) 8
4-week, 8
(29.1%) 8
mmHg. 8
attributes, 8
39] 8
docking, 8
screening: 8
medaka, 8
(SRY) 8
depolarization. 8
flowing 8
(extended 8
amphipathic 8
Adenoviral-mediated 8
(CPA) 8
cisternae 8
monomer, 8
AHS. 8
A467T 8
fibrosis; 8
cladribine 8
infiltrates. 8
amphotericin 8
unfortunately 8
ccKDM5B 8
KMT6 8
sulforaphane 8
channels; 8
MEK5-ERK5 8
MLC-2v 8
light-chain 8
mutase 8
oligoastrocytomas. 8
Ets/TCF 8
rs2853669 8
1p 8
(Cmax 8
(NSAID) 8
(Btk) 8
optimise 8
HEK293T 8
synovitis 8
injections) 8
granulopoiesis 8
Form-36 8
E2-dependent 8
Development, 8
Biologists. 8
biotechnology. 8
200-fold 8
Ziconotide, 8
up-titration 8
EP1 8
allodynia, 8
incisional 8
Ca(V)2.2 8
0.19, 8
diazepam. 8
OCT3-ir 8
T(H)2 8
brainstem. 8
(SIR) 8
Epidemiology, 8
FANCI 8
(FANCA, 8
FANCE 8
mortalities 8
(FA-D1). 8
Lithuanian 8
BRCA2*6174delT/886delGT 8
medulloblastoma; 8
BRCA2*I2490T/ 8
5301insA 8
vacuoles. 8
2/ARNO 8
Switching 8
PLC 8
contractions, 8
vasorelaxant 8
ERT, 8
mean) 8
395 8
primordium 8
matured 8
(iPSCs). 8
(NB) 8
BMC 8
IGF-1R 8
NF-IGF-1 8
angiomyogenesis 8
Indices 8
mIGF-1 8
Prostate-specific 8
Snapin 8
TGF-β-mediated 8
ID1 8
RhoGEF 8
serovar 8
IL1β 8
Evolutionarily 8
CyN 8
27). 8
gene). 8
Autologous 8
Epithelial-to-mesenchymal 8
wound, 8
44) 8
ERA-EDTA. 8
Quality-of-Life 8
integrin. 8
(2+) 8
(EPI) 8
homeostasis/signaling 8
HOM 8
TFCONES: 8
factor-encoding 8
(http://tfcones.fugu-sg.org) 8
poise 8
binding-site 8
silence. 8
DUX4. 8
(incomplete) 8
FSHD-specific 8
vicinity. 8
decondensation 8
spirochete 8
IL-1α, 8
hESC-RPE 8
monolayers 8
Ni 8
(SNAS). 8
(SNAS) 8
tolerating 8
(Systemic 8
twenty-four 8
Azathioprine 8
effaced 8
(lymphocytes, 8
IgG4+ 8
IgG4/IgG 8
phlebitis. 8
(IgG4-RTD). 8
IgG4-RTD 8
Integrin-linked 8
water) 8
ILK/liver-/- 8
hepatectomy, 8
ensue 8
isoflurane, 8
17.4 8
phrenic 8
SCh 8
Presynaptic 8
melatonin, 8
clocks. 8
Dock 8
Elmo-Dock-Rac 8
G-proteins 8
ELMO1/DOCK180 8
ELMO 8
Src-family 8
511 8
co-express 8
pneumophila 8
attachment, 8
(IκB) 8
XTT 8
epigenomes 8
(1.2% 8
cervix. 8
(PCNA) 8
Pospiviroidae, 8
(PSTVd), 8
circle. 8
sunblotch 8
(PSTVd) 8
Potato 8
RNA-templated 8
left-hand 8
viroid-specific 8
considerably, 8
alpha-amanitin, 8
ubiquitylation. 8
stimulator, 8
split-Cas9 8
Engineered 8
(BTK) 8
LCP1 8
pestis. 8
coregulate 8
(K201) 8
Ouabain 8
JTV-519, 8
HTK 8
receptor-independent 8
mRNA-like 8
HCCs 8
Oxantel 8
Tannerella 8
APJ 8
Protects 8
pericytes 8
adipokine 8
AI, 8
adipokines, 8
Apelin-13 8
(d) 8
manufacturer's 8
60.5% 8
ABL2, 8
paralogs, 8
effected 8
haplotyping 8
unify 8
H3K79me1, 8
(NP) 8
pulse-chase 8
(HF), 8
VD 8
abolition 8
prevails 8
telehealth 8
MeSH 8
Edc4 8
NANOS2 8
NANOS3 8
cited, 8
Agents: 8
(according 8
foregut 8
(apps) 8
Ultraviolet 8
V) 8
hemopoietic 8
(CD99) 8
Hodgkin/Reed-Sternberg 8
makers 8
bladder: 8
PAR 8
VAP21 8
EWS/Fli1 8
non-type 8
filters, 8
splice-junction 8
adapters 8
splitting 8
Linux, 8
illuminates 8
Estimating 8
Nav1.5 8
N2 8
Brugada-type 8
accentuate 8
α-syn, 8
rivastigmine, 8
(AS). 8
Hsc70- 8
halves 8
adaptability 8
3,5,3'-triiodo-L-thyronine 8
respiratory-chain 8
Hypo- 8
cytochromes 8
M-SKIP 8
fair-skinned 8
hypertriglyceridemia, 8
(BSCL2, 8
seipin) 8
SPG17 8
(distal 8
1.0) 8
pembrolizumab. 8
SCH-527123 8
envelope. 8
(PVN) 8
(Drp1), 8
rho 8
O2-induced 8
patency. 8
(MMC), 8
(MMS), 8
FANCD1/BRCA2 8
FANCG, 8
(33 8
Omega-conotoxin 8
P/Q 8
(terminal 8
proanthocyanidin 8
bradykinesia 8
(MID) 8
scores). 8
response-evaluable 8
(76% 8
(43%), 8
LC3-interacting 8
MG132, 8
caspase-independent 8
N-ethylmaleimide-sensitive 8
landing 8
flawed 8
∼100 8
nucleates 8
lastly 8
Leveraging 8
Pill 8
economy 8
thiazide 8
Transvection 8
interallelic 8
extraneous 8
breastfed 8
41-year-old 8
Meningeal 8
pheromone 8
gastropod 8
Tetraodon 8
pufferfish, 8
fishing 8
(I(Na)) 8
Korea, 8
real-time, 8
(DM), 8
myotonia, 8
Dystrophy 8
MYB, 8
Mst1 8
YAP1 8
cargoes 8
internalization. 8
(TCD) 8
Statins, 8
semiquantitatively 8
DNDs. 8
disability). 8
(n=4), 8
sparse, 8
(1980-1999), 8
(1982-1999), 8
Dialog 8
fluphenazine, 8
predominant, 8
pccBC 8
aciduria 8
21.3% 8
alpha-PCC 8
beta-PCC 8
rescue. 8
6.4.1.3), 8
carboxylases, 8
(bp) 8
PP1-PLN 8
Hsp20, 8
PP1. 8
fueled 8
n=40) 8
Radiographs 8
fluency, 8
subscores 8
renaissance 8
Unconventional 8
amphibia 8
VIIa, 8
ATXN3 8
inhibitory, 8
PHD2, 8
pseudohypoxic 8
(RET, 8
SDH5 8
sdhaf2 8
(WMS) 8
Autosomal-recessive 8
ADAMTSL2 8
microspherophakia, 8
V/cm), 8
orthologues. 8
acetyltransferases. 8
PCAF 8
trichostatin-A, 8
Slit2 8
cyanate 8
PBHCit 8
(MPO) 8
pro-B-type 8
unsolved 8
crystals. 8
ichi 8
1.00). 8
78%, 8
malaise 8
Estradiol 8
>180 8
TTR, 8
drug-free 8
Cyk3. 8
mitotic-exit 8
Cytokinesis 8
Hof1. 8
CYK3 8
Hypoglycemia 8
(facilitates 8
revealed, 8
chaperones. 8
totaled 8
deltaF508 8
autophagosome. 8
phosphoproteome 8
'Free 8
'embedded 8
62.5% 8
sequence) 8
retroposition, 8
sub-set 8
(PT) 8
NADPH:protochlorophyllide 8
angiosperm 8
PORA, 8
cv. 8
decarboxylation 8
DOMAINS 8
REARRANGED 8
METHYLASE 8
endoreduplication 8
Mutator 8
relative, 8
calf, 8
LITAF 8
Sardinian 8
Order 8
(Australia, 8
ATF-2/c-Jun 8
ATF-2-c-jun 8
(IFN 8
AMs, 8
cervical, 8
notes 8
subjecting 8
reassess 8
three-year 8
154), 8
debates 8
CEP290, 8
cohesive 8
(5.1%) 8
1.25; 8
planned. 8
cholesteryl 8
high-fat, 8
reabsorption, 8
AB). 8
(18.8%) 8
unilateral), 8
fronto-orbital 8
beak 8
Pro 8
Arg, 8
disc. 8
affiliated 8
premaxillary 8
zygomatic 8
(MBT) 8
psychotherapeutic 8
emotion, 8
Istradefylline 8
Classically, 8
antiparkinsonian 8
PD; 8
slice 8
lengthened 8
(KFERQ 8
Pax2. 8
LAMP2 8
(GAPDH) 8
(Heat 8
pushes 8
(Lysosome-associated 8
HCQ 8
UW 8
0-3 8
pausing. 8
P-TEFb, 8
compositions, 8
mTORC2. 8
Rictor, 8
feline 8
CKO 8
2D:4D, 8
>0,95 8
CIs, 8
5: 8
FTD. 8
FSH. 8
nonobese 8
HO-8910 8
T>C, 8
liver-related 8
NAFLD 8
Dialysis 8
HNE 8
Noninvasive 8
BCa. 8
63) 8
prophages. 8
(J 8
metachronous 8
erroneous 8
2.52, 8
modifier-1 8
skNAC-Smyd1 8
stain-free 8
practical, 8
DB71 8
35%; 8
Disrupting 8
suspension, 8
KIs 8
vandetanib 8
receptor-deficient 8
Plasmapheresis 8
Anti-GQ1b 8
negative; 8
Corticosteroid 8
fork, 8
own. 8
PR2) 8
fingerprint. 8
mixed, 8
chips 8
P21, 8
P21 8
Yiya 8
co-translational 8
bacteria: 8
reticulum) 8
subsarcolemmal 8
(XLMTM; 8
cosegregating 8
MSM 8
Bangladesh 8
obesity: 8
Oligomerization 8
2.4) 8
addiction" 8
Cancers 8
curious 8
Anaesthesia 8
follicle. 8
(yeast 8
FLO11 8
FOXOs 8
fkh1Δ 8
apc5(CA) 8
Longevinex 8
BBE, 8
Serologic 8
GM1b 8
CD3+ 8
1.8-fold 8
synoviocytes, 8
MiR-146a 8
miR-203. 8
TghuTNF 8
α-induced 8
TWIST1 8
(ICP) 8
(unilateral 8
one-fifth 8
EC. 8
(CD44s) 8
(SCCs) 8
(SD, 8
practice: 8
(33% 8
Multicomponent 8
five-year 8
stayed 8
[Beneficial 8
in-patient 8
BLAST, 8
Epigenomics, 8
Retroviral 8
Biosystems, 8
Augmenting 8
(OMIA) 8
Relapse 8
Methotrexate 8
guanylyltransferase 8
HOCOMOCO: 8
ChIPMunk 8
pitch. 8
HOCOMOCO 8
RAGE 8
coffee 8
PER3 8
ATM. 8
Pombe 8
architecturally 8
(SAGA) 8
structure/function 8
ZnF 8
TATA-box 8
CDC2/cyclin 8
Plk1, 8
polyQ 8
1,4,5-trisphosphate 8
PFOR 8
(probably 8
travellers. 8
Imported 8
serology. 8
compiling 8
adjustments, 8
Omega-3 8
comparative, 8
District 8
(0.4) 8
viewpoint 8
atoms, 8
current-voltage 8
irradiance 8
Quebec, 8
ChR2. 8
dismiss 8
Adams 8
1957 8
moisture 8
disappears 8
abduction. 8
Familiar 8
caregivers, 8
conference. 8
sln-/- 8
pumps. 8
gastrocnemius 8
WG, 8
SLN, 8
single-pass 8
S252W), 8
P250R), 8
detected) 8
FGFR3-associated 8
c.749C>G, 8
pre-eclampsia. 8
ethical, 8
Yorkshire 8
cyclase. 8
microRNA-1 8
Capsule 8
(BVT) 8
84-year-old 8
desorption/ionisation 8
14q, 8
AVERROES 8
ate 8
uplifted 8
columella, 8
chin), 8
deletion/mutation 8
penis, 8
Network-based 8
fine-mapping 8
(C. 8
annotation-based 8
Cytoscape 8
plug-in 8
state-of-the 8
P-values 8
GeneMANIA 8
system-related 8
XLMR 8
Wwtr1 8
FPC 8
amniotes. 8
speciation, 8
PGI2 8
exuberant 8
(Th) 8
mDCs 8
Iloprost 8
prostacyclin, 8
Faculty 8
(ATR) 8
alglucerase 8
voxel-based 8
NaCl. 8
ruthenium 8
extrahepatic 8
toto, 8
IKK-α, 8
CHIP-mediated 8
platensis 8
owe 8
phycobiliproteins. 8
Phormidium 8
580 8
acetic 8
downward 8
long) 8
Fremyella 8
phycobilisome, 8
diplosiphon 8
long-branch 8
zygomycetes. 8
microsporidians. 8
zygomycetes 8
Bilateria 8
phyla, 8
Nosema 8
EMD, 8
de-novo 8
bradyarrhythmias 8
tendon, 8
(EMD) 8
brothers, 8
(dabigatran, 8
(PRP) 8
LMWH 8
JNCL 8
TRalpha1. 8
(HMMs) 8
HMMs 8
Model, 8
False 8
3.9% 8
(>100 8
region; 8
GC-content 8
depolymerization. 8
micrometers 8
ARPE-19 8
TNF-α. 8
FET3. 8
Newfoundland 8
Microcephaly, 8
2q22. 8
echography 8
posits 8
SEs 8
rheostat 8
transcription-factor-binding 8
lineage-status 8
epigenome. 8
hyperacetylation. 8
tentatively 8
LFS. 8
endocrinologic 8
married 8
(15.4%) 8
mispairs, 8
N6-methyladenine 8
back-up 8
FLEX 8
PK, 8
esophagogastric 8
oesophago-gastric 8
(CR 8
evaluated; 8
Cell-type 8
chemistries 8
radical-trapping 8
Methodological 8
(mRS) 8
Shift 8
free-radical-trapping 8
Caution 8
6-point 8
1.46; 8
appetitive 8
askHERMES 8
INDOC: 8
accentuates 8
rT3, 8
(FANCL), 8
(ssDNA) 8
L); 8
Xp22.31 8
mystery. 8
allopurinol-treated 8
electrochemiluminescence 8
Neurofilaments 8
qualify 8
(NC), 8
neuroasymptomatic 8
725 8
ECL 8
thawing 8
(NFL), 8
S-100B 8
(cut-off 8
post-infarcted 8
30.0 8
TRalpha1- 8
(beta-MHC) 8
CONT. 8
flower 8
obstetrics 8
MSRE 8
euploidy 8
Kd 8
immunoprecipitates. 8
four-stranded 8
self-transcribed 8
miRNAs), 8
CGIs. 8
miRNAs/miRNA 8
PER 8
Cry2 8
non-teaching 8
nationally 8
non-teaching-intensive 8
nestin-positive 8
5-methyl 8
UHRF1 8
UHRF2 8
founded 8
(TRbeta1) 8
beta-/- 8
FgfD 8
stickleback 8
HCNE-rich 8
shuffling 8
Converting 8
corticosteroid. 8
(LN) 8
non-African 8
willow 8
(PRS-I) 8
CMTX5, 8
selenite 8
ester. 8
adenylate-uridylate-rich 8
stress-response 8
S100, 8
nucleoli, 8
production: 8
(TJ) 8
C3H/HeJ 8
baricitinib. 8
polyubiquitylation 8
Extrapolation 8
MUC1 8
ConA 8
oligo 8
isovolumic 8
RYR2, 8
HDACi-induced 8
A/J 8
MLP. 8
MLP, 8
Mlp84B-null 8
1994). 8
sarcomeres. 8
(215 8
untransfected 8
HCC827, 8
T790M, 8
"in 8
LCRs 8
lipomas, 8
MEN1, 8
nonendocrine 8
lait 8
dislocation. 8
ExPEC 8
energy, 8
CSFV 8
replication: 8
(functional 8
subcontinent. 8
NEMO, 8
(CDO) 8
(BOC) 8
Ihog 8
(Shh), 8
cyclopamine 8
Nox4, 8
Nephronophthisis 8
(NPHP) 8
AHA 8
released, 8
PHQ-2 8
hydrosol 8
1×10(6)/mL. 8
calcein-AM 8
hDPCs-sodium 8
self-defined 8
87%± 8
Me-Gel 8
HAVIC 8
bio-engineered 8
mushroom 8
non-proliferating 8
G→T 8
CAN1 8
HER2-amplified 8
NG108-15 8
succinimide 8
mibefradil. 8
LiCl 8
Aliskiren, 8
symbiotic 8
gal 8
UK). 8
dnaA46ts 8
wrapping 8
Lys3 8
operators 8
Caulobacter 8
46; 8
dose). 8
approach; 8
rizatriptan 8
nonresponse 8
registry: 8
iminium 8
patient-level 8
AlPc 8
discouraged 8
(13.5%) 8
Gliadel, 8
78.5%, 8
1,3-bis 8
(2-chloroethyl)-1-nitrosourea 8
abscess, 8
(Stupp 8
OBJECT: 8
chemotherapies, 8
spaces. 8
FAAP100 8
anemia-associated 8
(STR) 8
Vital 8
bullae. 8
MER41, 8
MER48, 8
MER50, 8
MER51, 8
RMER3, 8
Interspersed 8
(DMN) 8
resting-state 8
associative 8
synthetase-I 8
(blue 8
assay), 8
paraplegias 8
AR-HSP 8
ICE 8
46%, 8
mg/dL). 8
cystadenocarcinoma 8
PTC, 8
internally. 8
pyroptosis, 8
denticola, 8
premolars 8
Caf1 8
Pop2 8
CCR4, 8
acpB 8
CysC/Cr 8
glomerulosclerosis 8
equation. 8
average-risk 8
Established 8
91.7% 8
Geneticists 8
Attitudes 8
70-80% 8
18p, 8
over. 8
(hypoPP). 8
bendroflumethiazide 8
anterioris 8
2007), 8
hyperkalemic 8
dichlorphenamide--a 8
inhibitor--has 8
meals, 8
Dichlorophenamide 8
bifida-Chiari 8
measure: 8
HOQ. 8
modifiable. 8
interpretability. 8
(Pediatric 8
0.77. 8
≤10 8
Humans. 8
0.50) 8
(0.90-1.21), 8
1.10; 8
1.2; 8
1981 8
fathers), 8
(ORs 8
MASP-2 8
clinician's 8
armamentarium. 8
Ppt1 8
hPaf1 8
relaxes 8
repressed. 8
Set2-mediated 8
rRINm5F 8
hCM 8
554 8
P=0.003). 8
nonuniform 8
Phenotyping 8
Nucleotide-binding 8
Nod2. 8
Innate 8
CXCL13 8
omental 8
BAY 8
Endocrinology. 8
Tri-DAP 8
MDM 8
PADs 8
(MBP) 8
9.5%. 8
(anti-CCP) 8
anti-PAD-4 8
excretions 8
nit 8
infestation, 8
conjunctiva 8
bugs 8
Parasites 8
maltose-binding 8
SERCA2, 8
AAV9-mediated 8
'CpG 8
0.7). 8
1·03, 8
obstetrical 8
482 8
59.5 8
SC. 8
Post-surgical 8
Palmini, 8
Radiologic 8
Epo 8
retrotransposons) 8
Aft1-dependent 8
H3K36me, 8
H3K4me. 8
damage-prone 8
desmins, 8
appreciated, 8
neuropathies(CMT1), 8
22(PMP22) 8
1(GJB1), 8
gene(MPZ), 8
2(EGR2), 8
gene(MTMR2), 8
L-periaxin 8
gene(PRX), 8
HMG-BOX 8
10(SOX10) 8
gene(GDAP1). 8
EGR2, 8
(classified 8
v2.0 8
LAMP-2A, 8
I93M 8
disintegrin 8
clip 8
30%) 8
hypocretin/orexin 8
Binary 8
weights. 8
0.51) 8
ε4- 8
hyperabsorption 8
(codons 8
BE 8
EARLY 8
RAS-mutant 8
clash 8
IFT80, 8
fingolimod, 8
daclizumab 8
(2000 8
eutherians 8
gases 8
(Day 8
Xic 8
inter-repeat 8
epiblast 8
hypoacetylation 8
G6PD, 8
self-templating 8
TDP-43. 8
molecules; 8
Chompret 8
2014), 8
Peroxiredoxin-2 8
peroxide-induced 8
Srx 8
(DCs), 8
(GPUs) 8
optimized, 8
texture 8
GPU-CUDA 8
single-threaded 8
end-to-end 8
rectum 8
5-years 8
DUX4-FL 8
vivo-morpholino 8
55%, 8
(5.4 8
30-bp 8
EDG-1 8
coexpressing 8
SWATH-MS 8
(16% 8
arise. 8
FASEB. 8
RASF 8
RA; 8
oblongata, 8
(1)H 8
Lineage 8
recG 8
helicase-dependent 8
primosome 8
bubbles 8
morning, 8
excitatory, 8
"good" 8
K8 8
(EDC), 8
Post-natal 8
jSR 8
One-hundred 8
N9 8
HDAC8 8
Virtual 8
ETA 8
49.5% 8
fluorimetric 8
0·04). 8
(ctDNA) 8
L(-1) 8
Fgfr3(P244R) 8
Registries 8
EU/ml 8
(VE 8
SAEs 8
sporozoite 8
vaccines: 8
57), 8
gastroenteritis 8
Member 8
OR5AN1, 8
MOR244-3, 8
paralleling 8
BORIS. 8
molecule), 8
(TMBBs) 8
top-performing 8
N-to-1 8
tab 8
http://service.bioinformatik.uni-saarland.de/tmx-site/. 8
(OMP) 8
globular/TMH 8
98.8% 8
MOMP 8
Brachyury 8
Barriers 8
iatrogenic, 8
herpesviral 8
subpallium, 8
nfo 8
gonorrhoeae 8
PcrA 8
UV. 8
(n=10) 8
miR-657 8
triphosphatase-dependent 8
owl 8
dystonia-parkinsonism: 8
"Lubag") 8
(NBIA) 8
gentleman 8
chorea. 8
Smell 8
Island. 8
V-PI 8
anti-breast 8
(fatigue, 8
mmHg). 8
procedure', 8
PTA. 8
post-procedural 8
post-PTA 8
"chronic 8
MSIS-29 8
repeatable 8
MS: 8
239) 8
(ESS), 8
procedures): 8
estimated, 8
former. 8
AABB. 8
Test-retest 8
(white 8
MLL1, 8
GFI1 8
hemogenic 8
Ikaros, 8
independence-1B 8
20-amino 8
independence-1B) 8
erythroblasts. 8
Thalidomide: 8
(ENL). 8
nonmutant 8
macrocytosis 8
(FGF23) 8
α-KL 8
nicotinamide. 8
"anoikis". 8
Detachment 8
reorganize 8
Anoïkis 8
tryptase 8
(SEA0400), 8
NO-induced 8
(determined 8
tension. 8
squid 8
Ca(2+)(i) 8
CINAHL, 8
SAM, 8
Deamination 8
deaminase, 8
lymphoedema, 8
genodermatoses 8
surgeries, 8
LMO2 8
FXR. 8
p450 8
FXR, 8
OGG1, 8
H1R(-/-) 8
electrodes, 8
"overrepresentation 8
analysis" 8
"threshold 8
significance." 8
toxicogenomics 8
F344 8
Personalized 8
viable. 8
Ca(v)2.1 8
CDI, 8
(FND) 8
ala 8
FND 8
scapula 8
XVI 8
condensed, 8
nNOS-binding 8
42-45) 8
separated. 8
CDKL5 8
4a 8
kinase-like 8
Riedel's 8
(VEGFR), 8
VEGFR, 8
helicases, 8
manufactures 8
internet-linked 8
alkanes. 8
ppb, 8
Bland-Altman 8
LiMAx 8
tidal 8
reproducibility. 8
interchangeably 8
tests). 8
Method. 8
5-6 8
non-responders. 8
0.201). 8
tetrachloride 8
overgrowth/mental 8
macrocephaly/mental 8
Microdeletion 8
mmol/l. 8
hypocalcemia, 8
agreement. 8
(rt-PA) 8
Thrombosis 8
scaffolds, 8
14-3-3. 8
PKC-zeta 8
(SZ) 8
DNMT-3a 8
all-trans 8
miR-148 8
(GCA). 8
UFCO 8
identities, 8
Ste12 8
Sir 8
Arf6GAP 8
4-day 8
meters 8
6.8% 8
Ad-Mouse 8
(DEX) 8
kg-1, 8
Surveys 8
lorazepam 8
(p65), 8
p52, 8
drug-associated 8
piRNA-guided 8
HeT-A 8
spn-E 8
ping-pong 8
OSS 8
uapC 8
artemin, 8
endothelin-signaling 8
full-thickness 8
MTC, 8
SCN1B 8
megakaryocytopoiesis 8
Ki-67-positive 8
IXa 8
noninferiority, 8
SSR 8
Democratic 8
flavivirus, 8
chikungunya 8
arboviral 8
rise, 8
pharmacists, 8
re-emergence 8
(PIC), 8
metamorphosis, 8
'ESKAPE' 8
Dovitinib, 8
SK-HEP1 8
Platelet-derived 8
m-E 8
phosphoserine/phosphothreonine 8
p38α 8
c-Jun-N-terminal 8
phosphotyrosine, 8
aims. 8
thicknesses 8
anterior, 8
presenilin, 8
(semagacestat) 8
(LY450139). 8
C99 8
Defense 8
revertant 8
(CRM) 8
unavailability 8
RFLP 8
hyperuricemia, 8
Lesch 8
Nyhan 8
(AdoMet), 8
rats: 8
NMC-A 8
failures. 8
2R 8
(n=1) 8
recesses. 8
minisatellites 8
chipmunk 8
RNA-derived 8
Lumbosacral 8
Minimally 8
modes: 8
(SHAM). 8
Viable 8
Cdc2, 8
SCC-4 8
DAAs 8
mericitabine 8
decomposition, 8
G3 8
BID, 8
multiscale 8
viewpoint, 8
SmbFT 8
university-affiliated 8
non-traumatic 8
intraparenchymal 8
miR-106a 8
early-stage, 8
M059J 8
psoriasis) 8
LN229 8
KRAS(G12D) 8
invariable 8
never-smokers 8
digoxin, 8
T4/T3 8
(fludarabine, 8
A20 8
IKKβ, 8
labial 8
tears, 8
motion. 8
thirty-two 8
intra-abdominal 8
bars, 8
7.9% 8
Genie 8
Erlotinib 8
(MINOS) 8
Sam50 8
metaproteome 8
metaproteomic 8
metagenomes 8
oligotrophic 8
scopolamine 8
TRalpha(1)+/m 8
(PAS) 8
PolyA 8
altitude, 8
DEEP-VISTA, 8
80.1% 8
89.64%. 8
benefit/risk 8
0.58) 8
0.14). 8
A/G 8
(QT 8
WNT16B 8
CPT 8
chromate 8
nitrite 8
UVB-treated 8
MR-proADM 8
(AOR, 8
≥80 8
Ranasmurfin, 8
H3K9me2/3 8
re-formation 8
>35 8
(nebulin), 8
(beta-tropomyosin), 8
(gamma-tropomyosin), 8
p.Phe352Ser 8
rods, 8
alpha-tropomyosin-3 8
(NEB), 8
beta-tropomysin 8
(TPM2) 8
lupus, 8
DM. 8
supermatrix 8
(Stat3) 8
20.4 8
anti-IL-6, 8
IRF9 8
department: 8
SCALES: 8
Face 8
87) 8
0.30). 8
methyl-transferase 8
eotaxin-3 8
DFTD 8
MTA1 8
MTA1, 8
Sirt-1 8
perturbations. 8
FVE 8
Pomc 8
C(4) 8
skeletons 8
LC/IRMS 8
GC/C/IRMS 8
derivatives) 8
dating. 8
rex 8
A.D. 8
α-MHC, 8
phones. 8
low-income 8
alertness. 8
Discontinuations 8
armodafinil. 8
(nCPAP) 8
OSA/HS 8
TD. 8
CPT-induced 8
grains 8
peptide). 8
(DEND), 8
(hemoglobin 8
SCH23390 8
pridopidine. 8
E13 8
Leeds 8
Conference, 8
somehow 8
RPL35A, 8
RPS10, 8
Nonmelanoma 8
carcinomas) 8
unirradiated 8
solar-simulated 8
drowning'? 8
'Parkinson's 8
'stridor' 8
'airway 8
obstruction' 8
'laryngospasm' 8
'laryngeal 8
dystonia' 8
'bilateral 8
palsy'. 8
drowning', 8
Laryngospasm 8
drowning'. 8
(PSD) 8
BDI 8
aphasia, 8
caregiver's 8
carers' 8
0.000), 8
rapid-prototyping 8
printing) 8
Alfa, 8
(infusion 8
0·26 8
dyshormonogenesis 8
termini. 8
(autophagy) 8
PQC 8
Magnaporthe 8
Htt 8
standpoint, 8
platinum-refractory 8
Theileria 8
sl 8
squirrel 8
(TH). 8
virus-host 8
defence, 8
(PPARγ) 8
ETRA 8
morbidity/mortality 8
aerosolized 8
(haplotype 8
planning. 8
GF109203X. 8
tunicamycin 8
6.9; 8
POSH 8
milliseconds, 8
LASER 8
hard-X-ray 8
'snapshots' 8
input. 8
alphaKAP 8
'castration 8
resistant' 8
~3-fold 8
DHEA, 8
I-associated 8
alpha-ENaC2 8
SFFVp 8
harmonized 8
Networks 8
sustainability 8
(MP) 8
unrealistic 8
recipients' 8
moderating 8
non-penetrance 8
72-144 8
(Panthera 8
Defect; 8
Prp19 8
Pds5, 8
Esco2 8
(FACS) 8
THDOC 8
=20 8
1): 8
carboxymaltose, 8
carboxymaltose. 8
8.8% 8
IDA. 8
FCM-treated 8
(FCM, 8
Ferinject) 8
(AUB), 8
non-dialysis-dependent 8
Hb. 8
22.2% 8
least-square 8
multi-site, 8
(1.3). 8
10/18 8
8/19 8
7/19 8
parameterized 8
Multiplexed 8
(SCN1A) 8
CAGEr, 8
Crucially, 8
AT2 8
(tissue 8
miR-26a 8
SG-nucleating 8
AMPK-α2 8
total. 8
Wnt-3A 8
Pten 8
B/Akt. 8
3.6-GFP 8
Typically 8
950 8
3.2% 8
off-treatment 8
pioglitazone, 8
5.4% 8
pioglitazone. 8
fibrates 8
down- 8
Co-A 8
Dot1-mediated 8
spermiogenesis, 8
Mek1 8
Dot1l 8
MLL-rearranged 8
(M 8
(DOT1L) 8
Eyes 8
beta-hCG 8
(uE3) 8
spp 8
self-healing 8
35.7 8
distractor 8
posttest 8
(Frankel 8
Spine 8
iodine. 8
Amplified 8
industrialised 8
anti-RANKL 8
cancellous 8
phytopathogenic 8
pIndi 8
α-β 8
5-methyl-dCTP. 8
monophosphates 8
(8-oxo-dGTP) 8
MutT-related 8
MTH2 8
16.1% 8
(maintenance 8
progressed. 8
TX. 8
Interferon-alpha 8
mg/m2/day. 8
(anhedonia) 8
admission). 8
account: 8
intervention: 8
affect) 8
folinate 8
FOLFOX 8
NPC2 8
Npc1 8
SKOV-3 8
spoke 8
PTPN22. 8
TRAF1-C5, 8
CCL21, 8
MMEL1-TNFRSF14, 8
PRKCQ, 8
IL2RB, 8
Suggestive 8
TRAF1/C5, 8
IL2/IL21, 8
1976; 8
HLA-SE. 8
Sweden: 8
turmeric 8
texture, 8
EAN 8
Lesion 8
FA-H) 8
SGK1-mediated 8
SD-1029. 8
immunoreactive) 8
DNA-damage-response 8
intra-S-phase 8
autochthonous 8
diet) 8
Coeliac 8
hETB 8
P383L 8
(FD) 8
p97/Cdc48p 8
myristoylation 8
V600-mutant 8
BRAF(V600E/K) 8
KAs 8
SCCs. 8
B-RAF 8
(percentage 8
tachycardia; 8
parvalbumin- 8
Par3 8
Zeb1/deltaEF1 8
afterwards 8
inward-rectifier 8
S2814 8
Spi(-) 8
Liu 8
resedation 8
mixed-drug 8
convulsions, 8
BDZ-positive 8
(3.4%), 8
miR-27a. 8
hypoacusis 8
Sequencer 8
(LDS) 8
poly(IC) 8
(BTBR) 8
FXS 8
DB1 8
HRC(WT) 8
HRC(WT). 8
HRC(WT), 8
postmyocardial 8
EKG 8
H3K27. 8
IQR 8
geochemical 8
nov., 8
Nutrient 8
hNEP 8
pulses, 8
alpha-proteobacterial 8
Mucopolysaccharidosis 8
Hunter's 8
(105 8
EPHB6, 8
ephrin-B1 8
ephrinA1, 8
U373 8
Rrm3p. 8
(peripherally) 8
desflurane, 8
4%-to-8% 8
miosis, 8
(p50 8
p105), 8
(p52 8
p100), 8
(T-cell 8
music, 8
(F(1,24) 8
SKP1, 8
NIS 8
straining 8
encephalomyelitis, 8
angle. 8
Nup107/160 8
IFNAR1, 8
(5-Aza-CdR), 8
(PRD). 8
HSP70; 8
CYLD-deficient 8
HSG 8
deprotonation 8
Medicarpin, 8
alfalfa, 8
phenylpropanoid 8
stereotactically 8
(ATXN3) 8
perforin 8
non-CAD 8
thyroxine-treated 8
redox-sensitive 8
p21(CT) 8
p15INK4B) 8
leptin-induced 8
pre-TRH 8
sympatho-adrenomedullary 8
(TRH). 8
adrenals 8
[3H]MeTRH 8
(related 8
non-HFE 8
Hepatology 8
HJV 8
phosphatase-1. 8
(CBs) 8
NOX, 8
hemangioblastomas, 8
(TEN). 8
HSR) 8
HLA-B(*)5701 8
abacavir-based 8
Pharmacogenetic 8
neuro-ectodermal 8
pyrimidines 8
Nimotuzumab, 8
DQB1*06 8
GABA-ergic 8
HIV/simian 8
(SIV) 8
LINE-1-mediated 8
deaminases, 8
G6PDd 8
(HVA) 8
homotetrameric 8
intubation-surfactant-extubation 8
(INSURE) 8
(n=32) 8
AAP 8
RDS. 8
acclimation 8
DN-hTERT-expressing 8
Shadow 8
VTE. 8
df 8
omission 8
TAS-102, 8
[(18)F]FLT 8
arthropods 8
Thaumetopoea 8
touching 8
caterpillars, 8
offending 8
fluconazole-resistant 8
Biofilms 8
cerebellar, 8
Galactocerebrosidase 8
bona-fide 8
dicotyledonous 8
trophozoites. 8
schizont 8
(IE). 8
cross-react 8
Phobia 8
gravity 8
red-haired 8
Kallikrein 8
V5 8
collisions, 8
(Firmicutes). 8
immunofixation 8
retrospectively, 8
Antonio 8
(PTEN, 8
PCGF2 8
TIMP3, 8
incidents 8
bat 8
ULC 8
(CSTB). 8
radiography) 8
Orf135 8
dATP, 8
antibody-negative 8
EPP. 8
protoporphyria, 8
(T-DNA) 8
RHD. 8
(ABPP) 8
(MudPIT) 8
amine. 8
U6-associated 8
(snRNPs). 8
Aβ1-42 8
knot-free, 8
bisdioxopiperazine 8
M(r) 8
(SHAPE) 8
gnathostomes. 8
HoxA, 8
translated, 8
b-paralogs 8
Unexpectedly 8
amphioxus. 8
modular, 8
lamprey 8
megabases. 8
(T2C), 8
shoulders 8
SOD1-G93A 8
coagulopathy, 8
suburethral 8
Dps 8
sequence-directed 8
masculine. 8
non-mainstream 8
hBNP 8
CSW 8
anti-DARA 8
antiglobulin 8
MoAbs, 8
dacetuzumab 8
OikoBase: 8
FtsZ. 8
Therapy-Melanoma 8
(BPI) 8
HbA1C 8
(Ser96Ala) 8
Unintentional 8
Barrett 8
71) 8
visits: 8
vitality 8
polyurethane 8
herpetiformis: 8
acaricide 8
4E 8
2A(pro) 8
(HuR, 8
ELAVL1), 8
Drosophila-like 8
(ELAVL) 8
hinge-RRM3 8
ELAV/Hu 8
MDa 8
M- 8
BMP-2-induced 8
(MEF2) 8
raptor, 8
objection 8
(M6P) 8
sortilin, 8
cathepsins 8
prosaposin 8
forward, 8
4.0% 8
(24.4% 8
vedolizumab. 8
CD: 8
kg⁻¹ 8
circumcision 8
EA 8
postanesthesia 8
degradosome 8
holB 8
S100A13, 8
immunoenhancing 8
drd1 8
psychiatry, 8
O6-methylguanine 8
CCNU-induced 8
agent) 8
G:C-->A:T 8
Oxidase 8
EMD-treated 8
Oulu 8
Europeans. 8
psychotropics 8
non-OCD 8
(number 8
Prescribing 8
NLs 8
NL 8
STN 8
IVH 8
Riordan 8
Cameron 8
treatment.There 8
(IgM 8
amyloid-like 8
Redwood 8
visits, 8
sI(AHP) 8
aetiopathogenesis 8
housing 8
justice, 8
commonplace 8
non-medical 8
particulates, 8
Z-Val-Ala-Asp-fluoromethyl 8
SLC16A2) 8
Microglia 8
R-values 8
SLCO1B1*1b/*1b 8
non-HDL 8
Papua 8
Guinea 8
tropica, 8
utilisation 8
anopheline 8
GDH 8
parasitized 8
pfOPRT 8
(spot 8
PfNT1 8
habitation 8
malaria]. 8
antibodies; 8
665 8
Brca2/Fancd1 8
(Brca2(Delta27/Delta27) 8
(CFCs) 8
unconditioned 8
interleukin-11 8
Fac 8
IntraPEritoneal 8
inosine, 8
(IGFBP7) 8
taxane-resistant 8
P-Rex1 8
diapedesis 8
hyperactivated 8
MDDCs 8
degradation-resistant 8
Orthostatic 8
(SLC6A2) 8
gametogenesis. 8
811 8
PLX3397. 8
Segmental 8
(MALT) 8
Adenocarcinoma 8
clear) 8
mild/moderate 8
Index) 8
usability. 8
(coprimary 8
IL-23. 8
FKBP 8
IMMs 8
Ancestral 8
ESA 8
adenotonsillectomy. 8
(Ngb) 8
sour 8
frontosubcortical 8
One-third 8
Guam 8
frontolimbic 8
Guadeloupe. 8
Annonaceae 8
NSABP 8
(cytosine-5-)-methyltransferases 8
EcoRII 8
2.05 8
Foxd3 8
chordae 8
undergone. 8
mice]. 8
Upf1, 8
Upf2 8
UPF2 8
sup111, 8
UPF 8
HDL2 8
AH. 8
(6-12 8
bruising, 8
2(V) 8
lymphangiogenesis, 8
fibrothecoma 8
(4/22) 8
adenofibromas, 8
TRIM37del2 8
TRIM37del2:TRIM37 8
(17q22-23) 8
pericardectomy, 8
N-glycosidic 8
Mispairing 8
p38β, 8
p38γ, 8
p38δ), 8
myofibers, 8
Col1a1 8
GBP, 8
PC-induced 8
[Gemcitabine 8
well-tolerant 8
CHEK2--in 8
NCT01682772; 8
CRUK/11/029.). 8
BRCA-like 8
Foxa 8
sativa) 8
L/min. 8
Bronchiolitis 8
iodide, 8
Oesophagitis 8
dnaA 8
hemoglobinopathies 8
high-binding 8
BIS-11 8
0.39). 8
coiled-coil-helix 8
Tom20 8
A-tails 8
temperature-specific 8
macronuclear 8
NELF-mediated 8
junB 8
neurocysticercosis 8
first-cousin 8
462 8
aqueducts, 8
HADDOCK 8
RCF 8
template-based 8
DockoMatic 8
immunobiological 8
CYP3A 8
0.025 8
garlic 8
human-mouse-rat 8
intra-amygdalar 8
sativus 8
cerebroside 8
Mangifera 8
Citrullus 8
meals. 8
RyR2-V2475F(+/-) 8
RyR2-G230C 8
HLA-B*1502, 8
NOTCH2, 8
αSNAP 8
threonine-3 8
arrests. 8
attachments 8
harmine 8
AtHaspin-tdTomato 8
under-recognized 8
Cos-7 8
ghrelin's 8
Medium 8
p14ARF 8
E2a-Pbx1 8
runtime 8
I-dependent 8
(fibroblast 8
Neolithic 8
(N6-adenosine)-methyltransferase. 8
5-Hydroxymethylcytosine 8
PGC7 8
5mC, 8
thymus-specific 8
MOF 8
Cas9-sgRNA 8
eighth 8
Wolf-Hirschhorn 8
motoneurones 8
achondroplastic 8
AHF 8
arsenite-injection 8
hepatectomized 8
XK0 8
foals 8
(SMEI), 8
(KCNQ2 8
RE, 8
BNFC. 8
Q3, 8
(MMSE) 8
bismuth-based 8
visualisation 8
KLK2 8
Large, 8
CdLS 8
196R 8
THC 8
Nox1/Nox4 8
apoE(-/-) 8
(Gro) 8
licensure 8
epidemics. 8
Pharmaceuticals) 8
740 8
B1-Alu 8
Alzheimer-type 8
Rab3a 8
(ClinicalTrials.gov, 8
NCT00136045) 8
(CGI-1), 8
(RLS-6), 8
RLS-quality 8
(RLS-QoL) 8
CGI-1, 8
RLS-6, 8
EoM 8
1/Aagenaes 8
Lymphedema-cholestasis 8
Rivastigmine 8
TNBS-treated 8
leprosum, 8
subcapsular 8
Berlin, 8
(BRCA1 8
risk-reduction 8
"Krokodil" 8
codeine 8
DLP1 8
nonspherocytic 8
mass-screening 8
baboons 8
niraparib. 8
somatic) 8
PARP2 8
(MK-4827), 8
poly(ADP-Ribose) 8
ERCC1 8
MRgHIFU 8
Thalamic 8
cavitation 8
cobalt 8
(NCT00803049) 8
Teriflunomide, 8
(Oral 8
(PEG)ylated 8
PASI-75 8
Hellenic 8
5.476% 8
Circularization. 8
kilogram, 8
Nephropathy 8
(NOX5) 8
bazedoxifene 8
ZNF335/NIF-1, 8
SIV-infected 8
Anti-PD-L1 8
4-component 8
Serogroup 8
NadA-1, 8
(OMV) 8
MHC-I 8
inflexible. 8
*.CEL 8
https://bitbucket.org/cob87icW6z/cafe/ 8
dbSUPER: 8
GeneCards, 8
Entrez. 8
name. 8
inducer-initiated 8
Scurvy, 8
SCAR 8
NSAID, 8
(CI95%: 8
TEP 8
agranulocytosis 8
pharmacist 8
phenomenon) 8
tid 8
palpable. 8
CJD, 8
RASA2, 8
RasGAP, 8
curators 8
GN, 8
Contrave, 8
(Contrave) 8
(Saxenda) 8
(Belviq), 8
5p15.32. 8
Marshfield 8
9q, 8
melanism 8
"Animal 8
Inhalational 8
rabbits) 8
12] 8
E1-activating 8
EsSUMO-1 8
20q(-) 8
+8. 8
case; 8
(1/5). 8
monosomic 8
(7/10) 8
18q- 8
18p 8
luminance 8
In5 8
macroalbuminuria 8
V: 8
(111)In-DTPA-PEG-annexin 8
lefty 8
low-, 8
middle-, 8
Naproxen 8
Rofecoxib 8
aprotinin, 8
anti-fibrinolytic 8
(Ovid 8
SP) 8
18-month 8
Chaperone 8
agalsidase, 8
sulfonylurea, 8
84.9% 8
Q-nexus 8
furin. 8
(n=171), 8
(n=249), 8
[METABRIC] 8
n=1980). 8
receptor-negative-ACT; 8
n=697), 8
(Nottingham-NeoACT; 8
n=200), 8
Anderson-NeoACT; 8
n=508), 8
NeoACT; 8
NCT00455533; 8
n=253). 8
PAM50-HER2 8
PAM50-LumB 8
1·71, 8
1·07-2·74, 8
p=0·024; 8
Nottingham-ACT: 8
8·75, 8
2·42-31·62, 8
Charity 8
Lucille 8
Geest 8
SPAG5, 8
Polynesia 8
self-limited. 8
carboxylate. 8
oseltamivir. 8
Tamiflu 8
anti-flu 8
Neuraminidase 8
endoproteolysis, 8
Ubiquitin-conjugating 8
(Ubc9), 8
pro-life 8
Replication. 8
RAP80 8
RNF4 8
crayfish 8
peri-implant 8
Clovis 8
CDx 8
HLP. 8
ApoE3 8
(allele)-specific 8
outgrowth; 8
chylomicron 8
apoE-2 8
(XLH). 8
(vortioxetine: 8
(least-squares 8
http://mcm.h-its.org/webSDA/. 8
beans, 8
(precursor 8
Cys10 8
SoxE 8
creases 8
Marden-Walker 8
Slitrk 8
IP5K 8
CSN8 8
UPS-mediated 8
ubiquitin/26S 8
5/6-kinase 8
CSN7 8
psoriasis), 8
(ERAP)1 8
(PIM) 8
CAM-ICU 8
psychopathology 8
intra-articular 8
capsulitis. 8
PMA, 8
p22(PHOX) 8
nephrocalcinosis 8
1,25(OH)(2) 8
pseudo-Bartter's 8
sella 8
basic-helix-loop-helix-leucine 8
(bHLHZip) 8
canthorum 8
WS2. 8
Mitf 8
mi 8
pygmy 8
loris 8
Runx2/Smads 8
Gli1/2 8
Col10α1 8
(PTHrP), 8
Gli-2, 8
HS-PGs 8
Nkx3.2 8
R-spondin 8
MCTD 8
alfa: 8
PB-06-002 8
PB-06-003 8
NCT00705939. 8
(9-60U/kg 8
2weeks) 8
(spleen 8
NCT00712348. 8
(FOP). 8
(NOG) 8
holoprotein 8
HETEROCHROMIA 8
IRIDUM 8
DEAF 8
SCHOOL 8
neurilemmoma. 8
(RN-624), 8
muMab-911, 8
osteoarthritic 8
pharmacokinetics), 8
inflammatory-mediating 8
Panton-Valentine 8
CA-MRSA. 8
88.9% 8
(MRSA 8
MRSASelect, 8
MRSA) 8
MRSA-negative 8
healthcare-associated 8
LA-MRSA 8
AVA 8
SLNs 8
vardenafil 8
Hz)-induced 8
10(-8)-10(-3)) 8
epitranscriptome. 8
(NMF) 8
Zimbabwe. 8
2629 8
UC-781 8
TMC120-R147681 8
Retroviruses 8
Opportunistic 8
[Bexsero, 8
GNA1030 8
NNV 8
vaccinees 8
Determines 8
Zinn, 8
scleral 8
trochlea 8
Atrophy: 8
(ISIS-SMNRx 8
396443) 8
electrocardiographs. 8
Exam-Part 8
(HINE-2) 8
(CHOP-INTEND) 8
HINE-2, 8
CHOP-INTEND, 8
NCT01839656. 8
CHOP-INTEND 8
(p=0·0013), 8
(p=0·0103) 8
(p=0·0014). 8
Biogen. 8
CCAL 8
immune-regulating 8
PE-induced 8
xanthine/xanthine 8
ceramide-induced 8
U46619 8
self-cycle 8
apocynin), 8
(Sakha) 8
micronecrotic 8
trabeculectomy. 8
immunohistologic 8
TSPYL4 8
MTBITC 8
tanshinone 8
Bauer, 8
(p<.01), 8
(NSD 8
(MRPs), 8
antimonial 8
[4]. 8
PC5 8
Fsp27(ΔAd) 8
WR. 8
CIDEB, 8
0.016 8
(PFI) 8
TH17/Treg 8
PUAs 8
transillumination 8
203100), 8
son. 8
hypopigmentary 8
HexDiff 8
APOE-epsilon3 8
APOE-epsilon4 8
dread 8
CENP-A) 8
SRSF1 8
(serine/arginine-rich 8
SZ-associated 8
DISC1 8
ERBB4. 8
mucocutaneous, 8
Clr4p 8
Cut9 8
EGFR-inducible 8
overlaid 8
differentiated. 8
SGCs 8
H2A-H2B 8
(BIND) 8
Reactivity 8
(SASP). 8
tumour-promoting 8
PARP3 8
non-survivors. 8
PRISM, 8
COL3A1 8
Tpeak-Tend 8
herg1b 8
I593R 8
Rab4 8
cataloged, 8
harmless, 8
undergraduate 8
interviews: 8
18.00% 8
16.60% 8
36.89% 8
Coincident 8
PR-Set7-mediated 8
polymyalgia 8
alar 8
kobenerisation' 8
(QALYs). 8
HRQOL. 8
beams. 8
RBE, 8
reconsidered. 8
MeV 8
DAG 8
(PNET)-like 8
neuropil-like 8
pilomyxoid 8
ependymal-like 8
xanthoastrocytoma 8
(PXA)-like 8
lysine(27)-to-methionine 8
Gly34Arg/Val 8
(G34R/V) 8
R132H 8
v4, 8
(ADHD)-associated 8
Meniere's 8
Approximate 8
phylogenies; 8
HS-associated 8
subserosal 8
PCT 8
SOFA 8
CBP20 8
oculo-visual 8
G47D 8
pigment) 8
(DTA) 8
(TDT) 8
Swr1, 8
Swc2 8
Bdf1, 8
Multiciliated 8
Ocular/oculodermal 8
(oculo[dermal]) 8
Wills 8
thermotherapy. 8
Melanosis 8
(PAM) 8
arils 8
(SYLVANT 8
herpesvirus-8 8
(MCD). 8
erythematous 8
diphtheria-like 8
ulcerans. 8
CASR 8
PMA1 8
looping-competent 8
18,201 8
antigen-binding 8
A's 8
BOK 8
pitting 8
lymphangiectasia, 8
Triatominae 8
Poorly 8
Biocytin 8
diaminobenzidine 8
chromogen 8
gold-conjugated, 8
silver-intensified 8
avidin. 8
folium 8
rosette-shaped 8
long-latency 8
polysynaptic 8
vestibulocerebellum 8
intra-tumorally 8
Coordinates 8
PCP/Wnt 8
NB-UVB 8
mJ/cm(2) 8
Parl 8
crossreact 8
(MdDS) 8
Darwin 8
T-Cell 8
heat-killed 8
Vigilance 8
3-Imino-1,2,4-thiadiazinane 8
1,1-Dioxide 8
Cleaving 8
diaryl 8
amide-substituted 8
3-imino-1,2,4-thiadiazinane 8
1,1-dioxide 8
BACE2, 8
(BACE) 8
IDH+/p53-/1p19q-; 8
IDH+/p53-/1p19q+; 8
IDH+/p53+/1p19q-; 8
Ectopia 8
GAMES 8
GGGGCC 8
(GRN) 8
(pta1-Delta75) 8
MAGO 8
EB1 8
trabeculation 8
transesophageal 8
trabeculations 8
concentrates, 8
Non-vitamin 8
Aripazine 8
Rearrangements 8
MTHFR. 8
cryptococcosis 8
Lymphangiogenesis 8
(UDCA) 8
(Hepatology 8
Vanoxerine's 8
MICE 8
Bukharian 8
(HRV), 8
(Apis 8
MACCE 8
epilepsy-related 8
(SUDEP), 8
(SUDEP): 8
CstF 8
ssu72 8
SRS. 8
pre-deployment 8
Iraq. 8
teriparatide. 8
Mis14-18. 8
mis16, 8
(CENP-A), 8
Mis18α's 8
DNMT3A/3B, 8
CULT 8
β-tent 8
Hepadnaviral 8
(cccDNA) 8
ducklings 8
SMYD3 8
smyd5 8
H3.1). 8
β(3)-adrenoceptor 8
β₃-adrenoceptor 8
-adrenoceptors 8
PANTHER-PSEP: 8
(Zinplava™) 8
cytotoxic/cytopathic 8
rs1426654 8
riceland 8
Sulcia 8
extraadrenal 8
pheochromocytoma-induced 8
institution's 8
123I 8
acute/chronic 8
BETWEEN 8
chronic), 8
circ-Foxo3 8
Cdc45) 8
"C 8
NaPi-IIc 8
1,25 8
hash 8
Transform 8
BLAT, 8
computation, 8
60cobalt 8
(FHB) 8
threshold-free 8
orthology. 8
Eutheria, 8
Boreoeutheria 8
Euarchontoglires, 8
Euarchontoglires. 8
magnetoreception 8
needling. 8
neuroradiologist. 8
Tolvaptan 8
steroid-resistant 8
intussusception 8
IIA+B, 8
AAAS 8
convolutional 8
AML-M4Eo 8
t(1;12)(q25;p13): 8
3'rapid 8
ends-polymerase 8
(3'RACE-PCR), 8
(ARG) 8
1q25, 8
SH3, 8
ARG. 8
exudation 8
Alirocumab 8
Stribild 8
dreams, 8
rs1081274. 8
(rs12356233, 8
P=0.019) 8
(rs4690093, 8
P=0.040). 8
(rs2857859, 8
P=0.042). 8
BLAT. 8
NNS-dependent 8
Long-SAGE 8
(serial 8
Nrd1-dependent 8
Nab3-binding 8
telangiectasia, 8
misregulate 8
MLN2238 8
ULN, 8
re-randomised 8
T-brain-1 8
(+∕-) 8
Brujin 8
Bruijn 8
(Belviq) 8
(9.5 8
Exosomes, 8
II-binding 8
SII-dependent 8
S-II, 8
S-II. 8
SGLT1/SGLT2 8
CGM 8
streaming 8
anti-correlation 8
Foxp3(+)) 8
Δtdd8 8
AHA-Ret 8
sunscreen 8
INPs. 8
Tara 8
INPs 8
non-eQTL 8
chicoric 8
tetra-GA-motifs 8
poly(A)-segments. 8
Alu-elements 8
homoduplex 8
UCSs 8
(XUTs) 8
(aslnc)RNAs 8
(XUT), 8
DevR 8
JAK1-dependent 8
Su(Hw) 8
cGAS 8
sub-megabase 8
Tf2 8
SKIL 8
TGF-βRI 8
(PrPC) 8
multiple-species 8
Browser: 8
YLR228c 8
RNF4. 8
β-d-glucopyranosyloxymethyluracil 8
JBP1/2 8
hydroxylate 8
strains) 8
Maat-Kievit-Brunner 8
Ohdo, 8
Substantiating 8
GHS 8
2.0), 8
initiation-elongation 8
rpb9 8
fyv4, 8
gim5, 8
htz1, 8
yal011w, 8
ybr231c, 8
soh1, 8
vps71, 8
vps72 8
Nucleosome-free 8
methylation-and 8
methylation-free. 8
Psygenet2r 8
DDX1 8
dabigatran-mediated 8
DDR. 8
Crow-Fukase 8
encyclopaedist 8
dolor, 8
Morexella 8
1244_1247delACAG 8
BMPR1A. 8
OI, 8
SERPINH1 8
LEPRE1, 8
CRTAP 8
2.9-kbp 8
impure 8
manta 8
intravertebral 8
(women) 8
Modulator. 8
moxifloxacin 8
filgotinib, 8
s1pr 8
tnf 8
ibd 8
databases; 8
http://docs.bioinfo.cipf.es/projects/cellbase. 8
TFC6 8
Reb1, 8
Tbf1 8
Heterophile 8
Notice 8
x, 8
nonplant 8
Copro 8
erythrasma. 8
fusidate 8
trichomycosis 8
capitis, 8
SIOD. 8
matrix-associated, 8
(GBM): 8
week's 8
intra-axial 8
mycotic 8
q11 8
low-concordance 8
(20-30%) 8
studies/pipelines. 8
https://github.com/popitsch/wtchg-rg/ 8
niko@wtchg.ox.ac.ukSupplementary 8
invivo. 8
Circ-ZNF609 8
E526V 8
brachyury 8
Histone-Acetyltransferase 8
Tsc1+/- 8
Cebocephaly 8
(hypotelorism, 8
assortativity. 8
Hi-Cap 8
Contacts 8
(FACIT-F), 8
apnea: 8
0.09, 8
Apnoea 8
≥15 8
preterm/bronchopulmonary 8
Vegfd 8
1/2a 8
Poly(ADP-ribosyl)ation 8
insulation. 8
pore: 8
MinION™ 8
Nanopore 8
Technologies, 8
USB-connected, 8
soon, 8
scalable. 8
scale-up 8
(MEFV) 8
incidents, 8
behçet 8
gov 8
Statistics. 8
<.0001. 8
throats 8
tonsillopharyngitis 8
(CP-690,550), 8
bmal1 8
PHOENIX 8
(population 8
0-3, 8
psa 8
abaloparatide 8
Auxin-Sensitive 8
IAA5 8
SHY2/IAA3 8
TaIAA1 8
BrIAA 8
briaa 8
dipus 8
widely-used 8
right-most 8
arbitrariness 8
(sequencing) 8
structure; 8
arbitrary. 8
LDB1-regulated 8
enhancer-gene 8
(fevipiprant 8
timapiprant). 8
MBV: 8
++ 8
Anti-CGRP 8
trastuzumab-induced 8
DPOAE 8
449 8
Pibrentasvir 8
signeR: 8
++, 8
itojal@cipe.accamargo.org.brSupplementary 8
ML-18 8
(periportal 8
signs). 8
(PPFA) 8
supramesocolic 8
inframesocolic 8
pneumoperitoneum. 8
pneumoperitoneum 8
PWMs. 8
Homepage: 8
http://ccg.vital-it.ch/snp2tfbs/. 8
JUN-FOS 8
receptor-TF 8
serological, 8
(pSS) 8
(A→I) 8
(ADAR) 8
RNA-DNA-differences 8
(RDDs) 8
157/MEDI9929), 8
epithelial-cell-derived 8
(TSLP), 8
(Cervus 8
elaphus 8
swim 8
alkyne 8
SLAM-R 8
NAI 8
echinoderm 8
Subpallial 8
Lines: 8
Jaffé-based 8
mentalization-based 8
DBT, 8
FEN 8
C-genome 8
vaginitis. 8
vaginitis 8
Architect 8
ethics. 8
diffloop, 8
Paloma 8
0.02. 8
Phototoxicity 8
Doxycycline: 8
Manifestations, 8
Cofactors, 8
sunburn-like 8
(burning, 8
erythema) 8
large-area 8
photodermatitis. 8
low-certainty 8
NCIT 8
Heerfordt-Waldenström 8
Paralog 8
(SSR) 8
5'-exoribonuclease 8
5-HT-6 8
Idalopirdine 8
Intepirdine 8
chocolate. 8
https://github.com/fukunagatsu/RIblast 8
t.fukunaga@kurenai.waseda.jp 8
mhamada@waseda.jp. 8
[Paroxysmal 8
Panencephalitis 8
FACT-G, 8
BFI. 8
CYP1A2 8
speA 8
(VCF) 8
htslib 8
PLINK 8
v1.9 8
vcftools. 8
rodentium 8
(PARPi) 8
PCR-free 8
1.00]) 8
Deficiency, 8
Enteropathy, 8
Thrombosis. 8
Sirtuin1 8
vanishes. 8
CancEr 8
(ARIEL2). 8
chaffeensis, 8
halys. 8
'probing' 8
Typhi, 8
Gallbladder 8
Fexinidazole: 8
benznidazole-susceptible, 8
GeneComp 8
Afterglow 8
phosphorescence 8
Romo 8
ADG 8
INCB3619 8
disialoganglioside, 8
14G2a, 8
Pcorr= 8
(SHR), 8
anti-ICAM-1 8
16.2%). 8
die. 8
1148 8
1150 8
RS-exon 8
GGL 8
LOX/L 8
cable-tie 8
(eRNA) 8
GAG 8
Trpm2 8
CTCF-expressing 8
(Valtrex, 8
valaciclovir, 8
penciclovir 8
Melanocortin 8
Arg151Cys 8
p.R151C, 8
blonde 8
care-related 8
(EPAS1, 8
PPARA) 8
lowlanders 8
highlanders 8
controversy, 8
(Cse4/H4)2 8
tetrasomes. 8
Cse4/H4/H2A/H2B 8
Ishihara 8
(DRPLA) 8
abortus. 8
I155T, 8
(KRT14) 8
(Leishmania) 8
Foxp2 8
markedly, 7
690 7
0.13) 7
role; 7
Shah-Waardenburg, 7
Cartilage-hair 7
(RET 7
EDNRB). 7
Non-syndromic 7
non-familial, 7
lactating 7
Signals 7
Ligands 7
cytokeratin 7
HapMap 7
FDC-S 7
betacellulin, 7
ligand-receptor 7
9.0 7
histamine, 7
P<0.001; 7
31.2 7
signaling-competent 7
papilin, 7
homologous, 7
TSR 7
disulfide-linked 7
spliced, 7
stage-dependent 7
siRNAs, 7
RefSeq 7
3-month-old 7
EOC, 7
miR-199a-3p, 7
Foundation, 7
72, 7
extremes 7
gravis, 7
2009) 7
immunomodulators 7
difficulty, 7
informing 7
press 7
announced 7
autopsies 7
hip. 7
Raloxifene 7
DVL1, 7
(qRT-PCR), 7
2.66 7
appealing. 7
rashes 7
[Paraneoplastic 7
Bazex. 7
well- 7
dermatoses, 7
three-month 7
elbows 7
knees 7
Obligatory 7
symmetrically 7
trunk. 7
usually, 7
tarda 7
anti-arrhythmia 7
sodium-, 7
potassium-, 7
calcium-channels 7
sodium-channel 7
exponential, 7
block-frequency 7
relation. 7
(potassium-channel 7
blockade) 7
(IK) 7
(acquired 7
upstroke 7
(time 7
detergents 7
Notch-3 7
hepatoblasts 7
Hes5 7
Gpx1 7
H2O2, 7
anti-androgen 7
(enzalutamide, 7
abiraterone, 7
(ELM-PC 7
deaths). 7
0·92, 7
770 7
[2%]), 7
[38%] 7
rPFS 7
PSA50 7
9%; 7
(36% 7
(29% 7
BID). 7
Prednisolone 7
2C19. 7
antiandrogens 7
DU145, 7
212Pb-trastuzumab 7
HER2-expressing 7
Landes 7
Bioscience 7
(i.p.) 7
Irradiation 7
HRPC. 7
(HRPC) 7
2+, 7
213Bi-Herceptin 7
MTS 7
parental, 7
individually. 7
CDK2 7
(LTR) 7
MLL-AF9 7
(Oct4, 7
Takahashi 7
VEGFR2 7
Sendai 7
transgene-free 7
disadvantages, 7
GCTs 7
silenced. 7
(EBs) 7
(SVZ) 7
15.4%, 7
teams. 7
knowledge-based 7
Kyoto 7
homologues. 7
milestones. 7
protein-level 7
capture, 7
reversal, 7
list. 7
pannexin1 7
pannexins 7
localizations, 7
Vibrio 7
teleosts. 7
POLG-related 7
cosegregation 7
inhibitors). 7
conduction, 7
incredible 7
reinfarction 7
exertional 7
ivabradine, 7
postinfarction 7
beta-blocker, 7
mg/kg/day), 7
prognoses. 7
toxicosis. 7
classic, 7
Israel. 7
striking. 7
Connections 7
'writing' 7
(pre-mRNA) 7
FOS 7
parallel. 7
teenage 7
musculature. 7
nomenclature. 7
9.6% 7
MethyLight 7
proteins' 7
32%. 7
hastened 7
Ca2+, 7
deletional 7
23%, 7
Spontaneously 7
doubly 7
additives 7
betaine 7
dilution, 7
filtration. 7
TRH-induced 7
carboxylic 7
B6 7
Adelaide 7
Island, 7
(2.9 7
tails, 7
K8, 7
side-by-side, 7
GCN5 7
acetamide 7
acetyl-CoA 7
male), 7
myotomy 7
2-16; 7
ileo-colonoscopy. 7
(affected 7
(one). 7
(0-3) 7
(age: 7
disaccharide 7
(percutaneous 7
uncontrolled. 7
(IL-1β), 7
transcription-3 7
kazal 7
(TLR4) 7
thermosensitivity 7
1/2. 7
DHA 7
preadministration 7
mirroring 7
synergized 7
(IRF-1) 7
kinases) 7
382 7
>99% 7
JNKs, 7
substrate's 7
Pipeline 7
TAILS 7
peptidic 7
phagocytosis, 7
MS2 7
meninges 7
chromothripsis. 7
(p.Trp535Leu) 7
AKT1, 7
hemispheres. 7
Antiepileptic 7
usefully 7
stiripentol 7
protein-1) 7
(LCM) 7
nervous, 7
MES 7
rotorod 7
pentylenetetrazol 7
NMDA-induced 7
EWS-FLI-1 7
FLI1. 7
nonrelated 7
(EWS) 7
ES, 7
first-in-human, 7
EWS-ETS 7
TC32 7
drawbacks, 7
C5a. 7
infusions, 7
atypical. 7
ml/kg 7
Anthropometric 7
AgRP 7
weigh 7
afternoon 7
SIE 7
0.018) 7
(energy 7
GH, 7
21.1 7
expended 7
(450 7
PP) 7
8); 7
lifestyle-related 7
Mv1Lu 7
downstream. 7
Requirement 7
DYNLRB1 7
(AIS). 7
.005), 7
colostomy 7
distension, 7
gastroenterological 7
viscera 7
Uterine 7
laparotomy. 7
Endometriosis, 7
Perceived 7
tests; 7
(intraclass 7
509 7
postexercise. 7
0.33, 7
31st 7
three). 7
runners. 7
ultra-endurance 7
(passive 7
enthusiastic 7
BNP. 7
respectively] 7
Francisco 7
1.64; 7
updated, 7
1.34 7
Exposures 7
hypothesis; 7
enhancement, 7
themes 7
outcomes) 7
11-month 7
informational 7
NUP98, 7
Looking 7
paradigmatic 7
respects 7
isolate, 7
Lp(a), 7
001). 7
Low-density 7
anti-PCSK9 7
Administration's 7
hypercholesterolemia: 7
enroll 7
Lipoprotein 7
monthly, 7
[9%] 7
proposition 7
gone 7
mg/dl) 7
(51%) 7
hypoxia-upregulated 7
T-UCRs, 7
'hypoxia-induced 7
transcripts' 7
(HINCUTs), 7
Co-option 7
elements'. 7
samples: 7
uc.43, 7
uc.73, 7
uc.134, 7
uc.230, 7
uc.339, 7
uc.399 7
0.0139) 7
0.0325) 7
0.0315). 7
0.0183), 7
(UCRs) 7
DNA-independent 7
thymine. 7
byproduct 7
north 7
mesna 7
avidin-biotin 7
N-CAM 7
purportedly 7
ES/pPNET 7
genetical 7
pathway-activated 7
iterations. 7
NCT01327053. 7
13·9 7
10·1-17·3). 7
(36%, 7
24-50) 7
25-43) 7
(43%, 7
28-59) 7
2-45) 7
28-48) 7
(17%, 7
5-39) 7
[60%] 7
[36%]) 7
[5%]). 7
Corporation. 7
dysgeusia, 7
(weekly, 7
6-7 7
(36.4 7
4.49 7
1.93 7
CHK1 7
uncorrected, 7
(HU) 7
postreplication 7
terminators. 7
(G4) 7
RNA.DNA 7
(Ig) 7
AIP-negative 7
2-3% 7
prolactinomas, 7
young-onset 7
revise 7
two-generation 7
unaccompanied 7
cTnC, 7
Defined 7
E134D 7
cTnI. 7
RCM, 7
E134D, 7
C84Y, 7
lattice 7
Cardiomyopathy 7
Ca(2+)-sensitivity 7
(2001) 7
Abbott 7
W, 7
(CV 7
59) 7
points). 7
supposedly 7
'correct' 7
located, 7
pack-year 7
Cessation 7
prophase, 7
H3K4me2, 7
timepoints 7
IP, 7
chromocenters. 7
chromatin-dependent 7
SUMO-1, 7
Raf1 7
GV 7
354 7
GV1001. 7
retained. 7
Messenger 7
(reviewed 7
(coding 7
nonstimulated 7
CT26 7
immunoregulation 7
c-Src, 7
(shRNAs) 7
signalings 7
(HGF/SF) 7
MKN74 7
(PI3-K) 7
transiently. 7
Exp. 7
admissions, 7
antivirals, 7
Pandemic 7
outbreak, 7
vaccination) 7
reactogenicity 7
AS03-adjuvanted 7
(8.1%) 7
P<0.0001), 7
0.87; 7
Apgar 7
decidual 7
1.21; 7
Deaths 7
(0.9%) 7
infant: 7
symptom-onset 7
Brain-Lung-Thyroid 7
case-finding 7
BLTS 7
[c.890_896del 7
(p.Ala327Glyfs*52)] 7
allaying 7
deletions) 7
syndrome' 7
ABCA3, 7
desquamative 7
unreported. 7
(29.8 7
Histopathologic 7
(18, 7
0.01% 7
cAMP/PKA 7
phosphoprotein. 7
(CCA), 7
RIalpha 7
(110 7
off‑target 7
CSC. 7
oligonucleotides. 7
neurospheres 7
AIDS, 7
IL-22, 7
(IL)-4 7
(Th2)-mediated 7
15.1% 7
microliter 7
0.08; 7
Eighty-four 7
trauma-induced 7
6-month-old 7
5q-trisomy 7
NELL-1, 7
Runx2. 7
Saos2 7
Ocn 7
RECQL4 7
Crouzon, 7
FGFR2. 7
PKCalpha 7
gene]. 7
grandfather 7
thimble-like 7
clinicogenetic 7
tumourigenesis 7
(CDKs) 7
10.2 7
26.1 7
9-cM 7
vascularis 7
deaf-mutism. 7
allied 7
Enlarged 7
EVA. 7
Papillary 7
thyroidectomy. 7
Enlargement 7
deamidated 7
maximizes 7
precious 7
(FASP), 7
proteomes, 7
ERF 7
subgroups: 7
self-reports 7
ns). 7
attempt. 7
2,200 7
cubic 7
coordinates. 7
design; 7
JASPAR, 7
meta-database 7
CORE--an 7
FAM--a 7
phyloFACTS--a 7
Dermatitis. 7
Olmsted 7
genodermatoses, 7
IFAP/BRESHECK 7
(photophobia, 7
grandmother 7
Males 7
thromboelastography, 7
(3.7%) 7
P2Y12, 7
(ischemic 7
21-63.8 7
6.8-51.2 7
zonisamide 7
(RT). 7
RPA) 7
RT; 7
(P=.057; 7
1.17), 7
(30.5%) 7
(23.4%) 7
0.49-0.93). 7
TMZ-based 7
waste. 7
inputs. 7
lysosome-related 7
nutrient-rich 7
(HIF-1α) 7
EB, 7
CLEAR 7
gemfibrozil 7
endolysosomal 7
ampicillin, 7
SYBR 7
lysing 7
muraymycins, 7
substituent 7
antibiotic. 7
mersacidin: 7
mechanism? 7
Y-85,54728 7
Jani, 7
tunicamycin-treated 7
teichoic 7
diacetyl-L-Lys-D-Ala-D-Ala, 7
Ramoplanin, 7
lipoglycopeptide 7
Transcriptomic 7
Erythromycin 7
(HRQOL) 7
break. 7
B3, 7
c-Kit, 7
13). 7
booklet 7
tiredness. 7
14%. 7
[Comparison 7
metastases]. 7
deteriorated. 7
myalgia. 7
preplanned 7
proteins), 7
PIBIDS 7
appreciate 7
osteosclerosis, 7
AHR, 7
indoleamine 7
MyD88-dependent 7
fibroblasts: 7
CXCL10, 7
myofibroblasts, 7
FLS. 7
MCI. 7
(extraversion, 7
neuroticism, 7
Model. 7
sentences 7
Extraversion, 7
aging-associated 7
AACD 7
MPT 7
ie 7
traffic, 7
626 7
transplantation; 7
trialled 7
(142 7
0.84; 7
1.23; 7
algorithms: 7
(June 7
quasi-RCTs 7
2.97 7
1.65, 7
mis-sense 7
DA. 7
cytology. 7
rhabdomyosarcomas, 7
(RT-PCR)-based 7
21q22. 7
(= 7
beta2-microglobulin 7
rosettes. 7
myxoid 7
cohesin-non-CTCF 7
enhancer-markers 7
haploinsufficient 7
Nonallelic 7
(HepG2), 7
re-entry 7
(RNAPII). 7
H3K9ac 7
metaphase. 7
I-hypersensitive 7
(ORF71) 7
Rad21-CTCF 7
~60 7
plasmid-borne 7
Hypothesis 7
instabilities 7
disarray, 7
Microscopically 7
(RSTS). 7
impressions 7
Aire. 7
toti- 7
Deaf1 7
ribonucleoside-enhanced 7
Crosslinking 7
Cross-linking 7
31.5 7
encountered, 7
460 7
10-m 7
sagittal, 7
ARG1 7
Validity 7
Hip 7
Retrospective, 7
strike 7
Timed 7
tests) 7
administer, 7
percentage. 7
PTP 7
fertilized 7
predicted, 7
unavailable 7
P-like 7
3C-seq 7
Plans 7
opinion. 7
RNA-containing 7
gain-of-toxic 7
Ubiquilin 7
(RBP) 7
NMJ 7
TDP-43-dependent 7
autophagy-deficient 7
connexin43 7
liposomes. 7
factor-A 7
(TGF)-beta 7
Infarct 7
happiness, 7
marital 7
cM. 7
variance-covariance 7
influences, 7
moderated 7
50-mg 7
hepatically 7
intervals) 7
5-fold. 7
Sulphation 7
opicapone-induced 7
M6P-dependent 7
desorption/ionization-time 7
(MS/MS) 7
Acp2 7
Acp5 7
fused, 7
infectant 7
notorious 7
mazei 7
peak. 7
halophilic 7
marismortui 7
biased, 7
kb), 7
Archaeal 7
adnexal 7
MFT. 7
spiradenomas. 7
assayed. 7
MFT, 7
histories, 7
lymph-node 7
molecular-genetic 7
undetected. 7
TRPV4, 7
conversions 7
course; 7
choriocarcinoma 7
GluA1 7
CaM-kinase 7
neurons; 7
PKC, 7
plasmodium 7
thapsigargin, 7
thapsigargin-induced 7
A23187 7
(EADs) 7
10/11 7
pRB 7
0.15, 7
beta-subunits 7
(Chk2Delta4 7
Chk2del(2-3)) 7
Chk2Delta11 7
Chk2isoI 7
endpoints, 7
imbalanced 7
novel: 7
Enteroviruses 7
cardiomyopathy]. 7
Enterovirus 7
Resonance 7
CCM. 7
CCM1, 7
stereotypic 7
employee 7
Krev 7
spindle. 7
VI. 7
hypermetabolism 7
diiodothyropropionic 7
Hypertrophy 7
P<0.05, 7
rate; 7
I/R. 7
diastole, 7
44.5 7
obliterated 7
scintigraphic 7
cauda 7
equina 7
cyst). 7
Lipinski's 7
saxagliptin) 7
enterohepatic 7
"vildagliptin", 7
"sitagliptin", 7
"saxagliptin", 7
"alogliptin", 7
"linagliptin", 7
"dutogliptin" 7
(MH-OR: 7
(166 7
-4.0 7
69.6% 7
'linagliptin' 7
0.98, 7
patents. 7
59%). 7
zeta-associated 7
Krebs 7
axes 7
wakefulness, 7
neurochemistry 7
zolpidem, 7
unconscious 7
state: 7
Coma/Near-Coma 7
slopes 7
emergence, 7
(MCS) 7
(MMP-3) 7
(CHF) 7
LDGs 7
zinc-dependent 7
zinc-binding 7
hazardous 7
warm-blooded 7
F) 7
(BTX) 7
strabismus. 7
deadliest 7
acetylcholine. 7
Spermidine 7
spermidine, 7
(α-Syn) 7
leukodystrophy, 7
French-Canadian 7
autopsied 7
Pleiohomeotic 7
(Pho), 7
cytosine-5 7
methyltransferases: 7
C5-MTases 7
Faithful 7
tobacco, 7
Dnmt3 7
N-terminus. 7
Overlapping 7
missegregation, 7
CAAT 7
boxes, 7
autoantigen. 7
Kinetochores 7
groove. 7
Parenteral 7
lysine-9 7
androgens. 7
motifs) 7
vertebrate. 7
pseudogenes, 7
MYST 7
gondii. 7
antiprotozoal 7
Clr7 7
MAF1 7
Fv 7
Tbx21 7
Chd4 7
CHD4. 7
pp32r1Y140H 7
antisilencing 7
N., 7
NlMof 7
759 7
H3K4, 7
(ART) 7
hydrogen-bonding 7
Centromeric 7
sunflower 7
L.), 7
antagonistically 7
nucleoplasm, 7
HOS 7
diagnose, 7
Pc 7
self-associates 7
Chromator 7
NTD 7
collaborates 7
GLP 7
(H1) 7
directionally 7
broadband 7
Smooth 7
chromobox 7
Repressed 7
(TSG) 7
MTT, 7
(GFP). 7
exons) 7
ATPases, 7
eukaryota. 7
non-vertebrate 7
2015: 7
KaryoView 7
MatrixView 7
(KaryoView 7
MatrixView) 7
(PhyloView 7
AlignView) 7
menu. 7
dofetilide 7
sotalol, 7
Warfarin, 7
propagation. 7
endocrinologists 7
beta-blocking 7
multidetector 7
81.8% 7
(VF) 7
Tick-borne 7
(AMPH) 7
AMPH 7
dextroamphetamine 7
(d-AMPH) 7
d-AMPH. 7
AMPHs 7
OCT1 7
TIEG-1 7
dibutyryl 7
alpha). 7
ng/ml. 7
MW 7
CsA, 7
Mfn1 7
Submitochondrial 7
density-gradient 7
93-kDa 7
cyanide 7
digitonin 7
marker) 7
HSL 7
hFis1 7
Mgm1/OPA1 7
Prospective, 7
symptomatically 7
Attenuation 7
pyrimethamine 7
excitotoxic 7
0%. 7
antioxidants, 7
calculations. 7
semi-synthetic 7
PAM50, 7
(ER+), 7
479 7
availed 7
rationalisation 7
estrogen-receptor-positive 7
CD68, 7
(P<0.05 7
exercises, 7
RIA 7
12%), 7
seasons 7
exonucleases, 7
circularize 7
(MAOA), 7
SP-1 7
MAOA, 7
methylation) 7
MAOA's 7
4,4 7
Arg14-deletion 7
Na/K-ATPase. 7
WT-PLN), 7
hypertensive, 7
T-G 7
late-onset, 7
superinhibitory 7
(HEK) 7
costing 7
supplements. 7
g/kg) 7
max. 7
y; 7
catalase. 7
does. 7
thiobarbituric 7
IL-10) 7
(CK) 7
(placebo 7
Coenzyme 7
status), 7
athletes: 7
fatty-acid 7
(groups 7
ARS 7
(G526R) 7
GlyRS. 7
glycyl-adenylate, 7
diffracts 7
GlyRSs, 7
terminals, 7
acids; 7
inconsistent, 7
transform, 7
tedious 7
ZNF217. 7
larvae, 7
(15)N 7
premeiotic 7
H4K16 7
demethylases. 7
dimethylation, 7
accurately. 7
(K4) 7
leukoplakia, 7
leukoplakia. 7
Age-associated 7
Congenita 7
aspirate 7
Graft 7
citation 7
(57% 7
synergy, 7
LV/BW, 7
Ⅰ, 7
Ⅲ 7
reoxygenation 7
apoptosis), 7
(PDCD4), 7
BRCT 7
BARD1 7
(BRCA1) 7
regeneration: 7
facility 7
(63% 7
(TNF-α 7
LRPPRC 7
IIM 7
infiltrations 7
(confirmed 7
double-membrane 7
SQSTM1 7
extensively. 7
medications: 7
10(-11) 7
(CMAH) 7
human-like 7
(Xarelto), 7
(Eliquis) 7
postponed 7
thrombogenic 7
anti-IIa 7
(Pradaxa®), 7
(Xarelto®) 7
Edoxaban 7
fibrillation? 7
anticoagulants]. 7
1990s 7
Opposing 7
phosphoenolpyruvate: 7
Dimers 7
inter-molecular 7
/bicarbonate 7
/bicarbonate, 7
host-associated 7
(atxA) 7
CO2/bicarbonate, 7
signals: 7
RNA-deficient 7
sigma(70)-RNA 7
RNA-regulated 7
sigma(S)-dependent 7
sigma(70) 7
sigma(S) 7
-containing 7
in-line 7
charge, 7
non-autonomous 7
BM-destructive 7
submucosa, 7
hindgut. 7
mapped. 7
(66.7%) 7
nevi, 7
(EDNRB, 7
breakage. 7
xeroderma 7
anti-proteasome 7
relapsed-refractory 7
cavin 7
reconstructing 7
cholesterol-rich 7
doesn't 7
(MCA) 7
vasodilators 7
Coat 7
caveolin-1. 7
Establishing 7
bound, 7
immobile 7
Provided 7
ncRNA. 7
time) 7
bands, 7
"open" 7
20-25 7
brain-dead 7
ferret 7
abbreviation 7
TRIM5α-mediated 7
(CR). 7
PRY 7
Tripartite 7
tubulovesicular 7
canalicular 7
gonads. 7
(FMF), 7
TRIM5 7
spawned 7
receptors), 7
defence. 7
defend 7
"guilt 7
(http://www.igs.cnrs-mrs.fr/FusionDB/) 7
Link 7
stochastic, 7
solubility, 7
labor. 7
right-handed 7
escapes 7
polyubiquitin. 7
oncoproteins. 7
EVI1 7
MLN9708 7
routes, 7
schedule, 7
maximum-tolerated 7
1.45 7
markers) 7
Elg1 7
TOF1, 7
phase-mediated 7
(Sgs1) 7
(Top3) 7
RecQ-mediated 7
(Rmi1) 7
CCAAT 7
DR5 7
blasts. 7
H2AFX 7
Prespecified 7
joining. 7
evaluable. 7
24.6 7
50.0% 7
piperlongumine 7
Act 7
NIH. 7
TRα1. 7
(RTH) 7
RTH. 7
Rho-associated 7
UCC 7
Orai3 7
renoprotection 7
tubule. 7
Rationale, 7
low-potency 7
disposal. 7
both), 7
686 7
0.05); 7
11.6, 7
transplantation). 7
fT3/fT4 7
hypertrophic, 7
KIAA1530 7
untranscribed 7
(P-TEFb) 7
accomplishes 7
UV61 7
CPD 7
remarkably, 7
(HGF), 7
G-CSF. 7
Welfare 7
disappear 7
Smith-Magenis 7
eccentric 7
log(10) 7
non-insulin-dependent 7
U12 7
Staphylococcal 7
dialyzed 7
pastoris. 7
(IgG) 7
Theoretical 7
IgM, 7
upto 7
moist 7
Biopsies 7
zero. 7
unclear; 7
pericardium, 7
Peutz-Jeghers 7
(APC). 7
Tokyo 7
pneumothorax. 7
preneoplastic 7
Striking 7
microm, 7
oppose 7
axilla 7
epirubicin-based 7
5FU 7
Anthracyclines 7
ondansetron 7
82%, 7
cost-benefit 7
64%; 7
(Roche 7
Medica 7
50); 7
haemodynamics 7
beta-adrenoceptors 7
imprecision 7
query-based 7
Sag 7
sulfamate 7
tight-binding 7
(volume 7
neddylation. 7
CRL-mediated 7
EFS 7
NF-kappaB-dependent 7
CDT1, 7
W. 7
(2010) 7
shuts 7
Bethesda 7
be, 7
chest. 7
encourages 7
stratification, 7
DX. 7
JNK3 7
8]. 7
(GPCR) 7
(PMA) 7
PMA 7
Query 7
Kabat 7
376 7
catalogs 7
post-stroke. 7
1.38, 7
falling. 7
0.85, 7
0.93; 7
349 7
shoe 7
programmes, 7
frail 7
Coast 7
facilities, 7
7-month 7
facilities. 7
nurse. 7
antibiotic-resistant 7
frailty, 7
2.26 7
41%, 7
physician-rated 7
sub-optimal 7
Jarid2, 7
Il22, 7
Il10, 7
Il9, 7
Atf3. 7
genitalia 7
(1.4%) 7
FGFR2b-signaling 7
thoraco-omphalopagus 7
Clindamycin 7
acid). 7
cohort) 7
germs 7
sensitivity) 7
1953. 7
woman: 7
0.1-1 7
(isotretinoin, 7
opacities 7
oral-nasal 7
retinoid-treated 7
trans-RA 7
(cis 7
mandible, 7
teratogenesis 7
cephalic 7
restraining 7
cis-imidazoline 7
RPL6, 7
blueprint 7
5.99.1.3) 7
kd 7
congener 7
(SAEs). 7
6-position 7
I-induced 7
(EAD) 7
intercalators, 7
amiloride, 7
intercalators. 7
amiloride. 7
Quinoline 7
poison. 7
rests 7
4-h 7
amsacrine) 7
(A. 7
miR-143 7
HSV, 7
SK 7
mis-splicing 7
(PSP) 7
4R-tau 7
(miR-22, 7
miR-29c, 7
miR-138, 7
miR-218, 7
miR-344, 7
miR-674*) 7
12-month-old 7
IHCs 7
HEK(GLT1) 7
GltPh. 7
EAATs 7
Li(+) 7
(GABA) 7
5-HT4(a)R 7
endosome. 7
non-existent 7
Stains-All 7
0.5-1 7
thrombin-induced 7
First-in-human 7
brief, 7
thioaptamers 7
R12-2, 7
liposome-based 7
AMD 7
multi-centre, 7
neovascularisation 7
phenotyping. 7
soil. 7
cultivars 7
chive 7
Enzymes 7
scrutinize 7
binders, 7
corrections. 7
masses, 7
Considered 7
cerebella 7
Medulloblastomas 7
Erk1/2 7
zones, 7
FHOD1, 7
ensues 7
Twist, 7
club-ended 7
filopodia, 7
dbSNP, 7
passengers 7
MCC, 7
623 7
Super-resolution 7
nucleoids, 7
thyrocytes. 7
prednisone) 7
Prednisone 7
n=10). 7
GLU 7
nonhealing 7
RAI 7
(34% 7
Europeans, 7
Ca(2+)-ATPase. 7
T3), 7
beta-MyHC, 7
TCE. 7
occasionally, 7
capacitance 7
I(f)-channel 7
(4.2 7
(ESRD). 7
IGF-1. 7
ESRD. 7
malnutrition, 7
'lower' 7
0.034 7
predictor, 7
(2.6 7
Cox's 7
systemic, 7
lingual, 7
misinterpreted 7
Triple-negative 7
Mage-A4 7
PU-H71 7
G(2)-M 7
calreticulin, 7
triple-negative, 7
IDH2 7
angiomyolipomas. 7
Complex, 7
TSC2-deficient 7
interstitium. 7
F7 7
1b-2 7
0.85; 7
(ADCC) 7
2-fold. 7
XDR-TB. 7
Affiliated 7
1.65 7
plaque. 7
Org 7
10172 7
atherothrombosis, 7
cardioembolism, 7
0.926, 7
C/T 7
epidemiologically 7
pathogenetically 7
U/ml 7
non-vascular 7
1.55, 7
infection]. 7
p=0.001) 7
intelligibility. 7
integrally 7
intelligibility 7
intonation 7
Acoustic 7
speaking 7
sentence 7
voice, 7
recordings, 7
terminal, 7
Neuron 7
components) 7
Algorithm 7
Forkhead-box 7
(FoxO) 7
disables 7
Nissen 7
airways, 7
(Torax 7
standardized, 7
west 7
transform. 7
galactosialidosis, 7
beta-galactosidase. 7
(DDMS). 7
craniocerebral 7
sinuses, 7
parieto-occipital 7
Capillary 7
paresis 7
Positron 7
orbit 7
cleft, 7
(BTHS) 7
(BTHS), 7
weakly. 7
carbonylation 7
trifunctional 7
intermittently 7
cdc2, 7
β-catenin, 7
(H3K36me), 7
co-immunoprecipitation. 7
acceptors 7
CK1. 7
serine. 7
(1991) 7
2-3) 7
1.38; 7
end-of-study 7
warfarin: 7
0.76). 7
Digoxin 7
(88% 7
easy. 7
superposition 7
discoideum, 7
slime 7
reliability. 7
detoxification, 7
2.6% 7
uncharacterized, 7
kg/m(2)) 7
FNAC 7
burgeoning 7
true, 7
macroH2A, 7
(HP1), 7
(Barr 7
lampbrush 7
Xs 7
blue. 7
'omics' 7
methionine, 7
88%. 7
unlabelled 7
species: 7
Hybrid 7
Concurrently, 7
non-polar 7
quantitation. 7
0.20). 7
77, 7
(2.3%) 7
Squibb; 7
ximelagatran, 7
dabigatran; 7
(0.75, 7
GC/MS-based 7
Succinate 7
alveolar-epithelial 7
inflammation; 7
anti-hepcidin 7
iron-restricted 7
Retroviridae, 7
Flaviviruses 7
2-3. 7
polyprotein 7
HCV, 7
HCV. 7
cigarettes; 7
VLNC 7
seven-day 7
Product 7
party 7
(GCS), 7
criticized 7
(ICC). 7
comatose. 7
0.98). 7
off-the-shelf 7
Young's 7
Additive 7
non-biological 7
physics 7
splints, 7
print 7
construction. 7
-0.43 7
nonestrogen 7
toremifene, 7
modulator) 7
models; 7
well-suited 7
educating 7
Choice 7
Millions 7
index), 7
(vaginal 7
(IRLSSG) 7
oxycodone 7
centred 7
use). 7
flexible-dose 7
alpha-expansin 7
(Cucumis 7
accommodation 7
amphibians, 7
(TALENs), 7
nuclease-mediated 7
CGD 7
hypochondroplasia 7
CALM1, 7
untimely 7
long-established 7
common) 7
Rescue 7
(14%), 7
-40 7
LES. 7
(plasma 7
Myasthenic 7
31). 7
consultation, 7
SOX1 7
checklist, 7
0.94, 7
polymyxin 7
somewhere 7
bridges. 7
operons. 7
coelicolor 7
epidermidis, 7
type-A 7
Obviously, 7
cataracts-facial 7
MIM: 7
CTDP1 7
Serbia, 7
Romania. 7
electrophysiologically. 7
surrounds 7
Medallists 7
0.15) 7
Aspects 7
endings 7
SETMAR) 7
dsDNA 7
Metnase, 7
DSB. 7
1,500 7
P388 7
bax 7
immortalize 7
immortalization, 7
pro-inflammatory, 7
SSBs 7
transgenically 7
morphology; 7
double-null 7
recur, 7
HbVar, 7
http://globin.cse.psu.edu. 7
Huisman 7
"all 7
professor 7
(Genome 7
TFA 7
Yap 7
straight 7
PP2C 7
DAD 7
eviction. 7
binder 7
roadblock 7
GLI-Krüppel 7
(3'-UTR) 7
(rs75932628-T) 7
(TREM2), 7
Iceland 7
2.92; 7
2.90; 7
Plasmids 7
delta-distance 7
Representation 7
thermophilic 7
protists. 7
diagonal 7
depicts 7
assuring 7
tremendously 7
III: 7
four-generation 7
marriage 7
Mut 7
Cardiomyopathies 7
(MYH7), 7
MYH7-associated 7
NCI-H520, 7
CD133+ 7
complex-dependent 7
(PRC2). 7
nucleophosmin 7
ESS. 7
recombined 7
Biglycan 7
Impressive 7
27.3% 7
coarctation 7
570 7
244 7
(3.5 7
alimentary 7
Republic, 7
Particles 7
monophosphorylated 7
CPEB1, 7
(PV) 7
scaffolding, 7
relocalize 7
Inulin 7
Z. 7
pressurized 7
GF3 7
(40, 7
sucrose, 7
kcal/mol, 7
oligosaccharides 7
friction 7
TandemHeart 7
(PARK2) 7
(LRRK2) 7
Parkin, 7
parkin, 7
Parkin-mediated 7
reverse-mode 7
Ranolazine, 7
μM; 7
(INa) 7
INa, 7
fully, 7
ischaemia, 7
11.3% 7
Stroma 7
informatics 7
drug-resistance 7
(ATP 7
host-parasite 7
factory 7
wheel-running 7
(CML), 7
48-hour 7
KIT. 7
Lyn, 7
∼15% 7
(Ph 7
ALL) 7
incurable. 7
radically 7
First-line 7
Indication 7
ACA 7
81.8%, 7
allogenic 7
(q34;q11) 7
CMR. 7
little, 7
leukemia; 7
(Gleevec) 7
protein-tyrosine 7
RT-qPCR 7
10(9)/L 7
discoveries. 7
hydroxyurea, 7
accumulating. 7
>80% 7
evolution) 7
mobilisation 7
10%), 7
translocation) 7
periorbital 7
extramedullary 7
146) 7
6-8 7
feedback. 7
lead-in 7
hyperhidrosis 7
reference, 7
10mg 7
429 7
30. 7
hygroma 7
effusions. 7
temporal-specific 7
NimbleGen 7
cross-regulation 7
nanog 7
thioglycollate 7
F9 7
anti-lamin 7
autophagosomes, 7
quality-control 7
monitored, 7
(RNAi). 7
(CRISPR) 7
G-C 7
evolving. 7
(ANN) 7
parts. 7
equilibrated 7
trees, 7
29.3 7
Relaxation 7
transvenous 7
rightward 7
prevalences 7
(PGC-1 7
(Ago) 7
disease-circRNA 7
Circ2Traits 7
(http://gyanxet-beta.com/circdb/), 7
fatalities. 7
compounded 7
judgment 7
tachycardia/fibrillation 7
minutes; 7
166; 7
blows. 7
Canada) 7
(47% 7
demographically 7
internationally. 7
blunt, 7
hardness 7
matches. 7
16q24.1. 7
curled 7
Kelch 7
gigaxonin, 7
intracisternal 7
BTB-KELCH 7
Filament 7
Painful 7
context- 7
trafficked 7
HCC, 7
PSEN1 7
A4 7
hub, 7
fpg, 7
polB 7
dinB 7
membrane; 7
polymerizes 7
scission. 7
Dyn2 7
virion. 7
TAp73. 7
Pirh2 7
Proteasomal 7
(p=0.041). 7
DLBCL, 7
1p36.3 7
Low-affinity 7
sensed 7
salts, 7
FRE1, 7
factor-β1 7
diffusing 7
N-ras, 7
mutationally 7
puzzle 7
aminopeptidases. 7
beta-phenylethylamine, 7
antimycin 7
T4) 7
Avenue, 7
NY 7
10001, 7
interferon-β 7
alemtuzumab-treated 7
beta-1a, 7
Contrast 7
(p<0·0001). 7
serious. 7
thyroid-associated 7
Genzyme 7
Spotlight 7
immunomodulation. 7
Campath 7
1.89 7
sclerosis]. 7
spliceR: 7
interna 7
depression: 7
adaption 7
overactivation 7
intrusive 7
Compulsive 7
confirmed) 7
leukemia/lymphoma 7
stopped, 7
21- 7
reality. 7
0.048). 7
0.015) 7
(linear 7
(CAA) 7
apparent, 7
(bapineuzumab 7
solanezumab) 7
carriers), 7
midregion 7
AN1792 7
levothyroxine. 7
olds 7
1980, 7
overtreatment. 7
1977. 7
epidemiological, 7
Euro-American 7
E23 7
human-chimpanzee 7
ancestrally 7
posited 7
notoriously 7
offspring, 7
uniform. 7
1.49, 7
unconfounded, 7
Obstacles 7
mothers' 7
California. 7
reviews. 7
ZFs 7
non-muscle-invasive 7
E2A 7
deltaEF1, 7
Ets1, 7
DeltaEF1 7
cell-substrate 7
presence, 7
healthy. 7
embryology 7
Angelman, 7
IDDM 7
HS4 7
stored. 7
RLS-like 7
fatigability, 7
thermoregulation, 7
(PLMD) 7
prepulse 7
reported: 7
indentified 7
mononucleosome 7
conformationally 7
BRD7, 7
reporting. 7
Persian 7
impotence, 7
Operation 7
Three-month 7
Air 7
606 7
Syndromes 7
reasoning, 7
hypoperfusion. 7
54, 7
update, 7
mesothelioma, 7
BIBF 7
18.3% 7
life) 7
metalloproteinase-1 7
CaSR, 7
breviscapine 7
non-transgenic 7
high-glucose 7
7-15 7
occupation 7
MNCV 7
F-wave 7
referent 7
OPs. 7
imagings 7
sectional 7
workers. 7
17.4% 7
15.1 7
cadmium 7
user-friendly, 7
invalid 7
amphoterin 7
1217 7
cell-extracellular 7
CD11c 7
award 7
subspecialties. 7
faculty 7
researcher 7
rank. 7
par 7
specialties. 7
acidification, 7
Editorial 7
wear. 7
bruxism: 7
habits, 7
restorations 7
Satisfaction 7
0.062). 7
psychological, 7
meditation, 7
post-intervention, 7
melatonin. 7
DHEAS 7
0.43, 7
Programme. 7
Community 7
(HADS), 7
Continence 7
biopsy) 7
20.6%, 7
rationalise 7
with. 7
locally. 7
social-emotional 7
contractures; 7
mIU/l; 7
0.5-4 7
mIU/l) 7
(HPT) 7
hormone-insulin-like 7
calcitonin. 7
nine-fold 7
vimentin. 7
(hsFRP) 7
plasma-derived 7
85%) 7
NHSII. 7
neurotoxicity, 7
response-mediated 7
PERK 7
(PMS) 7
Luteal 7
(PMDD) 7
paroxetine. 7
continuous, 7
Lifetime 7
desire, 7
beliefs, 7
secondly 7
(F[1,13] 7
openly 7
gliosarcoma. 7
VEGF-targeted 7
Derived 7
VEGF. 7
Angiogenesis, 7
gluconate 7
VEGF-A, 7
switch. 7
cytopenia 7
begun. 7
outbreaks, 7
(hot 7
thermoregulation. 7
hypnotic. 7
mosaics. 7
placement, 7
(2006) 7
hho1Delta 7
Hho1p. 7
folded, 7
Characteristically, 7
(PARN) 7
qRT-PCR, 7
Zn2+ 7
Mn2+ 7
3'-poly(A) 7
PAM2 7
Pan2-Pan3 7
FEV1, 7
last-observation-carried-forward 7
interleukin-17A 7
ORF1 7
lifetime, 7
NF1-associated 7
phenotype: 7
499 7
GAP-related 7
proline. 7
extragenic 7
inactivated, 7
(MPM) 7
knottin 7
α5β1 7
integrin-binding 7
endothelial, 7
tumor-induced 7
chimpanzees, 7
premessenger 7
(De 7
2002; 7
BBS1 7
Retinitis 7
precursor-mRNA 7
expiry 7
noncompliance 7
Total, 7
juice. 7
fortified 7
juices 7
(TC) 7
mmol/L; 7
0.046), 7
0.60, 7
conceptions 7
Minos 7
MACS2 7
methylomes 7
MYD88 7
DCs, 7
condyloma 7
arbor 7
efficacies. 7
launch 7
profession 7
0.55% 7
Value 7
access, 7
(baseline) 7
12.7% 7
3.56 7
26.6% 7
million, 7
Gnotobiotic 7
Mucosal 7
health: 7
underdeveloped 7
D-dimer 7
Stratified 7
Max 7
allelic, 7
aplasia, 7
(cAMP 7
maximized 7
3.05, 7
uneventful. 7
leptomeninges 7
(q24; 7
In-silico 7
(aa) 7
t-butyl 7
Primitive 7
(3.6 7
intervertebral 7
portends 7
didn't 7
is. 7
ascites: 7
nts 7
believed. 7
single-copy, 7
(8-MOP), 7
1.96 7
315 7
AUTHORS' 7
Blinded 7
0.43; 7
neurosteroid 7
(Cyld(Delta 7
nonrenal 7
Scr 7
alpha-synucleinopathy 7
alpha-synuclein-positive 7
LB. 7
NFTs, 7
powerfully 7
immunonegative 7
GCIs 7
fronto-temporal 7
globose 7
bowel: 7
midtrimester 7
Echogenic 7
(12.8%) 7
EIF 7
fetalis, 7
detected; 7
informative. 7
4B 7
archetype 7
polyphosphate 7
[Severe 7
H2BK123ub1 7
angiographically 7
AICAO 7
futility. 7
PTMs, 7
(UHPLC) 7
WI-38 7
Lys-9 7
K20 7
accrue 7
oxidations 7
Gene-specific 7
torsional 7
RIM1α 7
DmSUMO-1 7
conjugates. 7
NPH 7
Trigonella 7
foenum 7
reductions, 7
ketoacidosis, 7
(improvement 7
inaccessible 7
tetrapeptide 7
PCOS, 7
adjunction 7
commenced, 7
30; 7
synaptosomes 7
nano-liquid 7
spray 7
PAGE, 7
autolysis 7
TripleTOF 7
self-cleavage 7
catalysing 7
congruence 7
Psychiatry 7
Co-occurrence 7
vulnerability. 7
(1.09-1.89)] 7
(0.87-1.24)] 7
576 7
hypereosinophilia. 7
HES. 7
EOS 7
48h 7
(IL-5) 7
spirometry 7
(IL-5). 7
GlaxoSmithKline) 7
nonpharmacological 7
(IgG1/κ) 7
(HES), 7
μg/mL. 7
(P=0.002). 7
Cincinnati 7
induration 7
lumican, 7
suum 7
Dr 7
Hermann 7
atonic 7
inefficiency 7
Epileptic 7
semiology 7
Hz. 7
atonia 7
tone. 7
epilepticus. 7
mobility; 7
MED25 7
BSCL2, 7
(HSCT) 7
pathomechanism 7
(HERG), 7
facial, 7
22-fold 7
KCNE1. 7
(SSCP) 7
(QTc 7
510 7
Auditory 7
Acral 7
excision. 7
(KS) 7
(24%). 7
few, 7
(Ki-67) 7
protective, 7
Melanin 7
(II) 7
(III) 7
post-angioplasty 7
PI3K/Akt/mTOR/p70S6K 7
hormonal, 7
anti-oxidant, 7
anticarcinogenic 7
Protocol). 7
Optikgeräte 7
keratectasia 7
scarring, 7
-4.50 7
superior, 7
eyes; 7
4.0, 7
oxcarbazepine 7
pediatrician 7
preadolescent 7
visceral, 7
calpain. 7
paradox-induced 7
Bad 7
perfusion, 7
2-day-old 7
recombinants 7
0.99, 7
559 7
necroptosis, 7
SERT. 7
dose-dependently, 7
desipramine. 7
ED(50) 7
2-phase 7
matter? 7
overestimate 7
hydroxychloroquine 7
querying. 7
'database-journal'. 7
encephalopathy) 7
(confusion, 7
cutaneous, 7
(SNFMI). 7
dorsomedial 7
priorities 7
polyphenols, 7
oftentimes 7
RNAs) 7
Roadmap 7
Hardy-Weinberg 7
Normalized 7
coumarin 7
52.9% 7
EPHX1 7
African-Americans 7
quinone 7
warfarin's 7
chorioallantoic 7
angiogenin-1 7
dapagliflozin. 7
disease- 7
Mellitus 7
kcal/mol 7
GBA, 7
chaperoning 7
subcloned 7
Restriction 7
L444P 7
Pulse-chase 7
Loading 7
6433C 7
VEGFR-2 7
(HNC). 7
21/39 7
20/39 7
(51.3%) 7
23/39 7
(58.9%) 7
(LRFS) 7
pO(2) 7
detoxify 7
MMC-induced 7
nephron 7
non-vesicular 7
THP 7
9,000 7
Myef2 7
HSC. 7
p37 7
KSKK 7
p32-induced 7
Gfi-1/1b 7
Lineage-restricted 7
IIIb 7
handwriting 7
risperidone) 7
impulsiveness, 7
risperidone. 7
antipsychotics. 7
QOL. 7
Kir2.1, 7
89%). 7
Electrophysiologic 7
regenerate. 7
failure; 7
repurposing 7
hiPSC 7
nonviral 7
RAS/MAPK 7
venous, 7
inefficient, 7
recording. 7
GOSHS 7
1981, 7
posteriorly 7
stress; 7
instability; 7
surgeries. 7
hypoventilation. 7
trichorrhexis 7
invaginata, 7
desmoglein 7
desmosome 7
LEKTI, 7
(NS). 7
grafts. 7
immunoblot. 7
missing. 7
age-at-onset 7
intravesical 7
Modifier 7
penetrated 7
insular 7
zonal 7
ureter. 7
(ICN) 7
Ligand-induced 7
mAbs. 7
Abs. 7
(HIV-1). 7
Virol. 7
MARE 7
heme. 7
30min 7
Nrf2. 7
hyperoxic 7
supershift 7
fibrosarcoma 7
megakaryocytes, 7
megakaryocytes. 7
hemin. 7
R329Q. 7
R329Q- 7
(0.022+/-0.005 7
0.005+/-0.001 7
nmol/h/ml: 7
p<0.05); 7
2:10 7
8:10, 7
GalNAcalpha1-O-Ser/Thr 7
(CH3) 7
MAC. 7
RS-124922 7
RS-118641 7
(RBT), 7
DORA 7
motions 7
OX(2)R 7
lorcaserin, 7
Suvorexant, 7
mmol/l; 7
pollakiuria 7
(1.2%) 7
multi-faceted 7
Committee. 7
SUs 7
durability, 7
calorimetry. 7
single-pill 7
Publications 7
titles 7
obesity-induced 7
hydrogen-bond 7
modelling, 7
multi-target 7
somites 7
(WGD) 7
Chorionic 7
SRY, 7
&amp; 7
95.2% 7
periinfarct 7
animals), 7
circled 7
depolarizations, 7
Coronal 7
hasten 7
traversing 7
alpha-PBN 7
co-reconstituted 7
cyclopiazonic 7
carbachol 7
eightfold 7
(SERCAs) 7
aortas. 7
downhill 7
Leukemia. 7
Hairy 7
WDR5 7
Structure-guided 7
polycomb-group 7
DZNep, 7
HMTs, 7
(PsA), 7
(trichostatin 7
non-cell 7
attributed, 7
E-box, 7
5'-regulatory 7
cardiogenesis. 7
CARP 7
Co-transfection 7
2.2-fold 7
5.5-fold 7
tissue-restricted 7
cardiac- 7
Isocitrate 7
(P=0.004). 7
1p/19q, 7
(DMARDs). 7
ACR20, 7
ACR50, 7
clinical. 7
CP690,550 7
co-administering 7
29.2% 7
TALEs 7
HBB 7
Cas9, 7
MVIIA, 7
leftward 7
nonopioid 7
bicuculline 7
mexiletine, 7
0.29, 7
analgesic, 7
IT 7
EPSCs 7
grandparents 7
FANCI. 7
19.8 7
1,373 7
FANCF 7
BRCA2*6174delT/C3069X 7
BRCA2*Q3066X/E1308X. 7
alternatives, 7
beta-glucuronidase 7
Ndr2 7
LPA 7
Rab35 7
CycD1 7
Arf6 7
GD1a 7
(BBS). 7
gene-editing 7
infarct, 7
alpha-sarcomeric 7
mammography 7
Eighty-nine 7
introduction. 7
LIM-only 7
ABAD-inhibiting 7
amyloid-beta. 7
evolution-mimicking 7
silico. 7
interactors 7
F-actin. 7
beings 7
caspase-1. 7
1]. 7
Interleukin-1beta 7
(human, 7
(depending 7
Ela2 7
serpin 7
oscillate 7
(TGFβ1) 7
(RCC), 7
exemestane 7
[23%] 7
tensor 7
radial, 7
adhesions, 7
mechanosensor 7
paxillin 7
(RyR2), 7
shortcut 7
imposition 7
cardiologists 7
exercise- 7
http://ancora.genereg.net, 7
DUX4: 7
(H3K36me3) 7
(IL-10) 7
MMP9, 7
IFNalpha. 7
Age-related 7
Antipsychotic 7
(FGA) 7
itch, 7
prick 7
clinicopathological, 7
1,973 7
(D2-40) 7
fibroinflammatory 7
ß1 7
(DMARDs) 7
TGFβ1, 7
Osteoclast-specific 7
Liver-specific 7
albuminuria, 7
podocytes, 7
cell-ECM 7
fetoprotein 7
squared 7
hyperpolarization 7
anesthetics. 7
end-plate 7
hydrolysis, 7
constituents, 7
palmitoylation, 7
TBCs 7
CCR7- 7
CXCR4-dependent 7
Elmo 7
Elmo2, 7
Dock2-binding 7
Dock2. 7
Gαi2 7
ELMO1. 7
ced-12. 7
395, 7
CED-5 7
(Dock180 7
Dock180.ELMO1 7
polyproline 7
Legionella 7
overloaded 7
K63 7
IKKalpha. 7
Immunolocalization 7
SAHA, 7
(FDR 7
p15(INK4B), 7
PCNA-binding 7
(PSTV) 7
CEV. 7
upstream, 7
(-) 7
specified. 7
Tertiary-care 7
thirty-four 7
postconceptual 7
(indel) 7
MCL. 7
(e. 7
(Syk), 7
Btk, 7
prescription, 7
AEDs. 7
stimulant 7
clefts. 7
Plague 7
RyR2s 7
sarcoplasmic/endoplasmic 7
(JTV519) 7
FKBP12.6. 7
calstabin2. 7
tachycardia-induced 7
KB 7
bromide, 7
coronary-perfused 7
(MALAT-1) 7
NCTs, 7
XIST, 7
oxantel 7
replenishment 7
26.7% 7
PABPC4, 7
E6, 7
E6. 7
H2O2-induced 7
Ward 7
T-waves 7
Pre-mRNA 7
(siRNAs), 7
interdomain 7
SR-associated 7
Langendorff-perfused 7
Ca(2+)-activated 7
Ca(2+)-calmodulin-dependent 7
nifedipine. 7
2011) 7
intelligent 7
underserved 7
(P-bodies). 7
LMKB 7
SRSF3 7
oocyte-specific 7
faint 7
EIA 7
(PA). 7
(117 7
Apple 7
noncutaneous 7
10p 7
H/RS 7
(PAR1) 7
CD99-related 7
Genetically, 7
stocks 7
(totally 7
carcinoids 7
HBA71 7
Ewing-like 7
RNA-Seq. 7
low-quality 7
estimation, 7
positives. 7
Challenges 7
cost-efficient 7
NEUMA 7
Patch 7
(caused 7
donepezil, 7
synucleinopathies 7
intends 7
James 7
amyloid. 7
T(3)-induced 7
ionophore 7
p43(-/-) 7
weight; 7
age-paired 7
photoprotective 7
variants: 7
5'-cap 7
improperly 7
(SPG17) 7
11q12-q14 7
cousin 7
0.59; 7
CheckMate 7
T-lymphocyte-associated 7
99.5% 7
(PD-L1), 7
nonsquamous 7
Invasion 7
Nude 7
c-FLIP(L) 7
(FAA 7
41. 7
SNORD115, 7
hyperphagia. 7
(array 7
Germ-line 7
Rab11a 7
Surprisingly 7
Glucocorticoids, 7
caspases. 7
extra- 7
10-50 7
consumers 7
Flushing 7
(58%, 7
indoor 7
cyclins. 7
mitoses 7
Cdc14. 7
Ras-dependent 7
MSI+ 7
5-fluorouracil-based 7
factor: 7
miR-30. 7
miR-30c 7
clinicians' 7
Bifidobacterium 7
attracts 7
clarity 7
cardiothoracic 7
smooth-muscle 7
repairs, 7
Operative 7
RSNA, 7
39) 7
Valsalva, 7
17.3 7
predators 7
inermis 7
lunaris 7
Thais 7
(DM2) 7
used: 7
form; 7
3q21 7
ZNF9. 7
myotonia 7
20%) 7
nonstatin 7
CA. 7
1.55; 7
DCI. 7
autoregulation. 7
immersed 7
shells 7
longitudinal, 7
cisterns 7
(CGI) 7
2.78, 7
administration: 7
AP-induced 7
antipsychotics, 7
2.92 7
(HAM-D) 7
mesolimbic 7
PCCB. 7
(AAV) 7
MUT 7
carboxylase, 7
12-14 7
Propionyl-CoA 7
lethargy, 7
Online. 7
threonine, 7
unremarkable 7
phosphatase-1, 7
1.3%) 7
(BFMDRS) 7
(NCT00142259). 7
-20·8 7
17·1; 7
-47·9%; 7
-26·5 7
(19·7; 7
-61·1%; 7
n=31) 7
-25·1 7
(21·3; 7
-57·8%; 7
n=32). 7
(-5·7 7
8·4]; 7
-34%) 7
(-4·3 7
[10·4]). 7
non-serious 7
XV 7
necklace, 7
stereocilia, 7
stereocilia. 7
concentrated, 7
myosin-V, 7
hair-cell 7
adaptation; 7
rootlets 7
rigidly 7
stereocilia; 7
110. 7
IκBs, 7
IkappaBalpha, 7
B/Rel 7
reservoirs. 7
Fibrillin 7
fibrillinopathies. 7
low-intensity 7
(TTField) 7
RGBM, 7
TTFields, 7
pemetrexed. 7
G2-M 7
516, 7
acetyl-specific 7
S6K2. 7
neurotensin 7
.006). 7
PTM, 7
protein/peptide 7
transporter-1. 7
SepB 7
template-primer 7
And-1/CTF4 7
alpha-primase 7
postmenopausal, 7
involvement: 7
goserelin 7
müllerian 7
peritoneal, 7
ATAC 7
(chitin 7
inhibition); 7
Chs2-V377I 7
Chs2, 7
Cdc14-dependent 7
ill-defined, 7
constriction. 7
AMR 7
nonetheless, 7
OFC 7
hypoglycemia: 7
(minichromosome 7
Tof1-Csm3 7
works. 7
leftmost 7
word. 7
reviewers. 7
5T 7
(CFTR), 7
exocrinopathy 7
300-bp 7
Alu-associated 7
nonstandard 7
500,000 7
(new 7
chaperone-like 7
CPP1 7
(PLBs) 7
photoreduction 7
chlorophyllide 7
dark. 7
(POR) 7
barley. 7
plastids. 7
oat, 7
Oat 7
lyase, 7
Locus-specific 7
(CpHpH, 7
DNA). 7
Maize 7
chromomethylases 7
CMT3, 7
knob 7
ecotype 7
demyelinating, 7
m/s 7
criteria). 7
(ARCMT) 7
Amish 7
clustered, 7
NCV, 7
ATF-2 7
homodimers 7
ATF-2/c-Jun, 7
I(Y), 7
I(Y). 7
MEME 7
unconstrained 7
<6 7
resection). 7
progression/recurrence 7
progression/recurrence-free 7
0.29). 7
Retreatment 7
postresection 7
medium-size 7
136) 7
(2%; 7
female-to-male 7
cilium, 7
divergence, 7
(100%). 7
Secretory 7
1.36; 7
PLA(2) 7
inefficacy 7
(elevated 7
risk). 7
RELEVANCE: 7
(Cmax) 7
(slope 7
τ 7
hSGLT-1. 7
classification), 7
Talocalcaneal 7
Tarsal 7
tibia. 7
FOA 7
retrusion 7
8-10% 7
(n=11) 7
789 7
(P250R)), 7
percent, 7
alternation 7
L-dopa-induced 7
authorities, 7
exam. 7
pre-, 7
3T 7
motif). 7
Etexilate 7
skin-type 7
pol-II 7
IGS1 7
cerevisiae), 7
circannual 7
CH. 7
vivid 7
αB-crystallin 7
PKCε 7
Akt2 7
thymocytes. 7
leaks 7
right, 7
ADHD, 7
Lobar 7
Nasu-Hakola 7
3.84 7
Cache 7
sAD 7
refocused 7
PSEN2 7
phosphorus, 7
.0001 7
sub-group 7
Fatty 7
AUROC 7
100.0% 7
40.0% 7
14.5% 7
Honokiol 7
norvaline. 7
SUMO-protein 7
nuclear-to-cytoplasmic 7
skNAC 7
G9a. 7
ventilator 7
"black 7
workflow, 7
bd 7
equivalent. 7
Transplant 7
sequestration, 7
ganglioside. 7
G=C 7
rates) 7
equality 7
gef 7
E-cad 7
RKO 7
PI3-K 7
p16(INK4A), 7
HSF1, 7
Hemizygous 7
Myotubular 7
tubules. 7
sisters. 7
Burst 7
env 7
LTRs 7
Env 7
intrasubtype 7
.03), 7
adipocytokines 7
intend 7
EGFR-activating 7
ODE 7
amnesia 7
anaesthesia: 7
hypercapnic 7
room. 7
Anaesthesiologica 7
sedation: 7
bispectral 7
4.55 7
476 7
(TOF) 7
postdischarge 7
sevoflurane/nitrous 7
GSDMA 7
Colony 7
Cj1516 7
leaders 7
THI1 7
serine-rich 7
(98% 7
fkh2 7
scavenging. 7
FoxO1, 7
monophosphate-activated 7
ingredients 7
Sirtuins 7
anti-GM1 7
house 7
anti-GalNAc-GD1a-positive 7
ataxia) 7
rituximab. 7
Synoviocytes 7
(CDK-2) 7
MicroRNA-146a 7
(miR) 7
MicroRNA-223 7
synovium, 7
hsa-mir-499 7
codominant 7
2.11; 7
Tregs. 7
vault. 7
(FGFRs) 7
CD44s, 7
CD44v6, 7
(20%), 7
patching 7
metastasis]. 7
ELISAs. 7
nocturia, 7
Involuntary 7
instability: 7
Tolterodine 7
void 7
urination 7
drill 7
continent 7
53%; 7
mind, 7
urgency. 7
Disease-modifying 7
CARRA 7
parsimonious 7
nonbiologic 7
DMARD. 7
5.2, 7
polyarthritis, 7
withdraw 7
15.6 7
RNGTT 7
denatured 7
motifs), 7
Psoriasin 7
S100A15 7
Koch's 7
IU/mL, 7
"low 7
(>5 7
MAYP/PSTPIP2 7
CSF-1-mediated 7
MAYP, 7
MAYP-stimulated 7
uncapping 7
morphogenesis: 7
(ribs) 7
fascin-free 7
salt, 7
Spt-Ada-Gcn5-acetyltransferase 7
(DUB) 7
TBP. 7
petite 7
homology-independent 7
PFOR2 7
sense. 7
WWW 7
eggs. 7
compromise. 7
travelers. 7
radiculopathy 7
schistosomiasis) 7
probable, 7
quantity. 7
α-tocopherol 7
quai, 7
phytoestrogens, 7
clover 7
gamolenic 7
glucosidase 7
(GAA). 7
monospecific 7
GAA. 7
emits 7
Protein), 7
Channelrhodospin-2 7
ventricular, 7
opsins 7
3-state 7
virus-mediated 7
ChR 7
16%. 7
urologists 7
Hakim's 7
cornified 7
immobilizing 7
(WG). 7
EDL 7
ATPase) 7
FLAG 7
trains 7
superinhibition 7
Thr-17 7
nigricans, 7
hypochondroplasia, 7
syndromal 7
non-invasively 7
cost-efficient, 7
Coombs 7
negatives. 7
Discordant 7
negatives 7
I-1c 7
Cardiac-specific 7
short-hairpin 7
circumflex 7
Bradykinin 7
multi-centre 7
statements 7
BVT, 7
automaticity 7
transposons' 7
palatability. 7
nontreated 7
haplo-insufficiency 7
anomalies-mental 7
[1998: 7
(ZFHX1 7
(TGGCCCC) 7
1773 7
(1773 7
delTGGCCCC) 7
604 7
(604 7
Physician 7
walk-based 7
restart, 7
GUILD 7
positives, 7
elegans), 7
Endeavour 7
Rattus 7
618 7
plug-in, 7
spatial, 7
benchmarks, 7
polycystin-2, 7
functions; 7
Neoaves 7
2030 7
deep-level 7
stochasticity 7
bats 7
Prostaglandin 7
Park, 7
diethanolamine 7
(84% 7
Raynaud's 7
Charles 7
(MGS) 7
Majewski 7
(MOPD) 7
Hematological 7
IU/kg 7
deuterated 7
mannose-6-phosphate-independent 7
epistaxis 7
Hsp90-dependent 7
scratch-wound 7
line-specific 7
MIBC 7
17-Allylamino-17-demethoxygeldanamycin 7
hypoxia-stimulated 7
clients, 7
Ink4c 7
Wnt/β-catenin, 7
MEMRI 7
(CHIP) 7
Polyubiquitination 7
Phycocyanin 7
phycoerythrin, 7
maxima 7
Obtaining 7
Rubisco 7
cpeA 7
Nostoc 7
Kinases 7
duplications/triplications 7
(PLK2), 7
synucleinopathy-diseased 7
PLK2/α-synuclein 7
intracellular, 7
Microsporidia, 7
revised. 7
Mexico. 7
propositus. 7
co-segregate 7
(rivaroxaban), 7
(VKAs) 7
Till 7
0.27 7
islets, 7
non-neural 7
ARB2 7
collagen-encoding 7
0.008 7
%/h, 7
Phobius, 7
decoding. 7
Phobius 7
(HMM) 7
LHGRs 7
Anolis 7
interdependency 7
rerio) 7
CsCl 7
uncovered, 7
HDAC6-mediated 7
anatomical, 7
(OSCC). 7
(FGFs) 7
FGFR1-4. 7
FGFR1. 7
non-EMT 7
HOC313 7
EMT-permissive 7
CDX2 7
E-cadherin/beta-catenin 7
FET3, 7
EMBO 7
iron-replete 7
Aft2, 7
279, 7
cytosolic/nuclear 7
SPR 7
Aft1-1(up) 7
callosum: 7
hypospadias, 7
flare, 7
(MR)-multiple 7
(60% 7
H3K4me1, 7
Set1/COMPASS 7
monomethyltransferase 7
SE-associated 7
('epicentres') 7
14th 7
amenorrhoea, 7
galactorrhoea 7
sixty-six 7
mismatches. 7
MUG/TDG 7
leucovorin 7
ECX. 7
weekly; 7
[including 7
oesophagogastric 7
166, 7
72000) 7
(gefitinib, 7
Stroke-Acute 7
(SAINT 7
benefit: 7
hemostasis. 7
Benefit 7
flibanserin, 7
excitement, 7
(http://www.askhermes.org/), 7
EAGLi 7
(http://eagl.unige.ch/EAGLi/), 7
HONQA 7
INDOC 7
OHSUMED 7
asphyxia 7
(high) 7
CONT 7
Texas, 7
pNFL-H 7
HIV-related 7
FL 7
27.4 7
(r(s) 7
T-tau 7
tau-positive 7
(suggesting 7
Abeta42 7
(Expanded 7
AMI-THYR, 7
(EF%) 7
(SEM, 7
AMI-THYR 7
(od) 7
(DRON), 7
(HYPO) 7
(R). 7
(alpha-MHC) 7
HYPO, 7
actinin 7
45Ca2+ 7
Ca2(+)-ATPase 7
betalain 7
osteodystrophy, 7
Collaborating 7
spasms. 7
94.8% 7
exiting 7
34.8% 7
accepting 7
nail, 7
filament. 7
HCNE/enhancer 7
laminopathies, 7
transcription-translation 7
mCry2 7
mcry1 7
rhythmicity, 7
photic 7
evening-time 7
Per1, 7
427 7
procedures). 7
26.5% 7
residencies 7
1.14, 7
SVZ 7
corpuscles 7
Dicer-like 7
Usp7 7
Reactivation 7
TIMP3. 7
Dimerization 7
dual-luciferase 7
Dnmt2 7
normoalbuminuric 7
HOMA-IR 7
hyperaemia 7
LDLr 7
domains," 7
Fish-mammal 7
anthracyclines. 7
slightly. 7
Convertase 7
23), 7
maleate 7
THX 7
101.8 7
(CgA) 7
disequilibrium, 7
pfcrt 7
OsAMT1;1 7
indica 7
PRPS1. 7
0.07) 7
639 7
Folate 7
(AREs) 7
AREs 7
(NF1). 7
HSP72 7
thermotolerance 7
TGFβ1/HuR 7
TTP-HuR 7
temporal, 7
hVSMC 7
sprouting, 7
mRNA) 7
CCI 7
(BDNF 7
postoperation. 7
polyUb, 7
polyUb 7
IP(3) 7
Pax6 7
contaminant 7
tag. 7
digoxin. 7
words: 7
(following 7
neurocardiac 7
Simulated 7
(endoplasmic 7
(P=0.02); 7
Ca-induced 7
chemotherapeutics, 7
CD146 7
PCI-24781 7
AN-9 7
pursued. 7
12-week-old 7
2000) 7
Metab 7
TCAP 7
myofibrils. 7
SLIM1 7
(T790M) 7
HCC827 7
Switch 7
(FGFR4) 7
FGFR4, 7
scissors 7
1.07-Mb 7
Fetuses 7
insulinomas, 7
photographed, 7
histologically. 7
confetti-like 7
hyperfunctioning 7
91%, 7
leiomyomas, 7
aggresome 7
pestis, 7
masse. 7
mutant's 7
Shewanella 7
CIMT 7
NS3, 7
NS5B. 7
HBsAg 7
pigmenti, 7
antiseizure 7
reception 7
encircles 7
(Shh). 7
BCAA 7
δ) 7
AZD2014 7
inhibitor-associated 7
in-stent 7
nephronophthisis. 7
(Lef1) 7
(Tcf1) 7
Collecting 7
purmorphamine 7
9-item 7
MAHVI 7
hospital; 7
66) 7
Rrm3 7
clr4, 7
Suv39h1/SUV39H1 7
non-living 7
silk 7
o-quinone 7
condense 7
encapsulating 7
(hMSCs) 7
widths 7
(stationary 7
leuC427, 7
1A1 7
stemming 7
specialists, 7
Pharmacogenomic 7
N9831 7
dihydropyridines 7
protein-rich 7
ribosome. 7
mitoribosomes 7
ribosome, 7
neurohumoral 7
Renin 7
hypertension]. 7
ASPIRE 7
(RAS) 7
wide-angle 7
eucaryotes 7
review). 7
HMG1 7
Hin-mediated 7
photosynthesis 7
Monkey 7
3.0) 7
Concentration 7
9%), 7
7%). 7
domain: 7
relax 7
0.1; 7
penetration, 7
U-105MG 7
LD50 7
haematoporphyrin 7
ferrochelatase 7
FECH 7
placement), 7
benefit; 7
2.8; 7
ventriculoperitoneal 7
1.8%, 7
months: 7
concomitant/adjuvant 7
"Stupp 7
protocol") 7
implantation; 7
(PACT), 7
(RNAi)-based 7
single-site 7
HTLV-I 7
decompression, 7
Gardner 7
vertigo. 7
expansion: 7
FAAP100-deficient 7
hallmark. 7
IIIalpha 7
(FA). 7
exemplifies 7
TIRs 7
data-driven 7
(EFS) 7
MIB-1 7
collected, 7
Laminin 7
conspicuously 7
residuals 7
fluctuating, 7
candidate, 7
microenvironmental 7
repositioned 7
subgingival 7
ml/min 7
quartile, 7
formula. 7
760 7
(ISMG) 7
juncture, 7
ISMG 7
provider, 7
T18 7
detection.With 7
counselors 7
usefulness, 7
woman), 7
DNA-NIPT 7
1982 7
services, 7
paralyses 7
point). 7
Hypokalemic 7
school-aged 7
malfunction. 7
ventriculostomy 7
Mark 7
QOL: 7
parent-child 7
Questionnaire), 7
condition's 7
Strengths 7
(Cronbach 7
person-years. 7
variance-based 7
0.002); 7
SLEDAI, 7
(MBL) 7
PSs 7
Sydney, 7
CTR 7
(13.3% 7
(reciprocally 7
should, 7
selenocysteine. 7
assumption, 7
walls, 7
focussing 7
(IL6 7
IL8, 7
Periodontal 7
Citrullinated 7
scrapie 7
slit-lamp 7
bloody 7
neglected. 7
traveling 7
misdiagnosis. 7
siRNA- 7
(TAC-FH) 7
(FH), 7
predesigned 7
(NRVCs) 7
phospho-RyR2, 7
phospho-CaMKII, 7
phospho-PLB 7
Opinions 7
sucrose-density 7
(HRC(569-852)), 7
polyglutamic 7
(HCP). 7
coenriches 7
FKBP-12, 7
sucrose-density-purified 7
I-band. 7
Ca2+) 7
Suggesting 7
triadin-CS 7
structural-functional 7
1204 7
determinate 7
(hypertension, 7
vasoconstriction. 7
Predefined 7
0.5). 7
hypervolemic 7
reserves 7
encoded. 7
3.67 7
19.5 7
Ic 7
8-34); 7
36-204)) 7
Engel's 7
seizure-free. 7
MCD, 7
MCD. 7
columnar 7
VBM 7
inspection. 7
blurring 7
FDG 7
U/kg 7
∼2% 7
tensile 7
keratins, 7
discernable 7
cytopathic 7
SSNHL 7
Greyhounds 7
APTX, 7
PRX, 7
Lamp2a 7
(CMA). 7
lamp2 7
reninangiotensin 7
(CIMP) 7
Barrow 7
Aneurysm 7
coiling. 7
FIAT 7
conventional, 7
(ISAT) 7
embolization, 7
rebleeding, 7
cataplexy 7
hypocretin 7
narcolepsy-cataplexy 7
aMCI 7
adjusted, 7
FANTOM 7
TU 7
http://fantom3.gsc.riken.jp/. 7
doublets 7
Hyperoxaluria 7
Malabsorption 7
hotspot) 7
CAN 7
budget 7
candidate-based 7
nephronophthisis-related 7
ATD. 7
ift80. 7
IFT172, 7
IFT-A. 7
(anterograde 7
ATPase/motor 7
blood-CNS 7
self-tolerance 7
laquinimod, 7
Nonidet-40 7
(NP-40) 7
(SCNT) 7
Tsix. 7
XIST. 7
PGK 7
obstacles, 7
IL 7
orthologue, 7
factories. 7
(LDK378): 7
(PRDX2), 7
Prdx2 7
peroxidase, 7
GPUs 7
GPU, 7
general-purpose 7
(CPU) 7
ng/g 7
localized, 7
(FSHD), 7
biceps 7
Microinjection 7
DUX4c 7
hypermutating 7
deaminate 7
APOBEC3B. 7
Spatio-temporal 7
μg/L 7
(Se) 7
median, 7
RA-associated 7
ACPA-positive 7
RCT, 7
(NICE) 7
Cere 7
CSD. 7
leucoencephalopathy 7
liganded 7
HI. 7
junction-specific 7
(oriC) 7
equals 7
recombination-dependent 7
Stalevo 7
tapping 7
AIMS 7
453 7
'wearing 7
obviating 7
Keratins 7
SSH 7
TT3 7
nadolol 7
Reproducible 7
spontaneously, 7
geometry. 7
Hit 7
indole 7
PDE-5 7
type-5 7
selenium-dependent 7
10.1% 7
thyroid-specific 7
selenocysteine-containing 7
selenium-deficient 7
echostructure 7
"selenostasis" 7
MTND6 7
MTND6*LDYT14459A 7
Ni-phenanthroline 7
outweighed 7
withheld 7
leflunomide, 7
believed, 7
tags-DeepCAGE: 7
ultra-high-throughput 7
co-primary 7
Africa: 7
558 7
Initiative. 7
culmination 7
(p<0·0001) 7
bacteraemia 7
clinicians. 7
Sub-Saharan 7
p=0·0001) 7
inelastic 7
tunnelling 7
(Algorithm 7
Segmentation 7
one-cell-stage 7
standardizes 7
connectivity. 7
BETAWARE: 7
proteins--a 7
TMBHMM: 7
siderophores, 7
TMBHMM, 7
TMBETAPRED-RBF 7
(K-NN) 7
http://yanbioinformatics.cs.usu.edu:8080/TMBKNNsubmit. 7
Lempel-Ziv 7
TBBPred, 7
profile-based 7
673 7
visualized. 7
ascidian 7
anomaly-mental 7
acidergic 7
FDC 7
utilises 7
overdoses. 7
disseminating 7
<20 7
skillful 7
HCF-1 7
nth 7
ischemic-reperfusion-induced 7
stabilizer, 7
VAs 7
Na+-dependent 7
(APD). 7
I(Kr) 7
transducin-like 7
APC. 7
cancer-1 7
miR-224 7
stimulate, 7
Rag-, 7
Ragulator-, 7
P-loop 7
dominating 7
DBS, 7
d4 7
generalization. 7
culturally 7
lubag. 7
Rodamine 7
(MMP). 7
Apoptosis-inducing 7
colorimetry. 7
μmol/L. 7
caspase-activated 7
mmHg) 7
Sclerosis) 7
AZ 7
1946), 7
Departments 7
0.012). 7
65.2% 7
2.1% 7
depression; 7
Catheter 7
cerebrovenous 7
endeavors 7
15.6% 7
MS-related 7
reluctance 7
(gfi) 7
(Gfi) 7
runx-1, 7
ikaros 7
cd41, 7
Gfi1b: 7
Egr1 7
knocked-down 7
Erythroid 7
Gfi-1B, 7
GATA-2 7
auto-regulation 7
transfusion-dependent 7
comeback 7
(α)-granules 7
(neurobeachin-like 7
6-thioguanine 7
bone-kidney 7
0.33; 7
rickets: 7
FADD 7
prodomain 7
(SNP), 7
superfusion 7
6.0, 7
(KB-R7943). 7
IC50s 7
pigmentosa. 7
(p>0.05). 7
cotrimoxazole 7
weak. 7
retrieved, 7
1.05, 7
458 7
irrespectively 7
neuromodulatory 7
agouti-related 7
GAL 7
(LoF) 7
completely, 7
β-arrestin 7
Ldb1 7
BAs 7
cholangiocytes 7
HrLXR 7
steatosis. 7
SWR1, 7
reanalyzing 7
PCs. 7
cGy 7
eukaryote. 7
Lab 7
PSG. 7
wondering 7
utlraconserved 7
'winner-takes-all' 7
4351 7
(UGRBs). 7
Ca(V)1.2-LQT8 7
Alx4 7
redundancy. 7
cranium. 7
taxonomy. 7
bifid 7
EcTI 7
Cortactin 7
catenation 7
kilobases. 7
PMO 7
UHPLC 7
485 7
resin. 7
Angelman-like 7
obviate 7
stereotypical 7
(24%), 7
(BS), 7
WRN 7
by. 7
endemic, 7
99.9% 7
VOCs, 7
desorption, 7
Kovats 7
curve), 7
sensitivity=71.2%, 7
72%. 7
13[C]-urea 7
CW 7
pylori-positive 7
article: 7
Fd(late) 7
batimastat. 7
batimastat 7
intrathoracic 7
abnormalities) 7
(90%). 7
(GDM) 7
VDR 7
(25(OH)D 7
investment 7
1-mg/mL 7
81.1% 7
reappraisal 7
thrombi. 7
anistreplase 7
synapse-associated 7
(KSR) 7
MEK, 7
approx. 7
detoxifying/antioxidant 7
Corto 7
KSR-1, 7
MAPK/ERK 7
p-ERK 7
RPMI8226 7
tRNA-derived 7
DNMT-1 7
procainamide, 7
BAG-1 7
Complementation 7
2.6%, 7
INK4a 7
MyoG 7
cocultures 7
adherens-junctions 7
GnT-III 7
GnT-V 7
AP2 7
chinese 7
AluYb8 7
(PSCs), 7
NeuroD1 7
MafA 7
(FBG) 7
three-gene-modified 7
quartet 7
(BIS) 7
min-1 7
dosages, 7
extubated 7
hypnotics 7
kinase-inactive 7
Counting 7
coupled, 7
attaching 7
propagation, 7
adipogenic, 7
sterility, 7
(NRO) 7
AGO3 7
germlines. 7
Neurotrophic 7
innocuous 7
arrhythmogenesis, 7
COPD: 7
MDM2-amplified, 7
liposarcoma: 7
(Peg-IFNα 7
2a), 7
Patent 7
epicanthal 7
WHO. 7
Entomological 7
flying 7
4.02 7
(YFV), 7
Asia; 7
Portugal 7
metamorphosis 7
receptor-beta 7
ventilator-associated 7
good, 7
Liver. 7
macroglobulinemia 7
PDGF-BB- 7
serum-mediated 7
JNK1/2 7
DUSP1 7
subfamilies, 7
Achieving 7
Mitogen-Activated 7
phosphatases) 7
DUSPs. 7
Technique 7
acceptable. 7
intra-observer 7
9500 7
(UEBW) 7
OBJECTIVES 7
widest 7
Ultrasonic 7
CDSs 7
CBDS 7
(HPRT). 7
teratocarcinoma 7
4-bp 7
miR181a 7
authenticated 7
Crithidia 7
cis-antisense 7
colistin 7
EUCAST 7
Outbreak 7
SOX4 7
Cypriot 7
Apical 7
paving 7
MacroH2A 7
mH2A2 7
MLV 7
macroH2As 7
reforming 7
DXZ4 7
LVW, 7
(g) 7
pseudarticulation 7
56-year-old 7
pseudarthrosis 7
vertebrae. 7
(TRα1) 7
debutyl-dronedarone 7
(DBD), 7
0.05] 7
p<0.05. 7
Cdk1, 7
Cycloheximide 7
DIM-mediated 7
alfa-2a 7
interferon-free 7
alisporivir 7
pangenotypic, 7
c-di-AMP 7
1.64, 7
hypertension) 7
dead. 7
pre-neoplastic 7
MiR-155 7
mimics. 7
miR-15b 7
miR-192, 7
Representing 7
chemoprotective 7
miR-194 7
I3C 7
I3C. 7
83) 7
.006) 7
broadly. 7
0.853 7
anti-thymocyte 7
speculative. 7
Ossificans 7
L3 7
Malgaigne-type 7
threaded 7
dislocations 7
Caudal 7
IKK-NF-kappaB 7
aggrecan 7
Mlx 7
HNF4alpha 7
28.7 7
XL647 7
MINOS1, 7
CHCHD3) 7
(mtDNA). 7
degraders 7
metabolites) 7
alpha-proteobacteria. 7
malignant. 7
post-zygotic 7
I(to), 7
TRalpha1-mediated 7
KCND2/3 7
Identifier 7
alligator 7
Sox 7
biotic 7
polyadenosine 7
stabilities 7
enhancers) 7
cell-lines, 7
http://cbrc.kaust.edu.sa/deep/. 7
GSTM3 7
Nonsustained 7
(nucleotide 7
plasmacytoma 7
respectively]. 7
p15/Ink4b 7
HPL-2. 7
excisional 7
2004), 7
45%. 7
1960 7
deliveries, 7
Calgary, 7
(MBC) 7
streptozocin 7
octanoate 7
palmoxirate 7
supertree 7
indicate, 7
distance-based 7
nonparametric 7
non-infectious 7
which. 7
[range 7
seven-cohort, 7
1,148 7
(members 7
48). 7
methylation-based 7
IL-13-induced 7
acetyltransferase, 7
ASO 7
Ume6p 7
HDACs, 7
reinduction 7
catch 7
AAs, 7
(SAHA), 7
academia 7
1-4, 7
sleep/wakefulness 7
amination 7
purging 7
napping 7
SWSD. 7
neutrophilic 7
phosphatidate 7
FADD, 7
lessened 7
PMSCs 7
DLM8 7
Na(v)1.5 7
Ca(2+)/calmodulin 7
PNDM 7
KCNJ11, 7
names, 7
twenty-seven 7
-0.1 7
(≤90 7
[(18)F]Fluorodeoxyglucose 7
Inc), 7
(LCLs) 7
RPL15 7
(DBA). 7
RPL35a, 7
indisputably 7
Skin-Cancer 7
Chemoprevention. 7
ONTRAC 7
ACTRN12612000625875.). 7
8-oxo-7,8-dihydro-2'-deoxyguanosine 7
(CPDs) 7
stridor, 7
case-finding. 7
1.00. 7
ERS 7
incubations 7
discrimination, 7
bioinorganic 7
biocalcit, 7
bio-polyphosphate 7
biosilica 7
biogenic, 7
OAC-ICH. 7
tail-vein 7
Belgium. 7
(TT) 7
reduction). 7
hemostasis, 7
either. 7
Akt-dependent 7
PFK1 7
propeptide, 7
(n=5), 7
stasis, 7
borreliosis. 7
borreliosis, 7
conclude, 7
Anaplasma, 7
California, 7
garinii. 7
2.5%. 7
(6.6 7
Rosiglitazone 7
P-glycoprotein. 7
(ET)-1 7
weekly), 7
(ACT-064992), 7
São 7
1300 7
SMILE 7
ribosyl 7
Unstained 7
(DCIS). 7
.87). 7
2.6-18.2). 7
interval0.91-0.99). 7
laser. 7
electrons 7
nanocrystals, 7
Spectrometer 7
Neu5Ac 7
17A1 7
Abiraterone 7
6-[(7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthamide, 7
CYP17A--a 7
hormones--and 7
11β-hydroxylase 7
(CYP11B1) 7
U4atac, 7
TALS 7
UCR 7
GAD65 7
autoantibody-mediated 7
(CTSR), 7
EU-funded 7
Excellence, 7
country: 7
standardised. 7
inequality 7
Transplanting 7
iMSC 7
radio-resistant 7
3:1. 7
right. 7
PJS 7
states; 7
overfitting 7
Probabilistic 7
Branch 7
fast-evolving 7
36-Item 7
Queensland 7
(response 7
Hyperthyroidism 7
explained. 7
phlebotomy. 7
Sororin, 7
UBL5 7
(CoATs) 7
Esco1/2 7
LSI 7
Zolpidem 7
effects) 7
LUX-Lung 7
death), 7
sucrose. 7
(50%, 7
0.6%) 7
gastro-intestinal 7
Ganzoni-calculated 7
isomaltoside 7
severe), 7
Least-square 7
27.77% 7
-32.57% 7
-22.97%) 7
13.89 7
10.17 7
-2.54% 7
7.06%) 7
12.50 7
12.84 7
-30.03% 7
-36.82% 7
-23.24%; 7
1.22-g/dL 7
0.57-1.88 7
6.64% 7
-11.37% 7
-1.91%; 7
.007), 7
41.06% 7
23.95%-58.17%; 7
NCT00891202. 7
g/dL), 7
Negatome 7
PEWCC 7
PROCOMOSS 7
Vote 7
SVMhmm 7
PIPE 7
PGC. 7
multi-locus 7
10(-7)). 7
nosology, 7
mania 7
(HTLV-1), 7
APOBEC3A, 7
5-methylcytosine. 7
Lac- 7
CAGEr: 7
meantime, 7
(BB), 7
thick, 7
TIMP3 7
MMPs/TIMPs 7
EZH2/miR-200c/E2F3 7
peptide-specific 7
EZH2-291 7
EZH2-735 7
(enhancer 7
5.81; 7
=.003). 7
AMPK-α2, 7
AMPK-α1. 7
telephones. 7
Interphone. 7
NMT 7
≥1640h 7
β-catenin-mediated 7
LRP6 7
Wnt/TCF 7
prohibits 7
WNT/CTNNB1 7
14-3-3zeta. 7
(GSK3beta) 7
confluence. 7
LEF/TCF-mediated 7
serum-responsive 7
B/Akt-Ser(473) 7
wortmannin, 7
PI3K/Akt/GSK3beta/beta-catenin/LEF 7
PWS/AS 7
prediabetes, 7
Asia-Pacific 7
μg/day 7
PPAR-α 7
ranges, 7
teenager 7
Parp-1 7
15-18 7
microcirculatory 7
densitometric 7
protamine-based 7
TNP1 7
TNP2 7
Tpl94D 7
Grappa-equivalent 7
coli-elicited 7
epididymo-orchitis 7
TNP1, 7
protamine-compacted 7
Andrology 7
Andrology. 7
(Gpp) 7
Gpp-D 7
methylation-defective 7
Wnt-responsive 7
demethylated. 7
chromatograph 7
self-assembled 7
11-pass 7
immunological, 7
hyodysenteriae 7
Echinococcus 7
ml, 7
Shaw 7
T12. 7
extraspinal 7
56. 7
(0.01 7
phenols 7
≥14 7
hRAD51 7
Brc1 7
TOP2A 7
Cx45 7
(n=2 7
triphosphates/diphosphates 7
sanitize 7
8-oxo-GDP. 7
A-to-C 7
mutT 7
8-oxoG 7
grim 7
Survival, 7
2.44 7
37.0% 7
alpha-2a 7
orally) 7
23-61 7
mg/m2/day, 7
Gradual 7
Emotional 7
Rapamycin-Eluting 7
Evaluated 7
(RESEARCH) 7
anhedonia, 7
22.1% 7
Oxaliplatin 7
JAK2/STAT3 7
sterility 7
ertumaxomab 7
PAN 7
re-expressed 7
Ciliary 7
4/7 7
(R620) 7
(W620) 7
OLIG3/ 7
auto-antibodies 7
Drive, 7
>4,000 7
P=.00002), 7
EIRA 7
SLC22A4, 7
1858T-allele 7
30-40%) 7
non-genetic 7
anti-fatigue 7
phytochemical, 7
longa, 7
(BCRP) 7
25.5 7
FA-C, 7
FA-A, 7
Tunisia, 7
chordoma: 7
FET 7
Sleep-wake 7
Hypocretin 7
CA-GFP 7
(TNNI3K) 7
CARK 7
Taz1 7
Phosphatase 7
Dbf4-dependent 7
Mcm4 7
HLA-DQ8 7
EdnrB 7
excising 7
Manifestation 7
statistic. 7
EV71 7
poly-ubiquitin 7
SAKS1 7
BRAF(V600) 7
2013), 7
arthralgia. 7
(GSK2118436). 7
V600K 7
Reproducibility 7
76%, 7
keratoacanthoma 7
keratoacanthomas 7
71%; 7
NDO 7
KRW 7
Caring 7
Typing 7
Error-prone 7
Par 7
tamoxifen-resistant 7
(GRNs) 7
"re-wiring" 7
GRNs, 7
pro-oxidant 7
genome." 7
sclerosis-like 7
OD 7
one-month 7
overdose; 7
incrementally 7
110) 7
gDNA 7
RainDance 7
thermoregulation 7
syndrome's 7
T+tf/J 7
Donepezil 7
(DHF) 7
EBP 7
Catecholaminergic-induced 7
HRCS96A 7
(HRC(WT)) 7
(HRC(S96A)) 7
HRC(WT)- 7
HRC(S96A)-infected 7
biostimulation 7
Fe(III)-reducing 7
Fe(II) 7
groundwater, 7
Challenge 7
enduring 7
electrostimulation 7
Rickettsiaceae 7
expansive 7
EFNB2, 7
EFNB3 7
U251MG 7
TKO 7
RIP1-RIP3 7
backup 7
dilates 7
cloralose 7
alpha-I 7
dapiprazole; 7
Desflurane 7
pupillometry. 7
unblocked 7
pupils. 7
persons). 7
pupillo-constrictor 7
nfkb2 7
Davis 7
swift 7
Domains 7
ALGS 7
26. 7
(31%), 7
Cognition 7
(z, 7
KLF2 7
hCdc4, 7
isomerase. 7
Fbxw7, 7
anyone 7
illegal 7
Theiler's 7
"enhancer 7
gonadotropes 7
also. 7
Pom121 7
Ndc1p 7
cis-Golgi 7
NPCs. 7
(IFNAR1) 7
(T24 7
BIU-87) 7
nonbilharzial 7
5-Aza-CdR. 7
TPEF 7
low-level-expressing 7
high-level-expressing 7
prions: 7
(HSP)70; 7
HSP27, 7
HSP40, 7
disaggregation. 7
prion, 7
SUP35-NM, 7
Smad7 7
AdoMet. 7
Multi-color, 7
(smFISH) 7
smFISH 7
SCG-Pred 7
few. 7
Alfalfa 7
Ukrain 7
tendency, 7
Stichting 7
superresolution 7
SABP 7
extrahypothalamic 7
SHR, 7
hepcidin-related 7
anti-dsDNA 7
oxygen-sensing 7
pertuzumab. 7
ERBB 7
HER3/HER2 7
4-8% 7
individualization 7
Euro 7
co-evolution 7
27.0 7
myelotoxicity 7
[MMR]) 7
dTip60 7
GSK3beta, 7
Alcohol-induced 7
(BSC) 7
offsets 7
GIST: 7
SAMHD1s 7
SVA 7
scene. 7
(MCV), 7
0.826 7
VCAM-1, 7
WBCs 7
(0.01, 7
s.c.). 7
3,4-dihydroxyphenylacetic 7
84%, 7
Δexon9 7
L-mediated 7
Lmna(Δ9/Δ9) 7
dynamics; 7
terminators 7
G-quadruplexes, 7
48.3% 7
freezer 7
tipiracil 7
thymidylate 7
flea 7
Urticating 7
Hylesia 7
Anaphae) 7
moths, 7
cocoons), 7
ophthalmia 7
dendrolimiasis 7
pararamose 7
caterpillar), 7
lonomism 7
Anaphe 7
venata). 7
CgCDR1, 7
CgCDR2 7
azole-based 7
Biofilm 7
(galactosylsphingosine), 7
1637C 7
maize-rice 7
sorghum, 7
reichenowi, 7
parasite-infected 7
merozoites, 7
localisations 7
ASIP, 7
(APOE) 7
(AH) 7
≤20 7
(HCTZ) 7
explainable 7
replication-transcription 7
Apc(Min/+) 7
sFLC 7
vial 7
PLD, 7
evaluable, 7
surveying 7
Blot 7
1958 7
innocent 7
(5.9 7
HWE. 7
pouring 7
eNO 7
optimised 7
sorbent 7
Mycobacteria. 7
sarcoidosis]. 7
MutT-type 7
origin-dependent 7
5'-diphosphate, 7
G.C-->A.T 7
(CC-->TT) 7
G.C-->T.A 7
alkA 7
photoprovocation 7
EPP 7
sunlight-intolerance 7
cAMP, 7
blood-borne 7
tzs 7
VirE2 7
copies/mL 7
UGT1A1*28 7
SmD1 7
Lsm6. 7
Aβ(42) 7
globule. 7
Hi-C, 7
F14512, 7
Walker 7
(Losoxantrone) 7
(SHAPE-Seq). 7
α. 7
C-induced 7
monoubiquitinate 7
missed, 7
(Callorhinchus 7
milii) 7
holocephalian 7
((AB)(CD)) 7
HoxD) 7
(HoxC) 7
inertia 7
3D-FISH, 7
propylene 7
glycerol. 7
P23H 7
diathesis 7
(October 7
wrapper 7
30.0% 7
non-competitive 7
(hereditary 7
dioica. 7
interrogates 7
(http://www.geneontology.org/) 7
(http://www.ebi.ac.uk/interpro/) 7
downloads. 7
rod-shaped 7
filamentation, 7
divisome 7
radiodurans. 7
(mean±SD) 7
α(v) 7
Leprechaunism 7
onward. 7
nares, 7
S96A 7
sun-exposed 7
101, 7
45%) 7
metastasized 7
vemurafenib-induced 7
3080 7
1.88 7
sago 7
(percent 7
enteropathy, 7
gluten. 7
Thermus 7
culling 7
TBEV 7
titin. 7
HDAC4 7
law. 7
OCRL 7
(Mayo 7
addressin 7
natalizumab. 7
preschool 7
Reassessment 7
holoenzyme. 7
hindbrain. 7
proTα(100-109), 7
PBMC, 7
negative), 7
creative 7
inactiveness 7
person-to-person 7
(WT), 7
valence 7
(CCNU) 7
N-ethyl-N-nitrosourea 7
(PCa). 7
osteogenesis-related 7
GC-TRS 7
destabilise 7
USH 7
CD24, 7
0.931 7
hsa-miR-29b 7
3.2%, 7
linezolid 7
charts, 7
Hypomethylation 7
deiodinase-2 7
deiodinase-3 7
cancer.Vitamin 7
higher-than-recommended 7
allowance 7
levels.Since 7
methods.CRP 7
heparin-plasma 7
IVCs 7
(PSA, 7
CEA, 7
CA27.29 7
CA15-3) 7
protein.Our 7
levels.In 7
Fragments 7
puerperium 7
non-squamous 7
(47)LQVVR(51) 7
payer's 7
chondrogenesis 7
Pi 7
Nifedipine 7
I(Ca(L)) 7
saccade 7
universe. 7
Notwithstanding, 7
Ocean 7
H1650, 7
followup. 7
urodynamics, 7
Health) 7
expenses 7
spondyloarthritis 7
integrity; 7
(RBCs), 7
AHDS. 7
(AHDS). 7
(R271H) 7
selumetinib, 7
sodium-iodide 7
radioiodine; 7
scars. 7
(MN) 7
SV. 7
(fraction 7
R-value 7
pre-clinically 7
(ICH 7
(UGT) 7
bilirubin. 7
blood-stage 7
importation 7
(CQ) 7
PfAQP 7
defences. 7
stephensi 7
Mannich 7
TrxR 7
trophozoites 7
gallinaceum. 7
imago 7
phosphatidylserine. 7
brucei, 7
adriamycin. 7
L-T(3) 7
Brca2(+/Delta27) 7
CFCs 7
carcinomatosis. 7
(0.7%) 7
adenosine-to-inosine 7
polypeptide-like 7
15q11-13. 7
(p<0.02). 7
ACT 7
enterography 7
Secukinumab, 7
0/1 7
CCL20, 7
Rheumatism 7
baseline-adjusted 7
Mrj 7
Calmodulin 7
PPIase 7
immunosuppressants 7
hCyPJ 7
FMSF 7
tmAC 7
(sAC) 7
LCOS 7
(rNGB) 7
clopidogrel-treated 7
Health; 7
227 7
model). 7
(p<0.002), 7
dystrophin; 7
skipping-based 7
acetogenins 7
indicators. 7
mastectomy, 7
(M.HhaI) 7
HhaI. 7
antibioticus 7
4'-thio-2'-deoxycytidine 7
th 7
(NS-3), 7
NS-3. 7
ethanol) 7
tier 7
F8 7
mentioning 7
FAIRE-seq 7
Dcp1p, 7
Xrn1p, 7
yeast) 7
sup113, 7
prion. 7
normoglycemic 7
pectoris. 7
neuro-oncology. 7
N-propeptides 7
alpha1(V)(COL5A1) 7
Inter-observer 7
TSC2-null 7
28.8) 7
(KIAA0898) 7
nanism-associated 7
(TRIM, 7
RING-B-box-Coiled-coil 7
RBCC 7
c.745C>T 7
(p.Gln249X), 7
c.1411C>T 7
(p.Arg471X), 7
c.2056C>T 7
(p.Arg686X), 7
(c.1314+507_1668-207del 7
p.Arg439fsX4). 7
(c.965G>T) 7
(p.Gly322Val) 7
geranylgeranyl 7
AlkA, 7
Alkylation 7
5-formyluracil 7
adenine, 7
Gpa1 7
UBPY 7
507 7
MKK3 7
cementogenic 7
(HERS), 7
sialoprotein, 7
HERS, 7
ADRs. 7
(GEMOX) 7
(70.9% 7
g/m(2) 7
22/60), 7
23/60) 7
(25%, 7
15/60) 7
(45/60). 7
(49/60), 7
(15/49). 7
(25/60). 7
nonplatinum 7
platinum-resistant/refractory 7
(45.5%) 7
Olaparib, 7
overarching 7
nasal-cannulae 7
HFNC, 7
H2O 7
2.47 7
no-NC 7
mononucleated 7
neurogranin, 7
neurogranin. 7
mumol/l) 7
prepropeptide 7
T68 7
(S19, 7
genera. 7
graphs. 7
680 7
aortopathy 7
c-erbA/TR 7
(5-HT2AR) 7
(5-HT(2A)) 7
(2-16 7
(16-20%). 7
(regional 7
DV) 7
3-25% 7
10-120 7
postinjection) 7
[18F]altanserin, 7
0.005, 7
MPA 7
620W, 7
ANCA 7
(RF+) 7
SAM50, 7
Tom 7
NELF/DSIF 7
TS; 7
anaplasia 7
daughter. 7
carriers: 7
proarrhythmogenic 7
chloride/bicarbonate 7
ZDOCK 7
DockRank 7
CSAR 7
CD4+CD25+ 7
highest, 7
John's 7
reached; 7
triphosphatase, 7
evolutional 7
1.41, 7
miR-132. 7
Cucurbita 7
12th 7
insulinemic 7
Lamotrigine 7
LTG-induced 7
HLA-B 7
OXC-induced 7
secretase 7
seen; 7
TSIX 7
SRC. 7
PTPN13 7
miniaturized 7
pustulosis 7
icterus, 7
mesalazine 7
Studies. 7
(CID). 7
esterification 7
α) 7
response-4 7
(Par-4), 7
ghrelin-mediated 7
PGE2, 7
gingiva 7
cathepsin-B 7
p19Arf 7
Bmi-1-/- 7
ink4a 7
bmi-1-deficient 7
OC, 7
FPGA 7
assay). 7
Dex-induced 7
maneuver 7
Bnip3 7
Mitochondrially 7
CyaY 7
p19ARF. 7
KDM6A, 7
disease-like 7
hyperphosphorylation, 7
5hmC, 7
5hmC-mediated 7
ANCCA 7
ASH1 7
miR-2400 7
SUMO1, 7
Gadd45beta 7
(STAT3). 7
(Hsps) 7
Hsp 7
translation-promoting 7
Troglitazone 7
(PLMVd). 7
ND3 7
foals. 7
PBT2. 7
Ginkgo 7
guanidinium 7
isomers, 7
co-coordinately 7
suppressed; 7
templated 7
α-amanitin 7
RNAP-II 7
Swelling 7
cribriform 7
dispute. 7
KLK5, 7
KLK6, 7
KLK6 7
ATRX, 7
ICR, 7
MVI 7
autoimmune-disease-associated 7
1858C/T 7
Carriage 7
cannabis, 7
Nox1/4 7
target-two 7
IL-1RI:IL-1RAcP 7
(Fab) 7
IL-1RI. 7
non-CSC 7
myelofibrosis, 7
Mtases 7
Cys-81-S- 7
folinic 7
EIEE 7
DnaK 7
anti-TNF-alpha 7
3.8; 7
v. 7
rubella 7
Bioscience, 7
1.77 7
Cleveland 7
mAS 7
(born 7
1907-1935) 7
1967. 7
(MA), 7
Ecuador. 7
epistasis. 7
streaks 7
(ULN) 7
SynIII 7
accidentally 7
anti-TNFalpha 7
DBH 7
θ-defensins 7
BRCA1/2. 7
North-East 7
c.7806-2A 7
mastectomy. 7
Desomorphine 7
desomorphine, 7
ledipasvir 7
non-spherocytic 7
mediterranean 7
(6PGD) 7
6PGD 7
baboon 7
D178N 7
Pontine 7
radiosensitized 7
PARP-mediated 7
JAMM 7
Tremor. 7
less-invasive 7
PDQ-39 7
hypogeusia 7
resolved), 7
resolved). 7
160), 7
procedure's 7
NCT01304758.). 7
Toronto, 7
Virginia 7
phase-III 7
MIR-143 7
-145 7
(NCT00134563). 7
742 7
DMF 7
TEMSO; 7
(gender, 7
(incidence, 7
kilogram. 7
64,814 7
recruits, 7
0.651% 7
9.917% 7
0.201%. 7
SERDs 7
SUM-44 7
RNA-interference 7
Avelumab 7
NIR-PIT 7
RESCUE-ESE, 7
doi: 7
4CMenB, 7
229, 7
MenY, 7
MenW, 7
MenC, 7
MenX, 7
HadA 7
browsing. 7
web-servers 7
tauopathies, 7
Pseudohyperphosphorylation 7
paired-helical 7
(PHFs) 7
Pseudophosphorylation 7
anti-tau 7
four-fold 7
Oxtr 7
tibia, 7
1or 7
DRESS 7
oxypurinol 7
regioneR: 7
Randomization 7
Artistic-2.0 7
hydrazine 7
Dyskinesia 7
PrP. 7
(TSE) 7
RasGAPs 7
humanly 7
centralised, 7
functio 7
multipass 7
(potassium)-hydrogen 7
acetylation-dependent 7
Ubiquitin-like 7
(PFO) 7
12p13. 7
-7/del(7q), 7
(-5/5q, 7
specimen, 7
(CC). 7
(P=0.0001). 7
17p13.3 7
DGS 7
8.4% 7
21q 7
5p. 7
KCNJ10, 7
IPV 7
netilmicin 7
microparticles 7
RIII 7
poly(L-glutamic 7
quercetin. 7
HYNIC-annexin 7
ezetimibe. 7
noncaseating 7
Dnah9 7
diclofenac, 7
Sibutramine 7
non-amenable 7
(AT1001, 7
1-Deoxygalactonojirimycin) 7
HSV-2, 7
EV-specific 7
ChIP-exo/Nexus 7
Q-nexus: 7
ChIP-nexus. 7
non-statin 7
supress 7
Month 7
aspect. 7
neuraminidases. 7
Daxx 7
Readers 7
profit, 7
P.gingivalis 7
BRCA-mutant 7
post-replicative 7
promoters) 7
structure), 7
(HLP). 7
apoE-1Harrisburg, 7
Arg----Cys) 7
(ApoE) 7
gene-linked, 7
hypomineralization 7
XLH. 7
(Lu-AA-21004; 7
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 7
hydrobromide) 7
5-HT1D 7
2014) 7
contrast-induced 7
cannulation 7
traversed 7
melanogenic 7
SP-1, 7
DDB1 7
(HiSCR) 7
Suppurativa. 7
Sartorius 7
VIII, 7
Stulberg 7
Met1-Ub 7
nonintubated 7
scores: 7
(DOS) 7
chromDraw: 7
(GPL) 7
small-pox 7
EBP50 7
(NoxO1) 7
PMA-elicited 7
PKC-mediated 7
PMA-independent 7
NADPH-binding 7
(NOXO1), 7
(AZD9291) 7
hypokalaemic 7
hypokalaemia 7
tubulopathies 7
hypocalciuria 7
vector: 7
deletions), 7
(WS2), 7
deafness-pigmentation 7
c-KIT, 7
rumen 7
beta(S)-globin 7
syndecans-3 7
BMP7 7
mineralizing 7
femur, 7
labialis. 7
Left-Right 7
Pond 7
[3, 7
formin-actin 7
asymmetry-breaking 7
7], 7
[8]. 7
cytosine) 7
CAGE-defined 7
(ACVR1) 7
BMPR1A, 7
unions 7
Aph1B-containing 7
(WS2) 7
WAARDENBURG'S 7
POPULATION. 7
(dystopia 7
canthorum), 7
(Plm 7
Region. 7
plasmepsins, 7
Community-associated 7
(HA-MRSA) 7
Methicillin-Resistant 7
(MRSA). 7
creep 7
correctional 7
Deprivation 7
RR: 7
Professionals 7
(STENDRA™, 7
SPEDRA™, 7
Zepeeed™) 7
dysfunction-erectile 7
partner's 7
(SEP 7
56; 7
P=0.007) 7
71; 7
4-weekly 7
microbicides. 7
Prevent 7
vaginalis, 7
Version 7
serogroups 7
(4CMenB; 7
TN 7
11.7% 7
(OCD). 7
ERb 7
ecchymotic 7
factitious 7
54-year 7
orbit. 7
intracanalicular 7
(<60 7
(ERAP1, 7
ERAP2, 7
IRAP) 7
MLCK 7
(4-hydroxy-3-methoxy-acetophenone)] 7
imbalance. 7
MyD88, 7
AGEs 7
infectious. 7
forchlorfenuron 7
co-exist 7
GS-607601. 7
Reflex 7
Frankel 7
(SAMS). 7
Sacubitril 7
dihydroxyphenylacetic 7
(DOPAC) 7
AH; 7
PPARgamma2. 7
-14.746, 7
-4.885, 7
-12.482, 7
-3.280, 7
-11.662, 7
-2.997, 7
(Functional 7
Coefficient 7
(R2) 7
Ripples 7
http://code.google.com/p/methylkit. 7
GITRL 7
(ONH) 7
ONH 7
buffalo. 7
SLC45A2. 7
(OCA1, 7
relocation. 7
concert. 7
kinetochore. 7
co-occupancy 7
myelitis 7
Su(var)3-9p, 7
Clr4p. 7
DILI. 7
GdCl3 7
(ADA) 7
(vedolizumab, 7
visilizumab, 7
visilizumab 7
hyperbilirubinemia-induced 7
kernicterus. 7
[Characteristics 7
X/46, 7
mar 7
PICU. 7
erythropheresis. 7
SLC40A1, 7
ferritin, 7
DOI: 7
Mi-2beta) 7
histone-deacetylase-2 7
(HDAC2)-containing 7
MTA2, 7
abrupt, 7
polysomnogram 7
ensued, 7
Suv4-20 7
atlantoaxial 7
(lumbar 7
ligament) 7
microcrystalline 7
(CBSs) 7
genomic-DNA-fragment 7
chromosome-conformation-capture 7
reconfigures 7
planus. 7
protontherapy 7
(RBE) 7
p-CSI. 7
Dilemmas 7
medulloblastoma/PNET. 7
retinoblastomas, 7
Intensity-modulated 7
breeds. 7
(HIST3H1B). 7
v4: 7
dual-energy 7
strand-transfer 7
CENP-A(Cse4) 7
ℓ 7
bit-vector 7
word; 7
lymphangiectasia: 7
lymphoscintigraphy 7
trans-splicing 7
Q-rich 7
pri-miRNAs. 7
MicroRNAs. 7
pri-miRNAs, 7
Microprocessor 7
albinism: 7
donkeys 7
double-row 7
supraspinatus 7
cadavers 7
MRgLITT 7
Neoplasms 7
histone-fold 7
FoxJ1. 7
Enucleation, 7
twice-yearly 7
I125 7
brachytherapy. 7
flammeus 7
iMCD, 7
cellulitis, 7
anophthalmia 7
pretibial 7
DRD4 7
0102 7
AST, 7
TFIIB, 7
completed: 7
(RE-LY) 7
Aristotle 7
Bev 7
warts, 7
non-nicotine 7
CDG 7
phospholipid-lysophospholipid 7
Th2-related 7
kinetoplastids 7
thymidine-hydroxylases 7
J-biosynthesis. 7
re-modeling 7
J-synthesis, 7
J-DNA 7
Chromosome-internal 7
cat, 7
neurofilaments, 7
nodulus 7
PFA 7
PFB 7
C11orf95-RELA 7
Fzd2 7
Wnt/PCP 7
(P=0.048) 7
xerosis 7
psoralen-containing 7
photochemotherapy 7
Angptl3 7
hypolipidemia, 7
ANGPLT3, 7
PARL 7
small-locular 7
(middle-locular) 7
(large-locular) 7
fat-storage 7
monolocular 7
(cytoplasm-rich 7
multilocular) 7
fat-depleting 7
-consuming 7
(1-11 7
thermogenetically 7
17-40% 7
(20-39 7
drowning, 7
assumedly 7
518A2 7
deduced. 7
sand 7
potting 7
salinity 7
soil-dwelling 7
gloves 7
β-Amyloid 7
atypia, 7
stroke-pilot 7
(GAMES-Pilot) 7
SUR1-TRPM4, 7
(K 7
TOPAZ1, 7
single-molecule, 7
non-randomised, 7
cohort), 7
v.4.0. 7
restaging. 7
7/15 7
8/15(53%) 7
calluses 7
v1.1 7
8505c 7
FTLD-TDP 7
C/EBPepsilon 7
GATA-1/PU.1 7
methylome. 7
(MIRA-Seq) 7
crops, 7
prion-infected 7
(33.1%) 7
Mechanism, 7
DOACs 7
creases, 7
Photosensitivity 7
penile/scrotal 7
Gonads 7
46,XX,dup(17)(q23.1q24.3)/46, 7
SRY-specific 7
17q23-24 7
sex-reversed 7
.0001; 7
(EBOV) 7
MTHFR: 7
ATR-mediated 7
Ikaros. 7
Ikaros-Foxp1 7
IK6 7
G2A, 7
Foxp1. 7
53%. 7
(AFL) 7
TATA-box, 7
Web-server 7
http://nplb.ncl.res.in 7
Standalone 7
https://github.com/computationalBiology/NPLB/ 7
(Mac 7
OSX/Linux). 7
l.narlikar@ncl.res.in 7
ADAMTSL4. 7
pupillae. 7
(p.R62C), 7
JSRV 7
fibrillinopathies 7
Rilonacept 7
Tropilaelaps 7
Neurodevelopment. 7
forecasting 7
ethinylestradiol 7
Semaglutide 7
non-DHS 7
85.3% 7
IMR90, 7
Dlgap2 7
Polδ 7
QCT 7
0.98. 7
spCENP-A/Cnp1. 7
Mis15 7
Mis17 7
Mis6. 7
RbAp46 7
DNMT3A/3B. 7
japonicus 7
protein-free 7
cry, 7
CdCS 7
heart-chamber 7
amhc 7
myod 7
myog. 7
Lilly) 7
Lys-to-Met 7
H3.1/H3.3 7
dibasic 7
variant-containing 7
jointly, 7
RCRC 7
078. 7
(PDE4) 7
host-range 7
(LR+ 7
diaphoresis, 7
initiative. 7
renocardiac 7
circRNA-miRNA-mRNA 7
385 7
Sap1/Girdin 7
6-subunit 7
pre-replicative 7
(ARHR) 7
(M1V) 7
1484-1490 7
(1484-1490del) 7
(ARHR), 7
(FGF23). 7
sodium-phosphate 7
(XLH), 7
daughters, 7
R567X 7
PHEX, 7
rickets/osteomalacia 7
(HHRH) 7
FPSA 7
MTX-naive 7
(EULAR) 7
memory-efficient 7
MAQ 7
(Sequence 7
Alignment/Map) 7
FANSe2 7
http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, 7
Windows, 7
Unix 7
0.93). 7
(snRNA), 7
cajal 7
p80 7
trichothecene 7
http://lola.computational-epigenetics.org. 7
re-coding 7
constrained, 7
(CNCs) 7
hyperglycosylated 7
puffiness 7
diuretic-resistant 7
Neighborhoods 7
(Arg/Abl2) 7
macroaneurysms, 7
CI. 7
adalimumab). 7
asf1-33 7
K56 7
(Asf1) 7
Anti-silencing 7
LARVA: 7
PIP 7
corroborative 7
Rrp6. 7
(LDL-R) 7
≥20% 7
(methotrexate, 7
sulfasalazine). 7
NCT01172938. 7
erythematosus: 7
ustekinumab: 7
knockouts, 7
TBR1-regulated 7
Disruptive 7
Brain-specific 7
hMcm8 7
k-mers. 7
traversal 7
vismodegib 7
CAMUR, 7
(database) 7
(Breast, 7
Neck, 7
Cancer) 7
(TCGA) 7
non-TCGA 7
examination; 7
Myc:Max 7
VE-cadherin 7
TFIIF. 7
TFIIS-induced 7
267, 7
Sotagliflozin, 7
0.06% 7
assembler. 7
TEPIC 7
NOMe-seq. 7
Accessibility 7
(TB), 7
dosR 7
DosR/DevR 7
regulon-encoded 7
Kmt5a-deficient 7
GMC-1 7
PDO 7
ARSs 7
neurexins 7
Appendix 7
S1) 7
poly(A)-segment. 7
G's 7
('pure 7
GA-sequences'). 7
poly-A-, 7
poly-G-, 7
poly-GA-, 7
poly-GAAA-sequences 7
GA-containing 7
hexa-nucleotide 7
Supported 7
d(GA 7
(RNA-seq), 7
1,658 7
frames. 7
lithium-containing 7
Xrn1-deficient 7
XUTs. 7
(3'-ss) 7
XUT 7
(SIRT1) 7
ARM 7
Coombs' 7
(eQTLs), 7
(constitutive) 7
(developmental). 7
4C-seq 7
Dileep 7
Il11 7
(http://genome.ucsc.edu), 7
(genome.ucsc.edu) 7
"tracks". 7
viewer 7
FHN1, 7
NPR1, 7
PRR2 7
Sut1 7
mating. 7
PRM4. 7
Battery. 7
grapheme-color 7
89Zr-DFO-AMG102 7
(APL) 7
Patisiran 7
APOLLO 7
DeQuervain's 7
granted. 7
fCNT 7
Propranolol, 7
Overrepresented 7
(NCP1, 7
ERG2, 7
(ERG11, 7
CDR1, 7
YOR1, 7
SMF12, 7
CBP1). 7
pump-encoding 7
(hmU). 7
J-associated 7
(JGT) 7
samExploreR 7
(KEYNOTE-006). 7
(intermediate 7
nonclassic 7
SDO 7
(synthetic 7
Dst 7
SOH1 7
DST1; 7
TAF14, 7
SUA7, 7
GAL11, 7
RTS1, 7
TYS1 7
soh1 7
SRB5 7
SIN4 7
DST1. 7
NTP-depleted 7
Exon-enrichment 7
DR1 7
period3 7
Horne-Ostberg 7
(MDA5) 7
Prevotellaceae 7
Connecting 7
Dst1, 7
Dst1 7
TMEM132: 7
under-investigated 7
holozoan 7
choanoflagellates 7
Virchow, 7
Aulus 7
Cornelius 7
response-redness, 7
Menetrier's 7
jps 7
eQTLs 7
IFITM5 7
SERPINF1, 7
teratozoospermia 7
ICR-mediated 7
tgm 7
reevaluate 7
Strelka: 7
small-variant 7
impurity. 7
allele-frequency 7
calling, 7
varscan 7
addiction: 7
69.7% 7
59.4% 7
misuse, 7
High- 7
(90%CI, 7
RPC1063 7
unconnected 7
(Ribi 7
grfs 7
ribi 7
rubrum 7
keratolysis, 7
corynebacteria 7
cruris, 7
(SIOD). 7
Mimicking 7
glioma) 7
t(11;22)(q23;q11), 7
phenotype-positive 7
bland. 7
FITZROY 7
CD19-directed 7
H3K9me2/3, 7
ROF2 7
YY1-mediated 7
(1.12-5.35), 7
0.02]. 7
4/9 7
12.89 7
(7.67-2167), 7
macrolides 7
USP28-induced 7
kissing." 7
kissing, 7
1q12 7
non-Rabl 7
alobar 7
(SBQ), 7
DOR 7
0--2 7
kg/m 7
HCO3 7
RSV-related 7
vegfc 7
VEGF-D 7
adp 7
http://github.com/opencb/hpg-pore. 7
gene-distal 7
mm/h 7
(RADT) 7
pfs 7
Period-Arnt-Sim) 7
(CACGTG). 7
CLOCK:BMAL-mediated 7
STATEMENT 7
Repressors. 7
5]. 7
auxin-signaling 7
rapa. 7
TaNAC69-1 7
tanac69 7
axr5 7
cephalopagus 7
pygopagus 7
Hindu 7
twins: 7
double-click 7
Ctf4-interacting 7
Sld5. 7
CIP, 7
i,i+6 7
EGFRvIII/integrin 7
empower 7
(http://www.facebase.org) 7
forums 7
LINC-PINT-dependent 7
pro-invasion 7
EGR1. 7
LDB1-mediated 7
afucosylated, 7
benralizumab. 7
Q8W 7
QTLtools 7
https://qtltools.github.io/qtltools/ 7
olivier.delaneau@unige.ch 7
annulo-aortic 7
Prinzmetal's 7
remedied 7
fibula 7
vara, 7
demonstrated; 7
Methadone 7
Sodium-Glucose 7
Cotransporter-2 7
factorisation 7
nonconvexity 7
parametrization 7
mGluR5's 7
bulb). 7
(accuracy, 7
95.7%) 7
abolish, 7
SNP's 7
(PWM) 7
ChIP-exo. 7
Stress-regulated 7
ELS 7
postdonation 7
PrPCWD 7
cervid 7
virginianus) 7
2N 7
proteomically 7
Redox-modified 7
polymer, 7
cleanly 7
redox-selective 7
PEGylation, 7
Click 7
Click-reacted 7
oxidised 7
end-points, 7
computations, 7
Lhx6 7
postmenopause. 7
(DBT). 7
(MBT). 7
δ3 7
hyperflexion 7
miners 7
facie 7
diffloop: 7
Detect 7
Foot: 7
relic? 7
UV-protective 7
Travelers 7
Mefloquine 7
hoxb4a 7
EIMs 7
SSRs 7
(DNase-seq 7
ATAC-seq) 7
9953 7
(Cistrome 7
Browser), 7
http://cistrome.org/db, 7
CARDIOFORM 7
Occluder 7
cluster-randomized 7
hemithorax. 7
Ala148Thr 7
(Achenbach 7
3-11 7
panencephalitis, 7
NVP-BGJ398 7
Whole-Genome 7
http://www.bioconductor.org/packages/SeqArray. 7
zhengx@u.washington.edu. 7
MODIFY 7
1-Tudor-interacting 7
Tudor-interacting 7
region/LC3 7
sequence/Atg8-interacting 7
(LIR/LRS/AIM) 7
LIR-containing 7
(LIRCPs). 7
LIRCPs, 7
LICRPs 7
OSAFED 7
Brd4 7
temsirolimus. 7
CCI-779 7
sScl 7
americanum). 7
americanum. 7
Reflex: 7
Series. 7
(drug 7
induced), 7
7.7) 7
Lyme-like 7
parasitoids 7
g-HAT. 7
2-subsituted 7
Fbxo7 7
θ) 7
oscillators 7
methadone, 7
abstinence-based 7
(level 7
ADAM 7
Aβ4-42 7
pyroglutamate 7
emphysema, 7
bullae, 7
Heavy 7
nonuremic 7
SCCRO3 7
fibroproliferative 7
NOTCH1. 7
HR-NB 7
dinutuximab, 7
ciRS-7/ 7
miR-7. 7
Olink 7
Multiplex, 7
317) 7
308) 7
Eurasians 7
ZipFix™ 7
SP3 7
IRS4 7
(ATAC-seq) 7
nerve/tunnel 7
mm(2); 7
Valaciclovir 7
labialis 7
eumelanin, 7
Asp294His 7
p.R160W 7
redheads, 7
86insA 7
537insC 7
(DARE), 7
(LILACS), 7
(CCTR). 7
conferences: 7
Infections. 7
cryptococcal, 7
cryptococcus, 7
cryptococcosis, 7
(N=518), 7
Sherpa 7
highlanders. 7
Oxidase-A 7
MAOAuVNTR 7
Irritability, 7
3-repeat 7
Tca 7
Dicentric 7
claudin-7 7
clove 7
EVs 7
simplex. 7
(KRT5) 7
KRT14. 7
IgE-mediated 7
ORSA 7
FOXP2. 7
DVD 7
(Review). 6
ubiquity 6
(RVs) 6
dHPLC 6
RVs 6
PACAP 6
factor-α, 6
(CCA) 6
(TNBC) 6
binding: 6
hydroxyproline 6
(HB-EGF), 6
32D/EGFR 6
dissimilar 6
AR. 6
cell-autonomously 6
Papilins 6
Differentiation, 6
sugar. 6
borders, 6
sixty 6
siRNAs. 6
Ensembl 6
immunoblots, 6
Involved 6
proteoglycans. 6
PEMF 6
ingesting 6
miR-510 6
miR-509-5p 6
PLK1 6
(p<0.001, 6
existed. 6
100,000. 6
menstruation 6
0.186 6
fatigability 6
temporary, 6
steroid-induced 6
Radiology 6
Ohio 6
(November 6
satisfactory. 6
attempts, 6
timeframe 6
compression; 6
ADT 6
enlarging 6
cabazitaxel 6
agent; 6
One-way 6
473 6
dsh 6
55-year-old 6
helices, 6
eruption. 6
1965 6
neoplasm, 6
reappearance 6
diaphragm. 6
"Sicilian 6
Gambit" 6
IKs-channel. 6
remains, 6
extrasystoles 6
hypothesis). 6
NOTCH3, 6
Notch-1, 6
implication, 6
osteoarthritis, 6
transfectants 6
H2O2. 6
higher). 6
drug-treated 6
enzalutamide 6
0.59 6
offices) 6
America) 6
NCT01193244. 6
2353 6
1560 6
(n=781) 6
(n=779). 6
8·4 6
3·7-16·6). 6
13·8 6
13·1-14·9) 6
8·7 6
(8·3-10·9) 6
0·71, 6
0·63-0·80; 6
20·7 6
14·2-25·4), 6
31·4 6
28·6-not 6
29·5 6
(27·0-not 6
0·79-1·08; 6
p=0·31). 6
[1%]), 6
[46%] 6
placebo-prednisone 6
grades) 6
17,20-lyase. 6
chemotherapy-naïve 6
TAK-700) 6
38.8 6
µm, 6
CYP2B6, 6
2C9, 6
Draft 6
(TAK-700)--an 6
inhibitor--in 6
dehydroepiandrosterone-sulfate 6
resistance" 6
tumor-to-nontumor 6
(111)In 6
CWR22 6
(prostate 6
0.3; 6
%ID/g 6
Genentech, 6
pro-drug 6
(Taxotere) 6
(Herceptin), 6
Taxanes, 6
warranted, 6
metastatic. 6
(EGFR 6
(trastuzumab, 6
HER-2-positive 6
growth-regulatory 6
emitting 6
[What 6
minireview 6
124) 6
2); 6
19), 6
semisynthetic 6
Her-2/neu 6
dihydrotestosterone 6
(EV) 6
teratomas, 6
Used 6
factors' 6
ADP-ribosylation. 6
AlphaMed 6
hESCs, 6
DNp73, 6
cMyc 6
Germ 6
ES-like 6
research; 6
neXtProt 6
ProteomeXchange 6
proteomic, 6
HUPO 6
pillars 6
Organization's 6
Tryptic 6
gene- 6
SRM 6
biobank 6
PeptideAtlas 6
zfPanx1 6
voltage-activated 6
connexins 6
AMP, 6
P2X7 6
pathogen-associated 6
endotoxin 6
structural/functional 6
POLG, 6
Authors; 6
gamma. 6
encephalomyopathy 6
(10%, 6
(NYHA 6
42%. 6
36.1 6
(BP), 6
(34%), 6
bpm 6
telemetry 6
10.4% 6
(4.0 6
metoprolol, 6
(HRR) 6
dystonias 6
hypointensity 6
hyperintensity 6
Described 6
Wilson 6
copper. 6
rarity, 6
whorls, 6
spliced. 6
PGC-1, 6
contraction-independent 6
Usually, 6
contractures. 6
shoulder, 6
flexion, 6
limb-girdle 6
3-5. 6
(DCIS) 6
p<0.0001, 6
TG(CxT) 6
concurrence 6
'sense' 6
[Ca(2+)](SR). 6
l(-1)), 6
[Ca(2+)]; 6
[Ca(2+)]-dependent 6
67%) 6
18-wk-old 6
44.2 6
357 6
telemetric 6
13%) 6
10%) 6
caffeine. 6
atria, 6
RyR1. 6
channel), 6
(19%). 6
[3H]ryanodine 6
prolonged. 6
(HILIC 6
M). 6
reserpinized 6
microelectrode 6
Rue61a 6
Echinacea 6
N-acetylated 6
all-alpha-helical 6
(general 6
acetylated-lysine 6
TFIID, 6
unhindered 6
manometry 6
sufficient, 6
Esophagus. 6
(non-inflammatory 6
non-coeliac 6
1-11; 6
colonoscopy, 6
(129/144 6
8/27 6
(88/148 6
7/30 6
(84/138; 6
61%) 6
(2/23; 6
Enterocolitis 6
2-13 6
proforma. 6
Paneth's 6
denervation. 6
anti-hypertensive 6
Suggestions 6
-Jun 6
cells]. 6
(SA) 6
C/EBPbeta 6
(JNKs) 6
autophosphorylation, 6
tylophorine 6
AP1 6
Elk-1, 6
Proteases 6
publication. 6
membrane-type 6
neo-N-terminal 6
(SPARC) 6
Amine 6
Isotopic 6
repertoires 6
displacement. 6
1,046 6
TRAF7, 6
active) 6
clobazam, 6
phenytoin, 6
pyrazole 6
Europe) 6
modifications; 6
verprolin-homologous 6
ketimine 6
Lacosamide, 6
alias 6
sarcoma/primitive 6
phenotypic, 6
EYA3, 6
cell-of-origin 6
EWS/FLI1. 6
rhabdomyosarcoma. 6
YK-4-279 6
enantiomers. 6
(Ewing 6
siRNA-transfected 6
oncogene-driven 6
q12) 6
phenyl 6
microangiopathy, 6
HUS, 6
uncommonly 6
prodrome 6
widely. 6
FB 6
antiinflammatory, 6
72-year-old 6
breakfast, 6
ANOVA), 6
P<0.001, 6
circuitry, 6
ur 6
inactivity, 6
bicycle 6
sprint 6
(SD): 6
ratings, 6
meal, 6
~17% 6
normal-weight 6
cycled 6
ml). 6
unmethylated. 6
(MR 6
alone). 6
urokinase, 6
Oct4) 6
>75% 6
28.8 6
p=0.002) 6
gravid 6
64%. 6
(21.4%) 6
15-55 6
dysmenorrhoea 6
co-morbid 6
co-morbidity 6
innervating 6
hyperalgesia, 6
sensation. 6
Duke 6
(22% 6
menorrhagia, 6
3.6, 6
play, 6
(HL) 6
cross-cultural 6
care; 6
hs-cTnT 6
runners, 6
(HRV) 6
post-training 6
Eighty-one 6
cyclists. 6
depiction 6
hemodynamically 6
intensities, 6
judo 6
1.37 6
Massachusetts, 6
Ever 6
(around 6
register. 6
over-abundance 6
2.7), 6
12.6), 6
1.3), 6
2.2). 6
8.0). 6
slow-growing 6
≥5 6
data-based 6
systems; 6
constructive 6
(P<.001) 6
(H3K27). 6
'Sotos-like' 6
EP300, 6
nosologic 6
convincingly 6
2142 6
(Apo) 6
35.8%) 6
nmol/l, 6
placebo- 6
GAUSS-2 6
(primarily 6
(SOC) 6
apheresis, 6
hypercholesterolaemia, 6
evolocumab-treated 6
muscle-related 6
adventure 6
normal), 6
moderate- 6
biweekly; 6
(0.5) 6
HINCUTs 6
(miRNAs); 6
HINCUT, 6
uc.475 6
HINCUT-1) 6
HINCUT-1 6
Kb 6
(piRNAs), 6
coactivator. 6
(ncRNA), 6
uc.338 6
TUC338 6
C-5 6
(SAM), 6
(AdoMet). 6
cysteines, 6
DNA/RNA-binding 6
Courses 6
(PRs) 6
Myelosuppression 6
small-round-cell 6
antigenically 6
Neuroectodermal 6
Leu-7 6
cell-adhesion 6
reactive. 6
polyphenotypic 6
LIF, 6
two-year-old 6
preselect 6
(ADME) 6
morpholine 6
3.29 6
metabolized. 6
(Me(3)Pso) 6
breakage, 6
fac 6
CFU-GM 6
mock-corrected 6
unwind 6
(2012) 6
C-rich 6
(G-rich) 6
Aip 6
state), 6
(FIPA). 6
Aryl 6
PRL-secreting 6
somatotropinomas 6
Rarely 6
FIPA. 6
prolactin-secreting 6
chr 6
dilemmas 6
(PRE) 6
Fitting 6
cTnC-A31S 6
subfragment 6
(cTnI) 6
phenocopies. 6
(decreased 6
PyMol 6
disassociation 6
troponin, 6
Ear 6
Melbourne, 6
acupoints 6
self-assessment 6
36), 6
points: 6
Shoulder 6
(16.6%) 6
(control) 6
24.8% 6
public. 6
ceased 6
organisms; 6
(HMTases) 6
DIM-5, 6
Proposed 6
heterochromatin-associated 6
pachynema, 6
missing, 6
modifications) 6
exapted 6
adaptor, 6
subdomains. 6
reverse-transcriptase-subunit 6
penetrates 6
concurrently. 6
ELISPOT 6
adjuvant. 6
16-amino-acid 6
Sham 6
phosphate-buffered 6
score; 6
staged 6
TAT 6
Pull-down 6
telomerase-specific, 6
prohibit 6
Slug. 6
ERK/Akt 6
mRNA; 6
HGF-mediated 6
preestablished 6
nontumorigenic 6
(MAP2), 6
PHA-665752, 6
Akt/GSK-3beta 6
hematogenous 6
explained, 6
irreparable 6
(KC) 6
Chem., 6
PKB 6
H1N1/09 6
comorbidity, 6
anti-influenza 6
CDC. 6
postvaccination 6
endomyocardial 6
gestation), 6
(1.1%) 6
AS03 6
encouraged. 6
294 6
endpoints: 6
Denmark. 6
Nationwide 6
gestation) 6
(12.9%) 6
request. 6
villi, 6
schooling, 6
660 6
exposed) 6
(9.7%) 6
Obesity, 6
index) 6
11.6% 6
admitted. 6
Update. 6
childhood-onset, 6
(BLT) 6
(IMH) 6
(c.177delG 6
c.153_166del14). 6
BLT-like 6
y). 6
phenotype-selected 6
single-photon 6
(TTF-1)--critical 6
Surfactant-related 6
chromatine 6
disaturated 6
(DSPC) 6
(2)H(2)O 6
(13)C-leucine; 6
L941P, 6
(43.2 6
24.8%/day); 6
0.5%/day) 6
content). 6
neonatal/pediatric 6
Syndrome". 6
-C 6
surfactant-associated 6
internalize 6
clathrin- 6
17th 6
RIα 6
PRKAR2B 6
AMP-dependent 6
TENS 6
(ANOVA, 6
RFECS: 6
random-forest 6
(Random 6
21%. 6
rounding 6
RNA-like 6
(GRN163L) 6
33342 6
countered 6
Simultaneously 6
IL-4/13 6
(EASI) 6
(P=0.16). 6
32%) 6
300-mg 6
periostin. 6
protocol-defined 6
wrap 6
relatives) 6
Boy 6
paracentric 6
triplication 6
ridging 6
Nell-1, 6
osteocalcin, 6
promoter-luciferase 6
supershifted 6
11p15 6
aplasia/hypoplasia 6
Rothmund-Thomson 6
Pfeiffer, 6
immunoglobulin-like 6
S252W 6
calvaria 6
Caesarean 6
fronts 6
Nat 6
redefinition 6
preaxial 6
PIWI/piRNA 6
Uc283+A 6
Uc.346+ 6
(UCGs) 6
cancerogenesis, 6
UCGs) 6
Wave 6
prepubertal 6
Pendrin 6
KCNE1, 6
aqueducts. 6
mutism 6
scintigraphy, 6
goiters 6
Follicular 6
Hürthle 6
securing 6
aqueduct: 6
pendred 6
(49/57 6
Securing 6
inconstant 6
recharacterized 6
Pendred&apos;s 6
sulphonylureas; 6
agonists; 6
dipetidylpeptidase-4 6
meglinitide 6
analogues; 6
reabsorbed. 6
(sodium-glucose 6
SGLT2) 6
anti-hyperglycaemic 6
(SGLT2). 6
masquerading 6
23-yr-old 6
CD57 6
immunophenotyping 6
orbitrap 6
hydrophobicity, 6
(DRS) 6
proteinase. 6
thiosulfate 6
SDS-PAGE, 6
pattern) 6
(LT). 6
(LT) 6
'normal' 6
(14%). 6
(CLBP). 6
0800 6
Actiwatch 6
Recall 6
thaliana; 6
profiles: 6
similarity, 6
1-year-old 6
fibrils; 6
lyonization 6
keratitis, 6
34C>T 6
PRINC 6
(Plavix 6
Intervention) 6
(cytochrome 6
family), 6
CYP3A5, 6
P-450 6
.002), 6
MATERIALS 6
paraoxonase 6
VPA- 6
TMZ-related 6
Program) 6
(Radiation 6
Group/European 6
0.44-0.71). 6
0.59-0.94 6
0.52-0.84 6
non-AEDs. 6
16.9 6
P=.16). 6
(P=.047; 6
0.27-1.07), 6
1.37-1.61). 6
P=.26). 6
26981-22981/National 6
began, 6
AED-free, 6
(EIAED) 6
non-EIAED. 6
VPA/LEV 6
lysosome: 6
LSD. 6
TFEB-mediated 6
endosome/lysosome, 6
(CLEAR) 6
RRAG 6
lysosome-autophagy 6
glycogen. 6
non-lysosomal 6
efflux, 6
PPARα, 6
misregulated 6
peracerosum-strigosum-littorale 6
D-cycloserine, 6
secondly, 6
culture-based 6
Ramoplanin 6
disprove 6
enterococci. 6
Blumbach, 6
Ganguli, 6
Klesel, 6
Limbert, 6
Seibert, 6
Antibiot. 6
45:839-845, 6
Biosyntheses 6
Dependent 6
fast-growing 6
Revealing 6
Fosfomycin 6
GeneChip 6
Ciprofloxacin 6
lysine. 6
liothyronine 6
hypothyroidism: 6
(P=.03). 6
Single-agent 6
(AA). 6
anti-glioma 6
cycle). 6
Norris 6
(VAS 6
40%. 6
astrocytoma: 6
(96 6
(early 6
(6.7%) 6
treatment-free 6
receptor-alpha 6
neutropaenia 6
post-radiotherapy 6
468 6
dehiscence 6
leukopenia, 6
blepharitis, 6
prognostically 6
59%. 6
bid) 6
1.18; 6
1.63, 6
polarizing 6
(GWAS). 6
CYP1A1, 6
IL23, 6
synovia. 6
synovia 6
BaP 6
complex-mediated 6
D3. 6
resident, 6
RASFs, 6
Microarrays 6
HOXD 6
3.3; 6
NEO 6
remembered 6
conceptualization 6
tap 6
patient- 6
informant-rated 6
Munich 6
57%). 6
octreotide, 6
RAD001, 6
(rat 6
2005), 6
6.97 6
1.32 6
0.88) 6
(QTLs) 6
reaction: 6
(q24;q12) 6
translocational 6
(NCBI 6
archives. 6
Beta-actin 6
intent. 6
25. 6
break-apart 6
Clinicopathological 6
Immunohistochemically, 6
(MCF-7), 6
functionally, 6
cobinds 6
edge: 6
>2.5 6
bud. 6
LMP2A 6
loci; 6
3D-FISH 6
NELF-A, 6
interaction: 6
variants) 6
hypertension), 6
iPSC-CMs 6
books 6
MYH7, 6
TNNT2, 6
tissue; 6
Translocations 6
4-7 6
localized. 6
maydis, 6
losses. 6
MsDef1, 6
anti-fungal 6
stinking 6
monophosphate, 6
diffracted 6
miRNA-target 6
comply 6
deep-sequencing 6
Moloney 6
PARalyzer 6
dependently. 6
kinetically 6
SD: 6
TgAb, 6
18.7 6
22.2 6
[Use 6
(PTU) 6
diplegia: 6
compensations 6
self-selected 6
femoris 6
individualised 6
Construct 6
4-month-old 6
hemiplegia. 6
plane, 6
Ninety-seven 6
(gait 6
stiff 6
equinus 6
Eighty-six 6
LSU 6
supravalvar 6
10(-5)). 6
UAA 6
(PTP) 6
peroxidation. 6
nonmammalian 6
opportune 6
self-associate. 6
mutant-induced 6
ortholog. 6
unbiased, 6
(NMJ) 6
ribonuclear 6
RNA-recognition 6
(FUS), 6
FUS(R521C) 6
FUS(R521C)-positive 6
FUS/TLS, 6
cryoinjury 6
Cx43-deficient 6
scar. 6
Regeneration 6
C57/BL6 6
Smads 6
self-esteem 6
non-additive 6
explanatory 6
SWB 6
success: 6
assumed, 6
(S-COMT) 6
5-h 6
short-living 6
food) 6
36.1% 6
glycoproteins. 6
gel, 6
1-DE 6
(Man-6-P) 6
LC/MS/MS. 6
MPRs. 6
tempting 6
methanogenic 6
Methanocaldococcus 6
jannaschii. 6
jannaschii, 6
cdc6 6
Cdt1. 6
hispanica 6
orc 6
structuring 6
solfataricus 6
R758X 6
cylindroma. 6
pleiomorphic 6
G>T 6
autosomally 6
BSS. 6
showed, 6
spiradenocylindroma 6
BCCs 6
(familial 6
(69%), 6
681 6
dome-shaped 6
SMN1, 6
patterns: 6
butyrate, 6
Rheb, 6
(developmental 6
immunoreactivity, 6
IH, 6
protein-dependent 6
rottlerin, 6
src 6
Modulators 6
poly(ADP)ribose 6
Ca++/calmodulin-dependent 6
(EADs 6
hearts) 6
cPLA2 6
32P 6
MLC(20) 6
KCl-induced 6
Ca(2+)-mediated 6
Cdc25A, 6
Duplication 6
(5.3 6
Reveals 6
CCM3. 6
(s) 6
CCM1/KRIT1, 6
urchin 6
6.2% 6
trapped-1 6
(Krit1) 6
Rap1A, 6
KRIT1, 6
(KRIT1) 6
(programmed 6
Rap1A 6
osmosensing 6
aggressiveness, 6
Diiodothyropropionic 6
d) 6
P<0.05), 6
ischemia-reperfusion. 6
obscured 6
(THs) 6
arterioles. 6
pellets. 6
548 6
hemodynamics, 6
(375 6
(87 6
(59 6
(3.8 6
clips. 6
radiculopathy, 6
ejaculations 6
resolved, 6
Sacral 6
photopenic 6
myelography 6
(Tarlov 6
"sitagliptin," 6
"vildagliptin," 6
"saxagliptin," 6
"alogliptin," 6
"linagliptin," 6
"dutogliptin." 6
Ligand-based 6
pivot 6
highest-scoring 6
Apparent 6
Saxagliptin 6
widen 6
≥24 6
comparators, 6
275 6
-0.34 6
-0.4 6
(DPP4i) 6
DPP4i. 6
0.82). 6
(MH-OR 6
0.36, 6
-0.80, 6
Nonlinear 6
WAI 6
I(2) 6
fall. 6
lixisenatide, 6
speaking, 6
(VH 6
(n=9). 6
goodness-of-fit 6
profile: 6
BCL6 6
wakefulness. 6
1-wk 6
emergence. 6
Ghanaian 6
(NYHA) 6
(32.8% 6
So, 6
interferons, 6
memories 6
molecule) 6
(5.6 6
advisable. 6
poultry, 6
sub-domain 6
hyperhidrosis. 6
Alleviation 6
(progressive 6
carrier, 6
(LO) 6
(4H) 6
hypogonadotrophic 6
∼300 6
inventories 6
(BX-C). 6
Located 6
reporter. 6
energy-dependent 6
transgenes. 6
(C5-MTases) 6
(GUS) 6
palm, 6
met1 6
FoxM1 6
CENP-B 6
fertile. 6
PARP-1, 6
Cenpa, 6
Cenpb, 6
Bub3 6
micronuclei 6
(Chd1) 6
lays 6
CHD7, 6
60-80% 6
follicle-stimulating 6
subterminal 6
distribute 6
ARKS 6
spermiogenesis 6
hPc2 6
(H3K9). 6
SNF2-like 6
TgMYST-A 6
MAF2. 6
lysines. 6
split, 6
Chp1 6
destinations. 6
NCCs 6
Chd5 6
HY5 6
factor-mediated 6
MBD2 6
(chromodomain 6
resonance, 6
RITS 6
co-repressor, 6
Gypsy 6
CHD7S 6
Directed 6
[human 6
(SCID) 6
minus-sense 6
polypurine 6
found: 6
redistributes 6
Wnt-β-catenin 6
cementoblasts. 6
(>50% 6
(ABR) 6
emissions 6
(minimum 6
bore 6
H3K9me3. 6
(MSI). 6
seven, 6
M-phase 6
tri- 6
HP1γ 6
(PHD) 6
wing. 6
AVAILABILITY: 6
prolongation. 6
iv. 6
quinidine, 6
ventricle) 6
3.3%; 6
(LGE) 6
OR: 6
2.92, 6
2012; 6
tegmental 6
guanidino 6
(GCs), 6
N-methyltransferase, 6
negligible, 6
GCs. 6
1-methyl-4-phenylpyridinium 6
(K(m) 6
(KLF10) 6
doxazosin 6
cows 6
Hep3B 6
transfection, 6
RANKL-induced 6
mOPA1 6
Opa-1 6
Drp-1 6
93- 6
unexplained, 6
deoxy 6
(FS) 6
decision-tree 6
(PI3K)/AKT 6
(45.7%) 6
Excitatory 6
remain. 6
0·02 6
PAM50 6
Individualised 6
(TAILORx)) 6
Programme 6
ran 6
SE. 6
fearful 6
lipid, 6
seasons. 6
linoleic 6
(splice 6
tissue/developmental-stage-specific 6
Disabling 6
ceRNA 6
miR-138? 6
antisense. 6
remark 6
miR-138. 6
equation, 6
(123 6
Iowa 6
(CGIs), 6
methylatable 6
(alcohol 6
pVNTR 6
AEI 6
ARVD/C 6
DSP, 6
p.Arg14del 6
37.7 6
'arrhythmogenic 6
cardiomyopathy'. 6
oxalate-facilitated 6
PLN-knockouts 6
(PLN-KO). 6
Ca-kinetics 6
PLN-KO, 6
hyper-contractile 6
(NKA) 6
PLN-R14Del-YFP 6
NKAα1-CFP, 6
phospholemman. 6
PLN-knockouts), 6
PLN-KO) 6
valvular, 6
G26 6
Arg-Leu 6
(R9L). 6
G-A 6
Arg-His 6
(R9H). 6
(L39stop). 6
calories 6
Vitamins 6
minerals. 6
maximum, 6
(LDH), 6
(placebo). 6
VO2 6
(BC) 6
Years 6
Asx 6
CoQ(10) 6
years], 6
(1:1 6
assumption. 6
sportsmen 6
taken, 6
harm, 6
neuropathy-associated 6
(ARS) 6
(CMT2D), 6
involvement]. 6
motor-dominant 6
CMT-related 6
Charcot-Marie-Tooth-linked 6
transgene-rescued 6
aminoacyl 6
(GARS)-associated 6
G240R 6
non-conservative 6
control; 6
tRNA-charging 6
Gaussian 6
truth 6
MATLAB 6
P16 6
ERalpha 6
SMCX 6
H3K9, 6
imprints 6
H3-specific 6
obviates 6
(H3-K4) 6
head/neck 6
congenita: 6
problems: 6
X-linked. 6
BMF. 6
ACD, 6
RTEL1, 6
otolaryngologist 6
recessive: 6
TERT. 6
(180 6
reticulate 6
subset, 6
plasmatic 6
transvalvular 6
-24, 6
-210, 6
-494, 6
-499 6
-29, 6
-199a, 6
miR-210 6
neoangiogenesis. 6
pri-miR-21 6
miR-92a, 6
Mcl-1, 6
miR-29, 6
sprouty1 6
(SPRY1), 6
sprouty2 6
(SPRY2) 6
preconditioning, 6
BACH1, 6
destinations 6
TFIIH, 6
assess. 6
normoxia, 6
normoxia 6
(leucine-rich 6
ATG8 6
3-kinase) 6
(IFN-γ), 6
TLR2, 6
U0126 6
CM, 6
immuno-electron 6
utophagy 6
10(-8)), 6
CD84, 6
0.8). 6
monophosphate-N-acetylneuraminic 6
Neu5Gc, 6
Kawasaki 6
epitope-recognition 6
anti-TPO 6
surpassing 6
diet-related 6
(prothrombin 6
approach: 6
disciplines. 6
thrombocytopenia) 6
ml/min) 6
contra-indicated 6
(Eliquis®) 6
(Eliquis(®)) 6
misinterpretation 6
Dabigatran, 6
Drug-drug 6
marketed. 6
(H 6
H199 6
H379 6
Co-affinity 6
bis(maleimido)hexane 6
(BMH) 6
homo-multimers. 6
Cys→Ser 6
multimerized, 6
C402S, 6
EIIB 6
(pag, 6
cya) 6
(edema 6
(lethal 6
atxA-coding 6
km-2 6
P2; 6
atxA-mediated 6
mutant-infected 6
coli: 6
exponential- 6
6SRNA 6
Cytisine 6
quit. 6
Considerations 6
cysteine. 6
pseudogene. 6
(MPN) 6
tet 6
TET2, 6
shunt, 6
recombination-mediated 6
aberrations; 6
semiconservative 6
flavin 6
First-in-class 6
marizomib 6
(GvHD). 6
molecule(s) 6
Cav-1(-/-) 6
centrifugation, 6
fibrillarin 6
denucleation. 6
cohesin-mediated 6
(H3 6
middle-to-late-replicating 6
1993; 6
(T(1)AM) 6
triiodothyronine. 6
ferrets 6
v1 6
capsid. 6
80K-H 6
gustavus 6
ASC, 6
v3, 6
v3 6
VAS. 6
Heterozygotes 6
association." 6
non-homology 6
FusionDB, 6
PLEX 6
Phydbac 6
triplets, 6
linkage, 6
noncomplementing 6
hints 6
PSPC1-NONO 6
(PSPC1) 6
PSPC1 6
copurified 6
particle. 6
bioavailable, 6
(RECIST) 6
3.8% 6
mg/m(2)). 6
(inhibition 6
PS341 6
loader 6
CSM3, 6
CHL1, 6
(AZD-2281) 6
TRAIL-mediated 6
inhibitor-mediated 6
(PARP1) 6
11q23 6
platinum-containing 6
(66 6
(topoisomerase 6
31.1% 6
(Dr. 6
Delinassios), 6
(TLS) 6
(VEGFR) 6
coinhibition 6
(PARPi). 6
(HDACi), 6
cotreatment. 6
SAHA+olaparib. 6
conductance. 6
remained. 6
HAM-D 6
GAPs 6
RhoA/ROCK 6
invasion/migration 6
STAT1, 6
ROCK, 6
(T2 6
968 6
PLP 6
disorder-to-order 6
assemblies, 6
gating, 6
Tanabe 6
RaO 6
(p=0.016) 6
decrease; 6
1.9; 6
p=0.001). 6
actuarial 6
calstabin 6
(TCR). 6
CSA 6
strand-specific-PCR 6
(SS-PCR). 6
(PIKK) 6
verification, 6
AB1157 6
sub-pathway 6
Rad16 6
7-methylguanine 6
DAR 6
rad26 6
GGR, 6
(missing 6
damage; 6
(MMD) 6
(G-CSF). 6
(-2 6
(5). 6
indirect, 6
17q25.3. 6
(SMS) 6
supraclinoid 6
58. 6
watershed 6
Angiographic 6
base-pairing 6
tangential 6
°C. 6
SpA. 6
manufacturing. 6
hydroxide. 6
1M 6
micrograms/ml, 6
hospitalisation. 6
pericardectomy 6
recurred. 6
four. 6
carcinoma). 6
Chase 6
facts, 6
cell-signaling 6
RCs 6
Subependymal 6
Rheb/m-TOR/p70S6K 6
acetyltransferase) 6
H2B. 6
H3K4. 6
can. 6
remodeler. 6
HP1a. 6
Paf1 6
(FEC-75) 6
02 6
fluorouracil, 6
Premenopausal 6
47.3% 6
8: 6
TTP. 6
Milan, 6
50. 6
(76.2%) 6
(P=0.01) 6
ended, 6
microgram/kg 6
Cardiopulmonary 6
(24% 6
range; 6
(P<.001), 6
(CPB) 6
co-occurrences 6
(cis-regulatory 6
CRMs). 6
neuroblasts, 6
MOPAT 6
tree), 6
(ECs) 6
(NAE), 6
anti-invasion 6
Bad, 6
MLN4924-treated 6
CRLs 6
NEDD8, 6
A375 6
thwarts 6
(NAE). 6
29). 6
NOXA, 6
Mechanism-based 6
yeast-two-hybrid 6
(HAX-1), 6
(CaMKII), 6
school-age 6
professionals. 6
qualification 6
Bearing 6
Ki-67. 6
Online, 6
St 6
MammaPrint, 6
anisomycin, 6
constitutive. 6
3] 6
[6], 6
JNK/SAPK 6
p54 6
p21(ras) 6
Fragment 6
IMGT(®) 6
(IMGT 6
peaks, 6
L1, 6
seeds. 6
machines, 6
Distinguishing 6
nonconserved 6
surpasses 6
Society, 6
Force, 6
Falls 6
Bone, 6
1.19, 6
1.24, 6
falls; 6
Home 6
45,782 6
(25(OH)D) 6
full-time 6
Residents 6
calcitriol 6
Four-year 6
3.75 6
(16.2%) 6
20; 6
9.4% 6
pilocytic 6
IFNγ-induced 6
controversies. 6
isotretinoin: 6
Details 6
(18.5%) 6
adverse-effect 6
comedonal 6
comedolytic 6
(medical 6
insured 6
64.7% 6
absorbed, 6
metabolized, 6
Hamster 6
2.14 6
toxicants 6
isotretinoin) 6
(acetylsalicylic 6
Teratogenicity 6
analogue-isotretinoin 6
malformations--in 6
0.3-0.3 6
i.u.-8.3 6
(0.13 6
mg/kg)- 6
i.u. 6
overdosage. 6
nonteratogenic 6
nasogastric 6
(Experiment 6
VITA 6
time-dependent. 6
heartbeat 6
curvilinear 6
shelves. 6
DMSO 6
lip. 6
Cis 6
dogma 6
ATM-mediated 6
Mdm2-mediated 6
Mdm2. 6
TRIAD1 6
intercalation, 6
distribution; 6
tenfold 6
carcinogenicity 6
tubules, 6
K50 6
extrapolating 6
AQ4N 6
DNA-intercalators 6
doxorubicin) 6
surface-enhanced 6
intercalatively 6
M06 6
lowest-energy 6
IIα 6
embodied 6
design' 6
chromophores 6
dimyristoylphosphatidylcholine 6
hindrance 6
Metal 6
structure- 6
miR-143, 6
Manipulating 6
NMDA-mediated 6
hypofunction 6
miR-137, 6
4R:3R-tau 6
transferable 6
α-synuclein(A30P)-transgenic 6
exocytosis, 6
1mM 6
H(+) 6
Glt(Ph), 6
EAAT4 6
MSG/kg 6
ASCTs 6
GPCRs 6
plasma-membrane 6
ezrin, 6
4MG 6
MPDC 6
passaged 6
p21-activated 6
PtdIns(3)P. 6
0.05%). 6
gel-free 6
ISA 6
stain. 6
Ruby 6
refinements 6
(CBS) 6
phospho- 6
'blue 6
(HPV16) 6
non-immunogenic. 6
nanotechnology, 6
aptamer-siRNA 6
(NMD). 6
ticlopidine 6
proportional. 6
EC(90) 6
mug/mL 6
(ODN) 6
unparalleled 6
ODN 6
ISS 6
ethylene 6
rotating 6
agriculture. 6
drinking. 6
Nalmefene 6
JKB-119 6
erbB2, 6
GNPs, 6
N-myc. 6
NEDD9, 6
prognostication. 6
3'-kinase 6
AKT. 6
Gli1 6
GLI 6
reorganisation 6
nucleating 6
edge. 6
EMT-inducing 6
numerous, 6
comparison: 6
driver. 6
applicable, 6
nucleoid. 6
currency 6
Agent 6
nucleoid-associated 6
vascularity 6
sonography, 6
aging-induced 6
(triiodothyronine, 6
TRbeta1-selective 6
Mst(3)CGP 6
(TCE) 6
tTFIID 6
Rash 6
If-inhibition 6
11%. 6
(DD) 6
-0.30, 6
concentrations) 6
mg/dL) 6
(Likelihood 6
0.000, 6
11.8 6
62) 6
differ, 6
Neurophysiology. 6
Shotgun 6
PARP1. 6
CRABP2 6
taxane-based 6
galectin-3 6
19. 6
hamartin/tuberin 6
48.0 6
brain), 6
p56 6
vitamins, 6
Esophageal 6
(mb) 6
ADCC, 6
anti-SLAMF7 6
EAT-2, 6
SLAMF7. 6
bedaquiline, 6
Jiaotong 6
(heterogeneity) 6
2.33 6
pylori/IgG-positive 6
[67.3% 6
61.8%; 6
1.272; 6
0.336]. 6
1.222; 6
0.688-2.171; 6
0.494]. 6
(univariate 6
1.368, 6
0.810-2.311, 6
0.241; 6
95%CI:0.311-2.758, 6
0.890; 6
1.852, 6
0.478-7.167, 6
0.366; 6
1.385, 6
0.726-2.639, 6
0.323; 6
0.832, 6
0.236-2.932, 6
0.775; 6
1.836, 6
0.396-8.503, 6
0.437). 6
risk; 6
2.11 6
bronchitis. 6
1.97; 6
3.00; 6
60-75 6
stoke 6
(p=0.007). 6
ulcer. 6
atheroma 6
(AMR) 6
intonational 6
speaker 6
speakers. 6
disorders) 6
phonatory 6
periodicity. 6
harsh 6
languages 6
(8). 6
FOXO3 6
PDGF, 6
feto-maternal 6
NERD 6
One- 6
(LINX 6
System; 6
Torax 6
Shoreview, 6
swallowed 6
11.9% 6
Sphincter 6
coarsening 6
gangliosidoses. 6
GD3 6
retinas, 6
ragged-red 6
neurovisceral 6
GLB1 6
R201C 6
appeared. 6
(beta-gal) 6
(RER) 6
beta-gal, 6
RER, 6
unlabeled, 6
arteritis: 6
(IQ 6
10-month-old 6
reticulated 6
calvarium, 6
airway, 6
sarcomeres, 6
acyltransferase-1 6
cardiolipin. 6
dissociating 6
384 6
(3.2%) 6
SAT, 6
BMAL1-dependent 6
Wee1 6
habituation 6
proteins]. 6
dpi 6
dpi. 6
derepression, 6
SRp20 6
(TP) 6
MBP, 6
stretch. 6
Ser-45 6
33. 6
regimen) 6
(6.5%) 6
non-convulsive 6
valproate, 6
mirtazepin, 6
2.00 6
endpoint) 6
[HR]: 6
(secondary 6
63.6% 6
ARISTOTLE, 6
RE-LY, 6
inflation 6
Once-Daily, 6
0.85). 6
866 6
Japan-specific 6
SPIKE: 6
exportable 6
musculus, 6
characterised, 6
engulfed 6
IMF 6
lipases. 6
A-mediated 6
S3-12, 6
droplets, 6
(XIST) 6
descendants 6
(10). 6
BBF 6
[Application 6
random. 6
Spectrometry. 6
biotechnology, 6
SCA. 6
organisation. 6
lipidomics. 6
viscera, 6
36,000 6
evaluated: 6
Sankt 6
Quality-adjusted 6
Constructive 6
society, 6
logistics 6
teamwork 6
Patient-centeredness 6
risk-signature 6
studies): 6
1.06, 6
study): 6
apixaban). 6
short-duration 6
IIa. 6
glutamine, 6
Univariable 6
CHD, 6
hampering 6
anemias 6
Rhabdoviridae 6
Vero 6
benzimidazoles 6
6-mercaptopurine 6
Poliovirus 6
(typical 6
780 6
1.3, 6
authority 6
0.05-0.09 6
tar 6
nicotine-containing 6
Device 6
wean 6
(Quest 6
(Weeks 6
Minnesota 6
smoking-related 6
emotion. 6
abstinent 6
80), 6
nicotine-free 6
Zealand) 6
Urgent 6
Notum, 6
glypicans 6
anchor. 6
(FOUR) 6
(eye 6
simplicity, 6
GCS. 6
Since, 6
unresponsiveness 6
(GCS 6
(GOS 6
alert, 6
(Kw 6
wise 6
fabricate 6
flexibility, 6
293FT 6
printing: 6
fluidity 6
Innovations 6
objects. 6
implants. 6
-0.37, 6
bazedoxifene, 6
over-the-counter 6
progestogen 6
commercialization 6
treats 6
journals, 6
IRLSSG 6
calcium-channel 6
(gabapentin, 6
pregabalin) 6
consulted. 6
enacarbil 6
(CGI), 6
xyloglucan 6
Trichoderma 6
conidia 6
expansin-like 6
alpha-expansins 6
X-CGD 6
neuroma. 6
Content 6
childhood; 6
(ACH) 6
IPI-504, 6
fold), 6
17-allylamino-17-demethoxygeldanamycin 6
Haplotypes 6
summarized, 6
neurocristopathies, 6
(EDN3, 6
MnCl2 6
Hodgkin-Huxley 6
Voltage-gated 6
occasion 6
Small-cell 6
opacity 6
(ACh) 6
released. 6
Paraneoplastic 6
IgGs 6
(CMAP) 6
CMAP 6
backed 6
ion-channel 6
channels: 6
biofilms, 6
amphiphilic 6
complexing 6
dehydrated 6
serines 6
DOPC 6
[Screening 6
Lom 6
(HMSNL), 6
(CCFDN), 6
[Congenital 6
Vlax 6
microcorneae, 6
living. 6
floppy 6
pseudoptosis. 6
esotropia. 6
5q31. 6
myoglobinuria 6
Myelinated 6
Unmyelinated 6
Pedigree 6
81.5 6
Controversy 6
sporulation. 6
(SETMAR) 6
joining, 6
Metnase's 6
anthropoid 6
transposases 6
Metnase. 6
nicks 6
homology-dependent 6
Mn(2+), 6
Phosphomimetic 6
p53-related 6
kinase; 6
leukaemia, 6
c-Abl, 6
safeguard 6
Myc-driven 6
promotion. 6
Myc-dependent 6
foreskin 6
senescence-signalling 6
p38-activating 6
p38-induced 6
senescence-executing 6
Tables 6
updates, 6
delta- 6
GALA 6
>600 6
paralogs. 6
ritonavir, 6
7.2% 6
5.9% 6
indinavir 6
precise, 6
anergy 6
DC/tumor 6
(45)Ca(2+) 6
(large 6
lysophosphatidic 6
53%, 6
(IRSp53) 6
IRSp53. 6
egression 6
kinase). 6
Cytoskeletal 6
incompetent 6
Yin 6
phosphate- 6
adenine-responsive 6
cryo-EM 6
0.63% 6
(7/504), 6
0/550). 6
≤65 6
set). 6
2261 6
4.09; 6
P=3.42×10(-10)). 6
(P=0.003). 6
history' 6
residence, 6
plasmid's 6
pO157 6
O157:H7, 6
pB10 6
chaos 6
log-normally 6
protist, 6
amitochondrial 6
observations: 6
energies, 6
abundance) 6
Compositional 6
f*XY/f*Xf*Y 6
f*X 6
f*XY 6
complement). 6
circumventing 6
specificities, 6
Technologies 6
disciplines 6
Integrative 6
deluge 6
nonspecific, 6
Celldex 6
recesses 6
ISUOG. 6
Carvajal 6
cTNT 6
recesses, 6
(RCM), 6
BHLHB3 6
PDCD5 6
(P< 6
PC-3, 6
(IPSS) 6
SF3B1, 6
(PMF) 6
(>or=5 6
EZH2/centromere 6
non-ambulant 6
muscle; 6
ataluren 6
3.4), 6
triple-marker 6
gonadotropin, 6
(AMD) 6
(PBs), 6
HCT116, 6
(Dcp2 6
Dhh1), 6
(Kem1/Xrn1), 6
(Edc3), 6
Me31B 6
FMRP-containing 6
(RNP) 6
bodies," 6
Turnover 6
(P-bodies) 6
postinfection. 6
enzyme-substrate 6
renewable 6
JA 6
sediment. 6
nov. 6
(m) 6
°C) 6
gel-filtration 6
serologically 6
predict. 6
taurine, 6
CoQ10, 6
PINK1, 6
EOPD 6
(PINK1) 6
corticostriatal 6
(<30 6
DJ-1, 6
Parkinsonian 6
compacta 6
Group, 6
AR-JP 6
(homozygous 6
DOCA-salt, 6
41.8 6
afterdepolarization 6
(APs) 6
<0.05) 6
dysrhythmias 6
(9% 6
([Ca2+]i) 6
inhibition), 6
(L-lactate 6
Glycolytic 6
"glycolytic" 6
cancer-positive 6
(p-value 6
(glutamine) 6
lactate. 6
highly-sensitive 6
vectorial 6
shuttles 6
MCT 6
GLUT-1 6
anti-tumoral 6
BCR/ABL. 6
t(9;22)(q34;q11.2), 6
Characterized 6
auto-inhibition 6
Akt/mTOR 6
Akt/mTOR, 6
LYN 6
failure-free 6
87.5% 6
flavopiridol 6
ALL, 6
STAT5a 6
Varying 6
LSCs. 6
newer, 6
triploidy 6
allosterically 6
(BCR-ABL) 6
1985. 6
(SCT) 6
tempered 6
22q- 6
210-kD 6
newly-identified 6
(extracellular-signal-regulated 6
override 6
(major 6
STI571. 6
>18 6
HHT, 6
67.5% 6
532 6
5-HT(1B) 6
noradrenaline, 6
mg/day: 6
17.6 6
5-HT3, 6
(selective 6
5-HT1A-R 6
(OC), 6
HAMA 6
HDRS-24 6
560 6
5.8% 6
2.01 6
-1.5 6
Lu-AA21004 6
parasite's 6
climatic 6
80%) 6
1977 6
Infinium 6
origin), 6
under-expression 6
TruSeq 6
Closely 6
CIBZ 6
PGCs 6
A-negative 6
B-type. 6
ductular 6
engulf 6
pyruvate, 6
eat 6
sequestration. 6
CRISPR-associated 6
cholerae 6
Prokaryotic 6
Intrastrand 6
[from 6
ciliated 6
reversed. 6
Stop 6
eukaryotic, 6
NNC 6
boxes. 6
TnI-203/MHC-403 6
(10-20 6
Wild 6
(MV) 6
Clinic. 6
4-14 6
children; 6
(ZDF) 6
agencies. 6
integral, 6
registry, 6
non-U.S. 6
balls 6
cordis) 6
(8.2) 6
[62%]), 6
Tyrolean 6
severities 6
accumulated, 6
16q24.1 6
Arab-Israeli 6
kyphoscoliosis 6
Gigaxonin, 6
aggregations 6
facilitator 6
(APP 6
leukoencephalopathy, 6
CK2α 6
budding. 6
actor 6
protrusive 6
amphiphysin 6
enveloped 6
ΔN 6
DeltaNp73, 6
hypomethylation, 6
ΔNp73β 6
subfamilies: 6
-6, 6
TAp63 6
(SVM) 6
Ctr2p, 6
MAC1 6
coordinated. 6
Ace1 6
FTR1 6
TGF-β1-mediated 6
NRas 6
N-Ras) 6
rasosomes 6
palmitoylated 6
K-Ras. 6
ERAPs 6
(ER 6
sympathomimetic 6
decarboxylated 6
(anti-CD52 6
mAb) 6
cytopenias. 6
(predominantly 6
Rituximab, 6
(IL)-2 6
(natalizumab) 6
μg, 6
Campath-1H 6
1-H 6
0.26; 6
10-point 6
imaging) 6
underutilized, 6
http://www.bioconductor.org/packages/2.13/bioc/html/spliceR.html). 6
hypothesis-guided 6
(MD). 6
resort 6
habenula 6
Yale-Brown 6
multiagent 6
progression-free-survival 6
Lunar 6
moon, 6
(ARIA). 6
phosphorylated-tau 6
topline 6
Importantly 6
vaccination). 6
(AN1792, 6
preaggregate 6
QS-21) 6
DIO2 6
(SCH) 6
male/female 6
raised, 6
Pennsylvania 6
16-year 6
quintiles 6
(0.60 6
0.86) 6
sampling; 6
"B" 6
(Lepidoptera) 6
Polymorphism 6
signal) 6
(homoplasy). 6
"noise" 6
synapomorphies 6
intraspecific 6
(mt) 6
phylogenetics 6
plagued 6
interpretations 6
mellifera, 6
hide 6
mellifera 6
P=0.003), 6
(SSRIs). 6
neurodevelopment, 6
pro-social 6
Antidepressant 6
(SSRIs), 6
causality. 6
Thrombin 6
3-9 6
fifty-eight 6
21.1% 6
(TCF4/ITF2) 6
E47 6
Semi-quantitative 6
ETV5 6
309 6
desmin. 6
OPN 6
myopathies, 6
Dohme; 6
regions" 6
Rev 6
Cassette 6
H-reflex 6
spells, 6
donors: 6
(active) 6
subcortex 6
clonidine. 6
agitated 6
657), 6
645). 6
1.02-1.77; 6
Banks. 6
bromo 6
BRD 6
HAT-acetylated 6
"gain-of-function" 6
37%, 6
9.6, 6
4.6, 6
war, 6
unfamiliar 6
GOM 6
capillaries. 6
perforating 6
α-actin 6
unpredictable, 6
monograph 6
distortion, 6
(FVC). 6
-114.7 6
-239.9 6
125.3 6
77.7 6
172.8; 6
-113.6 6
-207.3 6
93.7 6
142.7; 6
INPULSIS-1, 6
P=0.67); 6
INPULSIS-2, 6
NCT01335477.). 6
INPULSIS™ 6
(HRCT) 6
(BAL) 6
Silica-induced 6
necessity. 6
sores 6
IMS, 6
breathing, 6
attempts. 6
OPIDP. 6
microg/g 6
butyrylcholinesterase 6
(BuChE) 6
organophosphates. 6
land, 6
Agricultural 6
federal 6
ambiguities 6
(ChIP), 6
(G) 6
1beta, 6
(ISH) 6
histologic, 6
astrocytosis 6
consolidating 6
rainbow 6
(LPS)-stimulated 6
p150,95 6
funding. 6
Bibliometric 6
grants, 6
advancement. 6
(h 6
h-indices 6
academia. 6
professors, 6
authorship 6
weighting 6
433 6
intra-esophageal 6
sphincter. 6
restorations. 6
interocclusal 6
occlusal 6
homes. 6
episodes: 6
burst, 6
swallowing. 6
gentle 6
yoga, 6
plant-based 6
post-study 6
Latest 6
nocturia 6
(RCTs), 6
Prosdex. 6
AIDIT 6
IMPACT 6
61.9 6
practices, 6
aged-matched 6
(GPs) 6
keen 6
topics. 6
EL(97)12 6
Oxytocin 6
AVP 6
AVP, 6
(OGTT) 6
hypercalciuria, 6
Feeding 6
hypercalcemia, 6
(WBS), 6
1-month-old 6
(10.21 6
pmol/l; 6
10.29-24.45 6
pmol/l). 6
(99m)Tc-pertechnetate 6
(morphology 6
(37.9% 6
99m 6
7q11.23, 6
Imparied 6
sFRP3-transfected 6
FRZB/sFRP3 6
Frizzled-related 6
SELDI 6
IMAC 6
chips. 6
Investigated 6
microbeads 6
transferrin, 6
affinity-based 6
high-abundance 6
(cis-eQTLs) 6
(Ser129) 6
aspartate, 6
phospho-Ser 6
(synuclein 6
Subfertility 6
citalopram, 6
Herbal 6
phase-only 6
Ninety-nine 6
Symptomatology 6
(PRISM) 6
78.6% 6
immediate-release 6
(paroxetine 6
swings, 6
13.5% 6
(intermittent 6
withdrawals 6
(34%). 6
thalid 6
Neuroradiological 6
35%. 6
3-fold, 6
erosions. 6
rh-endostatin 6
(rh-endostatin), 6
16). 6
Ophthalmological 6
(VEGF, 6
(VEGF)-A 6
XVIII, 6
HIF-1alpha. 6
masse 6
Frequently, 6
(86.2%) 6
(5, 6
(BTX-A) 6
Will 6
KinderAGATE 6
[Drug 6
Interdisciplinary 6
disorders), 6
(NSAIDs), 6
subdivides 6
technique) 6
(PE). 6
(category 6
most. 6
documentation. 6
catalogued 6
127,998 6
30,675 6
20,059 6
hairpin-shaped 6
subsume 6
MDP 6
GH1 6
tetrahedral 6
folded. 6
rDNA. 6
Ume6 6
experimenting 6
Deadenylases 6
PUMs 6
CNOT8 6
DEDDh 6
conclusion. 6
diversify 6
Caf1-Ccr4 6
PABPC1. 6
Pab1p. 6
RNA's 6
Brodalumab 6
area-and-severity 6
(clear 6
210-mg 6
140-mg 6
69%, 6
IL-22 6
26%, 6
subpopulation. 6
psoriasis; 6
frames, 6
microdeletions, 6
schweinfurthin 6
beds 6
neurofibromas. 6
nevoid 6
ss 6
fulfills 6
Regulating 6
54.9% 6
cross-linker 6
syntheses 6
(CXCR4) 6
methylguanine 6
anti-integrin 6
fluorine-18 6
((18)F-FDG) 6
two-tissue 6
Durable 6
excellent, 6
nu 6
factor- 6
(DLT). 6
ORFs. 6
17: 6
BBS. 6
BBS1. 6
Adaptors 6
versa 6
(total, 6
Tomato-based 6
59%), 6
TC, 6
17.0) 6
0.002; 6
Transposon-free 6
noncoding, 6
MeT-DB 6
epigenetics. 6
accessions 6
mutated: 6
DC-SIGN+ 6
CD1a 6
(3.75 6
positive/ 6
beta-tropomyosin 6
alpha-actin. 6
$50,000 6
(intravenous 6
pre-index 6
post-index; 6
(SD=0.04), 6
(PMPM) 6
(8.3%) 6
PMPM 6
calibration, 6
routine, 6
valganciclovir 6
probenecid 6
SCT. 6
1917, 6
3B1 6
51449) 6
PTA-6475) 6
lactotransferrin, 6
hysterectomy 6
disconnected 6
(NO)-induced 6
KL 6
colitis; 6
homoplasmic 6
cramped 6
heterotopia 6
dyspraxia 6
afflicts 6
Mithramycin 6
neck: 6
effusion) 6
347 6
intracystic 6
useless 6
endonuclease-mediated 6
Translated 6
shielded 6
KH 6
c- 6
post-transcriptionally. 6
substituents 6
stranded, 6
Z-DNA 6
Me3-psoralen 6
psoralen, 6
8-MOP. 6
macromolecule 6
50.5% 6
ciclosporin 6
pending. 6
(Issue 6
0.93. 6
0.96. 6
(TBI), 6
ChAT 6
accidents. 6
oxime 6
D(3) 6
harmful, 6
(TRP) 6
BUN 6
(99m)Tc-DTPA 6
Donors 6
SEM) 6
PSer129 6
PSP/LBD 6
alphaS 6
premotor 6
alpha-synuclein-immunoreactive 6
Nigral 6
sonography. 6
Obstetric 6
6.4%. 6
chi(2) 6
gravida 6
hepatosplenomegaly. 6
Second-trimester 6
hyperechogenic 6
NORM, 6
Rec 6
86.7% 6
3-phosphatases 6
Myotubularin, 6
MTMR9 6
MTMR6/R9 6
PtdIns(3,5)P(2) 6
MTMR8/R9 6
MTMR8 6
paradox, 6
inhomogeneous 6
Strand 6
extremity. 6
storms 6
pimozide, 6
acetozolamide. 6
526 6
TBZ 6
nervousness 6
regime. 6
exertion 6
deubiquitinates 6
dreadful 6
Delamanid: 6
(Deltyba(®)), 6
nitroimidazo-oxazole 6
anti-tuberculosis-treatment 6
29.6% 6
COSS 6
STA-MCA 6
(15%). 6
12.8% 6
14.4% 6
inexperience 6
high-field 6
Optimized 6
isomers 6
abundances, 6
Spectrometry 6
G2/M, 6
modifications: 6
methanogens 6
plane. 6
(SIT) 6
vena 6
mirror-image 6
immediately. 6
usual, 6
mesentery 6
deSUMOylation 6
1α 6
non-SUMOylated 6
graceum 6
[liver 6
glibenclamide, 6
70.4% 6
glycaemia 6
closely-related 6
stack. 6
hyperandrogenism 6
Polycystic 6
hyperinsulinism 6
anti-Müllerian 6
AMH, 6
d; 6
immunoturbidimetric 6
hydrophobic, 6
chymotrypsin, 6
(15% 6
microwave-assisted 6
data-independent 6
workhorse 6
CTD. 6
roadblocks, 6
nonpairing 6
RNAP, 6
undertreated. 6
GAD, 6
points), 6
biologics, 6
Perhaps 6
Stratification 6
(HES) 6
361 6
0.49, 6
(48% 6
receptor's 6
βc 6
reslizumab). 6
CSS 6
0.064 6
HES, 6
L-HES 6
FIP1L1-PDGFRA 6
internists 6
Hypereosinophilic 6
Anti-interleukin-5 6
limitation. 6
0.92; 6
[ClinicalTrials.gov].). 6
oesophagitis, 6
GSK 6
Physician's 6
mRNA(+) 6
Atkins 6
(Dravet 6
voltage, 6
inattention, 6
helmets 6
metabolism; 6
phosphofructokinase 6
LGS, 6
Encephalopathy, 6
nosology 6
momentary 6
downward. 6
EEGs 6
(dHMN-V) 6
Lipodystrophy 6
(dHMN) 6
HSPB8. 6
<0.5 6
(ANC) 6
CN, 6
I/II/III 6
G325R 6
alpha-subunits 6
sequencing), 6
growth; 6
582 6
339 6
syncopes 6
494 6
LQT 6
(KS), 6
suspicion, 6
histogenetic 6
graft, 6
digit. 6
naevus 6
non-pigmented 6
SMC, 6
(Akt)/mammalian 6
(GFAP), 6
scratch 6
MDA-MB-231, 6
(AMPK). 6
(2.5-5 6
Plasmodium-infected 6
NCSM 6
severe) 6
pachymetry, 6
547 6
(PRK) 6
(CXL). 6
20/50 6
UDVA 6
LASIK 6
Athens, 6
inferior, 6
-29 6
4.64 6
1.63 6
3.39 6
38.0 6
Aβ(1-40) 6
unaltered. 6
(ADRs) 6
multiforme). 6
(indicative 6
necrosis), 6
MDL28170 6
LVDP 6
-paradox, 6
discs, 6
-dependent 6
(RdRp) 6
food-frequency 6
Prudent 6
meats 6
RIPK3 6
License, 6
SERT, 6
universal, 6
milnacipran 6
SERTs 6
disinhibition 6
2.7-fold 6
67) 6
0.11, 6
(HAQ) 6
had, 6
(CDAI) 6
438 6
hour), 6
(>30 6
reference(s) 6
administrator, 6
curator, 6
entry/correction 6
password-protected 6
Databaseaccess 6
(www.findbase.org), 6
WE, 6
[Wernicke 6
myelinolysis 6
misusing 6
(thiamin) 6
sequels 6
TD, 6
Alcoholism. 6
MRI/MRS 6
(glucose 6
nationale 6
médecine 6
interne 6
(thiamine) 6
mamillary 6
post-surgery 6
detoxifying 6
(MeCP2) 6
mildest 6
well-established, 6
challenged. 6
systematic, 6
(MCT8), 6
CYP2C9*3 6
nongenetic 6
K-dependent 6
isomer, 6
uremia 6
'Canagliflozin-SGLT2' 6
AChE' 6
Glucocerebrosidase 6
259T 6
virus-derived 6
glucopyranoside 6
(denoted 6
p42/44 6
(HIf1alpha 6
HIF2alpha) 6
(CA9) 6
head-neck 6
weeks--one 6
split); 6
LRFS 6
radioprotective 6
radioresistance 6
Hg), 6
occasions. 6
NTA 6
insipidus. 6
KT 6
DGF 6
Exosome 6
RUNX1-MYEF2, 6
TAL1, 6
ETO2 6
133:4913-4923, 6
MYEF2, 6
MYEF2 6
p32, 6
LSD1. 6
cognitive-behavioural 6
sulpiride, 6
(haloperidol, 6
enkephalin 6
Sections 6
695 6
(current 6
invention 6
(GOSHS) 6
Goldberg 6
non-consanguineous 6
performed; 6
Dev 6
Marfan-like 6
excavatum 6
disability; 6
attention-deficit 6
(SPINK5) 6
LEKTI. 6
lepromatous 6
non-endemic 6
(KLKs) 6
corneum. 6
dehydration, 6
extranuclear 6
deferoxamine 6
equilibrium, 6
AF-LB 6
Atg5, 6
SN 6
preganglionic 6
Iodothyronine 6
amphibians 6
correlated, 6
pretranslational 6
NICD 6
ICN, 6
RBP-Jkappa, 6
CBF1, 6
Lag-1) 6
instructive 6
Mam 6
Notch-mediated 6
NLK 6
(AUC). 6
>or=1 6
Vpr 6
976 6
translocator 6
marginale 6
infected. 6
gag 6
indomethacin-induced 6
2a) 6
injury; 6
engenders 6
gene-deficient 6
Normally, 6
ho-1 6
inter-species 6
alpha-NAGA-deficient 6
(Kanzaki) 6
2007). 6
(50%). 6
(HAART) 6
(6.2%). 6
mg/mouse/day 6
(DORAs) 6
Suvorexant: 6
minutes). 6
(latency 6
orexin-1 6
(DORA) 6
(EMPA-REG 6
OUTCOME™). 6
eight-point 6
-1.96, 6
1.5-2 6
(UTIs) 6
drug-naïve 6
(HbA1c 6
(double 6
0.8%, 6
≤12 6
radiochemical 6
kg; 6
Independently 6
diabetes-related 6
Sulfonylureas 6
0.6%, 6
[interquartile 6
nonoxidative 6
efficacy/safety 6
aliphatic 6
descriptors 6
pharmacophore-based 6
(zebrafish, 6
stickleback, 6
fugu) 6
(aCNEs) 6
"fish-specific" 6
6th-10th 6
DAZ 6
cffDNAs 6
fluorescent-polymerase 6
PGD, 6
(MCAOs) 6
depolarizations. 6
beading. 6
depolarization, 6
SDs, 6
(<6 6
(33.3 6
Compromised 6
dies 6
(PIDs) 6
evoking 6
phosphorylation-mediated 6
isoproterenol-stimulated 6
PLB-SMOE 6
CPA 6
24- 6
Airway 6
CaMKII-mediated 6
attainable 6
(K(d) 6
(AHS) 6
E873stop 6
cortex) 6
single-group, 6
thrombopoiesis. 6
splenectomy, 6
IC₅₀ 6
adenosine-containing 6
leukemia-1 6
Win 6
demethylase. 6
NY-ESO-1, 6
MAGE-A1, 6
(AdoHcy) 6
psammaplin 6
mL/min. 6
neuroprotection, 6
(2014). 6
for: 6
Upstream 6
chain-2 6
(cardiac 6
cardiogenesis 6
1-vs. 6
1-specific 6
enhancer-specific 6
heart-derived 6
cotransfected. 6
chlorampenicol 6
dimerized 6
temporospatial 6
backgrounds, 6
MEF-3 6
3/3 6
(P=0.037), 6
(P=0.027) 6
(P=0.007) 6
TERTp-wt 6
IDH-wt, 6
I-IV) 6
615 6
insert, 6
JAKs 6
1.70 6
key, 6
filings 6
IL-10. 6
3-variable 6
b.i.d.) 6
30.4% 6
extensive. 6
CYP1B1 6
regard. 6
laminae 6
immersion 6
blocker), 6
bicuculline-induced 6
nonadherent 6
micromol/kg) 6
(9.4 6
TROX-1 6
fluorescence-based 6
CaV2.2 6
margins. 6
ketamine, 6
Diazepam 6
5HT 6
2.4; 6
endocrinopathies, 6
FANCI, 6
aminoglycosides 6
protoplasts. 6
PKCα 6
FMNL2 6
DGKα 6
PKCs 6
glycines 6
Gla(-/0) 6
Transfected 6
TAT-ZFN 6
TALEN-specified 6
Checklist 6
E2Fs 6
aptameric 6
0.061 6
impedance 6
methane 6
Id1/3-PA7 6
poly-ADP 6
devise 6
thioredoxin-1 6
Taq 6
co-ordination 6
PRR 6
NLRs 6
NLRP3, 6
feed-back 6
insect, 6
CSps 6
immunosuppressant, 6
78) 6
(≥1 6
everolimus-treated 6
80.0%) 6
pneumonitis, 6
(85.7%), 6
[26%]), 6
(32%). 6
TSC-associated 6
1/5 6
(IL-1β). 6
asset 6
talin, 6
laminin. 6
replenish 6
β-blockers, 6
Spark 6
running. 6
MLAGAN. 6
CpG-poor 6
double-homeobox 6
MaLR 6
ERV 6
506 6
Immune-responsive 6
uteri. 6
methylcitrate 6
lipopolysaccharide-stimulated 6
(Irg1) 6
interferon-regulated 6
(IRG1). 6
fRPE 6
(hESC) 6
Stargardt 6
Practice-compliant 6
(AMD), 6
iPSC-RPEs 6
FGA 6
Loxapine 6
(headache, 6
74.7% 6
g/l, 6
IgG4-RSD 6
immunopathogenesis 6
holes 6
nephritis, 6
ILK-deficient 6
RhoA-ROCK 6
histomorphometric 6
beta(3) 6
disaggregation 6
dedifferentiate 6
tubocurarine 6
43.4 6
818 6
sevoflurane, 6
cRNAs 6
Acetylcholine 6
-100 6
d-tubocurarine. 6
Vecuronium 6
biventer 6
cervicis 6
nerve-stimulated 6
d-TC. 6
P2X 6
diffusion, 6
gating. 6
II' 6
MT2. 6
ramelteon 6
actin-related 6
TBCs. 6
plaque, 6
(extracellular 6
SOC. 6
(2002) 6
phosphorylation: 6
Hck, 6
K(48)-linked 6
(K)48-linked 6
comprehend 6
regulatory, 6
TRAF2 6
RASSF1A) 6
1.52; 6
2.2; 6
2-fold, 6
DNMT, 6
PCNA, 6
p15, 6
AS/MT 6
PSTV 6
accepts 6
Citrus 6
host-encoded 6
novo-synthesized 6
isostericity 6
ASBV, 6
(TAP), 6
CASK 6
CASK, 6
(Adempas(®)), 6
mg/L), 6
ototoxicity 6
0.022, 6
SBT 6
>40 6
gm 6
toolkit. 6
Cas9/sgRNA 6
(sgRNAs) 6
progeny, 6
(5-year 6
3-kinases 6
chemo-free 6
Gilead 6
Tonic 6
(PI3K). 6
-a 6
antiepilepsy 6
sandwiched 6
1973 6
non-failing 6
K201, 6
(JTV519), 6
K201. 6
receptor-calcium 6
RyR-bound 6
ischemia/reperfusion-induced 6
3.2%; 6
cardioplegic 6
cardiomyocyte. 6
MALAT-1, 6
MD-miniRNA 6
Nucleases. 6
Malat1-null 6
LT, 6
forsythia, 6
Islet 6
Reduces 6
APJ(Δislet) 6
brown-like 6
apelin, 6
leakage. 6
chemiluminescence 6
E6-expressing 6
NFX1-123, 6
>80 6
CPSF 6
RIN1. 6
engagement. 6
Romano 6
H3K79me1 6
nucleosome-positioning 6
FITC 6
equivocal. 6
values; 6
PMal 6
beta-AR 6
explain, 6
Staff 6
(cys-ser), 6
decitabine-incorporated 6
118-amino 6
nuclease-digested 6
persuaded 6
rottlerin 6
Quervain's) 6
determinations. 6
thyroiditis]. 6
[2.6%]), 6
[0.9%]), 6
alcohol-use 6
ring1B 6
H3S28 6
Ring1B-mediated 6
USP16 6
TCAB1) 6
myelodysplasia, 6
maintenance; 6
NOLA1 6
telomere. 6
growth/survival 6
gland: 6
MT99/1 6
element; 6
Cd99, 6
unusual, 6
CD99-L 6
reticulocytes 6
Xg(a) 6
chromosome(s) 6
MIC2, 6
neuroglial 6
Cufflinks, 6
non-uniform 6
landscape, 6
MITIE 6
jasmonate 6
ever-increasing 6
base-level 6
SpliceTrap 6
BrS-related 6
NaV1.5 6
Ito, 6
[Brugada 6
underdiagnosis 6
Alpha-synuclein, 6
alpha-Synuclein, 6
140), 6
synphilin-1, 6
synphilin-1A, 6
Synphilin-1A 6
synphilin-1A 6
Ssa1p. 6
NUB1 6
ligation, 6
proliferator 6
15-day 6
NMSC, 6
photoprotection 6
1.66; 6
lightly 6
#269700). 6
polyubiquitinated. 6
immune-checkpoint-inhibitor 6
7.3) 6
0.81; 6
BRAF/MEK 6
8%). 6
Chemokine 6
G31P 6
SCH-527123, 6
oxaliplatin, 6
Hypothalamic 6
(H/MBII-52) 6
(H/MBII-85) 6
15q11.2. 6
SNRPN. 6
(HBII-85) 6
mb 6
(Drp1)-mediated 6
CDK5 6
arteriosclerosis. 6
Drp1-dependent 6
19-kDa 6
ER-specific 6
SFK 6
Rab11 6
endothelin, 6
mitochondrial-derived 6
constricts 6
Mdivi-1 6
gluconeogenesis 6
FANCG. 6
damages. 6
Recessively 6
arrhythmias; 6
3'-termini, 6
GC-donor 6
intron-specific 6
(distributed 6
isavailable 6
http://www.plantgdb.org/PlantGDB-cgi/GeneSeqer/AtGDBgs.cgi, 6
http://www.plantgdb.org/PlantGDB-cgi/GeneSeqer/OsGDBgs.cgi 6
http://www.plantgdb.org/PlantGDB-cgi/GeneSeqer/PlantGDBgs.cgi, 6
http://bioinformatics.iastate.edu/cgi-bin/sp.cgi. 6
parameterizations 6
Ca(v)1.3 6
Slo(27) 6
µg/ml 6
catheterization. 6
NDM 6
hemagglutination 6
CJC 6
arms: 6
rash; 6
(40%); 6
ULK1 6
GABARAP, 6
NBR1, 6
ATG3 6
autophagocytosis 6
Aut7p. 6
phosphatidylethanolamine, 6
multipolar 6
bypassing. 6
perpendicular 6
farnesyltransferase 6
radiosensitize 6
Ki-RAS 6
396 6
atenolol, 6
ng/mmol 6
prescribing, 6
80.8% 6
enteritis. 6
BbF 6
cystlike 6
AoD 6
(4.3%) 6
microfibrillar 6
Flow-mediated 6
0.013), 6
spadiceus 6
TTX-IC 6
assayed, 6
seas, 6
tetrodotoxin-producing 6
niphobles, 6
TTX-bearing 6
carnivorous 6
electrophysiologically 6
(DM1) 6
19q13.3. 6
Mst2 6
statin-related 6
simvastatin. 6
0.70). 6
3-hydroxy-3-methylglutaryl 6
(DCI) 6
(32% 6
0.34), 6
(Short 6
DINDs. 6
evanescent 6
polar, 6
(n=4). 6
Clozapine 6
Adjunctive 6
nonadherence 6
antipsychotic. 6
psychoses. 6
loss). 6
BWG 6
contacted. 6
2.10 6
loxapine 6
PCCB, 6
propionyl-coenzyme 6
Pcca(-/-) 6
phenol-chloroform 6
PAC 6
phosphatase-1/GM/phospholamban 6
8.1% 6
G-CSF; 6
(BP-DBS) 6
sham-stimulation 6
Arithmetic 6
symptom-related 6
myoclonus-dystonia 6
administration), 6
p105.NF-kappaB 6
exposed. 6
immunocytochemically 6
flavin-adenine 6
findings; 6
15q21.1, 6
responses): 6
(14/120) 6
(2/10) 6
nonresponders. 6
radiotherapy/TMZ 6
Therapy/TMZ. 6
Therapy/TMZ 6
anti-mitotic 6
(TTFields), 6
PC1-0 6
EPC. 6
(S6K1 6
S6K2) 6
miR-363-5p 6
LSECs 6
eGFR, 6
μmol 6
456 6
dysfunctional. 6
(GINS) 6
ctf4Delta 6
(Chromosome 6
AI-associated 6
Antiestrogen 6
arm; 6
(13.8%) 6
(2.0%) 6
68.0 6
libido, 6
hormone-releasing 6
settings: 6
63.7%. 6
recurrent/persistent 6
Estrogen, 6
synthetically 6
(whose 6
221 6
pro-metastatic 6
Progressively 6
(RPC) 6
(TPR) 6
(go 6
san) 6
(RPCs) 6
MCM. 6
mini-chromosome 6
Mcm2-7, 6
Cdc45-MCM-GINS 6
Tim1-Tipin 6
repetitions 6
rightmost 6
(3.9%) 6
(ISC), 6
57.5% 6
24.7%, 6
cAMP-regulated 6
cftr 6
'junk': 6
'junk 6
DNA' 6
UTRs. 6
Primate-specific 6
retrotranspositional 6
(scored 6
transpose 6
retroposed 6
likewise, 6
(sCJD) 6
(Pchlide) 6
(TEM) 6
lamellae 6
greening 6
LHPP 6
etioplasts. 6
photomorphogenesis, 6
PORC 6
angiosperms 6
mevalonate 6
IPP 6
lovastatin, 6
mays 6
resisted 6
rye, 6
benralizumab). 6
TREATMENT 6
0.012, 6
(enzymes 6
zygote. 6
locular 6
zmet2 6
unmethylated, 6
sequences) 6
MET1, 6
(Zmet2), 6
Metz 6
truncates 6
internalised 6
Gene) 6
LRSAM1. 6
Ganglioside-induced 6
associated-protein 6
(ADCMT). 6
ADCMT 6
Dnm2-deficient 6
B-associated 6
Dnm2 6
genes/loci 6
373 6
infection) 6
ATF2/c-JUN, 6
(CPT) 6
MMDiff 6
interoperable 6
fronto-orbito-basal 6
pterional 6
Log-rank 6
progressed/recurred 6
3.26, 6
Gross-total 6
retreatment-free 6
retreatment, 6
challenged, 6
preoperatively. 6
[48%] 6
25), 6
MTs 6
adjoining 6
manner: 6
Maori 6
follow-up). 6
NICM 6
DE, 6
mid-wall, 6
glycerophospholipids 6
published: 6
PO 6
PCI, 6
3.37 6
≥7 6
OATP1B1/1B3 6
glucuronosyltransferase 6
(BA), 6
limping, 6
ibuprofen, 6
walker 6
boot, 6
coalitions 6
coalitions, 6
calcaneocuboid 6
perichondrial 6
pure-tone 6
revisions, 6
(IgII-IGIII 6
brachycephaly 6
non-Muenke 6
epiphysis, 6
(FGFR3(P250R) 6
(TMJ) 6
FgfR3(P244R) 6
Jackson-Weiss 6
(FgfR3 6
(P244R)) 6
waitlist. 6
(searched 6
71.4% 6
what's 6
nondopaminergic 6
Suitability 6
widened, 6
fibrofatty 6
breath-hold 6
p=0.002). 6
s-IBM 6
Hsc73 6
NRK-52E 6
KFERQ. 6
Annexins 6
double-membraned 6
enlarged, 6
End-Stage 6
ecchymoses 6
1.72 6
tumour-associated 6
mesophilic 6
0.2, 6
flagellar 6
synthases, 6
peptidoglycan. 6
(PTGS2) 6
(DRB 6
beta-1 6
capping, 6
Ser2-P 6
lifespan-sustaining 6
low-copy-number 6
Historical 6
nerve) 6
characteristic, 6
Ca-transport. 6
(rapamycin-insensitive 6
mTOR), 6
Raptor 6
(mTORC2). 6
SREBP-1c 6
T-regulatory 6
dominance, 6
(digit 6
(Δ(r-l)) 6
photocopies 6
9044 6
3.22, 6
extragenital 6
3.58 6
S6K. 6
proteinuria-induced 6
G>A, 6
CVC 6
MetS, 6
Hgb 6
discrepancies. 6
manuscripts 6
mandates 6
(IL-8, 6
ANG, 6
APOE) 6
banked 6
urine-based 6
cut-point 6
synthases 6
REBASE 6
micro-organisms 6
AMDS 6
Discordance 6
R497K 6
8.3% 6
capecitabine, 6
CDK4, 6
DMAPT 6
instillation 6
Percentages 6
cooled 6
GAPDH, 6
HKP 6
R788. 6
TCL1 6
diabetogenic 6
Rigel 6
TNFalpha, 6
c-ret 6
non-responder 6
EBV-associated 6
(PRO) 6
457) 6
transaminases. 6
Platelets 6
Transfusion 6
fibroblast. 6
triggering. 6
physiochemical 6
[Miller-Fisher 6
(GBS). 6
fossa, 6
(GBS), 6
GM1, 6
intra-genomic 6
corollaries 6
acid-specific 6
PR2-biases 6
C(2)-type 6
(PR2), 6
(Parity 6
fumigatus 6
CD105 6
p14(ARF) 6
SUZ12, 6
lncRNA-LET 6
butyric 6
pinpointing 6
p.R69C 6
(XLMTM). 6
novel) 6
HIV-associated 6
eradicating 6
Siberian 6
superinfection 6
subregion 6
resistance: 6
Ictal 6
(ADP) 6
.02) 6
Obese 6
sensitization, 6
(CDH) 6
2.8) 6
(totaling 6
machine, 6
systematically. 6
balances 6
affirmatively 6
inactivation--a 6
"Oncogene 6
l/min 6
(73.9 6
(American 6
(60/100) 6
(33/100) 6
anaesthetics 6
remifentanil-based 6
remifentanil 6
2.42 6
697 6
co-operative 6
pound 6
Gasdermin 6
Gsdma3 6
cell-growth 6
multicopper 6
oxidases. 6
noncollagenous 6
telomere, 6
FOXO3a, 6
(BBE), 6
nose. 6
(diffuse 6
proprioception 6
denied 6
Locked 6
miR-155. 6
IRAK-1 6
miR-146a-regulated 6
miR-26, 6
rs3027898 6
5-azaC 6
miR-34a*. 6
XIAP, 6
microRNA-223 6
(miR-223) 6
miR-223-positive 6
microRNA-18a 6
miR-17-92-derived 6
Cytotoxic 6
multiplexing 6
curatively 6
WiDr 6
CD44v. 6
SLX 6
Isoforms 6
incontinence: 6
oestrogens 6
17.7% 6
appointment 6
significant). 6
out-patients 6
Viewer, 6
(JIA) 6
1.59; 6
repositories, 6
conjunctiva, 6
skin; 6
TSH. 6
PANC-1 6
actin-associated 6
(MAYP) 6
Cdc15 6
(CSF-1R), 6
ruffling, 6
Actin-crosslinking 6
Rho-GTPases 6
(IRSp53 6
IRSp53-dependent 6
Cdc42-induced 6
(VASP). 6
barbed-end 6
DdVASP, 6
WT-like 6
formin-mediated 6
(IMD). 6
lamellipodium 6
Helisoma 6
6--12% 6
H4) 6
TBP 6
high-order 6
Sgf73. 6
(quantified 6
rotarod 6
non-coding, 6
fossils 6
Replicating 6
grapevine 6
rodlike 6
Viroids: 6
satellites 6
chloroplast, 6
quasi 6
available). 6
Eosinophilia 6
schistosome 6
[Diagnostic 6
seroconversion. 6
schistosomicides 6
fever) 6
hepatosplenic 6
isoflavones, 6
Bibliographies 6
flushing. 6
alpha-glucosidases 6
AalphaGlu 6
immunodiffusion 6
1-deoxynojirimycin 6
maltase-deficient 6
2800 6
(ECGs) 6
GAA, 6
728 6
Replacing 6
muscle-wasting 6
HURP's 6
MLN8237. 6
HURP 6
irradiances 6
model-predicted 6
ion-channels 6
(NpHR), 6
archaerhodopsin-3 6
(Arch) 6
synchronization. 6
light-activated 6
ever-growing 6
photocurrent 6
Channelrhodopsin2 6
intellect 6
continence. 6
hydrocephalus--progressive 6
incontinence--have 6
Thorough 6
alpha-keratins 6
KAbetaPs 6
Marburger 6
(Autism 6
Interview-Revised, 6
Schedule, 6
Kinder-DIPS) 6
bilateral) 6
bilateral). 6
ARX 6
Möbius 6
muscle-based 6
residues; 6
sarcolipin-null 6
(-dF/dt) 6
(dKO) 6
T5 6
autocamtide 6
sarcolipin. 6
epitope) 6
tissue-dependent 6
genotypically 6
(IFAR) 6
karyotypically 6
thanatophoric 6
eyelids, 6
100800), 6
146000), 6
602849), 6
187600, 6
187601) 6
Lacrimo-Auriculo-Dento-Digital 6
RhD(-) 6
pre-conception 6
>1,600 6
(NC) 6
AAV9-S100A1 6
Essentially, 6
launched. 6
kallikrein-kinin 6
C1-INH 6
1.55), 6
1.41 6
suddenly, 6
(SB 6
(PBL) 6
schemes. 6
CHADS(2) 6
haemorrhages 6
Absorption 6
lightheadedness, 6
OMIM#235730) 6
2q22.3 6
(ID)-distinctive 6
gestalt-multiple 6
rescue, 6
2q22 6
(Smad 6
ZFHX1 6
48-nucleotide 6
44-nucleotide 6
lobes, 6
Hypospadias, 6
deletion/mutation-positive 6
(18/39). 6
delays/mental 6
Ophthalmologic 6
vhnf1, 6
(nonsense 6
Text 6
gene-disease 6
experimentation. 6
Faster 6
Ontology, 6
vocabularies 6
organism-specific 6
motif-based 6
microscope, 6
orpk 6
416 6
reptile 6
rejecting 6
Amniota 6
2386 6
UCE-anchored 6
outline, 6
first-diverging 6
elephants 6
tenrecs 6
(Afrotheria). 6
"anomaly 6
(Chiroptera) 6
Perissodactyla, 6
Cetartiodactyla, 6
Amniotes. 6
(PGI2) 6
treprostinil) 6
(PGI(2)) 6
(SSc) 6
noncompartmental 6
(oral 6
well-balanced 6
log-transformed 6
subcutaneous, 6
Inhaled 6
ERK. 6
MGS 6
short-stature 6
ATRIP-deficient 6
(ear-patella-short 6
(Meier-Gorlin 6
Imiglucerase 6
Cambridge, 6
splenic, 6
Alglucerase 6
high-dosage 6
(GCase), 6
SCARB2 6
cytocidal 6
Medulloblastoma, 6
Hsp70-bound 6
XAP2 6
(C-PC), 6
C-Phycocyanin 6
phycobilisomes 6
niches. 6
Streamline 6
concentration-dependently 6
B-phycoerythrin 6
buffer. 6
Phycoerythrin 6
reagent. 6
635 6
chromatically 6
diplosiphon. 6
Anabaena 6
hemiparkinsonian 6
spore-forming 6
cuniculi 6
-20°C 6
disinfection 6
six-kingdom 6
Protozoa, 6
Animalia, 6
branch, 6
subphylum 6
Code 6
infrakingdom 6
emerin. 6
explanations. 6
defects; 6
CaCl2 6
(LMWH) 6
potencies, 6
0.007, 6
LAP/ACP2 6
Biosynthesis 6
TRbeta1) 6
Mitigating 6
inevitable, 6
factor-I. 6
(IGF-I). 6
(Increlex, 6
Ipsen, 6
(FSR) 6
flood-primed 6
tendon) 6
[skin: 6
(CTRL); 6
tendon: 6
SE]. 6
0.001%/h). 6
system's 6
taxanes, 6
alpha-tubulin, 6
Flybow 6
proboscis 6
spindle- 6
cobble 6
stone-like 6
stemness. 6
C1.1 6
IFN-gamma) 6
(TGF-beta1) 6
(MDCK) 6
phenocopying 6
beta-catenin/TCF-3 6
pp60c-src 6
reductases, 6
respirable 6
Ssn6 6
thioredoxin-like 6
FOB. 6
stability; 6
regulon. 6
Iron-responsive 6
Iml3 6
iron-regulon 6
Hans 6
conformer 6
valves, 6
Whenever 6
embryological 6
flared 6
COMPASS-like 6
super-enhancers. 6
by, 6
Disease, 6
perturbation, 6
wound-repair, 6
(ESCs). 6
13q 6
Prolactin 6
acromegalic 6
adenomas; 6
(XDG) 6
xanthine-containing 6
glycosylases. 6
guanine, 6
productively 6
G:T 6
O6 6
interleaved 6
mispaired 6
adenine. 6
TAMs 6
3-T(1)AM 6
carboplatin/paclitaxel 6
(PLF) 6
(EGFR)-targeting 6
1250 6
OS: 6
weekly). 6
272, 6
multi-institutional 6
m-2 6
(n=3), 6
fissures 6
Neuroprotection 6
Industry 6
nitrone 6
Beijing, 6
question: 6
(Stroke-Acute 6
ECASS-II 6
unwarranted 6
care). 6
-0.6 6
(http://services.hon.ch/cgi-bin/QA10/qa.pl). 6
FA-D2 6
eight-protein 6
restarted 6
postasphyxial 6
CBV 6
varied. 6
SCI. 6
pg/mL, 6
(baseline 6
mTBI 6
morphometry 6
boxing 6
non-fluent 6
dementias. 6
NfH 6
MHPG 6
gemcitabine-based 6
(AMI, 6
(SHAM, 6
(AMI-THYR, 6
thickness/LVIDd 6
constriction, 6
3,5,3' 6
alpha-Myosin 6
HYPO. 6
DRON, 6
(IU/L 6
thyroids 6
(LVH) 6
44%, 6
pumping 6
PaDOD1 6
onychodystrophy, 6
Wellcome 6
twin. 6
9-20 6
3'-H3K4me3-marked 6
iPABP 6
neural, 6
nanotube 6
maybe 6
extensions. 6
(microsynteny) 6
gambiae, 6
1824 6
salt-sensitive 6
checkpoints, 6
Rev-erbα 6
(definition 6
SUMMARY 6
Low-risk 6
Prominin-1 6
7-nitroindazole 6
(MMS) 6
concave 6
(DMRs). 6
human; 6
EBNA 6
-3B 6
overhangs 6
Ser515 6
carteri. 6
ion-dependent 6
DNMT3B3Delta5 6
beta+/+ 6
P450R 6
deserts 6
[placebo]), 6
17.2 6
enalapril. 6
valvar 6
sinonasal 6
(carcinoid 6
synaptophysin. 6
53.6% 6
sensitivities, 6
Sweden). 6
0.035) 6
insulinomas. 6
non-insulinoma 6
MUCs 6
LN. 6
chloroquine-resistant 6
(c.830A 6
p.Gln277Pro) 6
DFN2. 6
Enzymatically, 6
PRPS1-disorders 6
PRPS1-related 6
replenishing 6
alpha-tocopherol 6
GPx-1 6
(aHR 6
certificate 6
amputation, 6
1.16; 6
presence. 6
proto-oncogenes, 6
sequence's 6
HuD 6
HuA 6
escort 6
indiscriminate 6
uridine-rich 6
(GLUT1) 6
(MC). 6
miR-29a 6
dysplasia) 6
neointima 6
basally 6
polysomes, 6
vitally 6
elavl1 6
HuR-binding 6
(JAKs) 6
CCI, 6
(iNOS). 6
(NF-κB). 6
GDNF) 6
hemisected 6
(3H)lysine 6
postoperation 6
wounds. 6
IP(3)R1 6
abscisic 6
concanavalin 6
anti-digoxin 6
disposable 6
surfaces, 6
lectin, 6
RNase, 6
oligo(dT) 6
afterdepolarizations. 6
(VF). 6
(DNA) 6
pointes. 6
R4497C 6
AA98 6
vivo: 6
anti-invasive 6
mechanics, 6
(sarcoplasmic 6
Circulation 6
Knöll 6
telethonin 6
alpha-actinin, 6
alpha-actinin-2 6
cytochalasin 6
C797S 6
TMDRSI 6
TX, 6
time-varying 6
0.047 6
bite. 6
mutation-type 6
pyelectasis 6
Metaphase 6
Menin, 6
(adrenocortical, 6
carcinoid) 6
(lipoma, 6
angiofibroma, 6
collagenoma, 6
meningioma) 6
(parathyroid, 6
pituitary) 6
(gastrinoma, 6
glucagonoma) 6
lithiasis 6
(mother 6
SMAD4/DPC4 6
insulinomas) 6
non-endocrine 6
angiofibromas. 6
ataxin-3, 6
Josephin 6
AT3 6
N-terminus, 6
resistin 6
(CSFV) 6
(position 6
0.7% 6
Union. 6
intraepidermal 6
Brother 6
self-interaction 6
(Ihh), 6
(IHH) 6
duodenum 6
total-amino-acid 6
patched 6
(SMO) 6
(VSMCs) 6
2-stage 6
(PHQ-9 6
(109 6
false-positives 6
1991). 6
heterochromatinization 6
7,8) 6
(Me-HA) 6
(Me-Gel), 6
bioprint 6
(HAVIC). 6
appointed 6
polyP·Ca(2+)-complex, 6
(TAM). 6
G→C 6
leuC 6
tetracycline-regulated 6
LYS2 6
process(es). 6
Polzeta. 6
thiopurine 6
speak 6
Laboratories, 6
(confidence 6
55-0396 6
trimethadione, 6
flick 6
Gallopamil 6
[3H](+)-isradipine 6
Mibefradil 6
L7/12 6
cardio-renal 6
ARB 6
Pkn2 6
HUalpha 6
co-crystal 6
winged 6
Hlps 6
triptans. 6
Olcegepant 6
44370 6
NTG 6
Subjects. 6
313 6
HTR 6
freedom, 6
SPF24NAE, 6
PR2NAE. 6
antagonised 6
bed. 6
alphaCGRP 6
microm; 6
7%) 6
proximal, 6
CH-157MN 6
hematotoxicity. 6
judiciously 6
20.7 6
deep-vein 6
GLIADEL 6
(KPS), 6
temozolomide). 6
(P=0.0003) 6
(BCNU, 6
pre-microRNAs 6
(NR) 6
(TRBP) 6
cervicomedullary 6
symptomatology. 6
large-animal 6
Publication 6
(BLM) 6
Fancd2 6
SLX4, 6
561 6
transplant-free 6
rhabdomyoma 6
sclerosis-related 6
41.0 6
33.9% 6
bulla 6
16p13.3, 6
CLB 6
reiteration 6
(TIRs) 6
Repeats) 6
(SPG55). 6
(ICE) 6
CD20, 6
66%) 6
42) 6
IPI 6
(etoposide-ifosfamide-methotrexate)-DHAP 6
(cisplatin-cytarabine-dexamethasone) 6
(R; 6
(DHAP 6
(PTC), 6
well-preserved 6
angiograms 6
(60%). 6
canal. 6
whorls. 6
bodies; 6
membrane-free 6
(psammoma 6
deep-tendon 6
NP-Lambert-Eaton 6
remind 6
(SCLC), 6
flagellin 6
caspase-1-dependent 6
mir-30d 6
Microbiota 6
DEDD 6
paraspinal 6
lumbago 6
(11;22)(q24;q12), 6
thoracopulmonary 6
pXO2(+) 6
-13 6
(CKD-EPI) 6
eGFR(cys) 6
equations, 6
CAC 6
'gold 6
47,XXY, 6
(cffDNA 6
performed: 6
XO 6
(MPS) 6
amniocyte 6
tetrasomy 6
46,XN 6
positives). 6
non-invasive, 6
Care. 6
paralyses. 6
anecdotal. 6
begin. 6
triggers, 6
interattack 6
Social-Emotional 6
24%) 6
(SD)) 6
boys) 6
Toronto. 6
79) 6
translatable 6
solicit 6
social-emotional, 6
cognitive. 6
51-item 6
Questionnaires, 6
(0.93, 6
0.88-0.96), 6
0.79-0.93), 6
1.01-1.53). 6
SEARCH 6
preconceptional 6
losses, 6
(summary 6
801 6
periods) 6
Lectin 6
Hafnia 6
ficolin-3, 6
rMASP-3 6
MASP-2/ficolin-3 6
MK-3475, 6
mono-phosphorylated 6
RNAPII, 6
Lys(44) 6
H2Bub1, 6
(rs2535629) 6
1.21, 6
(CTLA-4) 6
Principles 6
(11.9%) 6
87.9% 6
Ipilimumab, 6
1.1) 6
notice 6
strands). 6
spatio-temporally 6
microbes, 6
bacterial-derived 6
intravital 6
nonhematopoietic 6
TTSS. 6
chemokine/cytokine 6
(Nod1/2 6
DKO) 6
Accordingly 6
extravillous 6
RICK 6
(PGN) 6
acid-containing 6
ligand-injected 6
PGNs 6
bolstering 6
lymphotoxin 6
oligomerisation 6
(NGT). 6
(IL6) 6
11-7082 6
(NOD1) 6
prostaglandins 6
IRF-1-binding 6
MDMs 6
NOD1-dependent 6
clearance; 6
(PADs) 6
ex-smokers 6
PAD-4 6
Office 6
shampoo 6
girl's 6
eyelids. 6
larva 6
eyelid. 6
Tick 6
nits. 6
translucent 6
lotion. 6
Residing 6
Ca(2+)-homeostasis, 6
divided, 6
protein-to-protein 6
lumenally 6
(0.1-1 6
(Guo 6
digoxigenin-CS, 6
digoxigenin-HCP, 6
calcium-calmodulin-dependent 6
(CAMKII) 6
597 6
mmol/day 6
1.6). 6
>3) 6
hypocalcemia 6
angiogram 6
SAH; 6
principle. 6
edaravone-treated 6
edaravone, 6
saline) 6
denoting 6
2.99, 6
40.0 6
OR- 6
Vienna 6
0.08), 6
auras. 6
meningioangiomatosis. 6
malformations: 6
Clinicopathologic 6
Erythropoietin 6
(last 6
scientists, 6
alike. 6
plectin, 6
PER1 6
INS-1 6
CMT4D 6
(NDRG1) 6
splice-acceptor 6
accelerated. 6
RAB7, 6
GAN1, 6
SETX 6
[Update 6
NDRG1, 6
MTMR13/SBF2. 6
SM/LPS 6
(C). 6
Consequences 6
reinsertion 6
TRPML1 6
chloroplasts, 6
Carvedilol 6
intervene 6
2143 6
steering 6
vaccination: 6
DQB1*0602 6
57.6% 6
93%, 6
gyrus. 6
[(18)F]fluorodeoxyglucose 6
tracers 6
LMCI 6
Basic/Analysis 6
Databases: 6
Cap-analysis 6
CAGE, 6
(TUs). 6
Mining 6
Fantom3 6
H-InvDB 6
protein-coding. 6
nephrolithiasis, 6
hyperoxaluria 6
JIB 6
(PTH). 6
(V600E 6
committees 6
BREAST 6
Trials, 6
ATC 6
retrograde) 6
motor-based 6
motor. 6
rheumatology, 6
Dimethyl 6
disorders]. 6
struggle 6
Chugai 6
monitors, 6
(GEL) 6
NCT00676715. 6
68-97; 6
(89-99; 6
GEL 6
1·3-2·3) 6
(5%; 6
4·6-6·3) 6
relapse-related 6
NP-40 6
postimplantation 6
MeCP2, 6
reveal. 6
preattachment 6
12: 6
X-inactive-specific 6
Tsix, 6
Xce 6
connections, 6
dopamine-β-hydroxylase 6
PrLDs 6
fibrils, 6
TAF15 6
cop8 6
does, 6
Next-Generation 6
(Prx2) 6
peroxides. 6
Microarray-based 6
(ELISA), 6
defenses. 6
(PCG) 6
Tetrac 6
electrocardiography, 6
debridement 6
sinusitis. 6
retroelements. 6
predominates. 6
(PITX1) 6
paired-like 6
2-mediated 6
virions, 6
Duchene 6
(hA3) 6
(FDR) 6
N-glycoproteome 6
wild-derived 6
lysates, 6
PY), 6
(ACR50, 6
(STA) 6
intracortical 6
VSMCs. 6
Primers 6
OMCG1 6
stalling, 6
Ter 6
University. 6
(L-dopa) 6
3OMFD 6
high-pressure 6
graphically 6
carboxamide 6
K18, 6
K19 6
AD-associated 6
limited; 6
M-type 6
TT3, 6
TRDN 6
Beta-blockers 6
known; 6
Relatives 6
Lead 6
Catalyst/HypoGen 6
0.95) 6
U/ml, 6
GD: 6
89·9 6
(18·4); 6
98·8 6
(19·7), 6
Interventional, 6
LSPR-peak 6
colloids 6
(V) 6
Pro252Arg 6
(FGFR-3)-associated 6
acrocephalosyndactyly 6
Experts 6
(TSS), 6
Arnt2 6
NCT00866619. 6
13·7 6
4993 6
45) 6
Trust. 6
pertussis 6
MPL 6
financing 6
MPAC 6
intra/interchromosomal 6
compartmentalisation, 6
CTCF-like 6
(ZF) 6
ASSET: 6
invaginations, 6
saps-1(RNAi) 6
sidekick-1 6
chimera, 6
subcloning 6
BETAWARE 6
linux-based 6
in-home 6
filtering. 6
computers, 6
BOCTOPUS: 6
BOCTOPUS; 6
(HMMs). 6
Q3 6
Predictions 6
Baum-Welch 6
http://rbf.bioinfo.tw/~sachen/tmrbf.html. 6
TMBpro: 6
beta-contact 6
(TMBpro) 6
(TMBpro-SS), 6
(TMBpro-CON) 6
(TMBpro-3D) 6
86.4% 6
PRED-TMBB: 6
(PRED-TMBB, 6
http://bioinformatics.biol.uoa.gr/PRED-TMBB) 6
(SVM). 6
ANN 6
back-propagation 6
77.4%. 6
(MCC) 6
http://www.imtech.res.in/raghava/tbbpred). 6
whole-protein 6
accuracy). 6
PROFtmb 6
sequence-profile-based 6
77.91% 6
Chou's 6
BOMP: 6
(BOMP), 6
locates 6
Omp2b 6
AMPs 6
OMBBs 6
96%. 6
organizer. 6
isothiocyanate 6
R695X 6
Q433X, 6
melanoblasts 6
U). 6
steeper 6
SNAPtide 6
Intoxication 6
microtitre 6
(MTBP) 6
lined 6
naloxone, 6
'cascade 6
method' 6
overdose: 6
bag-valve-mask 6
74) 6
abused 6
drift. 6
human/mouse 6
uvrB, 6
eubacteria, 6
stearothermophilus 6
Cho 6
P3 6
hRyR2 6
2.29 6
NiS-transformed 6
(HCC); 6
SLC38A9, 6
RagA/B 6
Philippines. 6
dystonia-parkinsonism/Lubag 6
fentanyl, 6
TAF1/DYT3 6
DYT3, 6
(PARK9) 6
putamina. 6
Panay. 6
PC-3. 6
V-FITC/propidium 6
pigment, 6
venography, 6
(0.1%) 6
Re-stenosis 6
Purpose: 6
obstructions 6
44.4% 6
stents. 6
51.0% 6
intraprocedural 6
ITG 6
461 6
1012 6
safety-related 6
fluoroscopy 6
safe? 6
564 6
stent, 6
AZY 6
AZY, 6
SP. 6
.003) 6
strictures 6
(ASCs) 6
new? 6
Gfi1a 6
paralog, 6
HSC, 6
hematopoiesis; 6
gfi1b. 6
scl 6
gata1. 6
lmo2, 6
scl, 6
runx-1 6
c-myb 6
HSPC. 6
E10.5 6
TGFBR3, 6
1-gamma 6
(TIF1-gamma). 6
(TbetaRIotaII) 6
(siRNA). 6
cytotoxic. 6
Sox6, 6
Pbx1 6
(Velcade), 6
(Thalomid), 6
concisely 6
structure-sequence 6
N, 6
(GPS), 6
Nbeal2 6
BEACH 6
nuclease-null 6
aptamer-modified 6
Parathyroid 6
0.34; 6
far-reaching 6
detachment-induced 6
CIIA 6
NCX(REV) 6
(SEA0400) 6
+50 6
K(+), 6
macules. 6
620 6
cotrimoxazole. 6
malnourished 6
1.95, 6
threats 6
1.68; 6
pro-opiomelanocortin 6
(POMC) 6
System, 6
deamination-independent 6
APOBEC3D 6
(A3F), 6
ssRNA 6
delta4-10 6
missense). 6
incontinenia 6
leukocytosis, 6
(IP). 6
NEMO. 6
anhidrotic 6
(BA) 6
cholestyramine 6
(fasted, 6
Unconjugated 6
(FXR), 6
TM. 6
chordates. 6
signal-induced 6
Thr-55 6
chemoprotection 6
Podbat 6
tool), 6
pcd 6
H2AZ, 6
ZNF668 6
Remote 6
UCNEs. 6
http://ccg.vital-it.ch/ucne/ 6
UCNEbase--a 6
UGRBs. 6
D3T 6
methods). 6
[Ca(2+)]i. 6
overactivity, 6
vocalization, 6
>480 6
Fallot, 6
Emx2 6
Alx3 6
(MT1-MMP), 6
severing 6
80-fold 6
Louis 6
(ORFs). 6
(PFGE), 6
2OMePS 6
(involving 6
one-shot 6
missegregation. 6
Rad21, 6
cohesin-independent 6
Slavic 6
bi-directional 6
(CDKL5) 6
(MeCP2), 6
Milder 6
rarest 6
INH 6
deviation). 6
34.3 6
negative" 6
RECK. 6
BB-94 6
n=18, 6
passages, 6
escaping 6
decaying 6
imaginary 6
briggsae 6
gymnasts 6
keywords: 6
(GDM), 6
≥25 6
race/ethnicity 6
ff 6
(49), 6
Hypovitaminosis 6
70.6% 6
omega-6 6
cross-referenced 6
(CVC) 6
enrollment; 6
Organization. 6
Alteplase: 6
(regimen 6
(B), 6
Streptokinase, 6
streptococci, 6
streptokinase, 6
bleedings 6
thrombolytics 6
saruplase 6
(VSMCs). 6
MEK2-specific 6
hDlg, 6
MEK1/MEK2 6
Scaffold 6
Cbl-CIN85 6
Trithorax 6
Corto, 6
beta-arrestin2 6
Partner 6
KSR1 6
p14 6
RhoAGTP 6
lymphomagenesis. 6
HDAC2. 6
regulations. 6
miR-29s 6
INterspersed 6
Element-1 6
Enhancer/Suppressor 6
P=0.000). 6
copeptin 6
subfunctionalization 6
non-lymphoid 6
re-silencing 6
p57kip2 6
bias: 6
Myosin-II 6
SMAP1. 6
AMAP2/DDEF2 6
Sildenafil, 6
PCSs 6
dream 6
EBs 6
(SECIS), 6
UPF1 6
UTR, 6
SevAn 6
ICU. 6
(73%), 6
h-1 6
steroidogenesis 6
oxycodone-thiopental 6
(Ramsay 6
Midazolam 6
means. 6
496 6
TPL-2 6
p52. 6
nonhemolytic 6
indocyanine 6
Markedly 6
(Gilbert-Meulengracht, 6
Crigler-Najjar, 6
glucuronidation 6
Gilbert's 6
message, 6
Introns 6
ADAR2 6
auto-editing 6
Agrobacterium-mediated 6
piRNA-dependent 6
Idefix 6
gametogenesis, 6
transposition. 6
piNG-body, 6
Aub, 6
HeT-A, 6
TAHRE, 6
Fcy21p 6
(GDNF, 6
persephin 6
GFRalpha1 6
Neurturin 6
Consistently 6
GFRA2 6
GDNF. 6
MEN2B 6
pheochromocytomas, 6
families), 6
(Q55X) 6
RG7112-dependent 6
(P53, 6
[MIC-1], 6
JAK2V617F-positive 6
decoy, 6
PRT4445, 6
etexilate, 6
(adomiparin), 6
(semuloparin, 6
RO-14), 6
AZD0837), 6
(REG1,2), 6
262084, 6
clavatadine 6
VII/tissue 6
(tifacogin, 6
274836, 6
593214), 6
(recomodulin, 6
solulin), 6
(TB402), 6
thrombin/factor 6
(EP21709, 6
tanogitran), 6
"anticoagulants 6
endoxaban, 6
overcome. 6
fondaparinux 6
VTE, 6
LMWH, 6
(IPD), 6
(OCD), 6
cicatricial 6
amegakaryocytic 6
backache, 6
reconstitution. 6
world-wide. 6
Egypt 6
Pistacia 6
human-to-human 6
biogeography 6
DENV, 6
provinces 6
albopictus 6
Province 6
(ACT). 6
anuran 6
xTNF-alpha 6
Fas-associated 6
(Gleevec), 6
stereotypy 6
lisuride 6
family-wide 6
(DUSPs), 6
(organ 6
obstruction: 6
(DWT) 6
Weight, 6
diverticulosis, 6
trabecolations 6
(pseudo-diverticula), 6
post-void 6
ICI-RS 6
agreements 6
1.57 6
1.49 6
APPwt 6
APPswe 6
several-fold 6
ATHENA-Opioid 6
gout 6
amplifications, 6
X-chromosome. 6
S-methylmethionine 6
crassa. 6
ertapenem 6
Matrix-assisted 6
OXA-48 6
β-lactamase 6
ChromID 6
(14), 6
Sme, 6
IMI, 6
GES, 6
marcescens 6
copy, 6
tie 6
(FMTC) 6
STARR-seq, 6
enhancer-screening 6
cistron 6
macroH2A1-containing 6
Adaptation 6
lysine-4 6
non-radioactive 6
hybridisation. 6
apex, 6
amiodarone-treated 6
BS. 6
L4/5 6
Degenerative 6
turkey 6
1C 6
(p) 6
B-ring 6
vaniprevir 6
HCV-infected 6
NS4A 6
ACH-806 6
Alisporivir 6
parahaemolyticus. 6
stroke/TIA 6
dialing 6
AVMs 6
paracancerous 6
Ratios 6
miR-127, 6
miR-154, 6
miR-323, 6
miR-370, 6
miR-183, 6
miR-181a 6
tumor-suppressing 6
(MCs) 6
CaP. 6
HGPIN 6
nicotine-induced 6
miR-29b 6
DNA-PK 6
M059K 6
Houston, 6
miR-133b. 6
(let-7i, 6
mir-21) 6
-221 6
EGFR-TKI, 6
Kv1.5 6
multichannel 6
(2-year 6
AraC, 6
(FLAMSA-RIC), 6
69%. 6
E-mediated 6
IkB 6
holocomplex 6
SS, 6
NOD/LtJ 6
(SjS) 6
nonautoimmune 6
Professional 6
avulsion 6
arch. 6
parturition 6
biomechanics 6
meticulous 6
pVHL, 6
pulposus 6
overproduction. 6
islets. 6
TKI. 6
(gefitinib 6
erlotinib-resistant 6
858 6
(8.2 6
0.0008 6
erlotinib), 6
cardiolipin-binding 6
phosphatidylglycerol. 6
(TOM) 6
Mitofilin 6
Fcj1 6
TOB/SAM 6
IMM 6
ecosystem. 6
Metaproteomic 6
sediments, 6
metaproteomics. 6
ecology. 6
Oregon 6
represented, 6
Flavobacteria 6
Tight 6
grandmother's 6
low-copy 6
back, 6
57, 6
G1336X 6
TRalpha1-deficient 6
KCNE1-overexpressing 6
KCND2 6
KCNA4 6
calcium-activated 6
gauge 6
HPLC-MS/MS. 6
Untargeted 6
Agilent 6
2F2R 6
CrTrxR1 6
ecosystems 6
(TSC2). 6
(minor 6
GSTP1, 6
M301K 6
(SCENAR) 6
XRCC6 6
Cr(VI) 6
Arf 6
mutagenized 6
(respectively 6
(19% 6
TRbeta, 6
Polypedates 6
(HPL-2) 6
ChIP-on-chip 6
long-lived, 6
diapause, 6
HPL-2, 6
hpl-1 6
desiring 6
(1/15) 6
post-operatively. 6
Barrier 6
expectant 6
endometriomata. 6
sub-fertility 6
5.21 6
non-surgical 6
IVF, 6
commencing 6
alpha-actin). 6
1q22-23, 6
2q21.1-q22, 6
Z-band 6
(TNNT1). 6
2,559 6
SAB 6
(APS) 6
renovascular 6
hypoinsulinemia, 6
(triiodothyronine) 6
isoproterenol. 6
(1-20 6
MSAs. 6
SuperTRI 6
Essentially 6
R6/1 6
2006-2010 6
JNJ-26854165, 6
immunogenicity, 6
fluorodeoxyglucose. 6
17), 6
surgery). 6
q2w 6
interleukin-6/Stat3 6
(IL-6)/signal 6
paclitaxel-induced 6
(CBR) 6
Cheson 6
93%) 6
objective-response 6
stroke? 6
non-stroke 6
staff. 6
0.39) 6
AtHD1 6
KLOTHO 6
Dnmt 6
SurKex 6
depsipeptide 6
DNA-hypermethylated 6
ERVs 6
documented; 6
mycotoxins 6
mycotoxins, 6
FLC 6
JMJD3 6
(ER+) 6
HDACis 6
LANA-1 6
genistein, 6
Androgenetic 6
influence, 6
radiocarbon 6
boots 6
δ13C 6
palaeoecological 6
LC/IRMS-derived 6
TFA/IP 6
Dakota 6
β-MHC, 6
0.39; 6
1-4: 6
sulfone, 6
hygiene, 6
Wakefulness 6
Headache, 6
nCPAP-adherent 6
SWSD 6
apnea/hypopnea 6
131; 6
lipin-2-deficient 6
CDK6 6
NADPH-dependent 6
(alkaline 6
37°C 6
VCaP 6
sulprostone 6
ET-1. 6
(receiving 6
SU. 6
sulphonylurea 6
Delay, 6
ketoacidosis. 6
keywords, 6
cortico-striatal 6
dopamine-stabilizing 6
(b.i.d.). 6
(AUC0-∞ 6
GSH, 6
strengthened. 6
target: 6
E3s, 6
informs 6
LCLs. 6
RPS26. 6
dactyl 6
ribosomopathy. 6
probands) 6
RPS19. 6
Biogenesis 6
chemoprevention. 6
ssUV 6
sleep-disordered 6
stridor. 6
PSD, 6
stroke-related 6
0.60) 6
professionals, 6
Proxy 6
(PSDRS), 6
(Ham-D). 6
Examination. 6
MDDM; 6
carers. 6
(December 6
(35.2%) 6
TSA. 6
anti-proliferation 6
TSA/paclitaxel 6
SFKs 6
driven, 6
(idarucizumab, 6
apart) 6
Reversal. 6
Sordaria 6
macrospora 6
Atg9 6
conidiation 6
BAG3 6
Huntingtin 6
(HD), 6
Atg11, 6
YLR356W 6
post-log 6
(ATG) 6
PK/efficacy 6
7- 6
(ABK) 6
AAK. 6
OspA 6
(serotype 6
phagocytophilum, 6
(0.6% 6
genospecies, 6
Europe: 6
squirrels 6
Estonia. 6
Estonia 6
persulcatus 6
north-eastern 6
borrelia 6
MCT8. 6
(11.3 6
LT(4) 6
R280A) 6
ago). 6
ketoconazole, 6
metabolising 6
LS180 6
(P-gp, 6
pregnane 6
ETs 6
orally-active, 6
(ETA 6
ETB), 6
(97.5% 6
tadalafil, 6
soon. 6
49.7% 6
two-part, 6
EoE 6
EoE. 6
Georgia 6
(CFTR). 6
admixed 6
Rio 6
results: 6
T2D. 6
leiomyosarcoma 6
Histology, 6
22-46). 6
HER2+; 6
ER/PR/HER2 6
LFS-associated 6
stars 6
lasers. 6
Femtosecond 6
microcrystals 6
"probe 6
micrometer 6
mimivirus 6
non-crystalline 6
single-crystal 6
size). 6
lasers, 6
(XFELs) 6
apoptosis/necrosis 6
(Neu5Ac) 6
CMP-Neu5Ac 6
Neu5Gc-expressing 6
Neu5Gc-binding 6
GcIg 6
competitors 6
testicular, 6
suspension. 6
>30% 6
rats--an 6
androgen-synthesis 6
I/TALS. 6
124G>A, 6
30G>A, 6
50G>A, 6
50G>C 6
U4atac/U6atac 6
di-snRNP 6
U4atac/U6atac.U5 6
Jafarifar 6
polycythemic 6
Sp1. 6
isolations 6
CD29, 6
CD33, 6
CD73, 6
CD90, 6
CD105. 6
osteogenic, 6
radioiodine, 6
Phelan–McDermid 6
22q13.3 6
MBD5 6
2q23.1 6
KANSL1 6
17q21.31 6
adenylosuccinase 6
(ADSL), 6
(duplications), 6
MEF2C, 6
ATRX. 6
NHE6. 6
concluding 6
(heterotachy). 6
artefacts 6
selection) 6
model--which 6
summing 6
tree--and 6
spirituality 6
couples. 6
HADS. 6
cross-sectional, 6
Drainage 6
(POF) 6
tigris 6
necropsy, 6
Sheep 6
cyanosis, 6
fallot 6
Overriding 6
Echocardiography. 6
Smc1, 6
mis-segregation 6
region/c-abl 6
(BCR/ABL) 6
der22, 6
exponent 6
hypothesis: 6
zolpidem. 6
myorelaxant 6
anticonflict 6
43-year-old 6
succinate) 6
desvenlafaxine-treated 6
means: 6
874 6
(standard) 6
G/L 6
Iron-deficiency 6
μg/L. 6
≤60 6
μg/dl, 6
FeSulf. 6
infusion) 6
four; 6
centrally) 6
(between-group 6
(Genz-112638) 6
harder 6
non-interacting 6
metaPIS 6
ProRank 6
restarts 6
transposon-mediated 6
transposons) 6
A3G/B, 6
retargets 6
(L1), 6
CAGEr 6
http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html. 6
communis 6
5-Aza 6
VE-cadherin, 6
metalloproteinases) 6
metalloproteinases). 6
cooverexpression 6
miR-26b 6
antigen-defined 6
(TMAs) 6
hepsin, 6
pim-1 6
(ECAD; 6
alpha-methylacyl-coenzyme 6
racemase, 6
repressor). 6
TMAs 6
=.021), 6
10.91; 6
=.009), 6
2.96, 6
5.61; 6
6.77; 6
[Cell 6
phones, 6
OR=1.8, 6
GSM 6
RF-EMF 6
IARC 6
Interphone 6
β-cells 6
hUC-MSCs 6
OSU03012 6
phosphatidylinositide 6
Chibby 6
kinase-3beta-dependent 6
negated. 6
Porcine 6
monocytes/macrophages 6
recombineering 6
GFP-MSCs 6
(FRAP) 6
(UPD) 6
short-time 6
19,000 6
S- 6
subjects). 6
(AleNephro) 6
(PPAR)-α/γ 6
Aleglitazar, 6
comparators. 6
imminent 6
recommendation). 6
Volume 6
maneuvers, 6
anticoagulant/antiplatelet 6
(H3K79me2) 6
Set1-dependent 6
Hop1 6
Dot1, 6
telomere-specific 6
DOT1L-deficient 6
mucin-like 6
sight-threatening 6
secretome 6
myomas 6
babies. 6
Vaccinology 6
surface-expressed 6
dysentery 6
tegumental 6
MenB. 6
ruminantium 6
(IFN-γ) 6
cysto-peritoneal 6
case) 6
listened 6
piano 6
43.2% 6
"Mozart 6
TBS 6
39.5% 6
(Mozart 6
K.448), 6
Mozart. 6
34). 6
(T12) 6
"death 6
CO23 6
Subthreshold 6
proaggregatory 6
alphavbeta3. 6
thyromimetic, 6
pro-angiogenesis 6
(MKIs) 6
radioiodine-refractory 6
Bub1 6
(wild-type 6
jaw, 6
syringes 6
FbFP-based 6
pH-sensitive 6
(SRE) 6
Tat 6
coral 6
p67phox 6
unresponsive. 6
DR_1025 6
dGTP 6
8-oxo-dGTP/8-oxo-GTP 6
∼50 6
mutT(-) 6
(fast 6
(8-oxo-dGTP), 6
mutT, 6
MutM 6
G:C-->T:A 6
Antibacterial 6
MTH2, 6
mg/m(2)/day) 6
staurosporine, 6
STEMCCA 6
excisable 6
(HADS) 6
TGFβ-induced 6
Foxp3. 6
NEAT2 6
1,000-fold 6
ENE 6
herpesviruses, 6
miR-675. 6
(Ovis 6
another; 6
damper 6
TRAF1-C5 6
PRM1, 6
Greece, 6
rs7574865 6
autoantibody-negative 6
(rs7574865), 6
(rs10499194 6
rs7574865STAT4 6
2.18) 6
rs2476601PTPN22 6
2.26) 6
rs10499194 6
rs6920220 6
(Pcorr 6
Pcorr 6
0.180, 6
(rs2476601), 6
(rs2240340), 6
(rs3087243) 6
NHSII), 6
7900 6
(Applied 6
Lincoln 6
Foster 6
94404 6
(HLA-SE) 6
1.46, 6
2.08). 6
RF-negative 6
1.84] 6
1.40] 6
PADI-4). 6
(P=.004) 6
UA-patients, 6
6-min 6
multipurpose 6
neuritis. 6
post-TBI. 6
gamma-rays, 6
Bednar 6
glucocorticoid-inducible 6
p18-deficient 6
Ser314. 6
10-26 6
copper/zinc 6
undesirable, 6
11th 6
proteases) 6
Nbs1 6
HDR 6
(Rap1-interacting-factor-1), 6
early-S-phase 6
nuclear-insoluble 6
late-M-to-early-G1 6
chromatin-loop 6
early-S-phase. 6
rif1Δ, 6
rif1(+), 6
early-firing, 6
Rif1's 6
checkpoint-defective 6
Rif1-mediated 6
rif1 6
CRII 6
prereplication 6
RVxF/SILK 6
Hemophilia 6
Gluten 6
FGID 6
allergies 6
intolerances 6
FGIDs. 6
nonceliac 6
transglutaminase. 6
gliadin, 6
introgressed 6
13q22 6
G57S 6
BRSK2 6
p97 6
gp78, 6
p97/VCP, 6
CD3delta 6
DNAJB14 6
B; 6
BRAF(V600)-mutated 6
BRAF. 6
(71% 6
squamoproliferative 6
soles, 6
[14%], 6
ERVA 6
[27%] 6
(OAB), 6
Dry 6
dinucleotide-dependent 6
ERK1/2-dependent 6
Gain- 6
B56alpha 6
>550 6
genome' 6
p53: 6
Ser-33 6
CHCHD10. 6
c.197G>T 6
p.G66V 6
co-ingested 6
hypertonia, 6
two-phase 6
woke 6
(CGIS), 6
crying 6
(Ro 6
(TRβ1), 6
NGS-based 6
100.0) 6
cDNA-probe-based 6
TGFBR1/2 6
partitioning, 6
Shapiro's 6
over-grooming, 6
vocalisations 6
Impairments 6
SINV 6
Caprin1, 6
USP10, 6
Caprin1 6
USP10 6
athletes' 6
virology 6
RNASEH2A, 6
RNASEH2B, 6
RNASEH2C, 6
collated 6
AGS, 6
groundwater. 6
Fe(III), 6
Clone 6
sodA 6
predictive, 6
rpsC 6
prowazekii. 6
X-chromosome, 6
(stages 6
colocalise 6
EphrinA1, 6
EphB4/EphrinB2 6
retromobility 6
RRM3, 6
Rrm3p, 6
C(1-3)A/TG(1-3) 6
(cdc6) 6
(ORB) 6
cFLIP 6
RIP1/RIP3 6
pupil. 6
defect) 6
dapiprazole. 6
supraspinal 6
PNS 6
apposition 6
Osterix 6
Rel/NF-kappaB 6
pattern-recognition 6
Peyer's 6
emphasise 6
(JAG1) 6
postcancer 6
Frequently 6
PT+CBT 6
(F-box 6
protein)-type 6
degradation; 6
Sel-10) 6
fbw7(∆Cb) 6
(Rs 6
fencers, 6
cannabinoids 6
toxicosis 6
enhancer-derived 6
eRNAs. 6
E2-3 6
(Cga), 6
thyrotropes, 6
IFN-induced 6
βTrcp 6
ligand-inducible 6
PKD2 6
Ser(535) 6
adaptin 6
SCF(betaTrcp) 6
follistatin 6
Sup35 6
embryomic 6
(eIF)2alpha 6
CAP-Gly 6
SGTs. 6
SGT 6
NF-kappaB-related 6
dCYLD 6
CYLD(-/-) 6
(Cyld) 6
SU(Z)12, 6
(H3) 6
Single-molecule 6
(EI), 6
(N) 6
SCGPred 6
finders 6
graph. 6
Baylor 6
pterocarpan 6
alfalfa. 6
medicarpin, 6
CASP8, 6
HIC1, 6
Caki-1 6
CHS, 6
Omani 6
Beige 6
(ENU) 6
ESCRTs 6
pHin 6
p18(Ink4c) 6
(CDK4) 6
p15(Ink4b) 6
p15INK4B 6
SK-OV-3 6
A-Cdk2 6
OIH 6
n=4, 6
(TRHR) 6
TRHR, 6
preoptic 6
Hepcidin, 6
(SLC40A1) 6
Inhibitor-1 6
NCLK 6
PP2A. 6
phosphatase-2A 6
flares 6
SIRL-1 6
clinico-pathologic 6
Node-negative 6
oncotype 6
hemangioblastomas. 6
vacuolated 6
PanNET 6
HIF2A, 6
pheo 6
ligand-driven 6
HLA-B*57:01 6
drugs), 6
clinic: 6
(ABC 6
productive. 6
tenofovir, 6
races. 6
medicines. 6
microRNAs: 6
miR-335, 6
miR-335/MEST 6
purine-pyrimidine 6
20.3 6
His(+) 6
Met(+) 6
mutagenic/antimutagenic 6
subpopulation(s) 6
YqjW 6
PolX 6
exoA 6
experience) 6
Ten-Item 6
(emotional 6
reassembly 6
Mohs 6
SAMHD1. 6
anti-LINE-1 6
ORF2p-mediated 6
ORF2p 6
encapsidating 6
Alu. 6
LINE-1, 6
PPP 6
limiting, 6
MCV, 6
Channel 6
4.07 6
(CRP 6
POD1-2) 6
0.870, 6
0.843. 6
Vo(2) 6
DIND. 6
VP 6
Nociceptive 6
L-3,4-dihydroxyphenylalanine 6
DOPAC, 6
(3-OMD), 6
[1]) 6
ELBW 6
(InSurE) 6
Extubation) 6
SLI 6
BiPAP 6
HVS 6
(CD95L) 6
blebs 6
(expansion 6
SB203580. 6
(SOT-095), 6
sub-types 6
"shadow" 6
RAREs 6
(PFA) 6
(TFT) 6
conventional-dose 6
Five-year 6
blisters 6
caterpillars) 6
urtication 6
54-15-Spd 6
fluconazole. 6
OL, 6
(psychosine) 6
pathologic, 6
(GLD) 6
(E.C. 6
grape 6
3D7, 6
pfmc-2tm 6
reichenowi. 6
merozoite, 6
parasite-derived 6
Pfmc-2TM 6
age-, 6
antirifin 6
exception. 6
teenagers 6
52), 6
Soviet 6
tooth, 6
established; 6
haired. 6
melanosome 6
(TYRP1) 6
LRP-1 6
Tpl2-deficient 6
Hydrochlorothiazide 6
irbesartan 6
metabolism) 6
Bmal1, 6
shift-workers 6
polyps, 6
PER2, 6
neutropenia), 6
(ISPOR). 6
(bortezomib 6
mg/m2/h 6
SUMMIT 6
BTZ 6
(SHH) 6
Ptch+/- 6
pathway-driven 6
effector, 6
Bmi1(+/+) 6
inflow 6
divers, 6
neuro-haemodynamic 6
EEG-fMRI 6
(metabolites 6
(products 6
8s 6
(alkanes 6
alkane 6
1-methyl-, 6
3-heptanone, 6
methylcyclododecane, 6
heptane, 6
2,2,4,6,6-pentamethyl-, 6
benzene, 6
1-methyl-4-(1-methylethyl)-, 6
23/42 6
in19/42 6
(p<0.04). 6
(95.7% 6
78.9% 6
cross-validation); 6
1-methyl- 6
(19/23) 6
(18/18), 6
Mutagenic 6
extract: 6
misincorporates 6
elicited, 6
phototherapy, 6
SPTs 6
photodermatoses 6
risk-safety 6
tanning. 6
drought 6
VirD2 6
(DMD), 6
palsy-like 6
referable 6
body-wall 6
CSQ-1 6
U6 6
B/B', 6
omega-conotoxins 6
NMDA-stimulated 6
self-similar 6
(Lieberman-Aiden 6
Power-law-like 6
power-laws 6
NYH 6
enzyme: 6
NYH/187 6
LC-172 6
Suramin 6
protein-nucleic 6
Luteolin 6
loci-2 6
FA-B, 6
vasculopathy, 6
floridae, 6
Hoxa13 6
HOM-C 6
actinopterygian 6
(T2C): 6
kbp) 6
(restriction 6
fragment) 6
(RiUP) 6
prescribers 6
(vWF) 6
[Recurrent 6
(3.3%) 6
Supranuclear 6
86.0%, 6
Norepinephrine 6
difference) 6
second-choice 6
microg/kg) 6
CSW. 6
56.4 6
stroma-directed 6
cell-mediated-cytotoxicity 6
Daratumumab-dependent 6
"de 6
SBH 6
Physiopathological 6
assert 6
p>0.05 6
-0.02 6
Natriuretic 6
(MMSE), 6
(Trails 6
1.1-3.6; 6
P=.02) 6
Trails 6
1.2-2.7; 6
P=.01), 6
Fluency 6
0.9-2.2; 6
P=.19). 6
AD-related 6
tubulin-like 6
FtsA 6
C-telopeptide 6
dacarbazine+placebo 6
dacarbazine+10 6
(n=33), 6
histologically-confirmed 6
(nc) 6
(Donohue 6
HRC. 6
RAS/RAF/MEK/ERK 6
848 6
40-60% 6
ps<0.01). 6
'consequences', 6
'emotional 6
conjoint 6
D's 6
interoperability 6
D.O. 6
dapsone. 6
DH. 6
environmental, 6
seven-fold 6
MutS2, 6
ttMutS2 6
fim 6
Hirschprung 6
Lagopus 6
lagopus 6
louping-ill 6
goats 6
73-98% 6
Chk2/p38(MAPK) 6
Posttranscriptional 6
(U2AF65) 6
1)/TIAR 6
snRNP-mediated 6
CL6 6
BMP-2, 6
protein.DNA 6
mAKAP 6
HDAC5, 6
-D 6
rictor, 6
linguistics. 6
SNX1 6
ETCs 6
SUMMARY: 6
anti-adhesion 6
(EA) 6
Preoperatively, 6
additive. 6
PolC. 6
(ProTalpha) 6
carboxy-terminus 6
proTalpha's 6
fProt-alpha 6
misattribution 6
disgust 6
20-49 6
(PANSS). 6
larger-controlled 6
impulsivity. 6
error, 6
impairments, 6
sertindole 6
stoichiometrically 6
Cys-69 6
dealkylation 6
glycine-160 6
O6-Alkylguanine 6
DNA-alkyltransferase 6
(O6-alkG) 6
O6-BzG, 6
hATG160W 6
O6-BzG 6
alkyltransferase, 6
Ada+) 6
(Ogt- 6
Ada-) 6
Ogt+ 6
CCNU, 6
T:A 6
uvr- 6
Ca(OH)2 6
Endodontists. 6
738 6
SureSelect 6
blend 6
publically 6
HTT, 6
HPV-18 6
shows, 6
papillomaviruses 6
MYH 6
rs7967622 6
5-HT2C 6
ideation/suicide 6
5HTTLPR 6
homes 6
Ascorbic 6
governmental 6
alpha20 6
site). 6
enthalpy 6
anti-Vel 6
30S 6
538 6
[1%] 6
Joining 6
(IMC-11F8), 6
(Genomic 6
nAChR 6
PKCepsilon 6
pretreating 6
+10 6
TRH-T 6
MN 6
Botany, 6
BRIP1 6
RNs 6
RN 6
(67%). 6
LPT 6
(148 6
Nonresponders 6
histone-bound 6
Graves 6
Mct8, 6
Mct10 6
c.1A>T 6
hyperglycaemia, 6
Selumetinib-enhanced 6
(AZD6244, 6
ARRY-142886) 6
Attenuates 6
G93A 6
C-C 6
NIND 6
(Alzheimer's 6
(conjugated) 6
(unconjugated) 6
UGT1A1-mediated 6
OATP1B1-, 6
OATP1B3-, 6
MRP2-mediated 6
glucuronides 6
α1, 6
Eprotirome 6
Sobetirome 6
person's 6
msp-2 6
SSB 6
HC-Ad 6
midgut, 6
Pf 6
OPRT 6
Monomeric 6
miltefosine 6
nexus 6
45-kDa 6
plasmodial 6
trans-species 6
ODC 6
Chlorella 6
fungicides 6
anthracyclines; 6
DOX-induced 6
0.047) 6
tumor-free 6
(EGFP) 6
transductions 6
sub-Mendelian 6
flexed-tail 6
registered, 6
cytoreduction, 6
peritonectomy 6
[Importance 6
time-point 6
Non-melanoma 6
(NMSC) 6
MKN45/PAR1 6
Actopaxin 6
Rac1/Cdc42 6
Binder 6
Arl 6
(BART) 6
BART-Rac1 6
BART-dependent 6
BART. 6
actin-cytoskeleton 6
GTPase. 6
icariin 6
(MDA-MB-435). 6
ASCA 6
Standardised 6
20-39 6
552 6
(younger 6
WHAT 6
4.41, 6
[i.e. 6
serine/threonine-protein 6
CHEK2*1100delC 6
(TIM) 6
mod 6
FIXTURE 6
anti-IL17A 6
IL-17F 6
spondyloarthropathies. 6
≥4-fold 6
CRAC 6
switching, 6
NFAT-dependent 6
(CsA). 6
isomerases 6
bonds, 6
(tmAC) 6
(FANTOM4) 6
(ESA) 6
rs3783988 6
hypoxic/ischemic 6
(decrease 6
randomisation, 6
Institute; 6
(h(2) 6
fronto-subcortical 6
soursop, 6
Predominant 6
phenotypes? 6
(>50%), 6
T2-hypointensity 6
soursop 6
Guam, 6
1952 6
Adjuvant!. 6
Indiana 6
progesterone-receptor 6
1(st), 6
poster 6
5-azacytidine. 6
2-H 6
HhaI, 6
THTR2 6
brain", 6
re-expansion 6
prazosin 6
PCNEs, 6
COUP-TFII 6
(pain 6
handsearched 6
neuralgia, 6
Sgf73, 6
Sem1 6
HLA-matching 6
Upf 6
Upf3p. 6
Upf3 6
HCF-1C 6
Schirmer 6
occupationally 6
felodipine, 6
post-introduction 6
42.6% 6
hypo-fractionated 6
People's 6
temozolomide-based 6
I/II. 6
alphal 6
(EDS 6
ligaments 6
risk-stratify 6
(ABCD-score), 6
(ABCD2-score). 6
ABCDE+ 6
'etiology' 6
ABCD-score 6
LTD 6
neuroectodermal, 6
papular 6
twentieth 6
workshop. 6
prepuberty, 6
Puberty 6
11.1-15.0), 6
midpuberty. 6
virilization 6
3.5-18.3 6
oligoasthenozoospermia 6
azoospermia. 6
ubiquitin-ligase 6
fundi 6
cardiopathy, 6
kD. 6
Peroxisomal 6
(PEX1(-/-)) 6
(PEX5(-/-)) 6
(PEX7(-/-)) 6
methylpurine 6
5-formyluracil. 6
(Escherichia 6
MutS. 6
Smurf2 6
MH2 6
Lys134 6
fibrillin-1. 6
Protrusio 6
acetabuli 6
mass: 6
radiographs. 6
"proteomic 6
ruler" 6
vif 6
(p38alpha, 6
ras-induced 6
Directing 6
bone; 6
cementum-derived 6
(p<0.03). 6
somnolence. 6
initiation) 6
GBP. 6
minute) 6
50.5 6
(63.6%) 6
"pioneer" 6
Nucleosome-binding 6
(iCMs) 6
GMT. 6
Resident 6
cardio-inducing 6
heal 6
(BTK), 6
NSG 6
cool 6
trend, 6
avidin 6
streptavidin, 6
biotin/(strept)avidin 6
proceedings. 6
PDP 6
cell-intrinsic 6
sublaminal 6
terminally-differentiated 6
(Ng), 6
(Ng48-76), 6
Islets 6
β-hairpin 6
GERD-rs 6
S33/35, 6
T432, 6
(T68A, 6
Q69E) 6
Ori-Finder 6
(TGFβ) 6
(5-HT2A 6
[(11) 6
C]MDL 6
5-HT2B 6
Altanserin, 6
fluorobenzoyl 6
>100-fold 6
D2/3 6
drying 6
N-dealkylation 6
vasculitides 6
polyangiitis 6
ANCA-positive 6
(ASP) 6
PTPN22*620W 6
THYx 6
1,000,000 6
low-activity 6
AluYb 6
thermophila. 6
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole 6
CsA. 6
(IDH1) 6
FAP. 6
pre-incision 6
impulses. 6
Ca-calmodulin 6
CaMKIIδ(C) 6
beta(2a) 6
(+20+/-5% 6
+3+/-4% 6
ISO, 6
(3.9+/-0.5 6
2.0+/-0.4 6
microm(-1).s(-1), 6
CaMKIIdelta-knockout 6
(KN-93 6
ISO-induced 6
pendrin) 6
near-native 6
VinaMPI 6
Interface 6
bonding, 6
antigen-induced 6
TCR-mediated 6
LLGL4 6
(Scrib) 6
GISTs, 6
Ssn6-Tup1 6
radon. 6
MUTYH, 6
rs9572903 6
[G] 6
1.06-1.30, 6
0.0020; 6
1.15-1.74, 6
1.11-1.45, 6
0.0005; 6
1.60, 6
1.22-2.10, 6
0.0007) 6
broad-based 6
foremost 6
Linn, 6
Tricosanthes 6
cucumber, 6
LCB 6
(P<0.05, 6
(LPO) 6
CBZ 6
CBZ-tolerant 6
PHT-induced 6
T-cell-related 6
NOTCH1/FBXW7 6
MKP-1 6
dormancy, 6
SRC, 6
integrin-independent 6
Suppresses 6
Repo-Man 6
Survivin-D70A/D71A 6
(anti-TNF-α) 6
NRH 6
azathioprine-induced 6
Hemolysis 6
LPAR1 6
SIFT 6
(nsSNPs) 6
pathways). 6
2VO 6
response-4. 6
(MCAO). 6
GHS-R1a. 6
MCAO, 6
GO. 6
EC9706 6
Bmi-1-mediated 6
balding 6
BLASTP 6
JNK1/2, 6
(mPTP). 6
dimebon 6
IPoC 6
IPost 6
ZO 6
β3AR 6
μg/kg) 6
hexokinase 6
Pre—treatment 6
Frataxin 6
WTAP-dependent 6
BSC-1 6
cycloleucine 6
(m6A), 6
MBs, 6
KDM6A 6
orco 6
odorant-binding 6
micromol/g 6
trigger. 6
H2S 6
pluripotency-related 6
Cck 6
menin-null 6
COMPASS 6
SKIP 6
dCas9 6
codependent 6
osteopontin, 6
tubes, 6
osteotomy, 6
c-jun(Δli) 6
TNFR-mediated 6
Gadd45b(-/-) 6
JAB1, 6
co-activator, 6
CRSP/Med 6
debranching 6
calpain-1 6
ICa,L 6
U/day) 6
pathogenicity, 6
(-)PSTVd 6
Pospiviroidae. 6
self-ligation 6
(L. 6
rhabdomyolysis, 6
umbrella 6
Rolandic 6
Q5 6
(NTB) 6
NTB 6
biloba 6
etanercept; 6
plastically 6
hyperproliferation, 6
(LRES), 6
PCDHs 6
INHBB 6
(TFIIS) 6
ENL, 6
T1/CDK9 6
eradicated. 6
sclerostin-interacting 6
4EBP1, 6
deprivation-induced 6
rhinorrhoea 6
CE-MRC. 6
Kallikreins 6
(Gallus 6
Kallikrein-related 6
linearity, 6
confusional 6
TRAF1 6
α-enolase 6
(CCP) 6
anti-CEP-1 6
<0.00001), 6
HLA-SE, 6
CCP+ 6
arthritis? 6
1858T, 6
subject), 6
Leiden. 6
receptor-modulating 6
Schild 6
orchestrator 6
(IL-1RAcP), 6
antigen:antibody 6
antigen:Fab 6
co-structures 6
human-engineered 6
ciclosporin, 6
calcium/calmodulin-stimulated 6
2B) 6
(IDPs) 6
KIX 6
cdx4 6
ALDH 6
CD44/24 6
imetelstat-treated 6
lipid-conjugated 6
MRT. 6
Imetelstat, 6
enzyme-DNA 6
5-H 6
DNA-(cytosine-C5)-methyltransferases 6
Co-transfections 6
C-->A 6
E-->A 6
PCQ 6
E-->A, 6
E-->D 6
E-->Q 6
VI) 6
centre, 6
Pvu 6
Hha 6
9q34.11 6
STXBP1-related 6
SCN1A. 6
serositis, 6
nulliparity, 6
Leishmania. 6
Khyber 6
Sexually 6
HCW 6
Life-threatening 6
notification 6
AMF 6
PA) 6
Norway. 6
cII 6
thousand, 6
GEMs 6
gene-set 6
inter-CNE 6
self-similarity. 6
Microtubule-associated 6
WED/RLS 6
"urge-to-move" 6
(WED). 6
door-to-door 6
Ecuador, 6
causation, 6
(RLS/WED), 6
(n=17, 6
assessment), 6
708 6
pseudoxanthoma 6
CCBE1 6
lymphedema-cholestasis 6
(Aagenaes 6
(SMD) 6
0.30) 6
ASAT 6
(SKT) 6
Hepatotoxic 6
2446 6
vacuous 6
Junction. 6
Rev, 6
prurigo 6
dopamine-ß-hydroxylase 6
N-methyltransferase) 6
(CORT) 6
CORT 6
pheochromocytoma]. 6
1-amino 6
AADC. 6
CFBD 6
647 6
Mutations. 6
credence 6
Maximising 6
menarcheal 6
(Gen 6
Gen 6
AJ 6
BRCA2) 6
BRCA-associated 6
USPSTF 6
BRCAm 6
Serbia 6
SIRs 6
krokodil 6
misused 6
sofosbuvir, 6
ribavirin, 6
G-6-PD-deficiency 6
U/g 6
PolyPhen 6
6-phosphogluconate 6
FFI, 6
(rucaparib, 6
veliparib) 6
Diminished 6
clinical-stage 6
PARP-trapping 6
Niraparib: 6
Recombination. 6
[42%]), 6
(ABT-888), 6
(MRgFUS) 6
MRgFUS, 6
millimeters 6
diffusion-tensor 6
tremor-mediating 6
lymphopenic 6
(CAR)diac 6
(M)esoderm 6
(E)nhancer-associated 6
(N)oncoding 6
mesoderm-specifying 6
Regorafenib 6
(anti-proliferative 6
anti-angiogenic). 6
(ALDH, 6
CD133). 6
teriflunomide: 6
Nine-year 6
NNTs 6
Teriflunomide: 6
Episode 6
Sclerosis), 6
(MRI; 6
thinning), 6
RMS, 6
traps. 6
anemic 6
darbepoetin 6
Microautoradiography 6
CD8(+)NKG2D(+) 6
Systemically 6
dermatologist 6
>2.4 6
SLAMF7, 6
IFE 6
CD38-targeting, 6
podocyte-specific 6
NOX5. 6
RCSC 6
lagomorphs 6
Nox/Duox 6
Nox5, 6
degrader, 6
GDC-0810 6
(ARN-810), 6
Bioavailable 6
Degrader 6
Demonstrates 6
Tamoxifen-Resistant 6
Xenografts. 6
Znf335 6
embryonically 6
avelumab) 6
Lymph 6
avelumab; 6
non-splice 6
splice-associated 6
quarantine 6
hNPCs 6
(hSBA) 6
MenY) 6
P1.4 6
MenY 6
lactamica. 6
PorA-containing 6
(Neisseria 6
anti-hsp90 6
sander.h.bollen@gmail.com 6
nancy.mah@mdc-berlin.de 6
996 6
types/tissues/diseases, 6
439, 6
(5879, 6
(1774) 6
(904). 6
name, 6
type/tissue 6
P301L 6
pseudohyperphosphorylation 6
inducer-mediated 6
hyperphosphorylated, 6
Selectivity 6
unerupted 6
Baumeister 6
birth) 6
necrolysis. 6
(SCARs), 6
SCAR. 6
(TEN), 6
Structurally 6
MINDY 6
Ub-containing 6
Found 6
MINDY-family 6
License. 6
(http://www.bioconductor.org/packages/regioneR). 6
rmalinverni@carrerasresearch.org. 6
Kasumi- 6
DIOB 6
DIOB-induced 6
(DILI). 6
time: 6
dyscrasias 6
endure 6
resource. 6
RUPP 6
rotavirus 6
sQTLseekeR. 6
allotype 6
Athelia 6
athelia 6
GOA 6
(GN) 6
ER/bupropion 6
carbonaria 6
Huntingtons 6
MUHDRS 6
β-Gal 6
β-Gal, 6
patient/carrier 6
SINEUPs: 6
raxibacumab's 6
(LVX) 6
raxibacumab. 6
moribund 6
Inhalation 6
levofloxacin/placebo 6
monkeys). 6
(r=0.9, 6
18]) 6
18]; 6
[9 6
14], 6
NCT00639678.) 6
MdSIZ1 6
holocentric 6
Bcd 6
EsUbc9 6
(solanezumab, 6
2(5.4%) 6
R-banding 6
66.1% 6
hybridization(FISH) 6
D15S11, 6
D15S10, 6
nonlymphocytic 6
Unbalanced 6
abnormality: 6
mos 6
XX, 6
SNP-Array 6
(PWS). 6
KCNJ10. 6
(EAST 6
1954, 6
bioassays 6
Anip973 6
positive/PI 6
boxed 6
acid)-paclitaxel 6
mite 6
LDF 6
E2a 6
Smad2/3 6
valdecoxib 6
Anti-fibrinolytic 6
TXA 6
SCOUT 6
(Sibutramine 6
OUTcomes) 6
Amicus 6
α-galactosidase, 6
meter; 6
[study 6
Leads 6
(GL-3) 6
QOD. 6
cell-containing 6
GLP1 6
T2D, 6
excursion. 6
3-hydroxy-3-methylglutaryl-coenzyme 6
PDCs 6
pravastatin, 6
3-Hydroxy-3-methylglutaryl-coenzyme 6
include:1. 6
(HD5) 6
(CDI), 6
Zfp207 6
Path2PPI, 6
miR-539, 6
miR-539/SPAG5 6
Oseltamivir: 6
Flu. 6
H10N8 6
H7N9 6
ephedrine 6
CVVHD 6
PDB. 6
2014-2015 6
APH-1, 6
gamma-cleavage 6
SUMO1-3, 6
enzyme-UBC9 6
SENPs, 6
asystole 6
PKC-dependent 6
XL, 6
Kir6.2-G324R 6
CHI-D 6
fetoplacental 6
endodontic 6
Design: 6
(LOH 6
5·7 6
>52 6
V2-V3 6
TG-rich 6
post-heparin 6
158. 6
2/2 6
Cysteamine 6
(6/10 6
antacid-induced 6
(CVR) 6
[X-linked 6
Papilledema 6
inclusion/exclusion 6
favourable. 6
posology 6
"multi-modal" 6
5-HT3A, 6
HAM-A 6
Cohen's 6
1.33; 6
(Vigna 6
δ-tocotrienol-induced 6
BN999 6
thyroxin 6
T4-TTR 6
(PNS), 6
thyroxine-binding 6
melanosomes 6
grasping 6
AER 6
Arthrogryposis 6
touch 6
B9 6
CRL-CSN 6
cullins. 6
homeologues 6
(Constitutive 6
E3-cullin 6
(CRLs). 6
signalosome, 6
Ubiquitin-proteasome 6
cardiomyocyte-restricted 6
CSN-mediated 6
(AP)-1, 6
Deltac-Jun(1-226), 6
CSN-specific 6
CSN-directed 6
SCF(TIR1). 6
CUL4 6
&lt;10 6
(ew, 6
eow, 6
Adalimumab, 6
HS-PGA 6
white. 6
sparing. 6
radiography. 6
tubercle 6
PUB 6
wards 6
capsulitis, 6
(SMW) 6
bars. 6
graphics, 6
(EPS 6
SVG), 6
image-editing 6
installed 6
calves 6
Diphtheria, 6
forgotten. 6
Akkermansia 6
PMA-dependent 6
(View 6
NOXA1. 6
Organizer 6
NoxO1 6
Noxo1, 6
Noxo1beta 6
(NOX 6
p22phox, 6
Non-Small 6
rociletinib, 6
hypochloremic 6
hypomagnesemia 6
BS, 6
MODOMICS 6
haemolysis, 6
hypomelanocytoses: 6
SNAI2, 6
genes]. 6
melanoses 6
melanocytoses 6
hypomelanocytoses, 6
(in-frame 6
non-stop 6
albinoid-like 6
albinism-deafness 6
(Tietz 6
(TYR, 6
Foxc1 6
Atf4(-/-) 6
antibody-treated 6
Chondrocytes 6
Dev. 6
273, 6
121, 6
remember 6
rosacea 6
biopsied 6
(orofacial 6
plicata) 6
Granulomatous 6
U/kg, 6
biweekly. 6
Ff 6
MN; 6
Frog. 6
symmetry-breaking 6
snails. 6
breaking, 6
formylation 6
Fire 6
Fybrodysplasia 6
BMP-p38 6
(FAD), 6
(SAMP8) 6
subunit: 6
Choroidal 6
(5/20, 6
25.0%) 6
c.20A>G, 6
c.332C>T, 6
c.647_649delGAA, 6
c.649A>G, 6
c.763C>T. 6
(3/14), 6
15.0% 6
Heterochromia 6
iridis 6
Fleckvieh 6
meniscal 6
Tanezumab, 6
Plasmepsin, 6
WEHI-842 6
(PvPMs) 6
proplasmepsin 6
meticillin-resistant 6
broth-enriched 6
BDGO 6
nasal, 6
(IDI-MRSA 6
carriage, 6
decolonization 6
(MRSA), 6
pvl-positive 6
Robert 6
entrapment 6
firstline 6
endpoints). 6
nerve-sparing 6
tumescence 6
cavernosum 6
(n=129), 6
(n=131), 6
(n=130). 6
(P≤.002), 6
NCT00809471. 6
microbicides 6
Chemotherapy. 6
Women. 6
occurred: 6
P=0.046) 6
[14C]dapivirine 6
IVR 6
SILCS 6
meningococcus]. 6
Critically, 6
(Bexsero), 6
Pfizer, 6
detrimental? 6
psychologic 6
Dissertatio 6
transphenoidal 6
bloc, 6
chiasm. 6
circRNA_finder, 6
find_circ, 6
CIRCexplorer, 6
CIRI, 6
MapSplice 6
punctures; 6
post-lumbar 6
22-gauge 6
24-gauge 6
atrophy; 6
puncture-related 6
diaminobenzoic 6
IRAP 6
cross-presentation 6
MPP+-induced 6
PKCdelta- 6
oAβ. 6
PGE(2), 6
Ab; 6
BRECs 6
AGE-mediated 6
RBA-1 6
iodonium) 6
Sept9 6
SEPT2 6
SEPT9 6
Shs1p 6
SCN1A-negative 6
(2015). 6
teloRZ 6
prediction; 6
LCZ696 6
▼ 6
(Entresto™) 6
ddc 6
afobazol 6
(aromatic 6
hydroxylase. 6
licking 6
[(11)C]5-HTP 6
L-dihydroxyphenylalanine 6
1015), 6
6R-BH4 6
6-OHDA-lesioned-rats. 6
3-hydroxybenzyl 6
neurotransmitter-like 6
dopamine: 6
halothane 6
pbmrp 6
MRP5/ABCC5, 6
↓. 6
proregion 6
(pro) 6
(mature 6
phosphoErk1/2 6
alpha-like 6
(CIDEC; 6
etomoxir 6
HMGCS2 6
intermuscular 6
CIDEC) 6
adipocyte, 6
PPRE 6
Akt1/2- 6
JNK2-dependent 6
FT 6
triage. 6
Kansas 6
3.6+/-1.31 6
5.5+/-4.58, 6
PFI, 6
(OPS-1) 6
spills 6
co-upregulation 6
IL-23). 6
CD28SupA 6
triptolide 6
mid-line 6
Morsier's 6
OCA-1 6
SLC24A5) 6
Polynesian 6
402 6
melanocyte-stimulating 6
underwhite 6
(uw) 6
OCA3, 6
OCA1, 6
castellii. 6
urate. 6
oxygen-consuming 6
Hst1-Sum1-mediated 6
coadapted 6
"sensu 6
MCAST: 6
P-value-based 6
conformation-prone 6
SAP 6
ULEs 6
weapon. 6
PS-ODN 6
SZ, 6
Celf3 6
malar 6
neuritis, 6
lesions") 6
(symptom 6
Self-perpetuating, 6
paramutation 6
kernels 6
antinutrients 6
1.9%, 6
week-6 6
-3.0, 6
Glia 6
Hyperbilirubinemia. 6
(TSB) 6
interwave 6
PPC 6
twinning, 6
oxandrolone 6
(HFE, 6
TFR2, 6
L129P 6
(59)Fe 6
[ferroportin 6
IV], 6
(classical 6
erythrocytes; 6
BBM 6
(Iks) 6
(Ikr) 6
repolarising, 6
reopening 6
depolarisation 6
HERG-or 6
QTcmax 6
syndrome', 6
ATR-associated 6
coimmunoprecipitate, 6
coelute 6
Sen1. 6
Pcf11, 6
(CPAC), 6
(CTD)-interacting 6
'as 6
head'. 6
Reassurance 6
H4K20me1, 6
licensing, 6
(H4K20me3). 6
ORCA/LRWD1. 6
(CDS), 6
rheumatica, 6
bendability. 6
Gene-loop 6
MET16, 6
INO1, 6
GAL1p-BUD3 6
Lichen 6
dactylitis 6
"deep 6
Koebner" 6
enthesis, 6
[Unusual 6
P=.004). 6
medulloblastoma/PNET 6
WBI 6
appositional 6
hypothalamus-pituitary 6
Acyl-CoA:diacylglycerol 6
(DGAT) 6
DGAT2 6
unmarked 6
HaploReg, 6
GTEx, 6
Geuvadis, 6
55-90% 6
vestibulum 6
gadolinium-contrast 6
mumps, 6
LH2 6
tenascin-X 6
PNH. 6
H2A.Z/H2B 6
INO80. 6
ANP32E, 6
Barcoding 6
lane, 6
ChIP-sequencing. 6
Y-shaped 6
over-amplification. 6
Cbr1+/- 6
(receptor 6
SAF 6
edemas 6
NOS3 6
phosphatidylcholine, 6
hesperidin 6
1,013 6
domesticus 6
testis-determining 6
11-kilobase 6
χ2 6
sepsis-associated 6
II,then 6
DCL1 6
pre-miRNAs 6
hairpins. 6
NF90 6
203100). 6
1903. 6
17.5% 6
Asinara 6
large-to-massive 6
SWE 6
DTA 6
MRI-Guided 6
Epilepsy: 6
DTA-HGG 6
anaplastic) 6
Wake 6
2011-December 6
NeuroBlate(®) 6
(9.7 6
Swi2/Snf2-related 6
Swr1p 6
Yaf9, 6
Swc7, 6
SEF, 6
sef 6
AtSWC6 6
Geminin. 6
maple 6
soapberry 6
methylenecyclopropylglycine 6
1976, 6
(JVS) 6
JVS 6
MCPG 6
MCPF-Gly 6
MCPA-Gly 6
sickness: 6
(Jamaican 6
(INAD) 6
22q12-q13 6
NBIA, 6
INAD 6
HHV8-negative 6
Anemia-Related 6
(Anti-IL6 6
Antibody) 6
(CBR; 6
fever/night 6
size) 6
60.5) 6
antagonises 6
degrons, 6
PTCH1 6
Ser(886) 6
systematically, 6
annulare, 6
tox-positive 6
Extrapharyngeal 6
extrapharyngeal 6
interleukin-18 6
BLM10 6
holo-TFIIB 6
ENGAGE-AF 6
Acetylsalicylic 6
XOAC 6
1·8 6
1.08; 6
immunohistochemistry-positive 6
Ona 6
Monovalent 6
shedding. 6
MET-expressing 6
Criteria, 6
MC148R1 6
MC54L 6
Contagiosum 6
FV 6
Pneumonic 6
Val129 6
executor 6
(PIB) 6
Chromatid 6
Recruiting 6
Replisome. 6
anasarca, 6
Tafazzins 6
tafazzin-deficient 6
Delta5 6
Peirates 6
Reduviidae). 6
thale 6
cress 6
thalianol. 6
Operon-like 6
mometasone 6
(LS 6
(IL-4) 6
(IL-13) 6
JBP1- 6
anti-J 6
PTUs) 6
JBP1-specific 6
PTUs 6
synthesis/localization 6
acetyltransferase-positive 6
dendrites, 6
PRC2-deficient 6
Jarid2-deficient 6
Wnt9a, 6
Prickle1, 6
E3.5 6
dyslipidemias. 6
dyslipidemias 6
HDL-cholesterol 6
A-I-containing 6
(UCP1). 6
Prdm16 6
1-adrenergic 6
(UCP1) 6
phage-based 6
self-motion 6
gardens 6
MD-2, 6
>40-fold 6
(MK-8931)-A 6
iminothiadiazinane 6
Verubecestat, 6
LGG 6
"triple 6
(Glyburide 6
Injection) 6
occludens-1 6
(ZO-1). 6
intracerebrally 6
LX1 6
A2058 6
orally), 6
intravenous). 6
Blood-tumor 6
(BTB) 6
(trans)) 6
(trans) 6
36.6%, 6
14.2%, 6
(-14.2 6
13.1%, 6
(117.1 6
43.4%), 6
(63.1 6
22.1%, 6
gorilla, 6
apes. 6
FTLD-C9ORF72 6
Rtt109, 6
condensin-mediated 6
biologists, 6
expansions, 6
anti-MUC1 6
CLIPs 6
hTrx 6
Transthoracic 6
Portola 6
hemangioma, 6
hypotelorism, 6
WHS 6
ovotesticular 6
Foxo1 6
microfibrils. 6
(ZMapp), 6
Guinean 6
Ebola. 6
EVD, 6
(EVD) 6
MB-003 6
Cocktails 6
(CBS). 6
Mandel 6
334:763, 6
(FVL) 6
FVL. 6
thrombosis: 6
non-S-phase 6
non-enzyme-inducing 6
IK6, 6
GPR132 6
IKZF1-deleted 6
Pds5B-deficient 6
CdLS. 6
Pds5A(-/-) 6
taffazin 6
underrecognized. 6
microL) 6
forearm, 6
PIK3CA-mutant 6
pictilisib, 6
ribociclib, 6
scans) 6
(GDC-0941), 6
(Ocaliva(TM)) 6
farnesoid-X 6
formulary 6
UDCA. 6
OCA+UDCA 6
1.2%, 6
cirrhosis) 6
AF/AFL 6
bepridil 6
tachyarrhythmias: 6
cardioversion. 6
lentis: 6
(52.9%) 6
ADAMTSL4, 6
22.74 6
21.3-24.2) 6
27.54 6
24.2-30.9) 6
(ADAMTSL4) 6
(R62C) 6
c.184C-->T 6
(p.R62C) 6
hyperopia. 6
time-domain 6
pNN50) 6
propositi 6
Regeneron) 6
Amyloidosis 6
pemphigus. 6
anti-interleukin-4 6
type-2-mediated 6
0·05]; 6
379 6
Pest 6
Industry. 6
DWV 6
ceranae 6
(TAZ/G4.5) 6
mice--including 6
ciliary, 6
pterygopalatine, 6
submandibular, 6
ganglia--arise 6
Everolimus-Eluting 6
XIENCE 6
[OR]: 6
(SRS). 6
near-total, 6
EP-DNN: 6
Algorithm. 6
91.6%, 6
RFECS, 6
96.8% 6
sterols 6
phosphatidylglycerophosphate, 6
[14C]linoleoyl 6
cytidinediphosphodiglyceride, 6
PTSD, 6
Australians 6
blosozumab, 6
Latino 6
prison 6
inmates 6
SPAN 6
self-rating 6
history; 6
CULT, 6
β-meanders 6
Mis16-Mis18 6
Regulate 6
Replication-independent 6
HJURP(Scm3), 6
Mis18/Scm3(HJURP) 6
Mis18. 6
non-sense-mediated 6
chromatinized, 6
trypsinized 6
28.6 6
5p15.2 6
Smyd3-specific 6
morpholino-oligonucleotides. 6
mantel 6
(LEE011; 6
H3.3), 6
(K27M). 6
OSTN 6
osteocytes. 6
cystometry, 6
Aδ-fibers 6
mirabegron. 6
haloperidol-induced 6
(520 6
(267 6
0.63-1.00; 6
0.52-0.99; 6
(LCRC) 6
1.77; 6
1.02-3.06) 6
1.02-4.07). 6
rs9784100 6
(RCRC) 6
rs6124509, 6
rs4243289 6
rs12218935 6
LCRC. 6
'reference' 6
http://pantherdb.org/tools/csnpScoreForm.jsp 6
ftp://ftp.pantherdb.org/cSNP_analysis/PSEP/ 6
pdthomas@usc.edu 6
[ESTEEM] 6
nonplaque 6
Culicoides 6
(arboviruses) 6
metanephrine 6
value: 6
(ADQI). 6
primary/secondary 6
origination 6
CRS: 6
backsplicing 6
microRNA-7 6
(miR-7) 6
microRNA-138 6
(miR-138), 6
(IRR 6
fires 6
double-hexameric 6
directional. 6
Corriedale 6
(IBSP). 6
M1V 6
UMR-106 6
(1x10(-7) 6
[Scriver 6
rachitis: 6
'autosomal 6
Scriver 6
OH 6
+5G&gt;A] 6
Dent's 6
umami 6
Fractionated 6
RA-SF 6
IFN-score 6
MAQ, 6
(BWA), 6
BLAT 6
Aligner's 6
reads) 6
MapReduce 6
radiotherapy]. 6
(60Co) 6
IGRA 6
(LTBI) 6
LTBI. 6
(rRNA)-rich 6
(coiled 6
FGF-2(23) 6
CBs. 6
Fam118B, 6
Lyst-mutant 6
(DON). 6
inoculations 6
Epha4 6
misplaced 6
CTCF-associated 6
Moschcowitz 6
RNA-editing 6
Dalpha6 6
fruitfly, 6
magr 6
steroid-non-responsive 6
FMF. 6
oligodendroglioma, 6
Fkh1p 6
rDNA-associated 6
Tof2 6
NAR 6
RUT 6
GE 6
Merland-Cognard 6
Borden, 6
embolisation 6
cross-organismic 6
compatible, 6
VMAT2 6
(microcornea, 6
disk), 6
(narrow 6
telecanthus, 6
micrognathia), 6
(Triple 6
(ETV6/TEL) 6
12p13 6
(AML-M4Eo) 6
CBFb/MYH11 6
t(1;12)(q25;p13) 6
ARG-ETV6 6
(Abelson-related 6
Abl2) 6
PTKs) 6
ABL2/ARG 6
Tularemia 6
LVS 6
(IRVAN). 6
panretinal 6
(LDL-C). 6
elvitegravir 6
Stribild(®) 6
dolutegravir 6
(BWS) 6
TLR5(rs5744174) 6
ratio(OR) 6
CIA-I 6
(MHL) 6
hepatoblastoma, 6
hemangioendothelioma 6
hamartoma, 6
(HJMD) 6
moments 6
lucinactant, 6
(<1000 6
MTREC 6
Backmasking 6
Roy 6
HuH7 6
LDLR. 6
ALN-PCS 6
[79%] 6
factor-like-A 6
'Hy's 6
(P/Pc 6
Law, 6
TNF-a, 6
TBR1, 6
TBR1-bound 6
misexpressed 6
Icelanders. 6
(TBR1) 6
GRIN2B 6
Tbr1(+/-) 6
(MCM2-7 6
Mcm4(Chaos3) 6
MCM5 6
Mcm2/4/6/7 6
saves 6
MRTF-A 6
CDC-48 6
H1085Y 6
Arrested 6
Structure. 6
(LX4211), 6
sotagliflozin-treated 6
(CGM) 6
148.8 6
0.010) 6
170.3 6
70-180 6
(3.9-10.0 6
68.2% 6
54.0% 6
(10.0 6
metaSPAdes: 6
stifling 6
NDR 6
(M.CviPI) 6
nucleosome-depleted. 6
CAME 6
CD4(+)CD25(+) 6
tb-expanded 6
pfkB, 6
ALDH2-deficient 6
ALDH2(+/-) 6
pet. 6
Materials 6
E2F1/Dp 6
INP 6
reiterated 6
Expression), 6
(TUCRs) 6
migRI-TIMP-1-GFP 6
TUC.338-siRNA. 6
Napabucasin 6
mat1 6
Deflazacort 6
poly(A)-segments 6
('GA-ribbon'), 6
('associated 6
DNA-loops'). 6
GA-ribbon 6
730-fold 6
tetra-GA-motifs. 6
tetra-GA 6
'denuded'. 6
DNA-loop 6
Alu-transcripts 6
GA-sequences. 6
10(-16) 6
[b]. 6
<0.5%), 6
d(GA) 6
homopurine 6
(nc)RNAs 6
Kem1), 6
(RNAPII)-dependent. 6
ncRNA-mediated 6
3'-ss 6
NMD-targeted 6
anticomplementary 6
Dbp2. 6
(housekeeping) 6
cSLE 6
CVID 6
hemoperitoneum 6
valley 6
WEB 6
SCIENCE, 6
ASCO, 6
ESMO 6
SNO 6
(4113 6
(HR=0.63, 6
(HR=0.60, 6
(HR=0.63; 6
(HR=0.70, 6
(HR=0.52, 6
emMAW: 6
(VLPP) 6
term; 6
Shimmer, 6
chilblain 6
Ufd1-Npl4-Cdc48 6
Abp1 6
gene-CUT 6
CUT-based 6
TGFβR1 6
Anti-Neuroblastoma 6
(ch14.18) 6
(TGF-βRI), 6
on/14 6
lomustine. 6
Aβo 6
annotations-generated 6
collaborators-display 6
"tracks" 6
pCREB 6
UPC2. 6
synaesthesia 6
Vmw110 6
As₂O₃-induced 6
PML-V 6
DMVD. 6
tenosynovitis. 6
article) 6
expressly 6
tenosynovitis, 6
DeQuervain 6
O2-saturation, 6
exogenously-supplied 6
(RPS30, 6
(CDR1, 6
YOR1), 6
(INO2, 6
ACE2, 6
UPC2), 6
(MET6, 6
SAM2, 6
SAH1, 6
5'-VNCGBDTR 6
5'-TCGTATA. 6
CDR1 6
upc2Delta/upc2Delta 6
Upc2p-activating 6
(lovastatin 6
hypoxia) 6
HOMedU 6
hydroxymethyluracil 6
trypanosomatids. 6
glucosyltransferase. 6
diphosphoglucose 6
Ten-Eleven 6
(TET) 6
Lujan 6
MED12, 6
(KEYNOTE-006) 6
Xu, 6
Stevinson, 6
Chmielowski 6
protocol-specified 6
Austria, 6
(RECIST 6
v1.1), 6
melanoma), 6
anti-CTLA-4, 6
cause). 6
(n=279), 6
(n=277), 6
(ipilimumab 6
n=278). 6
22·9 6
16·0 6
0·53-0·87 6
p=0·0009 6
0·53-0·86 6
p=0·0008). 6
KEYNOTE 6
(KEYNOTE 6
TET1 6
HP1α, 6
MCF10. 6
nucleotide-depleting 6
rpb9Delta, 6
Spt8-containing 6
unproductive 6
psygenet2r: 6
psygenet2r, 6
adversity 6
Jakinib 6
PRRs 6
TRIM40 6
OTU 6
enterotypes 6
YIT 6
(GWAS-based 6
Types), 6
Idarucizumab-Mediated 6
impairment) 6
Idarucizumab-A 6
anticoagulating 6
(Praxbind), 6
four-factor 6
luis.sanchez-pulido@igmm.ed.ac.uk. 6
polyarteritis 6
Tumor, 6
dolor 6
cum 6
calore 6
dolore, 6
(redness 6
Graeco-Roman 6
C.), 6
(rubor, 6
PDX1 6
SMAD4-related 6
BMPR1A-related 6
TF-binding 6
SERPINH1, 6
cartilage-associated 6
DMR0 6
ftp://strelka@ftp.illumina.com/. 6
SomaticSniper, 6
com 6
seq 6
"puffy 6
methadone-substituted. 6
8.9, 6
7.0, 6
IVDA 6
(RPC1063), 6
Modulator: 6
Sphingosine 6
ponesimod 6
ceralifimod 6
Low-Fat 6
Hematoma 6
ich 6
ct 6
Rap1. 6
(GRFs), 6
Rap1) 6
mononucleosis. 6
Virus-specific 6
M: 6
EBNA-1 6
years.Metazoan 6
Explorer: 6
http://trantor.bioc.columbia.edu/Target_Explorer/ 6
SCFTIR1 6
Mcm4-aid 6
i-AID 6
iaid 6
mycoses 6
coral-red 6
Whitfield's 6
keratolysis. 6
(skin 6
(onychomycosis). 6
porphyrins 6
#242900) 6
SIOD, 6
(p.Arg247Pro) 6
(p.Glu848*). 6
sartans. 6
Marcal1 6
R561C 6
c.1334+1G>A 6
c.2142-1 6
(175). 6
enuresis, 6
serpentine 6
Splenium 6
Callosum. 6
parotidectomy 6
110,000. 6
sSMCs 6
der(22)t(11;22)(q23;q11.2) 6
maldeveloped 6
talipus 6
spermatocyte. 6
CIMP-positive 6
phenotype' 6
spinal, 6
bioconductor 6
haplogroup 6
G11778A 6
biochip 6
vc 6
rg 6
polyubiquitin-binding 6
UIMs 6
CTCF-Mediated 6
Lamina 6
Oscillating 6
Transcription. 6
NPC-specific 6
destabilized. 6
Re-insertion 6
Papers 6
(yes/no) 6
exposed/unexposed 6
meta-analysed 6
0.00001]. 6
nonerythromycin 6
Lentivirus-transfected 6
invivo 6
(reads 6
[RPKM] 6
9.31). 6
FBXW7-185aa. 6
AFib 6
(Sequenom 6
Chordoma: 6
Chordomas 6
differentiated). 6
INI1, 6
(NM_003073) 6
(RMC) 6
miR-671-5p 6
CCs. 6
SMARCB1/INI 6
telocentrics 6
Rabl-like 6
Sad1-containing 6
Funded 6
Tg-AD 6
ethmocephaly 6
TFN's 6
174; 6
events/h), 6
Sleepiness, 6
(FSS 6
(ESS 6
5--8 6
Lehane 6
immunoprophylaxis 6
pre-F 6
non-NHT 6
(LAPC). 6
non-operable 6
siG12D-LODERs, 6
(0.025mg, 6
0.75mg 6
3.0mg). 6
LAPC. 6
hpg 6
PF-04523655, 6
TKM-080301, 6
Atu027, 6
SYL040012, 6
SYL1001, 6
QPI-1002, 6
QPI-1007, 6
p.Met694Val 6
pyrin, 6
SW982 6
orchitis 6
clinicaltrials 6
IGC 6
NEVLP 6
Appropriateness 6
pharyngotonsillitis. 6
GABHS. 6
preschoolers 6
1.70), 6
CLOCK: 6
CLOCK:BMAL-independent 6
scn 6
ustekinumab; 6
PRP. 6
(adalimumab, 6
Malvern, 6
1275, 6
Centocor 6
ustekinumab-treated 6
psummit 6
35S::TIR1 6
IAA3 6
Chiifu 6
RcBr 6
sliaa15 6
arf5 6
TaSHY2 6
ischiopagus 6
pyopagus 6
union, 6
AND-1. 6
Fo47 6
αvβ8 6
Waldenström's 6
FACEBASE 6
(OCDM), 6
co-dependence 6
elbow: 6
swallowing, 6
appraised 6
trismus, 6
Benralizumab, 6
emmanouil.dermitzakis@unige.ch. 6
-0.93 6
-1.53 6
-1.53, 6
Radius 6
AO/OTA 6
LAF: 6
(LAF), 6
CGRP, 6
(TEV-48125), 6
CGRP-mAb, 6
CGRP-mAbs, 6
depression-evoked 6
vinorelbine, 6
re-irradiation 6
(DIPG). 6
Vinorelbine 6
fibular 6
(tibia 6
multi-planar 6
MPTA 6
vara) 6
(ISS-N1) 6
inspire, 6
(www.nematodegenomes.org/). 6
(ABT-493; 6
(ABT-530; 6
pibrentasvir, 6
(DKA) 6
type-1-Diabetes 6
Glucosuria 6
high-end 6
servers, 6
(Klinefelter 6
MSX 6
Aβo-induced 6
APPswe/PS1ΔE9 6
neuromedin 6
GRPR 6
BLP 6
CSEQ-SIMULATOR: 6
SIMULATOR 6
CLIP-SEQ 6
EXPERIMENTS. 6
Cseq-Simulator 6
pneumoperitoneum, 6
CINs. 6
mIPSC 6
ATF4-deficient 6
H-ras(V12) 6
Cdkn2a, 6
B-Cell 6
Tezepelumab 6
nondonors. 6
QUS 6
Osteopenia 6
(BAP, 6
ICTP) 6
RCAS: 6
Centric 6
(RCAS), 6
Wasting 6
CWD, 6
virginianus), 6
hemionus), 6
CWD-positive 6
CWD. 6
Glycated 6
Kcnj6 6
(21; 6
McEnhancer: 6
McEnhancer, 6
disulfides, 6
spectrometric-based 6
Becline-1, 6
progestin-only 6
DS-GPA 6
co-alterations 6
ALK/EGFR 6
CAP. 6
proadrenomedullin 6
(ProADM) 6
CreERT2 6
HBP 6
RMP. 6
tibolone 6
estren 6
alaninate 6
Genie: 6
(LEG), 6
pentoxifylline, 6
byzantina 6
hominis 6
S/CO 6
Eichhoff's 6
principles: 6
nonmaleficence, 6
OM. 6
.75-.93) 6
.65-.93), 6
"co-regulated" 6
"anti-regulated" 6
"neutral" 6
biosimilars 6
FullSSR: 6
Designer. 6
DNase-seq 6
GORE® 6
(Zieve's 6
non-PsA 6
atp9 6
AUX 6
chondroma 6
chondroma. 6
rabies. 6
Rabies: 6
Equatorial 6
hsa_circ_006054, 6
hsa_circ_100219 6
hsa_circ_406697 6
(Risk 6
Annotations) 6
(Achenbach's 6
HIGS 6
≥60, 6
(FACT-G), 6
(CFS). 6
2-sample 6
MPM. 6
Implications. 6
AUC0-72h 6
SHP-1 6
SCARLET 6
FEVER. 6
antistreptococcic 6
(scarlet 6
EspL 6
PTENβ 6
mutated-dependent. 6
(decay-accelerating 6
Costimulatory 6
mTORSer2448 6
combination-therapy 6
ANXA1 6
osteocyte-like 6
BMP2, 6
s-IGF-1 6
melanomagenesis. 6
"drop" 6
languages, 6
Toxline, 6
Unpublished 6
41.2) 6
18.3), 6
estimate. 6
Mid-Atlantic 6
UBQLN1 6
releases, 6
Marmorated 6
Stink 6
pistachio 6
gallbladder. 6
ΔcsgA 6
ΔyihO 6
nitroimidazole 6
Antitrypanosomal 6
cruzi, 6
(CL 6
(Y 6
(Colombian 6
nifurtimox. 6
(cure) 6
parasitological, 6
(VL-10 6
Benznidazole 6
arteritic 6
TAK. 6
interior) 6
POLQ 6
IL11 6
RDG 6
5.6, 6
MULTOVL: 6
MULTOVL 6
video-telemetry 6
CUA 6
non-uremic 6
H19/miR-675 6
PA2G4, 6
(ch14.18; 6
Unituxin™) 6
disialoganglioside 6
dinutuximab. 6
human-murine, 6
aldesleukin 6
(interleukin-2 6
[IL-2]), 6
[RA]) 6
(Unituxin, 6
Therapeutics) 6
granulocyte- 6
interleukin-2, 6
2G 6
ciRS-7: 6
RNA-7 6
invovled 6
PROSEEK 6
MGUS 6
acute-stroke 6
(ICTUS) 6
t-PA. 6
ICTUS 6
RGS 6
"A/T 6
ciclopirox 6
pedis, 6
farmworkers 6
santomea 6
(rs10966900, 6
redheads 6
I155T 6
p.D84E, 6
p.D294 6
yellow/blond) 6
IAN 6
(N=1316) 6
cells/microl, 6
<150 6
cells/microl. 6
(N=1316), 6
0.21, 6
(N=798), 6
1.80). 6
2.62). 6
TBN-dominant 6
PPARA 6
non-Tibetan 6
IKZF1, 6
EPAS1. 6
Admixture 6
introgression. 6
offenders 6
ASPD, 6
ASPD. 6
Brown-Goodwin, 6
Assault 6
ERPs 6
(Cse4) 6
∼120-bp 6
Centromere-specific 6
closely-spaced 6
http://dx.doi.org/10.7554/eLife.01861.001. 6
Etravirine 6
etravirine 6
telomere-telomere 6
Denisovan 6
claudin-1 6
D3RKO 6
RVM 6
R-SKF38393 6
SEH 6
triskelia 6
triskelion 6
hair), 6
alpha-melanotropin 6
lal-/- 6
organisations 6
(MHRA). 6
pyrexial 6
digoxin), 6
AQP1 6
post-INR 6
Miconazole 6
UPD7 6
miR-129-5p 6
oligogenic 5
familiality 5
co-existence 5
1/5,000 5
(EGF), 5
HB-EGF, 5
affinities, 5
ns 5
decompose 5
Anti-EGFR 5
PFS: 5
(TGFα), 5
Histamine 5
pg/ml), 5
nontransformed 5
matrix-associated 5
mesoderm, 5
Papilin 5
metalloproteinase. 5
vitronectin, 5
actin- 5
hemocytes 5
guanidine 5
uronic 5
sulfation 5
nonspliceosomal 5
multiexonic 5
catalog. 5
(FAK), 5
integrin/FAK 5
kda 5
Pulsed 5
ovariectomy-induced 5
metformin-induced 5
minerals, 5
(850 5
0.19) 5
miR-100, 5
miR-141, 5
miR-200c, 5
Some, 5
miR-143) 5
small-nucleolar 5
Let-7a 5
HRs 5
0.049). 5
intercurrent 5
Immunologic 5
Zoledronic 5
FRAX. 5
Worldwide 5
AHRQ 5
ibandronate, 5
nonvertebral, 5
cabazitaxel, 5
subsequently. 5
(immune 5
therapy). 5
ranelate, 5
calculator 5
canakinumab, 5
NTDs. 5
1p36 5
Similarity 5
nails. 5
squamocellular 5
aural 5
nigricans 5
pemphigus, 5
Gougerot 5
Rupp 5
1922) 5
Griffiths 5
eponym 5
cutanea 5
b-adrenoceptor 5
Williams, 5
s). 5
pro-arrhythmic 5
Leukoencephalopathy 5
multimers. 5
somites. 5
sinusoids. 5
hepatoblastomas. 5
Senescence 5
Pooled-analysis 5
(abiraterone 5
orteronel). 5
5.75, 5
orteronel) 5
rPFS, 5
17%), 5
2%). 5
Gonadotropin-releasing 5
ELM-PC5 5
17.8, 5
27.7, 5
3A4/5 5
µm). 5
(DDIs) 5
theophylline, 5
(-7.5 5
radionuclides 5
HercepTest 5
1+, 5
Erb-hcAb 5
antibody), 5
Radiolabeled 5
radiometal 5
AWT 5
AWT, 5
ErbB3, 5
(LNCaP, 5
quinazolines 5
substituents. 5
(trastuzumab 5
Conjugation 5
(i.v.), 5
non-tumor-bearing 5
envelopes 5
trastuzumab-mediated 5
hormone-independent 5
transurethral 5
Citrate 5
(89%), 5
Shed 5
mg/mL). 5
independence. 5
growth-factor 5
10-fold. 5
PB, 5
descend 5
[Nature 5
PARylation 5
CD133, 5
CytoTune™-iPS 5
suit 5
(MEF) 5
fluid-derived 5
ADCs 5
0.97), 5
4.10 5
Chromosome-Centric 5
"missing 5
"missing" 5
roadmap 5
obtainable 5
agency 5
Danio 5
pannexin 5
(~50 5
innexins, 5
denervation, 5
gradient, 5
Myoclonus 5
(mtDNA), 5
b.p.m., 5
placebo); 5
(19%, 5
(CAD 5
hyperpolarization-activated 5
sham, 5
ivabradin 5
electrolytes, 5
(38%). 5
revascularisation. 5
(ejection 5
MI) 5
0.1%, 5
HRR. 5
(WD) 5
orthotropic 5
COMMD1 5
ceruloplasmin 5
image. 5
gliosis, 5
(very 5
infrequently. 5
investigated; 5
cap-binding 5
coupled. 5
D4Z4-encoded 5
girdle, 5
therapist, 5
21.8 5
EcoRI/BlnI 5
(MMT) 5
shoulders, 5
scapular 5
4q35, 5
pre-invasive 5
(IBC), 5
hyperplasia/flat 5
(ADH/FEA), 5
(p=0.01). 5
co-overexpression 5
(CASQ2). 5
CASQ2. 5
reverts 5
automaticity. 5
junctin-deficient 5
([Ca(2+)](SR)). 5
aftercontractions. 5
[Ca(2+)]: 5
activator-inhibitor 5
Negatively 5
Ca(2+)-handling 5
Hz). 5
W., 5
phospholipids. 5
(PI), 5
precisions 5
hormone: 5
27.8 5
7.7%, 5
(10(-3) 5
metoclopramide, 5
sewage 5
Plasmid 5
Gram-positive, 5
ZXY-2 5
(SWI/SNF) 5
K16 5
angstrom 5
Discrimination 5
bundle. 5
correlation? 5
Dysphagia 5
pneumatic 5
female), 5
Heller 5
difficulty. 5
distension. 5
(58.3%), 5
Unrecognized 5
contact, 5
alertness, 5
sensitization. 5
RY10-4 5
province, 5
diagram 5
JNK1 5
heart; 5
(Nrf2) 5
Vice 5
overwhelmed 5
JNK1β1 5
MEKK1 5
purity, 5
subfamilies. 5
(TAILS), 5
protease-generated 5
(iTRAQ) 5
protein-4, 5
surround 5
SMARCB1. 5
PI3K/AKT/mTOR 5
p-4E-BP1 5
958 5
Trp535Leu) 5
localization-related 5
serum; 5
sampled, 5
continue. 5
plausibly 5
lanthionine 5
927, 5
bicuculline, 5
supressor 5
C3H10T1/2 5
Analogously, 5
agar, 5
non-specifically 5
(PARP-1) 5
microsatellite-containing 5
ETS-type 5
[Atypical 5
ADAMTS13 5
59-year-old 5
(bortezomib, 5
(aHUS), 5
TMA. 5
Incomplete 5
eculizumab. 5
Fresh 5
HUS. 5
allograft. 5
Publishers. 5
anorectic 5
(EI) 5
EI. 5
session), 5
skinfolds 5
video-based 5
ingestion, 5
12-h 5
changed. 5
non-weight-bearing 5
[control 5
0.0005) 5
23.1 5
62.1 5
SE) 5
exercise: 5
decreased; 5
hormones; 5
CCK 5
GH. 5
Syrian 5
40.8, 5
282, 5
Smad2-dependent 5
(PAI-1) 5
Smad3-dependent 5
RFC 5
bait. 5
ZGA 5
miR-430 5
cystitis, 5
Comorbid 5
43.0) 5
31.6), 5
32.6), 5
conservatively. 5
menorrhagia 5
Ganglia 5
levels). 5
(SP), 5
3-5% 5
(PMDD), 5
(IBS), 5
IBS, 5
particularities 5
degenerate. 5
bleeding]. 5
Section 5
Surgery, 5
asymptomatic; 5
information; 5
24.7 5
debriefing 5
Multi-trait 5
multi-item 5
(information 5
services) 5
(0.68) 5
needs, 5
cTn 5
postexercise, 5
(cTnT) 5
823 5
amateur 5
troponins 5
[NT-pro-BNP] 5
[BNP] 5
(ECG), 5
(DTI) 5
Strenuous 5
mountain 5
microg/L 5
competition, 5
noncardiac 5
47.5 5
deceleration 5
1.30 5
estrogen-only 5
totality 5
1127 5
29-79 5
Connecticut, 5
Carolina, 5
Area, 5
0.63-0.96). 5
Insurance 5
Institution 5
estradiol-only 5
neuromas 5
frequency-matched 5
contraception, 5
0.92-2.10) 5
1.50, 5
0.95-2.36). 5
commence 5
exposures. 5
0.6, 5
(FM) 5
websites. 5
self-efficacy, 5
(4.5 5
therapists 5
motivational 5
coping, 5
interference) 5
20.6% 5
acceptable, 5
follow-ups. 5
self-management. 5
ambiguous. 5
ASXL1) 5
allele) 5
percentile, 5
splice-site, 5
Macrocephaly 5
non-high-density 5
29.5% 5
35.7%) 5
nmol/l. 5
voice-response 5
anti-dyslipidemic 5
mipomersen 5
lead, 5
Mipomersen 5
(US, 5
monthly) 5
614 5
Q2W, 5
mmol/L. 5
mistery, 5
Solexa 5
M.BspRI 5
5-fluorodeoxycytidine 5
nucleophile 5
south-constrained 5
sarcoma) 5
(ESB) 5
PNs 5
microscopic, 5
immunophenotypic 5
(neuron-specific 5
[HNK-1], 5
kd, 5
S100) 5
(36%). 5
antiserum, 5
tumor? 5
rhabdomyosarcomas. 5
female: 5
(ES/pPNET) 5
priori. 5
PI3K/AKT/mTOR, 5
predose, 5
1-22), 5
29-43; 5
57-99). 5
(AMS). 5
LC-AMS 5
Unabsorbed 5
feces). 5
(95.3 5
suspected). 5
(MF), 5
BCR-ABL-negative 5
(JAK2) 5
Me(3)Pso 5
monoadducts, 5
colony-formation 5
(+/+) 5
(+/-) 5
equitoxic 5
4N 5
(GGGGCC)·(GGCCCC) 5
transcriptionally-induced 5
AGO2 5
patrolling 5
(5'UTR) 5
(>200 5
(hybrid) 5
Transsphenoidal 5
6: 5
postzygotic 5
McCune-Albright 5
FIPA, 5
protein(AIP), 5
young- 5
lactotroph 5
sporadically, 5
non-functioning 5
>20% 5
somatotropinoma. 5
(CDKN1B) 5
changes: 5
domains) 5
menin, 5
complimentary 5
children/adolescents 5
sufficient. 5
cross-bridges 5
TnC 5
Reconstituted 5
dichroism, 5
(DCM), 5
cross-bridge 5
cardiomyopathy-related 5
L29Q, 5
1.9-fold 5
2-fold) 5
ClinicalTrials.gov: 5
(27.1%) 5
2.24 5
Internet-assisted 5
nonrandomly 5
alternately 5
(38.5%) 5
(H3S10P) 5
activation/silencing. 5
HP1β 5
immunoFISH 5
HP1β. 5
Clr4p, 5
(H3K9me), 5
Su(var)3-9-like 5
SUVH-like 5
methyltransferase), 5
postmeiotic 5
(XX) 5
breakdown. 5
Raf1, 5
HSP90, 5
HSP90. 5
non-resectable 5
2/5 5
6·0 5
[19%] 5
[11%] 5
survival-related 5
stabilizers, 5
complexation 5
Shock 5
advantageous. 5
GV1001-specific 5
beta-transducin 5
beta-catenin/Tcf 5
/Akt 5
anti-HGF 5
Cyclooxygenase-2 5
IκB, 5
p85α/p110α 5
p85α/p110δ, 5
CCN1/Cyr61 5
Migration 5
beta-MHC, 5
(IAP) 5
IAPs 5
IAPs, 5
0.04); 5
IAPs. 5
(0.45 5
epicardium. 5
PI3-kinase 5
1L-6-hydroxymethyl-chiro-inositol 5
2-(R)-2-O-methyl-3-O-octadecylcarbonate, 5
culture; 5
(TBG) 5
plus) 5
consequence. 5
risk' 5
(5.4%), 5
(3.5%) 5
H1N1) 5
0-7 5
323 5
exposure: 5
stillbirth 5
5-minute 5
curettage 5
(9.4%) 5
(9.9%) 5
over, 5
to. 5
trimesters. 5
avoidable 5
368 5
(0.3%) 5
{CI}, 5
3.43 5
outcome: 5
birthweight, 5
Pregnancy, 5
(>40 5
IMH) 5
BLT 5
c.177delG 5
(p.H60TfsX11) 5
c.153_166del14 5
(p.A52RfsX351) 5
(CH 5
pes 5
choreoathetosis 5
TTF-1)--critical 5
33) 5
TGN. 5
Calpha 5
ChromaGenSVM 5
non‑small 5
Processive 5
(Imetelstat) 5
phosphoramidates 5
GRN510 5
antagonization 5
anticytokine 5
IL-13. 5
difficult-to-control 5
2-associated 5
(EASI-50, 5
eczema) 5
near-clearing 5
itch) 5
EASI-50 5
Side-effect 5
dose-limiting. 5
Sanofi; 5
NCT01259323, 5
NCT01385657, 5
NCT01639040, 5
NCT01548404.). 5
821 5
CCL18, 5
lebrikizumab, 5
(LABAs). 5
exacerbation; 5
(Th2)-associated 5
Th2-driven 5
LABAs, 5
Th2-associated 5
NCT01312961.). 5
reaffirmed 5
synostoses 5
synostoses. 5
pseudohypoparathyroidism 5
coronal, 5
hydrocephaly, 5
5q35. 5
craniosynostosis-related 5
rescued. 5
(CS), 5
(ALP), 5
Neutralizing 5
constraint, 5
MSX2-mediated 5
P4, 5
coned 5
(n=283) 5
HR+, 5
HER2- 5
(associated 5
Tunisia 5
(TPO) 5
upwards 5
spindle-shaped 5
colloid 5
audiometry, 5
deletion/insertion 5
(IVS2 5
discomfort. 5
congenitally 5
Canagliflozin, 5
co-transport 5
≥45 5
tomography-guided 5
(PNET). 5
identifications. 5
workflows, 5
tied 5
TTR. 5
SIL 5
nL 5
FASP, 5
elemental 5
970 5
sulfite 5
globules 5
Fatigue, 5
PAL 5
RT3 5
Number, 5
nations. 5
Multilevel 5
Results, 5
participant. 5
0.43) 5
day-time 5
browsing, 5
date: 5
non-redundant, 5
Introduction. 5
noncicatricial 5
(ichthyosis 5
(brain 5
(nail 5
alternatively, 5
genodermatosis. 5
photography 5
G681A 5
thienopyridine 5
(n=40), 5
66%), 5
T-allele, 5
.04) 5
(*2 5
C→T 5
gene-dose 5
C3435T 5
Q192R 5
(ABCB1), 5
(PON1) 5
(57.3 5
posit 5
Sub-analysis 5
non-AEDs 5
New-onset 5
chemoradiation. 5
(68.6%) 5
(LSDs), 5
LSD, 5
TFEB-/- 5
starvation- 5
antiatherogenic 5
(PPAR) 5
LAMP1, 5
Closterium. 5
Charophytes 5
irregular-shaped 5
ampicillin-treated 5
two-state 5
machinery: 5
eubacteria 5
Antimicrob. 5
gallidermin 5
mersacidin-induced 5
UDP-N-acetylmuramoyl-pentapeptide, 5
UDP-N-acetylmuramoyl-tripeptide 5
vanA 5
MIC, 5
conforming 5
auxotrophic 5
Psychosocial 5
preselected 5
21.5 5
[AUC] 5
(PFS-6) 5
portion, 5
25.6 5
nonsignificantly 5
day; 5
post-RT 5
Ninety-one 5
23.9% 5
(PFS6). 5
8-14 5
64), 5
chi-squared 5
BUdR 5
(59.4 5
cross-reacting 5
anti-vascular 5
0-1, 5
STUPP 5
supratentorial, 5
(RTOG) 5
IBIDS 5
shafts 5
IL-17A. 5
IL23R, 5
smoked. 5
pDCs, 5
Synovial 5
Immunocytochemistry 5
staining) 5
(MCI). 5
0.008, 5
(apolipoprotein 5
111) 5
0.26), 5
resilient 5
Late-life 5
1.83, 5
percentile). 5
informants 5
Conscientiousness, 5
Decline 5
replicable 5
facets. 5
Caregivers 5
mRCC 5
time-to-progression 5
allografts 5
p70S6K, 5
TOR-I, 5
micromol/L; 5
(1966-June 5
2.02 5
prohibitive 5
cross. 5
splice-variants 5
translocation: 5
database), 5
EWS-Fli1, 5
neuroblastomas. 5
0.32; 5
Wilms 5
(2/5) 5
NSE 5
12/13 5
EWS-FLI1/ERG 5
Rad21-cohesin 5
ER-bound 5
anchors. 5
DJ(H) 5
J(kappa) 5
V(kappa) 5
LMP1 5
motifs: 5
ChIP-seq. 5
germlines 5
CCTC-binding 5
insulator, 5
SA2, 5
multiloop 5
Coordination 5
herpesvirus. 5
TRF1 5
Venus 5
chromophore 5
mutation-induced 5
mutation-specific 5
(SCD), 5
(ASA) 5
HOCM 5
enthusiasm, 5
DDD 5
(CBP), 5
DHPLC-based 5
DHPLC. 5
machine. 5
(predicting 5
KP4-like 5
germinating 5
EGTA 5
(other 5
Mg2+. 5
thymus. 5
PAR-CLIP. 5
microRNA-containing 5
(miRNPs) 5
mappability 5
friendly 5
Mixture 5
interactions: 5
SILAC-based 5
miRNPs 5
(Photoactivatable-Ribonucleoside-Enhanced 5
Immunoprecipitation) 5
4-thiouridine 5
(4-SU) 5
6-thioguanosine 5
(6-SG) 5
(thyroid-stimulating 5
vague 5
(AIT). 5
RAIU 5
0.9%, 5
MBq 5
131I 5
resemblance. 5
lower-body 5
upper-body, 5
full-body 5
toddlers 5
planes. 5
diplegic 5
jump 5
(Cr), 5
HSP, 5
midstance 5
In-Hand 5
Calcaneal 5
lengthening, 5
Vojta 5
Varied 5
Adolescents 5
I-III) 5
P<.001, 5
quick, 5
yrs) 5
dosage) 5
reminders 5
quantitative-PCR 5
neurofibroma 5
bracketed 5
precisely, 5
selenocysteines. 5
(FL) 5
compounding 5
selenium. 5
decoded 5
HSelP 5
r3Cseq: 5
Decision 5
disease-linked 5
aggregation-promoting 5
coopted 5
mutant-FUS. 5
ALS-causing 5
(F) 5
Hek293T 5
proteinopathies. 5
PRMT1-mediated 5
(FUS/TLS) 5
PRMT1. 5
DNA- 5
processes: 5
Infiltrating 5
(NF)-kappaB 5
CD117 5
(newly 5
Happiness 5
(biological, 5
endocrinology 5
Neuroscience 5
35-50% 5
Heritability 5
12,000 5
DZ 5
(OPC) 5
(Child-Pugh 5
(CL/F) 5
1.4-fold, 5
1.7-fold 5
3.3-fold 5
opicapone), 5
0.8-3.2 5
sulphated 5
above), 5
61.6 5
(k(off)) 5
(k(off) 5
dose-independent 5
carboxypeptidase 5
MS/MS. 5
SPRY1, 5
infectants 5
"junk" 5
Orc1 5
pulmonis 5
volcanii. 5
replicons. 5
K1, 5
DSM 5
spiradenomas, 5
appendages, 5
PLAG1 5
TEs, 5
c.1843delT 5
(neither 5
BSS 5
63-linked 5
(BSS) 5
Interfamilial 5
skin-coloured 5
deubiquitinate 5
Aspartic 5
16q12-13, 5
ankle. 5
280, 5
Johannesburg 5
Cape 5
distorting 5
Smn 5
VRK1 5
Cushing's 5
TSC1-TSC2-TBC1D7 5
(TSC-TBC) 5
TSC-TBC 5
phosphatidylserine, 5
postsynaptically 5
Ca(2+)/CaM-dependent 5
βCaMKII 5
KN-92. 5
CCK-8 5
pupae 5
KN93. 5
thapsigargin-mediated 5
ionomycin 5
PP2, 5
4/10 5
71, 5
cdk 5
prelabeled 5
NE-induced 5
VSMC, 5
(CMT1A) 5
12.1% 5
Number: 5
neuregulin-1 5
MFN2 5
CMT2, 5
palsies 5
Neuropathies 5
meningoencephalitis, 5
sepsis-like 5
virus-positive 5
10(8) 5
disintegration 5
migraines 5
CCM3/PDCD10. 5
CCM2/MGC4607 5
angioma 5
stop-codon 5
0.1-0.5% 5
CCM1). 5
Krit1, 5
4-Mb 5
Ccm2 5
kinase-mediated 5
salvage. 5
11%), 5
hours' 5
clips 5
cysts: 5
perineurium 5
Microsurgical 5
English) 5
(H), 5
16.971, 5
Acceptors 5
PaDELDescriptor 5
rule-of-five 5
Ligand-Based 5
Substructure 5
("no 5
difference") 5
("proof 5
difference"). 5
dipeptidylpeptidase-4 5
Equivalence 5
±0.25% 5
effectiveness; 5
agent-alogliptin-failed 5
(alogliptin, 5
SAVOR 5
TIMI-53 5
(Saxagliptin 5
Recorded 5
mellitus--Thrombolysis 5
Infarction-53) 5
78-week 5
sitagliptin; 5
metformin) 5
below. 5
MACE, 5
alone; 5
outcome; 5
English. 5
glucose-dependent 5
(HbA(1c)) 5
rosiglitazone, 5
(twice 5
thiazolidinediones 5
Generally 5
added, 5
10.3%; 5
IgV(H) 5
sleep/wake 5
stimulants, 5
(MCS), 5
Library. 5
hyperbaric 5
conflicting, 5
flaws 5
(among 5
dantrolene 5
metalloproteinase-3 5
II-IV 5
proMMP-9 5
interleukins, 5
ECM. 5
Experiences 5
inconvenience 5
Elements) 5
Toxin 5
Cattle 5
95%. 5
1140 5
432 5
Tehran, 5
fur 5
BoNT/CD-HCR 5
duality 5
gift 5
und 5
Christian 5
ophthalmologist 5
3,4-diaminopyridine 5
3,4-DAP 5
Multilocus 5
hypogonadism) 5
POLR3-related 5
[i.e., 5
Ataxia, 5
POLR3A, 5
leukoencephalopathies 5
architectures. 5
tumor- 5
consensus-binding 5
pleiohomeotic 5
Inspection 5
activation) 5
tabacum 5
tobacco. 5
MTases. 5
callus 5
Dnmt3, 5
AtDNMT2 5
enigmatic, 5
U2OS 5
p16(INK4A) 5
blebbing, 5
Cenpc 5
602 5
(25.8%) 5
Chd1, 5
∼10 5
Because, 5
Chd7(Gt/+) 5
(GnRH) 5
GnRHR 5
8q 5
depressed, 5
Sciara 5
(embedded 5
(CDY) 5
CDY, 5
CDYL, 5
CDYL2. 5
CDYL2 5
desert 5
ubiquinone 5
Cbx 5
K27me3; 5
(CDs) 5
CD2, 5
CD1. 5
cpSRP43 5
Electrophoresis 5
MRG15, 5
Rb. 5
PAM14 5
(scFv) 5
MRG15. 5
dMi-2 5
decompacted 5
SNF2/SWI2-like 5
conceivably 5
ACHN 5
(NCCs) 5
PAA 5
Jr. 5
Elp3 5
UTX, 5
chromoshadow 5
S10 5
Sox2. 5
HP1(Swi6) 5
helicase/ATPase 5
T2) 5
MRG-1 5
synapsis, 5
(NTD) 5
chromosomes; 5
5.3% 5
β-catenin-dependent 5
3.5-fold 5
Mediator. 5
terminated. 5
0.037) 5
laterality 5
kHz 5
CenH3 5
(MSS), 5
35.7% 5
CD44. 5
maturating 5
Clr4. 5
Swi6, 5
confinement 5
Cubitus 5
Pax2, 5
primacy 5
setting; 5
waned 5
1986. 5
(P=0.05) 5
midwall 5
Bulgaria. 5
genus) 5
tick-born 5
(WNV), 5
Da) 5
(SLC) 5
blood-to-brain 5
S-adenosylmethionine:guanidinoacetate 5
guanidinoacetate. 5
transporters: 5
xenobiotics. 5
distribution: 5
(TIEG1), 5
CGNPs 5
cellular, 5
homoharringtonine 5
supernatants. 5
SW1990 5
HPV-16 5
E7. 5
Bcl-X(L) 5
Mn 5
(AβPP) 5
(LHON), 5
apoptosis-induced 5
inter-membrane 5
dynamin-1 5
Mfn2, 5
H295R 5
fuse. 5
Atrophy. 5
K⁺ 5
immunolocalization 5
(VAS), 5
mucosae. 5
(PTC). 5
(FTC). 5
operationally 5
MINPP1 5
(GLT1) 5
survive, 5
GLT-1 5
Remaining 5
cephalosporin 5
h; 5
(O)Estrogen 5
(NCCP) 5
utilised, 5
DXtrade 5
hormone-receptor-positive, 5
(NN) 5
(ER, 5
BAG1) 5
corticotropin 5
(ACTH), 5
km 5
(T4), 5
ml-1 5
swimming, 5
insignificantly 5
guaranteed 5
miR-145. 5
(MAO 5
(detected 5
unhealthy 5
HTR2A, 5
NR3C1, 5
(ND) 5
electrocardiograms, 5
founder, 5
825 5
R14del- 5
absent/depressed 5
Leu, 5
1,014 5
Chagas, 5
(R9). 5
R9L 5
R9H 5
Arg9 5
Leu39 5
R14 5
L39stop 5
carbohydrate, 5
RAST 5
sport, 5
VC, 5
dismutase, 5
standardization. 5
Biostimine 5
(TAC) 5
(main 5
(CG) 5
RE. 5
(GSH), 5
high-protein, 5
(PUFA) 5
(UI) 5
denervated 5
threatening; 5
c.815T>A, 5
p.L218Q 5
(dSMA-V). 5
CMT2D/dSMA-V. 5
Glycyl 5
large-diameter 5
gene-trap 5
weaning. 5
pixel 5
(M-FISH) 5
inflexible 5
dKDM4A 5
Txr1p 5
thermophila, 5
SU(VAR)3-9 5
DCC-dependent 5
H4K16ac 5
reorganizes 5
Residue 5
co-occupy 5
old). 5
Set9, 5
Hoyeraal-Hreidarsson 5
Malignancies 5
(IBMFS). 5
(ST). 5
(NCI) 5
DC; 5
mildest. 5
DKC1, 5
TINF2, 5
efficacy; 5
considered; 5
Dyskerin 5
pseudouridine, 5
NOP10 5
telomere-related 5
cancer-prone 5
Z-scores 5
deactivate 5
variance) 5
(necrosis 5
-150, 5
-195, 5
-214 5
miR-1/-133 5
miR-210, 5
preconditioning. 5
Preconditioning 5
miR-126, 5
[such 5
(PI3K), 5
Ischaemic 5
H(2)O(2)-mediated 5
BRCA1/BARD1 5
TFIIE 5
autoubiquitination 5
complicated. 5
(GEM) 5
(MCF-7 5
µmol/L 5
γ-tocotrienol 5
lipidated 5
buffered 5
form), 5
Atg5-dependent 5
LC3II 5
(LPS). 5
Hyperglycemia 5
p21-dependent 5
hijacks 5
sc 5
DAS 5
210) 5
multi-ethnic 5
HPLC, 5
coronaries 5
N-Glycolylneuraminic 5
15.9 5
polyclonal. 5
Neu5Gc-containing 5
(Pradaxa), 5
(Pradaxa(®)) 5
time), 5
obstacles. 5
antidotes. 5
available: 5
(P-gp) 5
Xa. 5
withdrawn. 5
operon, 5
histidine-tagged 5
[AtxA(His)] 5
anti-AtxA(His) 5
RNA-directed 5
CRI 5
participants); 5
aura, 5
alteration, 5
HSPA9) 5
MDS/AML. 5
SNP-array 5
22). 5
CTNNA1 5
Filtering 5
(EZH2). 5
0.011 5
(SEMA3A) 5
submucosa 5
Ret, 5
(del 5
forwarded 5
(2.8%) 5
neonate. 5
hindgut 5
(36.4%) 5
[Fanconi 5
(DSB). 5
ionising 5
NFκB. 5
κB- 5
proteasome-selective 5
inhibitor(s), 5
reagent, 5
stearic 5
pacsin 5
condense. 5
constraining 5
slightly, 5
mori 5
Omission 5
Cohesin-based 5
Mb-sized 5
sub-Mb-sized 5
noncycling 5
SP100 5
leukemia-associated 5
(NBs) 5
(Cremer 5
1993) 5
closure, 5
Hz; 5
mol/L 5
One-half 5
(SPRY) 5
SPRY/B30.2 5
sub-families. 5
phosphoinositol 5
80K-H, 5
(hpf) 5
adaptation, 5
Darwinian 5
B30.2(SPRY) 5
MosaicFinder: 5
'genetic 5
FusedTriplets. 5
MosaicFinder, 5
co-evolving 5
tedious, 5
inaccurate. 5
676 5
SFPQ/NONO 5
PSP1 5
PR. 5
NEAT1 5
protein:protein 5
RS-OS, 5
contradiction 5
BCL2. 5
anti-hormonal 5
(1.6 5
24/25 5
GRP78. 5
fatigue; 5
(PS-341) 5
post-dose 5
yeast: 5
MRC1, 5
C-like 5
proficiency 5
Dukes' 5
(175 5
Rad18 5
Rnf8 5
1.1). 5
62; 5
23; 5
33.4 5
cisplatinum, 5
HL/GO20 5
cell-lines 5
Division 5
dl922-947 5
IGF-I, 5
SHBG, 5
Retardation 5
transdominant 5
TRs, 5
Receptors 5
RhoB, 5
(ROCK) 5
TSGH 5
tumorous 5
RB1, 5
(Ta 5
T1; 5
stable-isotope 5
anti-hyperglycemic 5
(Invokana™), 5
Mitsubishi 5
Johnson, 5
conferences. 5
<0.2 5
(p<0.0001) 5
nmol/L, 5
FT3/FT4 5
index/reverse 5
dilated, 5
remainder. 5
(CSA) 5
TFIIH 5
Strand-specific 5
(CPD) 5
smart 5
(DHFR) 5
argE3 5
signifies 5
7MeG 5
3MeA 5
alkyladenine 5
lesion: 5
lesion-containing 5
AA8 5
lesion-recognition 5
Past 5
Willis 5
syndromes). 5
RNF213 5
azoospermia, 5
hemorrhagic, 5
demographics. 5
6.57 5
stupor 5
17q25, 5
17q. 5
17q11.2. 5
sequencer. 5
trigone 5
arteriosclerosis 5
NIDDM. 5
(UUCCUUAAC). 5
Fcγ 5
SpA, 5
coarse-grained 5
3.0. 5
(Li 5
protonation 5
withstood 5
rifapentine 5
Rifampin 5
Bronchoscopy 5
mediastinoscopy 5
bacteremia. 5
(69% 5
Disseminated 5
polyserositis 5
AMLAs 5
purulent 5
21.0 5
micronodular 5
pneumocyte 5
cyst-positive 5
PEComa 5
168-kDa 5
CHD6-9 5
SLIK 5
(Kd) 5
modification-recognition 5
Isw2 5
transcription-related 5
frq 5
HR-positive 5
50.2 5
9.8% 5
diarrhoea. 5
23.5% 5
31.4% 5
75. 5
CI], 5
.025) 5
nodes; 5
emetic 5
Oncol 5
seventeen 5
patient). 5
10(-3), 5
F). 5
(ALT), 5
requirement, 5
journal, 5
cross-clamp 5
mean), 5
forty-two 5
micrograms.kg-1.h-1 5
Raising 5
CisMiner: 5
motifs; 5
CisMiner, 5
itemsets 5
Frequent- 5
itemsets. 5
degeneracy 5
top-ranked 5
V-FITC 5
ATF-4 5
Quantifiable 5
AlphaScreen. 5
thioester, 5
Lysates 5
β-subunit 5
(CRL) 5
chemokines. 5
UBL 5
p53-negative 5
Vpx/Vpr-induced 5
SIVmac 5
milestone, 5
(HNSCC), 5
(DLBCL), 5
deoxynucleoside 5
reverse-transcribed 5
(E2). 5
F., 5
muM 5
SERCA2's 5
codistributed 5
subordinate 5
athletes]. 5
ascertaining 5
cardiologist 5
Signature 5
Recommendation 5
judicious 5
reproducibility, 5
van't 5
breast-conserving 5
apply. 5
intermediate- 5
(SAPKs), 5
TPY 5
[4, 5
phosphorylation; 5
phosphatase(s) 5
BAF3 5
[9]. 5
JNK-inactivating 5
3,600 5
HTML 5
concepts: 5
aligned, 5
main-chain 5
IU/d 5
(800 5
(1982 5
AMED 5
1004 5
616 5
1.18). 5
falling, 5
Sixty-two 5
306 5
0.34, 5
falls: 5
0.77-0.96). 5
date; 5
545 5
best-practice 5
programs; 5
eligibility, 5
0.51, 5
54) 5
46) 5
1.86 5
3.09 5
cross-sectionally 5
psychic 5
Gliolan 5
overtreatment 5
ChIP. 5
Cheilitis 5
suicide. 5
Woman 5
papulopustular 5
defects: 5
Pregnancies, 5
26.6, 5
(84%), 5
15-minute 5
aside 5
RAs 5
5.54 5
unity 5
teratogenicity) 5
subgerminal 5
intaamniotic 5
doses-100 5
B-carotene. 5
[Hummler 5
Teratology 5
50:184-193]. 5
26). 5
all-trans-RA, 5
teratogens. 5
embryo: 5
Accutane) 5
Keratolenticular 5
(Peters' 5
anomaly) 5
(SER) 5
neural-crest 5
RING-finger 5
chapter. 5
Mdm2-p53 5
nutlin-3 5
ubiquitinating 5
E2F1. 5
ATM-dependent 5
HDM2, 5
HDM2-mediated 5
reactivating 5
(MDM2) 5
aporphine 5
'cleavable' 5
nalidixic 5
mAMSA 5
dihydrochloride) 5
(MDR), 5
MDR. 5
manageable. 5
cyanomorpholinyldoxorubicin 5
cross-links; 5
(unwinding) 5
morpholinyldoxorubicin 5
cMAP 5
(m-AMSA), 5
fagaronine 5
theoretically, 5
alkaloids, 5
liposomes, 5
viscosity, 5
m-AMSA. 5
(this 5
1961 5
thermodynamics 5
carcinogens, 5
nonaromatic 5
AD41 5
miR-34, 5
epilepticus, 5
immuno-inflammatory 5
(SK). 5
20-fold) 5
antagomir-132 5
CD31-enriched 5
(presumably 5
SK. 5
MicroRNA-132 5
binding- 5
GATA2, 5
neuromorphological 5
tract-binding 5
(3NP)-induced 5
upregulation-dominant 5
downregulation-dominant 5
Drosha-DGCR8, 5
Exportin-5, 5
5months, 5
concomitantly. 5
3NP 5
spiral. 5
GluR4 5
Reticulon 5
EAAC1-associated 5
GTRAP3-18, 5
RTN2B, 5
reticulon 5
GTRAP3-18 5
L-glutamate 5
cysteinylglycine 5
GltPh 5
Aspartate 5
multimers; 5
EAAT3, 5
Glu, 5
GltT-GltM 5
Na(+), 5
mitogens, 5
NR2B 5
phox 5
CASP 5
phosphatidylinositol-3-phosphate 5
nexins 5
489 5
98.71% 5
GT-AG 5
0.56% 5
(0.73%) 5
EST-supported 5
stain, 5
rival 5
Ruby. 5
zwitterionic 5
one- 5
(CCB) 5
CCB 5
(2-DE) 5
"conventional" 5
A2). 5
GST-pull 5
previously; 5
(Macugen) 5
horizons. 5
targeted-therapy, 5
assortment 5
protease-activated 5
battle 5
(siRNA), 5
(TM), 5
regulatable 5
(derived 5
non-destructive 5
guanine-rich 5
10(3) 5
Foc1 5
emitted 5
variety) 5
cubense, 5
subsistence 5
MMP13 5
802 5
Moore 5
chromosomal, 5
Bilambdoid 5
(RTK) 5
Shh-induced 5
Bim, 5
Janus-activated 5
Src. 5
hedgehog-induced 5
Cilia 5
Shh. 5
N-Myc 5
cancer-causing 5
TGF-β. 5
Twist1, 5
immunoreactivities 5
'driver' 5
exon-targeted 5
reanalyzed 5
dog-human 5
PCGs 5
powerful, 5
endosymbiont 5
bends 5
coexisted 5
(HMG) 5
unsettled. 5
Continuation 5
32). 5
(71.4%) 5
MMI 5
7.6% 5
0.000). 5
(ATA) 5
alpha1, 5
alpha-MyHC 5
spermatogenesis: 5
abacavir-associated 5
P=0.021). 5
18.0 5
AKI, 5
forms) 5
(3.7 5
0.016, 5
0.048, 5
1.47 5
tertiles 5
taste. 5
stinging 5
three-tier 5
Tyk2, 5
galectin 5
Stat1 5
(PKB), 5
diffract 5
Tsc1-Tsc2 5
(S6K) 5
(CO) 5
widening 5
Hasake 5
lymphocytopenia, 5
Infusion 5
diarylquinoline 5
rate-corrected 5
Unexplained 5
replicating, 5
sterilizing 5
eradication. 5
predication 5
HP 5
acting, 5
2.20, 5
eradication, 5
noncardioembolic 5
=0.04). 5
(enzyme 5
2.91; 5
1.84; 5
titre 5
Atherosclerotic 5
1.43 5
origin: 5
case-controlled 5
(ci) 5
0.87-2.76), 5
0.75-2.67) 5
3.63; 5
1.37-9.65) 5
1.09-11.4). 5
cardioembolism 5
communication: 5
tiring 5
Augmentative 5
(DDK) 5
syllable 5
phonation, 5
autosegmental-metrical 5
accent 5
MSD 5
phrases 5
apraxia 5
Dysprosody 5
Interrater 5
consonant 5
pathological, 5
(OA). 5
klotho, 5
decidualization. 5
conceptus. 5
trophoblast, 5
dehydration. 5
LINX(®) 5
Paul, 5
System: 5
competence. 5
bolus, 5
endoscopy, 5
undue 5
augmentation. 5
gangliosidosis. 5
retinas. 5
(MERRF) 5
Alpers' 5
(genetic 5
GM1-gangliosidosis, 5
brothers. 5
beta-D-galactosidase 5
TIM 5
cross-correction 5
galactosialidosis 5
putamen, 5
cisternae. 5
protein" 5
ventriculomegaly. 5
hemiatrophy: 5
sulci 5
14-month-old 5
aspergillosis, 5
homolateral 5
(PET), 5
CHA 5
pellucidum, 5
polymicrogyria 5
Tafazzin, 5
byproducts 5
mitochondria-targeted 5
mito-Tempo 5
chromosome-linked 5
cardiolipins 5
caspase-8. 5
remodelled 5
supercomplex. 5
Annals 5
shRNAs 5
PSL. 5
novelty. 5
double-deficient 5
CRY2 5
locomotion, 5
uncovered. 5
Kinetics 5
Suz12 5
pyrosequencing, 5
ERK7 5
CK1, 5
40-fold 5
KKQK 5
yielded, 5
(Km 5
moderate-to-high 5
mL/min) 5
(J-ROCKET 5
digitoxin, 5
2.26, 5
Explanations 5
polymorbidity 5
<90 5
non-central 5
1.66 5
3.25 5
1.10, 5
warfarin; 5
56%), 5
(stroke 5
cTTR 5
reason. 5
curator&rsquo;s 5
graphic 5
sapiens, 5
mold 5
secreted. 5
eukaryote, 5
feeds 5
IMTG 5
LSDP5 5
scarcity. 5
lipogenic 5
oleate 5
(FNAC) 5
smears. 5
1940s, 5
Murray 5
stains. 5
X-chromatin 5
painted 5
plume 5
(genomics, 5
fluxomics). 5
spectrometers 5
inductively-coupled 5
glucosinolate-rich 5
lipidome 5
Rev. 5
Lipidomics 5
(MammaPrint(®)) 5
4-9 5
(93%), 5
Luminal 5
positive) 5
0.013). 5
QALY, 5
226), 5
0.31; 5
(0.96 5
moment, 5
concerned, 5
ALI, 5
cataplerosis 5
AAH. 5
AAH, 5
lipotoxic 5
(BVDV), 5
positive-sense 5
Picornaviridae, 5
Paramyxoviridae, 5
Reoviridae; 5
(Herpesviridae 5
Flaviviridae, 5
Poxviridae). 5
Diarrhoea 5
haematologic 5
uncleaved 5
cigarettes: 5
quit-smoking 5
(NRT). 5
quit, 5
aid. 5
abstinence. 5
telephone-based 5
economics 5
paying 5
zic-1 5
neoblasts 5
excretory 5
Yki 5
(28.3%) 5
stuporous 5
pattern), 5
(ICU). 5
Pair 5
radio 5
merge 5
implants, 5
craniomaxillofacial 5
organs), 5
tissue-engineered 5
art, 5
3D-bioprinted 5
tissue-engineering 5
"blueprints" 5
organs; 5
printing; 5
postprocessing 5
gels, 5
0.90, 5
non-estrogen 5
ospemifene. 5
(VVA) 5
antiestrogenic 5
histomorphometry 5
VVA. 5
Menopause 5
locally, 5
lasofoxifene 5
menopause-related 5
(61.4%) 5
smear, 5
Dopaminergic 5
(augmentation) 5
cabergoline 5
(IRLS), 5
(CGI-I), 5
trial), 5
CGI-I 5
Societies, 5
(print 5
publications) 5
rating. 5
Cabergoline 5
taskforce 5
CGI, 5
asleep 5
consulting 5
30-kDa 5
semi-thin 5
extensibility 5
7%. 5
AAVS1 5
ensue. 5
Avoid 5
3(FGFR3) 5
HLA-B, 5
Dicoumarol, 5
(17-allylamino-geldanamycin 5
novobiocin) 5
Ras/Raf/extracellular 5
hsp70, 5
15-30% 5
over-transmission 5
DGGE 5
classified. 5
Ranking 5
Voltage-dependent 5
-80 5
excitation. 5
inside-out 5
(ICa) 5
(LES) 5
60%) 5
transfer" 5
acknowledgement 5
prognosis,as 5
epidermoid 5
(66%). 5
immunologic, 5
anti-P/Q-type 5
anti-beta-subunit 5
titer, 5
Profound 5
Lantibiotic 5
antimicrobials. 5
lacticin 5
LanT 5
too, 5
Lactococcus 5
nisin, 5
thioether 5
gene-encoded 5
type-B 5
604168) 5
Gypsies 5
dysmorphism-neuropathy 5
(CCFDN, 5
604168), 5
rhabdomyolysis; 5
18qter 5
cataracts; 5
aphakic 5
nonophthalmologic 5
myoglobinuria, 5
nonprogressive 5
73.5 5
risk? 5
(United 5
enjoyed 5
1.17; 5
workload, 5
sanglifehrin 5
small-RNA 5
faster. 5
nutrient, 5
Hfq 5
outbred 5
SET-transposase 5
DNA-binding, 5
(TIR)-specific 5
non-TIR 5
(NHEJ). 5
quinolone 5
quinolones, 5
DSB-induced 5
Mucin 5
ROS-generating 5
superoxide-generating 5
pro-senescent 5
Myc-evoked 5
senescence-associated, 5
Wrn. 5
ARF-p53-p21Cip1 5
p16INK4a-pRb 5
IL-8. 5
(MYC) 5
ATM/ATR 5
reactivated, 5
MYC-induced 5
indistinguishably 5
G(0)/G(1) 5
lifespan; 5
HbVar: 5
[Huisman 5
1998]. 5
Queries 5
alpha1-globin 5
(HBA1) 5
H.J. 5
(LSDB) 5
LSDB 5
alpha-thalassemia 5
(http://globin.cse.psu.edu/globin/hbvar/) 5
Updates 5
α-, 5
acetonitrile 5
8.5% 5
CPM, 5
SH-Sy5y 5
hydroxylates 5
(junctin), 5
(junctate). 5
families; 5
(210 5
6-78 5
chemosensitizers 5
Netrin-1 5
Yes-associated 5
YAP. 5
TEAD 5
Yap, 5
ill-defined. 5
diaphanous 5
Trafficking 5
mDia1-FH2 5
connector 5
gelsolin 5
translocases 5
evict 5
quenched 5
4.07; 5
16.9; 5
exome, 5
R47H), 5
Icelanders 5
3.91; 5
P=2.1×10(-12) 5
DRAP 5
Chaos 5
Game 5
(CGR), 5
subsequence 5
granularity 5
Distance. 5
signature' 5
extremes: 5
'general 5
between-species 5
Interpretations 5
delta* 5
quantities. 5
Bid, 5
hunt 5
TCM 5
bioinformatics. 5
glycome 5
glycomics 5
limpet 5
EGFRvIII-positive 5
EGFRvIII, 5
NCCM, 5
Biology: 5
Contraction. 5
(DSP) 5
co-segregation 5
restrictive, 5
Autosomal-dominant 5
2.1) 5
strains; 5
NT2 5
JC-1 5
re-replication 5
PM, 5
(PcG), 5
chromatin-modifier 5
thrombocythemia 5
Nonsyndromic 5
CRT. 5
(MLL) 5
(NPM) 5
HOXA9 5
<10% 5
three-way 5
dystrophins 5
drisapersen. 5
'rare 5
2b/3 5
elastin. 5
abortion. 5
3600 5
(2.4 5
1.23). 5
termination) 5
0.37, 5
YB-1 5
(Pan 5
Bodies 5
Derepression 5
Cumulatively, 5
Pacman, 5
cataloguing 5
Dendrites 5
Talf1 5
inulin, 5
885 5
LPG. 5
liquefied 5
(270 5
(FOS) 5
niger, 5
GF2 5
(25.3 5
nkat 5
exoinulinase 5
(50, 5
l. 5
thermostable 5
Michaelis-Menten 5
10.4, 5
5.61, 5
high-fructose 5
sector. 5
audible 5
decompensation. 5
afebrile 5
ensues. 5
electromechanical 5
[Experimental 5
CVB3 5
fission/fusion 5
(PARK2), 5
(PARK6), 5
early-onset. 5
(PARK15), 5
PTEN-induced 5
PARK7, 5
DJ-1. 5
homo-dimer 5
juvenile-onset 5
30s 5
NCX1.1-mediated 5
whole-heart 5
30.2 5
P<0.005). 5
Ran. 5
LQT2. 5
0.42 5
desensitizes 5
Subsequently 5
ATX 5
mg/h 5
ordering 5
(MCT4) 5
(TO 5
COX) 5
co-exist, 5
glycolytic, 5
literally 5
"feeding" 5
MCT4(+) 5
MM20(-) 5
(TMAs; 5
energy-transfer 5
(Cav-1) 5
PKM1 5
PKM2 5
stromal-epithelial 5
"feed" 5
Cav-1. 5
metastasis-promoting 5
(aerobic 5
Mdm-2 5
Gadd45alpha 5
Mdm-2, 5
Gadd45alpha, 5
imatinib-induced 5
BCR/ABL, 5
six-year 5
nonhematological 5
later-generation 5
(ABL) 5
bosutinib 5
t(9;22), 5
"escapes" 5
c-ABL, 5
P210 5
Sokal 5
AP-CML 5
93.7% 5
43.8% 5
basophils, 5
(Philadelphia 5
t(9:22) 5
HLA-matched 5
(Glivec) 5
t(9;22)(q34;q11), 5
years' 5
(7.1%) 5
aberration, 5
ins 5
t(9;22)(q34;q11). 5
precedents 5
phase; 5
evolution). 5
mesylate), 5
CD34, 5
IM, 5
CML: 5
break-through 5
receptor-type 5
chimerical 5
remissions, 5
(Gleevec, 5
harvests 5
Ph- 5
19%; 5
additive, 5
γ-aminobutyric 5
(mixed 5
measurements). 5
(MADRS 5
-5.5 5
congresses. 5
Descriptions 5
6-9), 5
5-HT1B, 5
slowness 5
5HT2A 5
nasopharyngitis. 5
(2.5, 5
35.2%) 5
multi-site 5
(1:1:1:1:1) 5
-1.7 5
(4%); 5
shortcoming, 5
customizable, 5
publication-ready, 5
(BED), 5
bedGraph 5
calcifications. 5
serodiagnostic 5
comprehensive. 5
IPW, 5
moles 5
origin) 5
(DAE) 5
CEPH 5
PEG10 5
(ZNF331) 5
cSNPs, 5
Angelman's 5
copy. 5
Catalogue 5
LINKAGE 5
v3.0 5
BAP1 5
screenings 5
EMSA 5
FAK. 5
cycle-signaling 5
Klf2, 5
latipes) 5
filament-type 5
(P19) 5
A-expressing 5
Wide-field 5
dimmer 5
Oct-3/4 5
Tra-1-60, 5
Tra-1-81, 5
SSEA-4. 5
adhering 5
recycles 5
microbes. 5
IRGM 5
vacuolization 5
spacers 5
(Cas) 5
CASS 5
u 5
tryptophan, 5
usages 5
Clues 5
anticodons 5
appear, 5
1962 5
(cumulative 5
biomedicine. 5
mass-spectrometric 5
(M-alphaMHC(R403Q/+): 5
M-alphaMHC(+/+): 5
F-alphaMHC(R403Q/+): 5
ANOVA, 5
0.47, 5
3.21 5
(whether 5
alpha-MHC403/+ 5
uncontaminated 5
Annuloaortic 5
insufficiency; 5
AT-1R/AMPK-MAPK 5
trimetazidine, 5
Millar 5
lean, 5
(STZ)-induced 5
(XIAP) 5
intervened 5
abort 5
udden 5
meet. 5
whites 5
.004). 5
occuring 5
9; 5
contradict 5
baseball, 5
informal 5
padding 5
(baseball 5
catchers 5
lacrosse/hockey 5
goalies), 5
resuscitation/defibrillation 5
narrows 5
collision-induced 5
spongy 5
precondition 5
shoots 5
non-plant 5
16q23.2 5
keratin, 5
BACK 5
GAN, 5
re-introduction 5
Algerian 5
Gigaxonin-encoding 5
intra-cellular 5
beta-APP 5
repulsion 5
necks 5
cryogenic 5
internalization, 5
self-assemble 5
aPKC, 5
BAR 5
DeltaN 5
(SAC) 5
etiologically 5
MII 5
BRCA1-associated 5
p73beta 5
(TAp73 5
p53-responsive 5
(DLBCL) 5
retinoids, 5
Metal-sensing 5
iron-sensing 5
corporately 5
dismutase) 5
precedent 5
replisomes 5
RBD 5
K) 5
phosphatidylinositol-3-kinase 5
HRas 5
61. 5
(ERAP2) 5
adipocyte-derived 5
amines: 5
3-iodothyronamine, 5
Thyronamines 5
(RRMS). 5
IL-17F, 5
quarterly 5
CD52. 5
Agency, 5
quarterly, 5
0.58; 5
reactions; 5
Pharma. 5
Natalizumab 5
addiction, 5
decision-making, 5
suicidality 5
FDG-PET, 5
T-PLL. 5
consolidation, 5
FMC 5
remissions; 5
remissions). 5
cytogenetic, 5
Prolymphocytic 5
post-thymic 5
(ALL), 5
mycosis 5
chemotherapy-refractory 5
717 5
mutated) 5
.005; 5
starts, 5
β42 5
β42-induced 5
Solanezumab's 5
non-immunized 5
Have 5
tau-based 5
(senile 5
plaques) 5
bapineuzumab. 5
abandon 5
microhemorrhages, 5
abandoning 5
noncarriers. 5
halted, 5
decays 5
Deiodinase 5
rs7140952 5
372 5
MassARRAY 5
hypertension-related 5
P=0.011). 5
"endothelial 5
levothyroxine, 5
(10.7%) 5
Seoul 5
coalesce 5
Longevity 5
urticae 5
continents. 5
livestock-associated 5
spoligotype 5
descendant 5
(phylogenetic 5
"false" 5
speciation. 5
suborder 5
revision. 5
taxonomy, 5
isopod 5
craniometric 5
Datasets 5
robustness, 5
critique 5
"proof 5
Stockholm 5
onwards. 5
causality, 5
autism: 5
Population-based 5
ceruleus 5
(BLBC), 5
BLBC. 5
subject? 5
add? 5
22.8% 5
E2-2A 5
E2-2B 5
(E2-2A 5
E2-2B) 5
gene-profiling 5
Tcf4 5
E12/E47), 5
metaplastic 5
(1.4%). 5
RCM 5
E413K 5
alpha-actin, 5
CryAB 5
delta-sarcoglycan 5
myofibrils 5
OPN, 5
PTMs. 5
Breaking 5
52) 5
regions). 5
cycle" 5
trophoblastic 5
Biophys 5
IDDM. 5
Night 5
compel 5
bed, 5
asleep. 5
aluminum 5
Diurnal 5
magnitude, 5
deficits; 5
(long 5
(HDACs). 5
(BET) 5
BPTF 5
(BRD) 5
signal-dependent 5
phospho-specific 5
veterans' 5
Anaconda 5
Twenty-four-hour 5
troops 5
Construction 5
service, 5
microvessels, 5
meninges, 5
arterioles, 5
1700 5
(PNETs) 5
VHL-associated 5
risk-adapted 5
nintedanib. 5
understood; 5
(Ofev(®)) 5
Agency's 5
(αSMA) 5
gavage 5
Personalised 5
laser-scanning 5
(RyR). 5
PPI-1, 5
hyperglycaemia 5
propionate 5
calstabin-2 5
beta-actin 5
(IMS) 5
muscles) 5
physiotherapy, 5
organophosphorus-induced 5
crease 5
over-activation 5
sequel 5
atropine 5
assessment) 5
herbicides 5
arsenical 5
Threshold 5
Intoxications 5
Electromyography 5
[Late 5
organophosphates]. 5
polyneuropathic 5
cultivating 5
distal. 5
axonopathy. 5
agriculture, 5
lumber 5
workers; 5
candida 5
polyneuropathy: 5
Toxicological 5
idiosyncratic, 5
Polyneuropathy 5
parathion. 5
rBDV 5
replication-competent 5
noncytolytic 5
(<20%). 5
protein-positive 5
BDV-specific 5
Architecture 5
PTI-NB 5
(BD). 5
(IL-6), 5
p.i. 5
nelarabine 5
sibling, 5
Pentostatin 5
months); 5
NF-kB, 5
Interleukin-12 5
523 5
CD18 5
career 5
neurosurgeons, 5
lowest. 5
Montreal 5
73.7%. 5
72.2% 5
Dentists 5
20-minute 5
REM, 5
splinting 5
abrasion 5
recession 5
wait-list 5
invite 5
MBSR-C 5
(MBSR) 5
(SBP) 5
Treatment) 5
aid, 5
Wales, 5
Prosdex 5
coordinated, 5
programme, 5
(baseline), 5
testing: 5
67.0% 5
LUTS. 5
bother 5
GPs. 5
views, 5
pre-diabetes 5
nephrocalcinosis, 5
Constipation 5
urinalysis. 5
tolerance; 5
L-thyroxinewas 5
sibutramine. 5
(31.5%) 5
FT3, 5
(74.7%). 5
-0.8 5
4.25 5
(GHRH) 5
(FT3 5
(CRF) 5
Frzb/secreted 5
Beta-catenin 5
cyclotron 5
lower-abundance 5
(IgG), 5
(1.1 5
fly) 5
(2013) 5
GRIK 5
self-administration. 5
S129A 5
(Ser129). 5
Ser129-phosphorylated 5
�-synuclein 5
UPR. 5
Premenstrual 5
2.18, 5
HAMD, 5
sedating 5
13.6, 5
Disorder: 5
Objective: 5
9.5% 5
phobia. 5
clomipramine 5
maprotiline, 5
5-HT) 5
(TCAs), 5
phobia, 5
(PDD) 5
complaint. 5
PDD. 5
(RR). 5
cis-retinoic 5
O(6)-methylguanine-DNA 5
Irinotecan 5
vascularised 5
gains. 5
PF4 5
antiangiogenic, 5
Angiostatin 5
POD 5
neoangiogenesis 5
Placental 5
ephrins, 5
g). 5
(CNV) 5
tumstatin 5
intensities. 5
heparin. 5
(MH) 5
heretofore 5
38.6 5
20.5 5
mg/m2. 5
Avascular 5
switch" 5
possibilities, 5
25.8 5
arborization, 5
physiopathology, 5
stromal, 5
kif6 5
escitalopram, 5
ejaculatory 5
lifelong. 5
PSD502 5
IELT 5
self-help 5
(adverse 5
boards 5
agomelatine, 5
Croatia. 5
Antidepressants 5
85.6% 5
Croatia 5
hypnotics. 5
manages 5
[Therapy 5
(categories 5
ejaculation. 5
Thereafter 5
1995-1996 5
obsolete 5
pill, 5
nightly 5
pattern-discovery 5
60-80 5
(templum 5
intentio 5
templints) 5
SNP-coding 5
multi-cellular 5
Ontogeny 5
structured, 5
cap-interacting 5
metal-ion 5
catalysis, 5
endows 5
neomycin 5
sulfate. 5
3'-5'-deadenylases 5
deadenylated 5
V(max) 5
≤100 5
280-mg 5
[P=0.02], 5
827), 5
L1(IGL) 5
hyperexcitability 5
hyperproliferation 5
hMLH1, 5
mutagens 5
(PTT) 5
RasGAP 5
disable 5
(second 5
12-kb 5
asbestos-related 5
MPM, 5
αvβ3, 5
knot 5
cilengitide-induced 5
size: 5
U87-MG 5
cilengitide-treated 5
(EMD121974; 5
Darmstadt, 5
0.038, 5
DCE-MRI 5
osteolysis, 5
intrapatient 5
180, 5
alpha(v)beta(3) 5
CMRIT 5
5'-UTR, 5
LEPR 5
Exonization 5
18: 5
five-generation 5
U1-concentration 5
U1-based 5
statutory 5
pharmacies. 5
hypocholesterolemic 5
HMGCR. 5
0.009; 5
normocholesterolaemic 5
transposon-derived 5
470 5
DataBase 5
hypermutations 5
morphometrically 5
beneficiate 5
micrognathia. 5
autism-related 5
life-years 5
Rivastigmine, 5
fears 5
governments, 5
markets: 5
Slovakia, 5
payers; 5
co-payments 5
reconsidered 5
Charlson 5
fills 5
cash 5
Managed 5
William 5
ppm. 5
proportionate 5
(AUCs) 5
cidofovir 5
CDV 5
hepaticus-associated 5
hepaticus-infected 5
co-colonization 5
reuteri. 5
microbiomes 5
flares, 5
benzoate 5
non-obese 5
SEM 5
IFN-gamma. 5
heritable, 5
CMI, 5
367 5
3.04; 5
Pentasomy 5
syrinx. 5
clinodactyly, 5
syringomyelia 5
craniectomy 5
present; 5
stillborn 5
FOXP1 5
dyspraxia. 5
EWS/Fli-1 5
Junction 5
HDAC1. 5
(58.3%) 5
sacrum. 5
(11; 5
located; 5
survivin. 5
cIAP2, 5
Aspiration 5
twisted 5
posttranscriptionally. 5
photobiological 5
remaining. 5
(good 5
882 5
5-8 5
(p=0.03). 5
10.25 5
11.27 5
(BDNF) 5
(GOS), 5
observers 5
(FBS), 5
alphaSYN 5
pre-symptomatic 5
thioflavine 5
amygdaloid 5
permutations 5
HSS 5
Discrete 5
(CLBs) 5
(NACP) 5
alpha-synuclein) 5
C-terminal, 5
electrodense 5
(FEB) 5
(FEB). 5
prematurity. 5
FEB. 5
0.4%. 5
32.2% 5
maternofetal 5
fetalis 5
0.2% 5
[20%] 5
euploid 5
drug; 5
(R), 5
MTMR12 5
(PI 5
Myotubularin-related 5
[PtdIns(3)P] 5
3,5-bisphosphate 5
myotubularins, 5
postradiotherapy 5
relentless 5
benzhexol, 5
dystonicus 5
80.5% 5
79.3% 5
deformans 5
eliminated. 5
Npl3 5
Tb 5
Bacille 5
Calmette 5
(BCG) 5
(≤8 5
(≤2 5
inunfavourable 5
TB-positive 5
approval). 5
delamanid-based 5
nitro-hydro-imidazooxazole 5
anastomosis. 5
anastomosis 5
Antithrombotic 5
23.5 5
data). 5
0.052) 5
off-line 5
isotopically 5
HMGA1a 5
Interpreting 5
<1% 5
gcn5Delta 5
otherwise. 5
Oxidation 5
crack 5
automation 5
Eukarya 5
Guidelines. 5
hypovolemic 5
2+) 5
priming, 5
Potency 5
alloxan-induced 5
triglyceride, 5
glibenclamide. 5
Opening 5
extrapancreatic 5
body-weight 5
Leu 5
exocytotic 5
anovulatory 5
2.49 5
20-41 5
27), 5
ovulate 5
Asp-N 5
95.9 5
apolipoproteins 5
lysozyme 5
complexome 5
replicates, 5
(SRM) 5
5600 5
glycoprotein. 5
MtbMfd 5
(Mfd 5
rewinds 5
RecG, 5
Stalled 5
mortality: 5
psychotherapy. 5
(SNRI), 5
1.52, 5
75-mg 5
(minimal 5
terminology 5
(IL)-5 5
0.0003). 5
asthmatics. 5
percentage, 5
776 5
Anti-IL5 5
LLC. 5
0.05-10 5
0.163 5
mL/h/kg 5
mL/kg. 5
64-75% 5
Fip1-like 5
Still 5
EoO 5
0.033) 5
0.57; 5
0.35; 5
(GSK) 5
>1500 5
offered, 5
inhalant 5
eczematous 5
IL-3, 5
mainstays 5
28-week 5
Ascaris 5
(GEFS+) 5
(comparable 5
laws. 5
seizures: 5
intense, 5
basis; 5
neutropenias 5
myelopoiesis 5
neutropenia; 5
7); 5
(LQT2), 5
(LQT3) 5
vary. 5
KCNE2 5
(LQTS). 5
(pRb) 5
Calabar 5
Calabar, 5
third. 5
discourse 5
0.022), 5
melanin, 5
60.5 5
Breslow 5
13-year 5
cent. 5
(1984 5
sun-induced 5
non-white 5
Populations 5
1974 5
preponderance. 5
mTOR: 5
(oxLDL) 5
oxLDL, 5
Ly294002 5
PI3K/PDK1/Akt, 5
polyphenol. 5
(trans-3,4', 5
5-trihydroxystilbene) 5
(LY294002) 5
(SH-6) 5
ROS-dependent 5
(LNCaP) 5
DR4 5
mTOR-dependent 5
sensitizers 5
IR-resistance 5
22RV1 5
IR-activation 5
ATM-AMPK-p53-p21(cip1)/p27(kip1) 5
erythrocytes: 5
4-HNE-carbonylation 5
Odisha, 5
rosetting 5
(Oculus 5
Variance 5
0.053 5
Corrected 5
refraction 5
Fourier-domain 5
(AS-OCT) 5
midperipheral, 5
protocol); 5
3.33 5
Surgical, 5
AMPK- 5
(TNF)-alpha 5
2.2%, 5
salutary 5
Anti-amyloid 5
Scale-cognitive 5
Ketamine 5
(eg. 5
massage, 5
phantom 5
69.3% 5
withdrawing 5
intravenous) 5
ketamine. 5
(MAPK), 5
4.2%, 5
Caspase-3 5
subepicardial 5
hypercontraction 5
eicosanoids 5
reversed, 5
Ca2+-related 5
intra-molecular 5
NS5. 5
Hsp/Hsc70 5
Ingenuity 5
g/day 5
HDL-C, 5
017 5
quintile. 5
RIPK 5
Colon 5
Intricate 5
catastrophe. 5
Attribution 5
6-hydroxydopamine, 5
AN, 5
(NET). 5
Clomipramine 5
autoreceptor 5
IgM-RF 5
Anti-CCP 5
225) 5
rheumatologists 5
Distributions 5
(continuous 5
DAS28. 5
28-joint 5
549 5
SDAI 5
sexes; 5
seropositivity, 5
immunoregulation, 5
Microsoft 5
area) 5
ataxia), 5
gravidarum. 5
Wernicke, 5
SLC19A3 5
anorexic 5
[Wernicke's 5
amnestic 5
Obesity. 5
neuroimmune 5
grave 5
vitamin-B1 5
confusion) 5
Encephalopathy: 5
Workup 5
Discussion. 5
Korsakoff 5
Severely 5
incessant 5
TBX5, 5
areas: 5
(re)programming. 5
short-interspersed 5
pollution, 5
(D1) 5
rs1057910 5
interpatient 5
Demographic, 5
diversified 5
descent, 5
pharmacogenetics. 5
CYP2C9. 5
egg. 5
lactogenin 5
diabetes? 5
enzoinformatics 5
correlation]. 5
L444P, 5
NB-DNJ 5
5.5% 5
non-carrier 5
0.21). 5
organomegaly. 5
4-methyl 5
GD, 5
PvuII 5
parent, 5
aminothiol 5
Radioprotective 5
kill. 5
(used 5
hypovascularity 5
(WR-2721) 5
MDA468 5
non-hydrolyzed 5
WR-2721, 5
supraclavicular 5
UF 5
gamma-glutamyl 5
make, 5
-80°C 5
(DD). 5
Contamination 5
RT-qPCR. 5
longterm 5
DSM-III-R 5
(clozapine, 5
dilutions 5
(2/2) 5
cardiodysrhythmic 5
polygenetic 5
mastered. 5
LEOPARD 5
(hiPSCs), 5
air-Q 5
engendered 5
Marfanoid-craniosynostosis 5
habitus, 5
carinatum, 5
square-shaped 5
(NTS) 5
monounsaturated 5
ceramides 5
KLK5 5
macrophage-derived 5
focus-forming 5
hair-shaft 5
recurrent. 5
hK7, 5
hK7 5
thrive. 5
predominate. 5
α-syn. 5
(ECL) 5
deiodination, 5
(Sec) 5
CSL, 5
CBF-1/Suppressor 5
Hairless/Lag-1) 5
margin, 5
psVs 5
(CTLs) 5
58, 5
meningitidis. 5
meningitidis, 5
forests 5
autoantibody-positive 5
42). 5
tumor; 5
2G12 5
295, 5
HO-2 5
electrophiles. 5
myristate 5
(genotype 5
heme-dependent 5
musculoaponeurotic 5
hemin 5
sorting, 5
normalise 5
hetero-oligomers 5
(sialyl 5
glycoconjugates) 5
(Tn-antigen; 5
NAcalpha1-O-Ser/Thr) 5
R329W/Q, 5
R329W/Q. 5
Tn-antigen. 5
Prevalence, 5
admitting 5
(3-4 5
European, 5
tuberculomas 5
RBT 5
next-day 5
onset). 5
suvorexant-a 5
aprepitant, 5
varenicline, 5
(hypocretin) 5
-2.1 5
(treatment-naïve 5
-0.4%, 5
-0.5%, 5
-0.6%; 5
(+0.09%)]. 5
-1.29 5
-1.61 5
-1.72 5
(+0.04 5
mmol/l)]. 5
(32.9%) 5
thirst 5
(2.0% 5
(1.6%) 5
m(2); 5
(eGFR 5
PKs 5
dose-ranging, 5
Exposure-response 5
Resting 5
MCF-7, 5
78-83% 5
("lost") 5
Rapidly 5
WGD. 5
(CVS) 5
presentin 5
correct. 5
cordocentesis 5
(CBF(LSF)) 5
Embolization 5
macrospheres 5
(8/14 5
(2/14) 5
(4/14). 5
circuitry. 5
"area 5
risk" 5
protein-expressing 5
expediting 5
oxygenation. 5
23.3 5
weighed, 5
Viability 5
thresholds, 5
(FN) 5
occluded. 5
β-Adrenergic-stimulated 5
bilayers, 5
(1.5-fold) 5
acidic, 5
aortas 5
ASM 5
(although 5
excision) 5
ERK-positive 5
(HCL) 5
breathing. 5
sides. 5
antimycotic 5
[Successful 5
HMTs 5
(HTS) 5
3-h 5
(HMT) 5
KDM5B/Jarid1B/PLU1 5
chemiluminescence-based 5
streptavidin-coated 5
NaBt 5
ERK5. 5
MEF2A 5
16-18 5
cardiocyte 5
USF, 5
chamber-specific 5
co-factors, 5
factor-2a. 5
(T3Rs) 5
T3R. 5
Egr-1) 5
T3Rs 5
2-3-fold 5
oligomer. 5
oligoastrocytomas, 5
Kaplan-Meier's 5
(IDH) 5
(491 5
CIC 5
IDH2) 5
19q 5
~3.5 5
differentiation; 5
CD80/CD86 5
JAK3, 5
PKi 5
AE, 5
(fostamatinib) 5
(MTX-IR), 5
(DMARD)-IR, 5
(TNF)-inhibitor-IR. 5
JAK-mediated 5
JAK1, 5
(tofacitinib) 5
STAT6 5
39.2% 5
4-variable 5
non-specificity 5
succession 5
ecosystems. 5
ARNT 5
dye. 5
Devices 5
hyperpolarized 5
sub-threshold 5
injurious 5
(mOCT3) 5
(ASP(+), 5
mOCT3-mediated 5
ASP(+) 5
(hOCT3) 5
1-methyl-4-phenylpyridinium, 5
tetrapentylammonium 5
(TPA(+)), 5
TPA(+), 5
non-transported 5
(lck) 5
mOCT1/2(-/-) 5
epinephrine, 5
histamine. 5
rostrocaudal 5
CI), 5
miscarriages 5
anemia-predisposing 5
radiosensitivity. 5
PKCα. 5
Interplay 5
hyperactivity. 5
(80% 5
(AKT) 5
Ras-related 5
Axin 5
Gbeta2gamma2 5
Frizzled 5
polarization. 5
Gb3 5
salicylate 5
mmol/l) 5
-30G-->A 5
(McKusick 5
Cre-recombinase 5
EDRz 5
OPCs 5
(mESCs) 5
Y-linked 5
miR-302/367 5
(heterozygous) 5
motivation. 5
BMCs 5
miR-34 5
immunohistopathology 5
IGF-1/HGF 5
IGF-1Ea 5
excitement 5
factor-1, 5
(CPCs) 5
(IGF)-1 5
3beta 5
CSCs-ECCs 5
5100 5
self-renewing, 5
clonogenic, 5
cardiomyocytes: 5
know. 5
Committee, 5
assess, 5
INTERNATIONAL 5
antigen: 5
Snapin, 5
bone-derived 5
2-hybrid 5
colocalised 5
small-sized 5
effecter 5
Rho-GEF 5
co-localizing 5
Inflammasomes 5
IL-18, 5
hypersecretion 5
PYD 5
caspase-5 5
Diptera 5
Diptera. 5
Drosophila: 5
long. 5
pre-mRNA, 5
(ELANE) 5
cathelicidin 5
minors 5
granulopoiesis. 5
(CN), 5
uncoated 5
hormone-receptor 5
39). 5
53.3% 5
SEGA, 5
antiepileptogenic 5
non-target 5
(Afinitor) 5
seizure; 5
Smad-dependent 5
α5 5
fibrillogenesis 5
α6-integrin 5
(9, 5
actors 5
alpha-actinin. 5
(NFAT), 5
objective. 5
Peroxisome 5
intra-genic 5
atlas. 5
(IRG1) 5
Spirochetes 5
CXCL1, 5
immunogen 5
MAP-infected 5
receptivity 5
dehydratase 5
(IFN)-alpha/beta-inducible 5
6-16, 5
Ishikawa 5
animals) 5
30-50 5
CDTI 5
loxapine, 5
(9%), 5
originality 5
(Ni) 5
(ACD) 5
Nowadays 5
Lactose 5
NiOH 5
(RTX) 5
telopeptide 5
(0.1% 5
Hepatocytes 5
Bridging 5
plates, 5
nerve-diaphragm 5
(0.025 5
M-1 5
entrained 5
pacemaker, 5
Ncdn 5
EGF-dependent 5
Vinculin 5
force-dependent 5
dock180 5
(Elmo1) 5
(Dock180) 5
engulfment. 5
elmo1 5
vessel, 5
ced-12 5
ELMO1/Crk/Dock180 5
CrkII/Dock180/Rac 5
host-mediated 5
gratuitous 5
Commentary, 5
costimulation 5
Lys-48 5
mitochondria-mediated 5
MG-132 5
nonproteolytic 5
proteolytic, 5
(TRAF) 5
(K(63))-linked 5
TRAF2-interacting 5
K(63) 5
K(48)-polyubiquitinted 5
A20. 5
specificity). 5
(DAC) 5
cisplatin-resistant 5
TGCTs, 5
mucoepidermoid 5
polymer-based 5
.001; 5
(16.4%, 5
people: 5
PanIN 5
(gastric 5
(CEV) 5
III-like 5
chromatin-enriched 5
solubilised 5
Nucleoprotein 5
(8WG16) 5
plus- 5
HSP60, 5
reelin 5
(Adempas): 5
(CTEPH) 5
haemodynamics, 5
postmenstrual 5
NICU 5
agar. 5
mg/mL) 5
(U 5
1219 5
Golden 5
reinhardtii. 5
F0 5
inquiry 5
(PI3K 5
-inhibitor 5
fostamatinib-inhibitor 5
lymphocytosis 5
anencephaly, 5
folate, 5
teratogenicity, 5
registered. 5
multi-channel 5
benzothiazepine 5
K562/MDR 5
taxol, 5
PC-14 5
(JTV), 5
baseline: 5
(I(Ca)). 5
no-flow 5
cardioplegia, 5
MALAT-1. 5
Milan 5
(ncRNA). 5
ESS, 5
beta4 5
(n=70). 5
Σ 5
forsythia. 5
anthelmintic 5
metronidazole, 5
Leydig 5
adipocytokine 5
chol 5
Procedural 5
Big 5
PABP3 5
adjacent, 5
distant, 5
autoregulated 5
ABL2 5
homodimerization. 5
(Abl) 5
(Arg) 5
(Abelson 5
(ECG). 5
JT, 5
Pathophysiological 5
(RW) 5
Jervell-Lange-Nielsen 5
Stress-induced 5
trans-regulatory 5
Intermolecular 5
SERCA1 5
J2N-k 5
Tyr(6) 5
ischemia-reperfused 5
cAMP. 5
(BK) 5
Na(+)/Ca(2+)exchanger 5
VD-HF 5
Isoproterenol 5
0.96), 5
E1, 5
anti-PLB 5
7-13 5
empowered 5
orient 5
technology-based 5
coexists 5
Composition 5
1094 5
Scp160 5
intraspecies 5
Hypomethylating 5
Decitabine-Induced 5
DNMT1o, 5
KEN 5
PKCδ 5
KG-1 5
KG-1a 5
RFX6 5
B4 5
EIA. 5
Echo 5
Weight-loss 5
end-users 5
everything 5
that's 5
dental, 5
PRDM1, 5
(H/RS) 5
PAR1. 5
proliferations 5
BHK-21 5
forgotten 5
94), 5
ORMAN 5
TopHat 5
non-trivial 5
heuristics 5
interchange 5
graph, 5
alternatively-spliced 5
sophistication 5
RSEM 5
gene-level 5
mappable 5
INa. 5
sleep: 5
V1-V3 5
[Risk 5
loosing 5
clinical-electrocardiographic 5
V3. 5
ajmaline, 5
body-like 5
bi-directionally 5
antiaggregatory 5
galantamine 5
beta-synuclein 5
competimer 5
LightCycler 5
subregional 5
soleus. 5
PGC-1alpha, 5
(p43) 5
(20, 5
micrograms/100 5
thyroid-treated 5
sc. 5
D294H: 5
(1.19-1.70) 5
(1.06-6.65) 5
UVB, 5
3.04 5
CMT2/dHMN 5
Ser90Leu 5
#270685). 5
seipin-related 5
Squamous-Cell 5
(Anti-Programmed 5
Antibody, 5
BMS-936558, 5
ONO-4538) 5
129) 5
dacarbazine-treated 5
(IL-8) 5
847 5
arcuate 5
somatotrophs 5
Underlying 5
interrupts 5
Cornu 5
Dynamin-related 5
curved 5
palmitate-induced 5
(BH3)-only 5
(DN) 5
DN. 5
intramitochondrial 5
BRCA2-deficient 5
nonsignificant). 5
Catecholamine-induced 5
D307H 5
CPVT-causing 5
Ca2+-induced 5
tachycardias. 5
6/16 5
5'-terminus 5
http://gremlin1.gdcb.iastate.edu/~volker/SB05B/BSSM4GSQ/ 5
BayK 5
8644 5
Ca(v)3.3 5
(Ca(V)1.2) 5
noradrenaline. 5
1.2, 5
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 5
6-hydroxydopamine 5
(18%; 5
profit 5
antiadhesion 5
adoption, 5
duration). 5
ASsessment 5
FAST. 5
diaries, 5
0) 5
(Velcade, 5
PS-341), 5
epoxyketone 5
delanzomib 5
carfilzomib/marizomib 5
better). 5
(MLN9708) 5
antimyeloma 5
#NCT00963820. 5
(PCT) 5
0-2, 5
NBR1 5
ATG12 5
GATE-16, 5
Flaviviridae) 5
Polynesia. 5
Senegal 5
gossypii, 5
fluctuate 5
Nuclei 5
spindles 5
microtubule-stabilizing 5
(H-DNA). 5
Raf/mitogen-activated 5
radiosensitizes 5
amplicons. 5
Ras/MAPK 5
IMProving 5
50mg 5
(0.83 5
silencers. 5
element-mediated 5
consultants 5
difficile-associated 5
Marfan-Syndrome 5
13.4 5
ostium 5
non-Marfan 5
operations, 5
repairs. 5
0.29), 5
BAV 5
sale 5
juveniles 5
vertically 5
waters, 5
Raoultella 5
(72 5
stipulated 5
nonspecifically 5
3q 5
discharges, 5
MR. 5
Rican 5
FOXO. 5
Yap1 5
dysregulated, 5
EGFR-mediated 5
Cholesterol-reducing 5
angiogram, 5
pre-ICH 5
0.11). 5
(n=2) 5
0.61). 5
hyperemic 5
hepatitis. 5
anisotropic 5
gamma-tubulin, 5
tubulins 5
schizophrenia-like 5
1.86). 5
reviewers, 5
(molindone 5
thioridazine 5
anorexigenic 5
pccB 5
pccC 5
β-subunits 5
dependencies 5
desperately 5
Ad5 5
acidemia: 5
>G, 5
T428I, 5
L519P, 5
odd-numbered 5
conservatively 5
nonidentical 5
Size-exclusion 5
heteropolymer, 5
father's 5
PCC, 5
Hsp20. 5
(G147D) 5
PP1, 5
(n=15) 5
2.7%) 5
settled 5
lapse 5
pallidum 5
21.1) 5
(21.9) 5
(p=0.009; 5
[21.1]%, 5
11.6-37.1). 5
(arrest 5
posterolateroventral 5
GPi. 5
externus 5
[GPe]). 5
PHRC; 5
Foundation: 5
Fondation 5
Motrice/APETREIMC; 5
INSERM 5
Network; 5
(ANG) 5
angiogenin-binding 5
cytoplasmic. 5
IkappaBgamma 5
specific) 5
-53 5
(NLS). 5
trabeculectomy 5
acromelic 5
Metalloproteinase 5
involvement) 5
15q21.1. 5
.92, 5
P<.0001), 5
(TTFields, 5
fields) 5
GBM.The 5
syncitial-type 5
'out 5
field' 5
TTFields. 5
in-field 5
RGBM 5
chemotherapy): 5
TEC 5
apoptosis) 5
(left 5
(high-sensitivity 5
lesion-derived 5
Mcm10p 5
primase-polymerase 5
Mcm10-And-1 5
70%-95% 5
endocrine-responsive 5
(experimental 5
37.8 5
(AIs) 5
PM-BC 5
goserelin. 5
(3.1%) 5
exam, 5
(Arimidex, 5
Combination) 5
SH3-domain-containing 5
ingression, 5
RAF-MEK-ERK 5
PI3K-AKT 5
MEK1. 5
RPCs. 5
ctf18Δ 5
(Cdc45-MCM-GINS) 5
Immunodepletion 5
53.5% 5
0.000) 5
electrolytes 5
(AMs) 5
AM. 5
chromosomes). 5
2674 5
128,406), 5
Edited 5
high-light 5
Prolamellar 5
photoactive 5
PORs 5
greening. 5
angiosperms, 5
translocon 5
yellowish 5
exchanged 5
mevalonic 5
acid-derived 5
night, 5
dominates 5
Physiol. 5
light-grown 5
(daclizumab) 5
(lebrikizumab) 5
cis-aconitate, 5
maternally-deposited 5
CMT3-induced 5
gametophyte 5
TFL2 5
gametophyte. 5
(above 5
180-bp 5
GDAP1, 5
1.5-Mb 5
DI-CMTB 5
CMT1C 5
consanguinity. 5
S194X 5
onion 5
MCMV 5
IRF3 5
p300/CBP 5
CBP, 5
(upstream 5
ATF2/c-Jun, 5
Cell-specific 5
multinomial 5
E-value. 5
grading. 5
1.78, 5
nuances 5
regrowth. 5
resections, 5
Radiosurgery 5
Simpson's 5
99%, 5
non-Grade 5
154) 5
Centrosome 5
centrosome, 5
Cep135, 5
(MT) 5
flagella, 5
taxon-specific 5
NEURL4 5
CPAP, 5
band. 5
(63%). 5
mid-myocardial. 5
I-II) 5
5145 5
2572) 5
2573) 5
1.02-1.82; 5
NCT01130246. 5
darapladib 5
OUTCOMES 5
sPLA2, 5
CFR 5
FMD 5
(eGFR). 5
(ESRD), 5
conditions), 5
Cmax: 5
(%CV) 5
74.3 5
co-administration. 5
GMR, 5
[(14)C]-alpha-methyl 5
(AMG) 5
hSGLT-5 5
hSGLT-6 5
[(14)C]-mannose 5
[(14)C]-myo-inositol 5
[(3)H]-labelled 5
HEK293-hSGLT-2 5
hSGLT-2. 5
SGLT-1 5
facility. 5
62.1% 5
FGFR3Pro250Arg 5
(n=5). 5
downslanting 5
plagio-brachycephaly, 5
grandfather. 5
proptosis 5
calvaria, 5
intersphenoidal 5
spheno-occipital 5
synchondroses, 5
Corti. 5
medication; 5
Responsiveness 5
FCBT 5
self-report, 5
istradefylline, 5
Istradefylline, 5
dyskinesias, 5
day-to-day 5
(T1, 5
Noncontrast 5
ms). 5
t1 5
Hsc70. 5
Ammonia 5
[the 5
lysosomal-associated 5
XI, 5
nephrectomy. 5
cardiologist. 5
poorly, 5
mucin-type 5
(ETD) 5
sialyl 5
methylase, 5
metal-binding 5
action: 5
solutes 5
hysteresis 5
ice-binding 5
serine-5 5
promoter-paused 5
unilaterally, 5
methysergide, 5
excruciating 5
Attacks 5
Topiramate 5
methysergide 5
dodecylphosphocholine 5
(mTORC2), 5
(RNAi)-mediated 5
Lrictor(KO) 5
handedness 5
Second-to-fourth 5
(R-L) 5
(n=57, 5
(α=0.05). 5
(2D:4D 5
OPLs 5
0.13, 5
0.010; 5
(LUTS) 5
masculinization 5
Triggering 5
Degeneration 5
IgV-set 5
low-prevalence 5
sAD, 5
(NFTs), 5
phosphoproteomics. 5
tubulointerstitial 5
cancer-free 5
60- 5
Homeostasis 5
(MetS), 5
resistance). 5
adiposity. 5
Alternatives 5
cystoscopy 5
PAI-1, 5
.0001); 5
HAS1 5
HAS2-HYAL-1 5
continues. 5
palindromes) 5
Palindromes 5
motivates 5
IUPAC 5
(Nature 5
october 5
requests 5
(35.8%) 5
response). 5
CyclinD1 5
(N-cadherin, 5
os) 5
EESB 5
Erk, 5
705 5
CD8(+), 5
0.047, 5
0.031, 5
leucyl-tRNA 5
kinetic, 5
norvaline 5
Sentrin/small 5
(SENP2) 5
factor-beta-independent 5
Smads. 5
Lys-50 5
Lys-to-Arg 5
Nse2 5
Mms21/Nse2 5
ubiquitin-interacting 5
Copenhagen, 5
MODS 5
box" 5
β-actin, 5
destaining-free 5
Immunodetection 5
GAPDH. 5
morbid. 5
Eμ-TCL1 5
(68.9%) 5
(MCL), 5
glomerulonephritis. 5
regimes. 5
KI, 5
Meetings 5
(ITP). 5
GvHD, 5
anisocoria 5
antiganglioside 5
under-diagnosed 5
fluid; 5
aetiopathogenesis. 5
1-5% 5
ganglioside, 5
Emilia-Romagna, 5
inhabitants). 5
phleomycin, 5
RAD52, 5
phleomycin. 5
chl1 5
ctf4 5
TOF1 5
diversities 5
Result 5
apoptin 5
CREB. 5
more: 5
Proteostasis 5
GABA(C) 5
E-C 5
nonconservative 5
man), 5
histomorphological 5
ultra-deep 5
educate 5
EIAV 5
Coinfection 5
onwards, 5
introductions 5
digitized 5
provincial 5
waist-to-hip 5
orexin, 5
excessive, 5
succeed. 5
linger 5
Brice 5
(P=0.000). 5
dreamed 5
reoccurrence 5
sevoflurane) 5
(PONV) 5
GSDMD 5
meanwhile, 5
gasdermins 5
sebocytes 5
(TMD) 5
isopropyl 5
glucoamylase 5
diploids 5
FKH1 5
(FoxOs) 5
anti-ageing 5
Bcl2/Bax 5
aging: 5
FOXO-dependent 5
watery 5
(anti-GDIa, 5
anti-GDIb, 5
anti-GM1, 5
anti-GM2, 5
anti-GM3, 5
anti-GQIb 5
anti-GTIb 5
nerves) 5
7000 5
microRNA-146 5
(TRAF6) 5
(IRAK-1), 5
tissue/fibroblasts. 5
microRNA-221/222 5
microRNA-323-3p 5
miR-seq 5
TghuTNF-SF 5
SF, 5
(TRAP)-stained 5
(pre-miR-18a)-transfected 5
miR-18a. 5
pre-miR-18a-transfected 5
(PBMC), 5
scaphocephaly, 5
dorsum 5
(61%), 5
72.7% 5
craniofrontonasal 5
expressivity, 5
(v2) 5
0.031). 5
thymomas 5
0.011, 5
CD44v3, 5
ACs 5
emptying. 5
Urge 5
Daytime 5
(82%). 5
emphasised 5
Read 5
PATHWAY 5
Dogs 5
Alliance 5
rheumatologist 5
substance. 5
27.6 5
bridge. 5
guanine-7 5
RNMT-activating 5
(RNMT-activating 5
hMTr1 5
dinucleoside 5
psoriasin. 5
(psoriasin) 5
(koebnerisin) 5
Pantoprazole 5
22.6 5
OPCAB 5
Precautions 5
(CaMKIV) 5
Ca²⁺-induced 5
CaMKIV. 5
(12.5%) 5
Eps8-IRSp53 5
barbed-ends 5
Cdc42-IRSp53-Eps8 5
(DdVASP) 5
dDia2, 5
DdVASP-null 5
(WAVE2) 5
Mena 5
MIM, 5
(nucleosome 5
Spt20 5
(DUBm) 5
Tsc1(+/+) 5
ProPCA 5
EXpression 5
APEX 5
(SCA2). 5
(polyQ) 5
(PCs) 5
Cdk5 5
time-consuming. 5
RNA), 5
robustness. 5
pathogen-specific 5
conferences, 5
Eggs 5
(sometimes 5
travelling 5
encapsulation 5
(391). 5
trip 5
Uganda]. 5
safari's 5
faeces. 5
mpMoRFsDB: 5
disorder-based 5
(1966-February 5
perimenopausal 5
45-59 5
herbs 5
(0.3) 5
Gaa 5
processing/transport 5
normalized, 5
(rhGAA) 5
CRIM-negative 5
ventilator-free 5
6/11 5
(2.9-37.8 5
10,445 5
(6.7% 5
ectopy; 5
(Pompe) 5
transgene-encoded 5
Syndrome), 5
non-ATP 5
pAurora 5
(MTs), 5
MLN8054 5
(Hepatoma 5
Up-Regulated 5
MT-associated 5
MLN8054, 5
optogenetics: 5
appraisal: 5
gliotransmission 5
juxtacellular 5
photoactivation. 5
NpHR 5
prelimbic 5
prostheses 5
SGNs 5
successor 5
hoping 5
Urologic 5
26.9% 5
40). 5
microl 5
(NPH) 5
arousal, 5
Gefitinib, 5
resilience. 5
EDCRP 5
corneous 5
alpha-keratin 5
beta-cells. 5
bonded 5
trichocyte 5
2q, 5
velo-cardio-facial 5
Subgroups 5
Ca(2+)ATPase 5
(DPC) 5
molding 5
monocrotaline 5
luminal, 5
electrotransfer. 5
51.0 5
-1.0 5
IVS4 5
clastogenic 5
FGFR3c 5
traced. 5
Incidentally, 5
polydactyly, 5
47,000 5
149730).Here 5
antenatally 5
90) 5
BNP116 5
mechanic 5
anaphylaxis, 5
(DX-88) 5
(ecallantide, 5
55.5 5
reciprocated 5
forth. 5
Bigeminy 5
channelopathy. 5
A-B 5
MEIS1 5
443 5
cyclohydrolase-1 5
RLS3. 5
(UCB). 5
SB11 5
Mos1 5
extrapolate 5
OAT 5
nalmefene. 5
harmonic 5
loss--a 5
(MCA), 5
35: 5
617-623] 5
(MWS). 5
flaring 5
saddle 5
M-shaped 5
smiling, 5
pediatricians). 5
Psychomotor 5
[Mowat-Wilson 5
[OMIM 5
605802] 5
ZFHX1B. 5
Endeavour, 5
well-developed 5
nominated 5
(Aerts 5
we, 5
Java 5
v-akt 5
curate 5
multi-view 5
query. 5
Motivated 5
Génie 5
PINTA 5
growth-arrested 5
PKD 5
cilium. 5
mechanosensory 5
ciliogenesis 5
cilia-mediated 5
mechanosensation 5
polaris 5
(PKHD1) 5
Neotropical 5
canopy. 5
timescales, 5
Phylogenomic 5
well-supported 5
(sequence 5
falcon 5
lepidosaurs. 5
monophosphate. 5
SSc. 5
Treprostinil, 5
[a 5
vasoconstriction, 5
prostanoids 5
intravenous, 5
Prague, 5
IP1 5
ORC4, 5
CDC6 5
(microcephalic) 5
Ear, 5
Corporation, 5
1q21. 5
abruptly 5
reaffirm 5
cytopenia, 5
microchimerism 5
(IGF-IR 5
c-Met), 5
(Akt, 5
Erk1/2) 5
(FOXOs 5
NF-κΒ), 5
CGP 5
(Bmp) 5
U-box 5
Ca(2+)/S100A2 5
cochaperones 5
hsc70-interacting 5
(AhR) 5
nutraceutical 5
biliprotein 5
blue-green 5
624 5
Polysiphonia 5
Agarose 5
Porphyridium 5
B-PE 5
CE-LIF 5
Palmaria 5
palmata 5
diode 5
Phycobilisomes, 5
wavelength, 5
(1600 5
II-containing 5
rpeB 5
PLK3 5
discarded. 5
(ABSTRACT 5
LPI 5
emerin, 5
SND 5
Lys37del 5
immunohystochemical 5
elbows. 5
alpha2, 5
appearances. 5
implanted. 5
TF-induced 5
Histochemical 5
P0 5
HMMpTM: 5
membrane), 5
re-entrant 5
Philius 5
Correlates 5
splitomicin 5
acetylation: 5
multidimensional, 5
"tubacin," 5
Brainbow: 5
bright, 5
β1-subunit 5
TGF-β2. 5
(epithelial-mesenchymal 5
(PDAC). 5
(SHh) 5
Notch-1. 5
Notch1) 5
glycosyltransferase 5
reoxygenation. 5
evil 5
transdifferentiation. 5
vitro/in 5
connection, 5
IGF1R, 5
High-affinity 5
aft1 5
import/export 5
HMG-box 5
activation-dependent 5
Aft2. 5
iron-dependent 5
Grx4 5
low-iron 5
benomyl 5
nontranscriptional 5
Iml3. 5
Iml3, 5
aft1Δ 5
418 5
(TTN) 5
breed. 5
Chengdu. 5
100%), 5
fetopathological 5
Agenesis 5
(SMADIP1 5
SIP1), 5
frameshift) 5
(H3K27ac) 5
Mll3/4 5
35S 5
Inflammation-sensitive 5
(ChIP-seq). 5
(several 5
-5.4 5
lactation. 5
appendicitis 5
1975. 5
microadenoma 5
(182 5
ovulation. 5
non-ergot 5
(C/X, 5
T/X, 5
G/X, 5
A/X 5
flipping, 5
C/U 5
T/U 5
A/U. 5
(TDG) 5
still-unknown 5
iodothyronines 5
SULT 5
Cetuximab, 5
Necitumumab, 5
matuzumab, 5
Matuzumab, 5
IIIB/IV 5
0.994 5
(IHC), 5
side-effect. 5
triacylglycerols 5
LDs, 5
11,000 5
(absorption, 5
salvageable 5
Cerebrovascular 5
OGD 5
tPA, 5
alteplase-related 5
approving 5
underpowered 5
Hypoactive 5
HSDD, 5
HSDD 5
Distress 5
369 5
sword. 5
MedQA 5
ID-III 5
deiodination 5
1000-fold 5
(PBLs) 5
Hypothermia 5
usable 5
Tesla 5
serum) 5
n=10), 5
bvFTD, 5
virus-related 5
0.042) 5
repetitive, 5
RRMS, 5
26.9 5
n=20), 5
(exact 5
Abeta42, 5
MSA-C 5
CXCR4/CXCL12 5
(PDAC) 5
Ethnic 5
antibody-induced 5
Cos7 5
TH. 5
ellipsoidal 5
71.5 5
2266 5
area; 5
D(2) 5
LVH 5
cardiomyocyte, 5
beet 5
BvMYB1 5
PaDOD2 5
alpha-1-antitrypsin, 5
DMRs, 5
(MSP) 5
RASSF1A. 5
78.1% 5
82.1% 5
foreseeable 5
devised. 5
Cfp1 5
Scanning 5
microfilaments, 5
insolubility 5
Aëdes 5
predominatly 5
progerin 5
mCry1/mCry2 5
prerequisites 5
day-night 5
nonallelic 5
DD, 5
(CRY1). 5
CRY1. 5
receptor-γ 5
Per2) 5
self-sustained 5
inexperienced 5
effect). 5
methicillin-sensitive 5
Network. 5
Seasonal 5
residents, 5
staffing 5
risk), 5
(2.7% 5
Inside 5
Discharge 5
ethylnitrosourea 5
manipulations. 5
(eGFP) 5
eGFP+ 5
NSPs 5
(NOS) 5
(BMSCs) 5
dance. 5
5-azacytidine, 5
(DNMT1). 5
5.7, 5
48.4 5
Unregulated 5
(PND) 5
AsPC1 5
TERalb. 5
normo-albuminuric 5
(LDLr) 5
Carbohydrate 5
increase) 5
gel-shift 5
neurocristopathies. 5
realm 5
(SVR) 5
SVR 5
exercised 5
(persistent 5
breathlessness 5
evening, 5
[AHR] 5
0.84-1.47) 5
0.67-1.41]). 5
0.31-3.14]) 5
3.27 5
corticosteroid-induced 5
Thymic 5
pNET 5
IEC-IR 5
53.4 5
predating 5
phenology 5
Heliconius 5
hitchhiking 5
genealogical 5
(O. 5
domestication 5
(DFN2), 5
(CMTX5) 5
PRS 5
(DFN2). 5
Inverse 5
[IL-6], 5
group]). 5
796 5
Elav-like 5
element-containing 5
type- 5
T118. 5
(COX)-2 5
DICER 5
miR-29a, 5
HuR-regulated 5
A1-RNP 5
Elavl1 5
BM, 5
intrinsic, 5
CRM1 5
fibromuscular 5
myeloid-specific 5
Occludin 5
(HuR/occludin 5
CANDLE 5
cytoplasmic-nuclear 5
TUNEL(+) 5
curtailed 5
extracerebral 5
storm 5
lysine-63-linked 5
gonadotrophs 5
type-dependent. 5
Arteries 5
TRAF6, 5
structure-dependent 5
immobilize 5
DNAs, 5
fM 5
C18 5
hybridize 5
puromycin 5
prey 5
L-thyroxin 5
genotype-positive 5
(SUD). 5
myofibrils, 5
concepts]. 5
(SQTS). 5
electrocardiograms. 5
channel/ryanodine 5
[CPVT]). 5
R2474S 5
(Ryr2-R2474S 5
arrhythmias), 5
4/8 5
evicted 5
JNJ-26481585 5
Bcl-X(L), 5
MLP's 5
(Arber 5
(Bos 5
2010; 5
2003). 5
Mlp84B, 5
D-titin 5
cardiomyopathy-associated 5
W4R-MLP 5
2-week-old 5
MLP-deficient 5
shuttled 5
790 5
L858R) 5
ddPCR 5
0.03% 5
AZD9291 5
(EGFR)-tyrosine 5
PPS 5
SDF-1/CXCR4 5
(CXCR4), 5
strove 5
23-mediated 5
(GAs) 5
14-40 5
0.0075, 5
.0018). 5
coreceptor, 5
Klotho, 5
(GA 5
38-40 5
.0035), 5
.0029), 5
silico" 5
REPcen, 5
REPmid, 5
REPtel, 5
Non-allelic 5
REPcen 5
REPtel 5
haploinsufficiency: 5
(deletion 5
recession, 5
ventriculomegaly, 5
(MEN1). 5
(MEN1; 5
Wermer 5
glands; 5
Hyperparathyroidism 5
(neuroendocrine 5
40-70% 5
colagenomas 5
clinician. 5
95-100% 5
MEN1-related 5
(German 5
prolactinoma, 5
Punch 5
non-neuroendocrine 5
(SCA3) 5
brainstem, 5
CAG/polyglutamine 5
finish 5
MJD/SCA3 5
reticulum-mediated 5
untangle 5
aggravating 5
Anomalies 5
dissipating 5
genome) 5
(dominant 5
AA-induced 5
Promyelocytic 5
inhabitants. 5
pigmenti: 5
IKBKG. 5
electrographic, 5
Eye, 5
(mental 5
diphenhydramine 5
Chart 5
Distribution, 5
Sonic, 5
Indian, 5
BOC. 5
Copy-number 5
(glioma-associated 5
AZD-2014 5
pruritus. 5
self-limiting, 5
p-mTOR 5
35.6% 5
conflicts. 5
enriched, 5
M31. 5
dicentric 5
mid-stage 5
late-pachytene 5
heterochromatin-induced 5
PEV, 5
replacements. 5
Materialia 5
hydrogel, 5
(3B'09). 5
(3B'09) 5
'Eploratory 5
Committee' 5
3B'09. 5
maturing. 5
β-sheet 5
bioartificial 5
bone-related 5
13-14 5
Bioactive 5
Lac(+) 5
C-to-A 5
transversions. 5
disputed 5
Denmark) 5
DBA/2J 5
55-0396, 5
Block 5
antihyperalgesic 5
mitoribosomes. 5
Aliskiren: 5
RAAS-blocking 5
nowadays. 5
HMG2 5
invertasome, 5
ligase-mediated 5
bend 5
trypanosomes, 5
HLPMt 5
T-containing 5
poly-(R)-3-hydroxybutyrate 5
bent 5
specialization 5
apicomplexan 5
crescentus. 5
[(11)C]MK-4232 5
CGRP-receptor 5
pre-dose 5
5-HT1B/1D 5
triptan-related 5
dilator 5
0.62, 5
1.15) 5
dihydroergotamine 5
2.3%, 5
C-6 5
zolmitriptan. 5
efficacy-plus-tolerability 5
0.16, 5
calcitonin-gene-related 5
receptor-like 5
1960s. 5
HpD 5
Photobiology. 5
6.3; 5
leakage, 5
AGT 5
(6.3% 5
(13% 5
-value 5
board-approved 5
thirty-three 5
novo) 5
plots, 5
73±5 5
≥90% 5
(11). 5
GBM; 5
bis-chloroethylnitrosourea, 5
Gliadel(®)) 5
meaningfully. 5
circumstance, 5
PACT, 5
TRBP, 5
SRA 5
NR 5
slicing 5
(miRNA). 5
avid 5
Enzymatically 5
Failing 5
sarcoplasm 5
FANCD1, 5
FANCL, 5
finally. 5
Damaged 5
subclonal 5
DOG-1 5
NEIL1 5
excises 5
short-patch 5
(PDGFR), 5
Monro 5
NMI 5
86.5% 5
MEdium 5
Reiteration 5
(MER) 5
Rodentia, 5
MIR 5
(Mammalian-wide 5
EMCS 5
subserving 5
paraparesis. 5
Leigh-like 5
chemosensitive 5
vincristine. 5
(DLBCL). 5
evaluable). 5
vs, 5
P<.002) 5
interdigitation 5
cerebellopontine 5
disposed 5
storiform 5
SFT. 5
centrifuged, 5
transversely 5
cytologically 5
phosphorous 5
villi. 5
nidus 5
MIB1 5
Recklinghausen's 5
(P-Lambert-Eaton 5
(NP-Lambert-Eaton 5
patient-tailored 5
immunogenic, 5
clathrin-independent 5
exploitable 5
Pyroptosis 5
Candida. 5
ox-LDL 5
lysis, 5
actinomycetemcomitans, 5
apically 5
microflora. 5
BTG2, 5
deadenylase, 5
Localized 5
cavity: 5
diaphragm, 5
pXO2 5
PlcR 5
cereus 5
hospital-associated 5
1.17 5
(CysC) 5
(CG), 5
iohexol 5
policy-makers, 5
aneuploidy: 5
consanguinity, 5
polymorphism-based 5
accuracies. 5
45X. 5
socio-demographic 5
trisomy, 5
Gynaecologists 5
(II-2A) 5
Massively 5
severity-weighted 5
DCP, 5
phases: 5
2/4 5
bedside, 5
(MRC 5
HCO3(-) 5
mail. 5
delays; 5
neurosurgery/neuropsychology 5
(0.56 5
0.20; 5
(0.64 5
0.047). 5
intelligence. 5
surgeons' 5
61), 5
(Pearson 5
hydrocarbons 5
(SEER) 5
(P(interaction) 5
1983-1997 5
(n=480) 5
interviewed. 5
Ficolin-1, 5
Ficolin-3, 5
MASP-1, 5
FCN3+1637delC 5
(P=0.025). 5
Collection 5
O-specific 5
PSs, 5
Squibb's 5
Non-small-cell 5
TiO(2) 5
pre-enrichment 5
snapshot 5
phosphopeptides. 5
phosphopeptides, 5
Rpb1 5
ubiquitin-acceptor 5
Uncoupling 5
868 5
822 5
46.4% 5
10.1%) 5
NCT01866319.). 5
Johns 5
Hopkins 5
dacarbazine, 5
Dohme. 5
Intronic 5
stratified. 5
Challenging 5
Endopterygota 5
infraclass, 5
no-longer 5
pseudogenisation. 5
Nodosome: 5
NLRs) 5
Blau 5
suppressor-related 5
(iE-DAP). 5
(IL)-1beta 5
intravitreally 5
system.Three-month-old 5
(Wt) 5
body/organ 5
LPS+PGN 5
Tnfα, 5
Il-10 5
hours.Systematic 5
Sensing 5
participatory 5
AS160 5
FOXO1. 5
intraarticular 5
(NFκB). 5
VCAM1 5
polarize 5
gamma), 5
Adipocyte 5
7.13 5
noncancer 5
immunoglobulins, 5
anaerobically 5
Affinity-purified 5
autoantigens. 5
Abbreviated 5
sports-related 5
crab 5
louse. 5
conjunctivitis, 5
Biomicroscopic 5
palpebrarum. 5
misdiagnosed. 5
Dermatologic 5
unsuccessfully 5
Ca(2+)-uptake, 5
Ca(2+)-release, 5
Ca(2+)-load, 5
Ca(2+)-ATPase2, 5
Ca(2+)-homeostasis: 5
Ca(2+)-sensitive. 5
intra-luminal 5
fine-cross 5
Ca-uptake, 5
cytosine-phosphate-guanine 5
co-methylation 5
aneurysmatic 5
30th 5
vasospasm) 5
699 5
tramadol 5
MgSO4. 5
.017) 5
postrandomization 5
microsurgery 5
definitive. 5
[SD], 5
loads. 5
plakoglobin, 5
non-coronary 5
desmocollin-2 5
restriction-enzyme 5
Edaravone, 5
TAI 5
traumatized 5
Concordantly, 5
weight-drop 5
(TUNEL) 5
98.5 5
4.00 5
1.36, 5
(T(3)), 5
dysplasia? 5
0.06), 5
0.7), 5
mesial 5
neuropathologists 5
FINDINGS 5
MSC-EPO 5
"tail" 5
Microscopically, 5
CEA 5
Spumavirinae 5
clocks, 5
(HC). 5
punch 5
neuropathies(CMT2), 5
gene(NEFL), 5
gene(KIF1B), 5
gene(GAN1), 5
A/C(LMNA) 5
tyrosyl-DNA 5
1(TDP1). 5
(CMT4D). 5
form); 5
genes/proteins 5
chloroquine. 5
Chloroquine 5
Lamp-2a 5
deglycosylation, 5
Bax-induced 5
hsc70 5
(LAMP-2A), 5
"old" 5
tolvaptan 5
near-complete 5
basilar 5
resuscitation, 5
aneurysms: 5
p=0.03). 5
autoimmune, 5
seasonality 5
dated 5
Date 5
[(18)F]flutemetamol 5
0.86). 5
whole-brain 5
radiopharmaceutical 5
fluorine 5
(18)F-BAY94-9172 5
"new" 5
check, 5
RYGBP. 5
jejunoileal 5
Secretariat 5
stakeholders, 5
Provincial 5
FOLLOWING 5
CANCER: 5
oxaliplatin-based 5
WT) 5
dynein-2, 5
TCTEX-1 5
DYNLT1) 5
TCTEX-3 5
DYNLT3), 5
roadblock-1 5
DYNLRB1) 5
roadblock-2 5
DYNLRB2), 5
LC8-1 5
LC8-2 5
(DYNLL1 5
DYNLL2, 5
NudCD3 5
dynein-1. 5
dynactin, 5
LIS1 5
PAFAH1B1) 5
BICD2 5
dynein-2. 5
(asphyxiating 5
dystrophy). 5
FAP133, 5
DYNLL1 5
motors. 5
dynein-IFT 5
(HBV) 5
immunogenetic 5
NMO 5
(DMTs) 5
MS; 5
horses. 5
(Xic). 5
Xist/Tsix 5
early-mid 5
sense-antisense 5
heritable. 5
(cRNA) 5
NT-derived 5
(28.5%) 5
electroporation, 5
oxytocin, 5
(mPFC) 5
ChR2-expressing 5
misfold 5
'prion 5
fus4 5
sarcoma/translated 5
(ALK)-positive 5
crizotinib-naïve 5
peroxiredoxin-2 5
single-stage, 5
thecal 5
gonadotropins. 5
L-cysteine 5
endotoxic 5
cysteine-based 5
Heinz 5
operator, 5
speedup 5
silico, 5
stereographic 5
entrance 5
p=0.01) 5
electrocardiography. 5
R0 5
CD117-positive 5
Extra 5
excision, 5
rhinosinusitis, 5
emphasising 5
lifelong, 5
(TPE) 5
knows 5
homeobox-containing 5
(DUX4). 5
DUX4's 5
(PMO) 5
Myf5 5
hetero- 5
A3A, 5
Foamy 5
mRNA-editing 5
(ORFs) 5
RWPE-1 5
GPX1 5
SOD2-Ala16+ 5
SEP15 5
(Se), 5
GSH-Px 5
furzeri. 5
autoantigens, 5
ACPA-negative 5
TNFα. 5
OLE 5
Certolizumab 5
(CDP870) 5
K-GG 5
SILAC-labeled 5
base-paired 5
Blocks 5
oriK 5
supercoiling 5
Competition 5
decides 5
12-hour 5
pulsatile 5
(UPDRS) 5
(QoL) 5
selegiline 5
Fluorodopa 5
Antibody-based 5
desquamation. 5
atomistic 5
FasR 5
unperturbed, 5
Elastic 5
nonsurvivors 5
SS18L1 5
spells. 5
severity) 5
family-specific 5
Cardiomyocytes. 5
systole. 5
iPSC. 5
(Japanese 5
hH(3)R 5
alleged 5
Catalyst 5
Hypo1 5
CoMSIA 5
triazole 5
anti-HCV 5
β2-adrenergic 5
sigma(1) 5
(TPOAb) 5
overtly 5
(s-Se) 5
97) 5
(TPO-Ab) 5
(TPO-Ab 5
830). 5
98·4 5
(24·9)) 5
0·86). 5
TPO-Ab 5
(linear: 5
0·97; 5
multivariate: 5
0·27). 5
Selenium, 5
system-thyroid 5
derailed 5
[Selenium 5
interleukin-15 5
ND6 5
Representative 5
hot-spot 5
Promisingly, 5
CAPP-Seq 5
mutation--case 5
conception. 5
perinatally. 5
LEF 5
DeepCAGE. 5
hippocampus: 5
EIF2AK2, 5
(PKR). 5
STAT3-PKR 5
PKR-dependent 5
batches 5
pilot-scale 5
983 5
2·2 5
vaccine: 5
public-health 5
S/AS 5
schedules, 5
imperative. 5
Ag-specific 5
de-escalation 5
sporogony 5
haematology 5
sites). 5
Meningitis 5
Scenario 5
'topological 5
domains', 5
TADs, 5
hydrogen/deuterium 5
(isomers 5
atoms) 5
testes-specific 5
(CTCFL)/BORIS. 5
pro-tumourigenic 5
11ZF 5
remethylation 5
http://www.biocomp.unibo.it/∼savojard/betawarecl 5
Supersecondary 5
pseudo-energy 5
filter. 5
β-strands, 5
SVMs 5
Machines 5
Q(3) 5
SOV 5
0.95. 5
unseen, 5
2-state 5
tmbhmm 5
(Beta 5
TransMembrane 5
eXposure), 5
(TMBs). 5
8-22 5
(TMH) 5
cross-validation. 5
per-residue 5
di-peptides 5
97.1%, 5
0.876 5
Structure, 5
ANN-based 5
PSI-BLAST. 5
SVM, 5
ANN, 5
"leave 5
cross-validation" 5
(LOOCV). 5
over-fitting 5
four-state 5
(up-, 5
down-strand, 5
periplasmic-, 5
outer-loop) 5
http://www.rostlab.org/ 5
services/PROFtmb/. 5
(OMPs) 5
burial 5
SwissProt 5
sequences). 5
obeying 5
Omp2a 5
custom-designed 5
thin-tail 5
switches, 5
2(1/2)-year-old 5
MWS-spectrum 5
25-week 5
nonneural 5
(hiPSC) 5
aminoisobutyric 5
∼0.3 5
standard' 5
(oprozomib) 5
Bik. 5
oversight 5
Naloxone 5
4.58 5
glycoconjugates. 5
Oct-1 5
breakpoint, 5
adducts. 5
uvr 5
Uvr 5
DPCs. 5
(0.1, 5
RyR2-P2328S 5
(0.03 5
(CA-miRNAs) 5
communicated 5
(FLCN) 5
RagB 5
RagC 5
guanyl 5
RagC/D 5
intronic, 5
phenomenology 5
Philippine 5
Dystonia-Parkinsonism 5
(XDP 5
"lubag" 5
(20.5 5
orange-ethidium 5
40.18 5
10-40 5
8.43% 5
47.71% 5
poly-(ADP-ribose) 5
oligonucleosomal 5
(IJV) 5
thromboses. 5
2.5%, 5
Colour 5
.001 5
venoplasty, 5
vein). 5
instruments; 5
post-procedure 5
Hemodynamics 5
discouraged. 5
Zamboni, 5
CCVI 5
49.0% 5
52.5% 5
(EDSS), 5
(MSIS-29), 5
Intolerance 5
(HIS) 5
(FSS). 5
appointment, 5
assessment). 5
HIS. 5
duplex-detected 5
(261 5
(8, 5
22.7 5
mL. 5
depositions 5
(balloon 5
procedures) 5
(2.4% 5
Restenosis 5
advantage, 5
today's 5
Translating 5
philosophies 5
Francis 5
Cole 5
blinding), 5
denial. 5
final, 5
Marbán 5
(Compiled 5
JACC 5
editors). 5
Myoblast 5
(trans)differentiation 5
Gfi1b-deficient 5
sac, 5
-7, 5
co-repressors. 5
Gfi1. 5
Gata1 5
self-renew 5
R/R 5
del(5q), 5
(CC5103 5
revlimid) 5
hitting 5
thrombocytopenic. 5
defect(s) 5
BEACH/ARM/WD40 5
Rice 5
0.45; 5
ECM) 5
colonizing 5
(RIP) 5
deendothelialization 5
syndecan-4 5
oxygen-glucose 5
Na(+)-dependent 5
2-[4-[(2,5-difluorophenyl) 5
methoxy]phenoxy]-5-ethoxyaniline 5
steel 5
piebald 5
FLVCR-related 5
SLC49. 5
SLC49A1 5
importer. 5
SLC49A2 5
Fowler 5
MFSD7 5
DIRC2 5
SLC49A3 5
SLC49A4 5
SLC48A1 5
(heme 5
HRG-1), 5
(AB) 5
2767 5
(SAM). 5
mobilization. 5
Malawian 5
4.1%, 5
galanin 5
0.080 5
31.0 5
cages 5
striped 5
Birds 5
NESS038C6 5
DIO 5
vif-deficient 5
adenines 5
osteopetrosis, 5
osteopetrosis 5
ophthalmic, 5
X-dominant 5
TNF-alpha. 5
NEMO) 5
proteinase-activated 5
pseudopodia. 5
pseudopodial 5
pores. 5
GATA1. 5
myeloid/lymphoid 5
RT-quantitative 5
tempol 5
chenodeoxycholic 5
FXR(+/+) 5
(ataxia 5
24h. 5
Htz1p 5
drug-treatment 5
chromatids. 5
readjustment 5
phonocardiography-based 5
0.027) 5
wires 5
(http://ccg.vital-it.ch/UCNEbase) 5
cross-linked. 5
viewable 5
computational, 5
biologist 5
aberrance 5
Curve 5
roscovitine 5
TS2-neo 5
fatality, 5
Val 5
speeding 5
ALX-related 5
>A) 5
Pbx 5
folds. 5
appendicular 5
Darwin's 5
PPS, 5
subendothelial 5
invadopodia: 5
enzyme(s) 5
size-variation 5
X2180-2D. 5
(S-type). 5
XhoI, 5
hybridizing 5
meter-scale 5
deep, 5
In-house 5
26,000 5
(53% 5
1m 5
STB. 5
condensin 5
Ability 5
55%. 5
Minnesota, 5
cord; 5
Disposition 5
≥3, 5
mitochondria: 5
polyaniline 5
Ninety-five 5
Pathogen-specific 5
isotopically-labeled 5
Sensitized 5
New-Zealand 5
(INH) 5
[(13)C] 5
(13)CO(2), 5
[(13)C]-urea 5
INH. 5
lung-targeted 5
urease-positive 5
60). 5
HOMA 5
351 5
29; 5
P(ET,CO(2)) 5
(13)C-MBT 5
Practices 5
33.3 5
carboxyhaemoglobin 5
average) 5
computer. 5
intoxications. 5
traceable 5
microvessels 5
n=26) 5
(invasive 5
inhibitors-the 5
adenomas) 5
bcl-2, 5
nontrivial 5
drift, 5
p-endosymbiont 5
Candidatus 5
mechanism" 5
Ratchet 5
stops 5
cavum 5
brazilian 5
SET-Domain 5
spice 5
Xq22.3 5
tournament 5
AA: 5
vaginosis, 5
<25 5
prepregnancy 5
intracrine 5
-0.31 5
l(-1). 5
Mysore 5
IA-2 5
catheters, 5
thrombus-related 5
(CVADs). 5
CVADs. 5
practicality 5
catheter(s). 5
Data, 5
Cryopreserved 5
cryopreserve 5
CVAD 5
descendancy 5
ascendancy 5
streptokinase. 5
(TIMI) 5
non-antigenic 5
activator; 5
Scandinavia 5
[Indications 5
disc-large 5
(hDlg), 5
epithelial-epithelial 5
(MEK)2, 5
IQGAP1, 5
MP1, 5
Endophilin 5
KSR-deficient 5
boosts 5
MEK-ERK-Nrf2 5
dMP1, 5
(DA). 5
Shoc2/SUR-8 5
Raf. 5
WD-40 5
Ment 5
NPS 5
DNMT3B7 5
(ATRA) 5
pharmacophore) 5
substrate-like 5
procaine 5
OsDRM2 5
retrotranspose 5
esculenta 5
Ty1/copia-like 5
defining, 5
follow-up: 5
INK4b-ARF-INK4a 5
INK4b 5
co-stimulation, 5
Treg-specific 5
re-expression. 5
wingless-type 5
Subtraction 5
corrected. 5
artifacts. 5
Sir4 5
N-glycans 5
31.4 5
apes 5
PSCs, 5
Renilla 5
redox-active 5
SelL 5
UGA. 5
60-65 5
eukaryotes: 5
cotranslational 5
base-pairs. 5
score-based 5
58%, 5
A-line 5
Autoregressive 5
(AAI) 5
<24 5
dexmedetomidine. 5
Lipofundin 5
MCT/LCT 5
(propofol 5
scores; 5
receptor-bound 5
(ICUs). 5
p50, 5
dependant 5
(RHD) 5
crops. 5
Red/ET 5
receptor-induced 5
(ICV) 5
Panoramix 5
Asterix, 5
"Panoramix," 5
piwi-interacting 5
25- 5
[Su(Ste)] 5
squash 5
zucchini, 5
pathway-specific 5
AtAzg1 5
NRTN, 5
PSPN) 5
MTCs 5
persephin. 5
GFRalpha 5
Bax(-/-) 5
FMTC 5
(GDNF), 5
(SCs) 5
GPI-linked 5
(10.5%) 5
SUNDS 5
Sotos' 5
purification-mass 5
NRT, 5
1440 5
2009-015522-10. 5
4·86 5
4·38-7·97; 5
3·48 5
(2·05-4·09; 5
p=0·0001), 5
(give 5
timepoint, 5
3·03 5
(1·23-4·93; 5
p=0·003) 5
-5·05% 5
-12·55 5
0·05; 5
p=0·01). 5
MIC-1 5
biopsy-driven 5
p53-MDM2, 5
unit-granulocyte 5
burst-forming 5
unit-erythroid 5
JAKV617F(+) 5
Betrixaban, 5
(VTED) 5
VTED 5
(INR). 5
(10%; 5
Eighty-two 5
entropion 5
Ophthalmology. 5
Worldwide, 5
Sierra 5
attenuated, 5
Sudan 5
Arabia 5
2.06, 5
forest-dwelling 5
Sylvatic 5
suites 5
slave 5
trade, 5
aegypti. 5
viremic 5
viruses: 5
arthropod-transmitted 5
Cameroon 5
mosquito-transmitted 5
Oceania, 5
Haemagogus 5
target-based 5
biofilms. 5
/M 5
slippage. 5
CDK1 5
Dovitinib. 5
Dovitinib-mediated 5
bFGF-induced 5
combinatory 5
myocyte, 5
Dusp16-deficient 5
drug-discovery 5
MKPs. 5
MKP-DUSPs 5
(BPE). 5
(hyperplasia/hypertrophy 5
detrusor) 5
decompensationi 5
(fibrosis), 5
[thickness 5
hypoechoic 5
serosa 5
mucosa] 5
(Estimated 5
EBW) 5
(BOO) 5
gr. 5
7.5-4 5
MHz 5
(BVM 5
MHz). 5
intra-operator 5
(4.6 5
5.1%) 5
interoperator 5
(12.3%) 5
cc). 5
Intravescical 5
Protrusion 5
(IPP), 5
Measurement, 5
cervico-urethral 5
DWTand 5
paremeters 5
diverticula, 5
Bothell, 5
ultrasound-estimated 5
thickness: 5
(BWT). 5
BWT. 5
bladders 5
suprapubic 5
correctly. 5
posterior, 5
<0.05), 5
decreases. 5
urodynamics 5
DAPT 5
GSIs 5
usability, 5
(low) 5
0.1. 5
hNSCs 5
271) 5
MTA. 5
adenosylmethionine 5
(SMM) 5
S-methyltransferase 5
SMM. 5
vSET 5
Rb, 5
Hodge 5
PCRs 5
Carbapenemase-producing 5
carbapenemases, 5
(MALDI-TOF 5
combined-disc 5
SENTRY 5
KPC-2 5
Serratia 5
VIM-1-producing 5
VITEK2 5
CLSI 5
susceptible. 5
bilaterians. 5
novelties. 5
Thyroidectomy 5
39.3 5
RET-positive 5
Tyr791Phe 5
protooncogene. 5
hypertrabeculation 5
13%o 5
sparkling 5
acclimatization 5
Macro 5
proviruses 5
copurifies 5
macrochromatin 5
Xi, 5
(Dron) 5
component-specific 5
(T3)-regulated 5
(LVW) 5
Dron. 5
T3-regulated 5
TR- 5
TRbeta2 5
buttock 5
mega-apophysis 5
(magnetic 5
stretched 5
LVPG 5
(AMI), 5
SR(Ca)ATPase 5
74.5% 5
species-mediated 5
(DIM) 5
GADD153 5
plumbagin's 5
Cdc25C. 5
IOA's 5
cdc25C. 5
IOA-induced 5
MK-5172 5
As-resistant 5
bottled 5
fluoroquinolones 5
norepinephrin 5
119, 5
RND-type 5
308 5
(20.9% 5
2.5) 5
(TIA), 5
twenty-two 5
abuse: 5
amphetamine, 5
miR-15a, 5
miR-93, 5
miR-203, 5
C-cell 5
miR-106b, 5
carcinogen. 5
miR, 5
miR-126) 5
Sixty-three 5
azoxymethane 5
TCF4 5
317 5
2.00, 5
2.37, 5
high-linear 5
(LET) 5
ISH/IHC 5
miR-106a, 5
let-7i, 5
cell-compound 5
class; 5
serrated 5
Spry2 5
EGFR-tyrosine 5
H441 5
Burden 5
multifactorial. 5
arrhythmias: 5
THRB 5
low-normal 5
non-relapse 5
mg/m(2)), 5
CR1. 5
(NF-κB 5
A20, 5
degranulation. 5
osteolysis. 5
IKKalpha, 5
-γ 5
B-lymphocyte 5
urethra, 5
shearing 5
acetabulum 5
mechanized 5
Orthofix 5
Tile. 5
Orthopedic 5
content-balancing 5
(HIF-1α), 5
SIRT6-deficient 5
HIF-1, 5
(carbohydrate 5
consideration, 5
statuses 5
Mitofilin, 5
CHCHD3, 5
MitOS 5
metatranscriptomics 5
(metaproteomics) 5
redistributing 5
oceanic 5
Chesapeake 5
bloom 5
karyotyped 5
neurosurgeon. 5
exact). 5
facto 5
found; 5
NFI 5
thorax, 5
KCNA4, 5
KCND2, 5
2335 5
suppressible 5
-293 5
-2335 5
-1654 5
(G-1651T) 5
TRbeta1- 5
(G-73T) 5
TRbeta(1) 5
TRalpha(1) 5
NVAMD 5
FDR 5
mining, 5
[Study 5
literatures. 5
"shared 5
shrimp 5
1978 5
CrCYP9AT2 5
contaminants. 5
sourced 5
plausibility. 5
0.37), 5
1.81, 5
M301K, 5
tall, 5
(SQT1), 5
unremarkable, 5
noninducible 5
gently 5
16B 5
Sun 5
microhomology-mediated 5
MMEJ 5
repaired, 5
carcinogen, 5
GIN 5
(EJ) 5
linearized 5
matrix-scaffold 5
S/MARs). 5
MARs. 5
Immulite 5
TRbeta(-/-) 5
daf-2/IIS 5
dauers. 5
LIN-61 5
synMuvB 5
deceptive 5
(p=0.0001) 5
Endometriomas 5
non-randomized 5
2.04-13.29). 5
(53.3%) 5
Nebulin 5
static, 5
unevenness 5
immunocytochemically. 5
(depressed 5
inferences. 5
ESC, 5
co-transcriptionally. 5
(89 5
(DLTs) 5
(S), 5
[PET-CT 5
rituximab: 5
fluorodeoxyglucose, 5
thoracoscopy, 5
plasmocellular 5
dia-gnosis 5
(Mabthera 5
Lymphadenopathy 5
/m2 5
wasn't 5
(n=15). 5
9- 5
(pStat3) 5
Stat3-induced 5
bcl-XL, 5
SKOV3-pEGFP-Stat3 5
thiazolyl 5
(MTT). 5
(IC(50)) 5
A(490) 5
[69% 5
(18/26)] 5
(20/26) 5
(6/26), 5
(2)A 5
pStat3 5
bcl-XL 5
µg/ml), 5
(0.49, 5
(0.0010, 5
(0.71, 5
0.0021 5
µg/ml; 5
Haematological 5
18%. 5
siltuximab-a 5
6-in 5
disease.. 5
Prehospital 5
(CPSS), 5
(PPV), 5
replaced. 5
neuroradiologists), 5
emergency-department 5
53), 5
715 5
reexpressing 5
common-type 5
nonepigenetic 5
UVB-exposed 5
HDA6-mediated 5
siRNA-directed 5
HDA6 5
Gal4-VP16-activated 5
H4K16. 5
arginase-1 5
(HDACs), 5
miR-449 5
misregulation. 5
Asf1, 5
flowering. 5
SUPPRESSOR 5
deploy 5
aromatase, 5
(HDACis) 5
ANG. 5
"mutant" 5
parietal, 5
vertex 5
80. 5
cod 5
heterogenic 5
bone-specific 5
chromatography-isotope 5
chromatography-combustion-isotope 5
(GC/C/IRMS) 5
dissolve 5
delta13C 5
paleodietary 5
(delta(13)C) 5
delta(13)C 5
foraging 5
release) 5
Mesencephalic 5
SAHA. 5
self-monitored 5
120) 5
socio-demographic, 5
NREM 5
copper-catalyzed 5
misalignment 5
AUC(τ) 5
intensity; 5
(17% 5
(blood 5
shift-work 5
Entry 5
(72% 5
Axis 5
nCPAP, 5
co-IP 5
lipin-2, 5
aged, 5
single-basepair 5
baicalin 5
(GFP)-tagged 5
D-type 5
(Trypan 5
T8993G 5
Pterostilbene 5
iopamidol 5
Huh7 5
apoaequorin 5
micronucleus 5
PTS2 5
Alizarin 5
3-(4, 5
(0.95, 5
(IP 5
(NDM), 5
(SU). 5
iDEND 5
KCNJ11. 5
KCNJ11) 5
tablets. 5
school. 5
cross-references, 5
(PMs) 5
amphetamine-induced 5
(Symbol 5
Modalities, 5
Reitan 5
Change. 5
Unmethylated 5
Col5a2, 5
cyclins, 5
(heat 5
multicatalytic 5
Lessons 5
retarding 5
toxicogenomics, 5
hTBCA 5
drug-response 5
703 5
chemogenomic 5
RPL15, 5
RPS17. 5
Thumb 5
cords, 5
seborrhoeic 5
Endoscopy 5
signs: 5
misclassification. 5
(BDI), 5
Revised-based 5
invalidating 5
'functional' 5
(MDL) 5
(MDDM). 5
PSDRS, 5
Ham-D; 5
MDL, 5
Ham-D. 5
FK901228 5
Hyperacetylation 5
istone 5
concentration- 5
HDIs 5
materially 5
mineral. 5
bioinert 5
rising, 5
take. 5
(OAC-ICH). 5
(rising-dose 5
investigation). 5
(aPTT), 5
epistaxis). 5
dTT 5
0·06 5
0·01 5
(99% 5
RE-VERSE 5
NCT02104947.). 5
Alport 5
(Morgans 5
Trotter, 5
1958). 5
RPKM 5
Atg19. 5
safeguards 5
Alfy, 5
3-phosphate-binding 5
Smatg8 5
Smatg4 5
macrospora. 5
4-kinases 5
PtdIns4P 5
oryzae. 5
unneeded 5
(Cvt) 5
Insulin-dependent 5
lysosome-like 5
nullified 5
involution 5
biochemically, 5
AS). 5
endo-reduplication 5
T-NHL 5
polyploidization 5
bipolarity 5
18F-3'-fluoro-3'-deoxy-l-thymidine 5
(FLT-PET) 5
FLT 5
bavariensis 5
immunizations 5
travel, 5
nymphs 5
(Borrelia 5
Neoehrlichia 5
divergens, 5
miyamotoi, 5
nymphal 5
ss, 5
(Ixodes 5
ricinus) 5
vulgaris) 5
nymphs, 5
18.9% 5
15.8% 5
questing 5
spotted 5
lowland 5
canonical, 5
DUSP8 5
rosiglitazone's 5
PDTC 5
ETRA/ETRB 5
PCWP 5
(ET), 5
Macitentan: 5
ETR 5
(ΔBP: 5
HRCT 5
licensee 5
frontiers 5
1:2000, 5
1:7000 5
1:2500 5
non-CF 5
Canada). 5
State, 5
1:2000 5
reminder 5
BKCa 5
1-induced 5
(63-83 5
(LCLS) 5
Property 5
Diagnostics 5
scattering) 5
photons 5
nanocrystallography. 5
micrometer-sized 5
irreproducible 5
lysozyme. 5
oversampling 5
particle, 5
nanocrystallography 5
pulses. 5
unsolved. 5
SNAP 5
uniporter 5
B27/N2 5
milk) 5
Carnivora. 5
mL/min/kg 5
3.94 5
"clinical 5
NCI-H295 5
gonadotropin-injected 5
ACTH-injected 5
100mg/kg 5
37.5, 5
TID 5
deformations, 5
[microcephalic 5
Taybi-Linder 5
(TALS); 5
polyomavirus 5
MICA 5
wells 5
GM2-1 5
GAD-ab 5
registries: 5
wheelchair 5
teens 5
twenties/thirties. 5
<5/10,000). 5
13,500 5
Germany), 5
delays. 5
Patient-tailored 5
specific-derived 5
(iMSCs) 5
SB431542. 5
FTC, 5
ophthalmologic, 5
Gilfillan 5
al.2008] 5
SLC9A6, 5
sodium/hydrogen 5
NHE6, 5
glutamate/glutamine 5
non-sister 5
revived 5
considered: 5
trajectory. 5
neuropsychologic 5
Caregiver 5
frustrated 5
trajectories, 5
(24.5 5
(37.5 5
neuro-oncology 5
Fund 5
norms 5
FACT-G 5
black. 5
(Ser196Asn), 5
tigris) 5
outflow, 5
(pentalogy 5
baby's 5
Defect 5
SNW1 5
sororin, 5
Smc3, 5
SA1 5
Pds5B, 5
Pakistan. 5
thiopurines, 5
(8% 5
triazolam 5
hypnotic, 5
10-month, 5
(-9.28) 5
(-8.92) 5
(SNRIs). 5
summarize, 5
4%; 5
100-mg/day 5
(DSM-IV) 5
(-11.5) 5
(-9.5, 5
Intensity 5
2013). 5
105) 5
25.6% 5
nondialysis-dependent 5
(t.i.d.), 5
two-to-three 5
[Hb], 5
[TSAT] 5
(86.3% 5
60.4%; 5
42; 5
90.5% 5
68.6%, 5
AUB. 5
(FERINJECT) 5
0.6967). 5
7.9%, 5
alternate-week 5
(ERT). 5
NCT00943111, 5
2008-005223-28. 5
-8·8%; 5
-17·6 5
4·2). 5
-17·6% 5
non-inferiority. 5
Dropouts 5
imiglucerase). 5
Genzyme, 5
paraproteins 5
GD1 5
(MDR1) 5
rotatable 5
2.0: 5
post-processing 5
iPTMClust 5
sensible 5
edges. 5
EPOF, 5
CMC, 5
RRW 5
CP-DR 5
10(-9)), 5
SCZ 5
schema 5
biologically-relevant 5
(A3B) 5
close-to-equal 5
E68Q 5
E255Q 5
polyradiculoneuropathy. 5
46.6 5
G-CSF-treated 5
Nkx-2.5 5
loss- 5
PCSCs 5
(DU145 5
embryonic, 5
cancer-reactive 5
(located 5
RING1 5
users: 5
20-80 5
contralateral, 5
2.45, 5
1.0). 5
rapamycin-sensitive 5
ISCs 5
14-3-3zeta 5
adipocyte. 5
fundament 5
milk, 5
-2.7% 5
6.0). 5
haemodilution, 5
ESP 5
(DINDs) 5
hemorrhage]. 5
urgently. 5
hypervolaemic 5
tri-methylation; 5
me2 5
me3, 5
γH2AX, 5
ALLs 5
stage), 5
siRNA-induced 5
prosecretory 5
salicylic 5
MoM. 5
hCG. 5
FPR 5
MoM, 5
Acid-Dependent 5
SLC38A9. 5
RHEB 5
unsymmetrical 5
Fenestration 5
(men 5
extensible 5
craniotomy. 5
tentorial 5
K.448, 5
Dream 5
K.545). 5
(1998). 5
0.790 5
-0.994 5
(MSCC). 5
(MSCC) 5
stabilisation. 5
(T15) 5
curve) 5
TGs 5
TRβ-selective 5
TRα-selective 5
analogs: 5
RARbeta2 5
optimising 5
ranelate 5
Bisphosphonates 5
metastastic 5
Tet-On 5
oxygen-dependent 5
subsp. 5
LacI 5
subfield 5
microfilaments 5
following. 5
MutT1 5
(Rv2985) 5
ADPRase 5
(Rv1700) 5
tools/strategies 5
∼0.9 5
∼9.5 5
∼0.04 5
mycobacteria), 5
8-oxo-dGTP, 5
equally. 5
(mutY, 5
(MTH1) 5
μg/ml, 5
radicals. 5
19.4% 5
(MRP) 5
(SPECT). 5
Patient-specific 5
(Cell 5
Chapman 5
(mortality, 5
MIs, 5
readmissions, 5
failures). 5
(PAS 5
>23) 5
hedonics 5
anhedonics 5
1.11-4.26). 5
anhedonias 5
(ACS), 5
1.58; 5
(65/286) 5
13.2% 5
(121/920) 5
[1.19-2.32], 5
16.61, 5
[1.03-2.22], 5
0.036), 5
socio-demographics, 5
peak-dose 5
Niemann 5
gamma-secretases, 5
mGSH 5
(amyloid 5
triacylglycerol. 5
SATB1, 5
Foxp3, 5
Her2-positive 5
BT/Her(R) 5
anti-neoplastic 5
disagreement 5
3+, 5
Functionality 5
arginine-rich 5
nucleus; 5
BBN 5
evidence: 5
PTPN22.6, 5
PTPN22.6. 5
R620 5
W620 5
PTPN22.1 5
(-1123G 5
probe-based 5
KIF5A-PIP4K2C. 5
IRF5 5
intensively-characterized 5
rs3761847 5
rs10818488 5
rs6920220). 5
1.2*10-13 5
3.91). 5
9.2*10-6; 5
9.5*10-4; 5
Candidate-gene 5
2,370 5
1,757 5
(NARAC) 5
(EIRA) 5
(CT60 5
(PADI4_94, 5
NARAC 5
(P=.0006). 5
priori, 5
57-75%) 5
ACPA-positive. 5
57-90%) 5
1858T-allele. 5
ACPA-levels 5
non-1858T 5
ACPA-levels. 5
these: 5
MIF. 5
arousing 5
(TRH), 5
Therapy-Fatigue 5
FACS, 5
Curcumin, 5
surgical. 5
endothelial-to-mesenchymal 5
CCM1-CHM 5
ethnical 5
(CDKIs). 5
hypophosphorylated 5
Ser314, 5
(SGK1), 5
U-CH1 5
(TDP-43), 5
committing 5
(1.31 5
cardiomyogenesis, 5
HDR. 5
early-G1-phase 5
Cdc7/Hsk1 5
hsk1. 5
(HU). 5
timings 5
pfa4Δ 5
Intra-S 5
mec1Δ 5
(pre-RCs). 5
Dbf4 5
DDK. 5
motif-dependent 5
DQ8 5
gluten, 5
extra-intestinal 5
(WS4). 5
heterozygotes) 5
Sox10Dom 5
embryologic 5
Waardenburg-Shah 5
reovirus 5
VCP/p97 5
degradation: 5
Cdc48p 5
AAA-ATPase 5
malfolded 5
Actions 5
ubiquitin- 5
ricin 5
35%) 5
60%), 5
GDC-0973, 5
4800 5
BRAF-positive 5
eruptions, 5
(PLX4032) 5
10.3%, 5
(alone 5
2.6) 5
LVOTO 5
UI. 5
9.17 5
7.37 5
1.79 5
TEADs 5
electrographic 5
optogenetically 5
Scientists 5
Embedded 5
programes 5
PZ-HPV-7 5
mis-localization 5
Staurosporine 5
Zeb1/deltaEF1. 5
de-bundling 5
depolymerisation 5
Snail1-Zeb1/deltaEF1 5
ZEB 5
endocrine-sensitive 5
MicroRNA-1 5
(Cx43) 5
logic, 5
mab-9 5
intersubunit 5
genome". 5
antigenotoxic 5
TA-p73, 5
LOSMoN/SMAJ. 5
matrix-targeted 5
flumazenil; 5
unconsciousness. 5
Unconscious 5
Matthew 5
Lawson 5
inserted, 5
regaining 5
injected. 5
efficaciously 5
cautiously, 5
Flumazenil: 5
benzodiazepine. 5
BDZ 5
3.41 5
longer-acting 5
comatous 5
sedatives, 5
100mg, 5
MicroRNA-27a 5
TargetScan, 5
Hereby 5
PCR-based, 5
COL4A3 5
workflow. 5
exon-enriched 5
hypothermic 5
oppositional 5
(MIA) 5
commonly-used 5
ProSAP1/Shank2(-/-) 5
self-grooming 5
vocalizations 5
(postnatal 5
inflexibility 5
Tsc2f/-;Cre 5
ASD-related 5
PPI, 5
Somatosensory 5
Gabrb3 5
Tbx1 5
G3BP1- 5
G3BP2-depleted 5
G3BP1-mediated 5
GAP161 5
ubiquitylate 5
(shRNA)-mediated 5
(DF), 5
"bait", 5
postdural 5
sine 5
Sometimes 5
(ISGs) 5
multicomponent, 5
phage, 5
predation 5
reducers, 5
(Northern 5
LAAs 5
Rifle 5
chemostat 5
U(VI), 5
uraniireducens, 5
reduction; 5
Oak 5
microcosm 5
(2nd 5
6-week-old 5
Rhodospirillaceae 5
endosymbiont. 5
purple 5
exists: 5
GOBASE 5
Activity-dependent 5
AAV6-hSERCA2a 5
hSERCA2a 5
Reticulum 5
SERCA3 5
(normal, 5
leucocytes, 5
EphB2. 5
NB, 5
target-site 5
recombinational 5
anaerobes 5
onnurineus, 5
gammatolerans 5
abyssi. 5
RIP3-dependent 5
RIP1. 5
conducts 5
helpful. 5
dark-adapted 5
aly/aly 5
Casper 5
Polarizing 5
plants--and 5
lineages--where 5
timelines 5
α-fetoprotein 5
ATL 5
proline, 5
endothelial-specific 5
photographic 5
HPE 5
(JAG1), 5
mandate 5
Palliative 5
PCBT-I 5
post-cancer 5
mind-body 5
radiotherapy: 5
compared: 5
Sel-10, 5
Pin1 5
Skp1, 5
degron. 5
handball 5
1.91 5
(>8 5
p=0.001), 5
Eating 5
gymnastics 5
(LD 5
(TMEV) 5
CyPD 5
(EAE). 5
Deficits 5
RNAs" 5
indicted 5
oestrogen-dependent 5
17β-oestradiol 5
(E2)-bound 5
E2-upregulated 5
eRNAs, 5
ER-α-regulated 5
E2/ER-α/eRNA-induced 5
Tet1. 5
(RNAPII), 5
Pom121. 5
(NPCs). 5
infers 5
NDC1--a 5
nucleoporins, 5
gp210. 5
cisternal 5
1,783-amino 5
58-amino 5
betaTrcp 5
ligase) 5
re-activated 5
(67.2%) 5
Tia1/Pub1 5
TNFR-associated 5
Foxp3-expressing 5
tubulin. 5
n-SET 5
CFP1, 5
RbBP5 5
mechanical/molecular 5
H3-Lys4 5
S-adenosyl-l-homocysteine 5
Meisetz 5
orthology 5
-related 5
hybridization-based 5
ESTs. 5
(HSPL, 5
RNASPL), 5
(HEXON), 5
(FEXH) 5
(FGENEH) 5
(CDSB) 5
(HBR) 5
contamination) 5
Weizmann 5
Colletotrichum 5
KLF4-transfected 5
CRL1579 5
APN 5
C>T, 5
Chediak 5
Higashi 5
(HLH) 5
HLH. 5
lvsB 5
.0001, 5
LVDP%, 5
tRNA([Ser]Sec) 5
Selenophosphate 5
SPS2, 5
D1-driven 5
PNET, 5
discontinuously 5
Cdk4. 5
(p16INK4 5
p18INK4C 5
(SABP) 5
TRH-leptin 5
(thyrotropin-releasing 5
VWF 5
STRs 5
intracerebroventricularly 5
Centrally 5
adrenals. 5
Bmax 5
hemochromatosis: 5
Lanka, 5
immigrant 5
Ser(67), 5
Ser(67). 5
dopamine- 5
Stokes' 5
(DARPP-32), 5
thin-layer 5
PP1-dependent 5
Thr35 5
C1q 5
anti-neutrophil 5
eIF4E-transporter 5
VHLS 5
65. 5
3p25. 5
Pertuzumab, 5
ERBB3 5
(HER3) 5
c-terminal 5
ethics: 5
SJS/TEN, 5
SSP 5
epicutaneous 5
operationalization 5
PREDICT-1 5
HLA-B*5701. 5
B*5701, 5
19-25 5
3´ 5
repressions. 5
MEST 5
ODNs, 5
tremors. 5
dismal. 5
bi-weekly 5
III-IV).Maintenance 5
immunochemotherapy 5
(stiff-man) 5
43). 5
Stress-promoted 5
(adaptive 5
(hisC952 5
metB5 5
leuC427). 5
RecA, 5
PerR, 5
σ(B), 5
mutY, 5
prototrophy. 5
YqjW, 5
UmuC/DinB 5
mother-child 5
ε-amino 5
Lys-40 5
HDAC6-specific 5
Tubastatin 5
depolymerized 5
A-treated 5
uniaxial 5
kinesin-1 5
neuromodulator 5
threefold). 5
(NAD)--dependent 5
SIRT2-mediated 5
(219 5
C708/T 5
milligrams 5
(A-H), 5
CD4(+)H9 5
person, 5
sickle-cell 5
Amazon. 5
Organism 5
marker--as 5
(27.0 5
Admission 5
(18.0 5
(41.0 5
40.2 5
0-4, 5
E-selectin, 5
P-selectin, 5
potassium-evoked 5
animal) 5
L-DOPA/benserazide 5
<750 5
end-expiratory 5
(RDS). 5
(CPAP). 5
<32 5
Take 5
poractant 5
datasets: 5
Extracting 5
Fas-Fas 5
(ITL) 5
CD69, 5
labeling) 5
apoptotic. 5
Thyrocytes 5
thyroids, 5
Fas. 5
Fas-sensitive 5
genome's 5
transcribable 5
LHCII, 5
plants; 5
terminators, 5
polyadenylate 5
(BACs), 5
reporters, 5
(RAREs) 5
Incident 5
(X2 5
1.01-4.29), 5
refrigeration, 5
(TPI). 5
0.35). 5
periarticular 5
ornamental 5
candidal 5
Fluconazole 5
CgCDR 5
azole-sensitive 5
Hsn-5. 5
antifungals 5
GDH1407 5
6115/06 5
acrylic. 5
Psychosine 5
OLs. 5
psychosine-induced 5
(affecting 5
tritium-labelled 5
galactocerebrosidase, 5
information-retrieval 5
(LIMEs), 5
grasses. 5
RIFIN, 5
PF13_0006 5
PfEMP1, 5
vivax, 5
Rifin, 5
Stevor 5
IgG3 5
K- 5
Subtelomeric 5
sub-families 5
AS-Control. 5
reservation 5
formative 5
jaws 5
tetracycline, 5
dentition. 5
0.9, 5
pigment-related 5
OCA2, 5
SLC24A5 5
store-overload-induced 5
duty 5
(apoE), 5
E-containing 5
HDL-PAF-AH 5
mg/mouse) 5
0.088). 5
(CD31). 5
indapamide 5
hydrochlorothiazide. 5
Thiazide 5
Abstracts, 5
Irbesartan 5
97.5 5
adaptively 5
(ii), 5
modification), 5
metabolism), 5
Cleft 5
0.3%, 5
N2A, 5
renewing 5
syncopated 5
auto-PBSCT 5
Rifampicin 5
fatalities 5
64, 5
(kidney 5
moieties, 5
4q28.3 5
19/26 5
(OTX2) 5
(41/44 5
0/5 5
(17/44 5
14/39) 5
3p21.3 5
normal/tumor 5
baseballs, 5
VEEG 5
(theta) 5
centromere-distal 5
more-severe 5
(cyclohexane 5
derivatives). 5
culture), 5
G:C-->T: 5
misinsertion 5
exonuclease-deficient 5
Fitzpatrick 5
anti-drug 5
α-MSH. 5
trans-zeatin 5
galls 5
anions, 5
(TL) 5
interrelations 5
Poland 5
anti-contamination 5
cingulate, 5
C9ORF72, 5
diphenylamide 5
chemotype 5
(snRNPs) 5
Lsm10 5
sDMA 5
LSm4, 5
ribonucleoprotein. 5
L- 5
epipodophyllotoxin 5
vectored 5
etoposide-induced 5
LC-172/VP 5
mixtures. 5
convex 5
MKN45 5
COT 5
suggestive. 5
lanceolatum 5
splits 5
lobe-finned, 5
(bichir 5
teleosts). 5
coelacanth, 5
bins) 5
Ctcf, 5
hyperfluorescent 5
seborrheic 5
androgenital 5
dermatologists, 5
co-inducer 5
Arimoclomol, 5
SOD(G93A) 5
bioprosthesis. 5
small-intestinal 5
Angiodysplasia 5
existence, 5
(ABS) 5
Papanicolaou 5
"FemAssist" 5
MutY, 5
Architectural 5
1-4% 5
PAM 5
(Tet1, 5
Kabaddi 5
talent 5
Youth 5
skill, 5
visual-spatial 5
coaches' 5
caps. 5
(running 5
soccer) 5
(masculinized) 5
second-to-fourth 5
sabre) 5
(épée 5
foil 5
fencing). 5
non-elite 5
injury) 5
(DARA), 5
(0.1-10 5
idiotype 5
[Clincal 5
comorbidities). 5
(4;14) 5
Transplant-ineligible 5
(VMP) 5
(MP, 5
43.1 5
lenalidomide-based 5
(12.7 5
Rancho 5
Bernardo 5
administered: 5
Fluency. 5
(≥450 5
pg/mL; 5
n=198) 5
P≤.001 5
(GAS) 5
anti-αv-integrin 5
1-2, 5
95), 5
anti-αv 5
(RECIST). 5
TEAEs 5
APOE, 5
GDNFOS1 5
GDNFOS2 5
down-regulated; 5
hyperaldosteronism 5
proreceptor 5
(HRC)-binding 5
Leu35Leu 5
(A/G), 5
Ser43Asn 5
(G/A), 5
(T/G), 5
Glu202_Glu203insGlu 5
(-/GAG), 5
Asp261del 5
(GAT/-), 5
His321. 5
9.620; 5
2.183-42.394; 5
Ala/Ala 5
Ser/Ser 5
arrythmogenesis 5
4.191; 5
0.838-20.967; 5
(10-fold), 5
isoproterenol) 5
aftercontractions 5
Ser96) 5
Ser96). 5
(1.6-fold) 5
(4-fold) 5
RTK 5
ARMS-PCR 5
AEBP1 5
V600R 5
p.Val600Lys 5
banks 5
78, 5
Proteome, 5
phosphoproteome, 5
leiomyomas 5
10.9%; 5
23%; 5
Insyght 5
paradigms. 5
Sockeye 5
mycelium 5
Fermentation 5
production) 5
LBM 5
oxalic 5
(TRAP). 5
dermal-epidermal 5
dapsone, 5
precipitates 5
biopsy-confirmed 5
adhered 5
(61%) 5
radiation-resistant 5
13939. 5
UV-irradiation 5
RecD2 5
aberration. 5
(LIV) 5
Deer 5
LIV 5
deficit) 5
NS1 5
TIA1/TIAL1, 5
Sequestration 5
obstructs 5
Z-lines 5
HDAC4, 5
PKCalpha, 5
(MPRs), 5
(LIMP-2) 5
sortilin. 5
(EE), 5
receptor-hydrolase 5
(TCs) 5
GGA 5
cation-dependent 5
gut-specific 5
Vedolizumab-treated 5
GEMINI 5
interleukin-23, 5
AJM300, 5
gut-selective 5
therapy-refractory 5
TNF-antagonist 5
endpoint), 5
Watcha 5
post-anesthesia 5
kg⁻¹). 5
Discomfort 5
Post-anaesthetic 5
facemask 5
kg-1) 5
3-8 5
anesthetic. 5
(CMRglu) 5
iNPH 5
18F-FDG 5
(INPH) 5
(FDG) 5
(PET/CT) 5
Examination, 5
alanine-scanning 5
21-30, 5
acylphosphatase 5
Co-localization 5
adipose-enriched, 5
(CEBPα). 5
unexpected. 5
degradosome. 5
Regrettably, 5
S100A13 5
(DC). 5
caspase-cleavage 5
decapaptide, 5
weaker. 5
ProTalpha(89-102) 5
donor-lymphocytes' 5
proTalpha(89-102) 5
AMLR 5
peptide(s). 5
review; 5
endeavor 5
wakefulness/fatigue 5
didactic 5
memantine 5
(O6-methylguanine-DNA 5
phosphotriester 5
(hAT) 5
hAT 5
Ogt, 5
hAT, 5
neuropilin-1 5
LDL/HDL 5
EMD. 5
37°C. 5
pulpal 5
0.049) 5
user-specified 5
HiSeq 5
vaccine's 5
(ICC) 5
resource-poor 5
OS-Seq 5
A>G 5
non-mosaic 5
Stratifying 5
DCE, 5
ulcers. 5
(NL) 5
(TCS) 5
phantom, 5
internus, 5
ventro-intermediate 5
(5me)C 5
tiered 5
NBL2 5
adenoma-carcinoma 5
Olig2 5
ascorbate, 5
(ascorbic 5
Ascorbate 5
unfolding, 5
non-erythroid 5
alpha20-21/beta1-2 5
faces. 5
side-to-side 5
hyperbilirubinaemia. 5
thrombophilias 5
formulated. 5
puerperium. 5
postpartum. 5
(lupus 5
gas-phase 5
necitumumab. 5
(developed 5
clinicaltrials.gov. 5
LQVVR 5
(type2). 5
((47)LQVVR(51)) 5
AmylPred, 5
lab. 5
Reflectance 5
Fourier-Transform 5
Spectroscopy 5
recommendations: 5
Conclusion: 5
ERBB2+, 5
chondrogenesis. 5
ethanol, 5
eNOS. 5
8-15 5
nitrendipine 5
K+-induced 5
PRL, 5
2-6 5
(DUF) 5
H358, 5
H292, 5
bone-anchored, 5
readjustable, 5
retropubic 5
47.3 5
50.4 5
I157T 5
8/1,646 5
2/400 5
3/302 5
2,105 5
phenotypically- 5
geographically-selected 5
BRCA1/2-positive 5
CHEK2_1100delC 5
Questionnaire: 5
on-the-job 5
"a 5
Employees 5
work) 5
unemployment, 5
3.97, 5
strategy: 5
absenteeism. 5
incidents. 5
tract: 5
Apoptosis, 5
vacA 5
(133 5
assays). 5
bulging 5
Na/K 5
glycemia, 5
cixutumumab, 5
(anti-IGF-1R 5
unconfirmed), 5
601 5
(iodine-131) 5
positron-emission 5
iodine-131 5
77), 5
NRAS. 5
NCT00970359.). 5
+3 5
dermaroller 5
(mSOD1) 5
(Keogh. 5
clearance: 5
UDP 5
UCB, 5
TRβ2 5
autobiographical 5
AMA1 5
spiralis 5
plasmodia 5
ookinetes 5
RBC. 5
chabaudi 5
PfMDH 5
ferrocene 5
GAT 5
Plasmodia 5
SAO 5
OMPDC 5
plant-like 5
A-like 5
Trx 5
CDKs 5
schizonts. 5
sulfa 5
s(-1), 5
sacharovi 5
fantofarone 5
partially. 5
NADPH. 5
tropica 5
Mosquitos 5
acid-modified 5
Acyl 5
PfACP 5
anthracycline-induced 5
chelators 5
Phyllanthus 5
urinaria 5
(83% 5
ONE 5
Gdf10, 5
(Flu) 5
(AraC) 5
lentivirus-transduced 5
Fancf. 5
luteoma. 5
(Brca2(Delta27/Delta27)) 5
mild-conditioned 5
HIPEC. 5
applied: 5
poly-chemotherapy 5
(ADARs) 5
eukaryotes; 5
editomes 5
65.7% 5
ADARs. 5
CCL5, 5
CCL5 5
Quint 5
cell-bone 5
siRNA-knockdown 5
disregulation 5
MDA-MB-435 5
p21-binding 5
domain-PAK 5
Rac3, 5
APOBEC3H, 5
proteins--APOBEC3D, 5
APOBEC3H--in 5
deaminations 5
Vif-A3 5
(hNET) 5
ETB 5
); 5
UPD 5
(YAC) 5
0.0006) 5
32.3 5
(-6.6 5
transpeptidase 5
pre-adipocytes 5
characters, 5
OKSCs 5
tenosynovial 5
(CSF-1) 5
(MDSC). 5
BRAF(V600E)-driven 5
TIMs 5
MHCII(low) 5
MHCII(hi) 5
(TIL) 5
TILs 5
Marginal 5
amyloidosis: 5
(11.8% 5
ERASURE 5
Year 5
IL-23/IL-17 5
1-3% 5
secukinumab-treated 5
IL-17E 5
(p=0.002) 5
ISM 5
score), 5
(IL-17A) 5
vaccinations, 5
fiber-type 5
ionophore-induced 5
over-responsivity 5
(FKBPs) 5
FKBPs 5
CYP20-3 5
acrosome 5
mES 5
Csnk1e(tau/tau) 5
Neuroglobin-overexpression 5
pAdEasy-GFP 5
(pAdEasy-GFP 5
(Genotype 5
Safety) 5
reduced-function 5
Heart, 5
metabolization 5
TRITON-TIMI 5
Dystromirs 5
Dystrophy. 5
Ullrich 5
(UCMD) 5
(dystromirs) 5
miR-133a,b, 5
MiR-1, 5
miR-133a,b 5
guadeloupean 5
(Gd-PSP), 5
parkinsonism), 5
unclassifiable, 5
Annona 5
muricata 5
(soursop) 5
(PDC, 5
31%) 5
parkinsonism-related 5
Postural 5
pseudo-bulbar 5
Pitre, 5
War, 5
DX® 5
DPP4 5
co-factor, 5
(ZCyt) 5
(cytosine-C5) 5
methyltranferases 5
ZCyt's 5
C5)-methyltransferases 5
5,6-dihydro-5-azacytosine. 5
C5-MTase. 5
Oligodeoxyribonucleotides 5
cytosine-specific 5
elements-1 5
SFRP 5
Calcified 5
(armoured 5
concussion. 5
HSS+3 5
687 5
overestimation 5
TREX2 5
heterotetrameric 5
appraise 5
seriousness 5
FAIRE-seq, 5
ATAC-seq, 5
UPF2, 5
sup113 5
Upf2p 5
rent2 5
(dose, 5
bopindolol 5
(1.16 5
.0007) 5
FGS 5
(6.3 5
post-cRT 5
α2-chain 5
COL5A1, 5
ehlers-danlos 5
(log10 5
linkage) 5
Diabetes) 5
large-artery 5
[95%CI] 5
symptom: 5
disabling. 5
1210 5
6000 5
9q 5
cyclic-AMP 5
JP 5
histiocytosis 5
Mag1p 5
mag1 5
mag2 5
[3-5]. 5
III), 5
5-Formyluracil 5
mispair 5
Kobayashi, 5
Ohyama, 5
Ide, 5
274, 5
(MutS). 5
2-12 5
endonuclease. 5
NEDD4-1 5
Artificial 5
PS1/gamma-secretase 5
oligo-ubiquitination 5
arachnodactyly 5
(I107T) 5
anti-APOBEC3G 5
3G 5
α-form 5
p38alpha, 5
MKK6 5
p38delta 5
reinfection, 5
pulpectomy 5
prescription-event 5
drowsiness/sedation, 5
malaise/lassitude, 5
Neurologic-related 5
crises, 5
39.1%. 5
"Bookmarking" 5
Oncoprotein 5
Epigenotype? 5
FoxA, 5
"bookmark" 5
(epigenetic 5
FoxA's 5
FOX 5
Myocd 5
Tbx5. 5
(GMT). 5
CFs 5
Ibrutinib, 5
(PCI-32765), 5
(NSG) 5
enrolment. 5
THR 5
not) 5
(34.2%) 5
NIV, 5
distending 5
non-humidified 5
L/min) 5
AOP. 5
infant's 5
FGFRs, 5
FGF2 5
MuSCs 5
Ng, 5
Ng48-76, 5
(p=0.012) 5
mmol/l), 5
Cshepc 5
preprohepcidin. 5
Hepc25 5
ferroportin. 5
bass 5
(GFD). 5
(35.0%) 5
(checkpoint 5
Dephosphorylated, 5
'pure' 5
dimer; 5
S33/35). 5
ATM+/+ 5
ATM-/- 5
S33/35 5
T378 5
aortopathy, 5
F+ 5
nonepithelial 5
hiPS-CMs 5
transit-amplifying 5
RXR 5
v-ErbA 5
5-HT2ARs 5
[(3) 5
Landrace 5
Barratt 5
Lister 5
SPM 5
Hostility 5
time-activity 5
granulomatosis. 5
fragment-length 5
(ANCA)-positive 5
WG). 5
22-620W 5
LYP, 5
PCR-restriction 5
1.69, 5
colitis), 5
17%, 5
ESPOIR 5
0.4-0.8, 5
HLADR 5
ophthalmopathy 5
CD34(-) 5
hindlimb. 5
28,377 5
marking, 5
baculoviruses 5
Thbs3 5
new. 5
deficiency-induced 5
temperature-regulated 5
IFN-stimulated 5
Gdown1 5
NELF. 5
hSpt5 5
time-frame 5
MxA 5
picolinate 5
Glioblastomas 5
gliosarcomas 5
encountered; 5
café 5
Predisposing 5
late-infantile 5
fibroblast's 5
(infantile 5
UvrA2B2 5
gyrase 5
autonomously, 5
opener 5
Thr-594 5
(5.2 5
endolymph 5
audiometry 5
69.4% 5
deafness: 5
(RTH). 5
cooccurrence, 5
(p<0.002) 5
(p=0.09) 5
kindreds, 5
CDK2. 5
GalaxyDock 5
S100B-FGF2 5
LiGenDock, 5
dasatinib-mediated 5
nonreplicating 5
Llgl4 5
RAS-MAPK 5
Scribble. 5
1-day 5
R0) 5
imatinib-insensitive 5
D842V-mutated 5
Bcr-Abl-expressing 5
radon 5
reverse, 5
CNVs. 5
ultraconservation. 5
TAATTA, 5
conditioning, 5
Antidiabetic 5
(Cucurbitaceae) 5
pectin-treated 5
bread 5
7(Z)-octadecenoic 5
7(Z),10(Z)-octadecadienoic 5
S4153R 5
CPVT-linked 5
Carbamazepine 5
TEN. 5
dysfunction-induced 5
T-ALLs 5
perphenazine 5
minisatellite 5
(Xic), 5
spindle, 5
Haspin, 5
kinetochore-microtubule 5
Mps1 5
INDELs 5
Allowing 5
thiazide-sensitive 5
two-vessel 5
28-amino 5
vagotomy. 5
vagotomy, 5
(NG) 5
viraemia 5
Atm(-/-) 5
p14ARF, 5
telomere-independent 5
pRb, 5
p16(ink4a) 5
EET 5
myomiRs, 5
hyperinsulinaemic–euglycaemic 5
base-calling 5
Mercury 5
instructions. 5
atractyloside 5
damages, 5
NIM-811 5
NIM-IR 5
2', 5
PSCs. 5
Iso/Ade 5
pyrrophenone, 5
1-oleoyl-2-acetyl-sn-glycerol 5
lactacystin 5
GSK-3beta. 5
alectinib-resistance 5
zinc-bound 5
MT-B, 5
(MT-A70). 5
odorant-gated 5
D466E 5
(ORs). 5
tau-protein 5
nitric-oxide 5
CMS-exposed 5
I2PP2A 5
hmC 5
(Tet) 5
Dppa3, 5
menin-dependent 5
underpinned 5
hPaf1/PD2 5
interlocked 5
(VZV), 5
untested. 5
interference-based 5
WHSC1L1 5
SUMO2/3 5
FALS 5
MSC, 5
tonsillectomy, 5
otological 5
(HIFs) 5
polarities 5
A50/C51 5
U284 5
CAGACG 5
longer-than-unit 5
unit-length, 5
ribozymes. 5
circularization. 5
CVd-III 5
Watson-Crick 5
(ND3) 5
(MLS). 5
muscular, 5
immunohematology 5
(IVS1-1G>A) 5
(R222G 5
adsorption-elution 5
hematologically 5
(CYBB), 5
(RPGR), 5
transcarbamylase 5
(OTC). 5
choreatic 5
psychopathology, 5
1023 5
RP3 5
HIFs. 5
L-leucine-induced 5
particular. 5
new-born 5
(IGE). 5
KCNQ3) 5
SCN1B, 5
ADAS-Cog 5
mini-review 5
MMSE, 5
(VL) 5
15N 5
island-associated 5
conscripts 5
SCTR, 5
ENL 5
(18.4%) 5
high-complexity, 5
Wise, 5
mTORC1; 5
localise 5
tunable 5
(KLK) 5
KLK3, 5
KLK3 5
gallus) 5
KLK8 5
sheath, 5
TFIIIB 5
gravidarum, 5
necrotising 5
onset; 5
SE-positive 5
rs2476601/Trp(620) 5
p-values. 5
DNASE2 5
HLA-shared 5
1-3), 5
4-chloro-m-cresol 5
siNOX1 5
ApoE(-/-) 5
gevokizumab, 5
counter-regulatory 5
IL-1β-associated 5
(gevokizumab), 5
Hierarchy 5
co-regulators 5
anti-neurogenic 5
Groucho/Tle 5
Groucho/TLE 5
immortality. 5
ALT. 5
5-fluorocytidine 5
PCN 5
M.MspI 5
Phe50 5
Glu74 5
D96A 5
Asp96 5
Arg130 5
Asn167 5
Arg202 5
R295A 5
p23, 5
STXBP1, 5
ENG, 5
OIs 5
Tankyrases 5
oceans, 5
Dakota. 5
permucosal 5
(HIV 5
Ross 5
viruses) 5
(HAMLET). 5
nephrotoxicity. 5
checking 5
X-rays. 5
(Alu-equivalent) 5
3'-processing 5
b1 5
2.99 5
lacI 5
Gems 5
Conserved, 5
interactome: 5
"Emplotted 5
rural, 5
Scales-21. 5
[12.6] 5
[58%]), 5
rs4626664 5
PTPRD 5
questionnaire). 5
sensorimotor-related 5
graduated 5
LCS1, 5
LCS1 5
25-OH 5
(83.3%) 5
bioenergetics: 5
mitochondria; 5
bioenergetics. 5
phosphatidylserines. 5
Aminotransferase 5
tacrine-treated 5
ULN). 5
Kurtz 5
(-33.3%). 5
chewing 5
0.125 5
Ia/b 5
Dap160 5
Confirmatory 5
PNMT 5
Residues 5
HD5, 5
Patients: 5
altruistically 5
sake 5
multi-professional 5
BRCA-1 5
ovary]. 5
person--carrier 5
mutation--was 5
breast-ovarian 5
Risk. 5
homemade 5
heroin. 5
Data. 5
(RBV) 5
ledipasvir/sofosbuvir 5
Ledipasvir/Sofosbuvir 5
(harvoni): 5
MFF 5
0-27% 5
caste, 5
caste 5
Orissa 5
Kerala-Kalyan. 5
[Glucose-6-phosphate 5
(G-6-PD) 5
musculus. 5
Iganga 5
distric 5
was; 5
79.59% 5
12.65% 5
7.76% 5
0.11) 5
episodes/year 5
(2505 5
parasites/μL; 5
20.41% 5
A-mutation, 5
15-32% 5
diatheses 5
jaundiced 5
Deficiency: 5
hyperbilirubinaemia, 5
Kaiping 5
linked). 5
Argentine 5
(putative 5
(PrP) 5
lobule 5
tics. 5
EMA, 5
SIRT2, 5
PARP1, 5
non-gBRCA 5
MSI/MSS 5
(MSS) 5
EC50s 5
Trapping 5
PARP-1/2 5
High-Grade 5
ERCC1-deficient 5
thalamotomy, 5
Skull 5
Leading 5
lesioning 5
89·4% 5
81·3% 5
paraesthesias 5
(tcMRgFUS) 5
thalamotomies 5
(CLTs) 5
CLT 5
radiation-free 5
BoNT/B 5
palpation 5
wrinkles 5
optica. 5
immunomodulators, 5
ocrelizumab. 5
anti-B-cell 5
Teriflunomide-treated 5
(maximum) 5
(325) 5
≤2.5; 5
≤0.48). 5
Pre-specified 5
strata, 5
subtype), 5
(gadolinium-enhancing 5
TEMSO. 5
(ESAs) 5
EMPs 5
EPO. 5
erythropoietin) 5
40-kDa 5
Peginesatide: 5
tea, 5
(Part 5
weeks: 5
Hemoglobinopathy 5
Lepore 5
(0.079%) 5
hemoglobinopathy-S 5
(0.543%). 5
Circularization 5
reserved.</ 5
Drugs. 5
(natural 5
Infusion-related 5
Interferon-γ 5
(NOX) 5
11l 5
(GDC-0810 5
ARN-810) 5
tamoxifen-sensitive 5
degrader. 5
vertebrate-specific, 5
H3K4-methylation 5
REST/NRSF, 5
neural-specific 5
(Avelumab) 5
Antibody-Dependent 5
Inhibitor. 5
1947 5
epidemic, 5
(IgM) 5
(MATS) 5
2009-2013: 5
non-carbohydrate 5
(ST)-269. 5
serogrouped 5
genogrouped 5
serosubtype 5
MLST. 5
(69.4 5
(CC); 5
1-2/3 5
CC; 5
6.1% 5
(NHBA). 5
cross-protective 5
septicemic 5
NadA, 5
oropharynx 5
NadA. 5
(rNadA) 5
(fHbp, 5
ligand-bound 5
SEA: 5
Super-Enhancer 5
(SEA, 5
http://sea.edbc.org). 5
rTg4510 5
GABA, 5
Neurofibrillary 5
analogies 5
cDNA(HA)-Ires-Cre 5
scurvy, 5
Paris. 5
Koa 5
Stevens 5
emergencies 5
granulysin 5
inevitable. 5
Enzymes. 5
Ub-conjugated 5
DUBs. 5
FAM63A) 5
propargylated 5
realign 5
D-2 5
RAUs 5
nodosum, 5
furan 5
hepatotoxicities 5
Dic 5
drug-dependent 5
Wearing-off 5
self-efficacy. 5
Catechol-O-methyltransferase 5
31.5% 5
phenomenon: 5
200-mg 5
shadows 5
levodopa/DCI 5
transparent 5
Geuvadis 5
465 5
(sQTLs), 5
PrP(Sc). 5
0.7%, 5
Track 5
biocuration 5
MINT 5
literature: 5
vocabulary, 5
Orexigen 5
27-45 5
peppered 5
hyperkinesis. 5
(Slc9a6 5
lacZ/β-galactosidase 5
(β-Gal) 5
(PCs). 5
transcriptional/XCI 5
syndrome-linked 5
cation/proton 5
(ID), 5
Uchl1, 5
(Uchl1), 5
Uchl1-derived 5
Doman 5
SINEUP, 5
(AS 5
exotoxins. 5
likelihood-ratio 5
LVX-raxibacumab 5
(P=0.0874). 5
n=39) 5
n=37), 5
(P=0.1016). 5
Toxin-neutralizing-activity 5
toxin-neutralizing 5
anthrax-related 5
7/8, 5
herbivore 5
fully-human 5
post-exposure 5
Ulp2 5
>4,300 5
>1,000 5
SU(VAR)3-7. 5
Earliest 5
SUMOs 5
HS-induced 5
mGluR7 5
modifier) 5
RAP1 5
aducanumab) 5
Contiguous 5
912C3 5
(SKY) 5
CCA. 5
Monosomy 5
(FACS), 5
15(q11-13) 5
misidentified 5
13/21 5
salt-losing 5
Gitelman-like 5
luteum 5
burns, 5
torsion. 5
SP-A 5
abscesses. 5
(99m)Tc-HYNIC-AnxV 5
(annexin 5
pollen 5
Extent 5
mg/dl; 5
(fibrates 5
statins) 5
pravastatin-treated 5
Bezafibrate 5
persons) 5
tendons. 5
765 5
HELP 5
dysglycaemia 5
(coronary 5
melanoma; 5
nitro 5
0.15). 5
[Vioxx]) 5
middle-income 5
re-operation 5
companies. 5
(α-Gal) 5
(ERT), 5
(amenable) 5
Migalastat. 5
(P=0.30). 5
(-18.6 5
α-Galactosidase 5
Co-Administered 5
Infused 5
Agalsidase. 5
50mg, 5
Volunteers. 5
838 5
organoid 5
radiobiological 5
(EBV), 5
HSV-2 5
rhinoviruses 5
A-C 5
HPeV 5
HSV-2-meningitis 5
Echovirus 5
persistence, 5
PeakXus: 5
ChIP-Exo 5
caller 5
doctors' 5
parameters) 5
2102 5
bacilli, 5
5.1%), 5
adenoviral-mediated 5
Path2PPI: 5
sperm-associated 5
metastasis-positive 5
conclusions, 5
immigrants 5
cognizant 5
taking, 5
'Tamiflu') 5
(Roche). 5
worse, 5
(Oseltamivir 5
Zanamivir) 5
endoproteolysis. 5
homologues: 5
Aph-1, 5
pen-2. 5
N160 5
proteoform 5
XL: 5
(KATP) 5
gingivalis. 5
gingivitis 5
Prevotella 5
Tregs, 5
Abcg2 5
75%) 5
TWa 5
UBQLN2, 5
ubiquilin-2 5
HLP, 5
APOE*2 5
Apoe 5
isoproteins 5
apoE-4, 5
apoE-3. 5
triglyceride-rich 5
81.0% 5
apoE-1 5
(Lys146-->Glu) 5
(XLHR) 5
PHEX-gene. 5
XLHR, 5
OPHTHALMIC 5
LITERATURE 5
UNUSUAL 5
CAUSE 5
PAPILLEDEMA 5
SUBSEQUENT 5
OPTIC 5
ATROPHY: 5
wide, 5
papilledema, 5
Disadvantages 5
(HAM-A) 5
Impression-Improvement 5
(Depression 5
0.983, 5
1.650), 5
0.728, 5
0.554 5
WKBL 5
adzuki 5
immunopotentiating 5
(Phaseolus 5
non-digestible 5
soybean, 5
amyloidoses 5
125I-T4 5
malposition 5
1,250 5
neonatology 5
sores, 5
24%. 5
pseudomembranous 5
glial-melanocytic 5
anlage 5
piezo-type 5
PIEZO2. 5
B12, 5
Slitrks 5
MDM2-p53 5
E2-related 5
CSN1, 5
(CR-Csn8KO) 5
Csn8/CSN 5
deneddylation, 5
Signalosome 5
well-powered 5
(PIONEER 5
registry-based 5
58.9% 5
AbbVie; 5
Perthes' 5
epiphysis. 5
complaint, 5
officers 5
doses: 5
(LUBAC) 5
Neecham 5
decisive. 5
(frozen 5
set; 5
chromosomes-karyotypes-are 5
ideograms 5
collinearity 5
collinearity. 5
Measles, 5
little-known 5
Edward 5
Pox 5
immunology. 5
overweight/obese 5
(NOX1), 5
(NOXA1), 5
ABCB1-overexpressing 5
ABCB1- 5
(CLCNKB) 5
hydramnios, 5
hyperprostaglandin 5
chondrocalcinosis 5
(enhancers) 5
(silencers) 5
rerio). 5
Detector 5
Vision 5
HELLP, 5
reascertained 5
(Smith 5
MyoD, 5
MYF5, 5
TRP-1, 5
QNR-71, 5
EDN3. 5
Proteobacteria, 5
microbiome. 5
Foxa2, 5
Foxa3. 5
Ihh-dependent 5
(HS-PGs) 5
HS-PG 5
(rIhh-N) 5
rIhh-N 5
heparinase- 5
rIhh-N, 5
Syndecan-3 5
misexpressing 5
osteogenesis, 5
syndecan 5
perichondrium. 5
BMPR-IB 5
PTHrP, 5
(IHH)-parathyroid 5
non-damaged 5
furrowed 5
nonpitting 5
Palsy: 5
granulomatosa 5
cheilitis. 5
glucocorticosteroids 5
5years 5
Biotherapeutics, 5
Israel) 5
1year 5
tRNAHis 5
ST2 5
(PBC), 5
Dec. 5
(FOXG1), 5
FOXG1. 5
CDKL5. 5
Foxg1 5
progressiva. 5
17q21-22 5
kyphosis. 5
taxon. 5
uvula, 5
PAX3. 5
cited.Five 5
forelocks. 5
interocular 5
normal.The 5
Mackenzie's 5
Evaluations 5
PHN 5
hill 5
artemisinin 5
V105 5
T108 5
Predict 5
ST239Kras 5
BBR 5
creeps 5
nares 5
RVS-MRSA 5
Who 5
leukocidin 5
CA-MRSA, 5
PVL 5
pvl 5
CA-MRSAG 5
aac(6')/aph(2") 5
ORSAB 5
ECD 5
photodissociation, 5
DIA 5
Avanafil: 5
<2% 5
(ICP)/mean 5
SEP2 5
SEP3 5
84.6% 5
Longer-acting 5
(56%; 5
(-27%; 5
-133 5
31; 5
P=0.45), 5
NCT01617096 5
(NNRTI) 5
lactobacilli 5
80, 5
price. 5
Meningococcus 5
asplenia, 5
immunogens 5
(Bexsero(®)). 5
NZ98/254 5
seroprotective 5
Re-evaluating 5
England: 5
multi-component 5
DOMV 5
4-mm 5
capsulotomies 5
ameliorative 5
ERa 5
Proteasomes 5
Zinn' 5
'of 5
Valsalva'? 5
Statin-associated 5
SLCO1B1*5 5
LDL-c 5
linc00617 5
tumour-related 5
apocynin) 5
Ang-II 5
N27 5
(oAβ) 5
(fAβ); 5
oAβ-induced 5
Cl(-)-cotransport 5
(N-acetyl 5
SP600125) 5
apraxia, 5
meningitis-like 5
0.025; 5
ssp. 5
Federation. 5
1940 5
encephalitic 5
meningo-radiculo-neuropathy, 5
neuroborreliosis. 5
("autoimmune") 5
ELISA/immunoblot 5
54/10% 5
22/0% 5
0.003/0.034; 5
intrahousehold 5
septin-2 5
filament-forming 5
heteropolymer 5
filamentation. 5
Cdc42p 5
GS-607601 5
(LOXL2) 5
Child-Pugh 5
Statin-Associated 5
Symptoms. 5
unlikely, 5
hyperexcitability. 5
[Neurochemical 5
NSD-1015]. 5
(NSD-1015) 5
6S-BH4 5
neurointermediate 5
(3-hydroxybenzylhydrazine 5
5-hydroxytryptaminergic 5
MHPG/NE 5
hypothalamic-hypophysial 5
cyanamide-induced 5
(MAO) 5
Pseudouridine 5
13/14 5
MRP2/ABCC2 5
enterocytes, 5
(hTfR1) 5
KTECER100 5
↓LA, 5
Lys95 5
desferrioxamine 5
(HEPATOLOGY 5
2013;). 5
(BMP-9). 5
decanoyl-Arg-Val-Lys-Arg-chloromethylketone 5
(CMK) 5
holo- 5
apo-transferrin. 5
iron-transferrin 5
therapeutic/diagnostic 5
haemochromatosis, 5
TAGs. 5
Fat-specific 5
Fat-Specific 5
27/CIDEC 5
Steatohepatitis 5
(ASH) 5
(FSP-27)/human 5
(Fsp27(Hep-/-) 5
Lieber-Decarli 5
binges 5
(GW9662) 5
(PPARG). 5
(sh) 5
biopsy-proved 5
Chronic-plus-binge 5
AH, 5
ASH, 5
Cidec) 5
Fsp27(Hep-/-) 5
adenovirus-Fsp27shRNA 5
PPARG 5
(CREBH) 5
Fsp27α 5
FSP27β 5
Fsp27/CIDEC 5
[cell 5
humans] 5
(FAO) 5
accumulated/exported 5
FSP27/CIDEC, 5
HFD, 5
again, 5
(R=.725), 5
(EWAT) 5
(R=.475) 5
(R=.706), 5
(R=-.787), 5
(R=-.706), 5
(R=-.679). 5
(R=.660), 5
(R=.468), 5
(R=.599); 5
(R=-.422, 5
P=0.051). 5
(CIDE) 5
pre-adipocytes, 5
ATGL 5
Agonists 5
inter-rater 5
(OPS-2). 5
IEGs. 5
IEG 5
co-upregulation. 5
ripple 5
CCL-1 5
septooptic 5
Sometimes, 5
insipidus, 5
Electroencephalogram 5
Murrah 5
OCA2. 5
20/200 5
(rs1126809) 5
p.R402Q 5
copper-containing 5
glycoenzyme 5
copper-binding 5
oculo-cutaneous 5
(OCA2). 5
MCAST's 5
priors 5
http://meme-suite.org 5
http://alternate.meme-suite.org 5
mcast, 5
ABCA1. 5
apoE4-(72-299) 5
apoE4-(1-231) 5
isoformic 5
dihexanoylphosphatidylcholine. 5
apoE-(1-191) 5
apoE-(1-231) 5
3H-LDL 5
(apoE4-(72-299)), 5
(apoE4-(1-231)), 5
(apoE4-(1-191)) 5
apoE3-(72-299) 5
apoE3-(1-231) 5
apoE-deficient 5
Cse4, 5
(HJURP 5
H3-Cse4 5
wrapped 5
inflammation", 5
"butterfly 5
rash", 5
"wrist 5
petechiae", 5
"enanthema 5
membrane", 5
delocalised 5
(nda3). 5
(POI). 5
Substantially 5
KCs 5
quinoa 5
TNF-blocking 5
non-naive 5
1-Year 5
Golimumab/Standard 5
391,252 5
(93,155 5
374,377 5
(89,137 5
'golimumab' 5
'ulcerative 5
colitis' 5
antagonist-naive 5
(Program 5
IBDQ 5
originator 5
Ugt1 5
Ugt1a1 5
Kernicterus 5
(Mbp) 5
iran. 5
MAPK14 5
Dyslipidemia 5
(sSMC) 5
forgetting 5
MacroH2A.1 5
epiblast, 5
macroH2A.1 5
TFR2 5
Hyperferritinemia 5
wide-range 5
D181V 5
(A846T) 5
G80V 5
(G543T) 5
hyperferritinaemia,. 5
G267D 5
(G1104A) 5
hyperferritinaemia, 5
(CFSE 5
(Annexin 5
binding), 5
(Fluo3/AM 5
fluorescence) 5
(ROS; 5
fluorescence). 5
CFSE-labeled 5
ATP/ADP 5
DMT1, 5
(IKr) 5
delta1261 5
Na(+)/K(+) 5
(ATM)- 5
phosphatidylinositol-kinase 5
(PIK)-related 5
HK-2 5
Suv4-20h. 5
Suv4-20h1/h2. 5
Suv4-20h1/2 5
Suv4-20h1, 5
H4K20-specific 5
dens, 5
crown-like 5
wrist, 5
spondylodiscitis 5
Striae: 5
koebnerization' 5
[Psoriasis 5
isomorphic 5
canal, 5
nonpsoriatic 5
IMRT. 5
photons, 5
$21 5
716/QALY, 5
$11 5
773/QALY, 5
$20 5
150/QALY, 5
standpoint. 5
proton-beam 5
normal-tissue 5
photon-beam 5
developmental) 5
megavoltage 5
plates), 5
sac) 5
Sparing 5
morbidity-free 5
intensity-modulated 5
breeds, 5
CoA:diacylglycerol 5
wax 5
H3K9M 5
KDM3B/JHDM2 5
H3K9M-containing 5
(H3K9 5
H3K36) 5
K-to-M 5
K27M. 5
(http://compbio.mit.edu/HaploReg) 5
43.8 5
Gadolinium-contrasted 5
Tenascin-X 5
FLNA 5
(LS) 5
(pro)collagen 5
cord-like 5
IIEF-5 5
raltegravir 5
hydroxamate 5
siderophores 5
co-depletion, 5
DOXO-mediated 5
NOS3(-/-) 5
Lymphangiectasia 5
Waldmanns 5
osteomalacia 5
nPTX3 5
sepsis; 5
66, 5
[prothrombin 5
(F(1+2))] 5
[plasminogen 5
(PAI-1)]. 5
SAPS 5
F(1+2) 5
(DCL1). 5
NF45 5
oculocutaneus 5
(EGF)-like 5
203200), 5
OCA3 5
203290), 5
HPS 5
rate-limiting, 5
feral 5
Rotator 5
delaminated 5
double-layer 5
Overview. 5
Neuroradiology. 5
extent-of-resection 5
(43°C 5
extent-of-coverage 5
criteria-(1) 5
line-had 5
convection 5
HGGs, 5
evicting 5
α2 5
SWC6 5
AtSWC2. 5
Ependymal 5
morphogens 5
/Lynkeas 5
photocoagulation, 5
pigmentovascularis 5
(Blighia 5
aril 5
(Acer 5
husks. 5
toxicity: 5
BSC. 5
Lymphoma, 5
MCD-related 5
0.0012). 5
(>10% 5
dose-toxicity 5
delay/discontinuation 5
terminal-phase 5
17.73 5
20.64 5
CBR 5
[complete 5
11], 5
N-degron 5
PAX6 5
monolateral 5
L13a 5
interscapular 5
lipoidica. 5
diabeticorum: 5
Granuloma 5
time? 5
NCTC 5
coryneform 5
cat. 5
STs 5
IL-18BP. 5
(IgAN). 5
TFIIB: 5
(glutamic 5
BLM10, 5
SAC3, 5
GAL10, 5
SEN1, 5
(AVERROES) 5
attack: 5
1·07 5
.71). 5
slides. 5
78.3% 5
(MET 5
ORR, 5
Th17-mediated 5
(S1P) 5
tumor-like 5
contagiosum: 5
Recalcitrant 5
impetigo, 5
(Hex 5
SSPCS 5
rooted 5
chemoattractants 5
Stereoselective 5
Hydroxylation 5
pharmacotherapies, 5
(liraglutide, 5
BCL-2/BAX 5
alpha5-alpha6 5
Bcl-xL. 5
Bcl-x(L) 5
989 5
Chl1's 5
replisomal 5
lymphangiography 5
Reduviidae 5
disease-resistance 5
(SOLO 5
NCT02277743 5
NCT02277769 5
immunostained. 5
lobules. 5
uvula 5
folia 5
brush-like 5
branchlets. 5
basket 5
scrambler 5
EPSC 5
Metabotropic 5
mGluR2/3 5
K27M--including 5
H3.2K27M--mutations 5
location-related 5
(PFB), 5
(TKD) 5
MYB/MYBL1 5
NTRK1, 5
NTRK2, 5
NTRK3 5
50%). 5
(TL-01) 5
(TMP) 5
(0.005%) 5
TMP 5
APOB, 5
angiopoietin-like 5
ANGPTL3. 5
Angiopoietin-like 5
(ANGPTL3) 5
(0.97±0.16 5
0.56±0.20 5
hypoalphalipoproteinemia 5
(p.G400VfsX5, 5
p.I19LfsX22/p.N147X) 5
triglyceride-containing 5
pre-β-high-density 5
B-depleted 5
(ABCA1-, 5
SR-BI-, 5
ABCG1-mediated 5
efflux); 5
(2.52±0.38 5
Distinction 5
(brown 5
BAT) 5
(SNS) 5
"beige" 5
"brite" 5
UCP1, 5
mimotope-elicited 5
(HMW-MAA) 5
anti-HMW-MAA 5
Mimotopes 5
NXS2 5
IL-21 5
MdDS. 5
gardens? 5
Landscape 5
saprophyte 5
melioidosis: 5
fibrinolysis. 5
Utah 5
granulocytes. 5
bacillus 5
endemicity. 5
Fur 5
(1p19q+) 5
(INA) 5
(GAMES-RP) 5
18-80 5
defences 5
GSDMA3 5
Ovary-specific 5
orangutan 5
propranolol-treated 5
therapy-induced 5
TDP-43-negative 5
TMEM106B 5
GATA-1s. 5
(IB) 5
PU.1(-/-) 5
CPF-associated 5
geneticists, 5
illustrated. 5
"genetic" 5
aptamer-induced 5
noncompaction, 5
2.1; 5
Reversing 5
Drugs: 5
ciraparantag) 5
ciraparantag, 5
postaxial 5
slanting 5
intersex 5
bipotential 5
endocarditis. 5
LTBP-3 5
porphyria, 5
cocktails, 5
Guinea. 5
postexposure 5
Going 5
cardio 5
5,10-methylenetetrahydrofolate 5
CdLS; 5
Curiously, 5
34; 5
1.2-22.6 5
signal-averaged), 5
microvolt 5
1.8. 5
count: 5
Hypocholesterolemia 5
prealbumin 5
MERRF, 5
inheritance). 5
Timing 5
Palbociclib, 5
66.0% 5
VEGF-C. 5
preregistration 5
Cholangitis. 5
(EL; 5
superior-temporal 5
c.1948 5
(p.Arg650Cys) 5
20/20 5
-2.50 5
nonpenetrance. 5
ADAMTSL4-associated 5
optometry, 5
slitlamp 5
B-ultrasound, 5
gonioscope 5
checking, 5
biomicroscopy 5
(UBM) 5
(IOP; 5
Goldmann 5
applanation 5
tonometer). 5
Prism 5
3730 5
c.184C>T 5
(p.Arg62Cys) 5
Arg62Cys 5
ClinVar, 5
24-32, 5
microfibril, 5
correspondingly, 5
cryopyrin-associated 5
(CAPS) 5
Malassezia 5
Varroa 5
parasympathetic. 5
Cre-reporter 5
bi-potent 5
everolimus-eluting 5
left-main 5
low-intermediate 5
(older 5
COPD) 5
Unprotected 5
(CVA) 5
death/MI/CVA. 5
liraglutide, 5
koos 5
(IMR90). 5
same-cell 5
subtleties. 5
PEDLA: 5
(cardiolipin). 5
(cardiolipin) 5
galactose 5
Cardiolipin, 5
accessed, 5
compare: 5
predeployment; 5
postdeployment. 5
1.06-1.65) 5
0.67-1.01). 5
predeployment 5
1.08-1.97). 5
Clinician-Administered 5
anti-osteoporosis 5
Teriparatide, 5
osteoporosis-related 5
785/CDP7851) 5
anti-sclerostin 5
DRD2 5
Taq1A 5
DTS-K 5
HJURP. 5
cereblon, 5
Mis18β, 5
YIPPEE 5
Mis18BP1, 5
HJURP(Scm3) 5
HJURP(Scm3). 5
Mis18-interacting 5
(Eic1 5
Eic2), 5
Eic2 5
Fta7(CENP-Q/Okp1), 5
Cnl2(Nkp2) 5
Mal2(CENP-O/Mcm21), 5
Scm3sp 5
CENP-A(Cnp1) 5
aneusomy 5
Pfizer), 5
HR-positive, 5
Abemaciclib 5
(Ibrance; 5
Tazemetostat 5
GBM/DIPG 5
Urology. 5
NEW 5
beta-3 5
antimuscarinics 5
C-fibers 5
β₃-AR 5
β3-adrenergic 5
214), 5
Bezlotoxumab: 5
(CDIs) 5
antibody/toxin 5
BI/NAP1/027 5
BK/NAP7/078 5
027. 5
apremilast-treated 5
PPPGA 5
arboviruses. 5
Insecta) 5
phloem-feeding 5
Nasuia 5
Nasuia-ALF 5
LR+ 5
diagnose. 5
pallor 5
pernicious 5
'CKD 5
cardiomyopathy', 5
CSN1S1 5
co-/post-transcriptional 5
"microRNA 5
sponge" 5
4q21 5
non-collagenous 5
SLC34A3, 5
dihydroxyvitamin 5
(40,000 5
hydroxyvitamin 5
microgram/day) 5
phalloides 5
Aligner 5
(BWA) 5
IOR 5
1,000-2,000 5
rad) 5
41.6%. 5
INTRAGO: 5
multiforme—a 5
protein-RPS19 5
S17 5
(RPS17) 5
Sperm 5
FISH: 5
painting. 5
t(13;14) 5
t(14;21) 5
neighbourhood 5
21: 5
gems. 5
RAS2 5
necrotrophic 5
TaMetRS 5
megabase-scale 5
rewire 5
TAD-spanning 5
WNT6/IHH/EPHA4/PAX3 5
guanosine. 5
Subdural 5
prowess 5
PRB 5
membranoproliferative 5
Oedema 5
Process 5
g/dL, 5
CIP 5
epigenomes. 5
Fkh-activated 5
fork-head 5
chemobrain 5
Granule 5
Transarterial 5
csDAVFs. 5
csDAVFs 5
guided. 5
Quintero-Cadena, 5
Sternberg. 5
EMBER 5
UBE3B, 5
Basset: 5
Arg/Abl2 5
1BLCTS 5
Ultraviolet-A 5
Arg+. 5
(PTKs) 5
(NHEK) 5
nonperfusion 5
2016) 5
therapy-naïve 5
Loci 5
(SSCprofiler) 5
description, 5
Ectodermal 5
CLAST: 5
CUDA 5
(CUDA 5
Fermi 5
(local 5
option), 5
preprocessed 5
(equal 5
FR-HIT) 5
AMHR-II 5
overdispersion 5
LARVA. 5
β-binomial 5
overdispersion. 5
LARVA, 5
LARVA's 5
(larva.gersteinlab.org). 5
peptide-containing 5
Rrp6, 5
Nrd1-Nab3 5
Air1 5
Air1/2 5
(SUTs, 5
(CUTs, 5
sdAbs 5
(102 5
HCV-G3 5
(DILI) 5
amoxicillin-clavulanate 5
ALF. 5
Notwell 5
Ntng1, 5
(-∕-) 5
TBR1. 5
Mcm8 5
Mec1 5
MCM4 5
Dpb11 5
Mcm7 5
Mcm7, 5
Lighter 5
encode, 5
read-length 5
Chikhi 5
(genes). 5
tool.We 5
dmb.iasi.cnr.it/camur.php 5
emanuel@iasi.cnr.it 5
screen-positive 5
MIAT 5
SII, 5
SII-independent 5
(Reines, 5
(C-ribbon) 5
Chromatins, 5
mononucleosomes 5
(linker) 5
(MNase). 5
core/linker 5
traversal, 5
Nurk 5
Methylome- 5
NOMe-Seq, 5
(NDR) 5
(NOMe-seq). 5
scNOMe-seq 5
non-respiring 5
(Mtb), 5
impervious 5
Rv3133c 5
EtOH-induced 5
pet, 5
pregenome. 5
hepadnavirus, 5
(DHBV), 5
pregenome-encoding 5
Facilitating 5
Promoter-Proximal 5
Regions. 5
Kdm7b 5
overproduction-mediated 5
tretinoin, 5
forearms, 5
(Klu) 5
neuroblast. 5
(GMCs) 5
GMCs. 5
NBs. 5
Epigenetically-inherited 5
regions? 5
hospitalized, 5
CA10 5
TC-sequences 5
GA-sequences, 5
AC-, 5
TG-sequences. 5
GC-sequences. 5
d(GGA)n 5
d(GGGA)n 5
tetra-stranded 5
TC)(n) 5
UCSs, 5
Restricts 5
Blocked 5
Double-Stranded 5
(IL-2, 5
correlates. 5
1125 5
non-nucleosomal 5
-time 5
-space 5
bytes 5
RAM. 5
fast; 5
internal-memory 5
https://github.com/solonas13/maw 5
GPL). 5
alice.heliou@lix.polytechnique.fr 5
solon.pissis@kcl.ac.uk. 5
IVIG's 5
midurethral 5
pressure-associated 5
clarifies 5
(0.0625-1.0 5
velopharyngeal 5
cGAMP 5
Recruit 5
Ubiquitylated 5
CMG. 5
SUTs) 5
(cryptic 5
prompts 5
abp1 5
rrp6Δ 5
S288c, 5
Σ1278b, 5
JAY291 5
S.paradoxus 5
N17 5
groucho-related 5
Grg4 5
(ADCC). 5
TGFβR1, 5
(aNK) 5
23(3); 5
ATP-mimetic 5
SMAD2, 5
MED12-related 5
analyzing, 5
antifungals. 5
sterol-response 5
auto-induction 5
Upc2. 5
Ste12-binding 5
ergosterol, 5
Synesthesia 5
lateralization 5
α-like 5
PcircRNA_finder) 5
find_circ 5
Q3W, 5
Q3W. 5
ICP0-null 5
PMLIV 5
PMLV 5
E1B-55K 5
Coleoid 5
cephalopods 5
(octopus, 5
cuttlefish) 5
resourceful 5
cephalopod-specific 5
suckers 5
(hATTR) 5
Carcinoid 5
CaHD 5
transoesophageal 5
Hemangioma. 5
<12 5
ulceration, 5
tapering. 5
Osh7p 5
SWI2/SNF2-like 5
(HOMedU) 5
Fe(2+)/2-oxoglutarate-dependent 5
hydroxylases. 5
subSeq: 5
subsampling. 5
Subtype 5
ts 5
blepharophimosis. 5
[p.Arg1148His] 5
c.3493T>C 5
[p.Ser1165Pro]) 5
[p.His1729Asn]) 5
KAT6B 5
calculator. 5
paramedics 5
osteoporosis]. 5
BMD) 5
WHO, 5
advice/reassurance, 5
(DEXA) 5
MYO15A 5
TET1, 5
Med13 5
(Srb9) 5
Spt8, 5
subform 5
rpb4Delta, 5
(DNMT1/DNMT3B 5
(http://bioconductor.org/packages/release/bioc/html/psygenet2r.html). 5
juanr.gonzalez@isglobal.org 5
laura.furlong@upf.edu. 5
JAK3-mediated 5
JAK3-dependent 5
50-170 5
(HLA), 5
DR, 5
positivities 5
-DR, 5
DR1, 5
0.0069 5
positivity). 5
0.037; 5
morningness-eveningness 5
Jakinibs: 5
post-gastric-bypass 5
GARLIC: 5
Def1 5
dabigatran-treated, 5
45-64 5
65-80 5
(DE; 5
Dabigatran-prolonged 5
≥2.5 5
NCT01955720. 5
over-correction 5
DDX54, 5
immediate-to-early 5
RPE65 5
(TERRA) 5
Sir2/3/4 5
laesa 5
body; 5
(functio 5
laesa) 5
dolor). 5
ofloxacin, 5
Polyposis 5
Editrice 5
Gastroenterologica 5
S.r.l. 5
echocardiogram. 5
away, 5
imperfecta, 5
Masitinib 5
parent-of-origin-dependent 5
(IC1) 5
Mouse/human 5
(ICR), 5
Imprinting-Control 5
chs4 5
EBCall, 5
Mutect, 5
Virmid 5
cancer-normal 5
illumina 5
gc 5
mutect 5
Kummel 5
insufficiencies, 5
adulterants. 5
bandage 5
bandages]. 5
addicts. 5
Buprenorphine 5
(S1P1) 5
FTY720 5
immune-mediated, 5
positive-controlled, 5
(escalated 5
time-matched, 5
placebo-corrected, 5
(ΔΔQTcF). 5
113/124 5
(91.1%) 5
ΔΔQTcF 5
10-millisecond 5
ΔΔQTcF. 5
ozanimod's 5
low-fat), 5
(RP101988 5
[major], 5
[minor]) 5
(fed/fasted) 5
RP101075, 5
0.76-0.88). 5
≤2, 5
>1) 5
17.9% 5
crawling 5
borrelial 5
Reb1p, 5
Rap1p, 5
Abf1p, 5
(GRF) 5
Boolean 5
grf 5
rap1 5
>RESULTS</b>: 5
Auxin-inducible 5
mycoses. 5
porphyrins. 5
78-year-old 5
mycological 5
ointment, 5
tetracyclines, 5
Streptococcal 5
vulva, 5
january 5
december 5
(Ubx) 5
1129 5
Glioblastomas: 5
pseudopalisading, 5
fluid-filled 5
anti-c-kit 5
anti-p63 5
anti-Myb 5
fashions. 5
10p, 5
10q, 5
(Kufs' 5
mri 5
chromosome; 5
{der(22)t(11;22)} 5
karyotyping: 5
47,XX,t(11; 5
22)(q23;q11),+der(22)t(11;22)(q23;q11). 5
from; 5
q23 5
Ependymoma 5
methylation-induced 5
PPARG. 5
workflow: 5
Accessing 5
SRA, 5
GTEx. 5
metadata, 5
inclusive. 5
Novartis's 5
CD19-specific 5
CTL019, 5
KYMRIAH™ 5
(tisagenlecleucel), 5
CD19 5
Pennsylvania, 5
cd19 5
Kearns-Sayre 5
(KSS), 5
Lactic 5
Acidosis 5
(MELAS), 5
Ragged 5
ND4 5
LHON/MELAS 5
99mTc-HMPAO 5
(AtFKBP62) 5
Polarity 5
Looping. 5
4C-seq. 5
super-enhancer. 5
3d 5
hi 5
Interchromosomal 5
"DNA 5
codes" 5
(Put3) 5
Put3 5
I-targeted 5
kissing 5
alpha-chain. 5
Aalpha 5
RMC 5
embryonal, 5
destabilized, 5
proto-silencer, 5
STAR. 5
Cohabitation 5
telomere-proximal 5
STARs, 5
silencer-driven 5
multimerized 5
HPC 5
(saracatinib) 5
AZD0530, 5
Sum 5
100-125 5
(ATTR) 5
holoprosencephaly 5
TFNs. 5
OSA; 5
Stop-Bang 5
overnight, 5
rhinitis. 5
hRSV 5
hospitalisation, 5
siG12D-LODERTM 5
FOLFIRINOX. 5
(89%); 5
(10/12) 5
15.12 5
38.5%. 5
NCT01188785. 5
SGPT, 5
alcoholic. 5
AntimiR-122 5
Naturally, 5
M694V, 5
COL1A2. 5
eIF4A-III 5
immunostain 5
non-GAS 5
pharmacists. 5
1040). 5
703). 5
conditions-presence 5
dispensers, 5
1.03-2.23], 5
1.48; 5
1.11-1.99), 5
1.44; 5
1.09-1.91) 5
1.01-1.71). 5
0.75-0.93). 5
pharyngotonsillitis, 5
throats. 5
(spectrum 5
bias). 5
23-31%). 5
swollen, 5
(1,125-mg 5
.025. 5
(enzastaurin, 5
1.28; 5
1.65), 5
.13) 5
1.12; 5
.54). 5
AEs; 5
drug-related). 5
disease-related. 5
uc 5
crohn 5
jak 5
bHLH-PAS-containing 5
Nuclear/cytoplasm 5
1.4). 5
etiopathogenesis, 5
pityriasis 5
Centocor, 5
anti-p40 5
interleukin-12/23. 5
hPTH(1-34) 5
alectinib, 5
IAA6/IAA19 5
EgrIAA4 5
IAA9, 5
auxin-related 5
SlIAA15, 5
arf 5
taiaa1 5
ARF5/MP 5
mp 5
tashy2 5
taiaa7 5
thoracoomphalopagus 5
Ischiopagus 5
parapagus 5
twinning. 5
ischiopagi 5
Genome-Stability 5
Stapled-Peptide 5
(GLUT10). 5
Tortuosity 5
FOL 5
sp 5
basilicum 5
commune 5
FA-103 5
fluorescens 5
lycopersici, 5
Six6 5
foliage 5
procarbazine 5
human/computer 5
atlases, 5
(NIDCR) 5
atlases; 5
pancreatectomy. 5
GATA1/TAL1/LMO2 5
erythroid-expressed 5
(LCR)/β-globin 5
transcription-activation 5
Cas9-directed 5
manipulative 5
supination 5
Anti-Eosinophil 5
Trait! 5
humanised, 5
(FEV1), 5
Benralizumab--a 5
cytotoxicity--a 5
Anti-IL-5-based 5
(hmAbs) 5
hmAb 5
IL-5R) 5
IL-5-signaling 5
NAb 5
-0.21±2.62 5
-0.29±2.81 5
noninferiority; 5
P=0.85 5
14.6% 5
disjunctive-normal-form 5
(if-then 5
rules). 5
Fremanezumab-A 5
Antibody-Inhibits 5
Thinly 5
(Aδ) 5
Nociceptors. 5
inner-city 5
663 5
(Blount's 5
osteotomy. 5
vara). 5
fasciotomy 5
radiograph. 5
School. 5
(KKS), 5
(OAD), 5
DPOAEs 5
Kopetzky 5
(obscure 5
dysfunction). 5
SHHI 5
'live 5
'electronic 5
conversation. 5
least) 5
parasitism, 5
Genomes: 5
1-6-infected 5
all-oral, 5
(Belsomra®) 5
Belsomra®) 5
Ox1 5
Diuresis 5
CellMaps. 5
http://cellmaps.babelomics.org/ 5
https://github.com/opencb/cell-maps 5
Java. 5
jdopazo@cipf.es 5
transsexuals 5
subareolar 5
57.8, 5
135.0), 5
6.6) 5
45.9 5
+, 5
(Aβo) 5
Cseq-Simulator, 5
iCLIP-data. 5
(p=.020). 5
stranding 5
(BEV) 5
VOR 5
sweats. 5
pSS. 5
cryoglobulinemia 5
Postdonation 5
hyperprolactiaemia) 5
meta-gene 5
http://bioconductor.org/packages/release/bioc/html/RCAS.html 5
http://rcas.mdc-berlin.de. 5
cervids, 5
nelsoni), 5
moose 5
(BSE) 5
contagious, 5
BDA 5
Tc1 5
FGFR-associated 5
GIT 5
masse, 5
(SLEDAI), 5
BILAG 5
CXCL10 5
Cyp40 5
SEWS 5
Proadrenomedullin 5
non-CAP-LRTI 5
anesthesia/surgery 5
ERαAF-1 5
anti-TG2 5
pain-mediated 5
DBT. 5
Linehan 5
Flap 5
'Sun 5
'Kanota' 5
ASCUS 5
urealyticum 5
antigen/antibody 5
success; 5
Finkelstein 5
bellies 5
(EPB) 5
retinaculum) 5
(stretching 5
Gliding 5
proximal/distal 5
APL. 5
Brunelli's 5
Coal 5
Respect 5
Islamic 5
justice 5
Diffloop 5
https://bioconductor.org/packages/release/bioc/html/diffloop.html. 5
aryee.martin@mgh.harvard.edu. 5
bone," 5
"osteomyelitis," 5
"diabetic 5
foot" 5
1946 5
0.803); 5
1,666 5
(0.87) 5
(0.91); 5
atovaquone-proguanil 5
anti-inflammatory-dose 5
stifle 5
STIR 5
gonadectomized 5
Testis-biased 5
simulans. 5
ROCHE 5
454® 5
Caiman 5
latirostris, 5
Salvator 5
merianae, 5
Aegla 5
platensis, 5
Zilchiopsis 5
collastinensis. 5
pipeline; 5
nonexpert 5
transposase-accessibility 5
(REDUCE) 5
proportions, 5
DHX36 5
Symplekin 5
poly(A)-rich 5
poly(A)-tails 5
WMH 5
pleura. 5
Abandoned. 5
screening/prophylaxis/management 5
Rabies 5
metatranscriptome 5
polyphenol-rich 5
Cocoa 5
GWAS-enriched 5
multi-trait 5
ENCODE/Roadmap 5
Schizophrenia. 5
GTEx 5
transcription-factor-binding-sites 5
DNA-hypersensitive-sites. 5
haematomas 5
Macau 5
pathway-amplified 5
emm12, 5
ANTIGENIC 5
RELATIONSHIPS 5
STRAINS 5
HAEMOLYTICUS 5
ISOLATED 5
FROM 5
penicillins 5
shock-like 5
enteropathogenic 5
(actoxumab-bezlotoxumab) 5
Pax 5
domain-interacting 5
(PTIP), 5
PIGA 5
(GPI)-anchored 5
hck(-/-) 5
sealing 5
MRL-lpr 5
splenocytes 5
BRD3 5
variants), 5
AVC 5
Sost-/- 5
(pQTLs). 5
STARI 5
CLEAA 5
lonestari, 5
MIR155 5
E,4 5
E,6 5
Z)-decatrienoate 5
Pentatomidae), 5
Pentatomidae) 5
infectiosum 5
(g-HAT). 5
six). 5
funder, 5
5-10: 5
1-10: 5
1-7: 5
μL). 5
NCT01685827. 5
pre-screened. 5
(n=2). 5
-6·4% 5
(97·06% 5
-11·2 5
-1·6; 5
p=0·0029). 5
[81%] 5
[3%] 5
(TCZ) 5
tocilizumab. 5
Lemaître 5
Arntl 5
3:3. 5
GeneComp, 5
stored, 5
vBMD 5
W.Th 5
44%), 5
(n=61, 5
46%), 5
(n=14, 5
embolism-unlikely 5
(n=88, 5
embolism-likely 5
(n=46, 5
'solitary' 5
17-beta-hydroxysteroid 5
(HSD17B1) 5
Arg264Cys 5
P450, 5
XIX 5
genotype) 5
3.06; 5
1.21-7.74; 5
3.02; 5
1.08-8.43). 5
CYP19 5
NASs 5
thiosulphate 5
warfarin-induced 5
Calciphylaxis, 5
Calciphylaxis: 5
parathyroidectomy 5
NEDD8. 5
periostin-/- 5
H19-siRNA 5
outweighing 5
Dinutuximab, 5
"Pattern 5
Finder" 5
G4-forming 5
c10orf2) 5
unimolecular 5
circ-ABCB10, 5
circRNAs' 5
enlimomab, 5
antibody: 5
(ICAM)-1 5
2078 5
0·86-1·25; 5
p=0·364). 5
Short: 5
(RS-site), 5
Subdivision 5
LOX-like 5
hyaloid 5
post-sternotomy 5
sternum 5
implant-to-bone 5
KLK3e 5
Hbs1 5
(ADPR) 5
TRPM2-deficient 5
PhenCode 5
corporis, 5
antecedents 5
Df(4)C1-10AT, 5
[uncovered 5
PARK2 5
"TALE-iD", 5
abiding 5
nipple/areola 5
OXA-13 5
CTS-driven 5
CTCF-induced 5
affected; 5
tunnel. 5
(male, 5
GlaxoSmithKline), 5
(Famvir, 5
acyclovir. 5
(Famvir), 5
537insC, 5
shade 5
homozygotes/compound 5
beard 5
pheomelanin. 5
ColE1-containing 5
HIFPH2, 5
606425) 5
603349), 5
lowlanders. 5
IKAROS 5
(IKZF1), 5
Denisovans 5
(MAOA)-uVNTR 5
maltreatment 5
Students 5
c8.1 5
Neandertal 5
formalin-injected 5
ml/kg, 5
rule" 5
overruled 5
brucellosis, 5
biovar 5
brucellosis. 5
ExsA 5
exsA 5
R163Q, 5
(L48P, 5
R67W, 5
H70Y, 5
P72L, 5
S83P, 5
R151H, 5
S172I, 5
L206P, 5
T242I, 5
G255R, 5
P256S, 5
C273Y, 5
C289R 5
R306H); 5
C273Y 5
Polyphen-2, 5
PROVEAN 5
HEAT-repeat 5
B56γ 5
WNK4 5
KLHL3 5
PASA 5
EB-MD, 5
EBS. 5
palmo-plantar 5
EBS-generalized 5
FXIIIA 5
IgE-associated 5
fibrin-affinity 5
long-wave 5
AFLP 5
Tegumentary 5
Lanka. 5
antimony 5
viannia 5
Kharve, 5
warfarin-antibiotic 5
INR. 5
BORSA, 5
BORSA. 5
ST25 5
beta-lactamase-producing 5
sulbactam 5
4-kb-long 5
UTR), 5
miR-129-5p, 5
brain-enriched 5
miRNA-FOXP2 5
ileum. 4
European- 4
Chinese-descent 4
>4-fold 4
(rs2435357: 4
10(-43) 4
ancestry; 4
10(-21) 4
MCS+9.7. 4
norm 4
RVs. 4
RV. 4
NTN3, 4
sex-ratio 4
(M/F 4
4/1) 4
HC11 4
(AREG) 4
MEC 4
(TGFα) 4
Intergenic 4
34), 4
hypothesis-generating 4
(MFs) 4
epiregulin, 4
constants. 4
0.00002) 4
U73122 4
paracrine, 4
activities; 4
HLH-2 4
mig-6 4
migrations, 4
metalloproteases. 4
peritrophic 4
cytoskeleton-associated 4
fine, 4
sugars. 4
K562. 4
transcribed), 4
intron-removal 4
transcribed: 4
"co-transcriptional 4
splicing." 4
CoSI 4
spliced" 4
NONCODE 4
(lnc) 4
tRNAs, 4
TPA 4
osteoclast-specific 4
OPG. 4
BMMs 4
multi-nucleated 4
μg/dL-min, 4
miR-200c) 4
(FIGO 4
serum-derived 4
miR-145) 4
underexpressed 4
miR-103 4
Let-7 4
3.87 4
relapsed) 4
22-nucleotide 4
under-expressed 4
(p=0.011). 4
(QMG) 4
EuroQoL 4
0.626 4
0.286 4
0.782 4
thymectomy 4
RANKL-mediated 4
(ADT) 4
denosumab) 4
survival) 4
(hormonal 4
teriparatide, 4
Tool) 4
universal. 4
2011: 4
(CaP) 4
-0.11 4
achieve. 4
(EMA). 4
belimumab, 4
ipilimumab) 4
antibody-drug 4
(CRPC), 4
agents: 4
anti-catabolic 4
(EMEA) 4
alendronate, 4
(DXA) 4
men: 4
nomogram. 4
NTDs 4
53.90 4
(Dvl-1) 4
similarity) 4
(65%). 4
neoplastica 4
Bazex?]. 4
paraneoplasia 4
erythematosquamous 4
(acrokeratosis 4
(Bazex' 4
Soc 4
Fr 4
Syphiligr 4
72:182, 4
1965; 4
Br 4
102:301-306, 4
black, 4
adenopathy 4
(18). 4
1989). 4
Arteriopathy 4
Subcortical 4
Infarcts 4
R90C 4
Wildtype 4
myotome 4
polyubiquitinated, 4
Immunohistological 4
Jagged 4
liver: 4
-4). 4
Notch-2 4
epithelium; 4
(PSC) 4
ductules 4
neovessels 4
NOTCH4 4
JAGGED1 4
Antibody-mediated 4
(mCRPC) 4
mCRPC 4
(rPFS) 4
5047 4
placebo-treated), 4
mitoxantrone-prednisone: 4
hypokalemia: 4
15.90; 4
0.0008; 4
risk-ratio 4
2.29, 4
5.17; 4
docetaxel-pretreated 4
abiraterone-prednisone 4
cabazitaxel-prednisone 4
(mitoxantrone-prednisone). 4
enzalutamide-induced 4
orteronel-induced 4
ELM-PC 4
26%), 4
orchidectomy. 4
(>30%) 4
hyperlipasemia 4
hyperamylasemia 4
(Grades 4
P450-mediated 4
2B6, 4
3A4/5. 4
[I]/Ki 4
>0.1 4
(PBPK) 4
repaglinide, 4
(S)-warfarin 4
<1.25. 4
DDIs, 4
'non-inhibitor' 4
PBPK 4
naphthalene 4
1mg/kg 4
[TAK-700]) 4
castration. 4
chemotherapy-naïve, 4
97), 4
(-45.3 4
μg/dL) 4
Unconfirmed 4
causality; 4
17,20-Lyase 4
bio-distribution 4
Re-188 4
manners 4
Herceptin-treated 4
immuno- 4
(2+ 4
chelator. 4
tumor-to-blood 4
AWT-induced 4
ErbB3 4
AWT. 4
[(111)In]-labeled 4
DU145) 4
Her2, 4
RTKs, 4
radioimmunoconjugate 4
LS-174T 4
CA), 4
antivascular 4
Antitumour 4
25-fold 4
palliative. 4
palmitate-loaded 4
overexpresses 4
ACBCC 4
HER-kinase 4
HER3, 4
HRPC 4
nonresponding 4
CaP 4
level-dependent 4
HER-2-overexpressing 4
specimens; 4
intensity) 4
estramustine 4
=50% 4
Herceptin, 4
anti-HER2/neu 4
tumors; 4
(89% 4
18-fold 4
LNCaP, 4
BCL-XL 4
interchangeable 4
toxin-like 4
10-11 4
STX-0119 4
SeV 4
cMYC 4
OSKM 4
its' 4
(TAp73) 4
(4TF, 4
(Pou5f1), 4
Thomson 4
prioritizes 4
chromosome-by-chromosome 4
grand 4
Industrial 4
ambitious 4
biomolecules, 4
disease-oriented 4
urges 4
transparency 4
21,000 4
accomplishment 4
proteins" 4
Consortium. 4
Panx1. 4
Connexin43 4
coordination. 4
partners) 4
K(+). 4
Pannexin2 4
cross-sections 4
Paralichthys 4
olivaceus. 4
poPanx1, 4
hepatopancreas 4
retinae, 4
Ophthalmoplegia 4
electroencephalogram, 4
variant). 4
neurogastrointestinal 4
SHIFT 4
79.6 4
(87% 4
diastole 4
(BP). 4
≥70 4
minute, 4
HCN 4
(9.1%) 4
dysfunction) 4
=70 4
0.016) 4
30%). 4
Iva. 4
QRS, 4
beta-blockade 4
Kayser-Fleischer 4
ATP7B 4
chelating 4
(zinc, 4
extrapyramidal-pyramidal-dementia 4
HSD 4
pantothenate 4
HSD. 4
antemortem 4
T(2)-weighted 4
sign". 4
WD. 4
hypodensity 4
(RB) 4
Cotranscriptional 4
Eighty-seven 4
Digenic 4
FSHD1, 4
normal-sized 4
wheelchair-bound. 4
intraretinal 4
Ophthalmology 4
7-8 4
(<35 4
3.3-kb 4
HIN1, 4
Sat2M1 4
TG(CSQ) 4
expressional 4
(TG), 4
29%) 4
decayed 4
beating, 4
work-performing 4
125I-calsequestrin-binding 4
calsequestrin-affinity 4
overlay, 4
LC-MS/MS) 4
proteotypic 4
hydrophilic-interaction 4
bioanalytical 4
spectrometry: 4
(PE), 4
precipitation, 4
(10(-5) 4
H9C2 4
5-HT2 4
(dp/dtmax, 4
-dp/dtmax, 4
Vpm, 4
pre-treatment, 4
strip, 4
antishock 4
sympathomedullary 4
phenanthrenivorans 4
aerobic, 4
ortho 4
rRNAs. 4
R3.8 4
Antarctic 4
bromodomain, 4
brahma-related 4
BRD2, 4
acetyllysine-binding 4
unacetylated 4
factor). 4
(follow-up: 4
harvested, 4
nonpathological 4
GI) 4
(69.4%), 4
duodenitis 4
non-autistic 4
(27/36) 4
pancreaticobiliary 4
Symplicity 4
RSD. 4
procedure- 4
device-based 4
catheter-based 4
spillover 4
SYMPLICITY 4
HTN-3 4
(TIMP) 4
(NF-κB), 4
Ras/Raf/MAPK 4
malfunctioning 4
1/2, 4
kinase-specific 4
T91/T93 4
IL-1-induced 4
promoter-reporter 4
Stat1, 4
tylophorine-mediated 4
harmonization 4
N-Terminal 4
deactivated 4
beta). 4
erks 4
(Jnk), 4
Ser-63 4
cleaved, 4
(TAILS) 4
Vimentin, 4
galectin-1, 4
proteome-wide 4
arginine, 4
unpredicted 4
(NF2) 4
SHH-GLI1 4
AKT1-MTOR 4
p-STAT3 4
coverings 4
AKT1E17K, 4
subnetworks 4
individualizing 4
levetiracetam, 4
oxcarbazepine, 4
felbamate, 4
rufinamide, 4
(LCM), 4
(SPM 4
(R)-2-acetamido-N-benzyl-3-methoxypropionamide, 4
harkoseride 4
ADD 4
234037) 4
sound-induced 4
Frings 4
electroshock 4
(MES)-induced 4
kindling 4
6Hz 4
chemoconvulsants 4
pentylenetetrazol, 4
picrotoxin, 4
LOX-PP 4
tumorigenic, 4
FLI-1. 4
ESFTs 4
miR-mediated 4
examine, 4
FLI1, 4
(RNAseq) 4
(pMPCs) 4
RNA-277 4
[EWSAT1]) 4
pMPCs. 4
EWSAT1. 4
(HNRNPK) 4
HNRNPK-repressed 4
EWSAT1, 4
HNRNPK 4
EWS/FLI1- 4
Ewings 4
Y1 4
DPPs 4
NPY. 4
releasable 4
NPY, 4
22)(q24; 4
(Kd 4
"core" 4
bone-associated 4
sarcoma-transformed 4
(GSTM4) 4
(C3), 4
ε 4
TTP/HUS 4
mitomycin, 4
gemcitabine-induced 4
CFH 4
Shiga 4
C3b 4
I-mediated 4
bleomycin, 4
plasmapheresis, 4
Pneumococcal 4
one; 4
consuming. 4
Publicado 4
por 4
España. 4
recently: 4
index: 4
EVASYON 4
13-16 4
SPA. 4
stimulated, 4
(PYY) 4
24.2 4
(2.9) 4
Appetite 4
buffet 4
END 4
0.0005). 4
(15.7 4
high-carbohydrate 4
(35% 4
(PYY), 4
90-min 4
throughout. 4
exercise/control 4
'exercise-induced 4
anorexia' 4
exhaustion 4
exhausting 4
TGFß 4
autoinduction 4
Smad3, 4
TGFbeta-mediated 4
hRFC. 4
verified, 4
CLinical 4
CLEAN), 4
1.16, 4
LVO 4
ordinal 4
CLEAN 4
(ZGA) 4
(MZT). 4
nanog, 4
sox19b 4
pou5f1 4
pre-MZT. 4
Gynecology. 4
gynecology 4
laparoscopy. 4
sterilisation 4
intensifying 4
hospital-based, 4
[AOR=1.9, 4
(1.03-3.87)]. 4
gastroenterologist 4
355 4
study--Part 4
1992-2001. 4
5540 4
EM, 4
.025). 4
migraineurs, 4
EM. 4
QLQ-INFO25. 4
follow- 4
Psychometric 4
ultramarathon 4
postrace 4
HRV. 4
(before, 4
before: 4
after: 4
runner 4
post-race 4
(NT-proBNP), 4
top-level 4
psychophysical 4
45). 4
<0.001), 4
yr; 4
55.3 4
0.6). 4
estradiol-progestin 4
HRT, 4
2000-2002 4
20-69 4
progesterone) 4
Chicago 4
mail 4
oophorectomy 4
(CIs), 4
658 4
Self-monitoring, 4
web-based, 4
(SMARTLog) 4
anonymous, 4
publicity 4
4.16, 4
IHCA 4
self- 4
conflict. 4
Internet-based 4
thoughts, 4
histones: 4
non-redundantly 4
>97th 4
gestalt. 4
2.2-Mb 4
(n=37) 4
(n=13) 4
missense) 4
2184. 4
(lacking 4
3/6 4
B100 4
hyperlipidaemic 4
(Q4W), 4
(Apo 4
Q4W, 4
145): 4
1,359 4
(23.3% 4
Lp(a). 4
biopharmaceutical 4
(secukinumab, 4
necitumumab, 4
interleukin-17a 4
(lambrolizumab, 4
50.4% 4
52.1% 4
(lomitapide), 4
≥11 4
intention-to-treat. 4
fraught 4
dismantle 4
alirocumab, 4
hepatosteatosis, 4
flu-like 4
FH, 4
(Goal 4
Intolerant 4
monthly; 4
(1.9 4
(10) 4
elements' 4
Promiscuity 4
SUPRs 4
gene-associated 4
homeodomain-containing 4
ucRNAs 4
Lac 4
5-substituted 4
pseudosugar 4
(aka, 4
chondrosarcoma. 4
confident 4
relapses, 4
(PNET), 4
ultrastructural, 4
ESB. 4
ESB, 4
p30/32MIC2 4
highly, 4
(Mab) 4
HBA71, 4
HBA71. 4
O13. 4
anti-leukocyte 4
N-myc, 4
PN, 4
vismodegib, 4
BMS-833923, 4
MTDs 4
MF-related 4
(JAK2 4
V617F) 4
EXPERIMENTAL 4
crosslink-induced 4
kinase: 4
slow-down 4
SV40-transformed 4
cross-linker-induced 4
checkpoints. 4
typifies 4
extruding 4
encounter, 4
CG-rich 4
nontemplate 4
hybrid. 4
col 4
(CGG) 4
CGG) 4
FXTAS 4
55-200 4
CGG). 4
FMR1. 4
DNA:RNA 4
(DRIP) 4
(55<CGG<200 4
(DOX)-inducible 4
tomedical 4
974G>A 4
(p.Arg325Gln). 4
electropherogram, 4
(hemizygous 4
AIP-positive 4
wellknown 4
somatotroph 4
macroadenomas. 4
(FIPA), 4
CDKN1B, 4
20-40% 4
adult/elderly 4
19q13.4 4
21q22.1. 4
somatotrope 4
R304* 4
remission; 4
expertise. 4
macroadenoma 4
(<5%) 4
TNNC1-A31S, 4
A31S, 4
sensor, 4
inhibition). 4
(2008) 4
McTnC. 4
(1.9, 4
MB, 4
Dong 4
actoS1-ATPase 4
run-in, 4
credibility 4
sticking 4
(SP 4
Shen 4
Mouth 4
1.61, 4
somatotopic 4
non-smoker 4
half. 4
multiplied 4
Acetylated 4
H3K27me2 4
CENH3. 4
Glimpses 4
heterochromatinization. 4
Arabidopsis- 4
inactivation: 4
placental) 4
growing, 4
Cul4, 4
H3-Lys9 4
Suv39h 4
HIF-1α. 4
GV1001-treated 4
Th1-like 4
naive, 4
(830 4
Trial, 4
98·25% 4
oligomer-induced 4
(NSCs). 4
Aβ₂₅₋₃₅-injured 4
.05; 4
(GRVAC1), 4
(Vx-001). 4
(HSP90) 4
antitelomerase 4
temozolomide: 4
(78%). 4
6.6%). 4
CTCL 4
CD4/CD8 4
β-TrCP 4
(BAY 4
Skp1-Cullin1-F-box 4
NF-kappaB-activating 4
(HGF)/c-Met 4
MAPK/Akt 4
prostaglandins, 4
IκB-α 4
CAY10452 4
(Akt) 4
(H/R) 4
H/R 4
H/R, 4
FLIPL 4
factor/C-met 4
Akt2. 4
C-MET 4
PI3-kinase/Akt 4
kinase-Akt 4
(ADR)-induced 4
ADR, 4
Cell-surface 4
biotin-labeling 4
sunburn 4
c-met, 4
downstream-element 4
Anchorage-independent 4
substratum. 4
473. 4
HGF/ 4
(CDC) 4
radiography, 4
recourse 4
30), 4
oxygenation, 4
Réunion. 4
cohort-study 4
Ocean. 4
viremia. 4
wave. 4
0.79, 4
2009-2010 4
0.96) 4
score-matched 4
6642 4
profession. 4
adaptations, 4
(influenza 4
2.84 4
Pandemrix(®) 4
pandemics 4
A(H1N1)pmd09 4
(OR=1.41, 4
(TITF1) 4
"brain-lung-thyroid 4
syndrome", 4
whole-gene 4
2.6-Mb 4
(NK2 4
(SP)-B 4
(SFTPB 4
c.493C>T 4
(p.R165W) 4
c.786_787del2 4
(p.L263fs) 4
(ILD), 4
NKX2-1-p.L263fs 4
contrast,NKX2-1-p.R165W 4
WTNKX2-1, 4
SP-C 4
p.L263fs) 4
NKX2-1-p.R165W). 4
(SAR) 4
Tubulobulbar 4
spermatocyte 4
tubulobulbar 4
20- 4
50-nm 4
FRET-based 4
Control, 4
TENS-2 4
processively 4
limitless 4
N3'-->P5' 4
Tumor-initiating 4
Fluorescently 4
bolstered 4
anti-IL4R 4
"atopic 4
dermatitis" 4
antiasthma 4
pathophysiologically 4
abnormalities). 4
377 4
FGFR3) 4
triplication. 4
Craniosynostosis-associated 4
nell-1 4
Revisiting 4
Roberts 4
dysostosis 4
primer. 4
calphostin 4
(FGFR1, 4
-3) 4
breech 4
position) 4
(1994): 4
Dysmorphol 4
Cohen 4
polymicrogyria, 4
phocomelia 4
inherit 4
subclass, 4
T-UCR-based 4
multi-level 4
aberrancies 4
hemopoiesis 4
debut. 4
amended 4
Pfizer. 4
[Pendred 4
(PDS). 4
perceptive 4
pre-pubertal 4
complying 4
Actually 4
DFNB4 4
organification) 4
PCCL-3 4
tofogliflozin, 4
Hypertension. 4
misassignment 4
endoproteinase 4
LTQ-Orbitrap 4
(SC), 4
lit 4
674 4
Elite 4
tepidum 4
Cba. 4
expenditures. 4
Presumably, 4
podocin 4
fear-avoidance 4
(PAL), 4
FAR 4
pain? 4
t-tests 4
Back 4
tri-axial 4
in. 4
0.66). 4
14days 4
p=0.01), 4
lab-based 4
daily-life 4
LBP. 4
triaxial 4
7.5. 4
CPs 4
minute. 4
cross-correlation 4
(http://jaspar.genereg.net) 4
provided, 4
2014: 4
curated, 4
total). 4
acanthosis, 4
constitution. 4
(enamel 4
uncles 4
psoriasis-like 4
neuroichthyosis 4
eyebrows 4
deposition; 4
Blaschko. 4
577 4
(29.7%) 4
34T 4
[CYP] 4
(P-glycoprotein) 4
diphosphate-receptor 4
(G/A) 4
(MACE; 4
928 4
MACE. 4
carriers) 4
15.5%, 4
2011; 4
post-clopidogrel 4
aggregometry 4
(76.7%) 4
Redistribution 4
HSC70 4
(TFEB) 4
interleukin-1β, 4
PPARγ, 4
PGC1α 4
Peptidoglycan 4
slide, 4
differentially, 4
nucleoid, 4
hybridised 4
plate-based 4
cables 4
aminopropane 4
hexahydro-2-imino-4-pyrimidylglycyl 4
(epicapreomycidine) 4
urea-valine 4
>64 4
Rethinking 4
MurG 4
[Brötz, 4
Bierbaum, 4
Markus, 4
Molitor, 4
Sahl, 4
H.-G. 4
Chemother. 4
714-719]. 4
KM 4
[undecaprenyl-diphosphoryl-N-acetylmuramoyl-(pentapeptide)-N-ac 4
ety 4
lglucosamine] 4
moenomycin. 4
p-chlorobenzyl 4
LY264826 4
(A82846B) 4
L-[14C]lysine 4
microgram/ml, 4
UDP-muramyl-peptide 4
acyl-D-alanyl-D-alanine 4
acyl-D-alanyl-D-lactate 4
megaterium, 4
UDP-N-acetylmuramyl-pentapeptides 4
(UDP-MurNAc-pentapeptides) 4
1/100th 4
L-alpha 4
acid)-D-alpha 4
alpha-D-alpha 4
Gaffkya 4
homari 4
UDP-MurNAc-tetrapeptide 4
toluenized 4
ramoplanin, 4
transpeptidation. 4
(undecaprenyl-P-P-MurNAc-pentapeptide) 4
peptidoglycan-synthesizing 4
N-acetylglucosaminyltransferase-catalyzed 4
racemase 4
Middlebrook 4
hypersusceptibility 4
29213 4
peptidoglycan, 4
purine, 4
(global 4
Vorinostat, 4
self-evaluation 4
90), 4
permitted. 4
dose-intense 4
(anaplastic 4
27.3%, 4
nausea/vomiting 4
Grades 4
Rechallenge 4
<50% 4
=6 4
3%). 4
(EIAEDs). 4
(7%). 4
preoperative, 4
ml/min). 4
Carboplatin 4
atrasentan 4
rhinitis, 4
microinfusion 4
TGF-alpha 4
DT. 4
neutrophilia 4
glioblastoma) 4
(BIBF 4
9806). 4
9806 4
(MST) 4
0.95-1.46; 4
0.93]. 4
MST 4
0.73-1.36; 4
0.48), 4
1.17-2.27; 4
refusal. 4
(photosensitivity 4
Orthopaedic 4
ubiquitous. 4
distinguished: 4
Polarization 4
trichothiodystrophy). 4
trichothiodystrophy. 4
dysphonia, 4
ichthyosis. 4
IL17A, 4
IL17F, 4
2,3 4
dendritic, 4
pDC 4
(SFs) 4
transformed-appearing 4
Fibroblast-like 4
(SF). 4
CXCL8 4
CCR5 4
autoimmune-disease 4
autoimmune-related 4
high-inflammation 4
(PB). 4
meta-analyzed 4
0.81-0.97, 4
extraversion 4
tentative. 4
[Latin 4
Letter 4
E]-4 4
-0.34), 4
openness, 4
agreeableness. 4
Vulnerability 4
APA, 4
correlational 4
Discrepancies 4
DAT. 4
rating, 4
(MPT). 4
negatively, 4
diverting 4
antibodies), 4
CYP450 4
(temsirolimus 4
Akt-mTOR-p70S6K 4
p70S6K. 4
Akt-mTOR-p70S6 4
(sirolimus 4
(TOR-I) 4
2005) 4
reports) 4
(bevacizumab 4
cis-regulated 4
(eQTLs) 4
(RI) 4
ASE 4
resistance) 4
Eae23 4
lymphomas) 4
ES/pPNET. 4
ewing 4
FLI-1 4
cores. 4
One-step 4
promoters: 4
P2. 4
cohesin/CTCF 4
revealed: 4
diverse. 4
non-expressing 4
IGF2/H19 4
CTCF: 4
interleukin-3 4
cohesin-dependent 4
Sarcoma-Associated 4
LANA, 4
vCyclin, 4
vFLIP, 4
v-miRNAs, 4
Kaposin 4
reactivation, 4
regulatory. 4
glycyrrhizic 4
herpesvirus: 4
CTCF-cohesin-mediated 4
Glycyrrhizic 4
licorice, 4
LANA. 4
SPT5, 4
bait, 4
subtelomeres 4
complementation. 4
HCM-related 4
chamber, 4
LVOT 4
failure-related 4
MYBPC3, 4
TNNT2 4
4-8). 4
cyclic-AMP-regulated 4
transferases. 4
RSTS, 4
(RSTS) 4
demanding, 4
CREBBP. 4
undescended 4
RTS. 4
c.4134G 4
(KP4) 4
KP1 4
defeat 4
buffers. 4
self-immune 4
co-precipitate 4
complementarity, 4
CLIP, 4
systems-wide 4
wavelet 4
nucleotide. 4
PAR-CliP--a 4
RNA-RBP 4
RNA-RNP 4
(RIP-Chip) 4
(RRE) 4
(CLIP). 4
UV-crosslinked 4
non-crosslinked 4
nucleoside-labeled 4
4-SU, 4
6-SG 4
Hafner 4
mIU/L 4
remits 4
men), 4
levels), 4
pmol/l 4
(11.4 4
(VICON 4
Mx3+; 4
ViconPeak(®), 4
Oxford, 4
UK) 4
ViconPeak(®) 4
(Plug-In-Gait). 4
height) 4
walkway. 4
(Flexion/extension 4
(elevation 4
Upper-body 4
kinematics, 4
limbs; 4
peculiarity 4
Argininemia 4
pan-ethnic 4
raters. 4
knee, 4
raters 4
Reliability 4
83.33% 4
prenatal, 4
perinatal, 4
quadriplegia. 4
adducted 4
girls; 4
(dimensions 4
1-minute 4
equation: 4
(levels 4
PTPN11 4
(heteroduplex 4
Mis-sense, 4
non-sense, 4
(45/68) 4
DEAE 4
(His-Pro) 4
890 4
r3Cseq, 4
(outcome) 4
academics, 4
(R495X) 4
R495X 4
(H517Q) 4
(R521G) 4
FUS-mediated 4
NMJ. 4
MAP1B, 4
microtubule-dependent 4
TDP-43-mediated 4
co-deposit 4
fALS 4
FTLD-FUS 4
FUS-opathies. 4
sarcoma-positive 4
(fALS), 4
atg5(-/-) 4
autophagy-dependent 4
nucleus-cytoplasmic 4
(NLS), 4
Proteins. 4
Tenascin 4
(TGF)-beta, 4
(IL)-10, 4
intramyocardially. 4
preprogrammed 4
connexin-43, 4
NKx-2.5 4
TGF 4
temperament 4
handicap. 4
matters: 4
(females) 4
(males). 4
(Emax) 4
3,4-dihydroxy-l-phenylalanine 4
(levodopa) 4
3-O-methyldopa 4
(entacapone 4
(placebo), 4
Opicapone, 4
eluates 4
(essentially 4
spectrometry) 4
papain 4
arrival, 4
unesterified 4
Glycoproteins 4
Man-6-phosphorylation 4
EWS/FLI. 4
NR0B1. 4
EWS/FLI-dysregulated 4
cytoplasmically 4
PARC 4
Origin-less 4
RadA, 4
eukaryal 4
ATP-bound 4
Pyrobaculum 4
(core) 4
Bacteria, 4
synchronously 4
denser 4
acidocaldarius 4
579 4
Orc1/Cdc6 4
crenarchaeal 4
multigeneration 4
MTF 4
16q21-13 4
(FC), 4
disfiguring 4
appendageal 4
DKK2 4
bilayered 4
c.2041+1 4
GLI1-dependent 4
cHL, 4
16q12-q13. 4
participants; 4
exonization, 4
(IVS12 4
G-->A) 4
NAIP 4
H4F5, 4
H4F5 4
self-oligomerization 4
norm. 4
Cape, 4
non-targeted 4
vaccinia-related 4
VRK 4
TSC3. 4
WST-1 4
metamorphosis. 4
synaptogenesis 4
Ca2+/calmodulin 4
ERK2, 4
kinase-negative 4
multiplies 4
untransformed 4
KN-92-treated 4
pan-caspase 4
Ca(2+)-independent 4
norepinephrine-induced 4
(MAP 4
(VSMC). 4
dissipated 4
PXT3003 4
pictures. 4
T118M 4
Charcot 4
echo 4
multiple/familial 4
non-sense 4
Surveying 4
corroborates 4
leaking 4
FERM 4
anti-KRIT1 4
interpolar 4
strongly; 4
(ICAP1 4
angioma. 4
20-like 4
(CCM1), 4
ccm3 4
STKs 4
(CCM1). 4
KRIT1/CCM1 4
(krev 4
1/cerebral 4
MEKK3 4
(CCM2/malcavernin/OSM), 4
3/programmed 4
(CCM3/PDCD10). 4
quantified, 4
[Cerebral 4
7q, 4
hormone-specific 4
grounds 4
(1-2 4
(I/R). 4
3,5 4
18%) 4
Thyroid-stimulating 4
thyroid-related 4
80-mg 4
lighter 4
beta-adrenergic-mediated 4
midline. 4
multiloculated 4
nerve-root 4
ganglion, 4
endoneurium. 4
scanty 4
cramping 4
myelography. 4
drained 4
ganglion. 4
triglyceride. 4
(-0.18 4
(peak) 4
lipophilicity 4
DPP4. 4
placebo/active 4
1.19[1.03; 4
1.37]; 4
(monotherapy 4
metformin), 4
-0.56% 4
'dutogliptin', 4
'vildagliptin' 4
'metformin'. 4
0.0001]; 4
(0.25, 4
Plots 4
error. 4
nonlinear, 4
(BI 4
plasmin, 4
467 4
hypoglycaemia. 4
r(2) 4
1.30; 4
insulinotropic 4
(<1%). 4
55.3% 4
(1.1%). 4
(1)H-NMR-based 4
LPL, 4
invoke 4
protriptyline 4
fluoxetine. 4
P=0.007), 4
Research; 4
nontraumatic 4
(levodopa, 4
baclofen 4
6-18 4
PK-Merz 4
neurocognitive, 4
(valproic 4
electroconvulsive 4
enrollment). 4
suggestive, 4
dantrolene, 4
hemozoin 4
5A/6A 4
5A/5A 4
0.039). 4
metalloproteinase-2. 4
(LDGs) 4
anti-MMP-9 4
LMAN1 4
Gelatinase 4
trimers. 4
MMPs. 4
Hyperosmia 4
gender- 4
Affective 4
lincRNAs. 4
~20 4
(binding 4
serotypes, 4
(MBA) 4
serotypes. 4
provinces. 4
bioassay, 4
AB. 4
BoNT/D 4
BoNT/D-HCR. 4
Botulinumtoxin 4
notifiable, 4
ding 4
Kerner 4
Scott 4
spasm. 4
penetration. 4
prodrugs 4
plasma-based 4
Parkinson`s 4
advancing, 4
α-Syn. 4
crowns 4
(figure), 4
hypogonadism). 4
hypodontia. 4
syndrome); 4
LO. 4
allelic. 4
"core 4
matrisome" 4
Completion 4
stroma-derived 4
bioinformatically 4
GAGA-factor-binding 4
HS1, 4
860-bp 4
230-bp 4
chromatin-specific 4
nuclease-hypersensitive 4
HS3. 4
Polycomb-dependent 4
mini-white 4
Pho 4
Glaser, 4
S.C.R. 4
Elgin, 4
J.T. 4
Lis, 4
regulation: 4
(MET1, 4
high-copy 4
GATC 4
cells? 4
1kb 4
Met1-5 4
Met2-21 4
'mantled' 4
calli 4
early-passage 4
CENPA, 4
Cenpa-GFP 4
H3-like 4
Mad2 4
Cenpb 4
Cenpc, 4
poly(ADP-ribosyl)ated 4
CENPI 4
sliding, 4
hypermethylated, 4
H3-lysine9-dimethylation 4
non-CG-context 4
introgressed. 4
protein-induced 4
(CHD7) 4
imbalances. 4
Ecuador 4
SDS-polyacrylamide 4
CHD8. 4
coprophila. 4
ScoHET1/ScoHET2 4
histomorphologic 4
H1.4 4
G9a). 4
BRK 4
helices. 4
HOXA 4
5-azadeoxycytidine 4
Cbx2, 4
Cbx4, 4
Cbx6, 4
Cbx8. 4
K9me3. 4
Chloroplasts 4
(cpSRP). 4
cpSRP 4
54-kDa 4
43-kDa 4
(cpSRP43). 4
(CD1, 4
CD3) 4
CD3. 4
cpSRP54. 4
cpSRP54-cpSRP43 4
(EMSA) 4
restructuring 4
protozoa. 4
HATs 4
plentiful 4
Clr8 4
Clr8, 4
MORF4. 4
MORF4 4
MAF2 4
beta-sandwich 4
(Protein 4
interdependent. 4
Mi-2 4
dermatomyositis, 4
Gata3 4
(Chd4) 4
(CHD4), 4
transacting 4
Chromodomain-helicase-DNA-binding 4
1p36, 4
light-mediated 4
Cdyl-/- 4
Nilaparvata 4
lugens 4
Radical 4
mb-1 4
(CHD1L) 4
coefficients. 4
E12.5 4
phosphorylation) 4
hHP1β 4
assigns 4
Rpd3S/Sin3S 4
PHD1 4
S473A 4
HP1-β 4
Stimulated 4
45S 4
CHD7L 4
PS1. 4
differentiation-dependent 4
self-primer 4
CBX2 4
BRIT1 4
mrg-1 4
5-aza-dC 4
(P=0.03), 4
non-PC 4
GLP. 4
protocol: 4
Chd7(Gt)(/+) 4
Chriz 4
LSCC 4
(GCs) 4
Pre-messenger 4
cotranscriptionally. 4
Swi6/HP1. 4
homodimerization, 4
nucleosome, 4
suspicion. 4
interruptus. 4
intra-aortic 4
waxed 4
anti-arrhythmic, 4
Estudio 4
propafenone 4
1960's 4
1970's 4
seeds, 4
tachyarrhythmia. 4
hepatotoxicity, 4
radiating 4
(MF) 4
(LA) 4
(7%+/-7% 4
P=0.5). 4
2.39, 4
6.58; 4
delayed-enhancement 4
(61.5%) 4
Usefulness 4
(CE-CMR) 4
CE-CMR, 4
Scar 4
mid-myocardial 4
>7 4
Bulgaria, 4
Bulgaria 4
Viruses 4
pestiviruses 4
fragment-based 4
barrier: 4
Guanidino 4
creatine, 4
phosphocreatine, 4
methylguanidine, 4
guanidinosuccinic 4
γ-guanidinobutyric 4
β-guanidinopropionic 4
guanidinoethane 4
α-guanidinoglutaric 4
(BCSFB) 4
(CRT/solute 4
6A8) 4
(TauT/SLC6A6) 4
TauT/SLC6A6) 4
OCT2 4
paraquat. 4
TIEG1. 4
sanctuary 4
Nmyc 4
(BMP2) 4
12.03 4
Dairy 4
SiRNA 4
Hep3B, 4
OLI-neu 4
mitochondria-shaping 4
metastasizing 4
(mitofusin 4
progresses. 4
A11 4
Yme1. 4
m-chlorophenyl 4
hydrazone 4
prohibitins. 4
(mitochondrial 4
lilR3 4
fragmented, 4
midgestation 4
define, 4
wide-field 4
microscopy) 4
A-kinase 4
disruptor 4
Dopa 4
system). 4
BMS, 4
(0.8%), 4
-PTEN 4
PI3KCa- 4
CS-like 4
as-yet 4
10q23.3, 4
Cowden's 4
polymerase-chain 4
I-III, 4
34.5% 4
(vehicle 4
19). 4
penumbra, 4
(MND) 4
atovaquone 4
Borreliosis 4
ALS: 4
polypeptide) 4
burgdorferi. 4
capsules. 4
[62%] 4
8-9 4
RxPONDER 4
(SWOG 4
S1007) 4
Mamma-Print 4
randomizations 4
IndiviuaLized 4
survival-ductal 4
(IDFS-DCIS) 4
11-25. 4
RSs. 4
TAILORx. 4
high-risk. 4
pleomorphism, 4
BAG1 4
climbers 4
(P<0.05); 4
(SCE) 4
(fT4), 4
jumps 4
untrained 4
(T4 4
scant 4
regulons 4
cholangiocarcinoma, 4
(df 4
(1.7%) 4
upstream; 4
four-repeat 4
loci), 4
c.40_42delAGA 4
low-voltage 4
elude 4
(Genetics 4
Disease; 4
http://www.clinicaltrials.gov/ct/show/NCT00138931?order=1; 4
NCT00138931) 4
mutant-PLN 4
superinhibition. 4
nonreversible 4
T116G 4
(L39stop), 4
naturally-occurring 4
(PLN 4
PKA-mediated 4
contraction/relaxation 4
performances. 4
excess, 4
supplementations 4
(FRAP), 4
(IL)-8 4
rowers. 4
(correlation 4
(SH), 4
P<0.01, 4
presented: 4
8-hydroxy-2'-deoxyguanosine 4
stress-associated 4
repetition 4
MDA. 4
rhamnosus 4
paracasei 4
Antioxidative 4
retinol, 4
(GPx) 4
low-calorie 4
protein-isolate 4
non-trained 4
charging, 4
complementation, 4
(p.Ser581Leu) 4
GARS-mediated 4
hGlyRS 4
(GlyRS), 4
NMJs 4
lumbrical 4
>A, 4
7p. 4
tRNA(Gly) 4
(dHMN-V). 4
neuronal-specific 4
viability; 4
multi-spectral 4
observer. 4
c-means 4
Homotopy 4
threshold-based 4
Slides 4
cells/tissue 4
Relocation, 4
immunophenotyped 4
CD133; 4
ZNF217 4
(HMTases), 4
X-Y 4
EBV, 4
B95-8 4
H3K9me2/me3, 4
(DZNep), 4
drug) 4
P16, 4
(DNMT1 4
G9a) 4
REST, 4
HMTase. 4
Set 4
Suv39 4
non-centromeric 4
Revesz 4
characterised; 4
IBMFS. 4
IBMFS, 4
smoking). 4
antithymocyte 4
(BMF) 4
+21 4
E6/E7 4
population), 4
development) 4
age). 4
miR-21-targets 4
ECM- 4
TGF-β-signaling-related 4
variance), 4
TGF-ß 4
Ad-GFP, 4
(miRNAs 4
miRs), 4
(∼18-24 4
nucleotide) 4
miR-24, 4
-92a, 4
ischaemia-associated 4
I/R-triggered 4
Controversial 4
TMEM49 4
cardiac-enriched 4
Sirt-1, 4
miR-320 4
IP-mediated 4
pre-miR-21. 4
Mirn21) 4
sprouty 4
(Spry1). 4
antagomir 4
(antagomirs) 4
enforcement 4
cancer-linked 4
repair: 4
Bmi1. 4
gammaH2AX, 4
ablates 4
γ-tocotrienol-induced 4
LC3-II, 4
[tumor 4
0.01] 4
angiopoietin 4
chemoresistant 4
(NSE), 4
(LC3-II) 4
GFP-LC3 4
clean 4
(PM) 4
sIBM 4
HBD-3 4
PM. 4
beclin 4
normo- 4
MAPK-dependent 4
Iron, 4
vacuolation 4
Anti-tumor 4
SLAM/CD2 4
self. 4
pathogens: 4
~3 4
Neu5Gc-epitopes. 4
sialoglycan 4
hypothyroidism/Hashimoto's 4
Mann-Whitney) 4
(paratope) 4
chemoenzymatically 4
(Neu5Ac)-containing 4
(differing 4
atom) 4
xenoreactive 4
Neu5Gc-deficient 4
xenotransplantation 4
(NOACs)--apixaban, 4
rivaroxaban--have 4
complicated: 4
wary 4
(FIIa) 4
FVIIa 4
Fondaparinux 4
(prevention 4
"real-life" 4
practice) 4
daltons. 4
usage; 4
>75 4
drug-food 4
NOACs, 4
enoxaparin, 4
(phosphenolpyruvate 4
(PRD) 4
PagR 4
S-layer 4
Qbeta 4
(mol. 4
Esigma(70) 4
Esigma(38) 4
liposarcoma) 4
pragmatic, 4
(174 4
paucisymptomatic 4
Submicroscopic 4
cnLOH 4
IFN-γ-producing 4
(MDSs) 4
(MDS/MPN). 4
(TET2) 4
0.049, 4
(ENS). 4
distended 4
(NCC). 4
(Chr7:83634610A→T) 4
rs797821 4
newborns) 4
p<0.05 4
(33.3%) 4
IND 4
ventriculo-peritoneal 4
settlement 4
HSCR-associated 4
RET-CDS 4
F961L 4
estimations, 4
bilious 4
(short-segment 4
cysteine-90 4
(C90R). 4
(Fanconi 4
complementing) 4
(55.5%) 4
pre-incubation 4
endotoxemia 4
sphingolipids. 4
leap 4
types; 4
caveolae. 4
palmitic 4
oleic 4
EHD2 4
lens. 4
marginalization 4
baculovirus-infected 4
peristromal 4
chromatin-localizing 4
relocation, 4
chromatin-exclusive 4
lineage-affiliated 4
cohesin-regulated 4
space: 4
(CTs) 4
Zirbel 4
&quot;closed&quot; 4
mol/L) 4
repeated. 4
L-thyroxine, 4
-3.3 4
TRIM5α. 4
VCE 4
splA 4
"SPRY-only" 4
PRY/SPRY 4
PRY/SPRY, 4
Trim50 4
neuritogenesis. 4
B-box 4
neuritogenesis 4
B30.2/SPRY 4
blastomeres 4
Apparently, 4
(RyR 4
amplifying, 4
vies 4
non-transitive 4
tractable, 4
space' 4
high-false-positive 4
separators 4
FusedTriplets 4
MosaicFinder 4
address: 4
http://sourceforge.net/projects/mosaicfinder. 4
neighborhood, 4
EXplorer 4
interactively 4
Phydbac2, 4
non-similarity-based 4
Phydbac2. 4
prediction: 4
sub-network. 4
prokaryotes), 4
precomputed 4
category: 4
(DBHS) 4
(RRMs), 4
NONA/paraspeckle 4
Crystallography. 4
relocates 4
coregulators, 4
myometrium 4
corepressor, 4
progesterone. 4
PR-mediated 4
WNT5A 4
deubiquitinases, 4
AML1 4
AME 4
D4, 4
blood; 4
ctf8 4
(CRC), 4
determined; 4
(Bcl-2) 4
unfit 4
75), 4
[31%] 4
[19%]), 4
4.0. 4
(BRCA1/2) 4
platinum; 4
31.6) 4
193; 4
38.1), 4
23.9), 4
43.7), 4
eight; 4
84.3) 4
47.4), 4
47.7), 4
59.9), 4
57.3), 4
65.1) 4
Difference 4
Poly 4
(PCNA). 4
T₄, 4
rT₃, 4
daughter) 4
skill 4
Compensatory 4
RhoA/Rho-kinase 4
Y-27632, 4
PI-3K 4
Ras-transfected 4
Y-27632 4
tetramerization 4
eGFP 4
AMPA-Rs 4
(along 4
CANVAS 4
8.2%, 4
0- 4
6-h 4
g; 4
RaO. 4
<6% 4
(960 4
2.12 4
pg/mL. 4
IV: 4
Na+, 4
increase; 4
pmol/L; 4
2.5; 4
Sensitivity, 4
ng/dL, 4
(FHC). 4
CALR3 4
(Lys82Arg, 4
Arg73Gln) 4
(Leu39Ter). 4
(DAR) 4
factories, 4
sub-pathways 4
(gg) 4
(DNA-PKcs), 4
DHFR 4
(ChIP). 4
cross-links, 4
GGR. 4
Comet-FISH 4
XP 4
HCR 4
fluences 4
subpathways: 4
(transcription-coupled 4
TCR) 4
6-4 4
(GGR), 4
UvrAB* 4
8-oxoguanine, 4
(bFGF), 4
BRCC3 4
(moyamoya 4
angiopathy. 4
17q25-ter 4
graying 4
puff 4
approximated 4
17q11.2 4
classifications: 4
logarithm 4
races 4
microduplications 4
12p. 4
-418 4
Pathologically, 4
stenosed 4
Multifactorial 4
6q, 4
428 4
8q23 4
Willis) 4
Japanese. 4
equipment, 4
magnetic-resonance 4
Angiography 4
hemiplegic 4
(NIDDM) 4
spliceosomes. 4
NOL1 4
(P120) 4
shaking 4
CG-MD 4
hIgG1. 4
fermentation, 4
nonpolar 4
preparation), 4
Clofazimine 4
culture-negative 4
mycobacteriophage 4
TM4, 4
endobronchial 4
pus 4
rifabutin, 4
bronchoscopy 4
excavated 4
(AIDS) 4
32.0 4
TRAPS 4
focus. 4
two-month 4
fibrino-purulent 4
effusive 4
parenterally 4
Tuberin, 4
(TSC2), 4
tuberin-hamartin 4
estrogen-containing 4
spirometric 4
AMLs, 4
rashes, 4
Ifn 4
(perivascular 4
tumors). 4
melanogenesis-related 4
PEComas, 4
(Spt-Ada-Gcn5 4
post-translational, 4
"marks" 4
reposition 4
activation-related 4
Ioc2 4
Ioc4, 4
Ioc3, 4
Isw1. 4
light-regulated 4
spt5 4
Fluorouracil, 4
Rico. 4
axilla, 4
taxane-anthracycline 4
FEC(90) 4
chemotherapy: 4
Locoregional 4
monochemotherapy 4
(5FU) 4
(44.6%) 4
(44.7%), 4
anthracycline-containing 4
(+ 4
G-CSF) 4
granisetron 4
74%, 4
anthracycline-naive 4
mg/m(2)); 4
MBC, 4
(SEQ 4
SEQ 4
premenopausal, 4
(Pharmacia 4
Italy) 4
(Asta 4
Frankfurt, 4
(75) 4
10.2%, 4
D22S1 4
D22S15, 4
inotrope 4
(0.8 4
microg.kg(-1) 4
0.113 4
46%; 4
ng/dL] 4
P<.001) 4
requirements; 4
microgram/kg), 4
justifying 4
accesible 4
http://genome2.ugr.es/cisminer. 4
Computationally 4
ChIP-information 4
Faced 4
Decoding 4
vasculogenesis 4
anti-angiogenesis 4
MLN4924-mediated 4
on-target 4
rationales 4
adduct, 4
NAEβ. 4
CRLs. 4
KLF5, 4
CD40L-expressing 4
stroma-mediated 4
Noxa 4
Rbx1 4
NEDD8-targeting 4
p21(Waf1), 4
p21(-/-) 4
radiant 4
quicker 4
tumor-selective 4
µM. 4
Ma, 4
Wu, 4
UAE 4
E1-E2 4
Ca(2+)-affinity. 4
203-245 4
16-22 4
GST-HAX-1, 4
glutathione-matrix, 4
His-HAX-1 4
GST-PLN. 4
SERCA2a/PLN 4
575-594 4
203-245. 4
active/inhibitory 4
Gm 4
restrictions, 4
36th 4
Conference. 4
coaches 4
sizeable 4
mandating 4
still, 4
disqualification 4
70-Gene 4
Receptor-Positive, 4
HER2-Negative 4
$$ 4
pT1c-3, 4
pN0-1a, 4
(AOL). 4
AOL, 4
AOL 4
DX(®) 4
MammaPrint(®), 4
Remarkable 4
low-genomic 4
prognosis-signatures. 4
(0/23), 4
29/144 4
Group: 4
(EWG) 4
chemotherapy), 4
prevented). 4
EGAPP-commissioned 4
summaries, 4
(JIP) 4
JNK2α2 4
JNK1α1 4
JNK1α 4
(JIP3) 4
JIP1 4
JIP2 4
JNK-containing 4
M3/6, 4
SAPKbeta 4
8] 4
hippocampi 4
JIP-1 4
(IgSF) 4
IMGT-ONTOLOGY 4
structures: 4
L2, 4
(25OHD) 4
(1985 4
PEDro 4
(fallers) 4
institutionalised 4
wearers 4
trials). 4
714 4
0.42, 4
institutionalized 4
25(OH)D, 4
femur. 4
Hypercalcemia 4
Exacerbations 4
Singapore. 4
<.001). 4
(9.5%) 4
39.9% 4
Anorexia 4
Nutritional 4
11-item 4
127) 4
55) 4
underweight, 4
overweight. 4
certified 4
(5-ALA, 4
Neurología. 4
eloquent 4
(pre)malignant 4
Levulan 4
ALA-methyl 4
Metvix 4
ALA-hexyl 4
Hexvix 4
Immunity, 4
(iPledge) 4
1743 4
tiredness, 4
effect(s) 4
failures, 4
3-5%, 4
stopping, 4
1%). 4
Isotretinoin, 4
data), 4
MED-ECHO 4
(hospitalizations) 4
ISQ 4
(births 4
1984-2002, 4
(date 4
40.1). 4
isotretinoin; 4
moisture, 4
1982. 4
60-day-old 4
group--1 4
group--vegetable 4
amputated. 4
palates 4
reminiscence 4
isotretinoin-treated 4
(all-trans-RA) 4
all-trans-4-oxoRA, 4
13-cis-4-oxoRA 4
g-1) 4
(0.66 4
Retinoids 4
All-trans-RA 4
(Macaca 4
h/ml 4
(GD 4
beta-glucuronide 4
GDs 4
Tigasone 4
(etretinate, 4
TIG) 4
Roaccutane 4
ROA), 4
7-9 4
TIG 4
ROA 4
(52, 4
anti-BrdU. 4
crests. 4
mesodermal-endodermal 4
focusing, 4
anlagen 4
(13-cis-RA, 4
pyknotic 4
40-hr 4
25.6; 4
57.5). 4
Monoubiquitination 4
auto-ubiquitination 4
p53-p300 4
BAX, 4
Mdmx, 4
MDM2-dependent 4
MDMX 4
subsides. 4
HDMX, 4
intercalator, 4
DNA-incising 4
follows. 4
(m-AMSA, 4
anthraquinones 4
aloe-emodin 4
DOX, 4
DOX. 4
AQ4 4
NAT2 4
727357 4
Design, 4
morpholinyl 4
doxorubicins, 4
(L1210) 4
SER 4
drug/topoisomerase 4
complexes) 4
4'-(9-acridinylamino)methanesulfon-m-anisidide. 4
Amiloride 4
complex" 4
orientations, 4
Amsacrine 4
IIβ 4
II-DNA 4
non-intercalating 4
cross-resistant 4
Ho33342 4
S3 4
TOPO 4
microRNA. 4
3'untranslated 4
patho-mechanisms 4
(status 4
target(s) 4
biofluids 4
anti-miR-132 4
(antagomir-132) 4
HSV-infected 4
NMDA-regulated 4
miR-124, 4
(PTBP2), 4
miR-132/PTBP2 4
Micro-RNA 4
Micro-RNAs 4
surpass 4
TaqMan(®) 4
-based 4
TGFβ, 4
(miR-10a, 4
-10b, 4
-212, 4
-132, 4
-495) 4
(miR-132) 4
miR-132-recognition 4
miR-124a, 4
miR-219 4
micro-RNA-mediated 4
(GLAST) 4
somata 4
pillar-cell 4
modiolar 4
(EAATs) 4
GTRAP3-18. 4
RTN2B. 4
EAAC1) 4
(<10%) 4
ecgltP 4
mGluRs 4
transporter-1), 4
monosodium 4
EAAT3 4
transporters) 4
GltPh, 4
SLC1 4
Q386E 4
A382T 4
T459R 4
Internalization 4
HBMEC 4
linker, 4
N206S 4
sodium. 4
coculture, 4
Git1/2 4
(SNX27), 4
DGKζ 4
early/recycling 4
combinations). 4
0.69% 4
EST-verified 4
120-fold 4
resorting 4
near-infrared 4
Staining 4
boiling 4
CyDye 4
coomassie 4
brilliant 4
silver' 4
conjugates, 4
(small, 4
binding) 4
(vWF), 4
vWF. 4
oligonucleotide-based 4
thioaptamer, 4
monothioate-modified 4
(AMD). 4
subfoveal 4
transfect 4
cell-binding 4
(Musa 4
cross-reaction 4
cubense. 4
volatiles 4
(FOC), 4
f.sp. 4
Caused 4
1876, 4
menadione 4
oxysporum. 4
anthropologic 4
17-year 4
herniation, 4
narrowing, 4
dyssynostosis 4
triradiate, 4
Benz," 4
bossing 4
Cytometry 4
(NT-3) 4
down, 4
(48%). 4
IGF1 4
Dephosphorylation 4
myristoylated 4
GNP 4
Aurora-A, 4
miR-193a, 4
miR-224/miR-452 4
miR-182/miR-183/miR-96 4
disabled. 4
(TGF-β)-stimulated 4
TGF-β-stimulated 4
clinically-relevant 4
Twist1-induced 4
Epithelial-Mesenchymal 4
Podosome-like 4
comet-embedded 4
Podosomes 4
podosome-like 4
podosomes. 4
Tensin 4
'Cancer' 4
genomes/exomes, 4
cross-talk, 4
conserve 4
(qPCR), 4
MCC 4
27.7% 4
(GRB) 4
DCGs 4
adjusts 4
CNAs. 4
μm, 4
spacing. 4
erroneously 4
homeostasis; 4
(EF) 4
AMIO-ON 4
23.8 4
questionnaire-based 4
(62%vs. 4
wk). 4
TR-alpha1 4
3,3'-triiodothyronine 4
signaling-mediated 4
(TH)-responsive 4
(MyHC) 4
hypothyroid- 4
beta-MyHC 4
hypothyroid-like 4
TH-responsive 4
TCE, 4
(Schäfer 4
ethnicities 4
HSRs. 4
8.6, 4
0.039, 4
(HFrEF), 4
HFpEF, 4
HFrEF 4
HFpEF. 4
strides 4
HFPEF, 4
exertion, 4
Improve 4
65.2 4
hs-CRP, 4
hypothyroid. 4
-0.54, 4
non-traditional 4
'higher' 4
Low-T3 4
(leucocyte 4
LCA), 4
CD10. 4
CD43. 4
immunotherapeutics 4
RAB25, 4
link. 4
portrait 4
presurgical 4
open-field 4
AMLs. 4
Taylor's 4
(tuberous 4
1830 4
Elotuzumab, 4
321 4
molecule-F7 4
(SLAMF7, 4
CS1, 4
CD319, 4
CRACC) 4
SLAMF7-expressing 4
PBL/myeloma 4
co-cultures. 4
QT-interval 4
bedaquiline. 4
undermine 4
rifamycins 4
microbiology, 4
2004-May 4
antiretrovirals. 4
unlikely. 4
urticaria. 4
test]. 4
non-cardioembolic 4
52%) 4
2.69, 4
extragastric 4
mimicry, 4
(significant 4
P=0.001). 4
(56.3%) 4
0.27; 4
gene-A-bearing 4
(CagA)-bearing 4
immunoassays) 4
(114/190; 4
60.0%) 4
(99/229; 4
43.2%; 4
P=0.015). 4
predisposition, 4
one-week 4
cytotoxins 4
63.9% 4
4.3, 4
habit. 4
microimmunofluorescence 4
small-artery 4
0.71). 4
Interventional 4
p=0.01). 4
commonality 4
singing 4
post-test 4
harmonics 4
t-test. 4
(FAS) 4
MSDs 4
accentuation, 4
phrasing. 4
accents 4
charting 4
tasks: 4
prolongations 4
Cyclical 4
Noncyclical 4
dysprosody. 4
Perceptual 4
flaccid, 4
spastic, 4
neurolinguistic 4
vowels 4
Osteoarthritis 4
FoxO1 4
MnSOD 4
LNF 4
Need 4
gap' 4
Medical) 4
Linx 4
25.7 4
LINX® 4
PPIs. 4
(18/20) 4
erosion. 4
(Tay-Sachs 4
asialo-GM1 4
alpha-galactosidase, 4
NB-DGJ 4
ceramide, 4
[Lysosomal 4
sulfatide 4
matters. 4
leupeptin 4
"protective 4
(hemiatrophy) 4
drowsiness. 4
hemispherectomy 4
communications. 4
hemiatrophy). 4
"metabolic 4
calvarium 4
hyper-pneumatization 4
peduncle 4
Syndrome). 4
Otherwise 4
transacylase, 4
(BTHS). 4
obligated 4
acyltransferases 4
hpf, 4
acyltransferase-1, 4
V-positive 4
(PSL) 4
Bmal1(-/-) 4
BMAL1. 4
Arnt-like 4
(Suz12), 4
(Bmi1), 4
hides 4
(me3) 4
(K27), 4
(LIF) 4
Hoxa1 4
overrode 4
Hca-F 4
CK1delta 4
(CK1) 4
gamma). 4
H4IIE 4
phosphoamino 4
Shorter 4
283, 4
3.52, 4
impairment), 4
932 4
(stroke/systemic 4
P=0.666). 4
P=0.867). 4
(moderate-risk 4
Xa-inhibitor 4
nebivolol, 4
U/ml. 4
14,264 4
Fibrillation). 4
stroke/transient 4
1.57; 4
Hospitalization 4
(rivaroxaban: 4
0.62) 4
1.26, 4
6,000 4
Nonvalvular 4
mL/min), 4
Stroke/systemic 4
http://www.clinicaltrials.gov. 4
confirmed; 4
assimilation, 4
tiers 4
NPD 4
surprises 4
phagocytosis. 4
PSVs 4
LIPID 4
PLIN2 4
Lipolysis 4
Organisms 4
N-ethylmaleimide 4
decades-old 4
TIP47 4
plano-convex 4
SMCHD1, 4
microanatomist 4
Barr, 4
'Barr 4
body'. 4
provisional, 4
thesis 4
monosomies 4
X-inactivation, 4
Lyon 4
since. 4
toluidine 4
autosome 4
omics, 4
microchip 4
attomole 4
myrosinases 4
single-S-cell 4
proteomics: 4
TIRF 4
discarded 4
LTQ 4
(shotgun 4
Ultra 4
MammaPrint(®) 4
BC. 4
Oestrogen 4
Categories 4
ER/PR 4
(multivariate 4
(Agendia 4
3%), 4
(2.7%) 4
1.18) 4
(0.28 4
ximelagatran; 4
Hopefully, 4
setting: 4
trichloroacetic 4
IL-1beta+TNFalpha 4
N-acetyl-L-cysteine, 4
HIF1A. 4
ALAS1 4
(**)p<0.01) 4
(*)p<0.05), 4
180-day 4
NOTCH-dependent 4
β-hydroxybutyrate 4
uremia, 4
intra-individual 4
filtration, 4
anemias. 4
BVDV, 4
Pestiviruses 4
Pestiviruses; 4
Flavivirus) 4
(6-MP) 4
Syncytial 4
NS2 4
intending 4
(58% 4
precessation 4
Exemption 4
69,185). 4
0.59+/-0.06, 4
0.3+/-0.05, 4
7-10), 4
346), 4
(NRT 4
date), 4
(conventional 4
cigarette, 4
date). 4
(16.4% 4
(fMRI). 4
lozenges 4
Quitline) 4
non-smokers. 4
accommodates 4
decapitation, 4
pole, 4
vertebrates) 4
GCS, 4
PFSS 4
Score) 4
hemorrhage), 4
kappa: 4
polycaprolactone 4
microporous 4
ingrowth. 4
native-appearing 4
respected 4
Integrated, 4
Otolaryngology—Head 4
bionic 4
electronics 4
stereo 4
robotic 4
pre-surgical 4
printers, 4
Modeling, 4
motivate 4
lightweight 4
computer-aided, 4
manufacture 4
[SMD] 4
-37.5, 4
-41.83 4
-33.17, 4
9.24, 4
7.70 4
10.79, 4
-0.89, 4
-0.98 4
agonist/antagonist, 4
NAMS 4
vagina, 4
Modulator 4
60-mg 4
nights 4
PLM 4
restlessness 4
posted 4
companies, 4
(Level 4
dropouts 4
improvement), 4
putaminal 4
RLS-6 4
unsteadiness 4
placebo-unresponsive 4
EVIDENCE: 4
alpha-expansin, 4
CMC-Na 4
beta-glucan. 4
EglD 4
germination. 4
sativus) 4
swollenin 4
overexpressors 4
non-mycorrhizal 4
nucleases: 4
(GT) 4
Activator-Like 4
ZFN-mediated 4
rank-specific 4
CompoZr 4
CoDA 4
tension-type 4
hypochondroplasia. 4
rhizomelic 4
pressure; 4
bowed 4
Sfc 4
PCR-DGGE 4
i(21q) 4
380(G380R) 4
treatment.tumor 4
HSPA1B, 4
LGALS3, 4
FAM84B, 4
FDPS, 4
GOLPH2, 4
HBA1, 4
HIST1H1C, 4
MARCKS. 4
Securin, 4
proneness. 4
dicoumarol. 4
Akt/protein 4
dicoumarol, 4
Securin 4
growths 4
genetics: 4
(ENS) 4
(rare 4
Kendall 4
gut). 4
SNaPshot 4
135G>A 4
2.7. 4
Hirschsprung: 4
(D584G), 4
(+2T 4
(A654T), 4
(T706A). 4
(2/28; 4
1/24). 4
2307T 4
(-26 4
(A301T); 4
277). 4
(4/28) 4
(3/28), 4
-60 4
all-or-nothing 4
-30 4
predated 4
(LEMS). 4
4R. 4
(P/Q-type) 4
changes; 4
frequency.There 4
cancer,9 4
57.6±4.9.Nine 4
69.All 4
myasthenia,mainly 4
extremities,2 4
(median:6 4
cancer.Treatment 4
Lambert 4
Eaton 4
H146 4
omega-CgTX 4
omega-AgTX 4
type(s) 4
IgG-mediated 4
(SCLC). 4
nerve-evoked 4
flutter, 4
areflexic 4
video-assisted 4
anti-VGCC 4
(p=0.0001), 4
interviewing 4
Cytologic 4
antibodies). 4
VGCCs 4
non-SCLC 4
synaptotagmin 4
pM. 4
bacteriocins 4
lanthionine/methyllanthionine-containing 4
peptides/proteins 4
mimicry. 4
NAI-802 4
3147 4
producers. 4
quorum 4
lactis, 4
lanthionine. 4
prenisin 4
non-lantibiotic 4
lanthionine-containing 4
quartz 4
synthesis) 4
endogamous 4
18q23 4
parainfectious 4
rhabdomyolysis. 4
curable, 4
manageable, 4
1-3). 4
'transcription 4
some. 4
hypomyelinating/demyelinating 4
chambers. 4
powers 4
year), 4
Portland 4
Histidine 4
KipI 4
KinA 4
isomerases. 4
scaffolds. 4
cytoplasm: 4
(MA) 4
(AP). 4
AP, 4
AP. 4
QTL. 4
NHEJ. 4
TIR-specific 4
evolution; 4
hPso4 4
domesticated 4
transposase, 4
subvert 4
Transposase 4
SETMAR, 4
Hsmar1-Ra 4
mobilizes 4
reverted, 4
p53-inducible 4
mdr1 4
P388/SPR 4
RasV12 4
Nox4-generated 4
Myc/macrophage 4
tango: 4
style. 4
Ras/Raf-prototypic 4
failsafe 4
oncogene-orchestrated 4
p19(Arf)-p53 4
(cyclin-dependent 4
hyper-proliferative 4
senesced 4
Wrn, 4
oncogene- 4
re-assessment 4
Myc- 4
Wnt-driven 4
permanently, 4
Osteosarcomas 4
ras, 4
p53-DNA 4
gammaH2AX 4
"transformation 4
suppressor" 4
(7q31.1). 4
p53/p21-dependent 4
Subcytotoxic 4
subcytotoxic 4
ARF/p53 4
mek1 4
ARF-null 4
populations." 4
Huisman, 4
(hhtp://globin.bx.psu.edu/hbvar). 4
simpler, 4
Population-specific 4
succinct 4
advances: 4
population-specific 4
β-thalassemias 4
inter-connected 4
Open-Access 4
(http://www.lovd.nl), 4
microattribution 4
inter-relation 4
saquinavir, 4
fmol/microL 4
MK-3475) 4
MK-3475 4
AbetaH-J-J, 4
aspartyl-beta-hydroxylase, 4
(P1 4
P2) 4
AbetaH 4
Aspartyl 4
9-fold 4
Scatchard 4
BAH-related 4
GGylation 4
Hippo-YAP/TAZ 4
YAP, 4
Homeostatic 4
mammalian-specific 4
YAP/TAZ-TEAD 4
Yes 4
protrusion. 4
POPX2 4
ring-like 4
(DRFs) 4
endow 4
ATP-independent 4
Iec1-Ino80 4
RSC-nucleosome 4
RSC, 4
Trem2 4
biases) 4
renaturation 4
disjoint 4
Dinucleotide-odds 4
base-step 4
(abbreviated 4
delta-distances 4
CTAG 4
(16S 4
fastidious 4
(sample 4
arginine; 4
ChaFRADIC 4
HiRes 4
'downstream' 4
advancements, 4
phosphoproteomics, 4
cyanobacteria. 4
"omics" 4
Metabolome 4
(CDX-110, 4
Therapeutics), 4
ventricle(s) 4
(TPM1), 4
HCM/DCM 4
co-segregates 4
(severe, 4
acantholytic 4
sons 4
430 4
pE96K 4
photothermal 4
SERS 4
NCI-H1299, 4
NCI-H446 4
molecules), 4
mL) 4
Musashi1 4
NCI-H460, 4
ribosylation 4
1.6; 4
Bcl-x(L), 4
immortal 4
NCI-H520) 4
(neuronal 4
(CIN) 4
LR-PSS 4
FLT3 4
94.7% 4
PHF1 4
Drisapersen 4
2'-O-methyl-phosphorothioate 4
9mg/kg 4
6mg/kg 4
Modifying 4
NADPH-oxidases 4
cadre 4
omphalocele, 4
Oesophageal 4
decision. 4
(1.02 4
1.99 4
[Prenatal 4
Down, 4
47,XYY 4
neighbour 4
60-70% 4
1:100 4
(4.2%) 4
(0.4%) 4
Jiangsu 4
Thames 4
translated. 4
PABP, 4
deadenylation, 4
3'-to-5' 4
Dcp1a, 4
mRNA-containing 4
DCP1a, 4
dDcp1 4
Dhh1 4
homologue) 4
staufen- 4
RNA-degradative 4
Dcp1p 4
Xrn1p/Pacman 4
(argonaute), 4
(Upf1p), 4
(Dhh1p/Me31B) 4
discs. 4
DCP2, 4
EDC3, 4
GEMIN5, 4
STAU1 4
Exonuclease 4
exosome-independent 4
hXRN1 4
(G3BP). 4
transportin 4
digestible 4
exo-inulinase 4
Penicillium 4
128, 4
propane 4
aqueous-organic 4
Highest 4
mL(-1)) 4
chicory 4
6.5. 4
Hydrolysis 4
99%. 4
CCT 4
CVB3-RNA 4
Parkin-binding 4
PD-linked 4
suprathreshold 4
Lewy-body 4
(PARK 4
heterozygous) 4
conclusively. 4
NCX1.1, 4
postprocedural 4
deoxycorticosterone 4
τ, 4
Detergent 4
glutathionylation 4
myofilaments, 4
TdP 4
(P(o)) 4
spectrophotometry. 4
I(Na). 4
[Ca(2+)](i). 4
I(Na)) 4
.017). 4
d[Ca2+]i 4
NSTE-ACS 4
(H2O2), 4
Lactate 4
"Autophagic 4
mechanism(s). 4
"weapon" 4
ketones) 4
Experimentally, 4
MCT4, 4
autophagy/mitophagy 4
"fuel" 4
3-hydroxy-butyrate 4
Ringer's 4
CL3 4
(MDA-MB-231) 4
phosphorylation), 4
instruct 4
micro-environment 4
"corrupt" 4
Warburg's 4
suprachiamstic 4
thymocytes, 4
CAMKK2. 4
AMPKα 4
AMPKα1 4
T315I, 4
c-Kit. 4
BCR/ABL-expressing 4
Campus 4
ponatinib. 4
ABL-tyrosine 4
Rat-1 4
BCR/ABL-T315I 4
Oridonin 4
(Ph+ 4
Raf/MEK/ERK, 4
Label-free 4
plasma: 4
CHR 4
CCyR 4
ACAs 4
responded, 4
HSCT, 4
blood) 4
protuberans. 4
twenty-six 4
CMR, 4
(CHR) 4
hepatitis: 4
bcr-abl, 4
BCR-ABL-positive 4
B2A2 4
Novartis). 4
re-established. 4
(Ph), 4
Scotland 4
(9;22) 4
1973. 4
base-line 4
e6a2 4
Brc-Abl 4
T315I. 4
BCr-ABL, 4
BCr-ABL 4
busulfan 4
FTIs 4
kappaB) 4
synthase). 4
intentions 4
Gleevec, 4
leukaemias 4
target-directed 4
blast-phase 4
leukemias: 4
filgrastim 4
(HHT) 4
(STI571) 4
AP-CE 4
(signal 4
571) 4
4]. 4
158) 4
ECGs, 4
5-HT3A 4
response/remission 4
lag, 4
forebrain. 4
buspirone, 4
antagonism; 4
(combining 4
antidepressant. 4
2-wk 4
HAMD-24 4
>19 4
(SDS), 4
HARS 4
(placebo) 4
(-2.0 4
publication-quality 4
(BEDPE). 4
(https://github.com/dphansti/Sushi) 4
(http://bioconductor.org/packages/release/bioc/html/Sushi.html). 4
Sushi. 4
toxoplasma 4
enquiring 4
toxoplasmosis. 4
chorioretinitis. 4
herbivorous 4
Paediatrics 4
1978, 4
dsPIG: 4
dsPIG. 4
http://www.shoudanliang.com/dsPIG/. 4
novel-imprinted 4
paternal) 4
3,877 4
2,625 4
candidate-imprinted 4
"flipping" 4
PCC/PGL. 4
SeqCap 4
EZ 4
SETBP1 4
UM. 4
Mxtx2-Nodal 4
nanog-like 4
(YSL), 4
Nanog-like-Mxtx2-Nodal 4
Cul3, 4
Cdk6 4
gliomasphere 4
tumourigenicity 4
Cxcr4b, 4
(Oryzias 4
1,083 4
Hemopoietic 4
Lamins 4
(1.4-fold) 4
(<20 4
lamins) 4
nodules) 4
outputs. 4
lysosome/vacuole 4
autophagy: 4
se; 4
sword 4
PBMC. 4
PBMC) 4
collaterally 4
psiRNAs 4
v/(u 4
v), 4
(mu 4
selections 4
AT. 4
GC-biased 4
two-codon 4
Sueoka 4
Developments 4
F-alphaMHC(+/+): 4
26.2 4
unknown) 4
1%), 4
(69 4
(maximal 4
blunts 4
alpha-MHC. 4
chymotrypsin 4
403/+ 4
labile, 4
valve-sparing 4
procedures; 4
32.2 4
64.5 4
intraindividual 4
(patent 4
morbidity; 4
MAPK8/JNK1-BCL2 4
MAPK8, 4
BECN1-BCL2 4
MAPK8-BCL2 4
(Spontaneous 4
p67-phox 4
Azan 4
Mallory 4
caspase-12 4
p-p38 4
UCF-101. 4
county 4
cardioverter-defibrillators. 4
ICD, 4
athletes). 4
>500 4
judgment, 4
catastrophes 4
football. 4
Surviving 4
youthful 4
fortuitous 4
mathematically 4
trivial? 4
Menzerath's 4
Z=Y/X, 4
1/X. 4
4%) 4
demographically, 4
.84), 4
95%), 4
baseball/softball 4
cricket, 4
playground. 4
blow. 4
barriers) 4
low-impact 4
mummy, 4
clothing 4
iceman 4
Ha 4
(red 4
shoots, 4
debilitate 4
cotyledons 4
peripherin 4
Tightly 4
c.98A>C 4
c.158C>T 4
c.371T>G 4
c.1342G>T 4
Precisely 4
post-injection. 4
Generating 4
under-evaluated 4
eluded 4
ramifications. 4
(PSEN1) 4
inversa 4
PROTEIN 4
Appa 4
scission, 4
constrict 4
His6-tagged 4
pit 4
dynamin-mediated 4
VPS4 4
MVB 4
nucleation. 4
yeasts, 4
FFS 4
1-matrix 4
curvature. 4
doxycycline-inducible 4
PIR2. 4
P1) 4
CU-rich 4
RNPC1 4
ΔNp73, 4
ΔΝp73 4
(NSCLCs). 4
(TAp73). 4
DeltaNup73 4
Notably 4
isoforms) 4
executing 4
celecoxib. 4
DLBCL. 4
(Delta 4
copper-zinc 4
(Cu,Zn-superoxide 4
Ccs1 4
CCS1 4
YFR055w, 4
FTR1, 4
converge. 4
N) 4
Lys-117 4
(RTK). 4
Ras-mutant 4
weapon 4
H-, 4
(H-Ras, 4
K-Ras4A, 4
distinctively 4
effectors; 4
[3H]-p-tyramine 4
[125I]-3-iodothyronamine 4
O(2) 4
thyronamines. 4
meetings. 4
alemtuzumab-induced 4
CD4(+)CD25(+)CD127(low) 4
thereafter; 4
antihistamines, 4
cytolysis 4
β-1a 4
Marketing 4
Campath(®)) 4
rater-blinded 4
49%-74% 4
42%-71% 4
(Comparison 4
Rebif 4
Sclerosis; 4
CARE-MS1), 4
0%) 4
heralding 4
(At 4
2.26; 4
0.019), 4
rater-masked, 4
cutaneous) 4
(Sanofi) 4
Schering 4
Daclizumab 4
settings; 4
alemtuzumab's 4
microg) 4
47%). 4
bundle, 4
dependency, 4
perception, 4
psychopharmacological 4
accumbens. 4
task). 4
habenular 4
Providing 4
pleasurable 4
Dysfunctions 4
anhedonia. 4
Obsessive-compulsive 4
15-month 4
Scarce 4
(T-PLL). 4
(FMC), 4
FMC, 4
FMC-A. 4
Exclusively 4
alemtuzumab-consolidated 4
reactivations 4
morphologic, 4
fungoides 4
Campath-1H) 4
4-45 4
rupture: 4
C250T 4
0.041). 4
(Kaplan-Meier 4
Aβ-aggregates 4
alive? 4
releases. 4
solanezumab-treated 4
microhemorrhage 4
composition: 4
Bapi-AD 4
NI-AD 4
appeal 4
synaptotoxic 4
3D6 4
burdens, 4
Anti-β-amyloid 4
anti-beta-amyloid 4
Tarenflurbil 4
adjuvants, 4
circumference. 4
Thr92Ala 4
"heart 4
challenge--first, 4
52.8% 4
819 4
Bundang 4
nonuse 4
brachial-ankle 4
systolic, 4
hypothyroidism-associated 4
overzealous 4
athleticism 4
Copenhagen 4
METs) 4
mec 4
sublineages, 4
(DR) 4
homoplasic 4
genera, 4
pennatulaceans 4
contradictory, 4
crustaceans 4
dependable 4
Homoplasy 4
veracity 4
large-bodied 4
papionin 4
coding. 4
characters-the 4
dentition-are 4
Paranthropus 4
polyphyletic, 4
de-emphasise 4
australopiths. 4
corollary 4
Homoplasy, 4
electromorphs 4
2.08) 4
hyperserotonemia 4
colleagues, 4
mothers) 4
Causality 4
vitreoretinopathy 4
Slug/Snail2 4
GSK-3β-mediated 4
3β 4
BLBC 4
Claudin-low 4
(CLBC) 4
CLBC. 4
(TCCs) 4
24.1% 4
E-Cadherin 4
(BACs) 4
matrilinear. 4
[Genetics 4
known: 4
(dystrophin 4
tafazzin), 4
phosphokinase. 4
irregularly 4
immunotherapies, 4
ligand-1 4
(MK-3475) 4
attacking 4
response); 4
Willi 4
meantime 4
(ICRs). 4
"life 4
(BWS), 4
Prader-Willi, 4
(IGF-II) 4
(cHS4) 4
titers. 4
promoter/enhancer 4
co-assemble 4
ferroxidase 4
08:30 4
pica, 4
(Venofer(®), 4
RenaPharma/Vifor, 4
20×100 4
(Duroferon(®), 4
(P=0·0043). 4
P-ferritin 4
Vox 4
Sanguinis 4
Transfusion. 4
numb 4
remedy, 4
RLSAP). 4
problem? 4
move; 4
7%-11% 4
Rebound 4
Anti-convulsant 4
syndrome--possible 4
routines. 4
severest 4
awakenings, 4
co-morbidities, 4
TAF1 4
(Bdf1) 4
TAF1. 4
Rsc4 4
rsc4 4
Forces 4
post-Gulf 4
Armed 4
(GWS), 4
Tora 4
Bora, 4
Kabul 4
nonexposed 4
Lal 4
Farm, 4
legitimacy 4
dysmnesia, 4
wartime 4
forty-nine 4
Naval 4
participated; 4
inventory. 4
analysis-derived 4
cognition," 4
disorientation, 4
(Mini-Mental 4
53.5 4
osmiophilic 4
arteriopathy, 4
microvasculature 4
N3ECD 4
(MEN2), 4
tumors]. 4
fibrosis]. 4
INPULSIS 4
(IPF). 4
groundbreaking 4
Antifibrotic 4
Bleomycin 4
monotherapies 4
View, 4
(STZ, 4
(CaSR 4
Ren-2 4
SERCA-2a 4
(p<0.01 4
diabetic, 4
sc, 4
Ca(2+)-release 4
CPU0213 4
'intermediate 4
fasciculations, 4
(diaphragm, 4
(arterial 4
offensive 4
phenomena: 4
stimulus; 4
'decrement-increment 4
response'); 4
('decrementing 4
response'). 4
(OPs) 4
crisis; 4
F- 4
deltoid 4
SNCV 4
velocities. 4
hydraulic 4
methamidophos, 4
fenthion, 4
chlorpyrifos. 4
'chronic 4
Organophosphate 4
claw 4
drop, 4
Egypt. 4
more) 4
myelopathy, 4
39.1 4
24.4% 4
Parkinson, 4
(57%), 4
neurotoxin. 4
sequela 4
subsides 4
toxicologic 4
Occupational 4
amend 4
(13). 4
borna 4
intercistronic 4
(BDV), 4
pseudotyped 4
neuron-glial 4
Orf 4
(OL) 4
(TNF-alpha), 4
ara-GTP 4
CRs 4
Pu.1 4
(Oncorhynchus 4
(Th1) 4
AP2, 4
AP3, 4
bibliometrics 4
1225 4
101) 4
Scopus. 4
(bivariate 4
fellowships 4
subspecialties, 4
News 4
departmental 4
Programs 4
Residency 4
95th 4
"top 4
$100,000 4
salary 4
(SB), 4
inspection, 4
poured 4
dietary, 4
parafunctional 4
wore 4
bruxism. 4
cross-over, 4
(SB). 4
masseter 4
HCl) 4
bursts, 4
RMMA/microarousal 4
EMG, 4
non-rapid 4
deviation; 4
splint 4
attrition, 4
(wear, 4
cracks), 4
(gingival 4
mobility) 4
muscle-joint 4
Satisfactory 4
esthetics, 4
0.0%, 4
70.7% 4
16.5%), 4
post-intervention. 4
0.032), 4
meditation 4
postintervention, 4
(frequent 4
attitude, 4
behavior; 4
-0.52, 4
realistically 4
co-operation 4
BRCA2). 4
collaborators 4
47.2% 4
29.4% 4
(32.4% 4
urologist 4
(sensitivity) 4
cancers) 4
87%) 4
(OT) 4
quarters 4
mild), 4
Hypotonia 4
hyperextensible 4
nephrologist 4
supravalvular 4
39.2 4
kilograms 4
GH-stimulation 4
GH-treatment. 4
hypothyroidism; 4
multispecialist 4
analogue. 4
(WBS). 4
(GHD) 4
(hGH) 4
-4.2 4
"coarse" 4
(>50 4
microU/ml; 4
0.2-4 4
2.8-5.6 4
6.6-14 4
pg/ml); 4
(CRH) 4
osteoprogenitor 4
Dickkopf-1 4
OGS-derived 4
(Wnt) 4
Biosciences 4
FT-ICR 4
IgY 4
(HSA), 4
HSA, 4
LC-FTICR 4
facilitated. 4
SDS/PAGE 4
(expression 4
expedited 4
AC068718.1, 4
578 4
de-represses 4
lincRNA-RoR 4
lincRNA, 4
linc-RoR, 4
GRIK2, 4
addictive 4
necropsy. 4
disease/dementia 4
PMS, 4
ethinyl 4
DRSP/EE 4
Library), 4
PsycInfo, 4
-0.45 4
-0.22; 4
fluvoxamine, 4
1.62 4
serotonin-reuptake 4
SRIs 4
85%. 4
(clinician-rated) 4
(chi2(1) 4
seventy-three 4
disorder-specific 4
.013). 4
sites), 4
Scale-Mood 4
formulation) 4
studies), 4
generalization, 4
(5-hydroxytryptamine, 4
(panic 4
5.3) 4
4.9) 4
5.1) 4
17.6; 4
completers. 4
peptides; 4
(p=0.09). 4
C.I. 4
cGy. 4
(FDG-PET) 4
angiopoietins, 4
VEGF(165)b 4
VEGFA 4
study's 4
CNV. 4
0.0004) 4
(vascular 4
endostatin) 4
corneas 4
limbal 4
cornea. 4
chlorhexidine 4
(whole 4
VEGF-dependent 4
networking 4
Endostatin, 4
40.5 4
18.9 4
Rai 4
28.9 4
(p<0.001 4
p=0.002 4
225, 4
0.0002 4
Robo3. 4
Cntnap2 4
Canada; 4
DPat, 4
unauthorized 4
intercourse, 4
uses. 4
Fluvoxamine 4
conduct. 4
Countries 4
phytoestrogens 4
(sildenafil, 4
intracavernous 4
surveys. 4
ideal. 4
intergenic/intronic 4
380,084 4
double-stranded, 4
Cross-genome 4
(0.006%) 4
GSCKs 4
units) 4
(sites 4
GH5, 4
r.m.s.d. 4
abolished, 4
Sparse 4
"H1 4
dimer" 4
processivity, 4
PUM1 4
PUF-mediated 4
deadenylation-dependent 4
mega-Dalton 4
(Caf1p). 4
pombe) 4
Mn(2 4
PABPC1 4
eRF1-eRF3 4
trypanosomal 4
CCR4. 4
poly(G) 4
poly(A), 4
lifecycle 4
brodalumab. 4
p<0.001 4
microbiome, 4
IL17 4
from, 4
Brodalumab, 4
(ACR 4
itch. 4
Nf1± 4
(MLPA). 4
recombinogenic 4
disfigurement 4
phenotypically, 4
messenger, 4
PDGFRA. 4
locus; 4
Transplacental 4
del 4
insulinoma, 4
neurofibroma, 4
temperature-gradient 4
(DGS) 4
47.1% 4
dinucleotide, 4
(10.1%) 4
neurofibromin. 4
substantially, 4
1423 4
αIIbβ3 4
N-methyl 4
RGD-peptide 4
N-OEG 4
tumor-produced 4
ILP 4
learning-machine 4
(CTCs) 4
65.5 4
protagonists 4
(RGD) 4
cell-membrane 4
beta3 4
beta5 4
Alu-derived 4
G). 4
ESE 4
Angelis 4
99:9456-9461, 4
103: 4
3758-3763, 4
565-743, 4
Incitti 4
1675-1682, 4
(Denti 4
snRNA-mediated 4
dose-dependent. 4
(RPGR) 4
c.1245+3A>T 4
(U1). 4
U1. 4
(U1 4
DNA-damage-induced 4
expiry. 4
chlorogenic 4
HMGCoA. 4
Lycopene, 4
49.3% 4
51.7 4
habits. 4
0.029), 4
TC:HDL 4
TC: 4
allowed) 4
ketchup 4
Polycomb-regulated 4
"transposon-free 4
opossum 4
m6Am 4
(ncRNAs). 4
MeRIP-Seq 4
portal. 4
chloroplast. 4
BAFF/APRIL 4
relegated 4
B16 4
(p: 4
(2.33 4
CD40-positive 4
population; 4
AITL 4
predominated, 4
sparsely 4
arborization. 4
Cost-utility 4
ambrisentan. 4
QALYs. 4
package--roles 4
prioritisation. 4
Britain, 4
legislation 4
co-payments, 4
prices. 4
(FD), 4
appraisals; 4
inhaled) 4
ambrisentan; 4
beta; 4
C1s 4
broadest 4
Authorization 4
authorization) 4
(394 4
non-orphan 4
amortized 4
(commercial 4
Medicaid) 4
(Medicare 4
Advantage) 4
ICD-9 4
$6617 4
PSPM 4
(Viagra), 4
(MCO) 4
cost-share, 4
1,681 4
1,362 4
(81.0%) 4
(19.0%, 4
users) 4
appealed 4
PMPM. 4
cost-share 4
26.6%, 4
MCO. 4
expenditures 4
prohibited 4
parameterization 4
recalibration 4
mass-to-charge 4
chip. 4
60,000 4
"lock 4
mass" 4
Parts 4
valganciclovir, 4
Foscarnet 4
foscarnet 4
SOT 4
Transplantation. 4
(SCT). 4
8-week-old 4
mpk/B. 4
PTA-6475 4
(P<0·0001) 4
(n=16). 4
Typhlocolitis 4
IgG2c 4
(P<0·005) 4
caecal-colonic 4
interleukin-1α 4
(IL-1α), 4
factor-β, 4
speculative, 4
treatment-induced 4
Examining 4
(commensal 4
bacteria) 4
jejuni. 4
interleukin-10(-/-)), 4
CD4(+)CD45RB(high) 4
endophenotypes 4
Klippel-Feil 4
CTDs 4
CMI. 4
Müllerian 4
syrinx 4
(15q21.1-22.3). 4
(9q21.33-33.1) 4
DMXL1, 4
rotatory 4
Plain 4
male:female 4
FOXP1, 4
emit 4
surroundings 4
plateau. 4
translocation--t(11;22)(q24;q12)--that 4
conundrum 4
IGF1R 4
Puma, 4
ESFT, 4
(ESFTs) 4
Ewing/PNET 4
histogenesis, 4
ETS-transcription 4
TP53-deleted 4
Nutlin-3 4
TC-135 4
aberrant, 4
ilium 4
asbestos 4
2B+32 4
Ramos 4
Her-2/neu, 4
thecoma. 4
Demons-Meigs 4
cystadenoma. 4
50-year 4
distention 4
CRD-BP: 4
Determinant-Binding 4
KH-domain-containing 4
Infiltrated 4
spectroscopic, 4
contributions. 4
mobilities 4
3,4,4',5'-tetramethylazapsoralen 4
macromolecule, 4
azapsoralens 4
≤8 4
Pharma; 4
consciousness) 4
characteristics; 4
73.7% 4
P=0.35). 4
Phlebitis 4
3.03; 4
4.66). 4
12h 4
Zetoc 4
Controlled-trials.com 4
disagreement. 4
progesterone-vitamin 4
Neurotrauma 4
ACTRN12607000545460. 4
postinjury. 4
Scale-Extended 4
Seventy-seven 4
industry-sponsored 4
neuroprotective, 4
(SCr) 4
nephropathies. 4
(IRIS) 4
5G4 4
autopsy-confirmed 4
cross-reactivity. 4
(alphaS) 4
CB. 4
grays 4
(alpha-syn) 4
(MSA), 4
ubiquitin; 4
CLBs. 4
insula 4
precursor/alpha-synuclein 4
FEB, 4
bowels, 4
UAD 4
reiterates 4
gestations 4
IUGR, 4
(7.6%). 4
para 4
spectrophotometry 4
(29%). 4
B-19 4
African-American, 4
Intra-amniotic 4
Amniocentesis 4
TMZ-STAB 4
TMZ-STAB+REP 4
MTMRs 4
ceMTM3 4
worms. 4
RME-8 4
phosphatases: 4
hMTMR2 4
cofractionate 4
fraction; 4
30-fold, 4
MTMs 4
influenzae, 4
nebulous. 4
lenticular 4
(one); 4
(marked 4
(10.3%), 4
myoglobinuria. 4
H2BK123ub1, 4
RNA-independent 4
(OPC-67683), 4
nitro-dihydro-imidazooxazole 4
(nearly 4
delamanid, 4
(161 4
medium; 4
fluoroquinolone 4
(COSS) 4
artery-middle 4
(STA-MCA) 4
Thirty-day 4
adjudication 4
dH1 4
intricacies 4
"top-down" 4
deletions). 4
down" 4
1,800 4
quadrupole/Fourier 4
nephrectomy, 4
dextrocardia 4
short-axis 4
CRMP2AAA 4
CRMP2/CaV2.2 4
(SUMO-1) 4
pupal 4
glargine 4
breastfeeding. 4
(LM) 4
[MDA 4
(Malondialdehyde)] 4
[SOD 4
(Superoxide 4
dismutase), 4
(Reduced 4
peroxidase)] 4
TFG, 4
(8.71%) 4
(3.87%) 4
mg/150 4
diazoxide 4
channels). 4
channel) 4
NIDDM 4
sensitivity?) 4
IGT, 4
receptor-ligand 4
Lys, 4
Lys-Asp-Glu-Leu 4
(KDEL), 4
compartment(s) 4
KDEL-containing 4
pH-dependent 4
lipidic 4
myo-inositol, 4
hyperandrogenism. 4
clomifene 4
kg/ 4
(p=0.04). 4
(PCOS). 4
0.036) 4
0.311, 4
LH/FSH 4
equal. 4
equal: 4
(HOMA) 4
suboptimal, 4
14-wk 4
0--50%) 4
0--22%) 4
quantitation, 4
(82% 4
macropore 4
Trypsin 4
Digestion 4
sulfate, 4
sciences, 4
SK-BR-3 4
membrane-tethered 4
LC-ESI 4
Glu-C 4
resumes 4
NFZ 4
translocase. 4
non-bulky 4
Mfd-dependent 4
(TRCF, 4
(RNAP); 4
SF2 4
sociodemograhics, 4
Benzodiazepines 4
Revision 4
478 4
DSM-IV/V 4
worry, 4
2.04, 4
(FEV1) 4
61) 4
anti-IgE 4
EOS. 4
(anti-IL-5 4
Bronchoalveolar 4
54.5% 4
-0.21, 4
versican 4
proteoglycan, 4
(ICS) 4
eosinophil-related 4
oesophagitis: 4
sustained, 4
(L-HES) 4
auto 4
(anakinra, 4
polynuclear 4
L-HES. 4
anti-tyrosine-kinase 4
hyperresponsiveness. 4
varieties, 4
Brigham 4
(APT) 4
APT. 4
(TARC) 4
TARC 4
tissue), 4
RBM 4
SmithKline 4
CD34(+)/IL-5Ralpha(+) 4
eosinophil/basophil 4
CD34(+)/IL-5Ralpha 4
airway. 4
-sensitive 4
tissue-resident 4
(MAE; 4
phase' 4
attributing 4
tonic, 4
atonic, 4
seizures; 4
(myoclonic-astatic 4
epilepsy): 4
1970. 4
(13%); 4
bathing, 4
(LGS), 4
diet: 4
retarded. 4
(LGS) 4
theories, 4
chr. 4
Dravet's 4
6q 4
EDA 4
GBSSW 4
(control), 4
orthoses 4
difficult; 4
AARS 4
GARS1-associated 4
(reduction 4
touch, 4
(EMG), 4
alternate-day 4
40/44 4
10/10 4
micrograms/kg/d 4
Rac2 4
perioperatively 4
71.1%. 4
QT-prolonging 4
testing). 4
Presymptomatic 4
heteromultimeric 4
530 4
Long-QT 4
262 4
(HERG). 4
syndome 4
[squamous 4
patient] 4
(melanoma). 4
(n=26), 4
whites. 4
41%). 4
UVB. 4
Scant 4
Asiatic 4
Whites, 4
Blacks 4
abroad. 4
cardio-protective 4
resveratrol's 4
lesions: 4
SIRT1/S6K 4
Anecdotal 4
PC3, 4
prostates 4
DR5, 4
cell-death 4
NAD+ 4
reduces, 4
plant-derived 4
kinase(PI3K)/Akt 4
(PrCa) 4
PrCa. 4
Ionizing 4
AMP-Activated 4
Androgen-insensitive 4
(PC3), 4
(22RV1) 4
(2-8 4
(γH2Ax) 4
(cleaved-caspase 4
p21(cip1) 4
p27(kip1). 4
carbonylated 4
phagocytose 4
rosetting, 4
567 4
(P<0.0001), 4
Keratoconus 4
irregularity 4
Scheimpflug 4
diopters 4
3.80 4
thinnest 4
overcorrection. 4
Respective 4
60.4 4
20/40 4
-2.00 4
(UVA) 4
Uncorrected 4
(flat) 4
(steep). 4
protocol): 4
47.78 4
7.36 4
52.09 4
52.54 4
3.23 4
-19.94 4
7.21 4
-34 4
-21.83 4
12.07 4
-66 4
-6.86 4
5.77 4
Kanellopoulos 4
Alcon 4
Wavelight 4
Technologie 4
AG; 4
Avedro, 4
i-Optics 4
Asimellis 4
ASCRS 4
ESCRS. 4
68%; 4
TLRs. 4
(EOAD), 4
(bound 4
Aβ1-40 4
screening; 4
Dying 4
Touch 4
mg/24 4
hr) 4
"Calcium 4
paradox" 4
(p43-ERK, 4
p38-MAPK). 4
TTC 4
LVEDP, 4
paradoxic 4
-free 4
8.6%, 4
10.8% 4
ATP-induced 4
Normothermic 4
histochemically 4
inhomogeneity 4
Ca2+-ionophore 4
lanthanum 4
'calcium 4
Krebs-Henseliet 4
guanylyltransferase, 4
fixed. 4
RdRp. 4
alpha-loop 4
1.27; 4
desserts, 4
sweets 4
dissertations 4
lamb, 4
beef, 4
1.76, 4
french 4
fries, 4
Necroptosis, 4
necrostatin-1. 4
irradiation-induced 4
hippocampus; 4
reboxetine 4
phenelzine, 4
(AN) 4
AN. 4
5-HTTLPR 4
(GRR) 4
2.0. 4
DOV 4
primates: 4
occupied. 4
microiontophoretic 4
LAC. 4
anti-CCP2 4
DMARD-naive 4
Practicing 4
(Health 4
QUEST-RA 4
self-report. 4
t-tests. 4
genders. 4
0-100 4
>65 4
submission, 4
data: 4
worldwide; 4
misdiagnosed, 4
linitis 4
plastica]. 4
importants, 4
(hCG). 4
15-month-old 4
(MCT) 4
80-year-old 4
surgery]. 4
tangible 4
obesity-associated 4
sleeve 4
thalami 4
B-vitamin 4
Presentation. 4
permanent. 4
Het 4
phenocopy 4
methylation; 4
biomolecule 4
concrete 4
(acetylation, 4
Polyphenols 4
(CVD), 4
Well-known 4
muscle: 4
investigate, 4
(SM) 4
extrathyroidal 4
D2-generated 4
rs17650 4
SNPs; 4
*3 4
(4.7 4
HDA 4
Amplicons 4
-1639G>A 4
CYP2C9*2 4
Moslems 4
0.53, 4
CYP4F2, 4
-1639 4
S-enantiomer 4
G6853C 4
*5 4
alleles; 4
0.015), 4
S-warfarin, 4
14,000 4
10.5, 4
kDa). 4
(RNase 4
63, 4
killing, 4
Utility 4
(chemically 4
Canagliflozin) 4
π-π 4
(CAS) 4
(ΔG) 4
(GBA), 4
98.7% 4
Spain: 4
utations 4
geneticin 4
N370S, 4
influence. 4
(Mean 4
0.0006). 4
(splicing 4
sibships, 4
7.16 4
25.3 4
neuronopathic) 4
VEGF-A. 4
(WR-2721, 4
Ethyol) 4
cis-platinum 4
hypoxia-mimetic 4
inducer; 4
(VEGF-A) 4
Radioprotection 4
osteodifferentiation 4
acidity 4
alpha/beta-ratio 4
transaminases, 4
chemoembolization, 4
chemoembolization. 4
anemia--chromosome 4
DEB- 4
glomerulus 4
Nanoparticle 4
desmopressin 4
agrin 4
solution: 4
(diameter 4
"atypical" 4
"classic" 4
(ME) 4
HRQL 4
47%) 4
mV). 4
dysrhythmia 4
Kir2.1. 4
Monophasic 4
hump 4
inward-rectifying 4
Nonspecific 4
microvasculature, 4
dedifferentiation 4
hiPSCs, 4
disease-modeling 4
arterial, 4
(APD) 4
BMP-4 4
CVPCs 4
(MTs) 4
SCG10, 4
(KBP) 4
SCG10 4
facies 4
malrotation 4
subclavian 4
clover-leaf 4
SGS, 4
high-arched 4
disorders). 4
sutures; 4
Neurocristopathies 4
Haddad 4
electroencephalography, 4
lympho-epithelial 4
diffraction. 4
kallikreins. 4
LEKTI-1 4
ligand-based 4
(serine 4
ichthyoses 4
Strongly 4
undetectable, 4
21-26. 4
linearis 4
circumflexa 4
self-inactivating 4
15-domain 4
culprits 4
pore-like 4
1965, 4
(SN) 4
2000). 4
hatching 4
C1, 4
6-propyl-2-thiouracil 4
(NICD) 4
(ANK) 4
MAML1 4
multimerization. 4
(N(ICD)) 4
preactivation 4
CSL.intracellular 4
Notch1.Mastermind-like 4
(RHR) 4
(RHR-n 4
RHR-c) 4
125-residue 4
RHR-n 4
(RBP-Jkappa 4
(recombination-signal-sequence-binding 4
Jkappa 4
genes)-associated 4
(MAML1) 4
CSL.ICN 4
Nemo-like 4
NotchICD, 4
(CBF-1, 4
hairless, 4
LAG-1) 4
co-receptors 4
(pcorr 4
IHC-positive 4
MSP2 4
18/25 4
Bach1-mediated 4
heme-containing 4
bZIP 4
ARE-like 4
(HO)-1 4
exits 4
ARE. 4
region-leucine 4
Hmox-1 4
Bach1-deficiency 4
(AST) 4
HO-1. 4
prooxidant 4
radical-scavenging 4
betaMHC 4
75%), 4
SnMP 4
de-repression 4
Deficient 4
aminoterminal 4
MARE-dependent 4
p45 4
ho-1. 4
O-glycans 4
alpha-NAGAL 4
MTB. 4
MAC, 4
MAC-related 4
pulmonologist. 4
BACTEC 4
cells/microL 4
RS-112997, 4
RS-118641, 4
phospho-N-acetylmuramyl-pentapeptide 4
translocase, 4
MIC50/90 4
(mg/L) 4
1/2; 4
0.5/2; 4
avium, 4
4/8; 4
intracellulare, 4
avium-M. 4
PYF 4
SPNs 4
H(37)Rv, 4
1581 4
(NRP) 4
Balb/C 4
H(37)Rv 4
drug-sensible 4
subinhibitory 4
lipid. 4
prescriber 4
49.9 4
(-2.3 4
(GPCRs) 4
GPCRs, 4
π-stacked 4
orthosteric 4
OX(1)R 4
ramelteon, 4
underpinnings. 4
-0.97 4
[eGFR] 4
1·73 4
[16%] 4
EMPA-REG 4
OUTCOME™ 4
≥7.0% 4
(41% 4
m2. 4
974; 4
1-100 4
two-compartmental 4
disposition, 4
carbon-14 4
(empagliflozin 4
(208-week) 4
79.5 4
E-R 4
Acetyl-CoA 4
SBPs 4
fgf8a 4
teleost-specific 4
QF-PCR 4
(82 4
fund 4
photothrombosis 4
Lesioning 4
SDs. 4
near-control 4
Perfusion 4
cats: 4
CN. 4
craniectomies 4
monofilament 4
bregma. 4
maximal. 4
lyophilized, 4
P-creatine, 4
(Pi), 4
P-creatine 4
wavefront. 4
bioluminescent 4
nonlinearly 4
(p<0.01), 4
impedance. 4
KCl. 4
spin-trap 4
interconverts 4
(helical 4
associated), 4
(unfolded 4
detached), 4
enzyme-bound), 4
noninhibitory. 4
PLN's 4
SERCA's 4
Apt-9 4
1.22-fold 4
Ca-transient 4
Na/Ca 4
phospholamban-to-sarco(endo)plasmic 4
strips. 4
sarcoendoplasmic 4
SERCA1, 4
voltage-dependent, 4
anesthetics, 4
nonmuscle 4
denuded 4
pentamer, 4
wt/non-phosphorylated 4
N27A 4
22-31) 4
truncated, 4
thalamus; 4
((a) 4
striate 4
disease--Alpers-Huttenlocher 4
polymerase-γ 4
microvesicular 4
Hairy-Cell 4
daily)--one 4
evaluated) 4
(treated 4
Associazione 4
Ricerca 4
sul 4
Cancro 4
2011-005487-13; 4
NCT01711632.). 4
lymphoma). 4
dabrafenib) 4
vemurafenib-treated 4
eventually, 4
[Pulmonary 4
x-ray, 4
aspergillus 4
relapsed. 4
projections. 4
HTS 4
antimalarials. 4
(BIX-01294) 4
TM2-115, 4
unexploited 4
life-cycle 4
EHMT2 4
(MLL1) 4
JmjC 4
AlphaLISA 4
(CTA), 4
MAGE-A3, 4
(KMT) 4
(KDM) 4
SFN 4
(5-aza-dC), 4
sclerosis-causing 4
microglial-derived 4
ANF 4
estrogen-responsive 4
avians 4
tracts, 4
Ca2+-ATPases 4
-regulatory 4
regionalization 4
ventricular-specific 4
(HF-1b) 4
MLC-2 4
nonmyogenic 4
Mutually 4
C250T, 4
16/105 4
16/63 4
13/18 4
17/45 4
Tumors. 4
CP-690,550. 4
Projected 4
Cave50 4
profile]. 4
2,3-dioxygenase 4
5.20 4
kinases: 4
nasopharyngitis; 4
transaminase, 4
(IFN)-γ 4
(IL-17) 4
JAKs, 4
IL-4-induced 4
CD14+ 4
56.0% 4
(4.8%), 4
PBNC 4
week). 4
AUC(12) 4
(CP-690,550 4
10%; 4
(57%, 4
ACR50 4
Oryzias 4
RGENs 4
(SSBs) 4
nickases 4
Cnr2 4
(VSCCs). 4
VSCC 4
(7-day) 4
flinch 4
hot-plate 4
administrations 4
cross-tolerance 4
Ziconotide: 4
incision, 4
microg/h 4
VASPI 4
(Prialt), 4
[125I]-labeled 4
channel-specific 4
PGE2-induced 4
FLIPR 4
fascia, 4
(<24 4
morphine, 4
Ca(V)2 4
(Ca(V)2.2) 4
occlusions, 4
sodium-independent 4
low-affinity, 4
basophil-dependent 4
(5-hydroxytryptamine 4
[5-HT]) 4
polyspecific, 4
Keeping 4
5-HTT 4
chemotherapy-related 4
RAD18 4
PSF2, 4
contemporarily 4
PSF2 4
HNSCCs 4
cisplatin-based 4
Myelodysplastic 4
G2-phase 4
FANC-mutations. 4
RPL4 4
twofold. 4
autoinhibition. 4
cytohesins 4
Recycling 4
3/GRP1 4
sialidase 4
Kindlin-binding 4
Kindlins 4
DIX 4
COX1 4
rings. 4
hemizygotes 4
Egr-1 4
remyelination. 4
Transglutaminase 4
duchenne 4
CRISPR-Cas9. 4
HD-Ad5/35 4
repopulating 4
engrafted 4
genes--Sry 4
Uty. 4
lipodystrophy, 4
Surveyor 4
(ZFNs). 4
Cre/LoxP 4
(PSC). 4
IGF-1R(+) 4
affinity-binding 4
neuregulins 4
SDF-1alpha 4
intramyocardially 4
2n 4
instrumented 4
screen-detected 4
Policy 4
CANCER 4
early- 4
PA207 4
(SNARE) 4
CD4⁺ 4
(inhibitors 4
Id3. 4
Guanine 4
Tgat 4
Tgat-induced 4
(CE) 4
shuffling, 4
pepstatin 4
FLASH 4
DAPK-1-dependent 4
epithelial-expressed 4
hyperinflammatory 4
(NLRs) 4
Typhimurium 4
caspase-11 4
necroptotic 4
caspase-2 4
(hth) 4
ungapped 4
third-codon 4
likelihood, 4
calibrate 4
amniote 4
gambiae. 4
reception. 4
395) 4
ELA2) 4
S97L 4
Ela2. 4
(UPR), 4
(ELA2) 4
antitrypsin 4
monolayer. 4
alpha-SMA 4
EXIST-1. 4
EXamining 4
Complex-1 4
(NCT00789828), 4
pre-baseline 4
trough: 4
8.3, 4
(HR(+)) 4
rhabdomyomas, 4
exemestane, 4
SEGA. 4
(RAD001): 4
(EXIST-1): 4
(titrated 4
(n=78) 4
axial, 4
ROIs 4
Everolimus: 4
(C2485). 4
inoperable, 4
milliliter. 4
(63.4±12.4) 4
(62.1±14.2) 4
(57.8±14.0). 4
Novartis; 4
NCT00411619.). 4
(BMPs) 4
GFs. 4
GFs 4
Cadherin 4
Contributions 4
hβ1-D759A-expressing 4
Attachment 4
MYOF 4
(hESCs). 4
outgrowths 4
hiPSC- 4
sacroplasmic 4
recticulum 4
Calcium-sensing 4
(TUNEL). 4
Amplitude 4
measurements) 4
(NCX1) 4
(HET) 4
(HOM) 4
decompensatory 4
(CPVT2) 4
Concepts 4
promoter-level 4
mammal. 4
'housekeeping', 4
Promoter-based 4
vivo-transcribed 4
redundancy, 4
double-homeodomain 4
Testis 4
near-significant 4
CSS. 4
CD40. 4
CXCL5, 4
CCL2, 4
sonicated 4
alphaherpesvirus 4
postinfection, 4
ruminants. 4
hormone-regulated 4
hatched 4
interferon-alpha-regulated 4
periimplantation 4
antiestrogen, 4
182,780. 4
midsecretory 4
Elov14 4
Stargardt, 4
capacities. 4
(hESC-RPEs) 4
(iPSC-RPEs) 4
xenogeneic 4
GMP-compliant 4
SGAs. 4
(D2), 4
(SNAS), 4
(gastrointestinal 4
forbidden 4
(IL-2) 4
desensitizing 4
low-nickel 4
urines 4
itching, 4
Highlights 4
lactase 4
low-Ni 4
(IgG4-RSD) 4
glucoregulation 4
4.37 4
unravelling 4
IgG4-RD 4
re-treated 4
IgG4RD 4
fibroblast-restricted 4
TRAP-Cre 4
Livers 4
nephrin 4
alpha-actinin-4 4
synaptopodin 4
disorderly 4
reinvestigated 4
Irreversible 4
(0.6 4
(NDMRs). 4
Concentration-effect 4
acetylcholine-induced 4
NDMRs 4
Isoflurane 4
combination), 4
alpha4beta2 4
S.E.M.; 4
(1-100 4
alpha-bungarotoxin 4
microM)-induced 4
analogue) 4
(d-TC). 4
antagonising 4
suramin. 4
2X 4
(P2X) 4
NF023 4
NF279, 4
d-TC, 4
prolonged-release 4
psychiatric, 4
(HETLIOZ™) 4
daylight 4
Tasimelteon, 4
Zolpidem, 4
Live-cell 4
Photobleaching 4
α-actinin1 4
α-actinins 4
Rab5-positive 4
(AFM) 4
speed. 4
zyxin. 4
potential; 4
hMSC 4
force-induced 4
paxillin, 4
synemin 4
CXCL12-mediated 4
Gαi2-dependent 4
Rac2. 4
chemokine-controlled 4
Gαi2, 4
ELMO1/Dock180, 4
Rac2, 4
corpses 4
(Hck) 4
(Scott 4
277, 4
28238). 4
80-kD 4
Pro-rich 4
216, 4
511, 4
720. 4
Crk 4
activators/effectors 4
pneumophila. 4
nonreplicative 4
K11 4
divert 4
sword? 4
TRAF3, 4
(IKKbeta), 4
PTPRR 4
(46.8%), 4
105/127 4
79/127 4
TGCTs. 4
NPM1 4
(suberoylanilide 4
5-Azacytidine 4
pAKT 4
WY-14,643 4
non-genotoxic 4
frequency). 4
low-expressing 4
over-expression. 4
56) 4
p21(CIP1), 4
hMLH1 4
(-)-viroid 4
sarkosyl. 4
(+)-strand 4
(-)-strand 4
GC-boxes 4
(HDV); 4
PINK1. 4
alpha4 4
Full-length 4
Pael-R 4
(adempas): 4
Duavee, 4
contraceptive; 4
(Adempas) 4
(Opsumit) 4
age-based 4
5-15-mg/L 4
Gentamicin 4
OAE 4
0.006, 4
(PK 4
MIC. 4
NONMEM 4
determinations, 4
sgRNAs. 4
Gate 4
nickase 4
exon(s) 4
CRISPR/CAS9 4
selectable 4
guides, 4
BCR-associated 4
Mantle 4
node, 4
MIPI 4
phosphoinositol-3 4
Sciences' 4
compulsory 4
(<10 4
0.3). 4
drug-using 4
22.7; 4
warfare 4
benthamiana 4
(K201), 4
[Ca²⁺](i) 4
[Ca²⁺], 4
glutathione. 4
4-CmC 4
FKBP12, 4
clofilium-induced 4
methoxamine 4
(increase 4
(JTV-519) 4
9.1%, 4
n.s.), 4
I(Ca), 4
ischaemia-reperfusion 4
JT 4
delta-isoform 4
81.6% 4
MALAT-1) 4
stage- 4
11q13. 4
(murine 4
Frd 4
forsythia 4
denticola. 4
Apelin, 4
apelin-APJ 4
UCP1. 4
Alzet 4
unnatural 4
TBI-induced 4
Beclin-1, 4
vaso-occlusive 4
vaso-dilatory 4
(PABPC4) 4
(RNA) 4
PABPCs, 4
HFKs. 4
relocalisation 4
PABPs. 4
LDLR, 4
PABP5 4
homodimerization 4
Lck, 4
Tec 4
Abl-related 4
RIN1, 4
RAS, 4
SH3-SH2-tyrosine 4
(c-Abl) 4
Apg-2 4
11p15.5 4
KVLQT1-gene 4
derepolarization 4
JTc 4
(JLN) 4
IsK 4
RW, 4
hypokalaemia, 4
ideas, 4
(H3K9ac) 4
recalls 4
cAMP- 4
Cys(24) 4
Forskolin, 4
3',5'-cyclic 4
Thr(17), 4
GRK2, 4
micromol/l 4
2D12 4
chronicity 4
useable 4
purifications. 4
relieved. 4
non-translating 4
self-aggregation 4
open. 4
Ge-1 4
lines; 4
Bid 4
Decitabine, 4
decitabine-based 4
P1A 4
decitabine, 4
LINE. 4
nonmethylated 4
49%. 4
Rfx6 4
Coxsackie, 4
hand-foot-mouth 4
scintigraphy. 4
enteroviruses. 4
enteroviruses, 4
antigens) 4
82) 4
(65.2%) 4
apps, 4
Android 4
app. 4
audiences 4
photograph 4
Promoting 4
intervention; 4
NOP10) 4
(DKC) 4
leucoplakia. 4
DC1 4
305000) 4
5.31 4
KLF6 4
Xp 4
CD15 4
tumor/Ewing's 4
E2/MIC2 4
MT99/2, 4
mic2 4
hCD99cytoI 4
hyperchromatic 4
rosette-like 4
excision; 4
RAG 4
XGR 4
expressors, 4
expressors 4
homology) 4
(CD99; 4
32-kDa) 4
anti-CD99 4
EFT 4
multimapping 4
biases, 4
(Mixed 4
Montebello 4
variational 4
maximization 4
sampled. 4
leverages 4
Reconstruction 4
assemblers, 4
lengths, 4
Windows 4
Cufflinks. 4
Rnnotator 4
RefSeq, 4
BrS, 4
"Brugada 4
pattern" 4
plakophilin-2 4
cardiomyopathy). 4
lidocaine) 4
PD: 4
p62-dependent 4
antiaggregation 4
symptomatological. 4
anti-aggregation 4
140) 4
lewy 4
constitutive/heat-inducible 4
(Hsc/p70) 4
α-Syn, 4
chaperone-α-Syn 4
Ssa1p-α-Syn 4
tweezer, 4
10-45 4
97-102. 4
Ssa1p-derived 4
minichaperone 4
presynapses 4
factor-1α, 4
coactivator-1α, 4
PPARalpha, 4
marked, 4
activity-induced 4
(T(3))] 4
Tim23 4
mtHsp70 4
TFB2M 4
PGC-1α 4
beta-F1-ATPase 4
alpha-glycerophosphate 4
(SOR) 4
1.39 4
SORs 4
Canary 4
Islands. 4
491 4
stress]. 4
17; 4
#270685) 4
seipin/BSCL2-related 4
Silver's 4
calnexin, 4
13.3) 4
NCT01642004.). 4
945 4
PD-L1-negative 4
3-mg/kg 4
immune-pattern 4
Carcinoma. 4
clear-cell 4
G31P, 4
(NF)-κB 4
CXCR2-mediated 4
AZ10397767 4
(HBII-85), 4
(HBII-52), 4
SNORD109 4
SNORD64 4
(HBII-13), 4
NPAP1 4
(C15ORF2). 4
FLAG-tagged 4
ARC 4
(5-HT2C) 4
dsRNAs 4
Paternally 4
transcript(s) 4
CGH), 4
∼236.29 4
(Pwcr1/MBII-85) 4
hyperphagia, 4
mealtime 4
Interdependence 4
Mitophagy 4
mitophagic 4
GSK3β-induced 4
apposed 4
mitochondrion, 4
ΔΨm 4
roscovitine, 4
morphologies, 4
tipped 4
(dynamin-related 4
(optical 4
RNAi-induced 4
reticulum-specific 4
Bcl-2- 4
Bcl-2/adenovirus 4
(BNIP1), 4
BNIP1-induced 4
fusion-fission 4
Closure 4
nick-end 4
neurons: 4
Monoallelic 4
co-precipitation 4
©2012, 4
CPVT: 4
Myocytes 4
sudden, 4
salvoes 4
(V2306I, 4
P4902L, 4
R4959Q), 4
Ni(2+) 4
Ca(v)1.2, 4
hastens 4
flunarizine, 4
LCa(v)1 4
6-OHDA 4
P-fimbriated 4
L-CJC 4
lipopolysaccharides, 4
anti-adherence 4
cranberries. 4
fructosyltransferase 4
(P<.05) 4
G3, 4
lists. 4
Assistant 4
dyslipidaemia. 4
acceptability. 4
Maalox 4
episode, 4
ketoprofen, 4
1-39); 4
≥3). 4
(0.48-2.23 4
#NCT00932698. 4
2·97 4
ULK 4
lactacystin. 4
(Stbd1) 4
metabolism: 4
GABARAPL1. 4
E2-like 4
lipidation 4
staurosporine-induced 4
(BH3) 4
enzyme) 4
Senegal, 4
vittatus 4
filamentous, 4
branchpoints. 4
subdivide 4
cMTs, 4
cMTs. 4
microtubule-organizing 4
imaging: 4
s), 4
speeds. 4
capture/shrinkage 4
yeast-like 4
Triplex: 4
'triplex'. 4
Biostrings 4
GRanges 4
GenomeGraphs, 4
rtracklayer 4
Gviz. 4
(HUVEC). 4
prenylation 4
prophylactically 4
illnesses, 4
polypill-based 4
lisinopril 4
11-dehydrothromboxane 4
bithorax-complex 4
gastroenterology 4
nurseries 4
live, 4
(63 4
district 4
worsening. 4
mL; 4
0.13). 4
9.8) 4
annulus, 4
banned 4
flesh 4
spawning. 4
pufferfish. 4
TTX, 4
non-toxic, 4
43.6 4
reticularis 4
chromatography/tandem 4
(TTX). 4
toadfish 4
snakes 4
pufferfishes 4
victim 4
bile, 4
Edible 4
genetically, 4
DM1. 4
(CTG)(n) 4
(PROMM) 4
Yorkie, 4
LATS1 4
impinge 4
aSAH, 4
not). 4
30.5%; 4
0.277), 4
0.468), 4
0.281), 4
1-2: 4
18.2%; 4
0.416) 4
cholesterol-reducing 4
normal-dose 4
dose), 4
S100-assessed 4
vasospasm-induced 4
3-5). 4
1-yr 4
(HMG-CoA) 4
independence, 4
statin-use 4
DNDs 4
DNDs, 4
Review- 4
non-users 4
(DCI), 4
DCI, 4
pressure-reactivity 4
>160 4
transaminitis 4
simvastatin-treated 4
elasticity, 4
nanotubes 4
(outer 4
torque 4
alphabeta-tubulin 4
protofilaments 4
lengthwise 4
beta-tubulins 4
Crystallography 4
"GDP-tubulin" 4
"GTP 4
(n=8), 4
46%) 4
Olanzapine 4
(1966-1999), 4
PSYNDEX 4
(1977-1999), 4
PsycLIT 4
Datastar 4
(doctors' 4
1.86; 4
77). 4
(apart 4
quetiapine, 4
hyperprolactinemia. 4
inroads 4
quetiapine 4
Citations 4
3.19 4
antipsychotic, 4
Bodyweight 4
kg/m2 4
action; 4
help. 4
neuroleptics. 4
supersensitivity 4
(PCC; 4
Adeno-associated 4
(PCC). 4
methylmalonic 4
out-of-frame 4
D-methylmalonyl-CoA. 4
nuclearly 4
13q32 4
13.3%, 4
G112D 4
alpha-beta 4
S106R, 4
E168K, 4
pccb 4
R514X) 4
5'-ends 4
C----T 4
isoleucine, 4
beta-subunits. 4
1/2-year-old 4
(P20L) 4
(S16A/T17A). 4
coimmunolocalization 4
MDS/AML 4
myelodysplasias, 4
myelodysplasia/acute 4
(MDS/AL). 4
(n=101), 4
(n=60), 4
(GSDIb) 4
(SDS)(n=55). 4
G-CSF, 4
1994, 4
glomerulonephritis, 4
camptocormia 4
Twiddler's 4
Preservation 4
medications) 4
Trail 4
bursting 4
(LFPs) 4
patients); 4
(IMDS). 4
IMDS. 4
MYO15 4
Myo6 4
MYO6. 4
4-5-fold 4
TAFI 4
stimulus-induced 4
IkappaBalpha. 4
HDAC3, 4
IkappaBgamma.NF-kappaB 4
nonobligatory 4
stimulus-responsive 4
kappaB1 4
Rutter 4
coworkers 4
SDH1-1, 4
SDH. 4
SDHAF2. 4
SDH1 4
microspherophakia 4
ADAMTS17 4
Acromicric 4
(49% 4
homogeneity, 4
liquefaction 4
full-blown 4
presenile 4
(tumor-treating 4
(Tumor 4
Fields; 4
TTFields) 4
"in-field" 4
(48.8%). 4
TTFields-related 4
TTF 4
(RGBM) 4
fundamental, 4
<or= 4
(dose 4
NovoTTF100A(TM) 4
ECs, 4
microarray-based 4
hepatectomy) 4
ammonium-containing 4
carbamylation. 4
cyanate, 4
Cyanate, 4
MPO, 4
researching 4
nephrectomized 4
arginines, 4
carbamyllysine 4
incoordination. 4
secondary-active 4
P290R, 4
transporter-1-mediated 4
l-glutamate, 4
Noise 4
closing, 4
(Ctf4) 4
(Cdc45)/minichromosome 4
(Mcm2-7)/Go, 4
Ichi, 4
Nii, 4
(hCMG) 4
complex] 4
Spodoptera 4
frugiperda 4
(Sf9) 4
AI-induced 4
East-West 4
Daegu 4
Daegu, 4
20±5 4
(F=30.261; 4
(F=21.698; 4
aggravated. 4
33.0 4
(26.1 4
(TTP). 4
514 4
antiestrogens, 4
38.2 4
arm: 4
.0023). 4
(anastrozole, 4
exemestane) 4
raloxifen. 4
neoplasia), 4
33%. 4
(p<0.001); 4
(8.5%). 4
(23.7%) 4
Taxanes 4
po 4
(DFS), 4
DFS, 4
(M-Cdk1), 4
Cyk3, 4
Inn1. 4
myo1 4
iqg1 4
PXXP 4
F-BAR 4
inn1Delta 4
many, 4
dwarfism, 4
(Skp1/cullin/F 4
box), 4
[3-5], 4
Dia2. 4
RPC, 4
hydroxyurea-treated 4
four-subunit 4
Tim1-Tipin, 4
Tof1-Csm3, 4
exponentially. 4
automata 4
WCS 4
polymorphism) 4
(4.3%), 4
(3.6%), 4
(2.9%). 4
Alveolar 4
proteosomal 4
engulfs 4
non-delta 4
SRP9/14, 4
Alus. 4
'miRNA 4
ERP) 4
4.5S 4
[3H]thymidine 4
(AFM), 4
AFM, 4
seedlings. 4
dimers) 4
photo 4
skotomorphogenesis 4
photolabile 4
porB 4
xantha 4
(highly 4
chlorophyll-deficient) 4
MEP 4
NADPH-protochlorophyllide 4
violaceus 4
PORs. 4
etioplast-chloroplast 4
light/dark 4
galactolipids 4
(so-called 4
rye 4
etanercept) 4
gain-and-loss-of-function 4
TERMINAL 4
FLOWER2 4
(TFL2) 4
ripening. 4
(DRMs) 4
pericarp. 4
zmet2-m1 4
inbreds 4
(CMT3), 4
"chromomethylase" 4
(CMT1) 4
1/10(-7) 4
Col-0 4
Ler, 4
RLD, 4
retrotransposon, 4
(CMT1 4
trait). 4
(LRSAM1) 4
(Really 4
R120W 4
(NEFL) 4
2E 4
(CMT2E) 4
(demyelinating 4
axonal) 4
neurophysiological, 4
LITAF, 4
CMT1C. 4
stark 4
Gly358Arg 4
Lys558Glu 4
Thr855_Ile856del 4
ambulation, 4
IRF-3/IRF-7, 4
HMGI(Y). 4
(p50/p65), 4
ATF-2/c-jun, 4
IRF-7, 4
HMGI(Y), 4
enhanceosome-dependent 4
VO2, 4
NT-pro 4
MMDiff, 4
data-adaptively 4
craniotomies 4
thoracic, 4
(50%; 4
meningiomas: 4
grade: 4
progress/recur 4
Subtotal 4
2.47, 4
radiosurgery, 4
1.41-45.0; 4
2.18-218; 4
detaching 4
outdated 4
ninety-one 4
353 4
patient-years. 4
5-, 4
179), 4
(158 4
Cep135/Bld10, 4
centrosomes. 4
C-NAP1 4
sterility. 4
pericentriolar 4
Filamentous 4
HA- 4
narrower 4
0.97-1.61; 4
[3.4%] 4
[2.2%]; 4
1.16-2.39; 4
A-002 4
(CFR) 4
substudy, 4
(hsCRP) 4
lipoprotein-apoE 4
nothing. 4
(AUC0 4
-∞ 4
failure/end 4
(CLR 4
UGE. 4
(GMR: 4
AUC0-∞ 4
AUC(τ,ss) 4
(AB 4
absorbed. 4
audiometry. 4
orbital-globe 4
revisions 4
maturity 4
includes: 4
condyles 4
FGFR2-related 4
family; 4
ATN 4
(MBT-AS) 4
MBT-AS. 4
(cognitive-behavioral 4
CBT) 4
clients. 4
experiences, 4
symptomology 4
non-ASD 4
couples, 4
lesioning. 4
toxin-induced 4
A(2A) 4
'on' 4
amyloidotic 4
King's 4
non-contrast 4
p=0.008), 4
Separately, 4
LGE, 4
inclusion-body 4
(α-syn), 4
4.4-fold 4
demonstrates, 4
KFERQ-containing 4
box-related 4
Pax2 4
96-kDa 4
(lgp96), 4
lgp96 4
(LAMP-2A). 4
Danon 4
pair-fed 4
mediated-autophagy. 4
being. 4
microautophagy, 4
(hydroxychloriquine) 4
"Apoptosis: 4
Decades 4
Later". 4
thin-walled 4
Extremely 4
RE-LY 4
(126 4
AFPs 4
synthases. 4
carboxylate, 4
sub-zero 4
UW/AFP 4
58) 4
constrictions, 4
deoxyuridine 4
superfamilies, 4
hydration. 4
THPs 4
SHM 4
AID-dependent 4
postinitiation 4
Ser-5 4
Pausing 4
Cdk7 4
establish, 4
CTD, 4
Ser5 4
SIRT6, 4
Struvite 4
21-30 4
baclofen. 4
(hypothalamic) 4
dihydroergotamine. 4
fast-acting 4
(CH). 4
Units 4
sphenopalatine 4
ergotamine 4
series). 4
recurs 4
migraine: 4
(SERCA2), 4
(NFκB) 4
(epsilon 4
(CKO) 4
migrate, 4
right-hand 4
ratio; 4
95%) 4
(1,491-13,107) 4
≤0.95. 4
2D:4D. 4
(HRs 4
0.92-1.08 4
0.93-1.08 4
length: 4
urolithiasis, 4
21-hydroxylase 4
(FTLD), 4
APOEε4. 4
(1216 4
1.29-11.44]; 4
AD; 4
6.19 4
1.86-20.61]; 4
0.0007 4
FTD). 4
2.93×10(-17)). 4
sAD. 4
Aβ₄₂ 4
MPP(+) 4
Subjecting 4
Hyperactivation 4
signaling) 4
four- 4
kinase/protein 4
GHSR1a 4
HSP60 4
FAIM2 4
(OR=1.02, 4
6-16 4
peroxiredoxins 4
miR-205, 4
equal, 4
(BCa). 4
exfoliated 4
16-fold 4
Syndecan 4
genitalium 4
4-palindrome 4
6-palindrome 4
M.jannaschii 4
prophages 4
semi-palindromic 4
Markovian 4
significance: 4
rs7736074 4
rs4975596 4
10-9). 4
(mCRC). 4
89) 4
76) 4
EGFR-R497K 4
(p=0.045). 4
G/G 4
centrally. 4
68.5% 4
4.7% 4
35.8% 4
7.7% 4
Kirsten 4
JAK/STAT3 4
Epimedium 4
(RCC). 4
frustrating 4
radiosensitizing 4
STAT1-dominant 4
pSTAT3, 4
Inhibits 4
carcinogen-induced 4
0.035, 4
(AARSs) 4
mis-incorporation 4
non-standard 4
myostatin, 4
Senp2(-/-) 4
MEF2A. 4
c-Ski 4
(SUMO-1). 4
(Lys-50). 4
PIASx 4
SnoN. 4
Myogenic 4
USP25. 4
(USP25), 4
(UIMs) 4
(HIE) 4
(NEC) 4
34.5 4
rewarming. 4
noncooled 4
stripping 4
β-tubulin, 4
(TPN). 4
diaphysis 4
radius, 4
porosity 4
modeling-based 4
Giant-cell 4
Dmab 4
(fostamatinib 4
disodium), 4
Syk, 4
FcgammaR-mediated 4
RIP-mOVA 4
IL-10-producing 4
microCi 4
cohorts: 4
(1/9) 4
R940406 4
(R406), 4
SYK. 4
fostamatinib. 4
(Fostamatinib) 4
(Ibrutinib, 4
AVL-263). 4
GDC-0834, 4
PRT318 4
CXCL12, 4
CXCL13, 4
Anisocoria 4
clearest 4
Laryngological, 4
Otological 4
fluctuated 4
[Miller 4
GQ1b, 4
Demyelinating 4
unusual. 4
WSS1 4
SRS2 4
Polalpha 4
asymmetric) 4
Evol. 4
Chargaff 4
immunodeficiencies, 4
CCND1 4
(UCA1) 4
locus), 4
Neurodegeneration 4
proteostatic 4
Unfolded 4
(PQC) 4
(myotubularin) 4
immunoprecipitate 4
Retrievers 4
centralization 4
grandson 4
sisters, 4
quasispecies 4
Alamos 4
Kimura 4
educated 4
Henan 4
subtyped 4
CRF01-AE 4
virus-1 4
Shanghai, 4
efavirenz 4
10.RU.6637 4
superinfection. 4
82%) 4
Bangladesh, 4
migraineurs. 4
T-ADP 4
neurotransmittors 4
Paediatrica. 4
(ARB) 4
(10.1 4
addiction." 4
permeabilize 4
irrevocably 4
abatement 4
overrides 4
angiogenesis-dependent. 4
Oncogenes 4
"addiction" 4
illusion 4
"oncogenic 4
shock," 4
hypercapnia-induced 4
post-anaesthesia 4
1670 4
ml(-1); 4
ml(-1)) 4
1.90 4
1.28 4
sevoflurane/remifentanil 4
procedures: 4
GSDMD, 4
8%. 4
tandem, 4
antipeptide 4
ER-targeted 4
fkh1 4
FKH2. 4
Anaphase-Promoting 4
Fkh 4
fkh2Δ 4
fkh2Δ, 4
Ageing 4
phytate 4
insulin/insulin-like 4
Deacetylation 4
tetraparesis 4
Edwin 4
neuro-ophthalmologic 4
cst-II 4
(Asn51), 4
GalNAc-GD1a. 4
GalNAc-GD1a 4
anti-GM1b-positive 4
'anti-GQ1b 4
(absent 4
(OA), 4
interleukin-1beta, 4
miR-146a/b 4
MicroRNA-124a 4
hypothesized, 4
Histocompatibility 4
miR-146a/b, 4
miR-150, 4
(IRAK1), 4
(OASFs) 4
(5-azaC). 4
SC-514. 4
OASFs 4
LPS; 4
ESR, 4
miR-346, 4
FLS, 4
*, 4
(SF), 4
(TghuTNF, 4
Tg197) 4
(miR-seq) 4
miR. 4
miR-323-3p. 4
Wnt/cadherin 4
β-transducin 4
miR-seq-based 4
WNT/cadherin 4
SLE: 4
JRA 4
(TT 4
p=0.007) 4
Gly380Arg 4
bregma 4
synostosis) 4
single-amino-acid 4
oesophagectomy. 4
4.7; 4
Colo320 4
0%; 4
26%). 4
0.027, 4
hyaluronate 4
HA-induced 4
17/85 4
clonotypes 4
6(v6) 4
immunohistochemically. 4
poorest 4
CD44v5, 4
CD44v7 4
(2.2%). 4
BCC, 4
CD44-9v 4
CD44-6v 4
4.14 4
cystometry. 4
(36.9%), 4
09 4
05 4
06 4
64.1% 4
51.5% 4
practitioner. 4
biofeedback, 4
Anglo-Saxon 4
countries) 4
retraining 4
terodiline. 4
38%. 4
Information. 4
Archive, 4
(OMIA), 4
PubChem 4
Snat 4
summarised. 4
2023 4
3.6-7.6), 4
1.7-12), 4
oligoarthritis 4
4.1, 4
DMARD, 4
(JIA). 4
93%. 4
(n=1), 4
synechia 4
oligoarticular 4
(range) 4
RNMT. 4
SAHH 4
cap1 4
(S100A7) 4
allergen. 4
sucralfate, 4
aluminium-containing 4
antacids, 4
criteria), 4
renin, 4
high-expression 4
membrane-permeable 4
Arp2/3 4
bundling/filopodium-forming 4
SH3-binding 4
(MIM) 4
IRSp53/MIM 4
filopodium-inducing 4
IMD-induced 4
SH3-dependent 4
IMD. 4
Spt-Ada-Gcn5 4
TBP-associated 4
ZnF, 4
Hamartin, 4
1-880), 4
Plk1-binding 4
(T310 4
S332). 4
T310 4
S332 4
(T417, 4
S584 4
T1047) 4
Biomolecular 4
58Q 4
viroidlike 4
translated; 4
enzymes) 4
Database: 4
viroid. 4
doubted 4
schistosomulae, 4
helminthic 4
Praziquantel 4
(PZQ) 4
17/23 4
PZQ. 4
(n=28), 4
anti-helminthic 4
faeces, 4
steroid, 4
Lake 4
divers. 4
cercarial 4
laborious 4
gradually. 4
Spanish. 4
Preventative 4
0.005%/h 4
0.031 4
trials.gov 4
clarification. 4
mpMoRFsDB 4
eighty-two 4
(HDL), 4
menopause-associated 4
progestins, 4
medroxyprogesterone 4
flashes: 4
enlisted 4
magnet 4
AAV9-DES 4
"pseudodeficiency 4
alpha-glucosidase". 4
p.R600C, 4
p.S619R 4
p.R437C 4
p.C103X 4
halfway 4
p.G576S 4
glycogen, 4
p.E689K, 4
Anti-human 4
immunodiffusion, 4
immunotitration 4
(glycogen 4
hindbrain, 4
early-onset, 4
(GAA), 4
Fractions 4
CRIM-positive 4
ventilated, 4
rhGAA 4
(4.8%) 4
muscle-a 4
Glycogen-storage 4
Asp-645-->Glu 4
tissue/organ 4
(H134R) 4
voltages, 4
irradiance- 4
offers: 4
irradiances; 4
(activation, 4
inactivation); 4
Temperature-scaling 4
(Q10) 4
experimentally-validated 4
Light-sensitive 4
(NpHR) 4
Opsins 4
brain-states 4
Gq 4
Laurentian 4
Mountains, 4
millisecond 4
monoexponential 4
ChR2, 4
potential: 4
"optical 4
clamp" 4
light- 4
voltage-sensitive. 4
light-driven 4
channelrhodopsin-2, 4
ChR2) 4
halorhodopsin, 4
NpHR) 4
ingenetically-defined 4
behaviorally-relevant 4
neurons) 4
confined, 4
(ChR2). 4
monopolar 4
channelrhodopsin-1 4
Channelrhodopsin-2 4
FTIR 4
photointermediates 4
(PAP), 4
Hakim--Adams 4
(NPH): 4
NPH, 4
Juan 4
(normotensive 4
TOB1 4
(Iressa) 4
gefitinib-sensitive 4
feathers 4
36%. 4
6-17 4
[Behavior 4
(VSK); 4
(MBAS)]. 4
WISC-III, 4
35/46 4
MBAS 4
VSK 4
Lujan-Fryns 4
hypomelanosis 4
disorders--less 4
Sln 4
futile 4
Sln-null. 4
calcium-calmodulin 4
RSYQY 4
69.8 4
millinewtons) 4
proteoliposomes 4
died; 4
99%) 4
(67% 4
Scalp 4
435, 4
LADD 4
Hypochondroplasia, 4
encoded, 4
(Ach 4
Hch). 4
unquestionable 4
Muenke-type 4
74-100% 4
paternal); 4
(c.1138G>A) 4
DNA(cffDNA) 4
(Rh) 4
D-negative 4
technique; 4
Rhogam 4
Fruitful 4
(those 4
MassArray 4
(cff) 4
fundamentals 4
BNP116.I-1c 4
10(13) 4
AAV9:hYAP 4
CUPID 4
2b) 4
Enrolled 4
PP1β 4
S100A1, 4
Transgene 4
extracardiac 4
sarco-endoplasmic 4
Cinryze 4
kallikrein. 4
ecallantide, 4
kallikrein, 4
Dyax 4
Corp.) 4
ping 4
pong 4
BVT. 4
DAD-induced 4
VT, 4
KCNJ2. 4
infrahisian 4
"bidirectional 4
tachycardia", 4
univocal. 4
BTBD9, 4
Prompted 4
(CaM), 4
Ca2+/CaM 4
PBL-derived 4
non-CKD 4
[Atrial 4
things, 4
fewest 4
Crib-biting 4
Narcotic 4
t1/2, 4
peripupillary 4
p.Tyr1055Cys, 4
p.Ser1071Pro 4
p.His1045Arg, 4
C-zinc-finger 4
(C-ZF) 4
Variable, 4
mutation-dependent, 4
C-ZF 4
[1998], 4
MCAs 4
"Mowat-Wilson 4
occurrences; 4
hallmark, 4
disease/Mowat-Wilson 4
lymphocyte-derived 4
KNGP 4
(RWR) 4
ORIENT 4
(neighbor-favoring 4
reinforcement) 4
intensified. 4
cross-validation, 4
lab, 4
2006), 4
norvegicus 4
Trust 4
1096 4
GPEC: 4
MedSim, 4
relatedness. 4
DADA 4
meant 4
yeast). 4
cystogenesis 4
p75NTR 4
vestigial 4
hottest 4
P/LPXY 4
Glis3. 4
Cysts 4
ciliogenesis. 4
pck 4
rainforest 4
776-1516 4
53-77% 4
delimitation, 4
phylogeographic 4
understory 4
museum 4
time-scales 4
Neoaves, 4
capture) 4
1,541 4
(iloprost, 4
treprostinil. 4
[Long-term 4
451 4
bosentan. 4
(EP2 4
EP4). 4
placebo-corrected 4
anti-cytokine 4
FP 4
fluorescein-labeled 4
ORC4 4
menstruation. 4
224690) 4
(ear, 4
(SS). 4
(MGS). 4
microtia 4
receding 4
ATR-SS 4
pediatrics 4
beta-glucocerebrosidase, 4
earmark 4
reticulum-localised 4
H(2)(15)O 4
50.1 4
synthesis: 4
α-syn-GCase 4
macrophage-targeted 4
French, 4
RT4 4
(sq) 4
(EMSA), 4
tumor-selectively 4
phospho-Akt, 4
cancer-initiating 4
BCICs 4
(17-AAG), 4
benzoquinone 4
ansamycin 4
IGF-IR, 4
IKK-β, 4
sequestration-mediated 4
(MDB) 4
MDB. 4
well-understood. 4
MB. 4
Ca(2+)/S100 4
FKBP52, 4
Hsp70/Hsc70 4
single-turnover 4
microalgae 4
Algal 4
industries. 4
(C-PC) 4
2.25 4
faintly 4
remnants. 4
phycobilisomes, 4
Phycocyanin--a 4
bilin 4
FRAP 4
urceolata. 4
565 4
R-phycoerythrin. 4
microalga 4
Phycobiliproteins 4
phycocyanin, 4
cytometer 4
cpeB, 4
7601 4
bases) 4
7120. 4
ceylanicum 4
phycocyanin-producing 4
Rod 4
beta-allophycocyanin 4
beta-phycocyanin 4
PLK2, 4
(KO), 4
(Het) 4
kinase-2, 4
2536 4
PLKs 4
aggregate. 4
hypodermal 4
artifacts, 4
re-assess 4
earliest-diverging 4
sex-locus 4
(RPS9-RPL21) 4
(glutamyl-prolyl 4
ubiquitin-ribosomal 4
S30) 4
choanoflagellates, 4
filasterean 4
opisthokonts 4
TPT, 4
HMG, 4
hellem 4
isolate). 4
idiomorphic 4
TPT 4
sex/sex-related 4
Plantae 4
subkingdom, 4
kingdoms, 4
Protozoa 4
Nomenclature, 4
Protozoa. 4
Animalia 4
bilaterian 4
subkingdoms: 4
subkingdom 4
Archaebacteria 4
TRUNCATED) 4
intestinalis, 4
Microorganisms 4
(HIV), 4
(SND) 4
Emery 4
attested 4
FXIa 4
namely: 4
Propagation 4
(UFH, 4
argatroban, 4
Btn1p 4
CLN3P 4
E295K 4
ARB1 4
-37%) 4
-42%) 4
-85%) 4
-73%). 4
(TAK1) 4
generates, 4
-I 4
N/O-linked 4
1460 4
membrane-impermeable 4
probabilities. 4
7.7%. 4
energy-saving 4
Isochores 4
region: 4
mosaics 4
next. 4
Spectral 4
GRK2/HDAC6 4
balanced, 4
CHO10 4
CG-4 4
nocodazole, 4
Domain-selective 4
(HDAC6)-mediated 4
7,392 4
p58, 4
a-tubulin 4
excisions 4
disc, 4
colors. 4
vitreo 4
TGF-β2-treated 4
(HRE). 4
matrices), 4
Notch-1is 4
CCN1-induced 4
CCN1-dependent 4
(cancer 4
ST3GAL1/3/4 4
FUT3 4
FUT2 4
MMP-2/9 4
TbetaR-I. 4
Cytomix, 4
(TbetaR-I). 4
TbetaR-I, 4
TbetaR-I 4
Multistep 4
Ha-Ras 4
(TGFbeta-R) 4
TGFbeta-R 4
transition; 4
E-cadherin; 4
FGF-1 4
dependency. 4
iron-starved 4
Atm1 4
paralog. 4
glutaredoxins 4
Grx3 4
FOB 4
(ferrioxamine 4
resonance) 4
AFT2 4
non-reductive 4
Hydrophobic 4
flurry 4
#235730) 4
polytopic 4
prenatally. 4
(SSCP). 4
UTX 4
35Senh 4
P300 4
autosomal-dominant, 4
LFS, 4
(LOH). 4
leuprolide 4
Hyperprolactinemia 4
galactorrhea. 4
physiologic, 4
impotence. 4
hyperprolactinemia, 4
medically, 4
perforated 4
389 4
hyperprolactinaemic 4
(59.2 4
gonadotrophins 4
Infertility 4
G:U/T 4
pyrimidine-binding 4
N(4)-ethenocytosine. 4
(Mug), 4
U: 4
2-chloroacetaldehyde 4
G.C 4
A.T 4
(Mug) 4
Djungarian 4
chronotropy, 4
inotropy, 4
quotient, 4
ketonuria, 4
cisplatin/vinorelbine 4
(AE). 4
47). 4
matuzumab-treated 4
(OG) 4
Refinement 4
dataset: 4
V(2) 4
(SD)] 4
lethargy 4
(100, 4
Confirming 4
uncouplers 4
GRAF1a 4
Exclusive 4
oxygenated 4
(Plasmodium 4
'piggyback' 4
PSD-95 4
nitrones 4
PBN-nitrones 4
PBN 4
OKN-007 4
panels), 4
reporting, 4
years]; 4
(tPA) 4
(APC), 4
(PAI-1), 4
3306 4
activities-of-daily-living 4
3195 4
(1588 4
(1607 4
P=0.33 4
trichotomization 4
NCT00061022 4
[ClinicalTrials.gov].) 4
Missing 4
case: 4
(SAINT) 4
full-scale 4
1.42). 4
1.98; 4
flibanserin-treated 4
Usability 4
engines 4
RAD18-mediated 4
(FANCI)-FANCD2 4
monoubiquitylation. 4
MRE11 4
inactivation; 4
hypoxia-reperfusion 4
(neuro)protective 4
surge. 4
radical-induced 4
nonprotein-bound 4
germane 4
stenting. 4
harmful. 4
deferred 4
Within-group 4
(Nf) 4
Dallas, 4
0.021) 4
corticobasal 4
neopterin 4
neuroasymptomatics 4
HAD 4
GFAp 4
NF-light(®) 4
73.3% 4
Nf 4
(95.4 4
(4.4 4
p<0.0001 4
bvFTD 4
0.45, 4
astrogliosis, 4
multiple-system 4
astrogliosis. 4
CXCR4-positive 4
relapse). 4
CXCL12. 4
(P=0.005), 4
triiodothyroacetic 4
49.5 4
2.7) 4
SERCA/PLB 4
2.0-fold, 4
LacZ 4
'low 4
T3-deprived 4
T3-supplemented 4
(P=0.003) 4
banded 4
immunodetectable 4
CV-1 4
255 4
americana 4
phalangeal 4
Assisted 4
PLAC4 4
RT-MLPA 4
(MSRE 4
PCR) 4
AIRE/RASSF1A 4
0.33-1.77, 4
(95/98). 4
chromosome-21-specific 4
'random' 4
non-promoter 4
Trimethylation 4
~15% 4
(H3K4me1 4
(PABPs) 4
micron) 4
ethmoid 4
9-10 4
elasticity 4
NF-H 4
Ranged 4
lecture 4
progerin, 4
endeavour 4
terrible 4
GGC 4
mCry1 4
(CRY1), 4
pacemakers 4
cryptochromes 4
(Cry1 4
Cry2) 4
/Cry2(-/-) 4
(E 4
box). 4
(D 4
euthanized 4
Dbp 4
ultradian 4
USP2a 4
dampens 4
laminectomies 4
Outreach 4
Categorical 4
6.4%). 4
immersive 4
[48 4
ICUs 4
overcrowding 4
P=0.70). 4
(data 4
(RRR 4
1.40, 4
postinjury 4
non-neurogenic 4
Meissner 4
DNMT3 4
IGF2R, 4
PEG10, 4
Cp 4
tudor 4
"maintenance 4
methylation." 4
de-ubiquitinating 4
Lee, 4
Muller, 4
SET7 4
(DNMT1), 4
veratridine. 4
veratridine 4
methyltransferase-1 4
515 4
S515A 4
3b. 4
48.3 4
zebularine, 4
(DNMTs), 4
projecting 4
protooncogenes, 4
Estrogens 4
Creation 4
[DNA 4
(AER) 4
vasodilation, 4
Balb/c 4
PV. 4
malformation(s), 4
arrangements. 4
(0.25 4
SVR, 4
SVI, 4
kg[-1] 4
min[-1] 4
L/min 4
aids. 4
dystrophin-deficient 4
75.5 4
12.2%, 4
VFs. 4
Relief 4
(1987-2009). 4
1.63-6.55]), 4
1.04-4.57]) 4
6.88 4
2.91-16.27]). 4
metabolisms 4
ascribable 4
alendronate. 4
24-year-old 4
Alendronate 4
intestinal-type 4
51.2% 4
chow-fed 4
enterocyte 4
73.3%, 4
65.6% 4
MUC 4
brood 4
species-wide 4
poplar 4
SLC2A4 4
sweep) 4
HmB 4
bar. 4
fix 4
lyrata 4
Phylloscopus 4
warblers 4
h=0 4
peer-reviewed, 4
(CMTX5). 4
19; 4
18). 4
U/gHb 4
[RR], 4
2.27 4
3.71; 4
(16.2 4
nitroprusside) 4
ODQ 4
RASMCs 4
H(2)O(2)-dependent 4
AMP:ATP 4
AUUUA 4
M9 4
alanine-rich 4
HSP72. 4
adenylate-uridylate 4
[HuR-SIRT1 4
mRNA] 4
Physiologically, 4
branching. 4
FGF10 4
DICER1 4
Col1a, 4
Col3a 4
Post-transcriptional 4
Antiapoptotic 4
apoptosome. 4
Elavl1, 4
Areata 4
Baricitinib. 4
attains 4
L/h. 4
(1.2μg/100g 4
cross-roads 4
immune-endocrine 4
acid-soluble 4
(MTOR) 4
Mtor-ablated 4
IKKγ 4
Ubc13(flox/flox)K5-Cre 4
linkage-specific 4
(VSMC) 4
homeoproteins 4
aptamer-based 4
chelate 4
B-form 4
(MCF-7) 4
(MUC1) 4
12-mer 4
eluting 4
magnetoimmunosensor 4
(EDC) 4
mL(-1), 4
Phosphopeptides 4
subnanomolar 4
AuNPs 4
lysate, 4
(SH) 4
609 4
genotype-negative 4
-binding 4
Tachycardia. 4
shocks. 4
Ca(2)(+) 4
CaCl(2) 4
SQTS, 4
risk-stratified 4
anti-adrenergic 4
Young, 4
(channelopathies) 4
Leaky 4
RyR2-specific 4
(S107) 4
14RyR(R4496C)) 4
5/14 4
RyR(R4496C), 4
beta-blockers) 4
caffeine: 4
(P=0.56 4
(VF), 4
topoisomerase-negative 4
Chemoprevention 4
Connectivity 4
(VPA), 4
TRAIL-resistant 4
(MLP). 4
4-week-old 4
sensor. 4
W4R 4
(C58G) 4
HCM-causing 4
MLP-N-RAP-alpha-actinin. 4
1100 4
CRP3 4
T790M. 4
rociletinib 4
CNS-collapse 4
(16.7 4
XAV939 4
WZ4002 4
mid-third 4
sequentially, 4
FGF-TX 4
<.01). 4
philtrum 4
Alu-related 4
(NSD1), 4
bite, 4
menin. 4
non-MEN1 4
appropriated 4
Men1 4
1-12 4
Men1(+/+) 4
(proliferation 4
enteropancreatic 4
cosegregate 4
collagenomas 4
gastrinomas, 4
hemi- 4
18q, 4
nonhereditary 4
valosin-containing 4
importer 4
Tn-seq: 4
Desulfovibrio 4
acceptor. 4
cataloged 4
Trait 4
postulates, 4
dysglycemia 4
dysglycemia, 4
NS3-NS5B 4
GST-pull-down 4
flaviviral 4
(deleterious 4
0.014 4
Genotoxicity 4
micronuclei. 4
hepatocarcinogenesis, 4
XPF, 4
p.Ser489X 4
1:19, 4
(4.0%) 4
encephalopathic 4
white-matter 4
Smoothened, 4
adhesion-like 4
molecule-related, 4
Ihog, 4
nonorthologous 4
BOC 4
Hh-mediated 4
Hh-containing 4
lattices. 4
(Ihh). 4
proestrus 4
(1.5, 4
coitus: 4
dpc). 4
Gli1) 4
periepithelial 4
Hhs 4
IHH. 4
(FU) 4
EpCAM-positive 4
GSCs 4
hyper-activated 4
hydroxychloroquine, 4
V617F 4
503 4
90.9% 4
(73.3%) 4
mCP 4
transcription-replication 4
skew, 4
(412 4
position-effect-variegation 4
meta- 4
contain, 4
M31(p21). 4
sex-chromosome 4
chromosomal-context-dependent 4
context: 4
Me-HA, 4
glyosaminoglycans. 4
turbinate 4
sonication. 4
gelatin, 4
(BG) 4
trichrome 4
L929 4
High-levels 4
low-transcription 4
Transcription-Associated-Mutagenesis 4
Top1p-DNA 4
Top1p 4
osteoarticular 4
Drawing 4
keys 4
Trastuzumab. 4
99.6% 4
advice, 4
Rochester, 4
immunochemistry 4
T-channel 4
ETX 4
Ca(v)3.2, 4
1H, 4
K(I) 4
1G 4
1H 4
mM. 4
(ZNS), 4
lomerizine, 4
tremulous 4
(TJMs), 4
anti-TJM 4
T-type-channel 4
(+)- 4
gallopamil 4
(MRPs) 4
(mitoribosome) 4
protein-rich, 4
stripped 4
monosome 4
10(-)(7) 4
s(-)(1) 4
diuretic, 4
low-molecular-weight, 4
hypertension-induced 4
intrarenal 4
angiotensinogen 4
(MAS) 4
(NMR) 4
(AT1R) 4
expelled 4
IHF. 4
Southwestern 4
invertasome 4
(GalR) 4
Fraction 4
dnaA46ts. 4
hupA 4
hupB 4
HUbeta. 4
DnaA, 4
hmU-containing 4
cPHB. 4
repressosome 4
maritima. 4
constrains 4
(NAPs) 4
NAP, 4
single-dose, 4
AIx 4
(1.10, 4
NTG-induced 4
freedom. 4
(BBB), 4
triptan 4
(BIBN4096BS) 4
2-24 4
1263 4
ee. 4
27%. 4
CGRP-induced 4
co-localisation 4
[N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-yl)piperidine-1-carboxamide] 4
200-300 4
8.43 4
aura. 4
microm) 4
aluminium 4
OM, 4
0.012 4
(SPECT) 4
notable. 4
Lipophilic 4
cm(-2) 4
infections) 4
TA121 4
0.89). 4
unstudied 4
reproduced. 4
5.2%, 4
Westphal 4
240) 4
4.85 4
neuroperformance 4
(9.1% 4
confines 4
methylguanine-DNA 4
(MGMT); 4
carmustine-impregnated 4
rER 4
Dicer-dsRBD 4
magnum. 4
manifestations]. 4
anticipation, 4
(FANCL) 4
(FANCM), 4
FAAP100, 4
subcomplex. 4
FANCM, 4
bleomycin. 4
Tempol 4
JP4-039 4
phlebitis, 4
exchanges, 4
pleotropic 4
Anemia: 4
SNM1B 4
casting 4
net. 4
Res. 4
NM3 4
COX-1 4
unintended 4
Select 4
STR 4
14.8% 4
GFAP-positive 4
Rodentia 4
disconnections 4
patients--19 4
(VS), 4
(EMCS)--and 4
tractography, 4
Resting-state 4
stimulation; 4
(CORAL) 4
(R-ICE) 4
(R-DHAP). 4
immunophenotype 4
(DHAP) 4
R-ICE 4
(21% 4
ASCT 4
courses, 4
lymphoma]. 4
NHL. 4
lamellated 4
microcystic 4
(80%), 4
psammona 4
interposing 4
histogenesis. 4
plexus; 4
entwined 4
microcores 4
microns. 4
Hydroxyapatite 4
various-sized 4
malformative 4
extracellularly 4
passively 4
LAMBERT-EATON 4
MYASTHENIC 4
SYNDROME: 4
eATP 4
macrophage-like 4
flagellins 4
IMPORTANCE 4
unmanipulated 4
intermedia 4
nucleatum 4
Plaque 4
dark-field 4
ligature-induced 4
gathers 4
CNOT6L 4
PAB1 4
yCAF1 4
Mg2+-dependent 4
q12), 4
Homer 4
ets 4
acpB. 4
pXO1(+) 4
-35 4
SigA 4
+36 4
15-fold. 4
mycoides 4
PlcR-regulated 4
GFR. 4
creatinine) 4
survive. 4
FGF-23 4
m(2)) 4
1.72; 4
Lyon, 4
Cockcroft-Gault 4
3-hour 4
Alpine 4
CrCl 4
(BTP) 4
m) 4
eGFRcr-cys 4
eGFRcr 4
NRI 4
Iohexol 4
0.0001. 4
enough? 4
renal-related 4
perfecting 4
amplification-free 4
1861 4
US-based 4
non-invasively, 4
counselors' 4
46.8% 4
0.0168% 4
€257.09 4
aneuploidies]. 4
T18, 4
T13, 4
47,XXN 4
Karyotypes 4
positive). 4
cytotrophoblastic 4
collections, 4
dating, 4
monochorionic 4
(III-B) 4
accredited 4
assurance. 4
-depleted 4
CA). 4
(DCP) 4
(HypoPP) 4
opener, 4
pinacidil 4
myotonias, 4
Administration-orphan 4
dystrophy-1 4
(DM-1). 4
DM-1, 4
oligonucleuotide 4
CLCN1 4
7a 4
DM-2. 4
molecularly-based 4
5%). 4
IQ, 4
List 4
Abilities 4
II-hydrocephalus 4
crude. 4
myelomeningocoele 4
voluntarily. 4
0.17) 4
17.0; 4
RESULTS. 4
(5-18 4
parent-completed 4
[worst 4
QOL] 4
[best 4
QOL]). 4
overdrainage, 4
(Hydrocephalus 4
(gross 4
measures), 4
Inventory). 4
F-test). 4
1.32, 4
smoke, 4
Risks 4
1.91; 4
18; 4
1.22; 4
counties), 4
0.72-1.3]. 4
fathers). 4
0.80-1.45) 4
ever-smokers 4
0.75-1.78). 4
for<1 4
for>or 4
amides, 4
N-nitroso 4
(acBSA) 4
(TCC). 4
[Systemic 4
(P=0.42). 4
alvei. 4
H-ficolin 4
Hakata 4
complement-activating 4
fibrinogen-like 4
Ficolin-3-mediated 4
(LCP), 4
MBL-associated 4
protease-3 4
mannose-binding 4
Ficolin-2, 4
Ficolin-3. 4
(Hakata 4
1203 4
1205 4
(nivolumab, 4
[MK-3475]) 4
(BMS-936559, 4
MPDL3280A). 4
(CheckMate 4
063): 4
multi- 4
antiphosphotyrosine 4
Phosphopeptide 4
Spt5, 4
PAF 4
cdk9 4
ZNFs 4
p85alpha, 4
1193 4
rs2535629. 4
1.05-1.39, 4
0.0077). 4
0.98-1.26, 4
0.092). 4
(schizophrenia 4
MDD) 4
1.03-1.28, 4
ITIH4 4
GLT8D1 4
pre-planned 4
102, 4
[CIs], 4
74.1%, 4
68.4%, 4
58.2%, 4
P=0.0005; 4
0.69; 4
P=0.0036). 4
(33.7%) 4
(32.9%), 4
89.4%, 4
96.7%, 4
(19.9%). 4
Anti-programmed 4
anti-cytotoxic 4
PD-1-based 4
Pembrolizumab, 4
PD-1-targeted 4
-14 4
Late-replicating 4
anything, 4
constancy 4
is: 4
non-selenoprotein 4
recognises 4
vessel-organ 4
TAK1, 4
P65 4
NOD1-RICK-NF-κB-mediated 4
NACHT-LRR 4
Nod2fs 4
SCW 4
g-d-glutamyl-meso-diaminopimelic 4
(iE-DAP) 4
IL8; 4
(MMP9) 4
VCAM1. 4
NFκB, 4
Nod2, 4
TLRs, 4
prolabor 4
myeloid, 4
hyporesponsive 4
domain-1 4
MNs. 4
(PPARγ, 4
Mongolian 4
(WAT) 4
ovalbumin 4
(PADs), 4
peptidylcitrulline 4
metabolism-associated 4
arginines 4
collisional 4
gingipains 4
citrullinate 4
Autoimmunity 4
epitope(s) 4
precordium 4
athletics-related 4
offices. 4
Wayne 4
permethrin 4
inoculating 4
infestations, 4
nymph 4
zoonoses 4
margin. 4
blepharitis 4
blepharoconjunctivitis; 4
overcrowded 4
(Linnaeus, 4
1758). 4
phenothrin 4
(20-35 4
coimmunostaining 4
histidine- 4
acid-rich 4
(320-460 4
(74-90 4
SERCA2-binding 4
triadin-binding 4
(609-699 4
aa). 4
HRC-triadin 4
friend. 4
Ca-release, 4
sub-compartments. 4
(Hsp20) 4
(HAX1). 4
(CpG) 4
10(-4)) 4
undermethylated 4
0.28). 4
Council. 4
randomized-controlled 4
hemodilution, 4
(clazosentan, 4
magnesium). 4
www.ClinicalTrials.gov 4
(Extended 4
magnesium. 4
23%. 4
On-treatment 4
.083). 4
(MgSO4) 4
(GOS). 4
hemodilution 4
grades. 4
outcome" 4
bibliographies 4
Emergent 4
clinicaltrials.gov, 4
Disparate 4
plakoglobin. 4
connexin43. 4
interconnecting 4
17q21, 4
CCI. 4
6h 4
Free-radical 4
One, 4
2.46 4
2.38 4
20.7, 4
scavenge 4
nullify 4
l-thyroxine 4
philosophical 4
3a). 4
0.14), 4
Epigastric 4
IIA. 4
(ILAE). 4
with/without 4
gliosis. 4
detectability 4
Ia 4
digitalized 4
(κ 4
second/third 4
(EPO) 4
RDM-1 4
RDM-3 4
rod. 4
hpf). 4
salpingo-oophorectomy 4
leiomyoma. 4
desmins 4
electrophoretically 4
hog 4
virus]. 4
leukocytosis 4
Disturbance 4
Loss. 4
CRY2, 4
rhythmicity. 4
Wee1) 4
subpopulation, 4
β-cells. 4
signaling; 4
periodical 4
str 4
metal-response 4
HMSNL 4
Romani 4
IVS8-1G>A 4
genocopies 4
NMSNP(MIM 4
*604484) 4
3q13. 4
Greyhound. 4
4D. 4
Founder 4
HK1 4
fact. 4
neuropathy]. 4
(CMT2), 4
SETX. 4
miR-508-5p 4
SM/LPS-Res 4
CSPCs 4
(LAMP-2A) 4
amaurosis 4
hsp90, 4
(lamp) 4
PPCA 4
lamp2s 4
mucolipidosis 4
MLIV 4
(Ca(+)) 4
antidiuretic 4
Ikr, 4
Iks, 4
Ikl 4
coiling, 4
Kosnik 4
vasospasm), 4
"favorable 4
Ireland, 4
cataplexy. 4
629 4
children). 4
ASO3-adjuvanted 4
Am+ 4
SUVR 4
(PiB) 4
clusterin, 4
(imaged 4
PiB 4
hypermetabolic 4
(18)F-flutemetamol-based 4
Aβ-specific 4
[(11)C]PiB 4
(11)C 4
ε4+ 4
EMCI 4
(Aβ). 4
florbetapir 4
cow, 4
pathomechanisms. 4
LINES 4
700-kb 4
dG 4
dC 4
49%, 4
poly(A)+ 4
nephrolithiasis. 4
mumol/24 4
mmol/24 4
formers 4
sMTC. 4
sectors 4
12/13, 4
(codon12/13) 4
Economics 4
CHEMOTHERAPY 4
POPULATION 4
In-Process 4
Non-Indexed 4
cetuximab-irinotecan 4
ATC. 4
motors 4
(dynein-2) 4
AAA+ 4
ocrelizumab) 4
ofatumumab. 4
alpha-4 4
(alemtuzumab) 4
(ocrelizumab 4
ofatumumab). 4
CD20-expressing 4
Abs, 4
CD3(+)CD20(dim) 4
(alemtuzumab, 4
biologicals 4
(tocilizumab), 4
BG-12 4
Pegylated 4
florid 4
DMT 4
leukoencephalopathy. 4
alemtuzumab); 4
atacicept, 4
diversifying 4
Ocrelizumab, 4
Recognizing 4
F(1) 4
MS), 4
A-repeats 4
domestica 4
XCI, 4
Thanks 4
XIST/Xist 4
randomness 4
Xite, 4
Preferential 4
footprints, 4
inconspicuous 4
photostimulate 4
pre-autonomic 4
VLM 4
lever 4
BLINK1 4
FGs 4
prionogenesis 4
RRM-bearing 4
repeat-induced 4
co-regulate 4
gene-poor 4
(ACC), 4
85%-90% 4
sulfiredoxin 4
(PRDX2) 4
(Prx2), 4
anti-Prx2 4
thiol-dependent 4
probed, 4
EF-2 4
erythrocyte, 4
(GPGPUs) 4
MODFLOW, 4
(UPCG) 4
Jacobi, 4
fill-in 4
modified-incomplete 4
lower-upper 4
(LU) 4
factorization, 4
preconditioners. 4
MODFLOW 4
solver, 4
CPU-GPGPU 4
OpenMP 4
threads, 4
reformulation 4
(NRM) 4
NRM 4
centisecond 4
processors. 4
COS1 4
esophagus. 4
(STI571 4
notice. 4
symptoms--bronchiectasis, 4
sinusitis--and 4
trapezius 4
TRIM43 4
MBD3L2 4
Rules 4
myogenesis-specific 4
myofibers. 4
FSHD1. 4
lending 4
fin 4
coinjection 4
106, 4
EDG-1. 4
cytokines) 4
receptors); 4
allude 4
deaminases. 4
encapsidated 4
APOBEC3C, 4
SIV(mac) 4
de-repressed 4
(HP1alpha), 4
ew 4
consistently, 4
selenium-containing 4
SEPP1-Ala234 4
selenoenzymes 4
selenoprotein, 4
Physicians' 4
(SELECT) 4
Se-containing 4
curiosity 4
aging-related 4
Pathogenetic 4
ACPA(+) 4
receptor-specific 4
RASF. 4
(OLE) 4
PY, 4
PY). 4
pegol, 4
DMARDs, 4
detailed, 4
AP-MS 4
PBLs 4
facilitation, 4
TR(alpha) 4
(P398H) 4
catecholamine-stimulated 4
cSDR, 4
polA 4
ColE1-type 4
reassembled 4
bypassed. 4
Omcg1 4
RNaseH 4
rearrangements; 4
stability: 4
bubble 4
late. 4
RecG. 4
codirectional 4
Mounting 4
dopa-decarboxylase 4
levodopa/dopa 4
(2.6%) 4
(COMT), 4
catechol-O-methyl-transferase 4
MDA-MB-436 4
re-elevation 4
kallikreins, 4
caspase-mediated 4
K8-null 4
I-like 4
pellucida 4
congruently 4
Desmosome 4
Lis1 4
(STEMI) 4
0.142, 4
value) 4
trios. 4
∼10% 4
CPVT-related 4
Cell-derived 4
keratinocytes) 4
p.T59R 4
(Ryr2) 4
channel-forming 4
Verapamil 4
GOLD 4
acceptors, 4
MMP-13 4
(BACE-1) 4
(Hypo1) 4
CysLT(1) 4
μ 4
boron 4
SMNT 4
hyperthyroid. 4
selenium-sensitive 4
GPx1 4
GPx3, 4
endocrine-immune 4
(AITD) 4
AITD 4
microchimerism, 4
intestine; 4
reproduction, 4
selenium-treated 4
nanoplasmonics 4
detectors 4
methylcytosines 4
specific-tumor 4
pre-analytical 4
c.749C 4
[Safety 4
teratogen. 4
nonphosphorylatable, 4
palmitate. 4
Immunogenicity 4
lot. 4
fisetin 4
falcipain-2 4
(R3R 4
(R3C 4
(C3C 4
8922 4
6537 4
39-50) 4
(34-41) 4
9585 4
6616 4
36·3%, 4
31·8-40·5) 4
7396 4
(28·3%, 4
23·3-32·9); 4
(32·2%, 4
46·9) 4
(1·1%, 4
-23·0 4
20·5). 4
6170 4
25·9%, 4
19·9-31·5) 4
5444 4
(18·3%, 4
11·7-24·4); 4
(17·3%, 4
-9·4 4
37·5) 4
(10·3%, 4
-17·9 4
31·8). 4
1774 4
1387-2186) 4
1363 4
(995-1797) 4
592-1337) 4
(158-926) 4
Biologicals 4
PATH 4
anticipates 4
(CSP) 4
malaria-prevention 4
(PrP₂₋₁₀ 4
67), 4
(EPI). 4
RTS,S/AS01E 4
Gabon. 4
according-to-protocol 4
diaper 4
postinjection 4
upgraded 4
collaborating 4
Group; 4
statements, 4
(SINE) 4
Implausibility 4
olfaction. 4
musk-recognizing 4
muscone, 4
(methylthio)methanethiol-recognizing 4
deuterated, 4
OR5AN1. 4
muscone-d30 4
1,380- 4
1,550-cm(-1) 4
odor. 4
nonodorant 4
olfaction, 4
CTCF/BORIS 4
RGCs 4
homophilic 4
X-100 4
solubilize 4
type-II 4
PC-like 4
87%. 4
http://boctopus.cbr.su.se/. 4
TMBB 4
84.2% 4
2,225 4
Posterior-Viterbi 4
pipeline: 4
globular, 4
SWISS-PROT, 4
SOSUI, 4
TCDB. 4
ion-transport 4
drastically, 4
target-template 4
(Q(2)) 4
77.8%, 4
0.67. 4
<6.0 4
<5.0 4
GDT_TS 4
60.0. 4
http://www.igb.uci.edu/servers/psss.html. 4
Genetics, 4
retrained 4
jack 4
discriminator, 4
selective. 4
rejects 4
(<30%) 4
programming, 4
lipid-water 4
TMHPs 4
(788 4
(366 4
4346 4
(E-value 4
1e-10) 4
SwissProt. 4
http://www.bioinfo.no/tools/bomp. 4
(MOMP) 4
porin. 4
"consensus" 4
Theatre: 4
hardcopies 4
long-range, 4
CRM, 4
DePCRM 4
gsc 4
Wnt-induced 4
074 4
DMPK(-/-) 4
Positional 4
(Madison, 4
WI) 4
pan-neuronal 4
LC. 4
quench 4
endosome, 4
fg/mL 4
(TopBP1-interacting, 4
protein/TopBP1-interacting, 4
regulator), 4
Sld3 4
holohelicase 4
fell, 4
dyadic 4
(opioid 4
antagonist). 4
Co-ingestion 4
overdoses 4
comatose, 4
(s.q.). 4
breaths/min. 4
Quiescent 4
Zeb2 4
neurexin 4
(PUVA) 4
UvrD, 4
UvrD-like 4
DPCs 4
transactions, 4
)channel 4
μg/kg/min 4
11%) 4
VAs, 4
Triggered 4
APs, 4
arrhythmogenicity 4
I(Ca,L) 4
CPVT; 4
RyR2-FKBP12.6 4
stabiliser 4
fibrillation/flutter 4
dogs) 4
intra-atrial 4
component) 4
Carcinogenesis 4
MiRNAs, 4
DDX20 4
miRNA-140 4
proto-oncogenes. 4
B-ALL 4
microRNA-216a 4
miR-375. 4
amino-acid-mediated 4
Ragulator-binding 4
charging. 4
bromide. 4
d2-d4 4
d3-d4 4
XDP. 4
visuospatial, 4
XDP, 4
ccUPSIT 4
density-weighted 4
cousins. 4
Striatal 4
XDPD 4
perchlorate, 4
-8, 4
A375-S2 4
(systolic 4
IVUS 4
(AZ) 4
1199) 4
(0.2%) 4
(ARR) 4
mixed-effect 4
semi-objective 4
DMTs. 4
Dislocation 4
1974), 4
stenoses: 4
dilated. 4
cava 4
worsening, 4
59.75% 4
36.75%. 4
office. 4
primarily, 4
(208 4
placement; 4
procedure; 4
presently, 4
Calgary 4
burdened 4
DTG 4
45.4 4
21-79) 4
[34 4
recoil, 4
confuting 4
(55.8%), 4
(44.2%). 4
(0.3% 4
Adipose-derived 4
mesoderm- 4
nonmesoderm-derived 4
(BM)-derived 4
fiction? 4
Autologous, 4
therapies? 4
ectoderm, 4
Perspective, 4
birch 4
species-level 4
EHT. 4
Gfi1b. 4
Gata1, 4
(Gfi1) 4
GFI1B-expressing 4
(Gfi-1B), 4
(TPR, 4
RARA, 4
(MEPS) 4
granulomonocytic 4
(GMPs) 4
equivalently 4
Myelopoiesis 4
EpoR-Cre 4
Hbb-bh1 4
Hbb-y 4
factor-independence 4
meis1 4
GATA-1-mediated 4
endosteal 4
(MM)-and 4
(Thalomid). 4
(R/R) 4
(Velcade) 4
myelosuppression. 4
Lenalidomide, 4
non-barbiturate 4
"wonder 4
drug" 4
non-neurotoxic. 4
(normalized 4
GPS, 4
18-mer 4
tenapanor 4
TRPV5 4
αKlotho 4
Fgf23 4
WNK4. 4
matrix(Extracellular 4
environment; 4
adherent-independent 4
"anoikis," 4
microdomains, 4
death-associated 4
Brain-derived 4
apoptotic-like 4
NCX-mediated 4
0.23+/-0.08 4
obviously, 4
[Ca2+]i, 4
exchange), 4
Na(i)(+) 4
2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea 4
microglia: 4
Na+,K+-ATPase, 4
piebaldism, 4
Steel 4
RCT). 4
4.0; 4
1.74, 4
1.17, 4
GHS-R 4
Ghsr(-/-) 4
Ghsr(-/-)-M 4
WT-M 4
intake: 4
bouts, 4
NJ) 4
OX 4
(AgRP) 4
circuit, 4
HiSat 4
dC-to-dU 4
RNase-H 4
(TAR) 4
cytidine, 4
deaminating 4
oligomerize 4
(hypermutation) 4
Basis 4
Family. 4
(A3G), 4
99.3% 4
Hypohidrotic 4
(Xq28) 4
consults 4
(NEMO; 4
NEMO/IKKgamma, 4
(NF-kB) 4
NEMO/IKKgamma. 4
unreported, 4
bullosa, 4
KRT14, 4
identical) 4
LCRs, 4
deletion; 4
(EDA-ID) 4
(hNFL) 4
punctuate 4
partnerships. 4
Ski's 4
apoF 4
(FXR, 4
Nr1h4) 4
SOCS3 4
cholic 4
withholding 4
Cyp27 4
involvements 4
Microbiome 4
acid-activated 4
hexosamine 4
FGF19 4
ORMs 4
ileal, 4
ORM 4
ADH1 4
TR-FRET 4
Sesn2 4
FAs, 4
oxyphilic 4
pollution 4
Models. 4
remodeller 4
FANCG) 4
repair-defective 4
h2a1 4
SGC7901 4
telematic 4
self-measured 4
transmissions 4
Beidou 4
Telemonitoring 4
65). 4
wirelessly, 4
-6.5 4
<120 4
GUI 4
GSEA 4
Weighted 4
topology-based 4
acid-treated 4
supportive. 4
(Area 4
CaV1.2-TS 4
son, 4
CACNA1C, 4
Mexiletine 4
perseverative 4
CDI. 4
aristaless-like 4
blade 4
Carm1 4
co-activators, 4
elucidation. 4
Cart1, 4
of. 4
ALX4 4
selenoproteome 4
SDF1α, 4
(PAK1), 4
(uPAR). 4
PIX. 4
chromatids: 4
decondensed. 4
cdc15 4
PFGE 4
15-50% 4
2580-2680 4
1340-1500 4
(S-type), 4
S-type. 4
haploids 4
ascus 4
1340, 4
1780 4
1475-1610 4
1520-1680 4
1820-2010 4
segregants. 4
subcultures.(ABSTRACT 4
skipped, 4
silica-C18 4
Velos 4
trial-and-error 4
50mm 4
equilibration 4
monolith 4
anion-exchange 4
Cell-cycle 4
Mis4/Ssl3, 4
pre-requisite 4
2-microm 4
plasmid-partitioning 4
cooperative. 4
Sccl 4
poles. 4
MECP2, 4
long-read 4
1976. 4
Riedel's/thyroiditis 4
etc... 4
generous 4
isthmus 4
antifibrosing 4
400-mg 4
Progeroid 4
(HGPS) 4
(segmental 4
syndromes) 4
Assessment, 4
photoacoustic 4
industry, 4
Exhaled 4
Fractional 4
resorcinol 4
anaesthetized 4
Acetone 4
body), 4
ppb 4
hepatology. 4
point-of-care. 4
(NAFLD). 4
BreathID 4
GBT 4
microg/kg/h, 4
Bedside 4
P( 4
ET,CO(2)) 4
Hepatologists 4
hepatology 4
"definite 4
Hispanics, 4
CO-haemoximetry, 4
COHb% 4
RCV 4
COB 4
PaCO(2)-EtCO(2) 4
analyser. 4
litre/min 4
near-patient 4
(F344) 4
(BB-94), 4
(MMPI) 4
batimastat, 4
MMPI, 4
proopiomelanocortin 4
MMP-9). 4
(uPA), 4
83.33%, 4
62.96%. 4
F8, 4
F8-related 4
informations 4
Wright-Fisher 4
Wright, 4
Muller. 4
model], 4
(SoS) 4
total/partial 4
c.4736dupG 4
c.3938_3939insT 4
CGH. 4
p=0.003). 4
1.89), 4
pre-eclampsia, 4
[25(OH)D] 4
GDM, 4
(25[OH]D) 4
nmol/l) 4
nmol/L. 4
Ff, 4
LGA 4
(MoM) 4
IQR, 4
unacceptably 4
Ln-25OHD 4
32-33 4
Holdsworth 4
Mysore. 4
babies' 4
l(-1)) 4
changed, 4
Fibrinolytics 4
thrombus-occluded 4
0.5-2 4
2-2.5 4
60-120 4
57-100% 4
pediatric-specific 4
centrally, 4
613 4
conjectural. 4
2.5-mL 4
cryopreserving 4
86%). 4
resistances 4
thromboectomy 4
extended. 4
(22.4%) 4
hazard; 4
plasmin 4
rt-PA). 4
postphlebitic 4
sterling 4
Double-blind, 4
mg/kg/24 4
reteplase, 4
lanoteplase 4
reteplase 4
disc-large. 4
PSD-95, 4
disc-large, 4
domain-2 4
RTAV 4
IQGAP1. 4
PKC. 4
MEK-mediated 4
interactome, 4
KSR-2, 4
(RAF-MEK-ERK) 4
A-RAF 4
c-RAF. 4
(MP1) 4
anti-cell 4
NRAS-driven 4
phospho-ERK 4
biosensor, 4
Raf-1, 4
learning-induced 4
(GPCRs). 4
GAD67 4
(Dnmt3b) 4
ICF 4
1/10 4
hydralazine, 4
2'-deoxycytidine, 4
BAG 4
dimethylation. 4
post-implantation 4
Rhox 4
Dnmt3a, 4
5.1% 4
(Manihot 4
En/Spm-like 4
probrain 4
Ez 4
(H3K37me2/3), 4
nonproliferative 4
co-populated 4
Foxp3-deficient 4
proliferation; 4
p57kip2, 4
EED, 4
Snail2/Slug 4
Eed, 4
>2-fold 4
(mock 4
(MSL) 4
topics, 4
(non-specific 4
peak-callers 4
(ChIP-Seq) 4
Rigorous 4
ChIP, 4
clathrin-dependent 4
E-cadherin-mediated 4
Dia 4
(and/or 4
membrane-proximal 4
chewable 4
bioequivalent 4
Elonza 4
(generic 4
sildenafil) 4
suppliers 4
(ADOA) 4
(GTPase) 4
ATP7A 4
homeodomain. 4
Unconditional 4
hot/cold 4
MafA. 4
PDX-1 4
(pancreatic 4
homeobox-1), 4
(neurogenic 4
differentiation-1) 4
(V-maf 4
(Ad-Mouse 4
PDX-1-IRES-GFP, 4
NeuroD1-IRES-GFP 4
Mafa-IRES-GFP) 4
predecessor 4
selenosulfide 4
UGA/Sec 4
Naegleria 4
(selenophosphate 4
(Sec), 4
disordered, 4
GGGA 4
Recoding 4
SBP, 4
Analgesia 4
device: 4
fluoride 4
patient-oriented 4
post-infusion 4
comfort, 4
(PICU). 4
(Q) 4
(midazolam 4
c-Rel 4
Rel-homology 4
icteric 4
sclerae 4
bilirubinemia. 4
99mTc-DISIDA 4
Crigler-Najjar 4
hyperbilirubinemias 4
spliceosomes 4
bp). 4
endonucleases, 4
traumatic, 4
SFM-XF 4
myelin-related 4
fingolimod. 4
nontransposon 4
RNAi-defective 4
reanimating 4
KD-approach, 4
small-RNA-mediated 4
HeT-A-containing 4
(dimethylation 4
I-element 4
HMS 4
Beagle. 4
(Telomeric 4
reporter's 4
Piwi-piRNA 4
guardians 4
retrotransposon. 4
AzgA-like 4
NAT 4
nucleobase 4
uapA 4
acid-xanthine 4
permeases, 4
UapC 4
areA 4
PSPN, 4
NVP-AST487 4
RET/GFRalpha1-expressing 4
GFRalpha1-4. 4
GFRalpha. 4
NG108-15, 4
GFRalpha2-4. 4
PLCgamma. 4
U73122. 4
PD98059. 4
GFRalpha-2 4
neurocristopathy]. 4
918 4
polygenic: 4
(Glial-Derived 4
Factor) 4
interstitium 4
GFRalpha1.RET 4
wave, 4
collapse, 4
deletions/insertions. 4
(8x), 4
(G400A) 4
H558R 4
alleles) 4
47.1 4
(SUNDS), 4
#117550) 4
varenicline) 4
Varenicline 4
'other' 4
EED) 4
Narrative 4
RG7388, 4
chromosomal-negative 4
(MPNs) 4
(HSC). 4
MPNs 4
AZD0837, 4
letaxaban, 4
darexaban, 4
LY517717. 4
etexilate) 4
anti-FXa 4
(tecarfarin). 4
otamixaban, 4
(EXPERT). 4
(DVT) 4
Aplastic 4
communicable 4
Peru. 4
d'Ivoire, 4
Leone, 4
multi-dose 4
Arthropod-borne 4
priorities, 4
reemerging 4
Forsskaolea 4
Crataegus 4
Loranthus 4
acacia 4
mg% 4
Antarctica. 4
disjunct 4
Mosquito-transmitted 4
virus: 4
Aedes, 4
chemoprophylaxis 4
Soledad 4
CHI 4
Erythropoiesis. 4
(TBP) 4
Erythropoiesis 4
(ESKAPE) 4
carbapenem-resistant 4
(VAP) 4
diminutive 4
(Enterococcus 4
ms), 4
(11.6 4
27.3 4
half-logistic 4
anesthetic-induced 4
curve-fits 4
Ca(2+)-sensitive 4
faCaTs 4
loads, 4
sparks) 4
RYR 4
hypertrophy/heart 4
(DHT) 4
CHT 4
radioligand. 4
remoxipride, 4
neostriatum 4
Tiapride, 4
D2-long 4
D2-short 4
tiapride. 4
Selecting 4
cooperative, 4
Fos-like 4
catalepsy 4
IL-12p40 4
Ang-1-induced 4
phosphoserine, 4
phosphothreonine, 4
non-proteinaceous 4
MKP 4
inactivators 4
kinases). 4
Dual-Specificity 4
phospho-tyrosine 4
phospho-serine/threonine 4
JNK-dependent 4
(dual-specificity 4
(c-Jun 4
DUSPs, 4
phosphoserine/threonine 4
(ICC: 4
Automatic 4
ultrasonography-estimated 4
(US)-derived 4
transperineal, 4
SUBJECTS 4
'blinded' 4
transabdominal, 4
(-0.34) 4
(0.54) 4
(0.33). 4
trigonal 4
(0.56). 4
transabominal 4
Abrams-Griffiths 4
Sonographic 4
Ninety-four 4
γ-secretase. 4
β-peptide 4
secretase. 4
(LY450139) 4
operationalize 4
VA/DOD 4
Non-Cancer 4
workable 4
ATHENA-DSS 4
self-directed 4
computerized, 4
6.2, 4
board-certified 4
re-referred 4
(85%), 4
HGprt 4
LND. 4
Teratocarcinoma 4
9.7 4
[3H] 4
hypoxanthine. 4
macro-deletions 4
radioimmunoassay. 4
Lmx1a 4
gouty 4
(LPS)-induced 4
E(z), 4
epsilon-amino 4
PR/SET 4
anciently 4
S-methyltransferase, 4
(SAMe), 4
SMYD2 4
well-defined. 4
Cajal-Retzius 4
HAR1 4
OXA-48, 4
NDM-1, 4
extended-spectrum 4
(ESBL) 4
urgent. 4
PBA 4
IMP-1 4
(PFGE) 4
spp, 4
Etest 4
(GRBs), 4
dysplasia), 4
G691S 4
RET-620 4
5-generation 4
83.3%) 4
macroH2A1, 4
carp. 4
cistron. 4
(GFP)-mH2A1 4
GFP-H2A, 4
(MCB). 4
Xi-specific 4
Xq24. 4
pM; 4
(e) 4
MAPc 4
(Myomorpha), 4
(Sciuromorpha), 4
(Caviomorpha). 4
quasi-dimers 4
articulated 4
articulate 4
769 4
fluoroscopically 4
L6-S1 4
operatively 4
Disc 4
interspace 4
occurrence; 4
disopyramide 4
74.5 4
propafenone, 4
(AMI-DBD). 4
(LVEF%) 4
[33 4
79(2.5) 4
[22(1.1) 4
33(2.1), 4
altered; 4
rebuild 4
de-differentiation 4
TH-thyroid 4
oxamate 4
N-acetylcysteine, 4
Butyrate 4
cyclinB1 4
Costunolide 4
lactone 4
ROS/NO 4
inductions 4
3,3'-diindolylmethane 4
OVCAR-3 4
Emodin 4
content; 4
A375.S2 4
(ERK1/2), 4
II-1 4
(SPTs) 4
interferon-based 4
BMS-788329-resistant 4
host-targeting 4
underground 4
Actinobacteria 4
waters. 4
RND 4
Smb 4
discussions. 4
marinus 4
'minimal 4
outliers 4
coevolutionary 4
(48.7 4
(33.3% 4
18.7% 4
binge. 4
calculable). 4
noncocaine 4
jurisdictions 4
blacks. 4
ecstasy 4
subarachnoidal 4
Chief 4
AVM. 4
miR-21* 4
.006 4
biodiesel 4
regression-based 4
(IRS). 4
(p=0.003) 4
miR-9*, 4
4.2-fold 4
miR-494, 4
miR-101, 4
BCL-2, 4
WRL-68 4
miR-107, 4
TGM2, 4
NDRG2) 4
CaP, 4
miR-206, 4
Maryland, 4
radiation-promoted 4
IR-promoted 4
non-irradiated, 4
esophagus: 4
PRG1, 4
IL-23a, 4
FOXP3, 4
pAkt 4
preneoplastic/neoplastic 4
endoscopically 4
imperfectly 4
lymphoma/leukemia 4
tumorigenesis; 4
topic, 4
TRβ1, 4
THRA 4
RIC 4
FLAMSA 4
aplasia-inducing 4
thiotepa 4
HSCT. 4
fludarabin 4
amsacrin 4
(FLAMSA)-reduced 4
(alloSCT) 4
survivors: 4
CCD 4
ABIN-2 4
answered, 4
(NEMO). 4
NOD.B10-H2b 4
leukocytic 4
promoting, 4
cared 4
Compression 4
check-up, 4
1-16 4
weight). 4
childbirth 4
automatically, 4
YACOP 4
satisfactorily. 4
HMMgene. 4
Phat 4
weather 4
Hypoxic 4
alpha-mediated 4
substrate-1 4
Hif1alpha 4
Oct1 4
GLUT3 4
suppressed, 4
synovitis, 4
GLUT1, 4
isomerase, 4
phosphofructokinase, 4
TKI-resistant 4
initially. 4
EGFR) 4
erlotinib; 4
39.0 4
[Lung 4
H1975) 4
86.2% 4
EXEL-7647 4
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 4
("never 4
(MIB) 4
SAMM50. 4
MINOS, 4
plus: 4
metaproteomics, 4
metaproteomes. 4
microcosms 4
aquifer. 4
Fragmentation 4
upwelling 4
houses 4
chemosynthetic 4
pter 4
collaboration. 4
lissencephaly 4
17q11.2, 4
proposita 4
proband) 4
483 4
TRalpha1R384C 4
TRalpha1-dependent 4
1-expressing 4
alpha1- 4
28-fold 4
peak-picking 4
Fourier-transform 4
Metlin 4
metabolin 4
GYHS 4
Chinese). 4
(AATAAA) 4
AATAAA, 4
Chironomus 4
pre-mRNAs, 4
PmToll 4
AAUAAA-dependent 4
(Aβ 4
(t-tau) 4
pre-dementia 4
late) 4
ADAS-cog 4
TACT 4
2077 4
703. 4
Vespucci: 4
un-annotated 4
855 4
1,160 4
1997-2008 4
(TERT), 4
8q24.21 4
(CCDC26/MLZE), 4
(CDKN2B), 4
11q23.3 4
(PHLDB1/DDX6), 4
(RTEL1). 4
P(interaction) 4
0.68) 4
+61 4
northwest 4
phone, 4
IRs 4
rectification. 4
(neutral) 4
89%. 4
T-waves. 4
c.2264G 4
afflict 4
condition: 4
(SQT2) 4
(SQT3). 4
Notwithstanding 4
LPO 4
bioelectronical 4
(DU). 4
sinus. 4
Giuseppe 4
syndrome," 4
chromate-induced 4
pRSVcat 4
micronuclei, 4
"islands" 4
CRP. 4
7093 4
strokes) 4
ADAR-dependent 4
nongenic 4
surfactants. 4
frog, 4
hpl-2, 4
SETDB1 4
Endometrioma 4
conceive, 4
CENTRAL. 4
insemination 4
ampoules 4
ART, 4
ART. 4
IMPLICATIONS 4
eighty-nine 4
gonadotropins, 4
pick-up 4
NM. 4
myopathy-related 4
membrane-permeabilized 4
p.Phe352Ser. 4
unravelled 4
cross-bridges. 4
(TPM3 4
(ACTA1). 4
codon: 4
TAG>TAT 4
(tyrosine), 4
TAG>CAG 4
TAG>TGG 4
(tryptophan). 4
(RYR1) 4
core-rod 4
slowness. 4
15q21-q23 4
10.65 4
D15S993. 4
alpha-tropomyosin-1 4
(TPM1) 4
[Pregnancy 4
anti-phospholipid 4
(APS). 4
diseases? 4
7.8%, 4
stays, 4
beta-receptor 4
(STZ). 4
WKY, 4
day-1 4
Sophisticated 4
GUIDANCE 4
misinterpret 4
unweighted 4
FreeTree 4
RAPD 4
TIBA 4
estimator. 4
confidence) 4
rearrangement-based 4
results-an 4
branch-length 4
CAG/CTG 4
high-resolution, 4
Eaf3 4
H3K36, 4
FACT. 4
asf1Delta 4
dose-escalating 4
plc 4
plausible. 4
CNTO 4
dose-escalation, 4
12-mg/kg 4
herpesvirus-8-seronegative 4
NCT01024036. 4
(n=53) 4
(n=26). 4
34·0%, 4
11·1-54·8, 4
p=0·0012). 4
[47%] 4
[54%]) 4
[19%]) 4
1-1031] 4
[23-666]). 4
sepsis). 4
antibody; 4
328), 4
IL6. 4
(Sp), 4
(NPV), 4
88.77% 4
86.11-91.43%), 4
68.79% 4
64.88-72.70%), 4
87.40% 4
85.97-88.83%), 4
71.52% 4
67.71-75.33%) 4
0.503. 4
Relatively, 4
89.97% 4
87.44-92.64%), 4
83.23% 4
80.08-86.38%), 4
92.66% 4
90.46-94.86%), 4
74.41-81.41%) 4
0.584. 4
0.05).The 4
0.718 4
0.582, 4
counterbalancing 4
DNAi 4
NEO1 4
crassa, 4
DGCR8. 4
Drosha/DGCR8 4
5-aza-2-deoxycytidine 4
CDKN2A. 4
hda6 4
heterochromatin-dependent 4
PAK1, 4
Set3C 4
Hdac3 4
arginase-1, 4
tendinitis 4
acetylations 4
(WB) 4
FUM21, 4
NY-ESO1 4
IDLVs 4
type-dependent 4
vehicles. 4
AAR 4
HUVECs. 4
RRRGL 4
AGA. 4
dutasteride, 4
Finasteride 4
(IRMS). 4
ZooMS 4
Britain. 4
demineralization 4
ATR-IR 4
HCl, 4
osteonal 4
fragmentary 4
mastodon 4
280) 4
mir-208 4
L-T₄ 4
2.53; 4
(mHealth) 4
gap, 4
promotion, 4
Message 4
beverage 4
regular, 4
SMS-based 4
district, 4
below, 4
Text4baby 4
radioligand, 4
sleep-promoting 4
cataplexy, 4
(dual) 4
(NDA) 4
(SWD), 4
night-shift 4
working, 4
PM) 4
(armodafinil 4
392 4
(Majeed 4
Lipin-1 4
Baicalin 4
phospho-AKT 4
UCP2-transfected 4
F1F0-ATPase 4
H/RO-induced 4
H/RO 4
mROS 4
FW 4
ailments, 4
FME 4
outflow. 4
billion. 4
48°C 4
48°C/150 4
Amniotic 4
(3)H-thymidine 4
INCB018424 4
K7M3 4
DPSCs. 4
Osteogenic 4
Endodontic 4
5-dimethylthiazol-2-yl)-2, 4
5-diphenyltetrazolium 4
2-period, 4
200-μg 4
1.06) 4
selexipag. 4
up-titrated 4
all-treated 4
illustration 4
SU, 4
C166Y 4
citations, 4
Computing 4
Swiss-Prot 4
PIR-International 4
(n=56), 4
(n=58) 4
(n=58). 4
-2.8 4
stabilizers. 4
metabolizers 4
PMs 4
Q111 4
(MermaiHD): 4
stabilisers, 4
mMS, 4
tissue-regulated 4
hyperparameters, 4
+100 4
Anomalous 4
systems-based 4
7298 4
ρ 4
0.8. 4
clinically-interesting 4
(ATC) 4
SW1736 4
(UPR). 4
concept" 4
PS-341) 4
(VELCADE; 4
E3s 4
Velcade 4
pharmacogenomics. 4
gossypol 4
923 4
CellMiner 4
reticulocytopenia, 4
RPL26 4
aplasia: 4
RPS14 4
RPS16, 4
photolesions, 4
nicotinamide's 4
Mantoux-positive 4
UVA) 4
OTC, 4
larynx 4
inspiration. 4
ng/ml; 4
apneic 4
stridor) 4
dyspneic 4
[11C]raclopride 4
ninth 4
yrs), 4
(CESD) 4
0.95), 4
(HDRS) 4
specificity:0.83; 4
(PHQ)-9 4
CESD, 4
HDRS 4
Discriminating 4
(38.0%) 4
Inter-rater 4
(ICC 4
wards. 4
replication; 4
infectivity, 4
LIV1, 4
TPEN 4
suspensions. 4
N-didemethylated 4
expression-based 4
ERS-induced 4
raloxifene. 4
Matrine 4
(5-aza-CdR) 4
re-activation 4
(comparing 4
(IL-10), 4
(47%). 4
hemorheological 4
scaffolds: 4
bioseed 4
Hemospray™, 4
Endoclot™ 4
premarketing 4
18·5-29·9 4
Services, 4
pseudorandom 4
(dTT), 4
(ECT), 4
(AUEC2-12) 4
NCT01688830. 4
flushes), 4
(epistaxis); 4
haematoma), 4
haematuria 4
KG. 4
Hypoplasia 4
thyroglobulin. 4
branchio-otorenal 4
dyshormonogenesis. 4
COL4A5 4
7q31 4
c.662_663insG 4
(VNTR), 4
TPM 4
Ty1/copia 4
(VLPs) 4
nutrient-limited 4
PI3P-binding 4
Alfy. 4
p62(SQSTM1)-positive 4
Atg12, 4
Atg16L, 4
SmATG8 4
SmATG4 4
inadequacy, 4
sequestosome 4
S403 4
(Htt), 4
pexophagy, 4
Atg32 4
organelle-specific 4
ER-phagy 4
pexophagy. 4
Yarrowia 4
insulin-transferrin-supplemented 4
electronic-dense 4
anti-CD68, 4
anti-cathepsin 4
anti-myeloperoxidase 4
sequestrated 4
phosphatidyl-inositol-3-kinase 4
Akt-specific 4
p70S6K-dependent 4
cytoplasm-to-vacuole 4
Ape1 4
CCPA 4
pharmacokinetic/pharmacodynamic/efficacy 4
(AAK). 4
cyclin-A 4
polyploid 4
(PIC) 4
mg/d), 4
pharmacokinetic/pharmacodynamic 4
hexavalent 4
bacterial, 4
lato, 4
spielmanii, 4
(ss), 4
pacificus 4
spirochetes, 4
spielmanii 4
garinii, 4
unweaned 4
unfed 4
Saaremaa 4
Seroprevalence 4
30-40 4
localities 4
599 4
(14.7%), 4
(13.7%) 4
Switzerland, 4
rickettsiae 4
(84 4
40,000 4
p65/RelA 4
UL42-dependent 4
P-gp, 4
CYP2C19. 4
sphere 4
ambrisentan, 4
Dahl 4
(25mg/kg/day). 4
(TGF-β1), 4
(FN), 4
extradomain 4
(EDB(+)FN) 4
α-I 4
FN, 4
EDB(+)FN, 4
α-I(IV) 4
sclerodermic 4
ETA/ETB 4
non-lesional 4
(Opsumit®) 4
Eisenmenger 4
cisplatinum 4
killed, 4
steady-state. 4
sunitinib-induced 4
intedanib, 4
Nippon 4
Shinyaku 4
(ET)(A) 4
film-coated 4
t(max) 4
budesonide 4
eos/hpf, 4
1:2000. 4
Negro, 4
migrant 4
1:10,000 4
F508) 4
non-Ashkenazi 4
Yemenite 4
Cyprus 4
R553X 4
Paulo 4
Bahia, 4
Saguenay-Lac-Saint-Jean 4
Venezuela 4
phagophores 4
TRPC1 4
submandibular 4
LVAD 4
(estrogen 4
single-shot 4
pump--probe 4
nanocrystallography, 4
(WAXS) 4
begins. 4
WAXS, 4
Possibilities 4
WAXS 4
(solution 4
movies 4
atomic-resolution 4
airborne 4
earth 4
fs) 4
withstanding 4
(X-FEL)-based 4
Calculations 4
10(-6), 4
pulse. 4
isotropic 4
orientations. 4
kinase-1, 4
multienzyme 4
Nonhuman 4
non-specificity, 4
(IAVs) 4
Neu5Gc-rich 4
glycocalyx 4
cytotoxin 4
toxin's 4
Prog 4
17A2 4
Orteronel(®), 4
½ 4
androgens), 4
mineralocorticoids 4
galeterone 4
VT-464 4
≥3mg/kg 4
17-hydroxyprogesterone 4
estrogen-synthesis 4
Orteronel, 4
300mg/kg, 4
0.1mg/kg 4
300mg/kg 4
15mg/kg/day 4
(7.5mg/kg/treatment, 4
[bid]) 4
1.5-times 4
adrenal-origin. 4
0.2mg/kg/day 4
(0.1mg/kg/treatment, 4
bid). 4
gyral 4
(snRNAs) 4
(30G>A, 4
55G>A, 4
111G>A) 4
210710]. 4
ENaC 4
-68 4
subregion. 4
LADA 4
GAD(65) 4
non-acetylated 4
(T1DM) 4
GAD-ab-associated 4
registries) 4
CTSR-registered 4
35,495 4
(96) 4
(25), 4
paediatric/adult 4
Unit. 4
CTSR. 4
(ERNs), 4
CTSR 4
developeda 4
Flk-1+ 4
(AD-MSCs) 4
homed 4
AD-MSC 4
MECP2-related 4
(Rubinstein-Taybi 4
(Christianson 4
(Pitt-Hopkins 4
Heterotachy, 4
homotachy 4
reversible-jump 4
lineages: 4
simplistic 4
immigration 4
phylogenetics. 4
(ML). 4
MP. 4
heterotachous. 4
irrational 4
"heterotachy." 4
"heterotachy. 4
descriptive, 4
trajectories. 4
tools: 4
loved 4
helpless, 4
caregiving 4
Group-based 4
high-decreasing 4
low-decreasing 4
0.09), 4
carers, 4
moods 4
Endothelin-B 4
(16.7%, 4
(10+/-3 4
means+/-S.D.) 4
(P=0.024, 4
(P=0.037, 4
radiographs, 4
(tetralogy 4
Fallot), 4
Sapsaree 4
anomalies: 4
fallot; 4
Aorta; 4
Atresia; 4
biorientation 4
BCR-ABL+ 4
5q31, 4
0.030), 4
nonrandom, 4
-Y 4
>5% 4
Ph. 4
alpidem 4
[omega 4
(BZ1) 4
isoniazid-induced 4
curarized 4
electrocorticographic 4
sleep-wakefulness 4
DSM-IV-defined 4
≥20 4
(-8.42). 4
CLINICALTRIALS.GOV 4
IDENTIFIER: 4
NCT00863798 4
http://clinicaltrials.gov/ct2/show/NCT00863798?term=00863798&rank=1. 4
titration. 4
risk-to-benefit 4
elevations, 4
HAM-D(17). 4
MEASURES 4
p=0.018); 4
(-11.0) 4
(p=0.065). 4
(p=0.038) 4
Scale-Pain 4
=10% 4
attempt, 4
HER4. 4
10-30% 4
(LUX-Lung 4
12·0 4
[14%] 4
(<1%) 4
carefully, 4
Actual 4
30-44 4
MHI 4
Hb, 4
megakaryopoietic 4
.049). 4
90.7% 4
inconvenient 4
.015). 4
FCM-based 4
obstetrics, 4
1000. 4
(30%). 4
doses). 4
(FeCarb), 4
FeCarb:63 4
FeSulf) 4
>2.0 4
0.0051) 4
0.0346). 4
323.5 4
(43.5 4
28.5 4
GENZ 4
treatment-related. 4
Property-based 4
D-threo-1-phenyl-2-decanoylamino-3-morpholino-propanol 4
(PDMP) 4
2-(2,3-dihydro-1H-inden-2-yl)-N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)acetamide 4
(CCG-203586), 4
MDR1. 4
15%), 4
(GD1), 4
99), 4
<1.5% 4
metabolizers. 4
multi-objective 4
meta-server 4
meta-method, 4
'metaPIS' 4
web-server 4
meta-prediction. 4
cliques 4
subnetwork 4
cliques, 4
RNSC 4
100-kb 4
footprint. 4
coexpress 4
nonviral, 4
gene-transfer 4
AS3MT, 4
ITIH3, 4
NDDs 4
SCN2A, 4
Widely 4
STAB1 4
(Val54) 4
(activation-induced 4
L1. 4
MutH 4
MMR. 4
YY1, 4
43.0 4
13.0 4
brachii 4
0.5) 4
(MI 4
PEUU 4
MSC(GATA-4) 4
(RKIP) 4
tri-marker 4
markers). 4
limelight 4
H3K27Me3. 4
sh-EZH2 4
hormone-refractory, 4
EZH2-derived 4
RARB2, 4
HLA-A24+ 4
-299 4
BMI1, 4
(EZH2, 4
(GS) 4
margins, 4
CD117, 4
six-fold 4
TMB-Hunt2), 4
crossvalidation 4
>95%, 4
96.7% 4
94.2% 4
TMB-Web 4
(http://www.bioinformatics.leeds.ac.uk/TMB-Web/TMB-Hunt2). 4
(OR=0,92; 4
interval=[0.53-1.59]), 4
(OR=0,74; 4
interval=[0.43-1.28]) 4
(OR=1.15; 4
interval=[0.65-2.05]). 4
1990's 4
(OR)=1.71, 4
(CI)=1.04-2.81 4
OR=2.29, 4
CI=1.56-3.37. 4
L-WRN 4
HCCC-9810 4
protein-5 4
LRP5, 4
Fra-1, 4
Wingless 4
(GSK)-3beta 4
(PKB)-mediatefd 4
GSK3. 4
PI3K/PKB 4
Tcf/Lef 4
Cby-mediated 4
SNAIL 4
CCND1, 4
ISCs, 4
intriguingly, 4
ISCs. 4
ISC, 4
bridged, 4
PTEN/Akt 4
founders 4
shapes, 4
C57/Bl6 4
emotionality 4
GFP-positive, 4
Lv-αS1cE2hisG 4
fosmid 4
GFP, 4
oligos 4
loops) 4
(IC) 4
Insulin-resistant 4
≥5.7% 4
<6.5%) 4
ALEPREVENT 4
1,999 4
1,996 4
(1,581 4
pre-T2D). 4
vs12; 4
(n=150) 4
(n=152), 4
-7.7, 4
-3.4% 4
-8.5, 4
(0.77%; 4
-4.5, 4
plateaued 4
AleNephro 4
(non-inferior) 4
NCT01043029 4
(93 4
0.043). 4
receptor-alpha/gamma 4
(SYNCHRONY): 4
tesaglitazar 4
Electrocardiographic 4
monocytes/macrophages. 4
Parp-1-deficient 4
Parp-1+/+ 4
automodification 4
fasudil, 4
thrombolytics, 4
antifibrinolytics 4
Fasudil 4
61.7% 4
cm/second, 4
mechanisms; 4
haemoglobin, 4
haemodilution 4
neuroradiology 4
aphasia. 4
responsible. 4
pachynema 4
meiosis-defective 4
Homeotic 4
K79 4
AF9 4
zip1 4
Pch2 4
Lgr5(+) 4
totipotent 4
(H3K79me3) 4
DOT1L/KMT4 4
(H3K79). 4
NCI-H1299 4
nonproliferating 4
lacritin. 4
TGM2 4
sweat. 4
defensin 4
≅ 4
dermcidin-derived 4
250, 4
mid-trimester 4
Venezuela. 4
2.10, 4
provide, 4
Ragulator-RAG 4
genome-based 4
vaccinology. 4
genome-derived 4
spirochaete 4
cds 4
viral, 4
ruminants 4
ruminantium. 4
pathogen's 4
(ICP). 4
cysts; 4
cable 4
conversely 4
cystocisternostomy 4
(AED). 4
Pianos 4
Epileptiform 4
heard 4
sonata. 4
pretest-Verbal 4
semi-prospective 4
years-data 4
groups--Group 4
0-8, 4
84), 4
9-11, 4
12-15, 4
18-86; 4
Gastro-intestinal 4
vertebrectomy 4
(39/201)--the 4
metastases? 4
Tokuhashi. 4
months", 4
(P<0. 4
0001). 4
(r=0. 4
833, 4
P<0. 4
slow-growth 4
TRβ. 4
GC-1, 4
noniodinated 4
iodothyronines, 4
GC1 4
KB- 4
2115 4
(a). 4
preliminary. 4
98059, 4
T(4)-agarose, 4
[N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic 4
acid]. 4
23425. 4
tyrosine, 4
-adrenergic 4
3,5-diiodo-4-hydroxyphenylpropionic 4
(DIHPA) 4
T3/mg 4
V30M 4
MKI 4
(E7080) 4
RR-DTC 4
unmanageable 4
cabozantinib. 4
detailed. 4
Lenvatinib, 4
immunolocalized 4
RANK-RANKL 4
dickkopf-1 4
phosphatase; 4
(denosumab) 4
Glucagon-like 4
MitoTimer 4
(input) 4
underexplored. 4
soils 4
extra-chromosomal 4
IC, 4
half-lives, 4
phagosome 4
metalloenzymes 4
periplasm 4
photochemical 4
nucleotide-diphosphate-X, 4
29,400 4
β-γ 4
(8-oxo-GMP) 4
GDP. 4
8-oxo-GMP. 4
(MtuMutT2) 4
(MsmMutT2) 4
grower) 4
hydrolysing 4
mutM 4
PAO1 4
23-residue 4
A:T-->C:G 4
μg/ml. 4
mutM, 4
nth) 4
inducer. 4
delivered. 4
6.32 4
1.7-5.7). 4
tamoxifen) 4
propylthiouracil. 4
indistinguishable. 4
2008), 4
(29/663) 4
(23/211); 4
2.55 4
1.46-4.34, 4
2.84, 4
1.58-5.10) 4
2.25-13.99) 4
0.003. 4
pleasure, 4
Consecutively 4
291) 4
(HAD-D) 4
(1-4 4
(hedonics: 4
anhedonics: 4
[MI]) 4
readmission, 4
25-93 4
1.16-2.14; 4
ACM, 4
ACM 4
1206; 4
(286/1206). 4
"I 4
PG. 4
naltrexone, 4
50.7 4
(40.5%) 4
XELOX 4
phospholipid, 4
Npc1(nmf164) 4
clamping. 4
anti-amyloidogenic 4
Intracerebroventricular 4
regulation; 4
T0901317 4
ent-ALLO, 4
(T(reg) 4
(T(eff) 4
SATB1-mediated 4
trastuzumab-resistant 4
ciRNAs 4
(metastasis-associated 4
ENE-like 4
tRNA-like 4
∼20% 4
aries) 4
CCDC40, 4
(SE), 4
(NAN) 4
FCRL3, 4
KIF5A-PIP4K2C, 4
IL10-1082G/A 4
trans-ethnic 4
ethnicities. 4
STAT4. 4
Non-major 4
immune-signaling 4
TaqMan-MGB 4
low-to-moderate 4
Denmark). 4
rs1160542 4
(AFF3), 4
rs1678542 4
(KIF5A), 4
(PTPN22), 4
rs3087243 4
(CTLA4), 4
rs4810485 4
(CD40), 4
rs5029937 4
(6q23), 4
rs10760130 4
(TRAF1/C5) 4
(STAT4)) 4
OLIG3/TNFAIP3, 4
peptide) 4
I]. 4
HLA-independent 4
C5/TRAF1 4
TNFAIP3-OLIG3 4
polymorphism(s) 4
(HLA, 4
STAT4) 4
RA-susceptibility 4
RA-susceptibility, 4
(PTPN22-R620W) 4
(FcgRIIa-H131R, 4
FcgRIIIa-F158V 4
FcgRIIIb-NA1/NA2), 4
FcgRIIIa-V/V158 4
FcgRIIIb-NA2/NA2 4
FcgRIIa/IIIa 4
TNFR2, 4
keenly 4
VAS-E, 4
vigor 4
POMS, 4
manage, 4
agroclimatic 4
rhizome 4
phytochemicals 4
(CUR), 4
DLEC1 4
BCRP 4
A2780(cisR) 4
compatible. 4
microglia/macrophages 4
(p53, 4
hemorrhage-prone 4
CCM3-deficient 4
Trapped 4
extralesional 4
malformation; 4
core; 4
rebleedings 4
rebleedings, 4
Rebleedings 4
FA-D, 4
FA-E, 4
FA-F. 4
2%. 4
(FA-A, 4
(FANCA) 4
'Moroccan 4
Malawi. 4
000, 4
(CT). 4
[Percutaneous 4
Fluoroscopy-guided 4
TDP-43-positive 4
horns, 4
TATA-binding 4
PTE 4
hypocretin-1, 4
EDS) 4
generically 4
hypersomnias 4
apoptosis-associated 4
corpse 4
TNNI3K. 4
rTNNI3K 4
contraction) 4
PP1/Rif1 4
CDK/DDK. 4
(Rap1-interacting 4
(HDR), 4
Rad51. 4
replicons: 4
are. 4
RIF1: 4
Glc7. 4
RVxF 4
SILK, 4
(Glc7). 4
RVxF/SILK-dependent 4
Sld3, 4
(FGIDs), 4
FGIDs, 4
Ednrb(sl), 4
F344-Ednrb(sl/sl) 4
197, 4
endothelins 4
Recording 4
favorite 4
(n=31), 4
Caki 4
BAX. 4
p97/VCP 4
pulls 4
ERAD-M 4
IB, 4
NHK 4
Aguadilla 4
ER-localized 4
Derlin1. 4
gp78 4
gp78-p97/VCP-Derlin1 4
methodologies, 4
systems-level 4
UBX 4
cytosolic, 4
0.68; 4
V600-mutated 4
QTc; 4
Confirmed 4
BRAF-inhibitor 4
carboxy-, 4
(mild) 4
(16%; 4
BRAK 4
48.2 4
Paradoxical 4
Sanger, 4
NPA 4
150/2 4
(GSK2118436): 4
keratinocytic 4
Neoplastic 4
(KAs) 4
(recently 4
Administration) 4
pathology-proven 4
vemurafenib's 4
Melanomas 4
LGE. 4
7.1%, 4
non-SCA 4
19%) 4
recording; 4
syncope; 4
tachycardia). 4
Arg719Trp 4
Union, 4
oxybutynin. 4
OTG 4
dollars) 4
Tead 4
coactivators. 4
CCR6, 4
(P(combined) 4
epitope" 4
microsatellites. 4
light-determined 4
compartments). 4
astrocyte-related 4
spatiotemporally 4
hyperexcitable 4
opsin 4
variability-causing 4
n, 4
nongrowing 4
Par6. 4
progression-particularly 4
EGF-mediated 4
depolymerisation, 4
cross-modulation. 4
cytoskeleton/focal 4
factor-initiated 4
cross-modulate 4
aPKC. 4
ST, 4
(Snail1, 4
Zeb1/deltaEF1) 4
QRT-PCR, 4
(MT-PCR) 4
(paxillin) 4
ST+EGF 4
ST+EGF. 4
MT-PCR 4
(EGFR, 4
CAV1, 4
CYR61, 4
S100A4) 4
(NLF1, 4
NLF2, 4
EPHB4). 4
disease-recurrence. 4
interconnected. 4
TamR 4
(miR-1) 4
miR-133a, 4
miR-133b 4
43. 4
intervenes 4
MiR-1 4
paced, 4
miR-1-overexpressing 4
GJA1 4
Genome, 4
'the 4
instigates 4
genome," 4
PTEN: 4
arginine-serine-rich 4
MAR-binding 4
miR-504, 4
genome", 4
complex-type 4
TA-p73 4
oxidase-negative 4
(c.176C>T; 4
p.Ser59Leu) 4
p.Ser59Leu 4
UK: 4
(BZD) 4
(OD) 4
4504 4
BZD-related 4
enquiries, 4
chlordiazepoxide 4
charcoal, 4
coma), 4
800-bed, 4
teaching, 4
INTERVENTIONS; 4
oxygen; 4
indwelling 4
"waking" 4
dysrhythmia, 4
antidepressant-intoxicated 4
nondrug-induced 4
flumazenil), 4
resedated; 4
discretion, 4
1900 4
amoxapine 4
nortriptyline; 4
1928 4
amoxapine. 4
coingested 4
16.03 4
Clear 4
1.000 4
MED13, 4
MED13 4
miR-208a 4
(NRVMs) 4
α-MHC. 4
Captured 4
multiplexicity, 4
uniformity, 4
all-known 4
2q37.3 4
(TGFBR1 4
TGFBR2) 4
Meckel 4
(MKS) 4
leucoencephalopathy. 4
liquid-based 4
Single-lane 4
sectored 4
shivering, 4
Neurodevelopmental 4
touchscreen 4
(BTBR), 4
self-injury, 4
Grin1 4
(AMPA) 4
Antipurinergic 4
vocalizations. 4
SYNGAP1 4
marble 4
burying 4
NR1 4
vocalization 4
anxiety-related 4
(mGluR5) 4
(DENV-2) 4
PMP22-depletion. 4
Ras-GAP 4
Ras-GTPase 4
protein-SH3-domain-binding 4
(G3BP1 4
G3BP2-expressing 4
RNA-interacting 4
pseudoknot 4
WTs. 4
region-to-risk 4
PPSP 4
H1c 4
interferon-related 4
(TREX1, 4
Soil 4
As(V) 4
arrA 4
nearing 4
acetate-amended 4
remediation 4
depleted, 4
ompC 4
ompB 4
Colorado 4
hypothesized. 4
reoxidation 4
deprotonated 4
Model-based 4
reactive-transport 4
proteogenomics 4
consortia 4
admit 4
16,17-double 4
syringe-focused 4
needles. 4
NEP, 4
NeuN, 4
chimaerism 4
mitochondria-related 4
Rickettsiaceae, 4
Tom40, 4
twelfth 4
(XLID) 4
dSERCA 4
dSeipin 4
identified-SERCA1, 4
SERCA3. 4
organ-site-specific 4
SY5Y 4
Ephrins 4
colocalisation 4
EphA2. 4
ephrin-B 4
mol/L. 4
cells,and 4
SHG-44 4
CHG-5 4
invariantly 4
Pif1p 4
MRC1 4
RFB 4
rrm3-induced 4
broke 4
Themococcales. 4
life.In 4
(Ori) 4
Themococcales, 4
heterotrophs-peptide 4
fermenters, 4
TNFR1 4
rip1 4
(TKO) 4
Rhabdomyolysis 4
OHC 4
(RIP1 4
Edinger-Westphal 4
alpha1-adrenergic 4
dapiprazole 4
NIDD 4
IDD 4
ANS 4
-0.81, 4
RelA, 4
(NIK) 4
NF-kappaB2/p100 4
p52-RelB 4
nfkb1 4
kilodalton 4
EpCAM, 4
γ2 4
HPMCs 4
TGF-β-related 4
10,172 4
monocots 4
dicots 4
(140-200 4
Myr) 4
1x10(-11) 4
2x10(-11) 4
RRs, 4
Spondylocostal 4
Jag1 4
DLL1 4
1618 4
Hypnosis 4
professionally 4
CBTI 4
(FACIT) 4
WL 4
Rehabilitation. 4
n=76) 4
psychologist. 4
restructuring, 4
(F(1,26) 4
Cognitive-behavior 4
routing 4
(Fbw7), 4
Skp-Cullin-F 4
G-CSFR-T718 4
Fbw7) 4
(SCF)-type 4
Taxol. 4
anlage. 4
hAgo) 4
DEK 4
Ago, 4
containing-7), 4
NSC/NPC 4
under-reported. 4
nonathletes. 4
(NIS) 4
dysuria 4
heights 4
(p=0.02) 4
Illinois 4
told 4
gymnastics, 4
(49.5%) 4
19.9 4
polydactyly. 4
forearm. 4
CyPD-knockout 4
ITAbP 4
unanswerable 4
RON 4
hypothalamic/pituitary 4
iodination 4
DEM-induced 4
POM121 4
triple-A 4
Ndc1p. 4
Charge 4
NET3. 4
detergents, 4
PII 4
endoglycosidase 4
Lys48- 4
Lys63-linked 4
IFNR 4
Ser535, 4
(beta-transducin 4
repeats-containing 4
Ubiquitination, 4
SCFbeta-Trcp 4
transducin 4
hyper-methylated 4
BIU-87). 4
(62.8%, 4
59.5%) 4
(73.4%) 4
5-Aza- 4
2'-deoxycytidine 4
5-Aza-CdR; 4
cylindromas. 4
G(1)/S-phase 4
deacetylase-6 4
Bcl-3, 4
G(1)-to-S-phase 4
deubiquitinase-independent 4
Cyld(-/-) 4
(SGT) 4
dTRAF2 4
DUB, 4
(CYLD(ex7/8)), 4
NF-κB-target 4
relB-specific 4
pro-immunogenic 4
Cyld(Delta9) 4
(cylindromatosis), 4
(TRAF2), 4
(TRAF2) 4
TNFR 4
CD40-mediated 4
(RbBP5, 4
WDR5) 4
induced-fit 4
Rbbp5, 4
Ash2, 4
trimethyllysine 4
double-reciprocal 4
E(Z), 4
SCGPred: 4
SCGPred, 4
http://bio.scu.edu.cn/SCGPred/. 4
DGSplicer) 4
http://csrl.ee.nthu.edu.tw/bioinf/ 4
cclu@ee.nthu.edu.tw. 4
(SplicePredictor) 4
http://bioinformatics.iastate.edu/cgi-bin/sp.cgi 4
EST-based 4
5'-coding, 4
3'-coding 4
0.90. 4
RINGS 4
URL 4
A-ring 4
SDS-PAGE). 4
isoflavonoids 4
elicitation, 4
(3R)-vestitone, 4
legumes. 4
(-)-medicarpin 4
6aR, 4
(MGM), 4
afrormosin-7-O-glucoside 4
(AG), 4
(AGM) 4
afrormosin 4
[(14)C]phenylalanine 4
IM-R 4
tumor-host 4
anti-proliferative, 4
Brains 4
H&E 4
CHS1/LYST, 4
(c.925C>T, 4
p.R309X). 4
Levodopa-induced 4
cytopathies, 4
(POLG1) 4
(aa)-a 4
gun-metal 4
fur-commonly 4
Violet 4
(aammpp) 4
Sapphire 4
(aapp). 4
(c.9468delC) 4
(p.Leu3156Phefs*37). 4
coagulant. 4
Hemophagocytic 4
well-trained 4
21.4 4
LVEF. 4
(hereafter, 4
(ESCRTs) 4
CHMP5 4
FREE1 4
gankyrin 4
high-molecular-mass 4
Caov-3 4
PA-1 4
mutant-type 4
Conversely 4
D2-Cdk4 4
G1-specific 4
encephalic 4
medullectomized 4
[( 4
(HRC). 4
type1 4
(FPN). 4
(HJV), 4
(HAMP), 4
(TFR2) 4
protein-2, 4
Ser(65) 4
Ser67-phosphorylated 4
Nonphosphorylated 4
kinase-phosphorylated 4
SDS/PAGE; 4
HPLC; 4
PKC-α, 4
PKC-α-dependent 4
fodrin 4
I-1Thr35 4
neutrophils: 4
vitro-generated 4
APS. 4
microRNA- 4
TRBP) 4
payment 4
510(k) 4
node-positive, 4
phacomatosis 4
neuroaxis 4
(3p25-26). 4
epididymis, 4
(1/36,000 4
(model 4
angiogenesis). 4
HIF-independent 4
haemangioblastomas 4
cystadenomas. 4
Trastuzumab, 4
HER2Mab 4
Incidence, 4
tackling 4
(DRESS) 4
personalised 4
HLA-B*5701-negative 4
non-White 4
Initiating 4
HSRs, 4
HLA-B*5701); 4
HLA-B*5701-positive 4
confirm, 4
prospective-screening 4
(3.4%) 4
furthered 4
pre-prescription 4
14-3-3sigma 4
(CpG 4
(ODNs) 4
esophageal, 4
(No. 4
cuban 4
Cuba, 4
nimotuzumab's 4
ependymoblastoma 4
(n=1); 4
Lansky 4
≥50. 4
(CTCAE). 4
(14/22) 4
16.5 4
researched 4
microg/dL, 4
1,986% 4
82.5 4
U/L, 4
FTI 4
5.7. 4
vasculitic 4
(insulin-dependent) 4
SMS, 4
SMS. 4
DQB1*0201 4
Nfo, 4
ExoA, 4
Nth 4
his, 4
(EPDS). 4
nursing, 4
α-tubulin. 4
MEC-17, 4
(SirT2), 4
Immunoblotting, 4
SirT2 4
SirT2. 4
nocodazole-treated 4
pyrazole, 4
(Wld(S)). 4
nephropathy; 4
ScaI 4
T708 4
DFSP 4
(CD117) 4
(surgical 4
introduction, 4
$0.01 4
PMPM), 4
($0.01 4
~11% 4
(hA3G), 4
anti-L1 4
(APOBEC) 4
(HCT), 4
(near 4
MCHC, 4
MCH 4
nonexcitable 4
(CRP)--an 4
(19.8 4
mg/l). 4
0.0045). 4
ip). 4
P-induced 4
SCH23390, 4
(i.t.) 4
animal; 4
3-O-methyl-DOPA. 4
ALAAD, 4
Madopar 4
probably, 4
Oxygenation 4
MV, 4
SURfactant 4
(controlled 4
bilevel 4
FiO(2) 4
2.24, 4
.002, 4
OntoGene 4
(HVS) 4
F-score 4
BioMap 4
effector-target 4
CD95L 4
Fas/Fas 4
immunoprivilege 4
ITL. 4
(24-36%) 4
(10-15%) 4
FasL-producing 4
preapoptotic, 4
Lmna(Δ8-11/Δ8-11) 4
Caspase-6 4
interacting, 4
LA/C-rich 4
microdomains. 4
nontranscribable 4
biosphere. 4
PSII 4
transcription: 4
Cloned 4
apo-C-II 4
Up-regulating 4
relaxin-1 4
(RLN1, 4
Chr1) 4
(G)-rich 4
berberine. 4
BACE1, 4
(PD20) 4
(PD25). 4
telomerase-inhibited 4
1.92 4
Sufficient 4
refrigeration. 4
freezer. 4
television, 4
cold-chain 4
trifluorothymidine 4
5FU-resistant 4
TK1 4
antimetabolite 4
FTD-dependent 4
nucleosides. 4
(TNBC), 4
cyclophosphamide-based 4
Janeiro 4
Euproctis 4
chrysorrhoea 4
interpretation]. 4
Lepidopterism. 4
caterpillar. 4
Caterpillars 4
moths. 4
(moths, 4
butterflies, 4
self-limited; 4
threatening. 4
Antipruritic 4
envenomation, 4
antivenin 4
manufactured. 4
Phe14-His15 4
His18-His19 4
imidazole 4
Candida-associated 4
Histatins, 4
poly(methyl 4
methacrylate) 4
(0.01-100 4
(1-200 4
GDH18, 4
UTR-14 4
6122/06 4
(concentration 4
biofilm) 4
(planktonic 4
Planktonic 4
Biofilm-associated 4
1-200 4
[Hepatic 4
galactosyl-sphingolipids 4
galactocerebroside 4
(globoid-cell 4
leukodystrophy; 4
GLD) 4
Beta-galactocerebrosidase 4
GLD. 4
(GALC-GC) 4
activity-reducing 4
Calif) 4
produce, 4
LIMEs. 4
(repetitive) 4
(nonrepetitive), 4
enzyme-coding 4
1491 4
(779 4
CNSs. 4
maize-sorghum 4
rif, 4
rif-A, 4
PfMC-2TM. 4
RSpred 4
knowlesi 4
clefts, 4
SURFIN4.2 4
LMV 4
manualised 4
(FRIENDS) 4
Generalised 4
37), 4
post-treatment; 4
SLC24A5, 4
TYRP1 4
SLC45A2, 4
IRF4, 4
Oceania. 4
Islanders. 4
SUD 4
acetylhydrolase 4
hydrolysed 4
icatibant 4
Captopril 4
captopril, 4
(61%). 4
IMFs 4
(tpl2) 4
thiazides 4
betablocker 4
medoxomil 4
CCB, 4
Telmisartan 4
(HCTZ). 4
83.1 4
101.1 4
(n=128), 4
collide 4
37.2 4
reconstructive 4
grasp 4
Syndactyly 4
0.4%, 4
(Bmal1, 4
Clock, 4
(Myc, 4
non-shift-workers 4
day/night-dependent 4
(>or=12 4
(Cry) 4
(51%). 4
profiles; 4
(BOR) 4
(THAL) 4
THAL-resistant 4
LCQ195 4
(PCL), 4
1-21, 4
MyVTD. 4
6-42 4
P-Akt 4
Medulloblastomas, 4
PTCH1, 4
SUFU) 4
CREBBP) 4
MYT1L) 4
(p=2x10-5), 4
(6/7; 4
Crebbp, 4
Myt1L, 4
Nfib, 4
Tead1 4
Tgif2) 4
MassCLEAVE 4
11/44 4
(DAOY) 4
re-expressing 4
PCDH10, 4
SmoA1;Bmi1(-/-) 4
SmoA1 4
195,745 4
Tags 4
tallied 4
amplicons, 4
(TSGs; 4
p15(INK4b), 4
TSLC1, 4
cerebella). 4
(p14(ARF), 4
RIZ1; 4
(p15(INK4b), 4
TSLC1), 4
tumour-specificity 4
NBCCS 4
22.4 4
msec(1/2) 4
19,153 4
(corrected 4
pitcher 4
slides, 4
EVLW. 4
diving. 4
fMRI. 4
bathing. 4
water-immersion 4
FENO, 4
Viet 4
[IQR] 4
time-slice 4
C-statistic 4
characteristic)=0.85 4
sensitivity=84.0%, 4
specificity=64.7%) 4
C-statistic=0.76 4
(smear 4
microscopy), 4
(sputum 4
(chest 4
5'-triphosphate, 4
orf135- 4
2-OH-dATP. 4
dATP 4
gap-filling 4
8-OH-dGTP 4
8-hydroxy-dGTP 4
(2-OH-dATP) 4
Protoporphyria. 4
mild; 4
Clinuvel 4
NCT01605136 4
NCT00979745.). 4
Narrowband 4
phototherapy. 4
(EPP). 4
2], 4
(EPP) 4
chemicals, 4
IX. 4
ETFP 4
(MSH) 4
(PP), 4
Tzs 4
(indole-3-acetic 4
grobacterium 4
interactor 4
T-region 4
co-inherited 4
Capital 4
pipetting 4
stakeholder 4
cortices. 4
saccades 4
competence, 4
Frog 4
Indians 4
Ninety-six 4
4b 4
(SMN). 4
SmB, 4
-D1, 4
-D3. 4
SmD3 4
Lsm-containing 4
U7-specific 4
pICln 4
Sm/Lsm 4
Sm-class 4
(CB), 4
CBs, 4
([125I]omega-conotoxin 4
(MVIIC) 4
MVIIC, 4
non-entangled 4
collapses 4
1988) 4
proximity-based 4
megabase. 4
"fractal 4
globule" 4
IIA-bound 4
G-segment 4
(PDB 4
ID: 4
polyamine-containing 4
F14512-induced 4
putrescine, 4
drug-sensitive 4
ADP. 4
sublines. 4
(0.78 4
LC-5 4
relaxing 4
hyperthermia. 4
anthrapyrazoles, 4
937, 4
mitoxantrone; 4
941, 4
azatoxin; 4
937; 4
daunorubicin-induced 4
OC-NYH 4
Sensitivities 4
High-Throughput 4
0.79). 4
1,7-naphtyridine-3-carbonitrile, 4
4-anilino-6-aminoquinoline-3-carbonitrile 4
C-8 4
kinome 4
orders. 4
necroses 4
girl) 4
HoxC 4
2.25-kb 4
(mmA13CNS) 4
Hibadh 4
Limb 4
Bichir 4
(Actinopterygii, 4
(Polypterus 4
senegalus), 4
pseudoobscura 4
outgroups, 4
extemporaneous 4
wound. 4
arteriosclerotic 4
irritative 4
hydroxylamine 4
Response. 4
coinducer 4
inducer, 4
celastrol 4
Hsps 4
AVS 4
3.16 4
4-50). 4
Faecal 4
bulking 4
InVance™ 4
Systems, 4
midterm 4
Femassist 4
(24.4%) 4
(4.9%) 4
carbon-starved 4
putida 4
PolV 4
SUVmax 4
Component 4
Relocation 4
p63, 4
colored 4
illuminating 4
self-associating 4
3.5-15.6%. 4
appealingly 4
Sry, 4
bradyarrhythmic 4
[125I]-(-)-CYP 4
kabaddi 4
(Δ 4
ratio), 4
endurance, 4
surfers. 4
male-dominated 4
masculinized) 4
seeking. 4
fencing, 4
potency) 4
Sporting 4
(CBF). 4
4: 4
alloantibodies. 4
DARA-containing 4
denatures 4
anti-idiotype 4
anti-CS-1 4
[Daratumumab--breakthrough 4
daratumumab: 4
DCX 4
(M1V), 4
ß 4
Chemists. 4
vascular-related 4
hydrolyse 4
polymerization/depolymerization 4
Spy0269 4
sacculi 4
cell-division 4
ftsA 4
characterized: 4
297F 4
αν 4
(intetumumab) 4
75-mg/m(2) 4
0.014), 4
17%) 4
N-telopeptide 4
psychometrics, 4
HRQoL. 4
Psychometrics 4
(n=127) 4
13.0±2.6 4
g/dl, 4
394±454 4
IU/l. 4
1.6±2.2 4
54.5±7.2, 4
psychometrics: 4
0.74. 4
postbaseline 4
BPI. 4
anti-α(v)-integrin 4
dacarbazine+placebo, 4
dacarbazine+intetumumab, 4
complete+partial 4
intetumumab-dacarbazine 4
Transient, 4
nonrecurring, 4
22-30% 4
intetumumab-treated 4
infusion-reaction 4
chills) 4
16-73% 4
intetumumab-related 4
laboratory/electrocardiogram 4
Vomiting, 4
chills 4
dose-proportionally 4
ncRNA-dependent 4
sortilin-related 4
(SORL1) 4
51A 4
pro-regions 4
intra-exon 4
GDNFOS3 4
(MTG) 4
(pol) 4
leprechaunism. 4
Bartter-like 4
hyperaldosteronism, 4
p.Leu795Pro 4
syndromes]. 4
commensurate 4
TRalpha/TRbeta 4
Discoveries 4
anti-ErbB3 4
PLX4032-resistant 4
vemurafenib-resistant 4
BRAF-I 4
non-p.V600E 4
nonacral 4
[2 4
(75.4%) 4
8.8, 4
SDS, 4
biobanks 4
(FFPE), 4
pipet-tip 4
time-the 4
phosphosites 4
atorvastatin-treated 4
OCT-frozen 4
Biologically 4
58; 4
post-diagnosis. 4
perceptions, 4
Comorbidity 4
P's<0.001). 4
13%; 4
utilisation. 4
(n=125) 4
niche-specific 4
starch. 4
plating. 4
20542 4
(LBM), 4
pfkA 4
L(-1)) 4
Bio 4
∆oahA 4
#76 4
cadA 4
10.1, 4
ELISAs 4
dermatoses. 4
buttocks. 4
anti-transglutaminase 4
8-month-old 4
pathognomic 4
uninvolved, 4
stromelysin 4
endomysial 4
blister 4
DRB1, 4
DR7 4
DR2 4
(GFD) 4
diet; 4
RifR 4
point-mutation 4
repair-associated 4
integration--suggesting 4
(homeologous) 4
thermophilus 4
CFT073 4
UPEC 4
L-ON 4
predominating. 4
O(6)-alkylG 4
O(6)-alkylG:T 4
sibs, 4
proxy, 4
altitudes 4
Scotland, 4
Ixodid 4
farms 4
epizootic 4
arthropods, 4
stress-responses, 4
circumstances: 4
Eif4enif1 4
regulons. 4
titin/connectin 4
100-residue 4
10(6); 4
string-like 4
(BMP-2) 4
(MEF-2A). 4
MEF-2A. 4
Factor-2 4
Mef2 4
MC1568 4
MADS-box 4
(ANF). 4
(MEF2C), 4
MEF2A, 4
LST8, 4
(regulatory 4
6-day-old 4
(TGN). 4
(GCase) 4
(RAP), 4
(prosaposin 4
sphingomyelinase 4
LIMP2 4
detergent-resistant 4
M6PR 4
DRMs. 4
multi-ligand 4
TGN, 4
100-nm 4
tubular-vesicular 4
wortmannin. 4
recently-delivered 4
endocyted 4
VPS10 4
(CIMPR) 4
25.7% 4
Nasopharyngitis 4
UC: 4
(natalizumab, 4
(ustekinumab) 4
PF-00547,659 4
α(4) 4
β(7) 4
Post-operatively, 4
clonidine-induced 4
ketorolac, 4
0.064). 4
0.24-0.78) 4
(0.09-1.17), 4
postsevoflurane 4
(P=0.05). 4
BIS(nadir) 4
suitably 4
deteriorated, 4
PLN/SERCA2a 4
PRPF6 4
heteronuclear 4
Petri 4
extendable 4
PolC, 4
dnaE 4
machineries, 4
(proTα), 4
prothymosin-α 4
ProTα. 4
(C)-terminus. 4
monocyte-dependent 4
(proTalpha) 4
carboxy(C)-terminus 4
Calf 4
trypsinised, 4
1-14, 4
31-87, 4
89-102 4
103-109) 4
donor- 4
(AMLR), 4
lymphokine-activated 4
perforin, 4
ProTalpha(1-14), 4
proTalpha(21-30) 4
proTalpha(31-87) 4
non-mammalian 4
group-x-time 4
non-sleep 4
0.24, 4
KOs, 4
modafinil-induced 4
PCP-induced 4
set-shifting 4
baited 4
SANS 4
fluency 4
naturalistic, 4
stabilized, 4
hypofunctioning 4
1-14; 4
15-28) 4
0.026; 4
alkyltransferase. 4
A316P/W336A-Ada-C 4
16-mer 4
(Ogt+ 4
misreplication 4
O6-chloroethylguanine, 4
Ada+ 4
Ogt- 4
Ada- 4
O6-chloroethylated 4
methanesulfonate, 4
dibromoalkane 4
(MTases) 4
O4-alkylthymine, 4
C:G 4
2.5-, 4
1.7-fold, 4
V79 4
ATases 4
O6-methylguanine-DNA 4
(ada 4
mutants) 4
metabolite(s) 4
A316P/W336A 4
6-alkylguanine-DNA 4
alkyltransferase(alkyltransferase) 4
6-alkylguanine 4
4-alkylthymine 4
O6-Alkylguanine-DNA 4
2.1.1.63) 4
uVNTR 4
ODD 4
rs6323 4
(MAO-A 4
clorgyline 4
anti-depressant 4
DSPP, 4
odontogenesis-related 4
hDPSCs 4
odontoblast/osteoblast-like 4
N-acetylation 4
EMDgel 4
capped, 4
extracted, 4
amelogenins 4
(BDI) 4
follow-ups, 4
mo), 4
nondepressive 4
iPLEX 4
NFAs. 4
NFAs 4
ShotGun 4
dyskeratosis. 4
Hi 4
Seq 4
Long-PCR 4
Analyzer 4
TGFBR2, 4
intra-chromosomal 4
warts. 4
practice? 4
pain). 4
Organized 4
(VLP) 4
(HPV 4
LGR5 4
C10orf137, 4
extracolonic 4
-181c, 4
miR-590-3p 4
(hsa-miR-29b 4
hsa-miR-375) 4
(PBMCs), 4
hsa-miR-29b, 4
hsa-miR-375, 4
7.3, 4
antiulcer 4
Mirtazapine 4
approach? 4
TCAs 4
MED. 4
medial-lateral 4
TCS-assisted 4
Peroperative 4
note. 4
ruber. 4
(ALU, 4
SAT2) 4
SAT2 4
COBRA 4
ALU 4
metaplasias, 4
(TRAMP) 4
IVH, 4
Ewan 4
g/day, 4
(H2O2). 4
H2O2-mediated 4
(≥20 4
sensitivity/resistance 4
Pauling 4
(L-ascorbate, 4
Spectrin 4
beta-spectrins 4
alpha,beta-heterodimers 4
stochastically 4
(HEalpha13,14) 4
beta-spectrin 4
(HEbeta8,9), 4
type" 4
detergents. 4
2-ME 4
high-prevalence 4
percent), 4
abruption. 4
thrombophilia, 4
aPC 4
threaten 4
anti-beta2-glycoprotein 4
(bevacizumab, 4
(temsirolimus, 4
ramucirumab 4
Squibb), 4
dosing) 4
Well 4
dx, 4
GEP 4
normal-like, 4
Nifedipine, 4
chondrogenesis, 4
NMDARs 4
APV 4
binge 4
Cd2+ 4
VDCCs 4
HAP 4
cAMP-differentiated 4
[(3)H]D-aspartate 4
nM; 4
Releasing 4
Bell's 4
follows; 4
jerks 4
protirelin 4
1983. 4
saturated. 4
habitats. 4
DUFs 4
(DUF4488) 4
SrfN, 4
SrfN 4
FLZ 4
afatinib) 4
(wild 4
EGFR-specific-siRNAs. 4
Properly 4
periurethral 4
AUS 4
(CHK2) 4
CHEK2-H143Y 4
CHEK2-positive 4
CHEK2-P85L, 4
cell-cycle-checkpoint 4
(CHEK2 4
1100delC) 4
903 4
Work-related 4
supervisors 4
coworkers. 4
(presenteeism). 4
problems) 4
$2 4
$13 4
12-month, 4
income 4
employees. 4
3.42, 4
employment. 4
"presenteeism" 4
absenteeism-presenteeism 4
non-remitted 4
psychiatrically 4
expenses. 4
spondyloarthritis. 4
gastroscopy 4
laddering, 4
s1a 4
silicosis 4
defined; 4
nonfibrogenic 4
polyinosinic 4
(poly(I), 4
poly(I) 4
interleukin-converting 4
silica-mediated 4
ketone. 4
silica, 4
ICE, 4
BrdU/anti-BrdU 4
Commun 4
(1-6 4
tween 4
ouabain-binding 4
(CPK), 4
hypotonia/dystonia, 4
deficiencies: 4
(Allan-Herndon-Dudley 4
Mct8. 4
Lat2 4
(liver 4
misfolding. 4
paraplegia. 4
phenomics 4
(MCT8 4
disability* 4
posturing 4
Dystonic 4
t(X;9)(q13.2;p24) 4
blown 4
non-AHDS 4
Slc7a3 4
3+3 4
CVA, 4
cixutumumab. 4
pERK 4
pS6 4
HLA-ABC 4
iodine-refractory 4
redifferentiating 4
Plexus 4
Adv 4
Pharmacol 4
63:1-42, 4
(UGT1A1) 4
(OATP) 4
coincubation 4
faldaprevir-mediated 4
(a.k.a. 4
(seven, 4
*1a/*1a, 4
*1b/*1b, 4
*1b/*15 4
*15/*15, 4
SLCO1B1*1b/*15 4
*15/*15 4
5.12 4
SLCO1B1*15/*15 4
T.BIL 4
D.BIL 4
(TRβ) 4
brain-damaged 4
condition/group. 4
(66.6%) 4
recreation 4
improvised 4
initiative) 4
echinococcosis), 4
Trichinella 4
amoebic 4
flavoprotein 4
Pf-SSB 4
ΔE1 4
(MSP)-1 4
β-actin 4
(cox1, 4
spectacular 4
(Pf), 4
yoelii-infected 4
PfRh2b 4
DBA/2 4
co-speciation 4
hominin 4
deregulated. 4
aquaglyceroporin 4
GMPS 4
anthropophilic 4
5'-monophosphate 4
phosphoethanolamine 4
sPLA(2)s 4
Thioredoxin 4
ketone, 4
Pfmrk 4
Cell-mediated 4
Parasitemia 4
hydroperoxide 4
m(-1) 4
PfAMA1 4
rPfHinge-ODC 4
NADP 4
juvemon 4
mg/l, 4
berghei, 4
DDT 4
sucking 4
four-day 4
(ACP) 4
(PM), 4
lycorine 4
LT1 4
GRASP 4
suppression; 4
Myelosuppression, 4
mucositis, 4
hepatopathy, 4
chronic; 4
pharmacokinetic-pharmacodynamic 4
doxorubicin-iron 4
2.8- 4
growth/differentiation 4
GDF10 4
P28. 4
(Cy); 4
non-alkylating 4
pretransplant 4
posttransplantation. 4
Cy-treated 4
reverted. 4
genotoxins 4
(I-II) 4
(upfront, 4
rEOC 4
encapsulates 4
labor-intensive, 4
subforms 4
guanine. 4
transcript: 4
caucasians 4
Micrographic 4
base-modified 4
CCL5-stimulated 4
PDGFRβ, 4
α-thrombin 4
(α-parvin) 4
rac 4
CCL2-induced 4
Cudratricusxanthone 4
MDA-MB-453 4
icariin, 4
disperse 4
(ELMO1) 4
(Dock180), 4
(GEF), 4
(APOBEC3) 4
A3F. 4
seven-member 4
provirus. 4
encapsidation, 4
(A3F) 4
A3C 4
edits 4
posture. 4
(OI). 4
hNET-wt 4
hNET-wt. 4
(POTS) 4
blackouts 4
nonphysiologic 4
platelet-related 4
depart 4
MSPCR 4
stricturing 4
084 4
1988-1990 4
2006-2007 4
KNOWN 4
THIS 4
HtSDS 4
EIM 4
anti-CBir1 4
T(1)AM, 4
γ-glutamyl 4
Pairs 4
H₂S 4
N991D 4
hCHK2/hCds1 4
lesioning, 4
(CSF1R), 4
lymphomatous 4
antimesenteric 4
Thomas 4
epithelial-enriched 4
Merlin's 4
PAK2. 4
high-titer 4
(secukinumab) 4
≥75% 4
(almost 4
anti-17RA 4
spondylitis: 4
Ankylosing 4
(n=24) 4
strictured 4
non-strictured 4
(one-sided 4
(9/23) 4
q4w, 4
(AIN457), 4
IgG1/κ 4
(LY2439821) 4
anti-IL-17RA 4
Th1/Th2 4
interleukin-17A-blocking 4
secukinumab. 4
funneled 4
2B/calcineurin 4
NCS-1 4
NFATc3 4
CHP 4
Two-site 4
over-responsivity, 4
specializing 4
(CYPs) 4
(PPIase) 4
CypA 4
synapsins 4
CyPBP37 4
Elevating 4
(sAC). 4
HYPB/Setd2 4
resource: 4
tT4 4
12:12) 4
(CK1epsilon) 4
infectious, 4
ultra-early 4
(Ngb-Tg) 4
pre-injury 4
3NT 4
TBI; 4
ticagrelor. 4
each), 4
PRI 4
Clopidogrel 4
Packard 4
ADP-induced 4
CADP-CT 4
Maoris 4
dopa-resistant 4
jerky, 4
sop 4
(corossol), 4
videopolysomnography. 4
sex-, 4
disease-duration- 4
disability-matched 4
synucleinopathy, 4
(limb 4
8.3%+/-8.7% 4
0.1%+/- 4
0.2%; 4
24.3%+/- 4
0.7%+/-2.0%) 4
Gd-PSP, 4
aggregation), 4
sop. 4
Indies. 4
(quinolines, 4
rotenoids). 4
corticobulbar 4
(PDC) 4
inversed 4
acetogenins. 4
Pitre 4
fifths 4
(SPSP) 4
dopa-unresponsiveness, 4
neurodegenerations 4
bodig 4
Guam. 4
teas 4
uPA/PAI-1 4
Nova 4
B-14 4
sub-cohort 4
DX) 4
GATA-binding 4
(lumpectomy, 4
Oncoytpe-DX 4
19(th), 4
OVID 4
Marchionni 4
(Key 4
#2 4
Oncotype-DX; 4
estimators 4
(cytosine-5)-methyltransferases, 4
N-5 4
(zebularine 4
aglycon) 4
riboside 4
(zebularine). 4
5-aza-2'-deoxycytidine: 4
ZCyt. 4
(ZCyt-ODNs) 4
(C5 4
haemolyticus 4
C5)-methyltransferase 4
C5-MTase). 4
(M.HhaI), 4
5,6-dihydro-5-azacytosine 4
(DZCyt), 4
sp3-hybridized 4
(CH2) 4
NH 4
non-aromatic 4
DZCyt. 4
G-C-G-C 4
nucleophile, 4
81, 4
carbon. 4
NaeI 4
phosphoramidite 4
Foxp3+ 4
MDS-L 4
overdrainage. 4
(CSDH), 4
CSDH. 4
haematoma. 4
[Montirelin 4
(0.03-0.1 4
(0.1-0.3 4
pentobarbital-induced 4
30- 4
scopolamine, 4
muscarine 4
bradycardiac 4
assays--including 4
amphioxus--and 4
Disease-corrected 4
Fanconi-anaemia-specific 4
(PHN) 4
checkerboard 4
284, 4
PGD. 4
non-desired 4
deliberative 4
accessible/open 4
(Upf1, 4
Upf2/Nmd2, 4
Upf3) 4
reinitiate 4
upf1 4
PTC-containing 4
Upf2p, 4
(error-free 4
NMD2, 4
UPF3. 4
sup111 4
decay) 4
splicing-dependent 4
immune-associated 4
A8 4
(calgranulin 4
lactoferrin 4
alpha1-acid 4
140/90 4
(CCAs) 4
19%, 4
OAS 4
Hypo-fractionated 4
IMRT 4
chemo-radiation 4
(54%). 4
30-72 4
Re-irradiation 4
procarbazine, 4
radio-chemotherapy 4
'Stupp 4
protocol'). 4
Radiologists. 4
[Glioblastoma 4
Glioblastoma, 4
fibrillogenesis. 4
skip, 4
acceptor-site 4
pro-alpha1(V) 4
(IVS4-2A-->G) 4
N-propeptide-encoding 4
1(V)2 4
3(V). 4
+6 4
0.00). 4
[age, 4
(ABCD) 4
(ABCD3) 4
Essen 4
Instrument 4
II] 4
(Age, 4
weakness: 4
(c 4
point]: 4
point] 4
periungual 4
(encodes 4
MMP-3, 4
interneuron-specific 4
Orbital 4
predict, 4
GP, 4
cardiopathy 4
nanism: 4
Finn 4
0.02-52 4
-3.1 4
triangularity, 4
gracile 4
(96%), 4
flammei 4
hypotonicity 4
MUL. 4
nanism), 4
Postmortem, 4
(c.1233delA) 4
Pericardectomy 4
mandibuloacral 4
HGPS 4
farnesylated 4
multiple-turnover 4
Mag2p 4
tagA 4
(fU), 4
(fU:A) 4
(fU:G) 4
(Masaoka, 4
Terato, 4
Honsho, 4
25136-25143), 4
2'-deoxyribonucleoside 4
2.6-6.7 4
T(template):A(primer). 4
T:G 4
fU. 4
poly-ubiquitination. 4
poly-ubiquitination, 4
mono-ubiquitination. 4
degron, 4
ATPase-binding 4
(PS1), 4
myoblastic 4
R-Smad 4
dolichostenomelia 4
anti-A3G 4
I107T 4
A3G(+) 4
lysine-free 4
humor 4
p38δ. 4
p38delta) 4
p38gamma, 4
OESCC 4
ligament-like 4
OC-Cre;Catnb(lox(ex3)/+) 4
predentin 4
crown. 4
Dspp 4
odontoblasts. 4
Bsp 4
PC-1 4
Phex 4
TNAP 4
Dmp1 4
periodontium. 4
(PDL) 4
gabapentin-related 4
(ADRs). 4
fainting, 4
fainting 4
day(-1); 4
subtherapeutic 4
1034 4
salt) 4
Tel 4
Aviv 4
Sourasky 4
curve=5) 4
38-86) 4
(94.3%) 4
44.3% 4
4.3-8.3] 4
4.6-7.9) 4
13.6-18.1) 4
10.0-27.8) 4
Platinum-sensitive 4
GEMOX 4
Anti-angiogenic 4
totals 4
(DCR), 4
40.7%; 4
endostar- 4
neutropenic 4
-refractory. 4
36.4%, 4
4/15. 4
7.0-13.0) 4
0.061). 4
treat-ment-associated 4
OXA 4
underway/planned, 4
crizotinib) 4
PARPis, 4
BRCA1/2(MUT+) 4
FoxA: 4
EBNA1, 4
episomes 4
recombinases, 4
memory). 4
EBNA1-EBNA1 4
patho-epigenetic 4
reflected, 4
(Fox) 4
'pioneer 4
stably. 4
photobleaching, 4
FoxA1 4
FoxA2 4
NF-1, 4
HMGB1. 4
Mesp1 4
GMT). 4
Hand2, 4
Tbx5) 4
β4 4
Srivastava's 4
(cardiomyocytes) 4
treatment-naive, 4
4-yr 4
cylinder, 4
Curved 4
non-randomness 4
island-like 4
5'-terminus, 4
CpG/CpNpG 4
Gene-associated 4
18.7). 4
humidified, 4
(HHHFNC) 4
L/min, 4
closed-mouth 4
HFNC. 4
litres/min. 4
requirement: 4
range): 4
(1-8) 4
(7.5-19.25) 4
p<0.001] 4
[10.5 4
(4-21) 4
(11.5-29) 4
p=0.03]. 4
NC, 4
FGFs 4
quiescent. 4
sub-population 4
CELL 4
FACTS: 4
myonuclei/g, 4
man; 4
cells/g, 4
conditions-high 4
myonuclear 4
muscle-forming 4
Meso 4
immunoaffinity-mass 4
(HI-MS). 4
HI-MS. 4
subdimension 4
30.1% 4
atypical/silent 4
(15.2%; 4
primary-care 4
1198 4
2541 4
dysphagia; 4
5459 4
5404 4
dyspeptic 4
2525 4
histology; 4
thetaiotaomicron. 4
terminuses 4
H.pylori 4
mollicute 4
table, 4
phylogeography 4
RNA-bait 4
flow-sorted 4
200-fold. 4
(HbF), 4
adult-like 4
postembryonic 4
wtES 4
c-ErbA/ 4
adequately. 4
F] 4
radiophysical 4
fluorine-18. 4
F]MH.MZ. 4
H]MDL 4
100907, 4
F]MH.MZ, 4
ketanserin. 4
tissue-compartment 4
radiometabolites. 4
Dexfenfluramine 4
micro-positron 4
Hooded 4
5HT(2A) 4
BP(P) 4
[(18)F]altanserin. 4
ILL 4
CW. 4
V3' 4
Visualisation 4
rodent. 4
5-HT2aR 4
BP(nd) 4
5.0) 4
ANCA-associated 4
vasculitides. 4
sib-pair 4
ASP-based 4
0.037). 4
1.03-2.78). 4
T1D. 4
(SNP; 4
rs2476601) 4
PTPN22*R620W 4
tobacco/hormonal 4
intra-cohort 4
HLADR1 4
demography, 4
pack-years, 4
Gene-environment 4
(RERI), 4
(SI). 4
0.0001]. 4
TSHR. 4
hindlimb, 4
steroidogenic 4
DnaJC11. 4
DnaJC11, 4
CHCHD3 4
(metaxins 4
SAM50 4
DnaJC11 4
1-binding 4
untagged 4
Ya5a2 4
reticulocytopenia. 4
(RP), 4
65.5% 4
pC6 4
SerH 4
i-ag 4
rseB 4
pause-inducing 4
Gal4-VP16-mediated 4
DSIF- 4
CsA-binding 4
PMS2 4
Sarcomatous 4
>29 4
alive). 4
reticulin 4
O-Methylguanine 4
1p/1q, 4
19p/19q, 4
7/epithelial 4
PTEN/DMBT1 4
codeletion) 4
100), 4
gliomatosis 4
Opposite 4
oligoclonal 4
Biphasic 4
G749T 4
35.9 4
A.D.) 4
B.C. 4
beta-subunit, 4
beta-N-acetylhexosaminidase 4
subject's 4
Sachs 4
c.459+5G>A 4
recQ 4
incisions. 4
unrepaired, 4
strand-separating 4
27-mer 4
pathological. 4
Wenxin-Keli 4
WXKL 4
S2814D 4
digitalis-induced 4
glycosides. 4
extrarenal 4
Thyroidal 4
((123)I 4
hr: 4
20.2% 4
8-40), 4
(examined 4
perchrolate 4
thiocyanate 4
(p.T537P) 4
(p.H723R) 4
Duox 4
P7. 4
OBJECTIVE, 4
PATIENTS, 4
unsuppressed 4
[Phenotypic 4
goitre--a 4
audiogram, 4
'partial' 4
cheaper, 4
(EVA) 4
EVA; 4
(L465W 4
G497R) 4
(T410M, 4
R409H, 4
T505N 4
IVS1001+1G>A) 4
(G497R/wt). 4
α1I 4
HotLig 4
M3 4
hCA 4
Vina 4
Pocket 4
LiGen, 4
Glide 4
Arg216Gln 4
smear. 4
G10578 4
DXS6797, 4
Arg216Gln. 4
(SFK), 4
(Lck). 4
succinimidyl 4
P3, 4
Matrigel-coated 4
polarity-cell 4
Ras-mitogen-activated 4
state-of-the-art. 4
SSG 4
XVIII/AIO 4
(SSG) 4
(AIO) 4
filed 4
(DSS). 4
Pentavalent 4
hMTH1 4
RAS-transformed 4
MTH3 4
PNP 4
CREB-regulated 4
experience-dependent 4
code" 4
(SSC) 4
SSC. 4
cerebroside(SCC) 4
base(LCB) 4
indica, 4
Rats, 4
CCT-diet 4
LPO, 4
hyperglycemia/diabetes 4
pickled 4
α-glucosidase. 4
(CBZ) 4
(HLA)-B*1502 4
B*1502 4
telomerase-positive 4
(25.0%), 4
PI3K-AKT-mTOR1 4
(>18 4
presentation-relapse 4
TRB@ 4
GATA3, 4
voles, 4
RNA-polymerase 4
grading, 4
Tyr(397) 4
732 4
GFK 4
aspin 4
5-ITu 4
misaligned 4
AtHaspin, 4
GFP-α-tubulin 4
AtHaspin-GFP 4
meristem, 4
(H3-pT3) 4
areata-like 4
nonscalp 4
leucopoenia 4
azathioprine-related, 4
trade-off 4
5-ASA 4
stools, 4
Pericarditis 4
frameshifts. 4
MS4A3 4
solid-tumor 4
MS/MS/MS 4
LuciPHOr 4
hyperplasia-inducing 4
channel-blocking 4
Cathepsin-L, 4
disease-mediated 4
(KGF), 4
mitogen, 4
p21-Rb 4
stage-related 4
ATM- 4
hypoproliferative 4
dMSCs 4
c-miRNAs 4
myomiR 4
oblivious 4
branch-and-bound 4
FPGA-accelerated 4
calculation. 4
FPGA. 4
IPC 4
nmol/mg 4
774 4
(ZO 4
MCU-mediated 4
BRL37344 4
Antamanide 4
Supplying 4
stress—induced 4
Gallic 4
stress,decrease 4
ALK-TKIs, 4
alectinib-resistant 4
MP-CAFEE. 4
V1180L 4
I1171T 4
Thermodynamics 4
NFS1 4
persulfide 4
(Fe-S) 4
stabilities. 4
(FRDA), 4
manganese-superoxide 4
hyperexpansion 4
within-species 4
FGF8 4
HPVs 4
Ral 4
PKN 4
m6As 4
N6-Methyladenosine 4
AdoMet-binding 4
microsequenced. 4
anti-MT-A70 4
2.0-kilobase 4
580-amino 4
(N6-adenosine)-methyltransferases, 4
SPO8, 4
re-sequencing, 4
VUAA1 4
DEET 4
odorants. 4
hUCB-MSC 4
(CMS). 4
CMS. 4
AF267B 4
hmC/dG 4
5-methylcytocine 4
Tet2, 4
Tet3), 4
oxidization 4
5-hydroxy 4
(Tahiliani 4
acetylase 4
trimethyltransferase 4
Dlx1, 4
MLL1-mediated 4
(Clustered 4
Regularly 4
Interspaced 4
(CRISPR)-based 4
miR-142-deficient 4
glial-derived 4
55.1% 4
emissions, 4
bowing, 4
1988). 4
1-17 4
TCPOBOP 4
(PH), 4
TCPOBOP. 4
arsenite-injected 4
15min 4
SP600125-treated 4
hepatopoietin 4
Ser727 4
STAT3-PTEN 4
Med220 4
beverages 4
(-)strand 4
Pospiviroidae) 4
juxtaposed, 4
microg/ml. 4
ATPase-6 4
aMLC 4
chorea-acanthocytosis 4
VPS13A 4
XK. 4
acanthocytes. 4
(IVS2+5G>A) 4
(Xp21.1) 4
5.65 4
TCTE1L 4
(omega=dN/dS) 4
7453-bp 4
grandson, 4
(E327K). 4
Kell-protein 4
E327K 4
immunohematologic 4
anti-Kx 4
necrosome. 4
necrosome, 4
RIP3-MLKL 4
SM-induced 4
HIFs 4
L-leucine 4
116R 4
(JIE) 4
benign-familial 4
foals, 4
mouse-model 4
(SIGEI), 4
IE. 4
semeiologic 4
SIGEI. 4
SIGEI 4
BNFC, 4
KCNQ2-SNP 4
SIGEI, 4
(IGE) 4
(MPACs) 4
PBT1 4
"metal 4
(PBT1) 4
β-isoforms 4
PBT2-induced 4
synapto-trophic 4
amyloid-beta42, 4
Neuro-psychological 4
Abeta(42) 4
Abeta-metal 4
VL) 4
H/D-exchange 4
multiphasic. 4
vanishes 4
amide-proton 4
isomerization. 4
'non-native' 4
back-isomerization 4
Backbone 4
distance: 4
carcinogenesis? 4
re-enforcement, 4
CIMP+ 4
metacarpals 4
template-product 4
bismuth 4
(intention-to-treat 4
accumulative 4
PPI-AR 4
(7.4%), 4
(11.1%), 4
anhydrase, 4
LRP5/LRP6 4
Sost. 4
Sost, 4
Lrp5 4
BMPs. 4
Lkb1 4
Hypoxia-induced 4
unenhanced 4
(three-dimensional 4
(3D-CISS)) 4
(CE-MRC) 4
radioisotope 4
LaTcOm: 4
LaTcOm, 4
cluster' 4
implemented: 4
%MinMax 4
codon-based 4
PAUSE 4
kallikrein-like 4
19q13.3-q13.4. 4
KLK12, 4
KLK4, 4
KLK10 4
chi2 4
19q13.4, 4
SAGE 4
post-treatment. 4
multianalyte 4
mg/M2 4
DRFS. 4
DRFS 4
(CTCF). 4
encephalopathy--global 4
ataxia--is 4
vermis, 4
474 4
ERAS 4
rs2900180 4
AFF3, 4
unadjusted, 4
689 4
CCP, 4
Auto-antibodies, 4
PTPN22: 4
5'-allele 4
8.86 4
10.05, 4
(HLA)-DRB1 4
4.8, 4
9.5, 4
anti-CCP. 4
RA-related 4
(12.5% 4
9q33.2 4
cannabis. 4
Adelaide, 4
amphetamines, 4
vasospastic 4
[Cannabis 4
well-kown 4
non-atherosclerotic 4
precipitant 4
Substance 4
crypts. 4
CD86, 4
Neurotoxicity 4
oxidase-generated 4
apoE(-/-)/p47(phox-/-) 4
GKT136901, 4
Nox4-containing 4
Noxes 4
(Nox1, 4
GKT137831, 4
IL-1RI 4
0.85% 4
fold) 4
dimethylsulfoxide. 4
910 4
BPV 4
enterocolitis: 4
LNH, 4
IDPs 4
IDP 4
oligomerized 4
DisCons 4
CtBP 4
(Grg) 4
(MRT). 4
MRT 4
BT-12, 4
G401, 4
RT-peri, 4
Imetelstat-treated 4
G401 4
telomerase-active 4
Geron; 4
poly(dG-dC) 4
processive) 4
Bi-Bi 4
M.SssI 4
R241A 4
R246A 4
TRD), 4
R292A, 4
R297A 4
R292A 4
N167A 4
R202A 4
VIII) 4
B(+) 4
(Ohtahara 4
neuroblastoma2A 4
EIEE. 4
encephalopathies, 4
PCDH19, 4
telomerase-independent 4
FKBP52 4
97%. 4
Turdus 4
(≤10 4
RABV 4
(CPE) 4
CPE 4
Water 4
(JEV) 4
Update: 4
Langat 4
arboviruses, 4
ISRCTN94237756. 4
(HAMLET) 4
infarct; 4
precision-cut 4
Whole-blood 4
Transcription, 4
3'-processing, 4
processed, 4
28.1% 4
(9.4% 4
single-vessel 4
multi-vessel 4
Arch 4
per-base 4
PhiX174 4
here), 4
(loss) 4
ssNMR 4
bodies--the 4
proteosome-mediated 4
β-amyloid. 4
MAP-1B 4
detyrosination, 4
glutamylation 4
glutamylation, 4
Ku70-binding 4
(Kub5)-Hera 4
(K-H)/RPRD1B 4
DNA-PKcs, 4
(RLS/WED) 4
(ICI) 4
narratives" 4
"behavioral 4
observations" 4
uncomfortable, 4
5,764 4
[OR]MA 4
2.7-4.8]) 4
1.2-5.2]). 4
1.3-4.0]) 4
1.1-2.9]) 4
generally. 4
MRI-evident 4
syndrome-quality 4
RLS-QoL. 4
(EoM) 4
(rotigotine 4
[n=458]). 4
RLS-QoL 4
EoM. 4
CGI-1 4
Syndrome/Willis-Ekbom 4
grip, 4
advised. 4
(LCS; 4
Cholestasis 4
(LSC 4
Parent-child 4
CLS 4
(LCS, 4
ENA 4
-0.04; 4
0.10; 4
1.82 4
(75.6 4
μmol/kg) 4
BuChE 4
FoF(1) 4
compounds' 4
phosphatidylserines 4
reviewer 4
(diarrhoea, 4
2.8-5.1). 4
SVs 4
≤$50 4
rats), 4
thalidomide-treated 4
intra-nuclear 4
(PF 4
D'Arcy 4
Griffin, 4
React 4
Toxicol 4
13:65, 4
thalidomide: 4
(FDA's) 4
Hansen's 4
S.T.E.P.S. 4
retail 4
(AAAD), 4
non-ischaemic 4
(tachycardia-induced 4
pacing) 4
dopamine-beta-hydroxylase 4
phenylethanolamine-N-methyltransferase 4
leu-enkephalin 4
C3-C31, 4
C5-C20, 4
C10-C30 4
antiviral, 4
10.2%) 4
gene)-1 4
sub-genotype 4
c.676delT 4
tubal, 4
family? 4
clinical-laboratory 4
Obstetrics, 4
Apolinárská 4
persons--12 4
woman--breast 4
2-4% 4
24.7% 4
BRCAwt 4
exception: 4
oophorectomy, 4
DCIS, 4
Ukraine 4
"crocodile", 4
home-made 4
heroine, 4
poly-drug 4
(Harvoni) 4
Harvoni 4
(SVR12) 4
Ledipasvir/sofosbuvir 4
(Harvoni): 4
Erythrocytic 4
Bania 4
enzyme-defect. 4
Etiological 4
(Schulz 4
1977), 4
G-6-PD-deficient 4
(primaquine) 4
1-ethyl-1-nitrosourea-treated 4
Durham713G 4
galactosaemia. 4
galactosaemia 4
galactose-1-phosphate 4
uridyltransferase 4
C853T 4
R285C 4
A1220C 4
K407T, 4
(2.2%) 4
wildtype. 4
20-month-old 4
c.1187C>G 4
(p.Pro396Arg), 4
Scientists, 4
Turkey: 4
(1.9%, 4
6/323) 4
(6.6%, 4
43/653). 4
.0008). 4
scarcely 4
27.9% 4
Canton 4
Afghan 4
(1.3%) 4
PrPres 4
Scrapie 4
(FFI), 4
178Asn 4
protease-resistant 4
stereotypies, 4
tic 4
HDC 4
cancer-lessons 4
deficiency-the 4
(HRD). 4
(PARP), 4
tumour-selective 4
HRD. 4
P13K/AKT 4
States), 4
SIRT3 4
(PDX) 4
microscopy-based 4
poly(ADP-ribose), 4
talazoparib. 4
Mre11, 4
PARP-1/PARP-2 4
BRCA-deficient 4
fractionated), 4
[20%]), 4
TNKS 4
Server, 4
Purpose 4
magnetoencephalogram 4
nondestructive 4
discreet 4
ablations 4
hemibody). 4
overactivities. 4
thermolesions 4
millimeter 4
dysbiosis 4
migraines, 4
interferon-β-1a, 4
Choosing 4
PFS0 4
PFS1 4
1-sided 4
Sclerosis. 4
TOWER, 4
(TEMSO, 4
dimerizing 4
peginesatide. 4
±1.0 4
5.8%; 4
(0.1-5 4
(glomeruli, 4
capabilities; 4
Affymax 4
industry/antidoping 4
0.54), 4
Pharmaceutical; 4
excretion) 4
pegylated, 4
peptide-based, 4
(Hb). 4
(Exondys 4
Sarepta 4
chimerism. 4
hormone/insulin-like 4
(metabolic 4
(reproductive 4
CD11a, 4
Oral-treatment 4
veterinarians 4
Itch 4
districts. 4
hemoglobinopathies: 4
recruits. 4
one-point 4
thalassemic 4
reserved.</C 4
isatuximab 4
cells/monocytes) 4
(MM 4
(127 4
dose-expansion 4
lenalidomide), 4
8.1), 4
Genmab; 4
NCT00574288.). 4
(ADCC), 4
II-stimulated 4
(Nox5(pod+)). 4
Nox5(pod+) 4
(RPTs) 4
4.2±0.7-fold, 4
5.2±0.7-fold, 4
2.8±0.5-fold 4
4.5±0.2-fold 4
6.2±0.2-fold 4
(P=<0.001, 4
n=6-14/group). 4
Ionomycin 4
diphenylene-iodonium 4
NOX5-siRNA 4
(-45.1±3.2% 4
mock-siRNA, 4
n=6-8) 4
D1-like 4
(-32.5±1.8%) 4
(-14.8±1.8). 4
NT; 4
NOX5, 4
exceptions; 4
DUOXes. 4
Receptor-Positive 4
RAD1901: 4
degraders, 4
(ESR1) 4
estrogen-free 4
(head 4
nivolumab) 4
PD-1/PD-Ls 4
Programed 4
death-1/programed 4
anti-programed 4
(Avelumab). 4
immunopathology. 4
PD1/PD-L1 4
PD1 4
photoimmunotherapy 4
NIR-PIT, 4
(mAb), 4
photo-absorber, 4
IR700DX, 4
administered; 4
NIR-PIT. 4
PD-L1-expressing 4
(MSB0010718C) 4
MSB0010718C 4
atezolizumab 4
ZIKV, 4
albopictus. 4
ZIKV(BR) 4
2015-July 4
(6E3) 4
hydrogen-deuterium 4
206-249). 4
6E3, 4
Fc-mediated 4
[Bexsero], 4
[fHbp], 4
[NHBA], 4
[NadA]) 4
MATS. 4
underestimates 4
vaccination; 4
ST-162 4
44.6% 4
NadA-2, 4
NadA-3, 4
NadA-4. 4
(ST-213) 4
NadA-5, 4
NadA-4, 4
-3. 4
NadA-2 4
NadA-3 4
NadA-2/3 4
NadA-4 4
NadA-5 4
NadA-4/5 4
(NadA-6), 4
porin, 4
commensal, 4
fHbp, 4
Heparin-Binding 4
sub/variants 4
enterocolitica 4
Chang 4
internalizes 4
AVAILABILITY 4
IMPLEMENTATION: 4
archive. 4
super-enhancer-directed 4
input-output 4
[1-(13)C]glucose 4
pR5 4
rTgTauEC 4
NFT-associated 4
Fluid 4
Injury: 4
tau-induced 4
Hyperphosphorylation, 4
(OXTR) 4
moderation 4
disease", 4
antiscorbutic 4
perifollicular 4
gums 4
Deficiencies 4
ligaments. 4
synthesise 4
diasthesis 4
sufferings 4
lanuginose 4
grows. 4
hypertrichosis, 4
TEN/SJS 4
Allopurinol, 4
(AGEP), 4
scalded 4
Stevens–Johnson 4
Necrolysis 4
peeling 4
(SCAR), 4
CVA6 4
allopurinol-SCAR. 4
13.7 4
indications; 4
(TEP) 4
5,889,210 4
distributed; 4
1.54-1.66) 4
0.10-0.13) 4
Kasumi-1 4
chromane 4
TGZ. 4
N-acetylcysteine. 4
cyanide-trapped 4
ultra-performance 4
akinetic 4
stasis. 4
(1967-June 4
WRA. 4
treatment-as-usual 4
(wearing-off 4
(tid), 4
levodopa/benserazide. 4
(sickness 4
profile) 4
Diarrhea 4
Hoehn 4
Yahr 4
L-dopa/DCI 4
voiding; 4
(recommended 4
anti-PD 4
Investigators' 4
entacapone-treated 4
tid. 4
t.i.d. 4
half-time 4
Hsp104, 4
PrionHome 4
limb-mammary 4
scalp-ear-nipple 4
hypothelia 4
eyebrow 4
areola 4
text. 4
dictionary 4
(Critical 4
Biology) 4
PSI-MI 4
NLP 4
Workshop. 4
gauged. 4
EntrezGene 4
IDs 4
(ACT) 4
PubMed® 4
"PPI 4
relevant" 4
automatically.BioCreative 4
(IAT), 4
(UAG) 4
critiquing 4
competitions 4
PPI-ACT 4
PPI-IMT 4
Naltrexone/bupropion 4
Contrave(®) 4
naltrexone. 4
like? 4
belnoranib, 4
brightening 4
(naltrexone 4
NB32 4
VNTR, 4
0.406. 4
5p, 4
200-kilobase 4
Repeats 4
Vitro 4
Approach. 4
easy-to-install 4
(∆(287)ES(288)) 4
CbC-hyperintensity 4
(MAbs). 4
Ovary 4
(AS-eln) 4
SINEUP-mediated 4
(Uchl1) 4
UCHL1 4
(SINEB2 4
translation), 4
levofloxacin, 4
IFN-β, 4
Rule". 4
BioShield 4
Rule"). 4
bioterrorism. 4
antigen-targeting 4
raxibacumab) 4
insecure. 4
spore-challenged 4
levofloxacin/ 4
raxibacumab-treated 4
COVERED 4
CPEBs 4
CPEB4 4
modifier), 4
(E1), 4
ULPs 4
Algorithmic 4
cruzi: 4
(TcSUMO) 4
epimastigote 4
double-tagged 4
metacaspase-3 4
K839; 4
lamblia: 4
Post-Translational 4
SUMO-2/3, 4
pattern: 4
gadd45α 4
RelB. 4
mitten 4
crab, 4
Eriocheir 4
sinensis. 4
Tg2576 4
PB-FISH 4
10,362 4
DD/ID 4
DD/ID. 4
Willi/Angelman 4
t(4;17)(q31;p13) 4
4q22-q24 4
deletions; 4
del(7q), 4
del(20q). 4
-5/del(5q), 4
del(20q) 4
(N=52), 4
(N=7) 4
(N=15) 4
t(7;21)(p22;q22) 4
cytomorphology 4
5,7 4
significance]. 4
-7/7q-) 4
-7/7q-. 4
(CBMF) 4
Jacobsen 4
[del(11)(q24)c] 4
i(7)(q10), 4
i(7q) 4
SpectrumGreen 4
D7S486 4
G-banding. 4
MDS-RAEB 4
MDS-RAEB. 4
SpectrumRed 4
Fallot's 4
GTG-banding 4
heteromorphism 4
GABRB3. 4
velocardiofacial 4
(7q31) 4
t(18;21), 4
(48%/52%). 4
t(18;21) 4
Cri-du-Chat 4
(epilepsy, 4
tubulopathy) 4
splice- 4
translation-blocking 4
non-progressive, 4
Ba2+ 4
ERGs 4
photopic 4
OPV 4
ex-4 4
nunamycin 4
nunapeptin 4
Obtained 4
LH/hCG 4
DOTAP/E7 4
CD31/annexin 4
samples), 4
PMNs 4
4-[18F]FBA 4
negative/PI 4
antiCD95 4
[(99m)Tc]annexin 4
Française 4
V-negative 4
dbcAMP 4
counter. 4
lpr/lpr 4
[COURAGE] 4
734). 4
immunoseparation 4
(remnant-like 4
cholesterol: 4
RLP-C) 4
(>or=5.0 4
(200-400 4
bezafibrate-treated 4
(PD)-1 4
threatening, 4
tolerable. 4
Cdc25A. 4
granulomas, 4
(PD-1), 4
aPD-1 4
(mRCC) 4
Lefty. 4
Spaw 4
morphogen 4
celecoxib, 4
antitussive 4
non-opioid 4
Lists 4
(EMLs) 4
Intercontinental 4
(IMS 4
(rofecoxib, 4
etoricoxib) 4
nonuse. 4
EMLs, 4
33.2%, 4
14.7-58.7%). 4
EMLs 4
EMLs. 4
minimising 4
(TXA), 4
aminocaproic 4
(EACA) 4
non-urgent 4
EACA 4
aprotinin. 4
Nonsteroidal 4
valdecoxib, 4
lumiracoxib. 4
lumiracoxib 4
amfepramone 4
(diethylpropion) 4
18-month, 4
active-controlled 4
(1.5:1), 4
migalastat, 4
(-11.0 4
-2.2)); 4
NCT00925301; 4
Pre-results. 4
biologics-based 4
(Replagal) 4
(Fabrazyme). 4
fixed-treatment 4
(0.2, 4
1.2- 4
5.1-fold 4
(95.6%). 4
agalsidase. 4
HCl-related 4
NCT01196871. 4
[Enzyme 4
(alglucerase) 4
(imiglucérase, 4
Cerezyme(®)), 4
(agalsidase 4
Replagal(®) 4
Fabrazyme(®)) 4
(Hurler 4
Scheie 4
(Hunter 4
(Maroteaux-Lamy 4
laronidase 4
(Aldurazyme(®)), 4
idursulfase 4
(Elaprase(®)) 4
galsulfase 4
(Naglazyme(®)), 4
Alglucosidase 4
(Myozyme(®)) 4
peri-tubular 4
(HSV-1, 4
HSV-2), 4
(VZV). 4
(HSV-2). 4
(Mollaret's 4
meningitis) 4
26-35 4
HSV-2. 4
neuralgic 4
buttocks, 4
perineum 4
meningitis: 4
Ebro 4
Iberian 4
[Adult 4
13]. 4
Kernig's 4
Atlanta 4
Inhibitor) 4
GLP1, 4
TZDs, 4
ChIP-nexus, 4
barcodes. 4
(IDR), 4
http://charite.github.io/Q/ 4
1.06), 4
(HMG-CoA 4
LDH, 4
Wounds 4
Ser166 4
nonrandomised 4
Statin-induced 4
CPK 4
elevations. 4
027, 4
3680 4
62.6±15.3 4
628; 4
7.8%) 4
[atorvastatin 4
1327; 4
1191; 4
6.5%), 4
326; 4
3.4%), 4
5.8%); 4
p=0.041]. 4
(HR)=2.68, 4
p=0.011]. 4
[FBG, 4
HR=1.11, 4
HR=1.02, 4
p=0.005]. 4
LDL-cholesterol. 4
synchronizing 4
p409 4
http://bioconductor.org/packages/Path2PPI/ 4
ina.koch@bioinformatik.uni-frankfurt.de 4
Woman. 4
Concern. 4
Nile, 4
B19 4
dengue. 4
3-12 4
buster 4
(swine 4
flu) 4
Y-maze 4
balconies 4
Japan; 4
microdialysis. 4
flu-season 4
ARDS 4
ECMO 4
13-24 4
zanamivir. 4
PB2 4
Geno3D. 4
Arguslab 4
0.04A° 4
-15603.529 4
-17620.740 4
-17652.242 4
Zanamivir. 4
swine-origin 4
intramembrane-cleaving 4
CTF, 4
co-introduced 4
NTF-CTF 4
Pen-2, 4
Aph-1b 4
Crumbs 4
Co-overexpression 4
PS1/Pen2/Aph1a 4
Venus. 4
presenilin-associated 4
(PS2), 4
aph-1a 4
Abeta42:Abeta40 4
PLK-1 4
(Plk1) 4
duplicating 4
adoption. 4
922 4
DECIPHER 4
vendors 4
SUMO1-3 4
sumoylation-mediated 4
EMSA, 4
(SUMO-1), 4
nucleus-bound 4
I/protein 4
swine. 4
K180A, 4
K221A) 4
(SIM) 4
SUMOylation-defective 4
Tec1, 4
SUMO-specific 4
WSSV 4
SAE2, 4
(Kir6.2, 4
(FimA) 4
AgP. 4
actinomycetemcomitans 4
(EMA), 4
PRACTICE: 4
(ARIEL2 4
(Jan 4
2016), 4
(n=82), 4
camsylate 4
MDR1) 4
derivations. 4
Repolarization 4
HSP70-HSP110 4
client-bound 4
act. 4
ubiquilin. 4
DPR 4
(UBQLN2) 4
Arg158Cys 4
particles; 4
Type-III 4
(apoE2), 4
LPL 4
Kurashiki 4
glomerulopathy. 4
R158C 4
E: 4
chylomicrons 4
Arg----Cys), 4
(apo 4
(E2, 4
E4) 4
isotyping 4
10.3% 4
(20.0% 4
hypertriglyceridemia. 4
Wiedemann 4
1)]. 4
XLHR 4
right-angled 4
Z-osteotomies. 4
Cranio-Maxillo-Facial 4
neurocranium, 4
AETs 4
[Vortioxetine: 4
episodes]. 4
multimodal, 4
5-HT1D, 4
(5-HTT). 4
53.2% 4
19.3%). 4
Pre-approval 4
functioning) 4
(6-8 4
vortioxetine) 4
EuroQol 4
0.28) 4
Montgomery- 4
Åsberg 4
HAM-D/MADRS 4
[SMD]) 4
-0.217 4
-0.313 4
-0.122) 4
1.652 4
1.321 4
2.067) 4
1.399 4
1.104 4
1.773), 4
inhibitors/agomelatine 4
SMD 4
(0.081, 4
-0.062 4
0.223) 4
0.815, 4
1.135) 4
0.843, 4
0.575 4
1.238) 4
0.541, 4
0.308 4
0.950) 4
(AEs; 4
1.530, 4
1.144 4
2.047) 4
0.957). 4
hot-water 4
Mucuna 4
nondigestible 4
(NDF) 4
FP-hgf 4
δ-tocotrienol 4
cv 4
POPs, 4
polychlorinated 4
biphenyls 4
(OH-PCBs), 4
pentachlorophenol 4
(PCP), 4
perfluorooctane 4
(PFOS), 4
TTR-binding 4
nations 4
(2.5%): 4
bradyarrhythmias) 4
non-arrhythmic 4
(hypotension, 4
"an 4
forefoot 4
varus. 4
hallucis 4
feet); 4
vagal, 4
Melanocytes, 4
dedifferentiating 4
schwannian 4
Schwann-like 4
sheathing 4
Fabp7. 4
Schwann-cell 4
NC-derived 4
nevocellular 4
2-microglobulin 4
crest; 4
ET3 4
caudalmost 4
(PIEZO2). 4
c.8057G>A 4
E2727del 4
Suboptimal 4
L-methylfolate 4
system-level 4
melanoderm 4
dysautonomic 4
hexakisphosphate 4
(IP6) 4
Ligases 4
IP6 4
5-like 4
rust. 4
TaCSN5 4
(CSN6) 4
364, 4
(E7.5). 4
(E10.5), 4
Csn6. 4
γ-irradiation-induced, 4
γ-irradiation-induced 4
(Mpr1p 4
Pad1p 4
N-terminal) 4
(atCSN1), 4
Proteasome, 4
PCI-containing 4
Rpn6 4
atCSN1 4
repeat-I, 4
repeat-II, 4
CSN1-CSN7 4
(apo-CSN) 4
CSN-Skp1-Cul1-Fbox 4
situates 4
repeat-II 4
CSN6, 4
CSN1. 4
(UEV), 4
COP1, 4
DET1, 4
CSN, 4
CULLIN4 4
CDD, 4
CUL4-based 4
atitpk-1 4
(LOE 4
(NCT00918255). 4
depression). 4
Adalimumabtherapy 4
aprocrine 4
gland-bearing 4
(Humira) 4
(HS). 4
(20.7%) 4
40-mg 4
mg/wk. 4
[12.9] 4
[11.7] 4
Index; 4
fistulas; 4
(7.1) 4
13-29) 4
(Hidradenitis 4
Response): 4
epiphysis 4
PF. 4
fasciitis: 4
(VAS). 4
enlisted, 4
fasciotomy. 4
LUBAC. 4
Met1-polyUb 4
kcat 4
nonventilated 4
OPEN 4
EVAR 4
geriatrician. 4
(0.89-1.00) 4
(0.86-0.88) 4
NEECHAM. 4
assessment: 4
non-intubated 4
(chi-square 4
Samples, 4
(SSTAR). 4
SMW 4
28.2% 4
proline-->arginine 4
FGFR1c 4
15,000 4
smallpox, 4
wildlife, 4
Jenner 4
Smallpox 4
mucin-degrading 4
post-fertilization, 4
p22(phox), 4
p22(phox). 4
betaPix, 4
(Nox1) 4
non-phagocytic 4
Noxa1(R103E), 4
T84 4
p22(PHOX), 4
Noxo1gamma, 4
gp91(phox)/Nox2, 4
flavocytochrome 4
Nox1-dependent 4
Tks 4
NoxA1, 4
Tks4 4
1,497 4
rs8004379 4
rociletinib) 4
(Rho 4
Henle, 4
hypomagnesemia, 4
polyhydramnios 4
Basque 4
0.021 4
tetany 4
(Ψ) 4
panhypopituitarism 4
(HELLP 4
Excel 4
syncytin 4
de-pigmented 4
irides. 4
c.648A>C 4
c.648A>C; 4
(R216S), 4
c.1183_1184insG 4
hyperopic 4
(microphthalmia-associated 4
WS2A, 4
WS2A 4
melanocyte-specific 4
R203K 4
S298P, 4
(WS1), 4
(WS2). 4
WS1 4
Waardenburg-like 4
Sun-exposed 4
MITF-M 4
MITF-M, 4
MITF-A 4
MITF-H 4
(hypopigmentation/deafness) 4
Mitf(mi-bws), 4
103500) 4
(Firmicutes, 4
Bacteroidetes, 4
p<0.05) 4
sickled 4
multiribozyme 4
Gli2. 4
osteochondral 4
(Col10α1) 4
(Gli) 4
COL10A1 4
250-bp 4
downgrade-proliferation 4
upgrade-differentiation 4
Morphogenetic 4
(BMP-6), 4
(X) 4
Vortkamp 4
Kif3a 4
Chondrocyte 4
Greig 4
Bmps 4
(Roberts 4
PTHrP(-/-) 4
gallbladders. 4
Ena 4
Profil 4
Anti-SS-A 4
(Anti-Ro) 4
Anti-RNP 4
includes, 4
MCTD, 4
MRS, 4
neuro-mucocutaneous 4
Melkerrson-Rosenthal 4
[Melkersson-Rosenthal 4
"lingua 4
plicata" 4
PB-06-003; 4
30-33 4
baseline/time 4
-1.0% 4
(±1.9%; 4
+9.3% 4
(±9.8%; 4
(MN), 4
-19.8% 4
(±9.9%; 4
+0.9% 4
(±5.4%; 4
-51.5% 4
(±8.1%; 4
-36.5 4
(±8.0%; 4
91:661-665, 4
U/kg; 4
(50.1%; 4
64.6%) 4
(25.6%; 4
24.4%) 4
(16.0%; 4
(45.7%; 4
114.0%), 4
(71.5%; 4
82.2%). 4
91:656-660, 4
60U/kg, 4
mild/moderate; 4
(Protalix 4
1year. 4
parallel-dose, 4
respectively: 4
30.9% 4
ERT-naïve 4
GD1, 4
units/kg, 4
units/kg 4
Eucaryotic 4
(formylated) 4
rpsL 4
EOAD 4
(1%), 4
IL-33 4
mainstream 4
(P=0.005) 4
Dorsomorphin 4
2-aminopyridine-based 4
LDN-193189 4
17q22) 4
G91C 4
(283G 4
(A95T) 4
Progressiva 4
non-skeletal 4
protein/DNA 4
617G>A 4
progressiva, 4
miR-148a. 4
ACVR1/ALK2 4
peptidomes 4
(http://unipept.ugent.be) 4
ER-retention/retrieval 4
Presenilins 4
Gamma-secretase-mediated 4
(AbetaPP) 4
AbetaPP. 4
presenilin-2 4
beta-secretases, 4
APP(S) 4
stub, 4
(;AICD'-APP 4
Abeta(1-40) 4
Abeta(1-42), 4
Iris 4
isolated-Hirschsprung 4
(syndromic-HSCR), 4
heterochromia. 4
DPN 4
μg/kg, 4
Plms 4
SBDD, 4
SBVS, 4
WEHI-842, 4
(PEXEL). 4
(PmV) 4
hydroxyethylamine 4
'on-target', 4
pursuable 4
PmV. 4
PEXEL 4
anti-malaria 4
prosegment 4
EGEE 4
(methicillin-resistant 4
Pneumonia 4
fusidic 4
PPVs 4
66.7%, 4
achromopeptidase 4
detection: 4
infection-control 4
IDI-MRSA 4
0.5%, 4
(PVL) 4
azithromycin, 4
ST5-MRSA-IV 4
Community-acquired 4
HCA-MRSA 4
herds) 4
supplier 4
procalcitonin 4
(1.8%) 4
community-onset 4
CID-MS/MS 4
isoaspartic 4
(PDE5-Is) 4
PDE5-Is 4
qualifies 4
2.9%) 4
avanafil. 4
(IIEF), 4
(SEP2 4
SEP3) 4
phosphodiesterases. 4
tumescence. 4
200% 4
Intraduodenal 4
ICP/mean 4
(ACh; 4
10(-8)-10(-3))-induced 4
73%. 4
(PE; 4
(1-40 4
(SNP, 4
(10(-8)-10(-3)) 4
(taken 4
(IIEF-EF) 4
9.2). 4
(SEP) 4
Q2 4
GAQ. 4
citations. 4
(MD: 4
2.78; 4
epitranscriptome 4
maraviroc, 4
comfortable 4
maraviroc 4
Dapivirine, 4
elastomer 4
NNRTI 4
ml/day) 4
IVRs 4
(Dapivirine) 4
dapivirine. 4
dapivirine-releasing 4
Use) 4
syphilis. 4
PrEP 4
septicaemia 4
InfoVac-France 4
InfoVac 4
reimbursed 4
Vaccinating 4
5.61 4
serogroups. 4
pentavalent 4
(>70%) 4
post-implementation 4
vaccine-naive 4
11-17 4
Bexsero(®), 4
ubiquinone-8 4
neisseria 4
(Bexsero; 4
introductory 4
pricing. 4
recently-licensed, 4
multi-component, 4
(Bexsero(®), 4
halftime 4
capsulotomy. 4
non-ablative 4
'late 4
nuclei' 4
thermocapsulotomy 4
(UPS). 4
UPS- 4
(nucleus, 4
reticulum). 4
N-degron) 4
cholate 4
nonlysosomal 4
Purpura 4
(GDS) 4
(ASS) 4
Zinn', 4
anatomist 4
botanist 4
Johann 4
Gottfried 4
(1727-1759) 4
Descriptio 4
humani 4
(Anatomical 4
1755). 4
aspect; 4
heads; 4
levator 4
backsplice 4
mushroom-type 4
Behaviorally, 4
ASP-RNAi 4
London-type 4
V642I-AbetaPP-induced 4
peptides) 4
SN56 4
Tetsuro 4
Hirose 4
Shinichi 4
Nakagawa. 4
NOX4, 4
phenylephrine-induced 4
NOX-mediated 4
Ang-II-induced 4
p67phox. 4
Apocynin 4
Ceramide-induced 4
p47(phox). 4
bradykinin- 4
A-23187-induced 4
vasorelaxation. 4
PEG-catalase 4
COX-2/PGE(2)/IL-6 4
(HTSMCs). 4
HTSMCs 4
CSE-regulated 4
(SB202190), 4
(U0126), 4
(SP600125), 4
(helenalin); 4
(N-acetyl-l-cysteine); 4
p42, 4
CSE-induced 4
(AGEs) 4
neopterine 4
(Neo), 4
(Indo), 4
(U0126, 4
(N-acetylcysteine), 4
phagocytizing 4
Dectin-1 4
(apocynin 4
HTSMCs-monocyte 4
(Gö6976), 4
(APO)], 4
(BAPTA/AM), 4
PI-PLC 4
(U73122), 4
(calmidazolium 4
chloride), 4
(KN62), 4
(garcinol), 4
(Bay11-7082), 4
[N-acetyl-L-cysteine 4
(NAC)] 4
capacitation 4
dipsogenic 4
pressor, 4
bradycardic, 4
Neuro-2A 4
AdwtRac1 4
River; 4
pan-encephalitic 4
mid-Viliui 4
Yakutsk. 4
intra-household 4
(VE), 4
VEM 4
Guamanian 4
septins: 4
SEPT3 4
AspE 4
schistosomes 4
spines, 4
retracting 4
FCF 4
septin-septin 4
SEPT5 4
CDCrel-1 4
anti-LOX 4
(GS-639556, 4
M64) 4
(GS-607601, 4
AB0023) 4
GS-639556 4
intracameral 4
subconjunctival 4
subconjunctivally 4
euthanization). 4
LOX- 4
LOXL2-targeting 4
(GS-607601) 4
NAFLD. 4
non-Dravet 4
truncating/splice 4
vaccination-related 4
SUDEP: 4
Unexpected 4
Tehran 4
p21), 4
(telomerase 4
anti-telomerase 4
Poor, 4
0.4489 4
0.0568, 4
0.3376-0.5602), 4
rescored 4
done; 4
postestimation 4
1-120) 4
(p<.01) 4
prognosticating 4
Nox1-4 4
Nox5) 4
(HMGCoA) 4
SAMS. 4
Perspective. 4
advocate 4
neprilysin, 4
(Entresto-Novartis) 4
carvedilol 4
(Entresto) 4
DoRiNA 4
2.0--upgrading 4
l-amino 4
DA-immunopositive 4
aromatic-l-amino-acid 4
4.1.1.28) 4
(MAO-A), 4
biodegradation. 4
Afobazole 4
(5-OTP) 4
(5-HIAA) 4
(5-OTP 4
enzyme). 4
afobazole, 4
precursor) 4
hippocamp), 4
Ladasten 4
HVA/dopamine 4
DOPAC/dopamine 4
hippocamp. 4
DOPA-CHE 4
(DOPA 4
6R-BH4. 4
(5-HTP), 4
Long-Evans 4
3-O-methyl-DOPA 4
p.), 4
3-OMD, 4
3-OMD. 4
Krebs'-Ringer 4
(KRP) 4
calcium-independent, 4
push-pull 4
air-stepping 4
air-stepping. 4
5-day-old 4
microliters 4
physostigmine 4
benzoate-induced 4
72,145 4
Cynomolgus 4
HPLC-mass 4
f(5)U 4
xenobiotics, 4
'ABCC' 4
(SURs), 4
ABCC11 4
elasticum 4
MRP9/ABCC12 4
glucuronate. 4
oxyanions, 4
(MRPs 4
1-3) 4
seedlings, 4
subtilisin-like 4
PACE4 4
CIDEC/FSP27 4
fasting- 4
hepatosteatosis. 4
(peroxisome 4
PPARα-stimulated 4
fasting-induced 4
anti-Fsp27 4
(FSP27, 4
lipid-coating 4
fat-storing 4
800-fold 4
PKA-CREB-CRTC2 4
because: 4
(etomoxir) 4
(Hmgcs2 4
FAO 4
Voluntary 4
Wheel 4
(WR) 4
Cide 4
(Fsp27), 4
Western-blot. 4
(CIDEA, 4
CIDEB 4
(FSP27; 4
CIDEC), 4
perilipin1 4
(PLIN1), 4
Droplet 4
recovery: 4
orpington 4
(OPS). 4
117) 4
OPS, 4
handicap 4
Rivermead 4
"poor" 4
Stay 4
(TH1), 4
TH2, 4
(Tregs). 4
Forkhead-Box-Protein 4
(FoxP3), 4
RAR-related 4
receptor-γT 4
(ROR-γT) 4
Immunoassay 4
(Macrophage 4
protein-1α 4
(MIP-1α), 4
Treg-related 4
FoxP3 4
TH17-related 4
RORγT 4
epiphenomenon 4
DRKS00005954. 4
eGFP(+) 4
PSL-induced 4
GITRL-GITR 4
CatS 4
Australasia 4
Dysplasia: 4
dysplasia" 4
nystagmus. 4
OCA-4 4
heritage 4
POINTER 4
11q14-21, 4
606933) 4
c.1114delG 4
uw-mutant 4
melanosomes, 4
Fraser 4
Hemiascomycetes 4
stricto" 4
DAL2 4
t.bailey@imb.uq.edu.au 4
william-noble@uw.edu 4
non-CRM 4
pair-rule 4
Ahab, 4
Buster, 4
MSCAN, 4
MCAST, 4
LWF. 4
(MSCs). 4
"plaques" 4
epsilon2, 4
epsilon3, 4
epsilon4. 4
(mMSCs) 4
mMSCs, 4
osteo-inductive 4
adipo-inductive 4
ApoE-related 4
beta(1-40) 4
Sophophora 4
poleward 4
tailless 4
schizophrenia-related 4
serosal 4
(28.2%) 4
26.4% 4
6%) 4
68%) 4
Devic's 4
erythematosus]. 4
Rembrandt's 4
Bockenolle 4
deformities: 4
Mating-type 4
SPB, 4
Cut2 4
mat 4
Clr4-mediated 4
Palb2 4
subfertility/infertility, 4
anemia/BRCA 4
Fanca(tm1Hsc) 4
(KCs) 4
(G4.5) 4
G5 4
PCLS 4
Bolivian 4
(non-naive 4
30-years 4
PURSUIT-SC 4
PURSUIT-M 4
0.122 4
thiopurine, 4
5-aminosalisylic 4
immunmodulators 4
30%- 4
PURSUIT). 4
antagonist-naïve 4
(IBDQ) 4
NAP1 4
UCB. 4
sensorneural 4
convulsion, 4
(2.16 4
BAER 4
(176 4
donated 4
calculated, 4
lobule, 4
Activity. 4
Argentina: 4
31st, 4
1.01-1.43). 4
0.82-0.86). 4
(χ2: 4
71.02, 4
df: 4
(37/22, 4
(105/81, 4
Lemeshow 4
macroH2A2 4
Utx, 4
'lock' 4
reprogram. 4
heritably 4
macroH2A.1, 4
macroH2A.2 4
25-fold. 4
9th 4
hyperferritinaemia 4
(p.Cys326Phe) 4
p.C282Y 4
reactions). 4
NIRCA 4
(non-isotopic 4
V162 4
(R178G) 4
disease," 4
(b/b) 4
non-heme 4
impulsivity-like 4
microcytic, 4
transporter/divalent 4
transporter/solute 4
(DMT1/DCT1/SLC11A2), 4
natural-resistance-associated 4
(Nramp) 4
senzorineural 4
(11p15.5), 4
(7q35), 4
(3p21) 4
(21q22), 4
(4q25-27), 4
"gene-specific" 4
Prolong 4
1/10000. 4
droperidol, 4
thioridazine) 4
(paroxetine), 4
(methadone), 4
(H1 4
(domperidone 4
cisapride). 4
pointes". 4
'long 4
trioxide-induced 4
hERG-expressing 4
NAB(HERG), 4
(herg) 4
ether-a-go-go 4
herg1 4
norfluoxetine 4
MinK 4
hERG. 4
SEN1 4
Nrd1. 4
ncRNA, 4
Sen1-Pol 4
pcf11-13 4
sen1-1 4
Grzechnik 4
Scholar, 4
banging 4
noises, 4
SET8/PR-Set7 4
SUV4-20H1 4
SUV4-20H2 4
furthering 4
(H3K56Ac), 4
(H4K20me). 4
<CopyrightInformation>© 4
WHY 4
SHOULD 4
EMERGENCY 4
PHYSICIAN 4
AWARE 4
THIS?: 4
CDS. 4
biopsy), 4
(steroids, 4
subside 4
87-year-old 4
Axial 4
ligaments, 4
Looping 4
suction-blistered 4
vitiliginous 4
erythma 4
migrans]. 4
Koebner's 4
PUVA, 4
Protons 4
non-secreting 4
(p-CSI) 4
(x-CSI) 4
in-homogeneity 4
under-dosage, 4
underdosage 4
bio-effect 4
medullolastoma 4
"low-risk" 4
irradiation: 4
oblique, 4
"inverse" 4
nontarget 4
WBI. 4
NTCP 4
techniques? 4
(posterior 4
craniospinal), 4
DGAT1. 4
spine); 4
genes--were 4
HumanMethylation450K 4
17-46), 4
rs3130683 4
electrocochleography 4
ECoG 4
(vertigo, 4
tinnitus) 4
vertiginous 4
extensibility, 4
periodontium, 4
non-ossified 4
GIQLI 4
SGOT 4
VFx 4
(pain, 4
long-haul 4
cavernosal 4
metalloprotein 4
H2A.Z(Htz1) 4
hCPC 4
doxorubicin-related 4
(DOX), 4
TRZ 4
non-inferiority, 4
1·5 4
Hesperidin 4
quercetin-mediated 4
monoHER 4
Double-balloon 4
enteroscopy 4
lacteals. 4
Protein-losing 4
antiplasmin 4
PIL, 4
hepatorenal 4
old; 4
J774a.1 4
(SIRS) 4
fatality) 4
(optimal 4
pri-miRNA. 4
CBP80 4
miR159 4
(pri-miRNA). 4
individuals]. 4
Oculocutaneus 4
1379delTT 4
D42N 4
(Gorilla 4
(oculocutaneous 4
203300), 4
(CHS1), 4
214500), 4
OA1 4
(MIM#300500). 4
OCA, 4
PCR-sequencing. 4
I-Mutant 4
p.C89S 4
p.H180R 4
S192Y 4
hampered, 4
intra-melanosomal 4
19-469) 4
R422Q 4
R422W 4
biomass. 4
intramelanosomal 4
R278X 4
(FGFR2), 4
Cuff 4
qDASH 4
EQ-5D 4
KL-TOE 4
minimal-access 4
DTA, 4
(photodynamic 4
SWR1-mediated 4
H2A.Z-containing 4
αC 4
SWR1-complex-dependent 4
preassembled 4
fourteen-subunit 4
Swc3, 4
Arp4 4
Swc4. 4
Arp4, 4
H2AZ-H2B 4
H2A-containing 4
swc4 4
ARP6 4
ARP6, 4
[Choroidal 4
melanosis]. 4
melanosis. 4
Conjunctival 4
beta-irradiation. 4
Circumscribed 4
cryotherapy. 4
HGA, 4
VIA 4
iPLA2-VIA, 4
PARK14-linked 4
l-dopa-responsive 4
homogeneous, 4
Neurodegenerative 4
virus-8 4
(HHV-8)-negative 4
(iMCD) 4
sits 4
hematology/oncology, 4
HHV-8-positive 4
name: 4
Herpesvirus-8-Negative) 4
inflammatory- 4
q3w) 4
0.708; 4
92%) 4
(C1D8), 4
(61%; 4
C1D8 4
-0.395; 4
0.00607), 4
(TIBC; 4
-0.354; 4
0.01694), 4
0.599; 4
TIBC 4
siltuximab-treated 4
Investigator-assessed 4
Grade-≥ 4
(Sylvant). 4
authorised 4
HHV-8. 4
(degrons) 4
N-degrons. 4
Degron 4
ATE1-deficient 4
ODA 4
407 4
glutamyl-prolyl 4
multisynthetase 4
45,14 4
2DM 4
(Boulton 4
annulare. 4
(DRD4) 4
Parent 4
D4.4 4
non-toxigenic 4
caseous 4
lymphadenitis 4
clindamycin. 4
cardiopathies 4
(DT), 4
DtxR 4
Wisconsin. 4
(STs) 4
G571W 4
(CHAMP 4
DAMP 4
lysine) 4
HEM3. 4
(TFIIB). 4
ssl2 4
H508R 4
non-inferior, 4
'Alive, 4
(VKAs), 4
warfarin-controlled 4
(Randomized 4
[RELY]), 4
[ARISTOTLE]), 4
(XOAC) 4
(apixaban) 4
Engage 4
Timi 4
(edoxaban; 4
data)-was 4
0.488 4
'group 4
sponsors 4
0·93 4
Medco 4
b.d. 4
(NCT01590719) 4
6.77 4
0.71-1.63; 4
5.95 4
0.60-3.20; 4
.45). 4
10.61 4
0.64-1.75; 4
.83). 4
8.51 4
8.48 4
0.45-2.78; 4
.80). 4
Bev) 4
GEC. 4
MET/HGF 4
Sphingosine-1-phosphate 4
chemokine-like 4
contagiosum. 4
poxvirus, 4
"Avoid 4
Patient. 4
painful. 4
pearly 4
immunoinflammatory 4
microMT 4
cethromycin 4
MIP-2 4
P4502B6 4
CYP2B6-catalyzed 4
stereoselective. 4
stereoselective 4
(Contrave), 4
Met129 4
PrP, 4
Bax/Bak 4
reinstate 4
Bax- 4
Kv1.3 4
G(-248)A 4
tBid 4
Chl1-Ctf4-GINS 4
protein-losing, 4
exsudative 4
Chennai, 4
HLA-DR, 4
(CDG) 4
2.3.1.23) 4
Transacylase 4
(Cytogenetic 4
Location: 4
Xq28) 4
fatality. 4
HX4D 4
transacylation 4
transacylations 4
(Delta5) 4
bugs, 4
avenacin 4
thalianol 4
diterpenoid 4
momilactone 4
1469 4
furoate 4
Lund-Mackay 4
22-item 4
SinoNasal 4
AD.` 4
-74% 4
(β-D-glucosyl-hydroxymethyluracil) 4
JBP2) 4
tarentolae. 4
T.brucei 4
J-specific 4
vestibulocerebellum. 4
brush, 4
P12, 4
calretinin-positive: 4
immunonegative. 4
pre-embedding 4
ringlet 4
cells/mm(2)). 4
zebrin 4
Tbr2-positive 4
mGluR1alpha 4
DIPGs, 4
ubiquitously-associated 4
(TP53/PPM1D) 4
(ACVR1/PIK3R1). 4
(GBM; 4
TL-01 4
lamps. 4
nineth 4
APOA5, 4
abetalipoproteinemia. 4
hypolipidemia. 4
hypobetalipoproteinemia, 4
(PARL) 4
cold- 4
non-shivering 4
physiologically, 4
Plac8 4
catabolize 4
cautionary 4
Thermogenesis 4
thermogenin 4
CFL1 4
PRDM16 4
mimotopes, 4
Mimotopes, 4
mimotope, 4
tumor-antigen 4
boost. 4
Phl 4
Debarquement 4
motion-induced 4
vestibulo-ocular 4
ground: 4
rhizosphere 4
pneumonia-derived 4
TLR2-/- 4
South-East 4
anti-coagulation 4
IL-12p70, 4
PC-T2D 4
rs5743551 4
rs5743618 4
Pam3CSK4. 4
TLR1, 4
TLR5, 4
India: 4
aniline, 4
inefficiencies. 4
C-N 4
diastereoselective 4
Mannich-type 4
Ellman 4
sulfinyl 4
guanidinylation. 4
(verubecestat), 4
aducanumab), 4
(RAGE) 4
(azeliragon) 4
cromolyn 4
(ALZT-OP1). 4
(LGG) 4
(immunohistochemical 4
Internexin 4
+/INA- 4
VPP 4
LGG. 4
INA 4
mR132H 4
prescreening 4
non-mutated) 4
injection) 4
GAMES-Pilot 4
two-center 4
EPITHET 4
MMI-MRI 4
GAMES-Pilot, 4
0-4-90% 4
0.049; 4
RP-1127-treated 4
RP-1127. 4
Edema. 4
Receptors. 4
(Testis 4
(∼1 4
contiguity 4
submetacentric 4
iodine: 4
BRAFV600E-positive 4
bearers 4
p.Ser292del 4
FTLD. 4
commitments 4
antagonistic. 4
GATA-2, 4
C/EBPepsilon(27) 4
methylated-CpG 4
(MIRA), 4
MBD2b-MBD3L1 4
MIRA 4
(MIRA-seq). 4
MIRA-Seq 4
ADAMTS5. 4
Swd2.2 4
HGMD 4
(HGMD) 4
genetics" 4
aptasensors 4
contaminations 4
commercialization. 4
Aptasensors 4
bioreceptors. 4
reusable. 4
(PrPSc) 4
(trxA) 4
trxA-based 4
TrxA-based 4
TrxA 4
anti-peptide 4
noncompaction: 4
ventriculography. 4
stagnant 4
clots. 4
thrombi, 4
Anticoagulative 4
metamemory 4
helmet 4
Neurosurgeons 4
DOACs, 4
(AnXa) 4
Options. 4
concentrates. 4
Ingelheim) 4
(r-Antidote, 4
PRT064445; 4
edoxaban). 4
(DOACs) 4
DOAC-associated 4
Alfa 4
ANNEXA-A 4
ANNEXA-R 4
fibrillation; 4
(DSD), 4
46,XY 4
(FBN-1) 4
protrusio, 4
saccular 4
porphyria. 4
porphyrias. 4
ZMapp) 4
ebolaviruses. 4
cross-neutralizing 4
F(ab')2 4
plant-made 4
post-challenge. 4
petechia 4
TKM-Ebola 4
(MAbs), 4
MB-003, 4
ZMAb 4
compassionate-use 4
benign]. 4
(Ala222Val) 4
Hyperhomocysteinemia, 4
Hyperhomocysteinemia 4
677C>T 4
anti-GBM 4
INVM 4
G4.5. 4
MELAS, 4
mitochondriopathies. 4
Antiestrogen-sensitive 4
antiestrogen-resistant 4
(pictilisib; 4
doses/schedules 4
Longer-term 4
therapies), 4
buparlisib, 4
alpelisib, 4
taselisib), 4
entinostat, 4
palbociclib, 4
abemaciclib), 4
non-measurable 4
pan-class 4
CMML 4
Mx1-Cre, 4
(LECs) 4
cholangitis, 4
Acid: 4
under-responsive 4
Ursodeoxycholic 4
(OCA), 4
Specialty 4
RPh, 4
(AMA) 4
Vanoxerine, 4
vanoxerine, 4
reinduction. 4
(AERP), 4
appendage, 4
Bachmann's 4
posteroinferior 4
(CLs) 4
hourly 4
vanoxerine: 4
AFL, 4
75-180 4
noninducibility 4
76-99 4
AERP 4
BB, 4
CLs; 4
thresholds; 4
noninducible. 4
ectoplia 4
particular: 4
(p.R974C) 4
PKC1 4
Pkc1p, 4
23-32 4
Polyphen 4
c.2261A 4
(p.Y754C), 4
gene-mutation-positive 4
(MFS1) 4
TGFBR1, 4
Classic, 4
24-40. 4
fibrillin, 4
IVS46+5G>A 4
Florence, 4
microfibrils, 4
cbEGF12-13 4
15q21.1 4
ChIPpeakAnno: 4
GenomicFeatures 4
BSgenome, 4
agonist: 4
interteukin-4R 4
'biological') 4
452 4
shadowing 4
tumida 4
fibroelastosis 4
(<33). 4
0.43-1.50). 4
(≤22) 4
0.34-1.45); 4
(23-32), 4
0.53-1.62). 4
DESs, 4
≤32. 4
death/MI/CVA/target 4
(MACCE) 4
556 4
285) 4
271). 4
(12.7% 4
0.892), 4
(27.0% 4
11.8%, 4
10.7%, 4
0.948), 4
14.1%, 4
EUROSCORE, 4
16p 4
dulaglutide, 4
semaglutide. 4
semaglutide-free 4
seizure-related 4
Epilepsy-related 4
Tfr4 4
adenylates 4
Trf4/TRAMP, 4
CstF-64 4
ssu72. 4
Pti1p 4
(House-Brackmann 4
(rs 4
(Koos 4
Schwannomas. 4
GKRS. 4
serviceable 4
6%. 4
HepG2, 4
(https://github.com/wenjiegroup/PEDLA), 4
Diphosphatidylglycerol 4
SFP 4
nonionic 4
Miranol 4
Co2+ 4
CDP-diglyceride-independent 4
CPT1 4
6-fold. 4
packing. 4
copper-treated 4
Military 4
areal 4
HR-QCT 4
non-vertebral, 4
anti-sclerosin 4
efficaciousness 4
(Q4W) 4
-3.5 4
bone-formation 4
bone-resorption 4
BRS 4
scores' 4
(IES), 4
(IES-R, 4
IES, 4
inmates. 4
(PTSD); 4
affirm 4
Val66Met 4
thalidomide-binding 4
cereblon 4
catastrophies 4
compex 4
(DDB1) 4
4A, 4
(cereblon 4
thalidomide), 4
δ-proteobacteria. 4
β-meander 4
β-meander, 4
cradle-shaped 4
β-sheets. 4
pseudosymmetry, 4
subdomain-sized 4
Scm3(Sp) 4
(error 4
unreplicated 4
Simian 4
salt-treated 4
SEMAF 4
(CdCS) 4
SMYD1, 4
SMYD2, 4
SMYD3, 4
SMYD4 4
smyd5-MO 4
(LEE011), 4
(LY2835219). 4
(LY2835219; 4
binimetinib 4
(pedHGG) 4
(H3.3) 4
pedHGG 4
pyrosequencing-based 4
~80 4
SETD2-mutant 4
[MIRABEGRON--A 4
DRUG 4
OVERACTIVE 4
BLADDER]. 4
episodes/24 4
100mg 4
micturitions 4
microcontractions 4
SAAs 4
Mirabegron: 4
≥8 4
TEAE, 4
EGb 4
do, 4
aripiprazole. 4
fluoropyrimidine-based 4
7849 4
(rs7849), 4
2.39; 4
1.04-5.52), 4
3.70; 4
1.42-9.64), 4
2.89; 4
1.54-5.41). 4
rs2421099, 4
rs16983007, 4
rs10211390 4
rs6590611 4
rs6124509 4
rs11195893 4
exotoxins 4
FcRn 4
Antitoxin 4
nail/scalp 4
1255 4
Nail 4
(N=505) 4
p=0.0295 4
(-0.20) 4
(-0.07; 4
p=0.0073). 4
≥3%, 4
(24%; 4
p=0.0098) 4
NCT01212770. 4
562, 4
apremilast). 4
(5.3%, 4
(61.0%) 4
-88% 4
-81% 4
32-52). 4
Rheumatology-20 4
(10.3%, 4
psoriasis). 4
(DLQI), 4
(PDE4), 4
Psoriasis: 4
Tofacitinib. 4
mid- 4
amotosalen 4
xylem-feeding 4
Auchenorrhyncha, 4
headaches; 4
(CT, 4
0.6%. 4
palpitation. 4
"headaches, 4
palpitations" 4
onlyone 4
normetanephrines 4
heart/kidney 4
failure-acute 4
failure-chronic 4
(AHF-ACS) 4
(CHF-CHD) 4
reno-cardiac 4
(again 4
primum 4
(circRNA), 4
CSN1S2, 4
CSN2 4
Arraystar 4
China) 4
circRNA-CER 4
anomaly: 4
Anomaly 4
gE 4
Pre-replication 4
PfMCM 4
MCM2, 4
MCM6 4
schizonts, 4
nucleosolic 4
PfMCM6 4
threonine-phosphosphorylated 4
CDC6, 4
MCM2-7. 4
Cdt1p, 4
Mcm2-7p 4
Cdt1p 4
T" 4
(DMP1), 4
ARHR-affected 4
1,25(OH)(2)D. 4
(98G>A, 4
W33X), 4
DMP 4
bi-parental 4
well-recognised 4
Hypophosphatemia 4
hypophosphatemias 4
rickets--a 4
rickets/osteomalacia: 4
rickets/osteomalacia. 4
HHRH. 4
NaP(i)-IIc 4
PND70 4
differentially-expressed 4
SREBP1 4
STAT3-inducible 4
dimethyloxalylglycine, 4
EFNA3 4
synergised 4
(biologics) 4
HCs 4
Reade 4
SSAHA2 4
(BWA-SW), 4
increased-dose 4
68.6%. 4
necrotomy 4
added; 4
44.4%. 4
7.5%. 4
IORT, 4
compiles 4
(IORT). 4
sterilize 4
60Co. 4
RPS 4
(RPS19R62W). 4
Pre-rRNA 4
normocellular 4
(LSI) 4
(WCP) 4
12.79% 4
14.36% 4
WCP 4
nullisomy 4
Roberstsonian 4
(ROBs) 4
"class 4
acrocentrics. 4
nonhomologues 4
robertsonian 4
tirilazad, 4
21-aminosteroid, 4
CBs) 4
gems/CBs 4
(CBs), 4
nucleoplasmic, 4
HLH, 4
AP-3 4
graminearum, 4
culmorum. 4
cereals. 4
plasmapheresis. 4
1924 4
Moschcowitz, 4
Coombs-negative 4
thrombocytes 4
PFO, 4
ADAR. 4
RNA-specific) 4
Auto-regulatory 4
neuro-transmission 4
re-coded 4
dADAR, 4
Caenorabditis 4
ADAR-mRNA 4
guanosines 4
virus--a 4
β-hCG 4
cytotrophoblast 4
REACH 4
high-resource 4
eCry1b 4
much-needed 4
Magnetoreception 4
non-osmotic 4
tolvaptan, 4
protein-creatinine 4
g/g, 4
albumin-creatinine 4
diuretic); 4
(doubling 4
CFE 4
15q11q13. 4
Hamlet 4
Prdm12 4
painlessness 4
rarity. 4
Driver 4
fhl1 4
"Ctf4-interacting-peptide" 4
CIP-box. 4
CIP-boxes 4
Ctf4-dependent 4
"chemobrain" 4
scopolamine-induced 4
cotinine 4
(DAVFs) 4
DAVF. 4
4D-CTA 4
4D-CTA. 4
DAVFs, 4
729 4
(AVFs) 4
Cognard, 4
(Cognard) 4
(Borden). 4
classification: 4
AVFs. 4
ncsDAVFs, 4
ncsDAVF 4
Collybistin 4
tetrabenazine. 4
blepharophimosis-ptosis-intellectual 4
Toriello-Carey 4
alacrima 4
alacrima, 4
CNNs 4
DNase-seq, 4
Basset, 4
p190RhoGAP, 4
pFLAG-CMV2 4
1BSCTS 4
1BLCTL, 4
1BSCTL, 4
1ASCTS 4
filopodia-like 4
p190RhoGAP 4
1ALCTL, 4
1ALCTS, 4
1ASCTL 4
tail-like 4
1BLCTL 4
1ALCTL 4
PTKs 4
NHEK, 4
(ABL-related 4
zoonosis 4
MPF 4
LpnA 4
Tularemia, 4
[Early 4
nonperfusion. 4
neuroretinits 4
734 4
(Praluent) 4
(Praluent®; 4
Sanofi/ 4
(Repatha®; 4
Amgen), 4
emtricitabine 4
Co-formulated 4
Tenofovir 4
DF. 4
(EVG/COBI/FTC/TDF; 4
Stribild(®)) 4
elvitegravir/cobicistat/emtricitabine/tenofovir 4
elvitegravir/cobicistat 4
(p-value<0.05) 4
88.95% 4
84.16% 4
http://www.imbb.forth.gr/SSCprofiler.html. 4
tandem-affinity 4
purification/mass 4
Set2, 4
H3/H4. 4
tetramer-disrupting 4
heterotetramer 4
MHL 4
fibrolamellar 4
Pathol 4
Isaacs 4
hydrops, 4
(EEM) 4
pole. 4
(c.965A-->T) 4
isoleucine; 4
(c.829delG) 4
Cdh3 4
E12.5, 4
(HJMD), 4
16-kDa 4
SZ95 4
adipocyte-secreted 4
luteinized 4
pH-neutral 4
(PIP) 4
humps 4
metaphyses 4
hypoxemia 4
(CBC). 4
Rrp6/exosome 4
termination; 4
RRP6 4
hyper-elongation 4
Elongated 4
Nrd1-unterminated 4
Unstable 4
Nrd1-Nab3-Sen1 4
L1s) 4
fine-tuning. 4
Sox2/HDAC1 4
factor/lymphoid 4
(TCF/LEF) 4
copy-and-paste 4
Scattered 4
118: 4
(ixazomib), 4
EGF-A 4
P36, 4
P37, 4
P46 4
S-S 4
(proprotein 4
apoB-containing 4
hepatic-specific 4
Blp 4
Blp-c 4
[n=3], 4
normolipidemic 4
fluorophore-labeled 4
one-site 4
31-52) 4
LDLRs, 4
hypercholesterolaemia. 4
proteinuric 4
apoM 4
0.125, 4
HCV-G1 4
LLTs 4
fold-baseline 4
baseline-corrected 4
CD271 4
company's 4
INF- 4
(CLASI) 4
48) 4
NJ, 4
homodimerizes, 4
speech/language 4
1995, 4
mcm 4
DDK/cyclin-dependent 4
Mcm9 4
S/T-Q 4
structure-bound 4
OCM 4
toroidal 4
NGS-specific 4
Coding. 4
compress. 4
BARCODE, 4
(50-100 4
compressors, 4
BARCODE 4
text]-mers 4
BFs 4
(FPR). 4
(kBFs), 4
FPR, 4
extended-release) 4
phentermine-topiramate 4
(Qsymia). 4
Belviq 4
Sonidegib, 4
(laBCC) 4
phosphate: 4
Egyptian-tailored 4
conventions 4
Siemens 4
beta-chorionic 4
oestriol) 4
1406 4
919 4
Stored 4
lncRNA-MFDL 4
exosome-mediated 4
CUL-2LRR-1 4
(msRNAPs) 4
msRNAP 4
H1085Y, 4
nucleotidyl 4
TFIIS-dependent 4
"backward" 4
Factor-dependent 4
3795-3800). 4
C11. 4
IIS, 4
endo-exo 4
nucleosome-associated 4
(MNase-seq). 4
condition-dependent 4
MNase-based 4
(matched) 4
experiment-to-experiment 4
unstandardized 4
Tup1-dependent 4
un-matched 4
tup1Δ 4
(technical) 4
(Tup1-dependent) 4
nucleosome-induced 4
retreat 4
countered, 4
octamer, 4
SGLT1. 4
(3.0% 4
[21 4
patients] 4
insulin/vehicle 4
(UGE). 4
Clinicaltrial.gov 4
(LX4211) 4
MetaSPAdes 4
Megahit, 4
efficiency-namely, 4
Minia 4
LightAssembler. 4
NGA50 4
Methylome 4
(Taberlay 4
GSE57498. 4
templates-Bisulfite 4
(MAPit-BGS) 4
tb, 4
DosR-dependent 4
shift-down, 4
Non-replicating 4
(NRP). 4
kinases-DosS 4
(Rv3132c) 4
(Rv2027c), 4
(Rv3133c). 4
(Dos) 4
MSMEG_3935 4
ΔdosR 4
Rv0079 4
(DosR 4
regulon) 4
Rv0079, 4
granulomas. 4
nonrespiring 4
Na(+)/K 4
pma1 4
H37Rv 4
Homologs 4
archaebacteria. 4
integrases 4
Rv1998c 4
methylisocitrate 4
phosphonomutase. 4
Rv0572 4
domain-encoding 4
tdd8 4
Rv0081, 4
Rv1735c, 4
Rv1737c 4
DATIN, 4
DATIN 4
drinkers, 4
Photoaging: 4
photodamage. 4
Cosmetic 4
Superficial 4
roughness 4
84. 4
Photoaging 4
photodamaged 4
Notch-induced 4
overproliferation. 4
(GMCs). 4
vanguard 4
specification: 4
Va 4
GMC; 4
(Notch-OFF) 4
(Notch-ON) 4
SERTAD 4
Taranis 4
(INPs) 4
tara 4
(GMCs); 4
(NBs), 4
Btd 4
0.807, 4
0.939. 4
(BBI608) 4
PrCSCs 4
(neocentromeres) 4
kluyveri 4
dives 4
federations 4
Undersea 4
Hyperbaric 4
Snorkeling 4
Chicoric 4
antiallergic-related 4
vitamins) 4
echinacea-containing 4
popular. 4
urticaria/angioedema). 4
neuroligins 4
5mC/5hmC 4
5'-d(GA)4(T)4 4
Tm 4
homoduplexes 4
d(GA.TC)n 4
d(TC)20 4
5'-GA:GA-3' 4
dodeca-satellite 4
CVE: 4
Oncotator 4
druggability. 4
logos 4
fly's 4
Drk, 4
ARM, 4
's) 4
IL-13) 4
(IL-31) 4
(erythropoietin, 4
IL-23; 4
poly(A)(+) 4
(S2, 4
Kc167, 4
DmBG3-c2, 4
OSC). 4
boundaries) 4
dCTCF, 4
dCTCF 4
inter-bands 4
inter-nucleosomal 4
Ulianov 4
aSLE 4
(AIHA) 4
(GBM, 4
(AG, 4
antiepileptics, 4
(GSK)-3 4
3/40 4
8/37 4
20/37 4
(8.8 4
suddenly; 4
7-9/24 4
(29.2-37.5 4
Levin 4
C-beta, 4
Positioning 4
H2A.Z-associated 4
Anp32e, 4
eukaryote-specific 4
TVT 4
VLPP, 4
[UH, 4
(EI)] 4
0.5-6 4
103.6 4
H2O, 4
28.6° 4
7.2°. 4
-0.798, 4
-0.313X 4
60.95, 4
(χ 4
4.9130, 4
0.0267). 4
TVT-ABBREVO 4
clitoral 4
transobturator 4
(analgesic 4
liquid, 4
voice) 4
aerodynamic 4
/u/ 4
"interferonopathies" 4
Aicardi-Goutieres 4
(USP18)-deficiency. 4
SAID 4
"segregase". 4
Ubiquitylation 4
mutated). 4
CUTs). 4
(NFRs) 4
bidirectionality 4
signals-that 4
RNAPII-Ser5P 4
grg 4
Grg3 4
TGFβ1-induced 4
anti-neuroblastoma 4
NOD-scid 4
Neuroblastomas 4
DNAM-1, 4
NKp30, 4
804-13. 4
Zenarruzabeitia 4
615. 4
factor-βRI 4
(TGF-βRI) 4
pSMAD2 4
MDC/CCL22 4
monohydrate, 4
AUC024 4
LSN3199597 4
(R)1 4
p-Smad2/3 4
c.5898dupC 4
biosynthesis-dependent 4
Sut2. 4
AR1c. 4
ScUpc2 4
CaUpc2 4
CgUpc2 4
SRE/AR1c 4
UPC2-AR1b 4
SREBP 4
Saccharomycotina. 4
YlUPC2, 4
YlSRE1, 4
YlSre1 4
upc2 4
PRM4 4
STE12 4
sterols, 4
Upc2p. 4
lanosterol 4
PM20D1 4
synesthesia. 4
synesthesia, 4
grapheme-colour 4
left-lateralized 4
hemifield 4
naming 4
graphemes 4
CircTest 4
PcircRNA_finder: 4
CIRCexplorer), 4
rRNA-/RNAase 4
PcircRNA_finder 4
starBase 4
Imaging. 4
mFOLFOX-6 4
intravenously; 4
6AU-sensitive 4
PPR2, 4
RNAPIIs 4
rpo30 4
PIC1 4
PIC1. 4
camera-like 4
prehensile 4
colouration 4
two-spot 4
octopus, 4
Octopus 4
bimaculoides. 4
bilaterians, 4
protocadherins, 4
DMVD 4
valvulopathy 4
[Changes 4
twisting. 4
ammonium-functionalized 4
(fCNT)-mediated 4
includingTrp53,Mep1b,Ctr1, 4
andEGFP 4
fCNT-targeted 4
nanocarbon-mediated 4
(davunetide), 4
cardially 4
(IHs) 4
LCA10 4
Delta8-Delta7-sterol 4
isomerase-encoding 4
squalene-synthase 4
Ergosterol 4
8-16-fold 4
(beta-d-glucosyl-HOMedU). 4
glucosyl-transferase 4
J-null 4
http://github.com/StoreyLab/subSeq/. 4
gt11. 4
Berk 4
(S1 4
mapping) 4
UV5 4
Top2 4
top2-10 4
blepharophimosis-ID 4
(MKB) 4
(c.3443G>A 4
(c.5185C>A 4
Say/Barber/Biesecker/Young/Simpson 4
(c.5898dupC) 4
MED12. 4
600-kb 4
YWHAE 4
Opitz-Kaveggia 4
[MIM 4
*300188] 4
(mediator 4
Lujan, 4
FG, 4
Co., 4
submission. 4
(Q3W) 4
C30 4
QLQ-C30) 4
endpoints; 4
(GHS)/HRQoL 4
270); 4
266); 4
240). 4
178), 4
GHS/HRQoL 4
-10.0 4
ipilimumab). 4
Q2W; 4
ipilimumab), 4
CLINICALTRIALS. 4
undiscounted 4
pQCT 4
abridged 4
osteoporotic, 4
(hip 4
NF1(+/-) 4
Cdh23 4
(ahl) 4
(c.1184G>A 4
(c.4118C>T) 4
TET-catalyzed 4
evicts 4
chromatin-related 4
Hensgens 4
true: 4
DNMT1/DNMT3B 4
reoccupy 4
state" 4
Cytokines, 4
[(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide] 4
oxazolone-induced 4
(0.069) 4
non-24-h 4
(Bonferroni's 4
7.79; 4
1.59-38.3) 4
morningness 4
eveningness. 4
AA-NAT 4
(Jaks) 4
(jakinib) 4
Tulane 4
RIG-I, 4
DEAD 4
Paraprevotella 4
70-90% 4
non-coding), 4
rpb4∆ 4
Paf1, 4
Spt4, 4
ESS1 4
Abasic 4
DST1, 4
fidelity, 4
IV-tPA 4
thromboelastometry 4
IR-exposed 4
DDR-related 4
Glomeruloid 4
glomeruloid 4
edema/effusions. 4
(AAV2-hRPE65v2) 4
20/60 4
meridian, 4
multi-luminance 4
(MLMT) 4
0·2 4
Voretigene 4
untreatable. 4
TERRA. 4
GAR 4
trf2 4
fifth-functio 4
laesa, 4
function-was 4
promulgated 4
Rudolf 4
Chemokine-Receptor 4
Functions. 4
function.[...]. 4
objects, 4
co-occurrence, 4
eQTL-mapping 4
hydranencephaly. 4
collagenopathy 4
Russell-Silver 4
SERPINF1 4
BMP1, 4
TMEM38B, 4
5-AzaCdR 4
macrosomia 4
pre-implantation. 4
allele-discriminating 4
TgM 4
ICR') 4
TgM, 4
ICR-containing 4
beta-like 4
j 4
ccctc 4
mz 4
dz 4
porosity. 4
risedronate 4
VarScan 4
callers, 4
somaticsniper 4
snvs 4
august 4
http 4
edu 4
ebcall 4
genomevip 4
UNLABELLED 4
github 4
Kummell 4
screw 4
hands": 4
pitting, 4
ultrasound) 4
cellulitis. 4
Low-stretch 4
garment, 4
bandages. 4
bandaging. 4
self-bandaging 4
stays. 4
multifactorial: 4
garments, 4
hard-core 4
03 4
arterious 4
S1P1-eGFP 4
Article 4
author(s) 4
employer(s) 4
1-phosphate 4
(ACT128800), 4
(BAF312), 4
(ONO-4641), 4
GSK2018682, 4
>METHODS</b>: 4
rpc1063 4
rp101075 4
(2.4, 4
stinging, 4
Sufferers 4
dermopathy 4
tickborne 4
parasitosis 4
trust 4
HGVA 4
Nonexonic 4
Elements: 4
Phylogenomics. 4
ESC2 4
RRPE 4
Rpd3L 4
poly(G)s 4
saccharomyces 4
reb1 4
antired 4
Anti-VCA 4
IgM/IgG 4
pleuritic 4
adolescent, 4
'tight' 4
'Tet-OFF' 4
phytohormone 4
scf 4
dpb11 4
mcm10 4
mounts 4
mentagrophytes 4
Coral-red 4
well-demarcated 4
oxydans. 4
(Copro 4
keratolysis 4
inframammary 4
interspaces 4
intergluteal 4
crural 4
dermatophytosis, 4
250mg 4
antibacterials 4
clindamycin, 4
soaps 4
axillaris 4
Staphylococci 4
ecthyma 4
erysipelas 4
erythrasma: 4
lamp, 4
SWI/SNF2 4
(SMARCAL1) 4
(R561H) 4
virus-negative 4
(MIM:20606622) 4
dissymmetric 4
ubx 4
winged-like 4
(BG). 4
(2/3) 4
(1/3), 4
(2/3), 4
acc 4
tracheotomy 4
(sSMCs) 4
+der(22)t(11;22)(q23.3;q11.2). 4
[der(22)t(11;22)(q23.3;q11.2)], 4
carrier: 4
(q23.3; 4
q11.2). 4
11;22 4
+der(22)t(11q23;22q11). 4
Eliminates 4
Domains. 4
"contact 4
loci-almost 4
cohesin-lying 4
co-segregate. 4
Step-by-step 4
(GLPG0634/GS-6034), 4
(DARWIN 4
(GLPG0634, 4
GS-6034) 4
(JAK1)-selective 4
9-39], 4
p=0·0077). 4
Tisagenlecleucel 4
(CTL019) 4
CD19-expressing 4
(CAR)-engineered 4
impressively, 4
(CART19) 4
tisagenlecleucel 4
Fiber 4
DIDMOAD 4
LHON-associated 4
MELAS 4
CRVO 4
ILVAT 4
parp1 4
HSP90.1 4
6.80-25.9), 4
1.69-9.91). 4
CONCLUSION</b>: 4
p-tau/tau 4
WIREs 4
Myogenesis. 4
grs 4
Aalpha-chain 4
R554L 4
SMARCB1-deficient 4
(CCs). 4
/INI1 4
mir 4
(L)) 4
9q12, 4
abutted 4
Yq12 4
Rabl-orientation 4
sad1 4
Subtelomeres 4
Sub-Telomeric 4
(STARs). 4
Tbf1p- 4
Reb1p-binding 4
STARs. 4
(Prolia, 4
anabolism, 4
hFOB 4
GluN2B 4
(n-3 4
synaptotoxicity. 4
drug:placebo 4
AZD0530. 4
Boxes) 4
Plasma/CSF 4
0.4. 4
One-month 4
NCT01864655. 4
TTR-FAP 4
Vitreous 4
p.Gly87Arg 4
T60A 4
blind-ended 4
ethmocephaly. 4
single-nostril 4
nose) 4
interorbital 4
proboscis) 4
hypotelorism 4
collaborative, 4
STOP-Apple 4
(cut-off=3) 4
(BQ), 4
(STOP), 4
(DOR) 4
author's 4
63.3% 4
cholecystectomy. 4
Arabic-speaking 4
Ain 4
Apnea/hypopnea 4
≥5/h 4
ninety-three 4
≥5) 4
(≥3) 4
0.834-0.972). 4
≥5, 4
≥15, 4
96.75, 4
99.70 4
(NPVs) 4
Cormack 4
technologists 4
METHODS</b>: 4
Palivizumab, 4
5C4 4
non-recipient 4
(AAP) 4
2207 4
LVD 4
lymphangiogenic 4
glutamyltransferase 4
exudate. 4
gravimanus 4
RNAi-Based 4
Market. 4
Melo's 4
(AntimiRs) 4
PKN3, 4
microRNAs); 4
hepatitis; 4
(ocular, 4
intratumoral). 4
(delivery, 4
barriers), 4
cancersubtypes 4
"anti-insulin 4
Cognition. 4
Study-Activities 4
Instrumental 4
(13.1%), 4
pyrin. 4
MEFV, 4
Anatolia, 4
Arabs, 4
COL1A1, 4
2(I) 4
100-mm 4
visual-analogue 4
pain), 4
(0.5±1.0 4
2.1±2.6) 4
(-44.7±24.3 4
-16.0±32.5 4
Celgene; 4
NCT00866359.). 4
(Otezla(®)), 4
type-4 4
(PDE-4), 4
RBM6, 4
IGCs, 4
miRNA-targeting 4
POC 4
Throat 4
(fever 4
>38.5°C, 4
cough) 4
aminosalicylates 4
apoE-/- 4
chain-containing 4
(possible 4
(P=0.39), 4
(P=0.55), 4
(P=0.10), 4
(P=0.76), 4
1500. 4
NCT00787202.). 4
BMAL1-dependent. 4
binding-dependent 4
E-elements 4
CRY, 4
Id2(-/-) 4
per2 4
crh-1 4
CREB1Δ 4
Lenti-CREBWT 4
recaptured 4
anti-IL-23 4
12/23 4
pyoderma 4
Ustekinumab. 4
-23, 4
"humanized" 4
(hu-Ig) 4
IL-12Rβ1 4
IL-12/23 4
(PHOENIX 4
Anti-p40 4
briakinumab: 4
Horsham, 4
.34), 4
nonresponders), 4
vdh 4
180-mg 4
Alectinib 4
P<0.00001, 4
Auxin-induced, 4
(ARFs) 4
BDL/IAA12 4
Auxin/indole-3-acetic 4
IAA9-inhibited 4
parthenocarpy. 4
hypocotyl/stem 4
IAA3. 4
pavement 4
palisade 4
mesophyll 4
iaa17 4
dibrachius 4
(18.5%), 4
pygopagus, 4
head) 4
SLC2A10, 4
GLUT10 4
wilt. 4
soilborne 4
oxysporum, 4
Fo5176-SIX4 4
Tom1, 4
alpha-tomatine 4
glycoalkaloid 4
mix-breed, 4
faceted 4
spokes 4
ontological 4
(CHDO) 4
(Linc-pint) 4
ampulla 4
Vater 4
(CAV) 4
(supination-flexion 4
hyperpronation) 4
supination-flexion. 4
75(th) 4
95(th) 4
("nursemaid's 4
elbow") 4
(subluxation 4
interposition 4
radiocapitellar 4
Radial 4
elbow', 4
chewing, 4
interincisal 4
jaw-mobilizing 4
MIO 4
TOG 4
(marginal 4
antibody-directed 4
eosinophil-depleting 4
pre-bronchodilator 4
online.<br> 4
Evolocumab. 4
planning). 4
performance). 4
yearly, 4
EBBINGHAUS 4
NCT02207634 4
(min: 4
max: 4
affluent 4
noticing 4
Alignment-free 4
substrings 4
(k-mers) 4
(button 4
technique), 4
Sellers 4
rarities 4
TEV-48125) 4
fremanezumab's 4
high-threshold, 4
A-δ 4
dynamic-range 4
patients.SIGNIFICANCE 4
(CSD). 4
CGRP-mAbs 4
(centrally). 4
Aδ-HT 4
0270-6474/17/3710587-10$15.00/0. 4
Fremanezumab, 4
PHARE 4
metroTMZ 4
nimotuzumab/vinorelbine 4
postero 4
vara. 4
LSG 4
metaphysis 4
(SPINRAZA™) 4
(Spinraza), 4
affirmed. 4
Spinraza™ 4
help-seeking 4
co-variable. 4
KKS 4
speech-hearing 4
audiograms), 4
names. 4
Hinchcliffe 4
literacy 4
prospect. 4
'959 4
Genomes'--a 4
community-curated 4
Nematoda. 4
(DAA) 4
(MAGELLAN-1) 4
(GLE) 4
SURVEYOR-I 4
SURVEYOR-II 4
ribavirin. 4
12weeks. 4
(SVR12). 4
Twelve-week 4
97-100%, 4
96-100%, 4
83-94%, 4
4-6, 4
Eight-week 4
300mg 4
120mg 4
3-infected 4
97-98% 4
post-nadir 4
12weeks 4
92%-100%; 4
Identifiers: 4
NCT02243280 4
NCT02243293. 4
http://www.clinicaltrials.gov/show/NCT02243280, 4
http://www.clinicaltrials.gov/show/NCT01939197. 4
ABT-493), 4
3/4A 4
(NS3/4A) 4
ABT-530), 4
2.9-6.3-fold, 4
OBJECTIVE</b>: 4
mg/120 4
Impairment. 4
ENDURANCE-4 4
orexins 4
Ox2, 4
(canagliflozin) 4
glucose: 4
hypoinsulinemia. 4
reserving 4
Klinefeleter 4
retracted. 4
Mammography, 4
microcalcifications. 4
(FNAB), 4
Madden's 4
(cirrhosis), 4
gynecomastia. 4
3518 4
222.8, 4
651.0) 4
48,XXYY 4
36.7, 4
132.5). 4
SomaticSignatures: 4
cross-dataset 4
TJA 4
TJA+MetS 4
cholesterol), 4
Maintains 4
Rescuing 4
Phenotypes. 4
Aβo-dependent 4
check-points 4
anti-PD-1/PD-L1, 4
cell-tumor 4
BRAFv600 4
(177)Lu-AMBA 4
Univ.Lig 4
BRS-3 4
nonpeptide 4
NMBR 4
perforation: 4
(p=.16). 4
(p<.0001). 4
(p=.008). 4
(p=.002). 4
Supine 4
ligament), 4
cavity), 4
inverted-V 4
folds), 4
(localized 4
quadrant). 4
air), 4
appendix 4
stranding. 4
BCL10 4
(ATF4), 4
Raynaud 4
SS-associated 4
non-MALT 4
pSS-related 4
L265P 4
noneosinophilic 4
(events 4
patient-year) 4
(medium 4
[P=0.01], 4
[P=0.002]). 4
MedImmune 4
Group] 4
NCT02054130 4
impotence 4
threatened 4
Prolactinomas 4
puzzles 4
moose, 4
scrapie, 4
CWD-negative 4
96SS 4
farmed 4
(POCT) 4
(A1c) 4
(MPG) 4
(A1C), 4
survivable 4
21q22.1 4
(Ts21) 4
Twist1(+/-) 4
(SLEDAI 4
non-renal 4
LHA 4
intensify 4
Isles 4
SS-PGA 4
LBT 4
(SLEDAI). 4
ALK-induced 4
ALK-driven 4
X-396 4
(ALK), 4
ALK/KRAS 4
ALK-tyrosine 4
NPM/ALK. 4
(CAP). 4
MR-pro-adrenomedullin 4
CURB. 4
CURB65. 4
CURB65, 4
CRB65, 4
(LRTI). 4
LRTI 4
(0.65%) 4
≤0.75 4
I); 4
(8.6% 4
≤1.5 4
0.75-1.5 4
(21.6% 4
9.8%, 4
LRTI. 4
Procalcitonin-guided 4
prohosp 4
isrctn.org 4
ISRCTN: 4
ISRCTN95122877. 4
ELAD 4
(MELD 4
11.2*[PT-INR] 4
6.4) 4
6.4. 4
(male: 4
106; 4
63.8 4
>14 4
<b> 4
(in-hospital 4
6-variable 4
5XFAD 4
Las 4
Ral, 4
toremifene 4
(SERMs), 4
desmoid 4
Cyp17a1 4
ERs 4
Raloxifene, 4
(+/-progestogen) 4
LY2066948 4
transamidation 4
sophisticated, 4
organ-threatening 4
sarcoidosis: 4
mentalization 4
mentalizing. 4
resident's 4
supervisors. 4
inquiring 4
PGY-4 4
FREIDA 4
tumultuous 4
underemphasis 4
returned. 4
schema-focused 4
nonsuicidal 4
δ, 4
Lagging 4
δ4 4
(FEN1) 4
ligated, 4
fatua 4
tetraploid 4
A/D 4
intergenomic 4
Gardnerella, 4
sp, 4
vaginitis, 4
p24. 4
(p24 4
POCT. 4
EAAA 4
combo 4
stenosing 4
claimants 4
justice. 4
Childress--autonomy, 4
justice--have 4
dilemmas. 4
Analytic 4
non-maleficence 4
(autonomy, 4
nonmaleficence 4
justice) 4
morality 4
DFO 4
(probe-to-bone 4
(simple 4
Ulcer 4
(79.5%) 4
moderate-certainty 4
toenails 4
Melanogenesis 4
Phototoxic 4
Doxycycline. 4
quinine, 4
mefenamic 4
perforant 4
metabolism‑associated 4
r5 4
MGA 4
CistromeMap 4
664 4
GORE 4
HELEX 4
Nucleome 4
[Zieve's 4
hyperlipaemia 4
hyperlipemia 4
alcoholism). 4
NOR-DMARD 4
≤4 4
tauCstF-64 4
DSEs 4
3'-dA 4
tRNA(Tyr) 4
half-molecules 4
chondroma: 4
pseudocapsule 4
rabies, 4
(LLPS) 4
LLPS 4
criminal 4
Idalopirdine, 4
Intepirdine, 4
Phase-3 4
ChEI's 4
Mammography 4
Registers. 4
(1998-2010), 4
4417 4
non-consumers, 4
≥3-4 4
servings/week 4
6851 4
(I(2)=24.3%). 4
Flavanol-rich 4
(TCGA), 4
TCGA. 4
breast-mammary 4
Genotype-Tissue 4
(GTEx) 4
risk-of-relapse 4
(ROR-P) 4
spouse 4
single-trait 4
Achenbach's 4
7/12, 4
territory-wide 4
1988-2002 4
Macau. 4
(male:female 4
7:3) 4
vaccine-associated 4
PDGFR, 4
PDGFR. 4
on/2 4
AZD4547, 4
pan-FGFR 4
N87-TR 4
OP449 4
angiomotin-like1 4
(circ-Amotl1). 4
Circ-Amotl1 4
circ-Amotl1-transfected 4
142-fold 4
c-myc. 4
leg-pain 4
"head-to-head" 4
PGB-GBP 4
BPP: 4
STUDIES 4
BIOLOGY 4
agglutinates 4
streptococcus. 4
Scarlatinal 4
hemolyticum 4
spe 4
speA, 4
speB, 4
speC, 4
speF. 4
Beijing 4
blanching 4
Erythrogenic 4
erythrogenic 4
BioArchive 4
(MODIFY 4
MK-3415A, 4
Akkermansia, 4
Put 4
htopoI 4
(STRs), 4
3001 4
repeat-primed 4
(RP-PCR). 4
(212/212, 4
[0.98, 4
(208) 4
(2786/2789, 4
[0.997, 4
flagged 4
(NLGN3), 4
PI3K-mTOR 4
NLGN3, 4
Nlgn3 4
PI3K-mTOR, 4
synapse-related 4
CD59, 4
CD55- 4
Snoring 4
polycythemia, 4
(chi 4
collagenolytic 4
extraterminal 4
58.2-82.2] 4
55.8-79.9) 4
0.77-1.76; 4
0.47]. 4
22(19); 4
Temsirolimus, 4
ProteinGoggle 4
sex-biased 4
mass-spectrometry, 4
bEnd.3 4
osteocytic 4
pHo 4
(32.0±7.19 4
s-IGF-1, 4
osteoclast-derived 4
BMP6 4
osteoclast, 4
Scl-Ab 4
non-calcified 4
pulps. 4
DEGs 4
protein-acyl 4
ZDHHC13, 4
ultraviolet-B-induced 4
G1-like 4
melanomagenesis 4
you? 4
mid-20th 4
Tick-control 4
tick's 4
eQTLs, 4
BXD 4
wistfulness 4
self-loathing, 4
exposition, 4
[Ebstein's 4
lithium]. 4
manio-depressive 4
lithium-administered 4
hurts: 4
lithium-exposed 4
(ACE910) 4
ehrlichiosis 4
(WTD; 4
Odocoileus 4
ewingii. 4
amblyommii, 4
lonestari 4
maculatum 4
parkeri, 4
DeepLoc: 4
BotaniGard(®) 4
(BMSB) 4
BMSB. 4
wettable 4
parasitism 4
Bug 4
(BMSB), 4
exanthem 4
fever); 4
65-80%), 4
Typhoid 4
curli 4
ΔwcaM 4
ΔbcsE 4
fL 4
fL, 4
RDWI 4
sickness. 4
benznidazole. 4
vasculitis: 4
mofetil, 4
aGCA 4
Tocilizumab, 4
corticoid 4
Gsk3β 4
"alternative 4
end-joining" 4
Tnfrsf11b 4
terabytes), 4
losslessly 4
compressed). 4
NGC, 4
SAMZIP, 4
naltrexone) 4
Ultralong 4
Phosphorescence 4
Water-Soluble 4
Nanoparticles 4
autofluorescence, 4
semiconducting 4
(OSNs) 4
afterglow 4
Trabecular 4
co-receptors, 4
Keap1-Nrf2 4
allantopyrone 4
Sofosbuvir-based 4
sofosbuvir-based 4
imaging-genomics 4
(IL11RA) 4
fibroblast-specific 4
Il11ra1 4
AβPP/PS1 4
56.1%, 4
moderate-risk 4
(CTPA). 4
Vojvodina 4
Qanadli 4
(1.6%), 4
(71.6%) 4
<25%, 4
25%-50%, 4
78.2%-96.6%], 4
3.11%-55.6%), 4
72.4%-93.2%) 4
4.5%-70.7%). 4
(6.8 4
(31.33% 4
26.64%, 4
Values, 4
scorings, 4
46%). 4
CYP19. 4
(CYP19). 4
17beta-hydroxysteroid 4
Tecfidera(®) 4
Unit: 4
"exploding 4
twilight 4
Aβ3-42. 4
disease/vanishing 4
VLS 4
non-uraemic 4
arteriolopathy, 4
inhibitor-κB 4
system-mediated 4
SCCRO 4
DCN1-UBC12 4
DI-591 4
BIR, 4
NPWT 4
DIRAS3, 4
miR-19b-modulated 4
Sox6. 4
DUSP5, 4
0.0115) 4
0.0330) 4
0.0108). 4
antipyretics, 4
warnings. 4
(Dinutuximab) 4
HR-NB. 4
(Unituxin(R)) 4
(1964 4
Application, 4
32-day 4
G4P 4
3G, 4
2G, 4
ddi 4
miR-1271 4
Nardilysin 4
(N-arginine 4
convertase; 4
NRDc 4
Horn 4
Monotest 4
(PEA, 4
Olink) 4
ninety-two 4
(with/without, 4
MMP10 4
ImmunoAssay 4
MGUS. 4
MM-ASCT 4
EEN 4
inflammation-associated 4
anti-rat 4
(1A29), 4
subclass-matched 4
(IgG1), 4
1A29-sensitized 4
1A29-treated 4
(Wistar 4
SHR), 4
1A29. 4
1A29, 4
(ICTUS 4
[2×500 4
h]). 4
≥95. 4
NCT00331890. 4
Ferrer 4
Grupo. 4
biotherapeutics, 4
IAM 4
SNSs. 4
SNSs 4
recursively 4
'RS-exon' 4
RS-site. 4
RS-site 4
RS-exons 4
RS-exons. 4
"large 4
introns" 4
RP-sites 4
bioinformatic, 4
phylogenetic, 4
kuzbanian, 4
outspread, 4
zonule 4
(excision 4
∼30-mer. 4
XR-seq, 4
(6-4) 4
pyrimidine-pyrimidone 4
[(6-4)PPs]. 4
(6-4)PPs. 4
aPelota 4
Melastatin 4
Ca(2+)-permeable 4
hyperproduction 4
calcium-permeable 4
LSDBs 4
Pan-cancer 4
hijacking. 4
hijacking) 4
SCNAs, 4
cancer-type-specific 4
Df(4)C3, 4
Hemizygotic 4
45-50 4
PONDS-forming 4
ATAC-seq. 4
Transposase-Accessible 4
i3C 4
pagetic 4
eczematoid 4
immunoreactions 4
PBP-A 4
11-zinc 4
(CTSs) 4
insulators). 4
2xCTSes 4
p.G2019S 4
(RPS19), 4
exaptation, 4
dysesthesia, 4
CTS, 4
(LOX). 4
famciclovir) 4
labialis, 4
Acyclovir 4
Glaxo 4
androstenone, 4
phaeomelain 4
tan 4
UVR. 4
(MSH), 4
(MC1R): 4
red-heads 4
(red-haired 4
'R', 4
'r', 4
melanin; 4
yellow/blond 4
pheomelanic 4
Mc1r-dependent 4
Agouti 4
(ASIP) 4
Eco 4
TBN 4
HAN 4
1q42.2 4
2p21. 4
HAA 4
(0.029 4
rs186996510) 4
High-Altitude 4
(HMOX2) 4
Tibet. 4
Nepalese 4
Sherpa, 4
natives 4
EPAS1/HIF-2α 4
(PFC: 4
ACC: 4
overand 4
underreactive 4
liability, 4
incarcerated 4
aggression-related 4
Tcf7l2/Tcf4 4
CENP-T 4
viscerotropic 4
Hospitals' 4
Laboratories' 4
color-blindness 4
keratan 4
hominins 4
Destiny 4
Chromosomes: 4
(Xarelto®), 4
(Eliquis), 4
(Savaysa) 4
Apixaban: 4
(BMS-562247) 4
flinching 4
(laminae 4
tail-flick 4
lamina-genome 4
(cLADs) 4
cLADs. 4
CLCb 4
three-legged 4
IFN-γ(-/-) 4
Introgression. 4
aponeurotomy 4
fasciectomy 4
apportionment 4
unusually, 4
3,142 4
(1000G) 4
1000G 4
(EHH) 4
disease-risk 4
Jablonski 4
Chaplin 4
2010;107:8962-8968), 4
Arg160Trp, 4
Asp294His, 4
B56γ-PP2A 4
S410L 4
(EVs) 4
Protamine 4
simplex: 4
(D17S74: 4
(D12S17: 4
COL2A1: 4
(PLEC1) 4
hemidesmosomal 4
(EBS). 4
mechanobullous 4
cell-deficient 4
short-wave 4
UVC 4
(200-280 4
direct-current 4
person/year 4
periodically; 4
review) 4
RAD9 4
panamensis 4
antimonite 4
antimonials, 4
(V.) 4
Ld-CC 4
overanticoagulation. 4
fluconazole, 4
mecC 4
oxacillin-susceptible 4
pbp2 4
(BORSA). 4
Velogene 4
MRSA-Screen 4
(FOXP2) 4
(DVD), 4
UPD7. 4
CNTNAP2 4
model-free 3
analyzes. 3
(L-HSCR) 3
(S-HSCR). 3
suggesting, 3
oligo-/polygenic 3
MCS+9.7 3
20%-30%/47% 3
54%-62%/88% 3
European/Chinese-ancestry 3
10(-5)) 3
short-segment, 3
long-segment, 3
"cellular-recessive" 3
alleles' 3
10q11.2 3
Gdnf-/- 3
Ret-/- 3
IP-10 3
K5(+)K19(-) 3
epiregulin 3
(HB-EGF) 3
communications 3
substrate-specific 3
potent. 3
MPNSTs. 3
Xaa-Pro 3
(AR, 3
EREG) 3
distinctions. 3
epigen 3
goblet 3
(amphiregulin 3
full-length, 3
breach 3
MIG-6S 3
lethally 3
PS3 3
proteoglycan-like 3
thread 3
RNA-seq, 3
computationally. 3
Ensembl. 3
OPG-mediated 3
(RANKL). 3
TNF-related 3
osteoblast-specific 3
Static 3
17β-estradiol 3
pro-osteoclastogenic 3
Brucella-activated 3
Osteoclasts 3
osteoclastogenic 3
568 3
3765 3
caner 3
miR-510, 3
miR-509-5p, 3
miR-508-3p 3
miR-483-5p 3
OSC, 3
novel-candidate 3
2222 3
miR-200a, 3
microRNA-100 3
let-7a: 3
platinum, 3
miR-199a-3p 3
Let-7i 3
69, 3
92, 3
93, 3
thymoma. 3
about. 3
(SR-Pyr) 3
Astonishingly, 3
instant-release 3
SR-Pyr. 3
288.1 3
171.0mg. 3
unproblematic 3
SR-Pyr, 3
factor' 3
(MMM) 3
impairment; 3
databank 3
GCTB 3
endothelin-A 3
(SRC) 3
RANKL/RANK 3
Alendronate, 3
trials]. 3
(bisphosphonates, 3
horizons 3
sipuleucel-T 3
timely. 3
sipuleucel-T, 3
bone-metastatic 3
ever. 3
Nondrug 3
sponsor. 3
nondrug 3
costs) 3
2000s, 3
Amgen, 3
Thousand 3
2010]. 3
publishes 3
accomplished. 3
ADT. 3
Alternatively 3
Garvan 3
(NTDs) 3
(DVL) 3
2.06 3
Diversification 3
(dsh) 3
DVL 3
1995). 3
Dishevelled-2 3
DVL1. 3
dermatosis, 3
hyperkeratoses 3
(APB) 3
1965. 3
maligna, 3
gyratum 3
repens, 3
lanuginosa 3
acquisita, 3
necrolyticum 3
1980). 3
(Bazex's 3
digits, 3
digitalis. 3
amiodarone) 3
rested 3
slow- 3
NOTCH4. 3
NOTCH-mediated 3
Notch3, 3
Numb. 3
Jagged1, 3
(Notch-1 3
co-ordinated 3
Delta, 3
reextends 3
senesce 3
P<0.0001; 3
1,099 3
[NA], 3
non-Europe/NA) 3
Inventory-Short 3
(radiographic 3
[rPFS], 3
[PSA50], 3
0.886; 3
0.739 3
1.062; 3
.190). 3
0.760; 3
0.653 3
0.885; 3
Orteronel-prednisone 3
.128). 3
orteronel-prednisone, 3
23%), 3
6,7-dihydro-5H-pyrrolo[1,2-c]imidazole 3
growth: 3
Her2-overexpressing 3
Re-188-labeled 3
Herceptin- 3
Re-188-treated 3
anti-ErbB2 3
(PC). 3
tracers. 3
chelator, 3
(DTPA) 3
DU-145 3
postinjection. 3
postinjection, 3
AG1478, 3
affibody 3
heregulin 3
AG825 3
treatments) 3
viral-based 3
(RTKs) 3
neck). 3
acini 3
(HER) 3
blot) 3
p27. 3
Herceptin) 3
HER-2/neu-positive 3
(ZD1839, 3
LNCaP-LN3 3
(HER-2/neu) 3
uninterpretable 3
5); 3
3-drug 3
W.B. 3
Saunders 3
depolymerization, 3
androgen-dependent, 3
androgen-induced 3
EGF-stimulated 3
KLF4)-expressing 3
(PBMNCs) 3
Dox 3
transplantable 3
Artd1/Parp1 3
ADP-ribosyltransferase 3
(Artd1; 3
[Parp1]) 3
poly(ADP-ribosylation) 3
(PARylation) 3
translocation-2 3
(Tet2) 3
Essrb) 3
2012;488:652-655]. 3
(Artd1-/-) 3
Artd1-mediated 3
(Fgf4) 3
Artd1-/- 3
(c-myc, 3
GBM-SCs 3
15-44 3
µM) 3
(CD44, 3
SeV-based 3
vector-based 3
OSKM). 3
researches. 3
(GCTs) 3
Sox2) 3
medicine; 3
retrovirally 3
donors' 3
Oct3, 3
Lin28, 3
simplistic, 3
Wnt3a, 3
TYRP1, 3
(NSCs) 3
GFP-positive 3
immunoprecipitation)-on-chip 3
E14.1 3
co-occupied 3
C-HPP, 3
chromosome-based 3
946 3
Encyclopedia 3
(HPP) 3
announcement 3
engaged. 3
MSY 3
industries, 3
teams, 3
consortium, 3
encode. 3
851 3
982 3
healthcare, 3
initiatives. 3
initiative, 3
developments, 3
MRM 3
rerio. 3
invaginating 3
hemichannel 3
opposition 3
airways. 3
ions: 3
conductances 3
48.7 3
flounder. 3
polyinosinic-polycytidylic 3
stimulations. 3
Edwardsiella 3
drPanx1a 3
split. 3
drPanx1b 3
(ANS) 3
62.3 3
(23%, 3
HF) 3
class). 3
pectoris 3
(IVA), 3
nitrates 3
MERLIN-TIMI 3
nucleotide-gated 3
(HCN) 3
failure]. 3
30.4 3
(cardiovascular 3
beats/min. 3
70/min. 3
day(-1)) 3
MI-remote 3
Metoprolol 3
copper-transporting 3
anywhere 3
Rarer 3
ICT 3
(KF) 3
objections 3
liver-copper 3
1:1, 3
degeneration) 3
(males 3
ere 3
fly. 3
reciprocally: 3
epiallele 3
disease--is 3
appliances 3
musculature, 3
exudation. 3
7-month-old 3
Strabismus. 3
(CMS) 3
interrupted. 3
asymmetric, 3
(EcoRI/BlnI 3
Vignos 3
lifting 3
38-kb 3
(LINE1, 3
Sat2 3
Alu) 3
TWIST1, 3
(CSQ) 3
([Ca](i)) 3
catheterized 3
KCl) 3
20-25%. 3
(jSR). 3
117% 3
calsequestrin: 3
>/=4 3
attached; 3
3-, 3
(JCN) 3
3-wk-old 3
48%) 3
ion-conducting 3
73%, 3
(Jones, 3
Zhang, 3
Sanborn, 3
Jorgensen, 3
Kelley, 3
30787-30796). 3
"KEKE" 3
(Guo, 3
9027-9030). 3
(SRM). 3
bare 3
(Cho), 3
phosphocholine 3
choline-containing 3
PC, 3
mumol/l, 3
iv). 3
iv), 3
phenoxybenzamine 3
atrium, 3
Inotropic 3
Tyrode 3
manganese. 3
phentolamine, 3
cimetidine, 3
Rue61a. 3
quinaldine 3
arsenic, 3
atrazine 3
EpSL27, 3
KI72. 3
alpinus 3
Peninsula. 3
lysine-acetylated 3
(BD1 3
(extra 3
BD1, 3
ramification 3
switching/sucrose 3
nonfermenting 3
yGCN5 3
biosynthesis). 3
bromodomain: 3
E2F, 3
(BD1, 3
74-194) 3
BRD2. 3
acetylated. 3
mM); 3
histone-acetyltransferase 3
lysine, 3
lymphonodular 3
gaseousness, 3
transcatheter 3
paramount. 3
catheter-based, 3
LPS-mediated 3
ELISA; 3
remedies 3
sub-G1 3
Lipopolysaccharide 3
SP600125. 3
BSP 3
HPLC. 3
S63 3
multiphosphorylation 3
T91/T93/T95 3
amplifier 3
(regulated 3
IFNbeta 3
kappaB, 3
JNK1alpha2 3
424 3
-beta, 3
MAP3K 3
(MKK4 3
constitutively-active 3
reconstituting 3
ATF2, 3
non-transcription 3
c-Fos, 3
44-kDa 3
Ser-73. 3
(LC-MS/MS). 3
Trans-Proteomic 3
Kleifeld 3
neutrophil-specific 3
(MALDI-TOF) 3
MT6-MMP 3
CXCL5 3
CCL15 3
(TAILS). 3
iTRAQ-TAILS 3
neo-N-termini 3
p-mTOR, 3
p-p70S6K 3
E17K 3
1,437 3
SMO. 3
lacosamide, 3
eslicarbazepine 3
stiripentol, 3
Anticonvulsant 3
(spinal 3
Bennett 3
sorely 3
protein/protein 3
(NFTs). 3
antiepileptic. 3
(CRMP-2). 3
Lacosamide: 3
affinity-labeling 3
collapsin-response 3
(CRMP-2 3
DRP-2) 3
CRMP-2 3
LCM's 3
lacosamide. 3
(4.5mg/kg 3
pro-convulsant 3
LOX, 3
(EWS/PNET) 3
adipocytic 3
sarcomagenesis. 3
miRNA-708, 3
miR-708, 3
miR-708 3
EYA 3
EYA3-mediated 3
(NR0B1), 3
steroidogenesis, 3
Sarcoma. 3
(S)-YK-4-279 3
EWSR1. 3
(PNETs), 3
(NFkappaB) 3
disruptors 3
donating 3
eculizumab, 3
redefine 3
Nephrology 3
(HUS), 3
hematuria, 3
bruises 3
FFP 3
microangiopathy. 3
heighten 3
Rico: 3
prodrome, 3
diarrhoea-associated 3
empyema 3
STEC 3
Asociación 3
1974. 3
Penetrance 3
assorted 3
(GLP-1 3
GLP-1, 3
amide. 3
two-way 3
obese) 3
biceps, 3
flexed, 3
(SPA) 3
(-1.1 3
rope 3
yrs, 3
(295 3
min); 3
(288 3
(4.3) 3
SIE. 3
(11.5 3
low-fat, 3
Insulin, 3
pre-exercise 3
~16 3
curve: 3
appetite-related 3
postprandially 3
rested. 3
(3-h 3
post-breakfast 3
post-exercise). 3
EI, 3
ghrelin; 3
cholecystokinin 3
"stress" 3
(gastrin, 3
(norepinephrine, 3
GH) 3
Exercise-induced 3
SRIF-LI 3
(HCCCs) 3
motility-associated 3
275, 3
Smad2. 3
dynein-mediated 3
(RFC) 3
(consistent 3
p=0.0001) 3
1.54, 3
symptoms) 3
(81.5%) 3
Netherlands: 3
IAT. 3
retraction, 3
None. 3
endometriosis-associated 3
diagnosable 3
Adhesions 3
colectomy, 3
Hartmann's 3
Maternity 3
Alexandria. 3
nulligravidae 3
(AOR)=4.0, 3
(2.2-7.6)]. 3
[AOR=6.1, 3
(2.9-12.8)]. 3
[AOR=3.5, 3
(1.89-6.71)]. 3
[AOR=1.2, 3
(1.19-1.43)]. 3
Nulliparous 3
gastroenterologist, 3
Defecation 3
Referral 3
defaecation 3
Coloproctology 3
bloating 3
4.7-5.7]), 3
7.2-9.3]), 3
3.5-4.5]), 3
subfertility 3
6.9-9.9]), 3
postcoital 3
5.7-8.2]), 3
5.7-9.4]), 3
1.3-1.8]) 3
2.5-3.6]). 3
co-morbidity. 3
UK's 3
3.1-3.9]). 3
2.2-2.8]). 3
P2X3 3
colon-specific 3
10%-15% 3
afferents, 3
sure 3
gynaecologic 3
survivors--results 3
(long-term) 3
1,448 3
1,135 3
(78.4 3
provision. 3
Survivorship 3
North-Middle 3
QLQINFO25, 3
(α>0.70) 3
(α>0.90) 3
(0.67) 3
>0.70). 3
(r>0.40) 3
(r<0.30). 3
QLQ-INFO-25 3
representations, 3
desires 3
questionnaire: 3
INFO 3
international/multi-cultural 3
(NT-pro-BNP) 3
[A], 3
(1.62 3
one: 3
[cTnT] 3
cTnI, 3
100-km 3
ng/L) 3
ng/L; 3
growth-regulating 3
(28%). 3
cytoplasmatic 3
(BNP), 3
myoglobin 3
(R2 3
R2 3
0.2), 3
1.31 3
estrogen-progestin 3
1.29, 3
1.40-fold 3
Estradiol-only 3
56.6 3
557 3
(heterogeneity 3
oestrogen-progestagen 3
2.4, 3
1.79; 3
1.18-2.71) 3
Guidance. 3
psycho-educational, 3
self-referred, 3
SMARTLog 3
Within-subject, 3
univariate, 3
Individualized, 3
personally-tailored 3
645 3
3.78, 3
2.79, 3
interactive, 3
on: 3
Tailoring 3
IHCAs 3
Sotos, 3
p.Leu1815Trp 3
p.Gln274* 3
(www.sanger.ac.uk/genetics/CGP/cosmic/) 3
NUP98 3
MLL2, 3
paths; 3
inclined 3
(AMG145), 3
(AMG145) 3
(HDL-C), 3
1252 3
(non-HDL-C), 3
56.8 3
(Lp)(a) 3
plasminogen-like 3
apolipoprotein(a), 3
isoform-independent 3
24.5% 3
(20.4% 3
28.7%) 3
0.5134; 3
0.5203; 3
≤125 3
>125 3
ezetimibe-controlled 3
LDL-C, 3
watch 3
ramucirumab, 3
evolocumab+SOC 3
[SE, 3
achievable. 3
(TESLA 3
B): 3
funder 3
(RUTHERFORD-2): 3
(MTP) 3
ALN-PCS. 3
[PCSK9 3
MTP 3
alirocumab) 3
evolocumab) 3
apheresis. 3
let 3
hypolipidaemic 3
(HeFH) 3
(atorvastatin 3
mg], 3
intolerance: 3
QM 3
MENDEL-2 3
monthly. 3
AEs, 3
liter) 3
ultracentrifugation, 3
(±SE) 3
YUKAWA 3
AE. 3
(UCE) 3
SUPR-associated 3
pre-RNA 3
SNORD123, 3
U70C 3
ACA59B 3
Evf-1, 3
Evf-2. 3
poly(rC) 3
(PCBP2) 3
PCBP2 3
590-bp 3
(T-UCR) 3
K-12 3
5-fluoro-2'-deoxycytidine. 3
dcm 3
K-12; 3
CCA/TGG. 3
5-fluoro-2'-deoxycytidine 3
C5-C6 3
Self-methylation 3
MTase. 3
C.G 3
T.A 3
(cytosine-5-)-methyltransferase 3
base-flipping 3
carbocyclic 3
groove, 3
destination. 3
tumor" 3
(ICM) 3
pPNET 3
HD-CAV 3
77%; 3
Ganglioside 3
HNK-1, 3
(N-CAM), 3
P61 3
N-CAM, 3
HNK-1-defined 3
(SRCTs). 3
SRCT 3
t(11;22)(q24;ql2) 3
rhabdomyosarcomas 3
gathered. 3
t(11;22)(q24;q12). 3
preselection 3
(GLI1, 3
SPHK1, 3
SHROOM2, 3
PDLIM3, 3
OTX2) 3
Hh-nonactivated 3
Crosstalk 3
colocalization. 3
experiments). 3
BFU-E, 3
(FA[C]) 3
FAC- 3
(neo 3
FAC-corrected, 3
(CTG)n, 3
(CAG)n, 3
(CGG)n, 3
(GAA)n, 3
neuron-like 3
Double-R-loop 3
(FXS) 3
copurifying 3
class-switch 3
(AID). 3
CSR 3
adenohypophysis 3
(MAS), 3
hyperfunction 3
adenomas: 3
soma- 3
totroph 3
[Aryl 3
adenomas]. 3
disfunction 3
aryl-hydrocarbon-receptor 3
thyrotropinoma 3
R81X 3
Neoplasia 3
(11q13) 3
extra-pituitary 3
15-25% 3
[Familial 3
[Multiple 3
coreceptors. 3
adenoma: 3
FIPA: 3
2p16-12; 3
3q28; 3
4q32.3-4q33; 3
8q12.1, 3
Q315X, 3
acromegaly, 3
microadenomas 3
hand: 3
spin-labeled 3
(A8V). 3
history-negative 3
TnC-extracted 3
cTnC-A31S:50% 3
cTnC-WT 3
cTnC-WT, 3
myofilament, 3
(TNNC1) 3
(c.363dupG) 3
(c.363dupG 3
p.Gln122AlafsX30) 3
D145E) 3
D145E. 3
HCM-susceptibility 3
parameters). 3
(SL) 3
2.0-fold 3
C-L29Q, 3
leucine-glutamine 3
(EAP) 3
three-arm 3
abstinence, 3
four-item 3
styloid 3
Gan 3
Men, 3
(20.3%) 3
Points 3
3.10), 3
41.1% 3
acupuncture-education 3
smoking; 3
Singapore, 3
Volunteers 3
electroacupuncture 3
YFP-tagged 3
(MeDIP) 3
replication-linked 3
Chromocenter 3
kryptonite 3
9-specific 3
H3methylK9 3
'histone 3
code' 3
spermatocytes, 3
marsupials, 3
(H4K20me3, 3
H3K9me3). 3
DCAF 3
telomerase-derived 3
85-90 3
(n=5)]. 3
I-II). 3
1001‑specific 3
(DTH, 3
telomerase‑specific 3
ras‑specific 3
(antigenic 3
spreading) 3
(TeloVac): 3
proportion. 3
2-4, 3
1062 3
772 3
(peptide 3
covered. 3
platin 3
year: 3
Telomerase-specific 3
IκBs. 3
SCF(β-TrCP) 3
IκBs 3
(CLU) 3
(beta-TrCP), 3
IkappaB-alpha 3
CLU. 3
IkappaB. 3
betaTrCP1, 3
vivo), 3
IkappaBs, 3
ubiquitination-dependent 3
IKKbeta. 3
5%-22% 3
/AKT 3
immuno-histochemically. 3
TGF-β/Smad 3
phosphory-lation. 3
ERK/Akt, 3
(CDDP) 3
(RTKs)(1) 3
(HGFR/c-Met) 3
autocrined 3
(rh-HGF) 3
E7050 3
translation-dependent 3
scatter, 3
HGF+EGF 3
PI3k-Akt-dependent 3
FLIPL, 3
Fas-related 3
cardiogenesis, 3
Nkx 3
alpha-MHC, 3
(XIAP), 3
livin, 3
C-Met 3
50). 3
HGF/C-Met 3
N1/N2 3
N0 3
Akt-XIAP 3
5-Bromo-2'-deoxy-uridine 3
HGF/SF-mediated 3
UVB-damaged 3
(Met; 3
Saulnier 3
Res., 3
222: 3
360-369, 3
serum-starved 3
Met; 3
Rahimi 3
271: 3
24850-24855, 3
PKB/Akt 3
Victoria, 3
Myocarditis 3
biopsies), 3
register-based 3
maternity 3
0.89; 3
1818 3
(1.11, 3
small-for-gestational-age 3
0.91) 3
primigravida 3
(330 3
(7.3%) 3
657 3
(Swine 3
Flu) 3
Pregnancy. 3
2009/2010 3
5-65 3
(Modder, 3
(CMACE). 3
www.cmace.org.uk, 3
(Yates 3
Technol 3
14(34):109-182, 3
A[H1N1]pdm09) 3
mothers; 3
688 3
stillbirth, 3
trimester) 3
pdm09 3
Liaoning 3
(BHC) 3
Hypoperfusion 3
staggering 3
(p.Val205Phe) 3
Clathrin-coated 3
(PRKAR1A) 3
(FRET)-based 3
(PRKAR1A/PKAI) 3
PRKAR1A/PKAI 3
PRKAR1A/PKAI, 3
(PRKAR2B/PKAII) 3
PRKAR1A, 3
PRKAR1A/PKA 3
PRKAR1A's 3
Ialpha 3
Transcutaneous 3
McGill 3
setbacks 3
Melting 3
Duplexes 3
Phase-I 3
(GRN163L)--telomerase-based 3
quo 3
off-label. 3
(ustekinumab, 3
IL-31, 3
TSLP, 3
CRTH2. 3
Dupilumab: 3
37%) 3
(>2-fold 3
(K16 3
MKI67), 3
(CD1b 3
CD1c) 3
TH2-associated 3
(CCL17, 3
CCL22, 3
CCL26) 3
TH1-associated 3
(IFNG). 3
TH2-centered 3
hyperresponsiveness 3
filaggrin 3
IIIa/c) 3
multisuture 3
reoperation, 3
GNAS, 3
alpha-stimulating 3
PHP1A), 3
(FGFR2, 3
dup(5q) 3
runx2. 3
identitifed 3
(OSE2) 3
OSE 3
supershifts 3
Runx2(-/-) 3
p2213. 3
p325 3
(p.D68N) 3
association: 3
reassigned 3
RAPADILINO 3
genealogy 3
IIIc) 3
P253R 3
cadherins 3
FGFR-2 3
(943G 3
Ala315Ser) 3
enlarges. 3
VACTERL 3
hematopoetic 3
4p. 3
epiphyses, 3
seminoma 3
startling 3
eukaryotes' 3
Assignments 3
19-24 3
interpretative 3
First-in-Class 3
Palbociclib 3
Could 3
Usher 3
HER2-negative, 3
(PD-0332991) 3
Accrual 3
20.2 3
0.508, 3
none, 3
Deafness 3
features) 3
7q31. 3
deafness; 3
PDS. 3
7q22-31.1. 3
Currents 3
vibrating 3
densitometry. 3
underproduction 3
chloride/iodide 3
138. 3
-1G>A) 3
1231G>C 3
(A411P). 3
412G>T 3
(V138F). 3
96. 3
(125)iodide 3
T717A 3
forskolin. 3
(UTI) 3
area: 3
end-points. 3
ipragliflozin 3
0.024) 3
ES/PNET 3
monoisotopic 3
MASCOT 3
fimbrial 3
1DE 3
(SIL) 3
microdissection, 3
CD90(+) 3
cleanup 3
sample), 3
reactor 3
Aided 3
reactor, 3
endoproteinases 3
sulfide, 3
DSR 3
ZG 3
ERF, 3
(refs. 3
2,3,4,5,6,7), 3
(premature 3
sutures) 3
Erf 3
synostosis; 3
RUNX 3
nephrologists 3
oxygen-free 3
(NGAL), 3
avoidance-endurance 3
underuse 3
overuse 3
RMDQ 3
operant 3
punishment 3
activity-related 3
(CLBP) 3
performers 3
Chapters. 3
weekdays 3
allocate 3
SETTING: 3
MEASURES: 3
pilot-study 3
standing, 3
participant's 3
occupational, 3
teachers 3
accelerometry. 3
leisure 3
Nighttime 3
moderator 3
Endurance 3
technique). 3
high-quality, 3
457 3
versions. 3
JASPAR-the 3
subcollection, 3
profiles-with 3
immunoprecipitation-seq 3
subsetting. 3
BioPython 3
photophobia) 3
IFAP/BRESECK 3
dysplasia/hypoplasia 3
(BRESEK 3
(BRESHECK 3
months-old 3
p.R429H 3
rectourethral 3
IFAP. 3
hypotrichosis, 3
ichthyotic 3
bald 3
acitretin. 3
candidiasis, 3
hernia: 3
inexorable 3
urticaria, 3
(8.5%) 3
(1.5%). 3
ssociation 3
P2Y12). 3
1,200-mg 3
75- 3
CYP2C19*1*1 3
(9%, 3
(51%, 3
(Australia 3
Registry; 3
ACTRN12606000129583). 3
revascularization) 3
75: 3
*2, 3
*3) 3
GDSCs. 3
GDSCs 3
.CONCLUSION 3
(95.8%) 3
61.7-67.3) 3
52.5-69.5) 3
0.43-0.92; 3
.016), 3
O(6)-DNA 3
methylguanine-methyltransferase 3
2-months' 3
LSDs 3
Ppargc1α 3
Ppar1α. 3
V-ATPases 3
V-ATPase. 3
V-ATPases. 3
V-ATPases, 3
progranulin-deficient 3
Progranulin 3
(PGRN) 3
Lamp1, 3
Lamp1-positive 3
GRN-deficient 3
nissl-positive 3
fluoro-jade 3
B-positive 3
MTORC1-mediated 3
MTORC1-dependent 3
coatings 3
nanoceria 3
autophagy-lysosomal 3
gemfibrozil, 3
crossroads. 3
autophagy-lysosome 3
positive-feedback 3
mid-cell 3
re-emerged 3
microgel 3
fluorochrome, 3
microgranular-fibrilar 3
β-lactams 3
assure 3
subtilin 3
epidermin 3
PG-binding 3
antibiotic-induced 3
nucleoside-lipopeptide 3
LL-AA896. 3
(MIC 3
mug/mL). 3
muraymycin 3
(ED50 3
ramoplanin: 3
cyclicdepsipeptide 3
UDP-muramyl-pentapeptide 3
UDP-muramyl-pentadepsipeptide 3
N-acetyl-[14C]glucosamine-labeled 3
membrane-plus-wall-fragment 3
Aerococcus 3
viridans 3
lactate-containing 3
D-alanine, 3
alrA 3
smegmatis. 3
D-cycloserine. 3
2.56 3
MurA, 3
enolpyruvyl 3
sub-MIC 3
fosfomycin. 3
UDP-GlcNAc 3
alanine-alanine. 3
time; 3
(5%); 3
vorinostat-bortezomib 3
(340 3
anti-epileptics 3
MFI 3
(P=0.0260) 3
(P=0.0141) 3
irinotecan-bevacizumab. 3
(XRT) 3
(VEGFA) 3
VEGFA/VEGFR2 3
completion). 3
(OS; 3
(amplification 3
(North 3
interruptions. 3
3); 3
EIAEDs. 3
(PFS-6), 3
(9; 3
Tiredness 3
(temozolomide). 3
HRQOL, 3
>or=10 3
progressing. 3
TP-38 3
exotoxin, 3
convection-enhanced 3
1950's 3
halogenated 3
1985, 3
"early 3
toxin: 3
Material 3
CRM197 3
Bevacizumab, 3
43%. 3
%); 3
(TTD) 3
sulfur-deficient 3
complex". 3
shafts, 3
Trichothiodystrophy 3
freely. 3
osteosclerosis 3
hair) 3
genetically-induced 3
designations. 3
brittle, 3
(AHR), 3
(IL)-17A. 3
AHRR, 3
IL22, 3
IFNG, 3
TBX21, 3
IDO1 3
Two-colour 3
(mo-DCs) 3
benzo(a)pyrene 3
(BaP) 3
AHRR 3
TBX21 3
mo-DCs 3
mo-DC 3
PolyI:C, 3
(IDO)1 3
IRAK4 3
Migratory 3
(rheumatoid 3
(PMN), 3
CCL21 3
monocyte/macrophages 3
(HOX) 3
chicks. 3
double-staining 3
3.1; 3
1.08-1.18, 3
5.11, 3
3,285), 3
2.34, 3
(neuroticism: 3
1.2-3.5), 3
(conscientiousness: 3
0.4; 3
0.2-0.9) 3
5.2; 3
0.6) 3
3.33, 3
percentile) 3
clinical-pathologic 3
Hypotheses 3
.06). 3
conscientiousness. 3
uninvestigated, 3
Agreeableness, 3
informant 3
neuroticism. 3
(N1), 3
Assertiveness 3
(E3), 3
(E4). 3
Rated 3
Ideas 3
(p=0.013). 3
inpatients, 3
type: 3
Immunosuppressive 3
mTOR-targeted 3
anti-VEGFR 3
Sirolimus 3
potential) 3
Line. 3
INS1). 3
70S6K. 3
Akt: 3
comparison). 3
(WMD, 3
-18.31 3
-30.96 3
thrombocytopenia: 3
anaemia: 3
4.27 3
mL/min; 3
higher-dose 3
CNI, 3
-9.46 3
-12.16 3
CNI. 3
disturbance). 3
hard-endpoint 3
(TOR-I; 3
(sirolimus, 3
0.65) 3
(c3-eQTLs) 3
pQTLs. 3
c3-eQTL 3
QTT 3
phenotype-based 3
Noteworthy 3
subseqent 3
CWS-study 3
80-90 3
[bone 3
(PNET)]. 3
transcription)-PCR. 3
CWS 3
(Cooperative 3
Weichteilsarkomstudie, 3
CWS-91 3
CWS-96) 3
Euro-E.W.I.N.G. 3
-primer, 3
amplifiable, 3
Thereof 3
(I. 3
Kiel, 3
investigations) 3
ES/pPNETs 3
10/13 3
13/13 3
ES/pPNETs, 3
EWS-Fli1-positive 3
.008), 3
.014) 3
SK-NEP-1 3
(EFTs). 3
EFTs, 3
(24.1 3
Therapeutically, 3
(17.8 3
negativity 3
tissues]. 3
(P2), 3
(P1). 3
runx1. 3
CREs. 3
CTCF) 3
virus-immortalized 3
episome 3
packaging. 3
~24,000 3
within, 3
read-depth 3
∼5 3
Higher-order 3
Scc3/SA1 3
conformation? 3
(NAD)-regulated 3
(CTCF)/cohesin 3
Parp 3
Compaction 3
~2.5-Mb 3
D(H)-J(H) 3
DFL16 3
(Eμ), 3
D(H)-J(H)-Eμ-C(H) 3
D(H) 3
cohesins. 3
ORF50, 3
RTA. 3
revealded 3
∼1-2 3
(TIF) 3
subtelomeres, 3
(YFP) 3
Cerulean 3
YFP. 3
nonfluorescent 3
(S/N) 3
non-fluorescent 3
cytometer. 3
1/500 3
postulated, 3
(CMs) 3
CMs 3
(PubMed) 3
16p, 3
10%). 3
(CREB-binding 3
aliquoted 3
script 3
amplicon. 3
six-year-old 3
(46, 3
16p13.3. 3
4-6) 3
c.2728A 3
0.5-1% 3
(RSTS), 3
(CH1, 3
CH2, 3
CH3) 3
smut. 3
broadly, 3
kingdoms. 3
defensin, 3
Medicago 3
defensins, 3
MtDef2, 3
RsAFP2, 3
tritici) 3
(Tilletia 3
maydis-infecting 3
(UMV4) 3
symbiosis 3
five-stranded 3
beta-sheet. 3
scorpion 3
Deaf1. 3
clone-forming 3
Deaf1, 3
PUM2, 3
snoRNA-derived 3
(MTIs) 3
photoactivatable-ribonucleoside-enhanced 3
miRNA-RNA-protein 3
439 3
GLD-1 3
(PTGR) 3
RBP. 3
RBP-binding 3
PTGR 3
Photo-Activatable 3
Ribonucleoside-enhanced 3
CrossLinking 3
ImmunoPrecipitation 3
surmount 3
pull-downs 3
low-complexity 3
Protein-RNA 3
(UV 3
immunoprecipitation) 3
(Figure 3
4.7-fold 3
glucocorticosteroids, 3
TPOAb, 3
TRAb 3
TMNG 3
MBq). 3
iodine-rich 3
(900 3
carbimazole 3
Paraparesis 3
(infancy 3
childhood) 3
(SD). 3
Analysis; 3
kinematics 3
hyperammonemic 3
argininemia. 3
split-screen 3
OGS. 3
intrarater 3
mid-stance, 3
reliabilities 3
(wk 3
(GA). 3
distinguish, 3
clearly, 3
lengthening. 3
Etiologic 3
one-minute 3
nonhandicapped 3
ankles 3
[Purpose] 3
(CP). 3
(ankle 3
dorsiflexion, 3
GMFM 3
dimension. 3
assistive 3
anti-phase 3
HIVE 3
(p=0.001). 3
(despite 3
[TUG] 3
Stairs 3
sit-to-stand 3
[STS] 3
tetraplegia 3
STS, 3
intercorrelations 3
LSU, 3
user-friendly. 3
(GMFM-88), 3
Biodex 3
microsatellite/restriction 3
MPNSTs). 3
LOH-negative 3
LOH-positive 3
microlesions 3
(IVS7-2A>G, 3
3731delT, 3
6117delG) 3
(1888delG, 3
4374-4375delCC, 3
R2129S, 3
2088delG, 3
2341del18, 3
4083insT, 3
Q519P) 3
(R2429X) 3
cloning/sequencing. 3
PTP, 3
(SeP) 3
Whole-mount 3
migrates 3
803 3
TGAs 3
(viewpoint) 3
(PIPs) 3
Decision, 3
applicants, 3
waiver 3
1,282 3
FUS: 3
ALS? 3
publications). 3
(PABP). 3
(pfy1Δ). 3
pbp1Δ, 3
pfy1Δ. 3
ATXN2, 3
PBP1, 3
ataxin 3
0270-6474/14/348083-15$15.00/0. 3
cords. 3
proteinopathy, 3
APC-RNP 3
silent. 3
sorbitol 3
Transactive 3
aminoacidic 3
organelles; 3
RFP-LC3-positive 3
FUS/TLS. 3
neurodegeneration: 3
scar-based 3
cardiomyocyte-based 3
(Cx43), 3
factor-A, 3
fibrin. 3
matures, 3
(53 3
endogenic 3
typology 3
Psychologists, 3
(0.261 3
L-allele, 3
0.522 3
L-alleles, 3
religiosity, 3
paroxysms 3
2.37) 3
(empirical 3
.209). 3
Biometric 3
families). 3
endowments. 3
OPC. 3
OPC, 3
Cmax, 3
BIA 3
cannulas 3
(12/3 3
(3-OMD) 3
∼76-84% 3
1.7- 3
2.3- 3
2.4-fold, 3
administrations. 3
gender-balanced, 3
interval). 3
(Cmin) 3
opicapone) 3
entacapone) 3
opicapone). 3
(Cmax)) 3
(AUC)) 3
AUC. 3
Emax) 3
effect-time 3
(AUEC)) 3
(AUEC) 3
(Emax 3
sustainably 3
(MPR) 3
6-phosphate, 3
Man6P 3
cholesterol-binding 3
Man-6-P-containing 3
MPR-purified 3
subproteome 3
(11;22)(q24;q12) 3
"knock-down" 3
Neuroblastoma-Ews/Fli-1 3
RY 3
orc/cdc6-adjacent 3
haloarchaea. 3
(proved 3
part) 3
ORBs 3
(origin 3
boxes) 3
orc/cdc6 3
origin-associated 3
Orc/Cdc6 3
ORB 3
haloarchaeon 3
haloarchaea 3
(oriC1) 3
Wigglesworthia 3
Cnidaria, 3
replications 3
calidifontis 3
O2, 3
furthest 3
crenarchaeon 3
Sulfolobus. 3
higher-level 3
acidocaldarius. 3
oriC2 3
oriC1 3
uniformity 3
cdc6/orc1 3
decatenation. 3
accumulating, 3
skin-colored 3
nasolabial 3
epithelioma 3
c.1462delA 3
(P.Ile488fsX9) 3
c.2128C>T 3
Gln710X) 3
c.2822A>T 3
Asp941Val) 3
Brooke-Spiegler, 3
TRK 3
TRKB 3
TRKC 3
Membranous 3
spiradenomas 3
periauricular 3
abluminal 3
basal/myoepithelial 3
Apocrine 3
16q. 3
intra-familial 3
16q 3
Snail. 3
9q22.3 3
(TEs) 3
ever, 3
(CYLD(C/S)) 3
cyld 3
oncogenicity 3
(carrying 3
(BCCs), 3
trichoblastoma 3
signet 3
[52%] 3
2272C>T 3
(R758X) 3
5q13 3
2,3), 3
neuron) 3
SMN1/SMN2 3
exon-skipped 3
SMNDelta7 3
minigenes 3
pseudogene, 3
SMN-deficient 3
pontocerebellar 3
invariably, 3
lentiginosis. 3
Ca2+/CaM-dependent 3
lentiviral-mediated 3
inactivity-induced 3
KN-92, 3
Manduca 3
viz., 3
HIF-1-dependent 3
BAPTA-AM 3
(CaM) 3
171) 3
CPE-binding 3
Depolarization 3
PKC-delta 3
VSM 3
12,13-dibutyrate 3
zygotes 3
oocysts 3
ionophores 3
p56(Lck). 3
Ca++-induced 3
(ICa); 3
ICa. 3
ICa-dependent 3
=.024). 3
KN-93- 3
=.015). 3
p27kip1 3
washout. 3
VSMC. 3
PC12h 3
(CMT1A), 3
CMT1. 3
CIDP. 3
HNPP 3
(baclofen, 3
Rer1 3
PMP22(L16P) 3
Methionine 3
Marie 3
(PMP22, 3
CMT1, 3
SH3TC2 3
signified 3
17p12 3
parechoviruses 3
CB3 3
susceptibility-weighted 3
Ccm1 3
CCM3) 3
(CCMs). 3
951 3
Krit1B: 3
gene-1. 3
736-amino 3
ICAP1A 3
Krit1B, 3
Krit1B/Krit1A 3
exon/gene-prediction, 3
Krit1A 3
noninherited 3
mapped, 3
MGC4607 3
TF-1 3
meninges. 3
sibling. 3
fortuitously 3
pseudoexon 3
tingling 3
haemorrhages. 3
7p, 3
Mct8-deficient 3
rT(3) 3
"Key 3
infarction; 3
pg/mg, 3
DITPA-treated 3
worsened, 3
BVD 3
dimension, 3
microg/100 3
1,236 3
dysuria. 3
(TCs). 3
Perineural 3
herniation. 3
Planar 3
consultations. 3
8-month 3
lipids: 3
(n=53), 3
difference-in-means 3
[-0.29; 3
-0.06] 3
(-7.0 3
[-11.2; 3
-2.50] 3
mg/dL); 3
vildagliptin) 3
CYP-mediated 3
dipeptidylpeptidase 3
dutogliptin 3
metformin: 3
active-controlled, 3
(-3.7 3
Hypoglycemic 3
Peptidase-4 3
(MH-OR) 3
0.93[0.51-1.69]; 3
(MACE), 3
www.clinicaltrials.gov, 3
20,312 3
13,569 3
DPP4i, 3
1.020 3
[0.742-1.402]; 3
(0.786 3
[0.357-1.734], 3
0.55), 3
0.689 3
[0.528-0.899], 3
2.13), 3
0.85), 3
0.001] 3
-0.74), 3
(ALOG), 3
(SAXA), 3
(SITA), 3
(VILD). 3
2.63 3
dipeptidylpeptidase-IV 3
reassuring 3
(DPP)-4 3
linagliptin. 3
-0.60) 3
1.41; 3
alogliptin) 3
alogliptin). 3
(statins), 3
agents), 3
[rifampin]) 3
diltiazem) 3
(IGHV) 3
44.7% 3
IGHV4 3
(12.5%), 3
15.3% 3
1H-NMR 3
(IGHVs) 3
(ZAP70) 3
(n=29) 3
glycerol, 3
PLS-DA 3
ZAP70 3
tryptophan. 3
Dopa, 3
methylphenidate, 3
(DRS; 3
discontinued) 3
NCT00970944.). 3
(DOC) 3
wakeful, 3
(PK-Merz) 3
0.28), 3
commands 3
(MMP)-9 3
[Assessment 3
1.39; 3
NET-externalised 3
externalised 3
B/matrix 3
metalloproteinases-1 3
hydroxamates 3
inspire 3
odors, 3
Olfactory 3
enterotoxin 3
food-borne 3
MLVA 3
analysis), 3
Iran 3
258 3
(21.8 3
cheese 3
limit, 3
BoNT/C 3
[Botulinum 3
dosis 3
1817, 3
blood-brain-barrier 3
cleft. 3
sausage 3
A30P, 3
leukodystrophy: 3
neuroradiologic, 3
Leukodystrophy 3
(initially 3
geneticist, 3
specialist, 3
Swallowing 3
Leukodystrophies 3
tremor-ataxia 3
(TACH) 3
10q22.3-23.1 3
TACH 3
TACH, 3
4H, 3
LO, 3
leukodystrophies 3
nuclear-coded 3
leukodystrophy-3, 3
complex-interacting 3
(AIMP1). 3
(centered 3
-59 3
(R.L. 3
Thomas, 3
hsp26, 3
nucleosome-free, 3
R.L. 3
inducibility. 3
maximum-likelihood 3
allotetraploid 3
[Is 3
CCGG 3
DRM2 3
5m 3
Rad23, 3
(DNA-METase) 3
meristems 3
Polyclonal 3
DNA-METases 3
591 3
inflorescence 3
SWI2/SNF2 3
PAI 3
1534 3
methylases, 3
alpha-satellite 3
Partially 3
missegregation 3
BubR1, 3
Cenpc. 3
sequence-independent 3
gamma-irradiation 3
neocentromeres 3
CENPC 3
Undifferentiated 3
anti-CENPI 3
(62.5%) 3
kinetochores. 3
assembling, 3
suvh4 3
suvh5 3
suvh6 3
Otx2 3
Fgfr1, 3
gypsy 3
blastopia 3
CHARGE-like 3
Coloboma, 3
choanae, 3
(CHARGE) 3
(chromodomain) 3
serine-42, 3
Cbx2. 3
lysine-27, 3
TMPRSS2 3
penetrant. 3
bulbs, 3
Glomerular 3
methylation-mediated 3
hPc2. 3
CReMM, 3
(chromatin-related 3
modulator). 3
SNF2/ATPase, 3
A/T-DNA-binding 3
(DBD). 3
mobility-shift 3
Chromodomain-containing 3
Zeste 3
(MORF-related 3
(MRG15-associated 3
coil-coil 3
MAF1, 3
hMOF, 3
intracellularly, 3
9-methylated 3
energetic, 3
methylammonium 3
caged 3
senescence-inducing 3
SSRP1 3
ATPase/helicase-like 3
LBR 3
CHD-1, 3
Th 3
¹H, 3
¹³C 3
¹⁵N 3
CHD3, 3
(ACHN 3
untransduced 3
including; 3
mei4 3
OFT. 3
NCCs, 3
H3-binding 3
PICKLE 3
hypocotyl 3
PKL/EPP1 3
hypocotyls 3
hydratase 3
Cdyl+/+ 3
(MBD2) 3
Z., 3
p66α-MBD2 3
acetyltransferases, 3
agriculturally 3
ATPase/helicase 3
(135 3
(PGC) 3
(mRNA: 3
H3T3, 3
(HP1). 3
crystallographically 3
(H3K9me) 3
Ser-473 3
SETDB1, 3
genesis, 3
selector 3
PS1/PS2 3
bradykinin, 3
lineage-determining 3
CDP-2, 3
tumor-inducing 3
(HOS) 3
nude/SCID 3
(PPT) 3
cleavage). 3
loss) 3
coregulators 3
promyelinating 3
Egr2 3
leptotene/zygotene 3
36.5 3
mm(3). 3
CGH, 3
HIS-24K14me1 3
trimethyllysine. 3
H3K9Me(2) 3
H3K9Me(3) 3
chromatography-based 3
PRC2. 3
somitogenesis. 3
segmentation, 3
Cbx3-induced 3
168) 3
(SRF) 3
maldevelopment 3
mononucleotide 3
56.4% 3
HP1γ, 3
cation-π 3
Clr4/Suv39 3
H3-Lys-9-Me2 3
affinity; 3
ectoderm. 3
place, 3
Genomicus, 3
http://www.dyogen.ens.fr/genomicus 3
ftp://ftp.biologie.ens.fr/pub/dyogen/genomicus. 3
Anti-arrhythmic 3
DIAMOND-CHF 3
ICDs, 3
ICDs. 3
'broad 3
spectrum' 3
pro-arrhythmia, 3
Digoxin, 3
Macrolides, 3
Floroquinolones 3
[Recent 3
lengthen 3
effects). 3
effects), 3
neferine 3
groups), 3
death]. 3
DE-CMR 3
LA. 3
Cine 3
42+/-17 3
681+/-249 3
9%+/-11% 3
(102/192) 3
%DE 3
(r=-0.3; 3
(r=-0.4; 3
1,063 3
0.045), 3
1.53 3
hyperenhanced 3
syncope) 3
HCMshowed 3
0.001], 3
(VT). 3
(TBE) 3
(Flavivirus 3
polyspecific 3
debated, 3
Shh-mediated 3
(CGNPs) 3
differentiator 3
Gene-1 3
velcade. 3
down-regulation, 3
oxide-mediated 3
TGF-beta-inducible 3
TGF-beta-regulated 3
NO-mediated 3
quinazoline-based 3
alpha1-adrenoceptor 3
(TGF-beta 3
effectors: 3
cows. 3
DGAT1, 3
(HepG2 3
TGF-β1-resistant 3
factor-β-inducible 3
antimetastasis 3
G1-phase 3
(AdTIEG1) 3
C2C12. 3
(HPV-16) 3
HPV-associated 3
(TIEG) 3
Bcl-XL. 3
piriform 3
Mdivi-1, 3
immunoprecipitation/immunoblotting 3
degenerated, 3
leading, 3
prohibitins 3
mitofusin-1 3
J2 3
(Mfn1 3
Mfn2) 3
∼40% 3
post-mitochondrial 3
(HSL), 3
exencephaly, 3
Na⁺/Ca²⁺ 3
stretch, 3
placebos 3
Aloe 3
(AV) 3
(tongue 3
day), 3
dysesthesia 3
Overlaps 3
(BMS). 3
concealment, 3
capsaicin, 3
alpha-lipoic 3
(France, 3
-the 3
10q23.3 3
mesodermal, 3
(follicular 3
subtype). 3
FTCs 3
FTC. 3
ceftriaxone-induced 3
axotomy 3
D7 3
glutamate-mediated 3
promoter: 3
Cu/Zn 3
expression), 3
(5.8%) 3
astrocyte-specific 3
x(c)(-) 3
anti-Babesia 3
verifiable 3
mefloquine. 3
minocycline, 3
arimoclomol, 3
neuroborreliosis 3
0·51 3
(gastrointestinal, 3
Stroke. 3
either: 3
(0-100) 3
ana-lysis 3
pleomorphism. 3
(Allred 3
<2, 3
15.5%) 3
HA, 3
IBAT 3
bout, 3
5'-D 3
supramaximal 3
(fT3), 3
14%), 3
13%), 3
21%). 3
0.52) 3
0.55). 3
pituitary-gonadal 3
Flight 3
(FFA) 3
FFA 3
joggers. 3
(rT3) 3
T3) 3
rT3) 3
90-km 3
cross-country 3
ski 3
pre-raced 3
Pseudogene 3
Lalaouna 3
(2015) 3
"backsplicing," 3
donor) 3
acceptor). 3
Lasda 3
Parker; 3
GcvB, 3
gltIJKL 3
1/intron 3
cholangiocytes. 3
atherosclerosis: 3
Era 3
(199 3
bisulfite, 3
0.42) 3
0.24). 3
(COMT, 3
DAT1, 3
GABRA1, 3
GNB3, 3
GRIN2B, 3
HTR1B, 3
5-HTT, 3
MAOB, 3
NOS1, 3
TPH1 3
TH). 3
(1.4% 3
(high- 3
low-MAOA) 3
underplaying 3
uVNTR's 3
nature: 3
CpGs, 3
transcription-factor 3
CGI-associated) 3
(IAS). 3
IAS, 3
(ASPD), 3
(ND)). 3
3,3 3
0.10). 3
MAOA. 3
nondesmosomal 3
(p.Arg14del) 3
Cys, 3
His, 3
multifaceted: 3
echocardiographic, 3
Arg9Cys 3
PLN-L39stop 3
null). 3
Ca2+-adenosine 3
myocellular 3
failure-a 3
accomplishing 3
absorptive 3
RQ 3
sec 3
optimal, 3
embark 3
isocaloric 3
chronically, 3
antioxidant-rich 3
(GPx), 3
rowing 3
(TBARS), 3
(P=0.08). 3
Heretofore, 3
Cr's 3
monohydrate 3
60-90 3
pyramid 3
(8-OHdG) 3
deny 3
nutritionist 3
.03 3
group's 3
adaptogen 3
Borg 3
IUs) 3
LP. 3
(TAA) 3
TAA. 3
unsaturation 3
acid-reactive 3
Soy 3
T; 3
(CMT2D). 3
C3H 3
low-efficient 3
non-useful 3
dual-detector 3
multiple-threshold 3
top-hat 3
detecting/counting 3
(M-FISH), 3
Orthogonal 3
Matching 3
Least 3
invokes 3
subjectivity. 3
segmentation. 3
from: 3
KDM4A 3
demethylates 3
Ezl2p 3
(HMT). 3
(H4K16ac) 3
(Zp) 3
ionophores, 3
Suv420h1, 3
Zp 3
methylations. 3
demethylases, 3
contribution. 3
DNMT3b) 3
enhances, 3
Partitioning 3
Suv39h1, 3
post-SET 3
(H3-K9). 3
Suv39h1 3
lysine-preferring 3
lacy 3
(epiphora, 3
ectropion, 3
entropion, 3
trichiasis), 3
(caries, 3
taurodauntism). 3
(Hoyeraal 3
Hreidarsson 3
(Revesz 3
vary: 3
(flow-FISH) 3
BMF: 3
abnormal; 3
self-examination 3
dermatologist; 3
non-leukodepleted 3
rupture); 3
X-linked: 3
DKC1. 3
dominant: 3
TINF2. 3
WRAP53. 3
DC-related 3
sparing, 3
7.52 3
pseudouridylation 3
H/ACA 3
partial) 3
leukoplakia 3
(Hoyeraal-Hreidarsson 3
21(miR-21) 3
(Ad-GFP 3
(Ad-miR-21 3
sham-surgery 3
(H&E). 3
glucose-free 3
(H/R). 3
LVSP, 3
+dp/dt(max), 3
dp/dt(min), 3
hypoxia/reoxygenation- 3
oncomiR. 3
miR-23a 3
miRs, 3
preconditioning-regulated 3
etc, 3
(ROS)-induced 3
pressure-overload 3
E3-ligase 3
Ring-domains 3
E2s 3
(BRCT) 3
GEM 3
(IL-6; 3
(HGF; 3
PBS. 3
5-Bromo-2'-deoxyuridine 3
(LC3)-II 3
proliferation-, 3
inflammation- 3
MC-University 3
(aspartate 3
3.2-fold 3
6.0-fold 3
42.3-fold 3
(HGF 3
cytostasis, 3
mitochondrion-associated 3
MAP1S 3
LC3-I 3
(LC3), 3
IIM. 3
Ras-independent 3
T80 3
punctae 3
NOD/SCID 3
p53-/-, 3
QC-mediated 3
PARP, 3
LC3B-II 3
EAV 3
DMVs 3
ER-derived 3
139, 3
(SAP), 3
B-T 3
Losing 3
Anti-Neu5Gc 3
signify 3
0.0003, 3
nanogram 3
apixaban: 3
(VKA). 3
pentasaccharide 3
etexilat 3
"direct" 3
heparins, 3
(Xarelto(®)), 3
(RE-LY 3
expecting 3
(Quick 3
dabigatran). 3
Anti-Xa 3
dose-adjustment 3
prohemostatic 3
PRD1 3
PRD2 3
notions, 3
ptsHI, 3
HPr 3
PTS, 3
540-base-pair 3
riboregulator 3
sigma-70 3
holoenzymes, 3
beta/beta' 3
holoenzymes 3
regulator,which 3
upshift, 3
pRNAs.Here, 3
stem(conserved 3
CRIV) 3
(conserved 3
CRIII 3
CRIV). 3
dimethylsulfate 3
pRNAs. 3
(264 3
copy-neutral 3
oligo-SNP 3
aCNA 3
cnLOH, 3
(CTNNA1 3
attests 3
Conditionally 3
BM-infiltrating 3
classically-affected 3
Y641C 3
21q22 3
repressed, 3
methylation/deacetylation 3
(P=0.06). 3
IDH1/2, 3
SRSF2 3
(ENPs). 3
Western-blot, 3
immunohistology. 3
43.75% 3
(14/32) 3
colons. 3
PCR-sequencing 3
(15.5%) 3
hypoganglionosis, 3
Hirschsprungs 3
transanal 3
(ET-3) 3
(EDN3). 3
transversions, 3
(messenger 3
(P<0.0001) 3
D2) 3
rewarding 3
"standard" 3
caveolins 3
cavins 3
indentation 3
homing. 3
SSD 3
Pre-incubation 3
SKF 3
Integrity 3
sphingolipids, 3
80S 3
begin, 3
erthyrocytes 3
Denucleation 3
Rearrangement 3
Fibrillarin 3
floret 3
microfoci 3
BAP 3
prohibitin. 3
remnant. 3
substructures 3
ultrastructure. 3
coprecipitating 3
nucleopolyhedrovirus 3
BmN 3
virogenic 3
(VS). 3
late-gene 3
occlusion-derived 3
marginalized 3
ie1, 3
lef3, 3
p143, 3
hsrω 3
Plasticity 3
endocycling 3
Me(3)K4 3
compartmentalization. 3
PML/SP100 3
NBs, 3
matrix: 3
(space 3
suprachromosomal 3
Mbp. 3
Gene-dense, 3
gene-poor, 3
C-bands. 3
"open," 3
arborized 3
agnostic 3
length; 3
fura-2 3
resensitization 3
Henseleit 3
56.8% 3
PHASE 3
(PRY/SPRY) 3
PRY-SPRY 3
multilamellar 3
TRIM67, 3
FN3 3
Ras-mediated 3
Strongylocentrotus 3
gustavus, 3
(SPRY 3
two-cell 3
postfertilization 3
whole-mount 3
(TRIM) 3
(TRIM5alpha) 3
nonsynonymous/synonymous 3
non-SPRY 3
Lineage-specific 3
13-aa 3
"patch" 3
SPRY-domain 3
SOCS-box 3
GUSTAVUS. 3
phosphosite 3
profiles) 3
coinheritance, 3
fusion-based 3
Methanobacterium 3
thermoautotrophicum, 3
661 3
non-POU-domain-containing 3
(NONO) 3
non-POU 3
(NONO), 3
Printed 3
(PSF) 3
MATR3 3
neocarzinostatin. 3
RNF43 3
PSF, 3
PSF 3
P54nrb 3
mSin3A 3
Gja1 3
PSPC1/NONO 3
co-expressed, 3
reading-frame 3
Ubiquitin-tagged 3
endocrine-resistant 3
(bortezomib) 3
Gynecologic 3
[1.5 3
mg/m(2)/dose 3
(CHOP) 3
mg/m2; 3
mg/m2), 3
(diarrhea, 3
>/= 3
PI. 3
AIPCa 3
ELG1 3
(RLC) 3
G(2)/M. 3
PJ34, 3
(TNM) 3
(AZD-2281, 3
Ku-0059436) 3
Noteworthy, 3
[33%] 3
[26%] 3
[35%] 3
[7%]). 3
AstraZeneca. 3
RAD18(-/-), 3
RAD18(-/-)/RNF8(-/-) 3
tablets, 3
10.9, 3
-associated 3
BRCA1/2-associated 3
piperlongumine. 3
(BER), 3
VEGFR2, 3
BCSC-enriched 3
(2-D 3
(TRbeta) 3
3-week- 3
Scales. 3
Rho-kinase 3
Ras/RhoA 3
Urothelial 3
(Y-27632) 3
glutaminase 3
pyridoxal 3
5'-phosphate 3
anabolism 3
one-carbon 3
rigid-body 3
STIM1 3
borate 3
ultrastructure, 3
ligand-gated 3
AMPA-Rs. 3
AMPA-R 3
spares 3
Canagliflozin: 3
Issues 3
reabsorbed 3
SGLT1, 3
dual-tracer 3
mixed-meal 3
(incremental 3
RaO, 3
63%, 3
(14.4%) 3
mUI/l; 3
p=0.014) 3
128) 3
pmol/L, 3
2.7; 3
(fT4) 3
p=0.004) 3
-77-bp 3
-77A-->G, 3
sorcin 3
(SRI), 3
(FKBP1B), 3
(CALR3) 3
(CALM). 3
(Asp63Glu). 3
photolesions 3
excitingly, 3
end-labeled 3
3-kinase-related 3
ggNER 3
DMSO-induced 3
MALDI-TOF-Mass 3
(P-TEFb). 3
CyclinT2/CDK9 3
initializing 3
Arg(+) 3
methanesulfonate-induced 3
operative, 3
Ad5HCMVsp1lacZ 3
XP-C 3
proficiently 3
reaches, 3
TCR-specific 3
RAD26, 3
UV-C 3
repair; 3
(CSB) 3
W303-1B 3
glycol, 3
6p25.3->p23 3
12q24.32->qter 3
6p. 3
12q. 3
transmittance 3
TAAD 3
angiopathy, 3
MTCP1/MTCP1NB 3
BRCC3. 3
moyamoya, 3
(ACTA2) 3
pseudoisodicentric 3
chromosome: 3
(25)/46,X 3
psu 3
idic 3
(Y)(11.2) 3
(BAV) 3
cm; 3
isochrome 3
Xq), 3
BAV). 3
ischemia; 3
suitable. 3
neurofibromatosis-1 3
steno-occlusive 3
17q25.3, 3
(lod) 3
8.07 3
D17S704. 3
crossovers 3
3.5-Mb 3
D17S1806 3
Leiden, 3
del(17)(p11.2p13.1). 3
aCGH, 3
17p11.2-p13.1 3
RAI1 3
crossover. 3
Four-vessel 3
FMMD 3
3p]. 3
non-expression 3
8q23. 3
[maximum 3
3.6] 3
12p12 3
(MLS=2.3). 3
GeneScan 3
3.11 3
D17S939. 3
(<1. 3
0x10(-5)) 3
D17S785 3
D17S836, 3
Koreans 3
3p24.2-p26. 3
3p24.2-26. 3
NPL 3
MM-DS 3
branch/3' 3
RNA/RNA 3
clan 3
(E) 3
stirred 3
bioreactor 3
lactose, 3
SpA-hIgG1 3
breakup 3
hIgG1 3
disengagement 3
(SPA), 3
(IEC) 3
(IgG). 3
biomimetic 3
triazine 3
22/8 3
Immobilized 3
Computer-aided 3
92%. 3
rifapentine, 3
(C57BL/6J--bgj/bgj) 3
four-drug 3
gastrointestinal. 3
rifampin, 3
nonvirulent 3
bronchus 3
forty-six 3
increases; 3
nontuberculous 3
multiple-drug 3
Clarithromycin 3
azithromycin. 3
23S 3
broth, 3
20-50% 3
Autoinflammatory 3
Colchicine 3
steroid-dependence 3
mellitus]. 3
intrapericardial 3
cardiomegaly 3
atelectasis. 3
ensues, 3
phakomatoses, 3
"hamartomas," 3
"two-hit" 3
(LKB1), 3
Yeung 3
Knudson, 3
Kobayashi 3
Hino. 3
under-emphasis 3
(Tsc2), 3
(chromo-ATPase/helicase-DNA 3
directionalities. 3
chromodomain-mutant 3
transcription-induced 3
permissible 3
Spt4-Spt5 3
chd1 3
arginine-methylated 3
(Z1041): 3
Neoadjuvant 3
September, 3
epirubicin: 3
(fluorouracil, 3
cyclophosphamide) 3
(30.6%) 3
1986, 3
595 3
207) 3
195) 3
Richardson 3
(Ann 3
dose-intensity 3
=.07). 3
DTX 3
T), 3
75). 3
43.6% 3
59.7% 3
(18.7%) 3
author, 3
tabulated. 3
GIK/T3 3
81) 3
=.013). 3
=.01). 3
micrograms/kg 3
cross-clamp, 3
transiently, 3
[+/- 3
vasodilators. 3
removal) 3
endeavor. 3
TRANSFAC. 3
clade-specific 3
MOPAT: 3
'orthologous' 3
B16F10 3
H2A.X, 3
bortezomib-resistant 3
NEDD8-binding 3
(CUL)-RING 3
microenvironment-driven 3
Substrate-assisted 3
protein-activating 3
NEDD8-AMP 3
E1s 3
neddylation-dependent 3
Vpx-mediated 3
Cerenkov 3
15-min 3
instrumentation. 3
synergizing 3
MLN4924/TRAIL-induced 3
>2) 3
(27%), 3
(GCB) 3
nucleolytic 3
CDT1 3
radiosensitization, 3
SERCA2a) 3
athletes; 3
'an 3
non-traumatic, 3
non-violent, 3
health'. 3
Athletic 3
work-up, 3
nivocarditis, 3
dilatative 3
mentioned, 3
GCVD 3
Multigene 3
objectivity 3
overlook 3
driven. 3
high-genomic 3
(BCSS) 3
0.036). 3
assays: 3
(p38) 3
CL100/MKP-1 3
(JIP-1) 3
AT1aR 3
30-60 3
expansion-induced 3
polyglutamine-mediated 3
delta-like 3
DSPs 3
threonine-tyrosine 3
arsenic. 3
17,000 3
Da, 3
IMGT, 3
ImMunoGeneTics 3
immunoinformatics. 3
Moléculaire 3
(RPI) 3
8,000 3
concepts, 3
(scFv), 3
displays, 3
IgSF 3
vertebrates; 3
IMGT/DomainGapAlign 3
(TR). 3
Bence 3
Jones 3
L3, 3
RdDM 3
numbers: 3
(1806 3
registers, 3
1.90, 3
participants).For 3
fallers, 3
participants).The 3
stroke.One 3
glasses. 3
2.25) 3
Tai 3
1.02; 3
(616 3
659 3
(305 3
2.72; 3
period: 3
IU/day 3
Mid 3
17-month 3
pre-intervention 3
alfacalcidol 3
procalcitonin, 3
1.69 3
2.36 3
P< 3
Assessment. 3
MNA 3
"failure 3
cutoff. 3
under- 3
clusters: 3
withstand 3
(23.1 3
(PpIX) 3
dermatology, 3
(5-ALA) 3
Escobar 3
(2014) 3
(enChIP). 3
(TAL) 3
IFNγ-responsive 3
IFNγ-mediated 3
genitalia, 3
autopod 3
discordance, 3
iPledge 3
less). 3
occasion, 3
pilosebaceous 3
FGF7 3
nullipara 3
(CTG) 3
Propionibacterium 3
tests? 3
1292 3
907 3
mg%. 3
6-micron 3
teratogenic. 3
(13-cis-RA) 3
ignores 3
RA) 3
toxicant. 3
Retinoid 3
31. 3
13-cis-RA. 3
13-cis-4-oxo-RA, 3
Gestational-age-dependent 3
(VITA) 3
(HCG) 3
(pre-HCG 3
peak). 3
maxillofacial 3
9.5. 3
teratogens, 3
Accutane). 3
Descemet's 3
3H-thymidine. 3
TCA-insoluble 3
day-12 3
shelf 3
retinoid-induced 3
[13-cis-retinoic 3
RA)] 3
arches, 3
embryopathy. 3
thymic, 3
microtia/anotia 3
infants), 3
aortic-arch 3
optic-nerve 3
teratogenesis. 3
heterodimerize 3
Mdmx. 3
anaplastic, 3
Noxa, 3
self-ubiquitination. 3
finger-dependent 3
self-ubiquitination 3
E2F1, 3
Akt; 3
FKBP25 3
alkaloids. 3
(+)-bulbocapnine 3
non-planar 3
strained 3
(143 3
23-day 3
matrix-attached 3
distamycin, 3
Quinacrine 3
daunorubicin) 3
nuclear-associated 3
UV-sensitive 3
L5178Y 3
m-amsacrine. 3
m-amsacrine, 3
cell-selective 3
amonafide, 3
(Pgp)-mediated 3
myeloblasts 3
(sAML) 3
sAML. 3
(NSC 3
bisindenoisoquinoline 3
hydrochloride), 3
oligopyrrole 3
carboxamides 3
epoxy 3
Rutaceae, 3
(stauranthine, 3
skimmianine, 3
3',6'-dihydroxy-3',6'-dihydrostauranthine, 3
trans-3',4'-dihydroxy-3',4'-dihydrostauranthine) 3
B3LYP 3
functionals. 3
pi-pi 3
skimmianine 3
dipole-dipole 3
drug-DNA 3
m-AMSA, 3
methoxy 3
headgroup, 3
ligands: 3
non-covalently 3
non-cycling 3
antimalarial, 3
0.02-0.06 3
w/w) 3
bis-intercalators 3
polypyridyl 3
photocleavage 3
denaturation, 3
DNA-crosslinking 3
DNA-cleaving 3
traverse. 3
2-methyl-9-hydroxyellipticinium 3
2-Me-9-OH-E+ 3
passage, 3
derivatives: 3
acrylamide 3
(J. 3
organometallic 3
arene 3
Ru-arene 3
thoughtful 3
pyridoacridine 3
kDNA 3
pyridoacridines 3
resealing 3
Inflammation, 3
impacted. 3
antagomirs 3
miR-134 3
seizure-damage 3
epilepsy-regulated 3
information-carrying 3
(paracrine) 3
affective, 3
neuromorphological, 3
schizophrenic, 3
DPYSL3, 3
Arrays. 3
(miR-92a, 3
miR-99b, 3
miR-422a) 3
synaptosomal 3
chips, 3
(EAAT3) 3
Glutamate/aspartate 3
(GLT-1) 3
(∼130 3
E18 3
photolysis 3
D-aspartate 3
postembedding 3
glutamate-aspartate 3
(GLAST 3
(VGLUT1), 3
(GluR4) 3
6-9 3
cochleotopic 3
GLAST. 3
(GLT1, 3
(K(m)) 3
HEK(GLT1), 3
310, 3
T1R1 3
EAAT1, 3
BW/day. 3
(alanine, 3
(SLC1), 3
EAATs) 3
hypoxia-ischemia 3
GRK2-deficient 3
SIRT4 3
Microvascular 3
ΔgltT 3
ΔgltM 3
hGLT-1 3
EAAT2. 3
early-differentiated 3
NR2B, 3
(GIT) 3
62-kDa 3
SNX27. 3
NHERF 3
5-HT4R 3
CTLs, 3
(IS), 3
NR2C 3
PDZ-containing 3
DGKζ. 3
entries. 3
(HTG). 3
HTG. 3
GC-AG), 3
AT-AC), 3
HTG 3
pairs; 3
0.73% 3
99.24% 3
GT-AG, 3
GC-AG, 3
600) 3
(ISA) 3
Pro-Q 3
Ruby, 3
(PLoS 3
fluorophores 3
2D-DIGE 3
sensitivity; 3
(CBB) 3
dyes. 3
classical, 3
aptamer-targeted 3
Aptamers, 3
factor-specific 3
co-stimulation. 3
monophasic. 3
ARC1779. 3
(151 3
(196 3
angiogenesis-dependent 3
tempo 3
angiogenesis: 3
liposome-mediated 3
62-base-pair, 3
monothio-phosphate 3
backbone, 3
oligofectamine 3
(OF), 3
TFX-20, 3
Transmessenger 3
Jammer 3
(GJ) 3
thio-modified 3
OF-transfected 3
Eyetech 3
hyperpermeable 3
Regulatable 3
10(14) 3
(R10-60 3
D-R15-8) 3
activate. 3
ISS-ODN 3
multicolored 3
Musa 3
RealAmp 3
acuminata 3
cultivar 3
842 3
defense-related 3
leachates 3
mycelial 3
FOC. 3
trisulfide 3
banana. 3
Dead 3
Pathogens 3
Referred 3
ABSTRACT 3
soils. 3
defenses, 3
phytoalexin, 3
μ-opioid 3
Opioids 3
Naltrexone- 3
nalmefene- 3
opioidergic 3
trisutural 3
pattern," 3
biparietal 3
Benz" 3
BLSS 3
Patched, 3
RB. 3
NT-3; 3
trkC 3
TrkC-mediated 3
NT-3 3
c-fos. 3
MBs. 3
Medulloblastoma: 3
intellect, 3
(GNP). 3
3beta-dependent 3
Gli1. 3
hedgehog-mediated 3
expression/activation 3
Na,K-ATPase, 3
miR-193a 3
Shh-dependent 3
GNPs 3
GLI1, 3
formin, 3
(MMPs). 3
(Lu) 3
concert, 3
Src-dependent 3
Y38/60F 3
TGF-β- 3
Hic-5-induced 3
invadopodia-mediated 3
invadopodia-embedded 3
rocketed 3
Resembling 3
EMT-experienced 3
MT1-matrix 3
protruded 3
Plectin, 3
alphaII-spectrin, 3
alpha(3)beta(1) 3
alpha(v)beta(5) 3
Pacsin 3
DriverDB: 3
oncogenomics 3
DriverDB 3
(http://ngs.ym.edu.tw/driverdb/), 3
6079 3
exome-seq 3
Cosmic) 3
gene/mutation 3
3,205 3
"driver" 3
"passenger" 3
unchecked 3
Wnt/TGF-beta 3
Wnt/VEGF 3
MAPK/focal 3
5q22.2 3
SMAD4. 3
(mutated 3
Chaos3 3
Neurofibromin 3
CNAs 3
distinction. 3
apicobasal 3
heterozygosity), 3
zebrafish-human 3
nucleoids. 3
Nucleoid 3
self-contained 3
TFAM, 3
(given 3
(4-20), 3
[4 3
range). 3
Pisa, 3
AMIO-OFF 3
mixed-type 3
9.3% 3
94.1% 3
(FT(3)) 3
(FT(4)) 3
(10-30 3
thyrotoxicosis: 3
ATA 3
(91%vs. 3
Europe; 3
colour-flow 3
(21%vs. 3
34%vs. 3
65%vs. 3
(31%vs. 3
(16%vs. 3
reinstituted, 3
'wait-and-see' 3
(FR) 3
training-induced 3
+28 3
(TCE). 3
(300-400 3
(tTFIID) 3
TCE-lacking 3
tTFIID. 3
5-8% 3
13.1, 3
17.1, 3
hypersensitivity: 3
0.0032), 3
16.9, 3
fraction: 3
(6.0 3
db/db, 3
(MPI) 3
0.042), 3
0.038 3
(44.3 3
P=0.007). 3
TFTs 3
(creatinine 3
(31.4%) 3
postrenal 3
82.9% 3
2-10 3
p=0.013). 3
(sex, 3
hemodialysis, 3
subclinically 3
ROC, 3
45.4; 3
CAPD 3
(2.7 3
fT3. 3
0.028). 3
(24.7%) 3
0.000 3
unremitting 3
psychophysical, 3
TNBCs. 3
TNBCs, 3
Mage-A4, 3
Her2-positive/ER 3
epithelial-like 3
(TNBCs) 3
ER-, 3
lactoferrin, 3
peroxiredoxin-2, 3
atypia. 3
co-dependent 3
Mx1, 3
CD74. 3
MUC18, 3
plexins, 3
Stat1/CD74 3
Proteomics: 3
leaked 3
protein-specific 3
hyper 3
forced-swim 3
(TST), 3
inline 3
sclerosis-associated 3
AMLs 3
4E-BP1, 3
complex-associated 3
FCD. 3
TSC-related 3
S6K1, 3
TSC1/hamartin 3
TSC2/tuberin, 3
mTOR/S6K1 3
mTOR/S6K1-signalling. 3
Expression, 3
GDP, 3
Crystals 3
47.9 3
diffractometer. 3
brain). 3
(TSC1 3
TSC2) 3
DrosophilaTSC1/TSC2 3
PI-3-kinase-Akt-mTOR 3
acid-TOR 3
genetically. 3
interlobular 3
seated 3
dissipation. 3
acclimation, 3
1330 3
(SLAMF7) 3
EAT-2. 3
EAT-2-negative 3
SLAMF7-mediated 3
EAT-2 3
(SHIP-1), 3
CD45-deficient 3
SLAMF7-triggered 3
Bedaquiline: 3
TB) 3
times/week 3
isoenzyme. 3
energized 3
dormant, 3
non-replicating, 3
extracellular. 3
SYNTHESIS: 3
pyrazinamide. 3
fluoroquinolones. 3
erroneous. 3
Branch, 3
Gastroenterology, 3
Renji 3
IgG), 3
denying 3
(Hp) 3
gastritis. 3
CNKI 3
Totally 3
2.68 3
CagA-seropositive 3
76.6 3
atherosclerosis; 3
cerebral, 3
rate), 3
anti-infective 3
(72.5%) 3
Japan) 3
<0.001) 3
monocytes/macrophages, 3
anti-Hp 3
(IL-8), 3
UBT 3
LDL-cholesterol, 3
large-vessel 3
3.04, 3
0.21; 3
wheather 3
atheroma. 3
2.21 3
p=0.02) 3
1.16 3
(37.3 3
act, 3
accent-based 3
instability? 3
tremor) 3
prosody, 3
English). 3
Recordings 3
Neurologists 3
37%. 3
Imprecise 3
Estimation 3
GOD 3
ROS-scavenging 3
(PPI). 3
hiatal 3
bloating, 3
antireflux 3
reflux: 3
single-group 3
®) 3
(GERD), 3
standard; 3
heartburn. 3
(PPI), 3
(clinicaltrials.gov 3
NCT01057992, 3
NCT01058070, 3
01058564) 3
belching 3
reapproximate 3
manometry, 3
self-resolved 3
cardia. 3
implant. 3
device-related 3
GERD-related 3
electroretinograms 3
hyperacusis 3
decerebrate 3
gray-matter 3
(MELAS) 3
sialidosis 3
deficiency), 3
small-size 3
amendable 3
system.(ABSTRACT 3
(GM1 3
ceramide-specific 3
sphingomyelin) 3
protein/cathepsin 3
GM1-gangliosidoses, 3
proteolysis) 3
enhanced-MRI 3
peduncle. 3
preictal 3
irregularity. 3
hemiatrophic 3
encephalomalacia. 3
enigma. 3
self-resolving 3
kind. 3
hemiparesis. 3
gyri. 3
[DDMS]). 3
DDMS. 3
(spatial 3
Ghana 3
Postmortal 3
Probably 3
cistern 3
pachygyria. 3
acyltransferase, 3
(TAZ). 3
taz1Δ 3
deacylated 3
resynthesis 3
tetralinoleoyl-cardiolipin 3
chronic/cyclic 3
c.83T>A, 3
p.Val28Glu, 3
(UCL) 3
variants; 3
(SAT), 3
219. 3
more). 3
(27.9%) 3
spleen) 3
per1, 3
per2, 3
per3, 3
wee1 3
longevity: 3
specifically; 3
partner) 3
prepares 3
preadipocyte 3
Bmal1. 3
fiber, 3
Biologie, 3
(dpi). 3
(LAT). 3
LAT. 3
chromatinization 3
already-silenced 3
MLL-AF9-transduced 3
K9me3 3
hepatocarcinoma 3
CLIC1. 3
Hca-P 3
CLIC1, 3
Rho-guanine 3
2-DE, 3
n-4 3
D4476 3
inhibitor-2 3
kinase-1. 3
(CK2) 3
I-2 3
Ser86 3
(GSK-3) 3
CK2. 3
pentadecapeptide 3
264) 3
thrombo-embolic 3
3.31, 3
Subanalyses 3
1280 3
polymorbid 3
88-years-old 3
(body-mass-index 3
19.95) 3
lisinopril, 3
rivaroxaban-intake 3
anti-Factor 3
Xa-activity 3
body-mass-index, 3
Non-Central 3
Non-Valvular 3
arm). 3
(NVAF) 3
OAC 3
Advantages 3
Fibrillation, 3
prostheses. 3
6229 3
ratio=2.0-3.0) 3
blind. 3
(2.57% 3
2.05%/100 3
P=0.0068) 3
(4.63% 3
2.74%/100 3
(2.29% 3
2.85% 3
ratio=0.80; 3
0.63-1.02) 3
(2.00% 3
2.10%/100 3
ratio=0.95; 3
0.76-1.19; 3
P=0.313), 3
(≥75 3
4.86% 3
4.40% 3
ratio=1.11; 3
0.92-1.34; 3
2.69% 3
2.79%/100 3
ratio=0.96; 3
0.78-1.19; 3
P=0.336). 3
TI, 3
double-dummy 3
Non-inferiority 3
(DB) 3
DB. 3
searchable 3
SWISS-2DPAGE 3
visualised 3
SWISS-PROT 3
discoideum. 3
Giardia. 3
amoebae 3
macropinocytosis 3
vesicle. 3
PI-3 3
NDP 3
cytoprotection. 3
(fasting 3
Perilipin 3
(IMF) 3
LSDP5, 3
ADFP 3
Adipophilin, 3
2.58. 3
cytomorphologic 3
flourishing 3
enterprise 3
Lyonization. 3
Lyonization 3
judiciously. 3
Sohval 3
Gains 3
(5,6,7,8,9). 3
(BVI) 3
BVI 3
potentiality. 3
chromosomes: 3
three-dimensionally 3
(LAESI) 3
Electrospray 3
Ionization 3
omic: 3
atmospheric 3
near-field 3
metabolomics. 3
microfabricated 3
sequencers 3
microfluidics 3
below; 3
nano-LC-MS/MS 3
nanoLC-MS/MS 3
(m/z) 3
fisheries 3
GLR 3
GHR 3
(QALYs)) 3
euro12.000. 3
BCSS 3
0.62). 3
(ET 3
2%), 3
(CED). 3
Studied 3
(organizational) 3
patient-centeredness 3
Pre-post 3
implementation-time 3
percent): 3
low/high 3
test-results 3
diffusion; 3
"what-if" 3
realistic. 3
drafting 3
0.4). 3
0.55; 3
0.44; 3
thromboembolism: 3
ximelagatran 3
(0.49 3
1.03) 3
(0.12 3
1.27) 3
rivaroxaban; 3
1.50) 3
1.34) 3
idraparinux 3
(GC/MS), 3
Succinate: 3
peritonitis. 3
zymosan 3
contribute, 3
3.0% 3
(ALI) 3
HIF-dependent 3
Hmbs(-/-) 3
succinyl-CoA 3
ALAS 3
deoxycholate 3
(NICD1) 3
(Pdp1) 3
caspase-11, 3
chirality 3
(UCP2), 3
sirtuin-2 3
(SIRT2), 3
GPR109A 3
hydrocaboxylic 3
(HCAR2). 3
NLRP3-mediated 3
BHB-mediated 3
Anti-hepcidin 3
2-phenylbenzimidazoles 3
i.e.: 3
(SI 3
anti-Flaviviridae 3
BHK 3
pestivirus 3
(HCV), 3
cytotoxic, 3
monolayers. 3
6-MP 3
bulkier 3
(quinolizidin-1-yl)alkyl 3
Simplex 3
Vaccinia 3
NS2/3 3
NS2-3. 3
NS2-3 3
free. 3
(∼1.2 3
nicotine) 3
cigarette. 3
toxicants. 3
(NRT) 3
libitum. 3
cessation; 3
Selectively 3
blood-oxygen 3
(BOLD) 3
21-mg 3
cigarette) 3
stapler). 3
Event-related 3
(ROIs) 3
subserve 3
reward, 3
amygdala--a 3
randomised-controlled 3
deacylates 3
carboxylesterase 3
palmitoleate 3
deacylase. 3
notum 3
4-5) 3
(Spanish 3
Version) 3
(Kw) 3
attacks). 3
drowsy 3
0.89-0.97) 3
0.91-0.96) 3
0.94-0.98) 3
0.93-0.97). 3
-0.78; 3
3-6), 3
aided-designed, 3
3-dimensionally 3
bioscaffolds 3
bioscaffold 3
Communications 3
(DICOM) 3
porous, 3
Bioresorbable 3
laser-based 3
acid/collagen 3
composites. 3
meniscus 3
layer-by-layer 3
hydrogels. 3
glycosaminoglycans. 3
biomaterials. 3
tooling 3
molds, 3
one-of-a-kind 3
Fueled 3
(Three 3
Printing, 3
Sintering, 3
Stereolithography, 3
Plotting/Direct-Write/Bioprinting) 3
fabricating 3
tissue-like 3
refinement, 3
printer 3
Layer-by-layer 3
solidified 3
thermo-reversible 3
"printing 3
paper". 3
prototyping 3
ejected 3
object, 3
goods 3
revolutionised 3
1,772 3
tmax 3
29.1 3
Supplemental 3
lubricants 3
oncologist 3
Vulvar 3
lists, 3
76), 3
(wake 3
(30.8 3
32.1 3
improved" 3
5.3%, 3
guidance: 3
consensus-based 3
"What 3
pergolide 3
dopamine-receptor 3
Meta-analyses 3
Central, 3
α₂δ 3
-5.47 3
-0.24, 3
substance, 3
nighttime. 3
cramps. 3
high-potency 3
Sleep-related 3
cramps 3
PLMD. 3
ESRD, 3
Impressions-Improvement 3
Dizziness 3
pregabalin: 3
(PLMs) 3
afternoon. 3
CLASSIFICATION 3
(PLM) 3
pains 3
endoglucanase 3
cellulase 3
carbohydrate-binding 3
CBD 3
Root 3
alpha-Expansins 3
wall-loosening 3
redressing 3
anti-Alzheimer 3
(ZFNs), 3
nuclease, 3
stutter 3
Deterioration 3
detriment 3
obesity; 3
provider. 3
sports; 3
50%; 3
dysplasias, 3
growth-plate 3
electrophoresis(DGGE) 3
(Gly380Arg) 3
[Mutations 3
achondroplasia]. 3
4p16.3 3
IPI-504-treated 3
twenty-five 3
iso-effective 3
c-raf-1 3
akt 3
hsc 3
hsp90beta, 3
semaphorins 3
C620R 3
cristopathy. 3
megacolon/Hirschsprung 3
NRG1. 3
guts 3
ErbB2. 3
neurogenesis/gliogenesis 3
ileus 3
Siblings 3
SOX10). 3
urea-formamide 3
(GC-rich) 3
(CDGE). 3
15.7% 3
3p21 3
(INa). 3
+40 3
conductance; 3
digiti 3
minimi 3
guanidine. 3
Voltage-sensitive 3
(LCNEC) 3
[Difficulties 3
pulmonologists. 3
pT2N0M0 3
"unmasking" 3
anticholinesterases 3
activity]. 3
(-40 3
terminal. 3
opsoclonus-myoclonus 3
bronchioloalveolar 3
PCD, 3
thoracoscopic 3
anti-neural 3
SCLC-LEMS 3
AGNA 3
(32%, 3
workup. 3
Assignment 3
10p12 3
(91.7%) 3
voltage-operated 3
(VOCCs) 3
radiation-related 3
[Association 3
deliberately 3
antimicrobials/cell 3
antilantibiotic 3
nisinase 3
C-termini, 3
(FIC) 3
LanM 3
alba 3
mesolanthionine, 3
3-methyllanthionine, 3
dehydroalanine, 3
dehydrobutyrine. 3
prepeptides, 3
antibiotics? 3
labyrinthopeptin 3
A2. 3
NisT 3
microbalance 3
DPoPC 3
Phospholipids 3
hypogonadotrop 3
emigration 3
18th 3
Cataracts 3
Dysmorphism 3
Para-infectious 3
18qter, 3
theta=0 3
(CCFDN). 3
Balkan 3
Gypsies: 3
Wallachian 3
Gypsies, 3
Sofia 3
microcorneas. 3
(n=196) 3
1930 3
Watts 3
LF/HF 3
(0.9 3
5.4, 3
cyclophilin-like 3
kingdom, 3
nonimmunosuppressive 3
CHT1 3
Torpedo 3
Choline 3
tCHT1 3
MA, 3
early-life 3
(D483A) 3
Metnase/SETMAR 3
extinct 3
SETMAR. 3
(TIR) 3
SETMAR). 3
(H3K36), 3
decatenation, 3
transposase-related 3
Metnase-TIR 3
Metnase: 3
HTH 3
19-bp 3
ChemDiv 3
Lys36. 3
(AS), 3
SRp55 3
CHOP, 3
(apoptosis). 3
(topo 3
(P-gp), 3
oxidant-mediated 3
Ras/MEK 3
REF52 3
TIG-3 3
p16Ink4a. 3
Nox-generated 3
3T9 3
immortalized. 3
proto-oncogenic 3
cancellation 3
ROS-associated 3
(p53(val135)) 3
ARF(-/-) 3
mdm2(-/-) 3
MYC. 3
transactivator, 3
Georgia, 3
GA, 3
hematologists, 3
flat-file 3
XPRbase 3
(http://www.goldenhelix.org/xprbase), 3
ITHANET 3
upon. 3
http://globin.cse.psu.edu/gala/) 3
optimization: 3
(MW 3
flow-through 3
(DMSO) 3
MALDI-FTICR 3
lopinavir, 3
nelfinavir. 3
Anti-PD-1 3
Treg-cell 3
tumor-mediated 3
muted 3
PD-L1) 3
Engagement 3
B7 3
co-inhibitory 3
H-J-J 3
aspartyl-beta-hydroxylase 3
(AbetaH), 3
Junctate 3
ER/SR 3
(we 3
alpha-ketoglutarate-dependent 3
Tagging 3
InsP(3) 3
(aspartyl 3
beta-hydroxylase), 3
4.2kb. 3
35-107 3
(hAspH) 3
perfectly. 3
GGylation-dependent 3
(YAP), 3
(transcriptional 3
(TEA 3
(LPA) 3
Yap(S112A) 3
Regenerative 3
applications; 3
mDia1, 3
nucleator 3
mDia1(-/-) 3
Rho, 3
60-amino 3
transcription-start-site 3
equilibrium. 3
[2]. 3
Gal4-VP16 3
Iec1-ino80-mediated 3
Ino80-associated 3
(YY1) 3
arp8, 3
ies6, 3
ies2 3
cdc22 3
Rtt109. 3
RTT109 3
Nucleosomal 3
bound. 3
(sufficiently 3
delta-distances) 3
extremes. 3
signature) 3
dissimilarity 3
>/=50 3
(rho*XY) 3
Arginine 3
charge-based 3
1459 3
cathepsins. 3
tackled 3
science: 3
transcriptomics. 3
Glycomics 3
Rindopepimut: 3
keyhole 3
rindopepimut, 3
Rindopepimut, 3
MYH7B 3
(JUP) 3
isoform-1 3
(TNNT2) 3
pE96K, 3
.023), 3
.033), 3
1.8; 3
2.4-fold 3
immunoblot, 3
HBE4-E6/E7. 3
SW480, 3
Cyr61, 3
H520-Cyr61 3
H460-Cyr61 3
autozygosity 3
BMI1. 3
intermediate-1 3
2.65 3
γδ 3
PMF. 3
(CL/P) 3
CL/P 3
54.1% 3
12.0% 3
HOX, 3
cell- 3
22Rv1), 3
191) 3
>or=2). 3
34/125 3
<2), 3
(25/46) 3
0.0009) 3
hormone-naïve 3
wheelchairs 3
concerns; 3
CD68 3
SMTC1100 3
utrophin. 3
Exon-skipping 3
NF-KB, 3
(TGF-α) 3
(TGF-β)/myostatin 3
1987, 3
ask: 3
amniocenteses 3
appliance 3
34. 3
bifida, 3
oesophagus 3
fathering 3
(XXY) 3
Case-control: 3
EUROCAT 3
terminations) 3
1.45); 3
1.38); 3
1.79); 3
1994-2007 3
Patau, 3
47,XXX 3
47,XYY. 3
"other 3
(1.49) 3
1084 3
threshold: 3
(89.5%) 3
4.4% 3
26,803 3
27,313 3
35. 3
eIF3, 3
eIF4E, 3
HT1080 3
24-36 3
pseudohyphal, 3
edc3/edc3 3
MILI 3
MIWI2 3
piP-bodies, 3
"P 3
DHH1 3
(Me31B). 3
TRIM71. 3
PolyPhen, 3
PANTHER, 3
5&apos;-3&apos; 3
exoribonucleolytic 3
polysomes. 3
bodies). 3
Edc4. 3
aggregated, 3
plus-strand 3
Pan3 3
Dcp1a 3
Xrn1. 3
P-body-like 3
rRNA. 3
DOCK6 3
bioprocesses. 3
inulin-rich 3
bailii 3
petroleum 3
depressurization 3
LPG, 3
LPG 3
bar, 3
catalysts 3
7571 3
7571, 3
11.89% 3
20.83% 3
dahlia 3
Lowest 3
fructose. 3
deep-sea 3
inulin. 3
(max) 3
(V, 3
KRF1(T) 3
thermostability, 3
Agave 3
salmiana 3
fructose, 3
96.4% 3
42.0 3
d-fructose 3
(K(i) 3
4.44 3
thermostability 3
syrup. 3
exanthema 3
readmitted 3
anamnestic 3
fulminating 3
paradoxically, 3
Astragalus 3
Membranaceus 3
Q10(CoQ10) 3
(CVB3) 3
inbreeding 3
non-manifesting 3
(LTP), 3
(PARK7), 3
levodopa-responsive 3
<45 3
(PARK9), 3
(PARK14), 3
FBX07 3
triplications 3
(SNpc) 3
L166P 3
4p, 3
(RM) 3
periprocedural 3
postprocedure. 3
(6% 3
(DOCA)-salt 3
(I(Na)), 3
(E/E':sham, 3
P=0.018). 3
(sham, 3
Hg/L; 3
(DOCA-salt, 3
seconds; 3
P=0.0004). 3
(Shannon 3
E4031 3
P(o) 3
oscillations, 3
(CF), 3
mCa2+ 3
anemone 3
RAN 3
isometrically 3
CAO, 3
exchangers 3
sodium-hydrogen 3
[Na(+)](i)-dependent 3
electrodynamic 3
"two-compartment 3
metabolism" 3
onco-metabolite. 3
0), 3
risk-assessment 3
"parasitic" 3
detoxifies 3
peroxide) 3
"energy 3
"metabolic-coupling" 3
Metabolism", 3
glutamine) 3
end-products 3
glycolysis) 3
myo-fibroblastic 3
glycolysis). 3
(caveolin-1 3
myo-fibroblast 3
gamma-radiation, 3
mPer2-deficient 3
[t(9;22)(q34;q11), 3
chromosome] 3
Nilotinib 3
immunoreceptor 3
tyrosine-based 3
(quantification 3
"gatekeeper" 3
ABL-kinase 3
(AKIs) 3
57.8 3
(HEM-AP 3
Correlative 3
72.7%. 3
(Ph(+)) 3
(HSCT). 3
dysregulate 3
(BCR-ABL 3
(STI 3
571; 3
Gleevec; 3
KIT-positive 3
477). 3
t(9;22;15;19) 3
(q34;q11;q15;q13). 3
42-65%, 3
F359I 3
L387M 3
(B-ALL) 3
brighter 3
Philadelphia-chromosome, 3
tyrosin 3
hronic 3
Molecularly 3
(42.9%) 3
leukemia). 3
1960, 3
blasts, 3
Abl-specific 3
9q-. 3
Continuing 3
lesion--the 3
everyone's 3
preeminent 3
CML; 3
BP, 3
leukaemia) 3
(haemopoietic 3
phase), 3
Switzerland), 3
Src/Abl 3
(Ph)-chromosome) 3
Bcr 3
Stromal 3
(SCF). 3
CML-like 3
(FTIs) 3
(t(9;22)) 3
10(6)/kg 3
uninterrupted 3
Glivec, 3
Gleevec) 3
proliferation/survival 3
dose-effect 3
improvement; 3
A/S 3
(GAD). 3
opinion) 3
AA21004), 3
-7.1 3
harmed? 3
http://www.ncbi.nlm.nih.gov/pubmed/, 3
http://www.clinicaltrialsregister.eu 3
'vortioxetine' 3
'Lu 3
AA21004', 3
posters 3
(NNH) 3
non-elderly 3
8-17). 3
24-70). 3
6-7), 3
37-240), 3
23-38), 3
weight-gain 3
(SERT). 3
SNRIs 3
5HT1A 3
(ASEX) 3
(OC). 3
226) 3
out-patient 3
(HAMA) 3
(nominal 3
Impressions-Global 3
46.4 3
.05 3
(MDE) 3
significant; 3
(p<0.0001, 3
Sushi.R: 3
Sushi.R, 3
Sushi.R 3
paediatricians 3
vegetarian 3
chorioretinitis 3
gondii, 3
retrotransposable 3
(LINEs) 3
GC-rich, 3
Elongin 3
phaeochromcytomas 3
Diego, 3
Y35F 3
(siRNA)-transfected 3
30-mer 3
Oct-4, 3
ask, 3
null, 3
cross-functional 3
HEDGEHOG-GLI 3
(HH-GLI) 3
(ES)-like 3
GLI1-NANOG-p53 3
Gonadal 3
(PGCs) 3
Spermatogonia 3
restimulation 3
eight-cell 3
lamin-genome 3
plants), 3
"degradation 3
lysosomal/vacuolar 3
machinery," 3
(PND). 3
"housekeeping" 3
pathways) 3
autophagy-mediated 3
populations; 3
cas 3
RNA-Cas 3
invaders. 3
invader-targeting 3
psiRNAs. 3
defense: 3
CRISPRs 3
O395 3
directions, 3
T-A 3
(AT-pair) 3
(GC-pair)] 3
GC-pair 3
AT-pair], 3
protozoa, 3
glutamine. 3
guanine-plus-cytosine 3
Micrococcus 3
luteus 3
generality 3
teleological 3
GC% 3
(97% 3
genome-predicted 3
(eccentric 3
FHC-causing 3
Myofilament 3
alphaMHC(R403Q/+) 3
0.18, 3
chain: 3
alphaMyHC 3
MYH6 3
(G(s)alpha 3
bpm) 3
crossbridge 3
alphaMHC403/+ 3
activation), 3
ectopy. 3
Gln 3
n=4), 3
low; 3
nosology. 3
referral, 3
(1/3) 3
(2/3). 3
angiotensin-II 3
(DHE), 3
(HE) 3
p-JNK 3
db 3
fa/fa 3
shortening/relengthening 3
+/-dL/dt 3
UCF-101-induced 3
AMPK-associated 3
11-30 3
coroner 3
unpredictability 3
maker 3
(ICD), 3
American. 3
suddenly. 3
(72%), 3
Proportion 3
(39%; 3
(Minneapolis, 3
Minnesota). 3
continents 3
2:3 3
U.S.; 3
internationally) 3
air-filled 3
projectiles 3
lacrosse 3
balls). 3
Consumer 3
baseballs 3
baseball. 3
cordis: 3
CPR 3
defibrillation. 3
Iceman, 3
Iceman 3
reopens 3
mummy. 3
medico-legal 3
mummy 3
similarities. 3
2,700-year-old 3
steppe 3
(lon1-1 3
lon1-2) 3
OXPHOS. 3
lon1-1 3
lon 3
debilitated 3
lon1-1. 3
post-germinative 3
respiratory-deficient 3
PIM1 3
inflorescences, 3
gigaxonin. 3
PRPH 3
Neuropathy, 3
(p=0.013) 3
Measure. 3
straight-haired 3
GAN-deficient 3
(AAV2) 3
AAV9/GAN 3
symptomatologies 3
phenotypic-genotypic 3
805C>T 3
4(Arg545His 3
1634G>A 3
11(Arg269Trp 3
(CMT2). 3
Neurofilaments, 3
GAN/CMT2. 3
GAN/CMT2, 3
KELCH 3
Explaining 3
pathology; 3
NRTI-induced 3
Gan1 3
FGF, 3
PiD 3
PiD, 3
Hes1 3
trans-activate 3
(CADASIL). 3
polymerize, 3
pre-formed 3
finite, 3
reformation. 3
pit. 3
maturation; 3
fission; 3
author(s). 3
Attribution–Noncommercial–Share 3
Alike 3
Unported 3
(http://creativecommons.org/licenses/by-nc-sa/3.0). 3
(endosomal 3
ostensibly 3
Vps32/CHMP4B 3
Dynamin-2 3
acto-myosin 3
(CNM) 3
brightness 3
endophilin 3
DeltaNp73alpha 3
anti-survival 3
polyubiquitination-dependent 3
DeltaNp73. 3
DeltaN'p73 3
anti-oncogenic 3
BubR1 3
TAp73-deficient 3
TAp73(-/-) 3
deltaNp73 3
promoter-dependent 3
RNPC1, 3
antagonistic, 3
Isoform-specific 3
density-dependent 3
p73alpha 3
NH2-terminus 3
cooperated 3
Cooperation 3
TP73 3
induce, 3
DeltaNp73(AS) 3
high-intermediate 3
CD10, 3
tumor/normal 3
calpains, 3
calpains 3
isomeric 3
IGR-N-91 3
2002). 3
oncosuppressor 3
copper-induced 3
pools. 3
Gal4/Mac1p 3
MAC1(up1) 3
nonspecific. 3
CDC45, 3
GINS) 3
CMGs 3
85, 3
KRas-driven 3
RTKs 3
Ki-, 3
(reactive 3
protein-membrane 3
K-Ras4B). 3
(ERAP) 3
Octopamine, 3
(IC(50)=109 3
IC(50)=94 3
genistein. 3
immunodepleting 3
reconstitution, 3
IL-4-producing 3
(TSH, 3
thyrotropin-binding 3
(TBII) 3
IFNB-1a 3
TBII 3
(IFNβ-1a), 3
IFNβ-1a; 3
alemtuzumab-mediated 3
Alemtuzumab: 3
beta-1a) 3
0.14-1.2 3
0.41-0.77 3
CAMMS223 3
CARE-MS2 3
(7.2-8.66 3
4.9-5.7 3
person-year). 3
concerning; 3
(17%-18% 3
5%-6%) 3
assiduous 3
charts. 3
units; 3
Alemtuzumab's 3
transmigration 3
Alemtuzumab-treatment 3
(CD52-specific 3
Composite. 3
436 3
(236 3
p<0·0001), 3
peripheral-blood 3
0.36; 3
0.41; 3
[23% 3
(anti-CDw52). 3
differed. 3
say 3
factor-alpha. 3
subgenual 3
(Cg25/24), 3
capsula 3
(ALIC), 3
(NAcc). 3
habenula) 3
TRD 3
DBS. 3
psychosurgical 3
apathy 3
anhedonia--the 3
activities--and 3
psychotherapy, 3
(HDRS 3
alemtuzumab-based 3
protooncogenes 3
pentostatin; 3
(NR), 3
autograft. 3
reshaped 3
(p=0.84). 3
wild-type) 3
0.043), 3
1.01-1.88, 3
telomerase-associated 3
(IDH)1 3
"disease-modifying" 3
tragedies 3
non-demented 3
compels 3
re-examine 3
exhaustively 3
ϵ4 3
semagacestat, 3
anti-amyloid-β 3
neuropathology, 3
Bapineuzumab: 3
(AN1792) 3
ahead. 3
completers 3
tarenflurbil 3
anti-amyloid-beta 3
propagating, 3
Abeta-antibody 3
complex-induced 3
immuno-supperssive 3
hurdles, 3
immunosenescence, 3
polyepitope 3
|| 3
(DIO2) 3
(PCR-RFLP). 3
(sHT) 3
textbooks, 3
<70-75 3
wait-and-see 3
covariate. 3
1634 3
(CABG). 3
mediastinitis, 3
(45.5% 3
29%; 3
2.552; 3
1.117 3
5.830; 3
cm/s 3
40.5% 3
4-10% 3
(>6 3
mIU/L). 3
>85 3
mU/L 3
athleticism, 3
alumni 3
play. 3
jogging, 3
vigorous, 3
Alumni 3
(p, 3
(referent), 3
[trend] 3
.007). 3
(259 3
tour 3
municipalities 3
990 3
"C" 3
nonhomoplastic 3
(SCCmec) 3
(IV, 3
difference); 3
RD-defined 3
Genotypic 3
incongruence 3
Rotifera 3
fossil 3
Ploimida 3
parsimony, 3
trees: 3
homoplasy-inducing 3
insertion/deletion. 3
clade; 3
chimpanzee-gorilla 3
align, 3
contradictory; 3
insertion/deletion; 3
gorillas. 3
tree/species 3
[based 3
(COII) 3
sequences], 3
taxonomy: 3
divergences 3
fruitful 3
Tigriopus 3
reconstruction: 3
trivial, 3
Sequence-based 3
"tree 3
"bottom-up" 3
(LBW), 3
discourage 3
County, 3
0-17 3
(3.34, 3
7.47, 3
(tricyclic 3
antidepressants) 3
Serotonin, 3
1.2-4.3]), 3
1.8-7.8]). 3
NE-LC 3
hydroxylase) 3
conflicting; 3
(Snail) 3
(Slug) 3
(ZF), 3
(E2-box: 3
CAGGTG/CACCTG) 3
ZFs. 3
slug-mediated 3
snail-2 3
(SLUG) 3
(TMAs). 3
(UCBs). 3
Ta/T1/Tis, 3
T2-T4). 3
CUBIII 3
UCBs 3
UCBs, 3
Twist. 3
repressors; 3
OE33 3
(ZEB1) 3
SIP1, 3
TGF-beta- 3
Ets1-induced 3
ECs. 3
Desmin-related 3
Restrictive 3
desmin-related 3
Dobermann 3
GenBank, 3
sarcoglycan, 3
Dystrophin 3
delta-sarcoglycan, 3
dominant-dilated 3
(DAG) 3
DAG, 3
des(-/-) 3
Osteopontin 3
'drug 3
year'. 3
diarrhea; 3
44), 3
66). 3
(BWS). 3
hydroperoxides 3
Perturbed 3
neuro-developmental 3
erasure, 3
Hydatidiform 3
mole. 3
perturbed. 3
(1993): 3
(IDDM) 3
site-4 3
transgene-mediated 3
equated 3
jeopardize 3
shelter 3
ferritins 3
Fe3+ 3
FtH 3
SPECT-determined 3
biodynamic 3
(11)C-methylphenidate 3
19:30) 3
illusion, 3
worrisome 3
gastrointestinally 3
legs; 3
seated, 3
shin 3
creepy, 3
shock-like, 3
tense, 3
electric, 3
buzzing, 3
itchy, 3
(RLSAP) 3
"achy 3
pain." 3
theorize 3
RLSAP), 3
D2R 3
VMAT. 3
rub 3
soothe 3
distressed 3
embarrassed 3
150% 3
suspects 3
dopaminergic, 3
benzodiazepine, 3
hyperexcitability, 3
monitorization 3
parasomnias 3
cyclopeptide 3
Spt7 3
weakly, 3
Lys14, 3
"loss-of-function" 3
purifies 3
gcn5Delta, 3
alpha-tubulin. 3
there. 3
20.9, 3
16.2-27.0), 3
loss/lack 3
19.6, 3
15.5-24.8), 3
6.5-15.2), 3
8.3-11.1) 3
3.2-6.6). 3
Undiagnosed 3
Canadian, 3
veteran's 3
atmosphere. 3
musculoskeletel 3
lymphadenopathies, 3
uranium. 3
airport 3
(GWS). 3
picture]. 3
eye-movement 3
neuro-ophthalmologically 3
late-appearing 3
300). 3
CCT, 3
SPECT, 3
(parent 3
("impaired 3
headaches), 3
("confusion-ataxia," 3
impotence), 3
("arthro-myo-neuropathy," 3
lifting, 3
paresthesias) 3
("phobia-apraxia"), 3
("fever-adenopathy"), 3
("weakness-incontinence") 3
somatoform 3
FLAIR 3
hypoperfusion 3
p.R544C 3
p.C99MfsX3 3
HSVDB. 3
well-defined, 3
∼70% 3
MAX, 3
(gDNA), 3
Carney-Stratakis 3
(VHL). 3
pheochromocytoma-paraganglioma 3
nonmedullary 3
(PDGF)/PDGF 3
Pirfenidone, 3
ASCEND 3
N-acetylcysteine) 3
IPF; 3
Nintedanib, 3
breakthrough. 3
(September 3
≥40 3
(PDGF), 3
diabetic-4 3
diabetic-8 3
water). 3
high-sugar 3
α(PKC-α) 3
SERCA/PLN 3
Meanwhile 3
RyR. 3
(HDL-C) 3
(RSV), 3
IP), 3
mid-1980s. 3
signs) 3
Delays 3
instituting 3
non-depolarising 3
relaxants. 3
depolarising 3
suxamethonium 3
decrementing 3
self-injected 3
nerves: 3
interosseous 3
non-occupational 3
polyneuropathies, 3
(COPIND). 3
Babinski 3
malathion, 3
Nicaraguan 3
ranchers 3
fishermen 3
OPs, 3
poisonings. 3
eight-year-old 3
Biochemical, 3
farmers 3
dippers 3
non-exposed 3
dipping 3
farmers, 3
hazards, 3
mortality). 3
68.6% 3
motoric 3
April, 3
vibrotactile 3
circumstantially 3
2,4-dichlorophenoxyacetic 3
(2,4-D) 3
applicator 3
polyneuropathy--Organophosphorus 3
Neurotox-icity 3
(OPIDN). 3
half-linkers 3
nonsegmented, 3
(L), 3
noncytopathic, 3
D1701-VrVp40 3
(nucleoprotein) 3
(phosphoprotein), 3
recloning 3
(Fas, 3
neuropeptides. 3
Schedule 3
HLA-identical 3
DCF. 3
first-dose 3
(2'-deoxycoformycin; 3
DCF) 3
NF-IL6, 3
AP4, 3
CHOP/CEBP 3
1s 3
617 3
IL-12. 3
p150,95. 3
URE. 3
proteobacteria 3
Portfolio 3
ranks, 3
fellowships. 3
classifications. 3
posttraining. 3
h-indices, 3
posttraining, 3
Accreditation 3
oncologists. 3
conformed 3
exponents 3
percentiles 3
instructors, 3
professors 3
Kruskal-Wallis; 3
instructor 3
[Conover]). 3
Departmental 3
chairs 3
3-55) 3
0-62). 3
Plot 3
0.995, 3
chairperson. 3
Angeles, 3
Irvine, 3
specialties, 3
specialty, 3
0.12). 3
Porto 3
Alegre, 3
pH-metry/endoscopy 3
Lipp 3
(α=.05; 3
power). 3
(13.3%) 3
(31.1%). 3
(P=.017; 3
1.40-30.98), 3
Prosthetic 3
Dentistry. 3
μm. 3
<15 3
teeth; 3
regurgitated 3
Continual 3
Intra-esophageal 3
5-mL 3
UMIN 3
UMIN000002923. 3
ASDA, 3
Association; 3
electromyogram; 3
GER, 3
reflux; 3
LES, 3
sphincter; 3
NREM, 3
bruxism; 3
UES, 3
metal-ceramic 3
Metal-ceramic 3
dentures 3
Bruxism 3
stomatognathic 3
discomforts, 3
(CRO) 3
(90-day 3
approximately). 3
CRO 3
short-burst 3
gastric-acid-inhibiting 3
12.6%, 3
(RMMA 3
hour; 3
(swallowing 3
saliva). 3
salivation 3
A:V 3
within-subject 3
dyads 3
ESULTS: 3
immune, 3
eight-week 3
Mindfulness-Based 3
NK, 3
NKT, 3
signed 3
17.7 3
catalogues 3
interim, 3
(ERSPC) 3
sub-sample 3
(ISRCTN92187251 3
ISRCTN20141217) 3
transaction 3
(web-logs), 3
web-logs. 3
[rho] 3
-0.44, 3
user: 3
ISRCTN48473735; 3
http://www.controlled-trials.com/ISRCTN48473735 3
http://www.webcitation.org/5pqeF89tS). 3
informed. 3
friend 3
NHS. 3
effectiveness: 3
consumers. 3
(executive 3
letter) 3
NHS, 3
Staffordshire 3
AVP. 3
pre-diabetic 3
age-gender-BMI 3
(elastin 3
(hypercalcemia, 3
puberty). 3
vocational 3
Refer 3
calcium/creatinine 3
metre) 3
gluttony. 3
sibutramine, 3
morpho-volumetric 3
0.2-17.2 3
thyroglobulin) 3
free-T3, 3
free-T4, 3
thyroperoxidase 3
(TPOA) 3
(TgA), 3
1.7-34.9 3
hemiagenesis. 3
pertechnetate 3
microg/24 3
(WS); 3
contrast. 3
calcitonin/calcitonin 3
FRZB 3
Quantitation 3
(sFRP3) 3
DN-LRP5 3
(FzE3) 3
hsFRP. 3
0.001]. 3
high-abundant 3
Microcon 3
Centrifugal 3
Montage 3
Deplete 3
glycoprotein-specific 3
haptoglobin 3
fourier 3
(lincRNA) 3
modENCODE 3
Posttraumatic 3
Detroit 3
(H3K9me3), 3
Demethylation 3
miRNA-response 3
ESC. 3
JunB 3
potentiation, 3
GRIK3 3
cortico-subcortical 3
flop 3
(rAAV) 3
(Gprk2) 3
�-Synuclein 3
rotenone, 3
reticulum-Golgi 3
modification-specific 3
Ser-129. 3
truncation, 3
(medication 3
PMS. 3
(March 3
Paroxetine: 3
2008) 3
spironolactone, 3
PMS/PMDD 3
-23.9, 3
-51.3 3
-6.2, 3
.014; 3
-18.6, 3
-32.5 3
-4.6, 3
(CGI). 3
HAMA, 3
calendar. 3
continuous-treatment 3
37.5-93.8% 3
intermittent-treatment 3
end-point. 3
Symptom-onset 3
3-15 3
"PMDD 3
level" 3
psychopharmacologic 3
-12.58 3
-18.40 3
-7.51 3
-13.40 3
-8.7 3
-15.7, 3
-1.7; 3
=.015; 3
-12.1 3
-18.9, 3
-5.3; 3
stomach; 3
elderly: 3
Disorder, 3
request, 3
self-questionnaires 3
anger, 3
mother-daughter 3
polymorphous 3
TCAs; 3
nefazodone 3
clomipramine. 3
psychobiology 3
worthlessness, 3
(mood 3
dyscontrol, 3
conflicts) 3
5.94; 3
toxicities: 3
PFS/OS. 3
47%. 3
cramps, 3
schedule; 3
(2-14 3
(66.7%). 3
TT-group 3
13-21 3
soundness 3
52.9%. 3
Optimum 3
supposition 3
4-fold, 3
XVIII 3
thrombospondin-1, 3
VEGF(165) 3
926 3
packaging, 3
(SDF-1α) 3
MICR. 3
overproducing 3
pericytes, 3
thrombospondin, 3
Tsp1, 3
Tsp1 3
PDT, 3
Immunoreactivity 3
former, 3
angiogenesis) 3
13.1 3
C3(1)/Tag 3
P125A 3
Fms-like 3
consequences: 3
capillaries, 3
receptors; 3
"disease 3
Kinesin 3
skolios 3
GWAS. 3
pathfinding. 3
Foodborne 3
Alaska 3
Nunavik 3
Nations 3
My 3
BTX-A, 3
Sertraline, 3
ejaculation: 3
guideline]. 3
and-in 3
disorder-duloxetine 3
claiming 3
long- 3
Sertraline 3
off-label, 3
beginning. 3
dysfunction]. 3
(paroxetine, 3
sertraline) 3
Dapoxetine, 3
Financial 3
dapoxetine, 3
(1.44 3
2001-2002. 3
breast-feeding: 3
vis-à-vis 3
priapism. 3
PNAS, 3
Rigoutsos 3
organisms: 3
retro-transcripts 3
MDP. 3
GII, 3
(phosphate, 3
H5, 3
unstructured. 3
bead, 3
(MET15) 3
(hho1Delta) 3
SIR1 3
HML. 3
sir1Delta. 3
preexistent 3
(ChCA) 3
"30-nm" 3
Driven 3
Poly(A)-specific 3
(PARN): 3
poly(A)-specific, 3
CCR4-NOT. 3
(CNOT) 3
CNOT 3
CCR4-POP2-NOT 3
Pop2p, 3
Pop2p-type 3
complexes--Caf1-Ccr4 3
Pan2-Pan3--play 3
eRF3, 3
Tob, 3
whole-organism 3
(Caenorhabditis 3
7N+23A 3
25N+2A 3
26N+1A 3
poly(A)) 3
Poly(U), 3
poly(C), 3
12-30-fold 3
non-poly(A)-specific 3
(>/=45 3
uncapped 3
Nocturnin, 3
GW 3
substrates; 3
Psoriasis. 3
skin), 3
(IL)-12, 3
tildrakizumab, 3
subcutaneously) 3
anti-interleukin-17-receptor 3
imputation. 3
Demographics 3
112) 3
ACQ 3
noted; 3
0.38). 3
L1), 3
relocate 3
element), 3
nocifensive 3
scratching, 3
incurable, 3
deletion: 3
MtDNA 3
2.39 3
Cowden, 3
Turcot, 3
(Gorlin) 3
NF2, 3
hPSM2, 3
PTCH, 3
causation. 3
insulinoma. 3
non-NF1 3
(NF1 3
NF7 3
3,500 3
PTT 3
similar: 3
5-methylcytosines 3
Lisch 3
p120GAP 3
pathway]. 3
R), 3
anoikis-sensitive 3
αvβ5, 3
aminooxy 3
integrin-targeting 3
peptidomimetic 3
UW479 3
cilengitide's 3
Cilengitide's 3
¹⁸F-FDG 3
VB 3
treatment-specific 3
12-15 3
radiochemotherapy, 3
(n=9), 3
CTCs, 3
CEC 3
recruiting. 3
gliomagenesis. 3
αvβ(3)/α(v) 3
αvβ(3) 3
αvβ(5) 3
immunohistology 3
αvβ(3)/αvβ(5) 3
outside-in 3
500-mg 3
alpha(nu)beta(3) 3
alpha(nu)beta(5) 3
suspending 3
alphavbeta5, 3
one-hour 3
600, 3
1200, 3
whether, 3
Microvessel 3
(10/15) 3
versatility. 3
exonizations 3
retroposons 3
neglected, 3
"Alu-exons" 3
(p75TNFR) 3
Alu-SINE, 3
U1-snRNA 3
Dys-nNOS 3
snRNA-antisense 3
Δ44 3
reframe 3
(BBS) 3
c.479G>A 3
BBS1-associated 3
(U1), 3
(5'ss) 3
+2. 3
5'ss. 3
TT-adapted 3
transcript-targeting 3
adaptors. 3
generics 3
ranitidine 3
HMGCR: 3
naringenin. 3
Bioavailability 3
(47.3 3
3.63 3
PUFA-enriched 3
(26.5 3
sauce, 3
(5.38 3
5.51 3
(4.08 3
4.22; 3
(5.02 3
5.13%; 3
cutpoints, 3
86%) 3
(≥6.21 3
(≥4.14 3
(≥6%), 3
with<1.5 3
tropicalis. 3
N(7)-methylguanosine 3
regions), 3
stabilise 3
MeT-DB: 3
Methyltranscriptome 3
MethylTranscriptome 3
(MeT-DB, 3
http://compgenomics.utsa.edu/methylation/) 3
(FTO) 3
(TP53 3
FBXW7, 3
Far 3
Socs1-silenced 3
Ags 3
Socs1-shRNA 3
DC-SIGN 3
HIV-HPV 3
Notoriously 3
membrane-stable 3
infiltrate, 3
venules, 3
requested, 3
state-transition 3
epoprostenol, 3
rationing 3
concludes, 3
lessons: 3
bans 3
reimbursement; 3
obliged 3
reimburse 3
laws 3
contentious 3
tax 3
lthough 3
requiring: 3
(index 3
date); 3
post-index. 3
PAH-specific 3
disenrollment 3
bosentan), 3
(SD=0.05). 3
72.6% 3
(SD=170) 3
(1.82) 3
(1.98) 3
706 3
managed-care 3
(p=0.009). 3
(p=0.003). 3
67,914 3
20,281 3
54.1 3
15,644 3
(77.1%), 3
12,720 3
(81.3% 3
claims) 3
necessity, 3
doping 3
chromatography-high 3
mass' 3
Requirements 3
analyzers. 3
analyzer, 3
MS(3) 3
ppm) 3
foscarnet, 3
cidofovir. 3
Cidofovir 3
interleukin-2-deficient 3
colitogenic 3
noncolitogenic 3
(SPF), 3
germfree 3
(GF), 3
(IL-2-/-) 3
monocolonized 3
mpk, 3
cocolonized 3
adipsin 3
enterocytes. 3
cecum 3
(CMI) 3
3.45, 3
Ltd/University 3
London. 3
GTG 3
3): 3
(300% 3
syringomyelia. 3
MURCS 3
pentasomy 3
(CMI; 3
118420) 3
narrowly 3
(0.955, 3
characteristic. 3
retardation: 3
philtrum, 3
Ethiopian 3
heterotopias 3
heterotopia, 3
meningomyelocoele. 3
gyration, 3
MVs 3
tumorigenicity, 3
(IGF1R) 3
p300-mediated 3
mdm2-mediated 3
(41.7%). 3
45.5%. 3
42.9%, 3
Alongside 3
ESFT. 3
buttock. 3
[Chromosomal 3
sarcoma]. 3
BIRC5 3
inhibitors]. 3
AZD1152-hQPA 3
tumor-association 3
(Bax, 3
Pleural 3
hydrothorax. 3
adnexectomy 3
antigen-125, 3
(fibroma). 3
Postovarian 3
endoribonuclease. 3
1705-1886 3
746-962 3
endoribonuclease, 3
5'Un 3
fibroadenomas, 3
CRD-BP-positive 3
249-nucleotide 3
CRD-binding 3
Hoff 3
(GT)n 3
B-Z 3
(20) 3
phototherapeutic 3
macromolecule. 3
tetramethyl 3
phototoxicity, 3
moderate-to-severe, 3
15.2% 3
PROTECT 3
NCT00822900.). 3
Interruption 3
(P-value 3
short-and 3
(SCI), 3
BDNF, 3
15-F(2t)-isoprostane 3
Water-soluble 3
battlefield 3
C-20 3
nonprogesterone 3
injury? 3
Health-sponsored, 3
Reviews. 3
rehabilitative 3
Over-expressing 3
Routinely, 3
nephrons 3
kynurenic 3
(CKD), 3
KYNA/TRP 3
vancomycin-associated 3
BUN: 3
mGFR. 3
east 3
(Thy1)-[A30P]alphaSYN 3
LBD. 3
alpha-synuclein-immunostaining. 3
cortical, 3
(NT), 3
magnification 3
centrum 3
broad, 3
alpha-syn. 3
GCIs, 3
(NFTs) 3
paralimbic 3
(entorhinal 3
hippocampus), 3
(frontal 3
cortices) 3
filiform 3
nigra: 3
"cloud-like" 3
(6.7%). 3
chromosomal/genetic 3
(29.2%) 3
12/20 3
Vic., 3
reassuringly, 3
ultrasound-detected 3
ultrasonography: 3
(IUGR) 3
64,048 3
(72.3%) 3
8,173 3
19.5% 3
5.8-15.9) 3
1.5-2.9). 3
France), 3
(7.0%), 3
(3.7%), 3
(3.7%). 3
computed. 3
5.4%, 3
couple's 3
fetalis. 3
Brightly 3
peritonitis, 3
intraamniotic 3
cite 3
multifetal 3
Hispanic, 3
cent) 3
intra-amniotic 3
JNKs. 3
Phospho-p38 3
(PtdIns) 3
MTM1. 3
hypotrophy 3
Endosomal 3
(MTMR2) 3
PI(3,5)P(2) 3
Catalytically 3
MTMR6 3
pseudophosphatase 3
CMT4B2 3
[PtdIns(3,5)P(2)] 3
D-3 3
PtdIns(3)P, 3
(myotubularin)/MTMR 3
(myotubularin-related) 3
Foreign 3
Trihexyphenidyl 3
craniopharyngioma. 3
trihexiphenydile 3
dystonia; 3
dystonicus, 3
aetiologies, 3
(one) 3
worsening) 3
82.8% 3
62.9% 3
akathisia 3
(9.5%). 3
improved) 3
improved). 3
non-Jewish, 3
Mexican-American 3
musculorum 3
hyperpyrexia, 3
H2B-specific 3
(H2BK123ub1) 3
viral-vectored 3
(Mtb) 3
45.4% 3
(41.9%, 3
delamanid. 3
Otsuka 3
Commercialization; 3
NCT00685360.). 3
rifampicin) 3
Linezolid 3
(ICA) 3
(OEF) 3
blinded-adjudication 3
ninety-five 3
randomized: 3
(22.7%) 3
NCT00029146. 3
Extracranial-intracranial 3
extracranial-intracranial 3
(EC-IC) 3
21.0% 3
ipsilateral, 3
data) 3
On-line 3
FTICR-MS 3
H3) 3
automate 3
Collective 3
nanoflow 3
Bottom 3
instrumentation, 3
forms). 3
"basis 3
set" 3
chip-based 3
(ECD) 3
15%) 3
information-rich 3
(MS/MS). 3
mass) 3
Da). 3
Mb), 3
laparoscopic-assisted 3
pre-dialysis 3
Neurally 3
afterwards, 3
(LV). 3
(AAA) 3
axon/dendrite 3
collapsin 3
(CRMP2) 3
(CaV2.2). 3
KMD 3
(K374A/M375A/D376A; 3
CRMP2AAA) 3
DmUba2(C175S) 3
"In 3
marvelous". 3
(TFG), 3
[500 3
(HM)] 3
(57.25%)], 3
(54.28%), 3
(62.5%)] 3
(33.59%), 3
(58.7%)] 3
(44.9%)] 3
(58.7%) 3
[Liver 3
(58.55%), 3
(40.20%)], 3
(55.46%), 3
(56.4%)] 3
(JACQ) 3
64.4% 3
openers 3
nicorandil 3
ATP-regulated 3
(K(ATP) 3
NIDDM, 3
tolbutamide 3
(IGT; 3
tolerance) 3
(maninil) 3
=13), 3
(0.33 3
Asp, 3
compartment(s), 3
Vero, 3
NRK, 3
rab1 3
(MHV) 3
stack, 3
trans-TGN 3
beta-COP-containing 3
buds/vesicles 3
[Evaluation 3
(non-metformin) 3
non-metformin 3
(P=0.039). 3
BMI>32 3
sensitizer, 3
(Metformin 3
month's 3
m(2). 3
androgen-suppressed 3
0.012), 3
metfromin 3
oligo/amenorrhoeic 3
hyperandrogenaemia, 3
end-points: 3
(13.1-15.7) 3
(12.6-15.7) 3
(5.3-8.2) 3
(5.6-9.6) 3
<28 3
(0.63-0.79) 3
(0.15-0.31) 3
(0.34-0.68) 3
(0.27-0.62) 3
(0.43-0.91) 3
(0.06-0.60), 3
insulin-sensitive 3
placebo-controlled. 3
[23.6 3
56]. 3
placebo-treatment 3
ovulations 3
(CC)-resistant 3
sectioned 3
GeLC-MS/MS 3
241) 3
hypertriglyceridemic 3
chymotrypsin/trypsin 3
lipid-storage 3
bodies' 3
IW-11 3
(Proteomics 3
experiments: 3
nano-LC 3
(acid 3
SWATH 3
Data-independent 3
O-glycosylated 3
glycophorin 3
(different 3
AspN 3
amino-acids 3
hexamer. 3
collapsing, 3
Earlier, 3
N(2)-f-dG 3
nanomanipulation 3
cyclopyrimidine 3
MSH2 3
rad7 3
msh2 3
PMS1, 3
UvrA. 3
NusG 3
4256) 3
army 3
Income 3
GAD. 3
Fifth 3
semistructured 3
35) 3
ICD-10. 3
44.8% 3
life: 3
superimposed. 3
strive 3
tertile) 3
1.53, 3
P=0.008). 3
GlaxoSmithKline; 3
ACQ-5 3
eosinophilia-associated 3
α-chain, 3
-0.44 3
750-mg 3
NaCl) 3
(IL-5R) 3
IL-5-specific 3
(MEDI-563), 3
IL-5-mediated 3
MedImmune, 3
dysphagia. 3
interleukin-5. 3
nonreactive 3
(M-HES) 3
life-threatening, 3
1-platelet-derived 3
(FIP1L1-PDGFRA) 3
antagonist), 3
esophagitis. 3
histologically, 3
P=0.02) 3
FEV(1) 3
Mepolizumab: 3
240563, 3
240563. 3
table). 3
enrol 3
(CSS) 3
granulomatosis, 3
[Diagnosis 3
pemphigoid, 3
(interleukin 3
improvement' 3
activation-regulated 3
allergen- 3
diluent-injected 3
Bronchial 3
(RBM) 3
myelocytes 3
anti--human 3
Naive 3
(Ala27Gly 3
Asn40His), 3
suum--sensitive 3
bronchoconstrictive 3
suum. 3
IL-2--induced 3
eosinophilia), 3
>80%. 3
immunotoxicity 3
Monkeys 3
Eosinophil 3
corticosteroid-responsive 3
(LTG) 3
LTG. 3
Documentation 3
MAE, 3
(RUF) 3
absence; 3
cryptogenic, 3
migrational 3
1.5-2.5 3
interictally, 3
(10-13 3
rufinamide. 3
callosotomy. 3
'epilepsy 3
myoclonic-atonic 3
seizures'. 3
zonisamide, 3
felbamate. 3
(58%); 3
Doose; 3
vaccine-related 3
ethosuximide. 3
Landau-Kleffner 3
diet's 3
glycogenosis 3
(LGS). 3
epilepsy" 3
encephalopathy" 3
others) 3
epilepsy]. 3
Felbamate 3
(i. 3
(JME) 3
West's 3
Lennox 3
Gastaut 3
Epilepsies 3
(EDA) 3
atonia, 3
Video-EEG 3
twitching 3
clonic, 3
spikes, 3
surgeons, 3
shoes 3
bracing, 3
thenar 3
drop. 3
[less 3
dSMA-V 3
neuronopathy/axonopathy 3
intramedullary 3
(ELA-2 3
ELANE). 3
ELA-2 3
G6PC3, 3
Kostmann 3
(SCNIR) 3
neutropenias. 3
r-metHuG-CSF 3
hypersplenism 3
MDS/leukaemia 3
R-metHuG-CSF 3
promyelocytes. 3
(rhGM-CSF) 3
1,000/microL. 3
infection-related 3
(GTPases), 3
nontreatment 3
mSSCP 3
(TdP). 3
(LQTS 3
hand/foot, 3
Lange-Nielson 3
(LCSD) 3
Type-1 3
Shannon 3
(full 3
A344V 3
two-electrode 3
Dominant-negative 3
KCNQ1-deltaF339 3
two-microelectrode 3
(CTT) 3
(KCNQ1-deltaF339). 3
KCNQ1-isoforms 3
KCNQ1. 3
individuals). 3
'private' 3
missense. 3
splice-donor 3
non-lethal 3
KCNE2. 3
(I(Ks)) 3
Heterologous 3
hyperpolarizing 3
palmar, 3
plantar, 3
albinos. 3
excised; 3
43.5 3
81.8 3
lentigo 3
maligna 3
T1799A 3
world-wide, 3
focused, 3
aggressiveness; 3
Albino 3
nonmelanomas. 3
6.15 3
nailbed 3
82.1 3
62.9 3
Racial 3
Non-white 3
Enugu 3
(1975) 3
Hutchinson's 3
melanotic 3
freckle 3
sinister 3
1,2 3
70-year 3
Igbos 3
Ugandan 3
chemo-preventive 3
cytostatic, 3
near-toxic 3
(RSV, 3
trans-3,4,5-Trihydroxystilbene), 3
wines, 3
Sirt1- 3
AMPK-independent 3
Intraplantar 3
AMPK-TSC-mTOR 3
rapamycin-induced 3
4E-BP1. 3
insulin/IGF 3
healthspan 3
(3,4',5-trihydroxystilbene; 3
RSV), 3
anti-inflammation, 3
Ca(2+)/AMPK/mTOR 3
Ca(2+)/AMPK-mTOR 3
macrophage-mediated 3
A(2), 3
non-cerebral 3
Malian 3
44-45% 3
0.19-0.61, 3
0.0005, 3
blood-group 3
non-malarial 3
refractive, 3
topometric, 3
pachymetric, 3
accelerated, 3
Wetzlar, 3
+0.38 3
+1.10) 3
+0.20 3
+0.90) 3
meridian) 3
46.56 3
3.83 3
39.75 3
58.30 3
44.44 3
3.97 3
36.10 3
55.50 3
43.22 3
36.00 3
53.70 3
98.48 3
43.47 3
208) 3
pre-operatively 3
76.80 3
38.41 3
190) 3
Decentration 3
0.091 3
0.275 3
0.057 3
0.040 3
0.208 3
451.91 3
40.02 3
353.95 3
370.52 3
58.21 3
(transepithelial 3
cross-linking). 3
-1.00 3
cross-linking: 3
athens 3
Protocol: 3
same-day 3
haze 3
COX-2-dependent 3
Obesity-related 3
Ischemia-reperfusion 3
(remodeling) 3
48.6 3
5.6%, 3
toll 3
(25%; 3
DIAN 3
(A4) 3
LY2062430. 3
radioiodinated 3
1-40 3
compound's 3
oncology: 3
opiates 3
ladder. 3
opiates, 3
Patient-controlled 3
affection, 3
coanalgetics 3
54.5 3
58.0% 3
1051 3
Vulvodynia 3
vulvodynia 3
Lidocaine 3
prescriptions, 3
rotations. 3
psychotomimetic 3
route, 3
ridibunda 3
ridibunda. 3
calcium-paradox-conferred 3
MDL28170, 3
repletion-induced 3
(ERK)1, 3
14.3%, 3
Bcl-2/Bad 3
-repletion 3
-repletion. 3
KCl- 3
Krebs--Henseleit 3
histochemically. 3
alpha-glucan-phosphorylase, 3
beta-hydroxybutyric 3
midmyocardium 3
Ca2+-overload 3
eicosanoid 3
compartmentation 3
chicks 3
vegetables) 3
2,083 3
(TC), 3
(-0.5 3
7.5%, 3
hydrogenated 3
peas, 3
honey, 3
nuts, 3
leafy 3
(GSK3B) 3
(5FU)-treated 3
GSK3B-silenced 3
PARP1-dependent 3
AIF-mediated 3
RIP1-independent 3
pathways; 3
(Fas-associated 3
interleukin-1-converting 3
enzyme-like 3
Interconnections 3
infarction) 3
Bcl2-family 3
-16.7 3
nervosa. 3
(AN 3
(doses 3
milnacipran, 3
CA(3) 3
Latin-American 3
admixture. 3
anticyclic 3
anti-CCP2, 3
(IgM-RF). 3
demographical 3
U, 3
narrowing. 3
prebiologic 3
era; 3
Gender, 3
(DAS28), 3
5,161 3
(4,082 3
1,079 3
(0.12, 3
underweight 3
DAS28, 3
SOFI 3
HAQ, 3
fifty-seven 3
indexes. 3
ESR. 3
fare 3
(disease 3
styles 3
interwoven 3
Microsoft's 3
PivotViewer 3
Silverlight 3
Population-ethnic 3
journey. 3
National/ethnic 3
upgraded, 3
(cerebellum, 3
surely 3
(coming 3
Heller-Dor 3
myotomy) 3
thiamine. 3
triad). 3
confuse 3
misusers 3
discussed) 3
unaided 3
beriberi, 3
alcoholics, 3
Acetate 3
(WE). 3
multilevel 3
3h 3
multivitamins 3
gray, 3
gastrectomy. 3
MR-imaging 3
Consequence 3
Syndrome-Case 3
(AIDS); 3
topped 3
(BDNF), 3
(MECP2). 3
pathfinding 3
(GABA). 3
wringing, 3
twisting, 3
clapping. 3
(skewed) 3
unmitigated 3
epigenetics: 3
renewal. 3
Signatures 3
thorough, 3
exposure-driven 3
transgenerational 3
epimutations 3
Hospitalized 3
THRA1, 3
nmol/d, 3
96) 3
[Impact 3
rs9923231 3
rs10871454 3
over-anticoagulation. 3
Administration-cleared 3
(*3) 3
VKORC1-1639A 3
34.2% 3
36.7% 3
CYP2C9*3), 3
pharmacogenentics. 3
V66M 3
sixty-two 3
CYP2C9*2, 3
(p=0.01) 3
EPHX1, 3
polypharmacy, 3
information]. 3
(NQO1) 3
European-American 3
(INR; 3
Disulfide 3
angiogenin; 3
cyanogen 3
cellulose-based 3
GIP 3
weight), 3
saccharide 3
lyases 3
Dapagliflozin--do 3
gliflozin 3
cardiovascular/clinical 3
'Invokana' 3
'Autodock4.2'. 3
'Canagliflozin 3
CAS 3
-10.03 3
-9.40 3
Q457 3
'Canagliflozin-CAS 3
(S203, 3
H447 3
E334), 3
(S203 3
H447) 3
SGLT2-Canagliflozin 3
AChE-Canagliflozin 3
' 3
(SEM) 3
(L444P) 3
Gba1 3
glucosylceramides 3
(NB-DNJ) 3
glycosphinglipid 3
NB-DNJ. 3
2.3-, 3
best-ranked 3
(56%), 3
3.74 3
2.59 3
0.68). 3
aucher 3
1342C 3
84GG 3
G6490-->A 3
conceptus 3
IVS 3
NciI 3
(acute) 3
beta-Glc 3
WR-1065. 3
eIF2alpha/ATF4 3
scavenging, 3
(Ethyol) 3
transferase. 3
anomalies), 3
mustard 3
clinical/biological 3
nanovesicles 3
aquaporin 3
(AQP2), 3
intra-assay 3
centrifugal 3
Tamm 3
Horsfall 3
lectins. 3
(NGAL) 3
freeze-thaw 3
receptor). 3
spectrophotometric 3
Ultrafiltration 3
delusions, 3
Reviewed 3
clozapine: 3
neuroleptic-induced 3
clozapine-treated 3
negativism 3
Girls 3
methylphenidate 3
non-cognitive 3
(HRQL) 3
SF-36. 3
Propensity 3
polypharmacological 3
(ATS), 3
"atypical 3
(≥2 3
(5/7) 3
members) 3
643 3
T75R-Tg 3
Terminally 3
integrate, 3
cardiology. 3
screens, 3
spawn 3
immaturity. 3
mobilization/recruitment 3
applicability, 3
matrigel 3
microtubule-related 3
(GSS) 3
sibs. 3
Shprintzen 3
(Goldberg-Shprintzen 3
consanguineous, 3
fiberoptic 3
SKI 3
fontanel 3
anus, 3
(Shprintzen-Goldberg 3
skull; 3
(Shprintzen-Goldberg) 3
microfibril 3
intelligibility, 3
TGFBR2. 3
C1/C2 3
craniosynostosis; 3
Cobb 3
10q21.3-q22.1 3
10q22.1, 3
tetratrico 3
neurocristopathy, 3
scaling, 3
(NS, 3
256500) 3
leprosy. 3
erythroderma. 3
PAR-2 3
immunoallergic 3
(LEKTI). 3
based, 3
(OTC) 3
mouse/human 3
granulosum 3
anti-microbial 3
Lamellar 3
1430+2 3
T-->G 3
hK7. 3
micturition. 3
minimally-invasive 3
coeruleus. 3
tilting 3
PD-II 3
mTor 3
DYT1 3
severer 3
hallmarks: 3
bladder; 3
pericentral 3
Oligonucleotides 3
ECL1711 3
ECL1715 3
E14 3
(Km) 3
-0.84), 3
4.3-60 3
170-313 3
0.15-1.45 3
<0.1 3
CSL. 3
multimerizes 3
Skip 3
Mastermind. 3
CSL-binding 3
Mastermind-like-1 3
astrogliogenic 3
(GFAP). 3
CSL-dependent 3
(NLK) 3
HES1 3
polymorphic. 3
beta-core 3
-Cw, 3
-DRB1, 3
synthetase) 3
0.024 3
DRB1 3
(HNPCC) 3
C4714 3
SQSTM1, 3
MAPT, 3
cancerogenesis. 3
(HO) 3
ZnPP 3
(HMOX1), 3
let-7c, 3
miR-98 3
3'-UTR-dependent 3
let-7c 3
1] 3
ARE-regulated 3
BACH1. 3
(HO-1). 3
biochemically. 3
486 3
Antioxidants 3
(Bach1(-/-)) 3
biliverdin, 3
(Hmox-1) 3
Bach1(+/+) 3
45%), 3
423 3
Hepa 3
IX) 3
transducers, 3
(NAC) 3
monoxide, 3
NF-E2 3
bach1-deficient 3
(MARE) 3
(SA), 3
HS-40 3
MafK 3
SIM2 3
heterodimerizes 3
cancelled 3
cadmium, 3
breakdown, 3
diffusum, 3
0.77% 3
alpha-L-fucosidase, 3
beta-mannosidase 3
aspartylglucosaminidase, 3
(G-->A 3
11018 3
(986 3
cDNA) 3
Arg-329-Gln 3
exoglycosidase 3
(MTB) 3
NTM 3
thirty-five 3
L-J 3
MGIT-960 3
genus-specific 3
complex-specific 3
16S-23S 3
Spacer 3
(preferably) 3
cell/mL 3
(8.8%) 3
intracellulare. 3
7H9 3
broth. 3
0.06/0.5. 3
non-MDR 3
RS-112997 3
smegmatis, 3
bacilli. 3
(HIV)-infected 3
7,000 3
(HIV). 3
SPN 3
Regardless, 3
Nonpharmacologic 3
minutes), 3
(OX2R) 3
orexin-B 3
lipid-mediated 3
peptidergic 3
2-period 3
249) 3
Dose-related 3
sleep) 3
Orexins/hypocretins 3
(OX(1)R) 3
(OX(2)R) 3
Dosed 3
arousal. 3
aids, 3
insomniacs 3
Hypnotic 3
(UGE), 3
77.1, 3
80.9, 3
93.0 3
-1.56, 3
-2.31, 3
-2.37 3
-0.86 3
-2.21, 3
-2.42, 3
-2.54 3
(9.5%); 3
(no. 3
NCT00885118). 3
(T2DM; 3
3.02 3
benzylic 3
purities 3
(qd) 3
kg/m², 3
133.5 3
10-25 3
EGP 3
(EudraCT 3
Single-pill 3
drug-likeness 3
Scramble 3
ZINC 3
purchased 3
products' 3
ranking. 3
Fgf8 3
pan-vertebrate 3
tetrapod-specific 3
Transgenesis 3
CVS. 3
X/Y 3
AMELX/Y+SRY 3
relevant? 3
10(th) 3
sexing 3
penumbra: 3
phase-specific 3
anoxic 3
redefined 3
(ADC) 3
midpenumbra 3
periinfarction 3
MABP 3
detrimentally 3
pentamers 3
mismatch, 3
ion, 3
(PLB-KO) 3
(CCh) 3
47.4 3
bladders, 3
CCh 3
PLB:SERCA 3
[Ca2+]i. 3
(MH), 3
(CCD), 3
Brody 3
endothelium-intact 3
>98% 3
(SR)-associated 3
phospholamban: 3
labeled. 3
Alpers-Huttenlocher 3
T(2) 3
HCL. 3
(MEK)-extracellular 3
erythro-, 3
(2008), 3
tritiated 3
(>40%) 3
ANKA 3
4-11 3
Isothermal 3
(H3K9), 3
histone-lysine 3
(EHMT2; 3
dimethylation; 3
DPY-30 3
2,4-pyridine-dicarboxylic 3
(HDMs). 3
2,4-pyridinedicarboxylic 3
(2,4-PDCA) 3
HDM 3
KDM4C. 3
HDMs 3
LANCE 3
DOT1L: 3
H3-lysine79 3
Cancer-testis 3
repression/activation 3
gene-induction 3
MAGE-A3 3
KMT6, 3
KDM1, 3
deoxyazacytidine 3
(DAC)-mediated 3
DAC-DZNep 3
MAGE-A3. 3
DZNep 3
neplanocin 3
antibody-coated 3
EHMT1, 3
t(1/2) 3
(NaBt) 3
Gene-based 3
attempted, 3
antiporter 3
MEK5 3
(MEF)2 3
HDACs. 3
Cardioprotection 3
(casq2) 3
Sol8 3
trabeculated 3
trans-activates 3
MCK 3
cis-elements 3
Nkx-2.5/Csx, 3
OTF-1, 3
PPAR/RXR, 3
TREs. 3
E-boxes, 3
E8.5 3
BF-2 3
(PGAM-M) 3
skeletal-muscle-specific 3
MEF-2. 3
gliomagenesis 3
60.8% 3
807) 3
(Hazard 3
(HR)=1.50). 3
IDH-mut 3
(OS)>17 3
IDH-mut, 3
OS=97.5 3
OS=31.6 3
OS=15.4 3
Tert 3
IDH1, 3
alterations: 3
1087 3
triple-positive), 3
472 3
triple-positive, 3
Tofacitinib: 3
(1970 3
(mCIA) 3
once- 3
homodimers, 3
congress 3
2.63) 3
2.80 3
Xeljanz, 3
tofacitinib) 3
(GLPG-0634) 3
adjuvant-induced 3
AIA 3
[Regulation 3
(tofacitinib), 3
(CIA) 3
cancel 3
50.7% 3
DAS28-CRP 3
(ACR20 3
59.2% 3
22.0% 3
272) 3
(4.8%). 3
(15-25 3
MTX; 3
66%, 3
Jak2, 3
ARNT, 3
ERα, 3
trefoil 3
TALEN-induced 3
(TALEN)-based 3
α-thalassemia 3
CRISPR/Cas, 3
CRISPR/Cas-mediated 3
0.27% 3
alpha(1B) 3
1326 3
halves. 3
mu-opioid 3
antinociception. 3
Antinociception 3
care? 3
omega-conotoxin, 3
snail, 3
Conus 3
magus. 3
pain-sensing 3
(IT) 3
agents--N-type 3
NCCBs. 3
Structurally, 3
neuronal-type 3
(PGE2), 3
(alpha2delta-subunit 3
ligand), 3
(N-type 3
(serotonin 3
neurochemically-induced 3
NMDA- 3
Fluo-3 3
other) 3
(SNX-111), 3
intrathecally. 3
use-dependent 3
10-minute 3
retrosplenial 3
linings 3
projections, 3
decynium-22 3
[in 3
nonatopic 3
Connecticut 3
RAD18-knockout 3
(MMC)- 3
(DEB)-induced 3
phytohemagglutinin. 3
(28.95%) 3
(54.54%) 3
(36.36%) 3
(2.63%) 3
(45.45%) 3
dup(1)(q12-q24), 3
inv(7)(p11pter). 3
(276 3
Turkmens, 3
Turkmen 3
(p.Val1233del), 3
(p.Val311SerfsX2), 3
(p.Thr367AsnfsX13). 3
tested) 3
p.Ser858Arg 3
6.2-44.2, 3
Lys3326X 3
FANCD1) 3
3.38, 3
1.97-6.91, 3
proposition, 3
DC), 3
(FANC) 3
exons), 3
non-functional, 3
multiday 3
IQSCMaRTEA 3
gentamicin. 3
non-conventional 3
Downstream 3
integrin-positive 3
protrusion, 3
Rac-mediated 3
Phosphoinositide 3
gangliosides, 3
(FAK)/protein 3
reused. 3
Dishevelled. 3
Axin. 3
DVLs 3
R301Q 3
autogenous 3
VSMCs, 3
graft. 3
myelin-forming 3
(OPCs) 3
OLGs. 3
OLGs 3
disease-dyslipidemia, 3
motor-neuron 3
Differentiating 3
TALEN, 3
(CCR5, 3
Hypothermic 3
TAT-TALEN-mediated 3
TALE-based 3
β- 3
baculoviral 3
Nkx2.5, 3
Isl1 3
infarct-related 3
Pigs 3
IGF-2, 3
AT1R, 3
hCSC 3
IGF-2 3
(IGF-1)-IGF-1 3
infarcts, 3
(IGF-1)MSCs 3
3-kinase, 3
CPCs, 3
multipotent. 3
Connexin 3
FVB.Igf+/- 3
simulated. 3
Kingdom) 3
overestimated 3
policy. 3
(Lmo2) 3
cysteine-containing 3
genetically-selected 3
Pep80, 3
N-ethyl 3
maleimide 3
richest 3
ID1/3-PA7 3
ID1. 3
eight. 3
(MMS). 3
Id1, 3
Id1/3-PA7, 3
Id3, 3
ES-2 3
(Id) 3
(PARP). 3
Aptamer-derived 3
Tgat. 3
Trio 3
(potent 3
Abeta-binding 3
antioxygenic 3
TRX. 3
pre-selection 3
SELEX. 3
G-quartet 3
DRD-binding 3
stefin 3
thioredoxin, 3
blebbing 3
inflammasomes 3
(nucleotide-binding 3
(NOD)-like 3
Caspase-1 3
microcolonies 3
NOD-like 3
Caspase-1, 3
ITAM 3
pro-IL-1beta 3
AIDS. 3
(IL-1beta) 3
caspase-4. 3
yakuba, 3
procedure) 3
(CyN). 3
CyN-associated 3
CN-associated 3
overlapped. 3
CN/CyN 3
ELANE. 3
CyN, 3
leukemogenesis; 3
haplotype: 3
(Ela2) 3
(P13L, 3
R52P, 3
S97L), 3
(W212stop 3
P110L), 3
(V72M) 3
neutropenia: 3
elastase, 3
one). 3
TGFβ-dependent 3
epicardium 3
oversimplified 3
angiomyolipoma; 3
≥1.0 3
(16/30) 3
(0/14) 3
everolimus- 3
(56.5, 3
78.3 3
(82.6, 3
TSC.The 3
NCT00789828; 3
http://clinicaltrials.gov/ct2/show/NCT00789828?term=EXIST-1&rank=1. 3
hormone-receptor-positive 3
everolimus-related 3
13.5-year-old 3
mg/m. 3
EXIST-1 3
(33-38 3
(NCT00411619) 3
titrated, 3
4.7-47.1). 3
65%-79% 3
(AE), 3
(46.4%), 3
(35.7%). 3
(RAD001), 3
stomatitis/mouth 3
symptoms--eg, 3
0-65 3
Federation, 3
internet-response 3
4·5 3
response--ie, 3
NCT00789828. 3
(n=39). 3
15-52; 3
[21%]), 3
[15%]). 3
pharmacologically, 3
review); 3
(EXIST-1) 3
nonworsening 3
new/worsening 3
hydrocephalus). 3
TSC; 3
regrowing 3
biotinylation, 3
cFN 3
micropatterned 3
Ln, 3
cross-scale 3
α5. 3
PCTK1 3
KAP0 3
β1-null 3
hβ1-expressing 3
adhesion-associated 3
messengers. 3
(I(NCX)) 3
Reverse-transcription 3
store. 3
line-scan 3
(CaSRs) 3
on" 3
NCX1, 3
3.1-fold 3
Postpartum 3
RyR). 3
subsumes 3
flux, 3
pt 3
Saskatchewan 3
Unraveling 3
exosome-sensitive, 3
Shortening 3
Actually, 3
HEY1, 3
disagreements 3
coalescing 3
developping 3
retrogene. 3
ChCS 3
TNF- 3
ANA-1 3
burgdorferi, 3
TRAF1, 3
poultry 3
antiserum. 3
K-562 3
His-tag 3
immunize 3
(LE) 3
LE 3
RU486 3
uteri 3
blastocyst. 3
P4-regulated 3
questionable, 3
(RPE), 3
(HESC), 3
Stem-cell-based 3
hESC/hiPSC-derived 3
Manufacturing 3
(>220 3
Near-normal 3
teratoma/tumor 3
inexhaustible 3
quantify, 3
passaging 3
cell-RPE 3
iPSC-RPE 3
laminin-111. 3
hESC-RPEs. 3
xeno-free, 3
First-generation 3
zuclopenthixol, 3
flupentixol. 3
SNAS, 3
BraMa-Ni 3
nickel-containing 3
occupations 3
extracutaneous 3
exceptional, 3
IL5 3
13.04 3
(FVHT 3
thyroiditis). 3
IgG4, 3
Rose 3
Ig4-related 3
(submandibular 3
RTX. 3
TGFβ1. 3
antigen-positive 3
glomerulosclerosis, 3
effacement, 3
integrin-associated 3
beta1-integrin/FAK 3
ECM-signaling 3
hexamethonium 3
(C6) 3
(Tc) 3
fibre. 3
hyperpolarization. 3
(alpha(2), 3
epsilon) 3
8.4-11.4 3
33.6-53.3 3
897 3
699-1150 3
685-1001 3
Coapplication 3
NDMRs. 3
NDMRs, 3
Oocytes 3
succinylcholine 3
Nerve-stimulated 3
(ACh)-induced 3
triangularis 3
sterni 3
(NF007, 3
NF023, 3
NF279 3
NF449) 3
ACh-induced 3
receptors' 3
synchronisation 3
Co, 3
jet 3
almorexant, 3
(τ 3
fibronectin-coated 3
aim, 3
arc 3
VASP, 3
adhesiveness 3
IIα, 3
DHHC1/10 3
enlarge 3
phospho-protein 3
LIM-domain 3
ELMO1/Dock180 3
receptor/Gi 3
Morpholino-based 3
anastomotic 3
Unc5B 3
GTPbinding 3
ELMO-Dock180 3
ERM-binding 3
ELMO1-mediated 3
(WASP), 3
(WIP), 3
U937. 3
(WASP) 3
(WIP). 3
84-kDa 3
LCV, 3
ankB 3
whistle 3
symphony 3
(IKK)-activating 3
non-proteolytic 3
non-classic 3
"Autophagy 3
TRAF2: 3
DAPK 3
Tumoral 3
(P=0.021). 3
DAPK, 3
(ROC 3
82.2% 3
DNMT1/3b 3
pretherapeutic 3
(platinum/5-fluorouracil)-treated 3
histopathological/clinical 3
(P=0.03/P=0.008) 3
(P(log-rank)=0.001). 3
platinum/5FU-based 3
(TGCT) 3
SOX2. 3
(9.0%), 3
(9.0%) 3
1.82; 3
vorinostat-treated 3
UHRF1, 3
(herpes 3
protease). 3
metallothionein 3
DMH 3
pAKT, 3
DEHP 3
C46359T 3
(-149C>T), 3
84.8%, 3
mucosae 3
(hMLH1), 3
(+)-viroid 3
nicked 3
(NH(4))(2)SO(4) 3
alpha-amanitin-resistant 3
(+)-stranded 3
(-)-stranded 3
tuberosum. 3
(-)-strands, 3
(+)-PSTVd, 3
Primer-extension 3
(-)-strands 3
PSTVd's 3
planta. 3
heptapeptide 3
compensatory, 3
(ASBV) 3
polycrylamide 3
viroid-infected 3
Proteins: 3
LRPPRC, 3
unmasks 3
ASIC 3
(synonyms: 3
Pael 3
parkin-binding 3
insoluble, 3
ubiquitinated. 3
MAGUK 3
Riociguat: 3
persistent/recurrent 3
CTEPH, 3
chronic/persistent 3
Parameter 3
requesting 3
Formulary 3
prioritized. 3
audit. 3
mg/l. 3
(12%). 3
17.6% 3
microg/mL. 3
coagulase-negative 3
microg/mL) 3
>0.6 3
bilobed 3
breeding, 3
alga, 3
reinhardtii, 3
Cas9n 3
loxP 3
isoprenoid 3
recombinase. 3
Apicomplexa, 3
coevolution 3
(fostamatinib), 3
Aberrantly 3
homing, 3
xenotransplant 3
LCP1. 3
PI3K-δ 3
chemokine-mediated 3
GS-1101 3
(NAC). 3
homocysteine. 3
nonepilepsy 3
AED-exposed 3
supplement, 3
litters 3
8005 3
parity. 3
specificity? 3
Spina 3
trabeculae. 3
NO-donor 3
NOC12, 3
(12.6 3
N4104K, 3
microg/kg/min) 3
pointes, 3
FKBP12.6-mediated 3
JTV519; 3
FK506-induced 3
Fifth, 3
JTV519-untreated 3
PKA-hyperphosphorylated, 3
decreasing. 3
4-wk 3
1,4-benzothiazipine 3
JTV-519. 3
photoaffinity 3
MRP1 3
MRP1, 3
cardioprotectant 3
(cisplatin, 3
(0.3-3.0 3
indol-loaded 3
2-wavelength 3
fluormetry 3
(R405/500). 3
R405/500 3
JTV(-), 3
42.7 3
JTV(+), 3
22.0 3
transsarcolemmal 3
I(Ca). 3
reperfusion-related 3
cardioprotective. 3
metastasize. 3
deregulation. 3
parts: 3
(hcn), 3
7-kb 3
6-7-fold 3
metastasise. 3
metastasised 3
BC1 3
BC200, 3
nt), 3
(Frd) 3
ip 3
browning 3
pericytes. 3
normothermic 3
No.2 3
apelin-13. 3
visfatin, 3
visfatin 3
Homocysteine 3
vasodilation. 3
631 3
(27/101 3
(23/38 3
(43/44 3
(P=0.022 3
P=0.020, 3
(PABPC1 3
RORA, 3
PABP4, 3
(p(Het) 3
0.034) 3
PABPs, 3
ABL1. 3
mined 3
CD4(+)CD8(+) 3
(k(cat)/Km) 3
ABL-mediated 3
CRK, 3
PSTPIP1, 3
DOK1, 3
RIN1-mediated 3
SRC-mediated 3
ABL1T315I, 3
Constitutively 3
MuSK 3
(LQT3). 3
channel). 3
(JLNS), 3
Syncope 3
"reading" 3
"writing" 3
H2BK5me1, 3
H3K27me1, 3
pre-steady-state 3
phosphoenzyme 3
(Ca2+) 3
humanely 3
Ca2+-uptake 3
PKA, 3
re-sequestration 3
(Cys(24)) 3
pre-ischemic 3
nitration 3
sparks. 3
Forskolin 3
+-calmodulin-dependent 3
Thr(17)phosphorylation 3
(beta-AR) 3
VD, 3
VD-HF. 3
beta-adrenergic-induced 3
CM-kinase-II 3
Tele-pain 3
posttreatment, 3
CBOCs 3
smartphones 3
smartphone-delivered 3
SMART2 3
Solutions 3
money, 3
Telemedicine 3
dollar 3
anesthesiologists 3
directed. 3
translation; 3
DCP1. 3
(RFP) 3
Physiologists. 3
non-membranous 3
cargoes. 3
calorimetry, 3
decapping, 3
exoribonucleases 3
Two-hybrid 3
Tia1 3
TIA1 3
noteworthy, 3
Bfr1 3
Pat1, 3
presumably, 3
Dcp2-positive 3
based. 3
NAD-related 3
(Dacogen®) 3
MAGE-A 3
Demethylating 3
p15. 3
(decitabine, 3
MSNP 3
bisulfite-converted 3
Mitchell-Riley 3
Morpholino 3
tadpoles, 3
enteroendocrine 3
adenovirus. 3
thyroiditis--lack 3
(interval 3
Stool 3
Enteroviral 3
EIA, 3
RIA, 3
[Studies 3
HLA-Bw35 3
(56.7%) 3
phone-based 3
price, 3
dermatology-related 3
[26.6%]), 3
self-surveillance/diagnosis 3
[17.9%]), 3
[17.0%]), 3
[8.7%]), 3
sunscreen/UV 3
[8.3%]), 3
[5.2%]), 3
teledermatology 3
[3.5%]), 3
[2.2%]), 3
dermoscopy 3
[3.5%]). 3
(355 3
reviews), 3
VisualDx 3
(306), 3
(128), 3
iSore 3
(61), 3
SpotMole 3
(50). 3
Paid 3
computers) 3
iTunes 3
Play 3
myFitnessCompanion® 3
apps) 3
(EMA)-daily 3
behavior-to 3
psycho-education 3
TIN2, 3
C16orf57, 3
TINF2 3
(codes 3
dyskerin), 3
(code 3
telomerase) 3
recessive) 3
prism 3
3100 3
Dkc1 3
haemopoiesis, 3
EWSR1-ETS 3
(CD99wt) 3
short-form 3
(CD99sh) 3
ACTR2, 3
ARPC1A, 3
Rho-associated, 3
(ROCK2) 3
ezrin/radixin/moesin 3
CD99wt, 3
stop-migration 3
promigratory 3
miR-9-modulated 3
PRDM1/BLIMP1 3
redifferentiation. 3
(cHL). 3
lowly 3
(PRDM1/BLIMP1). 3
miR-9-mediated 3
PRDM1 3
PAX5, 3
CD79α 3
CD19, 3
PRDM1. 3
CD99-miR-9-PRDM1 3
cHL. 3
Production, 3
divergency 3
orthologs: 3
CD99L2, 3
PBDX, 3
CD99L1 3
autosome, 3
CD99L2 3
addition-attrition 3
transfectants. 3
NBL-1 3
ectodomain. 3
XG: 3
antithetical 3
Anti-Xg(a) 3
Alloanti-Xg(a) 3
insignificant; 3
autoanti-Xg(a) 3
anti-CD99. 3
X-borne 3
MIC2/CD99-positive 3
(EFT) 3
MIC2/CD99 3
EWS/ETS 3
S-100, 3
product) 3
anti-E2 3
CIC-FOXO4 3
aligner 3
Integer 3
acknowledged, 3
path. 3
arriving 3
FASTQ 3
Accurately 3
developed; 3
MISO 3
mixtures, 3
LGPL 3
exon-inclusion 3
IsoformEx 3
Uniquely 3
coved 3
Sociedade 3
Portuguesa 3
PKP2, 3
Sleep-disordered 3
SDB. 3
BRU-SDB 3
Brugada's 3
reentry. 3
Laos. 3
normalises 3
unmasking 3
normalize; 3
paranuclear 3
LC3-positive 3
112, 3
(KPI) 3
disorders? 3
Synphilin 3
Synphilin-1 3
synphilin-1 3
1912, 3
alpha-synucleinopathies 3
segregated, 3
3,5,3'-Levo-triiodothyronine 3
(L-T3) 3
μg/kg/day) 3
6.9%), 3
(6.34 3
33.7 3
6.21%) 3
infarct-scar 3
mitoKATP 3
plantaris 3
myocardial-specific 3
COXI, 3
COXIV) 3
PPAR-alpha), 3
coactivator-1alpha 3
capacities, 3
AMPKalpha 3
[3,5,3'-triiodo-l-thyronine 3
(mtHsp70). 3
involves, 3
contradictory. 3
thyroid-induced 3
receptors? 3
NRF-1alpha 3
nuclear-mitochondrial 3
Tfam 3
(mt)DNA 3
(PGC-1alpha), 3
1.6-fold 3
Chemically 3
Dosages 3
malic 3
melanocortin-1-receptor 3
(NMSC), 3
3527 3
9391 3
(SCC): 3
(1.24-1.76), 3
(1.15-1.69) 3
(1.35-1.91), 3
darker-pigmented 3
phototype 3
decapped 3
[Seipin/BSCL2-related 3
Seipinopathy 3
(CGL2) 3
lipoatrophy, 3
Seipin/BSCL2-related 3
"seipinopathies". 3
seipinopathies 3
hyperreflexia 3
(NCV) 3
SPG17, 3
S90L. 3
seipin, 3
16.7) 3
0.76; 3
P=0.002), 3
Caco2, 3
IL-8-induced 3
CXCR2-specific 3
(FAA) 3
SNURF-SNRPN 3
(HBII-438A 3
Metaphase-FISH 3
examplifies 3
1' 3
(sno) 3
(VMH) 3
(ARC) 3
cortex; 3
(IC). 3
hyperphagic 3
(PWCR1/HBII-85) 3
snoRNA. 3
Igf1 3
INF2, 3
Drp1S616 3
(SFK) 3
E4orf4 3
arteriosus. 3
Tubular 3
Dorsal 3
GTP-binding, 3
Shifts 3
(CA), 3
Sixty-nine 3
exonic. 3
breast-cancer-susceptibility 3
421 3
colonoscopy. 3
FANCD1/BRCA2, 3
CSQ(K206N) 3
immunoblots. 3
CSQ(K206N)-expressing 3
exercise-emotion-triggered 3
(c.923C>T), 3
(CASQ(307/307)) 3
CASQ2-null 3
(CASQ(DeltaE9/DeltaE9)). 3
proportions) 3
Mg(2+), 3
electrical-mechanical 3
leakiness, 3
effort-induced 3
Mg2+, 3
(T66A 3
V76M). 3
DeltaF/F(0) 3
washing. 3
boutons. 3
Co-assembly 3
afterhyperpolarisation 3
BAPTA, 3
close. 3
(Slo(27)) 3
Ca(V)2.2/Ca(V)beta(3) 3
Ca(V)1.2/Ca(V)beta(3) 3
vascularly 3
high-K+ 3
vascularly-perfused 3
cadmium. 3
sensitivity: 3
Nothing 3
post-MCA 3
fimbriae. 3
HB101 3
palatability 3
P-fimbriae 3
mutans, 3
0.2/mL 3
1mg/mL 3
FTF, 3
Nintendo 3
Wii 3
electronic-monitoring 3
mentoring 3
psycho-social 3
(frequency 3
Smartphone 3
(PAA) 3
descriptively 3
paper-based 3
ambulant 3
ranitidine. 3
cytotoxics. 3
serendipity 3
myelomagenesis, 3
MYC-driven 3
(18)F-fluorodeoxyglucose 3
1-21) 3
all-oral 3
ULK2, 3
ATG13 3
GABARAPL1, 3
(GABARAP-like 3
(GABA(A) 3
GABARAPL2 3
(GATE-16). 3
ATG12-ATG3 3
autocatalytic 3
GFP-p62 3
DeltaN63 3
(GABARAP), 3
chain-3 3
hAtg7 3
hAtg3 3
lipidation, 3
tested: 3
Ma. 3
complex/cyclosome 3
asynchronously. 3
Mitoses 3
GFP-labelled 3
wild-type-like 3
benomyl, 3
modeled. 3
(cMT) 3
autonomy. 3
cycle-specific 3
Hyphae 3
OPs; 3
Upgrade 3
'triplex' 3
(bioconductor.org). 3
lexa@fi.muni.cz 3
supraphysiological 3
(MEK1/2) 3
prenyltransferase 3
rectified 3
disappointingly 3
'Use 3
Events' 3
(UMPIRE) 3
guideline-indicated 3
UMPIRE, 3
(England, 3
Netherlands), 3
UMPIRE 3
EudraCT: 3
2009-016278-34 3
CTRI/2010/091/000250. 3
'Single 3
(SPACE)' 3
collaboration, 3
'IMProving 3
(IMPACT)' 3
'Kanyini 3
Polypill 3
(Kanyini-GAP)' 3
(IMPACT) 3
atenolol. 3
(ACTRN12606000067572). 3
(Polycap) 3
(TIPS): 3
VSL#3 3
armamentarium; 3
Bb 3
38.7% 3
(5.1 3
acidified 3
orthopedic, 3
Bentall 3
dissections, 3
type]. 3
implemented, 3
pathomorphological 3
(30.8%) 3
Freedom 3
Intra- 3
mL/m(2); 3
selling 3
markets. 3
(17.8%) 3
92.4% 3
predators. 3
Atlantic 3
smooth-backed 3
Kyushu 3
contained. 3
Arothron 3
1992-1993. 3
coast; 3
terrigena, 3
niphobles. 3
Puffer 3
non-acid-fast, 3
non-sporing 3
gutB01) 3
(ITS) 3
Coast, 3
inhabits 3
MU/g), 3
Na(v)1.4 3
gastropods, 3
allowable 3
Pufferfish 3
TTX-free 3
slugs 3
gastropods 3
exogenous; 3
starfish, 3
necrophagous 3
small-to-medium 3
snails, 3
niphobles 3
brackishwater 3
biocellatus 3
specimens) 3
(female 3
tetrodotoxin, 3
dinoflagellates, 3
predator 3
FFD 3
seafood 3
Scales, 3
(CCTG)n 3
myopathy/proximal 3
origins: 3
PROMM 3
(CCTG) 3
200-540 3
Rica 3
myopathic, 3
interfamilial 3
(HbF) 3
Mob 3
ndr-like 3
yeast; 3
Salvador 3
Mst1/Mst2, 3
YAP1, 3
progenitor/stem 3
Ajuba 3
Ras-MAPK 3
Jub 3
nTSGs 3
outputs, 3
2week 3
40mg/day 3
(170 3
(DIDs) 3
DIDs 3
Single-center 3
Neurointensive 3
278) 3
(DNDs) 3
(vasospasm) 3
case-control) 3
(timing 3
males). 3
fibrinolysis, 3
(n=14) 3
(DINDs). 3
autoregulation, 3
history) 3
51%, 3
Stokes 3
Angular 3
nanoscopic 3
22.8 3
Conduct 3
20-40 3
(molindone) 3
(TEOSS) 3
(plus 3
benztropine) 3
Akathisia 3
between-drug 3
akathisia. 3
(2RCTs 3
n=60 3
molindone. 3
BWG, 3
animals; 3
psychiatrists, 3
decreases, 3
(WMD) 3
6.99). 3
antipsychotic; 3
4.15 3
sertindole, 3
least. 3
depot 3
valproate) 3
phenothiazines 3
pccA 3
14-bp 3
eficiency 3
dodecamer 3
Austria 3
U1snRNA 3
(5' 3
acidemia]. 3
(CoA) 3
>A 3
A497V 3
N536D), 3
R512C 3
R165Q 3
(PA, 3
232000 3
232050) 3
structurally. 3
odd-chain 3
G131R, 3
G198D, 3
V205D, 3
chaperone-assisted 3
R512C, 3
backcross 3
betaPCC 3
1540insCCC, 3
253. 3
Austria. 3
b-PCC 3
1209 3
539 3
(0.3), 3
unclassified. 3
valine, 3
Y439C, 3
1527del3, 3
1357insT, 3
IVS12-8T-->A, 3
31del10, 3
Alleleic 3
56.3% 3
betaPCC-subunit 3
phosphatase-1/phospholamban 3
glycogen-targeting 3
SERCA2/phospholamban 3
LLGL2, 3
(SCN), 3
MDS/AML, 3
Long-term, 3
3.70 3
before-and-after 3
hemiballismus 3
neurostimulation; 3
(-15.8+/-14.1 3
(-1.4+/-3.8 3
swallowing), 3
dislodgment. 3
NCT00142259 3
(while 3
38, 3
subtests 3
Card 3
LFPs 3
Deep-brain 3
46.3+/-21.3 3
21.0+/-14.1 3
11.6+/-5.5 3
6.5+/-4.9 3
(24.6+/-17.7 3
34.6+/-12.3, 3
pallidotomy 3
GPi, 3
Proliferating 3
Sef, 3
interleukin-1, 3
(p50:p65) 3
(IkappaB) 3
IkappaBbeta 3
IkappaBepsilon 3
Pit-1 3
p105.Ikappa 3
Bgamma 3
Ikappa 3
Bs 3
p105, 3
imports 3
IkappaBgamma) 3
IkappaBgamma. 3
NLS. 3
-63 3
-36 3
p50-p65 3
repeat: 3
NF-kappaB/Rel-IkappaB 3
HsN3 3
thalamic, 3
Tax-protein-mediated 3
B2)-inhibited 3
ankyrin-motif-containing 3
B-alpha 3
B2). 3
conductance, 3
lens, 3
zonules 3
(WMS), 3
Disintegrin-like 3
ThromboSpondin 3
ADAMTSL2. 3
19p13.3-p13.2 3
lenses, 3
19p13.3-p13.2. 3
glaucomatous 3
KLN205 3
pemetrexed, 3
(1-3 3
kHz), 3
dielectrophoretic 3
(TTFs) 3
TTFs 3
sub-lines 3
sub 3
asses 3
peri- 3
in-vitro, 3
TTFields-chemotherapy 3
tuned, 3
stunts 3
NovoTTF-100A 3
(transcription 3
factors), 3
markers), 3
Isl1+ 3
(endothelial 3
"angiocrine" 3
undisclosed 3
chosen, 3
EC, 3
haematopoiesis. 3
sinusoids 3
homocitrulline 3
one-class 3
HDL. 3
3-chlorotyrosine 3
HDL-associated 3
Cdc45/Mcm2-7/GINS 3
(hCtf4 3
hCtf4, 3
benzonase 3
salt-resistant 3
ctf4(S143F) 3
Tof1 3
Saitama 3
(SBCCSG-06). 3
hormone-responsive, 3
IIIA 3
87.5, 3
84.3, 3
83.5 3
FACT: 3
258) 3
256). 3
.91); 3
56-year 3
AIs, 3
(Tomao 3
leuprorelin, 3
leuprorelin 3
anastrazole 3
Ottawa 3
Arimidex, 3
1-98), 3
6a, 3
33). 3
thrombolic 3
(9.1%). 3
p=0.014, 3
p<0.02). 3
(Arimidex), 3
(CLBC). 3
0.062), 3
Chs2. 3
MEN-deficient 3
bud-neck 3
[PS]), 3
phospholipids; 3
Hof1, 3
AMR. 3
furrow. 3
syndrome-specific 3
(OFC) 3
0-36 3
Igf-2 3
aggressive. 3
Cul1, 3
SCF. 3
Dia2, 3
pick 3
concatenates 3
trivially 3
ftp://www.ieeta.pt/~ap/maws. 3
notions 3
(HSAS) 3
F508del, 3
0.019) 3
5T/(TG)12_13 3
81.9% 3
96.3% 3
74.1% 3
F508-CFTR 3
DeltaF508, 3
DeltaF508 3
G551D 3
agonist-induced 3
titrate 3
retrotranspositionally 3
'source 3
prosimian 3
(sCJD). 3
Angiosperms 3
(POR). 3
poly-l-lysine 3
appr. 3
oxidoreductase, 3
Light-induced 3
desiccated 3
pregranal 3
NADPH: 3
low-temperature 3
pigment. 3
Chl 3
(PORA) 3
a, 3
PORC. 3
etioplast 3
photomorphogenic 3
porA-1 3
de-etiolated 3
dwarfing 3
etiolation, 3
plastid, 3
first-step 3
isoprenoids, 3
1-D 3
oxidoreductase. 3
PCC6803 3
carotenoid-deficient 3
chlorophyll. 3
reetiolated 3
Tailored 3
omalizumab. 3
omalizumab, 3
ligelizumab 3
lumiximab) 3
(FcϵRII). 3
(canakinumab), 3
C5a 3
(eculizumab). 3
lebrikizumab. 3
corticoids 3
Metabolomic 3
Immunoresponsive 3
methylenesuccinic 3
decarboxylating 3
glyoxylate 3
ZMET2, 3
(BAH) 3
zmet2. 3
outcrossing 3
m/s), 3
(MUAPs) 3
c.2046+1G 3
LRSAM1-associated 3
NF-L 3
(giant 3
m/s) 3
19p12-13.2 3
(CMT1C) 3
(G112S, 3
T115N, 3
W116G) 3
LITAFgene 3
(lipopolysaccharide-induced 3
Slovenian 3
GDAP1. 3
GDAP1-associated 3
(CMTI) 3
9q33-q34. 3
11.6-Mb 3
8.06. 3
(cDNA) 3
(c.2047-1G>A) 3
(p.Ala683ProfsX3). 3
ARCMT 3
Neuropathologic 3
NCV 3
haematological, 3
Glu222Lys 3
CMT4A 3
IRFs 3
[HMG 3
I(Y)]. 3
I(Y)-dependent 3
(ATF2/c-JUN, 3
NF-kappaB), 3
(CBP). 3
Deletion, 3
(enhanceosome). 3
(79% 3
0.34-0.98) 3
1.4-6.3) 3
N-amino 3
representation, 3
borrowed 3
count-based 3
closes 3
cosmo, 3
satisfy. 3
formulated, 3
MEME, 3
reliance, 3
cosmo 3
(I-II 3
III-IV), 3
II-III) 3
Recurrence. 3
(0%; 3
0%-17.6%). 3
1.3%-98.7%). 3
eighty-three 3
'heroic' 3
reresection 3
Regrowth 3
6.42, 3
<35 3
(3- 3
81%, 3
contradicting 3
DTS. 3
[28.6%] 3
DTS, 3
cartwheel, 3
centrioles; 3
Pakistan 3
axoneme 3
flagellum 3
centrioles. 3
UNIMOD 3
Centrosomes 3
underneath 3
alpha-helix, 3
#10 3
discouraging 3
lipoprotein-associated 3
Phospholipase 3
darapladib, 3
antiatherosclerotic 3
0.5; 3
IIa, 3
PARTICIPANTS: 3
(SPIDER-PCI) 3
(P=0.14). 3
substudy 3
Mateo, 3
ng/mL), 3
2.77 3
0.36). 3
(apoB)/human 3
(CETP)/human 3
(TTT) 3
Western-type 3
apoB/human 3
Surfactant, 3
(Jardiance): 3
(AUC0-∞) 3
(GMR): 3
2.50 3
(q.d.) 3
(AUC(τ,ss)) 3
[GMR] 3
110.4; 3
103.9, 3
117.3) 3
(max,ss)) 3
107.6; 3
97.0, 3
119.4) 3
103.1; 3
98.9, 3
107.3) 3
(max,ss) 3
108.5; 3
100.7, 3
116.9) 3
(31.3%) 3
(AE): 3
OAT3 3
(AUC0-∞: 3
osteochondromas. 3
osteochondromas 3
osteochondroma 3
osteochondromatous 3
FGFR3(P250R) 3
(FgfR3(P244R)) 3
synchondrosis 3
resting, 3
perichondrium 3
44.0% 3
otolaryngologist, 3
(Muenke 3
craniosynostotic 3
resorbable 3
Midfacial 3
skull) 3
anomalies; 3
(short 3
changes). 3
"Muenke" 3
"non-Muenke" 3
propounded 3
FgfR3P²⁴⁴R, 3
(FgfR3(P244R) 3
chondroprogenitors 3
1(Ptch1). 3
H4C-positive 3
chondroprogenitors, 3
II- 3
X-expressing 3
spongiosa 3
FGF2/FGF9 3
Ptch1 3
superficial/polymorphic 3
chondroprogenitors. 3
eminence/glenoid 3
TMJ, 3
Beare-Stevenson 3
MBT-AS 3
rumination 3
Concluding, 3
Skills 3
(MASSI) 3
MASSI 3
8-14; 3
metaphors 3
externalizing 3
SRS-P) 3
(FCBT) 3
(ICBT; 3
ICBT 3
at-home 3
FCBT. 3
reasoning. 3
model-building 3
anxiety/depression. 3
anxiety/depression 3
family/peer 3
family-based, 3
(HFA) 3
teacher 3
istradefylline. 3
(-0.99 3
antidyskinetic 3
subepicardial, 3
amyloid, 3
3-T 3
0.052 3
fibrosis) 3
midventricular 3
lamp2a--receptor 3
(lamp1, 3
lamp2, 3
limpI 3
limpII) 3
pax2] 3
hsc73 3
lymphangiomyomatosis 3
CNS-related 3
Manifestations 3
negating 3
vigabatrin 3
ECA 3
Conformité 3
IIa) 3
Thermodynamic 3
cold-adapted 3
antifreeze 3
dehydratases 3
freeze 3
Winter 3
liver-type 3
activator) 3
Ser-2 3
rebound, 3
GRα 3
uninduced 3
heptad 3
hsp70. 3
Enforcement 3
RIF1 3
Ltd/Anatomical 3
sir-2.1 3
second-site 3
life-extending 3
(ICPMR) 3
2009-2011 3
Rofe; 3
Baker; 3
age-groups 3
age-group 3
contemporaneous 3
61-70 3
RDA 3
headache--acute 3
Sumatriptan 3
mimics, 3
work-up. 3
transitional, 3
indomethacin, 3
(IU) 3
anesthetizing 3
paces 3
(6.6% 3
switches. 3
(64.8%) 3
70; 3
87.5 3
lbs 3
phosphoproteins, 3
SERCA-mediated 3
Inactive 3
microRNA-mediated 3
S473 3
LY 3
294002 3
SREBP-2 3
mSin1, 3
mLST8/GβL 3
2D/4D) 3
Vernier 3
caliper 3
(testosterone 3
(SHBG)) 3
7:00AM 3
11:00AM. 3
1.98, 3
6258 3
<60, 3
(α 3
malignization 3
utero, 3
CIN. 3
HPV-negative 3
gene? 3
(TRUS). 3
(6.4%) 3
1.75, 3
Degeneration. 3
(TREM)2 3
(NHD). 3
NHD 3
(p.R47H), 3
682 3
(>95%) 3
endophenotypes, 3
(rs75932628, 3
(R47H), 3
3.22 3
lipomembranous 3
osteodysplasia 3
Antioquia, 3
APOE4 3
mTOR-controlled 3
phosphoinositide-3 3
Ovaries 3
gonadotropin-primed 3
3-II 3
FSH-mediated 3
S6K, 3
AKT-mediated 3
ghrelin-induced 3
respectively], 3
target". 3
Nonalcoholic 3
(NAFLD) 3
parathormone 3
.03) 3
Hispanics 3
431 3
GNPDA2 3
rs10938397, 3
rs6265, 3
areata, 3
FLT3. 3
ZD6474, 3
SU11248, 3
AEE 3
788, 3
vatalanib, 3
AG-013736. 3
AGE, 3
CEL, 3
HNE, 3
(DS). 3
Keywords 3
urothelium 3
eg 3
0.84-0.93), 3
(83 3
1677 3
Kit. 3
.021) 3
85.4% 3
standardizing 3
528 3
RM-systems 3
against. 3
well-determined 3
k-neighborhood 3
blasted 3
nr-GENBANK 3
Int 3
28(7):1254-1261, 3
486(7404):532-536, 3
70), 3
metastases; 3
Laboratories 3
EQA 3
Intratumoral 3
773 3
38.0% 3
38.1% 3
0.00, 3
panitumumab; 3
wildtype, 3
Icaritin, 3
prenyl 3
Genus, 3
phospho-STAT3 3
STAT3-regulated 3
Interleukin-27 3
Pathways. 3
(CD3(+), 3
CD4(+), 3
p-STAT3, 3
STAT3) 3
(pSTAT3) 3
evasion. 3
acid-tRNA 3
mischarged 3
(EcLeuRS) 3
editing-deficient 3
AARS-based 3
PIAS1, 3
Smyd1 3
Smyd1. 3
sharp-1 3
Sharp-1-dependent 3
HIE. 3
hypoxic-ischaemic 3
cooling, 3
Whole-body 3
33.5 3
(longer 3
transparent, 3
(DB71) 3
staining-a 3
dye-binding 3
immunodetection-may 3
neuroscientific 3
immunoreaction. 3
non-sample-related 3
employed: 3
(HKP) 3
(LCLs). 3
bone: 3
antifracture 3
(achieved 3
6-month, 3
arthritis; 3
Eμ- 3
BCRs 3
BCR-signaling 3
immunoreceptors, 3
syk 3
APCs 3
immunoglobulin, 3
(B 3
lymphocytes) 3
disodium, 3
(B-NHL). 3
cytopenias, 3
FL, 3
R-406, 3
ureteric 3
agenesis. 3
pannus 3
Fcgamma 3
posttransplant 3
EBV+ 3
PTLD 3
fostamatinib-treated 3
7.40 3
(0.99), 3
80-600 3
80-400 3
12-21 3
Inc.. 3
(KIs) 3
TLR4-mediated 3
lupus-prone 3
P505-15 3
Tcs 3
59±6% 3
pharyngeal-cervical-brachial 3
bifacial 3
inclusive 3
APT070 3
antiGQ1b 3
immunoadsorption 3
searched, 3
both? 3
internuclear 3
proteinocytologic 3
spectacular. 3
(hyponatremia, 3
sixty-one 3
(37.5%). 3
Chulalongkorn 3
enteritis, 3
GD1a, 3
Emilia-Romagna 3
practising 3
recruited; 3
disturbances) 3
Coordinated 3
PSY2 3
(Pol1p) 3
Spt16p-Pob3p 3
Pol1p 3
chromatin-reorganizing 3
slowdown 3
strand-symmetric 3
pressures: 3
dGTP-oxidation 3
cytosine-deamination 3
G/(G+C)=A/(A+T)=0.5, 3
G/(G+A)=C/(C+T)=G+C, 3
G/(G+T)=C/(C+A)=G+C. 3
Here. 3
A+T+G+C=1. 3
departures 3
[Mol. 3
1371] 3
(8-oxo-guanine) 3
(dGTP-oxidation 3
hypothesis) 3
letter: 3
(Ala, 3
Pro, 3
Ser4, 3
Thr), 3
G(2)-type 3
(Arg4 3
Gly), 3
T(2)-type 3
(Leu4 3
Val). 3
C(2)-->T(2) 3
C(2)pG(3) 3
T(2)pG(3) 3
(T(2)-type) 3
(asymmetric) 3
14,026 3
translation-coupled 3
taxal 3
(P3). 3
(0.30-0.80). 3
(0.80-1.00), 3
prints. 3
Symmetrical 3
immunodeficiencies 3
gammaretroviral 3
(CGD) 3
unavailable, 3
HSPCs 3
metachromatic 3
arylsulfatase 3
ARSA 3
(LVs) 3
sulforhodamine 3
[Long 3
expression]. 3
Lovo 3
P53, 3
(CDKN2B, 3
TGFβ-2) 3
EP300) 3
UMUC-2 3
(MALAT1) 3
cochaperone 3
BAG3, 3
cotranslationally 3
Folding 3
(MTM) 3
myotubularin-deficient 3
simulates 3
linkage-based 3
antiphosphatase 3
S.pombe 3
(E-C) 3
myo-nuclei. 3
3-phosphoinositides 3
RyR1-mediated 3
arthrogryposis, 3
(1314-1315insT) 3
myotubularin-coding 3
PtdIns(5)P 3
hypotrophic 3
6-14 3
(DHPLC). 3
OMIM# 3
310400) 3
MIM310400). 3
independant 3
(21/24) 3
Skewed 3
grubii 3
interruption, 3
BioEdit 3
Zhengzhou, 3
province. 3
(HAD) 3
non-CNS-derived 3
CNS-derived 3
(DI) 3
loads; 3
<0.1% 3
strategies; 3
bioelectric 3
FFM 3
μg/mL) 3
μg/mL), 3
Responders 3
Paediatrica 3
hyperreactivity, 3
sufferers. 3
WHR 3
3.5) 3
(IL)-1, 3
oncomiRs 3
(computed 3
(lung 3
prodeath 3
mutations-a 3
enforcing 3
Myb 3
'Achilles 3
heel' 3
amnesia, 3
angiogenesis-dependent? 3
centric" 3
"Oncogenic 3
shock": 3
ANOVA. 3
89.4 3
Hypercapnic 3
(sevoflurane 3
propofol) 3
Fentanyl 3
infarction). 3
1.84 3
566 3
3.35 3
(-1) 3
18.6 3
propofol/remifentanil 3
(adult) 3
(paediatric) 3
Sevoflurane/sevoflurane 3
(propofol/propofol 3
propofol/ 3
(propofol/sevoflurane 3
propofol/isoflurane). 3
Gsdmd 3
(GSDM 3
GSDMB, 3
Proline 3
pro-NRGs 3
anchoring, 3
monooxygenase 3
siderophore 3
HT-1080 3
immunogenic. 3
Placing 3
CD20. 3
TAX1 3
TAG-1 3
phosphatidylinositol. 3
sex- 3
Sirts 3
FoxO3, 3
FoxO4 3
quiescence, 3
civilization 3
forkhead/winged 3
life-shortening 3
bodes 3
methylprednisolone, 3
albuminocytological 3
(BBE). 3
71%), 3
anti-GM1b-positive, 3
GQ1b. 3
Antecedent 3
titer. 3
blink 3
11), 3
(AO) 3
79-year-old 3
antibody]. 3
(miR-146) 3
CD68+ 3
T(h)-17 3
Immunogenetics. 3
miR-363 3
miR-498 3
(FAF1) 3
(miRNA)s 3
CD4+T 3
miRNA-146a 3
(IRAK1, 3
mir-146a) 3
rs1059703 3
-16 3
microRNA-34a* 3
microRNA-34 3
(miR-34) 3
miR-34b/b*, 3
miR-34c/c* 3
miR-34a/34a* 3
FasL- 3
miR- 3
34a* 3
0.609 3
0.694, 3
pre-miRNA-146a 3
pre‑miRNA-499 3
rs3746444, 3
mir-146a 3
rs2910164, 3
trigonocephaly, 3
Bony 3
scaphocephaly 3
synostosis). 3
angulation. 3
plagiocephaly: 3
(retrusion 3
supraorbital 3
rims) 3
hypertelorism. 3
bandeau 3
FGFR. 3
lymphadenectomy 3
uterus: 3
nonexistent 3
thymuses, 3
thymomas, 3
22%), 3
70%; 3
v2. 3
CD44s) 3
2F10 3
(anti-CD44v6) 3
M23.6.1 3
(anti-CD44v2), 3
0.0160 3
0.0125, 3
indicator. 3
implicated, 3
4296 3
(ACs) 3
microwave 3
v6, 3
pneumocytes 3
BMN 3
cystometry? 3
Urogynaecology 3
Division, 3
Post-Graduate 3
nephro-urology, 3
Karachi. 3
=8 3
voids/24 3
(AUA 3
21-74 3
(29.4%), 3
Cystometry 3
co-relation 3
(LUT). 3
"bladder 3
training." 3
(inpatient 3
20.5%. 3
wetting. 3
(BT) 3
>or= 3
(pelvic 3
training) 3
chart, 3
(4.1 3
objectively. 3
Basing 3
Cure 3
[Personal 3
Anamnestic 3
urodynamical 3
multistep-therapy 3
CO2-cystometry 3
terodiline/placebo 3
(NCBI) 3
Entrez, 3
Programming 3
Utilities, 3
MyNCBI, 3
(BLink), 3
Splign, 3
UniGene, 3
HomoloGene, 3
ProtEST, 3
dbMHC, 3
Maker, 3
Tools, 3
HIV-1/Human 3
(GEO), 3
Probe, 3
(MMDB), 3
(CDD), 3
Retrieval 3
www.ncbi.nlm.nih.gov. 3
Internet, 3
(CARRA) 3
2748 3
1246 3
2.5-6.6). 3
(RF)-positive 3
2.9-6.6), 3
(PsA; 3
2.0-4.4), 3
2.1-3.7). 3
DMARD; 3
3.8-16), 3
AC. 3
(18/22; 3
.009), 3
II-III, 3
JIA-associated 3
0.87). 3
uveitis: 3
methyltransferase). 3
miniprotein), 3
(CTD). 3
2'-O-ribose 3
alphavirus 3
nsP1 3
(SFV) 3
(R. 3
SFV 3
(guanine-7-)-methyltransferase 3
Sephadex 3
triphosphate, 3
G(5')pppG 3
(S100 3
cornea, 3
mS100a7a15 3
(RAGE). 3
pantoprazole 3
non-thyroidal 3
microparticle 3
important: 3
(FCM), 3
low-expression 3
Vivo. 3
NuA4, 3
LC-MS/MS-based 3
rolled 3
Facilities 3
Ataxin-2, 3
Proline-rich 3
Instability 3
(SCA2) 3
(PFOR). 3
Grapevine 3
(GLVd) 3
(AHVd-like 3
polarities, 3
talents. 3
cells--that 3
Viroidlike 3
precellular 3
'brotherhood' 3
1971, 3
existence. 3
Vienna, 3
μg/ml) 3
pg/ml). 3
Schistosomiasis 3
praziquantel 3
fever]. 3
rigor, 3
swimmer's 3
KLH 3
mansoni. 3
(CT 3
anodic 3
NCT00794079. 3
(MoRFs) 3
collect, 3
MoRFs. 3
mySQL 3
Jmol 3
applet 3
http://bioinformatics.biol.uoa.gr/mpMoRFsDB 3
danazol, 3
methyldopa, 3
Nonprescription 3
sexuality 3
clover, 3
ginseng, 3
primrose, 3
cohosh 3
Isoflavone 3
quiet 3
Forms 3
root-mean-square 3
solvent-accessible 3
G377R 3
G483R. 3
(G377R), 3
misled 3
(G483R). 3
maltase 3
P545L/P545L, 3
Y455F/Y455F 3
Fluoro-Jade 3
(DNJ) 3
DNJ, 3
maltase-glucoamylase. 3
alpha-glucosidase-deficient 3
GAA-deficient 3
110-kD 3
76-kD 3
subfractions 3
Quail 3
4200 3
nmol.h-1.mL-1 3
1290 3
nmol.h-1.mL-1, 3
nmol.h-1.mL-1. 3
invasively 3
Pompe-affected 3
(glycogen) 3
tetracycline-controllable 3
humans-induction 3
long-affected 3
waddling 3
fluorometric 3
solves 3
technology; 3
mono-exponential 3
approximation. 3
light-triggered 3
subiculum 3
hardware, 3
light-responsive 3
colliculus 3
Virus-mediated 3
(FTIR) 3
channelrhodopsin 3
desensitized 3
(benign 3
possibilities. 3
Minority 3
Survey. 3
65-74 3
appear. 3
(0.66%) 3
circa 3
check-ups 3
81.3%, 3
fixed-limit 3
Salomón 3
normal-pressure 3
1964 3
Messert 3
Baker 3
(28.8%) 3
cell-proliferative 3
KRTAPs 3
thiol-ene 3
antistatic 3
keratinous 3
lizard 3
mats 3
thermally 3
heteropolymers 3
enveloping 3
cross-section 3
45,X/46,XY 3
Myhre 3
'new' 3
(Lee, 3
NST 3
[Research 3
sarcolipin-a 3
ATPase]. 3
phopholamban 3
soleus, 3
(CaMKII). 3
sarcolipin, 3
isoform), 3
Fallot. 3
co-reconstituting 3
micelles, 3
PLN-SERCA 3
subdomains: 3
1-6), 3
7-14), 3
15-26), 3
27-31). 3
sarco(endoplasmic)reticulum 3
Ca(2+)-ATPases 3
(SLN 3
units). 3
((27)RSYQY), 3
Arg(27) 3
Tyr(31) 3
(Arg(27)stop) 3
Arg(27)stop 3
FAC, 3
16); 3
preleukemia. 3
hypermutability 3
unscreened 3
[amniocentesis/chorionic 3
(CVS)]. 3
RhD-positive 3
[+]) 3
false- 3
Anti-D 3
[RhD(+)] 3
consciously. 3
[RhD(-)] 3
alloimmunisation 3
husbands. 3
TagMan 3
prob 3
RhD(+). 3
RhD(+) 3
RhD(-). 3
tumor), 3
96.1%, 3
contaminates 3
Hypermethylated 3
(I-1c) 3
(AAV9) 3
AAV1/SERCA2a 3
Intracoronary 3
event-driven 3
failure-inducible 3
myocardial-targeted 3
benefitted 3
AAV9.SERCA2a 3
professional. 3
(ecallantide 3
HAE. 3
HAE, 3
alfa; 3
(DX-88), 3
DX-88, 3
concentrate, 3
[Bidirectional 3
(arguments 3
reentry)]. 3
180/min 3
ventriculogrammes 3
precordium. 3
realising 3
100/min, 3
extrastimuli 3
versa; 3
(P(nom)≤0.004, 3
MAP2K5/SKOR1 3
1.47). 3
teens, 3
12q, 3
20p 3
(RLS1 3
G2019S, 3
77-year-old 3
casual, 3
PARK8. 3
-sensing 3
SB11), 3
DNaseI 3
fields; 3
derivation. 3
transgenesis, 3
30-59 3
gambling. 3
16-week, 3
buffet-meal 3
intakes. 3
elation, 3
Nalmefene: 3
hr). 3
.97) 3
q12h 3
horse. 3
glucuronide. 3
intersubject 3
dose-normalized 3
GTDC1. 3
ARHGAP15, 3
under-diagnosed, 3
deletions/mutations 3
neonatologists 3
average). 3
Prioritization 3
(KNGP) 3
2-Mb 3
gene-prioritization 3
rare-term 3
RaJoLink 3
Neighbor-favoring 3
weight-reinforcement 3
gene-projected 3
sub-graph 3
ToppGene, 3
BioGraph, 3
(direct 3
disregarded. 3
Pinpointing 3
Septo-Optic 3
voting 3
Matlab 3
techniques; 3
hunches 3
ordering. 3
http://toppgene.cchmc.org, 3
SUSPECTS 3
requirement) 3
diabetes-genome-wide 3
(granted 3
Welcome 3
Consortium) 3
(http://toppgene.cchmc.org; 3
access) 3
(PPIN)-based 3
PageRank 3
HITS 3
K-Step 3
GPEC, 3
polygenic, 3
Ontology. 3
FunSimMat 3
(http://www.funsimmat.de). 3
3D, 3
TH) 3
Algorithms 3
functionalities. 3
kernel, 3
92.3% 3
ADPKD 3
neurotrophin 3
'infectious' 3
barrier) 3
subgranular 3
(SGZ) 3
1898 3
nonmotile 3
mechano-, 3
(PKD) 3
Glis3(zf/zf) 3
perturbed, 3
Polaris 3
tubulogenesis 3
Ray-Finned 3
Fishes 3
Amia 3
Lepisosteus 3
(Holostei) 3
elopomorphs 3
osteoglossomorphs 3
(chicken) 3
archosaurs. 3
genomic-scale 3
1145 3
crocodilians, 3
Supernatants 3
multiparametric 3
(IP), 3
tablet, 3
Corp, 3
Triangle 3
3-period, 3
dose-exposure 3
250-calorie 3
scleroderma. 3
Prostacyclin 3
beraprost 3
epoprostenol 3
subcutaneously, 3
inhalation. 3
(idiopathic 3
359 3
dose-related, 3
DP1 3
ILO 3
ORC1, 3
ORC6, 3
ear-patella-short 3
patellae. 3
1994: 3
sociocultural 3
Ataxia-Telangiectasia 3
RAD3 3
ATRIP, 3
ATR-Interacting 3
(ATRIP), 3
interaction; 3
ATR-deficient 3
sub-class 3
ears), 3
crowding. 3
tunica 3
BMP5 3
Intrafamilial 3
Patellae, 3
macrophages: 3
loss: 3
prosaposin. 3
Structure/function 3
R131C 3
detrimental. 3
reflectometry 3
leaflet. 3
deficiency--macrophage-targeted 3
(glucosylceramidase). 3
1966. 3
spleens. 3
Splenic 3
miglustat 3
markedly. 3
(MIBC), 3
Bladder-sparing 3
(CRT) 3
erbB2 3
MIBC. 3
MTT-based 3
RT4, 3
RT112 3
p18Ink4c 3
manganese-enhanced 3
T3N1-3M0 3
(TPR), 3
chaperone-bound 3
Tom70, 3
(C-terminus 3
Hsp70. 3
p23. 3
Carboxyl 3
(hsp90) 3
sucrose-gradient-fractionated 3
cosmetics, 3
(HepG2) 3
orange) 3
(phycocyanin, 3
cyanobacteria--holds 3
3.85 3
498, 3
535, 3
R-PE 3
native-PAGE 3
(VASP) 3
P47 3
(49%) 3
sub-G0/G1 3
Preparative 3
cruentum 3
expanded-bed 3
acid-sodium 3
R-phycocyanin 3
spectroscopy; 3
fluorescent, 3
putrescine 3
allophycocyanin, 3
30,000. 3
dim 3
7601. 3
7601, 3
(LR35 3
LR36), 3
(1450 3
cpe 3
green-light-grown 3
phycoerythrin-associated 3
LR35 3
LR36 3
cpeB 3
55%). 3
wavelengths 3
nitrate, 3
WH8020. 3
II-associated 3
cyanobacterium. 3
1600-base 3
1750 3
rpeA 3
rhodophyta, 3
(PLK2). 3
syn 3
S129, 3
high-efficiency 3
beta-syn 3
(Plk-2) 3
M3, 3
parisii 3
reclassifications. 3
attraction, 3
spores, 3
concordant. 3
spores. 3
flagellates 3
DarkHorse 3
ceranae, 3
microsporidial 3
atriomyopathy 3
SND-associated 3
laboratorial 3
Dreifuss 3
propositus: 3
teens. 3
dysrhythmias. 3
laminopathy 3
doing, 3
postcervical 3
AR-CMT2 3
EDMD-AD 3
Emerin 3
(<5% 3
Dabigatran: 3
10,000-fold 3
(BMS-593214), 3
aggregometry. 3
VKAs, 3
farthest 3
platelet-poor 3
ETP, 3
0.019, 3
0.049 3
CLN3. 3
V(1) 3
461-677del 3
(FM, 3
n=12), 3
n=4). 3
(TRalpha1, 3
(ARB1 3
ARB2) 3
ARB1, 3
TRalpha1-specific 3
beta-activated 3
TRalpha1-induced 3
topogenic 3
extra-membrane 3
http://bioinformatics.biol.uoa.gr/HMMpTM. 3
perfect. 3
MetaTM, 3
2362 3
(DBNs). 3
Philius, 3
HMM, 3
submodel. 3
DBN 3
decoder 3
grammar 3
Viterbi-style 3
full-topology 3
Toolkit. 3
HMM_RA: 3
HMM_RA) 3
Benchmark 3
Backward 3
LHGR 3
reptilian 3
(expressed 3
quadratic 3
elements; 3
45.6% 3
zones: 3
match. 3
richness 3
neutralist 3
criticism 3
orthologous. 3
isochore. 3
species' 3
intra-isochore 3
(local) 3
inter-isochore 3
(global). 3
Intra-isochore 3
'long-range' 3
(paclitaxel 3
IDN5390) 3
(1A9 3
1A9 3
PTX22). 3
acetylation/deacetylation, 3
polymerization-promoting 3
GRKs 3
Flybow: 3
Brainbow-2 3
Flybow. 3
Gal4-upstream 3
Flp-FRT 3
cassettes. 3
Flp-FRT-based 3
repressible 3
marker; 3
recombinase-based 3
subesophageal 3
parsing 3
cell-to-ECM 3
Tumor-infiltrating 3
re-activate 3
fulfilled: 3
EGF/bFGF-induced 3
immunohistological 3
EMT-like 3
Madin-Darby 3
cAMP-elevating 3
H89, 3
TGF[beta] 3
molecularly. 3
Ha-Ras-transformed 3
(EpRas), 3
effector-specific 3
IGF-II, 3
beta-catenin; 3
NBT-II 3
cholera 3
AFT1, 3
Iron-regulated 3
non-induced 3
1995) 3
(NES)-like 3
NES-like 3
Nhp6 3
coactivating 3
insufficiency-responsive 3
ferrioxamine 3
uptake: 3
ARN 3
Arn3. 3
(surface 3
FOB-uptake 3
peroxides 3
amplitudes. 3
Gadolinium-enhanced 3
R-amplitude 3
(CSRP3), 3
cardio-specific 3
indirectly. 3
(Smad-interacting 3
Indonesian 3
Checklist. 3
happy 3
chin, 3
open-mouth 3
predeliction 3
type; 3
studied); 3
valves; 3
males); 3
language; 3
(H3K4me1) 3
Trr, 3
enhancer-mediated 3
monomethyltransferases 3
Trr/Mll3/Mll4 3
Egr2-bound 3
cell-type. 3
enhancer-dense 3
enhancers). 3
cofactors/chromatin 3
'super-enhancer' 3
Disease-associated 3
Convergence 3
(SEs) 3
kilobases), 3
super-enhancer-associated 3
apoplexy 3
menses 3
Gonadotroph 3
gynecomastia 3
unmarried. 3
unmarried 3
(2.5-5.0 3
Galactorrhoea 3
bromocriptine.(ABSTRACT 3
ovulatory 3
thwarted 3
non-hydrolysable 3
substrate-nucleotide 3
G:U 3
abasic-DNA 3
MUG-substrate 3
chloroacetaldehyde 3
self-complementary 3
uracil. 3
3,N4-ethenocytosine 3
N-methyl-N'-nitro-N-nitrosoguanidine, 3
deiodinated 3
3-Iodothyronamine 3
levels/schedules 3
Fibonacci 3
3-weekly 3
15/44 3
5/9 3
Pemetrexed 3
mg/m², 3
17-49] 3
41-74) 3
sided). 3
2.9-8.1) 3
4.4-8.5) 3
ECX, 3
7.5-16.2), 3
9.8-13.8 3
1256 3
intercompartmental 3
matuzumab+/-paclitaxel. 3
PCR/sequencing 3
(D-HPLC) 3
antiepidermal 3
(HN) 3
(lapatinib, 3
EMD72000 3
(matuzumab), 3
(66.7%), 3
72000 3
(matuzumab) 3
bronchospasm 3
results]. 3
irinotecan-based 3
(hK3), 3
channeled 3
differentiated) 3
(LDs). 3
ago: 3
thaliana), 3
discoideum). 3
shorter), 3
Roundtable 3
(STAIR) 3
2,4-disulfonylphenyl 3
theoretical, 3
Anti-cancer 3
BBB, 3
Peking 3
state) 3
(Cu(ss)) 3
measurement; 3
rigor 3
journals. 3
(mRS). 3
Round 3
table) 3
suspended. 3
1722 3
1.89; 3
P=0.003) 3
-1.4 3
(MSAA), 3
(MSAA) 3
(HSDD) 3
Sprout 3
(HSDD). 3
FSDS-R 3
FSFI 3
[0.1] 3
[0.1]), 3
solicitations 3
Flibanserin, 3
(5-HT)(1A) 3
Treatment-induced 3
8-OH-DPAT, 3
Unaltered 3
Provide 3
Onelook 3
5'-deiodination 3
damage-activated 3
ubiquitylating 3
MRE11, 3
fibro-blasts 3
PBLs. 3
"FA 3
core" 3
89%), 3
8%), 3
restarted. 3
FancD2 3
HR-mediated 3
asphyxia: 3
Free-radical-induced 3
Groningen 3
Utrecht, 3
survived, 3
Preschool 3
electroencephalogram). 3
(n=23) 3
72-96 3
reperfusion/reoxygenation 3
(imminent) 3
post-asphyxial 3
(18.7 3
SEM; 3
registrations 3
CBV, 3
serum). 3
tract-based 3
cSCI 3
Minocycline 3
neurofilament-H 3
contusions 3
PNFA 3
(marker 3
timepoints. 3
UmanDiagnostics 3
(32.4 3
0.0002), 3
previously-developed 3
Aβ42/P-tau 3
ILOCA 3
3-methoxy-4-hydroxyphenylethyleneglycol 3
(NSE) 3
P=0.016), 3
CXCR4-expressing 3
MDX-1338 3
Lauren 3
(P=0.024), 3
receptor-alpha1 3
Vs. 3
(95) 3
sphericity 3
(2.0) 3
3886 3
(566) 3
(206) 3
1860 3
(46) 3
1633 3
(120) 3
P=ns. 3
(2*Posterior 3
decreased) 3
45.8 3
(1.7), 3
(435) 3
(200), 3
2*Posterior 3
isoforms-alpha1 3
-beta1 3
(TRalpha1 3
TRbeta1-treated 3
LacZ-treated 3
rodent, 3
[Ca2+] 3
hormone-like 3
SR-specific 3
30-month-old 3
rats). 3
age-induced 3
serum-containing 3
MYB-like 3
complex). 3
Deafness, 3
(DOORS) 3
collaborators, 3
tonic-clonic, 3
(UK), 3
BY. 3
aspirated 3
dichorionic 3
foetus, 3
qPCR. 3
(RT-MLPA), 3
ploidy, 3
plasma/serum 3
21q22.3 3
di 3
(sense) 3
3'-H3K4me3. 3
5'-CAGE-tag 3
syn-expressed 3
iPABP, 3
ePABP 3
protofilaments, 3
mesenchymal, 3
wool 3
filamentsin 3
stiff. 3
rod-packing 3
cubic-like 3
corneocyte 3
Malfunction 3
Hsd3b6 3
timekeeping 3
arrhythmicity 3
non-circadian 3
mCry 3
hour-glass-like 3
timekeeper 3
Ser-557-phosphorylated 3
Ser-557 3
CRYPTOCHROME 3
1179-1198 3
DD. 3
(Cry1), 3
morning-time 3
box/E' 3
Cry1(-/-):Cry2(-/-) 3
circadian-controlled 3
USP2a-dependent 3
Rev-Erbα, 3
Fbxl3 3
E-box-driven 3
(SSI) 3
climatological 3
90; 3
grampositive 3
(OSCE 3
Boston, 3
univariable 3
winter, 3
judging 3
trainee 3
LOS, 3
June. 3
LOS. 3
promoted) 3
riskier 3
July/August 3
errors: 3
risk-adjusted 3
FTOR 3
nestin. 3
retinoids. 3
polysialated-neural 3
(PSA-NCAM)-immunoreactivity. 3
telencephalon 3
Prominin-1(+) 3
multipotentiality 3
varicose 3
cutaneus 3
Pacinian 3
NSC. 3
locating 3
marker), 3
macaques, 3
Snrpn 3
dehydroxymethylases. 3
Structure-based 3
size-specific 3
(DNMTs). 3
embryonic/fetal 3
DNMT3a, 3
E2F6. 3
(Dnmt1). 3
Uhrf1, 3
PLoS 3
microirradiation 3
(Dnmts), 3
(KCl) 3
serine-515 3
2.0). 3
60.8 3
(9%). 3
D4Z4, 3
(Met1) 3
21.5-kb 3
(M-MTase) 3
met1, 3
RFTS 3
DNA-containing 3
retracted 3
Dnmts 3
5-Lipoxygenase 3
DNMT3a. 3
(TERalb) 3
Transcapillary 3
FBF 3
exceeded. 3
Drinking 3
excess-induced 3
(ChREBP) 3
41%) 3
GH3 3
GH3-PV 3
SK-Hep-1-PV 3
T3-activated 3
P450R-TRE 3
20-30-fold 3
duplicates. 3
"bivalent 3
Bivalent 3
correspondences 3
Potassium 3
insufficiency). 3
[MCI] 3
[LVESWS]) 3
(TGA) 3
SVR. 3
enalapril-induced 3
deteriorate, 3
(Enalapril) 3
(23). 3
introduction). 3
profitable 3
operation). 3
dystrophy-associated 3
Haemodynamic 3
(0.21) 3
(MG), 3
euthymic 3
prednisolone-treated 3
fractures: 3
ITACs 3
pancytokeratin, 3
napsin 3
GATA-3 3
52.4 3
[AIP] 3
cardio-vascular 3
physio-pathological 3
cardiodepressive 3
Malmö, 3
Sweden) 3
EURIA 3
69.0% 3
IEC 3
VC-IR(Δ/Δ) 3
64.8 3
0.001. 3
Populus 3
photoperiod 3
sweeps. 3
bp), 3
melpomene 3
HmYb 3
sweep, 3
quickly, 3
(pi 3
violated 3
"hidden" 3
(Pi) 3
sativa, 3
OsAMT1;1, 3
paddy 3
(PRPS1)-related 3
postlingual, 3
non-progressive. 3
Audiogram 3
flat. 3
CMTX 3
IU/d. 3
fortification 3
flour 3
0.94-0.99), 3
0.53-0.94). 3
selenium, 3
chromium), 3
1.70; 3
1.21-2.38). 3
Q10-60 3
-0.20, 3
-0.25, 3
-0.35, 3
(>150 3
38.1 3
person-years; 3
1037 3
1.05; 3
328 3
(RASMCs) 3
sGCα2 3
(sGC 3
"young 3
cell" 3
uracil-rich 3
(ELG) 3
G2/M. 3
nuclear-cytoplasmic 3
(PAI-2) 3
(AREs), 3
eotaxin, 3
mRNA-stabilizing 3
IL-4. 3
(HDF) 3
UVL 3
Dicer1 3
(TGF)β 3
RNA-IP 3
ZFP36-knockout 3
uPA, 3
MMP-13, 3
otherwise, 3
nucleolin. 3
immunoselected 3
reduced) 3
IMR-90 3
(intimal 3
arterialized 3
(hVSMCs). 3
hVSMCs 3
(ProTalpha), 3
(UVC) 3
heavier 3
HuR-overexpressing 3
(Elavl1Mø 3
KO), 3
(BMDMs) 3
3'-UTR. 3
BMDMs 3
BMDMs, 3
(VEGF)-A, 3
Vegf-a 3
BMDMs. 3
subintestinal 3
miR-200b. 3
zVEGF 3
CUGBP1. 3
bi-exponential 3
∼2 3
fulfilled. 3
deiodinase. 3
substitutive 3
hemisection. 3
hemisection 3
buffer) 3
(3H)lysine. 3
dissolved, 3
acid-precipitable 3
somatomotor 3
Mtor 3
(4E-BP1). 3
MTOR-containing 3
complex-1 3
(MTORC1) 3
Mtor, 3
(IP(3)) 3
(IP(3)Rs) 3
Ca(2+)-gated 3
αT3-1 3
(Sliter, 3
Kubota, 3
Kirkpatrick, 3
Alzayady, 3
Gygi, 3
Wojcikiewicz, 3
35319-35328). 3
IP(3)R2 3
IP(3)R3 3
PROLI/NO 3
DETA/NO 3
Lys(63)-linked 3
1a) 3
Pathogen 3
reactors 3
(ICERs) 3
bioreactors 3
Immobilization 3
sugars, 3
Lightning-Link® 3
square-wave 3
phage-displayed 3
amperometric 3
HRP-labeled 3
screen-printed 3
demands, 3
HER-3 3
(LC/MS). 3
TiO2 3
SELEX 3
Enriched 3
nanoprobes 3
rFIP-fve 3
rFIPs 3
multi-parametric 3
TF-DNA 3
magneto 3
caries-risk 3
specifically. 3
disastrous 3
[Ca(2+) 3
37.2% 3
Cardiology/American 3
female). 3
VF. 3
mutation-carrying 3
appropriate). 3
4,967 3
amino-acids. 3
Electrical 3
pathology: 3
RyR-mediated 3
tachycardia), 3
(ARVD2). 3
"second-generation" 3
0-2) 3
HDACi-activated 3
HDACi-treated 3
MS-275, 3
Bak, 3
231-BR 3
PCI-24781, 3
(STS), 3
AN-7, 3
94.4% 3
H-ras-induced 3
NaB. 3
heart's 3
passive, 3
88:393-403, 3
(Zolk 3
101:2674-2677, 3
88:78-85, 3
Geier 3
107:1390-1395, 3
2003; 3
Hershberger 3
Transl 3
1:21-26, 3
111:943-955, 3
Circ 3
106:695-704, 3
Mohapatra 3
80:207-215, 3
(MLP), 3
CSRP3, 3
TTN-encoded 3
CSRP3-encoded 3
TCAP-encoded 3
cardiomyocyte's 3
MLP/TCAP-HCM 3
myofilament-HCM 3
cytoarchitecture 3
N-RAP, 3
EFE, 3
(K69R). 3
MLP-knockout 3
CRP3/MLP 3
α-actinin, 3
modification; 3
5-mC 3
15.4%; 3
29.5%; 3
(cfDNA) 3
L858R/T790M 3
gefitinib-resistant 3
NCI‑H1975/GR 3
T790M-negative 3
25.1 3
(EGFR-TKIs). 3
threonine-to-methionine 3
TKIs), 3
(afatinib) 3
vorinostat), 3
transmyocardial 3
(bFGF)-incorporating 3
degradable 3
(TMDRSI) 3
time-points. 3
(none 3
SDF-1α/CXCR4 3
Akt-MSC 3
Prevascularization 3
7.3%, 3
fullness, 3
macrosomia. 3
translucency, 3
milestones, 3
bell-shaped 3
translucency. 3
megaloencephaly, 3
dysgenesis, 3
colpocephaly. 3
crowding, 3
Hypodontia 3
premolars, 3
recession. 3
labioclination 3
malocculusion 3
46,XX. 3
5q35.2. 3
000), 3
gastrinomas 3
somatotrophinomas. 3
Mathematical 3
β-cells, 3
glands-areas 3
vipoma, 3
gastrinoma, 3
insulinoma) 3
(SSCV) 3
Angiofibromas 3
Collagenomas 3
(72%). 3
cafe 3
collagenomas, 3
carcinoid. 3
Cdc7 3
expulsions 3
calculus 3
Subsequent, 3
mechanism). 3
temsirolimus) 3
sorts 3
tubulin-binding 3
(MJD), 3
ataxias, 3
meningitis; 3
Solving 3
Tn-seq. 3
tobramycin 3
metalloendopeptidase 3
Resistin 3
NS4A, 3
research: 3
Rice, 3
oncogenetic 3
(CIs). 3
replication-associated 3
Acetaldehyde 3
P=0.03). 3
immigrants. 3
CF, 3
16%) 3
anthropological 3
(6.9 3
cases/100,000 3
patient-based 3
Ashkenazi, 3
(29.4%) 3
(5.9%) 3
tissue: 3
Blaschko 3
Ito 3
neonate, 3
hemimegalencephaly 3
#308300) 3
IP-affected 3
seizure: 3
duodenum, 3
2004). 3
DHH 3
Raptor, 3
In-vitro 3
GSC 3
(4E-BP1), 3
MPN. 3
mIAS 3
hypoxia-exposed 3
(PHQ-9), 3
AHA-recommended 3
PHQ-9) 3
≥10) 3
ideation, 3
screened; 3
886 3
ideation. 3
91.2%, 3
.001. 3
Rad52 3
factor-independent 3
(HP1beta) 3
Modifiers 3
loci--Cbx-rs1--maps 3
(Chr), 3
Amg 3
(Suv39h1) 3
(SUV39H1) 3
(LCRs) 3
(M31) 3
(HP1; 3
locations; 3
(hASCs) 3
free-scalable 3
LaBP. 3
pre-differentiated 3
hASCs 3
reach. 3
fibroin-gelatin 3
gelation 3
bioprinting, 3
alginate/gelatine/SaOS-2 3
[polyP·Ca(2+)-complex], 3
47-55 3
kPa, 3
kPa. 3
alginate/gelatine-agarose 3
poly(ethylene 3
replicon, 3
pJlacS, 3
"transcription-associated 3
mutagenesis" 3
mutagenic. 3
pGAL-CAN1 3
topoisomerase. 3
transposed 3
process(es) 3
trinucleotides 3
1950s. 3
gene-wide 3
healthcare. 3
deserving 3
UK-based 3
stories 3
aspires 3
HercepTest. 3
(NCCTG) 3
concurrently, 3
Concordance 3
88.1% 3
high-volume, 3
(HercepTest; 3
Dako, 3
carcinomatosis, 3
Biotin-labeled 3
(BiotHER) 3
Situ 3
Ethosuximide 3
electrographical 3
EP(4) 3
AKAP150 3
db-cAMP 3
intraplantar 3
Disrupted 3
(T-type) 3
low-threshold 3
methsuximide, 3
alpha-methyl-alpha-phenylsuccinimide 3
(MPS), 3
current), 3
(ethosuximide 3
Blockers 3
metals. 3
Cochlear 3
exposure; 3
MRPs. 3
mitoribosome. 3
mitoribosomal 3
487 3
light-scattering 3
antihypertensives. 3
RAAS-acting 3
aldosterone. 3
RAAS. 3
action]. 3
Concern 3
RAS. 3
ALTITUDE 3
sensitisation 3
Bezold-Jarisch 3
spinning 3
hexamer, 3
acidophilum 3
solvents. 3
insensitive, 3
compacting 3
super-coiling 3
26-kDa 3
lysine- 3
"histone-like" 3
Fis 3
Supercoiling 3
basic, 3
(hmU) 3
aspartate. 3
Short-chain 3
operators, 3
Plastid 3
occludes 3
protomers 3
protomers, 3
kinks 3
obfuscated 3
crescentus 3
(CGRP-R) 3
MK-0974 3
T(max) 3
Telcagepant, 3
telcagepant) 3
nitroglycerin-induced 3
(NTG). 3
measured: 3
CGRP-mediated 3
zolmitriptan, 3
ergot 3
1068 3
rizatriptan. 3
<.05) 3
αCGRP 3
RAMP1, 3
αCGRP-induced 3
600-1000 3
alphaCGRP-induced 3
(pA(2) 3
pK(B) 3
7.89 3
7.78 3
calcitonin-like 3
activity-modifying 3
countries; 3
tryptophan-74 3
Single- 3
(PDT). 3
(PpIX), 3
5-ALA-PDT 3
ABCG2-mediated 3
ALA-PDT 3
phthalocyanine 3
AlS4Pc 3
Photofrin-II 3
delocalized 3
5-ALA-induced 3
Photobiology 3
Cures 3
awarded 3
gliadel 3
(carmustine) 3
0.017; 3
[1.2-7]). 3
35.4%. 3
78.4%, 3
6.5; 3
[2-20]) 3
[2-20]). 3
(27-229), 3
(10-362) 3
radionecrosis 3
BCNU) 3
implant) 3
1.00), 3
3.7%, 3
56-month 3
Multiple-regression 3
Karnowsky 3
CO(2), 3
<90% 3
nitrosoureas 3
impregnated 3
(12). 3
29-month 3
retrospective. 3
(GB), 3
16-17 3
coregulators. 3
(TRBP), 3
endoplasmatic 3
siRNA-loaded 3
co-sediment 3
Dicer-2 3
Rift 3
Valley 3
duplexes. 3
dsRBDs 3
Dicer-substrate 3
Arnold 3
intraspinal 3
neuroradiologist 3
SERCA2a: 3
Sarcoplasmic/ 3
Trinucleotide 3
(SBMA), 3
(FRAXA 3
FRAXE), 3
(SCA1), 3
(DRPLA). 3
SBMA, 3
SCA1, 3
DRPLA, 3
FANCN/PALB2 3
oxidase) 3
FancD2(-/-) 3
CAPAN1 3
pathway--the 3
inspires 3
gleaned 3
(ICLs) 3
long-time 3
imatinib-mediated 3
54.4% 3
foramina, 3
Questionnaire" 3
(73.9%) 3
muscle-like 3
lymphangioleiomyomatosis, 3
yr). 3
57.3% 3
progenies. 3
CD34-positive 3
DOC, 3
consciously 3
(AR-HSP) 3
c12orf65 3
e., 3
Ofatumumab 3
REF 3
ASCT. 3
Novel, 3
subclassification 3
BCL6, 3
PCNSL 3
ESHAP/DHAP 3
CYVE 3
etoposide) 3
refractory/relapsed 3
202; 3
Three-year 3
full-dose 3
DHAP-VIM-DHAP 3
relapsed/progressive 3
NHL: 3
HOVON 3
(cisplatin-cytarabine-dexamethasone)-VIM 3
PR) 3
(P=.01). 3
(FFS24; 3
(PFS24; 3
FFS24 3
0.29-0.57 3
0.37-0.70) 3
overall-survival 3
(OS24: 3
[0.41-0.89] 3
[0.52-1.10]) 3
re-induction 3
cisplatin-cytarabine-dexamethasone)-VIM 3
(dexamethasone, 3
[Preliminary 3
degeneration/death 3
scintigram 3
microcysts 3
desmosomes, 3
FMs 3
SFT, 3
lamination 3
Ga 3
calcareous 3
meningocytes 3
20-60 3
"matrix 3
thick. 3
apatite 3
Meningioangiomatosis 3
lambert-eaton 3
paresthesias. 3
neurotrophins, 3
TLR5 3
krusei, 3
Inflammasome 3
Oxidized 3
macrophage, 3
Caspase-1-induced 3
caspase-1-induced 3
cytokine-independent 3
supragingival 3
saprophytes 3
community: 3
Actinomyces 3
BTG2. 3
CCR4-Not 3
RNases, 3
processive, 3
PAN2 3
nuclease. 3
DnaQ 3
DNase/phosphatase 3
CCR4-like 3
exonucleases. 3
neurectodermal 3
Wright-type 3
neurosecretory 3
(MSCT) 3
(PPNET) 3
microglobulin 3
[t(11;22)q(24;q12)], 3
Small, 3
21q22, 3
capBCAD 3
Dai 3
[Z. 3
Dai, 3
Sirard, 3
Mock, 3
Koehler, 3
Microbiol. 3
16:1171-1181, 3
1995]) 3
cis-Acting 3
AbrB, 3
9-bp 3
protein(s), 3
capsulation 3
thuringiensis 3
quartiles, 3
mg/g) 3
1.83 3
elders, 3
C/creatinine 3
Toulouse 3
equations: 3
Birmingham, 3
Minneapolis, 3
35.6 3
m(2)), 3
CAC. 3
MDRD-4 3
(mGFR) 3
Beta-trace 3
2.56; 3
protein:creatinine 3
proteinuria) 3
formulae 3
446 3
GFR, 3
Hilbert 3
36-item 3
detectable, 3
SNP-based 3
informatics-based 3
sample-specific 3
(94.7%) 3
[Non-invasive 3
woman) 3
Accounts 3
confusing 3
Grey 3
guideline. 3
(II-2B) 3
personal, 3
territorial 3
(II-1A) 3
unreliable. 3
20-week 3
(HyperPP), 3
Paralysis. 3
PSPP 3
DCP. 3
Paralysis 3
(HOPP)-associated 3
dichlorophenamide, 3
Cl- 3
HOPP-associated 3
acetazolamide. 3
prematurely, 3
shunted 3
Participating 3
participation) 3
accrued; 3
0.21. 3
Learning, 3
Problems, 3
Metacognitive 3
(ETV) 3
cHOQ 3
HOQ, 3
boys). 3
0.652) 3
0.672). 3
Distribution-based 3
anchor-based 3
Index-2 3
(HUI-2), 3
HUI-2. 3
.12 3
.10. 3
.03. 3
HUI-2 3
.77. 3
instrument's 3
tobacco-smoke 3
H139R, 3
0.10), 3
2,223 3
1.6) 3
smoke: 3
northwestern 3
466 3
[relative 3
Angeles. 3
0.90-1.5) 3
0.95-1.6). 3
0.02); 3
Ficolins 3
21.6μg/ml 3
17.0μg/ml 3
(P=0.0098). 3
(Rho=-0.29, 3
P=0.015) 3
(SLICC)/American 3
Index] 3
(SDI) 3
(Rho=0.27, 3
P=0.026). 3
(P=0.0053) 3
(P<0.0076). 3
SDI 3
ficolins, 3
alvei 3
(mannose-binding 3
ficolin-2, 3
ficolin-1), 3
C5b-9 3
neuro-worsening 3
narrowing; 3
discharge; 3
(LCP) 3
sMAP. 3
MASP1 3
MASP-3. 3
CHO-DG44 3
6.4mg/l 3
2-12.9mg/l) 3
Ficolin-2 3
rMASP-1. 3
initiators. 3
(allele 3
(M), 3
(academic, 3
centres) 3
NCT01721759. 3
(14·5%, 3
8·7-22·2) 3
3·3 3
2·2-4·8), 3
8·31-not 3
applicable); 3
4·7-10·9). 3
[3%]), 3
[3%]). 3
Squibb. 3
TiSH--a 3
TiO2, 3
SIMAC, 3
HILIC. 3
post-fractionation 3
(SIMAC) 3
"TiSH"). 3
group(s) 3
Spt5. 3
P-TEFb/Cdk9 3
Mono-ubiquitylation 3
(H2Bub1) 3
Cdk9, 3
H2Bub1. 3
episomes. 3
docking/recognition 3
p21CIP¹ 3
PolII) 3
PolII. 3
Sp3-dependent 3
Sp3-mediated 3
modification-dependent 3
chromatin-silencing 3
PolII 3
hsp82-2001, 3
p85alpha 3
'cytoplasmic 3
TRbeta1' 3
TRbeta1-associated 3
PI3K. 3
mega-analysis 3
cross-disorder 3
3p21.1 3
lymphocyte-associated 3
Anti-programmed-death-receptor-1 3
anti-programmed-death-receptor-1 3
p=0·96). 3
[18%] 3
stratified, 3
later-replicating 3
covarying 3
(1.9%). 3
chromosome(2,3). 3
chromosome(4). 3
Drake 3
(Drake 3
1993). 3
streptomycin-treated 3
Rip2. 3
(SPI-2) 3
(TTSS), 3
SPI-1 3
SPI-2 3
FK565, 3
(Nod)-1 3
arteritis/valvulitis 3
FK565. 3
(Mmp) 3
HTR8 3
iE-DAP, 3
iE-DAP. 3
P65, 3
Nod1-Nod2 3
Nod1-induced 3
trophoblasts, 3
γ-D-glutamyl-meso-diaminopimelic 3
intestinal, 3
(NFKB), 3
adjuvanticity 3
flora, 3
enteroinvasive 3
pathogen-resistant 3
(-791 3
-782) 3
anti-IRF-1 3
(MDMs) 3
NOD1-mediated 3
OVA 3
OVA-specific 3
FK156-treated 3
autoantibody, 3
(deimination) 3
PAD2, 3
plasminogen-binding 3
hypercitrullination, 3
2CA 3
hypercitrullination 3
instruction 3
commensals 3
BHI 3
anti-cyclical 3
truncations. 3
deiminases, 3
CA2 3
struck 3
pacemaker. 3
heart'. 3
(chi2 3
Nonpenetrating 3
cordis), 3
Palpebrarum 3
Crab 3
Louse: 3
Petrolatum 3
Jelly 3
Permethrin 3
Shampoo. 3
crusty 3
hyperaemia. 3
petrolatum 3
jelly 3
(Vaseline) 3
(Kwellada 3
shampoo). 3
Pediculosis 3
(pubic 3
lice) 3
Phthriasis 3
ectoparasitosis 3
crusts 3
ectoparasite 3
hyperemia 3
venereal 3
vaseline 3
infestation. 3
shaved 3
donkeys. 3
cardiophysiology 3
(HRCBP) 3
shores. 3
R-DMRs 3
myeloerythroid 3
type), 3
hypermagnesaemia 3
high-range 3
controlled-trials.com 3
(26·2%) 3
(25·3%) 3
0·85-1·25). 3
2047 3
0·96, 3
0·86-1·08). 3
Fisher, 3
[Protective 3
hypervolemia). 3
inter-observer 3
Jadad 3
0.292, 3
1.750, 3
1.598, 3
1.074-2.377, 3
MgSO(4) 3
quartiles. 3
(IMASH): 3
www.strokecenter.org/trials 3
Sulphate 3
[IMASH]) 3
(NCT00124150). 3
Meta-analysis. 3
(DCI): 3
0.46-0.83) 3
0.53-1.00), 3
51%; 3
WFNS 3
11-point 3
codeine, 3
piritramide 3
0.2; 3
hypermagnesemic 3
drains 3
bought 3
(Rankin 3
dose-adapted 3
DIND, 3
randomized; 3
.083) 3
.040) 3
54.6 3
Episodes 3
GOS. 3
benefit) 3
Mg 3
DCI) 3
8.9). 3
eclampsia. 3
II-IV) 3
Paper 3
<0.0001) 3
desmosomes. 3
beta-catenins, 3
plakophilin-2, 3
desmoplakin-1, 3
Gap 3
elliptical 3
10mg/kg 3
Feeney's 3
(n=45), 3
7.10 3
9.54 3
14.12 3
3.40 3
4.39 3
5.02 3
8.78 3
2.16; 3
94.8 3
22.8, 3
19.0, 3
15.6, 3
55.4 3
18.5, 3
12.3, 3
11.0, 3
ssDNA-positive 3
antioxidant. 3
hydroperoxide, 3
dihydrotestosterone, 3
occlude 3
non-metabolizable 3
grid, 3
Normal-appearing 3
(EPSCs) 3
large-amplitude 3
dysplasia-associated 3
cortices, 3
55.6% 3
adults.Both 3
recognized.Type 3
lobe.Clinical 3
lobes.New 3
life.Brain 3
dysplasias.THE 3
MOST 3
COMMON 3
IMAGING 3
INCLUDE: 3
gray-white 3
T2- 3
FLAIR-weighted 3
epilepsy.However, 3
seizure-generating 3
MEG, 3
intra-cranial 3
management.With 3
ST-Segment 3
insult, 3
(MSC 3
DesQ389P 3
mechanosensing 3
blistering, 3
cDNA: 3
somites, 3
fins. 3
keratinizing 3
married, 3
diameter) 3
intranodal 3
gizzard 3
TSH-BAb 3
[Subacute 3
PER1, 3
CKlε 3
C26 3
Per2, 3
CCGs 3
nightwork 3
duration-dependent 3
(NDRG1). 3
teasing 3
50k 3
Greyhounds. 3
(c.1080_1089delTCGCCTGGAC) 3
(p.Arg361SerfsX60) 3
SBF2/MTMR13, 3
HMSN-P 3
formations, 3
Slovakia. 3
APTX 3
NMSNP 3
604484) 3
3q12.3. 3
(miR-126, 3
21-25 3
64). 3
CSPC 3
Lamp-2a. 3
lipid-challenged 3
Rpe65(-/-) 3
Bcl-2-related 3
UCH-L1. 3
LAMP-2A. 3
microdomain 3
oxidized, 3
Hsp40 3
2a. 3
recapitulation 3
Carvedilol: 3
multiple-action 3
aquaporin-2 3
norepinephrine) 3
"electrical 3
Ruptured 3
clipping. 3
(mRS 3
pre-hospital 3
ISAT 3
detachable 3
(hcrt) 3
Pandemrix 3
hypnagogic 3
vaccinations. 3
Slight 3
n=28) 3
liberal 3
Thioflavin 3
AD) 3
PET), 3
AD-affected 3
(SVM), 3
volume-based 3
radiopharmaceuticals 3
18F-florbetapir 3
ADNI 3
non-significant, 3
Neuritic 3
Florbetapir 3
p=0.009). 3
noise'. 3
syntenically 3
exhibit: 3
all; 3
remaining, 3
less); 3
single-exon 3
(8/11); 3
lncRNAs; 3
over-represented. 3
Mammalia. 3
over-represented, 3
LINEs, 3
stability/exclusion 3
shortage. 3
isochores; 3
(vii) 3
(Alu, 3
hyperoxaluria, 3
Roux-en-Y 3
hyperoxaluria. 3
high: 3
stones. 3
oxalate, 3
14C-oxalate 3
hypercalciuric 3
enzyme), 3
seventy-seven 3
52.4% 3
QMC-PCR 3
KRAS/BRAF 3
versatile. 3
(LOD), 3
25%/12.5%/6%/3%/ 3
1.5%/0.8% 3
(CCO) 3
Ontario.Evidence-based 3
(PEPP). 3
PEPP, 3
(THETA) 3
reports.THE 3
REPORTS 3
PUBLICLY 3
ACCESSED 3
WEBSITE 3
AT: 3
www.health.gov.on.ca/mas 3
www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlGENE 3
EXPRESSION 3
PROFILING 3
GUIDING 3
ADJUVANT 3
DECISIONS 3
WOMEN 3
AnalysisEpidermal 3
EGFR-Targeting 3
AnalysisK-RAS 3
CONDITION 3
TARGET 3
Duke's 3
Citations, 3
REVIEW: 3
N-, 3
ATCs 3
(ATPases 3
acetate), 3
JC 3
Ag-presenting 3
MOAB 3
(PML), 3
human-derived 3
compounds), 3
(LY2127399) 3
Genentech 3
Holding 3
morula 3
come. 3
1.6, 3
(55%). 3
AUCG 3
tetraloop 3
(Xist). 3
Xist-mediated 3
compensation, 3
non-translated 3
parentally 3
Albeit, 3
Chic1 3
X;autosome 3
panoply 3
(internal 3
IVP, 3
vivo-generated, 3
vitro-derived 3
(77.7%) 3
Xp21 3
TC. 3
palatable 3
repeatable, 3
ophthalmology 3
Sup35. 3
(RRM) 3
bioinformatics-predicted 3
COP8 3
(p.Q290X) 3
ET, 3
25-kDa 3
(43-kDa 3
300-400-kDa 3
hybridization), 3
Li 3
-naïve 3
chemotherapy-pretreated 3
(LDK-378). 3
SIGNIFICANCE: 3
0.020, 3
corpora 3
profiler 3
moDCs 3
kappa-light-chain-enhancer 3
IKB 3
Peroxiredoxins 3
overoxidation 3
AECA 3
0·05). 3
Intraerythrocytic 3
Prx2, 3
tribbles 3
5-kinase 3
SOD1. 3
state-to-state 3
wavepacket 3
MODFLOW. 3
OpenMP. 3
GPGPU, 3
algebra 3
GPGPU; 3
GPCPU 3
iteration 3
unconfined 3
parallelize. 3
multicore 3
CPUs 3
preconditioners 3
parallelized. 3
bandwidth 3
interpolation 3
scanner. 3
non-ToF 3
40.7 3
OSEM 3
Izhikevich 3
(GP) 3
parallelism 3
stereoscopic 3
card. 3
(CPU)-based 3
3,5,3',5'-tetraiodothyroacetic 3
(tetrac) 3
tetrac, 3
double-KO 3
TH-dependent 3
(TRIAC) 3
musculoskeletal, 3
Ten-year 3
Christchurch 3
(Christchurch, 3
59-76) 3
extra-gastrointestinal. 3
30-90) 3
register, 3
girl: 3
colon-located 3
Kashmir 3
precaution 3
Glivec) 3
KS. 3
radiologist. 3
immotility 3
since, 3
dextrocardia. 3
Zivert-Kartagener 3
dyskinesia: 3
viscerum 3
Facio-scapulo-humeral 3
FSHD-causing 3
how. 3
Paired-like 3
family's 3
DUX4-fl, 3
MYF5 3
PITX1. 3
EMSAs, 3
5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3' 3
TAAT 3
Pitx1-LUC 3
GIT1-depleted 3
GIT1-cortactin 3
VP16, 3
EDG-1, 3
Clin. 3
SPP, 3
insults, 3
restitution. 3
Rac), 3
Linked 3
Activities. 3
virus-encoded 3
reservoir. 3
R5-tropic 3
vDNA 3
lentiviruses, 3
SIV(SM)/HIV-2 3
venues 3
APOBEC3A. 3
Gag/APOBEC3 3
APOBEC3. 3
(Deltavif) 3
middle/late 3
(SQ-PCR). 3
heterochromatic. 3
heterochromatinization, 3
verification. 3
accurately, 3
bigenic 3
SEPP1 3
Se, 3
(BPH) 3
SBP1 3
-0.42 3
lipofuscin 3
captivity 3
Medaka, 3
(Gasterosteus 3
unthinkable 3
arthritis-relevance 3
(ACPAs). 3
Abatacept, 3
CII 3
(cFn) 3
(CZP) 3
OR) 3
TNFi 3
TOXLINE 3
2094 3
(NNTB) 3
(DAS-28) 3
pegol. 3
certolizumab; 3
(ERG) 3
non-English 3
619 3
'biological' 3
bDMARDs 3
asks 3
glycinylation 3
eIF2Bε 3
(Notch 3
Thra 3
cSDR 3
(Xu, 3
Clayton, 3
3135-3143). 3
(R-loop) 3
priming. 3
richness. 3
Erythrocytes 3
milligram) 3
carbidopa, 3
revising 3
apomorphine. 3
good" 3
COMT-inhibitor. 3
Catechol-O-methyl 3
fluctuations, 3
fuelled 3
titrating 3
Tolcapone, 3
COMT, 3
(MAO-B) 3
19-6327 3
xenographs 3
outermost 3
ESVD 3
ACVD. 3
increase), 3
Cytoskeleton 3
K8/K18 3
SPOTS 3
cuticle 3
Desmosomes 3
skeletonized 3
86.0% 3
45.5% 3
TT4, 3
aggregate/inclusion 3
mutant-derived 3
oligo(dT)-positive 3
(speckles) 3
P525L. 3
alternans. 3
arrhythmias) 3
(RYR2), 3
(ventricular 3
(TRDN) 3
(Ca2+ 3
Sinus 3
calsequestrin-2 3
intertwined, 3
killifish, 3
blastulae, 3
dinucleotides. 3
bidentate 3
monodentate 3
H(3) 3
muM. 3
MMP-8 3
QSAR) 3
(16â32) 3
chalcone 3
spirocyclic 3
3D-model 3
(cGMP), 3
Hypo-AT(1)-7 3
IU/ml) 3
TPOAb-matched 3
selenite/day, 3
selenoprotein-encoding 3
adrenomedullary 3
radioimmunoassays 3
(2.53 3
MTND5 3
14,459 3
(MTND6*LDY 3
T14459A) 3
Nanoplasmonic 3
biosensor: 3
bio-signatures 3
(E542K 3
E545K) 3
(LSPR) 3
(AuNPs). 3
(PNA) 3
69-bp 3
PNA-probed 3
(mCpG), 3
107% 3
fM) 3
mCpG 3
theranostic 3
(CAPP-Seq), 3
biopsy-free 3
CAPP-Seq. 3
envision 3
nickel(II) 3
phenanthroline 3
([Ni(phen)(2)PHPIP]·2ClO(4)) 3
P244R) 3
Fgfr3 3
snout 3
skewed) 3
malocclusion 3
2/364 3
(anti-CD20 3
CTLA4Ig) 3
Azathioprine, 3
sulfasalazine, 3
Antimalarial 3
unsafe 3
disagree 3
MMF. 3
solicited 3
myricetin 3
sporozoites 3
anti-CSP 3
Reaching 3
collaborators. 3
Initiative; 3
morbidities 3
expanded-programme-on-immunisation 3
Ghana, 3
Tanzania, 3
tetanus, 3
(28%, 3
(29%, 3
Gabon 3
pursued, 3
malaria-naive 3
(CS 3
gametocyte 3
p<0.01 3
48%), 3
27%), 3
Please 3
discussions, 3
estimation; 3
Planning 3
coarse, 3
Le 3
vibrations. 3
(Dyson, 3
Wright) 3
vibrations: 3
tunnelling. 3
spectroscope 3
G-protein. 3
odour 3
seems, 3
BORIS-binding 3
BORIS, 3
BORIS-negative 3
BORIS-positive 3
BORIS/CTCFL 3
50-bp 3
IPL 3
Sidekick-1 3
connect. 3
sidekick-2 3
QLVILA 3
purkinje 3
(D3) 3
deiodinases. 3
(32)P-labeled 3
deiodinase, 3
5D 3
neurohypophysis 3
0.73. 3
C(α)-C(β) 3
unseen 3
78.1%. 3
out-pointing 3
non-oligomeric 3
colored, 3
snake-plots 3
HMM. 3
(TMBs), 3
fairish 3
(TCDB). 3
Function, 3
hydropathy, 3
amphipathicity. 3
entropy. 3
Tom40 3
(IM), 3
Discriminant, 3
IDQD, 3
(TMHPs) 3
(nonouter 3
membrane) 3
multitape 3
S-attribute 3
grammar) 3
0.65. 3
porins. 3
test-cases 3
(PHD, 3
Dsc, 3
Sopma) 3
"generalist" 3
depth-dependent 3
AMPs. 3
OMBBs, 3
OMBBpred, 3
out-clamps, 3
in-plugs, 3
conquer 3
http://www.hgmp.mrc.ac.uk/Registered/Webapp/theatre/. 3
savignyi 3
CNS-specific 3
155-bp 3
NCNRs 3
thinness 3
ModuleSearcher 3
cer 3
Spemann-Mangold 3
VegT 3
gastrula 3
hPLN 3
N30C-PLB 3
2q22.3q23.1 3
duplication). 3
botulinum, 3
neurotoxin-A 3
benzoic 3
(API) 3
(FDC) 3
coating) 3
immuno-biochemical 3
antitoxin. 3
microplate 3
lumped 3
junctin/triadin-associated, 3
junctin-associated, 3
re-associated 3
dyads, 3
(RyRs), 3
(jSR) 3
polymerise 3
5-10-fold. 3
naloxone: 3
witness 3
pre-and-post 3
self-completed 3
(n=219) 3
18.3/26 3
(±3.8) 3
21.2/26 3
(±4.1) 3
(Z=9.2, 3
workforce, 3
intent, 3
policy, 3
distributing 3
breaths/min, 3
-1.55, 3
$12.30/patient, 3
$10.70/patient 3
skilled 3
sturgeon 3
hyperacetylation, 3
H3(K4) 3
LTRrs 3
3R 3
neuronal, 3
Zeb2) 3
UV-A 3
xth 3
Helicases 3
Translesion 3
ischemic-reperfusion. 3
(CaCl(2)) 3
dofetilide-induced 3
(RyR2 3
stabilizer) 3
Pacing 3
Calstabin2 3
sec) 3
(hepatocellular 3
HCC) 3
Etiologically, 3
logically 3
"oncogenes" 3
"tumor 3
genes", 3
HCC-related 3
delineated, 3
(TSLC1) 3
TSLC1. 3
miRNA-216a 3
TSLC1 3
MicroRNA-375 3
amino-acid-sensitive 3
GATOR1, 3
Sestrins 3
GATOR2 3
amino-acid-sensing 3
Birt-Hogg-Dubé 3
fibrofolliculomas 3
(TFEB). 3
FLCN-interacting 3
(FNIP1) 3
FLCN. 3
acid-mediated 3
remifentanil, 3
lubag): 3
'lubag') 3
"Lubag"). 3
Sex-linked 3
adult-onset, 3
rapid-onset 3
("Lubag") 3
("lubag") 3
26-75 3
(ccUPSIT) 3
'Lubag' 3
Patchy 3
(Lubag). 3
Phenomenology 3
(XDP), 3
Adductor 3
dystonia-Parkinsonism 3
adductor 3
aspiration. 3
(lubag) 3
(x-linked 3
parkinsonism). 3
(Zmax) 3
Philippines 3
SGC-7901 3
Caspase-3, 3
(PD98059) 3
azygos, 3
IJ, 3
1202 3
IJV. 3
interventions). 3
openings 3
Spiral 3
1974) 3
webs 3
treated; 3
MS-like 3
self-decided 3
(21/23 3
M/F; 3
EDSS, 3
0.829), 3
0.31-0.89, 3
remitting--RR, 3
re-stenosis, 3
drain 3
0.2-0.5 3
dexmedetomidine, 3
journeyed 3
avail 3
therapy' 3
(venoplasty) 3
RATIONALE: 3
33.76 3
post-PTA, 3
84.44% 3
66.67% 3
0.085), 3
17.78% 3
44.44% 3
(DMTs). 3
insufficiency' 3
abstract, 3
narrowings 3
blockages 3
fifty-nine 3
(MSIS-29) 3
67.9% 3
53.0% 3
(PPMS) 3
Neurosonology 3
(ESNCH) 3
antecedant 3
theorized 3
jurisdictions, 3
(131 3
93.0% 3
(239 3
257). 3
257); 3
retreated 3
(Calgary, 3
"CCSVI" 3
sinovenous 3
(6.9%) 3
reinterventions]. 3
(fluoroscopy 3
1.0%); 3
(6, 3
1.2%). 3
Procedure-related 3
(15, 3
3.0%), 3
in-stent/in-segment 3
1.6%), 3
recoil 3
0.2%); 3
136.3 3
purpose-specific 3
["Chronic 3
system?]. 3
expedient. 3
malformations; 3
circulations. 3
temporarily. 3
CCVSI 3
ce 3
(IJVs) 3
(AZY) 3
positive-enhanced 3
(Gad+), 3
(patency 3
IJV, 3
96%; 3
3.5-72.5; 3
Gad+ 3
.008) 3
ischemically 3
(MSCs), 3
Non-ischemic 3
cardiac-like 3
Innovation 3
pluripotential 3
political 3
upregulating, 3
downregulating, 3
t-AML 3
20q. 3
EGR1, 3
formaldehyde-assisted 3
(FAIRE) 3
DNase1 3
MYC/MYCBP 3
CDKN1A. 3
(PLD1, 3
IL6ST), 3
RAC3) 3
(RAC3, 3
JEM-1, 3
RBBP6) 3
ZDHHC17, 3
ZNF292 3
GNAL, 3
GNL3L, 3
GPR65, 3
TMEM30, 3
(GTF2H3, 3
ATXN3). 3
Gfi1b:green 3
37- 3
cross-regulatory 3
haematopoiesis, 3
neutropenic. 3
Ela2, 3
neutropenias, 3
Gfi-1. 3
erythropoietin-independent 3
Erythroblasts 3
proerythroblast 3
non-zinc 3
(gfi1b) 3
knockout, 3
Donor-matched 3
N-acetyl-cystein 3
Gfi1b(-/-) 3
non-proteasome 3
panobinostat, 3
pomalidomide, 3
pomalidomide. 3
Summit, 3
sponsor 3
threading 3
sequence-sequence 3
platelets/mature 3
(MKs), 3
MKs, 3
sucrose-gradient 3
CAS9 3
activation-based 3
(TALs) 3
Phosphate 3
(PTH), 3
CKD-related 3
1,25(OH)2 3
α-KL. 3
SGK1, 3
calcium-phosphate 3
924 3
0.65, 3
hypophosphatemia. 3
herein, 3
anti-anoikis, 3
transformation(EMT) 3
etc.. 3
niches, 3
consequential 3
(bFGF). 3
homeless 3
roadblocks 3
entosis 3
(DAP3) 3
(death-associated 3
DAP3. 3
cell/matrix 3
tensional 3
(tensegrity) 3
anoikis-induced 3
chondroitin 3
efflux) 3
influx). 3
Na(+). 3
NCX(REV), 3
PPADS 3
proarrhythmia. 3
sotalol-treated 3
veratridine-treated 3
coordination, 3
MPTP-induced 3
oxide-induced 3
(PKG) 3
p38) 3
OGD-induced 3
isobutyl 3
methylxantine. 3
(I/R), 3
31P 3
(LVDP) 3
H(i)(+) 3
2002), 3
concurs 3
2-[2-[4-(4-nitrobenzyloxy) 3
phenyl]ethyl]isothiourea 3
KB-R7943; 3
Ca2+-ATPase, 3
challenge-induced 3
CALM 3
POPLINE, 3
PRISMA 3
amoxicilllin 3
adressed 3
susceptibility-studies 3
stricly 3
medians: 3
27-55%) 3
17-23%) 3
population-weighted-means 3
23-57%) 3
35.4% 3
6.7-42%). 3
Susceptibility-studies 3
OTP 3
1.31, 3
1.07, 3
88.7%, 3
90.9%, 3
85.1% 3
2.11). 3
4.8%, 3
7.4%, 3
2.24; 3
2.64). 3
(p=0.27). 3
personnel. 3
rORX-B 3
autocrine, 3
(ARBs) 3
Telmisartin 3
telmisartan-treated 3
telmisartan, 3
cafeteria 3
(ENK) 3
ENK 3
WT-O 3
Nutrition. 3
perifornical 3
(GAL) 3
PVN. 3
Brunswick, 3
drinking, 3
nmol), 3
neuronally 3
rimonabant, 3
pups. 3
obesogenic 3
3'+5' 3
(-)SSDNA 3
NPM 3
cell-encoded, 3
H) 3
30.2% 3
anti-HIV-1 3
(OL-HED-ID). 3
NF-κβ 3
(HED-ID) 3
(delta4-10)--a 3
nonconsanguinous, 3
appertain 3
pathohistological 3
Croatian 3
(Bloch-Sulzberger 3
neurology, 3
(IP; 3
MIM308310) 3
NEMO-gene 3
factor-KB 3
synonym: 3
OL-HED-ID, 3
enzymopathy. 3
∼115 3
Diseased 3
NEMO-deficient 3
MSMD-causing 3
(XR) 3
CYBB, 3
skeins, 3
ubiquitinization. 3
stoichiometry. 3
GPA. 3
erythroleukaemic 3
GATA1-mediated 3
FOG-1, 3
EKLF, 3
erythroleukemia, 3
cross-antagonize 3
membrane-anchored 3
acid-producing 3
MRP3. 3
O-GlcNAcylated 3
LXRs, 3
GW4064, 3
Pregnane 3
(BAs) 3
PKCζ 3
dehydrogenases 3
(TR-FRET) 3
Sirt1. 3
runt-related 3
1%) 3
FRTL-5 3
(H2A.X 3
H2A.Z) 3
analyze, 3
User 3
0.6; 3
curiously 3
H2A1 3
SQ 3
Polη 3
UVC-induced 3
Ub-FANCD2 3
dynamicity 3
Dream® 3
HPSG 3
(nasal 3
RHR, 3
supervised, 3
disaster 3
antiterrorism 3
trans-abdominal 3
support; 3
bandwidth, 3
Mobile, 3
self-measurement 3
72) 3
interval], 3
[-0.8 3
-12.2] 3
[9.3 3
-5.0] 3
0.57). 3
1.6] 3
2.2] 3
codivilla-spring 3
affixed 3
assured 3
telemonitor 3
VTAM 3
elaborated. 3
Gaining 3
Sets 3
meaningful, 3
insights, 3
Scoring, 3
&quot;functional 3
scoring&quot; 3
Dendrite 3
G402S, 3
equivalent) 3
waveform. 3
TS1. 3
8A 3
QT-RR 3
Monogenic 3
TS-1 3
TS2) 3
homozygous) 3
ovale, 3
mosaicism; 3
small; 3
non-excitable 3
(G406R) 3
Ca(V)1.2. 3
V421 3
VDI 3
BayK8644 3
clefting: 3
donor-splice-site 3
Cited2, 3
Tbx15, 3
Gli3, 3
acrania 3
meroanencephaly 3
iconic 3
finch 3
ALX3, 3
ALX4, 3
pterostilbene. 3
β1, 3
metalloprotease, 3
chemokine-induced 3
Arp2/3-dependent 3
dephosphorylated, 3
matrix-digesting 3
PBDu. 3
cortactin-rich 3
invadopodia-like 3
Superimposed 3
damage- 3
NAD(+)-dependent 3
synthetase, 3
DNA-like 3
over/splice 3
have. 3
3500 3
RNA-targeted 3
2'-O-methyl 3
(AONs), 3
Intramuscular 3
62), 3
NanoLC-MS/MS 3
speeds, 3
5600, 3
Velos, 3
silica-C₁₈ 3
well-approved 3
High-efficiency 3
1038 3
wpl1, 3
wpl1 3
nonessential, 3
wpl1-dependent 3
cohesin-STB 3
equipartitioning. 3
(ChIP 3
chip) 3
Scc1p, 3
Scc3p, 3
Smc1p, 3
Smc3p, 3
'Cohesin' 3
CpG-binding 3
3b, 3
Ukraine. 3
(6.9%), 3
(0.9%). 3
Rett-like 3
heteroduplexes 3
(70%). 3
mediastinitis 3
(38% 3
extracervical 3
puncture-aspiration 3
20.5% 3
(77%; 3
(TKI258/CHIR258) 3
accommodated 3
I-catalyzed 3
(PSs) 3
progeria, 3
evidencing 3
sapiens. 3
syndromes--phenotypes 3
"normative" 3
malpractice 3
2993 3
(0.86 3
(FeNO) 3
condensate. 3
breaths 3
99.8% 3
tube-mass 3
manoeuvres 3
SIFT-MS 3
thermodilution 3
methacetin, 3
PDR 3
(n= 3
microg/kg/h 3
PE). 3
CO. 3
Bland 3
(FE(NO)) 3
ICS. 3
ex-smokers) 3
immunochromatographic 3
End-tidal 3
34.4 3
African-Americans, 3
volumetry 3
CO-haemoximetry 3
(Q 3
rugged 3
PaCO(2) 3
VCap 3
Fdlate, 3
catheter, 3
Bias 3
posttherapy 3
zymography, 3
Silastic 3
diethylstilbestrol 3
(DES). 3
b.w.) 3
Batimastat 3
PCNA-positive 3
BB-94. 3
MMPIs 3
(acromegaly 3
n=21, 3
n=1, 3
nonsecreting 3
nontumourous 3
(obtained 3
metalloproteinases-2 3
(TIMP-2), 3
(uPAR), 3
(tPA), 3
(IL-6). 3
n=50, 3
n=34). 3
(87%). 3
(faintly 3
Adenomas 3
Nonsecreting 3
P=0.053). 3
uPA-system 3
metalloproteinases-9, 3
inhibitor-TIMP-1, 3
behavior]. 3
abounding 3
(forty-nine 3
non-parameter 3
95.9% 3
(47/49), 3
(28/49), 3
75.5% 3
(37/49) 3
89.8% 3
(44/49) 3
(12/12), 3
(11/12), 3
(8/12), 3
(11/12) 3
zinc-containing 3
TIMP-3 3
mRNA/beta-actin 3
fluctuation. 3
Absorbing 3
unadaptive 3
Venezuelan 3
virus-vector 3
Fluctuations 3
assemblage 3
Robertson 3
"ratchet 3
correctness 3
Fisher-Muller 3
Fitness 3
AUY922 3
HSP990 3
(GEP) 3
protein-90 3
CGH: 3
trained, 3
"vitamin 3
50-g 3
(25[OH]D 3
61.2% 3
specificity) 3
mid-gestational 3
(VDR) 3
Shariati 3
(AGA) 3
(1.01; 3
MoM) 3
Westmead 3
non-GDM 3
IGT 3
71.2% 3
-0.26 3
741 3
(<25 3
(<12.5) 3
25(OH) 3
0.17-0.78). 3
edition, 3
six-hours 3
stoke. 3
thrombolysis, 3
Excluding 3
embolus, 3
symptoms). 3
continue, 3
revascularisation 3
embolism(APE), 3
urokinase(UK). 3
APE. 3
Sixty-minute 3
(t-PA) 3
Neuhaus 3
streptokinase/60 3
(TIMI 3
(D). 3
87.0% 3
reoccluded. 3
1.2%. 3
Nadir 3
alpha2-antiplasmin 3
mg/ml, 3
plasminogen), 3
anistreplase, 3
neutralise 3
(re)administration 3
re-exposure 3
reinfarction. 3
rt-PA) 3
contraindicated, 3
streptokinase; 3
thrombolytics]. 3
ligand-sensitivity 3
interplay. 3
A1. 3
Ras/mitogen-activated 3
(KSR), 3
KSR, 3
KSR. 3
345, 3
MEK-ERK-mediated 3
IKAP, 3
AIF, 3
ubiquitin-proteasome, 3
crosstalks 3
ERK1. 3
Pertussis 3
RAF/MEK/ERK 3
flavone 3
Modular 3
MP1. 3
agonist-specific 3
Rho-activated 3
RhoA-activated 3
Dnmt3b-/- 3
SZP. 3
ADCA-DN 3
rs6119954 3
ITP, 3
dimethyl-H3-K4/dimethyl-H3-K9 3
methylation-silenced 3
proper. 3
Dnmt3a2 3
isoschizomer 3
'jumping 3
Mutator-like 3
LTR-retrotransposons, 3
Ty3/gypsy-like, 3
(r=0.415, 3
[3432 3
1100-54991) 3
978 3
123-1705) 3
P=0.000]. 3
2.72-7.99; 3
ineffectual 3
chromatinized 3
compacts 3
ARF, 3
attenuates, 3
PRC 3
differentiation: 3
RUNX3. 3
Dicer(-/-)ES 3
Pluripotency 3
adenocarcinoma; 3
methods.We 3
dual-channel 3
dye-bias 3
chromatin-immunoprecipitation 3
chromatin-state 3
base-composition 3
∼1% 3
Sir2, 3
"hyper-ChIPable", 3
adherens-junctions, 3
SMAP1, 3
clathrin-interacting 3
(Arf6) 3
Mardin-Darby 3
Arf6GAPs 3
Arf6-GTP), 3
AMAP2/DDEF2. 3
phorbolester-induced, 3
caveolae-mediated 3
SMAP1-regulated 3
dileucine 3
juxtamembrane 3
commercial, 3
C(max), 3
AUC(0-24), 3
(Unison 3
Thailand) 3
AluSx 3
pallor, 3
tritanopia, 3
paracentral, 3
cecocentral 3
scotomas. 3
ADOA. 3
HIGM 3
hyper-IgM 3
Hesx1/HESX1, 3
Alu-containing 3
HESX1-associated 3
65-kbp 3
PDX-1, 3
Insulin-producing 3
Immunohistochemistry, 3
(IPGTT) 3
MIN6. 3
acts, 3
SECISearch3 3
SECISearch 3
SECIS, 3
SECISaln 3
diselenide 3
U) 3
AUGA 3
GGGA-type 3
(5'DI) 3
GNRA 3
Protein. 3
3'UTRs 3
changes), 3
BIS, 3
(9.2 3
(AnaConDa), 3
remifentanil. 3
awake, 3
alpha2-agonist 3
aroused 3
.046), 3
(V1) 3
(V2) 3
variabilities 3
prolactin, 3
Diprivan-10 3
emulsifier 3
Intralipid 3
(Diprivan-10) 3
SAZN). 3
mg/kg/h 3
3.1, 3
expiration 3
p50/NFkappaB1 3
non-haemolytichyperbilirubinemic 3
Rotor, 3
(Crigler-Najjar 3
co-transcriptionally), 3
remarkable. 3
purifications, 3
BACs, 3
Reconstructive 3
xeno-free 3
sparked 3
MSC-based 3
glutamate-induced 3
Prospects 3
lively 3
piRNA-Dependent 3
Protect 3
Misrouting 3
Pathway. 3
HRDE-1, 3
sterile. 3
Run-On 3
NRO 3
(Aub, 3
Spn-E) 3
germarium 3
(Piwi, 3
Ago3, 3
Mael) 3
germarium, 3
P-element-based 3
'Piwiless 3
pocket' 3
Pilp, 3
TE-derived 3
piRNA, 3
"ping-pong" 3
transpositionally 3
(nuage) 3
(Aub), 3
aub 3
Aub-associated 3
Immunopurified 3
Aub-piRNA 3
trans-silencing 3
maternally-transmitted 3
wreckage, 3
Argonaute3, 3
mischievous 3
Purine-Related 3
(PRT/NCS1) 3
Transporters. 3
=O2 3
C4-NH2 3
gateways 3
binuclear 3
AtAzg2 3
nonmendelian 3
demographic/clinical 3
Antagonists 3
Pedigrees 3
GFRA 3
SOX10) 3
Neurturin. 3
(NTN), 3
coreceptors 3
enolase. 3
(GPI)-linked 3
NTNR-alpha 3
favism. 3
>0.05). 3
(ARVD) 3
ARVD 3
I137M, 3
coved-type 3
BrS1-associated 3
transmembrane-spanning 3
extrasystoles. 3
ignore 3
readthrough-enhancing 3
G400A 3
nonfunctional. 3
1649 3
woman; 3
(K1527R 3
A1569P) 3
Heterologously 3
R367H, 3
pore-lining 3
DIS5 3
DIS6 3
A735V, 3
(DIIS1) 3
DIIS1 3
DIIS2, 3
R1192Q, 3
(LVNC), 3
thromboemboli. 3
quitting. 3
1.71 3
0.53; 3
quitting, 3
internet, 3
(Ovid), 3
(MK) 3
RG7112-mediated 3
endomitosis 3
RG7112-induced 3
megakaryocytopoiesis. 3
(ASOs) 3
VKAs. 3
convened 3
fondaparinux. 3
(Explore-Xa). 3
2.0-3.0. 3
63.4%. 3
wafarin. 3
kids 3
Well-documented 3
advanced. 3
cochrane 3
medscape, 3
SCOPUS, 3
"anticoagulants", 3
"blood 3
inhibitors", 3
thromboembolism", 3
fibrillation", 3
"'antithrombins." 3
formularies 3
etc). 3
P-glycoprotein) 3
Xa: 3
betrixaban]. 3
fondaparinux) 3
(TKR) 3
q12h, 3
(operated 3
leg) 3
DVT, 3
10-14. 3
14/70 3
(20%; 3
10/65 3
(15%; 3
4/40 3
(IBMFS) 3
(SDS). 3
(YF) 3
~15%. 3
Congo, 3
shivers, 3
2-8 3
P-glycoproteins 3
temephos 3
Alphavirus 3
Quang 3
aegyptii 3
larvicidal 3
Egypt, 3
Coronilla 3
khinjuk 3
scorpioides, 3
tenacissima, 3
sinaica, 3
1.85, 3
Antarctica 3
wMel 3
CHIKV 3
1901, 3
2006-2010. 3
Haute-Kotto 3
Bangui 3
reservoir, 3
(Stegomyia) 3
65.4% 3
Travel 3
overseas 3
municipality 3
ground-level 3
blood). 3
prohaemostatic 3
(GTFs), 3
(TAFs), 3
GTF 3
TAF10-containing 3
(TFIID, 3
SAGA) 3
TAF10. 3
tadpole 3
A6 3
xTNF-alpha. 3
(AHI, 3
ESKAPEing 3
struggled 3
species). 3
cyclophosphamide-induced 3
persist. 3
bacteremias 3
(TKI258; 3
CHIR-258) 3
WEE1. 3
topoisomerases. 3
waveforms 3
(CSQ), 3
-65 3
(RYRs) 3
RYRs 3
dyad. 3
cell-wide 3
Stochastic 3
cortex: 3
pimozide) 3
(remoxipride) 3
(FLI) 3
cataleptic 3
stereotypy. 3
serotonin-stimulated 3
Dusp16tp/tp 3
DUSP1, 3
DUSP4, 3
mitigation 3
cross-talks 3
(MKPs) 3
p38α. 3
carrageenan-induced 3
SB202190 3
MAPK-pathways. 3
DUSP, 3
slingshots, 3
PRLs 3
(phosphatases 3
liver), 3
(Cdc 3
cycle), 3
PTENs 3
(phosphatase 3
suggests, 3
kinase-interacting 3
0.81) 3
(Verathon 3
WA, 3
US-estimated 3
Questionnaire-Male 3
(ICIQ 3
M-LUTS) 3
(IPSS 3
QoL). 3
0.216, 3
0.032); 3
0.246, 3
0.014); 3
0.304, 3
0.260, 3
UEBW, 3
Incontinence-Research 3
(ICI-RS) 3
urodynamics: 3
(DWT), 3
DWT, 3
Videourodynamic 3
dyssynergia 3
voiding. 3
85.7%, 3
90.7%, 3
75.0% 3
95.1%. 3
0.908. 3
thicknesses. 3
0.113). 3
(2.6) 3
Urology 3
27%). 3
(BPH). 3
3.42 3
Abeta1-42 3
ester) 3
(LY450139), 3
beta-lowering 3
ATHENA-DSS. 3
computable 3
(EMR), 3
operationalizing 3
vague, 3
insure 3
DSSs 3
actionable, 3
dashboard. 3
care.Interactive 3
Management, 3
multi-method 3
out-of-pocket 3
dashboard, 3
conflict, 3
decision-aiding 3
decision-related 3
6.0. 3
ATHENA-Decision 3
Technology: 3
guideline-adherent 3
patients’ 3
mistakes 3
phosphoribosyltransferase. 3
c.245T>G 3
(p.Ile82Ser) 3
p.Ile82Ser 3
hyperuricaemia 3
Disease? 3
(cAMP), 3
PDE10A 3
gout-like 3
heterozygote, 3
74-bp 3
phosphoribosyl-transferase 3
HGPRT 3
(HGPRT) 3
focusing. 3
phosphoribosyltransferase: 3
choreoathetosis, 3
NBTI 3
PBL-LN 3
(macro-) 3
macro-deletions. 3
(20033bp), 3
(13307bp) 3
(9454bp), 3
19bp 3
admittedly 3
macro-mutations, 3
macro-alterations 3
Gs 3
Alu-sequence 3
hprt 3
Nurr1, 3
HPRTKinston 3
(APRT) 3
Documented 3
Splice 3
LPS-treated 3
(E(Z)), 3
lysine-substrate 3
(HMT)(1) 3
(Hcy). 3
l-SMM 3
(S,S)-AdoMet 3
aKMT, 3
aKMT 3
Fungal 3
SasA 3
Kim, 3
253, 3
acceleration. 3
reelin, 3
34.4% 3
ionization-time 3
isolates; 3
AmpC 3
non-carbapenemase-producing 3
carbapenems 3
Enterobacteriaceae: 3
NMC-A, 3
(ETP) 3
IPM 3
beta-lactamases, 3
KPC-3 3
20.2%) 3
Virginia. 3
SME-2-producing 3
Ohio, 3
IMP-1-producing 3
(Enterobacter 3
(Klebsiella 3
pneumoniae). 3
imipenem, 3
(Becton 3
meropenem, 3
ertapenem. 3
2/20 3
>16 3
meropenem. 3
vim-1-carbapenemase-producing 3
cloacae. 3
carbapenemases-producing 3
hox 3
HHEX, 3
SOX4, 3
IRX3. 3
WGD 3
bilaterians 3
dismantling 3
ankyrin-repeat-containing 3
Iroquois-specific 3
Iroquois-Sowah 3
Iroquois; 3
Iroquois-CRMs 3
Retroposition, 3
deserts. 3
duplication-mediated 3
neutral, 3
(n=2), 3
(BRAF), 3
S904S 3
25%) 3
RFLP. 3
20%o, 3
7%>. 3
10%>. 3
mid-ventricular 3
40%o. 3
Hormone-responsive 3
Eip74. 3
mH2A2. 3
summer. 3
(H3K27me2; 3
(H3K4me3; 3
L41gene, 3
mH2A1-immunoprecipitated 3
SAF-A 3
"nuclear 3
intraperitoneally, 3
(13.2 3
Desethylamiodarone 3
Cy, 3
ThR 3
T3R-mRNA 3
AT-1 3
lemurs 3
Myr 3
relaxed. 3
Bertolotti 3
L5-S1 3
neoarticulation, 3
impingement 3
extraforaminally 3
Radiofrequency 3
ilium. 3
infrajacent 3
articulates 3
pseudoarticulation 3
single-level 3
facetogenic 3
facet-related 3
cheerleader 3
generators. 3
streptomycin 3
interstitium, 3
geometry: 3
TOD-AMI 3
geometry; 3
DM-AMI 3
[37.9 3
DM-SHAM]. 3
[WTI, 3
(Left 3
Diameter 3
diastole)/2*(Posterior 3
thickness)], 3
DM-AMI; 3
2D-Strain 3
(L-T4 3
L-T3) 3
EF%, 3
(regulating 3
geometry) 3
magnolol 3
LDH-A, 3
p-CDK1 3
GFs, 3
sesquiterpene 3
productions 3
(IGF-1R), 3
Cdc25C, 3
cdc2; 3
caspase- 3
species/c-Jun 3
plumbagin-induced 3
(ASK1) 3
(HCV 3
prefusion 3
sofosbuvir. 3
S282T 3
peginterferon 3
SPT's 3
FLR3-1 3
MK-5172. 3
(DAAs) 3
(RBV). 3
Direct-acting 3
DAA 3
BMS-788329 3
TID) 3
G3a 3
Efflux 3
Latium 3
MdrM 3
tetA-carrying 3
heterotrophic 3
autotrophic 3
751 3
(65.6% 3
1.22-2.21), 3
(61.1% 3
83.9%) 3
0.15-0.60), 3
68.5%) 3
0.05-0.21), 3
41.9%) 3
0.19-0.70), 3
(70.6% 3
5.86, 3
3.07-11.20), 3
(61.3% 3
79.6%) 3
0.21-0.78), 3
17.2%) 3
3.03, 3
1.53-6.00). 3
cocaine-induced 3
CAA, 3
Neurovascular 3
cocaine-positive 3
Cocaine-associated 3
Cocaine-positive 3
4.90; 3
2.19-10.97), 3
3-times 3
cocaine-negative, 3
3.95 3
2.21; 3
2.36; 3
Grady 3
3.3-11.8), 3
3.2-8.7) 3
1.1-3.3) 3
non-cocaine 3
detected). 3
Diego 3
undetermined, 3
(HCVD) 3
HCVD 3
foregoing 3
thromboaspiration 3
TIAs 3
1990) 3
(RT-qPCR) 3
microRNAs-155 3
IBDs 3
0.057). 3
MMR-targeting 3
MSI-driven 3
FCs, 3
(MTC). 3
miR-375) 3
real-time-polymerase 3
sMTC, 3
hMTC, 3
(CCH). 3
(n=34) 3
CCH 3
8.8-fold 3
6.6-fold 3
5.8-fold 3
6.1-fold 3
miR-375, 3
miR-181a/b 3
MiR-15b 3
carcinomatous 3
Receiver-operating 3
unfavorable, 3
miRNAs: 3
(control). 3
miR-19b, 3
miR-17, 3
anti-miR-16 3
tea. 3
IR-(especially 3
IR) 3
high-LET-irradiated-cells 3
largest, 3
miR-21-targets: 3
up-regulation/activation 3
ErbB/Stat3 3
IR)-promoted 3
(miR-34a 3
miR-155) 3
Radiation-induced 3
M059K, 3
Barrett's, 3
multicenter-based 3
carbamate-induced 3
indole-3-carbinol. 3
indole-3-carbinol 3
(I3C) 3
(VC)-induced 3
VC-induced 3
chemopreventive/chemotherapeutic 3
miR-18a, 3
(changes 3
SLE). 3
miR-181b, 3
PDA 3
fluke 3
viverrini-associated 3
-activated 3
[UC] 3
regulator) 3
KRAS(G12D);NOS2KO 3
HELF 3
Spry1, 3
Pdcd4 3
(ISH). 3
tyramide 3
cancer-secreted 3
Precancerous 3
top-up-regulated 3
regressing 3
(GSC), 3
DLD1 3
RCC, 3
lymphomagenesis, 3
5-phosphatase 3
never-smoker 3
Fibrillation. 3
250,000 3
dofetilide, 3
0.044; 3
(NPM1(mut)) 3
(Flt3-ITD), 3
18.4-69.3 3
NPM1(mut)/FLT3(wt) 3
2.155, 3
0.263-0.964, 3
P=0.039) 3
0.19-0.898, 3
P=0.048) 3
FLAMSA-RIC. 3
NPM1(mut)/FLT3-ITD 3
allo-SCT 3
karyotype--results 3
(HSCT), 3
(CK-AML). 3
day+120 3
GvL 3
CK-AML 3
FLAMSA-RIC, 3
CR/CRi 3
GvHD≥II 3
0.222±0.098, 3
0.235±0.104, 3
0.367±0.120 3
0.481±0.123, 3
22.5%, 3
interchain 3
(HTLV-1) 3
90,000 3
TAK1. 3
IKKγ/NEMO. 3
-γ. 3
TNFα-stimulated 3
(IKKalpha 3
IKKbeta) 3
unsure. 3
IKKs 3
relaying 3
NEMO-binding 3
IKKalpha(-/-) 3
IKKbeta(-/-) 3
IKKbeta(WT) 3
factor-alpha-induced 3
85. 3
Ser(68) 3
TNF-alpha-induced 3
kappaB. 3
solved. 3
IgH 3
SjS, 3
(autoimmune 3
epithelitis). 3
comparing, 3
isolating, 3
suffering, 3
NOD.IL-4-/- 3
adoptively 3
psoas 3
subluxations 3
chiropractic 3
intraabdominal 3
injuries; 3
lumbocostal 3
pelves 3
cadavera 3
pattern). 3
(fracture 3
foramina 3
foramina), 3
[Conservative 3
GeneMark.hmm-E 3
GeneMark-ES 3
(unsupervised 3
gene-predicting 3
Genscan 3
N.crassa. 3
FFG 3
customize 3
pinpoints 3
System) 3
q(9) 3
GLUT1. 3
pY-STAT3 3
Hif1alpha, 3
(GLS) 3
oxygen-independent 3
HIF-2alpha 3
normoxia. 3
(HIF)-1 3
(Src) 3
(HIF-1 3
[Management 3
(4/11) 3
(EGFR-TKI), 3
(L858R) 3
(EGFR-TKI) 3
Gefitinib- 3
receptor-tyrosine 3
Leptomeningeal 3
tegafur-uracil 3
PC-9, 3
mg/d). 3
0.5%. 3
R497KEGFR 3
(WT 3
(Iressa), 3
(HFD)-induced 3
Sam50, 3
MIB 3
(APOO) 3
O-like 3
(APOOL) 3
hetero-oligomeric 3
(mitofilin, 3
(MINOS). 3
mitofilin/Fcj1 3
(formation 3
MINOS. 3
Fcj1, 3
Fcj1. 3
(OMM) 3
biogeochemical 3
subdominant 3
metagenomics, 3
families) 3
(species 3
protein-stable 3
microcosms, 3
(tandem 3
trends. 3
ocean 3
Spectra 3
oceans. 3
assemblages 3
Bacteroidaceae, 3
gutless 3
symbioses 3
Ocean, 3
pHHH202, 3
EW301 3
(cen-p11.2) 3
EW206 3
(cen-q12) 3
pHHH202 3
(q11.2-q12). 3
7AE-11. 3
microcell-mediated, 3
chromosome-transfer 3
neo-marked 3
large-fragment 3
17;22 3
-year-old 3
gliosarcoma, 3
shoulder. 3
4c 3
Monozygotic 3
lymphoblastoid, 3
mosaic, 3
fibromatosis 3
TR-deficient, 3
Telemetry 3
Patch-clamp 3
KCNQ1-KCNE1 3
"metamorphosis"? 3
(PE, 3
PE-T3 3
Phorbol 3
Ad-wtPKC 3
alpha(1) 3
(WT). 3
XCMS 3
ESI-MS 3
reaffirming 3
IRBC 3
YYDS 3
mass-based 3
Su 3
METLIN: 3
METLINincludes 3
cross-correlated 3
(FTMS) 3
Sox33 3
hemocyte 3
Toll 3
pAlu14. 3
20mg/L 3
Cd 3
Genomic, 3
440,000 3
(poly(A)) 3
AAUAAA, 3
1-42, 3
p-tau 3
"positive 3
ECNP. 3
"mixed" 3
breath-holding 3
method: 3
+61G/A 3
1.48, 3
2.35, 3
NQO1, 3
GSTM1, 3
GSTT1 3
life-style 3
kind, 3
0.97-2.34), 3
nonsmokers, 3
Short-QT 3
(SQTS6). 3
narrow, 3
p.Ser755Thr), 3
Ca(v)1.2α1 3
Ca(v)β(2b), 3
Barium 3
(I(Ba)) 3
I(Ba) 3
Ca(v)1.2α1, 3
J-wave 3
n=4) 3
Quinidine 3
T618I-HERG 3
ICD-related 3
majority, 3
neuralgia--a 3
(SCENAR). 3
stroked 3
fastened 3
otorrhea, 3
Fusobacterium 3
subtemporal 3
Adam 3
opacification 3
(WNT16B) 3
microenvironments 3
XRCC6/Ku70 3
BLM, 3
carcinogenic, 3
incorrectly, 3
rays. 3
Transformed 3
scavenger. 3
rhodamine 3
Carcinogen-induced 3
multistage-tumor 3
(121 3
(HF 3
SPAN-100. 3
(SPAN) 3
≥100. 3
Bivariate 3
home). 3
15-item 3
(∼80-200 3
TRalpha1(-/-) 3
TR, 3
blue-coloured 3
leucomystax. 3
leucomystax, 3
crystallized. 3
40.9, 3
lin-61 3
Rb-related 3
weight-matched 3
(22/46). 3
(27/38). 3
(57/58) 3
(p=0.001) 3
(12/19) 3
(quartile) 3
(45-52) 3
(44-52) 3
Inter 3
plea 3
unquestionably 3
appraises 3
endometriomas. 3
well-designed, 3
Excisional 3
Endometriomata 3
endometrioma; 3
(1980- 3
handsearching 3
3cm 3
0.06-0.38), 3
0.01-0.51) 3
non-menstrual 3
0.18-0.93) 3
0.47-4.15) 3
(ICSI) 3
(Fertil 3
Steril 3
(>3-5 3
(68%), 3
self-reporting 3
'ideal' 3
respondent 3
IVF-ET. 3
Proceeding 3
did, 3
bodies" 3
histopathologically, 3
[Nemaline 3
affected]. 3
Polyhydramnios 3
IIIrd 3
(rods) 3
Gomori 3
femoris, 3
gastrocnemii. 3
nebulin. 3
(I-band 3
indistinct 3
(epitopes 3
M176-181 3
1q42 3
obstetrician 3
STATA 3
TX). 3
0.022). 3
arthritis]. 3
(SLE 3
0.024); 3
Pre-eclampsia 3
Judicious 3
APS, 3
LBW, 3
1,425 3
(23.2%, 3
11.1%, 3
27.4%, 3
manage. 3
DNAshape: 3
sliding-window 3
instantly 3
twist). 3
DNAshape 3
http://rohslab.cmb.usc.edu/DNAshape/. 3
MBC. 3
RVH 3
micrograms.kg-1.day-1) 3
U.kg-1.day-1) 3
streptozocin-induced 3
excrete 3
lipotropic 3
i.v.)-induced 3
(STZ-D) 3
g.kg-1.day-1 3
micrograms.kg-1.day-1 3
8-wk 3
STZ-D 3
MSAs 3
SuperTRI: 3
SuperTRI, 3
probability) 3
parsimony. 3
thirdly, 3
bootstrap, 3
(sexual 3
NP-hard 3
blocks). 3
cubically 3
8,380 3
patented 3
(2006-2010) 3
benzodiazepinediones, 3
cis-imidazolines, 3
oxindoles, 3
spiro-oxindoles, 3
AT-219, 3
spiroindolinone 3
(anti-IL-6 3
(plc) 3
49%) 3
q2wks, 3
q3wks, 3
q4wks) 3
q3wks 3
q4wks 3
anti-IL6 3
tools; 3
(Recognition 3
Room) 3
(Face 3
(dsDNA) 3
DNAi. 3
Lys1349 3
Lys1415 3
GK 3
methyltransferase-independent 3
SHREC 3
Clr6 3
HIRA 3
(SurKex) 3
SurKex-induced 3
spacers. 3
accumulate. 3
(H4K16) 3
Sir4, 3
SIR-chromatin 3
devil 3
Devil 3
β2-microglobulin 3
(PERVs) 3
PERVs 3
Set3 3
ThPOK 3
tenocytes. 3
(ASO) 3
(cleaved 3
miR-449. 3
(GR) 3
rRNA-encoding 3
895 3
redifferentiation 3
fumonisin 3
colonizes 3
FUM1, 3
CREMα 3
non-hematopoietic 3
retinoblastoma-associated 3
OVEREXPRESSION 3
(FT), 3
IDLV 3
(p53 3
alcohol-exposed 3
Ribonuclease/angiogenin 3
stressed, 3
(tiRNA), 3
ribonuclease/angiogenin 3
(RNH1) 3
tiRNA 3
KSHV-infected 3
LANA-1, 3
L35P 3
subconfluent 3
digitonin-permeabilized 3
imported. 3
isothiocyanate-conjugated 3
abolishment 3
(male 3
(AGA), 3
self-esteem, 3
comb. 3
synonym 3
medieval 3
underivatized 3
forensics. 3
symbolic 3
(LC/IRMS) 3
occur) 3
Bones 3
stratigraphic 3
presented; 3
bone-matrix 3
LC-IsoLink 3
Tyrannosaurus 3
(Reports, 3
alpha1(I) 3
Matjes 3
rock 3
(13C/12C 3
13C) 3
Missouri 3
Arkansas 3
1000, 3
4.26 3
IMSS. 3
(2DE) 3
SHT. 3
cyclodextrins. 3
prevention: 3
security, 3
nuanced 3
sugary 3
drinks) 3
(n=26) 3
(n=24). 3
prompts. 3
27.9) 3
(22/26) 3
(16/23) 3
(16/21) 3
6.51), 3
-2.41 3
-5.22 3
P=.09). 3
(r=-.36; 3
P=.08), 3
Clinicaltrials.gov: 3
NCT00939081; 3
http://clinicaltrials.gov/show/NCT00939081 3
http://www.webcitation.org/6KiIIcnk1). 3
quasi-experimental 3
am 3
medium-to-large 3
control). 3
piloted 3
implementation: 3
places, 3
OX1R 3
almorexant 3
OX1 3
surmountable 3
binding; 3
(slow 3
enantioselective 3
(MK-4305). 3
dialkyl 3
(MK-4305), 3
receptor-selective 3
C1m 3
allotted 3
Psychopharmacology 3
chronobiotics 3
(pharmacological 3
nonpharmacological) 3
longer-lasting 3
narcolepsy: 3
(CGI-C), 3
(ESS). 3
(474 3
narcolepsy), 3
(420/743) 3
(95/743) 3
[180/731]), 3
[123/731]), 3
[99/731]) 3
[3.6/2.3 3
Hg], 3
[6.7 3
minute]) 3
(CGI-C) 3
CGI-C 3
(-4.8 3
polysomnography. 3
daytime. 3
MWT 3
chronobiotic 3
(amphetamine), 3
driving), 3
under-recognised 3
latencies, 3
(ulcerative 3
unmatched 3
Sweet 3
diacylglycerol. 3
phosphatidylinositol-3 3
uncoupler 3
iodixanol 3
(PTCs) 3
iodixanol. 3
3-d 3
wounds, 3
U.S., 3
38°C, 3
HAF 3
(NPs) 3
cytokinesis-block 3
osteocalcin. 3
Mineralization 3
Journal. 3
Conjugated 3
Multiple-dose 3
{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic 3
(ACT-333679) 3
(MCT)-PAH 3
E(3) 3
(EP(3)) 3
(2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide. 3
Selexipag: 3
N(1325)S 3
inhibitions 3
Sulphonylurea 3
2-month-old 3
grandmother, 3
(I167L) 3
MgATP 3
tolbutamide. 3
Glibenclamide 3
(KCNJ11) 3
beta-cell, 3
parent; 3
R201H. 3
weakness; 3
R201H 3
15-yr-old 3
Kir6.2, 3
co-, 3
co- 3
NRL-3D 3
Bank. 3
PIR 3
urethane-anaesthetised 3
Pridopidine, 3
Microiontophoretic 3
(0.2-3 3
(10/16). 3
(6/16). 3
SCH23390. 3
MermaiHD 3
(RCT). 3
(86.4%) 3
79.6% 3
90/113]; 3
101/125]; 3
95/115]) 3
(8.0% 3
9/113], 3
16/125], 3
8.7% 3
10/115], 3
OLE, 3
(67.9% 3
163/240]) 3
(56.6% 3
64/113]). 3
EKG-related 3
metabolizer 3
(-)-OSU6162, 3
(mMS; 3
centres; 3
0·025 3
0·05 3
NCT00665223. 3
-0·99 3
(97·5% 3
-2·08 3
0·10, 3
p=0·042) 3
(n=144), 3
-0·36 3
(-1·44 3
0·72, 3
p=0·456) 3
(n=148) 3
(n=114), 3
-1·29 3
(-2·47 3
-0·12; 3
p=0·014) 3
(n=120). 3
NeuroSearch 3
EPI-743 3
desirable, 3
enigma, 3
spermiogenesis. 3
CpG:GpC 3
C643 3
cytotoxicities 3
(Velcade(®)) 3
(ER)-associated 3
chemoresistance, 3
melanoma-derived 3
factor-kappaB. 3
proteasome-ubiquitin 3
Pharmaco-miR 3
miR-TS-SNPs 3
(PK). 3
Pharmacogenomics, 3
biomedical, 3
pharmaceutical, 3
(PTX), 3
(JAS), 3
ΔCt 3
NCI-60, 3
>100,000 3
~30-50 3
1-3. 3
(RPS19 3
(NAD(+)), 3
Energy-dependent 3
(ssUV). 3
ssUV-induced 3
(8oxoG) 3
8oxoG 3
Nicotinamide, 3
story. 3
(MAOA): 3
(Xp21-p11) 3
rodent-human 3
Xp21-p11. 3
glottis 3
(MSA). 3
MSA: 3
[18F]dopa 3
disease--a 3
IPD, 3
2907 3
Scale-depression 3
(HADS-D), 3
(HAMD), 3
0.88-0.93 3
0.88-0.92 3
0.93-0.96 3
0.89-0.91 3
standard) 3
25/71 3
carer 3
27/71 3
18/30 3
(60.0%) 3
(specificity) 3
GDS 3
observer-rated 3
ward, 3
Charts 3
(Beck 3
Psychiatrists 3
glucuronidation, 3
ESI 3
N-monodemethylated 3
Trichostatic 3
bromide) 3
Bcl2, 3
geared 3
SMMC-7721 3
OCUM-8 3
PTX 3
(HDIs) 3
(NaB) 3
(4.4%) 3
1.02-1.54). 3
-0.451, 3
0.408, 3
safest 3
peroxidase: 3
neurosensory 3
Non-complementation 3
ref(2)P, 3
multiadaptor, 3
macropexophagy 3
macrospora, 3
ubiquilins) 3
destinies, 3
aggresomes, 3
Tremendous 3
5-kinases 3
Snx41 3
(SQSTM1/p62) 3
(mitophagy). 3
macroautophagy? 3
Alcohol 3
(Atg) 3
schematic 3
YLR356W, 3
elaborates 3
appressorium 3
extrusion, 3
Ulk1, 3
Trs85 3
pastoris, 3
morphologically, 3
gsa1 3
pfk1 3
Bcl-2-associated 3
autophagosome, 3
aggregate-like 3
Atg19 3
Ape4 3
53) 3
P53. 3
measurements; 3
PK/PD/efficacy 3
extravascular, 3
(303, 3
narrower. 3
mantle-cell 3
Histologies 3
kinase-induced 3
[100%] 3
days' 3
ara-C. 3
alisertib/ara-C 3
BIM. 3
Babesia, 3
helvetica, 3
venatorum 3
TBD 3
ricinus. 3
OppA2 3
(Sciurus 3
(s.s.). 3
Hereafter, 3
biogeographic 3
winter. 3
s.l., 3
227), 3
s.s., 3
5S-23S 3
s.l 3
Borrelia-positive 3
5.5%, 3
2007-2009 3
coinfections 3
"Candidatus 3
1.5%, 3
lusitaniae, 3
spring. 3
metabolization. 3
abated 3
Occurring 3
p50/NF-κB1. 3
TNF-α-stimulation. 3
2R/2A 3
(R279A, 3
3R/3A 3
(R113A, 3
R279A 3
UL42. 3
(CNSs) 3
Jurkat, 3
ETRB 3
PASMC 3
ERAs 3
ET-1-dependent 3
N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide 3
(Macitentan), 3
embarked 3
(macitentan, 3
ACT-064992) 3
ENG 3
diseases' 3
dysfonction 3
Diuretics 3
multiple-ascending-dose 3
endothelin-receptor 3
3-mg 3
oxide. 3
endothelin-induced 3
edema/fluid 3
tissue-targeting, 3
pVEGFR2, 3
pAkt, 3
endothelin-contracted 3
Cs 3
OATP 3
(0.79, 3
SKOV3ip1 3
IGROV1, 3
injections), 3
galenical 3
(ACT-064992) 3
(86.7%) 3
Pseudomonas, 3
(88%). 3
spermatogonia, 3
CFRD 3
represented: 3
Quebec. 3
1/902 3
association? 3
atresias 3
(IHPS) 3
1988, 3
Channels 3
tunicamycin, 3
transactivity 3
3MA 3
ZR-75-1 3
2-aminoethoxydiphenyl 3
(20-40 3
tripled 3
CaCC 3
TMEM16a 3
Tg, 3
macrophages; 3
chelation. 3
1.5- 3
diabetes-prone 3
unloading, 3
0.3-4.1 3
LFS; 3
HER2+, 3
resolvable 3
Matter 3
(FEL), 3
1968 3
nowadays, 3
pictures, 3
'diffract-and-destroy' 3
bioparticles 3
orientations) 3
SLAC 3
Accelerator 3
keV. 3
nanometer 3
microcrystals. 3
sun. 3
Mn(4)CaO(5) 3
keV 3
(SFX) 3
micrometers) 3
Blastochloris 3
viridis 3
X-FEL 3
intercepted 3
well-diffracting 3
3,000,000 3
(∼200 3
briefer 3
nonperiodic 3
pulse, 3
megadalton 3
X-rays, 3
holography 3
(CDI). 3
cons. 3
electrons. 3
TbCatB 3
Progressing 3
cryoEM 3
(MAD) 3
Ca(2+)-loaded 3
(SI) 3
SR-AIP 3
phosphatidylinositol-dependent 3
tonically 3
CAMKII 3
Collins, 3
GRMD 3
(HESC) 3
culturing. 3
Neu5Gc-incorporation 3
(IgY) 3
own) 3
(Neu5Ac). 3
sialoglycoproteins, 3
mono-specific 3
Non-immune 3
CMP-Neu5Gc. 3
CMP-N-acetylneuraminic 3
human-adapted 3
SubB 3
17α-hydroxylation 3
Phase-III 3
microsomes), 3
Orteronel. 3
½) 3
L/kg, 3
76.4, 3
1,764 3
4,652 3
17,518 3
3,178 3
CYP17. 3
C17,20-lyase 3
multi-targeting 3
Sipuleucel-T, 3
CYP-17 3
17α-hydroxylase, 3
postchemotherapy 3
g.55G 3
AAAT 3
(UCR) 3
(5'-GGGCGGG-3') 3
Sp1-like 3
Ets1. 3
GGAA 3
Tax1 3
CACCC-like 3
-58 3
PTHrP-specific 3
-94 3
-34. 3
Sp1-specific 3
Schneider 3
Humoral 3
3.8%, 3
diabetes-associated 3
paired-pulse 3
Anti-glutamic 3
(GAD-ab)-associated 3
DMD/BMD 3
AD-MSCs 3
FNAB. 3
tomography/computed 3
Cytology 3
inaugural 3
(IVS10-1G 3
LKB1. 3
harmatomatous 3
one-base 3
Polyps 3
rates-across-sites 3
attraction. 3
(heterotachy) 3
correctly, 3
artefactual 3
consuming, 3
Rate-across-site 3
Parsimony 3
Attraction 3
(LBA) 3
Thornton, 3
unrealistic. 3
(heterotachy), 3
Thornton. 3
LBA 3
eschewed 3
1289 3
end-of-life 3
Pennsylvania. 3
spirituality. 3
confirmed: 3
patients/caregivers 3
Therapy--Brain 3
(FACT-Br) 3
(CRA), 3
phenomenological 3
occur; 3
S.D. 3
mastery 3
mediator, 3
period? 3
reoperations 3
P=0.001 3
non-conversion 3
37.7% 3
tigris). 3
3-week-old 3
tachypnoea, 3
hypoxaemic 3
5-month-old 3
TORCH 3
VSD 3
shugoshin 3
e8a2 3
2-10% 3
22q11.2, 3
12p13, 3
(WBC), 3
(MRP), 3
(5%), 3
sorter 3
(CD34+, 3
(Ph). 3
t(9;22)(q34;ql1) 3
p2lO(BCR-ABL) 3
'functional', 3
RB, 3
"minor" 3
"major" 3
p210(BCR/ABL)-transformed 3
p185BCR/ABL-positive 3
p185(BCR/ABL)- 3
p210(BCR/ABL)- 3
GNF-2, 3
(Ph') 3
9q+ 3
bcr-c-abl 3
MDR, 3
alpha,21-dehydroxy-5 3
alpha-pregnane-20-one 3
(THDOC), 3
metrazol-induced 3
Neuropharmacological 3
[N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide 3
hemitartrate] 3
withdrawal: 3
(BZs). 3
neuropharmacologic 3
(selectivity 3
1-BZ 3
BZs. 3
(78.9%) 3
(11.5%), 3
50-400 3
(placebo: 3
0%). 3
n=1,342) 3
(100-400 3
n=463) 3
23%) 3
(DSM-IV 3
L858R, 3
BIBW2992, 3
HER3. 3
10·8 3
(BIBW 3
Course 3
guide. 3
isomaltose 3
Budget 3
(Polyquest 3
Prescriber 3
Analysis, 3
Switzerland). 3
Personnel 3
Tarmed 3
fee-for-service 3
tariffs 3
(Spezialitätenliste, 3
MiGeL). 3
USD, 3
200/500/1,000 3
101/210/420 3
144/375/721 3
22-31 3
Savings 3
(application 3
applications). 3
savings, 3
(Crohn's 3
(platelets 3
iron-replacement 3
nonanemic 3
FERGIcor 3
1181 3
39.4% 3
0.38-1.00; 3
4.0%). 3
59.0% 3
8.1%, 3
81.2% 3
83.1% 3
61.6% 3
efficious, 3
1000mg 3
FERGIcor, 3
[Hb] 3
7-12 3
[female] 3
[male]) 3
(Hb 3
g/dL); 3
IS-treated 3
[65.8%] 3
[53.6%]; 3
[72.8%] 3
[61.8%]; 3
11.0% 3
112638 3
enzyme; 3
GM3 3
2010;116(6):893-899). 3
(-52% 3
(-24% 3
000/mm(3). 3
.012), 3
osteopenic 3
(8/18 3
(10/18 3
multisite, 3
NCT00358150. 3
crises. 3
bid, 3
supervised-learning 3
learns 3
(NIPs) 3
Negatome, 3
liable 3
(PEWCC) 3
PTMClust 3
(MOG) 3
structure-functionality 3
subgraphs 3
vertices 3
attachments, 3
Multi-objective 3
Similarity) 3
metaPIS: 3
meta-methods 3
(0.181) 3
http://202.116.74.5:84/metapis. 3
EAGLE, 3
NFC, 3
MCODE, 3
DPClus, 3
IPCA, 3
SPICi, 3
Core-Attachment. 3
Macropol 3
RRW, 3
weighted. 3
NWE 3
(Node-Weighted 3
percolation 3
PDB 3
17-fold 3
transposability 3
P-element 3
multiple-transposon 3
(PSD), 3
ITIH3/4, 3
SDCCAG8, 3
PGC, 3
(ITIH3/4, 3
SDCCAG8) 3
10(-11)) 3
10(-9)). 3
p=0.02). 3
manic 3
Bipolar 3
polypeptide-like) 3
(A3B), 3
deaminase). 3
A3B's 3
solvent-exposed 3
cytosolic. 3
C-to-U 3
artifactual. 3
4C-Seq 3
ATF3, 3
GABPA, 3
JUND, 3
interactomes. 3
biopsy: 3
lipofuscin, 3
6.4), 3
9.1). 3
7.8). 3
[extensor 3
(VL), 3
(TA)] 3
(AT1) 3
2C, 3
multi-lineage 3
CLCs 3
DiI-stained 3
actin-positive 3
GATA-4. 3
polyester 3
BMSCs, 3
Homogeneous 3
multiparameter 3
Paracrine 3
RKIP/EZH2 3
repression-associated 3
(Suz12) 3
H3-K27-me3 3
H3-K9-me3 3
miR-101. 3
miR-101 3
pro-tumoral 3
EZH2-targeting 3
binding/differentiation 3
(ID4) 3
hyper-methylation 3
C81) 3
immuno-precipitation 3
C81 3
Autoregulatory 3
PIN. 3
Myc-regulated 3
(CTLs). 3
immunomagnetic 3
(p=0.023) 3
Antigens 3
(EZH2-243 3
-252, 3
-299, 3
-;742) 3
RING1, 3
semi-quantitatively 3
(PROB) 3
hydrophobic. 3
TMB/extracellular 3
TMB/cytoplasmic 3
TMB/non-TMB 3
Phones 3
hazard. 3
(INTERPHONE), 3
Cancer, 3
30-59, 3
(+/-5 3
electoral 3
rolls. 3
OR=1.8,95% 3
CI=1.1-3.2, 3
CI=1.1-2.8, 3
CI=1.1-2.9. 3
calls, 3
OR=1.10, 3
CI=1.02-1.19, 3
OR=1.11, 3
CI=1.01-1.22, 3
OR=1.09, 3
CI=1.01-1.19. 3
microwaves 3
1980's 3
(IARC) 3
24-31 3
non-ionising 3
(RF-EMF), 3
'possible', 3
OR=1.25, 3
CI=0.31-4.98 3
OR=1.35, 3
CI=0.81-2.23, 3
OR=1.81, 3
CI=0.73-4.45. 3
OR=2.55, 3
CI=1.50-4.40 3
(HR)=1.2, 3
CI=1.002-1.5 3
governments' 3
responsibilities 3
IRS1, 3
LY294002-induced 3
β-catenin/TCF 3
phosphoinositide-dependent 3
(PDK1), 3
mitochondrial-dependent 3
CCI-779. 3
(Wnt)-3A 3
B/AKT 3
trophoblast-specific 3
Wnt-3A-induced 3
EVT. 3
trophoblasts; 3
metalloproteinase-2, 3
trophoblasts. 3
Fine-tuning 3
nuclear-catenin 3
(Cby) 3
Pten(flox/flox);Amhr2(cre/+) 3
GCT. 3
Cocktail 3
(ISCs). 3
(Wnt-1-induced 3
Wnt-1-beta-catenin 3
Bcl-X(L). 3
defied 3
neuromodulators 3
transgenics. 3
(RFP), 3
dentinogenesis. 3
pulp. 3
epifluorescence 3
G0 3
cd45:DsRed 3
Mononuclear 3
mhc2dab:GFP 3
GFP-positive. 3
born; 3
galK 3
"reporter" 3
intrastriatal 3
(CMV). 3
hsp22 3
Ube3a 3
Neuron-specific 3
Ube3a-ATS 3
isodisomy 3
early-childhood 3
15q11.2-q13 3
(ACS). 3
adjudicated. 3
(3.4% 3
R-warfarin 3
moxifloxacin, 3
PPAR-γ 3
[(14)C]-labeled 3
μg/day) 3
m(2)). 3
SYNCHRONY 3
Glycemic 3
(PPARα/γ) 3
hypertriglyceridemic, 3
PPARα/γ 3
drug-naive 3
n=2 3
(PPARs) 3
Causal 3
89%; 3
sympathectomy 3
(Parp-1) 3
immunopurification 3
tat-mediated 3
antifibrinolytics, 3
Health/National 3
0.040). 3
(41/55) 3
(37/60) 3
Force. 3
hypervolemia 3
clots, 3
DID 3
manipulations, 3
made: 3
intrathecally), 3
vasodilating 3
(PGE(2)) 3
enzymes' 3
p.o.), 3
DOT1 3
(H3K79 3
immunoglobin 3
adaptor. 3
(H3K79me) 3
Dot1. 3
nonprocessive 3
MLL-AF4 3
preimplantation, 3
COS12 3
TEL-VII-L, 3
(mixed-lineage 3
Lacritin, 3
cytokine-treated 3
syndecan-1 3
poorly. 3
Nonsynonymous 3
12q13. 3
pterygium 3
Tears 3
ng/100 3
incorrect. 3
(AMPs) 3
HSP70. 3
semen, 3
DPTL/DOPS 3
tBLM 3
ϕtrans 3
DCD-1L, 3
beta-hCG, 3
procedure-specific 3
AFP, 3
uE3 3
assay-specific 3
5071 3
amino-acid-induced 3
meningococcus. 3
live-attenuated 3
mucohaemorrhagic 3
Brachyspira 3
immunogens. 3
SWISS-MODEL 3
sheet, 3
heartwater, 3
sandfly 3
Sylvian 3
ICP, 3
cisterns, 3
EEG-based 3
Kaohsiung 3
Kaohsiung, 3
NN50 3
low-frequency/high-frequency 3
sonata 3
processed. 3
Music 3
43.3% 3
(cTBS) 3
spatial-temporal 3
(EMR) 3
EMR 3
k.545 3
mozart 3
k.448 3
K.545, 3
32.7% 3
K.448; 3
31.8 3
Spectrogrammatic 3
spectrogrammatic 3
chronologically 3
carryover 3
musicians 3
NBG. 3
(T12, 3
T15, 3
0.0385). 3
0.0032) 3
38(34.9%) 3
39(35.8%) 3
32(29.4%) 3
28(25.7%) 3
42(38.5%) 3
0.116). 3
contemplating 3
[Predictive 3
52.5 3
high-fat-diet-induced 3
HFD). 3
α-selective 3
(DITPA). 3
alphaVbeta3. 3
(L-T(4) 3
L-T(3)) 3
(proaggregation) 3
(degranulation) 3
L-T(4)-agarose, 3
L-T(3), 3
4)-agarose 3
XT199 3
micromol/ 3
(tetrac; 3
phospholipids/protein 3
[Thyroid 3
possibilities]. 3
[predominantly 3
-I- 3
(T3)] 3
developped 3
GC1, 3
T4-agarose, 3
Proangiogenesis 3
10(-8)-10(-7) 3
(b-FGF) 3
b-FGF 3
XT199, 3
b-FGF. 3
alphavbeta3, 3
3,5-diidodothyropropionic 3
DIT 3
tyrosine. 3
3,5-Diiodo-4-hydroxyphenylpropionic 3
(Kaff 3
M-1) 3
+dP/dtmax, 3
-dP/dtmax, 3
time-to-peak 3
time-from-peak 3
Muscles 3
(0.3125 3
neuronal-glial 3
(DIMIT) 3
3,5-diiodo-3'-isopropylthyroacetic 3
adrenalectomy 3
hydrocortisone 3
triiodo 3
transthyretin: 3
non-cooperative 3
inhibitable 3
carcinomas: 3
(VEGFR1-VEGFR3), 3
(FGFR1-FGFR4), 3
(PDGFRα), 3
(RET), 3
v-kit 3
Hardy-Zuckerman 3
(KIT) 3
(RR-DTC). 3
VEGFR-targeted 3
37%-63%) 3
9.9-16.1 3
33%-82%). 3
angiopoietin-2 3
2015;121:2749-2756. 3
cabozantinib, 3
subtype- 3
2CdA 3
F-ara-A 3
(BRCA)2, 3
(hRAD51), 3
BRC1-8, 3
BRC1-5 3
BRC1-3. 3
TNBC, 3
HER-2, 3
MDA-231 3
crosstalk, 3
1-34 3
bone-targeted 3
risk:benefit 3
anabolic. 3
Antiresorptive 3
activation; 3
Anabolic 3
cancer- 3
Timer 3
flavin-based 3
Flavin-based 3
(FbFPs) 3
Soft 3
Expressing 3
luminescent 3
HAP1 3
T27A3.1 3
p40phox 3
lipid-binding 3
precursor-like 3
glaA 3
gradual, 3
fixing 3
protoplasts, 3
anhydrases 3
alphaCA 3
betaCA 3
default, 3
ozone 3
sutured 3
fluorochrome 3
Fiske-SubbaRow 3
NudD 3
MM_0920 3
mazei. 3
8-oxo-GMP 3
nucleoside-diphosphate 3
(14)C-labeled 3
CaCl2-permeabilized 3
PAO1. 3
(mutS, 3
cleaning 3
BW535 3
0.2-14.1%), 3
34.6%). 3
5.9-30.9%) 3
astrocytomas) 3
hypericin 3
polyethylene-glycol-liposomal 3
Propylthiouracil 3
mesenchymal-to-epithelial 3
cMyc, 3
(iPSCs)(1-4). 3
(STEMCCA) 3
factors(6). 3
scarring) 3
Freshly 3
consistent, 3
pluripotency-associated 3
(Science 3
joy 3
cheerfulness) 3
Hospital; 3
Thoraxcenter 3
62.2 3
(deaths 3
MIs 3
correlates-depressed 3
interest). 3
post-ACS 3
(MDE). 3
Connecticut. 3
(ACM) 3
(MACEs)-myocardial 3
urgent/emergency 3
revascularization)-actively 3
MACEs; 3
14.8%): 3
Screen 3
282). 3
slowing, 3
bromocriptine. 3
Oxaliplatin, 3
oxaliplatin. 3
Centers. 3
24.3%; 3
41.2%). 3
216+ 3
126+ 3
447+). 3
[NCI-CTC]) 3
7.9%. 3
2.6%. 3
felines 3
cholesterol-storage 3
hAESC 3
Albeit 3
(LTP) 3
C1-deficient 3
ABCA1, 3
mTOR-independent 3
APP-CTFs 3
(Niemann-Pick 3
C1) 3
npc1 3
endosomes/lysosomes 3
(NPC1(-/-)) 3
(NPC1(+/-)) 3
stereoisomer 3
Vbeta8+ 3
superantigen 3
(cetuximab) 3
lapatinib, 3
trastuzumab-sensitive 3
CD3, 3
ErbB2-overexpressing 3
HercepTestTM 3
(PAN) 3
borrow 3
ENEs 3
noncoding. 3
extra-embryonic 3
ruminant 3
(BBN) 3
nuclear-enriched 3
DNAI2, 3
DNAH5, 3
DNAH11, 3
DNAI1, 3
High-speed 3
CCDC39, 3
©ERS 3
"radial 3
"null" 3
ciliopathy. 3
HLA-DRB1. 3
(n=333) 3
(n=490) 3
Cree/Ojibway 3
dihydropyrimidine 3
amminoacid 3
shared-epitope 3
3209 3
3692 3
(HLA-DRB1, 3
TRAF1/C5) 3
Scale-Energy 3
(VAS-E), 3
VAS-E. 3
(VAS-E) 3
(POMS) 3
(FACIT-F). 3
normotrophic, 3
(TNF-α, 3
DLEC1. 3
CUR. 3
cyclohexanone 3
cur 3
Phytochemicals 3
(coded 3
Urban 3
Malformation. 3
ICAP-1 3
FA-G) 3
322delG 3
2000;96:4064-4070) 3
FA-G, 3
(Q356X). 3
alterations) 3
(80%); 3
gamma-H2AX 3
foci) 3
(BMT) 3
43), 3
mutation' 3
FAD2). 3
amplified. 3
probands), 3
A-->G 3
Chordoma 3
U-CH2 3
PIIT 3
fluoroscopic 3
chordomas]. 3
(VAS)≥8 3
SD-1029 3
Cu(II)(atsm) 3
(P-bodies; 3
XRN-1 3
ubiquitin-immunoreactive 3
(SOD1), 3
R521C 3
neurotransmitter. 3
(86%, 3
typing), 3
(MSLT) 3
actigraphy. 3
(72%): 3
(EDS; 3
MSLT) 3
(daytime 3
'sensu 3
strictu' 3
pre-TBI) 3
presentation: 3
respiratory-suppressant 3
worsen, 3
sundowning 3
toxin-dependent 3
(death 3
TNNI3K-mediated 3
phospho 3
MAPKKK, 3
infarction-induced 3
1p31.1 3
DDK, 3
Rif1/PP1 3
(ATM- 3
Nbs1, 3
Mre11. 3
(DDK), 3
disordered; 3
spurs 3
breaks/ends 3
ATM/53BP1 3
in-turn 3
knees. 3
Wheat 3
FGID. 3
HLA-DQ2 3
(s). 3
(AGH-Ednrb(sl)×F344-Ednrb(sl)) 3
Gdnf, 3
EDNRB-deficient 3
Ednrb. 3
HSCR/IND 3
neutrophic 3
Endothelin-3 3
(EDNRB). 3
(3%, 3
teledietetics 3
sharing, 3
terminals--mostly 3
PDAs 3
email. 3
6-Shogaol 3
(STS). 3
EV71-induced 3
PI3K-dependent 3
reovirus-infected 3
VCP 3
VCP/p97. 3
retro-translocated 3
N-glycans. 3
gammaD 3
Cdc48p/Npl4p/Ufd1p 3
p97/Cdc48p, 3
Sec61p 3
Der3/Hrd1p 3
proteasome-defective 3
3,4-dichloroisocoumarin 3
SPP 3
Yos9 3
Hsc70, 3
J-protein 3
multiple-step 3
(Dabrafenib) 3
(Trametinib) 3
BRAFV600-mutant 3
15%). 3
(40%). 3
non-inducible 3
iBRAF 3
88.8% 3
(17%; 3
MEDLINE/PubMed 3
GSK2118436, 3
(BREAK-2) 3
Histologically 3
cSCC 3
(NPA) 3
(BRAF(mut)) 3
dabrafenib; 3
Grover's 3
nonsun-damaged 3
leptomeningitis 3
inhibitor): 3
dacarbazine. 3
GSK2118436 3
eruptive 3
impractical. 3
response), 3
Roche; 3
commentary, 3
BRAFV600 3
45), 3
68.3% 3
188) 3
nonreferral 3
14.0% 3
[65%]). 3
malfunction, 3
(53.8%) 3
96%). 3
CE-MRI 3
[51%] 3
"hump" 3
sign" 3
STHS 3
mediated) 3
(27%). 3
(anti-tachycardia 3
defibrillation) 3
(aborted 3
oxybutynin, 3
self-care 3
homes, 3
12.02 3
2.85 3
OAB; 3
substantial, 3
$8.2 3
$16.4 3
(1993 3
dollars). 3
$26.3 3
$3565 3
Taz, 3
TAZ; 3
YAP-TEAD 3
Vgll1 3
IRF5, 3
P<1.00E-15 3
Funnel 3
humans; 3
invest 3
10(-11)), 3
interactions) 3
ictogenesis 3
Synchronized 3
(ssDNA), 3
Unpaired 3
Wright 3
unpaired)/nx(highest 3
-DeltaG 3
unpaired), 3
DeltaG 3
substituted. 3
nonstart 3
Numb: 3
fibroblastoid 3
interrelated. 3
SMAalpha 3
Vimentin) 3
miR-1. 3
AVB 3
AVB, 3
-2.7 3
I(K1). 3
microRNA-based 3
(Ca(2+)/calmodulin-dependent 3
S2808 3
Kir2.1) 3
VMC 3
autofluorescence 3
(worms, 3
'guardian 3
cyclotherapy 3
exemplar 3
phosphoinositol-3-kinase/AKT 3
1,25D 3
miR-504 3
miR-25 3
eternal 3
(RD) 3
Se's 3
irreparably 3
(SEPW1) 3
DYRK2 3
suppressor: 3
breaching 3
UVB-irradiated 3
pylori-associated 3
(34.9%) 3
TA-p63) 3
guardians--p53, 3
p63--of 3
"assistant" 3
genome? 3
rightly 3
(LOSMoN/SMAJ; 3
#615048), 3
SMAJ 3
727kb 3
SHGC-106816 3
D22S345. 3
NPIS 3
enquiries 3
Poisons 3
OD. 3
0.3%. 3
(8.8%). 3
Ventilation 3
antagonist]. 3
Midazolam, 3
detoxification. 3
continuous-infusion 3
self-induced 3
tranquillising 3
mg/h) 3
required) 3
chloral 3
(low-risk) 3
Controversies 3
resedation, 3
Open-label 3
(3.25 3
0.69) 3
BDZ-negative 3
NAS 3
puncture) 3
sedatives/hypnotics 3
10.93 3
mono-intoxications, 3
flumazenil); 3
1,4-imidazobenzodiazepine, 3
CNS-depressant 3
15-1788) 3
alphaMHC 3
BRCA1/BRCA2 3
out-competed 3
summation 3
(reads) 3
c.1739_1740insAlu 3
c.156_157insAlu 3
sequencers, 3
97.8% 3
94.7 3
98.9% 3
96.8 3
99.3 3
100.0). 3
massively-parallel 3
demanded 3
per-sample 3
cost/sample 3
(gDNA) 3
low-cost, 3
regenerable 3
re-sequencing. 3
SPG30, 3
paraplegia: 3
p.R350G, 3
KIF1A. 3
p.A255V, 3
COL4A4 3
junior). 3
reconsider 3
(MKS1, 3
TMEM67, 3
TMEM216, 3
CC2D2A 3
RPGRIP1L). 3
MKS, 3
microdroplet-PCR 3
IlluminaGAIIx 3
(his 3
brother). 3
(c.1102A→T 3
(p.R368X)) 3
grandmother. 3
(454 3
Sciences) 3
6-bp 3
thermoregulation: 3
clinico-radiological 3
neuropsychometric 3
Hypermelatoninemia 3
fragilis 3
stereotypic, 3
lower-order 3
Amphetamine 3
C58/J, 3
C57BL/6J. 3
marble-burying. 3
poke 3
holeboard 3
non-social, 3
familiarization 3
highly-sociable 3
Slc6a4, 3
C58/J. 3
Grin1, 3
Nlgn1, 3
Sapap3, 3
Slitrk5, 3
VPA600 3
Shank 3
autism-like 3
30-35) 3
(inanimate 3
objects). 3
sniffing, 3
retest: 3
paradigm). 3
(BDNF)-induced 3
(TrkB) 3
inanimate 3
Gr-1(+) 3
(NMDAR) 3
Genes, 3
1:110 3
MALTT 3
"unaffected" 3
FXS, 3
MeCP2+/- 3
PTLS 3
RNA-host 3
(DENV). 3
DENV-2. 3
(ISGs), 3
IFITM2 3
(sfRNA), 3
CAPRIN1, 3
sfRNA 3
(G3BP) 3
nsP4 3
nsP2 3
nsP3. 3
(EBP) 3
month), 3
qua 3
neuraxial 3
parturients 3
(LP) 3
post-partum, 3
Ca-storage 3
Ca-transport, 3
Lausanne 3
Recommendations. 3
1101 3
Zymoseptoria 3
tritici 3
death-domain-associated 3
ADAR). 3
Dechloromonas, 3
biostimulated 3
EVO 3
biostimulation. 3
capabilities, 3
amendments 3
metal-reducing 3
Mine 3
ppm), 3
couple. 3
Fe(III)-grown 3
Subsurface 3
assimilatory 3
copious 3
rod-shaped, 3
Rf4T, 3
0.5-0.6 3
Geobacter. 3
Pelobacter 3
Constant 3
sorb 3
sediment-grown 3
anaerobically. 3
Ridge, 3
FRC-D1 3
U(IV). 3
pstB 3
phoU 3
metal-resistant 3
hydrological 3
Geobacter-mediated 3
U(VI). 3
composition; 3
acetyl-coenzyme 3
delayed-rectifier 3
mongoloid 3
(QTc) 3
endocardium 3
rs939348 3
SHRs 3
postdocetaxel 3
P45017alpha. 3
Convection-enhanced 3
neprilysin: 3
amyloid-β-degrading 3
(NEP) 3
dispute 3
Rickettsiales, 3
Ochrobactrum 3
(30) 3
Reclinomonas 3
Anaplasmataceae, 3
alpha-proteobacteria, 3
enslavement 3
presequence 3
rickettsia-like 3
alpha-Proteobacteria 3
endosymbiotic 3
(1,111,523 3
typhus. 3
(host) 3
'neutralized' 3
Rickettsiaceae. 3
solvent. 3
euthanasia. 3
enzymes). 3
(E1) 3
systole, 3
unter 3
hirsutism 3
U87, 3
brain; 3
low-stage 3
pathobiological 3
Conditioned 3
EphA2-targeted 3
[Detecting 3
Twice 3
>1000 3
cDNA-mediated 3
RRM3. 3
dNTPs 3
Fob1p 3
(rDNA), 3
rrm3Delta 3
ORI, 3
Ori-Finder, 3
DoriC. 3
Entities 3
FK2 3
NF-κB-mediated 3
IκB-α, 3
Receptor-interacting 3
ZVAD 3
RIP1, 3
siRIP3 3
RIP1-RIP3-DRP1 3
Psychosensory 3
wired, 3
melansopsin 3
isocoric 3
eye-drops 3
third-nerve 3
iris, 3
cardioselective 3
i.t. 3
piloerection, 3
POB 3
ALK2, 3
c-Rel. 3
nfkappab2 3
serines, 3
nfkb1-derived 3
rel 3
SCCHN 3
cytoskeletons. 3
(TGF) 3
-β, 3
Spindle 3
archives 3
peritoneum. 3
(PEST) 3
9q33-34 3
Tenascin-C 3
gain). 3
Factor-like 3
O-fucose 3
Fringe 3
dysmorphologists 3
hemivertebrae, 3
DLL3 3
(SCDO1: 3
277300), 3
MESP2 3
(SCDO2: 3
LFNG 3
(SCDO3: 3
Hairy-and-Enhancer-of-Split-7 3
truncating, 3
CRF 3
RCTs), 3
non-fatigued 3
CAF 3
(CBT-I) 3
VCBT-I 3
(CBTH) 3
(CBT), 3
confront 3
(T1), 3
0.015, 3
life). 3
rehabilitation: 3
(PT+CBT 3
(PT 3
n=71). 3
nonintervention 3
(WLC 3
pain-fatigue-sleep 3
FACIT 3
linearly. 3
post-assessment 3
SCF(FBW7) 3
SCF(Fbw7). 3
FBW7-mediated 3
Mutating 3
Fbxw7-deficient 3
(Hoeck 3
fbw7 3
Fbw7-knockout 3
(fbw7(∆Cb)) 3
arborisation. 3
Fbw7-deficient 3
supranumeral 3
junAA 3
arborisation 3
(JNK)/c-Jun 3
Roc1/Rbx1 3
RING-type 3
para-aortic 3
Fbw7(-/-) 3
Hey1, 3
nonathlete 3
self-questionnaire 3
54.7%, 3
Urgency 3
jumping. 3
Questionnaire-Short 3
measures; 3
dancers, 3
athlete. 3
(LH) 3
od 3
fit, 3
hypertelorism 3
Ser252Trp 3
Pro253Arg) 3
pustular 3
peripherally, 3
nociception, 3
MK, 3
CyPD, 3
SJL 3
(Abs) 3
(MS): 3
15-DOS 3
MS? 3
unfulfilled. 3
locomotion. 3
lovastatin-treated 3
exclusions 3
MyoD/MyoG), 3
hypomethylated, 3
Ndc1p: 3
NDC1/NET3 3
Yeasts 3
envelope: 3
Nup93, 3
Nup53, 3
Nup205. 3
Nup53 3
(CTD), 3
submembranous 3
Gp210 3
Gp210. 3
mutB 3
nucleoporins. 3
D2. 3
(IFN-α) 3
(AP2)-clathrin 3
(IFN)-alpha/beta 3
postinternalization 3
TYK2 3
specifics 3
(TSGs). 3
(hepaCAM) 3
methprimers 3
PCR; 3
5-aza-CdR. 3
Re-activation 3
Homoplasmic 3
(91.8%), 3
(93.5%), 3
(91.9%), 3
(80.9%) 3
Q/N-rich 3
self-propagating 3
Codependent 3
RSK2. 3
codependency. 3
RASMCs. 3
(Brooke-Spiegler 3
(U0126) 3
beta-catenin-mediated 3
(Fz) 3
(Dvl). 3
polymerization-prone 3
hyperubiquitination 3
NTHi 3
NTHi-induced 3
NF-�B 3
SETDB1) 3
constituency 3
(E(z)), 3
(trx) 3
RbBP5. 3
S-adenosyl-L- 3
[methyl-(3)H] 3
Ash2L. 3
Instructions 3
PKMTs 3
free-energy 3
co-incident 3
prophase. 3
meiosis-specific 3
ESC-E(Z) 3
MBP-G9aDelta634 3
SUV39H 3
5'-RACE 3
variegation, 3
(AdoHcy). 3
'exon-intron' 3
'intron-exon' 3
'None' 3
WPSS 3
maydi, 3
chi2-test 3
impossible) 3
reasoning). 3
Cai 3
al.'s 3
less-studied 3
third-order 3
GeneSeqer, 3
non-cognate 3
http://www.plantgdb.org/cgi-bin/AtGeneSeqer.cgi 3
http://www.plantgdb.org/cgi-bin/GeneSeqer.cgi, 3
http://bioinformatics.iastate.edu/cgi-bin/gs.cgi. 3
GeneBuilder: 3
(Burset 3
Guigo, 3
Genomics, 3
353-367, 3
4' 3
11aR)-medicarpin. 3
954 3
Suspension 3
Cultures. 3
medicarpin-3-O-glucoside-6''-O-malonate 3
afrormosin-7-O-glucoside-6''-O-malonate 3
THBS1, 3
THBS1 3
ccRCC 3
Fyn/ERK 3
SPARC. 3
(SPARC), 3
p21(Cip1/Waf1) 3
SPARC-silenced 3
H322 3
SPARC-sup 3
LYST. 3
(c.1540 3
CGA>TGA, 3
c.9893T, 3
F3298fsX3304) 3
R1836X 3
RAB27A 3
hyperimmune 3
1q43. 3
RVEF 3
RV, 3
McNemar 3
LVDP% 3
T3-limiting 3
DBD 3
debutyldronedarone 3
ischemia-reperfusion, 3
(SelD) 3
SelD 3
specialized, 3
FEMS 3
LIP5 3
VPS4, 3
two-color 3
SNAREs 3
D1/Cdk4 3
(p21(CT)) 3
D(149)FYHSKRR(156) 3
D-cdk4 3
cdk4. 3
suppressor-I 3
subclone 3
(retinoblastoma) 3
OVCAR-3, 3
GTG) 3
(p16INK4, 3
p16INK4, 3
Cdk-activating 3
CDK4/6-inhibitors 3
p18. 3
penchant 3
cdk2. 3
seven-transmembrane 3
G-->C 3
Z-DNA-forming 3
S/-221C 3
L/G-221 3
factor(s). 3
.01, 3
WKY. 3
medullectomy 3
(1.7-fold) 3
HRC-infected 3
overexpresssion 3
(1.8-fold), 3
(JH) 3
(HJV) 3
(HAMP). 3
thalassemia. 3
(Pakistan, 3
Thailand). 3
Hemochromatosis 3
threat. 3
HH, 3
PCT. 3
genotypes: 3
EF-hand 3
phospho-Ser(67) 3
diphospho-Ser(65)/Ser(67) 3
Thr(35)-phosphorylated 3
[GST-I-1(T35A)] 3
cdc2-like 3
(NCLK) 3
chromatographies. 3
anti-NCLK 3
kinase-active 3
I-1). 3
I-1(T35A) 3
protamine, 3
ninety 3
threonyl 3
residue; 3
32000-Mr, 3
5min 3
I-1alpha 3
LL-37, 3
LL-37 3
NETosis, 3
'NET' 3
neutrophil. 3
(IFNα) 3
netting 3
Antiphospholipid 3
(HB) 3
unspecific, 3
VHL. 3
suggested; 3
53,000 3
(2A, 3
2C) 3
haemangioblastomas, 3
phaeochromocytomas 3
non-VHL 3
GH-PRL 3
alerted 3
(HIF). 3
von-Hippel-Lindau 3
(HIFalpha), 3
HIFalpha-independent 3
failure.In 3
beta-domain 3
CD59) 3
(HER2Mab), 3
6× 3
necrolysis, 3
(4.7%). 3
infection). 3
testing), 3
skin-patch 3
patch-test-confirmed 3
Abrogating 3
'example' 3
(HSS). 3
pre-testing, 3
transcriptases 3
annum, 3
(HLA)-B*5701 3
(ABC), 3
(PGx) 3
test-positive 3
prescribing. 3
Abacavir, 3
nucleoside-analogue 3
(H3K4me3 3
MIR22, 3
(autonomously 3
Octanucleotides 3
(PuPyPuPy)2 3
Over- 3
under-represented, 3
methylase. 3
trinucleotides, 3
GCA.TGC 3
CTA.TAG 3
prokaryotic, 3
anti-angiogenic, 3
2400 3
gliomas]. 3
U/L. 3
TRAB-positive 3
cryoglobulinemia. 3
(IDDM). 3
GAD-67, 3
GAD-67 3
YwqL 3
mfd: 3
post-exponential 3
comA 3
comK. 3
absences 3
postplacement. 3
EPDS 3
postplacement 3
extraverted. 3
postadoptive 3
extroversion, 3
unipolar/bipolar 3
tubulin(K40Q) 3
acetylation; 3
bouton 3
sirtinol, 3
tubacin 3
class-I-specific 3
-0.46 3
not? 3
Dermatofibrosarcoma 3
(DFSP) 3
Summary: 3
IFN-alpha 3
qd. 3
(223 3
A3G. 3
shRNA-based 3
ORF1p 3
elements) 3
zinc-coordinating 3
suspect's 3
PPP, 3
thalassemia, 3
(Xq28)-were 3
10(-6)) 3
(G6PD), 3
disadvantageous 3
non-deficient 3
Amazon, 3
Macrostomum 3
lignano 3
bleed, 3
(ECF) 3
(DIND) 3
(CRP)/white 3
0.0253, 3
0.0087, 3
0.00167, 3
0.0026, 3
Floating 3
(VP) 3
dopamine-lesioned 3
benserazide) 3
(LID). 3
l-DOPA-primed 3
Antinociceptive 3
GluR1 3
orolingual 3
Eticlopride 3
(1.0, 3
3-methoxytyramine. 3
(Madopar) 3
(Sinemet) 3
7p14-p22. 3
cisternae, 3
NRDS 3
(n=32). 3
resource-limited 3
(ELBW) 3
RDS, 3
cFTOE 3
dioxide, 3
Karolinska 3
(INSURE 3
oxygen) 3
Care) 3
http://staff.science.uva.nl/~bui/PPIs.zip 3
mentions 3
biomedicine 3
(Cdc2) 3
(P-P) 3
Cdc2-cyclin 3
(thyrocytes) 3
(Lmna(Δ8-11/Δ8-11)) 3
(Lmna(Δ9/Δ9)) 3
lamin-depleted 3
laminopathies 3
networks: 3
blebs, 3
LA/C 3
caspase-6, 3
healthiest 3
(GV) 3
maturity, 3
G9a-mediated 3
Lmna-/- 3
quanta 3
Light-harvesting 3
(LHCII) 3
neoxanthin 3
LHC 3
(RNA•DNA 3
CTG•CAG 3
GAA•TTC 3
r(GGGGCC)n 3
(STAT)3, 3
berberine-induced 3
Anti-amyloidogenic 3
α-secretase 3
α-Secretase 3
(ADAMs), 3
intramolecular, 3
replicational 3
telomestatin: 3
quadruplex 3
canalization 3
"bring 3
end-result 3
conditions" 3
vegetables. 3
non-predefined 3
population-attributable 3
(22%; 3
Diet, 3
CARD15 3
psychrotrophic 3
Yop 3
HT29, 3
'BRCAness' 3
TNBCs 3
Uncommon 3
rubber 3
serviceman 3
erucism: 3
Larvae 3
wilkinsoni 3
groves 3
irritating 3
Lepidoptera. 3
vomited 3
wilkinsoni. 3
glabrata, 3
histatins 3
(OLs). 3
psychosine-mediated 3
LPC 3
PLA2. 3
(LOGLD) 3
(psychosine; 3
PS) 3
(GALC-PS) 3
galactose. 3
30-kb-deleted/502T 3
62- 3
809G>A 3
50s 3
galactocerebrosidase. 3
asparagine-linked 3
HMGal 3
3.2.1.46: 3
galactocerebrosidase) 3
(twitcher 3
mutant). 3
(LRs) 3
Sepharose 3
coding-sequence 3
papaya 3
[Carica 3
papaya], 3
[Populus 3
trichocarpa], 3
[Vitis 3
vinifera]), 3
monocots. 3
Grass 3
pfmc-2tm, 3
non-immune 3
reichenowi 3
RIFINs, 3
RIFINs. 3
(A-type) 3
(B-type). 3
Giemsa-stained 3
neighborhoods, 3
(VSA) 3
IEs 3
malaria-infected 3
exports 3
Pf332 3
dysthymia 3
school-based 3
attention-support 3
AS-Control 3
caries. 3
incisor 3
dentin. 3
EVCs 3
Melanesian 3
Solomon 3
CASQ2-associated 3
CPVT2. 3
examiners, 3
basics 3
channelopathic 3
E189D, 3
(SOICR). 3
SOICR, 3
judicial 3
transmembranous 3
very-low-density 3
plasma-borne 3
("classic") 3
("alternative") 3
platelet-activating 3
apoE-containing 3
self-limited, 3
angioedema, 3
nonusers 3
mesenchyme-specific 3
Tpl2, 3
dimethylbenzanthracene/12-O-tetradecanoylphorbol-13-acetate 3
(TPA) 3
natriuresis. 3
ABPM 3
olmesartan 3
amlodipine/olmesartan 3
SPCs 3
three-phase, 3
multi-center, 3
116.8 3
6.04 3
HCTZ. 3
.40). 3
.042; 3
.043, 3
pre-NSAID 3
pressure.(ABSTRACT 3
valsartan-hydrochlorothiazide 3
monotherapy: 3
ValVET 3
valsartan/hydrochlorothiazide 3
(nonsynonymous) 3
co-oriented 3
(J, 3
L), 3
biogenesis), 3
(posttranslational 3
conversion), 3
functionalities, 3
Upton 3
phalanx 3
(S252W, 3
Dominantly 3
limbs) 3
Ser252Phe 3
digits. 3
central-peripheral 3
AP1-controlled 3
Jet-lag 3
desynchronizes 3
clock-SNS-peripheral 3
gene-mutant 3
CylinB1and 3
C-myc. 3
CylinB1 3
C-myc 3
SW480) 3
22-28 3
department]. 3
safely. 3
Hitachi 3
3.5-mg 3
Narita 3
Judgment 3
complied 3
(IMWG). 3
BOR, 3
(69.0%) 3
PCL. 3
Perrino 3
Brindisi, 3
PCL). 3
1-4; 3
8-11, 3
(PBSCT) 3
bortezomib- 3
(cyclophosphamide 3
2-5; 3
[modified 3
CODOX-M 3
protocol]) 3
antigen-identical 3
PBSCT, 3
Excerpta 3
amyloidosis]. 3
(VD) 3
(BZM) 3
(EGCG) 3
BZM. 3
Relapsed/refractory 3
low-performance 3
drug-resistance. 3
EGFR-dependent 3
0.9-1.5 3
myalgias, 3
dose-delays, 3
dose-reductions, 3
SUMMIT. 3
vial. 3
(PegLD). 3
PegLD 3
near-CR, 3
anthracycline-refractory 3
(PRs). 3
PRs. 3
Bortezomib/PegLD 3
mutagenised 3
gene-sets 3
SB-mutagenised 3
processes; 3
29), 3
p19(Arf), 3
Bmi1-dependent, 3
(NBCCS). 3
Ptch(+/-) 3
codon; 3
<340 3
protector. 3
miles 3
vest 3
wall-motion 3
hemodynamic, 3
(ULCs) 3
immersion. 3
Diving 3
"generalized" 3
praxis 3
startle, 3
non-reflex 3
identiﬁcation 3
convolution 3
spike-and-slow-wave 3
(VEEG). 3
fronto-temporo-parietal 3
fronto-parietal-occipital 3
΁ 3
hyperperfusion 3
bath. 3
immunopathology, 3
culture-confirmed 3
2-hydroxy-dATP. 3
2-hydroxy-2'-deoxyadenosine 3
A:T-->G:C, 3
2-aminopurine-2'-deoxyriboside 3
2-amino-2'-deoxyadenosine 3
T-->G: 3
T-->C: 3
8-hydroxy-dGTP. 3
repair-type 3
supF 3
G-->T 3
G*2-OH-dATP 3
incorporated, 3
photodermatosis 3
phototoxicity. 3
U.S 3
270-day 3
69.4 3
40.8 3
P=0.005), 3
146, 3
vitiligo: 3
(NB-UV-B) 3
anti-α-MSH 3
(ADA). 3
Pre-existing 3
(CUV1647) 3
HHD, 3
HHD. 3
([Nle4-D-Phe7]-alpha-MSH) 3
counterfeit 3
'Melanotans' 3
portrait. 3
light-related 3
60-day 3
tumefaciens. 3
nopaline-type 3
cytokinin. 3
pathogenesis-related 3
sending 3
VirE2, 3
Ti 3
pTiChry5, 3
T-regions 3
recalcitrance 3
Ct 3
32.9% 3
trisomies, 3
Oculomotor 3
G71R 3
CS-HA 3
CASQ2(D307H) 3
csq-1 3
calcium-regulatory 3
hyperthermia, 3
country's 3
high-throughput, 3
(sDMA) 3
RG-rich 3
Lsm11, 3
B/B' 3
UsnRNPs 3
snRNPs. 3
Lsm) 3
'mature' 3
reclamation 3
post-pubertal 3
omega-conotoxins. 3
GVIA. 3
globules. 3
fractal, 3
non-fractalness 3
entangles 3
molten 3
strings 3
(Grosberg 3
log-log 3
benzoxazoles, 3
over-active 3
II)-inhibiting 3
efficacies, 3
Bisdioxopiperazine 3
closed-clamp 3
937 3
(NCI 3
screen). 3
Anthrapyrazoles, 3
cleavage) 3
N592 3
noside) 3
aclarubicin. 3
aclarubicin, 3
Aclarubicin 3
protein-concealed 3
alpha-related 3
MNNG-induced 3
CCAAT/enhancer 3
quinoline-3-carbonitrile 3
Osaka 3
8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles 3
8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-methyl-1H-imidazol-4-yl)methylamino]quinoline-3-carbonitrile, 3
thieno[3,2-d]pyrimidines 3
are-by 3
definition-hypersensitive 3
diepoxybutane, 3
ascertainment: 3
Inferences 3
anemia-like 3
16- 3
131-bp 3
Hoxd13, 3
disintegrating 3
(Hox) 3
colinearity 3
(HOM-C) 3
buzzatii. 3
buzzatii 3
proboscipedia, 3
Polypterus 3
senegalus) 3
rayfinned 3
(actinopterygian) 3
D); 3
Gnathostoma. 3
actinopterygians. 3
predates 3
lamprey, 3
non-vellus 3
anagen 3
macrophotographic 3
nonvellus 3
growth/scalp 3
contactant 3
anteroseptal 3
self-inflicted 3
sensitizations 3
co-inducers 3
RP, 3
retinae 3
(respectively, 3
(MR). 3
Haemostasis. 3
bioprostheses, 3
syndrome--the 3
compelling. 3
1958. 3
replacement?]. 3
valve-stenosis 3
evaluation). 3
31.7% 3
sphincter? 3
costal 3
ischiopubic 3
pads/day 3
text, 3
urethra. 3
anomalies). 3
Perineal 3
Uratape 3
tape. 3
(GSUI) 3
bacteriuria 3
A-to-G 3
(28) 3
Accuracy, 3
Voxels 3
Dimensions 3
time-specific 3
blueprints 3
SC35-positive 3
lineage-specific, 3
Brg1, 3
interior. 3
fluorochromes. 3
1&emsp14;kb 3
1.1-2.5%, 3
Cas9/CRISPR 3
Cas9-mediated 3
(CRISPR)/CRISPR-associated 3
(n=18), 3
n=17). 3
58.8% 3
professions. 3
prowess, 3
(soccer), 3
competition-level 3
rugby). 3
right-left 3
2D:4D) 3
estrogen) 3
caps, 3
First-choice 3
134) 3
(NT)-proBNP 3
703.9 3
pg/mL±179.1 3
hyponatremic 3
1001.16 3
pg/mL±131.52 3
normonatremic 3
826.43 3
pg/mL±337.43 3
ICP>15 3
ICP≤15 3
beta-natriuretic 3
NK/T 3
killer/T 3
(ENKTL), 3
ENKTL, 3
asparaginase-based 3
(83.8 3
(78.7 3
0.074). 3
53.0 3
58.0 3
non-asparaginase-based 3
chemoregimens 3
ENKTL 3
ENKTL. 3
MoAb, 3
(IATs) 3
novo" 3
non-polyposis 3
colo-rectal 3
her/his 3
(ET2DS). 3
ABI, 3
cIMT, 3
'g') 3
'possible' 3
(HADS 3
≥8) 3
1.20, 3
2.70; 3
co-variates 3
-0.02, 3
-0.07 3
'g'; 3
ET2DS 3
impairment: 3
RAGE, 3
CetZ 3
FtsA27 3
FtsZDr 3
monogenic, 3
protofilaments. 3
PR), 3
0.795), 3
0.163). 3
26%); 3
27%); 3
23%). 3
(NTx), 3
(CTx) 3
PSEN1, 3
51A) 3
complexity; 3
17A) 3
(GPR51, 3
leprechaunism 3
rh-IGF-1 3
(leprechaunism; 3
*246200) 3
(middle 3
PDGF-BB, 3
hypertrophied/failing 3
(AAC) 3
rarefaction, 3
receptor/fetal 3
(SOICR) 3
P-S6 3
cancers: 3
"drug 3
BRAF-targeted 3
IUBMB 3
GNAQ, 3
GNA11. 3
(BRAF 3
Sorafenib, 3
intra-tumor 3
resistance-conferring 3
colo205/V 3
rare; 3
3-7% 3
teratoma), 3
1112 3
177). 3
(51.4%) 3
(V600E)BRAF 3
anti-RAF 3
non-cutaneous 3
palms, 3
(p≤0.05) 3
antigen-retrieval 3
(n=572) 3
(scales 3
0-100; 3
61; 3
Ds. 3
(Beta=-0.09), 3
(Beta=-0.12) 3
(Beta=-0.08), 3
(OR=0.54; 3
95%CI=0.44-0.66;all 3
emotionally. 3
'concern' 3
response' 3
(15.1%), 3
(11.6%). 3
5.3%; 3
(18.8 3
24.4%; 3
'coherence' 3
'timeline', 3
'identity', 3
'concern', 3
representation'. 3
interrelatedness. 3
elicits. 3
P<.01). 3
(distressed) 3
(DS14), 3
P<0.0001) 3
Insyght: 3
navigating 3
syntenies 3
symbol! 3
displays: 3
legibility 3
Sockeye: 3
Java-based 3
TKK 3
SKR10, 3
horticulture 3
ultraviolet, 3
N45 3
UNCS1 3
g/g 3
glycerol-based 3
(cadA) 3
(10-25 3
StemRegenin 3
HPCs. 3
backcrossed 3
Lew-TRAP 3
anti-tTG/anti-npG 3
IgA/neutrophil-mediated 3
life-long, 3
DQ2 3
DQ8. 3
DQ8+ 3
DQ 3
reintroduce 3
cCD 3
gamma/delta 3
afterward 3
(IgA 3
DQA1, 3
DQB1 3
probable. 3
antigliadin 3
mutS/L 3
MutS, 3
MutL. 3
incises 3
retained, 3
(MLH1) 3
MMR-deficient 3
MutH-independent 3
Firmicutes. 3
RecD2, 3
MMR-related 3
eATL 3
(HNPCC). 3
Recovered 3
scoticus, 3
LIV, 3
vegetation 3
warmer 3
Ticks 3
prME 3
connexion 3
transformer 3
2β 3
(Tra2β) 3
(TRA2β1 3
-5) 3
(Chk2)- 3
(p38(MAPK))-mediated 3
S88 3
39-nucleotide 3
arsenite-stimulated 3
Tra2β 3
Tra2β-dependent 3
39-nt 3
[S88A], 3
S100A, 3
T118A) 3
S88D, 3
S100D, 3
T118D) 3
TRA2β4-related 3
ELAVL1 3
(ELAVL1, 3
HuR) 3
(Eif4enif1), 3
(4E-T) 3
cytopathology, 3
nucleo-cytoplasm 3
TIA1/TIAR, 3
2A(pro)-expressing 3
I-band 3
Frank-Starling 3
titin's 3
stretched. 3
M-line, 3
(Mayans, 3
Ven, 3
Wilm, 3
Mues, 3
Furst, 3
Wilmanns, 3
Gautel, 3
863-869). 3
Myofibrillogenesis 3
27,000 3
(BMP-2)-induced 3
2A-dependent 3
MEF-2A.DNA 3
MEF-2-specific 3
MEF-2A-mediated 3
MEF-2A-dependent 3
calcineurin/mAKAP 3
(silencing 3
PCAF. 3
MEF2-dependent 3
GATA-dependent 3
MEF2/GATA-4 3
cardiomyogenesis. 3
myocardium; 3
-D. 3
phosphorylations, 3
Rictor-mTOR 3
rictor. 3
Protor 3
(S6 3
Protor-2 3
26-day-old 3
GbetaL) 3
sin1. 3
mLST8, 3
sin1 3
PRAS40. 3
(M6PR). 3
(SNX1)-positive 3
SNX1-dependent 3
(ETCs). 3
EE-derived 3
EEs 3
Ultrastructure 3
60-100 3
light-EM 3
marker: 3
UDP-N-acetylglucosamine 3
1-phosphotransferase 3
α-N-acetylglucosamine-1-phosphodiester 3
α-N-acetylglucosaminidase. 3
adaptins 3
GlcNAc-1-phosphotransferase 3
thiopurines 3
gut-homing 3
747 3
[CDAI] 3
≤150, 3
(≥100-point 3
(P=0.23). 3
39.0% 3
21.6% 3
P=0.004 3
15.3%), 3
(44.1% 3
40.2%), 3
3.0%). 3
NCT00783692.). 3
25.5% 3
15.9% 3
5-aminosalicylates, 3
antagonists) 3
Moving 3
gut-selective, 3
CD) 3
widely; 3
(IL)-12/23 3
anti-alpha4beta7 3
.096) 3
.095) 3
.17). 3
kg-1. 3
(O2/N2O: 3
40/60). 3
(bupivacaine 3
kg-1). 3
'objective 3
scale'. 3
39%; 3
adenoidectomy. 3
day-surgery 3
mug/kg 3
midazolam-treated 3
bupivacaine; 3
postanaesthesia 3
Intranasal 3
Nuchal 3
placement: 3
(2.95 3
4.38 3
10(-7)) 3
48.7%. 3
"neuronal 3
plasticity" 3
patient]. 3
precise. 3
homopentameric, 3
mutation-sensitive) 3
mutation-sensitive). 3
PUGNAc-treated 3
PfPRMT5 3
PfSmD1 3
PfSm 3
enzyme-based 3
co-evolution, 3
polC. 3
phosphorylase. 3
gamma-Proteobacteria. 3
progenote 3
Actinobacteria. 3
assures 3
lingering 3
Aggregated 3
(C2) 3
proTα(100-109)-stimulated 3
proTα(100-109)-induced 3
proTα. 3
proTα 3
Ca²(+)-dependent 3
peptide-deficient 3
HCT116) 3
metalation 3
SAS 3
(composite 3
'Cognitive 3
Enhancers'. 3
problem-solving. 3
creativity 3
(d 3
drd4 3
autoradiography, 3
methamphetamine-dependent 3
psychostimulant 3
s.c.), 3
pharmacotherapies. 3
nonacute 3
taper, 3
characterisation. 3
stop-signal 3
shifting. 3
2.1.1.63), 3
Cys-321 3
O6-alkylguanine. 3
ATase, 3
refactory 3
(O6-BzG), 3
(G160) 3
(W). 3
G160 3
(hATG160W) 3
calf-thymus 3
W160 3
O6-alkG 3
hAT. 3
G/W-160 3
YSGG 3
YSGGG 3
(YAGG 3
YAGS 3
Dat 3
subtilis), 3
YRWG 3
YKWS 3
YRGGF 3
AdaB 3
Subtilis. 3
Finally,conformational 3
stereoelectronic 3
alpha-pi-unsaturated 3
alkyltransferases. 3
O6-Methylguanine 3
L-arabinose 3
(10-, 3
O-alkyl 3
O6-alkylguanine-DNA-alkyltransferase 3
premutagenic 3
Contrarily, 3
ada- 3
fnr 3
ogt::kanr 3
2,4-diamino-6-benzyloxy-5-nitrosopyrimidine. 3
(AGT) 3
2,4-diamino-6-benzyloxy-5-nitrosopyrimidine 3
(5-nitroso-BP), 3
(Ada-C) 3
built, 3
HIF1α, 3
∼1000 3
∼1500 3
MAOA-u 3
mediational 3
DPC. 3
with100μg/mL 3
(CCK8) 3
alizarin 3
hDPCs, 3
accumulation; 3
thermoresponsive 3
sol 3
sialophosphoprotein, 3
papilla, 3
dentin-like 3
subjacent 3
calcium-hydroxide-treated 3
Neurosurgery. 3
postsurgery. 3
(KPS 3
3.3-5.8 3
non-depressed 3
10.0-11.7 3
Neurosurgery, 3
Crown-Crisp 3
Experiential 3
58.2 3
decoupled 3
tissue-based 3
dbSNP 3
Platform, 3
AbCD 3
tribe 3
mother) 3
Palmoplantar 3
dual-genome 3
baits 3
SBS 3
97.5% 3
(SNV) 3
criterion), 3
95.6% 3
EBV-transformed 3
(36× 3
(>28× 3
(>76× 3
wart 3
averting 3
gained, 3
QALY. 3
(redness, 3
Pap 3
re-infection 3
G>C 3
transmitted, 3
mosaicism: 3
(DGGE) 3
miR-298 3
protein-converting 3
enzyme-1 3
(miR)-590-3p 3
hsa-miR-590-3p 3
(0.685 3
0.111, 3
0.079), 3
-0.615, 3
0.0237). 3
rs7300593, 3
rs17695156, 3
rs12821290, 3
rs17695156 3
rs176951056 3
nontransmural 3
resonance. 3
NSVT 3
mirtazapine-treated 3
mirtazepine 3
PHEBE 3
(90.5 3
chronically. 3
hypnosedative 3
(DBS), 3
(<25% 3
(STN) 3
teleradiographic 3
ventriculography 3
films, 3
STN. 3
(bisulfite-seq) 3
Stage-specific 3
5-methyldeoxycytidine, 3
0.2-kb 3
inter-methylated 3
(AIMS) 3
hypomethylations 3
hypermethylations. 3
Carcinomas 3
Intraventricular 3
(IVH) 3
TRα. 3
therapeutic: 3
(ascorbate) 3
reexamined. 3
refutes 3
reevaluated. 3
Cysteine 3
pervade 3
spectrin, 3
three-helix 3
alpha-actinin) 3
dystrophin), 3
lengthwise. 3
beta-spectrin, 3
alpha,beta-dimers, 3
sawtooth 3
microscopy-forced 3
bimodal; 3
ultracentrifuge 3
(alpha20-21/beta1-2; 3
alpha18-21/beta1-4). 3
two-motif 3
four-motif 3
vise 3
alpha21 3
alpha21-beta1 3
alpha20-beta2. 3
anti-Vel. 3
thumb, 3
beaked 3
(IUGR), 3
abruption, 3
thrombophilia]. 3
APO 3
20210 3
loss/intrauterine 3
One-hundred-and-two 3
occasion. 3
G20210A 3
70S 3
thermophilus. 3
four) 3
1093 3
hypomagnesaemia 3
receptor-directed 3
Southwest 3
SQUIRE 3
NSCLC: 3
tivantinib 3
disease-directed 3
IgG(1) 3
ChIRP 3
-seq 3
QALYs, 3
regulatory-scientific 3
bioclinical 3
valuable, 3
use: 3
(eNOS) 3
thenoyltrifluoroacetone 3
108-15 3
niguldipine 3
K(+)-evoked 3
dihydrochloride 3
hindleg 3
crush. 3
30/Cd 3
8th 3
(TRH)]. 3
(PRL) 3
convergence, 3
Protirelin 3
gender-related 3
monosynaptic 3
definite, 3
(thyrotropin 3
drip 3
vibratory 3
Focal, 3
small-to-moderate 3
Families. 3
GTs 3
unearthed 3
PFAM 3
correlation-based 3
Sampling 3
DUF581 3
zf-FCS 3
DUF2233 3
(T3Rbeta1-delta337T) 3
(MHC 3
caspase3/7 3
spectrophotometry, 3
fluorimetry, 3
"resistance" 3
(AUS) 3
55.5% 3
73.0%, 3
22.2%, 3
stricture 3
(55%), 3
BAUS 3
FU 3
ISD. 3
CHEK2, 3
R117G, 3
R117G 3
R145W 3
737 3
Absenteeism 3
12%. 3
(0.32-0.53) 3
manualized 3
1.05). 3
hospital-employed 3
safety; 3
1,171 3
0-to-10 3
little." 3
quality-of-care 3
$1,346 3
Upper-boundary 3
$9,000 3
nation 3
financial, 3
(62%). 3
(work 3
performance: 3
workgroup 3
manager 3
reduce, 3
12.4) 3
1.03 3
3.24, 3
1.11-9.48) 3
1.22-8.48) 3
5.69, 3
1.77-18.27, 3
1.76-8.98), 3
3.90, 3
1.83-8.31), 3
0.58-0.86), 3
1.00-1.08) 3
employment, 3
enhanced-care 3
customer 3
representatives, 3
ROI 3
(PGL). 3
(MZBCL) 3
Nonresponder 3
analogon 3
(SRT), 3
9/14 3
oligonucleosome-length 3
dUTP-biotin 3
(ISEL) 3
(apoptotic 3
concordant, 3
ethanol-derived 3
(PCD), 3
Ostling 3
Johanson 3
(Biochem 3
123:291-298, 3
1984) 3
(9.5) 3
BMG-1 3
(1-24 3
"neck" 3
subpopulations, 3
V/Propidium 3
Iodide 3
7A6 3
eighty 3
Pi/mg 3
erythroleukemic 3
14months, 3
p.A224T, 3
mct8 3
qPCR, 3
(MCT8, 3
4y) 3
Pelizaeus-Merzbacher 3
3',3,5-triiodothyronine 3
Ruling 3
(MCT8/SLC16A2) 3
>2.0, 3
AHDS-like 3
(c.629insA) 3
(c.1A>T 3
c.1673G>A) 3
c.1673G>A 3
(NM_006517) 3
p.75. 3
X-breakpoint. 3
PubMed/ 3
0.70-1.17, 3
0.448), 3
0.69- 3
0.472) 3
0.51-1.00, 3
0.49-0.57, 3
0.00), 3
1.60-5.77, 3
0.18-0.67, 3
9.775; 3
3.143-30.395, 3
2.371; 3
1.690-3.327, 3
"targeted" 3
Nutlin-3A. 3
microneedling 3
papilla 3
'excellent' 3
Myelin-Derived 3
Activates 3
Brain's 3
Choroid 3
Immunoregulatory 3
myelin-derived 3
(IDO) 3
Deconvoluting 3
hyperbilirubinemia: 3
(NMEs) 3
(ICH); 3
guidelines; 3
(M3). 3
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf 3
NMEs 3
(Sedlak 3
Snyder. 3
113(6):1776-1782, 3
hypoalbuminuria, 3
bilirubin; 3
(FDA/CDER. 3
http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf 3
2012).This 3
processes-involving 3
follow, 3
Caveats 3
book. 3
reader. 3
(Dubin-Johnson 3
MRP3 3
glucuronides, 3
rifampicin-mediated 3
(OATP1B1; 3
0.029 3
0.028) 3
Thyromimetics: 3
hold? 3
Thyromimetic 3
desssicated 3
DT4 3
isoforms- 3
TRα2, 3
TRβ2. 3
CVS, 3
hepatoselective 3
pituitary- 3
indane 3
liver-selective 3
PLA2g2a 3
Scale-Revised. 3
condition). 3
familiar) 3
post-coma 3
technology-aided 3
improvisation 3
37.21 3
competencies 3
1(msp-1), 3
(msp-2) 3
(Glurp) 3
Ogun 3
RO33 3
(MSP-1);FC27, 3
(MSP-2) 3
KI; 3
MAD; 3
RO33) 3
FC27; 3
3D7). 3
Glurp 3
antagonism, 3
"immune 3
ovale: 3
(1992-2011)]. 3
Indonesia. 3
mission 3
parasitoses 3
Angiostrongylus 3
(sleeping 3
Pbsdha(-) 3
apicoplast. 3
mupirocin, 3
curling 3
1H-imidazol-2-yl-pyrimidine-4,6-diamines 3
anti-malarials. 3
invades 3
MDMs. 3
Pcc-infected 3
PfSIR2A 3
Parasitology 3
salt-bridge 3
mosquito. 3
PfSir2 3
orotate 3
ATPPase 3
PfGMPS 3
4MCHA 3
DB75. 3
climates 3
OZ277 3
TBP-TFIIB 3
PfAOP 3
orotidine 3
Phosphatidylcholine 3
phosphatidylcholine. 3
MG96 3
stephensi. 3
TBVs 3
oocysts. 3
(Trx). 3
thiols. 3
host-cell 3
Walter 3
Trypanosomes 3
tsetse 3
(Swiss-Prot 3
glycosylphosphatidylinositols 3
269, 3
protozoans. 3
myristoyl-CoA. 3
4917 3
tropica. 3
entirety 3
VR 3
100-fold, 3
hemoglobin-degradation 3
blood-sucking 3
Algae, 3
fertilizers]. 3
aegypti--Plasmodium 3
Synochocystis 3
seaweeds 3
powder, 3
nitrogen-containing 3
fertilizer--ammonium 3
regulators]. 3
aegypti-P. 3
dimilin, 3
pyrethroids 3
deltamethrin 3
cypermethrin 3
deltametrin 3
cypermetrin 3
pyretroids 3
pyretroids, 3
[Lack 3
bloodsucking 3
31P-NMR 3
2,3-diphosphoglycerate 3
quinine 3
Pfs48/45 3
drug-based 3
District, 3
KPom1 3
cox3, 3
PfPKAc 3
pepsin-like 3
P.falciparum, 3
Golgi-dependent 3
phospholipid-sensitive 3
calmodulin, 3
61.9% 3
Pharmacokinetic-pharmacodynamic 3
concentration-dependent. 3
leucopenia. 3
(PU) 3
(NAC, 3
factor-10 3
(GDF-10), 3
(BMP-3). 3
52,000. 3
RXXR 3
(Gdf10), 3
Bmp3b, 3
(TGF)-ß 3
VZ 3
VZ, 3
E18.5, 3
SEEN. 3
133, 3
surface; 3
Slx4, 3
Btbd12-deficient 3
Btbd12(-/-) 3
senesce, 3
Slx4) 3
Xpf-Ercc1 3
Zfp276 3
fanca/fancc 3
0.044) 3
707 3
Controls, 3
p=0.011). 3
normothermic, 3
nonintraoperative, 3
consolidation). 3
platinum-free 3
Cytoreduction 3
chemoperfusion 3
peritonectomy, 3
16.7%. 3
(A-I 3
editing) 3
(ADATs) 3
PDGFRβ 3
retraction. 3
MALDI-TOF/MS 3
actopaxin-induced 3
phosphomutant-expressing 3
(T17N) 3
PI3K/Akt-PAK1 3
PAK1. 3
growth-inhibiting 3
GEF, 3
APOBEC3DE, 3
IFNs, 3
Virion-encapsidated 3
(-)DNA, 3
VifIIIB- 3
VifHXB2-mediated 3
VifHXB2 3
VifIIIB 3
D128K 3
Vif-APOBEC3G 3
co-encapsidation 3
Vif-A3G 3
Vif-A3F 3
D(14)RMR(17) 3
A457P 3
(Ala457Pro) 3
bleomycin-treated 3
kinase-3B. 3
dentists, 3
BP2 3
Caries 3
PW 3
disomy. 3
disomy, 3
(deletion, 3
UPD, 3
(UPD). 3
320-kb 3
D15S63 3
D15S174, 3
PAR5, 3
MN7 3
16p. 3
70). 3
colitis) 3
10-19-year 3
(1988-1990) 3
stricturing, 3
(p=0.002). 3
(-3.5 3
(0.232 3
0.203 3
pmol/ml, 3
fdfBLAST. 3
protein--a 3
functionally-related 3
horikshii 3
units/mL 3
752 3
CHK2, 3
CHK2 3
tobacco-related 3
aero-digestive 3
252) 3
PSD-95. 3
lipopolysaccharide. 3
(RTK), 3
enterography, 3
writer 3
1:200 3
sprue 3
proliferative/profibrotic 3
PAK2-mediated 3
Erbin, 3
Erbin/Merlin 3
GTPase-bound 3
(clear) 3
55.2% 3
self-injection 3
77.1% 3
upcoming. 3
IL17A-induced 3
(IL17Rs), 3
IL17RA-IL17RE, 3
(IL17A-F) 3
(IGA) 3
Anti-interleukin-17A 3
IL-17E, 3
'good' 3
reactant 3
IL-22. 3
γδ-T 3
(Agrippal 3
Menjugate, 3
(hemagglutination 3
[HI; 3
virus] 3
[SBA; 3
meningitides]) 3
serotypes), 3
postvaccination. 3
20/25 3
19/25 3
(≥4-fold) 3
301, 3
-4.9 3
p=0.043) 3
(-1 3
(CaN). 3
(NCS) 3
NFAT4 3
CHP, 3
Ca(2+)/CaM 3
Ca(2+)/CaM. 3
Cn 3
(SEN) 3
46.5 3
29.2 3
2-17 3
lactobacilli. 3
12,984 3
Avon 3
3.73, 3
12.6; 3
laxative 3
notes. 3
450K 3
maculans 3
FKBPs, 3
napus 3
peptidylprolyl 3
Epac-mediated 3
sAC. 3
(tmACs), 3
(sAC, 3
sAC, 3
(H3K36Me3), 3
(CAGE), 3
(M2H) 3
(http://fantom.gsc.riken.jp/4/). 3
oliguria, 3
LCOS. 3
p=0.045). 3
post-injury. 3
oxidative/nitrosative 3
focused. 3
[GIFT]; 3
NCT00992420). 3
48.9% 3
(P2Y12 3
(rs4244285). 3
PAPI 3
ADP-stimulated 3
clopiogrel 3
IVS10+12G/A 3
Islanders 3
eteplirsen&apos;s 3
tau-containing 3
annonacin, 3
minipumps 3
(Gd-PSP) 3
electro-oculographic 3
[visually 3
(VGS), 3
antisaccades 3
pursuit], 3
[electromyographic 3
polygraphy, 3
jerk-locked-back-averaging 3
(JLBA) 3
long-loop 3
C-reflex]. 3
VGS 3
saccadic. 3
24-76 3
JLBA 3
pacific 3
Carribbean 3
Indies, 3
Caparros-Lefebvre 3
derivates 3
Poor-prognosis 3
ER-rich 3
HER-2-positive, 3
anti-HER-2 3
N+ 3
RS-guided 3
CU 3
preclusion 3
Institute-sponsored 3
Dx, 3
acceptably 3
Ontario. 3
chemotherapy; 3
(DPP4) 3
5-azacytosine. 3
procainamide. 3
Dnmt3A/3L 3
phthalimide 3
differs. 3
5-Azacytosine 3
Zebularine: 3
cytosine-[C5]-specific 3
MTases) 3
(AzadC) 3
(FdC) 3
pyrimidinone 3
exocyclic 3
ETH 3
7451. 3
4'sulfur 3
azr1+ 3
Protocols 3
MDS-derived 3
5-Aza-CdR, 3
KG1 3
hole 3
High-field 3
brain". 3
brain" 3
K9, 3
extra-pontine 3
i.v 3
mEq/l, 3
osmolality 3
montirelin 3
pentobarbital-narcotized 3
Scheffé 3
F-test]. 3
MBP. 3
Deeply 3
propositions 3
(PCNEs) 3
cis-regulation 3
Ets, 3
potentially, 3
HSS-9 3
disease-free. 3
disease-corrected, 3
sessions) 3
sessions). 3
fibromyalgia.To 3
reviews; 3
equivalent), 3
(LOCF) 3
dropouts, 3
(1437 3
common.There 3
top-tier 3
fibromyalgia.Second-tier 3
(PDN), 3
PDN, 3
second-tier 3
3.1) 3
6.6). 3
withdrawals; 3
8/153 3
14/119 3
placebo.More 3
5.7). 3
all.It 3
alpha(2)delta-subunit 3
=4 3
reverse-transcribed, 3
Sac3 3
Sgf11-ZnF 3
TREX-2. 3
unethical 3
PGD/HLA-typing 3
anticipating 3
3778 3
(over-)activated 3
genuine, 3
reinitiation. 3
supported, 3
mRNAs). 3
NMD-specific 3
Upf2p/Nmd2p, 3
Upf3p, 3
Sup45p 3
Pab1p, 3
[PSI+], 3
(nonsense-mediated 3
ribosome-associated 3
Pat1 3
Upf1. 3
nucleosome-specific 3
PR/SET07. 3
pr-set7 3
lethal: 3
competitive. 3
HCF-1N 3
tears: 3
2D-nanoLC-nanoESI-MS/MS 3
(HIS): 3
(3-year) 3
(HDL2 3
HDL3). 3
HDL3) 3
g/m2; 3
(1.2%; 3
(6.4%; 3
(-22.1%; 3
-0.70; 3
mmHg; 3
three-week 3
(diastolic 3
single-drug 3
bepridil, 3
ALA-Fluorescence-guided 3
(FGS) 3
Stupp-protocol 3
isodose. 3
51.3% 3
ePD, 3
ePD 3
judgement 3
skipped; 3
Pro-alpha1(V) 3
entirety. 3
soluble. 3
officer 3
0.018, 3
ECS. 3
(19.2%) 3
ABCDE⊕ 3
-'DWI-positivity'- 3
ABCD-score. 3
(13.3%, 3
9.3-18.2%) 3
(0.67[0.55-0.75]) 3
-score 3
(0.48[0.37-0.58]; 3
(0.50[0.40-0.61]; 3
'DWI-positivity' 3
Yield 3
148) 3
fibromas 3
foramen, 3
TSC2(+/-) 3
Ser(1210) 3
fibroblastic, 3
JM, 3
Franz 3
unknowns 3
workshop 3
0.7-76 3
immunohistocemical 3
66/89 3
(74%). 3
tumours), 3
neuropituitary 3
Langerhans 3
(peliosis), 3
(alpha-SMA). 3
nanism, 3
clavicular 3
scleroderma-like 3
AlkA. 3
rad16 3
andexogenous 3
bases,resulting 3
[1,2]. 3
MpgII, 3
Aquifex 3
aeolicus 3
methylmethanesulfonate 3
fU, 3
helix-hairpin-helix 3
alkylbase 3
mEndo 3
CIITA. 3
RNF12 3
kidney)-293 3
pen-2, 3
Smad1, 3
UBPY-mediated 3
de-ubiquitination 3
oligo-ubiquitination, 3
Scoliosis, 3
valgus. 3
quantifications 3
A3G/A3F, 3
apoplipoprotein 3
enzyme-catalytic 3
SN-2 3
adjuvantinduced 3
COX- 3
pyridinylimidazoles 3
nonimidazole 3
ureas, 3
pyrazoles, 3
pyrazoloheteroaryls, 3
pyridazines, 3
indoles, 3
pyridines, 3
triazolopyridines, 3
heterocycles 3
delta/gamma 3
myofiber-associated 3
under-studied 3
p-p38δ 3
redundant. 3
-beta2 3
-delta 3
Pseudofam 3
foramen. 3
characterized; 3
Histological, 3
cementogenesis 3
perpendicularly 3
Gabapentin: 3
Voiding 3
cmH(2)O 3
(46.7%) 3
<60% 3
nonhepatic 3
gabapentin]. 3
(somnolence, 3
fatigue), 3
nontitrated 3
(Rapid 3
(Slow 3
intellectually 3
(1.67+/-0.67 3
1.25+/-0.69, 3
0.697, 3
-0.400+/-0.089 3
-0.283+/-0.159, 3
0.961, 3
0.0107). 3
Somnolence 3
behavioral. 3
(τ) 3
Gemcitabine-oxaliplatin 3
III/IV) 3
leucopenia/neutropenia 3
10%-54%) 3
1.50). 3
Foxa2 3
endoderm-derived 3
(FOX) 3
HCFs 3
iCMs, 3
(~3 3
GMT-transduced 3
refined, 3
dish, 3
SMARCD3 3
MYOCD 3
"master 3
ibrutinib. 3
lymphocytosis. 3
Waldenstrom 3
Ibrutinib: 3
IgH.ETμ 3
(Shyper) 3
handgrip 3
(NCV), 3
(SPPB) 3
(Eut) 3
2.97, 3
Hoffmann's 3
T4-binding 3
0.0004), 3
fast. 3
mU/l. 3
SH. 3
Noninferiority 3
CPAP; 3
reintubated. 3
reintubation. 3
ACTRN12610000166077.). 3
infants]. 3
NIV. 3
(NCPAP). 3
7.2) 3
neonatal, 3
Heated, 3
post-extubation 3
'weaning' 3
internet-based 3
Distending 3
prongs. 3
blended 3
(NC). 3
≥28 3
FiO(2)<0.30 3
FiO(2)=0.21 3
re-instituted. 3
NC-group 3
≤0.30 3
xanthines, 3
(<0.5 3
AOP 3
(PDP) 3
5.5-kb 3
FGF2, 3
Pax7 3
declines. 3
Isolation, 3
progenies, 3
dysfunctioning 3
magnetic-activated 3
(MACS). 3
cardiotoxin 3
(CTX)-induced 3
FBS+10% 3
α-Sarcomeric 3
Actinin, 3
MyoD1, 3
PAX7. 3
Osteocalcin, 3
PPARγ2 3
(peroxisome-proliferator-activated 3
γ2) 3
Red-O 3
(satellite 3
mesoangioblasts, 3
non-dividing, 3
(synaptotagmin, 3
3A), 3
(Gap 3
synaptobrevin), 3
(neurogranin 3
synaptopodin) 3
high-fat/high-sucrose 3
sensibly 3
glucose/l. 3
secretion; 3
micrograms/dL) 3
micrograms/kg, 3
microUnits/mL 3
/mL 3
C/EBP, 3
sheets. 3
alpha-Proteobacterium 3
crescentus, 3
(ori) 3
DnaA-, 3
CtrA- 3
IHF-binding 3
cell; 3
tabular 3
Emulsion 3
PCR-coupled 3
enrichment: 3
popularly 3
Panel. 3
MiSeq 3
population-level 3
Fluidigm 3
Conexio 3
aortopathy. 3
flow-sorting 3
Roche/454, 3
ABI/SOLiD 3
Technologies/Ion 3
Commonly, 3
40:60 3
gamma- 3
beta-thalassemia, 3
frog. 3
ASCs, 3
tetrabromobisphenol 3
flame 3
crypt-villus 3
(3,5,3'-triiodothyronine 3
[T3]) 3
(identified 3
RXR, 3
pluripoietin-like 3
CFU-S 3
LT3 3
metabolite-corrected 3
[18F]Altanserin 3
[18F]-altanserin 3
releaser 3
placebo/drug 3
PET-radiotracer 3
bolus. 3
insula, 3
dexfenfluramine-induced 3
Metabolite-corrected 3
(5-HT1 3
5-HT7), 3
5-HT2B, 3
5-HT2C. 3
colliculus, 3
pedunculopontine 3
legmental 3
myelencephalon 3
raphe, 3
radioligands, 3
[11C]ketanserin 3
[18F]spiperone 3
[11C]methylspiperone 3
([11C]NMSP), 3
[18F]setoperone 3
[PubMed], 3
5-HT1 3
([18F]altanserin) 3
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-[11C]methoxybenzyl)ethanamine 3
([(18)F]altanserin) 3
BPP 3
neuroimaging. 3
(Lt. 3
akinetic-rigid 3
(UPDRS 3
between-subject 3
ketamine-induced 3
2.6%) 3
[11C]WAY100635 3
displacers 3
autoradiograms. 3
pmol/g 3
onward, 3
specific-to-nonspecific 3
[18F]altanserin-PET 3
(5-HT)(2A) 3
[18F]altanserin-positron 3
4-(4-fluorobenzoyl)piperidine 3
(FBP) 3
piperidine 3
altanserinol, 3
1-(4-fluorophenyl)-1-(piperidin-4-yl)methanol 3
(FBPOH), 3
[18F]Altanserinol 3
NaBH4 3
[18F]altanserinol, 3
[18F]FBP 3
detectable; 3
radiometabolite 3
Displacement 3
5-HT2C, 3
1,756, 3
imaging-based 3
WM-induced 3
(620W) 3
7.858, 3
1.91], 3
0.00012, 3
CSS), 3
(Hashimoto 3
(rs2476601, 3
R620W) 3
1496 3
1019 3
Sweden; 3
CI] 3
anti-CCP-positive 3
TSHR, 3
orbit, 3
TAO. 3
(TSHR). 3
(translocase 3
METAXIN, 3
mtOM64 3
kD). 3
METAXIN 3
immunocaptures 3
CHCHD6 3
signal-anchor 3
CelZC97.1 3
CelF39B2.i, 3
Alkali 3
Sf21 3
Ni2+-chelate 3
Mtx 3
"master" 3
retropose, 3
notwithstanding 3
ribosomopathy 3
9:1. 3
(SerH3) 3
SerH3, 3
SerH3-ts1 3
Exceptions 3
i-antigens 3
(I, 3
NaCl-supplemented 3
P-TEFb. 3
BRD4. 3
Mediator, 3
TFIIF, 3
NELF, 3
-C, 3
(DRB) 3
(NELF), 3
junB, 3
(FKBP) 3
sevelamer 3
"café-au-lait" 3
(TS1). 3
Subtle 3
(5.9% 3
glioblastomas). 3
[Familiar 3
(MIM276300) 3
malignomas 3
HNPCC-associated 3
hematochezia 3
[Turcot 3
apt 3
(FAP). 3
hemicolectomy 3
polypectomies 3
(medulloblastoma, 3
oligodendroglioma), 3
(Ashkenazi 3
delta496C, 3
498C-->G, 3
835T-->C 3
(S279P). 3
Phosphoimaging 3
late-infantile-type 3
HEX 3
cherry 3
c.459+5A>G 3
c.1305C>T 3
damage-binding 3
UvrC. 3
targets: 3
Arrhythmia 3
APD 3
mediate(s) 3
phosphomutant 3
Ser-516) 3
implied. 3
watch, 3
δ(C) 3
(8-week-old 3
Ca-calmodulin-dependent 3
(VTs) 3
4.9), 3
Angioplasty 3
"liberation 3
advertising 3
DOCA 3
(zone 3
ClC-5 3
endolymph. 3
Slc26a4(-/-) 3
hypoacusis, 3
anamnesis 3
recognised. 3
adequate, 3
L-thyroxine. 3
aetiologies. 3
(1079C>T) 3
(A360V) 3
(2168A>G) 3
(H723R). 3
(1343C>T) 3
(S448L). 3
(A360V). 3
sensori-neural 3
sole, 3
Presuming 3
higher-risk 3
JLNS. 3
CSBB-ConeExclusion, 3
α1I-peptide 3
CAPRI 3
20-26. 3
unrestrained 3
PKC-θ 3
meta-PPISP 3
MMFF94 3
precalculated 3
desolvation 3
vdW, 3
speed-up 3
ion-mobility 3
non-enumerative 3
LiGenDock 3
LiGenPocket, 3
"click 3
agranular 3
(XLTT) 3
XLTT 3
alpha-granule 3
(BMS-354825) 3
lgl 3
LGL4 3
Uncharacterized 3
LGLH3 3
evolutionary-conserved 3
Small-interfering 3
CD74-dependent 3
Scribble, 3
Raf-mediated 3
ginseng 3
lawsuits 3
Southeastern 3
suits 3
categorization, 3
R$ 3
advanced/metastatic 3
collectives 3
gliomas; 3
Warsaw, 3
inoperable/metastatic 3
Rgt1. 3
(MTH1): 3
(MTH1), 3
detoxifier 3
dGTP. 3
homolog-1 3
dGTP, 3
Thr45 3
cytosine. 3
mir-124 3
mature-miR-132 3
epilepticus). 3
Argonaute-2, 3
injury-group-detected 3
'tolerance'. 3
preconditioning-induced 3
NeurimmiR 3
NeurimmiRs 3
multivalency 3
utilissimum 3
Roxb, 3
Benincasa 3
hispida 3
Thunb 3
Cogn 3
anguina 3
Nees, 3
Ethanolic 3
Roxb 3
diabetics--a 3
sweetened 3
fleshy 3
SSC, 3
P<0.05); 3
P<0.01) 3
cucurbitaceae 3
pepo, 3
Praecitrullus 3
fistulosus 3
d(-1) 3
(p.o.) 3
(50-300 3
lipidperoxidation 3
pre-standardized 3
(supplemented 3
2-thiouracil) 3
kidney), 3
peels. 3
wt/day) 3
sativius 3
pectin-administered 3
(yogurt) 3
high-glycemic 3
(Stichopus 3
japonicus). 3
japonicus. 3
α-glucosidase-inhibitory 3
cucumber. 3
G230C, 3
HLA-A31 3
HLA-B51 3
(MPE) 3
LTG-tolerant 3
cADRs. 3
Toxicology 3
(OXC)-induced 3
(44.44%) 3
(11.11%), 3
(P=0.294). 3
CBZ- 3
non-Chinese 3
SJS, 3
PHT 3
MPE, 3
(FA-A) 3
35-40% 3
XPF 3
leukaemia/lymphoma 3
(NOTCH1, 3
NOTCH4) 3
NOTH4 3
(GSIs). 3
anti-NOTCH1 3
TRB@/NOTCH1 3
(voles 3
rat) 3
DXPas34, 3
Xist), 3
voles. 3
taxon-specific. 3
chromosome/autosome 3
(XY) 3
37-kb 3
Y397FAK 3
Y416Src 3
Y-phosphorylation 3
Y397 3
P-FAK 3
A375P 3
Sp-1, 3
FAK-Y397 3
haspin, 3
haspin. 3
Haspin/Gsg2 3
H3T3ph. 3
H3Thr3 3
Haspin. 3
(H3T3ph), 3
kinetochores, 3
CHR-6494 3
adventitious 3
Organisation. 3
Persistence 3
vomit, 3
slight, 3
Leucopoenia 3
(p=0.001), 3
[Nodular 3
INVESTIGARTIOS: 3
Pancytopenia 3
azathioprine-related. 3
(NRH). 3
rheumatological, 3
abscesses, 3
obliterans 3
pause, 3
Leukopenia 3
Eosionophilia 3
teratogenic, 3
(0.85 3
mutation/MB) 3
disease/neutral 3
driver/passenger 3
4.2% 3
doubts 3
(CID) 3
Na-Cl 3
spectrometry(n) 3
target-decoy 3
(2VO) 3
(ghr-/-) 3
C57/Bl6J 3
Ammonis(CA)-2/3 3
hippocampus-a 3
(Fluoro-Jade) 3
object-recognition 3
TNF-receptor 3
Dulbecco's 3
Eagle 3
(DMEM) 3
Streptomycin 3
Penicillin. 3
transcriptase/polymerase 3
overgrowth: 3
cathepsin-L-deficient 3
UDP-N-acetyl-glucosamine 3
-L 3
gingivae. 3
gingivae 3
transcribed-polymerase 3
debridement, 3
HOXC13 3
B-cell-specific 3
p16(Ink4a). 3
postnatal, 3
p16/p19 3
pre-T 3
Hpc-2 3
(p16) 3
Bmi-1-deficient 3
p19Arf, 3
ink4a, 3
BMI-1-mediated 3
PNS, 3
p16INK4a/p14ARF 3
ceasing 3
TotalReCaller, 3
soft- 3
[field-programmable 3
(FPGA)] 3
fine-grained 3
parallelization 3
reconfigurability 3
ClustalW 3
postcond-CsA 3
LPS‑induced 3
surgery), 3
MPP 3
TRO-19622 3
Iso 3
NIM811 3
IPoC, 3
I/R+NIM811, 3
prediabetic 3
ZL 3
isothiourea 3
(MCU) 3
D-binding 3
CyP-D 3
idebenone 3
cluster-containing 3
frataxin-depleted 3
I154F 3
peptidase. 3
heterozygous. 3
tau-associated 3
Al, 3
cold-spots, 3
AmnSINE1 3
diencephalon 3
exaptation 3
land. 3
Papillomavirus 3
CR2 3
pRb-like 3
HPV-induced 3
K-Ras(12D) 3
E6-induced 3
five-amino-acid 3
CR3 3
p107, 3
p130. 3
p107 3
himself 3
iceman's 3
Naïve 3
WTAP 3
surveyed, 3
"basal" 3
Methylations 3
SV40-infected 3
processing-linked 3
(14/175) 3
MLL2-binding 3
(7/175) 3
M-stage 3
(53/220) 3
Correlating 3
MLL2- 3
KDM6A-driven 3
(K4+/K27-) 3
(TSG), 3
OTX2-bound 3
VUAA1, 3
repelled 3
odours 3
scent 3
presenilin1 3
7-nitroindazole. 3
(7.19+/-3.19 3
763.9+/-91 3
p=0.0005), 3
kinase-3. 3
pretangle 3
AF102B 3
(Cevimeline, 3
EVOXACTM: 3
AF267B--1) 3
non-amyloidogenic 3
(alpha-APPs) 3
oxidative-stress-induced 3
[PHF]; 3
impairments.) 3
(LC-MS) 3
cell-differentiation 3
ten-eleven 3
Treg-cell-specific 3
Tet- 3
hydroxymethylated 3
Esrrb, 3
Prdm14, 3
Tcl1 3
Zfp42) 3
Declining 3
(5mC), 3
mESCs 3
Menin 3
DPY-30L 3
ASH2L 3
DPY-30L(C) 3
Hut-78 3
Prefrontal 3
1-regulated 3
(shRNA), 3
Repeats), 3
(CRISPRi)-mediated 3
conjugation, 3
ultracomplex 3
postscreen 3
high-complexity 3
sublibraries 3
(CRISPRi)-based 3
(MDSCs) 3
SMSCs 3
"fail" 3
(30.4%) 3
Tympanometry 3
tympanostomy 3
(71%); 3
eustachian 3
chondrodysplasia 3
anticipatory 3
syndromes; 3
diethylnitrosamine 3
N-acetyl-L-cysteine 3
JAK2-mediated 3
(Jun 3
2,4,6-trinitrobenzene 3
(4E-BP1) 3
(S6K1), 3
high-protein 3
(HPD) 3
Ser(473) 3
(IRS-1) 3
Tyr(612). 3
Rbp-Jk, 3
split-1, 3
O1. 3
mTORC1-STAT3 3
acid-impaired 3
HPD-activated 3
Tsc2(-/-) 3
CRSP/Med2 3
DBR1, 3
lariats 3
decoys 3
High-glucose 3
intra-mitochondrial 3
([Ca2+]m) 3
Diabetes-induced 3
cardiomegaly, 3
ICa,L. 3
Ca(2+)-transport 3
ribozyme-based 3
nucleotides), 3
non-encapsidated 3
self-cleaving 3
rolling-circles, 3
strands: 3
Rolling 3
cDNA-free 3
Modahl 3
Lai, 3
72:5449-5456, 3
1998), 3
[32P]orthophosphate 3
lysolecithin-permeabilized 3
(ATPase-6). 3
cytochrome-c 3
(TR)/c-erbA 3
CAPN3 3
electroneuromyography 3
immunohematology, 3
XK/Kell 3
Immunohematology 3
McLeod. 3
phosphokinase, 3
tics 3
TGG- 3
to-TAG 3
(C977T) 3
977, 3
K(O) 3
1095 3
(RIP3) 3
pro-necrotic 3
Interacting 3
TNFR-1 3
(α/β) 3
mRIP3 3
necrosomes 3
TLR3/TICAM-1 3
cIAPs 3
Injury. 3
RIP-1 3
progenies 3
[3H]-thymidine 3
L-Leucine 3
8q24 3
JIE 3
(p.Lys116del) 3
(p.Glu299Lys) 3
p.Ile592Met, 3
p.Ala381Val, 3
p.Pro574Ser). 3
p.Ile592Met 3
(p.Ala381Val 3
p.Pro574Ser) 3
p.Pro574Ser 3
(rs1801545) 3
(IGE, 3
date) 3
solubilisation 3
ALOIS, 3
Clioquinol 3
5.4; 3
trail 3
(-48.0 3
-83.0 3
-13.0; 3
Receiver-operator 3
improver 3
=0.76, 3
p=0.0007), 3
=0.93, 3
p=1.3 3
=0.72, 3
amyloid-beta-metal 3
Increasingly 3
[50%] 3
(PCDH) 3
blastemal 3
headloop 3
1:1,000, 3
(H3K9Ac 3
EN1, 3
Concordant 3
26%. 3
CIMP- 3
10(-8), 3
(RNAP-II). 3
immunodepletion 3
non-bismuth-based) 3
bismuth-containing 3
Chitosan 3
Eudragit 3
L100 3
emulsification/coagulation 3
(PPI-AR). 3
Post-treatment 3
epsilometer 3
bleeding? 3
ulcer-related 3
low-cost-for-care 3
(Spain) 3
chloride. 3
gremlin-1, 3
fetuin 3
midkine, 3
sclerostin-MBP 3
Phex, 3
asporin 3
erbB-3. 3
LRP5G171V 3
sclerosteosis 3
SOST, 3
Rheb-GTP 3
Cryptotanshinone 3
beta-2-transferrin. 3
sodium-fluorescein 3
fat-suppressed 3
spin-echo 3
9/17 3
10/17 3
nicely 3
HRCT, 3
beta2-transferrin 3
SIH 3
Tc-99m 3
Sherlocc 3
sigmoid). 3
LaTcOm 3
http://troodos.biol.ucy.ac.cy/latcom.html. 3
KLK1 3
pig, 3
(Canis 3
familiaris) 3
clipped 3
Kb) 3
dilutions. 3
imprecision. 3
(C(T)) 3
=2000-fold 3
3.2%-5.7%. 3
C(T). 3
specifications 3
100-unit 3
CD68. 3
(41.9%) 3
thalami, 3
unrecognized. 3
Norfolk 3
(PADI4) 3
(RA); 3
(SLC22A4 3
(CD); 3
(PDCD1) 3
[maximal 3
>0.05)], 3
<0.00001) 3
PDCD1, 3
(HLA-SE), 3
[rheumatoid 3
(anti-CCP)], 3
arthropathies. 3
nephelometry 3
7.05 3
10(-10), 3
4.57, 3
2.76-7.57 3
1.89-4.74, 3
1.88-53.73). 3
polyarthritis. 3
[SE]) 3
1p13 3
736 3
Biobank 3
2.14-42.43 3
19.5, 3
4.47-84.81), 3
1.36-7.54) 3
antibodies-negative 3
RFUW 3
FDRs 3
(CCP), 3
antigen-shared 3
anti-CCP-seropositive 3
45-fold 3
RA-risk 3
(184 3
(187), 3
(161), 3
(105) 3
(92). 3
amphetamines. 3
Cardioembolism 3
RCVS 3
thunderclap 3
yaers, 3
amnesia. 3
(toxic 3
inflammatory) 3
Albanese 3
arteriography 3
(THC) 3
marijuana/THC 3
EF-hands 3
versa). 3
spectrofluorometry 3
(4-CmC, 3
1,1'-diheptyl-4,4'-bipyridinium 3
dibromide 3
(DHBP, 3
DHBP. 3
antineurotoxic 3
microglial-mediated 3
(DN). 3
GKT137831. 3
tubulointerstitium. 3
ROS-sensitive 3
siNOX2 3
ulcerations, 3
perpetuated 3
interferon-α 3
(IL)-1 3
IgG(2), 3
intermediate-dose 3
0.017), 3
IL-1β-neutralizing 3
once-every-month 3
Interleukin-1β-regulating 3
(gevokizumab) 3
Gevokizumab, 3
(XOMA-052), 3
gout. 3
microsomes: 3
phosphatases), 3
kinase-catalyzed 3
Microsomes 3
[poly(A)] 3
Ileo-colonoscopy 3
(IDP) 3
Brinker 3
Brk 3
gro 3
CcN 3
Misexpression 3
Gro-mediated 3
cofactor-activated 3
Gro/TLE1. 3
minireview, 3
Groucho/TLE-mediated 3
(BXD-1425EPN, 3
R254), 3
(E520) 3
Thrombocythemia. 3
66%. 3
value; 3
Myelofibrosis. 3
intermediate-2-risk 3
enzyme-DNA-AdoHcy 3
reassociation 3
N-ethylmaleimide, 3
catalyst. 3
Cys-81 3
Pro-Cys 3
nucleophiles 3
Mtase 3
cytosine-5-methylation 3
5-methyl-6-Cys-81-S-5,6-dihydrocytosine. 3
expulsion 3
Hydroxide 3
V-shaped 3
N6 3
(m(5)C) 3
Folinic 3
widens 3
dosage-sensitive 3
(STXBP1) 3
(11/15) 3
geldanamycin-induced 3
B/Akt 3
MR.Hsp90 3
11,19-oxidoprogesterone 3
redistribution. 3
leishmaniasis). 3
odds, 3
Th-2 3
killer. 3
(Mfn) 3
phenols, 3
benzothiophenes 3
[4.3.3]propellane 3
tankyrases 3
neuroinvasion 3
ixodid 3
locality 3
ground. 3
Pakhtunkhawa 3
refilling 3
Powassan 3
(US 3
Virgin 3
(Flaviviridae) 3
hepatotropic 3
diathesis. 3
vector's 3
Hemisphere 3
WNV, 3
http://www.controlled-trials.com. 3
-21 3
27%; 3
non-randomised 3
Non-randomised 3
(ARR 3
CYP-induced 3
benzene-exposed 3
rescinded 3
Amifostine-antioxidant 3
Antineoplastic 3
chemically, 3
bounding 3
24-day-old 3
hyperfractionated 3
Alza 3
preclinical, 3
300-nucleotide 3
III-transcripts 3
SRP 3
(FLAM) 3
Gensini 3
2.58, 3
Sub-clinical 3
Gensini's 3
specific-locus 3
alkylation, 3
mutants/plaques, 3
Gemini 3
Genistein 3
OVX-induced 3
Fractality 3
methodologies: 3
box-counting, 3
hAS 3
LB-enriched 3
ATP13A2, 3
calmodulin/Src 3
PP2A/C 3
10-nm 3
ligase-like 3
(TTLL) 3
Kub5-Hera/RPRD1B 3
(Ku70, 3
p15RS) 3
(Topoisomerase 3
helicases), 3
repair/replication 3
(PARP1, 3
Ku, 3
K-H-depleted 3
(MLH1 3
PMS2) 3
Pan-caspase 3
deficiency/microsatellite 3
k-h 3
expression/copy 3
(RLS/WED): 3
RLS/WED, 3
syndrome/ 3
Narratives" 3
"Behavioral 3
Observations" 3
Disease/Restless 3
Conditions. 3
disease/restless 3
(WED/RLS) 3
(NDCs), 3
"urge-to-move". 3
(WED) 3
quality) 3
move. 3
dexterity 3
(tremor 3
(movement 3
grooved 3
pegboard 3
Angioid 3
Norweigian 3
(LCS1)/Aagenaes 3
lymphedema. 3
episodes? 3
cholestatic. 3
macronutrients, 3
Aagenaes, 3
1968. 3
cholestasis-lymphedema 3
6.6-cM 3
antidementives 3
WITHDRAWN: 3
'tacrine', 3
'tetrahydroaminoacridine' 3
'THA' 3
details). 3
Scale-noncognitive, 3
0.43). 3
MiniMental 3
(0-30; 3
=good) 3
-0.13). 3
5.7; 3
4.1-7.9). 3
pooling, 3
individual-patient 3
valid/eligible 3
enrichment-design 3
rechallenged, 3
Tremulous 3
videotaping 3
site-1 3
synapsin, 3
(long-term 3
22-1716). 3
J-POST 3
UMIN000004179 3
JMA-IIA00046. 3
HIV/AIDS, 3
STEPStrade 3
(System 3
Celgene, 3
well-known, 3
Procedures 3
sympatho-adrenomedullar 3
NE-containing 3
Neuropeptide 3
(partly) 3
Defensins 3
β-defensins 3
θ-defensin 3
β-defensin 3
5382insC, 3
recollection 3
prophylactically. 3
Tracking 3
Suggestion 3
Proofs 3
28-55 3
Myriad 3
sequencing) 3
FACTORS 3
2-year, 3
9000 3
1937 3
(HBOC) 3
PSR 3
cryopreservation. 3
(7.4 3
ex9-12del 3
HISPANEL 3
8,005 3
(BRCA1, 3
untested) 3
street 3
"krokodil" 3
narcotics 3
opium, 3
Inventory), 3
(WHO), 3
Krokodil 3
Virus? 3
sofosbuvir/ledipasvir 3
Liquid-liquid 3
ledipasvir, 3
Harvoni(TM) 3
CHC 3
(HCC), 3
MiD51 3
MiD49 3
Pex11pβ 3
turkish 3
Glucose-6-Phosphate-Dehydrogenase-Deficiency, 3
red-cell-enzyme 3
'aboriginal' 3
Mediterranean. 3
Hemizygous, 3
deamino-NADP 3
Durham713G, 3
chronic. 3
Mexico, 3
Mahidol 3
Manaus, 3
Amazon 3
dehydrogenase-deficient 3
enzymopathy, 3
Afghanistan, 3
baboons. 3
(G6PD 3
(D178N-129M 3
haplotype). 3
Spongiform 3
(PrPres) 3
region-dependent 3
dysautonomia. 3
(PrP(Sc)). 3
GAC----AAC 3
aunt 3
129. 3
olivary 3
tourette 3
cortico-basal 3
(Hdc), 3
feels 3
perform. 3
N400I 3
L-histidine 3
contribution, 3
(TD). 3
(HRD), 3
most-investigated 3
(HGSOCs), 3
HGSOC 3
PDXs 3
gBRCA 3
SN-38, 3
irinotecan) 3
lines¸ 3
(MTT 3
p53-defective 3
less; 3
NCT00749502. 3
[48%]), 3
[35%]), 3
[24%]), 3
[23%]), 3
36·4 3
32·8-46·0). 3
19-64]) 3
[7-93]) 3
(SSB). 3
673, 3
Technological 3
symptom-unrelated 3
tremors 3
(MRgHIFU) 3
inducement. 3
HIPAA-compliant 3
postcentral 3
transcranial, 3
(focused 3
DBS). 3
points); 3
cerebellothalamic 3
CTT 3
Botulism. 3
holotoxin 3
chili 3
myofascial 3
(Botox) 3
esthetic 3
hyperfunctional 3
novelties 3
myoablation 3
myeloablation 3
introduced: 3
Myeloablative 3
(anti-CD52), 3
anti-CD20) 3
(RR)MS, 3
B-cell-depleting 3
REGOSARC 3
FREEDOMS 3
anaphylactoid 3
multi-use 3
epoetins 3
filtrate 3
mounted 3
peginesatide-treated 3
nondialysis 3
Hematide™/peginesatide 3
1990's, 3
cheating 3
EPO; 3
(ESAs). 3
Hematide™) 3
cheating, 3
immune-purification 3
revelation 3
registration: 3
(rHuEPO), 3
rHuEPO, 3
UT-7/EPO 3
MesoScale 3
(ESA), 3
hemodialysis; 3
(Callithrix 3
jacchus). 3
2.26-Gb 3
(6×) 3
primate, 3
"almost 3
Lymphocytes 3
γc 3
Jaks 3
IL-15, 3
1/JAK2 3
baricitinib-treated 3
owners 3
microcytosis 3
CopyrightInformation> 3
Gets 3
(anti-SLAMF7) 3
lenalidomide-dexamethasone 3
bortezomib-dexamethasone. 3
(complement-dependent 3
nivolumab. 3
[33%]) 3
(daratumumab 3
60.7% 3
29.1%, 3
(19.2% 3
45.3% 3
TaqMan-PCR 3
64-80del 3
p67phox, 3
oxidases: 3
NOXes, 3
DUOXes 3
RAD1901-treated 3
uterotropic 3
(SERMs)/SERD 3
(SSHs) 3
antiestrogens 3
182,780 3
(ICI, 3
fulvestrant) 3
mutant-expressing 3
(PD-L1). 3
uncertainty, 3
clear: 3
programed 3
(PD1)/programed 3
HIV/SIV 3
PD1. 3
myloid/macrophage 3
Infrared-Photoimmunotherapy 3
(NIR-PIT) 3
antibody-photo-absorber 3
Avelumab-IR700 3
tumor-background 3
Tumor-bearing 3
i.v.; 3
anti-PD-1/PD-L1 3
mAb-mediated 3
lysis; 3
IL12 3
ADCC. 3
PD-1-positive 3
enriched; 3
boundaries; 3
RESCUE-ESE 3
Flavivirus. 3
explosively 3
Maternal-fetal 3
ZIKV-infected 3
hNPCs, 3
phenotype-the 3
syndrome-has 3
forecasts 3
Rico, 3
(4,5). 3
(PRDH) 3
(6,7). 3
672 3
spain 3
2-weeks 3
subtyping. 3
expandable. 3
http://pubmlst.org/neisseria/NadA/. 3
noncapsular 3
PorA. 3
specific; 3
MenB-associated 3
meningitidis); 3
nasopharynx. 3
versa) 3
fhbp 3
nadA. 3
FetA, 3
OMV. 3
neisseriae. 3
Bexsero: 3
Oca 3
autotransporter 3
purpuric 3
ARF6, 3
recombinant-soluble 3
anti-MenB 3
(cc) 3
recently-approved 3
highly-conserved 3
JNPL3 3
P301L. 3
JNLP3 3
subfraction, 3
ribophorin, 3
neurofibrillar 3
reelin-signal 3
schizophrenia; 3
MAP1 3
oxytocin's 3
monogamy 3
Report: 3
scurvy: 3
Renaissance 3
Barlow 3
Holst 3
irritability) 3
Subperiosteal 3
dehydroascorbic 3
oxidant-antioxidant 3
acts. 3
Baumister 3
Panoramic 3
inv 3
(8)(p11.2q23.1) 3
Balducci 3
8q22 3
Ages. 3
epidermolytic 3
sFasL 3
(HLA)-B, 3
HLA-B*58:01, 3
allopurinolinduced 3
Koreans. 3
carbamazepine-tolerant 3
A*3101 3
SCARs 3
immunoglobulin. 3
Steven-Johnson 3
SCAR's 3
Naranjo 3
allopurinol-SCAR 3
DR1/PKA/P-tau 3
[Thalidomide 3
reactional 3
sixties 3
Thalomid 3
myeloma) 3
leprosum. 3
DIOB, 3
DIOB. 3
bioactivation. 3
[Reactive 3
drugs]. 3
P-450, 3
microsomial 3
exaggerates 3
Electrochemical 3
troglitazone: 3
ATV 3
ATV-related 3
hypochlorous 3
protein-reactive 3
GSH-Br 3
Chemistry 3
re-emerge. 3
(WRA). 3
(UPDRS). 3
0.0059) 3
(T1/2) 3
3-O-methyldopa, 3
80%d 3
0.025); 3
53.9% 3
predicated 3
Cl 3
fluctuation, 3
off' 3
levodopa/AADC 3
availability; 3
resultant, 3
prionogenic 3
IPEC-J2 3
MIN6 3
T1DM, 3
(LDL), 3
(PrP(C)) 3
(iCJD) 3
(PrP(C)). 3
augmented. 3
athelia. 3
Ptprf 3
amastia, 3
repositioning, 3
biocurators 3
curation. 3
inter-annotator 3
documentation, 3
UniProtKB 3
Benchmarking 3
Biocreative 3
Knowledgebase. 3
"A 3
56-week 3
placebo-subtracted 3
30-45 3
(Contrave): 3
Management. 3
reduced-calorie 3
bodyweight-related 3
(NB32 3
IWQOL-Lite 3
5p15.3. 3
10-10 3
perikarya, 3
endings, 3
endings. 3
polyQ-HTT 3
Karaite 3
huntington. 3
JPH3, 3
TBP, 3
ZDHHC17 3
JPH3 3
Ma 3
Ma). 3
OSX 3
(RedHat/CentOS) 3
BSD-style 3
https://www.github.com/faircloth-lab/phyluce/ 3
(https://binstar.org/faircloth-lab/phyluce) 3
installs 3
dependencies, 3
iPlant 3
Atmosphere 3
(tag: 3
phyluce). 3
http://phyluce.readthedocs.org/en/latest/ 3
10.6084/m9.figshare.1284521. 3
brant@faircloth-lab.org 3
Glu(287) 3
Ser(288) 3
(∆ES) 3
(CHO/AP-1, 3
SH-SY5Y) 3
homodimer, 3
Epilepticus 3
Trichotillomania 3
HPD) 3
(3/3) 3
minimum. 3
Raxibacumab: 3
Bioterrorist 3
germinate 3
tripartite: 3
post-challenge, 3
levofloxacin/raxibacumab. 3
Gompertz/second 3
levofloxacin/raxibacumab 3
PA-raxibacumab 3
anthrax: 3
(ABthrax) 3
CPEB3 3
CPEB3, 3
germ-cell 3
proteases: 3
Ulp2. 3
poly-SUMO 3
SUMO. 3
APH1387) 3
phagocytophilum-occupied 3
(AVM). 3
AmpA. 3
poly-SUMOylated, 3
poly-SUMO2/3 3
lysine-deficient 3
tactic 3
SUMO2 3
11S 3
SIMs. 3
SUMO-interacting 3
JASSA 3
nucleolin, 3
Lys-294, 3
Bicoid 3
(Ubc9) 3
Sall 3
Thr308 3
hMSC-telo1 3
Shelterin 3
Ends 3
Compacting 3
Chromatin. 3
Telomeres, 3
E4, 3
Aducanumab 3
del(12p) 3
isochromosomes 3
Magenis 3
Velocardiofacial 3
IonTorrent 3
(LOH), 3
4q22.3-q25 3
(4q) 3
t(1;4)(p21;q24), 3
ins(5;4)(q23;q24qter), 3
RP11-356L5 3
RP11-16G16 3
(14.6%). 3
4q22-q25 3
(SNP-A)-based 3
SNP-A, 3
(MC+FISH), 3
(MC+SNP-A), 3
(FISH+SNP-A) 3
-20/del(20q). 3
relativity 3
(56.8%) 3
(24.3%) 3
mini-clonal 3
Multi-probes 3
patient' 3
disorders--an 3
leukemogenesis? 3
multicolor-FISH 3
add(21)(q22) 3
YAC912C3 3
AML/MDS 3
42.5% 3
7q-. 3
(t-MDS) 3
t-MDS. 3
examiner 3
beforehand, 3
YAC248F5 3
(5q31), 3
YAC938G5 3
(7q32), 3
CEP8 3
(20q12) 3
-/7q-, 3
20q-) 3
(20q-, 3
5(-5/5q-) 3
(c-v) 3
(VCFS), 3
(9), 3
CA-repeat 3
probes). 3
(15) 3
-7. 3
(ANLL). 3
(41A 3
P13) 3
(D22S) 3
submitting 3
(DGS), 3
5q-. 3
'5q- 3
interphase- 3
IST 3
rhuG-CSF 3
D5S23-D5S721 3
/CSP7, 3
-7/7q-, 3
misclassified 3
chi 3
domestically 3
D5S23 3
D5S721 3
46,XY,der(5)t(5;18)(p15.1;p11.31)dn 3
Kcnj10 3
tubulopathy, 3
inwardly-rectifying 3
tubule, 3
phot 3
cd 3
s/m2 3
jubilee 3
(OPV) 3
1959. 3
co-incubated 3
bioactivities 3
LH. 3
DOTAP-generated 3
keratocytes 3
6.14 3
V+ 3
externalisation 3
cyanine 3
torsed 3
250% 3
(SP-A) 3
infradiaphragmatic 3
areas; 3
burden; 3
18F-labelled 3
aminophenylboronic 3
IFN-regulated 3
iPLA(2) 3
(99m)Tc-GNPs-Annexin 3
3.52 3
0.53% 3
orange/ethidium 3
V-Cy3, 3
hesperetin-induced 3
V-Cy3. 3
Fundamental 3
cytochalasin-D-treated 3
Wright-stain, 3
hydrazinonicotinamide 3
(HYNIC) 3
conlusion, 3
(COURAGE) 3
COURAGE 3
2,287) 3
Ezetimibe 3
(occurring 3
Simon 3
judgments 3
MAGE 3
(coefficient 3
statins; 3
antilipidemic 3
Inhibitors: 3
immune-checkpoint 3
(CTLA-4), 3
self-reactive 3
VEGFR-TKI. 3
CPI 3
(CTLA-4). 3
combination) 3
lefty, 3
reaction-diffusion 3
FurinA 3
Lefty, 3
NSAIDs. 3
clobutinol, 3
Antiobesity 3
Joachim 3
1.17). 3
1.52), 3
post-sibutramine 3
essential; 3
lipids; 3
Sertindole 3
PEM 3
(Galafold™)-a 3
α-galactosidase-has 3
≥16 3
unblinding, 3
capillary) 3
-0.30±0.66 3
-1.51±1.33 3
left-ventricular-mass 3
(-7.7 3
-15.4 3
-0.01), 3
-38.2 3
indigestion 3
Therapeutics; 3
NCT00925301 3
AT1001-011] 3
NCT01458119 3
AT1001-041].). 3
(lyso-Gb3) 3
(QOD) 3
(HEK)-293 3
proliferative. 3
Lgr5 3
smear- 3
(4.08%) 3
(2.55%) 3
(1.53%) 3
Queen 3
(bacterial, 3
cryptococcal), 3
%): 3
(HIV)-positive. 3
HIV-positive. 3
(HRVs) 3
HRV-A 3
HRV-C. 3
EV, 3
HRVs, 3
[Serous 3
HSV-IgG 3
HSV-IgM 3
parestesia 3
radioimmunotest 3
Basin. 3
Europe's 3
wetlands 3
uneven, 3
Basin 3
(Bucharest, 3
Algeria), 3
(CSF).METHODS: 3
VP1 3
Drug-Drug 3
Tofogliflozin 3
Glucagon-Like 3
post-prandial 3
dysphasia 3
TZDs 3
TF-specific 3
(UMIs) 3
https://github.com/hartonen/PeakXus 3
tuomo.hartonen@helsinki.fi 3
jussi.taipale@ki.se. 3
Golgi. 3
GlcCer 3
statins? 3
hyperCKaemia 3
(CENTRAL), 3
Rho/Rho-associated 3
use), 3
deteriorates 3
authoritative 3
"Statins", 3
"Randomized 3
Trial", 3
sensitivity", 3
resistance", 3
Secretion", 3
"Diabetes 3
Mellitus" 3
anyway 3
IFN-related 3
GBEC 3
GBEC. 3
PPARgamma, 3
are:1. 3
inflammation.2. 3
inflammation.3. 3
meta-analysis.We 3
HF.2. 3
analysis.3. 3
treatment.4. 3
intervention.5. 3
control.The 3
cerivastatin 3
patients.2. 3
[Combined 3
SEA. 3
patients.. 3
(HD5), 3
FY99 3
rosuvastatin, 3
SAC-inducing 3
RACK1 3
RACK1-Lck 3
COpy 3
(CONEXIC) 3
CCNE1, 3
GRB7, 3
CDK4). 3
MAP2K4, 3
LHP, 3
THY1, 3
Infection: 3
(74%), 3
(6). 3
reportable 3
traveler 3
someone 3
globalization 3
Ann 3
Neurol 3
un-translated 3
Nanchang 3
Auxiliary 3
(25mg/kg 3
100mg/kg; 3
(i.p.)), 3
mPFC; 3
(STP) 3
steered 3
(GPU)-accelerated 3
oseltamivir-resistance 3
"avian" 3
H1N1pdm 3
"swine" 3
N1-subtype 3
neuraminidase. 3
perinathal 3
A/H1N1. 3
venovenous 3
ECMO, 3
(0-12 3
25-36 3
37-48 3
occurred; 3
zanamivir, 3
influenza-infected 3
(PS1 3
PS2) 3
endoproteolytic 3
(FAD)-associated 3
membrane-embedded 3
(37-43 3
presenilin-1, 3
(PS1)-derived 3
PS1(-/-)/PS2(-/-) 3
NCT(-/-) 3
detergent-resistant, 3
Aph-1a 3
I/I 3
(NCT), 3
Pen2 3
[correction 3
nacastrin], 3
aph-1a, 3
Notch-like 3
Bora. 3
SPAT-1/Bora. 3
CDK-1 3
SPAT-1 3
SPAT-1/Bora 3
Plk1/Plx1 3
Plx1 3
Ser274 3
(SENP 3
(sPE) 3
Extra- 3
stimuli/stressors 3
hypoxic-activated 3
immuno-blotting 3
hyper-SUMOylation 3
SENPs 3
mGlu5 3
photobleaching/photoconversion 3
mGlu5R-dependent 3
mGlu5R 3
Gαq/PLC/Ca(2+)/PKC 3
ubiquitinylation 3
UBC9. 3
sumoylating 3
fusion-directed 3
miR-214 3
Hsp27, 3
RNF4, 3
PIASy, 3
G324R, 3
(Kir6.2-G324R) 3
day(-1)). 3
tolbutamide, 3
Kir6.2-E23K 3
channel; 3
NSSK 3
periodontally 3
Aggregatibacter 3
gingivalis-positive 3
fimA. 3
rectus, 3
intermedia, 3
GAgP 3
Non-Homologous 3
ARIEL2, 3
somatic), 3
NCT01891344. 3
2·8-10·1). 3
12·8 3
9·0-14·7) 3
(5·3-7·6) 3
5·2 3
(3·6-5·5) 3
0·27, 3
0·16-0·44, 3
(0·62, 3
0·42-0·90, 3
p=0·011) 3
[5%]), 3
progression). 3
Program, 3
Stand 3
Cancer-Ovarian 3
Alliance-National 3
Coalition 3
Team 3
Grant, 3
Award. 3
(CO-338; 3
8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 3
((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic 3
(CDx). 3
Abcg2. 3
cancer.. 3
PMI. 3
PMI 3
Omnious 3
inversions: 3
(EKG) 3
pseudo-Wellens' 3
lambda, 3
Mediates 3
Autophagy-Independent 3
Aggregate 3
Proteasome. 3
UBQLN2. 3
polyubiquitylated 3
shuttles. 3
Zealand: 3
(OPTN) 3
(HLP), 3
(HLP) 3
(APOE*2). 3
Apoe*2. 3
E-1Harrisburg: 3
isoprotein, 3
apolipoprotein. 3
E-1 3
E-2 3
two-unit 3
(cysteine 3
Cys142 3
apoEBethesda 3
dysbetalipoproteinemia, 3
E2/2 3
IV/V 3
hyperlipidemic 3
Gaza 3
Baden 3
(136 3
33), 3
bilambdoidal 3
unilambdoidal 3
Beckwith 3
(p<.001) 3
10mg/d. 3
L’Encéphale, 3
(Brintellix) 3
relapse-prevention, 3
subscore, 3
-0.87 3
0.803 3
0.279] 3
-0.81 3
0.791 3
0.306] 3
(≥5% 3
questionnaire) 3
actions: 3
12-item 3
3.3, 3
(FAS, 3
comparability, 3
-0.05 3
abruptly, 3
(OR=3.01, 3
CI=2.22-4.09, 3
Z=7.08, 3
P=0.00001), 3
HINARI. 3
(WMDs) 3
WMDs 3
-3.92; 3
-5.258 3
-2.581). 3
1.38). 3
glucosamine 3
Affi-gel 3
Superdex 3
WRL68 3
KATO 3
angularis), 3
Azuki 3
flora-fermented 3
(FP) 3
hgf 3
(FP-hgf) 3
phytohemagglutinin 3
Dragon 3
δ-tocotrienol, 3
ACF 3
bean, 3
(SSA) 3
AED-associated 3
88. 3
Besançon 3
varus: 3
[79%]) 3
delaminate 3
HNK1 3
ectoderm 3
glial-specific 3
founder. 3
Sox9 3
Melanocytic 3
epaxial 3
hypaxial 3
Foxd3-positive 3
delamination 3
(p.Arg2686His) 3
(GS), 3
PIEZO2, 3
SAMe, 3
Harlequin's 3
postganglionic 3
(hemifacial 3
hypohidrosis) 3
(harlequin 3
CSN5/Jab1. 3
(CSN5/Jab1), 3
cullin-neural 3
(Nedd8)isopeptide 3
di-isopeptide 3
Nedd8-binding 3
active/inactive 3
deneddylase 3
monomer-dimer 3
(COP9 3
CSN) 3
proteosome, 3
E3-mediated 3
AtItpk-1, 3
painand 3
(N=154) 3
(ew), 3
(eow), 3
(VAS; 3
(PHQ-9; 3
54.3±26.5 3
≥10. 3
(P&lt;0.001) 3
(63.9±23.3) 3
(47.4±26.7). 3
ew-treated 3
45.8%; 3
29.4%; 3
23.8%) 3
50.0%; 3
37.9%; 3
29.6%), 3
(≥median 3
depressivesymptoms 3
-34.03% 3
+2.26%; 3
P&lt;0.01). 3
(Humira®) 3
(26.0% 3
27.6%, 3
(EW) 3
(EW 3
51.8%) 3
(32.2%) 3
EW 3
(-24.4) 3
(-28.9) 3
(-15.7 3
-9.5, 3
groin. 3
antiandrogens, 3
factor-α) 3
suppurativa, 3
26.0% 3
Legg-Calvé-Perthes' 3
factor-V 3
(Odds 3
countrywide 3
symptomatically. 3
derotational 3
fascia. 3
Extremity 3
computation. 3
splinting, 3
OTULIN. 3
LUBAC, 3
MRC 3
disaggregases 3
dissolves 3
404 3
under-detection 3
user-friendliness 3
78·3 3
0·95. 3
99·19%, 3
0·99 3
0·99-1·00). 3
wards, 3
glenohumeral 3
MediaWiki. 3
activities.Database 3
http://fantom.gsc.riken.jp/5/sstar/. 3
3-18 3
remarkable, 3
short-limbed 3
Presently 3
1953 3
vaccinate 3
1979. 3
muciniphila, 3
mucus. 3
UTRs), 3
poly(A)-position 3
(3P-seq) 3
3P-seq 3
>79% 3
CPA, 3
superoxide, 3
p67(phox) 3
p47(PHOX), 3
(+97%) 3
(+384%), 3
S154A 3
S154D 3
Pulldown 3
phos-phorylation 3
NOXA1, 3
p22(PHOX). 3
organiser 3
(-/y) 3
NoxA1. 3
Tks5 3
HM61713, 3
EGF816, 3
(AZD9291, 3
fixed-dosing 3
non-Asian 3
HM61713 3
Vitro. 3
osimertinib. 3
ABCG2-overexpressing 3
Ther; 3
ROMK 3
nephron. 3
normotensive, 3
mOsm/kg 3
ACE-inhibitor 3
Henle. 3
hypokalemia-hypomagnesemia 3
cotransporter, 3
Miscellaneous 3
(CPPD) 3
pseudogout 3
RMBase: 3
Base, 3
http://mirlab.sysu.edu.cn/rmbase/), 3
RNA-modifying 3
IU/L, 3
31.7, 3
placentae 3
(p.Arg217Ile) 3
Microphthalmia-White 3
(Mitf(Mi-wh) 3
/+) 3
SCA, 3
Lrp4, 3
Atf4(-/-);Col2a1-Atf4 3
osteochondrogenesis 3
(Shh-N) 3
three-week-old 3
three-day-old 3
128% 3
Shh-N-treated 3
ALPase 3
PTH/PTH-related 3
perichondrium, 3
enchondromatosis 3
plate: 3
(1-34) 3
PTHR-1 3
BMPR-IA 3
PTHrP-LacZ-knockin 3
PTHrP-null 3
load-induction 3
PTHrP-expressing 3
PTHrP-knockout 3
encroach 3
IHH-driven 3
load-induced, 3
IHH-PTHrP 3
HhAntag 3
diaphyseal 3
skeletogenesis 3
(Hui 3
Joyner, 3
cephalopolysyndactyly 3
extra-toes 3
241-246; 3
Bitgood 3
McMahon, 3
Bmp 3
172, 3
126-138; 3
Lanske 3
hedgehog-regulated 3
663-666; 3
613-622). 3
Hammerschmidt 3
14-21). 3
(Johnson 3
4161-4170; 3
Dominguez 3
Sending 3
signal: 3
1621-1625; 3
Marigo 3
GLI3 3
273-283). 3
(ihh), 3
gli-expressing 3
Bmp-4 3
3163-3174; 3
Kawakami 3
122, 3
3557-3566). 3
ihh, 3
primordia 3
indefinitely 3
Steroids 3
latex, 3
fovea, 3
palpation. 3
aeroallergens, 3
Anisakis 3
(C3, 3
C1-esterase 3
CH50, 3
Thorax 3
(deflazacort, 3
metronidazole), 3
Presented 3
scrotal 3
non-neutralizing 3
carrot-cell-expressed 3
30U/kg 3
30-U/kg 3
60-U/kg 3
14.2%; 3
29.4 3
73.7%; 3
58.5% 3
66.1%. 3
mild/moderate, 3
rehydration. 3
NCT01132690. 3
S12 3
phosphoreum 3
(EOAD) 3
(Parkinson's 3
(APP, 3
(DILI), 3
B-induced 3
HBV-induced 3
L02 3
(0-11) 3
LDN-193189. 3
BMP-induced 3
dorsalization 3
BMP-Smad 3
BMP4, 3
42-bp 3
activin-like 3
(http://unipept.ugent.be/peptidefinder) 3
in-browser 3
senescence-accelerated 3
Senescence-accelerated 3
Modulate 3
oxadiazine 3
CD147 3
CD147, 3
blepharochalasis, 3
fissure, 3
hypochromia 3
hydroxyamphetamine 3
(RPOA) 3
(PHN). 3
PHN, 3
Cystitis 3
(joint 3
Fighting 3
malaria: 3
nonpeptidomimetic 3
2.4-Å 3
malaria-specific 3
Picomolar 3
Protease, 3
Achieved 3
death-toll 3
600,000. 3
PmV, 3
PExEl 3
PExEl-secretion, 3
(~ 3
compounds). 3
P' 3
P2', 3
PExEl-based 3
(PEXEL), 3
(PMV). 3
non-digestive 3
vivapains 3
(PM4) 3
(PvPM4) 3
genebank. 3
bi-lobed, 3
P.vivax 3
Synthesis, 3
Falcipains 3
MRSA-colonized 3
rooms 3
Community-Associated 3
Krasnoyarsk, 3
ST239 3
(BBR) 3
log10 3
c.f.u./ml 3
(37.0%) 3
91.7%, 3
22.5% 3
non-beta-lactam 3
MRSASelect 3
Cepheid 3
vancomycin-intermediate 3
hVISA 3
VS-MRSA 3
hospital-wide 3
MRSA; 3
Pulsed-field 3
kaempferol 3
Laurus 3
nobilis 3
fluoroquinolones, 3
gentamicin, 3
ST111-MRSA-I 3
ST80-MRSA-IV 3
ST5-MRSA-II, 3
CC398. 3
(60-80 3
SSI. 3
area-level 3
catchment 3
[RR]: 3
mecA, 3
nontypable 3
Spread 3
Córdoba 3
healthcare-onset 3
MRSA-Select 3
sector 3
protease-digested 3
protonated 3
Zn(2+)-polyhistidine 3
ᅟ. 3
HPMC 3
while, 3
Minutes 3
Dysfunction: 3
avanafil's 3
(published 3
(retina) 3
(vessels, 3
etc), 3
(EFD) 3
(VSS) 3
35-70 3
Corp., 3
≥60% 3
Tmax 3
3A4. 3
dyspepsia. 3
pyrimidine-5-carboxamide 3
(r), 3
Acceptability 3
experienced. 3
antiretroviral-containing 3
microbicide, 3
colposcopy, 3
Rwandan 3
microbicide. 3
vaginal, 3
(IVRs) 3
dapivirine-loaded 3
lining. 3
Antiretroviral-containing 3
trachomatis, 3
2016: 3
(PrEP) 3
hydrophilicity 3
rejected. 3
(meningococcus 3
vaccine) 3
1502 3
(CEA) 3
Bexsero®, 3
non-vaccination. 3
TreeAge 3
Pro® 3
(official 3
underreporting) 3
82.97 3
€109,762 3
€26,599 3
tornado 3
NHBA) 3
signatures" 3
Bexsero(®)): 3
Bexsero(®)) 3
two-center, 3
Trumemba(®) 3
anti-FHbp 3
(FH)-binding 3
FHbp, 3
Unvaccinated 3
0-99. 3
litigation 3
£20,000 3
(€25,420, 3
$32,677) 3
(26.3% 3
£3 3
(€3.8, 3
$4.9) 3
(51.8% 3
£4 3
economically, 3
teenagers, 3
Christensen 3
vaccinees, 3
LC-MS(E) 3
MenB-FHbp 3
Wyeth 3
MenB-4C 3
2-dose 3
0-99 3
one-off 3
(34) 3
8461 3
catch-up, 3
24.9% 3
(20+ 3
€96.96 3
>€500,000 3
1.4. 3
Diagnostics, 3
Offering 3
(TN), 3
linear-quadratic 3
dose-protraction 3
intrafraction 3
single-fraction 3
capsulotomy, 3
(GKAC) 3
extreme, 3
(YBOCS). 3
pre-radiosurgery 3
34/40, 3
39/40, 3
39/40. 3
isocenters 3
midpoint. 3
MC3T3E1 3
The-N-End 3
Rule: 3
End. 3
PAI-2·proteasome 3
MARCH 3
Ube4b 3
intersegmental 3
ER-to-Golgi 3
apoB, 3
(26S) 3
DMRV, 3
Bleeding: 3
intracutaneous 3
tender, 3
PPDDM 3
parasitosis, 3
epistaxis, 3
fasciotomy, 3
Gardner-Diamond's 3
(1666-1723) 3
altera 3
(First 3
Dissertations), 3
Valsalva's 3
Opera 3
omnia 3
1740. 3
re-named 3
Valsalva-Zinn' 3
mistake 3
Ophthalmologica 3
clinoidectomy 3
resection) 3
orbits 3
palpebrae 3
superioris 3
decompression: 3
grossly. 3
fraying 3
dural/arachnoid 3
pia 3
Transphenoidal 3
dural-arachnoid 3
symptoms-solute 3
(SLCO1B1) 3
rs4149056-also 3
[LDL-C] 3
(LDL-c). 3
sickness" 3
intelliCage 3
(APP.V717I). 3
12- 3
CA1. 3
Swedish- 3
caspase-3/7 3
oxaliplatin-resistant 3
(fold 3
taxonomy1, 3
(T1D) 3
MLC20 3
losartan, 3
gp91phox 3
paraquat, 3
(MPP+), 3
PD-like 3
anions) 3
(PKCdelta) 3
Rottlerin, 3
PKCdelta 3
Diphenylene 3
burst-generating 3
N-ethylmaleimide. 3
(BRECs). 3
AGEs, 3
(PKC)-beta2 3
GF10923X, 3
LY379196 3
PKC-beta2 3
polysaccharides, 3
MCI-186). 3
HDAC4. 3
triazolo 3
pomace 3
procyanidin 3
meningoencephalitic 3
tetraparesis. 3
Even, 3
catfish 3
FCF-induced 3
Septin9 3
SEPT7 3
mother-bud 3
forchlorfenuron, 3
ΔaspB 3
SEPT8 3
prospore 3
septin-ring 3
PtdInsP(2) 3
Simtuzumab 3
simtuzumab 3
myoclonic, 3
(8/15) 3
dissected, 3
vaccination-proximate 3
15-21 3
(Dravet's 3
immortality 3
tanshinones 3
TNQX 3
extrabone 3
p<.001) 3
(Nox). 3
Noxes, 3
EF-hand-containing 3
Nox5S) 3
coexpressed, 3
oligomerization: 3
polybasic 3
(PBR-N) 3
sensor-containing 3
(CiVSP) 3
co-immunoprecipitating 3
∼350 3
Nox5S, 3
calcium-stimulated 3
non-adherence 3
Benefit-risk 3
rosuvastatin-associated 3
muscle-, 3
liver- 3
Rosuvastatin-induced 3
PARADIGM-HF 3
LCZ696, 3
bang 3
fraction.(1) 3
valsartan.(1-3) 3
Sacubitril/Valsartan 3
63-Year-Old 3
spironolactone 3
receptor-neprilysin 3
(SCI). 3
Ddc 3
(20μM) 3
l- 3
d-tyrosine. 3
Neurochemical 3
cyclohexyl 3
TPH 3
1015. 3
5-hydroxytryptamine, 3
(5-HTP) 3
dopa-decarboxylase, 3
micrograms. 3
dihydroxyphenylalanine 3
decapitated 3
flesinoxan 3
fluorodopa 3
back-to-back 3
N-acetyldopamine 3
1915, 3
Pus1p 3
pre-term 3
ABCC12, 3
hCNT3 3
(MRP1/ABCC1, 3
MRP2/ABCC2, 3
MRP3/ABCC3, 3
MRP4/ABCC4, 3
MRP6/ABCC6, 3
MRP7/ABCC10, 3
MRP8/ABCC11 3
MRP9/ABCC12) 3
ABCC7 3
regulator; 3
ABCC9 3
ATP-sensing 3
MRP10/ABCC13 3
pseudo-gene 3
(LTC(4) 3
MRP1/ABCC1), 3
(MRP2/ABCC2, 3
MRP3/ABCC3), 3
(MRP4/ABCC4), 3
(MRP4/ABCC4, 3
MRP8/ABCC11), 3
glucuronosyl-, 3
sulfatidyl 3
MRP/ABCC-mediated 3
ABCC-MRP 3
'C' 3
ABCC). 3
1-9, 3
BMP/HJV/SMAD 3
Transferrin 3
(MAPK/Erk) 3
transferrin-dependent 3
(Erk) 3
holotransferrin, 3
phosphoSMAD1/5/8 3
2-null 3
holotransferrin-dependent 3
hepcidins 3
RRRRR(59)DT, 3
(alpha1-PDX) 3
preproFurin 3
(ppFurin). 3
RRRRR(59)DT 3
activity-deficient 3
LoVo 3
(PACE4), 3
Furin. 3
RRRRR(59) 3
SSSSS(59) 3
BACKGROUND/AIMS: 3
(10(-7), 3
10(-9), 3
adipocyte-specific 3
FSP-27)/human 3
(CIDEC/Fsp27) 3
cattles. 3
Ad-36 3
pET-28a(+), 3
animo 3
rasorial 3
973 3
42.90 3
54.30 3
SSA 3
0.81). 3
Cidec. 3
-219/-207 3
stroke' 3
in-patients. 3
upper-extremity 3
0.805 3
0.863 3
0.806 3
Macrophage-T 3
GITR-dependent 3
Neuroimmune 3
CD4+CD25+Foxp3+ 3
superagonist 3
(CD28SupA), 3
expander, 3
neuritis-affected 3
neuropathy-induced 3
Frey 3
ng/ml), 3
telomere-length 3
telomerase-mediated 3
ABCE1. 3
conserved: 3
ABCE1, 3
consultative 3
examination.The 3
pellucid 3
plus. 3
"septo-optic 3
(4/5), 3
(3/5) 3
herd, 3
hooves, 3
buffalo, 3
1,431 3
477. 3
Aboriginal 3
type1a. 3
(tyrosinase-positive) 3
TYR. 3
milky 3
c.1426A>G 3
(p.Arg77Gln) 3
tyrosinase. 3
Tyrp1 3
MATP 3
melanosomes. 3
Cis-regulatory 3
Locating 3
motif-specific 3
p-values, 3
http://meme.sdsc.edu/MCAST/paper 3
(SAP) 3
"pathological" 3
correction: 3
oligomers; 3
Abeta; 3
MAP2c 3
non-AD 3
gun 3
DG 3
Brachypodium 3
future? 3
Woolsorters' 3
Yorkshire's 3
centuries. 3
legislative 3
experimented 3
war-winning 3
Anglo-American 3
pustule 3
cenH3/H4/H2A/H2B 3
∼80-bp 3
(CDE 3
'hemisome'. 3
octamers. 3
Saudis. 3
(53.7%), 3
(53.26%), 3
(36.18%), 3
malar/butterfly 3
(27.6%), 3
(22.6%), 3
(21.6%), 3
(21.1%) 3
(19.09%). 3
adult-onset), 3
36.4%), 3
35.5%) 3
(11.4% 3
Complicated 3
Neuromyelitis 3
anti-DNA, 3
[Cutaneous-visceral 3
lupus-cheilitis 3
("visceral 3
pathology-cardiovascular 3
polyserositis. 3
teleangiectasia 3
"visceral 3
pathology-renoparenchymatous 3
livedo, 3
"musculoskeletal 3
disorders") 3
[Butterfly 3
rash: 3
lupus]. 3
Gpt/l 3
(3000/microl). 3
Clr-C 3
meiocytes 3
cycle-independent 3
Institute's 3
0-2.32 3
0.04-4.73 3
0.31-6.64 3
(fancl 3
fancd1(brca2)) 3
Tp53 3
(p53), 3
feminizing 3
oocyte-derived 3
alter. 3
fancd1(brca2) 3
(Fanca), 3
Fanca(tm1.1Hsc) 3
gonadotrope 3
MMP. 3
ethylenediaminetetraacetic 3
liposome-encapsulated 3
rotavirus. 3
antinutrient 3
ash 3
(Lycopersicon 3
esculentum) 3
mg/100g) 3
antinutritional 3
Budesonide 3
foamwill 3
80/40 3
immunomodulator 3
464) 3
54; 3
47.0% 3
31.2% 3
.010 3
(27.8% 3
42.4%) 3
(15.6% 3
26.6%; 3
.004 3
(23.2% 3
41.7%, 3
NCT00488631. 3
-α, 3
dose-confirmation 3
1064 3
6-12; 3
-1.0, 3
mg/50 3
200/100 3
400/200 3
(both, 3
.0014, 3
3.0%, 3
ischiorectal 3
NCT00487539. 3
aminosalicylates, 3
meta-analysis: 3
(NMA) 3
1.72-3.47 3
1.37-1.99 3
1.52-2.62 3
1.46-2.14 3
goliumumab 3
NMA 3
[Golimumab 3
Colitis]. 3
Immunomodulators 3
acetylation) 3
UCB-induced 3
blood-CSF 3
mashhad, 3
third-day 3
auto-toxic 3
asphyxia, 3
ventilations 3
Bahaman), 3
Mashhad. 3
interpeak 3
III-V 3
BAEP 3
ATM(-/-) 3
11.4%. 3
1/2,500 3
"fear" 3
TRC 3
dermatoglyphic 3
executive, 3
mouse: 3
monosomy, 3
non-transfused 3
meager. 3
Hosmer 3
<8. 3
99.8 3
0.843 3
(0.765, 3
0.903). 3
(46.2%), 3
(68.1%). 3
Mortality-2 3
macroH2A2, 3
dKO-induced 3
EpiSCs. 3
p.Cys326 3
c.386T 3
>C 3
(FPN) 3
p.H63D 3
(p.K240E), 3
(FPN1 3
COL3A1, 3
MSTN, 3
metal-induced 3
Fe(2+), 3
compounds) 3
(GDF15) 3
Vesicles 3
K(lysine)897T(threonine) 3
eag-related 3
nonglycosylated 3
897K/K 3
ppk29 3
ATF6 3
Nedd4-2 3
PLX-4720 3
hERG-mediated 3
TKI) 3
axitinib, 3
Ruijin 3
40-year 3
G2/M-arrested 3
Dens 3
CPDD 3
colchicine. 3
subchondral 3
retropharyngeal 3
Looped 3
juxtaposes 3
Met28, 3
Ino2, 3
activator-independent 3
minor. 3
neither. 3
inception. 3
interphalanges 3
mutilans, 3
enthesopathy, 3
keloids 3
keloid 3
UVB]. 3
vulgaris]. 3
Intradermal 3
2014). 3
4-15 3
(gEUD) 3
RBE) 3
gEUD 3
(n=19) 3
4-103) 3
11-63) 3
P=.004), 3
P=.04; 3
P=.009; 3
P=.05). 3
posteroanterior 3
sac. 3
posteroanterior, 3
pre-porting 3
diagnostic-quality 3
odynophagia) 3
25.1% 3
(DVHs) 3
(3D-CRT), 3
(IMRT), 3
(nonintensity 3
modulated) 3
sarcomas) 3
DVHs 3
block). 3
3D-CRT) 3
3D-CRT); 3
chiasm, 3
protons) 3
White, 3
Guzerá 3
retinyl 3
ramanniana 3
transformation: 3
intraaxial 3
transcallosal 3
fullness; 3
labyrinthic 3
panic-phobic 3
meningo-encephalitis 3
younger) 3
neuro-otologic 3
"idiopathic 3
"secondary 3
spells 3
himself, 3
dislocation) 3
Index), 3
63.5 3
LH1 3
eugonadal 3
(mutations 3
penis. 3
raltegravir-chelator 3
(RCD) 3
MBG. 3
(RCD-4, 3
RCD-5) 3
hydroxypyrone 3
(RCD-1). 3
deformylase 3
salmon 3
Immediate-early 3
CENP-A(Cse4). 3
DOXO 3
Stat3, 3
(TRZ) 3
DOX+TRZ 3
Cardiotoxic 3
DOX-treated 3
(top1mt) 3
≥300 3
Doxorubicin-based 3
cardiotoxicity: 3
(predoxorubicin 3
postdoxorubicin 3
nonaspirin 3
Enteropathy. 3
g/dL). 3
anasarca 3
chylous 3
fat-soluble 3
Exsudative 3
Videocapsule 3
contributive. 3
Whipple's 3
(stomach, 3
jejunum, 3
ileum) 3
chyle 3
engorgement 3
Medium-chain 3
lacteal 3
overloading. 3
antiplasmin, 3
permanent, 3
reappear 3
effusion(s) 3
[Limb 3
disease)]. 3
upper, 3
Hypoproteinemia, 3
stocking. 3
bad? 3
Hypoproteinemia 3
unsuccessful, 3
lymphangiectasis 3
Dual-energy 3
appositioned 3
94, 3
mortalities. 3
73, 3
trauma-related 3
(LD50) 3
disulfide-bond 3
pentraxin, 3
up: 3
azurocidin 3
AZU1 3
(cap-binding 3
cbp20 3
cbp80 3
DOF 3
CDF2, 3
DCL1-mediated 3
miR156 3
miR172 3
RNAse 3
DICER-LIKE1 3
(DCL1), 3
Pre-miRNAs 3
MHV68 3
NF90-NF45 3
#203100). 3
dopaquinone. 3
(H19Q, 3
R521, 3
R77C, 3
G97R, 3
C289R, 3
L312V, 3
P313R, 3
F340L 3
H404P), 3
(W80X 3
R116X) 3
(53delG 3
delG). 3
'Snowflake'. 3
(Tyr) 3
gorilla). 3
('Snowflake'). 3
1.14.18.1), 3
'Snowflake', 3
Snowflake, 3
Albinism-causing 3
OCA1B; 3
temperature-sensitive. 3
insolubility, 3
OCA1B); 3
donkey 3
11q14-q25. 3
(c.937del8, 3
c.1379del2) 3
(R278X) 3
(OCA1): 3
Arthroscopic 3
(DB), 3
mRCT 3
21.2 3
tendon. 3
medium-large-sized 3
subacromial 3
overcome, 3
(LITT), 3
"stereotactic 3
ablation," 3
transsulcal, 3
transportal 3
76%-92%), 3
60%-87%), 3
84%-100%). 3
[LITT]) 3
(HGGs). 3
thermography 3
Cryotherapy, 3
superhelix 3
linker-binding 3
DNA-(H3-H4)2 3
tetrasome 3
assembly-histone 3
htz1Delta 3
SERRATED 3
LEAVES 3
(SEF), 3
(SWR1C) 3
petals 3
SWR1C, 3
H2A-H2B. 3
CENP-C, 3
Mcidas, 3
(Gmnc 3
Lynkeas), 3
Foxj1 3
(ODM) 3
ophthalmoscopically, 3
Phacomatosis 3
melanosis) 3
Nevus 3
frameworks 3
(PubMed, 3
sycamore 3
pseudoplatanus 3
methylenecyclopropylglycine. 3
(MCPG), 3
(AES). 3
MCPG. 3
methylenecyclopropylacetyl-glycine 3
(MCPA-Gly) 3
methylenecyclopropylformyl-glycine 3
(MCPF-Gly). 3
0.99. 3
≥80% 3
≤20% 3
Fulminant 3
Sickness. 3
Reye 3
hepatoxicity 3
acidaemia 3
constitutent, 3
hypoglycin, 3
sapida) 3
4-3840 3
hypoglycin. 3
231.19+/-62.5 3
hypoglycinA/kgBW 3
215.99+/-63.33 3
hypoglycinA/kgBW, 3
hypoglycin/kgBW 3
1.50+/-0.07 3
hypoglycinA/kgBW/day. 3
exhibits. 3
dyshomeostasis. 3
Sylvant, 3
HIV-negative, 3
phase-1 3
phase-2 3
cholesterol) 3
N-degrons, 3
arginylation 3
UBR 3
Anophthalmia 3
ODA, 3
AARSs 3
(EPRS) 3
(GAIT) 3
transcript-selective 3
NS1-associated 3
(Cdk5) 3
Cdk5/p35 3
disciformis 3
chronica 3
infliximab: 3
right-lower-extremity 3
orange-yellow 3
hue. 3
cosmesis 3
infusions). 3
NLD, 3
KP 3
ulcerating 3
diabeticorum, 3
paradigms, 3
dermonecrotic 3
C-S 3
13129 3
prophage. 3
lysogenized 3
gene-carrying 3
lysogenization 3
pseudotuberculosis 3
Toxigenic 3
ulcerans: 3
non-diphtheria 3
amoxicillin-clavulanate. 3
Coryne 3
Romanian 3
mitis 3
socio-economical 3
Human-to-human-transmitted 3
diphtheria-causing 3
hypocalciuric 3
pleiotropy, 3
Guest 3
OGR1 3
18--binding 3
ischemia--reperfusion 3
I/R-mediated 3
(IL-18) 3
IL-18/IL-18BP 3
Laparotomy 3
(El 3
Kaderi, 3
Medler, 3
Raghunayakula, 3
Ansari, 3
25015-25025). 3
(CF1) 3
Rna15. 3
looping-defective 3
(Pap1) 3
Rna14 3
MET16 3
INO1 3
Pap1, 3
Rna14, 3
Pcf11. 3
promoter-terminator 3
cold-sensitive 3
(NT-proBNP, 3
GDF-15, 3
LYG 3
embolism; 3
2·0-3·0). 3
1·4-2·3). 3
NTC00412984. 3
3436 3
2·46 3
3·24 3
0·76, 3
0·56 3
1·03); 3
1·23 3
0·82, 3
0·65 3
1·03; 3
interaction=0·71). 3
0·77 3
-0·08 3
1·63) 3
0·22 3
(-0·03 3
0·47) 3
0·09-2·04) 3
(0·54-1·32) 3
Characteristics, 3
apixaban-treated 3
RRRs 3
(stroke: 3
831 3
interpret. 3
e-training 3
2+/3+ 3
562 3
coli-derived, 3
affinity-matured 3
knob-into-hole 3
antibody-like 3
Sema 3
Plexins, 3
Semaphorins, 3
Sema-PSI), 3
β-chain 3
β-chain) 3
bivalency 3
PC-9/hHGF 3
(shed) 3
(sMET) 3
nonclinically 3
(mouse, 3
VTEs 3
1990. 3
non-self 3
poxviral 3
CXCL12α 3
MCV. 3
supercoils. 3
MCV-TOP(82-323) 3
patterns; 3
MC54L, 3
mollusca 3
tuberculoma 3
hypofluorescence 3
relapsing, 3
shortterm 3
pseudotuberculosis; 3
ancestral, 3
microorganism, 3
high-priority 3
Nebbi 3
postapproval 3
deterrent 3
(24.2%) 3
Addiction. 3
Prescribers 3
(Qsymia), 3
(lorcaserin). 3
permeabilization, 3
BAX/BCL2 3
BH1 3
(Bax 3
NPR 3
Bax) 3
subserosa. 3
Lymph, 3
edemas. 3
multisegmental 3
subserosa 3
misglycosylated 3
1-palmitoyl-2-[14C]linoleoyl-phosphatidylcholine:monolysocardiolipin 3
linoleoyltransferase. 3
A-form 3
(taz) 3
tetralinoleoyl 3
arcuatus 3
tribelocephaline 3
(mitogenome) 3
Opistoplatys 3
Tribelocephalinae. 3
ND5 3
Reduviidae: 3
geological 3
atromaculatus, 3
fulvescens 3
Duplicated 3
E<10(-5)) 3
bio-machinery 3
stops. 3
tarentolae 3
vestibulocerebellar 3
mGluR1 3
Immunostained 3
(Eps8) 3
Ras/Rac 3
Rab5. 3
Eps8, 3
Eps8-antibody 3
cell-class 3
calretinin, 3
flocculo-nodular 3
paraflocculus, 3
lingula, 3
moderate-to-low 3
paraflocculus. 3
immunoreactive, 3
immunostained, 3
dense-core 3
rosettes.(ABSTRACT 3
NG. 3
UBCs. 3
(UBC), 3
II-immunoreactive 3
cerebellum: 3
(EPSC) 3
unspecialized 3
stubby 3
(mHGG) 3
38-matched 3
2.9-23.3 3
11.2-32.2 3
intra-pontine 3
co-mutated 3
BCOR 3
prognostically-relevant 3
therapeutically-targetable 3
sub-clones 3
cerebrum. 3
oncohistone 3
K27-AAG 3
JMJ 3
(60.9%) 3
psoralen-UVA 3
(PUVA-soak 3
soles. 3
PUVA-soak 3
ANGPTL4 3
(cHLP), 3
PARKIN 3
PARL's 3
rhomboids, 3
presenilins-associated 3
(BAT). 3
beige/brite 3
BAT-mediated 3
obesity/diabetes. 3
dyslipidemias, 3
(PPARgamma), 3
PPARgamma-coactivator-1alpha 3
(PGC1alpha), 3
PRD1-BF1-RIZ1 3
(PRDM16), 3
(C/EBP-beta) 3
(BMP7). 3
adenosine-5'-triphosphate 3
BAT's 3
beta)-adrenergic 3
SNS-mediated 3
Prdm16, 3
"Brown-Fat-in-Microstrands" 3
microstrands 3
expenditure, 3
acclimated 3
cold. 3
1-receptors 3
1-receptor 3
BAT. 3
darkly 3
virus-like-particle 3
VLPs. 3
HMW-MAA 3
m.w. 3
pVIII-9mer 3
225.28S. 3
225.28S 3
HMW-MAA. 3
bursal 3
IBDV 3
r5EPIS 3
epitope-specific 3
mimotope-DNA 3
K1. 3
rocking 3
Domestic 3
Irrigation 3
Nitrates 3
clay. 3
809 3
TTS1 3
grasses, 3
semi-quantified. 3
grazing 3
droppings 3
pasture. 3
subcontinent 3
pyogenic 3
in/on 3
TLR2. 3
(PMN) 3
friends, 3
ST-562 3
activator-deficient 3
IHA 3
serodiagnosis 3
potassium, 3
0.47; 3
Guangxi, 3
disused 3
Madagascar 3
Sarawak, 3
881 3
oligoastrocytoma. 3
parlance. 3
Homocystinuria 3
(1p13.2-q21.1). 3
(p.Y595X; 3
c.1785T-->G) 3
ADAMTS-like4 3
1-transient 3
Sulfonyl 3
anti-edema 3
Sulfonylurea 3
(Sur1) 3
(GSDMD) 3
membrane-disrupting 3
PIWI, 3
Zwille 3
Pachytene 3
Topaz1--deficient 3
MSCI 3
Topaz1(-/-) 3
normocytic 3
tolfenamic 3
anaemia). 3
TCD. 3
∼3 3
other; 3
intention-to-treat, 3
NCT01286753. 3
18·8 3
14·2-26·0) 3
(6·7-20·3) 3
(best 3
38·5%, 3
20·2-59·4). 3
γ-glutamyltransferase 3
dyspnoea 3
8505C, 3
BHP27 3
β2-specific 3
ICI118551, 3
β1-specific 3
(HK2) 3
phosphate‑buffered 3
phospho-MAPK 3
Sensitizes 3
BRAF-Mutant 3
Vemurafenib. 3
Vemurafenib-induced 3
CCCCGG 3
(FTLD-TDP). 3
degeneration: 3
proliferation/differentiation 3
c.2T 3
animal-to-animal 3
(Holstein) 3
(Angus) 3
breed-dependent 3
3Kb 3
(-2500 3
+500 3
NTRK2 3
transcription-dependent, 3
Ssu72-mediated 3
Swd2.2, 3
Sub1 3
inadequacy 3
(HGMD 3
Anti-MUC1 3
Binding. 3
(anti-MUC1 3
S2.2) 3
bioreceptor 3
APDTRPAP 3
(APDTRPAP) 3
(APDTRPAPG) 3
MUC1-G, 3
(PrPc). 3
23-231) 3
glycosyl-phosphatidyl-inositol-(GPI) 3
LAMP-I, 3
thioredoxin-A 3
(TrxA) 3
EB1- 3
EB3-binding 3
swiggle 3
internalisation 3
Thioredoxin. 3
(epitopes), 3
ligand-regulated 3
non-isolated 3
(17.4%) 3
BTHS, 3
Bank 3
skiers 3
helmeted 3
unhelmeted 3
snowboarders 3
Brussels 3
Calculated 3
(DOACs), 3
antithrombin:LMWH 3
inhibitor-related 3
(e.g.: 3
antidotes, 3
(ciraparantag) 3
23.4 3
PER977 3
(TSOAC) 3
agent-specific 3
10-30 3
TSOAC-associated 3
TSOACs. 3
Metopic 3
anteverted 3
trisomies: 3
(4;13)(p16;q32) 3
(WHS) 3
4p16 3
qter 3
t(4;13)(p16;q32) 3
WHS. 3
(Patau's 3
Y-chromosomal 3
DSD, 3
muscle-secreted 3
Marfans 3
palate) 3
1969 3
(TNF)α 3
(1,25[OH]2D3) 3
CD28. 3
CD28(-), 3
(CD4(+): 3
CD8(+): 3
31.9%, 3
CD4(+)CD28(-) 3
CD69(+)CD45RA(-) 3
(CCR)7(-) 3
perforin(+) 3
CX3CR1, 3
C-X3-C 3
(CXCR6), 3
CCR10-consistent 3
CD28(+) 3
(3.6-fold, 3
1.5-fold, 3
1.2-fold, 3
TNFα; 3
.01); 3
1,25(OH)2D3 3
TNFα-rich 3
variegate 3
protoporphyrinogen 3
pan-ebolavirus 3
Fc-dependent 3
NHPs. 3
(variant 3
cocktail, 3
(EVD). 3
97.5%. 3
employee(s) 3
EVD. 3
Antibodies. 3
boy]. 3
betaine. 3
B(6)-non-responsive 3
T353 3
D444 3
C667T 3
methylenetetrahydrofolate-reductase 3
B(6)-non-responsive, 3
c.664G> 3
(p.V218L), 3
c.1316T> 3
(p.F435S) 3
c.1733T> 3
(p.V574G), 3
c.1780delC 3
(p.L590CfsX72). 3
c.1420G> 3
(p.E470X). 3
(p.V218L; 3
p.A222V) 3
p.E470X 3
c.677C>T 3
hypomethioninaemia 3
677TT 3
1298AA 3
systolic-diastolic 3
B(12) 3
(677C-->T 3
1298A-->C). 3
(1762A-->T, 3
1134C-->G) 3
(1727C-->T, 3
1172G-->A, 3
1768G-->A, 3
358G-->A), 3
MTHFRs 3
hyperhomocysteinaemia, 3
cardiovasculopathy 3
hyperhomocysteinaemia. 3
metaanalyses 3
homocysteine-lowering 3
(-/-)mice 3
VEP 3
Mthfr(-/-) 3
(phospho-H2AX) 3
(H2O2)-treated 3
H2O2-treated 3
(ATR), 3
γH2AX. 3
DNA-PK, 3
(γH2AX). 3
path, 3
HC, 3
(Cilengitide, 3
(CdLS) 3
(APRIN). 3
cohesinopathies. 3
(CdLS), 3
PDS5, 3
(PDS5A 3
PDS5B). 3
Pds5A-deficient 3
E11.5 3
homozygous-heterozygous 3
(R1292Q) 3
CdLS, 3
PDS5A 3
G4. 3
Criterion 3
type-with 3
(noncompacted) 3
trabeculated. 3
Hydrops 3
diagnostic: 3
acid-Schiff 3
Window-of-Opportunity 3
49). 3
0.48; 3
0·73 3
0·72 3
models-assessment 3
(MALDI) 3
(GDC-0941, 3
2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine) 3
[5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine] 3
maximal-tolerated 3
phosphatidylinositol-3-kinases 3
Kras(D12) 3
myristoyl 3
FLT4) 3
NR4A1. 3
LECs 3
claudin-5 3
e-NOS), 3
licenced 3
transplant). 3
comparisons) 3
Vanoxerine: 3
(SP). 3
circuit) 3
CL. 3
driver's 3
mA) 3
refractoriness, 3
1,4-dialkylpiperazine 3
rhythm) 3
lens) 3
12/15 3
(Gln256Profs*38) 3
(Leu249Tyrfs*21), 3
(Ala388Glyfs*8), 3
(Arg746His), 3
(Gly592Ser), 3
(Arg865His). 3
logarithm-of-odds 3
Programs. 3
c.2920. 3
974 3
(p.R974C). 3
(IEL) 3
LTBP2 3
glaucoma) 3
habitus). 3
IVS4-1G>A/IVS4-1G>A 3
MASS 3
Jaagsiekte 3
host-specific 3
JSRV. 3
jaagsiekte 3
circuit(s) 3
intron-based 3
Ghent-1 3
Ghent-2 3
24-40 3
24-32. 3
arachnodactyly. 3
1-base 3
(skeletal, 3
haploinsufficiency) 3
157) 3
22q11.21 3
nMFS 3
CAPS. 3
(CIAS1) 3
FCAS 3
gout, 3
Inc) 3
pie 3
Venn 3
biomaRt 3
BioMart 3
safeness 3
(FEV1 3
NCT01854047, 3
2013-000856-16. 3
p=0·0008; 3
p=0·0063) 3
0·39 3
0·21 3
0·06-0·36; 3
p=0·0063]) 3
0·43 3
[0·11-0·40; 3
p=0·0008]) 3
(0·18 3
0·05]). 3
μL: 3
p=0·0034; 3
p=0·0086), 3
(70-70·5%), 3
(71·2-80·7%), 3
(59·9-67·6%). 3
(33-41% 3
(13-26% 3
β2-agonist 3
Sanofi-Genzyme 3
IgE-dependent 3
mellifera) 3
(Acari: 3
destructor. 3
bees, 3
c.553A>G 3
p.Met185Val. 3
aunt, 3
monolysocardiolipin/cardiolipin 3
(CM), 3
bi-modal 3
PCI: 3
NOBLE 3
LDLRAP1, 3
exenatide, 3
Diabetes, 3
(T2D), 3
diet/exercise 3
mg)/levonorgestrel 3
(semaglutide-free) 3
(steady-state 3
escalation: 3
AUC0-24 3
(post)ictal 3
Postictal 3
unwitnessed 3
(87%), 3
think? 3
(14.3%). 3
GTCS 3
Nrd1/Nab3-dependent 3
"fail-safe" 3
exosome/Rrp6. 3
pre-snoRNAs 3
EETTA 3
root-entry 3
(2004-2013), 3
(39%), 3
retrosigmoid 3
(29.5%), 3
(26.5%), 3
translabyrinthine 3
(94%), 3
Maximizing 3
isodose 3
1,114-dimensional 3
95.0% 3
types/tissues, 3
95.7% 3
major. 3
Bufo 3
(typified 3
[3H]palmitoyl, 3
[14C]linoleoyl, 3
[14C]arachidonoyl 3
[3H]CDP-diglycerides 3
sn-glycero-3-phosphate 3
hypotonic 3
diacylglycerols 3
(CL), 3
packing, 3
aa3 3
fumarase 3
(AUC=0.66, 3
0.53-0.79) 3
0.91. 3
Permutation 3
responsivity 3
Dlgap2. 3
Haploinsufficient 3
Pold3(+/-) 3
hydrocephaly 3
romosozumab. 3
Buchem 3
Carcinogenicity 3
romosozumab: 3
(LRP5 3
LRP6) 3
Weight-of-evidence 3
romosozumab-related 3
dose-proportionally. 3
(PINP) 3
66-147%, 3
(sCTX) 3
15-50%, 3
4-7%. 3
osteocyte-derived 3
eight-group 3
convergent, 3
(Hospital 3
in-site 3
contrasts. 3
(CAPS), 3
DTS-S 3
STEP-BD 3
ambulance, 3
licensing: 3
Mis18α, 3
LacO 3
mis19 3
(upf2 3
ebs1), 3
(snf5, 3
snf22 3
sol1). 3
Mis16-Mis18-Mis19-Mis20 3
CENP-A-recruiting 3
Amajor 3
(CCC) 3
salt. 3
whole-arm 3
(SEMAF) 3
5p15 3
mewing 3
setd7 3
HR(+) 3
(PD0332991, 3
(LY2835219, 3
(LEE011, 3
4/6-inhibitor 3
(HR+) 3
(HER2). 3
(EZH1, 3
(17.9%) 3
HGGs). 3
G34R/V, 3
Illumina. 3
(OSTN), 3
NPR-C 3
(YM-178, 3
Betanis®) 3
(YM-178), 3
Astellas 3
(cAMP). 3
AUC(0-τ) 3
ureteral 3
OnabotulinumtoxinA 3
(KHQ). 3
α1A 3
α1D 3
relaxations 3
5.6) 3
mirabegron-induced 3
Geriatrics 3
Taiwanese, 3
i.c.v.) 3
aripiprazole, 3
antibiotic-associated 3
(gut) 3
(N297Q) 3
(ESTEEM) 3
[9/87 3
group)]. 3
(30.8% 3
(knee 3
(worsening 3
treatment-related; 3
(Otezla(®)) 3
PALACE). 3
enthesitis 3
peculiarities, 3
28.8% 3
33.1%. 3
0·001). 3
Ethiopia 3
PPARA, 3
(SLC24A5) 3
Maharashtra 3
midges 3
Tahyna 3
neuroinvasive 3
Columbia 3
Arachnida). 3
virus). 3
haematophagous 3
intercontinental 3
bloodmeal 3
"gut 3
cofeeding 3
provisioning 3
symbionts, 3
muelleri 3
deltocephalinicola, 3
Macrosteles 3
quadrilineatus 3
(Auchenorrhyncha: 3
Cicadellidae). 3
Sulcia-ALF 3
(190 3
Multimodality 3
catecholamine-producing 3
useful: 3
1.5-2-fold 3
polydipsia. 3
[INTERRELATIONS 3
MICROALBUMINURIA 3
RENAL 3
FUNCTION 3
CONTRACTILE 3
ABILITY 3
LEFT 3
VENTRICLE 3
CARDIORENAL 3
PATIENTS]. 3
Cocroft-Gault 3
MA. 3
(25,4±5,8 3
miR-544 3
CDK2) 3
(circRNAs), 3
4,804 3
4,048 3
2,231 3
Degradation. 3
(ECM)-related 3
evolutive 3
DAMPs 3
VZV-induced 3
colorectum 3
1973, 3
Cdc6/Cdc18, 3
MCM, 3
Cdc18/Cdc6 3
orc1 3
ORC1O→D 3
5ARIs 3
GAL4-binding 3
ORC-Cdc6 3
lordosis 3
XLH, 3
1.15-2.58 3
mmol/l). 3
isodisomy. 3
hypophosphatemias: 3
phosphaturia 3
NaPi-IIc. 3
phosphatonin, 3
osteoblastic/osteocyte 3
extracelular 3
hypercalciuria: 3
(NM_080877.2:c[ 3
heterozygosis 3
(NaPi-IIc). 3
calcitriol, 3
CLCN5 3
ectonucleotide 3
pyrophosphatase/phosphodiesterase 3
(X.L.F.H.R.) 3
deforming 3
mushrooms 3
(ALF) 3
SSc, 3
PND70. 3
6-mediated 3
12-gene 3
'signature' 3
70%). 3
STAT-3 3
Ktrans 3
lymphoid, 3
Macrophage-derived 3
EGLN3, 3
lupus). 3
table-based 3
10-20x 3
SAMtools 3
http://maq.sourceforge.net. 3
SOAP2 3
gigabytes 3
BWASW-PMR 3
BWA-MT, 3
hg19 3
40M. 3
IORT. 3
(ependymoma, 3
oligodendroglioma). 3
nourish 3
INTRAGO, 3
(kV) 3
applicators, 3
INTRAGO 3
sections) 3
MTD) 3
IORT-related 3
radiotoxicity. 3
NCT02104882 3
(Registration 3
Date: 3
03/26/2014). 3
(19.5 3
(21.5 3
Tuberculin 3
IGRAs 3
birthday 3
30%-50% 3
RPL24, 3
RPL29, 3
RPL34, 3
RPL9, 3
RPL37, 3
RPS23, 3
RPL10A, 3
RPS12, 3
RPS18, 3
RPL30, 3
RPS20, 3
RPL7A, 3
RPS6, 3
RPL27A, 3
RPLP2, 3
RPS25, 3
RPS3, 3
RPL41, 3
RPLP0, 3
RPL21, 3
RPL36AL, 3
RPS29, 3
RPL4, 3
RPLP1, 3
RPL13, 3
RPS15A, 3
RPS2, 3
RPL38, 3
18S-E 3
pre-rRNA. 3
ribosomopathies. 3
erythroblastopenia. 3
phenotype--the 3
(c.2T>G), 3
+158 3
(Met-Ser-Arg-Ile). 3
S24 3
erythroblastopenia, 3
ROBs. 3
acrocentrics, 3
chAB4-specific 3
rob(13q14q) 3
rob(14q21q). 3
rob(21q22q) 3
15/21 3
tirilazad. 3
1.21). 3
(FGF-2(23)) 3
SMN-promoted 3
FGF-2(23)-dependent 3
(inactive 3
(SmD1, 3
SNRPD1). 3
SmD1, 3
Tagged 3
(CHS). 3
chédiak-Higashi 3
(HLH), 3
writing. 3
mu3 3
spikes. 3
FgNoxR 3
germinated 3
FgNOXR 3
spikelets 3
gamma-aminobutanoic 3
AreA. 3
putrescine. 3
mycelium, 3
rachis 3
Gpmk1 3
tri5 3
aestivum) 3
(DON) 3
phytotoxic 3
ecotypes. 3
(dexamethasone 3
47; 3
10.89, 3
thrombotic-thrombocytopenic 3
(Moschcowitz 3
factor-cleaving 3
(ADAMTS-13) 3
flights 3
5727 3
inosines 3
modifiers; 3
Rdl 3
(Resistant 3
dieldrin), 3
Adar-overexpressing 3
(cis-RNA 3
cis-edQTLs, 3
edQTLs 3
Kurmangaliyev 3
re-codes 3
Dalpha5, 3
β-HCG 3
β-hCG, 3
syncytiotrophoblast 3
geomagnetic 3
GMF 3
Ganglion 3
compass 3
Prussian 3
magnetoreceptor 3
MagR 3
cry1 3
acupuncture: 3
evacuation. 3
Fengchi 3
effacement 3
(ISKDC), 3
Sher-I-Kashmir 3
Soura, 3
Srinagar. 3
(98.45%) 3
pedal 3
(91%). 3
Hypercholesterolaemia, 3
sign--recurrent 3
embolism--and, 3
Furosemide 3
tiopronin, 3
spilling 3
(FMF). 3
Equivalent 3
cyanosis. 3
non-MCD 3
Meta 3
paediatrics. 3
Intussusception 3
Caralluma 3
disorders--Angelman 3
disomy) 3
(HSAN) 3
(CIP). 3
PRDI-BF1 3
RIZ 3
Prdm 3
H3.3-mutated 3
Fkh2p, 3
Fkh2p 3
CIP-Box 3
Helicase. 3
BTV 3
AD: 3
transverse-sigmoid 3
biplane 3
(Borden 3
(DAVFs), 3
(85.7%; 3
fistulae 3
angioarchitectural 3
eIF3 3
gephyrin 3
RAD 3
Valbenazine 3
KOS. 3
(c.556C>T, 3
p.Arg186stop) 3
(homologous 3
E6-AP 3
terminus) 3
(c.1166G>A, 3
p.Trp389stop) 3
KOS, 3
age/osteoporosis 3
(85%). 3
CASE 3
alacrima. 3
alacrimia. 3
advance-deep 3
(CNNs). 3
Kelley 3
P185BCR-ABL 3
arg-/- 3
coccobacillus 3
consensual 3
nonoutbreak 3
assimilate 3
photodiagnosis 3
non-perfusion, 3
IRVAN. 3
photocoagulation. 3
neuro-retinitis, 3
funds 3
40%-60% 3
(LDLC 3
mg/dl), 3
EVG/COBI/FTC/TDF 3
Patient-Reported 3
pain/numbness/tingling 3
hands/feet 3
diarrhea/loose 3
Coformulated 3
ritonavir-boosted 3
coformulated 3
(Stribild®): 3
single-tablet, 3
(INSTI); 3
enhancer; 3
(tenofovir 3
DF), 3
(elvitegravir/cobicistat/emtricitabine/tenofovir 3
mg/300 3
Stribild®) 3
0.010,q 3
TLR1(rs4833095) 3
2.8(1.1-7.4),p 3
0.037,q 3
NLRP3(rs10754558) 3
0.045,q 3
6.2(2.4-16.3),p 3
0.0002,q 3
regions--a 3
(yAsf1) 3
(hAsf1a 3
hAsf1b) 3
photoreactive, 3
yAsf1-histone 3
yeast-human 3
hAsf1a 3
hAsf1b 3
yAsf1. 3
T270 3
Asf1-histone 3
CAF-1/HIRA 3
yAsf1's 3
ASF1-EGFP 3
Set2. 3
Asf1-H3-H4 3
K56ac 3
Nap1 3
Lys-56 3
rad53 3
literature]. 3
(BDH) 3
(HMH) 3
BDH 3
Pediatr 3
In: 3
editor. 3
PA: 3
Saunders, 3
HJMD 3
P-cadherin, 3
(endocrine 3
exocrine) 3
intralobular 3
microglobules 3
gentamicin-induced 3
sebocytes. 3
immunochemistry. 3
cPLA(2) 3
anti-Mullerian 3
MMTV-Wnt-1 3
α-SMA, 3
pits, 3
ileum, 3
supplementations. 3
sinapultide, 3
beractant. 3
underpowered, 3
(MUTs) 3
TRAMP. 3
IWRXY 3
Trf4/5-Air1/2-Mtr4 3
ZnK4 3
Trf4 3
rrp47 3
backwards. 3
(SUTs), 3
information-protein-coding 3
strand-in 3
leukemoid 3
vulnerabilities 3
dosing). 3
Subtilisin 3
Kexin 3
peptide/s 3
LDLRs. 3
2018. 3
0·400 3
[7%] 3
Amgen. 3
convertase, 3
LDL-R. 3
alternation. 3
R306S 3
0.041), 3
CD81 3
LDL: 3
IGM 3
pathognomonic. 3
B*1801 3
15,353 3
ULN. 3
Law' 3
PHQ-8 3
inappropriate. 3
enthesitis, 3
dactylitis, 3
(PALACE) 3
Tbr1, 3
Cntn2 3
Cdh8 3
c-FOS-positive 3
amygdalae. 3
d-cycloserine, 3
telencephalons. 3
Eomes 3
MINICHROMOSOME 3
MAINTENANCE 3
heterohexamer, 3
(MCM7) 3
cyclin/cyclin-dependent 3
E/Cdk2 3
Ser-121. 3
MCM3/MCM5/cdc45 3
MCM7. 3
MCM7-overexpressed 3
HL-7702 3
B/Cdk1 3
cyclin/Cdks 3
Cdc7. 3
Cdc7/Dbf4 3
(Dbf4-dependent 3
DDK), 3
Mcm4(Chaos3)) 3
MCM2 3
(Mcm) 3
Mcm2~7 3
Orc1-like 3
Inspired 3
(Mcm2-7) 3
ORC/Cdc6/MCM2-7 3
'initial' 3
ORC-Cdc6-Mcm2-7 3
(FACSs), 3
Rizk 3
(WABI'12) 3
assemblers. 3
LightAssembler 3
resource-efficient 3
Filters. 3
(BFs) 3
slower. 3
FPR. 3
56-week, 3
18-70 3
obesity). 3
$48,340 3
$74,480. 3
hinges 3
$190 3
Sonidegib: 3
LDE225 3
1:555 3
1:770 3
Egyptian-specific 3
sonar. 3
Medians 3
participants/week. 3
Equations 3
Prisca 3
multiples-of-median 3
1:270. 3
Log-linear 3
[AFP/uE3 3
10(A+B*GA)] 3
[CG 3
A*e 3
(B*GA)] 3
medians. 3
Oestriol 3
halved) 3
Egyptians 3
78.2 3
peculiarities. 3
inhibin-A 3
14-22 3
box-specific 3
migration-related 3
TAD. 3
IEP, 3
IE62, 3
Exosome-mediated 3
NKG2D-dependent 3
TEX 3
UBXN-3 3
CMG, 3
UFD-1 3
NPL-4. 3
CUL2 3
CUL-2LRR-1, 3
UBXN-3, 3
FAF1. 3
metazoa 3
NMP 3
NTP. 3
(1992) 3
mobile. 3
C-ribbons 3
dissociable 3
μs 3
Embryogenesis. 3
(K392R) 3
Ertugliflozin 3
sotagliflozin. 3
hydrogen-bonded 3
neuropreservatory 3
assembler 3
metaspades 3
5-aza-2'-deoxycytidine, 3
LAMB3 3
1(RUNX3 3
NOMe-Seq 3
configurations: 3
TSS; 3
occupied, 3
monoallelically 3
Reconfiguration 3
(NDRs) 3
phasing, 3
"decommissioning" 3
Taberlay 3
(HMs) 3
java 3
settled. 3
drug-tolerant 3
tb) 3
test-reactor 3
(esxB 3
fbpB) 3
(hspX, 3
mb2660c) 3
hspX, 3
mb2660c 3
esxB 3
(Rv3133c) 3
DosS, 3
DosR. 3
Rv1733c, 3
ALDH2-deficiency 3
beverages, 3
net, 3
(DHBV). 3
pet-dependent 3
Peel 3
Microdermabrasion 3
35-70, 3
microdermabrasion. 3
Glogau 3
49.55 3
11.61 3
majorities 3
IRCT2015121112782N8. 3
double-conjugate 3
cosmeceutical 3
idebenone, 3
retinoid. 3
(ATRA 3
roughness, 3
1990-1994. 3
cutoffs. 3
elastosis, 3
+/-11.5 3
nonacne 3
(all-trans-retinoic 3
tretinoin-induced 3
hydroquinone 3
Neuroblasts 3
E(spl)mγ 3
m8, 3
dpn, 3
GMC/INP 3
GMC4-2a 3
RP2 3
FIRE: 3
cis-expression 3
hg19/GRCh37 3
https://sites.google.com/site/fireregulatoryvariation/. 3
nilah@stanford.edu. 3
-eQTL 3
adenosyl 3
thioretinaco 3
ozonide 3
stemness-high 3
mat1. 3
stability) 3
ARSs, 3
yeast-specific 3
Meselson-Stahl 3
XIV 3
Lachancea 3
diving, 3
ACOG 3
emboli. 3
men]. 3
refrain 3
echinacea: 3
privately 3
(SPT) 3
radioallergosorbent 3
echinacea, 3
ingested, 3
rechallenged. 3
"challenges" 3
atopic. 3
"echinacea-naïve" 3
unsupervised) 3
Echinacea-associated 3
anaphylaxis. 3
medicines, 3
Andrographis 3
paniculata, 3
Ginseng 3
neuroligin 3
calyx 3
cerebellin-1 3
transsynaptic 3
dystrophin-glycoprotein 3
NL2 3
Precedes 3
Underscoring 3
T-cell-specific 3
d(GA)n, 3
guanine-adenine 3
thymine-adenine 3
20mer 3
(GA)10 3
(GA)3 3
(GA)3(TA)4(GA)3, 3
(TA)4 3
(TA)10. 3
20mer, 3
(GATA)5, 3
(TA)10, 3
(GA)10, 3
reversibly. 3
d(GA)20 3
d(G1-3A)n 3
parallel-stranded 3
NaCl, 3
purine-rich 3
gentisic 3
skin-lightening 3
tautomerase 3
pyrimidine-purine 3
(CVE), 3
Shiny 3
cohort-wide 3
boards. 3
http://bioconductor.org/packages/CVE/ 3
nutrient-sensitive 3
Davunetide's 3
Xrn1/Exo2-sensitive 3
asXUTs 3
Spt6 3
anti-correlating 3
paired-sense 3
clockwork 3
Anesthesia-resistant 3
(ARM) 3
synthesis-independent 3
(APOQUEL(®)) 3
insulator-like, 3
TAD-boundary-like, 3
TAD-interior-like 3
AIHA 3
History, 3
(meQTLs), 3
(Hi-C 3
ChIA-PET), 3
"recombination 3
valley" 3
valleys 3
doublestranded 3
Pharmacotherapies 3
biomarker-stratified 3
'tumor-treating 3
fields' 3
postsurgically 3
RR/YY 3
10-bp 3
Represses 3
inflorescence. 3
4,862 3
regions--typically 3
wide--decorated 3
"Z 3
loci" 3
(26.9%) 3
APOE-ε4 3
amyloid-42 3
(64.5%) 3
Urethral 3
(TOT) 3
burns 3
PONV. 3
One-hundred-twenty-five 3
dexamethasone: 3
0.0625, 3
Nonparametric 3
Proportional 3
vomit 3
(0.0625 3
otolaryngology 3
nurse, 3
Affect 3
Adults? 3
(fundamental 3
[F0], 3
estimated: 3
Jitter, 3
interferon-mediated 3
GMP-AMP 3
Erythematosus. 3
SAID, 3
Nrd1-complex 3
(Groucho-related 3
TGF-β/Smad3 3
kinase/ALK5 3
Kinase/ALK5 3
(10.7 3
(TβR)-I 3
monohydrate), 3
monohydrate) 3
(LY2157299), 3
coligos, 3
L-loop 3
coligos 3
P-Tau 3
tracks) 3
"tracks." 3
BAM, 3
Ecm22/Upc2-dependent 3
SUT1 3
SUT2 3
Ste12. 3
SUT1/SUT2 3
Fhn1, 3
Npr1 3
Prr2 3
Sut2 3
Gal4-type 3
(upc2) 3
pheromone, 3
pheromone-induced 3
upc2-1 3
UCP1-independent 3
(http://www.synesthete.org). 3
synesthetes 3
colours 3
Stroop-type 3
synesthetes. 3
Gfral 3
postrema 3
UROBORUS. 3
http://ibi.zju.edu.cn/bioinplant/tools/manual.htm 3
fanlj@zju.edu.cnSupplementary 3
rilotumumab. 3
immuno-PET 3
Methods: 3
8·8 3
backtrack 3
promoter-independent 3
A12.2 3
(nc)RNA 3
element-encoded 3
TFIIIC. 3
PML-dependent 3
PML-depleted 3
PMLI 3
(BRET) 3
As₂O₃ 3
(APL). 3
EYFP-linked 3
PMLI, 3
PMLII 3
PMLIII, 3
PML-IV 3
APOLLO, 3
18-85 3
investigator-estimated 3
5-130, 3
≤IIIb. 3
NIS+7 3
Norfolk-Diabetic 3
NIS-weakness 3
Score-31 3
NCT01960348 3
(GFRAL) 3
fibroosseous 3
nanocarbon 3
fCNT/siMep1band 3
fCNT/siTrp53significantly 3
meprin-1β 3
fCNT/siRNA 3
fCNTs 3
kidney-specific 3
Microtubule-stabilizing 3
(NAP). 3
(davunetide) 3
1-1.5 3
PR-interval, 3
PR-interval 3
propranolol's 3
involution, 3
involuted 3
propranolol-responsive 3
.01; 3
cryosurgery 3
ergost-8-enol, 3
SR31747A 3
Exogenously-supplied 3
zymosterol 3
Vps4p 3
AUS1 3
9763S. 3
beta-d-glucosyl-hydroxymethyluracil 3
(JBP2) 3
Tb927.10.6900 3
sequencing-by-synthesis 3
GSNAP 3
Bar-seq 3
samExploreR: 3
(m 3
bootstraping) 3
short-reads 3
CKII 3
30-cM 3
Xp11.21 3
(ALAS2) 3
(COL4A5). 3
splice-sites 3
Dysmorphic 3
philtrum. 3
ID; 3
Xq13.1 3
c.4147G>A 3
(p.Ala1383Thr). 3
chordee, 3
rethink 3
Ipilimumab-Naïve 3
meta-static 3
partitioned-survival 3
postprogression 3
data-including 3
trial-and 3
$63,680 3
perpatient 3
$81,091 3
($68,712 3
life-year) 3
Pellissier, 3
fee 3
bureau 3
fees 3
Chmielowski, 3
Pellissier 3
polices 3
"cost-effectiveness 3
trials-good 3
CHEERS 3
(Keytruda(®)) 3
immunoinhibitory 3
(unresectable 3
metastatic) 3
cohorts) 3
002 3
006. 3
006), 3
immature), 3
BRAF-mutation 3
002). 3
INTERPRETATION 3
calculator, 3
FRAX®-based 3
T-score, 3
numerically, 3
seventy-two 3
20.1 3
10.5%, 3
0.12-0.16). 3
Underestimation 3
≤-2.5 3
4.2), 3
Rs 3
fall? 3
Paramedics 3
(GPs). 3
(usual 3
edition. 3
pre-BMD 3
2005-2009 3
(38/81) 3
(10/81) 3
osteopaenic 3
(12/35) 3
(5/35). 3
70-100%), 3
31-50%), 3
9-27%) 3
90-100%) 3
osteopaenia, 3
C57BL/6NTac 3
5-carboxylcytosine 3
"splicing 3
5metC 3
RNA-map, 3
(68.55%) 3
HP1α. 3
non-outbreak 3
CDI-027, 3
(outbreak 3
Ribotype 3
isolates). 3
Bosnia 3
PPR2 3
ppr2Delta 3
NTP-depleting 3
TFIIS-lacking 3
[rRNAs 3
(RP)], 3
SFP1. 3
NTP 3
Sfp1 3
NTP-depletion, 3
"ground 3
(cluster 3
type-independent 3
oscillates 3
Outside 3
(N-24). 3
(hPer3) 3
clock-gene 3
(Per), 3
Per3. 3
tendencies. 3
cytokines/cytokines 3
(Jakinibs), 3
JAKs; 3
JAK. 3
(TV) 3
DNAJB1 3
co-amplified 3
gen. 3
Prevotella. 3
co-exclusion 3
agrarian 3
H(2)-producing 3
'Prevotellaceae' 3
NER-dependent 3
DVT 3
(aPTT 3
neutralised 3
PCCs, 3
Milek 3
thrombocytosis, 3
Organomegaly, 3
Endocrinopathy, 3
(ODE), 3
(52%). 3
ODE, 3
cystoid 3
perisinusoidal 3
conglomeration 3
'polyneuropathy, 3
lesions'. 3
erythrocytosis 3
castleman 3
immunoelectrophoresis 3
(pass 3
≥125 3
lux 3
<125 3
lux). 3
Graders 3
1011 3
0·3 3
NCT00999609, 3
mITT 3
1·1) 3
(1·0) 3
1·6, 3
0·72-2·41, 3
p=0·0013). 3
lux), 3
product-related 3
transcriptome), 3
(telomeric 3
chromosome-end-specific 3
TLC1, 3
(TRF1) 3
(TRF2), 3
K9me3), 3
DNA-damage-sensing 3
h3 3
Functio 3
Laesa: 3
Resistance. 3
pro-resolving 3
vasodilatation, 3
19th-century 3
Rudolph 3
Julius 3
Cohnheim 3
Elie 3
Metchnikoff. 3
(responding 3
reactants) 3
Blalock, 3
Selye's 3
Dantzer 3
[Between 3
antiquity]. 3
semiotics, 3
doctrine 3
interpretants, 3
(significant) 3
(significance) 3
metaphorical 3
poetic 3
writings 3
Hippocraticum 3
materialistic 3
(4th 3
D.), 3
physiologist 3
D.) 3
fought 3
[see 3
algotherapy, 3
epic 3
poets. 3
Homer's 3
Odyssey 3
(8th 3
hero's 3
Virgil's 3
Aeneids 3
C.) 3
symbolizes 3
defencelessness 3
goddess 3
[Staphylococcus 3
pneumoniae), 3
aureus), 3
aeruginosa), 3
catarrhalis, 3
(p.Ser144Stop). 3
4-generation 3
PDX1. 3
unaffected/undiagnosed 3
Curacao 3
SMAD9 3
(1st-hit) 3
(HHT). 3
cystically 3
cuboidal 3
50%-60% 3
interpreted. 3
tgf 3
85-90% 3
Extra-skeletal 3
sclera, 3
hyperlaxity, 3
proα1(I) 3
proα2(I) 3
PP1B, 3
SP7/Osterix 3
(OSX), 3
prolyl-3-hydroxylase-1 3
(P3H1, 3
cyclophilin-B 3
CRTAP/LEPRE1 3
PPIB, 3
bonafide 3
imperfecta: 3
pro-alpha1 3
pro-alpha2 3
bisphosphonates. 3
Masitinib, 3
5-AzaCdR, 3
locus-wide 3
erased 3
(DMRs), 3
oligo-astheno-teratozoospermia 3
(OAT). 3
DMR. 3
Hyper- 3
(DMR). 3
teratocarcinomas, 3
SV40-induced 3
hepatocarcinomas. 3
1.7-kb 3
ICR; 3
DMR1, 3
usa 3
tg 3
hs4 3
mrna 3
4xmut 3
bone-quality 3
anticatabolic 3
hypogonadal 3
microarchitecture. 3
>RESULTS</b> 3
EBCall 3
depths. 3
JointSNVMix 3
Strelka. 3
udt 3
MuTect, 3
nist 3
tcga 3
cox 3
pik3ca 3
rhoa 3
vacuum 3
"Puffy 3
excipients. 3
users]. 3
(26-37) 3
4.6), 3
(1.5-5, 3
2.3). 3
Duplex 3
Lymphangiography 3
pseudoaneurysm, 3
S1P1, 3
β7 3
amiselimod 3
ligand: 3
MT-1303. 3
siponimod, 3
rp101988 3
qtcf 3
δδqtcf 3
CTA. 3
(corneal 3
OAC-associated 3
hematoma: 3
icu 3
affliction 3
debilitating. 3
spirochetal 3
uvulopalatoplasty 3
laser-assisted 3
LAUP 3
ultraconserved, 3
outgroup, 3
∼3600-∼3800 3
subsampling, 3
passerine 3
Abf1. 3
'memory 3
roadblocks. 3
Nrd1p-Nab3p-Sen1p 3
NNS-terminated 3
non-RPG 3
nutrient- 3
biogenesis: 3
Gene-regulation 3
(CRM), 3
(output). 3
drawn: 3
occupancies; 3
three-state 3
non-Boolean 3
examples; 3
plateaus 3
regimes); 3
mechanistic-to-mathematical 3
nuclesomes 3
obscuring 3
GRFs. 3
erythematous, 3
Non-A, 3
Ganciclovir 3
explorer 3
(td) 3
(AID), 3
auxin-based 3
Shizosaccaromyces 3
Mcm4-aid, 3
F-box-interacting 3
(improved-AID 3
i-AID), 3
(off-AID 3
Pol1 3
off-AID 3
mcm4 3
dermatophytes, 3
Trichosporon 3
Corynebacterium-associated 3
axillae, 3
intertrigo, 3
chloramphenicol; 3
cost-related 3
inoculate 3
folliculitis. 3
dermatomycoses 3
splinters 3
thorns 3
furuncles 3
Corynebacteria 3
dermatitic 3
folliculitis 3
cruris 3
copro 3
sabouraud 3
trichophyton 3
vulva. 3
(SWI/SNF 3
Related, 3
Associated, 3
Chromatin, 3
Subfamily 3
A-Like 3
HARP, 3
immune-osseous 3
Non-hodgkin 3
Marcal1, 3
(trxG) 3
trxG 3
wing-to-haltere 3
242900) 3
SWI/SNF-related, 3
(SMARCAL1). 3
(SIOD) 3
focal-segmental 3
(FSGS), 3
consanginous 3
[SMARCAL1 3
parents's 3
Pathogenicity 3
c.1933C>T, 3
Arg645Cys. 3
G>A. 3
5155 3
glu377gln 3
marcal1 3
pcg 3
≤70, 3
myoclonia 3
"clearcut" 3
fungi-containing 3
myb 3
loh 3
tp53 3
bg 3
palatoplasty. 3
Palatoplasty 3
t(11;22)(q23;q11.2) 3
Chromosome: 3
Der(9)t(7;9)(p22;q22) 3
Rearrangement. 3
t(7;9)(p22;q22)mat 3
non-Robertsonian 3
16,604, 3
der(22)t(8;22)(q24.1;q11.1) 3
der(13)t(13;18)(q11;p11.21) 3
der(21)t(18;21)(p11.21;q11.1) 3
der(13 3
21)t(13 3
21;18) 3
sSMC-cases, 3
non-mosaic. 3
non-mosaic, 3
complex-sSMC-associated 3
placentation. 3
der(22)t(11;22): 3
nine-year-old 3
"Loop 3
"Compartment 3
superenhancers 3
co-localize, 3
≥4-week 3
(ACR)20 3
(≥65% 3
ACR70, 3
ACR-N, 3
(TEAE) 3
(∼40%). 3
NCT01894516. 3
colonic, 3
(3:1) 3
NCT02048618. 3
Galapagos. 3
OKs 3
tumor-site 3
single-target 3
Multi-target 3
CAR-engineered 3
receptor-engineered 3
Genome-Editing 3
CART19 3
Therapy: 3
Pennsylvania-designed 3
(CART-19) 3
(CTL019, 3
tisagenlecleucel-t, 3
Kymriah 3
novartis 3
crispr 3
cas9 3
hetyerogenous 3
(MIDD). 3
4216 3
G3460A 3
m.13046T>C 3
11778G 3
3460G 3
mutation? 3
G13513A 3
pre-excitation 3
Finns 3
LHON, 3
RIO3, 3
AWP1 3
usual. 3
UIM 3
Lys48-linked 3
phosphatidylinositol-phosphate 3
(AtFKBP65) 3
heat-stress 3
fine-scale 3
naïve/primed 3
(YY1), 3
Yy1 3
Beagan 3
2466 3
[aOR], 3
8.26; 3
2.62-26.0); 3
1.24-7.20). 3
10.51 3
4.48, 3
24.66). 3
back-splicing 3
"junk 3
DNA", 3
teleregulatory 3
20-47% 3
"kissing" 3
affectation. 3
liver-kidney 3
genotyping). 3
865 3
(OncoMap 3
hME 3
Genotyping). 3
(A877S), 3
(T41A), 3
(Q61R), 3
(E545K), 3
(R130), 3
(R58*), 3
(R40*). 3
mutation/loss 3
CCs 3
reported/target 3
SMARCB1/INI1-immunonegative 3
miR-671-5p- 3
miR-193a-5p-mediated 3
ccs 3
mirnas 3
precisely. 3
Alu-rich 3
dendrite, 3
from) 3
outwards 3
ndc10 3
nocodazole. 3
rosette, 3
(Sad1 3
(SPB)). 3
Kms1 3
Spo15 3
Cut12, 3
SPB-related 3
(centromere-microtubule-Sad1 3
spb 3
Sub-telomeric 3
relayed 3
proto-silencers 3
cdc6-1 3
Δrif1 3
TPE, 3
"cushioning" 3
cis-elements. 3
TEF2-UASrpg 3
Maxillofacial 3
Prolia 3
(Postn) 3
(Sost) 3
Df(16)A+/- 3
miR-185 3
(HPC) 3
discernment 3
B2m 3
TTR-noPN 3
ATTRm 3
nostril 3
PtGA 3
"apple 3
ProQuest 3
theses 3
A&I 3
(RDI). 3
events/h). 3
54%; 3
4.30, 3
5.13, 3
4.85, 3
47%; 3
621%; 3
2.68, 3
5.05, 3
3.71, 3
1.45, 3
58%; 3
3.10, 3
6.51, 3
3.37, 3
Apnea. 3
(68.5%), 3
hypopnea 3
SACS 3
Populations: 3
Meta-Analysis. 3
>SUMMARY</b>: 3
coughing, 3
(28.1%) 3
(36.8%) 3
66.2% 3
≥30. 3
67.1%, 3
50.6% 3
20.2%, 3
Rhinitis 3
Ø 3
2.5. 3
(34.9% 3
28.5-41.7%). 3
<29 3
price/tariff 3
€12,728/QALY 3
€4,256/QALY 3
health-economic 3
palivizumab. 3
existent 3
rehospitalization 3
micrographs. 3
Vegfc 3
lymphangiogenesis. 3
RESULTS</b 3
AntiHCV, 3
10,000/microl. 3
SGOT, 3
meaningfulness 3
Greek-Cypriots 3
FMF-related 3
Pyrin/Marenostrin 3
Fever. 3
E148Q, 3
S1791 3
DeepBlueR: 3
hypofunctional 3
taller 3
RsaI 3
speckled 3
speckles) 3
sub-speckles 3
EYFP-NHPX 3
"Splicing 3
speckles" 3
polyA(+) 3
mRNA-coding 3
GFPeIF4A-III 3
Subnuclear 3
speckles/interchromatin 3
(POC) 3
432) 3
Sore 3
write 3
(RAT). 3
medicalisation 3
Brussels, 3
PED 3
2118 3
throats, 3
5-16 3
(38.7 3
27.6; 3
1.79) 3
Streptococcus) 3
exudate, 3
nice 3
aflibercept 3
mgmt 3
GSK2586184 3
disparity: 3
indirectly; 3
CLOCK:BMAL1 3
Cryptochrome1a 3
CLOCK:BMAL 3
CRYs, 3
Crys 3
(zCry1a, 3
CLOCK:BMAL-independent. 3
CLOCK:BMAL-dependent 3
zCLOCK3-DeltaC 3
zCry1a. 3
mbmal1 3
withdrawal/re-treatment 3
anti-IL-12/23 3
ax 3
Ustekinumab: 3
(IgG1k) 3
3278 3
(CNTO-1275, 3
Stelara, 3
(ABT-874, 3
Abbott, 3
IL). 3
ABT-874 3
developer 3
antigen-recall 3
IL-12- 3
IL-23-mediated 3
PSUMMIT-1 3
PSUMMIT-2 3
vdH-S 3
phoenix 3
90-mg 3
q8w 3
alectinib-treated 3
Alectinib, 3
(ALCL). 3
ALKis 3
tasquinimod 3
(anti-CTLA-4) 3
(a-PD-1) 3
(pembrolizuamb, 3
nivolumab), 3
PD-1/programmed 3
(PD1-L) 3
auxin-mediated 3
Eucalyptus 3
IAA) 3
suspension-based 3
BDL/IAA12. 3
DR5::GUS 3
tir1-1 3
COI1, 3
SCF(TIR1)-dependent 3
SlIAA15-inhibited 3
SlIAA15-suppressed 3
R2R3 3
crucifer 3
siliqua 3
belive 3
brassica 3
tfs 3
iaa5 3
iaa19 3
iaas 3
chiifu 3
rcbr 3
RESPONSE 3
axr3 3
TaIAA7, 3
TaIAA7 3
AXR5 3
iaa1 3
union. 3
Pygopagus 3
incarnations 3
dicephalus 3
tripus 3
flaps, 3
pygopagi 3
fertilisation 3
conjoining 3
Cephalothoracopagus 3
janiceps 3
midline, 3
tortuosity, 3
slc2a10 3
BCE 3
Butanolic 3
Mycelial 3
Tomato-Wilt 3
Pathogen, 3
tomato-wilt 3
SIX 3
NPF 3
I-2-mediated 3
SIX6 3
WCS365 3
radicis-lycopersici, 3
microbubble 3
vitronectin-enrichment, 3
A172 3
U-87MG 3
Hypoglossal 3
[Hyperviscosity 3
globulins 3
ophthalmologists. 3
standpoint 3
Example 3
Foundational 3
hyperpronation. 3
maneuver. 3
I2, 3
35%). 3
hyperpronation, 3
Hyperpronation 3
pronated, 3
Pulled 3
(nursemaid's 3
elbow) 3
Ultimate 3
(annular 3
displacement) 3
Annular 3
(ALD)--also 3
elbow--can 3
instructing 3
caretakers. 3
pronated 3
Subluxation 3
... 3
pronation. 3
MIO. 3
Trismus, 3
temporo-mandibular 3
anti-IL5 3
Pharmacokinetic/pharmacodynamic 3
pharmacodynamic/pharmacokinetic 3
Afucosylation 3
dislike 3
0·57, 3
Fractures. 3
Retrospectively, 3
DRUJ 3
scapholunar 3
11.8-17.7) 3
4.7%. 3
malunion 3
Healthcare, 3
fixation; 3
comminuted 3
(9/282). 3
(8/24, 3
33%) 3
neurolysis 3
(conservative 3
plating). 3
tendineae 3
declamping 3
secundum 3
LY2951742 3
TEV48125 3
Trigeminovascular 3
Fremanezumab: 3
Antibody. 3
(CGRP-mAbs), 3
(TEV-48125) 3
receptor-2-positive 3
GLS 3
36-73 3
Greenebaum 3
<50%. 3
vinorelbine. 3
RECIST. 3
locally-relapsing 3
re-irradiated. 3
posteromedial 3
intoeing, 3
thrust. 3
physis. 3
4° 3
spica 3
FAT 3
alone) 3
menisci 3
Ilizarov 3
Oblique 3
multi-axial 3
Multi-Axial 3
(Biomet, 3
Parsippany, 3
non-circular 3
placing, 3
managing, 3
fixator. 3
(pre-operative, 3
(MAD), 3
tibial-femoral 3
(TFA), 3
(MPTA), 3
(PPTA) 3
(40.2 3
(15.9 3
medial), 3
(8.0 3
varus), 3
(83.7 3
pin 3
non-union, 3
130.6 3
44.8). 3
120.6 3
21.2). 3
torsion, 3
beaking 3
nucleic-acid-based 3
motor-milestone 3
seeking? 3
self-image 3
(preferendum) 3
notches 3
'audiological 3
rehabilitation' 3
Barcham 3
Stephens 3
(1980). 3
moodiness) 3
personalities. 3
whole-organism, 3
democratized 3
Wiki 3
machine- 3
human-readable 3
favourite 3
worm. 3
Wikipedia, 3
database-driven 3
polished 3
newcomers 3
genomicists. 3
www.nematodegenomes.org. 3
(6/6, 3
61-100), 3
(21/22, 3
78-99), 3
(19/22, 3
67-95) 3
Virologic 3
2017;66:389-397). 3
Japanese) 3
170) 3
two-arm, 3
(100-1200 3
(40-200 3
AUC24 3
1-6) 3
NCT02651194 3
(SURVEYOR-II, 3
ENDURANCE-4) 3
(ENDURANCE-2). 3
98.5-100) 3
97.6-100) 3
reward. 3
orexin-based 3
Belsomra), 3
scaffold-hopping 3
[{(1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl}(4-methyl-[1,1'-biphenyl]-2-yl)methanone] 3
OXB 3
Ox2. 3
M17 3
anion-gap 3
ketones. 3
(Invokana): 3
(DKA), 3
MedWatch 3
19.2- 3
57.8-fold 3
julian.gehring@embl.de, 3
whuber@embl.de 3
citrated 3
TJA-MetS 3
urban, 3
definitions. 3
IRS. 3
(SAM, 3
BMS-984923) 3
Aβo. 3
Aβo, 3
mGluR5-directed 3
91-153. 3
mGluR5, 3
Immunotherapy: 3
Combinations, 3
Outcome. 3
PDL-1, 3
CTLA-4. 3
gastrin-releasing 3
(GRP) 3
radiolabelled 3
(GRPR, 3
NMBR, 3
EMY-98, 3
Z=4.62>Z(0.01)=2.326). 3
perforations. 3
(CINs) 3
Dlx2, 3
(CKOs), 3
CKOs 3
synaptic, 3
PV+ 3
DLX2 3
Gad1, 3
Gad2, 3
Vgat 3
(ATF4). 3
pro-adaptive 3
(ATF4) 3
ATF/CREB 3
(TME), 3
(SGE), 3
anti-Ro/SSA 3
anti-La/SSB 3
hypocomplementemia 3
(95%CI): 3
[6.5-42.5], 3
[95%CI]: 3
210.0 3
[10.0-4412.9], 3
hypochondrium, 3
(CT-scan) 3
contours 3
round-oval 3
CT-scan, 3
prednisone), 3
extraglandular 3
trachea]. 3
MALT-type 3
(pSS), 3
pseudolymphoma 3
pertains 3
677C 3
1298A 3
ideally, 3
donation: 3
living-donor 3
non-donors. 3
(<0·5% 3
wages, 3
regrets 3
1589 3
(5.7% 3
(4.3% 3
post-donation 3
predonation 3
(13.3%), 3
Prolactinoma: 3
Z-score. 3
[Hyperprolactinaemia 3
density]. 3
pituitary.The 3
mamotrophic 3
lactogenesis. 3
galactorrhea 3
gynecomasty, 3
homone 3
Hyperprolactiaemia 3
hypoestrogenism 3
hyperprolactinaemia). 3
Hyperprolactinaemic 3
MEDPRESS. 3
lactotrope 3
(QUS) 3
os 3
calcis, 3
QUS: 3
(BUA), 3
(SOS) 3
Z-scores. 3
30.53 3
7.8): 3
I--32 3
II--43 3
(33.59 3
4.7). 3
DXA. 3
unfavourably, 3
<b>INTRODUCTION</b>: 3
>CASE 3
PrP(CWD) 3
CWD-infected 3
moose. 3
hunter 3
virginianus). 3
Shedding 3
96GG 3
TSEs 3
antepartum 3
burdensome 3
Kir3.2 3
14-18 3
(14; 3
Aneuploidy 3
Tc1/Ms2Yah 3
foetuses 3
Craniosynostosis. 3
Craniosynostosis: 3
microspectroscopy 3
flares. 3
SLEDAI. 3
LFA-REAL 3
REAL 3
SLICC/ACR 3
nephritis. 3
Fine-needle 3
CD30, 3
Lung-molGPA 3
(ALK(+)) 3
ALK(+) 3
X-376 3
EML4 3
(EML4) 3
understandings 3
ALK-positive. 3
(EML4)-ALK 3
t(2;5)(p23;q35) 3
Neuroblastoma, 3
F1174L 3
VCL-ALK 3
autoactivation 3
NPM/ALK 3
CAP; 3
Respirology. 3
(NIMV), 3
MRproADM 3
0.011); 3
significance). 3
Mr-pro-ADM 3
76.5%; 3
77.8%) 3
88.9%; 3
77.0%; 3
87.5%) 3
NIMV; 3
88.7%; 3
intubation; 3
53.5%; 3
70.6%) 3
82.1%; 3
55.3%) 3
81.29% 3
[63.41%-99.17%], 3
87.58% 3
[75.54%-99.62%], 3
PSI, 3
MELD. 3
sickest 3
Jaffe 3
<0, 3
0-6.9, 3
7-13.9 3
haemodialysis; 3
MELD-MDRD-6 3
p=0.03), 3
bone-acting 3
(SERM). 3
(SERMs). 3
RLX 3
flushes. 3
SPRM 3
virilism 3
lasofoxifene, 3
alaninate, 3
DT56a 3
AI/SERM 3
SERM-treated 3
TG2, 3
Sarcoidosis. 3
memorize 3
non-DBT-based 3
lobe/supramarginal 3
perigenual 3
neutral) 3
self-directedness 3
Dialectical-Behavior 3
(BPS). 3
(BPD). 3
psychiatrists-in-training 3
Pain-mediated 3
emotion-regulating 3
(DBT), 3
"dialectical 3
therapy" 3
FEN-1 3
PolI 3
PolN 3
FENs 3
flaps. 3
clamps. 3
SaFEN 3
iRNA 3
PGPR 3
green-oat 3
GOE 3
pearl 3
millet 3
monosomes 3
Lrk10 3
SAs 3
amine-like 3
KOH 3
p24-positive 3
98%) 3
(99.7% 3
AHI, 3
4th-gen-EIA 3
30,201 3
LIA 3
MTN-003 3
Determine™ 3
Alere™ 3
sub-districts 3
test-negative 3
fifth-generation 3
pulley 3
[Finkelstein's 3
tenosynovitis]. 3
deviation. 3
miners, 3
dust. 3
universalisable 3
four-principle 3
rulings 3
"four 3
strong; 3
travellers, 3
(HEMn-DP) 3
nonphotosensitive 3
sparfloxacin, 3
fenbrufen, 3
prochlorperazine 3
maleate. 3
Oracea 3
Anti-inflammatory-dose 3
gyrus; 3
lastingly 3
hippocampal-related 3
hilus 3
thermometer 3
Ichthyosiform 3
Bhubaneswar, 3
pathoradiological 3
nonsmoking 3
uveoparotid 3
HLA-DRB1* 3
co-evolutionary 3
RIDGEs 3
hoxb3a/Hoxa3 3
antiplatelet-only 3
HELEX® 3
Occluder) 3
post-randomization 3
infarct) 3
subject-based 3
multiplicity. 3
confounding. 3
occluders 3
registration-URL: 3
http://clinicaltrials.gov/show/NCT00738894. 3
StereoGene: 3
StereoGene, 3
binarization 3
Validated 3
Hepatitis: 3
Alcohol-associated 3
hyperlipidaemia, 3
(ZS), 3
hyperlipoproteinaemia, 3
remittent 3
stromal. 3
[IRR 3
PsO 3
PsC. 3
topicals, 3
3'-extremities. 3
non-adenosine 3
mRNA's 3
trans-splicing/polyadenylation 3
monocistronic 3
A+ 3
vRNA 3
13' 3
11' 3
half-molecule 3
near-universal 3
chondromas. 3
periodically. 3
extradrenal 3
SLMs 3
paraadrenal 3
components-the 3
tumors-are 3
1977, 3
(Prevention 3
preDIVA 3
nurse-led, 3
cluster-randomised 3
DAPA 3
(Forxiga) 3
Forxiga 3
SFTP 3
hypoinsulinemic 3
14.5×9.0×9.0cm 3
overnight. 3
(TFSP). 3
TFSP 3
rabies: 3
blood-spinal 3
(PMLOs), 3
DPRs 3
2050, 3
(ChEI's) 3
Alzforum 3
normo-weight 3
chocolate, 3
cocoa/ 3
cocoa-rich 3
(rich 3
polyphenols) 3
Lung, 3
Luxembourg 3
flavanol-rich 3
flavanol 3
berries 3
high-polyphenol 3
chocolate/cocoa 3
1155 3
hsa_circ_103110, 3
hsa_circ_104689 3
hsa_circ_104821 3
0.73-0.90) 3
RNA-sequence 3
885) 3
multi-threaded 3
"Achenbach 3
syndrome") 3
haematomas, 3
reassure 3
alarmed. 3
(crenezumab, 3
(intepirdine), 3
(E2609, 3
AZD3293, 3
verubecestat), 3
(TRx0237) 3
Panencephalitis: 3
measles-specific 3
SSPE-associated 3
PNG 3
immunised 3
uncharacteristic 3
Host-induced 3
(HIGS) 3
plant's 3
enacted 3
VEGFR1-3 3
FGFR1-4 3
BGJ398, 3
BGJ398 3
PD173074, 3
BaF3 3
FGFR2-mutant 3
FGFR2-mutated 3
sorafenib-resistant 3
Tumor-take 3
tumor-forming 3
(PGB) 3
vesicles-genetically 3
microbes-have 3
harmonic, 3
multiplexed, 3
(speA) 3
erythromycin-resistant 3
scarlatiniform 3
Morphologically 3
(TSLS). 3
tonsillopharyngitis, 3
banking 3
stressor-exposed 3
stressor-induced 3
non-stressed 3
rodentium. 3
EPEC 3
(Actoxumab-Bezlotoxumab) 3
Facilitates 3
non-antibiotic 3
FGF13, 3
Nucleostemin 3
Dolzhenko 3
sheddase. 3
dystonias, 3
Eculizumab, 3
GPI-AP 3
BCS 3
PVT. 3
PVT, 3
CD16 3
CRAO 3
CD59-deficient 3
Cheyne-Stokes 3
hypoxemia, 3
bradyarrhythmias. 3
nonapneic 3
uPARAP/Endo180 3
osteopetrotic 3
sealing-zone 3
Radiochemotherapy 3
26082). 3
26082 3
methylguanine-DNA-methyltransferase 3
chemo-radiotherapy 3
(OS12). 3
>38 3
noncomparative 3
OS12 3
standard-treated 3
(95.5%). 3
OS12. 3
0.13; 3
0.04-0.47; 3
37.6%, 3
benefitting 3
4797-806. 3
proteoforms, 3
(aka 3
2699 3
0.53). 3
Aβ42-induced 3
Sost/sclerostin 3
(rhSCL) 3
MEPE-ASARM 3
co-addition 3
ECR5 3
sost 3
RAB10, 3
Palmitoylation-dependent 3
MC1R-targeted 3
palmitoylation. 3
C57BL/6J-Mc1re/eJ 3
terminated, 3
(pQTL). 3
reflex: 3
triggered, 3
ways; 3
FoundationFocus 3
(Rubraca™) 3
(Boulder, 3
5·4 3
nonallergenic 3
Lasso 3
ProteinLasso 3
specifications. 3
EXTRACTION 3
nephrogenic 3
In-utero 3
anomaly; 3
ARIA-H 3
verubecestat-treated 3
ribosome-bound 3
Ribosome-bound 3
(RQC), 3
polyubiquitylates 3
escorts 3
43.9) 3
bypassing-agent 3
prophylaxis; 3
HAVEN 3
NCT02622321 3
VIII. 3
Masters 3
ubiquilins 3
Ubiquilin's 3
Pentatomidae). 3
Jersey 3
railroads 3
pentatomid 3
pheromone-baited 3
Climate 3
horticultural 3
roseola, 3
(fifth 3
Mozambique 3
(10/99). 3
Colonization. 3
gallbladder-associated 3
pre-malignant 3
gallstones, 3
establishment/maintenance 3
Bessman 3
(MCV2 3
Gambiense 3
throughout, 3
benznidazole-treated 3
(DNDi) 3
short-course, 3
(HAT). 3
Randomised-controlled 3
(humanised 3
glucocorticoid-free 3
taper. 3
(TAK) 3
Abatacept 3
SCFFbxo7 3
HTTExon1 3
(altEJ) 3
"theta-mediated 3
end-joining." 3
helicase-like 3
sofosbuvir/velpatasvir/voxilaprevir 3
Nkx2.1-Bmal1-/- 3
affordability 3
QVZ 3
micro-opioid 3
luminesce 3
whole-animal 3
OSNs 3
endocortical 3
(IL-11) 3
Il-11 3
ACDC 3
(V/Q) 3
17beta-HSD1 3
(Tecfidera™) 3
payers' 3
suggestions. 3
unpleasant, 3
terrifying 3
lights 3
hypnic 3
Crenezumab, 3
N‑truncated 3
5XFAD, 3
Tg4-42, 3
TBA42, 3
APP/PS1KI, 3
3xTg. 3
Aβ3-42, 3
Aβ1-42. 3
bronchopleural 3
Bullous 3
emphysema. 3
Ludhiana 3
traceable. 3
hemithorax, 3
subpleural 3
Trispecific 3
(calciphylaxis) 3
Nonuremic 3
breathed 3
(FGF21) 3
FGF21, 3
cullins, 3
deneddylases 3
deneddylation. 3
NEDD8-specific 3
neddylation) 3
sometimes, 3
(atypical 3
neddylation). 3
CRL5 3
MDSC-like 3
thrombopoietin 3
DIRAS3. 3
α-MHC 3
softwares 3
TargetScan. 3
(VICs) 3
H19-induced 3
DUSP5/ERK1/2 3
DUSP5/ERK1/2. 3
UTC 3
ch14.18-NCI 3
(MoAb) 3
GD2. 3
3F8. 3
cytoxicity 3
Transverse 3
neuroblastoma: 3
(ANBL0032) 3
adaptor-ligated 3
50-nucleotide 3
DNA-Binding 3
(ChIP-exo). 3
(ChIP-exo) 3
Method: 3
Protein-DNA 3
Precision. 3
h-IBM. 3
COX-deficient 3
rejoin 3
section) 3
(QFP), 3
GSIS. 3
asylum 3
(TST) 3
pneumological 3
INF 3
CCL11, 3
23). 3
Olink), 3
enlimomab. 3
(OR=0.91, 3
P=0.30), 3
P=0.85), 3
(OR=0.98, 3
P=0.82) 3
citicolne 3
citivoline 3
(CDP-choline) 3
g/kg), 3
intraperitoneally. 3
CDP-choline, 3
hLOXL2 3
Asn-644 3
Metformin. 3
CFS/ME 3
CFS/ME, 3
SNS 3
non-protein-coding, 3
"recursive 3
splicing," 3
re-splicing 3
points--5' 3
recreated 3
splicing-a 3
donor-acceptor 3
RP-sites. 3
LINEs) 3
dermo-epidermal 3
poly-ether-ether-ketone 3
(PEEK) 3
sternotomy 3
(CWs) 3
6.1%, 3
CW). 3
0.067, 3
0.04-9.16, 3
P=0.72). 3
4/31 3
Wire 3
cost-consuming 3
AR-regulated 3
II)-based 3
Dom34/aPelota 3
Trpm2-/- 3
melastatin-2 3
antigen-stimulated 3
MMCs. 3
Ca2+-permeable 3
TRPM2, 3
TRPM2-AS 3
prM 3
serine-to-asparagine 3
PhenCode: 3
(Phenotypes 3
ENCODE; 3
http://www.bx.psu.edu/phencode) 3
SP3, 3
(SCNAs) 3
SCNAs 3
7,416 3
pan-cancer 3
IRS4, 3
SMARCA1 3
intersecting 3
super-enhancer, 3
DiseaseEnhancer 3
enhancer-driven 3
efinaconazole 3
lacquer. 3
tavaborole 3
"tinea 3
capitis. 3
dermatomycosis 3
30-year 3
Microsporum 3
Dakar 3
Df(4)B2-2D, 3
BAC-based 3
Bedlington 3
LCRs. 3
(BMP2-OP1-responsive 3
AGCCC 3
(ATAC-seq). 3
structure-to-function 3
3C-based 3
introduce, 3
"i3C", 3
osteoclast. 3
carcinoembryonic 3
(CEA), 3
(DCIS 3
G3). 3
paramyxoviral 3
nipple. 3
Lys70 3
K562, 3
Parkinson´s 3
(RP)S19 3
'grammar' 3
(CTS). 3
CTS. 3
VO-induced 3
BAPN 3
Zelitrex), 3
L-valine 3
aciclovir, 3
anti-herpesvirus 3
(Zovirax((R)), 3
(Denavir, 3
nongenital 3
zoster) 3
L-valyl 3
(Zovirax, 3
galaxolide. 3
amyl 3
eugenol, 3
Galaxolide, 3
mercaptans, 3
1573). 3
Galaxolide 3
(OR7D4, 3
266). 3
(UVR). 3
Eumelanin 3
phaeomelanin, 3
UVR, 3
tans 3
(MC1R, 3
(45.2%), 3
(24.8%), 3
(0.9%), 3
3.77; 3
2.11-6.78), 3
1.45-3.52), 3
3.43; 3
1.92-6.15), 3
Asp84Glu, 3
His260Pro, 3
Val60Leu, 3
Val92Met, 3
Arg142His, 3
Arg151Cys, 3
lightening 3
GWA 3
red-headed 3
red, 3
Tibet 3
(E(D1)). 3
c.157G 3
ColE1. 3
Plateau 3
(TBN) 3
(HAN) 3
(HAAs) 3
"dominant 3
carrier" 3
HAA. 3
(EPAS1) 3
homozygosity-based 3
highland 3
(rs186996510, 3
D4E) 3
lowlander 3
(Fst 3
0.709 3
(0.56-2.27%), 3
Neutrality 3
(∼8,400 3
rs186996510 3
acclimatized 3
(45.6 3
rs4786504:T>C 3
rs4786504 3
HMOX2, 3
admixture-mediated 3
BAT-based 3
diet- 3
psychopathic 3
Impulsivity 3
(G×E) 3
G×E 3
Scale-11 3
(BIS-11) 3
individuals: 3
group×genotype×abuse 3
(F(2,49)=4.4, 3
p=0.018), 3
(t(1,36)=2.3, 3
p=0.025). 3
Symptoms, 3
Suicidality, 3
suicidality, 3
(3-5) 3
Brown-Goodwin 3
Aggression, 3
47.9% 3
59.8% 3
psychobiological 3
(MAOA-H) 3
emotion-processing 3
LORETA. 3
120-280ms 3
post-stimulus, 3
temporo-occipital 3
threat-related 3
Monoamines 3
Non-linear 3
(T941G) 3
COCAPHASE 3
UNPHASED 3
(chi=4.696, 3
P=0.03) 3
(chi=5.089, 3
offender 3
offenders. 3
antisocial, 3
rs1799836 3
Nkx2.2 3
caldophilus 3
GK24 3
SAHA-BPyne, 3
H4S47 3
(cenH3 3
H4s 3
unpositioned 3
PPMO 3
YFV-DakH1279 3
red-green 3
colour-vision 3
TUMS 3
cricketers 3
batting 3
27-OHC 3
EUG 3
Hs578t 3
TNF-α-stimulated 3
fibrocyte-secreted 3
HPSCs 3
tipranavir/ritonavir 3
c29B 3
loss/degeneration 3
monocentric 3
dicentrics 3
relicts 3
apes, 3
IIq. 3
Gorilla 3
CMT1A-REP. 3
(Pradaxa®) 3
(Lixiana®) 3
VII, 3
oleifera 3
BRL 3
formalin-evoked 3
Swim 3
formalin, 3
Ce 3
Clove 3
triskelion, 3
insulates 3
melitensis 3
Brucella. 3
abortus, 3
MAPK/NF-κB 3
meliloti 3
lectin-like 3
IL-12/β2-m 3
3p21.31 3
metacarpophalangeal 3
Dupuytren 3
admissions. 3
dendricity 3
melanocortins 3
(eumelanin) 3
red/brown 3
coatomer 3
(COPA), 3
p.R142H, 3
HD1B 3
TOGs 3
TOG5-specific 3
Assay. 3
CL1-5, 3
KLF5. 3
Anticoagulants. 3
Weber-Cockayne 3
Köbner 3
PLEC1. 3
hemidesmosomes, 3
P24L 3
EBS-MP. 3
(KRT14). 3
Verrucous 3
Dowling-Meara, 3
epidermolysis. 3
blistering. 3
K5 3
releasates 3
ratti 3
anti-helminth 3
Fc&#949;RI-bound 3
FceRI. 3
SLC10A4 3
perennial 3
Solar 3
long-wavelength 3
rhythm; 3
(holiday 3
fibrillation--rheumatic 3
stable? 3
timolol, 3
(chronic). 3
AXIN1 3
amastigotes. 3
infantum 3
presentations: 3
digenetic 3
phlebotomine 3
Sb(III) 3
(VL). 3
Leishmaniasis, 3
ZINC29590262 3
3-oxoacyl-ACP 3
UDP-galactopyranose 3
UGM 3
mexicana 3
Lankan 3
zymodeme 3
peruviana 3
(RAPD-PCR) 3
Warfarin-antibiotic 3
warfarins 3
coumarins 3
NNRTIs 3
PBP 3
oxacillin. 3
oxacillin, 3
ST1 3
beta-lactamase. 3
(BORSA 3
BBL 3
DVD--5 3
(UPD7), 3
DVD, 3
DVD. 3
underexpressed. 3
Foxp2+/- 3
non-disease-related 3
Hirschsprung, 2
RET-SOX 2
intestine) 2
Midtrimester 2
amniography. 2
amniography 2
(rs2435357). 2
v.17.0 2
"enhancer" 2
91.66% 2
cyclase-activating 2
STAT5, 2
non-differentiated 2
AREG. 2
(PI3K)-AKT 2
hMEC 2
A>G, 2
rs9996584 2
C>T) 2
C>A 2
PI3KCA 2
Betacellulin 2
(BTC) 2
binding-EGF 2
ligands' 2
TACE-dependent 2
EGFRs 2
(EGF, 2
[TGF-α], 2
amphiregulin, 2
epigen) 2
sub-nanomolar 2
dipeptidase 2
dipeptides 2
(93.3 2
mCRC. 2
epiregulin. 2
Tyr1045 2
Y1045F 2
z-cbl 2
c-cbl 2
Tyr992. 2
Y992F 2
Amphiregulin 2
P<0.01; 2
78.5 2
19.3 2
epithelial-derived 2
HB-EGF. 2
juxtacrine 2
(AREG), 2
epigen. 2
co-opted 2
FOS-1A 2
Daughterless 2
HLH-2: 2
cdh-3, 2
mig-6/papilin 2
him-4/hemicentin. 2
AC, 2
hermaphrodites 2
(MIG-6L) 2
(MIG-6S) 2
MIG-6 2
amino-end 2
papilins 2
carboxyl-end 2
F-spondin, 2
UNC-5, 2
ADAMTS, 2
TRAP) 2
thrombospondin-1 2
IgC2 2
gastrulation, 2
hemocytes, 2
space-filling 2
non-competitively 2
glutactin, 2
Kc 2
papilin. 2
cross-reacted 2
electrophoresed 2
glucosamine, 2
(lincRNAs), 2
(ancRNAs), 2
tree-based 2
PDF 2
http://www.bioinf.uni-leipzig.de/publications/supplements/10-010. 2
HM587422-HM587426. 2
628 2
rRNAs, 2
(TRAIL). 2
binding-independent 2
12-O-Tetradecanoylphorbol 2
nd 2
Adipocytes 2
MC3T3/RAW 2
Factor-kB 2
factor-kappaB-ligand 2
TNFSF11, 2
Saos-2, 2
RANK, 2
OPG, 2
(OVX), 2
abortus-infected 2
(BMMs) 2
abortus-activated 2
occured 2
(M-CSF). 2
Anti-diabetic 2
Absorption. 2
(TT4) 2
metformin-naïve, 2
(pre-metformin 2
3893 2
post-metformin 2
588 2
(miRNA), 2
(miR-200a, 2
MiR-200a, 2
MicroRNA-203 2
(miR-203), 2
promotive 2
65.38 2
(102/156) 2
III+V) 2
I+II) 2
(FIGO) 2
Advanced-stage 2
(OSC) 2
OSC. 2
768 2
microRNA-200 2
(miR)-182, 2
0.0005 2
0.784). 2
inhibitor-transfected 2
(PLK1) 2
EOCs. 2
EOCs 2
2-ΔΔCT 2
correlation). 2
0.29-0.96) 2
(0.26-0.89) 2
1.28-11.66) 2
3.48 2
1.25-9.67) 2
[adjusted-HRs 2
0.15-0.66) 2
0.22-0.75) 2
disease], 2
relapsers 2
let-7i) 2
cis-platinum. 2
bank. 2
Trizol 2
miRNAs-21, 2
abstract. 2
neostigmine, 2
depriving 2
justify. 2
thymectomy, 2
denosumab: 2
vertebroplasty? 2
(XGeva) 2
(RANKL)-antibody 2
appearance), 2
11-gauge 2
vertebroplasty. 2
RANK-ligand 2
Denosumab: 2
(GCTB) 2
osteoclast-like 2
scheduling, 2
factor-kB 2
(Prolia®) 2
Sates 2
(RANK) 2
GCTB, 2
(ZA), 2
bisphosphonate, 2
Radium-223, 2
[Bone 2
(tanezumab). 2
AHRQ's 2
(aledronate, 2
(raloxifene), 2
denosumab(approved 2
familiarize 2
androgen-deprivation 2
(FDA)-approval 2
bone-targeting 2
MDV3100 2
aflibercept, 2
SRE, 2
SREs, 2
wholesale 2
17.5%, 2
2010s 2
(denosumab, 2
(brentuximab 2
vedotin) 2
(bone-targeted 2
Prolia(™), 2
Oaks, 2
(Prolia(®)) 2
zoledronate, 2
attention; 2
x-ray. 2
(FDA). 2
(Dvl/Dsh) 2
multi-module 2
Dvl1(-/-) 2
Dvl2(-/-) 2
craniorachischisis, 2
Resequencing 2
submucous 2
(Dvl) 2
divergent, 2
dsh-homologous 2
DVL-3. 2
(wg, 2
Wnt-1), 2
695-amino-acid 2
dsh. 2
DVL-1; 2
(GSK3). 2
Dishevelled-1 2
Wnt-overexpressing 2
(PC12/Wnt). 2
Dvl-2 2
SQ-PCR 2
underexpression 2
pyriform 2
paraneoplastica): 2
primary. 2
erythemosquamous 2
Esophagogastroscopy 2
ulcerovegetant 2
APB 2
improving, 2
Bazex: 2
adenopathy, 2
paraneoplastica: 2
paraneoplastica, 2
dermatologists. 2
tonsil. 2
paraneoplastica) 2
class- 2
(Vaughan 2
A-C, 2
NOTCH3. 2
C49Y 2
NOTCH3-luciferase 2
NOTCH-regulated 2
fuction. 2
Notch1-3 2
Numb, 2
(Notch1-4) 2
(Delta1 2
Jagged1) 2
hepatoblastoma. 2
Notch2. 2
NRR 2
There, 2
senescence: 2
clearer, 2
reset, 2
passage) 2
countries-cancer, 2
dementia--are 2
precedents. 2
Cu/Zn-superoxide 2
H2O) 2
Cip1 2
NTERPRETATION: 2
ARN-509, 2
ODM-201) 2
(galeterone). 2
Rhenium-188-labeled 2
emitter, 2
Rhenium-188 2
(Re-188). 2
(Re-H), 2
Her2/p-Her2 2
Tendencies 2
3+), 2
HER2-positive. 2
EGFR- 2
ErbB2, 2
ErbB2: 2
(trastuzumab), 2
2C4 2
(pertuzumab) 2
anti-ErbB2-compact 2
Erb-hcAb. 2
2C4. 2
(BUN), 2
xenografts: 2
111In- 2
125I-labeled 2
affibody. 2
Radionuclide 2
7-kDa) 2
HER2-binding 2
(125)I 2
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 2
maleimido 2
CHX-A″ 2
diethylene 2
triamine 2
pentaacetic 2
radioiodination 2
[(125)I]-N-succinimidyl-para-iodobenzoate 2
residualizing 2
(111)In-label 2
[(111)In]-ABY-025 2
7.1±0.8% 2
ID/g) 2
47±13 2
[(111)In]-CHX-DTPA-trastuzumab 2
11±4% 2
ID/g 2
18±7. 2
gamma-camera 2
Residualizing 2
nonresidualizing 2
radiohalogen. 2
ErbB3. 2
(AWT); 2
LNCaP-AI 2
C4-2. 2
pRNS-1-1 2
(AR-T877A), 2
AG879. 2
ErbB4); 2
CHX-A″DTPA-trastuzumab 2
testosterone-driven, 2
(hormone-refractory) 2
(LNCaPdcc), 2
androgen-deprived 2
phospho-Ser(81)-AR, 2
(R1881) 2
phospho-Tyr(1221/1222)-Her2, 2
ErbB4 2
Ser(81) 2
trastuzumab-bound 2
ErbB-3 2
(Her-3) 2
ErbB-4 2
(Her-4). 2
(trastuzumab/Herceptin™ 2
cetuximab/Erbitux™) 2
(gefitinib/Iressa™ 2
erlotinib/Tarceva™). 2
Lapatinib 2
(Tykerb™), 2
EGFR/ErbB-2 2
ErbB-2-positive 2
gefinitib 2
HER2: 2
HER2-targeting 2
CHX-A"-DTPA 2
chelate:protein 2
Radiolabeling 2
radioimmunoconjugate, 2
(51.18 2
13.58) 2
(SKOV-3) 2
(A375) 2
111In-HuIgG 2
130.85 2
273.34 2
γ-scintigraphy 2
Alabama. 2
HER-2. 2
payload-conjugated 2
p-AKT 2
docetaxel/trastuzumab 2
Anti-HER2 2
Cremophor 2
immunoemulsions, 2
hydroalcoholic 2
immunoemulsion. 2
cystic/basal 2
HER-2/neu. 2
extraprostatic 2
(trastuzumab) 2
HER2-directed 2
trastuzumab-RT 2
(Western 2
fmol/mg 2
RX 2
(HRPC). 2
immunoradsorbent 2
trastuzumab/docetaxel 2
HPRC 2
specimen/not 2
nonfeasibility 2
40-patient 2
(Herceptin). 2
Herceptin. 2
alpha-conjugate 2
overexpression/amplification 2
Archival 2
artifact, 2
Docetaxel, 2
docetaxel/estramustine 2
(AIPC). 2
unacceptable. 2
>50%. 2
taxane, 2
Low-molecular-weight 2
HER2/neu. 2
reasonable. 2
[Herceptin; 2
CA]). 2
anti-Her-2/neu 2
anti-EGF 2
C225 2
ips 2
source-peripheral 2
blood-has 2
oriP/EBNA1-based 2
(SFFV) 2
CD3(-)/CD19(-) 2
T/B 2
cell-depleted 2
MNCs 2
banking, 2
(Dox). 2
MLL-AF9, 2
STX-0119, 2
STX-0119. 2
Olig2, 2
SOX2) 2
(SeV) 2
CytoTune™ 2
non-integrating 2
zero-footprint). 2
Laurence 2
Daheron 2
Sunita 2
D'Souza. 2
(HMGA1) 2
ECCs 2
HMGA1-derived 2
LIN28, 2
cMYC, 2
(DNp73). 2
generation? 2
DNp73(actually 2
DNp73α) 2
Lentivirus-mediated 2
(Pou5f1, 2
"Yamanaka 2
donors; 2
premortem 2
efficiency-improving 2
modular. 2
phosphatase-positive 2
lenti-viral 2
(AP+) 2
(AP+/-) 2
(AP-) 2
AP+/- 2
AP- 2
TRA-1-60, 2
TRA-1-81, 2
SSEA-3 2
SSEA-4 2
(SOX2, 2
OCT3/4, 2
mEFs, 2
PhosphoSitePlus 2
C-HPP. 2
proteogenomic 2
chromosome-centered 2
(B/D-HPP) 2
IAB 2
governance 2
colocated 2
-omics 2
universities, 2
organized, 2
organ-based 2
7092 2
3282 2
20,859 2
neXtProt. 2
(HPP, 2
www.thehpp.org 2
S/N 2
(B/D-HPP). 2
870 2
http://www.c-hpp.org 2
NAPPA 2
GenomewidePDB, 2
GenomewidePDB 2
N-glycosylated 2
Cx43-/- 2
(approved 2
Cx43, 2
pannexin1, 2
connexins, 2
(Panx) 2
Panx1-mediated 2
ectonucleotidases 2
ADP, 2
[K(+)]o 2
open-channel 2
anion-selective 2
~500 2
reactivities 2
Single-particle 2
(Panx2) 2
Pannexins 2
Pannexin3 2
(Panx3) 2
glycosylated, 2
MDCK, 2
N-glycosylated, 2
Panx2, 2
olivaceus, 2
mariculture 2
PoPanx1 2
6.46. 2
(PAMPs; 2
LPS) 2
anguillarum. 2
PAMP-induced 2
large-pore 2
Preserved 2
"gap 2
hemichannel-like" 2
space; 2
T-tubules. 2
Myocerebrohepatopathy 2
(MCHS), 2
(MEMSA), 2
(arPEO), 2
(POLG), 2
disease-autosomal 2
ophthalmoplegia-and 2
defective, 2
ataxia-neuropathy 2
3D-structure 2
dysphagia/dysarthria. 2
POLG. 2
p.T851A 2
encephalomyopathy. 2
(TP). 2
MNGIE 2
b.p.m. 2
897; 2
5.6%) 2
0.023); 2
CSAP 2
population). 2
life-limiting 2
·day(-1) 2
(sham 2
63.1 2
SCCF 2
HR-lowering 2
(46%), 2
<40% 2
10,917 2
(Iva), 2
(AT(1)) 2
AT(1) 2
heart-rate-reducing 2
HRR, 2
incompetence, 2
filling, 2
(-18% 2
geometry, 2
(tremor, 2
penicillamine 2
(WD), 2
hepatolenticular 2
(HSD), 2
neuroacanthocytosis, 2
dopa-response 2
(DRD). 2
Lafora 2
dentato-rubro-pallido-luysian 2
(PANK2) 2
20pl3 2
"eye-of-the 2
non-Indian 2
toxicosis, 2
WD; 2
micromol 2
copper-related 2
nonceruloplasmin 2
caeruloplasmin. 2
caeruloplasmin 2
(hepatolenticular 2
Dermatoglyphics 2
Cu-67, 2
52.7% 2
hypothenar 2
Nascent-seq 2
∼3% 2
posttranscriptional. 2
=90% 2
posttranscriptional, 2
snRNP-associated 2
U5 2
protein-DNA, 2
protein-RNA, 2
cotranscriptional. 2
(capping 2
cleavage/polyadenylation) 2
humeral 2
shortened. 2
3.3kb 2
4q35) 2
FSHD--consisting 2
Coats-like 2
Coats 2
fascioscapulohumeral 2
Becker's 2
dorsiflexion. 2
exonal 2
sarcoglycanopathy 2
Brooke 2
Consensual 2
thigh, 2
Extrapolating 2
nonlinked 2
(RASSF1A, 2
CYCLIND2, 2
RARbeta, 2
hypermethylated. 2
(p=0.04, 2
p=0.02, 2
p=0.005 2
p=0.046, 2
(TRN), 2
(JUN) 2
TG(CSQ). 2
JUN 2
(TrD) 2
(JnC), 2
thapsigargin. 2
calsequestrin) 2
64%) 2
6-, 2
n=6-8, 2
Asp4878, 2
Asp4907, 2
Glu4908 2
SR-proteins, 2
relaxation: 2
Ba(2+) 2
1-overexpressing 2
Hz), 2
l-type 2
choline-related 2
homogenized 2
chloroform/methanol/water 2
Recoveries 2
analytes. 2
(31)P 2
C₁₈ 2
Hydrophilic-interaction 2
(doubly 2
bioanalysis, 2
glycerophosphocholine 2
lysophosphatidylcholine 2
LPC, 2
Hydrophilic 2
Chromatography 2
cytostatics, 2
phenylurea 2
pro-TRH 2
(10(-4) 2
(10(-7) 2
augmentative 2
0.1-10 2
mumol/l 2
(11.1 2
(MAP), 2
dp/dtmax, 2
Vpm 2
reserpine 2
i.v.), 2
(Sphe3). 2
non-motile, 2
polluted 2
quinaldine-degrading 2
pARUE113 2
pARUE232 2
lignin 2
4-hydroxyphenylacetate 2
Datong 2
Basin, 2
arsenic-contaminated 2
B6. 2
tolerates 2
ofArthrobactersp. 2
Jilin 2
announce 2
human-pathogenic 2
4.6-Mb 2
nylon 2
oligomer-degrading 2
psychrotolerant 2
Rothera 2
Point, 2
chitinolytic 2
pi-helix, 2
piD 2
H4-AcK12 2
H4-AcK12. 2
(bromodomains 2
CDK8 2
TRAP220, 2
BD2), 2
Lys12. 2
crystal. 2
left-handed, 2
alphaZ 2
H3-AcK14 2
(KD 2
sterically 2
side-chains 2
up-and-down 2
acetyltransferase. 2
dilatations 2
myotomy, 2
318.5 2
282.0-393.0 2
436.9 2
312.6-602.5 2
0.0987). 2
84,000 2
16,000-143,000 2
177,000 2
114,000-244,000 2
0.0707). 2
0.0-94.7 2
0.0-60.2 2
0.8826). 2
nonautistic 2
mL/min). 2
(RSD) 2
percutaneously. 2
"renal 2
denervation" 2
re-innervation 2
reductions: 2
HTN-2 2
32/12 2
hypertension". 2
opportunity. 2
rising. 2
diuretic) 2
pressure-lowering 2
cell-impermeable 2
extracellular-regulated 2
182780. 2
E2-BSA 2
Citalopram 2
protoapigenone 2
(MMP-2), 2
reversion-inducing 2
production-stimulating 2
canceled 2
Sinodielide 2
thermosensitizing 2
Yunnan 2
antipyretic, 2
(%) 2
44˚C 2
(ERK1/2). 2
(qPCR). 2
osteoblast-related 2
SK-MEL-3 2
WM164, 2
JNK1. 2
SP600125, 2
(LVEDP), 2
Catecholamine 2
TRM 2
docosahexaenoic 2
(DHA) 2
NF-E2-related 2
Multisite 2
(CGC) 2
T91T93 2
T95 2
CGCs 2
T95-dependent 2
Astrocyte 2
(IFNgamma) 2
Ribonuclease 2
IL-1/IFNbeta-induced 2
super-repressor 2
(C/EBPbeta) 2
Jun, 2
UV-mediated 2
Fos-activating 2
p38-activated 2
AP1-driven 2
c-Jun-mediated 2
tylophorine. 2
Tylophorine, 2
phenanthroindolizidine 2
alkaloid, 2
Tylophora 2
indica. 2
Tylophorine 2
(AP1), 2
(ATF) 2
NF-κB/PKCδ_(MKK4)_JNK 2
PI3K_PDK1_PP2A_eEF2 2
(eEF2) 2
PI3K_PDK1_eEF2 2
three-tiered 2
pure, 2
ATF2 2
MEKK-C 2
MKK4 2
Rheumatic 2
MKK7) 2
SH2/3 2
Sos, 2
described--c-Raf, 2
c-Mos, 2
Mekk--that 2
Mek, 2
Mek 2
Erk1, 2
Erk2, 2
Erk3. 2
Erk1 2
Erk2 2
41-kDa 2
ubiquitously. 2
Erk3-related 2
erk2 2
22q11.2; 2
erk1 2
16p11.2; 2
ek3-related 2
18q12-21. 2
smkl, 2
mpk1, 2
hog1, 2
fus3, 2
kss1. 2
Jnk 2
Thr. 2
N-terminomics: 2
chromatography-coupled 2
terminomics 2
colleagues. 2
MT6-MMP, 2
CCL23 2
secretomes 2
MT6-MMP. 2
ɛ-amine 2
polyglycerol 2
N-terminal-labeled 2
degradomes 2
elongates 2
(iTRAQ-TAILS) 2
(gelatinase 2
protein-3, 2
location-dependent 2
schwannomatosis 2
SMARCE1, 2
(SHH)-GLI1 2
SUFU, 2
p-4E-BP1, 2
p-AKT, 2
one-fourth 2
TRAF7 2
(K409Q) 2
AKT1(E17K), 2
~5% 2
distinctive-nearly 2
betweenness 2
centrality 2
coadministered. 2
(pharmacologically 2
TDM, 2
primidone, 2
zonisamide. 2
tiagabine, 2
vigabatrin, 2
Neuropathic 2
lidocaine. 2
valnoctamide, 2
biphenyl 2
Collapsin 2
protein-2: 2
kinase-3β 2
kinase-5 2
tianeptine 2
EWS/FLI1) 2
LOX. 2
EWS/PNET, 2
EWS/FLI-1, 2
"neurite-like" 2
elongations. 2
type-1-expressing 2
metastagenicity. 2
Sarcomas 2
proclivity 2
EWS-FLI-1-induced 2
'undruggable' 2
(ES). 2
EWS-knockdown 2
midzone, 2
R565 2
RGG3 2
EWS-dependent 2
road, 2
driver? 2
rewiring. 2
Y5 2
(Y5Rs). 2
(TNF). 2
NFkappaB. 2
dimethylamino 2
0.84). 2
EWS-FLI.(1-5) 2
tumorigenesis.(6,7) 2
fusions,(8-14) 2
reported.(8,10,11,13,15-21) 2
terminology, 2
complement-related 2
(MCP), 2
C5, 2
autoinhibitors 2
anticomplement 2
Hemolyitic 2
Shiga-toxin-producing 2
Gemcitabine-induced 2
Fattouma 2
Bourguiba 2
Universitary 2
Monastir 2
CFH, 2
anti-FH 2
Nephrologists 2
Thrombomodulin 2
C4b 2
procarboxypeptidase 2
anaphylatoxins 2
(FFP) 2
Hemolytic-uremic 2
gemcitabine: 2
Hemodialysis, 2
[Reversible 2
(STEC) 2
O145 2
diarrheal-associated 2
dipyridamole. 2
verocytotoxin-producing 2
Database) 2
VO(2 2
(moderate 2
lunch, 2
session: 2
appetite-controlling 2
Madrid 2
(-48.4%, 2
3-36 2
SPA, 2
inactivity. 2
(-0.4 2
zero), 2
zero). 2
TEE 2
0.0003 2
appetite-regulating 2
47.0 2
kcal, 2
liked 2
Sprint 2
46.3 2
breakfast. 2
Acylated 2
carbohydrate) 2
and; 2
~157 2
~40%, 2
~11, 2
~813%, 2
(EB) 2
glucagon, 2
strengthening) 2
(PYY). 2
students: 2
ml.kg(-1).min(-1) 2
(means 2
6.5-h 2
7-h 2
Two-way 2
1,411 2
110, 2
1,381 2
1,750 2
ob 2
[gastrin, 2
(CCK), 2
insulin], 2
(cortisol, 2
uptake--VO2max), 2
perfomed 2
treadmill, 2
cycloergometer. 2
VO2max, 2
teptin 2
gastrin, 2
somatostatin-like 2
brain-gut 2
12.4, 2
RhoA/actin-based 2
NTPase-regulatory 2
km23-1, 2
Mulder, 2
Ding, 2
TGFβ-sensitive 2
TGFβ-mediated 2
TGFβ. 2
TGFbeta/Smad3 2
(DLC) 2
TbetaRII 2
kinase-deficient 2
dynamitin, 2
TGFbeta-stimulated 2
km23, 2
block-1 2
Existence 2
hRFC 2
(vanadate) 2
serous, 2
created: 2
(LVO) 2
centers); 2
(1183 2
(1903 2
(dataset 2
p=0.019; 2
(shift 2
445 2
(89.0%) 2
NTR1804, 2
ISRCTN10888758.). 2
CLEAN, 2
unproven. 2
aspiration, 2
retrievable 2
analysis); 2
SYNTHESIS 2
RESCUE 2
rtPA 2
BASICS 2
appendectomy 2
Tuberculous 2
laparotomy, 2
us. 2
endometriosis? 2
1.5%. 2
(PID) 2
PIDor 2
5.1-6.9]) 2
3.1-4.6]) 2
(DRG). 2
vanilloid 2
colon/rectum 2
(L1-S3 2
Nociception 2
pERK- 2
nonheadache 2
headache-related 2
(IC), 2
.002) 2
Migraineurs 2
FM, 2
10.6, 2
[Intestinal 2
intention. 2
masquerader. 2
Cross-cultural 2
Informational 2
QLQ-INFO25, 2
dimensions: 2
(North) 2
33.8 2
47.1, 2
giving, 2
patient-targeted 2
26-item 2
INFO26) 2
Questionnaire-hypothesised 2
Taiwan) 2
(α>0.70), 2
correlations>0.70). 2
(α>0.90). 2
(r>0.40). 2
(r<0.30) 2
INFO-25 2
wishes 2
(cTn) 2
preexercise, 2
preexercise 2
(range): 2
early-to-atrial 2
160-km 2
ultramarathon. 2
planes, 2
795 2
NT-pro-BNP, 2
Marathon 2
39.6 2
138.6 2
27.35 2
p=0.012) 2
triathlon 2
(mean+/-SD, 2
Championship 2
post-competition. 2
Pro-BNP 2
(27+/-21 2
7+/-2 2
pre-race, 2
19+/-14 2
pre-race). 2
pre-race 2
proB-type 2
NT-proBNP. 2
caveat 2
strenuous, 2
physiological. 2
bike 2
cyclists, 2
Myo 2
racing 2
popularity, 2
(ANP), 2
ANP, 2
50-79 2
[1.35 2
(1.22-1.49), 2
(1.06-1.42) 2
(1.20-1.43), 2
[1.09 2
(0.99-1.19), 2
(0.78-1.08) 2
(0.95-1.16), 2
respectively]; 2
separately) 2
1994-2009 2
(131,480 2
131,248 2
users), 2
30-80%, 2
non-users. 2
1.05-1.36), 2
0.89-1.32), 2
1.03-1.75) 2
1.02-2.45), 2
oestrogen-only 2
exogenous, 2
pre-menopausal 2
OCs 2
Meningioma 2
emanates 2
progestagen 2
(EPIC). 2
276,212 2
3.61; 2
1.75-7.46). 2
tailored, 2
employer 2
33.8%), 2
2.46), 2
2.52) 2
thematically 2
limitations; 2
(IHCAs) 2
prefer. 2
empowerment 2
smartphone-based 2
smartphone-intervention 2
feelings, 2
therapist. 2
paper-and-pencil 2
catastrophizing, 2
within-group 2
(P=.04) 2
NCT01236209; 2
http://www.clinicaltrials.gov/ct2/show/NCT01236209 2
commented 2
camptodactyly. 2
(23/39), 2
10/39), 2
(6/39). 2
(6/33) 2
(16/33) 2
subtilizin/kexin 2
(a), 2
1314, 2
(44.6%, 2
59.3% 2
(63.7%, 2
54.8%) 2
[Lp(a)], 2
49.2% 2
Adjudicated 2
ASCVD 2
(LDL-C), 2
industry's 2
brodalumab), 2
(alirocumab, 2
bococizumab), 2
nivolumab). 2
Open-Label 2
(OSLER) 2
OSLER 2
(mipomersen) 2
(evolocumab). 2
lipid-regulating 2
(<11 2
NCT01588496. 2
30·9% 2
-43·9% 2
-18·0%; 2
anti-evolocumab 2
institutions) 2
(18-80 2
2·6 2
2:2:1:1 2
sponsor, 2
4·1 2
(yes/no). 2
NCT01763918. 2
(n=111), 2
(n=110), 2
(n=55). 2
(every-2-weeks 2
59·2% 2
53·4-65·1], 2
61·3% 2
[53·6-69·0]; 2
(60·2% 2
54·5-65·8] 2
65·6% 2
[59·8-71·3]; 2
[1%]). 2
Dyslipidaemia 2
lomitapide 2
pretty 2
anticholesterol 2
(SAR236553/REGN727), 2
(PCSK9). 2
bococizumab 2
statin-intolerance, 2
apolipoprotein-B 2
(mipomersen), 2
(anacetrapib, 2
evacetrapib) 2
(evolocumab, 2
alirocumab). 2
subtilisin/ 2
dyslipidaemias 2
IgG₂ 2
[40 2
mg]) 2
IMPORTANCE: 2
Subjects) 2
(2:2:1:1) 2
(QM) 2
ezetimibe-treated 2
intolerant. 2
Subjects-2; 2
NCT01763905). 2
<190 2
Framingham 2
≤10% 2
(1:1:1:1:2:2) 2
(Monoclonal 2
Reduce 2
Easing 2
Levels-2 2
[MENDEL-2]; 2
NCT01763827). 2
hypercholesterolemic, 2
risk--primary 2
<1.8 2
(3.0) 2
SUEs, 2
Dlx-5 2
Dlx-6 2
Dlx/dll 2
Evf-1. 2
homeodomain-specific 2
(ucRNA) 2
ucRNA 2
ucRNAs, 2
(uc.338), 2
TUC338. 2
anchorage-dependent 2
~200 2
(UCRs). 2
Sequence-specific, 2
#177 2
self-methylation 2
#177. 2
Deoxycytosine 2
(Dcm) 2
enzyme-induced 2
[5-methyl]cytosine 2
metK84 2
invoked 2
S-adenosylmethionine, 2
fidelity) 2
(m5C-MTase) 2
Cys156 2
antipodal 2
pucker 2
"small 2
ES), 2
("classic-type"), 2
neuroendocrine), 2
Merkel-cell 2
carcinoma), 2
(EFT), 2
(osseous 2
Rosai 2
Ploidy 2
82%. 2
(pPNETs; 2
sarcoma), 2
(HD-CAV). 2
methods--immunophenotypic 2
O13: 2
PN. 2
P30/32MIC2, 2
Mab 2
ES/PNs 2
SRCT-like 2
ES/PN; 2
SRCTs 2
ES/PN 2
non-lymphoblastic 2
lymphomas). 2
immunoreacted 2
anti-desmin 2
ES/PN. 2
rhabdomyosarcoma) 2
Pathologists 2
Indistinguishable 2
cos5 2
VIIIF2 2
contig, 2
neoadjuvant, 2
RAS/RAF/MEK/ERK, 2
smoothened-a 2
BCR-ABL-driven 2
(ICLs). 2
FANCs 2
deciphered 2
FANCs-RMN 2
CHK1-siRNA-treated 2
nullizygous 2
ICL-induced 2
double-R-loops 2
(CAG)·(CTG) 2
(CCG)n 2
double-R-loop 2
configurations, 2
RNA-bound. 2
(CTG)·(CAG) 2
Double-R-loops 2
single-R-loops. 2
slipped-DNA 2
Slipped-DNAs 2
RNA-interference-dependent 2
pause-site 2
DICER, 2
1γ 2
(HP1γ) 2
unwinding, 2
Zhou 2
Ginno 2
loops), 2
nonrepeating 2
A-resistant 2
rnhA1 2
H2. 2
(OH), 2
AGCT 2
AID-replication 2
parathyroid. 2
young-onset, 2
aip 2
variant? 2
c.241C>T 2
(p.R81X) 2
non-pituitary 2
MEN4 2
CDKN1B. 2
c.286A>C 2
(p.K96Q) 2
c.356T>C 2
(p.I119T). 2
K96Q 2
I119T 2
p27(I119T) 2
(p.S56T, 2
p.T142T, 2
c.605+36C>T) 2
MEN4. 2
GH- 2
AIP, 2
(HRPT2) 2
PRKAR1-alpha, 2
HRPT2 2
c.943C 2
(p.Q315X) 2
p.Q315X 2
apoplexy. 2
phenocopy. 2
noncarrier 2
GNAS1 2
acromegaly; 2
MENIN 2
PRKA1RA 2
17q22-24 2
FHC-associated 2
(TnC) 2
(TnI) 2
TnI 2
TnI. 2
monocysteine 2
holo 2
TNNC1) 2
PurposeHypertrophic 2
c.363dupG 2
(A23Q) 2
HCM-like 2
F27W 2
cTnCs 2
C-domain. 2
bis-ANS 2
nonphysiological 2
(A8V, 2
frame/splice 2
1025 2
TNNC1: 2
L29, 2
Asp2, 2
Val28, 2
Gly30, 2
(McTnC). 2
D2N/V28I/L29Q/G30D 2
(NIQD) 2
Phe(27) 2
(F27W) 2
1.3- 2
McTnC(F27W). 2
(McTnC(F27W)). 2
1.4-fold) 2
mum) 2
TNNC1, 2
Hoffmann 2
Schmidt-Traub 2
Perrot 2
Osterziel 2
KJ 2
Gessner 2
Mut17, 2
524]. 2
Finley 2
NL, 2
Abusamhadneh 2
Gaponenko 2
Seabrook 2
Howarth 2
JW, 2
Solaro 2
RJ, 2
Cheung 2
EJB 2
Lett453, 2
107-112]. 2
L29. 2
troponin. 2
Ca2+-saturated 2
(actoS1)-ATPase 2
(ear) 2
insignificant. 2
end-exhalation 2
(HT 2
Zhongwan 2
Zusanli 2
(adrenal 2
53.7 2
Sympathetic, 2
non-smoking-cessation-related 2
(Knee, 2
Elbow, 2
(12.1%) 2
chosen--an 2
somatotopically 2
semi-permanent 2
2.07); 2
1.96, 2
3.86). 2
Website 2
(0.6%) 2
(134 2
Kaplan 2
orthodox 2
auriculotherapy 2
Auriculotherapy 2
economic. 2
quasi-factorial 2
pack) 2
Trend 2
smokers--a 2
21.9% 2
post-treatment, 2
26.2%, 2
(KSHV), 2
H3K9-me3, 2
H3K27-me3 2
XIST-independent 2
XIST-controlled 2
(XY). 2
mammal), 2
(H4K20me1), 2
(H3K27me3, 2
H3K9me2). 2
therian 2
(marsupial 2
oogenesis: 2
primordial, 2
fully-grown 2
CLRC, 2
Raf2, 2
Rik1. 2
Rik1, 2
(H3-Lys9) 2
(Suv39h 2
HMTases) 2
Tumor-suppressive 2
HIF-1α-VEGF 2
Tie2+ 2
CD11b+ 2
TeloVac 2
three-group, 2
0-2. 2
(sequential 2
chemoimmunotherapy), 2
(concurrent 2
chemoimmunotherapy). 2
(GM-CSF; 2
(0·56 2
thereafter). 2
ISRCTN4382138. 2
1572 2
(358 2
2·4-12·2). 2
(7·9 2
7·1-8·8] 2
6·9 2
[6·4-7·6]; 2
1·19, 2
0·97-1·48, 2
p=0·05), 2
(8·4 2
7·3-9·7], 2
1·05, 2
0·85-1·29, 2
p=0·64; 2
χ(2)2df=4·3; 2
p=0·11). 2
KAEL-GemVax. 2
(IRI) 2
C57BL6/J 2
(tubular 2
(hTERT). 2
80-95% 2
hTER. 2
T-oligo 2
complete/partial 2
230,000 2
MEK/ERK, 2
beta-lapachone, 2
polyfunctional 2
1/6 2
skin-homing 2
(hTERT), 2
16-aa 2
delineation. 2
busy 2
modes; 2
β-TrCP, 2
-mediated 2
beta-chain 2
IkappaB, 2
(SCF)(betaTrCP) 2
interleukin-1. 2
E3RS(IkappaB/beta-TrCP), 2
IKK, 2
HGF-MET 2
Met/VEGF 2
E7050, 2
Met/Gab1/PI3K/Akt 2
BAY11-7082 2
factor-inducible 2
transcription- 2
HGF(+)/c-Met(+) 2
3alpha. 2
Uveal 2
disseminates 2
(HGF)-triggered 2
(ERK)1/2 2
phospho-ERK1/2 2
phospho-Akt. 2
FasL-Fas 2
FLICE-Like 2
(FLIP). 2
Wortmannin 2
LY303511, 2
H1N1/09. 2
(MonoGrippol 2
extra-pulmonary 2
extra-corporeal 2
'at 2
(N=267) 2
post-authorization 2
stillbirths. 2
(94.6%), 2
preterm). 2
(<2.5 2
(2009 2
(pdm). 2
(H1N1/09)v 2
twelve-week 2
(ILI) 2
Reunion 2
(157 2
ILIs 2
untyped). 2
ILI 2
(38.9 2
viral-strain 2
preparedness, 2
A(H1N1)v2009 2
non-adjuvanted 2
embryo/fetus 2
combined) 2
gestation). 2
1.25). 2
Vaccinated 2
0.92) 2
(H1N1)/2009 2
0.7; 2
Registry-based 2
(PORs) 2
53,432 2
(6989 2
[13.1%] 2
A[H1N1]pdm09 2
[345 2
6644 2
trimester]), 2
13,284 2
(6642 2
12,909 2
(6543 2
(5.5%) 2
0.60-2.45). 2
0.76-2.31), 2
6543 2
6366 2
0.84-1.17). 2
(7.6%) 2
0.46-1.37), 2
0.87-1.09). 2
015 2
A(H1N1)pdm09; 2
12%; 2
2.01-4.02]). 2
1.55-7.56]). 2
1.15-2.20]). 2
2009/10 2
documents. 2
BJOG 2
RCOG. 2
(N=142) 2
(N=710). 2
Subanalysis 2
(hospitalized) 2
18.8% 2
(6/32) 2
(52/707), 2
2.35 2
5.36, 2
3013.0 2
3223.3 2
(8/32) 2
(82/710) 2
(OR=0.979, 2
0.749~1.279)and 2
0.917~2.169) 2
(OR=53.726, 2
131.165~2477.918). 2
1.034 2
0.968-1.106) 2
9.667 2
0.750-124.59) 2
6.750-1121.39) 2
influenza: 2
hey 2
Chorea: 2
non-choreiform 2
cavus, 2
kyphosis, 2
(99m)Tc-ECD 2
(ECD-SPECT) 2
NKX2-1, 2
brain-thyroid-lung 2
Clathrin-mediated 2
endocyctic 2
inhibition1). 2
propriety 2
6.9, 2
(25) 2
clathrin/actin 2
(CCVs) 2
(TGN), 2
caveolin-mediated 2
nanoparticles; 2
spotty 2
PGE1 2
non-detectable 2
RIIalpha 2
(Calpha) 2
(TENS) 2
submaximum 2
Placebo, 2
TENS-1 2
Erb's 2
inflated 2
(MPQ) 2
'current 2
intensity' 2
'worst 2
experienced', 2
One-factor 2
MPQ 2
nonequilibrium 2
conditions). 2
telomerase-expressing 2
Topics 2
(TIC) 2
clonotypic 2
(CSC). 2
CD138 2
(OCT3/4, 2
BMI1) 2
mimetics. 2
5'-palmitoyl 2
(Imetelstat), 2
[Status 2
portas]. 2
cyclosporine; 2
tocilizumab) 2
IgE, 2
pitrakinra, 2
tralokinumab 2
difficult-to-manage 2
cohort-based 2
1993-2002, 2
.0003). 2
more-indolent 2
(deltaN377), 2
Crouzon-like 2
(PHP1A), 2
brachyturricephaly, 2
hydrocephaly. 2
cheeks, 2
(deltaN377). 2
PHP1A, 2
1/3,000 2
mBAND, 2
between-arm 2
Boston-type 2
5q-trisomy: 2
Kleeblattschädel 2
halluces, 2
46,XY,der(10)t(5;10)(q33;q26.3). 2
46,XX,der(17)t(5;17)(q35.1;p13.3). 2
gaping 2
fontanelle. 2
t(9;11)(q33;p15). 2
non-genic 2
craniosynostosis-radial 2
BGS 2
poikiloderma. 2
craniosynostosis-associated 2
(FGFR1-, 2
MSX2) 2
extracellular, 2
(Ap) 2
(FGFR-2) 2
Ap 2
anti-E-cadherin 2
COLIA1, 2
follows, 2
Ala315Ser, 2
FGFR2: 2
craniosynostosis? 2
Crouzonoid 2
skull: 2
front. 2
P6. 2
brachydactyly 2
carpal/tarsal 2
(1997): 2
(1996): 2
Glu181Stop 2
toe. 2
minority. 2
caretaker 2
cancer-the 2
subtype-have 2
18.1 2
deafness]. 2
perchloriate 2
L445W, 2
7q21-34 2
Exactly 2
1896, 2
(MM#274600). 2
7.5-10/100,000, 2
GATA23F5 2
D7S687 2
(PDS 2
7q. 2
goitrous 2
SLC26A4, 2
sulcus 2
Slc26a4-/- 2
Malform-ations 2
(performed 2
Phenocopies 2
(Pendred's 2
goiters. 2
reveals, 2
(16/16) 2
68.8% 2
(11/16) 2
goiters, 2
(4/16) 2
(IVS4-1G>A, 2
IVS7-2A>G, 2
IVS9- 2
1G>A), 2
(1548insC) 2
(T67S, 2
H723R). 2
IVS7- 2
2A>G 2
1548insC, 2
T67S, 2
IVS4-1G>A, 2
IVS9-1G>A, 2
amenorrhea. 2
goiter; 2
DFNB4, 2
mutated; 2
Probands 2
(NSRD 2
EVA) 2
NSRD 2
tofogliflozin. 2
lowering, 2
tumor/extraskeletal 2
(CD99, 2
CD56). 2
EWSR1, 2
biopsying 2
FCI 2
hydrazide 2
(filter-aided 2
preparation) 2
Deamidation 2
tolerances 2
offline 2
'filter 2
preparation' 2
detergent-based 2
identifications, 2
OVOS2, 2
Vit-1, 2
PC-IDMS 2
OVOS2 2
SRM-based 2
ILFAPT 2
weight-based 2
(MED), 2
elution. 2
MED-FASP 2
unused 2
Chlorobaculum 2
phototrophic 2
SOX 2
dsrM 2
2D-LC-MS/MS 2
osteogenesis. 2
RAS: 2
RAS-ERK 2
multifactor 2
answer, 2
glomerulopathies. 2
interrelationships 2
(CRSs) 2
vignettes 2
CRSs 2
(KIM-1), 2
(CSP), 2
normalisation 2
(LBP). 2
Roland 2
resolve. 2
spousal 2
persisters, 2
persisters 2
underestimators 2
accelerometer. 2
fear. 2
laboratory-based 2
(29=distressed; 2
9=non-distressed) 2
(activPAL 2
monitor) 2
(standing 2
walking), 2
p<0.05), 2
accelerometer, 2
handicaps. 2
(LBP) 2
biaxial 2
0.44). 2
nights. 2
(Actiwatch 2
AW-64). 2
non-dominant 2
Cognitive-behavioral 2
overuse. 2
Kiel 2
accelerometry 2
(Tracmor), 2
Tracmor 2
http://jaspar. 2
2010: 2
c.1360G>C 2
(p.Ala454Pro) 2
phenotype/genotype 2
follicularis; 2
308205) 2
BRESHECK 2
mentality 2
dysplasia/hypoplasia) 2
spinulosa 2
decalvans 2
(KFSD; 2
308800) 2
(c.671-9T>G) 2
photophobia), 2
pachyonychia, 2
periorificial 2
concomitance 2
Photoletter 2
editor: 2
IFAP-PPK 2
globes 2
staphyloma. 2
tonofilaments 2
Bowman 2
keratocyte 2
film, 2
keratoconjunctival 2
inflammations, 2
Photophobia 2
hyerkeratotic 2
inguineal 2
herniae, 2
(MBTPS2) 2
nosologically 2
enlarges 2
photophobia). 2
Atrichia, 2
keratopathy 2
stent-based 2
C34T 2
ADP-inhibition 2
(49.74 2
32.61) 2
"clopidogrel." 2
revascularization). 2
52G>T, 2
52G>T 2
(n=210), 2
(n=223), 2
(n=17), 2
(n=127), 2
(n=329), 2
4.02-fold 2
34C 2
14.9). 2
*17 2
Reduced-function 2
A-allele, 2
clinically-driven 2
[MI], 2
TLR) 2
(14.0% 2
22.3%, 2
(22.0% 2
28.1%, 2
noncarriers, 2
increased-function 2
thrombus, 2
(52.3% 2
P=0.0002). 2
(P=0.00006). 2
(Circ 2
99-105). 2
(LOF; 2
(GOF; 2
*17) 2
(3435 2
2677 2
G→T/A) 2
paraoxonase-1 2
(PON-1; 2
Q→R) 2
HTPR 2
PON-1 2
glioblastoma-derived 2
GBMs, 2
BTE 2
AED. 2
(VPA). 2
supplied. 2
(LEV) 2
137/143 2
59/86 2
41/100 2
16/37 2
(43.3%) 2
LEV, 2
89/116 2
(28/36) 2
25/36 2
(69.5%) 2
38/63 2
(60.3%) 2
Polytherapy 2
lysosomal-autophagic 2
6-aminonicotinamide 2
LAMP2A, 2
nanotherapeutics 2
autophagosome-lysosome 2
(Coordinated 2
Regulation) 2
lipid-induced 2
macrophage-specific 2
autophagy-derived 2
proteins/organelles. 2
prodegradative 2
autophagic, 2
MiT 2
(micropthalmia-associated 2
Axin1, 2
survivability 2
(T. 2
Vol 2
pp. 2
epidermidis 2
cinnamycin 2
cinnamoneus 2
cinnamoneus), 2
phosphatidylethanolamin 2
Mbl, 2
helicoid 2
sidewall 2
Mbl. 2
Mbl 2
MurG, 2
enterococci 2
problem; 2
Bacitracin 2
high-level, 2
faecium. 2
D-Alanine 2
D-cycloserine 2
HG001. 2
covered, 2
sedoheptulose-1,7-bisphosphate 2
UDP-MurNAc-pentapeptide 2
alanine-seryl 2
far-ranging 2
metabolome. 2
(deoxy)nucleotides 2
UDP-MurNAc-peptides 2
(Goldberg's 2
GHQ-28), 2
bodyweight, 2
anxiety/insomnia 2
short-course 2
fractions) 2
Module 2
P=.02), 2
(P=.02). 2
(GB). 2
Macdonald 2
0.5-5.6 2
(150-200 2
Nonhematologic 2
naïve, 2
bevacizumab-naïve, 2
irinotecan-bevacizumab]. 2
irinotecan-bevacizumab 2
Norris) 2
Inventory-20 2
(MFI) 2
irinotecan-bevacizumab, 2
radiotherapy-chemotherapy. 2
mg/m²/day), 2
every-3-week 2
(HGG). 2
1-20 2
(24.5%) 2
54.2%, 2
mg/m(2)/d 2
(5.8%). 2
anti-VEGF/VEGFR 2
accrued. 2
thrombotic/embolic 2
bidimensional 2
Pazopanib 2
EIAEDs 2
3.4%. 2
26.0 2
thrombocytopaenia 2
neuroradiographic 2
Bevacizumab-related 2
(5; 2
(7; 2
(4; 2
(2; 2
Radiotherapy-related 2
eamined 2
booklet. 2
postoperative). 2
Hypofractionated 2
60-100%). 2
atrasentan-related 2
Intra-arterial 2
reached) 2
myelotoxicity, 2
indications) 2
(bid), 2
non-relevant 2
Price 2
(ichthyosis, 2
stature). 2
Photosensitive 2
IBIDS). 2
PBIDS. 2
defy 2
cousins; 2
tail" 2
(trichothiodystrophy). 2
neuroectoderm. 2
Tay-syndrome. 2
Tay-syndrome 2
monogen-inherited 2
ektodermal 2
ichtyosis, 2
ichtyosis 2
(orthocerathosis 2
paraceratotic 2
strings). 2
(brittle 2
diseases?]. 2
(trichothiodystrophy) 2
BIDS 2
arthritis) 2
trans-migration. 2
anti-B 2
CCL3, 2
CCRL2 2
CXCR2. 2
cell-attracting 2
heterogeneity: 2
synoviocyte 2
subclassification, 2
beta/activin 2
A-inducible 2
(insulin-like 2
2/insulin-like 2
low-inflammation 2
Myofibroblast-like 2
joints: 2
(etanercept) 2
(infliximab). 2
(TUNEL 2
anti-TNF-mediated 2
1.6-6.0) 2
1.4-7.4) 2
10(-6)), 2
dementia? 2
PsycINFO. 2
reviewer, 2
3.34, 2
1,687), 2
1,687). 2
NEO-Five 2
allele(s) 2
neuropathology: 2
7.5) 2
2.7). 2
Neuroticism's 2
Implications, 2
paragraph 2
767 2
(DAT). 2
(NEO-FFI). 2
modal 2
etap(2) 2
.04, 2
episodic/semantic 2
case-comparison 2
(NEO-FFI) 2
revaluated. 2
frustration 2
Target-of-Rapamycin 2
(Sirolimus, 2
Everolimus), 2
drug), 2
(mRCC). 2
sunitinib. 2
(objective 2
8.5%; 2
PI3K/PTEN/AKT 2
rapamycin-like 2
carcinoma]. 2
(CCI779) 2
(RAD001) 2
deforolimus. 2
sirolimus. 2
3966 2
1.65; 2
(1980-June 2
2005)., 2
(27), 2
(1)). 2
-5.67), 2
(leucopenia: 2
3.66; 2
16.36; 2
2.20). 2
2.06). 2
1.43) 2
7.41), 2
TOR-I/standard-dose 2
TOR-I/reduced 2
-6.76) 2
GFR) 2
[Medical 2
(QTT) 2
"physiological" 2
profiled, 2
(ASE) 2
(cis-eQTL) 2
Fine-mapping 2
Eae23, 2
(LEW.1AV1xPVG.1AV1)F2 2
(G10) 2
(AIL) 2
Eae23a 2
Eae23b. 2
splice-specific 2
Zfhep1 2
(SBRCTs). 2
(DSRCTs) 2
(4/25) 2
ews/ 2
pair) 2
contingent 2
Therapy-related 2
(EWS-FLI1, 2
EWS-ERG) 2
(14) 2
(16/18) 2
(2/7) 2
calponin 2
92.3 2
interpretable, 2
lymphoma) 2
LMP2B 2
EBVΔCTCF166 2
EBVΔCTCF166. 2
human/mammalian 2
chromosome-boundary 2
establishing/maintaining 2
ENCODE. 2
full-spectrum 2
33/34-mer 2
(22/26-mer); 2
between, 2
Hi-C. 2
organizing/maintaining 2
coincide, 2
cohesin: 2
CTCF/cohesin-mediated 2
(UTR). 2
ChIP-Chip 2
TCF 2
(CTCF).1-3 2
(NAD)-dependent 2
poly(ADP 2
ribose) 2
Sirt 2
nutrition-associated 2
ecent 2
4C. 2
subtelomeres. 2
telomere-induced 2
Pcdhα 2
Hox-PBC 2
Venus-based 2
enhancements 2
Accession 2
linkers. 2
(>1,400 2
theory: 2
non-uniformities 2
load), 2
(iPSC)-derived 2
1:500. 2
Nurse 2
Practitioners. 2
TNNI3 2
TNNI3. 2
37; 2
(CREBBP), 2
financially 2
wrote 2
protein] 2
generations; 2
(probands 2
halluces. 2
Proband 2
(ganglioglioma) 2
p.Thr910Ala), 2
p.Thr910Ala 2
Glu1459, 2
Leu1668 2
Glu1724 2
(rs129974/c.3836-206G 2
(p.Asp1340Ala); 2
(rs130002) 2
(p.Asn435Lys) 2
rs129974, 2
rs130002 2
(c.3836-206G 2
(76.9%) 2
Totivirus 2
verticillioides 2
moss 2
mycotoxin-producing 2
(RabA4b) 2
(EYFP) 2
tip-localized 2
maydis-KP1, 2
KP6-which 2
P1, 2
P1M2 2
toxin-encoding 2
field-testing 2
smuts 2
seed-transmitted 2
KP4. 2
legally 2
KP4-transgenic, 2
soil-grown 2
(45)Ca 2
6,2'-O-dibutyryladenosine 2
3':5'-cyclic 2
exterior. 2
K42, 2
maydis: 2
UMV4, 2
(non-fungal) 2
UMV4 2
alpha/beta-sandwich 2
cross-overs 2
protuberance 2
Similarities, 2
(7-14 2
well-studied, 2
(Eta)-1. 2
(AIRE) 2
Transcriptome-wide 2
miRNPs. 2
nucleotide-enhanced 2
snoRNA-associated 2
microRNA-target 2
miRTarCLIP. 2
scratch, 2
3'UTRs, 2
multi-threading 2
miRTarCLIP, 2
CLIP-seq 2
browser, 2
MTIs. 2
http://miRTarCLIP.mbc.nctu.edu.tw. 2
(RBPs). 2
MOV10 2
non-experimentally 2
shortcomings, 2
wavelet-based 2
Argonaute2 2
Polycomb. 2
wavClusteR, 2
substitution-based 2
AGO 2
PARalyzer: 2
seed-matches 2
http://www.genome.duke.edu/labs/ohler/research/PARalyzer/. 2
Mukherjee 2
Lebedeva 2
HuR-RNA 2
cross-link-induced 2
CLIP. 2
iCLIP--transcriptome-wide 2
(RIP-CHIP). 2
non-physiological 2
CLIP-seq). 2
(individual-nucleotide 2
CLIP), 2
25-69) 2
1.9-11.7; 2
over-warfarinisation 2
(RAIU) 2
27.1 2
5.8) 2
pmo/l 2
4,2 2
5h 2
TMNG. 2
16.2 2
RAIU, 2
thyrotoxicosis]. 2
y.o. 2
idiopatic 2
miocardiopathy, 2
amioradone-induced 2
(34.3 2
(10.6 2
iodine-induced 2
(DXT). 2
kinematic, 2
arginase 2
argininemia, 2
c.[32T>C]+[913G>A] 2
(p.[Ile11Thr]+[Gly305Arg]) 2
equinus, 2
2-dimensional 2
N-acetylaspartate 2
well-matched 2
Cr/NAA, 2
Cr/Cho 2
mI/NAA 2
NAA/mI 2
Cr/NAA 2
ambulators, 2
(OGS). 2
3-DGA. 2
(wk) 2
walking? 2
Test: 2
in-hand 2
METHOD: 2
nursery 2
(spastic, 2
athetoid, 2
mixed) 2
(leg 2
elevation) 2
[Results] 2
[Conclusion] 2
GMFM-66 2
dynamometer 2
plantarflexors, 2
dorsiflexors 2
tilt, 2
Spasticity 2
[Methods] 2
(HIVE). 2
mo-19 2
MRI), 2
Go 2
[TUDS] 2
[LSU] 2
(N=35; 2
14.97±2.03y). 2
GMFM-88 2
E), 2
TUG, 2
TUDS, 2
intercorrelations, 2
(MANOVA). 2
LSU) 2
YGMFM-88 2
5.708 2
.402 2
X1-minute 2
.920 2
XLSU 2
.404 2
X10-meter 2
MANOVA 2
(Λ=.163, 2
F=14.732, 2
η(2)=.596), 2
(8-10 2
Balance 2
neurofibromatosis-Noonan 2
(NFNS). 2
controversially 2
NFNS. 2
(4288A>G, 2
p.N1430D) 2
(922A>G, 2
p.N308D) 2
hypersignaling 2
(MPNSTs). 2
IVS27b-5C>T, 2
(p=1.8 2
>T, 2
selenocysteine, 2
congolense 2
UGAs 2
(HSelP) 2
UGA, 2
dienes 2
CuCl2- 2
AAPH-induced 2
selenoprotein. 2
11-day 2
Webster/NIH 2
selenoprotein-P-type 2
2075 2
5'-leader 2
CACTCC 2
(His-Ser) 2
CATCCCs 2
(His-Pro), 2
CAC/TCC/AC/T. 2
His-Pro 2
Om(1D) 2
painfully 2
slow! 2
Regulation, 2
(PDCO) 2
ataxin-2, 2
(PABP1), 2
(F305L, 2
F341L, 2
F359L, 2
F368L) 2
RNA-binding-incompetent 2
(R518K 2
R521C). 2
leucines 2
(4F-L) 2
RNA-binding-competent 2
RNA-binding-deficient 2
RBPs). 2
Futsch/MAP1B 2
TDP-43-induced 2
Futsch 2
Polysome 2
fractionations 2
nontranslating 2
ALS-like 2
Futsch, 2
0270-6474/14/3415962-13$15.00/0. 2
(216-315) 2
Transportin-mediated 2
(fALS). 2
(FTLD-FUS). 2
fALS-associated 2
PY-NLS. 2
Transportin, 2
(PRMT1) 2
(FUS-dC), 2
FUS-dC-mediated 2
SMN) 2
model" 2
stipulates 2
RNA-Binding 2
FUS-immunoreactive 2
perikaryon 2
post-mortem. 2
ubiquitylation-based 2
(FUCCI) 2
alk5b 2
(tgfbr1b) 2
SB431542 2
C-associated 2
infarct-myocardium 2
noninfarcted 2
comediator 2
(pSmad) 2
healing-specific-matricellular 2
(TNF)-alpha, 2
(eNOS), 2
HSMP 2
secretory-leucocyte-protease-inhibitor 2
(SLPI) 2
(TGF)-beta(1). 2
clodronate-containing 2
macrophage-depleted 2
nonresorbed 2
thinning. 2
clot, 2
Monocytes 2
collagen-based 2
dense, 2
factor-beta-preprogrammed 2
(TGF)-beta-preprogrammed 2
(c-kit)-positive 2
(CD117+) 2
isolated) 2
TGF-beta1) 2
troponins, 2
NKx-2.5, 2
were. 2
decorin 2
non-myocytes 2
TGF-beta/Smad 2
websites: 2
gland) 2
laughter, 2
heritability, 2
broad-sense 2
Born 2
Wellbeing 2
(quality 2
happiness) 2
wealth, 2
marriage, 2
friendships 2
reflect, 2
contravened 2
upbringing. 2
endowments 2
reinforcement, 2
9-1106 2
Opicapone: 2
69.9% 2
98.0% 2
BIAL 2
Portela 2
Cª 2
S.A. 2
(Man6-P) 2
perspectives, 2
(M6P), 2
monodimensional 2
(MPR 2
MPR46 2
MPR300. 2
(Man6-P), 2
6-phosphorylated 2
lyososomal 2
mannose-6-phosphate, 2
Man6P-containing 2
lysosomal. 2
(Man-6-P), 2
glycopeptides. 2
wt-p53 2
Ews/Fli-1. 2
punctate-pattern 2
p21(WAF1). 2
identify. 2
stretches. 2
oriC1. 2
1,388 2
Orc1-1 2
/cdc6-associated 2
single-origin 2
hydra 2
Porifera 2
crenarchaea, 2
islandicus. 2
replication-biased 2
log-phase 2
multireplicon 2
replicons 2
pHV1 2
pHV4 2
Aeropyrum 2
S2, 2
str. 2
eubacteria) 2
NRC-1. 2
(921,863-922,014) 2
(1,806,444-1,807,229), 2
ggggtgggg 2
ccccacccc, 2
2253delG, 2
positionally 2
(BSS), 2
(MFT), 2
BSS, 2
FC, 2
YLD 2
SCCs, 2
Maspin. 2
Germ‑line 2
Brook‑Spiegler 2
CYLD-defective 2
follicle-related 2
cylindroma, 2
spiradenoma, 2
atients 2
ultiple 2
expression-mediated 2
GLI1-mediated 2
16q12-q13, 2
microscopically. 2
(identical 2
ubiqutin 2
(Familial) 2
factor-A. 2
(cHL) 2
HRS 2
(sub)clonal 2
rooke-Spiegler 2
16q12-q13 2
c.1684 2
1G> 2
2322delA 2
E774DfsX2. 2
BCCs, 2
spiradenoma. 2
trichoepitheliomas) 2
8-30 2
(42%). 2
(UBP), 2
D681G 2
trichoepitheliomas. 2
(TRAF)2- 2
TRAF6-mediated 2
(TNFalpha)-induced 2
TRAF2. 2
CYLD-D681G 2
TRAF2, 2
UBP 2
(Cys601, 2
His871, 2
Asp889). 2
D295 2
HAUSP/USP-7 2
D681 2
intra-family 2
neuraxis. 2
q11.2-13.3. 2
Africans: 2
(indigenous 2
Africans) 2
Town 2
1980-2001. 2
phenylbutyrate, 2
(snRNPs), 2
prdblems 2
(VRK1) 2
SMA-PCH 2
striae, 2
(PPNAD), 2
membrane-permeant 2
calcium/calmodulin- 2
kinase-selective 2
BeWo 2
AMPA-receptor 2
scaling. 2
GluA1, 2
βCaMKII, 2
uptake), 2
(5-50 2
sphinx 2
sexta 2
PKC-alpha, 2
(VSM) 2
CaMKII-delta(2), 2
PDBu- 2
PDGF-stimulated 2
ookinetes. 2
ookinete, 2
W-7 2
calmidazolium 2
KN-93-treated 2
chitinase 2
oocysts, 2
blood-fed 2
(KN-92). 2
ionomycin-induced 2
p56(Lck), 2
CaMK-II 2
kinase-II 2
(CaMK-II) 2
Rasmussen, 2
cdk4, 2
envelope, 2
KN-62 2
Ca(+)/calmodulin-dependent 2
(MLC(20)), 2
histamine-induced 2
(PDBu) 2
PDBu-stimulated 2
step(s) 2
(1990) 2
265, 2
han 2
(27.3%) 2
duplication/deletion 2
1A. 2
PXT3003. 2
(Phase 2
(CMTNS) 2
CMTNS 2
(NRG1) 2
39.5 2
ER-localised 2
PMP22(G150D), 2
Tooth, 2
(CMT1A). 2
INC 2
1652 2
EV. 2
stool, 2
adeno- 2
heart-transplanted 2
nested-Polymerase 2
Reaction. 2
PFU 2
CCM3). 2
(GRE) 2
CCM-causative 2
dural-based 2
meningioma-like 2
(p.Gln112PhefsX13) 2
GRE 2
(SWI) 2
post-gadolinium 2
PDCD10-mutated 2
hypersprouting 2
debut 2
glance. 2
CCM1), 2
OSM 2
malcavernin) 2
Synteny 2
floridae 2
MYs 2
E34*, 2
E68*, 2
E97* 2
E140*, 2
evolvements 2
(741delTC) 2
(H271X). 2
741delTC 2
(CCM1) 2
D3S1763 2
D3S1614. 2
PDCD10, 2
(ccm3Delta) 2
ccm1 2
ccm2. 2
CCM3Delta 2
CCM3, 2
MST4 2
(MST4), 2
(STK24), 2
STK25, 2
stk 2
stks 2
STK25 2
moesin. 2
KRIT1. 2
cavernoma 2
vessels; 2
gradient-echo 2
eldest 2
mulberry-shaped 2
CCM-related 2
Exceptional 2
d), 2
four). 2
β-type 2
(KC), 2
(MCP-1), 2
cells/HPF, 2
pg/mg 2
Detrimental 2
DITPA. 2
affairs 2
pellet, 2
vessels/mm(2) 2
dP/dt 2
797 2
28.3 2
22.1 2
II/microg 2
presacral 2
(6.7 2
S-2 2
sleeve/sacral 2
intrapelvic 2
S1-S2 2
Multilocular 2
tarlov 2
lumbo-sacral 2
italian 2
transforaminal 2
(TFESI). 2
TFESIs 2
TFESI. 2
myelograms. 2
insemination. 2
[Scintigraphic 2
cyst]. 2
99mTc-MDP 2
hemibody, 2
31.7 2
hydrostatic 2
(sacral 2
cysts) 2
endoneurium 2
75-87% 2
Numerical 2
(V(d)) 2
V(d) 2
half-lives. 2
Durations 2
3A5 2
60-85% 2
generalizations, 2
-0.63% 2
-6.9 2
(-6.1 2
-0.40% 2
(-4.4 2
-2.2 2
63.2-74.1% 2
3.0-5.5% 2
3.8-12.7% 2
SOURCES: 2
[weighted 2
(0.17, 2
0.40), 2
CI(0.60, 2
1.02), 2
<0.00001], 2
(0.89, 2
[risk 2
(0.15, 2
0.02], 2
(0.27, 2
0.72), 2
CI(0.55, 2
0.70), 2
<0.00001]. 2
-0.49, 2
(-0.57, 2
-0.40), 2
(-0.87, 2
(0.22, 2
0.67), 2
[RR=0.54, 2
1.19), 2
0.13], 2
(0.72, 2
1.50), 2
0.82], 2
1.10), 2
0.77]. 2
High-quality, 2
Publicly 2
[WAI], 2
intertrial 2
WAI. 2
8.5-fold 2
DPP-8/9 2
(DPP-IV) 2
90-fold 2
(fa/fa) 2
(metformin, 2
(I(2) 2
0.60; 2
antihyperglycemics. 2
Saxagliptin. 2
thiazolidinedione, 2
Vildagliptin. 2
8.05% 2
mmol/mol); 2
-0.77% 2
-0.82 2
-0.72%), 2
(I(2)=96%). 2
0.4-0.5% 2
[exenatide 2
albiglutide] 2
linagliptin) 2
(liraglutide). 2
Dipeptidylpeptidase-4 2
DDP-4 2
(ketoconazole, 2
IGHV-IGHD-IGHJ 2
(M-CLL) 2
(U-CLL), 2
M-CLL 2
8%; 2
(Binet 2
ZAP70. 2
(UM-IGHV; 2
n=10) 2
(M-IGHV; 2
(PLS-DA; 2
R(2)=0.74, 2
Q(2)=0.36). 2
UM-IGHV 2
pyridoxine, 2
3-hydroxybutyrate 2
disease-state 2
(IgV(H)) 2
agents' 2
adrenalin 2
Consciousness 2
desipramine, 2
consciousness: 2
depressants. 2
cortico-thalamo-cortical 2
MCS. 2
amantadine), 2
sparse-sampling 2
L/h/kg 2
(regress) 2
recanalisation 2
wks) 2
Scale-Revised, 2
(methylphenidate), 2
(amitriptyline, 2
buproprion), 2
(amantadine, 2
carbidopa/levodopa), 2
(Provigil), 2
transmagnetic 2
Accepting 2
gathering 2
neurobehavioural 2
(rs3918242) 2
parasitemia. 2
-1171 2
53.6 2
1171 2
15.2%; 2
NET-induced 2
self-antigen 2
LMAN1, 2
lectin-carrier 2
N-glycosylation-deficient 2
secretion-compromised 2
gelatinase 2
3.4.24.35) 2
trimer. 2
hydroxamate-type 2
binders. 2
angiogenesis]. 2
endopeptydases 2
recquire 2
proteolityc 2
(ECs). 2
transendothelial 2
hyperosmia 2
odor-related 2
bilateral. 2
smell. 2
Reed 2
(Encyclopedia 2
9,640 2
18,000 2
cross-referencing 2
lncRNome 2
envisioned 2
(BoNT), 2
immunogen. 2
produce. 2
5±0 2
botulism: 2
99-100% 2
subclusters 2
477 2
clostridia. 2
euthanasia 2
C-D 2
(HCR) 2
K1136 2
1735. 2
1793 2
uncooked 2
sausages. 2
"pharmakon" 2
(potion, 2
remedy). 2
Theophrastus 2
Bombast 2
Hohenheim 2
Paracelsus 2
(1493/94-1541) 2
dictum 2
"alle 2
sind 2
nichts 2
gift; 2
alein 2
macht 2
das 2
ein 2
kein 2
ist" 2
poisonous). 2
Baden-Württemberg 2
poet 2
Justinus 2
Ermengem 2
seventies 2
Alan 2
spasticities 2
torticollis 2
bioterrorist 2
weapons 2
2.76 2
Hebei 2
weapon]. 2
unheated 2
intentionally 2
polyamines. 2
neuroimages: 2
POLR3B: 2
leukodystrophy's 2
POLR3B 2
sequencing(1) 2
(C527R 2
[C.1579T>C] 2
V523E 2
[C.1568T>A](2)). 2
Pol-III 2
"Pol-III 2
III)-related 2
leukodystrophies." 2
microgliosis. 2
oligodendroglia 2
Layers 2
~50% 2
Hypomyelination, 2
(4H 2
(ADDH); 2
Tremor-ataxia 2
(TACH); 2
(LO); 2
Hypomyelination 2
(HCAHC). 2
Wiedemann-Rautenstrauch 2
neurologist, 2
dentist, 2
ophthalmologist, 2
can't 2
LO 2
ECM-associated 2
"matrisome" 2
[encoded 2
Trithorax-like 2
(Trl) 2
gene] 2
Frontabdominal-7 2
(Fab-7), 2
HS1 2
Trithorax-like. 2
(GA)n 2
(HSEs) 2
-340, 2
-135 2
-85 2
G.H. 2
E.S. 2
Siegfried, 2
211:751-761, 2
(Q. 2
Lu, 2
L.L. 2
Wallrath, 2
B.D. 2
Allan, 2
225:985-998, 2
-347 2
-341, 2
HSE. 2
(-347 2
-341), 2
(-135 2
-85), 2
P-element-mediated 2
(prior 2
congruent: 2
DRM) 2
(genomic 2
endonucleases. 2
MET2a, 2
MET2b, 2
MET3) 2
(MTase-11), 2
(11483 2
MTase-11 2
Carrot 2
(Met1 2
Met2) 2
(suspension 2
primordia), 2
(Met1-5). 2
(AtDNMT2) 2
(Elaeis 2
guineensis 2
regenerants 2
DNA-(cytosine-5) 2
EgMET1 2
EgCMT1 2
calli. 2
DDM1 2
tail-to-tail 2
PAI2 2
Foxm1(-)(/)(-) 2
p21(Cip1) 2
p27(Kip1). 2
(CENPA), 2
-C. 2
re-assembly 2
fusion-protein 2
Cenpag/g 2
cell-cycle-dependent 2
pseudodicentric 2
poly(ADP-ribosyl)ated. 2
Sp1-binding 2
island, 2
Neocentromeres 2
centromere-specific-DNA-binding 2
straight, 2
extranucleosomal 2
ISW1a 2
angle, 2
grooves. 2
Pairing 2
H3-lysine-9-dimethylation. 2
operator/lac 2
CMT3-mediated 2
estrus 2
placode. 2
GnRH1 2
bending. 2
deformability. 2
8q12.1. 2
M33), 2
low-mobility 2
higher-mobility 2
(CHD8) 2
coregulator 2
androgen-stimulated 2
Atresia 2
Retarded 2
heterochromatin), 2
dipteran 2
germline-limited 2
"L" 2
(Chd2). 2
Chd2-mutant 2
glomerulopathy, 2
epigenetically-mediated 2
[transcriptional 2
SIN3A, 2
(cytosine-5-) 2
rbbp4, 2
2] 2
CHD7. 2
hPc2, 2
post-translation 2
Immunoprecipitated 2
(HMM)-generated 2
Msl-3 2
pseudogenes) 2
GNAT 2
C2HC 2
Pcu4 2
mat2-P 2
mat3-M 2
anti-chromodomain 2
dimethyl- 2
trimethyllysine-containing 2
cation-pi 2
PAM14. 2
MORF4-Related 2
(MRG15) 2
zipper, 2
MRG 2
nature; 2
dMi-2(BL1) 2
dMi-2(BL7) 2
dMi-2(BL12) 2
virilis 2
msl-3 2
Alp13 2
MSL3L1 2
mays. 2
msl-3/MRG15 2
fungus/animal 2
puffs 2
box-containing 2
197-kDa 2
sequence-selective 2
CHD-1 2
Gata3/Chd4 2
SNF2/ISWI2 2
(ANP32C) 2
pp32 2
p53wt 2
nuclear/cytoplasmic 2
ACHN, 2
ACHN-pp32r1Y140H 2
isotope-coded 2
(ICPL) 2
Capping 2
(CAPG) 2
cyclinD1 2
Transcription-induced 2
Epe1. 2
Mmi1 2
Red1, 2
Red1 2
(Chd7) 2
PlexinA2 2
PlexinA2, 2
homeodomains 2
ENHANCED 2
PHOTOMORPHOGENIC1 2
(EPP1), 2
(PKL), 2
chromodomain/helicase/DNA 2
elongation-related 2
Y-like 2
(CDYL) 2
enoyl 2
Cdyl 2
(iPS 2
methyl-cytosine 2
(GATAD2A/p66α) 2
(CHD4/Mi2β) 2
MBD2-mediated 2
(Gnanapragasam, 2
Scarsdale, 2
Amaya, 2
Webb, 2
Desai, 2
Walavalkar, 2
Zu 2
Zhu, 2
Ginder, 2
MBD2-NuRD 2
anti-parallel 2
MBD3-like 2
MBD2. 2
planthopper 2
(BPH), 2
pests 2
planthopper, 2
GNAT-type 2
MOZ-SAS 2
lugens. 2
helicase/adenosine 2
PITX1, 2
TBX4, 2
HOXC13, 2
protein)1, 2
RIPPLY2. 2
(QRT-PCR) 2
0.8; 2
Multivalent 2
CHD5-PHD(1-2) 2
methyl-mark 2
H3-tail. 2
RKS 2
H3-HP1 2
H3K36me(2/3), 2
(PHD1) 2
Chp1, 2
Ago1-containing 2
(RITS) 2
siRNA-bound 2
RNA- 2
Chp1-CD 2
H3K9me, 2
Kruppel-associated 2
KAP-1, 2
HDAC1/2, 2
chromodomain-containing, 2
Msx1 2
(Helianthus 2
annuus 2
('chromoviruses'), 2
chromoviruses 2
HP1(Swi6). 2
CHD7L, 2
Sox2-mediated 2
Japan/Blackwell 2
FADPS1 2
(PS1-M146V) 2
ZNF237, 2
Ca²⁺-signaling 2
(Chd2), 2
SNF2 2
housekeeping, 2
HP1-containing 2
(GC/MS) 2
non-tumorogenic 2
integrase. 2
RT's 2
chromodomain) 2
heat-inactivated 2
(CHD7). 2
photographs, 2
trimethylates 2
combs 2
members: 2
5-exon 2
532-amino 2
CBX2-1 2
4-exon 2
CBX2-2, 2
corepressors, 2
detect, 2
BRIT1, 2
ATPase-dead 2
break-inducing 2
synaptonemal 2
Chromator, 2
(ChD) 2
ChD 2
NTD. 2
5-aza-2-deoxycytidine, 2
A549-EGFP-CHD5 2
57.7 2
indolent, 2
(CHD1). 2
surveyed. 2
MRG-1. 2
Dnmt3aK44me2. 2
GLP, 2
CHD8, 2
Linker 2
HIS-24 2
Tuning 2
=15 2
sliding. 2
∼3-fold 2
300-kDa 2
chromatograms 2
Chd3 2
Tentative 2
(ZFH), 2
(Chd3), 2
ZFH/Chd3 2
Translationally 2
0.034). 2
somitogenesis 2
(chd7) 2
chromodomain-DNA-binding-protein 2
ossicles. 2
stapedial 2
protein-chromodomain 2
proportional-hazards 2
interband-specific 2
Z4 2
(Fam174b) 2
(Chd2-2) 2
(Cbx3) 2
Dia-1/SRF 2
activator-dependent, 2
PHO5 2
(Chd1), 2
Hep-2 2
(p<0.05), 2
LSCC. 2
CenH3. 2
CenH3-GFP 2
DIM-5 2
CHD2, 2
CHD9 2
MSI-L/MSS 2
di-methylated 2
encloses 2
Tyr83 2
protein(s). 2
(pre-mRNAs) 2
chromatin-borne 2
Lys(9). 2
tetramerize 2
sticky 2
(generally 2
H3R2 2
Kismet 2
Kismet, 2
kismet 2
tropicalis, 2
in>150 2
Dofetilide 2
Grupo 2
Sobrevida 2
lsuficiencia 2
Cardiaca 2
(GESICA) 2
Piloto 2
Argentino 2
Muerte 2
Subita 2
Amiodarona 2
(EPAMSA) 2
Failure-Survival 2
(CHF-STAT) 2
Implanted 2
Cardioverter 2
Def 2
ibrillators 2
haemodynamically-compromising 2
equi-effective 2
dromotropic 2
ERP 2
Sotalol 2
relevancy 2
intragastrically 2
epigastralgia 2
flanks 2
Pancreatitis 2
iodine, 2
iodine-deficient 2
-defibrillator. 2
LVMF, 2
LVMF 2
3.4%, 2
p=0.0001). 2
SCD/aborted 2
Delayed-enhancement 2
(DE-MRI). 2
forsymptomatic 2
DE-MRI 2
insymptomatic 2
hyperenhancement, 2
(33.8%) 2
hyperenhancement. 2
pattern.The 2
(DCE) 2
0.01]; 2
0.74) 2
0.42). 2
doctors. 2
diarrhea). 2
propagate. 2
hepaciviruses 2
antropod-borne. 2
pandemics, 2
(DENV), 2
coeruleus, 2
OCT3/Slc22a3-deficient 2
transmitters. 2
choline, 2
(MPP(+)) 2
OCT2-OCT-3 2
rodents; 2
TGFbeta/BMP-6 2
protein-6 2
(BMP-6) 2
TGFbeta/Smad 2
TIEG1-induced 2
factor-beta- 2
(TGF-beta-) 2
1-adrenoceptor 2
TGF-beta1-regulated 2
TGF-beta1-inducible 2
treatmen 2
Bcl-2/Bax]. 2
Bcl-2/Bax. 2
time-and 2
cow. 2
mobilise 2
somatotrophic 2
(PDK4, 2
AHSG) 2
Smad4, 2
Smad7, 2
TGF-β-sensitive 2
TGF-β1-sensitive 2
KLF10, 2
DMBA/TPA 2
NFATc1, 2
DC-STAMP. 2
(TIEG)-1 2
TIEG1-mediated 2
TIEG2/KLF11 2
OLI-neu, 2
factor-beta-mediated 2
Zn-finger 2
caspases-3 2
(TGF-beta(1))-inducible 2
3-like 2
Manganese 2
MitoTracker 2
Mn-exposed 2
attractant 2
(opa-1) 2
(fission 2
(optic 2
CypD 2
6E10 2
Prohibitins 2
Phb2 2
mitofusins 2
Delta(12,14) 2
(15d-PGJ2) 2
15d-PGJ2, 2
E11.5. 2
A-P 2
granularity. 2
diffusibility 2
[Ca²⁺] 2
(followed 2
mitofusin1 2
OPA1-silenced 2
Ca²⁺/H⁺ 2
antiporters 2
Adrenergic 2
perilipin, 2
lipases 2
(OPA1), 2
constrictions 2
protector, 2
perioral 2
.010) 2
Catuama 2
(ALA), 2
3%-10% 2
clinic-based 2
DTC, 2
(NCCN) 2
4.8%. 2
tumour-initiating 2
BRAF- 2
PI3K)/AKT 2
(FTC) 2
(MMAC1, 2
TEP1) 2
hamartomas, 2
trichilemmomas, 2
non-medullary 2
10q23 2
(MMAC1/TEP1) 2
10q23. 2
10q22-23. 2
ectodermal, 2
7/26 2
2/27 2
MINPP1, 2
c.809A 2
IVS3 2
cue-induced 2
alcohol-preferring 2
dosedependent 2
(GLT-1). 2
lesioned 2
minocycline. 2
Phases 2
(0.55 2
µg/mL). 2
BID) 2
closed. 2
NCT00349622. 2
riluzole, 2
minocyclin, 2
PBA, 2
acetylcysteine) 2
seropositive, 2
x(c)(-), 2
xCT. 2
ceftriaxone-mediated 2
GLT1. 2
stroke/ischemia, 2
Ceftriaxone, 2
PHFA 2
NF-kappaB-mediated 2
(ceftriaxone, 2
ONO-2506, 2
memantine, 2
riluzole 2
antiglutamatergic 2
Beta-lactam 2
Rothstein 2
chelators, 2
cephtriaxone 2
Participants, 2
caregiver. 2
-0·06 2
[72%] 2
[56%] 2
High-altitude 2
ACTH, 2
f) 2
GH/IGF-I 2
IBAT. 2
(IGF-I), 2
60-s 2
28%), 2
tT 2
jumping, 2
pituitary-adrenocortical, 2
amenorrheic 2
eumenorrheic 2
T3/T4 2
5'-monodeiodination 2
(rT3). 2
TRH-stimulated 2
autumn. 2
km, 2
ergometer. 2
hemoconcentration. 2
compostiion 2
pronouced 2
arachidonic, 2
OCT4-pg4, 2
end: 2
mRNA-derived 2
GcvB 2
sponge-mediated 2
Hfq-dependent 2
(SroC) 2
GcvB. 2
A)-an 2
neurotransmitters-revealed 2
(VNTR 2
genotype), 2
products) 2
[(11)C]clorgyline, 2
endophenotype. 2
disorder? 2
bisulfate 2
DSM-VI. 2
BSP-sequencing. 2
160). 2
5.80E-35 2
158). 2
HTR2A 2
NR3C1 2
0.046). 2
S-COMT, 2
twin-pairs 2
(AEI) 2
(T890G) 2
(C1409T) 2
(R2=0.5 2
dysplasia/cardiomyopathy 2
(106 2
TFC 2
DSC2, 2
DSG2, 2
V4 2
V6 2
Lethal, 2
echocardiograms. 2
(L39X). 2
anti-inflammatories 2
countermeasure 2
(P). 2
FRAP, 2
repeated-sprint 2
Cr-supplemented 2
health-promoting 2
0.048) 2
(1.9%; 2
±2.5%). 2
(training 2
arborescens 2
Mill. 2
pro-oxidant-antioxidant 2
rowers 2
Team. 2
(TBARS) 2
bout. 2
O2•¯ 2
TAS 2
experimental, 2
Q(10) 2
isoprostanes 2
Rahimi, 2
Cond 2
25(12): 2
3448-3455, 2
2011-Creatine 2
guanidine-acetic 2
ergogenic 2
endurance. 2
resistance-trained 2
[21.6 2
[21.2 2
maltodextrin 2
maximum) 2
8-hydroxy-2-deoxyguanosine 2
(QC); 2
isoquercetin, 2
epigallocatechin 2
gallate, 2
(P), 2
QFO 2
four-week 2
(EPA) 2
docosahexanoic 2
LCPUFA 2
LCPUFAs 2
judo-training 2
male: 2
Rosea, 2
utilisation, 2
VO(2) 2
zinc-supplemented 2
(MDA), 2
beneficially 2
erythrocyte-membrane 2
nonprofessional 2
fish-oil 2
Body-mass 2
soy- 2
swimming-trained 2
leaner 2
leukomalacia. 2
c.1904C 2
p.Ser635Leu 2
c.1787G 2
p.Arg596Gln. 2
glycylation. 2
Aminoacyl-tRNA 2
(hGlyRS) 2
transversus 2
abdominis 2
(TVA) 2
TVA 2
c.598G>A 2
(D200N) 2
c.794C>T 2
(S265F), 2
ligates 2
tRNA(Gly). 2
mislocalizes 2
[YARS 2
(tyrosyl-tRNA 2
gene)]. 2
(1,2, 2
…,22,X,Y) 2
[Gaussian 2
(GMM)] 2
initialization 2
GMM 2
acquirement, 2
89.85% 2
mathematics 2
representation-based 2
L1-norm 2
pixel-wise 2
(AFCM) 2
Pursuit 2
(OMP), 2
Angle 2
(LARS), 2
cycle- 2
dKDM4A-regulated 2
TXR1 2
Ezl2p. 2
Wbp7 2
(SET1a 2
SET1b, 2
MLL1-MLL4) 2
MLL4 2
(GPI) 2
(H3K9)-specific 2
SUV39H, 2
H3K9-specific 2
dG9a 2
difference: 2
tri-methylation) 2
RASSF1a, 2
(ERalpha) 2
PGR 2
REST-mediated 2
SAS3-dependent 2
SUVH 2
SUVH4 2
H3K27, 2
DDM1, 2
(H3-K9) 2
Primarily 2
domain-depending 2
logarithmically 2
Suv39h1-mediated 2
H3-K4. 2
Set9-mediated 2
Suv39h1. 2
h1, 2
10-20-fold 2
h1 2
Fludarabine, 2
Heavily 2
(GVHD) 2
GVHD. 2
Zinsser-Engman-Cole 2
cancer". 2
dyskerin, 2
guides. 2
(TERC) 2
TERC. 2
(CFE) 2
caries, 2
taurodontism 2
root/crown 2
development). 2
interactomics 2
miRNA-miRNA 2
interstitial, 2
(TGFβRIII) 2
TGFβRIII. 2
phosphorylated-Smad3 2
(p-Smad3). 2
primiR- 2
myocytes' 2
hypoxia/ischemia. 2
miR-320, 2
Sirt1, 2
(∼22 2
(HSP)60, 2
HSP20, 2
(Pdcd4), 2
LRRFIP1, 2
(FasL), 2
etc.], 2
intermediate-term 2
IP-regulated 2
21~23 2
unstranlated 2
(Ad-miR-21) 2
Ad-miR-21. 2
(H(2)O(2)). 2
Pre-miR-21-mediated 2
H(2)O(2)-treated 2
Dynamics, 2
Ring-Ring 2
Ring1b. 2
UbcH5a, 2
embraces 2
Ring-domain. 2
BARD1, 2
BRCA1:BARD1 2
hyper-phosphorylated, 2
monodansylcadaverine 2
1A/1B-light 2
(LC3B-I) 2
(LC3B-II), 2
(RFS; 2
non-pCR 2
carcinoid, 2
non-NE 2
Blot, 2
pentatricopeptide 2
repeat-containing) 2
autophagosomal 2
(phosphoinositide 2
Ursolic 2
Wortmannin, 2
lipopolysaccharide-activated 2
bimodal, 2
IFN-γ-primed 2
(tfLC3) 2
beta-defensin 2
Preischemic 2
1-alpha 2
24-, 2
Ras- 2
(FAC), 2
marker); 2
FAC-induced 2
CD133. 2
LGM 2
LGM, 2
chain3 2
Huh-7con 2
Huh-7sh133 2
quinacrine 2
p21-/- 2
Acridine 2
p53-/- 2
autophagy-independent 2
(LC3). 2
nonlipidated 2
Noticeably, 2
2,706 2
733), 2
894), 2
1,071). 2
(rs6427528) 2
1q23 2
(ΔDAS) 2
ΔDAS 2
etanercept-treated). 2
etanercept-treated 2
0.4), 2
151, 2
Ly108, 2
Ly9, 2
Ly108 2
self-signal: 2
(mya) 2
mya 2
hominids). 2
dualistic 2
Neu5Gc-presence 2
Neu5Gc-absence 2
(Cmah(-/-) 2
knockout). 2
Cmah(-/-) 2
non-Neu5Gc-reactivity 2
coronaries. 2
enzyme-immunosorbent 2
31.1 2
0.0000, 2
μg/mL). 2
xenogenic 2
dressings 2
anti-non-αGal 2
acellular 2
Dabigatran-related 2
Warfarin-related 2
NOAC-related 2
Unapproved 2
factor-Xa 2
(GIHP) 2
(Xarelto(®)); 2
30ng/mL 2
propositions, 2
(aPCC) 2
(FEIBA(®) 2
30-50U/kg) 2
(50U/kg). 2
haemostasis. 2
[Hemorrhagic 2
assays]. 2
hypocoagulation 2
clot-based 2
Pro-hemostatic 2
(FEIBA(®)), 2
(NovoSeven(®)), 2
anti-thrombotic 2
ways?]. 2
vitamin-K 2
HIT 2
(heparin-induced 2
(Arixtra®) 2
HIT. 2
Fondaparinux. 2
(Eliquis®), 2
("bridging": 2
yes 2
no?). 2
[Anticoagulation 2
new?]. 2
Vitamin-K 2
(NOA) 2
(dabigatran); 2
easier: 2
(prophylactic 2
embolisms). 2
(filtration 2
(FGR) 2
(FGR<30 2
low-molecular 2
medicaments 2
long‑term 2
anti-Xa, 2
haemorrhages, 2
heparins. 2
(Xa), 2
5-9 2
undertreated 2
fibrillation' 2
NOAC-investigating 2
VKA. 2
Xa-analog 2
182-kb 2
pagR, 2
(Sap 2
EA1). 2
"Sap-layer" 2
"EA1-layer". 2
Sap 2
eag. 2
PagR, 2
(capsule 2
S-layer). 2
(R-alpha) 2
(--), 2
"6S" 2
poly(C) 2
EF-Tu 2
hairpin/stalk 2
TLS, 2
cytisine, 2
1310 2
quitline 2
mail, 2
vouchers 2
lozenges. 2
Low-intensity, 2
telephone-delivered 2
quitline. 2
655) 2
(203 2
655), 2
14.5). 2
Zealand; 2
ACTRN12610000590066.). 2
2-23 2
~\n10% 2
(CTNNA1, 2
(aCNAs) 2
(cnLOH) 2
Oligo-SNP 2
896 2
5q31.2, 2
cnLOH: 2
(UPD 2
(4q), 2
(7q), 2
(20q11.21), 2
(21q22.3). 2
Coincidently, 2
HSPA9 2
cnLOHs 2
Stat4, 2
T-bet. 2
trio-based 2
contributes. 2
(Y641F, 2
Y641N, 2
Y641S 2
Y641H) 2
(NHL). 2
Y641 2
7q35 2
MDS/MPN-like 2
MDS/MPN. 2
Ezh1, 2
derepressed. 2
CFU-E 2
(P-values, 2
intermediate-2/high-risk 2
multi-variate 2
(P=0.044) 2
(AML; 2
P=0.039). 2
75-80% 2
(RAS 2
(ASXL1 2
(SF3B1 2
non-motile 2
(rs7804122 2
rs797821) 2
(GG 2
AG) 2
(48.74 2
24.8%; 2
0.0013) 2
30bp 2
(rs78301778 2
rs6596422) 2
rs78301778 2
rs6596422 2
classiﬁcations 2
signiﬁcant. 2
Ret-tyrosine 2
2508C 2
(S836S) 2
(Fisher 2
10q11.2-q21.2) 2
D10S208 2
D10S196, 2
10q11.2, 2
(Lubs 2
Lubs 2
Non-parametric 2
(12.7%), 2
hyperganglionosis 2
Neurocutaneous 2
endorectal 2
pull-through 2
V145G, 2
Y483X, 2
V636fsX1, 2
V145G 2
S390R 2
C109R 2
N104I 2
Deoxyribonucleotides 2
deoxyribonucleotide 2
deoxyribonucleotides. 2
oxido-reductase, 2
radicals; 2
matters, 2
"unhooking" 2
[15, 2
51], 2
[29], 2
]0], 2
convenience. 2
Marizomib, 2
Oprozomib, 2
Delanzomib, 2
cinnabaramides, 2
rocilinostat 2
flask-shaped 2
deformable 2
stiffening. 2
transduced. 2
(indomethacin, 2
L-NAME, 2
Shear 2
Caveolae, 2
60-80nm 2
Caveolin 2
organizers. 2
submicroscopic, 2
non-clathrin 2
coat, 2
commence. 2
nucleoskeleton, 2
'factories' 2
ICP8 2
nearer 2
SP100, 2
SP100-HMG 2
&quot;open&quot; 2
&quot;open,&quot; 2
3-iodothyronamine. 2
(I(to)) 2
B(max), 2
oxalate-supported 2
(measurement 2
method; 2
60-minute 2
(10(-9) 2
FURA-2/AM 2
even-reduced 2
Aequorin 2
interhexamer 2
capsid, 2
capsids. 2
N-terminus) 2
PRY-like 2
Phylogenetic, 2
"SPRY 2
only" 2
(TRIM5α) 2
pattern-sensing 2
curvatures. 2
TRIM/RBCC 2
GFP-TRIM50, 2
TRIM50-associated 2
canaliculi, 2
canaliculi 2
(TRIM)-containing 2
PRG-1 2
N1E-115. 2
TRIM67. 2
purpuratus, 2
micromeres 2
micromeres, 2
Vasa-interacting 2
(GusΔSOCS) 2
(gus) 2
SSB-1-like 2
SSB-4-like 2
hpf 2
Pyrin, 2
proIL-1beta 2
NALP3, 2
Cow 2
LOC505265 2
N-tropic 2
virus-restricting 2
defence? 2
super-family 2
(BTNs), 2
(SOCS-box 2
SSB1-4) 2
(SOCS), 2
(DDX1, 2
hnRNPs), 2
(HERC1, 2
Ash2L). 2
B30.2-domain 2
BTN 2
PRY. 2
defender 2
(344R/Q/P) 2
RING, 2
(v1, 2
v2, 2
v4) 2
occasional, 2
plasm, 2
(gus), 2
oskar 2
(osk). 2
phylogentic 2
(PLEX). 2
(PLEX), 2
http://bioinformatics.icmb.utexas.edu/plex 2
Phydbac2: 2
(phylogenomic 2
Phydbac2), 2
web-service. 2
Phydbac) 2
benchmark, 2
bio-terrorism 2
shopping 2
http://igs-server.cnrs-mrs.fr/phydbac/. 2
astonishing 2
84%. 2
STRING: 2
conceptually, 2
scoring-framework 2
inferred, 2
033 2
http://www.bork.embl-heidelberg.de/STRING/. 2
intracategory 2
http://fusion.bu.edu. 2
(NOPS) 2
C2, 2
90.90, 2
67.18, 2
94.08 2
Å, 2
99.96°. 2
diffraction-quality 2
pseudosymmetric 2
bottlenecks. 2
crystallization, 2
pseudosymmetry 2
Matrin 2
(p54) 2
PSP1, 2
corepressor. 2
(non-POU-domain-containing, 2
PSF. 2
myometrium. 2
behavior/human 2
(PSF), 2
(p54nrb), 2
PSPC1, 2
NONA 2
Hrp65. 2
gamut 2
(Menε/β) 2
NONO. 2
20-Å 2
RS-OS 2
TOPFlash 2
mesomelic 2
DRS-affected 2
Wnt-5a 2
DRS. 2
regulatory-particle-associated 2
(UCHL5) 2
(USP14), 2
AML1/MDS1/EVI1 2
(ATO) 2
(MDS1) 2
MDS1 2
AME-, 2
AML1/MDS1-, 2
MDS1/EVI1-, 2
EVI1-positive 2
thiostrepton 2
sub-apoptotic 2
5-week 2
gavage. 2
EOC/PPC 2
(cycle 2
mg/m(2)/dose. 2
Insensitive 2
inhibition-mediated 2
hypotension) 2
B-related 2
mg/m2/dose 2
RLC 2
Elg1, 2
mrc1Delta, 2
tof1Delta, 2
csm3Delta 2
DCC1. 2
DCC1 2
Ctf8p 2
Ctf18-RFC, 2
(CHL1, 2
BIM1, 2
KAR3, 2
VIK1) 2
Csm3p 2
Tof1p 2
low-passage 2
PJ34 2
TRAIL/PARP 2
lymphoma-2 2
CD34-enriched 2
[9%]), 2
RNF8(-/-), 2
(poly(ADP 2
ribose)polymerase 2
RNF8(-/-) 2
measureable 2
PARP1/2. 2
Gemtuzumab 2
ozogamicin 2
CD33-positive 2
CD33 2
GO-induced 2
GO-resistant 2
piperlongumine, 2
PARP-inhibitor, 2
cediranib. 2
none). 2
BrCA-MZ-01. 2
ALDH+ 2
needed: 2
downmodulation 2
(TR)-α1 2
T₃, 2
(father 2
reanalysis 2
T₄ 2
betaPV) 2
T3-target 2
1409 2
isoenzymes, 2
hormone-binding-domains 2
(p=0.027), 2
8301 2
(wortmannin) 2
PI-3K, 2
phalloidin 2
Y-27632. 2
cystectomy, 2
(p21), 2
RHOA 2
hydroxymethyltransferase 2
SHMTs 2
SHMT 2
tetramer, 2
PLP, 2
SHMT2 2
kainate, 2
subtypes) 2
iGluR 2
AMPARs 2
(2-APB) 2
Ca(2+)-selective 2
2-APB. 2
designing. 2
co-transporters 2
empagliflozin), 2
PPG. 2
volume-related 2
Ipragliflozin 2
reabsorption. 2
luseogliflozin. 2
excretion: 2
600-kcal 2
(3)H-glucose, 2
(14)C-glucose, 2
(RaO) 2
[AUC0-2h] 2
(UGE0-6h, 2
(576 2
1,018 2
(∼10%) 2
peptide: 2
90.8% 2
37%). 2
(24.8%) 2
13.8, 2
BNP). 2
NT-proBNPs, 2
(15+/-8 2
&gt 2
64) 2
1-nmol/L 2
sufficiently. 2
DCMP 2
(1.31+/-0.37 2
2.01+/-0.72, 2
<or=1.7 2
Paulo, 2
p=0.012). 2
atrial, 2
PLN-encoded 2
sarcomere, 2
L39X 2
1,064 2
UV(s)S 2
neurodegenerative, 2
(ochre) 2
supE44 2
amber 2
helix-distorting 2
damage-sensing 2
end-labeling 2
(GGR). 2
Elc1, 2
elongin 2
Rad16, 2
TCR-deficient 2
GGR-deficient 2
Rad16. 2
assay: 2
30kb. 2
(Comet) 2
10-100-fold 2
(Comet-FISH) 2
genotoxins. 2
Comet-FISH. 2
matrix-attachment 2
supercoiled, 2
"heads", 2
"tails" 2
N-methylpurines 2
(TGs) 2
(Aag) 2
Aag, 2
Aag 2
deficient) 2
NER-deficient 2
(CS). 2
underly 2
genotoxicity. 2
synthesis/ligation. 2
XPC-HR23B 2
UV-inhibited 2
infliction, 2
Cockayne's 2
(QPCR) 2
Rad26. 2
Spt(-) 2
delay/intellectual 2
duplicated/deleted 2
OMIM-annotated 2
Dosage-sensitive 2
factor-β₁ 2
(TGFβ₁), 2
PubMed/Medline 2
TGFβ₁, 2
(autosomal-dominant 2
aneurysm), 2
6%-12% 2
brcc3 2
endothelium-specific 2
brcc3. 2
BRISC 2
785,720 2
10(-10)). 2
Algeria. 2
Hypergonadotropic 2
adulthood), 2
summary. 2
neurofibromatoses 2
broad. 2
member-only 2
anomalies/mental 2
(RAI1) 2
17p11.2 2
(occlusion 2
Willis). 2
3p24.2-p26 2
(FMMD) 2
TIMP4 2
non-MMD 2
cholesterin 2
252350) 2
lambda(s)>40. 2
17q25 2
D17S785-D17S836 2
Nor 2
identical-by-descent 2
3.46 2
D3S3050. 2
exams. 2
VH3 2
(IgBDs), 2
SpA-immunization 2
E.coli. 2
BL21 2
(w/v) 2
(IgG1). 2
Martini 2
interactional 2
disappearance, 2
rSPA 2
liter 2
adsorbents 2
"hot-spots" 2
polylysine 2
amikacin. 2
open-labeled, 2
avium. 2
BL/6 2
intracellularly. 2
[Mycobacterium 2
mediastinoscopy. 2
(n=68) 2
(AIDS), 2
isoniazid, 2
(CFU) 2
micrograms/ml. 2
non-AIDS 2
Clarithromycin-resistance 2
Cross-resistance 2
Mueller-Hinton 2
7.4) 2
Oleic 2
acid-albumin-dextrose 2
7H12 2
7.4. 2
'susceptible' 2
'resistant' 2
azithromycin) 2
macrolide-resistance. 2
(TRAPS), 2
(DeltaY103-R104) 2
R92Q 2
IgM-type 2
IgG-type 2
haematogenous 2
tamponade 2
non-resolving 2
fibrinolytics 2
pericardectomy. 2
Constrictive 2
seven; 2
bacteriologic 2
shaggy-type 2
(20-30 2
antituberculous 2
pericardiectomy, 2
overlooked? 2
under-recognized, 2
cyst-negative 2
(sporadic 2
LAM) 2
(Tsc2). 2
tubules) 2
Ink4 2
RC-derived 2
Ink4-Ifn 2
alpha-Ifn 2
Monro, 2
SAGA- 2
SLIK-dependent 2
(SAGA-like) 2
SLIK. 2
(Lys 2
(frq) 2
tail-binding 2
Chromo-helicase/ATPase 2
(CHD1) 2
30-65% 2
coin 2
panel) 2
NCT00513292. 2
(56·5%, 2
47·8-64·9) 2
(54·2%, 2
45·7-62·6) 2
2·3%, 2
-9·3 2
13·9). 2
[25·3%] 2
[31·7%] 2
[4·3%] 2
[8·5%]). 2
(0·8%) 2
(2·9%) 2
(7·1%) 2
(4·6%) 2
trastuzumab+capecitabine 2
75(fluororracil, 2
cyclophosphamide). 2
PgR-, 2
3+). 2
paclitaxel-FEC 2
Her-2 2
II-IIIC 2
weekly-trastuzumab 2
epirubicine 2
50-72 2
prematurely. 2
densification 2
fluorouracil/epirubicin/cyclophosphamide 2
(FEC) 2
FEC(60) 2
FEC(100) 2
FEC(90), 2
pegfilgrastim 2
(vomiting 2
)and 2
(PST) 2
allowed. 2
FEC-HD 2
M2, 2
.04 2
.0006, 2
bone-only 2
fared 2
anthracyclines). 2
epirubicin-alone 2
epirubicin- 2
50-group 2
193) 2
emesis 2
P.S. 2
5-fluorouracil-epirubicin-cyclophosphamide 2
cyclophosphamide-methotrexate-5-fluorouracil 2
(CMF) 2
mitomycin-methotrexate-mitoxantrone 2
antiemetic 2
(absence 2
58.6% 2
Epirubicin-based 2
Nausea/vomiting 2
(49.2% 2
56.9%; 2
47.6%; 2
=.06) 2
(P: 2
=.012 2
(17.9, 2
18.9, 2
=.49). 2
ORR. 2
Fleming 2
Taxotere 2
alternated 2
131-month 2
53.4%, 2
42.5%, 2
=.05) 2
=.02) 2
=.05). 2
64.3%, 2
56.6%, 2
=.25), 2
=.10). 2
=.046). 2
DFS. 2
(fluorouracil: 2
cyclophosphamide:500 2
serially. 2
grafting? 2
GIK 2
AXC. 2
AXC 2
GIK, 2
crossclamping 2
hemo-dynamic 2
crossclamp 2
10; 2
microg.kg(-1).h(-1) 2
microg.kg(-1).min(-1) 2
Mean+/-SEM 2
0.0035+/-0.0001 2
[0.23+/-0.01 2
0.001+/-0.0001 2
[0.7+/- 2
ng/dL]; 2
0.0133+/-0.0004 2
[0.87+/-0.03 2
(liothyronine 2
sodium) 2
SD] 2
[1.2 2
liter]), 2
supranormal 2
(2.97 2
(1073 2
1235 2
dyn.sec.cm-5, 2
resistances, 2
disappointment. 2
post-CPB 2
unclamping 2
(125I-iodocyanopindolol) 2
Post-CPB 2
(cross 2
(pg.ml-1) 2
pre-CPB 2
Unveiling 2
imperfection 2
mode). 2
'CPModule'. 2
homotypical 2
matching-based 2
impractically 2
SOP-specific 2
SOPs 2
lola 2
plug 2
CRL, 2
(flow 2
(JNK 2
bortezomib-sensitive 2
CD138(+) 2
5122-6012 2
MLX, 2
EID1, 2
ORC6L, 2
MAGEA6, 2
MORF4L2, 2
MRFAP1, 2
MORF4L1, 2
TAX1BP1 2
multiunit 2
Stromal-mediated 2
phospho-IκBα, 2
rebalancing 2
(BCR)-associated 2
adenylate, 2
intraenzyme 2
(UBLs) 2
cognate-activating 2
Cul2 2
Cul3 2
radiance 2
IL-6) 2
96-hour 2
Wilm's 2
NF-{kappa}B-dependent 2
regressions. 2
SAMHD1-mediated 2
nedd8-activating 2
CRL4, 2
Vpx-induced 2
(NEDD8 2
Enzyme), 2
1.5. 2
Ubiquitin-activating 2
(UAE 2
E1) 2
NAE, 2
(Brownell, 2
Liao, 2
Yang, 2
Li, 2
NEDD8-adenylate 2
(+)-ATPase 2
(+)-calmodulin-dependent 2
β1-adrenergic 2
(+), 2
(+)-cycling. 2
(Wolff-Parkinson-White 2
QT-syndrome, 2
cascade-screening 2
pioneered 2
athletics. 2
[Causes 2
gravitate 2
saudden 2
(GCVDs) 2
symptomatic) 2
leisure-time 2
Consensus, 2
Veer 2
H: 2
ER-positive, 2
microassay 2
(<61 2
kinase/stress-activated 2
(JNK/SAPK) 2
p38/RK/CSBP 2
SAPKbeta, 2
p46 2
SAPKgamma 2
(JNK1) 2
p21(rac) 2
(G12V), 2
(G12V) 2
MKP-3. 2
(DSPs) 2
MKP7, 2
JIP-1. 2
(SAPK) 2
(DSPs), 2
SAPK, 2
XILPXLXL, 2
hVH5-M3/6 2
RILPHLYL, 2
RILPHLYL 2
SAPK-mediated 2
LYL 2
SAPK. 2
well-characterized. 2
Laboratoire 2
Montpellier 2
Montpellier, 2
(IG), 2
(MhcSF). 2
immunoinformatics 2
(IG) 2
superfamilies 2
(NUMEROTATION) 2
cards, 2
renumbered 2
IMGT/Collier-de-Perles 2
humanization 2
(CDR) 2
nomenclature), 2
labels), 2
numerotation 2
Colliers 2
Perles). 2
Organization/International 2
immunologists 2
DRM2, 2
DNMT3. 2
BLASTX 2
(Dnmt1, 2
Dnmt2, 2
Dnmt3) 2
TaMET2a 2
leaf, 2
21,416 2
20,687 2
9640 2
33,977 2
24,500 2
yields, 2
status: 2
1500-2000 2
(February 2
0.80; 2
bordered 2
Chi 2
9324 2
26,747 2
podiatry 2
1.54; 2
Wales. 2
resistance]. 2
Limiting 2
(Geriatric 2
11.4% 2
32.4% 2
prefrail 2
frail: 2
Directors 2
622 2
III; 2
(15.3% 2
drive, 2
thrive" 2
77.1 2
(Exam 2
weight: 2
200) 2
1181) 2
Longitudinally, 2
unfounded. 2
Five-aminolevulinic 2
(Gliolan, 2
medac, 2
Wedel, 2
5-ALA) 2
64.3 2
infratentorial 2
Gliolan®) 2
VISIONA 2
€ 2
Gliolan(®)) 2
5-ALA. 2
ALA-induced 2
(ALA-FD) 2
(ALA-PDT) 2
urology, 2
otorhinolaryngology, 2
gastroenterology. 2
"bench" 2
"bedside" 2
diligence 2
ALA-esters. 2
Pharmacokinetical 2
Gliolan. 2
MATERIAL 2
PXD000461. 2
enChIP. 2
Vertebrates 2
(HOXD3-HOXD13) 2
dermatologist. 2
One-fifth 2
mg/gm/day. 2
FGFR2-signaling 2
dermalepithelial 2
acne-prone 2
FGFR2b 2
embryotoxicity. 2
(IGF-1), 2
FGF-mediated 2
phosphate/tretinoin 2
antiacne 2
nodulocystic 2
anticomedogenic 2
(</= 2
CTG, 2
All-trans-retinoic 2
no-observed-adverse-effect-level 2
(NOAEL) 2
lowest-observed-adverse-effect-level 2
(LOAEL) 2
8-11) 2
(all-trans-RA, 2
13-cis-4-oxoRA) 2
(13-cis-RAG). 2
(13-cis-RA 2
all-trans-4-oxoRA) 2
NOAEL, 2
rabbit; 2
LOAEL, 2
NOAEL) 2
LOAEL) 2
(2.08 2
hr.g-1) 2
(5.34 2
(RARs), 2
(1.14 2
g-1). 2
(tretinoin) 2
negligibly 2
no-observed 2
lowest-observed 2
absorption) 2
fascicularis) 2
(0-24-h 2
area-under-the-concentration-time-curve 2
all-trans-4-oxo-RA. 2
all-trans-RA. 2
wt) 2
preskeletal 2
Meckel's 2
situated. 2
Pre-ossicular 2
pre-mandibular 2
blastemata 2
lenticonus 2
apposing 2
precontacting 2
(3H-TdR) 2
10(-5)M, 2
cis-RA 2
degenerate, 2
DMSO. 2
micrograms/ml) 2
maxilla, 2
4-oxo-13-cis 2
RA-induced 2
day-10 2
Waymouth's 2
cysteine-to-alanine 2
(C462A) 2
p21/CDKN1A, 2
14-3-3σ. 2
CBP/p300, 2
p300-p53 2
(Hdm2), 2
nutlin-3. 2
PUMA, 2
Coculture 2
key. 2
alpha-agonists 2
prohypertrophic. 2
regulators: 2
HAUSP. 2
MDM2's 2
p53) 2
p300/CPB-associated 2
(K466/467Q) 2
autoubiquitination. 2
K466/467Q 2
ring-finger 2
(RFD) 2
resides, 2
Crosses 2
translocalizes 2
HDM2. 2
HDMX-mediated 2
(p53). 2
(+)-dicentrine 2
Bulbocapnine, 2
methoxyl 2
bulbocapnine 2
11-hydroxyl 2
methylenedioxy 2
"adaptive" 2
oxoaporphine 2
liriodenine. 2
U.V. 2
Amsacrine, 2
antileukemogenic 2
rhinorrhea 2
(K50 2
deem 2
DNA-enzyme 2
oxolinic 2
post-UV 2
sizeably. 2
Merbarone 2
Novobiocin, 2
(A-T) 2
II-inhibitor 2
(mAMSA)]. 2
antitopoisomerase 2
mAMSA-induced 2
kill, 2
(assayed 2
mAMSA. 2
carcinogens. 2
anthraquinones, 2
emodin, 2
aloe-emodin, 2
danthron, 2
bisbenzimide 2
mutagenicity. 2
(AD 2
teniposide, 2
(1,4-bis[[2-(dimethylamino)ethyl] 2
amino]-5,8-dihydroxyanthracene-9, 2
10-dione 2
bis-N-oxide 2
AQ4, 2
intercalator. 2
discolouration 2
>50%, 2
6-amino 2
arylamine, 2
transferase-2 2
(NAT2) 2
arylamines 2
amonafide) 2
arylamine. 2
acetylated, 2
numonafides) 2
amonafide; 2
daunorubicin. 2
bis(trifluoroacetate) 2
indenoisoquinoline 2
(cMAP) 2
NB-cMAP 2
(http://pob.abcc.ncifcrf.gov/cgi-bin/cMAP), 2
amsacrine/DNA, 2
drug/DNA/topoisomerase 2
moiety) 2
micro-SER 2
(particular 2
(DC3F/9-OHE 2
(DC3F). 2
4'-(9-acridinylamino)methanesulfon-m-anisidide-induced 2
linking, 2
Topoisomerases 2
qualitatively. 2
intercalates 2
"cleavable 2
amiloride's 2
I-DNA 2
benzophenanthridine 2
indolocarbazole 2
poison: 2
4'-amino-methanesulfon-m-anisidide 2
headgroup. 2
3'-methoxy 2
Shifting 2
2'-position 2
(o-AMSA), 2
1'-substituent 2
nonintercalative 2
cross-sensitivity 2
(anthramycin) 2
(distamycin 2
[adriamycin, 2
4'-(9-acridinylamino)methanesulphon-m-anisidide 2
(mAMSA)] 2
(VP16-213) 2
DNA-intercalating 2
drug/protein 2
drug/DNA 2
interactions); 2
reductively-activated 2
hypoxia-selective 2
'carriers' 2
(sequence-, 2
regio- 2
site-specifically) 2
Indolo[2,3-b]quinolines 2
neocryptolepine, 2
ghosts 2
bis(10-methyl)acridinium 2
unsubstituted 2
ruthenium(II) 2
Ru(II) 2
DUMs 2
4'-(9-acridinylamino)methane-sulfon-m-anisidine, 2
24-fold 2
mAMSA-treated 2
mitoxantrone-treated 2
L1210 2
intercalator-induced 2
DACA 2
asulacrine, 2
Fornace, 2
Biol., 2
gadd153CAT/HeLa 2
UV-mimetic 2
DNA-cross-linking 2
gadd153CAT 2
σ-bonded 2
Cystodytes 2
shermilamine 2
cystodytin 2
epipodophyllotoxins, 2
miR-140, 2
miR-132) 2
∼1600 2
epileptogenesis, 2
epilepticus) 2
Tauopathies 2
(3R) 2
(4R) 2
early-symptomatic 2
∼0.013 2
μm⁻³), 2
GLT-1. 2
MNI-D-aspartate 2
(4-methoxy-7-nitroindolinyl-D-aspartate) 2
EAAC1-mediated 2
innervation. 2
(IHCs) 2
suggestion. 2
declining. 2
L-cystine 2
(gamma-glutamylcysteinylglycine). 2
20-110 2
L-homocysteate 2
HEK(GLAST), 2
L-homocysteine 2
L-[14C]cyst(e)ine 2
L-cystine. 2
counter-transport 2
Glt(Ph). 2
Asparagine 2
312, 2
89. 2
piglets. 2
T1R3 2
(taste 2
(metabotropic 2
EAAC-1 2
carrier-1), 2
GLAST-1 2
(glutamate-aspartate 2
(glutamate 2
T1R1, 2
T1R3, 2
BW/day, 2
alanine-serine-cysteine 2
ASCT1, 2
A382T, 2
T459R, 2
l-aspartate. 2
l-aspartate 2
l-glutamate. 2
5.5; 2
A382T. 2
TM7 2
TM8 2
GRK2-deficiency 2
GLutamate 2
ASpartate 2
GFAP-GRK2(+/-) 2
excitotoxin 2
GltT-GltM-dependent 2
3Na(+) 2
1H(+) 2
countertransport 2
l-anti-endo-3,4-methanopyrrolidine-dicarboxylic 2
(MPDC) 2
(2S,4R)-4-methylglutamate 2
(4MG), 2
Ser/Gly 2
hGLuT-1 2
hEAAC1 2
2,4 2
electrogenic 2
(EAAT2), 2
(EAAT1-5) 2
(HGRP), 2
(HAPC), 2
GRPs 2
(BMP-4). 2
(NR2B), 2
MRP4. 2
6-[(14)C]mercaptopurine, 2
6-[(14)C]mercaptopurine. 2
(PAK) 2
(β-Pix)-G 2
SNX27-PDZ 2
GST-SNX27 2
(p21-activated 2
kinase-interactive 2
(ETNL). 2
β-Pix. 2
β-Pix·Git 2
SNX27-dependent 2
variant: 2
C-termini. 2
SNX27a 2
zeta-interacting 2
SNX 2
PDZ-dependent 2
zeta. 2
zeta-dependent 2
polarizes 2
protein-gated 2
(Kir3) 2
nexins, 2
(PI3P) 2
Phox 2
N-Methyl-d-aspartate 2
NR2C. 2
ζ 2
(DGKζ), 2
metabolises 2
polarise 2
Downmodulation 2
antigen-triggered 2
815 2
entries) 2
SpliceDB 2
(156 2
fluorochromes 2
trypsin) 2
ionization, 2
Stains-All. 2
(α-casein, 2
β-casein, 2
phosvitin) 2
Blue, 2
post-electrophoretic 2
e22394) 2
CBS. 2
(2D-DIGE). 2
solubilizing 2
cysteic 2
Z-CyDyes 2
co-detection 2
ProQ-Diamond, 2
SYPRO 2
densitometry, 2
BioSafe 2
(Bio-Rad) 2
NCCB 2
Spots 2
μg/μL 2
impregnation 2
best-in-class 2
Tumor-targeted 2
aptamer-siRNAs 2
Antidote 2
(siRNA)-mediated 2
tumour-targeted 2
(GM-CSF)-expressing 2
shepherd 2
siRNA-based 2
prasugrel, 2
NCX-4016, 2
anti-von 2
Wet 2
pegaptinib, 2
Technology, 2
clarity, 2
(R-aptamers) 2
fluorochrome-labeled 2
nonselected 2
ODN. 2
multimerization, 2
nonaggregating 2
R-aptamers. 2
loop-mediated 2
(Foc), 2
(Panama 2
spp.). 2
soil-borne 2
cultivar, 2
(Foc1) 2
(Foc 2
TR4) 2
triploid 2
Cavendish 2
(DGE) 2
intercropping 2
(Allium 2
tuberosum 2
FOC, 2
2-methyl-2-pentenal 2
(dimethyl 2
disulfide, 2
dipropyl 2
50-100 2
Banana 2
Wilt 2
grown, 2
planting 2
nontraditional 2
plantations 2
cultivars, 2
Grand 2
biosynthesized 2
banana: 2
genealogies. 2
distant. 2
Cladograms 2
partition-homogeneity 2
"F. 2
cubense" 2
bananas 2
(MOR1) 2
MOR1. 2
∼1.2 2
(LY2196044, 2
ALKS-29, 2
ALKS-33) 2
(Nal) 2
JKB-119, 2
Nal, 2
Nal 2
decompressions. 2
overcorrection 2
Multisutural 2
(BLSS) 2
turribrachycephaly, 2
concavity, 2
syndromic, 2
(6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine), 2
1-aminobenzotriazole 2
VPA-stimulated 2
AMPK/ACC 2
IGF-R 2
TrkC, 2
deregulation, 2
(CGNP), 2
cells-of-origin 2
(IGF), 2
CGNP 2
Akt-mediated 2
Driving 2
Shh/Ptc 2
Shh/Patched 2
steroid-like 2
EGF-associated 2
cancer-relevance 2
cilia-dependent 2
WNT, 2
(GNP) 2
germinative 2
SHH-Gli 2
cyclopamine, 2
SHH-GLI 2
metastasise 2
mesenchymally 2
Flavonoids, 2
(Qu), 2
Qu 2
extravasation, 2
basally-localized, 2
lamellipodia, 2
(exome-seq) 2
'Gene', 2
genes/mutations. 2
type/dataset 2
'Gene' 2
'Meta-Analysis' 2
customer-defined 2
genes/mutations 2
identification) 2
'passenger' 2
cancerous) 2
identification-based 2
"tuning" 2
driver- 2
ApcMin/+ 2
non-silent 2
http://linus.nci.nih.gov/Data/YounA/software.zip. 2
Inbred 2
(DCGs), 2
(PCGs), 2
establishment/maintenance. 2
(RASA3, 2
NUPL1, 2
DENND5A 2
AVL9). 2
trade-off. 2
(reflecting 2
oncogenomic 2
(MPNSTs) 2
aneuploid, 2
(CNAs). 2
CNAs, 2
co-gained 2
co-lost 2
equidistant 2
clustered. 2
tubes. 2
mtDNAs 2
Abf2, 2
ClO(4) 2
methimazole 2
mU/liter 2
euthyroidism. 2
n=5) 2
(9.4%, 2
adolescent. 2
thyroiditis: 2
(MMI 2
MMI-GLU 2
mCi) 2
sarcoplasmatic 2
L-channel 2
948 2
hypesensitivity 2
enanthema 2
(cough, 2
dyspnoea) 2
Cough 2
(HFpEF), 2
db/db-Iva. 2
elastance 2
mmHg/µL, 2
N2B 2
cholesterol-enriched 2
(92% 2
ml/min/kg 2
56.3 2
(9.9 2
[FT4] 2
(28.6%), 2
(n=29). 2
p=0.024). 2
17.1% 2
TFT. 2
(0.1-4.5 2
mIU 2
L(-1)), 2
1-60) 2
s-albumin, 2
(VCAM)-1 2
VCAM-1) 2
s-albumin 2
47.8; 2
micro-inflammation 2
nutritional, 2
(LVMI) 2
(EF). 2
(113.4 2
49.8 2
P=0.001, 2
ratio=3.76, 2
0.033, 2
0.013, 2
hs-CRP 2
pg/ml. 2
xerostomia. 2
Aetiology 2
aetiologic 2
citizens, 2
12-18%. 2
neuropathological, 2
immunohistologically 2
(B-LBLs) 2
B-LBLs 2
(TdT), 2
immunophenotypically, 2
TdT 2
(ER)(-) 2
(Her2)-positive 2
(PgR), 2
PAGE/silver 2
immunohistochemistry) 2
therapy-amenable 2
Mage-A 2
positive/estrogen 2
CD44(hi) 2
mesenchymal-like 2
lipolysis-stimulated 2
(LSR), 2
S100A14 2
(MUC1), 2
31-gene 2
PU-H71, 2
PU-H71. 2
PU-H71-bound 2
(HER2-, 2
PR-) 2
MDH2, 2
PGK1, 2
TKT, 2
Aldolase1), 2
(CK7, 2
(vimentin, 2
L-plastin), 2
NME1-NME2, 2
TIF 2
singled 2
EF-1-beta, 2
hierarchal 2
rationale-based 2
matrigel. 2
ER(-) 2
Isotope 2
SEC14L2 2
high-risk, 2
alpha-defensins 2
(DEFA) 2
DEFA 2
biosignatures 2
thromobospondin 2
zinc-α2-glycoprotein, 2
aldolase 2
(triple-negative 2
bisindolylmaleimide 2
Bis-probe 2
serine/arginine-rich 2
anxiety- 2
tail-suspension 2
(AMLs). 2
(S6K), 2
hamartin, 2
tuberin. 2
mTOR/S6K 2
Kinases, 2
dS6K 2
dS6k 2
(mTOR, 2
dTOR 2
Drosophila). 2
mTOR/S6K1-signalling 2
GAP-like 2
(Rheb) 2
Ras/Rap 2
mTOR/S6K1/4EBP 2
insulin-signalling 2
vapour-diffusion 2
hRheb-GDP 2
P2(1)2(1)2(1), 2
70.6 2
C222(1), 2
71.9 2
Rhebs 2
rheb 2
1)-Tsc2 2
Tuberin 2
(Tsc1) 2
Tsc2, 2
TOR-dependent 2
retinopathy; 2
(HIP) 2
nationalities. 2
(TLC) 2
heating. 2
nonthermal 2
enhance, 2
thermoregulatory 2
1530 2
36.7 2
3.47 2
0.14) 2
mb, 2
rehydration 2
(elotuzumab 2
19.4 2
0.70; 2
AbbVie 2
Biotherapeutics; 2
ELOQUENT-2 2
NCT01239797.). 2
(PBL)/myeloma 2
Luminex 2
(IL)-2Rα 2
CD3(+)CD56(+) 2
elotuzumab. 2
(TB). 2
(MDR-TB). 2
diarylquinoline, 2
R207910, 2
TMC207 2
tuberculosis; 2
Bedaquiline's 2
semireplicating 2
hypometabolic 2
pyrazinamide 2
extragastrointestinal 2
[idiopathic 2
(IDA)], 2
(stroke, 2
publications; 2
(anti-H. 2
(anti-Cag 2
4,041 2
ten, 2
(1.21-2.11), 2
IgG; 2
(1.76-3.09), 2
(1.11-2.47), 2
Cytomegalovirus, 2
(Cp). 2
(AOR 2
Cytotoxin-associated 2
Cag-A 2
sex-age- 2
background-matched 2
by[13]C-urea 2
1.37-5.30). 2
the: 2
pylori-infected 2
pylori), 2
extradigestive-related 2
pylori-induced 2
C(-260)T 2
63.2%, 2
19.2%, 2
95%). 2
(IgG 2
fibrinogen) 2
recommendable 2
Harasanshin 2
combined: 2
2.57; 2
1.09-6.08) 2
infection/inflammation 2
thrombogenesis 2
codeterminant 2
infectious/inflammatory 2
4.14, 2
endarterectomy 2
(57.5%) 2
carotic 2
(42.8% 2
[mean+/-SD] 2
49-65 2
(59.4%) 2
(77.5%) 2
(86.3%) 2
(57.9%) 2
Neighborhood 2
3.31; 2
9.56) 2
plaque: 2
Appropriately 2
[Infections 2
pylori]. 2
"Classical" 2
prospectic 2
(1.63 2
58.6%, 2
(F0), 2
shimmer, 2
(MSDs). 2
(CON) 2
(AT), 2
approach's 2
AT, 2
FAS, 2
Acoustic-phonetic 2
(maximum-phonation-duration, 2
F0-variability) 2
phrase, 2
(AT) 2
group? 2
Vowel 2
ataxic-dysarthric 2
Lab. 2
loudness 2
(vocal 2
prosody. 2
monologue 2
framework: 2
pitch, 2
loudness, 2
monopitch, 2
monoloudness, 2
breathy 2
(voice 2
ataxic, 2
Dysarthric 2
speech: 2
Neuromedicine 2
OPD 2
Kolkata. 2
consonants 2
dysarthrias. 2
upper- 2
lower-motor 2
spastic-flaccid 2
spoken 2
Assistive 2
phonetic 2
Knee 2
hemeoxygenase-1 2
Statin-mediated 2
FoxO. 2
FoxO, 2
FoxO3a, 2
morbidities: 2
retentions 2
76.9 2
79.1 2
cutting-edge 2
Stretta 2
transoral 2
incisionless 2
fundoplication, 2
(LINX). 2
incompetency 2
'therapy 2
LINX( 2
surgeon]. 2
symptom-defined 2
Asa 2
symptom,treating 2
narrow. 2
anti-reflux 2
ignored, 2
treatment.The 2
(Linx), 2
hernioplasty, 2
nonthoracic 2
esophagectomy. 2
(GEJ). 2
(23/23) 2
Gangliosidoses. 2
dysostosis, 2
Cherry-red 2
gangliosidoses, 2
Macrocephaly, 2
Neurochemical, 2
51-fold 2
asialo-GM2 2
somatic-facial 2
mucopolysaccharidosis, 2
sea-blue 2
histiocytes 2
glucosidase, 2
hexosaminidase, 2
clinical-pathologic-biochemical 2
deficiency): 2
Arg49----Cys. 2
Arg457----Ter 2
Arg201----Cys 2
Ile51----Thr. 2
COS-I 2
findings]. 2
chronic) 2
gangliosidosis). 2
β-domain 2
N-butyldeoxygalactonojirimycin 2
(GSL) 2
(beta-gal), 2
catabolyzes 2
(B6) 2
p-5 2
transfer: 2
gangliosidosis, 2
extents, 2
beta-galactosidose, 2
beta-galactosidase-like 2
(beta-galactosidosis): 2
cerebroside, 2
sulfatide. 2
parenchimal 2
month- 2
(DDMS), 2
conundrum, 2
pulselessness 2
bruit 2
pansystolic 2
hemicircumference 2
sensorium 2
Temporo-spatial 2
seizures/month 2
neuroradiologically 2
discrimination), 2
Electroclinically, 2
lateralized 2
[Two 2
hemiatrophy]. 2
hemiplegia/hemiparesis 2
petreous 2
perinatally 2
davidoff 2
masson 2
hemitrophy 2
Hemiatrophy 2
(during 2
lentiform 2
extremities) 2
burr 2
[Dyke-Davidoff-Masson 2
(26.5%) 2
(69.2%) 2
commented. 2
hemicranium, 2
ipsilaterally 2
syndrome-causing 2
acyl-transfer 2
Mitochondria-targeted 2
mito-Tempo. 2
Mito-Tempo 2
heart-on-chip 2
(iPSC-CMs), 2
'heart-on-chip' 2
Sarcomere 2
(hpf). 2
nonlooped 2
mitochondrion-specific 2
full-yield 2
accumulates. 2
(respirasome) 2
I+III2+IVn 2
I+III 2
III+IV. 2
association/stabilization 2
acyllysocardiolipin 2
(tafazzin) 2
shipping 2
TAZ-specific 2
TAZ. 2
caspase-specific 2
891 2
(c891_893delTGA), 2
mitochondrial-mediated 2
tafazzins. 2
(51.6%), 2
triiodothyronine) 2
(p=0.0632). 2
time-keeping 2
Suppressing 2
(C26) 2
(L929) 2
Etoposid, 2
Cisplatin. 2
Clock-/- 2
intersession 2
habituation. 2
formation; 2
(Bmal1), 2
KD. 2
organization: 2
Conformation 2
H3K36me2 2
(K27me3), 2
Nestin. 2
Insulin/IGF-I-dependent 2
(2-DE)-based 2
SRp20, 2
S-transferase-pi. 2
MG-132, 2
ERK7, 2
NCC27/CLIC1, 2
pS-X-X-S, 2
(MBP), 2
(K/R-X-K/R-X-X-S/T) 2
SCS-binding 2
'phosphate-directed' 2
CK1a 2
Lys232 2
b-catenin 2
pSer-Xaa-Xaa-Ser. 2
"priming" 2
synthase-3 2
prescribes 2
38-65 2
Pro-44 2
Pro-52 2
-2. 2
Ser120/Ser121 2
seryl 2
CK2, 2
Ser174 2
I-2. 2
prephosphorylated 2
residue(s), 2
FEBS 2
persistent. 2
warfarin). 2
subanalysis, 2
3.25, 2
.700). 2
rivaroxaban- 2
.58-1.95; 2
.86-1.45; 2
.488). 2
.46; 2
.09-2.37; 2
.49; 2
.22-1.11; 2
.935). 2
fibrillation). 2
major/nonmajor 2
74, 2
≥90 2
DBP 2
DBP, 2
(An 2
Fibrillation: 2
NCT00403767). 2
AF-related 2
secondarily, 2
ECV, 2
PCV, 2
1.46 2
0.58). 2
(1.88% 2
(OAC) 2
OACs 2
14,624) 2
6.20 2
5.05/100 2
25.60 2
23.28/100 2
6.42 2
1.73/100 2
9.16, 2
0.0044) 2
Once-Daily 2
XANTUS 2
[Xarelto(®) 2
(SVD) 2
SVD; 2
SVD. 2
(19.8% 2
16.8% 2
1.25, 2
putting 2
NCT00403767. 2
(73% 2
38%), 2
p<0·0001 2
cTTRs 2
TI. 2
0.41% 2
[confidence 2
0.79% 2
–. 2
(n=1,280) 2
18.04% 2
16.42% 2
0.87-1.42; 2
[non-inferiority]). 2
P=0.050). 2
SPIKE--a 2
Carefully 2
interplays 2
commonalities 2
(NPD) 2
proteomes: 2
Chlamydomonus 2
reinhardti, 2
K12, 2
Methanoscarcina 2
acetivorans. 2
proteome--the 2
(slug). 2
biologist. 2
amoeba 2
parts-list 2
HAPPY 2
rivals 2
aconitase 2
Orange 2
macropinocytosis. 2
prespore 2
PSVs. 2
perilipins 2
energetics. 2
intramyocellular 2
(indirect 2
calorimetry) 2
(perilipins 2
(PLIN1) 2
(PLIN2) 2
PAT-1 2
(ADFP), 2
non-adipose 2
Forster 2
[perilipin, 2
adipophilin/adipocyte 2
(ADRP), 2
tail-interacting 2
kilodaltons 2
(TIP47), 2
(MLDP)/oxidative 2
tissues-enriched 2
(LSDP5)]. 2
(basal 2
Rabs, 2
perilipin-coated 2
(Perilipin, 2
TIP47), 2
adipophilin 2
PRC2-independent 2
SMCHD1-HBiX1 2
HBiX1, 2
(HP1)-binding 2
(SMCHD1), 2
XIST-associated 2
(XIST-H3K27me3) 2
decompaction, 2
XIST-H3K27me3 2
'Your 2
gender': 2
(intersexuals, 2
homosexuals 2
transsexuals). 2
'chromosomal' 2
'genetic' 2
conviction 2
arbiter 2
overturned. 2
Barr's 2
HMG-I/Y 2
heteropycnotic, 2
DXZ4, 2
SAP30, 2
case-based 2
students' 2
X-inactivation: 2
Ironically, 2
say, 2
captivated 2
fascination 2
realisation 2
"Barr 2
body" 2
one? 2
post-coitum 2
reawakened 2
formaldehyde-fixed, 2
4,6-diamidino-2-phenylindole 2
dihydrochloride-stained 2
smoother 2
(RF). 2
Plume 2
LAESI 2
technologies-secondary 2
(SIMS) 2
(MALDI 2
MS)-are 2
micro-bioanalytical 2
SIMS, 2
SIMS 2
submicron 2
microprobe 2
micro/nanofluidics 2
third- 2
miniaturization 2
specialisation 2
Dehydrin 2
(ERD14_ARATH), 2
(BGL37_ARATH 2
BGL38_ARATH), 2
(ANXD1_ARATH), 2
(VSP1_ARATH 2
VSP2_ARATH) 2
(METE_ARATH, 2
SAHH1_ARATH, 2
METK4_ARATH 2
METK1/3_ARATH) 2
(ADK1_ARATH), 2
epidermal/cortical 2
S-cells. 2
glucosinolate 2
glucoraphanine 2
TGG2 2
TGG1 2
glucosinolates, 2
glucosinolates 2
infusion/injection 2
shotgun) 2
agglomeration 2
mass/charge 2
Lateolabrax 2
japonicas, 2
Ctenopharyngodon 2
idellus, 2
Carassius 2
auratus. 2
sub-ppm 2
(Mass 2
approaches: 2
lipidomics) 2
infusion-based 2
(MDMS-SL) 2
methanolysis 2
sphingoid 2
very-low-abundance 2
sphingosine, 2
psychosine, 2
lysosphingomyelin) 2
sphingolipidomics). 2
gene-signature 2
(DMFS) 2
MammaPrint. 2
Responsive: 2
Beach, 2
(http://www.adjuvantonline.com) 2
$1440 2
life-year. 2
$10,000 2
$700 2
DDFS 2
CT), 2
964 2
pT1 2
DMFS 2
12,938 2
0.33-1.29) 2
0.36-3.73) 2
0.64-1.20). 2
warfarin) 2
conventional-therapy 2
16,701 2
16,611 2
4.79). 2
(0.57, 2
0.84), 2
(0.76 2
2.95 2
71.82) 2
(0.72 2
(0.67 2
(0.42 2
1.08) 2
6.89 2
(0.36 2
132.06) 2
(dabigatran) 2
β-oxidation 2
(glycolysis 2
3-HB 2
stretch-exposure 2
conditions--an 2
(HIF1A) 2
ventilator-induced 2
HIF1A-stabilization 2
endothelia, 2
¹³C-glucose 2
liquid-chromatography 2
(AIP), 2
hydroxymethylbilane 2
(HMBS), 2
5-aminolaevulinic 2
(ALA). 2
(ALAS) 2
Hmbs 2
phenobarbital. 2
(-52%, 2
(**)p<0.01), 2
(-50%, 2
(-55%, 2
α-ketoglutarate 2
(-64%, 2
(-48%, 2
(-53%, 2
(*)p<0.05). 2
II-driven 2
arginate 2
global, 2
encounter. 2
biochemicals 2
dysbiosis. 2
(HMacs) 2
(mtROS) 2
Pdp1 2
mtROS, 2
HMac 2
endotoxin-mediated 2
(BHB) 2
acetoacetate 2
(AcAc) 2
low-carbohydrate 2
BHB, 2
AcAc 2
CARD 2
(NLRC4) 2
(AIM2) 2
speck 2
starvation-regulated 2
crystal-induced 2
(Epo) 2
Cooke 2
“anemia 2
diseases”). 2
5-acetyl-2-arylbenzimidazoles 2
Title 2
(ssRNA(+)) 2
negative-sense 2
(RNA(-)), 2
BVDV 2
0.8-8.0 2
CC(50)/EC(50) 2
>100). 2
Flaviviruses; 2
CVB-2 2
polynucleotide-stimulated 2
RNA-stimulated 2
enzymologically 2
2-Arylbenzimidazoles 2
(24) 2
benzimidazole 2
2-[(benzotriazol-1/2-yl)methyl]benzimidazoles, 2
(dialkylamino)alkyl- 2
(Yellow 2
(YFV)) 2
(Bovine 2
(BVDV)), 2
Hepaciviruses 2
Paramyxoviridae 2
[HCV]), 2
Pestivirus. 2
standard-nicotine 2
brand, 2
(0.6, 2
cigarettes). 2
1-hydroxypyrene 2
(VLNC) 2
smoked, 2
Precessation 2
brands 2
denicotinized 2
mg/24-hr) 2
cessation? 2
489) 2
lozenge. 2
79); 2
76); 2
NRT-based 2
1,410 2
Quitline 2
Māori, 2
Control. 2
reinforcer 2
phospholipase, 2
glycophosphatidylinositol 2
palmitoleate. 2
Planarian 2
neoblast 2
proceeds, 2
planarian 2
planarians 2
yki 2
WNT-inhibitor 2
notum. 2
UnResponsiveness 2
respiration). 2
PCPC 2
(FOUR 2
(intracerebral 2
64y, 2
36.1y). 2
0.768 2
0.699 2
0.683 2
0.682 2
0.748 2
0.704 2
(nurse/fellow, 2
nurse/consultant, 2
fellow/fellow, 2
fellow/consultant). 2
1.00) 2
(71%). 2
intensivists. 2
904 2
bioengineering. 2
cell-seeded 2
cochlea-shaped 2
reception, 2
listen 2
audio 2
naturally-derived 2
Fabrication 2
printing/electrospinning 2
fibrin-collagen 2
biomimicking 2
Nozzle 2
3D-printing 2
printers 2
discussed; 2
-0.30 2
[3H]-ospemifene 2
29.0 2
preclinically 2
(NAMS) 2
Trustees. 2
VVA, 2
arzoxifene 2
Bazedoxifene 2
VVA) 2
hold) 2
VVA-related 2
Ospemifene: 2
(Osphena™) 2
QuatRx 2
Shionogi 2
filing 2
303) 2
302) 2
605) 2
dyspareunia: 2
(51.0%) 2
(ospemifene 2
3.6%); 2
826 2
5.0, 2
lubricants. 2
awakenings 2
symptoms), 2
"much 2
719 2
P=0.001) 2
afflicted. 2
RLS/WED?" 2
(QoL). 2
(α₂δ 2
-0.21). 2
sensorimotor, 2
(codeine, 2
tramadol, 2
oxycodone) 2
pregabalin). 2
irresistible 2
antiepileptics 2
appropriate) 2
STANDARD 2
OPTION 2
6-week, 2
(CGI-I) 2
123.9 2
38.2%; 2
322.50 2
(+/-98.77), 2
unsteadiness, 2
sensorial 2
sensations. 2
(oxycodone, 2
tramadol) 2
lyase. 2
(endoglucanase 2
pectinase) 2
Cel5A 2
mixed-linkage 2
Cel5A, 2
maximum/final 2
modification/degradation 2
molecule/network 2
Pectinase 2
(Pel1, 2
lyase) 2
alpha-expansin-induced 2
xyloglucan-cellulose 2
alpha-Expansin 2
Cel12A's 2
Expansin 2
Cel5A's 2
Pel1's 2
esterified 2
pectin. 2
expansin-related 2
hypercellulolytic 2
inducers. 2
expansin/family 2
endoglucanase-like 2
(EEL) 2
lignocellulose 2
eglD 2
Trichoderma, 2
Swollenin, 2
reesei, 2
(CBD) 2
cellulose-binding 2
arbuscular 2
extensibility. 2
Glomus 2
versiforme. 2
(anti-EXPA1 2
anti-EXPA2, 2
alpha-expansins) 2
roots: 2
anti-EXPA1 2
anti-EXPA2 2
Mycorrhizal 2
double-labelling 2
cellobiohydrolase-gold 2
alpha-expansins. 2
Alongside, 2
viral-mediated 2
IL2Rgamma 2
ROSA26 2
ZFNs, 2
electroporated 2
Oxidase-deficient 2
"safe 2
harbor" 2
ZFNs. 2
assembly) 2
mild) 2
0·024). 2
0·001), 2
disproportional 2
stocky 2
N540K. 2
retrusion. 2
apnea; 2
orthopedist 2
Monitor 2
hanging 2
fluorescence-enhanced 2
(G1138A), 2
380. 2
polymorphism(PCR-RFLP) 2
14/17 2
PCR-DGGE. 2
PCR-RFLP, 2
[Differentiation 2
analysis]. 2
ACH. 2
short-limb 2
omit 2
IIB. 2
(radicicol 2
geldanamycin), 2
Bergerat 2
gyrase. 2
Radicicol 2
17-allylamino-17-demethoxygeldanamycin, 2
4125 2
4133 2
142623) 2
SEMA3D 2
SEMAs 2
over-representation, 2
"protective" 2
RET-induced 2
RVs, 2
(NCCs; 2
precursors) 2
(ErbB2 2
(Ret 2
Nrg1 2
Gdnf-induced 2
Gdnf 2
Nrg1-signaling 2
(NaB), 2
peristaltic 2
10q11.2. 2
(84.3% 2
2071G>A 2
2712C>G 2
1/30,000 2
1/5,000. 2
G698R 2
(c.73 2
9277T 2
heterozygosis. 2
4q31.3-q32.3. 2
2.54 2
S-HSCR 2
NCI-H146, 2
(TTX)-sensitive 2
pA). 2
anodal 2
Mn(2+)-induced 2
step-depolarizing 2
+45.2 2
Nernst 2
Na(+)-selective 2
(-60 2
activation/inactivation 2
membranes; 2
infinity, 2
pA 2
pS. 2
68-year 2
man: 2
myasthenia-like 2
LCNEC 2
pmol/L. 2
AChR 2
spontaneously-occurring 2
CACNAIA, 2
alpha1A 2
ACh. 2
"passive 2
(DHP) 2
Nicardipine 2
(NMJ), 2
LMS 2
RNS 2
Radiological, 2
gaze-evoked 2
hyporeflexia 2
(CIDP) 2
autoimmune-like 2
anti-glial 2
Bulbar 2
tachypnea 2
P/Q- 2
CACNB2 2
CACNB4 2
anti-N-type 2
(VGCCs) 2
125I-omega-conotoxin 2
125I-omega-CmTx-labelled 2
Rabbit 2
individuals; 2
radiation-associated 2
Actinoplanes 2
actagardine 2
lantibiotic, 2
preservation, 2
LanBC 2
Planomonospora 2
(methyl)lanthionine 2
alba, 2
[Lantibiotics, 2
antibiotics]. 2
detergent-like 2
preservative, 2
subtilin, 2
epidermin. 2
methyllanthionine. 2
phosphoethanolamine. 2
LabKC. 2
enzymes; 2
LabKC 2
Lantibiotics, 2
voltammetry 2
Jew 2
Russe 2
(HMSNR), 2
(LGMD2C), 2
syndrome--first 2
Rudari. 2
(CTDP1) 2
Underlie 2
antropomorphological 2
dysmorphism-neuropathy. 2
(Gypsy) 2
ethnicity; 2
(Gypsies; 2
refs. 2
1931, 2
MSS, 2
Hypergonadotrophic 2
D5S1995-D5S436 2
MSS. 2
leucoencephalopathy, 2
Marinesco-Sjögren/myoglobinuria 2
3.55, 2
co-localises 2
"Tour 2
France" 2
gruelling 2
(n=465), 2
(n=173) 2
rode 2
1964. 2
Dates 2
(st) 2
"athlete's 2
heart," 2
"ECG," 2
"echocardiography," 2
"endurance 2
exercise," 2
"longevity," 2
Athlete's 2
harmonically 2
training-related 2
training-unrelated 2
endurance-exercise, 2
1.10). 2
Gold, 2
silver, 2
bronze 2
(1.13, 2
1.13) 2
(1.05, 2
1.08). 2
medal, 2
glory. 2
Lifelong 2
ns), 2
work-rate 2
adults? 2
11.2; 2
Sports, 2
prolines. 2
life-span 2
late- 2
trade-offs 2
Transposases 2
(Lig 2
Lig 2
oncogenicity. 2
Hsmar1-derived 2
littered 2
F460K, 2
F460 2
Pso4 2
(hPso4) 2
Metnase-hPso4-DNA 2
Metnase-hPso4 2
decatenating 2
automethylation. 2
gamma-H2Ax 2
metnase 2
R432 2
R432A 2
DDE-like 2
transposases, 2
methylatransferase 2
inverted-repeat 2
paired-ends 2
transposase/nuclease 2
quinolones 2
Chk1, 2
S495A 2
bcl-x 2
c-flip, 2
caspases-8 2
Bcl-x, 2
KSR1, 2
ZAK 2
pro-apoptotic, 2
sub-lethal 2
3/7 2
EMSA. 2
Xbp-1 2
MUC4. 2
bcl-X 2
bcl-X-L 2
Skp2-SCF 2
p53/Pten-deficient 2
RAS/BRAF 2
oncogene-evoked 2
(DDR). 2
AKT-driven 2
disregulation, 2
cell-nonautonomous 2
Remarkably 2
SASPs 2
promote, 2
Erosion 2
NHFs 2
(0.05%) 2
Lymphomas 2
Eμ-tTA/tetO-MYC 2
addicted. 2
Milestones 2
Huisman). 2
Huisman's 2
Augusta, 2
acetonitrile-DMSO 2
dimethylsulfoxide 2
tenfold. 2
(dimethylsulfoxide) 2
6.0% 2
(CT-011) 2
cell/myeloma 2
DC-mediated 2
costimulation. 2
PD1/PDL1 2
down-modulate 2
autologous, 2
CTLA-4-blocking 2
ipilimumab-treated 2
Anti-PD1 2
(nivolumab 2
beta-hydroxylase. 2
(asparaginyl)-beta-hydroxylase 2
(AAH) 2
Asn 2
Jagged, 2
neuroblastic 2
Cdk-5 2
(aspartyl-beta-hydroxylase), 2
259, 2
junctate-1, 2
-3). 2
Ca(2+)/mol 2
k(D) 2
COS-7-transfected 2
hASPH 2
hASPH. 2
(Asph, 2
BAH) 2
(6,629 2
4,419 2
(2,789 2
(humbug) 2
geranylgeranylation 2
pathway-dependent 2
YAP/TAZ. 2
TAZ, 2
YAP/TAZ-dependent 2
coactivator, 2
netrin-1 2
uncoordinated-5 2
netrin-1, 2
(Yes-associated 2
LATS1/2 2
14-3-3-binding 2
phosphodegron 2
(YAP) 2
(TEAD) 2
coactivate 2
YAP/TAZ, 2
protrude 2
(mDia) 2
blebbistatin 2
mDia1. 2
SRF-mediated 2
(DIAPH1). 2
RhoA. 2
Formin-family 2
ROCK-dependent 2
(mDias) 2
(F-actin) 2
mDias 2
connector, 2
mDia3-FH2 2
DRFs 2
FHOD1. 2
DRF. 2
ruffles. 2
FH3 2
'barriers' 2
off-centered 2
corkscrew 2
advance. 2
HDAC-independent 2
Rpd3, 2
Rtt109-independent 2
Rsc 2
reposition, 2
restructure 2
TP-dependent 2
SWI/SNF. 2
(TREM2; 2
chr6p21.1), 2
immunoglobulin/lectin-like 2
(Mt) 2
(a-Mt) 2
Clostridium-like 2
Sulfolobus-like 2
archaebacterium. 2
similar) 2
Mt 2
cementing 2
endospore 2
delta-distances. 2
Extremes 2
TpA 2
bacteriophage; 2
GpG/CpC 2
superhelicity, 2
organization), 2
(delta*) 2
>94%). 2
gamma-Proteobacteria 2
epsilon-Proteobacteria 2
unculturable 2
Buchnera. 2
monomethyl, 2
dimethyl, 2
∼160 2
Icp55 2
peptidase, 2
icp55 2
peptide-centric 2
culture) 2
metabolomics: 2
glycomics, 2
glycoproteomics 2
hemocyanin. 2
tumor-specific, 2
(EGFRvIII) 2
EGFRvIII-expressing 2
(CDX-110), 2
rindopepimut. 2
7B 2
LVNC, 2
ITGA7 2
CFTD. 2
(MYH7). 2
(MYH7) 2
DSP. 2
5208_5209delAG 2
1,736 2
DSP-1. 2
(TNNT2). 2
LVNC-associated 2
(hcTNT) 2
(mut 2
cTNT). 2
mut 2
LVNC. 2
shell-core 2
nanostructures. 2
nanostructure-based 2
(NIR) 2
45-base 2
oligonucleotide) 2
(HeLa 2
(NCI-H157, 2
absorb 2
(~10 2
bronchioalveolar 2
NCI-H596 2
transcription-PCR. 2
SK-MES-1 2
G(0)-G(1) 2
rs1862214 2
3.6; 2
(PCR-SSCP). 2
NCI-H446, 2
(U-373G 2
T98g), 2
(IMR-32 2
SK-N-MC), 2
(Du145, 2
LNCaP), 2
(SK-OV-3, 2
SW626, 2
(BT-20, 2
BT-549, 2
BT-474), 2
(SW1116, 2
116) 2
(CAPAN 2
As-PC-1) 2
(A-549 2
Ad-AS-CLN3 2
Cysteine-rich 2
H460, 2
60-90% 2
(AADC), 2
(non-neuronal) 2
A549) 2
(4'-N-benzoyl 2
staurosporine), 2
(adenocarcinoma: 2
NCI-H520). 2
significantly; 2
PHC1, 2
polyhomeotic 2
BMI1-AURKA 2
BMI1-induced 2
coamplification 2
3.01 2
LR-PSS. 2
(Ezh2). 2
PRC2-associated 2
del6p 2
AEBP2, 2
SUZ12; 2
AEBP2. 2
AEBP2 2
ETV6, 2
PMF, 2
PPV-MF, 2
PET-MF 2
(41.4%) 2
CBL 2
EZH2-mutated 2
(25.9%) 2
CL/P. 2
6p23, 2
provisionally 2
OFC1. 2
ESCCs, 2
MLL-associated 2
JAZF1/PHF1 2
JAZF1 2
6p21, 2
6p21. 2
t(6p;10q;10p) 2
(EPC1) 2
10p11; 2
EPC1 2
non-ambulatory 2
⩾9years, 2
⩾1 2
⩽4years, 2
12mg/kg), 2
3-9mg/kg 2
3-6mg/kg 2
drisapersen, 2
2'-OMe 2
(AON) 2
(stop 2
through) 2
skipping) 2
MI-regulated 2
fibrillins, 2
anti-miRs 2
years]. 2
1593 2
29. 2
Republic]. 2
(Institute 2
390.06 2
(449.08 2
327.93 2
7.0), 2
6.1), 2
(2.2 2
gastroschisis 2
(15.8 2
incidences. 2
paediatrician 2
live-born. 2
1:5000 2
929 2
5627 2
(1.11; 2
5.26). 2
975 2
1.2-1.6) 2
2.1-2.5) 2
pregnancies) 2
gonosomal 2
brackets) 2
2,244 2
(16.58) 2
63.37%, 2
(3.85) 2
79.93%, 2
68.87%, 2
(2.81) 2
79.89%, 2
(0.45) 2
59.74%, 2
(1.20) 2
73.65% 2
(0.16) 2
Space-time 2
pre-disposing 2
1985-2003 2
K-function 2
Knox 2
49,806 2
1:270 2
2,116 2
Province]. 2
southern, 2
25.1, 2
1,244 2
(1990-91) 2
DCP1/2, 2
(1-7), 2
hedls/GE-1 2
GW182. 2
RCK/p54, 2
CPEB). 2
Lsm1-7 2
heptamer. 2
Lsm1 2
DCP1:DCP2 2
(consisting 2
DCP2) 2
GW-bodies 2
(because 2
depletions 2
decapping. 2
Dcp2, 2
cross-reacts 2
U2OS, 2
WI38, 2
Hedls, 2
Rck/p54. 2
MIWI2-TDRD9-MAEL 2
DDX6/p54, 2
MAEL 2
Staufen- 2
FMRP-associated, 2
(Scd6p/trailer 2
hitch) 2
FMRP-driven, 2
argonaute-dependent 2
discs; 2
bantam 2
XRN1/Pacman 2
decapped. 2
(Pacman), 2
(XRN1), 2
(Xrn1p). 2
pacman 2
100-300 2
I-Mutant-2.0 2
PhosSNP 2
1.0. 2
FastSNP. 2
miRSNP 2
exosome-associated 2
hDIS3L, 2
hXRN1, 2
S315 2
TAK1-JNK 2
aggregating, 2
decapping/Xrn1 2
Importin-beta 2
importin-beta 2
cargo(es) 2
(ARE)-containing 2
microRNP 2
microRNA-repressed 2
dlP-bodies 2
mRNPs 2
Inulinases 2
1-ketose 2
fructose-6-phosphate 2
Jerusalem 2
artichoke 2
50-80% 2
syrups 2
producer, 2
8.67 2
inulinases, 2
SSF 2
fermentable 2
montmorillonite 2
min⁻¹) 2
biocatalyst 2
Y-7571 2
gases, 2
propane, 2
n-butane, 2
(LPG), 2
26.62% 2
(kestose), 2
30.62% 2
(nystose) 2
8.47% 2
GF4 2
(fructosyl 2
nystose) 2
(77.19% 2
GF2; 2
14.03% 2
0.07% 2
GF4) 2
mL(-1)). 2
w/v) 2
28°C 2
peptone 2
(13.8 2
Microbulbifer 2
endo-inulinase, 2
β-fructofuranosidase. 2
kutaonensis 2
mg/min, 2
°C, 2
H). 2
ascomycetous 2
Fructans 2
thermophile 2
Thielavia 2
8126 2
mesophile 2
Cichorium 2
terrestris 2
ºC 2
(2.15 2
(115 2
µmol/min/mg 2
exoinulinase's 2
cane 2
K(M) 2
industries 2
beta-(2,1)-D-fructoside 2
D-fructose. 2
myopericarditis, 2
Echocardiogram 2
dismissed 2
pVAD 2
TandemHeart. 2
rapidity 2
Medicine]. 2
anti-virus 2
lighten 2
(EOPD) 2
PARK2, 2
PARK7 2
ROHs 2
19p13.3, 2
homolog-induced 2
endophenotypic 2
stimulus-evoked 2
endophenotype 2
-50% 2
-15% 2
<45. 2
-1-8%, 2
-1-2% 2
30s, 2
(pyramidal, 2
dystonic, 2
disturbances). 2
certain. 2
mishandling 2
puzzle. 2
MPP+ 2
word, 2
PINK-1 2
parkin-mediated 2
(FDOPA) 2
accepted, 2
ischemia- 2
glycoside-induced 2
(NCX1.1) 2
Na+/K+-ATPase 2
Na-H 2
INa), 2
(Ca2+i) 2
Anti-anginal 2
.011). 2
(TdP) 2
Ca(2+)transients 2
Mahajan 2
546 2
hearts). 2
Ca(i) 2
solution; 2
O2·- 2
cCa2+ 2
I(Na,L) 2
(RAN) 2
ester, 2
CaT 2
I(Na,L)-induced 2
(ATX-II, 2
ATX-II, 2
microg/kg/min 2
FWft 2
vehicle). 2
Gs. 2
47.6%). 2
Gpp[NH]p 2
Gs/adenylate 2
hierarchically 2
(Warburg 2
carcinogen-rich 2
"fertilizing" 2
fuels, 2
autophagic-senescent 2
smoke-induced 2
neo-angiogenesis. 2
immuno-staining 2
post-diagnosis). 2
10-y 2
~97% 2
(-32) 2
(-14) 2
druggable-target, 2
MCT-inhibitors 2
AR-C155858, 2
AR-C117977, 2
AZD-3965). 2
Pyruvate 2
(PKM1 2
ketones, 2
Metabolism." 2
genetically-engineered 2
co-injected 2
laser-capture 2
"lactate 2
shuttle" 2
mono-carboxylate 2
fibroblasts; 2
MCT4. 2
N-acetyl-cysteine. 2
MCT1, 2
MCT1 2
Stromal-epithelial 2
"cancer 2
nests" 2
unreasonable 2
visa 2
"parasites" 2
anywhere, 2
go, 2
(glutaminolysis) 2
1.5). 2
(GSEA) 2
(lactate, 2
Ketones 2
(3-hydroxy-butyrate 2
L-lactate) 2
∼2.5-fold, 2
vascularization/angiogenesis. 2
chemo-attractants, 2
∼10-fold. 2
unwise 2
Lactated 2
solution) 2
L-lactate. 2
(a.k.a., 2
effect)--producing 2
pyruvate/lactate 2
AMPK-mTORC1 2
fasentin 2
sorafenib-induced 2
Abl/Src 2
SHP2 2
[Chronic 2
imatinib: 2
Lome 2
(Togo)]. 2
9.22). 2
Lomé 2
RT-PCR). 2
Splenomegaly 2
188.71 2
(24.4-350). 2
491.15 2
(108-2000). 2
G250E 2
Mutation-induced 2
one-two 2
(CML-CP). 2
CML-CP 2
BCR-ABL-T315I. 2
BCR/ABL-kinase 2
'gatekeeper' 2
GNF2 2
(PDLTC) 2
ALL-patients. 2
LYN/mTOR 2
kinases.They 2
growth-signaling 2
oridonin, 2
bcr/abl 2
SUP-B15 2
Raf/MEK 2
hiladelphia 2
(final 2
optimal-dose 2
1420 2
MSE 2
disclosing 2
MS(E) 2
FLT-3 2
multi-country 2
(CHR), 2
(CCyR), 2
(C/MMR). 2
C/MMR 2
53.1, 2
30.5 2
phase-chronic 2
0109 2
(ACAs; 2
HEM-AP), 2
(ACA-AP) 2
ACA). 2
(P=NS) 2
(P=0.0053). 2
92.8% 2
58.3% 2
(P=0.0052). 2
ACA. 2
Broader-target 2
(imatinib) 2
(dasatinib 2
nilotinib) 2
hTERT. 2
BCR-ABL-mediated 2
BCRABL- 2
marrow) 2
Pigmentary 2
Hypopigmentation 2
(LSC) 2
monoexponential, 2
biexponential, 2
triexponential, 2
continual, 2
non-compliance 2
2011), 2
chromosome--positive 2
(CP), 2
BC-CML 2
70%-80% 2
Gleevec), 2
Imatinib-induced 2
BCR-ABL-expression 2
imatinib-treated 2
(Philadelphia). 2
(Ph)-positive 2
[Tyrosine 2
CML]. 2
p210 2
IRIS 2
resposes 2
kinase-domaine 2
B3A2 2
'cause' 2
region--Abelson 2
region-Abelson 2
(resistance) 2
(intolerance). 2
(600-800 2
1840s. 2
(then 2
busulfan, 2
hydroxycarbamide, 2
interferon-alfa 2
(IFN-α). 2
onwards 2
(TK). 2
downstreams 2
e13a2 2
e14a2 2
(22;9). 2
bcrabl, 2
SRC-ABL 2
INNO 2
406. 2
MK0457, 2
polyamide-chlorambucil 2
conjugate. 2
(traditionally 2
surpassed 2
'cure' 2
(BMT). 2
formidable, 2
treatment- 2
Preimatinib 2
imatinib-based 2
counts; 2
(IFn 2
IFn 2
flulike 2
wBC 2
CHr. 2
lived, 2
CHR. 2
VAC 2
(etoposide, 2
carboplatin). 2
BMT. 2
myalgia/arthralgia. 2
(blast 2
crisis), 2
cytokine-non-responsive 2
bcr-abl-positive 2
haemopoiesis 2
bcr-abl; 2
(farnesyl 2
IAP-1 2
protein-1), 2
(inducible 2
[MAPK 2
kinase)/ERK 2
1/2] 2
succession. 2
IM-resistant 2
pathophysiologies 2
break-points. 2
(bcr-abl) 2
60-fold 2
Study) 2
Ara-C, 2
censoring 2
Glivec 2
lucky 2
TKs, 2
receptor(PDGF) 2
c-kit. 2
Philadelphia(Ph) 2
mesylate) 2
2-phenylaminopyrimidine, 2
Gastro-Intestinal 2
(GIST), 2
BCR/ABL-induced 2
Bcr-Abl. 2
CGP57148B, 2
(stem-cell 2
(Bcr 2
Abl), 2
withheld. 2
(STI571, 2
semi-solid 2
DNR 2
(Ph-) 2
CE). 2
(STI571; 2
(HHT), 2
KBM5 2
KBM7 2
(9/22 2
protein--the 2
nonlymphoid 2
cytarabine-based 2
STI571, 2
bis-aryl-sulphanyl 2
5-HT(1D), 2
5-HT₃ 2
5-HT₇ 2
duloxetine-referenced 2
[Montgomery-Åsberg 2
responders; 2
149) 2
151). 2
P<0.0001, 2
flexible-dose, 2
serotonin-noradrenaline 2
corticolimbic 2
5-HT1A-Rs, 2
(marketed 2
mesocortical 2
PFC, 2
(5HT1A 2
5HT1B 2
5HT7 2
antagonism), 2
(5HT3 2
antagonism) 2
Arizona 2
HAM-D24 2
(0.74) 2
6-wk 2
≥30, 2
medication-free 2
(HAMD)-24 2
MADRS-S 2
(19.1 2
9.4%), 2
(17.1 2
15.1%) 2
7.0%), 2
(HARS) 2
duloxetine-referenced, 2
(analysis 2
forward). 2
HAM-D(24) 2
≥26 2
(n=50). 2
n=155) 2
MMRM 2
LOCF, 2
(n=105) 2
AA21004: 2
(7%); 2
venlafaxine: 2
Lu-AA21004, 2
toxoplasmosis: 2
1995-2013 2
1920s 2
1930s, 2
retinochoroiditis 2
triads: 2
ZFAT-AS1, 2
ZFAT 2
syncytiotrophoblasts. 2
hydatidiform 2
(paternal 2
gDMRs, 2
A3. 2
methylome, 2
arbitrary-sized 2
GENEHUNTER-IMPRINT 2
phaeochromcytoma 2
(PGL); 2
phenotype-directed 2
(Illumina 2
repeated). 2
annovar. 2
MAX. 2
(<$A800 2
reagents) 2
(results 2
reception). 2
(SGS), 2
(UM) 2
Exome-wide 2
exome-enrichment 2
Oct-3/4, 2
Sox-2 2
Y174F 2
60-mer, 2
Fgf4, 2
Mtf2, 2
Rex1, 2
Sox1, 2
Yes, 2
Zfp143, 2
Cripto, 2
Zfp57 2
(LIF)/Stat3 2
IL6st, 2
(Atf3, 2
Jdp2, 2
Hist1hic, 2
Bcl6), 2
E2f1, 2
Tob1, 2
Smarcc1 2
cycle-pathway 2
LIF/Nanog 2
hyper-responsive 2
Cxcr4b. 2
gonads, 2
perpetually 2
(Ol-Nanog) 2
PGCs. 2
PGCs, 2
Sdf1a 2
Ol-Nanog. 2
Ol-Nanog, 2
Sdf1a, 2
STEM 2
CELLS 2
2009;27:2081-2091. 2
xenograft- 2
NANOG. 2
NANOGP8. 2
NANOGP8 2
transactivators 2
peritubular 2
non-seminomatous 2
morulae 2
(A-type 2
(cirrhosis 2
macroregenerative 2
guards 2
purview 2
out? 2
recycled. 2
macroautophagy-whether 2
nonselective-and 2
omegasome, 2
endosomes/multivesicular 2
compartmentalized. 2
tonoplast 2
'autolytic' 2
'non-autolytic' 2
autolysosomes, 2
autolysosomes 2
Autophagy: 2
self-digestion 2
cortactin-dependent 2
flip 2
pathogens; 2
Alzheimer's, 2
DEX, 2
inconclusive, 2
self-non-self 2
(CRISPRs) 2
invader-derived 2
(psi)RNAs) 2
RAMP 2
Cmr) 2
psiRNA-Cmr 2
furiosus, 2
(crRNAs) 2
crRNAs 2
O395. 2
(cas 2
cholerae. 2
Cas3 2
furiosus. 2
invaders 2
furiosus 2
A/T-biased 2
equilibria. 2
(GC/AT 2
anticodons. 2
economization 2
(AT/GC 2
pressure), 2
GNN 2
heterogenicity 2
(GC%) 2
microD, 2
(1962, 2
48:582-592). 2
proportionately 2
navigate 2
discovery-driven 2
(shotgun) 2
(targeted) 2
2-month-old, 2
(R403Q) 2
α-myosin 2
hypertrophy) 2
characterize, 2
TnI-203/MHC-403) 2
crossbreeding 2
Gly203Ser 2
(TnI-203) 2
(MHC-403) 2
(M-alphaMHC(R403Q/+) 2
F-alphaMHC(R403Q/+), 2
(M-alphaMHC(+/+) 2
F-alphaMHC(+/+), 2
5.70 2
2.52 2
probands). 2
Q1065H 2
Arg403-->Gln 2
(403) 2
x403). 2
0.5%) 2
0.5%), 2
min(-1)) 2
G(s)alpha, 2
(Arg403Gln) 2
(37.1 2
small-amplitude 2
length-perturbation 2
(alphaMHC403/+). 2
Genetically-manipulated 2
(alpha-MHC403/+), 2
axis; 2
backbone. 2
(FHC), 2
beta-isoform 2
Constructs 2
(Arg-249-->Gln) 2
(MVP). 2
>2. 2
reintervention 2
Nosology. 2
(MVP) 2
0.17; 2
[Serial 2
prolapse; 2
Echocardiograms 2
42.8%, 2
9.5%, 2
23.8%. 2
Bentall-De 2
Bono 2
13.6% 2
bpm; 2
beta-blockers; 2
mm/year 2
Paepe 2
(1996). 2
exams, 2
(17/20). 2
hereditable 2
labetalol 2
Torii) 2
angiotensin-II. 2
AT-R/MAPK 2
Torii-SDT) 2
AT-R, 2
cascades-related 2
caspase-12. 2
hemotoxylin 2
AT-1R, 2
Ang-(1-7) 2
mas 2
Tak1, 2
p-AMPKα1, 2
DHE, 2
diabetes), 2
negative-AMPK 2
db/ 2
troglitazone. 2
P-AMPK. 2
liporegulatory 2
5-[5-(2-Nitrophenyl) 2
furfuryliodine]-1,3-diphenyl-2-thiobarbituric 2
(UCF-101) 2
steptozotocin 2
FVB 2
kg(1)). 2
STZ-treated 2
mum 2
(+/-dL/dt), 2
(TPS) 2
(TR(90)). 2
Steptozotocin-induced 2
TPS 2
TR(90) 2
Steptozotocin 2
Thr172 2
Omi 2
stress-regulated 2
endoprotease, 2
(Omi/HtrA2), 2
apoptosis-independent 2
offices 2
defibrillators. 2
(VT/VF) 2
(highest 2
(CVDs) 2
584 2
basketball, 2
national, 2
incurring 2
0.2-51 2
15±9 2
24; 2
return-to-play 2
second-most 2
softer 2
"safety" 2
Resuscitation 2
defibrillation 2
Return 2
Blunt 2
Paleoproteomic 2
cloth 2
500-year-old 2
mummies. 2
1991-discovered 2
5300-year-old 2
Oetzi, 2
leather 2
parentage 2
Scythian 2
king 2
(NF-L) 2
"giant" 2
"giant 2
c.1634G>A 2
c.224 2
hypoacousia 2
(GAN): 2
(GAN)(1) 2
BTB/Kelch 2
proteins.(1) 2
Filaments 2
(IF)-cytoskeletal 2
(Gan1). 2
(GAN, 2
256850) 2
frizzly 2
(AD); 2
DLDH 2
Amyloidβ 2
AMYLOID 2
BETA 2
PRECURSOR 2
Dll1 2
Dll1, 2
Notch/Wnt 2
differentiative 2
TFIIE. 2
(Mgm1) 2
around, 2
nucleotide-dependent 2
necks. 2
vesiculation, 2
neck's 2
pinching 2
dynamins 2
(MVB) 2
midbodies, 2
(Dyn2) 2
~100kDa 2
(TIRF) 2
breast-cancer 2
Dissemination 2
iota 2
dynamin-2. 2
line-based 2
BIN/amphiphysin/Rvs 2
(BAR) 2
amphiphysin, 2
endophilin. 2
deform 2
apoptin. 2
Apoptin 2
p53/p73 2
TAp73beta 2
TAp73-dependent 2
TAp73-mediated 2
TAp73; 2
(PIR2). 2
(p53RFP), 2
TA/DeltaNp73 2
PIR2, 2
TAp73/DeltaNp73 2
(DeltaN) 2
(TAp73(-/-)) 2
Trp-73 2
(deltaN) 2
Mdm2-dependent 2
neddylated 2
transcriptionaly 2
dominant-negatively 2
heterocomplexes 2
TAp73β 2
p130, 2
(ΔN) 2
TAp73gamma 2
DeltaNp73(-/-) 2
p53-REs 2
domain-p73 2
TAp73alpha 2
p73KO 2
Cyclooxygenase 2
DeltaNp63 2
Bcl-6 2
IRF4 2
B-cell-like 2
GCB-like 2
p63(+) 2
(TAp73, 2
DeltaN'p73, 2
Ex2p73 2
Ex2/3p73) 2
age-dependent, 2
DeltaNp73) 2
delta). 2
(DeltaN 2
tazarotene. 2
tazarotene 2
tazarotene-induced 2
amino-truncated 2
nonmutated 2
transactivations, 2
immortalizes 2
(DeltaNp73), 2
VMA 2
(OS: 2
CTR1, 2
CTR3, 2
FRE7, 2
YJL217w. 2
gamma-lyase 2
CYS3. 2
Mac1, 2
Mac1(up1), 2
metallothioneins 2
CUP1 2
CRS5 2
Copper-induced 2
Copper-mediated 2
Cu-dependent 2
CTR1 2
(K, 2
farnesol 2
CAAX 2
m-CN-AGOH 2
(H, 2
TGF-β1-induced 2
KRas, 2
Rasosomes 2
80-100 2
(H-Ras 2
(PM). 2
rasosome 2
Golgi, 2
H-Ras? 2
(Ha-, 2
explainable, 2
Ha- 2
Ki-Ras 2
H-Ras-mediated 2
Ha-, 2
N-ras. 2
2DE, 2
stress-70 2
dihydropyrimidinase-related-protein 2
GDP-dissociation 2
c-Myc-responsive 2
Rcl, 2
H-Ras. 2
mutagens, 2
contexts; 2
GEFs; 2
compartments; 2
site-specified 2
isoforms-H-Ras, 2
transduction/transplantation 2
aminopeptidases: 2
aminopeptidase/insulin-regulated 2
aminopeptidase. 2
"marker" 2
EpCAM(+). 2
EpCAM-interacting 2
cytoplasm/ER 2
vesicles) 2
leukocyte-derived 2
A-LAP 2
L-RAP 2
p-tyramine, 2
octopamine, 2
tryptamine. 2
[(3)H]-p-tyramine 2
[(125)I]-3-iodothyronamine 2
p-tyramine. 2
potency: 2
p-tyramine 2
thyronamines, 2
CARE-MS 2
Alemtuzumab-treated 2
TGF-β1-, 2
IL-10-, 2
IL-21, 2
CAMMS223, 2
Relapsing-remitting 2
(n=334) 2
(SC 2
57.3 2
(P<.0001). 2
(MS).When 2
methyl-prednisolone, 2
antipyretics; 2
Goodpasture's 2
syndrome.Alemtuzumab 2
alemtuzumab-exposed 2
immunocompetence 2
(interferon-beta), 2
low-contrast 2
334) 2
letters) 2
0.013; 2
0.010). 2
18-50 2
μg. 2
NCT00530348. 2
(122 2
(119 2
0·45 2
0·32-0·63]; 2
54·9% 2
0·70 2
0·40-1·23]; 2
p=0·22). 2
Infections, 2
Campath-1H, 2
CD25, 2
(alemtuzumab), 2
(daclizumab), 2
VLA-4 2
sclerosis-A 2
alemtuzumab/day 2
(70-88%) 2
glatiramer. 2
1:2:2 2
NCT00548405. 2
(201 2
0·39-0·65]; 2
49·4% 2
0·58 2
0·38-0·87]; 2
p=0·008), 2
[66%] 2
Suitable 2
Campath-1H. 2
(Alemtuzumab) 2
2.48 2
-0.15 2
managed, 2
(9.0% 2
26.2%; 2
(0.10 2
(P=0.005). 2
T(1)-weighted 2
3%] 2
[3% 2
1%]) 2
12-mg 2
24-mg 2
NCT00050778.) 2
neurology. 2
hCD52 2
scans; 2
"meta-analysis", 2
0.09-0.24) 2
(0.14-0.42; 2
anything 2
(CD52) 2
(Campath-1H), 2
hypomania, 2
schizophrenia) 2
(NAcc-DBS) 2
procognitive 2
compelled 2
standardized. 2
reward-guided 2
serotonergic, 2
fronto-striatal 2
implantation) 2
system--in 2
structure--are 2
(Y-BOCS), 2
(HDRS), 2
(HARS), 2
(GAF) 2
pychosocial 2
(Y-BOCS 2
pursuant 2
GAF 2
immunophenotypic, 2
rituximab-based 2
12(p13) 2
immunophenotype. 2
leukemia/lymphoma, 2
shortly. 2
fludarabine. 2
palliated 2
(anti-CD52, 2
CD4-positive 2
28-kd 2
(C228T, 2
C250T) 2
(187/322; 2
(10/36, 2
0.0056). 2
0.0056) 2
(unpaired 2
t-test, 2
(>60 2
expression/TA 2
(≤60 2
solaneuzumab, 2
aggregation). 2
biomarkers), 2
solaneuzumab 2
targets? 2
80-years-old 2
prefibrillar 2
metastability 2
manifold. 2
amyloid-lowering 2
oligomer-targeting 2
Oligomer-targeting 2
[Aβ 2
amyloid-β-protein 2
(amyloid-cascade 2
immunotherapies: 2
(ARIA)-E 2
(ARIA-H). 2
microinfarcts 2
above-described 2
instigator 2
genuinely 2
N-terminal-directed 2
PET-Pittsburg-B 2
bapineuzumab) 2
AD-type 2
anti-AD 2
SELDI-TOF 2
Aβ₁₋₄₂ 2
entirety, 2
(L-T4) 2
Jordanian 2
Hospitals. 2
rs225011, 2
rs7140952, 2
rs225012 2
rs2839858 2
L-T4, 2
(Thr92Ala), 2
(64.8% 2
47.1%; 2
Thr92 2
3.89). 2
elderly? 2
<55-60 2
(>65 2
(>80 2
"hypothyroidism," 2
"subclinical 2
hypothyroidism," 2
"ageing," 2
"elderly," 2
"L-thyroxin," 2
"thyroid," 2
"guidelines," 2
"treatment," 2
"quality 2
life," 2
"cardiovascular 2
risk," 2
failure," 2
"coronary 2
"atherosclerosis," 2
dysfunction." 2
Analyzed 2
mIU/L. 2
(>85 2
(IHD); 2
IHD. 2
Practitioner 2
5.01-10.0 2
(40-70 2
(&gt;70 2
(fatal 2
nonfatal) 2
3093 2
1642 2
49.9% 2
(multivariate-adjusted 2
0.39-0.95). 2
(12.7%) 2
0.59-1.33). 2
(baPWV), 2
(P=0.006) 2
baPWV. 2
l-T(4) 2
(male/female 2
59.5% 2
(4/21 2
sub-population. 2
treat? 2
autoantibodies; 2
strictu. 2
('dosage 2
52,000 2
eff 2
stair 2
occurring. 2
kilocalories), 2
joggers: 2
jogging. 2
Jogging 2
17,589 2
20-98 2
1,878 2
(1,116 2
35-year 2
10,158 2
nonjoggers. 2
0.67) 2
57.5 2
(<4 2
(METs)) 2
(4-<6 2
self-reported, 2
1680 2
.36). 2
deaths), 2
age-standardized 2
2259 2
skating 2
Follow 2
recreational, 2
internodal 2
subclade 2
rooting 2
ecological, 2
Aglais 2
COI 2
(A+T=90.91%) 2
(consistency 2
0.9591) 2
parsimony-informative 2
MSSA. 2
Haarlem, 2
sublineages 2
RD219 2
sublineage 2
spoligotypes 2
sublineages. 2
spoligotypes. 2
spoligotyping 2
Symbion 2
pandora 2
(homology), 2
(homoplasy) 2
Phylogeny 2
ND2 2
mtMutS 2
pennatulacean 2
paraphyletic 2
misinterpretations 2
Hormogaster 2
n. 2
Conflict 2
Earthworm 2
habitat, 2
morphologically. 2
Spain). 2
delimitation 2
Janira 2
trnV 2
copepod 2
(homology) 2
protocerebral 2
typifying 2
Taxa 2
incongruences 2
(comparative 2
pangolin 2
myrmecophagy 2
(convergent 2
character. 2
matR 2
rosid 2
informativeness 2
evolving/unconstrained 2
Relaxed 2
ancestry) 2
character-state 2
convergences 2
reversals). 2
"distance 2
method" 2
purports 2
tree-construction 2
homoplasies 2
homoplastic 2
electromorphs, 2
truncatus. 2
sequence). 2
reconstructions. 2
communicative, 2
LBW 2
2001-07. 2
4429 2
(1828 2
2601 2
43,277 2
(1679 2
16,845 2
(n=589,114) 2
subgrouping, 2
prevalence: 2
raise. 2
Whitaker-Azmitia 2
secular 2
1507 2
(3.3%). 2
mg/kg/d) 2
confounder. 2
ZF1 2
ZF2, 2
ZF3 2
ZF4 2
E2-boxes 2
non-equivalent 2
immuno-privileged 2
E/N 2
PI3K/PKC-ζ/mTOR 2
(PAR-1) 2
PVR 2
(GSK-3β) 2
(S92/96A 2
S100/104A) 2
Slug/Snail2-mediated 2
Slug/Snail2. 2
unctional 2
OE33. 2
ownregulation 2
Zeb1 2
ETV5-promoted 2
Beta-Blocker 2
(BEST). 2
SW13 2
clumping 2
(Val459Ile) 2
low-penetrant 2
(RCM) 2
MHCbeta, 2
non-sarcomeric 2
cardiac-restricted 2
trait; 2
beta-miosin 2
DCMs 2
(7.7% 2
(actin, 2
desmin) 2
DCM; 2
Hypothesizing 2
"evidence-based" 2
defect-related 2
Barth's 2
methylglutaconic 2
beta-tubulin, 2
(z-bands) 2
Anti-desmin 2
reconvalescence 2
perimyocarditis 2
OPN. 2
des(-/-)OPN(-/-) 2
glycation, 2
showcased 2
MAP-ERK 2
anti-PD1/PDL1 2
MPDL3280), 2
receptor/programmed 2
(PD-1)/its 2
immune-modulation 2
"Breakthrough 2
Therapy" 2
(anti-PD-1) 2
(RECIST), 2
(52%; 2
55] 2
49], 2
NCT01295827.). 2
deve 2
lopment, 2
(imprinting 2
human-assisted 2
imprinting-related 2
"imprinting 2
erasure 2
Angelmann 2
interest), 2
nesidioblastosis, 2
pseudohypoparathyroidism. 2
examples. 2
apoptosis: 2
[Nicholls 2
54:733-740], 2
[Sapienza 2
(1990): 2
Biochim 2
1072:51-61; 2
Feinberg 2
4:110-113], 2
[Julier 2
354:155-159; 2
9:284-292]. 2
IDDM2 2
locus) 2
USF-1/2 2
cHS4, 2
"core", 2
insulate 2
insulators/enhancer-blockers 2
Stil, 2
Tal1 2
non-expressed 2
Map17 2
cost/benefit 2
Hairy-wing 2
spurt 2
(<2 2
persons; 2
[Restless-leg 2
irritated 2
uremia. 2
(ASR) 2
donor/acceptor. 2
haemochromatosis. 2
uraemia, 2
[Restless 2
sleep-deficit. 2
opiate, 2
affections 2
hypersynchrony 2
(sinusoidal 2
waves). 2
conductibility 2
(signs 2
(LSWS) 2
LSWS, 2
DSWS, 2
LSWS 2
sleep). 2
acetyllysine-specific 2
3,5-dimethylisoxazoles 2
histone-acetylation 2
surrogates, 2
PHD-adjacent 2
H4K16ac, 2
dictating 2
co-activators. 2
(glutathione 2
S-transferase) 2
tetra-acetylated 2
Bdf1-2 2
acetyl-lysines 2
HNE1 2
co-localization. 2
expanding. 2
Polycomb, 2
Gcn5, 2
PCAF, 2
Tat, 2
phosphorylated; 2
Lys14 2
co-ordinates 2
Swi/Snf 2
phosphorylation? 2
veterans: 2
we: 2
non-deployed 2
(GWV) 2
(NGWV). 2
42,818 2
NGWV 2
2.5-2.8). 2
warfare. 2
(DU) 2
British, 2
Kosovo, 2
tons 2
legacy, 2
(2002), 2
Jalalabad, 2
Spin 2
Gar, 2
civilians 2
bombing 2
raids; 2
bombing; 2
sympotom-free 2
isotopes, 2
(234)U, 2
(235)U, 2
(236)U 2
(238)U, 2
multicollector, 2
inductively 2
Jalalabad 2
non-depleted 2
Yaka 2
Toot, 2
Mal, 2
Makam 2
Khan 2
Arda 2
Bibi 2
Mahro, 2
Poli 2
Cherki, 2
bombsites 2
job-related 2
(active, 2
reserve), 2
elsewhere), 2
nonparent). 2
"Gulf 2
Syndrome," 2
Twenty-fourth 2
Reserve 2
Battalion 2
retired 2
battalion. 2
Two-stage 2
Dichotomized 2
3.5-44.8) 2
unemployed 2
48.4% 2
malingering. 2
67, 2
39. 2
(RVCL) 2
(N3ECD) 2
non-CADASIL 2
comparable-age 2
Granular 2
KIF1Bβ, 2
paraganglia. 2
organ-sparing 2
(MEN-1) 2
[Novel 2
Fibrosis. 2
stainings. 2
factor-β1, 2
pirfenidone, 2
phLF. 2
(Trumenba) 2
antihemophilic 2
(recombinant), 2
(Obizur) 2
(Esbriet) 2
(Ofev) 2
Daedalus 2
Enterprises. 2
30-79% 2
FVC. 2
(identifiers: 2
NCT01335477). 2
(homodimer) 2
(PDGF-BB). 2
(TGFβ)-induced 2
(TIMP-1), 2
medium-term 2
150�mg 2
(mRen-2)27 2
7-wk 2
(GLUT4) 2
TR(90), 2
GLUT4, 2
FDP-Sr 2
calcium-modulating 2
Sr 2
mg·kg(-1)·d(-1), 2
ig, 2
iNOS, 2
FDP-Sr, 2
Cardioprotective 2
HSYA 2
handing 2
Ca2+ATPase 2
Slowed 2
(P2+ 2
Organophosphates 2
injection-induced 2
Organophosphorus 2
Acutely, 2
decontamination 2
Atropine 2
OP. 2
(MNCV), 2
(CMAP), 2
(SNCV), 2
toxicokinetics 2
pyrethroid 2
disruptors, 2
organochlorines 2
hectares 2
capita. 2
dimethyl-2,2-dichloro 2
(DDVP). 2
Electroneurography 2
Conduction 2
(3/7) 2
findings) 2
Cramping 2
paraesthesiae 2
high-stepping 2
non-excitability 2
electromyographical 2
(NTE) 2
NTE 2
attribution 2
OP-induced 2
pre-marketing 2
triaryl 2
plasticisers 2
tri-ortho-cresyl 2
chlorpyrifos, 2
dichlorvos, 2
isofenphos, 2
mipafox, 2
trichlorfon, 2
trichlornat, 2
phosphamidon/mevinphos 2
carbamates. 2
omethoate/dimethoate, 2
parathion 2
merphos. 2
referents, 2
chlorpyrifos-exposed 2
(9.72 2
(64.16 2
mg/m(3). 2
3,5,6-trichloro-2-pyridinol 2
(TCP) 2
(108.6 2
(7281 2
8176 2
mU/ml; 2
B-esterases 2
Persistent, 2
grip- 2
pinch-strength 2
1996; 2
non-neuropathic 2
Grip 2
OP-poisoned 2
dippers. 2
handlers, 2
palsies, 2
neuro-behavioral 2
(infertility, 2
phosphide 2
Zn3P2 2
Ventilatory 2
12.8%. 2
cerebro-organic 2
disfunctions, 2
locomotory 2
sympathicotonia 2
hydroponic 2
improbable 2
doubting 2
chemical; 2
(pharmacokinetics); 2
2,4-D; 2
Ranch 2
Hand; 2
insecticide. 2
neurotoxicity: 2
biocidal 2
(NIOSH) 2
leptophos, 2
isofenphos. 2
federally 2
accidental, 2
assay--neurotoxic 2
(NTE)--to 2
electroencephalograms 2
workmen, 2
hexachlorcyclohexane, 2
electromyograms 2
workman 2
peripherical 2
motoneuron. 2
parathion, 2
nonneurotoxic 2
(7, 2
Ligation 2
MmeI 2
ChIP-enriched 2
GCC, 2
HiC 2
ChIA-Pet) 2
negative-strand 2
heifer 2
BDV, 2
Bo/04w, 2
gerbil 2
exploration, 2
developmental-neuromorphological 2
cytolysis, 2
(TGF-beta1), 2
IL-1Ra, 2
TGF-beta1. 2
microgliosis 2
egr-1, 2
c-jun. 2
mob-1, 2
Homogenates 2
SKNSH 2
(BDV). 2
p.i., 2
Nelarabine 2
nelarabine. 2
2-deoxycoformicin 2
deoxycoformycin 2
(DCF), 2
chlorambucil 2
2-30 2
fate-determining 2
(IRFs). 2
mykiss). 2
mykiss) 2
luciferase-based 2
RLM-RACE. 2
(RTG-2) 2
P2-4 2
(IL-12) 2
GATA, 2
(Sp1, 2
NF-kB) 2
leukocyte-specific 2
(PU.1) 2
(URE) 2
m-quotient, 2
g-index, 2
Expenditures 2
award, 2
grant, 2
grants 2
m-quotient 2
.184). 2
grant. 2
career. 2
Scholarly 2
scholarly 2
listings 2
869 2
faculty. 2
fellowship- 2
nonfellowship-trained 2
13.0, 2
0.96). 2
trauma/critical 2
subspecialty. 2
19.71; 2
0-61). 2
"manually 2
calculated" 2
subspecialty 2
Fellowships-approved 2
29.5. 2
conforms 2
log-linear 2
.99) 2
neurosurgery: 2
phenomenon? 2
1120 2
Service-listed 2
Scholar. 2
0-68), 2
75th, 2
90th, 2
publishing 2
metric. 2
certification, 2
salaries 2
Hirsch 2
(h-index), 2
earn 2
ophthalmologists, 2
otolaryngologists, 2
professor, 2
71.6% 2
0.000001). 2
incisors 2
self-sustaining 2
post-MBSR-C 2
(before/after 2
Mindfulness 2
Peer 2
pre-post 2
(pro-inflammatory) 2
times/day), 2
DHEAS, 2
"inverted-V-shaped" 2
"V-shaped" 2
better-controlled 2
QLQ 2
C-30), 2
(POMS), 2
(SOSI), 2
helper, 2
postintervention. 2
departure 2
programme? 2
overdiagnosis 2
(intervention) 2
450,000 2
(2002-2008). 2
(Prostate 2
ProtecT, 2
111,000 2
attendees 2
(22/227), 2
0.22-0.83) 2
0.35-0.52). 2
45-49 2
(442/1299, 2
34%) 2
(10/442). 2
Sixth 2
(Identification 2
ProstAte 2
(www.impact-study.co.uk), 2
makers. 2
(ISRCTN20141297). 2
50-69 2
'abnormal' 2
urology 2
(41.5%) 2
Informed 2
worries 2
(DRE) 2
Interviews 2
DRE 2
Finland) 2
EL(97)12. 2
~28 2
gregarious 2
strangers, 2
gene-behavior 2
(AVP) 2
(music), 2
(cold). 2
Hemizygosity 2
(WSCR) 2
Syntaxin-1A 2
WSCR, 2
Stx-1a. 2
7q11.23 2
(WBSCR) 2
(ELN). 2
disabilities; 2
speech/language, 2
pamidronate. 2
hyperopia, 2
Orthodontic 2
malocclusion. 2
stenoses; 2
Multivitamins 2
occurrences, 2
parent-to-child 2
growth-retarded 2
growth-rate 2
cm/year. 2
hypospermatogenesis. 2
Supravalvular 2
(SVAS) 2
SVAS 2
adulthood: 2
(sFRP) 2
A498. 2
A498 2
Hs891.T). 2
ANGPT1 2
Osteoblast 2
checked, 2
4/4 2
nineteen 2
keratin-8 2
(MMP)-2 2
(DN-LRP5) 2
Arg324Gly 2
Gly324 2
Arg200Trp 2
607 2
5.1, 2
ProteaPrep 2
albuminome 2
SELDI-TOF-MS. 2
preprocessing. 2
CM10, 2
(<6.2 2
filter; 2
kit). 2
CM10 2
unassigned 2
glycoform 2
prefractionation 2
CSF: 2
kits, 2
depletion-methods 2
setup. 2
GenCord 2
lincRNAs, 2
[eQTMs]), 2
eQTMs 2
eQTMs. 2
1,119 2
disorder's 2
LincRNA-p21 2
let-7/Ago2 2
lincRNA-p21, 2
JUNB 2
1p34.3 2
ionotropic, 2
GRIK3, 2
kainate-type 2
proposita. 2
Glutamatergic 2
(GRIA) 2
(GRIK) 2
(S129) 2
S129D 2
(Tg 2
synucleinopathy. 2
S129A-α-synuclein 2
Ser(129), 2
alpha-synuclein-overexpressing 2
Ser(129) 2
Asp-115, 2
Asp-119, 2
Asn-122, 2
Tyr-133, 2
Asp-135. 2
Asp-119-truncated 2
body-associated 2
synuclein; 2
Î±-syn 2
PMDD: 2
drospirenone 2
(DRSP/EE). 2
visits) 2
branded 2
Deterministic 2
(year 2
subgrouped 2
-0.39; 2
-0.41, 2
-0.53 2
-0.29; 2
(fluoxetine, 2
clomipramine) 2
(PTSD), 2
(SAD) 2
SAD, 2
contraception. 2
hoc. 2
NCT00620581. 2
(luteal 2
calendar, 2
Depression/Anxiety 2
(HAMD/HAMA), 2
CR). 2
(SRIs) 2
SRI 2
(mean+/-SD 2
37+/-6.3 2
55-56 2
(1.4) 2
(0.5). 2
SRIs, 2
3-arm, 2
(VAS)-Mood 2
(PMDD).Method: 2
(VAS)-Mood, 2
lability.Results: 2
-6.76; 2
-1.62; 2
tolerated.Conclusion: 2
(irritability, 2
mood) 2
elderly), 2
[major 2
disorder], 2
Liebowitz 2
[social 2
disorder] 2
[PMDD]). 2
administration). 2
etiopathogenic 2
cravings, 2
Karen 2
non-psychiatric 2
citalopram. 2
menses, 2
phenylpiperidine 2
TCAs. 2
(5-hydroxytryptamine; 2
(5-30 2
anxiety/tension 2
unabated 2
libido 2
(AGs) 2
≥70, 2
53%), 2
28%) 2
10%(95% 2
144). 2
higher) 2
urosepsis. 2
adjuvantly 2
O-6-methylguanine-DNA 2
EIACs 2
anti-angiogenetic 2
150-200 2
6PFS 2
(BSG) 2
5,580 2
(rounded 2
(whichever 2
lower). 2
peritumoral 2
18-fluorodeoxyglucose 2
cRA 2
single-institution, 2
extirpation 2
T-group 2
>/=18 2
(77.8%). 2
(76.5% 2
(11.8%). 2
12-40) 2
16-64), 2
(antiangiogenic 2
Proangiogenic 2
EA.HY 2
rh-Endostatin 2
proangiogenic, 2
MICR 2
duplicate. 2
correction). 2
collaterals. 2
APPsw 2
PS1/APPsw 2
vision-threatening 2
(FGF), 2
angiotensin, 2
antioangiogenic 2
(PEDF), 2
CNV). 2
E-selectin. 2
(induced 2
Interindividual 2
Thrombospondin-1 2
(Tsp1), 2
RenCa 2
tumstatin. 2
PDGF-A 2
(FGFs), 2
vasostatin, 2
verteporfin 2
RPE-Bruch's 2
vasculogenesis, 2
(pigment 2
epithelium-derived 2
[PEDF]; 2
angiostatin; 2
restin; 2
intrastromal 2
wounding. 2
CD31(+) 2
F4/80(+) 2
heparin-like 2
heparin-Sepharose 2
bFGF. 2
CD31-positive 2
Overexpressing 2
nature's 2
matrix-localized 2
sFlt-1 2
adenovirally 2
19-fold 2
angiostimulatory 2
IVox, 2
IVox 2
0-II 2
preinvasive 2
sE-selectin 2
XVIII. 2
factor-4, 2
]. 2
syngenic 2
matrix; 2
Identifies 2
Scoliosis. 2
3p26.3 2
Robo3 2
(HGPPS), 2
DSCAM 2
CNTNAP2, 2
Columbia. 2
ready-to-eat 2
restaurants; 2
non-Native 2
home-prepared 2
fetus? 2
[Depressive 2
KinderAGATE: 2
(25.8 2
systemic. 2
Definitions 2
(IELT) 2
(SSRI). 2
(IPE), 2
PSD502, 2
(FMS) 2
("Arbeitsgemeinschaft 2
Wissenschaftlichen 2
Medizinischen 2
Fachgesellschaften", 2
AWMF; 2
041/004) 2
("Deutsche 2
Interdisziplinären 2
Vereinigung 2
für 2
Schmerztherapie", 2
DIVS), 2
(meta-analysis 2
life), 2
multi-step, 2
SpringerLink 2
"Supplemental"). 2
Trazodone 2
trazodone. 2
bulimia, 2
benzodiazepine/alcohol 2
(behavioral 2
trazodone's 2
flashes) 2
acid-ergic 2
neuropharmaceuticals 2
emulate 2
tianeptine. 2
Postprostatectomy 2
Questionnaire-Urinary 2
Incontinence-short 2
postprostatectomy 2
11/18 2
(duloxetine, 2
milnacipram, 2
(EMEA), 2
(SNRIs), 2
Non-hormonal 2
Gynaecological 2
gabapentine 2
estrogen-sensitive 2
"natural" 2
Phosphodiasterase 2
tadalafil) 2
meticolous 2
intraurethral 2
alprostadil. 2
Vacuum 2
Testosterone 2
("stop-start" 2
"squeeze" 2
lidocaine/prilocaine-containing 2
IELT. 2
geometrical 2
Dapoxetine 2
scored. 2
Duloxetine, 2
million) 2
2001-2002, 2
68%. 2
psychotherapy\behavior 2
antiquated 2
psychological/behavioral 2
mid-1980s 2
Picking 2
arisen, 2
NeuroAIDS. 2
bar-codes, 2
(1997) 2
dinuncleosomes 2
(GI 2
GII) 2
unfolded, 2
charge. 2
H5). 2
perchlorate), 2
charge-screening 2
GII. 2
"winged-helix" 2
GH5 2
Four-way 2
entry/exit 2
derepression. 2
hho1 2
Sporulation 2
(Hho1). 2
Ume6, 2
sporulation: 2
Ume6-repressed 2
histone-Hho1p 2
(PARN), 2
m(7)G-cap 2
allostery 2
CNOT6L, 2
meticulously 2
Pumilio 2
mRNAs: 2
PUFs 2
PUM2. 2
deadenylases, 2
deadenylation: 2
eRF3-mediated 2
Pan2-Pan3. 2
eRF1-eRF3, 2
Pan2-Pan3, 2
polyadenylate-binding 2
Pan3, 2
PABC 2
Caf1-Ccr4. 2
Ccr4p. 2
Mpt5p-regulated 2
HO. 2
thaliana). 2
pombe), 2
Metazoa 2
AtPARN 2
3'-->5' 2
Kiss 2
goodbye: 2
exoribonucleases. 2
turnover--the 2
anti-interleukin-17 2
[AMAGINE-2] 2
P<0.001); 2
AMAGINE-2 2
AMAGINE-3 2
Background: 2
82%; 2
ixekizumab; 2
tildrakizumab; 2
inflammatory/autoimmune 2
spondyloarthritides 2
IL12/IL23 2
IL23 2
anti-IL17RA 2
[P=0.05] 2
85.9% 2
210, 2
(ACQ) 2
high-reversibility 2
IL-17R 2
IL-17), 2
Leukemic 2
6-kb 2
(LINE 2
retrotransposing 2
constitutionally 2
(7kb 2
Broadly 2
L1-ORF2 2
truncated. 2
pEGFP-C1 2
scratching 2
cDNA-PCR 2
Schweinfurthin 2
prenylated 2
(MPNST) 2
27b 2
plexogenic 2
NF1-PAH 2
BMPR2 2
vasculopathies. 2
blastomere 2
1:3,500 2
NF1DeltaE7 2
(ICC; 2
genotoxicants 2
(NF-1) 2
162200) 2
(NF1); 2
(IVS6 2
888+1, 2
(SDHD) 2
heterozygously 2
(NF2), 2
merlin 2
Trp53. 2
PTT, 2
<20% 2
CpG. 2
disactivation 2
(CLS), 2
multi-symptomatic 2
schwannoma, 2
Arg1276 2
(GRD)-the 2
R1276P, 2
GRD 2
Ras.GTP 2
neurofibromine 2
Gap1m. 2
Gap1m 2
GAP. 2
(neurofibromatosis 2
[NF1]) 2
RAS2Val-19 2
integrin-expressing 2
3650-fold 2
pentapetide, 2
(HUVECs). 2
N-oligoethylene 2
(N-OEG) 2
cyclo[RGDfNMeV] 2
N-Me 2
cyclopeptides 2
N-OEG2 2
N-OEG11 2
N-OEG23 2
nonadhesive 2
annexin-V/propidium 2
polyHEMA 2
30/55 2
αVβ3/αVβ5 2
ILP. 2
melphalan, 2
Arg-Gly-Glu(RGD)-containing 2
aza-peptide 2
aza-residues 2
aza-peptides 2
Aza-amino 2
cyclo[R-G-D-f-N(Me)V] 2
RGD-mimetic 2
18F-FDG. 2
k3 2
(P=0.033 2
k2 2
VB. 2
α(v)β(3) 2
α(v)β(5) 2
AlphaVbeta3 2
alphaVbeta5 2
VCT, 2
β(5) 2
(DCE-) 2
VCT 2
Arginine-Glycine-Aspartate 2
alpha(V)beta(3) 2
(V)beta 2
c[-RGDf(NMe)V-] 2
(Cilengitide) 2
kessler 2
3033-3040). 2
707544), 2
histologically- 2
cytologically-confirmed 2
240, 2
850, 2
mg/m(2)/infusion. 2
time-invariant. 2
mg/m(2)/infusion, 2
single-modality 2
neovasculature, 2
bcl-2. 2
Ci 2
LEPR, 2
AluJb-derived 2
prosimians, 2
AluJb-related 2
(fourth 2
diversification. 2
Alu-SINE 2
exonization: 2
exonized. 2
infraorders, 2
vitae 2
awakens 2
splicing.Here, 2
(MYA) 2
MYA 2
catarrhine 2
(Old 2
apes). 2
ere, 2
(DMD): 2
45; 2
Dystrophin-nNOS-HDAC2 2
(DAPC) 2
miR29c, 2
Dys-nNOS-HDAC2 2
snRNA) 2
c.165+1G>T 2
(FANCC) 2
(snRNA) 2
Haemophilia 2
(snRNA). 2
ExSpeU1s 2
'target 2
'U1 2
snRNP) 2
Adaptor 2
Generic 2
compliance: 2
Claims 2
Juice 2
LDL+VLDL-C 2
Cu(2+)-mediated 2
0.039), 2
total-C/HDL-C 2
(4.25 2
phytochemicals. 2
HDL) 2
lycopene. 2
(tomatoes, 2
pizza) 2
FFQ 2
27,261 2
serving/d, 2
(GDP) 2
∼7600 2
>140,000 2
12,500 2
9440, 2
transposes 2
coldspots. 2
3,951 2
mammal, 2
TFR 2
Syntenically 2
TFRs. 2
(m(6)A), 2
m(6)A, 2
Single-nucleotide-resolution 2
individual-nucleotide-resolution 2
(miCLIP) 2
antibody-RNA 2
N(6),2'-O-dimethyladenosine 2
(m6Am), 2
(snoRNAs) 2
m6A-containing 2
(m6A 2
m5C) 2
(untranslated 2
publicaly 2
(MeRIP-Seq), 2
methyltranscriptome. 2
exomePeak 2
m(6)A. 2
ideograms, 2
N(6)-methyl-adenosine 2
embryo-lethal 2
(mRNA), 2
(m(7)G) 2
N(6)-methyl-2'-O-methyladenosine 2
(m(6)Am), 2
2'-O-methylation 2
(Nm) 2
(m(5)C). 2
m(5)C 2
(snRNP), 2
distinguished, 2
(NOTCH1), 2
exportin 2
(XPO1), 2
(MYD88) 2
kelch-like 2
(KLHL6). 2
XPO1 2
unestablished 2
(SF3B1, 2
ZMYM3, 2
MAPK1, 2
DDX3X). 2
Belimumab, 2
SLE-specific, 2
(Socs1) 2
Socs1-silencing 2
T/Treg 2
Amazonas, 2
HIV-positives 2
2.54) 2
(p=0.018), 2
p=0.05), 2
(CD40L) 2
sCD40L, 2
non-cleavable 2
co-cultivation 2
sCD40L 2
(CD40L-WT) 2
Angioimmunoblastic 2
(AITL) 2
hypergammaglobulinemia. 2
antigen-loaded 2
66-year-old 2
nonautonomous 2
Markov-type 2
Viagra: 2
rationing? 2
exaggerated. 2
containment. 2
insurances 2
health). 2
Enbrel 2
Celebrex 2
Zyban. 2
Zyban 2
judgments, 2
unspoken, 2
(n=251) 2
(n=455), 2
insured, 2
2.4. 2
(PSPM) 2
$5,332 2
$3,632 2
class) 2
expenditures, 2
runaway 2
copayments. 2
HRAMS 2
full-scan 2
Benzyldimethylphenylammonium 2
drifts 2
'lock 2
calibrants 2
(lock 2
masses) 2
manufacturers. 2
calibrant 2
MS3 2
nanoelectrospray 2
C-trap. 2
Ions 2
CMV: 2
pneumonia) 2
(25.6%) 2
probenecid. 2
substantiated, 2
lobucavir 2
(IL)-2-deficient 2
vulgatus. 2
Colonization 2
monocolonization 2
vulgatus, 2
rone 2
Nissle, 2
RegIII 2
RegIII[gamma] 2
receptor-[gamma] 2
adiponectin. 2
mpkM/B. 2
(microbiome), 2
Gnotobiological 2
(isolators 2
rearing) 2
non-cultivable 2
bacteria). 2
(ApoE)-deficient 2
low-cholesterol 2
disease-protective 2
prebiotics) 2
microcirculation 2
(KL) 2
Ca2+/Pi 2
(IBD)-associated 2
osteopenia/osteoporosis. 2
(IFN)-gamma 2
(mpkDCT4 2
mIMCD3). 2
3.07, 2
(Chr8, 2
Chr12, 2
2.09) 2
"CTD-negative" 2
(GDF6, 2
GDF3) 2
(KFS). 2
KFS 2
cervicothoracic 2
(5q35.1). 2
520.7 2
ADCY9, 2
SRL 2
1/85,000 2
nondisjunction 2
hypogenitalism. 2
5q15 2
5q22 2
FBN2 2
del(1)(q23q31.2). 2
experienced, 2
1:3 2
septar 2
3p13-14.1 2
FOXP1. 2
11:22 2
frontline, 2
EWS, 2
radiation), 2
confronting 2
EWS. 2
HDAC, 2
Oncogene-targeted 2
EWS/FlI1 2
intratumourally. 2
Independently, 2
intratumoural 2
"undruggable." 2
mithramycin, 2
mithramycin-treated 2
(mithramycin 2
2388 2
2319 2
1766 2
2872 2
(peripheral 2
endosialin 2
imperative, 2
Dual-color 2
uvea. 2
stomach--a 2
t(11;22)(q24;q12), 2
regimes, 2
time-effective, 2
(EW7, 2
CADO-ES1 2
TC32) 2
(SK-N-MC) 2
engraftments. 2
t(11;22, 2
q24;q12) 2
PDGF-BB-induced 2
PLD2 2
sarcomas; 2
cytogenetically, 2
average), 2
root: 2
(EES) 2
dumbbell 2
L5/S 2
sleeve. 2
H-c-sis 2
(BIRC5) 2
IAP-family 2
BIRCS 2
(79%). 2
(N=4) 2
DSS, 2
triggers. 2
cIAP1, 2
AZD1152, 2
NOD/SCID/γc(null) 2
AZD1152 2
CA-125, 2
survivin), 2
implication. 2
Survivin) 2
FHIT, 2
CA-125: 2
(CA-125) 2
dyspnea; 2
adnexa. 2
pseudosyndrome 2
well-translated 2
ribosome-deficient 2
tRNA-depleted 2
(ACA) 2
bipartite, 2
CRD-BP/IMP-1 2
hCRD-BP/IMP-1 2
(CRD-BP), 2
co-sediments 2
furocoumarins, 2
8-(omega-diethyl 2
aminopropyloxy)psoralen 2
5-isomer 2
(II), 2
chiroptical 2
Helix 2
geometries 2
congeners 2
photoreactivity 2
III/photoreversal 2
photoreacted 2
(Me3-psoralen) 2
monoadducts 2
(20). 2
exo 2
(GT)12ATGT 2
(CG)6TA(CG)6 2
(34). 2
hyperreactivity 2
Azapsoralens: 2
photochemotherapeutic 2
bioisoters 2
photochemical, 2
4,4'-, 2
4',5'-dimetyl, 2
4,4',5'-trimethyl 2
4,4',5'-trimethylazapsoralen, 2
irridiated 2
(365 2
photoconjugates 2
diadducts. 2
magnitude: 2
4,4',5'-trimetylazapsoralen 2
(4,4',5'-TMAP) 2
(3,4,4',5'-TMAP) 2
4',5'-dimethylazapsoralen 2
(4',5'-DMAP) 2
4,4'-dimethylazapsoralen 2
(4,4'-DMAP). 2
dimetylazapsoralens 2
derivate 2
tetramethylazapsoralen. 2
Azapsoralens 2
tetrametyl, 2
dimethylderivatives 2
mautagenic 2
WP2 2
TM6 2
photobinding, 2
4,4',5'-TMAP 2
8-MOP, 2
1195 2
[on 2
consciousness] 2
pupil) 2
Proportional-odds 2
BHR 2
SYNAPSE 2
NCT01143064.). 2
8h 2
3-months 2
21%); 2
5≤GCS≤8, 2
neuro-protective 2
concealment 2
9.16 2
1.34, 2
remyelination, 2
subsided. 2
Wobbler 2
ProTECT 2
injury]. 2
ProTECT: 2
postresuscitation 2
progesterone; 2
postinjury, 2
(PROG) 2
meanfuling 2
understudied 2
B(NF-κB) 2
kynurenine 2
(KYN) 2
(KYNA) 2
p-values 2
(Scr 2
(272 2
infants). 2
(17.2%) 2
(15.6%) 2
(p<0.001; 2
2.23, 2
1.27-3.93) 2
(BUN):Scr 2
(mGFR). 2
(eGFR), 2
diaethylene-triamine-pentaacetic 2
((99m)Tc-DTPA) 2
GFR≥80mL/(min×1.73m(2)) 2
GFR≥70mL/(min×1.73m(2)) 2
(CCr) 2
differently-aged 2
(>55 2
(≤55 2
70mL/(min×1.73m(2)) 2
80mL/(min×1.73m(2)) 2
self-controlled 2
(AST), 2
Proteinuria 2
1088.6 2
131.1, 2
699.9 2
118.3, 2
433.9 2
68.7, 2
416.1 2
646.9 2
89.1, 2
hospital- 2
α-synucleinopathies 2
TKEGVVHGVATVAE 2
44-57 2
α-synuclein) 2
(5G4), 2
(alphaSYN) 2
Neuropathologically 2
neuritic/terminal 2
LBD, 2
(TH)-positive 2
TH-positive 2
anti-phosphorylated 2
anti-alpha-synuclein- 2
-phosphorylated 2
(LBs), 2
CP13, 2
TG3, 2
DLBD 2
pretreatment, 2
NI, 2
star-like 2
AFshp 2
prosencephalon. 2
immunolabeling 2
weakest 2
immunoreactive. 2
MSA, 2
2005-Dec 2
(UAD), 2
intra-partum 2
Databases. 2
21(+5) 2
(15(+1) 2
-35(+5) 2
106/139 2
(LB), 2
8/139 2
(IUD), 2
11/139 2
(7.9%) 2
(TOP) 2
14/139 2
fibrosis.Uterine 2
106/130 2
(FGR), 2
95/106 2
(89.6%) 2
1/106 2
(0.94%) 2
IUD. 2
17/24 2
(70.1%) 2
FGR, 2
11/24 2
(45.8%) 2
4/24 2
TOP, 2
7/24 2
IUD.In 2
20/106 2
(18.9%) 2
Brittany, 2
(Brittany, 2
Brittany 2
1992-2007 2
289). 2
(84%). 2
intra-cardiac 2
Cardiomegaly, 2
Bart 2
hemisphere) 2
Sonographically, 2
utero-placental 2
Karyotypic 2
bright. 2
aneuploid. 2
brightly 2
malformations) 2
comarker 2
trisomy-21. 2
echogenicity. 2
referrals, 2
Asian. 2
(1.5%), 2
-TMZ), 2
(+I/R; 2
oximetry 2
reperfusion-mediated 2
timing-dependent 2
(NORM), 2
perfusate): 2
(TMZ-STAB), 2
(TMZ-REP), 2
(TMZ-STAB+REP), 2
(Rec) 2
[1153.2 2
(121.0) 2
1152.1 2
(86.8) 2
1573.5 2
(138.2), 2
TMZ-REP, 2
Rec) 2
(13.3) 2
TMZ-REP 2
(7.7) 2
D5 2
catabolized 2
Biochemically, 2
heteroligomers 2
mtmr12 2
nucleation, 2
myotubalarin 2
3-phosphatase 2
MTMR2. 2
phosphorylation-deficient 2
substrate(s) 2
3-monophosphate, 2
phosphatase-like 2
MTM-related 2
PI(3)P. 2
hMTM1 2
3-phosphatase. 2
sheaths. 2
phosphoinositide-3-phosphatases, 2
(PI(3)P) 2
bisphosphate 2
PI(3,5)P2. 2
3-phosphoinositide 2
(PTPs) 2
D3-phosphorylated 2
PtdIns(3)P-3-phosphatase 2
(MTMR) 2
MTMR8. 2
disparate. 2
CX(5)R 2
(MTMR6), 2
MTMR7, 2
MTMR8, 2
MTMR9. 2
substrate; 2
1.4-fold 2
PtdIns(5)P, 2
Consequentially, 2
MTMR5, 2
c-Src/phospho-Src-(Tyr⁴¹⁶), 2
(ectoplasmic 2
specialization), 2
elongating/elongated 2
EPS8 2
ARP2/3 2
(actin-related 2
2/3) 2
TBC 2
(tubulobulbar 2
spermiation 2
strand-independent 2
co-located 2
(i 2
Archaeoglobus 2
herpesviruses 2
frequencies) 2
levodopa-carbidopa 2
Segawa 2
calcifications]. 2
decompensations 2
iatrogenous 2
panhypopituitarism. 2
dystonicus: 2
dystonicus. 2
chlormethiazole. 2
thalamotomies, 2
pre-status 2
(TBZ), 2
monoamine-depleting 2
dopamine-receptor-blocking 2
31.1; 2
57.4% 2
(36.5%), 2
(28.5%), 2
(15.0%), 2
(11.0%), 2
(TBZ) 2
increments; 2
Myoglobinuria 2
Curarization 2
Lea1 2
Msl1, 2
htb-K123R 2
cerevisiae-particularly 2
SUS1, 2
overubiquitination 2
ubiquitin-protease 2
misspliced 2
SR-like 2
Bre1 2
BRE1 2
anti-Tb 2
(bedaquiline 2
delamanid) 2
MDR-Tb 2
XDR-TB 2
Delamanid, 2
PA-824 2
OEF 2
(AICAO) 2
Parallel-group, 2
arteriographically 2
Anastomosis 2
29.2%; 2
13.9% 2
31.6%; 2
.78, 2
-10.4% 2
13.8%). 2
(14/97) 2
(2/98) 2
19.9%). 2
EC-IC 2
postoperative; 2
(FTICR)-mass 2
exchange-hydrophilic 2
LC/RPLC 2
∼24 2
(H4, 2
dH1. 2
K27, 2
proteome-scale 2
Histones 2
UHPLC-MS 2
(Xenopus 2
collision-activated 2
"histone 2
code." 2
diphosphorylated 2
FTICR 2
G(2), 2
inescapable 2
refuting 2
LYS4 2
spt7Delta, 2
ahc1Delta, 2
rtg2Delta, 2
SLIK, 2
ADA. 2
acetylations, 2
Reciprocity 2
Lys(14) 2
Lys(18) 2
Lys(23) 2
performic 2
H3: 2
H2B.A 2
DNA-predicted 2
MJ0556, 2
20-kDa 2
acetivorans 2
(largest 2
totalis: 2
"mirror 2
image" 2
SIT, 2
cava-aorta 2
ganglionated 2
cardioinhibitory 2
Δεcr 2
normality. 2
hepatomas 2
scrolling 2
K502 2
CaV2.1 2
docking/priming 2
SUMO-mediated 2
DmUba2(wt) 2
century: 2
aspart 2
antidiabetics 2
therapy--a 2
Parkia 2
biglobosa 2
tube) 2
Aqueous 2
(hypertension 2
potassium-specific 2
gliclazide, 2
acetohexamide 2
Retention 2
(Lys-Asp-Glu-Leu) 2
Asp-50 2
traffic. 2
KDEL, 2
erd2 2
(single-letter 2
erd2p 2
insulin-lowering 2
PCOS-related 2
BMI≤32 2
metformin/clomiphene 2
Gynaecologists. 2
[Indication 2
oligoanovulation, 2
Citrate, 2
30.63 2
29.88 2
p=0.04). 2
53.12% 2
32.25% 2
(non-significant 2
follicles/stroma 2
21-44 2
16-44 2
androstenedione, 2
(E2), 2
0.564, 2
0.328, 2
-0.374, 2
-0.691, 2
0.310, 2
0.352, 2
-0.300, 2
ovaries/PCOS 2
gastrectomized 2
clomiphene-resistant 2
ovaries: 2
(PCO). 2
PCO 2
Clomiphene 2
(PCO) 2
lane. 2
calibrators. 2
10.0% 2
calibrators 2
Workflows 2
preparation; 2
enzyme-to-substrate 2
(DOE), 2
cleavage-isotope 2
(SDS-PAGE, 2
soft-shelled 2
sinensis) 2
(ACEI) 2
IW-11, 2
Lineweaver-Burk 2
ACE. 2
SSTEW, 2
SSTEW 2
lysozyme, 2
3117-3123) 2
"macropore" 2
(myoglobin), 2
endoprotease 2
semitryptic 2
Amino-functionalized 2
Microwave-assisted 2
mixture) 2
(TMT) 2
trypsin-based 2
deoxycholate, 2
urea), 2
deoxycholate-assisted 2
Getting 2
highlighted, 2
Dried 2
spot. 2
Asp-N, 2
triplicate. 2
(trypsin, 2
LysC, 2
LysC/trypsin) 2
Lys-labeled 2
prepared, 2
homogenization 2
de-O-glycosylation 2
deglycosylated 2
backbones. 2
In-gel 2
divinyl 2
3.4.21.19). 2
buffers, 2
(PNGase 2
PNGase 2
Alg3p 2
N-glycosylation. 2
(TC-NER) 2
road-blocks 2
(Mfd) 2
1234 2
∼2-fold 2
nusA11(ts) 2
nitrofurazone 2
(NFZ) 2
4-nitroquinolone-1-oxide 2
N(2)-furfuryl-dG 2
(N(2)-f-dG) 2
NFZ, 2
(NER)-dependent 2
NFZ-induced 2
ERCC6, 2
obstruct 2
'backtracked'. 2
suppressor) 2
stall. 2
anxiolytics, 2
(XR), 2
DSM-IV, 2
DSM-V, 2
75-year-olds 2
Gothenburg, 2
51.7% 2
84.4% 2
74.3% 2
phobias, 2
1046 2
(Spielberger 2
State-Trait 2
1.02-2.27 2
1.08-3.86 2
4.56; 2
(P=0.004), 2
(omalizumab) 2
(lebrikizumab), 2
Parasitic 2
hypereosinophilia-related 2
bronchoprovocation 2
(SBP-Ag) 2
SBP-Ag. 2
eosinophil-deficient 2
unsurprising 2
eosinophil-associated 2
1131). 2
-0.29×10(9)/L, 2
-0.14×10(9)/L, 2
-6.05%, 2
-9.34 2
-2.77%, 2
(AQLQ) 2
PEF, 2
PC20 2
P>0.05), 2
Juniper 2
75-, 2
250- 2
hyaluronan, 2
versican, 2
prednisone-dependent 2
tapering, 2
Pharmacology, 2
mepolizumab-a 2
5-is 2
analysts 2
p=0·0005), 2
GlaxoSmithKline. 2
"smart" 2
(MEDI-563) 2
eosinophil-driven 2
(Bosatria(®), 2
(EE) 2
high-powered 2
heartburn, 2
furrows, 2
montelukast 2
eosinophilopoietic 2
eosinophil-mediated 2
reslizumab. 2
periostitis, 2
use) 2
Canakinumab) 2
(cryopirin 2
deficency 2
Churg 2
Strauss 2
angiitis, 2
inhibitiors 2
(Bevacizumab) 2
800-kb 2
hyper-reactivity 2
(EoO) 2
inhibitor-refractory 2
(>20 2
number/high 2
dysphagia) 2
number/hpf) 2
endoscopically, 2
(-54%) 2
(-5%) 2
EoO, 2
EoO. 2
NCT00274703. 2
prednisone-sparing 2
(32) 2
AQLQ 2
0.19; 2
tapered. 2
1.94 2
[+/-SD] 2
eosinophilc 2
eosinophilia) 2
(NCT00292877). 2
levels.A 2
2006.A 2
mepalizumab 2
(NCT00244686) 2
(NCT00358449) 2
(NCT00274703). 2
mepolizumab.A 2
(NCT00527566). 2
CSS, 2
workups 2
yet; 2
'success' 2
'marked 2
(PGA). 2
SCORing 2
(SCORAD), 2
Fluticasone 2
0.05%, 2
0.115), 2
SCORAD 2
0.293), 2
(<50% 2
allergen-challenged 2
anti-IL-5, 2
remodelling) 2
eosinophilia). 2
anti-IL-5. 2
(eosinophilic 2
esophagitis), 2
tenascin, 2
Beecham) 2
pro-genitors 2
myelocytes, 2
metamyelocytes, 2
eosinophils), 2
methylcellulose 2
(bronchial 2
=.017) 2
metamyelocytes 2
=.006) 2
=.003), 2
CD34(+), 2
=.04). 2
CD34(+)/IL-5 2
eosinophilopoiesis. 2
(mepolizumab), 2
bronchoconstriction 2
1/platelet-derived 2
(F/P)-negative 2
(HES). 2
Lymphocytic 2
81.25% 2
exploratory, 2
07/2007 2
12/2010 2
Epivista. 2
'pre 2
LTG), 2
'titration 2
'follow-up 2
phase'. 2
dose-effect-relationship 2
two-sided). 2
Herman 2
non-generalized 2
Ketogenic 2
metabolism-based 2
FIRES 2
Statement 2
RUF. 2
7/8 2
6/8 2
5/8 2
Lennox-Gastaut-Syndrome, 2
effective). 2
α1-subunit, 2
(GEFS+), 2
Postmarketing 2
hesitant 2
Levetiracetam 2
deterioration; 2
hepatotoxic. 2
periconceptional 2
SCN1A-related 2
variant; 2
spasms; 2
(Doose) 2
SMEI 2
ABPE/PLS 2
favorable; 2
Myoclonic-astatic 2
[Positive 2
falbamate 2
epileptology 2
differentation 2
turning-point 2
meaning. 2
"epilepsia 2
myoclonica 2
astatica," 2
JME 2
(Aicardi's 2
(Early) 2
Infancy), 2
(Lennox-Gastaut-Dravet 2
Myoclonic-Astatic 2
Doose, 2
(BME), 2
(Childhood 2
myoclonias, 2
Epilepsy) 2
video-polygraphic 2
inflammatory; 2
lobe; 2
Atonic 2
fits. 2
hypertrophic. 2
shoes, 2
Other: 2
(Charcot-Marie-Tooth 2
Hirayama's 2
(CMT2D/dSMA-V), 2
(N88S 2
S90L). 2
(A57V). 2
dHMN-V. 2
CMT2D, 2
Electrophysiology 2
7p15 2
(rHu)G-CSF 2
ANCs 2
10(9)/L. 2
intravenously). 2
(ANC). 2
Peptostreptococcus 2
promyelocytes 2
RhoGDI 2
LyGDI 2
fistula, 2
(QTc, 2
syndrome-1 2
(LQTS-1) 2
KQT-like, 2
channel-1 2
(KCNQ1; 2
607542). 2
947 2
LQTS1. 2
swimming. 2
P320H 2
Consent 2
20s. 2
LQT1), 2
492 2
(syncope, 2
arrest/sudden 2
2.62, 2
(Kv7.1), 2
bupivacaine, 2
KCNQ1/KCNE1 2
+30 2
Ankyrin-B 2
intervals: 2
malign 2
(V254M-V417M) 2
Voltage-clamp 2
ms(1/2) 2
KVLQT1) 2
Shaker-like 2
(LQT1 2
deafness). 2
mechanism) 2
LQTS: 2
(Romano-Ward 2
coassemble 2
(RWS) 2
KCNA9) 2
"private" 2
(ALM) 2
ALM. 2
anti-p16 2
ALMs 2
nonulcerated 2
(55.2%), 2
urged. 2
EGFR-NRAS-BRAF 2
departments; 2
melanomas) 2
18-21) 2
child: 2
two-and-a-half-year-old 2
literature) 2
nevus. 2
(Ki-67 2
photocarcinogenic. 2
sun-sensitive, 2
sun-resistant, 2
well-tanning 2
melanoma-inducing 2
sun-screen 2
lotions 2
nonmelanomas, 2
Xiphophorus. 2
Clark 2
cm2. 2
below-knee 2
Port 2
1987) 2
skin-colour 2
non-whites. 2
Nigeria-pathological 2
2:1. 2
73.2% 2
variety. 2
Nigerians 2
Onuigbo 2
quoted. 2
overemphasised, 2
28,4%. 2
faring 2
Negroes 2
resveratrol? 2
inhibition/activation 2
aging-suppression 2
P-AKT 2
PTEN-dependent 2
-independent. 2
sirtuins. 2
(RES), 2
Androgen-independent 2
(C42B, 2
(RWPE-1). 2
(HGPIN) 2
SIRT1/S6K-mediated 2
DR4, 2
FASN 2
IGF/mTOR 2
inhibitory-complex 2
anti-tumor, 2
adnocarcinoma 2
Resveratrol-induced 2
monodansylcadaverine, 2
Fura2-AM 2
3-methyladenine, 2
RSV-induced 2
phospho-AMPK 2
phospho-Raptor, 2
phospho-p70S6K. 2
ion-chelating 2
(RBC). 2
Carbonylation 2
Dd2, 2
4-hydroxy-2-nonenal 2
(4-HNE) 2
(liquid 2
4-HNE 2
Ankyrins 2
4-HNE-modified 2
parasite-driven 2
hemichrome 2
A(1), 2
(n=110) 2
[CM]; 2
n=130 2
[NCSM]; 2
n=103) 2
(p=< 2
(OR=5.0) 2
(OR=2.5). 2
ABO-blood-group 2
firework 2
(CDVA) 2
20/100 2
(OU) 2
refraction: 2
+4.00, 2
135° 2
+3.50, 2
55° 2
keratometries 2
42.3, 2
17° 2
35.8, 2
151.3°. 2
Cornea 2
CXL) 2
wavelight 2
topographically 2
(UDVA) 2
+0.50, 2
5°. 2
-0.50, 2
170° 2
(WaveLight 2
ALLEGRETTO) 2
mW/cm(2)) 2
riboflavin 2
(UDVA), 2
(CDVA), 2
equivalent, 2
Pentacam), 2
20/45 2
(2.25 2
logMAR) 2
CDVA. 2
keratoplasty. 2
ectasias 2
higher-fluence 2
keratometry 2
with-the-rule 2
against-the-rule 2
astigmatism. 2
nondiabetic, 2
metformin-containing 2
mg·kg(-1)·day(-1)). 2
12-wk 2
(29.6 2
(65.8 2
OGTT) 2
connected? 2
100mg/kg) 2
(score: 2
TLR-dependent 2
84%; 2
165% 2
50mg/kg. 2
parent's 2
(preclinical 2
AD). 2
A4. 2
unbound) 2
equilibria 2
(LY2062430) 2
alzheimer 2
LY2062430, 2
mid-domain 2
F19A 2
LY2062430 2
(solanezumab) 2
null-alleles 2
null-allele, 2
COL5A1. 2
COL5A1/COL5A2 2
major--if 2
only--cause 2
Oxcarbazepine, 2
antiepileptic, 2
[Pain 2
pharmacokinetics]. 2
environment.In 2
analgosedation 2
care.In 2
system/lumbar 2
EMLA® 2
traumatized.For 2
malignancy- 2
O2-saturation 2
personnel/physical 2
cuddling, 2
etc.The 2
pharmacy. 2
registering 2
1373 2
remit 2
Mucositis 2
postoperative, 2
(16.7%), 2
rotations, 2
hydromorphone 2
fentanyl. 2
=.009). 2
=.018). 2
nonneuropathic 2
Stanford. 2
5-16.6 2
[Transmural 2
paradox]. 2
paradox", 2
A23187, 2
Ca++-free 2
Zimmerman 2
Hulsmann, 2
"calcium 2
paradox". 2
Chizzonite 2
Zak 2
post-hatched 2
9-day-old 2
paradox' 2
calcium-fre 2
paradox). 2
(NS5) 2
10-residue 2
((7Me)GpppA(2'OMe)) 2
guanine-N7-methyltransferase, 2
nucleoside-2'O-methyltransferase 2
well-folded 2
solved; 2
(Kunjin 2
(5D4, 2
4B6, 2
5C11 2
6A10) 2
354-389 2
5H1) 2
(7G6) 2
(FFQ) 2
FFQs 2
meats) 2
P-trend 2
pre-processed 2
meats. 2
(saturated/trans 2
-0.7 2
3.1). 2
18.2% 2
TC:HDL-C, 2
non-HDL-C 2
TG, 2
triacylglycerols, 2
sweets, 2
butter, 2
soda, 2
coconuts 2
non-leafy 2
potatoes, 2
meats, 2
grains. 2
Evasion 2
kinase-directed 2
HCT116p53KO 2
5FU-treated 2
GSK3B, 2
FLIP: 2
Cancerous 2
anticancer- 2
anti-ischaemia 2
ischaemia-induced 2
apoptosis-modulating 2
co-effects 2
'yin-yang' 2
mitoptosis) 2
p53). 2
generalizes 2
p-chlorophenylalanine; 2
(N=86) 2
forced-titration 2
(12.5-75 2
(75-375 2
28.6) 2
LOCF 2
8.59) 2
-17.3 2
8.99) 2
venlafaxine-treated 2
-3.42, 2
4.54, 2
p=0.784). 2
df=1, 2
(SLC6A2, 2
NET) 2
homogenate 2
occurs) 2
nomifensine, 2
indatraline, 2
21,947 2
216,303 2
(SNRIs) 2
[(11)C]MADAM 2
[(18)F]FMeNER-D(2) 2
hyperbolic 2
(Kd(plasma)) 2
Kd(plasma) 2
NET, 2
S33005, 2
neurones, 2
alpha2-adrenergic 2
therein, 2
minipumps) 2
suppressant 2
raphe. 2
(LAC) 2
1128 2
polyautoimmunity 2
19.8-fold 2
(DMARD)-naive 2
polyarticular 2
Rheumatologists. 2
chi-squared, 2
(GEE) 2
28/erythrocyte 2
(DAS28-ESR4), 2
GEE 2
DAS28-ESR4 2
dataset; 2
categorical) 2
(0.23, 2
0.21); 2
Heijde-Sharp 2
TotSharp 2
SDAI/CDAI 2
(SDAI) 2
(RF), 2
553 2
Ioannina 2
2.5:1 2
49.4 2
+/-15.6 2
signficantly 2
FINDbase, 2
summaries. 2
(http://www.getpivot.com) 2
(http://www.silverlight.net), 2
FINDbase. 2
group-specific 2
drug-metabolizing 2
(thalami, 2
cortex), 2
B1(thiamine) 2
(HG), 2
(CPM). 2
wernicke 2
"gestational 2
thyrotoxicosis". 2
alcoholics]. 2
Alcoholics 2
drink; 2
drink. 2
gastroenterocolitis. 2
Sleeve 2
monocarboxylic 2
encephalopathy-Korsakoff 2
(WE-KS) 2
(TD; 2
(THAL). 2
(EtOH) 2
AcCoAS 2
TD-induced 2
12days 2
n=13) 2
CCL2) 2
deficiency-related 2
delivered, 2
OBSERVATION: 2
[Wernicke´s 2
Bariatric 2
Wernicke´s 2
encephalopathy--a 2
disorder-is 2
B(1)). 2
B(1) 2
SG. 2
tachypnea, 2
Breathing 2
(Mecp2) 2
nutritional-environmental 2
(re)programming 2
(stem) 2
defective/sucrose 2
non-fermenting 2
NKX2-5. 2
Chromatin-level 2
chromatin-level 2
Tobacco-smoking, 2
polyphenols. 2
Consolidated 2
Epigenomics 2
noncommunicable 2
acetylases/deacetylases 2
methyltransferases/demethylases, 2
hyperinsulinemia. 2
T4( 2
(NTIS). 2
(D1, 2
D2), 2
(SBP2) 2
THRB1, 2
RXRG 2
SMRT, 2
pM), 2
sonicates. 2
sonicates 2
(catalytic 2
efficiency) 2
calculations, 2
(D2) 2
rs7294, 2
VKORC1-1639 2
genotypeguided 2
co-morbidity, 2
co-medication, 2
(INR), 2
mini-sequencing 2
rs1799853 2
coumarins. 2
Allele) 2
over-anticoagulation 2
0.096 2
73.9%. 2
(*2, 2
*5, 2
*6, 2
POL3S 2
(HDA) 2
(430C>T 2
1075A>C) 2
(CYP2C9*2 2
African-descent 2
D36Y 2
"sensitive" 2
"resistant" 2
inpatients. 2
CYP2C18 2
[Warfarin 2
"lower 2
enzymes." 2
patiens 2
4-hydroxycoumarin 2
(VKORC1). 2
Building 2
PROC, 2
GGCX, 2
ORM1, 2
Chapel 2
Hill. 2
CYP2C9*3. 2
VKORC1*1173. 2
R- 2
blood-vessel-inducing 2
14,595. 2
sequence: 2
ribonucleases, 2
fmol 2
(isoelectric 2
9.5), 2
Mono 2
Lactogenin 2
(RNase) 2
derangements, 2
DIP 2
heparin-derived 2
decasaccharides, 2
14,120), 2
(mmol/l)(-1) 2
both]. 2
(GlcCer) 2
c.1226A>G 2
(N370S) 2
c.1448T>C 2
IL-4-regulated 2
(11) 2
firefly 2
N-butyl-deoxynojirimycin 2
(NB-DNJ, 2
Miglustat), 2
(CSG) 2
(G418) 2
1.3-, 2
2.1-, 2
3.6-, 2
9.9-fold 2
S364R, 2
V15M, 2
M123T 2
L336P, 2
S465del 2
P266L 2
NB-DNJ, 2
CSG, 2
"chemical 2
chaperone", 2
Miglustat, 2
reducer 2
GD) 2
42.7% 2
Co-morbidity 2
enquiry 2
RANGE: 2
(1763 2
genomic) 2
StyI 2
"mild" 2
"Pv 2
+" 2
1448C, 2
radioactively 2
Genotype/phenotype 2
anti-glucocerebrosidase 2
(subacute 2
Pv1.1- 2
single-base-pair 2
single-point 2
(beta-Glc) 2
RFLP, 2
radioprotectants 2
Amifostine: 2
re-oxygenation, 2
repopulation, 2
carrier-mediated 2
stagnation 2
dyspnoea. 2
blood-cell 2
non-Fanconi 2
flow-based 2
Exosomes: 2
semi-quantitative. 2
(NTA) 2
fluorophore, 2
CD24- 2
AQP2-positive 2
pre-NTA 2
NTA. 2
4°C 2
frozen, 2
reduced; 2
(uEVs) 2
uEV 2
(OPG), 2
End-stage 2
(30-150 2
(ELVs) 2
40-200 2
(THP) 2
ELV 2
GMVs 2
TRPC6, 2
mRNAs) 2
TRI 2
SeraMir™ 2
(capability 2
deliverability 2
drugs,and 2
populations). 2
"Early 2
Intervention" 2
child- 2
gain: 2
decanoate) 2
FosB-like 2
schizophrenia? 2
first-episode 2
met5-enkephalin-like 2
caudate-putamen 2
haloperidol-treated 2
Broader 2
0.4%) 2
(PCS) 2
Monotherapeutic 2
ATS." 2
CPVT) 2
Mutation-positive 2
(15/20) 2
ATS, 2
(2/28) 2
(n=45, 2
(n=21, 2
(n=24, 2
53%). 2
QUc 2
[(A): 2
(B): 2
ms] 2
U-wave 2
(0.24 2
R82Q, 2
R82W, 2
G144D 2
T305S 2
QT-U 2
dysarrhythmias, 2
T75R 2
(R67W) 2
[81%]) 2
[40%]) 2
"Andersen 2
stenosis), 2
dish" 2
promises, 2
minicircles, 2
(hiPSC-ECs) 2
protein-4. 2
CD31+ 2
hiPSC-EC 2
cardioactive 2
(CVPCs) 2
(hPSCs), 2
hPSC-derived 2
(GSK3) 2
hPSCs, 2
feeder- 2
CVPCs, 2
(GOSHS, 2
#609460) 2
(KBP), 2
KBP-depleted 2
kinesins. 2
Kif1-binding 2
protein/KIAA1279 2
Shprintzen. 2
235730). 2
Ser305Asn, 2
Ser305Asn 2
supraglottic 2
intuitively 2
LDS, 2
SKI, 2
half-sibs 2
metaphyses, 2
malrotation, 2
pragmatically 2
rubric 2
(SGS). 2
undermodeling 2
undermodeled 2
frontometaphyseal 2
aortography 2
[1982: 2
Furlong 2
[1987: 2
26:599-604] 2
Lacombe 2
Battin 2
[1993: 2
down-slanting 2
C-1 2
stigmata. 2
phonological 2
dolichocephaly; 2
(dolichostenomelia, 2
malformation); 2
(hydrocephalus, 2
malformation). 2
regurgitation/incompetence, 2
7.3±4.4 2
102.8±16.9 2
49±16 2
Dislodgement 2
pseudoarthrosis. 2
dislodgements 2
polymicogyria 2
Intercellular 2
CER 2
NTS. 2
(lymphoepithelial 2
type-related 2
keratinization, 2
NS, 2
overprocessing 2
1958, 2
atopy. 2
(lympho-epithelial 2
unopposed 2
KLK7 2
(PAR-2) 2
(MDC) 2
Vectors 2
Lympho-epithelial 2
KLK-mediated 2
uppermost 2
pro-kallikrein 2
matriptase 2
LEKTI-deficient 2
c.891C>T 2
SPINK5-encoded 2
(SCTE), 2
transglutaminases. 2
NTS, 2
plasmin. 2
serine-protease 2
Netherton&apos;s 2
Braak's 2
agitans, 2
subsantia 2
bradykinesia. 2
conservative, 2
long-held 2
PD-I, 2
descriptions. 2
Atg12 2
neurodegnerative 2
torsinA 2
apparition 2
extranigral 2
"pure" 2
expressed: 2
deiodination. 2
E17 2
ECL1711M 2
62-72% 2
(27-32 2
[3',5'-125I]rT3 2
[3',5'-125I]T4 2
[3,5-125I]T3 2
125I. 2
[Michaelis-Menten 2
D1: 2
D3: 2
nM]. 2
(MAML). 2
"RAM" 2
MAML-1 2
selection-based 2
(ANK), 2
(MAML-1). 2
astrogliogenesis 2
CSL-mediated 2
instructively 2
CSL-/- 2
astrogliogenesis. 2
gliogenesis. 2
(Mam) 2
(NotchICD). 2
NotchICD 2
Notch-dependent 2
NLK. 2
NLK-phosphorylated 2
Notch1ICD 2
paired, 2
untwisting 2
NotchIC, 2
Mastermind, 2
CSL-NotchIC-Mastermind 2
(Env) 2
Envs 2
Tier 2
89, 2
61, 2
NMB. 2
myopathies: 2
(HLA-A, 2
-DQA1) 2
0.010, 2
mannose-dependent 2
virion-associated 2
glycan- 2
polypeptide-epitope 2
immunoprotective 2
ehrlichial 2
epidemics, 2
(BACH1) 2
ME1, 2
Bach1/small 2
(MARE). 2
Bach-1 2
24h, 2
Bach-1, 2
UVA-mediated 2
oxidants 2
[BTB 2
(broad-complex, 2
tramtrack 2
bric-a-brac) 2
(cap'n'collar 2
macroscopically, 2
Myeloperoxidase 2
(Bach1), 2
HMOX1, 2
antioxidant-induced 2
ach1 2
(bZip) 2
(CO), 2
biliverdin. 2
injuries: 2
carrageenin, 2
kinin 2
(BTB 2
(Bach1(+/+)) 2
16%), 2
36%), 2
HO, 2
TAC-induced 2
repressively 2
(CP 2
Soret 2
hematopoietic, 2
pro-atherosclerotic 2
rate-controlling 2
anti-oxidants 2
pathways--is 2
oxygenase-1, 2
ARE-governed 2
mutant) 2
diamide 2
microspheres. 2
bach1-ablation 2
IX, 2
NAD(P)H:quinone 2
t-BHQ. 2
succinylacetone 2
SA-treated 2
Hemin 2
MARE. 2
desferrioxamine, 2
oxygenase, 2
microenvironments, 2
Bach2. 2
kinase-1/2 2
bovine, 2
hypoxia-mediated 2
globins 2
(E.C.3.2.1.49). 2
alpha-N-acetylgalactosaminidase: 2
Avium 2
Hospitals: 2
Recognition, 2
Co-Infection 2
(2004-2005), 2
(NTM). 2
(2006- 2
related/likely 2
US-born. 2
foreign-born. 2
anti-MAC 2
ZN 2
100.0 2
TCD4+ 2
48.5 2
cell/microL), 2
80.0 2
cell/microL). 2
HAART; 2
mycobacteremia 2
Killing 2
mycobacterium: 2
mycobacterium, 2
avium-infected, 2
tuberculosis-infected, 2
titer-dependent 2
EuroSIDA 2
(PYF), 2
communicable, 2
2.2), 2
SPNs, 2
Maa2520, 2
resisting 2
MK-4305 2
(22.3 2
-28.1 2
-22.3 2
driving. 2
hypocretin) 2
cataplexy; 2
chimaera, 2
horseshoe-like 2
62], 2
61], 2
59], 2
61]) 2
<0.01) 2
nonelderly 2
neurokinin) 2
ramelteon. 2
orexin-B. 2
orexin- 2
faded 2
$63.2 2
doxepin, 2
Diversifying 2
customizing 2
(CBT-I). 2
Merck&apos;s 2
n=290) 2
n=374) 2
NCT01164501. 2
-0·52% 2
-0·72 2
-0·32) 2
-0·68% 2
(-0·88 2
-0·49) 2
-0·42% 2
(-0·56 2
-0·28) 2
[12%]), 2
[6%]) 2
Ingelheim, 2
Lilly. 2
macro-/microvascular 2
≤9.0%), 2
≤10.0%), 2
dummy) 2
≥691 2
<1.3 2
pooled). 2
pectoris) 2
592 2
7034 2
Asia). 2
kg/m2, 2
NCT01131676. 2
q.d.; 2
(30.8%), 2
allometric 2
∼25% 2
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol 2
Carbon-14 2
98.5%. 2
(there 2
[haemoglobin 2
≤10%] 2
(QD), 2
QD), 2
0.15% 2
7.8-8.1%). 2
-28 2
-2.9 2
(29.6-48.6%), 2
(36.6%) 2
(35.2%). 2
Hypoglycaemia 2
(4.0% 2
(2.5% 2
(4.0%). 2
Na+-glucose 2
BTBR.Cg-Lep<ob>/WiscJ 2
(BTBR 2
ob/ob) 2
equicaloric 2
μg·kg 2
wt(-1)·day(-1) 2
glucosuria, 2
(SUs) 2
diet/exercise. 2
macro- 2
1549 2
1545 2
55.9 2
(10.4) 2
7.92 2
(0.84)%, 2
30.11 2
(5.59) 2
(15.9) 2
(9.4) 2
function/damage. 2
NCT01167881. 2
(E-R) 2
(glycosylated 2
[HbA1c 2
], 2
[FPG] 2
excretion). 2
748, 2
E-R. 2
(144 2
dl(-1) 2
maximums. 2
genital/vulvovaginal-related 2
(Jardiance()), 2
g/3 2
g/5 2
28.2 2
11] 2
disposal, 2
mM(-1) 2
empagliflozin-induced 2
glycemia. 2
registration. 2
non-systematic 2
ACC2 2
(Hypo1_ACC2) 2
(Hypo1_ACC1) 2
ACC1 2
(HBD) 2
Cat-Scramble 2
Specs, 2
NCI, 2
(r(training) 2
r(test) 2
Hypo1, 2
target-oriented 2
Protein-based 2
Pharmacophores 2
(SBPs) 2
macromolecule-ligand 2
(holo) 2
building. 2
QSAR. 2
they? 2
campaigns, 2
VS. 2
fish-specific 2
skin-specific 2
gene-linkage 2
ret-specific 2
Six3 2
Six3. 2
(QF-PCR) 2
6-11 2
determination: 2
noninvasively, 2
(MEDLINE), 2
(HAS) 2
Non-Invasive 2
6(th)- 2
Gestation 2
Couples 2
periinfarct, 2
subacute, 2
photothrombotic 2
Astroglial 2
beading 2
SD-like 2
Peri-infarct 2
Calomel 2
Depolarizations 2
(SDs; 2
5.24 2
(LDs; 2
64.7 2
(TDs; 2
cats; 2
repolarization) 2
TDs 2
29.9% 2
22.8%) 2
(51.5 2
48.0%). 2
ml/gm/min), 2
ml/min), 2
echo-planar 2
.81, 2
Slowly 2
malperfused 2
mm/min. 2
fastigial 2
normalizes. 2
rCBF, 2
Impedance 2
mm3 2
T-state 2
pinwheel 2
(domains 2
Ia) 2
11° 2
13°, 2
helix-helix 2
proteoliposomes, 2
isotherms. 2
up-take 2
phospholamban-mediated 2
antrum. 2
PLB-knockout 2
Bethanecol 2
Caffeine 2
contractility: 2
gene-altered 2
(PLB-KO 2
(41.5 2
WT), 2
smooth-muscle-specific 2
(PLB-SMOE 2
SMP8 2
12-fold. 2
CCh-induced 2
27-kDa 2
Endothelium-dependent 2
PLB-deficient 2
GM. 2
relieved, 2
transcription/translation 2
ASM, 2
Overnight 2
fura-2-loaded 2
non-electrolyte 2
(K27A 2
R9C) 2
(I47A) 2
R9C-PLN 2
phospholamban/Ca(2+)-ATPase 2
myocite 2
tense 2
(pPLN). 2
pPLN 2
Ib. 2
Cys11 2
E873stop/A467T. 2
(E873-TAG) 2
nonsense-associated 2
(POLG) 2
(Alpers' 2
images) 2
polyspikes. 2
Inexorable 2
hepatocerebral 2
paresis, 2
high-amplitude 2
POLG1 2
macrovesicular 2
dropout, 2
neutropenia]. 2
MEDICAL 2
HISTORY 2
COURSE: 2
hematologist 2
cladibrin 2
compactions 2
Halo 2
piperacillin/tazobactam 2
linezolid. 2
voriconazole 2
filgrastim, 2
insufficiently. 2
AUTOPSY 2
DIAGNOSIS: 2
hepato-splenomegaly, 2
granulo- 2
Clots 2
prohylactic 2
(HMTs) 2
Histone3-lysine79 2
(>4500-fold) 2
MLL-translocated 2
MV4;11 2
THP1 2
DOT1L:nucleosome 2
(S-adenosyl-L-methionine) 2
campaigns. 2
IVMBIX-01294, 2
EHMT2, 2
EHMT2. 2
5µM 2
pronuclear, 2
(Win) 2
demethylations 2
H3K4me3/me2-specific 2
(JHDMs). 2
JHDMs, 2
(ccKDM5B, 2
1-769). 2
ccKDM5B, 2
(app) 2
H3(1-15)K4me3, 2
HDMs. 2
ccKDM5B. 2
2,4-PDCA 2
KDM4A/C 2
KDM5B. 2
CARM1. 2
DOT1L-inhibitor 2
N6-methyl 2
(PRC) 2
(DZNep) 2
3-deazaadenosine 2
(DZA) 2
(Nep 2
SKBr3 2
biotinylated-histone 2
Sulforaphane 2
(SFN), 2
SFN. 2
(5-Aza-2'-deoxycytidine) 2
chloride) 2
Wnt5a, 2
5-aza-cytidine 2
SW620. 2
(MND), 2
Kennedy's 2
overactivation; 2
scavengers, 2
xC- 2
cystine/glutamate 2
xCT/Slc7a11) 2
pro-inflammatory/neurotoxic 2
TNFa 2
anti-inflammatory/neuroprotective 2
Ym1/Chil3 2
AG1478 2
(ER)alpha 2
MCAT 2
Avian 2
TEF-1 2
MEF- 2
MEF-2) 2
85-bp 2
Ca2+-ATPase-2 2
hSERCA2 2
q24.1 2
Contig 2
NT_009770.8, 2
cardiac/slow-twitch 2
SERCA2b 2
225-bp 2
G+C-rich 2
TATA-like-box, 2
E-box/USF 2
CAAT-box, 2
(TRE). 2
-410 2
-661 2
-919 2
-1410 2
5-regulatory 2
-225 2
-1232 2
TATA-like 2
MCBF 2
(musS) 2
(AP-2A, 2
NRE1, 2
NRE2, 2
Spel 2
TFI-IIA). 2
post-birth. 2
HF-la/MEF-2 2
co-factor. 2
ankyrin-like 2
HF-1 2
sub-element 2
(HF-1) 2
HF1a 2
HF1b/MEF2 2
7.5-8.0 2
coitum. 2
receptoralpha 2
Myocyte-specific 2
HF-1b/MEF-2 2
-165 2
+41 2
-505 2
-165. 2
C3H10T1/2, 2
NKX-2.5, 2
MEF-2C, 2
GATA-4/5/6. 2
3'Ile 2
(TERTp-mut) 2
807 2
TERTp 2
ETV1-5 2
TERTp-mut, 2
74.2% 2
codeletion). 2
11,590 2
tasocitinib, 2
CP-690550, 2
Rheumatism. 2
(HAQ-DI). 2
malignancies; 2
Postmarket 2
tofacitinib's 2
DMARDS. 2
(1-15 2
mCIA, 2
(Cave50) 2
(ED50) 2
~40 2
Cave 2
Cmin), 2
~2-fold 2
JAK1/JAK3 2
(1.58 2
(1.10 2
2.93 2
differing, 2
disclosures 2
(AIA) 2
Hind 2
CD3+, 2
JAK3-Stat6 2
JAK3-deficient 2
JAK3. 2
pan-JAK 2
CP-690,550-treated 2
(IFNγ) 2
507) 2
(52.9% 2
58.1% 2
(33.3%). 2
(DAS28-CRP), 2
<2.6. 2
headache; 2
384) 2
71.9% 2
0.105), 2
(7.7%), 2
CP690,550, 2
(paw 2
differentials 2
5-100 2
(IL-6 2
pre-disease 2
MTX/CP-690,550) 2
103.06% 2
99.00, 2
107.29]. 2
MTX/MTX) 2
89.53% 2
77.38, 2
103.57), 2
(pain), 2
(HAQ-DI) 2
(44%, 2
HAQ-DI 2
=0.3 2
INCB18424 2
Jak1/2 2
(AHR) 2
(ARNT) 2
(ERα). 2
NCoA3, 2
E2-induced 2
tale 2
(TALE-TFs), 2
interest; 2
medaka. 2
β-Thalassemia 2
(β-Thal) 2
(HBB). 2
recombination-based 2
β-globin. 2
finger-mediated 2
(RGENs), 2
cleavages. 2
276, 2
MVIIA. 2
Gly(1326) 2
microg/hr) 2
hrs). 2
microg/hour 2
Morphine 2
(spinally). 2
morphine-tolerant 2
ziconotide; 2
analgesia; 2
(PRIALT) 2
hysterectomy, 2
microg/h) 2
(VASPI) 2
.040). 2
ziconotide-treated 2
microg/h), 2
microg/h. 2
SNX- 2
111, 2
tetrahydroisoquinoline 2
optimizations 2
Caliper's 2
Allegro 2
PerkinElmer 2
TopCount. 2
150,000 2
[125I]GVIA 2
analgesics: 2
N-methyl-D-aspartic 2
(NMDA), 2
bicuculline. 2
(GABA)A 2
NMDA-, 2
PGE2-, 2
(ziconotide) 2
Calcium, 2
(4-7 2
post-surgery) 2
ED(50)4 2
nmol) 2
nmol). 2
(</=1 2
hindpaw; 2
(heat) 2
state-dependence, 2
use-dependence, 2
CaV2.2-selective 2
>20-fold 2
corticosterone-sensitive 2
OCT3-like-immunoreactive 2
(OCT3-ir) 2
colliculi, 2
Calleja, 2
subiculum, 2
circumventricular 2
corticosterone-induced 2
(5-HT)/serotonin 2
(OCT3)/plasma 2
(PMAT) 2
(D-22) 2
tractus 2
solitarius 2
D-22 2
PMAT, 2
basophil-derived 2
(OCT3), 2
basophil 2
IL-33. 2
PMBCs 2
brake 2
serotonin-transporter-deficient 2
transporter-deficient 2
5HTT-deficient 2
5HTT 2
aspergillosis. 2
Anaemia 2
certificates, 2
replication- 2
damage-dependent 2
FA-dependent 2
(HNSCCs) 2
HNSCCs, 2
raison 2
d'être 2
[N. 2
Howlett 2
(Wash. 2
297: 2
606-609, 2
[M. 2
CMML/JMML 2
mitogen-sensitivity 2
377-378delGA 2
cousins) 2
Stopcodon 2
(ICL) 2
interacting. 2
Sense 2
nonsense: 2
Aminoglycosides 2
(TBT). 2
gag. 2
(readthrough) 2
(frameshift). 2
CAR-YYA 2
leakiness 2
UAG. 2
Motility 2
β1-integrins 2
Ndr2-null 2
Chloride 2
LPA-induced 2
RCP-mediated 2
Phosphatidic 2
Cdk4/6 2
factor-guanine 2
(ARF-GEFs) 2
identity). 2
3/GRP1. 2
(RCCs). 2
(CLIC3), 2
FAK/AKT. 2
MMP1 2
MMP7; 2
integrin-recycling 2
FAK/AKT 2
FERM-domain-containing 2
internalized, 2
(SNX17) 2
SNX17 2
β1-integrin-tail-binding 2
Dishevelled-mediated 2
Gbeta2 2
Dishevelled, 2
(Xdsh) 2
membrane-targeted 2
(dishevelled, 2
(Gb3) 2
(Gla) 2
micromol/l) 2
Anderson-Fabry 2
(Gb(3)), 2
impressively 2
allograft, 2
Gb(3) 2
3.2.1.22; 2
alpha-galactosyl 2
301500). 2
cortex-specific 2
lamination, 2
thalamocortical 2
neurocircuitry 2
Ephrin 2
(Egr-1) 2
TG2(-/-) 2
muscle-degenerative 2
frameshifting, 2
knockin) 2
DMD-patient-derived 2
helper-dependent 2
helper-dependent, 2
capsid-modified 2
(HD-Ad5/35) 2
293-Cre 2
ccr5 2
TALEN-based 2
(hPSCs). 2
hPSCs. 2
CFTRΔF508 2
loxP-flanked 2
CCR5-modified 2
Cre. 2
SCD-corrected 2
Baculoviral 2
Neo-eGFP 2
Seamless 2
(HBB) 2
dinner 2
nightmares, 2
Nkx2.5 2
up-regulations, 2
Nkx2.5+ 2
miR-34a. 2
fosters 2
positive-CD45 2
IGF-1R, 2
c-kit(+) 2
c-Kit/Sca-1 2
endothelial-primed 2
IGF-1Ea-mediated 2
bioactivity, 2
GATA-4-positive 2
nanofibers 2
nanofiber-mediated 2
nontransduced 2
phospho-Akt 2
tunnels 2
nonautologous 2
(CSCs-ECCs) 2
microm3 2
(HGF)-c-Met 2
sonomicrometric 2
Overdetection 2
(European 2
0.09) 2
citizens 2
citizens' 2
HTA 2
mammography, 2
Lmo2-induced 2
Stabilisation 2
Lmo2, 2
destabilises 2
GST-pulldown 2
Gata 2
p16-cyclin 2
D-pRB-E2F 2
E2F-responsive 2
DPs, 2
E2F's 2
DP. 2
cyclin/CDK-pRB-E2F 2
stimulation- 2
short-peptide-aptamers 2
retrovirally. 2
Pep80 2
Pep80. 2
Pep80-mediated 2
Ca²⁺/NFAT 2
Factor-β 2
oncogenically 2
diverted 2
traps, 2
(ID1/3-PA7) 2
(IP(20)) 2
monophosphate-dependent 2
QCM 2
mU 2
RAD51-binding 2
TbBRCA2 2
paralogues. 2
PA-1. 2
(GEFs) 2
GDP/GTP 2
RhoGEFs 2
Tgat, 2
Trio, 2
TRIP 2
TRIP(E32G), 2
TRIP(E32G) 2
peptide-aptamer-based 2
CE. 2
(structurally 2
(ABAD) 2
ABAD 2
(TRX). 2
TRX 2
TRX, 2
rebalance 2
"redox 2
equilibrium" 2
(DRD) 2
FLASH. 2
TRIPalpha, 2
GEFD2 2
TRIAPalpha 2
(TRio 2
APtamer), 2
GEFD2-exchange 2
(death-activated 2
DAPK-1. 2
DAPK-1core 2
MAP1B. 2
Immunobinding 2
miniprotein 2
1-126 2
12-amino 2
DAPK-1, 2
microscopy; 2
DAPK-1-stimulated 2
MAP1B-mediated 2
immunity]. 2
patterns) 2
inflammasomes. 2
CASPASE-1 2
(CASP1), 2
pro-IL-18, 2
ctivation 2
Casp11 2
Casp1 2
TIR-domain-containing 2
interferon-inducible 2
neutrophil-mediated 2
caspase-1-mediated 2
inflammasomes, 2
NLR, 2
pro-caspase 2
IL1β. 2
autoactivation. 2
executioner 2
SIRS. 2
caspases' 2
ITAM-containing 2
ananassae, 2
virilis, 2
gambiae), 2
Caenorhabditis, 2
Saccharomyces. 2
phastCons, 2
HCEs 2
(uc) 2
ontogeny. 2
nongapped 2
(CyN) 2
W212stop 2
emerges, 2
prognoses, 2
BiP/GRP78 2
XBP1 2
(DDITS) 2
protease-independent 2
prodomains 2
leukemia/myelodysplasia. 2
serpins 2
maldistribution 2
myelopoiesis. 2
chalone 2
ela2. 2
myelopoiesis, 2
substantiating 2
myeloid-committed 2
mutant-protein-mediated 2
elastase. 2
Referring 2
Monocyte 2
(TSCs), 2
factor-β/connective 2
cardiospheres 2
TGFβ-receptor 2
SB431452, 2
niche-like 2
3D-multicellular 2
CPCs. 2
actin). 2
Wnt3a-induced 2
VICs 2
VICs, 2
(HR)-positive, 2
everolimus: 2
Everolimus, 2
receptor-2-negative 2
sulthiame 2
directions) 2
(ROIs). 2
geniculo-calcarine 2
diffusivity. 2
(subependymal 2
astrocytoma) 2
(angiomyolipoma) 2
(GFs) 2
stripes 2
10-h 2
Vn, 2
β1integrins, 2
TnC, 2
Fn. 2
Fibronectin, 2
proteoglycans, 2
ECM-mediated 2
Integrin-dependent 2
X-FERM 2
periostin, 2
β1. 2
hβ1- 2
mechanosensors 2
non-channel 2
bindings). 2
αV-integrins 2
Integrins, 2
epistem 2
α6- 2
β1-, 2
kPa) 2
organelles: 2
fuels. 2
initiations 2
explantation 2
Na(+)/Ca 2
(ENDO) 2
(SO) 2
ENDO, 2
EPI-ENDO 2
ENDO 2
(IMR90 2
KS1) 2
(H7 2
HES3) 2
Beating 2
20-day-old 2
hESC-CMs 2
recptor-2 2
calcium-ATPase 2
(Jun) 2
(TRDN), 2
immeasurably 2
G-protein-PLC-IP3 2
ischemiamimetic 2
re-incubated 2
GdCl3, 2
CaSRs, 2
energetics, 2
Maladaptation 2
"switch 2
(PKC)-beta 2
II-expressing 2
catheterizations 2
transaortic 2
(TAC). 2
HET 2
hypertrophied, 2
TAC, 2
HET, 2
sinks 2
Arrhythmia-associated 2
Ca²(+) 2
arrhythmia-associated 2
(CPVT1) 2
'pharmacodynamics' 2
Compact 2
antagonists' 2
(MeSH) 2
alpha-induced 2
Asymmetrical 2
mis-expression 2
(MaLRs), 2
(ERVL 2
ERVK) 2
HSATII 2
DUX4-activated 2
DUX4-bound 2
repeat-initiated 2
repeat-mediated 2
retrogene, 2
pivot-point 2
discovery-oriented 2
4QA 2
CD56(+) 2
noncontracted 2
contraction-dependent 2
(FSHD2) 2
FSHD2) 2
(MPS). 2
Dux 2
IFN-gammaR(-/-) 2
TNFRp55(-/-) 2
synthase(-/-) 2
p47phox(-/-) 2
transcriptome-profiling 2
IFN-gamma-coregulated 2
immunoresponsive 2
IFN-gamma/TNF-triggered 2
Interleukin-10 2
PTGS2, 2
IP-10/CXCL10, 2
stimulants. 2
Marek's 2
MDV 2
economics. 2
(ESTs). 2
pET32a(+) 2
fusion-expressed 2
IRG1h 2
(IRG1), 2
smegmatis-infected 2
MAP, 2
implantation: 2
LIF-regulated 2
Irg1, 2
P-regulated 2
receptivity, 2
RU486, 2
(Irg1), 2
lipopolysaccharide-inducible 2
(P4) 2
dehydratase. 2
(PKC)-regulated 2
Irg1. 2
Stem-cell-derived 2
cobblestone-like 2
(fRPE) 2
feeder-free, 2
dorsomorphin, 2
Chx10 2
pharmacoepidemiology 2
Brogan's 2
(CDTI). 2
specialty. 2
Weighting 2
Quarterly, 2
FGAs 2
Remoxipride 2
haloperidol. 2
(H1), 2
(5-HT2) 2
1)-blocking 2
benzamide 2
hyposensitization 2
Ni-allergic 2
5(th) 2
Ni/week 2
flare-up 2
skin) 2
metal. 2
sulphate. 2
datum 2
[Nickel 2
Sistemic 2
urticaria-like 2
troubles, 2
rush, 2
changing, 2
manifestions 2
(contact 2
pompholyx, 2
dyshydrosis, 2
urticaria) 2
(p>0.05) 2
oxidant, 2
hitching, 2
troubles. 2
nickel-contact 2
nickel-related 2
seventy-eight 2
SNAS. 2
(Allergic 2
SCD) 2
(intestinal 2
reintroduced. 2
urticaria/angioedema 2
16-64 2
nickel-allergic 2
significantly) 2
(Ig)G4-related 2
(IgG4-RSD), 2
0.179 2
thyroiditis).A 2
inadvisable.In 2
FVHT 2
Immunol 2
DMARDs; 2
Mikulicz's 2
hypophysitis, 2
prostatitis, 2
pseudotumor. 2
(over-)expression 2
QLT0267. 2
QLT0267 2
ILK. 2
(ILK). 2
ROSA26R 2
(ILK(+/-); 2
(+/-)) 2
110: 2
960-967, 2
(ECM)/integrin 2
ILK:liver-/- 2
liver:body 2
times), 2
cell-ECM-adhesion 2
LoxP/Cre 2
ILK-floxed 2
ILK, 2
matrix-related 2
super-differentiated 2
edrophonium 2
model; 2
87, 2
Tc. 2
C6. 2
(m.e.p.cs) 2
m.e.p.cs 2
ionophoretic 2
(EC50ca. 2
Tc, 2
ionophoretically 2
neuronal), 2
combination). 2
d-tubocurarine). 2
pancuronium. 2
+- 2
pancuronium). 2
equieffective. 2
alphabeta1epsilondelta 2
Methamidophos 2
lasting, 2
perijunctional 2
cats, 2
(+)-tubocurarine 2
endplate. 2
(k+D 2
s-1) 2
(ACh). 2
(zaleplon-CR, 2
lorediplon, 2
EVT-201), 2
(filorexant, 2
MIN-202), 2
histamine-H1 2
(LY2624803), 2
(ITI-007), 2
melatonin/serotonin5-HT1A 2
(piromelatine) 2
(indication 2
GABAAR 2
(ramelteon, 2
tasimelteon) 2
dim. 2
sighted 2
tasimelteon, 2
readjustment. 2
TIK-301, 2
MT1/MT2 2
non-24 2
Vanda 2
phase-shift 2
eszopiclone 2
Ramelteon 2
chrono-hypnotic 2
Randomly 2
elastomeric 2
circles, 2
α-actinin 2
neurochondrin 2
CSS-Palm 2
DHHC3/7 2
(z1/11) 2
arteriole 2
zyxin-silenced 2
(vinculin, 2
EGF-responsive 2
paxillin-positive 2
receptor-based 2
(TBCs) 2
adluminal 2
N-WASp, 2
Arp2/3, 2
anti-zyxin 2
(B71) 2
B71 2
ectoplasmic 2
specializations. 2
Nanotopography 2
grating 2
force-dependent, 2
zyxin-positive 2
topography, 2
forces; 2
actin-myosin 2
zyxin-deficient 2
zyxin/alpha-actinin 2
(vasodilator-stimulated 2
NAD+-dependent 2
leptomycin 2
matrix) 2
Synemin 2
alpha-synemin 2
beta-synemin 2
elmo1-dependent 2
intersomitic 2
parachordal 2
tg(fli1:EGFP) 2
ERMs 2
RhoG, 2
Dock180-ELMO 2
RhoG-ELMO-radixin 2
migrations. 2
CED-12/ELMO 2
amoebas 2
Legionella-containing 2
(LCV) 2
counterproductive 2
(hMDMs), 2
Dot/Icm 2
surplus 2
topologies, 2
diseases." 2
Differently 2
(Lys, 2
polyubiquitins 2
(N27) 2
methyl-DNA 2
DNMT3B-mediated 2
scrapings 2
MethyLight, 2
(97.9%) 2
RAR-β 2
(42.6%). 2
(P=0.035 2
P=0.046, 2
(RAR-β, 2
CDH1, 2
0.911, 2
TGCTs 2
(DNMT). 2
(DNMT1, 2
DNMT3B), 2
DNMT3A(mutant) 2
DNMT3A(wild-type) 2
2.09; 2
HumanMethylation27 2
DNMT3A2, 2
Tip60, 2
metallothionein, 2
5-Azactydine 2
proliferator-induced 2
(w/w), 2
-283T>C, 2
87.3% 2
NPC, 2
(CIN), 2
(Stage 2
amino-terminus 2
(1-248) 2
DEI 2
(AL), 2
(RT-PCR); 2
(MSP-PCR). 2
56), 2
AS/MT. 2
TMK-1 2
NS/MT 2
/or 2
1-15 2
alpha-amanitin-sensitive 2
I- 2
promotors 2
A(111) 2
A(325). 2
(105)GGAGCGA(111) 2
(319)GGGGCGA(325). 2
YSPTSPS) 2
PMG 2
cleavage-extension 2
II-arrested 2
(sarcin/ricin) 2
tertiary-structural 2
Isostericity 2
disruptive, 2
tertiary-structure-function 2
(HSP90, 2
CDC37), 2
assay; 2
(GRP75, 2
TUFM). 2
acid-sensing 2
PDZ-mediated 2
polyubiquitination. 2
PSMA7, 2
XAPC7, 2
protein,which 2
Pael-R. 2
neurexin, 2
Tbr-1, 2
CINAP 2
Reelin 2
NR2b 2
[inoperable 2
surgery] 2
endarterectomy, 2
Head-to-head 2
inflammation). 2
riociguat, 2
(15-20 2
Network, 2
(NICU) 2
2,347 2
Gentamicin, 2
audit, 2
Vancomycin, 2
ototoxicity. 2
(actual 2
dosings. 2
(SBT), 2
(MIC). 2
macro-broth 2
(59.1%) 2
mg/mL), 2
(McNemar 2
0.7905). 2
(U=51.5; 2
p=0.1947). 2
77.0; 2
p=0.1710). 2
(1/8), 2
</=40 2
culture-proven 2
Vancomycin-associated 2
gm. 2
interlobe 2
genome-engineering 2
(Cas9) 2
protospacer-adjacent 2
motif-proximal 2
(PAMPNs). 2
varietal 2
(CRISPR)/Cas9/single 2
orange, 2
Xcc-facilitated 2
CsPDS 2
(CRISPR)/Cas9 2
FKB12 2
Cas9/sgRNA-mediated 2
(Cas9n) 2
zygotes. 2
repeats), 2
CRISPR/CAS9-based 2
CRISPR/CAS9, 2
GT1 2
crRNAs) 2
(BCR), 2
PI3Kδ 2
(idelalisib). 2
(MCL) 2
(MIPI) 2
Idelalisib 2
[Chemotherapy-free 2
leukemia?]. 2
molecule: 2
obinutuzumab, 2
BH3-mimetic 2
immunopharmaceutical 2
(SMIP) 2
TRU-016), 2
dinaciclib), 2
chemo-reduced 2
membrane-specific 2
(LCP1), 2
lymphocyte-specific 2
solidifying 2
clinicaltrials.gov; 2
OSU-0025 2
OSU-0156. 2
neurotubular 2
(NTDs), 2
meningomyelocele, 2
aperta. 2
nutraceutics 2
varying. 2
GSH. 2
NAC. 2
(UI): 2
4.0-21.2); 2
3.3-9.5); 2
1.3-7.8); 2
1.1-4.5) 2
0-15) 2
pharmacoepidemiologic 2
<2.5 2
MCMs 2
(5.6%, 2
(6.1%, 2
Cesarean 2
interferon-gamma. 2
exencephaly 2
GM-CSF. 2
IFN-gamma+VA, 2
GM-CSF+VA 2
Teratogenic 2
methylphenobarbital, 2
Folic 2
Periconceptional 2
prevention). 2
3,625 2
(IPIMC). 2
(still 2
Diaphragmatic 2
Bifida 2
0.0364) 2
producible 2
F1-V 2
Yersinia, 2
resolution) 2
phosphate-binding 2
(RyR2s) 2
[Ca²⁺]-transients, 2
(sparks/waves) 2
µmol·L⁻¹). 2
-/calmodulin-dependent 2
(RyR2-Ser(2814) 2
phosphorylation). 2
(Ca²⁺ 2
(SparkF) 2
frequency), 2
RyR-Ser(2814) 2
SparkF 2
Ser(2814) 2
S107. 2
(FKBP12) 2
(2,3,4,5,-tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine), 2
RyR1-FKBP12 2
[(3)H]S107 2
∼2. 2
myoplasmic 2
4-chloro-3-methyl 2
(4-CmC) 2
4-[-3{1-(4-benzyl) 2
piperidinyl}propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine 2
(K201, 2
JTV519) 2
dioxole 2
embody 2
Deng, 2
Torsades 2
receptor-stabilizing 2
channel-stabilizing 2
methylcoumarin 2
derivate, 2
4-[3-(4-benzylpiperidin-1-yl) 2
propionyl]-7-methoxy-2,3,4,5-tetrahydro-1, 2
4-benzothiazepine 2
monohydrochloride 2
(MRP1) 2
KB/MRP 2
(VP16), 2
ADM 2
Photoaffinity 2
[285800]. 2
(JT) 2
chelerythrine 2
5-hydroxydecanoic 2
overloading-induced 2
1,5-benzothiazepine 2
histidine-tryptophan-ketoglutarat 2
(HTK) 2
cardioplegia. 2
Anti-ischemic 2
GF109203X, 2
alpha(1)-, 2
A(1)-, 2
B(2)-receptor 2
isozyme-specific 2
(EMT)-associated 2
NSCLCs, 2
polyoma 2
(SSH) 2
oncongene-expressing 2
miniRNA 2
(qRT-PCR). 2
(PCA3) 2
43.5% 2
(lncRNA), 2
hepcarcin 2
procarcinogen-induced 2
(HCCs) 2
HCCs, 2
non-hepatic 2
(4/4) 2
stage-I 2
stage-II 2
tumours' 2
(eIF4A1, 2
Hepcarcin; 2
Long, 2
(NCTs) 2
(>400 2
NCTs. 2
gingivalis-infected 2
Oxantel, 2
(APJ) 2
BCM. 2
Browning 2
Pericytes 2
APJ, 2
fibrovascular 2
active-caspase 2
APJ. 2
Wistar-Albino 2
crystalloid 2
A12, 2
A12 2
Phe(13) 2
obese. 2
ghrelin) 2
last, 2
chol- 2
meth-fed 2
reoccur 2
Endothelin-1 2
VOEs 2
92.5% 2
PABP1. 2
Spermiogenesis 2
Spermatid 2
Mass-spectral 2
>3-fold 2
(hnRNPA2/b1, 2
hnRNPA3, 2
hnRPDL, 2
hnRNPK, 2
hnRNPL, 2
hnRNPM, 2
PABPC1, 2
PCBP1, 2
PCBP3, 2
PTBP2, 2
PSIP1, 2
RGSL1, 2
RUVBL2, 2
SARNP2, 2
TDRD6, 2
TDRD7) 2
Retrogene-encoded 2
NFX1, 2
PABPC4). 2
NFX1-123 2
NFX1-123. 2
(HFKs) 2
C33A 2
(PPP1R3B, 2
SALL1, 2
Poly(A)-binding 2
relocalisation. 2
0.033 2
HDL-C. 2
(PABPN1), 2
(CPSF) 2
PABP4. 2
markers: 2
PABP5, 2
NUP214-ABL1 2
ABL-family 2
SH3-SH2-TK 2
(Src 2
3-Src 2
2-tyrosine 2
-bundling 2
phosphoregulation 2
actin-filament 2
tyro-sine 2
IL3 2
(Abl1, 2
Mertk, 2
Mst1r, 2
Tnk1) 2
TCR-dependent 2
(Abl1) 2
(Abl2), 2
(v-abl) 2
(JAnus 2
TKs 2
phase-I 2
Abl1 2
Abl) 2
Abl1-related 2
Abl2 2
Arg) 2
MuSK. 2
SH3-domain 2
(SH2-CD 2
linker). 2
c-Abl. 2
damage/repair 2
Proto-oncogene 2
(c-ABL) 2
(Apg-2), 2
QT(c) 2
electro-cardiographic 2
(LQT1), 2
7q35-36 2
3p21-24 2
4q25-26 2
(LQT4). 2
(S1-S6), 2
S5 2
co-associated 2
(syncopes 2
QT(c). 2
(LQT2, 2
LQT4) 2
S1-S6 2
Gly-216-Arg 2
KVLQT1. 2
(CHL). 2
(QT-d, 2
JT-d, 2
QTc-d, 2
JTc-d) 2
Iks 2
(D222N) 2
JLN 2
carboxyterminus 2
Imbalance 2
theories. 2
beta1-agonists 2
E2P 2
Ca2+-ATPase. 2
(CaMK) 2
hamster. 2
Ca-ATPase, 2
(Ser16, 2
KB-R7943. 2
N-(1-pyrenyl)maleimide 2
(PMal), 2
tetranitromethane. 2
co-reconstitution. 2
nitroTyr(6) 2
phosphoSer(16) 2
Arg(13) 2
coil-to-helix 2
ryanodine-sensitive 2
fluo 2
phosphorylation-induced 2
daltons) 2
(SDS-PAGE), 2
C2. 2
Ser(16)and 2
Ser(16)phosphorylation 2
(I(Ca)) 2
anti-phospholamban 2
2D12, 2
K(Ca) 2
PKA-phosphorylated 2
concentrations), 2
(CM-kinase-II) 2
Phospholamban, 2
proteolipid, 2
Ca2+/phospholipid-dependent 2
phosphorylatable 2
videoconferencing. 2
logs 2
video-teleconferencing 2
providers; 2
undertreatment 2
erode 2
e-health 2
dedicates 2
paragraphs 2
telehealth. 2
management; 2
project-a 2
Contributing 2
money 2
km. 2
(dollar 2
cost-saving. 2
Granules 2
unstressed, 2
Parallels 2
Nanos3 2
depots, 2
mRNA-tagging 2
Dcp2-knockdown 2
P-body-associated 2
ribonucleoprotein) 2
(stress 2
NGs 2
Pdc1 2
PB) 2
Ge-1, 2
(P-body) 2
core-decapping 2
LMKB. 2
interferons. 2
HNRNPA1 2
upregulations 2
1.2-fold 2
polysome-associated 2
Δscp160 2
DECAPPING 2
(P)-bodies 2
deposited, 2
NADH. 2
tumors? 2
development? 2
response? 2
NF-κB2 2
MMP2 2
Eca109 2
MAGE-A8 2
NF-κB2, 2
DAC) 2
(azacitidine, 2
Vidaza)--currently 2
profiling: 2
(5-aza-2'-deoxycytidine) 2
MDS; 2
Haemoglobin 2
duodenal/jejunal 2
(FUO). 2
coxsackie 2
A9, 2
B4, 2
B5 2
Parainfluenza 2
Adeno 2
67.4%, 2
(14.1%). 2
Cw1 2
(32.1%), 2
Cw3 2
(46.5%). 2
iPhone 2
Program). 2
18.83% 2
(SD=13.24; 2
range=0%-65%) 2
technology-enhanced 2
scanners 2
(46.7%). 2
motivation, 2
promotion: 2
fun 2
games? 2
iPhone/iPad 2
(HE), 2
Apps 2
Prevention's 2
(ECPOP) 2
goals) 2
gaming 2
61.4 2
games, 2
$1.05 2
1.66. 2
Dermatology-related 2
Apple, 2
Android, 2
Blackberry, 2
Nokia, 2
Popularity, 2
storage/sharing 2
[51.1%]). 2
[48.9%]) 2
$0.99 2
$139.99 2
$2.99). 2
[51.1%]), 2
[41.0%]), 2
[7.9%]). 2
calculators, 2
apps: 2
myFitnessCompanion®. 2
Smartphones 2
(PHR) 2
HealthVault 2
technology: 2
Blackberries, 2
iPhones, 2
palm-top 2
health-behavior 2
"needs 2
assessment" 2
iPhone(©) 2
reminding 2
(TINF2). 2
unification 2
maintenance-"the 2
telomereopathies." 2
atypical) 2
(TINF2), 2
Zinsser-Cole-Engman 2
dominant/recessive 2
Androgens, 2
(dyskerin, 2
NHP2) 2
(TIN2) 2
NOLA1, 2
c.390A 2
p.H28L 2
(TERC, 2
TERT) 2
1226C-->T 2
(P409L) 2
1058C-->T 2
(A353 2
DXS1073. 2
Xq3274 2
DXS1108. 2
2.6-kb 2
postconception 2
KLF6. 2
(EWSR1) 2
(PNET/ES) 2
(CD99). 2
PNET/ES. 2
(VIDE) 2
EUROpean 2
(EURO-E.W.I.N.G. 2
PNET/ES 2
MT99/2. 2
MT99/1, 2
(hCD99cytoI) 2
B-lymphoblastoid 2
XGR(low) 2
XGR(high), 2
(CD99-L, 2
CD99-H) 2
Xg(a-)/ 2
(anti-Xga) 2
12E7 2
(anti-CD99) 2
159+/-13 2
960+/-50 2
molecules/cell, 2
Xg(a-) 2
747+/-28 2
200+/-22 2
copies/cell, 2
Xg(a-)/CD99-H 2
XGR(high) 2
(VAP21) 2
(#11875 2
28276) 2
VAP21) 2
antigen; 2
cDNA-transformed 2
immunolocalised 2
(MIC2) 2
LFA-1/ICAM-1-mediated 2
(NgM). 2
NgM: 2
Leu-7, 2
neurofilament. 2
EWS/FLI1chimeric 2
NgM, 2
fortifies 2
p30/32MIC2, 2
transbilayer 2
cytofluorimetry 2
merocyanine 2
anti-E2-induced 2
well-demarcated, 2
WT1, 2
ptimal 2
esolution 2
ultimapping 2
mbiguity 2
A-Seq 2
Reads), 2
read. 2
IdEntification) 2
RNA-seq. 2
Montebello, 2
TIGAR: 2
http://github.com/nariai/tigar 2
nariai@megabank.tohoku.ac.jp 2
trimmed 2
min-cost 2
flows. 2
IsoLasso. 2
Traph 2
LASSO, 2
(MULTo), 2
(Grape 2
prealigned 2
annotation-guided 2
Unannotated 2
(DRUT), 2
DiffSplice 2
Omicsoft 2
exon-exon 2
easily. 2
tradeoffs 2
seqbias 2
base-specific 2
between-base 2
(POME) 2
SpliceTrap, 2
RSEM, 2
assembler, 2
(IsoformEx) 2
Rnnotator, 2
(Normalization 2
Mappable 2
Area), 2
gene-wise 2
(≥0.2 2
lead. 2
concealed, 2
Cardiologia. 2
(PKP2) 2
CACNa1c, 2
GPD1L, 2
MOG1. 2
HL-1-derived 2
(PKP2-KD). 2
PKP2. 2
PKP2-deficient 2
(SDB) 2
n=9), 2
D1430N 2
Brugada-like 2
tsA201 2
(incubation 2
none" 2
ajmaline 2
(ICD). 2
(Vl-V3) 2
disappear). 2
Prolyl 2
oligopeptidase 2
proline-containing 2
(ATG), 2
ATG5, 2
ethnic-matched 2
p62/SQSTM1-dependent 2
autophagy-lysosome, 2
encircled 2
phospho-α-synuclein-positive 2
Atg-5 2
inclusion-containing 2
(α-Syn), 2
(alpha-synuclein 2
126, 2
dementias 2
(APP770 2
APP751) 2
alpha-synuclein(1-120) 2
Neurosciences 2
nitration, 2
truncation. 2
nitrated, 2
propensities. 2
aforesaid 2
Heinrich 2
PK-resistant 2
neurites; 2
fibrilar 2
Bioenergetic 2
T4-induced 2
MnSOD) 2
mtTFA, 2
ErbAalpha 2
PGC-1alpha. 2
Nuclear-mitochondrial 2
myosin) 2
T3-regulation 2
(ARCM) 2
fast- 2
(Tfam), 2
T(3)- 2
(Tim) 2
Tom34, 2
Tim17. 2
Tom34 2
Tim17 2
114% 2
(MDH) 2
mtHsp70, 2
mtHsp70. 2
Tim44. 2
mediates, 2
TFB2M, 2
Twinkle, 2
NRF-1 2
determinative 2
regulator: 2
bigenomic 2
in-spite 2
Tfam. 2
(mTR) 2
(DR2) 2
(UCP2) 2
suckling 2
mitochondrial-encoded 2
respiration; 2
L-thyroxine/200 2
L-thyroxine/100 2
permissive, 2
cytochrome-c1 2
ANT2 2
biogenetic 2
inner-membrane 2
oxidation-reduction 2
seven-pass 2
non-pigmentary 2
Caucasians: 2
(1.53-4.89) 2
D84E. 2
28%. 2
(RHC: 2
R160W; 2
NRHC: 2
T314T) 2
Islands, 2
EDC4, 2
DCP1-DCP2 2
metazoan. 2
handed 2
DCP1, 2
(SLiMs). 2
EDC4. 2
asparagine-arginine 2
NR-loop) 2
EVH1 2
Seipin. 2
[PD-1] 2
0.42; 2
nivolumab-plus-ipilimumab 2
067 2
receptor-1, 2
19.6 2
5.98 2
5.4) 2
025 2
axis) 2
SB225002 2
CXCR1/2 2
(CXCR1 2
CXCR2) 2
IL-8-overexpressing 2
NF-κB/mitogen-activated 2
(MAPK)/AKT 2
TRAIL- 2
(SCH-527123, 2
SCH-479833) 2
(AZ10397767) 2
CXCL 2
FAE). 2
ag-gt 2
23-bp 2
GCAG 2
60-66% 2
NPAP1/C15orf2 2
C15orf2, 2
1156 2
InterProScan 2
POM121. 2
'Nuclear 2
C15orf2. 2
developmentally. 2
ISDN. 2
psnoRNAs. 2
psnoRNAs 2
low-abundance, 2
fibrillarin-associated 2
SNORD115-derived 2
PWS-encoded 2
MBII-85 2
(SNORD116) 2
dsRNAs. 2
15q11q13, 2
SnoRNA 2
(DRP1), 2
DRP1(S616) 2
fission-defective 2
Drp1-deficient 2
TAT-Drp1-SpS 2
Ammonis 2
unilamellar 2
DRP1-expressing 2
(ΔΨm) 2
CDK5-dependent 2
(CDK5) 2
(HUVECs) 2
Mfn 2
FIP1/RCP. 2
Src-transformed 2
PO2-dependent 2
endothelial-derived 2
constrictors, 2
kinase- 2
616. 2
Mitochondrial-targeted 2
PO2-induced 2
siDRP1 2
obligatory, 2
flexneri 2
Mdivi-1. 2
siRNA-depletion 2
Sereny 2
(Drp1). 2
(IGF-I) 2
3XTg.AD 2
nonconsensus 2
Mfn1, 2
spirals, 2
FANCA-deficient 2
FA-D1/BRCA2 2
IVS7 2
SB1690CB 2
XRCC3. 2
BRCA2-FANCD2 2
BRCA2-FANCD2. 2
FANCD1/BRCA2-FANCD2-FANCG-XRCC3 2
(D1-D2-G-X3). 2
phospho-Ser7-FANCG, 2
D1-D2-G-X3 2
RAD51-paralog 2
null-allele 2
after-depolarizations, 2
relative. 2
c.939 2
5G>C 2
c.381C>T 2
hyperglycosylation 2
(CPVT-2). 2
defibrillations, 2
p.Y55C 2
(c.164A>G) 2
p.P308L 2
F189L 2
tachycardia]. 2
F189L, 2
ion-mediated 2
Catecholamines, 2
insidious, 2
"leakiness" 2
post-tetanic 2
IPSCs 2
PTP. 2
Ca(2+)-channels, 2
52.9+/-3%. 2
26.6+/-5%, 2
"agonist", 2
18.7%+/-7%, 2
bouton, 2
25.5+/-6%, 2
45.2%+/-16%, 2
L-channels 2
I(CaT) 2
kurtoxin, 2
compacta. 2
LCa(v) 2
1.2. 2
DHP 2
(6-OHDA) 2
MC65 2
substantiates 2
HB101pDC1 2
PACs 2
macroscale 2
regrown 2
fimbriated 2
nonfimbriated 2
me 2
UTI. 2
appraised. 2
bacteriuria. 2
reinfection. 2
proanthocyanidins, 2
fimbriae, 2
mutans. 2
nondialyzed 2
(NDM) 2
(FTF), 2
FTF 2
NDM, 2
NDM. 2
anti-adhesive 2
G2, 2
(6.8%) 2
WiiPD 2
Remote. 2
mini-games, 2
engine, 2
Home: 2
non-IT 2
mentored 2
self-monitoring, 2
hospitalisations 2
self-manage 2
[Telemedicine 2
hypersensitivity]. 2
product's 2
allergists 2
Luxembourgian 2
MENSSANA 2
allergist's 2
allergenic 2
readable 2
"virtual 2
community" 2
(www.wikifood.eu) 2
13.000 2
wikifood.eu. 2
(FAST): 2
warmth, 2
tingling. 2
<250 2
equivalents, 2
3-6/aspirin 2
[ASA]), 2
NER/ASA 2
placebo/ASA 2
(OTE) 2
>0.7 2
OTE 2
patient-rated 2
OTE, 2
OTE. 2
0.29-0.38 2
0.66-0.86 2
niacin-induced 2
Haemoassist--a 2
Haemoassist, 2
Haemoassist 2
self-documentation 2
diabetics: 2
capitalize 2
unsupervised, 2
five-item 2
Heartburn 2
Self-medication 2
home-monitored 2
advertisements 2
regularly, 2
HRR) 2
(146 2
(18)F-FDG-PET/CT 2
IL-6- 2
(1·68-3·95 2
NCT01217957. 2
3·95 2
2·23 2
4·0 2
8%); 2
45-70) 2
Atg1 2
ULK1, 2
FIP200 2
GABARAPL2/GATE-16), 2
orthologue. 2
pull-down, 2
Starch-binding 2
Glycogen, 2
autophagy-like 2
starch-binding 2
(200)HEEWEMV(206) 2
cargo-specifying 2
Nix. 2
AIM, 2
W203 2
V206, 2
"glycophagy". 2
free! 2
anti-GABARAP 2
GABARAPL1: 2
CHEM-CENT 2
PTG-NTER 2
PTG-FL 2
(Atg8 2
MAP1LC3 2
ATG5. 2
ATG8/LC3 2
ATG8/MAP1-LC3/GABARAP 2
GFP-NBR1 2
(LC3 2
GATE-16/GABARAP) 2
GABARAP-L1 2
delipidation 2
intra-Golgi 2
SNAREs. 2
pseudo-continuous 2
beta-sheets. 2
GATE-16. 2
(hAtg8) 2
E1-like 2
(ZIKV; 2
forests. 2
Senegal. 2
Mosquitoes 2
July. 2
furcifer 2
africanus 2
villages. 2
(APC/C) 2
securin 2
AgCdc20p 2
AgPds1p 2
APC/C. 2
mitoses. 2
Cyclins 2
asynchronously 2
AgClb5/6p 2
cohabitation 2
branchpoints, 2
AgHsl1p 2
Nim1-related 2
AgMih1p 2
Cdc25 2
Swe1p 2
tip. 2
(SPB) 2
plus-end 2
SPBs, 2
(nMT) 2
nMTs 2
nMT 2
FEAR 2
septation, 2
dynein-driven 2
(directly 2
indirectly) 2
dynein. 2
(cMTs) 2
AgCnm67, 2
emanated 2
stream. 2
Bik1, 2
Kip2, 2
Kip3, 2
(cMTs), 2
bypassing, 2
(+)end 2
Bik1 2
Kip2 2
Kip3 2
Polymerization 2
shrink, 2
+ends 2
tips. 2
mobilities. 2
K-ras. 2
65%-100% 2
59%) 2
77.6% 2
duct-derived 2
E6/E7/st 2
mutant-enriched 2
K-ras; 2
fibrosi 2
(UMPIRE): 2
shortfall 2
process-related 2
(IMPACT): 2
Māori 2
non-indigenous 2
('polypill') 2
Māori. 2
polypill) 2
12.5mg 2
guidelines-recommended 2
dispensing, 2
polypill), 2
2053 2
45-80 2
(n=412) 2
hydrochlorthiazide 2
NCT00443794. 2
6.1-8.1) 2
(4.7-6.4), 2
(2.2/1.3 2
4.7/3.6 2
6.3/4.5 2
drugs). 2
0.62-0.78), 2
0.72-0.93; 2
p=0.04); 2
(283.1 2
229.1-337.0) 2
(350.0 2
294.6-404.0), 2
(348.8 2
277.6-419.9) 2
intolerability 2
pill. 2
synapsed 2
(BX-C) 2
E.B. 2
Lewis, 2
unrearranged 2
trans-splicing. 2
Zeste, 2
self-aggregation. 2
(transvection 2
iab-5,6,7 2
BX-C), 2
transvection-like 2
Pairing-dependent 2
"trans-vection 2
zeste-independent. 2
polymerase-II-transcribed 2
promoter/gene. 2
'transvection', 2
transvection, 2
melanogaster]. 2
(synapsis-dependent 2
69.5% 2
53.4% 2
0.00013). 2
probiotic-containing 2
yoghurt 2
(79.5% 2
71.8%, 2
(83.3%). 2
(70.7% 2
prescribers) 2
pouchitis 2
(67.5% 2
prescribers). 2
probiotics. 2
strain-specific, 2
gastroenterology: 2
probiotic-based 2
marketing. 2
16-question 2
http://links.lww.com/JCG/A14) 2
yogurt-based 2
infantis 2
35624 2
(Align), 2
VSL#3. 2
expert-panel-generated 2
breast-feeding 2
non-starch 2
polysaccharides. 2
Fort 2
(Italy). 2
not-uncommon 2
undergird 2
arch, 2
[Marfan 2
Bernhard 2
1896; 2
meso- 2
ectodermed 2
"arachnodactyly". 2
arteria 2
sinotubular 2
laminectomy. 2
restructurings 2
74.8 2
Pathohistological 2
(ED), 2
postpone 2
96.2% 2
74.6% 2
bifurcation. 2
(104 2
(AAD) 2
(25.0% 2
5.1%, 2
-0.42, 2
happening 2
(HPLC 2
LC-MS) 2
immuno-chromatographic 2
(TTX-IC) 2
(387 2
lunaris(LL), 2
(LS)) 2
2011-February 2
94.0% 2
Larval 2
(TTX), 2
Oceans. 2
echinoderms, 2
coast, 2
Nagasaki 2
Prefecture, 2
blowfish 2
MU/g. 2
Thailand's 2
Siam 2
Siam, 2
reticularis; 2
(5.56 2
0.93%, 2
spadiceus. 2
(MIDI) 2
terrigena. 2
(MALDI-TOF). 2
reiterate 2
Collected 2
garter 2
TTX. 2
puffer(s)) 2
vermicularis 2
wheeleri 2
rivulata 2
rubripes 2
pardalis. 2
phytoplankton 2
Toxins 2
saxitoxins, 2
palytoxin, 2
nodularin, 2
domoic 2
diatoms 2
Fluidic 2
tainted 2
(ZNF9 2
21.3. 2
myotonia. 2
DM1, 2
[Intergenerational 2
Rica]. 2
unstranslated 2
Dystrophic 2
(HBS1L-MYB) 2
HBS1L 2
myeloblastosis 2
Mats/Mob1 2
Salvador, 2
Ser127 2
Reexpression 2
LATS 2
Warts 2
WTIP 2
Sav/Wts/Hpo 2
(YAP/TAZ 2
(1948 2
SinoMed, 2
VIP 2
(5/19) 2
(12/20) 2
DIDs. 2
sub-arachnoid 2
study- 2
(MBI) 2
cm/sec) 2
0.31). 2
hemorrhage? 2
(pooled) 2
1.48]), 2
1.13]), 2
1.24]), 2
1.10]). 2
vasospasm; 2
0.99), 2
6.25, 2
1.8+/-1.3 2
(P=0.041). 2
(P=0.063) 2
(hypertensive, 2
hypervolemic, 2
hemodilution; 2
P=0.045) 2
(P=0.001); 2
ictus). 2
Autoregulation 2
(THRT) 2
DINDs, 2
(Days 2
0-5, 2
(THRRs) 2
THRRs. 2
THRT 2
myositis. 2
rebleed, 2
hydrocephalus) 2
(angiography 2
V(MCA) 2
m/sec). 2
laboratory-defined 2
S100beta 2
(103+/-41 2
149+/-47; 2
DID. 2
Lawton 2
Self-Maintenance 2
microtubule, 2
microtubule-cytosol 2
modulus, 2
wave-number 2
tweezers. 2
trapping, 2
pN·nm/rad(2)·mW 2
microtubules: 2
'GDP-tubulin' 2
'cap'. 2
shrinkage. 2
Microtubules: 2
alpha-tubulins 2
cap." 2
Protofilaments 2
2-20 2
Problem 2
(molindone, 2
information-Treatment 2
Adolescents; 2
http://www.clinicaltrials.gov, 2
NCT00053703. 2
(PANSS) 2
nonpsychotic 2
(1974-1999). 2
(August 2
calculating, 2
(NNT 2
NNH). 2
n=150, 2
4RCTs 2
n=146, 2
6.99, 2
olanzapine; 2
zotepin, 2
thioridazine; 2
sertindole; 2
ziprazidone, 2
amisulpiride, 2
BWG. 2
orlistat, 2
explain. 2
"at 2
'Atypical' 2
antipsychotic), 2
'typical' 2
(1974-1999) 2
psychoses 2
ordered, 2
re-inspected 2
thioridazine. 2
exception). 2
pounds. 2
weight-reducing 2
molindone; 2
p.R410W 2
12S 2
transcarboxylase 2
shermanii 2
interfaces, 2
pccB, 2
(alpha-subunit) 2
pccC, 2
Pro228Leu 2
Ile408 2
407, 2
acidemias 2
ss) 2
MMAuria 2
cblC 2
D- 2
hyperammonemia 2
injected, 2
18bp 2
c.653A>G 2
IVS10-11del6 2
3'-splice 2
(IVS18-6C 2
1746G 2
C398R, 2
G197E 2
IVS18+1G 2
PCCA; 2
A153P 2
IVS9+1G 2
PCCB). 2
923-924insT, 2
IVS18-6C 2
R399Q 2
(17/30). 2
R410W, 2
A153P, 2
26.7, 2
beta-PCC, 2
PCCB-deficient 2
L17M 2
(K218R, 2
R410W 2
R67S, 2
Croatia, 2
carboxybiotin 2
biotin-binding 2
PCCA-deficient 2
800-kDa 2
alpha(6 2
)beta(6) 2
3-7, 2
(R44P, 2
I408del, 2
M442T) 2
(R165W, 2
D178H, 2
P228L, 2
R410W) 2
(R67S, 2
R165W, 2
W531X, 2
N536D) 2
beta-beta 2
1-kb 2
(pccb), 2
Propionyl 2
bps 2
DdeI 2
(R499X, 2
mutation(s). 2
Greenlandic 2
790-791insG. 2
M442T 2
L17M+790-791insG 2
E168K 2
coli-based 2
patients-21 2
57-183 2
gt/ag 2
56/58 2
insertion/deletion, 2
odd 2
acidemia--propionic 2
(PCC: 2
3.). 2
PCC) 2
(Caucasians 2
Japanese): 2
(0.32) 2
6.4.1.3). 2
(subgroups 2
BC), 2
acylcarnitines 2
carnitine, 2
L417W/Q293E 2
Next- 2
CSF3R, 2
ZC3H18, 2
BM. 2
AML-associated 2
(RUNX1 2
(SUZ12 2
EP300). 2
(MDS/AML). 2
(2.3%/year 2
(MDS/AML) 2
cyclic, 2
0.018 2
oralis 2
(Voa/Vop) 2
GPi-DBS 2
(GPi-DBS) 2
drug-refractory 2
dystonias. 2
Hardware 2
twisting 2
Raven 2
Matrices 2
Scale-R, 2
Grober 2
Buschke, 2
(WCST), 2
cognitively. 2
WCST. 2
EMGs 2
bursts. 2
8-16 2
generalized, 2
BrdU. 2
SL1 2
(CTCTCTCTCTCTCTCTCCCTC) 2
(ABE). 2
NF-kappaB-independent 2
NF-kappaB1, 2
IkappaBbeta. 2
IkappaBgamma, 2
IkappaB.NF-kappaB 2
nonspecific) 2
IkappaBbeta, 2
IkappaBalpha.NF-kappaB 2
(ARD) 2
TD-IkappaBalpha 2
postinduction 2
(ARDs), 2
ARDs 2
ARD-containing 2
53BP2 2
GABPbeta, 2
HTLV-I, 2
B1/p1O5 2
1,2). 2
HC9 2
p1O5 2
I-kappa 2
limbic, 2
hypothalamic, 2
Tax-dependent 2
(RelA). 2
p100; 2
p100-mediated 2
hSDH5) 2
paraganglioma: 2
smiling. 2
Paragangliomas 2
(succinate 2
SDH) 2
At5g51040, 2
stomatal 2
malonate, 2
sdhaf2, 2
micro-respirometry 2
lens), 2
glaucoma; 2
miotics 2
Geleophysic 2
microspherophakic 2
(reprolysin 2
(TSR)]. 2
ADAMTS1 2
AMTSL 2
LTBP1 2
(Latent 2
build, 2
0.010), 2
cM). 2
Presenile 2
277600). 2
microfibril-associated 2
brachymorphia, 2
spherophakia. 2
NovoTTF-100A™, 2
resistivity 2
(C11) 2
(B16F10) 2
VX-2 2
two-directional 2
kHz. 2
intra-tumoral 2
(U-118) 2
(DTIC) 2
1316). 2
39+ 2
derived, 2
Ccl4 2
(Nts) 2
(angiocrine 2
unlocking 2
OFT-ECs 2
(ESC)-derived 2
Isl1-ECs 2
ESC-derived 2
engraftment, 2
(Timp-1) 2
(THBS3) 2
stimulation) 2
Slit2, 2
trophogens 2
(LSECs) 2
hepatovascular 2
Wnt2. 2
co-cultures, 2
Id1(-/-) 2
Wnt2 2
proteins/peptides 2
accumulates, 2
time-averaged 2
enticing 2
2.3; 2
transplantation) 2
.10 2
(carbamoylation) 2
carbamyl 2
urea-induced 2
degree: 2
isocyanic 2
homocitrulline/mol 2
N-termini, 2
chaotropic 2
carbamylates 2
epsilon-carbamyllysine 2
(homocitrulline), 2
myeloperoxidase-catalyzed 2
replication-initiation 2
helicase-go 2
san 2
alpha)-primase 2
Anastrozole-associated 2
joint-pain 2
1-38). 2
(ER(+), 2
PGR(+)) 2
(PM-BC) 2
end-point; 2
PGR(+), 2
Cerb-B2 2
(13.2%). 2
(7.9%). 2
(12.5%). 2
71.9%. 2
63+) 2
63+). 2
"switched 2
setting" 2
(Arimidex-Nolvadex 2
[ABCSG 2
Intergroup 2
Exemestane 2
Study), 2
MA.17, 2
ABCSG 2
AIs. 2
Outstanding 2
fulvestrant. 2
GnRh 2
59). 2
24.3%, 2
58.8%. 2
Time-to-progression 2
Anastrozole, 2
eighty-one 2
vasomotor, 2
atrophic, 2
(p=0.0039 2
p=0.001, 2
(p< 2
=0.0001). 2
46-86) 2
>270 2
>360 2
progesterone-positive 2
progesterone-negative 2
tumoricidal 2
36.9 2
(86.9% 2
84.5%, 2
0.76-0.99; 2
0.70-0.96; 2
0.71-0.96; 2
0.65-0.93; 2
0.38-1.02; 2
0.32-0.98; 2
Letrozole 2
417 2
0-10 2
(ERMS) 2
SDF-1 2
RasGRF1-kd 2
GTP- 2
cardio-facio-cutaneous 2
(CFC) 2
MEK1, 2
papilloma, 2
three-fourths 2
gastro-esophageal 2
Osteofibrous 2
RPA. 2
transactions. 2
"replisome 2
unword 2
contexts) 2
1998). 2
Ussing 2
CBAVD. 2
March, 2
F508del/5T 2
F508del/R117H 2
R117H. 2
Non-Caucasian 2
9.25 2
(I(2)= 2
(Egger's 2
0.160). 2
(DeltaF508) 2
(18.1%), 2
c.2183_2184delAAinsG 2
(2183AA>G) 2
(6.5%), 2
(5.8%), 2
c.2789+5G>A 2
p.G542X 2
p.R334W 2
c.3130delA 2
c.406-8T>C, 2
c.2576delA, 2
c.2752-1_2756delGGTGGCinsTTG, 2
c.3850-24G>A, 2
c.1342-?_1524+?del, 2
UK-specific 2
deltaF508, 2
0.2-0.4). 2
trypsinogen 2
(F508) 2
frame-shift, 2
ingest 2
phagosomes, 2
V., 2
cepacia) 2
cargos 2
beclin1 2
(BECN1) 2
CFTR, 2
nine), 2
five), 2
Israelis 2
three) 2
Aip1, 2
Ede1 2
arms). 2
SRP9/14. 2
RNP, 2
sRight 2
'JUNK' 2
knowledge: 2
TFBS, 2
splice-site-mediated 2
Retro-transposition 2
exonized 2
dsRNA-mediated 2
sponge'. 2
detectable? 2
50-100-fold 2
U2.13 2
abuts 2
7SL-like 2
These, 2
BC200 2
transcription; 2
tetramers. 2
[35S]methionine 2
RNA/cDNA 2
POR1 2
chlorophyllide, 2
factor1 2
oxygenic 2
1-2μm 2
mica 2
1μm. 2
Illumination 2
(Pchlide), 2
AFM. 2
(pro)thylakoid 2
blue-shift 2
25min. 2
blue-shift. 2
HgCl2 2
poikilochlorophyllous 2
Xerophyta 2
humilis 2
desiccoplasts 2
77K 2
desiccation 2
rehydration, 2
photoactive, 2
655nm 2
dark, 2
meristematic 2
etioplasts, 2
lifetimes. 2
Angiosperms, 2
Etioplasts 2
Pchlide:POR:NADPH 2
Chlide 2
NADPH-POR-protochlorophyllide 2
NYB. 2
oxidoreductases 2
(light-harvesting 2
oxidoreductase:protochlorophyllide) 2
porC 2
development-during 2
PORA-overexpressing 2
Chloroplast 2
thylakoids 2
non-mevalonate 2
(MEP) 2
isoprenoids 2
plastoglobuli 2
carotenoids 2
PLBs. 2
Starke 2
Weibull), 2
Ryberg 2
Sundqvist 2
(1982, 2
Plant., 2
125-132). 2
36000 2
(POR), 2
chlorophyllide. 2
proto-plant 2
symbiosis. 2
Gloeobacter 2
PCC7421 2
Photoactive 2
protochlorophyllide. 2
epicotyls 2
agranal 2
spectrally 2
carotenoid 2
cdPLBs 2
reorientation 2
looser 2
coalescence 2
Lamellae 2
sativum 2
rye. 2
MGDG/DGDG 2
[PERSONALIZED 2
ASTHMA: 2
ISSUE 2
ANTI-INTERLEUKIN-5 2
ANTIBODIES]. 2
50C) 2
Pericarp 2
gyspsy-like 2
Inversely, 2
locus-specific, 2
near-isogenic 2
zmet2-m1. 2
B73, 2
zmet2-m1, 2
Mo17, 2
Methylation-sensitive 2
Mo17. 2
inbreds, 2
methylation). 2
(SUP) 2
SUP 2
drm 2
SUP, 2
DRMs 2
Chromodomains 2
No-0, 2
Evelknievel, 2
Ler 2
RLD 2
Evelknievel 2
No-0 2
nonessential. 2
Cardaminopsis 2
arenosa, 2
loosened 2
self-fertilizing 2
(MNCV) 2
m/s). 2
DI-CMT, 2
DNM2, 2
YARS, 2
GNB4, 2
DI-CMT. 2
KARS, 2
PLEKHG5 2
RI-CMT. 2
(CMT1; 2
118200) 2
dominant-inherited 2
#118220) 2
17p11.2, 2
(PMP22; 2
1F 2
demyelination; 2
NF. 2
EGR2) 2
CMTI 2
(NEFL), 2
'intermediate' 2
CMT: 2
DI-CMTA, 2
DI-CMTC. 2
beta3/beta4 2
Lys558, 2
(c.68C>G) 2
co-segregating 2
T23R 2
LITAF/SIMPLE 2
1C. 2
16p13.1-p12.3. 2
nerve; 2
nerve-crush 2
nerve-transection 2
SIMPLE, 2
161-amino 2
T115N 2
W116G 2
most-common 2
CMT2; 2
neurofilament-light 2
(C64T) 2
type-1A 2
17p11.2p12 2
8p21. 2
(Spain); 2
Asp551_Glu553del; 2
Lys550fs 2
America); 2
Lys558del 2
(Belgium); 2
(Belgium). 2
Charcot-Marie-Tooth-related 2
(Lys558), 2
neutropaenia. 2
(41-46 2
thickenings--findings 2
hetero-bZIP 2
PRDIV 2
IFN-alpha4 2
MCMV-mediated 2
(IRF) 2
(NF)-kappaB, 2
(ATF)-2 2
PRDIV-PRDIII 2
subsites. 2
(IRF-3). 2
IRF3, 2
ATF2/c-JUN 2
c-JUN 2
IRF-3, 2
coactivator-mediated 2
CBP-RNA 2
stereospecific 2
template-committed 2
TFIID-TFIIA-USA 2
enhanceosomes 2
enhanceosome; 2
TFID, 2
TFIIA, 2
TFIIB; 2
9%) 2
CPT, 2
thyreostatic 2
3.2-34.6). 2
CAD, 2
-0.294, 2
0.353, 2
Inferring 2
dependencies. 2
(here: 2
Neighbourhood 2
(NCPC) 2
Dependence 2
Graph 2
(DDGraph), 2
NCPC 2
DDGraph 2
ddgraph, 2
cosmo. 2
unaligned 2
ZOOPS 2
profile-likelihood 2
BIC. 2
(OOPS, 2
ZOOPS, 2
TCM) 2
guarding 2
mis-specified 2
MEME. 2
http://cosmoweb.berkeley.edu. 2
(http://bioconductor.org). 2
dPattern: 2
TFBS: 2
Rome. 2
removals 2
0.0354 2
0.0485, 2
AMs. 2
thoracolumbar) 2
19-75] 2
1-179] 2
asymptomatically. 2
perioperatively, 2
1-13] 2
2.22 2
(Simpson 2
1957, 2
goal: 2
teaching. 2
University-affiliated 2
Nodular-type 2
179) 2
94.9% 2
(SAS-6, 2
Ana2) 2
(Asl, 2
DSpd-2 2
D-PLP) 2
135-kDa, 2
2002: 2
MCPH 2
mutation's 2
C-NAP1, 2
centriole. 2
bld10 2
centriole, 2
Bld10, 2
Bld10p 2
Bld10 2
axonemes 2
BLD10/CEP135 2
MT-based 2
BLD10/CEP135, 2
CBB-assembly 2
(SAS6, 2
SAS4/CPAP 2
BLD10/CEP135), 2
CBBs. 2
CP110. 2
pericentrin 2
CEP135. 2
(Cdk1) 2
Cdks 2
endoreplication 2
duplicated. 2
γ-tubulin 2
immunoscreening 2
stripe 2
Delta3 2
non-Maori, 2
(MACE) 2
rehospitalisation. 2
cines 2
0.3-2.0). 2
CAD). 2
non-Maori), 2
non-Maori 2
12±7% 2
(dilated 2
methotrexate) 2
non-IL-6-dependent 2
darapladib). 2
risk]. 2
(PLA(2)) 2
lysophospholipids, 2
grounds, 2
STABILITY 2
SOLID-TIMI 2
PLA 2
(sPLA2s), 2
(varespladib), 2
Ldlr(-/-) 2
Pla2g10(-/-) 2
PLA2G10 2
varespladib; 2
.029). 2
Anthera 2
SETTING, 2
myonecrosis 2
0.85) 2
SPIDER-PCI 2
(Anthera 2
(FMD) 2
wire. 2
3.66 2
2.45% 2
(Varespladib) 2
1.73% 2
FMD, 2
pre-PCI 2
-1.16 2
1.68%; 2
0.5. 2
(sPLA2-IIA) 2
sPLA2-IIA-modified 2
CETP. 2
3-way, 2
84.04, 2
80.86 2
87.34). 2
63.22, 2
56.74 2
70.44) 2
dose-proportional, 2
AUC0-∞: 2
1.01). 2
7.76 2
(17.1) 2
[OAT3] 2
(FgfR3P244R) 2
basicranial 2
synchondroses. 2
Audiological 2
audiologist 2
(FOA) 2
fusion; 2
work; 2
IV; 2
foreheadplasty 2
variability: 2
unilateral); 2
skull), 2
turribrachycephaly 2
"tower-shaped" 2
(asymmetry 2
face). 2
mild); 2
Strabismus 2
33%-100% 2
individuals); 2
(~33%); 2
epilepsy; 2
fusions; 2
clinodactyly; 2
broad) 2
cone-shaped 2
epiphyses. 2
pediatrician, 2
remodeling) 2
lubrication 2
(broad 2
Extracranial 2
(CT)-verified 2
midsagittal 2
2853 2
763 2
Psychotropic 2
Skill 2
(within-group 2
literal 2
youth: 2
(Social 2
Scale-Parent 2
(SRS-P); 2
in-session 2
behavior) 2
typically-developing, 2
anxiety-disordered 2
(CBT). 2
8.67). 2
Coded 2
At-home 2
support/bullying 2
perspective-taking, 2
322) 2
Asperger 2
188), 2
Specified 2
child-, 2
parent- 2
teacher-report 2
HFA 2
PFC. 2
PFC-lesioned 2
preladenant 2
'dopamine 2
replacement' 2
(KW-6002) 2
fipamezole), 2
istradefylline), 2
talampanel), 2
levetiracetam) 2
(5-HT)1A 2
sarizotan) 2
quetiapine). 2
P=.003) 2
non-troublesome 2
antagonists; 2
permeate 2
l-dopa. 2
agonist-sparing 2
dyskinesia-ameliorating 2
risky, 2
convince 2
physicians: 2
grown. 2
¹⁹F 2
T2* 2
mmol/kg 2
gadobutrol. 2
(T1 2
native), 2
(ECV) 2
Look-Locker 2
LVMI 2
biopsy-quantified 2
gadolinium-based 2
Tesla. 2
0.15mmol/kg 2
gadopentate 2
0.037, 2
0.009, 2
0.063 2
mmol/kg). 2
slice. 2
(HCM 2
HCM; 2
(r=0.56, 2
(s-IBM) 2
muscle-fibre 2
intramuscle-fibre 2
Lysosome-associated 2
(LAMP2A) 2
(Hsc70) 2
s-IBM, 2
biopsies; 2
(CHMFs) 2
CMA-targeted 2
CHMFs 2
s-IBM. 2
vehicle-injected 2
(LAMP2a) 2
(hsc-73)] 2
LAMP2a 2
diabetic-induced 2
(SEGA), 2
cortical/subcortical 2
(seizures, 2
behaviour), 2
0.037), 2
PT/INR 2
Case. 2
105.7 2
Hemoclot 2
HTI 2
(<40 2
(APTT) 2
HAS-BLED 2
excessively, 2
80s. 2
coagulometric 2
(PT), 2
PT/aPTT-based 2
(extrinsic/intrinsic 2
APC-resistance 2
seconds). 2
IV-rtPA 2
IV-rtPA. 2
insensitive. 2
(n=80) 2
(n=762) 2
O-linked, 2
Arctic 2
notothenoids, 2
sialylated 2
psychrophilic 2
kcal/mol). 2
21-hour 2
(fractional 2
-diastolic 2
AWT-S 2
cryopreservation, 2
MoeA. 2
FlgA 2
pilus 2
dehydrogenases, 2
hexuronate 2
carbohydrates. 2
pili 2
SET, 2
water-water 2
ice-like 2
(THPs) 2
crystals) 2
non-colligative 2
Experimentally 2
'-DT-K-' 2
mistargeting 2
DIVAC 2
IgL 2
endoperoxide 2
polymerase-II 2
5'-region 2
5'-accumulation, 2
(Ser-5) 2
(Ser-2) 2
parturition. 2
(H3S10) 2
JIl-1-mediated 2
brahma 2
E75A 2
ecdysone-responsive 2
IIo(ser5)), 2
JIL-1-null 2
IIo(ser2)) 2
Promoter-proximal 2
Pause 2
Cdk9-cyclin 2
(P-TEFb); 2
Cdk9-activating 2
Cdk9-dependent 2
events--Pol 2
incoherent 2
elongationally 2
gamma-actin 2
regions) 2
choreography 2
(IGS1) 2
forcibly 2
fork-blocking 2
Fob1. 2
SIR2. 2
(NAD(+)-dependent 2
deacetylases) 2
dSir2 2
dSir2. 2
FOXO-induced 2
PML-induced 2
PML-mediated 2
supplements: 2
stereotypic--they 2
(n=3) 2
pericranial 2
influenced, 2
5/10,000 2
histaminic 2
cephalalgia, 2
Horton's 2
Attack-free 2
resort. 2
unmistakable 2
Lithium, 2
[Cluster 2
aborting 2
days/month, 2
MIDAS 2
96; 2
(add-on 2
headache]. 2
ketoprofen. 2
phospholamban/SERCA2a 2
regulatome. 2
SERCA/PLN-ensemble 2
linewidths 2
(micros-to-ms) 2
mTORC2-specific 2
miR-424/503 2
LTM. 2
layering 2
electroencephalography. 2
(PVR). 2
SIN1, 2
Akt-independent 2
PRAS40, 2
single-positive 2
SIN1 2
indentify 2
Aloe-emodin 2
PRR5 2
one-standard 2
2D:4D: 2
0.93-1.34]. 2
one-SD 2
ΔR-L: 2
0.87-1.23]. 2
6.92; 2
Caucasians; 2
LIN28b 2
(OSCC)-the 2
cancer-and 2
(OPLs) 2
tobacco-consuming 2
Fingers 2
Adobe 2
Photoshop 2
1524 2
4D) 2
0.57-0.80). 2
0.09-0.21). 2
263), 2
408 2
37.1%, 2
Right-hand 2
TRUS 2
[correlation 2
-0.038, 2
0.466]. 2
-0.140, 2
184; 2
182), 2
(3.26 2
1.07-2.84] 2
1.33-7.78). 2
3172 2
2169 2
4.12, 2
1.21-14.00, 2
32,598 2
4.11, 2
2.99-5.68, 2
5.27×10(-18)). 2
-0.482, 2
-0.582; 2
5.1. 2
2974 2
(427 2
2540 2
1.3-8.8; 2
0.0076). 2
0.0029 2
(sAD) 2
sAD-characteristic 2
(rs63750847) 2
embracing 2
neurogenetics 2
apprentice 2
epoch 2
dawn. 2
"TREM-ming" 2
beta-amyloid, 2
rs9877502 2
10⁻⁹ 2
tau) 2
10⁻⁸ 2
TREM 2
4.86 2
(PLOSL) 2
(p.Trp198X) 2
affirming 2
immunity's 2
Bcl-2/Beclin 2
Tsc1-null 2
Ca(2+)-signaling 2
mTOR-mediated 2
obesity-mediated 2
acid-albumin 2
(GHSR1a). 2
HO-8910, 2
ghrelin/GHSR1a 2
D-Lys-3-GH-releasing 2
peptide-6 2
ghrelin-regulated 2
rs1034528 2
G>C, 2
rs2295080 2
rs2536 2
(42.7%) 2
(HSP60 2
(MetS). 2
MetS: 2
(WC) 2
≥88 2
≥130/85 2
≥150 2
anthropometric, 2
30.9 2
(96/311) 2
assessment-insulin 2
(HOMA-IR) 2
anti-HSP70 2
WC, 2
HOMA-IR, 2
(JIS) 2
"to 2
alence 2
(rHuEPO) 2
bioimpedance 2
ATP-III 2
(Hgb), 2
(10-12 2
66.3% 2
84.8%; 2
(2679.3 2
1936.1 2
3702.5 2
2213.0 2
mo; 2
bolic 2
(CFA) 2
sub-group, 2
racial/ethnic-specific 2
1999-2010, 2
CFA 2
race/ethnicity-specific 2
Loadings 2
non-Hispanic-blacks 2
C-reactive-protein, 2
Non-Hispanic-black-males 2
clinically-accessible 2
MetS-related 2
rs7138803 2
(GRS) 2
partitioning. 2
multiple-kinase 2
lipoxidation 2
MDAL 2
(Prxs), 2
(SOD2) 2
cystoscopy. 2
risk-stratification 2
case-control, 2
ROCs 2
UroVysion® 2
multi-analyte 2
(BCa) 2
MMP-10, 2
SDC1, 2
A1AT, 2
8-biomarker 2
97%), 2
97%). 2
BTA-Trak 2
(PUTs) 2
(ZEB1/ZEB2) 2
PUTs. 2
LG 2
NMP22. 2
cystoscopy, 2
immunofluorometric 2
end-user 2
(HAS1, 2
HAS2, 2
HYAL-1) 2
Hyaluronic 2
(HA1, 2
HA2, 2
HA3), 2
hyaluronidase, 2
(CD44s, 2
RHAMM), 2
72); 2
148). 2
HYAL-1, 2
RHAMM 2
.019), 2
.027) 2
.019) 2
.046) 2
79.5% 2
.004; 2
6.7). 2
Voided 2
ELISA-based 2
(AUROC) 2
1.51; 2
urine: 2
hematuric 2
"no 2
529 2
"true" 2
Altman 2
plots). 2
hematuria. 2
(Patholog 2
2011:932932, 2
2010).Prediction 2
PIK3CA). 2
10-9) 2
5.69 2
cetuximab-treated 2
(AMDS) 2
Degraded 2
Bioanalyzer 2
anti-Epidermal 2
95%: 2
EGFR-497R 2
2/33 2
A+61G 2
pCR, 2
irinotecan-refractory 2
CBI 2
FCGR3A, 2
BOND2, 2
Slovene 2
(wt-KRAS) 2
non-mutated 2
cancers]. 2
949 2
analyses; 2
649 2
(0/9) 2
p=0.013), 2
36.3% 2
Times 2
(P=0.037) 2
P=0.004). 2
first-line. 2
786-O 2
Renca, 2
(STAT3(Y705)) 2
(JAK2), 2
Icaritin-induced 2
Radioresistance 2
honokiol 2
(E-cadherin, 2
γ-catenin) 2
vimentin) 2
IL-8/CXCL8, 2
CXCL5) 2
(STAT1 2
siRNAs) 2
(Stattic) 2
JAK-dependent 2
(SNAIL), 2
(vimentin) 2
IL-27-treated 2
IL-27. 2
receptor-driven 2
pro-carcinogenic 2
AZD1480-treated 2
Scutellaria 2
Don 2
CRC-related 2
mm), 2
IL-6/STAT3 2
anti-apoptosis, 2
Sumoylated 2
sumoylated. 2
(skNAC; 2
NACA) 2
m-Bop/Smyd1, 2
sarcomerogenesis, 2
(PML)-like 2
sarcomerogenesis. 2
255. 2
sumoylation-defective 2
Sharp-1. 2
UIM. 2
SUMO2/3, 2
(1)H, 2
(UBDs) 2
BMRB 2
19111, 2
Neonatology 2
41%. 2
Necrotizing 2
(MODS) 2
mattress. 2
35.5 2
(+/-0.5 2
rewarming 2
(26-30), 2
(1.0-1.7), 2
(12-45). 2
(88%-97%) 2
strength; 2
thromboelastography. 2
inotropes 2
cooled. 2
experimentalist 2
researchers: 2
run; 2
quantitatively; 2
reprobing 2
DB71, 2
CBB, 2
2.5-40 2
loaded. 2
DB71's 2
Months 2
trial]. 2
(Dmab) 2
PKC-β 2
Syk-kinase 2
7-OH-MTX 2
APCs, 2
(intestine) 2
kg(-1), 2
duct-cannulated 2
(BCR)-mediated 2
B-NHL 2
(FL), 2
(MZL), 2
lymphoplasmacytic 2
leukemia/chronic 2
(SLL/CLL). 2
SLL/CLL, 2
BCR-induced 2
SLL/CLL. 2
#NCT00446095. 2
crescents 2
R-406 2
(gestation 2
12.5, 2
retroesophageal 2
3-month, 2
0.01]). 2
R788/R406, 2
(MTX-IRs) 2
(non-biologic) 2
mimic, 2
phosphatidylinositol-3'-kinase 2
(R788), 2
Self-administered 2
(HRQOL), 2
PtGA, 2
R406) 2
(PKs) 2
(LKs) 2
attractiveness 2
LKs 2
(alvocidib), 2
BMS-387032 2
(SNS-032), 2
Multi-tyrosine 2
(ZD6474) 2
(SKI-606), 2
TKI258 2
(CHIR-258), 2
(GW786034) 2
axitinib 2
(AG013736) 2
CAL-101 2
PI3Kδ-specific 2
LK 2
receptor-4 2
scrutinized. 2
PCI-32765, 2
LFM-A13, 2
AVL-101, 2
AVL-292, 2
R343, 2
R112, 2
BAY-61-3606, 2
C-61, 2
piceatannol, 2
bafetinib, 2
SU6656 2
R788-treated 2
(APCs) 2
luciferase(+) 2
(R-788) 2
excesses 2
Too 2
collagen-characteristics 2
monocytosis 2
sinusotomy 2
Rhinological, 2
(atxGBS), 2
13.1%. 2
enteritidis, 2
Antiganglioside 2
episodes), 2
[GQ1b 2
GD1b 2
(50%)]. 2
enteritidis 2
nosographical 2
jejuni, 2
gastroenteritis, 2
LPSs 2
GD3, 2
1992-3: 2
(3,909,512 2
departments, 2
357.XX 2
0.14/100000/year 2
0.07-0.25) 2
0.09/100000/year 2
0.04-0.18) 2
WSS1, 2
SGS1, 2
TOP3, 2
Wss1 2
Psy2 2
Spt16p 2
Constituents 2
alpha-binding 2
MRX 2
Lobry 2
C=G 2
DNAskew 2
(substitution 2
strand) 2
cell-targeted, 2
(SIN) 2
(SINfes.gp91s) 2
(gp91(phox)) 2
(X-CGD). 2
WASP 2
WAS 2
reinfused 2
MLD 2
MLD. 2
reinfusion 2
CD105-specific 2
mCD105-LV 2
Double-suicide 2
double-suicide 2
HOXC 2
12q13.13. 2
0.021), 2
lncRNA/mRNA 2
cell-cycle-associated 2
3.564). 2
INK4A-ARF-INK4B 2
kb-long 2
INK4A-ARF-INK4B. 2
H3K27-trimethylated. 2
(P=.001). 2
(chaperone-mediated, 2
macro, 2
GABA(C)-ρ1-receptor 2
immunoisolated 2
XBP1, 2
(proteostasis). 2
Misfolding 2
ML346 2
FOXO, 2
HSF-1, 2
(mis)folding. 2
chaperonins. 2
Chaperonins 2
spreadsheet 2
organisms--Bacteria, 2
Eukarya--have 2
c.205C>T 2
ENMC 2
9-11 2
XMTM 2
PI3P 2
T-tubule 2
MTM1-related 2
normals 2
unassisted. 2
Retrievers. 2
Retrievers, 2
14-26 2
ringed 2
accumulations. 2
p.N155K, 2
GFP-MTM1 2
p.N155K 2
(myotubular) 2
(CNM). 2
CNM, 2
exonisation 2
Mtm1-deficient 2
CNM. 2
c.1234A>G 2
XLMTM. 2
myotubulatin 2
E404K 2
5-phosphate 2
(MTM1), 2
3-monophosphate 2
[PI(3)P], 2
phosphatidylinositide-3-kinase 2
formatted 2
[R37X, 2
(137-11) 2
(592-593) 2
insA, 2
T197I, 2
R253X, 2
G378R, 2
G402R] 2
[P199S, 2
(1644+2) 2
insG]. 2
(1314+3A/G). 2
Sbfl 2
4B. 2
Xq13. 2
(PTP). 2
MTM1) 2
Ugandans 2
(Burst 2
disappeared, 2
T-lymphocytes. 2
(protease/reverse 2
transcriptase) 2
2009-2011. 2
7.1.3). 2
Phylip 2
3.67) 2
neighbor-joining 2
two-parameter 2
value). 2
MSM. 2
CRF. 2
Province, 2
MEGA 2
CRF07-BC 2
MSMs 2
nonproductive 2
CNS- 2
anti-retroviral 2
nevirapine 2
Novosibirsk 2
02_AG 2
CRF02_AG 2
ultradeep 2
(UDS) 2
(MSM). 2
therapy-naive 2
UDS. 2
monoinfection 2
coinfected 2
Superinfection 2
4.96 2
2.67-9.22); 2
8.6%-22.1%). 2
3.56-5.36). 2
Intrasubtype 2
Diego; 2
Bangladesh. 2
5a 2
(CRF64_BC) 2
CRF64_BC 2
subregion, 2
gluteofemoral 2
[HMW], 2
intercept 2
.047). 2
3.2; 2
.016) 2
3.8). 2
(3.70 2
Orexins 2
methylene-tetrahydrofolate 2
obesity--and 2
(EMs) 2
(BMI)-matched 2
headache-free 2
HMW-ADP 2
4.0) 2
(8.6 2
adiponectin: 2
connection? 2
(TNF)-alpha. 2
thoughtfully 2
oncogen- 2
interconnection 2
Puma 2
c-MYC. 2
hc-Myc 2
miRNA-based 2
momentous 2
Weinstein 2
series; 2
imaging), 2
[phosphorylated 2
Akt1, 2
Myb-coordinated 2
single-driver 2
network" 2
usurp 2
addiction," 2
vapour 2
normocapnia. 2
Hypercapnia 2
6.0-7.3 2
l/min. 2
[4.4 2
0.01], 2
22.6) 2
(25th-75th 2
percentiles) 2
(10.1-22.1) 2
(8.8-17.6) 2
1347 2
0.002. 2
anaesthetics. 2
15.08 2
18.97, 2
20.78 2
20.92, 2
12.76 2
12.82 2
1.54 2
10.99 2
13.15 2
27.16 2
56.55 2
11.88 2
18.80 2
5.19, 2
7.89, 2
4.11 2
6.01, 2
2775 2
1449 2
2797 2
rocuronium-induced 2
Sugammadex, 2
gamma-cyclodextrin, 2
relaxant-binding 2
vecuronium. 2
acceleromyography 2
train-of-four 2
glycopyrrolate 2
kg(-1)) 2
rocuronium. 2
means). 2
Predictability 2
neostigmine: 2
sugammadex-treated 2
neostigmine-treated 2
Sugammadex 2
(Clinicaltrials.gov 2
NCT00451217). 2
oxide/sevoflurane. 2
(nitrous 2
commands. 2
(94/174 2
(204/256 2
(249/267 2
(propofol/propofol; 2
(propofol/isoflurane; 2
predischarge 2
sevoflurane/sevoflurane 2
215/241 2
89/170 2
(Chi 2
70.3, 2
0.1-0.3% 2
(Gsdm) 2
Gsdm 2
Gsdma, 2
GSDMA), 2
GSDMC, 2
GSDMC 2
hair-loss 2
finnegan 2
preputial, 2
meibomium, 2
ceruminous 2
NRGs 2
pro-NRG 2
pro-NRG-producing 2
Nitrosomonas 2
hydroxylamine. 2
AMO), 2
Cu(2+) 2
CopA 2
"twin 2
arginine" 2
Cj1161c 2
thi1 2
THI1, 2
immunogold-labeling 2
Testisin, 2
collagenous 2
TAP-independent 2
reticulum: 2
flocculin 2
sporulation-specific 2
S1. 2
E1-beta-galactosidase 2
subfragments 2
TAG-1. 2
DAF-16 2
low-grade, 2
PGC-1α, 2
FoxOs, 2
SirTs 2
FoxOs. 2
bran 2
gavaged 2
nemo-like 2
path: 2
"double-edge 2
sword" 2
ageing--a 2
longevity? 2
inflamm-aging 2
ripe 2
Sirtuins, 2
'longevitarians'). 2
hSir2(SIRT1). 2
(EBV). 2
(ophthalmoplegia, 2
antibody-associated 2
anti-GQ1b-syndrome, 2
Anti-GM1 2
GT1a 2
postinfectious 2
roof. 2
GM2, 2
GM1b, 2
(GBS, 2
anti-GD1a 2
anti-HSV-1 2
HSV-associated 2
Herpetic 2
encephalitis? 2
N20 2
F-waves 2
(AO). 2
27.3%. 2
ballism-like 2
left, 2
concurrently-Fisher 2
syndrome-that 2
bendamustine 2
antibodies]. 2
mydriasis, 2
[Probable 2
recover. 2
(TNFalpha). 2
TaqMan-based 2
miR-146a. 2
poly(I-C), 2
CD79a+ 2
mir-146a, 2
miRNA-155, 2
miRNA-124a, 2
mir-203, 2
mir-223, 2
mir-346, 2
mir-132, 2
mir-363, 2
mir-498, 2
mir-15a, 2
mir-16 2
(JRA), 2
979 2
(asthma: 2
402, 2
JRA: 2
0.108, 2
0.553 2
0.519-0.929, 2
0.0138). 2
Mexicans. 2
pre‑microRNA 2
(hsa-mir-146a 2
hsa-mir-499) 2
Tetra 2
system-polymerase 2
hsa-mir-146a 2
[TT 2
1.08-4.11; 2
p=0.029; 2
3.88; 2
1.68-8.98; 2
p=0.002], 2
2.64; 2
1.48-4.72; 2
(TC-CC 2
3.05; 2
1.36-6.83; 2
2.49; 2
1.63-3.81; 2
(χ2=0.348, 2
p=0.841). 2
umor 2
MicroRNA-323-3p 2
RNAs,∼ 2
miR-323-3p, 2
14q32.31. 2
squamosal 2
acrocephaly 2
Gly380Arg, 2
1138G>A) 2
oxycephaly, 2
(g.C749). 2
deformation. 2
31.8% 2
brachicephaly, 2
Children&apos;s 2
Crouzon's 2
P250L 2
(749C-->T) 2
(211 2
mediastinal, 2
dissection) 2
(v6) 2
negativity, 2
Heparan 2
CD44v-expression 2
Ki67. 2
hyperplasias 2
(AEH) 2
AEH 2
CD44v3- 2
v6-positivities 2
AEH, 2
CD44v3-expression 2
D44 2
Masaoka 2
selectins 2
(B-CLL). 2
85-95 2
68/85 2
moAb 2
"mixes" 2
HA-coated 2
HA-signaling 2
activatory 2
LDT 2
HT29m 2
LeX 2
CSLEX-1. 2
(27.6%) 2
malignomas. 2
MDA-MB435, 2
4151 2
-v9 2
lymphogenic 2
(90.3%) 2
anti-CD44v6 2
[23 2
(79.3%) 2
(40.6%); 2
0.01]. 2
(Cochran-Armitage's 2
Formalin-fixed, 2
v4/5, 2
v10, 2
v6. 2
CD44v) 2
6v 2
119) 2
108) 2
Kaufmann 2
Lancet, 2
345: 2
615-619, 2
(pT1+pT2) 2
grading). 2
CD44-9v, 2
CD44-6v-containing 2
Life-Short 2
Form, 2
incontinence-related 2
pharmacology. 2
modulators) 2
(urge-, 2
stress-, 2
overflow-incontinence). 2
floor: 2
muscle-dependent, 2
Non-drug 2
toilet 2
'Urinary 2
incontinence' 2
(>or= 2
(244 2
times; 2
BT. 2
(- 2
87%). 2
opinions. 2
researcher. 2
motivation]. 2
Descriptive. 2
Nijmegen 2
environs, 2
cystocele 2
practise 2
elders. 2
elders 2
suturing 2
incontinent; 2
cured. 2
Terodiline 2
(mictiogram) 2
well-tried 2
hospitalisation/bladder 2
training/medication 2
Hospitalisation 2
female]. 2
BRD. 2
Urodynamically 2
urethrocystographic 2
18-82) 2
12-54) 2
Eysenck 2
Introverted 2
extraverts 2
psychodynamic 2
enuretic 2
GenBank® 2
(PMC), 2
Primer-BLAST, 2
COBALT, 2
dbVar, 2
(CDART), 2
sift 2
Snat, 2
OrfFinder, 2
Chromosomes, 2
GENSAT, 2
(OMIM), 2
(COGs), 2
Animals): 2
NCBI. 2
(OMIM). 2
MySQL 2
(ANGIS) 2
http://omia.angis.org.au/. 2
(NCBI; 2
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omia). 2
Curation 2
enabled. 2
post-methotrexate 2
Inactivity 2
≤0.5+ 2
(8/13; 2
69%) 2
7.3). 2
(6/13; 2
Relapse-free 2
.033). 2
0.07; 2
0.01-0.86; 2
.038), 2
TNFalpha-blocking 2
DMARD's/ 2
(ciclosporine 2
mofetil) 2
(expert 2
U-CE 2
7.82 2
5'-phosphatase) 2
mini-protein). 2
(RNMT) 2
(5,6-dichloro-1-β-D-ribofuranosylbenzimidazole)-dependent 2
RNMT, 2
(methyl 2
(S-adenosylhomocysteine 2
hydrolase), 2
FTSJD2 2
ISG95). 2
guanylyl 2
(GTP:mRNA 2
2.7.7.50) 2
enzyme-GMP 2
32P-labeled 2
nsP1-guanylate 2
guanine-7-methyltransferase 2
Gomatos, 2
Virology, 2
114, 2
542-554, 2
1981). 2
guanine-7-methyltransferase, 2
virus-specified 2
G(5')pppN- 2
(S100A7), 2
A7) 2
psoriasin, 2
Psoriasin, 2
coli-killing 2
meibomian 2
1q21, 2
Inflammation-prone 2
mastitis 2
udder, 2
dissatisfied 2
Proton-pump 2
antacids 2
Food, 2
espresso 2
Malabsorptive 2
two-period 2
TSH) 2
Off-pump 2
96, 2
repercussions 2
80.3 2
grafting: 2
(FT3), 2
(NTI). 2
Catecholamines 2
state". 2
F-ascin 2
zymography. 2
(P=0.075), 2
RNA-expressing 2
(P<0.005) 2
(35.7%) 2
microspikes 2
(PKCalpha), 2
PKCalpha. 2
fascin/PKCalpha 2
3D. 2
Acetyltransferase) 2
Eaf1p 2
TAF-independent 2
(Spt-Ada-Gcn5-acetyltransferase) 2
Spt20, 2
Mid2 2
(SAGA). 2
(ZnF) 2
tautomeric 2
histidines. 2
α-helix. 2
ZnF-DNA 2
SAGA's 2
Spt8 2
UPS2 2
2006). 2
(UPS2). 2
APEX-SMT 2
LsmAD 2
Hymenoptera 2
microaggregates. 2
Q58 2
Deranged 2
(Atx2). 2
SCA2. 2
Atx2-58Q 2
SCA2-58Q 2
RyanR 2
Cdk5. 2
Cdk5-p25 2
portions, 2
(satRNAs) 2
pre-cellular 2
PERL 2
PFOR. 2
GLVd 2
Apscaviroid, 2
AHVd-like 2
comprehending 2
inquiry. 2
(ex. 2
announcements), 2
http://subviral.med.uottawa.ca. 2
246-399 2
CChMVd, 2
CChMVd 2
small--one 2
fiftieth 2
viruses--that 2
auto-replicable 2
(>39°C), 2
malaise. 2
(33-42% 2
anthelminthic 2
coagulability 2
(0.57-1.17 2
311-384 2
microparticle-associated 2
(1.64 2
obliterative 2
hematobium. 2
Endemicity 2
pro-fibrogenic 2
(mostly) 2
nephrosis 2
nephritic 2
tourists 2
CBA 2
schistosomicide 2
cercaria. 2
spending 2
alarm 2
[Acute 2
fever)]. 2
fever): 2
water; 2
schistosomiasis: 2
(keyhole 2
haemocyanin) 2
mansoni: 2
echodoppler 2
cardiography, 2
scan) 2
neuroschistosomiasis, 2
Salmonella, 2
Staphylococci, 2
Hepatosplenic 2
anymore. 2
(worm 2
(pulmonary 2
neuroschistosomiasis). 2
anti-schistosomal 2
Beads 2
training], 2
supplementations), 2
(n-3) 2
postabsorptive 2
hyperaminoacidemic-hyperinsulinemic 2
clamp. 2
Corn 2
SEM: 2
0.051 2
0.008%/h 2
hyperaminoacidemia-hyperinsulinemia-induced 2
0.003%/h 2
mTOR(Ser2448) 2
p70s6k(Thr389) 2
(morning/evening) 2
(glycine 2
Blatt-Kupperman 2
Greene 2
(IOVE) 2
IOVE 2
Blatt 2
Kupperman 2
Nonestrogen 2
(1959-February 2
mirtazapine, 2
clover. 2
Initial, 2
megestrol 2
(AMED) 2
quai 2
nonprescription 2
abate 2
herbs, 2
Randomised, 2
(end 2
acid-alpha 2
PC-responsive 2
PC-unresponsive 2
C647W 2
1-22) 2
hyperCKemia, 2
(GSDII; 2
(AalphaGlu) 2
GSDII. 2
6neo/6neo 2
(6neo/6neo) 2
month; 2
"Silver 2
degeneration" 2
rotorod, 2
hanging, 2
fault 2
GSDII 2
17q25.2-25.3. 2
(R224W, 2
S619R, 2
R660H). 2
CRIM 2
rhGAA. 2
rhGAA, 2
newborn-screening 2
dried-blood 2
(1-deoxynojirimycin 2
duvoglustat 2
hydrochloride) 2
(ER)-retained 2
(P545L 2
GAA). 2
(Tg/KO) 2
less-frequent 2
(6(neo)/6(neo)) 2
fertile, 2
Hum. 2
(C1935-->A) 2
alpha-D-glucosidase. 2
Aat 2
861 2
equipotent, 2
hydrolase, 2
alpha-1,4-glucosidase 2
590 2
glycogen-degrading 2
Channelrhodopsins-2 2
biexponential 2
ChRwt, 2
Neurosci. 2
4-state 2
ChETA, 2
optostimulation 2
voltage-clamp-measured 2
optically-triggered 2
targetable, 2
Sound 2
(SGNs) 2
Approximation 2
optical, 2
prosthetics. 2
Chimeras 2
channelrhodopsin-2. 2
(ChR1) 2
Glu-129 2
(Glu-90 2
numbering), 2
channelrhodopsins. 2
sight? 2
prostatitis), 2
manipulation; 2
prostate-cancer-specific 2
high-dimensional 2
Thompson 2
(55.2%) 2
Written 2
thematic 2
"prevention," 2
faith 2
organ-confined 2
(<4.0 2
campaign, 2
(100,000 2
2,119 2
13.0%. 2
easy-to-use, 2
91.1%). 2
pharmacist. 2
(DRE, 2
TRUS, 2
biopsy...). 2
immunometric 2
cutoff-based 2
sample-based 2
PSA; 2
conclusions: 2
provide. 2
[Monosymptomatic 2
hydrocephalus]. 2
Normal-pressure 2
Dios 2
Bogotá, 2
22/28 2
(78.5%) 2
Transducer 2
erbB2.1 2
Feathers 2
keratin-associated 2
feathers. 2
acrylate 2
beta-proteins 2
alpha-layers 2
alpha-layer. 2
beta-cells, 2
pliable 2
wool-derived 2
nanofibres 2
(they 2
formaldehyde, 2
dithiothreitol/urea 2
crosslinks, 2
K5-K14 2
trans-dimer 2
Cys367 2
K14's 2
Hard 2
multi-scale 2
Solubility 2
string. 2
hydrates 2
shaft. 2
abducent 2
Occasionally 2
chew, 2
swallow, 2
premutation, 2
Steinert 2
Duchenne's 2
Goldenhar 2
HEADD 2
(fragile-X, 2
hypo-melanosis 2
(Behaviour 2
VSK; 2
MBAS). 2
retarded) 2
(PLB, 2
PLN) 2
Mg(2+). 2
Curr. 2
Ca(2+); 2
state; 2
(NST) 2
(Sln), 2
(Serca) 2
Serca 2
imbalancing 2
contractivity; 2
(sln-/-) 2
Patch-clamping 2
afterdepolarization, 2
(RG), 2
(EDL), 2
RG, 2
(+dF/dt). 2
+dF/dt; 2
10-Hz 2
dKO 2
Threonine-5 2
(T5) 2
T5-->alanine 2
T5-->glutamic 2
WT-SLN 2
(VSD) 2
monomerization 2
Sarcolipin, 2
anti-FLAG 2
1-22 2
1-23, 2
vector-injected 2
(P(t)) 2
(123.9 2
(562.3 2
300.7 2
(+dF/dt) 2
(750-ms 2
(6.36 2
6.39 2
(SERCA1a), 2
(DeltaK(Ca) 2
reestablishes 2
malfunctions. 2
(IFAR). 2
IFAR 2
[0% 2
oncogenes; 2
allele-loss 2
p.Ala334Thr. 2
p.Ala391Glu 2
p.Pro250Leu 2
dysplasias: 2
(IIIc) 2
p.Ala334Thr, 2
βF 2
FGF1. 2
alloimmunised 2
(RhD) 2
Event" 2
(cell-free 2
cffDNA), 2
rhesus-negative 2
progression) 2
RHD-negative 2
Pure 2
RASSF1A: 2
amplifiable 2
reengineered 2
cardiotropic 2
reengineering 2
(BNP116). 2
(vg), 2
10(12) 2
vg, 2
preload-recruitable 2
deleteriously 2
(Calcium 2
Up-Regulation 2
2b, 2
present) 2
ultrasound-mediated 2
Doxorubicin-induced 2
shRNA. 2
AAV9 2
Today's 2
(AAV)-S100A1 2
(AAV9)-S100A1 2
AAV9-luciferase 2
uncompromised. 2
(CUPID) 2
(SERCA2a). 2
Akt/FoxO3A-dependent 2
FoxO3A 2
previously), 2
contamination, 2
attacks: 2
SD], 2
-0.47 2
(Berinert 2
Cinryze); 2
(conestat 2
Rhucin); 2
[DX-88]); 2
bradykinin-2-receptor 2
(icatibant). 2
Berinert 2
(kallikrein-kinin) 2
'ecallantide', 2
'DX-88' 2
'hereditary 2
angioedema' 2
Pubmed/Medline, 2
ClinicalTrials 2
Google. 2
(ecallantide), 2
DX-88. 2
larynx, 2
dysinhibition 2
non-intravenous, 2
nonplasma-derived 2
ischema. 2
ethiology 2
aconitine 2
cathecolaminergic 2
Anderson-Tawil 2
Concealed 2
2n-1 2
inscribed 2
parasystolic 2
bifocal 2
BTBD9: 2
(iRLS), 2
iRLS 2
MEIS1, 2
MAP2K5/SKOR1, 2
PTPRD, 2
time-of-flight) 2
RLS-positive 2
RLS-negative 2
(P(nom)≤0.08, 2
1.33). 2
(P(corrected)=0.0013, 2
Reanalysis 2
9p: 2
loci? 2
four-generational 2
RLS3 2
RLS1, 2
RLS2, 2
RLS4, 2
RLS5 2
(RLS3*) 2
3.60 2
D9S974 2
D9S1118 2
9.9-Mb 2
RLS3, 2
D9S2189 2
(PARK8) 2
(p.F90L) 2
F90 2
'IQ' 2
(hH1) 2
inactivation-a 2
channel-gating 2
integrants 2
(TSSs), 2
SB-mediated 2
Tol2. 2
(PB), 2
iPS. 2
derivation, 2
piggyBac, 2
(SB11), 2
elderly]. 2
drugs(dabigatran 2
bid. 2
Anticoagulants 2
clot-bound 2
1%-2% 2
82.4 2
microg/dl. 2
eat. 2
palatable. 2
reward-related 2
Model-independent 2
beta-glucuronidase/sulfatase 2
hydrolysable 2
conjugate(s) 2
period.(ABSTRACT 2
semifluid 2
appetites, 2
ridden. 2
lightheadedness. 2
(medulloblastoma 2
morphometry-based 2
Duhamel's 2
Surgically 2
morphometrically. 2
ganglions 2
(cloaca 2
aproctia), 2
BACKGROUND/PURPOSE: 2
(KYNU, 2
GTDC1). 2
TPN. 2
network's 2
prioritizations 2
Rankboost 2
gene-pairs 2
HGNC 2
15: 2
source; 2
cooperatively. 2
pathophenotype 2
GUILD. 2
top-ranking 2
install 2
BioHEL 2
GAssist, 2
two-level 2
"translated" 2
hus, 2
paths, 2
(GP-MIDAS-VXEF). 2
two-sample 2
Kernel-based 2
Hunting 2
method's 2
benchmarked, 2
ENDEAVOUR. 2
(D. 2
update: 2
sources), 2
client, 2
TXTGate 2
pro.ling 2
Textual 2
pro.les 2
frequency-based 2
term-frequency 2
document-frequency 2
eVOC 2
Man's 2
Dysmorphology 2
1-SVM, 2
tachykinin 2
(rs1384401), 2
(rs4319896), 2
(rs12487452), 2
FOXO1A 2
(rs10507486 2
rs7323267), 2
(rs897959). 2
rs897959 2
fuzzy-based 2
GWAS-based 2
ToppNet 2
(GPSy), 2
arduous 2
vocabularies. 2
server: 2
XLMR. 2
gene-phenotype 2
Gene-gene 2
SEPT5, 2
DADA: 2
Degree-Aware 2
Prioritization. 2
paths. 2
DADA, 2
(OMIM) 2
prioritization, 2
http://compbio.case.edu/dada/. 2
accompaniment 2
(XLMR), 2
non-XLMR 2
(>80%) 2
(ADPKD), 2
ADPKD. 2
Dentigerous 2
p75 2
Aβ‑bound 2
structured/damaged 2
AD‑model 2
gyrus's 2
encoding, 2
PDGFRalpha 2
via, 2
polycystins, 2
ift88 2
Tg737) 2
ciliogenic 2
(PKD). 2
Wwtr1/TAZ 2
(Glis3(zf/zf)) 2
cilium-associated 2
Wwtr1/TAZ, 2
glomerulocystic 2
Glis3-mediated 2
Glis3, 2
enjoying 2
symmetry, 2
die, 2
improperly. 2
CEP290--a 2
Rab8a 2
Cholangiocyte 2
polycystin-1, 2
cholangiociliopathies 2
88/polaris 2
cell-cycle, 2
Orpk 2
Ductal 2
PKD, 2
(ARPKD), 2
bronchi, 2
ARPKD, 2
Immunoreactive 2
duct-lumen 2
polycystins 2
fibrocystin/polyductin/tigmin 2
immuno-light 2
-electron 2
Pkd1 2
(UCEs). 2
Ray-finned 2
32,000 2
unrealized. 2
vexed 2
systematists 2
(ML) 2
tropicbirds 2
(Phaethontidae) 2
sunbittern 2
(Eurypygidae) 2
bustards 2
(Otididae) 2
turacos 2
(Musophagidae). 2
waterbird 2
landbird 2
passerines 2
parrots 2
non-monophyly 2
raptorial 2
hawk 2
waterbirds 2
landbirds, 2
turtles, 2
tuatara. 2
lizards, 2
tuatara 2
(lepidosaurs), 2
crocodiles 2
(archosaurs). 2
archosaurs 2
lepidosaurs 2
beraprost, 2
(ONO-1301) 2
iloprost. 2
Th22 2
beraprost) 2
mDCs. 2
(poly 2
I:C-induced 2
analogue; 2
(AUC0-12) 2
(AUC0-24) 2
36-h 2
250-500 2
non-compartmental 2
scleroderma) 2
Epoprostenol, 2
precapillary 2
6MW 2
L/min/m(2) 2
Dyspnea 2
sicker 2
PPH. 2
PPH 2
DP1, 2
4.4, 2
(ILO) 2
(TRP), 2
(FLUO-BSA) 2
binding/uptake 2
FLUO-BSA-ILO 2
CAY10449. 2
PEI 2
F(ILO) 2
PEI-g-ILO 2
-4.5 2
ears¹⁻³. 2
CDC6. 2
Gorlin 2
neuromotor 2
spermatic 2
vaginalis. 2
[Lacombe 2
Ann. 2
37:184-191], 2
LMX1B 2
SHOX 2
#224690) 2
incisors, 2
know, 2
(Cerezyme, 2
MA), 2
(non-neuronopathic) 2
imiglucerase: 2
"Gaucher 2
cells", 2
(cytokines, 2
hydrolases...) 2
[Gaucher's 2
late]. 2
hemorragic 2
mis-identified 2
Alglucerase. 2
pharmacoeconomic 2
alglucerase, 2
chaperon-mediated 2
glucocerebrosidase-associated 2
(18)F-fluorodopa 2
52.6 2
GBA-mutation 2
(putamen 2
GBA-associated 2
Saposin 2
PSAP 2
GCase, 2
GD-related 2
118-137. 2
electrostatics, 2
conduritol-β-epoxide-bound 2
milieux, 2
F202L, 2
GBA), 2
GBA. 2
β-glucocerebrosidase, 2
tetroxide 2
DJ1 2
(PARK7) 2
(PARK9). 2
(kcat 2
Ser, 2
nucleophile. 2
Nci 2
(GBA, 2
PLGD 2
α-syn·GCase 2
(children) 2
(5.3%). 2
(Ashkenazim). 2
bruising. 2
(microchimerism) 2
enzyme-deficient 2
pancellular 2
re-growth 2
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 2
(17-DMAG), 2
noncytocidal 2
CDDP-induced 2
(IAP), 2
MDB 2
extraneural 2
D-dependent 2
haplo-insufficient 2
Ptc(1+/-) 2
INK4C 2
(CGP) 2
(GCP) 2
(medulloblastoma). 2
(MB), 2
(MEMRI) 2
Patched-1 2
Hsp-interacting 2
MLNs 2
MLNs' 2
Ca2+/S100 2
chaperone-associated 2
Hsp70/Hsp90-organizing 2
(Hop), 2
CyP40, 2
(PP5), 2
S100A2 2
CHIP-chaperone 2
CHIP-proteasome 2
Hdj1-stimulated 2
Aha1 2
heat-denatured 2
Hdj1 2
pollutants. 2
immunophilin-like 2
Hepa-1c1c7 2
AhR-hsp90 2
phycobiliprotein, 2
supplement. 2
inclination 2
C-PC, 2
platensis. 2
g/L/d, 2
(C-Pc) 2
cyanbacterium 2
spp.: 2
phycoerythrins 2
phycobilin 2
(lambda(max)) 2
4.52. 2
7.49, 2
(alphabeta)(3) 2
Grev. 2
Grev, 2
pumped 2
Q-Sepharose 2
hydroxyapatite. 2
mobilization, 2
radicals) 2
B-Phycoerythrin 2
(B-PE) 2
microalgae. 2
pink 2
cruentum. 2
centrifuged 2
Streamline-DEAE 2
debris, 2
eluate 2
Gradient 2
tetrapyrrole 2
electrophoresis-laser 2
(CE-LIF) 2
(SDS)and 2
652/660, 2
615/647, 2
565(494)/575 2
60-500 2
ing 2
oceanographic 2
macroalga 2
homogenisation 2
mW 2
TO-PRO-3. 2
phycobilisomes. 2
neglectum 2
displosiphon, 2
1500-base 2
coli-like 2
"-10" 2
"-35" 2
polypeptide), 2
(RSM) 2
ceylanicum. 2
(UFC). 2
UFC 2
1.05. 2
63.50%. 2
UV-Vis 2
chromoproteins 2
phycobilisome. 2
algae, 2
(phycobiliproteins) 2
Cyanophora 2
paradoxa 2
lambda-EMBL3 2
genes--the 2
genes--are 2
(alpha-allophycocyanin 2
alpha-phycocyanin) 2
bases). 2
1400-base 2
Rhodella 2
antennae 2
(Phospho-α-Syn) 2
Ser129. 2
Total-α-synuclein 2
(PLK3, 2
(GRK5) 2
GRK6) 2
pan-PLK 2
PLK1-3 2
Total- 2
BI2536 2
synucleins 2
Ser-118, 2
non-amyloid 2
Plk-2 2
obligate, 2
protozoans 2
keratoconjunctivitis, 2
rainy 2
keratoconjunctivitis 2
Microsporidian 2
endoparasites. 2
"nematode 2
perivermis 2
microsporidiosis 2
wild. 2
60°C 2
microwaving 2
GHz 2
haemocytometer 2
processors 2
infraphylum. 2
kingdoms: 2
Chromista. 2
(superkingdom, 2
infrakingdom, 2
superphylum, 2
infraphylum) 2
recognized). 2
'zoological' 2
Zoological 2
Bacteriological 2
'botanical' 2
(Plantae, 2
Chromista) 2
Botanical 2
Nomenclature. 2
Circumscriptions 2
Cavalier-Smith 2
(1981). 2
classes; 2
Myxozoa 2
mesozoans 2
Radiata 2
(phyla 2
Porifera, 2
Placozoa, 2
Ctenophora), 2
Myxozoa, 2
Mesozoa 2
phyla). 2
phyla: 2
Acanthognatha 2
(rotifers, 2
acanthocephalans, 2
gastrotrichs, 2
gnathostomulids), 2
Brachiozoa 2
(brachiopods 2
phoronids) 2
Lobopoda 2
(onychophorans 2
tardigrades), 2
Archezoa, 2
Metamonada 2
Trichozoa, 2
Rhizopoda 2
'rhizopods' 2
Cercozoa. 2
Mycetozoa 2
Archamoebae 2
infraphyla) 2
Conosa 2
Amoebozoa 2
Lobosa, 2
lobosean 2
Multicilia. 2
Haplosporidia 2
microsporidian) 2
metchnikovellids 2
Sporozoa. 2
Archezoa 2
Neozoa 2
circumscription 2
Discicristata, 2
Percolozoa 2
Euglenozoa). 2
megasystematics, 2
Posibacteria 2
Unibacteria, 2
Negibacteria, 2
infrakingdoms: 2
Lipobacteria, 2
Glycobacteria, 2
Microspora; 2
predilection, 2
male-restricted, 2
Genealogical 2
(Lys37del) 2
LEM 2
Buccal 2
50-70% 2
emerin-positive 2
[Emery-Dreifuss 2
19-years-old 2
ankles, 2
creatinekinase 2
(EDMD). 2
Pacemakers 2
post-cervical 2
(AD-EDMD) 2
-/-) 2
1B, 2
humero-peroneal 2
(LMNA 2
1q11-q23. 2
310300) 2
(EDMD-AD; 2
181350). 2
(LMNA), 2
Rigidity 2
triceps, 2
sarcoglycans, 2
alpha5, 2
gamma1 2
F8C 2
DXS52 2
disease?]. 2
X-coupled 2
Emery-Dreyfus 2
myodystrophy. 2
myopathologic 2
scapulo 2
EDS: 2
wasting; 2
S4 2
fibrin-bound 2
argatroban) 2
(BMS-262084) 2
pre-incubated 2
heparin-induced 2
phenprocoumon 2
(ANT) 2
LMWH), 2
hirudin, 2
melagatran, 2
bivalirudin. 2
ATH 2
predecessors 2
mitogenesis 2
Xa) 2
thrombogram 2
(Vmax) 2
IC2x 2
Vmax, 2
0.048 2
0.022 2
(Batten 2
Cln3-targeted 2
Btn1p, 2
btn1-Delta 2
CLN3P, 2
PANDER-induced 2
(JNCL) 2
16p12.1. 2
PANDER 2
CLN3, 2
[juvenile-onset 2
(JNCL)], 2
(CLN3) 2
yhc3 2
(juvenile-onset 2
JNCL), 2
16p11.2-12.1. 2
alpha1-specific 2
[thyroid 2
receptor]1 2
http://MetaTM.sbc.su.se. 2
Alpha-helical 2
machine-based 2
(YRC) 2
signal-peptide 2
DBNs 2
http://noble.gs.washington.edu/proj/philius. 2
http://www.yeastrc.org/philius, 2
YRC 2
http://www.yeastrc.org/pdr. 2
alphabets 2
probabilities, 2
(MEMSAT3) 2
http://bioinf.cs.ucl.ac.uk/memsat. 2
(HMM-TM) 2
TMHMM, 2
SignalP, 2
cross-prediction 2
Phobius. 2
26.1% 2
19.0% 2
TMHMM/SignalP, 2
isochore-like 2
isochore, 2
amniotes 2
nonadaptive 2
AT-rich) 2
archosaurian 2
reptiles 2
clawed 2
tag) 2
build. 2
Isochores, 2
replicon. 2
than) 2
GC4 2
soybeans 2
megabases; 2
"isochore" 2
rerio 2
homogeneous? 2
statistical/mathematical 2
subwindow 2
taxanes: 2
nucleus--and 2
activation--of 2
motility-based 2
S670 2
GRK2-K220R 2
GRK2-S670A 2
GRK2/HDAC6-mediated 2
outs 2
α/β 2
(tubulin 2
protein/p25) 2
Lys-40, 2
vinblastine, 2
GRK2-HDAC6 2
(GPCRs), 2
colorful 2
HMGN2 2
miR-23a. 2
Sialyl 2
(sLe(x)) 2
(sLe(a)) 2
Ser62 2
CDX2. 2
sLe(x/a). 2
cellularly 2
AMCM-induced 2
factor-beta. 2
factor-beta-induced 2
(89.5%), 2
TGF-alpha, 2
(COX)-2-derived 2
factor-BB, 2
ERK1/2-specific 2
8-Br-cAMP, 2
IBMX, 2
Rp-cAMP, 2
PGE2. 2
SC-58635 2
COX-2-derived 2
IGF-IR-stimulated 2
neomorphic 2
(TGF-betas) 2
confluency 2
epithelium-to-mesenchyme 2
subconfluency. 2
c-src 2
AFT1: 2
AFT1-1up, 2
AFT1-regulated 2
(PyPuCACCCPu) 2
FRE2, 2
FTH1 2
CCC2. 2
extracytoplasmic 2
reductases. 2
Ferrous 2
oxidase-FTR1 2
(Yamaguchi-Iwai 2
14: 2
1231-1239, 2
URA3, 2
IRO1 2
(Chen, 2
Crisp, 2
Valachovic, 2
Bard, 2
Winge, 2
Kaplan, 2
29513-29518). 2
Atm1, 2
Nar1, 2
Cfd1, 2
Nbp35. 2
Atm1-depleted 2
NAR1, 2
CFD1, 2
NBP35 2
SMF3 2
MRS4 2
TGCACCC 2
monothiol 2
bathophenanthroline 2
sulfonate, 2
(55)Fe(II) 2
Fe/S 2
Yah1p-depleted 2
UV-vis 2
nanoparticles, 2
DMPK, 2
(R14del) 2
DES. 2
FDCM 2
TNNT2. 2
muscle's 2
SERCA2a-PLN 2
unleased 2
70-75%. 2
1-108 2
hypomotor, 2
versive, 2
manifestations; 2
treat: 2
frontally 2
near-to-continuous 2
Slowing 2
indonesian 2
235730) 2
under-reaction 2
sociable 2
demeanor. 2
hypogenesis 2
media; 2
[Mowat 2
(1998); 2
35:617-623], 2
2q21-q23 2
rearrangements) 2
Walker-Warburg 2
oro-facial-digital 2
FOXG1B 2
anomaly/mental 2
earlobes, 2
sling) 2
(ZFHX1B), 2
Enhancer-associated 2
Trithorax-related, 2
Mll3/Mll4. 2
Set1), 2
enhancers: 2
dSet1, 2
Trithorax, 2
Trithorax-related 2
(Trr). 2
Mll3 2
c-Jun-bound 2
(Egr2/Krox20) 2
Egr2-binding 2
cauliflower 2
(H3K4me3). 2
Super 2
Cancers, 2
super-enhancers? 2
(SEs), 2
stretch-enhancers, 2
∼12,000 2
(∼400 2
12q 2
adenocarcinomatosis 2
Li-Fraumeni/SBLA 2
leukaemias, 2
adenocortical 2
22q11, 2
nephew 2
Li-Fraumeni-Syndrome 2
periadrenal 2
Ultrasonography, 2
oligomenorrhea/amenorrhea 2
Microadenomas 2
galactorrhea). 2
conservatively, 2
uneventful, 2
Hachimijiogan, 2
Base-excision 2
extruded 2
rotate 2
kink 2
U:G 2
U:A 2
N6-Methyladenine 2
pseudo-Watson-Crick 2
(hTDG). 2
TDG 2
C-DNA 2
methylmethanesulfonate, 2
ethenobases. 2
tightly, 2
cooperatively, 2
salt-dependence 2
Mug. 2
tremendously. 2
Thyronamines--past, 2
(TAMs) 2
trace-amine 2
TAMs, 2
(3-T(1)AM) 2
(T(0)AM), 2
T(1)AM: 2
cDNA-expressed 2
SULTs 2
SULT1A3 2
T1AM, 2
SULT1E1 2
EGFR-directed 2
BMS099 2
anti-Her-2 2
panitumub, 2
nimotzumab, 2
PLF. 2
benefiting 2
n=7; 2
n=8. 2
(13.3 2
PLF, 2
paclitaxed 2
0.332). 2
1124 2
covariate, 2
ch806, 2
(DLs) 2
(MTD). 2
43-82), 2
11-47) 2
DL 2
STAT-3. 2
[Targeting 2
receptor(s), 2
HN 2
matuzumab), 2
pan-inhibitors 2
HKI 2
PKI 2
EKB-569, 2
AEE-788), 2
dose/schedule 2
paronychia, 2
(RR=0%, 2
0-9.5%), 2
Toxicity, 2
2=6, 2
1=7) 2
1=4). 2
transduction; 2
lowest-dose 2
PRs 2
80%-90% 2
(IgG(1)) 2
matuzumab-related 2
(panitunumab, 2
matuzumab) 2
569) 2
(ABG-EGF), 2
EGFR-targeting 2
hK3, 2
hKLK3, 2
nonprostatic 2
multifarious 2
LDs' 2
LDs. 2
droplets) 2
(FAs) 2
non-adipocyte 2
Model), 2
inverted, 2
Reasons 2
1993-2006, 2
PBN, 2
nitrone-based 2
NXY-059) 2
(SAINT-II). 2
mumol/L 2
(OGD) 2
NXY-059: 2
20-45 2
(55-75 2
(dosing 2
7-hour 2
chloride; 2
(steady 2
100,200, 2
Linearity 2
questioning), 2
20-26 2
kg/m(2)]). 2
Cu(ss) 2
98.3 2
[8.9], 2
202.1 2
[18.3], 2
287.9 2
[25.4] 2
Chinese:white 2
1.077 2
1.009-1.150]). 2
linearity. 2
(thirst 2
[each 2
placebo]; 2
NXY-059]). 2
Today 2
trap/radical 2
thing? 2
combinational 2
(ultrasound 2
bat, 2
7-category 2
NINDS, 2
disappointment 2
(Stroke 2
(FDA/NIH), 2
discipline 2
devote 2
nature-target 2
neuroprotectant, 2
Stroke-Acute-Ischaemic-NXY-Treatment 2
(SAINT-I) 2
reinvigorated 2
SAINT-II 2
3-period 2
(mRS), 2
(bed-bound, 2
mRS; 2
index; 2
(Cochran-Mantel-Haenszel 2
P=0.002, 2
(37.6%) 2
SSEs, 2
agonist/5-HT2A 2
copulation 2
marmosets. 2
Desire 2
male-female 2
pairmates. 2
restraint. 2
8-OH-DPAT-treated 2
pair-bond 2
bid), 2
qd) 2
(http://www. 2
definitional 2
spent, 2
ID-I 2
(p27) 2
[125I]T3 2
DTT. 2
PTU. 2
RAD18, 2
Lys164, 2
monoubiquitylated 2
FANCL-catalyzed 2
FANCL-mediated 2
ATR-binding 2
ATRIP. 2
TopBP1 2
(CC), 2
FANCD2-FANCI 2
(FancA/C/E/F/G/L) 2
monitor, 2
investigated: 2
iminobiotin, 2
deferioxamine, 2
allopurinol, 2
xenon, 2
neuroprotectants, 2
11.06 2
(birth 2
asphyxia). 2
(ALLO; 2
xanthine-oxidase 2
(microM), 2
(MDA; 2
CBV; 2
mL/100 2
electrocortical 2
(ECBA) 2
microvolts 2
ECBA 2
Nonprotein-bound 2
ALLO-treated 2
CBV-CONT 2
CBV-ALLO 2
ECBA-CONT 2
ECBA-ALLO 2
ECBA. 2
illnesses: 2
titles, 2
"euthyroid 2
(ALS/control, 2
3.91 2
(CSTs) 2
age-similar 2
(CSTs, 2
fasciculi 2
[SLF], 2
callosum) 2
CSTs 2
CST 2
neuroimaging-based 2
blood-based 2
iSCI 2
CCS 2
(ASIA) 2
NfL: 2
CT+ 2
CT- 2
NfL, 2
(Aβ42), 2
Society/American 2
injury), 2
(intrathecal 2
immunoactivation) 2
CSF/Plasma 2
(blood-brain 2
integrity) 2
200), 2
(cART) 2
85), 2
204). 2
cells/μL. 2
Neopterin 2
aging-like 2
tells 2
boxers. 2
non-boxing 2
Span, 2
(NfH(SMI) 2
electrochemiluminescence-based 2
820 2
(47.7 2
(1055 2
0.256). 2
(28.3 2
0.086). 2
biofluid 2
Guillain-Barré-syndrome 2
(79.4 2
n=46) 2
CP) 2
n=68, 2
n=67, 2
(r=0.48, 2
p=0.033), 2
(r=0.79, 2
(r=0.70, 2
(r=0.11, 2
p=0.3739). 2
91.3% 2
91.0%. 2
(NfL(Umea47:3)); 2
NfH(SMI35) 2
CIS 2
(T-tau), 2
<16 2
2000-2010 2
Laboratory, 2
(bvFTD). 2
(PNFA), 2
tau-positive. 2
PNFA), 2
tau-negative, 2
tau-positive) 2
p=0.017). 2
5,542 2
(P-tau), 2
large-caliber 2
P-tau 2
NFL. 2
T-tau. 2
in>80% 2
(EDSS, 2
women? 2
EAD. 2
ILOCA. 2
(5-HIAA), 2
(MHPG) 2
ng/L, 2
42.5 2
(LOCA). 2
prognosis: 2
(1,334 2
(distant 2
anti-CXCR4 2
CXCR4-CXCL12 2
CD4, 2
CXCL12-induced 2
BMS-936564/MDX-1338 2
CXCR4. 2
(C-X-C 2
Node-positive 2
7.5-fold) 2
(<7.5-fold). 2
CLM. 2
CLM 2
Sentinel 2
Node 2
centripetal 2
(TRs), 2
TH-activated 2
pups, 2
Serca-2 2
Endocrinología 2
Nutrición. 2
reshapes 2
mmHg/s) 2
2,035 2
SERCA/Phospholamban 2
1.98 2
hypothyroxinemia 2
(beta- 2
destroyed) 2
(intact 2
thyroid) 2
septation. 2
74.1 2
(D(2)) 2
(aortic 2
Ca(2+)-adenosinetriphosphatase 2
SR-dependent 2
gestation-associated 2
(SR 2
Ca(2+)-ATPase) 2
isograft 2
pigments. 2
betalains 2
MBW 2
beets. 2
co-option 2
Phytolacca 2
americana. 2
bHLH, 2
exome-sequencing 2
Tbc1d24 2
TBC1D24. 2
CIHR 2
(Canada), 2
NIHR 2
Trust, 2
Henry 2
Charity, 2
Campeau 2
transcervical 2
Syncytiotrophoblasts 2
electrophoresis/Tandem 2
(SELDI-TOF/MS) 2
Desorption 2
Flight/Time 2
(MALDI-TOF/TOF) 2
glyco 2
MeDIP 2
placentally 2
adopted: 2
pre-selected 2
(AIRE, 2
1q32.1 2
(CD48 2
FAIM3 2
2p14 2
(ARHGAP25 2
12q24 2
(SELPLG 2
Bisulphite 2
abnormalities: 2
NIFTY) 2
certain, 2
japonica. 2
CxxC 2
H3K4me3. 2
iPABP. 2
proteins-1 2
(PABP1 2
PABP4) 2
Stably 2
turnip 2
PABP2 2
TuMV 2
potyvirus 2
TuMV. 2
pab2 2
mM-Na+ 2
protofibrils 2
Sinonasal 2
teratocarcinosarcoma 2
SNTCS. 2
recurrence; 2
calcination, 2
35-55 2
IFs). 2
α-keratins 2
hagfishes, 2
stiffer 2
(NFs) 2
10-nm-diameter 2
sidearm 2
sidearms 2
interfilament 2
caliber. 2
sidearms. 2
tunneling 2
(STM) 2
24-25 2
(IFs). 2
(cryo-EM) 2
microdiffraction. 2
Angstroms 2
templating 2
model", 2
cryo-transmission 2
hydrated, 2
subfilametous 2
consists, 2
corneocytes 2
subfilament 2
subfilaments 2
(antioxidants, 2
supplements) 2
Carnitine 2
unresponsiveness, 2
ankle-brachial 2
adventitial 2
(progerin) 2
NCT00094393.) 2
clock-deficient 2
Cry-null 2
Hsd3b6. 2
Cryptochrome-1 2
(Cry1) 2
Cryptochrome-2 2
(Cry2) 2
(Cry-null 2
(mPer1 2
mPer2) 2
(mCry1 2
mCry2) 2
mPer2, 2
cryptochrome-deficient 2
multi-unit 2
cryptochrome-1 2
clock-related 2
arrhythmic. 2
Cry1-/- 2
E-box-mediated 2
(wavelength 2
dish. 2
oscillator, 2
"molecular 2
nutrient-responsive 2
(3'UTR) 2
PERIOD2 2
(Cry1(-/-) 2
12:12-h 2
ZT18 2
Cry1(-/-) 2
ZT22 2
box) 2
Cry1-proximal 2
(RREs) 2
phase-vector 2
(Per1/2) 2
(Cry1/2) 2
promoter-binding 2
(Dbp) 2
(Pparg) 2
arteries; 2
(Rev-erba), 2
kidney; 2
contraction-related 2
subordinated 2
transcriptional/translational 2
(Per1 2
FBXL3-mediated 2
USP2a, 2
Usp2a 2
F-box/leucine 2
rich-repeat 2
(Fbxl3)-deficient 2
long-circadian 2
Rev-Erb/retinoic 2
(RRE)-mediated 2
Rev-Erbα:histone 2
summer: 2
57,559 2
1.11/100 2
procedures); 2
24,466 2
0.88/100 2
procedures), 2
33,093 2
1.29/100 2
380; 2
41; 2
cocci, 2
0.008; 2
laminectomy/laminoplasty 2
residents) 2
intern 2
"August" 2
Examinations 2
[142 2
119; 2
69; 2
minted 2
(summer 2
orienting 2
(275 2
(185 2
25.3% 2
quarter. 2
DATA: 2
July: 2
difference-in-difference 2
1353 2
(18.8% 2
(22.5% 2
1.9% 2
P=0.45) 2
P=0.21). 2
teaching- 2
May. 2
month-to-month 2
effect") 2
(1998-2003). 2
outcomes-the 2
Effect;" 2
HNCA 2
Rhinological 2
0.9) 2
(ENU). 2
stab 2
ENU-exposed 2
SVZ. 2
neuroepithelia 2
subculture, 2
VEGFR1, 2
Neuropilin-1 2
SGZ 2
corpuscles. 2
nestin⁺ 2
(VZ/SVZ). 2
Dnmt1's 2
M1235S 2
5-cytosine 2
5-hmC 2
redox-dependent 2
ddm1/DDM1 2
ddm1/ddm1 2
DNMT1-mediated 2
flip-out 2
(-CH(3)) 2
DNMTs-DNMT3A, 2
DNMT3L-was 2
(SNRPN, 2
PLAGL1) 2
size-dependent 2
Cp, 2
Cp. 2
(291-1620) 2
S-adenosyl-L-homocystein. 2
S-adenosyl-L-methionine, 2
coprecipitate 2
(Usp7), 2
KIR 2
lupus-like 2
CD70 2
quinoline-based 2
SssI 2
SGI-1027 2
CHK1, 2
Gelfiltration 2
elutes 2
co-immunoprecipitations 2
310-629) 2
co-ordinated. 2
5)-1 2
AtT-20. 2
Nnat 2
changeable 2
S515 2
(S515A) 2
(S515E), 2
S515E 2
(EKIYIS(P)KIVVE) 2
non-phosphorylated 2
TDNMT3a 2
(56-78 2
(16-48 2
(73.2 2
(75.4 2
(52.7 2
nonsmokers 2
(58.1 2
(C-->T) 2
hemimethylation 2
M-MTases, 2
ProDom 2
PD003757, 2
DNA-replication 2
Met1/Dnmt1 2
Volvox, 2
perpetuates 2
methylation-only 2
silent) 2
(cytosine-5) 2
doxorubicin-mediated 2
demethylase(s) 2
ion- 2
reinvestigation 2
genome-wide/local 2
re-activating 2
(RFTS) 2
(Dnmts) 2
(Dnmt3a, 2
Dnmt3L). 2
CGC 2
AER. 2
(TERalb), 2
plethysmography. 2
(TC, 2
0.615; 2
LXRs 2
repeat-4 2
LXRE2 2
reciprocally. 2
S14 2
EE, 2
Tissue-specific 2
PV/TRpbeta1 2
TR-mediated 2
NADPH:cytochrome 2
promoter/chloramphenicol 2
beta1) 2
Synorth: 2
Synorth 2
http://synorth.genereg.net/ 2
categorizing 2
chordates 2
Fgf17, 2
Fgf24 2
radiation; 2
unearthing 2
BLAST-like 2
KCL 2
CICU 2
[K(+)] 2
(0.30 2
L/min/m(2); 2
=.55). 2
(-8.59 2
g/cm(2); 2
=.033) 2
=.11), 2
=.0003) 2
anthracycline-exposed 2
Afterload 2
TGA. 2
s/p 2
ramp 2
W/kg/min) 2
(VO2), 2
(SVI) 2
Two-tailed 2
(rest/peak), 2
afterload, 2
(14.5+/-6.2 2
d[-1], 2
(6.4+/-2.6 2
6.7+/-2.6 2
[placebo]). 2
(102+/-34% 2
125+/-34% 2
[placebo]; 2
P<.02). 2
(3.5+/-0.9 2
3.8+/-0.9 2
(18.3+/-9 2
20.5+/-7 2
(57.5+/-17 2
55.4+/-19 2
(247+/-181 2
261+/-197 2
[placebo]) 2
enalapril]. 2
(These 2
Benalapril) 2
(Fontan 2
digitalis). 2
unserious 2
cough). 2
physiatrist 2
5-41) 2
symptom-free, 2
(LVEFs) 2
25-40%. 2
LVEFs 2
vomited, 2
enalaprilat 2
u.m2, 2
failure" 2
steroid-dependent 2
tacrolimus. 2
ovariectomy. 2
ovx 2
TNF-producing 2
THX, 2
tried, 2
tacrolimus, 2
(22.6%). 2
ibandronate 2
PAO 2
(chromogranin 2
positivity) 2
TTF-1, 2
(pNET) 2
West, 2
50), 2
93.6 2
Secretogranins, 2
(chromaffin) 2
Vasostatin 2
(Euro 2
Diagnostica, 2
NEOLISA 2
(GEP-NEN). 2
GEP-NEN 2
87.5%, 2
(HFD). 2
adiposity, 2
IR(fl/fl) 2
(CHGA)-positive 2
PNETs. 2
25-164) 2
39-94) 2
27-9021), 2
91.9%, 2
CgA, 2
CgA. 2
histopathologically. 2
synaptophysin; 2
non-Africans 2
subcentromeric 2
stalk-eyed 2
Teleopsis 2
field-collected 2
latitudinal 2
balsam 2
poplar, 2
Argonaute-2 2
simulans, 2
30-100 2
transporter-4 2
(SLC2A4) 2
Wing 2
"hotspots" 2
genotype-by-phenotype 2
genealogies 2
Consider 2
Appl 2
Probab 2
hitchhiking, 2
breed-defining 2
warblers. 2
warbler, 2
warbler 2
MC1R) 2
subdivision, 2
demes: 2
(-24 2
(P=0.03, 2
h=1/2, 2
co-dominant. 2
[0, 2
co-dominant 2
2hs. 2
√(N/s) 2
'soft' 2
sweeps, 2
(PRSs) 2
Nucleotides 2
(PRPS1), 2
overproduction, 2
Postlingual 2
(J.C., 2
beta-carotene, 2
0.99-1.02), 2
0.88-1.14), 2
development/presence 2
(January/1949-March/2012) 2
reviewers). 2
toenail 2
1.69-2.37). 2
homocysteine) 2
Q10-supplemented 2
0.35, 2
antioxidation 2
Beta-Carotene 2
beta-carotene-supplemented 2
Alpha-tocopherol 2
selenite, 2
Se-methyl-selenocysteine 2
41.1 2
.65), 2
1.14; 2
1.01; 2
.93). 2
Predictably, 2
1.95; 2
1.83; 2
prevention; 2
1.22), 2
5-amino-imidazole-4-carboxamide 2
riboside, 2
AUUUA-mediated 2
lymphokines 2
five-nucleotide 2
(ELAV) 2
members; 2
Hel-N1, 2
HuC 2
HNS, 2
(KNS) 2
translatability, 2
(NF1-PBRs, 2
NF1-protein-binding 2
NF1-PBR1. 2
(RRM1 2
RRM2), 2
(RRM3). 2
AREs. 2
ARE, 2
AUUUA-containing 2
U-stretch-containing 2
AUF1), 2
(t1/2 2
run-off 2
(HSP72) 2
(nucleotides 2
S88, 2
alpha-dependent 2
adenosine-5'-O-(3-thio)triphosphate-induced 2
shuttling. 2
epiblast-induced 2
pseudoglandular 2
Tbx4. 2
Fgf10 2
Tbx4 2
FGF9. 2
(HL). 2
antimiR-9 2
ZFP36) 2
(ELAVL1), 2
(AU-rich) 2
non-tumourigenic 2
MiR-29a 2
TTP:HuR 2
restrains 2
RNA-immunoprecipitation 2
(RIP)-Chip 2
A1-RNPs 2
HuR-depleted 2
pre-spliced 2
counterpart) 2
A1-RNPs. 2
downmodulates 2
RNASEL-null 2
(UTR), 2
ligand(s) 2
enterocolitis, 2
Elavl1-/- 2
(CARM1) 2
(HDFs), 2
CUG-binding 2
(CUGBP1) 2
HuR-governed 2
LY3009104 2
INCB028050), 2
dose-linear 2
time-invariant 2
(baricitinib, 2
INCB-039110) 2
transection 2
tyrosinated 2
(mRNA 2
3,5,3'-triiodothyronine, 2
posttrauma, 2
sympathoadrenal 2
antioxidant) 2
nonproteasomal 2
(K)-63-linked 2
(polyUb) 2
cumbersome. 2
K11, 2
K63Ub-modified 2
polyUb. 2
Chains 2
(K48) 2
(K63) 2
K48- 2
NONOate 2
Lys(48)-linked 2
(heat-shock 2
70-interacting 2
paracrine) 2
preconcentration 2
(ABA) 2
oligonucleotidesable 2
bio-ABA 2
elution, 2
non-B-DNA 2
biotinylation. 2
Biotin 2
Thermo 2
selections. 2
aptamer-functionalized 2
nano-bio-probe 2
AS1411 2
CdTe 2
NPs). 2
mL(-1) 2
antibody-mimicking 2
immuno-magnetic 2
hIgG 2
agarose. 2
magnets 2
(ConA) 2
mannoside. 2
Neville. 2
LC-ESI-MS/MS. 2
(NT-proBNP). 2
carboxylic-modified 2
(HOOC-MBs) 2
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 2
N-hydroxysulfosuccinimide 2
(sulfo-NHS), 2
microplates 2
HNE. 2
pM 2
botanical 2
(maltase, 2
invertase, 2
lipase) 2
1-(3-dimethyl-aminopropyl)-3-ethyl-carbodiimide 2
N-hydroxysuccinimide 2
HSPC 2
-coated 2
data-dependent 2
533 2
renewal, 2
antibody-targeted 2
Nonetheless 2
magnetically 2
enrichment). 2
Capture-SELEX 2
(SuBLiME), 2
biotin-labeled 2
streptavidin-coupled 2
SuBLiME 2
FIPs 2
FIP-nha 2
LZ-8 2
His-affinity 2
Flammulina 2
rLZ-8, 2
rFIP-nha 2
hemagglutinating 2
rLZ-9 2
biosensor. 2
streptavidin-modified 2
over-treatment, 2
sICAM-1 2
sVCAM-1 2
mU/l), 2
LILACS. 2
congresses 2
anxiety-induced 2
myocytic 2
calcium-ion 2
48±94 2
(sudden 2
arrest) 2
clue. 2
CPVT-like 2
14q31-32. 2
(c.161A>T 2
[p.Asn53Ile]) 2
(c.293A>G 2
[p.Asn97Ser]) 2
p.Asn97Ser 2
calmodulin-binding-domain 2
autopsy: 2
autopsy-negative 2
SUD, 2
(SCD)-predisposing 2
iPSCs-CMs 2
(ACA), 2
flecainide: 2
unreliable, 2
CPVT-1 2
interrogations 2
beta-blocker/verapamil 2
120), 2
R3570W 2
uniform, 2
blocker-inducible 2
Channelopathies. 2
option; 2
(ECC) 2
after-depolarisations, 2
answers? 2
Ca2+-activated 2
single-residue 2
R2401H 2
("channelopathy"), 2
outflow-tract 2
(RVO-VT). 2
pathoanatomy, 2
receptor/calcium 2
(SCD): 2
(CCD) 2
suramin, 2
C170HM2 2
5-fluorouracil/Leucovorin 2
stage; 2
exit, 2
p70S6kinase 2
tumor-endothelium 2
tumor-matrix 2
RAD001-VPA 2
monotreatment 2
MDA-MB-468 2
deactylase 2
MDA-MB-231-BR 2
catastrophe 2
PCI-24781-induced 2
Rad51, 2
molecular-based 2
butyroyloxymethyl-diethyl 2
(MVD) 2
4T1 2
(P<0.02). 2
22Rv1 2
AN-7-treated 2
(HDAC). 2
(MMP)-2, 2
NaB-treated 2
Closer 2
angiotensin-II, 2
(Ca(2)(+)) 2
(FFR) 2
FFR, 2
Z-disk 2
(mlp84B) 2
wings. 2
(MLP, 2
(CSRP3, 2
CRP3)) 2
muscle-specific-expressed 2
79:221-231, 2
mechanisms-how 2
sarcomere: 2
mechano-sensory 2
stretch-sensing 2
Mlp84B-deficient 2
telethonin. 2
21.6+/-6 2
(DHPLC), 2
MLP-mutation 2
DCM-associated, 2
MLP/TCAP-associated 2
myofilament-HCM. 2
myofibrillogenesis 2
(muscle-LIM-protein) 2
(MLPKO) 2
relengthened 2
slack 2
mtDNA/nuclear 2
fibroelastosis. 2
Q9R 2
alpha-actinin-2. 2
LIM1 2
Protein-binding 2
(SLIM1) 2
sheet 2
Pressure-volume 2
pressure-strain 2
Transmural 2
lim 2
T-cap 2
(ex19del 2
ex19del 2
AZD9291. 2
threonine(790)-methionine(790) 2
EGFR(L858R,T790M) 2
MK-2206 2
T790M-containing 2
EGFR-WT 2
EGFR-TKI: 2
Post-progression 2
(PPS) 2
(26.8 2
Wnt/β-Catenin 2
T790M-mediated 2
Caspase-independent 2
Transmyocardial 2
bFGF-incorporating 2
miniswine. 2
none-treatment 2
self-made 2
factor-1(α) 2
(SDF-1(α)) 2
(CSC)-mediated 2
miniswine 2
miniswines 2
5-Bromo-2-deoxyuridine 2
upregulative 2
5-bromo-2-deoxyuridine-positive 2
FGF-2, 2
TB4) 2
Akt-MSCs, 2
Akt-MSC-mediated 2
factor-incorporated 2
(Sos), 2
Subtracting 2
fontanels, 2
LCT(4) 2
cysteinyl 2
FLT4 2
(SoS). 2
(LCRs), 2
(NAHR) 2
(SoS19) 2
(SoS109) 2
29-kb 2
(SoS44). 2
1.9-Mb 2
SoS19, 2
SoS109, 2
28-kb 2
SoS44. 2
NAHR 2
repeat-related 2
deletions/duplications. 2
3-5, 2
9-13, 2
19-21, 2
specialities 2
(MEN1)-associated 2
(Men1(+/-)). 2
(Men1(+/+)) 2
5-bromo-2-deoxyuridine 2
anti-BrdU 2
Pancreatic, 2
0.999. 2
lactotrophs 2
(<2%), 2
somatotrophinomas 2
endocrine-specific 2
1? 2
counsel 2
nonsense), 2
Furthermore. 2
SSCV 2
Md. 2
anti-VEGF-A 2
Men1-related 2
parathyroids, 2
Candidates 2
SCA3. 2
hemispheres, 2
SCA3-associated 2
deubiqutinating 2
(PolyQ) 2
glutamines, 2
PolyQ 2
inhibitor-779, 2
peptidase-15, 2
peptidase-15 2
DUb 2
Ataxin-3, 2
Machado 2
Joseph 2
(AT3) 2
aggresomes 2
(SAXS) 2
(SCA3/MJD), 2
historical, 2
MJD, 2
ataxias 2
keystone 2
transposon-genome 2
Hildenborough 2
anaerobe 2
aeruginosa. 2
method), 2
γ-proteobacterium 2
MR-1. 2
pathogenomics 2
TEA 2
(CIMT) 2
CIMT. 2
hyperandrogenic 2
NS4B, 2
NS5A, 2
NS3-catalyzed 2
unwinding. 2
Contradictory 2
31-amino 2
NS3+NS4A 2
two-column 2
(SR-B1) 2
CD81, 2
Popular 2
(inhibited 2
boceprevir) 2
autoprotease, 2
NS4B 2
NS2B 2
3F8, 2
K(d.) 2
2.5μM. 2
fascile 2
non-nucleoside, 2
Bloom, 2
replication), 2
DSBR 2
C18067T 2
A17893G 2
A4541G 2
(HBV)-related 2
PML), 2
HBsAg-transgenic 2
HBV-related 2
tumourigenesis, 2
surveys, 2
0.737/10,000 2
0.797 2
outlier, 2
0-14 2
1:9200 2
1:6600; 2
15-24 2
1:13,200 2
1:7600; 2
1:56,600 2
1:12,400. 2
predicted) 2
Uruguay 2
individuals/100,000 2
D1152H, 2
W1089X, 2
IG-->A 2
9,430 2
1:28, 2
1:42 2
Sephardi, 2
African, 2
(46.3%) 2
W1282X 2
delF508; 2
G542X; 2
3849 2
10Kb 2
(C-->T; 2
(5.3%) 2
D1152H; 2
N1303K; 2
IG-->A; 2
W1089X; 2
S549R. 2
1717-1G-->A, 2
G85E, 2
T360K 2
7,383, 2
1,558, 2
nonperfusion, 2
preretinal 2
discussed: 2
13-day-old 2
swirled 2
activin, 2
TGF(beta+) 2
(Ptc1), 2
Shh(-)(/)(-) 2
(hh) 2
pointy 2
denticles, 2
(SHH), 2
(DHH) 2
(PTCH1 2
PTCH2) 2
GLI2 2
GLI3. 2
FOXE1 2
97.6% 2
divergent. 2
tIssue 2
TAKA-1 2
CSC-related 2
(HIF-1α). 2
mTOR-HIF-1α-VEGF 2
radiosensitization. 2
mTORC1/2 2
AZD-2014. 2
(3-MA) 2
(PV), 2
stomatitis. 2
P27, 2
mTOR/P70S6K 2
Hyperplasia 2
Mellitus. 2
PAVSMC 2
PAVSMCs 2
Nox4-dependent 2
Association: 2
BACKGROUND- 2
2-item 2
(PHQ-2) 2
RESULTS- 2
0.93) 2
0.59) 2
CONCLUSIONS- 2
(PHQ). 2
(26.8%) 2
inpatients: 2
(PHQ-2 2
well-accepted, 2
Elmhurst 2
(Queens, 2
York). 2
Suicidal 2
nurse-administered 2
92.6%, 2
93.4% 2
-dependent, 2
NusA, 2
bisulfite-sensitivity 2
(R-loops), 2
nusG 2
FACT-depleted 2
conflicts, 2
412) 2
G(2)-specific 2
(phosH3) 2
phosH3 2
(Singh 2
(HP1(beta)) 2
(HP1(beta)), 2
HP1(&agr;) 2
PEV-modifier 2
Su(var)3-9. 2
Schizosaccharyomyces 2
clr4. 2
Chromatin-dependent 2
centromere) 2
silenced-a 2
(PEV). 2
non-centromeric. 2
Adipogenic 2
laser-printed 2
Laser-assisted 2
(LaBP) 2
LaBP 2
ECM-derived 2
cytocompatible 2
(SF-G) 2
gelatin. 2
PEG-HA 2
sulfolobus 2
thermoacidophiles 2
β-D-glycosidase 2
(lacS) 2
(pJlacS) 2
Lac(-) 2
slipped-strand 2
pRN1 2
(chain 2
175-fold 2
frameshift-reversion 2
lys2-TAG 2
allele). 2
2.1- 2
47- 2
58- 2
52-fold, 2
zeta). 2
8-oxoGuanine, 2
≈50% 2
TOP1 2
Hotspots 2
Top1-dependent 2
Top1, 2
(pGAL1 2
pTET) 2
pTET- 2
pGAL1-driven 2
prefentially 2
5'-ACATAT-3' 2
Can(R) 2
1-deficient 2
(top1Δ) 2
(-2/-3nt) 2
RAD1 2
MUS81 2
Pharmacogenetics: 2
genotypes.The 2
testing.Significant 2
(anticancer, 2
psycotrophic, 2
drugs).Recent 2
5'-diphosphoglucuronosyl-transferase 2
mercaptopurine 2
cancer.Moreover, 2
osteoporosis) 2
estrogens). 2
response.Although 2
trials.The 2
bioethics 2
(Erbitux), 2
Herceptin's 2
epistemological 2
logistical 2
privacy, 2
(HER)-2⁺ 2
>96% 2
(neu, 2
erbB-2) 2
assurance, 2
False-positive 2
neu 2
anti-HER-2/neu 2
244.1 2
NCCTG 2
doxorubicin/cyclophosphamide 2
Originally, 2
mandatory, 2
85.8% 2
2,535 2
94.3% 2
immunoenzymatic 2
054 2
109/194 2
64%-81%] 2
36%-58%) 2
BiotHER-positive 2
3.848; 2
1.952-7.582), 2
0.438; 2
0.303-0.633] 2
0.566; 2
0.368-0.870) 2
(ETX), 2
handling-induced 2
AKAP-dependent 2
channels) 2
gasotransmitter, 2
(i.pl.) 2
AKAPI, 2
ZnCl(2) 2
electroencephalogram. 2
Theta 2
paclitaxel-evoked 2
cystathionine-γ-lyase 2
(CSE), 2
H₂S-forming 2
Ca(v)3.1, 2
oligodeoxynucleotides. 2
(DRG), 2
re-examines 2
1G, 2
1I. 2
1I 2
spike. 2
ZNS 2
TJMs 2
non-sedating 2
transitivity 2
microg, 2
intracisternal) 2
rat-tail 2
anticonvulsant. 2
Briefly 2
dihydropyridine, 2
non-dihydropyridine 2
(-)-gallopamil 2
tsA201-cells 2
alpha(1c)-, 2
alpha(2)delta-, 2
beta(1a)- 2
beta(2a)-calcium 2
gallopamil. 2
bradycardic 2
gallopamil, 2
Amlodipine 2
phenytoin. 2
NIHL 2
(55S) 2
rRNAs 2
Wada, 2
"mitoribosome") 2
(ETC) 2
55S 2
mitoribosome, 2
formaldehyde-fixed 2
cesium 2
g/cm(3), 2
(1.48 2
(1.74 2
monosome. 2
bacterial-type 2
Ec) 2
EF-G 2
equivalency 2
Ec 2
compositions. 2
PG-system 2
kaliyuretic 2
breakthrough, 2
DRIs 2
DRI 2
TAKE 2
HOME 2
MESSAGE: 2
(ARB), 2
enlighten 2
placebo-like 2
nonpeptide. 2
(PRA). 2
PRA 2
47-51%. 2
Hypotension 2
Aliskiren's 2
(cholesterol 2
magic 2
losartan. 2
Histone-like 2
Structuring 2
(H-NS) 2
mycoplasma, 2
condensing 2
symbiosis, 2
procaryotes. 2
beaded 2
Mobility 2
HMGs 2
"primitive" 2
DNA-packaging 2
dinoflagellates 2
IHF: 2
IHF, 2
vice-versa. 2
HU-less 2
inhibit) 2
trachomatis. 2
DNA-bending 2
inversion. 2
DNA-multiprotein 2
galDNA 2
tetramerization. 2
non-reactors 2
tuberculin. 2
PCR-amplified, 2
Myxococcus 2
HUB) 2
HU-beta 2
enterobacteria, 2
HUalphabeta, 2
sub-units 2
sub-units. 2
hupAB 2
synchrony, 2
dnaA46 2
(dnaA46ts), 2
(hupAB 2
background) 2
asynchrony 2
dnaAcos, 2
dnaA46hupAB 2
Visibly 2
homologues; 2
TF1, 2
SPO1, 2
Gln(TF1-K3Q) 2
TF1 2
TF1-K3Q. 2
TF1-K3Q 2
kinking. 2
saltbridge 2
Asp26 2
(cPHB). 2
(cPHB), 2
salt-solvating 2
solvating 2
anti-cPHB 2
operators. 2
rhodophyte 2
plastids, 2
architects 2
endosymbionts, 2
Horizontal 2
(Hlps) 2
dinoflagellate 2
Hlps. 2
proteobacterial 2
HU2-eYFP 2
Ripley's 2
K-test 2
swarmer 2
stalked 2
predivisional 2
NAPs. 2
ittle 2
[11C]MK-4232. 2
sumatriptan: 2
time-weighted 2
gepants, 2
(http://www.merck.com/research/pipeline/home.html). 2
antagonists: 2
(olcegepant, 2
MK-3207 2
TA) 2
between-treatment 2
(gepants)-olcegepant 2
(BIBN 2
4096 2
BS), 2
(MK-0974), 2
MK3207, 2
TA-are 2
NTG. 2
(AIx) 2
(BAD). 2
-18.50 2
(-21.02, 2
-15.98) 2
-17.28 2
(-19.80, 2
-14.76) 2
BAD 2
(1.12, 2
1.17) 2
BAD, 2
171), 2
38.3%, 2
Numerically 2
(Clinicaltrials.gov; 2
triptans: 2
naratriptan, 2
almotriptan, 2
frovatriptan, 2
flat, 2
nonvasoconstrictor 2
Background.- 2
(difference: 2
1585) 2
attacks; 2
poor/no 2
(44/111, 2
(tablet 2
successes, 2
organocatalysis 2
organocatalytic 2
cocatalyst 2
necessnary 2
stereogenicity 2
Doebner-Knoevenagel 2
C3-C4 2
desfluoro 2
impurities 2
<0.2%. 2
lactamization 2
t-BuCOCl 2
epimerization-crystallization 2
caprolactam 2
cleanly. 2
Isolating 2
2-24-hour 2
(SPF24NAE), 2
(SPR24NAE), 2
(PF2NAE), 2
(PR2NAE). 2
SPR24NAE, 2
PF2NAE 2
Zolmitriptan 2
SPR24NAE 2
PF2NAE, 2
SPR24NA 2
44370, 2
drug-the 2
tryptophan-84 2
infinity. 2
0.94), 2
BIBN4096BS 2
(olcegepant) 2
(telcagepant), 2
aliquot 2
microL 2
isocratic 2
PPT 2
Calibration 2
(5-ALA 2
PDT) 2
vitro-PDT 2
(KT21-MG) 2
A172, 2
T98G) 2
PDT-mediated 2
(PDGF-BB) 2
ALA-PDT. 2
photocytotoxicity 2
AlS2Pc, 2
0.019 2
tumor's 2
placed, 2
photosensitized 2
III/III 2
3H-TPP 2
dequalinium 2
5-Aminolevulinic 2
(HBL-52 2
BEN-MEN-1), 2
(FECH) 2
Photochemistry 2
reirradiation 2
lieu 2
(gliadel 2
temozolomide) 2
(TA121) 2
Wessex 2
Southampton, 2
TA121. 2
(55-60 2
(GBMs) 2
GKS 2
involved-field 2
(polifeprosan 2
[BCNU] 2
1013 2
wafer. 2
non-Gliadel 2
(2.8% 2
.33), 2
(4.9% 2
23.6 2
Wafers 2
(14.7 2
(12.9 2
2.73 2
165.1 2
80.75 2
Wafer 2
101.9 2
43.06 2
millimetres 2
implant, 2
(BCNU: 2
N,N'-bis[2-chloroethyl]-N-nitrosourea) 2
'treatment 2
EORTC-NCIC 2
(BCNU 2
(14.5 2
(11.7 2
carmustine, 2
case-matched 2
12,943 2
26-48% 2
contemporary, 2
pseudoprogression, 2
[Karnofsky 2
19-71 2
[total 2
(Gy)] 2
(4,6,8). 2
glue-secured 2
opened, 2
contra-indication. 2
[RISC]) 2
pairing, 2
(SRA) 2
NR-mediated 2
complexes), 2
(PACT). 2
(RISC). 2
dsRNA, 2
(DsiRNA). 2
UL29 2
653 2
immunostimulation 2
syringomyelic 2
unnecessary. 2
narrowness 2
malformation: 2
downbeat 2
(AAV1) 2
antegrade 2
[dP/dt(max)] 2
cancer/leukemia 2
FNACI, 2
FANCJ, 2
FANCN). 2
(mitomycin 2
chromatin-IP-based 2
eChIP 2
crosslink-specific 2
(BRCA2, 2
FANCJ/BACH1, 2
FANCN/PALB2), 2
I/D2 2
FANCN, 2
XPA 2
XPC 2
recombination-independent 2
FANC-core 2
oxidants, 2
(superoxide 2
FA-deficient 2
hydrocephalia, 2
erythrophagocytosis 2
oversensitivity 2
Radiosensitivity 2
total-body 2
radioprotector 2
postirradiation 2
FancG(-/-) 2
transgene-restored 2
(ñ 2
FANCC- 2
FANCD2-mutant 2
FANCC/FANCD2-mutant 2
features]. 2
hematologists. 2
(FANCD2), 2
(FANCJ/BACH1/BRIP1), 2
(FANCD1/BRCA2), 2
(BLM, 2
ATR) 2
melphalan). 2
Fanconi-defective 2
PL11, 2
individuals' 2
FANCJ. 2
(ICLs), 2
Biophys. 2
(1979) 2
Phys. 2
(1977) 2
(1993) 2
discoveries, 2
FANCG/XRCC9 2
NM3, 2
UV40 2
glycosylase-dependent 2
Environ. 2
Paolo 2
children), 2
seizure-free, 2
transplantations 2
LAM. 2
Rhabdomyoma 2
rhabdomyoma. 2
Asan 2
(SGCA) 2
SGCA. 2
NHLBI 2
3-yr 2
registry; 2
38.9 2
(Taylor's 2
IIb), 2
(HME) 2
TSC). 2
inspiration, 2
pleurectomy, 2
mucosas 2
1/10,000 2
Clobazam 2
(fMRI) 2
task-negative 2
acquisitions 2
debatable 2
(PVS) 2
cingulated 2
AR-HSPs 2
assaying, 2
(BN-PAGE) 2
(c.394C>T, 2
p.R132X) 2
HSPs. 2
(COXPD7) 2
C12orf65, 2
SPG4, 2
transplant-eligible 2
(DHAP), 2
second-line, 2
lymphoma? 2
aracytine, 2
(ASCT). 2
regimen: 2
[DHAP] 2
Solu-Medrol, 2
[ESHAP] 2
[GDP] 2
45%); 2
(COO) 2
(DLBLC), 2
(R-DHAP) 2
.04), 2
(ESHAP) 2
R) 2
(PCNSL). 2
thiotepa, 2
PCNSL, 2
R-DHAX 2
CD20(+) 2
Responding 2
hodgkin 2
unattenuated 2
(1-5 2
not: 2
CORAL 2
(ifosfamide, 2
cisplatin), 2
(R-ICE 2
R-DHAP). 2
lymphoma(NHL) 2
regimen(cisplatin 2
dexamthsone) 2
(44.4%) 2
30.8% 2
76-year-old 2
hyperostosis 2
SFTs 2
fascicles 2
7/10 2
1.5%). 2
glycogen-containing 2
Immunoreactivities 2
clinicopathologically 2
neoplasms]. 2
Postoperatively 2
[Meningiomas: 2
bodies]. 2
cisterns. 2
meningotheliomatous 2
1977-1985 2
arachnoid, 2
calcospherites 2
spicules 2
arachnoid. 2
Calcospherites 2
lobulated, 2
calcifying 2
vesicles), 2
Mineralized 2
microanalyzer, 2
(ACh), 2
release; 2
anti-VGCC-positive 2
VGCC. 2
anti-M1 2
mAChR 2
cancer--case 2
Eaton-Lambert 2
shoulders. 2
VCC 2
necrotic, 2
microvesicle 2
P2X7R 2
NAIP5/NLRC4 2
KF 2
inflammasome-independent 2
warheads 2
antipyroptotic 2
multitarget 2
foxo3a 2
CD36 2
(O 2
flagellin-detection 2
inflammasome; 2
thailandensis 2
forsythensis, 2
plaque-related 2
exopolymer 2
mulatta 2
edentulous 2
BTG/Tob 2
Tob/BTG 2
CCR4-associated 2
(Caf1), 2
hCaf1 2
ribonuclease. 2
endonuclease-exonuclease-phosphatase 2
(EEP) 2
single-wavelength 2
Pop2. 2
contains, 2
deadenylase/3'-5'-exonuclease 2
(mCAF1) 2
(y) 2
3'-5'-RNase 2
yCCR4 2
deadenylate 2
ycaf1 2
mCAF1. 2
yCAF1. 2
CAF1, 2
(deadenylases) 2
periosteum, 2
extrapulmonary 2
MSCT. 2
ovoid 2
gangliocytic 2
dismal, 2
t(11;22). 2
histogenesis), 2
(tumors 2
t(21;22)(q22;q12) 2
ESs 2
capB-lacZ 2
pX01 2
capBCAD. 2
pXO1(-) 2
pXO2-53; 2
NC002146.1:49418-50866), 2
AcpB 2
AcpA 2
acpB-null 2
atxA; 2
sigma(A)-containing 2
SigH. 2
as-yet-unknown 2
AtxA-controlled 2
bicarbonate/CO(2). 2
Institut 2
Pasteur. 2
atxA-lacZ 2
posttranslationally. 2
thuringiensis. 2
phosphatidylinositol-specific 2
C-derived 2
(CKD-EPI 2
73.9% 2
80+ 2
Die-P 2
CLP. 2
albumin-to-creatinine 2
(UACR) 2
(eGFRCrCyC), 2
FGF-23, 2
UACR, 2
eGFRCrCyC 2
Ninth 2
Revision, 2
(≥100 2
(eGFR(cys)). 2
slowness, 2
2.75) 2
2.87; 2
(IRR, 2
1.53; 2
eGFR(SCr) 2
(CysC/Cr) 2
(PCA). 2
PCA, 2
0.72) 2
0.78). 2
creatinine/cystatin 2
0.78) 2
Cockcroft-Gault, 2
mL/minute/1.73 2
EF. 2
glomerulopathies 2
California), 2
4.1) 2
68; 2
1,199 2
MICROS 2
6-parameter 2
Virga 2
(Virga) 2
(MDRD-4). 2
Creatinine-based 2
creatinine- 2
GFR-estimating 2
subject) 2
(RMSE 2
0.024), 2
(9.2%) 2
mg/L; 2
(1.05 2
CRUSADE 2
(eGFR; 2
ml·min(-1)·1.73 2
reclassifying 2
(GFR), 2
four-variable 2
CVD; 2
eGFR. 2
β-trace 2
genome-position-dependent 2
HilbertVis, 2
obstetricians. 2
academic-based, 2
practice), 2
societies, 2
history/experience 2
(86.1%) 2
GC-induced 2
contingently 2
triploidy, 2
47,XYY, 2
19,488 2
Bayesian-based 2
934/935 2
61.5-99.8%) 2
97.9-100%), 2
99.78%. 2
obeyed 2
99.71%. 2
guanine/cytosine 2
21--theoretical 2
(1/20) 2
XO(+), 2
del(X) 2
opinions, 2
survey; 2
items, 2
alternatives: 2
63.5%) 2
72.0%), 2
0.0094% 2
0.0064% 2
dominated: 2
€311.74 2
k€94 2
157% 2
€660.94 2
k€460 2
(k€141). 2
T21. 2
NIPT-negative 2
45,X[16]/47,XXX[14]. 2
8.54% 2
0.186) 2
4004 2
12-35(+5) 2
4003 2
(1.65%) 2
(T21), 2
(T18), 2
(T13), 2
(45,X/46,XN), 2
47,XXN, 2
46,XY,rec(14)dup(14q)inv(14)(p12q14)pat. 2
13/18/21 2
Motivations 2
adopter 2
varying, 2
sequencing-by-ligation 2
-3.0 2
(aneuploidy, 2
(unpublished) 2
assessment-related 2
agencies, 2
(Table 2
(II-2) 2
multiples. 2
(I-A) 2
Counselling 2
non-directive 2
(III-A) 2
[Cell-free 2
aneuploidies, 2
contingent, 2
(II-2E) 2
sonographers 2
sonologists 2
territory. 2
audited 2
trisomies. 2
packages: 2
IRanges, 2
GenomicRanges, 2
GenomicFeatures. 2
paralyses, 2
mass; 2
(SF36) 2
strategy; 2
pinacidil, 2
mannitol 2
Chronically, 2
dichlorphenamide, 2
potassium-sparing 2
acutely. 2
PSPP. 2
Diclofenamid 2
"permanent" 2
scale)returned 2
(0-3/5) 2
acetazolamide-resistant 2
dichlorophenamide 2
Cl-. 2
HOPP 2
BEH 2
SickKids, 2
aqueductal 2
(WISC-IV). 2
3.9) 2
ETV, 2
shunt) 2
WISC-IV, 2
confounder 2
(HUI3). 2
any. 2
version). 2
Vancouver, 2
mo). 2
202) 2
1984-1991 2
286) 2
H139R 2
(OR(no 2
exposure) 2
OR(≤3 2
hours/day) 2
0.52-3.34; 2
OR(>3 2
hours/day 2
3.18, 2
0.92-11.0; 2
P(trend 2
1.4) 2
fathers. 2
(CBTs) 2
IARC. 2
(1,218, 2
0-19 2
histotypes, 2
[<2,500 2
1.73; 2
1.06-2.84], 2
day: 2
4.71; 2
1.69-13.1), 2
preservatives 2
1.22-3.01). 2
1.04; 2
1.05-1. 2
40; 2
2.08; 2
1.08-3.98; 2
(CBTs). 2
Seattle, 2
WA 2
county). 2
dial 2
case:control 2
Seattle 2
nitrosamine-containing 2
incense 2
sidestream 2
1.5; 2
alvei, 2
opportunist 2
TLR4/MD-2/CD14-LPS 2
extraintestinal, 2
MBL. 2
H-ficolin) 2
interesting. 2
whites, 2
ficolin 2
ficolin-3. 2
ficolin-2 2
PCM 2
LPS/ficolin-3 2
C4b-deposition 2
magnesium-dependent 2
neoglycoconjugate 2
(BSA) 2
(NSCLC): 2
tremelimumab, 2
anti-melanoma 2
lambrolizumab), 2
pidilizumab 2
adsorptive 2
~6600 2
peptides/condition 2
phosphopeptides/μg) 2
specificity>94%. 2
anti-phosphotyrosine 2
2814 2
(IMAC) 2
Ppt1-deficient 2
sequence- 2
(TSLP) 2
4164 2
TSLP-dependent 2
(SCX) 2
(TiO(2)) 2
Kc167 2
phosphoramidate 2
E1A-mediated 2
hBre1 2
Rtf1 2
E1A-dependent 2
(PAF) 2
(CTR) 2
K123 2
hexapeptide 2
methylation-independent 2
(P-TEFb), 2
phosphorylation-site 2
cell-morphology 2
H2Bub1-deficient 2
H2Bub1-pathway 2
(ZNFs) 2
H3K36me3. 2
(Leu(116) 2
Leu(117)), 2
Lys(44), 2
Leu(116) 2
Leu(117) 2
6-azauracil, 2
SIR-regulated 2
shock-inducible 2
drug-inducible 2
YFR057w, 2
MDD-bipolar 2
(P<5 2
083-53 2
P=5.9 2
rs2535629). 2
Family-based 2
(AS3MT, 2
rs11191454) 2
overtransmission 2
AS3MT 2
rs11191454 2
rs52535629 2
(χ²=0.14, 2
P=0.707). 2
Mismatch-Repair 2
Deficiency. 2
"non-self" 2
colorectal. 2
[P<0.001], 2
[P=0.05]). 2
noncolorectal 2
(immune-related 2
patients]; 2
patients]). 2
1782 2
(P=0.007), 2
NCT01876511.). 2
anti-glutamic 2
dermoscopy, 2
alveolus. 2
Dermoscopy 2
dermoscope. 2
(RECIST, 2
full-analysis 2
NCT01295827. 2
(n=89) 2
(n=84). 2
doses--21 2
[37%]), 2
[18%]). 2
DNA? 2
(GT). 2
nucleotypic 2
Evolution© 2
225-fold 2
synchronously, 2
inactivation(1). 2
'chromosome 2
engineering' 2
chromosomes(5). 2
from(6). 2
micro-array 2
un-rearranged 2
Nod1ins/del 2
CCL20. 2
TNF-α-dependent 2
prematurity; 2
Nod1, 2
(iE-DAP), 2
GRO-α, 2
labor, 2
Nucleotide-oligomerizing 2
oligomerizing 2
NOD1's 2
(MNs), 2
CFUs 2
IL1β, 2
MDMs; 2
MNs 2
Atg9, 2
Mtb. 2
Tri-DAP. 2
pgdA(-) 2
NOD1. 2
Chlamydophila 2
FK156 2
DO11.10 2
dipeptide, 2
Alzheimer's-related 2
PAD4, 2
encephalopathies) 2
citrullination; 2
Non-enzymatic 2
deiminase. 2
HBP35 2
higher-energy 2
(HCD) 2
citrulline, 2
PAD. 2
arginine-containing 2
(deiminate) 2
ex-smokers, 2
(54.6% 2
(35.7% 2
33.6%). 2
0.581, 2
0.661, 2
0.424, 2
0.523, 2
deiminase-mediated 2
(PADs)-mediated 2
PADs, 2
upset 2
RA-specific 2
(RA)-specific 2
citrullinating 2
Heijde 2
once-obscure 2
peptidylarginine, 2
blow 2
idioventricular 2
third-degree 2
[Sudden 2
'commotio 2
cordis' 2
'concussion 2
concussion, 2
lacerations, 2
(1978-1983) 2
Examiner's 2
Detroit, 2
Michigan. 2
pediculosis 2
discerned. 2
doubt, 2
50years 2
21.57years. 2
reddish-brown 2
mechanically. 2
Parasitological 2
(lice 2
palpabrae) 2
blepharoconjuctivitis. 2
clothing. 2
exfoliative 2
nits, 2
protuberances 2
hyperpigmentary 2
lids 2
drops. 2
[Phthiriasis 2
phthriasis 2
infestations. 2
(nits) 2
undeveloped 2
shampoo. 2
beats/min) 2
(0.6-1.0 2
(CPA), 2
ryanodine-binding 2
(RyR)/Ca(2+) 2
HRCBP, 2
(DNAm) 2
shores'. 2
shore 2
C-DMRs 2
"shores." 2
(MeDIP-seq) 2
MeDIP-seq 2
(glial 2
shores, 2
[0.2] 2
(MASH-2): 2
centre) 2
mmol/day, 2
outcome-defined 2
Scale-3 2
(ISRCTN 2
68742385) 2
2006-003523-36). 2
follow-up), 2
Samplings 2
trade-offs. 2
0.75). 2
0.17). 2
0.07), 2
vasodilator. 2
SAH-induced 2
13/30(43%) 2
7/30(23%) 2
0.398, 2
0.131-1.211. 2
(Good 2
0.616-4.974.From 2
ours) 2
(Mantel-Haenszel, 2
Robins-Breslow-Greenland), 2
0.620, 2
0.389-0.987, 2
(IMASH 2
MASH2) 2
IMASH 2
magnesium-treatment 2
9.98 2
3.04-32.74). 2
hrs, 2
magnesium-treated 2
.002); 2
vasodilatation. 2
rCBV, 2
MASH-II 2
NMDA-receptor 2
0.328). 2
modifed 2
0.084), 2
1.0), 2
consents, 2
0.14. 2
Hunt-Hess 2
Glasgow, 2
.0003), 2
higher; 2
1.14). 2
1.09). 2
Mg++ 2
cm/second 2
MgSO4, 2
"magnesium 2
sulfate" 2
"MgSO(4)" 2
"subarachnoid 2
hemorrhage" 2
"cerebral 2
vasospasm". 2
co-authors 2
(Oxford, 2
dependency) 2
0.36-0.81]). 2
0.51-2.65]). 2
(0.25-1 2
(12.3 2
Plakoglobin 2
(Jup) 2
myocardia, 2
restrictively 2
keratoderma: 2
overcornification 2
compensational 2
cardiocutaneous 2
(HEK293) 2
S39_K40insS 2
(ARVC8) 2
plakophilin 2
(ARVC9) 2
signal-transducing 2
(ARVC). 2
ECG/echocardiographic 2
Milos. 2
contusion 2
73.7 2
-vehicle-treated 2
(O2 2
(∙-) 2
(TAI), 2
TAI, 2
(3.0mg/kg) 2
8-hydroxy-2'-deoxyguanosine, 2
0.3mg/kg 2
edaravone. 2
rats]. 2
(n=88), 2
(n=72), 2
weight-dropping 2
(p-ERK1/2) 2
terminal-deoxynucleotidyl 2
(pg/unit) 2
(2.05 2
4.40 2
6.70 2
(9.60 2
12.68 2
16.94 2
3.92, 2
25.82 2
4.61 2
2.61 2
0.58); 2
(119.8 2
25.0, 2
105.6 2
24.5, 2
21.8, 2
92.0 2
6.3, 2
8-OHdG-, 2
4-HNE-, 2
scavenges 2
tert-butyl 2
αVβ3: 2
αvβ3. 2
(tetrac), 2
(L-thyroxine; 2
3'-triiodo-L-thyronine) 2
up-down 2
MeAIB 2
Thymidine 2
SC, 2
(Barkovich 2
135, 2
1348-1369; 2
S2-S8) 2
Blümcke 2
sub-types. 2
schema, 2
(Neurology 2
62: 2
S2-8, 2
Epilepsia 2
52: 2
158-174, 2
(80-450 2
epileptogenicity 2
collars 2
spindled 2
histopathologic, 2
meningioangiomatosis, 2
medically-intractable 2
IIIc). 2
[Classification 2
conditions]. 2
microdysgenesis 2
(mMCD), 2
macroscopical 2
(1971) 2
bizarre, 2
grotesque 2
"focal 2
epilepsy." 2
(FCD), 2
Greenfield's 2
mMCD. 2
merges 2
IIb. 2
dysplasia: 2
8.1+/-4.8 2
2.1+/-0.4 2
mental/psychomotor 2
multilobar 2
neurosurgically 2
microcolumnar 2
microcolumns 2
countings 2
(3/38), 2
(20/38), 2
(5/38) 2
(5/38). 2
resective 2
(Palmini's 2
(VBM) 2
MTLE/HS 2
(mMCDs) 2
(cortical 2
(13.7% 2
epilepsy-associated 2
Drug-eluting 2
Epo+MSCs 2
(EPO 2
extrasarcomeric 2
DesD399Y 2
Unrelated 2
RDM-G, 2
protofilament-like 2
RDM-2 2
unit-length 2
RDM-2, 2
1798 2
T/SSYRRXF/Y 2
[I/V]-X-[T/A/C/I]-Y-[R/K/H]-X-[L/M]-L-[D/E], 2
CAYUG 2
somitogenesis, 2
Prim-6 2
hpf), 2
protruding-mouth 2
leiomyomatosis 2
55,000 2
Mesothelial 2
(intermediate) 2
vimentins 2
desmins. 2
495/36 2
125, 2
polymerization-competent 2
(1.500 2
(Rev-Erbα, 2
Cry1) 2
Dbp, 2
Per2. 2
Per, 2
Cry. 2
1126 2
1174 2
NPAS2 2
forskolin-stimulated 2
PER1/2 2
CRY1/2. 2
CLOCK/BMAL1, 2
GC-related 2
stretcher 2
(str), 2
CMT4D: 2
(160-500-fold) 2
R148X, 2
(g.2290787G>A), 2
IVS8 2
R148X 2
2.88% 2
4.68% 2
Mutat 2
22:129-135, 2
neuropathies; 2
SIMPLE/LITAF, 2
ARHGEF10 2
KIAA1985, 2
PRX 2
CMT4 2
HSPB1, 2
KCC3, 2
GIB1 2
CMT); 2
CMT-DI 2
velocities); 2
minifascicular 2
cramp 2
periaxin 2
SBF2/MTMR13 2
TDP1 2
transnational 2
Slovakia 2
Roma. 2
499) 2
logBNP. 2
instillation. 2
malonyldialdehyde 2
patho-physiology 2
lysosomal-mediated 2
autophagy), 2
(LAMP-2), 2
lysosomal-membrane 2
(UCH-L1) 2
inhibition-associated 2
(LAMP) 2
CMA-defective 2
Oxidation-induced 2
(lamp2a), 2
(lamp2a) 2
lamp2s. 2
positively-charged 2
lamp2a, 2
lamp2s, 2
multimerize. 2
(LAMP2A), 2
calcium-handling. 2
infarction/ischemia, 2
Undoubtedly, 2
overloads, 2
supervenes, 2
vasoconstricts 2
CIMP 2
sympathoexcitation 2
chemosensitive. 2
cause-and-effect 2
baroreceptor-denervated 2
baroreceptor-mediated 2
[Pathophysiology 2
counterregulatory 2
(ADH) 2
(BRAT). 2
Two-hundred 2
thirty-eight 2
1.30, 2
p=0.25). 2
(anterior 2
giant, 2
fusiform 2
outcomes.We 2
Flow-Diverter 2
(observation, 2
stenting, 2
clipping) 2
GDC 2
age>70 2
(4--14 2
MCA/PCA 2
0--3, 2
9--12), 2
(0--3 2
bleed). 2
(poor 2
69.16 2
44.06 2
Clipping 2
(n=1070) 2
(n=1073). 2
1055 2
(23.5%) 2
hcrt 2
hcrt-cells 2
HLA-peptide-TCR 2
Pyogenes, 2
H1N1-infection 2
H1N1-vaccination, 2
precipitants 2
narcolepsy-cataplexy, 2
man) 2
HLA-DQB1*0602. 2
Tribbles 2
(5.6%) 2
if, 2
MTA+ 2
amyloid-independent 2
[(18)F]Flutemetamol 2
(Pittsburgh 2
setting) 2
4G8 2
Bielschowsky 2
(spearman's) 2
(ApoE), 2
[imaged 2
[(11)C]Pittsburgh 2
PET], 2
[(18)F]fluro-deoxyglucose 2
MRI). 2
hypometabolism, 2
Aβ-independent 2
AD-typical 2
non-Aβ 2
Degree 2
WML 2
'Alzheimer-like', 2
MRI-based 2
(MCI), 2
precuneus, 2
volume- 2
(18)F-flutemetamol- 2
(85.2%), 2
SVM. 2
(FDG). 2
positron-emitting 2
Aβ-binding 2
Aβ-containing 2
commercialization, 2
(18)F-labeled 2
[(18)F]3'-F-PiB 2
(Flutemetamol), 2
(18)F-AV-45 2
(Florbetapir), 2
(18)F-AV-1 2
(Florbetaben) 2
(18)F-PET 2
radiopharmaceuticals. 2
antiamyloid 2
ApoE4, 2
F18 2
(55-94 2
[EMCI], 2
[LMCI], 2
p=0.0009) 2
(p<0.27). 2
(p<0.027, 2
pathology-based 2
radiotracers, 2
((18)F)-labeled 2
((18))F-AV-45; 2
Amyvid™) 2
Amyvid 2
Abeta-specific 2
(18)F, 2
0.3]) 2
0.2]; 2
102,801 2
FANTOM3 2
"mystery". 2
"youngest" 2
transposed) 2
"mystery" 2
TTTT/AA 2
arises: 2
isochores? 2
membership, 2
intergene 2
retrotransposase 2
discard, 2
Alu/LINE1 2
retrotransposase, 2
trimers, 2
observed/expected 2
evidence-the 2
isochores-support 2
(LINE1) 2
unevenly 2
Alus, 2
Densities 2
doublets, 2
50kb 2
118Mb 2
5mC/CpG 2
(namely, 2
(unmethylated) 2
(5mC/CpG) 2
YAC-deficient 2
YACs 2
SINES 2
B2) 2
BamHI 2
Kpn 2
repeats; 2
embedded. 2
surgery-induced 2
oxalate. 2
supersaturation. 2
(39.3%) 2
1.112 2
55-400 2
low: 2
Oxalate 2
(JIB), 2
oxalate-containing 2
normocalcaemic 2
Glycosaminoglycans 2
calcium-containing 2
hydrocolloid 2
diarrhoeal 2
(sMTC) 2
occurence 2
tracheal-bronchial 2
C742T, 2
G746T, 2
G747T 2
G35T 2
463 2
p110α. 2
Arg88, 2
Arg93, 2
neoangiogenesis, 2
fluoropyrimidine. 2
Agencies 2
comments, 2
editorials, 2
letters. 2
chemotherapy.For 2
(KRAS 2
K-, 2
H-RAS 2
ATCs. 2
(dynein-1) 2
Dyneins 2
ATP-hydrolysis 2
ADP.vanadate. 2
motor's 2
activites: 2
AAA1-AAA6). 2
buttress 2
microtubule. 2
(MZSDS) 2
anti-neuroinflammatory 2
mastinib, 2
siponimod). 2
laquinimod 2
(yet) 2
respresent 2
beta-interferons 2
(natalizumab 2
leukoencephalopathy; 2
onwards) 2
convenience; 2
antibody-negative). 2
anti-lingo-1) 2
CD20-positive 2
polyradiculoneuropathy, 2
High-yield 2
Injectable 2
expirations, 2
teriflunomide), 2
(laquinimod) 2
(NMO). 2
cell-fostering 2
cell-targeted 2
NMO, 2
ofatumumab), 2
anti-IL6-R 2
complement-blocking 2
(eculizumab), 2
AQP4-Ig 2
(aquaporumab, 2
BAFF/BAFF-R-targeting 2
[Emerging 2
[dimethyl 2
fumarate], 2
cladribine, 2
dalfampridine) 2
alemtuzumab). 2
remyelinating 2
herein: 2
2010-2012. 2
Janus-faced 2
SELECT/SELECTION 2
GNbAC1, 2
BIIB033, 2
MOR103 2
MEDI-551. 2
expire, 2
ocrelizumab), 2
(natalizumab); 2
(daclizumab, 2
[Ly-2127399], 2
[AIN457]). 2
(anti-CD52) 2
rituximab/ocrelizumab 2
(anti-CD20). 2
optica; 2
siRNA-treated 2
inactivation-specific 2
Goals 2
eutherians, 2
IST, 2
(X-inactivation) 2
diesel 2
exhaust 2
(microarray 2
B-raf 2
Xist) 2
vivo-produced 2
10: 2
X-inactivated-specific 2
spretus 2
HOBMSKI2 2
(Xist 2
A-repeat 2
elect, 2
(Xp) 2
deepen 2
transcription? 2
(Xist), 2
Monodelphis 2
Slc16a2 2
Delving 2
mono-allelic 2
labile. 2
"paints" 2
(ZGA). 2
PGK, 2
Equal 2
(XIC). 2
(46.1%) 2
(72.1%) 2
marsupials 2
(XIC/Xic) 2
(XIST/Xist) 2
ligation-mediated 2
mesonephric 2
ridges 2
microcell 2
CF150, 2
(X-inactive-specific 2
channelrhodopsins 2
experimenters 2
experimenter 2
virology, 2
channelrhodopsin. 2
Optogenetics, 2
photoactivation 2
sub-population-specific 2
(CVNs). 2
subpopulation-specific 2
photostimulation, 2
photostimulation 2
CVNs. 2
Cre/loxP 2
Sim-1 2
Cre-driver 2
Rosa-CAG-LSL-ChR2-EYFP 2
Cre-responder 2
Rosa-CAG-LSL-ChR2-tdTomato 2
PVN, 2
photo-evoked 2
hypothalamus-brainstem 2
prelimbic) 2
infralimbic 2
intra-IL 2
(rAAV5/CaMKIIa-ChR2(H134R)-EYFP) 2
(rAAV5/CaMKIIa-EYFP). 2
region- 2
ChR2(H134R) 2
Cre-dependent 2
(DβH)(Cre/0) 2
intersectional 2
Cre/Flp 2
Cre/Dre 2
retargetable 2
TIGRE, 2
Cre/tTA-dependent 2
glycoprotein-pseudotyped 2
tetracycline-dependent 2
(tTA) 2
("TLoop") 2
channelrhodopsin-2-YFP 2
(ChR2YFP). 2
microinjections 2
eNpHR3.0-eYFP 2
eYFP 2
yohimbine-induced 2
eNpHR3.0-injected 2
eYFP-injected 2
channelrhodopsin2 2
pronociceptive 2
Optogenetics. 2
palette 2
blue-light-induced 2
(BLINK1) 2
photosensory 2
Kcv. 2
light-exposed 2
(FGs), 2
(FAs), 2
hnRNPA1 2
hnRNPA2/B1 2
zippers 2
(PrLD) 2
Prion-like 2
prions, 2
too? 2
FUS/TLS-related 2
commonalities, 2
proteasome-COP9 2
complex-eIF3 2
HnRNP 2
A2/B1. 2
tremor/ataxia 2
(FXTAS), 2
(ALS)-associated 2
FXTAS. 2
Hrb87F 2
Hrb98DE. 2
TBPH. 2
repeat-triggered 2
A2/B1-targeted 2
CGG-mediated 2
parkinsonism; 2
702 2
(FTLD). 2
co-labeled 2
proteinopathy. 2
relationship; 2
TDP-43-FUS/TLS 2
export/import. 2
subcompartments 2
organized. 2
protein-dense 2
polymerizing 2
"factories" 2
self-organization 2
millions) 2
debate; 2
scale? 2
Fraumeni 2
p53-associated 2
Ceritinib: 2
(1974 2
LDK378, 2
48-67) 2
≥400 2
114). 2
41-67) 2
44-78) 2
crizotinib-exposed 2
47-70) 2
78). 2
41-70) 2
44-81) 2
(PRDX-2) 2
(intracellular 2
post-race, 2
(Srx) 2
lutea. 2
moDCs, 2
(Prx-2) 2
sulfinic 2
Srxn1(-/-) 2
Srx1 2
(HUVEC) 2
0·01) 2
(0%, 2
time-courses. 2
(MCP)-1 2
(Prdx2), 2
reductant, 2
Complicating 2
(peroxiredoxin 2
cdk5. 2
2-cys 2
autoxidation. 2
sink 2
lithium's 2
(TRB3), 2
phosphatidyl 2
antimanic 2
latexin, 2
carboxypeptidase, 2
phospho-EF-1beta 2
13q12. 2
Amish, 2
MTPAP 2
tail-length 2
split-operator 2
(CPU). 2
22.11, 2
38.80, 2
44.80 2
CUDA. 2
List-mode 2
(ToF) 2
backprojection 2
(CUDA) 2
ordered-subsets 2
(OSEM) 2
Execution 2
ToF-specific 2
LORs, 2
iterations, 2
CPU. 2
GPU-generated 2
(DoI), 2
(PSFs). 2
Toolbox 2
MATLAB. 2
Gillespie 2
(SSA), 2
(LDM) 2
Sop-GPU: 2
C(α)-based 2
(SOP) 2
Langevin 2
(SOP-GPU 2
program). 2
∼90-fold 2
timescale, 2
force-extension 2
(v(f) 2
μm/s) 2
tweezers-based 2
v(f). 2
wall-clock 2
SOP-GPU 2
GPGPUs 2
GPUs. 2
workstation. 2
displaying. 2
Quadro 2
FX 2
displays. 2
mct8. 2
3,3',5-triiodothyroacetic 2
(triac) 2
Triac 2
Pax8-knockout 2
Mct8/Pax8 2
Mct8-KO 2
tetrac. 2
3?, 2
5-triiodo-thyroacetic 2
3,5,3'-triiodothyroacetic 2
(SAECG) 2
(VT), 2
214.3 2
death? 2
high-malignant-potential 2
Imatinib: 2
reports]. 2
mesenchimal 2
colectomy. 2
(PDGFRA) 2
Ciliated 2
KARTAGENER 2
RARE 2
CONGENITAL 2
DISEASE 2
CHARACTERISED 2
TRIAD 2
SYMPTOMS: 2
rhinosinusitis 2
instituted, 2
dyneins, 2
dyneins 2
cilia: 2
Bjorn 2
1933, 2
Manes 2
Kartagener, 2
Zurich 2
Ph.D. 2
(triad) 2
"situs 2
totalis". 2
[Epidural 2
dextrocardia, 2
cilial 2
anesthesiologist 2
dyskinesia). 2
colds 2
dyskinesia) 2
autossomical 2
repetition. 2
Kartagener&apos;s 2
clinicomorphological 2
(bronchiectasis, 2
viscera) 2
25-60 2
TPE 2
4q35- 2
facio-scapulo-humeral 2
MYOD1 2
<11 2
D4Z4. 2
non-spliced 2
FSHD-linked 2
DUX4-FL, 2
FSHD-related 2
adult-derived 2
('Majority 2
Rules'), 2
('Minority 2
Rules'). 2
FSHD-associated 2
DUX4-encoded 2
homeodomain-type 2
(D4Z4) 2
homeodomains. 2
exon-based 2
~17,000 2
(>2-fold, 2
(2185 2
3006, 2
797, 2
RNA-silencing 2
FSHD) 2
tet-repressible 2
morpholinos. 2
octaguanidinium 2
dendrimer-conjugated 2
(vivo-morpholino) 2
triceps 2
angular-shaped 2
4A(159/161/168) 2
27.5% 2
(DUX4-fl) 2
(DUX4-s). 2
receptor-2-interacting 2
Spa 2
250-420) 2
Cortactin-S405 2
Rac1/Cdc42. 2
FKF1 2
Rosenfeldt, 2
Invest. 2
cross-communication 2
PDGF-induced 2
edg-1 2
colon: 2
fibronectin); 2
phospholipases, 2
GTPases); 2
E-cadherin) 2
metalloproteinases); 2
Retroviruses, 2
Invasion: 2
Clash 2
Titans. 2
belongs. 2
counterattack 2
Cullin5 2
(Cul5)-based 2
(PFV) 2
PFV-based 2
[Antiviral 2
(APOBEC)3 2
APOBEC3A-G. 2
immuno-deficiency 2
(SIV), 2
SIV(agm). 2
22,000 2
0.24% 2
SWATH-MS. 2
Proteomics. 2
LOQ 2
SWATH™ 2
'any 2
interest' 2
reproducibly, 2
selenoprotein-deficient 2
microg/L). 2
1.19; 2
SOD2-Val16 2
1.43; 2
1.60; 2
low-selenium 2
cancer/aggressive 2
ever-smokers, 2
remove, 2
GPX4 2
SEP15, 2
PCa-specific 2
1,267 2
rs561104 2
NEM 2
selenoenzyme 2
(GSH-Px) 2
inter-relationships 2
Fish 2
life-history 2
furzeri, 2
Aging-related 2
Teleost's 2
life". 2
aculeatus) 2
"pufferfishes" 2
Tetraodon, 2
latipes), 2
storage; 2
Coselection 2
citrullinations: 2
Citrullinations 2
citrullinations 2
Autoantigens 2
autoreactivity. 2
Citrulline 2
α-enolase, 2
arthritogenic 2
(HLA-DRB1 2
RA-HLA-DRB1 2
Cirullinated 2
(NETs). 2
GFOGER 2
α10β1 2
α11β1 2
RA: 2
(CII) 2
α2β1 2
citrullinome 2
(RASF), 2
(OASF) 2
peptidyl-citrulline 2
anti-cFn 2
anti-modified 2
cFn, 2
OASF 2
OASF, 2
TNF(+) 2
PAD4(+/+) 2
PAD4(-/-) 2
TNFα-overexpressing 2
4049 2
pooling; 2
0.04-7.6). 2
SIE, 2
0.73/100 2
5.61/100 2
1.35/100 2
4.35, 2
29.30). 2
CZP-treated 2
4.33/100 2
0.47/100 2
CZP-exposed 2
0.63/100 2
PY) 2
0.76/100 2
0.05/100 2
CZP, 2
2394 2
(sc). 2
pegol: 2
improvement: 2
6.01 2
9.40) 2
-0.32) 2
(scale 2
5.27 2
8.71), 2
-0.32). 2
3.30). 2
4.25); 2
2.81 2
5.75); 2
2.71 2
5.66). 2
(MTX), 2
mono-therapy 2
FAST4WARD 2
(bDMARD) 2
cDMARDs 2
Lys-ɛ-Gly-Gly 2
(K-ɛ-GG) 2
(GG) 2
(HER2), 2
diglycine 2
(GlyGly) 2
monoglycine 2
epsilon. 2
(diglycine) 2
NEDD4 2
Fas-Ligand 2
(Fas-L)- 2
dementing 2
(N3ECD). 2
AdTR(alpha) 2
AdTR(alpha)-infected 2
(TRalpha) 2
(P398H). 2
3.4-fold 2
hormone-catecholamine 2
SP6 2
presynthesized 2
formamide. 2
(Ovum 2
ATR/ATM 2
Omcg1-deficient 2
cotanscriptional 2
clashes 2
transcription/replication 2
R-Loop 2
replication-priming 2
Virology 2
some) 2
RDR 2
D-loop/R-loop-dependent 2
replicons, 2
DnaA-dependent 2
oriC, 2
DNA-damaged 2
(cSDR) 2
inflict 2
(CSB 2
S-RBC-COMT 2
0.30-1.29 2
72.9 2
levodopa/carbidopa/entacapone, 2
50/12.5/200, 2
75/18.75/200, 2
100/25/200, 2
125/31.25/200, 2
150/37.5/200 2
200/50/200 2
ergots 2
reassessed. 2
disease". 2
(Orion) 2
Movements 2
AUC, 2
(Comtess/Comtan) 2
Pharma's 2
entacapone/levodopa/carbidopa 2
non-ergoline 2
pergolide. 2
upward. 2
levodopa: 2
FDOPA/PET 2
(OR-611), 2
catechol 2
O-methyl-transferase 2
OR-611 2
(DDC) 2
40-7592 2
(3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), 2
(N-(2-aminoethyl)-5-chloro-2-pyridine 2
HC1). 2
reorganised, 2
K18 2
K19. 2
corneocytes, 2
k35 2
k85 2
full-atomistic 2
toughness 2
α-keratin. 2
II/type 2
FasR-death 2
full-field 2
ultrahigh-resolution 2
FF-OCT 2
bulbs 2
Engineers 2
[cytokeratins 2
(CKs), 2
lamins] 2
(acidic 2
CKs: 2
CK14, 2
CK18 2
CK19) 2
ovarii. 2
CKs 2
5/keratin 2
moduli 2
Microscope 2
Pa, 2
(euthyroid) 2
457, 2
p=0.007). 2
(TT3), 2
kinase-B 2
thyrotrophin 2
165) 2
>0.41 2
<0.0001). 2
3.0; 2
KIAA0693) 2
(FALS). 2
(bidirectional 2
polymorphic). 2
self-terminate. 2
episode) 2
emotion). 2
180°-QRS 2
"stable" 2
100-120 2
workload. 2
(1-2.5 2
(2-4 2
Non-selective 2
asthma). 2
(recurrence 2
maintained/optimized 2
LCSD, 2
LCSD. 2
CALM1- 2
RYR2-related 2
CPVT:CASQ2- 2
TRDN-related 2
RYR2-genotyped 2
(KCNJ2) 2
adrenergically-mediated 2
diastole. 2
depolarizes 2
2-linked 2
ultra-structural 2
CASQ2(-/-) 2
CASQ2-R33Q 2
CSQ2 2
CSQ2. 2
(ASPH) 2
codons; 2
4.1; 2
1.5-11.5; 2
P=0.007, 2
treated) 2
0.3-19.0 2
noncompliant. 2
6.7-year 2
1.4-20.9 2
calcium-regulation 2
sing 2
LigandScout 2
ionizable 2
GOLD. 2
Catalyst. 2
studio 2
superimposition 2
HBA 2
5-tetrahydroquinolinylidine 2
aminoguanidine 2
SHE 2
(GASP) 2
CoMFA 2
(q(2)) 2
(r(2)) 2
(HDAC8) 2
complimenting 2
proton-coupled 2
hPAT1 2
prodrugs. 2
MOE 2
(molecular 2
environment) 2
studio. 2
ionizable, 2
0.76. 2
CATALYST 2
HypoRefine 2
CatalystHipHop 2
(1â15). 2
3D-pharmacophore 2
(10a-g), 2
carboxylated 2
5D-QSAR 2
(test 2
PDE-5. 2
Hypo-ET(A)-1, 2
5-lipoxygenase 2
HipHop 2
(lithium, 2
interferon-alpha, 2
selenomethionine, 2
reductases 2
thyreocytes 2
(IL-15) 2
AITD. 2
PACAP-regulated 2
immunoassays]. 2
radioimmunometric 2
lomicronw 2
peroxidases, 2
thioredoxine 2
selenocystein. 2
Selenium-dependent 2
(TgAb) 2
IU/ml. 2
(TPOAb)-matched 2
micromol) 2
selenite/d, 2
IU/ml 2
TgAb 2
Ukrainian 2
Alba 2
thyroiditis) 2
Near-identical 2
m.14487T>C 2
m14487T>C 2
22.4% 2
'hotspots' 2
14487T>C 2
Leigh's-like 2
11778G>A 2
recent, 2
(np) 2
Moderately 2
np 2
14459 2
ganglial 2
"liquid 2
biopsy" 2
∼0.02%. 2
p-hydroxy-phenylimidazo-1,10-phenanthroline 2
(PHPIP) 2
Ni-complex 2
(Ni-complex) 2
interacts/binds 2
ctDNAs. 2
electrochemically. 2
β=4.29×10(5) 2
C749G 2
Nortriptyline. 2
[(1997); 2
91: 2
555-564] 2
4p16. 2
trigonocephaly 2
(HCH) 2
RISK: 2
PREGNANCY: 2
2009-2010. 2
biologics: 2
abatacept. 2
TNF-inhibitors 2
(MMF) 2
lot-to-lot 2
(NCT01323972) 2
anti-CS-responses 2
0-1-2 2
litres-fermentation 2
Consistency 2
batch. 2
(RTS,S) 2
pre-erythrocytic 2
RTS,S-vaccinated 2
individual-participant 2
bednet 2
AS02. 2
pivotal, 2
parasitaemia 2
Processes 2
EPI. 2
(inactivated 2
whole-cell), 2
hepatitis-B 2
NCT00436007. 2
27-41), 2
21-35), 2
22-36) 2
anticircumsporozoite 2
site-adjusted 2
26-70; 2
p=0·0012) 2
(36-74; 2
33-73; 2
p=0·0002) 2
16-45; 2
p=0·0003). 2
61·6% 2
35·6-77·1], 2
p<0·001; 2
63·8% 2
[40·4-78·0], 2
p<0·001, 2
WHO-sponsored 2
Biologicals. 2
anti-circumsporozoite 2
RTS,S-based 2
-experienced 2
AS01-adjuvanted 2
MHCII(high) 2
AS02 2
Gabonese 2
RTS,S/AS02(D), 2
vaccinated. 2
(serial-feed 2
sound, 2
(ITT). 2
16/5,949 2
1/2,974 2
9/4,358 2
3/2,179 2
Editors' 2
Summary. 2
artemisinin-based 2
Guyana 2
Suriname; 2
non-malaria 2
Malaria; 2
roadmap; 2
elimination; 2
soon-to-be 2
Tool; 2
Strategy 2
(2016-2025).Policy 2
Meeting 2
vibrations 2
acetophenone 2
acetophenone-d8, 2
odour. 2
key-regulators 2
protein-partners, 2
PARYlation. 2
CTCF-paralogous 2
promoter(s) 2
NY-ESO-1. 2
sf1 2
MAGE-A1 2
MAGE-A1. 2
5-azadC 2
"cancer-testis" 2
lamina-specific 2
(RGCs) 2
arborize 2
molecules--Dscam 2
(Down's 2
DscamL 2
Sidekick-2 2
sublaminae 2
Dscams, 2
Sidekick-1, 2
(HIVAN). 2
sidekick-1, 2
preimmune 2
(+/-2.4 2
5-deiodinase 2
(PTU), 2
type-III 2
isozyme, 2
(type-III) 2
(type-I 2
hypothyroidism) 2
(PseAA) 2
sequence-order 2
(Chou, 2
43: 2
246-255), 2
porins, 2
4290 2
training/testing 2
β-Barrel 2
databank. 2
(resolution 2
1.8-3.0 2
Å). 2
rmsd 2
75-222 2
BTMC, 2
BTMI 2
HTMI 2
(HMPs) 2
propensities, 2
buried/exposed 2
80.42% 2
AAIndex 2
non-OMPs 2
93.2% 2
(OMPs, 2
GPs) 2
(OMPs 2
non-OMPs). 2
(omps) 2
crystallizing 2
"wrapping" 2
already-formed 2
TransFold 2
(<or=200 2
jack-knife 2
Chlamydia. 2
(VDs) 2
turns. 2
VDs 2
FORESST, 2
Omp2a, 2
16-stranded 2
Omp2b. 2
(MPs) 2
crystallize, 2
MPs 2
(AMP) 2
(OMBBs). 2
α-helices. 2
OMBB 2
OMBBpred 2
http://biomine.ece. 2
ualberta.ca/OMBBpred/OMBBpred.htm. 2
enumeration, 2
PagP 2
accuracy; 2
"model" 2
ansmembrane 2
elicitation 2
Lmbr1 2
Ci-Galphai1 2
papillar 2
CRM. 2
77.9% 2
ModuleScanner 2
Otx2, 2
ChIP-qPCR 2
Sia 2
blastula 2
persists, 2
CisView 2
co-reconstitution 2
FITC-PLB 2
phospholamban-SERCA2a 2
crest-specific 2
cephalic, 2
anlagen. 2
(50-60%) 2
a-CGH 2
(27%): 2
7p21.1 2
2q24.3q31.1 2
3p13p12.3 2
379Kb 2
NF1-REP-P1 2
REP-P2 2
sub-duplicons. 2
nontoxigenic 2
terrorist 2
supplies. 2
(BoNTs). 2
BoNT-A 2
Immunomagnetic 2
peptidases. 2
BoNT-A. 2
13-amino 2
quencher 2
FIQ 2
BoNTs, 2
dichain 2
(H-chain) 2
(L-chain) 2
~50 2
L-chain 2
(lysed 2
unlysed) 2
µl 2
MBA-negative 2
gold. 2
UV-Visible 2
excipients 2
<or=100 2
calsequestrin/triadin/junctin). 2
triadin/ryanodine 2
triadin/calsequestrin 2
re-association. 2
curtail 2
GCaMP6f 2
t-tubules 2
jSR, 2
(CSQ); 2
(Jct), 2
(Tr), 2
CSQ-ryanodine 2
353, 2
triadin/junctin 2
polymerisation, 2
exterior 2
RyRs, 2
perimeter 2
zippered 2
center-initiated 2
overdose? 2
Heroin 2
undermining 2
naloxone-related 2
45%). 2
they: 2
usual; 2
>92%; 2
breaths/min; 2
>35.0 2
<37.5 2
beats/min 2
beats/min; 2
tri 2
CEDs 2
apocentric 2
A/C(-/-) 2
3R. 2
bull. 2
hZeb2 2
Zeb2, 2
BAC-FISH 2
CCRs 2
6Mb 2
(Sip1, 2
c.2372del 2
p.T791fsX816). 2
E87X 2
(mono- 2
bi-functional) 2
uvrAC 2
PUVA-induced 2
PUVA-treated 2
nicking. 2
adducts, 2
UvrC, 2
(DPCs) 2
DPCs, 2
nfo, 2
azaC 2
acid-fast 2
excinuclease 2
multi-enzymatic 2
cho 2
manifold 2
rates; 2
(2.2-fold 2
hyper-recombinational 2
"global" 2
(4-[3-{1-(4-benzyl)piperidinyl}propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine 2
monohydrochloride) 2
dogs; 2
KN-3 2
content--in 2
activation--affects 2
(RyR2(R4496C+/-)) 2
[Na(+)] 2
patch-clamping 2
(APs), 2
load--in 2
stimulation--is 2
indo-1 2
nM)-induced 2
isoprenaline. 2
Arrhythmogenesis 2
Disagreement 2
FKBP12.6-RyR2 2
(RyR2(R4496C+/-)). 2
Superfusion 2
FKBP12.6/RyR2 2
epinephrine. 2
RyR2/FKBP12.6 2
tachycardia-linked 2
Calstabin2-deficient 2
calstabin2-/- 2
calstabin2+/- 2
calstablin2. 2
calstabin2(-/-) 2
calstabin2(+/-) 2
cardioverted 2
reinduced. 2
fibrillation/flutter, 2
mg/kg/min). 2
I(K.ACh) 2
component). 2
MicroRNA-657 2
(TLE1) 2
miRNA-657 2
16HBE 2
double-negative 2
[Review 2
miRNA-containing 2
miRNA-140, 2
tumor-supressor 2
around/on 2
(hsa-miR-9, 2
hsa-miR-129 2
hsa-miR-137) 2
hsa-miR-9 2
bisulphate 2
hsa-miR-9-1, 2
hsa-miR-129-2 2
hsa-miR-137 2
hsa-miR-9-1 2
20-23 2
abovementioned 2
t(11;14)(q24;q32) 2
pre-BI 2
15-folds 2
migration/invasion 2
miR-375-mediated 2
(AEG-1) 2
AEG-1. 2
AEG-1, 2
cholesterol-conjugated 2
2'-O-methyl-modified 2
(Chol-miR-375) 2
rag 2
lysosome-anchored 2
RagA-mediated 2
amino-acid-starvation-induced 2
RNF152-mediated 2
RagA. 2
lysosome-based 2
(Ras-related 2
GTPases) 2
v-ATPase, 2
GATOR 2
(GAP 2
Rags), 2
(RagA 2
RagD) 2
amino-acid-dependent 2
Leucyl-tRNA 2
mTORC1-signaling 2
(LRS) 2
Rheb-GTP, 2
inhibits, 2
Rag, 2
H(+)-adenosine 2
Non-traditional 2
(Lubag 2
(DSC3), 2
(d4). 2
d3 2
TAF1, 2
d2-d4. 2
[d2-d4/wild-type 2
d2-d4/DSC3] 2
(d3-d4/wt 2
d3-d4/DSC3). 2
d2-d4/wt 2
d2-d4/DSC3. 2
d3-d4/wt 2
d3-d4/DSC3. 2
Panay, 2
Capiz, 2
1:4000 2
Parkin-, 2
PINK1-, 2
DJ-1-associated 2
(PARK2, 2
(DYT3), 2
(DYT12) 2
DYT16 2
(PANK2)- 2
(PARK14)-associated 2
neuroferritinopathy, 2
SENDA 2
FBXO7-associated 2
(SPG11), 2
SLC6A3 2
jaw-opening 2
ZNF261, 2
DXS10017, 2
DXS10018. 2
DYT3 2
(cervical) 2
carbidopa/levodopa. 2
nonprogressive. 2
3.19) 2
3.02). 2
(XDP; 2
Lubag; 2
OMIM*314250). 2
Clinico-pathological 2
putamina 2
reticulata, 2
cinematographic 2
myorhythmia. 2
Parkinson's-plus 2
(rCMRGlc 2
GMR) 2
[18F]fluorodeoxyglucose 2
(lubag). 2
x-chromosome. 2
generalized. 2
cryothalamotomy. 2
dystonia--one 2
non-Filipino. 2
non-Filipino 2
Xp11.22-Xq21.3 2
dystonia-parkinsonism). 2
Xq12 2
Xq21.31 2
(DXS159-DXYS1X). 2
perchlorate-induced 2
premyelocytic 2
-1, 2
(SP600125) 2
DNase, 2
Ac-YVAD-cmk, 2
(IJ) 2
(IVUS) 2
lumen-diameter 2
52.9%, 2
venography. 2
phlebograpy 2
neurologist-confirmed 2
institutes. 2
(reintervention) 2
(1037 2
(162 2
Phlebography 2
(98.9%) 2
99.2% 2
(1209 2
thrombosed 2
venographic 2
(4.2%). 2
angioplasty: 2
contrast-calculated 2
case-controlled, 2
imaging-blinded 2
venography) 2
.013) 2
.021, 2
.033) 2
.024). 2
wrong? 2
coining 2
('CCSVI'). 2
Zamboni's 2
implausibility 2
Provinces 2
(CDMS) 2
phlebography 2
dexterity, 2
assessors, 2
30.6±6.1 2
(bleeding, 2
re-stenosis: 2
(0.45±0.62 2
0.76±0.99; 2
p=0.021), 2
(1.98±0.92 2
2.27±0.93; 2
p=0.037), 2
neurosonology 2
intracranial, 2
before; 2
incorrect; 2
medicine) 2
"liberation" 2
(unblocking 2
angioplasty) 2
(immediate 2
(ITG)), 2
(DTG)). 2
0.12% 2
0.66% 2
0.081), 2
stenosies 2
(IJVs-AZ) 2
perfusional 2
phlebographic 2
truncular 2
mostly, 2
webs. 2
IJVs, 2
AZ. 2
etiology? 2
ballooning 2
Pyramidal 2
(TMS). 2
rebrospinal 2
neuro-physiological 2
anaemia/breast 2
FANCJ/BRIP1, 2
FANCN/PALB2, 2
FAVL, 2
FAAP95 2
FANCL) 2
FAAP95, 2
(BMCs), 2
(PBSCs) 2
therapy-mediated 2
ago-the 2
Holy 2
Grail 2
stem/stromal 2
intermediate-sized, 2
few: 2
used? 2
delivery? 2
effects? 2
transdifferentiate 2
endoderm, 2
morphotypes 2
ecotypes, 2
investigate: 2
Betula 2
platyphylla 2
CHH 2
chimpanzees. 2
vulnerabilities. 2
histones) 2
"cellular 2
epigenome"; 2
(EHT). 2
trigger, 2
Gfi1- 2
megakaryopoiesis 2
Hrasls3, 2
β-like 2
Hrasls3 2
haemogenic 2
endothelial-haematopoietic 2
Runx1, 2
Gfi1B, 2
13q, 2
haploinsufficiency, 2
(Evi1 2
Gfi1:Gfi1b 2
pre-T-cell 2
domain-dependent, 2
Gfi1b-null 2
erythro- 2
(Mx-Cre, 2
Cre-ERT) 2
(EpoR-Cre) 2
Mx-Cre 2
Cre-ERT 2
Hba-x, 2
TER119+ 2
12.5-17.5 2
p.c. 2
Bcl11a, 2
punctual 2
(Oct) 2
four-to-five 2
implication; 2
MLLT3 2
(MLLT3), 2
Gfi-1-like 2
(Zolinza), 2
romidepsin 2
(Istodax) 2
tanespimycin) 2
cytotoxicity-mediated 2
(Revlimid), 2
(CC-5013, 2
Revlimid; 2
NJ), 2
IMiD 2
non-del(5q) 2
Erythropoiesis-stimulating 2
(IMiD), 2
subquadratic 2
O(21C 2
NM) 2
O(log(N 2
M)). 2
ingenious 2
Zhang 2
O(n2log 2
n). 2
NBEAL2, 2
NEABL2 2
73,000 2
Cas9/single 2
underfilling 2
Phosphorus 2
FGFs. 2
-0.21; 2
α-Klotho 2
(1,25VitD3). 2
FGF23-α-KL 2
FGF23. 2
sKL 2
tertiles, 2
calcinosis 2
calcinosis, 2
(Fgf23), 2
4weeks, 2
disease-altered 2
anoikis-apoptotic 2
(apoptosis 2
Developed 2
Termed 2
(Greek 2
Homelessness), 2
engraftment. 2
tensegrity 2
RGD-like 2
activator-1, 2
kininogen. 2
granzymes 2
zymogens 2
recolonization 2
ERK/BCL-2 2
Detachment-induced 2
non-adherent 2
serum-dependent. 2
exchanger: 2
(NO)-cyclic 2
paradox-mediated 2
NO-NCX-mediated 2
PPADS, 2
(NCX(REV)), 2
SN-6, 2
([Ca(2+)]i) 2
fura 2
SN-6 2
(MAPs) 2
(MPTP)-induced 2
deficits) 2
T(1)-mapping 2
post-MnCl(2) 2
ryanodine. 2
NCX1-heterozygous 2
(NCX1(+/-)) 2
(2-[4-[(2,5-difluorophenyl)methoxy] 2
phenoxy]-5-ethoxyaniline), 2
pressure-induced 2
(ERK1/2, 2
Na(+)/Ca(2+)-exchanger 2
-0.04+/-0.01 2
mV; 2
0.11+/-0.03 2
n=7), 2
0.49+/-0.12 2
n=7). 2
Fura-2 2
138+/-7% 2
210+/-11% 2
(27.6 2
SEA-0400 2
(SEA), 2
(forward 2
Ca(2+)/Ca(2+) 2
stunning). 2
(2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline) 2
macules, 2
homology-1 2
leukoderma 2
Legius 2
SPRED1 2
Café-au-lait 2
piebaldism: 2
SLUG 2
(SLF). 2
depigmentation. 2
(leukoderma) 2
(poliosis). 2
(microphthalmia 2
Val620Ala 2
OVID-MEDLINE, 2
COCHRANE, 2
GLOBAL-HEALTH, 2
AFRICA-WIDE-NiPAD, 2
nutritional-cure 2
0.27). 2
Susceptibilities 2
35.2%. 2
infered 2
LILACS, 2
outreach 2
Plumpy'Nut, 2
2.20 2
0.046) 2
de-worming 2
3.23) 2
2.83) 2
Hickey 2
NCT01000298.). 2
g/kg/day 2
QM7 2
prepro-orexin 2
rORX-A 2
rORXs 2
Ski, 2
LRT 2
telmisartan. 2
melanin-concentrating 2
neuromodulation 2
CCR2, 2
galanin. 2
(GAL), 2
24-26 2
(Ghsr(-/-)-M, 2
WT-M, 2
bouts. 2
(14.2 2
Re, 2
rubiscolin-6 2
27-month-old 2
hunger. 2
appetite-decreasing 2
evidenced: 2
liver; 2
overeating 2
fat-rich 2
USat 2
(OX) 2
(PFLH). 2
OX, 2
(virus 2
(-)HIV-1 2
(-)DNA 2
(+)DNA, 2
uracils, 2
C/G→T/A 2
deaminase-independent 2
counterstrategy 2
ssRNA. 2
dimer/oligomer 2
(Deltavif 2
virions), 2
(HPLC), 2
Pediatría. 2
(delta4 2
-10)--a 2
swirling 2
nails; 2
many--if 2
most--cases 2
NEMO-gene]. 2
hypopigmentations. 2
(IKK)y). 2
X-linked-dominant 2
microdeletion. 2
[Inherited 2
genodermatoses]. 2
distubances 2
genodermatoses. 2
genodermatoses: 2
bullosa. 2
dystrophic, 2
Kindler 2
COL7A1, 2
COL17A1, 2
laminin). 2
viremia 2
Pneumocystis 2
xerotic 2
wrinkling, 2
OL-HED-ID. 2
(HED-ID), 2
(LCR1-LCR2, 2
(IKBKGP). 2
LCR1, 2
recombine 2
(IKBKGdel) 2
micro/macro-homologies, 2
repeat/repetitive 2
inter-locus 2
IKBKGP 2
IKBKG/NEMO, 2
p.Glu390ArgfsX61 2
IKBKGdel 2
promoterB, 2
promoterA. 2
Alu-Alu-mediated 2
replication-based 2
[NEMO 2
gamma) 2
most-upstream 2
Amorphic 2
NF- 2
X-recessive 2
(IKBKG), 2
(NEMO), 2
anhydrotic 2
gamma-deficient 2
Guérin 2
(EM). 2
diseases-incontinentia 2
(NEMO/IKKG), 2
XR-MSMD. 2
3.0-micrometer 2
invadopodiome 2
pseudopodiome 2
PAR2 2
interactors. 2
microprocesses 2
pseudopodia-localizing 2
(pY) 2
pY 2
(TDP43) 2
(TG)nTm 2
(UG)(6-12) 2
hNFL 2
(TDP43), 2
[Identification 2
(LMO2-C), 2
Maltose 2
(MTHA) 2
Semiquantitative 2
(GPA) 2
MBP-LMO2-C 2
MTHA 2
LMO2-L, 2
LMO2-L 2
(81.13 2
0.68)%. 2
[(51.00 2
1.58)%] 2
(PIAS3) 2
ETS, 2
NR1I2, 2
ETS. 2
Ldb1, 2
Tal1, 2
Eto-2 2
prehaematopoietic 2
Ski-GATA1 2
erythropoiesis: 2
affair 2
68, 2
NR1H4 2
5-bisphosphate 2
(SOCS3). 2
(DCA) 2
DCA 2
FXR-induced 2
FGF15/19 2
FGF15/19-induced 2
T-β-MCA 2
(FXR). 2
Halocynthia 2
LXR 2
gills, 2
TGR5 2
Cζ 2
(SHP) 2
SHP. 2
SHP-mediated 2
(SHP, 2
Nr0b2) 2
alpha: 2
(FXRα) 2
FXRα 2
ADH1A 2
ADH1B 2
Enterohepatic 2
transfer-based 2
(farnesoid 2
NRIH4), 2
chemoprotection/chemoresistance 2
Alexander 2
FXR/RXR. 2
ABCB4, 2
TCEA2, 2
CCL14, 2
KRT13 2
FXR/RXR-expressing 2
FXR-mediated 2
FXR-dependent 2
dichromate, 2
artesunate 2
LXRα-dependent 2
Sestrin2 2
LXRα-mediated 2
LXRE-luciferase 2
(Sirt1) 2
femurs 2
(OVX)-induced 2
(MUTYH) 2
(H2AFX 2
(H2AFX))) 2
non-oxyphilic 2
8-OxoG 2
imparted 2
biomonitoring 2
MgH2A.X 2
MgH2A.Z 2
(H2AX 2
H2A.Z), 2
ubiquitination) 2
(INO80, 2
SWI/SNF, 2
NuRD) 2
Swr1-independent 2
visualize, 2
Swr1. 2
Inter-individual 2
(ATM, 2
NBN, 2
LIG1, 2
LIG4, 2
(137)Cs 2
gamma-rays. 2
G(0)/G(1)-phase 2
cGy, 2
0.2-2.6 2
foci/cell 2
mean+/-SD 2
1.00+/-0.57). 2
post-irradiation 2
post-irradiation, 2
mutagens. 2
varphi 2
residue) 2
h2ax 2
bradyzoites 2
bradyzoite 2
"SQEY," 2
H2A.X-F 2
<or=55 2
1057C 2
1.80, 2
(trend) 2
methyl-methanesulfonate 2
Rad54. 2
exhibited: 2
Rad54-mediated 2
H1L 2
I-SceI 2
TRF1. 2
Ser137 2
Photochemically 2
Imaginal 2
Tip60-H2AX 2
Rev1, 2
p-RPA32 2
MDC1. 2
"γ-H2AX" 2
IR-responsive 2
(gammaH2AX) 2
gamma-H2AX) 2
(ionizing 2
chemicals) 2
phosphorylatio 2
WICH, 2
Home-polysomnography 2
(HPSG) 2
Sleepbox® 2
Dream®, 2
camera, 2
Skype® 2
sensors: 2
Insight-HF 2
(MHR), 2
(RHR), 2
devices), 2
RHR. 2
China's 2
Navigation 2
(BD1) 2
sizing, 2
cardiotocographic 2
telecommunications 2
sensor; 2
emergencies, 2
wearable 2
prosthesis, 2
mono-lateral 2
telerehabilitation 2
heel. 2
furnishes 2
Fall 2
(VST) 2
acquires, 2
(ECGs), 2
(SaO2) 2
(GUI). 2
electrodes; 2
SaO2 2
percentages, 2
(Vetement 2
Tele-Assistance 2
Medicale) 2
T-shirt 2
woven 2
shock/fall 2
garment 2
methods), 2
disregarding 2
SPIA 2
crosstalk. 2
non-detected 2
(PEP), 2
Maxlink, 2
(VPA)-treated 2
sample's 2
meta-analysis-based 2
&quot;overrepresentation 2
analysis&quot; 2
ventricular-like 2
Voltage-gated, 2
dihydropyridine-sensitive 2
α(1) 2
(Ca(v)1.2) 2
α(2)δ, 2
AKAP79/150 2
Ca(v)1.2-TS 2
C-tails, 2
(CaV1.2-TS) 2
equalize 2
[Ca(2+)]i, 2
(TS1), 2
(TS1) 2
G402S/G406R 2
(TS2). 2
Splawski 2
[2004] 2
(p.Ala1473Gly). 2
(TS-1) 2
TS2-like 2
TS2 2
(TS2-neo) 2
tone-cued 2
(LQT8), 2
arteriosus, 2
Hand/foot 2
(index), 2
(middle), 2
(ring), 2
(little) 2
interval; 2
(Ca(V)1.2). 2
(G402 2
G406) 2
G406 2
IS6 2
Ca(v)beta 2
G363E 2
(I(Ca,L)). 2
pointes) 2
BayK8644. 2
nasi, 2
low-set, 2
250K 2
12q21. 2
(CART1) 2
(c.531+1G 2
neural-tube 2
frontonasal, 2
nasomedial, 2
nasolateral, 2
Pbx1;Emx2 2
Alx1, 2
Tbx15 2
Scapular 2
pectoral 2
OAR/aristaless 2
Aristaless-related 2
OAR- 2
aristaless-related 2
Prx1, 2
Alx3, 2
Alx3. 2
extinguishes 2
chondrosarcoma 2
Cart1-homozygous 2
birth-a 2
finches 2
Potocki-Shaffer 2
EFNB1, 2
ALX1, 2
FND1, 2
FND2, 2
FND3 2
CGH) 2
Invadopodia-associated 2
invadopodia-associated 2
wound-healing, 2
transwell, 2
(MMP-9). 2
Enterolobium 2
contortisiliquum 2
(EcTI), 2
N-WASp 2
Community, 2
1,531,974 2
(39.9%) 2
(Ty) 2
checkpoint-, 2
defence-deficient, 2
lifespan-deregulated 2
AOs 2
AO-mediated 2
splice-correction 2
'exon 2
skipping' 2
splice-modulation, 2
AONs. 2
chemistries. 2
prefractionation. 2
i.d. 2
nL/min 2
MPa. 2
98,977 2
9510 2
8712 2
"transcription 2
regulation"-related 2
"transport"-related 2
"one-shot 2
proteomics" 2
nano 2
refined. 2
glutamicum 2
coli). 2
competitiveness 2
time-efficient 2
poly(styrene-co-divinylbenzene) 2
monoliths 2
steepness 2
monolith. 2
(n(c)=370). 2
flow-rate, 2
(steepness 2
gradient) 2
0-0.5 2
flow-rate 2
"single-copy" 2
STB 2
plasmid-cohesin 2
high-copy-number, 2
"selfish" 2
mtw1-1 2
spindle-associated 2
PeakFinder, 2
semiperiodic 2
size; 2
separin 2
separin. 2
Eco1p(Ctf7), 2
Pds1p 2
(Cut2p), 2
sister-separating 2
Esp1p 2
(Cut1p). 2
Pds1p, 2
Scc2p, 2
Cohesin's 2
Eco1p(Ctf7p), 2
separase 2
undercondensed 2
Separase, 2
Lengthwise 2
condensin-dependent 2
passes 2
halving 2
readers, 2
Scc4 2
Scc2/Scc4 2
biphasically 2
(MeCP2). 2
archives, 2
(64.7%) 2
90.6% 2
p.R133C 2
MR; 2
MECP2-positive 2
RTT-positive 2
4b, 2
transcriptional-repression 2
MECP2. 2
clinician, 2
protein2 2
R168X 2
(20.4%) 2
(R168X 2
R255X) 2
R306C) 2
Long-read 2
44/55 2
non-diagnostic 2
two-tiered 2
(209) 2
(19) 2
frameshifts), 2
carboxyl-terminus 2
patterns). 2
hypoparathyroidism. 2
tracheostomy. 2
Attempted 2
&quot;ERRE&quot; 2
&quot;Esrrb-responsive 2
element&quot;) 2
(131)I 2
(30.7%) 2
(48.7%) 2
14C-dovitinib 2
9%). 2
benzimidazole-quinolinone 2
bisbenzimidazole 2
33258. 2
33258-DNA 2
5.99.1.2) 2
IIα. 2
enzyme-cleavage 2
'segmental 2
syndromes', 2
PSs. 2
lamins-associated 2
A-associated 2
progerias 2
pigmentosa-Cockayne 2
(XP-CS) 2
classes--those 2
(unimodal 2
Progeria 2
(WS; 2
"Progeria 2
Adults"). 2
RecQ-type 2
(sensors) 2
disposable, 2
humidity. 2
ppbv 2
(r(2 2
0.9705 2
96). 2
biosensors 2
intensivists 2
(SAW) 2
FeNO-based 2
Sepsis 2
(SIFT-MS) 2
SIFT-MS. 2
Anthropomorphic 2
hydroxybutyrate 2
(glycated 2
haemoglobin) 2
(fingerprick) 2
ppb) 2
macronutrients 2
(IGR) 2
non-liver 2
TIPS, 2
hepatologists 2
Hepatology. 2
CONCLUSIONS/SIGNIFICANCE: 2
<80 2
validly 2
ventilation/perfusion 2
>or=36 2
(87.2 2
3-116 2
MBT. 2
output: 2
Output 2
Altman. 2
analysers 2
(NIOX 2
MINO) 2
53+/-12) 2
intra-subject 2
8.7%. 2
(30.5 2
[19.8-49.8]) 2
[19-94]) 2
(p<0.044). 2
[15.8-151]) 2
"normalised" 2
(35.3 2
[13.5-35.3]) 2
ex-smokers. 2
severities. 2
C-urea 2
(EtCO2) 2
3-17 2
nebulization 2
(PEFR), 2
(PASS), 2
32.6 2
PEFR 2
PASS 2
(35.6 2
32.9 2
PEFR, 2
PASS, 2
RAPIRUN 2
(C-UBT) 2
(HM-CAP 2
EIA). 2
positive" 2
Asian-Pacific 2
ethnicity). 2
'limits 2
agreement' 2
0.08% 2
0.09% 2
RCVEGA 2
RCVHEM 2
-0.14 2
10-90% 2
light-weight, 2
spectrophotometer 2
measurement) 2
(22.5 2
97.6 2
capnography 2
87.6 2
VCap, 2
(PBF) 2
(COeff). 2
COeff 2
(R2=0.96; 2
S.D.) 2
litre/min. 2
litre/min; 2
Duplicate 2
(FT-IR) 2
PTTG, 2
(RECK). 2
under-expressing 2
adrenocorticotropin-secreting 2
higher-density 2
gelatinolytic 2
works, 2
plaque-to-plaque 2
transfers. 2
gD 2
neurovirulence 2
equate 2
transfers, 2
Vector-borne 2
VEEV 2
extinction, 2
path-integral 2
mutation-selection 2
ratchet: 2
most-fit 2
forever. 2
meltdown 2
(p-endosymbionts) 2
p-endosymbionts, 2
Riesia 2
My. 2
endosymbiosis 2
finite-population 2
Hill 2
randomly-generated 2
Muller' 2
doomed 2
magnified 2
fecundity, 2
clone-to-clone 2
(ratchet-like) 2
inexorable, 2
ratchet-like, 2
[Muller, 2
mutation-free 2
ratchet-like 2
least-mutated 2
phi 2
Mullers 2
[one-dimensional 2
(1D) 2
[two-dimensional 2
phospho-rylation 2
PHH 2
sparseness 2
vergae. 2
sotos 2
SoS. 2
SoS, 2
(p.C1593W), 2
p.R1984X 2
p.V1760Gfs*2. 2
(p.D312Rfs*2) 2
ethno-geographical 2
Europe/North 2
(70-93%) 2
(10-19%). 2
non-mutations 2
hetereogeneity. 2
Reversed 2
Gymnasts 2
(RGs) 2
Athletica. 2
RGs 2
menstruation, 2
athletica 2
(r= 2
(25-OHD) 2
(2008 2
(1981 2
(pre-eclampsia, 2
circumference). 2
3357 2
(1.79, 2
2.58), 2
(1.85, 2
2.26). 2
D" 2
"status" 2
"deficiency" 2
"insufficiency" 2
"pregnancy". 2
small-for-gestational 2
(SGA). 2
1.50-2.90)], 2
(1.12-1.70)], 2
(1.08-2.31)] 2
(1.08-2.15)]. 2
SGA. 2
22.39 2
(17.67, 2
29.38) 2
25.86 2
(19.09, 2
34.88) 2
26-28 2
September). 2
3.31 2
1.52-7.19; 2
3.93 2
2.00-7.73; 2
(62.9% 2
(66.7% 2
71.0% 2
75-g 2
P=0.009), 2
D-replete 2
(56.3 2
1.19-4.13). 2
[Vitamin 2
calcium-phosphorus 2
C-peptide, 2
Post-intervention, 2
50-80 2
0.90). 2
6?12 2
FF, 2
63.4% 2
(102), 2
(78), 2
(15), 2
11(+0) 2
-13(+6) 2
Antenatal 2
0.16; 2
hypocalcaemia 2
IGT/GDM, 2
Acting 2
53.8 2
(sd). 2
-0.35 2
-0.12). 2
(r-0.20, 2
-0.08), 2
-0.08) 2
-0.09). 2
(-0.13, 2
(1.92, 2
0.89-4.17). 2
GCT-50 2
pr 2
GTT-100 2
Carpenter 2
Coustan 2
OGTT-100 2
(DAISY) 2
DAISY 2
Willett 2
0.8-7.3 2
GAD(65), 2
Unadjusted 2
(rt-PA), 2
Restricting 2
Activator. 2
Scans 2
appraisal. 2
(0.99). 2
0.7. 2
metaanalyses, 2
postlicensing 2
mg/2 2
40-50%. 2
embolism]. 2
APE 2
angiography(CPA) 2
(2-h 2
(Qd 2
thromboectomy. 2
group(P 2
Alteplase. 2
activator: 2
Nonocclusive 2
(streptokinase, 2
alteplase) 2
(anisoylated 2
SEK3090 2
9660 2
$US35 2
(ETTT) 2
venograms 2
obstructed 2
venogram 2
29%). 2
ETTT 2
alteplase; 2
(APSAC) 2
almost, 2
urokinase. 2
hazardous, 2
recanalised 2
actin-bound 2
EGFR-ERK 2
KSR-scaffolded 2
(kinase 2
Ras), 2
beta-arrestin, 2
partner-1, 2
preassembling 2
[van 2
Hoeven, 2
Wal, 2
Ruurs, 2
Dijk 2
Blitterswijk 2
297-306], 2
GTPase-activating-like 2
(MEK)-ERK 2
699-905) 2
phenethyl 2
isothiocyanate- 2
(p38, 2
corto 2
ERK) 2
archetypical 2
(dMP1). 2
beta2-adrenergic 2
Beta-arrestin 2
(betaARs), 2
beta1AR 2
Gbetagamma 2
beta2AR 2
(KSR)is 2
Ras/Raf/MEK/ERK 2
Ser(392) 2
Thr(274) 2
KSR1.TVSA 2
KSR1. 2
anthocyanidins 2
insilico 2
Ca2+-mediated 2
Partner-1 2
"scaffold" 2
(MEK1 2
U266 2
RPMI8226-shIQGAP1 2
(clone 2
RPMI8226-shRNA 2
scaffold-MAP 2
ERK-regulated, 2
pro-migratory 2
(KSR1), 2
GAB2. 2
p14. 2
Ras/ERK 2
Ras-binding 2
scaffold: 2
13-acetate, 2
cytoskeletally 2
potentiation. 2
HAV-N 2
Erk-1/2 2
cadherin-mediated 2
N-cadherin/IQGAP1/Erk-2 2
(GRKs) 2
desensitising 2
GRK2-mediated 2
GRK2. 2
EGF-induced, 2
Rho- 2
methyltransferases1 2
(DNMT3a) 2
GAD67-positive 2
GAD67-GFP 2
decarboxylase67-enhanced 2
(GAD67-GFP) 2
GFP-immunopositive 2
GAD67-positive, 2
(BLA), 2
≈30% 2
NeuN-immunopositive 2
DNMT1-positive. 2
homo-oligomerization, 2
Dnmt2-mediated 2
DNA-methyltransferases, 2
DNA-methyltransferase-3a 2
(DNMT-3a) 2
-3b 2
(DNMT-3b). 2
DNMT-3b 2
(NPS) 2
DNMT-1, 2
SZP 2
DNMT3B7, 2
imprinting; 2
Kcnq1 2
98.9%, 2
DNMT1-overexpressing 2
DNMT3B-overexpressing 2
DNMT3b1 2
3B. 2
(miR)-29 2
(29a, 2
29b, 2
29c) 2
complementarities 2
(DNMT)3A 2
methyltransferases), 2
(H19, 2
Dlk1/Gtl2 2
(Dnmt3a 2
Dnmt3b) 2
(Dnmt3L) 2
prospermatogonia 2
Dnmt3a2, 2
GCA, 2
OsDRM2, 2
Crantz). 2
Cassava 2
Crantz), 2
(En/Spm)-like 2
Ty1/copia, 2
En/Spm 2
Mecops 2
Megyps 2
Athila 2
(Meens) 2
Hybridisation 2
(Ty3/gypsy 2
En/Spm) 2
(Ty1/copia) 2
retroviral-like 2
Xinxiang 2
('good 2
outcome'=0-2 2
'poor'). 2
copeptin) 2
Neuroendocrinology. 2
(UFCO). 2
INK4b, 2
INK4a, 2
ARF. 2
Developmentally 2
(MyoG) 2
remodeling? 2
polyubiquitination-proteasome 2
(mES) 2
Dicer(-/-)ES. 2
EZH2; 2
suppression-dependent 2
p57kip2-suppressed 2
chromatin: 2
pleiotrophic 2
immunoprecipitation-on-chip) 2
5585 2
chip-sequencing 2
(peak-calling). 2
C++. 2
Input 2
(un-normalized) 2
PCR-artefacts 2
transcriptional, 2
immunoprecipitation-sequencing 2
(Suppressor 2
Hairy-wing) 2
(H3K36me3). 2
Paired-end 2
ChIP-library 2
mappable-genome 2
(Seq), 2
(Sir) 2
Sir3, 2
hyper-ChIPable 2
ChIP-quantitative 2
immunoprecipitations. 2
nuclear-localized 2
expression-dependent 2
glycosyltransferases 2
N-acetylglucosaminyltransferases 2
N-acetylglucosaminyltransferase-III 2
-V 2
(GnT-III 2
GnT-V). 2
RhoGEF2 2
actomyosin-driven 2
(Myo-II) 2
(Dia) 2
Myosin-II. 2
RhoGEF2, 2
Myo-II 2
p120-uncoupled 2
p120-binding 2
clathrin-dependent, 2
transferrin-negative 2
[test 2
AUC(0-∞). 2
(PDE-5) 2
(6MWT) 2
(13-58) 2
48.1 2
(31-79). 2
hypertensions 2
(IPAH) 2
(PVRi) 2
(PVR/SVR) 2
PVRi, 2
PVR/SVR 2
sell 2
citrate. 2
internet. 2
gibbons, 2
AluYa5a2 2
382-bp 2
high-score 2
supposed. 2
Polyadenylated, 2
Rec12 2
(Spo11) 2
prl 2
ORFs, 2
(P<or=5.5 2
preferentially, 2
coldspots 2
(hotspots) 2
MiRNA-375 2
(hiPS) 2
passaging, 2
lentivirally 2
glucose-dependant 2
trypanosomatids 2
EFSec 2
SElenoCysteine 2
Seblastian 2
(SelS) 2
(Sec(188)) 2
(Cys(174)). 2
Cotranslational 2
SelS. 2
(variants 2
SECIS-containing 2
gruberi. 2
Sec, 2
SelD/SPS2 2
Se-dependent 2
chemiluminescent 2
SEC 2
Nucleolin 2
SECIS-binding 2
co-translationally 2
element) 2
selenoproteome. 2
(SBP2). 2
SelL, 2
UxxU 2
reducible 2
Neospora 2
single-celled 2
invariant. 2
selenocysteine-encoding 2
SEPN1 2
Readthrough 2
near, 2
3-kb 2
SelM-encoding 2
SelM 2
3" 2
cytidines 2
SelR 2
ECIS 2
(GPx). 2
probing, 2
surmounting 2
5'DI, 2
5'UGAY3': 2
5'UGAU3'. 2
tRNA(Sec) 2
5'DI 2
Burn 2
dressing 2
sedatives 2
Valid 2
(RSS), 2
sedation/extubation 2
(eta-coefficients 2
0.902 2
0.836, 2
stages). 2
intra-class 2
0.670 2
0.676 2
agreement). 2
(BIS 2
24.73, 2
21.08 2
28.37; 2
20.90, 2
14.64 2
27.16). 2
Inorganic 2
AnaConDa 2
SevAn), 2
(phases 2
ProRe(1), 2
ProRe(2)), 2
sedate 2
ProRe(1): 2
7.47 2
5.05 2
ProRe(1) 2
SevAn, 2
units: 2
(SD; 2
(66; 2
4-178) 2
mg.kg(-1) 2
(0.9) 2
mg.kg(-1).h(-1). 2
pancreatic-amylase 2
0.127). 2
limits; 2
randomly, 2
mg/kg/h. 2
4.1+/-1 2
4+/-0.9 2
(p=0.59.) 2
75+/-15 2
15+/-10.5 2
(p=0.0045). 2
Pre-infusion 2
pre-infusion 2
(p=0.36). 2
(p=0.231). 2
mechanichally 2
irritations 2
nonemergent, 2
hrs. 2
63.0 2
.044). 2
PICU, 2
dangerously 2
NONMEM. 2
weight-proportional 2
min-1, 2
l, 2
kg-1P 2
0.035 2
l-1, 2
s.e. 2
0.2-2.5 2
SAZN) 2
(Cl), 2
(Vd,ss), 2
(t1/2,beta) 2
(t1/2,alpha) 2
ml/kg/min, 2
l/kg, 2
SEM, 2
SAZN, 2
Diprivan-10, 2
(ns). 2
(100) 2
Propofol, 2
mg.kg-1.hr-1) 2
(PaO2/FiO2 2
mg.kg-1.hr-1. 2
nil, 2
extreme) 2
2.9, 2
3.9, 2
Swan-Ganz 2
radioimmunoassay, 2
micrograms.kg-1) 2
micrograms.kg-1), 2
2.6)) 2
909 2
100)) 2
7)) 2
44); 2
33)) 2
(TIMP1) 2
intermediate-length 2
sedation); 2
underutilization 2
Rel/NF-kappaB-family 2
Rel-A, 2
Rel-B, 2
NF-kappaB/p50 2
NF-kappaB2/p52 2
tumour-necrosis 2
co-regulatory 2
rela, 2
relb, 2
crel, 2
nfkappaΒ1, 2
nfkappaB 2
differentially. 2
Jaundice 2
non-haemolytic 2
hyperbilirubinaemias 2
(Dubin-Johnson- 2
Rotor-syndrome). 2
post-transcriptionally). 2
intertwined. 2
CMV-DNA 2
P3-P7 2
considerations: 2
site-tethering 2
FGF-R2 2
transformation-competent 2
(TAC)-based 2
CreloxP 2
stacked 2
(MSC), 2
(ITH) 2
S1P3 2
"Stem 2
Strategies" 2
[Transplantation 2
studies]. 2
(IVIg) 2
transplanted, 2
interdependencies 2
30-nt 2
nuage-associated 2
(piRNA 2
granule. 2
AGO3, 2
Tud, 2
Spn-E, 2
Bel, 2
Squ, 2
Cuff, 2
piNG-bodies 2
Tud 2
csul 2
Trans-Silencing 2
(TSE), 2
P-transgene 2
Sequences, 2
"TAS") 2
P-lacZ 2
HP1) 2
TSE. 2
piRNA-based 2
MILI- 2
MIWI2-deficient 2
homolog)-deficient 2
MVH-deficient 2
TE-directed 2
PIWI-mediated 2
PIWI-regulated 2
PIWI-targeting 2
piRNA-silencing 2
nongonadal 2
mycelia, 2
ammonium. 2
UaY 2
AreA 2
related) 2
permease. 2
uapC, 2
2-thiouric 2
ammonium; 2
uaY 2
(mediating 2
61,251) 2
UapA 2
(23-34% 2
hydropathy 2
Modelling, 2
AzgA. 2
(TMSs 2
(TMS8) 2
well-regulated 2
AtAzg2, 2
adenine-guanine-hypoxanthine 2
8-azaadenine 2
cell-line-derived 2
glial-cell-line-derived 2
(GFRalpha) 2
GFRalpha-2. 2
NTN); 2
ECE-1); 2
GDNF/GFRalpha-1 2
NTN/GFRalpha-2, 2
(NTN) 2
GFRalpha-1 2
RET/PTCs, 2
(Multiple 2
Neoplasia) 2
(Familial 2
Medullar 2
Carcinomas) 2
enlightening 2
Ret/ptc2 2
proto-Ret). 2
Shc 2
Ret/ptc2Y620F 2
phosphotyrosines, 2
sympathetic, 2
Artemin, 2
ligand/receptor 2
acetylcholinesterase, 2
stigmata, 2
ganglioneuromatosis 2
MTCs, 2
GDNFR-alpha, 2
GDNFR-alpha 2
RET-specific 2
(PSPN) 2
GFRalpha2.RET) 2
GFRalpha2.RET 2
GFRalpha1. 2
glycosyl-phosphatidylinositol 2
GDNFR-alpha) 2
tyrosine-phosphorylation 2
GPI)-linked 2
Tunisia: 2
GdA(-) 2
GdB(-) 2
10.72 2
cultivation. 2
I137M 2
ARVD; 2
Coexistence 2
(p.W1095X, 2
c.3284G>A) 2
(R27H, 2
E901K, 2
G1743R 2
V728I, 2
N1443S 2
E1152X). 2
p.Arg222X) 2
Ala2>Thr, 2
Ala735>Thr 2
Val1340>Ile) 2
SCN5A-encoded 2
nonwhite 2
2,111 2
E1784K 2
(14x), 2
F861WfsX90 2
(11x), 2
D356N 2
G1408R 2
(7x). 2
TSA201 2
short-coupled 2
storm. 2
W822X 2
nonsense-mutated 2
W822X, 2
co-transfected, 2
88.4% 2
</=.001). 2
whole-cell, 2
pilsicainide 2
share, 2
V95I, 2
A1649V 2
Valine 2
(c.4810+3_4810+6dupGGGT) 2
(asymptomatic 2
(96.7%) 2
R367H 2
A735V 2
R1192Q 2
(D1790G) 2
(D1795) 2
Hyperinsulinemic 2
genito-urinary 2
4.6-11.0 2
12-49 2
diazoxide. 2
21/27 2
microdeletion). 2
Age-appropriate 2
(tall 2
macrocephaly), 2
parotitis. 2
recognisable 2
gigantism, 2
coincidence, 2
CRAPome) 2
pharmacotherapies: 2
Stopping 2
1.34; 2
nortriptyline, 2
(varenicline 2
1.91), 2
spray, 2
1.79), 2
SAEs. 2
1.67), 2
1.26; 2
Nortriptyline 2
1.63; 2
NRT. 2
harms. 2
smoking? 2
random- 2
mixed-treatment 2
(MTCs) 2
decision-analytical 2
0.92). 2
non-electronic 2
2000-3000 2
disadvantaged 2
(RG7112) 2
FXI, 2
ASOs 2
YM150). 2
auspices 2
formularies. 2
pentasaccharide, 2
(AF); 2
-xabans). 2
eribaxaban, 2
(thrombin) 2
idrabiotaparinux. 2
hirudin 2
(lepirudin), 2
bivalirudin, 2
darexaban 2
non-requirement 2
rivaroxiban, 2
(betrixaban 2
YM150) 2
(apixaban, 2
Heparins 2
iatrogenicity, 2
(heparins, 2
pharmacodynamic, 2
(PRT054021): 2
unmonitored 2
(EXPERT) 2
(EXPLORE-Xa), 2
(APEX). 2
(deep 2
[dabigatran 2
(BIBR 2
1048), 2
AZD0837)], 2
(flovagatran 2
sodium), 2
[rivaroxaban 2
59-7939), 2
YM150, 2
DU-176b, 2
LY-517717, 2
GW813893, 2
TAK-442, 2
0348292] 2
[idraparinux, 2
idrabiotaparinux 2
(biotinilated 2
idraparinux; 2
126517), 2
ultra-low-molecular-weight 2
(ULMWH: 2
AVE5026, 2
RO-14)]. 2
AZD-0837) 2
DU176b, 2
idrabiotaparinux). 2
(PRT054021), 2
N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, 2
eribaxaban 2
(tecarfarin) 2
genotype/phenotype/cancer 2
IBMFS 2
Interpupillary 2
(PFL), 2
A-scan 2
(pigmentary 2
retinopathy) 2
trichiasis 2
Syndrome-specific 2
antedate 2
hematologists 2
thrombocytopenia). 2
Cameroon, 2
Cote 2
Abim, 2
Agago, 2
Kitugun 2
Sudan. 2
YF. 2
17D-204 2
freeze-dried, 2
Revaccination 2
(YFV). 2
Travelers, 2
Regulations 2
(IHR) 2
(IFN-α/β) 2
(IFNAR⁻/⁻ 2
YFV-17D, 2
YFV. 2
IFNAR⁻/⁻ 2
YFV-17D 2
temephos-treated 2
Re-emergence 2
(verapamil 2
AaegP-gp 2
Orthobunyavirus 2
ArboChip5.1 2
aegyptii, 2
4.80, 2
3.84, 2
2.01, 2
filariasis 2
acceptance. 2
biocontrol, 2
Wolbachia-based 2
Ombella-Mpoko, 2
Ouham-Pende, 2
Basse-Kotto, 2
capital. 2
mosquito-only 2
Kamiti 2
Binh 2
Nakiwogo 2
Calbertado 2
previously: 2
caspius), 2
theileri 2
vexans, 2
vexans 2
cinereus. 2
insect-only 2
alphaviruses. 2
Health-care 2
pre-travel 2
Governments 2
revaccination 2
Mosquito-borne 2
chikungunya, 2
Malambo, 2
Sabethes 2
Malambo 2
(CHI). 2
(weight, 2
(CrCl) 2
(venous 2
bleeding), 2
dialysed 2
XLgoo 2
Amphibian 2
T(3)-dependent 2
(TNFR1) 2
(VAP). 2
stewardship 2
Acintobacter 2
(SOT), 2
bacteremia-related 2
antitumor, 2
21-0208 2
FGFR/VEGFR/PDGFR 2
FGF-induced 2
FGFR-1, 2
FRS2-α 2
FGFR/PDGFR-β/VEGFR-2 2
p-histone 2
H2A-X 2
p-cdk-2 2
(WM), 2
WM, 2
BAPTA 2
aequorin-injected 2
(h-L) 2
half-curve 2
inflection 2
(m-E) 2
(faCaT) 2
(CaT) 2
photoprotein 2
aequorin, 2
faCaT 2
(dCa/dt(max)) 2
curve-fitted 2
0.9740 2
0.9654 2
0.9895 2
0.9812 2
(Ca(2 2
+)) 2
t-tubule 2
(Ca(2+))-induced 2
CSQs 2
Waves 2
TBQ 2
buffering. 2
RYR, 2
ultra-violet 2
twitch. 2
dyad, 2
loose-patch 2
(LCC) 2
(CHT) 2
LCC-RyR 2
hit, 2
DHT, 2
"intermolecular 2
failure." 2
junctophilin, 2
"Ca(2+) 2
spikes," 2
desynchronized, 2
integrals 2
CHT. 2
"stability 2
margin," 2
Putting 2
regenerative, 2
RyRs. 2
Calcium-dependent 2
(trifluperazine, 2
raclopride, 2
(melperone, 2
seroquel, 2
perlapine, 2
sertindole) 2
neostriatum: 2
(chlorpromazine, 2
remoxipride 2
risperidone). 2
(chlorpromazine 2
haloperidol) 2
neostriatum, 2
nonantipsychotic 2
tiapride, 2
fluperlapine, 2
melperone 2
Neuroleptics 2
(EPS) 2
metoclopramide 2
(AP, 2
agonist-antagonist 2
dopamine-stimulated 2
(0.4-0.8 2
d-amphetamine 2
dihydroxyphenylactic 2
olfacotry 2
tubercles. 2
Dusp16/MKP-7 2
(Dusp) 2
Dusp16 2
Dusp16. 2
Tie-2 2
Ang-1 2
SAPK/JNK 2
phosphatases-, 2
atypical-, 2
function-structure 2
MAPKKs 2
DUSP16 2
activivity 2
(MAPKs), 2
MKP-DUSPs, 2
MkpB, 2
post-aggregative 2
ameba 2
mkpB 2
MkpB 2
(DUSP1) 2
DUSP1(-/-) 2
puckered 2
lambda-phosphatase 2
Ser413, 2
low-molecular-mass 2
CH2 2
(Cdc25 2
surface-charge 2
substrate-interaction 2
loop-to-strand 2
activity-inhibition 2
active-pocket 2
Khalid 2
BladderScan 2
(Diagnostic 2
Ultrasound, 2
WA) 2
measurements: 2
postvoid 2
Invalid 2
filling. 2
BWTs 2
(UF) 2
post-voiding 2
790). 2
0.568). 2
2.8), 2
3.1), 2
2.6), 2
0.2959). 2
0.079, 2
Strong, 2
subvesical 2
nomogram; 2
(54, 2
N/cm2), 2
BWT; 2
(sd) 2
(3.9) 2
N/cm2, 2
N/cm2 2
N/cm2. 2
Kidneys 2
-0.12, 2
0.014) 2
0.17, 2
3.08 2
genders, 2
Ultrasound: 2
eight-four 2
videocystourethrography 2
(VCU) 2
(102) 2
VCU 2
urodynamics. 2
VCU. 2
(LY-450139) 2
(GSM) 2
Aβ38. 2
Tarenflurbil, 2
Washout 2
IC(50)s 2
LY450139. 2
LY450139-mediated 2
Aβ(1-15) 2
Aβ(1-16) 2
E2012, 2
LY450139, 2
Aβ(1-37) 2
Abeta1-40 2
Abeta1-14, 2
Abeta1-15, 2
Abeta1-16 2
(GSIs), 2
(hydroxylvaleryl 2
monobenzocaprolactam), 2
N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine 2
engines; 2
(CDSs) 2
ATHENA-Hypertension, 2
VA/Department 2
initiating, 2
titrating, 2
medications; 2
guideline-concordant 2
(CBDS) 2
(PCPs) 2
"treat" 2
practice). 2
PCPs' 2
"prescribed" 2
c.203T>C 2
PRPP 2
HPRT-deficiency 2
10A 2
neural-related 2
hypoxanthine, 2
(k(cat)) 2
Lesch-Nyhan-diseased 2
hypoxanthine-phosphoribosyltransferase 2
HPRT, 2
(hNSCs) 2
Totipotent 2
parasexual 2
mutagenization 2
blastocyst-stage 2
embryology. 2
HPRT1-cells 2
endoduplication 2
(HGPRT), 2
charactistic 2
amidophosphoribosyltransferase. 2
amidophosphoribosyltransferase 2
PP-ribose-P 2
Lesch-Nyhan-syndrome 2
Hypoxanthine-guanine 2
HPRT1. 2
(HPRTFlint). 2
HPRTFlint 2
Alu-sequences, 2
MicroRNA-mediated 2
En1/2 2
miRNA-binding 2
Wnt1 2
phosphoribosyltransferase-deficient 2
oxypurine 2
(LNS). 2
LNS 2
Paz 2
wheelchair, 2
himself. 2
(NM_000194.2: 2
c.552 2
exon-5 2
(SAMe) 2
methylthioadenosine 2
(MTA) 2
MTA's 2
MTA, 2
cell-permeant. 2
SAMe's 2
Lys-27 2
SET. 2
(PRDM2) 2
(MMT). 2
methionine-sensitive 2
-insensitive 2
S-methyltransferases 2
(SMM:Hcy 2
HMT) 2
yagD 2
Met, 2
AtHMT-2 2
pro-R 2
AdoMet:Met 2
pro-S 2
stereoselectivities 2
Phosphorylation-mediated 2
coactivator-associated 2
Coactivator-associated 2
1month 2
EI1, 2
S-Adenosyl 2
non-SET 2
~25 2
synthetases. 2
sasA 2
Hülle 2
mutant/SAM 2
"bump-and-hole" 2
SMYD2. 2
(PRMTs) 2
PRMT 2
c-557 2
[14C]methyl 2
Paik 2
'human 2
regions', 2
HAR1, 2
(HAR1F) 2
HAR1F 2
six-layer 2
REST. 2
(HAR1), 2
VIM-1; 2
VIM-2 2
OXA-23. 2
phenylboronic 2
acid- 2
bla(IMP), 2
bla(VIM), 2
bla(SPM), 2
bla(SIM) 2
bla(GIM), 2
bla(KPC), 2
bla(NDM) 2
VIM-1, 2
OXA-162 2
β-lactamases. 2
Check-MDR 2
CT102 2
(NDM, 2
VIM, 2
IMP) 2
ESBLs 2
KPC-producing 2
co-production 2
>or=5 2
MicroScan 2
(BD 2
metallo-carbapenemases. 2
Producers 2
IMP-, 2
VIM-, 2
KPC-type 2
cephalosporins 2
1x10(1) 2
CFU/ml. 2
ESBLs, 2
metallo-beta-lactamase 2
strains), 2
VIM-1 2
SME-2 2
MbetaL-producing 2
serine-carbapenemases 2
non-carbapenemase-mediated 2
(IPM), 2
(MEM), 2
BA-based 2
double-disk 2
combined-disk 2
IPM, 2
MEM, 2
3-aminophenylboronic 2
(extended-spectrum 2
AmpCs, 2
metallo-beta-lactamases, 2
(2000-2004). 2
(2000-2004) 2
[MIC], 2
riboprinting 2
clonality. 2
37,557 2
(0.32%) 2
Arkansas, 2
America), 2
Carbapenemases 2
(KPC) 2
microg/mL, 2
ceftazidime 2
metallo-β-lactamase-producing 2
blaVIM-1 2
integron 2
IncHI2 2
order; 2
vestige 2
CDKAL1 2
IRX3 2
(RCEs) 2
histones). 2
Otx 2
Islet, 2
thought-involving 2
∼12% 2
genome-and 2
Kbp 2
gene-free 2
(Lmbr1 2
Rnf32). 2
(n=34), 2
46.7%. 2
31.6% 2
v-raf 2
MTCs: 2
(M918T) 2
(C618S 2
C620S). 2
(C618S), 2
(C620S), 2
(M918T). 2
RET-negative 2
MTC. 2
Tygerberg 2
phaeochromocytoma, 2
cases); 2
G691S/S904S 2
(C618R) 2
MEN2A) 2
HSCR-MEN2 2
(MTC), 2
pheochromocytoma). 2
FMTC/MEN2, 2
MEN2-associated 2
Cys611Tyr 2
MEN2A, 2
MEN2B, 2
(FMTC), 2
AS-MTC 2
MEN2A/FMTC-HSCR. 2
C620S 2
620, 2
[Non 2
27%o 2
20%> 2
47%o 2
Non-compaction 2
hypertrophy: 2
hypertrabecularisation 2
non-compacted 2
following-up) 2
(17.5%, 2
7/40). 2
(30.3%) 2
(SSS) 2
matrilineal 2
(m)H2A 2
gene-reprogramming 2
seasonally 2
carp, 2
macroH2A1-dependent 2
pro-pol 2
MLVs, 2
proviruses. 2
macroH2A1/H2B 2
winter-acclimatization 2
colder 2
(hnRNP) 2
(BW) 2
(propyleneglycol) 2
+/-1.6 2
(10.3 2
(RT-PCR)/enzyme-linked 2
(DEA) 2
DEA, 2
(f) 2
ActD, 2
DEA. 2
almokalant, 2
Haber 2
AluY 2
Malagasy 2
19-nucleotide-long 2
"retropositional 2
prosimians 2
Castellvi 2
type1a 2
ODI 2
neoarticular 2
Unsuspected 2
extraforaminal 2
Fluoroscopically 2
anesthetic/corticosteroid 2
circumferentially 2
buttock, 2
neo-articulation 2
mega-apophysis. 2
diagnostic-therapeutic 2
ala. 2
(chronic, 2
vertebra). 2
[MR] 2
[CT]). 2
protrusion) 2
vertebra. 2
Chicken 2
intensity-based 2
(iBAQ) 2
Intensity-Based 2
mix, 2
pharmacologically. 2
EDP 2
stretch-activated 2
Stretch 2
non-stretched 2
wall) 2
flecainide-induced 2
running, 2
Flecainide, 2
(LVPG) 2
disopyramide, 2
36.6 2
26.4 2
myectomy 2
1c 2
administrated. 2
HtzD3KO 2
Dio3 2
(TOD) 2
TOD 2
TRa1 2
wallstress, 2
remodeling: 2
reconsider? 2
"index 2
event" 2
supra-physiological 2
n=8), 2
n=8). 2
n=9). 2
(SI, 2
1.51(0.03) 2
1.64(0.03) 2
improved: 2
(2.1) 2
4250 2
(127) 2
2278 2
(55) 2
2737(233) 2
1508 2
3866 2
(310) 2
2137(111) 2
-THYR, 2
(TH)-TH 2
"rebuild" 2
fetal-like 2
"cardiac 2
metamorphosis": 2
"switch" 2
sulforaphane-derived 2
sulforaphane-induced 2
Cdk1. 2
bark 2
(MMP), 2
(Cyto 2
(CDK1). 2
CDK1/cyclin 2
oxamate. 2
DICO, 2
flavonoid, 2
Macrothelypteris 2
torresiana. 2
DICO. 2
p-cdc25c 2
cdc25C 2
p21WAF1-related 2
(C(15)H(20)O(2)) 2
dose-and 2
(Δψm) 2
p53-mutant 2
Cdc2-p21WAF1 2
costunolide-induced 2
25C 2
(Cdc25C), 2
SKOV-3, 2
TOV-21G, 2
Growth-inhibitory 2
H(2)A.X 2
Ser139 2
(DN-Chk2). 2
DN-Chk2 2
Rheum 2
palmatum 2
emodin-mediated 2
psi(m)) 2
emodin-induced 2
plumbagin 2
S-G2/M 2
plumbagin-mediated 2
plumbagin-triggered 2
Isoobtusilactone 2
species/apoptosis 2
isoobtusilactone 2
(IOA) 2
cdc2 2
EUK8 2
cystenine 2
Ser(967) 2
GS-563253, 2
II-1). 2
L159F/L320F 2
(prodrug 2
PSI-6130) 2
(L159F/L320F) 2
3.1- 2
palmitoyltransferases 2
(transplanted 2
hepatocytes). 2
SPT; 2
Vaniprevir 2
(Incivek) 2
(Victrelis). 2
DAAs, 2
(NS5A 2
NS3-V36A 2
BMS-788329. 2
NS5A-L31V 2
NS5A-Y93A 2
Daclatasvir 2
(BMS-790052), 2
ACH-806, 2
GS-9132) 2
(p14) 2
Telaprevir 2
(PEG-IFN) 2
non-dimeric 2
BMS-790052, 2
400mg 2
G2/3-infected 2
-0.21 2
antivirals. 2
(NS5A) 2
(BMS-790052) 2
(MOA) 2
lifecycle, 2
Latium, 2
lentic 2
lotic 2
ars 2
As-containing 2
arsenic-toxicity. 2
TolC-like 2
HgdD 2
resistance-nodulation-cell 2
(RND) 2
all3143 2
All3143 2
All3144, 2
AcrB 2
AcrA, 2
cyclic-di-AMP 2
self-protection, 2
GS-5 2
tetracycline-resistant 2
ramR 2
(mode 2
parC 2
83, 2
AcrAB-TolC 2
nodulation 2
(RND)-type 2
KAM33 2
hypersusceptible 2
VmeCD, 2
VmeEF, 2
VmeYZ 2
(MICs) 2
chassis 2
cell/chassis 2
streamlining 2
preconditions 2
genome-driven 2
Pelagibacter 2
Vesicomyosocius 2
okutanii 2
300-350 2
genome'. 2
sets' 2
parts-list, 2
refocusing 2
(18.7% 2
0.0022) 2
2.28 2
(MRS 2
non-crack-cocaine 2
abusers. 2
Forensic 2
5,142 2
(63.5%) 2
(36.5%) 2
(P=.004), 2
(37.7% 2
8.6%) 2
(36.1% 2
65.7%). 2
aneurysmal. 2
[HSP]). 2
3.73; 2
5.21). 2
24.97; 2
infinity; 2
3.29), 2
2.35), 2
3.83; 2
8.46), 2
2.48; 2
5.20), 2
3.87), 2
(Atlanta, 2
Ga.) 2
civilian, 2
non-institutionalized 2
four-vessel 2
arteriogram 2
aneurysms; 2
32.8 2
52.2 2
(berry) 2
jurisdictions. 2
cases--an 2
(In 2
Jefferson 2
13.6%. 2
4.9%. 2
1994. 2
non-black 2
Hypertensive 2
maternal/fetal 2
abusers, 2
7.60% 2
8.33% 2
(freebase) 2
(April 2
addicts]. 2
amphetamine-like 2
1983, 2
hemorrhagic) 2
stem) 2
(intranasal 2
47.8%. 2
15a*, 2
34a*, 2
34b*, 2
551b, 2
873, 2
876-3p, 2
1274a 2
BRAF(V600E). 2
tumor-node-metastasis 2
(III/IV), 2
BRAFV600E. 2
transcriptase-quantitative 2
miR-21/miR-106a 2
Borrmann 2
0.969 2
0.871 2
miR-106a. 2
miR-27a, 2
miR-148a, 2
miR-196a, 2
kappa-light-chain 2
B-cells-1 2
(Nfκb1), 2
kinase-8 2
(Mapk8) 2
v-Ki-ras2 2
(K-ras) 2
follicular-cell-derived 2
poorly-differentiated/anaplastic 2
(PD-AC)). 2
PCs, 2
PD-ACs, 2
Nonneoplastic 2
inflammatory-related 2
54). 2
CRY61, 2
|Z-score| 2
(hMTC) 2
(sMTC). 2
miR-127 2
miR-572, 2
miR-923, 2
miR-638, 2
miR-660, 2
miR-142-5p, 2
miR-30b, 2
miR-let-7f, 2
(labeled 2
25MC10 2
serum-induced 2
onco-miRNAs 2
Microribonucleic 2
miR-17), 2
miR-181, 2
miR-449, 2
miR-486, 2
let-7a) 2
microcystins 2
MC-induced 2
MC-LR. 2
post-transcriptomics, 2
MCs. 2
cancer--from 2
(HGPIN). 2
non-organ-confined 2
Micro 2
mirVana 2
hsa-miR-let7c, 2
hsa-miR-15a, 2
hsa-miR-16, 2
hsa-miR-21, 2
hsa-miR-25, 2
hsa-miR-32, 2
hsa-miR-100, 2
hsa-miR-143, 2
hsa-miR-145, 2
hsa-miR-146a, 2
hsa-miR-191, 2
hsa-miR-199a, 2
hsa-miR-206, 2
hsa-miR-218. 2
7500 2
Mix. 2
2(-ΔΔCT) 2
RNU43 2
miRNA-targeted 2
single-, 2
(miR-16, 2
miR26b, 2
miR27b, 2
miR-203) 2
adenocarcinoma: 2
1.13-3.75), 2
miR-17 2
1.10-3.61), 2
1.27-4.42) 2
2.16, 2
nicotine-treated 2
Nicotine-mediated 2
IkappaBα 2
(Bay-11-7085) 2
NF-κB-binding 2
COX-2/prostaglandin 2
E₂ 2
(PGE₂) 2
nicotine-mediated 2
nicotine-promoted 2
EP2/4 2
miR-29b, 2
miR-34a/b/c, 2
IALT 2
Polyphenon-60 2
(green 2
tropomyosin-1. 2
Fluorescence-based 2
codetection 2
receptor-mutant 2
1.04-2.77) 2
transcriptase-PCR. 2
IL-12a 2
ANXA1, 2
IL-17a, 2
HLA-DRA 2
(/Z-score/ 2
>1.5) 2
IL-12a, 2
NOS2a, 2
miR-768-3p, 2
miR-139-5p, 2
miR-497 2
miR-20b, 2
miR-18b, 2
miR-421, 2
miR-340*, 2
miR-19a 2
miR-658. 2
(ablation 2
evagination 2
invagination), 2
(skin-specific 2
psoriasisspecific 2
process), 2
miRNA). 2
miR-125a, 2
miR-99a, 2
nontumorous 2
1.2-5.2) 2
1.4-3.9), 2
miR-205 2
HER2; 2
EMT-specific 2
miR-205. 2
PDA. 2
PDA-derived 2
viverrini 2
up-regulation) 2
STAT3-dependent 2
KRAS-induced 2
alveoli 2
oncomiRNAs. 2
ERK/NF-κB 2
(HELF) 2
Pten, 2
Spry1 2
CCL20 2
intramucosal 2
IEN 2
miR-21-null 2
polypoid 2
(low- 2
(LNA)/DNA 2
biotin-free 2
miR-21-expressing 2
LNA-ISH 2
self-reinforcing 2
protumorigenic 2
miRNAomes 2
GSC. 2
Sprouty2 2
(5-FU) 2
(mir‑21) 2
Spry2-associated 2
chromophobe 2
(ccRCC) 2
oncocytoma 2
ccRCC, 2
TCCs. 2
usher 2
TMZ-induced 2
miR-148a) 2
MRL/lpr 2
autoimmune-associated 2
miR-221) 2
HS766T 2
microRNA-21(miR-21) 2
lymphoma/leukemia. 2
(CD3(-)CD56(+)) 2
(ASO-21) 2
(ASO-155) 2
AKT(ser473). 2
never-smokers. 2
miR-138) 2
never-smoker-derived 2
(mir-21) 2
MRE 2
JB6 2
miR-204 2
insulin; 2
(let-7 2
Ras) 2
(miR-143, 2
miR-26a-1, 2
miR-21). 2
diagnosis-related 2
DALYs 2
1-1.5% 2
blockers: 2
(R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone 2
(KVI-020/WYE-160020) 2
KVI-020 2
(4g) 2
NS8593 2
AF-ablation 2
high-normal 2
tract), 2
(ATG-Fresenius), 2
(FLAMSA)-RIC 2
intermediate-2 2
HLA-mismatched 2
0.19). 2
FLAMSA-based 2
sAML) 2
g/m(2), 2
FLAMSA). 2
-10, 2
(ATG-Fresenius) 2
(FLAMSA-ATG-TBI) 2
radio/chemotherapy, 2
alloSCT 2
TBI/cyclophosphamide/ATG) 2
alloSCT. 2
engrafted, 2
nonrelapse 2
leukemia-free 2
standard-risk 2
<55 2
NEMO's 2
five-Ala 2
seven-Ala 2
(IKKα 2
IKKβ) 2
NEMO/IKKγ 2
Tax, 2
virus-transformed 2
IκBα. 2
IKKβ), 2
SNAP-23, 2
target-membrane 2
(SNARE). 2
ELKS, 2
(IKKα, 2
IKKγ/NEMO), 2
TGFβ-activated 2
TH+ 2
factor-kB-related 2
IKK-β 2
diseases,such 2
(IKK)-complex 2
IKKγ. 2
IKKalpha). 2
IKKgamma; 2
CC2 2
LZ 2
NF-kappaB) 2
IKKbeta(DeltaNBD) 2
IKKalpha(WT) 2
IKKalpha(DeltaNBD) 2
IKKalpha-IKKbeta-NEMO 2
(IKK1, 2
IkappaB-Kinase 2
IKK-binding 2
IKKbeta/IKKgamma 2
α-Synuclein-induced 2
(SSB) 2
hypofunction. 2
accommodating 2
(BAFF). 2
FR3, 2
FR2 2
FR1c 2
monoclonality 2
dacryoadenitis 2
SjS 2
NOD.B10-H2(b) 2
lachrymal 2
effecting 2
Exocrine 2
mouth) 2
xerophthalmia 2
eyes). 2
SjS-like 2
CVF 2
(SS), 2
moisture-producing 2
attitudes. 2
appearing, 2
(Sjögren's 2
xerostomia, 2
flexion-extension 2
ununited 2
ramus, 2
extraperitoneal 2
realignment 2
polytraumatized. 2
Sacroiliac 2
massive, 2
Fixation 2
authours 2
polytrauma 2
dislocation, 2
(PTF) 2
(double-vertical) 2
fracture/dislocations. 2
half-pins) 2
5-mm 2
forty-seven 2
posterior-superior 2
pelvises. 2
female--case 2
"Banjica" 2
Belgrade, 2
supracondylar 2
cradle 2
(1/4 2
traction, 2
Traction 2
gravitational 2
cradle, 2
sacrum, 2
parses 2
Criticia, 2
Glimmer 2
ZCURVE. 2
32.3% 2
N.crassa, 2
GenScan, 2
HMMGene, 2
GeneMark, 2
FFG, 2
(GHMM) 2
GENSCAN, 2
programs: 2
FGENES, 2
GeneMark.hmm, 2
Genie, 2
Genescan, 2
HMMgene, 2
Morgan, 2
MZEF. 2
re-analyzed 2
(FEXH, 2
GeneParser3, 2
GEN-SCAN 2
q(9), 2
FGENES; 2
Gene-Mark.hmm; 2
Genie; 2
Genescan; 2
HMMgene; 2
Morgan 2
MZEF, 2
s(p) 2
(c-Myc) 2
CACGTG 2
P-enolpyruvate 2
carboxykinase 2
(PEPCK) 2
(threefold) 2
6-phosphofructo-2-kinase 2
fourfold) 2
threefold) 2
glucokinase, 2
hexokinase-I. 2
GLUT2 2
grows, 2
ref. 2
Sirt6 2
Hif1alpha. 2
homeostatically 2
(LDHA), 2
miR-23a/b 2
Myc-mediated 2
shift: 2
PVHL 2
Vhlh 2
glucose-mediated 2
Ser-140 2
Glut3. 2
p65/NF-kappaB 2
Ras-expressing 2
(HIF)-1alpha, 2
GLUT-1, 2
oxemic 2
2-deoxyglucose 2
non-hypoxic 2
prosurvival, 2
-2alpha 2
endoglin 2
glucose-signaling 2
Mlx. 2
pp60c-Src 2
(HIF)-1alpha 2
pp60(c-Src) 2
Src-induced 2
cap-dependent 2
heterodimerisation 2
Rat1a 2
phosphoglucose 2
Rat1 2
MODY1 2
HNF4alpha. 2
(PI3K)/Akt/mammalian 2
Adenocarcinomas, 2
(T790M 2
(60-70%) 2
(tumour 2
[Re-treatment 2
inhibitor(EGFR-TKI)for 2
adenocarcinoma]. 2
(5/11) 2
Re-administration 2
Summarizing, 2
leucine-to-arginine 2
(L858R). 2
"addicted" 2
receptor(EGFR)-tyrosine 2
inhibitor(TKI)(such 2
erlotinib)treatment 2
erlotinib). 2
<0.0001, 2
tegafur-gimeracil-oteracil 2
paraffin. 2
[Advances 2
(L858R 2
Iressa) 2
Gefitinib-sensitive 2
"never 2
smokers" 2
In-frame 2
alterations; 2
gefitinib-refractory 2
(Tarceva), 2
undocumented, 2
erlotinib-refractory 2
smokers"), 2
2-28 2
proteins-components 2
ChChd3), 2
STED 2
(STED) 2
transport-associated 2
Sam50. 2
architecture: 2
CJs 2
Mitofilin/Fcj1, 2
(IMM), 2
MITO-MAP 2
Fcj1/Mitofilin, 2
Mitofilin/Fcj1 2
postgenomic 2
oceanography. 2
freshwater, 2
seawater, 2
Metatranscriptomics 2
Culture-independent 2
(8.3% 2
photosynthesis, 2
Burkholderiales, 2
Actinomycetales, 2
Rhizobiales 2
fluorene 2
Bottom-up 2
"who 2
there?", 2
"what 2
doing?", 2
"how 2
compare?". 2
functioning: 2
(DNA, 2
biocatalysts. 2
DNA-based, 2
mRNA-based, 2
plankton 2
SAR11 2
OM43 2
biogeochemistry. 2
TonB-dependent 2
rhodopsins 2
(metaproteomes). 2
metaproteomes 2
Replicated 2
exchanges. 2
CO(2). 2
Olavius 2
algarvensis, 2
symbionts. 2
D17Z1, 2
EW206, 2
HHH202 2
3.86 2
D17Z1 2
markers--p17H8, 2
EW204--were 2
D17S57 2
7AE-11 2
(NF13) 2
t(17;22) 2
(q11.2;q11.2). 2
NF13 2
(17q11.2 2
17q11.2-q12). 2
schwannoma. 2
lissencephaly) 2
lissencephaly, 2
(17p13.3), 2
heteropias. 2
Duplicon-mediated 2
exophthalmos 2
LOH; 2
Astroblastoma 2
astroblastoma-sarcoma, 2
recurrent-remittent 2
(NFI) 2
(25/61) 2
(21/25) 2
orifice 2
c.4821delA 2
(p.Leu1607fs). 2
vitrification, 2
Trophectoderm 2
CAL 2
(c.654 2
monozygosity. 2
discordance. 2
[NF1 2
neuro- 2
disorder-neurofibromatosis 2
Adaptations 2
(TRalpha1+m 2
HCN4. 2
cardiomyocytes; 2
TH-induced 2
responsive, 2
(Ad) 2
caPKC 2
dnPKC 2
alpha-transduced 2
(T3)-responsive 2
adenosinetriphosphatase 2
Excised 2
chromatography/high-resolution 2
(LC/MS) 2
urine), 2
peak-generating 2
Methodology 2
Metlin. 2
spectrometer, 2
log2 2
132, 2
enough, 2
MS/MS, 2
METLIN, 2
(IRBC) 2
(LC-Q-TOF-MS), 2
seven-step 2
LC-Q-TOF-MS 2
XCMS, 2
yin-yang 2
estrodiol, 2
leucotriene, 2
(HMDB), 2
Madison 2
(MMCD), 2
Metlin, 2
MAPS. 2
Bufonis 2
chromatography/electrospray 2
Feature 2
1-Linoleoylglycerophosphocholine 2
(http://metlin.scripps.edu), 2
repository, 2
MMA 2
interfaced 2
(METLIN) 2
acylcarnitine 2
XCMS(2) 2
(METLIN). 2
336-bp 2
277-bp 2
Fenneropenaeus 2
chinensis. 2
shrimp, 2
(17.5%) 2
hexamers, 2
AAUAAA. 2
riparius 2
(AATAAA). 2
bisphenol 2
Cd, 2
monodon. 2
gill, 2
3F3R 2
48h. 2
Triticeae. 2
Triticeae 2
1R 2
Triticum 2
dicoccoides 2
(Nicotiana 2
(CPSF), 2
CPSF, 2
(AAUAAA) 2
2543 2
1-42) 2
(p-tau 2
181p) 2
tau/Aβ42 2
ratio" 2
trends, 2
(p-tau), 2
pseudo-dementia. 2
forme 2
fruste 2
GRO-seq) 2
33.0% 2
(G/G 2
Non-smokers 2
1.29-2.30, 2
1.10-2.99, 2
ever- 2
current-smokers. 2
2005-2007. 2
(alcohol, 2
trauma) 2
Northwest 2
488,435 2
inhabitants, 2
5.73/10(5)/year 2
3.69/10(5)/year, 2
60-79. 2
GSTM3, 2
(Val-Ala) 2
105/114 2
0.99], 2
allergies, 2
pets 2
89,835 2
40-59 2
Linkages 2
0.29-1.07), 2
SQTS; 2
M301K. 2
M301 2
M301R 2
(positive), 2
M301A 2
probands; 2
(SQTS1). 2
(HQ), 2
HQ. 2
HQ 2
N588K 2
SQT1 2
(QTc=316 2
C1853T 2
(T618I) 2
HEK-cells 2
(146.1 2
pA/pF) 2
-78.6 2
-29.3 2
+20 2
I(kr) 2
I(ks) 2
I(k1) 2
oversensing, 2
ibutilide, 2
IKr, 2
interval/heart 2
artrofoon 2
self-regulation, 2
enuresis 2
enuresis. 2
showcase 2
mastoidectomy. 2
(AOM), 2
necrophorum 2
necrophorum. 2
plasmacytoma. 2
20(th) 2
named. 2
1904, 2
(WNT16B). 2
(MMEJ) 2
mirin, 2
(Mre11) 2
3'-5'-exonuclease 2
Mre11-exonuclease 2
mirin 2
MMEJ, 2
incompletely, 2
rays 2
Fe-induced 2
ray-induced 2
'sensitized' 2
Fe-irradiated 2
rampant 2
CDKN2B 2
p16/Ink4a 2
Hexavalent 2
chromate, 2
'particulate' 2
Foci 2
2.98; 2
1.64-5.43). 2
1.09-fold 2
bioactivated 2
benzo[a]pyrene 2
(B[a]P, 2
(1.40 2
1.29-1.51] 2
1.15-1.33], 2
B[a]P 2
K178R 2
B[a]P. 2
(error-free) 2
(HOK-16B) 2
(NHOK). 2
HOK-16B 2
non-microhomology-mediated 2
immortalized, 2
HaCaT, 2
c-Ha-ras 2
(non-, 2
benign- 2
malignant-tumorigenic) 2
SCC-derived 2
oxygen-treated 2
Ha-ras-HaCaT-clones 2
SCC-cells, 2
ligate 2
(repair 2
DSB), 2
pZ189. 2
non-tumorigenic, 2
HaCaT-clones 2
II-4. 2
HaCaT-clone 2
II-3, 2
SCC-cells 2
UVB- 2
reenter 2
DNA-PKcs-mediated 2
p53; 2
ubiquitin-proteasome-dependent 2
(hs)-IL-6 2
fT3<2 2
midregional 2
pro-adrenomedullin 2
NIHSS-100 2
(SPAN-100; 2
0.175; 2
quintiles. 2
≥95, 2
tPA. 2
(55.4% 2
40.2%; 2
(5.6% 2
3.9%; 2
(VISTA) 2
disability/modest 2
2731 2
[AOR], 2
9.03 2
6.68-12.21]) 2
5.03 2
4.06-6.23]) 2
0.06-0.13]). 2
disability/death 2
0.29-0.71]) 2
0.85-1.07]). 2
AIS, 2
TRalpha1R384C, 2
phosphoenolpyruvate-carboxykinase 2
TRalpha1L400R 2
ubiquitously, 2
T3-inducible 2
TRalpha1(-/-)TRbeta(-/-) 2
D1-mediated 2
crosslink. 2
P2(1) 2
59.9, 2
45.0 2
93.3 2
Self-rotation 2
9.676 2
keV, 2
met-2, 2
(H3K9MT), 2
Perinuclear 2
(WTMM) 2
lin-13 2
projection, 2
TRAPP. 2
HPL-1. 2
hpl-1;hpl-2 2
energy: 2
non-comparative 2
(Canadian 2
II-2). 2
North-West 2
(7.2) 2
12-39 2
10.9% 2
conceiving 2
0.19-0.53), 2
0.12-0.44). 2
conceive. 2
AAGL. 2
endometriosis-related 2
infertility: 2
excision/stripping 2
vaporization/coagulation 2
excisional-vaporization 2
diathermy 2
Interceed, 2
Oxiplex/AP 2
Adept 2
laparoscopies 2
(1966-August 2
CINHAL 2
dysmenorrhea 2
0.02-0.56), 2
0.05-0.79) 2
excsional 2
0.04-1.16). 2
subfertile, 2
population]. 2
pregnancy's 2
52] 2
III-IV). 2
(P=0.79). 2
subfertile. 2
2-50% 2
IVF/intracytoplasmic 2
within#10; 2
</=35 2
folliculogenesis; 2
(days), 2
(56.2%) 2
folliculogenesis 2
(34.5%) 2
0.424). 2
(4); 2
promising: 2
conceptions, 2
UK? 2
cystectomy) 2
multiple/bilateral 2
'offer 2
ART' 2
'normalization' 2
showed: 2
ovum 2
non-operated 2
RYR1 2
"nemaline 2
ACTA1, 2
NEB, 2
TPM3, 2
TPM2, 2
TNNT1, 2
CFL2 2
myopathologically 2
NM: 2
(NEB 2
Pelin 2
alpha-skeletal 2
(ACTA1 2
Nowak 2
alpha-slow 2
Laing 2
(TPM2 2
Donner 2
(TNNT1 2
Johnston 2
(CFL2 2
Agrawal 2
ACTA1. 2
hamstring 2
progressiveness, 2
TPM2), 2
(TNNT1), 2
(NEB). 2
(TNNT1) 2
alpha-actin) 2
51%) 2
17%); 2
(StataCorp, 2
Station, 2
(362/7 2
383/7 2
pre-RA 2
Alberta 2
progesterone-only 2
leflunomide-exposed 2
non-leflunomide-exposed 2
inordinate 2
(T1D). 2
(210) 2
Dataset 2
1912 2
1.38), 2
babies, 2
aRR=1.66, 2
(1.22, 2
2.26)), 2
(aRR=1.78, 2
(1.21, 2
2.60)), 2
(aRR=1.86, 2
(1.32, 2
2.60)) 2
4.04 2
3,264 2
13,574 2
FTB 2
tertogenicity 2
STZ. 2
(RVH) 2
cardiodepressant 2
Krebs-Henseleit 2
loss.(ABSTRACT 2
palmoxirate, 2
carnitines 2
palmoxirate. 2
hearts.(ABSTRACT 2
"GUIDe 2
AligNment 2
ConfidencE" 2
(GUIDANCE) 2
BASE 2
Heads-or-Tails 2
unreliably 2
Supermatrix 2
panacea, 2
(non-dominant) 2
sets; 2
Bovidae 2
(Mammalia, 2
Ruminantia), 2
firstly, 2
http://www.natur.cuni.cz/~flegr/programs/freetree 2
http://ijs.sgmjournals.org/content/vol51/issue3/) 2
unit-jackknife 2
four-taxon 2
two-branch 2
hepadnaviruses 2
(Myc-ER) 2
Suz12, 2
complex(es) 2
(H3K56) 2
Spt10. 2
K56Q 2
H3K56Q 2
Th17, 2
sarilumab, 2
sirukumab, 2
olokizumab, 2
clazakizumab, 2
anti-multiple 2
S/plc. 2
pre-dexamethasone 2
(EBMT) 2
0.869, 2
0.345), 2
0.213), 2
36.8 2
1.353, 2
0.103). 2
Siltuximab/placebo 2
29%), 2
RPMI 2
HMCLs 2
JAK1-STAT3 2
murine-human 2
three-part 2
mg/L). 2
mgkg-¹ 2
6mgkg-¹ 2
non-cytotoxic 2
IRF9. 2
Siltuximab. 2
IFNα2. 2
sensitizer 2
IL-6-producing 2
stroke.Our 2
(2003 2
Signs, 2
(46%). 2
risk-stratifying 2
(302 2
haemorrhages), 2
labyrinthitis 2
of>0 2
83-90), 2
36-47), 2
57-66), 2
68-81), 2
0.723. 2
off>0 2
(323+141)/715. 2
pathobiology. 2
repositioning. 2
(RNAi), 2
phototropism 2
Anergy 2
hypoacetylated 2
HCHC 2
3/8 2
GATA4-negative 2
MCF-12A 2
HB2. 2
150-fold. 2
8/23 2
HB2 2
AcH3K9; 2
deacetylated, 2
bishydroxamide 2
pi 2
hypermethylation-based 2
Chp2 2
(Snf2/HDAC 2
photocarcinogenesis 2
MBD1, 2
CpGs. 2
nonhybrid 2
Mad1 2
(ER)-negative 2
(SAHA 2
EGF-initiated 2
crisply 2
DFTD. 2
evolvability 2
(ERVs) 2
ERVs, 2
(Set3C) 2
(H3K4me2) 2
5'-transcribed 2
PI3K-mediated 2
ThPOK, 2
(NAD(+))-dependent 2
nicotinamide-induced 2
(HepG2, 2
Huh7) 2
HDAC1-3 2
miRs. 2
Sirt1-mediated 2
(DEX). 2
RUNX2-mediated 2
Vpr-binding 2
Promoter-localized 2
RARs 2
RXRs, 2
FUM 2
FUM8. 2
FUM8 2
FB-inducing 2
noninducing 2
FUM1 2
(CREM)α 2
H3K18 2
CpG-DNA 2
ARF-p53 2
transrepression, 2
Chz1 2
anti-silencing. 2
FVE, 2
cold-responsive 2
(RbAp), 2
(FLC) 2
acg1 2
Dnmt3b-HDAC1-Egr1 2
Dnmt1-PCNA-UHRF1-G9a 2
(glioma 2
AAR-induced 2
Jmjd3 2
Atf4-knock-out 2
AAR-dependent 2
mexicanum 2
laevis, 2
(5aza) 2
TSA-treated 2
HDACis, 2
alcoholism-inherited 2
F3 2
Amyloidogenic 2
ApoA-I 2
(ANG), 2
(KS). 2
PEL 2
BJAB 2
P112L 2
V113I 2
K60E 2
His114 2
(31)RRR(33) 2
31-35 2
non-nuclear 2
R33A 2
RRAGL, 2
R33 2
R31 2
R32 2
31RRRGL35 2
leupeptin, 2
sequence-assisted 2
2%-5% 2
HairMax 2
(minoxidil 2
finasteride), 2
(LLLT) 2
regrowth: 2
postsurgery, 2
monoxidil 2
alopecia; 2
5-alpha-reductase 2
(Propecia) 2
cosmetically 2
(Gadus 2
isotope-based 2
offshore 2
(IRMS) 2
spectrometers, 2
outliers. 2
Paleolithic 2
Archaeological 2
inaccuracies 2
mixed-mode 2
cemetery 2
farmers. 2
hobnailed 2
Bulk 2
C(3) 2
δ(15) 2
march 2
(LC/IRMS). 2
(NACME) 2
AAs 2
hydrolysates 2
N-trifluoroacetyl 2
(TFA/IP). 2
arginine). 2
EA/IRMS-derived 2
Inconsistencies 2
NACME- 2
combustion, 2
combustion. 2
NACME 2
trifluoroacetyl 2
(GC/IRMS) 2
(LC/IRMS), 2
derivatisation, 2
(leaf 2
grain) 2
(-4.1‰), 2
(+3.5‰) 2
(-3.2‰). 2
archaeology, 2
food-web 2
(14)C 2
Longin 2
Uummannaq 2
ZipTip) 2
ka@10 2
Comment 2
"Protein 2
authentication 2
Asara 2
deamidation, 2
faunal 2
IsoLink 2
embedded, 2
foragers 2
Rock 2
Shelter 2
(delta(15)N) 2
mid-Holocene 2
hunter-gatherers. 2
interbirth 2
prehistory, 2
corn. 2
isochronous 2
(A.D. 2
1400) 2
corn, 2
mir-208. 2
5/6Nx, 2
Collagenase 2
3DE 2
non-infarct 2
arteriolar, 2
capability, 2
security 2
commentary. 2
Prevention: 2
innovation, 2
coded, 2
reminders, 2
messaging, 2
low-resource 2
loss-sustaining 2
attention-control 2
postbaseline. 2
8:00 2
Medium-to-large 2
pounds, 2
message-based 2
18-35 2
Vulnerabilities 2
campaigns 2
learned. 2
(MCH) 2
RapidSMS-MCH 2
mother-infant 2
Rwanda 2
CHW 2
successully 2
well-organized 2
ACTION 2
(Adult 2
Neighborhoods), 2
churches) 2
underserved, 2
materials; 2
phone-delivered 2
756 2
(OXR) 2
(SB-649868), 2
insomnias 2
almorexant. 2
9-13 2
Merck. 2
Ru-based 2
diazepane 2
94.5% 2
Ru 2
catalyst, 2
zero-order 2
OX2R, 2
Somnolence, 2
(2-SORA), 2
(C1 2
m), 2
(DORA), 2
(NREM) 2
Fos-IR 2
commute 2
(Nuvigil(®), 2
Cephalon, 2
Frazer, 2
nonamphetamine, 2
jet-lag 2
R-modafinil 2
(AUC(τ)) 2
naps 2
(sleep 2
(1.6) 2
(SWSD) 2
under-recognised, 2
undertreated, 2
SWSD, 2
(OSA/HS) 2
(MWT) 2
patient-estimated 2
(BFI) 2
133; 2
131); 2
130). 2
49.2 2
[8.9] 2
[9.4] 2
white), 2
110.3 2
[24.9] 2
111.9 2
[24.0] 2
(+1.9 2
[7.3] 2
[8.6] 2
CGI-C, 2
BFI 2
[5.0] 2
[4.7], 2
[2.2] 2
[2.0], 2
ulcer) 2
Unmatched 2
keratins. 2
cleaner 2
proteome: 2
FBS. 2
elute 2
MaConDa: 2
Contaminants 2
Lipin 2
lipins 2
lipin-1, 2
S734L 2
Lipin-2 2
dermatosis. 2
dyserythropoiesis, 2
(c.2327+1G>C) 2
steatotic 2
allografts. 2
blue) 2
F1F0-ATP 2
H/RO, 2
externalization, 2
IC90 2
iso-osmolar 2
iohexol, 2
Cytotoxicity, 2
lucigenin-enhanced 2
(FW) 2
volunteer. 2
Dye 2
genotoxic. 2
Fenugreek 2
fas 2
(IOP) 2
IOP 2
ChAT. 2
Tridham 2
Impaction 2
polymerisation 2
58°C; 2
alamarBlue™ 2
Dunnett’s 2
(alamarBlue™) 2
Blue). 2
58°C 2
cemented 2
cell-viability 2
µL/mL). 2
low-cytotoxic 2
(0.05, 2
SCGE 2
liquid-holding 2
banks, 2
HAF, 2
custodial 2
Particle 2
FSP-1, 2
phospho-JAK1 2
PDMP 2
alloy 2
CoCrMo) 2
multifractal 2
(trypan 2
Dipyrithione 2
3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium 2
w/v 2
CD73 2
Runx-2 2
OCN 2
stearate 2
line-dependent. 2
dose-strength 2
Film-coated 2
2-treatment, 2
crossover, 2
up-titration, 2
(reference: 2
(test: 2
B-A 2
ACT-333679, 2
(86%), 2
(73%). 2
Î¼g 2
(B/A) 2
AUCÏ 2
Cmax,ss 2
(0.80, 2
1.25) 2
(0.92, 2
1.14), 2
(0.94, 2
1.07), 2
end-point, 2
-44.7- 2
-12.2; 2
p=0.0045, 2
(I(NaL)) 2
Na(v)1.1 2
ATX-II-induced 2
(N(1325)S). 2
tetrodotoxin) 2
Ca(2+)(i), 2
contraction-relaxation 2
trabeculae, 2
(iDEND 2
mmol/mol). 2
KCNJ11/S225T, 2
del226-232 2
KCNJ11give 2
intermediate-DEND 2
(iDEND). 2
Glyb 2
insulin: 2
glibenclamide; 2
Sulphonylureas, 2
Reevaluation 2
59V>M 2
provides: 2
diagrams, 2
(http://www.ebi.ac.uk/RESID), 2
Institute--Frederick 2
(http://www.ncifcrf.gov/RESID). 2
(PIR). 2
Swiss-Prot, 2
TrEMBL 2
PIR. 2
amino-terminal, 2
Sequence-Structure 2
metabolizers, 2
dopidines, 2
disease-slowing 2
glutamines 2
Q7 2
(3)H-dopamine 2
micromol/kg), 2
CHDI 2
ALN-HTT 2
(Alnylam 2
Inc/Medtronic 2
(Edison 2
LNK-754 2
(Link 2
Corp) 2
(NeuroSearch 2
A/S). 2
epigenetic, 2
placental, 2
(mouse) 2
(CpG)n 2
Htf9 2
exon; 2
Methylation-free 2
HTF 2
CAII 2
CpG-depleted 2
symporter, 2
IκB), 2
Bcl-XL, 2
STAT-3), 2
chemo-/radio-sensitizing 2
marizomib) 2
(D'Arcy 2
(19S 2
RP) 2
(20S 2
CP). 2
proteasome-associated 2
USP14 2
UCHL5, 2
shutdown. 2
RNF40 2
estrogen-independent 2
Farnesyl 2
'proteotoxicity' 2
EerI 2
ATF3 2
ALLN, 2
epoxomicin) 2
chemo-sensitizing 2
Bortezomib: 2
PS-341 2
E6AP 2
speedy 2
E3s. 2
mechanism-driven 2
pharmacogenomics' 2
'Pharmaco-miRs'. 2
protein-drug 2
21-23 2
toxicology-related 2
miRNA-related 2
(miR-TS-SNPs) 2
miR-TS-SNPs. 2
perceptibility 2
miRNA-processing 2
Dicer. 2
(miRNA)-related 2
fastest-moving 2
[paclitaxel 2
L-nicotine 2
(NIC), 2
melamine 2
(mela)] 2
geNorm, 2
NormFinder, 2
BestKeeper, 2
hRNU44, 2
hRNU48, 2
hU6, 2
hRNU47, 2
18s 2
Pharmacologically 2
HumanHap1M 2
Omni. 2
knowledgebase, 2
miRNA-biogenesis 2
miR-151-3p 2
paroxetine-sensitive 2
miR-151-3p. 2
miR-212, 2
miR-30b*, 2
let-7b 2
>1.5-fold 2
LCL 2
RPL26, 2
Pre-ribosomal 2
(RPL5, 2
RPL11), 2
RPS24. 2
oncoretroviral 2
(RPs). 2
sizable 2
39]lower 2
(8-oxo-7,8-dihydro-2'-deoxyguanosine) 2
wavebands 2
(DTH) 2
(ss)UV 2
(UVB 2
(385 2
Mantoux-induced 2
longwave 2
Longwave 2
sunscreens, 2
[4,5]. 2
PstI-digested 2
Xp. 2
DXS14 2
recurred, 2
39.7 2
(RBD). 2
sleepiness) 2
(dyspnea, 2
Parkinson. 2
hopoxemia 2
(52.5%), 2
vocalisation 2
(47.5%), 2
levodopa-sensitive 2
responsive. 2
(54.4 2
60.6 2
antecollis, 2
stimulus-sensitive 2
RESULT: 2
Misclassification 2
(Signs 2
2004-October 2
[inter-quartile 2
59-76], 2
0.09-0.68). 2
VAMS 2
culture-specific 2
(Hamilton 2
78.1%, 2
74.6%. 2
underrecognize 2
supported: 2
depressed) 2
depressed), 2
psychiatrists). 2
G47Delta 2
Antitumoral 2
Hepatoma 2
trichostatin. 2
Trichostatin, 2
HDACi, 2
LIV1. 2
(HA)-based 2
nonreduced 2
N-mono- 2
(HA 2
Score); 2
LM8 2
Blotting 2
TSA/TXT 2
TSA/erlotinib 2
hsp90. 2
(ERS) 2
ERα-positive 2
(ERβ) 2
(TSA 2
Tricostatin 2
SkBr3 2
peroxidase-mediated 2
UKF-NB-3 2
UKF-NB-4 2
b5 2
ellipticine-derived 2
hepatoma. 2
chemo-sensitizer 2
5-FU, 2
SN38 2
MKN-74 2
DAPK-2 2
cancer-preventive 2
SFKs. 2
Lyn 2
(1.5-4.3 2
(0.03-0.33 2
2-hr 2
microg/kg/day) 2
(FR901228, 2
FK228), 2
Interleukin-6, 2
(28.9%) 2
(13.3%). 2
drew 2
(89%). 2
third) 2
1.9-5.0); 2
1.2-3.1); 2
1.0-2.36); 2
1.3-3.4); 2
0.8-2.1). 2
(ischemic, 2
(mNIHSS) 2
(HPLC-EC). 2
(56%). 2
rheological 2
mRs) 2
gradient-dependent 2
mRs, 2
quartiles). 2
(13.7 2
19.46 2
15.88, 2
(84.36 2
27.97 2
25.64, 2
-0.504, 2
0.263, 2
0.042; 2
0.381, 2
IL1beta 2
atherothrombosis. 2
molecule-1. 2
atherothrombosis 2
andexanet, 2
PER977) 2
H723R 2
screening-detected 2
(Cremers 2
widend 2
Arch. 2
0). 2
centiMorgan 2
IVS7-2A>G 2
phenocopies]. 2
(OMIM274600) 2
pendrin--an 2
non-autoimmune 2
two-hundred 2
T4/fT4, 2
endocrinologist's 2
T4/ 2
PDB, 2
midnight 2
(RPKM) 2
invariance 2
Rho1-mediated 2
(autophagy), 2
(hemocytes) 2
Rho1-induced 2
fruiting-body 2
ascospore 2
germination, 2
PQC. 2
(patho)physiology, 2
disease.This 2
"Focus 2
Metabolism". 2
Vps34 2
4-kinase 2
Pik1 2
Mss4 2
rice-blast 2
Snx41-GFP 2
Magnaporthe. 2
Oxp1, 2
Snx41-dependent 2
(S403) 2
"sequestosomes" 2
polyglutamine-expanded 2
exon1 2
puncta, 2
sequestosome-1/p62 2
PINK1/Parkin-mediated 2
S16 2
poly-SUMOylation, 2
pathophysiologies, 2
Ylr356w 2
mitophagy-defective 2
ylr356wDelta 2
mitophagy-specific 2
ATG33. 2
oryzae 2
turgor 2
tough 2
appressorium-mediated 2
atg5 2
atg7, 2
ulk1 2
ATG1 2
(autophagic 2
MPP(+)-induced 2
"ER-phagy", 2
marcoautophagy. 2
delimiting 2
derive, 2
(orthologs) 2
fungi) 2
(paralogs), 2
Atg19, 2
(peroxisomes, 2
oleate/ethylamine 2
glucose/ammonium 2
Cvt18/Gsa12 2
GSA12 2
CVT18, 2
Gsa12 2
gsa12 2
engulfment, 2
Cvt18 2
phosphofructokinase. 2
PFK1. 2
PAS. 2
Ypt1, 2
Atg11 2
(macroautophagy), 2
nutrient-sensing 2
lysosomes/vacuoles 2
Ams1 2
(GFP 2
mCherry) 2
sI/R 2
A(1) 2
(Cvt), 2
(commonly 2
S6, 2
(54%), 2
cyclin-A/Cdk2 2
vMCF-7DRaf-1 2
(PTCL) 2
PTCL, 2
[73%], 2
[100%], 2
(Alk-Neg) 2
[100%]. 2
CRL-2396 2
TIB-48 2
80-100nM. 2
PARP-cleavage 2
HisH3 2
endo-reduplication. 2
AMKL. 2
(Alisertib), 2
AURKA, 2
(AMKL) 2
anti-AMKL 2
(AAK), 2
platinum-treated 2
(21-day 2
(n=25), 2
6.9-11.1 2
2.86 2
grade≥3 2
19%); 2
DLTs. 2
exposure-related 2
OspA-based 2
(serotypes, 2
spirochetes. 2
OspC 2
0-3-6 2
tattoo. 2
climatic, 2
(TBPs), 2
7050 2
(including; 2
Borrelia, 2
Bartonella, 2
Neoehrlichia, 2
Coxiella, 2
Francisella, 2
mikurensis, 2
venatorum), 2
miyamotoi), 2
(Bartonella 2
henselae) 2
TBPs, 2
Borreila 2
(n=70) 2
bites. 2
(Myodes 2
glareolus) 2
q-PCR 2
5.55% 2
garinii) 2
hermsii 2
Sciurus 2
road-killed 2
accord-ing 2
(Mediterranean, 2
Atlantic, 2
Continental, 2
Alpine), 2
2003–2010. 2
trianguliceps. 2
squirrels, 2
Squirrels 2
sensu-lato 2
(s.l.), 2
nest. 2
sciurids 2
genospecies. 2
co-distribution 2
persulcatus, 2
lato. 2
115.4 2
2006-2009, 2
2833 2
24.2% 2
ricinus-16.3% 2
(NT29 2
20047) 2
(NT28 2
VS461) 2
NT29, 2
Station 2
Poppenricht 2
(43.1%) 2
23.3% 2
(4×) 2
(3×). 2
mikurensis," 2
6.4%, 2
19.6% 2
dragging 2
stricto, 2
beats/min), 2
pmol/liter), 2
(LT(4)) 2
mU/liter). 2
(3.18 2
PTU, 2
microg/kg.d) 2
adipose, 2
NF-B 2
tissues), 2
Torque 2
teno 2
IKKgamma. 2
eudicot 2
splicing-associated 2
Rosiglitazone, 2
caucasian 2
(NCT00903331) 2
-0.20 2
aminotransferases 2
(transporters) 2
(CYP3A4), 2
ABCB1), 2
(SLCO1B1), 2
uridinediphosphate-glucuronosyltransferase 2
1A3 2
(UGT1A9). 2
(PXR). 2
(BCRP), 2
SLCO1B1, 2
SLCO1B3. 2
receptor-A 2
BQ123 2
BQ788) 2
Bosentan 2
(imatinib), 2
(riociguat), 2
(selexipag), 2
(macitentan) 2
sulfamide 2
'Pulmonary 2
sub-groups: 2
(PCWP) 2
(PCWP 2
(epoprostenol, 2
trepoprostenil, 2
iloprost), 2
(bosentan, 2
tadalafil). 2
(ACT-132577) 2
(alphaSMA) 2
&#945;SMA 2
8.5-fold. 2
6β-hydroxycortisol/cortisol 2
Worsening 2
tomorrow? 2
Prostanoids, 2
inconveniences, 2
Riociguat, 2
guanylatecyclase 2
Long-awaited 2
tyrosin-kinase 2
imatinib); 2
(riociguat); 2
(selexipag); 2
(macitentan). 2
(SERAPHIN) 2
ERA, 2
Opsumit®) 2
(14)C-macitentan 2
73.6% 2
6.2%) 2
3.9%) 2
4.8%) 2
depropylation 2
Antivascular 2
HeyA8-MDR 2
(intraperitoneal, 2
cisplatinum. 2
resensitized 2
30±5% 2
24±3%, 2
sums 2
12.3±1.5 2
Tempol, 2
25.9±2.3 2
approve 2
scleroderma-ILD 2
salts. 2
(ETR) 2
(daily 2
administrations), 2
ETRs 2
pMAPK. 2
ACT-064992. 2
8h) 2
AUC(0-t) 2
AUC(0-infinity). 2
(EoE) 2
(Th-2) 2
inhaler 2
(>90% 2
Aerosolized, 2
pan-esophageal 2
1:40,000. 2
vitamins. 2
clubbing, 2
pseudo-Bartter 2
readily. 2
manpower, 2
India; 2
pediatricians, 2
1:3300, 2
Libya 2
(1:2700), 2
Iraq 2
inhabited 2
Greek-Cypriots, 2
1:25,000 2
394delTT 2
F508), 2
508, 2
exon-11 2
XV-2c, 2
KM19, 2
MP6d-9, 2
J3.11 2
calculations: 2
(1221), 2
(1222), 2
(2111), 2
(2221) 2
(1122), 2
(1112), 2
(2222) 2
(1111) 2
1678 2
Switzerland.(ABSTRACT 2
birthplaces 2
1:4700, 2
Immunohystochemical 2
1:25. 2
Conductance 2
(Cl(-)) 2
azoospermia 2
(CBAVD), 2
oligozoospermia, 2
CFRD. 2
(NBF) 2
Saguenay-Lac-St-Jean 2
1/2000-1/2500 2
livebirths 2
SLSJ 2
kinship 2
Brazil: 2
1:3500 2
(Caucasian) 2
Janeiro, 2
7cen-q22. 2
communication), 2
3,200 2
1/2500 2
Studies, 2
fenilalanine 2
endothelium-independent 2
iberiotoxin 2
partner-interacting 2
Adipoq 2
(3MA) 2
post-lipidation 2
(PLC) 2
baicalein 2
PLC-dependent 2
(thapsigargin 2
tunicamycin). 2
(Tg), 2
store-depletion 2
TRPC1-mediated 2
TRPC 2
SKF96365 2
undigested 2
disease-specific, 2
(AIRg) 2
F13a1 2
Pamr1 2
Ripk2 2
Steap4 2
Thapsigargin-induced 2
(BiP), 2
(P-) 2
triple-positive 2
receptor-positive/progesterone 2
receptor-positive/HER2-positive). 2
multi-crystal 2
high-flux, 2
Photo-induced 2
femtoseconds 2
solid-density 2
X-ray-matter 2
electron-ion 2
collisions. 2
radiative-collisional 2
"exotic" 2
happen, 2
Coulter 2
Microscopy 2
Cytometry. 2
FEL 2
nanoscale, 2
fs 2
10(18) 2
10(21) 2
eV 2
imperfections 2
harness 2
(PS 2
O-O 2
ultrashort 2
SFX 2
difficult-to-crystallize 2
Lipidic 2
micro-jet. 2
outrun 2
explodes 2
(image) 2
32-nm 2
full-period 2
undulator 2
ultra-short 2
Diffractive 2
oversampled 2
hand-in-hand 2
crystallisation 2
(X-feL), 2
(<100 2
(∼10(12) 2
photons) 2
problem: 2
complex-valued 2
hologram 2
(XFELs), 2
"diffraction-before-destruction" 2
two-particle 2
(XFELs). 2
XFELs. 2
Computation 2
Zernike 2
Ultrashort 2
sub-picosecond 2
derived. 2
molecule-sized 2
SMI 2
coherent, 2
femtosecond-long 2
brilliance 2
physics, 2
multiwavelength 2
(FELs) 2
orientational 2
sprayed 2
beam. 2
magnetization 2
photon-shot-noise 2
molecular-resolution 2
electron-density 2
Coulomb 2
(FEL) 2
ultra-fast 2
destroy. 2
cGMP-PKG 2
ischemia/reoxygenation. 2
(pGC), 2
cGMP-elevating 2
SI/reoxygenation 2
cGMP-inducing 2
8-bromo-cGMP 2
(8-Br-cGMP, 2
S-nitroso-N-acetylpenicillamine 2
(SNAP, 2
KT-5823 2
KT-5720 2
pPLB/PLB 2
8-Br-cGMP 2
pGC 2
(SR-AIP) 2
Ser2815 2
Ser2815/RyR2 2
(KBR7943) 2
CaMKII-inhibition 2
(KN-93), 2
(necrosis), 2
(apoptosis), 2
(thapsigargin/dantrolene), 2
(ruthenium 2
red/RU360), 2
(cyclosporine 2
apoptotic-necrotic 2
Akt-E40K 2
IIdelta 2
Thr(17). 2
SR-targeted 2
/calmodulin-dependent 2
CaMKIIbeta(4) 2
(Simmerman, 2
Theibert, 2
Wegener, 2
Jones, 2
(1986) 2
261, 2
13333-13341). 2
retriever 2
(BMD, 2
(DMD, 2
xeno-autoantibody 2
trap-Fourier 2
noggin: 2
B27/N2/noggin 2
IAV. 2
N-glycolylmannosamine. 2
A/Memphis/1/1971 2
(H3N2), 2
(CMAH-MCF7 2
Thr155 2
CMAH-MCF7 2
IAVs. 2
"decoy 2
receptor" 2
GcIg) 2
IgG-containing 2
Ferrets 2
(IAV). 2
(CMAH). 2
AB(5) 2
SubAB 2
17α,20-lyase 2
17A2. 2
(P450) 2
pregnenolone 2
Prog. 2
482, 2
17α-hydroxylase. 2
25.4 2
(64%), 2
orteronel; 2
ARN-509. 2
cortisol-mediated 2
(orteronel, 2
VT-464) 2
[Prostate 2
Medline(®) 2
Embase(®) 2
"castration-resistant 2
cancer", 2
"abiraterone 2
acetate", 2
"orteronel", 2
"enzalutamide", 2
trials" 2
RNA-509 2
ODM201. 2
'promiscuous' 2
CYP17, 2
strategies-including 2
galeterone--are 2
Cabazitaxel, 2
(Orteronel, 2
Galeterone, 2
CFG920), 2
(ARN-509, 2
ODM-201, 2
AZD-3514 2
EZN-4176) 2
Prostvac, 2
RP-HPLC 2
photodiode 2
inter-day 2
re-engages 2
17α-hydroxylase/17,20-lyase 2
(CYP17), 2
I/TALS 2
yellowish-gray 2
chilblains-like 2
2½ 2
alpha-ENaC 2
(Sp1-binding 2
TTCAAGTCCCGCCCTCCGCT 2
PEBP/CBF. 2
(SFFVp) 2
(5'-TGCGGTC-3'). 2
SFFVp, 2
protein/core 2
(PEBP/CBF) 2
CAAT/enhancer 2
PEBP/CBF 2
LVb 2
enhancer), 2
Ets-PEBP 2
fa-responsive 2
element(s). 2
antigen-independent 2
avidities 2
LADA. 2
insulin-deficient 2
units/ml, 2
(39/39) 2
inter-assay 2
facilitatory 2
Antibody-Associated 2
Late-Onset 2
Siblings. 2
(Grave's 2
[Infrastructure 2
(remudy)]. 2
(DMD/BMD); 2
DMD/BMD. 2
globalized, 2
papillary-type, 2
medullary-type 2
unsatisfactory. 2
autophagy-targeted 2
(papillary 2
carcinoma) 2
PET/computed 2
(post 2
thyroidectomy) 2
iodine-avid 2
aggressive) 2
synoptically 2
realms, 2
grouping, 2
MICRO 2
Cerebral-oculo-facial 2
dysmorphologic 2
Inaugural 2
conference: 2
Peutz-Jegher's 2
(PJS) 2
PJS. 2
136-155). 2
Wnt-associated 2
violations 2
concatenation 2
monophyly 2
lengths) 2
within-gene 2
(among-lineage 2
ALRV) 2
inadequately, 2
probabilistic-based 2
"ON" 2
Dirichlet 2
heterotachy) 2
distorts 2
NJ 2
phenomenon--known 2
heterotachy--can 2
distort 2
branches, 2
Akaike 2
Artifactual 2
bad, 2
ugly. 2
(inconsistency). 2
likelihood. 2
stationary. 2
geometry-based 2
"different 2
speed" 2
Greek). 2
time--i.e., 2
'heterotachous 2
sites'--are 2
diagnose; 2
wishes. 2
Spirituality 2
(FCs). 2
Resilient 2
Subsyndromal 2
post-diagnosis 2
distress; 2
(51.1 2
caregivers) 2
(48.9 2
(75.5 2
(40.9 2
(21.6 2
Carers 2
Perceptions 2
caregiving, 2
themes: 2
Unmet 2
Needs 2
subscales, 2
mastery, 2
(PMBT). 2
statewide 2
recipient's 2
ENS. 2
lock, 2
neurocytes 2
(Hirschsprung 2
[HSCR]), 2
irides; 2
(R201X) 2
post-heart 2
(38.9%, 2
(27.8%, 2
(11.1%, 2
(15.4%, 2
(ONCAB, 2
(PRISM; 2
triiodothyronine: 2
(P=0.09) 2
(P=0.001), 2
4.425; 2
1.745-11.235; 2
3.107; 2
1.087-8.875; 2
P=0.03, 2
(50.4 2
[Relationship 2
Undergoing 2
Craniotomy 2
Abscess. 2
Anaesthesiologist, 2
POF 2
anaesthesiologist 2
POF, 2
Superspeciality 2
Bisoprolol 2
spells--a 2
69-year 2
bisoprolol 2
ram's 2
ovale. 2
dextropositioned 2
over-riding 2
penta-cardiac 2
caesarian 2
gondiiand 2
Cytomegalovirus. 2
(Atrial 2
Shunt), 2
(Ventricular 2
shunt), 2
(Patent 2
Ductus 2
Arteriosus 2
arteries), 2
Aorta 2
SF3a120 2
APC2 2
PRPF8 2
intron-less 2
Wings-apart 2
(Wapl). 2
Cdk1/cyclin 2
Erk2. 2
Sororin's 2
cohesin-DNA 2
20-50 2
BCR-ABL- 2
Groups. 2
LC(50) 2
i(17q) 2
+17 2
i(17q), 2
BC, 2
discerned, 2
[Progress 2
(t(q;22)) 2
(q34;q11). 2
BCL 2
ABL-related 2
T/NK 2
region-ABL 2
(YAC)-derived 2
(D107F9) 2
(cos-abl 2
BCR, 2
(RT/PCR) 2
b2a2 2
b3a2 2
junction; 2
b2a3, 2
b3a3, 2
e1a2 2
e6a2. 2
AML1-EVI1 2
one-mutation 2
times: 2
Philadelphia-chromosome-positive 2
abl. 2
b3-a2P210bcr-abl 2
BP-2 2
t(5;9;22) 2
t(5;9;22)(p15.1; 2
q34; 2
q11.2), 2
5p15.1-->pter, 2
BCR(22q11.2-->qter) 2
der(5), 2
Ph-chromosome 2
t(BCR\ABL). 2
Approximately, 2
(9;22;21)(q34;q11;p12) 2
region-1 2
(M-BCR-1) 2
P210BCR-ABL 2
ALL). 2
P190 2
Hasford 2
anticonflict, 2
antineophobic 2
2-aryl-3-indoleacetamide 2
2-hexyl-indoleacetamide 2
[N,N-di-n-hexyl-2- 2
(4-fluorophenyl)indole-3-acetamide], 2
steroidogenesis. 2
anti-isoniazid 2
convulsant 2
THDOC, 2
11195. 2
FGIN-1-27. 2
Alpidem, 2
FGIN-1-27, 2
neophobic 2
conflict-punishment 2
Vogel 2
anxiolytic-like 2
11195 2
anxiety.(ABSTRACT 2
receptors] 2
receptors]. 2
(evaluated 2
pentylenetetrazole-, 2
electroshock- 2
convulsions) 2
flumazenil-induced 2
zolpidem-treated 2
neuropsychopharmacological 2
flunitrazepam, 2
myorelaxation 2
pentetrazole-induced 2
electrocorticographically) 2
punished 2
hypersynchronization 2
chlordiazepoxide, 2
chlordiazepoxide-associated 2
anticonvulsant, 2
15-1788 2
8216 2
Abuse, 2
abused, 2
ofzolpidem 2
BZs, 2
BZ 2
abuser 2
zolpidem's 2
valid; 2
ofGABAA 2
(11.5%). 2
(37.2%), 2
(10.5%), 2
(10.2%). 2
ITT-LOCF 2
(HAM-D₁₇) 2
-4.76 2
-4.05); 2
HAM-D₁₇ 2
SNRI 2
straight-forward 2
(DVS) 2
n=1,116; 2
desvenlafaxine: 2
n=1,834), 2
18%). 2
anorgasmia 2
suicide; 2
electrocardiograms; 2
desvenlafaxine. 2
(n=1,108). 2
(HAM-D(17)); 2
-1.9; 2
(P=.024). 2
HAM-D1(17) 2
=150% 2
(HAM-D(17) 2
=7: 2
18%; 2
kinase-type 2
broad-reaching 2
(erlotinib 2
gefitinib) 2
EGFR-TKIs, 2
HER4 2
HKI-272, 2
BIBW-2992 2
anilino-quinazoline 2
2992) 2
chemotherapy/erlotinib/gefitinib 2
EGFR/HER1 2
(IBD 2
observe, 2
µmol/l 2
thromboVIT 2
G/L). 2
(14%, 2
0.143). 2
(536 2
G/L; 2
250), 2
≤13 2
subcohort 2
90.4% 2
≤12/13 2
>12/13 2
8.62, 2
1.74-41.66). 2
needed? 2
Ferumoxytol 2
ceiling. 2
(45%). 2
1000-1500 2
β-glucosidase, 2
(GENZ 2
112638), 2
58%-89%) 2
72%-98%) 2
=1.05-2.18 2
(40.3%; 2
23.7-57.0 2
(-38.5%; 2
-43.5%--33.5%), 2
(-17.0%; 2
-21.6%-12.3%), 2
(0.31 2
Z-score; 2
0.09-0.53). 2
(chitotriosidase; 2
CCL18; 2
varied; 2
Eliglustat, 2
MN) 2
proportionality. 2
~6-hour 2
classifiers. 2
CYC2008, 2
log-likelihood 2
simpler. 2
sophisticate 2
http://imi.kyushu-u.ac.jp/~om/. 2
http://mips.helmholtz-muenchen.de/proj/ppi/negatome). 2
non-interactions 2
Excerbt, 2
NIP 2
300%. 2
http://faculty.uaeu.ac.ae/nzaki/Research.htm. 2
iPTMClust, 2
k-means 2
NDComplex 2
inherence 2
all-clique 2
core-attachment 2
subgraphs. 2
neighbors. 2
neighbors' 2
f-measure, 2
https://github.com/gangchen/epof. 2
(ClusterONE, 2
CFinder, 2
MCode 2
Core) 2
Spectral, 2
(Y2H) 2
HKC, 2
HKC 2
k-core 2
NWE: 2
Node-weighted 2
WI-PHI 2
CYC2008 2
(Markov 2
Clustering), 2
clustering-based 2
(CPM) 2
k-clique 2
Engine 2
PIPE. 2
(TAP 2
vid30c. 2
any) 2
unobtainable 2
subunits) 2
moth-derived 2
non-P-element 2
(ADHD), 2
genes-common 2
disorders-included 2
ANK3, 2
CACNB2, 2
CNNM2, 2
CSMD1, 2
DPCR1, 2
NT5C2, 2
PPP1R11, 2
SYNE1, 2
TCF4, 2
TENM4, 2
TRIM26, 2
ZNRD1. 2
2640 2
(CLOZUK), 2
2504 2
2878 2
CLOZUK, 2
PGC-associated 2
78-100%) 2
(16,374 2
14,044 2
(rs4765905, 2
ANK3 2
(rs10994359, 2
ITIH3-ITIH4 2
(rs2239547, 2
ODZ4. 2
NEK4-ITIH1-ITIH3-ITIH4. 2
ITIH3/4-region 2
16p11.2, 2
CACNB2. 2
PBMR1 2
NEK4-ITIH1-ITIH3-ITIH4 2
privileged 2
APOBEC3G/APOBEC3B 2
Y19D 2
Y19D, 2
substitutions-F126S 2
W127A-caused 2
localization-determining 2
preintegration 2
deviations, 2
base-base 2
(VSP) 2
C*G 2
Vsr, 2
endonuclease) 2
RARG 2
1-5) 2
chloroquine-induced 2
troponin-I, 2
connexin-43. 2
(13.63 2
5.97% 2
Progeny 2
cardiomyoblast-like 2
balloon-occlusion 2
post-transplantation 2
nkx2.5 2
Placement 2
cellularization 2
ePTFE 2
%FAC 2
patching, 2
embryonic-like 2
(GATA-4, 2
Nkx2.5/Csx, 2
stromal-derived 2
(SDF-1) 2
Transplanted 2
MSC(GATA-4)-treated 2
microsphere 2
postinfarct 2
injury/repair 2
0.19% 2
(Gata-4, 2
Notch-2, 2
Nkx-2.5) 2
(Tbx-3, 2
Akt). 2
(aerobic) 2
mixed-sports 2
anaerobic) 2
(anaerobic) 2
(PCSCs) 2
LNcap 2
non-PCSCs. 2
PCSC 2
"composite 2
index" 2
6.57, 2
14.31, 2
statuses, 2
E2F3. 2
E2F3-induced 2
miR-26b, 2
non-prostate 2
EZH2-driven 2
(EZH2 2
120-128, 2
165-174, 2
569-577, 2
665-674, 2
699-708) 2
120-128 2
165-174 2
HLA-A2-restricted 2
PRC1, 2
PRC4 2
escalate 2
MKI67. 2
Heterogeneously 2
(EZH2)-derived 2
HLA-A24 2
HLA-A24-restricted 2
EZH2: 2
HPH1, 2
HPC1, 2
HPC1 2
(α2-integrin, 2
α6-integrin, 2
OCT3/4) 2
α2-integrin 2
28.4% 2
<7 2
OCT3/4 2
RBF 2
PSSM 2
1251 2
TMBETADISC-RBF, 2
http://rbf.bioinfo.tw/~sachen/OMP.html. 2
MspA. 2
PROB 2
PE-PPE 2
Mce 2
hypothetical, 2
PROB, 2
TMB-Hunt, 2
BOMP, 2
(MT0318, 2
MT0356, 2
MT2423) 2
CD4T 2
MHC-II 2
1,617 2
Uppsala-Orebro, 2
Linköping 2
Göteborg 2
1,429 2
1,470 2
(OR)=1.3, 2
(CI)=1.04-1.6, 2
OR=1.7, 2
CI=1.2-2.3, 2
OR=1.3, 2
CI=1.02-1.8 2
OR=1.2, 2
CI=0.9-1.6. 2
microwaves, 2
OR=2.3, 2
CI=1.2-4.1. 2
neurinoma 2
OR=4.4, 2
CI=2.1-9.2 2
OR=1.04, 2
CI=1.01-1.08. 2
Uppsala-Orebro 2
(1994-96) 2
(1995-96) 2
phone. 2
69-1.41. 2
0.61-1.56 2
0.62-1.44 2
Non-significantly 2
0.78-7.76, 2
2.40, 2
0.52-10.9 2
∼20 2
β-cell-specific 2
PKA/CREB, 2
48.1% 2
cyclin-D1, 2
hUC-MSCs. 2
preadipocytes: 2
(LRP5). 2
GCT, 2
wnt/GSK-3beta/beta-catenin 2
FRS2-GRB2-GAB1-PI3K-AKT 2
GSK3beta-dependent 2
FBXW1 2
(betaTRCP)-mediated 2
SNAIL. 2
FGF20 2
cysteine-rich, 2
heparin-binding, 2
Fas-ligand 2
Neurobiological 2
GnRH-green 2
Lentivirally 2
transgenics, 2
fertilization/preimplantation 2
larger-body 2
pOBCol3.6GFPtpz 2
(sh)RNA 2
(pol2) 2
(Xenotransplantation, 2
38). 2
pol2 2
xenotransplants 2
technology--animal 2
welfare--has 2
reproductory 2
sows 2
pre-induction 2
epifluorescent 2
dynamic. 2
(DIC) 2
microscopes, 2
double-transgenic 2
DsRed 2
E2-CSFV 2
HIV-based 2
(Lv-G), 2
αS1casein 2
(Lv-αS1cE2hisG). 2
Lv-G 2
four-cell 2
trancriptional 2
E2his 2
0.422 2
posttransplantation 2
bodywall 2
C46G7.2 2
consistently. 2
parvalbumin 2
hair-bundle 2
amputation. 2
hsp 2
decondensation. 2
SNORD116. 2
PWS-like 2
15q11.2-q13. 2
stature; 2
individuals), 2
(original 2
MS-MLPA 2
γ; 2
study-specific 2
PPARalpha- 2
PPARgamma-related 2
Metabolism, 2
nonrandomized, 2
radioactivity, 2
M6, 2
(PPAR)α/γ 2
PPAR-related 2
(MDRD) 2
135-day 2
63-day 2
(328 2
0.0035 2
125% 2
0.0007). 2
A-II 2
lipid-modifying 2
PPAR-alpha 2
PPAR-gamma 2
</=two 2
4-5-week 2
(n=55 2
(n=57) 2
NCT00388518. 2
(n=0 2
n=1 2
-0.36% 2
-0.70, 2
p=0.048) 2
-1.35% 2
-1.70, 2
mug. 2
Oedema, 2
(0.52 2
(Switzerland). 2
7,228 2
(Pio; 2
(Feno; 2
Pio/Feno 2
rosuvastatin. 2
Non-ventricular, 2
Causing 2
93%), 2
post-effort 2
U-waves 2
oscillated 2
U-waves. 2
Cardiología. 2
target? 2
1:10 2
000. 2
(RYR2, 2
TRND, 2
[Catecholaminergic 2
(PCVT) 2
lachycardia 2
betablockade 2
TVPC 2
FKBP1B, 2
ATP2A2 2
SLC8A1 2
VPCs. 2
poly-ADP-ribosylation, 2
(PARP-1; 2
2.4.2.30) 2
10min 2
oly(ADP-ribose) 2
Parp-1-deficiency 2
12,488 2
(Parp-1-/-) 2
(Parp-1+/+) 2
9,907 2
12,353 2
Hsp70.2 2
Hsp70.8, 2
mH2A1.1. 2
AR4-2J 2
Cycloheximide-induced 2
3-Aminobenzamide 2
4-hydroxyquinazolone, 2
(tat) 2
virus-carrying 2
ribosylation. 2
outpouching 2
bifurcation 2
ruptures, 2
magnesium; 2
securement; 2
(Nimotop), 2
(Lovenox) 2
level-1 2
trialed 2
hypovolemia 2
[Recommendations 2
Suggested 2
triple-H-therapy 2
One-quarter 2
delayed-onset 2
53%-58% 2
(SAB) 2
PATHOPHYSIOLOGY. 2
CALCIUM 2
ANTAGONISTS. 2
pial 2
HYPERVOLAEMIC 2
HAEMODILUTION. 2
30%-33% 2
hypovolaemia 2
haemoconcentration. 2
INDUCED 2
ARTERIAL 2
HYPERTENSION. 2
CONCLUSION. 2
Hypovolaemia 2
haemoconcentration 2
Normoventilation 2
hypocapnic 2
SAB. 2
revolution. 2
treatment-principally 2
procedures-have 2
(COX)-downstream 2
[(COX-1, 2
(mPGES), 2
(cPGES), 2
(PGIS), 2
(EP(1), 2
EP(2), 2
EP(4)) 2
(IP)] 2
(size 2
bradykinin-receptor 2
(R(17)H(18)R(19)) 2
AF10 2
(H3K79me1) 2
readers. 2
dot1 2
H3-K79A 2
H3-K79R 2
checkpoint-imposed 2
synapsis-defective 2
Mec1/Tel1-dependent 2
HOP1 2
interhomolog 2
H3K79-me 2
Dot1l-null 2
Nonprocessive 2
Mll-AF4-associated 2
(TPEV). 2
TEL-VII-L 2
silencing-1 2
(Dot1) 2
TPEV 2
(DOT1-Like), 2
Dot1/DOT1L-mediated 2
translocation-associated 2
lacritin-induced 2
Acinar 2
prosecretory, 2
cytoprotective, 2
optimum, 2
Tgm2 2
nonprimate 2
organ-specific, 2
glycosaminoglycan-binding 2
neuroglycan 2
fibulin-2 2
residues), 2
laminin-1, 2
entactin/nidogen-1, 2
gland-corneal 2
Reverse-phase 2
tear-specific 2
N-65 2
Anti-Pep 2
lipophilin 2
C-25 2
ceased. 2
10-100 2
lacritin; 2
dermcidin, 2
sweat-derived 2
CHEC-9 2
(DCD) 2
casework 2
Y-P30/Dermcidin 2
neuritogenic 2
(DCD-1L), 2
mercury-supported 2
permeabilizes 2
floating 2
Mr. 2
Dermcidin 2
myomas. 2
AFP--1.18 2
estriol--1.29 2
(beta-hCG), 2
5.8%. 2
governments 2
protein-A 2
(2.99 2
feto-protein, 2
Wald 2
1:250 2
fetoprotein, 2
H(+)-ATPase. 2
(SLC38A9) 2
membrane-resident 2
vaccinology, 2
micro-organism's 2
hyodysenteriae. 2
bacterin 2
non-vaccinated 2
Taenia 2
asiatica 2
(Access 2
CN653186 2
CN649593) 2
Eg_PSGRS_13B09 2
protoscolex 2
3'end 2
Qinghai 2
1,449 2
aa(104-124), 2
inside. 2
helix-beta 2
Mg(2+)-binding 2
aa(190-199) 2
aa(49-57) 2
aa(228-236) 2
aa(206-213) 2
Glu(210), 2
granulosus. 2
ruminantium-immune 2
lymphocytes; 2
heartwater. 2
infantum. 2
Rhipicephalus 2
anti-tick 2
(MCFAC). 2
MCFAC 2
hosptial 2
(mean=5.4 2
(S). 2
sylvian 2
M/1 2
microprocessor 2
intraparenchymally, 2
check. 2
arbitrarily 2
recording), 2
on; 2
cyst) 2
discriminating, 2
obliteration. 2
arachnoidea 2
448. 2
listening. 2
interferon-γ, 2
simulator. 2
"spatial 2
reasoning." 2
Theater 2
nonmusical 2
K.545. 2
music) 2
K.545) 2
(28.1 2
(RMSSD), 2
(SDSD), 2
(bpm) 2
(LF 2
nu), 2
nu). 2
cTBS, 2
imagery. 2
representations. 2
pianos 2
53.2±47.4, 2
64.4±47.1, 2
71.6±45.8%, 2
Arousal, 2
pleasant 2
piece) 2
sad 2
enjoyment, 2
material-Mozart, 2
pretest-Mozart-Verbal 2
nonmusicians. 2
left-hemispheric 2
rhyming 2
Baur 2
Linden 2
Rades 2
Katagiri 2
"more 2
viewpoints 2
Jan. 2
Tomita. 2
(Karnofsky 2
(P=.000, 2
(P=.0002 2
(P=.0058). 2
(P=.9131, 2
iodothyronine, 2
3,5-diiodo-L-thyronine 2
(3-fold; 2
CO23. 2
ERK1/2) 2
avb3 2
(3,3',5-triiodothyronine) 2
Fluorescent-labeled 2
("hypothyroid" 2
wo 2
T4(3,3',5,5'-tetraiodo-L-thyronine), 2
rT3(3,3',5'-triiodo-L-thyronine), 2
D-T3(3,3',5-triiodo-D-thyronine), 2
3,5-T2(3,5-diiodo-L-thyronine), 2
(3,5-diiodo-L-tyrosine), 2
(3-monoiodo-L-tyrosine), 2
(3,3',5,5'-tetraiodo-thyroacetic 2
triac 2
3',5-triiodo-thyroacetic 2
3,5-T2, 2
D-T3 2
3,5-Dimethyl-3'-isopropyl-L-thyronine 2
(IpTA2), 2
(3,5,3'-L-triiodothyronine, 2
3,5,3'-D-triiodothyronine, 2
3,3',5'-L- 2
3,5,3'-L-triiodothyroacetic 2
myosin; 2
3,5,3'-L-triiodothyronine 2
isoenzyme, 2
amyloidoses. 2
L-thyronine 2
(TTR). 2
monoamines, 2
DECISION 2
MKIs, 2
MKIs 2
MKI. 2
iodine-131, 2
lenvatinib. 2
18.3 2
64.8% 2
responses) 2
�, 2
(CAs) 2
Clofarabine, 2
Clofarabine 2
(2-chloro-2'-fluoro-2'-deoxyarabinosyladenine, 2
ClF) 2
2'-deoxyadenosine 2
(2-chloro-2'-deoxyadenosine, 2
2CdA) 2
(9-beta-d-arabinosyl-2-fluoroadenine, 2
F-ara-A). 2
(RARbeta2), 2
(MSRA) 2
96h 2
640nM 2
50nM, 2
BRCA2-stimulated 2
negatively. 2
BRC4 2
hRAD51, 2
BRCA2(BRC1-8) 2
Pull 2
BRCA2(BRC1-8), 2
BRCA2(BRC1-8). 2
Rad3/ATR 2
serine-128/-129 2
γH2A 2
BRC6 2
(BRC1, 2
(BRC8), 2
(BRC3, 2
estrogen/progesterone 2
DSS1, 2
DSS1(high) 2
DSS1(low) 2
ssDNA, 2
βAR-blockers 2
"vicious 2
RANKL-expressing 2
(1.) 2
dickkopf-1, 2
PTHrp 2
calcilytics; 2
(2.) 2
osteoclast-osteoblast 2
(3.) 2
osteoclast-stimulating 2
noncytotoxic 2
antiosteoclast 2
hypocalcemia. 2
(ergocalciferol 2
cholecalciferol), 2
(calcitriol, 2
alphacalcidiol, 2
doxercalciferol), 2
D-mimetics 2
(paricalcitol, 2
maxacalcitol), 2
calcimimetics 2
(cinacalcet), 2
(teriparatide), 2
(denosumab); 2
disarrays 2
MM-related 2
osteoprotegerin, 2
Initials 2
RANK/ 2
162), 2
Timer, 2
DsRed1-E5, 2
dsRed, 2
matures. 2
(Gfp) 2
flavin-binding 2
photosensors 2
(GFP)-namely, 2
putida, 2
brightness, 2
holoprotein, 2
(4-11), 2
60°C), 2
min.). 2
FbFP 2
(iLOV) 2
nonperturbative 2
(10-40 2
recovery). 2
palette, 2
Rot 2
mCherry 2
Pectobacterium 2
carotovorum 2
brasiliensis 2
Pcb_mCherry 2
RKN 2
(A5) 2
A5 2
pIndi, 2
territory-interchromatin 2
(CT-IC) 2
connexin45 2
one-trial 2
kainate-induced 2
gamma-oscillations 2
neuron-directed 2
perirhinal 2
CA3, 2
HAP1, 2
T27A3.1. 2
isoforms; 2
[green 2
DsRed2] 2
Kusabira-Green 2
hepatocyte- 2
"live" 2
(glaA) 2
fed-batch 2
metabolizable 2
glaA-promoter 2
maltose 2
[RTRG](n) 2
RFP 2
HTP-screening 2
HiB5 2
label. 2
dual-labeling 2
Carbonic 2
betaCA6 2
betaCA1 2
OspA, 2
OppAIV 2
beta-phycoerythrin, 2
Timer. 2
(weight 2
dNTPs, 2
misincorporated 2
(MRs) 2
PAOMY-Mgm 2
mutators. 2
(mutM, 2
mutT) 2
8-dihydro-8-oxo-dGTP 2
8-oxo-dGTPase 2
8-oxo- 2
7,8-dihydrodeoxyguanosine 2
NUDT5. 2
(AgNP) 2
(planctonic 2
biofilms) 2
AB1157, 2
proteamaculans 2
-150 2
AgNP. 2
SOS-response 2
RpoS, 2
LuxI/LuxR 2
Quorum 2
Serratia. 2
OmpF 2
OmpC 2
BW535, 2
8-oxo-7,8-dihydrodeoxyguanosine 2
mMTH2 2
C-mediated 2
25-mg/m(2) 2
DLT, 2
Gy/d 2
3.65 2
oligoastrocytoma 2
(CPT-11) 2
(0-100 2
polyethylene-glycol 2
Multifocal 2
phase-II-study 2
(TAM), 2
hypericin: 2
Broca's 2
paracentral 2
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium 2
hypericin, 2
25-50 2
anecdotally, 2
Propylthiouracil-induced 2
tamoxifen-induced 2
0.03. 2
ESC-equivalent 2
Gtl2. 2
Gtl2(ON) 2
Gtl2(OFF) 2
microRNA-29b 2
(OSKM), 2
miR-29b-DNMT 2
therapies(5). 2
iPSCs(7-9). 2
employed(9), 2
transactivator. 2
floxed-excisable 2
described(10,11) 2
lentivirus. 2
ESC-like 2
SSEA-4, 2
Tra-1-60 2
Tra-1-81. 2
-Myc 2
transducing, 2
(OKSM), 2
Yamanaka, 2
126(4):663-676, 2
Okita 2
(Stem 2
instructions, 2
fatigue-sadness 2
[HR]=1.8, 2
1.1-3.0, 2
P=.025) 2
(HR=1.8, 2
1.1-2.9, 2
P=.025). 2
(HR=1.6, 2
0.9-2.8, 2
P=.102) 2
cognitions 2
(HR=1.3, 2
0.7-2.2, 2
P=.402) 2
Inventory-Fast 2
HADS-D 2
enjoy 2
things" 2
HADS-D, 2
ultrafiltrate 2
myelosuppressive, 2
tri-exponential 2
ultrafilterable 2
cumulative, 2
Capecitabine 2
Filipin 2
Amplex 2
35-fold 2
NPC(-/-) 2
precipitous 2
(Npc1(-/-) 2
spheroids. 2
(Npc1(nmf164)) 2
(Npc1(nih), 2
Npc1(spm)). 2
bile-duct 2
(hUCB-MSCs) 2
Rota 2
efflux-related 2
LXRα, 2
ABCG5 2
cerebrum, 2
MAP2-positive 2
GABA/glutamate 2
GAT1, 2
GAD6 2
APP-CTF 2
cyclodextrin 2
(Abeta). 2
Counts 2
GFAP-Npc1E, 2
(DRD2) 2
(NPC1(+/+)) 2
NPC1(+/+) 2
SREBP-1 2
lipoprotein-derived 2
endosomes/lysosomes, 2
(PXR) 2
activation: 2
allopregnanolone 2
(ALLO) 2
T0901317, 2
microglial-associated 2
ent-ALLO 2
ALLO, 2
(NPC), 2
NPC1-deficient 2
[NPC1 2
(-/-)] 2
cholesterol-fed 2
non-superantigen 2
Satb1 2
(special 2
AT-rich-binding 2
SEB-energized 2
cancer--current 2
(lapatinib) 2
Well-designed 2
HER2-positivity 2
scientific, 2
statistical, 2
(HER2/neu) 2
2+/fluorescence 2
hybridization-negative). 2
co-targeting 2
heat-sensitive 2
(DAKO 2
A/S, 2
Glostrup, 2
(HerceptinR, 2
HercepTestTM. 2
ci-ankrd52, 2
(nuclear-enriched 2
MENβ 2
(ENE). 2
long-noncoding 2
neoplasia-β 2
(MENβ) 2
duplex-triplex 2
nuclear-retained 2
(polyadenylated 2
nuclear) 2
gammaherpesvirus 2
Malat1. 2
(metastasis 2
H19's 2
long-sought 2
ruminant. 2
introns; 2
blastocyst, 2
co-ordinately 2
overridden 2
CCDC114, 2
CCDC65, 2
video-microscopy 2
(HVMA) 2
PCD-related 2
1072 2
CCDC103, 2
ARMC4, 2
KTU/DNAAF2, 2
LRRC50/DNAAF1, 2
LRRC6, 2
DYX1C1, 2
ZMYND10, 2
CCDC164, 2
HYDIN, 2
RSPH4A 2
RSPH1. 2
defect." 2
disorganisation 2
Ccdc40 2
CCDC39/CCDC40 2
disorganisation. 2
Non-HLA 2
'shared 2
epitope' 2
2-5%, 2
REL. 2
ratio=2.2, 2
1.6-3.1, 2
MMEL1-TNFRSF14 2
REL 2
1,509 2
DerSimonian-Laird 2
rs7551957 2
Fc-gamma 2
(FCGR2A) 2
1.25-1.99). 2
(DPYD) 2
(rs6685859; 2
10(-4), 2
rs7550959; 2
rs7531138; 2
rs2269310, 2
(SPTB) 2
never-ending 2
PRF1. 2
depicted, 2
3311 2
(UK, 2
3709 2
immunology: 2
5,968 2
subanalyses 2
(SJC)). 2
autoantibody-positive. 2
SJC 2
arthritis--part 2
(rs7574865, 2
rs6822844, 2
rs3087243, 2
877 2
[P=0.031], 2
[P=0.051], 2
[P=0.041], 2
[P=1.66x10(-11)], 2
[P=5.6x10(-5)], 2
[P=1.8x10(-3)], 2
(ACPA)-positive 2
IL2/IL21 2
ancestries, 2
PADI4; 2
FCRL3; 2
CD244. 2
Recherche 2
sur 2
Polyarthrite 2
(ARP) 2
Thyrotopin-releasing 2
"cytokine-induced 2
behavior" 2
TRH/saline 2
TRH-based 2
longa 2
planted 2
station 2
Land 2
(MSP), 2
(CUR) 2
(MRP1 2
MRP5). 2
β-diketone 2
MACs 2
(cur), 2
TGF-β2, 2
Monofunctional 2
Platinum-containing 2
Pyridine-based 2
Acts 2
Synergistically 2
better-able 2
tris(imidazo(1,2-α)pyridine) 2
chloroplatinum(II) 2
LH6) 2
A2780, 2
A2780(ZD0473R) 2
imidazo 2
(1,2-α-pyridine) 2
platinum-DNA 2
A2780 2
di(2-ethylhexyl)phthalate 2
curry 2
spice. 2
Sp. 2
o.o. 2
N,O-carboxymethyl 2
curcumin-treated 2
microRNA-21, 2
TLR4/MyD88/NF-κB 2
TLR4⁻/⁻ 2
post-injury, 2
staining; 2
HSPs, 2
HSF1 2
(27, 2
CDK1, 2
Sulindac 2
CCM3-knockout 2
endothelial-cell-selective 2
Wnt-receptor-independent 2
β-catenin-driven 2
TGF-β/BMP 2
cavernomas. 2
Nodules 2
Hispanic-American 2
4X10(10).1). 2
cavernous-malformation 2
heritage. 2
c.30 2
5_6delinsTT, 2
FANGF, 2
[Creation 2
(TFAR)]. 2
(TFASG), 2
(TFAR). 2
TFASG 2
(www.fanconi-tunisie.net). 2
genoidentical 2
endogamy 2
circumstance 2
HLA-compatible 2
Non-homologous 2
Fanca-/- 2
(Bednar 2
protuberans, 2
FAH). 2
(A-H). 2
(non-Ashkenazi) 2
2172-2173insG 2
mutation'; 2
'Tunisian 2
'Indian 2
Tunisia]. 2
fourty-one 2
(FA 2
A-H) 2
K.J. 2
Patel, 2
"evolving" 2
leukemia-diagnostic 2
flowcytometric 2
chromosomal/chromatid 2
clinico-investigative 2
notochord. 2
Vincristine, 2
(PIIT) 2
patient); 2
SD-1029, 2
Cu(II)(btsc)s 2
TDP-43-and 2
Co-treatment 2
Tar 2
(NF) 2
(UG) 2
RRM2 2
(Staufen 2
RNA-IP-PCR, 2
ALS/FTLD. 2
PTE. 2
[Sleep 2
institutionalisation 2
levelled 2
Korsakow 2
hypersomnolence 2
sundowning. 2
hypopharyngeal 2
hypersomnic 2
medication- 2
breathing-related 2
hypersomnolence. 2
causes) 2
hypersomnolence, 2
Kleine-Levin 2
Hypersomnia 2
(SAS), 2
(insufficiency), 2
legs/periodic 2
(RLS/PLMS) 2
grounds. 2
(orexin) 2
hypocretin-2 2
hcrt-1 2
executors 2
β-barrel. 2
typify 2
Q-VD-OPh 2
(1,25D) 2
QVD 2
Progenitor 2
Caspases, 2
Draper 2
CICD 2
(cysteine-containing 2
aspartate-specific 2
anti-platelets/anti-thrombotics. 2
cardiac-selective, 2
high-copy-number 2
Ser22/Ser23 2
Ser43 2
Thr143 2
Adenovirus-mediated 2
Ad-TNNI3K. 2
Ad-TNNI3K 2
H-leucine 2
endophenotypes. 2
"silent" 2
transplanting 2
p38/JNK-mediated 2
(CARK) 2
heart-enriched 2
Ser-rich 2
dual-specific 2
Cdc7-mediated 2
ESPRIT 2
truncation), 2
evolution-like 2
(CRI 2
CRII) 2
39th 2
Rosenthal 2
hemophilia. 2
(Hemophilia 2
bleed. 2
bio-marker 2
eruption, 2
(gluten) 2
Endothelin-3-endothelin 2
Sox10. 2
Titration 2
Mennonite 2
10q11, 2
16q23; 2
10q11 2
non-complementation 2
intercrosses 2
EDNRB/EDN3 2
emigration, 2
fonctional 2
(hETB) 2
125I 2
G57S, 2
(G57S 2
R319W) 2
Gaq, 2
Galphai 2
Galphas. 2
differenciation 2
(ET-B) 2
Phe 2
174, 2
878, 2
(HSCR2). 2
HSCR-associated. 2
(A183G, 2
W276C, 2
R319W, 2
M374I 2
Ligand-receptor 2
A183G, 2
W276C 2
system-the 2
36%; 2
3.87, 2
lentigines 2
(freckles), 2
19.9, 2
296.2; 2
healthy-eating 2
Functionalities 2
vendor 2
food; 2
Store 2
social-network-enabled 2
personalization: 2
multiple-sensor 2
PaCa 2
(MOMP), 2
vinblastine 2
Encephalitis 2
Extrinsic 2
Bax(+/+) 2
improperly-folded 2
retrotranslocation. 2
AAA-type 2
Cdc48-Ufd1-Npl4 2
retro-translocation 2
SSZ1 2
cdc48-10 2
pSSZ1 2
Ssz1p 2
RPN4 2
pcdc48-10 2
degradation). 2
alpha1,2-mannosidase 2
retrotranslocation/dislocation 2
hypofibrinogenemia. 2
UPR, 2
HRD1 2
directionality. 2
disposes 2
6myc-Hmg2p 2
Ubc7p, 2
Sec61 2
translocon. 2
Ubc7p. 2
Proteasome-dependent 2
p97/VCP-interacting 2
(SVIP) 2
co-fractionated 2
Derlin1, 2
gp78. 2
antiparasitic 2
(ER)-localized 2
misassembled 2
p97-dependent 2
VIMP 2
p97/Cdc48Ufdl/Npl4 2
(dislocation) 2
J-protein, 2
DNAJB12, 2
J-domain 2
(ERQC) 2
destinations, 2
incompletely/mis-folded 2
ERQC/ERAD 2
trametinib. 2
cross-over. 2
cobimetinib. 2
(14/14), 2
(21/7), 2
(28/0). 2
(intention-to-treat). 2
final. 2
NCT01271803. 2
cobimetinib: 2
14/14 2
21/7 2
28/0 2
effects-one 2
21/7. 2
64%), 2
non-acneiform 2
9%]), 2
2·8 2
2·6-3·4). 2
10·1-17·5). 2
Roche/Genentech. 2
non-BRAF-mutant 2
(anti-CTLA4), 2
metastasectomies, 2
(PLX-4032), 2
anti-CTLA4 2
(hydroxy-, 2
desmethyl-dabrafenib) 2
(hypromellose:gelatin 2
capsule) 2
moderate), 2
hydroxy-, 2
desmethyl-dabrafenib 2
(83.5%), 2
69.3 2
(64.1%), 2
3608 2
(17.2%), 2
shell, 2
MIA, 2
(dabrafenib) 2
(vemurafenib). 2
iBRAF. 2
metastases: 2
(960mg 2
non-resectable, 2
(0.1-11.3) 2
(n=22). 2
4.7-37.4%) 2
3.0-5.5) 2
3.9-6.6) 2
(42%; 2
22.1-63.4) 2
(38%; 2
18.8-59.4) 2
3.4-39.6%) 2
(pretreatment 2
archival) 2
melanoma-specific 2
loss/mutation 2
[18.3 2
9.1-24.3) 2
24.1-33), 2
P=0.059]. 2
(P=0.009) 2
(P=0.012) 2
mutation/copy 2
(mut(+) 2
MM). 2
70.3), 2
28.7). 2
(cSCC) 2
pre-approval 2
CE-marked 2
(GSK1120212, 2
trametinib, 2
BRIM3 2
DDC, 2
(cobas 2
(1799T>A) 2
(PLX4032), 2
(RG7204/PLX4032), 2
Vemurafenib: 2
0.77]). 2
(KA). 2
over-amplification, 2
(anindependent 2
(LGE). 2
J-point 2
345) 2
690; 2
(SCA 2
subgroup). 2
(42.9% 2
(1987 2
Defibrillators 2
17%). 2
16.2) 2
(7.9%/year). 2
4.0%/year. 2
RF. 2
(33.7%), 2
>or=3 2
LGE-positive 2
P=0.04), 2
(event 2
(P=0.002) 2
gene-positive 2
replicated, 2
"hump." 2
Holter, 2
Australia; 2
Measured 2
(NDO), 2
(UI).The 2
MEDLINE®, 2
EMBASE®, 2
bifida) 2
876 2
relevant: 2
Humanistic 2
Incontinent 2
NDO. 2
Socioeconomic 2
Won 2
(KRW, 2
Koea) 2
5204 2
OAB-related 2
(urge 2
study-the 2
data-provides 2
1835628 2
$710.44 2
$387 2
$338.47 2
$371.97 2
$1267.85 2
($1.18 2
billion) 2
Pharmacotherapy, 2
cost-of-illness 2
Limitations, 2
CATTCC 2
Teads. 2
TEAD-interacting 2
Cyr61. 2
TEADs, 2
Vgll1-TEAD 2
coactivators, 2
(ACPA, 2
Dense 2
HLA-DRB1*01 2
S3P 2
arthritis-associated 2
patience, 2
P<5 2
10(-12)), 2
5,539 2
20,169 2
6,768 2
8,806 2
41,282 2
IL6ST, 2
SPRED2, 2
RBPJ, 2
PXK. 2
(IL2RA 2
CCL21) 2
AFF3. 2
SNP-SNP 2
(SNP 2
lithium-pilocarpine 2
gliotransmitters 2
type-selective 2
HFS 2
82.4% 2
apical-basal 2
P21Cip1 2
pRB, 2
cleaved-capsase 2
Rb-/-, 2
p21cip1-/- 2
p21cip1were 2
TGFbeta-driven 2
Neutralising 2
VAL 2
LVH. 2
(AVB) 2
microinjection. 2
Ca,L) 2
K1). 2
Alternations 2
Ca,L 2
LNA-modified 2
antimiR-1 2
miR-133a/b 2
IK1 2
rotors 2
(Kir)2.1 2
Kir2 2
(Cx) 2
mV: 2
-5.9 2
<.05). 2
Kir 2
Cx 2
tachystimulation 2
(miRNAs/miRs) 2
paring 2
miR-1; 2
Foxo3a 2
MiR-29 2
MiR-208 2
inexactly 2
significant) 2
(ciCNEs) 2
CNE-associated 2
're-wiring' 2
coordinators 2
'hard-wired' 2
Guardian 2
intermyofibrillar 2
p53-Based 2
cyclotherapy: 2
"as 2
pro-oncogenic 2
TIGAR 2
Roughly 2
chemoradiation, 2
MAR-associated 2
SMAR1-mediated 2
arginine-serine 2
(RS)-rich 2
nutlin-3a 2
miR-30d 2
RD, 2
RD. 2
Mdm4) 2
HIPK2 2
TLR3. 2
degradated 2
Mdm2/Mdmx-p53 2
bastion 2
nongenotoxic 2
p53-activating 2
Mdm2/x 2
p53-mimicking 2
nonpeptidic 2
Antigenotoxic 2
B--induced 2
successively. 2
(UVB)-induced 2
kJ/m(2) 2
dipyrimidines. 2
loss-of-heterozygosity 2
demons 2
miR-145/let-7/miR-34/TRIM32/PTEN/FBXW7. 2
TA-p73/p63 2
let-7, 2
miR-15/16a, 2
miR-30, 2
miR-146a; 2
RBs, 2
CDKN1a/b/c, 2
CDKN2a/b/c/d; 2
CycG2, 2
DEC2, 2
genome! 2
c.197G 2
G66V 2
(Heimann-Patterson 2
(22q11). 2
(C22orf16) 2
(later 2
CHCHD10) 2
high-scoring 2
double-missense 2
(R15S 2
G58R) 2
coil-helix-coiled 2
coil-helix 2
1,481 2
Rican) 2
G58R, 2
R15S, 2
Practically 2
GABA. 2
hypnosis, 2
Continuous-infusion 2
Bolus 2
reversal; 2
9-day 2
myoclonic-like 2
54-y-old 2
awakening, 2
drowsiness, 2
inappropriate, 2
overdosing. 2
Intramuscular, 2
Resumption 2
expeditious 2
(TCAs); 2
dysrrhythmia. 2
awakening. 2
utilising 2
lift 2
Empiric 2
proconvulsant 2
contraindicate 2
safely, 2
(BDZ) 2
resedated. 2
mg/10 2
(NAS). 2
71.3 2
(7.13 2
95.06 2
(3.4%). 2
propoxyphene 2
BDZ. 2
Anterograde 2
imidazo-benzodiazepine, 2
flunitrazepam 2
anaesthesiology. 2
1.0mg 2
anaesthesiology, 2
2.0mg 2
mg/hour). 2
agents.(ABSTRACT 2
(Anexate, 2
RO 2
15-1788). 2
[Antagonism 2
15-1788)]. 2
0.3-0.8 2
8.000-fold 2
(Vdes) 2
1.200 2
ml/min, 2
miR-208a. 2
miR-350 2
(miR-208) 2
screens: 2
wet/dry 2
benchtop 2
called. 2
Equimolar 2
NGS. 2
scale-up, 2
<US$200. 2
(COL4A5), 2
(COL4A4) 2
(COL4A3). 2
(p.Ser1147Phe 2
p.Arg1682Trp 2
COL4A4) 2
cilia; 2
M456, 2
B9D1. 2
MKS1 2
hemizygously, 2
frameshifting 2
ArrayCGH 2
1.713 2
CEP290; 2
p.R2210C, 2
(UCDs); 2
more-comprehensive 2
UCDs 2
2240-feature 2
medium-density 2
199-kb 2
(ornithine 2
carbamoyltransferase), 2
CPS1 2
(carbamoyl-phosphate 2
mitochondrial), 2
NAGS 2
(N-acetylglutamate 2
≥10-fold. 2
bar-coded 2
bicytopenia 2
1969. 2
hypermelatoninemia: 2
Melatonin, 2
photoperiod-dependent 2
sweated 2
profusely 2
cool. 2
myopia. 2
(>1,000 2
0-150 2
pinealocytes 2
4-year-old-girl 2
technetium 2
99m-labeled 2
hexamethylpropylene 2
cyproheptadine 2
"spontaneous 2
hypothermia" 2
105). 2
transitive 2
discriminations 2
(VPA600) 2
DMS 2
ProSAP1/Shank2 2
vocalisations. 2
pup 2
vocalisations, 2
Shank3-deficient 2
SHANK 2
mitokines-signaling 2
mitochondria-that 2
antipurinergic 2
dysmorphology, 2
P2Y2 2
Hyperpurinergia 2
MIA) 2
auditory-evoked 2
MALTT, 2
fmr1 2
Congenic 2
VPA-treated 2
(Dp(11)17/+) 2
(executive) 2
automatic, 2
task-switch 2
(SH3 2
(Ras-GTPase-activating 2
Peripartum 2
homonymous 2
quadrantanopia. 2
(ICVT). 2
seal 2
non-invasive/conservative 2
(AUC: 2
0-10), 2
hours/month) 2
medication/month). 2
-22% 2
Postdural 2
Bier 2
1898. 2
small-gauge 2
needles, 2
pencil-point 2
(Quincke-point 2
large-gauge 2
12-20 2
SIH. 2
SIH, 2
lumboperitoneal 2
overdrainage 2
17-yr-old 2
Post-dural 2
vexing 2
large-gauge-needle 2
puncture), 2
pachymeningeal 2
pachymeninges, 2
(WTs) 2
(86.6+/-2.6% 2
58.3+/-4.0% 2
(23.1+/-1.7% 2
41.1+/-2.5% 2
9+/-0.9% 2
TGs, 2
20.4+/-2.9% 2
(1-2/100000 2
year). 2
2/100,000 2
("ChIP-seq") 2
(CenH3), 2
knock-outs 2
LAT 2
TREX1, 2
ADAR: 2
mutation-proven 2
(>2·466) 2
neutralisation 2
12·90, 2
6·14-20·41) 2
0·93, 2
0·57-1·30). 2
RNASEH2B 2
(tested 2
(CSF, 2
r=-0·604; 2
r=-0·289), 2
Neutralisation 2
Union's 2
Programme; 2
High-performance 2
Betaproteobacteria 2
Ralstonia, 2
Rhodoferax, 2
Polaromonas, 2
Delftia, 2
Chromobacterium) 2
amendment. 2
ion-reducing 2
c-type 2
(U) 2
geochemistry 2
Ranger 2
Territory, 2
Identifications 2
cultivable 2
Bacillus. 2
Paenibacillus, 2
Lysinibacillus, 2
Klebsiella, 2
Chryseobacterium 2
acr3-1 2
Stimulating 2
floodplain 2
Shiprock, 2
N.Mex. 2
Geobacteraceae, 2
U(VI)- 2
Desulfuromonas 2
most-probable-number 2
DOE 2
sedimentary 2
bioremediation; 2
Fe(III). 2
feoB 2
nitrate. 2
electron-accepting 2
Geobacter, 2
Clostridium, 2
FeRB 2
(gltA) 2
carbon-amended 2
1.2-2.0 2
flagellum. 2
6.5-7.0 2
Mn(IV), 2
anthraquinone-2,6-disulfonate, 2
'Geobacter 2
humireducens' 2
JW3 2
(95.9 2
similarity), 2
bremensis 2
Dfr1T 2
bemidjiensis 2
BemT 2
(95.1 2
(=ATCC 2
BAA-1134T 2
=JCM 2
13001T). 2
OmpB, 2
sterilized, 2
Colorado, 2
sodA, 2
Oxygen-exposed 2
subsurface. 2
fumarate-grown 2
constraint-based 2
dehalogenans 2
saprolite 2
Field-Scale 2
(IFC) 2
TN. 2
gene-targeted 2
Ridge 2
IFC 2
cells/g 2
reoxidized 2
uranium-bacteria 2
g(-1)cell 2
wt.) 2
L(-1), 2
bioaccumulated 2
U-phosphate 2
crystallinity 2
bioprecipitation 2
Microcosm 2
biominerals 2
motivating 2
build-up 2
bioremediation, 2
remedial 2
CO). 2
(SRBs) 2
reducers 2
SRBs 2
Energy's 2
(IFRC) 2
gltA 2
Abundances 2
biostimulation, 2
proteomics-based 2
U-contaminated 2
M21 2
bemidjiensis-like 2
intervals<320 2
Buryat 2
shortening). 2
shortening) 2
TDR(max) 2
(lipid 2
Lille 2
MONICA 2
527 2
Castrate-resistant 2
androgen-receptor 2
pre-chemotherapy 2
chemotherapeutic, 2
(17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 2
17alpha-(4-pyridyl)androst-5-en-3beta-ol 2
(hNEP) 2
MHz, 2
gene-delivery 2
(hNEP), 2
KunMing 2
(50V/cm, 2
20ms 2
pulse) 2
post-transfer. 2
electrostimulation, 2
electrotransfer 2
(CED) 2
NEP-specific 2
Iba1. 2
Aβ(40) 2
Aβ(40)-degrading 2
Aβ(42)) 2
α-proteobacteria 2
proto-eukaryote 2
disputes, 2
(Rickettsia 2
Rhodospirillum 2
rubrum, 2
Rhodopseudomonas 2
palustris, 2
Rhodobacter 2
sphaeroides, 2
anthropi) 2
matches, 2
44.19% 2
(38) 2
anthropi, 2
34.88% 2
alpha-proteobacterium. 2
alpha-proteobacterium 2
non-sulphur 2
protein-import 2
Rickettsiales. 2
chaperonin 2
aerobically 2
respiring 2
hydrogenosomes, 2
alpha-proteobacteria 2
reannotated 2
originated. 2
GenBank; 2
T3/T7 2
GluA1-containing 2
IQ-like 2
headpiece 2
domain-domain 2
all-atoms 2
headpiece. 2
harmony 2
Ca²⁺-ATPase 2
(BSCL2), 2
dSeipin, 2
ER-to-cytosol 2
lipophilicity, 2
Sarco/Endoplasmic 2
surface-exposed, 2
inheritance: 2
(MPS 2
11/12 2
(6/7 2
non-carriers). 2
alpha-mannosidase, 2
2.5-year-old 2
mucopolysaccharidoses. 2
mg/mmol 2
mg/mmol) 2
dermatan 2
sulphates. 2
alpha-iduronidase, 2
N-acetylgalactosamine-6-sulphatase, 2
arylsulphatase 2
beta-glucuronidase. 2
sulphatase 2
Xq25, 2
deficiency? 2
fathers; 2
receptors/ephrins 2
EphB6 2
EphA6, 2
EphA8, 2
EphB1 2
Ephrin-A3 2
26-fold 2
EphA8 2
EphA1/EphA8 2
Eph/Ephrin 2
EPH 2
(erythropoietin-producing 2
(EPHB6) 2
(EFNB2, 2
EFNB3) 2
4S) 2
EFNB2 2
(P<0.005), 2
(P<0.00005). 2
(EPHB6, 2
EFNB3, 2
TrkA) 2
(>90%). 2
gene," 2
IMR5 2
Ephrin-As, 2
ephrin-As. 2
ephrin-A1, 2
EphA2-integrin 2
vinculin, 2
ephrin-As, 2
cancer-enhancing 2
kinase-activity 2
EphB2, 2
EphB4. 2
ephrin-B1-induced 2
-13. 2
valine-175, 2
histidine-177, 2
serine-178. 2
ephrinA1. 2
phrinA1 2
EphB4, 2
(r=0.86, 2
(p=0.002 2
progress-free 2
EphrinA1. 2
Ephrina1 2
(invading 2
receptor/ligand 2
EphB/ephrin-B, 2
-B2 2
ephrin-B2, 2
ephrin-B1, 2
EphB2/Fc 2
ephrin-B2. 2
EphrinA5 2
ephrinA5-transfected 2
c-Cbl 2
ephrinA5-Fc 2
EphA2-Fc 2
ephrinA5, 2
antioncogenic 2
ephrinA1/EphA2 2
ephrinA1-based 2
EphrinA1-PE38QQR 2
Ephrin-A1 2
adhesion-independent 2
ephrin-A1-transfected 2
Ephrin-B3 2
repulsive 2
expressor 2
microscopy]. 2
fibrilary 2
(GFAP)or 2
(CHG-5,and 2
SHG-44). 2
poorly-differentiated 2
72.48+/-33.78,and 2
96.80+/-36.98, 2
(56.7+/-21.7, 2
53.6+/-18.8). 2
22.3+/-15.3, 2
47.5+/-16.7. 2
Rad52-dependent 2
Multimeric 2
extragenomic 2
healed. 2
PIF1 2
(dNTPs) 2
dNTP 2
Pfh1p. 2
Tof1p-Csm3p 2
CSM3), 2
fork-releasing 2
fork-protection 2
stalling: 2
rrm3-dependent 2
SGS1/TOP3 2
MRE11/RAD50/XRS2 2
(MRX) 2
MUS81/MMS4 2
Rad51p-mediated 2
Sgs1p/Top3p. 2
(RFB). 2
sir2 2
rrm3-generated 2
Rrm3p-dependent. 2
fob1 2
non-RFB 2
nonnucleosomal 2
Rrm3p-dependent 2
VII-L 2
X-bearing 2
III-L 2
Y'-bearing 2
abyssi, 2
Limits 2
ubiquitome. 2
(TUBEs) 2
FK2-specific 2
FADD-mediated 2
pro-survival/inflammation 2
fadd 2
(RIP1)-mediated 2
OHCs 2
necrostatin-1 2
Necroptosis 2
RIP3), 2
pupillometer 2
0-10. 2
-unblocked 2
eyedrops 2
size--indicative 2
Vasomotor 2
drive. 2
adrenal, 2
'non-cardiovascular' 2
(sweating, 2
Dark-adapted 2
[SNS] 2
(NIDD, 2
IDD, 2
alymphoplasia 2
(aly/aly) 2
Nik 2
p100ΔGRR, 2
(NF)-kappaB2 2
IkappaBs 2
NF-kappaB2. 2
factor-kappaB1: 2
p50:p65, 2
p50:p65 2
subunit; 2
(p105 2
p50). 2
mitogens 2
(IkappaB 2
B-inducing 2
Tax-induced 2
alpha-helices, 2
ankyrin-repeat 2
amino- 2
NF-kappaB2, 2
p100/p52, 2
RelB-deficient 2
LTbetaR 2
p50-RelA 2
LTbetaR-induced 2
(HTLV), 2
p52: 2
nfkb2-derived 2
p100/p105 2
GRR, 2
Lymphotoxin 2
(NIK)-, 2
IKKalpha-, 2
synthesis-dependent 2
RelB-containing 2
processing: 2
(NFKB1) 2
threonine. 2
p75c-rel 2
Casper/c-FLIP 2
(p105), 2
Casper-induced 2
(BCSCs). 2
BCSCs 2
(SCCHN). 2
cytokeratins, 2
Invasion. 2
progression.In 2
co-stimulation 2
scattering. 2
OSCC. 2
redeployment 2
(HPMCs) 2
α-SMA 2
progression]. 2
apolarity, 2
branch-specific 2
self-assembly. 2
HK 2
HKs 2
separate) 2
domain(s) 2
neighbourhood/context 2
fusions/fissions. 2
lower-bounded 2
upper-bounded 2
fissions 2
fusion/fission, 2
"duplication/deletion," 2
plasmid-mediated 2
"cut 2
AFP-NICD 2
t(11;14)(q13;q32) 2
9qter 2
Sclerosis, 2
Dysostosis). 2
cushion 2
NOTCH2), 2
Holoprosencephaly 2
(HPE), 2
6qter 2
DELTA 2
(DLL1), 2
NOTCH. 2
HPE. 2
spondylocostal 2
dysostosis. 2
ribs. 2
muscles). 2
608681), 2
MIM609813) 2
(SCDO4). 2
SCD-causative 2
HES7. 2
(HES7), 2
bHLH-Orange 2
(NOTCH2). 2
(Jagged 2
63/105 2
JAG1. 2
JAG1, 2
5-bp 2
20p12, 2
20p12. 2
Tool. 2
Postcancer 2
animated 2
VCBT-I, 2
stepped 2
Savard 2
attitudes, 2
referrals. 2
fatigue-perpetuating 2
Acceptance 2
100; 2
(baseline, 2
.13). 2
ONCLUSION: 2
(T1) 2
(T2). 2
(WL) 2
Alertness 2
Profile. 2
(CBT, 2
WL, 2
CRF; 2
psycho-educational 2
Rigorously 2
Mind-body 2
Co-occurring 2
imagery/hypnosis, 2
Imagery/hypnosis 2
CBT/CST 2
individually: 2
hypnosis. 2
radiotherapy-related 2
CBT. 2
22.8; 2
11.45; 2
5.18; 2
9.34; 2
11.95; 2
cognitive-behavior 2
pretest/posttest 2
nonequivalent 2
71: 2
promoted. 2
Survey), 2
(G-CSFR) 2
endosomal-lysosomal 2
neutropenia/acute 2
(SCN/AML 2
patients)) 2
G-CSFR. 2
(GSK3β), 2
G-CSFR/G-CSFR-T718 2
hes5 2
HES5 2
Fbw7β, 2
Fbw7(Δ/+) 2
NICD/HES5/FBW7β 2
Fbw7β 2
(FBW7), 2
cullin-1 2
FBW7), 2
hAgo, 2
substrate-recognition 2
Skp1-Cullin-F-box 2
Fbw7, 2
SEL-10, 2
Skp1-Cul1-F-box 2
(F-box/WD 2
7; 2
CDC4, 2
Sel10, 2
(Skp1/Cullin/F-box 2
(adenomatous 2
coli) 2
(NSCs/NPCs) 2
ubiquitin-proteasome-mediated 2
(Fbw7) 2
(Skp1-Cul1-F-box 2
protein-Rbx1)-type 2
"high-impact" 2
(PFM) 2
6.73 2
4.36 2
.009) 2
games 2
41.5% 2
(95.5%) 2
18-40 2
p=0.005). 2
4.9%, 2
(27.8%) 2
High-impact 2
sport: 2
fluid-structure 2
(62.2%) 2
4.03 2
college-age 2
midwest: 2
Bristol 2
dare 2
(golf) 2
(trampolinists). 2
dancers. 2
ballet 2
38.8% 2
amenorrhoea 2
bradycardia. 2
cyclicity 2
forty-four 2
10q26; 2
exophthalmia, 2
malocclusion, 2
(44.4% 2
acrocephalosyndactyly, 2
sporadic; 2
(M(2) 2
underway, 2
MOG-EAE. 2
Encephalomyelitis 2
calpeptin 2
(BBB). 2
TMEV-infected 2
[Frohman 2
Racke 2
Raine 2
354:942-955]. 2
(CyPD), 2
(PTP), 2
TLR9. 2
"danger 2
(Igs) 2
anti-myelin 2
mono-episodic 2
autoimmune. 2
autoantigen; 2
Freund's 2
encephalitogenic 2
forepaw 2
hypoalgesia 2
monocytoid 2
RON-deficient 2
Lovastatin 2
Apparently 2
dialysis) 2
outnumbering 2
ENCyclopedia 2
(ENCODE; 2
GENCODE) 2
(70-80%) 2
consistencies, 2
enhancers), 2
stress-causing 2
diethyl 2
(DEM). 2
3') 2
HO-1enhancer 2
E2-3; 2
E2-3) 2
DEM 2
NRF2-dependent 2
DEM-inducible 2
eRNAE2-3 2
eRNA-producing 2
NLS-mediated 2
RanGTP 2
NLS-dependent 2
stacks 2
NEs 2
ELYS, 2
curvature-sensing 2
Nup133, 2
ALADIN, 2
NDC1-mediated 2
Polyproline 2
unordered 2
(PII) 2
bond-promoting 2
trifluoroethanol 2
(TFE), 2
TFE 2
SPXX 2
WW 2
PII-binding 2
SDS-resistant, 2
Anti-gp210 2
autoepitopes 2
namely; 2
(human) 2
NUCLEAR 2
DIVISION 2
PORE 2
MEMBRANE 2
kD) 2
Ligand-stimulated 2
IFN-α/β 2
(PKD2) 2
Phosphorylation-dependent 2
manner) 2
(CK1 2
Ser(532), 2
-Trcp 2
1205Lu 2
43-9006 2
(interferon-alpha 2
IFNAR2, 2
Jak1 2
(Janus 2
beta-TrCP2 2
TrCP2 2
Ser535 2
(Lys501, 2
Lys525, 2
Lys526), 2
SCF(HOS) 2
Slimb 2
(IFNalpha). 2
Skp1-Cullin1-HOS-Roc1 2
(SCF(HOS)) 2
TPEF/HPP1 2
(transmembrane 2
(APC, 2
p14(ARF)) 2
coverage). 2
p19/p16 2
subclones 2
reactivant 2
two-protein 2
Pub1 2
Mitogen 2
(DUB), 2
63-deubiquitinating 2
CYLD+/+ 2
factor-α-induced 2
(AG1478). 2
bacteraemic 2
bacteria-induced 2
entry). 2
HSG, 2
Thymocyte-specific 2
modulator-dependent 2
(Cyld(Delta9)) 2
thymocyte-restricted 2
reciprocates 2
TCR-restricted 2
(Cylindromatosis) 2
Bcl-3 2
balloon-injured 2
E2F. 2
CYLD-dependent 2
NF-κB-essential-modulator 2
(NEMO)-dependent 2
(LckCre-Cyld(flx9/flx9) 2
-Ikk2(flx/flx) 2
H2Bub-dependent 2
methyltransferases) 2
METTL 2
NOP2/Sun 2
electrostatics 2
plugin 2
well-ordered 2
repositioned. 2
Wdr5 2
(PKMTs). 2
(lysine) 2
J.-H., 2
Skalnik, 2
41725-41731). 2
KIAA1076, 2
Set1B. 2
Wdr5, 2
Wdr82. 2
Lys(4). 2
123-amino 2
Wdr5. 2
trimethyllysine-14 2
Rubisco. 2
des(methyl) 2
10-fold) 2
[3H-methyl]-S-adenosylmethionine. 2
Double-reciprocal 2
monomethyllysine 2
HsSET7/9 2
monomethyltransferase) 2
SpCLR4 2
dimethyltransferase) 2
epsilon-amine 2
monomethyltransferases, 2
trimethyltransferases 2
enzyme-bound 2
ping-pong-like 2
H1-like 2
Hc1 2
un- 2
rH3, 2
(meiosis-induced 2
(HMTase). 2
NURF-55. 2
>1,000-fold 2
SU(Z)12 2
VEFS 2
MES-2, 2
MES-6, 2
MES-3, 2
(HMTase) 2
Pr-Set7 2
[Su(var)3-9, 2
Trithorax], 2
ERG-associated 2
gene)-associated 2
zest 2
trithorax) 2
(ESET) 2
mSin3A/B 2
(smFISH), 2
(WPSSM) 2
'UCI 2
Repository 2
databases'. 2
Reconstructing 2
(Sp) 2
(promoter 2
potential), 2
0.88. 2
WebGene 2
http://www.itba.mi. 2
cnr.it/webgene 2
TRADAT 2
(TRAncription 2
Tools) 2
launcher 2
http://www.itba.mi.cnr.it/tradat. 2
SeqHelp 2
hypertext-linked 2
glycobiology 2
Glycan 2
L). 2
XXII. 2
elicitor-inducible 2
7-O-methyltransferase. 2
(B-ring) 2
daidzein. 2
isoflavone-O-methyltransferase 2
(IOMT), 2
7-hydroxyl 2
daidzein 2
IOMT, 2
O-methyltransferases 2
(50.5% 2
IOMT8 2
6a-hydroxymaackiain 2
3-O-methyltransferase 2
Pisum 2
sativum. 2
O-methylation 2
6a-hydroxymaackiain. 2
chickpea 2
cowpea, 2
7-OMT 2
formononetin 2
7,2'-dihydroxy-4'-methoxyisoflavanol, 2
1245-bp 2
stereospecificity 2
(35,918) 2
(1.35 2
vestitione 2
(IFR), 2
(-)-medicarpin. 2
(pIFRalf1) 2
2'-hydroxyformononetin 2
stereospecifically 2
(35,400) 2
Mrs 2
(roots 2
glucoside. 2
stereochemistry. 2
Elicitor-Induced 2
Isoflavonoid 2
Conjugates 2
lindemuthianum, 2
MGM. 2
unelicited 2
conjugated. 2
(14)C-labeled, 2
l-alpha-aminooxy-beta-phenylpropionic 2
elicitor-induced 2
lindemuthianum. 2
extractable 2
Sparc-deficient 2
preneoplasia 2
(atypia 2
(NB). 2
CDKN1A, 2
HIN1 2
TIG1 2
D425 2
Ad-DsRed-SP 2
Caki-2, 2
μmol/l 2
imatinib-sensitive 2
osteonectin, 2
KLF4-induced 2
SPARC-specific 2
(MET). 2
(secreted 2
migration) 2
(migration) 2
II-IV. 2
U87T2 2
A2b2, 2
collosum. 2
(U87T2 2
A2bi 2
73.4 2
A2b2 2
C2a4 2
(c.9827_9832ATACAA), 2
(p.Asn3276_Thr3277del), 2
CHS-related 2
(c.11362 2
p.G3725R) 2
c.961 2
p.C258R, 2
Reexamining 2
premises 2
autosomal, 2
(CHS1/LYST) 2
Oman. 2
89.6 2
(H2015R) 2
H2015R 2
(PRF1, 2
FHL2), 2
munc13-4 2
(UNC13D, 2
FHL3), 2
(STX11, 2
FHL4), 2
munc18-2 2
(UNC18-2/STXBP2, 2
FHL5) 2
Hemophagocyic 2
Lymphohistiocytosis 2
(FHL), 2
Griscelli 2
LvsB 2
lvsA 2
lvsB-null 2
proteinases. 2
MMU13 2
chediak-higashi 2
perforin-containing 2
tragic. 2
discipline, 2
(RV). 2
DGE 2
51.1 2
LV. 2
Post-event 2
septum-a 2
.0027, 2
.077, 2
Dron-treated 2
TRalpha(1)-selective 2
tRNASec, 2
tRNA([Ser]Sec), 2
wobble 2
SPS1, 2
selenophosphate 2
selenide, 2
Vcx1 2
CHMP5. 2
LIP5-mediated 2
LIP5NTD 2
Tsg101 2
Chmp4b, 2
Alix, 2
(ESCRT), 2
ubiquitin-independent 2
transport) 2
(MVBs). 2
Multivesicular 2
abscission 2
abscission, 2
PNETs, 2
pinealocyte 2
Cdk4-mediated 2
senescent-like 2
PNET. 2
(P16) 2
CDK4. 2
gankyrin, 2
gankyrin. 2
p21(Waf1/Cip1/Sdi1) 2
p21(Waf1/Cip1/Sdi1), 2
Cdks. 2
Cdk4-bound 2
NOE 2
Cdk4, 2
cyclin-Cdk 2
(cdk) 2
cdks 2
(WRO) 2
(FRO) 2
(CGA-TGA, 2
Arg-Stop) 2
1-intron 2
FRO 2
ARO 2
(GCC-GTC, 2
Ala-Val). 2
preexisted 2
(PA-1, 2
SK-OV-3, 2
Kuramochi), 2
(AAC 2
GAC) 2
(Asn 2
Asp) 2
Caov-4 2
798: 2
TGG) 2
704: 2
six: 2
(SK-OV-3) 2
p27KIP1. 2
Codeletion 2
mesotheliomas. 2
spindle-cell 2
mesotheliomas 2
(cdk4) 2
(p16INK4/MTS1/CDKN2) 2
p16INK4. 2
p27-cyclin 2
(OIH), 2
(HFD, 2
(si)RNA 2
prepro-TRH. 2
prepro-TRH 2
obesity-enhanced 2
GHR, 2
LIPC, 2
SLC4A1, 2
VWF) 2
CAST(calpastatin), 2
LIPC 2
(hepatic 2
lipase), 2
SLC4A1 2
(band 2
transporter), 2
hormone), 2
(von 2
adipocyte-released 2
n=6, 2
n=6) 2
TRH-antiserum 2
(8-14 2
tail-cuff 2
3H-(3-MeHis2) 2
3H-MeTRH. 2
single-transgenic 2
cross-breeding 2
heart-directed 2
(JxT). 2
HFE-related 2
(juvenile 2
(hemojuvelin, 2
ferroportin) 2
Phenotype-genotype 2
TfR2, 2
forearms 2
PCT, 2
HH. 2
HFE-hemochromatosis 2
phospho-proteins. 2
PP1's 2
inhibitor-1-based 2
Phosphatase-1 2
PPI-1 2
G147D 2
adenoviruses 2
D147 2
oxido-reductive 2
hydroxyacyl 2
Thr(35). 2
phospho-Ser(65) 2
(PP1). 2
I-1(T35D) 2
DARPP-32 2
inhibitor-1: 2
radii; 2
Staphylococcus-aureus-V8-protease-generated 2
electrophoresis/chromatography; 2
immunoblotting; 2
(inhibitor-1). 2
20-30min 2
calcineurin-dependent 2
Non-phosphorylated 2
I-1, 2
PKA/PP1 2
(PP2A), 2
6-fold) 2
2-fold). 2
I-1beta, 2
DNase-I 2
C1q. 2
NET-bound 2
LL37, 2
(HNP), 2
Kit, 2
co-varies 2
MPO-ANCA-associated 2
(SVV), 2
Netting 2
normal-density 2
(NETs), 2
(MPO), 2
3-nitrotyrosine 2
NOS, 2
proatherogenic. 2
NET-derived 2
SLE-associated 2
classifiers, 2
slide-based 2
cost-benefit. 2
Dx 2
ER-negative, 2
(ER)-negative, 2
(Microarray 2
Node-Negative 2
Chemotherapy). 2
chord, 2
hippel-lindau 2
as; 2
(Pheo), 2
c.194C>G 2
(p.Ser65Trp) 2
Hippel-Lindau: 2
(PanNET). 2
PanNET. 2
craniospinal-axis 2
(ELSTs). 2
(60-80%) 2
ELSTs. 2
phaeochromocytoma 2
phaeochromocytomas. 2
(VHLS) 2
hyper-vascular 2
(pVHL) 2
vascularisation 2
[Von-Hippel-Lindau 2
nonrepresentative 2
arises, 2
Ga-68 2
(pheo), 2
(HB). 2
19.7 2
Pheo 2
(VMA) 2
HIF. 2
stigmata 2
pancreaticoduodenectomy 2
(98.5%) 2
(P=0.016). 2
HER1-HER2 2
HER2-HER3 2
(HER2)-positive 2
BT474, 2
Calu-3 2
mCRP 2
opsonization 2
ERBB-mediated 2
HER2Mab-induced 2
EGFR/HER3 2
(HER3-2-3) 2
(HER3-2-2) 2
AKT/ERK 2
HER3-2-3 2
(NRG-1). 2
HER3-2-2 2
NRG-1, 2
HER3's 2
pertuzumab, 2
scFv800E6 2
CLEOPATRA 2
HER1. 2
rollout 2
HLA-B∗5701 2
HLA-B∗1502 2
(DIA) 2
(KRAS/panitumumab 2
HLA-B*5701/abacavir), 2
strives 2
(TPMT) 2
abacavir-related 2
B*5701-positive 2
pharmacogenetics, 2
quality-assured 2
lipodystrophy. 2
(immunologically 2
HLA-B*5701-negative. 2
pharmacogenetics: 2
(PGX) 2
Assumptions 2
forward--not 2
registration--and 2
(late08). 2
(early09), 2
block-buster. 2
profitable. 2
$1135 2
$1139, 2
lamivudine, 2
efavirenz. 2
($/QALY). 2
Abacavir-based 2
30.93 2
16.23 2
$472,200 2
$110, 2
$36,700/QALY 2
antigen-b*5701 2
[IC] 2
HSR). 2
>/=12 2
(32.3%) 2
(7.2%) 2
1945; 2
110-34,352). 2
900; 2
38-21,045). 2
abacavir: 2
HSR, 2
ascertainment. 2
(prospective-screening 2
47.9%. 2
(7.8%) 2
NCT00340080.) 2
hypersensitivities 2
nevirapine. 2
powered, 2
HLA-B5701 2
feasibly 2
HLA-B57 2
B17 2
non-hypersensitive 2
1.5-41.4], 2
6.4-132.3; 2
comparator, 2
22,811 2
Apc-mutant 2
H3-acetylation) 2
miR-211, 2
Wnt-regulated 2
NALM-6. 2
TSA-upregulated 2
extronic 2
MGC14376. 2
NALM-6 2
(H3K27triM) 2
H3K27triM 2
ethylation 2
epigenetic-miRNA 2
(ORIs) 2
Preincubation 2
Z-DNA. 2
Prokaryotic, 2
(PyPuPyPu)2. 2
(staggered 2
loop) 2
unstacked 2
Strand-symmetric 2
functionals 2
tri-, 2
tetranucleotides 2
methylation/deamination/mutation 2
Homodinucleotides 2
(AA.TT, 2
CC.GG) 2
homooligonucleotides 2
CCA.TGG 2
tetranucleotides, 2
four-base-pair 2
under-representations 2
motifs); 2
("CpG 2
suppression") 2
signal" 2
AU 2
context--which 2
humans--is 2
tremors, 2
31.06 2
17.76 2
21.07 2
12.63 2
32.66 2
2-y 2
54.2%. 2
[Nimotuzumab 2
nimustine 2
(21.4%)and 2
(42.9%), 2
64.3%. 2
30.6%. 2
vomitting 2
nimotuzumab-related 2
cross-references 2
<0.005 2
(FTI) 2
10.7, 2
(TSI) 2
(TRABs). 2
microIU/mL, 2
TSI 2
248%, 2
rigidity; 2
ankylosis, 2
vesicle-associated 2
Glutamic 2
HLA-DQB1*0201 2
HLA-typed 2
IDDM-protective 2
sequence-related 2
electromyographically 2
curare, 2
centrally-acting 2
Ung 2
Rif(r) 2
Stationary 2
subtilis' 2
(41, 2
Adaptive, 2
stationary-phase, 2
(stationary-phase) 2
hypermutable. 2
SOS-induced 2
(DinB 2
(UmuC 2
yqjW 2
YqjH, 2
hisC952 2
(hisC952, 2
metB5, 2
leuC427) 2
growth-limiting 2
polX. 2
(PolX). 2
stereotype 2
personality: 2
caring, 2
(Sirtuin 2
p110α, 2
p110α 2
platelet-endothelial 2
molecule-1-positive 2
Microtubule-dependent 2
Akt-GSK3beta 2
niltubacin, 2
agonist), 2
phosphoserine-22, 2
GSK3beta. 2
HDAC) 2
Pronatriodilatin 2
pronatriodilatin 2
(C708 2
T708) 2
A2/A1 2
C708 2
(TERalb: 2
C708: 2
5.5+/-1.7 2
7.8+/-2.0%/h, 2
8.3+/-3.9 2
15.3+/-7.7 2
0.0003; 2
A2: 2
6.05+/-2.2 2
7.3+/-2.1%/h, 2
8.53+/-4.6 2
14.5+/-7.4 2
0.0024, 2
leakage; 2
(albumin 2
dextrans 2
g/L.h 2
imatinib-related 2
protuberans: 2
mesylate? 2
bland-appearing 2
DFSPs 2
micrographic 2
Budgetary 2
[mg] 2
alone), 2
BSC 2
(ACOSOG) 2
Z9001 2
100,000) 2
Kitpositive 2
"with" 2
imatinib). 2
10.8, 2
16.2, 2
$505,144 2
$757,717 2
$1,010,289 2
$21,564, 2
$38,145, 2
$56,605 2
Avoided 2
$61,583 2
$156,702 2
$233,849 2
$465,126 2
$639,159 2
$833,044 2
PMPM). 2
11.7%-21.9% 2
micro-GIST 2
Manruer, 2
=25 2
myelocytic 2
polychemotherapy. 2
A3C, 2
(LINE-1). 2
MusD 2
APOBEC3G- 2
suspect, 2
police 2
identikit. 2
(r=-0.185, 2
formula: 2
(age=relative 2
-1.5/-0.005). 2
(R(2)) 2
(5%, 2
wild, 2
(PPP) 2
(G6PD). 2
(RBCs) 2
cytoadherence 2
African-Americans: 2
record-based 2
2315 2
1904) 2
411) 2
(HGB), 2
(MCH), 2
(MCHC). 2
MEdical 2
GEnomics 2
(eMERGE) 2
~1.2 2
Human1M-Duo 2
malaria-HBB 2
(11p15.4), 2
HBA1/HBA2 2
(16p13.3), 2
rs7120391 2
HBB) 2
rs9924561 2
HBA1/A2) 2
rs1050828 2
G6PD) 2
MCH, 2
(G6PDd) 2
1478 2
A-variant 2
(0.7%; 2
(AOR: 2
malaria-related 2
Bioelectrical 2
flatworm 2
lignano, 2
lignano. 2
hsCRP, 2
1-point 2
(intracranial 2
Prospectively, 2
ECF 2
postadmission 2
.0055, 2
.0266, 2
.0266) 2
.0423, 2
.0041, 2
.0004) 2
post-hemorrhagic 2
nonshunt 2
amperometry 2
urethane-anesthetized 2
dopamine-depletion 2
(carbidopa 2
l-DOPA-induced 2
Vehicle 2
(0.9% 2
NaCl), 2
ip)+the 2
WAY100635 2
mg/kg+15 2
(AIMs) 2
l-DOPA-naïve 2
AIMs 2
l-DOPA-related 2
entirely, 2
L-DOPA-treated 2
each; 2
i.p.)+Benserazide 2
AIMs. 2
(i.t.), 2
(MPTP)-treated 2
L-DOPA/benserazide) 2
JL-18, 2
D(4) 2
L-Dopa/benserazide) 2
JL-18 2
L-Dopa-induced 2
3-methoxytyramine 2
3-O-methyl-dopa. 2
(L-dopa), 2
(PDI), 2
aromatic-L-amino 2
(ALAAD, 2
decarboxylase), 2
3-O-methyl-dopa 2
PDI. 2
DA/L-dopa 2
3-OMD/L-dopa 2
PDI 2
arrythmogenic 2
exercise--or 2
stress--induced 2
tachyarrythmias, 2
(CPVT 2
1q42-43 2
RYR2. 2
25-Mb 2
3.17 2
(NRDS), 2
enteroolitis, 2
pneumorrhagia 2
NRDS, 2
500-1000 2
in-drawing 2
Fio(2) 2
>0.4 2
InSurE. 2
NICU; 2
74.8% 2
≥750 2
>26 2
≤26 2
0.0017, 2
1.44-5.07). 2
(MV), 2
pO(2)/FiO(2) 2
<218, 2
a/ApO(2) 2
<0.44 2
MV) 2
(Intubation 2
intubating 2
<8 2
INSURE, 2
INtubation-SURfactant-Extubation 2
surfactant. 2
[Intubation-Surfactant-Extubation 2
approach] 2
(intubatio-surfactant-extubation) 2
(intubation, 2
extubation) 2
aEEG 2
rScO(2) 2
INtubation- 2
SURfactant- 2
1.76 2
arterial-to-alveolar 2
INtubation 2
(Karolinska 2
INtubation-SURfactant-Extubation) 2
GA-dependent, 2
(Intubation-SURfactant-Extubation) 2
approach--i.e., 2
(Intubate, 2
Extubate) 2
room, 2
instillation, 2
-0.27, 2
AIMed, 2
BioInfer, 2
HPRD50, 2
IEPA 2
LLL 2
F-scores 2
cross-corpora 2
bqchinh@gmail.com. 2
TNF-receptor-family) 2
execution. 2
meshworks 2
(FCS). 2
(LB1) 2
(LA). 2
LB2. 2
blebs. 2
LB1 2
Review: 2
(IVM), 2
destiny. 2
Antinuclear 2
(Ku), 2
p70/p80, 2
excitations 2
earth. 2
45° 2
a/b 2
photosystems 2
earth, 2
Earth, 2
(LHC 2
(RNAPs) 2
polyuridine 2
[poly(U)] 2
slips 2
(his, 2
t500, 2
tR2) 2
Tension 2
-234 2
-213 2
apo-A-II 2
(-497 2
-471), 2
apo-A-I 2
-196 2
-179), 2
apo-E 2
(-409 2
-391), 2
apo-C-III 2
-116 2
-103). 2
non-ATG 2
translation) 2
Nuclease 2
G-quadruplex. 2
APPsα 2
ADAM10. 2
Fanconia 2
MKK3/6 2
(PD25); 2
Dominant-negative-hTERT-expressing 2
PD25; 2
flow-FISH, 2
cytosine-arabinoside 2
post-myelodysplasia 2
3]. 2
Dorsal, 2
[5]). 2
'shadow', 2
ovo 2
trichomes. 2
trichomes 2
‘Healthy’, 2
‘Prudent’, 2
Mediterranean’ 2
‘DASH 2
compliant’. 2
Tromsø 2
"prudent 2
diet" 2
"Pasta 2
Meat" 2
unhealthy, 2
"prudent-healthy" 2
INTERHEART 2
646 2
fried 2
salty 2
snacks, 2
72,113 2
sweets/desserts. 2
6011 2
1154 2
3139 2
(21%; 2
DASH 2
'prudent' 2
civil 2
fridge 2
(10.3, 2
sub-analysis 2
refrigerate 2
Trifluridine 2
(thymidine 2
fluoropyrimidine 2
TPI 2
1:0.5 2
fluoropyrimidines, 2
rest) 2
1:0.5. 2
α,α,α-trifluorothymidine 2
[(3)H]FLT 2
TAS-102. 2
micellar 2
NC-6004 2
nanotechnology-based 2
fluorodeoxyuridine 2
(FdUrd), 2
FdUrd 2
TPI-independent 2
envenomation. 2
envenomation 2
poisonous 2
bristles. 2
skin: 2
(envenomation 2
(dermatitis 2
moths). 2
(caterpillar 2
dermatitis) 2
Resolute. 2
processionary 2
(erucism) 2
obliqua 2
histatins, 2
non-albicans 2
dhvar4, 2
PGLa, 2
B-resistant 2
Histatins 2
cationic, 2
(Hsn-5; 2
24-amino-acid 2
Ala-Ala 2
(F14A/H15A 2
H18A/H19A) 2
[ED50s], 2
F14A/H15A 2
H18A/H19A, 2
(ED50, 2
galactosylation 2
UDP-galactose:ceramide 2
galactosyltransferase 2
(CGT), 2
7,7-dimethyleicosadienoic 2
(DEDA). 2
NBS 2
ulcerations. 2
(GalCase), 2
pathogenomic 2
1,00,000 2
Iysosomal 2
lax 2
(galactocerebroside 2
beta-galactosidase). 2
Protracted 2
tetraparesis, 2
(T1886G), 2
pcDNA3 2
(Invitrogen, 2
Carlsbad, 2
(globoid 2
incoordination 2
enlarged. 2
(GCL 2
GCL. 2
GALC, 2
psychosine. 2
Globoid-cell 2
galactocerebroside. 2
(GLD). 2
22,650-fold 2
6-Hexadecanoylamino-4-methylumbelliferyl-beta-D-galactopyranoside 2
(HMGal) 2
disease/twitcher 2
mouse/Krabbe 2
mouse/positive 2
Galactosylceramide 2
garnering 2
(TWI) 2
(beta-galactosylceramidase) 2
TWI 2
Retrovirus-mediated 2
LASTZ/MULTIZ 2
California-Santa 2
lyrata) 2
conserved). 2
(5'-UTR) 2
PRIN2 2
LAF3 2
pointers 2
dicots, 2
(CNSs), 2
knotted1 2
showthat 2
adh1 2
lock-in 2
stevor, 2
PF13_0006, 2
schizogony. 2
culture-adapted 2
rif-B, 2
3D7. 2
merozoite. 2
MSP3 2
GLURP 2
EBA-175 2
transcendent 2
3D7) 2
splenectomized 2
PfMC-2TM 2
(PfEMP1)/ 2
RIFIN/SURFIN, 2
(PfHRP2), 2
Pexel/VTS 2
(2TM) 2
MC. 2
RIF-29 2
SURFIN 2
merozoites. 2
SURFINs 2
cotransported 2
parasitophorous 2
bloodstream. 2
rifin: 2
knobs, 2
PIESPs, 2
repeated-interspersed-antigen 2
(RIFINS) 2
RIFINS 2
(RIF 2
RIF 2
hyperendemic 2
infected-erythrocyte 2
reinfection 2
(RIF_A 2
RIF_B). 2
RIF_A 2
RIF_B 2
HB3 2
RIF_As. 2
RIF_As 2
[Comorbidity 2
Sfax 2
23.37% 2
defiant 2
School-based 2
african-american 2
(AS-Control; 2
restructuring. 2
Teenagers 2
manual-based 2
youths. 2
(Rebich 2
1983), 2
formation-mineralization 2
aboard 2
COSMOS-1129 2
Biosatellite. 2
resorptive 2
spaceflight, 2
earth's 2
tetracyclines. 2
fluoresce 2
single-observer 2
blond, 2
prevalence-adjusted 2
colors, 2
blond-red, 2
dark-blond, 2
(MC1R). 2
MATP, 2
outlined, 2
Asian, 2
KITLG 2
SLC24A4, 2
TPCN2, 2
reflectance 2
p.Arg402Gln 2
754 2
(BrS). 2
Calsequestrin-associated 2
CPVT2 2
EIVA 2
shocks, 2
coroners, 2
Deadly 2
proposal: 2
foundation, 2
Legal 2
(ARVC2), 2
/familial 2
(FPVT). 2
(LRP1) 2
(VLDLR) 2
(apoER2). 2
LDLR-related 2
(LRP-1), 2
M1→M2 2
CVND-AD 2
plaque-like 2
apoE-poor 2
hyperandrogenism, 2
[Angiotensin-converting 2
options]. 2
antiallergic 2
2004-2009 2
Clement 2
Zablocki 2
blockers; 2
(V20 2
[volume 2
Gy] 2
≤37% 2
(7.4%). 2
0.032). 2
V10 2
V20, 2
V30 2
(CAC). 2
(IMFs) 2
(AOM)/dextran 2
IMFs, 2
TGF-β3. 2
Apc(min/+)/Tpl2(-/-) 2
[Diuretics 2
nondiuretics 2
(ADVANCE) 2
(PROGRESS) 2
(HYVET). 2
cites 2
(TELMI) 2
chlorothiazide, 2
indapamide, 2
metolazone, 2
25-200 2
chlorothiazide 2
medoxomil-based 2
blocker-based 2
antihypertensives 2
simplification 2
SPC 2
ARB-based 2
Endpoint 2
(AII) 2
160/12.5 2
(n=128) 2
≥140/90 2
320/25 2
(-17.3 2
-8.6 2
<.0001) 2
(-13.6 2
=.096). 2
P<.05) 2
P<.0001). 2
genes? 2
Paul 2
Head-on 2
encounters, 2
co-directional. 2
Interruptions 2
simulated, 2
leading/lagging 2
hand--angiographic 2
5-digit 2
Hand. 2
symphalangism 2
phalanx. 2
(syndromic 2
syndactyly) 2
days/cm 2
(62.5 2
syndactylous 2
fusion), 2
P253R) 2
symbrachyphalangism, 2
serine-proline 2
IgII 2
IgIII 2
sitting. 2
deepened 2
3.7, 2
diastrophic 2
positive/negative 2
non-shift-workers. 2
Period1 2
Cryptochrome1 2
cancer-prone. 2
Per-mutant 2
k562 2
C-MYC, 2
(Per2(m/m)) 2
Wee1, 2
Cyclins, 2
Period2 2
unfit, 2
(BIPN), 2
BIPN-related 2
NRS 2
3.5. 2
[Reported 2
(TERMS®) 2
auto-PBSCT, 2
TERMS® 2
(rifampicin 2
(dexamethasone) 2
co-administration, 2
(proteasome 2
bortezomib-alone 2
pharmacokinetics-evaluable 2
(AUC(72h)) 2
AUC(72h): 2
(sFLC) 2
agent-based 2
vials, 2
36.2% 2
target" 2
Bortezomib-treated 2
organs) 2
(1-4) 2
remission) 2
self-medicate 2
"miracle 2
herb" 2
(-)-epigallocatechin 2
gallate 2
1,2-benzenediol 2
(BZM, 2
MG-262, 2
PS-IX), 2
non-boronic 2
(MG-132, 2
PS-I, 2
nelfinavir). 2
caspase-7 2
28-d 2
(VTD). 2
[VTD 2
Myocet 2
(MyVTD)]. 2
treated: 2
VTD 2
MyVTD 2
0.10-0.55), 2
vandetanib. 2
EGFR-activated 2
(P-Akt). 2
myeloma:: 2
time-to-event 2
SUMMIT, 2
(BTZ), 2
vials. 2
BTZ. 2
PegLD, 2
BMI1and 2
PCGF2, 2
Hh-driven 2
SmoA1, 2
SmoA1; 2
SmoA1;Bmi1(+/-) 2
Bmi1(-/-) 2
nonproliferative, 2
(6.2% 2
PCNA-positive, 2
GFAP-positive, 2
(29.6% 2
TUNEL-positive). 2
Bazett 2
114,334 2
(234 2
biphasic, 2
msec(1/2)) 2
5,511 2
(1.25%) 2
[SDs] 2
5,473 2
(1.63%) 2
(0.03% 2
msec(1/2), 2
0.39/100,000 2
tachyarrhythmia, 2
Fridericia 2
<320 2
QTfc, 2
QTnc 2
0.10%, 2
0.08%, 2
0.06%, 2
fielders 2
fielder 2
batted 2
thrown 2
fielding 2
baserunning 2
faceguards, 2
ball, 2
headfirst 2
(average, 2
softballs, 2
pucks, 2
protectors, 2
comet-tail 2
(ULC) 2
Ironman 2
ULCs. 2
E/Em 2
EVLW 2
PCWP, 2
"comet-tail" 2
water-thickened 2
divers 2
(pre- 2
aspecific 2
subclinical) 2
"focal" 2
orgasm. 2
into: 2
'HWE 2
(n=198) 2
HEW 2
4q24-q28. 2
4q24-q28, 2
3.50 2
D4S402. 2
Centromere-proximal 2
D4S1572 2
D4S2277, 2
NEUROG2, 2
ANK2, 2
UGT8 2
CAMK2D, 2
Arabia, 2
Arabia. 2
lukewarm 2
Hot-water 2
(HWE), 2
shower 2
25.4% 2
exhale 2
(FENO) 2
Papua, 2
[ppb]; 2
11.6-13.8) 2
ppb; 2
14.2-19.5; 2
(nadir 2
vital-capacity 2
1.05-7.12; 2
low-technology, 2
(eNO). 2
Hanoi, 2
Nam, 2
smear-positive, 2
84). 2
handheld 2
[ppb], 2
10-20) 2
12-19, 2
0.517) 2
(8.5 2
5-12.5, 2
68-86) 2
47-75). 2
condensate 2
(H2O2) 2
H202 2
TBARs 2
(1022.96+/-186.02 2
4.22+/-0. 2
(398.15+/-37.10 2
0.48+/-0.17 2
sanitization 2
orf135 2
deoxynucleotides 2
sanitization. 2
(catalytic) 2
2-OH-dATP) 2
eta 2
(8-OH-dGTP) 2
dTTP 2
(G), 2
4.5. 2
phototypes 2
nonsegmental 2
continued; 2
repigmentation, 2
61.0 2
.001]; 2
69.0 2
.003]). 2
48.64% 2
39.49%-57.80%) 2
33.26% 2
24.18%-42.33%) 2
NCT01430195. 2
([Nle4-D-Phe7]-α-MSH, 2
Scenesse®) 2
anti-afamelanotide 2
washings 2
1,390 2
α-MSH, 2
Hailey-Hailey 2
Nle4-D-Phe7-α-MSH 2
HHD 2
(α-MSH). 2
drug-exposed 2
Nonsurgical 2
betulinic 2
GDC-0449; 2
alpha-melanocyte-stimulating 2
afamelanotide; 2
capecitabine. 2
(Clinuvel 2
Australia) 2
PP-related 2
(Nle(4)-D-Phe(7)-alpha-MSH), 2
melanocortin-1-receptor, 2
transferring, 2
acetosyringone 2
AS-induced 2
T-DNA-encoded 2
Agrobacterium-produced 2
growths, 2
'crown 2
gall', 2
tzs-fs 2
Tzs, 2
stage(s) 2
jasmonic 2
disarmed 2
IAA, 2
agrobacteria 2
"crown 2
galls" 2
transferred-DNA 2
Ti-plasmid 2
Tmr, 2
VIP1, 2
Agrobacterium. 2
Chry5, 2
soybeans, 2
opines 2
lactone, 2
pTiChry5 2
Amadori 2
TL. 2
KYRT1 2
pKYRT1 2
borders. 2
mutagenizing 2
T-complex, 2
T-DNA, 2
ecotype. 2
Pre-analytical 2
anti-D 2
7/10. 2
1539) 2
104). 2
10-39, 2
1317). 2
sex: 2
150/161 2
130/135 2
[96.3% 2
91.6-98.8%)]. 2
concordancy 2
401/403 2
[99.5% 2
98.2-99.9%)]. 2
(174/528) 2
users; 2
them; 2
CAH 2
(Non-invasive 2
monosomy. 2
(Perry 2
P150(Glued) 2
(DCTN1). 2
(18)F-fluorinated 2
N-3-fluoropropyl-2-ß-carboxymethoxy-3-β-(4-iodophenyl) 2
nortropane 2
([(18)F]FP-CIT) 2
DCTN1. 2
Oculogyric 2
[(18)F]FP-CIT 2
frontotemporoparietal 2
p.Y78C 2
Parkinsonism. 2
[123]I-metaiodobenzylguanidine 2
disease-segregating 2
DCTN1) 2
CS-HAHT 2
CS-HA3D 2
CASQ2(D307H). 2
60,000-Da 2
calsequestrins, 2
(CASQ) 2
CASQ 2
replicas. 2
muscle) 2
UGT1A1*6 2
Malays 2
irinotecan-induced 2
Centre. 2
demography. 2
UDP-glucuronosyltransferase 2
UGT1A 2
individualization. 2
snRNPs: 2
Lsm11 2
sDMA-modified 2
RG-tails, 2
LSm4 2
sDMAs 2
Gemin5 2
suborganelle 2
U2, 2
U4, 2
U5, 2
(GST)-pulldown 2
(ANA) 2
"cytoplasmic 2
golgin 2
Arginine/glycine 2
(RG)-rich 2
Sm, 2
like-Sm 2
(LSm), 2
fibrillarin, 2
(Gu), 2
GWBs 2
(AD): 2
microhemorrhages. 2
ponezumab, 2
BAN2401, 2
gammaguard 2
octagam. 2
calcium-mediated 2
(omega-conotoxins 2
([3H]nitrendipine), 2
MVIIA) 2
MVIIC) 2
L-, 2
omega-Conotoxins 2
Electrically-induced 2
non-adrenergic 2
Lys(7) 2
Pro(7) 2
Thr(11) 2
"fractal-globule" 2
biophysics 2
derivations 2
co-clustering 2
(linearity 2
Insertions 2
Eliminations 2
(characteristic 2
life-cycle) 2
II-inhibiting 2
2RGR). 2
1c, 2
3c, 2
3e 2
onco-hematology. 2
(characterized 2
senescence-based 2
Thr(34)-phosphorylated 2
like-growth 2
F14512. 2
core-targeting 2
anchor, 2
BD3 2
G35 2
BD13, 2
BD14 2
BD16 2
EPG85-257RNOV 2
EPG85-257RDB 2
EPP85-181RNOV 2
EPP85-181RDB 2
MCF-7/Adr 2
D79/86RNOV 2
fibrosarcoma, 2
MeWoETO1 2
D23 2
HT-29RNOV 2
HT-29RDB 2
D24 2
MDA-MB-231ROV 2
ATP/ADP-induced 2
ICRF-193, 2
MKN28 2
enzyme-DNA-drug 2
(NYH/187) 2
485, 2
161-165 2
drug-selected 2
temperature-conditional 2
bisdioxopiperazines 2
-193 2
<0.25 2
Kinetoplast 2
wt, 2
open-clamp 2
microculture 2
(VP-16), 2
VP-16, 2
VM-26 2
Cytometric 2
VP-16-induced 2
redistribution, 2
anti-topoisomerase 2
re-ligation 2
4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyra 2
preincubating 2
m-AMSA; 2
m-AMSA- 2
VP-16-induced, 2
II-active 2
Ehrlich 2
minicircle 2
PC-7/CDDP 2
PC-14/CDDP, 2
cisplatin-sensitive 2
6.1-kilobase 2
180,000 2
(SHAPE-Seq) 2
(SHAPE-Seq), 2
v2.0, 2
'universal' 2
SHAPE 2
sequence-structure 2
life's 2
antiperitoneal 2
N-methyl-N'-nitro-N-nitrosoguanidine 2
(MNNG). 2
Honokiol-treated 2
atom-based 2
(r(2)= 2
protein-1. 2
TPL2 2
Tpl2-mediated 2
kinase/ERK 2
RANKL-stimulated 2
8-halo-4-(3-chloro-4-fluoro-phenylamino)-6-[(1H-[1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles 2
8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles. 2
(Cot/MAP3K8) 2
MEK. 2
4-anilinoquinazoline 2
(erlotinib, 2
Tarceva), 2
4-nitroanilines. 2
urther 2
thieno[2,3-c]pyridine 2
nhibition 2
subtyped. 2
FA-I 2
FANCJ/BRIP1 2
ORL 2
Extrahematological 2
veno-occlusive 2
Fanconis 2
(fungal) 2
Overwhelming 2
Heterodontus 2
francisci. 2
gene-coding 2
(Scyliorhinus 2
"temporal" 2
"spatial" 2
"distal 2
enhancer," 2
non-Hox 2
Evx2 2
Lnp. 2
Evx1, 2
Hibadh, 2
Tax1bp, 2
Jaz1. 2
(E11.5-E13.5) 2
mmA13CNS-Hsp86-lacZ 2
Hoxa13/Evx1/Hibadh/Tax1bp1/Jaz1, 2
Evx1- 2
Evx2-like 2
element(s) 2
bass. 2
euteleosts 2
cis-sequences 2
actinopterygians 2
(Lethenteron 2
japonicum). 2
oligonucleotide- 2
renewable, 2
spreads. 2
Nd:YAG 2
Hypertrichosis 2
5-months 2
vellus 2
1982), 2
(additional 2
scalp) 2
scotoma, 2
metamorphopsia 2
macula. 2
limitated 2
reexamination. 2
investigators' 2
36.5% 2
48; 2
solvents, 2
butylene 2
polysorbate, 2
tilling 2
arrests, 2
intolerance; 2
"polymyalgia 2
Tritanomaly 2
min-1. 2
0.751 2
min-1) 2
m-2). 2
Upjohn-sponsored 2
gunshot 2
underreporting 2
Sclerosis: 2
Arimoclomol. 2
Dismutase 2
mis-handling 2
bulbar, 2
rhodopsin, 2
misfolding, 2
arimoclomol. 2
Cholinergic 2
survival-promoting 2
staurosporin 2
ristocetin 2
vWF:CB 2
Gastroscopy 2
cecum. 2
10-33; 2
youth, 2
Electrocoagulation 2
argonium 2
bioprothesis 2
patient-year; 2
Bioprosthetic 2
patient-year 2
patient-year. 2
bioprosthetic 2
[Calcifying 2
bioprosthesis 2
embolisation. 2
(AVMs) 2
(AS); 2
professional, 2
market: 2
sphincter® 2
(Minnetonka, 2
band® 2
(Feldkirch, 2
Austria). 2
(anal 2
ABS 2
silicon-coated 2
pads/day, 2
urologist. 2
screws 2
polipropylene 2
rami, 2
silicon/polipropylene 2
(Invance) 2
Invance 2
(Porgés). 2
CHRU 2
Lille. 2
T.O.T. 2
non-elastic, 2
polypropylene 2
(UraTape, 2
Mentor-Porgès) 2
mid-urethra. 2
emptying 2
medical-grade 2
securely 2
meatus 2
nonenteric 2
pseudomonads. 2
DNA-protecting 2
(Pol)V 2
RulAB 2
dps-defective 2
rulAB 2
adenine), 2
neighbors, 2
(LSIs) 2
Conformation-Capture 2
(3C)-based 2
3D: 2
uniqueness, 2
co-injection 2
CRISPR/ 2
repeats/CRISPR-associated) 2
repeats/CRISPR-associated). 2
melt 2
Tg(-5.1mnx1:egfp) 2
(tyr, 2
golden, 2
mitfa, 2
ddx19). 2
75-99%, 2
null-like 2
Cas9-induced 2
non-iodinated 2
single-lead 2
(38.8% 2
inhomogeneity. 2
Bangalore 2
r-l) 2
inducted 2
(WC), 2
multi-staged 2
Your 2
survives 2
posttest-only 2
intercollegiate 2
Collegiate 2
(crew, 2
football, 2
nonathlete). 2
0.182). 2
Men's 2
5-star 2
Qualifying 2
Newquay, 2
coach's 2
Newquay 2
(0.023) 2
0.976 2
(0.028). 2
forwards, 2
backs) 2
Ospreys 2
Rugby 2
Club 2
(caps) 2
backs 2
club 2
tries. 2
occupation: 2
firefighters. 2
Occupations 2
masculinity 2
maleness 2
(sex 2
ratios), 2
givens 2
(demographic, 2
fertility-related, 2
firefighters, 2
occupation. 2
expectation, 2
firefighters 2
ranks. 2
left-handedness, 2
pubertal-adolescent 2
sex-hormonal 2
Contests 2
instincts. 2
ratio-a 2
pneumatic-induced 2
collagenase-induced 2
nesiritide 2
(hBNP) 2
24-28. 2
(TNF-alpha 2
IL-6; 2
(F4/80; 2
(Fluoro-Jade 2
hBNP. 2
Hyponatremia 2
SIADH, 2
natriuretic, 2
vasorelaxant, 2
aldosterone-inhibiting 2
Electrocardiogram 2
(800+/-150 2
(55+/-9 2
(traumatic 2
11-donor-cell 2
(sCD38) 2
sCD38 2
anti-kappa 2
MDX-1097, 2
(PLMs), 2
(CCR). 2
repair)'s 2
ADNA 2
Ape 2
TGF-beta-II-receptor, 2
nonstroke 2
Intensified 2
(TIME-CHF) 2
hospitalization-free 2
2.94; 2
1.15-7.51, 2
0.025], 2
'g'. 2
vocabulary-based 2
'g' 2
(ß 2
-0.09, 2
-0.13 2
-0.03, 2
N-terminal-pro 2
pilot-study. 2
1.5×) 2
(alpha2-macroglobulin, 2
apolipoprotein-A1, 2
Metalloproteinases-1 2
Trombospondin-2) 2
(1.9×). 2
FtsZ/tubulin 2
CetZ1 2
ring-associated 2
ZipA. 2
midcell 2
Z-ring) 2
moonlighting 2
murein 2
Chlamydiae 2
cryotomography, 2
chlamydiae 2
Chlamydiae. 2
sacculus 2
non-essential. 2
dcw 2
mycoides. 2
168. 2
leprae, 2
(TEAEs) 2
10-mg/kg-treated 2
TEAEs; 2
intetumumab-related. 2
5-mg/kg 2
FDs 2
Fractal 2
17A, 2
x-42/Αβ 2
x-40 2
beta-secretase-1 2
(BACE1), 2
BACE1-AS 2
(RMS). 2
(HOCM) 2
(rhIGF-I). 2
post-binding 2
rhIGF-I 2
leprechaunism, 2
INSR. 2
(6702 2
mU/mL). 2
(p.T910M 2
E1047K). 2
day-old, 2
(rh-IGF1) 2
rapid-acting 2
α-glycosidase 2
adenoidal 2
T910M 2
E1047K 2
rhIGF1 2
INSR, 2
derangement, 2
p.Arg890X 2
p.Tyr818Cys 2
alphabeta 2
'elfin' 2
(hypertrichosis, 2
lips), 2
nipples. 2
>2,100 2
>2,331 2
pmol/l, 2
Diplex 2
East. 2
("Leprechaunism"), 2
PTU-treated 2
PDGFR-β 2
(S96A) 2
(HRC 2
vistas 2
bleak 2
Life. 2
(MUP) 2
C>T/G>A 2
phospho-ErbB3 2
mutation-targeted 2
cholangiocarcinomas, 2
VE1-positive 2
cholangiocarcinomas 2
VE1 2
pan-uveitis 2
(N-terminal 2
(V600)BRAF 2
BRAFi 2
Braf(V600E) 2
serologic, 2
(ARMS)-PCR. 2
tube: 2
dideoxy 2
colo205 2
1799T>A 2
temporary. 2
PI3K/Akt-CREB-AEBP1-NF-κB 2
V600K. 2
(BRAF-I) 2
listed. 2
V600E, 2
Ras-Raf-Mek-Erk 2
774), 2
111), 2
(44.9%) 2
[497 2
(99.6%)] 2
(0.4%)]. 2
p.V600E 2
[86 2
(17.2%)]. 2
[18 2
(16.2%)] 2
mucosal, 2
uveal, 2
88) 2
PGC1α. 2
respects, 2
p.Val600Glu 2
sun, 2
nonchronically 2
scarce, 2
PDAC. 2
gray. 2
"shotgun" 2
EAE-induced 2
IP-specific 2
spink 2
specimens: 2
(XIV), 2
(VI), 2
SNC73. 2
fresh/frozen 2
Tris-HCl, 2
beta-octylglucoside, 2
CAAR 2
Hundreds 2
shotgun-based 2
leiomyomas. 2
(IHC). 2
historically, 2
frozen/optimal 2
(OCT)-embedded 2
frozen/OCT-embedded 2
atorvastatin-regulated 2
OCT-frozen, 2
atorvastatin-related 2
survivorship, 2
personality) 2
(1998-2008) 2
4446 2
(DS14); 2
(n=3080). 2
PROFILES 2
1-10years 2
(DS14) 2
(B-IPQ); 2
(n=3977) 2
(23.3%), 2
(20.3%), 2
bothered 2
1-5: 2
22%; 2
>5: 2
7%; 2
(SF-36 2
EORTC-QLQ-C30) 2
572 2
role-function 2
(SF-36: 2
status/QoL, 2
(EORTC-QLQ-C30: 2
EORTC-QLQ-C30 2
5.56). 2
(35-64%) 2
(20-36%). 2
14%; 2
(57.8 2
75.6), 2
(73.1 2
88.7), 2
(61.7 2
80.6), 2
(67.8 2
89.4) 2
(54.5 2
72.8) 2
self-evaluation, 2
worry. 2
worried 2
diverse: 2
Insyght. 2
http://genome.jouy.inra.fr/Insyght. 2
Ensembl-derived 2
Sockeye. 2
Java3D 2
compactly 2
cross-sequence 2
200-5-3 2
cubes 2
refuse 2
SKR10. 2
refuse, 2
20+/-2.0 2
20.0+/-1.0 2
l(-1), 2
28.5+/-2.2 2
31.0+/-1.7 2
l(-1) 2
alpha-amylase 2
hydrolysate 2
TN484-M1. 2
starch, 2
20542. 2
lactose-based 2
873 2
growth-associated 2
lactose) 2
(5.1-fold) 2
g/l) 2
LBM. 2
dark-brown, 2
18.0%. 2
lovastatin) 2
terreus. 2
6-phosphofructo-1-kinase 2
(PFK1) 2
inhibition-resistant 2
productivities 2
mycelium. 2
fermentations, 2
itaconate 2
acid: 2
pharmacy, 2
g/(L 2
mol%. 2
char 2
terreus, 2
foam, 2
fermentation. 2
48-h 2
niger. 2
48: 2
602-611, 2
biotechnol 2
(mttA, 2
mfsA) 2
mfsA 2
transformants. 2
non-acidifying 2
D15#26 2
oxaloacetate 2
(oahA) 2
D15#26. 2
N201, 2
(N201CAD) 2
AB1.13. 2
(D.O.) 2
N201 2
HBD2.5 2
(HBD 2
(mDCs 2
(HPCs). 2
(SR1), 2
clinical-scale 2
BDCA2(+)BDCA4(+) 2
BDCA1(+) 2
mDCs, 2
BDCA3(+)DNGR1(+) 2
(IFN)-α, 2
probasin 2
(Lew-TRAP) 2
(prostatic 2
carcinoma-1 2
(58/206; 2
28.2%) 2
(0/16) 2
nonapeptides 2
autoimmunity-driven 2
gluten-dependent 2
non-DH 2
herpetiformis]. 2
anti-endomysial 2
Uncertainty 2
tissue-deposited 2
skin-bound 2
clarified: 2
transglutaminase, 2
transglutaminases 2
challenge) 2
26.6 2
seven) 2
(strict 2
seven). 2
(cCD) 2
(DH). 2
metalloelastase 2
(MMP-12) 2
blisters. 2
explants, 2
gluten-sensitive, 2
(Ig)A 2
oats, 2
[Dermatitis 2
childhood]. 2
antireticulin 2
antiendomysium) 2
DBP1 2
DR3 2
DQW2. 2
IgA-gluten) 2
(IgA-AGA) 2
(DH), 2
GFD. 2
knees, 2
MutSDelta798 2
methyldirected 2
acetobutylicum 2
uvrD). 2
MutHLS 2
MMR, 2
MutS2 2
(hMLH1) 2
(UPEC), 2
propel 2
ascension 2
locked-ON 2
(L-ON) 2
Isogenic 2
mutH, 2
ΔmutH 2
ΔmutS 2
Cochallenge 2
MMR-defective 2
occurring, 2
MutH-dependent 2
BAS4289 2
self-aggregate. 2
MSB8 2
TmL. 2
(eATL) 2
MMR-mediated 2
methyl. 2
MutH. 2
DS-related 2
defecation 2
polymalformation 2
(58.8%) 2
(41.1%) 2
male:female) 2
(0.02%), 2
killing? 2
Parasite-mediated 2
Culling 2
treating, 2
culling, 2
parasite? 2
cull 2
policies, 2
host-vector-pathogen 2
wildlife. 2
humidity, 2
generalists, 2
zoonotic. 2
multi-host 2
two-patch 2
(TBEV) 2
Louping 2
group/genus 2
GGEV. 2
RNA-positive 2
Lancashire. 2
pathogen-host-vector 2
upland 2
grouse, 2
scoticus) 2
(rSFV) 2
(LIV), 2
LIV. 2
louping-ill, 2
ELAVL1, 2
4E-Ts. 2
ELAVL1-regulated 2
(2A(pro)) 2
TIA1/TIAR 2
ribonome. 2
ribonomic 2
ARE-based 2
ribonucleosomes 2
all-exon 2
66-75 2
splicing) 2
stability/translation 2
titin: 2
Titin-based 2
mammals; 2
myofibril 2
[Titin 2
reaction-single 2
(PCR-SSCP) 2
G13053A 2
(TTN 2
X90568) 2
(Gly4351Asp)] 2
(1.7%). 2
Gly4351Asp 2
line-deficient 2
unloading-induced 2
strain-dependent 2
Dalton 2
daltons 2
Z-lines. 2
Z-line, 2
'molecular 2
ruler' 2
micron. 2
twitchin 2
titin/twitchin 2
immunoglobulin-C2 2
super-repeat 2
LMM 2
C-protein. 2
(poly) 2
factor-β/bone 2
calcineurin/MEF2 2
MEF2-target 2
adrenergic-induced 2
cardiomyogenesis-related 2
Gli- 2
MEF2-binding 2
II-specific 2
(MEF2D) 2
HDAC4-HDAC3-MEF2D 2
differentiation-induced 2
deacetylase(s) 2
(HDAC4) 2
MEF2, 2
MEF2D. 2
HDAC7, 2
HDAC9 2
MEF2-specific 2
MADS 2
autoacetylation. 2
LST8. 2
Raptor-mTOR 2
Akt-FOXO 2
S6K1. 2
Rictor-binding 2
mTOR-Raptor 2
mTOR)-mLST8 2
mTORC1), 2
mTOR-Rictor 2
(rapamycininsensitive 2
mTOR)-mLST8-Sin1 2
mTORC2). 2
Protor-1, 2
(controls), 2
INS, 2
(raptor, 2
mTOR) 2
SEC13 2
(stress-activated 2
Protor-2. 2
AGC 2
TGN-endosome 2
interorganellar 2
(GFP)-based 2
time-axis 2
TGN-derived 2
4min). 2
GFP-MPRs 2
adaptors, 2
GGAs. 2
FRAP. 2
MPR-containing 2
(LERP), 2
GGA, 2
Sortilin 2
non-enzymic 2
prosaposin, 2
(DRMs). 2
M6PR. 2
GGAs, 2
retromer, 2
(CI-MPR) 2
Rac1-cofilin 2
tubulopathy. 2
(MPR)-mediated 2
endosome-to-trans 2
retromer-positive 2
OCRL-depleted 2
PI(4,5)P(2) 2
monoesters 2
N-glycans, 2
MPRs, 2
(CPY). 2
(YPR079w) 2
MRL1) 2
MRL1 2
Mrl1p 2
retromer-mediated 2
CIMPR, 2
CD8-reporter 2
aromatic-containing 2
Anti-adhesion 2
corticosteroid-refractory 2
Gut-selective 2
31.7; 2
>1), 2
37.2; 2
P<0.001] 2
40.4; 2
P<0.001]). 2
NCT00783718.). 2
(integrin 2
colectomy 2
corticosteroid-free 2
vedolizumab-naive 2
UC; 2
Rollover 2
dosed; 2
(58.3%; 2
1.7, 2
rollover 2
leveling 2
155, 2
491. 2
anti-mucosal 2
molecule); 2
IL-23/T 2
(tofacitinib). 2
anti-metabolites 2
here? 2
(anti-α4β7), 2
etrolizumab 2
(anti-β7 2
(anti-MAdCAM-1 2
12/23p40 2
toafacitinib. 2
alpha4beta7 2
α4 2
alicaforsen 2
rhuMAb 2
β7, 2
CCX282-B, 2
benefit:risk 2
(CAMs) 2
CAMs, 2
CAMs 2
certolizumab, 2
employed; 2
molecules: 2
MLN-0002 2
(Vedolizumab) 2
2302 2
(Alicaforsen) 2
vedolizumab) 2
monoexponentially 2
nonlinearly. 2
(C(max) 2
vedolizumab-treated 2
anti-TNF-a 2
alicaforsen, 2
pan-α4 2
(MNL-0002), 2
Pharmaceutical's 2
gut-specific, 2
integrin-neutralizing 2
anti-alpha(4) 2
0.3-0.4 2
alpha(4)beta(1) 2
alpha(E)beta(7) 2
alpha(4)beta(7)-expressing 2
[IC(50)] 2
gastrointestinal-specific 2
Vedolizumab: 2
(Entyvio™) 2
integrin-receptor 2
α4β7/α4β1 2
guardian. 2
(average: 2
satisfied" 2
.34). 2
(epidural) 2
anaesthesia/analgesia 2
EA, 2
telephoned 2
awakened 2
adenoidectomy 2
unpremedicated 2
alfentanil 2
pain/discomfort 2
8/25 2
(62%, 2
16/26 2
13/24). 2
electroencephalographic-derived 2
premedicated 2
premedication. 2
50%-oxygen 2
eyelash 2
(BIS(nadir)), 2
(immediately 2
intubation), 2
frequencies; 2
(BIS(nadir)). 2
BIS(nadir). 2
(oxygen 2
50%-nitrous 2
postanaesthetic 2
premedicant. 2
(high-risk) 2
PAPP-A, 2
cut-offs, 2
Krauss 2
Larsson 2
Stein-Langfitt 2
scale), 2
MMSE) 2
(decreasing) 2
(increasing) 2
candidacy, 2
determinant, 2
spectacular, 2
shunt; 2
Shunt 2
distractibility 2
(Met-PLN28-52) 2
SERCA1a, 2
(HA-PLN28-52) 2
21-29 2
(PLN1-20-PLN30-52) 2
"supershifted" 2
PLN1-20-PLN30-52 2
Flag-PLN28-52 2
Flag 2
monomeric, 2
monomer.SERCA2a 2
acylphosphatase, 2
anti-SERCA2a 2
glutathione-Sepharose 2
(K(D)) 2
anti-PLN 2
Asp. 2
Ser(16)-phosphorylation 2
intra-erythrocytic 2
heptameric 2
PfSMN 2
Spliceosomes 2
compile 2
T-invariants 2
T-clusters 2
multi-megadalton 2
(Firmicutes) 2
DnaE. 2
content) 2
pSM19035 2
epsilon(2) 2
operons: 2
γ-secretase, 2
domain; 2
learning/memory. 2
β-secretase, 2
NEXT, 2
(Nct) 2
C230S 2
(C3) 2
(ProTα), 2
anti-necrotic 2
Ca²(+), 2
Ca²(+)-binding 2
co-released 2
Δ88-98 2
necrosis-inducing 2
extacellular 2
Keap1, 2
prothymosinalpha-Keap1 2
"acidic" 2
ProTalpha, 2
Glu-rich 2
perchloric 2
yields. 2
parathymosin 2
(1-88) 2
esculenta. 2
Prot-alpha 2
20-63 2
(PANSS), 2
50-200mg/day. 2
Simpson-Angus 2
(SAS) 2
(EPS), 2
(P<0.006), 2
(total), 2
P's>0.5). 2
test/confirm 2
sleeping. 2
pro-mnemonic 2
Non-verbal 2
creativity. 2
CANTAB 2
clozapine-induced 2
flexible-dosed 2
(2-((diphenylmethyl)sulfinyl)acetamide) 2
129/SJ 2
go-no 2
phencyclidine 2
PLSR 2
Deficit/Hyperactivity 2
mania. 2
post-polio 2
ID-ED 2
digging 2
(1.25 2
neurochemical, 2
debilitating, 2
avolition. 2
tapers, 2
D-serine, 2
celecoxib) 2
(ADHD). 2
rehabilitate 2
alkylacceptor 2
guanidine, 2
denaturant. 2
heat-coagulated 2
thermodynamically 2
O6-benzylguanine, 2
Ada-C, 2
O6-benzylguanine. 2
Ala316 2
(A316P) 2
Trp336 2
(W336A) 2
(W336G). 2
Cys321 2
oligodeoxyribonucleotide. 2
benzylated 2
16-mers. 2
benzyl 2
K-12. 2
dibromoalkanes, 2
dibromoethane 2
dibromomethane, 2
uvrABC 2
excision-repair 2
mucAB 2
dibromomethane) 2
dibromoethane) 2
dibromoalkanes 2
ATases, 2
repairable 2
(O6-AlkG) 2
O4-alkylthymine 2
(O4-AlkT) 2
ATase. 2
(MNU) 2
counters 2
ada+ 2
-Pro-Cys-His-, 2
lacI-d 2
resting-associated 2
biphasic; 2
Lacc 2
LacI-d 2
ATase-deficient 2
5'PuG 2
SN1 2
compound(s). 2
alkylnitrosoureas, 2
ada::Tn10 2
Overproduction 2
5-nitroso-BP. 2
tryptophan-336 2
lysine-314 2
alanine-316. 2
BG. 2
5-nitroso-BP 2
W336A, 2
K314P/A316P 2
A316P 2
R335S 2
alkyl-transferase 2
(ada-1) 2
alkylation. 2
84A 2
MNNG-hypersensitive 2
alkyltransferase-deficient 2
6-benzylguanine. 2
A:T-->G:C 2
6-methylguanine 2
4-methylthymine 2
QUANTA 2
CHARMm 2
(hAT 2
1-85), 2
92-207) 2
residue-for-residue 2
hAT175. 2
solvated 2
CHARMm. 2
iron) 2
iron). 2
129% 2
11-15 2
(BMI; 2
-0.25 2
MAOA-dependent 2
(5-HT, 2
serotonin), 2
delusion, 2
p=0.002, 2
MAO-B) 2
pro-differentiation 2
variable-number 2
anticorrelated 2
decoupling 2
MAOI 2
e.g, 2
(BMI). 2
VLDL, 2
(p<0.02) 2
(Ca(OH)2 2
Glycol 2
chitin-based 2
chitosan. 2
Proliferated 2
DSP-stained 2
Enamel 2
odontogenesis, 2
preameloblasts 2
odontoblast 2
paste 2
(Dycal). 2
glass-ionomer 2
cement. 2
0.031) 2
(1990-1992) 2
Sintonen's 2
15D 2
shortest, 2
(0.6), 2
(1.0) 2
(0.5), 2
Spike-in 2
super-SILAC 2
(SILAC)-labeled 2
5.97 2
31.96 2
32.88 2
advantages: 2
32× 2
45× 2
(10%); 2
(8%); 2
40×) 2
reads; 2
high-coverage 2
pre-estimated 2
(0.5-30×) 2
(20-10 2
(Europeans, 2
Americans). 2
DesignPlanner 2
low-depth 2
Haliwa-Saponi 2
(HBID). 2
(6-year-old 2
dyskeratotic 2
keratinisation. 2
HBID 2
M77T 2
17p13.2. 2
MitoCarta 2
blending 2
mtDNA:nuclear 2
10X 2
1,000X 2
(Numts). 2
25×, 2
obvious, 2
LVMHT 2
MB) 2
65×. 2
MS/NS 2
162,073 2
16,954 2
56-fold. 2
125X 2
stringency 2
T>C/A>G 2
(BCORL1-ELF4) 2
56×. 2
medium-depth 2
(8×) 2
Danes 2
opportunity, 2
infrastructures 2
therein 2
12-year-olds, 2
12-24-year-old 2
6/11/16/18-related 2
precancer, 2
84-98% 2
$43,600 2
16/18 2
Malaysia. 2
6.29 2
(genital 2
HPV-related 2
220,000 2
2700 2
olds. 2
'catch-up' 2
socio-cultural 2
30%; 2
pseudoexons 2
167-bp 2
83-bp 2
oligonucleotide-selective 2
resequence 2
>87% 2
rs8193 2
ALCAM 2
rs1157 2
rs17109924 2
0.35-0.93; 2
0.022; 2
0.33-0.94; 2
0.024, 2
0.12-0.90; 2
0.023, 2
rs17109924, 2
rs8193, 2
ALDH1A1 2
rs1342024 2
6.71, 2
2.71-16.63, 2
rs2234671 2
CSMD3, 2
population-matched 2
APE1, 2
Y165C 2
G382D 2
subpolymorphic 2
Scrutinizing 2
c.494 2
(p.Y165C); 2
c.1,145 2
(p.G382D). 2
Short- 2
nanogold 2
rats--potential 2
consumers, 2
(AuNP) 2
rno-miR-298 2
-29a/b 2
ceramides. 2
(hnRNP)-A1 2
(23.0 2
1.09-2.46). 2
11.3%; 2
2.36, 2
1.22-4.58 2
rs4016671 2
(2.724 2
0.570 2
1.076 2
0.187, 2
SL(R) 2
SL(G) 2
contraction). 2
(HC), 2
electrocardiographical 2
2.13 2
DCE-NT 2
mL/min/g, 2
NoDCE-C 2
NoDCE-R 2
17%; 2
PVCs 2
couplets 2
0.93), 2
NSVT) 2
indomethacin. 2
mirtazapine. 2
doxepin 2
trimipramine 2
nefazodone, 2
mirtazapine) 2
significant: 2
Age-stratified 2
chronicity, 2
122) 2
(MAOIs) 2
1.75), 2
(1.66, 2
1.77), 2
suicide/self-harm 2
(5.16, 2
3.90 2
6.83), 2
(1.37, 2
(1.63, 2
1.83) 2
epilepsy/seizures 2
(2.24, 2
3.15) 2
underdosing. 2
(13.4 2
92.3, 2
AMSP 2
37.9 2
34.8 2
72.3 2
doxepin. 2
Taurine 2
Gamma-aminobutyric 2
sonography-assisted 2
stereotaxy 2
carcinogenesi 2
stages; 2
Cacna1a. 2
TRAMP, 2
assay-assisted 2
80-100% 2
stroke-tissue, 2
(TRα) 2
TH-treated 2
IVC, 2
(PACMAN): 2
(15-125 2
Simon's 2
≥350 2
(1.46 2
ascorbate-insensitive 2
LaPC4 2
ascorbate. 2
lives) 2
Pauling's 2
mega-dose 2
ambiguous, 2
spectrin-actin 2
sheared 2
β-spectrin 2
force-enhanced 2
Stabilities 2
two-repeat 2
urea- 2
nonhelical 2
hinge. 2
(HEalpha4,5) 2
alpha-spectrin, 2
(HEalpha1,2) 2
(HEalpha2,3), 2
clusterings 2
Spectrins 2
β-chains 2
unite 2
chain; 2
Sedimentation 2
alpha20-21EF/betaABD1-2 2
kcal/mol. 2
coiled-coil. 2
restraints, 2
restraints 2
laryngopharyngeal 2
otolaryngological 2
uvula. 2
LPR 2
misleading, 2
enables. 2
Anti-Vel 2
Haemolytic 2
G-type 2
Phototherapy 2
FGFR-1 2
flattened 2
birth; 2
[Cohen, 2
1993: 2
45:300-307]. 2
generation) 2
placenta-mediated 2
PMPC 2
IUGR/PMPC 2
LMWH. 2
thrombophilia--both 2
acquired--will 2
Thrombophilias 2
demise, 2
0.9); 2
Antithrombin 2
double-heterozygotes 2
3.4-39.6) 2
0.5-13.7) 2
41.3 2
4.1-419.7) 2
0.8-103.2) 2
homozygotes) 2
fathered 2
Indians. 2
"mediates" 2
11·5 2
INSPIRE 2
web-response 2
[41%] 2
[15%] 2
HNSCC, 2
panitumumab) 2
(MEHD7945A, 2
RO5083945), 2
(vandetanib, 2
icotinib, 2
CUDC-101), 2
antisense, 2
interleukin-12, 2
VTX-2337), 2
OSI-906, 2
PX-866) 2
ImClone, 2
Lilly), 2
ImClone 2
(ARQ 2
ArQule 2
Daiichi 2
Sankyo). 2
Necitumunab 2
(DLT; 2
headache), 2
acneform 2
arms), 2
>or=600 2
(>or=40 2
DX(TM)) 2
(adjuvant 2
Mammostrat, 2
IHC4, 2
MapQuant 2
Theros-Breast 2
Assay, 2
IMPAKT 2
[Oncotype 2
Dx™, 2
(ROR-S), 2
EndoPredict] 2
PANEL 2
convincing. 2
score-guided 2
Calif), 2
hybrids; 2
technical, 2
trial--Oncotype 2
MammaPrint--has 2
pathologists' 2
evidential 2
hierarchies 2
Adjuvant!, 2
DX(™)), 2
(Mammaprint(®)), 2
breast-cancer-risk 2
oncotype-DX 2
(IVDMIA)." 2
IVDMIA 2
n-dimensional 2
Calculation 2
discerned 2
synaptogamin 2
α(3)β(2) 2
Cav1.2 2
(alpha(1C)) 2
PKCepsilon-induced 2
stellation 2
PKCepsilon. 2
2-amino-5 2
phosphonovalerate 2
(APV), 2
LTP, 2
Ethanol-tolerant 2
ethanol-tolerant 2
metallic 2
Ni2+, 2
hyperpolarizations 2
SMHs 2
(VDCCs), 2
IBX 2
Apamin 2
afterhyperpolarization 2
sI(AHP), 2
charybdotoxin 2
Calcium-channel 2
(omega-CgTx 2
GVIA; 2
N-type), 2
(L-type), 2
(omega-CmTx 2
MVIIC; 2
omega-CgTx 2
NPY(13-36) 2
GABA(B) 2
(-)baclofen 2
crush 2
[3H]PN200-110 2
(10-100 2
Nif 2
picrotoxin-induced 2
(CNS)-mediated 2
trans-synaptic 2
CNTF, 2
(max. 2
dysarythria 2
doll's 2
(supranuclear 2
fasciculations 2
interosseal 2
mesencephalon. 2
frontomesencephalic 2
(side-) 2
(MRC) 2
(15.6%), 2
nonbulbar 2
TRH]. 2
DN-1417, 2
neuropeptides, 2
(0.5-2 2
intramusculary. 2
neuromodulator. 2
dynametric 2
(2-19 2
mg/min) 2
(TRH, 2
L-pyroglutamyl-L-histidyl-L-prolinamide) 2
(weakness) 2
(spasticity). 2
Glycosyltransferases 2
DUF23, 2
DUF246, 2
DUF266. 2
uncharted 2
(DUF). 2
universe 2
co-variation 2
Critically 2
PF14869 2
(BACOVA_00364 2
ovatus, 2
BACUNI_03039 2
uniformis 2
BACEGG_00036 2
eggerthii) 2
resolutions, 2
(DUF1471) 2
YhcN 2
Representatives 2
YahO, 2
SssB/YdgH 2
21-91), 2
244-314)). 2
56-199-amino 2
DUF2233, 2
(DUF), 2
N-acetylglucosamine-1-phosphodiester 2
α-N-acetylglucosaminidase 2
("uncovering 2
enzyme" 2
(UCE)). 2
hUCE 2
delta337 2
T3Rbeta 2
microRNA-146a 2
(miR-146a) 2
(H358, 2
H1975, 2
H292). 2
(cetuximab). 2
(25.6 2
EGFR-specific-siRNAs 2
T790M-specific-siRNAs. 2
solved, 2
sling, 2
Slings 2
prostatectomies 2
63.0%, 2
14.5%, 2
10.0%, 2
Suburethral 2
AUS, 2
implantations 2
62). 2
ISD 2
AUS. 2
cancer-predisposing 2
711 2
5/903 2
1/1016 2
early-onset/familial 2
2392 2
CHEK 2
candidate; 2
gene,1100delC, 2
(WPAI) 2
WPAI, 2
problems), 2
(impairment 2
working), 2
syndrome/relapsing 2
presenteesim. 2
(on-the-job 2
issues). 2
support/resources). 2
stress/concerns 2
30-49, 2
separated/divorced/widowed 2
employees, 2
college. 2
Clerical/office 2
Managers 2
prioritize, 2
Telephone 2
Chemicals 2
depression-related 2
(LPT) 2
102), 2
Metropolitan 2
33.4% 2
illness-related 2
workgroup. 2
workforce: 2
amply 2
absenteeism/presenteeism. 2
Screening, 2
(438 2
72%). 2
50.8 2
12.2) 2
11.7) 2
2.14-5.80], 2
1.90-6.13), 2
2.05, 2
1.12-3.78), 2
1.02-1.08), 2
1.01-1.06). 2
Psychological, 2
ofpsychologically 2
.33-.54). 2
nonsignificant. 2
business 2
claims. 2
depression/anxiety, 2
back/neck 2
(N=69) 2
(N=363) 2
depression/anxiety. 2
investigation: 2
cutback 2
Employers 2
cost-offset. 2
employers. 2
(absenteeism, 2
incidents) 2
executives, 2
railroad 2
engineers. 2
disease-emphysema, 2
absenteeism-presenteeism. 2
(ROI). 2
"presenteeism," 2
jobs 2
χ 2
0.0015). 2
presenteeism) 2
-3.29, 2
subsyndromal 2
(diminished 2
work), 2
1,253 2
WPAI 2
Thailand: 2
Siriraj 2
[Gastric 2
(GIST)]. 2
CD-117 2
(c-kit). 2
non-metastasized 2
irresectable 2
S: 2
SRT: 2
SCT: 2
EII 2
asked. 2
MTT/XTT 2
replication-defective 2
infundibulum 2
cagA 2
virulence-related 2
digoxigenin-deoxyuridine 2
proliferation-associated 2
metaplasia, 2
cagA-strains 2
control-derived 2
A0 2
interrelation. 2
ladders, 2
simple. 2
Featured 2
sorbitan 2
monolaurate 2
(tween 2
(apoptosis) 2
HSB 2
Gray, 2
Transferase 2
(TdT) 2
Uridine 2
(UTP) 2
(TUNEL), 2
breaks; 2
DNA-flow 2
DNA-stainability 2
(DNA-fragmentation 2
Phycoerythrin-labelled 2
Apo2.7-assay, 2
[GG]). 2
(NDNG) 2
[GC]) 2
[GN]). 2
Thionamide 2
GG, 2
(1.77 2
(AIPh), 2
NDNG. 2
marrow). 2
sodium/potassium 2
[cytosine-beta-D-arabino-furanoside 2
(ARA-C)] 2
haemoglobin. 2
17months 2
-old 2
JEG3 2
Flp-in 2
G558D) 2
(G221R, 2
P321L, 2
D453V, 2
P537L) 2
(insV236, 2
G282C, 2
ko 2
Lat1 2
(AHDS)) 2
LT(3) 2
iodothyronines. 2
low/normal 2
THCT 2
constellations. 2
corticogenesis 2
Lat2. 2
MCT8-deficient 2
transthyretin, 2
(helix 2
>45 2
MCT10, 2
3,3',5-tri-iodothyronine 2
(L-thyroxine 2
(LT4)) 2
(c.1649delA) 2
(c.1834delC) 2
c.1834delC 2
Infancy 2
ambulate 2
IFNγ, 2
CD16(+)) 2
(FoxP3(+)) 2
(%CD25(+) 2
CD3(+)) 2
(RAI). 2
restratified 2
radioactive-refractory 2
DTC. 2
alopecia: 2
(III 2
+2 2
Dermaroller 2
rejuvenation. 2
Atrophic 2
deep-seated 2
0270-6474/15/356381-13$15.00/0. 2
MN. 2
(NKT) 2
(IGFBP)-1 2
ex-vivo. 2
Immunomodulation 2
α-galactosyl 2
(α-GalCer), 2
autonomous, 2
non-tissue 2
MN-based 2
accelerates, 2
T-cells) 2
(RANTES) 2
beta-chemokine 2
chemo-attractant 2
(NIND) 2
dismutase1 2
(ALS): 2
secret 2
(CNS); 2
reuptaken 2
OATP1B 2
rifampicin. 2
Faldaprevir, 2
[(3)H]bilirubin 2
faldaprevir. 2
unconjugated, 2
faldaprevir, 2
drug-bilirubin 2
OATP-C, 2
OATP2, 2
LST-1, 2
SLC21A6) 2
haematolysis, 2
(11.07 2
2.31, 2
13.01 2
8.21 2
bilirum 2
(T.BIL) 2
(16.69 2
4.09, 2
20.71 2
13.06 2
(D.BIL) 2
(7.69 2
(17.68 2
5.96 2
13.95 2
0.040), 2
5.72 2
4.35 2
12.00 2
9.61 2
3.15 2
0.035), 2
SLCO1B1*15 2
SLCO1B1*1a/*1a 2
eprotirome, 2
(liver) 2
thyromimetics. 2
lipid-modulating 2
STRM 2
(KB-2115; 2
Karo 2
idea. 2
sobetirome) 2
KB2115 2
eprotirome) 2
ipolipidaemic 2
antiaterogenic 2
KB-2115 2
(eprotirome). 2
(UWS) 2
UWS 2
(coma 2
re-acquired 2
programs' 2
videos, 2
requests, 2
(listening 2
to) 2
messages, 2
re-stimulate 2
multisensory 2
response-related 2
Ags, 2
2129 2
ovale). 2
citizens: 2
Russia's 2
sympatric 2
curtisi 2
wallikeri) 2
cestodes 2
(Taenia 2
solium 2
(neurocysticerciasis), 2
multilocularis 2
Spirometra 2
(neurosparganosis)), 2
(Toxocara 2
cati 2
(neurotoxocariasis), 2
(neurotrichinelliasis), 2
cantonensis 2
costaricensis 2
(neuroangiostrongyliasis), 2
Gnathostoma 2
spinigerum 2
(gnathostomiasis)), 2
trematodes 2
(Schistosoma 2
bilharziosis), 2
Paragonimus 2
westermani 2
(neuroparagonimiasis)), 2
(Toxoplasma 2
(neurotoxoplasmosis), 2
Acanthamoeba 2
Balamuthia 2
mandrillaris 2
(granulomatous 2
encephalitis), 2
meningo-encephalitis), 2
Entamoeba 2
histolytica 2
abscess), 2
malaria), 2
gambiense/rhodesiense 2
carbohydrates, 2
ETC 2
entomopathogenic 2
Xenorhabdus 2
Ec-SSB 2
four-dimensional 2
Codon-optimized 2
(ΔE1Ad) 2
(HC-Ad) 2
ΔE1Ad 2
(CAG) 2
cox3 2
cob) 2
Plasmodium. 2
eversion 2
inhibitor-binding 2
Genz-667348 2
anti-Hsp90 2
drug-binding 2
erythrocyte-stage 2
phagocytosed 2
AZT-MP 2
dGMP 2
TMPK 2
PfTMPK 2
dimorphisms 2
inter-population 2
(HZ), 2
reticulocytes, 2
orthochromatic 2
lethality). 2
lethality), 2
wild-born 2
Côte 2
Neu5Ac, 2
EBA 2
overabundant 2
PfSIR2A, 2
DeltaSir2a 2
subclasses. 2
[LDH-like] 2
L-Malate 2
(PfMDH) 2
L: 2
-lactate 2
(PfLDH). 2
PfMDH. 2
Ferroquine 2
(FQ 2
SR97193) 2
posses 2
(PfAQP) 2
PbCap380(-) 2
(Sir2) 2
Sir2. 2
surfactin 2
PfSir2, 2
IMP 2
(GMP 2
GMPS, 2
XMP 2
dcAdoMet 2
pfSPDS 2
AdoDATO 2
PK. 2
vivax: 2
diamidine 2
one-cycle 2
TLR9, 2
mortal 2
chemotypes 2
pfTBP-pfTFIIB 2
unligated 2
1-Cys 2
(Prxs) 2
Prxs 2
Yemen, 2
(RBCs). 2
non-apicomplexan 2
Orotate 2
co-eluted 2
homolactic 2
cofactor. 2
midgut. 2
652 2
Cys88-Cys93 2
thiol. 2
PfPK5 2
DC-CK1 2
anopheles 2
congolense. 2
fetuin-agarose 2
lactulose, 2
SM1 2
(Pfpka-c) 2
sulfonamide 2
(sulfa) 2
Sulfadoxine 2
(Fansidar), 2
sulfadoxine/pyrimethamine 2
peroxidase. 2
68200) 2
k(1)' 2
(AMA1) 2
AdoMetDC, 2
ODC/AdoMetDC. 2
PfNT1, 2
L-adenosine 2
Brumpt]. 2
precocene 2
(antijuvenoid) 2
suction. 2
vitellogenesis 2
mannosylation 2
(GPIs) 2
mannosylated 2
redesigned 2
NADP+-specific 2
SR33557 2
fantofarone, 2
hemoglobin-degrading 2
Malarial 2
1-2Man 2
(Pfg1 2
phototroph 2
fauna 2
USSR]. 2
pulcherrimus 2
mosquito-carriers 2
(ordram 2
propanide) 2
(fundozol 2
vitriol) 2
0.001-0.002 2
7-17% 2
0.004-0.05 2
USSR 2
(PYR), 2
PYR 2
(0.19 2
Eradication 2
23-megabase 2
∼5300 2
PkPSD 2
Nouakchott, 2
Nouakchott. 2
97.1% 2
Nouakchott 2
excel 2
District. 2
Apicomplexa 2
Cryptosporidium 2
TgDJ-1 2
microneme 2
Pfprex 2
LNA-ONs 2
cob). 2
equi. 2
equi 2
Lycoris 2
traubii 2
antitrypanosomal 2
semi-synthesis 2
histo-aspartic 2
(HAP), 2
pepstatin, 2
protein-secretion 2
calmodulin-sensitive 2
[Phase 2
(2''R)-4'-0-tetrahydropyranyladriamycin 2
anthracycline, 2
Leukocytopenia 2
nausea-vomiting 2
regimens; 2
83.8%, 2
(59.0%), 2
(48.8%) 2
(55.6%). 2
5306.75+/-461.62 2
(microM). 2
(VIT 2
8.5-fold, 2
VIT 2
3.3- 2
4.2-fold, 2
(tGSH), 2
tGSH, 2
caspase-9. 2
Growth/differentiation 2
factor-10: 2
protein-3. 2
(Gdf10) 2
(Koirala 2
Corfas, 2
e9198). 2
E14, 2
(VZ) 2
rhombic 2
(RL). 2
RL 2
RL. 2
(New 2
mmHg/s; 2
(initial 2
minute; 2
ml/m(2) 2
DEB. 2
REVIEW 2
level-one 2
catheter-related 2
(p=0.004). 2
SCR 2
no-HIPEC 2
Cautious 2
Organ-preserving 2
CCR-3 2
surgery/peritonectomy 2
(R0) 2
surgery/ 2
morbimortality, 2
(Sugarbaker 2
0-1), 2
(CC-2 2
Peritonectomy 2
patients- 2
"intraperitoneal 2
(P=0.12). 2
citoreduced 2
Citoreductive 2
second-look 2
risk-patients 2
platinum- 2
(66%), 2
(PCI 2
Trabectedin, 2
chemo-immunotherapy 2
[RNA 2
ofmRNA 2
ADR-1 2
adr-2 2
NcRNAs 2
smallRNAs 2
(smRNAs), 2
transcriptomes, 2
CCR1/CCL5 2
2/9 2
Castration-refractory 2
(CCR1) 2
(CCL5), 2
paclitaxel-resistant 2
(PC3PR) 2
CCR1. 2
Rac1/cdc42. 2
Rac1-driven 2
(MKN45/PAR1). 2
(α-thrombin 2
TFLLR-NH2). 2
TFLLR-NH2. 2
TFLLR-NH2, 2
(Quint), 2
(S4D/S8D) 2
metalloproteinase-driven 2
β-PIX 2
actopaxin-dependent 2
Intracellularly, 2
cadherin/catenin 2
p120-catenin 2
Rac1-PI3K/Akt 2
(Rac1), 2
p21-actived 2
(PAK1) 2
K299R, 2
PAK, 2
cdc42, 2
(RhoGDI2) 2
RhoGDI2-higher 2
RhoGDI2-lower 2
(CTXG), 2
cudratricusxanthone 2
tricuspidata, 2
(activator 2
protein-1). 2
Icariin 2
exterts 2
collaborates. 2
Herba 2
epimedii, 2
BGC-823. 2
Rac1-siRNA-dependent 2
VASP-siRNA 2
pcDNA3-EGFP-Rac1-Q61L 2
Autocrine 2
endogenously, 2
non-editing 2
APOBEC3-mediated 2
Vif-APOBEC3 2
IFN-α, 2
DRMR 2
Y(40)RHHY(44) 2
D128K-A3G 2
APOBEC1, 2
APOBEC3, 2
transporter: 2
(DMI). 2
tyramine 2
dihydroxyphenylglycol 2
DMI 2
DMI-treated 2
DMI-induced 2
sympathoinhibitory 2
hNET-wild 2
(hNET-wt). 2
A457P, 2
macroRNAs' 2
(4.1%-5.5%) 2
macroRNAs 2
(5.2%). 2
macroRNAs, 2
incentive 2
PD-induced 2
MMT, 2
(ET)A 2
serum), 2
(markers 2
processes), 2
mid-fifties, 2
A2), 2
discrimination. 2
tooth-brushing 2
practitioners, 2
BP1 2
oro-dental 2
(3-35 2
[Prader-Willi 2
imprinting]. 2
(MSPCR) 2
D15Z1 2
15p 2
Bisulfite-modified 2
131bp 2
(UPD15). 2
cyto-molecular 2
Clinical-neurologic, 2
Ribeirão 2
Preto. 2
KB17 2
Xba 2
(CA)*** 2
IR4-3R. 2
cytogenetical 2
PWS: 2
(microsatellite) 2
(D15S63). 2
ribonucleoprotein-associated 2
512) 2
recurrence-risk 2
PWS-associated 2
(9;15)pat 2
IPWIPAR1. 2
IPW 2
unexpressed. 2
16p11.2. 2
<40, 2
Eighteen, 2
40-59, 2
<17 2
(Montreal 2
Classification: 2
(1988-2007). 2
(1988-2007) 2
EPIMAD 2
(7428 2
4656 2
(+29%), 2
1997-1999. 2
(2006-2007). 2
10-19-year-old 2
43.7 2
(50.4%) 2
(35.5%) 2
(46,5%) 2
tunisian 2
younger- 2
older-onset 2
(4.9-15.5) 2
(9.4-19.3) 2
(T0), 2
T0, 2
(HtSDS) 2
mid-parental 2
01.4) 2
7.8), 2
EIM. 2
2.57, 2
4.23, 2
(0-7 2
ASCA. 2
(T(1)AM), 2
volunteer, 2
0.219 2
pmol/ml. 2
0.654, 2
0.705, 2
0.543, 2
0.675, 2
(PI3-kinase) 2
ng·g⁻¹ 2
ng·g⁻¹·day⁻¹, 2
ng·g⁻¹·day⁻¹) 2
(LY294002). 2
(IRS)-1 2
PI3-kinase, 2
fissions, 2
gene-fission 2
fission: 2
Accounting 2
flagellum-forming 2
chytrids). 2
Predictome, 2
methods--chromosomal 2
Predictome 2
(E2F) 2
)] 2
DNA-damage-inducible, 2
GADD45G 2
CHEK2)] 2
controller, 2
Promotor 2
(p14, 2
CHK2), 2
(p73, 2
DAPK), 2
(RARb, 2
WT1) 2
kidney) 2
unknown: 2
High-fidelity 2
Thr-68, 2
p-Chk2. 2
PP2A, 2
(hCHK2/hCds1) 2
Microglial 2
Giant-Cell 2
Tumor. 2
(CSF1) 2
co-crystallography 2
colony-stimulating-factor-1 2
M-CSF) 2
62-yr-old 2
5-yr 2
tomogram 2
54-month 2
gluten-containing 2
resected. 2
AIN457 2
(IGA 2
55.2%, 2
autoinjector/pen 2
autoinjector 2
hazard-free 2
Self-Injection 2
70.0%; 2
pre-filled 2
(2011 2
Assessment) 2
Regimens 2
1306 2
etanercept: 2
comparators). 2
65.3% 2
51.1% 2
HLA-B27 2
SpA) 2
IL-12), 2
IL-17A), 2
IL-17RA 2
IL17RA 2
IL17RC 2
IL17F 2
IL8 2
CXCL2, 2
CXCL9, 2
CXCL11. 2
IL17A/TNFα-induced 2
ixekizumab) 2
brodalumab) 2
Characterize 2
IGA. 2
(PGA) 2
a--focus 2
immunotherapeutics. 2
IL-17-mediated 2
(2×10 2
SpondyloArthritis 2
(ASAS20) 2
(Bayesian 2
NCT00809159. 2
ASAS20 2
(99·8% 2
Novartis. 2
(IL-17A; 2
IL-17) 2
IL-17A-deficient 2
Th-17A 2
ClASsification 2
ARthritis 2
(CASPAR) 2
p<0.1). 2
endpoint: 2
(3/13) 2
(2/13), 2
p=0.13) 2
(10/23) 2
(2/11), 2
p= 2
(5/23) 2
(1/11) 2
(p=0.039), 2
(p=0.038), 2
(SF-36; 2
p=0.030) 2
(93%)) 2
(79%)) 2
study); 2
noninfectious, 2
non-Behçet's 2
SHIELD 2
q2w, 2
125) 2
0·002, 2
0·005) 2
≥220 2
≤450) 2
2×10 2
Ancillary 2
18/59 2
(12/39 2
6/20 2
10/59 2
(8/39 2
(CDAI 2
=33.9 2
(19.7), 2
72.9) 2
4-10) 2
ΔCDAI=49; 2
(CRP≥10 2
calprotectin≥200 2
ΔCDAI=62; 2
125), 2
p=0.054 2
(p=0.00035 2
Bonferroni-corrected). 2
ClinicalTrial.gov 2
NCT01009281. 2
Ca(2+)-release-activated 2
(CRAC) 2
immune-system 2
Ca(2+)/calcineurin/NFAT 2
two-pronged 2
calmodulin-dependent, 2
serine/threonine-specific 2
Inhibition, 2
3,5-bistrifluoromethyl 2
fluorescent-tagged 2
Elk-1. 2
NFATs 2
GFP-NFAT 2
NFAT4. 2
(PP2B) 2
(NFAT). 2
DnaJ 2
Calcineurin, 2
Ca(2+)/calmodulin-stimulated 2
TRP 2
Ca(2+)/CaM, 2
FK506.FKBP12 2
drug-immunophilin 2
(Aramburu, 2
Garcia-Cozar, 2
Raghavan, 2
Okamura, 2
Rao, 2
Hogan, 2
627-637); 2
NFAT. 2
86-amino 2
Parent-reported 2
parentally-reported 2
population-derived 2
SEN. 2
soiling 2
faddy 2
neurotypical 2
Anxiety, 2
2,973 2
81.6 2
(constipation, 2
over-responsivity. 2
Lactase 2
(ALSPAC). 2
12,906 2
6.46, 2
stools/day. 2
Repeating 2
megarectum 2
megarectum. 2
24-96 2
Schedule-Generic, 2
Equilibrium 2
(LdCyp) 2
LdCyp 2
barrel. 2
Leptosphaeria 2
(Brassica 2
(IMMs). 2
FKBPs. 2
Cyclophilins: 2
(Cyps) 2
non-immunosuppressive 2
CYPs) 2
classified, 2
Chlamydomonas. 2
detector. 2
leishmanial 2
redox-related 2
Cyps 2
(cyclophilins) 2
CYP20-3, 2
Cys(171). 2
2-Cys 2
(PPIases; 2
5.2.1.8) 2
cyclophilins, 2
Immunophilins 2
isomerisation 2
(CyPs) 2
CyPJ 2
hCyPA. 2
His43 2
Gln52 2
CyP40-type 2
(PPIases), 2
isomerizing 2
CyP40 2
NcCyP41 2
A-sensitive 2
FK-506 2
cyclosporin-binding 2
IP20 2
]i 2
KV 2
G-protein-regulated 2
(tmACs). 2
(MAG). 2
(BDNF). 2
problematic; 2
MAG-dependent 2
0270-6474/14/349281-09$15.00/0. 2
(TMACs), 2
tmAC, 2
neurons' 2
ADCY10), 2
non-transmembrane 2
aka 2
fertilizing 2
ChIP-sequencing 2
Vezf1(-/-) 2
Mrg15/Mrgbp, 2
HYPB 2
Setd2) 2
competency 2
(deepCAGE), 2
FANTOM4 2
(CPB). 2
(9.8%) 2
nonerythropoietic 2
disturbances; 2
nonrapid 2
(B6.D2) 2
(D2.B6) 2
free-running 2
CK1epsilon, 2
Wnt/Rac-1/JNK 2
Wnt/NFAT 2
kinase-1-epsilon 2
(NGB) 2
[GOS], 2
[DRS], 2
[NRS-R]) 2
(tSNPs) 2
(rs3783988 2
rs10133981) 2
tSNP. 2
tSNPs 2
rs10133981 2
2.65-times 2
Represented 2
oxygen-binding 2
NGB. 2
neuron-specific, 2
hypoxia-responsive, 2
KA, 2
oxidant/antioxidant 2
nitrosative 2
GIFT 2
Testing) 2
GRAVITAS 2
(Gauging 2
assay-Impact 2
(OTR) 2
clopidogrel; 2
1,028 2
10(-15)), 2
10(-7)), 2
PON1, 2
3435 2
C→T, 2
P2Y(12) 2
PRU 2
PRU, 2
tripling 2
Impact-R 2
Impact-R. 2
vasoactive-stimulated 2
151), 2
P2Y₁₂ 2
steeply, 2
sex-appropriate 2
death-TMEM43, 2
MYBPC3. 2
Sciences; 2
Howard 2
Hughes 2
Lucile 2
Hewlett 2
Breetwor 2
P=0.008, 2
(ADP)-dependent 2
nonresponsiveness 2
(PAPI) 2
(2006-2008), 2
10q24 2
CYP2C18-CYP2C19-CYP2C9-CYP2C8 2
10(-13) 2
rs12777823, 2
rs12777823 2
10(-11)). 2
10.0%) 2
1.18-4.99; 2
(CADP-CT). 2
Coexisting, 2
(CYP3A4 2
CYP2C19*2) 2
T744C) 2
"responders". 2
(visit 2
responders" 2
allele), 2
thienopyridines, 2
prasugrel. 2
sub-studies 2
(6MWT).DMD 2
Steele, 2
Olszweski 2
Kii 2
peninsula 2
(PDC). 2
locales, 2
benzyltetrahydroisoquinolines 2
(Be-TIQ), 2
tetrahydroprotoberberines 2
(THPB) 2
(PSP), 2
(UP). 2
(PSP 2
UP), 2
(simultaneously) 2
isoquinoline 2
isoquinolines 2
Parkinson&apos;s 2
[Breast 2
Decisive 2
DX: 2
RS) 2
(N-) 2
(N+), 2
N+, 2
quoted 2
oncologists' 2
DX®; 2
RS. 2
RT-PCR-based 2
(uPA) 2
Plan 2
B-20. 2
SEER 2
Trialists' 2
(DRFI). 2
651), 2
DRFI, 2
[OS], 2
0.082 2
[DFS]), 2
0.357, 2
1952), 2
DRFI 2
0.219) 2
0.099). 2
alpha=0.83) 2
score=67%, 2
SD=0.23). 2
'don't 2
know' 2
numeracy. 2
(FOXA1) 2
(GATA3) 2
GATA3 2
dialog 2
NCI-sponsored 2
Accomplishments 2
beneficial? 2
down-regulator 2
(fulvestrant) 2
analysis? 2
combination? 2
Ecopnomic 2
I-IIIa) 2
3,315 2
TECHNOLOGY 2
CONCERN: 2
Oncotype-DX?How 2
Oncotype-DX)?How 2
result?What 2
Oncotype-DX?Is 2
tamoxifen?What 2
Oncotype-DX?Does 2
alone?How 2
Online?How 2
clinical/patient 2
decision-making? 2
(INAHTA) 2
evidentiary 2
Questions, 2
analysis,Studies 2
English,Studies 2
methodology). 2
Question. 2
#3), 2
survival). 2
#1, 2
#4 2
#5) 2
#3). 2
reproducible).Current 2
inflated; 2
negative:There 2
only),There 2
CMF/MF 2
tamoxifen.In 2
positive:There 2
anastrozole,There 2
tamoxifen.There 2
sizes; 2
particular:Of 2
(<40% 2
bias;Data 2
HER-2/neu-negative 2
women;There 2
analyses.Additional 2
considerations.There 2
clinician/patient 2
T1/T2, 2
T1a/T1b 2
T1c/T2 2
5-Aza-CdR-induced 2
Jurkat-T 2
2780 2
(FDPS) 2
(FDFT1), 2
(Jurkat-T, 2
HL60) 2
(WM-266-4) 2
FDPS 2
FDFT1, 2
WM-266-4 2
linker; 2
dodecane 2
pyrimidinone, 2
pyrimidinone-containing 2
oligodeoxynucleotide. 2
FdC. 2
zebularine. 2
2-(p-nitrophenyl)ethyloxycarbonyl 2
(NPEOC) 2
antibioticus. 2
(GCCGGC) 2
oriC. 2
R.NaeI 2
NaeI-specific 2
C5-methyltransferase 2
4'-Thio-2'-deoxycytidine 2
(C*) 2
GC*GC 2
P1I. 2
4'-thio-modified 2
>10-fold. 2
R-factor 2
R-free 2
0.231. 2
4'-thio-2'-deoxycytidine. 2
(C5Mtase) 2
(5-azaC) 2
checkpoint-dependent 2
Booster 2
pluripotency: 2
RSC133, 2
indoleacrylic 2
acid/indolepropionic 2
(DNMTIs), 2
azacitidine 2
(AZA), 2
(MDS); 2
DNMTIs 2
(decitabine/Dacogen®), 2
(DNMTi). 2
(HCT116, 2
SW48, 2
(DAC), 2
SLC 2
SW48 2
Psammaplin 2
(11c) 2
11c 2
HDAC7 2
MMTV-PyMT 2
zebularine-mediated 2
(5-aza-2-deoxycytidine) 2
[trichostatin 2
(TSA)] 2
DNMTIs. 2
Trimethylaurintricarboxylic 2
NSC97317 2
(5-aza-2'-deoxycytidine), 2
(DNMTi) 2
DNMTi 2
CSDH 2
unconsciousness, 2
Thinning 2
iso, 2
grainy 2
mud-like 2
(1.5T) 2
K4, 2
di-methylation 2
hyponatremia. 2
myelinolysis. 2
Konno 2
Wakui 2
(TRH-T). 2
motorcyclist, 2
accident, 2
ADH 2
hibernation, 2
(barbiturates, 2
(coma). 2
septo-hippocampal 2
Broca. 2
tract). 2
amyotropic 2
cis: 2
anatomy-specific 2
13/41 2
(∼30%) 2
trans-changes 2
cephalochordate 2
vertebrates--a 2
(HSS)-9 2
(NFAT)p 2
328,000 2
(CNS-62kb 2
CNS-66kb). 2
CNS-66kb, 2
CNS-62kb, 2
KLF4. 2
corrected, 2
non-controlled 2
design). 2
RAND 2
List, 2
Tampa 2
kinesiophobia, 2
Pregabalin: 2
hybridizations, 2
pockets/patient 2
U-133 2
forsythensis 2
rectus. 2
BOP, 2
(183 2
ZnF-UBP 2
(TREX2) 2
re-positioning 2
(hENY2) 2
co-activator; 2
TREX-2, 2
SAGA-dependent 2
deubiquitylation. 2
isopeptidase, 2
USP 2
Ubp8. 2
DUBm. 2
Sus1/ENY2, 2
Sus1. 2
stripe. 2
(DUBm), 2
aldehyde, 2
lobe," 2
LSM6 2
DHH1. 2
5'-->3' 2
LSM1 2
PAT1 2
singlegene 2
preconceptually 2
elect 2
'Saviour 2
(PGD), 2
win 2
seriously. 2
university- 2
(unequal 2
incidence). 2
arouses 2
misdiagnoses 2
upf 2
post-termination 2
reutilization. 2
non-nucleased 2
CAN1/LUC 2
FLAG-Upf1, 2
nucleased 2
reutilization 2
Cbc-bound 2
eIF-4E-bound 2
(pioneer) 2
marking," 2
rounds, 2
assembly." 2
nonobligate 2
NMD-sensitive 2
faux-UTR 2
NMD: 2
eRF3/Sup35p. 2
mini-pgk1 2
Sup35p. 2
Upf1p-associated 2
(PTCs). 2
(Sup45) 2
(Sup35) 2
Pab1, 2
Upf3. 2
sup45-n 2
(termination) 2
UPF3, 2
sup112, 2
(hUpf1p), 2
SMG-4) 2
hUpf2p 2
hUpf3p-X 2
(Upf1p 2
Upf3p) 2
Orthologues 2
eIF4G 2
SUP45 2
mutations]. 2
(PTCs)--nonsense-mediated 2
allele-specific. 2
1-555 2
allosuppresson 2
ade1-14 2
[PSI+]. 2
Upf2) 2
(BUT) 2
cation-exchange/reversed-phase 2
nano-scale 2
SEQUEST 2
BUT 2
immunity- 2
glycometabolism-related 2
A-II. 2
(DIGE) 2
LPRR4 2
IPG 2
2D-nanoLC-nano-ESI-MS/MS 2
ProtScore 2
>or=2 2
(>or=99% 2
confidence). 2
alpha-enolase, 2
alpha-1-acid 2
(calgizzarin) 2
prolactin-inducible 2
(PIP), 2
lipocalin-1, 2
4-protein 2
91.0%; 2
90.0%). 2
(alpha-enolase 2
A4) 2
A9. 2
active-treatment 2
whole-day 2
mmHg), 2
antihypertensive: 2
angina]. 2
Antihypertensive 2
[Isradipine 2
drivers]. 2
examinees 2
psychophysiologic 2
dihydropyridine-derivative 2
superset 2
gingiva, 2
lacidipine, 2
nilvadipine, 2
(amlodipine 2
isradipine) 2
regime), 2
regime) 2
(FGS-/radiochemotherapy-), 2
(FGS-/radiochemotherapy+) 2
(FGS+/radiochemotherapy+). 2
MGMT-methylation 2
(OAS). 2
fifty-three 2
16.6, 2
20.1, 2
(IMRT) 2
41-82 2
QoL. 2
Afterward, 2
O(6) 2
-methylguanine-DNA 2
(21.7 2
.021). 2
post-chemoradiation 2
(cRT) 2
'pseudoprogression' 2
(PsPD) 2
('Stupp 2
(STUPP 2
Angers 2
Nice 2
consist, 2
ofMS 2
'accuracy' 2
(ABCD(2)) 2
(RASP) 2
mimics' 2
inaccurate, 2
crescendo 2
PROMAPA 2
1,255 2
(PROMAPA 2
work-ups 2
1,137 2
(90.6%). 2
Seven-day 2
Large-artery 2
(LAA) 2
(16.7%). 2
ABCD3 2
[0.66, 2
0.54-0.77] 2
(0.61, 2
0.52-0.70), 2
ABCD3V 2
(0.69, 2
0.57-0.81, 2
0.51-0.69, 2
LAA 2
1.91-8.26, 2
3.11, 2
1.47-6.58, 2
1.28-4.31, 2
1.15-4.21, 2
ECS 2
symptomatic; 2
SOS-TIA 2
triaging 2
[> 2
point]; 2
[systolic 2
>140 2
Hg: 2
1[; 2
[unilateral 2
0]; 2
10-59 2
2]; 2
1]) 2
Asian). 2
points] 2
D2: 2
min]), 2
microembolic 2
Doppler, 2
[B], 2
[weakness/speech 2
disturbance] 2
[C], 2
[D], 2
[D]) 2
shagreen 2
hamartin) 2
tuberin) 2
airspace 2
rhabdomyomas 2
Tsc1(Emx1-Cre) 2
beings. 2
brave 2
IS; 2
peri-ungual 2
Rheb/mTOR/p70S6K 2
tsc1 2
tsc2 2
Ras-GAP. 2
4EBP1 2
Ser(1210). 2
semi-automated 2
TSC-causing 2
meioses. 2
non-linked 2
having, 2
angiofibroma 2
McCormack 2
FX, 2
Inoue 2
TV, 2
JP, 2
adenohypophysis, 2
-246 2
-373 2
TRIM37b, 2
TRIM37a. 2
TRIM37a 2
PPM1E 2
TRIM37b. 2
c.1894_1895delGA, 2
Mandibuloacral 2
FACE-1 2
Zmspte24) 2
Zmpste24-deficient 2
AlkA-catalyzed 2
protamers 2
pre-steady 2
Mag2p, 2
generators 2
Ogg1 2
glycosylase/lyase 2
endo 2
alka 2
hU, 2
3-Methyladenine 2
(HhH) 2
Dr_2584 2
helical-bundle 2
HhH 2
EcAlkA, 2
'pulling' 2
base-sugar 2
Qualitatively, 2
1-azaribose 2
Asp238 2
AlkA-DNA 2
Incision 2
Endo 2
nfi 2
Rsp5 2
NEDD4-1, 2
WSTF 2
PHD_EL5 2
(E2)-binding 2
(CIITA), 2
mono-ubiquitinated, 2
poly-ubiquitinated, 2
transactivity, 2
CIITA, 2
mono-ubiquitination, 2
degradation-independent 2
Hsc/Hsp70 2
CHIP-meditated 2
LDH. 2
unloading. 2
Smad4. 2
Receptor-activated 2
(R-) 2
Mad 2
Mono- 2
oligo-ubiquitinated 2
R-Smads, 2
Smad4/R-Smad 2
hetero-oligomerization 2
acetabuli, 2
laxity. 2
Radiologists 2
Otto 2
Kg; 2
m; 2
span: 2
protrusio), 2
counting, 2
omits 2
dataset-even 2
analysis-and 2
Nairobi 2
(LTSs) 2
LTS 2
co-infecting 2
I107 2
'viral 2
(Vif), 2
A3G-mediated 2
APBOEC3G 2
Vif-mediated 2
hijack 2
Abrogation 2
Cullin5-based 2
γ, 2
T106M 2
p38beta. 2
stromelysin-1 2
[MMP]-3) 2
(TNF)alpha 2
(IL)-1alpha 2
IL-1alpha-induced 2
TNFalpha. 2
chosen. 2
p38delta), 2
MKK6. 2
pyridinyl 2
p38γ 2
embryonic/neonatal 2
coactivated 2
Capone 2
Engelberg 2
p38alpha. 2
-δ 2
(p38alpha 2
p38beta) 2
cytokine-suppressive 2
C162S 2
effector. 2
E2F2, 2
WISP1) 2
Hyperactive 2
p38MAPK, 2
p38beta2 2
(DPSCs) 2
Pulpectomy 2
#80 2
PRP). 2
composite. 2
Cementum-like 2
DPSC 2
Cementum 2
bio-root 2
sleep-onset 2
bedtime. 2
(C3). 2
(Neurontin) 2
(AUC(0-infinity)) 2
4.52 2
4.41 2
-34% 2
-53%; 2
-38%; 2
-35%. 2
gabapentin: 2
dose-initiation 2
lead-in). 2
electroencephalograms. 2
(having 2
medic 2
Behaviors 2
tantrums, 2
defiance. 2
outburst 2
RALI-DHF 2
pro-type 2
Na-dependent 2
Ca-overload, 2
6-7, 2
tiron 2
(Ranexa) 2
Na-Ca 2
22.3-51.7]. 2
5.8-7.8), 2
12.2-20.8). 2
(81.5%), 2
2-8). 2
(PFI 2
PFI 2
.07) 2
(PFS 2
.0002). 2
28,6 2
(45.7 2
4-8) 2
12-22). 2
(14.3%), 2
(8.6%), 2
Non-hematologic 2
erytrodysestesia 2
(PPE) 2
"platinum 2
platinum/paclitaxel-resistant 2
platinum/paclitaxel-based 2
bleeding) 2
platinum: 2
Olaparib: 2
(Lynparza™) 2
Korea). 2
"at-risk" 2
cetuximab) 2
(imatinib, 2
(vemurafenib 2
olaparib) 2
Poly(ADP-ribose)polymerase 2
(PARPis) 2
(BRCA1/2(MUT+)) 2
endometrial, 2
PARPis 2
index<0.9), 2
(AstraZeneca) 2
Rfx-repressed 2
FoxA-bound 2
extinguished 2
i.e, 2
conceptional 2
activators: 2
VP16; 2
hepatogenesis, 2
FOXP 2
(HCFs) 2
GMT, 2
polygonal 2
MEF2C. 2
(HNGMT). 2
>50-fold 2
oscillation, 2
HNGMT 2
T-box5, 2
myocardin, 2
Inefficient 2
(CFs) 2
Q-PCR 2
Gata4 2
elicited. 2
fibroblasts,which 2
50%of 2
regulator" 2
(Gata4/Mef2c/Tbx5) 2
'pluripotent' 2
'differentiated'. 2
(TCL1) 2
kinase-functional 2
B-cell-receptor 2
17p13.1 2
Pharmacyclics 2
NCT01105247.). 2
macroglobulinemia. 2
Btk-mediated 2
cross-talk. 2
(PI3Kδ) 2
GS-1101, 2
hoarseness 2
Zoetermeer 2
73-94 2
(PPS), 2
rT3). 2
[Adynamia, 2
paresthesias]. 2
carpal-tunnel 2
rough, 2
005). 2
(FT(4)), 2
inclination, 2
GC-compositional 2
Highly-expressed 2
factor-biding 2
"putative" 2
(Chip-on-chip) 2
prongs 2
ventilation-induced 2
(NIV) 2
postextubation 2
cannulae. 2
HFNC; 2
(online 2
supplement); 2
circumstances; 2
78.1 2
30.9] 2
1.1] 2
1-L/min 2
open- 2
gender) 2
(pre: 2
1.4], 2
post: 2
1.2]; 2
septumerosion. 2
(CPAP), 2
HFNC), 2
prematurity: 2
(AOP) 2
ventilator-generated 2
(L/min) 2
0.68x, 2
0.72. 2
4,368 2
63-kD 2
162, 2
752) 2
Fgfr1 2
Pax7(+) 2
plasmalemma 2
myofiber. 2
Fgfr1-ablated 2
4',6-diamidino-2-phenylindole 2
multipotential 2
pectoralis 2
major) 2
(MuSCs), 2
aged. 2
Modulates 2
proliferating-cell 2
skeletal-muscle 2
Syndecan-4-expressing 2
engrafts 2
(satellite-SP 2
Syndecan-4, 2
hippocampal-dependent 2
EGR1/Zif268. 2
regions--the 2
cortices--were 2
rab 2
Glut2 2
b-cell 2
10⁻⁷ 2
b-cells 2
(fetal 2
hypothyroid) 2
drank 2
(376.2 2
57.1 2
pmol/islet/60 2
(618.1 2
85.2). 2
tri-iodo-thyronine 2
(BB) 2
K+, 2
theophylline 2
(0.11 2
nmol/l), 2
mumol/l), 2
secretagogues 2
(potassium 2
glyceraldehyde). 2
potassium. 2
microUnits/mL, 2
oxprenolol 2
mmol/glucose, 2
crocodile 2
(Hepc25) 2
Hepc25, 2
alanines 2
deprotection 2
gill 2
bis-disulfide 2
Cys*-X-Cys* 2
(GERD-rs) 2
GERD-rs, 2
(NERD). 2
non-CD 2
(12/20, 2
(15/20, 2
S33/35) 2
DoriC 2
DoriC, 2
pipientis 2
(ori). 2
hemE 2
COG1253 2
(CBS 2
CtrA 2
biologists. 2
Noise-reduction 2
noise-reduction 2
low-pass 2
FIMO 2
oriCs. 2
semiconductor 2
sequencing]. 2
Template 2
Sphere 2
prohibitively 2
16,569-bp 2
1301 2
Titanium 2
4-primer 2
Pools 2
DQB1, 2
FLX. 2
Chip 2
(WFA) 2
prepared. 2
(alpha(2)(G)gamma(2) 2
alpha(2)(A)gamma(2)) 2
(G)gamma:(A)gamma 2
70:30 2
(G)gamma 2
(A)gamma 2
gamma-thalassemias, 2
triplications, 2
sextuplications 2
deltabeta-thalassemia, 2
IUBMB. 2
BCL11A, 2
reactivators 2
touches 2
late-stage, 2
uterus-enclosed 2
Noggin. 2
Human-induced 2
hiPS-CM 2
hatching, 2
NH-3, 2
retardant 2
disruptor, 2
neuroblasts. 2
T(3)/TRα1 2
kallikrein-binding 2
(SVZ), 2
Outgrowth, 2
10(9)-fold 2
T(3)-regulated 2
fate: 2
AF-1 2
AF-2 2
ligand-operated 2
cooperation, 2
pluripoietins 2
post-mortem, 2
47.0±18.7, 2
23-86) 2
AQ 2
Tracer 2
volumes-of-interest 2
(prefrontal 2
caudatum) 2
2-tissue 2
dexfenfluramine. 2
18)F]altanserin 2
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-[11C]methoxybenzyl)ethanamine 2
G-protein–coupled 2
3-{2-[4-(4-[18F]fluorobenzoyl)-1-piperidyl]ethyl}-2-sulfanyl-3H-quinazolin-4-one 2
([11C]CIMBI-5), 2
3-{2-[4-(4-[(18)F]fluorobenzoyl)-1-piperidyl]ethyl}-2-sulfanyl-3H-quinazolin-4-one 2
bolus-infusion 2
Altanserin 2
HIP, 2
(LOF) 2
LOF, 2
[(18)F]-Altanserin 2
(5-HT(2A)R) 2
Exaggerated 2
(ILL 2
AN) 2
(CW); 2
(Lundbeck, 2
Valby, 2
Denmark), 2
5-HT1A-mediated 2
scanning). 2
(195 2
5-HT-induced 2
citalopram/pindolol 2
midscan 2
DV(3)', 2
-0.3% 2
h-1; 2
-7.3-7.2% 2
h-1) 2
DV(3)' 2
co-registered 2
match-to-sample 2
5-HT2a 2
(BP(nd)) 2
65.0 2
5.5); 2
69.7 2
5.0); 2
(AAVs), 2
[143 2
(Wegener's) 2
(GPA), 2
(MPA) 2
(CSS)] 2
14.73, 2
2.31); 2
0.0071, 2
7.258, 2
1.98), 2
0.0060, 2
7.541, 2
2.07) 2
0.000047, 2
16.567, 2
3.73). 2
(R620W) 2
N22 2
(MADGC) 2
collection: 2
alleles--aside 2
genes--had 2
(MADGC). 2
(Crohn 2
MADGC 2
community; 2
(PTPN22)*620W 2
9.2%, 2
0.0001] 2
Thyroglobulin 2
(TSHR) 2
(TAO). 2
TAO, 2
305-kDa 2
anti-Tg 2
(125)iodine 2
[(35)S]methionine 2
"thyroid-specific" 2
(THYx) 2
(TSHR); 2
(mg)/body 2
(F/B) 2
overarch 2
eludes 2
cytokine-specific 2
CD34(+)ColI(+)CXCR4(+)TSHR(+) 2
CD34(-)ColI(+)CXCR4(+)TSHR(+) 2
Akt/Pkb, 2
myofibrocytes 2
ColI(+)CXCR4(+)TSHR(+) 2
VEGFA-stimulated 2
(H3K27ac), 2
Tom22 2
Schellman 2
subfunctionalization. 2
(mtOM64) 2
metaxins, 2
Tom20. 2
preproteins 2
preprotein. 2
metaxin. 2
Tom22, 2
(Mtx), 2
Tom37, 2
(transposons 2
retrotransposons). 2
(Long 2
(LINE-1), 2
elements). 2
diversity/polymorphism 2
insertion) 2
dbRIP 2
"A-tails": 2
(LINEs 2
SINEs) 2
"A-tails" 2
retropositional 2
(Ya5), 2
causing) 2
"disease"-associated 2
Ta 2
(31.1%) 2
(75.6%) 2
0-12 2
ribosome-based 2
S19. 2
post-translationally, 2
anaemia) 2
Hallberg, 2
kilodaltons, 2
(i-ag). 2
<36 2
>36 2
(negative) 2
slot 2
i-antigen 2
SerH3-ts1, 2
20-36 2
(SerT) 2
SerT 2
pGpC6.295. 2
micronuclear 2
holotrich 2
(i-antigens) 2
(L, 2
S). 2
mechanism(s), 2
factors--NELF 2
(IFN)-stimulated 2
BRD4, 2
ISGs, 2
ISGs 2
uaRNAs 2
uaRNAs. 2
flavopiridol, 2
uaRNA 2
Spt4 2
1.55 2
NusG. 2
NusG-NTD 2
(DSIF), 2
Gal4-VP16, 2
DSIF. 2
(hSpt5), 2
lymphoblasts, 2
CsA-affinity 2
turcot 2
Kras(Asp12) 2
HMSH2 2
HMSH6 2
left-side 2
(colonic 2
(stable), 2
MSI-L 2
instability), 2
instability) 2
MSI-based 2
MSI, 2
TS1-associated 2
MSI. 2
quasimonomorphic 2
TS1, 2
TS1-related 2
microsurgically 2
(MIM114500). 2
(3634insT) 2
1,223 2
3634insT 2
two; 2
(FAP) 2
syndrome-a 2
syndrome-in 2
polyposis(FAP). 2
syndrome(autosomal 2
recessive): 2
number(< 2
FAP-associated 2
type(autosomal 2
dominant): 2
1p. 2
HNPCC, 2
polyposis) 2
glioma-polyposis 2
cytogenetically. 2
oligoastrocytoma, 2
gemistocytic 2
cerebri. 2
cerebri 2
(somatic) 2
neurosurgical, 2
polyposis-coli 2
(Turcot's 2
1:29 2
1:140 2
(IJ), 2
1:280 2
G749T, 2
(24/62). 2
TDS 2
1351 2
(C1351G), 2
451. 2
(21/62) 2
IJ. 2
(9/62) 2
"Jewish" 2
Moroccan) 2
(7/62) 2
"non-Jewish" 2
IJ-specific 2
(C1351G 2
G749T), 2
(D15S131, 2
D15S1025, 2
D15S981, 2
D15S1050) 2
17.0-72.6 2
g] 2
C1351G 2
80.4 2
44.5-116.3 2
(200-1052 2
1077 2
(1519 2
C1351G. 2
G-to-T 2
ay-Sachs 2
c.964 2
Gujarat 2
TSD, 2
beta-hexoseaminidase 2
(HEXA) 2
c.814G>A 2
recombination: 2
Illegitimate 2
hyperrecombination 2
YFP 2
damage-bound 2
UvrA-induced 2
broken, 2
2-(acetylamino)fluorene 2
(AAF) 2
22-mer 2
AAF 2
helicase-driven 2
(RNAP), 2
(G. 2
Lin 2
Grossman, 2
publication). 2
helicase-catalyzed 2
directionality, 2
RNAP-induced 2
CaMKII- 2
hyperglycaemic 2
evaluation? 2
Calcium-calmodulin-dependent 2
Calcium/Calmodulin-Dependent 2
Infarction. 2
(WXKL) 2
slow-response 2
sinoatrial 2
WXKL-treated 2
p-CaMKII 2
(Thr-286), 2
p-PLB 2
(Thr-17), 2
FK 2
Fura-4. 2
Molecule, 2
Ca(2+)/Calmodulin-Dependent 2
Stress; 2
Heart. 2
molecule" 2
(Ca(2+)/CaM) 2
T287 2
M281/282 2
CaMKIIδ 2
supreventricular 2
safety-profile. 2
CaMKII-induced 2
δ(C)-CaMKII 2
δ(C)-CaMKII, 2
Ser-516 2
hNa(V)1.5 2
GFP-δ(C)-CaMKII 2
Ca(2+)- 2
unbinding. 2
methionines 2
tide 2
Failure". 2
(PACs) 2
(Ran, 2
μmol/L). 2
Force-frequency 2
Hz: 2
mN/mm²; 2
mN/mm² 2
(S2814D) 2
caffeine/epinephrine 2
(S2814A) 2
CaMKII-targeted 2
(gain 2
(chronic) 2
clamp). 2
(prevented 2
KN93). 2
(late) 2
sodium-binding 2
isophthalate 2
[SBFI]), 2
intervals), 2
Calcium-calmodulin 2
98/462 2
RR-MS 2
miracle 2
("liberation 2
procedure"). 2
treatment" 2
(Duox) 2
pendrin/SLC26A4. 2
dyshormonogenic 2
qualified, 2
laryngological 2
USG 2
scyntography 2
labirynth 2
endolyphatic 2
canals. 2
audiological, 2
EVAS. 2
organified 2
83.6% 2
(complete), 2
adjunct. 2
scala 2
Perchlorate 2
dyshormonogenesis, 2
symporter), 2
THOX2 2
porter 2
(includes 2
(goiter). 2
repolarisation. 2
JLNS, 2
220400; 2
JLNS), 2
chemists 2
dockings 2
pose, 2
incursion 2
(High 2
Ambiguity 2
Docking). 2
beta-complex 2
rigid-receptor 2
flexible-receptor 2
GalaxyDock2 2
15ns 2
thieno[2,3-b]pyridine-5- 2
carbonitrile 2
glide 2
contour 2
DockRank, 2
(PS-HomPPI), 2
conformations) 2
conformations). 2
energy-based 2
(improving 2
HotLig, 2
Connolly 2
ligand-contacting 2
Å) 2
(RCF), 2
0.43), 2
monomer-based 2
multi-processor 2
CPUs. 2
Ways 2
template-free 2
(docking) 2
(ZDOCK) 2
computers. 2
Passing 2
multithreaded 2
AutodockVina, 2
multithreading 2
YASARA 2
(GUI) 2
DockTrina, 2
nonsymmetrical 2
(hCA 2
(QM/MM) 2
UBSAs 2
UBSA 2
(Pocket 2
CAVITY 2
(IM-MS) 2
information-driven 2
LiGenDock. 2
(DoE) 2
user-adjustable 2
approaches) 2
Screening. 2
femtomolar 2
chemistry" 2
in-situ" 2
fM). 2
design: 2
HIVgp41. 2
grid-based 2
FPS 2
grids 2
DOCK 2
crossdocking, 2
Autodock, 2
DOCK, 2
Vina. 2
I-deficient 2
diacetate 2
CD4+CD25- 2
Src/ABL 2
LCK, 2
LCK 2
dlg, 2
scrib, 2
A830015P08Rik 2
1-11 2
LGLH1, 2
LGLH2, 2
(miR), 2
miR-296, 2
(Scrib). 2
Re-expression 2
MDA-MB231 2
oss 2
Scrib(+/-) 2
LSL-KRas(G12D) 2
KRas(G12D) 2
CD74, 2
(SCRIB) 2
Pathology, 2
Paulo. 2
progressive/recurrent 2
(p=0.022). 2
>11% 2
61.5%, 2
92.0%, 2
p=0.022). 2
Wort 2
(SJW) 2
CAM-anticancer 2
SJW, 2
thistle 2
CAM. 2
Micromedex 2
microtubule-targeting 2
activation--Mad2, 2
Bub1, 2
perturbances, 2
4NG1 2
Post-imatinib 2
67.6% 2
(16.3%). 2
second-line/third-line 2
77%. 2
[99m 2
Tc-(V)DMSA] 2
Tc-(V)DMSA 2
tracer. 2
inhibitor--imatinib. 2
c-kit, 2
Ssn6-Tup1. 2
(hMTH1) 2
PI3K/Akt-mediated 2
HMLE 2
RAS-sustaining 2
(OGG1) 2
(oxidized 2
MTH1), 2
MTH3. 2
MTH1. 2
triphosphates, 2
8-oxo 2
(NUDT1), 2
8-oxo-7, 2
8-dihydrodeoxyguanosine 2
NUDT5, 2
NUDT1) 2
7,8-dihydro-8-oxoguanine 2
(8-oxo-G), 2
Oligogenic 2
Ile45Thr 2
Ile45/Thr45 2
7,8-dihydro-8-oxo 2
2-amino 2
two-ring 2
8-oxoGTP 2
8-oxoGDP 2
8-oxoGMP, 2
unusable 2
(PNP) 2
8-oxo-2'-deoxyguanosine 2
ribo-forms 2
monophosphates, 2
MTH1a 2
MTH1d(Val83). 2
2'-deoxy-8-oxoguanosine 2
2'-deoxy-2-hydroxyadenosine 2
microRNAs-including 2
mir-132-is 2
microRNA-132, 2
(RT-qPCR). 2
Pilocarpine-induced 2
(pri-miR-132) 2
(miR-132). 2
odor-exposure, 2
cocaine-injection, 2
pri-miR-132. 2
pri-miR-132 2
noninjurious 2
tolerant, 2
focal-onset 2
(tolerance) 2
(injury), 2
regulators; 2
NeurimmiRs) 2
'negotiators' 2
∼50,000 2
~3,700 2
~5,700 2
CTCFL- 2
~31,000 2
potentiality 2
Momordica 2
charantia 2
Linn 2
Coccinia 2
Whit 2
Arn 2
marinated 2
herring, 2
S(eq) 2
pepo 2
glycogenesis 2
glycogenolysis. 2
insulinemia 2
Tolbutamide, 2
ficifolia, 2
Opuntia 2
streptacantha, 2
Spinacea 2
oleracea, 2
Cuminum 2
cyminum 2
oleracea 2
Allium 2
menu 2
Stichopus 2
α-glucosidase, 2
rat-intestinal 2
sucrase 2
maltase. 2
K(IS) 2
Technologists® 2
tachycardia) 2
after-depolarizations) 2
(store-overload-induced 2
release). 2
luminal/cytosolic 2
SOICR-independent 2
1-547) 2
RYR2-S4153R 2
([(3)H]ryanodine) 2
(RyR2-V2475F(+/-)) 2
Ca(2+)-imaged 2
embryonic-lethal 2
Adrenergically 2
[catecholaminergic 2
(CPVT)]. 2
(RyR2-R2474S+/-, 2
RyR2-N2386I+/-, 2
RyR2-L433P+/-, 2
35.71%) 2
Rycal 2
(hRyR2) 2
(S2246L, 2
R4497C) 2
RyR2:FKBP12.6 2
hRyR2. 2
Thai, 2
HLA-B*1502. 2
(cADRs) 2
Thai. 2
cADRs 2
PCR-SSP 2
oxcarbazepine-induced 2
AEDs-induced 2
OXC-tolerant 2
8.8; 2
1.853-41.790; 2
(88.10%) 2
(11.90%) 2
54.76 2
14.62-205.13, 2
2.89 2
10(-12)]. 2
88.10%. 2
1.92% 2
99.96%. 2
ethnicity-specific 2
HLA-B*5901 2
Carbamazepine, 2
necrolysis: 2
non-Asian, 2
(CBZ)-induced 2
(MPE). 2
Non-erythroid 2
α-spectrin 2
(αIISp) 2
fibroblasts--a 2
Fancg-deficient 2
(stem 2
(G5 2
MEFs) 2
telomerase-based 2
(T-LL), 2
B-ALLs 2
T-ALLs) 2
(2.1%), 2
(2.0%). 2
B-precursor 2
T-lineage 2
Gfi1(-/-) 2
(GSIs) 2
proline/glutamic 2
acid/serine/threonine 2
HOX11, 2
HOX11L2, 2
SIL-TAL1 2
HOX11L2 2
HOX11. 2
coevaluated 2
(76%). 2
=10%), 2
subclone. 2
mutant-positive 2
threonine-rich 2
blood/bone 2
2/15 2
4/15 2
(Sel-10, 2
Fbxw7), 2
(Arg(465), 2
Arg(479), 2
Arg(505)) 2
hCdc4. 2
hCDC4-negative 2
(MKP-1). 2
(T-ALL/LBL), 2
t(7;9)(q34;q34) 2
7q34 2
CD8, 2
J1-5 2
end) 2
'head-to-head' 2
consitute 2
Hes1, 2
'X-inactivation 2
center' 2
(XIC/Xic), 2
inactive), 2
NEDD9. 2
(TNF)α-induced 2
pre-osteoblast 2
RAW267 2
factor-α-neutralizing 2
Y416 2
(FAK 2
pre-incubate 2
osteoblast, 2
Tyr(576/577). 2
PLCγ1 2
Tyr(576/577) 2
(αSNAP) 2
(NSF) 2
p85-Cortactin, 2
p110-AFAP1, 2
p130Cas, 2
p125FAK 2
editors, 2
EGFR/MEK/ERK/CDK5-dependent 2
(P-FAKSer732) 2
EGFR/MEK/ERK 2
Ser732 2
MTs. 2
EGFR/MEK/ERK/CDK5 2
Tyr925-FAK 2
1nM 2
PTPN13, 2
(P-FAK) 2
Sp-1 2
Ganfukang 2
α5, 2
FAK/Akt 2
cyclinD1, 2
Rgnef-FAK 2
paxillin-Y118 2
GEF-inactive 2
CPC, 2
CPC-Haspin-H3T3ph 2
PP1γ 2
H3T3ph, 2
H3T11ph 2
Haspin-mediated 2
Haspin: 2
inserts. 2
Gsg2 2
mitosis-specific 2
(CPC), 2
prometaphase, 2
B-stimulated 2
prometaphase. 2
B-dependent 2
Haspin-dependent 2
Shugoshin 2
CPC. 2
shugoshin, 2
Bub1-mediated 2
H2A-S121 2
H3-pT3 2
(chromosomal 2
TAF3 2
H3-threonine 2
spindle-kinetochore 2
nonbinding 2
MCAK 2
taxol. 2
H3T3ph-specific 2
composing 2
alopecia/alopecia 2
parakeratosis 2
pustules. 2
catagen/telogen 2
peribulbar 2
Thiopurines 2
TPMT 2
photography, 2
[Azathioprine 2
course]. 2
(AZA) 2
(52.7%) 2
AZA, 2
(27.4%). 2
non-leucopoenics 2
(p=0.005). 2
(27.4%) 2
MAR 2
azathioprine/6-mercaptopurine 2
(7.7%) 2
mesalamine 2
purpura: 2
[Hypersensitivity 2
route]. 2
mg/kd/day 2
eosionophilia 2
Mesalazine 2
desensitization, 2
hyperaesthesia, 2
sulfasalazine. 2
sulfapyridine 2
sulfasalazine-induced 2
malignances 2
autopsy). 2
(LPAR1, 2
NUFIP1) 2
R163W 2
NetDiseaseSNP. 2
conservation-based 2
service: 2
http://www.cbs.dtu.dk/services/NetDiseaseSNP. 2
Multiscale 2
splicing-site 2
(COSMIC) 2
(LPHN2, 2
MYH2 2
TGM2) 2
C10orf137 2
2,020 2
LPHN2, 2
MYH2, 2
(BRAF(V600E), 2
NRAS(Q61R) 2
Phosphoproteomics 2
fragmentations 2
x-ion, 2
b-, 2
y-, 2
Confident 2
40- 2
unambiguously, 2
serine-811 2
co-transporter, 2
NCC. 2
sodium-potassium-chloride 2
(18)O 2
(16)O/ 2
loss-dependent 2
(LTQ)-FT 2
aquaporin-4, 2
loss-directed 2
multiphosphorylated 2
impelling 2
A-medicated 2
(PHT), 2
[lipopolysaccaride 2
sCD14] 2
Help 2
scramble 2
Bmi-1-responding 2
BRE 2
p19(Arf) 2
correlatively 2
lentiviral-delivered 2
Bmi-1-controlled 2
Cdkn2A 2
AGA, 2
non-balding 2
Bmi-1; 2
Mel-18, 2
(h-TERT), 2
roads 2
lymphoma-derived 2
p16-dependent 2
homeobox-cluster 2
subcultured 2
retro-viral 2
liposome. 2
H-Ras-stimulated 2
p16Ink4 2
TrxG 2
mi-1 2
Arf, 2
NPECs 2
Bmi-1(-/-) 2
(carcinoma 2
p19ARF) 2
(30/46) 2
(p16INK4a/p14ARF) 2
(P<0.07). 2
E2a-Pbx1. 2
INK4A 2
t(1;19) 2
E2a-Pbx1; 2
INK4A-ARF. 2
bmi-1, 2
myc-1, 2
p16/p19ARF, 2
(=human 2
p19ARF). 2
squamous, 2
adeno-, 2
carcinoid); 2
tumour-free, 2
negative/weakly, 2
moderate-strong 2
moderate-high 2
(p16/p14ARF) 2
Campaign. 2
(c-miRNAs) 2
MicroRNA-494 2
j3. 2
C₂C₁₂ 2
(mtTFA) 2
j3 2
(Foxj3), 2
Foxj3. 2
miR-494. 2
(miR-146a 2
miR-222), 2
miR-221), 2
(miR-20a), 2
14; 2
(l 2
min−1) 2
mir-1 2
mir-133a 2
pre-training 2
Tested 2
TotalReCaller: 2
base-calling. 2
SNP-calls, 2
reference-guided 2
({A, 2
T}), 2
TotalReCaller's 2
peers-Bustard, 2
BayesCall, 2
Ibis 2
Rolexa-based 2
TotalReCaller 2
http://bioinformatics.nyu.edu/wordpress/projects/totalrecaller/ 2
fabian.menges@nyu.edu. 2
BLASTP, 2
BLASTP. 2
FPGA, 2
commodity 2
Xilinx 2
Virtex-II 2
FPGAs. 2
field-programmable 2
(FPGA). 2
Reconfigurable 2
subsequence. 2
VHDL 2
(VHSIC 2
language) 2
(Field 2
array). 2
special-purpose 2
Needleman-Wunsch 2
memory; 2
2(22). 2
NuBus 2
IIf/x, 2
TTL 2
clocked 2
MHz. 2
Postconditioning 2
TBTC 2
(Cyclosporine 2
(ALDH2) 2
ALDH2, 2
dose‑dependent 2
Alda‑1, 2
CTX 2
TNA2 2
SB216763 2
NIM-811. 2
(N-metyl-4-isoleucine-cyclosporine) 2
ischemic-reperfusion 2
(LDF) 2
cyclophilin-D 2
(SfA) 2
Protoporphyrin 2
Dimebon 2
permeabilization. 2
atractyloside, 2
(PSCs) 2
NIM811, 2
(TRO-19622) 2
coinjected 2
Mito-TEMPO 2
RPP 2
N-methyl-4-isoleucine 2
(NIM811), 2
CATR 2
(old 2
t-BH 2
pentobarbital-anesthetized 2
μL) 2
Atr 2
IPost, 2
multiphoton 2
[Ca(2+)](c), 2
conspire 2
STAT3-KO 2
Bnip3-induced 2
(ZL-/ZO 2
Con: 2
n.s. 2
A2α 2
(cPLA2α) 2
cPLA2α-deficient 2
cPLA2α 2
KT195, 2
Pyrrophenone 2
pyrrophenone 2
Pre-reperfusion 2
(BRL37344, 2
(mPTP), 2
Akt-NO 2
Antamanide, 2
phalloides, 2
phalloides. 2
Permeability 2
Phe6 2
Phe9, 2
D-independent 2
clotrimazole 2
pore-targeting 2
(non-transfected) 2
kinase-3beta. 2
(GSK-3beta). 2
Ser9, 2
oxidant-induced 2
3beta. 2
mTOR/p70s6K 2
GSK360A 2
IRI, 2
HKII. 2
ISCU 2
NFS1-ISD11-ISCU 2
ISCU, 2
IscX 2
frataxins. 2
cardio- 2
iron-promoted 2
X25 2
iron-loaded 2
S.cerevisiae, 2
(55)Fe 2
KIKI 2
ataxia: 2
helical) 2
Al-induced 2
(dfh), 2
iceberg 2
murids. 2
(CR2) 2
pleiotropism 2
(HPVs) 2
wheat-germ 2
PKN. 2
GST-E6 2
GST-16E6 2
CaSki 2
cytoplasm; 2
C-33A 2
HPV-16/18 2
p53-E6 2
RbAB 2
E7-RbAB 2
RbAB. 2
E7s 2
Iceman. 2
5,300-year-old 2
16s 2
(16s 2
rDNA) 2
perfringens, 2
ghonii, 2
sordellii, 2
Eubacterium 2
tenue, 2
Vibrio. 2
mummification 2
Sphingomonas, 2
Afipia, 2
Curtobacterium, 2
Microbacterium, 2
Agromyces, 2
comes, 2
wind 2
pluripotency-promoting 2
METTL3, 2
(WTAP, 2
METTL14, 2
KIAA1429) 2
WTAP-independent 2
Cycloleucine, 2
Cycloleucine 2
dimethyladenosine 2
m7GpppmAm. 2
cycloleucine, 2
cycloleucine-treated 2
sedimenting 2
cycloleucine. 2
Apm6ApC 2
Gpm6ApC, 2
FTO-dependent 2
Obesity-associated 2
RNA; 2
(SNV), 2
(K4-/K27-) 2
H3K27-methylation 2
KDM6B), 2
PRC2-target 2
PRC2-mediated 2
OTX2. 2
OTX2, 2
(Orco). 2
odorant-sensitive 2
VUAA1. 2
DEET. 2
Insects 2
odour-gated 2
ligand-selective 2
repellent 2
Carbon 2
mosquitos 2
aversive 2
aversion 2
(ORNs). 2
behavior-based 2
odorant-evoked 2
repellents 2
nonconventional 2
coreceptor. 2
(>15 2
CMS-exposed, 2
(p=0.025) 2
[811.71+/-218.1, 2
665.9+/-124.9 2
(M+/-SD) 2
(p=0.035) 2
(-60.06%) 2
Memantine. 2
Memantine 2
(paired 2
filament)-tau 2
beta-amyloid-mediated 2
(Tet/GSK-3beta 2
Tet/GSK-3beta 2
histopathological, 2
AF267B: 2
AF150[S] 2
>4500). 2
hippocampi, 2
microcebes 2
impairments), 2
5-Methylcytosine 2
mC) 2
mC 2
(WM) 2
8.9% 2
Stella) 2
Tet3-mediated 2
Tet1-mediated 2
mESC 2
Sulfide 2
Tet1- 2
Tet2-Mediated 2
Drive 2
Maintain 2
Homeostasis. 2
(H2S) 2
sulfhydrating 2
(NFYB) 2
(TGF-β)-activated 2
(IL-2)-activated 2
Stat5 2
Treg-cell-associated 2
(Tet1/2/3) 2
Tet1/2 2
Tet1/2/3 2
triple-knockout 2
Tets 2
teratomas. 2
reexpression, 2
Most, 2
TETs 2
Ten-Eleven-Translocation 2
Tet2-deficient 2
TET-à-tête-synergy 2
(Ito 2
(He 2
(Iyer 2
Loenarz 2
Schofield, 2
Tahiliani 2
TET-assisted 2
"TAB-array", 2
manic-like 2
ClockΔ19 2
VTA 2
MEN1-like 2
MLL1/MLL2-containing 2
trimethylate 2
islet-like 2
Dlk1-Meg3 2
PILECs. 2
MLL5, 2
profibrogenic 2
Set1/COMPASS, 2
MLL3/4 2
trimethylase 2
trithorax, 2
H3K4-specific 2
(H3K4). 2
Tat:P-TEFb 2
CDK9 2
DPY-30-like 2
leukemia-1) 2
BRE2 2
3-lysine 2
p52-depleted 2
HUT-78 2
Wdr82, 2
Set1A/B, 2
MLL1-4 2
GAD1 2
(Mll1), 2
MLL1/MLL2 2
TFF1 2
(pS2) 2
MOF. 2
cosedimentation, 2
MOF-mediated 2
K16. 2
a9, 2
activator-based 2
Regulation: 2
Tools. 2
(a-miR), 2
CRISPR-mediated 2
(sg)RNA. 2
miR-2400, 2
cell-cycling 2
miR-142 2
E2f8, 2
(CRISPRi-mediated) 2
end-stage. 2
horns 2
motoneuronal 2
SUMO3, 2
(MRF) 2
(SMSCs) 2
(SOD1-G93A). 2
MRF 2
(POLDIP3) 2
(variant-1) 2
(variant-2) 2
variant-2 2
(G93A) 2
(sMNs), 2
sMNs 2
SOD1-linked 2
NSC, 2
MSC. 2
(G86R) 2
spastic-like 2
5-hydroxytryptamine-2b/c 2
emissions. 2
(51.8%) 2
5(4.4%) 2
25.8% 2
46.3% 2
(42%); 2
(33%); 2
100800) 2
lordotic 2
(FGFR3); 2
G380R. 2
Anticipatory 2
gibbosity. 2
achondroplasia: 2
chondrodysplasias. 2
subtest 2
(Cobb 2
"towering" 2
tympanic 2
Audiograms 2
(AHF) 2
proliferation-inhibiting 2
34-35 2
22-23 2
chemically-induced 2
loss/death. 2
1,4-bis[2-(3,5-dichloropyridyloxy)]benzene 2
(TCPOBOP) 2
(c-jun(Δli)) 2
(DENA) 2
DENA 2
DENA/TCPOBOP-induced 2
c-jun/JNK 2
flatworms) 2
menadione-induced 2
menadione. 2
C-Jun 2
(wild-type, 2
TUNEL, 2
4-hydroxynonenal 2
Multiphoton 2
Kaplan-Meier). 2
MPT. 2
(TNFRs) 2
microbial, 2
Gadd45b 2
Jnk2-null 2
Arsenite 2
hapatocytes 2
MEK1/2-ERK1/2 2
CD40-induced 2
CD40-activation 2
JNK/ERK 2
(concomitant 2
Cholangiocytes 2
(EGF)-treated 2
Intracrine 2
(HPO)/ALR 2
(augmenter 2
regeneration) 2
hepatotrophic 2
HPO. 2
JAB1-mediated 2
1-63 2
MAPK-independent 2
rapalogues 2
mechanistic/mammalian 2
rapalogue 2
(VEGFs). 2
cystadenoma 2
Tsc2+/- 2
4E-BP1/eIF4E, 2
disconnect 2
4E-BP1/eIF4E. 2
HIF-1α-dependent 2
SREBPs, 2
YY1–PGC1α 2
CRSP, 2
TAF(II)s 2
700,000 2
700K) 2
33K 2
200K. 2
CRSP33 2
Med7, 2
CRSP150 2
Rgr1. 2
p200 2
TRIP2/PBP. 2
CRSPs 2
CRSP70 2
CRSP. 2
promoter-selective 2
multi-subunit, 2
coactivator-also 2
enhancer-bound 2
(activators) 2
(CRSP/Med2) 2
Med70 2
non-exclusive 2
H9c2, 2
ketotic 2
alloxan-rat 2
mg.kg-1.day-1) 2
v) 2
coconut 2
cadang 2
246-401 2
nt, 2
Avsunviroidae) 2
ribozymes, 2
autocatalytically. 2
RNAs). 2
organella, 2
Avsunviroidae). 2
Avsunviroidae, 2
autocatalytic, 2
replication/accumulation 2
silencing-a 2
cleavage/ligation 2
E-like 2
2',3'-cyclic 2
2',5' 2
reassortment 2
(ROS 2
17/2.8). 2
true-positives 2
(NM 2
aMLC), 2
ATPase-6, 2
T(3)-induction 2
(2.1-fold). 2
1.7-fold. 2
osteoblast-derived 2
Va, 2
VIc) 2
(II 2
TR/c-erbA 2
neuroacanthocytosis-related-genes 2
ChAc 2
MLS, 2
R133X 2
Chilean 2
(938-942delCTCTA), 2
Multisystem 2
(McLeod 2
hoarding, 2
jovial, 2
hypoperfusion, 2
acanthocytes 2
chorein, 2
neuroacanthocytosis: 2
proteins--XK, 2
chorein--might 2
KX 2
(W314X), 2
spontaneous. 2
fiber-specific 2
2-fluoro-2-deoxy-glucose 2
semidominant 2
Kell/Kx 2
(CGD). 2
anti-Km 2
(G>C). 2
C-nucleotide 2
3'-frameshift. 2
XS 2
408. 2
SRPX 2
(sushi-repeat-containing 2
XLRP 2
cosmids, 2
150-380-kb 2
Xp21. 2
Xk 2
PDT-induced 2
RIP1-dependent 2
cFLIP(L). 2
RIP3) 2
pronecrotic 2
(RIPK1/RIP1) 2
mimetics, 2
cIAP1 2
Ser(89) 2
RIP1/RIP3-mediated 2
(IFNs) 2
"necrosome" 2
(MLKL) 2
Ser-227 2
Thr-231 2
Ser-232 2
hRIP3 2
MLKL 2
TICAM-1 2
necrosome) 2
(DAMPs) 2
ThT, 2
amyloids 2
Rip1-Rip3 2
'necrosome', 2
(RIP)1, 2
(HI) 2
RIP-3) 2
(SDF-1)/CXC 2
(HIFs), 2
(mTOR 2
metastasis-initiating 2
twist. 2
cyclin/CDK 2
phospho-mTOR 2
up-front 2
Discovered 2
Easter 2
TORC1, 2
TORC2 2
4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide 2
SCH66336 2
resistance); 2
(Kv7.2) 2
(Kv7.3) 2
KCNQ4 2
(Kv7.4) 2
heteromultimers 2
M-channels, 2
flupirtine 2
KCNQ2- 2
KCNQ3-encoding 2
(BFNCs), 2
2043deltaT 2
M-current 2
KCNQ3, 2
GABRG2, 2
GABRA1 2
CLCN2 2
characteristic: 2
metal-chelating 2
(CQ), 2
Cu(II)(gtsm) 2
(Aß). 2
Aß. 2
MPACS 2
MPAC. 2
(RM, 2
LJ, 2
ELS) 2
Handbook 2
Interventions.The 2
carer, 2
(ADAS-Cog)) 2
13.24) 2
6.36 2
-0.50 2
13.23), 2
respectively.There 2
impression. 2
(impaired 2
vision) 2
drug.In 2
composite, 2
methodology; 2
(participants 2
IQ) 2
chaperones: 2
(Prana 2
Biotechnology), 2
"holistic" 2
evaluative 2
'metal 2
compound' 2
metal-sensitive 2
CQ-bound 2
dimebon, 2
Metals 2
radicalization 2
perturbance 2
chelators. 2
8-OH 2
clioquinol. 2
PBT2) 2
hypothesis." 2
(VH) 2
minimum-size 2
immunoreagents. 2
TOCSY 2
NOESY 2
VH. 2
beta-sheets 2
alpha-, 2
beta-, 2
gamma-protocadherin 2
PCDHA@, 2
PCDHB@, 2
PCDHG@, 2
Silenced 2
metanephric 2
Pcdhg@ 2
short-interfering 2
PCDHG@ 2
beta-catenin/T-cell 2
(TCF) 2
beta-catenin/TCF-reporter 2
16p11.2 2
neoplasias. 2
DNA/histone 2
2q14.2, 2
flanking, 2
(EN1, 2
acromicric 2
head). 2
metacarpal, 2
(NTPs). 2
antigenome. 2
scavenged 2
cap-donor 2
5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole 2
(DRB), 2
RNAP-II, 2
DRB-sensitive 2
(RNAPolII) 2
MLL. 2
ENL-associated 2
(EAPs) 2
[RNAPolII 2
CTD] 2
[pTEFb]), 2
(histone-H3 2
DOT1L) 2
(AF4, 2
AF5q31, 2
LAF4), 2
(RING1, 2
CBX8, 2
BCoR). 2
(vRNP) 2
depends. 2
vRNP 2
failing. 2
Well-designed, 2
mucoadhesive 2
mucoadhesiveness 2
rifabutin-based 2
PPI-based 2
R-containing 2
sclerostin-bone 2
decalcified 2
sclerostin-maltose 2
Eluted 2
sodium-dodecyl 2
(Thr202/Tyr204) 2
heregulin/neuregulin 2
(Sclerostin). 2
Lrp6 2
(LRP5(G171V)) 2
(HBM) 2
(LRP6(G158V)) 2
alpha-Sost 2
LRPs 2
target-of-rapamycin 2
[mammalian 2
(mTORC1 2
Rheb-GTPase 2
HIFalpha-mediated 2
TSC2-dependent 2
eIF2alpha, 2
eEF2, 2
AMPK/TSC2/Rheb/mTOR 2
hepatoma, 2
(CTC) 2
rhinorrhoea, 2
meningoceles 2
encephaloceles 2
patients--no 2
examinations--and 2
skull]. 2
(beta-trace) 2
cisternography, 2
diethyltriaminepentacetic 2
convexities, 2
Sherlocc, 2
('+45 2
pause'), 2
('+70 2
pause'). 2
KLK13, 2
rs3865443 2
KLK12 2
steroids: 2
mineralocorticoids, 2
KLK11, 2
KLK2, 2
(hK1-hK15 2
KLK1-KLK15) 2
hK4, 2
hK5, 2
hK6, 2
vector-control 2
19q13.4. 2
KLK10, 2
X-profiler 2
KLK1, 2
19q13.3-4 2
KLK11 2
KLK7, 2
KLK8, 2
fingerprinting. 2
(KLKs), 2
protease-encoding 2
(hKs), 2
hKs 2
DX), 2
q2 2
(pCR). 2
(IBC). 2
invasion-related 2
(ER)-related 2
(ER)-positive, 2
HER2/immunohistochemistry, 2
(PR)/immunohistochemistry 2
ER/immunohistochemistry 2
(DRFS). 2
GRB7 2
(TP53BP2) 2
Bcl2. 2
TP53BP2 2
protein-containing 2
condensin. 2
ETC; 2
COC). 2
ETCs/COC 2
ATR-X, 2
dizziness; 2
Treatable 2
biotin-thiamine 2
(BTBGD). 2
mid-brain 2
encephalomyelopathy. 2
SLC19A3, 2
transporter-2, 2
c.517A>G;p.Asn173Asp 2
BTBGD 2
psychosis--memory 2
confabulation--may 2
younger). 2
undiagnosed, 2
sequelae), 2
malabsorption. 2
multivitamin. 2
MVI, 2
fully. 2
caudate, 2
25/73 2
deliria 2
Addiction 2
B(1)), 2
(KIF5A, 2
TAGAP) 2
non-intronic 2
GIN1/C5orf30, 2
ANKRD55/IL6ST, 2
BLK 2
tag-single-nucleotide 2
(r(2)=0.8) 2
(n=571 2
n=880 2
p<0.2 2
(n=464 2
n=822 2
rs3890745 2
(p=2.6 2
p=0.003 2
OR=0.79). 2
rs12992492 2
(p=4.3 2
p=0.0021 2
OR=0.77). 2
(anti-CEP-1) 2
CEP-1 2
Anti-CEP-1 2
26.8% 2
(86.6%) 2
Erosive 2
DRB1*04 2
extend, 2
African-descent, 2
(BRASS) 2
(rs3087243). 2
2.18-4.25), 2
2.53, 2
1.83-3.5) 2
1.24-2.66) 2
1.84, 2
1.27-2.66). 2
1.01-2.17), 2
CCP. 2
(41.3 2
44.9 2
care-based 2
1,022 2
1.1-2.2]) 2
1.1-2.7]). 2
HLA-DRB1*01/*04 2
7.81 2
2.6-23.2]). 2
Arg620Trp 2
1.36 2
102) 2
CCP3, 2
CCP3.1 2
0.0001-0.01) 2
Anti-MCV 2
(1.18, 2
(ACPAs), 2
(Ig)M-rheumatoid 2
(1:4) 2
Breastfeeding 2
1.43-15.8]. 2
1.83-17.95) 2
0.15-0.93). 2
antibodies-positive 2
validation) 2
0.792 2
HLA-DRbeta1 2
UBXD2. 2
C5. 2
FDRs, 2
epidemiologic, 2
(RF; 2
isotypes) 2
1858T. 2
ACPAs, 2
antikeratin 2
antedating 2
RF- 2
1.89); 2
906 2
GG) 2
6.2%, 2
9q33.2. 2
heritability. 2
multi-tiered, 2
25,966 2
(661 2
cases/1322 2
596 2
cases/705 2
rs1953126, 2
(OR(common) 2
P(comb) 2
1.45E-06). 2
fine-scale-mapping 2
SNP-selection 2
MEGF9 2
STOM 2
staged-approach. 2
(P(comb)<0.01) 2
FBXW2 2
GSN. 2
PHF19 2
(trend 2
P(comb): 2
1.45E-06 2
5.41E-09). 2
differential. 2
196R, 2
RFs 2
196M/R 2
yrs. 2
ACPA. 2
(85), 2
(31). 2
serotonin-recapture 2
decongestants. 2
stroke]. 2
Occipital 2
hemi-hypesthesia 2
dyslipidaemia, 2
stroke/embolism 2
tetrahydrocannabinol-related 2
INVESTIGATIONS: 2
delta9-tetrahydrocannibol 2
pectoris; 2
18-30 2
~10 2
EF1 2
2MDa) 2
homotetramer 2
(~2.2 2
MDa) 2
RyR3, 2
Hyperphosphorylation 2
(RyR1-RyR3) 2
ribose, 2
(MH). 2
(4CmC), 2
xestospongin 2
MH. 2
(RyR1, 2
RyR3). 2
thrombin-treated 2
CD44-HA 2
Thrombin-induced 2
Hyaluronidase, 2
(LMW-HA), 2
LMW-HA 2
p47(phox-/-) 2
Haptotactic 2
CD44-dependent 2
plasma-soluble 2
HA-regulated 2
CD44-HA-dependent 2
GKT136901 2
(Nox1/4 2
Nox4. 2
•O(2)(-) 2
nox4 2
(ROS)-forming 2
Nox4). 2
panuveitis 2
gevokizumab), 2
(depleting 2
Uveitis 2
panuveitis, 2
98-day 2
4-21 2
21-97 2
days); 2
(T1D 2
T2D), 2
IL-1β-mediated 2
Engineering™ 2
PK-A) 2
(PP2C) 2
PK-A 2
(Ser-16 2
Thr-17) 2
cannonical 2
stem-loop. 2
readout. 2
679 2
2092 2
McLauchlan 2
Berget 2
309, 2
Postulated 2
regressive 2
Epithelial, 2
propria, 2
HLA-DR(-), 2
ensembles 2
kinase-inducible 2
(pKID) 2
pKID 2
fit. 2
stathmin, 2
solution-phase 2
Kolmogorov-Smirnov 2
IDPs, 2
(Brk) 2
(Gro), 2
Gro, 2
unconserved 2
(Gro)/TLE 2
E4f1 2
Groucho-mediated 2
Groucho/transducin-like 2
(Gro/TLE) 2
WRP(W/Y) 2
Ser-286 2
TLE 2
TLE/Grg 2
Groucho/TLE. 2
(Gro)/TLE, 2
Tle 2
(Gro)/transducin-like 2
(TLE) 2
Grorelated 2
Context-dependent 2
(46-fold 2
variation), 2
(CAPAN1) 2
(CD18) 2
doublings. 2
Crisis 2
(γ-H2AX) 2
(SA-β-galactosidase 2
(sub-G1 2
re-elongation 2
GRN163L. 2
(TICs). 2
chemoresistant, 2
repopulate 2
C-circle 2
assay/telomere 2
FISH/ATRX 2
covalently-lipidated 2
thiophosphoramidate 2
thrombocythemia. 2
millimeter. 2
[ongoing]). 2
(88%; 2
CALR 2
liver-function 2
NCT01243073.). 2
neoplasm-associated 2
20+) 2
10+) 2
(P=0.30) 2
(P=0.07). 2
U2AF1 2
21%), 2
NCT01731951.). 2
analogue-promoted 2
N(4) 2
(Mtase) 2
C5-methylcytosine 2
N6-methyladenine. 2
C5-cytosine 2
Mtases. 2
β-elimination 2
mechanics/molecular 2
Deprotonation 2
5-methyl-6-Cys-81-S-5,6-dihydrocytosine 2
Glu-119-CO2H 2
protonating 2
6-Cys-81-S-3-hydrocytosine. 2
reactants 2
6-Cys-81-S-3-hydrocytosine 2
(-)-trans-anti-B[a]P-N(2)-dG 2
GCGC 2
trans-anti-B[a]P-N(2)-dG 2
benzo[a]pyrenyl 2
dC. 2
(cytosine-5)-DNA 2
proton-donating 2
enzyme-dihydrocytosine 2
(methylatable) 2
(MTase), 2
2'-Deoxyoligonucleotides 2
antiquitin 2
(c.751G>A), 2
p.Ala251Thr 2
"STXBP1-related 2
(MUNC18.1), 2
MUNC18-1, 2
Rogawski, 2
Delgado-Escueta, 2
Jeffrey 2
Noebels, 2
Massimo 2
Avoli 2
Richard 2
Olsen. 2
SPTAN1, 2
TOR1A, 2
electroencephalograph 2
c.931dupT 2
(p.S311FfsX3), 2
(EIEE). 2
c.663 2
5G>A 2
drug-responsive 2
focal/lateralized 2
MPSI 2
(MUNC18-1) 2
West/Ohtahara 2
(HSP90 2
RHPS4/BRACO19 2
90-containing 2
radicicol, 2
retrotransport 2
FKBP51 2
hormone/MR 2
discovery: 2
17-allylamino-17- 2
demethoxygeldanamycin 2
(17AAG), 2
(TRF) 2
CCT018159. 2
(Hsp90), 2
re-folding 2
stress-denatured 2
ADP-Mg 2
gyrase, 2
(D93) 2
(E47) 2
Hsp82, 2
Hsp82. 2
Hsp82 2
(etanercept). 2
non-tuberculosis 2
non-TB 2
(n=29), 2
varicella, 2
micro-organisms, 2
Natives 2
relatives; 2
400) 2
0.21-0.87) 2
0.046); 2
0.16-0.66) 2
1.45-9.93) 2
Steinbrocker. 2
Pearsonand 2
43.2±14.1 2
Steinbrocker 2
9.1, 2
pleurisy. 2
Th-1 2
onsets 2
Nulliparity 2
P<.6). 2
P<.6) 2
(22.6 2
P<.008), 2
(P<.0001), 2
PINK1-phosphorylated 2
(PTEN-induced 2
homolog) 2
PINK-Parkin 2
PINK1-dependent 2
ubiqitination. 2
Mfn2-deficient 2
Parkin-deficient 2
PINK1/parkin-dependent 2
σ(70) 2
2-arylbenzothiophene 2
E/Z 2
diastereoisomeric 2
σ₁ 2
σ₂ 2
diastereomers 2
herbs. 2
Synthase 2
model_017 2
(Version 2
(QFIT) 2
(TNKS1 2
axin 2
property-based 2
subclinical. 2
20%-40% 2
WNV. 2
Rickettsia/Coxiella, 2
blackbird, 2
merula, 2
fences, 2
mountains, 2
glaciers, 2
desserts 2
co-feeding. 2
deploying 2
(DENVs) 2
bird-mosquito 2
circulated 2
Idaho 2
Occasional 2
Pakhtunkhawa, 2
hindrance. 2
Pakistan, 2
32.84-45.86) 2
38.61-62.91) 2
post-monsoon 2
mucosally 2
infections). 2
Rabensburg 2
mosquito-specific 2
37°C, 2
Flavivirus)serotypes 2
Venezuela, 2
American-Asian 2
nucleocapsid 2
holiday 2
patient-to-patient 2
Majorca. 2
(HCW) 2
POWV 2
enzootic/epizootic, 2
subtropics. 2
Florida. 2
(Flaviviridae: 2
ornithophilic 2
dead-end 2
rDENV-4 2
rLGTV 2
scapularis 2
(TBEV), 2
unpasteurized 2
(Chapter 2
flavivirus. 2
70. 2
hematophagous 2
(mosquitoes 2
ticks). 2
Arthropod 2
Incrimination 2
Life-Threatening 2
€127,000 2
>3. 2
1%; 2
37%; 2
14-60). 2
Paracetamol 2
(Acetaminophen) 2
(PAIS). 2
PAIS 2
p<0.001); 2
(intensive 2
'Hemicraniectomy 2
trial' 2
newly-conceived 2
(DEcompressive 2
(ATP), 2
Benzene 2
comprehended, 2
lowered. 2
concomitant, 2
70.4 2
(AMF) 2
AMF. 2
.05. 2
AMF, 2
organoplatinum 2
Nausea 2
(Ethyoltrade 2
thiophosphate 2
ethanethiol, 2
2-[3- 2
aminopropyl)amino]dihydrogen 2
(WR-1065) 2
oocyte, 2
B1-type 2
polymerase-III 2
dbEST 2
B1-homologous 2
Poly-(A) 2
3'-oligo-(U) 2
oligo(U) 2
(SRP) 2
(FLAMs) 2
proto 2
PB1, 2
PB1D10 2
PB1D7) 2
(tRNAiMet) 2
(TSH: 2
mIU/L, 2
HUNT 2
(P(trend) 2
0·005), 2
0·50-1·4 2
U/mL), 2
(SH 2
non-SH 2
43.8%; 2
p=0.087); 2
three-vessel 2
9.9%; 2
p=0.919); 2
13.4%; 2
p=0.892); 2
p=0.051); 2
p=0.794); 2
(62.4% 2
45.3%; 2
p=0.064). 2
multivessel 2
0.48, 2
0.34-0.68, 2
Intern 2
28; 2
P<0.05] 2
P<0.05]. 2
hyperthyroidism: 2
(p=0.026). 2
(r=0.109, 2
p=0.044) 2
(r=0.117, 2
3.74, 2
p=0.045) 2
mU/l 2
N-methyl-N-nitrosourea 2
MNU 2
(0.01--2.0 2
clonable 2
spermatogonia. 2
empiric 2
fractionated-dose 2
BS) 2
(4.5, 2
ethyl-nitrosourea 2
Dlb-1 2
Vomiero-Highton 2
Heddle. 2
LOH) 2
TAR-DNA 2
Disappearance 2
(GEMs). 2
snRNA), 2
U11/12-type 2
TDP-43-depleted 2
thalamus) 2
Seminar, 2
1-30 2
6th, 2
fractal-like 2
(αSyn), 2
αSyn 2
"fibrillation 2
(ssNMR) 2
77-82 2
(VAQKTV). 2
Temperature-dependent 2
(A53T, 2
E46K) 2
nucleation-dependent 2
Atomic-level 2
magic-angle 2
fibrils-greatly 2
15N-13C-13C 2
T22, 2
V26, 2
A27, 2
Y39, 2
G41, 2
S42, 2
H50, 2
V52, 2
A53, 2
T54, 2
V55, 2
V63, 2
A107, 2
I112, 2
S129. 2
'two 2
hit' 2
á-Synuclein 2
co-enriched 2
pathologies.To 2
small-sized, 2
purity. 2
α-Syn-mediated 2
Src-mediated 2
'language' 2
Glutamylation, 2
microtubule- 2
microtubule-interacting 2
detyrosination/tyrosination, 2
(poly)glutamylation 2
(poly)glycylation, 2
polyglutamylation, 2
polyglycylation 2
hyperelongation 2
Kub5-Hera/ 2
RPRD1B 2
28.04 2
37.80% 2
21.34% 2
Impulse 2
(ICBs) 2
13.29% 2
WED/RLS. 2
NDCs, 2
"emplotted 2
self-description 2
"suggested 2
test" 2
(SCIT). 2
narratives 2
WED/RLS-related 2
day-, 2
bed-, 2
SCIT. 2
"relieving-movements" 2
(26/26) 2
threshold) 2
NDCs 2
opioids) 2
shine 2
short-interval 2
relations, 2
postmortem, 2
deficiency-dopamine 2
affective/anxiety, 2
anxiety/anxiety 2
depression/depressive 2
mood/mood 2
neuropsychiatric, 2
panic/panic 2
quality), 2
comorbid. 2
WED).The 2
crawling, 2
tingling, 2
aching 2
Neupro 2
(rotigotine) 2
Horizant 2
(gabapentin 2
enacarbil) 2
Disease) 2
([RLS], 2
[WED]) 2
CH-RLSQ11 2
"mimics" 2
5.21), 2
6.5%. 2
neutrophil-to-lymphocyte 2
dysaesthesia. 2
Disease), 2
self-diagnosed 2
self-assess 2
'Do 2
Morbidity: 2
Burden, 2
Aspects, 2
Sleep. 2
(LSC1), 2
bruch's 2
elasticum, 2
lymphedemas 2
B-mode 2
multifrequency 2
bioelectrical 2
(DSM-BIA) 2
lymphedemas, 2
6.6cM 2
LCS. 2
Consanguineous 2
electively 2
CCBE1, 2
c.398 2
p.L133P. 2
'cholestasis 2
hydrops; 2
hypothetized 2
(p=0.04) 2
(0.02), 2
(0.05). 2
Supplements 2
(0.01) 2
Oyestein 2
patients.1 2
(CLS) 2
lessens 2
consanguine 2
LCS, 2
(lymphoedema 2
(LCS1)), 2
lymphoedema. 2
[Aagenaes 2
syndrome--lymphedema 2
cholestasis]. 2
exelon 2
"SDZ 2
(Cochrane 2
(JSB) 2
0.27, 2
basis) 2
lower) 2
galantamin 2
Anticholinesterases 2
ScheduleCognitive 2
(ADAS-Cog), 2
anticholinesterase, 2
glutamergic 2
(THA) 2
nonparenchymal 2
Synapsins 2
monocular 2
IIa/b 2
T-synapsin 2
IIIa) 2
(SynIII) 2
(social 2
(memory 2
Vesicle 2
periactive 2
oncolytics 2
77,821 2
6731 2
$227.23 2
$80.11 2
$147.14 2
Adherence, 2
MPR, 2
co-pay 2
sulfonate-induced 2
(TNBS)-induced 2
4th, 2
7th, 2
(IL-1β 2
10.34% 2
3.57%. 2
intra-nuclear) 2
NF-κB-containing 2
TNBS-induced 2
IL-1β). 2
Summaries 2
authors's, 2
precautions. 2
(ENL) 2
1954 2
ENL. 2
banned, 2
(Thalomid, 2
Celgene). 2
catecholamine-synthesis 2
AAAD 2
PNMT) 2
β-hydroxylase 2
phenyl-ethanolamine-N-methyltransferase 2
cathecolamine-synthesizing 2
(57.3%, 2
(47.0%, 2
Phenylethanolamine 2
cage) 2
(DBH), 2
E- 2
(LL) 2
SCG 2
E18. 2
enkephalins 2
defensin. 2
unfolding. 2
unfolds 2
C3-C31. 2
C5-C20 2
C10-C30. 2
θ-defensins. 2
α-defensins. 2
gorilla. 2
salamanders. 2
fudingensis. 2
disulfides 2
antimicrobial, 2
88.2% 2
(UVs) 2
UVs 2
(8665_8667delGGA) 2
(61.1%) 2
history.Candidates 2
1041_1043delAGCinsT 2
3746insA 2
(5804_5807delTTAA) 2
5.1%). 2
rs1466785 2
NEIL2 2
(endonuclease 2
VIII-like 2
(1.03-1.16), 2
10(-3)) 2
rs2304277 2
(8-guanine 2
glycosylase) 2
1.03-1.21, 2
10(-3)). 2
(OPOI), 2
T-test 2
(p=0.18). 2
sub-genotypes 2
het-norm/low 2
C61G 2
4153delA. 2
(LGRs) 2
13-19 2
LGR 2
Hofmann 2
(Max 2
Delbrück 2
Director 2
23andMe 2
customers 2
185delAG 2
6174delT 2
Non-carriers 2
consequences-especially 2
childbearing-in 2
e-mail. 2
qualitative, 2
participants-whether 2
diagnosis-and 2
"staying 2
alive" 2
goal; 2
childless 2
interviews. 2
childbearing, 2
1114 2
(D17S588, 2
D17S806, 2
D17S902, 2
D17S1325, 2
D17S855, 2
D17S1328, 2
D17S800, 2
D17S250) 2
(D13S220, 2
D13S267, 2
D13S171, 2
D13S1701, 2
D13S1698, 2
D13S260, 2
D13S290, 2
D13S1246) 2
DMLE 2
Istria, 2
Friuli 2
Venezia 2
Giulia 2
pre-screening 2
SNaPshot® 2
>G 2
(BRCA)-1 2
(AJ) 2
(185delAG, 2
5382InsC) 2
(6174delT). 2
Non-founder 2
Ashkenazim 2
4.4-88.9%). 2
Ashkenazim. 2
4-28% 2
(LGRs), 2
(4.61%) 2
(5.10%) 2
6.67% 2
8.77 2
57) 2
4.76% 2
LEAST 2
RISK 2
WERE 2
ENROLLED: 2
BRCA1/BRCA2-associated 2
PBC; 2
CBC; 2
5-year, 2
monogenically 2
1999) 2
9052 2
2317 2
1041 2
7171 2
(BCCR1; 2
(BCCR2; 2
10(-17)). 2
BReast 2
CAncer 2
wonder 2
postings 2
HBOC 2
parenting 2
(BRCA 2
(76 2
67.5 2
susceptibility: 2
biases; 2
(KOHBRA) 2
(early-onset 2
Breast/Ovarian 2
(9.1 2
16.0 2
gonadotropins 2
BRCA-untested 2
(2.9%; 2
mutation- 2
17.7] 2
14.2]; 2
353.4; 2
surgeries; 2
(DCIS), 2
oophorectomy. 2
[ex9-12del]), 2
ancestry-informed 2
BRCA-testing 2
First- 2
Carriers. 2
Manchester, 2
censored 2
31/12/2010; 2
oophorectomy; 2
16.67; 2
5.41 2
38.89). 2
50.00; 2
26.62 2
85.50). 2
1613 2
2.03). 2
1.88). 2
byproducts. 2
HepaRG) 2
Orbitrap-based 2
resolution-tandem 2
N-demethylation, 2
N-oxidation, 2
sulfation. 2
UDP-glucuronyltransferase 2
UGT1A8, 2
UGT1A9, 2
UGT1A10, 2
UGT2B4, 2
UGT2B7, 2
UGT2B15, 2
UGT2B17 2
HepaRG 2
(crocodile) 2
desomorphine. 2
OPIOID 2
SUBSTANCE 2
injective 2
opioids: 2
("Krokodile") 2
addictive, 2
OST 2
injectors, 2
psychotropic-narcotic 2
ince 2
then. 2
opioid-analogon 2
ingredients. 2
opioid-analogue 2
oneself. 2
Sofosbuvir/Ledipasvir 2
Cost-Effective 2
Affordable 2
Sofosbuvir/ledipasvir 2
(IS). 2
2100 2
400/90 2
(Sovaldi) 2
unforeseen, 2
(ledipasvir/sofosbuvir; 2
Harvoni(®)) 2
(sofosbuvir/ledipasvir). 2
durations, 2
Gilead's 2
(sofosbuvir/ledipasvir), 2
AbbVie's 2
Viekira 2
Pak 2
(paritaprevir/ritonavir/ombitasvir 2
dasabuvir), 2
Janssen's 2
Olysio 2
(simeprevir) 2
Mff. 2
DLP1. 2
Pex11pβ, 2
MFF, 2
Fis1, 2
abolishes. 2
Fis1; 2
Mediterranean, 2
sub-tropical 2
Punjab. 2
Punjab 2
2.75 2
cent, 2
haematocrit 2
[Manifestation 2
vivax-infection 2
(Malaria 2
tertiana), 2
malarious 2
homeland. 2
Chloroquin, 2
Primaquin 2
extraerythrocyte 2
developped. 2
minus. 2
newborn]. 2
NAD-diaphorase, 2
glucuronyl 2
kern-icterus 2
mediterranian 2
(51Cr-labelled) 2
Durham: 2
713, 2
238. 2
G6PD-deficiency 2
(NADP), 2
deamino-NADP, 2
Glucose-6-phosphate-dehydrogenase 2
is/has 2
0.95% 2
China-Myanmar 2
Kachin 2
Viangchan 2
(5.0%) 2
563 2
(Papio 2
hamadryas). 2
polymorphic; 2
Sardinia, 2
Sardinia 2
deficiency; 2
Amyloid-like 2
RT-QuIC 2
PrP) 2
seeding. 2
(CJD), 2
Gerstmann-Sträussler-Scheinker 2
parahippocampal 2
Gerstmann-Sträussler 2
(D178N) 2
(cis-129M). 2
challenge: 2
(sFI) 2
sFI 2
L-histidine-decarboxylase 2
aripiprazole 2
tics, 2
tic-like 2
Prepulse 2
DA-regulated 2
D2/D3 2
HA-DA 2
trichotillomania 2
SLITRK1, 2
(HDC) 2
(Slit 2
3'-untranslated-region 2
Ex527 2
XAV939. 2
HGSOCs 2
carboplatin/paclitaxel, 2
RAD51C 2
Artemis 2
PDX. 2
(HRD) 2
Polymerase. 2
"locks" 2
Poly-ADP-Ribose 2
Astrocytoma. 2
(pHGA) 2
radiosensitizers 2
pHGA. 2
pHGAs 2
Ki67). 2
(γH2AX 2
"PARP-trapping" 2
BMN-673. 2
(PARP1/2) 2
(AZD-2281), 2
Polymerase1 2
(olaparib, 2
(Joint 2
clustering): 2
widths. 2
JAMM's 2
streamlines 2
selecting, 2
ENCODE, 2
ROADMAP, 2
BLUEPRINT 2
DEEP. 2
closed-loop 2
non-cranium-opening 2
motor-related 2
diaschisis 2
Neurophysiologic 2
MRgHIFU-mediated 2
hyper-excitable 2
semiovale, 2
peduncle; 2
tract; 2
olive. 2
38%; 2
(ET). 2
29.9 2
CTT. 2
HF32 2
HF16 2
Saxony 2
feces, 2
faecalis. 2
Enterococci 2
pediatrician. 2
holotoxin, 2
(BoNT/B) 2
150-kDa 2
canned 2
officials 2
cannery 2
sauce 2
MPS, 2
Pain, 2
BTXA 2
Increasingly, 2
paralyzing 2
controversies, 2
Systems. 2
mankind. 2
ECTRIMS 2
Congress, 2
fore 2
(GdE) 2
ibudilast, 2
subspecializing 2
acetate; 2
fumarate); 2
mitoxantrone). 2
key-role 2
sunitinib-refractory 2
(1/1) 2
doxorubicin-refractory 2
(ClinicalTrials.gov: 2
NCT01900743). 2
Key-eligibility 2
≥18, 2
(NCI-CTC 2
V4.0); 2
randomization; 2
PFS-Rates, 2
pts. 2
(TRIAL 2
NUMBER: 2
N°: 2
2012-005743-24, 2
15(th) 2
SARC024, 2
(NCT02048371). 2
ridaforolimus 2
diphenylurea 2
DMF, 2
DEFINE 2
CONFIRM 2
(DMF), 2
(DEFINE, 2
NCT00420212; 2
CONFIRM, 2
NCT00451451), 2
(FREEDOMS, 2
NCT00289978; 2
NCT00355134), 2
NCT00134563; 2
NCT00751881), 2
corticosteroids), 2
Argentina, 2
TOWER) 2
erythropoietin-mimetic 2
(EMP) 2
21-amino 2
electrophoretic, 2
rhEpo 2
anti-anaemia 2
phenol. 2
EMP-based 2
suppression/enhancement, 2
(LOD, 2
epoetin-treated 2
event), 2
(Omontys) 2
68.1% 2
nondialysis, 2
agent-free 2
darbepoetin, 2
PEARL 2
0.36) 2
[PEARL 2
1], 2
[EMERALD 2
0.1-5 2
[(14)C]-peginesatide, 2
(QWBA) 2
[(14)C]-peginesatide. 2
mono-PEG. 2
excreted. 2
[(14)C]-peginesatide-derived 2
marrow), 2
Eteplirsen: 2
PROMOVI 2
skipping: 2
(30/50mg/kg) 2
6-Minute 2
Walk 2
(PFT). 2
151m 2
PFT 2
amenable. 2
3:3:3:1 2
Epigallocatechin-3-gallate 2
(product 2
KLRK1 2
γ-chain 2
(γc) 2
(IL-15Rβ) 2
Jakpot! 2
(Jaks). 2
intra-cellularly 2
(Jak3) 2
gamma-chain 2
(gammac), 2
IL-9, 2
IL-21. 2
8-mg 2
0·05) 2
PASI-75. 2
(Apoquel(®) 2
pro-allergic 2
pruritogenic 2
owner 2
kinase/signal 2
(JAK-STAT) 2
re-randomized 2
Hemoglobinopathies 2
(8.49%) 2
viscosity. 2
(anti-CD38) 2
(anti-CS1) 2
IgG1-κ 2
co-migration 2
(antibody-dependent 2
cytotoxicity) 2
cytotoxicity). 2
nonplasma 2
daratumumab's 2
CopyrightInformation>©2016 2
Research.</C 2
(anti-CD38 2
elotuzumab) 2
Arry-520. 2
SLAMF-7 2
CD38-targeted 2
(cycles 2
2-14). 2
cutoff, 2
IgGκ 2
98.2% 2
SMIM1. 2
EMBO. 2
glomerulopathies, 2
(RCSC). 2
(NOXes) 2
superoxide. 2
NOXes 2
DUOXs 2
(Oryctolagus 2
cuniculus) 2
Glires 2
it: 2
assymmetrical 2
hemes) 2
sites); 2
DUOX 2
ancestral-type 2
story: 2
reassured 2
estrogens/bazedoxifene 2
mammographic 2
Degraders 2
(SERDs), 2
ERE 2
Y537S, 2
HBD-ESR1 2
8p11-p12 2
WHSC1L1, 2
Invisible 2
Mutations: 2
absent; 2
(-0.6 2
[-4.6 2
SD]). 2
[-5.1 2
SD]), 2
ZNF335, 2
c.1399T>C 2
(p.C467R) 2
c.1505A>G 2
(p.Y502C), 2
(pembrolizumab 2
(atezolizumab, 2
durvalumab, 2
successes. 2
tumor-driven 2
immune-competent 2
avelumab. 2
Mesothelioma 2
Effusions 2
PD-L1+ 2
CD3-positive 2
Non-Muscle 2
Avelumab, 2
Calmette-Guerin 2
MB49(luc) 2
depletions. 2
durvalumab 2
(ZIKV), 2
forest, 2
time-spatial 2
Pan 2
Notifiable 2
declaration 2
Providers. 2
1947. 2
continental 2
Caledonia 2
(GEO: 2
(Strain: 2
hNPCs. 2
CMV-infected 2
Clinicians. 2
calcifications; 2
mottling; 2
Phenomenological 2
modern, 2
(MAC-ELISA)* 2
MAC-ELISA 2
23,487 2
PRDH 2
GBS; 2
5,582 2
Rico's 2
municipalities. 2
9,343 2
system-negative 2
Preapproval 2
low/very 2
(SBA) 2
SBA 2
[hSBA] 2
44/76-SL, 2
5/99 2
NZ98/254, 2
antigens; 2
(fHbp) 2
(PorA) 2
(OMV), 2
1-month. 2
(MATS). 2
63.5%-98.6%) 2
44.6%, 2
(78.4%), 2
(52.7%), 2
(0.7%). 2
86.4%, 2
fHbp. 2
(NadA).Of 2
sub/variant 2
PorA). 2
biogroup 2
(Oligomeric 2
adhesin) 2
adhesins, 2
YadA 2
invasin 2
integrins: 2
invasin. 2
septicemia. 2
NadA(24-210) 2
ARF6-regulated 2
MHC-I. 2
permeated 2
impermeable 2
FITC-GA 2
rNadA, 2
Rab11, 2
(TfR). 2
FITC-GA, 2
Rab11-rNadA 2
Rab11-TfR 2
ARF6-dependent, 2
Hsp90-regulated 2
meningoccoccal 2
NadA(Δ351-405,) 2
anti-hsp70 2
polymixin 2
GNA 2
(Genome-derived 2
Antigen) 2
1870 2
GNA1994 2
(NadA, 2
GNA2132 2
serogroup, 2
NadR, 2
catabolite 2
4-HPA, 2
22-24 2
mini-EPSC 2
(pR5 2
[1,2-(13)C]acetate. 2
Hippocampus 2
Calignon 2
deafferentation, 2
(AChE)-positive 2
Gallyas-positive 2
Alz50-positive 2
ISF 2
(AD)--widespread 2
tangles--have 2
tau: 2
tau-1 2
(Ser199/Ser202) 2
Alzheimers' 2
Aggregates 2
3xTg-AD 2
Igs 2
axon. 2
MAPs 2
~three 2
([PHF) 2
PHF/SF. 2
Manner. 2
neurohypophysial 2
(OXT) 2
OXTR-expressing 2
oxytocin. 2
'love 2
hormone' 2
parent-offspring 2
sharing. 2
food-sharing 2
limp, 2
"Barlow's 2
(14th 2
centuries) 2
voyagers. 2
1747, 2
Lind, 2
oranges 2
lemons 2
lemon 2
voyagers, 2
sea. 2
1883. 2
1907 2
Frolich 2
1914, 2
Alfred 2
pasteurization 2
income/materially 2
contorted 2
(corkscrew) 2
pseudoparalysis, 2
Haemorrhage 2
uncomfortable. 2
extravasation. 2
gingivitis, 2
Bone: 2
gingivia, 2
discolors, 2
heal. 2
biocompatibility 2
bleeding--a 2
plenty. 2
overemphasised. 2
deficiency" 2
"scurvy 2
Scott's 2
explorers. 2
nondiscriminatory 2
middle-age 2
treatable, 2
crowd-drawing 2
money-making 2
sideshow 2
dog-men, 2
hair-men, 2
werewolves. 2
antiverted 2
trapezoid 2
decidious 2
deciduous 2
anodontia. 2
TRPS1 2
TRPS1. 2
Trps1 2
follicle, 2
Entity. 2
q22) 2
arms; 2
inv(8)(q12q22). 2
q23-q24 2
8q23:46,XX, 2
rea(8)(8pter-->8q13::8q23.2-->8q24.1::8q13-->8q23.1::8q24.1-->8qter). 2
[Ambras 2
hypertrichosis]. 2
SJS. 2
2/1,000,000 2
"high" 2
Trimethoprim-sulfamethoxazole 2
sulfonamide-antibiotics, 2
aminopenicillins, 2
cephalosporins, 2
NSAID's 2
oxicam-type. 2
staphyloccocal 2
(SSSS). 2
SCORTEN, 2
1-5%, 2
25-35%; 2
pathogeneses 2
(Stevens-Johnson 2
syndrome/toxic 2
(SJS/TEN), 2
AGEP, 2
AGEP 2
TEN, 2
antigen-B 2
(AGEP) 2
(DRESS). 2
outnumbered 2
majorly 2
(HSS)), 2
B*1511 2
(SCARs) 2
SCARs. 2
DRESS. 2
2.1%, 2
sloughing 2
pustulosis. 2
HEV 2
(SCAR's) 2
(LTG), 2
oxicam 2
levofloxacin. 2
antihyperuricaemic 2
(DRESS), 2
HLA-B*58:01 2
antiparkinson 2
(possibly 2
deterioration) 2
Depot) 2
akinesia. 2
(lactic-co-glycolic 2
dermatology]. 2
nodularis, 2
aphthosis 2
Therapeutical 2
stressed. 2
2011/12. 2
20.3% 2
Pharmacoepidemiology 2
dispensed. 2
inhibitiory 2
CCK- 2
p-P38, 2
cleaved-Caspase-3, 2
(INF)-α 2
RAUs, 2
(TNF-alpha). 2
thalidomide's 2
sedative-hypnotic 2
activity? 2
cachexia, 2
labelling/product 2
Gradually, 2
leprous 2
infiltrations, 2
aphtosis), 2
(relapsed/refractory 2
Diosbulbin 2
hepatotoxicities. 2
tetrahydrofuran 2
cis-enedial 2
DIOB-treated 2
endosulfan. 2
α-endosulfan 2
isomer. 2
(4'-OH-Dic) 2
Phase-II 2
2.64 2
hepato-toxic 2
(TGZ) 2
methide. 2
TGZ, 2
troglitazone- 2
S-( 2
N-acetyl)cysteine 2
methide 2
ciglitazone 2
methide, 2
leukocyte-generated 2
metabolite-mediated 2
S-(1,2-dichlorovinyl)-L-cysteine 2
Steven's 2
agranulocytosis. 2
trappers, 2
trimethoprim 2
("acute 2
akinesia" 2
=48 2
akinesia; 2
BEWARE: 2
inescapable, 2
BEWARE, 2
VU 2
(BEWARE) 2
WRA 2
mono-disciplinary 2
NCT02054845. 2
Wearing-Off 2
(P<O.01 2
(DCI). 2
L-dopa/DCI, 2
aggravated, 2
hyperreflexia; 2
0.006); 2
(bladder-filling) 2
states) 2
shorten, 2
pain/aching, 2
cloudy/slowed 2
thinking) 2
depressive, 2
(Patient 2
Diary 2
"Off" 2
0.0038). 2
dopamine-mediated 2
(dyskinesia: 2
discoloration. 2
down-adjustment, 2
"overall 2
score" 2
(tid) 2
"wearing-off 2
82958 2
Isolated, 2
standard-release 2
100/25 2
(wearing-OFF 2
Levodopa-treated 2
('wearing-off') 2
('on-off'). 2
DRD 2
long-duration 2
levodopa-carbidopa, 2
IU/l, 2
[Benefit 2
L-DOPA-without-DCI 2
(decarboxylase 2
levodopa(without 2
levodopa; 2
dopamine.. 2
Pruisner. 2
ELNPM 2
prionoids, 2
prionoids 2
prions. 2
overview, 2
prionoid 2
conformer. 2
cooption 2
>2000 2
Rotavirus 2
PR-39 2
RV-infected 2
STZ‑treated 2
autophagy-modulating 2
(P=0.01). 2
Allotypes 2
Differs 2
hormone-associated 2
(UK) 2
sCJD. 2
iCJD 2
types). 2
sixty-four 2
Definite 2
tau), 2
gCJD 2
(CJD). 2
(EU) 2
nipple, 2
(athelia), 2
(amastia) 2
Coling 2
competition-style 2
protein-named 2
BioCreAtIvE, 2
Biocuration 2
contributions, 2
task); 2
(Molecular 2
IntAct 2
BioGRID 2
BioCreAtIvE: 2
countries). 2
text) 2
4536 2
COR-1, 2
COR-II, 2
COR-BMOD 2
COR-DM. 2
11-22 2
(5-9 2
Contrave. 2
(COR-I) 2
Naltrexone/bupropion: 2
Contrave(R); 2
SR/bupropion 2
Adults. 2
kg/m² 2
synergies 2
extended-release/bupropion 2
ER; 2
Contrave(®), 2
Mysimba(™)) 2
overweight) 2
32/360 2
(11.9 2
6A3 2
(SLC6A3; 2
DAT1) 2
5p15.33; 2
q, 2
ADHD: 2
10-repeat 2
[(99m)Tc]TRODAT-1 2
(DAT 2
classroom 2
(Biston 2
betularia): 2
Revolution, 2
typica 2
(carbonaria) 2
pollution. 2
coarsely 2
carbonaria-typica 2
1819, 2
microevolutionary 2
Lines 2
(HD; 2
143100), 2
Alter 2
dynein, 2
p150Glued 2
huntington 2
mHTT 2
HTT) 2
(polyQ-HTT). 2
devastating, 2
visuomotor 2
choraetic 2
characteropathy. 2
UHDRS 2
(MUHDRS) 2
-0.67; 2
-0.95; 2
summarised: 2
-0.91) 2
neuropsychological, 2
42-73% 2
980 2
(JPH3) 2
(HDL2). 2
Hyperintense 2
(CbC) 2
IQ. 2
AVI-4225. 2
AVI-4225 2
haploinsufficiencies 2
<CopyrightInformation 2
Uchl1) 2
Uchl1), 2
synthenic 2
UCHL1/PARK5. 2
Uch1 2
Nurr1-dependent 2
SINEUPs, 2
UP-regulators. 2
PPP1R12A 2
TRICHOTILLOMANIA 2
(HAIR 2
PULLING 2
Neurocognitive 2
Correlational 2
(HPD; 2
trichotillomania) 2
cAb29 2
96-h 2
45.2 2
Present-day 2
'for 2
systems' 2
politically 2
scientifically, 2
'therapies' 2
PAPER: 2
Raxibacumab. 2
HGS 2
stockpiles 2
(Cytoplasmic 2
Binding) 2
CPEB1 2
CPEB2, 2
(CPEB), 2
polyadenylation-induced 2
apple. 2
AtSIZ1 2
MdSIZ1, 2
apple, 2
AtSIZ1. 2
(ABA). 2
siz1-2 2
MdSIZ1-mediated 2
(E3s) 2
(ULPs) 2
ULP-like 2
'fine-tuning' 2
attachment/removal 2
Reveal 2
(Small 2
substrate-linked 2
pull-downs. 2
SUMO2, 2
CKB, 2
ATXN10, 2
BTF3, 2
HABP4, 2
BZW1, 2
co-transfecting 2
mori. 2
SUMOylation-deficient 2
congression 2
lamblia, 2
nitrosylation, 2
Thr76. 2
SUMO-2/3. 2
GRO-seq 2
(mGluRs) 2
SUMO-2 2
nucleolin-SUMO 2
sinensis, 2
EsUbc9, 2
II-1, 2
II-2, 2
III-2, 2
Spalt-like 2
MOdifier 2
SUMO-modified 2
Anti-PfSUMO 2
anti-PfSUMO 2
proliferation-induced 2
Decompacted 2
Recompaction 2
shelterin-mediated 2
astrocytosis, 2
crenezumab, 2
dyshomeostasis 2
Restores 2
2016). 2
(7.6% 2
CBA, 2
(93% 2
exon-targeted, 2
custom-designed, 2
(0.55%). 2
(10-93%). 2
(DD)/mental 2
ID/DD. 2
(P070/P036) 2
microdeletions/microduplications 2
(P245-A2) 2
(P106) 2
203). 2
ID. 2
1p36.33, 2
9pter. 2
P245-A2 2
P070/P036-E1 2
PDGFRA, 2
non-informative 2
17p13 2
fluorescence-in 2
situ-hybridization 2
RUNX1. 2
RUNX1-USP42 2
Array-based 2
GSCL, 2
TBX1 2
VCF/DiGeorge 2
Array-CGH 2
(20q(-)) 2
20q12 2
signal>7.16% 2
malignancies]. 2
7q31) 2
SpectrumOrange 2
4.51% 2
5.71% 2
490 2
5.68% 2
10.29% 2
7q21a222 2
7q31-35(ten 2
interphases 2
P=0.025). 2
del(7)(q22) 2
7q+ 2
dup(7q), 2
7p21 2
63:1282-1293]. 2
TWIST. 2
tMDS 2
SKY's 2
G-banding, 2
t-MDS 2
cytogenetics(CC) 2
22q11.2]. 2
(19th 2
pregnancy-36 2
truncus 2
(third 2
degree) 2
fluorescence-in-situ-hybridization 2
(5/5), 2
(2/20). 2
DGS/VCFS 2
Sorted 2
MRD 2
FACS/FISH/BUdR, 2
Angel-man 2
satellited 2
mitose 2
18.4% 2
non-clonal 2
80.5-97.5% 2
83.5-92.0% 2
85%-95% 2
75%-80% 2
der(17) 2
(p+), 2
"half-cryptic" 2
translocation). 2
3q;17p 2
G-negative 2
"full-cryptic" 2
8q;17p 2
Requests 2
D22S. 2
D22S, 2
DiGeorge, 2
velocardiofacial, 2
del(5q). 2
716 2
(n=637) 2
(n=637), 2
(5.96%). 2
t(6;22) 2
(q21; 2
t(9; 2
(q13; 2
p13) 2
t(3;5) 2
(?; 2
?). 2
(-7) 2
(IST) 2
(rhuG-CSF) 2
(13.6%) 2
(5q33) 2
EGR1/ 2
(5q31) 2
D7S522 2
D20S108/CSP8 2
(20q12/CSP8) 2
20.9% 2
(40/344), 2
45,XX,-21/46,XX,+r(21) 2
21q21.1. 2
18q23-qter. 2
[r(21)], 2
reinterpreted 2
45,XX,-18,-21,+der(18) 2
(q23;q21.1)/46,XX,-18,-21,+der(18) 2
(q23;q21.1), 2
+r(21) 2
(p13q21.1) 2
5p- 2
NFCs 2
cell-by-cell 2
FNRBCs, 2
5pter, 2
5qter, 2
18pter, 2
(SNP-Array) 2
Nsp/Sty 2
additionally. 2
(1-5). 2
18(n 2
15q12 2
GABRB3 2
salt-wasting) 2
Tubulopathy, 2
6-20y) 2
non-ambulant. 2
KCNJ10/Kir4.1 2
(p.R65C, 2
p.F75L 2
p.V259fs259X) 2
p.R297C, 2
KCNJ10-expressing 2
inwardly-rectified 2
V259X. 2
b-wave 2
Inactivated 2
(IPV), 2
Jonas 2
Salk 2
wild-like 2
hypothesis" 2
Exendin-4 2
V/PI 2
pre-conditioning 2
Ex-4 2
nonribosomal 2
NRPs 2
basidiomycete 2
Granta 2
CD105, 2
CD31, 2
μL/mL 2
µL/mL 2
zearalenone 2
Granulosa-lutein 2
(Mcl-1) 2
protein-xL, 2
Flavopiridol 2
liposome, 2
DOPC, 2
(BMDC). 2
CD86/CD80 2
DOTAP. 2
(DLN) 2
(antigen 2
DLN 2
DOTAP/E7-induced 2
ED50 2
(ofloxacin 2
netilmicin, 2
hypoxia-ischemia. 2
TUNEL-positive 2
destroyed. 2
4.2-8.1%) 2
3.7-6.9%) 2
5-12%). 2
'aged' 2
FITC-labelled 2
(bisfunctional 2
(Amersham, 2
Chalfont, 2
720-degree 2
(EPC) 2
KDRCD133, 2
CD34CD133, 2
CD34KDR) 2
normoalbuminuria 2
microg/min, 2
20-200 2
microg/min), 2
microg/min). 2
Aortas 2
macroautoradiography, 2
(T1/2, 2
9.3-fold 2
nonlesion 2
lesion-to-blood 2
3.0+/-0.37. 2
99mTc-HYNIC-rh-Annexin-V. 2
Abscess 2
annexin-V 2
(APBA-GNPs) 2
silver-enhanced 2
EC-50 2
WS-CM 2
TPM, 2
Fluorescence-activated 2
7-aminoactinomycin 2
(7-AAD) 2
(NASH) 2
8weeks. 2
fat-laden 2
Released 2
diacetate. 2
anti-DR5 2
(necrotic 2
V-Oregon 2
scraping, 2
R1: 2
R2: 2
R3: 2
positive); 2
R4: 2
HEPES-buffer 2
(arrowhead) 2
(arrow) 2
(B). 2
postapoptotic 2
C225, 2
%ID/g; 2
2.51 2
%ID/g), 2
(55.6%), 2
(Beckman 2
V(+)/PI(-) 2
V(+)/PI(+) 2
V(-)/PI(+) 2
SPECT/CT 2
uptakes 2
2.41 2
tightly. 2
Hesperetin, 2
antihypertensive, 2
(IC50, 2
(FADD), 2
Pharmacologie 2
Thérapeutique. 2
fractions: 2
(nonapoptotic) 2
(apoptotic). 2
MACS. 2
ICSI 2
sperm-oocyte 2
non-cytochalasin-D-treated 2
IGFBP-1 2
vitro]. 2
Technetium-99m 2
well-choreographed 2
(99m)Tc-HYNIC- 2
10-180 2
(99m)Tc-annexin 2
Thymus 2
sorter. 2
Fas-defective 2
(lpr/lpr 2
(anti-Fas) 2
r=0.78 2
anti-Fas, 2
anti-Fas 2
biotin-conjugated 2
Des-gamma-carboxy 2
V-FITC/PI 2
(HELP) 2
resins, 2
niacin, 2
absorption-inhibiting 2
(ezetimibe). 2
Heparin-induced 2
thin-cap 2
fibroatheroma 2
%NC 2
(S80, 2
(E10/S10, 2
postocclusive 2
LDF) 2
(mmol 2
E10/S10 2
S80 2
(lipid-lowering 2
pravastatin. 2
(+/-colestyramine/niacin) 2
Lipid-Coronary 2
[L-CAD] 2
PD-1-directed 2
(9.6%) 2
T-cell-directed 2
unleashing 2
Immune-Checkpoint 2
PD-1-PD-1 2
PD-L 2
(PD-1)/PD-1 2
teacher. 2
SKP2, 2
SKP2 2
(kip1) 2
immuno-oncology 2
nonsmall-cell 2
anti‑cytotoxic 2
T‑lymphocyte 2
antigen‑4 2
(CTLA‑4) 2
anti‑programmed 2
death‑1 2
(PD‑1), 2
PD-1. 2
Splenocytes 2
Blockading 2
(PD-Ls, 2
degradations 2
(VEGFR)-tyrosine 2
CTLA-targeted 2
1(PD-L1) 2
TT. 2
16.1 2
smad 2
Nodal-related 2
FAST-1 2
Window 2
Celecoxib 2
(hERG). 2
(Europe; 2
(SCOUT) 2
0.72). 2
0.70) 2
EACA. 2
0.99).Aprotinin 2
needed-to-treat 2
bias.When 2
1.11), 2
1.54) 2
review.When 2
either, 2
(2008). 2
Aprotinin 2
etoricoxib, 2
2013: 2
manifestations) 2
159) 2
222) 2
(14/82) 2
(15/77) 2
1.69). 2
(5/112) 2
(7/110) 2
2.14). 2
2.07). 2
Rofecoxib, 2
cyclo-oxygenase 2
Migalastat: 2
(GLA) 2
(lyso-Gb3). 2
(GR181413A) 2
binds, 2
stabilizes, 2
GL-3. 2
QOD) 2
Agalsidase 2
124), 2
mg-2000 2
(AUC∞ 2
1129-72 2
h/mL, 2
200.5-13 2
TQT 2
supra-therapeutic 2
adenocarcinomas; 2
P=0.006). 2
Lieberkühn. 2
cell-related 2
(crypt 2
(HSV-1 2
Elizabeth 2
(QECH), 2
Blantyre, 2
VZV, 2
rhinovirus 2
(sero)types 2
5'-NCR 2
HRVs 2
(EVs), 2
false-detection 2
spectrophotometrically. 2
EV-positive 2
HRV-A1b, 2
HRV-B14, 2
HRV-Crpat18 2
10-1,000 2
rhinoviruses; 2
HRV-positive 2
(HRV-A: 2
HRV-B: 2
HRV-C: 2
(HPeV) 2
PCR-positive 2
Serous 2
[Sensitive 2
viruses]. 2
IgM-antibody 2
MACRIA 2
(M-antibody 2
radioimmunoassay) 2
[Antibodies 2
region]. 2
stopping-off 2
towns 2
Alphaviruses, 2
Bunyaviridae) 2
(HAI). 2
HAI-specific 2
centrifuging 2
(12.5%; 2
Alphavirus; 2
Bunyaviridae). 2
(Ampolla, 2
Jaime 2
Montells), 2
WNV-related 2
Peninsula 2
SPORADIC 2
OCCURRENCE 2
VIRUS 2
TYPES 2
ASSOCIATED 2
ASEPTIC 2
MENINGITIS 2
ONTARIO. 2
(IL)-1â, 2
(IFN)-ã, 2
(TNF)-á, 2
protein-1â 2
(MIP-1â), 2
IFN-ã 2
meningitis.<CopyrightInformation>© 2
(E13) 2
Fukui 2
Prefecture. 2
111/mm3. 2
[Epidemic 2
[Outbreak 2
Misiones 2
province]. 2
(B26.1), 2
(A85.0), 2
(A84.1) 2
(A87.9) 2
Cyprus, 2
2000-2002. 2
Cyprus. 2
Peptide-1 2
decade-long 2
exenatide 2
lixisenatide. 2
Diabetes/Metabolism 2
deteriorates; 2
Danish, 2
sirup 2
gliclazide-induced 2
meglitinide, 2
23.1% 2
sulfonylureas). 2
received: 2
non-diabetics, 2
toothbrushing 2
peptidase-IV 2
(DPP-4), 2
HbA1c-lowering 2
diabetes-sulfonylureas, 2
Sulfonylureas, 2
meglitinides, 2
secretagogues, 2
a-glucosidase 2
Preeclampsia. 2
Lc3Cer 2
prenylation-dependent 2
cardiologists, 2
expect. 2
abstracted. 2
myofibre 2
infiltrate. 2
non-necrotic 2
LifeLink, 2
sub-cohorts 2
database). 2
1.01) 2
1.01), 2
"overactivity" 2
(lipids, 2
2760 2
-0.04 2
(all-cause 2
-0.73 2
-0.95 2
-0.52), 2
-2.32 2
5.28).The 2
(well 2
gained). 2
prices, 2
PDCs. 2
Plausible 2
JUPITER 2
(Justification 2
Prevention) 2
PPARalpha/PPARgamma 2
LXRalpha 2
NO-pravastatin 2
21.9 2
carcinoma-in 2
DOES 2
ADD?: 2
KPSC's 2
(myalgia) 2
non-fatty 2
(HD5 2
HD6), 2
difficile, 2
evades 2
(012, 2
014/020, 2
018, 2
078). 2
killing; 2
faecalis; 2
defensins. 2
32-residue 2
host-defense 2
HD5ox, 2
HD5ox 2
fluorophore-HD5ox 2
(LOS), 2
agalactiae 2
(simvastatin) 2
(pravastatin) 2
(NLA) 2
fiscal 2
FY00 2
VHA 2
Reimbursement 2
spline 2
Desynchronization 2
Checkpoint. 2
microtubules-kinetochore 2
attachment(s). 2
desynchronization 2
paclitaxel) 2
MPS1. 2
cytofluorometric 2
videomicroscopy 2
synchronization-desynchronization 2
Zfp207-depleted 2
Induces 2
Lck. 2
T409 2
(PML 2
pro-metaphase 2
nocodazole-triggered 2
POLH, 2
KIF23, 2
RAD54L, 2
wildly 2
2015-April 2
unborn 2
Settings 2
collaborated 2
Providers 2
3I 2
Columbia, 2
1-July 2
transmission; 2
(1,6). 2
nonpurulent 2
travel-associated 2
notifiable 2
Globalizing 2
Malformations, 2
Ebola, 2
Pesquisa 2
(microcephaly) 2
(Guillain-Barré 2
declares 2
vertical, 2
Hygiene 2
2013-2014. 2
syndrome--case 2
Polynesia, 2
co-epidemics 2
Indonesia 2
seroconvert 2
nasopharygeal 2
hydration, 2
antipyretics 2
(Zika 2
2015). 2
region), 2
count), 2
(oseltamivir). 2
zanamivir 2
(Relenza) 2
peramivir; 2
Province. 2
unconsciousness 2
DIAGNOSIS 2
neurostimulants. 2
(OTC), 2
(LTD), 2
neurostimulants 2
(OP; 2
Tamiflu) 2
Yodo 2
prefectures, 2
2007/8. 2
2-58 2
dabbling 2
(A/H1N1) 2
Warsaw 2
2009]. 2
(Female-64, 2
Male-45, 2
17-71 2
(TaqMan 2
A/H1N1) 2
-ARDS 2
(CVVHD) 2
nasogastrically 2
nasoenterically 2
ng•hour/ml, 2
ml/minute 2
2003-2004 2
2004-2005 2
3351 2
1485 2
(temperature, 2
reisolation 2
A-positive 2
Salt 2
2009-H1N1 2
2006-H5N1 2
2009-H1N1-NA 2
2006-H5N1-NA 2
H1N1-NA 2
Try347 2
H5N1-NA 2
H1N1-NA. 2
pandemic: 2
patient’s 2
(GS4104), 2
GS4071, 2
ferrets. 2
(CTL) 2
Subpopulations 2
T-helper, 2
T-cytotoxic 2
(10.8% 2
R292K 2
(NA), 2
Likert 2
'flu 2
influenzavirus 2
nonimmunized 2
percent; 2
Virginia, 2
(12.1 2
(AD)-characterizing 2
beta-peptide. 2
fibrillogenic 2
42-lowering 2
(CTFs) 2
non-raft 2
ErbB4, 2
constituents: 2
gamma-secretases. 2
cholesterol- 2
sphingolipid-rich 2
rafts, 2
TGN/endosome-resident 2
gradients, 2
co-residence 2
protein-lipid 2
immunoisolation 2
PS1- 2
6-positive 2
Lubrol 2
WX 2
-2), 2
-1b). 2
CRB2, 2
gamma-cleavage. 2
Pen2, 2
NCT-independent 2
multiproteic 2
PEN-2 2
nicastrin-dependent 2
1-gamma-secretase 2
FLIM 2
presenilin- 2
-secretase 2
calsenilin, 2
aph-1b, 2
PS1DeltaE9 2
p53-Dependent 2
Aph-1a, 2
Aph-1b, 2
Aph-1- 2
Pen-2-associated 2
APH-1a 2
APH-1b. 2
phospho-proteoform 2
Fusion, 2
entry: 2
(SPAT-1 2
Reports, 2
Sp/Tp 2
T52 2
GFP-Bora 2
Ser278. 2
tumorgenesis, 2
Ubc-9 2
pEGFP-N1-Ubc9. 2
pEGFP-N1-Ubc9 2
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 2
proliferation-related 2
physphorylated 2
physphorylation 2
(RVLM). 2
life-and-death 2
mevinphos 2
defunct 2
immunoneutralization 2
eventuality. 2
Ubc9-deficient 2
TCR-driven 2
(K179, 2
K180, 2
K220, 2
K221, 2
K246) 2
K179A, 2
K221A 2
Core-SUMO-1 2
K220A 2
Core-UBC9 2
(K179A, 2
K220A, 2
(K220A, 2
Stabilizes 2
Nonstructural 2
(SUMOylation) 2
SUMO-targeted 2
STAT2-mediated 2
(NS5), 2
SUMOylated. 2
"double 2
indemnity" 2
anti-DENV 2
Gam1 2
SAE1/SAE2 2
RAP80. 2
Kss1, 2
Tec1-Ubc9. 2
sumoylation-site 2
Tec1(K54R), 2
Daxx, 2
enzyme2 2
T98G 2
MOdifiers 2
ubiquitinylation. 2
(Ets-1 2
K15R/K227R), 2
SENP1, 2
desumoylate 2
Ets-1. 2
PIASxbeta, 2
E3-like 2
PIASxbeta 2
PIAS-SUMO 2
(UBC9), 2
modifier-conjugating 2
crystallin, 2
CryAB(R120G) 2
HPVE6 2
Imp13, 2
Ubc9-R13A 2
Ubc9-H20D 2
nucleus-enriched 2
SAE1 2
de-sumoylation 2
sentrin/SUMO-specific 2
(SENP)1 2
(IVD) 2
IVD 2
ATP-Sensitive 2
(CHI-D) 2
δ-cell 2
δ-cells 2
CHI-D, 2
(SUR1), 2
(periodontitis 2
NYPN, 2
NSSN, 2
DYPN 2
NSSN 2
NYPN 2
aspirates). 2
gordonii. 2
Ib) 2
(37.5%), 2
Ib/II 2
Saliva 2
AgP 2
P.gingivlias 2
co-infection. 2
peri-implantitis. 2
(rucaparib) 2
Rucaparib. 2
(BCRP/ABCG2) 2
(P-GP/ABCB1) 2
(AG-014699). 2
zosuquidar 2
Ko143, 2
AUC0-1 2
AUC0-24) 2
Abcb1a/1b 2
Abcb1a/1b. 2
(micro)metastases 2
BRCA-1/2 2
⩾12 2
Stents 2
catheterization, 2
MI), 2
wall(s). 2
(1.75 2
V3, 2
TWa, 2
pre-infarction 2
(MIs) 2
Easton 2
day-period 2
lovenox 2
95-99% 2
V4-V5 2
potential-like' 2
1959, 2
Cardiological 2
(stunned 2
myocardium), 2
V2-V4, 2
Auckland, 2
TARDBP, 2
(DPRs), 2
ALS-FTD-linked 2
(ALS-FTD). 2
(UBQLN2), 2
(ALS)/frontotemporal 2
ubiquilin-2. 2
299-residue 2
(TG)-rich 2
Cys112Arg 2
VLDL-cholesterol/high 2
ratio). 2
(HL), 2
(LPL) 2
(R158P) 2
(LPG) 2
Kurashiki, 2
stan-dard 2
Doubling 2
apoe2 2
(apo)E- 2
apoB100-containing 2
180% 2
(normolipidemic) 2
beta-migrating 2
xanthomas 2
(Arg158 2
Cys) 2
E2(Arg158----Cys). 2
flotation 2
Arg112, 2
E2-Dunedin 2
(228 2
Cys): 2
beta-VLDL, 2
dysbetalipoproteinemia. 2
apoE3), 2
158, 2
228. 2
Arg----Cys).(ABSTRACT 2
plasma- 2
Strip 2
0.073 2
ApoE-1 2
apoE1 2
Sagittal 2
Dolichocephaly 2
AETs, 2
nonvortioxetine 2
Inconsistent 2
milnacipran/levomilnacipran 2
anxiety) 2
antidepressants: 2
-0.118 2
-0.203 2
-0.033, 2
agomelatine. 2
(SNRI) 2
SSRI/SNRI 2
symptoms(Hamilton 2
(Sheehan 2
life(EuroQol 2
Dimensions), 2
Enjoyment 2
(10.4, 2
(7.9, 2
0.44), 2
(6.4, 2
vilazodone, 2
7,666 2
2,743 2
EBSCO, 2
(APA) 2
(SMD). 2
(OR=1.84, 2
CI=1.16-2.93, 2
Z=2.59, 2
P=0.010), 2
(ES=2.98, 2
(OR=1.47, 2
CI=0.95-2.30, 2
Z=1.71, 2
P=0.090). 2
(WMD). 2
randomized-effects 2
2287 2
(MADRS), 2
(HAM-D24), 2
CGI-Severity 2
(CGI-S), 2
Rey 2
options.. 2
1.61), 2
1.45; 2
60-kDa 2
(WKBL), 2
Q-Sepharose, 2
FPLC-size 2
benzo(a)pyrene-induced 2
forestomach 2
Non-toxic 2
Pinus 2
parviflora 2
Sieb. 2
Zucc 2
angula) 2
nondigested 2
(hgf) 2
(SCFAs) 2
erythroagglutinating 2
207.14±74.42 2
pN 2
(183.65±86.93 2
pN). 2
10(-9)±1.4 2
10(-8)±2.7 2
A-549 2
Glucosamine-Specific 2
Beans 2
cereals, 2
annatto 2
δ-Tocotrienol-induced 2
(Bax). 2
Negro 2
8025) 2
(AOM)-induced 2
butyrate. 2
(ACF) 2
acclimatization: 2
(intragastric 2
AOM. 2
(83.14%); 2
AU565 2
(THs). 2
triiodonine-binding 2
(Cys10 2
sulphonic 2
chemotype- 2
S-glutathionylation 2
function-specific 2
S-sulphonated, 2
S-cysteinylglycinated 2
S-glutathionylated 2
sterical 2
blood-CSF-barrier 2
explicated 2
transthyretin-bound 2
(POPs) 2
(T4-TTR) 2
(18-39 2
native-polyacrylamide 2
thyroxin-binding 2
POPs 2
TBG, 2
R-squared 2
OH-PCBs, 2
chlorophenols, 2
PFOS. 2
TTR-mediated 2
retinol. 2
(CSF)-circulating 2
retinol-retinol 2
transthyretin-null 2
Film 2
[(125)I]thyroxine 2
14th, 2
"postoperative 2
interbody 2
transoperative 2
(transplantation 2
immunocompromise 2
subarachnoid-pleural 2
nephropathy? 2
Differing 2
postsurgical, 2
electrolytes. 2
[Self-monitoring 2
his/her 2
negatives), 2
predictable. 2
non-iatrogenic 2
procedure". 2
paramedical 2
disinfectants 2
(0.04%) 2
Hallux 2
metatarsal-phalangeal 2
arthrodesis 2
Hawkins 2
Starch 2
Laparoscopy 2
(vancomycin 2
academic, 2
(49/62 2
[35%]). 2
(n=94) 2
[95%]), 2
(15/19 2
[76%]). 2
(12/19 2
[63%]) 2
[47%]). 2
(p=0.0021), 2
airwary 2
HNK1. 2
cranium, 2
Stringent 2
musculo-connective 2
myofibroblasts/smooth 2
multipotency. 2
unpigmented 2
crest-like 2
reacquire 2
cells/peripheral 2
N-nitroso-N-ethylurea-induced 2
N-nitroso-N-ethylurea 2
premelanosomes. 2
transplantability 2
Schwannian 2
pigment-producing 2
myelinating, 2
(HDAC1/2) 2
(P0) 2
(Fabp7). 2
Pax3, 2
anti-Schwann 2
nonmyelinating 2
high-proliferative 2
[Immunohistochemical 2
nevi]. 2
nevi). 2
alpha-subunit. 2
dysontogenic 2
progenitor-derived 2
somatopleural 2
angioblasts 2
chrondro- 2
47-53 2
(metacarpo-phalangeal 2
joints), 2
clubfeet, 2
uvula/cleft 2
(Fisher's 2
GS, 2
Arthrogryposis. 2
Mechanotransduction, 2
PIEZOs 2
I802F 2
PIEZO2-dependent, 2
(DA3), 2
(DA5), 2
(MWKS), 2
folates, 2
FOLATE 2
DEPRESSION: 2
B₆, 2
B₉, 2
B₁₂ 2
postgraduate 2
moderate/high 2
axo-dendritic 2
Slitrk2, 2
Slitrk2 2
LAR 2
Slitrk1. 2
(Slitrk1-6) 2
flush 2
oculosympathetic 2
'harlequin 2
Unnoticed 2
face: 2
Hemifacial 2
pupils, 2
sudomotor 2
Practice. 2
sign). 2
elevator 2
cullin-COP9 2
polyphosphates 2
(CSN2) 2
canyon 2
IP6, 2
"glue," 2
cullin-CSN2 2
Ins(1,3,4,5,6)P5 2
2-kinase 2
(IPPK/IP5K) 2
Depleting 2
neddylated, 2
Cul1 2
Cul4A, 2
Cul1/4A 2
dysregulating 2
derubylation 2
AtCSN5A 2
AtCSN5B 2
CSN5-like 2
TaCSN5) 2
PR1 2
(pathogenesis-related 2
(CSN5) 2
Cul3/Keap1-mediated 2
ubiquitination- 2
(CSN1 2
CSN8). 2
(CSN6): 2
(CSN1-CSN8). 2
deneddylating 2
Erlotinib, 2
DET1 2
(E2s) 2
UEVs 2
MMS2 2
UEV1. 2
(DDB1a) 2
(DET1), 2
(COP10, 2
DDB1, 2
DET1) 2
(UEA) 2
COP10, 2
HY5, 2
ubiquitylation-promoting 2
AXR1 2
HYH. 2
RBX1 2
Mediating 2
(CUL4) 2
DET1. 2
COP1-dependent 2
photomorphogenesis-promoting 2
(CSN7) 2
169) 2
non-PCI 2
CSN6. 2
CSN7. 2
lid, 2
signalosome-directed 2
JNK-independent 2
(5/6 2
(AtItpk-1) 2
(RL) 2
RL, 2
csn 2
suppurativa/acne 2
[Sartorius 2
efficacy]. 2
[Hidradenitis 2
Suppurativa-Physician's 2
2-grade 2
baseline] 2
(85.7%) 2
73.5% 2
excision: 2
trialing 2
(antitumour 2
CXCL9 2
CD11c+ 2
every-other-week 2
inflammatory-nodule 2
draining-fistula 2
27.6% 2
rank-ordered 2
(lesions, 2
NCT01468207 2
NCT01468233 2
immaturity, 2
latitude, 2
Anat. 2
Legg-Calve-Perthes 2
(LCPD) 2
rotation, 2
sex-adjusted 2
U/dL) 2
(19.5%), 2
Thickening 2
fascial 2
(PF)is 2
(68%). 2
30-65 2
3.36 2
traction. 2
(fasciosis) 2
running-related 2
posterior. 2
Forefoot 2
rearfoot 2
p=0.023). 2
1.99). 2
sex; 2
orthotics, 2
(LUBAC), 2
(FAM105B), 2
Otulin/Gumby/FAM105b 2
(DUBs). 2
PIM. 2
LUBAC-mediated 2
Met1-Ub. 2
RIPK2 2
linear) 2
Deubiquitinases 2
FAM105B), 2
diubiquitin 2
Met1-specific 2
Ub-binding 2
Glu16 2
240-fold. 2
poly(I:C) 2
RIPK1. 2
Hsp40, 2
Disaggregase 2
Reverses 2
Parkinson's-Linked 2
Fibrils. 2
DNAJB1, 2
Disaggregases, 2
resolubilize 2
fragmenting 2
NeeCham 2
regression) 2
29%. 2
(physician 2
nurse). 2
administrate 2
confused, 2
CAM-ICU. 2
19.8% 2
29.7% 2
chart-based 2
2.64, 2
friendliness 2
(Cronbach's 2
0.60. 2
DSM-IVcriteria 2
67.52, 2
to] 2
3.69, 2
intubed 2
shoulder: 2
shoulder) 2
'frozen 2
shoulder' 2
abduction, 2
pendulum 2
13-18 2
50-59 2
("frozen 2
shoulder") 2
arthrographic 2
coracohumeral 2
recess 2
physiotherapeutic 2
physiotherapists 2
BRIEF 2
ABAS-II 2
.70). 2
(C749G) 2
30,000 2
loss-including 2
Muenke, 2
Beare-Stevenson, 2
syndromes-that 2
duct, 2
(Pro252Arg), 2
(Pro253Arg) 2
(Pro250Arg), 2
FGF9 2
Pro253Arg 2
FGFR-3 2
c.749 2
C>G, 2
(P250R), 2
osteotomies, 2
Muenke's 2
nigricans. 2
(oral/intranasal) 2
cowpox 2
Geneva 2
solemn 2
cobwebs. 2
proud 2
Govt 2
Baciilus 2
Guerrin 2
(BCG), 2
(OPV), 2
Tetanus 2
(DPT), 2
Hepatitis-B 2
Hemophilus 2
(Hib) 2
Govt. 2
Vaccine, 2
altogether, 2
(WHO-Resolution 2
33.33). 2
variola-virus 2
Atlanta, 2
adheres 2
richness, 2
EBP50, 2
AngII-induced 2
gravity. 2
gp91(phox)/Nox2 2
(p47(phox) 2
Noxo1) 2
andanactivatorprotein 2
(p67(phox) 2
Noxa1); 2
p47(phox)-dependent 2
indispensable. 2
growth-factor-induced 2
FAD-binding 2
Electropermeabilized 2
Nox1-expressing 2
Rac; 2
Rac1(Q61L), 2
A27K 2
p22(phox): 2
Noxa1-Noxo1 2
Noxo1-p22(phox) 2
Noxa1: 2
Noxa1(W436R), 2
W436R 2
Rac1(Q61L). 2
Rac-Noxa1 2
binding-defective 2
Val-205 2
phosphoinositide-binding 2
module; 2
Noxo1beta. 2
Noxo1beta, 2
Nox1-3, 2
Noxo1gamma; 2
Nox; 2
p22 2
superSH3 2
NOXO1, 2
p47phox, 2
p47phox- 2
(NOXO1)-dependent 2
(NOX1) 2
isoform(s) 2
(-/-)) 2
diabetic. 2
(NoxA1) 2
Ser(172) 2
Ser(461) 2
(PRR) 2
Nox1-5 2
Duox1 2
PRR, 2
Vav2 2
(rs17049105, 2
rs13020355, 2
rs2682406, 2
rs2056116, 2
rs11190870, 2
rs9572903, 2
rs8004379) 2
uc.51, 2
uc.82, 2
uc.133, 2
uc.140, 2
uc.302, 2
uc.353, 2
uc.368, 2
1.01-1.58, 2
A/G, 2
(rs8004379 2
AC/CC 2
0.68-1.13 2
0.92-1.29 2
AG/GG 2
0.87-1.45 2
0.94-1.31 2
Precision 2
substitutions) 2
(osimertinib, 2
(ceritinib, 2
alectinib). 2
(1-2% 2
crizotinib); 2
tumors), 2
ASP8273, 2
PF-06747775. 2
T790M-positive 2
HM61713. 2
Resistance-Linked 2
ATP-Binding 2
(MDR1, 2
P-glycoprotein). 2
ABCB1-mediated 2
(AZD9291), 2
KBv200 2
(erlotinib), 2
(osimertinib 2
negates 2
Tagrisso™), 2
EGFR-T790M. 2
ClC-K 2
hypochloraemic, 2
Henle 2
Gitleman 2
hydramnios 2
KCNJ1 2
hyperaldosteronism; 2
(BLS), 2
BLS 2
salt-wasting 2
(chloride 2
wasting: 2
polyuria, 2
"Bartter 2
A204T 2
surreptitious 2
hyperreninaemic, 2
CH2O/(CH2O+CCl) 2
Frusemide 2
UOsm 2
FENa 2
sella. 2
Hypokalemia 2
hyperreninism 2
(GS); 2
(HPS/aBS); 2
(cBS). 2
HPS/aBS 2
NKCC2 2
CLC-Kb 2
ClC-Kb, 2
hyperkalemia 2
UTIs. 2
Na-K-2Cl 2
NKCC2, 2
ROMK. 2
mmol/kg/day), 2
hypermagnesuria 2
hyperreninemia 2
(Na-K-2Cl 2
cotransporter; 2
(ROMK); 2
(ClCNKb); 2
Barttin; 2
CaSR) 2
Henle's 2
hypomagnesaemia. 2
Rheumatologists 2
Pseudo-seq 2
CeU-seq 2
Aza-IP 2
m(6)A-seq 2
2'-O-methylations 2
(2'-O-Me) 2
RiboMeth-seq 2
sites/regions. 2
modTool 2
ribonucleosides, 2
neuroaxial 2
[Neurological 2
partum 2
large-droplet 2
aggressively, 2
preeclamptic 2
platelets): 2
33th 2
ophthalmoscopic 2
178). 2
32.7, 2
preeclampsia). 2
(37.9%) 2
(haemolysis, 2
pre-eclamptic 2
Placentae 2
p=0.012 2
prednisolone) 2
syncytin, 2
centuries 2
(HELLP), 2
(mi) 2
Mi/mi 2
WS2/TS 2
delR217, 2
mi/mi 2
serum-deprived 2
MITF: 2
far: 2
neural-crest-derived 2
melanocytes; 2
MITF-C 2
factor/c-Kit 2
Ser73 2
Ser409 2
RSK-1, 2
Ser298 2
MSH 2
Endothelins 2
(Mitf) 2
(Mitf(mi-enu198) 2
Mitf(mi-x39)), 2
(Mitf(mi-ws), 2
Mitf(mi-ew), 2
Mitf(mi-di)) 2
(Mitf(mi-x39), 2
Mitf(mi-ws)) 2
melanogenesis: 2
MITF]. 2
eu- 2
pheomelanins 2
(THI) 2
(TRP1 2
TRP2). 2
αS 2
THI, 2
GTP-cyclohydroxylase 2
(GTP-CHI) 2
MITF-Mdel, 2
TRP1 2
digesta 2
43.7%; 2
28.7%; 2
25.3%; 2
Spirochea, 2
Synergistes, 2
1.1%) 2
harvest, 2
caecal 2
HF-fed 2
apnoea. 2
(<200 2
HBB:c.20A>T 2
A→T 2
nanofluidic 2
anemia), 2
(LCR) 2
position-independent 2
3'-penultimate 2
(A-->T 2
Glu-->Val 2
interpretationally 2
Sickle-cell 2
(GAG 2
beta-thalassemia. 2
antisickling 2
beta--chain 2
(beta(S)) 2
gamma/beta(S) 2
multiribozymes 2
K562beta(S) 2
gamma/(gamma 2
zb21A 2
(PTHrP)-dependent 2
Axenfeld-Rieger 2
(Ihh)/Parathyroid-related 2
zipper-containing 2
(Ocn) 2
chondrocyte-derived 2
(Ptc) 2
Gli. 2
Ptc 2
Enchondromas 2
diseases). 2
(IHH). 2
enchondroma-like 2
BMP/Noggin 2
pre-hypertrophic 2
(1-40) 2
chrondrocytes 2
attesting 2
axes, 2
P15 2
Sox9-expressing 2
chondroprogenitor 2
HhAntag, 2
PTHrP-Indian 2
protein-4 2
(Indian 2
(Wnt 2
(Smo), 2
differentiation) 2
Pioneering 2
Lgr5-positive 2
organoids. 2
non-regenerating 2
noggin, 2
gallbladder-derived 2
tetrachloride-treated 2
organoid-forming 2
gallbladders, 2
(fissured 2
tongue), 2
paralysis). 2
(Lingua 2
Plicata) 2
mismanagement. 2
neuromucocutaneous 2
(lingua 2
plicata), 2
Lingua 2
Orofacial 2
laryngologists, 2
Silesian 2
Katowice. 2
reinnervation 2
sarcoidal 2
[Experiences 2
antileprosy 2
granulomatosa. 2
granulomatosa, 2
Gen-Probe 2
(macrocheilitis), 2
Miescher's 2
macrocheilitis 2
(26%), 2
PB-06-001, 2
parallel-dose 2
GD; 2
PB-06-001 2
PB-06-007. 2
PB-06-007 2
(30U/kg, 2
n=8; 2
n=9; 2
n=2); 2
(-8.7, 2
-6.9, 2
-12.4 2
(-0.6, 2
-0.4, 2
(-83.1%, 2
-93.4%, 2
-87.9%), 2
(CC 2
(-66.7%, 2
-83.3%, 2
-78.9%), 2
(+2.1, 2
+2.1, 2
+1.8mg/dL) 2
(+31,871, 2
+106,800, 2
+34,000/mm3). 2
NCT01422187. 2
(treatment-naïve) 2
[MN] 2
-26.0MN), 2
(-0.8MN 2
-0.9MN), 2
(-72.7% 2
-84.4%), 2
(+2.0g/dL 2
+2.3g/dL) 2
(+38,200/mm3 2
+138,250/mm3) 2
NCT01411228. 2
Shire 2
Therapies, 2
Carmiel, 2
comparison-dose 2
weight/infusion) 2
9-month, 2
20-infusion 2
centers) 2
Abs; 2
-31.9, 2
-21.8) 2
30-unit 2
-43.4, 2
-32.8) 2
60-unit 2
(Ff) 2
(QCSI) 2
(<0.23) 2
0.11-0.35). 2
(p=0.005), 2
36months. 2
(GD1) 2
α-mannose 2
postproduction 2
glycosidic 2
6months, 2
search: 2
units/g 2
units/kg. 2
spleens, 2
-79.87 2
-137.57 2
Formylation 2
step; 2
intracistronic 2
formylation: 2
formyl 2
antifolic 2
trimethoprim, 2
Ribosomes 2
(rpsL) 2
Runs 2
eucaryotes, 2
Volga 2
(LOAD) 2
LOAD 2
(NM_000311, 2
rs80356711) 2
candidate-gene-based 2
postmortem. 2
PSEN2) 2
(ADEOAD) 2
presenilin2 2
dimerizes 2
(STAT4) 2
discoverers 2
pixels 2
Mello 2
Score>or 2
respirasome, 2
Respirasomes 2
progressiva: 2
(FOP, 2
135100) 2
17q21-22. 2
Progressiva. 2
(BMPs). 2
Egr-1, 2
Egr-2, 2
ZBTB7A/LRF, 2
-762/-308 2
274G>C, 2
(EndMT) 2
ID3 2
MSX2, 2
Acvr1 2
ACVR1/ALK2). 2
Acvr1(CKO) 2
BMPR1B 2
Neofunction 2
IA/activin-like 2
TGF-beta/bone 2
kinase-2. 2
datavisualization. 2
peptidome: 2
Taxon-specific 2
Biodiversity 2
taxon, 2
visualizations. 2
Outputted 2
Unipept, 2
eases 2
42/40 2
gamma-secretases 2
PLs 2
pharynx-defective 2
(APH-1), 2
PS2beta 2
Oxadiazines 2
oxadiazoline 2
GSMs. 2
gamma-secretase-independent 2
aph-1 2
(CTFgamma). 2
CTFgamma 2
RO4929097 2
γ-secretase-complex 2
presenilin-2, 2
Assembly, 2
beta-peptides, 2
scissile 2
circulations 2
anhidrosis 2
Segregating 2
Heterochromia. 2
Illumina-HumanOmni2.5-Beadchip 2
(RET). 2
(cellular 2
cytosol) 2
Met91 2
(M91V) 2
(c.-248G/A; 2
-predicted 2
efficiency-) 2
(EDNRB 2
DACH1 2
inately 2
benign--in 2
[Iris 2
iridis, 2
irides, 2
colobomatous 2
mid-tibial 2
weight-bearing. 2
14-28. 2
Mid-tibial 2
tanezumab-treated 2
RPOA. 2
sprifermin/recombinant 2
factor-18, 2
tanezumab/monoclonal 2
β-nerve 2
cystitis. 2
(tanezumab 2
Σ5NC 2
(Plms) 2
strategies: 2
(SBDD) 2
(SBVS). 2
SBDD 2
SBVS 2
(order 2
standard), 2
Dipole 2
likeness 2
PEXEL-mimetic 2
cotranslationaly, 2
adhesin, 2
cytoadherence. 2
(PM 2
pharmaceutically 2
druggability 2
Explicit 2
Plasmepsins, 2
Y17, 2
V105, 2
T108, 2
L191, 2
L242, 2
Q275, 2
T298 2
achiral 2
proteinases, 2
FlexX 2
AutoDock. 2
parasite-coded 2
Plasmepsins. 2
falcipains 2
(aspartic 2
conservations 2
Methicillin 2
(MRSA, 2
known-positive 2
phenazines 2
floors, 2
chairs, 2
wiping 2
Aerial 2
rooms. 2
rooms, 2
colonisation 2
leukocidin-positive 2
non-ß-lactamase 2
ant 2
ermA, 2
ermC, 2
mrsA, 2
tetM, 2
gradually, 2
Healthcare- 2
Russia: 2
Factors, 2
ST8Kras 2
(strain 2
susceptive 2
(75.7%). 2
(DDDs/1000 2
bed-days) 2
0.905, 2
(BDGO) 2
(100%, 2
92.9% 2
MRSA), 2
(101 2
MRSA-infected 2
-colonized 2
nonnasal 2
overall). 2
99%), 2
(28/38 2
[74%]) 2
nonmultiresistant 2
(17/31 2
[55%]) 2
(susceptible 2
antibiotics). 2
IDI-MRSA. 2
Direct. 2
(meticillin)-resistant 2
direct- 2
enriched-culture 2
99.2%, 2
Agar, 2
Medium, 2
Nares: 2
subculture 2
nares. 2
Nares 2
VISA 2
anti-MRSA 2
(MRSA): 2
precautions, 2
patient-days) 2
(minimum, 2
polymorphisms) 2
kaempferol-3-O-alpha-L-(2'',4''-di-E-p-coumaroyl)-rhamnoside 2
kaempferol-3-O-alpha-L-(2''-E-p-coumaroyl-4''-Z-p-coumaroyl)-rhamnoside 2
norfloxacin 2
C3. 2
ST247-MRSA-I 2
ST45-MRSA-IV 2
PVL-positive 2
ST8-MRSA-IV, 2
care-associated 2
skin/soft-tissue 2
Pediatricians 2
t002 2
ST5-MRSA-I, 2
CC398) 2
herd) 2
herds; 2
linezolid, 2
MSSA-positive 2
(p=0.02). 2
(HA-MRSA), 2
(CLSI) 2
HA-MRSA. 2
dimension) 2
overcrowding, 2
MRSA-days-associated 2
(CA-MRSA). 2
tonsillitis, 2
septicemia, 2
(χ(2) 2
Gung 2
younger. 2
aureus-(CA-MRSA) 2
risk-factors 2
CA-MRSA-(n: 2
ST5-IV-PVL(+) 2
HAHO-, 2
HACO- 2
HA-MRSAG 2
clones: 2
PFGE-type 2
1997-2009. 2
farms, 2
colonized. 2
farming 2
758 2
(MRSA-ID, 2
urologists, 2
glycoproteomic 2
pGlyco, 2
HCD-MS/MS 2
HCD-MS/MS, 2
nitrogen. 2
ETD, 2
post-source 2
tris(2,4,6-trimethoxyphenyl)phosphonium 2
(TMPP) 2
(CID), 2
(ETD), 2
(FRIPS) 2
3-3 2
MSETD, 2
(AVA) 2
solubility. 2
(PDE5-Is). 2
(Pubmed, 2
Reaxys, 2
Scopus) 2
criteria-based 2
urinary/reproductive 2
underlying. 2
(4-week 2
stopwatch. 2
25.9%, 2
14.9%, 2
2.9%, 2
pyrazolopyrimidinone 2
compound-4a 2
PDE5Is, 2
competitors. 2
PDE5Is 2
phosfosdiesterase 2
(PDE5 2
(ED); 2
PDE1: 2
PDE6: 2
retina; 2
PDE11: 2
muscle), 2
abstracts); 2
PDE-related 2
non-PDE5 2
PDE1, 2
PDE6, 2
PDE11 2
vision-related 2
avanafil-treated 2
congestion; 2
phosphodiesterase-5, 2
Intracavernous 2
(121-fold) 2
phosphodiesterase-6 2
21-fold) 2
10,000-fold) 2
phosphodiesterase-1 2
(375-fold). 2
phosphodiesterase-11 2
25-fold). 2
34.6 2
intraduodenal 2
151.7 2
79.0 2
erection. 2
flicker 2
(100-mg 2
(100/200-mg 2
Type--Therapy 2
fix-dosed 2
(GAQ). 2
IIEF 2
(EFD 2
IIEF-EFD 2
(sildenafil 2
RigiScan® 2
(Dacomed 2
VSS 2
tumescent 2
(TAUs), 2
(RAUs), 2
five-point 2
Erection 2
dosing), 2
(100-120 2
20-40-min 2
TAUs 2
50-mg, 2
(7-15%) 2
phosphodiesterese-5 2
(Viagra™), 2
(Levitra™), 2
(Cialis™) 2
(Stendra™) 2
Function-Erectile 2
(IIEF-EF), 2
2225 2
[MD]: 2
4.47; 2
3.51 2
5.43), 2
SEP-2 2
17.41; 2
14.03 2
20.79), 2
SEP-3 2
20.01; 2
22.98 2
37.22), 2
3.94), 2
5.76), 2
6.06; 2
10.88) 2
7.54; 2
16.12) 2
3.99, 2
Epitranscriptomics 2
decorate 2
recoding, 2
N1-methyladenosine 2
(m1A), 2
(m5C) 2
'Epitranscriptome' 2
Author(s); 2
(ARV) 2
(tenofovir, 2
darunavir 2
dapivirine) 2
ARV-based 2
18-40. 2
Microbicide 2
Conducted 2
Healthy, 2
post-trial. 2
Participant 2
self-reports. 2
NCT01071174. 2
TZM-bl 2
Polymeric 2
dapivirine-containing 2
CVRs 2
Heterosexual 2
NNRTI-resistant 2
simulant. 2
Transcriptase 2
(NNRTI), 2
UC781 2
[15 2
microCi/ml]) 2
(quantities 2
>or=2.5 2
macaques). 2
unquantifiable 2
keratinized 2
deepest 2
(germinal) 2
>24 2
(LAI) 2
MT4 2
meriting 2
10-fold-higher 2
Dapivirine-loaded, 2
oxide)-coated 2
poly(epsilon-caprolactone) 2
(PEO-PCL) 2
nanoprecipitation 2
PEO-PCL 2
device--based 2
diaphragm--that 2
Diaphragm 2
overmolded 2
nonmedicated 2
polyoxymethylene 2
w/w 2
mcg/day. 2
coitally-dependent 2
5516 2
partner; 2
prevalent: 2
gonorrhoeae, 2
CROI 2
PrEP, 2
PrEP. 2
2286 2
tenofovir. 2
extrusion. 2
[Implementation 2
approval]. 2
online: 2
939 2
knew 2
undecided. 2
Pacini 2
Editore 2
Immunisation 2
Trumenba®. 2
Surface-expressed 2
Porin 2
(PorA); 2
situation; 2
strain-coverage 2
Proteinaceous 2
New, 2
BEXSERO® 2
(Novartis 2
Vaccines). 2
(Bexsero(®)), 2
observer-blind, 2
vaccine-experienced 2
IIb/III 2
seroprotection 2
outlook. 2
Trumemba(®), 2
(GNA) 2
1030 2
(Ub8), 2
GNA1030, 2
Ub8. 2
(NUbp). 2
(FHbp). 2
immunized, 2
Germany: 2
Standing 2
(STIKO) 2
adolescents; 2
unavailable.STIKO 2
properdin 2
asplenia 2
IMD, 2
hypogammaglobulinaemia 2
5-10-fold 2
aerosols, 2
271-fold 2
(-like) 2
100-200-fold 2
chemoprophylaxis. 2
toddlers), 2
POPULATION: 2
(Bexsero(®)) 2
(NNV) 2
>1000. 2
Modelled 2
Bactericidal 2
MATS-based 2
2007-2008, 2
55-85%) 2
72-95%). 2
hSBA. 2
Hi3 2
lots. 2
y-olds 2
Vaccines, 2
Siena, 2
Italy). 2
3-dose 2
university; 2
(Bexsero(TM), 2
Novartis/GlaxoSmithKline 2
Vaccines) 2
(NZ 2
OMV) 2
public-private 2
antigen-GNA1030 2
protein-GNA2091); 2
detergent-treated 2
(MenB-4C 2
Vaccines]) 2
'MenB' 2
unsuitable, 2
4CMenB) 2
anti-meningococcal 2
immunisation. 2
licensure, 2
radiosurgery. 2
GKRS, 2
(BED) 2
collimators 2
calibrations 2
halftimes 2
τ1 2
repair) 2
τ2 2
repair). 2
Gy/min, 2
GKRS-based 2
63-month 2
variables; 2
Radio 2
Européene 2
Stockholm. 2
capsular/ventral 2
gyri 2
process: 2
(PSGs). 2
pCMV-PAI-2 2
Ube4b, 2
N70 2
VCP, 2
VCP. 2
(ERa 2
proteasome) 2
(ERb 2
proteasome), 2
0.0125 2
ERa, 2
trypsin-treated 2
phospholipid. 2
multicatalytic, 2
envelope-ER 2
NE-ER 2
proteasome/ubiquitin-mediated 2
S6' 2
S7 2
X-114, 2
(apoB) 2
brefeldin 2
homogeneously, 2
unidirectionally 2
(DMRV) 2
(cathepsins) 2
Ca2+-dependent, 2
(calpain). 2
ATP-ubiquitin-dependent 2
(proteasomes) 2
DMRV 2
ATP-ubiquitin-proteasome 2
DMRV. 2
purpura). 2
Psychodermatologic 2
liaison 2
PCDs 2
self-mutilation, 2
purpura/Gardner-Diamond 2
psychopathologies 2
37-yr-old 2
thighs. 2
neurosis. 2
"hysterical" 2
ASS 2
psycho-emotive 2
ecchymoses/purpuric 2
auto-erythrocyte 2
incomitant 2
forwards 2
sclera. 2
landmarks. 2
(ICA). 2
Drilling 2
superiorly 2
posteriorly. 2
Dissections 2
cadaver, 2
myoneural 2
intra-orbital 2
blepharoplasty. 2
blepharoptosis 2
myotoxic 2
cadavers, 2
severed 2
Transnasal 2
transnasal 2
decompressing 2
orbitopathy. 2
"lost" 2
sub-Tenon's 2
Cadaver 2
stump 2
muscle/tendon 2
(2004-2014) 2
[72] 2
1.2-2.2]), 2
(0.90 2
[0.83-0.97]), 2
[0.2-0.9]). 2
("eventually 2
tolerant") 2
tolerant"). 2
(eventually 2
Never 2
nonstatins 2
(TC). 2
0.74-2.64]). 2
pharmacodynamics. 2
genomics-guided 2
ABCG2. 2
rs4149081 2
high-MTX 2
statin-specific 2
simvastatin/atorvastatin 2
pravastatin/rosuvastatin. 2
(GGST) 2
GGST 2
life" 2
18-24-month 2
Maze 2
IntelliCage-based 2
co-housed 2
Intellicage 2
(activity-regulated 2
hippocampus-dependent 2
5.5-month-old 2
Photinus 2
isoform) 2
(V642I, 2
APPLd2) 2
APPLd2 2
V642I-AbetaPP, 2
betaA4(1-40) 2
pre-Golgi 2
APP-London 2
betaA4(1-42) 2
betaA4(1-40), 2
beta-CTF 2
"London") 2
PS-1 2
APPSL 2
(APPSwe/Lon) 2
APPSL-Tg 2
LAMP-1 2
HA-epitope 2
fluorescent-protein 2
Protein-coding 2
TUNA, 2
chemo-resistant 2
change>2, 2
ENST00000518376 2
post-transcriptional-based 2
collision-based 2
stressors; 2
(GM). 2
"forgotten 2
organ" 2
10(13-14) 2
trillions 2
trillion 2
tract) 2
meta-omics 2
(10(14) 2
individual). 2
AT1R. 2
ML-7 2
(DPI). 2
oxidase-2 2
(PE)-induced 2
Hereto 2
cardiomyoblasts 2
(H9c2 2
Digital-imaging 2
(Nox2ds)-tat 2
NOX2-mediated 2
Nox2ds)-tat 2
Fibrotic 2
(145.5+/-9.0%; 2
98.6+/-1.6%) 2
(100.4+/-3.2%) 2
(9.5+/-3.3%). 2
aminoethyl-benzenesulfonylfluoride 2
(AEBSF, 2
100-1000microM), 2
(100-1000microM), 2
(DPI, 2
3-30microM), 2
DPI, 2
AEBSF, 2
(Kv) 2
(TXA(2)) 2
TXA(2) 2
U46619, 2
PKCzeta, 2
(PASMC), 2
dichlorofluorescein 2
polyethyleneglycol-catalase 2
(PEG-catalase, 2
catalase). 2
Bonn/Kobori 2
(generating 2
N-ethylmaleimide-induced 2
D-(+)-neopterine) 2
extract-induced 2
TLR4-dependent 2
(CSE) 2
(TLR4)/NADPH 2
TLR4/MyD88/TRAF6 2
c-Src/p47(phox) 2
TLR4/MyD88/TRAF6/c-Src/NADPH 2
COX-2/PGE(2)/IL-6-dependent 2
(UVB) 2
pro-form 2
(RBA-1 2
JEV-induced 2
(helenalin) 2
JEV-stimulated 2
p42/p44 2
particles: 2
(ROS)-driven 2
Phagocytes 2
phagolysosomes. 2
indigestible 2
β-glucan-specific 2
phagocytized 2
culture-supernatant 2
Cu(2+)/ascorbic 2
phagocytes, 2
β-glucan. 2
low-protein 2
ROS/NF-kappaB 2
IL-1beta-treated 2
(VCAM-1). 2
PI-PLC/PKCalpha/c-Src/ROS 2
PI-PLC/Ca2+/CaM 2
HTSMCs. 2
(diphenylen 2
(apocynin), 2
IGFBP1 2
(TTFA), 2
(O(2)(*-)) 2
II-sensitive 2
(Ad)-mediated 2
(AdN17Rac1) 2
(AdwtRac1) 2
AdwtRac1-treated 2
4-(2-amino-ethyl)-benzolsulphonyl-fluoride 2
(AEBSF), 2
VAS3947. 2
VAS3947, 2
XOD 2
VAS3947 2
Procyanidins 2
distilled 2
hydrosolubility. 2
procyanidins 2
(VEM) 2
Yakutia 2
(Yakut, 2
Evenk). 2
T-lymphotropic 2
parkinsonism-dementia, 2
kuru 2
Highlands 2
Jamaica). 2
ictaluri 2
septin-interacting 2
Sept7 2
Morphogenesis 2
tracks, 2
homodimers. 2
superclass 2
SEPT6 2
SmSEPT5, 2
SmSEPT10, 2
sporocyst. 2
miracidium 2
septin-based 2
guanosine-5'-triphosphate-binding 2
Importance: 2
conidiation, 2
septation 2
AspA, 2
AspB, 2
non-fermentable 2
Cdc11p 2
Cdc12p 2
cdc42V36G 2
filament-forming, 2
gauzes 2
Forchlorfenuron 2
NSF 2
Shs1p. 2
PtdInsP(2)-binding 2
H5. 2
GTPgammaS 2
foreshortened 2
KIAA0202. 2
septin, 2
tonsil, 2
TGF-β3 2
hemiclonic 2
anti-seizure 2
protocadherin-19. 2
6q16.3-q22.31 2
(15/18) 2
vaccination-induced 2
p.D377N 2
p.N340S 2
p.G60R 2
trains, 2
thermally-induced 2
parvalbumin-expressing 2
Charlotte 2
SMEI. 2
(CENTRAL, 2
stiripentol. 2
β(I) 2
(SMEI) 2
baleful 2
GEFS+, 2
[Dravet 2
(seizures 2
0.002] 2
(ASODN) 2
Varieties 2
ASODN 2
lipofectamine-mediated 2
PT67 2
virus-producer 2
retrovirus-containing 2
model), 2
CDK2, 2
telomerase-related 2
ribozyme, 2
hTR. 2
erucin 2
broccoli 2
4-methylthiobutyl 2
(MTBITC, 2
erucin) 2
mg/KG 2
b.w./d 2
anti-survival, 2
TMPyP4 2
MTBITC-mediated 2
DNhTERT, 2
cytostasis 2
MTBITC-induced 2
helenalin 2
tumor-associate 2
ortho-quinone 2
antisense- 2
(p=.001), 2
(p<.001), 2
"substantial" 2
perfect" 2
Survival-Related 2
Modalities 2
twice) 2
female=30 2
years? 2
60-81 2
78%. 2
oncologic, 2
(n=142), 2
1.80-5.01; 2
p<.001), 2
2.47; 2
1.48-4.14; 2
p=.001), 2
2.80; 2
1.66-4.72; 2
Sioutos, 2
Linden, 2
score-predicted 2
Ghori 2
(NOXO1/NOXA1 2
p47phox/p67phox/Rac 2
Nox2; 2
Nox3; 2
(19.5%) 2
reality, 2
'lowest 2
best' 2
(NAFLD), 2
Individualization 2
(Entresto®, 2
Neprilysin 2
(Entresto(®) 2
24/26 2
hydrated. 2
sacubitril/valsartan. 2
[LCZ696 2
(Entresto), 2
Corp.] 2
(HFpEF) 2
HFrEF. 2
Valsartan/sacubitril 2
Entresto) 2
valsartan/sacubitril 2
brexpiprazole 2
(Rexulti) 2
lumacaftor/ivacaftor 2
(Orkambi) 2
Sacubritil∗valsartan 2
(Entresto, 2
Novartis, 2
LCZ696) 2
dual-acting 2
(ARNi). 2
http://dorina.mdc-berlin.de. 2
reworked 2
uploads 2
installations 2
APIs 2
OSI-approved 2
re-use. 2
l-Amino 2
Decarboxylase 2
Cord 2
(5-hydroxytryptamine) 2
l-3,4-dihydroxyphenylalanine 2
(l-dopa) 2
(carbidopa) 2
(pargyline) 2
co-application, 2
∼94% 2
l-dopa-induced 2
(MO) 2
3-monooxygenase 2
1.14.16.2) 2
0-1000μM. 2
62.5-125μM 2
(200% 2
(250-500μM). 2
d-tyrosine 2
(62.5μM) 2
heteroexchange 2
l-TYR 2
L-3-,4-dihydroxyphenylalanine 2
(CHE), 2
non-effective 2
NSD-1015. 2
Carbidopa 2
(Trp) 2
tuberoinfundibular 2
6S-BH4, 2
L-amino-acid 2
(striatum, 2
hypothalamus) 2
aromatic-L-amino-acid 2
5-hydroxytryptamine; 2
1015); 2
pargyline). 2
(pcd) 2
(3,4-dihydroxyphenylalanine) 2
dopac 2
(L-DOPA) 2
5-HTP, 2
MnCl2, 2
pargyline 2
l-Dopa 2
3-hydroxybencilhydracine-HCl 2
1015). 2
NSD-1015-treated 2
stereotaxically 2
cyanamide 2
volitional 2
7-15% 2
postcyanamide 2
(Ro4-4602). 2
l-aromatic 2
(nucleus 2
accumbens) 2
Methylene 2
benzoate-treated 2
3,4-hydroxybenzyl-hydrazine 2
oxidase-B 2
(-)-deprenyl 2
19-6327. 2
(NSD-1015; 2
intraperitoneally) 2
N-acetyloctopamine 2
Schistocerca 2
gregaria 2
L-[3H]tyrosine 2
N-acetylcompounds 2
L-[3H]tyrosine, 2
haemolymph 2
metabolised 2
Ψ 2
2621 2
1911, 2
Psi 2
Derivatives 2
f(5)U-containing 2
(MDR1/P-glycoprotein 2
ABCB), 2
(BCRP 2
ABCG), 2
P-glycoprotein, 2
(MRP)/ABCC 2
(ABCC5) 2
(MRP5/18S-ratio 2
ABCC11, 2
ABCC13 2
(pseudo-gene) 2
(GS-X 2
pumps) 2
16q12. 2
(ABCC1-12), 2
resistance-like 2
ABCC12 2
(ABCC) 2
sub-family. 2
(MRP; 2
ABCC4. 2
double-transfected 2
concentrative 2
(ABCC)] 2
(ABCC-MRP), 2
glutathione-conjugates. 2
flag 2
resistance-related 2
(MRPs/ABCCs) 2
MRP1-MRP9 2
MRP6/ABCC6 2
Pseudoxanthoma 2
macrophages) 2
IL6/STAT3 2
72-aa 2
(pro-hepcidin) 2
[3] 2
hADSCs, 2
hADSCs. 2
C/EBPα), 2
(Cidec, 2
RIP140) 2
mol/L). 2
CIDEC/ 2
Adipocyte-specific 2
WAT, 2
(Fsp27(ΔAd)) 2
aP2-Cre 2
dispersed. 2
Fsp27(F/F) 2
diet-treated 2
(1-173 2
(174-238 2
106-173 2
ER-binding 2
lipid-deficient 2
FSP27, 2
120-220, 2
PLIN1. 2
lipolysis), 2
factor-α-like 2
PI-103 2
API-2 2
Akt1/2 2
JNK1, 2
droplet-coating 2
lipase, 2
fenofibrate, 2
FSP27/CIEDC 2
Fenofibrate 2
Awaiting 2
coffee, 2
prudent. 2
Implicit 2
'first 2
72.5 2
31-93] 2
OPS. 2
[1.72-2.72] 2
p=0.0025) 2
(Orpington 2
Fugl-Meyer 2
Units. 2
GUMS 2
neurosis 2
(GITRL) 2
(GITR) 2
(liposome-clodronate 2
Clophosome-A(TM)) 2
(anti-CD4 2
FTY720) 2
GITR 2
GITR(+) 2
Clophosome-A(TM). 2
Triptolide 2
(n=8 2
Z-FL 2
(CCL-1), 2
Telomerase: 2
Inside. 2
length-independent 2
Telomerase-mediated 2
indefinitely. 2
AAV9-Tert 2
post-recycling 2
final-or 2
re-initiation. 2
FeS 2
ribosome-recycling 2
eRF1-ABCE1. 2
(GTP)-bound 2
cryoelectron 2
termination/prerecycling 2
Ltn1 2
(SFBBM). 2
SOD. 2
Septooptic 2
IOP, 2
hypoplasia/dysplasia 2
chiasma 2
repetition, 2
Morsier, 2
[Optic 2
(OCA-1∼4, 2
(HPS-1-9, 2
CHS-1). 2
OCA-2 2
HPS-1 2
(Hermansky-Pudlak 2
syndrome-1) 2
HPS1 2
OCA-4) 2
(PUAs) 2
SLC45A2) 2
(p.C112R, 2
p.H363R 2
p.G379V 2
TYR) 2
PUA 2
(p.S222del 2
(p.P152H 2
p.W272X 2
p.A486T 2
co-transmit 2
(p.Q83X 2
p.A658T 2
p.G161R 2
p.G366R 2
p.S192Y 2
Type1A 2
(OCA1A) 2
husband, 2
(D11S1887 2
informative). 2
MboI-RFLP 2
MboI 2
albinism--minimal 2
hairbulb 2
matured. 2
Irides 2
biomicroscopy, 2
transparency. 2
(OCA1MP). 2
epidermal, 2
TYR-related 2
(TYRP1, 2
TYRP2), 2
(LAMP1) 2
geniculate 2
pseudogene-TYR 2
(TYRL, 2
11p11.2, 2
191270), 2
full-proof 2
TYRL. 2
"uncharacterized 2
mutations" 2
(UCMs) 2
evidences, 2
UCMs 2
TYRL 2
c.549_550delGT 2
OCA4. 2
p.I151S 2
wife 2
p.I151S, 2
albinism]. 2
(MATP). 2
OCA4, 2
uw/uw 2
(tyrosinase-related 2
Dct 2
(DOPAchrome 2
tautomerase); 2
pink-eyed 2
A481T 2
Q799H 2
"coincidence 2
syndrome"? 2
Ziprkowski 2
adaptive. 2
lato" 2
Naumovia 2
castellii, 2
allantoin, 2
non-inverted 2
castellii 2
DAL1 2
DAL4. 2
DAL4 2
(SUT614) 2
(HexDiff) 2
E3. 2
denaturant-resistant 2
MAP2c. 2
(ApoE2, 2
ApoE4) 2
(APOE 2
ε2, 2
ε3, 2
ε4) 2
(DG) 2
ɛ2, 2
ɛ3, 2
ɛ2 2
UCE-like 2
distachyon 2
drosophilids 2
(Robert 2
Koch 2
Pasteur), 2
persuade 2
anthrax-malignant 2
anthrax), 2
woolsorter's 2
(pneumonic 2
anthrax). 2
expression/activity 2
Telomelysin 2
field: 2
centromere-linked 2
LYS1 2
CYH1 2
TPS13 2
RAN1 2
'octasomes', 2
cenH3) 2
overproduced. 2
hemisomes. 2
Hemisome 2
gelFRET. 2
78-bp 2
octasome 2
Gomafu-associating 2
Gomafu/MIAT/Rncr2 2
SF1, 2
Cardiorespiratory 2
inspiration 2
lupus-induced 2
pleurisy 2
polyarthralgia, 2
AIH. 2
ninety-nine 2
Riyadh 2
(1990-2005) 2
7.23 2
58.79% 2
(78.6%) 2
opportunistic. 2
(C3 2
C4), 2
(childhood-onset 2
lupus/juvenile-type 2
pediatric-onset 2
342 2
Debrecen, 2
immunoserological 2
software.Gender 2
Anti-SSA, 2
anti-SSB 2
(15.2% 2
5.3%) 2
adults.These 2
NMO-IgG 2
arthralgia); 2
rash); 2
(proteinuria 2
hours); 2
(positivity 2
(ANF), 2
anti-double-stranded 2
Coombs, 2
aCL 2
IgM). 2
NMO. 2
Th1-mediated 2
"rhupus", 2
Rembrandt 2
Rijn's 2
(1606-1669) 2
Bockenolle, 2
rhupus 2
Kikuchi's 2
(NM), 2
(SPB). 2
IR-L 2
IR-R 2
APC/C-E3 2
Lys-9-dimethylated 2
complex-cyclosome 2
(APC/C)-ubiquitin-protein 2
(E3 2
Cut1, 2
Coincidentally 2
H3-Lys-9-Me2, 2
dg-dh 2
cen1 2
cut4, 2
cut9, 2
nuc2. 2
swi6Delta 2
APC-E3 2
dh 2
Clr4/Suv39h1 2
(Clr-C) 2
Ago1 2
RNAi-independent 2
Clr3 2
H4K16Ac 2
H3K4Ac, 2
H3K9Ac 2
H3K14Ac. 2
H3K14. 2
RNAi-deficient 2
BRCA1-PALB2 2
Brca2, 2
crosslinker. 2
PALB2-BRCA1 2
Conditioning 2
(GVHD), 2
(FLU), 2
(CY), 2
GVHD 2
HCT. 2
exporting 2
GFP-FANCA 2
GnRH-induced 2
thumb. 2
Zygotic 2
KCs. 2
CYP2B1/2 2
nanomaterials 2
yolk-sack, 2
fibroplasia. 2
clodronate, 2
propamidine, 2
clodronate 2
intra-hepatic 2
cells--the 2
liver--are 2
GdCl3-treated 2
Quillaja 2
Saponins 2
'coat' 2
Extract 2
Quintana 2
Roo 2
roasted 2
(14.6-28.7 2
inhibited/g), 2
(25.6-52.2 2
unit; 2
meal/ml 2
haemagglutination), 2
(1.9-2.3% 2
diosgenin 2
(8.4-10%). 2
phorbol-12-myristate 2
Quinoa 2
bitter-tasting 2
postharvest 2
saponin. 2
Phytochemical 2
esculentum 2
Antinutrients, 2
phytate, 2
glycoside, 2
tannin, 2
Phytate 2
(112.82 2
tannin 2
(0.21 2
phlobatanin 2
Callosobruchus 2
chinensis 2
groundnut 2
(phytic 2
(5-ASAs), 2
Qing-Dai 2
moderately-to-severely 2
'ménage 2
trois' 2
ménage 2
trois 2
drugs--comprising 2
golimumab--for 2
Current, 2
Biosimilars, 2
approved: 2
blood-mixed 2
Golimumab: 2
[PK] 2
[ER] 2
[PURSUIT] 2
[N 2
proportional, 2
SGC 2
Crohn’s 2
(ECCO) 2
non-flowering 2
(H2A.Z, 2
H2A.W) 2
auditory, 2
(kernicterus). 2
bilirubin: 2
"Kernicterus" 2
neuro-pathological 2
causes]. 2
ears) 2
(BAEPs). 2
jjs 2
jjs. 2
saline/saline 2
post-sulfa 2
kernicterus, 2
Ataxia-telangiectasia 2
MAPK14(-/-) 2
KU55933 2
Beclin1-PI3KIII 2
Beclin1-MAPKAPK2 2
Beclin1/PI3KIII 2
connectivity-based 2
7-14, 2
karyotype-proven 2
45,X/46,XX 2
Pyrosequencing 2
45,X; 2
mosaics, 2
remembering 2
eye-region 2
(46,XX). 2
twin's 2
cisterna 2
magna 2
(min). 2
(39,XO) 2
(45,XO). 2
X-monosomy 2
figure, 2
sequence-optimized 2
enucleation 2
γ-globin 2
(PIM2), 2
(PELOD) 2
Applicability 2
(70.6%) 2
adequately, 2
recalibration. 2
Fayoum, 2
(ISS), 2
PIM2. 2
mortality-2 2
Bahrami 2
value=0.741). 2
0.795 2
(0.715-0.875 2
(1.28-2.465 2
(AOR)=14.75, 2
(AOR=0.13) 2
(AOR=1.03) 2
hspita;ization, 2
[Validation 2
likehood; 2
Units' 2
dead, 2
x2 2
NICU. 2
post-implantation-derived 2
(EpiSCs) 2
Polycomb-deposited 2
EpiSCs, 2
(macroH2A) 2
mH2A-deficient 2
deferasirox 2
transferin 2
saturations. 2
(loss- 2
gain-of-function) 2
(hemochromatosis 2
4B). 2
egress. 2
(HH). 2
HFE, 2
p.R59G 2
p.G204S 2
c.-20G>A 2
c.718A>G 2
2,283 2
1467A>C 2
(R489S) 2
saturations 2
(MFS; 2
TGFBR1/TGFBR2 2
(GULP1, 2
DIRC1, 2
WDR75, 2
ASNSD1, 2
ANKAR, 2
OSGEPL1, 2
ORMDL1, 2
LOC100129592, 2
C2orf88, 2
HIBCH, 2
INPP1, 2
MFSD6, 2
TMEM194B, 2
NAB1, 2
GLS, 2
STAT4), 2
(COL5A2, 2
MSTN) 2
hypertrophy). 2
[Non-HFE-related 2
overload]. 2
Non-HFE-related 2
hemojuvelin, 2
non-HFE-related 2
(11-12 2
(+/b) 2
8-isoprostane 2
glutathione/glutathione 2
Iron-copper 2
Divalent 2
H(+)-coupled 2
hDMT1 2
Hypochromic 2
transition-metal 2
(BBM). 2
Ni(2+). 2
(BBMV) 2
(BLMV) 2
BBMV; 2
BLMV 2
Microcytic 2
(mk/mk) 2
G185R 2
(hERG 2
1a-G965X 2
(226 2
men/187 2
(QTmax), 2
QTV(2), 2
Deoxyribonucleic 2
2690A>C 2
(477 2
(441 2
0.026) 2
CONCLUSIONS; 2
depolarization-activated 2
segments), 2
segments). 2
voltages. 2
'slow 2
inactivation' 2
(As(2)O(3)), 2
As(2)O(3)-induced 2
(hERG-HEK) 2
As(2)O(3). 2
As(2)O(3) 2
HERG-mediated 2
(N598, 2
N629). 2
N598 2
N629 2
(N629Q) 2
(HERG 2
11.1) 2
pAML 2
2690 2
A>C 2
.0024). 2
897T 2
pAML. 2
norfluoxetine. 2
Prozac 2
IhERG 2
TCRT 2
(QVLQT1 2
LQT1, 2
LQT2), 2
(SCN5A 2
LQT3), 2
(KCNE1 2
LQT5 2
MiRP1 2
HERG). 2
(NAT) 2
(sei), 2
Ether-à-go-go 2
human-ether-a-go-go-related 2
N470D 2
EAG 2
Nedd4-2, 2
B-RAF. 2
related-gene 2
(TKI). 2
(n=51), 2
VEGFR1-3, 2
FGFR1-4, 2
mRCC, 2
mRCC. 2
CHD3 2
SWI2-related 2
online.. 2
Motifs 2
Adenylate 2
uridylate 2
Rich 2
UnTranslated 2
Dynamics. 2
[Case 2
fulgurating 2
yelling 2
cars 2
video-polysomnography, 2
video-polysomnography 2
N2; 2
snoring. 2
(Apnea 2
Hypopnea 2
Index: 2
prescribed; 2
Methylation, 2
Moiety 2
Time. 2
lysine-20 2
Suv4-20h2 2
H3K79Me2 2
replicator 2
Inc.</C 2
"crown-like" 2
HU) 2
CDS, 2
(CDS). 2
(10,100/µl) 2
(CRP; 2
8.63 2
antiparkinsonism 2
(CPDD) 2
spondylodiscitis. 2
rheumatica 2
crownlike 2
peri-odontoid 2
abarticular 2
occipito-temporal 2
Brudzinski's 2
fevers 2
cervico-occipital 2
segmentary 2
rotation. 2
(crowned 2
chondrocalcinosis. 2
soreness. 2
(XB-2) 2
1877 2
(lichen 2
damaged), 2
koebner 2
26-years. 2
psoriasis]. 2
0.055 2
exanthematic 2
Koebnerized 2
distensae. 2
(PPD), 2
(MRV), 2
eighth, 2
12th, 2
16th, 2
induration, 2
Koebner-negative 2
craniopharyngiomas, 2
panventricular 2
germinoma; 2
germinomas. 2
(WBI). 2
CT-scan-based 2
laterals 2
posterior) 2
two-field 2
6-field 2
"hand-made" 2
computer-optimized 2
9-field 2
subfrontal 2
preceeded 2
(NTCPs) 2
NTCPs 2
("hand 2
made" 2
"inverse") 2
(0.3-2.5%) 2
age-modifying 2
plans). 2
Modulated 2
subsites 2
Embryonal 2
acyl-CoA-dependent 2
size-exclusion 2
BnaC.DGAT1.a 2
acyl-CoA:diacylglycerol 2
O-acyltransferase 2
Pandharpuri 2
1,2-acylCoA:diacylglyceroltransferase-1 2
esterifies 2
TAG. 2
TAG, 2
V/cm 2
DGAT1-deficient 2
Diacylglycerol-O-acyltransferase 2
(DGAT1 2
I/D 2
dimer/tetramer 2
diacylglycerols, 2
DGAT2, 2
ARAT 2
Triacylglycerol 2
oilseeds 2
pollen, 2
(DGATs) 2
DGAT2-overexpressing 2
DGAT1-overexpressing 2
Mortierella 2
CoA:diacylgycerol 2
(EC; 2
DGAT) 2
RELA 2
fusion-positive 2
K27M-mutant. 2
GSKJ4 2
K27M-expressing 2
H3.1) 2
(R132H) 2
58.1%. 2
.020) 2
(CDK6) 2
damage-related 2
V4.1 2
Regulome 2
SNV. 2
rs9267576 2
17245 2
17425 2
low-tone 2
(hypoacusia, 2
dizziness) 2
abscessual, 2
unforeseeable 2
(ECoG) 2
Transtympanic 2
65/91 2
EH. 2
[Secondary 2
cochleo-vestibular 2
otosclerosis, 2
chronicotitis 2
hemophilus 2
embryopathic 2
Ménières 2
migraine-Ménière's 2
dizziness: 2
(EDSs) 2
EDSs. 2
EDSs 2
EDS), 2
(wrist) 2
(community 2
CPITN 2
(mucosa, 2
pulp) 2
(TMJ 2
ruptures. 2
syndrome(s) 2
traumas. 2
kyphoscoliosis-type 2
VI), 2
KESS 2
FBD 2
hyperelasticity 2
LH2. 2
guide, 2
[Ehlers-Danlos 2
hypermobility; 2
hypermobile, 2
arthrochalasis 2
dermatosparaxis 2
fibrillar-collagen 2
tenascin-C 2
EDS-PNH 2
pseudoaneurysm 2
calcium-phosphorous 2
(femoral 2
absorptiometry, 2
(Z-scores 2
Fractured 2
[Vascular 2
dominated. 2
tenderness. 2
Ultrasound. 2
Thrombophlebitis 2
thoracoepigastric 2
indurated 2
Braun-Falco 2
1955. 2
(MBGs), 2
hydroxypyridinonate, 2
thiol, 2
N-hydroxyurea 2
Fe(3+) 2
(HIV-1 2
IN) 2
(MBG) 2
(INSTIs) 2
raltegravir. 2
INSTIs, 2
(hydroxypyrones) 2
N-formyl-hydroxylamine 2
BB-3497 2
8-hydroxyquinoline 2
metalloprotein-focused 2
Interscience 2
VT-1129 2
VT-1161 2
Viamet 2
hydroxamate-containing 2
catecholate 2
LF. 2
LF, 2
compounds--2,2'-dipyridylamine 2
(DPA) 2
triazacyclononane 2
(TACN)--as 2
ZBGs 2
(phosphonoformate 2
trisodium 2
salt), 2
(CA, 2
subtraction-based 2
(DOXO) 2
hCPCs 2
calcium-related 2
SMP30 2
hCPCs, 2
(CBR1) 2
CBR1 2
doxorubicinol 2
Cbr1 2
[WT] 2
DOX+TRZ, 2
Twisting 2
ironing: 2
diligent 2
Novantrone 2
superoxide-inducing 2
Thepirubicin 2
cardiotoxic, 2
(Top1mt) 2
Top1mt, 2
52±10 2
5.5±3.0 2
244.5 2
71.4%; 2
70.9%; 2
0.741; 2
0.608-0.874; 2
(p47 2
Nox1) 2
All-trans 2
MDX 2
7-Monohydroxyethylrutoside 2
(monoHER) 2
monoHER. 2
monoHER, 2
with(out) 2
VCAM 2
(4-demethoxy-daunorubicin) 2
MHC-CB7 2
Lymphangiectasia. 2
(Waldmanns 2
(CA)25 2
(CAG)30 2
Y-chromosome. 2
(SHR). 2
LINE-L1 2
PEW 2
sTWEAK 2
in-hospital, 2
mPTX3 2
chorioamnionitis, 2
APGAR 2
µg/L) 2
µg/L; 2
000). 2
<0. 2
5%), 2
CK-MB 2
79; 2
value's 2
844, 2
Multidrug-resistant 2
19606 2
86. 2
CFU, 2
(KC, 2
RANTES) 2
recruitment/activation 2
10-fold-greater 2
postchallenge, 2
(1,561 2
shock: 2
ALBIOS 2
0·001) 2
Smaller 2
endotoxaemic 2
lung-common 2
post-admission, 2
admission: 2
=.00097). 2
537 2
(SIRS 2
(14.1 2
AUC(ROC) 2
0.66-0.81, 2
0.58-0.79, 2
sepsis) 2
28.In 2
(H2BK5me1, 2
H4K20me1) 2
active-promoter 2
159, 2
CBP80. 2
ABA-treated 2
cbp20/80 2
MYB33 2
MYB101 2
HYL1. 2
Analogously 2
non-protein-encoding 2
3'-poly 2
sequence-complementary 2
(pre-miRNA), 2
DGCR8, 2
miRtrons, 2
debranching, 2
gamma-herpesvirus 2
(MHV68) 2
tRNase 2
Z, 2
hosting 2
pri-let-7a 2
chopped 2
∼21 2
DCL1. 2
(pre-miRNA). 2
mir-23a 2
27a 2
24-2. 2
main, 2
sequon 2
204. 2
(F340L 2
H404P) 2
bindng 2
R52I 2
G97R 2
H19Q 2
hemocyanin, 2
Mendel's 2
hinted 2
Albinism, 2
[OCA]), 2
[OA]), 2
fovea 2
function/structure 2
(http://www.cbc.umn.edu/tad). 2
929insC. 2
IVS4+ 2
3A>T 2
G253E 2
IVS4+3A>T 2
G253E, 2
(Equus 2
north-west 2
albinisms 2
OCA1) 2
coloured 2
trio 2
exonintron 2
forecasted 2
nosogenesis 2
203100) 2
1.14.18.1) 2
CuA 2
CuB 2
(TYR). 2
(tyrosinase, 2
TRP1, 2
TRP2) 2
slaty 2
melanosome, 2
(HPS) 2
Double-Row 2
25.9 2
Xenograft 2
Polypropylene 2
(mRCT) 2
Re-tear 2
DB, 2
secondary. 2
Stiffness 2
knotless 2
transosseous-equivalent 2
(KL-TOE) 2
30° 2
127% 2
rotator-cuff 2
debridement; 2
Visualase 2
(MRgLITT) 2
Demographics, 2
America's 2
(90.2%) 2
64.3% 2
(laser 2
per-operative 2
immunotherapy...), 2
(radiosurgery, 2
focalized 2
ultrasounds, 2
radiosurgery-resistant 2
(LGGs) 2
gliomas' 2
(MRgLITT)) 2
LGGs. 2
19-month-old 2
navigation-guided 2
bolts 2
secured 2
ganglioglioma. 2
LGGs 2
cytoreduction. 2
trajectory-laser-while 2
midbrain-thalamic 2
post-ablation 2
coadjuvant 2
MRIgLITT 2
(radiofrequency, 2
microwave, 2
cryosurgery, 2
Gliomas. 2
LITT. 2
Frontal 2
(599-627) 2
LxxLF 2
Mcd1 2
SWR-C, 2
H3K56. 2
SWR1-Com 2
Swi2/Snf2-paralog. 2
(Htz1 2
H2AZ-binding 2
Swc6 2
Arp6 2
Swc5 2
H2AZ-containing 2
(Swr1 2
Swc2, 2
Arp6, 2
Swc5, 2
Swc6) 2
(arp4-td) 2
Swc7 2
Swc7. 2
Act1, 2
SWR1-catalyzed 2
H2A-H2B, 2
H2A.Z-H2B. 2
(Htz1p). 2
476-amino 2
acid-long 2
mutants' 2
Swc4p, 2
SWR1-C, 2
ARP6. 2
SEF 2
internodes, 2
bushy 2
noninductive 2
photoperiods. 2
MADS-AFFECTING 2
FLOWERING4 2
CONSTANS 2
photoperiod-independent 2
flowering1 2
(pie1) 2
(arp6) 2
pie1 2
SWR1C 2
(AtSWC6), 2
FRIGIDA 2
(SUF3) 2
PHOTOPERIOD-INDEPENDENT 2
(PIE1), 2
SWC6, 2
serration, 2
(FLC), 2
SUF3 2
SUF3. 2
PIE1, 2
SUF3, 2
atswc6 2
suf3. 2
SWR1C-like 2
FLC. 2
Chz1, 2
H3K56Q. 2
Msc1 2
Swr1-mediated 2
Bayes' 2
theorem. 2
10(-3). 2
(60.5 2
ODM-associated 2
cesioflammea 2
(melanocytosis 2
Melanocytosis 2
positing 2
meta-analyzed. 2
PS-TL 2
LTL 2
Cross-sectionally, 2
UHPLC-HRMS/MS. 2
(HGA) 2
sapida 2
Koenig), 2
nutritious 2
staple 2
working-class 2
samara 2
pasture 2
cartridges), 2
dansyl 2
UHPLC-HRMS/MS 2
0.8-500 2
μg/L). 2
446.9 2
87.8 2
(Suriname) 2
Fruit 2
Jamaica 2
"Jamaican 2
retardation/dementia 2
[14/29], 2
[15/29], 2
[11/29], 2
[11/29]). 2
p.F72L/p.R635Q; 2
B2: 2
p.Q452X/p.R635Q). 2
dystonia-parkinsonism, 2
atrophy/hypoperfusion, 2
(Sylvant™), 2
Gк 2
(herpesvirus-8 2
(iMCD), 2
IL-6), 2
discretion. 2
Hypertriglyceridemia 2
every-6-week 2
human/murine 2
G1kappa 2
(IgG1kappa) 2
EMA. 2
'degrons'. 2
degron-based 2
Ac/N-end 2
Arg/N-end 2
(N-recognins) 2
Gα(q)-mediated 2
(N-degrons) 2
"degron", 2
Degron-based 2
POI--degron 2
(A/M) 2
FOXE3 2
sclerocornea 2
anophthalmia/microphthalmia 2
(anophthalmia/microphthalmia) 2
c.70del20 2
AARSs. 2
event(s) 2
(EPRS), 2
L13a, 2
Cdk5-dependent-AGC 2
Ser(999); 2
Ser(77) 2
EPRS, 2
GAPDH 2
Diphosphorylated 2
Ser(999) 2
Lipoidica 2
0.3-1.2% 2
shins. 2
patient--case 2
Miescher 2
Becaplermin 2
lipoidicum 2
well-circumscribed 2
reddish 2
(Shall 2
practised, 2
dibeticum 2
(NBL), 2
Anti-TNFα 2
attention-demanding 2
Deficit 2
Hyperactivity 2
DRD5, 2
DRD2, 2
toxin-positive 2
ΦCULC0102-I, 2
13129. 2
(toxigenic 2
ulcerans) 2
toxoids 2
diphtheria: 2
(beta)(tox-201,tox-9) 2
(beta)(tox-107). 2
ulcerans]. 2
benzylpenicillin. 2
intradermally 2
corynephage 2
[Diphtheria 2
1956-1989. 2
bacteria]. 2
diphtheria-associated 2
tox, 2
dtxR, 2
Epidemic 2
biotype 2
overseas. 2
3,753) 2
Beaver 2
Dam, 2
decibels 2
2.79; 2
7.36). 2
chickenpox, 2
pertussis, 2
polio, 2
rubella, 2
ofapoptosis 2
pseudodiphtheriticum, 2
azure 2
Romanovsky-Giemsa. 2
Apoptogenic 2
tox-bearing 2
cost-effectively. 2
calciotropic 2
non-calciotropic 2
ligands; 2
Editors: 2
Jacques 2
Haiech, 2
Claus 2
Heizmann, 2
Krebs, 2
Thierry 2
Capiod 2
Olivier 2
Mignen. 2
(OGR1) 2
H(+), 2
(CASR) 2
change; 2
Study: 2
Participants. 2
8-17 2
inclusive) 2
visit). 2
4136 2
throbbing, 2
phonophobia). 2
18-binding 2
sham: 2
I/R: 2
IL-18BP: 2
IL-18's 2
IL-18BP) 2
IL-18-Binding 2
IL-27, 2
µg/kg 2
packed, 2
Ssl2/XPB 2
TFIIH. 2
(E62K) 2
(Rad25) 2
XPB 2
(H508R) 2
DEVH-containing 2
Ssl2, 2
0.88). 2
stroke', 2
[ROCKET-AF]), 2
≥3. 2
fibrillation-Rocket-AF 2
0.396 2
0.601). 2
0.892 2
0.840 2
0.947). 2
meaning). 2
-Rocket-AF 2
Asia: 2
hematocrit, 2
ROCKET-AF, 2
averages. 2
∼18 2
5.29 2
MB: 2
≥133 2
<65 2
<75, 2
>0.11 2
Unsuitable 2
Antagonist 2
unsuitable. 2
MET-inhibiting 2
Placebo-Controlled, 2
GO27819 2
(Ona 2
(Pla 2
Bev, 2
Bev. 2
METGastric, 2
(HER2)-negative, 2
MET-positive, 2
(OS 2
0.64; 2
MetLung 2
"embolic 2
onartuzumab-treated 2
MET/hepatocyte 2
MET-specific 2
tivantinib, 2
(Fc 2
CD80 2
MOG-specific 2
reverse-translational 2
plasmablasts 2
(HV). 2
IFN-beta-treated 2
neuro-antigens. 2
B-cell-targeted, 2
epratuzumab, 2
toxin-single 2
(DC2219), 2
abetimus 2
Subset 2
transmigrate 2
CXCR5 2
Checkpoints 2
B-cell-directed 2
immunodeficiencies. 2
S1P4 2
S1P2 2
CD69 2
beige-like 2
MC148R2. 2
MC148R 2
CXCL12α-mediated 2
MIP-1α-mediated 2
5'-(T/C)CCTT-3' 2
practitioners' 2
DocStyles 2
51-100 2
cases/year. 2
Cryotherapy 2
OB/GYNs, 2
curettage. 2
resolve", 2
spread", 2
"Don't 2
away" 2
given; 2
autoinoculation. 2
poxvirus. 2
papillomavirus, 2
accuminatum, 2
molluscum, 2
molluscum. 2
scabies 2
CMX-001, 2
poxviruses, 2
NF-кB 2
dermatotropic 2
MC159 2
(IVS8+5G>A, 2
IVS2+4delAGTA), 2
(c.621T>G 2
(p.D207E)) 2
(c.1211-1212delTG) 2
429. 2
c.621T>G 2
time-saving 2
Tay-Sachs-causing 2
(HEX 2
(Hex) 2
beta-D-N-acetyl-hexosaminidase. 2
Canadians 2
enzyme-defined 2
Azeri 2
-857C 2
2313 2
articular, 2
urogenital, 2
aphthae 2
aphthae, 2
Silk 2
Road 2
portacaval 2
patency, 2
PSE, 2
aphtha, 2
Fear 2
often-fatal 2
Δpla 2
Environment 2
(CDPHE) 2
luteola 2
carry, 2
CO92 2
mankind, 2
pandemics. 2
plague: 2
bubonic, 2
septicemic, 2
pneumonic, 2
antiplague 2
droplet-borne 2
inhalatory 2
Arua 2
YopJ 2
(nAChRs) 2
[NRT], 2
important; 2
gum, 2
inhaler, 2
contra-indications 2
(CYP2B6) 2
(CYP2B6). 2
chiral, 2
racemate, 2
(S)-bupropion 2
1.5-greater 2
(R)-bupropion, 2
XL. 2
anniversary 2
antidepressant-induced 2
(amfebutamone) 2
Abstinence 2
2.86, 2
brain-reward 2
bupropion's 2
(SAEs), 2
NRTs. 2
C(2)-ceramide, 2
Purified, 2
(PP2A/C) 2
nicotine-stimulated 2
Mechanistically 2
C(2)-ceramide-induced 2
6A7 2
13-19) 2
Bax-mediated 2
BAX/BAX 2
(DDs) 2
CASP3 2
DGF, 2
alanine. 2
death-promoting 2
evading 2
Bak-Bax 2
Bak-mediated 2
TM1 2
(Bax/Bak) 2
Bcl-2/Bcl-xL-inhibitable 2
multi-BCL-2 2
Bok(-/-)Bax(-/-) 2
Bcl-x(L)) 2
(Bax), 2
bax-induced 2
Manifested 2
Edemas 2
Effusions: 2
sometimes. 2
edemas, 2
dilemma.We 2
benefit.This 2
periumbilical 2
anastomoses. 2
jejunal, 2
lymphangiectasia]. 2
chylaskos 2
Treitz's 2
Intraabdominal 2
reoccurred 2
elastography, 2
Exudative 2
proliferation/capacities 2
α-1 2
colonoscopic 2
C-III 2
(CDG), 2
N-glycosylation, 2
ALG1-CDG 2
delays/intellectual 2
glycosylate 2
pinpointed. 2
(315 2
plants) 2
fungi). 2
(DBDs) 2
JASPAR2016 2
Mis-sesnse 2
owed 2
#302060)/3-Methyl 2
Glutaconyl 2
Aciduria 2
in-silico. 2
accessibilities 2
drifts, 2
Energetically 2
enzyme-ligand 2
Acyltransferase 2
divulges 2
Taffazin. 2
3-6h, 2
baculovirus-Sf9 2
1-[14C]palmitoyl-2-lyso-phosphatidylcholine. 2
phosphatidylcholine-cardiolipin 2
transacylation. 2
Transacylation 2
linoleoyl 2
oleoyl 2
arachidonoyl 2
CoA-independent, 2
acyl-specific 2
monolysocardiolipins 2
mitogenome 2
15,615 2
COII, 2
COIII, 2
tRNASer(AGN) 2
94-bp 2
Reduviidae, 2
Peiratinae 2
Stenopodainae, 2
Tribelocephalinae 2
Ectrichodiinae, 2
supports. 2
Heteroptera), 2
tribes 2
mitogenomics 2
Peiratinae) 2
turpis, 2
Polyp 2
Sinusitis 2
Polyposis: 2
0-8; 2
0-24; 2
0-110; 2
≥8.90), 2
(UPSIT) 2
0-40; 2
[9.4 2
[56.7%]; 2
asthma), 2
-0.3 2
-1.2) 2
-2.4 2
-0.7]; 2
-8.8 2
-11.1 2
-6.6; 2
-18.1 2
-25.6 2
-10.6]; 2
UPSIT 2
18.7]; 2
NCT01920893. 2
Omalizumab 2
co-determined 2
(JBP1 2
JBP1/2, 2
(GGGTTA) 2
Ts 2
JBP2-null 2
JBP2. 2
upstream) 2
Kinetoplastida 2
beta-D-glucosyl(hydroxymethyl)uracil, 2
J-containing 2
fasciculata 2
C.fasciculata 2
000-fold 2
C.fasciculata, 2
L.tarentolae. 2
43-63% 2
Euglena. 2
brush. 2
protodendritic 2
(P2-12), 2
(P12-16), 2
(P16-21), 2
dendriolar 2
(P21-28) 2
P12-P16 2
P21-P28 2
dendrioles, 2
claws. 2
appositions 2
Calretinin-immunoreactive 2
vermis. 2
calretinin-immunoreactive 2
vermal 2
(C57Bl/6), 2
(Wistar), 2
(Cercopithecus 2
aetiops) 2
cerebella. 2
NG, 2
(61.1 2
cells/mm(2)) 2
(P10). 2
(hemispheres, 2
cells/mm(2); 2
deserved 2
(UBC) 2
Vesicular 2
VGLUT2, 2
VGLUT1, 2
VGLUT(s) 2
(lobule 2
MFs. 2
mGluR1alpha(+) 2
calretinin-positive 2
vestibulo-cerebellum 2
dendrioles 2
TBR2-immunopsitive 2
postnatally, 2
synapses: 2
GluR5/6/7; 2
GluR6/7, 2
KA-2, 2
NR2A/B. 2
GluR5/6/7, 2
microns2. 2
(10-90% 2
(I-V) 2
AMPA/KA 2
acetyltransferase-immunoreactive 2
axon, 2
paintbrush. 2
intertwine 2
digitiform 2
claws 2
Branchlets 2
Extraordinary 2
semithin 2
PRC2-dependent 2
c.83A>T 2
(H3K27me2/3). 2
Jumonji- 2
ARID-domain-containing 2
Jumonij 2
(JMJ)/Jarid2 2
Zfp496 2
complex-2 2
(17/22; 2
(26/41; 2
63%) 2
(8/16; 2
glucocorticosteriods. 2
Meladinine 2
(20.9%), 2
(11.3%), 2
(3.5%), 2
nodularis 2
eczema.. 2
LDLRAP1. 2
APOC2, 2
LMF1, 2
GPIHBP1). 2
Abetalipoproteinemia 2
Sar1b-GTPase 2
Dysbetalipoproteinemia 2
catabolism; 2
apoAI, 2
lecithin: 2
'risk 2
allele' 2
913 2
cholesterol<5th 2
<2nd 2
HDL-cholesterol, 2
levels<2nd 2
decile. 2
homozygous/compound 2
PROD 2
Rhomboids 2
rhomboids 2
specializes 2
(27-33 2
cAMP/Protein 2
A/cAMP 2
Calorimetric 2
intake; 2
reinvigorating 2
(fat 2
ignites 2
α1-adrenergic 2
dissipation: 2
brown-adipose-tissue 2
after) 2
thermogenin, 2
overfeeding. 2
PRDM16, 2
adipocytokines. 2
(BAT), 2
PRDM16-C/EBP-beta 2
C/EBP-beta 2
heat-producing 2
energy-consuming 2
expend 2
hibernator, 2
hibernation 2
occupy, 2
(CR, 2
CR'), 2
(AP4-24H11) 2
autoinducing 2
(AIP4). 2
AIP4 2
(agrIV) 2
quorum-sensing 2
agr 2
AP4-24H11 2
agrIV-dependent 2
AP4-24H11. 2
AP4-24H11, 2
dermonecrosis. 2
225D9.2+ 2
(TACA) 2
multi-mimotope 2
(IBDV), 2
IBDV-specific 2
biopanning, 2
5epis 2
epitopes) 2
(F1-F7-B34-2B1-2G8) 2
GGGS 2
spacers, 2
pET28b. 2
mimotope: 2
monoclonal-antibodies 2
ICR-62) 2
M13 2
ICR-62 2
ICR62 2
anti-P-BSA 2
Elicited 2
phage-mimotope 2
self-nature 2
NXS2-challenged 2
IgG2a 2
biasing 2
(MdD) 2
(MdDS). 2
MdD(S) 2
blank 2
boat 2
ride. 2
MdDS, 2
rTMS 2
voyage, 2
p<0.005uncorr). 2
(region 2
pgACC 2
motion/balance 2
sea; 2
reexposed 2
motion/activity 2
antivertiginous 2
debarquement. 2
dizzy 2
disembarkation 2
oceangoing 2
vessel. 2
Asc 2
harvested. 2
Anti-IL-1β 2
gramnegative 2
co-trimoxazole. 2
septicaemic 2
masticator 2
(PNG) 2
C(+) 2
anti-B. 2
disease-endemic 2
Urokinase 2
uPAR-deficient 2
TLR-deficient 2
TLR6) 2
MD-2. 2
TLR4-/- 2
MIP-2, 2
Territory 2
Caledonia, 2
pursue. 2
mortalities, 2
host-protective. 2
diabetes-melioidosis 2
(PC-T2D 2
6]) 2
(WC-T2D 2
8]), 2
(TLR2, 2
CD14), 2
(CD11b 2
HLA-DR) 2
(interleukin-6 2
[TNF-α], 2
[MCP-1], 2
(TLR2), 2
PC-T2D, 2
WC-T2D, 2
T2D-melioidosis 2
(-7202A/G), 2
rs4833095 2
(742A/G), 2
(1804G/T). 2
rs5743618. 2
>99%. 2
rs4833095. 2
Pam3CSK4, 2
Pam3CSK4-induced 2
heat-killed, 2
bio-threat 2
K96243 2
HBPUB10303a, 2
(pathological 2
(Melioidosis). 2
TLR. 2
LY96 2
MD-2), 2
TLR10 2
distant-organ 2
Shows 2
TREM1, 2
Arginase-1, 2
Behaviour 2
Wheel. 2
Thailand, 2
friends 2
Cases. 2
Largely 2
Large-Scale 2
activator-associated 2
easy-to-perform 2
0.06; 2
low-lying 2
dwelling 2
autocorrelation 2
Burkina 2
Faso. 2
Anthropogenic 2
(MIF) 2
Borneo, 2
macrolides. 2
MK-8931)-A 2
Schemes 2
precursor-cleaving 2
neurotransmissions 2
neurophatological 2
IDH+/p53-/1p19q-, 2
IDH+/p53+/1p19q-, 2
IDH+/p53-/1p19q+ 2
66,290 2
13,700 2
catering 2
MYCC/MCYN 2
hMOF 2
β-synthase 2
(ectopia 2
cm3, 2
RP-1127≤10 2
102±23 2
50±33 2
Scale≤4 2
≤3). 2
NCT01268683. 2
NC(Ca-ATP) 2
(glyburide), 2
Pore-forming 2
Gasdermin-N 2
phosphoinositide/cardiolipin-containing 2
10–14 2
protomers. 2
two-domain 2
liposome-leakage 2
Dehydrogenase, 2
Convulsion 2
deficiency]. 2
"oxidative" 2
icterus. 2
nonsperocytic 2
Haiti. 2
high-starch 2
G6PDX 2
bilirubinemia 2
propositus, 2
codeine/codeine 2
Anyone 2
avoided; 2
hemolysis; 2
antipyretic 2
230--300 2
(NSTE-ACS). 2
(DAPT, 2
ticagrelor) 2
hominoids. 2
ALs 2
512 2
coalescent-based 2
gorilla-specific 2
30-40%. 2
ALS/FTD 2
clinic-pathological 2
GGGGCC/ 2
C9orf72. 2
C9ORF72-ALS. 2
(mt 2
9-linked 2
varied: 2
C9ORF72. 2
paranoid, 2
deluded 2
<4% 2
non-mutation 2
similarly. 2
delusions. 2
transactive 2
(TARDBP) 2
c.876_878delCAG 2
(p.Ser292del). 2
progranulin 2
FTLD-GRN. 2
(FTLD 2
388; 2
201). 2
modifier. 2
7.5%; 2
80; 2
FTLD; 2
subtype; 2
familial/sporadic 2
C9ORF72-associated 2
Hexanucleotide 2
(C9orf72) 2
rs1990622 2
(C9ORF72) 2
9p-linked 2
(3.6%) 2
Needle 2
10K. 2
(C/EBPepsilon) 2
(granulocyte) 2
(MBP). 2
eosinophil-specific 2
myelocyte 2
AML14.3D10. 2
MBP-P2 2
Co-immunoprecipitations 2
AML14.3D10 2
C/EBPepsilon(32/30) 2
epsilon(27) 2
C/EBPepsilon(27). 2
MIRA-seq, 2
looping" 2
BUD3 2
Ppn1 2
Database). 2
(HGMD®) 2
underlie, 2
141,000 2
5,700 2
biopharmaceuticals, 2
123,600 2
2012.1) 2
4,514 2
OsY14a 2
severely. 2
Morphologically, 2
nonfarnesylated 2
end-localizing 2
EB1-binding 2
Ser-any 2
residue-Ile-Pro 2
(SxIP) 2
SxIP 2
EB3, 2
EB1. 2
UNIT 2
internalisation. 2
1-metalloproteinase 2
single-variable 2
aptamer's 2
ITC 2
enthalpic 2
Aptamers: 2
expansile 2
(CLIPs) 2
≥3×10(10) 2
Glycation 2
ST(cys+)_(pep9) 2
HSP70: 2
(hTrx). 2
(Stat3)] 2
Anti-peptide 2
(aptamers) 2
superficially 2
biopolymers 2
Rev-binding 2
cusps 2
LiRP 2
gap. 2
block), 2
emboli, 2
(3-MGCA). 2
G4.5, 2
CMP 2
Skiers 2
1001 2
0.236, 2
(MGAP) 2
Triage 2
c-statistics 2
Universal, 2
NOAC-specific 2
postponing 2
education; 2
(DOAC; 2
edoxaban) 2
Non-specific 2
VIIa) 2
655075; 2
(Fab), 2
(PER-977, 2
ciraparantag; 2
Perosphere 2
(~500 2
anivamersen 2
(RB007; 2
Regado 2
pegnivacogin, 2
anticoagulant-antidote 2
heparin/protamine 2
stratified: 2
NCT02207725 2
NCT02220725.). 2
(idarucizumab 2
Xa- 2
(PRT064445), 2
VII. 2
(PER977) 2
Complete, 2
ankyloglossia, 2
46,XX[58]/47,XX,+13[42]. 2
glabellar 2
rocker-bottom 2
hyperconvextity 2
Wales: 2
like, 2
Pallister 2
Killian 2
deletions.. 2
reviewed; 2
jerks. 2
holoprosencephaly, 2
roe 2
male-determination. 2
Sry-negative 2
XXSR 2
Duplications 2
Foxo1. 2
fast-glycolytic 2
IRE1 2
musclin-induced 2
NPR3, 2
NPR3. 2
NP-homologous 2
NPR3 2
acetabuli. 2
Kulman's 2
(7/15) 2
fibrillinopathy, 2
(cbEGF) 2
cbEGF 2
combination; 2
(PCTF), 2
(EPP), 2
co-inheritance 2
coproporphyria), 2
alcohol) 2
hormones) 2
Variegate 2
1.3.3.4). 2
PPOX 2
IVS12 2
(intron 2
porphyric 2
(favipiravir 2
BCX4430), 2
(TKM-Ebola 2
AVI-7537), 2
(rNAPc2). 2
Zaire 2
ebolavirus. 2
Bundibugyo 2
ebolavirus) 2
broad-acting 2
ZMapp(TM) 2
MIL77 2
reignited 2
Kikwit) 2
(NHPs) 2
two-antibody 2
MIL77E, 2
NHPs 2
Makona, 2
MIL77E 2
ZMapp™ 2
2014-2016. 2
cycle-threshold 2
(≤22 2
>22) 2
favipiravir 2
Liberia, 2
Frequentist 2
-15 2
PREVAIL 2
NCT02363322 2
brincidofovir, 2
virus; 2
antiviral-drugs 2
preparedness. 2
preparedness 2
Glycoprotein 2
compassionate-treatment 2
GP—such 2
accessibility—also 2
mutagenesis), 2
escape, 2
MAb's 2
4G7 2
13C6 2
2G4 2
1H3. 2
6D8 2
13F6 2
filovirus 2
(EBOV), 2
KZ52, 2
complementarity. 2
biofarming 2
Ebolavirus 2
benthamiana. 2
[Methylenetetrahydrofolate 2
hallucination, 2
irascibility, 2
drowsing 2
giggling. 2
665C>T 2
deficiency-associated 2
folinate, 2
subluxation. 2
(homocysteinemia) 2
Counseling 2
(C677T 2
A1298C) 2
folate-dependent 2
657, 2
698, 2
1.6- 2
alluding 2
pending, 2
Hcy 2
Hyperhomocysteinaemia 2
TT-genotype. 2
'Mendelian 2
randomisation', 2
Betaine 2
(+/-)mice 2
(ChAT) 2
Phospho-H2AX 2
G0/G1, 2
(p=2.16×10(-4), 2
1.68×10(-3) 2
4.74×10(-3), 2
(p=1.05×10(-3), 2
1.78×10(-3) 2
2.43×10(-2), 2
p=1.64×10(-6), 2
8.11×10(-7) 2
2.04×10(-3), 2
GFP-XRCC1 2
single-ion 2
chromocenters, 2
Epileptogenic 2
0.61-0.92), 2
Evidence. 2
mono-treated 2
TMZ-irradiation 2
irradiation-VPA 2
1,869) 2
AVAGlio 2
(Avastin 2
Glioblastoma; 2
NCT00943826), 2
Status; 2
(PFS: 2
GL261 2
INVM. 2
gattii 2
seller 2
Strategically 2
3-Kinase 2
Maximize 2
Alpha-Positive, 2
PIK3CA-Mutant 2
antiestrogens. 2
GDC-0941, 2
dose/schedule, 2
fulvestrant-resistant 2
Short-term, 2
hypersensitized 2
burst. 2
metronomically 2
hours/day, 2
ER(+), 2
22(9); 2
2250-60. 2
Toska 2
Baselga, 2
2099. 2
HR-positive/HER2-negative 2
ER-positive/HER2-negative 2
(HER2)-negative 2
(2:1, 2
83.8% 2
79.0%) 2
75.4%) 2
[combination:anastrozole], 2
.03); 2
combination:anastrozole 2
.98). 2
(pictilisib), 2
Biomarkers: 2
acylcarnitines, 2
phosphatidylcholines, 2
PTEN-deficient 2
(GDC-0941). 2
inhibitor-resistant, 2
(FERGI): 2
PIK3CA-mutated 2
as-treated 2
NCT01437566. 2
[53%]) 2
[47%]) 2
[67%]) 2
(6·6 2
3·9-9·8]) 2
(5·1 2
[3·6-7·3]) 2
0·74 2
0·52-1·06]; 2
p=0·096). 2
(pictilisib 2
6·5 2
3·7-9·8] 2
5·1 2
[2·6-10·4]; 2
0·42-1·28]; 2
p=0·268) 2
(5·8 2
[3·6-11·1] 2
3·6 2
[2·8-7·3]; 2
[0·42-1·23]; 2
p=0·23) 2
(5·4 2
3·8-8·3] 2
10·0 2
[3·6-13·0]; 2
0·53-2·18]; 2
p=0·84). 2
Ia/Ib 2
140, 2
meaningfully 2
nonenhancing 2
homogeneous. 2
nontumored 2
brain-to-plasma 2
GNE-317, 2
(18)F-FDG-PET, 2
serine-473 2
h·μmol/L. 2
GCIG-CA125 2
once-daily. 2
JMML. 2
pictilisib), 2
JMML 2
deacylases 2
miRNA-138 2
(SOX4) 2
miR-138-mediated 2
Cholangitis 2
FGF-19 2
(& 2
FGF-15), 2
INT-747. 2
enterocyte-released 2
FGF19) 2
Cyp7A1-mediated 2
"cirrhosis", 2
Cholangitis: 2
(UDCA), 2
(AMCP) 2
Nexus 2
Navarro, 2
PharmD, 2
CPE-accredited 2
titled 2
"Medical 2
Cirrhosis." 2
panelists 2
Christopher 2
Bowlus, 2
MD; 2
Kenney, 2
MBA; 2
Gary 2
MBA, 2
CSP. 2
noncovered 2
anti-mitochondrial 2
polish, 2
Six-ethyl 2
(6-ECDCA), 2
anti-cholestatic 2
(OCA, 2
6-ECDCA, 2
INT-747), 2
UDCA) 2
(ALP, 2
PBC). 2
4.5%, 2
4.0%, 2
16.2% 2
61.1% 2
72.9%. 2
$63,000 2
$902,000 2
(1,330% 2
increment). 2
10.74 2
11.78, 2
$142,300 2
$633,900, 2
$473,400/quality-adjusted 2
$69,350, 2
$100,000/quality-adjusted 2
$18,450/year 2
2017;65:920-928). 2
-113 2
-130 2
liter, 2
liter; 2
(-0.02 2
[-0.3 2
liter], 2
[2.0 2
liter]; 2
POISE 2
NCT01473524; 2
ISRCTN89514817.). 2
offsetting 2
(MICE). 2
Torsade 2
Pointes 2
QT/TdP 2
hERG-blocking 2
torsadogen 2
non-torsadogenic 2
torsadogenic 2
hCav1.2 2
hNav1.5. 2
CiPA 2
CiPA. 2
(hK(v)11.1) 2
Consequently,we 2
(Na) 2
wedges 2
hK(v)11.1 2
waveforms, 2
amiodarone's 2
RESTORE 2
SHD. 2
200-, 2
300-, 2
(31.3% 2
1:48 2
20-base 2
2,061 2
dissections. 2
R240C 2
(JSRV) 2
(OPA), 2
goats. 2
lambs 2
moufflon 2
musimon). 2
bronchiolo-alveolar 2
(OPC), 2
(JSRV), 2
retrovirus. 2
GATA-1/2, 2
MZF-1). 2
(HGMD). 2
geno-phenotyping 2
(UMD-FBN1, 2
(HGMD), 2
Uniprot) 2
2,250 2
4,904 2
1,283 2
77.1%. 2
18.5-33.3% 2
(UMD-FBN1 2
HGMD) 2
UMD-FBN1 2
curated; 2
database.Genet 2
Molecular-genetic 2
c.4211-32_-13del 2
(p.Leu1405_Asp1446del). 2
(10-25% 2
25-27 2
FBN1gene 2
exon18 2
PSIC 2
(Ghent-1); 2
(Ghent-2) 2
(FBN1; 2
154700), 2
C1409S 2
D1155N 2
intron64 2
accepter 2
c.8227-1G>A 2
(UMD-FBN1) 2
dural) 2
locations) 2
fibrillinopathy 2
(structural 2
signalling). 2
frameshifts: 2
16bp 2
(Y1101C, 2
C1806Y, 2
T1908I, 2
G1919D, 2
C2251R) 2
(EGFcb) 2
(V449I) 2
non-calcium-binding 2
(EGFncb) 2
(G880S) 2
"hybrid" 2
IVS1-1G>A 2
IVS38-1G>A 2
46. 2
C628delinsK 2
(1904-1919del 2
(8025insC) 2
(R429X) 2
Y1101C, 2
R429X 2
fibrillinopathy." 2
"clinical" 2
(Ghent 2
nosology) 2
1,009 2
patient)] 2
underrepresented, 2
reaction/ 2
(PCR/DHPLC). 2
(insertion 2
(Exon 2
(46/47). 2
(UMD). 2
apparatuses 2
(University 2
Italy): 2
Cys-missense 2
59-65. 2
c.3602G>A 2
CSGE 2
(fibrillinopathies) 2
C1129Y 2
C1117Y 2
lobster 2
[2], 2
rubber-like 2
cbEGFs, 2
14q32 2
EYA1 2
STAAD, 2
STAAD 2
TAAD. 2
3p24.1 2
24-27 2
microfibrillopathies. 2
tropoelastin 2
Cryopyrin-associated 2
(Arcalyst(TM); 2
anakinra, 2
(FCAS) 2
(CINCA) 2
CINCA/NOMID 2
CIAS1 2
CAPS, 2
February, 2
'Orphan 2
Drug' 2
Trap/Arcalyst(), 2
Pemphigus 2
foliaceus, 2
Th2-dominant 2
(Ig)G1 2
Th1:Th2 2
bronchodilators, 2
Anti-IL-4 2
(dupilumab, 2
tralokinumab) 2
Th-17 2
yet-to-be-defined 2
eosinophils). 2
axes. 2
IL-4R 2
lymphopoetin). 2
phospodiesterase-4, 2
receptor-homologous 2
histamine-4 2
neurokine-1 2
'small 2
Antifungals 2
immunotherapy) 2
(Japan 2
blinding. 2
TOP2B/ 2
Microscopy. 2
polymers-actin 2
filaments-are 2
rotary 2
Aethina 2
Laccase 2
ng) 2
copyright. 2
mercedesae 2
mites 2
mellifera), 2
Nosema-positive 2
spores) 2
Scotia, 2
Prince 2
Island) 2
(Minnesota) 2
51-year-old 2
memorized 2
Domains, 2
intrinsic. 2
levels.DOI: 2
http://dx.doi.org/10.7554/eLife.02557.001. 2
Noordermeer 2
encephalopathy). 2
scalp-detectable 2
fail, 2
15q11.1q13.3 2
Rufinamide: 2
Rufinamide 2
(n=90) 2
(LMCAD). 2
LMCAD. 2
LMCAD, 2
Taxus 2
(SYNTAX) 2
beast 2
CABG, 2
newer-generation 2
-with 2
efficacy- 2
(Coronary 2
Grafting 2
Vs 2
Stenosis) 2
(Evaluation 2
Revascularization) 2
alpha-thalassemia, 2
chromosome16 2
(ATR-16 2
(alpha-thalassemia 2
retardation-16) 2
t(3;16)(q29;p13.3). 2
anticipation. 2
ANGPLT3/4, 2
(RFLPs) 2
Diabetes: 2
RAs) 2
RAs, 2
(2010-2015) 2
RAs. 2
albiglutide, 2
sitagliptin), 2
semaglutide), 2
(empagliflozin). 2
stroke). 2
agonists-one 2
semaglutide-have 2
diabetes]. 2
(imeglimin, 2
analogue). 2
fixed-ratio 2
Semaglutide, 2
contraceptive, 2
ethinylestradiol/levonorgestrel. 2
90%CI 2
(0.80-1.25). 2
(AUC0-24 2
steady-state/semaglutide-free; 2
(1.06-1.15). 2
levonorgestrel 2
[1.15-1.26]). 2
(-4.3 2
≥3x 2
semaglutide/oral 2
coadministration, 2
levonorgestrel. 2
3297 2
standard-care 2
2735 2
(83.0%) 2
1648 2
noninferiority). 2
Nonfatal 2
P=0.12); 2
2.7%, 2
(vitreous 2
photocoagulation) 2
1.76; 2
Nordisk; 2
SUSTAIN-6 2
NCT01720446 2
(103 2
AV-conduction 2
employment) 2
SUDEP-related 2
checklist. 2
peg 2
Psychinfo 2
Gustave 2
Flaubert's 2
tell? 2
stating 2
Bereaved? 2
"Possible 2
submersion 2
Scenarios 2
Centres 2
person-years). 2
non-SUDEP 2
misinformation 2
brain-heart 2
Gabrg2(+/Q390X) 2
parnafungins 2
parnafungins, 2
(parnafungin 2
(cleavage 2
transcription/RNA-processing 2
pRb-binding 2
hSsu72 2
pRb; 2
proliferation/survival, 2
hssu72 2
polyadenylated. 2
Nrd1p-dependent 2
transcanal 2
transpromontorial 2
IAC 2
Otolaryngology-Head 2
(AAO-HNS) 2
Schwannoma 2
transpetrosal 2
(DHI). 2
D90 2
DHI 2
glue-aided 2
schwannomas; 2
6-125 2
microsurgery. 2
'enhancer' 2
blackbox: 2
S3. 2
overlaps, 2
S3, 2
DNN, 2
DNN. 2
DNN 2
β-thalassemia. 2
Beta-thalassemia, 2
Thalassemia 2
Xmn 2
CDP-diacylglycerol. 2
phosphatidylinositol, 2
Yoshida 2
AH-130. 2
AH-130 2
;whole 2
sphingomyelin, 2
phosphoacylglycerols. 2
(4-month-old) 2
(33-month-old) 2
(cardiolipin); 2
16:0 2
polyglycerophosphatides 2
diphosphatidylglycerol) 2
(SFP) 2
(cardiolipin), 2
zwitter-ionic 2
detergent. 2
H2M, 2
Bio-Gel 2
A-1.5 2
phosphatidyl-glycerols, 2
Cu2+ 2
Hg2+ 2
Ni2+. 2
palmitoyltranferases 2
(carnitine 2
palmitoyltransferase) 2
chain-length-specificity 2
malonyl-CoA 2
60-fold, 2
fatty-acid-oxidizing 2
CL's 2
cls 2
cardiolipin-dependent 2
synthase-null 2
(ρ0). 2
Dichotomous 2
pathogen-induced 2
oxidase), 2
arenarum 2
full-grown 2
(DPG) 2
Predicts 2
Post-Traumatic 2
Deployment. 2
Trier 2
(B=-173.40, 2
t=-2.324, 2
p-value=0.023). 2
(N=93; 2
B=-0.054, 2
t=-3.706, 2
p-value=3.66 2
(B=0.037, 2
t=4.173, 2
p-value=6.98 2
Horvath 2
Hannum 2
PTSD-related 2
Post-traumatic 2
stressor, 2
maladaptation 2
Disks 2
Large-Associated 2
(Dlgap2) 2
PTSD-like 2
non-PTSD-like 2
re-dividing 2
(Bdnf) 2
(CA3). 2
(romosozumab 2
abaloparatide) 2
(odanacatib 2
romosozumab) 2
[Osteoporosis]. 2
Odanacatib, 2
cathepsin-K 2
holiday, 2
(aBMD) 2
(DXA). 2
3mg/kg 2
extra-skeletal 2
odanacatib 2
calcilytics, 2
comparator--oral 2
nonrecurring 2
NCT00896532.). 2
remodeling-dependent 2
(BRS) 2
discriminant, 2
(Connor 2
10-item 2
Situated 2
Resiliency 2
Adults) 2
Emotions 2
(Person-situation 2
Adults), 2
(Posttraumatic 2
(Perceived 2
(Davidson 2
.984; 2
Offers 2
Failure. 2
Tri-National 2
(SF)-36, 2
suffice. 2
1,229 2
IES-Revised 2
(IES-R). 2
-0.74 2
-0.79) 2
IES-R 2
MCS, 2
substance-use 2
1,179) 2
Spanish-language 2
Wender 2
(WURS); 2
(CIDI) 2
lifetime/current 2
SUD; 2
(DTS; 2
[PTSD]); 2
Iraq/Afghanistan-era 2
NHW 2
sample; 2
NHB 2
.0029) 2
SPAN. 2
Anger 2
64.6 2
(DTS): 2
generated: 2
78), 2
321). 2
18.1. 2
(SIP). 2
(DTS-S) 2
1,179 2
penal 2
(PTSD): 2
valid. 2
(SIP), 2
(DTS). 2
SIP 2
NIMH 2
(N=3158), 2
(BDII), 2
MINI 2
BDII 2
17-item, 2
(GHQ) 2
(centromere 2
telophase/G1, 2
Polo-ver. 2
built. 2
(Cnp1/CENP-A) 2
Cnp1, 2
Cnp1 2
(Mis18α, 2
M18BP1) 2
Mis18α-deficient 2
Partners 2
Mis18α/β 2
Centromeres. 2
CENP-A-specific 2
(Holliday 2
(Mis18BP1/hsKNL2). 2
(Lac 2
NDC80, 2
attachments. 2
βTrCP-mediated 2
Mis16, 2
Eic1, 2
CENP-A(Cnp1)-specific 2
CENP-A(Cnp1)/H4:Scm3sp 2
(tails). 2
Trypsinized 2
prefork 2
(Semaf) 2
Semaf 2
Cri-du-chat. 2
(5p-) 2
chat. 2
5p15.2. 2
(5p). 2
(5p-). 2
"critical 2
p15.2 2
SETD7, 2
amhc. 2
MYND 2
(SMYD) 2
SMYD5 2
(MO). 2
pu.1, 2
mpx, 2
l-plastin, 2
cmyb, 2
(PD 2
0332991), 2
Amplification/overexpression 2
amplification/overexpression 2
(PD-0332991), 2
D-cyclin-dependent 2
CDK4/6-retinoblastoma 2
(HER2-) 2
(Arm 2
(CDK4/6 2
First-Line 2
(CDK4/6) 2
D-CDK4/6 2
(Novartis), 2
(Lilly), 2
pRb-positive 2
(LEE011) 2
(EPZ-6438) 2
3.3. 2
paedHGG 2
IL-13Rα2 2
K27M, 2
RINTEGA, 2
Prophage 2
G-100 2
MYBL1 2
543 2
SETD2, 2
trimethyltransferase, 2
(11/73) 2
(5/65) 2
(0/45). 2
0.0492) 2
(4/14), 2
0.0055). 2
loss-of-function. 2
Single-molecule, 2
(SMRT) 2
BioSciences 2
species- 2
MEF2. 2
(Ostn) 2
(Ostn), 2
bone-active 2
Osteocrin, 2
COL2A1 2
Achondrogenesis 2
micromelic 2
physical-chemical 2
voided/micturition 2
treatment's 2
(NCT00662909, 2
NCT00689104, 2
NCT00912964) 2
(NCT00688688). 2
(FAS), 2
(FAS 2
(SAF). 2
antimuscarinics, 2
vision). 2
non-clinically 2
(HRQoL), 2
(PPBC). 2
HRQoL, 2
PPBC. 2
antimuscarinics. 2
AEU. 2
(OAB).To 2
tolterodine-controlled 2
(SAAs) 2
Aδ-fibers, 2
isovolumetric 2
1mg/kg, 2
(1mg/kg) 2
β₁- 2
β₂-ARs. 2
Cystometric 2
non-micturition 2
Top-line 2
(CYP)2D6 2
Mirabegron's 2
first-in 2
MEDLINE/PUBMED 2
oxide(NO) 2
over-activity 2
Beta-3 2
(OAB 2
(YM178) 2
(biochemistry, 2
urinalysis), 2
(91% 2
greater-than-dose-proportional 2
(OAB): 2
voided, 2
KHQ 2
-adrenoceptor, 2
pA2 2
μm], 2
SR59230A 2
Mirabegron. 2
(trials=3, 2
n=299, 2
WMD: 2
(trials=2, 2
anti-emetics). 2
Anandamide 2
Antipsychotics 2
anandamide 2
SR141716A 2
(30μg, 2
VCM 2
APDs 2
Merck&Co. 2
Toxin-mediated 2
paracellular 2
actoxumab-bezlotoxumab-mediated 2
FcRn-independent 2
paracellular, 2
transcellular, 2
Rodent 2
(anti-TcdA) 2
(anti-TcdB) 2
actoxumab/bezlotoxumab 2
(Scalp 2
≥3) 2
injections; 2
psoriasis.<CopyrightInformation 2
Apremilast's 2
256066, 2
Corp 2
Otezla®, 2
psoriasis.. 2
PSOR-005 2
Wolaita 2
Omotic-speaking 2
rs1834640 2
Eurasian 2
(rs1426654-SLC24A5, 2
rs1042602-TYR, 2
rs16891982-SLC45A2, 2
rs6058017-ASIP, 2
rs642742-KITLG) 2
rs1426654, 2
rs1042602, 2
rs16891982 2
Epizootic 2
rhabdovirus 2
southernmost 2
Akabane, 2
Peaton 2
bluetongue 2
D'Aguilar 2
Bunyip 2
Creek 2
(arbovirus) 2
transfusion-transmitted 2
(West 2
DV2 2
arbovirus/host 2
vectos. 2
scapularis-derived 2
(viRNAs), 2
viRNAs 2
Arachnida) 2
incriminated 2
Fevers 2
filariasis. 2
(IPM) 2
mermithid 2
(arboviruses, 2
Hanta 2
viruses), 2
[Entomological 2
emergences]. 2
globalization. 2
climate. 2
competences 2
feedings 2
mites, 2
neuropathogenesis 2
Zika, 2
molting. 2
contend 2
molting 2
transovarial 2
Successive 2
(dengue-1-2-3-4 2
smallest: 2
Phloem-feeding 2
insect. 2
Xylem 2
phloem 2
sap-feeding 2
Sternorrhyncha 2
Auchenorrhyncha. 2
phloem. 2
reassignment 2
Zinderia, 2
betaproteobacterial 2
spittlebugs. 2
Nasuia/Zinderia 2
co-resided 2
leafhoppers 2
spittlebugs 2
>260 2
Egger 2
palpitation 2
Diaphoresis 2
0.45), 2
Palpitation 2
normotension 2
citywide 2
(2000-2011) 2
PACS 2
56%; 2
85%; 2
71%). 2
spleen; 2
lipid-containing 2
bilaterality, 2
hiccups 2
[Suprarenal 2
lungs]. 2
neoplasma 2
"round 2
shadows" 2
pheochromosytoma. 2
Inquiry 2
polydipsia 2
atrophied 2
APS-II 2
serositis. 2
-including 2
diaphoresis-to 2
[Pheochromocytoma 2
scintigraphy]. 2
metanephrines 2
1,5 2
norme. 2
MIBG. 2
excessive: 2
77,5% 2
incidentaloms 2
(40.6%) 2
managements 2
perspiration 2
MIBG-J-131 2
extra-adrenal, 2
noticed, 2
ADQI 2
Cardio-renal 2
prevention/protection 2
2): 2
5): 2
"echocardioscopy") 2
function), 2
(PAPs) 2
(TAPSE), 2
echogenicity) 2
movens, 2
CRS; 2
movens 2
renal); 2
NAC, 2
MiRs 2
(~23 2
(15-22 2
Foxo3 2
(ciRNA), 2
p21works 2
circ-Foxo3-p21-CDK2 2
1,314 2
casein-coding 2
(CSN1S1, 2
CSN2, 2
CSN3) 2
CSN1S1, 2
miR-2284 2
(KANGCHEN, 2
practicability 2
hsa_circRNA_102682 2
(circRNA-CER) 2
CircRNA-CER 2
multi-stage 2
strand-specific, 2
periodicity, 2
five-exon 2
(PfGDV1), 2
steatohepatitis. 2
RACE 2
RNAase 2
occurrency, 2
cardiomegaly. 2
Semin 2
OIS 2
lysosome-mediated 2
organelles) 2
viruses). 2
anti-bacterial 2
trehalose 2
3-MA 2
VZV-infected 2
Incidental 2
0.61-0.86) 2
522 2
965 2
(PAR, 2
sophisticatedly 2
cyclindependent 2
primase-polα, 2
topoisomerase, 2
polδ, 2
polɛ 2
Orc1-6, 2
Orc1. 2
orthologues, 2
licenses 2
D-box 2
Orc2 2
Dup 2
5α-reductase 2
(Pre-RC), 2
C4-2AT6 2
Mcm6p 2
(pre-RC), 2
outcross 2
OvineSNP50 2
250C/T 2
(R145X) 2
"T 2
genotypes; 2
T"; 2
C"; 2
C". 2
Dmp1_knockout 2
R145X 2
"T" 2
Xp22.1 2
(c.849+1G>A) 2
(RT)-polymerase 2
(c.849+1G) 2
c.849+519G, 2
c.849+1G>A 2
1.6-Mbp 2
NaP(i)-IIc. 2
(c.228delC) 2
c.228delC. 2
XRN 2
(XLRH) 2
production.Current 2
anti-FGF23 2
FGF23-dependent 2
theories: 2
deffect 2
X.L.F.H.R., 2
higtological 2
invalidism. 2
(5'-nucleotides: 2
GMP, 2
IMP, 2
UMP, 2
XMP; 2
acids: 2
aspartic, 2
virgineoides 2
5'-nucleotide 2
(36.9 2
mg/g), 2
glutamate-like 2
(42.4 2
6.90 2
Agaricus 2
MELD, 2
dermatomyositis 2
anti-IFN 2
51-gene 2
PND1 2
(Hspa8, 2
Hnf4a). 2
'training 2
cohort' 2
75%). 2
p<0.05).Paired 2
biomarker(s) 2
cytokine-driven 2
hypoxia-treated 2
endothelial-based 2
(EFNA3), 2
(ANGPTL)-4 2
degrees: 2
>ANGPTL-4 2
>VEGF 2
>leptin. 2
HIF-2 2
EFNA3. 2
ANGPTL-4 2
HIFs, 2
metabolism-related 2
immune-activation 2
folate-metabolizing 2
MTX/folate 2
ABCC2 2
ABCC5, 2
biologics-specific 2
biologic-specific 2
14-week 2
infliximab-treated 2
league 2
rheumatism 2
=0.011). 2
(MMP12, 2
CCR2), 2
(IGF1, 2
HTR2B) 2
RA-SF. 2
macrophage-polarizing 2
(IFN)-signature 2
(Amsterdam 2
Amsterdam 2
IFN(high) 2
interferon-dependent 2
co-regulation. 2
gigabytes. 2
quality-aware 2
Burrows 2
Wheeler 2
hashing-based 2
aligners 2
SSAHA2, 2
http://bio-bwa.sourceforge.net 2
BWBBLE 2
Seed-based 2
Cloud 2
(BWASW-PMR) 2
Bwasw-Cloud. 2
(EBRT), 2
EBRT 2
23-40 2
Afterwards, 2
(IGRA) 2
(IGRAs) 2
(anti-TNFalpha) 2
T-SPOT.TB 2
QuantiFERON-TB 2
(ISD) 2
new; 2
spacer. 2
connected. 2
RPS24e 2
archeon 2
Pyroccocus 2
abyssi 2
pre-ribosomes. 2
ribosomapathies: 2
(http://www.dbagenes.unito.it). 2
(source) 2
(LOVD) 2
(RPL5) 2
L11 2
(RPL11) 2
RPS19-mutated 2
28S 2
CD34- 2
Nucleolar 2
(Cos-7 2
(NoSs) 2
RPS19: 2
Arg16 2
Gly120 2
Asn142 2
COOH-terminus. 2
Val15Phe 2
Gly127Gln, 2
NoS, 2
mislocalization, 2
[10q22-q23]) 2
13-15, 2
(rob(13q14q) 2
rob(14q21q)), 2
wastage, 2
Rob(14q21q) 2
rob(13q14q), 2
acrocentrics; 2
cen-pter 2
non-disjunction. 2
t(13q14q) 2
t(14q21q) 2
acrocentrics 2
(pTRA-2) 2
enzyme-digested 2
pTRA-2 2
20.4%, 2
21.5%, 2
17.1%, 2
nonacrocentric 2
nonhomologues. 2
13q14q 2
14q21q 2
"p" 2
additions, 2
paints. 2
cohybridization 2
zygotene, 2
pachytene, 2
Directory, 2
disability), 2
3821 2
Leukocytosis 2
nonglucocorticoid 2
concluded, 2
hypertensive-hypervolemic-hemodilution 2
hypervolemia, 2
tirilazad-treated 2
Coilin-p80 2
perimeter. 2
vitellogenic 2
molitor 2
coilin-interacting 2
TAFIID32 2
28-kDa 2
calpain, 2
coilin; 2
snRNP. 2
Nopp140, 2
ribonucleoproteins, 2
Gemin4 2
(hCINAP) 2
snoRNPs. 2
(AK6), 2
ATPase/GTPase 2
(Walker 2
hCINAP-Mg(2+) 2
His79 2
hCINAP-H79G 2
CBs), 2
amino-terminus. 2
p80-coilin, 2
preassembly 2
HeLa(GFP-coilin), 2
(GFP-coilin). 2
GFP-coilin 2
tiny, 2
importinβ, 2
SMN-coilin 2
SMN-importinβ. 2
low-throughput 2
langsethiae 2
Inoculation 2
FgNoxR, 2
ras2 2
map1 2
Ascomycete 2
culmorum 2
breeders 2
pathosystem 2
Tri101 2
FHB-causing 2
foliar 2
ΔFgOS-2 2
phytoalexin. 2
OS-2 2
usarium 2
MetRS 2
PH-1 2
scab 2
security. 2
re-annotation 2
primate. 2
scAAV9-SMN 2
(adeno-associated 2
Fairbanks 2
Gibbon 2
HSV-I 2
GALV-FMG 2
planned, 2
carbon-copy 2
(5C) 2
4.5-megabases 2
(Mb) 2
domain-wide 2
sense/antisense 2
neighbourhoods, 2
Linx. 2
DIC, 2
[Thrombotic 2
multiple. 2
Moschcowitz's 2
[Thrombotic-thrombocytopenic 2
fragmentocytes 2
<5% 2
specified; 2
<5%, 2
Moschcowitz' 2
Airplane 2
travel. 2
airport. 2
Flight-related 2
non-flight-related 2
14/35 2
"Economy 2
class" 2
airplane 2
flights. 2
eminently 2
http://lola.computational-epigenetics.org.nsheffield@cemm.oeaw.ac.at 2
cbock@cemm.oeaw.ac.at.<CopyrightInformation 2
>© 2
[adenosine 2
(ADAR)] 2
hard-wiring 2
dAdar 2
Dalpha7, 2
Dalpha6, 2
ADAR1 2
ADAR-induced 2
(Rhabdoviridae). 2
ADAR-editing 2
dADAT1 2
Tad1p, 2
ADATs. 2
dAdat1 2
(I), 2
age' 2
RRs) 2
(HG) 2
(ALT, 2
AST) 2
MoM; 2
non-trophoblastic 2
vasculature; 2
Priapism 2
hydroxyurea/kg 2
reappeared. 2
re-introduced, 2
hydroxyurea/kg, 2
priapism, 2
(GMFs) 2
Cryptochromes 2
(MFs). 2
Cryptochromes, 2
blue-light 2
compass. 2
Cry1a 2
robins, 2
Earth's 2
feat 2
pairs-magnetically 2
photoexcitation 2
Biogenic 2
navigation. 2
abdomens 2
3(rd)-5(th) 2
macropterous 2
(MagR) 2
(Cry). 2
cry2 2
corpuscle 2
low-field 2
endowing 2
(intramuscular 2
laminectomy, 2
entity; 2
C3-C5 2
isointensity 2
(WI) 2
T2WI. 2
stairs. 2
C2-T2 2
Therapists 2
g/L), 2
macro-proteinuria 2
(>3.5 2
Kashmir. 2
91.73% 2
(43.79%). 2
(FSGS) 2
(16.89%) 2
(13.4%) 2
(11.72%). 2
(4.48%), 2
(3.1%). 2
FSGS 2
(ESRD; 2
26.53%), 2
(71.42%) 2
(81.63%). 2
hypalbuminemia, 2
natriuresis 2
tiopronin 2
Blessed 2
straightforward: 2
oncotic 2
plains 2
protein/24 2
ratios). 2
1,608 2
3.5). 2
generalizability; 2
32-month-old 2
Nishi-Kobe 2
hyperalbuminuria, 2
hypercoagulopathy, 2
(FE(Na) 2
non-MCD. 2
Henoch-Schönlein 2
fimbriata 2
10-week 2
AS/PWS 2
(PRDM12) 2
(TRHDE) 2
CIP-associated 2
Prdm12. 2
hope. 2
(SCN11A, 2
PRDM12, 2
CLTCL1) 2
peduncle, 2
post-surgery. 2
thalassemia/mental 2
(FKH), 2
fkh2, 2
fork-head-associated 2
(FHA) 2
FKHs. 2
Bluetongue 2
(BTV) 2
chemotherapy-caused 2
chemobrain. 2
forgetfulness 2
"chemobrain." 2
"chemobrain," 2
chemobrain, 2
n-butyl 2
cyanoacrylate 2
perforations 2
thrombogenicity, 2
DSA. 2
DSA 2
dural-cortical 2
symbolized 2
"DES," 2
directness 2
Directness 2
(bridging 2
"isolated" 2
fistulas: 2
(SRS), 2
noncavernous 2
52.4%-73.6%). 2
0.66-4.46; 2
p=0.27). 2
1.07-5.28; 2
non-cavernous 2
(ncsDAVFs) 2
(csDAVFs) 2
(ev3, 2
Plymouth, 2
coils, 2
csDAVFs; 2
28-68 2
feeders). 2
petrosal 2
csDAVFs), 2
csDAVF 2
post-operatively, 2
post-embolisation. 2
(95.2%; 2
csDAVFs). 2
re-embolised. 2
embolising 2
Shucart 2
(ICDAVF) 2
Borden(*) 2
0.043) 2
5.880; 2
3.370-10.257; 2
(Expectation 2
Maximization 2
pRofiles), 2
ChIP-seq) 2
microarray) 2
dogmas 2
promoter-enhancer 2
disinhibited 2
deutetrabenazine 2
valbenazine) 2
HD-related 2
antiemetics 2
valbenazine, 2
(+)-α-isomer 2
welcome. 2
blepharophimosis, 2
Cerebro-oculo-facio-skeletal 2
Kahrizi 2
UBE3B-related 2
diagnoses: 2
Buntinx 2
UBE3B-associated 2
mimick 2
"Kaufman 2
blepharophimosis 2
clitoris. 2
slanted 2
seroconversion 2
(alacrima, 2
(ALADIN). 2
1,25-dihydroxy 2
Alacrima 2
A" 2
alacrima). 2
Valley. 2
alacrimia, 2
Alacrimia 2
insensitivity, 2
(Abl2) 2
F-actin- 2
Ph1 2
(Tel) 2
ARG, 2
Dasatinib-bound 2
DFG-in 2
activation-loop 2
family-inhibitor 2
c-abl, 2
aortitis. 2
ulceroglandular 2
(FUO) 2
FUO. 2
11-month-old 2
O-polysaccharide 2
OAg 2
Ab63 2
Ab52 2
terminal- 2
internal-binding 2
(tularemia) 2
tularemia-causing 2
bacterium's 2
inoculums 2
FTT1676, 2
engender 2
holarctica 2
Earth. 2
Prochlorococcus. 2
picoplankton 2
planet 2
non-perfusion 2
Photocoagulation 2
macroaneurysms 2
nonperfusions 2
Panretinal 2
Oftalmología. 2
REPORT: 2
neuroretinitis) 2
telangiectasias, 2
(P-ANCA). 2
exudation, 2
workup, 2
P-ANCA 2
peripapillary 2
neuro-retinitis. 2
Vasculitis 2
available), 2
angiograms, 2
maculopathy 2
noncontributory. 2
(LDLC) 2
(Repatha), 2
(HoFH) 2
FDA-insurance 2
HeFH-CVD 2
ODYSSEY 2
(Repatha) 2
(Praluent), 2
≥130 2
lomitapide, 2
(SAR236553/REGN727) 2
4‑week 2
neurocognition. 2
premiums. 2
(elvitegravir 2
[EVG]/cobicistat 2
[COBI]/tenofovir 2
[TDF]/emtricitabine 2
[FTC]). 2
EVG/COBI/TDF/FTC. 2
≥0.3 2
SCr 2
(EVG/COBI/FTC/TDF 2
Stribild™) 2
Open-Label, 2
Elvitegravir, 2
Cobicistat, 2
Emtricitabine, 2
Emtricitabine 2
guideline-recommended 2
virologically 2
FTC/TDF 2
weird/intense 2
trouble 2
co-formulated 2
bloating/pain/gas 2
INSTI-based 2
efavirenz/emtricitabine/tenofovir 2
(ritonavir-boosted 2
atazanavir) 2
emtricitabine/tenofovir 2
multiple-tablet 2
(1948-September 2
(1966-September 2
GS-9137, 2
9350, 2
quad 2
Stribild, 2
conferences 2
nucleoside/nucleotide 2
Dolutegravir 2
(245 2
cobicistat) 2
(0-24 2
h): 2
undergrowth 2
(Intrauterine 2
Restriction, 2
Metaphyseal 2
IMAGe-associated 2
Arboleda 2
(intra-uterine 2
11p15.5. 2
Intriguing 2
(intrauterine 2
case-case 2
DANBIO 2
(q-value) 2
IgM-rheumatoid 2
1.7(1.1-2.5),p 2
0.6(0.4-1.0),p 2
TLR10/1/6 2
TLR5. 2
disassembly), 2
Ascomycetes 2
(anti-silencing 2
Pyronema 2
confluens. 2
confluens 2
rtt106 2
cac2 2
KAT 2
H2AH2B 2
(H3H4)(2) 2
CIA 2
(CCG1-interacting 2
A)/ASF1, 2
CIA-histone-H3-H4 2
CAF-1 2
CIA-I/II 2
(ASF1a/b) 2
bromodomain-an 2
acetylated-histone-recognizing 2
domain-of 2
CCG1, 2
TFIID. 2
silencing/anti-silencing 2
dimer's 2
CIA-I. 2
CIA/ASF1-histone-H3-H4 2
semi-conservative 2
hand-off 2
Rtt101(Mms1) 2
Antisilencing 2
(ASF1) 2
(H3K56), 2
Vps75, 2
Rtt109-Vps75 2
S-phase-specific 2
Gcn5-dependent 2
HirA/CAF-I 2
Asf1-Rad53 2
chaperone-histone 2
multicystic 2
Children: 2
MHL, 2
crowded, 2
cholangioblastic 2
hepatoblastomas, 2
miming 2
adenomatosis 2
diabete 2
MODY3 2
macronodules 2
Bochdalek 2
HMH 2
cholangiopancreatography. 2
6700 2
hemangioendothelioma. 2
tumor.. 2
exeresis 2
hamartoma. 2
Finegold 2
Surg 2
Jr, 2
1997; 2
worst. 2
Syndromes: 2
Hypotrichosis 2
CDH3, 2
(CDH3) 2
report). 2
(stimulated 2
Intralobular 2
circumvallate 2
leptin-producing 2
parotid) 2
glucagon. 2
leptin-secreting 2
(silver-gold 2
avidin-biotin-peroxidase) 2
labelling, 2
gentamicin-treated 2
adipocytokines, 2
SFs 2
fat-secreted 2
lactate-buffered 2
PD-Bic 2
adipose-secreted 2
hyperleptinemic 2
hepatokines, 2
(HGF)) 2
female-type 2
male-type 2
pituitaries, 2
Metacarpal 2
(distal, 2
middle, 2
metacarpal 2
phalange). 2
cylinder 2
Gujjars 2
phalange 2
flatfoot 2
cracks, 2
corns, 2
humps, 2
forfeits 2
avert 2
(c. 2
802), 2
forefinger, 2
tibiotarsi, 2
tarsometatarsi 2
rarefied 2
phalanges. 2
μg/day, 2
Peri-dosing 2
variables.We 2
lucinactant; 2
peri-dosing 2
.254). 2
>200) 2
(least 2
(SRT) 2
(Surfaxin®) 2
lucinactant. 2
knuckles 2
AIR1/2 2
ZnK1-5 2
air1 2
exosome-binding 2
DECOID 2
mpp6Δ 2
rex1Δ 2
Rrp6-mediated 2
(uRNAs), 2
ess1 2
l1 2
synapse- 2
poly-I:C 2
mutated-deficient 2
nonlymphoblastic 2
non-Down's 2
flowcytometry. 2
Karyotyping 2
(JMML) 2
RAEB-T 2
Flowcytometry 2
(thalidomide, 2
pomalidomide), 2
ixazomib), 2
elotuzumab), 2
(Panobinostat). 2
SLAMF7-targeted 2
(MLN9708-MLN2238), 2
NFκB1 2
Ixazomib, 2
delanzomib. 2
(13, 2
pharmacokinetics-evaluable. 2
0.95-1.5 2
(~99%) 2
2.16) 2
1.82), 2
ixazomib's 2
telemetry. 2
IFN-α-2b 2
(BSA)-based 2
nonmem 2
time-independent 2
1000), 2
BSA-based 2
(153-421): 2
Lipoprotein-Cholesterol 2
∼10-12% 2
(aa153-421) 2
(aa314-355) 2
(P1-P51) 2
15aa 2
(aa153-421), 2
(aa323-358) 2
(aa365-384) 2
(P35-P39 2
P42-P47) 2
HuH7. 2
P47. 2
Cys(323)-Cys(358) 2
D(374)/Y 2
Cys(375)-Cys(378) 2
R(357)/H. 2
hPCSK9(365-384) 2
(∼3.5-fold) 2
PCSK9:LDL-R 2
atheroprotection 2
AML12 2
Ldlr, 2
Pcsk9-mediated 2
Pcsk9, 2
fab 2
bio-panning 2
PA4) 2
panning. 2
escorting 2
(causing 2
LDL-receptor, 2
Site-1 2
(SREBPs) 2
(Blp) 2
(S1P(f/f) 2
LDLR(-/-)S1P(f/f)) 2
Realtime 2
genes/protein. 2
(Blp-c) 2
S1P(f/f) 2
SREBPs. 2
LDLR(-/-) 2
Subtilisin/Kexin 2
sdAb-Fcs 2
Cys-His-rich 2
ALN-PCS, 2
41·8% 2
normocholesterolemic 2
(LDL-c) 2
(LDLR), 2
lathosterol-to-cholesterol 2
LDL-R, 2
B(100) 2
(apoB(100)) 2
Bel-7402 2
Lp-PLA(2)/apolipoprotein 2
antiproteinuric 2
ApoM 2
(n=39) 2
(HOMA-IR). 2
LVPr 2
(LDLC). 2
ultracentrifugation. 2
RLPc 2
microRNA-122 2
law') 2
A*3002 2
DRB1*1501-DQB1*0602 2
(0.92) 2
(0.02). 2
0.76-0.96) 2
(Drug-Induced 2
Score). 2
0.71-0.99) 2
0.75-0.77). 2
(0.89; 2
0.52-1.00) 2
(ALF). 2
771 2
episodes) 2
DILI, 2
TBL 2
(ALT 2
whichever 2
nR 2
chemotherapy-exposed 2
PHL 2
(eDISH) 2
fold-ULN 2
PDE4/CD271 2
(EQ-5D) 2
SF-36v2 2
Arthritis: 2
(Otezla). 2
aTNF 2
doubleblind, 2
1493 2
Discoid 2
(DLE) 2
DLE. 2
PsA: 2
Certolizumab-pegol: 2
Fc-free 2
(TNFi); 2
mAb; 2
TNFi. 2
51; 2
BID: 2
(PsO). 2
PsO. 2
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic 2
Tbr1-deficient 2
connections) 2
excitation/inhibition 2
(NMDAR 2
hypoactivity), 2
(CASK) 2
CASK-TBR1 2
Nmdar2b, 2
hypoactivity 2
Grin2b, 2
molecules-including 2
Cntn2-are 2
EOMES, 2
mcm2-7 2
mcm7 2
ovule 2
endosperm 2
cellularization, 2
endosperm-specific 2
Hexameric 2
unloader 2
late-S-phase 2
Mcm6 2
S/T-P 2
MCM2/7, 2
α-primase 2
dislodging 2
re-loading 2
Ctf4/And-1, 2
RecQL4, 2
Cdc45·Mcm2-7·GINS 2
(Cdc45·Mcm2-7·GINS) 2
Psf1 2
Psf3, 2
Mcm4, 2
Mcm6, 2
Mcm4/6/7. 2
ORC/Cdc6 2
ORC/Cdc6/Cdt1/MCM2-7 2
ORC-Cdc6-Mcm2-7-Mcm2-7 2
bulges 2
'novel' 2
superfluous 2
MetaSim 2
http://facs.biotech.kth.se. 2
Bloom::Faster 2
CPAN 2
http://search.cpan.org/ 2
palvaro/Bloom-Faster-1.6/ 2
henrik.stranneheim@biotech.kth.se; 2
joakiml@biotech.kth.se 2
compactly, 2
Rizk. 2
constitutes, 2
hash-based 2
hashing, 2
Karp-Rabin 2
fingerprint, 2
DBG 2
cache 2
text]-spaced 2
cautions, 2
(phentermine/topiramate 2
Qsymia™ 2
Belviq®) 2
(lorcaserin) 2
(topiramate 2
phentermine), 2
$861 2
$957 2
2030. 2
Qsymia, 2
unamenable 2
(Smo) 2
Vismodegib, 2
Taladegib 2
laBCC. 2
laBCC, 2
vismodegib. 2
sonidegib) 2
NMSC. 2
(Odomzo®), 2
BCC) 2
24-50]) 2
25-43]) 2
hydration). 2
receptor/gene 2
Ptch, 2
(SMO). 2
35-60% 2
Corporation.<CopyrightInformation 2
saridegib 2
(IPI-926), 2
sonidegib/erismodegib 2
PF-04449913, 2
LY2940680, 2
LEQ 2
506, 2
TAK-441], 2
200- 2
800-mg 2
27.8% 2
contemplated 2
1725 2
46,XX/47,XX, 2
tetraploidy 2
amniocentesis? 2
trisomy-21 2
negatives). 2
1:350, 2
amniocenteses. 2
included) 2
(0.5-1.0%), 2
(alpha-fetoprotein 2
15-22 2
manoeuvres. 2
"Triple-marker" 2
estriol; 2
amniocentesis; 2
stress" 2
Triple-marker 2
DS) 2
(MSAFP) 2
(+triple) 2
60.6% 2
immunoassay: 2
ITA) 2
syndrome-directed 2
1448 2
9.5-fold 2
median). 2
(urine 2
beta-subunit), 2
urine-serum 2
estriol). 2
Proliferation: 2
Matters. 2
ERK5, 2
Hsp90-Cdc37 2
superchaperone. 2
MEK5-dependent 2
MEK5-independent, 2
Cdc37, 2
box-binding 2
bHLHZip 2
Max. 2
MYH9, 2
MYL9 2
CYR61. 2
co-IP, 2
MRTF-A. 2
55-kilodalton 2
E1B-p53 2
L22Q/W23S 2
S476/477A 2
L22Q/W23S-mediated 2
MLL-mediated 2
KIX, 2
IE62. 2
(IE62) 2
trans-activation, 2
(TAD), 2
trans-activated 2
ORF61 2
ICP4 2
EHV-1 2
nucleolar-ribosomal 2
(AD1) 2
loop-helix 2
(LH), 2
Da/Sc 2
p300C-TAD 2
reverse-genetic 2
mRNA). 2
(LncRNAs) 2
Province: 2
#32 2
(ISG) 2
encephalomyocarditis 2
(EMCV) 2
EMCV 2
(ATF2) 2
CNCI 2
Exosomes-secreted 2
trans-endothelial 2
cargos, 2
(Assisted 2
40-100-nm 2
ubiquitary 2
urines, 2
urinoma 2
Exosomes. 2
down-modulation 2
EPC-derived 2
nano-sized 2
esRNA 2
(TEX) 2
Tconv, 2
TEX-mediated 2
CD39 2
CDC48-dependent 2
(CDC45-MCM-GINS). 2
CUL2LRR1 2
lrr-1 2
ubxn-3 2
3'-OH 2
TFIIS) 2
II/TFIIS 2
"intrinsic" 2
cuts 2
MNase-hypersensitive 2
(MNase 2
HS) 2
(TNFR1). 2
NF-[Formula: 2
text]B 2
CYS3HIS1 2
2-leucine 2
(CC2-LZ) 2
D406V 2
ZF, 2
di-Ub 2
(arrest) 2
salt-insensitive 2
(influenced 2
(TFIIS). 2
SII/TFIIS 2
uncoiling 2
recoils 2
nucleic-acid-binding 2
Cys4 2
Autodock4.2 2
"Click-By-Click"-protocol, 2
Ligplot1.4.3 2
"change 2
(ΔASA)-calculations" 2
AChE). 2
ΔG 2
SGLT2/SGLT1 2
Hydrogen-bonded 2
molecule-molecule 2
1402 2
(pump 2
[15.2%], 2
(-2.98 2
(-2.8 2
(P≤0.002 2
[17], 2
[4], 2
Lexicon 2
inTandem3 2
NCT02531035 2
insulin/vehicle, 2
neuropreservation 2
impact: 2
synapto-protecting 2
Faucet: 2
Faucet, 2
two-pass 2
meta-data 2
metadata-coverage 2
pairs-contain 2
graphs, 2
Fauceted 2
Faucet,o 2
14-110% 2
Minia, 2
LightAssembler, 2
https://github.com/Shamir-Lab/Faucet. 2
rshamir@tau.ac.il 2
eranhalperin@gmail.com. 2
viromic 2
contigs, 2
metagenomes, 2
metaSPAdes, 2
MEGAHIT, 2
IDBA-UD, 2
viromes. 2
viromics 2
SRCAP-mediated 2
(Nucleosome 2
Methylome-sequencing) 2
methylation-deficient 2
poised, 2
(OCRs). 2
segmentation-based 2
TEPIC, 2
OCRs 2
Histone-Marks 2
open-chromatin/HM 2
CAME: 2
MAPit-BGS 2
(Chromatin 2
Methylation), 2
seed-extension 2
http://sourceforge.net/projects/came/. 2
jechoi@gru.edu 2
khryu@dblab.chungbuk.ac.kr. 2
Methylome-sequencing 2
(scNOMe-seq). 2
epiG, 2
epi-allelic 2
SINE-Alu 2
H3K36-trimethylated 2
'nontuberculous 2
mycobacteria'. 2
(MDMs). 2
(D4GDI), 2
CD4(+C)D25(+)Foxp3(+)D4GDI(+) 2
tb-infected 2
Foxp3+) 2
low-oxygen 2
(70S). 2
microfluidic, 2
DosR-regulated 2
S30AE 2
Δ3935 2
(RafH) 2
DosR-mediated 2
'dormancy 2
Rv0079. 2
rel(Mtb) 2
ctpF 2
(Rv1997), 2
alkali/alkaline 2
CtpF. 2
Pma1 2
3.5-fold, 2
curb 2
(Dormancy 2
Regulator, 2
Rv3133c) 2
latency/dormancy. 2
Obligately 2
Dormant 2
antimycobacterials, 2
oxygen-limited 2
(alpha-crystallin 2
"conserved 2
hypothetical" 2
dormancy-induced 2
gene-disrupted 2
terD 2
(SCO2368) 2
DosR-like 2
coelicolor. 2
tellurite, 2
TerD 2
(tdd) 2
tdd8, 2
M145 2
prodiginine 2
NAD(+)/NADH 2
calcium-depleted 2
Tdd8 2
uninfected. 2
beverages. 2
genetic-epidemiologic 2
acetaldehyde-exposure 2
(lack 2
Aldehyde 2
acetaldehyde, 2
Huang 2
Summers, 2
68:1564-1572, 2
vitro-synthesized 2
net-like 2
hepadnavirus 2
woodchuck 2
DHBV, 2
P<.0001; 2
Tone 2
Hydration. 2
antiaging 2
kinetin, 2
polyhydroxy, 2
glycolic 2
Salicylic 2
P=.00008 2
P=.00221 2
P=.02770 2
LR2412 2
(Retinol 2
0.025%. 2
cosmeticity 2
cream) 2
rejuvenation 2
Ketoconazole 2
Ketoconazole, 2
Minoxidil, 2
isomerism 2
horny 2
(retinoic 2
creams. 2
35), 2
Langerhans' 2
vehicle; 2
decrease) 2
decrease). 2
(erythema 2
scaling) 2
management? 2
SCOPE 2
ATRA). 2
GENERAL 2
SIGNIFICANCE 2
INTEREST: 2
nanoformulations, 2
overpass 2
melasma. 2
(Retinova((R)) 2
photoageing: 2
photoageing. 2
elastosis 2
skin.. 2
bHLH-O 2
(neuroblast). 2
E(spl)mγ, 2
E(spl)mβ, 2
E(spl)m8 2
Deadpan 2
(Dpn), 2
helix-loop-helix-Orange 2
dpn 2
self-renew, 2
Dpn. 2
overproliferation 2
Dpn 2
(Tara) 2
Mis-expression 2
Tara-induced 2
Brat 2
(NBs). 2
neurons/glia. 2
GMC4-2b 2
GMC. 2
Mitimere 2
Nubbin 2
(GMCs), 2
inscuteable 2
(GMC), 2
hemisegment 2
GMC, 2
dPOU28/pdm-2 2
Sp8 2
Buttonhead 2
nonstochastic 2
cells-ganglion 2
(GMCs)-divide 2
Mother 2
Cells, 2
GMCs, 2
Napabucasin: 2
Stemness 2
over-activated 2
Organoid 2
BBI608 2
(Napabucasin), 2
programing 2
Diallyl 2
(Stat3), 2
napabucasin. 2
(BBI608), 2
MPN, 2
ruxolitinib 2
bi-orient 2
origin(s). 2
lcs 2
ARSs), 2
ARS-free 2
travelling. 2
flights) 2
mefloquine, 2
refraining 2
Gynecologists. 2
diving: 2
precautions?]. 2
micro-bubbles 2
Nitrox 2
risk-taking 2
dive, 2
countraindication 2
dive 2
Cell-Mediated 2
(dicaffeoyl-tartaric 2
(Cichorium 2
intybus) 2
(Echinacea 2
purpurea), 2
(HMC)-1 2
48/80-induced 2
skinprick 2
atopy, 2
echinacea-binding 2
Neurexins 2
postsynapses, 2
autism-associated 2
neurexins. 2
R451C 2
knockin, 2
R704C 2
anhydrase-related 2
neurexins, 2
CA10. 2
Nrxn1 2
gephyrin, 2
Antiparallel 2
oligodeoxynucleotide, 2
d(AG)4T-3', 2
d(GA)G7. 2
alphaG-G 2
alphaA-A 2
d(AG)4T-3' 2
4.6. 2
antiparallel-and 2
homoduplexes, 2
multistranded 2
purine.purine 2
gentisate 2
microg/mL), 2
Physicochemical 2
d(TC)n-d(GA)n, 2
d(TC)n-d(GA)n-d(CT)n. 2
TC)(22) 2
(UCSs), 2
fgao@tju.edu.cn. 2
4R 2
Davunetide 2
(XUTs). 2
(as)XUT's 2
nonpromoter 2
Wery 2
18-bp 2
sensor/regulator 2
dosRS 2
DOT) 2
DosR-controlled 2
ESAT-6 2
non-clock 2
(lamina) 2
(Tor, 2
Pi3K 2
Akt1) 2
(Atg5 2
Atg7) 2
Tor, 2
day/night 2
per01 2
synchronizes 2
immune/inflammatory 2
High-glucose-induced 2
high-glucose-induced 2
Nr1d1 2
Drk-mediated 2
anesthesia-resistant 2
Drk 2
Drok, 2
Drok. 2
Drk-Drok 2
Radish 2
(Rsh), 2
translation-independent 2
's>1000 2
®)) 2
5C 2
kilobasepair-sized 2
intrachromosome 2
insulator-like 2
DCC-defective 2
highest-affinity 2
roX1 2
HAS 2
(AIHA), 2
(platelet 2
AIHA. 2
immunosenescence 2
CD28+ 2
(increased) 2
CD21low 2
(ES): 2
intratubular 2
casts. 2
[Evans 2
preeclampsia]. 2
sequentially) 2
anaemia; 2
(notably 2
non-uniformly 2
O(6)-methylguanine-DNA-methyltransferase 2
26981/22981 2
NCIC 2
39.8-65.6). 2
11.9-17.9) 2
0.8-9.0) 2
10.1-17.9) 2
13.9-28.5) 2
Enzastaurin, 2
525-900 2
EIAED. 2
enzastaurin), 2
(cilengitide). 2
everolimus), 2
(vatalanib, 2
enzastaurin). 2
WW/SS 2
macroH2A-like 2
antisilencing, 2
HZAD 2
configures 2
SRCAP. 2
(186-232) 2
214-224, 2
Anp32 2
interleave 2
excitation-based 2
(PIE-FRET) 2
(FLIM-FRET) 2
(Htz1p 2
K12ac 2
K4me3 2
K36me3 2
EPHA2, 2
Intraparticipant 2
1.2-1.4) 2
IIQ-7 2
UDI-6 2
20° 2
CST, 2
"King's 2
43/56 2
10/56 2
(17.86%) 2
TVT-O 2
(n=55) 2
POP-Q 2
I-QoL, 2
PISQ-12, 2
PGI-S 2
(PELVILACE® 2
TO) 2
urogynecological 2
incontinency 2
(SUI), 2
absolute. 2
straining). 2
Burch 2
Transrectal 2
cystography 2
tonsillectomy]. 2
pharyngalgia, 2
2554 2
62.7%, 2
15.4% 2
appointment. 2
tonsillectomy: 2
vowels. 2
s/z 2
/a/ 2
/i/ 2
autoinflammation 2
Crow. 2
Chilblain 2
Learn 2
Interferonopathies? 2
TREX-1. 2
auto-inflammation 2
auto-immunity. 2
(IFNs), 2
(RIG-1), 2
(MDA-5) 2
gamma-inducible 2
protein-16 2
(IFI-16). 2
'interferonopathies'. 2
(Singleton-Merten 2
phosphate/pyrophosphate 2
interferonopathies. 2
autoinflammation, 2
haploinsuffiency 2
otulipenia), 2
TNF-associated 2
HiTAD 2
domain-based 2
sub-TADs 2
200-kb 2
long-known 2
longer-range 2
(tRNAs), 2
abp1, 2
300-600-nucleotide 2
Grg, 2
(gro) 2
Grg3, 2
SKIL, 2
ANGPTL4, 2
SNAI1, 2
c4orf26 2
Lomustine, 2
Lomustine. 2
=14 2
off), 2
pSMAD2). 2
placebo+lomustine 2
pSMAD2⁺ 2
0.4574). 2
R132H⁺ 2
0.5452). 2
(MDC/CCL22), 2
CD3⁺ 2
Fibrosis-related 2
SMAD1 2
non-collageneous 2
fibrosis-related 2
non-Smad 2
TGF-β2-induced 2
(Galunisertib) 2
"turn 2
[14C]-galunisertib, 2
[14C]-galunisertib 2
(40.3% 2
(M5, 2
mono-oxidation), 2
(glucuronide 2
M3) 2
9.0% 2
(36.8%). 2
(13.0% 2
CYP3A4-mediated. 2
non-CYP-mediated 2
itraconazole, 2
Lomustine 2
2:1:1 2
(OS); 2
(PKs), 2
(64.6%), 2
(75.3%), 2
(63.3%), 2
(93.7%). 2
∼8 2
[CrI]) 2
5.3-8.5), 2
5.7-11.7) 2
5.6-10.3) 2
26%]. 2
lomustine); 2
lomustine-treated 2
post-discontinuation 2
NCT01582269, 2
Huh7, 2
JHH6 2
SK-HEP1-derived 2
(SK-Sora) 2
(SK-Suni). 2
p-Smad2 2
p-Smad3 2
sorafenib-exposed 2
pharmacokinetic/pharmacodynamic-based 2
galunisertib-treated 2
Circularized 2
(coligos) 2
synaptotoxicity 2
Fyn. 2
saracatinib 2
PrPC-Aβo 2
hyperphosphorylates 2
(P-Tau) 2
PrPC, 2
T-Tau 2
sCHI 2
(Opitz-Kaveggia), 2
Lujan-Fryns, 2
(c.5898dupC). 2
niece 2
ID-related 2
c.2312T>C 2
(p.Ile771Thr) 2
NCBI, 2
tab-delimited 2
Saved 2
Session 2
Alignment/Map 2
(BAM), 2
Format 2
(whole-genome 2
whole-exome), 2
graphically. 2
formats, 2
bigBed 2
bigWig, 2
hosting. 2
pre-genome 2
tRNAscan-SE 2
Stabilizor 2
pCREB(Ser133) 2
pCREB-Ser(133) 2
(pCREB) 2
zinc-cluster 2
67.2, 2
selenomethionine 2
Saccharomycotina 2
Sterol-Regulatory 2
(SREBPs), 2
SREBPs 2
(Hms1) 2
(Cph2) 2
SREBP, 2
lipolytica, 2
deep-branching 2
(Sre1) 2
YlUPC2 2
Ylupc2 2
Ylsre1/Ylupc2 2
Sre1 2
lipid; 2
(pep4) 2
(kex2). 2
receptor-activated 2
Ste12, 2
Ecm22/Upc2 2
(upc2-1) 2
ergosterol. 2
nonsaponifiable 2
azoles 2
sterols. 2
G648D 2
M20 2
(PM20D1), 2
UCP1(+) 2
UCP1(-) 2
PM20D1, 2
UCP1+ 2
slipped 2
phrasing 2
color-taste 2
synaesthetes) 2
non-synaesthetes). 2
Grapheme-color 2
Synesthetes 2
experiment). 2
hemifield. 2
left-lateralization 2
non-synesthete 2
(GDF15), 2
(GFRAL), 2
GFRAL-deficient 2
GDF15-induced 2
GDF15, 2
mapper 2
back-splice 2
http://uroborus.openbioinformatics.org/. 2
miARma-Seq 2
(AMG102) 2
MET-positive) 2
(ex 2
ficlatuzumab, 2
1.4-2.7 2
(RILOMET-1): 2
(≥25% 2
≥1+ 2
intensity), 2
intolerability, 2
NCT01697072. 2
(rilotumumab 2
n=304) 2
n=305). 2
7·7 2
3·6-12·0) 2
9·4 2
(5·3-13·1) 2
7·7-10·2) 2
10·7 2
(9·6-12·4) 2
1·34, 2
1·10-1·63; 2
p=0·003). 2
[29%] 2
[14%]), 2
[50%]). 2
[10%]). 2
Ligand-blocking 2
gastric/GEJ 2
(HGF)/scatter 2
backtracks 2
6-azauracil. 2
rpb2 2
SII-activated 2
(6AU)-sensitive 2
transcription-elongation 2
TFIIS-encoding 2
TFIIS:RNAPII 2
600:1. 2
NTPs. 2
transcript-shortening 2
(TFIIS), 2
TFIIS-like 2
C11, 2
A14/43 2
A49/34.5 2
Rpb9p, 2
F32 2
I34 2
III-synthesized 2
Vmw110- 2
HAUSP) 2
ubiquitin-homology 2
(PIC1) 2
ND10. 2
Vmw110, 2
ND10, 2
PIC1-protein 2
Vmw110-dependent 2
I-IV, 2
(PML-NBs, 2
ND10) 2
ICP0. 2
(SIM), 2
Sp100 2
RNF4- 2
(As₂O₃) 2
poly-SUMO-dependent 2
PMLVII. 2
VI). 2
PMLVI, 2
PMLIII 2
PMLIII-SIM 2
As₂O₃. 2
PML-II 2
arsenic: 2
(RARα). 2
PML-RARα 2
SUMO-dependent, 2
arsenic-induced 2
PMLV, 2
PML-associated 2
SUMO-dependent 2
E1B-55K-dependent 2
cephalopods. 2
coleoid 2
cephalopods, 2
increase-not 2
decrease-in 2
(GDF15; 2
MIC-1) 2
GDF15-mediated 2
GFRAL-knockout 2
GDF15-GFRAL-mediated 2
metastasectomies 2
43%), 2
(myxomatous) 2
(DMVD) 2
(TGFβ), 2
valvectomy 2
mitro-aortic 2
bronchospasms, 2
hyperserotoninemia, 2
radial-sided 2
tendinosis 2
Decompression 2
Housewives 2
snippet 2
(ADNP) 2
microtubule-deficiency 2
microtubule-stabilizers 2
Subtypes 2
hemangioma; 2
ADBR2, 2
ADBR3 2
[0.04]; 2
[Infantile 2
propranolol: 2
"revolution". 2
bêta-blocker 2
vasoconstrictor, 2
(NIH), 2
prepropranolol 2
2003-2009), 2
2009-2011), 2
nonpropranolol 2
2009-2011) 2
laser). 2
(56.9%). 2
0.27-0.73), 2
(0.45; 2
0.15-1.38), 2
(0.44; 2
0.27-0.78) 2
Hemangioma: 2
Nadolol 2
value), 2
(1-9 2
15%-50, 2
20%-80, 2
SpCas9 2
Osh1p-Osh7p, 2
Osh6p 2
itraconazole. 2
TIR4 2
CCW12, 2
UPC2, 2
YHK8, 2
CUP1-1 2
(JPB1 2
Bur-0 2
pseudoobscura. 2
TopHat, 2
mappers 2
v@bio-complexity.comSupplementary 2
supervised). 2
(accuracy 2
top1 2
ts- 2
top2 2
knots 2
Unusually, 2
chk1 2
decatenase 2
relaxase 2
topoisomerases, 2
(FG) 2
(Maat-Kievit-Brunner 2
OSMKB), 2
c.5898insC 2
(p.Arg1148His) 2
Pembrolizumab: 2
ipilimumab-experienced 2
manageable/reversible. 2
KEYNOTE-006. 2
multiplying 2
portal-based 2
FRAX-based 2
(AFR) 2
non-BMD 2
DXA, 2
AFR 2
GOAL: 2
(FRAX). 2
T-score) 2
fatal-CVD 2
MOFR 2
HFR 2
absorptiometry. 2
fallen, 2
>50) 2
paramedic 2
care) 2
(proportion 2
economic) 2
NRES 2
ref.12/SC/0604. 2
preagreed. 2
36245726. 2
FRAX®, 2
(VC), 2
(FRAX; 2
http://www.shef.ac.uk/FRAX) 2
(Aus) 2
(FRAX®) 2
Australian-specific 2
40-90 2
(2006-2010 2
2000-2003, 2
Geelong 2
(Elderly 2
EFST) 2
EFST 2
(unadjusted 2
1.07). 2
(1.01, 2
G-protein-dependent 2
NF1-regulated 2
Nf1-null 2
(HDR) 2
'off-target' 2
Deaf 2
Cell-Like 2
c.4118C>T; 2
P-iPSCs), 2
(MYO7A 2
c.1184G>A 2
CF-iPSCs), 2
(MYO7A(WT/WT); 2
C-iPSCs). 2
P-iPSCs 2
(CP-iPSCs) 2
CP-iPSCs 2
stereocilia-like 2
protrusions; 2
C-iPSCs 2
CF-iPSCs. 2
c.4118C>T). 2
(MeCP2); 2
RAD21. 2
provirus 2
KTS+/KTS- 2
(AAD-vac1) 2
(ACI-35) 2
CDI-027 2
CDI-027. 2
7.1%; 2
0.058). 2
Nosocomial 2
NAP1/BI/027 2
027) 2
SDD 2
Herzegovina 2
(65.8%). 2
tfg1 2
tfg2 2
taf14Delta 2
dicarboxylic 2
(Dst1) 2
function(s).. 2
DNA-methylation 2
architectures; 2
(5-Aza-CdR) 2
Consolidating 2
DKO1, 2
HCT116-derived 2
DKO1 2
(methylomes) 2
(de)methylation 2
MNase-sensitive 2
Teif 2
probandwise 2
D-amino-acid-oxidase 2
activator/G30 2
MT(1), 2
MT(2) 2
5-HT(2c) 2
N-acetyltransferase 2
(DSPS). 2
P=0.0029). 2
gene-length 2
(4-repeat) 2
(5-repeat). 2
preference; 2
MDA5- 2
norovirus. 2
pathogen-sensing 2
PAMPs 2
TLR3, 2
TLR7, 2
TLR8, 2
MDA5, 2
minorities. 2
Conjunction 2
filament-like 2
(MAVS) 2
MDA5-MAVS 2
RIG-I. 2
(RIG-I)-like 2
(RLRs), 2
RLR 2
RLR-triggered 2
Asp(D)-Glu-(E)-Ala(A)-Asp(D) 2
"Prevotellamassilia 2
(Prevotellaceae, 2
Coprococcus, 2
Enterorhabdus) 2
noningestion 2
Bacteroidaceae 2
Prevotellaceae. 2
microbiota". 2
Enterotypes 2
(Bacteroides) 2
(Prevotella). 2
metatranscriptomic 2
Lachnospiraceae, 2
Ruminococcaceae, 2
Prevotellaceae, 2
Rickenellaceae 2
Gammaproteobacteria. 2
H(2)-utilizing 2
clara 2
xylaniphila 2
pleomorphic, 2
11840T 2
(<88% 2
Prevotella, 2
Hallela 2
Xylanibacter. 2
Rpb4, 2
pseudohyphal 2
YLR454w, 2
FKS1 2
Spt4/5, 2
6-AU. 2
Rad26, 2
UV-dimers 2
Def1, 2
rpb9Delta 2
can1-100 2
Snf2 2
SET2, 2
CDC73, 2
4700 2
Thromboembolism. 2
DVT. 2
subsegmental 2
Dabigatran-Associated 2
Misnomer 2
Miracle? 2
dabigatran-associated 2
canceled. 2
single-rising-dose 2
idarucizumab). 2
~45 2
Humanized, 2
overcorrect 2
reinitiated 2
dabigatran-treated 2
single-cohort 2
88%-98% 2
surgery/urgent 2
(minutes) 2
(specific 2
infliction 2
U/kg) 2
aPTT. 2
dabigatran- 2
Idarucizumab: 2
Coumadin 2
Coumadin. 2
Dabigatran-Induced 2
Anticoagulation: 2
plasmaproliferative 2
pathognomonic, 2
AEDV. 2
plasmacytoma, 2
papilledema. 2
ODE. 2
POEMS. 2
(CME), 2
(angiofollicular 2
hyperplasia). 2
nodosa: 2
nodosa. 2
17(70.8%) 2
hypothyroidism). 2
edema/effusions, 2
/effusions 2
(CIDP). 2
erythrocytosis, 2
angiofollicular 2
gammapathy, 2
paraprotein 2
crow 2
polysymptomatic 2
Repeat-containing 2
Rap1/Rif 2
Rap1/Sir 2
X-elements, 2
Rif1/2 2
Rat1-nuclease-dependent 2
Rif2. 2
telomere-encoded 2
template-encoding 2
maladies. 2
Telomere-repeat-encoding 2
TERRA) 2
k9me3 2
gar 2
shh 2
swelling) 2
redness. 2
lipoxins, 2
resolvins 2
non-phlogistic 2
humoral, 2
Celsus: 2
heat) 2
[... 2
Bakola 2
pygmies 2
tuberculosis-related 2
ailments 2
25923), 2
13883) 2
cattarhalis 2
14468)] 2
bark), 2
haemophilus 2
Nonfamilial 2
10q23.2, 2
Syndrome-Hereditary 2
Telangiectasia 2
ACVRL1, 2
Hamartomatous 2
(SMAD9(V90M)). 2
(2nd-hit) 2
SMAD4-/BMPR1A-related 2
(c.1244-1247delACAG) 2
(c.583C>T; 2
p.Gln195*) 2
SMAD4- 2
Genotype-defined 2
(27). 2
polyps: 2
BJS 2
(LDS), 2
(c.230+452_333+441dup1995), 2
(p.D112NfsX2). 2
life-time 2
BMP/TGF-beta 2
"landscaper 2
JPS) 2
JPS). 2
BMPR1A). 2
(HMPS). 2
hht 2
polyposis-hereditary 2
gi 2
curacao 2
(WES). 2
WNT1 2
CRTAP,FKBP10,LEPRE1,PLOD2,PPIB,SERPINF1,TMEM38B, 2
WNT1. 2
SCN9A,NTRK1, 2
SLC2A2, 2
indifference 2
Fanconi-Bickel 2
(FBS). 2
FBS 2
SCN9A 2
NTRK1 2
mineralisation, 2
platyspondyly, 2
hydranencephaly, 2
8days 2
c.338_357delins22 2
collagen-specific 2
(RSS). 2
11p15. 2
986 2
alpha1(II) 2
(CRTAP) 2
(CYPB) 2
LEPRE1. 2
Traveller 2
femurs), 2
"popcorn" 2
epiphyses 2
Imperfecta 2
(CRTAP, 2
SP7, 2
WNT1) 2
(BKS3). 2
Tolloid 2
(mTLD) 2
(BMP1). 2
AR-OI, 2
(BS). 2
PPIB. 2
COL1A1. 2
severe/lethal 2
masitinib, 2
cell-glia 2
mastocytosis, 2
reshape 2
Choriocarcinomas 2
(IGF2)-H19 2
5-Aza-2'deoxycytidine 2
(5-AzaCdR) 2
(JEG3). 2
Epimutations 2
1.4- 2
1.8-kb 2
maternally. 2
epigenotype. 2
H3K4me2/H3K27me3 2
mat/pat 2
(IVM) 2
IVM, 2
(GV), 2
(MII), 2
MI-arrested 2
MII-rescued 2
IVM 2
CTCF-bound, 2
(TgM), 2
allele-specifically 2
(insulated 2
TgM). 2
(5'HS4-deleted 2
(pseudo-WT 2
cre-loxP 2
pseudo-WT 2
5'HS4-deleted 2
VEZF1-dependent 2
cHS4. 2
(H19 2
ICR) 2
ligated. 2
(TgM) 2
4xMut 2
-9CG 2
(4xMut) 2
(4xMut 2
-9CG) 2
paternal-allele-specific 2
(K. 2
Tanimoto, 2
Shimotsuma, 2
Matsuzaki, 2
Omori, 2
Bungert, 2
Engel, 2
Fukamizu, 2
102:10250-10255, 2
parent-of-origin-dependent. 2
(H19(ICR∆IVS)), 2
(H19(ICR-8nrCG)), 2
(H19(ICR∆IVS) 2
H19(ICR-8nrCG)) 2
H19(SilK) 2
bi-functional 2
'formatting' 2
Igf2. 2
(DMR)1, 2
(MAR)3 2
DMR1 2
bi 2
9cg 2
rs10732516 2
icrs 2
"anabolic 2
microarchitecture, 2
Strontium 2
ipriflavone 2
usher, 2
pristine 2
[PTH 2
(1-34)] 2
(1-84) 2
(teriparatide, 2
(Teriparatide) 2
Callers 2
callers: 2
Seurat, 2
Indelocator, 2
Sniper, 2
(cancer-only) 2
JointSNVMix2 2
returned; 2
noise; 2
low-allelic-fraction 2
SRA081939, 2
http://code.google.com/p/snv-caller-review/ 2
david.adelson@adelaide.edu.au 2
ftp 2
csaunders 2
mutect2 2
wes 2
cosmic 2
August, 2
japanese 2
virmid 2
admixtures 2
na12878 2
giab 2
gatk 2
icgc 2
callers. 2
admixture, 2
lapatinib. 2
>AVAILABILITY 2
IMPLEMENTATION</b>: 2
<b>UNLABELLED</b>: 2
https 2
modalities; 2
D11 2
thoracic-lumbar 2
corset 2
painkillers. 2
Procedure 2
osteonecrosis, 2
nonunion 2
like.1 2
Kvmell's 2
Bacteriologic 2
ex-drug-addict 2
hand" 2
addict 2
fasciotomies 2
compartimental 2
innatural 2
subclavear 2
CD4+CD45RBhi 2
TNF-driven 2
Directions. 2
anti-α4 2
S1P5 2
etrasimod 2
(APD334) 2
(MT-1303). 2
TOUCHSTONE 2
First-in-Human 2
(S1P1R 2
S1P1R 2
S1P5R 2
ozanimod-related 2
(73-101 2
L/kg), 2
(204-227 2
L/h), 2
CCR7. 2
etrolizumab) 2
ozanimod). 2
(etrolizumab), 2
(MAdCAM-1, 2
PF-00547659), 2
(CXCL10) 2
Crohn's, 2
1-Phosphate 2
(S1PR) 2
EXPAND 2
cd20 2
(FREEDOMS 2
freedoms 2
act128800 2
baf312 2
ono 2
4641 2
gsk2018682 2
1303 2
qt 2
qtc 2
egfp 2
cd4 2
fty720 2
dc 2
pk 2
(NCCT) 2
CECT 2
23.2% 2
mL), 2
"swirl 2
NCCT, 2
intrahematoma 2
hypodensities, 2
29.1)] 2
(1.6, 2
15.9)] 2
[unilateral/bilateral: 2
(0.9, 2
20.1)/8.8 2
32.3)] 2
20.0)]. 2
0.65). 2
Findings. 2
non-OAC-associated 2
non-enhanced 2
3.47; 2
AEDH 2
к 2
"Morgellons 2
psychodermatology. 2
42.8% 2
excoriation 2
under, 2
contested 2
sensations, 2
ectropion 2
parasitosis. 2
'fibers' 2
psycho-dermatologic 2
"growing" 2
science-based 2
itchy 2
(auditory) 2
(LAUP) 2
(MEPs) 2
(MEVs) 2
MEV 2
Squamate 2
approaches-anchored 2
(AHE) 2
(UCE)-and 2
phylogenomics, 2
TFC6-ESC2 2
Tfc6p, 2
Tfc6 2
5'-extended 2
Esc2 2
downshift. 2
Abf1/Reb1/Tbf1 2
DBP7 2
(RPs) 2
repression/reactivation, 2
(Ribi) 2
bacteriophages. 2
lysogeny-lysis 2
casei 2
Lactococcal 2
TP901-1. 2
Cro 2
trans-regulated 2
Rsc3/30 2
Ascomycota 2
poly(A)s, 2
low-poly(G) 2
Cbf1 2
pre-whole-genome 2
post-WGD 2
switch-activating 2
Sap1 2
wgd 2
reb1p 2
pac 2
rrpe 2
tbf1 2
rpd3l 2
… 2
Anti-EA-D 2
gp125 2
lymphocytosis, 2
mononucleosis-like 2
subdiaphragmatic 2
theatre 2
ages: 2
~25% 2
IM. 2
Grampian 2
[measurement 2
(EBV-VL) 2
neutrophil/lymphocyte/monocyte 2
Tonsillar 2
Serological 2
(EBV 2
(HAV) 2
Heterophil 2
anti-CMV 2
<br> 2
<br><b 2
Auxin-Inducible 2
iAID: 2
(iAID) 2
dpb11-iAID, 2
mcm10-iAID. 2
dpb11-iAID 2
mcm10-iAID 2
iAID 2
scftir1 2
e3 2
Sabouraud's 2
mycoses, 2
33.8% 2
(33.7%). 2
(19.8%) 2
trichobacteriosis. 2
dyshidrosis, 2
erysipelas. 2
yeasts) 2
barbae, 2
manus, 2
Candidal 2
sporotrichosis. 2
carbuncles, 2
folliculitis, 2
Scalded 2
ecthyma, 2
(40.1%) 2
45.52 2
10.83 2
22-70 2
(56.2%). 2
(42.5%) 2
(38.4%). 2
hplc 2
microbacterium 2
trichosporon 2
intertrigo 2
whitfield 2
lamp. 2
Sabouraud 2
Mycological 2
maceration, 2
maceration 2
cm2 2
inhabitant 2
(SWI/SNF-related, 2
242900), 2
(swi/snf-related, 2
FSGS, 2
C1798T 2
complications--the 2
non-Schimke 2
4.9-30.5 2
3-21.8 2
(2591 2
height/leg 2
0.83. 2
1.01. 2
swi 2
1334 2
1g 2
snp 2
trxg 2
fsgs 2
r561c 2
Callosum: 2
14.0-19.8). 2
[Aspergillosis 2
multiforme]. 2
kufs 2
msi 2
egfr 2
mdm2 2
Single‑nucleotide 2
polymorphism‑array 2
22q11.1‑q11.21 2
11q23.3‑q25, 2
Dandy-Walker 2
q11) 2
der(22)t(11;22) 2
(OMIM609029). 2
(emanuel) 2
[Turner 2
(TS)], 2
(Warkany 2
palatoplasty 2
p11 2
malsegregation 2
h3k27 2
cimp 2
pfa 2
pfb 2
live-imaging 2
post-onset 2
(ALL 2
CLL). 2
postinfusion 2
(CR)/CR 2
preinfusion 2
haven't 2
Shelf. 2
CD19-positive 2
CART. 2
china. 2
cart19 2
ctl019 2
kymriah 2
pennsylvania 2
fda 2
neuro-ophthalmic 2
ND1/3460 2
subcutis. 2
aunt. 2
Multiorgan 2
Wolfram 2
(haplogroup 2
nps 2
haplogroups 2
MT-ND1 2
co-occuring 2
(LHON-MS) 2
Harding's 2
1281 2
NADH:ubiquinone 2
778 2
m.11696G>A 2
is(are) 2
M11, 2
G3640A, 2
(ARMS) 2
14484 2
14484T 2
Susac's 2
MTRR 2
A66G 2
encephalomyopathies. 2
Nonischemic 2
(Leber's 2
Neuropathy) 2
np14498, 2
np14568 2
reliablegenome 2
wgs 2
wtchg 2
non-degradative 2
AWP1, 2
CALCOCO2, 2
N4BP1, 2
TEX27, 2
TTC3, 2
UBFD1 2
ZNF313 2
ABIN-1, 2
ABIN-2, 2
RIO3 2
prednisone-treated 2
Lys48 2
Ubiquitin-specific 2
Lys48-, 2
Lys63-, 2
USP25, 2
virus-triggered 2
48- 2
(Cys178) 2
h3k9me2 2
parp 2
ROF1. 2
HsfA2 2
rof1 2
abiotic/environmental 2
XERO2). 2
stems, 2
"facing" 2
intermonomer 2
unknotted 2
pyloromyotomy 2
14,876 2
(0.29%) 2
ointment. 2
prudence 2
Prescriptions 2
2.77, 2
6.30, 2
eight-amino 2
(Thy1-aSyn 2
Thy1-aSyn 2
μg/mouse 2
Covalently 2
circ-ZNF609, 2
ribo-circRNAs 2
conjunctions 2
intrachromosomally 2
teleregulation 2
kissing". 2
proteins.<br> 2
put3 2
F521Sfs*27 2
G519Efs*30 2
G555F, 2
E526K, 2
E524K, 2
R554H. 2
anti-glomerular 2
amiloidosis. 2
AI. 2
aproximately 2
(Arg554Leu) 2
transversion. 2
azotemia. 2
non-neuropathic, 2
nephropathic 2
526. 2
(AFib), 2
A-alpha-chain 2
Glu526Val 2
Extra-cranial 2
(SDT), 2
SDT, 2
key-actors 2
SDT. 2
193a 2
(complementary 2
telocentrics), 2
ditelosomic 2
spacially 2
co-associated. 2
telocentric, 2
telocentrics) 2
spacial 2
telocentrics, 2
(Rabl 2
rabl 2
Osteonecrosis 2
anti-RANK 2
bisphosphonate-related 2
(Prolia), 2
xB 2
BR 2
(Prolia) 2
catenin 2
Postn(+/+) 2
Postn(+/+), 2
PTH-stimulated 2
periosteum. 2
TOPGAL 2
(TOPGAL;Postn(-/-) 2
αVβ3 2
periostin-blocking 2
Sost-blocking 2
antiboby 2
PTH-mediated 2
Osteoblastic 2
(hFOB) 2
(hOS) 2
hOS 2
(MHM, 2
KPDXM 2
Eggen) 2
mineralize. 2
(mOB) 2
RUNX2. 2
1a1 2
mGlu 2
(CIE)-exposed 2
C57Bl/6J 2
mGlu1/5 2
N-acetylglucosaminyltransferase 2
genotype-related 2
(LC-MSE) 2
LC-MSE 2
"oxidative 2
myelin-specific 2
Def) 2
Adq). 2
(NonTg) 2
NonTg 2
GALK1, 2
TK1, 2
GH1, 2
MYL4, 2
CFA9 2
HSA17q 2
(MMU11), 2
CFA9, 2
CRYBA1 2
CFA9. 2
HSA17 2
Multicolour 2
CCD-imaging 2
spectrum-based 2
plasmocytomas, 2
(Atm) 2
crystallin 2
ISO-1 2
isochromosomes. 2
computer-monitored 2
iso-lq 2
PCC4 2
azaR1, 2
22CD 2
serum-albumin-coated 2
(B2m) 2
B2M 2
all-acrocentric 2
sky 2
Transthyretin-associated 2
(TTR-FAP) 2
IENFD, 2
SGNFD, 2
PMNFD 2
NIS-LL 2
L32V 2
opacity. 2
p.Gly87Arg, 2
Congo-red-positive 2
Congo-red 2
amyloidogenic. 2
19F-NMR 2
WT-5FW 2
TTR-associated 2
(ATTR), 2
75.7% 2
Alobar 2
ethmocephalic 2
(synophthalmia). 2
maxillae, 2
ethmocephaly, 2
cyclopia. 2
two-orbit 2
cyclopia, 2
nostril. 2
(TFN), 2
rnapii 2
(HAQ-DI), 2
(PtGA), 2
Questionnaire-Rheumatoid 2
(p≤0.001) 2
DMARDs: 2
RA-BUILD 2
(baricitinib 2
RA-BEAM 2
Worst 2
body-type 2
(apple 2
pear) 2
age<18years 2
refusal, 2
(STOP-Apple 2
STOPBANG-Apple) 2
questionnaire's 2
sensitivity/specificity/positive 2
(+LR) 2
(cut-off=2) 2
96%/11%/1.1, 2
88%/39%/1.5. 2
STOP-BANG's 2
sensitivity/specificity/+LR 2
96%/19%/1.2, 2
STOP-BANG-Apple 2
(cut-off=4) 2
90%/39%/1.5. 2
(P=0.25). 2
score≥3 2
(67.4%), 2
1.2-5.3) 2
2.5-8.7). 2
(h-OSA) 2
(l-OSA), 2
h-OSA 2
l-OSA 2
22/664 2
41.6% 2
(269/647, 2
(31.2%) 2
(respectively) 2
(PSG). 2
PSG, 2
Yedikule 2
Apnea-Hypopnea 2
≥5/h, 2
≥15/h, 2
≥30/h, 2
0.18. 2
(>3) 2
>5, 2
>15, 2
0.27. 2
Survivors. 2
Kumasi, 2
Ghana. 2
(52-72) 2
(LR+, 2
(LR-, 2
kg/m2) 2
LRs, 2
RHD, 2
polysomnography--the 2
(RDI) 2
9,206 2
≥15), 2
≥30) 2
(PACU). 2
(<93%) 2
(77.7%), 2
(90.1%), 2
(88.4%). 2
plotted. 2
PACU 2
anaesthetisation 2
STOP-bang 2
consented 2
STOP-Bang, 2
intubation? 2
(Cormack 2
attempts) 2
SpO2, 2
(78.6% 2
38.7%) 2
(snoring, 2
daytime, 2
gender), 2
(Berlin, 2
STOP) 2
'B'-body 2
'A'-age, 2
'N'-neck 2
'G'-gender 2
STOP. 2
PSG's 2
RDI=5, 2
RDI=15 2
RDI=30 2
palivizumab-targeted 2
Provides 2
(pre-F) 2
postfusion 2
(post-F) 2
post-palivizumab 2
RSV-positive 2
non-recipients 2
4.78 2
1.1-20.7), 2
0.027. 2
£96,127 2
($151,880) 2
£137,954 2
($217,967) 2
Ribavirin 2
39-78% 2
conducted: 2
Neo-Adjuvant 2
(NHT) 2
(NHT, 2
non-NHT, 2
D2-40 2
(LVD 2
LVA, 2
field; 2
(512.8 2
174.9 2
202.7 2
72.8 2
µm2 2
VEGF-B 2
NHT. 2
-D, 2
77:255-262, 2
(VEGFs) 2
Vegfa 2
hyperbranching 2
Flt1 2
Dll4. 2
Kdr 2
(Vegfr2) 2
Flt4 2
(Vegfr3). 2
Lymphatic 2
VEGF-R3 2
LEC 2
VEGF-D. 2
LOcal 2
EluteR 2
(LODER(TM)) 2
G12D-mutated 2
(siG12D). 2
acid-like 2
(PARP1), 2
TFIIC 2
re-appeared 2
waist/hip 2
Alk 2
(GGT). 2
waist/circumference, 2
pearson 2
girth, 2
brother-sister 2
ER-Positive 2
(MMTV 2
LTR) 2
multi-nodulated 2
fibro-vascular 2
MMTV-negativity 2
LTR-specific 2
(PCNA), 2
Cytokeratin 2
(K19) 2
estrogen-dependant 2
Palamneus 2
(AST-SGOT), 2
amino-transferase 2
(GDH), 2
(SGOT 2
SGPT), 2
carbamoyltransferase 2
(OCT), 2
gamma-glutamyltranspeptidase 2
(gamma-GTP) 2
OCT, 2
gamma-GTP 2
1(1/2) 2
unisa 2
pushed 2
watched 2
(APP/PS1) 2
IRB 2
(IVIG), 2
Avagacestat 2
Dimebolin 2
[Immunotherapy 2
(Aß) 2
Aß 2
659) 2
663), 2
ADLs. 2
setbacks. 2
adjuvants. 2
P=0.06) 2
-0.2 2
Between-group 2
alarmingly 2
(54.6%) 2
(45.4%) 2
(23.1%) 2
Klebseila, 2
Streptococci, 2
(4.6%), 2
p.Val726Ala 2
(27.61%) 2
(19.40%). 2
p.Arg761His 2
(3.73%) 2
p.Ala744Ser 2
(2.24%) 2
rarest. 2
(18.28%) 2
p.Phe479Leu-p.Glu167Asp 2
(66.61%) 2
Fevers. 2
fever-associated 2
MEditerranean 2
FeVer 2
M694V/M694V 2
c.2330dupG 2
(p.Gln778Serfs*4 2
Q778SfsX4) 2
MEFV-mutated 2
E148Q 2
M694I 2
M694I, 2
E148Q+M694I, 2
marenostrin 2
12-mutation-strip 2
MEFV. 2
(M6801, 2
V726A) 2
(40.0%) 2
Armenians, 2
Turks. 2
51.9% 2
(MEFV), 2
Server 2
transforming, 2
http://deepblue.mpi-inf.mpg.de/R 2
3.4. 2
felipe.albrecht@mpi-inf.mpg.de 2
markus.list@mpi-inf.mpg.de. 2
(COL1A1/COL1A2). 2
sclerae, 2
1(I) 2
COL1A2). 2
procollagen, 2
P3H1, 2
SERPINH1. 2
Kozak 2
[alpha 2
(OI), 2
"brittle 2
procollagen. 2
interferon-alpha-2a, 2
immunosuppressives 2
phosphodiesterase-4, 2
arthropathies, 2
Speckles 2
Nucleus. 2
nucleoskeletal 2
relax, 2
diffusively, 2
U4 2
(EYFP)- 2
cyan 2
protein-NHPX 2
NHPX. 2
serine2 2
serine(2) 2
Paraspeckle 2
speckle-associated 2
shortage, 2
eIF4A-III, 2
(IGCs). 2
(GVs)) 2
bead-like 2
IGC-surface 2
RBM6. 2
GVs, 2
Blockbusters? 2
miRNAs' 2
re-thinking 2
Pig 2
miRNA(microRNA)-122. 2
Miravirsen, 2
locked-nucleic 2
LT. 2
MicroRNA-122 2
(miR-122) 2
miravirsen, 2
anti-miR-122 2
miravirsen. 2
miR-532-5p 2
pyogenes, 2
Lancefield 2
GAS. 2
Streptococci 2
>CONCLUSIONS</b>: 2
worth. 2
(PED). 2
A-beta 2
11·3%), 2
59·3%), 2
(40·7%) 2
three/four 2
65·5% 2
91·5% 2
beta-haemolytic 2
pharyngotonsillar 2
laterocervical 2
team, 2
glioblastoma? 2
aes 2
ly317615 2
ag 2
gsk 2
pbmcs 2
GSK2586184, 2
mongersen. 2
(ATD)-induced 2
(apoE-/-) 2
Atherosclerosis-prone 2
intragastrical 2
day-1) 2
Mac2 2
immuno-staining. 2
(PMC) 2
ATD, 2
F4/80 2
CD206 2
Ox-LDL 2
PMC 2
(ABCA1), 2
(PROs). 2
PRTI 2
CONCLUSIONS</b> 2
pfizer 2
mayo 2
PER, 2
CLOCK:BMAL1, 2
mBmal1 2
BMAL1-CLOCK 2
interlocks 2
S133 2
dephosphorylations 2
memory-related 2
consolidation. 2
Tnfα 2
CREB1Δ, 2
(PIAS1) 2
Lys271 2
Lys290 2
CREB1Δ. 2
RanBP2 2
Pc2 2
facilitated, 2
Lenti-CREB 2
sumo-mutant 2
(CREBK271RK290R) 2
Lenti-CREBWT-SUMO1 2
Lenti-CREBK271RK290R 2
(bdnf) 2
bdnf 2
0270-6474/14/349574-16$15.00/0. 2
(NCT01186744; 2
OPT 2
Retreatment) 2
W40, 2
W24: 2
ISI 2
ISI: 2
(5.0 2
(OPT 2
NAPSI 2
44.2% 2
(OPT) 2
Compare 2
(NCT01241591). 2
guselkumab, 2
(csDMARDs) 2
(ustekinumab), 2
anakinra; 2
canakinumab. 2
23-helper 2
(IL-23-TH17) 2
T-cell-derived 2
(TNF), 2
(RPLS) 2
IL)-12 2
(LAE) 2
199) 2
(TNF)-α-antagonists 2
etanercept), 2
(IL)12/23-antagonist 2
biologic, 2
(IL-12 2
therapies; 2
immuno-mediated 2
"biologics" 2
anti-CD11a 2
(efalizumab), 2
anti-LFA3/CD2 2
(alefacept) 2
cytokine(s) 2
Suspicion 2
carcinogenicity: 2
(etanercept, 2
etc.); 2
(single-blind), 2
score): 2
anti-ustekinumab 2
immunosuppression; 2
-23 2
(Stelara) 2
Assessors 2
73.8% 2
(P=0.01 2
65.1% 2
70.0% 2
NCT00454584.) 2
exposure-efficacy 2
1312; 2
11,624 2
[PASI] 2
665; 2
comorbidities) 2
(Abbott 2
Saint-Laurent, 2
QC,) 2
Ortho 2
ON) 2
(IL-12/23), 2
G1κ 2
Biotech 2
Biotech), 2
G1K 2
(IL)-12/23, 2
DTH 2
(arthritis) 2
wks. 2
races, 2
HLA-Cw6-positive 2
HLA-Cw6 2
Cw6-negative 2
18-mg 2
rrms 2
Interleukins 2
(n=255) 2
(48.2%) 2
centocor 2
abbott 2
osteosarcomas, 2
ALK-Rearranged 2
M4, 2
M4. 2
ALK-translocated 2
H3122 2
these-crizotinib, 2
alectinib-are 2
Into 2
Stage. 2
ALKis, 2
Safety. 2
(ALK)- 2
2011.We 2
(DCR). 2
4.97, 2
7.83, 2
I2=35%). 2
5.01, 2
I2=0%). 2
S100A9-targeting 2
ipiliumumab 2
continuation; 2
SCFTIR1-IAA6 2
SCFTIR1-IAA19 2
cambium 2
represented. 2
primary/early 2
epibrassinolide 2
aestivum), 2
TaIAA1, 2
light-sensitive, 2
15-30 2
cation, 2
calcium-chelating 2
brassinosteroid, 2
Auxins 2
phototropism, 2
Auxin/Indole-3-Acetic 2
Aux/ARF 2
rapa). 2
(PF02309). 2
(BrIAA) 2
(BrIAA-BrIAA) 2
(BrIAA-AtIAA) 2
Genebank 2
bud, 2
dreb 2
cbf 2
Sl-IAA 2
solanum 2
lycopersicum 2
ests 2
triticum 2
ca 2
AUXIN/INDOLE-3-ACETIC 2
ACID 2
AUXIN 2
iaa5-1 2
iaa6-1 2
iaa6 2
subclades 2
arfs 2
Wheat. 2
OsRSP3 2
osrsp3 2
IAA1 2
axr5-1 2
Thoracoomphalopagus 2
Twins. 2
dorsally 2
diprosopus 2
deities. 2
deities 2
dibrachius: 2
rachipagus, 2
dicephalus, 2
cephalopagus. 2
thoracopagus, 2
di-symmetrical 2
distinguished; 2
cephalopagus, 2
conjoints. 2
Craniopagus 2
forms' 2
inter-twin 2
Town, 2
streak 2
monoamniotic 2
stillborn, 2
liveborn, 2
parts". 2
tetrabrachius 2
Zaria: 2
twins; 2
anterolaterally 2
notochords 2
proximity; 2
craniopagi 2
neuropores, 2
cephalopagi 2
cloacal 2
thoracopagi 2
anlage; 2
omphalopagi 2
umbilicus 2
customary 2
1970-1977. 2
tripus) 2
Craniopagus-type 2
(joined 2
Cephalopagus 2
symmetry. 2
Interfacial 2
intersternal 2
situs. 2
co-twin. 2
72.5% 2
thoracophagus, 2
paraphagus, 2
omphalo-ischiophagus, 2
omphalophagus, 2
cephalophagus. 2
dicephalic 2
seperation 2
omphalopagus, 2
heterpagus 2
ishiopagus 2
GLUT10, 2
arteriopathies. 2
prognostic. 2
SLC210A 2
(elongation, 2
hernias, 2
keratoconus. 2
SLC2A10/GLUT10, 2
(ATS). 2
tgfbr1 2
glut10 2
smad7 2
wilts 2
(FOL 2
MN-25) 2
Manatee 2
(Fol) 2
tomatoes. 2
BHRS 2
fusaric 2
(causal 2
antifugal 2
2.7-fold, 2
4.1-fold, 2
13.4-fold, 2
mancozeb 2
pot 2
Solanum 2
antibiotic-producing 2
wall-degrading 2
LRB3W1 2
WCS365, 2
Fo5176. 2
SIX4 2
basil, 2
propagules 2
basil 2
Temperature 2
foliage-inoculated 2
(TFRR), 2
radicis-lycopersici. 2
glycosyl 2
non-fungitoxic 2
metalloids 2
(Lycopersicum 2
humic 2
2000mg/5/week 2
(CGT) 2
avβ3 2
avβ5 2
CGT-NP+UTMD 2
vitronectinenriching 2
autophosphorylated 2
EGFRvIII. 2
ITGB3 2
cilengetide 2
β3, 2
HZ 2
endpoints.Immunohistochemistry 2
(n=274) 2
(n=224).αvβ3 2
CENTRIC, 2
cilengitide.Integrins 2
MGMT-promoter 2
26·3 2
T98G, 2
immedicable 2
paraproteins) 2
condtions, 2
(polycythemia, 2
thrombocytemia) 2
cryoglobulinemia, 2
cryofibrinogenemia, 2
dysfibrinogenemia, 2
sclerocythemic 2
spherocytosis, 2
boney 2
Features. 2
(UPEP), 2
(SPEP), 2
dialysis-independency. 2
paraproteinaemia 2
Hyperviscosity 2
Plasmaphereses 2
endangered 2
dyscrasias. 2
macroglobulinemia, 2
Palate 2
E14.5 2
lateral, 2
factor/receptor 2
microanatomic 2
NIH-funded 2
Abstraction 2
(FMA) 2
NIDCR-sponsored 2
types.<br><b 2
Pulled/nursemaid's 2
backslab 2
repeate 2
applied; 2
1,228 2
(±12.6). 2
"hook 2
adjunct, 2
nonradiating. 2
("Hook 2
sign") 2
33-month-old 2
head; 2
douloureuse; 2
Chassaignac 2
lesion) 2
uninjured 2
subluxated 2
"nursemaid's 2
elbow," 2
'pulled 2
'dislocated 2
elbow' 2
'nursemaid's 2
trismus: 2
(HNC) 2
(MIO) 2
mastication 2
RT-induced 2
(TMJ), 2
mandibulectomy, 2
AOG 2
biotherapeutics 2
IL-5/IL-5Rα 2
marketed, 2
Reslizumab, 2
Benralizumab. 2
Pharmacodynamics 2
152). 2
every-8-week 2
CPT: 2
Pharmacometrics 2
IL-5-targeting 2
D2blockers 2
interleukin-based 2
anti-IL-5R 2
medium-dosage 2
Glucocorticoid-Sparing 2
[with 2
weeks]) 2
FEV1. 2
AstraZeneca; 2
ZONDA 2
NCT02075255 2
β2-agonists 2
12-75 2
(ICS 2
LABA) 2
(Q8W; 2
μL. 2
assigned: 2
benralizumab-treated 2
Kyowa 2
Hakko 2
Kirin. 2
IL-5Rα, 2
(IL5Rα) 2
(afucosylation) 2
[21%] 2
Randomized-effect 2
1951 2
Questionnaire-6 2
(ACQ-6) 2
ACQ-6 2
SIROCCO 2
CALIMA 2
anti-eosinophilic, 2
non-eosinophilic 2
(n=81), 2
MedImmune. 2
[63%] 2
>Results</b>: 2
information</b>: 2
Volar 2
(DRF) 2
2nd-5th 2
consultant), 2
(VariAx®, 2
Acu-Loc®) 2
Reoperations 2
charted. 2
5.4). 2
(n=451) 2
VariAx® 2
Acu-Loc®. 2
Intra-articular 2
AO/OTA-type 2
23C1-3, 2
malunion. 2
malunion, 2
(CRPS), 2
Socioeconomically 2
CRPS 2
Fixation. 2
Knifelight® 2
(Stryker, 2
Kalamazoo, 2
Michigan, 2
(Agee, 2
3M 2
type-C3 2
comminution 2
Gustilo-Anderson 2
30º-80º), 2
implant-related 2
[Case-control 2
fracture]. 2
epiphysiolysis 2
tendineae. 2
Complications- 2
tendineae, 2
regurgitation- 2
[ALD403 2
(eptinezumab), 2
AMG334 2
(erenumab), 2
(galcanezumab) 2
(fremanezumab)] 2
9-12) 2
(CSD)-sensitized 2
patient.SIGNIFICANCE 2
(central) 2
0270-6474/17/377149-15$15.00/0. 2
Add-On 2
Medicines. 2
(CM). 2
675/225 2
.0321). 2
7.1, 2
.0058), 2
.0414). 2
NCT02025556 2
NCT02021773. 2
Eptinezumab, 2
erenumab, 2
fremanezumab, 2
galcanezumab, 2
Migraine. 2
(675 2
migraine-specific 2
[triptans 2
ergots] 2
1130 2
above) 2
13.2, 2
12.8, 2
13.3, 2
4.3±0.3 2
4.6±0.3 2
2.5±0.3 2
fremanezumab-quarterly 2
fremanezumab-monthly 2
Teva 2
NCT02621931 2
target-therapy 2
cardiomyopathies? 2
unearth 2
Develop 2
LVEF, 2
Deformation 2
Anthracyclines, 2
15.9-34 2
two-chamber 2
-20.0 2
-17.6 2
-1.26 2
-1.13 2
sec(-1), 2
re-challenge 2
trastuzumab-associated 2
Reversibility 2
trastuzumab-treated 2
vinblastine. 2
W8 2
W18 2
157, 2
mg/m(2)/day, 2
MGMT-negative, 2
>Availability 2
stapling, 2
bar.We 2
complications.Twenty-one 2
knee). 2
(8-19 2
procedure.Patients 2
bracing 2
postero-medial 2
13° 2
valgus). 2
Femoral 2
'Z' 2
"fibulectomy 2
osteotomy" 2
fibulectomy 2
Z-shaped 2
femoro-tibial 2
18.2° 2
4.2° 2
22°. 2
plateau, 2
navicular, 2
calcaneus 2
(18) 2
Tibia 2
Vara 2
spontaneously? 2
one-in-three 2
0: 2
varus, 2
epiphysiodesis 2
bridging); 2
(superomedial 2
bridge). 2
'Tibia 2
vara'. 2
anteversion 2
wheelchair-bound 2
(osteochondrosis 2
tibiae; 2
Johannesburg. 2
burnt-out 2
biochemistry) 2
11.5-16.3 2
micronuent 2
differentiaion 2
inseparable 2
rckets 2
bowlegs 2
tibiofemoral 2
metaphyseal/diaphyseal 2
Exondys 2
Spinraza 2
(nusinersen), 2
2B), 2
(CNS)-targeted 2
(nusinersen/Spinraza) 2
Nusinersen: 2
attributions 2
help-seekers 2
help-seekers, 2
Distortion 2
DPOAEs. 2
SOAEs, 2
SOAEs 2
(KKS) 2
places. 2
(Obscure 2
Dysfunction, 2
OAD) 2
(white, 2
race/ethnicity. 2
(80, 2
Chinese) 2
Buprenorphine-Naloxone 2
Pibrentasvir. 2
glecaprevir-pibrentasvir 2
HCV-negative 2
(QD) 2
Dose-normalized 2
(R)- 2
(S)-methadone 2
(≤5% 2
(≤24% 2
norbuprenorphine 2
buprenorphine-naloxone. 2
Glecaprevir/Pibrentasvir: 2
[glecaprevir/pibrentasvir; 2
MAVIRET™ 2
(EU); 2
MAVYRET™ 2
(USA)] 2
AbbVie. 2
mg/40 2
tablets) 2
(genotypes 2
Glecaprevir/Pibrentasvir 2
Cirrhosis. 2
ENDURANCE-2 2
SURVEYOR-II, 2
SURVEYOR-II) 2
94.1-99.3) 2
83.6-97.3) 2
glecaprevir/pibrentasivr 2
glecaprevir/pibrentasvir. 2
NCT02640482 2
(ENDURANCE-2), 2
NCT02636595 2
(ENDURANCE-4), 2
NCT02243293 2
(SURVEYOR-II). 2
trials.<br><b 2
(DORAs). 2
Decade 2
Orexin/Hypocretin 2
Addiction: 2
Now? 2
orexin/hypocretin 2
morphine-seeking 2
"motivational 2
activation" 2
unpack 2
cues/contexts 2
motivational, 2
interconnectedness 2
(Belsomra(®)), 2
Scaffold-Hopping 2
(Ox1 2
(HLM), 2
3A4, 2
Opportunities. 2
(MK-4305, 2
(Belsomra) 2
7.08. 2
urinalysis 2
glucose-wasting 2
amputations 2
(Invokana) 2
(canagliflozin, 2
empagliflozin) 2
Nonconvulsive 2
SSRIs; 2
Patient; 2
Duloxetine-Induced 2
Galactorrhea; 2
Canagliflozin-Associated 2
Hypernatremia; 2
Vemurafenib-Induced 2
transsexual 2
24.7; 2
8.94 2
68.4) 2
9.78; 2
12.7) 2
mastectomy; 2
extirpation. 2
constitutional, 2
(abnormalities 2
estrogen/androgen 2
balance) 2
denominators. 2
gynaecomastia 2
Author/Acta 2
(excess 2
leukaemia--case 2
leukaemias. 2
testosterone-enanthate 2
gynecomastia, 2
decomposition. 2
SignatureEstimation, 2
"mutation 2
"mixed-membership 2
models" 2
pmsignature 2
(https://github.com/friend1ws/pmsignature) 2
https://friend1ws.shinyapps.io/pmsignature_shiny/. 2
TJA. 2
KS, 2
IL-1a, 2
TJA-MetS, 2
c-peptide 2
(IDF) 2
resistance/glucose 2
Nephrolithiasis 2
Risk: 2
triglycerides) 2
(abdominal 2
glucose) 2
harmonised 2
dysglycaemia, 2
91.5 2
lipoproteinaemia 2
Hypertension, 2
hypertriglyceridaemia, 2
hyperinsulinaemia, 2
hyper-tension, 2
hypercholesterinaemia 2
haemostatic 2
[elevated 2
cholesterol]) 2
(IRS), 2
triglycerides; 2
upper-body 2
antifibrinolytic 2
X: 2
excesses. 2
(atherogenic 2
profile), 2
(visceral) 2
noninsulin-dependent 2
(mGluR5). 2
(mGluR5), 2
agonists/antagonists, 2
91-153 2
mGluR5. 2
mGluR5-PrP(C) 2
PrP(C). 2
mAbs; 2
Multiforme: 2
Immune- 2
clincaltrials. 2
single-agents 2
irAEs 2
MEK-inhibitor. 2
dreadful; 2
inhibiting/deviating 2
exhausted. 2
anti-CTLA-4 2
GRP-R 2
(GRPR) 2
(177)Lu-AMBA. 2
gastrin 2
carcinoids, 2
bombesin-like 2
BRS-3) 2
Bn-receptor 2
over/ectopically 2
receptor-targeted-cytotoxicity. 2
subtype-3 2
PD176252 2
EMY-98 2
>100μM, 2
(16μM), 2
10nM 2
BA1 2
Gastrin-releasing 2
(GRP), 2
2A11 2
inferolateral 2
superomedial 2
triangular, 2
superolateral 2
border. 2
Conclusions: 2
Glioma. 2
glioblastoma.Treatment 2
BEV-containing 2
(VOR) 2
16.8%-44.4%). 2
7.6-12.8 2
pan-active 2
Dlx1 2
Dlx2 2
Interneuron 2
Synaptogenesis, 2
Dendritogenesis. 2
silenced-BCL10 2
BCL10-regulated 2
STAT1/ATF4/S100P/P65 2
aken 2
Stress. 2
(eIF2α) 2
ATF4-mediated 2
(extrasalivary) 2
poorer. 2
(RTX), 2
pSS-associated 2
pneumopathy. 2
lymphoma; 2
Schirmer's 2
scialoscintigraphy 2
stabilised. 2
mid-trachea. 2
antineural 2
hypergammaglobulinemia 2
lymphocytopenia 2
Anemia, 2
periductal 2
venules 2
rs1041569 2
rs12583006 2
immunocytomas 2
TSLPR 2
Donors: 2
grounding 2
donating), 2
donating) 2
"healthy" 2
(0.3%). 2
institution; 2
surveys; 2
1085 2
3213 2
predonation) 2
(73.7% 2
84.6%, 2
11.3%, 2
miscarriages) 2
8.8%. 2
(3/36) 2
FEI, 2
Deer. 2
postexposure, 2
non-experimental 2
elk) 2
decades-long 2
reindeer), 2
(deer, 2
moose) 2
Endemic 2
(Alces 2
alces 2
shirasi) 2
Wyoming 2
demography 2
(λ). 2
continent. 2
kuru, 2
field-applicable 2
(TSEs) 2
(PrP27-30) 2
amyloid-immunoreactive 2
neuropil, 2
nelsoni). 2
BSE. 2
TSEs. 2
glucose? 2
MPG, 2
(SMPG) 2
SMPG 2
(<6.5%, 2
6.5%-<7.5%, 2
7.5%-<8.5%, 2
8.5%-<9.5%, 2
≥9.5%) 2
(<6.1, 2
6.1-<7.8, 2
7.8-<9.4, 2
9.4-<11.1, 2
≥11.1 2
mmol/L). 2
MPG. 2
<6.4 2
>9.5 2
≥6.1 2
<7.8 2
>8.1%. 2
SMPG, 2
(MA 2
Star) 2
(intensification), 2
dysglycemic 2
A1c. 2
A1c-based 2
98.4% 2
(A1C). 2
A1C. 2
p<.05). 2
stamp 2
(exception 2
A1c) 2
devising 2
(DS; 2
CBS, 2
BCEI 2
Langdon 2
parents: 2
flabby 2
mile 2
(21;21) 2
(Hsa21) 2
Hsa21-derived 2
Ts21 2
21q11.2-21.05, 2
SF57 2
pter-->q22.1 2
amniocytes, 2
Abcg1-U2af1 2
aneuploidy; 2
1866, 2
Lejeune, 2
Gautier, 2
Turpin 2
religious 2
21-specific 2
craniosynostosis) 2
constricted 2
defection 2
nonsyndromic. 2
suture(s) 2
1/2000 2
1989-2003. 2
defects), 2
FGFR2), 2
Chromatinopathies 2
DV+ 2
1992-93 2
"Flare" 2
"flare" 2
(persistently 2
flare). 2
Sociodemographic, 2
anti-double 2
two-tailed 2
prediction) 2
Clinics/American 2
PGA) 2
SLAM-R, 2
MEX-SLEDAI, 2
rheumatologists, 2
[SLE 2
IUD 2
CSRMs 2
-0.08 2
SLAM 2
(British 2
tool: 2
cT4N0M0 2
EGFR's 2
Graded 2
2186 2
nonadenocarcinoma). 2
brigatinib 2
chemo/radiotherapies. 2
[also 2
(BMK1)] 2
(MEKK3), 2
(MEK5). 2
(PF-02341066), 2
(consequently, 2
NPM-ALK, 2
2p 2
EML4-ALK. 2
EML4-ALK-positive 2
2.25%) 2
less-differentiated 2
ALK-mutated 2
(ALK). 2
dimerisation 2
ligand-stimulated 2
lymphomoas, 2
co-alterations, 2
(-TKI). 2
ALK-TKI, 2
ALK-inhibition 2
(NPM)-ALK 2
(-TK) 2
2%-8% 2
ALK. 2
co-chaperone, 2
kinase-positive, 2
(ALK+ 2
ALCL) 2
JunB, 2
t(2;10)(p23;q22) 2
ERMS, 2
.046). 2
4-ALK 2
CURB65) 2
(PSI); 2
(IDSA) 2
Physiology, 2
(APACHE) 2
(SOFA); 2
(qSOFA) 2
76.9% 2
IDAS/ATS 2
Community-Acquired 2
SOFA. 2
co-adjuvant 2
risk-prediction 2
Confusion, 2
30/min, 2
0-1) 2
(2/98), 2
(6/90) 2
3-5) 2
(13/61). 2
Respirology 2
stratifications 2
(SEWS). 2
CRB65 2
SEWS; 2
11-17% 2
SEWS. 2
SEWS). 2
(sCD14-ST) 2
Presepsin, 2
SCAP 2
ARDS, 2
(OPTIMA 2
patients.<br><b 2
3.78×ln[TB] 2
11.2×ln[INR] 2
9.57×ln[creatinine] 2
6.43. 2
91.1% 2
formulae. 2
>35, 2
transjugular 2
portosystemic 2
(TIPS) 2
(Model 2
End-of-stage 2
HE. 2
(RMP) 2
(ID-MS). 2
RMP 2
≥0.937, 2
±20% 2
enzymatic-based 2
Portal 2
spleno-mesenteric 2
billirubin 2
(ELAD) 2
sAH, 2
ELAD. 2
INR, 2
cJafCreat 2
OBJECTIVES</b>: 2
2198.32) 2
(likelihood) 2
(2810.77 2
PSD95 2
(PSD)-95 2
(PSD-95) 2
(SVP) 2
SVP 2
IGF-1/IGF-1R/CaMKIIα 2
(synaptophysin; 2
CaMKIIα 2
(Hippocampus: 2
PFC: 2
psychotic-like 2
PSD95, 2
(GABA), 2
(RoM 2
agonists). 2
Pearl 2
osseointegration. 2
osseointegration; 2
estrogens. 2
Las, 2
(SERMs 2
SERM's 2
TSEC 2
SERM-membrane 2
LY-353381 2
Decision-Making 2
cultural, 2
Prev 2
10(11); 2
estradiol's 2
[Selective 2
SERM. 2
(ERs) 2
procedure+saline 2
(OVX+fusion 2
OVX, 2
micro-computed 2
droloxifene, 2
idoxifene, 2
triphenylethylenes. 2
estrogen-antagonistic 2
"Cherchez 2
Femme": 2
Modulators: 2
modulators: 2
(ERs), 2
raloxifen 2
ERbeta. 2
(SERM 2
SERM-mediated 2
hyperandrogenemia 2
antihormone 2
(EnCa 2
E2) 2
VEGFA. 2
alaninate. 2
β-estradiol 2
N-3 2
post-OVX 2
B-lymphopoiesis 2
B-lymphopoiesis. 2
arzoxifene, 2
Endocytosis 2
transcytosis 2
gliadin-containing 2
Gliadin 2
anti-gliadin 2
TG3 2
TG2-peptide 2
non-caseating, 2
multisystemic. 2
varies: 2
18FDG-PET 2
sarcoidologists 2
neurosarcoidosis. 2
sarcoidosis; 2
mL/y 2
Self-Directedness 2
Therapy]. 2
Investigate 2
symptomreduction. 2
Residents: 2
Curriculum. 2
non-suicidal 2
self-injury), 2
year-long 2
didactics, 2
videotape 2
graduates 2
graduation, 2
solving, 2
post-curriculum 2
insecure 2
cartoon-based 2
Mentalization-based 2
(self-referral), 2
thresholds.At 2
patience 2
Marsha 2
APD. 2
self-harming 2
therapists' 2
perceptions. 2
soaring 2
impulsive, 2
disorder) 2
parasuicidal 2
borderline-specific 2
well-specified 2
discontinuities 2
ε) 2
Discontinuous 2
primer-dependent 2
fragments) 2
rad27 2
(FEN-1). 2
PolN, 2
Rad27 2
δ/Fen1 2
wonders 2
bifurcated 2
5'-flaps 2
round) 2
initiate, 2
(flap 2
endonucleases) 2
pivotally 2
FEN-encoding 2
overhanging 2
Fen1(-/-) 2
Dna2p, 2
9°N 2
Cytarabine 2
DNA:DNA 2
(SV40)DNA 2
semi-discontinuous 2
un-inoculated 2
40-65 2
prolamin 2
allelopathic 2
Intergenomic 2
Avena) 2
A/D-C 2
(AACC), 2
7C 2
murphyi 2
Koch) 2
strigosa 2
A-genome 2
chromatin), 2
A-genome, 2
D-genome. 2
Pg9, 2
(Puccinia 2
Gravitropism 2
coleoptiles 2
gravitropism 2
58,904 2
Immigrants 2
intracellular/extracellular 2
diplococci 2
gonorrhoeae), 2
vaginalis), 2
ASCUS. 2
Coccobacilli, 2
(Gardnerella 2
vaginalis). 2
Smears 2
vaginosis. 2
Depopulation 2
Malodorous 2
trichomoniasis, 2
moniliasis, 2
(Amsel's 2
criteria): 2
Ureaplasma 2
mycoplasmas. 2
Acutely 2
AHI. 2
HIV-Ag/Ab-Combo 2
(S/CO≥1) 2
NAT. 2
(Ag/Ab) 2
(RDT) 2
(VOICE). 2
HIV-1/2, 2
Bio-Rad 2
Geenius™ 2
pre-seroconversion 2
CE-Marked 2
Ag; 2
reactive) 2
Multispot® 2
Combo. 2
BIOLINE 2
Bioline 2
Swaziland. 2
retesting 2
Genscreen 2
Ultra. 2
cells/ml 2
uMgungundlovu 2
KwaZulu-Natal, 2
Fourth- 2
wrongly 2
Delphi 2
styloid; 2
hand; 2
manoeuvre 2
lung" 2
pneumoconiosis. 2
(CWP) 2
provisions 2
dependents 2
Autonomy 2
(RFA) 2
enshrinement 2
Childress' 2
RFA 2
ethics; 2
Beneficence, 2
Non-maleficence, 2
Justice. 2
principles-beneficence, 2
justice-afford 2
'doing 2
ethics'. 2
lacunae 2
principlism, 2
Muslim 2
(beneficence, 2
nonmaleficence,justice 2
autonomy) 2
scope," 2
confidentiality. 2
anybody 2
else) 2
interests, 2
obligations; 2
making? 2
ethicality 2
Process. 2
counter-intuitively, 2
judgements 2
situational 2
'four 2
principle' 2
morals. 2
justifications 2
disciplinary 2
perverse 2
adjudicators 2
acknowledge 2
morality's 2
Childress 2
(otherwise 2
principlism) 2
'common 2
morality', 2
everyone 2
subscribes. 2
held. 2
psychiatry: 2
parties 2
precedence 2
community-level 2
non-maleficence. 2
Podiatric 2
DFU, 2
79%) 2
tests--probe 2
mm/hr, 2
cm²--although 2
cm2, 2
mm/h, 2
(60.0%). 2
(46.1%). 2
doubt. 2
(high-certainty 2
evidence) 2
evidence).Based 2
doxycyline 2
psoralens, 2
chloramphenicol, 2
dermatitis? 2
UVA-sensitivity 2
UVB-sensitivity 2
rosacea, 2
delayed-release 2
(anti-inflammatory-dose 2
category-D 2
medication). 2
nonsexually 2
NSAGU. 2
NSAGU 2
GWVIs 2
Zn/lipid 2
seizure‑induced 2
Dentate 2
head-fixed 2
navigation, 2
remapping 2
commissural 2
associational 2
fiber-mossy 2
decorrelating 2
(pattern 2
separation). 2
CA3c 2
fired 2
(PCL) 2
nonoperatively 2
Hyperflexion 2
hyperflexed 2
"dashboard" 2
midsubstance 2
sneezing, 2
CSI, 2
noncontact 2
38.3°C 2
35.5°C-41.1°C; 2
38.2-38.4°C) 2
37.7°C 2
(35.9°C-40.1°C; 2
37.7°C-37.9°C), 2
arthralgias, 2
nodosum. 2
droop, 2
30-pound 2
droop 2
cheek, 2
lymphangitis. 2
Ophthalmoscopy 2
chorioretinal 2
Nn. 2
facialis 2
[Heerfordt 2
gallium 2
ophthal 2
parotitis, 2
otolaryngologist. 2
otolaryngologists 2
pneumologists 2
stifle. 2
miR-132-3p 2
Interactions. 2
COGENT 2
(RIDGEs) 2
multi-cancer 2
hoxb5a, 2
hoxb3a/hoxb4a 2
rhombomeres 2
r6 2
Hoxa3 2
r6, 2
Hoxb3 2
r5. 2
Infliximab, 2
(IG-IBD) 2
repository: 2
Cistrome: 2
HMs 2
CR-HM 2
CistromeMap: 2
W.L. 2
Associates; 2
NCT00738894 2
homepage 2
http://stereogene.bioinf.fbb.msu.ru/. 2
favorov@sensi.org. 2
nucleome 2
anaemic, 2
(hyperlipidaemia, 2
Hyperlipidaemia 2
autohaemolysis 2
haemolysate 2
needle-biopsy 2
density-layer 2
pyruvate-kinase 2
ZS. 2
vitamin-E 2
ZS 2
membrane-linked 2
gasliquid 2
16-C 2
longchain 2
Theses 2
[Morphological 2
lipaemia 2
(arteries 2
veins), 2
Circulatory 2
reticulocytosis 2
rarene-s 2
hyperdense 2
Zieve-syndrome 2
(alcoholic 2
liver) 2
Hounsfield 2
clot. 2
cotton 2
exsudates 2
EuroQoL-5D-3L, 2
≤56 2
≤38 2
<2.6, 2
≤3.3, 2
≤2.8, 2
ACR/EULAR 2
(p≤0.008) 2
0.73). 2
evaluator's 2
reactants. 2
clinician-diagnosed 2
multivariate-adjusted 2
(psoriatic 2
Psoriasis, 2
Dermatology-Rheumatology 2
80.9% 2
(Pso) 2
mellitus/insulin 2
arthritis), 2
hansenii 2
250-300 2
poly(A)-polymerases 2
polyadenylated, 2
2-60% 2
polycistronic. 2
Polycistrons 2
GDF9 2
(s-poly 2
dinoflagellates. 2
nucleotide-long 2
-end 2
G4, 2
(vRNA) 2
3', 2
7' 2
9', 2
Symplekin. 2
Organellar 2
exoribonucleases, 2
(PNPase) 2
PNPase, 2
PNPase 2
poly(A)-tails, 2
polyadenylating 2
Polynucleotide 2
paraganglioma) 2
paragangliomas, 2
triad' 2
paraganglioneuroma. 2
condromatosis 2
paraganglioma; 2
pararenal 2
multi-neoplastic 2
[Carney's 2
generally: 2
leiomyoblastoma, 2
mediastinal), 2
84-year 2
patient-a 2
Well-differentiated 2
triad--gastric 2
paraganglioma--is 2
multicentricity 2
apropos 2
chondromatosis 2
paraganglioma). 2
chondromas, 2
paragangliomas) 2
(malignant 2
leiomyoblastoma), 2
trial-the 2
(preDIVA) 2
trial-over 2
Nurse-led 2
0.15; 2
ISRCTN29711771. 2
(preDIVA): 2
(PreDIVA): 2
(forxiga®) 2
SGLT 2
Mycotic 2
(DAPA) 2
(Farxiga 2
Forxiga) 2
mellitus(T2DM) 2
glycosuria. 2
≈2 2
(dapagliflozin) 2
(solitary 2
hypoglycemia) 2
(SFTP) 2
(DPS). 2
(Doege-Potter 2
"big" 2
Karl 2
Doege 2
(1867-1932) 2
Pilling 2
Potter 2
(1879-1968), 2
1930, 2
hemi-thorax 2
SFTPs 2
[Doege-Potter 2
incidentally, 2
cause: 2
multi-disciplinary 2
co-ordination. 2
bats. 2
develops, 2
Protocol, 2
treatable. 2
PMLOs 2
eIF4B 2
Sam68 2
phase-separated 2
nominate 2
Metataxonomics 2
DNAseq, 2
alibi 2
(RISA), 2
Miseq, 2
(1H-NMR), 2
Leukocytes 2
intakes, 2
health]. 2
(polyphenol 2
chocolate) 2
$A40 2
(£25; 2
€31; 2
$42) 2
Habitual 2
PWV 2
times/week, 2
non-chocolate 2
candy 2
(β=-0·16, 2
P=0·004), 2
flavonoids. 2
flavonoid-rich 2
flavanols 2
epicatechin 2
F&V, 2
pulse-wave 2
flavanol-poor 2
CircRNA/miRNA 2
neurolopsychiatric 2
opthalmopathy, 2
mentality. 2
(hippocampal 2
cognition) 2
resilience). 2
Residuals 2
biomarker-positive 2
CASP7 2
(LOAD). 2
LOAD, 2
nevogenic 2
V126D 2
TNN 2
TND 2
nevogenic, 2
nevogenic. 2
History-taking 2
3/12, 2
ischemia) 2
plague), 2
(NTFs), 2
(AChEIs) 2
ultrawide 2
1998-2015 2
wane 2
paediatricians, 2
(rubeola) 2
antimeasles 2
Panencephalitis. 2
(MeV) 2
MeV. 2
Moraten 2
measles/rubella 2
Edmonston 2
Judging 2
Madang 2
PNG, 2
monozygous 2
seedling, 2
(FHB). 2
deoxynivalenol, 2
germline-altering, 2
IVF-based 2
pronuclear 2
(PNT 2
MST). 2
(DDR), 2
(MDC1) 2
MDC1, 2
Polymerases 2
TNKS1 2
TNKSs 2
BRCA1A 2
previously-treated 2
platinum-antifolate 2
(TKI-258/CHIR-258) 2
TGR 2
23(15); 2
(FGFR), 2
sqRT-PCR 2
(nintedanib, 2
pazopanib), 2
Non-smoking 2
fluvoxamine. 2
30-85). 2
variation%) 2
(AUC0-72h) 2
2880 2
8290 2
(dovitinib 2
2.88 2
3.20] 2
1.95). 2
188% 2
tivozanib 2
palmar-plantar 2
erythrodysesthesia 2
multi-tyrosine 2
FGFR2-CCDC6 2
ponatinib, 2
(infigratinib), 2
Debio-1347 2
FGFR1/2/3 2
BLU9931 2
FIIN-2, 2
JNJ-42756493, 2
LY2874455 2
(VEGF)R2, 2
NCI-N87 2
dovitinib-resistant 2
FGFR2(mutant) 2
FGFR2(N550K) 2
milia 2
receptor-1-3, 2
receptor-β, 2
receptor-1-3. 2
dovitinib) 2
SHP-1-mediated 2
placebo-controlled-crossover 2
unpredictably 2
(PGB 2
disparate; 2
PGB). 2
interchange. 2
precluded. 2
interchange, 2
favoured. 2
Nanostructures. 2
nanomaterials. 2
https://github.com/zhqingit/BPP. 2
djguo@cuhk.edu.hk. 2
(GAS). 2
speC 2
toxin) 2
(STSS) 2
(NF). 2
immunpathological 2
LRD 2
Arcanobacterium 2
ssa, 2
emm4 2
2000-2011. 2
Antibiograms 2
erm 2
nonsusceptibility 2
17.2% 2
emm4. 2
4/50 2
ermB 2
emm12. 2
(2.0%), 2
scarlet-fever-related 2
streptococcal, 2
suburb 2
serums 2
blanch 2
Dochez's 2
Dick 2
[Epidemiology 2
S.pyogenes 2
TSLS, 2
nine-year 2
GAS) 2
9-yr 2
Umbilical 2
controlled-rate 2
thawing, 2
MNC 2
(conventional), 2
TWEs 2
(Mini-BioArchive 2
bag 2
Bioarchive 2
caspase-4/11 2
(EPEC), 2
rodentium, 2
effacing 2
(T3SS) 2
NleF-dependent 2
IECs 2
RHIM 2
RHIM-dependent 2
RIPK1, 2
RIPK3, 2
TRIF 2
ZBP1/DAI 2
EPEC-like 2
(EPEC). 2
2655 2
[109 2
395]; 2
-4.3; 2
[97 2
378]; 2
nanobodies 2
Mabs 2
Bezlotoxumab, 2
longitudinally. 2
Enterobacter. 2
Blautia, 2
Blautia 2
Punt 2
(Put) 2
PTENβ. 2
NS-mediated 2
"Dr. 2
Jekyll-Mr. 2
Hyde" 2
(heterogeneous 2
(LLPTs) 2
microcompartments 2
crowding-induced 2
liquid/liquid 2
(PIGA) 2
CD59. 2
(CD55, 2
hemoglobinuria. 2
(2/127) 2
BCS, 2
(1/100) 2
(4/85) 2
PNH-type 2
(PNH). 2
CD55, 2
macula, 2
diamtere 2
sympathovagal 2
occur-rence 2
Apnea: 2
Mechanisms, 2
Snoring: 2
desaturation. 2
SaO(2) 2
central. 2
apneas 2
(silent 2
symptomatic), 2
ceases 2
apneas. 2
airflow, 2
oxyhemoglobin 2
desaturation, 2
sleep-induced 2
electrocardiographic, 2
snore 2
snorers 2
motoneurons. 2
(apnea/hypopnea 2
uPARAP/Endo180. 2
src(-/-) 2
preosteoclasts 2
delimits 2
lacuna 2
Bromodomain-containing 2
(Brd2), 2
(bromodomain 2
INF-γ 2
JQ1. 2
BAFF, 2
NDT80 2
Bdf2 2
Brd4, 2
UUO 2
months/partial 2
rhabdomyosarcoma; 2
talampanel, 2
P=0.008) 2
Rash, 2
NCT00065468 2
(SAP 2
Proteoform 2
proteoforms. 2
non-ideal 2
proteoforms) 2
Proteogenomics 2
(cognate 2
near-cognate), 2
(small) 2
Venkatesh 2
NVU 2
local/paracrine 2
non-hormonal/systemic 2
sclerosteosis, 2
late-osteoblast/preosteocyte 2
MEPE-ASARM-dependent 2
preosteocyte 2
sclerostin-stimulated 2
(hOCy) 2
(CA2/Car2), 2
(CTSK/Ctsk), 2
(ACP5/Acp5). 2
CA2. 2
hOCy 2
(pHi) 2
(pHo) 2
co-presence 2
Car2-siRNA 2
Lrp6, 2
Car2, 2
Catk 2
perilacunar 2
postmenopausal) 2
26.55±6.67 2
28.65±7.70 2
p=0.031) 2
(β=-0.362; 2
postmenopause 2
osteocyte-expressed 2
(VFs). 2
(s-IGF-1). 2
[OR]=1.27, 2
CI:1.01-2.03), 2
CI:1.03-2.36), 2
P=0.006), 2
(OR=1.54, 2
CI:1.12-2.44) 2
(OR=0.58, 2
CI:0.39-0.88), 2
P=0.041), 2
(OR=0.42, 2
CI:0.21-0.90), 2
P=0.012), 2
(OR=0.19, 2
0.14-0.27), 2
Sclerosteosis 2
sclerosteosis-causing 2
Punctuated 2
intramembranously 2
endochondrally 2
Sclerostin-positive 2
BMP6, 2
preosteoblastic 2
apposition. 2
osteocyte, 2
Sirt1-activating 2
RANKL-dependent 2
mineralised 2
Reparative 2
pulps 2
(Scl; 2
sScl. 2
pmol/L/year, 2
SEC22B, 2
FLT1 2
galactose-α-1,3-galactose, 2
pork, 2
galactose-α-1,3-galactose. 2
496,032 2
InCHIANTI 2
IL6R 2
1.8x10(-57)), 2
CCL4L1 2
3.9x10(-21)), 2
IL18 2
6.8x10(-13)), 2
4.4x10(-10)), 2
GGT1 2
1.5x10(-7)), 2
3.1x10(-7)), 2
6.4x10(-6)) 2
IL1RN 2
7.3x10(-6)) 2
(IL6R), 2
(LPA), 2
(CCL4L1) 2
(GGT1). 2
6.8x10(-40)), 2
(rQTLs), 2
[cis-eQTLs]) 2
[cis-pQTLs]), 2
cis-pQTLs. 2
(approximated 2
pQTLs 2
chemotherapeutics: 2
(cis-) 2
(pQTL) 2
F(2) 2
pQTL 2
(D-MER). 2
nod 2
CDxBRCA 2
malignancies-olaratumab 2
atezolizumab) 2
BRCA1/2-mutated 2
HGOC. 2
cancer.<br> 2
Rucaparib, 2
somatic)-associated 2
Rucaparib's 2
rucaparib's 2
Mutation-Associated 2
iso-allergens 2
Assembling 2
detectability. 2
originate, 2
[Antidepressants 2
anti-depressants 2
applicated 2
SSRI's 2
tetracyclic 2
wort 2
polyhydramnios. 2
Socialist 2
lithium-induced 2
displaced. 2
proper, 2
atrialized 2
septum. 2
EA. 2
15-40) 2
927 2
340). 2
Birthweight 2
(3475 2
[660] 2
3383 2
[566] 2
(31.8% 2
Malformations. 2
1,325,563 2
lamotrigine. 2
(2.41%), 2
15,251 2
1,322,955 2
(1.15%), 2
1945 2
(1.39%). 2
2.68). 2
2.64) 2
3.80) 2
7.02) 2
0.60% 2
0.18% 2
2.66; 2
7.06). 2
lamotrigine-exposed 2
Health.). 2
(adjOR 2
preventative. 2
large-for-gestational-age 2
Tg2576-AβPPswe 2
(ARIA-H) 2
ACE910 2
(emicizumab) 2
FVIII 2
EM-like 2
(southern 2
illness). 2
Coxiella-like 2
(Lone 2
tick) 2
ehrlichiosis, 2
(Class 2
burnetii, 2
burnetii 2
(LST; 2
Ixodidae) 2
ehrlichioses, 2
"Tidewater 2
fever" 2
"R. 2
rickettsiosis." 2
Koch, 2
parkeri. 2
[STARI] 2
acquisition-fed 2
Monocytic 2
WTD 2
Ubiquilin1 2
(UBQLN) 2
ubiquilin-encoding 2
UBQLN5 2
Ubiquilin-client 2
(Ubqlns) 2
Ubqln1-/- 2
Ubiquilins, 2
(UBQLN), 2
categories; 2
soluble), 2
http://www.cbs.dtu.dk/services/DeepLoc. 2
https://github.com/JJAlmagro/subcellular_localization. 2
http://www.cbs.dtu.dk/services/DeepLoc/data.php. 2
jjalma@dtu.dk. 2
Instar 2
Bug, 2
(Heteroptera: 2
pest, 2
Beauveria 2
bassiana 2
(GHA) 2
emulsifiable 2
10⁷ 2
67%-80% 2
95%-100% 2
leguminous 2
Plautia 2
dispensers 2
lure 2
ZEZ 2
EEZ 2
lures 2
(BMSB, 2
halys) 2
mid-Atlantic 2
Trissolcus 2
parasitoid 2
herbivores 2
generalist 2
Electronically 2
dabbing 2
stylet 2
'probes' 2
(China, 2
peninsula). 2
bug. 2
Chile. 2
(Stål; 2
Hemiptera: 2
Kerman 2
nuts 2
Rashes 2
rosea, 2
infectiosum, 2
roseola 2
rosea 2
Christmas 2
Impetigo 2
"slapped 2
cheek" 2
Flesh-colored 2
umbilication 2
origin]. 2
Exfoliative 2
above-38 2
81.4%, 2
days-duration 2
86.6% 2
above-moderate 2
68.2%, 2
29.9%, 2
strawberry 2
ETC) 2
mitogenic, 2
mitogens. 2
exanthema. 2
ETB. 2
(localized) 2
tonsilla 2
microbiologically 2
2.91-4.78), 2
84-94%), 2
58-82%), 2
17-31%). 2
Typhimurium, 2
Vi 2
Oppositely, 2
(ΔwcaM 2
ΔbcsE) 2
Colanic 2
biofilm-forming 2
attachment/invasion 2
maintaining/inducing 2
host-barriers 2
carriage: 2
hepatopancreatobiliary 2
(SPI-1)-dependent 2
postinvasion. 2
flowthrough 2
postinoculation. 2
≤6 2
positivity; 2
μg/dL; 2
10(12)/L, 2
(11.1%) 2
2196 2
formulas: 2
(RDW), 2
(MCV/RBC), 2
(MCV 2
Hb- 2
Shine 2
MCH/100), 2
Ehsani 2
(MCV-10 2
RBC), 2
Srivastava 2
(MCH/RBC), 2
RDW/Hb 2
(RDW 2
RDW/RBC, 2
(MCV-RBC 2
Hb). 2
Green-King 2
MCV/RBC 2
trypanosomiasis. 2
microdialysis, 2
(FEX) 2
trypanocide 2
trypanosomiasis/sleeping 2
finger-prick 2
FEX, 2
oxaboroles. 2
(HAT), 2
nitroheterocycles, 2
anti-parasitic 2
(IC₅₀ 2
4-weeks 2
Ames 2
metabolites: 2
metabolite). 2
(fasted 2
field-adapted 2
food), 2
[time 2
h] 2
Fourteen-day 2
[HAT]), 2
trypanomiasis 2
Arteritis. 2
TCZ. 2
(aGCA, 2
n=11), 2
(rGCA-CS, 2
(rGCA-TCZ, 2
n=11). 2
(HCs) 2
hypoproliferating 2
IL-17-secreting 2
(IL-17+Tregs). 2
disproportionally 2
(Foxp3Δ2). 2
Foxp3Δ2-expressing 2
CD161, 2
linage, 2
HCs, 2
GCA-derived 2
TCZ, 2
aGCA. 2
(CD45RA-Foxp3high) 2
(CCR4) 2
large-size 2
controlateral 2
differently, 2
expanding, 2
relapsing/refractory 2
Takayasu's 2
AAV-associated 2
Tomm20 2
SCFFbxo7/PARK15 2
FBXO7 2
(Gsk3β), 2
(Tomm20), 2
(Wld(S) 2
Sarm1(-/-)), 2
trans-neuronal 2
C4-AP 2
(POLQ). 2
CRISPR-Cas9, 2
(2590 2
disordered). 2
(enzyme:DNA:nucleotide) 2
grasps 2
(SOF/VEL/VOX) 2
(Vosevi) 2
(FDC), 2
interferon-free, 2
have: 2
SOF/VEL/VOX-treated 2
SVR12. 2
hedonic 2
Tnfrsf11b, 2
REV-ERBα 2
entrains 2
3:3 2
RT-Biolumicorder. 2
anastamosed 2
wide-spread 2
NGC 2
ideas: 2
positions; 2
configurable 2
quantization 2
33-66% 2
alignment/map 2
files), 2
uncompressed 2
Lossy 2
rate-distortion 2
quasi-convex 2
minimized, 2
QVZ-compressed 2
CSAM 2
(Compressed 2
format), 2
decompress 2
(HMP) 2
(MetaHIT) 2
Gynecologists 2
Buprenorphine-naloxone 2
LAAM), 2
reopened 2
Monkeys. 2
(Romo), 2
(romosozumab) 2
plate-like 2
bone-increasing 2
28weeks. 2
self-regulation 2
3weeks, 2
Rs.De 2
ES/BS 2
AP-1/c-Jun, 2
E2-Related 2
Species-Induced 2
Priming. 2
Nrf2-regulated 2
S-transferase, 2
oxidoreductase-1 2
(NQO1). 2
Allantopyrone 2
payers, 2
outcry 2
budgets 2
payers. 2
(E4) 2
Aβ1-42-induced 2
HIPAA-compliant, 2
waived. 2
(ADG) 2
(RDG) 2
80.2%, 2
92.1%) 2
91.1%, 2
96.3%). 2
97%) 2
98%). 2
71.1%, 2
374%, 2
85.1%, 2
193.4%, 2
95.2%, 2
36.2%, 2
61.35%. 2
46.1%; 2
41.6%; 2
superiority. 2
0.8745, 2
0.9841 2
(Wells 2
avalvular 2
18+years 2
19months 2
32months 2
CTPE. 2
/A 2
C15 2
(17beta-HSD1) 2
estrone 2
(Tecfidera(®)) 2
Tecifidera 2
(Tecfidera): 2
harmlessness 2
malady 2
terrorizing 2
47-year 2
asleep, 2
INCB3619, 2
heregulin. 2
Akt), 2
fibroplasia, 2
(VLS), 2
bullectomy 2
Zhangye 2
Municipality 2
(Zhangye, 2
(GBE), 2
'vanishing 2
bullectomy. 2
Emphysema/Vanishing 2
emphysema): 2
paraseptal 2
trispecific 2
determinants: 2
(MPER), 2
V1V2 2
failure-associated 2
(CUA), 2
CUA. 2
(calciphylaxis): 2
(CUA, 2
calciphylaxis) 2
Warfarin-induced 2
calcification-induced 2
violaceous, 2
(livedo 2
reticularis) 2
elasticum. 2
FIO(2) 2
occlusion/thrombosis 2
vasculopathic 2
calciphylaxis; 2
HBOT 2
endoluminal 2
(Fgf21) 2
Arginase2, 2
OxLDL 2
HAEC, 2
NEDDylation. 2
Neddylation, 2
ubiquination 2
Buster 2
(NUB1L) 2
Proteotoxic 2
GFPu. 2
GFPu 2
CryAB(R120G), 2
SCCRO-promoted 2
~20% 2
UBE2F, 2
CUL5 2
Break 2
Break-induced 2
(BIR) 2
one-ended 2
hyper-mutagenesis, 2
(CD45+, 2
1+) 2
BO. 2
BO 2
Myeloid-derived 2
circulating, 2
CD45+ 2
haematopoietic-derived 2
Fibrocytes, 2
ahematopoietic 2
fibroblasts/myofibroblasts, 2
Valve 2
pro-osteogenic 2
BMP2. 2
(H19) 2
pEX-3-H19 2
overexpressing, 2
H19-RNAi 2
down-regulating, 2
pEGFP-C1-DUSP5 2
overexpressing. 2
DUSP5. 2
post-consolidation 2
ch14.18-UTC 2
Products' 2
Multi-institutional 2
DNA-proteins 2
rudimentary. 2
Guanine-quadruplex 2
(GQ) 2
(2G 2
(ddi) 2
distribution-matched 2
UV-VIS 2
"common 2
deletion", 2
hsa_circ_0058246 2
Nrdc) 2
M16 2
(ADAM) 2
Nrdc 2
Nrdc. 2
MafA, 2
nardilysin 2
Nrd1(-/-) 2
Islet-1 2
refugees 2
asylum-seeking 2
minors, 2
Rome, 2
(TST, 2
Psocare 2
2TE 2
PPD-L 2
dispensary 2
bacteria-excreting 2
students, 2
(Mantoux 2
100-year-old 2
(Mantoux) 2
tuberculosis-specific 2
Infarction: 2
CHILL-MI 2
Substudy. 2
CHILL-myocardial 2
STEMI, 2
(Olink 2
(BDNF, 2
DNER, 2
MMP3) 2
(OPG, 2
FS, 2
IL12B, 2
TIM, 2
IL6). 2
(PTX3 2
SELE). 2
CHILL-MI, 2
3394 2
ProSeek 2
I; 2
Kynureninase 2
42/33) 2
27/48; 2
(IL18), 2
CCL2/MCP1, 2
CCL11 2
CSF1, 2
sIL15RA, 2
sCD40, 2
sCX3CL1, 2
sIL18R1, 2
bNGF, 2
LN-associated 2
(MM-ASCT, 2
Adrenomedullin 2
(ADM, 2
.0004), 2
(GDF15, 2
I-related 2
(sMICA, 2
antia-poptotic 2
midkine 2
(Pcorr= 2
(TGFB1, 2
(sBAFF) 2
(Pcorr< 2
Plates) 2
Proseek® 2
HE4 2
(p=0.031). 2
donor/recipient 2
fractalkine, 2
I(96 2
96)), 2
(anti-ICAM-1 2
alphaMbeta2-integrin 2
AAV, 2
Trial.gov, 2
Revman5.0, 2
1027 2
4039 2
moderate-low 2
glycoproteins: 2
(urea 2
Rapigest 2
SF), 2
[dithiothreitol 2
tris(2-carboxyethyl)phophine 2
(TCEP)], 2
[iodoacetamide 2
(IAM)]. 2
apo-transferrin 2
TCEP 2
tyrosylquinone 2
hLOX 2
8,401 2
(2,317 2
Glargine 2
(ORIGIN) 2
3.73 2
3.40, 2
4.09) 2
3.59, 2
4.33) 2
1.24. 2
188-mg 2
syndrome/myalgic 2
rintatolimod 2
precancerous, 2
CTNNB1, 2
16.4% 2
(aDNA) 2
anthropological, 2
bioarcheological 2
Eurasians. 2
bc, 2
Anatolian 2
non-sequential 2
U2AF 2
nuclear/nucleolar 2
(like) 2
LOXL3 2
fibroblast-to-myofibroblast 2
(FMT). 2
FMT 2
LOXL2/3 2
LOX/LOXL2 2
EpCAM(+) 2
Poly-Ether-Ether-Ketone 2
peristernally 2
through. 2
device; 2
(KLK3), 2
KLK3e. 2
Directionality 2
Initiation. 2
thinly 2
(ERBSs) 2
∼3-5 2
(RBT) 2
(Dom34 2
Dom34) 2
aEF1α 2
Glycosaminoglycan 2
CXCL7, 2
(GAG). 2
GAG-bound 2
CXCL7-CXCL1 2
hyper-permeability 2
Acidification 2
TRPM 2
NUDT9 2
flufenamic 2
[Ca(2+)]cyt 2
TRPM2-KO 2
econazole 2
FFA. 2
[Ca(2+)]cyt. 2
(H(2)O(2)), 2
channel's 2
ADPR 2
(TRPM2), 2
(Transient 2
Lm 2
TRPM2. 2
thermosensitive, 2
melanoma-enriched 2
TRPM2-AS, 2
TRPM2-TE, 2
TRPM2-TE 2
amyloid-induced 2
TRPM2(-/-)/APP/PS1 2
[Ser139→Asn139 2
(S139N)] 2
S139N 2
NPCs, 2
(LSDBs) 2
beta-globins 2
(HBA, 2
HBB), 2
genomewide. 2
Swiss-Prot. 2
track) 2
consortium), 2
choose. 2
dbSNP. 2
UniProtKB/Swiss-Prot, 2
iST 2
single-pot 2
solid-phase-enhanced 2
quantity-limited 2
Single-Pot 2
Solid-Phase-enhanced 2
(SP3). 2
KBTBD4 2
'enhancer 2
hijacking' 2
PRDM6. 2
bindings 2
hijacking, 2
hijacking" 2
Onychomycosis 2
(tinea 2
unguium) 2
onychomycosis, 2
incognita" 2
mycologic 2
Dermatophyte 2
manuum 2
barbae. 2
versicolor, 2
furfur, 2
miconazole, 2
dermatophytoses, 2
Carolina. 2
camps 2
31.5%), 2
(foot 2
27.8%), 2
sunburn, 2
(1968-1997) 2
koranic 2
(42.66%), 2
scabiosis 2
(13.33%), 2
(15.33%), 2
keratodermia 2
immuno-suppressed 2
terbinafine 2
kerion 2
adoptees. 2
adoptees, 2
infectious; 2
32/36). 2
Df(4)G, 2
Df(4)M101-62f, 2
Df(4)B2-2D 2
(AT)n, 2
(GAA)n 2
(GAAA)n 2
A-tracts 2
microarray-CGH 2
terriers. 2
C04107 2
paralog-specific 2
normal-sequence 2
DNase/MNase-seq. 2
Buenrostro 2
noninflammatory, 2
unstructured, 2
biomechanically 2
disorganised 2
esophagectomies 2
esophagus" 2
mammary, 2
vulvar, 2
("in 2
situ" 2
hyperdensity 2
(1/8) 2
(15/23) 2
(4/23) 2
(6/21), 2
nonimmunoreactive 2
GCDFP-15. 2
intra-epidermal 2
(mammary 2
axilla. 2
visceral) 2
intraepidermal) 2
Extramammary 2
Her2/neu, 2
(97%), 2
1,25-(OH)2D3 2
osteopathy 2
hypervascularity, 2
acylation-deacylation 2
Ser115 2
β-lactamase-mediated 2
penicillinase. 2
Thermosynechococcus 2
beta-lactamases. 2
Omega-loop 2
L158E 2
TEM-1, 2
beta-Lactam 2
BlaC 2
(Felis 2
catus). 2
Canis, 2
pack-hunting 2
wolf 2
Canis 2
domestication, 2
carnivores, 2
taste, 2
Felis 2
silvestris. 2
hunt, 2
eat, 2
"monotony 2
kittens 2
16q22.1 2
SROs 2
KLF1. 2
HS2. 2
semantic, 2
syntactic 2
(dardarin) 2
sui 2
generis 2
(LRRK2 2
Dardarin) 2
(LRRK2/dardarin) 2
(PD); 2
PARK8 2
dardarin) 2
(LRRK2; 2
PARK8) 2
dardarin, 2
(LRRK2)/Dardarin 2
21S 2
MO 2
dots. 2
piecing 2
novelties-i.e. 2
Elaboration 2
enhancer-originating 2
yakuba 2
yakuba/santomea 2
hypervascularization 2
58.3 2
(42-75 2
epineurectomy, 2
61.5 2
(41-82 2
epineurectomy. 2
Electrodiagnostic 2
cause); 2
aortocaval 2
(ECM)-modifying 2
aldehydes. 2
elastin, 2
LOXL2/L3/L4 2
Valaciclovir: 2
L-valine, 2
patient-initiated 2
(CD+ 2
cells/microl), 2
realised 2
(Zovirax) 2
(Denavir 2
(Famvir). 2
(eGFR: 2
valacyclovir, 2
acyclovir-induced 2
(Denavir). 2
famciclovir. 2
"valacyclovir" 2
PHN. 2
('shingles') 2
Wellcome), 2
(Zovirax), 2
Wellcome). 2
Beecham). 2
(3-day) 2
(Zoviraxr, 2
herpetic 2
conspecifics 2
flavor 2
(OR7D4) 2
(SCNN1D). 2
ossicle 2
hair--a 2
155555). 2
red-yellow 2
black-brown 2
eumelanin. 2
3.11×10⁻¹⁴² 2
rs258322 2
1.33×10⁻⁶⁶). 2
layer-specific 2
(Mc1re/Mc1re) 2
(Mc1r) 2
sheets, 2
skins) 2
(P2.5) 2
26K 2
883, 2
2097 2
dark-haired) 2
care-specific 2
dark-haired 2
Basque, 2
Apache 2
(IAN) 2
haired) 2
Corah 2
cartridges 2
1:100,000 2
Pulpal 2
4-minute 2
tester. 2
cheek 2
Sepharose-4B 2
Phenotypically 2
ColE1-dependent 2
ColE1-determined 2
RecA-independent 2
EcoRI]. 2
RP4 2
over-produces 2
PHLS 2
cryptococcosis. 2
[Cryptococcal 2
meningitis]. 2
uncharacteristic. 2
hypoxia-related 2
EGLN1. 2
EPAS1, 2
non-Tibetans 2
Positively 2
pattern-low 2
(Tibetans, 2
Sherpas, 2
Ladakhis) 2
(Chinese 2
Han, 2
Tamils) 2
Himalayas, 2
Everest 2
natives. 2
Altitude 2
Himalayans 2
stock. 2
Tibet, 2
selection-nominated 2
PHD2), 2
Andeans. 2
EGLN1/PHD2 2
decay; 2
short-circuits 2
UCP1-mediated 2
(UCP1)-based) 2
UCP1-/- 2
SLN-/- 2
UCP1's 2
cold-acclimated 2
A-Jak2 2
(UCP)-1 2
moods. 2
(BPD), 2
[(11)C] 2
Harmine 2
VT), 2
MDE, 2
F6,102 2
.52, 2
.53, 2
.40, 2
.037; 2
.38, 2
-.44, 2
.023). 2
Kindergarten 2
maltreatment, 2
violence, 2
property-violent 2
crimes 2
self-reported. 2
alcoholism: 2
Antisocial 2
incarceration. 2
criminality. 2
non-incarcerated 2
Psychiatrists. 2
[(variable 2
(VNTR)] 2
troglodytes 2
psychopathy- 2
delinquency. 2
deliberation 2
Gro/TLE/Grg 2
SAHA-BPyne 2
HDAC-associated 2
liberates 2
winding 2
Ser(421) 2
nucleosome-RSC 2
unwrapping 2
Ramachandran 2
Kinetochore 2
Yeast. 2
"regional" 2
CENP-T, 2
CENP-I, 2
H3-rich 2
Biweekly 2
dystroglycan 2
phylotypes 2
Actinobacteria) 2
omnivores, 2
lacto-ovo-vegetarians 2
vegans. 2
(VEPs) 2
(1987). 2
Ishihara-tests 2
technicians 2
cricket 2
Isihara 2
Batting 2
Eugenol 2
oils 2
decorin, 2
fibroblast-secreted 2
Slit2. 2
α2β1, 2
αMβ2, 2
αXβ2 2
lumican-induced 2
Lumican, 2
type-1-infected 2
(CYP)3A 2
tipranavir 2
inducers: 2
Tipranavir, 2
Chimpanzee 2
hyperexpanded 2
satellites. 2
chromosome-2-specific 2
2q12-q14 2
ape-type 2
c29B, 2
5'(TTAGGG)n-(CCCTAA)m3'. 2
pretelomeres. 2
BAL-31 2
2q13 2
Chromosome-Specific 2
Estimate 2
Hominin 2
Genomes. 2
2q21.2. 2
chromosome-assigned 2
intermediate-sized 2
(Her2/neu), 2
αvβ6 2
(EpCAM). 2
claudins 2
trans-epithelial 2
cytoplasmic/nuclear 2
claudin 2
(CD326) 2
EpCAM-derived 2
EpCAM-targeted 2
(scFv2A9-PE 2
APE) 2
problematic, 2
(Lixiana®), 2
NOAC. 2
2.0-3.0) 2
Lixiana®), 2
factor-Xa, 2
Xarelto) 2
(rivaroxaban; 2
Pradaxa; 2
Eliquis). 2
Trypsin-Like 2
Opportunities, 2
Structure-Based 2
Rationales. 2
β-tryptase 2
Trypsin-like 2
195. 2
protein-inhibitor 2
190, 2
(LMWHs), 2
(NOACs). 2
drug/food 2
(fXa) 2
etexikate 2
(fIIa) 2
(FXa). 2
(Pradaxa, 2
(Xarelto, 2
HealthCare), 2
(Eliquis, 2
(Lixiana/Savaysa, 2
Daiichi-Sankyo). 2
(Eliquis™), 2
direkt 2
FXa-inhibitors 2
hemodialysed. 2
VTE-related 2
[(18)F]THK523, 2
[(18)F]THK5117, 2
[(18)F]THK5105 2
[(18)F]THK5351, 2
[(18)F]AV1451(T807) 2
[(11)C]PBB3 2
tracers, 2
T807, 2
THK-5117, 2
PBB3 2
18F-labeled 2
18F-THK-5351, 2
18F-T807 2
(18F-AV-1451), 2
18F-RO6958948 2
55°C, 2
antinoceptive 2
tapentadol, 2
ketorolac 2
Moringa 2
polysorbate-20 2
(formalin 2
1h) 2
(1-30) 2
antiallodynic 2
224289 2
15572 2
horn. 2
biphasic. 2
(2.5%, 2
(50µl 2
paw) 2
bahaviour 2
flinch-frequency 2
(5-15%). 2
1.75% 2
Eugenia 2
caryophyllata 2
chemogenic 2
(SSEHs). 2
hemilaminectomy 2
SSEH. 2
thoracic-cervical 2
SEH. 2
epidurally 2
(SEH) 2
DISH-like 2
T11. 2
(SEHS) 2
corpectomy, 2
C7-D1. 2
intra-thoracic 2
fatally 2
polyglutamine. 2
atrophin-1 2
Dentatorubral-pallidoluysian 2
(CLCs). 2
GPCRs. 2
post-golgi 2
clathrin, 2
triskelion) 2
polyhedral 2
pentagonal 2
hexagonal 2
triskelia, 2
pinwheel-shaped 2
Delineating 2
neurocentric 2
(FMRP) 2
FMRP 2
envelops 2
conduction. 2
O4(+) 2
mutilamellar 2
(OLs) 2
ensheathes 2
Seropositivity 2
PUO 2
(PUO) 2
zoonosis, 2
brucella 2
testicle 2
Chile 2
40-80% 2
Karnataka 2
sub-acute). 2
(82%), 2
L7/L12 2
rL7/L12 2
TLR6 2
Rhizobium 2
ExsA, 2
S2308 2
facultative, 2
RB51 2
IL-12/β2-microglobulin 2
IL-12-dependent 2
gram-negative, 2
12,1% 2
Denisova 2
non-Sub-Saharan 2
clinally 2
49.4% 2
66.5%) 2
rs35455589-G 2
level- 2
pigmentation-associated 2
(rs460879-T) 2
non-Africans. 2
neutral-and 2
frequency-in 2
Neanderthals, 2
early-generation 2
human-Neanderthal 2
interbred 2
9° 2
contracture]. 2
aponeurosis, 2
aponeurectomy 2
(MCP) 2
joints) 2
curl 2
contracture, 2
aponeurosis 2
palm. 2
PHARMO 2
60-79 2
118, 2
NDP-MSH 2
allele-expressing 2
cAMP-mediated 2
R142H 2
I155T. 2
Thr(111) 2
Thr(111)/Ala(111) 2
dopachrome 2
V60L-/- 2
V92M-/- 2
DCT 2
alpha-melanocortin 2
(alpha-MSH) 2
melanogenesis, 2
beta-MSH, 2
gamma-MSH 2
Val29Met 2
(alpha-melanocyte-stimulating 2
Val92Met 2
alpha-melanotropin. 2
Coatomer 2
(COPA) 2
Holsteins 2
(MC1RD) 2
(MC1Re). 2
MC1RD. 2
COPA 2
melanocyte, 2
(p.V60L, 2
p.I155T, 2
p.R160W, 2
p.R163Q 2
p.D294H 2
TOG5-microtubule 2
TOG5 2
(DNA-PKcs) 2
selenomethionine-labeled 2
(HEATR1) 2
Tor-Lst8 2
α-solenoid 2
segments: 2
800-residue 2
'spiral', 2
400-residue 2
low-curvature 2
'bridge' 2
'railing' 2
'cap' 2
α-helices 2
(Huntington-elongation-A 2
subunit-TOR) 2
PR65/A, 2
Pds5B. 2
Smc1 2
NCI-H1975 2
osimertinib-induced 2
WNK4, 2
R528H 2
PHAII 2
-regulating 2
KLF8-interacting 2
PARP-1(-/-) 2
KLF8-PARP-1 2
membrane-based 2
biofluids. 2
(TF)-binding 2
self-cooperative 2
aripazine) 2
+2.45, 2
COL1A1: 2
+0.97, 2
+1.37, 2
+0.33, 2
sites--the 2
L12 2
(PASA) 2
Köbner-type 2
(384 2
Leu-Pro) 2
Dowling-Meara-type 2
Arg-Cys) 2
2719de19, 2
QEA, 2
5866, 2
5866delC, 2
anti-plectin 2
(HD-1), 2
EB-MD. 2
PLEC1 2
Plectin 2
insertion/nonsense 2
(K14 2
M119T) 2
gradations 2
p.E477D. 2
keratinocyte-mediated 2
p120-catenin-dependent 2
SCC, 2
Bullosa 2
11-day-old 2
herpetiform 2
densa 2
clumps, 2
punctured 2
c.1424A 2
(p.E475G) 2
c.1237G 2
(p.A413T). 2
KRT 2
immunobullous 2
c.1237G>A 2
(p.Ala413Thr) 2
p.Glu411del 2
p.Ile467Thr 2
KRT5/KRT14 2
(K5) 2
(K14). 2
Dowling-Degos 2
K5/K14 2
Hindoestan 2
non-infarct-related 2
XIIIA 2
Marsh 2
Strongyloides 2
helminth 2
Cpa3Cre 2
IgE-independent 2
(allergic 2
implant-associated 2
immediate-type 2
non-allergic 2
Slc10a4 2
IgE/antigen-mediated 2
TGF-beta2, 2
battle. 2
degranulation-independent 2
medium-wave 2
(320-400 2
mid-wave 2
(320- 2
(290-320 2
short-wavelength 2
(320-340 2
agreed-upon 2
UV-C, 2
UV-B, 2
UV-A. 2
16%-60% 2
time-tested 2
hypothetically, 2
tachycardia-related 2
tachycardia-bradycardia 2
Elective 2
fibrillation]. 2
arrhythmia's 2
Empirically, 2
Alcohol-related 2
flutter: 2
pathogenesis]. 2
thyrotoxicosis--which 2
wavelets 2
250-350 2
bpm.(ABSTRACT 2
periodically, 2
chaotic 2
people; 2
fibrillations 2
(CST5): 2
CST5, 2
amazonensis 2
footpad 2
amazonensis, 2
tegumentary 2
canids. 2
protozoan, 2
Roth 2
Phlebotomus 2
argentipes. 2
Leishmanization 2
nationality 2
kala-azar 2
post-kala-azar 2
(kala-azar) 2
(post-kala-azar 2
Leishmaniasis. 2
AQP1. 2
antimonials 2
Pentostam 2
Glucantime) 2
(Sb(V)) 2
pro-drug, 2
(Sb(III)). 2
(AQP1) 2
antimonite, 2
VL. 2
squamipes, 2
rattus 2
(Ld-CC) 2
LmjF27.2440 2
Trypanosomatidae 2
3-hydroxyacyl-ACP 2
FASII 2
FcgammaR 2
leishmaniases 2
sandfly. 2
peruviana, 2
peruviana. 2
hypoprothrombinemic 2
(pre-INR), 2
(post-INR). 2
1.62). 2
post-corticosteroid 2
(38.5 2
(ethinyl 2
norethindrone) 2
(etonogestrel) 2
etonogestrel 2
55.8% 2
(resulting 2
etonogestrel, 2
(norethindrone). 2
norethindrone, 2
cephalexin, 2
overanticoagulation, 2
cephalexin 2
<0.05. 2
(F(15, 2
358) 2
0.0221). 2
0.0019), 2
expands, 2
Psychotropics 2
Regione 2
(6824 2
theophylline/aminophylline 2
ciprofloxacin/fluvoxamine 2
(930), 2
barbiturates 2
(567). 2
omeprazole 2
45.8, 2
bezafibrate, 2
lactulose. 2
antilipidaemic 2
coumarins: 2
fibrates. 2
hypoprothrombinaemic 2
phenylbutazone), 2
Isomeric 2
phenylbutazone, 2
0·0001. 2
Nystatin 2
134,833 2
mesothelin 2
Mesothelin 2
expected? 2
penicillinase-resistant 2
(PRPs), 2
PBP2a, 2
misidentified, 2
(MSSA). 2
Colorex 2
Brilliance 2
10(1)cfu/mL 2
ampicillin/sulbactam 2
t002, 2
t3478, 2
t13620 2
meat-derived 2
t011 2
meat. 2
(PBP)2a. 2
(MSSA), 2
borderline-oxacillin-resistant 2
(BORSA), 2
methicillin-resistance 2
(CA-MRSA), 2
border-line 2
cloxacillin 2
ORSA) 2
beta-lactamase-negative 2
intravegetation 2
(BORSA; 2
mecA-negative, 2
microgram/ml). 2
heteroresistant 2
SUMO3. 2
R553H 2
(DISC1, 2
SRPX2, 2
MiR200c). 2
song 2
stuttering. 2
non-communicable 2
(PNPPP) 2
OLS 2
investments, 2
(PACAP), 1
lactogenic 1
β-casein. 1
gammainduced 1
(IP)-10, 1
"regulated 1
secreted" 1
(RANTES), 1
(IGFBP)-3 1
(AREG). 1
β-casein 1
(MECs). 1
(hTERT)-immortalized 1
MECs 1
(K5(+)K19(-) 1
hMECs). 1
hMECs 1
differentiation-promoting 1
MEGM 1
MEK-Erk 1
molecular/biochemical 1
(EREG) 1
EREG 1
(rs11942466 1
C>A, 1
rs13104811 1
rs11942466 1
rs712829 1
G>T, 1
Ligand-dependent 1
(FDC-S). 1
FDC-AM09). 1
UO126 1
FDC-AM09. 1
FDCs. 1
FDC-AM09, 1
BTC 1
PI3KCA, 1
FDC-S. 1
levels' 1
anti-EGFRs. 1
(α-SMA)-positive 1
cotransplantation 1
(HLMFs) 1
HLMFs 1
HB-EGF-neutralizing 1
HLMFs. 1
HB-EGF/EGFR 1
(TACE)/ADAM17-dependent 1
TACE 1
(MPNSTs), 1
epigen, 1
transphosphorylation 1
MM-PBSA/GBSA 1
MM-PBSA 1
EGF>HB-EGF>TGF-α>BTC>EPR>EPG>AR. 1
EGF>HB-EGF 1
TGF- 1
α>BTC>EPR 1
>EPG 1
Prolidase 1
Prolidase, 1
(PEPD), 1
PEPD. 1
pro-proliferation 1
(mCRC), 1
(TGF-α), 1
(EREG). 1
(53.3 1
0.000008), 1
oluble 1
3.2-fold, 1
2.3-fold, 1
60.2 1
(2.1-fold 1
(CLCA1 1
qPCR) 1
(NHBE) 1
NHBE 1
Autocrine, 1
isogenically 1
HLH-2/E/Daughterless 1
FOS-1A, 1
HLH-2, 1
mig-17 1
migrations 1
(DTCs), 1
substrata 1
lagrin 1
Kunitz-type 1
MIG-6L 1
MIG-17/ADAMTS 1
MIG-17 1
class-s 1
non-fibrillar 1
Papilin, 1
apilins 1
TSRs 1
excorporeal 1
papilin-containing 1
wandering, 1
papilins. 1
'papilin 1
cassette' 1
metalloproteinases; 1
(TSR) 1
N-proteinase, 1
Malpighian 1
vitronectin: 1
myosin-containing 1
cytoarchitecture. 1
detergent-insoluble, 1
Papilin: 1
proteoglycan-like. 1
900,000 1
400,000. 1
4-methylumbelliferyl 1
xyloside, 1
CsCl/4 1
g/ml, 1
sulfate-agarose 1
protomer 1
15-nm 1
Oligomers 1
clover-leaf-like 1
galactosamine, 1
chains/core 1
Sulfate 1
O-linkage 1
glycosidases 1
evolutionarily. 1
poly(A)-site, 1
ribosome-mapping 1
sperm-specific 1
nonvertebrate 1
bosome-mapping 1
NONCODEv4: 1
(http://www.bioinfo.org/noncode/) 1
rRNAs). 1
(RNA-Seq). 1
NONCODE, 1
831. 1
018 1
http://www.noncode.org/. 1
snRNAs, 1
piwi-RNAs. 1
integrin/focal 1
signaling-dependent. 1
integrin/FAK/Akt 1
Transglutaminase-2 1
Transglutaminases-2 1
(Tgase-2) 1
TPA-treated 1
Cystamine, 1
signifi 1
cantly 1
specifi 1
fi 1
kda, 1
Tgase-2. 1
Tgase-2's 1
osteoblasts/osteoclasts 1
(OPG)/receptor 1
(RANKL)/RANK 1
osteoblastogenesis 1
Osteoprotegerin: 1
(TRAIL), 1
acceleration: 1
osteoblast- 1
osteoblast-osteoclast 1
Osteoblasts 1
RANK-RANKL-OPG 1
4D, 1
Plexin-B1 1
3.0×g 1
3.0×g. 1
(PEMF) 1
(Sham), 1
(PEMF). 1
deciphered. 1
(LTs) 1
Brucella-induced 1
abortus-induced 1
LTs, 1
Pre-activated 1
LTs 1
LTs. 1
p55 1
Osteoclast 1
(TRAP), 1
(VNR), 1
TRAP(+), 1
VNR(+) 1
osteoclastogensis 1
MC3T3-E1. 1
(CaMKK), 1
(TRAP)-positive 1
Raw264.7 1
tibiae, 1
Conclusively, 1
significances 1
(SEOC). 1
preamplification. 1
miR-103, 1
miR-92a 1
-638 1
(RNU48) 1
normalizers. 1
30-79 1
RNU48. 1
(ROC-AUC 1
(miR-200b 1
SEOC. 1
EOC). 1
EOCs, 1
(qRT-PCR)-validated 1
(miR-214, 1
miR-199a-5p, 1
miR-30a, 1
miR-30a*, 1
miR-30d, 1
non-relapsers. 1
(miR-200c, 1
miR-199a-5p) 1
non-relapsers, 1
miR-199a-5p. 1
0·094, 1
0·012-0·766, 1
p=0·0272) 1
(0·035, 1
0·004-0·311; 1
p=0·0026), 1
Nerina 1
Mario 1
Mattioli 1
Cariplo 1
(Grant 1
2010-0744), 1
unmatched, 1
C(t) 1
MiRNAs-21, 1
29a 1
MiRNAs-155, 1
99b 1
miRs-21, 1
CA-125. 1
fatiguable 1
Diplopia 1
Exacerbating 1
weather, 1
enquired 1
neurophysiology 1
'safety 1
CENTRAL) 1
definition.Types 1
inhibitor.Types 1
measuresPrimary 1
measureImprovement 1
treatment.Secondary 1
measures(1) 1
treatment.(2) 1
treatment.(3) 1
Gravis 1
treatment.(4) 1
author. 1
Gravis: 1
Modulation. 1
comorbidities; 1
nonthymomatous 1
osteolytic, 1
kappa-B 1
denosumab's 1
FREEDOM, 1
DECIDE 1
STAND 1
immature, 1
(RANK), 1
(WHO)/FRAX 1
alpha-emitting 1
(Atrasentan 1
Zibotentan) 1
Dasatinib. 1
first-on 1
subsequent-on 1
600,000 1
(50-69) 1
fracture) 1
radius; 1
75-90% 1
anemia; 1
[Metastatic 1
horizon]. 1
tumorigenesis-associated 1
2010-2011, 1
mHRPC, 1
(immunotherapy), 1
(chemotherapy). 1
mHRPC. 1
Quality(AHRQ) 1
(osteopenia) 1
(AHRQ) 1
men.The 1
bisphosponates; 1
cutoffs, 1
(DXA), 1
therapy.The 1
(alendronate, 1
denosumab). 1
high-strength 1
low-moderate 1
High-strength 1
recaps 1
cancer-death 1
(ADT), 1
docetaxel/prednisone 1
Health-economic 1
radium 1
700, 1
custirsen. 1
realities 1
65%-75% 1
$1.9 1
Skeletal-related 1
(SREs), 1
(NCT00321620) 1
Excel-based 1
payer, 1
SREs. 1
13-week 1
director 1
$35,341 1
($19,230 1
$16,111 1
$27,528 1
($10,960 1
$16,569 1
$7,813 1
$71,027 1
$51,319 1
1-way 1
$70,000, 1
$50,000, 1
$30,000 1
49.5%, 1
79.0%, 1
49.8%, 1
Fc-fusion 1
Fab) 1
cabazi-taxel 1
(cytotoxic 1
TAK-700 1
zibotentan 1
(endothelin-A 1
evolve, 1
Administrated 1
rechallenge, 1
[Austrian 1
Addendum 1
non-vertebral,and 1
hip-fracture 1
non-controversial, 1
ADT, 1
≤-1.5 1
toremifene. 1
changed? 1
calculators 1
Organization) 1
(FDA)--approved 1
(raxibacumab, 1
belimumab 1
DVL2 1
(p.Arg153Cys; 1
p.Glu544Arg; 1
p.Arg568Trp; 1
p.Val644Phe) 1
p=0.36). 1
Specimen 1
3.12 1
(39.71 1
4.53 1
6.79 1
vs) 1
(15.01 1
20.13 1
3.63) 1
hemichordates, 1
knockdowns, 1
Dvl1 1
Dvl2 1
Dvl3 1
sclerotome. 1
(Dvl-1). 1
3q27. 1
dsh-like 1
conjectural 1
velopmental 1
dishevelled. 1
large-1 1
(dlg), 1
postcoitum 1
Wnt-1 1
En. 1
engrailed-2 1
(En-2). 1
DVL-1, 1
glycogen-synthase-kinase 1
unreactive 1
(Wg) 1
Wg 1
(Yanagawa 1
PC12/Wnt 1
Wnt/wg 1
(SQ-PCR) 1
Psoriasiform 1
tumour: 1
1980).METHOD: 1
Bazex, 1
onychodystrophy 1
109; 1
remainder, 1
resolved) 1
signaled 1
(Bazex&apos; 1
[Principles 1
arrhythmias]. 1
(classes 1
Class-I 1
resting. 1
(24). 1
empirical. 1
(modulated 1
fast-recovery 1
Slow-recovery 1
effects.(ABSTRACT 1
Itch, 1
dermomyotome 1
Notch4 1
Delta1, 1
hepatoblastomas: 1
Hepatoblastoma 1
(hepatoblasts). 1
Cytogenetically, 1
1q. 1
hepatoblast 1
hepatoblasts. 1
anti-Notch 1
Anti-Notch 1
Fvs 1
(NRR) 1
(Hes5) 1
bidirectional. 1
RBPJ 1
HES1. 1
GSH/GSSG 1
(Sod1 1
dismutases 1
.O2-to 1
H2O2) 1
(Gpx1 1
Cip1. 1
tribute 1
P<0.00001). 1
FUNDING: 1
abiraterone: 1
"hormone 1
castration-resistance 1
immunoradiation 1
TCMC-Trastuzumab 1
212Pb. 1
3.9±0.99 1
PC-3MM2 1
60-80%, 1
pyruvic 1
Bioengineered 1
Enabling 1
payload 1
gene(s). 1
intra-cellar 1
antibodies/nucleotide 1
oncolysis 1
/Herceptin 1
Lentiviruses 1
(Herceptin, 1
antibody-binding 1
(GCV) 1
GCV 1
intratumorally 1
luciferase, 1
23.25% 1
11.75-38.63) 1
65.11% 1
49.07-78.99) 1
Potentiation 1
(HID) 1
PAC120 1
HID 1
HID28 1
tumour-bearing 1
(two-fold) 1
phospho-ERK, 1
signalisation 1
(ACBCC) 1
(c-erbB-2) 1
prostatectomy). 1
steam 1
ACBCC, 1
HER-kinase-directed 1
HER4, 1
HER-family 1
(trastuzumab). 1
Gefitinib-trastuzumab 1
androgen-refractory 1
gefitinib-trastuzumab 1
Bax:Bcl2 1
gefitinib-RT 1
(5830 1
DU-145. 1
('Iressa; 1
ZD1839) 1
HER-2-targeted 1
('Herceptin'), 1
(RX) 1
Chou 1
Talalay 1
ZD1839-trastuzumab 1
apoptotic-related 1
(synergism) 1
RX. 1
rastuzumab 1
ErbB-2, 1
Iressa), 1
alpha-conjugate. 1
alpha-particle 1
[213Bi]Herceptin 1
213Bi-Herceptin-induced 1
preangiogenic 1
micro-metastases 1
ytotoxicity 1
prostate? 1
review)]. 1
14-60%). 1
DOI 1
10.1002/cncr.10339 1
anti-ERBB2 1
(CISH) 1
copies) 1
ERBB2. 1
(LightCycler) 1
estramustine, 1
thrombembolic 1
Docetaxel/estramustine/trastuzumab 1
AIPC. 1
(AIPC) 1
docetaxel's 1
bcl-xL 1
Taxane-induced 1
G(2)M 1
estramustine. 1
docetaxel-induced 1
[IMC-C225]) 1
OSI-774, 1
PD182905, 1
PKI-166, 1
CI-1033, 1
ZD1839. 1
mn 1
(herceptin). 1
PaCa-2 1
ER-2/neu 1
experiment; 1
(ng 1
PSA/ml 1
serum/mm3 1
(CWR22, 1
1.0-fold, 1
2.35-fold 1
0.6-fold, 1
(6.25 1
s.c., 1
times/week) 1
costimulate 1
(DHT), 1
(CDK2) 1
p27Kip1. 1
antiandrogen 1
hydroxyflutamide 1
superfamily-mediated 1
'Yamanaka 1
leukemia-AF9 1
(MLL-AF9) 1
leukemia-initiating 1
(GBM-SC) 1
GBM-SC 1
WP1066 1
53-226 1
VEGF) 1
CD133) 1
GB-SCC010 1
026, 1
temozolomide-resistant 1
GBM-SC-specific 1
c-Myc). 1
Trp53, 1
Hras1 1
CD9-expressing 1
Euploid 1
seminomas, 1
Non-human 1
factors"). 1
SNL 1
Embryoid 1
factors") 1
rays, 1
c-MYC). 1
ET-3. 1
SILV, 1
Melanosomes 1
foreskin-derived 1
c-MYC) 1
obviated. 1
(ADCs) 1
(mEF) 1
(mEFs 1
68.70 1
2.62%, 1
70.61 1
68.72 1
(13.50 1
0.06%) 1
(118.20 1
38.28 1
0.77%) 1
mEF 1
(3.17 1
0.005%). 1
38-fold 1
amanaka 1
unregistered 1
chromosome-independent 1
lines) 1
11,278 1
8,305 1
28,205 1
3,033 1
proteins", 1
12,852 1
PXD000089. 1
domain/motif 1
(KEGG) 1
Proteotypic 1
(C-HPP). 1
(UniProt), 1
13985) 1
www.proteinatlas.org 1
HPP, 1
C-HPP). 1
promises. 1
(IAB) 1
visions 1
trusted 1
C-HPP) 1
(HPP), 1
20,300 1
HPP: 1
cross-analyses 1
HPP. 1
funders 1
(MSY) 1
chromosome's 1
leadership 1
Disease-Driven 1
biofluid-based 1
(www.hupo.org/research). 1
(HGP), 1
(C-HPP), 1
top-ranked, 1
neXtProt: 1
~20400 1
pillars: 1
antibody/affinity 1
(Ab), 1
bioinformatics-driven 1
(KB). 1
www.c-hpp.org 1
www.nextprot.org 1
UniProtKB/Swiss-Prot 1
www.uniprot.org 1
morphology-based 1
identities. 1
3844 1
inferred. 1
Protein/Antibody 1
Standard, 1
S/MRM, 1
Biobanking. 1
ProteoRed-ISCIII, 1
CCD18 1
B/D 1
biobanking 1
Chr-16 1
speciation: 1
peptide-targeted 1
6159 1
quadrupole, 1
ESI-Qtrap, 1
set-ups. 1
chip, 1
IT-infrastructure 1
LIMS 1
cross-site 1
Biobanks. 1
(GPMdb) 1
3615 1
13-origin 1
(zfPanx1) 1
(N2a) 1
N2a 1
hemichannels 1
Gja1) 1
interlinkages 1
(up-and 1
balanced) 1
(set 1
synergistically, 1
antagonistically, 1
neutrophil/macrophage 1
adenosine, 1
Panx1, 1
self-regulated, 1
permeant 1
P2X7R. 1
([K(+)]o) 1
P2X7R, 1
self-regulated 1
low-conductance, 1
permeabilities 1
(K(+)), 1
high-conductance 1
pS 1
ATP-permeable 1
pS) 1
drPanx1 1
drPanx1b, 1
urochordata 1
chordata 1
ohnologs 1
Panx1s 1
Pannexin 1
(Panx1). 1
Panx1(-/-) 1
Innervated 1
denervation-induced 1
(adPEO). 1
arPEO, 1
ANS. 1
(adPEO) 1
menopause-before 1
Cosegregation 1
γ), 1
γ. 1
(polγ), 1
exon-flanking 1
(p.T851A, 1
p.N468D, 1
p.Y831C, 1
p.G517V 1
p.P163S 1
#1: 1
p.P163S; 1
#2: 1
p.N468D). 1
(PEO) 1
(MNGIE) 1
PEO 1
(N846S 1
P587L). 1
(T251I). 1
Ivabradine: 1
(CSAP) 1
Angina 1
α-adrenoreceptors, 1
inotrope. 1
sino 1
β-blockers. 1
(MARISA 1
CARISA) 1
(ERICA 1
If), 1
atrio-ventricular 1
ivabradine: 1
rate-lowering 1
f-channel 1
(HR)-lowering 1
functional/molecular 1
I(f), 1
(IVA; 1
(LA), 1
post-mycardial 1
IVA) 1
patch-clamp; 1
(miRNA-1 1
miR-133) 1
IVA. 1
[Efficacy 1
clinicohemodynamic 1
(SCCF). 1
males--81.6%, 1
ivabradin, 1
creatinin 1
b/m. 1
b/m 1
0.068). 1
significant--9 1
(morBidity-mortality 1
EvAlUaTion 1
ventricULar 1
ivabradine. 1
=35%. 1
[Ivabradine 1
ofischemic 1
cardiovascular-event 1
beta-Blockers 1
(HRR). 1
Metoprolol, 1
incompetence. 1
mildly, 1
Ivabradine, 1
MI-induced 1
admix 1
ligation). 1
d(-1)), 1
dP/dt(max/min). 1
ATP7B. 1
polymerase-chain-reaction-based 1
D-penicillamine, 1
trientine 1
tetrathiomolybdate 1
advocated, 1
ATOX1 1
[Wilson's 1
(ATP7B). 1
H1069Q. 1
neurologic. 1
writing), 1
dysartria, 1
dysfagia 1
(neurologic 1
rings). 1
(D-penicillamine, 1
trientine) 1
ammonium-tetrahiomolybdene). 1
siblings) 1
curable; 1
de-copper 1
ICT) 1
child-year 1
125.9 1
110.2 1
Cu/L 1
breast-fed. 1
(19/22 1
(17/22 1
(11/22 1
choreo-athetosis; 1
commonest. 1
Hypodensities 1
[Variations 1
45th 1
varices. 1
truncate, 1
(Weinberg 1
0.243, 1
childhood? 1
caeruloplasmin). 1
degeneration). 1
both; 1
pseudobulbar 1
[Dermatoglyphics 1
40%; 1
33.16%, 1
28.82%, 1
Aue-Hauser, 1
1970) 1
triradius 1
interdigitum 1
upporting 1
∼0.55 1
5'-exon 1
Contrasted 1
single-intron 1
multi-intron 1
position: 1
"nascent 1
time" 1
Elongation. 1
intron-specific. 1
RpII215(C4) 1
(ChIP-CHIP). 1
chromatin-RNA 1
weakness-face, 1
Work-ups 1
1267G 1
acetyl-cholin 1
epsylon 1
(sister 1
brother) 1
C283Q 1
(LGMD). 1
facioscapular-humeral 1
(D4S139). 1
(F2) 1
kb/18.5 1
CMS, 1
LGMD 1
q35, 1
(EMG, 1
biopsy). 1
P13E-11 1
[kilo 1
bases]), 1
"Middle 1
sized" 1
16-29 1
"Small" 1
weakest. 1
97.8 1
4.7. 1
extensor, 1
winging. 1
"borderline" 1
triadin-to-calsequestrin 1
Heart-specific 1
(TG(CSQ)) 1
TRN. 1
(TG(CxT)) 1
TG(CSQ), 1
TRN-to-CSQ 1
calsequestrin-null 1
CASQ2-defective 1
8-day-old 1
(10mM 1
junctin/triadin 1
4-chloro-m-cresol, 1
10mM 1
UTP, 1
(RyR1 1
Ser(2809) 1
shortening- 1
Delta[Ca](i)-frequency 1
(0.5-4 1
staircase 1
shortening-frequency 1
[Ca](i). 1
(n=6-8). 1
69%), 1
57%) 1
(48.1 1
(389 1
beats/min, 1
Three-week-old 1
35%), 1
6-wk-old 1
4860-4917), 1
4581-4640) 1
200-232) 1
contractility; 1
rate-dependent, 1
tau(1), 1
(1:2:0.8) 1
PC-d(3) 1
Cho-d(3). 1
115% 1
yolks, 1
USDA 1
C(18) 1
monocharged). 1
"supercharging" 1
biomatrices 1
retentive 1
interferences. 1
ion-pairing 1
(AcCho), 1
(Bet), 1
(GPC), 1
(LPC), 1
lysophosphatidylethanolamine 1
(LPE), 1
(PCho) 1
(SM). 1
0.25-25 1
0.5-50 1
0.05-5 1
0.5-25 1
LPE, 1
0.02-5 1
Cho, 1
0.08-8 1
Bet, 1
Accuracies 1
83-105% 1
1.6-13.2% 1
yolk. 1
(RPLC). 1
pharmaceuticals, 1
HILIC, 1
dithiocarbamates 1
food/feed 1
end-product 1
>0.999 1
PC1, 1
Pro-TRH 1
pro-TRH/TRH 1
Hormones 1
(H9C2) 1
M), 1
HTB-11 1
5-HT. 1
23.2 1
force) 1
3.2%) 1
8.1%). 1
CNS-mediated 1
shock--cardiovascular 1
phenoxybenzamine. 1
M/L) 1
beta-receptors, 1
alpha-receptors. 1
phenanthrene 1
rod-coccus 1
creosote 1
Epirus, 1
survivalists. 1
sludge 1
(2-methylquinoline) 1
4,736,495 1
62.32%, 1
231,551-bp 1
pARUE232, 1
112,992-bp 1
arsenate 1
Pb2+, 1
anthranilate. 1
anthranilate 1
CoA-thioester 1
4-hydroxy-substituted 1
protocatechuate. 1
homoprotocatechuate. 1
osmoprotection, 1
aurescens 1
quinaldine, 1
high-arsenic 1
basin, 1
64.67%. 1
4,663,437 1
bp; 1
contigs. 1
3956 1
tRNA/rRNA-encoding 1
atrazine-degrading 1
Pesticide 1
(China). 1
pollutant 1
Echinaceapurpurea 1
Endophyte, 1
Able 1
Inhibit 1
Human-Opportunistic 1
Pathogens. 1
purpurea 1
Miceli 1
plantEchinacea 1
purpureaand 1
Nylon 1
Oligomer-Degrading 1
Bacterium 1
KI72 1
4,568,574 1
63.47%, 1
4,372 1
(CDSs), 1
Takehara 1
bacterium,Arthrobactersp. 1
R3.8, 1
cold-shock 1
plant-growth-influencing 1
cold-active 1
alpinusR3.8 1
acetyltranferases, 1
bromodomains' 1
bromodomain/acetyl-lysine 1
histone-directed 1
BD2, 1
C-terminal) 1
piD. 1
BD2-H4-AcK12 1
BD2. 1
Surrounding 1
collar 1
(Brg1) 1
H4-AcK8 1
H3-AcK14. 1
TAFII250 1
nucleosome-bound. 1
TAFII250, 1
Nepsilon-acetyllysine 1
diacetylated 1
N(epsilon)-acetylated 1
N(omega)-acetylhistamine 1
N-methylacetamide, 1
(HAT)-associated 1
110-amino-acid 1
(p300/CBP-associated 1
denervation: 1
nonresistant 1
II-aldosterone 1
adventitia 1
[RSD]), 1
Denervation 1
(Symplicity 1
HTN-3) 1
better-quality 1
"resistant 1
innervations 1
morbidities, 1
Spironolactone 1
Catheter-based 1
office-based 1
genotropic 1
(BMMs). 1
BMMs. 1
(E2-BSA), 1
182780, 1
203580, 1
(AP-1). 1
[Immune 1
BV2 1
(qRT-PCR); 1
ERK-, 1
p38-dependent 1
pro-caspase-3, 1
pro-caspase-9, 1
(p-STAT3). 1
(RECK), 1
(ERK)) 1
RY10-4. 1
Jellyfish 1
J774.1 1
phagocytotic 1
κBα 1
(IκBα), 1
guaianolide, 1
Sinodielsia 1
yunnanensis. 1
diaphoretic 1
Umbelliferae 1
(Apiaceae) 1
androgen‑independent 1
(ERK)1/2, 1
(40-44˚C) 1
42˚C) 1
slight; 1
thermosensivity. 1
44˚C) 1
(20.0 1
37˚C 1
(44˚C) 1
(10.53±5.02%) 1
(p-JNK) 1
(p-Akt) 1
44˚C. 1
MAPK/ERK1/2 1
bacteria-caused 1
non-treated, 1
ERK1/2; 1
phosphorylation-JNK 1
deficits--implications 1
proteasomal, 1
MG-115 1
inhibition-induced 1
SK-MEL-28, 1
(si)RNAs. 1
SK-MEL-3, 1
SK-MEL-28 1
WM164. 1
JNK1-specific 1
WM164 1
SK-MEL-3. 1
JNK2. 1
(TRM) 1
heart:body 1
(LVSP), 1
(+dp/dtmax 1
-dp/dtmax). 1
P-ERK1/2 1
P-JNK 1
P-p38 1
mitochondria-initiated 1
Docosahexaenoic 1
macrophages/microglia 1
lipopolysaccharide/interferon-γ-stimulated 1
JNK/AP-1 1
Nrf2/HO-1 1
91/93/95 1
trophic/potassium 1
election 1
c-Jun/activator 1
c-Jun/AP-1 1
TK-deprivation 1
c-Jun-expressing 1
switch-like 1
CGCs. 1
T91/93 1
lithium-mediate 1
TK-deprivation, 1
interferon-beta. 1
secreted), 1
CC-chemokine 1
(IL-1), 1
IFNbeta. 1
IFNbeta, 1
IFNgamma. 1
kinases), 1
(ISRE) 1
CAATT-enhancer 1
protein-beta 1
ISRE 1
Stat2 1
JNK2beta2. 1
autophosphorylate 1
autoactivation, 1
JNK1alpha2, 1
JNK2alpha2, 1
9-amino 1
sunlight, 1
proto-oncoproteins, 1
JNK/MAPKs, 1
MEKK1→MKK4→JNK 1
(MEKK1) 1
MAP2K 1
MKK7), 1
(MEKK-C) 1
MKK4/7 1
S/Y, 1
T/Y 1
inadequacies 1
JNK1β1, 1
precautionary 1
GSH-agarose 1
thioredoxin-His(6)-tagged 1
Ni(2+)-IMAC, 1
MKK4, 1
JNK1β1. 1
Ser-73 1
CLIPPER: 1
daunting.Therefore, 1
CLIPPER, 1
Pipeline(TPP). 1
CLIPPER 1
N-terminomics. 1
one-tube 1
reagents' 1
leukolysin, 1
(MMP25): 1
(MT6-MMP)/MMP-25/leukolysin 1
(PICS), 1
P6' 1
IGFBP-7, 1
"moonlighting" 1
MT6-MMP-cleaved 1
"eat-me" 1
3,152 1
1,054 1
C1r 1
dickkopf-related 1
thrombospondin-2. 1
gelatinases 1
AKT1. 1
p85α 1
p110γ 1
(p)-AKT, 1
p-p70S6K; 1
Notch-1; 1
p85αPI3K, 1
p-ERK1/2; 1
Histo-scores 1
(H-scores). 1
H-score 1
portended 1
fuelling 1
(serum/plasma) 1
repetitively, 1
noninvasive; 1
phlebotomist; 1
retigabine, 1
nonexistent. 1
Chung 1
SNL), 1
CCI) 1
(stiripentol, 1
(rufinamide, 1
neurodisease 1
(DPYSL2 1
CRMP2) 1
polymorphisms; 1
(GSK3β) 1
(CDK5), 1
collects 1
structure-regulating 1
SRA1/WAVE1 1
(specifically 1
Rac1-associated 1
protein-1/WASP 1
neuropathologies. 1
proofs-of-concept 1
identificating 1
(LOX), 1
(LOX-PP), 1
ERK/MAPK 1
LOX-PP, 1
EFST, 1
approachable 1
(RHA). 1
E-twenty-six 1
(ETS) 1
EWS-ETS-directed 1
signature-based 1
EWS-FLI1-targeted 1
resistance-inducing 1
EWS-FLI1-mediated 1
base-preferences 1
small-round-blue-cell 1
(ESFTs), 1
ETS-family 1
EWS-FLI1-driven 1
EWS-FLI1, 1
Y5Rs. 1
(DPPs), 1
NPY(3-36), 1
Y1Rs. 1
NPY-induced 1
(AIF). 1
Y5R 1
NPY-driven 1
DPPIV 1
DPP8 1
DPP9. 1
DPP, 1
TNFalpha-induced 1
NFkappaB-dependent 1
NFkappaB-driven 1
p65, 1
[Ewing's 1
FLI-1, 1
be: 1
ERG, 1
ETV1, 1
E1AF 1
FEV 1
(ESFT). 1
(YK-4-279), 1
EWS-FLI1/NR0B1 1
(TC32 1
TC71) 1
para-position 1
9u 1
GI50 1
(EWS-FLI1 1
cell.(15) 1
STEC-HUS 1
abnormalities]. 1
Shiga-toxin 1
(STEC)-HUS. 1
(CFH), 1
(CFI), 1
(THBD), 1
(CFB). 1
(DGKE) 1
plasminogen, 1
STEC-HUS, 1
triggers). 1
(MAHA). 1
MAHA 1
gammopathy. 1
VRD 1
dexamethasone) 1
non-diarrhea 1
overactivation. 1
thrombomodulin, 1
(THBD) 1
cell-expression 1
THBD 1
(CFH) 1
C3a 1
day-old 1
Tyr1177Cys 1
Eculizumab 1
aHUS, 1
self-tissue. 1
O157, 1
(MCP). 1
target) 1
self-tissue 1
(wrong 1
target). 1
self-tissues 1
(CD46) 1
80%). 1
live-related 1
stx2, 1
ehxA, 1
eae 1
favorably, 1
non-O157 1
Colombiana 1
Psiquiatría. 1
diarrhea-negative 1
enterohemorrhagic 1
ESCHERICHIA 1
COLI. 1
(Stx)2 1
Stx2 1
microangiopathies, 1
(aHUS). 1
(CD46), 1
infusion/exchange, 1
recipient: 1
Relapses 1
antilymphocyte 1
YY(3-36) 1
(PYY(3-36)) 1
GCG 1
HUGO 1
(mean+/-s.d., 1
23.4+/-4.3 1
22.5+/-1.0 1
(VO(2 1
max)): 1
45.9+/-8.5 1
(resting 1
session) 1
PYY(3-36), 1
(7-36) 1
(9-36) 1
PYY(3-36) 1
(high: 1
moderate: 1
PYY(3-36 1
fatness, 1
(OW/OB). 1
obese), 1
calorie-restricted 1
(10-40%), 1
min/day 1
z-score, 1
(triceps, 1
subscapular, 1
calf), 1
circumferences 1
waist, 1
thigh) 1
OW/OB. 1
non-conscious 1
gut-brain 1
(alpha-MSH), 1
(HomeCageScan 1
(HCS)). 1
(one-month) 1
intriguingly 1
transiently) 1
HCS 1
bed-rest 1
each): 1
60-d 1
aerobic/resistive 1
(TEE), 1
bed-rest-induced 1
MJ/d; 1
MJ/d, 1
bed-resting 1
nonexercise 1
(weight-bearing) 1
(non-weight-bearing). 1
mL/kg/min) 1
(rested 1
Ratings 1
PYY. 1
Appetite, 1
(10.2) 1
min(-1)] 1
(CON), 1
(END), 1
(SIE)] 1
68.1 1
1.75-2.75 1
END. 1
30-s 1
Wingate 1
2.25-2.75 1
bag. 1
0.052). 1
0.082). 1
YY. 1
postprandially. 1
moderate-fat, 1
moderate-carbohydrate 1
appetite). 1
endurance-trained 1
fat) 1
isoenergetic 1
moderate-fat 1
90-minute 1
pre-loaded 1
10-km 1
(fasting), 1
(non-fasting) 1
(GH). 1
VO(2max) 1
(REI) 1
(GLP-1). 1
REI 1
Somatostatin, 1
(SRIF-LI; 1
(279.0 1
107.7, 1
(121.1 1
(107.7 1
6); 1
(115.5 1
45.9, 1
km23-1/DYNLRB1 1
(Yue, 1
30765-30773). 1
(TβR)-interacting 1
(Jin, 1
Q., 1
19122-19132). 1
Sucrose 1
TβRII 1
Immunoprecipitation/blot 1
TGFβ-inducible 1
Smad2-independent 1
Ras/ERK/JNK 1
TβR 1
km23/DYNLRB/LC7/robl 1
DLCs, 1
km23-2, 1
(DYNLRB2) 1
(TbetaRII) 1
TGFbeta/Smad3-specific 1
Smad-binding 1
(SBE)2-Luc 1
(ARE)-Lux 1
Smad3- 1
Smad2-specific 1
(IP)/blot 1
km23-1. 1
DLC 1
Smad-specific 1
(TbetaR)-interacting 1
(dynein 1
chain). 1
TbetaRs. 1
immunoprecipitation/blot 1
activated) 1
TGFbeta/Smad2-dependent 1
ARE-Lux 1
RNA-resistant 1
TGFbeta/Smad3-dependent 1
SBE2-Luc 1
TGFbeta-dependent, 1
km23. 1
BacterioMatch 1
(hRFC) 1
(DYNLRB1) 1
HuTu-80 1
42%). 1
mucinous, 1
endometrioid/clear 1
undifferentiated) 1
intraarterially 1
(death). 1
(233 1
Retrievable 1
2.30). 1
21.2) 1
(32.6% 1
19.1%). 1
(IAT) 1
IAT, 1
sonolysis, 1
(stent-retriever). 1
NTR1804 1
2009)/ISRCTN10888758 1
[Intra-arterial 1
stroke--still 1
IMS-III, 1
retrievers 1
adolescents/young 1
vulvodynia, 1
anxiety), 1
1-7] 1
1-5], 1
cholecystectomy 1
endometriosisassociatedpelvic 1
unfortunate 1
generator, 1
“pain 1
head,” 1
disparagingly 1
“supratentorial” 1
byclinicians. 1
“dirty 1
dozen” 1
pain:1. 1
salpingitis 1
Adnexal 1
(nonendometriotic)9. 1
Endosalpingiosis 1
Hernias: 1
ventral, 1
inguinal, 1
femoral, 1
spigelian.I 1
operatively. 1
Sigmoid 1
psychologically. 1
(84.5%). 1
7.6%. 1
(82.8%), 1
71.3% 1
TRPv1 1
cross-sensitization 1
organs--the 1
colon--express 1
(P2X3) 1
capsaicin-sensitive 1
(TRPV1) 1
micro-injected 1
cryo-protected, 1
20-microm 1
uterus-specific, 1
viscerally 1
DRGs 1
TRPV1 1
viscerovisceral 1
cross-sensitization, 1
(pERK) 1
SP-positive 1
uterus- 1
SP-immunoreactive 1
Toledo 1
Disorders), 1
(FM), 1
(CFS), 1
9.6%, 1
dysmenorrhea, 1
1.0-4.7), 1
1.9-56.5), 1
1.1-11.5) 1
[Ileal 1
endometriosis]. 1
[Women 1
others?]. 1
somatoceptive 1
particularities, 1
practise, 1
fertile-age 1
Transplantation, 1
Policlinico 1
"Paolo 1
Giaccone", 1
Palermo. 1
gynaecologist 1
EUS-FNA 1
AOR=1. 1
varies. 1
Kruskall-Wallis 1
fifty-one 1
CD/tape/video; 1
satisfaction; 1
helpfulness. 1
67.2 1
(South)) 1
35.0 1
(South)). 1
57.9, 1
60.6, 1
(70.9, 1
70.4, 1
54.5), 1
(64.8, 1
70.2, 1
35.0), 1
(71.9, 1
73.9, 1
50.4). 1
(hs-cTnT) 1
training-matched 1
(24.0 1
constant-load 1
211.0 1
(11.2-794.5) 1
ng/l] 1
(9.7-305.6) 1
ng/l]. 1
hs-cTnT, 1
NT-pro-BNP. 1
finishers 1
[EF], 1
pressure/end-systolic 1
[SBP/ESV] 1
[E] 1
E:A) 1
tracking. 1
(NT-pro-BNP). 1
(25.5 1
(66.8 1
61.2 1
E:A 1
circumferentially. 1
postrace. 1
(BNP, 1
racing. 1
real,- 1
35+/-6 1
3:22 1
5:21 1
[cTnI] 1
ml(-1). 1
[cTnl] 1
0.098 1
p=0.028; 1
0.032 1
[cTnI]. 1
post-marathon 1
39+/-8 1
Triathlon 1
[cardiac 1
(pro-BNP)] 1
CTnT 1
(9+/-2, 1
E/A 1
(2+/-1, 1
athlete, 1
1-76), 1
active). 1
34-64 1
Visé-Maastricht-Visé 1
cortisol. 1
(BNP); 1
(96%). 1
troponin-T 1
(cTnI, 1
cTnT) 1
(males/females 1
88:153 1
25th/75th 1
115/770 1
ng/L), 1
36/254 1
37/196 1
74%; 1
cTnT, 1
Otztal 1
Radmarathon 1
1,128 1
803%. 1
CTnT, 1
0.043 1
0.224 1
cTnT. 1
(cTnT), 1
.VO2peak 1
mL.kg-1.min-1; 1
34,000 1
km.yr-1) 1
5-d 1
race: 1
(third-generation 1
TnT), 1
(CK), 1
(CKMB), 1
(Myo), 1
CKMB 1
CK, 1
CKMB, 1
75.3 1
pg.mL-1 1
(static 1
athletes), 1
(dynamic 1
athletes) 1
ultramarathons 1
Menopausal 1
1987-2011 1
3,500), 1
689), 1
1,197), 1
439), 1
273) 1
1.10-1.32, 1
(0.93-1.40, 1
(1.11-1.51, 1
(1.06-1.75, 1
(0.99-1.85, 1
(p(heterogeneity) 1
(p<0.005 1
estradiol- 1
woman-years). 1
Million 1
1,147,894 1
1,266 1
neuromas. 1
0.93-1.24) 1
1.42, 1
1.21-1.67 1
0.82-1.16) 1
HRT. 1
spouses 1
crude, 1
1.0-6.1]. 1
0.2-0.6). 1
0.4-0.9). 1
(pregnancy 1
mifepristone 1
55-84 1
2000-2009. 1
risk-set 1
(oestrogens 1
(<1, 1
<5, 1
<10, 1
4350 1
0.8-1.1) 1
(≥10 1
0.7-1.7) 1
0.9-2.6) 1
(0.4-1.6) 1
oestrogen-progestagen, 1
(0.9-5.5) 1
progestagen. 1
face-to-face. 1
scalability. 1
56.16 1
12.83), 1
(447/645, 1
69.3%), 1
(505/641, 1
78.8%). 1
(249/645, 1
38.6%), 1
(218/645, 1
(174/654, 1
27.0%). 1
self-management, 1
5.30, 1
unpleasantness 1
5.43, 1
2.69 1
4.24, 1
2.81, 1
2.79 1
(36.8% 1
(28.9%, 1
16.5% 1
(P=.006). 1
intervention's 1
collaborators: 1
opioid-treated, 1
ambivalence 1
opioids; 1
Feedback 1
dialogue-based 1
́s 1
dialogue 1
(health 1
literacy, 1
style). 1
tailoring, 1
web-page 1
on-page 1
competencies. 1
DRKS00003322. 1
therapist-written 1
smartphone, 1
(P>.10). 1
(M=-2.36, 1
8.41) 1
(M=.40, 1
7.20), 1
P=.045. 1
d=.33) 1
d=.73) 1
(P=.05) 1
http://www.webcitation.org/6FF7KUXo0). 1
Weaver: 1
counsel, 1
("pathognomonic" 1
postulation 1
heterogeneity? 1
propositi, 1
latter); 1
testable; 1
LAPLACE-2: 1
(ASCVD) 1
muscle-related) 1
Statin-intolerant 1
LDL-C-lowering 1
Goal 1
Statin-Intolerant 1
(GAUSS-2) 1
ezetimibe-controlled, 1
installment 1
"Antibodies 1
watch" 1
IX-Fc 1
VIII-Fc; 1
gevokizumab). 1
(obinutuzumab, 1
lambrolizumab, 1
bimagrumab, 1
daratumumab) 1
1104 1
(evolocumab+SOC, 1
n=736) 1
(n=368). 1
52.3% 1
1.8%] 1
0.8%] 1
1.0%] 1
P=0.31). 1
OSLER, 1
81.4% 1
73.1% 1
http://clinicaltrials.gov. 1
NCT01439880. 1
hypercholesterolaemia: 1
statin-refractory 1
ball-upcoming 1
sequestrants 1
evacetrapib 1
anacetrapib 1
Microsomal 1
CIII 1
Hypercholesterolemia 1
Lp-PLA2 1
cerebro-vascular 1
in-roads 1
adventure: 1
hypocholesterolemia. 1
dyslipidemias: 1
evidence]. 1
loweing 1
Guideline-recommended 1
Hypolipidaemic 1
yesterday 1
tomorrow 1
soon; 1
(ACC)/American 1
International, 1
European) 1
(HoFH). 1
(microsomal 1
HoFH. 1
post-dosing 1
LAPLACE-2 1
2067) 1
[10 1
[80 1
lipid-stabilization 1
1899) 1
Percent 1
73%) 1
84%) 1
83%) 1
(monthly) 1
evolocumab-, 1
ezetimibe-, 1
<2%). 1
NCT01763866. 1
901 1
57.0±2.1% 1
55.7±4.2% 1
61.6±2.6% 1
56.8±5.3% 1
48.5±5.2% 1
lipoprotein(a), 1
DESCARTES 1
NCT01516879.). 1
(±ezetimibe) 1
(QM), 1
QM. 1
UC). 1
-68.6 1
-63.9 1
(3.2) 1
Ultraconservation 1
2827 1
(SUPR) 1
1268 1
SUPR-containing 1
SUPRs. 1
EST, 1
non-SUPR-containing 1
non-SUPR-associated 1
(SUE) 1
core-promoter 1
Olfactores 1
hydrolase. 1
arabinose-inducible 1
P(BAD) 1
Dcm-mediated 1
arabinose 1
2.1.1.37) 1
Proposals 1
5-methyldeoxycytidine 1
Dihydrocytosine 1
thymidine. 1
BspRI 1
DNA-methyltransferase. 1
S-adenosyl-L-homocysteine, 1
M.BspRI, 1
[methyl-3H]AdoMet, 1
Cys181 1
S-methylcysteine. 1
m5C-MTases. 1
Caught 1
act: 1
Rotation 1
('base 1
flipping') 1
north-constrained 1
pseudosugar, 1
M.HhaI-DNA-AdoHcy 1
23/27. 1
EFT; 1
Very-high-dose 1
4,200 1
g/m2/d 1
mg/m2/d, 1
500/microL 1
100,000/uL. 1
relapse; 1
36+ 1
transplantation), 1
(autopsy 1
pPNET). 1
dose-intensive 1
[Peripheral 1
bones]. 1
c-mil/raf-1 1
c-fes 1
c-sis 1
c-ets-1, 1
clinicopathologic, 1
cytoreductive, 1
(SRCTs) 1
Cytogenetics 1
pseudodiploid 1
der(4)t(2;4)(q24;q35). 1
92-100% 1
intersects 1
pathways-RAS/RAF/MEK/ERK, 1
Notch-as 1
ATR-CHK1 1
ATR-NBS1-FANCD2 1
(FANCs) 1
RAD50/MRE11/NBS1 1
(RMN) 1
ICLs-induced 1
FANCs/NBS1 1
FANCD2/ATR 1
(Fac) 1
(fac) 1
(-/-), 1
(+/-), 1
(+/+). 1
MMC, 1
CFU-E, 1
(ICL). 1
CCG)n 1
(TREDs). 1
FXS. 1
TREDs, 1
Pif1's 1
3'-tailed 1
reel 1
refold, 1
unfolded. 1
Pif1-induced 1
G4-stabilizing 1
repair.DOI: 1
http://dx.doi.org/10.7554/eLife.02190.001. 1
loops: 1
lassoing 1
CpGi. 1
nonreplicative, 1
mtRNA 1
mtRNAs 1
single-stranded. 1
5&apos;UTR 1
(CSR) 1
AID. 1
S(mu), 1
S(mu)-mediated 1
non-R-loop 1
(R304Q), 1
(TPR)-containing 1
(TPR 1
neoplasia: 1
(MEN2-RET) 1
(MEN1), 1
MEN1/2 1
(TKR). 1
autodimerization 1
(GFL) 1
mutations--in 1
domains--influences 1
1:1000 1
somatotropinomas, 1
Gigantism 1
somatotropinoma 1
mutation-bearing 1
Hyperplasia-adenoma 1
Non-identical 1
neurosurgery; 1
Post-surgically, 1
E216X 1
AIP-variant 1
A299V, 1
gigantism 1
apoplexy, 1
A299V 1
microprolactinoma; 1
endocrinologists, 1
I*. 1
TnI, 1
cNTnC 1
opening/closing 1
cNTnC. 1
(SL)-dependent 1
SL-dependent 1
cTnC-cTnI-Tm 1
S22D/S23D 1
pseudophosphorylation. 1
weakened. 1
(RCM). 1
(TnC), 1
increase/decrease 1
RCM. 1
(S37G, 1
V44Q, 1
L48Q) 1
RCM-like 1
force). 1
(E40A 1
I61Q) 1
[Ca(2+)]). 1
(c)TnCs 1
34-71) 1
128-180). 1
(Landstrom, 1
Parvatiyar, 1
Pinto, 1
Marquardt, 1
Bos, 1
Tester, 1
Ommen, 1
Potter, 1
Ackerman, 1
Cardiol. 1
281-288). 1
Actomyosin 1
co-sedimentation. 1
2-(4'-(2''-iodoacetamido)phenyl)aminonaphthalene-6-sulfonic 1
metal-bound 1
D145E, 1
myofilament; 1
cTn, 1
(tropomyosin, 1
(cTnC), 1
(HcTnC) 1
(~0.4%) 1
HcTnC 1
C84Y 1
(A8V 1
D145E). 1
sarcomeric-HCM 1
(E134D 1
RMIT 1
point-prevalence 1
EAP. 1
Intention-to-treat 1
Freiburg. 1
cessation--a 1
(NADA 1
protocol), 1
acupoint 1
plasters 1
log, 1
(CAR), 1
Expectancy 1
Borkovec 1
Nau 1
NCT01389622 1
(registered 1
Jul 1
[Acupuncture 1
Russia]. 1
Jieyan 1
radius), 1
Shenmen 1
Sanyingjiao 1
acupoints: 1
Kou 1
(mouth), 1
Fei 1
(lung), 1
Shenmen, 1
Shenshangxian 1
gland), 1
Wei 1
(stomach), 1
Xin 1
(heart), 1
Neifenmi 1
(endocrine), 1
Qiguan 1
(trachea), 1
(liver). 1
re-taking 1
internet-assisted 1
acupressure, 1
IBM 1
Websphere 1
HTML, 1
Javascript, 1
JSP. 1
quasiexperimental 1
cotinine, 1
15.78% 1
2.56% 1
schools. 1
anti-smoking 1
[Smoking 1
acupuncture]. 1
Aarau 1
(Switzerland) 1
returned). 1
41.1%. 1
profited 1
tediousness 1
nervousness. 1
household. 1
Freiburg 1
experience]. 1
needles 1
self-retained 1
0.055, 1
-0.033 1
0.323). 1
Sarcoma-associated 1
(PEL). 1
ChIP), 1
latency-specific 1
H3K9/K14-ac 1
H3K4-me3 1
Rta. 1
Re-SET-ting 1
centromeres) 1
mysteries 1
chromatin/heterochromatin 1
H4-K20me3 1
histone(s), 1
fully-grown, 1
Rik1 1
DDB1-like 1
CLRC 1
DCAFs 1
WDxR 1
CLRC. 1
Cul4-Rik1 1
DCAF, 1
Suv39h-HP1-independent 1
(CPP). 1
Macromolecules 1
poly-lysine, 1
Anti-HSP90 1
(M1B 1
M1C) 1
IFNγ/IL-10 1
GV1001/temozolomide 1
(CTCL). 1
telomerase-specific 1
CTCL, 1
GV-peptide 1
GV1001-specifc 1
hTERT-specific 1
CTCL. 1
IFN-gamma/IL-10 1
T(H)1/T(H)2 1
immunomonitoring 1
pointless 1
obstacle, 1
(IκBs) 1
IκB-β-TrCP 1
NF-κB-associated 1
SCF(β 1
-TrCP) 1
presecretory 1
(psCLU) 1
DeltaCLU, 1
phospho-IkappaB-alpha 1
DeltaCLU. 1
DeltaCLU 1
BRAF-dependent 1
43-9006) 1
ubiquitination: 1
NF-[kappa]B 1
factor-kappaB) 1
phosphorylationbased 1
Met/PI3K 1
EGFR-TKI-resistant 1
Met/Gab1 1
HGF-transfected 1
Ma-1 1
(Ma-1/HGF) 1
Ma-1/HGF 1
HGF-Met 1
VEGF-VEGF 1
0.4791, 1
HGF(-)/c-Met(+) 1
(Ser(473)) 1
Cyr61-dependent 1
MET/EGFR 1
PI-3K/ 1
ANF, 1
MLC2v 1
sequela. 1
(H1N1/09) 1
0.31%-0.66%) 1
6094 1
0.21% 1
0.11%-0.36%). 1
summarised 1
(0.32 1
0.13-0.52 1
0.076 1
0.07-0.09). 1
CDC; 1
1-9 1
defervescence 1
33-40 1
vaginally 1
H1N1-affected 1
[Vaccination 1
(H1N1). 1
MonoGrippol 1
ofthe 1
(alanine 1
urea) 1
(IL-1alpha, 1
IL-1RA, 1
IFNgamma, 1
TNFalpha) 1
(HCG), 1
trophoblasitc 1
beta-1-glycoprotein 1
26.1%--general 1
(HCG, 1
TBG) 1
2010-2011 1
A(H1N1)v2009: 1
2009-09-28 1
2010-03-31 1
1329 1
0.36-2.19) 1
trimesters: 1
0.38-1.77; 1
preconception 1
0.13-2.64) 1
(Pandemrix) 1
identifier. 1
54,585 1
pregnancies; 1
7062 1
(1678 1
stillbirths). 1
1.16), 1
1.73) 1
(0.44, 1
(0.82, 1
1.53) 1
(0.77, 1
55,570 1
23,340 1
(42.0%) 1
[RR]=0.90; 1
[CI]=0.85, 1
RR=0.81; 1
CI=0.72, 1
percentiles; 1
RR=0.73; 1
CI=0.58, 1
RR=0.66; 1
CI=0.47, 1
arly 1
Notification 1
(SINAN), 1
1,861 1
0.197). 1
0.41-1.21). 1
trimesters 1
regnant 1
October. 1
Stillbirth, 1
'protective' 1
learn. 1
regnancy, 1
NKX2.1: 1
mo-18 1
'brain-lung-thyroid 1
series: 1
beginnings: 1
temporally, 1
components-adaptor 1
lipids-come 1
1,8-naphthalimides 1
∼17 1
ChemBioNet 1
1,8-napthalimides 1
∼80-120 1
3-sulfo-N-(4-aminobenzyl)-1,8-naphthalimide, 1
4-aminobenzyl 1
(26, 1
(24, 1
3-Sulfo-N-benzyl-1,8-naphthalimide, 1
domain-amphiphysin 1
clathrin/actin-based 1
blood-testis 1
trafficking: 1
(AP1) 1
μ-adaptin 1
AP1M, 1
CCVs 1
ICP-MS 1
placentas, 1
myxoma, 1
overactivity. 1
(RIα). 1
CNC, 1
(PGE1)-stimulated 1
AKAR3. 1
AKAR3 1
PGE1-induced 1
Epac1-camps. 1
gemcitabine), 1
PRKARIA 1
two--how 1
tens. 1
algorithm-optimized 1
poising 1
unviable. 1
ChromaGenSVM. 1
gamma-treated 1
∼21,000 1
∼90%, 1
comfortably 1
length-maintenance 1
∼60 1
(nonequilibrium 1
theme, 1
TIC. 1
n3'-->p5' 1
thio-phoshoramidates 1
thio-phosphoramidates, 1
3'-amino-3'-deoxy 1
2'-substituents 1
duplexes' 1
DeltaT(m), 1
2.2-4.0 1
nucleoside. 1
2'-OH- 1
(RNA-like), 1
2'-O-Me-, 1
2'-ribo-F-nucleoside 1
2'-deoxy- 1
2'-fluoro-phosphoramidate 1
T(m), 1
T(m) 1
isosequential 1
2'-Deoxy-N3'-->P5' 1
C3'-endo 1
sugar-ring 1
2'-deoxy 1
H-mediated 1
thio-phosphoramidates 1
Phase-I/II 1
etelstat 1
(TICs), 1
alpha(2)beta(1) 1
CD133), 1
holoclone 1
(DU145, 1
LNCaP). 1
GRN510, 1
mTERT 1
(SAEC) 1
SAEC, 1
2-cytokine-mediated 1
(IgE), 1
(IL)-5, 1
endotypes. 1
bronchodilators 1
aeroallergen 1
(deltaN377 1
runx2 1
(BGS) 1
218600). 1
phocomelia, 1
BGS, 1
(RTS), 1
noticeable. 1
R1021W 1
g.2886delT 1
poikiloderma, 1
(IVS17-2A>C). 1
calvaria. 1
MSX2. 1
acro-cranial-facial 1
(ADS). 1
ADS 1
genealogy. 1
FGFR2-mutation]. 1
dimerise, 1
FGFR-genes 1
Q289P 1
S267P 1
-62 1
IIIa. 1
mismatch. 1
(COLIA1), 1
anti-N- 1
N-cell 1
(N-CAM) 1
E-cadherins 1
preosteoblasts 1
beta-catenins 1
anti-N-cadherin 1
Cgamma 1
(PLCgamma) 1
(PKCalpha) 1
PKCalpha-specific 1
Gö6976 1
1-year-1-month-old 1
[Muenke 1
60:555-564]. 1
Jackson-Weiss, 1
Saethre-Chotzen, 1
Adelaide-type 1
brachydactyly-craniosynostosis 1
[Adès 1
51:121-130; 1
Gernet 1
63:177-184; 1
Reardon 1
34:632-636; 1
Bellus 1
14:174-176; 1
Hollaway 1
(1995): 1
4:681-683; 1
Glass 1
3:215-223]. 1
[1979: 1
15(5B): 1
13-63] 1
Roberts-SC 1
[Huson 1
al.,1990: 1
27:371-375]. 1
rediagnosed 1
Offspring 1
(Pro250Arg) 1
Brachydactyly 1
5qter. 1
PIWIL1, 1
PIWIL2, 1
PIWIL4, 1
TDRD1 1
non-seminoma 1
(PALOMA-1/TRIO-18): 1
anti-oestrogens. 1
sequentially: 1
(CCND1), 1
(INK4A 1
CDKN2A), 1
accrual; 1
NCT00721409. 1
27.9-36.0] 1
[25.5-31.1] 1
5.7-12.6) 1
(13.8-27.5) 1
0.488, 1
0.319-0.748; 1
p=0.0004). 1
(n=66), 1
(2.6-10.5) 1
(11.2-not 1
0.299, 1
0.156-0.572; 1
p<0.0001); 1
(n=99), 1
(7.1-16.4) 1
(13.1-27.5) 1
0.303-0.853; 1
p=0.0046). 1
[2%]). 1
neutropenia-related 1
Concurrence 1
thyroiditis), 1
coincidentally 1
coexisted, 1
siblings: 1
pseudo-Pendred 1
"pseudo-Pendred 1
(pseudo-PDS), 1
pseudo-PDS 1
(Slc26a4+/+) 1
(Slc26a4-/-). 1
double-barreled 1
microelectrodes. 1
vascularis, 1
Endolymph 1
Stria 1
hyperpigmented, 1
unalleviated 1
intact; 1
Endolymphatic 1
Na+/2Cl-/K+ 1
SLC12A2 1
GJB2. 1
interscalar 1
(Mondini 1
deformity) 1
(7q22.3-7q31.1) 1
80%), 1
Aqueduct 1
(EVA). 1
R409H/IVS2+1delG 1
L236P/K590X 1
GJB2, 1
GJB6 1
(mit-DNA). 1
IVS2+1delG 1
K590X 1
SLC26A4) 1
(c2168A 1
ins2110GCTGG), 1
(FT3, 1
Thyroglobulin) 1
(H723R/919-2A>G, 1
H723R/IVS15+5G>A, 1
H723R/R581S, 1
IVS7-2A>G/IVS8+1G>A), 1
(322delC). 1
sodium/glucose 1
UTI, 1
(CFU). 1
(UGC) 1
UGC 1
UGC. 1
Reabsorption 1
nonglycaemic 1
approved; 1
BP-lowering, 1
teratoma: 1
teratoma. 1
(undifferentiated) 1
teratoma, 1
large-volume 1
(SRBCT), 1
(FCI) 1
Leu-19 1
FI 1
ES/PNET, 1
SRBCT. 1
nanopolymers. 1
PAMAM 1
misassigned 1
amidated 1
peak; 1
19.34 1
mDa. 1
Tip 1
nanoLC 1
(Q-Exactive) 1
5400 1
ProteoIQ 1
±5 1
Discovery-based 1
lofty 1
UPLC 1
Q-Exactive 1
SCX 1
SpinTip 1
cartridge 1
ether-methanol 1
OCT; 1
two-steps 1
'pipette-tip' 1
microcolumns. 1
LysC-peptides 1
system-wide-fashion 1
RapiGest- 1
SDS-based 1
(MW) 1
RapiGest 1
(>1100 1
workflow), 1
MW, 1
Multi-peptide 1
nLC-PC-IDMS-SRM-based 1
ovomacroglobulin/ovostatin 1
(OVOS2) 1
vitellogenin-1 1
(Vit-1), 1
lipid-transport 1
(PC-IDMS) 1
un-depleted 1
Vit-1 1
(GeLC) 1
preparation-assisted 1
(FASP)-Assisted 1
(ILFAPT). 1
LCM-captured 1
CD90(-) 1
(FASP)- 1
pseudoshotgun 1
"pseudoshotgun" 1
ontology) 1
(passage 1
5000/injection), 1
(250-500/injection). 1
cells/injection 1
lysis/cleanup 1
MS-deleterious 1
(trichloroacetic 1
(CMW) 1
(FASP)) 1
protein-limited 1
K-12, 1
SDS-FASP 1
tepidum: 1
(Cba.) 1
oxidizes 1
sulfur, 1
gel-free, 1
2245 1
630-640 1
c-555 1
thiosulfate-oxidizing 1
sulfide. 1
tepidum, 1
DsrM 1
sulfite, 1
(DsrABCL) 1
(Sat-AprAB-QmoABC). 1
electron-transferring 1
Zymogen 1
(ZG) 1
ZGs 1
progressors 1
endurance-related 1
(Pain, 1
Disability, 1
Pain-responses 1
distress-endurance 1
(DER), 1
eustress-endurance 1
(EER), 1
(FAR) 1
pain-regulation 1
CSP 1
accelerometer-based 1
(PAL, 1
CSP) 1
overuse/overload 1
Advice 1
(RMDQ), 1
(Y/N), 1
0.57) 1
0.38) 1
ACTRN12609000282280. 1
operationalized 1
solicitous 1
Measure-Pain 1
(POAM-P) 1
avoiders, 1
behaviour) 1
behaviour). 1
Avoiders, 1
performers. 1
Avoiders 1
uptime. 1
avoiders 1
persisters. 1
Baecke 1
overestimators, 1
-0.27), 1
overestimators 1
SUBJECTS: 1
Pain? 1
Pain-related 1
RDQ 1
11.8), 1
(beta=0.39, 1
(beta=-0.19, 1
(beta=0.12, 1
(LBP), 1
overprediction 1
overpredictors, 1
(beta=-0.48, 1
(beta=0.50, 1
overpredictors 1
overpredict 1
painfulness. 1
(DRAM) 1
Distressed 1
(-1.47h, 1
-2.70 1
-0.23h, 1
1.01h 1
0.46h 1
(beta=-0.49, 1
spend 1
non-distressed 1
advising 1
(RMDQ). 1
ACTRN12609000282280]. 1
0.0125). 1
posture, 1
deconditioning 1
(in-doors 1
out-doors) 1
interpolated 1
splines. 1
relationships.A 1
Self-Organizing 1
(SOM) 1
SOM 1
variables? 1
accelerometer). 1
adaptive, 1
(Von 1
Korff 1
(CPG), 1
(KPI), 1
Funktionsfragebogen 1
Hannover-Rücken 1
FFbH-R) 1
(CP)). 1
(N=9), 1
(N=1) 1
(N=14). 1
copers 1
copers. 1
coper 1
underuse. 1
pocket-sized 1
offsets. 1
disuse 1
(unrestricted 1
devices). 1
(ADMR), 1
(RMR), 1
hood. 1
ADMR 1
RMR 1
.72 1
JASPAR: 1
cgb.ki.se. 1
versioning 1
matrices: 1
database-the 1
sub-database-has 1
sub-databases 1
language-independent 1
three-month-old 1
spiky 1
orthokeratotic 1
parakeratotic 1
XY. 1
heterogeneicity 1
MBTPS2. 1
(PPK). 1
hairlessness, 1
hyperkeratoses, 1
atrophoderma 1
noncicatrical 1
Sweat 1
starch-reaction 1
Blaschko, 1
boy's 1
Xp22.11-p22.13. 1
MBTPS2, 1
intelligence; 1
acitretin 1
(IFAP). 1
fingers.The 1
chill-like 1
proneness 1
non-obligatory 1
P2Y12) 1
(NCT00638326). 1
(VASP-PRI) 1
(HTPR) 1
(ADP 1
>46%; 1
VASP-PRI>50%). 1
GOF 1
HTPR. 1
heterozygotes), 1
non-LOF 1
(NCT00638326) 1
(CSCs), 1
reform 1
(GDSCs) 1
(BTE) 1
chemotherapy) 1
pharmacoresistance 1
BTE, 1
(polytherapy) 1
(OS).METHODS 1
MATERIALS: 1
OS.RESULTS: 1
'incinerators' 1
Ceria 1
Cerium 1
(nanoceria) 1
catalysts. 1
(N-acetylglucosamine, 1
polyvinylpyrrolidone) 1
(sequencing 1
immunoprecipitate) 1
glycosaminoglycans, 1
exo- 1
membrane-enclosed 1
endocytic, 1
PPARβ 1
gemfibrozil-mediated 1
PPAR-binding 1
Tfeb 1
drug-mediated 1
C32 1
Rab7, 1
CD63. 1
phospho-LRP6, 1
phospho-β-catenin, 1
signalosome/destruction 1
capsule-based 1
ellipsoid-shaped, 1
ovococcus 1
mid-cell, 1
pneumococcus. 1
threats. 1
Microtiter 1
drug-sensing 1
microtiter 1
Mascher, 1
Zimmer, 1
T.-A. 1
Helmann, 1
Antibiotic-inducible 1
stress-sensing 1
LiaRS 1
subtilis; 1
Chemother., 1
2888-2896) 1
gallinarum, 1
agar-plate 1
enterococci: 1
D-ala-D-Ala 1
non-glycopeptide 1
UDP-MurNAc-pentadepsipeptide 1
Racemase 1
Growth. 1
(alrA), 1
drier 1
more-raised 1
microg/ml, 1
30-fold-lower 1
(RT; 1
(TMZ). 1
Core-30 1
(QLQ-C30, 1
(QLQ-BN20). 1
QLQ, 1
insomnia) 1
(P=.01 1
8/14 1
5/16 1
mg/ml-min) 1
CYP3A-enzyme-inducing 1
[EIAEDs] 1
EIAEDs) 1
non-compliance, 1
90-100, 1
30.4, 1
61.0%) 1
months]. 1
NCT00953121). 1
postchemoradiation 1
(5/28-day 1
mg/m²)/day 1
mg/m²/day, 1
7/14-day 1
factorial-based 1
(VEGFR2). 1
21-78 1
(AG). 1
chemotherapies), 1
(50.8%) 1
>55 1
.052). 1
Mayo/North 1
N0074. 1
stable/improved 1
(enrollment 1
amplification/mutation, 1
(CYP3A4) 1
QD. 1
(48.9%, 1
(30.3%). 1
vIII 1
post-radiation 1
gefitinib-associated 1
(rash/diarrhea) 1
(TMZ)/radiotherapy 1
[B1], 1
[B2], 1
[B3]) 1
(Response 1
Tumors). 1
(B1, 1
27.3%; 1
7.4%; 1
35.7%). 1
14.8%, 1
35.7%; 1
60.7%. 1
(GW786034), 1
06-02). 1
(VEGFR)-1, 1
(PFS6 1
24-47 1
NCT00459381. 1
alkylator-based 1
36-70 1
(PCV: 1
cyclophosphamide: 1
1-30) 1
alkylator-refractory 1
C30. 1
(Tarceva, 1
OSI-774) 1
>or=90 1
Atrasentan 1
atrasentan's 1
25-70) 1
oliogodendroglioma; 1
70- 1
90-mg/day 1
4.2-9.5 1
(TGF)-alpha 1
PE-38 1
(TP-38) 1
PE-38. 1
deoxyuridines 1
(BUdR) 1
BUdR, 1
(400-600 1
Gy/day 1
biopsy/surgery 1
implanted; 1
reaction" 1
197. 1
Cross-reacting 1
(CRM197) 1
(Gly52 1
Glu) 1
better-define 1
embriogenic 1
sub-divided 1
CRM197: 1
CRM197, 1
3.0-10.9) 1
5.8-not 1
angiokinase 1
PDGFR-α/β. 1
(STUPP), 1
bevacizumab-based 1
(BEV). 1
RANO) 1
17+ 1
Trichothiodystrophy: 1
Photosensitive, 1
TTD-P, 1
TTD, 1
"trichothiodystrophy" 1
alin 1
"neuroectodermal 1
ofcysteine-rich 1
"tiger 1
ofhair 1
nudeotide 1
trichothiodystrophy-photosensitive 1
(TTDP). 1
Non-photosensitivepatients 1
trichothiodystrophy-nonphotosensitive 1
(TTDN). 1
sun-sensitive 1
TTD. 1
.We 1
Duane's 1
Perthes 1
[Trichothiodystrophy: 1
acrodermatitis 1
enteropathica. 1
Comèl-Netherton 1
syndrome--long 1
diseases--has 1
("lumping"). 1
Minor's 1
(JAK)-signal 1
IL-1R-associated 1
(IRAKs) 1
TLR/IL-1R 1
(pDC) 1
TLR7/9-induced 1
TLR7/9 1
viability-supporting 1
MSCs) 1
Washed 1
30-90 1
7-amino-actinomycin 1
cytomery. 1
MSC-derived 1
recruit, 1
retain, 1
HOXD9-expressing 1
HOXD9-positive 1
(FLS). 1
long-run 1
1671) 1
5054). 1
self-discipline 1
10(-9)) 1
moderates 1
conscientiousness) 1
Six-hundred 1
Scale-Cognitive: 1
2.8). 1
1-4.2; 1
90th 1
proxies. 1
proxies' 1
accentuated, 1
proxies 1
Diachronic 1
convergent. 1
785 1
older: 1
[Correction 1
Notice: 1
erratum 1
26(2) 1
Psychology 1
2011-05802-001). 1
Discussion, 1
Caveats, 1
Directions 1
heading. 1
correction.] 1
NEO-FFI. 1
Openness, 1
Stroop, 1
Simon, 1
Ex-Gaussian 1
Vincentile) 1
distribution) 1
distribution). 1
.17, 1
.08, 1
(-.90), 1
(-.09) 1
(.24), 1
Conscientiousness. 1
informant-reports 1
overreporting 1
(middle-aged 1
DAT) 1
McCrae's 1
noncognitive 1
reflect? 1
Aging-Associated 1
(AACD) 1
AACD. 1
(NEO-PI), 1
NEO-PI 1
A� 1
[Immunosuppressive 1
interactions]. 1
nondepleting 1
(polyclonal 1
globulin, 1
calcineurin-inhibitors 1
(cyclosporine, 1
tacrolimus), 1
belatacept, 1
immuo-suppressive 1
skin). 1
seperately. 1
calcineurin- 1
mTOR-inhibitors 1
in- 1
malignancies.This 1
[Mammalian 1
rapamycin(mTOR)and 1
[Targeted 1
neoplasias]. 1
antiangiogenics 1
sorafinib. 1
HER1, 1
5-20% 1
recipients: 1
(inception, 1
(1996-2005) 1
values<1 1
(WMD), 1
sirolimus, 1
(CNI) 1
0.74-1.44), 1
-5.67) 1
(leukopenia: 1
2.02; 1
1.12-3.66; 1
6.97; 1
2.97-16.36; 1
1.67; 1
1.27-2.20). 1
antimetabolites 1
0.71-0.99; 1
0.37-0.65, 1
1.32-2.06). 1
3,175 1
1.06-1.43) 1
1.12-7.41), 1
lower-dose 1
0.52-0.88), 1
-6.76). 1
GFR), 1
(HAS 1
ANSM). 1
KARE 1
highLDLhighTG 1
(Obesity, 1
(PAK7, 1
C20orf103, 1
NRIP1, 1
TRPM3, 1
NAV1) 1
highLDLhighTG. 1
(PAK7:R335P), 1
(C20orf103) 1
(TRPM3). 1
PVG 1
inflammation/demyelination. 1
Eae23b, 1
Eae23b 1
splice-variant 1
Zfhep1. 1
(IL2) 1
Zfhep2, 1
expressed; 1
Zfhep2. 1
METHODOLOGY/PRINCIPAL 1
sarcoma/PNET. 1
PAX3/7-FKHR 1
EWS-WT1 1
DSRCT. 1
(dopa) 1
DSRCTs. 1
SBRCT 1
sarcoma/PNET 1
t(11.22)(q24.q12) 1
EWS-FLI1. 1
.034) 1
Rh1 1
SK-NEP-1, 1
Rh1, 1
hydroxydaunomycin 1
22q12. 1
sarcomas/PNETs, 1
chemosensitive, 1
age-range 1
1-65 1
41/58 1
(70.6 1
(48/52) 1
(92.3 1
(17/18) 1
(94.4 1
(88.8 1
(6/20) 1
S100-P 1
(28.5 1
(3/4) 1
(5/24) 1
(20.8 1
(3/24) 1
focally. 1
sarcomas/PNETs. 1
23/28 1
(82.1 1
20/28 1
cores; 1
LCA 1
m-RNA 1
t(11;12)(q24;12) 1
(ES/pPNET). 1
non-ES/pPNET 1
LMP1/LMP2 1
(EBVΔCTCF166) 1
LMP1, 1
LMP2A, 1
EBV-immortalized 1
(OriP) 1
haracterization 1
ground-state 1
70-kb 1
6q24, 1
HYMAI 1
∼1.4-Mb 1
PLAGL1/Plagl1. 1
PLAGL1/Plagl1 1
P3/P4 1
STAG1 1
(Scc3/SA1) 1
ohesin 1
(IL-3) 1
colony-stimulating-factor 1
(GM-CSF, 1
CSF2) 1
(DHSs) 1
CTCF/cohesin-binding 1
icotinamide 1
enome-wide 1
self-avoidance 1
self-assemble, 1
I152L, 1
(UbFC) 1
complementation: 1
single-step, 1
(Sis1-Sis1, 1
Net1-Sir2, 1
Cet1-Cet1 1
Pho2-Pho4), 1
Nos: 1
EF210802, 1
pFA6a-VN-His3MX6; 1
EF210803, 1
pFA6a-VC-His3MX6; 1
EF210804, 1
pFA6a-VN-TRP1; 1
EF210807, 1
pFA6a-VC-TRP1; 1
EF210808, 1
pFA6a-VN-kanMX6; 1
EF210809, 1
pFA6a-VC-kanMX6; 1
EF210810, 1
pFA6a-His3MX6-P(GAL1)-VN; 1
EF210805, 1
pFA6a-His3MX6-P(GAL1)-VC; 1
EF210806, 1
pFA6a-TRP1-P(GAL1)-VN; 1
EF210811, 1
pFA6a-TRP1-P(GAL1)-VC; 1
EF210812, 1
pFA6a-kanMX6-P(GAL1)-VN; 1
EF210813, 1
pFA6a-kanMX6-P(GAL1)-VC; 1
EF521883, 1
pFA6a-His3MX6-P(CET1)-VN; 1
EF521884, 1
pFA6a-His3MX6-P(CET1)-VC; 1
EF521885, 1
pFA6a-TRP1-P(CET1)-VN; 1
EF521886, 1
pFA6a-TRP1-P(CET1)-VC; 1
EF521887, 1
pFA6a-kanMX6-P(CET1)-VN; 1
EF521888, 1
pFA6a-kanMX6-P(CET1)-VC. 1
un-associated 1
outmost 1
melting, 1
weaknesses. 1
fulfillment 1
Fragmented 1
(Arginine442Glycine) 1
'Cell 1
Proliferation' 1
iPSC-CMs. 1
irregularities. 1
human-inherited 1
bar? 1
'activation 1
status' 1
Biventricular 1
(LVOT), 1
myectomy, 1
(biV) 1
(acutely 1
long-term) 1
biV/LV 1
Sarcomeric 1
(MYH7, 1
TNNI3) 1
(CREBBP) 1
(PDA), 1
XY) 1
[cAMP 1
Thr910Ala) 1
Thr910Ala 1
greenhouse. 1
fungal-plant-bacterial 1
Ascomycota, 1
Basidiomycota, 1
Physcomitrella 1
patens. 1
29-56 1
dual-domain 1
Ascomycota. 1
plant-pathogenic 1
(killer 1
toxins) 1
P6, 1
13.4kDa 1
P1M1, 1
P4M2, 1
P6M2. 1
bunts 1
bunt 1
(Ustilago 1
caries), 1
greenhouse 1
KP4-transgenic 1
bunts, 1
Field-testing 1
fluxes. 1
preprotoxins 1
thereof) 1
respects: 1
peptidase). 1
precipitant. 1
P6(1)(5)22 1
dicroism 1
KP6 1
KP4-susceptible 1
immunotherapeutic, 1
Eta-1 1
Aire(-/-) 1
Eta-1. 1
AIRE: 1
4-thiouridine-treated 1
miRNPs, 1
QKI, 1
IGF2BP1-3, 1
AGO/EIF2C1-4 1
TNRC6A-C. 1
box-like 1
cataloged. 1
box-derived 1
miRNA-like, 1
iPAR-CLIP 1
PAR-CLIP) 1
GLD-1, 1
iPAR-CLIP. 1
so-far-unknown 1
orthogonal, 1
(IGF2BP1-3, 1
PUM2) 1
(20-23 1
rosslinking 1
UneCLIPsing 1
ross-linking 1
AR-CliP--a 1
Radioiodine 1
(RIT) 1
glu 1
ocorticosteriods. 1
(x 1
66.2 1
(TMNG) 1
54-89 1
yr), 1
(thyrothropin 1
(antithyroglobulin 1
anti-TSH 1
TRAb), 1
scintiscan 1
38.7 1
1.4), 1
25,3 1
5,8) 1
0,2). 1
18,0 1
3,8 1
35,7 1
9,1%, 1
two-year-observation 1
735.93 1
196.1 1
AIH, 1
1350 1
PTU-only 1
4.2) 1
earlier-by 1
thionamide, 1
AIT: 1
interrupted; 1
crouch, 1
nonclassifiable, 1
Tertiary-level 1
.45 1
.49 1
intrarater, 1
.50 1
.68. 1
kappa=0.8). 1
videos. 1
(NAA)/creatine 1
NAA/choline 1
NAA/myo-inositol 1
(mI), 1
Cho/NAA, 1
Cho/Cr 1
Cho/mI 1
developmen 1
(3-DGA). 1
Walking 1
kappas 1
(intrarater) 1
(interrater). 1
3-DGA 1
validity(wk 1
0.38-0.94). 1
nstruct 1
lengthening: 1
stance. 1
mid-stance 1
movements; 1
abducted 1
rotated, 1
dorsiflexed. 1
plantar-flexed. 1
[Subjects 1
Methods] 1
joint's 1
age+/-standard 1
9.11+/-4.8 1
KinCom 1
flexors, 1
adductors) 1
flexors 1
extensors, 1
abductors 1
adductors). 1
stride 1
cadence) 1
motion) 1
(GMFM-66) 1
dimension). 1
(strength 1
GMFM-66, 1
r2=.69). 1
ambulated 1
vojta 1
Vicon 1
strike, 1
Sociodemographic 1
(3DGA) 1
mo], 1
mo-6 1
3DGA, 1
extension). 1
7-42 1
829 1
Enjoji 1
(3rd 1
edition). 1
(GMFCS) 1
mo-8 1
mo-30 1
(41.9%), 1
leukomalacia, 1
porencephaly/periventricular 1
GMFCS 1
Up&Go 1
[TUDS]test, 1
[LSU]test) 1
(anteroposterior, 1
mediolateral, 1
overall) 1
(pro-reflex 1
stance, 1
4288A>G, 1
N1430D) 1
Brachial 1
plexopathy 1
27%-43% 1
IVS27b-5C 1
neurofibromatosis. 1
"twenty-first" 1
"processive" 1
selenocysteine) 1
P-expression, 1
(Sepp1) 1
Sepp1. 1
ApoER2, 1
Megalin, 1
(redox) 1
Sepp1) 1
bottleneck. 1
"recoding" 1
recruit. 1
"bottleneck," 1
UGAs. 1
isoform]. 1
(SeCys) 1
40th 1
HSelP280m, 1
HSelP280m 1
HSelP. 1
CuCl2, 1
2,2'-azobis(2-amidinopropane) 1
(AAPH) 1
SeP, 1
peroxynitrite-induced 1
SeP. 1
SeP) 1
intrigue, 1
selenocysteines, 1
cysteine- 1
histidine-rich. 1
selenocysteine/stop 1
57-kDa 1
nickel-agarose 1
anti-histidine 1
express, 1
purify, 1
immunochemically 1
selenoprotein-P 1
polyA-binding 1
juxtanuclear 1
aggresomes. 1
(LacZ, 1
PABP1-positive 1
granules) 1
FUS-expressing 1
salubrinal, 1
2-α, 1
Inclusions 1
disease-pathology, 1
TDP-43-associated 1
A315T 1
protrusions, 1
APC-containing 1
(APC-RNPs). 1
APC-RNPs 1
Fus/TLS 1
liposarcoma). 1
APC-RNPs. 1
stress-like 1
sorbitol, 1
stressor. 1
RNA/DNA-binding 1
responses: 1
TDP-43; 1
key? 1
"independent 1
"precursor 1
"seed" 1
(MI); 1
(HSMPs), 1
reperfused-ST-segment-elevation 1
(RSTEMI) 1
HSMPs, 1
HSMPs 1
secreted-protein-acidic-and-rich-in-cysteine 1
(OPN), 1
endothelial-NOS 1
(nNOS). 1
Healing 1
(TLR)-dependent 1
Extravasation 1
neovessels. 1
regress, 1
remnent 1
myocytes) 1
(non-myocytes). 1
Decorin 1
Health: 1
Factors- 1
Article. 1
sub-factors) 1
exogenic 1
(behavioral, 1
socialcultural, 1
geographical, 1
aesthetics 1
sub-factors). 1
sub-factors 1
Wiley& 1
(1990-2014). 1
(genetic, 1
attractiveness). 1
hipocamp 1
norepinefrine 1
endorphin) 1
oxitocin 1
(pituitary 1
undeniable. 1
inally, 1
hypermotoric 1
88), 1
Mx. 1
1157 1
micro-satellite 1
MERLIN 1
(logarithm 1
2.73, 1
0.095) 1
D19S254 1
cM, 1
D1S534 1
happiness). 1
(SWB), 1
54,540) 1
6,620). 1
co-twin 1
(violation 1
EEA). 1
mating, 1
biometric 1
happy? 1
(SWB) 1
SWB. 1
13-28 1
5,024 1
2,157 1
non-shared 1
heritabilities 1
upbringing 1
(PD; 1
post-dose, 1
(GMR) 1
(90%CI) 1
hepatic/control 1
(80-125 1
Cmax) 1
(PE 1
[90%CI]: 1
AUC0-∞, 1
[135-250 1
%]; 1
[144-249 1
%]). 1
∼35 1
unbound/bound 1
9-1103 1
(opicapone), 1
91.2 1
Emax 1
AUEC 1
first-pass 1
purged 1
cell-biological 1
glycoproteome, 1
biostatistical 1
"sticky" 1
purification) 1
Man-6-P. 1
(MPR). 1
precipitated, 1
dialyzed, 1
1-DE, 1
lane: 1
[provided 1
ionization-mass 1
(MALDI-MS)] 1
(provided 1
LC-MS/MS). 1
MPR-binding 1
46-/- 1
300-/-) 1
Secretions 1
ependymin-related 1
(MERP-2), 1
retinoid-inducible 1
66.3-kDa 1
MPR-affinity 1
MPR-mediated 1
ecretions 1
glycoproteome: 1
Constituent 1
Man6-P. 1
Man6-P-containing 1
glycoproteomes. 1
(LSDs) 1
CLN5 1
sulfamidase, 1
lipofuscinosis. 1
(1-D) 1
(2-D) 1
desorption/ionization-mass 1
(MALDI-MS) 1
NH4Cl 1
(leukocystatin 1
E1A-stimulated 1
mannose-6-phosphate-containing 1
Acp5. 1
(Man6P) 1
(Acp2/Acp5(-/-)) 1
tyloxapol-purified 1
Acp5, 1
Npc2 1
Acp2/Acp5(-/-) 1
glycoproteome. 1
nanospray 1
6-phosphorylation 1
lectins). 1
membrane-delimited 1
contaminants, 1
phosphotransferase, 1
glycoproteome 1
EWS/FLI, 1
EWSR1-derived 1
in-frame, 1
coordinately. 1
EWS/FLI's 1
treasure. 1
ETS-mediated 1
archaeon, 1
Ambiguous 1
(MJ0774), 1
(694,540-695,226 1
genom 1
(MM1314) 1
(MM1315), 1
1,564,657 1
1,566,241 1
MCM(2-7) 1
islandicus 1
orc1-1 1
glossinidia, 1
6803 1
(representing 1
multi-origin 1
calidifontis. 1
acidocaldarius, 1
Cdc6/Orc1 1
Orb-1, 1
(dN 1
dS) 1
Ortholog 1
(O1, 1
O3). 1
slowest 1
O1 1
O3, 1
Replication-biased 1
(enriched 1
functions), 1
"baby 1
machine" 1
(oriC2), 1
(oriC1), 1
1,197 1
(oriC3) 1
2,226-kb 1
X-shaped 1
oriC3. 1
Cdc6/Orc1, 1
pHV2. 1
cdc6/orc1-associated 1
pHV3 1
(442 1
(690 1
Extrachromosomal 1
pernix, 1
Sulfolobus, 1
elements--origin 1
boxes--have 1
Cell-cycle-dependent 1
centromere-like 1
cell-cycle-specific 1
reveal, 1
pernix 1
maripaludis 1
Picrophilus 1
torridus 1
9790 1
aerophilum 1
IM2 1
archaea? 1
cylindromatosis: 1
(turban 1
123850, 1
132700, 1
313100, 1
605041) 1
16q12-13 1
turban-like 1
adenoides 1
cysticum 1
16q, 1
(TRK) 1
BCCs. 1
TRKC, 1
lestaurtinib, 1
ndividuals 1
(PLAG1) 1
Reverse‑transcription 1
spiradenoma 1
pathway-related 1
Dickkopf 1
(DKK2-a 1
(sporadically) 1
spiroadenomas. 1
trichoepithelioma, 1
inter-family 1
(familial) 1
trichoepitheliomas: 1
(BSS). 1
confluent, 1
pink, 1
eyebrows. 1
TE, 1
PTCH) 1
CYLD: 1
CYLD-mediated 1
WAVE 1
apoptosi 1
Reed/Sternberg 1
(HRS) 1
KM-H2. 1
KM-H2 1
NFKBIA 1
exemplifying 1
[23%]) 1
question), 1
(81%), 1
underreported 1
"CYLD 1
(MFT, 1
601606) 1
2,317 1
redu 1
SOD-1. 1
single-generation 1
SOD-1 1
Brown-Vialetto-Van 1
Laere 1
(SMN1). 1
(FL)-SMN 1
FL-SMN 1
M344 1
both: 1
FL-SMN2 1
(SMAs) 1
(SMA-PCH, 1
[PCH1]) 1
SMA-PCH. 1
VRK1, 1
(p.Tyr130Cys 1
p.Tyr130His) 1
discrepancy. 1
Tyr130Cys 1
Tyr130His) 1
(ACTH)-dependent 1
ACTH-independent 1
(CNC), 1
PPNAD, 1
adrenalectomy, 1
hypercortisolism. 1
BeWo. 1
choriocarcinoma. 1
presynaptically, 1
(βCaMKII) 1
(Syt-Ab 1
synaptic-activity 1
PhTx 1
messenger. 1
(LX-2) 1
(0-50 1
81.76% 1
(81.76% 1
2.58% 1
96.63% 1
2.69%, 1
27.15% 1
(27.15% 1
2.86% 1
96.59% 1
2.44%, 1
78.27% 1
11.48% 1
LX-2 1
sexta. 1
insects) 1
6-10), 1
(non-hypoxic 1
(IH). 1
PKC-gamma, 1
HIF-1-mediated 1
KN 1
IH-induced 1
HIF-1alpha, 1
HIF-1-regulated 1
(CPEB) 1
(threonine 1
CPEB-dependent 1
luciferase; 1
CaMKII-delta 1
PKC-delta, 1
(PDBu)-stimulated 1
PKC-alpha 1
Gö-6976, 1
(Ad.HA-Ras(N17)) 1
PDBu-induced 1
ionomycin- 1
AG-1478, 1
PP2 1
ATP-stimulated 1
CaMKII-delta(2) 1
oocyst. 1
oocyst, 1
sporozoites. 1
MAPTAM, 1
TMB-8 1
calmidazolium. 1
autocamtide-2, 1
ookinete-specific 1
Pgs28 1
Ca(2+)/Calmodulin-dependent 1
k252a 1
Z-D-DCB 1
caspase-3-like 1
pro-caspase-3 1
CaM-kinase. 1
ERK2. 1
calcium-ionophore-induced 1
CaM-kinase-dependent 1
J.CaM1.6 1
J.CaM1/Rep3, 1
ionomycin. 1
J.CaM1 1
calcium-induced, 1
PMA-induced, 1
[Tombes, 1
Westin, 1
Grant. 1
Krystal, 1
Differ. 1
1073-1070; 1
201-207]. 1
(autonomous) 1
barometer 1
CaMK-II, 1
cdk2 1
p42MAP 1
(cdk2) 1
p21cip1 1
cdk2/cyclin 1
KN-93's 1
cycle-controlling 1
(NE)-induced 1
(cPLA2) 1
PLA2 1
[3H]AA. 1
PD-098059, 1
cPLA2. 1
PD-098059 1
Okadaic 1
cholinergic-stimulated 1
carbachol, 1
acid-secreting 1
H+, 1
K(+)-ATPase 1
isoquinolinesulfonamide 1
KN-62, 1
(Tokumitsu, 1
Chijiwa, 1
Hagiwara, 1
Mizutani, 1
Terasawa, 1
Hidaka, 1
4315-4320). 1
methoxybenzenesulfonamide, 1
Ca2+/phospholipid 1
Ca(2+)-phosphodiesterase. 1
8-Br-cAMP 1
PMP22-Related 1
charcot-marie-tooth 1
(PMP22), 1
(HNPP), 1
(CMT1E). 1
MLPA-negative 1
CMT1A/HNPP 1
(dup/del) 1
copynumber 1
dup/del 1
(PXT3003) 1
dysmyelination, 1
PXT3003, 1
sorbitol). 1
CMT1A, 1
2b/3). 1
(ONLS) 1
ONLS, 1
(0.4% 1
16.2%) 1
23.2%) 1
quasi-stability 1
Placebo. 1
CMT1A-diagnosed 1
2010-023097-40. 1
NCT01401257. 1
(EMA/OD/193/13). 1
Pmp22-transgenic 1
Mek-Erk 1
axonally 1
CMTs 1
(28.9 1
GJB1. 1
L16P 1
G150D, 1
Hrd1/SYVN1 1
gp78/AMFR, 1
PMP22(G150D) 1
PMP22(L16P), 1
Rer1, 1
Golgi-localised 1
calnexin-dependent 1
Rer1-mediated 1
Hrd1-mediated 1
CMT-1A. 1
Campania, 1
(CMT1, 1
[HNPP]) 1
(75.1%) 1
GDAP1) 1
HNPP, 1
(INC) 1
(CMTES). 1
997 1
(60.4%) 1
CMT1A/PMP22 1
CMT1X/GJB1 1
CMT2A/MFN2 1
CMT1B/MPZ 1
palsy/PMP22 1
NCT01193075. 1
CMT1A/ 1
Triplication 1
female-specific 1
paternal-originated 1
parechovirus 1
(PeV) 1
(PeV1) 1
(PeV2) 1
Picornaviridae 1
PeV, 1
PeV3 1
time-polymerase 1
swab, 1
full-term. 1
(CB3) 1
plaque-forming 1
(PFU) 1
millilitre 1
overgrowing 1
PFU/ml 1
NPXY 1
CCM1and 1
neurovasculature, 1
Glance 1
poster, 1
CCM3/ 1
(CCM2) 1
3q26-27 1
22-cM 1
D3S1262. 1
D3S3668 1
D3S1763, 1
970-kb 1
"TFAR15," 1
premyeloid 1
hemorrhaging. 1
Beta-galactosidase 1
ICAP1 1
(Itgb1bp1). 1
(four-year-old) 1
SCCP, 1
1902A 1
Y634X. 1
1902insA. 1
(QMPSF). 1
99-nucleotide 1
(c.262+132_262+133del) 1
/PDCD10 1
hyperpermeability, 1
RNA-treated 1
Pdcd10 1
Ccm 1
trials.Genet 1
188-196. 1
CCM2/malcavernin 1
thirties 1
haeadache 1
angiomas. 1
familily. 1
mambers 1
(c.263-10A 1
CCM1. 1
c.263-10A 1
malformations]. 1
3q, 1
20-40, 1
talk, 1
26-40 1
8.5-25 1
(2.1-2.4 1
β1-type 1
α1-type 1
Failure." 1
(3,5-diiodothyroproprionic 1
(ICAM-1), 1
(52.1%±5.7% 1
37.3%±3.6%, 1
(32±4 1
14±1 1
(14±2 1
7±1 1
(2.37±0.4 1
1.1±0.2, 1
(33.32±12.4 1
21.24±8.9 1
(112.3±78 1
37.3±25.9 1
3,5-Diiodothyropropionic 1
0.937, 1
1.875, 1
3.75, 1
mg·kg(-1)·day(-1) 1
DITPA-pretreated 1
(3,5-Diiodothyropropionic 1
Acid), 1
(n=57 1
n=29 1
morbidity/mortality. 1
failure-specific 1
(-20%), 1
(-30%), 1
(-11 1
lb). 1
Thyroidectomized 1
THs, 1
(echocardiograms 1
hemodynamics), 1
hypothyroid-induced 1
(BVD) 1
3,5-diiothyroprionic 1
analog) 1
BVDs. 1
DITPA-containing 1
5.2-mg 1
T(4)-treated 1
BVD. 1
echos, 1
transmurally. 1
subcutaneous) 1
(4,633 1
3,650 1
Hg/s). 1
l-NAME 1
L-arginine. 1
(II)/microg) 1
II/microg). 1
52.7 1
49.1+/- 1
longevities. 1
bimanual 1
nontender, 1
cyst-like 1
S2-S3 1
abdomen/pelvis 1
Beware 1
radiculopathy. 1
Resected 1
nonradicular 1
claudication. 1
(LAF237) 1
DPP4.DATA 1
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione 1
1356), 1
xanthine-based 1
[proposed 1
ONDERO; 1
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] 1
10(-5)/s 1
10(-4)/s 1
vildagliptin). 1
>/=10,000-fold 1
DPP-8, 1
DPP-9, 1
amino-peptidases 1
prolyloligopeptidase, 1
HanWistar 1
(sitagliptin/saxagliptin) 1
vildagliptin. 1
<7%. 1
8634 1
<7%: 1
glitazones). 1
0.410, 1
unpublished, 1
A(1c) 1
[WMD] 1
-0.76%; 1
-0.83 1
-0.68); 1
82%). 1
55), 1
-0.65%; 1
-0.71 1
1.68) 1
Japanese-specific 1
-1.67%; 1
-1.89 1
-1.44) 1
3.88) 1
0.04%; 1
0.16) 1
1.61) 1
hyperglycemics. 1
antihyperglycaemics 1
antihyperglycaemic 1
weight-neutral 1
Glycaemic 1
Hypoglycaemic 1
incretin: 1
2-diabetes. 1
[glucagon-like 1
inhibitors] 1
(gliptins): 1
Sitagliptin, 1
[glyburide], 1
pioglitazone/rosiglitazone) 1
(statins, 1
(ciclosporin), 1
(warfarin, 1
digoxin). 1
CYP3A4/5. 1
(rifampicin) 1
CYP3A4/5 1
CYP3A4/A5. 1
noting, 1
(pioglitazone, 1
rosiglitazone), 1
multimorbid 1
polypharmacy. 1
Biased 1
U-CLL 1
U-CLL, 1
IGHV3 1
(55.7%), 1
IGHV1 1
(27.3%), 1
IGHV5 1
(2.3%), 1
IGHV2 1
(1.1%), 1
IGHV6 1
IGHD 1
IGHD3, 1
39.1%; 1
IGHD2, 1
21.8%; 1
IGHD6, 1
12.6%; 1
IGHD1, 1
IGHD4, 1
IGHD5, 1
6.9%; 1
IGHD7, 1
1.1%. 1
IGHJ 1
IGHJ4 1
(48.9%), 1
IGHJ6 1
(28.4%), 1
IGHJ3 1
(11.4%), 1
IGHJ5 1
(11.4%). 1
complementarity-determining 1
CDR3) 1
lymphotic 1
CD82 1
DUSP22 1
Amantadine, 1
'wakeful 1
unresponsiveness' 1
noradrenalin, 1
deplete, 1
neurodormancy 1
Consciousness. 1
initiator, 1
CoA. 1
arouse 1
phenomenal 1
(DOCs) 1
DOCs 1
anaesthesia-induced 1
depressants 1
Awakenings 1
drugs? 1
unarousability 1
intralaminar 1
nuclei). 1
DOC. 1
Vegetative 1
cross-checking 1
'evidence-based 1
treatments'; 1
inconclusiveness. 1
[Amantadine 1
clinical-experimental 1
multivector 1
(PK-MERZ) 1
coma: 1
objectivism 1
neurobehavioural, 1
(1986-2002) 1
azospirones 1
indecisive 1
stepping-stone 1
(N=124) 1
poststudy 1
1562 1
Phagocytosis 1
(hemozoin) 1
(MMP)-9, 1
primiparae 1
(FC) 1
1.033 1
1.869; 1
2.15; 1
1.131 1
4.070; 1
(55.5% 1
39.3%; 1
(ERGIC-53) 1
secretion-competent 1
LMAN1. 1
metalloproteinases-1. 1
zymogen, 1
proMMP-9, 1
(TIMP-1). 1
homomultimers 1
heterocomplexes, 1
homomultimers, 1
reduction-sensitive 1
TEM, 1
TIMP-1. 1
tricky 1
anti-target 1
pays 1
SAR, 1
matrilysins, 1
collagenases, 1
stromelysins, 1
gelatinases, 1
zymogene 1
proteolitic 1
(EMMPRIN). 1
polimorphonuclear 1
neutrophiles 1
(PMNs) 1
E-cadherins, 1
unpleasant) 1
hyperosmics: 1
(14-75 1
hyperosmics 1
Odor 1
annoying, 1
hypoosmia 1
Anosmia, 1
Dysosmia 1
Butterworth 1
Publishers, 1
Publishing. 1
sheer 1
lncRNome: 1
knowledgebase. 1
http://genome.igib.res.in/lncRNome. 1
miRNA-lincRNA 1
Breast-cancer-related 1
(A-H) 1
(capture) 1
(KD's) 1
capture-detector 1
(L.O.D.), 1
ng/g. 1
BoNTs. 1
heat-labile 1
6.14±1.06IU/mL, 1
2.85±1.35 1
singleplex 1
81%. 1
bioterror 1
biocrime 1
adk, 1
atpH, 1
gyrB, 1
proC, 1
rpoD 1
spo0A 1
botulinum/sporogenes 1
(STs). 1
(multilocus 1
trace-back 1
secretions, 1
Gilan, 1
Golestan, 1
Hamedan 1
Seafoods 1
locally- 1
to18). 1
D/C 1
16140, 1
outbreaks: 1
authorities' 1
permission, 1
1118 1
1136 1
(BoNT/CD), 1
(∼two-third) 1
(∼one-third) 1
BoNT/CD 1
(BoNT/CD-HCR) 1
BoNT/D, 1
synaptosome 1
(S867-E1280) 1
HCRs: 1
jellyroll 1
β-trefoil 1
BoNT/D-HCR 1
K1118 1
E1114, 1
BoNT/D-HCR, 1
G1132, 1
Lysine-1118 1
E1247 1
(K1240-N1248). 1
Lysine-1136 1
Liposome-binding 1
Formulating 1
intoxication: 1
3,4-Diaminopyridine 1
ng/kg. 1
(3,4-DAP), 1
dual-action 1
3,4-DAP. 1
stigmines 1
3,4-DAP, 1
butyrylcholinesterase--a 1
esterase. 1
vacuum-packed 1
weapons. 1
aggregation--misfolding 1
approach-retraction 1
misfold. 1
A30P 1
POLR3-Related 1
dystonia], 1
spasticity] 1
dysfunctions). 1
oligodontia, 1
teeth). 1
arrested, 1
known). 1
(neonatal 1
POLR3B, 1
POLR1C. 1
physiotherapist, 1
pathologist, 1
neuropsychologist, 1
endocrinologist, 1
ear-nose-and-throat 1
(described 1
known) 1
R1005H 1
A1331T 1
system–based 1
[Central 1
hypodontia: 1
leukodystrophy]. 1
dysmetria. 1
puberal 1
leukoencephalopathies, 1
(BMs) 1
ameloblasts 1
odontoblasts, 1
amelogenin, 1
odontogenesis 1
amelogenesis 1
(AI). 1
matrisome 1
matrixome 1
ECMs, 1
matrisome--an 1
ECM-modifying 1
ECM-binding 1
ECM-bound 1
multicellularity, 1
matrisome: 1
matrisome. 1
maximum-parsimony, 1
allopolyploid 1
polyploidization. 1
(tobacco) 1
sylvestris 1
tomentosiformis 1
CAPS), 1
Homoeologous 1
(leaf, 1
flower) 1
repeat-rich 1
plants?]. 1
5'-end) 1
AtHD2s 1
(DNMT2) 1
(AtHD2s), 1
AtDNMT2: 1
ss-glucuronidase 1
athd2c 1
Jacq.) 1
somaclonal 1
Jacq.), 1
embryo-derived 1
feminization 1
EgMET1, 1
EgCMT1, 1
EgDRM1, 1
1543, 1
925, 1
nodular-compact 1
Nodular-compact 1
inflorescences 1
EgDRM1 1
methylation-deficiency 1
4720 1
(Skp2-Cks1) 1
m1 1
(Foxm1) 1
(CDKI) 1
Cdc25B, 1
CENPB. 1
Cks1, 1
Skp1-Cullin 1
1-F-box 1
p19(ARF), 1
(alphoid) 1
re-formed 1
YAC-based 1
(Cenpag/g) 1
(Cenpc, 1
Zw10). 1
nucleosomal/chromatin 1
(PARP-2) 1
disassociating 1
microtubule-inhibiting 1
Bub3. 1
PARP-1-binding 1
(Cenpa) 1
(Cenpa 1
postconception. 1
macronuclei 1
hypercondensation. 1
134-amino-acid 1
TFIID-binding 1
C+G-rich 1
CENPA/Cse4 1
chromatin-containing 1
dubliniensis, 1
ENPA/Cse4 1
Anti-CENPI 1
Anticentromere 1
CENPB, 1
CENPH 1
CENPE, 1
CENPF 1
INCENP. 1
Nt-CENPI 1
(UCTD) 1
Epitopes 1
CENPI, 1
deaf-blindness, 1
Kallmann 1
(olfactory 1
erratic 1
Bmp4 1
LTR-retrotransposons. 1
LTRs, 1
(errantiviruses) 1
bendability, 1
A-philicity, 1
(copia 1
CHD7-related 1
(micrognathia, 1
epicanthic 1
bridge), 1
t(4;8)(q34;q22.1). 1
t(4;8) 1
hypogonadism: 1
cryptorchidism; 1
p.Tyr1046Glyfs*23 1
diphophonate 1
calcium-vitamin 1
mineralisation. 1
AR-mediated 1
hyposmia 1
CHARGE, 1
electro-olfactogram 1
sustentacular 1
Green-striped 1
burrowing 1
Cyclorana 1
alboguttata, 1
droughts 1
aestivation, 1
Aestivation 1
alboguttata 1
aestivation 1
(1.1-3.5-fold) 1
aestivating 1
SIN3A 1
cytosine-5-methyltransferase 1
Brahma/BRG1 1
betabetaalphabeta 1
(MBD) 1
(HOXA) 1
Ring1b, 1
ACF1 1
SU(VAR)3-9, 1
beta-globin, 1
CTCF-CHD8 1
CHROMOMETHYLASE3. 1
KRYPTONITE 1
(KYP) 1
immunohistolocalization 1
CMT3-controlled 1
KYP 1
KYP, 1
deacetyltransferase 1
MOZ, 1
Ybf2/Sas3, 1
Sas2, 1
Tip60) 1
apicomplexa 1
(TgMYST-A 1
-B). 1
3.5-kb 1
TgMYST-B 1
(predominant) 1
(tachyzoites) 1
encysted 1
(bradyzoites). 1
TgMYST 1
Pcu4, 1
methyl-transferase. 1
Clr7, 1
Pcu4. 1
Nup189 1
nuclear-pore 1
(Pc) 1
dislodge 1
cell-lethal 1
Z-VAD 1
fmk. 1
Z-VAD-inhibitable 1
MRG, 1
E2F-activated 1
B-myb. 1
Rb-induced 1
Mi-2, 1
auto-antigen 1
(ATP)-dependent 1
(dMi-2) 1
76D5-6 1
(dMi-2a 1
dMi-2b). 1
dMi-2(BL3) 1
melanagaster. 1
lethal-3. 1
"male-specific 1
lethals" 1
(msls). 1
msls, 1
lethal-3 1
(msl-3), 1
msl-3. 1
cerevisae) 1
(MRG15 1
Lycopersicon 1
esculentum, 1
msl-3-like 1
Dm 1
MRG15) 1
(D), 1
interbands 1
SSRP1, 1
(LBR), 1
Functionally 1
(Gata3) 1
Th2-specific 1
Gata3/Chd4/p300 1
Gata3/Chd4-nucleosome 1
Th2-dependent 1
Chromatin-remodeling 1
(BMRB 1
18906). 1
Tyr>His 1
pp32r1Y140H. 1
(ANP32A) 1
HeLa) 1
p53(R248W) 1
MiaPaCa2 1
constrast 1
ACHN-pp32r1 1
pp32r1/pp32r1Y140H 1
CHD4) 1
Facultative 1
ssm4, 1
(DSR) 1
DSR-dependent 1
Mmi1, 1
Clr4/Suv39h 1
Mmi1. 1
(PAAs). 1
(OFT) 1
Brahma-related 1
(Brg1), 1
Brg1/Brahma-associated 1
(BAF) 1
(Ask1), 1
p21(cip1), 1
(Myh11) 1
PHD-mediated 1
(PHDs). 1
Chd5, 1
Chd5-PHD 1
chromatin-mediated 1
Photomorphogenesis 1
photoreceptor-dependent 1
ELONGATED 1
HYPOCOTYL5 1
(HY5) 1
anti-parallel, 1
(GATAD2A/p66α). 1
(MBD2)-nucleosome 1
U.S.A. 1
108, 1
7487-7492). 1
coiled-coils 1
MBD3, 1
(MBD3L1), 1
(MBD3L2) 1
p66α. 1
p66α 1
(MBD2 1
MBD3 1
MBD3L1 1
MBD3L2) 1
Mof, 1
(Stål). 1
Geometroidea), 1
NlMof, 1
1656bp 1
1353bp 1
Mi-2/NuRD 1
Mi-2/nucleosome 1
(Cd79a) 1
EBF1 1
Pax5. 1
NuRD. 1
MBD2-containing 1
Sparc/osteonectin, 1
cwcv, 1
kazal-like 1
(SPOCK1) 1
CHD1L; 1
(QGY-7703, 1
PLC-8024, 1
BEL-7402, 1
QGY-7701). 1
(nt-1662 1
+34) 1
agar; 1
caspase-3; 1
SPOCK1, 1
Talipes 1
gene-containing 1
Variants. 1
equinovarus, 1
0.006; 1
CHD5. 1
peptide-library 1
(beads 1
slides) 1
PHD(1) 1
PHD(2) 1
PHD(1-2) 1
H3R2, 1
H3T6, 1
4-11-fold 1
on/off 1
hHP1β-H3K9me3 1
protein-nucleosome 1
Microsecond-long 1
R8, 1
arginine-phosphoserine 1
(MRG 1
(H3K4me(0)) 1
H3K4me(2/3), 1
bivalency, 1
cooperativity, 1
MRG-binding-domain-dependent 1
MRG-Pf1 1
MBD 1
(Chp1-CD) 1
electrophoretic-mobility 1
(KRAB)-associated 1
(KAP-1) 1
(HP1-β) 1
Krüppel-associated 1
(KRAB) 1
(KAP-1), 1
telangiectasia-mutated 1
Co-repressors, 1
CHD3. 1
HP1-binding 1
Ser-473, 1
HP1-β, 1
KAP-1 1
KAP-1-mediated 1
Chk2-regulated 1
Netrin1 1
(Bmp2, 1
Bmp4, 1
Fgf10). 1
Otx1, 1
Hmx3, 1
polyploidy, 1
(∼3.5 1
Gb) 1
Sustaining 1
CHD7L. 1
CHD7S) 1
(CHD7L). 1
CHD7S, 1
(PS1/PS2) 1
(Ca²⁺) 1
(PS1/PS2-DKO) 1
c-jun-NH2-terminal 1
(Lee 1
Das 1
InsP3R-mediated 1
InsP3 1
(InsP3R1) 1
InsP3R1. 1
PS1-mediated 1
ZNF237 1
γ-secretase-specific 1
(PS1-D257A) 1
differentiation-dependent, 1
Chd2-dependent 1
Enforcing 1
Neurospora. 1
bitumen-challenged 1
bitumen-induced 1
cell-transforming 1
cells] 1
[nude 1
mice] 1
μl/ml) 1
(HOS 1
independency, 1
(serving 1
synthesis). 1
removals, 1
RT-directed 1
PPT, 1
RTs 1
Tf1-associated 1
removals. 1
RT-mediated 1
retrotransposon's 1
(coloboma 1
multiple-malformation 1
16/17; 1
14/18; 1
7/17; 1
11/13; 1
5/18; 1
15/17 1
14/15. 1
(10/13) 1
(12/15) 1
>85%. 1
subunits: 1
(Pc), 1
(Psc), 1
Polyhomeotic 1
(Sce). 1
CBX2, 1
CBX4, 1
CBX6, 1
CBX7 1
CBX8. 1
CBX2-2 1
Nab 1
(NGFI-A/Egr-binding) 1
(Egr2/Krox20), 1
(Chd4(loxP/loxP); 1
P0-cre). 1
(Id2, 1
p75), 1
Oct6/Scip, 1
Egr2/Krox20. 1
Chd4-null 1
Mta2, 1
MCPH1, 1
CHD4-depleted 1
SPO-11-generated 1
diakinesis. 1
pch-2, 1
mrg-1. 1
NH(2)-terminus 1
Chromator's 1
CHD5, 1
EGFP-CHD5 1
hyperethylated 1
Clonogenicity 1
47.83 1
A549-EGFP, 1
56.39 1
H1299-EGFP-CHD5 1
H1299-EGFP. 1
A549-EGFP 1
452.3 1
5q21 1
(LAPC4) 1
OPCN2 1
RWPE-1, 1
OPCN2-enhanced 1
SC-independent 1
(SC). 1
pairing; 1
synapsis. 1
GLP/G9a. 1
G9a-like 1
(GLP) 1
dimethylate 1
(K44) 1
K47 1
DNMT3A) 1
self-methylated 1
Dnmt3a-MPP8-GLP/G9a 1
development-dependent 1
immune-relevant 1
(HIS-24K14me1) 1
HP1/H1 1
tri-) 1
E52 1
K9Me(2) 1
K9Me(3,) 1
E52F, 1
E52I, 1
E52V, 1
E52D, 1
E52Q. 1
E52Q 1
KMe3, 1
=52 1
PCRs. 1
microrearrangements 1
Corepressor 1
EED 1
(H3K27), 1
oligonucleosome 1
H3K4me3- 1
CHD1-stimulated 1
(MuDPIT) 1
(PICs) 1
MuDPIT 1
CHD1-associated 1
PIC, 1
captured. 1
cementoblast-specific 1
mandible. 1
molar. 1
cementogenesis. 1
HCCs), 1
(TCTP), 1
(nt 1
-733 1
-1,027) 1
40.7% 1
Tyr15 1
(CHD1L/TCTP/Cdc25C/Cdk1), 1
Somitogenesis 1
presomitic 1
(PSM), 1
cdx1a, 1
dlc, 1
her7, 1
mespa, 1
ripply1. 1
spaw 1
PSM 1
chd7 1
prestin 1
(DPOAE). 1
Chriz-Z4 1
H3S10. 1
band-interband 1
looped-domain 1
interband 1
Interband 1
Z4, 1
BEAF 1
intercrosses. 1
subcongenic 1
B6.C-D7Mit318 1
(318) 1
C57BL/6ByJ 1
(B6By) 1
Parent-of-origin 1
cross-fostering 1
(GWAT) 1
Alpha-2,8-sialyltransferase 1
8B 1
(St8sia2) 1
GWAT 1
Repulsive 1
molecule-a 1
(Rgma) 1
GWAT. 1
Gln7Pro, 1
Fam174b. 1
Chromobox 1
arteriogenesis. 1
(165 1
Dia-1- 1
isw1Δ 1
pho80Δ 1
chd5 1
(LSCC) 1
bisulfate-specific 1
CHD5-transfected 1
(CENP-A) 1
CEN-C 1
(CENP-C) 1
CEN-T 1
(CENP-T). 1
∼150- 1
300-kbp 1
CenH3, 1
CEN-C, 1
CEN-T, 1
(H3K9me3). 1
dim-5, 1
CenH3-green 1
KDM5B, 1
self-renewal-associated 1
(MSI-H), 1
(MSI-L)/stable 1
MSI-H.These 1
deregulating 1
CHD-mediated 1
(MPP8) 1
MPP8, 1
(H3K9me3/H3K9me2) 1
lysine-9-containing 1
(QTARKS) 1
(KAARKS), 1
(Phe59, 1
Trp80 1
Tyr83) 1
(Asp87) 1
Thr84 1
Ser85. 1
PHD2 1
histone-binding 1
self-association-mediated 1
Swi6/HP1, 1
H3-Lys-9 1
Clr4/Suv39H1. 1
Clr4/Suv39, 1
self-association-defective 1
Clr4) 1
Chromodomain-mediated 1
nucleosome-bridging 1
H3K9-methylated 1
CDs. 1
vacant 1
Strengthening 1
CD-CD 1
(chromodomains) 1
mechanics-generalized 1
hydrophobically), 1
electrostatically). 1
203) 1
"rule-out" 1
=69). 1
(deletion/duplication 1
one/several 1
counselors, 1
interruptus, 1
Kismet/CHD8 1
&gt;150 1
Correcting 1
counter-pulsation 1
SWORD 1
ANDROMEDA 1
nifekalant 1
'apparent' 1
strength-interval 1
all-or-none 1
neferine, 1
anti-pulmonary 1
Nelumbo 1
nucifera 1
Gaertner's 1
co-administratered 1
RP-HPLC. 1
AUC(0-96) 1
neferine) 1
0.7-1.4 1
neferine. 1
amiodarone: 1
66-year 1
stone, 1
propafenone. 1
puzzled, 1
fascinated, 1
iodine-sufficient 1
lactation; 1
[Myocardial 1
implantablecardioverter 1
(20.38 1
15.55 1
15.96 1
10.20% 1
lifethreatening 1
(LVMF) 1
50.1+/-18.5 1
(42.1% 1
(LA 1
37.4+/-11.1 1
25.9+/-6.8 1
cm(2); 1
[SCD], 1
8.42; 1
0.047), 1
5.68, 1
31.07; 1
4.46, 1
13.01; 1
death/aborted 1
0.091). 1
VT/ventricular 1
(2-13) 1
(6-20); 1
(1-10.5) 1
(6-18); 1
(MaxLVWT), 1
MaxLVWT 1
anteroseptum, 1
septal, 1
non-VT 1
(JEV), 1
peptidic, 1
nonpeptidic, 1
3-deficient 1
(OCTs) 1
carrier-type 1
permeases 1
compacta, 1
non-aminergic 1
reticulata 1
(SNr), 1
SNr, 1
(SLC22A1), 1
(SLC22A2) 1
500Da) 1
harmful/toxic 1
ethidium, 1
phenanthridine 1
propidium, 1
transported. 1
OCT-mediated 1
OCTs. 1
reinforced. 1
TGF-beta) 1
TIEG-1-based 1
Nmyc. 1
(Sonic 1
hedgehog) 1
CGNPs. 1
(OB) 1
organismic, 1
(KLF10). 1
[TIEG2 1
(KLF11) 1
TIEG3/TIEG2b] 1
TIEG1's 1
(osteopenia/osteoporosis), 1
(hypertrophic 1
cardiomyopathy), 1
prostate). 1
(DeltaPsim). 1
(IMR-90) 1
Anti-TGF-beta 1
(6-fold) 1
Quinazoline-based 1
1-adrenoceptor-independent 1
tamsulosin, 1
sulphonamide-based 1
quinazoline-mediated 1
p21(WAF-1) 1
'latent' 1
8q, 1
Lipogenic 1
non-esterified 1
leptin) 1
peripartum 1
UCP2, 1
SCD1, 1
DECR1, 1
CRH, 1
CBFA2T1, 1
LEP 1
Transactivation 1
factor-β-susceptible 1
(TGF)-β-inducible 1
methylthiazoletetrazolium 1
Smad2, 1
(MIHA), 1
(Hep3B) 1
TGF-β-insensitive 1
Bel7404) 1
(Bel7404 1
HepG2). 1
4',6-Diamidino-2-phenylindole 1
Western-blotting 1
TGF-β-susceptible 1
LF10, 1
product; 1
IEG1 1
(TGF-β 1
lenti-TIEG1 1
TIEG1) 1
myogenin, 1
papillomavirus-16 1
(KLF) 1
early-response 1
mainteanance 1
Sp1/KLF-like 1
Tieg1 1
Tieg1. 1
Caspase3-dependent 1
TGF-beta-dependent 1
OLI-neu. 1
TGF-beta-mediated 1
SMAD-dependent 1
beta(1)-inducible 1
beta(1) 1
TGF-beta(1)-inducible 1
pancreas-derived 1
TGF-beta(1)-sensitive 1
Hep 1
TGF-beta(1)-induced 1
TGF-beta(1)- 1
trolox, 1
TGF-beta(1), 1
(mOPA1) 1
vesicular. 1
somas 1
manganese-induced 1
(Mn)-induced 1
Drp-1. 1
Δψm 1
Mn-injected 1
Mn-treatment. 1
Mn-induced 1
Manganism 1
elease 1
confinement. 1
(drp-1) 1
rhoGTPase-1 1
(miro-1). 1
anterior-localized 1
Tomm40. 1
Inhibiting, 1
(OPA1, 1
165500) 1
3q28-q29 1
13-19). 1
Msp1 1
Mgm1p 1
immuno-fluorescence 1
integrators 1
OPA1-dependent 1
PHB1 1
PHB2 1
PHB2-deficient 1
LRRK2-interacting 1
(mitofusins 1
OPA1). 1
LRRK2-mediated 1
LRRK2-induced 1
dynamin-superfamily 1
Extramitochondrial 1
extramitochondrial 1
(emOPA1) 1
cAMP-induced 1
emOPA1, 1
OPA1/COX 1
db-cAMP-induced 1
hFis1, 1
flattening, 1
hFis1-depleted 1
perilipin. 1
disorganized. 1
fragmented. 1
swell 1
Barbadensis, 1
aloe 1
randomly: 1
Anxiety-Depression 1
(OHIP-49). 1
0.210). 1
OHIP-49 1
(extraoral) 1
(alterations 1
(Catuama) 1
(VNS). 1
(FS: 1
(VNS: 1
.03; 1
FS: 1
(FS, 1
VNS: 1
Scoppus 1
concealment. 1
(amisulpride, 1
clonazepam), 1
UK), 1
clonazepam. 1
158350) 1
13-80% 1
"CS-like" 1
(DGGE), 1
(TTGE), 1
c.209T-->C. 1
auxilin. 1
c.209T-->C 1
PTEN/MMAC1, 1
Bannayan-Zonana 1
tumor-suppression 1
10q22-24 1
10q23.3. 1
c.122C 1
S41L 1
(Q270R) 1
subtype) 1
axotomized 1
axotomy. 1
(D28) 1
ceftriaxone-treated 1
D28 1
minocycline-treated 1
multi-phase 1
20-weeks. 1
(DSMB) 1
(Stages 1
grams/day 1
(ursodiol) 1
Stages 1
DSMB 1
(divided 1
dependent; 1
(0.97%) 1
HT22, 1
glutamate/cystine-antiporter 1
x(c)(-). 1
ceftriaxone-stimulated 1
intraperitoneal) 1
reperfusion). 1
(24-h) 1
(EAAT)-2 1
(PHFA). 1
-272 1
PHFA. 1
Riluzole 1
inviting 1
Talampanel 1
(AEOL 1
10150, 1
celastrol, 1
Q10, 1
copaxone, 1
IGF-1-viral 1
NAALADase 1
nimesulide, 1
scriptaid, 1
trehalose) 1
(motor 1
preclinical. 1
ALS) 1
diethyl-dithiocarbamate 1
(DDC); 1
Cu(II)-attenuating 1
EAAT2; 1
1,040 1
nutritionals, 1
beta-Lactams 1
neurotherapeutics 1
[Failure 1
multi-stage, 1
aminoacid 1
(EAAT2) 1
three-stage 1
(pharmacokinetics) 1
(safety), 1
(efficacy), 1
(ALSFRS-R) 1
ALSFRS-R 1
1·00; 1
p=0·0416), 1
(0·09, 1
0·24; 1
p=0·2370). 1
0·90, 1
0·71 1
1·15; 1
p=0·4146). 1
p=0·0004; 1
hepatobiliary, 1
[11%], 1
(0.17 1
L/kg); 1
17-21 1
(0.22-0.25 1
mL/min/kg). 1
climbers. 1
HA. 1
5200 1
Mt. 1
Everest. 1
both); 1
e) 1
Deiodinating 1
Interscapular 1
(IBAT) 1
(5'-D) 1
SCE. 1
Probably, 1
(tT), 1
(fT), 1
(GH), 1
(PRL), 1
(SHBG) 1
(Bosco 1
39%), 1
20%), 1
fT 1
PRL. 1
15-s 1
(SE). 1
(DSM-III) 1
miles/day 1
kcal/d 1
pigeons. 1
(GLI) 1
pigeons, 1
90-160 1
/T4 1
thyrotropin, 1
oestradiol 1
(autumn) 1
(spring). 1
monodeiodination 1
ng. 1
ml-1. 1
hemoconcentration 1
(increase) 1
monodeiodination. 1
luteal-phase 1
endocrine-metabolic 1
GcvB-mediated 1
acid-related 1
SroC 1
trans-encoded 1
IL-6-driven 1
(IAS) 1
IAS 1
loci-specific 1
(DRD4), 1
(SLC6A4/SERT) 1
n=182). 1
longitudinal-developmental 1
non-desmosomal 1
(ARVD/C) 1
(TFC). 1
(fulfillment 1
diagnosis), 1
(PKP2, 1
JUP) 1
TFC, 1
TFC. 1
ARVD/C, 1
Arg14del) 1
Netherlands-Phospholamban 1
(PREVEND) 1
grandparents' 1
Friesland. 1
PREVEND 1
8,267 1
(0.07 1
575-825 1
Friesland 1
(sex-, 1
age-matched) 1
+-adenosine 1
micronutritional 1
(RQ) 1
pre-exercise, 1
(F2-isoprostanes 1
carbonyls), 1
(ferric-reducing 1
Trolox 1
(TEAC), 1
(ORAC)), 1
(cytokine 1
(CRP)). 1
Pre-exercise 1
F2-isoprostanes 1
0.039 1
(137%). 1
carbonyls, 1
ORAC, 1
TEAC 1
(Cr) 1
Running-based 1
Anaerobic 1
(RAST). 1
35-m 1
(pre), 1
Average, 1
placebo-supplemented 1
Malondialdehyde, 1
Controversially, 1
supplementation: 1
Quercetin, 1
"Quercetin 1
Vit 1
C" 1
Fat-soluble 1
vitamins' 1
Isfahan 1
club. 1
IU), 1
Step 1
(myoglobin) 1
blackcurrant 1
anthocyanins) 1
5-km 1
time-trial 1
(~3.7 1
wks). 1
carbonyl, 1
erythrocytes), 1
(1.3%; 1
±1.3%). 1
elevated: 1
(23%; 1
±21%), 1
carbonyls 1
(27%; 1
±38%) 1
(8.3%; 1
±9.3%). 1
elite. 1
subelite 1
performance) 1
(TAC), 1
erythrocyte- 1
Rowers 1
7-d 1
antioxidant-intake 1
.29; 1
±.27), 1
.19; 1
±.22), 1
(.20; 1
±.23), 1
(.25; 1
±.27). 1
(-.32; 1
±.19) 1
(.27; 1
±.24). 1
Biostimine, 1
Rowing 1
ampoule 1
2,000-meter-maximum 1
preparatory 1
camp. 1
antecubital 1
(IL-6, 1
astaxanthin 1
Astaxanthin 1
(Asx) 1
acid-reacting 1
(AOPP), 1
(O2•¯), 1
(TAS), 1
sulphydril 1
superoxide-dismutase 1
(AST). 1
AOPP 1
(exercise 1
P<0.01 1
Postexercise 1
Immune, 1
(supplementation 1
melatonin). 1
beats/min). 1
(TAS) 1
Exhausting 1
(CoQ(10)) 1
(PG). 1
km) 1
(mountain 1
ultra-endurance), 1
climbing. 1
(8-OHdG), 1
isoprostane 1
hydroperoxides, 1
sTNF-RII 1
nonsense? 1
(QFO); 1
W(max) 1
(ferricreducing 1
[FRAP], 1
oxygen-radical 1
[ORAC]), 1
(F(2)-isoprostanes), 1
QC, 1
QFO, 1
(groups) 1
(times) 1
F(2)-isoprostanes, 1
ORAC 1
F(2)-isoprostanes 1
F(2)-isoprostanes. 1
(QFO) 1
502; 1
~10(9) 1
cells/day) 1
Faeces 1
501(®) 1
502(®), 1
(®) 1
(®), 1
Judo 1
eicosapentanoic 1
judoists. 1
(PUFAs; 1
EPA 1
DHA). 1
(judo-training 1
α-tocopherol, 1
(Rmax) 1
(CDmax) 1
malondyaldehide 1
long-chain-PUFA 1
(LCPUFA) 1
Rmax 1
oxidative-stress 1
(MDA, 1
Rmax, 1
CDmax, 1
NO) 1
α-tocopherol. 1
cardio-pulmonary 1
Max, 1
significative 1
(LP). 1
Post-training, 1
non-supplemented 1
wrestlers. 1
wrestling 1
wrestlers 1
supplementation; 1
(ELISA 1
(colorimetric 1
(zinc-supplemented 1
High-protein-PUFA 1
low-calorie, 1
-supplemented 1
3-g/day 1
supplementation.A 1
low-carbohydrate, 1
fish-oil-supplemented 1
Cocrystal 1
c.815T 1
L218Q 1
Gars(C201R), 1
15-day-old 1
Gars(C201R) 1
synthetases, 1
Finder: 1
http://code.google.com/p/fishfinder/downloads/list. 1
staining.Therefore, 1
KDM4 1
mis-regulated 1
(HP1a) 1
dKDM4A, 1
demethylase-dependent 1
(Txr1p) 1
ciliate 1
variation: 1
SET-domain-containing 1
EZL2 1
monomethylation-specific 1
H3K27-specific 1
HMT, 1
interdependences 1
H3K23, 1
ELZ2 1
Wbp7) 1
Pigp, 1
GPI-GlcNAc 1
Pigp 1
Wbp7(-/-) 1
anchor-dependent 1
LPS-triggered 1
dG9a, 1
DmSetdb1 1
DmSETDB1 1
equalizes 1
hermaphrodite-specific, 1
(DCC)-mediated, 1
SIR-2.1, 1
SET-1 1
SET-4. 1
versa); 1
Degrees 1
multifunctionality 1
degree-specific 1
H4K20me 1
(PGR) 1
bisulfite-pyrosequencing 1
(SUV39H1, 1
EZH2) 1
andERalpha 1
RASSF1a 1
unraveled, 1
transcription-activating 1
recruitmentbased 1
wild-type/acetylated 1
mutant/unacetylated 1
p300-dependent 1
JARID1C/SMCX, 1
JmjC-domain-containing 1
tri-demethylase 1
neuron-restrictive 1
RNA-interference-mediated 1
(SCN2A) 1
(SYN1) 1
SMCX-associated 1
acetylating 1
modifies, 1
SAS3. 1
sas3Delta 1
Set1p 1
Set2p 1
AtSUVH2 1
SUVH1, 1
(KRYPTONITE) 1
SUVH1 1
suppresses, 1
heterochromatization 1
YDG 1
CMT3. 1
(H3-K27) 1
monomethylation. 1
lysine-directed, 1
Postsynthetic 1
HMTase, 1
h2. 1
protein-labeled 1
[Dyskeratosis 1
update]. 1
NOLA2, 1
NOLA3, 1
TINF2) 1
poly-transfused 1
nonleucodepleted 1
CD34/kg 1
+40. 1
+30, 1
Congenita: 1
"Dyskeratosis 1
arise? 1
citing 1
(DBAR) 1
9458 1
observed-to- 1
observed-to-expected 1
tumor/leukemia 1
#NCT00106015. 1
lacey 1
syndromes), 1
congenita; 1
(identifier: 1
NCT00027274). 1
ontology-defined 1
0.9415, 1
synergistically. 1
condition-restricted 1
unravel. 1
miR-208, 1
miR-199b, 1
ischemia-related 1
(miRs), 1
(HSP)-70, 1
HSP-20, 1
miR(s) 1
down) 1
oncomir. 1
BRCA1-interacting 1
BARD1. 1
gamma-H2AX. 1
Suppressor: 1
Transport, 1
Locations. 1
1863 1
survival/apoptosis. 1
determines, 1
(B-cell-specific 1
Ring1a 1
UbcH6 1
E2/E3 1
BRCA1-dependent 1
BRCA1: 1
Brca1. 1
25-month-old 1
3/Atg8 1
8-hydroxydeoxyguanosine, 1
/Atg8 1
γ-Tocotrienol-induced 1
γ-Tocotrienol, 1
self-digested 1
(+SA) 1
MDA-MD-231) 1
0-40 1
γ-Tocotrienol 1
(MDC)-labeled 1
(CL-S1) 1
(MCF-10 1
LC3)-II 1
(LC3B) 1
(NCT) 1
(LABC). 1
nonpathologic 1
(non-pCR) 1
0.328) 1
extratumoral 1
0.008); 1
OS). 1
non-pCR. 1
intermediate-grade 1
AKTi 1
MK2206, 1
torin 1
hypoxia]. 1
hypoxia: 1
expressions; 1
3-MA, 1
Mitochondrion-associated 1
(microtubule-associated 1
C19ORF5 1
misfolded/aggregated 1
acid-associated 1
1-PI3KCIII 1
3-kinase)/Akt/mTOR 1
ATG5-ATG12 1
conjugate-mediated 1
UA-activated 1
LC3II, 1
LC3I 1
(Atg5) 1
UA. 1
Atg5-/- 1
Atg5+/+ 1
UA-induced 1
apoptosis-based 1
interferon-γ-primed 1
"prime" 1
"trigger," 1
IFN-γ- 1
autophagolysosomes, 1
β-defensin-3 1
(sIBM) 1
(IIM), 1
(HBD)-1, 1
HBD-2, 1
HBD-3, 1
CD8-positive 1
CD-68-positive 1
sIBM. 1
sIBM, 1
(Fis1), 1
(Opa1) 1
(Mfn2), 1
(NRF1) 1
(PGC-1α), 1
Fis1. 1
NRF1 1
(T80) 1
ATG5/ATG7-dependent, 1
beclin-1/hVps34-independent, 1
HEY 1
FAC-treated 1
Lysotracker) 1
U0126, 1
LC3-II/autophagic 1
H-Ras-overexpressing 1
(deferoxamine), 1
CD133/prominin-1-mediated 1
CD133/Prominin-1 1
pentaspan 1
medium(CM) 1
(LGM), 1
LM3 1
time-lapsed 1
shCD133 1
(Huh-7sh133) 1
CD133mAb 1
Quinacrine-mediated 1
(QC), 1
(HCT-116 1
sublines). 1
Bax/Bcl-xL 1
COMET 1
(AVs) 1
QC-treated 1
Equine 1
(EAV) 1
enveloped, 1
(DMVs). 1
EAV-infected 1
EAV, 1
(ATG7). 1
EAV. 1
EAV-induced 1
degradation-enhancing 1
α-mannosidase-like 1
(EDEM1), 1
distantly-related 1
coronavirus, 1
EDEMosomes 1
3-methylalanine 1
Simpson-Golabi-Behmel 1
(HIEC) 1
BECN1-labeled 1
proliferative/undifferentiated 1
Spinning 1
double-membrane-bound 1
lysosomes; 1
anergy, 1
SLAM-associated 1
Acellular 1
(PERV) 1
xenoantigens. 1
pig-skin 1
(maximum, 1
Ags. 1
anti-PERV 1
anti-αGal 1
Xa-inhibitors]. 1
Xa-inhibitors 1
antithrombotics, 1
(Lixiana®). 1
60'000 1
hip- 1
knee-joint 1
protheses, 1
predecessors, 1
Reservations 1
vitamin-K-antagonists 1
CYP-affecting 1
'dabigatran', 1
'rivaroxaban', 1
'apixaban', 1
'elderly', 1
'octogenarians', 1
'atrial 1
'anticoagulation' 1
industry-independent 1
Frail 1
dabigatran-investigating 1
evidence- 1
procedures? 1
Prescrire 1
aspirin), 1
experimen-Haemodialysis 1
bicarbonate/ 1
Qbeta. 1
74000), 1
64000), 1
47000) 1
33000), 1
(subunit 1
"S1" 1
"i") 1
strand-directed 1
nucleotide-polymerizing 1
Subunits 1
EF-Ts, 1
template-enzyme 1
(translocated 1
(Ewing's 1
Arg-Gly-Gly 1
(RGG) 1
cis-repression 1
residue: 1
CADASIL-like 1
cysteine-sparing 1
mid-life 1
(30s-60s) 1
(c.341-26_24delAAC). 1
RUNX1S291fs 1
RUNX1S291fs-induced 1
RUNX1S291fs/Ezh2-null 1
PRC1-mediated 1
Hoxa9. 1
(Y641C) 1
SKM-1 1
myelodisplastic 1
zest, 1
Vav 1
proto-oncoprotein 1
XNP 1
7q35-q36 1
"leukemia" 1
(TET2, 1
deacetylation) 1
http://bioinformatics.biol.uoa.gr 1
/ExTopoDB 1
http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/ 1
ж┴-helical 1
�-helical 1
(Meissner's) 1
(Aurbach's) 1
colorectum. 1
SPSS-17. 1
Binomial 1
Chi-Square 1
(84.5%) 1
hypoganglionosis 1
(IND 1
(71.8%). 1
(Meissners) 1
(Aurbachs) 1
melanin-producing 1
leptomeninges. 1
clean. 1
(ETB) 1
non-inbred 1
(N104I) 1
1170 1
(S390R), 1
(C109R). 1
polymorphous. 1
heregulins 1
tissues) 1
(3.33%). 1
63.64% 1
(27.27%) 1
der(1q) 1
inv(7). 1
revisited]. 1
(FANCA 1
FANCJ) 1
FANCD1 1
localisation. 1
(D1(BRCA2), 1
mono-ubiquitinylation 1
re-localization 1
MRE11/RAD50/NBS1 1
radiations. 1
replication-blocking 1
already, 1
tempted 1
ultraviolet-type 1
[18], 1
[50]. 1
hope, 1
renovated 1
impulsion 1
ambition 1
microscopy: 1
super-duper 1
inception, 1
subdomains, 1
microscopists. 1
SUPER-resolution 1
EM: 1
sub-10 1
Ludwig 1
PLOS 1
caveolin-3, 1
Limbe-Girdle 1
probe-induced 1
capacitance/impedance. 1
antennapedia 1
(A-CSD3). 1
A-CSD3 1
pipette, 1
dome. 1
mechanoprotective 1
less-often-traveled 1
quiescence-inducing 1
(SSD) 1
caveolae-dependent. 1
(80-150 1
(Cav-1(-/-)) 1
(1-25 1
dynes/cm(2)) 1
(L-NAME), 1
INDO), 1
epoxygenase 1
(SKF 1
525A). 1
INDO, 1
525A 1
Vessels 1
(Ephx2(-/-)) 1
SSD, 1
donor-detector-coupled 1
MCA. 1
epoxyeicosatrienoic 1
transcytosis, 1
potocytosis, 1
LPS-eNOS-TLR4-NFκB, 1
MKK3/p38 1
cPLA2/p38 1
STAT3/NFκB 1
IL-1β-IL-1R1 1
caveolae, 1
inconsistencies. 1
13%-14% 1
2035. 1
"aged" 1
cavins, 1
spreading: 1
why. 1
caveolin-1, 1
Caveolar 1
Folch 1
esterificated 1
BF3, 1
chromatograph-mass 1
anti-caveolin-1 1
GC/MS. 1
acid/caveolae 1
preparation/5 1
myristic 1
mechano-transduction, 1
immuno-isolation, 1
Cavin 1
1∶4. 1
Cavins 1
(MiniSOG), 1
tomograms 1
cavin-MiniSOG, 1
constrained. 1
substructures. 1
nucleolar-associated 1
ICP8. 1
MSH6; 1
Ku86, 1
Rad50; 1
BRM, 1
hSNF2H, 1
BAF155, 1
mSin3a, 1
ICP8, 1
WRN, 1
WRN-deficient 1
Ku70-deficient 1
50-fold, 1
ncRNA-containing 1
hnRNPs 1
remodelers, 1
ISWI, 1
invertebrate-vertebrate 1
urochordate, 1
Me(3)K4), 1
PML-RARalpha 1
t(15;17) 1
SP100-HMG, 1
group-1 1
(HMG-1) 1
&quot;open&quot 1
mol/L, 1
ischemia). 1
high-dose/long-term 1
donors) 1
length). 1
(FURA-2 1
"ratio 1
method") 1
mol/L), 1
mN/mm2 1
aequorin 1
luminescence, 1
Lmax, 1
(L/Lmax) 1
-3.4 1
(VCE) 1
(PHylogenetics 1
Evolution), 1
macaques' 1
(clades4-7). 1
clade3, 1
(4E100a, 1
10E147a) 1
(7R17b 1
13R11b), 1
animal's 1
SIV/HIV 1
RIM5α 1
TRIM5α) 1
urtecaria 1
(Cryopyrin) 1
pro-interleukin(IL)-1beta. 1
5alpha 1
TRIM6, 1
TRIM34, 1
TRIM22. 1
TRIM6 1
TRIM34 1
505265-mediated 1
Phylogenetically, 1
TRIM5/TRIM6/TRIM34 1
505265 1
evolutio 1
profiles), 1
coexpression), 1
Imposing 1
'component' 1
'composite' 1
rear-ranged, 1
bench-marked 1
SCOP 1
single-domain 1
Nature's 1
(MATR3), 1
microbeam. 1
radiomimetic 1
NONO; 1
SFPQ, 1
PSF/p54nrb 1
oncoprotein-interacting 1
RNF43-interacting 1
RNF43's 1
RNF43-associated 1
p54nrb. 1
recommences 1
DRB, 1
labor-associated 1
(Gja1). 1
PTB-associated 1
PR-DNA 1
progesterone-response 1
element-luciferase 1
(Gja1), 1
argeted 1
trioxide. 1
(AME), 1
t(3;21)(q26;q22) 1
AME, 1
MDS1/EVI1, 1
(EVI1) 1
AME. 1
nanoparticle-encapsulated 1
thiostrepton. 1
Thiostrepton, 1
thiazole 1
pharmaco-kinetic 1
mg/m2). 1
35-140). 1
VELCADE 1
MLN9708, 1
(EOC/PPC). 1
mg/m(2)/dose]. 1
(1/26), 1
exposure/activity 1
(2/29, 1
responses). 1
14-84% 1
27/28 1
EOC/PPC. 1
inhibitors-induced 1
Glucose-regulated 1
(GRP78) 1
ARO, 1
8305C, 1
(PS-341): 1
(mg) 1
PI; 1
(AIPCa). 1
AIPCa) 1
mg/m(2)/dose, 1
(decline 1
mg/m2/dose. 1
PS341. 1
pretreated. 1
ubiqutin-proteasome 1
(UP-S), 1
neuro-toxicities 1
loader, 1
RFC-like 1
RLCs 1
Rad24. 1
Rad24) 1
Mcd1/Scc1 1
elg1 1
ctf4. 1
Ctf18. 1
Kar3p 1
Vik1p 1
DNA-stress 1
(C/EBP) 1
(CHOP). 1
(XRCC2) 1
XRCC2-deficient 1
XRCC2-expressing 1
tumor-nodes-metastasis 1
Calvert 1
continuously) 1
NCT01081951, 1
retrospectively): 1
9.7-15.0]) 1
9.1-9.7) 1
0.34-0.77]; 1
p=0.0012), 1
[0.08-0.55]; 1
p=0.0015). 1
[74%] 1
[59%] 1
[69%] 1
[57%]), 1
[49%] 1
[39%]), 1
[42%] 1
[27%]), 1
[12%]); 1
[43%] 1
(HR)-mediated 1
γ-ray-induced 1
UBC13(-/-)clones 1
poison) 1
UBC13(-/-)cells, 1
UBC13(-/-)cells. 1
HR-dependent 1
Ubc13. 1
Ku70, 1
RAD18(-/-) 1
γ-rays, 1
UBC13(-/-)cells 1
CTCAE, 1
(PR/CR), 1
(duration 1
11.4, 1
11.9, 1
wks), 1
(-9% 1
-11.7% 1
NCT01583543. 1
coiled-coil-domain 1
(CCDC6), 1
<1. 1
NSCL 1
significatively 1
(CD33) 1
calicheamicin. 1
calicheamicin, 1
(HL/GO20) 1
Olaparib-alone 1
Piperlongumine 1
hyper-sensitivity 1
(NHEJ), 1
Ku70 1
DSB- 1
Olaparib. 1
piperlongumine-induced 1
VEGFR3. 1
accruing 1
unmasked. 1
expected). 1
NCT01116648. 1
17·7 1
14·7-not 1
9·0 1
5·7-16·5) 1
0·42, 1
0·23-0·76; 1
p=0·005). 1
none), 1
Cediranib 1
Reinvestment 1
U01 1
CA062490-16S2); 1
Intramural 1
(BCSCs) 1
BCSCs, 1
(BCL), 1
ALDEFLUOR 1
(ALDH+) 1
(ALDH-) 1
2-Dimensional 1
In-Gel 1
DIGE). 1
Differentially-expressed 1
gel-extracted, 1
BCLs. 1
BRCA1-mutated 1
HCC1937, 1
ALDH+, 1
BCLs, 1
dl922-947. 1
downmodulated 1
self-prescription 1
(T(3)). 1
Refetoff 1
>800 1
ng/dl 1
(80-180) 1
pg/dl 1
(230-420), 1
(HAM-D 1
(UCC) 1
GDIs, 1
GEFs. 1
urothelium. 1
UCC, 1
(p=0.0258) 1
(p=0.0272) 1
UCCs, 1
UCCs 1
Rho-related 1
Rho. 1
avail? 1
tissue-arraying 1
0.6-mm 1
CDKN1A 1
MKI67 1
(Ki67), 1
(Cox-2), 1
(alpha-catenin), 1
(beta-catenin), 1
RHOA, 1
RHOC, 1
VEGFC, 1
skeptical 1
(GAC) 1
bromo-benzophenanthridinone 1
968. 1
Dbl, 1
hyperactivates 1
(13)C-labeled 1
glutaminolysis 1
GAC. 1
refuels 1
(SHMT), 1
(PLP)-dependent 1
(SHMT1) 1
(SHMT2) 1
fluxes, 1
SHMT2, 1
apo-enzyme 1
cofactor-binding 1
SHMT1 1
(iGluRs). 1
iGluRs 1
(AMPA, 1
tetramerization--the 1
membrane--is 1
(AMPAR) 1
AMPAR 1
"interacting" 1
C-STIM1 1
STIM1/Orai1 1
Orai3, 1
Orai1, 1
C-STIM1. 1
2-aminoethyldiphenyl 1
STIM1-independent 1
AMPA-type 1
(AMPA-Rs) 1
GluA2cryst 1
interpretations. 1
receptor-expressing 1
AMPA-R-mediated 1
lowering? 1
tubule's 1
glycosuria, 1
single-nephron 1
(SNGFR) 1
safely) 1
insulin), 1
(CANVAS)--a 1
4,330 1
mid-September 1
7174 1
SGLT2-selective 1
re-entering 1
patients.A 1
event.During 1
peptide.In 1
positively. 1
negatively.TheT3 1
95.5% 1
87.7%. 1
65+/-12 1
(cumulative) 1
1-86 1
5.8-22.9; 1
5.4-35.2, 1
153) 1
<0.02) 1
3.5; 1
triiodothyronine/free 1
(DCMP). 1
62+/-12 1
12+/-8 1
(fT3)/free 1
predictivity 1
76.5+/-5.9 1
Sao 1
(89+/-23 1
101+/-16 1
14.3+/-8.1 1
(82.7+/-24.8 1
96.7+/-19.2 1
2.2-43, 1
PLN-HCM 1
0.65%, 1
KIAA1530, 1
CSA-dependent 1
(W361C), 1
propensity, 1
-an 1
(ochre), 1
hisG4 1
thr-1 1
(amber) 1
reversion-based 1
AB1157-based 1
alkB⁻ 1
CSB. 1
XPC/RAD23/Centrin2 1
subpathways, 1
ISWI/Cohesin 1
(T4endoV) 1
coprecipitated 1
photoreactivation 1
glycols 1
(BER). 1
(7MeG) 1
(3MeA) 1
(dhfr) 1
BER, 1
dhfr 1
(Aag 1
proficient, 1
7MeG, 1
3MeA. 1
UV-enhanced 1
UV-inducible 1
(XP) 1
bulk) 1
(XP-C) 1
XP-B, 1
XP-C, 1
XP-D, 1
XP-F, 1
XP-G, 1
CS-A 1
CS-B 1
XP-C) 1
ERCC6. 1
transcription-blocking 1
ERCC6 1
CSB/ERCC6, 1
RAD26. 1
RBP2 1
UV-, 1
cisPt- 1
rad26. 1
(6-4 1
(hamster 1
AA8, 1
G1-phase, 1
Abolition 1
UV-DNA 1
Non-transcribed 1
Indirectly, 1
UV-damage 1
(NTSR), 1
NTSR 1
photoproduct. 1
oligo(dC)-tailed 1
photoproduct 1
(6-4PP) 1
6-4PP 1
stalled. 1
rad26Delta 1
depurination 1
(T7 1
RNAP) 1
8-oxoguanine. 1
affair. 1
Rnf213 1
p.R4859K, 1
10(-43), 1
190.8, 1
71.7-507.9). 1
p.R4859K-negative 1
Moyamoya, 1
"hazy 1
smoke" 1
(ICAs) 1
(MCAs). 1
(MMD): 1
epileptic, 1
"other." 1
Willis, 1
ICAs, 1
MCAs. 1
Off 1
thalamoperforate 1
lenticulostriate 1
ICAs 1
conservatively; 1
combined/other 1
artery-MCA 1
(nerve) 1
(NF2). 1
neurofibromatoses. 1
(Factor 1
Methylene-tetrahydrofolic 1
20210A 1
3p26, 1
predispositions. 1
FMMD; 1
FMMD, 1
(FMMD 1
MMD: 1
9.56; 1
1.85-49.48; 1
non-MMD: 1
10.50; 1
2.02-54.55; 1
GAGGCTGGG 1
FMMD. 1
deposit, 1
2,100 1
1957. 1
fibrocellular 1
(HLA). 1
D6S441, 1
(MM-DS) 1
transfemoral 1
MM-DS. 1
Hemiplegia 1
phenomenon]. 1
(UUCCUUAAC) 1
opsonophagocytic 1
SpAKKAA 1
SpA-neutralizing 1
358A76, 1
SpA-immunized 1
SpAKKAA-derived 1
358A76 1
IgBD 1
IgBDs 1
(D-A-B-C) 1
pelB 1
additives, 1
IPTG, 1
380mgL(-1) 1
Tris-HCl 1
180mM 1
flask 1
tank 1
5.5gL(-1) 1
A-containing 1
⩾95% 1
(RP 1
HPLC) 1
(DE3). 1
immunoglobulin-binding 1
(RSM), 1
Compounds, 1
1.77% 1
(600) 1
RSM 1
A-immunoglobulin 1
SpA-IgG1 1
(hIgG1) 1
all-atom 1
(Glu143, 1
Arg146 1
Lys154) 1
(Phe132, 1
Tyr133 1
His137) 1
(rSPA), 1
ease, 1
(OD600), 1
desalting 1
western-blot. 1
Poisson-Boltzmann 1
(NaCl) 1
(hIgG1). 1
repulsions 1
(H137, 1
R146, 1
K154) 1
SpA-based 1
(ligand 1
22/8) 1
Teng 1
al.). 1
C(H)1 1
(TG 1
19318) 1
19318 1
(IgG, 1
IgE) 1
(serum, 1
ascities 1
supernatants) 1
25mg 1
IgG/mL 1
sanitation 1
(22/8), 1
(3-aminophenol 1
4-amino-1-napthol) 1
cyanuric 1
(triazine). 1
human> 1
51.9 1
IgG/g 1
NaOH 1
bacteremic 1
Amikacin 1
clofazimine, 1
mycobacterium. 1
PFU/ml), 1
cFU/ml), 1
(i.v.). 1
smegmatis-TM4 1
TM4. 1
mycobacterium 1
lung]. 1
non-productive 1
CT-scans 1
non-diagnostic, 1
P=.24) 1
(59% 1
P=.80) 1
(n=57), 1
(P=.21) 1
63%; 1
hazard, 1
95.1% 1
[0.7, 1
1.7]). 1
Clarithromycin, 1
macrolide, 1
Colony-forming 1
7H11 1
6.6, 1
CFU; 1
declined.(ABSTRACT 1
Nontuberculous 1
(KTR) 1
Pleuropulmonary 1
KTR 1
[Myopericarditis 1
Akinesia 1
mid-inferior 1
mid-posterior 1
V3-V6 1
aVR 1
coronarography 1
antimyolemmal 1
(AMLAs) 1
48-month 1
auto-immunological 1
Purulent 1
dissemination.This 1
localizable 1
subxiphoidal 1
tamponade, 1
pericardiectomy. 1
Intrapericardial 1
corticosteroids: 1
roentgenogram 1
tamponade. 1
Pericardial 1
caseating 1
extra-pericardial 1
non-shaggy-type 1
(9). 1
Shaggy 1
mass-like 1
pericardium 1
Non-shaggy 1
anechoic 1
shaggy 1
coating. 1
(39.6 1
non-shaggy, 1
shaggy, 1
(MMPH) 1
(39%). 1
(31.9 1
mother- 1
MMPH 1
(Tsc2) 1
(16p13. 1
time-of-day 1
clock- 1
set1 1
circadian- 1
Collar 1
(WC-2) 1
Δset1, 1
H3K4me 1
frq. 1
Spt4-Spt5, 1
FLO8 1
isw1 1
Chd1. 1
MeK4) 1
MeK4 1
alpha-helix. 1
beta-strands, 1
MeK 1
effective]. 1
breast(T2N1M0, 1
Bt+R1. 1
papillotubular 1
carcinoma,(ER-, 1
cancer(ER-, 1
metastic 1
trastuzumab+capecitabine. 1
off-trial 1
monitorized 1
(73.5 1
(61.4 1
HR-negative 1
(10.8 1
(CECOG). 1
=85% 1
personal/logistical 1
(FEC(90)), 1
(FEC(90)) 1
oedema). 1
FEC(75 1
hybridization-positive) 1
PST 1
29-81). 1
38.5%-70.7%). 1
concur 1
GETIS 1
nonmetastatic, 1
(IBC) 1
(FEC-HD) 1
lenograstim. 1
14.7%. 1
41.2%, 1
25-53 1
43-79 1
lenograstim 1
(FASG) 1
Scarff-Bloom 1
(SBR) 1
(207, 1
2301 1
cycles.(ABSTRACT 1
5-HT3-receptor-antagonist 1
emetogenic 1
5-HT3-receptor-antagonists 1
episodes,) 1
nausea,) 1
50.8% 1
63.7%, 1
0.018; 1
0.104; 1
suppl 1
204) 1
allocated, 1
(ALT); 1
T); 1
(P=0.110, 1
significant), 1
(52.3%) 1
(71.1% 1
(9.5, 1
=9%) 1
non-haematological 1
97-99% 1
(94.9%) 1
cycles-FEC. 1
431.7 1
(95.9% 1
(88.2%), 1
(42.4%), 1
(40.6%), 1
(40.7%), 1
Glucose-insulin-potassium 1
glucose-insulin-potassium 1
(GIK) 1
dextrose) 1
(n=160), 1
dextrose, 1
mmol.L(-1), 1
u.L(-1)) 1
mL.kg(-1) 1
(n=157), 1
(n=63) 1
GIK+T3 1
(n=60). 1
GIK/placebo 1
(AXC) 1
T3/placebo 1
(P=0.009 1
0.029, 1
crossclamp, 1
89). 1
drug/pressor 1
(arrhythmia/ischemia/infarction), 1
=.007) 1
(intra-aortic 1
0.40) 1
Triiodothyronine-treated 1
(CPB), 1
microgram/kg). 1
inotropes, 1
vasodilators, 1
(vasodilator) 1
'CPModule' 1
REDfly, 1
CRM-prediction 1
DISCOVER: 1
feature-based 1
'grammatical 1
organization' 1
formalisms 1
http://www.sailing.cs.cmu.edu/discover.html. 1
&apos;grammatical 1
organization&apos; 1
coregulation. 1
(SOPs), 1
Additionaly, 1
(11/29). 1
SOP 1
phylogeny-based 1
&apos;orthologous&apos; 1
Sag/Rbx2/Roc2 1
SAG 1
(Sensitive 1
Gene), 1
RBX2 1
ROC2, 1
(CRL). 1
E11.5-12.5 1
E15.5 1
MS-1 1
NTUB1 1
RT4). 1
(MTT), 1
(BrdU 1
incorporation), 1
labeling). 1
anti-proliferation, 1
anti-migration, 1
phospho-histone 1
phospho-Bcl2, 1
G2M 1
(caspase-4, 1
phospho-eIF2α, 1
CHOP) 1
activations). 1
cullin-ring 1
25-150 1
ANBL-6 1
<500 1
MM.1S 1
2× 1
(A171T) 1
UBA3. 1
UBA3 1
A171T 1
molecule's 1
CUL, 1
(NAE1), 1
NAE1 1
CUL 1
MTOR) 1
Neddylation-induced 1
winged-helix 1
(CLI) 1
OCI-Ly10. 1
centimeter 1
(%ID/cm(3)), 1
radiance, 1
(radiance/ID), 1
%ID/cm(3) 1
0.83) 1
radiance/ID 1
cost-to-return 1
(LPSs) 1
(dexamethasone), 1
TRAIL. 1
c-jun-NH(2)-kinase 1
phospho-c-Jun 1
c-FLIP, 1
[66 1
xenografts] 1
15-678 1
rereplication, 1
pIkappaBalpha, 1
germinal-center 1
Cdt-1 1
rereplication. 1
ABC- 1
GCB-DLBCL 1
ABC-DLBCL, 1
CUL4A 1
triphosphohydrolase 1
(HIV-2) 1
Vpx, 1
virion-packaged 1
co-opts 1
cullin4a-based 1
CRL4. 1
Vpx-containing 1
deoxynucleosides 1
Radiosensitization 1
(SKP1, 1
Cullins, 1
(20-100 1
WEE1, 1
WEE1 1
ubiquitin-activating 1
Sintchak, 1
Gavin, 1
Bruzzese, 1
Bump, 1
Soucy, 1
Milhollen, 1
X., 1
Burkhardt, 1
Loke, 1
Lingaraj, 1
Hamman, 1
Spelman, 1
Cullis, 1
Langston, 1
Vyskocil, 1
Sells, 1
Mallender, 1
Visiers, 1
I., 1
Claiborne, 1
Rolfe, 1
Bolen, 1
Dick, 1
102-111). 1
(Ube1) 1
5'-O-sulfamoyl-N(6)-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine 1
(Compound 1
UAE-dependent 1
ATP-PP(i) 1
transthiolation 1
Brownell 1
catastrophic. 1
athletes.As 1
countries.It 1
clubs, 1
arrhythmia-based 1
GCVDs 1
aspire 1
inadvisable 1
constituted, 1
GCVDs. 1
55-70 1
(T1-2, 1
N0) 1
good-prognosis 1
BCCS 1
1.7-122.2; 1
Gene-expression 1
JNK3. 1
394-443 1
reassociates 1
phosphatase-7 1
MLK 1
DSPs, 1
protein-centric 1
nephrology. 1
proteomics/peptidomics. 1
peptidome 1
(SQL) 1
5,010 1
http://imgt.cines.fr, 1
d'ImmunoGénétique 1
(LIGM) 1
(Université 1
CNRS) 1
IMGT-ONTOLOGY, 1
IDENTIFICATION, 1
CLASSIFICATION, 1
DESCRIPTION, 1
NUMEROTATION, 1
ORIENTATION 1
OBTENTION. 1
chart. 1
(repertoire 1
myelomas), 1
(IG 1
(detection 1
diseases) 1
(grafts, 1
vaccinology). 1
http://imgt.cines.fr. 1
IMGT/DomainGapAlign: 1
MHC, 1
MhcSF. 1
ImMunoGenetics 1
receptor/antigen 1
(IG/Ag, 1
TR/peptide/MHC) 1
(IgSF 1
MhcSF, 1
IG, 1
IMGT/DomainGapAlign, 1
axioms. 1
(CLASSIFICATION), 1
delimitations 1
(DESCRIPTION), 1
(FR-IMGT) 1
CDR-IMGT. 1
http://www.imgt.org. 1
humanization. 1
IMGT(®), 1
system(®) 1
(http://www.imgt.org), 1
IMGT/LIGM-DB 1
IMGT/GENE-DB, 1
IMGT/V-QUEST, 1
IMGT/HighV-QUEST, 1
IMGT/JunctionAnalysis 1
IMGT/2Dstructure-DB 1
(mAb, 1
-mab) 1
(FPIA, 1
-cept) 1
Nonproprietary 1
Name 1
(WHO/INN) 1
(IMGT/StructuralQuery, 1
IMGT/DomainSuperimpose). 1
applications: 1
now-known 1
24-34, 1
50-56 1
89-97, 1
CDRs 1
(31-35B, 1
50-65 1
95-102) 1
CDRL1 1
CDRH1 1
http://immuno.bme.nwu.edu 1
Conformations 1
(RdDM). 1
AGO6 1
NRPE5a 1
clsy1, 1
ktf1, 1
nrpd/e2, 1
TaMET1, 1
TaMET2a, 1
TaMET2b, 1
TaCMT, 1
TaMET3, 1
seed, 1
TaMET1 1
TaMET3 1
jointing 1
5508 1
7651, 1
5539 1
(www.proteinatlas.org). 1
GENCODE: 1
RefSeq. 1
3689 1
GENCODE, 1
3127 1
gencodegenes.org 1
Browsers. 1
meaningless 1
conservation: 1
ORFs-specifically, 1
by-product, 1
catalogs, 1
20,500. 1
principled 1
Reconciling 1
human-expressed 1
mouse-expressed 1
IU/d) 1
25OHD, 1
500-700 1
premature. 1
.Overall, 1
(1947 1
(RaR) 1
79,193 1
(99/159) 1
(66/110), 1
(96/131), 1
(60/159) 1
concealment.Multiple-component 1
3622 1
5333 1
multiple-component 1
Chi, 1
1563 1
1625 1
participants).Multifactorial 1
9503 1
13,617 1
participants).Overall, 1
treatment.Home 1
4208 1
therapist.An 1
1.57, 1
2.06) 1
1.91). 1
(597 1
glasses, 1
activity.Pacemakers 1
not.Gradual 1
participants).An 1
anti-slip 1
icy 1
falling.There 1
participants).Trials 1
knowledge/educate 1
2555 1
participants).No 1
fall-related 1
fractures.Thirteen 1
80-year-olds, 1
falling.Multifactorial 1
falling; 1
falling.Overall, 1
0.77-0.96) 1
insufficiencies. 1
50-75 1
5391 1
Employment 1
ambulant, 1
ACTRN12605000540617. 1
(incident 1
immune-modulatory 1
(2139 1
0.25-0.98], 1
calcitriol. 1
0.30-0.88), 1
0.44-0.98). 1
3.63, 1
1.51-8.73) 1
[Antibiotics 1
purulence 1
breathlessness, 1
purulence. 1
[Prospective, 1
(1994-1998) 1
COPD]. 1
(187) 1
(22) 1
(249 1
Communities 1
1827 1
Study-I. 1
Fried 1
65.9 1
7.26). 1
209) 1
591) 1
frail. 1
(OR)s 1
(1.23-2.33) 1
prefrailty 1
(1.08-5.15) 1
prefrail: 1
(1.08-3.20); 1
(1.12-8.50); 1
(1.12-4.57); 1
(1.07-13.16); 1
(72.5% 1
25.2% 1
(16.9% 1
4.8%; 1
7.7%; 1
P=.006). 1
(20.5% 1
13.3%; 1
P=.01). 1
satiation 1
MNA. 1
SCALES. 1
Honolulu, 1
Hawaii. 1
2275 1
Honolulu 1
71-92 1
dynamometer. 1
weight/height2; 1
underweight: 1
20-24.99, 1
overweight: 1
14.0). 1
Steep 1
(lowest 1
quartile). 1
underweight/ 1
underweight/not 1
weight/depressed 1
weight/not 1
overweight/depressed 1
overweight/not 1
675, 1
referent) 1
residents: 1
Confounding 1
1,245 1
cross-sectionally, 1
"usefulness" 1
5-ALA-derived 1
qualities, 1
"useful", 1
gangliogliomas 1
five; 1
(QALY), 1
4550 1
9021 1
Observational, 1
5-ALA: 1
p=.000; 1
48%; 1
p=.002. 1
Fluorescence-guided 1
radiochemotherapy.Previous 1
protoporphyrins 1
Aalborg 1
54-70% 1
Monodactylous 1
2q31 1
HoxD). 1
HOXD13 1
synpolydactyly, 1
HOXA13, 1
hand-foot-genital 1
(a-p) 1
zeugopod, 1
monodactyly 1
oligodactyly 1
penoscrotal 1
HOXD-cluster 1
non-polarized 1
receptor-2b-signaling 1
dermal-epithelial 1
comedogenesis, 1
FGFR2-gain-of-function 1
Androgen-mediated 1
interleukin-1alpha 1
FGFR2b-mediated 1
anti-acne 1
FGFR2b-signaling. 1
intracts 1
androgen- 1
factor-signaling 1
high-intensity, 1
narrow-band, 1
(ClearLight) 1
16-56 1
sebum 1
pustules 1
acnes 1
ClearLight 1
ClearLight. 1
mandibular-otic 1
approach]. 1
(E4s) 1
HA-ubiquitin 1
his-ubiquitin; 1
(URC) 1
ligase; 1
URC 1
E4; 1
Auto-ubiquitination 1
ubiquitins, 1
polyubiquitinate 1
E2s. 1
autocatalysis 1
Hdm2/p53 1
p53-Hdm2 1
Hdm2-mediated 1
(papillary, 1
medullary) 1
Hdm2, 1
bortezomib-nutlin-3 1
Hdm2 1
Unlocking 1
loop: 1
Mdmx/Mdm2 1
portrays 1
elaborate, 1
fine-tuned, 1
HAUSP, 1
MTBP. 1
gamma-irradiation, 1
(itself 1
MDM2/MDMX 1
RFD, 1
RFD 1
AD-lacking 1
hNumb, 1
UAS/GAL4 1
p53-HDMX 1
FKBP25, 1
immunophilin, 1
25kDa 1
(FKBP25), 1
MDM2-interacting 1
auto-ubiquitylation 1
ubiquitination/degradation. 1
p53-MDM2. 1
-dicentrine 1
J/m2, 1
Adriamycin-induced 1
val-->ala) 1
control-transfected 1
p53-sensitive 1
Subchronic 1
range-finding 1
chromodacryorrhea, 1
Marked, 1
Lymphoid 1
(spleen, 1
node), 1
hypocellularity 1
SV40- 1
Virus-transformed 1
A-T, 1
mAMSA-dependent 1
(5-10-fold) 1
protein-denaturing 1
Xeroderma 1
1,8-dihydroxyanthraquinones 1
stronger, 1
danthron 1
Anthraquinone-induced 1
alkylator 1
methanesulfonate. 1
anthraquinone-induced 1
N-benzyladriamycin 1
288). 1
N-Benzyladriamycin 1
288) 1
lipophilic, 1
(DOX). 1
II/DNA 1
II-catalyzed 1
CCRF-CEM 1
J774. 1
3'-hydroxy-3'-deaminodoxorubicin 1
288. 1
aminosugar 1
AQ4N, 1
cytotoxin, 1
(22.5-447 1
Amonafide: 1
Pgp-mediated 1
(efflux) 1
sAML, 1
sAML 1
Bisindenoisoquinoline 1
bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane 1
727357), 1
Indenoisoquinolines 1
(Top) 1
camptothecins 1
Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}-propane 1
727357) 1
Submicromolar 1
Top2-DNA 1
MJ-III-65 1
706744, 1
6-[3-(2-hydroxyethyl)aminopropyl]-5,6-dihydro-5,11-diketo-2,3-dimethoxy-(methylenedioxy)-11H-indeno[1,2-c]isoquinoline 1
Top2. 1
(combilexins) 1
conformatively 1
acridone, 1
acridine, 1
iminostilbene 1
pyrrole 1
battling 1
camptothecins. 1
(beta-lapachone, 1
diospyrin, 1
topostatin, 1
topostin, 1
flavonoids) 1
AT-specific 1
2',5'-bi-1H-benzimidazole, 1
2',(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl), 1
trichloride 1
(Ho33342), 1
VP16-213 1
'cleavable 1
scisson) 1
novobiocin 1
'rational 1
DNA-intercalators, 1
clinically-used 1
structure-experimental 1
chemists, 1
ligand/DNA 1
quinonoid 1
chromophores. 1
neocryptolepine. 1
Indoloquinoline 1
indolo[2,3-b]quinolines 1
Poct 1
carboxyfluorescein-trapped 1
(DMPC) 1
dimyristoylphosphatidylcholine:dimyristoylphosphatidylglycerol 1
(DMPC:DMPG, 1
9:1 1
pKa, 1
(HC50) 1
0.12-0.88 1
ghosts' 1
Bis-intercalative 1
chlorides 1
6-chloro-2-methoxy 1
substituted) 1
(CH2)4 1
(CH2)12 1
(CH2)4-linked 1
(CH2)6-, 1
(CH2)8-, 1
(CH2)10-linked 1
bisacridinium 1
(CH2)10- 1
(CH2)12- 1
[Ru(bpy)(2)(dppz)](2+) 1
(bpy=2,2'-bipyridine; 1
dppz=dipyrido[3,2-a:2,',3'-c]phenazine) 1
(1)H-NMR 1
orbitals 1
excited-state 1
density-functional 1
(DFT) 1
time-depended 1
DFT 1
(TDDFT) 1
planarity, 1
Helvetica 1
Chimica 1
Zürich. 1
duocarmycins 1
Pulse 1
contour-clamped 1
DNA-fragmenting 1
Duocarmycins 1
(DUMs), 1
ultrapotent 1
(kbp). 1
DUMA, 1
DUMB1 1
DUMB2 1
(mAMSA) 1
mAMSA, 1
mitoxantrone-induced 1
intercalators--4'-(9-acridinylamino)methanesulfon-m-anisidide 1
(2-Me-9-OH-E+)--differ 1
complexes). 1
(m-AMSA 1
2-Me-9-OH-E+) 1
2-Me-9-OH-E+). 1
aniline 1
drug-protein 1
N-phenylmethanesulfonamide, 1
anilino 1
asulacrine 1
(N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide 1
dihydrochloride), 1
co-incubation 1
N-phenylmethanesulfonamide. 1
HCT-8 1
o-AMSA, 1
methoxy-substituted 1
methyl-N-phenylcarbamate 1
amsacrine. 1
non-DNA-bound 1
Extractable 1
methyl-N-phenylcarbamate. 1
4196-4203, 1
Luethy 1
265: 1
16521-16526, 1
X-irradiation 1
Novobiocin 1
UV- 1
Lerman 1
metallointercalators, 1
trans-diamine 1
Pt(II) 1
"piano-stool" 1
Os(II) 1
[(η(6)-arene)Ru/Os(XY)Cl](+). 1
ethylenediamine 1
(en), 1
tetrahydroanthracene, 1
biphenyl, 1
p-cymene. 1
Arene-nucleobase 1
distortions, 1
arene. 1
cross-resistance, 1
non-cross-resistant 1
nonintercalating 1
Account, 1
Ru(II)- 1
Os(II)-arene 1
arene-DNA 1
intercalation. 1
N7-alkylating 1
metallated 1
{(η(6)-biphenyl)Ru(ethylenediamine)}(2+) 1
{(η(6)-tetrahydroanthracene)Ru(ethylenediamine)}(2+) 1
6-mer 1
ascidian: 1
dehydrokuanoniamine 1
kuanoniamine 1
eilatin 1
Fijian 1
ascidian. 1
pyridoacridine, 1
diplamine 1
(TOPO) 1
(kDNA) 1
pyridoacridines' 1
pyridoacridines&apos; 1
anthracyclines: 1
AD32 1
pUC18 1
AD32, 1
0-50 1
3&apos;-methoxy 1
three-plasma 1
three-miRNA 1
0.953 1
0.924-0.984). 1
[MSG; 1
(BW)/day] 1
sow-reared 1
mGluR1, 1
mGluR4, 1
BW/day 1
(GLAST). 1
GFAP-WT 1
mGluR-agonist 1
DHPG. 1
DHPG-exposed 1
ezrin-dependent 1
GLT-1-dependent 1
(SIRT)4, 1
sirtuin, 1
GLT-1, 1
L-Glutamate 1
microvasocular 1
(HBMEC) 1
(FBS) 1
[AM(-S)]. 1
AM(-S) 1
membrane-cytoskeleton 1
l-glutamate 1
HBMEC. 1
l-Glutamate 1
hGluT-1 1
threo-3-methylglutamate, 1
(2S, 1
4R)-4-methylglutamate 1
L-serine-O-sulfate 1
(N206S) 1
dihydrokainate 1
EAAT 1
GRP-derived 1
dihydrokainate) 1
EAAT2b, 1
gamma-Aminobutyric 1
(Glu) 1
midpiece 1
dihydrokainic 1
(DHK, 1
GLT1-selective 1
DL-threo-beta-hydroxyaspartic 1
(THA, 1
(GLT1 1
(NR1, 1
GluR6, 1
KA2) 1
(MRP4) 1
(MRP4/ABCC4) 1
5-HT4a 1
(5-HT4R) 1
transit. 1
(a, 1
peptide-affinity 1
5-HT4(e)R. 1
microvilli, 1
(upon 1
(SNX27a 1
Cytohesin 1
(CASP) 1
cytokine-inducible 1
Cytohesin/ARNO 1
nucleotide-exchange 1
Cytohesins 1
ARFs, 1
coiled-coil, 1
pulldowns 1
(SNX27). 1
CASP's 1
tumor-engaged 1
NK-92 1
Nexin 1
uropod, 1
SNX27, 1
Kir3.3 1
Kir3.2c 1
(-ESKV), 1
(-ESEI) 1
Kv1.4 1
(-ETDV). 1
(NR2C). 1
(PX) 1
(SNXs) 1
(Psd-95/Dlg/ZO1) 1
(NR2C) 1
SNX27-interacting 1
SNX27(-/-) 1
Subunit-specific 1
SNX27b 1
subunit-specific 1
SpliceDB: 1
(SpliceDB) 1
gene-centered 1
Infogene 1
3.73% 1
(91.23%) 1
Centre: 1
http://genomic.sanger.ac. 1
uk/spldb/SpliceDB.html 1
http://www.softberry. 1
com/spldb/SpliceDB.html. 1
multiplexing. 1
proteomists 1
"difference 1
electrophoresis" 1
"DIGE" 1
inconveniences. 1
desorption/ionization-time-of-flight-MS, 1
stain: 1
inter-protein 1
linear-dynamic 1
in-gel, 1
Blue--speed 1
sensitivity? 1
(Z-CyDyes) 1
2D-gel 1
fluorophores. 1
CyDyes 1
smearing 1
(Z-CyDyes). 1
titratable 1
CyDyes, 1
(2D-DIGE) 1
informatively, 1
(1DE) 1
(2DE), 1
Neuhoff 1
(NCCB) 1
SR; 1
gel-resolved 1
proteomes; 1
optimised, 1
(leaf) 1
NCCB, 1
dive: 1
fingers' 1
silver'. 1
Gel-based 1
protein-expression 1
respected. 1
0.0048 1
0.0480 1
μg/μL. 1
silver-stained 1
fixing, 1
rinsing, 1
soaking 1
impregnating 1
-combines 1
"foreign." 1
existing, 1
cells--an 1
process--is 1
clinical-grade 1
therapeutics: 1
therapeutics--matched 1
aptamer-antidote 1
(TRAs). 1
TRAs 1
Tumour-targeted 1
Delivery. 1
cangrelor, 1
ticagrelor 1
(AZD6140). 1
(Macugen), 1
ranibizumab 1
(Lucentis) 1
(Avastin). 1
Convincing 1
nourishment 1
biotech, 1
investing 1
cytokine-traps, 1
cellular-based 1
wide-scale 1
aptus 1
fit), 1
arenas. 1
"aptamers") 1
Multicolored 1
(TR4) 1
Foc, 1
planting. 1
(RealAmp) 1
pg/µl 1
spores/g 1
closed-tube 1
Cavendish, 1
(indels) 1
GFP-expressing 1
ethylene-responsive 1
(ERF) 1
TR4. 1
avendish, 1
Rottler): 1
volatiles. 1
Intercropping 1
Rottler) 1
(Fusarium 1
wilt) 1
leachates. 1
organosulfur 1
trisulfide, 1
trisulfide) 1
chive. 1
2-Methyl-2-pentenal 1
μl/l 1
cropland 1
biodiversity. 1
Defense-Related 1
Plants: 1
(Grand 1
Naine 1
(POX), 1
(PPO), 1
β-1,3 1
glucanase, 1
chitinase, 1
phenolics. 1
Plant's 1
productions. 1
1960. 1
trades 1
plantains. 1
2-hydroxy-9-(p-hydroxyphenyl)-phenalen-1-one, 1
phenalenone-type 1
(AAA), 1
Nain) 1
(MSB), 1
biosynthesis) 1
MOR1 1
ligand-initiated 1
Opioid-like 1
α-actin, 1
(Grp78, 1
PDI, 1
Hsp47) 1
(BLSS): 1
Neuhauser 1
dyssynostosis, 1
(C1368) 1
(PI). 1
Cignal 1
(etoposide 1
cisplatin) 1
C1368 1
Sigma 1
IC(30) 1
IC(50), 1
Myc. 1
medulloblastoma: 1
Kip1 1
(mTOR)-suppressing 1
(GSK-3 1
alpha/beta) 1
p27(Kip1), 1
mTOR-dependent, 1
hedgehog/Patched 1
(Shh/Ptc) 1
RCAS/tv-a 1
Shh, 1
(Shh)/Patched 1
factor-II, 1
(VC312) 1
(Daoy) 1
p21Cip1, 1
(Tyr(705)) 1
vanadate, 1
cilia-associated 1
hedgehog-dependent 1
Shh-stimulated 1
3'-kinase/AKT 1
Hedgehog-induced 1
Ser473-phosphorylated 1
(p)-AKT 1
3'-kinase/ 1
Hedgehog--Gli 1
paradevelopmental 1
Hedgehog-Gli 1
Gli1+ 1
Twist: 1
(EMTs), 1
'personalized' 1
ApcMin/+, 1
18q21.1-q21.2. 1
18q21.1-q21.2 1
(5q22.2 1
18q21.1-q21.2) 1
untangling 1
(CNAs), 1
(Nf1) 1
U-turn 1
(TFAM) 1
U-turn, 1
∼100nm 1
nucleoid: 1
mtDNA's 1
"extranuclear" 1
mitochondria-to-nucleus 1
HEPG2 1
protonmotive 1
canceling 1
ΔΨ(m), 1
valinomycin; 1
MFN2. 1
reintegration. 1
spacing, 1
1.10±0.2 1
Reintegration 1
reconnection 1
disintegrated 1
nucleoid-centric, 1
icons 1
nucleoid--detailed 1
crosscut 1
Nucleoids 1
autonomy: 1
(TFAM), 1
first-identified 1
Nonidet-P40 1
(ClO(4)) 1
(4-32), 1
(4-28) 1
pmol/liter 1
(4-20) 1
(values 1
8.3%. 1
Euthyroidism 1
(n=24; 1
AIT) 1
Endocrinology 1
1997-2010. 1
(EF<40%, 1
n=9) 1
(40%≤EF≤50%, 1
(EF>50%, 1
28.2±7.2 1
38.3±6% 1
57.1±3.0 1
59.8±6.6%, 1
P=0.242). 1
67±42 1
prednisone: 1
(AMIO-ON, 1
(AMIO-OFF, 1
0.326). 1
readministration 1
continuation. 1
AIT; 1
glucocorticoids; 1
(MMI) 1
(GLU) 1
(MMI-GLU 1
(healing) 1
85.7 1
0.730). 1
53.5-66.5 1
15.1-26.9 1
d). 1
Radioactive 1
hormone; 1
(RAI) 1
questioned, 1
RAIU. 1
adjusted-dose 1
echotexture 1
(<4%) 1
autoantibodies-all 1
29-80 1
(R50, 1
(EX, 1
(EX50, 1
hour/day, 1
days/week, 1
Na+/Ca+2 1
(L-channel), 1
(RYR), 1
(CQS) 1
(TRα1 1
TRβ1) 1
real-time. 1
L-channel. 1
NCX. 1
CQS 1
NXC. 1
TH-receptor 1
Enanthema 1
1-infection. 1
(HFPEF) 1
ventricular-arterial 1
HFPEF-model. 1
(db/db), 1
If-inhibitor 1
(db/db-Iva) 1
distensibility 1
(Ees) 1
db/db-Iva 1
Ees 1
MPI 1
0.0042). 1
encouraging: 1
If-channel 1
(HFpEF). 1
exertional, 1
METs 1
METs, 1
(14.0 1
ml/min/kg, 1
load-corrected 1
(Use 1
Exertional 1
Congestion; 1
ACTRN12610001087044). 1
(TFTs) 1
[TSH], 1
[T3] 1
occasions: 1
[45.7%], 1
(11.4%) 1
prerenal, 1
(prerenal 1
renal), 1
(n=13, 1
37.1%) 1
derangement. 1
(0.93 1
µU/mL, 1
0.35-2.27 1
µU/mL)and 1
(ro=-0.382; 1
AKI) 1
(hospital 1
(~70%), 1
improves. 1
47.8 1
[IL-6, 1
levels] 1
26; 1
inter-current 1
-0.61, 1
inflammation-malnutrition 1
(LBM-Cr), 1
(nPCR) 1
LBM-Cr, 1
nPCR, 1
LVMI, 1
0.017, 1
(0.01-2.98) 1
71.7% 1
(hs-CRP). 1
disappear. 1
67.9 1
(Kaplan-Meier) 1
microU/ml, 1
1.26 1
ng/dl, 1
33.6 1
FT3. 1
0,001; 1
CI; 1
1.73). 1
Kaplan-Meyer 1
fT3)) 1
(HR=0.50, 1
0.35-0.72) 1
local/systemic 1
Vitamin, 1
instituted. 1
fundamental. 1
Gerodontology 1
neurophysiologic, 1
subclinical, 1
hypoesthesia 1
(50-65%) 1
(20-25%) 1
mandibular, 1
(20-40%) 1
bilineage 1
mesenchymal/basal 1
luminal/basal 1
CD44(hi)/CD24(-) 1
CD44(hi)/CD24(lo) 1
oncogene-transformed 1
(HER2+, 1
Up-regulated 1
(NIF) 1
intra-sample 1
tumour/benign 1
tumour), 1
TIF, 1
TIFs, 1
blood/plasma/secretome 1
(ER(-)) 1
ErbB2+ 1
system-wide 1
(SILAC), 1
8,750 1
7,800 1
paclitaxel/radiation 1
paclitaxel/radiation. 1
(NR). 1
basal-like, 1
PR-). 1
sloughed, 1
1,6-bisphosphate 1
overexpresing 1
Basal-like 1
(Bis) 1
Bis-binding 1
(MDA-MB-231). 1
nucleoside-triphosphatase 1
(21%). 1
Bis-probe, 1
Bis 1
(SRPK1) 1
(PKR) 1
elevated-plus 1
(EPM), 1
(OFT), 1
(FST) 1
Rapamycin-treated 1
EPM/OFT 1
FST, 1
tumour-like 1
tumourigenesis.Despite 1
white-grey 1
hamartin. 1
(hRheb) 1
cocrystallized 1
GppNHp 1
hanging-drop 1
44.5, 1
52.3, 1
hRheb-GppNHp 1
102.9, 1
99.2, 1
hRheb-GTP 1
102.4, 1
98.3, 1
P2(1), 1
77.3, 1
47.9, 1
89.0 1
R-AXIS 1
IV++ 1
hRheb 1
insulin/TOR 1
endoreplicating 1
ploidy. 1
suspends 1
instar. 1
TOR. 1
growth-inhibitors, 1
(S6K). 1
scierosis. 1
TSC1) 1
(TSC2) 1
Tsc 1
amino-acid-TOR 1
(TOR) 1
TOR-mediated 1
(CFS) 1
CFS. 1
15-45 1
Pericytopathy: 1
pericyte's 1
Ren2 1
hypercellularity, 1
antipericyte 1
pericytopathy 1
rarefaction. 1
Shenzhen]. 1
Xinjiang 1
Shenzhen. 1
Shenzhen 1
(8-OH-dG) 1
stay,a 1
oliveira 1
tail/head 1
8-OH-dG 1
spouses, 1
33.1% 1
19.7% 1
(≥3 1
(r=0.946; 1
(V(o2 1
peak)) 1
donned 1
liquid-conditioned 1
C/h) 1
no-exercise 1
V(o2 1
peak) 1
(Tcore) 1
Tcore 1
(degrees 1
diminish, 1
(VO2max) 1
mb) 1
To) 1
0.12)% 1
56.53 1
1.56)ml.kg-1 1
44.78 1
2.39)ml.kg-1 1
76.08 1
2.81)% 1
To. 1
(MDR 1
once/day 1
P450-3A 1
bedaquiline's 1
reorganized. 1
Extragastrointestinal 1
myth? 1
IDA, 1
co-determine 1
Infection, 1
Mainly 1
0.89-1.67). 1
0.45-1.31). 1
gene-A-seropositive 1
(CagA) 1
CBMdisc, 1
infective, 1
3.27) 1
1.70, 1
2.62), 1
helicobacter 1
DM; 1
anti-H 1
76.7% 1
[Does 1
gastritis, 1
extradigestive. 1
platelet-H. 1
dyslipidemic 1
hypercoagulability, 1
receptor-lipopolysaccharide 1
(80.0% 1
60.0%, 1
(87.7%, 1
21.6%, 1
57.6%, 1
23.2%. 1
2003-04. 1
64.3+/-10 1
61.73 1
IgA) 1
proved, 1
Fukuoka 1
(FHAT). 1
(Fukuoka, 1
9.68; 1
3.56-33.08, 1
0.03-1.53). 1
in-patients 1
depravation 1
Townsend 1
(274/398 1
(69%)) 1
(206/352 1
(58.5%)). 1
1.33) 1
1.28). 1
extradigestive 1
(pts) 1
(13)C-Urea 1
(UBT), 1
anti-CagA 1
(LDL)-cholesterol, 1
re-examined. 1
83.75% 1
(33.75%). 1
gene-A--positive 1
(CagA), 1
70.2% 1
(P=NS), 1
19.7%, 1
6.49; 1
17.9%, 1
8.64; 1
(2.00+/-3.43 1
CagA-negative 1
(1.31+/-1.72 1
(P=0.072, 1
BAT.MA.N. 1
(232 1
64/80 1
190/320 1
45/58 1
139/232 1
(59.9%) 1
51/88 1
pylori-negative 1
Erlangen 1
(TOAST) 1
[Ischemic 1
("classical") 1
(58.8% 1
44.5%, 1
1.14-2.77), 1
1.02-2.60). 1
1.44-4.63), 1
1.12-4.38), 1
0.66-2.02), 1
p=0.5). 1
(29.7) 1
(26.2)%, 1
(59.6% 1
p=0.9) 1
(MPT), 1
(dB), 1
jitter, 1
(NHR), 1
diadochokinesis 1
MPT, 1
dB, 1
/K$\inve$/ 1
post-test. 1
[pa-ta-ka], 1
[pa] 1
[i-u]. 1
inter-syllabic 1
apraxic 1
Merwe's 1
(1997). 1
therapists. 1
Raters 1
therapists, 1
unreliability 1
temporal-acoustic 1
prevocalic 1
VOT, 1
postvocalic 1
phoneme-specific 1
phonemes 1
(Bakis, 1
Ergodic) 1
phoneme 1
speaker's 1
phonemes. 1
(topology 1
Phonation 1
otorhinolaringological 1
23-90 1
4-24 1
bearing. 1
t-BHP. 1
(CsA)-induced 1
[FoxOs; 1
(p-FoxO1) 1
(p-FoxO3a)] 1
(MnSOD), 1
hemeoxygenase-1. 1
p-FoxO1 1
p-FoxO3a 1
Bim. 1
FoxO-mediated 1
apoptosis-induction 1
(GOD), 1
8-OHdG. 1
Bim-the 1
FoxO3a-siRNA 1
GOD-induced 1
MnSOD, 1
Cu/ZnSOD, 1
LINX™ 1
(GORD) 1
LINX-related 1
GORD 1
Associates 1
fundoplication. 1
(LNF), 1
LNF, 1
flatulence, 1
re-admissions 1
LNF. 1
self-referred 1
GERD; 1
Nonmedical 1
(NERD), 1
NERD. 1
Antireflux 1
NERD-related 1
LINX� 1
Jansky-Bielschowsky 1
strokelike 1
Sandhoff's 1
(neuraminidase 1
GM1-gangliosidosis--pathophysiology 1
(adult 1
(proband): 1
grimace, 1
grimace 1
bedridden 1
mandibule. 1
board. 1
Slit-lamp 1
10-11, 1
data.(ABSTRACT 1
GM1-gangliosidosis. 1
Chinese: 1
alpha-Galactosidase 1
β-d-galactosidase. 1
reported). 1
(p.M1?, 1
p.E129Q, 1
p.G134R, 1
p.L236P, 1
p.G262E, 1
p.L297F, 1
p.Y331C, 1
p.G414V, 1
p.K493N, 1
p.L514P, 1
p.P597L, 1
p.T600I), 1
(c.246-2A>G, 1
c.397-2A>G, 1
c.552+1G>T, 1
c.956-2A>G), 1
(p.R22Qfs*8, 1
p.L24Cfs*47, 1
p.I489Qfs*4) 1
(p.Q452*). 1
c.75+2InsT 1
p.L337P 1
β-d-galactosidase 1
(201Arg-->Cys), 1
1/2-hour 1
beta-Galactosidase 1
asialo 1
(GA1) 1
imino 1
(NB-DGJ) 1
(p-2) 1
(GA1, 1
NB-DGJ-treated 1
p-2 1
p-21. 1
3.2.1.23) 1
Morquio's 1
(Morquio 1
skeletal-connective 1
Cross-correction 1
retrovirus-modified 1
gangliosidosis]. 1
(beta-galactosidosis). 1
(R201C) 1
galactosialidosis. 1
GlcCer, 1
LacCer, 1
GbOse3Cer, 1
GbOse-4Cer 1
nLcOse4Cer 1
asialo-GM1, 1
autopsized 1
(CHA) 1
commenting 1
postcerebral 1
emigrating 1
Treatment-refractory 1
dyke-davidoff-masson 1
woman---a 1
late-diagnosed 1
schizencephalic 1
anesthesiologist. 1
sufferer 1
DDMS, 1
trephination. 1
(73.5%) 1
(30.8%). 1
perimesencephalic 1
sulcal 1
unilaterally 1
diploic 1
roof, 1
hypoplasia/atrophy 1
complimentary, 1
hemiparesis/plegia, 1
amalgam. 1
Crossed 1
cerebro-cerebellar 1
facial-asymmetry, 1
cerebrocerebellar 1
[DDMS]) 1
cytidine-5'-diphosphate-1,2-diacyl-sn-glycerol 1
dysfunction.We 1
acyltranferase 1
(Taz1) 1
blue-native 1
Digitonin 1
I/III(2)/IV 1
I/III(2) 1
supercomplexes, 1
(TAZ 1
full-length) 1
collecting, 1
non-productive. 1
shRNAs. 1
TAZ-specific, 1
scrambled, 1
DIOC6 1
zVAD-fmk 1
Taffazin 1
(TAZ), 1
(c.584G>T; 1
c.109+6T>C; 1
c.86G>A). 1
tetra-linoleoyl 1
clock; 1
aging; 1
Bmal1-/- 1
(lungs, 1
brain-based 1
emotions. 1
habituation, 1
(repressors 1
BMAL1-mediated 1
theClock 1
BMAL1:CLOCK 1
(Wnt10a, 1
Dishevelled2, 1
TCF3) 1
[Three-dimensional 1
Polycomb-Group 1
PcG-bound 1
"Chromosome 1
Capture" 1
(DNMT): 1
(PRC1 1
PRC2) 1
PRC1/PRC2 1
HAND1, 1
HMX2, 1
SIX3, 1
PRC1. 1
RA-responsive 1
Hoxa1, 1
(specifically, 1
H4), 1
[Localization 1
spread]. 1
line-Hca-F, 1
line-Hca-P) 1
difference-gel 1
DIGE) 1
Immunofluorescence, 1
kinase-associated 1
CLIC3. 1
(NCC27/CLIC1) 1
p64. 1
CLIC 1
transducers. 1
(CK1delta) 1
(SBVS) 1
amino-anthraquinone 1
(derivatives 1
(IC(50)=0.3 1
sulfatide- 1
cholesterol-3-sulfate-binding 1
[sulfatide 1
cholesterol-3-sulfate 1
(SCS)] 1
[myelin 1
GTPase)] 1
p8 1
(positions 1
38-118) 1
M103 1
SCS; 1
CH-3S 1
CK1delta; 1
M103, 1
K-G-R; 1
(SCS-BPs) 1
(delta, 1
(MBP 1
TP) 1
CK1gamma. 1
(RhoA) 1
SCS, 1
CK1gamma 1
CK1; 1
Ck1alpha 1
serine/threonine, 1
[pS(-3)] 1
[pS(-4)] 1
pS(-4) 1
pS(-3) 1
K229KQK232 1
alanine-scan 1
n-4. 1
(Ser45) 1
acidic/phosphorylated 1
D4476, 1
cell-permeant 1
FOXO1a. 1
(MPDs). 1
O1a 1
(FOXO1a) 1
Ser322 1
Ser325 1
MPD, 1
CK1-mediated 1
MPD 1
FOXO1a 1
IC261 1
CKI-7, 1
(PP-1) 1
(I-2) 1
Ser86. 1
Ser174, 1
67-93 1
(Thr72), 1
p34cdc2 1
I-2(67-93), 1
72-93 1
78-93, 1
heptadecapeptide 1
(78-93). 1
(166-180) 1
(78-93) 1
SerP/ThrP-Xaa-Xaa-Ser/Thr, 1
[Flotow, 1
Graves, 1
Fiol, 1
Roeske, 1
Roach, 1
14264-14269; 1
Meggio, 1
Perich, 1
Reynolds, 1
Pinna, 1
Lett. 1
303-306] 1
GSK3, 1
SerP/ 1
ThrP-Xaa-Xaa-Ser/Thr 1
062 1
2514 1
(2.18 1
100-patient-years, 1
(4.78 1
(3.55 1
0.77). 1
Pinteraction 1
Once-daily 1
(principal 1
(14.9 1
events/100 1
1.11). 1
(<65, 1
pinteraction 1
0.59). 1
13,455), 1
781) 1
current/prior 1
(DBP) 1
Rivaroxaban: 1
(ECV), 1
(PCV), 1
321; 1
161] 1
160] 1
3.11), 1
3.55), 1
1.75; 1
3.42) 1
2.01; 1
2.68), 1
1.86%) 1
3.73%) 1
[ROCKET 1
AF]; 1
17.02 1
18.26 1
0.70-1.29), 1
0.23-1.14). 1
(P=.090 1
.776 1
(OACs) 1
≥75, 1
(apixaban 1
-$825, 1
=-$23), 1
$180 1
-$254, 1
-$367, 1
-$88, 1
OACs. 1
Drawbacks 1
Thienopyridine 1
Syndromes-Thrombolysis 1
(ATLAS 1
2-TIMI) 1
exercised, 1
XANTUS: 1
(Xarelto(®) 1
postauthorization, 1
(XANTUS-EL 1
America] 1
XANAP 1
Asia-Pacific]) 1
Asia-Pacific. 1
(14.1%) 1
[2.01 1
2.43%; 1
0.55-1.27] 1
(1.96 1
2.22%; 1
0.75-1.07; 1
1.05-1.49) 1
(14.2% 1
14.1% 1
0.94-1.10; 1
0.034), 1
'non-valvular 1
stroke-preventive 1
14,171 1
5239 1
(37%). 1
38%) 1
(5·41 1
4·30 1
patients-years; 1
1·17; 1
1·04-1·32; 1
p=0·0093), 1
(3·55 1
2·69 1
1·19; 1
1·03-1·39, 1
p=0·0201), 1
(1·68 1
1·12 1
1·36; 1
1·08-1·70, 1
p=0·0076). 1
HealthCare 1
AG. 1
(cTTR) 1
Rosendaal 1
INRs 1
finger-stick 1
interaction=0.71). 1
interaction=0.001), 1
cTTR. 1
(TIs) 1
TIs 1
AF), 1
(3-30 1
4692 1
(n=483) 1
(0.30% 1
interval]=0.74 1
[0.36-1.50]; 1
P=0.40). 1
(0.99% 1
interval]=1.26 1
[0.80-2.00]; 1
P=0.32). 1
AF.J-ROCKET 1
curator’s 1
knowledge-base 1
components.SPIKE 1
http://www.cs.tau.ac.il/&amp;~spike/) 1
Accentuate 1
negative: 1
(BLAST). 1
1628 1
PAGE) 1
slug. 1
immobilised 1
3.5-10) 1
(SDS)-PAGE 1
Micropreparative 1
electroblotted 1
polyvinylidene 1
difluoride 1
(PVDF) 1
amido 1
(pI) 1
(M(r)) 1
ExPASy 1
AAcompID 1
(http:// 1
expasy.hcuge.ch/ch2d/aacompi.html). 1
(matrix-assisted 1
10,300 1
[CAA]n, 1
Triplet 1
amoebozoa 1
proteome) 1
redundant) 1
dissipation), 1
Ros 1
starved, 1
macropinocytic 1
soil-living 1
Axenic 1
2108 1
(PSVs) 1
entire, 1
(thioredoxin 1
(rab7 1
calfumirin-1 1
calreticulin) 1
(actin 1
coactosin 1
PSV 1
Perilipins: 1
mal-adaptive 1
(obesity 1
complications) 1
lipocytotoxicity 1
urging 1
(FA)-induced 1
(IMTG) 1
(LIPID, 1
(SALINE). 1
SALINE. 1
FAT/CD36 1
glycerol-3-phosphate 1
(GPAT, 1
GPAT1 1
FAT/CD36), 1
(GPAT), 1
cross-breed 1
semimembranosus 1
PLIN1-stained 1
PLIN2-positive 1
IMF-divergent 1
extra-myocellular 1
intra-myocellular 1
LSDP5; 1
HSL-mediated 1
(OXPAT)/lipid 1
lipolytic). 1
(SNAREs), 1
[adipocyte 1
(ATGL)] 1
[Comparative 1
Identification-58 1
(CGI-58)], 1
OXPAT)/lipid 1
TIP47, 1
adipophilin. 1
heterogeneous: 1
S3-12 1
oleate-treated 1
oleate-dependent 1
oleate-induced 1
non-lipid 1
adipophilin, 1
genetics]. 1
polytenic 1
Teachers 1
demoiselle 1
trendy 1
mesmerising 1
lethal? 1
shutting 1
Mary 1
raised: 1
metamorphosis? 1
initiated? 1
gametogenesis? 1
retraces 1
"par 1
excellence" 1
INTRODUCTIONThe 1
<12.5 1
(dpc). 1
efficiency: 1
sexed 1
(Xi), 1
(Xa 1
territories). 1
XX) 1
X-specific 1
compositive 1
3D-reconstructed 1
flatter 1
rounder 1
dimensionless 1
roundness 1
0.1). 1
painted. 1
collimation 1
Ambient 1
etched 1
ionized 1
electrospray. 1
plume. 1
collimation, 1
~13, 1
amol 1
verapamil), 1
magnitude) 1
LAESI. 1
Collimation 1
'omics'. 1
sequencers. 1
biocatalysis. 1
microreactors 1
chemical) 1
biological) 1
fluxomics. 1
biocatalysis 1
bioprocess 1
EGF-receptor-mediated 1
0-5) 1
chambers, 1
on-chip, 1
'all-optical' 1
trap; 1
microcavitation, 1
micro-printed 1
agglomeration: 1
lipidomics, 1
off-machine 1
Xcalibur 1
peakwise 1
(intensity) 1
Pointwise 1
(m/z). 1
Xcalibur, 1
Agglomeration 1
https://github.com/optimusmoose/statistical_agglomeration. 1
Bin 1
Aggolmeration 1
MSpire, 1
https://github.com/princelab/mspire/. 1
positive- 1
negative-ion 1
wastes, 1
18:0/22:6, 1
18:0/20:4, 1
18:0/20:5 1
wastes 1
m/z. 1
lipidomics; 1
unfeasible 1
Multi-dimensional 1
Spectrom. 1
(2005), 1
367), 1
interrogation, 1
lipidome. 1
(ESI-MS/MS)-based 1
Holistic 1
(GoBioSpace), 1
un-targeted 1
intrasource 1
MDMS-SL 1
reverifies 1
MDMS-based 1
Sphingolipids 1
glycerophospholipid) 1
sphingolipidomes 1
(LN 1
4-9) 1
(GLR) 1
(GHR). 1
GHR. 1
progesterone-negative, 1
(Highly 1
Incompletely 1
absent). 1
2.17, 1
1.01-4.66) 1
6.35, 1
1.90-21.3) 1
breast-cancer-specific-survival 1
(BCSS). 1
315) 1
(DDFS) 1
0.07-4.98; 1
0.07-0.59; 1
0.03-2.02; 1
0.17-0.71; 1
Mammographic 1
metastasize, 1
(<or=2 1
0.2-25.2). 1
525), 1
3%) 1
439). 1
1.92-5.51; 1
.001]). 1
pT1ab 1
3.45 1
1.04-11.50, 1
.04]). 1
5395 1
2609 1
2635 1
[apixaban 1
therapy], 1
(<1.80) 1
(<3.5 1
NCT00643201). 1
ompared 1
anticoagulation: 1
antagonists? 1
Yes]. 1
(dabigatran). 1
Zymosan-induced 1
subside. 1
zymosan-induced 1
(PWF) 1
PWF, 1
zymosan-treated 1
3-hydroxybutyric 1
(3-HB) 1
PWF 1
zymosan-injected 1
β-oxidation. 1
(IL-1alpha) 1
Glutamate-stimulated 1
IL-1beta+TNFalpha. 1
GCMS-based 1
(PLS-DA), 1
indole-3-acetic 1
DSS. 1
(AAH), 1
Global, 1
Random-forest 1
lysolipids 1
glycodeoxycholate 1
erythron. 1
H63D 1
Ferroportin-1, 1
Epo, 1
hemoglobinization 1
anti-microbic 1
HFE-mediated 1
Styrylbenzimidazoles. 1
2-styryl-benzimidazoles 1
Poxviridae) 1
assays,against 1
MDBK, 1
anti-BVDV 1
1.7-16 1
CVB-2, 1
EC(50)= 1
(NTPase) 1
optima 1
MgCl2, 1
deoxyribopolynucleotide. 1
agents--Part 1
prosecution 1
2-diphenyl-benzimidazoles 1
5-Acetyl-2-(4'-nitrobiphenyl-4-yl)-1H-benzimidazole 1
(11,12,14,16,18,19,20,21,23,25-30) 1
MT-4 1
(CC50 1
tumours,using 1
1-substituted-2-[(benzotriazol-1/2-yl)methyl]benzimidazoles. 1
ssRNA+ 1
(HIV-1)), 1
picornaviruses 1
(Coxsackie 1
(CVB2), 1
type-1, 1
Sabin 1
(Sb-1)); 1
ssRNA- 1
(Respiratory 1
(RSV)) 1
(Vesicular 1
Stomatitis 1
(VSV)) 1
representative. 1
Reoviridae 1
(Reo-1). 1
(HSV-1; 1
Herpesviridae) 1
(VV; 1
RSV, 1
YFV, 1
CVB2. 1
2-arylbenzimidazoles 1
6-27 1
(6-MP), 1
Pestiviruses, 1
(NS3) 1
BVDV-infected 1
pestiviral 1
BVDV-1 1
Reduced-Nicotine 1
Cigarettes. 1
brands) 1
gram. 1
(16.5, 1
16.3, 1
Cigarettes 1
Products; 1
NCT01681875.). 1
Reduced-nicotine 1
semi-blinded 1
lozenge; 1
lozenge 1
addictiveness 1
Convention 1
microeconomics 1
(unit 1
price=cost/reinforcer 1
magnitude). 1
smoking-an 1
Planarians 1
wounding, 1
zic-1, 1
Zic-family 1
zic-1-expressing 1
descended 1
neoblasts. 1
double-RNAi 1
notum-expressing 1
foxD-expressing 1
injury-dependent 1
yorkie/YAP 1
yorkie 1
(yki; 1
(protonephridial) 1
WNT/β-catenin 1
sedated, 1
ill, 1
intubated. 1
Experienced 1
"expert 1
raters." 1
(PFSS), 1
Richmond 1
(PCPC) 1
nurse-rater 1
pattering 1
alginate/acrylamide 1
UV-curable 1
Gel-SC) 1
printer. 1
inks 1
dry. 1
"rule 1
mixtures" 1
interweave 1
two-dimensional, 1
nanoelectronic 1
load-bearing 1
multi-head 1
Electrospinning 1
five-layer 1
layered 1
cartilage-like 1
epoxy-based 1
ink 1
composites 1
multiscale, 1
high-aspectratio 1
balsa 1
wood. 1
3D-printed 1
attainable, 1
metal, 1
ink-based 1
(ink 1
paper). 1
prototypes. 1
customisation 1
ophthalmology. 1
eyeglasses, 1
revolutionise 1
eyeglass 1
blueprints. 1
4-hydroxyospemifene 1
4'-hydroxyospemifene. 1
(CV%) 1
(21.3) 1
(18.0) 1
4-hydroxyospemifene, 1
ospemifene: 1
agonist/antagonists 1
mucification 1
panel's 1
government-approved 1
moisturizers, 1
(indicated 1
dyspareunia). 1
about, 1
diagnosing, 1
Nonhormonal 1
(VVA), 1
(search 1
"[Selective 1
SERM] 1
[Vulvar 1
Vaginal] 1
Atrophy"), 1
agonists/antagonists 1
phamacodynamic 1
(maturation 1
dyspareunia) 1
lubricant 1
pramipexole: 1
(RLS)-related 1
73). 1
[WASO], 1
WASO 1
(-27.1 1
-26.9 1
pramipexole) 1
(-2.7 1
-7.9 1
0.0001]) 1
26.8 1
pramipexole). 1
(20.9 1
0.0001]). 1
(PLMAI) 1
PLMA/h 1
0.0001]), 1
identifier, 1
NCT00991276; 1
http://clinicaltrials.gov/show/NCT00991276. 1
improved"), 1
(reduction) 1
(71.4% 1
46.8%, 1
P=0.08). 1
NCT00806026.). 1
(RLS/WED). 1
evidence-grading 1
Pramipexole, 1
ropinirole 1
year); 1
α2δ 1
impression-improvement, 1
(PLMI), 1
(9596 1
0.78), 1
-5.12 1
levetiracetam), 1
-4.59 1
PLMI 1
(-22.50/h), 1
(-26.01/h), 1
(-34.46/h) 1
levetiracetam; 1
-8.48/h) 1
(-13.10/h). 1
SMD) 1
meta-regressions, 1
tried. 1
5-25% 1
hypocretins, 1
endorphins 1
tramadol. 1
3.0%. 1
RECOMMENDATIONS: 1
adults--an 1
meta-analyses: 1
Guideline. 1
AASM 1
ropinirole. 1
GUIDELINE 1
AGAINST 1
six-arm, 1
(N=137) 1
(E(max)) 1
(ED(50)) 1
(ED(90)) 1
37.3 1
dose-related. 1
[Restless-legs 1
Restless-legs 1
evening. 1
periodic-leg 1
deficit/hyperactivity 1
akathisia, 1
PLM. 1
severe-sleep 1
small-fiber 1
brain-iron 1
codeine; 1
(pramipexole, 1
rotigotine). 1
reesei. 1
reesei 1
CL847 1
Solka 1
Floc 1
cbh1/cel7a, 1
egl1/cel7b, 1
egl4/cel61a, 1
bgl1/cel3a, 1
bgl2/cel1a, 1
swo1 1
swollenin. 1
eel2 1
cel5b 1
EglD, 1
endoglucanase, 1
conidium 1
Breakage 1
reformation 1
expansins, 1
endo-beta1,4-glucanases. 1
swollenin, 1
cellulolytic 1
hydroponics 1
asperellum, 1
pki1 1
36-amino 1
36-mer 1
Botrytis 1
cinerea 1
syringae 1
pv 1
lachrymans 1
microbe-associated 1
Trichoderma-plant 1
100,000-fold; 1
choosing, 1
(ZFPs) 1
ZFPs 1
(ZFNs)) 1
convolutes 1
evinces 1
three-finger 1
constructions. 1
gene-modification 1
w5c1 1
s12c8, 1
modulated, 1
(X-CGD), 1
TALENs, 1
(Sigma-Aldrich) 1
(context-dependent 1
extractions 1
PIG-tailed 1
CopmoZr 1
(9-98%). 1
headache). 1
(>/=3 1
coughing. 1
Non-steroidal 1
64%). 1
postcraniotomy 1
neuroma, 1
apprehensive 1
Fears 1
determined: 1
(N540K) 1
(47,XX,+21/46,XX) 1
126.5 1
-3.76 1
Ventriculoperitoneal 1
suboccipital 1
adenotonsillectomy, 1
pressure-equalizing 1
arises; 1
kyphosis; 1
socialization 1
achondroplasia; 1
achondroplasia-specific 1
standards; 1
infancy; 1
myelopathy; 1
tympanometric 1
necessary; 1
Rear-facing 1
seats 1
soft-back 1
seats. 1
trampoline; 1
boards; 1
vaulting 1
gymnastics; 1
upside 1
condition), 1
system-coupling 1
G1138A 1
achondroplasia(ACH) 1
polymorphism(SSCP) 1
electrophoresis(DGGE). 1
pseudoachondroplasia(PSACH). 1
ACH, 1
SplI 1
3-generation 1
radicicol. 1
dissimilarities. 1
antitumoural 1
shibatae 1
IIB) 1
'Bergerat 1
fold', 1
cannot. 1
crenarchaeon) 1
euryarchaeon) 1
(7p12.1) 1
(7q21.11) 1
Semaphorins 1
A131T-SEMA3A, 1
S598G-SEMA3A 1
E198K-SEMA3D 1
A131T-SEMA3A 1
(8p12), 1
(ENS), 1
1/5000 1
butyrate: 1
impossibility 1
inactivating, 1
(SSCP), 1
branches: 1
uncle) 1
4q31-q32 1
(NPL) 1
(D4S413-D4S3351). 1
(12.2 1
Mb). 1
3p21. 1
RET-dependent 1
(S-HSCR) 1
HSCR-susceptibility 1
case-parent 1
five-marker 1
overtransmitted 1
(LES). 1
Titres 1
anti-acetylcholine-receptor 1
NCI-H209 1
NCI-H187. 1
tested), 1
H187 1
tested). 1
m(t)2 1
w-conotoxin 1
Apropos 1
(AChR) 1
ligand- 1
neuromyotonia 1
ganglionopathy 1
exchange) 1
(steroids 1
immunosuppressants). 1
myasthenia?]. 1
Anti-calcium 1
Tensilon 1
anti-acetylcholine 1
myasthenia. 1
Thoracotomy 1
neuro-muscle 1
(omega-CgTX 1
GVIA) 1
(omega-AgTX 1
IVA). 1
(Cm) 1
Exocytosis, 1
Cm, 1
Cm. 1
(-80 1
IgG). 1
Cm 1
38-84% 1
(Mar), 1
[3H]PN200-110, 1
3/12 1
VGCC, 1
(LMES) 1
(RNS) 1
Low-amplitude 1
decremental 1
13/15 1
unequivocally, 1
CAMP 1
infraclinical 1
flutter-opsoclonus-myoclonus 1
opsoclonus, 1
'cerebellar' 1
encephalopathic, 1
High-titre 1
opsoclonus 1
Antivoltage-gated 1
slurred 1
cerebelitis, 1
waxing 1
(50Hz) 1
elavated 1
lymphnode 1
anti-Hu, 1
1988-2008: 1
(NT-LEMS). 1
NT-LEMS 1
(p=0.0037), 1
(p=0.0002), 1
dysartria 1
(p=0.0091) 1
(p=0.007) 1
SCLC-LEMS. 1
NT-LEMS. 1
(AGNA), 1
AGNA-positive 1
SCLC), 1
SOX1, 1
time-frame, 1
encasement 1
(VGCC)/synaptic 1
(anti-MysB 1
(MysB 1
MysB 1
titers, 1
2q22-q23, 1
ion-channel-related 1
anti-P/O-type 1
(125I-omega-CmTx) 1
(125I-omega-CgTx), 1
24/72 1
125I-omega-CgTx. 1
125I-omega-CmTx 1
omega-CmTx 1
synaptotagmin. 1
Synaptotagmin 1
synaptotagmin-calcium 1
synaptotagmin, 1
omega-conotoxin-sensitive 1
VOCCs, 1
anti-VOCC 1
SCLC; 1
non-SCLC, 1
14.21 1
Anti-VOCC 1
hypometabolism. 1
neuromusculer 1
otoimmunity. 1
NAI-802, 1
sp., 1
NAI-802. 1
actagardine. 1
3147, 1
(colistin) 1
3147. 1
Checkerboard 1
Cronobacter 1
Nisin 1
haloduracin 1
lichenicidin 1
bacteriocins, 1
else 1
C39 1
salivaricin. 1
lantibiotic(s). 1
alba. 1
Actinomycetes 1
renowned 1
Planosporicin 1
Nonomuraea 1
39727, 1
they, 1
pspEF, 1
A3(2) 1
producer. 1
lantibiotics--models 1
prepeptide 1
self-protection 1
epidermin, 1
substrates: 1
cinnamycin-like 1
Methodologies 1
bioengineering 1
Leader 1
peptide-directed 1
self-immunity, 1
labyrinthopeptins, 1
labionin, 1
labionin 1
lyase-kinase-cyclase-type 1
Michael-type 1
cyclization. 1
NisT, 1
dehydrated, 1
Nisin, 1
nisA, 1
pentacyclic 1
NisB, 1
dehydrates 1
threonines; 1
NisC, 1
rings; 1
NisT. 1
nisABTC 1
prenisin. 1
nisBT 1
NisBC 1
excreting 1
(poly)peptide 1
bioactivities. 1
gallidermin. 1
Gallidermin, 1
(1,2-dioleoyl-sn-glycero-3-phosphocholine) 1
(C18/1) 1
(1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine) 1
(C16/1) 1
II-independent 1
gallidermin, 1
long-branched 1
nisin. 1
(pore 1
Hungary]. 1
Romas 1
C-terminal-domain 1
155-kb 1
non-transmitted 1
'not 1
descent' 1
(NQIBD) 1
FCP1, 1
machinery), 1
syndromes' 1
'purely' 1
fittest: 1
15,174 1
won 1
medals 1
Games 1
1896-2010. 1
birth). 1
winning 1
(males, 1
68.5+/-4.5 1
age-sex-matched 1
(work-rate 1
(1610+/-489 1
687+/-236 1
(142+/-10 1
138+/-18 1
(226+/-18 1
220+/-16 1
rate-pressure 1
(32,596+/-2952 1
30,838+/-3675, 1
SDNN 1
(r=0.58, 1
21-year 1
Veneto 1
1,386,600 1
(692,100 1
694,500 1
112,790 1
(90,690 1
22,100 1
non-athletic 1
4.9; 1
3,564; 1
5.1; 1
spliceosom-associated 1
molecule-based 1
(KinA) 1
phosphorelay 1
antikinase 1
C-domains 1
histidine-phosphotransfer 1
(DHp) 1
beta-sheet; 1
DHp 1
proline-mediated 1
medicines: 1
(alisporivir, 1
SCY-635, 1
NIM811) 1
cyclosporins 1
sanglifehrins 1
immunosuppressor-sensitive 1
immunosuppressor 1
peptidyl-prolyl-cis/trans-isomerase 1
non-transportable 1
hemicholinium-3, 1
immunosuppressors, 1
FK506, 1
choline. 1
immunosuppressors 1
A457-481, 1
FK506. 1
spans. 1
stocks. 1
metnase's 1
ssDNA-overhang 1
wt-Metnase 1
noncompatible 1
Pso4. 1
hPso4, 1
Metnase/SETMAR: 1
(protein) 1
stalling. 1
TopoIIalpha-dependent 1
linearizes 1
TIR, 1
subverted 1
untangled, 1
decatenated, 1
IIalpha) 1
tangled 1
ulated 1
decatenation: 1
IIalpha), 1
ICRF-193 1
decatenated 1
anti-sera 1
automethylates 1
K485, 1
(SETMAR)-binding 1
K36, 1
ScPSO4/PRP19 1
hPso4. 1
hPso4-siRNA 1
Metnase-mediated 1
sails 1
again: 1
Hsmar1, 1
Hsmar1-Ra. 1
cut-and-paste 1
(MITEs) 1
(MiHsmar1), 1
MITEs. 1
MiHsmar1 1
transpositional 1
40-58 1
terminal-inverted 1
SETMAR-binding 1
doublestrand 1
550,000 1
Metnase-dependent 1
Ser495 1
(S495) 1
Ser495Ala 1
(S495A) 1
S495 1
Splicing-sensitive 1
SC35. 1
well-demonstrated 1
SC35, 1
Ser-Rich 1
E2F1-target 1
p53-dependant 1
mda7/IL24, 1
mucus-producing 1
Capan-1 1
Mucus 1
apomucin 1
NFκB-activity 1
MUC4 1
mucins 1
mismatch-repair-dependent 1
Bcl-X 1
P388/SPR, 1
vinca 1
aphidicolin 1
Low-level 1
non-MDR-related 1
-Abl 1
/Raf-prototypic 1
Arf-p53-independent 1
Skp2. 1
oncogenic-stress-driven 1
Atf4, 1
myc-driven 1
Suv39h1-dependent 1
activation-although 1
well-is 1
countermeasure. 1
Emu-myc 1
senescence-related 1
tumor-prompted 1
Senescence-associated 1
(SASP) 1
epithelial-mesenchyme 1
SASPs: 1
promalignant 1
SASPs. 1
restrain, 1
senescencent 1
p53-dependent. 1
trans-repression 1
modification(s). 1
(NHFs) 1
(SSBs), 1
Ape-1 1
(RPLC) 1
8.3M 1
26,159) 1
low-range 1
pIs 1
non-retained, 1
(RTs), 1
RTs. 1
1D-GE 1
nano-LC-MS/MS. 1
2,5-Dihydroxybenzoic 1
(DHB) 1
DHB 1
shot-to-shot 1
spot-to-spot 1
reproducibilities. 1
lopinavir 1
precisions, 1
accuracies, 1
8.0% 1
85-117% 1
calibration. 1
(PDL)-1 1
PDL-2, 1
(CPM), 1
tumor-infiltrated 1
MHC-restricted 1
PD-L1(+) 1
CT-011's 1
CD4+, 1
CD8+, 1
CD69+ 1
coinhibitory 1
MK-3475), 1
(BMS-936 1
559, 1
RG7446, 1
MEDI4736), 1
anti-CD137 1
(urelumab), 1
anti-OX40, 1
anti-GITR, 1
anti-CD40 1
personalizing 1
PD-L2. 1
BMS-936559, 1
BMS-936558. 1
aspartyl-(asparaginyl)-beta-hydroxylase 1
(Cdk-5) 1
p25 1
kinase-Akt, 1
Cdk-5, 1
-159 1
(MEF-2), 1
MEF-3, 1
-hydroxylase 1
(Asph) 1
Asph 1
epitope-mapped, 1
calsequestrin-binding 1
BAH/humbug 1
BAH, 1
humbug 1
Geranylgeranylation 1
(GGylation) 1
Lats1, 1
Gγ 1
GGylated 1
Netrin-1, 1
laminin-related 1
(UNC5B) 1
STE20-like 1
(MST1/2) 1
(Lats1/2), 1
netrin-1-induced 1
YAP/TAZ-induced 1
1/2) 1
member) 1
LATS2 1
(neurofibromin 1
YAP-induced 1
LATS-mediated 1
Moroishi 1
Lats1/2, 1
(S168 1
S127 1
S112 1
assumptive 1
Chen 1
cell-contact 1
Significance. 1
high), 1
mDia1-3 1
tubular, 1
RhoGTPases 1
isoforms-mDia1, 1
mDia3-have 1
RhoGTPase 1
Rif. 1
surfaced 1
Rif 1
mDia1-built 1
cargo-filled 1
LIN7-IRSp53: 1
formation? 1
membrane:actin 1
LIN7 1
binucleate 1
RNAi-resistant 1
mDia2. 1
anillin, 1
anaphase/telophase 1
mDia2-induced 1
actin-nucleating 1
(WASP)-Arp2/3 1
nucleating-polymerizing 1
meshwork. 1
participate, 1
(SRF)-mediated 1
(SRE). 1
POPXs, 1
CDC42/RAC-activated 1
PAK 1
mDia-containing 1
SRE. 1
(PPM1F) 1
CDC42/RAC1 1
Ser1131, 1
Ser1137, 1
Thr1141 1
(FHOD1), 1
formin-family 1
actin/ADF 1
actin/cofilin 1
FH1 1
enclosing 1
Dimer 1
mDia-FH2 1
lasso 1
(connector). 1
mDia2, 1
mDia3 1
cosedimentation 1
dimerized. 1
Bundling 1
mDia3-FH2, 1
mDia2-FH2, 1
mDia1-FH2. 1
profilin, 1
repolymerize 1
repolymerization 1
actin/cofilin-1 1
deoxyribonuclease 1
Rac-binding 1
(Rho-associated 1
Rac-interacting 1
(formin 1
FHOD1-induced 1
Rho-ROCK 1
lamellipodia/membrane 1
Rho-interacting 1
(DAD) 1
Rac1-interacting 1
Rac1-binding 1
FH3-DAD 1
FHOD 1
'statistical' 1
'barriers', 1
gene-to-gene 1
twists 1
Nucleosomes, 1
remodelers' 1
eviction, 1
"chromatin 1
remodeling". 1
de-condensed 1
B-DNA. 1
chromatosomes, 1
chromatosomes 1
octamer. 1
(Rpd3L) 1
(Rpd3S) 1
LexA 1
Sin3, 1
Ume1. 1
RSC-enriched 1
dinucleosomes 1
mononucleosomes, 1
displaced, 1
rtt109-independent 1
vps75 1
miniarray 1
VPS75 1
replication/repair. 1
VPS75. 1
eviction/deposition 1
NF-кB-sensitive 1
miRNA-34a. 1
factor-кB 1
(NF-кB)-sensitive 1
miRNA-34a 1
chr1p36.22), 1
TREM2-3'-UTR 1
anti-miRNA-34a 1
(AM-34a) 1
NF-кB-mediated, 1
miRNA-34a-regulated 1
(DRAPs) 1
Immunoaffinity 1
HCT116. 1
Icp55. 1
(ChaFRADIC). 1
operate, 1
LC-MS, 1
icp55Δ 1
(MPP)-dependent 1
Isa2, 1
(GluC). 1
Defying 1
GluC 1
coevolution. 1
caspase-7, 1
fibrillarin. 1
intra-experimental 1
HiRes--a 1
'omics', 1
factorization. 1
cleansing, 1
http://hatch.cpmc.columbia.edu/highresmrs.html 1
Advance 1
(TCM). 1
diseases-TCM 1
(CHM), 1
"-omics" 1
TCM. 1
Meat 1
performances, 1
"muscle 1
conversion," 1
specific-characteristic, 1
(livestock 1
selection), 1
promotants, 1
pre-slaughter 1
(metabolomics, 1
interactomics, 1
modeling), 1
federated 1
warehousing, 1
multi-agent 1
Metabolomics, 1
mass-spectroscopy- 1
nuclear-magnetic-resonance-based 1
fluxomics, 1
Omics 1
biomarkers' 1
non-compact 1
disproportion 1
(CFTD) 1
(LVNC). 1
gene/s. 1
(MYH7B) 1
(ITGA7). 1
population.The 1
R890C 1
cardiomyopathy.The 1
E882K 1
mutations.This 1
non-penetrant 1
valvuloplasty 1
later; 1
aptamer-silver-gold 1
survivorship. 1
aptamer-Ag-Au 1
(SERS) 1
(A549 1
(0.20 1
cm(-2)) 1
(Rh6G 1
(Msi1), 1
BHLHB3: 1
(CCND1) 1
factor-I-dependent 1
(ADCA) 1
(PDCD5) 1
ADCA 1
Bcl-2/E1B 1
19kDa 1
protein3-like 1
(BNIP3L) 1
8p21, 1
E1B19K, 1
PCR-single 1
46.7% 1
(14/30) 1
(12/12) 1
26.7%(8/30) 1
0.404+/-0.070 1
0.575+/-0.065 1
detected.(3) 1
adenovirus-bearing 1
PA-1), 1
22-330% 1
adenovirus-expressing 1
(Ad-AS-CLN3) 1
DU-145, 1
BT-20, 1
SW1116, 1
T98g 1
PA-1) 1
(Cyr61) 1
p21(WAF1), 1
pRB2/p130 1
Cyr61-stably 1
(melanomas, 1
osteosarcoma) 1
liver-specific) 1
non-neuronal) 1
CGP41251, 1
xenograft, 1
NSCLS 1
neuroprogenitors 1
β-catenin/TCF4 1
antiapoptosis, 1
greater-than-predicted 1
Lower-Risk 1
(LR-PSS) 1
SRSF2, 1
U2AF1, 1
DNMT3A. 1
5.19 1
10.34 1
3.30 1
years]), 1
highest-risk 1
4.52). 1
worse-than-expected 1
(DNMT3A 1
JARID2) 1
517 1
(del6p). 1
1.1-Mb 1
gene--member 1
0.0033). 1
SUZ12. 1
postpolycythemia 1
vera/postessential 1
(PPV/PET) 1
(22.2%) 1
blast-cell 1
(52.6%) 1
(63.3%) 1
Leukemia-free 1
.028 1
PPV/PET-MF 1
clefting; 1
(multiallelic 1
P=6 1
clinical/prognostic 1
(CRT). 1
myeloid-lymphoid 1
polycomb, 1
(AMLs) 1
Downregulated 1
inv(16) 1
17-gene 1
intermediate/unfavorable 1
wt-NPM. 1
oncogene-associated 1
animal-imaging 1
siRNA-gene 1
H2AubiK119 1
H3metK27 1
Gene-silencing 1
6p21 1
EPC1/PHF1 1
t(7;17)(p15;q21) 1
(JAZF1) 1
(JJAZ1), 1
t(7;17) 1
t(6p;7p) 1
6;10;10 1
(PHF1) 1
t(6;7), 1
7p15, 1
Glomerulopathy 1
inflammatory/immune 1
disorder,' 1
(dystrophin) 1
DMD? 1
re-design, 1
de-risking 1
[Edwards 1
syndrome--most 1
benzopyrene 1
"golden 1
standard" 1
Gynecological-Obstetric 1
Poznań 1
1538 1
cystogenetic 1
hydramnion 1
dwards 1
[Course 1
Statistics) 1
(anencephaly, 1
encephalocele, 1
tetralogy, 1
gastroschisis, 1
4664 1
2754 1
1910 1
4600 1
brackets): 1
anencephaly 1
3.7), 1
5.2), 1
encephalocele 1
2.4), 1
5.0), 1
4.3), 1
4.4), 1
omphalocele 1
3.8), 1
3.9), 1
22.2), 1
2.6). 1
non-viable 1
stillbirths 1
nation-wide 1
diagnostics; 1
live-birth 1
(anencephaly 1
exception) 1
[Difficult 1
neonatologist, 1
anaesthesiologist]. 1
trachea. 1
1:3000-3500 1
specializations: 1
paediatrics 1
neonatology, 1
5.26) 1
2254 1
1989-1996, 1
16-45. 1
Republic: 1
1994-2007]. 1
Statistics). 1
Edwards, 1
aberrations" 1
inversions) 1
54.76%. 1
(ICBDSR, 1
EUROCAT). 1
child) 1
54.76% 1
[Amniotic 1
positive.]. 1
estriol) 1
1,893 1
(2.1%) 1
ultrasonograms 1
[Serum 1
trimester: 1
townships, 1
towns, 1
subdistricts 1
Jiangsu, 1
(f-betaHCG). 1
f-betaHCG 1
improvement? 1
(PBs). 1
eIF4G, 1
ARE-mRNA 1
PmScl-75 1
ARE-mRNAs. 1
SMG5, 1
SMG7, 1
Decapping 1
Dcp2; 1
X29, 1
U8 1
RNAs; 1
'scavenger' 1
DcpS, 1
Dcp1:Dcp2 1
Dcp1: 1
1801) 1
p53-stimulating 1
puncta. 1
component(s). 1
Maelstrom 1
(MAEL), 1
degradation/translational 1
pi-bodies, 1
MILI-TDRD1 1
"cementing 1
material" 1
gonocytes 1
piP-bodies 1
pi-bodies 1
(MVH) 1
Mael-mutant 1
gonocytes, 1
MIWI2, 1
TDRD9, 1
pi-body 1
MIWI2-dependent 1
TRIM71 1
&quot;P 1
bodies,&quot; 1
I-Mutant-2. 1
hDIS3 1
II/R 1
protein-hDIS3L2. 1
hDIS3L2, 1
stress-inducing 1
Poliovirus-mediated 1
RasGAP-SH3-binding 1
Edc3, 1
Edc4, 1
RNP-particles, 1
(dlPbodies), 1
motorized 1
dlP-bodies. 1
sweetening 1
inulinases. 1
endo-inulinases 1
TN-88(BAC16218) 1
TN-88(BAA19132), 1
(dock.compbio.ucsf.edu). 1
((2R,3R,4S) 1
fructose-6-phosphate) 1
-40.288094 1
Asp-22, 1
((3S,4R)-ketose 1
1-phosphate) 1
endo-inulinase. 1
β-2,1-linked 1
D-fructofuranose 1
sucrose-type 1
(JA) 1
Talf1, 1
Zygosaccharomyces 1
bailii, 1
bioethanol 1
biodesulfurization 1
(BDS) 1
bioprocessing 1
saccharification 1
(SSF) 1
ethanologenic 1
CCMI 1
(∼48%) 1
sugars), 1
dibenzothiophene 1
BDS 1
Gordonia 1
alkanivorans 1
desulfurization 1
μM/h 1
bioprocesses 1
Commercial 1
(LPG). 1
2³. 1
145.1 1
148.5% 1
min⁻¹), 1
FOS, 1
immobilization, 1
Yields 1
MTCC 1
3995. 1
Dahlia 1
(2%w/v) 1
rpm. 1
C-source. 1
Inulinase: 1
Sucrase 1
(I/S) 1
(17.9 1
(4.0) 1
50°C. 1
β-fructofuranosidase 1
inulinase-producing 1
JAM-3301, 1
KRF1(T). 1
KRF1(T), 1
Meyerozyma 1
(Pichia) 1
guilliermondii. 1
(VMEVH) 1
D1/D2 1
anamorphic, 1
nov 1
2.4027(T) 1
11388(T)) 1
fructans 1
(reference). 1
mg/ml). 1
Terrestris 1
Foetidus 1
Intybus 1
intybus 1
foetidus 1
66.0 1
Inulinase 1
4083 1
bagasse. 1
Exoinulinase 1
(beta-d-fructan 1
fructohydrolase, 1
3.2.1.80) 1
CCT4083 1
bagasse, 1
agroindustrial 1
preincubation. 1
raffinose 1
4.20, 1
27.89 1
47.55 1
raffinose, 1
d-fructose, 1
production--a 1
syrups, 1
acetone-butanol. 1
[Varicella 1
adult]. 1
27-years-old 1
chickenpox. 1
vesiculous 1
capillitium. 1
rhythmical 1
murmurs 1
rub, 1
130/90 1
dyskinesis 1
(isosorbide 1
mononitrate, 1
bisoprolol), 1
hemodinamically, 1
normalised, 1
dismission 1
echocardiograph 1
hyperimmunoglobulins 1
[Fulminating 1
myocarditis: 1
assistance]. 1
survives, 1
α-synuclein-enriched 1
depolarizaton, 1
(HEK293T 1
homozygosity.We 1
(ROHs) 1
1,445 1
6,987 1
ROH 1
ROH. 1
inbreeding. 1
chromosome19p13.3 1
cohort.There 1
EOPD, 1
ROHs. 1
dopamine-dependent 1
(PINK1(+/-) 1
PINK1(+/-) 1
(SNCA) 1
SNCA, 1
oss-of-function 1
(LRRK2), 1
PINK1]. 1
PARK6-linked 1
581 1
PINK1-mutation 1
-mutation 1
(1-methyl-4-phenylpyridinium 1
ion)-induced 1
neurosciences. 1
complex-I 1
M26I 1
pathogenically 1
PD/DLB 1
parkin-linked 1
[(18)F]6-fluorodopa 1
PARK 1
Europe), 1
Autosomal-dominantly 1
twin-studies. 1
2p13 1
(AR-JP, 1
PARK2; 1
602544), 1
40), 1
110-166 1
(202-203delAG, 1
255delA 1
321-322insGT) 1
(Trp453Stop). 1
(Lys161Asn, 1
Arg256Cys, 1
Arg275Trp 1
Thr415Asn) 1
(1,000 1
Periprocedural 1
.041). 1
Postprocedural 1
(creatine 1
kinase-MB: 1
(Ran) 1
Na(+)current, 1
K(+)current, 1
Ca(2+)current, 1
Ca(2+)overload. 1
models) 1
K(+)current. 1
(206 1
<0.05); 1
(204 1
(half 1
TdP. 1
(LVP), 1
Krebs-Ringer's 1
(O2·-), 1
NADH/FAD 1
(redox 1
O2·-, 1
cCa2+, 1
m[Ca2+] 1
c[Ca2+] 1
ranolazine-treated 1
emission, 1
(I(Na,L)), 1
(ATX)-II 1
fluo-4-acetoxymethyl 1
(CaTs) 1
beat, 1
pseudo-electrocardiogram. 1
RAN. 1
hearts--role 1
Anemonia 1
sulcata 1
(CAO) 1
free-wall 1
(FWft; 1
thickness/diastolic 1
thickness). 1
(FWft 1
stunned; 1
(0.51 1
.027). 1
(negligible) 1
ranolazine) 1
toxin-II 1
(d[Ca2+]i), 1
ATX-II. 1
Non-ST-elevation 1
(MERLIN)-TIMI 1
non-ST-elevation 1
(NSTE-ACSs) 1
6500). 1
80-mg/h 1
insufficiency) 1
730 1
NSTE-ACS. 1
principle: 1
([Na(+)](i)) 1
(arrhythmias), 1
tension) 1
(I(Na))) 1
[Na(+)](i). 1
(sustained/persistent) 1
ischaemia/hypoxia 1
anti-ischaemic 1
self-organized 1
rebuilt 1
dichloroacetate 1
PKM2) 1
PKM2), 1
"pseudo-starvation" 1
NFκB-dependent 1
3-hydroxy-buryrate. 1
immuno-histochemistry 1
metformin). 1
"fertilize" 1
MCF7-fibroblast 1
(analogous 1
micro-dissection). 1
(MitoTracker, 1
NBD-2-deoxy-glucose, 1
DCF-DA). 1
(spreads 1
vectorially 1
Fluoro-2-deoxy-D-glucose 1
(F-2-DG), 1
fold-change 1
"stemness," 1
ATG16L 1
cathepsins) 1
ENO1, 1
ALDOA, 1
LDHA 1
TPI1, 1
tamoxifen-resistance, 1
"glycolytic 1
phenotype" 1
Nutrients 1
CAMKK2 1
(CML): 1
BCR-ABL-targeted 1
bosutinib, 1
(2003-2013). 1
Cytopenias 1
CR-ABL-targeted 1
CFC, 1
LTC-IC, 1
NOD/SCID/IL-2Rγ 1
(null) 1
LTC-IC 1
retronectin 1
non-myeloablative 1
(CD31) 1
(ITIM)-containing 1
phospho-rylated 1
ITIM 1
E255K 1
ITIM-independent 1
(≥300 1
(360, 1
1360, 1
(170, 1
420, 1
shrank 1
Philadelphia-chromosome 1
ever-present 1
Ponatinib, 1
hopeful 1
(CML 1
Bcr-Abl+ 1
Flavopiridol, 1
Bcr-Abl(+) 1
responder, 1
phospho-Bcr/Abl, 1
-Stat5, 1
[Factors 1
imatinib]. 1
12-42 1
75-90%. 1
(COG) 1
AALL0031 1
pre-imatinib 1
B-cell-precursor 1
Ph-like 1
STAT5a, 1
STAT5b, 1
Gleevec. 1
treatment-resistance 1
marrow:a 1
tyrosyl 1
(MRD), 1
(RQ-PCR) 1
Aomori 1
Prefectural 1
(CMR). 1
(6-77) 1
(range)] 1
29.5 1
(11-84) 1
(range)]. 1
(2000-January 1
2008-2010 1
manufacturers' 1
cytarabine. 1
mutation-which 1
TKIs-continues 1
CP-CML 1
(LSCs) 1
BCRABL 1
LSCs, 1
LSCs 1
9:22 1
hepatotoxcity 1
harmonizing 1
free-survival 1
PGDF-receptor, 1
Ph) 1
(Philadelphia) 1
AMN107, 1
NS-187, 1
ON012380. 1
22q-, 1
0.0347), 1
Hematopathologic 1
(90.48%) 1
Dose-escalated 1
70-mg 1
Nilotinib, 1
-intolerant 1
chronic- 1
Chlorambucil 1
pyrrole-imidazole 1
1R-Chl, 1
1R-Chl 1
activity-independent 1
CR-ABL 1
(IM, 1
subclasses, 1
2-phenylaminopyrimidine-based 1
BMS-354825), 1
AP23464, 1
SKI-606, 1
PD166326 1
(AMN107) 1
INNO-406 1
(NS-187) 1
SKI-606 1
INNO-406, 1
ON012380, 1
MK0457 1
(VX-680), 1
BIRB-796, 1
blood-counts 1
46,XX,t(9;22)(q34;q11),der(18)t(2;18)(p11;p11)[1]/47,idem,i(17)(q10),-der(18)t(2;18),+der(22)t(9;22)[1]/46,idem,-t(9;22),der(9)t(9;22),ider(22)t(9;22)[12]/ 1
47,idem,-t(9;22),der(9)t(9;22),+22,ider(22)t(9;22)x2[1]. 1
BCR-ABL/G6PDH 1
[Imatinib 1
(IRIS 1
interferon+low-dose 1
1,106 1
90%; 1
82%), 1
allo-HSCT). 1
curability, 1
allo-HSCT. 1
treatment--new 1
interferon-containing 1
BCR-ABL-independent 1
IM) 1
partial). 1
(PBSC) 1
>/=2.0 1
microg/kg/day, 1
9/18 1
10/14 1
aphaeresis 1
0.14-2.18) 1
2.90 1
0.15-8.71) 1
(P&<0.005). 1
PBSC 1
mesylate-resistant 1
imatinib-sensitive/resistant 1
(Ara-C), 1
(DNR), 1
Isobolographic 1
majority. 1
(MCR) 1
MCR 1
chromosome-negative 1
(HUMARA). 1
MCR. 1
CCR. 1
p190(Bcr-Abl) 1
p210(Bcr-Abl) 1
(ALL; 1
(LyBC; 1
(CHRs) 1
(marrow-CRs) 1
(CHR, 1
marrow-CR, 1
CHRs 1
LyBC 1
CHR). 1
(clonal 1
(AP-CE), 1
(HEM-AP), 1
=.043) 1
=.007). 1
=.19) 1
=.0004). 1
STI 1
571-containing 1
CGP57148B), 1
3(4,5-dimethylthiazol-2yl)-2,5 1
diphenyl-tetrazolium 1
CalcuSyn 1
STI571/cytarabine 1
STI571/HHT 1
CML-derived 1
semisolid 1
[STI571 1
(Glivec)--a 1
cytogenic 1
favourable, 1
alpha-interferon 1
cytostatics 1
blasts), 1
[Ph(+) 1
35%], 1
[Ph(+), 1
90%]). 1
(landmark 1
=.001), 1
=.04), 1
late--chronic-phase 1
[Antileukemic 1
drug--a 1
kynase, 1
imatinib(STI571)]. 1
interferon-refractory 1
(n=158) 1
n=149) 1
n=151). 1
70.6%, 1
(15.2%), 1
(12.4%), 1
(9.8%), 1
(7.2%), 1
(6.8%). 1
Columbia-Suicide 1
Monoamine-based 1
glutamate-dependent 1
cognition-enhancing 1
glutamate-modulating 1
[5-HT] 1
[SSRIs] 1
[SNRIs]) 1
serendipity, 1
(5-HT1A-R) 1
SSRIs/SNRIs 1
autoreceptor-mediated 1
autoreceptors. 1
(atypical) 1
anxiolytic/antidepressant 1
enormously. 1
autoreceptors, 1
gepirone, 1
tandospirone 1
5HT2A/5HT2C/5HT3/alpha2 1
agonism; 1
5HT2C/5HT7 1
mechanisms). 1
5-HT(3), 1
5-HT(7), 1
5-HT(1D) 1
611) 1
(duloxetine 1
(HAM-D24). 1
Scale-Global 1
(SE)]: 1
-10.50 1
(0.76) 1
-12.04 1
-11.08 1
CGI-I, 1
[-13.47(0.75); 1
0.005] 1
51.0%, 1
37.5%, 1
46.9%, 1
#NCT00672620. 1
61.3% 1
≥10% 1
8.7. 1
(improved) 1
≤10), 1
≥22) 1
9.7%. 1
NCT00694304. 1
24-Item 1
(HDRS-24) 1
multiplicity) 1
NCT00735709. 1
(HAM-D(24)) 1
covariance, 1
29.0. 1
0.0011) 1
(53.2 1
(29.2 1
19.3%) 1
(duloxetine) 1
(21.8%) 1
(8.3%), 1
(n=639) 1
10mg/day. 1
≤10) 1
8).Patients 1
(n=396) 1
(n=192) 1
(n=204). 1
(full-analysis 1
1.26-3.21; 1
p=0.0035). 1
(n=27) 1
(open-label), 1
(double-blind). 1
(n=766) 1
p≤0.025 1
ANCOVA, 1
(LOCF)], 1
n=151) 1
(-1.4 1
n=149). 1
(MMRM) 1
(duloxetine), 1
'failed' 1
6-wk, 1
XR. 1
forward), 1
n=108), 1
n=100) 1
(n=112) 1
(AEs)--placebo: 1
(3%); 1
Pharmaceutical, 1
bisarylsulfanyl 1
R: 1
(BEDPE) 1
Lublin 1
connatal 1
(hydrocephalus 1
porencephaly 1
encephalomeningitis 1
lacerations. 1
punctures, 1
trepanations 1
(Spiramycin, 1
Daraprim, 1
Orisul). 1
toxoplasmosis]. 1
definitely, 1
origin-specific 1
(HIL) 1
informatic 1
(Beckwith-Wiedemann 1
Methylation450 1
(WRB) 1
(PPIEL). 1
(NHP2L1, 1
WRB 1
PPIEL) 1
1B. 1
mRNA/cDNA 1
1,082 1
GRB10, 1
INPP5F 1
ZNF597, 1
ZFAT, 1
GLIS3, 1
NTM, 1
MAGI2, 1
ZC3H12Cand 1
LIN28B, 1
Magi2. 1
(LTRs) 1
CpG(obs)/CpG(exp) 1
>0.6, 1
gDMRs 1
HYMA1 1
(SMRs). 1
SMRs, 1
=.0008), 1
SMRs 1
content>50%. 1
CpG(obs)/CpG(exp)>0.6, 1
SETBP1, 1
(aCML). 1
Asp868, 1
Ser869, 1
Gly870, 1
Ile871 1
Asp880, 1
Schinzel-Giedion 1
(CMML) 1
7/deletion 1
(-7/del(7q)) 1
Setbp1 1
Setbp1. 1
CMML. 1
BAP1. 1
uninterpretable. 1
exome), 1
quasi-complete 1
293, 1
Nanog-binding 1
tyrosines, 1
Y174F, 1
filopodia/lamellipodia 1
CtBP-interacting 1
(CIBZ) 1
CIBZ, 1
explains, 1
CIBZ-associated 1
MARCH-7, 1
RINGv 1
LIF-receptor. 1
(LIF)--a 1
E-3 1
LIF-receptor 1
cycle? 1
G₁/S: 1
Nanog; 1
miR's 1
MARCH-7. 1
ditags 1
3,006 1
differentiating. 1
nanog. 1
NK-2 1
Raji, 1
NT2/D1 1
B2. 1
lissencephaly. 1
Sertoli, 1
Leydig, 1
(lamins 1
non-seminomas 1
Seminomas 1
seminomas 1
Non-seminomas, 1
extraembryonal 1
(2.6-fold) 1
Comicroinjection 1
(t1/2=30 1
Gametogenesis 1
one-cell, 1
two-cell, 1
four-cell, 1
six- 1
Immature 1
(ductal 1
lamins: 1
nucleus-wide 1
lamin-promoter 1
"unlocking" 1
energy; 1
damaged, 1
superfluous, 1
belies 1
Classes 1
'autolytic', 1
'non-autolytic') 1
plant-pathogen 1
autolysosomes. 1
(proof 1
for) 1
lenient 1
disposing 1
organelles--common 1
denominators 1
(QC) 1
nutrient-regulated 1
QC. 1
multitiered 1
(Atg16L) 1
(IRGM) 1
antiautophagic 1
fourth, 1
p62/SQSTM1, 1
NDP52, 1
Atg32, 1
Nix/BNIP3L. 1
aggregates), 1
(PBMC). 1
volume; 1
7-AAD 1
DEX-induced 1
(activated 1
(non-activated 1
CRISPR-Cas: 1
(RRM), 1
CRISPR-cas 1
Cas2 1
COG1517 1
dormancy/suicide 1
(CASS) 1
O157 1
(CRISPR 1
pre-siRNA 1
(psi)RNAs 1
(psi)RNAs, 1
Slicer-like 1
CRISPR-derived 1
(pRNAi) 1
mature-length 1
groE-homologous 1
symbiont. 1
aphid 1
endosymbiont's 1
groE, 1
Unassigned 1
Mycoplasma. 1
anticodons, 1
'frozen', 1
anticodons: 1
"stop 1
capture," 1
UCA 1
UAA. 1
nondeleterious. 1
produced: 1
eubacterial, 1
halobacteria 1
methanococci. 1
INN 1
CNN 1
anticodons.(ABSTRACT 1
luteus, 1
GC-content. 1
C)-contents 1
AUY/A 1
(IIe), 1
GC-content: 1
74%) 1
NNG 1
NNU 1
NNA 1
GC-contents 1
U/C 1
NNU/C-type 1
anseriform 1
Cairina 1
moschata 1
eumycotes 1
(microD 1
0.123, 1
0.224, 1
0.130) 1
0.332, 1
0.323, 1
0.367, 1
post-TAC 1
post-TAC) 1
(RWT) 1
post-TAC, 1
RWT 1
pre-load 1
recruitable 1
(PRSW), 1
remodeling; 1
(2a) 1
(SERCA2a; 1
(PLN; 1
(β-MyHC; 1
FHC-TAC 1
β-MyHC 1
double-mutation 1
nontransgenic, 1
TnI-203, 1
MHC-403 1
M-alphaMHC(R403Q/+) 1
F-alphaMHC(R403Q/+) 1
(pCa(50)) 1
5.63 1
5.57 1
alpha-MHC(R403Q/+) 1
mN/mm(2)). 1
Unloaded 1
lengths/s), 1
tension-velocity 1
F-alphaMHC(+/+) 1
lengths/s 1
tension). 1
pCa(50) 1
Alpha-myosin 1
(betaMyHC) 1
434 1
(MYH6) 1
(P830L, 1
A1004S, 1
E1457K; 1
alphaMyHC, 1
(718+/- 1
(WT; 1
623+/- 1
(594+/- 1
bpm). 1
(LVEF), 1
(88+/- 1
(69+/- 1
(75+/- 1
(11.9+/- 1
(7.0+/- 1
(5.5+/- 1
(7.8+/- 1
0.3%) 1
403, 1
[QT 1
(QTd)] 1
extrastimulus 1
genotype; 1
(37.4 1
(R403Q), 1
Myofibrillar 1
(pCa 1
(submaximal 1
work-producing 1
work-absorbing 1
(b=11+/-1 1
15+/-1 1
c= 1
58+/-3 1
66+/-3 1
(0. 1
53+/-0.25 1
1.03+/-0.18 1
mW/mm3; 1
maximum. 1
preforce 1
debilitating), 1
(alpha-MHC403/+) 1
litter-mate 1
(EPS). 1
EPS. 1
ECG's, 1
alpha-MHC403/+) 1
beta-MHC. 1
His(6) 1
alpha-and 1
Ni(2+)-chelating 1
(S1), 1
actin-activated 1
MgATPase 1
alpha-S1 1
beta-S1 1
403/403 1
MHCs 1
168-amino 1
hinge/rod 1
>2, 1
(P=0.7). 1
(repair, 1
n=29; 1
MVP, 1
diameters. 1
(DSR). 1
90.3 1
51.6 1
(slope, 1
3.62 1
[0.56; 1
6.68]; 1
5.84). 1
suspicions 1
downgrading 1
regurgitation). 1
Labetalol 1
nitroprusside. 1
(lipotoxicity) 1
(TGZ). 1
P-AMPK 1
(PP2C), 1
myocardiocytes, 1
P-AMPK, 1
(2007-2008). 1
game, 1
certificates 1
SCDs. 1
nonorganized 1
Readily 1
ticker? 1
(Royal 1
Physicians). 1
considerations), 1
judgment) 1
tachycardia/fibrillation. 1
prophylactically, 1
prevented? 1
CVDs 1
102; 1
36%) 1
1,986 1
seven-fold). 1
Arg719Gln 1
Leu908Val 1
defibrillators, 1
43]) 1
marathon, 1
triathalon, 1
actively. 1
collegiate 1
triathalon 1
miles/week. 1
suddenly.(ABSTRACT 1
visibility. 1
tabulate 1
(1970-1993), 1
1994-2012, 1
(58%), 1
nonsurvivor 1
crossing. 1
(40%<3 1
5%>3 1
33%; 1
.045) 1
on-site 1
defibrillation, 1
(MEDLINE) 1
editorials. 1
projectile, 1
venues, 1
reoccurrence. 1
Commodio 1
low-impact, 1
hockey, 1
softball, 1
coaches, 1
baseballs. 1
Copper-age 1
decoded, 1
multiple-databases 1
-search 1
algorithms-driven 1
data-analysis 1
Inca 1
mummies 1
immunoassay-based 1
Oetzi's 1
animal-hair-bearing 1
accoutrement 1
43/91/130 1
6/91, 1
5/91, 1
leggings, 1
moccasins, 1
2/91, 1
(bio)chemical 1
((MALDI-TOF 1
MS)-based 1
Unknown 1
Hereby, 1
subfamilies/genera 1
MS/MS) 1
Oldest 1
Arzhan 1
(Siberia, 1
Russia). 1
micro-level 1
40-50-year-old 1
(Russia) 1
Macro-morphological 1
(macroscopy, 1
radiology) 1
micro-morphological 1
(histology, 1
scanning-electron 1
(1-D- 1
2-D-electrophoresis, 1
microlevel 1
king. 1
macerated 1
Lon4 1
dual-targeted 1
Lon2, 1
Physiologia 1
Plantarum 1
(PRPH) 1
neuropathologies 1
neurodegeneration." 1
c.1634G 1
57-131 1
frizzy 1
c.1456G>A 1
gigaxonin.We 1
16q24.1, 1
aggregation; 1
axons." 1
study(1) 1
(Gan) 1
antiretroviral-induced 1
(NRTIs). 1
excruciating, 1
unremitting, 1
horn, 1
([qPCR] 1
level). 1
(GAN). 1
alleles: 1
down-modulation. 1
Wingless, 1
(EFGR), 1
de-regulated 1
IGF, 1
HGF), 1
(WNT, 1
Notch), 1
AKT/MTOR 1
underexplored 1
brivanib), 1
(PiD; 1
(DLDH) 1
(dentate 1
gyrus) 1
absent), 1
Differential, 1
PRESENILIN1 1
Psen1) 1
starkly 1
APP). 1
G183V 1
Psen1-dependent 1
P242LfsX11 1
Fe65. 1
Kai1, 1
Hes1. 1
Alzheimer-type, 1
Myelodysplastic-type 1
s-phase 1
notch3 1
non-caucasian 1
(Arg90Cys 1
Arg133Cys) 1
(Cys174Phe) 1
epidermal-growth-factor-like 1
Notch3. 1
CSB/ERCC6 1
DNA-stimulated 1
ERCC6/CSB 1
XPA, 1
Bending. 1
Mgm1-driven 1
Arc/Arg3.1. 1
Activity-regulated 1
Arc, 1
bacterially-expressed 1
His6-Arc 1
(37°C 1
100mM 1
NaCl). 1
assembly-dependent 1
untagged) 1
Arc-mediated 1
counterintuitively, 1
Dynamin, 1
gene-edited 1
dynamin2-EGFP 1
dynamin2 1
spinning-disk 1
pits. 1
collar) 1
Cocucci 1
CHMP3 1
CHMP2B, 1
VPS4B/SKD1, 1
midbodies 1
CHMP3, 1
CHMP2B 1
abscission. 1
(cryo-EM), 1
angles. 1
neurosecretion, 1
Centronuclear 1
Myopathy, 1
polyamines: 1
permeant, 1
(FFS) 1
R369W 1
1μM. 1
Dyn2-R369W 1
Reflection 1
clathrin-containing 1
Dyn2. 1
CNM-associated 1
(MT1-MMP). 1
co-up-regulation 1
(aPKCι) 1
breast-tumor 1
aPKCι, 1
MT1-MMP-containing 1
F-actin-rich 1
MT1-MMP-positive 1
dynamin-2, 1
amphiphysin. 1
BAR-membrane 1
virion, 1
p53-independent, 1
Apoptin. 1
TAp73beta, 1
Apoptin, 1
E1A-induced 1
Pirh2, 1
up-regulates, 1
down-regulates, 1
P2), 1
(39/41 1
p53-p73 1
(Bub1, 1
BubR1). 1
deltaNp73, 1
NEDP1, 1
deneddylate 1
p73-responsive 1
conjunction, 1
NEDD8-dependent 1
TAP73 1
DeltaNP73 1
wtp53 1
TAp73β, 1
Δ133p53α/β/γ 1
TAp73α. 1
p53β, 1
Δ133p53α 1
p53γ 1
Δ133p53γ 1
(Δ133p53α, 1
Δ133p53β 1
Δ40p53α) 1
TAp73β. 1
convinced 1
RNPC1. 1
RNPC1-regulated 1
γ-H2A.X, 1
Snail-1, 1
ΔNp73. 1
totipotence 1
hypomethylation-induced 1
hypomethylation-associated 1
platinum-induced 1
BRCA1-expressing 1
∆Np73 1
Daoy 1
(MBL-03, 1
MBL-06, 1
MBL-07 1
MBL-10). 1
Trp73 1
ΔN. 1
apoptosis-/chemosensitivity 1
CD95, 1
TNF-R1, 1
TRAIL-R2 1
TNFRSF18. 1
caspase-2, 1
-9. 1
ΔNp73ß 1
isoforms' 1
-233 1
-204 1
(DeltaNp73(-/-) 1
oppositely. 1
E2F-1 1
AIP-4/Itch 1
p53RE, 1
FAS/CD95/TNFRSF6 1
TAp63) 1
-beta 1
(TA 1
DeltaN) 1
hinder, 1
TAp73alpha. 1
UT-7. 1
Proapoptotic 1
alternative-spliced 1
Deltaexon2 1
Deltaexon2/3. 1
Celecoxib-mediated 1
tetramerisation 1
CD10 1
ABC-like 1
(tumor-normal) 1
Varimax 1
(VrPCA) 1
non-disease 1
Rationally 1
PCA/SVM 1
degradation/stabilization 1
(UPS): 1
Itch/NEDD4-like 1
ubiquitin-independent) 1
calpastatin, 1
p73: 1
handicapped 1
p73alpha, 1
RARbeta/gamma-selective 1
Tazarotene, 1
acetylenic 1
P1p73 1
P2p73 1
tazarotene-mediated 1
SH-5Y5Y 1
TA- 1
N-p73 1
Btg2 1
p73-deficient 1
Zaika 1
6:765-780, 1
1,000-fold-higher 1
MEF-derived 1
fibrosarcomas 1
(NB), 1
tumor-control 1
(HR=7.93; 1
(HR=5.3; 1
HR=5.24, 1
P=0.012; 1
HR=4.36, 1
Np73) 1
3'). 1
Np73, 1
tumorogenesis. 1
copper-specific 1
metalloregulation 1
Cu-inactivation 1
Cu-inhibition 1
Cu-regulated 1
MAC1(up) 1
Cu-regulation 1
Cu-specific 1
Cu-repression 1
Lys-147, 1
regulator-mediated 1
(RFI). 1
-GFP 1
(AGOH) 1
AGOH 1
RFIs. 1
RFI 1
(TGF- 1
β1) 1
(N-ras(-/-)). 1
MEK/Erk, 1
Erk-independent 1
Hec1A 1
growth-factor-dependent 1
HRas-disrupted 1
HRas. 1
HRas, 1
galectins, 1
GDP-/GTP-bound 1
(C181S). 1
(PA)-GFP-H-Ras 1
rasosomes. 1
rasosomes, 1
PM-associated 1
rasosome-associated 1
Ki- 1
hree 1
N-Ras-occupy 1
endomembranes. 1
statically 1
localizations; 1
subsignals, 1
N-Ras- 1
endomembranes 1
K-Ras4B) 1
(P-LAP), 1
(A-LAP) 1
(L-RAP) 1
amimopeptidases, 1
"Oxytocinase 1
subfamily". 1
HEXXH(X)18E 1
Zn-binding 1
GAMEN 1
P-LAP 1
energy-transduction 1
Alemtuzumab-related 1
CAMMS223. 1
interferon-β-1a 1
IFNB-1a, 1
Rebif) 1
endocrinologist. 1
4%. 1
IFNB-1a. 1
TBII-positive 1
CD25(hi) 1
post-alemtuzumab 1
'reset'. 1
(outcomes 1
assessor) 1
(CAMMS223) 1
(McDonald, 1
(IFNB-1a), 1
Pelli-Robson 1
IFNB-1a) 1
4.31; 1
2.44; 1
=1.16 1
5.15; 1
triplet, 1
0.012; 1
CI=0.35 1
(0.080 1
0.0102). 1
experience; 1
prototypical, 1
"bench-to-bedside" 1
lymphopeniaassociated 1
alpha4beta1 1
blood-brain-barrier, 1
(rituximab); 1
(FTY720); 1
(rituximab) 1
(IV). 1
carbimazole-responsive 1
mitogen-induced 1
-0.36 1
1-H. 1
[Possibilities 1
principals 1
(hCD52) 1
Gr-1 1
asialo-GM-1, 1
cobra 1
rehearsal 1
irretrievably 1
TRD. 1
Psychosurgery 1
ultima 1
avolition, 1
reticence 1
psychosurgery, 1
prevails, 1
Neuroelectric 1
rewards 1
reward-learning 1
stimulus-outcome 1
(learning 1
task), 1
(choosing 1
feedback-related 1
cross-correlations 1
immense. 1
psychopharmacology 1
(DRN), 1
(LC). 1
(MDE's). 1
noradrenergic, 1
(PLL) 1
B-PLL, 1
fitter 1
B-PLL 1
subcategories. 1
immunophenotype, 1
(TCL-1 1
MTCP-1) 1
alemtuzumabin 1
sequential. 1
betterunderstanding 1
Sézary 1
fungoides/Sézary 1
(MF/SS) 1
Alemzumab 1
MF/SS, 1
CD52(pos) 1
CD52(neg) 1
CD52-positive, 1
CD52-negative 1
futile, 1
CD52-positive 1
CAMPATH-1 1
nonmodulating 1
glycosylphosphatidylinositol-linked 1
Telomerase-associated 1
(TA), 1
transcriptase-PCR, 1
O(6)-methylguanine 1
hTERT/TA-positive 1
hTERT/TA-negative 1
(6/100) 1
'disease 1
amyloid-β, 1
(Aβ, 1
(phosphorylation 1
diseasemodifying 1
methological 1
drug-treatments; 1
aβ 1
Viewing 1
(CAA). 1
Bapineuzumab-treated 1
(Bapi-AD) 1
(NI-AD) 1
(NDC) 1
histologically-demonstrable 1
leptomeningeal, 1
neuroparenchymal-amyloid 1
Aβ42:Aβ40 1
AβPP, 1
CT99 1
CT83 1
depositional 1
enhancements, 1
ostensible 1
ideas. 1
avail. 1
seduced 1
believing 1
progress? 1
Bapineuzumab. 1
cascade? 1
tarenflurbil, 1
(Hashimoto's 1
(l-T(4)) 1
1776.7+/-86.0 1
1674.3+/-79.2 1
l-T(4), 1
8/34) 1
(L-T(4)) 1
baPWV, 1
(1940.3+/-126.4 1
1726.4+/-110.4 1
cm/s, 1
P=0.046; 1
62.1+/-3.1 1
50.7+/-3.7 1
P=0.026, 1
(rho=-0.522, 1
P=0.046). 1
7/10), 1
1916 1
ect 1
(sports 1
climbing) 1
1972, 1
35-74 1
kcal 1
week(-1) 1
(8.4 1
MJ 1
'protective 1
ect' 1
17,815 1
45-84 1
4399 1
health; 1
13,485 1
climbing, 1
sports/recreation 1
2,539 1
storeys 1
climbed 1
[MET] 1
alumni, 1
physician-diagnosed 1
17,321). 1
(3728 1
630, 1
1680, 1
3150, 1
3150 1
6300, 1
6300 1
kJ/wk 1
adjusted. 1
(380 1
.99). 1
tour. 1
tour) 1
kilometers. 1
(0.48 1
1.44) 1
Phylogeography 1
Palaearctic. 1
CC398: 1
(CC398) 1
89), 1
4,238 1
VII-like) 1
human-associated 1
livestock, 1
phage-carried 1
(RD, 1
spoligotyping, 1
(T, 1
RD115, 1
RD122, 1
RD174, 1
RD182, 1
RD183, 1
RD193, 1
RD219, 1
RD726 1
RD761 1
RD724, 1
katG463/gyrA95 1
(PGG) 1
PGG3; 1
PGG2 1
RD115 1
RD174 1
RD182 1
IS6110-RFLP 1
Rotifera-Acanthocephala 1
(class: 1
Monogononta). 1
'species'. 1
Cycliophora 1
Acanthocephala, 1
Bdelloidea 1
Ploimida. 1
'species' 1
Ploimida; 1
Acanthocephala; 1
taxomic 1
(BH)3 1
BH 1
(homoplasy), 1
pens 1
(Anthozoa: 1
Octocorallia: 1
Pennatulacea). 1
Pennatulacea 1
(sea 1
pens). 1
Sessiliflorae 1
Subselliflorae 1
polyphyletic. 1
Umbellulidae, 1
Pteroeididae, 1
Kophobelemnidae. 1
abbatissae 1
(Annelida, 1
Clitellata, 1
Hormogastridae). 1
delimit 1
earthworm 1
Hormogastridae, 1
abbatissaesp. 1
n., 1
Sant 1
Joan 1
les 1
Abadesses 1
(Girona, 1
Hormogastridae 1
GMYC 1
Isopoda 1
crustaceans. 1
maculosa 1
isopods 1
crustacean 1
asellote 1
autapomorphies. 1
isopods: 1
nad1, 1
tnrL1, 1
rrnS, 1
trnS1, 1
cob, 1
trnT, 1
nad5, 1
trnF. 1
apomorphies 1
trnR 1
Valvifera. 1
californicus 1
tetraconate 1
Copepods 1
Arthropoda, 1
Tetraconata 1
hexapods), 1
copepods 1
Malacostraca 1
Hexapoda. 1
harpacticoid 1
californicus. 1
Deutocerebral 1
antennular 1
malacostracan 1
hemiellipsoid 1
Glomeruli 1
specializations 1
"T-bars" 1
dipterous 1
Serotonin-like 1
pervades 1
deutocerebral 1
Tetraconata, 1
Taxon 1
taxon-induced 1
incongruities 1
frequentist 1
(CGH)), 1
myrmecophagous 1
(ant/termite 1
eating) 1
orders/superorders 1
(Pholidota, 1
Tubulidentata, 1
Xenarthra), 1
(Pholidota), 1
sloth 1
(Xenarthra 1
fluorophores, 1
pholidotes 1
carnivores 1
xenarthrans, 1
chromosome-level 1
rosids 1
(Superorder 1
Rosanae, 1
Angiosperms). 1
informativeness. 1
matK, 1
atpB, 1
rbcL, 1
(angiosperms) 1
matK 1
faired 1
lineage's 1
informativeness, 1
Hemiplasy 1
interpretive 1
hemiplasy, 1
seeming 1
"phylogenetic 1
discordance" 1
hemiplasy 1
underdominant 1
disadvantage) 1
overdominant 1
longer-lived), 1
chiropterans 1
afrotherians. 1
cladistics 1
hemiplasy. 1
Noisy: 1
uncorrelated 1
patchwork 1
uninformative 1
quality". 1
http://www.bioinf.uni-leipzig.de/Software/noisy/. 1
pairs). 1
bumble 1
Bombus 1
terrestris, 1
Bulinus 1
electromorph, 1
Fst 1
principle" 1
serotonin-related 1
sociability 1
depression- 1
serotonemia 1
(CTM), 1
monoamines. 1
5-HT-raphe 1
CTM 1
(PN1) 1
PN10 1
hyperexcited 1
(>PN90). 1
single-neuron 1
stimulus-driven 1
CTM-exposed 1
ifferential 1
nail1 1
hrombin 1
Slug/Snail2, 1
S92/96A 1
S100/104A 1
xpression 1
9a 1
microenvironment-derived 1
receptor-alpha-positive 1
(MCF-7(IL-6)) 1
MCF-7(IL-6) 1
eltaEF1 1
LPP 1
lipoma-preferred 1
ETV5, 1
ETV5-transcriptional 1
desminopathy 1
DCM-associated 1
cardiomyopathy.]. 1
(smooth 1
Kinase, 1
SM22) 1
(patho)physiological 1
productively. 1
alphaB-Crystallin 1
(CryAB) 1
(R120G) 1
(DRM), 1
causative, 1
VASP-EHV1 1
(MAP4) 1
densification. 1
MAP4. 1
Dobermann. 1
Canine-dilated 1
Cardiomyocyte-specific 1
25-30%. 1
matrilinear 1
(overall, 1
DCMs). 1
cardiologist's 1
genetists 1
(2.6% 1
"final 1
pathway" 1
cytoskeletalopathy. 1
reaction]. 1
(myocytes, 1
endothel 1
(granulocytes, 1
lymphocytes). 1
myolemmal 1
collagen: 1
anti-laminin 1
well-described. 1
myolemma 1
antibodies.(ABSTRACT 1
desmin-deficient 1
(des(-/-)) 1
(OPN) 1
(OPN: 1
226×, 1
galectin-3: 1
26×, 1
osteoactivin/Gpnmb/DC-HIL: 1
160× 1
metalloprotease-12: 1
98×) 1
des(-/-). 1
OPN-deficient 1
nitration. 1
(desminopathies). 1
underexploited 1
desminopathies. 1
immune-directed 1
been, 1
amazing 1
high-valued 1
revolution, 1
headed. 1
PD-1)/its 1
"breakthrough 1
therapy". 1
(NPBI), 1
(AOPP) 1
(IPs). 1
(PAR), 1
[Genomic 1
pathology]. 1
eregulation 1
endocrinopathies. 1
Principally, 1
[Peterson 1
Sapienza 1
Annu 1
27:7-31]. 1
age-of-onset, 1
imprint. 1
INS-IGF2 1
lectin-stimulated 1
biallelic, 1
monoallelic. 1
factor-II 1
IGFs 1
lentivirus-vectors 1
hromatin 1
Insertional 1
approximation, 1
payloads 1
Recombinase-Mediated 1
Exchange 1
MAP17, 1
SCL/Tal1 1
Region-driven 1
Map17, 1
Cyp4x1, 1
Tal1. 1
Map17. 1
Nonhematological 1
unquestioned 1
weanling 1
400% 1
fragment-derived 1
hit. 1
(PFI-1) 1
acetyl-lysine-mimetic 1
Histone-lysine 1
subtype-selective 1
histone-bromodomain 1
3,5-dimethylisoxazole 1
bioisostere, 1
histone-mimicking 1
4-substituted 1
4d, 1
BRD2(1) 1
BRD4(1). 1
(H3K4me2/3). 1
acetyllysines 1
CBP: 1
382-acetylated 1
BRDs 1
p53K382ac 1
foundation. 1
romodomains 1
Suv39h, 1
Crb2/Rad9 1
MyoD. 1
forges 1
romodomain 1
(Bdf1 1
Lys14. 1
esa1 1
Replacements 1
Gcn5), 1
(HATs), 1
Swi2 1
HATs, 1
Gcn5-mediated 1
Swi2-dependent 1
Acetylation: 1
Acetylases 1
familiar, 1
acetyl- 1
ases 1
(patients: 1
hyperintensities. 1
postprocessing. 1
CADASIL: 1
microbleeds 1
31-69% 1
thalamo-capsular 1
onset: 1
interpeduncular 1
antiplatelets, 1
hypertensive. 1
antiplatelets 1
(HSVDB). 1
NOTCH3-negative 1
c.294dupA, 1
p.C99MfsX3. 1
scrutinized, 1
Re-examination 1
c.1630C>T 1
(p.R544C) 1
HSVDB 1
(GOM). 1
anti-N3ECD 1
0.2- 1
2-μm 1
A1-1 1
N3ECD-GOM 1
PGLs 1
PGL, 1
dehydrogenase-related 1
PCC-PGL 1
PCCs/PGLs, 1
EGLN1/PHD2, 1
tail/corpus 1
2.9-5.6 1
215-365 1
200-700 1
Histolopathology 1
Organ-sparing 1
FK506-Binding 1
(FKBP10) 1
imperfecta). 1
immunofluorescence), 1
(phLF). 1
(myo)fibroblasts 1
CD68(+) 1
go. 1
debility, 1
triple-tyrosine 1
(FGF). 1
fibrosis? 1
INPULSIS� 1
(Ofev(�)) 1
/PLN 1
Breviscapine 1
day(-2)). 1
(PPI-1), 1
(SERCA-2), 1
Functional, 1
(diabetic) 1
(non-diabetic) 1
non-transgenic, 1
Fibrosis, 1
pro-sclerotic 1
factor-beta, 1
IGF-I. 1
Streptozotocin 1
kg(-1). 1
time-to-PS 1
(TPS), 1
time-to-90% 1
(TR(90)) 1
(+/-dL/dt). 1
TPS, 1
+/-dL/dt, 1
TPS. 1
(FDP-Sr) 1
(non-diabetic), 1
OBRb, 1
PKCɛ, 1
(STZ) 1
splitomycin, 1
hydroxysafflor 1
Hydroxysafflor 1
(HSYA) 1
ECE, 1
PropreET-1 1
HSYA, 1
ET-ROS 1
Ca2+-release 1
PropreET1, 1
-release 1
enhancer/chicken 1
promotor-controlled 1
(SERCA2-TGR), 1
(1.5-fold), 1
(+26%) 1
(+37%). 1
SERCA2-TGR, 1
(+48%) 1
(+34%) 1
(+35%) 1
SERCA2-TGR 1
1.3-fold 1
compensates, 1
Metacid 1
(Methyl 1
parathion) 1
Nuvan 1
(Dichlorovos) 1
pesticides; 1
Dimethoate, 1
Profenofos, 1
Chlorpyrifos 1
Nepal. 1
atropine. 1
Cholinesterase 1
reactivators, 1
AChE, 1
Pesticides 1
pyrethroid, 1
carbaryl 1
organophosphates; 1
organochlorines; 1
prochloraz. 1
Andalusian 1
17,429 1
dataset) 1
Neurotoxic 1
prevention/therapy. 1
Myeloneuritis 1
(DDVP) 1
dug 1
landfill 1
kin) 1
(sNCT) 1
"non-neuropathic" 1
"neuropathic" 1
evolvement 1
dips 1
ceramics 1
splashing 1
dip. 1
concentrate. 1
Organophosphorous 1
anticholinesterases, 1
disorders' 1
Organo-phosphate 1
[Delayed 1
pesticides: 1
knowledge]. 1
(Zn3P2) 1
(EMG). 1
35.8 1
phosphide, 1
symptom(s), 1
(Zn) 1
(Cu), 1
(Fe), 1
(Mg) 1
gammaglobulin 1
0.005); 1
beta-globulin 1
B-lipoprotein, 1
B/alpha 1
Triglycerides 1
phospholipid/cholesterol 1
(exemplified 1
poisoning)]. 1
Pyrethroid 1
central-neurological 1
peripheral- 1
autonomic-neurological 1
Non-neurological 1
swellings, 1
lichen-ruber-like 1
efflorescences, 1
clotting, 1
Paraguay, 1
poliomyelitis, 1
Paraguayan 1
1.1/100,000 1
warmest 1
Nicaragua. 1
Vibrotactile 1
poisoned; 1
height-adjusted 1
[Nervous 1
hothouses]. 1
(1985, 1
1991) 1
hothouses 1
(vegeto-vascular 1
angiodystonic 1
vegeto-sensory 1
polyneuropathy). 1
(Fenthion), 1
pareses 1
post-exposure. 1
pesticide-workers 1
organophosphate-ester 1
poising. 1
[Electroneurographic 1
hexachlorcyclohexane]. 1
Paired-End-Tag 1
ChIA-PET, 1
Tool, 1
http://chiapet.gis.a-star.edu.sg). 1
micron-sized 1
(5,6). 1
tag-linker-tag 1
(PETs) 1
biotinylated, 1
streptavidin-magnetic 1
PETs 1
video. 1
chance, 1
over-estimating 1
statistical-mechanics 1
Jacob 1
Monod's 1
methodologies-crosslink 1
digest, 1
dilute, 1
ligate, 1
interactions-belies 1
(rBDV) 1
P/M-GFP, 1
nonpropagating 1
rBDV, 1
ΔGLLP/M, 1
transcomplementation 1
ΔGLLP/M 1
ΔGLLP/M-infected 1
transmissibility. 1
laboratory-adapted 1
Bo/04w 1
nonendemic 1
recombinant. 1
Parapoxvirus 1
D1701 1
(D1701-VrVp40) 1
antibody-producing 1
amphoterin/HMG-1. 1
far-Western 1
Microsequence 1
amphoterin, 1
infection-based 1
caspase-1), 1
bcl-x, 1
(microgliosis 1
astrocytosis) 1
(interleukins 1
1alpha, 1
(IL-1Ra), 1
(IL-1RI), 1
(IL-1R 1
AcP) 1
130, 1
parieto-frontal 1
postintracerebral 1
IL-1RI, 1
AcP 1
intercorrelated, 1
pro-opiomelanocortin, 1
AcPI, 1
dynorphin 1
neuropathophysiology 1
(i.c.) 1
immunomediated 1
i.c. 1
PTI-NB) 1
interleukins-1alpha, 1
-1beta 1
10-kb 1
60-, 1
38-, 1
(p.i.). 1
postthymic 1
progenitor-cell 1
infused. 1
arabinosylguanine 1
(ara-G) 1
ara-G 1
(ara-GTP) 1
.0003) 1
(440 1
1,438 1
(alemtuzumab]. 1
Rikshospitalet 1
meningoencephalomyelitis 1
chills. 1
T-prolymphocytic 1
(CRs) 1
durable, 1
autografted 1
pancytopenic 1
stimulus-activated 1
autoiummune 1
5'-noncoding 1
5'ends 1
AGTTTCTACTTT 1
(CD11c) 1
(CD11c/CD18) 1
TATA- 1
CCAAT-boxes, 1
5'-ends, 1
initiator-like 1
CD11c-based 1
-160 1
(FPI-FPIV), 1
(FPII 1
FPIV) 1
CEBPB 1
law: 1
Leaders 1
hire, 1
(SCOPUS, 1
B.V., 1
NL). 1
1-2. 1
salaries. 1
earners" 1
(>$100,000 1
annually) 1
(ophthalmology, 1
otolaryngology, 1
neurology), 1
(UC 1
Davis), 1
(assistant 1
professor). 1
310) 1
earning 1
earners. 1
ranking, 1
2.40% 1
chair. 1
Ophthalmologists, 1
academically 1
remuneration. 1
Guy's 1
advice/management 1
gypsum. 1
Casts 1
non-contacting 1
profilometer 1
Geomagic® 1
Qualify 1
Wear 1
1,078 1
77.7% 1
vegetable-based 1
prostate-healthy 1
(A:V) 1
cooking 1
self-maintained 1
(P=0.049). 1
A:V. 1
Dietetics. 1
(MBSR-C) 1
(QOL), 1
Moffitt 1
patient-caregiver 1
self-study 1
Kabat-Zinn 1
(QL), 1
yoga 1
QL, 1
Fifty-nine, 1
maintain. 1
high-fiber, 1
group-based 1
pre-study 1
10.1) 1
infinity) 1
Larger-scale 1
IMPACT: 1
(Advancing 1
Co-operation 1
Infrastructure 1
Predisposition) 1
endeavouring 1
(ACCs) 1
(EU). 1
ACCs 1
Community; 1
akin 1
Form-12 1
(SF-12) 1
'male' 1
(ICSmale) 1
(baseline). 1
SF-12 1
health-status 1
screening-specific 1
ahead? 1
'fast 1
track' 1
colleague, 1
publicised. 1
screened? 1
(LUTS, 1
'screened' 1
verbatim 1
worried. 1
Informing 1
estimate) 1
953 1
Fixing 1
alpha-antichymotrypsin 1
PSA). 1
Disseminating 1
enquirers, 1
withhold 1
Strategic 1
(CPP) 1
stenosis; 1
mesenchymal/osteoprogenitor 1
nonosteolytic 1
(OGS), 1
135-fold 1
serum-independent. 1
/sFRP3 1
(location 1
Wnt-beta-catenin 1
(FRZB, 1
sFRP3) 1
(970C>G) 1
(598C>T) 1
DACHS 1
(Darmkrebs: 1
Chancen 1
Verhütung 1
durch 1
Screening) 1
1.74-14.71, 1
7.52, 1
2.40-23.25, 1
3.66, 1
1.14-11.76, 1
immunoglobins, 1
Protea 1
depletion/isolation 1
(Sigma 1
ProteaPrep) 1
albuminomes 1
reported) 1
albuminome). 1
Vivapure 1
anti-HSA 1
gel-separated 1
Prefractionation 1
micro-solution 1
total-, 1
electropherograms 1
antitrypsin, 1
phospho-, 1
glyco- 1
nondepleted 1
ei 1
body-fluid-specific 1
(cerebrospinal 1
fluid). 1
CSF-specific 1
albumin), 1
99, 1
Mb; 1
LincRNA 1
(fruit 1
repressor: 1
(linc) 1
hypoxia-responsive 1
hypoxia-enhanced 1
Hypoxia/HIF-1α-induced 1
VHL-HIF-1α 1
VHL-mediated 1
vulnerability, 1
(DNHS) 1
(NHSII). 1
DNHS 1
HumanOmniExpress 1
>700,000 1
1963 1
GWAS-derived 1
Reactome 1
Mdig 1
dust-induced 1
(mdig) 1
dust, 1
adenocarcinomic 1
(lincRNA), 1
ndogenous 1
ammalian 1
GRIK3: 1
schizophrenia/intellectual 1
kainate/AMPA-type 1
(GRIK 1
kainate) 1
GRIK1, 1
GRIK4 1
GRIK5 1
neurotransmission, 1
(iGluR) 1
cortico-cortical 1
(OFC), 1
(DLPFC), 1
DLPFC, 1
GRIA3 1
GRIA4 1
(BEC) 1
OFC, 1
GRIA2 1
BEC 1
Ser129D 1
(S129A), 1
(S129D), 1
α-synuclein-positive 1
Ser-129-substituted 1
worm) 1
pan-neuronally 1
(S129A) 1
(S129D) 1
S129D- 1
A30P-α-synuclein 1
A30P/S129A 1
S129A-Tg 1
Daf-16/FOXO 1
S129A-α-synuclein. 1
aggregations, 1
aggregations. 1
typealpha-synuclein 1
2alpha, 1
UPRs, 1
discontinuation). 1
Quality. 1
$US4385 1
ratios>or=$US3450 1
(>or=0.37) 1
monetary 1
<or=$US3900 1
(LPDD) 1
2294 1
-0.53, 1
-0.34, 1
-0.17; 1
Withdrawals 1
SSRIs) 1
syndrome/premenstrual 1
(1950-March 1
PMS/PMDD. 1
ineffective; 1
Anxiolytics, 1
.007) 1
(paroxetine) 1
constipating 1
3-8% 1
-6.76 1
-1.62 1
alprazolam, 1
Buspirone 1
alprazolam 1
agoraphobia. 1
Pub 1
old-old. 1
[Psychiatric 1
Numerous, 1
III-R, 1
schizophrenics, 1
blamed 1
d-fenfluramine, 1
psychoanalytical 1
"femininity 1
complex", 1
ambivalent 1
Horney, 1
Freudian 1
feminine 1
sexuality, 1
negation 1
Homey, 1
"desire 1
penis" 1
sexual, 1
political, 1
cares 1
nineties, 1
Alprazolam 1
posologies 1
DSM, 1
cares. 1
auto-assessment 1
Paroxetine, 1
(NE/5-HT) 1
catecholaminergic, 1
(TCAs) 1
(5-HT(1A)) 1
(5-HT(1B/1D)) 1
autoreceptors 1
2D6. 1
saturable. 1
Paroxetine. 1
5-HT), 1
sertraline. 1
disorder). 1
TCAs, 1
(premenstrual 1
PMDD) 1
mg/day); 1
Sedation, 1
anorgasmia, 1
Four-month 1
29-78) 1
70-100). 1
4.2-8.0) 1
46%-75%). 1
8.5-16.4) 1
(p=0.07) 1
4-46%) 1
12-74%). 1
(EIACs). 1
=18 1
(PFS-6); 1
(NABTC 1
99-04) 1
(6PFS) 1
1-28) 1
32-84); 1
chemotherapy-naïve. 1
Non-fatal 1
granulocytopenia 1
(C.I.) 1
12-38%]. 1
(58.3% 1
8-54 1
(cRA) 1
(XRT). 1
XRT, 1
censored. 1
XRT. 1
(TT). 1
65-141 1
TT-patients 1
49-77 1
T-patients 1
20-52 1
Neuroradiologically, 1
T-group. 1
TT-group, 1
tachyphylaxis. 1
irradiated, 1
external-beam 1
accrued, 1
(proangiogenic 1
~12-fold, 1
5-fold, 1
young) 1
(2.7-fold) 1
(3.8-fold) 1
chemokines; 1
'wounds 1
heal', 1
A549. 1
(VEGF(165)) 1
(VEGF(165)b) 1
rh-endostatin, 1
(betulinic 1
VEGF(165)b-rh-endostatin 1
VEGF-mediated 1
SP1. 1
rh-endostatin. 1
peripherized 1
SDF-1α/CXCL12 1
PF4/CXCL4 1
PAR1-activating 1
(PAR1-AP), 1
P2Y1/P2Y12), 1
VI-targeting 1
collagen-related 1
PAR4-AP 1
engagements 1
PAR1, 1
diphosphate, 1
PAR4 1
(MICR), 1
angiopoetin 1
(Ang-2) 1
Surgery's 1
(POD) 1
(POD 1
7-13, 1
14-20) 1
P<0.0125 1
pro/antiangiogenic 1
218; 1
'poor' 1
'rich' 1
(PLGF) 1
PLGF 1
CHD; 1
PLGF, 1
cerebrovasculature 1
antiangiogenic. 1
Angiogenic 1
working-age 1
microaneuryms, 1
(TGF), 1
(PlGF), 1
(CTGF). 1
intergrins, 1
(PKC), 1
(VCAM), 1
(ECM-MMPs). 1
inteferon, 1
multipotential; 1
neovascularisation. 1
cytokeratin18, 1
"predominance 1
endostatin" 1
0.0245) 1
activation). 1
tamoxifen-associated 1
inhibitor--and 1
(PDGF)-A 1
(Ang2), 1
PDGF-B. 1
PDGF-B, 1
Ang1, 1
anti-VEGFR-2 1
0.0019). 1
post-PDT 1
disclosed. 1
privilege: 1
avascularity, 1
thesis). 1
avascularity 1
[VEGF]; 1
[bFGF]; 1
[MMP-2]; 1
1-MMP 1
[MT1-MMP]) 1
(bFGF 1
(PEDF, 1
restin, 1
MT1-MMP) 1
(NV) 1
de-epithelialization. 1
(HLD-) 1
NV 1
MMP-7 1
privilege 1
vessels). 1
minipumps. 1
5-bromodeoxyuridine(+) 1
factor-beta1, 1
alpha5beta1-integrin 1
peritonea 1
CG-injected 1
alpha(II) 1
prolyl-4-hydroxylase 1
metastases-tumor 1
VEGF165, 1
VEGF165 1
bFGF-stimulated 1
VEGF165. 1
ndostatin 1
Endostatin: 1
Judah 1
Folkman 1
1971. 1
Avastin 1
(anti-VEGF-antibody) 1
sees 1
microencapsulation 1
chloromas 1
neo-angiogenesis 1
1312-1317. 1
PEX, 1
(TSP)-1 1
TSP-1 1
TSP-2 1
CD36, 1
nontoxic, 1
endostatin/sFlt-1 1
(soluble 1
[VEGF] 1
sFlt-1. 1
MHES(r) 1
AdsFlt-1 1
sFlt-1) 1
Adnull 1
transgene), 1
ACI 1
MH/Adnull 1
MHES(r)/Adnull 1
MH/AdsFlt-1-group, 1
77-fold 1
MHES(r)/AdsFlt-1 1
ES(r) 1
sFlt-1; 1
multiplied. 1
HEPATOLOGY 1
(http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html). 1
Endostatin's 1
interpathway 1
Angiosuppressive 1
Cys(135)-Cys(165), 1
angioinhibitory 1
(fragments 1
angiosuppressive 1
cytokines: 1
90.5 1
100.1 1
(42.8 1
(p=0.008). 1
"angiogenic 1
angiostatin. 1
shrinks 1
C3(1)/SV40 1
(P125A) 1
VEGF(188) 1
(Flk-1) 1
(Flt-1) 1
Angiopoietin-2 1
CD-31 1
(platelet-endothelial 1
[PECAM]) 1
Flk-1 1
Flt-1, 1
angiopoietin-2, 1
Tie-1, 1
cadherin-5 1
PECAM) 1
endostatin-treated 1
endostatin; 1
sE-selectin, 1
vasculature-targeting 1
histologies. 1
(43.0 1
0.0002; 1
0.047; 1
Angiogenesis: 1
FGFs), 1
...) 1
neurooncology, 1
cancerology, 1
Marismastat 1
Thalidomid. 1
actors, 1
[Tumoral 1
perspectives]. 1
angiogenesic 1
tumoral, 1
proliferate; 1
tubulogenesis. 1
dormancy". 1
p.Asn786Ser, 1
p.Asn786Ser 1
Baschal 1
(kif6) 1
skolios, 1
(kif6(gw326) 1
(gw327, 1
gw328, 1
gw329) 1
(TALENs). 1
kif6. 1
kif6(gw326) 1
forthcoming. 1
∼327 1
rs1400180). 1
(rs10510181 1
1.29-1.73, 1
Robo 1
HL1 1
1985-2005. 1
1985-2005, 1
8.1%) 1
5.7%). 1
trazodone: 1
synergically 1
SSRIs' 1
deficit-induced 1
(venlafaxine, 1
gabapentin) 1
(0.24‰), 1
pre-adolescents 1
serotonine 1
(established 1
incontinence). 1
Questionnaire-short 1
formality, 1
agreed. 1
52-79). 1
5.56 1
1-18). 1
pads/d 1
harmless. 1
ymptomatic 1
company-based 1
"dapoxetine" 1
"SSRI." 1
Measures. 1
fold-increase 1
(IELT), 1
IELT, 1
ejaculation-delaying 1
commentaries 1
Manufacturer-funded 1
advantageously 1
nonfunded 1
neurobiopathology 1
TURP. 1
neobladder 1
1-35 1
(+/-6.5) 1
(+/-5.9). 1
2-8% 1
debates. 1
visit-based 1
2001-2002 1
(3.22 1
million). 1
1995-1996. 1
207,914 1
415,580 1
345,576 1
269% 1
279,275 1
psychotherapy/mental 1
troubling 1
emerged-the 1
ejaculation, 1
patients/couples 1
bolster 1
hypnotic: 1
Desyrel, 1
sedative-hypnotics 1
symposium. 1
NCDEU 1
aids; 1
non-benzodiazepine 1
six-months' 1
non-nightly 1
Insomniacs 1
therapy-seeking, 1
drug-seeking 1
self-escalate 1
NeuroAIDS/HIV: 1
immuno-neuropathogenesis 1
HoloGenomics. 1
yknons 1
(Parris 1
GE. 1
Biosci 1
2009;2:3-12.). 1
(MDP) 1
Generation-Specific 1
Keys 1
(GSCK) 1
Sall1-family 1
Dnmt3b-family 1
GSCK 1
two-cycle 1
(nmRNAs, 1
envisioned, 1
GSCKs. 1
punctuated 1
(Landsman, 1
287-288; 1
Ushinsky, 1
Bussey, 1
Ahmed, 1
Friesen, 1
Storms, 1
151-161), 1
(rHho1p) 1
di-nucleosome 1
rHho1p:core 1
rHho1p 1
H1-stripped 1
Spt 1
"globular 1
"domains" 1
chromatosome-length 1
(GH1 1
GH5), 1
protect. 1
competitor, 1
linker-histone-depleted 1
GI, 1
perchlorate) 1
folded; 1
bifunctional, 1
nucleosome-binding 1
H5) 1
(Hho1) 1
Intricate, 1
underlay 1
miRNA-induced 1
(miRISC), 1
GW182-mediated 1
PAN2-PAN3 1
CCR4-NOT, 1
poly(a)-specific 1
CNOT6, 1
Mn2 1
Zn(2 1
Mg(2 1
"deadenylation." 1
involved-so-called 1
deadenylases-are 1
(UTRs), 1
microRNAs) 1
Ccr4p-Pop2p 1
(Pumilio 1
Fem-3 1
"deadenylation. 1
Multifunctional 1
Mpt5p, 1
deadenylation). 1
Mpt5p 1
POP2, 1
Ccr4p-Pop2p-Not 1
deadenylates 1
dramatically: 1
elegans). 1
(AtPARN), 1
retarded, 1
bent-cotyledon 1
embryo-specific 1
hyperadenylated 1
Ccr4p/Pop2p 1
immunodepleted 1
Trypanosomal 1
mRNPs. 1
non-translatable 1
earliest, 1
cap-structure 1
(RBPs), 1
networked 1
(AMAGINE-2 1
AMAGINE-3), 1
(sPGA) 1
[AMAGINE-3]; 1
sPGA 1
[AMAGINE-3], 1
(P=0.08 1
ustekinumab) 1
(AMAGINE-2) 1
(AMAGINE-3) 1
NCT01708603 1
NCT01708629.). 1
Anti-IL-17 1
(secukinumab 1
interleukin-17, 1
(IL)17 1
(IL17RA), 1
(280 1
[P=0.03] 1
18%); 1
brodalumab; 1
NCT01516957 1
(PASI, 1
45.0% 1
76.0% 1
16.0% 1
70-mg, 1
140-mg, 1
210-mg, 1
(P<0.01 1
NCT00975637.). 1
Cytokine-targeted 1
(140, 1
302; 1
brodalumab). 1
(post-bronchodilator 1
20%; 1
0.53) 1
(NCT01199289). 1
Keratinocyte-expressed 1
IL17C, 1
timescale. 1
IL-17-responsive 1
transcriptomal 1
keratinocyte-expressed 1
"Psoriasis" 1
"IL-17" 1
Brodalumab: 1
(Th)17 1
Th17-related 1
IL-17E. 1
polymorphically 1
IGL 1
IGL). 1
IGL/3' 1
L1(IGL), 1
unclonable, 1
(ORF-1 1
ORF-2), 1
IGLlocus 1
L1.2, 1
L1.2 1
III-Pol 1
junk 1
jewel. 1
tRNA), 1
superfamilies. 1
"evolutionary 1
junkyard" 1
"fossils", 1
ORF2, 1
280-bp 1
280-9 1
ORF2) 1
ORF2. 1
(Nf1±) 1
histamine-dependent 1
sensitivity). 1
105. 1
NF1-GRD-dependent 1
stilbene 1
Nf1-/+;Trp53-/+ 1
(NPcis) 1
Nf1-/-;Trp53-/- 1
NF1-deficient 1
Breakpoint 1
multiexon 1
IVS27b 1
IVS48. 1
Multiexonic 1
arteriopathy? 1
(NF1-PAH) 1
(BMPR2) 1
autopsy-obtained 1
NF1-PAH. 1
(Plexiform 1
NF1.) 1
"associated 1
extrachromosomally 1
skewedly 1
(D310-tract). 1
Monozygosity 1
missplicing. 1
[c.910C>T 1
(R304X), 1
c.945G>A/c.946C>A 1
(Q315Q/L316M), 1
c.1005T>C 1
(N335N)] 1
(ESEs) 1
(NF1DeltaE7). 1
R304X 1
Q315Q/L316M 1
NF1DeltaE7, 1
N335N 1
somatostatinomas. 1
TGTT 1
(499 1
TGTT). 1
transcrips 1
Nf1. 1
"second 1
neurofibromatoses: 1
p21-ras. 1
Nf1;Trp53 1
Astrocytomas 1
infiltrative, 1
novo). 1
(W336X 1
Q315X), 1
(R304X) 1
(PTT), 1
(TGGE) 1
Upadhyaya 1
Cooper, 1
NNFF 1
Mutation-detection 1
53.7% 1
TGGE, 1
(80.2%) 1
47. 1
single-amino-acid-deletion 1
(GRD) 1
11-17. 1
cysteine/serine-rich 1
PKA. 1
Coincidence 1
12a 1
NF1) 1
double-hit 1
Neurofibroma 1
"neurofibromin." 1
neurofibroma. 1
"neurofibromin. 1
[Molecular-genetic 1
neurofibromatosis]. 1
merline, 1
Neurofibromine 1
resemblances 1
Merline 1
merline 1
C5839T: 1
(C5839T; 1
R1947X). 1
clone-specific 1
Methylation-dependent 1
hit) 1
[Heterogeneity 1
(p120GAP) 1
p120GAP. 1
immunogenecity 1
GapIII/Gap1IP4BP, 1
GapIII/Gap1IP4BP 1
inositol-tetrakis 1
31-39, 1
12,021 1
TATTTTA, 1
homologous/nonhomologous 1
NF1-mRNA 1
1371-1423 1
(GAP), 1
(F, 1
(missense) 1
RAS2Val-19-activated 1
ira 1
1434, 1
NF1s 1
1434. 1
1434 1
ysine 1
oxime-based 1
(knottin) 1
miniproteins 1
low-picomolar 1
non-natural 1
dialdehyde-containing 1
cross-linkers 1
chemical-based 1
oxime-conjugated 1
150-fold 1
pro-coagulative 1
Flow-based 1
(vWf), 1
(PAC1) 1
(CD62P) 1
cilengitide-dependent 1
[which 1
studies] 1
vWf 1
(0.01-1500 1
Tackling 1
N-OEG2, 1
N-OEG11, 1
N-OEG23, 1
Fmoc-N-OEG2 1
N-substituent, 1
epimerization 1
OEG 1
gliobastoma, 1
liophilicity 1
antimeningioma 1
0.813, 1
MRI-estimated 1
antimigratory 1
αvβ3/αvβ5 1
k1-k4. 1
30/35, 1
35/55, 1
k1 1
k4 1
(αvβ5) 1
(αvβ3, 1
PDGF), 1
(PTHrP 1
RANKL), 1
(collagen, 1
CD44) 1
(ILP) 1
bulky, 1
better-tolerated 1
alpha-V 1
perfusate. 1
intra-peritoneal 1
gliomatogenesis, 1
Aza-peptides 1
α-C-atom 1
aza-scanning 1
aza-pentapeptides 1
(Arg-Gly-Asp) 1
cyclo(R-G-D-f-V) 1
aza-glycine 1
cyclo(R 1
-G-D-f-V) 1
Cilengitide: 1
neuro-oncology]. 1
Last 1
radiations, 1
anchorage. 1
O⁶ 1
26071-22072). 1
dose-escalated 1
121974, 1
707544) 1
NCI-6735. 1
DOD/PCF 1
toxicity/progression. 1
(CECs) 1
CECs 1
ng/mL/month. 1
1/9 1
pts), 1
pts) 1
0; 1
(0-61) 1
(15-148). 1
(CENTRIC) 1
β(5 1
alphaIIbeta3 1
arginine-glycine-aspartic 1
2,000-mg 1
ligands-design 1
tumor-targeting 1
c[-RGDfK-] 1
breaching, 1
(polylysines 1
polyglutamates, 1
nanoparticles...). 1
alphavbeta3- 1
alphavbeta5-mediated 1
Program-sponsored, 1
6735 1
6372 1
(RIT), 1
HBT 1
3477 1
Cilengitide-treated 1
(200-260 1
(90)Y-labeled 1
1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic 1
(DOTA)-peptide 1
ChL6; 1
(CMRIT) 1
microg/dose; 1
Lower-dose 1
Ci) 1
0.514). 1
CMRIT, 1
RIT, 1
(LEPR) 1
Leptin. 1
crab-eating 1
AluJb 1
simians 1
prosimians. 1
orangutans, 1
T). 1
(minus 1
(5'ss). 1
(U1) 1
(ExSpeU1) 1
splicing-competent 1
ExSpeU1-mediated 1
Tethering 1
poly(A)-tail 1
prerequisite. 1
(index) 1
Refill 1
(MPR), 1
(MPR(UD)). 1
142,690 1
79,191 1
MPR(UD) 1
(MPR(UD) 1
0.901-0.951, 1
physician-induced 1
ranitidine: 1
expiry, 1
drug-utilisation 1
[DDD] 1
DDD) 1
trend-line 1
(branded, 1
generic) 1
government. 1
germ-fortified 1
lycopene) 1
97.7% 1
consumed. 1
urines. 1
Lycopene 1
soy-fortified 1
multiinstitutional 1
(PUFA)-enriched 1
eicosapentaenoic 1
(DHA). 1
phenolics 1
(181 1
(VCAM-1) 1
PUFAs 1
YTHDF2, 1
'reader'. 1
YTHDF2 1
'eraser' 1
liaison. 1
Aberration 1
m5C 1
destabilising 1
mRNA/lncRNA 1
species-specific. 1
m(7)G 1
(ALKBH5). 1
over-oxidative 1
N(6)-hydroxymethyladenosine 1
(hm(6)A) 1
N(6)-formyladenosine 1
(f(6)A). 1
ALKBH5, 1
"RNA 1
Epigenetics". 1
bisulfide 1
1,246 1
KLHL6 1
11q, 1
Tumour-derived 1
B16-IL-10(-/-) 1
(pcDNA3.1+-CD40L-M) 1
(pcDNA3.1+ 1
-CD40L-M) 1
(TPM2). 1
Glu41Lys, 1
(CNM), 1
(ESES) 1
BDNF/TrkB. 1
Na⁺/H⁺ 1
overacidification 1
NHE6-associated 1
impoverished 1
[Conclusions 1
case? 1
'Bundesausschuss 1
Arzte 1
Krankenkassen' 1
insurance. 1
Base-case 1
Lifetime. 1
Societal 1
payer. 1
$11,290 1
$11,230 1
$244 1
utilities, 1
(death) 1
(perfect 1
decisions: 1
Enbrel, 1
Zyban, 1
Celebrex. 1
authorization, 1
bosentan) 1
Parham, 1
outlays 1
hovered 1
inflation. 1
appropriateness. 1
chromatography--Orbitrap 1
(HRAMS) 1
(LC-HRMS) 1
LC-HRMS 1
±3 1
13-min 1
re-processed 1
'software 1
10-fold), 1
MaxQuant 1
www.maxquant.org 1
FTMS 1
Q-TOF 1
(OT), 1
single-digit 1
subppm 1
polydimethylcyclosiloxane, 1
PCM) 1
trap-orbitrap 1
peptides), 1
(LTQ)-Orbitrap, 1
electrosprayed 1
femtomole 1
LTQ, 1
orbitrap, 1
peptide-like 1
LTQ-Orbitrap, 1
frequency-only 1
(C-trap) 1
(LTQ 1
Orbitrap). 1
MS(n) 1
Antivirals 1
caveat, 1
monocompartmental 1
valganciclovir) 1
(4.8% 1
irreversible) 1
teratogenesis, 1
azospermia 1
(ganciclovir, 1
cidofovir) 1
(foscarnet) 1
valganciclovir: 1
Immunocompromised 1
(SOT) 1
Valganciclovir 1
ganciclovir. 1
CMV-seropositive 1
Party 1
(CDV) 1
prehydration. 1
(61.6%) 1
dditional 1
IL)-2-deficient 1
IBD-directed 1
T-bet(-/-) 1
Rag2(-/-) 1
Interleukin-2, 1
innate, 1
gnotobiology 1
scouring 1
pathomorphologically, 1
microulcerations, 1
mucin-positive 1
interdigitating 1
(CTH) 1
(PF), 1
CTH 1
morphometrics 1
Karyotype-phenotype 1
(proband) 1
hyposplasia 1
syndrome/association, 1
karyotype) 1
10q. 1
resolution), 1
(6p.25.3p23 1
1,587 1
T961G 1
MTRNR1 1
(12S 1
rRNA) 1
(CTDs) 1
KFS. 1
GDF3 1
GDF6 1
GDF6. 1
Agenesis. 1
Skenes 1
cubitus 1
microdeletion: 1
(RSTS, 1
180849) 1
610543). 1
ADCY9 1
SRL. 1
5q22.3q23.3. 1
karyotype-phenotype 1
5q?15 1
5q?22 1
(amongst 1
colobomata, 1
horseshoe 1
5q22.3q23.3 1
microbrachycephaly, 1
downturned 1
corners 1
fifth-finger 1
crease, 1
(F5, 1
1q23) 1
(F13B, 1
1q31-q32.1) 1
(AT3, 1
1q23-q25.1) 1
ATIII 1
abnormality--a 1
hypalagesia 1
craniogram 1
inion 1
platybasia. 1
Decompressive 1
syringosubarachnoid 1
Rhabdoneuroglial 1
flexure 1
oromotor 1
microvesicles. 1
vesicular, 1
organelle-like 1
(microvesicles, 1
MVs) 1
sarcoma-specific 1
TC135 1
251-343 1
Dichroism 1
251-280 1
251-343) 1
biding 1
(EFTs) 1
neuroepithelioma) 1
Rare-disease 1
endosialin. 1
endosialin-directed 1
EWS-Fli1. 1
(PDGF)-BB-induced 1
EWS-Fli1-knocked 1
(PL)-D2. 1
1-butanol, 1
alcohol), 1
proliferation-signaling 1
(solid 1
[Increase 1
SMAC/DIABLO 1
makings 1
BIRC5, 1
7:11. 1
(N=8) 1
Alu-generated 1
PTC+ 1
IAPs' 1
IAP-targeted 1
(BL) 1
-74 1
-104 1
Survivin-deltaEx3 1
survivin-2B: 1
(RCCs), 1
(survivin-deltaEx3) 1
(survivin-2B). 1
survivin-deltaEx3 1
survivin-2B. 1
RCCs 1
(PDEF) 1
RT/PCR 1
(FHIT) 1
3p14.2, 1
(TMA). 1
93.75%, 1
68.75% 1
46.25%, 1
Demons-meigs 1
(General 1
Thiers, 1
laparoscopico-laparotomic 1
paracentesis 1
objectified 1
re-operated 1
omentectomy 1
Demons' 1
/thecoma. 1
Meig's 1
90×109 1
CXR. 1
ascetic 1
120×100 1
adnexa 1
bowels 1
fibro/ 1
fibroma, 1
C-MYC 1
(CRD-BP/IMP-1) 1
(mCRD-BP) 1
(hIMP-1) 1
hCRD-BP/IMP-1. 1
(14.4 1
copies). 1
K-homology 1
zipcode-binding 1
furocoumarins: 1
counterion 1
DNA-affinity 1
exothermic, 1
enthalpies 1
furocoumarins. 1
dichroic 1
DNA-photobinding 1
methylpsoralen 1
(3,4'-dimethylpsoralen 1
3,4',8-trimethylpsoralen) 1
furocoumarin 1
3,4'-dimethyl-8-methoxypsoralen. 1
adenine-thymine 1
chromatin) 1
8-methoxy 1
(8-MOP). 1
3,4'-dimethyl-8-MOP 1
trimethylpsoralen 1
Z-DNA: 1
GAATTC(TG)6TA(TG)6. 1
5'TA 1
5'AT 1
EcoR 1
(GAATTC) 1
5'TAs 1
(TG)6TA(TG)6 1
Photoreaction 1
ColE1amp 1
Photobinding 1
monofuctional 1
10(4):1, 1
4,4&apos;,5&apos;-trimethylazapsoralen, 1
Score≤8 1
(1mg/kg 1
selfotel, 1
pegorgotein 1
(PEG-SOD), 1
deltibant 1
dexanabinol 1
reassessed, 1
(SPSS 1
IL, 1
6.31 1
2.27, 1
connotations. 1
(ChAT). 1
chromatolysis. 1
chromatolysis 1
myelin-producing 1
(Olig1) 1
Xiao 1
Fifth-six 1
(KPS). 1
PG, 1
(P>0.05); 1
GOS, 1
KPSin 1
(VDH), 1
PROG, 1
inexpensive. 1
institutionalized, 1
PROG 1
VDH 1
effective? 1
(CDSR). 1
CDSR 1
table. 1
Sex, 1
reputation 1
modulators). 1
acid/tryptophan 1
TRP, 1
KYN, 1
KYNA 1
(+103%) 1
(+44%), 1
(+56%) 1
(-35%). 1
0.622), 1
0.797), 1
micro-albumin/24-h 1
0.518) 1
-0.662), 1
<0.001. 1
71,149 1
population-, 1
(AGEN). 1
(eGFRcrea) 1
KidneyGen, 1
CKDGen 1
GUGC 1
consortia, 1
∼110,347 1
serine-129 1
(phospho-serine-129 1
[PSer129]) 1
Somal 1
lateral/basolateral 1
Lewy-like 1
(PSP/LBD). 1
(LBD), 1
(NFT) 1
PSP/LBD, 1
PSP/LBD. 1
nonphospho-tau 1
(Alz50, 1
CP9, 1
PG5, 1
PHFI) 1
Tau-immunoreactive 1
Meynert, 1
coaggregate 1
(DLBD) 1
subcortical, 1
DLBD, 1
alphaS-positive 1
(NI), 1
alphaS. 1
(SLA) 1
DLBD. 1
x100 1
NI. 1
NI 1
Neocortical 1
prodigious, 1
myelinated, 1
faintest 1
medianum, 1
immunolabeling, 1
sturdily 1
(GCIs) 1
GCIs. 1
high-molecular 1
GCI 1
(HSS) 1
Grossly, 1
sponginess 1
segregated. 1
4p15 1
synuclein-positive 1
(N=121). 1
(IUGR). 1
(23.2%) 1
resp. 1
22%). 1
gestatio 1
9067 1
(EIF) 1
(EB). 1
(22.9 1
28.0 1
(20.3% 1
4.5; 1
1.3-16.9). 1
0.76-0.91). 1
0.8-8.9). 1
EB. 1
[Fetal 1
significance?]. 1
subjectivity 1
significance? 1
7400 1
sonodensity 1
bleeding: 1
Spectrophotometric 1
blood-stained 1
(8/40 1
3/64 1
[5%], 1
hyperchogenic 1
ethnic/racial 1
Eastern, 1
Hyperechogenic 1
Postpuncture 1
(0.5%). 1
Trimetazidine, 1
[1-(2,3,4-trimethoxybenzyl)piperazine; 1
TMZ] 1
Ischemia/reperfusion 1
b.wt.) 1
(-I/R; 1
+TMZ). 1
pO2 1
hyperoxygenation 1
I/R). 1
p-Akt 1
Phosphatidylinositol-3,5-bisphosphate: 1
D-myo-inositol 1
PtdIns-3,5-bisphosphate 1
[PtdIns(3,5)P2] 1
PtdIns(3,5)P2 1
metabolic/physiological 1
PtdIns(3,5)P2, 1
"MTMRs"). 1
(MTMR12) 1
Triads, 1
whorled 1
MTMR12. 1
myotubularin-MTMR12 1
"MTMRs") 1
autophagosomal-lysosomal 1
ceMTM3, 1
FYVE-domain 1
feeding-based 1
atg-18 1
mtmr2 1
Ser(58), 1
S58E 1
(S58A) 1
PI(3)P-specific 1
PI(3,5)P2, 1
(RME-8) 1
DsRed-FYVE, 1
S58A 1
phosphatase-kinase 1
ten-amino 1
(hMTM1), 1
(hMTMR2) 1
(PI(3)P), 1
MTMR1, 1
MTMR3, 1
PI(3)P, 1
indistinguishable, 1
FYVE-finger 1
hMTMR3 1
Rac-inducible 1
©2002 1
phosphoinositide-3-phosphatase 1
MTMR13, 1
(CMT4B) 1
CMT4B 1
SET-binding 1
CMT4B, 1
MTMR2-MTMR13 1
MTMR13. 1
MTMR2: 1
PTPs. 1
GRAM 1
PI-specific 1
phosphatases). 1
(PTP/DSP) 1
metal-independent 1
Cys-X5-Arg-Thr/Ser 1
(CX5RT/S) 1
PtdIns3P 1
PtdIns(3,5)P₂ 1
PtdIns5P. 1
PtdIns5P 1
(XLCNM) 1
MTMR14 1
(JUMPY) 1
myotubularin-associated 1
inevitability 1
ter-region 1
genitalium, 1
fulgidus. 1
beta-type 1
gamma-type 1
oriL 1
oriL. 1
welve 1
(USP49) 1
RuvB-like1 1
(RVB1) 1
SUG1 1
>9000 1
(uH2B) 1
USP49, 1
U1A 1
U2B 1
uH2B 1
splicing; 1
coordinator, 1
Npl3, 1
NPL3 1
Bre1, 1
mono-ubiquitinates 1
RAD6 1
de-ubiquitinase 1
UBP8, 1
NPL3, 1
(Tb) 1
multi/extensively 1
(MDR/XDR-Tb) 1
2050 1
Guerin 1
MDR-TB.AREA 1
received>6 1
Extensively 1
(XDR-TB). 1
mismanagement 1
normalize, 1
nonsurgically 1
no.: 1
Critics 1
notes, 1
non-bypass 1
(1.30 1
normalize. 1
(54.3 1
(45.4 1
(100%; 1
(99%; 1
(top-down) 1
metal-free 1
30-nm 1
methylations, 1
non-CDK 1
yet-to-be-established 1
(FT) 1
charge-state 1
(ion 1
trap) 1
ProSight. 1
Ultra-high 1
resolution/high 1
modifications/variants 1
ESI/FT-ICR 1
laevis) 1
ESI/FT-ICR-MS. 1
(Gly102Ala, 1
Cys110Ala, 1
Gly111Ala) 1
Lys-9, 1
attached, 1
lysine--aminoethylcysteine--in 1
aminoethylcysteine 1
re-calculated 1
A1a. 1
HMGA1a, 1
electron-transfer 1
Arg25 1
OrbiTrap, 1
expression-centric 1
>10(4) 1
Lys-20, 1
Arg-3, 1
Arg-3 1
Lys-20 1
(K20) 1
K20-dimethylated 1
epigenetically. 1
salt-adducted 1
ESI-FTMS. 1
H2A.F/Z 1
alpha-N-acetylated, 1
H2A.O 1
H2A.C,D,I,N,P 1
bird's 1
+168 1
K9. 1
K23 1
+14 1
H3.1. 1
colchicine-treated 1
diphosphorylated, 1
S28. 1
H2B.Q, 1
H2B.A, 1
H2B.K/T, 1
H2B.J, 1
H2B.E, 1
H2B.B, 1
H2B.F, 1
monoacetylated 1
mid-S, 1
mid-G2, 1
mid-G1 1
"Histone 1
Code". 1
+112 1
atop 1
Lys20, 1
Lys16 1
(resolved 1
Deltam 1
0.036 1
"isomers" 1
next-best 1
projected. 1
Laparoscopic-assisted 1
totalis. 1
cT1bN0N0 1
D1+ 1
trocars 1
Specificities 1
procured 1
totalis--a 1
Comorbid- 1
ities 1
Explantation 1
20-month 1
agnosed 1
dextrocardia: 1
(NMS) 1
circumferential-radial 1
shear. 1
(MRT) 1
(εcc) 1
(Δεcc) 1
Circumferential-radial 1
(εcr) 1
apex-to-base 1
hovers 1
Torsion 1
εcr 1
(Δεcr) 1
deviates 1
equator. 1
Apex-to-base 1
equator, 1
equator 1
Invariance 1
εcc 1
Δεcc 1
previously-unrecognized 1
previously-unfound 1
diagnosis-making 1
totalis, 1
managements, 1
aneurysm: 1
minilaparatomy 1
evisceration. 1
obliquely 1
duodenojejunal 1
ileocecal 1
minilaparotomy 1
evisceration 1
hemiabdomen, 1
Rab3-interacting 1
(RIM1α) 1
"switching" 1
Uba2 1
(DmUba2 1
DmUbc9) 1
Aos1 1
(DmAos1 1
DmSUMO-1), 1
DmUba2/DmAos1 1
DmUbc9. 1
base-sensitive 1
challenges]. 1
record, 1
pre-mixed 1
insulins 1
meal-time 1
detemir 1
antihyperlipidaemic 1
(PB; 1
locust 1
bean), 1
condiment 1
spice, 1
(Daonil; 1
Sanofi-Aventis, 1
Paris, 1
(FPG), 1
(diabetic 1
Daonil 1
E)) 1
(non-diabetic 1
B)). 1
glibenclamide-treated 1
anti-arteriogenic 1
mellitus), 1
diazoxide- 1
nicorandil-activated 1
(KCOs) 1
NAD-system 1
potassium-dependent 1
KCO-mediated 1
de-energised 1
KSCN 1
(mitoK(ATP) 1
poor-controlled 1
gangrane, 1
chlorpropamide 1
IDDM, 1
toxity 1
sulfhydryl-specific 1
Arg-5, 1
Asp-50, 1
Tyr-162, 1
Asn-165, 1
Arg-5 1
His/Lys-Asp-Glu-Leu 1
Asp-Asp-Glu-Leu 1
sorting-proteins 1
destination, 1
erd2p-mediated 1
myo-inositol-monacolin 1
women]. 1
oligo/amenorrhea, 1
anovulation, 1
Hyperinsulinemia 1
monacolin 1
monacolinin 1
hirsutism. 1
myo-inositol/monacolin 1
nti-Müllerian 1
secretagogue, 1
(CIGMA) 1
(HOMA, 1
0.330, 1
CIGMA, 1
0.568, 1
hyperandrogenemia, 1
GeLC-MS/MS. 1
lanes 1
Protein-level 1
(697 1
(480 1
232) 1
(1677 1
3131), 1
(1150 1
(448 1
480). 1
interspecimen 1
monitoring-based 1
(qCCP) 1
monitoring-mass 1
(MRM-MS) 1
(SIS) 1
qCCP 1
LC-MRM-MS 1
SIS 1
99.4 1
102.6 1
equaled 1
106.0 1
metrologically 1
traceable, 1
traceability 1
(Pelodiscus 1
(SSTEW) 1
I-converting 1
lysozyme-derived 1
(IC50=4.39±0.31μM). 1
(Ala354 1
Tyr523) 1
S2' 1
(His513 1
His353) 1
purity) 1
yield) 1
food-derived 1
preanalytical 1
proteomics-grade 1
(HSA). 1
desalted 1
NIST 1
MSQC 1
"sequence 1
maps". 1
porcine). 1
(NH2 1
-MOSF) 1
-MOSF 1
preloading 1
(CICs); 1
(nano-LC-MS/MS). 1
factors-the 1
(C18-packed, 1
C8-packed, 1
column)-on 1
25-400 1
miscleaved 1
stimulation-assisted 1
focusing: 1
subsamples 1
IEF, 1
RP-HPLC-MS/MS. 1
IEF 1
subfractionation. 1
trypsins. 1
1000-fold. 1
high-mass-accuracy 1
autolytic 1
nontryptic 1
O-sulfated. 1
TMT-multiplexing 1
(dodecyl 1
(buffer, 1
RapiGest, 1
acetate). 1
(fragmentation) 1
newcomer 1
Pro. 1
reflections 1
Advion 1
Triversa 1
Nanomate 1
Label-Free 1
Data-Dependent 1
(MS1) 1
Data-Independent 1
(MS2) 1
Acquisitions. 1
MS2, 1
Data-dependent 1
SCIEX 1
(SWATH) 1
multiprotease 1
LysC/trypsin 1
(LysC 1
LC-ESI-tandem 1
O-glycoproteins 1
oxidation/elimination 1
restaining 1
picking, 1
α-casein 1
digestion). 1
Deglycosylation 1
N-glycoprotein 1
Alg3p. 1
peptide-N-glycosidase 1
Cis3p, 1
(MtbMfd) 1
Mtbmfd 1
(Ecomfd) 1
road-block 1
∼1.5-fold 1
MtbMfd, 1
(MfdΔC) 1
∼10-fold 1
MfdΔC, 1
EcoMfd 1
Rad26-independent 1
MSH3. 1
prioritised 1
nick, 1
"fast" 1
"slow" 1
factor/RNA 1
CarD 1
CdnL), 1
β-subunit. 1
2.9-Å 1
RNAP-β1 1
TRCF/RNAP 1
TRCF, 1
CarD, 1
A-resolution 1
TRCF. 1
Tudor-like 1
TRCF/RNA 1
uncoupled. 1
ops 1
(operon 1
nonstalling 1
imipramine, 1
(DSM-IV), 1
Mental, 1
(DSM-V), 1
Tenth 1
(ICD-10), 1
75-year-olds. 1
2005-2006, 1
777; 1
DSM-IV. 1
DSM-V. 1
46.9% 1
89.7% 1
75-year-olds, 1
venlafaxine-extended 1
(remission). 1
(8-week) 1
(6-month) 1
718 1
gender-stratified 1
0.94-2.47). 1
2.42, 1
1.16-5.07). 1
0.94-2.47) 1
glucocorticoid-dose 1
2.12, 1
P=0.04) 1
SIRIUS 1
NCT01691508.). 1
(SGRQ) 1
5-item 1
(ACQ-5). 1
SGRQ 1
MENSA 1
NCT01691521.). 1
dulipumab) 1
(phenoendotypes) 1
irreversibly, 1
SEPAR. 1
myositis: 1
Eosinophilia-associated 1
perimyositis. 1
perimyositis 1
non-hematologic 1
allergic, 1
(PDGFRA)-positive 1
PDGFRA-negative 1
(EOS) 1
Atopic, 1
(WLAC). 1
post-WLAC 1
EOS-specific 1
SBP-Ag 1
(299), 1
(99), 1
WLAC 1
(365)) 1
unseparated 1
(symptoms, 1
(FEV1%) 1
0.16), 1
FEV1% 1
(OCS): 1
spending. 1
I/IIa 1
ICS/OCS, 1
(DREAM): 1
12-74 1
0·9% 1
NCT01000506. 1
randomised: 1
2·40 1
1·24 1
31-61%; 1
1·46 1
19-54%; 1
1·15 1
36-64%; 1
oesophagus. 1
(asthma, 1
hay 1
eczema). 1
papules, 1
and/ 1
damage/dysfunction. 1
M-HES, 1
fip1-like1/platelet-derived 1
(FIP1L1-PDGFRA), 1
FIP1L1-PDGFRA-positive 1
interferon-alpha; 1
www.pubmed.gov 1
eosinophil-directed 1
[What's 1
medicine?]. 1
Antisynthetase 1
(Anti 1
JO1, 1
PL7, 1
PL12). 1
(Raynaud 1
phenomenom 1
"mechanic'hands") 1
"unexplained" 1
japonese 1
gastroenterologists, 1
hallmark: 1
(IgG4). 1
interleukin1 1
(multifocal 1
osteitis, 1
pustulosis) 1
sputum/blood 1
improvments 1
83.8+/-33.4% 1
47.7+/-40.5% 1
NCT00292877.) 1
50-week 1
(AQLQ, 1
important), 1
(FEV(1)) 1
bronchodilator, 1
sputum. 1
subject; 1
bronchodilator 1
(Current 1
ISRCTN75169762.) 1
myeloproliferative, 1
FIP1L1-PDGFRA. 1
Report). 1
augur 1
microliter. 1
5.26; 1
6.45; 1
6.7+/-1.9 1
4.3+/-2.6 1
NCT00086658 1
(400-1,000 1
beclomethasone 1
equivalent). 1
Morning 1
beta(2)-agonist 1
(blood, 1
0.065). 1
non-parasitic 1
hypereosinophilia]. 1
(>1500 1
10(9)/L) 1
suspected: 1
Fip1-like1 1
(FIP1L1) 1
[IL-5], 1
[GM-CSF]) 1
Eosinophil-derived 1
nonasthmatic 1
Eosinophil's 1
29-89%; 1
(45-76%, 1
67-100%, 1
(airway 1
antieosinophil 1
(IgG1/�) 1
F/P-negative 1
thymus-and-activation-regulated 1
600/μL. 1
(>1000 1
600/μL, 1
� 1
ASM8) 1
electro-clinical 1
(IEDs) 1
Doose's 1
diets: 1
nowadays; 1
(c.4205_4208delGAAA) 1
(c.3521C>G) 1
(ICE-GTC) 1
(MAE), 1
epileptologist) 1
(AEDs): 1
(can 1
cannabidiol, 1
Phenobarbital 1
AEDs: 1
choreoathetosis; 1
driving, 1
working/playing 1
heights). 1
(SCN1A-SMEI) 1
ICE-GTC 1
(MAE 1
mechanisms? 1
(McArdle 1
(ILAE, 1
1989), 1
2.2: 1
"Cryptogenic 1
syndromes." 1
Ref. 1
"generalized 1
(SMEI 1
epilepsy/pseudo-Lennox 1
(ABPE/PLS) 1
"epileptic 1
ABPE/PLS, 1
delayed). 1
Community-based 1
continuum. 1
neurobiologic 1
(1975-1985), 1
(Helsinki 1
Uusimaa) 1
Ranks 1
rank-order 1
LGS. 1
seizures) 1
6p11, 1
1p, 1
Yasuda 1
Inazuki, 1
Zara 1
(1995). 1
Unverricht 1
Lundborg 1
lipofuscinoses 1
Spielmayer 1
Voight 1
Battens 1
sialidosis, 1
dentadorubropallidoluysian 1
MERRF. 1
Lafora's 1
speedily 1
Electroencephalographic 1
(GBSSW) 1
atonia. 1
deteriorate. 1
callosotomy 1
intractability 1
(MAEE) 1
polygraph. 1
nodding 1
dropping 1
0.3-1 1
spike(s) 1
MAEE. 1
["Benign" 1
tonic. 1
hyperkinetic, 1
convulsive, 1
CMT2D/dSMA 1
(non-demyelinating) 1
EMG/NCV 1
physiatrists, 1
therapist; 1
ankle/foot 1
(AFO) 1
walking; 1
cavus; 1
crutches, 1
canes, 1
Achilles' 1
nitrofurantoin). 1
Career 1
(CMT2A1), 1
(CMT2A2), 1
RAB7A 1
RAB7) 1
(CMT2B), 1
(CMT2B1), 1
(CMT2B2), 1
TRPV4 1
(CMTC), 1
(CMT2E/1F), 1
(CMT2F), 1
(CMT2I/J), 1
(CMT2H/K), 1
(CMT2L), 1
(CMT2N). 1
GARS1-Associated 1
[CMT2D/dSMA-V]) 1
early-adult 1
muscles; 1
pinprick, 1
stocking 1
often] 1
glove 1
GARS1 1
hands; 1
toe-up 1
braces, 1
ankle-foot 1
orthotics 1
Hirayama 1
inquire 1
(dSMA) 1
(dHMN-V), 1
Sephardic 1
Neurophysiologically 1
(ELA 1
(MDS)/leukemia. 1
(ANC 1
>1,000/microL) 1
(rhG-CSF). 1
NFS-60. 1
G-CSF-mRNA 1
(rhG-CSF) 1
(RhoA 1
Rac2) 1
GDIs 1
(LyGDI 1
RhoGDI) 1
200/microL 1
G-CSF-induced 1
Ca(++ 1
)mobilization). 1
(GDP)-dissociation 1
2000;95:2947-2953) 1
Open-label, 1
rhGM-CSF. 1
(myelokathexis); 1
micrograms/m2 1
area.d 1
19.2 1
ano-rectal 1
G325R, 1
448-600ms). 1
ß-subunit, 1
voltage-dependence 1
12.0mV, 1
co-assembly 1
p.G316E 1
glycine-to-glutamate 1
guanine-to-adenosine 1
P320 1
arrhythmia-related 1
P320H, 1
P320A 1
filter/pore 1
risk-assessment, 1
mutation-site 1
Cardiology, 1
Silesia 1
Katowice-Ligota, 1
ECG) 1
Bioethics 1
Silesia. 1
Overexpression, 1
self-terminating, 1
warning. 1
degenerates 1
defibrillated) 1
preteen 1
LQTS; 1
beta-blocker-resistant 1
pointes; 1
RWS, 1
LQT2) 1
LQT3) 1
Other, 1
LQT5), 1
LQT6), 1
CAV3 1
LQT9), 1
SCN4B 1
LQT10), 1
AKAP9 1
LQT11), 1
SNTA1 1
LQT12) 1
KCNJ5 1
LQT13). 1
conservation) 1
conservation). 1
subcategorized 1
0-0.469; 1
(0.470-0.665; 1
1.58, 1
(>0.665; 1
196) 1
3.32, 1
KCNQ1A344V 1
toxicologically 1
ropivacaine, 1
mepivacaine 1
(KCNQ1wt/KCNE1: 1
2,431 1
KCNQ1A344V/KCNE1: 1
Luo-Rudy 1
(KCNQ1-P343S) 1
(KCNQ1) 1
(P343S) 1
V254M 1
V417M 1
(556 1
(V254M) 1
frame-shifts 1
'hot-spot'). 1
IKS 1
'poison 1
pill' 1
LQT1. 1
614, 1
Bsp12861 1
(R518X 1
A525T). 1
R518X 1
A525T 1
'sporadic 1
RWS' 1
IKr. 1
"family-specific" 1
alanine-to-threonine 1
(melanoma 1
wenty-nine 1
"garment" 1
postadmission. 1
Smaller-sized 1
nonlobulated, 1
spared. 1
parent-pressured 1
expounded 1
subsidy 1
Nigerians. 1
scant, 1
(lentigo 1
maligna) 1
Blacks, 1
over-all 1
histologica-ly 1
feer 1
Negro. 1
esveratrol 1
regiment 1
antiproliferation 1
TMZ-mediated 1
feedback-loop-relevant 1
ERK-MAPK 1
(P-AKT) 1
MCF-7. 1
mTOR/p70S6K 1
rapamycin-mediated 1
resveratrol-rapamycin 1
phytopolyphenol 1
PI3K/AKT/FOXO 1
(LY294002 1
Wortmannin) 1
PTEN-G129E 1
PTEN-G129R 1
FKHR, 1
FKHRL1 1
AFX 1
p27/KIP1, 1
(FOXO1-TM, 1
FOXO3A-TM 1
FOXO4-TM) 1
p27/KIP1 1
(FASN) 1
FASN, 1
Her2-overexpressed 1
cytotoxicity-based 1
Annexin-V-PI 1
immunobloting 1
(SKBR-3) 1
resveratrol-mediated 1
SKBR-3 1
PEA3, 1
H4-II-E 1
self-phosphorylation 1
eIF4E-BP1. 1
eIF4F 1
eIF2α. 1
Futhermore, 1
AMPK/mTOR 1
nPlasmodium 1
(163 1
(P=0.0003), 1
nonsevere 1
47.06 1
6.02 1
51.24 1
6.75 1
steep. 1
-6.70 1
-7.67 1
(-1.97 1
6.21 1
(+0.53 1
0.839). 1
43.97 1
5.81 1
46.55 1
6.82 1
-6.58 1
-7.69 1
(-1.56 1
(+0.45 1
-3.09 1
-4.19 1
2.96 1
flattened. 1
adiponectin-deficient 1
(APN-KO) 1
APN-KO 1
(COX)-2-dependent 1
carrier's 1
place: 1
E280A 1
angiopathy-associated 1
skepticism 1
per-kilogram 1
(Aβ1-40) 1
(F19A) 1
15-30) 1
tracer, 1
microhemorrhage, 1
plasma; 1
(http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_07_05_KP%20OxcarbazepineFDAlabel102005.pdf). 1
oxcarbazepine. 1
Web-based, 1
α(2)-δ 1
Pharmacovigilance 1
Lareb. 1
Lareb 1
First-time 1
pregabalin. 1
11-89), 1
questionnaire; 1
(76.5%) 1
drunk, 1
(<1.0%) 1
antidiabetics. 1
e-mailed 1
vulvodynia. 1
dermatomes 1
hugs 1
paroxysm 1
163-750 1
36-410 1
11.5-122.5 1
(400-km 1
hospital). 1
diphenhydramine. 1
amitriptyline. 1
NEFA, 1
Ca2+-ionophore. 1
6-keto-F1 1
prostacylclin), 1
LTD4 1
LTE4 1
(breakdown 1
LTC4). 1
Ca2+-overloaded 1
+-overload 1
-ionophore 1
Taurine's 1
(2-aminoethanesulfonic 1
lanthanum. 1
paradox: 1
methyltransferase-polymerase 1
completes 1
RdRP-MTase 1
inter-regulations 1
50,605 1
50-77 1
(3002 1
(7413 1
1.09; 1
47,231 1
Human-6 1
BeadChips®. 1
Flexarray 1
(IPA). 1
1,136 1
1,021 1
1,163 1
IPA 1
NCT: 1
NCT01343342. 1
cross-referencing, 1
Master's 1
theses, 1
concentrations: 1
non-HDL-C, 1
(TG). 1
Random-effects 1
1,401 1
(282 1
(-15.5 1
-20.3 1
-10.7), 1
TC:HDL-C 1
-0.2), 1
(-9.2 1
-12.7 1
-5.8) 1
(-10.6 1
-17.2 1
-4.0) 1
6.6%, 1
mayonnaise, 1
cookies, 1
eggs), 1
vegetables), 1
yogurt 1
yogurt, 1
bread), 1
mayonnaise 1
meat). 1
1.01-3.07) 1
1.32-5.23). 1
0.31-0.96). 1
1.25-4.06). 1
patterns-"prudent" 1
"Western"-and 1
0.60-0.98; 1
test,.03) 1
1.07-1.99; 1
test,.02) 1
0.44-0.92) 1
Weight-restored 1
(SLC6A4, 1
SERT) 1
(5-HTTLPR) 1
child+parents) 1
(TDT). 1
(McNemar's 1
chi(2)=0.01, 1
p=0.921, 1
0.7-1.5). 1
(NETpPR) 1
(chi(2)=0.48, 1
p=0.490). 1
NETpPR 1
Neurotransmitter 1
(Ki) 1
histamine1 1
"dual 1
inhibitor", 1
0.965) 1
0.983) 1
histamine1, 1
protein-coupled, 1
muscarinic, 1
&quot;dual 1
inhibitor&quot;, 1
(SERT), 1
radioligand) 1
>10nM. 1
reboxetine, 1
(NET), 1
Reuptake 1
potently) 1
parachloroamphetamine. 1
raphe-localized 1
WAY100,635. 1
ceruleus-localized 1
idazoxan. 1
ventrotegmental 1
(delivered 1
(RT(50)) 1
RT(50) 1
alpha(2)-adrenergic 1
WAY 1
100635 1
tabagism 1
(anti-CCP2) 1
(EAM), 1
EAM, 1
non-tobacco 1
7.7-fold 1
5.15-fold 1
(SOFI) 1
BARFOT 1
"Better 1
Anti-Rheumatic 1
FarmacOTherapy") 1
(TotSharp), 1
0.316, 1
0.313) 1
(ESR). 1
0.135 1
0.220) 1
[432 1
18-85); 1
2-548)] 1
SDAI, 1
CDAI, 1
0-100, 1
0.07-46.60) 1
(0.00-42.10). 1
(0.07-46.60) 1
(0.10-35.20) 1
(0.00-42.10) 1
(0.00-32.00). 1
(SDAI: 1
0.660, 1
CDAI: 1
0.671, 1
ESR) 1
(<45, 1
45-65 1
(ANOVA). 1
(<3.2). 1
>3.2, 1
DAS28(CRP) 1
expression? 1
1991-2000. 1
simmetricity 1
mm/1st 1
concerninig 1
min/1st 1
Emotion 1
(ambiguity, 1
gender-specificity 1
(psychological 1
well-being, 1
ambiguity, 1
gender-sensitive 1
(FIND 1
base; 1
http://www.findbase.org) 1
population/ethnic 1
(http://www.getpivot.com), 1
(http://www.silverlight.net) 1
affiliating 1
Proteomics, 1
HG, 1
Encephalopathy 1
Gastrectomy 1
Morbid 1
publisher 1
publisher. 1
(ENT) 1
EtOH-TD 1
(EtOH-TD5) 1
(TD5), 1
microglial-neuroimmune 1
ENT, 1
TD10 1
EtOH-TD10. 1
THAL, 1
(AcCoAS) 1
THAL. 1
glycerin 1
triacetate 1
(GTA) 1
neuroinflammation; 1
(controls+glucose, 1
n=6; 1
pyrithiamine+saline, 1
n=5; 1
pyrithiamine+glucose, 1
glucose-challenged, 1
N-acetyle 1
lactate) 1
(MCP-1, 1
nutrition]. 1
B1--in 1
load--delivered 1
vitamin. 1
thiamin. 1
amaurosis. 1
pellagra 1
pneumonia]. 1
mental-status 1
Pellagra 1
Niacin 1
Malnourished 1
niacin. 1
injure 1
DWI, 1
polyneuropathies. 1
7-week 1
examined: 1
Nystagmus: 1
malabsorptive 1
proves, 1
(SG), 1
Mecp2-null 1
TrkB, 1
(Het), 1
LM22A-4, 1
apneas, 1
LM22A-4 1
pruning 1
postnatally). 1
gamma-amino-butyric 1
birthplace 1
Epigenetics, 1
circuitries, 1
"landscape". 1
midadulthood. 1
packaged. 1
smoking/tobacco-related 1
F2RL3 1
polyphenol- 1
commonly-assumed 1
twins? 1
signalled 1
hydroxymethylation), 1
presently-understood 1
Maternal-foetal 1
nurture 1
modifications), 1
'metabolic 1
memory' 1
'wiped 1
clean' 1
Septic 1
(SAT). 1
(THRB1, 1
THRA1), 1
(RXRA, 1
RXRB, 1
RXRG), 1
(NCOR1), 1
(SMRT), 1
(SRC1), 1
(UCP3) 1
RXRA 1
orientated 1
(muscle) 1
(adipose 1
(D1 1
(D2). 1
D1-generated 1
deiodinase-expressing 1
T3/d 1
(S>F) 1
steady-dose 1
[CYP2C9 1
rs7294 1
(-1639 1
G>A)]. 1
expoxide 1
798 1
[rs12572351 1
rs9332146 1
rs4917639 1
(CYP2C9(*)3), 1
rs1934967 1
rs1934968 1
(VKORC1-1639 1
rs2359612 1
T] 1
representativeness. 1
CYP2C9(*)3 1
rs10871454G 1
VKORC1-1639G 1
92.04% 1
88.03%, 1
with-1639. 1
CYP2C9) 1
beware 1
bioenvironmental 1
signing 1
volunteer: 1
brand. 1
PROC; 1
co-medication 1
(amiodarone, 1
fluoxetine) 1
(phenytoin, 1
carbamazepine), 1
(*2) 1
dose/week 1
47.4% 1
*2) 1
dosing: 1
(-1639A 1
(*1/*2/*3) 1
(*A/*G) 1
0.112 1
0.528. 1
Sudanese, 1
*3, 1
*8, 1
*9, 1
*11), 1
CYP2C9*2,*5,*6, 1
*11 1
CYP2C9*1/*1 1
rs8050984, 1
rs7199949 1
*11; 1
-1639G 1
430C 1
1075A 1
>C) 1
Warfarin-based 1
mixed-raced 1
Brazilians. 1
VKORC1. 1
VKORC1--1639 1
(3673) 1
(94.1%), 1
African-descent. 1
Brazilians 1
(snps) 1
Jewish, 1
Moslem 1
PCR-RFLP. 1
Melt 1
Technology. 1
VKROC1 1
(0.21, 1
(0.13, 1
(p=0.0086). 1
VKORC1(-1639G>A) 1
(0-0.015). 1
non-mixing 1
(VKORC1, 1
CYP4F2) 1
86.7 1
0.0016, 1
overanticoagulation 1
(INR 1
>4) 1
12.8; 1
2.73-60.0). 1
VKORC1) 1
(n=311) 1
microcosting, 1
1.5-3.0 1
8.00 1
33.2% 1
(R(2)(Adj)=0.332) 1
G> 1
variabilit 1
warfarin-response 1
genotype-based 1
K). 1
Wide-spread 1
demographics; 1
Arg144Cys 1
(*2), 1
Ile358Leu 1
Asp360Glu 1
(*5); 1
Pro187Ser 1
(*1/*2); 1
*2; 1
6853C. 1
Possession 1
*1/*1 1
mg/week; 1
*1/*2 1
CYP2C9*1 1
(SNP)-based 1
drugresponse 1
(tag 1
SNPs). 1
S-isomers 1
S-Warfarin, 1
2C9. 1
angiogenin--a 1
unblocked. 1
H2N-Ala1-Gln-Asp-Asp-Tyr-Arg-Tyr-Ile-His-Phe10-Leu-Thr-Gln-His-Tyr 1
-Asp-Ala-Lys- 1
Pro-Lys20-Gly-Arg-Asn-Asp-Glu-Tyr-Cys-Phe-Asn-Met30-Met-Lys- 1
Asn-Arg-Arg-Leu-Thr 1
Arg-Pro-Cys40-Lys-Asp-Arg-Asn-Thr-Phe-Ile-His-Gly-Asn50-Lys- 1
Asn-Asp-Ile-Lys-Ala 1
Ile-Cys-Glu-Asp60-Arg-Asn-Gly-Gln-Pro-Tyr-Arg-Gly-Asp-Leu70- 1
Arg-Ile-Ser-Lys-Ser 1
Glu-Phe-Gln-Ile-Thr80-Ile-Cys-Lys-His-Lys-Gly-Ser-Ser-Arg90- 1
Pro-Pro-Cys-Arg-Tyr 1
Gly-Ala-Thr-Glu-Asp100-Ser-Arg-Val-Ile-Val-Val-Gly-Cys-Glu-Asn1 1
10-Gly-Leu-Pro- 1
Val-His-Phe-Asp-Glu-Ser-Phe120-Ile-Thr-Pro-Arg-His-OH. 1
Cys(27)-Cys(82), 1
Cys(40)-Cys(93), 1
Cys(58)-Cys(108). 1
6-22 1
65-75, 1
angiogenins 1
(HT-29) 1
cation-exchange 1
chromatography; 1
microgram/L 1
resorption-inhibitory 1
(milk 1
MBP). 1
pit-forming 1
anti-bovine 1
8.7-kDa 1
8.7, 1
angiogenin-1, 1
lactogenin, 1
CM-Sepharose 1
(tRNA). 1
7.75 1
pyroglutaminase-treated 1
BL4) 1
3-22, 1
26-27, 1
41-44, 1
46-50, 1
72-80, 1
83. 1
angiogenin-2 1
Uremia 1
blood-membrane 1
bio-incompatible 1
(GIP) 1
kD, 1
lightchain 1
glycosilation 1
2-microglobulin. 1
(DIP), 1
dialytic 1
uremic-dialytic 1
oligosaccharides. 1
disaccharides 1
hexadecasaccharides 1
ionize 1
subtracting 1
sub-picomole 1
(Arg-Gly)10 1
(Arg-Gly)15 1
decasaccharides. 1
0.05%) 1
O,N-sulfate 1
hexadecasaccharide 1
0.2-0.3%) 1
regularities 1
frail, 1
Invokana' 1
which: 1
C-peptide. 1
Placebo-subtracted 1
(LSM) 1
[LSM 1
NCT01081834 1
1); 1
NCT01106625 1
NCT01137812 1
Pseudogenes, 1
HincII 1
(GlcCerase). 1
glucocylceramide 1
GlcCerase 1
(hGBA) 1
hGBAs 1
dXBP1 1
dBiP. 1
Ambroxol, 1
hGBAs, 1
(GBA1) 1
EG 1
generalities, 1
España 1
glucosylceramide. 1
laden 1
(Gaucher 1
(V394L/V394L 1
D409 1
V/null). 1
change), 1
INFγ-regulated 1
cytokine/mediator 1
inert. 1
INFγ 1
IFNγ-regulated 1
39.4kb) 1
multi-species 1
(MCSs). 1
(TFBSs), 1
(Fluc) 1
Fluc 1
Gel-shift 1
nuclear-protein 1
R395C, 1
R463H, 1
W312R 1
V398I, 1
R359X, 1
c.708delC, 1
c.1214-1215delGC, 1
c.1439-1445del7 1
c.42-65del24). 1
68.7% 1
parkisonism, 1
hypoacusia 1
[c.160G 1
(V15M), 1
c.485T>C 1
(M123T), 1
c.914C>T 1
(P266L), 1
c.1124T>C 1
(L336P), 1
c.1207A>C 1
(S364R) 1
c.1510-1512delTCT 1
(S465del)]. 1
(L444P), 1
(4-methylumbelliferyl-beta-D-glucopyranoside, 1
4MU-Glu) 1
S364R 1
(psGBA), 1
psGBA, 1
disfunction. 1
(Dementia, 1
non-hematological, 1
Tuberculosis, 1
Gallstones 1
Schizophrenia). 1
Relative-Risk 1
Yates' 1
totalling 1
(69%): 1
10-85; 1
57.63%/F 1
42.37%), 1
35.91, 1
1-79; 1
56.82%/F 1
43.18%) 1
32.16, 1
Range: 1
1-76; 1
44.78%/F 1
55.22%. 1
9.69 1
2.00-63.99; 1
1.53-9.27; 1
52-12.50; 1
3.96 1
1.01-16.75; 1
0.27-6.75; 1
highten 1
D409H/D409H 1
(1226G, 1
IVS2+1. 1
84GG, 1
1504T, 1
1604T, 1
1297T) 1
1226G 1
(370Asn-->Ser) 1
1448C 1
(444Lcu-->Pro) 1
IVS1+2 1
1504T 1
(463Arg-->Cys) 1
(409Asp-->His) 1
(frame-shift), 1
1604A 1
(496Arg-->His) 1
1297T 1
(394Val-->Leu) 1
1226G, 1
D409H, 1
recTL, 1
recNcil, 1
P415R 1
(pTM-1). 1
recNcil-mutated 1
(8E4 1
2C7). 1
T7/EMC/vaccinia 1
umbelliferyl 1
lissamine-rhodamine 1
glucosyl 1
28.63 1
6.05% 1
51.90 1
115.75 1
12.64% 1
05% 1
98.5% 1
cancels 1
T6433-->C 1
fetus: 1
model? 1
3.1.2.45, 1
GBA). 1
(nonneuronopathic), 1
T6433C 1
G6468C 1
(A456P) 1
G6482C 1
(V460V), 1
(recNciI) 1
(recTL) 1
G5957C 1
(D409H). 1
(crossover, 1
fusion) 1
Macedonian/Ashkenazi 1
characterized.(ABSTRACT 1
0.0043, 1
0.0023 1
0.0063, 1
N37OS 1
69.77% 1
22.86% 1
non-Jews. 1
10.17% 1
1.43% 1
RecTL, 1
(1.43%) 1
"RecNciI" 1
(0.56%) 1
31.43%, 1
4.24%. 1
mutations--D409H 1
R463C--was 1
5.00% 1
3.57%, 1
R496H 1
1.13%. 1
90.40% 1
73.52% 1
6.(ABSTRACT 1
(370 1
(NciI 1
Ashkenazim, 1
(SSO), 1
(subacute) 1
"complex" 1
(6433C, 1
6468C, 1
6482C). 1
SSO 1
C-to-G 1
415. 1
T-to-C 1
Tsuji 1
(Jewish 1
non-Jewish), 1
GM1260) 1
selective-target 1
radioprotector. 1
port 1
sequellae. 1
radioresistance, 1
hypofractionation, 1
protected. 1
(HypoARC) 1
radiation-dose 1
protocoL 1
3.5-4Gy 1
fractions/week) 1
breast/chest 1
hypotention 1
HypoARC. 1
sequellae, 1
myoskeletal 1
plexopathy. 1
HypoARC 1
chemoembolization: 1
30-60% 1
WR-1065, 1
(biliary 1
hepatocytes) 1
epirubicin-50, 1
cisplatin-60 1
gelfoam 1
mg/m2: 1
(Blood 1
70/50 1
(vertebral, 1
anal, 1
tracheo-esophageal 1
(complementation 1
Xp22.2 1
phytohemagglutinin-stimulated 1
mustard. 1
FANCD2-monoubiquitination 1
cytometry-based 1
uEV-associated 1
carbohydrate-specific 1
ultracentrifugation-prepared 1
filtration-prepared 1
6/43 1
lectin-based 1
TWEAK. 1
nLC-(QQQ)MS/MS. 1
nidogen-1, 1
fibulin-1. 1
(KT). 1
(CIT) 1
KT, 1
(DGF). 1
NGAL, 1
physiopathologic 1
16-60 1
CIT 1
DGF. 1
non-DGF 1
KT. 1
exosomes/microvesicles 1
4.15×10(5) 1
copies/ul 1
miR-200c. 1
4℃ 1
-80℃ 1
(>94% 1
>76% 1
inter-assay), 1
(8-log 1
wide) 1
(R(2)>0.99). 1
miR-29c 1
communication--exosomes 1
messengers, 1
Subfractionation, 1
Tamm-Horsfall 1
(GMV)-enriched 1
5657 1
GMV 1
podocin/podocalyxin-positive 1
podocin/podocalyxin-negative 1
GDI 1
(nephrin, 1
INF2 1
nephron, 1
suited. 1
RiboGreen® 1
Reagent™ 1
miRNeasy®, 1
Reagent™, 1
SeraMir™, 1
miRCURY™, 1
mirVana™ 1
miRNeasy®; 1
freezing. 1
exoRNA 1
applicative 1
40-100 1
(ultra)centrifugation 1
TAL1: 1
TAL1) 1
TAL1. 1
[Psychotherapy 1
psychosis]. 1
pharmacotherapeutic, 1
settings,however,CBT 1
subsumed 1
psychosis,working 1
self-evaluations, 1
depression,managing 1
psychiasis?]. 1
"Cologne/Bonn 1
CER" 1
re-examination 1
subsyndromes 1
following, 1
"Schizophrenia", 1
CER-study 1
frank/manifest 1
psychiatry]. 1
neuroleptics? 1
zotepine, 1
neuroleptic. 1
zotepine). 1
(3.1, 1
0.0-0.5 1
(Kruskal-Wallis, 1
extrapyramidal-motor 1
handwriting's 1
planimetric 1
handwriting, 1
(SPET) 1
[(123)I]iodobenzamide 1
((123)I-IBZM). 1
(r=0.9; 1
neurochemistry. 1
bZip 1
FosB, 1
36-39 1
FosB 1
FosB). 1
caudoputamen. 1
c-Fos-like 1
DARPP-32. 1
"first-episode" 1
neuroendocrine, 1
Wyatt's 1
met5-enkephalin 1
striatopallidal 1
(CPN) 1
(MELI) 1
CPN 1
Acrolein-fixed 1
haloperidol-treated, 1
CPN, 1
MELI 1
drugs.(ABSTRACT 1
girls]. 1
neuropaediatric 1
(DSM-IV-TR) 1
shy, 1
hypersociable, 1
changeable. 1
methylphenidate. 1
repercussions, 1
1.5%) 1
fluoxetin 1
HRQL, 1
Monopharmaceutical 1
depot-antipsychotic 1
monopharmaceutical 1
polypharmaceutical 1
oriented, 1
(G144D) 1
recurrently) 1
(DAD)-like 1
epinephrine-induced 1
DAD-like 1
(T75R) 1
Wt-Tg 1
R67W 1
Cell- 1
Marching 1
pediatric-focused 1
extra-cardiac 1
Derivation 1
CD31. 1
8-bromoadenosine-3':5'-cyclic 1
angiopoietin-1 1
plugs 1
hiPSC-ECs. 1
Refining 1
BMP-4-directed 1
APD-related 1
(BMP-4) 1
dye-based 1
CVPC 1
(BMP4), 1
CHIR99021 1
monolayer-cultured 1
self-renewed 1
10(7)-fold 1
differentiation-inducing 1
Activin/Nodal 1
KBP-cytoskeleton 1
KIF-binding 1
KIAA1279-related 1
GOSHS, 1
(p.Arg90X, 1
p.Ser200X 1
p.Arg202IlefsX2) 1
KBP, 1
SH-SY5Y), 1
(polymicrogyria) 1
GSS, 1
propulsion 1
GSS. 1
[Fiberoptic 1
laryngoscope-guided 1
AirwayScope 1
-guided 1
size-2 1
inserted. 1
Fiberoptic 1
Supraglottic 1
(LDS). 1
TGF-β-responsive 1
Morpholino-induced 1
mosacism 1
(15q25-qter) 1
eldest, 1
anteriorly 1
keletal 1
Postnatally, 1
arches. 1
craniotubular 1
Craniofac 1
2:65-74], 1
220-224], 1
220-224] 1
Chiari-I 1
Craniocervical 1
Sphrintzen-Goldberg 1
(expressive 1
receptive) 1
(phonetic 1
(flexible 1
videolaryngostroboscopy, 1
loudness) 1
intelligbility, 1
hypernasality. 1
Furlong, 1
Camurati-Engelmann 1
C1-C2 1
fontanelle, 1
hernias; 1
clubfoot 1
deformity; 1
(rarely 1
indicated); 1
(SBE) 1
FFAs 1
(CERs) 1
disordering 1
(hK5), 1
(trypsin-like) 1
(hK7, 1
hK14 1
matriptase). 1
birthday. 1
SIN-lentiviral 1
572bp 1
(INVO) 1
leprosy: 1
coincidence? 1
(KLK5) 1
(ELA2). 1
ELA2, 1
pro-Th2 1
(thymic 1
lymphopoietin) 1
factor-α. 1
PAR-2-independent 1
E420K 1
repression-resistant 1
Gene-modified 1
(SPINK5). 1
retroviral-derived 1
[spleen 1
(SFFV)] 1
promoter-transgene 1
methylation-susceptible 1
SFFV 1
572-bp 1
(INVOp), 1
INVOp 1
syndrome-defective 1
epidermis: 1
extracellularly. 1
desquamation-related 1
desmoglein-1. 1
Matriptase 1
Auto-activation 1
pro-kallikrein-related 1
matriptase. 1
corneum, 1
matriptase-pro-kallikrein 1
(p.Cys297Cys), 1
Ex-vivo 1
syndrome-derived 1
hypernatraemic 1
OTCs 1
Transglutaminase1 1
granulosum. 1
transglutaminase3 1
faint. 1
SKALP/elafin 1
transglutaminase1 1
erythrodermia, 1
hypernatremic 1
Rom 1
c.1431-12G>A 1
SUMO-modified, 1
α-Synuclein: 1
runner. 1
rAAV 1
Often-accompanying 1
Synucleinopathies: 1
Interlacing 1
Synucleinopathy 1
ns, 1
perforate 1
(A53T) 1
(�-syn) 1
[Nosological 1
disease--comparative 1
(AF-LB) 1
Fichefet 1
AF-LB. 1
PD-I 1
anhidrosis, 1
PD-II. 1
63.9 1
AF-LB, 1
groups.(ABSTRACT 1
Synucleinopathies 1
Alpha-Synuclein 1
detergent-stable 1
'soluble 1
oligomers' 1
'mature 1
fibrils'. 1
FILA-1, 1
FILA-1 1
brainstem: 1
alpha-synucleinopathy. 1
Atg10, 1
Intra-cerebral 1
mTor, 1
11C-PIB 1
TorsinA 1
torsinA, 1
[Cognitive 1
ascend 1
amyloid-β. 1
amyloid-�. 1
neurorestorative 1
Greenamyre 1
(Betarbet 1
parabrachial 1
interconnected; 1
stimulus-specific 1
hypotension; 1
Onuf 1
pre-Bötzinger 1
(cDNAs) 1
(NFGSCTSecP 1
YIEEAH) 1
poly(A+) 1
(E17) 1
117-bp 1
ECL1715. 1
1360 1
D1s 1
(ECL1711M) 1
MGTR). 1
249-amino 1
58-62% 1
D1s. 1
127, 1
catalytic, 1
1366 1
near-full-length 1
(C1). 1
MAML1/RAM/ANK/CSL/DNA 1
MAML1/NICD/CSL 1
HX-MS. 1
(NTCs), 1
rigidifying 1
NTCs 1
paired-site 1
(PBMs) 1
(MAML1). 1
PBMs 1
multiprotein-DNA 1
kinked, 1
Notch:CSL 1
preassembled, 1
mastermind 1
GAL4-UAS-directed 1
looks: 1
freed 1
(NotchIC) 1
CBF-1, 1
Su(H), 1
Lag-1 1
(CSL)--the 1
Illuminating 1
intriguing, 1
Anti-V3 1
"principal 1
domain" 1
(Ab) 1
(clades) 1
pseudoviruses 1
(psVs) 1
(IC(50)), 1
56/98 1
46/88 1
9/24 1
28-42% 1
40/98 1
6/7 1
cross-clade 1
Vpr: 1
86, 1
93. 1
Env, 1
(IgA1), 1
Pro-Pro-Ser-Pro, 1
autoproteolytic 1
Immunogenetic 1
-DQA1 1
(IIM) 1
(8.1 1
AH) 1
anti-synthetase/anti-Jo-1, 1
-La, 1
-PM/Scl, 1
-Ro 1
AH-associated 1
B*0801 1
DRB1*0301 1
myositis-specific 1
myositis-associated 1
(MAA) 1
anti-PL-7 1
(anti-threonyl-tRNA 1
Cw*0304 1
anti-synthetase 1
anti-Jo-1 1
anti-PL-12). 1
HLA-B*5001 1
DQA1*0104 1
anti-signal 1
MAA, 1
DRB1*11 1
DQA1*06 1
anti-Ku 1
anti-La 1
70D 1
(hydrophilic)/71R 1
(basic)/74A 1
(hydrophobic), 1
anti-synthetase/anti-Jo-1 1
-PM/Scl 1
54), 1
MSH6. 1
MSI) 1
gp120. 1
substitutional 1
Trkola, 1
Purtscher, 1
Muster, 1
Ballaun, 1
Buchacher, 1
Sullivan, 1
Srinivasan, 1
Sodroski, 1
Moore, 1
Katinger, 1
70:1100-1108, 1
glycosidase 1
mannosidases. 1
high-mannose 1
332, 1
392, 1
flank. 1
amidst 1
Antigenic 1
marginale: 1
rickettsial 1
(MSP2), 1
variant-specific 1
Oklahoma 1
rickettsemia. 1
ese 1
HTLV-IIIB 1
(IIIB) 1
C/env 1
CEM-SS 1
19/32 1
D482 1
7/31(23%) 1
B3245 1
6/29 1
B/C1491 1
4/25 1
IIIIB 1
(HMOX1, 1
FTL, 1
FTH1, 1
SLC48A1) 1
(GCLC, 1
GCLM, 1
SLC7A11), 1
(ITPR2, 1
TFE3, 1
BCL2L11, 1
MAFG) 1
(CLSTN1, 1
PSAP, 1
BACH1-mediated 1
Bach1-dependent 1
(HO-1), 1
-reduced 1
hemeoxygenase 1
Hemeoxygenase 1
(Bach-1). 1
(pMCAO). 1
IL-10-deficient 1
IL-10-independent. 1
proto-porphyrin 1
(ZnPP) 1
pMCAO 1
nitro-oxidative 1
8h, 1
pMCAO. 1
ZnPP-induced 1
(3'-UTR)-dependent 1
50-70%, 1
tert-butyl-hydroperoxide 1
(tBuOOH), 1
(UVA; 1
320-380 1
detrimental, 1
severalfold. 1
MafK, 1
Bach1-specific 1
Crm1/exportin 1
antioxidant-response-element-mediated 1
electrophiles: 1
(antioxidant-response 1
(basic-region 1
zipper) 1
factor-erythroid 1
Nrf2-activating 1
Nrf2-dependent 1
+1411 1
feedback-inhibitory 1
(Bach1) 1
MIP1alpha 1
MCP1, 1
Bach1) 1
anti-oxidative, 1
erythroid-derived 1
(Nrf2). 1
(PHA) 1
gamma-interferon, 1
PMA-treated 1
HO-1-expressing 1
Maf-recognition 1
MicroRNA-196 1
(Con1 1
9-13) 1
Con1 1
J6/JFH1-based 1
Glo 1
(UTR)-dependent 1
HMOX1. 1
J6/JFH1 1
HMOX1/Bach1 1
Antioxidant-induced 1
(Nrf2), 1
Genistein, 1
Bach1-null 1
O(2). 1
protoporphyrin, 1
D-galactosamine 1
(GalN) 1
seaweeds. 1
GalN/LPS-treatment. 1
kinin-mediated 1
(Hmox-1). 1
Basso 1
N-coR. 1
biliverdin/bilirubin 1
oxygenase-1. 1
heme-oxygenase 1
(HO)-1. 1
(picro 1
Sirius 1
staining), 1
reexpressions 1
74%). 1
TAC-stimulated 1
tin-protoporphyrin, 1
antihypertrophic 1
antiremodeling 1
NRF2, 1
pro-oxidants. 1
(HMOX1) 1
arsenite-mediated 1
NRF2. 1
NRF2-mediated 1
(TXNRD1) 1
TXNRD1, 1
induction; 1
ARE-dependent 1
MafK. 1
heme-mediated 1
heme-titration 1
Bach1-heme 1
cm(-1) 1
heme-binding. 1
tin 1
mesoporphyrin. 1
Tin 1
mesoporphyrin 1
(SnMP), 1
NIH3T3-HO-1-luc 1
SnMP, 1
de-repressing 1
Heme: 1
(iron 1
Hap1, 1
heme-activated 1
cerevisiae; 1
IRR, 1
iron-dependant 1
Bradyrhizobium 1
japonicum; 1
2alpha 1
reticulocytes. 1
Bach1/heme 1
HO-11 1
Bach1-HO-1 1
(HO), 1
oxidative, 1
(Huh-7 1
heme-Bach1 1
Heme--as 1
bilirubin) 1
biliverdin 1
(MARE), 1
beta-globin. 1
MAREs 1
(Nrf1, 1
Nrf3) 1
MARE-driven 1
quenches 1
diamide, 1
Diamide 1
ARE-driven 1
(C574S 1
diamide-mediated 1
Bach1-suppressed 1
GFP-Bach1 1
C574S 1
bach1 1
bach1-Deficient 1
HO-independent 1
(I/M) 1
65.6%. 1
(I/M 1
45.6%). 1
(ARE)-mediated 1
oxidoreductase1 1
Hep-G2 1
Bandshift 1
Heme, 1
t-BHQ 1
t-BHQ-induced 1
(p45) 1
(Bach) 1
(Maf) 1
p45-null 1
maf 1
proplatelet 1
2N, 1
endomitosis. 1
Heme-dependent 1
site-40 1
(HS-40) 1
NF-E2/AP-1 1
site-binding 1
SA-treatment, 1
Bach1-effect 1
Crm1-dependent 1
GM02063 1
cadmium-inducible 1
(NES) 1
heme-induced 1
NES 1
Crm1. 1
18-19th 1
goat-anti-BACH1, 1
anti-heme 1
(HO1), 1
anti-ERG, 1
anti-RUNX1 1
anti-SIM2 1
BTB-basic 1
HO1. 1
HO1, 1
HO1 1
(MARE)-dependent 1
microlocus 1
(microLCR) 1
microLCR-beta-globin 1
(HS2), 1
microLCR 1
microLCR. 1
HS2 1
LCR. 1
MARE)-dependent 1
HO-2, 1
biliverdin/bilirubin, 1
Cys-Pro 1
dipeptide. 1
repressible, 1
(-427A 1
smoking-induced 1
Cadmium 1
(HO)-1, 1
Nrf2/small 1
cadmium-induced 1
Bach2 1
Crm1/Exportin-1 1
IXalpha. 1
CoCl(2) 1
Hemoprotein 1
Nrf2/Maf 1
(MAREs) 1
bach1/nrf2 1
compound-deficient 1
lactose), 1
repressor-activator 1
cysteine-proline 1
hetero-oligomer 1
MARES: 1
sensory-neuronal 1
[Schindler 1
disease/Kanzaki 1
maked 1
(Mckusick 1
104170). 1
(alpha-NAGAL; 1
E.C. 1
3.2.1.49) 1
alpha-N-acetylgalactosamine 1
glycolipids. 1
glycosylation-deficient 1
equivalence. 1
(Ziehl 1
Neelsen) 1
hsp65 1
cfp10 1
(Rv3875, 1
esxB) 1
fg 1
(77.24%) 1
bettered 1
(50.34%) 1
19.03 1
mycobacteraemia 1
38.09% 1
15.38% 1
0.06/0.5 1
JD. 1
HIV- 1
HAART, 1
0.45-0.74], 1
TB; 1
[0.74-1.22]). 1
(SPNs) 1
(MAC). 1
checkup 1
cavitation, 1
8.5) 1
0.053). 1
"tuberculoma" 1
count<100.0 1
anti-IL-10R 1
(Maa1979), 1
(Maa1980), 1
actinomycetes. 1
polyketide 1
dimycocerosyl 1
phthiocerol, 1
strain; 1
leprae. 1
Maa2521, 1
Maa2520 1
'real-world' 1
ondansetron, 1
sleep? 1
Orexin, 1
hypocretin, 1
(interindividual 1
CV%) 1
inter-compartmental 1
9.87 1
L/h 1
(26.9%), 1
5.16 1
L/h, 1
±30%, 1
2.5th 1
97.5th 1
smoking/alcohol 1
exposure-based 1
carbon-13. 1
carbon-13 1
Carbon-13 1
α-D-glucose-[(13)C6]. 1
radiosynthesis, 1
D-(+)-gluconic 1
δ-lactone 1
carbon-1 1
[(14)C]empagliflozin 1
radiosyntheses, 1
mCi/mmol, 1
diabetes). 1
weeks&apos; 1
(104weeks' 1
24weeks' 1
(typically76weeks' 1
31.6 1
mmol/mol, 1
{IQR}, 1
4.4] 1
5.2] 1
12.5] 1
15.4] 1
(EGP) 1
14] 1
16] 1
21] 1
18] 1
35] 1
32] 1
mM(-1), 1
ClinicalTrials.Gov 1
NCT01248364 1
2010-018708-99). 1
Funding. 1
Ingelheim. 1
'empagliflozin' 1
2012-2014. 1
inhibitor/sodium 1
linagliptin/empagliflozin 1
Protein:protein 1
"tool 1
kit" 1
carboxylase1 1
carboxylase2, 1
(HER 1
Specs 1
Spot' 1
hopping, 1
Cis-regulation 1
teleost/tetrapod 1
(Fgf8) 1
fgf8a. 1
slc2a15a 1
fbxw4 1
fgf8a/fbxw4 1
midbrain-hindbrain 1
olSix3.2 1
Six3, 1
silencer, 1
amelogenin 1
(AMELX/Y) 1
AMELX/Y, 1
83.3%, 1
82.1%, 1
97.5%, 1
(98.8%) 1
96.3%. 1
AMELX/Y+SRY. 1
(AciI) 1
ACTB 1
RASFF1A 1
ACTB. 1
Gestation. 1
6(th) 1
Nested 1
[Contribution 1
(CVS), 1
evolve? 1
reestablished, 1
cytokinins 1
stroke-induced 1
beading, 1
2-photon 1
ultraslow 1
pressure-dependent 1
Hyperoxia 1
pO(2). 1
ml/gm/min). 1
depleted) 1
until, 1
(MCAO), 1
'central 1
neuroprotection' 1
salvages 1
Conceivably, 1
PIDs. 1
(CSD), 1
>10-fold, 1
175% 1
conclude: 1
alpha-phenyl-butyl-tert-nitrone 1
(alpha-PBN) 1
(control: 1
28.3+/-16.3 1
23.7+/-7.4 1
mm3). 1
occlusion) 1
p<0.006). 1
alpha-PBN-treated 1
40-nucleotide 1
Apt-9, 1
(dissociation 1
concentration-response 1
phospholamban-specific 1
scant. 1
ion-motive 1
COOH-terminal. 1
dihydropyridine-sensitive, 1
lumenal, 1
gene-ablated 1
nitroprusside-mediated 1
diI-acetylated 1
counterstaining. 1
endothelial-vascular 1
PP1C 1
(ASM) 1
detectable). 1
CaMKII) 1
ASM. 1
Ca(2+)), 1
SERCA:PLN 1
70�% 1
Solid-state 1
bilayers: 1
Asn27 1
(N27A) 1
superinhibitor 1
(MLVs). 1
CD(3)-labeled 1
Ala24 1
N27A-PLB. 1
Ca(2+)-ATPase; 1
rotationally 1
PLB-PLB 1
MTSSL, 1
PLB-bound 1
IPSL 1
(POLG, 1
15q25). 1
Glu873Stop 1
G1681A 1
Ala467Thr 1
POLG: 1
valproate. 1
Electroencephalograms 1
absent/slow 1
(poly)spikes 1
migratory, 1
T(2)/fluid 1
alpers 1
dysmotility 1
overshadowed 1
vary; 1
muscularis 1
externa. 1
encephalomyopathy) 1
mitochondriopathy. 1
kinships). 1
(three) 1
(three), 1
Premortem 1
HCL-like 1
leukemias/lymphomas 1
(HCL-variant 1
kinase-activating 1
BRAF-mitogen-activated 1
(vemurafenib; 1
(trametinib) 1
HCL-like) 1
BRAF-MEK-ERK 1
HCL-specific 1
smoothening 1
'hair-raising' 1
pentostatin, 1
immunotoxins 1
(interferon-a, 1
cladribin). 1
miniaturized, 1
radioisotope-based 1
HotSpot(SM) 1
HMT. 1
small-library 1
LOPAC 1
NSD2, 1
PRMT4 1
[(3)H]-S-adenosyl-L-methionine 1
WDR5, 1
RbBP5, 1
Ash2L, 1
(WRAD), 1
WRAD 1
WDR5-Win 1
MLL1-related 1
signal-increase 1
(Z' 1
≥0.7) 1
(DZA 1
Nep 1
synergise 1
(LLOQ 1
(t(1/2, 1
λn)) 1
(CL(s)) 1
925.1 1
570.1 1
lung-to-serum 1
(K(p)) 1
60.2. 1
(MSTN) 1
MSTN. 1
(MyoD) 1
Hypoxia-mimicking 1
(cobalt 1
SW480. 1
H3Ac, 1
H4Ac 1
Wnt5a. 1
SW620, 1
anti-excitotoxicity 1
attempted. 1
Nerve, 1
[Differential 1
palsy) 1
antiglutamate 1
riluzole), 1
non-NMDA 1
ERK5-MEF2A-COX2 1
Heparin-binding 1
Transactivated 1
PI3K-Akt, 1
(10ng/ml) 1
[(3)H]-leucine 1
(ANF) 1
EGFR-ERK5 1
(COX-2). 1
EGFR-ERK5-MEF2A-COX-2 1
unstudied. 1
factor-a. 1
(TEF-1) 1
muscle-enriched 1
MCAT-driven 1
TEF-1-related 1
TEF 1
(DTEF)-1 1
(Hamburger-Hamilton 1
venosus 1
(16-18 1
AT-rich, 1
inlet 1
{alpha}-cardiac 1
-2.354/-1.36 1
cardiocytes 1
(MCK) 1
Ca2+-storage 1
murine, 1
(lambda 1
PAC) 1
pre-birth 1
epididymis 1
CARP, 1
HF-la 1
GST-CARP 1
HF-1-TK 1
tinman 1
Nkx2-5(-/-)embryos, 1
promoter-lacZ 1
Nkx2-5(+/-) 1
Nkx2-5(-/-) 1
HF-1-dependent 1
HF-1a/HF-1b/MEF-2 1
anterior/posterior 1
promoter/beta-galactosidase 1
ventricular/conotruncal 1
strain/methylation 1
ventricle/left 1
(BF-2). 1
MEF-2/BF-2 1
antithetic 1
(HF-1b/MEF-2) 1
HF-1b 1
RSRF 1
MEF-2-like 1
T(3)-stimulation 1
half-site 1
alpha(1)-adrenergic 1
"fetal" 1
NF-AT3. 1
NF-AT3 1
acetylases 1
cardiac/slow 1
nontissue-specific 1
CTnC 1
"ordinary" 1
"novel" 1
IDH2, 1
(18.2%). 1
78.4% 1
[Intracellular 1
trials.A 1
coculturing 1
CD45RA-positive 1
DCs; 1
(IRF)-7, 1
(IDO)-1 1
IDO-2. 1
tofacitinib: 1
anti-Tumor 1
(PKi), 1
molecule-related 1
Knowledge, 1
(SAE), 1
(DCAE) 1
4410 1
(JAK), 1
SYK, 1
cKit 1
4.63), 1
7.42). 1
hypertransaminasaemia, 1
8.43), 1
5.99), 1
(3.19 1
8.49) 1
9.24 1
(2.22 1
38.42), 1
PKi-treated 1
plethysmography, 1
RANKL) 1
Edema, 1
CD68/ED-1+, 1
RANKL+ 1
paws; 1
(transcript 1
non-steroid 1
'outside 1
in' 1
Th17. 1
(SCID)-HuRAg 1
over-produce 1
Stat6-deficient 1
over-production 1
surprise, 1
CIA. 1
15mg/kg 1
10-50nM 1
anti-IL-2 1
Th17-promoting 1
IFN--induced 1
IL-2-induced 1
3-30nM, 1
100nM. 1
JAK1-mediated 1
STATs, 1
(SCID-HuRAg 1
minipump. 1
SCID-HuRAg 1
anti-CD3-induced 1
STAT6, 1
TCR-associated 1
ZAP-70. 1
CP690,550-mediated 1
TYK2, 1
(PBNC) 1
edema), 1
PBNC, 1
AIA, 1
70.5%, 1
81.2%, 1
76.8% 1
(0.04-0.06 1
expense. 1
(Jak) 1
Jak1, 1
Stat6 1
Efficiencies 1
100000-fold 1
10(-9). 1
10%-50% 1
Livestock 1
2,3,7,8-tetrachlorodibenzo-p-dioxin 1
(TCDD)-dependent 1
P4501B1 1
(CYP1B1) 1
binding-deficient 1
TCDD-, 1
(E2)-, 1
TCDD 1
MCF7-AHR((ko)) 1
AHR(ko) 1
ARNT((ko)) 1
(GREB1) 1
TCDD-dependent 1
ARNT. 1
TCDD, 1
TALE: 1
(TALEs), 1
Xanthomonas 1
cipher 1
latipes. 1
(HMA) 1
TALEN-binding 1
CRISPR/Cas-derived 1
nickases. 1
pyogenes. 1
RGEN-mediated 1
Cas9. 1
RGEN 1
nickases, 1
D10A 1
sacrificing 1
RGEN-induced 1
CRISPR/Cas-induced 1
humanizing 1
"humanizing" 1
small-guide 1
Gly1326 1
S5-H5 1
barium:calcium 1
(Feng, 1
Hamid, 1
Doering, 1
Jarvis, 1
Bosey, 1
Bourinet, 1
Snutch, 1
Zamponi, 1
5726-5730). 1
1332 1
Glu(1332) 1
G1326P 1
vestibule 1
toxin-channel 1
Ziconotide's 1
neuroplasticity, 1
neurotoxicites 1
(1S)-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycyclohexyl)methyl]amino}ethanone 1
((S)-1h), 1
(S)-1h 1
hurdles. 1
Fluo-4, 1
dyeloading 1
no-wash 1
Corp. 1
(Sunnyvale, 1
CA): 1
Plus, 1
IMR-32 1
potassium-evoked, 1
MVIIA-reversible 1
(15,000 1
points/day), 1
0.6), 1
ziconotide's 1
N-triazole 1
oxindole 1
TROX-1, 1
Biological, 1
(3R)-5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-3-yl)-1,3-dihydro-2H-indol-2-one 1
(TROX-1) 1
ziconotide. 1
Cav2.2 1
open/inactivated 1
4.2, 1
-110, 1
-90, 1
-70 1
train. 1
Depolarized 1
Ca(V)2.1, 1
Ca(V)2.2, 1
Ca(V)2.3, 1
state-dependent, 1
non-subtype-selective 1
state-independent 1
Ca(V)2.2-selective 1
triazine, 1
CaV2 1
(CaV2.2) 1
(IC50=1.1 1
closed-state 1
(IC50=25 1
32°C 1
repriming 1
repriming. 1
ng/kg/h 1
(MAP2) 1
9-minute 1
reperfusion; 1
5-hydroxytryptamine-mediated 1
vagal-evoked 1
gabazine. 1
(mEPSCs) 1
(TTX)] 1
EPSCs. 1
phenylbiguanide 1
mEPSCs. 1
mEPSC 1
N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide 1
(WAY-100635), 1
granisetron. 1
EPSCs, 1
20-Hz 1
(5-HTT)/SERT, 1
gabazine 1
(5-HTT/SERT, 1
SLC6A4) 1
(OCT3, 1
SLC22A3), 1
(5HT) 1
(5HTT) 1
5HTT, 1
(OCTs). 1
OCT3, 1
potential-sensitive 1
5HT. 1
5HT-dependent 1
5HTT. 1
944 1
(784 1
relatives), 1
grandmothers 1
[SIR, 1
1.1-2.7]. 1
grandmothers, 1
(SIR, 1
1.1-5.2). 1
BRCA2-associated 1
FA-patients 1
(FANCD2) 1
ubiquitylation-resistant 1
D1/BRCA2, 1
J/BRIP1, 1
N/PALB2). 1
18,136 1
56.95 1
0.71-1.23, 1
3.089 1
8.78; 1
Chi2 1
4.767, 1
cetuximab: 1
excised. 1
bi-functionally 1
cancers.In 1
therapy-associated 1
embraced 1
genes] 1
2002]. 1
Sasaki, 1
(Lond.), 1
257: 1
501-503, 1
1975] 1
2002] 1
PHA 1
pokeweed 1
FANC-mutations 1
740-1083) 1
PTCs. 1
geneticin. 1
TBT. 1
repli-sampling 1
TBT 1
(IQSCMaRTEA). 1
geneticin, 1
(RPL4), 1
recoding. 1
RPL4-induced 1
RPL4-dependent 1
Gag-to-Gag-Pol 1
'error', 1
(TMV) 1
TMV 1
(tRNA 1
hopping) 1
re-examination. 1
constructions 1
UAG-CAA-UUA. 1
teh 1
anticodon-codon 1
Formin-like 1
β1-Integrin 1
formin-like 1
(FMNL2) 1
S1072 1
α-integrin 1
activity- 1
trafficking-relevant 1
Thr(788/789) 1
PKC- 1
β1-integrins, 1
Ndr2-deficient 1
arbor-specific 1
knock-down-induced 1
3A(-/-)-like 1
Ndr2-mediated 1
(CLIC4) 1
exocytic-endocytic 1
Rab35-positive 1
Rab35-dependent 1
LPA-dependent 1
α/atypical 1
PKC/β1 1
(DGKα), 1
pseudopods. 1
SDF-1α-induced 1
DGKα, 1
(CycD1) 1
keratinocyte. 1
exocyst 1
(Sec6) 1
(RalA), 1
rearward. 1
rapamycin-treated 1
atg3(-/-) 1
integrin-containing 1
LC3-stained 1
supresses 1
Arf6-dependent 1
endo/exocytic 1
dynamin-dependent 1
ARF6- 1
1-positive 1
Rab4a- 1
intracellular. 1
Gbetagamma-mediated 1
(Gnb2; 1
Gbeta2) 1
XWnt8 1
Gbeta2, 1
(W332A) 1
Gbeta1 1
Gbeta2. 1
Wnt/Frizzled-->Gbetagamma-->PLC-->Ca(+2)/PKC 1
(PCP) 1
9]. 1
[8, 1
20]. 1
Rho/Rac 1
mediolateral 1
K-->M 1
(dsh1), 1
cytoplasm-targeted 1
dishevelleds. 1
transduction: 1
axin) 1
(postsynaptic 1
zonula 1
occludens-1) 1
Egl-10, 1
pleckstrin) 1
Wnt-Fz-LRP5/6-DVL-AXIN. 1
A-knockout 1
Gb3. 1
Gla-knockout 1
(Gla(-/0)) 1
(COX). 1
Gla 1
COX-derived 1
(Gla(+/0)) 1
valeryl 1
NS-398 1
vasopressor 1
Fabry-related 1
disease--role 1
globotriaosylceramide. 1
(Gb(3)) 1
(pre-ERT) 1
unusally 1
B/Ets 1
negatively-acting 1
alpha-galactosidase. 1
regionalization, 1
telencephalon. 1
11.5. 1
barrels, 1
whiskers, 1
whiskers 1
Lhx2. 1
A5, 1
(EDRz) 1
no-gene 1
(OLGs). 1
cuprizone 1
de- 1
lags 1
Ad5/35 1
(ZFN)- 1
(miRNA)-based 1
miR-183-5p 1
miR-218-5p 1
ccr5. 1
HD-Ad5/35.ZFNmiR 1
(HS2) 1
ZFN)- 1
cassettes, 1
Lesch-Nyhan-Syndrome. 1
sensory-like 1
hPSCs 1
attractive, 1
novices 1
TALEN. 1
(LNA) 1
miRZip 1
(TALEs) 1
[homozygous 1
1448T>C 1
mutation] 1
CCR5- 1
Oct4/Sox2/Klf4/Lin28/Nanog/eGFP 1
monoallele 1
biallele 1
[TNC1 1
(βS/βS)], 1
HBB-specific 1
βS 1
βA 1
Cre, 1
βS/βA 1
(βA) 1
(βS/βS) 1
baculovirus-transcription 1
locus-directed 1
95.21% 1
baculovirus-Cre/LoxP 1
Hygro-mCherry 1
transduction-based 1
hiPSC-based 1
1840 1
conversation 1
Feelings 1
12.88 1
8.99-18.46). 1
RMMA) 1
Isl1, 1
with/out 1
factor-1(IGF-1) 1
sub-domains 1
peri-ischemic 1
Isl1. 1
(BMCs) 1
(IGF-1). 1
BMC-mediated 1
factor-1/hepatocyte 1
(IGF)-1/hepatocyte 1
(epCSCs) 1
IGF-1) 1
epCSCs 1
IGF-1/HGF, 1
epCSC 1
(myocytes 1
microvasculature) 1
peri-infarct/border 1
(hCSCs) 1
(IGF)-1, 1
IGF-2R, 1
C-kit(+) 1
IGF-2R 1
hCSCs. 1
biomaterial, 1
spectroscopy). 1
affinity-bound 1
Chemotactic 1
self-assembling 1
(NF-IGF-1), 1
+dP/dt, 1
-dP/dt, 1
230% 1
NF-IGF-1, 1
115%. 1
IGF-1-overexpressing 1
SDF-1alpha/CXCR4 1
(SDF)-1alpha. 1
((Norm)MSCs) 1
adenoviral-null 1
((Null)MSCs) 1
((IGF-1)MSCs). 1
(Null)MSCs). 1
Bcl.xL 1
(IGF-1)MSCs. 1
muL 1
DMEM 1
1.5x10(6) 1
(Null)MSCs 1
(n=4 1
(P<0.06 1
(Null)MSCs) 1
(n=6 1
(20-fold 1
ckit(+), 1
MDR1(+), 1
CD31(+), 1
actinin, 1
(mIGF-1) 1
favor, 1
newly-formed 1
2200 1
microm3. 1
43+/-13 1
155+/-48 1
capillaries/mm2 1
31+/-6 1
390+/-56 1
IGF-1B 1
(FVB.Igf+/-) 1
2.1-fold 1
nontransgenics 1
1.6-fold. 1
2.5-mo-old 1
nontransgenics, 1
131% 1
nontransgenics. 1
weight-to-body 1
Overdetection, 1
MISCAN 1
4-year-intervals 1
2378 1
4956 1
60,695,000 1
euro. 1
(23,669,000 1
euro). 1
country-specific 1
Face-to-face 1
10,228 1
quota 1
(Austria, 1
.07, 1
pamphlets 1
.06, 1
overestimation. 1
satisfied, 1
overtreated. 1
Forthcoming 1
Indicate 1
(HTA). 1
40-69 1
(205 1
carriers; 1
(21/300) 1
3.3%. 1
47·6% 1
(10/21). 1
INSTITUTE 1
RESEARCH. 1
PA207, 1
Trx-PA207, 1
(Ldb1), 1
Trx-PA207 1
associate, 1
zinc-coordination 1
Lmo 1
Complexities 1
growth-sensitive 1
Osteoclastic 1
ill-advised, 1
p16(INK4a)) 1
(agonist) 1
(antagonist) 1
aptamer- 1
ID1/3-PA7. 1
residues-H97, 1
D100, 1
R103, 1
D104, 1
L107, 1
A144, 1
C145, 1
D149, 1
D150 1
C154 1
promulgating 1
Aptameric 1
peptide-functionalized 1
(QCM) 1
electrode, 1
PKA), 1
Au-coated 1
dual-thiol 1
nitrilotriacetic 1
acid/Ni(II) 1
μL(-1) 1
22.33 1
μL(-1). 1
reagentless 1
forskolin/3-isobutyl-1-methylxanthine-stimulated 1
lysate. 1
(TbBRCA2) 1
procyclic 1
(Id1-4), 1
Ids 1
Intracellular-delivered 1
(CDKN2A) 1
E-proteins 1
(CDKN1A 1
CDKN1B) 1
IC(50). 1
selection-by-function, 1
Y-ligation-based 1
(P(i)101; 1
SCGG 1
IIII 1
SCIA) 1
(K(i); 1
STM. 1
STM 1
RhoA-specific 1
Trio. 1
(Rho-GEFs) 1
Rho-GTPase 1
GEFD1 1
GEFD2, 1
TrioGEFD2-mediated 1
TrioGEFD2 1
TRIPalpha 1
Rho-GEFs. 1
inflammasomes: 1
(PAMP 1
(PRR). 1
neosynthesis 1
médecine/sciences 1
Inserm. 1
pro-IL-1β 1
CASP1 1
CASP11 1
PYHIN 1
(PYRIN 1
HIN-200 1
domain-containing) 1
NLR/PYHIN 1
Caspase-11 1
Casp4), 1
knockouts. 1
typhimurium), 1
(TLR4)-dependent 1
adaptor-inducing 1
(TRIF)-dependent 1
pro-caspase-11 1
caspase-11. 1
Casp1(-/-) 1
(Casp1(-/-) 1
Casp11(-/-)). 1
caspase-11-dependent 1
[Inflammasome 1
pro-interleukin 1
(pro-IL1β) 1
cryopyrinopathies, 1
IL1β; 1
IL1 1
anti-IL1 1
(PYD) 1
protein-interacting 1
(PYD)/PYD 1
domain/caspase 1
Caspase-1. 1
1.7-Å 1
six-helical 1
PYDs, 1
Cys-8 1
Cys-108, 1
diametrically 1
survival-inflammation 1
decides, 1
(RIPK)-mediated 1
(SIRS). 1
(caspase-3 1
-7) 1
RIPK1 1
necrostatin-1, 1
RIPK1-RIPK3-mediated 1
pathological) 1
colorimetrically. 1
Caspase-2 1
caspase-2's 1
caspase-5's 1
ITAM-coupled 1
immunocomprimised 1
XBP-1 1
caspase-4, 1
tunicates 1
Dipteran 1
mojavensis. 1
3N 1
"ultraconserved" 1
mojavensis 1
rubripes). 1
(phylo-HMM). 1
PhastCons 1
phylo-HMM 1
3%-8% 1
(37%-53%), 1
(18%-37%), 1
Saccharaomyces 1
(47%-68%) 1
(HCEs), 1
ascertained, 1
HAX1 1
syndrome/acute 1
protease/inhibitor 1
serpins. 1
(MNEI) 1
MNEI 1
WASp, 1
Gfi-1, 1
adaptin, 1
ela2 1
interconnects 1
C/EPBepsilon, 1
RUNX1/AML1, 1
LEF1, 1
(PCR)-amplified 1
(HPS2) 1
AP3B1 1
ELA2). 1
puzzling. 1
dilative 1
Myofibroblast 1
regress. 1
"reparative 1
disorder". 1
TSCs, 1
non-myocyte 1
antigen-1-positive 1
Nkx2.5-positive 1
(CSps) 1
CSps, 1
explant-derived 1
CSp-derived 1
matrix-producing 1
(TGF)-β/Smad3 1
factor-rich 1
"stress-shielding" 1
TGF)-β/Smad3 1
fibroblast-mediated 1
lattice. 1
SMAD2. 1
(VIC) 1
denudation 1
(alpha-SMA), 1
nonwounded 1
monolayers, 1
pSmad2/3 1
alpha-SMA. 1
Everolimus. 1
(RAD001, 1
Afinitor®) 1
class-effect 1
expected) 1
BOLERO-2 1
(interruptions, 1
discontinuation); 1
2(1/2) 1
Matrix-Immobilized 1
Microcontact 1
BMP-Mediated 1
Migration. 1
conveying 1
adhesion-mediated 1
GF 1
(cFN), 1
GF-mediated 1
NeutrAvidin 1
cross-linker. 1
matrix-immobilized 1
(iBMP-2), 1
(sBMP-2) 1
sBMP-2, 1
iBMP-2 1
BMP-mediated 1
sBMP-2 1
iBMP-2. 1
lithography. 1
cFN, 1
passivated, 1
BMP-2. 1
scratch). 1
(Ln), 1
(Vn), 1
(Fn) 1
(TnC). 1
dependent: 1
(Fn), 1
TnC. 1
Fn 1
Vn. 1
Ln 1
Vn 1
Cross-Scale 1
Organizes 1
Topology. 1
underlain 1
paraxial 1
Integrin-Integrin 1
Integrin. 1
commences 1
tumor-affected 1
heparanase 1
PCTAIRE-1 1
(PCTK1), 1
Phosphoproteomic 1
Ser83 1
KAP0, 1
PCTK1-KAP0-myosin 1
X-β1 1
ECM-dependent 1
PNDA-3 1
PI-3K/AKT, 1
FAK-mediated 1
PNDA-3, 1
(hβ1) 1
D759A 1
hβ1 1
integrin-fibronectin 1
Non-channel 1
adhesion-stress 1
Mechanosensitive 1
mechanosensors; 1
Mechanosensors 1
non-soluble 1
stiffness), 1
cytoskeletons, 1
(catch 1
matrices) 1
(unfolding 1
"active" 1
(SFs), 1
ADF/cofilin 1
α6β1- 1
LIF. 1
α6-, 1
αV- 1
αV-depleted 1
αV-integrins. 1
Myoferlin 1
myoferlin 1
(MYOF) 1
(FAK(Y397)) 1
(PAX(Y118)), 1
PAX 1
(MDA-231(LVC) 1
stiffnesses. 1
stiffnesses 1
heart? 1
synchronised 1
(ANZSCTS) 1
(CSANZ). 1
intermediation 1
distinctively, 1
ambivalence: 1
(toxic) 1
tuned. 1
pumps), 1
mitochondria). 1
sodium-calcium-exchanger 1
heart--molecular 1
CaMK 1
(MEF2), 1
Na(+)-Ca(2 1
mini-review, 1
transplasmalemmal 1
transsarcoplasmic 1
toxico 1
(1990 1
blockers', 1
'myocardial 1
ischemia', 1
'pharmacokinetics', 1
vol-6 1
(revised 1
quarter) 1
phrase 1
'pharmacokinetics' 1
reprints 1
1,4-dihydropyridines 1
calcium-regulating 1
alpha-expressing 1
caffeine-elicited 1
alpha-calcium 1
(http://tfcones. 1
dystrophy]. 1
shoulder-girdle 1
[Facioscapulohumeral 1
non-contracted 1
FSHD2, 1
(2DLC-MS/MS) 1
atrophy-associated 1
DUX4-mediated 1
PTRF 1
MURC. 1
subtelomere. 1
sized. 1
burst-like 1
locus-intrinsic 1
(ChCS) 1
H3K9me3:H3K4me2 1
product-moment 1
FSHD2. 1
histone-3 1
lysine-36 1
≈28 1
H3K36me3-enriched 1
spirochete. 1
stimulant, 1
potentiated, 1
IL-10-inhibited 1
(TLR1), 1
IRAK3, 1
IFI44, 1
IFIT1, 1
modulation/and 1
RANTES/CCL5, 1
(MIP-2)/CXCL2, 1
MIP-1α/CCL3, 1
(G-CSF)/CSF3, 1
CCL4, 1
IL-9. 1
(MDV) 1
meq. 1
susceptibility/resistance 1
paratuberculosis, 1
paratuberculosis 1
MAP. 1
cDNAs, 1
smegmatis-induced 1
MAP-infected, 1
MAP- 1
kinase-independent. 1
Stat 1
Jak/Stat 1
LE. 1
LPS-inducible 1
proteoglycan. 1
back-cross 1
Tyrp2 1
Rap2a. 1
uninduced. 1
dibutyrl-cAMP 1
8-(4-chlorophenylthio)-cAMP 1
Chelation 1
1952, 1
neuroleptics: 1
amisulpride, 1
600-1200 1
50-150 1
(EUDRACT 1
2009-013923-43) 1
hyposensitizing 1
(NiOHT) 1
Ni-patch 1
Ni-poor 1
Ni-oral 1
Ni/week) 1
re-introduction, 1
0.016;) 1
NiOHT 1
restrictions) 1
(dizziness, 1
allergy: 1
immuno-genesis, 1
immune-tolerance: 1
(U-Ni) 1
(B-Ni). 1
only-eczema 1
Nickel-scanty 1
microdose 1
(nanograms) 1
sulphate: 1
immune-tolerance 1
effects]. 1
metalworkers) 1
cancerogenic. 1
Metallic 1
sensitizers, 1
immunotolerance. 1
Positivity 1
nickel-induced 1
hypolactasia. 1
nickel-low 1
Dermatitis). 1
richer. 1
undisputed 1
etc.).The 1
first-hand 1
usefullness 1
controversial: 1
certainties 1
uncertainties. 1
details--and 1
marginal. 1
(0.3ng 1
microg/week) 1
12-months 1
microg/week). 1
Randomly, 1
(antihistamines 1
steroids). 1
allergen-driven 1
IL13, 1
consumption) 1
NiOH-treated 1
reintroduction. 1
(ACD), 1
31.26 1
SNAS; 1
(PCGs) 1
nitrosylated 1
(NPs; 1
PCGs, 1
challenge; 1
LEARNING 1
POINTS: 1
hashimoto. 1
Hakaru 1
struma 1
lymphomatosa, 1
Hashimoto, 1
N.R. 1
Witebsky 1
[J 1
1956;76:417-427] 1
existential 1
imagine 1
'Swiss 1
cheese' 1
Thyrocyte 1
Infiltration 1
Riedal 1
G4(+) 1
(IgG4-RD) 1
organ(s). 1
steroid- 1
DMARD-refractory 1
IgG4-RD.Ten 1
subclasses; 1
Flare 1
Tool.Organ 1
parotid), 1
retroperitoneum. 1
discretion 1
activity.IgG4-RD 1
(IgG4RD): 1
(IgG4RD) 1
tumefaction 1
IgG4-positive 1
IgG4. 1
ack 1
"hepatostat" 1
(involved 1
[ECM] 1
hepatocyte-targeted 1
(PHx), 1
(ILK-KO-Liver) 1
pre-PHx 1
post-PHx 1
Podocyte-specific 1
Podocyte 1
ILK/nephrin 1
ILK-dependent 1
Edrophonium 1
"effect" 1
omohyoid 1
(e.p.cs) 1
anti-curare 1
e.p.c. 1
alpha-bungaratoxin. 1
(50-400 1
e.p.cs 1
hyperpolarized. 1
e-fold 1
CCh. 1
Ginsborg 1
Stephenson 1
(1974) 1
e.p.cs, 1
Methamidophos: 1
(O,S-dimethyl 1
phosphoroamidothiolate, 1
Tamaron), 1
acaricide. 1
cholinesterases 1
20-20 1
(0.5-0.7 1
nerve-hemidiaphragm 1
paraoxon 1
(Rocha 1
1996a), 1
paraoxon, 1
cholinesterase. 1
succinylcholine-induced 1
(SCh) 1
tubocurarine. 1
tubocurarine, 1
alpha-bungarotoxin. 1
alpha-Bungarotoxin 1
SCh-depolarization 1
competitively. 1
Ringer 1
(-90 1
Allowance 1
(stoichiometric 1
KDs 1
m.e.p.c. 1
microseconds, 1
(non-restorative 1
'Phase 1
'insomnia'. 1
Low-priced 1
exacerbating. 1
(DSM-5). 1
MT2-selective 1
MT1-selective 1
disorder-called 1
syndrome-because 1
resynchronize 1
sedative-hypnotics]. 1
zaleplon, 1
zopiclone, 1
z-drugs) 1
indiplon 1
GABA-A 1
eplivanserin 1
2-A 1
(ASTAR) 1
hypocretinergic 1
gabaergic 1
(FAs). 1
kindlin-2 1
25-28 1
kon 1
koff 1
actomyosin-generated 1
shape-dependent 1
pre-stress, 1
rectangles 1
(2000μm(2)) 1
micro-contact 1
equibiaxial 1
30min, 1
symmetry) 1
vinculin-positive 1
rectangular 1
(bipolar) 1
pY397-FAK 1
geometries, 1
(fibroblasts) 1
markedly; 1
LINC-anchored 1
mechanotransduction. 1
dyn/cm(2), 1
actin-cap 1
orders-of-magnitude 1
(LINC) 1
nesprin2giant 1
nesprin3, 1
mechanotransduction, 1
α-actinins. 1
fibers; 1
α-actinin1/4 1
α-actinin-independent 1
Y12 1
α-actinin4 1
Y265 1
DHHC1/3/10 1
(zDHHC1/3/11)-mediated 1
palmitoyl-proteomic 1
(Syd-1, 1
(TARP) 1
γ-2, 1
TARP 1
γ-8, 1
cornichon-2, 1
(Ncdn)/norbin), 1
(zyxin), 1
(TRPM8 1
TRPC1), 1
(orexin 1
palmitoylated. 1
DHHC 1
palmitoylating 1
Golgi-localized 1
Ncdn, 1
(zDHHC1/11; 1
z1/11) 1
Cys-3 1
Cys-4 1
Ncdn. 1
somato-dendritic 1
palmitoylation-dependent 1
DHHC1, 1
(z11) 1
substrate-enzyme 1
(zyxin) 1
mechano-sensor 1
(VSMC), 1
FN-coated 1
FN-bead 1
Whereas, 1
zyxin-shRNA 1
(TRIP6) 1
paxilin). 1
tight, 1
gaussian 1
shape) 1
nonfocal 1
(α-actinin, 1
(mitochondria, 1
paxilin) 1
carcinoma-derived 1
MKN1 1
instantaneously 1
Hs746T 1
plus-ends 1
lamellipodium-lamellum 1
zyxin-rich 1
(TGF-β)/Smad3 1
α5β1. 1
Smad3-mediated 1
cytoskeleton; 1
phospho-Smad3-dependent 1
vasodilator-activated 1
(VASP), 1
Zyxin-depleted 1
α5β1-dependent 1
K-ras-driven 1
phospho-Smad3 1
mechano-signaling 1
mechano-sensing 1
(hMSC) 1
polydimethylsiloxane 1
nanotopography. 1
gratings, 1
gratings. 1
nanotopography 1
force-sensing 1
trailing 1
mutants: 1
(ΔLIM) 1
(LIM). 1
ΔLIM 1
lithography 1
nanopatterns 1
micropatterns. 1
Zyxin-mediated 1
Enabled/vasodilator-stimulated 1
phospho-proteins 1
(Ena/VASP) 1
Ena/VASP. 1
E-cadherin-coated 1
monolayer, 1
Zyxin-deficient 1
zyxins 1
zyxin/VASP 1
phosphoprotein) 1
cell-substratum 1
stretching. 1
nuclear-accumulated 1
beta-synemin, 1
synemin. 1
(SNbetaTII) 1
SNbetaTII 1
ocked 1
elmo1- 1
motile, 1
postfertilization, 1
elmo1. 1
elmo1-deficient 1
CED-12/ELMO, 1
ced-2, 1
ced-5, 1
ced-10, 1
crkII, 1
dock180, 1
rac1, 1
ced-12, 1
elmo2. 1
CED-12 1
CED-12/ELMO-1 1
CED-5/Dock180; 1
Rac-GEF, 1
cancer-promoting 1
TRAF-2, 1
TRAF-6, 1
TRAF-3 1
IL1R, 1
IL-18R, 1
inflammation-driven 1
immunity/immunotherapy 1
-63. 1
K48 1
ubiquitin(K48R) 1
MG-132-induced 1
ubiquitin(K63R) 1
MG-132. 1
(PTPRR) 1
DNMTs. 1
(n=358) 1
DNMT3L. 1
DNMT3A: 1
(23.1%). 1
.022; 1
1.04-1.81), 1
1.13-2.05) 1
.003; 1
1.2-2.7) 1
1.4-3.3). 1
FLT3-ITD 1
.013; 1
1.16-3.77; 1
RFS: 1
2.65; 1
1.48-4.89). 1
(35.1%) 1
P=0.0486). 1
882, 1
dimethyl-H3K9, 1
vorinostat-mediated 1
26,333 1
14,104 1
2-class 1
5912 1
2151 1
0.8%). 1
DNMT3B1 1
DNMT3B2 1
acetylation-driven 1
DNMT1-associated 1
DMBA 1
5-azactydine 1
proliferators 1
(4-chloro-6-(2,3-xylidino)-pyrimidynylthioacetic 1
(di-(2-ethylhexyl)phthalate), 1
DEHP. 1
DEHP, 1
-579G>T 1
-283CC, 1
-283CT 1
-283TT, 1
86.1% 1
84.0%, 1
15.6%, 1
(P=0.589). 1
-597TT, 1
-597GT 1
-597GG, 1
15.2%, 1
(P=0.501). 1
-579G 1
(P<0.0001 1
CIN). 1
microinvasive 1
P=0.0690 1
CIN) 1
P=0.0176 1
IA), 1
(P=0.8259 1
(P=0.2304). 1
28/32 1
24/32 1
DNMT3b. 1
(1-248). 1
1-248 1
Line 1
satellite, 1
(DE), 1
(DEI), 1
(PanIN), 1
0.0012), 1
0.0224) 1
0.0294). 1
0.0469). 1
DNMT. 1
P15I(NK4B) 1
55.4% 1
methylation-silence 1
Dnmt1-(291-1620) 1
bisulfite-sequencing 1
hairpin-PCR 1
290-amino 1
Dnmt3A 1
Dnmt3B, 1
p16(INK4A). 1
fail-safe 1
(AS/MT: 1
5'-CGGTAC 1
GCGCCGGCATCT-3') 1
MKN-45 1
dispersed, 1
neurite-like 1
34.8+/-4.3 1
22.4+/-3.0 1
(p=0.0039). 1
(350+/-47.4 1
(248+/-41.5 1
(p=0.0065). 1
Muc2, 1
mucin, 1
(THBS-1) 1
(MINT)-1, 1
-12, 1
-31 1
THBS-1 1
carcinogenesis) 1
antigen-labeling 1
-viroid 1
nuclei-rich 1
Gynura 1
aurantiaca 1
(30-36 1
[(32)P]CMP 1
Mn(2+). 1
+), 1
+). 1
host&apos;s 1
PINK1-Interacting 1
(PD-) 1
ubiquitin-ligase, 1
PSD-95/Discs-large/Zona 1
Occludens-1 1
(PDZ) 1
(ASIC). 1
ubiquitin-ligase-defective 1
C-induced, 1
PICK1-dependent 1
ASIC2a 1
alpha4. 1
parkin-related 1
IBR-RING 1
parkin-dependent 1
(AR-JP) 1
(Pael-R). 1
AR-JP.Recently, 1
parkinmediated 1
Pael-R, 1
(Pael-R) 1
(MAGUK) 1
CASK-interacting 1
syndecans, 1
Mint1, 1
Veli/mLIN-7/MALS, 1
SAP97, 1
caskin 1
CIP98, 1
CINAP. 1
(NR2b) 1
Tbr-1 1
NMDAR, 1
Tbr-1-CASK-CINAP 1
riociguat; 1
hypertrophy/failure, 1
-all 1
(Adempas®) 1
Adempas®) 1
1990-2007, 1
1-121 1
24.6-44 1
pharmacostatistical 1
age-weight 1
patients/replicate 1
20-53%), 1
31-55%), 1
43-60%), 1
54-72%) 1
13-21% 1
unit's 1
114) 1
replied 1
neonate? 1
Aminoglycoside-induced 1
vancomycin-induced 1
(OAE), 1
(noGnoV), 1
(85/1,233); 1
(GnoV), 1
(42/949); 1
(VnoG), 1
(9/41) 1
(GandV), 1
(17/124). 1
noGnoV 1
GnoV 1
0.44-0.94) 1
VnoG 1
3.46, 1
1.54-7.75) 1
GandV, 1
1.26-3.83). 1
ototoxicity; 1
line-related 1
postconceptional 1
Trough 1
one-compartment 1
Nephrotoxicity 1
sediment) 1
split- 1
(CRISPR)-clustered 1
repeats-associated 1
function-based 1
Cas9/sgRNA. 1
crop. 1
agroinfiltration, 1
agroinfiltration 1
orange. 1
3.9%. 1
Off-target 1
CsPDS-related 1
system-a 1
replacement) 1
(rapamycin 1
rapamycin-resistant 1
>10(9) 1
Ispd 1
(floxing) 1
(Ispd) 1
pronucleus 1
C57BL/6NCr 1
one-cell 1
∼8% 1
born). 1
CRISPR/CAS9. 1
rop18 1
ROP18 1
leukemia--focus 1
(BMSC), 1
nurselike 1
(NLC), 1
BCMA, 1
BAFF-R) 1
chemoimmunotherapy. 1
kinase/SYK 1
kinase/BTK 1
(ibrutinib), 1
risk-stratification, 1
centrocytic 1
blastoid 1
t(11:14) 1
SOX-11 1
60%). 1
MIPI, 1
R-CHOP, 1
R-Bendamustine, 1
(NFkB 1
lenalidamide 1
(anti-angiogenesis) 1
Ibruitinib 1
(Bruton's 1
(PI3Ks) 1
shrinkage-a 1
average-in 1
acid-teratogenicity 1
VPA-teratogenicity. 1
30mM 1
(22.2%). 1
re-elevation, 1
"Multiple 1
Mechanism". 1
pteroic 1
dihydrofolic 1
(DHFA). 1
tetrahydrofolate 1
apoenzymes. 1
GSH-GSSG 1
NADPH/NADP 1
DHA-AA, 1
VPA-induced 1
Influencing 1
10-100) 1
10-70) 1
2,861 1
1999-2005 1
369,267 1
(66%, 1
1900) 1
961 1
epilepsy-pregnancies 1
<2,500 1
Small-for-gestational-age 1
epilepsy-pregnancies. 1
(MCMs) 1
AED-exposure 1
(GM-CSF) 1
(VA)-induced 1
prebreeding: 1
immune-stimulated 1
GM-CSF+VA. 1
28.0% 1
IFN-gamma+VA 1
dysregulatory 1
(MADRE). 1
(MADRE) 1
(1990-1996) 1
Clearinghouse 1
(ICBDMS). 1
methylphenobarbital 1
Hypospadias 1
Porencephaly 1
MADRE 1
[Should 1
carbamazepine? 1
(NTD). 1
valporic 1
prevention) 1
drug-malformation 1
diphenylhydantoin 1
phenobarbitone 1
1980-1983, 1
7,607 1
439,717 1
live) 1
Fourty-one 1
(5.39 1
1,000). 1
1.87. 1
Bifida, 1
Defects, 1
Clefts, 1
Hernia 1
F1, 1
deconstructed 1
virus-based 1
tungstate. 1
(PTPases) 1
PTPase, 1
Yop51, 1
PTP1B, 1
PTPase 1
PTPases, 1
phosphocysteine 1
tungstate-bound 1
oxyanion, 1
thiolate. 1
tungstate 1
oxyanion 1
356, 1
anion-binding 1
PTPases 1
rhodanese. 1
channel-FKBP12 1
∼48 1
∼52 1
Hillslope 1
dissociation; 1
FKBP12-depleted 1
RyR1s, 1
FKBP12-mediated 1
properties: 1
(~100 1
4-methoxy 1
[4-methoxy-3-methyl 1
(4-MmC)] 1
3.98 1
4-MmC 1
[Wehrens, 1
Lehnart, 1
Reiken, 1
Vest, 1
Cervantes, 1
Coromilas, 1
Landry 1
Marks 1
304, 1
292-296]. 1
FK506-treated 1
RyR2-wt 1
contributes, 1
alpha1-adrenoreceptor 1
methoxamine. 1
(n=74). 1
(6/6). 1
microg/kg/min, 1
clofilium-infused 1
clofilium; 1
acetamide. 1
SR), 1
(VCR), 1
(ADM) 1
3H-azidopine 1
VCR 1
(125)I-II-azidophenyl 1
agosterol 1
(125I-azidoAG-A). 1
/MRP 1
Tobacco. 1
1998; 1
[320195]. 1
[316749]. 1
overcontraction 1
[171668]. 1
nedaplatin) 1
(PC-14 1
CDDP) 1
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 1
MTT] 1
CDDP, 1
Coronary-perfused 1
34+/-4% 1
n=6). 1
postischaemic 1
(63+/-5% 1
block) 1
(CH, 1
(5-HD, 1
Ca?⁺ 1
metastasized, 1
SiRNA-mediated 1
Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 1
352) 1
-Associated-in-Lung-Adenocarcinoma-Transcript-1 1
(MALAT)-1 1
(HPV)-16 1
(BKVTAg), 1
(MPVmTAg) 1
MALAT)-1 1
Transwell® 1
tumour-derived 1
PCa-related 1
(AUC)-receiver 1
non-PCa 1
867.8 1
microlitre 1
84.8% 1
non-PCa, 1
Metastasis-associated 1
1(MALAT1), 1
3.280, 1
0.003).In 1
(MALAT1), 1
(CS0DI066YJ10) 1
(13/13) 1
(5/13 1
3/10, 1
prognosis-predicting 1
beta-4, 1
elF4A1), 1
metastasised. 1
(n=225) 1
Endoglin 1
RNA/MALAT-1. 1
RNA/MALAT-1 1
oxantel. 1
(BCM) 1
(APJ(Δislet)) 1
modestly. 1
Adipogenesis 1
Adipocytes. 1
expends 1
Hypoxia-Induced 1
Apoptosis. 1
apelin/APJ 1
(Bcl-2)/Bcl-2 1
(Bax) 1
arcuate, 1
supraoptic 1
(vehicle) 1
μl/h) 1
(0-90 1
apelin-12. 1
apelin-12 1
(H-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH, 1
A12) 1
(H-(N(α)Me)Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe-OH, 1
N(G)-Arg(N(G)NO2)-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe-NH2, 1
AII) 1
cardioplegia 1
Thomas' 1
(STH2) 1
STH2 1
(STH2 1
additives). 1
Cardioplegia 1
STH2. 1
C-Terminal 1
Bpa(13) 1
(α-Me)Phe(13) 1
Tyr(OBn)(13) 1
apelin-13, 1
western-blotting. 1
hypercholesterolemic-hyperhomocysteinemic 1
guinea-pigs: 1
hyperhomocysteinemic 1
chow, 1
(chol)-rich 1
(meth)-rich 1
meth-rich 1
(ADMA) 1
immunoassay; 1
autoanalyzer. 1
Visfatin, 1
ADMA, 1
arginine/ADMA 1
chol, 1
ADMA 1
(VOEs), 1
Vaso-constrictive 1
VOEs. 1
vaso-constrictive 1
vaso-occlusion. 1
caregiver-reports 1
VOEs, 1
(PABP3) 1
(70.1 1
PABP3- 1
PABP1-specific 1
PABP3-specific 1
(APOC1, 1
HNF1A, 1
GCKR, 1
HNF4A, 1
PTPN2) 1
(CRP, 1
IL6R, 1
IL1F10, 1
IRF1) 1
ASCL1, 1
BCL7B). 1
(P<2.9×10(-6)). 1
≈5% 1
variance; 1
mRNA-dependent 1
(PABP1) 1
PABP1, 1
relocalised 1
relocalisation, 1
@ 1
(GWA) 1
HDL- 1
(HDL-C, 1
LDL-C) 1
10,151) 1
2,363) 1
(p(Het)<0.05 1
trigycerides 1
rs6511720 1
(0.021 1
(0.157 1
0.023 1
p(Het) 1
ZNF664 1
(BCR-ABL1, 1
ETV6-ABL1, 1
ZMIZ1-ABL1, 1
EML1-ABL1, 1
NUP214-ABL1) 1
hemopathies, 1
(SFPQ-ABL1 1
RCSD1-ABL1) 1
damage-repair 1
HCK, 1
MERTK, 1
MST1R 1
TNK1 1
Abl/Arg 1
TCR-induced 1
Ligand-independent 1
(ABL1 1
JAK2). 1
Organization-defined 1
BCR-ABL1-positive 1
BCR-ABL1. 1
Agrin 1
(MuSK) 1
(AChRs) 1
(NMJ). 1
agrin-dependent 1
agrin-induced 1
Proteomic-based 1
"spontaneous" 1
unfaithful 1
BaF3-MIGR1 1
BaF3-BCR/ABL 1
(BaF3-BCR/ABL, 1
BaF3-BCR/ABL(T315I)). 1
BaF3-BCR/ABL(T315I) 1
SQTS) 1
(cLQTS) 1
(LQT1-12), 1
(aLQTS). 1
(SQTS1-5). 1
LQTS- 1
SQTS-associated 1
Harvey 1
ras-1 1
tachydysrhythmias. 1
trans-elements. 1
ChIP-Seq, 1
mRNA-Seq, 1
exon-array 1
Lys(514) 1
5-isothiocyanate 1
(FITC), 1
5-iodoacetamidofluorescein 1
(IAF) 1
Cys(674) 1
P-domains, 1
IAF 1
P-domains. 1
P-domain 1
desolvation, 1
N-domains 1
motions. 1
(10-50 1
ADP-sensitive 1
(E1P), 1
EGTA-induced 1
(E2P) 1
E1P. 1
isoform-dependent 1
[Mahaney, 1
Froehlich, 1
4400-4416]. 1
H+ 1
reflow, 1
Ca2+-pump 1
(CaMK), 1
serine-16. 1
serine-16 1
N-(1-pyrenyl)maleimide, 1
phospho-Ser(16) 1
Arg(13). 1
Ca-ATPase; 1
discrepancy, 1
goals: 1
(20/30 1
immunodetection. 1
beta-blockade. 1
lusitropic 1
("knockout") 1
(PLB-KO). 1
optically 1
large-conductance 1
(24,500 1
(cAMP)-dependent 1
14,400 1
centrifuge 1
2.5+/-0.6% 1
99.8+/-25.5% 1
(R1, 1
166.2+/-28.2%). 1
catecholamine-depleted 1
PKA-inhibitor, 1
H-89. 1
Ca(2+)in 1
Ser(16)dependent 1
Thr(17)on 1
Ca(2+)influx 1
Thr(17)at 1
Ca(2+)overload, 1
(VD), 1
(VD-HF) 1
(ISO), 1
ISO-stimulated 1
3-isobutyl-1-methylxanthine 1
Thr17; 1
2D12. 1
Ca(2+)-free, 1
Ca(2+)-bound 1
subsaturating 1
(yielding 1
PLB-free 1
Ca(2+)-pumping 1
42-fold 1
synapsin-1, 1
synapsin-1 1
000-60 1
Ca2+/calmodulin. 1
calmodulin-binding 1
(CBOCs) 1
Texas. 1
education/therapy 1
(Stress 1
Eraser®, 1
Helicor, 1
NY, 1
unpleasantness, 1
therapist-feedback 1
smartphone. 1
noninteractive 1
0-52). 1
9.20, 1
5.85) 1
15.71, 1
9.11, 1
d=0.87) 1
d=0.74, 1
P=.003), 1
d=0.54, 1
d=0.75, 1
P=.001). 1
http://www.webcitation.org/6DUejLpPY). 1
stigma; 1
(14,164 1
references) 1
(104,564 1
references), 1
telehealth-based 1
services; 1
telehealth; 1
place; 1
Technology-mediated 1
Adapting 1
writer. 1
objectives, 1
Videoconferencing 1
momentum. 1
satified 1
dependably 1
Dependable 1
consultation: 1
cost-saving, 1
42+/-9 1
314+/-170 1
(10/11), 1
(6/11), 1
(3/11). 1
24.5+/-9.5 1
(0.83-1) 1
2-4) 1
(6-8) 1
46-260) 1
anesthesiologists. 1
(Edc4) 1
(CCRF-CEM) 1
myc-tag 1
5'-capped 1
re-program 1
Nanos 1
CCHC-type 1
Nanos2 1
Nanos2/Nanos3 1
Nanos2-null 1
NANOS2, 1
CNOT8, 1
CNOT1 1
NANOS2. 1
DCP1-green 1
DCP2-GFP 1
dcp1 1
dcp2 1
DCP1-GFP/DCP2-red 1
DCP1-RFP/DCP2-GFP 1
localization: 1
granules). 1
granules), 1
Unidirectional 1
microfluidic-based 1
p-body 1
"hovering" 1
observable. 1
Myo4p/She2p 1
phase-transition 1
Dcp1, 1
phase-separation 1
LSm 1
Non-Commercial 1
NoDerivs 1
LMKB/MARF1 1
IFI44L 1
MARF1 1
Limkain 1
(LMKB), 1
MARF1, 1
Ge-1. 1
IFI44L, 1
LMKB/MARF1, 1
prioritized, 1
ATXN2,SMN, 1
HNRNPA2B1, 1
(ALS)/spinal 1
dementia(FTD), 1
dysregulations. 1
+2-fold, 1
Cdkn1a, 1
Ccnf, 1
Tprkb 1
vs.decreased 1
Inca1 1
+3-fold 1
Plin4, 1
Wdfy1, 1
Tbc1d24, 1
Pnpla2 1
−2.4-fold 1
Cntn4 1
haploinsufficiency.In 1
Dcp1b 1
Tial1. 1
Tardbp 1
TDP-43) 1
Atxn2 1
Δbfr1 1
Processing-body 1
PROTEIN1. 1
P-body-related 1
PROTEIN1 1
(DCP1) 1
AtDCP1, 1
XI-K, 1
XI-K 1
AtDCP1 1
membrane-coated 1
Interspecies 1
Serine/arginine-rich 1
(SRSF3), 1
serine/arginine 1
(SR)-rich 1
SRSF3, 1
(5'-UTR). 1
myxobacteria, 1
Gephyronic 1
(Edc3) 1
YjeF_N 1
hEdc3 1
Yjef_N 1
Yjef_N-containing 1
NAD(H). 1
NMT1o, 1
signa 1
antigens-A 1
(MAGE-A), 1
MAGE-A2, 1
-3,-9, 1
-A4 1
MAGE-A9 1
-A10. 1
47.2%, 1
MMP2. 1
-A4, 1
combing 1
(CTAs) 1
CTAs. 1
CTLs' 1
(MSNP) 1
(Affymetrix) 1
DAC). 1
95-06 1
French-American-British 1
benefited, 1
classification). 1
(>75 1
IPPS 1
endoderm; 1
Co-injection 1
RFX6. 1
(446 1
malrotation. 1
c.779A>C; 1
p.Lys260Thr 1
(K260T). 1
2.7-year-old 1
DRw8 1
38.2%, 1
(21.9%). 1
changes.(ABSTRACT 1
/sharing 1
smartphones, 1
(apps). 1
Stores 1
"Medical" 1
calculators). 1
advertisement 1
nonreferenced 1
institution-only 1
subscription, 1
portals. 1
mHealth. 1
Countless 1
avail-able 1
(TINF2) 1
TIN2. 1
non-pathogenic. 1
(X-linked), 1
dominant), 1
recessive), 1
WRAP53, 1
lung) 1
(DKC1) 1
(TIN2). 1
"cryptic/atypical" 1
Equally, 1
"telomere 1
dysfunction". 1
dkc1. 1
H+ACA 1
hTR) 1
hTR, 1
DKC 1
4.5-kb 1
10.5-18.5 1
(Purkinje 1
(mitral 1
Registry: 1
76/83 1
myelod 1
(XCIPs), 1
inheritances 1
(Q31K 1
T357A). 1
(ES)/primitive 1
12E7, 1
(XG) 1
(CD99), 1
CD99-expressing 1
(RAG) 1
nonerythroid 1
2000;95:1819-1826) 1
(P=0.009). 1
CD99-reactive 1
(P=0.119). 1
deadhesion 1
LFA-1/intercellular 1
(ICAM-1)-mediated 1
IM-9, 1
IM-9 1
LFA-1 1
LFA-1. 1
LFA-1-mediated 1
p30/32MIC2. 1
neuroepitheliomas. 1
HBA71-negative 1
esthesioneuroblastoma, 1
osteosarcomas 1
ectomesenchymoma, 1
(MIC2 1
trinitrobenzenesulfonate 1
(TNBS) 1
antiphosphatidylserine 1
540. 1
CD2. 1
PtdSer 1
(SRCSs) 1
CIC-FOXO4, 1
t(X;19)(q13;q13.3) 1
30-mm, 1
SRCS 1
CIC-DUX4 1
SRCS. 1
(Spanki). 1
stands, 1
out-performed 1
(Spanki), 1
http://www.cbcb.umd.edu/software/spanki. 1
Splice-junction 1
(Spanki 1
ORMAN: 1
multimappings 1
>17% 1
heuristics. 1
IsoLasso 1
CLIIQ, 1
ORMAN. 1
http://orman.sf.net 1
MITIE: 1
RNA-Seq-based 1
regularization 1
Programming. 1
multi-mapping 1
genome- 1
assembly-based 1
well-motivated 1
http://bioweb.me/mitie 1
IGAR: 1
jasmonate-treated 1
(isoforms), 1
minimum-cost 1
advantage: 1
flows, 1
solvers; 1
Parsimoniously 1
approximations 1
multiassembly 1
(Transcrips 1
gRAPHs), 1
http://www.cs.helsinki.fi/gsa/traph/. 1
identifiable, 1
identifiability. 1
(multimapping 1
reads). 1
MULTo 1
Environment). 1
FASTA 1
SAM/BAM 1
integrated. 1
http://big.crg.cat/services/grape. 1
Environment) 1
genome-guided 1
DRUT 1
DiffSplice: 1
divide-and-conquer 1
(ASMs), 1
diverge. 1
ASMs 1
http://www.netlab.uky.edu/p/bioinfo/DiffSplice. 1
OSA: 1
Benchmarked 1
4-10-fold 1
http://omicsoft.com/osa. 1
corrupted 1
non-proportional 1
percent-spliced-in 1
(PSI) 1
conflated 1
protocol-specific 1
uniformity. 1
dcjones@cs.washington.edu 1
transcript-level 1
digitally. 1
POME 1
http://www.stat.purdue.edu/~yuzhu/pome.html. 1
yuzhu@purdue.edu; 1
SpliceTrap: 1
expression-level 1
CSH 1
http://cancan.cshl.edu/splicetrap 1
http://rulai.cshl.edu/splicetrap/. 1
michael.zhang@utdallas.edu. 1
RSEM: 1
RSEM's 1
ambiguously-mapping 1
IsoformEx: 1
Validations 1
http://bioinformatics.wistar.upenn.edu/isoformex. 1
Rnnotator: 1
(54.3%). 1
>430 1
75-bp 1
13,692 1
3,724 1
1,304 1
transcriptome-based 1
pre-computes 1
isoform-wise 1
reads: 1
('consistency 1
coefficient') 1
"unmasked" 1
infequent 1
(BRU-SDB, 1
(BRU, 1
(CON, 1
n=8) 1
non-Brugada 1
(N2, 1
REM). 1
entropy-derived 1
apnea-free 1
epochs. 1
BRU. 1
BRU 1
CON, 1
Entropy-derived 1
"Brugada-like" 1
Q1476X, 1
immunocytolabelling 1
permeation. 1
Q1476X 1
cardioverter--defibrillator 1
[ST 1
epicardiac 1
3.4.21.26, 1
PREP) 1
nonhydrolytic 1
colocalizations 1
106774459T>A, 1
106774423C>A, 1
106774418C>A, 1
106774382C>A 1
106774206G>A, 1
106774464C>T, 1
SNP-106774030A>G 1
(rs510432) 1
Pale 1
SNpc 1
proteasome-depleted 1
(ATGs), 1
11313449G>A, 1
11313811T>C, 1
11313913G>A 1
11314041G>A, 1
11312947G>A 1
11313006C>G, 1
SNAP-25, 1
syntaxin-1 1
synaptobrevin-2, 1
FM1-43 1
alpha-synuclein(1-140) 1
'Lewy 1
(LBD) 1
viewpoint. 1
Jean-Martin 1
Charcot. 1
palsy; 1
Fritz 1
1919, 1
Konstantin 1
Nikolaevich 1
Tretiakoff 1
Lewy. 1
Lewy's 1
�-synuclein, 1
(�-Syn) 1
Synphilin-1-binding 1
nonfibrillar, 1
K-resistant 1
NUB1, 1
synphilin-1-binding 1
NUB1. 1
deposited. 1
Î±-synuclein, 1
[Alpha-synucleinopathies]. 1
61-95 1
Accumulations 1
aggegation 1
betaA4 1
alpha-synucleinopathies. 1
Alpha- 1
Beta-synuclein 1
SNCA140, 1
SybrGreen, 1
neuron-specific-enolase 1
deltadeltaCt 1
hormone- 1
(PGC-1alpha) 1
(AMPKalpha) 1
slow-twitch, 1
fast-twitch, 1
(NRF-1) 1
5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside 1
(AICAR) 1
[3,3',5-triiodothyronine 1
T(3)-mediated 1
receptor-gamma 1
1.3-fold, 1
1.6-fold, 1
Tfam, 1
T(3)-treated 1
ATP-synthase 1
3,5,3',5'-tetraiodo-L-thyronine 1
1-day-old 1
euthyroids, 1
(0-30% 1
6-8). 1
mini-infusion 1
(binding) 1
GH-specific 1
125I-bGH, 1
somatogenic 1
125I-bGH 1
growth-activated 1
adenine-nucleotide 1
translocator, 1
ANT2, 1
N,N'-dicyclohexylcarbodiimide-binding 1
4-5-fold. 1
cytochrome-oxidase 1
F1-ATPase 1
impermeability 1
aa3. 1
Vo2, 1
cytochromes. 1
[ATP]/[ADP][Pi] 1
clinically? 1
(SNPs, 1
(UVR)-protective 1
parameters), 1
[Nle4-D-Phe7]-alpha-MSH, 1
repigmentation. 1
5,160 1
12,119 1
1.17-1.84) 1
(SOR; 1
1.41-1.96) 1
MC1R-associated 1
3.14 1
(2.06-4.80) 1
freckles, 1
III/IV. 1
pigmented, 1
(1.59-4.78) 1
5.62 1
(2.54-12.42), 1
(1.90-4.86). 1
45. 1
25year-old 1
hyporeflexia. 1
55year-old 1
Concentric 1
heterogenity 1
[CTLA-4] 1
3.4) 1
9.5) 1
(11.2 1
reached] 1
7.1]). 1
16.3% 1
55.0% 1
NCT01844505.). 1
melanoma). 1
B/C 1
(HBV/HCV), 1
HCV/HIV 1
HIV/HCV 1
HCV-directed 1
nivolumab-treated 1
Renal-Cell 1
23.1) 1
(98.5% 1
(P≤0.0148). 1
3.68 1
9.72]; 1
P=0.11). 1
everolimus; 1
NCT01668784.). 1
KRAS/p53-mutant 1
(SB225002). 1
(CXCR2 1
(SB225002) 1
(CXCR1) 1
(IL8), 1
CXCR1/CXCR2 1
(3-72) 1
K11R/G31P, 1
Interleukin-8 1
Chemotherapy-induced 1
c-FLIP(S), 1
factor-kappaB-mediated 1
c-FLIP. 1
CXCR2/1 1
CXCR1, 1
noninfiltrated 1
neutrophil-derived 1
AZ10397767-treated 1
CXCR2(-/-) 1
CXCR2-independent. 1
HBII-438A 1
(dsRNAs) 1
argonaute-binding 1
Keima 1
tamoxifen-inducible 1
size/area 1
RAS(G12V)-mediated 1
RAS(G12V)-induced 1
hyper-fusion 1
616; 1
transformation-induced 1
dichotomizes 1
BRAF(WT) 1
Parkin-Mediated 1
Hearts. 1
irrelevant, 1
myocyte-directed 1
Alone, 1
Drp1-induced 1
hyper-mitophagy, 1
p62/sequestosome 1
(SQSTM1) 1
(LC3-II). 1
Ablating 1
GSK3β-mediated 1
(GSK)3β-dependent 1
Ser(40) 1
Ser(44), 1
Ser(40)Ser(44) 1
phosphomimic 1
(Aβ)-induced 1
TAT-Drp1-SpS, 1
(CA1) 1
tubulation 1
reticulum-bound 1
INF2. 1
INF2-dependent 1
INF2-mediated 1
(DRP1; 1
2-deoxy-d-glucose 1
(2-DG) 1
Mn(III)tetrakis(1-methyl-4-pyridyl)porphyrin 1
pentachloride 1
(TMPyP) 1
DRP1-suppression 1
TMPyP 1
2-DG 1
metabolite-induced 1
DRP1; 1
(S616) 1
CDKs, 1
Drp1's 1
fission-promoting 1
PARK6 1
(G309D) 1
Drp1- 1
Fis1-induced, 1
PINK1-mediated 1
(Mfn1). 1
chemoattractant-induced 1
ORF4 1
(E4orf4) 1
subverts 1
Rab11a, 1
Rab11a. 1
FIP1/RCP 1
Rab11a-mediated 1
E4orf4-induced 1
energy-requiring 1
∼350% 1
Ser-637 1
∼30%) 1
(mdivi-1), 1
(TUNEL)-positive 1
mdivi-1-treated 1
media) 1
mdivi-1 1
(K38A) 1
Drp-1-dependent 1
anion, 1
(Mfn1) 1
Mfn2. 1
gluconeogenesis. 1
gluconeogenic 1
dynamin-regulated 1
Drp1/Bax, 1
glucose-treated 1
Bim/Bax 1
DRP1-regulated 1
BIK-induced 1
DRP1-dependent 1
fission-linked 1
(Drp) 1
Middle, 1
(GED) 1
identified2 1
K38A 1
FA-D1/BRCA2. 1
FANCD1/BRCA2-deficient 1
non-D1 1
Brca2-deficient 1
FA- 1
HR-deficient 1
cross-linker-sensitive 1
interleukin-3. 1
FA-derived 1
chemoresponsiveness 1
(FA-D1) 1
*6174delT 1
/C3069X 1
BRCA2*Q3066X 1
/E1308X 1
connections? 1
BRCA2/FANCD1 1
(<55 1
CPVT2, 1
(p.L77P) 1
preemptively 1
L77P) 1
exercise-emotion 1
K206N 1
(K206N) 1
(CSQ(WT)) 1
Y55C 1
c.164A>G) 1
P308L 1
patients/family 1
evolutionarily, 1
189, 1
beings, 1
(LCa 1
Invertebrate 1
Lymnaea 1
stagnalis 1
(α1C) 1
(N_3o18, 1
F_3i10, 1
I_4i12) 1
DHP-sensing 1
(Q_3o18, 1
Y_3i10, 1
M_4i12) 1
N_3o18_Q 1
(S)-Bay 1
K8644. 1
(SNc). 1
SNc 1
Cav1.3 1
Cav1.3L-type 1
channels-isradipine-was 1
intrastriatally. 1
CTF)-induced 1
Cav 1
carrier-bound 1
μg/g/day) 1
Isradipine's 1
4/O 1
0.20-0.25 1
poly-L-lysine. 1
0.0034), 1
(47%; 1
coli-uroepithelial 1
(nonfimbriated 1
HB101pDC1) 1
(silicon 1
nitride), 1
(L-CJC) 1
proanthocyanidins 1
(PACs). 1
bacteria-uroepithelial 1
PACs. 1
cranberry-free 1
(345.8 1
(UTI). 1
proanthocyanidin. 1
Proanthocyanidin 1
Purity 1
(Vaccinium 1
macrocarpon) 1
proanthocyanidins' 1
upset. 1
[Myth 1
truth. 1
resume. 1
cranberries 1
molecular-scale 1
(CJC) 1
CJC, 1
oz 1
CJC. 1
(B37, 1
CFT073, 1
BF1023, 1
J96) 1
mannose-resistant 1
(B73 1
B78). 1
non-fimbriated 1
HB101, 1
nitride 1
(UTIs). 1
cranberry, 1
(n=28); 1
(n=27); 1
withdrew: 1
1/28 1
1/27 1
2/29 1
5/27 1
11/26 1
(42.3%) 1
18/27 1
(48.1%) 1
WiiPD--objective 1
remote. 1
inconvenience, 1
infrequency 1
On-demand 1
home-treatment 1
paper-diary. 1
paper-diaries 1
electronic, 1
paper-diaries. 1
Documentations 1
documentations. 1
home-care 1
pen 1
diary; 1
maalox 1
antacid 1
H2-antagonist 1
ranitidine, 1
'on 1
demand' 1
alarm-clock. 1
Maalox, 1
'slight 1
'strong 1
improvement'). 1
home-medicated 1
'escape' 1
VAS-scores 1
1407) 1
HRRs 1
452) 1
VAS-ratios 1
(VAS-score 1
Ketoprofen 1
self-medicated 1
iMyc(ΔEμ) 1
H2-L(d)-IL6 1
interleukin-6- 1
serial, 1
lesion-specific 1
PCT-bearing 1
(MLN2238), 1
(MLN9708), 1
ixazomib-treated 1
(LIR) 1
lysosome-dependent 1
Unc-51 1
(ULK) 1
ATG13, 1
FIP200, 1
ATG101. 1
phagophore. 1
(GEC1)-interacting 1
Dsred-GABARAPL1 1
FLAG-GABARAPL1-6HIS 1
GABARAPL-1 1
NBR1. 1
(LIR). 1
WXXL 1
GABARAPL-1/NBR1-LIR 1
(LC3B 1
GABARAPL-1). 1
enthalpy-entropy 1
LIRs 1
ATG12, 1
ATG3. 1
p62/SQSTM1. 1
GFPp62, 1
GFP-LC3B. 1
shut-off 1
GFP-LC3B 1
GFP-p62. 1
Inducers 1
GATE-16/GABARAP 1
LC3s 1
GABARAP/GATE-16 1
Autophagosome 1
(Atg4) 1
C54 1
(Atg4A-Atg4D). 1
delipidate 1
Atg8. 1
Atg4D, 1
(GABARAP-L1). 1
GABARAP-L1, 1
sensitises 1
(GABARAP-L1) 1
Phosphatidylserine 1
ubiquitylation-like 1
[14C]ethanolamine 1
E1-substrate 1
E2-substrate 1
hAtg7. 1
hAtg7, 1
hAtg3, 1
hAtg4B-digestion 1
LC3-phospholipid 1
arboreal 1
Spillover 1
18:00 1
21:00 1
(canopy 1
ground), 1
savannah, 1
village 1
(indoor 1
outdoor) 1
barren 1
1,700 1
(11,247 1
mosquitoes) 1
luteocephalus 1
taylori, 1
dalzieli, 1
hirsutus 1
metallicus 1
unilinaetus, 1
uniformis, 1
Cx. 1
perfuscus 1
coustani 1
Kédougou 1
village, 1
multinucleated, 1
AgClb1/2p 1
AgCdc23p 1
AgDoc1p 1
AgCdh1p 1
germlings 1
AgPds1p, 1
disappearance. 1
AgCdc23p, 1
AgDoc1p, 1
AgCdc16p 1
AgCdh1p. 1
AgAPC/C 1
meta-anaphase 1
D-box-dependent 1
cyclin, 1
AgClb3/4p, 1
Asynchronous 1
Synchronous 1
GFP-labeled 1
Neighboring 1
AgSic1p, 1
Homologues 1
(hyphae) 1
fungicides. 1
(synteny) 1
microm/minute 1
nuclei-free 1
nucleus-free 1
Anucleate 1
syncytia, 1
asynchronously, 1
division-cycle 1
repel 1
asynchrony, 1
synchronize. 1
lifetimes 1
"cells 1
cells." 1
membrane-limited 1
vesicle-like 1
(∼200, 1
∼150, 1
40-nm 1
Heterokaryon 1
DNM1 1
FZO1 1
Cdc 1
(FEAR) 1
hyphae, 1
Agtem1Δ, 1
Agcdc15Δ, 1
Agdbf2/dbf20Δ, 1
Agmob1Δ. 1
M/G1 1
Agcdc55Δ 1
AgCdc14 1
bypassings 1
DYN1 1
Jnm1, 1
Ndl1, 1
Num1 1
Num1. 1
powering 1
forward/backward 1
(oscillations) 1
AgSpc72, 1
AgNud1, 1
AgStu2 1
wild- 1
Agspc72Delta, 1
tangentially 1
Agnud1Delta 1
Agcnm67Delta 1
bridge/half-bridge 1
Agstu2Delta 1
AgNud1 1
AgSpc72. 1
Mobility, 1
(cMT)-dependent 1
microm/min), 1
microm/min). 1
cMT-independent 1
cotransport 1
cMT-dependent 1
(SPB), 1
SPBs 1
cortex-associated 1
growth-axis-oriented 1
Cytological 1
Hphl 1
BstNl 1
suspicious, 1
(HPDE) 1
K-Ras4B(G12V)-transformed 1
HPDE 1
(HPDE-KRas) 1
PD98059, 1
HPDE-KRas 1
coculture) 1
HPDE. 1
2C3 1
E6/E7/Ras/st. 1
prenyltransferases 1
superadditive 1
inhibitor-sensitive 1
Farnesyltransferase 1
nonpapillary 1
Ki-ras 1
CRC: 1
(MSI+) 1
2.08, 1
1.22-3.57, 1
p.Gly12Asp, 1
p.Gly12Val 1
p.Gly13Asp 1
Utilisation 1
economises 1
Somatic, 1
cardiofaciocutaneous 1
updating 1
nontumoral 1
NCT00443794 1
transvection. 1
(VSL#3), 1
(E. 1
1917), 1
(LGG, 1
reuteri), 1
boulardii) 1
antidiarrheal 1
Acidified 1
bifidobacterium 1
lactis: 1
Bifidobacteria 1
(BbF) 1
28.3% 1
0.0014). 1
1.33-2.6). 1
Probiotics, 1
Probiotic 1
yogurts. 1
powders. 1
(VSL 1
Lauderdale, 1
FL), 1
pouchitis. 1
center]. 1
Presidium 1
Vergata 1
(29.2%). 1
Division: 1
(David 1
procedure), 1
Yacoub 1
David 1
attention: 1
(sinotubular 1
aorta). 1
sewing 1
aneurysma 1
dissecans 1
ascendens 1
casuistics 1
organ-change--the 1
cysts--and 1
[Images 1
pseudomeningocele. 1
tailbone, 1
urinating. 1
S1-S3 1
self-catheterization, 1
aneurysm]. 1
endured 1
(Bentall 1
operation), 1
42.1 1
satisfactory, 1
stable: 1
85.1 1
bpm. 1
mucoid 1
ribbon-like 1
anuclear 1
cavities, 1
hyperelastosis, 1
multiplication, 1
straightening, 1
elastolysis. 1
(AoD) 1
chart-review 1
sheet. 1
10-years 1
years-old. 1
AoD, 1
Losartan 1
(TGF 1
Losartan, 1
(COzaar 1
Enlargement) 1
losartan-treatment 1
NTR1423. 1
82.7% 1
Presentations, 1
(54.3%) 1
(90.3% 1
(82.0% 1
material-enhanced 1
0.996 1
0.980, 1
mL/m(2) 1
0.0, 1
.171; 1
http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13122310/-/DC1. 1
valves]. 1
(BAV). 1
AAD 1
[(35 1
[(55.4 1
(42.6 1
8.6) 1
(69.2% 1
32.1%, 1
BAV-associated 1
valve; 1
(BSA). 1
(AscAd)/BSA 1
-0.39, 1
0.020) 1
AscAd/BSA, 1
Brinkman 1
AscAd 1
(AscA/BSA: 1
mm/m(2), 1
tetrodotoxin. 1
tissue(s) 1
male-attracting 1
unexpected) 1
Predation 1
spat 1
promptly. 1
Chromatography-Tandem 1
(LC-MSMS) 1
anti-TTX 1
Benthic 1
mollusks 1
intertidal 1
species-Gibbula 1
umbilicalis 1
Monodonta 1
lineata 1
UPLC-MS/MS. 1
blowfish, 1
1,230 1
(MU)/g 1
inermis. 1
MU/g 1
MU/g, 1
gallbladder, 1
Toadfish 1
lunais 1
(1810 1
[MU]/g), 1
(341 1
MU/g). 1
lunaris. 1
brown-backed 1
wheeleri, 1
(Na(v)). 1
Na(v) 1
(Na(v)1.4) 1
TTX-sensitive. 1
CODEML 1
PAML 1
p-loop 1
voltage-sensor 1
(Na(v)) 1
cord), 1
465-bp 1
Chelonodon 1
patoca 1
(puffer 1
fish). 1
Canthigaster 1
puffers. 1
vermicularis, 1
eaten 1
rubripes, 1
eaten. 1
rubripes. 1
5-deoxyTTX, 1
11-deoxyTTX, 1
6,11-dideoxyTTX, 1
5,6,11-trideoxyTTX, 1
Tetrodon 1
(SIM). 1
5,6,11-trideoxyTTX 1
6,11-dideoxyTTX 1
TTXs 1
(female) 1
stuffs 1
(FFD) 1
micrometer-diameter 1
fluidic 1
ELISAs). 1
dilutions, 1
discharges; 1
EMG. 1
(CTG 1
Interview-Revised 1
(ADI-R), 1
5-15, 1
(MR), 1
[Myotonia 1
dystrophica]. 1
myotonic, 1
endocrine-autonomic 1
"Hippo" 1
anti-differentiation, 1
Hippo, 1
ndr-family 1
Lats. 1
phospho-Lats, 1
phospho-Mats, 1
autoactivates 1
Furry 1
Tricornered. 1
Architecturally 1
WW45/Sav1 1
Lats1/Lats2 1
ndr1/ndr2. 1
gut; 1
evident; 1
Mst1Mst2 1
Lats1Lats2. 1
Hippo/Mst1&2, 1
Rassf 1
Warts/Lats1&2, 1
Trc/ndr1&2, 1
Hippo-Lats-Yorkie 1
Yap1, 1
HCC-derived 1
Lats1/2. 1
Yap1(Ser127) 1
Mst1. 1
Warts. 1
Warts) 1
LATS1, 1
LATS2, 1
salvador, 1
merlin, 1
LATS, 1
YAP1. 1
YAP1-induced 1
Mst2, 1
Mst1/2. 1
EGFR-MAPK 1
Jub. 1
EGFR-Ras-MAPK 1
Salvador. 1
EGFR-Hippo 1
EGFR-RAS-MAPK 1
WW45. 1
(endocytic 1
nTSGs), 1
nTSG 1
(SWH) 1
AP-2σ 1
Yki-signaling 1
SWH 1
(www.ClinicalTrials.gov; 1
NCT01077206). 1
(presenting 1
ictus) 1
simvastatin; 1
(Simvastatin 1
Haemorrhage; 1
http://www.stashtrial.com/home.html) 1
(eNOS). 1
P=0.84) 1
P=0.93). 1
Pre-ICH 1
Statins: 1
vasodilatory, 1
angiogenic, 1
vasoprotective, 1
[mRS] 1
(12.6%) 1
0.92-0.97), 1
0.94-0.98), 1
1.21-1.98), 1
4.21; 1
1.47-12.17; 1
pre-admission 1
(NIHSS). 1
(45.6% 1
56.1%; 1
'pleiotropic' 1
Strongest 1
[RR]=0.73; 1
(RR=0.38; 1
0.83), 1
(RR=0.22; 1
0.82) 1
6.7, 1
0.91), 1
(23% 1
0.46), 1
cholesterol-dependent 1
(aSAH) 1
Prerandomization 1
(P=0.044), 1
(P=0.068) 1
=0.01), 1
Unfavorable 1
Hydroxymethylglutaryl 1
disease/risk 1
angiography/transcranial 1
[TCD], 1
0.003; 1
angiography/TCD 1
baseline-to-final 1
nanorods 1
nanophotonic 1
Near-field 1
nonbiological 1
photonic 1
nanotweezers. 1
multiwalled 1
110-170 1
92.8 1
nanotubes. 1
nanoassembly 1
Microtubular 1
GER 1
coeliaca. 1
lumbal 1
granulated 1
(GER) 1
3-30 1
4-40 1
Nisonger 1
Form-Typical 1
Quotient 1
(NCBRF-TIQ) 1
Impressions-Severity 1
(CGI-S) 1
-Improvement 1
Swanson, 1
Nolan, 1
Pelham 1
scale-revised 1
(SNAP-IV) 1
ADHD-related 1
NCBRF-TIQ 1
CGI-S 1
SNAP-IV 1
(children 1
schizo-affective 1
(second-generation) 1
(olanzapine 1
(2.5-20 1
(0.5-6 1
(10-140 1
>or=20% 1
(molindone: 1
olanzapine: 1
34%; 1
risperidone: 1
Risperidone 1
6.99 1
(BWG) 1
(APs). 1
metabolic/endocrine 1
APs. 1
hyperlipidemia; 1
nizatidine, 1
(BWG), 1
[14,101]. 1
noticeably, 1
(Fig.1). 1
[14,48,101]. 1
[2,14,24,133,139,140] 1
[14,34,68,87,93,101,130] 1
sections: 1
BWG; 1
dysregulation; 1
consulted: 1
PsychINFO. 1
[Body 1
neuroleptics]. 1
Overweight 1
self-confidence. 1
observance, 1
acetylcholin, 1
Antipsychotics, 1
neurovegetative 1
caretaking 1
Antipsychotic-induced 1
antipsychotics-both 1
ones-on 1
English- 1
non-English-language 1
4.45 1
ziprasidone, 1
ziprasidone 1
jeopardise 1
metres 1
squared. 1
anoretic 1
Anticonvulsants, 1
Corticosteroid-induced 1
corticosteroid-associated 1
sulphonurea 1
medication: 1
fenfluramine 1
Thioridazine 1
Consenting 1
molindone- 1
thioridazine-treated 1
(BPRS) 1
BPRS 1
Haloperidol-treated 1
hydrochloride: 1
dihydroindolone 1
neuroleptic, 1
schizophrenics 1
p.W531X 1
p.R512C, 1
p.L519P 1
p.G112D 1
inter-trimer 1
happens, 1
non-complementing 1
intra-trimer 1
p.G246V. 1
CoA-carboxylase. 1
(M348K) 1
M348K 1
CoA-carboxylase 1
(beta-subunit) 1
pccBCC 1
Asn536Asp. 1
dupKICK140-143, 1
G-->T, 1
Lys466. 1
dupKICK 1
Arg410Trp, 1
"Ins.Del," 1
12-bp 1
heteromer 1
Arg410, 1
acidurias 1
α6β6 1
dodecamer. 1
(Grünert 1
p.V288I 1
134% 1
U1snRNA. 1
c.1209+3A>G 1
(IVS13+3A>G) 1
ss. 1
plicing 1
(Pcca(-/-)) 1
(AAV8) 1
AAV8-mediated 1
2-methylcitrate 1
AAV8 1
(MMAuria) 1
(c.414+5G>A) 1
(c.494G>C) 1
c.654+462A>G, 1
p.E168K 1
p.R165W 1
(c.1068G>A, 1
c.1587_1594del8 1
c.593delA) 1
MMAB 1
(c.349-1 1
G>C). 1
c.271dupA 1
mut(0), 1
cblB 1
cblA 1
mut(-) 1
(c.414+ 1
5G> 1
long-PCR 1
c.231+1g>c 1
aminoacids, 1
[Gene 1
3q13.2-q22 1
Sequencer. 1
(1079T 1
1102G 1
1850T 1
(716-2A 1
(1863delA) 1
(484G 1
601G 1
1253C 1
insertion-deletions 1
(167-179del13ins1, 1
560-561delCCinsT) 1
167-179del13ins1 1
methylmalonyl-CoA. 1
(Ad5) 1
Unmodified 1
dsRed 1
detargeted 1
retargeted 1
(PEG)-modified 1
8-mediated 1
606054) 1
lethargy. 1
mild-severe 1
long-PCR, 1
(aCGH), 1
73kb 1
(c.231+1G>C 1
c.1209+3A>G) 1
(c.1210delG 1
c.1430G>T), 1
sites-two 1
(c.154_183+17del46 1
c.183+2T>C), 1
(c.1498+2T>C) 1
replacements, 1
non-severe 1
(IVS21+3del4 1
IVS22-2A>G) 1
six-nucleotide 1
(delV217-K218). 1
Minigene 1
beta-PC 1
(Spain, 1
Austria) 1
in-frame. 1
PCCB) 1
R165Q, 1
A497V, 1
N536D, 1
G131D, 1
G198D), 1
beta-polypeptide, 1
6.4.1.3) 1
d-methylmalonyl-CoA. 1
alpha4beta4 1
alpha6beta6, 1
renumber 1
104.bp 1
acidaemia. 1
odd-chained 1
C57Bl/6JEi 1
Spret/Ei 1
RFLPs. 1
Jackson 1
BSB 1
catalysis: 1
d-methylmalonyl-CoA 1
(R512C, 1
R514X, 1
W531X), 1
(A51_R514insP). 1
GroESL 1
W531X. 1
(L519P, 1
A513_R514insP, 1
W531X 1
alphaPCC 1
propionyl-CoA. 1
greenland 1
Inuits 1
1540insCCC. 1
D3S2453, 1
mRNA-minus 1
gene-no 1
studied-while 1
b-deficient 1
M442T, 1
L17M, 1
V205D. 1
c1170insT. 1
V205D 1
L17M+790-791insG. 1
790-791insG, 1
67-amino-acid 1
transcriptrevealed 1
codingsequence. 1
1210. 1
muchreduced 1
lengthsequence. 1
(R288X), 1
(700del5 1
1115del4) 1
(1671IVS+5G-->C) 1
'background 1
noise' 1
PCC-alpha 1
54-bp 1
1771IVS-2del9, 1
1824IVS+3del4, 1
1824IVS+3insCT, 1
pre-beta 1
(58,205 1
pRc/CMV, 1
ribotranscripts, 1
PCC-dependent 1
[14C]-propionate 1
pccC). 1
beta-protein. 1
2-base-pair 1
1000-bp 1
exon: 1
single-codon 1
ketone-bodies, 1
3-OH-isovaleric 1
3-OH 1
methylmalonate 1
propionylcarnitine. 1
high-caloric 1
Q293E 1
L417W 1
debates, 1
Congenital, 1
853 1
(G-CSF 1
Filgrastim). 1
(NICU). 1
hemiballismus. 1
Voa/Vop-DBS 1
GPi-DBS. 1
(38-45 1
Burke 1
Fahn 1
Marsden 1
subitem 1
"trunk"). 1
(stuttering 1
dysarthria) 1
(IPG). 1
disconnection. 1
pacemakers. 1
pallidum. 1
Dystonia: 1
(dystonia 1
1-13). 1
(DYT13) 1
(SGCE). 1
myoclonus-dystonia, 1
postgentamicin 1
colabeling 1
endocytotic 1
ABE 1
angiogenin-dependent 1
herpesvirus, 1
Epstein-Bar 1
HDAC3. 1
HOXB7 1
-6. 1
redirecting 1
Pit-1. 1
NF-kappaB-regulated 1
(TD-IkappaBalpha) 1
acetate-phytohemagglutinin 1
RelA(p65) 1
TD-IkappaBalpha. 1
-44 1
p50-c-Rel 1
B1/p105 1
HC9. 1
Tax. 1
P105 1
alpha-MSH. 1
142-169 1
130-157 1
LTPBP2 1
iridectomy 1
mydriatics. 1
mydriatics 1
FBN1-related 1
ADAMTS10-related 1
LTBP2-related 1
spherophakia, 1
ADAMTS10. 1
WMS-like 1
(15q21.1) 1
(LTBP) 1
5074_5097del). 1
Saudian 1
(Zmax=5.99 1
D19S906). 1
D19S905 1
D19S901 1
D19S221 1
D19S840 1
brachymorphy, 1
spherophakia 1
Fields--TTFields, 1
type/MDR 1
emetine-resistant 1
sub-line 1
EmtR1; 1
mitoxantrone-resistant 1
MCF-7/Mx 1
MDA-MB-231/Dox 1
TTFields/drug 1
(TEC) 1
TEC. 1
striking, 1
Irx2 1
Zfp503 1
Alcam 1
Cd133 1
Gpr182 1
culture-expanding 1
TEC, 1
TEC-selective 1
(OFT-ECs), 1
CD144/vWF. 1
ISL1+ 1
progenitors) 1
progenitor- 1
Isl1-ECs, 1
BMEC. 1
mi-RNA 1
miR-363*) 1
EC-specific 1
anti-miR 1
setting). 1
matrigel, 1
ligand-mediated 1
Angiocrine 1
underinvestigated. 1
EphA2-deficient 1
angiocrine-induced 1
growth/motility, 1
growth/motility. 1
angiocrine-mediated 1
Inductive 1
endothelial-cell-derived 1
VEGFR3(+)CD34(-)VEGFR2(+)VE-cadherin(+)FactorVIII(+)CD45(-) 1
(VEGFR2) 1
endothelial-cell-specific 1
Id1. 1
Id1-deficient 1
LSEC-derived 1
VEGFR2-Id1 1
intrasplenic 1
Id1(+/+) 1
(Id1(-/-)Wnt2(+)HGF(+) 1
LSECs) 1
re-establishes 1
VEGFR2-Id1-mediated 1
VEGFR2-Id1-dependent 1
co-transplantation 1
VEGFR2(+)Id1(+)Wnt2(+)HGF(+) 1
denaturants 1
Protein/peptide 1
isotopic/isobaric 1
urea-derived 1
carbamylation's 1
(PBHCit), 1
1.5-3.9) 1
1.5-3.7). 1
PBHCit, 1
(PBHCit) 1
≤35%), 1
59-128) 1
μmol/mol 1
PBHcit 1
[eGFR]: 1
-0.37; 1
.006), 1
[MPO]: 1
examined) 1
1.3-2.6; 1
1.2-3.1; 1
carbamylation: 1
artefact? 1
urea-commonly 1
proteins-is 1
isocyanate. 1
ε-amine 1
isotope-labeling 1
iTRAQ, 1
carbamidomethylation 1
(CPs) 1
nephrectomised 1
homocitrulline, 1
carbamylation-derived 1
(CDP). 1
nephrectomy). 1
1264 1
theoretically. 1
SN=82.50% 1
SN=66.67%, 1
SP=100.00% 1
MCC=0.8097 1
carbamyl-lysine 1
[Data 1
https://helixweb.nih.gov/ESBL/Database/Carbamylation/Carbamylation_peptide_sorted.html]. 1
Cyanate 1
myeloperoxidase. 1
intima, 1
MPO. 1
3-chlorotyrosine, 1
lipid-droplet 1
HDL-receptor 1
α-amino 1
codified 1
protease/saquinavir 1
coplanar 1
thiocyanate, 1
foam-cell 1
disassociates 1
Mcm10p. 1
mcm10-1 1
MCM10 1
receptor-positive; 1
1981-2003. 1
(64.4%), 1
(13.6%), 1
(18.4%). 1
blurring, 1
(2.6%). 1
(23.7%). 1
Her2+ 1
(AIs), 1
FACT-ES, 1
FACT-ES 1
Normative 1
HRAS. 1
failure-to-thrive, 1
p.G12S 1
77.7%. 1
Weight-for-age 1
Height-for-age 1
Centiles 1
(5th, 1
50th, 1
95th) 1
rhabdomysarcoma 1
(ARMS). 1
SDF-1, 1
responsiveness; 1
SCID/beige 1
GDP-bound 1
CS-associated 1
Cardio-facio-cutaneous 1
somewhat. 1
secundum-type 1
Chaotic 1
disturbances), 1
normoglycemia. 1
papillomata 1
papilloma. 1
neuro-imaging 1
Nissen's 1
fundplication 1
quantitated. 1
mrc1Δ 1
ctf18жд 1
Skp1 1
substrate-determining 1
nucleosome-remodelling 1
RSC-mediated 1
remodeller, 1
Cdc45-MCM-GINS, 1
helicase(s) 1
partners: 1
GINS. 1
redeposited 1
(facilitiates 1
minichromosome, 1
Ctf18-RFC. 1
stronger. 1
Trie 1
length-weighted 1
Linear-time 1
(Crochemore 1
(Pinho 1
twofold: 1
arrays; 1
Pinho 1
http://github.com/solonas13/maw 1
(COPD), 1
(CFTR+/-) 1
(CFTR+/+) 1
(WCS); 1
CFTR-dependent 1
FEV1/FVC 1
Network's 1
32,900 1
(44.7% 1
(91.1% 1
47.7% 1
+/-) 1
(CBAVD): 1
deferens) 1
0.163) 1
0.115). 1
7.07-12.11, 1
0.000], 1
49.20%, 1
19.43 1
10.48-30.03, 1
0.391) 1
CBAVD, 1
(TG)12_13. 1
(Congenital 1
Vas 1
Deferens). 1
system)-PCR, 1
(Multiplex 1
Ligation-mediated 1
Amplification). 1
(113/138) 1
p.W1145R 1
p.F508del 1
p.S466X 1
p.N1303K 1
c.3120+1G>A 1
p.A566D, 1
p.T1036I, 1
p.W1145R, 1
81.9%, 1
S466X 1
N1303K 1
c.3120+1G 1
A566D, 1
T1036I, 1
W1145R, 1
biographies 1
www.cystic-fibrosis.org.uk). 1
5,274 1
Subcontinent 1
deltaF508/deltaF508, 1
deltaF508/Other 1
Other/Other 1
Registries. 1
Screen-positive, 1
variables--pancreatic 1
10-marker 1
CFTR. 1
(Di, 1
Brown, 1
Deriy, 1
Szeto, 1
Chen, 1
Huang, 1
Tong, 1
Naren, 1
Bindokas, 1
Palfrey, 1
Nelson, 1
933-944). 1
cftr(-/-) 1
acidify, 1
G551D, 1
cftr(-/-), 1
19-23 1
Irish, 1
born. 1
Cdc14, 1
SRP9/14 1
U1, 1
U3 1
(U1.101, 1
U3.5) 1
snRNA; 1
U3.5, 1
U1.101, 1
particle) 1
(prosimian 1
Monkey). 1
presented) 1
7SL-derived 1
retropositionally 1
Methylation- 1
mutation-dependent 1
DEAE-dextran 1
transfection/affinity 1
phosphate/DNA 1
cotransfected, 1
buffy 1
paralogues, 1
factor1/chaperone-like 1
(Cdf1), 1
(CPP1), 1
Cdf1/CPP1 1
J-like 1
holdase 1
dark-operative 1
POR. 1
1μm 1
Desiccoplast-etioplast-chloroplast 1
air-dried 1
floated 1
prothylakoid 1
non-photoactive 1
chlorenchyma 1
illuminated. 1
humilis. 1
POR:Pchlide 1
(LHPP) 1
LHPP? 1
five-unit 1
PORB. 1
dithiol 1
(Chlide), 1
photoenzyme 1
pigments: 1
(Chlide) 1
(Chl). 1
skotomorphogenesis. 1
photoautotrophic 1
sucrose-supplemented 1
PORA-specific 1
oxidoreductase-less 1
NYB 1
(Nanchong 1
Barley) 1
Chl-less 1
(POR)-less 1
PORB, 1
LHCIIb1 1
b1) 1
SSU 1
ribulose-1,5-bisphosphate 1
carboxylase/oxygenase) 1
stacking) 1
NYB, 1
supra-molecular 1
grana, 1
botanists, 1
freeze-fracture 1
freeze-etch 1
appressed, 1
grana 1
non-appressed 1
thylakoids. 1
Mevalonic 1
Isopentenyl 1
(IPP) 1
(MVA) 1
2-C-methyl- 1
D-erythritol-4-phosphate 1
IPP-derived 1
Heynh. 1
cla1-1, 1
plastidic 1
chlorophylls 1
7-day-old 1
extra-plastidal 1
(PORA), 1
Calvin 1
light-independent 1
lip1, 1
Etiolated 1
unexpanded 1
phytochrome, 1
PHYA 1
Cab, 1
Fed1, 1
RbcS 1
plastic. 1
lip1 1
deetiolated 1
det1, 1
det2, 1
cop1. 1
phytochrome 1
Carotenoid 1
norflurazon-treated 1
(cdPLBs) 1
(oPLBs). 1
1-anilino-8-naphthalene 1
(attached 1
pyrene 1
(situated 1
lipids) 1
oPLBs. 1
oPLBs) 1
cdPLBs. 1
Nitella 1
cristata 1
(cisternae). 1
Zea, 1
lamellae. 1
(prolamellar 1
crystalline. 1
etiolation 1
chlorophyll-deficient 1
(pchlide) 1
(chlide) 1
charged-to-alanine 1
(Pisum 1
pchlide 1
photoconversion 1
NADPH, 1
342) 1
thylakoid. 1
intraorganellar 1
Prolamellar-body 1
etiolated, 1
reetiolation 1
(PLBs), 1
'narrow 1
type'). 1
Rye 1
what, 1
('wide 1
type') 1
reincubation 1
(=reetiolation). 1
galactolipid 1
monogalactosyldiacylglyceride 1
(MGDG) 1
digalactosyldiacylglyceride 1
(DGDG) 1
biofluid. 1
21.0. 1
taconic 1
(<15 1
(25-45 1
(>45 1
(DI-CMT) 1
(RI-CMT). 1
[Charcot-Marie-Tooth 1
(CMT), 1
(HMSN), 1
*601097). 1
(NT-3), 1
*601097) 1
2E, 1
(CMT1F). 1
disorder(s) 1
(MPZ), 1
(GJB1); 1
101. 1
NF-L, 1
Leu268Pro 1
del322Cys_326Asn 1
(DL). 1
axons) 1
NFs 1
(CMT1F) 1
17-40/10,000. 1
(demyelinating; 1
(axonal; 1
(AR). 1
Dejerine-Sottas 1
16p13.1-p12.3 1
Pro22Ser 1
CMT2A 1
(1p35-p36), 1
CMT2B 1
(3q13-q22), 1
CMT2C 1
(unknown), 1
(7p14), 1
CMT2E 1
(8p21), 1
HMNSP 1
(3q13.1), 1
CMT2F 1
(7q11-q21). 1
ARCMT2A 1
(1q21.1-q21.3) 1
ARCMT2B 1
(19q13.3). 1
(connexin 1
neurofilament-light, 1
kinesin) 1
19p13.1-13.2. 1
(DNM2). 1
p.Met580Thr. 1
ambulation. 1
paresis. 1
pattern; 1
8q13.1-21.3 1
c.692C>T, 1
(p.P231L) 1
8q13, 1
electrophysiologic, 1
severe: 1
recordable 1
m/sec. 1
pseudo-onion 1
(NCVs). 1
fluorescense 1
17p. 1
asociated 1
CMT1A. 1
Dnm1 1
BIN1 1
(amphiphysin 1
[CMT4A] 1
[CMT2K]. 1
CMT2K 1
CMT4A/CMT2K 1
(PRDIV) 1
DNA-recognition 1
(bZIP). 1
homo-bZIPs, 1
ATF-2/c-Jun/PRDIV 1
(MCMV)-infected 1
while. 1
IFN-alpha/beta 1
UV-inactivated 1
ATF-2/c-Jun. 1
pM27, 1
2-specific 1
Jak/STAT 1
positive-IFN 1
(bZIP) 1
ATF-2-c-jun, 1
IRF-3-dependent 1
ATF-2- 1
c-jun-IRF 1
IRF-3. 1
IRF 1
(MEKK1), 1
MEKK 1
P/CAF, 1
virus-dependent 1
EF, 1
(assay 1
ml/min/kg) 1
fter 1
(NT-pro 1
0.058) 1
-0.289, 1
0.380, 1
(http://bioconductor.org/packages/2.11/bioc/html/ddgraph.html). 1
CRM-specific 1
MMDiff: 1
replicates.We 1
re-analyse 1
sets: 1
E-value 1
REFINEMENT 1
dPattern 1
up/down 1
object-oriented 1
generators, 1
BioPerl 1
http://forkhead.cgb.ki.se/TFBS/ 1
(OGMs) 1
(bifrontal, 1
fronto-orbito-basal, 1
pterional) 1
Retraction-related 1
0.0384); 1
0.0044), 1
0.0455), 1
0.0096), 1
0.0112) 1
0.0393) 1
0.0418) 1
OGMs 1
OGM 1
vs.>70 1
(<80 1
WHO-classified 1
STATA® 1
progressed/ 1
34.9 1
recurrence/progression 1
moderate-size 1
[HR]6.42, 1
recurrence/progression-free 1
88, 1
sinus) 1
Oslo 1
(Rikshospitalet 1
Ullevål 1
Hospitals) 1
surgery-specific 1
60.1 1
19-92 1
2.1:1. 1
(90.3%), 1
(5.6%), 1
(4.1%). 1
0.0-20.9 1
II+III 1
IV+V 1
4.9- 1
13.2-times 1
radiopathological 1
mater 1
DTSs, 1
Goldsher 1
[23.4%] 1
[14.9%] 1
psammomatous 1
[14.3%] 1
[6.5%] 1
angiomatous 1
[12.3%] 1
154). 1
[8.9%] 1
[20.1%] 1
[31.8%] 1
[8.4%] 1
[30.7%] 1
179). 1
(0.841) 1
0.818). 1
smooth-type 1
DTSs 1
[33.8%] 1
82.3% 1
knights 1
dynasty. 1
researches, 1
CEP57, 1
CEP63, 1
CEP152, 1
CEP164, 1
CEP215 1
CEP27, 1
CEP55, 1
CEP70, 1
CEP110, 1
CEP120, 1
CEP135, 1
CEP192, 1
CEP250, 1
CEP350 1
[Ohta 1
156:87-99]. 1
Cep135-interacting 1
Cep135; 1
Cep 1
135-binding 1
gamma-tubulin 1
pericentrin, 1
(MCPH) 1
(CEP135), 1
interference; 1
4q12 1
(MCPH8), 1
MCPH, 1
(CEP135) 1
splitting. 1
sterile, 1
axoneme. 1
BLD10/CEP135's 1
centriole-assembly 1
(SAK/PLK4, 1
SPD2/CEP192 1
CP110) 1
SAK/PLK4 1
taxon- 1
neuralized 1
interference-resistant 1
NEURL4. 1
NEURL4-HERC2 1
Plk4-induced 1
(Plk4) 1
procentrioles 1
Plk4, 1
hSas-6, 1
procentriole 1
hSas-6 1
procentrioles, 1
alpha-/beta-tubulin 1
hereas 1
RO3306, 1
Cdk1-inactivated 1
centrioles/centrosomes 1
Plk4 1
discoordination 1
Cep135. 1
(Cep135) 1
clam 1
1-1144) 1
(#10, 1
29-1144; 1
Delta3, 1
29-812) 1
whorl-like 1
parallel-oriented 1
dots, 1
higher-ordered 1
spheroids, 1
Delta3-containing 1
loose. 1
stripes. 1
next, 1
(NICM) 1
59±14years, 1
mean±SD) 1
ejection-fraction 1
33±10%), 1
14.2months, 1
CMR-derived 1
Doppler-estimated 1
5.32, 1
17.63, 1
NICM. 1
subendocardium, 1
non-transmural 1
transmural; 1
strip- 1
patch-shaped; 1
subendocardium 1
ventricles; 1
clumpy 1
ischeminc 1
inflammation-what 1
us? 1
Atherothrombosis 1
'upstream' 1
Journals.permissions@oup.com. 1
receptor-null 1
(PLA2G10) 1
X-deficient 1
(Pla2g10(-/-)) 1
Pla2g10(+/+) 1
(Th)1 1
(varespladib) 1
sPLA2s. 1
(sPLA2), 1
Dilution 1
reduction/protein 1
methyl, 1
DESIGN, 1
2012).INTERVENTIONS: 1
.04).CONCLUSIONS 1
ACS.TRIAL 1
REGISTRATION: 1
(sPLA(2)) 1
63±10 1
64±10 1
(P=0.39) 1
(P=0.018). 1
quartiles) 1
1.48) 1
(0.00 1
(P=0.81) 1
(-0.70 1
1.40) 1
(-0.12 1
1.72) 1
(P=0.23), 1
-2.85 1
(-3.40 1
-1.85) 1
(-0.20 1
NCT00533039. 1
SPIDER-PCI) 1
APPROACH 1
(p=0.019) 1
(p=0.013), 1
-45% 1
(p=0.045), 1
(p=0.009) 1
-48% 1
(p=0.015), 1
poractant- 1
Type-2 1
(metformin 1
q.d 1
.on 1
(AUC(τ,ss) 1
96.9; 1
101.7) 1
(C(max,ss) 1
GMR: 1
100.5; 1
88.8 1
113.7) 1
100.7; 1
105.6) 1
C(max,ss) 1
103.6; 1
96.5 1
111.2) 1
[OATP1B1]/1B3 1
35.1 1
23.47 1
rifampicin/probenecid 1
23.03 1
[GMR], 1
158.50% 1
151.77-165.53]; 1
115.00% 1
106.15-124.59]), 1
135.20% 1
129.58-141.06]; 1
175.14% 1
160.14-191.56]), 1
153.47% 1
146.41-160.88]; 1
125.60% 1
113.67-138.78]). 1
<2-fold, 1
OATP1B1/1B3, 1
glucuronosyltransferases 1
identifiers: 1
NCT01301742 1
NCT01634100. 1
OATP1B1]/1B3 1
function] 1
AUC(0-∞) 1
123.15% 1
(98.89-153.36) 1
103.81% 1
(82.29-130.95), 1
146.97% 1
(118.02-183.02) 1
123.31% 1
(97.74-155.55), 1
174.70% 1
(140.29-217.55) 1
148.41% 1
(117.65-187.23), 1
operation; 1
(wire 1
plate); 1
readvancement, 1
advancement; 1
anthropometry. 1
Whittaker 1
revision; 1
foreheadplasty; 1
redo 1
FOA). 1
cephalometry. 1
(n=15), 1
suturectomy, 1
FOA. 1
22.9 1
3-128 1
(n=7). 1
p.Pro250Arg. 1
(pan 1
synostosis), 1
bossing; 1
(p.Pro250Arg). 1
neurosurgeon, 1
radiologist, 1
psychologist, 1
audiologist, 1
worker. 1
(fronto-orbital 1
contouring 1
fused/synostotic 1
strabismus; 1
keratopathy. 1
protocol-driven 1
team; 1
assessments; 1
(pansynostosis), 1
FGFR-Related 1
(AN), 1
(isolated 1
FGFR3). 1
FGFR3; 1
possible; 1
(craniotomy 1
advancement) 1
needs; 1
proptosis. 1
(ATN). 1
Externalizing 1
metaphors: 1
concretizing 1
metaphors. 1
Works 1
Psyc-INFO) 1
psychology, 1
psychology 1
difficulties; 1
8.67) 1
(6-OHDA). 1
next? 1
Non-dopaminergic 1
(rigidity, 1
olfactory, 1
methyl- 1
ethyl-esterified 1
(etilevodopa 1
melevodopa), 1
rasagiline), 1
BIA-3202) 1
brasofensine). 1
sumanirole, 1
piribedil 1
BP-897) 1
rotigotine) 1
CEP-1347), 1
creatine), 1
leteprinim), 1
neuroimmunophilins 1
V-10367), 1
MITO-4509), 1
c-synuclein 1
PAN-408) 1
(n=126), 1
(n=123), 1
(n=124). 1
(-0.96 1
(-0.23 1
4.0%; 1
13.0%; 1
12.1%). 1
clinically-feasible 1
iron-overload 1
(1.5-T) 1
(shortened 1
look-locker 1
[ShMOLLI] 1
(1,140 1
(958 1
(979 1
(1,048 1
(1,009 1
1,020 1
(CVF%) 1
CVF% 1
(r=0.65, 1
(972 1
1014 1
(944 1
(r=-0.40, 1
(r=0.36, 1
Non-contrast 1
mapping: 1
(MOLLI) 1
25min 1
post-administration 1
dimeglumine 1
0.1mmol/kg 1
gadobenate 1
dimeglumine, 1
dimeglumine. 1
(λ) 1
(ΔR1myocardium/ΔR1blood), 1
(1-hematocrit). 1
(ECV: 1
0.287 1
0.267 1
0.028, 1
p=0.002; 1
λ: 1
0.481 1
inter-study 1
intra-study 1
(ECV:0.017 1
λ:0.025 1
~3% 1
normals). 1
cine, 1
Circumferential 1
slice, 1
1209±28 1
1225±42 1
1178±13 1
(r=0.32, 1
1228±41 1
1192±79 1
1254±73 1
1217±52 1
(r=0.42, 1
phosphocreatine/adenosine 1
(r=-0.59, 1
[e. 1
intermediaries 1
angiomyolipoma: 1
(1-46) 1
(0.7-18.0) 1
size.Eight 1
cm.Five 1
nephron-sparing 1
embolization.One 1
found.In 1
clinic.For 1
(>4 1
TSC-specific 1
non-existent. 1
Familiarity 1
(TAND) 1
large-to-average 1
tubers; 1
gender; 1
uberous 1
Coagulopathy 1
epistaxis. 1
downward, 1
(~80%). 1
aPTT) 1
(HTI) 1
Ecarin 1
(ECA), 1
time-international 1
(PT-INR) 1
(aPTT). 1
(<0.5-586 1
HTI. 1
PT-INR 1
(NVAF). 1
(36.0%). 1
intra-individuals. 1
Européenne(CE)-labeled 1
dabigatran-spiked 1
Lyophilized 1
non-clotting 1
amidolytic 1
(IV-rtPA) 1
arm/face 1
150-399 1
10(9)/L), 1
24.0-33.0 1
1.1. 1
IV-rtPA, 1
190-395 1
monitoring]. 1
Ideally 1
pharmacometric 1
(n=1,965), 1
contraindications. 1
ESI-MS/MS. 1
ESI-IT-MS/MS. 1
mucin-1 1
(MUC-1) 1
Tn, 1
per-acetylated 1
LC-separated 1
(c/z·-type 1
ions) 1
O-glycopeptides 1
low-resolution/low-mass 1
unimolecular, 1
two-state, 1
downshifted 1
stability-temperature 1
non-optimally 1
AFP. 1
Asp36-Arg39 1
Asp36 1
pe 1
Freeze-tolerant 1
non-colligatively 1
(AFPs). 1
104), 1
8/group) 1
(UW) 1
[FS], 1
[ESD, 1
EDD] 1
[AWT-S, 1
AWT-D, 1
PWT-S, 1
PWT-D]), 1
froze 1
AWT-D 1
18-hour 1
AFP-treated 1
ESD 1
(3.4 1
TUNEL-stained 1
freezing, 1
waist-like 1
proteins/Sialate 1
molybdopterin 1
CpaB, 1
StrU-like 1
UxaA/GarD-like 1
(SAF 1
superfamily). 1
CpaB-like 1
Flp 1
barrel-like 1
SAF, 1
dUTPase 1
decoration 1
molybdenum 1
apolar 1
shell. 1
eel 1
pout 1
(thermal 1
hysteresis) 1
A16T 1
A16Y 1
polar-like 1
A16C 1
apolar-like 1
hydrating 1
H-bonds 1
heterogenous. 1
polar/apolar 1
recognize, 1
'-K-DT-' 1
'-DT-K-'. 1
anti-freezes 1
(SHM) 1
diversifies 1
deoxycytosine 1
non-Ig 1
(IgL) 1
1.9-kb 1
(diversification 1
200-bp 1
350-bp 1
elongation/pausing. 1
SHM. 1
elongation/pausing 1
(prostaglandin 1
synthase-2) 1
5'-pausing, 1
transrepression. 1
synthase-2 1
(pol-II) 1
(GRα) 1
transrepress 1
transrepression 1
Splicing-dependent 1
IIo(ser5) 1
initiation-to-elongation 1
initiation-factor 1
elongation-factor 1
Cdk7--part 1
TFIIH--increases 1
ubiquitylation--in 1
relieve, 1
elongation: 1
handoff 1
(IIa) 1
(IIo) 1
Gapdh-2 1
IIo 1
YSPTSPS, 1
(promoter-proximal 1
dhsp70 1
(HSF), 1
Outcrossing 1
UAS-GAL4 1
SIRT1: 1
tipping 1
daf-16. 1
FOXO4, 1
SIR2 1
PML/p53-induced 1
(Ha-rasV12). 1
from. 1
harm? 1
19-50 1
calcium-rich 1
required). 1
stereotypical, 1
cephalalgias: 1
(16.4%) 1
(60.7%). 1
(66.0%) 1
aura) 1
mg/week 1
tablets/month, 1
(transformed 1
6.3/28 1
days/month 1
28.7/month 1
90.2 1
(5.8/28 1
5-120 1
lbs). 1
(first-line 1
monotherapy), 1
(rhinorrhea, 1
ergotamine. 1
Abortive 1
beta-Adrenergic 1
unleashes 1
Tsc1-/- 1
Tsc2-/- 1
leiomyoma-derived 1
Tsc2-deficient 1
ELT3 1
Tsc2-associated 1
(mTORC2): 1
Tsc2-defective 1
Tsc2-null 1
deficiency-mediated 1
MiR-424/503-mediated 1
miR-424/503. 1
miR-424/503-Rictor 1
torin1, 1
kinase-C). 1
torin1. 1
sh-RNA 1
S729 1
torin1 1
DN-PKCε 1
mTORC1). 1
(LTM) 1
(L-LTP). 1
LTM 1
dTORC2-deficient 1
mTORC2-deficient 1
L-LTP 1
Akt/mTORC1 1
Reversely, 1
exogenously-added 1
1(mTORC1) 1
(CA-Akt) 1
Akt/ 1
(Lrictor(KO)) 1
half-normal 1
Thr-308 1
GSK-3β, 1
AS160, 1
Tsc2. 1
insulin-activated 1
Lipin1 1
FoxO1. 1
mTORC2-dependent 1
Sin1-deficient 1
double-negative, 1
double-positive, 1
(nTreg) 1
TGF-β-dependent 1
nTreg-cell 1
(TNF-α)-mediated 1
rhegmatogenous 1
Akt/Tuberous 1
(TSC2)/mTOR 1
complex1 1
knocking-down 1
Akt/mTORC1, 1
PVR. 1
deletion-caused 1
Ser473. 1
Aloe-emodin, 1
aloe, 1
PKCα, 1
(ΔR-L), 1
Servicemen's 1
non-testicular 1
ambidexterity 1
CI)=0.65 1
(0.30-1.41)] 1
CI)=0.79 1
(0.44-1.44)] 1
ΔR-L, 1
3044 1
HPV, 1
(case-control) 1
retested 1
HPV. 1
nonadolescents. 1
(LUTS), 1
420; 1
350). 1
(22.4% 1
0.544), 1
(46.8% 1
(44/94) 1
23.6% 1
(17/72), 1
2.847, 1
1.445-5.610). 1
282; 1
126), 1
(46.7% 1
(sum 1
18/282 1
1/126 1
12/282 1
0/126 1
(0.0%), 1
fourth-digit 1
(CAH) 1
foetuses. 1
(2D/4D) 1
(p=0.000) 1
R47H) 1
APOEε4 1
(ptau), 1
tau/ptau 1
1,269), 1
ptau: 1
4.89 1
3q28 1
GEMC1 1
OSTN, 1
rs514716 1
ptau, 1
9p24.2 1
GLIS3 1
rs6922617 1
ptau) 1
6p21.1 1
10⁻⁴, 1
10⁻⁵, 1
endophenotype-based 1
pro-amyloidogenic 1
consortiums 1
(PLOSL, 1
Nasu 1
Hakola 1
1-Methyl-4-phenylpyridinium-induced 1
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1
(MPTP), 1
(LC3-II), 1
LC3-II. 1
kinome. 1
MAP1LC3-interacting 1
lysosomotropism 1
GFP-LC3, 1
hyperactivation. 1
signals) 1
Sox2-dependent 1
Obesity-mediated 1
CKDs, 1
reabsorbing 1
tubule-specific 1
renoprotective. 1
mTOR-based 1
Abnormally 1
(rs2536 1
rs1883965 1
rs17036508 1
rs3806317 1
T>G) 1
CT/CC 1
CG/CC 1
(1.13-1.78), 1
(1.07-1.55), 1
GT/GG 1
(0.64-0.92), 1
0.003], 1
(1.04-1.47), 1
0.016], 1
one-factor 1
rs17036508, 1
three-factor 1
41.9%. 1
anti-HSP70, 1
tigated 1
CRP) 1
'nonalcoholic 1
steatohepatitis' 1
(NASH), 1
NASH-related 1
liver-dependent 1
Nonalc 1
U/kg/6 1
no-MS 1
U/ 1
kg/6 1
MetS-focused 1
eq 1
(BMI)/obesity. 1
3046 1
ATPIII 1
(FTO 1
rs9939609, 1
MC4R 1
rs17782313, 1
rs7138803, 1
rs1805081, 1
SEC16B 1
rs10913469, 1
SH2B1 1
rs4788102, 1
PCSK1rs6235, 1
KCTD15 1
rs29941, 1
BAT2 1
rs2844479) 1
7900. 1
(GNPDA2 1
rs10938397: 1
(OR)=1.21, 1
(CI)=1.04-1.40, 1
P=0.016; 1
rs6265: 1
OR=1.19, 1
CI=1.03-1.39, 1
P=0.021; 1
rs7138803: 1
OR=1.20, 1
CI=1.02-1.40, 1
P=0.025); 1
(OR=1.09, 1
CI=1.04-1.15, 1
P=5.26×10(-4)). 1
P>0.05); 1
95%CI=0.96-1.08, 1
P=0.557). 1
tota 1
insulin-resistance, 1
rev 1
universalis. 1
ciation 1
glycoxidative 1
lipoxidative 1
glycoxidation 1
(advanced 1
N-carboxyethyl-lysine 1
N-carboxymethyl-lysine: 1
(4-hydroxy-2-nonenal: 1
malondialdehyde-lysine: 1
MDAL) 1
Bi-dimensional 1
glycoxidation, 1
anti-CEL 1
anti-HNE 1
Proteomics-driven 1
MALDI-TOF-MS 1
glutathione-S-transferase 1
omega1 1
histamine-N-methyltransferase 1
Histamine-N-methyltransferase 1
(PiD). 1
PiD. 1
unfulfilled 1
promise? 1
dipstick 1
cytologies, 1
(miR-145, 1
MiR-205 1
(LG) 1
0.992 1
0.997, 1
(sensitivity/specificity 1
95.8/96.7 1
100/91.7 1
PUNLMP, 1
0.870 1
84.2 1
ZEB1/ZEB2 1
PUTs 1
Mcm5, 1
urography, 1
NMP22® 1
Genito-urinary 1
210/1564 1
195/1396 1
62-75%) 1
92-95%). 1
0.71-0.79) 1
0.67-0.77) 1
(79/83; 1
88-99%) 1
≥pT1) 1
(72%, 1
69-74%). 1
(BTA-Trak©) 1
BTA 1
BTA-Trak©, 1
(AUC; 1
0.72-0.86). 1
(OR; 1
1.16-1.97, 1
caveat. 1
osmolarity 1
diagnosis". 1
ANOVA). 1
Osmolarity 1
mOsm; 1
mOsm) 1
10163 1
µmol/l, 1
9350 1
µmol/l) 1
(0.3297, 1
0.1155 1
AUROCs 1
AUROCs. 1
months)), 1
(Bland 1
(POCT). 1
AMDS. 1
cloning-sequencing 1
PIK3CA, 1
comfirmed 1
E542K 1
E545K 1
(89/89) 1
(52/70) 1
attempt; 1
AMDS, 1
Bioanalyzer. 1
90/105 1
(85.7 1
88.2 1
(153.5 1
276.5 1
0.0059). 1
(0-200 1
(35.5 1
[Observational 1
retro-prospective, 1
multicentric, 1
interventional, 1
(systematic/prospective 1
specific/retrospective), 1
39.8 1
[28.8; 1
37.9] 1
(65.3%), 1
(80.4%) 1
(73.9%). 1
(36.2%), 1
consensus). 1
(n=48) 1
EGF(R) 1
(RFLP). 1
K-allele 1
EGFR-497K 1
3.03 1
(EQA) 1
Assurance 1
laboratories; 1
laboratories' 1
Formalin-Fixed 1
Paraffin-Embedded 1
homogenously 1
47/131 1
HRM, 1
6/33 1
(18.1%) 1
3/33 1
EGF61 1
cetuximab-containing 1
Dworak 1
(5/11), 1
(11/53) 1
(1/54) 1
KRAS. 1
(cetuximab, 1
bevacizumab) 1
(BOND-2 1
(CBI) 1
(CB)(BOND2). 1
(31: 1
34: 1
(18: 1
NRP1 1
FCGR3A 1
V158F, 1
A870G 1
(wt-BRAF) 1
wt-KRAS 1
46.2% 1
wt-KRAS. 1
Summing 1
51.3%. 1
wt-BRAF) 1
(CCR), 1
DPD 1
reparases 1
GSTpi 1
pre-KRAS 1
1022 1
(299/747) 1
(108/743) 1
[74/108] 1
20.4% 1
[22/108] 1
(36/761) 1
(17/644) 1
(17/253) 1
(126/352; 1
0.07-0.22; 1
1.66-2.36; 1
(1.75, 1
1.47-2.09; 1
(2/24) 1
(124/326; 1
0.02-0.51; 1
p=0.0012); 1
(1/13) 1
(110/289; 1
0.007-0.70; 1
36.8% 1
(121/329; 1
0.00-0.89; 1
p=0.029), 1
1.33-4.78; 1
(3.29, 1
1.60-6.74; 1
p=0.0057). 1
order) 1
41.2% 1
(Stichting 1
tegen 1
Kanker). 1
sarcoma-2 1
EGFR-induced 1
RAS/RAF/MAPK 1
(TTPs) 1
(P=0.008) 1
P=0.0007). 1
(cetuximab 1
bevacizumab), 1
escalation, 1
7/7). 1
CRYSTAL 1
FOLFIRI 1
FOLFIRI-cetuximab 1
FOLFIRI. 1
FOLFIRINOX 1
else?]. 1
Germany; 1
DIN 1
EN 1
9001:2000. 1
40-53% 1
"non-targeted" 1
Radiosensitizing 1
Honokiol, 1
Magnolia, 1
(RPC-9, 1
PC-9/Van-R 1
PC-9/ER3) 1
exon19 1
1mm) 1
0.37±0.18 1
2.25±0.53 1
pJAK1, 1
pJAK2 1
(217 1
Barbata 1
redundantly. 1
needed.Scutellaria 1
barbataD 1
(EESB) 1
SB's 1
Dimethylaminoparthenolide, 1
parthenolide, 1
dimethylamino-parthenolide 1
(DMAPT), 1
parthenolide 1
39%. 1
(IL)-6-type 1
(IL)-6/STAT3 1
CD4(+)/CD8(+)) 1
(p-STAT3), 1
postoperative-week 1
pre-operation. 1
carcinoma-targeted 1
preliminarily 1
pT, 1
0.0049, 1
pT 1
(>80.0% 1
≤80.0%). 1
phospho-sumoyl 1
(NEC). 1
[Induced 1
Rigshospitalet, 1
HIE 1
0.4/1000 1
ventilator. 1
mattress 1
tain-Free 1
nonskeletal 1
7808 1
[Fracture 1
(FREEDOM) 1
antiresorptives. 1
ultradistal 1
flattens 1
antiresorptives 1
FREEDOM 1
4-7. 1
recurrent/unresectable/metastatic 1
Preference 1
medication-taking 1
chemo-immunotherapy, 1
biology-the 1
3-kinase/mammalian 1
(PI3K/mTOR) 1
receptor/spleen 1
(BCR/Syk) 1
C-beta 1
(PKC-β) 1
hematologist/oncologist 1
7-hydroxymethotrexate 1
(7-OH-MTX), 1
(0.85-1.20) 1
(0.90-1.40) 1
(0.82-1.35) 1
(0.83-1.36) 1
7-OH-MTX, 1
P=0.007 1
P=0.34 1
7%), 1
Syk-inhibition 1
Rigel; 1
NCT00665925.) 1
FcR. 1
BCR-mediated 1
early-established 1
insulin-specific 1
(complement, 1
neutrophils) 1
membrane-mediated 1
Syk. 1
ischemia-conditioned 1
kg(-1 1
14)C-R788) 1
2.0-2.8 1
excreta. 1
para-O-demethylated 1
(R529), 1
N-glucuronide 1
3,5-benzene 1
diol 1
O-demethylation 1
para-dehydroxylation 1
R529 1
7-19) 1
6-17) 1
twelve-week, 1
Fcgamma-activating 1
ascending-dose, 1
Twice-daily 1
diarrhea) 1
(<1,500/mm3), 1
anti-collagen 1
(COMP) 1
amid 1
MTX-IR 1
67-72% 1
bd), 1
43-57% 1
28-40%. 1
transaminitis. 1
Syk-induced 1
Posttransplant 1
(PTLD)-associated 1
(EBV)+ 1
LMP2a, 1
PTLD. 1
EBV-infected 1
PTLD, 1
PI3K)/Akt 1
(NCT00665925) 1
(PtGA) 1
-31.3 1
(2.45) 1
-17.8 1
(2.45), 1
-29.1 1
(2.26) 1
(2.42), 1
PtGA; 1
-0.647 1
(0.064) 1
-0.343 1
(0.062), 1
(1.00) 1
4.50 1
(0.94), 1
8.52 1
(0.77) 1
4.90 1
(0.78), 1
3.99 1
(0.93) 1
3.71 1
PRO, 1
safer, 1
kinome, 1
Pro455 1
Asn457 1
JAK1/3 1
VX-509, 1
TLR4: 1
Src-homology 1
(ITAMs). 1
lectins, 1
dectin-1. 1
(TLR4). 1
SYK-TLR4 1
(mmLDL), 1
mmLDL-induced 1
macropinocytosis, 1
host-derived, 1
mmLDL, 1
Hematology, 1
ACR/ARHP 1
Platelet-depleted 1
[Involvement 1
multi-chain 1
ζchain 1
FcR 1
immune-receptor 1
(ITAM). 1
Syk-mediated 1
(TLR)-9, 1
CD40- 1
TLR9- 1
Selective, 1
BCR-independent 1
P505-15, 1
nurse-like 1
cell-co-cultures. 1
BCR-dependent 1
CCL3 1
CCL4 1
(GvHD) 1
(Tcs). 1
anti-murine 1
Fostamatinib. 1
alloantigen-activated 1
anti-lymphoma 1
12-26 1
189-457 1
(875 1
(35-38%). 1
Fluctuating 1
Diameter. 1
35-42% 1
anisocoria. 1
unremarkable; 1
anti-GAD 1
outset 1
IVIG. 1
[Ataxia 1
ophthalmoplegia: 1
positivity]. 1
syndromes--new 1
paraesthesias), 1
(Bickerstaff 1
encephalitis). 1
(Mirococept), 1
pathogenic, 1
[Campylobacter 1
glycotope 1
arthritides 1
atxGBS. 1
polyneuropathy; 1
atxGBS 1
AtxGBS, 1
fisher 1
1.65. 1
(18%, 1
11/60) 1
(80%, 1
4/5) 1
anti-GQ(1b) 1
(KCMH) 1
"Miller-Fisher 1
"Guillain-Barré 1
(male:female; 1
3:3) 1
54.3 1
(IVIG). 1
KCMH 1
Immuno-pathogenesis 1
Lipopolysaccharides 1
(Penner) 1
serotyping 1
Serotypes 1
O:19 1
O:41, 1
O:1, 1
O:2, 1
O:4, 1
O:10, 1
O:19, 1
O:23, 1
O:36 1
O:41 1
GM2. 1
syndrome--an 1
flexia, 1
wss1Delta 1
(RAD52) 1
(RAD9 1
RAD24). 1
Tof1. 1
RAD52 1
SRS2, 1
TOF1. 1
(Polalpha). 1
Ctf4p. 1
POL1 1
Pol1p. 1
disassembling 1
ctf4Delta-interacting 1
Cohesin. 1
XRS2. 1
DNAskew: 1
LINUX 1
GBFF 1
(GenBank 1
flatfile) 1
fasta 1
http://www.epizooty.com/pub/stat/DNAskew. 1
(846 1
analyzed) 1
(0.25-0.75), 1
(Sueoka, 1
Translation-coupled 1
238, 1
53-58.). 1
rates). 1
0.22-0.96 1
0.25-0.75, 1
(0.75-0.96; 1
(A≈T 1
G≈C 1
intermingled, 1
(AHT 1
GHC 1
hemophilia, 1
FIX 1
bedside: 1
safety-improved 1
Gene-corrected 1
SINfes.gp91s 1
(WAS) 1
WASP, 1
WASP-expressing 1
HSPCs. 1
WAS. 1
Metachromatic 1
(MLD) 1
(ARSA) 1
mCD105-LV, 1
CD105-positive 1
nontargeted 1
LVs. 1
(huCD105-LV) 1
huCD105-LV 1
double-enhanced 1
apoptin, 1
HOTAIR, 1
(56.87%) 1
(staining 1
Quantified 1
48.4-fold 1
single-hit 1
dose-survival 1
lines(RKO, 1
Lovo) 1
RKO, 1
2Gy 1
Lovo(SF2=0.47) 1
RKO(SF2=0.53) 1
(38.6%). 1
lines(P>0.05), 1
lines(P<0.05). 1
lines(P<0.05), 1
different(P>0.05). 1
P53-P21-cyclin 1
carcinogenesis-associated 1
polyA-minus 1
1q41, 1
RNA-LET 1
(lncRNA-LET) 1
acetylation-mediated 1
(P=.008). 1
(P=.018). 1
RNA-transfected 1
wrong: 1
'recycled.' 1
indispensible 1
destructive, 1
γ-Amino 1
(GABA(C)) 1
ρ1 1
ρ1-receptor 1
(GeLC-MS/MS), 1
solution-based 1
(SoLC-MS/MS), 1
(MudPIT). 1
ρ1-receptor-interacting 1
Chaperone-assisted 1
nonnative 1
misfolded, 1
dispose 1
(CASA) 1
tension-induced 1
CASA 1
diabetes--all 1
aminoglycosides, 1
peptides--all 1
ML346: 1
(Hsp70): 1
ML346. 1
barbituric 1
HSF-1-dependent 1
Nfr-2. 1
"definitive 1
evidence" 1
(sigma 1
(σ(32) 1
σ(S)), 1
networks--a 1
co-evolved 1
undetectably 1
33rd 1
Soest. 1
Cardiff, 1
hMTMR5/Sbf1 1
hMTMR2, 1
(VPS) 1
VPS34, 1
(PI3P). 1
(spikes) 1
VPS34 1
PI4P 1
PI3P. 1
AAV-Cre 1
atrogenes 1
mutation.Muscle 1
(0.023 1
0.152 1
0.154 1
N-m/kg 1
twitch:tetanus 1
right-shifted 1
torque-frequency 1
(c.1467+1G) 1
N155K, 1
T-tubules 1
"Necklace" 1
("necklace 1
fibers"). 1
4-20% 1
(necklace) 1
necklaces 1
(p.E404K 1
p.R241Q), 1
novel; 1
c.205_206delinsAACT 1
Necklace 1
DNM2- 1
BIN1-related 1
[Unilateral 1
male]. 1
c.1420C>T, 1
p.Arg474X 1
(PtdIns(3)P) 1
(PtdIns(5)P), 1
phosphoinositide, 1
D278A. 1
XLMTM, 1
myonuclei 1
(G378R) 1
mutations-three 1
(R241C, 1
I225T, 1
P179S) 1
single-amino 1
(G294del)-were 1
39-year 1
orthovanadate, 1
phosphoserine. 1
ESTs, 1
Myopathy. 1
Neuro-Muscular 1
missenses 1
AIDS-related 1
grubii/neoformans 1
Th(2) 1
Ultra-deep 1
Co-receptor 1
T-lymphocytes, 1
X4 1
SimPlot 1
3.5.1 1
SplitsTree 1
2778±5 1
3162±8 1
(HXB2 1
numbering) 1
CRFs. 1
Italians, 1
integrase, 1
gp41 1
[Subtype 1
virus-1(HIV-1) 1
(MSM) 1
nested-PCR 1
Zhengzhou. 1
33.33% 1
(8/24) 1
41.67% 1
(10/24) 1
(6/24) 1
CRF07-BC, 1
Zhengzhou 1
system-derived 1
(n=82) 1
HAD. 1
LTRs. 1
Tat. 1
Routes 1
CRF07_BC, 1
drug-resistance-associated 1
zidovudine 1
(AZT), 1
lamivudine 1
(3TC), 1
(EFV) 1
(NVP) 1
(HAART), 1
daughter's 1
Russia. 1
oblast 1
Uzbekistan. 1
CRF02_AG, 1
02_AG. 1
Uzbekistan 1
SIV, 1
FIV 1
furthest. 1
(PNGS) 1
PNGS. 1
PNGS 1
gp41. 1
env. 1
HIV/AIDS. 1
BEAST 1
(97/118, 1
Myanmar, 1
1960's. 1
in-country 1
ten) 1
HIV-infections 1
(tMRCA). 1
tMRCA 1
114-134 1
Yunnan, 1
Dehong 1
epicenter 1
CRF07_BC 1
CRF08_BC, 1
(TDR) 1
Ottawa, 1
sub-populations. 1
TDR. 1
12.3%; 1
IDU. 1
D67N/K219Q 1
provincially. 1
1510 1
HIS 1
(FATM), 1
(FFM), 1
(TFATM), 1
(TFFM) 1
FFM, 1
TFFM, 1
migraineurs: 1
sumatriptan/naproxen 1
(T-ADP), 1
[LMW]-ADP), 1
T-ADP, 1
nonresponders) 1
(Confidence 1
LMW-ADP, 1
-0.002; 1
(12.52 1
(12.32 1
.017), 1
(12.65 1
(13.48 1
(2.29 1
.050. 1
(2.37 1
(2.76 1
1.9). 1
(m-BMI). 1
cardiocerebral, 1
Author(s)/Acta 1
[Metabolic 1
C677Tmutation 1
D-allele 1
angionten 1
headed 1
"chronification." 1
(high-molecular-weight 1
middle-molecular-weight 1
[MMW], 1
[LMW] 1
ADP) 1
Age- 1
[WHR] 1
BMI) 1
(T-ADP) 1
WHR, 1
(6.1 1
1.5) 1
MMW-ADP 1
1.2) 1
"migraine" 1
"adiponectin" 1
interventional. 1
oncogene-addiction 1
"EGFR 1
high-responder 1
ideas; 1
hypotheses; 1
addiction; 1
EGFR-addicted 1
trans-modulation 1
inactivation-induced 1
BIM, 1
EGFR(L858R)-driven 1
sentinels 1
interconnect 1
mitochondrion-dependent 1
C57BL/6-derived 1
(hc-Myc) 1
cross-bred 1
MYC-specific 1
proto-oncomiRs, 1
proto-oncomiRs 1
glean 1
anti-miRNA 1
Addictive 1
sword; 1
lynchpin 1
oncogenes: 1
Bishop 1
Varmus, 1
hopefully, 1
K-ras(G12D)--or 1
(ODEs) 1
(K-ras(G12D) 1
MYC), 1
Stat3/5 1
3/5), 1
p38] 1
(p53⁻/⁻, 1
Stat3-d358L, 1
myr-Akt1) 1
MLL-AF9-a 1
eradicates 1
Myb-dependent 1
Mad2-induced 1
Kras-driven 1
amnesia: 1
habit? 1
transgression. 1
"Achilles 1
heel") 1
(P=0.000) 1
Propofol/remifentanil 1
(3.5) 1
(4.6) 1
0.0024), 1
oxide/sevoflurane 1
(Gsdmd) 1
differentiations 1
(Gsdma3) 1
Gsdma3-related 1
Gsdma2, 1
Gsdma2. 1
Gsdma-related 1
(Alanine339Threonine). 1
GSDM 1
(GSDMA-D) 1
GSDMB 1
GSDMA, 1
GSDMA. 1
Defolliculated 1
(Dfl) 1
catagen 1
(Fgn), 1
defolliculated 1
(Gsdm3), 1
Gsdm3(Dfl) 1
Gsdm3(Fgn) 1
T278P. 1
gasdermin. 1
TMD, 1
Transautocrine 1
(NRGs) 1
pro-NRGs), 1
membrane-anchoring 1
membrane-exposed 1
transautocrine 1
trans) 1
cis)). 1
europaea. 1
(AMO) 1
europaea 1
[(14)C]acetylene, 1
AMO. 1
(alpha-subunit, 1
AmoA), 1
(beta-subunit, 1
AmoB), 1
(gamma-subunit, 1
c(1)) 1
alpha(3)beta(3)gamma(3) 1
sub-unit 1
AMO, 1
AmoB 1
(9.4+/-0.6 1
(3.9+/-0.3 1
AMO). 1
para-magnetic 1
air-oxidized 1
heme-Fe. 1
Multicopper 1
(Cj1516) 1
(Cj1161) 1
CueO, 1
trinuclear 1
Inductively 1
Cj1516, 1
p-phenylenediamine 1
(p-PD) 1
p-PD, 1
ferroxidase, 1
cuprous 1
anthrachelin 1
(3,4-dihydroxybenzoate), 1
copper-rich 1
(CueO) 1
Cj1161 1
(CopA) 1
charges. 1
acid-chain 1
7-11 1
presequences, 1
presequence) 1
(gusA) 1
anti-THI1 1
Prss21. 1
PRSS21. 1
A3.3-B; 1
PRSS21 1
pre-pro-protein 1
Testisin. 1
pro-region, 1
disulfide-bonded 1
85-95-kDa 1
surface-labeled 1
TAP-dependent 1
I-restricted 1
(50,000 1
peptides/cell), 1
sequence-targeted 1
TAP-transported 1
CD5 1
CD6. 1
FLO11, 1
flocculin. 1
glucoamylase. 1
FLO11. 1
4,104-bp 1
serine/threonine-rich 1
(glycosyl-phosphatidyl-inositol) 1
anchor-containing 1
threonine- 1
flocculation. 1
Flocculation 1
STA1 1
flocculating 1
flocculation, 1
FLO 1
diastaticus. 1
flocculins 1
FLO11-dependent 1
flocculation 1
al/alpha2. 1
(BPV-1) 1
(E1-259; 1
166) 1
E1-259-lacZ 1
(TAX1) 1
(TAG-1) 1
TAX1, 1
axonin-1, 1
(IgC2) 1
chick). 1
tripeptide, 1
1q32. 1
CNS: 1
FoxO6. 1
region-, 1
age-specifically 1
realtime-PCR. 1
dramatic, 1
HFD. 1
sex-dependent. 1
seat 1
extension? 1
insulin/IGF-1, 1
Ras-cAMP-PKA, 1
Sch9 1
ageing-mediated 1
lipofuscin. 1
nutriceuticals 1
piperine 1
resveratrol) 1
(commercially 1
Longevinex). 1
micronized 1
phytate), 1
Longevinex-treated 1
Corroborating 1
Sirt3 1
FoxO4, 1
O4 1
FOXOs. 1
NLK-mediated 1
co-occurs 1
NLK-dependent 1
Insulin/IGF-1 1
AKT/IKK/NF-kappaB 1
GH/insulin/IGF-1 1
dwarf 1
IGF-1/PI-3K/AKT 1
Caenorhabditiselegans, 1
PI-3K/AKT 1
cornucopia 1
dangers, 1
Clever 1
FoxO-dependent 1
cascades: 1
daf-16 1
inflamm-aging. 1
B/c-Akt-mediated 1
hSir2(SIRT1)-mediated 1
stress-regulating 1
hSir2(SIRT1) 1
Epstein 1
(BBE) 1
hyporeflexia, 1
(disturbance 1
areflexia) 1
encephalitis--Bickerstaff's 1
Philip 1
Cloake 1
astutely 1
anti-NMDA 1
plasmapheresis) 1
fisher-bickerstaff 1
guillain-barré 1
drowsy, 1
Neuro-ophthalmology 1
jejuni) 1
antibody-stimulating 1
areflexia), 1
hemisensory 1
N13), 1
R2) 1
potentials), 1
H-reflexes), 1
(prolongation 1
latency) 1
26: 1
000-000, 1
AO, 1
(32.4%) 1
horizontal-vertical 1
Binocular 1
45.5%) 1
54.5%). 1
AO. 1
ballism 1
12/mm3. 1
theta-waves. 1
student. 1
oculocephalic 1
slowing. 1
a(IgG, 1
IgM) 1
1(IgM) 1
oblongata 1
pyramida 1
Electroencephalography 1
tegmentum 1
pseudbulbar 1
[Bickerstaff's 1
encephalitis]. 1
ophtalmoplegia, 1
anti-G1Qb 1
pregulated 1
icroRNA-124a 1
iR-223 1
icroRNA-146a 1
ltered 1
iR-124a 1
iR-346 1
gene-targets 1
own-regulation 1
microRNA-34a 1
miR-34b/b 1
miR-34c 1
/c 1
dentification 1
iR-146a 1
verexpression 1
(RASFs 1
micro(mi)RNAs 1
T-Lymphocyte 1
icroRNA-323-3p 1
metopic, 1
lambdoid, 1
p.Gly380Arg 1
brachycephaly) 1
archeological 1
skulls) 1
pathoanatomical 1
skulls). 1
beaten 1
sellae 1
diastasis, 1
sigmoid-jugular 1
(20.3 1
(14.3 1
scaphocephaly: 1
(ipsilateral 1
oxycephaly 1
brachycephaly. 1
(1.8-2.1 1
(Saethre-Chotzen 1
skulls. 1
plagiocephalic 1
intraorbital 1
FGFR3), 1
microelectronic 1
pad. 1
microchip-DHPLC 1
&quot;hot 1
spot&quot; 1
[On 1
craniosynostoses]. 1
Craniosynostoses 1
ossifications 1
re-evaluated. 1
(1025G-->A 1
18/19 1
sulfate-binding 1
S-oligodeoxynucleotide 1
sulfate-treated 1
X-100-insoluble 1
moesin-precipitated 1
(CD44 1
thymuses. 1
Masaoka. 1
67%), 1
(II, 1
thymomas. 1
v9 1
(mAb 1
44-1V). 1
44-1V 1
44-1V. 1
44-1V, 1
44v8-10 1
CD44v8-10-positive 1
(SLX) 1
CD44-1V 1
(40.7%) 1
CD44-1V, 1
(sCD44) 1
MCF-7/ADR, 1
4134 1
(sc.) 1
(mfp.) 1
-v6, 1
-v6 1
CD44s. 1
MCF-7/ADR. 1
4134, 1
4296, 1
sCD44 1
MCF-7/ADR: 1
xenotransplanted 1
v7/8, 1
v10 1
v4/5 1
bronchiolar 1
CD44v4/5 1
squamoid 1
(v1-v10) 1
(PMM), 1
(MMM), 1
(BMN) 1
PMM, 1
MMM 1
v7/8 1
v5 1
Metastasis-promoting 1
homomultimeric 1
hyaluronate. 1
designates 1
Improvement. 1
1.96; 1
2.67-7.67) 1
0.33-2.67) 1
change). 1
Improvement, 1
doctors: 1
C--Special 1
"Special 1
aged" 1
Morbus 1
obstipation. 1
IJCPT 1
Exercise, 1
falling: 1
biphosphonates 1
(estrogen, 1
imipramine) 1
[Summary 1
revision) 1
Practitioners]. 1
Practitioners, 1
taking. 1
flavoxate 1
drill, 1
voids 1
childbirth, 1
lb 1
worrying 1
attended. 1
training: 1
bladders. 1
ml), 1
incontinence--therapeutic 1
concept]. 1
transference 1
unstable), 1
surroundings, 1
easier, 1
re-education 1
Website. 1
BioProject, 1
BioSample, 1
Snat: 1
GWAS, 1
(Snat) 1
UniProt, 1
AnimalQTLdb, 1
(GO), 1
(OMIA). 1
CGI-based 1
50K 1
Snat. 1
genes/variants 1
post-GWAS 1
Up-to-date 1
owners, 1
breeders, 1
veterinarians, 1
(CIDD), 1
(IDID) 1
(LIDA). 1
nline 1
ProSplign, 1
IBIS, 1
Peptidome, 1
OMSSA, 1
Spidey, 1
(CDART) 1
2.5-6.6) 1
uveitis? 1
(EBM) 1
(DMARD)/ 1
factor-alpha-blockers) 1
iridocyclitis 1
iridocyclitis. 1
(VA), 1
Uveitic 1
fellow 1
(JIA)-associated 1
(CE), 1
(U-CE 1
interval), 1
3.57; 1
10.00). 1
4.00) 1
3.23; 1
11.11). 1
sixty-seven 1
46/50 1
(1.8-15.8), 1
7.25 1
(1.25-15.7). 1
(0-72) 1
(1-12). 1
(3-27). 1
417/661 1
(1-14). 1
Kapβ2-mediated 1
RAM, 1
Kapβ2 1
(karyopherin 1
β2) 1
Methylation. 1
2.0-fold). 1
Myc-responsive 1
p-TEFb, 1
homoeostasis. 1
cap) 1
hMTr1, 1
Cap1 1
(splicing, 1
transport), 1
cap0, 1
cap2, 1
capping: 1
7-methyl-GMP. 1
G(5')ppp(5')N. 1
alphavirus-specific 1
[alpha-32P]GTP, 1
alphavirus-infected 1
nsP1. 1
enzyme-guanylate 1
S-Adenosylmethionine 1
(GTP, 1
dGTP) 1
pyrophosphate. 1
S-adenosyl[methyl-3H]methionine 1
7-Methyl-GMP 1
GMP. 1
P-15, 1
P-15 1
m7GTP 1
m7G(5")pppNm. 1
umnethylated 1
Dounce 1
homogenization; 1
165-fold 1
DEAE-cellulose, 1
DNA-agarose, 1
CM-Sephadex. 1
G-200. 1
triphosphate. 1
polyribonucleotides 1
G(5')pppG. 1
S20, 1
3.8, 1
56,000 1
G-200 1
psoriasin-expressing 1
adenoviruses, 1
sRAGE, 1
(RAGE), 1
shRNA, 1
sRAGE 1
psoriasin-dependent 1
RAGE. 1
Psoriasin: 1
barrier? 1
Berlin. 1
nasolacrimal 1
(~170 1
film. 1
(PSORS4) 1
(Koebner 1
(T(H)1) 1
T(H)17 1
S100A7A15-RAGE 1
(psoriasin)/S100A15 1
subfamily: 1
lately 1
1q21) 1
discriminate. 1
cow-derived 1
cow-specific 1
frequent-dose 1
tri-iodothyronine, 1
thyronine-binding 1
luteotrophic 1
H(+)-activity, 1
H(+)-activity 1
Queens 1
(lansoprazole) 1
0.45). 1
Nonthyroidal 1
(OPCAB) 1
FT4), 1
OPCAB. 1
(7:30 1
AM), 1
sternotomy, 1
Baseline, 1
CONCLUSIONS. 1
On-pump 1
Hormonal, 1
Friedman 1
(NTIS) 1
(T-uptake) 1
67.4+/-9.0 1
(87.5%). 1
NTIS. 1
TSH). 1
nmol/1 1
pmol/1. 1
extracorporal 1
PANC-1. 1
MMP-9; 1
lamelliopodia 1
Slug-transfected 1
cholangiocarcinoma: 1
neoplasms; 1
antifascin 1
fascin. 1
(>70% 1
cholangiocarcinomas. 1
.0082). 1
.0019), 1
.0205). 1
.0289). 1
.0085), 1
.0477). 1
Calpha: 1
C1B 1
S39D, 1
fascin/actin 1
fascin-PKCalpha 1
formins; 1
S39, 1
I-Matrigel 1
filopod-like 1
deubiquitination, 1
drought, 1
[TAFs])-dependent 1
RPS5, 1
RPL2B, 1
RPS11B, 1
Δeaf1 1
TAF-dependent 1
TBP) 1
Spn1-Spn4 1
spt20Δ 1
mid2(+). 1
Spn2 1
Mid2. 1
disconnects 1
(TBP)-interacting 1
Spt3, 1
(LC-MS/MS)-based 1
desired, 1
analysis-based 1
ProPCA, 1
peptide-protein 1
roll-up, 1
(APEX) 1
peptides' 1
abundances. 1
(SC); 1
Summed 1
(SMT), 1
cumulates 1
SMT 1
APEX-SMT) 1
~55-85% 1
APEX, 1
APEX. 1
ataxin-1[Q80] 1
ataxin-2[Q58] 1
Atx2-58Q, 1
Atx2-22Q, 1
(InsP(3)R1), 1
InsP(3)R1 1
PC-specific 1
3,5-dihydroxyphenylglycine 1
(DHPG) 1
DHPG-induced 1
ryanodine, 1
(RyanR). 1
Glutamate-induced 1
stabilizer. 1
SCA1-58Q 1
beam-walk 1
stereology). 1
ataxin-2. 1
(S/T)P 1
proline-directed 1
(Cdk5). 1
vitro(32)P 1
Phos-tag 1
(NF, 1
1-507), 1
(MF, 1
508-905), 1
(CF, 1
906-1313) 1
Cdk5-mediated 1
moderately. 1
ataxin-2-41Q 1
polyQ-expanded 1
Virus-associated 1
Homology-independent 1
viroid-derived 1
repeated-sequence 1
self-cleave 1
quasi-rodlike 1
wideness 1
ribozymes: 1
sunblotch, 1
chrysanthemum 1
chlorotic 1
mottle 1
(ASBVd, 1
ASBVd, 1
viroids--a 1
self-catalytic 1
http://www.callisto.si. 1
usherb.ca/jpperra 1
&apos;brotherhood&apos; 1
arteriolitis 1
cor 1
pulmonale. 1
glass-opacity 1
halo. 1
socio-economically 1
urbanization. 1
Recreational 1
co-habit 1
uropathy 1
Schistosomal 1
Cystoscopy, 1
invaluable. 1
cercariae 1
oxamniquine 1
pathology), 1
holidays 1
Mali. 1
years-old 1
Dogon 1
(south 1
Mali). 1
mansoni, 1
japonicum 1
haematobium. 1
feverish 1
visitors 1
companions 1
infection's 1
wheals 1
swam 1
swimmers' 1
Ova 1
formol-ether 1
fever). 1
3-man 1
dam 1
Transvaal 1
Lowveld 1
Two, 1
30-36 1
water-sportsman 1
water-contact 1
emphasised. 1
water-skiing 1
Volta 1
river. 1
oxamniquine, 1
Capture-EIA 1
(MBAC-EIA) 1
schistosomal 1
swimmer&apos;s 1
androgens]. 1
Aging-associated 1
sarcopenia: 1
strength) 1
growingly 1
"sarcopenia" 1
race), 1
(positively 1
negatively) 1
urgent, 1
start; 1
Multicentric, 1
(13.9%) 1
1,080 1
562) 1
518) 1
(CDSR), 1
(ATHMD) 1
Ginseng, 1
cool, 1
remedies, 1
clover), 1
E; 1
cream; 1
licorice 1
(EPT) 1
ET/EPT 1
progestogens 1
formulations) 1
progestogens, 1
enlist 1
harms, 1
adopted, 1
flash/flush, 1
climacteric, 1
(TCM 1
Ayurveda, 1
naturopathy, 1
chiropractic, 1
osteopathy, 1
homeopathy, 1
aromatherapy, 1
touch. 1
endometrium) 1
flashes; 1
(0.3). 1
(0.6); 1
Gamolenic 1
(GAA)). 1
rAAV2/9-DES-hGAA 1
(AAV9-DES) 1
bimonthly 1
(ERT)). 1
plethysmography 1
mass/gram 1
EDMc) 1
(eupnea). 1
(GAA)) 1
(NMJs) 1
α-Glucosidase 1
c.546G>T 1
bortezomib-responsive 1
M519V 1
GAAs, 1
M519V, 1
S529V, 1
(1.3-5.9-fold). 1
pompe 1
treated? 1
24-75) 1
(PFTs), 1
PFTs, 1
2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one 1
LSDs, 1
translocated. 1
deoxynojirimycin 1
chosen: 1
Y455F/Y455F, 1
525del/R600C 1
D645E/R854X. 1
N-(n-butyl)deoxynojirimycin 1
beta-hexosaminidase. 1
Y455F 1
P545L, 1
14.0- 1
7.9-fold, 1
10mumol/L 1
Cross-reactive 1
(CRIM)-negative 1
mg/kg/2 1
Glc(4). 1
1/21 1
4/21 1
ventilated. 1
serotiters 1
immune-capture 1
(Delta6/Delta6), 1
(Bijvoet, 1
Kamp, 1
Kroos, 1
Visser, 1
Bakker, 1
Verbeet, 1
Oostra, 1
Reuser, 1
Ploeg, 1
53-62), 1
GAA--transgenic 1
(Gaa-/-)--completely 1
microfluorometric 1
alpha-1,4-glucosidase. 1
Peter's 1
Salafsky 1
Nadler's 1
Pompe's 1
enzymes]. 1
manose-6-phosphate 1
quail. 1
resorufin-based 1
mistrafficking 1
resorufin 1
alpha-d-glucopyranoside. 1
4-methylumbelliferyl-alpha-D-glucopyranoside. 1
pK(a) 1
5'-shortened 1
reductase-deficient 1
Geneticin, 1
Iscove's 1
110-kDa 1
micrograms.ml-1 1
(activity, 1
mumol.hr-1.ml-1). 1
4-methylumbelliferyl-alpha-D-glucoside. 1
6-phosphate. 1
HURP&apos;s 1
(ChRwt) 1
mon-exponential 1
ChETA 1
(Gunaydin 1
13:387-392, 1
ChRET/TC 1
(Berndt 1
108:7595-7600, 1
ChRET/TC. 1
fast-spiking 1
(Wang 1
Buzsaki, 1
16:6402-6413, 1
(Golomb 1
Neurophysiol. 1
96:1912-1926, 1
rostate 1
PCA3 1
debate: 1
partners' 1
television 1
(SES), 1
self-completion 1
"expert" 1
negotiate 1
plainly 1
men.Although 1
races; 1
Certainly, 1
ora 1
urologist,where 1
setting.The 1
[31] 1
2950 1
biopsy.They 1
(n=927) 1
(OR=2.53, 1
1.49-4.31), 1
(OR=2.41, 1
1.22-4.77) 1
(OR=5.01, 1
2.53-9.90) 1
(OR=0.32, 1
0.12-0.88) 1
(OR=0.35, 1
0.22-0.54) 1
seeking, 1
(OR=1.76, 1
1.02-3.03) 1
(OR=236.3, 1
70.5-791.4) 1
(OR=2.30, 1
1.33-4.00), 1
(OR=2.91, 1
1.45-5.82), 1
attention/seeking 1
(OR=1.23, 1
1.07-1.40) 1
(OR=0.37, 1
0.22-0.64). 1
(OR=0.38, 1
0.20-0.71) 1
(OR=0.40, 1
0.19-0.85) 1
physician-patient 1
Michigan 1
saturation--that 1
anecdotes 1
analogies, 1
distrust 1
"bad 1
luck," 1
valuing 1
sake. 1
Eliciting 1
tumor-marker 1
importance: 1
know? 1
untold. 1
"neurodegeneration" 1
Hakim, 1
(TOB1) 1
NCI-H1975, 1
MDA-MB-453, 1
CDC25B 1
FOXM1, 1
DeltaN-FOXM1, 1
SKBR3) 1
MDA-MB-453), 1
presurgically 1
(KRTAPs) 1
(EDCRP), 1
EDCRPs 1
CCDPCQ(K/Q)(S/P)V, 1
subperiderm 1
barbule 1
subperiderm. 1
tris(2-carboxyethyl) 1
phosphine 1
resistivity, 1
thiol-acrylate 1
thiol-acrylamide 1
beta-proteins. 1
(KAbetaPs, 1
beta-keratins). 1
alpha-cells 1
oberhautchen, 1
pre-corneous 1
beta-layer. 1
(0.2-1.4 1
KAbetaPs. 1
hydrophobicy 1
gly-rich 1
beta-layer 1
cys-rich 1
ossible 1
[2-(acryloyloxy)ethyl]trimethylammonium 1
dyeability 1
non-leaching 1
Mats 1
nanofibre 1
electrospinning 1
wt.%, 1
wastewater 1
adsorb 1
heavy-metals). 1
realigned 1
keratinization 1
IF. 1
(K5 1
K14), 1
K14-Cys367 1
micro-beam: 1
Synchrotron 1
submicro 1
beams, 1
MGy. 1
proteic 1
micro-beam. 1
micro-beams 1
microm(2) 1
cross-section), 1
SAXS/WAXS 1
beamline 1
ID13 1
(ESRF) 1
materials: 1
Hair. 1
solubilize. 1
dissolving 1
alkaline, 1
jelly-like 1
hydrosyringomyelia: 1
hydrosyringomyelia. 1
[Syndromic 1
autism]. 1
conditions? 1
autism/autistic 1
autism/ 1
sarcolipin-bound 1
Re-sequestration 1
ATP2A1) 1
A.G. 1
Opin. 1
Struct. 1
547-554 1
Bal, 1
Maurya, 1
Sopariwala, 1
Sahoo, 1
Gupta, 1
Shaikh, 1
Pant, 1
Rowland, 1
Bombardier, 1
Goonasekera, 1
Tupling, 1
Molkentin, 1
Periasamy, 1
1575-1579), 1
homo-bifunctional 1
(1,6-bismaleimidohexane) 1
PLB: 1
PLB; 1
°C), 1
Sln(-/-) 1
Ucp1 1
NST. 1
Serca-mediated 1
(Ryr1)-mediated 1
Serca-activated 1
Sln-mediated 1
SERCA) 1
heart) 1
(TOF), 1
(CASQ, 1
TOF, 1
VSD. 1
ddY 1
Ca(2+)-ATPases. 1
termini: 1
Met-Leu-Leu 1
Arg-Ser-Tyr-Gln-Tyr 1
(NF-SLN) 1
kidney-293 1
progressively. 1
RSYQY, 1
78/BiP 1
(SERCAs). 1
(NF-SLN), 1
SERCAs 1
-0.22 1
-0.37 1
DeltaK(Ca) 1
PLN.SERCA 1
pentamers. 1
26); 1
(R548X 1
L554P) 1
(322delG 1
Q13X) 1
non-FA-C 1
studied). 1
(3% 1
9%] 1
79%]; 1
preleukemia 1
Ala391Glu 1
Pro250Leu 1
Alloimmunisation 1
isoimmunised 1
cordocentesis. 1
micromanipulation. 1
haemoglobinopathies, 1
Duchenné's 1
others.Further 1
cells.A 1
disorder.A 1
rhesus-D 1
allo-immunized. 1
(biological 1
medication) 1
"Adverse 1
(AE, 1
n=23) 1
"No 1
(NAE, 1
n=76). 1
237€ 1
115-644) 1
331€ 1
236-644) 1
208€ 1
115-366) 1
allo-immunization 1
+36.2% 1
+105.3%. 1
cost-reduction 1
[Genome 1
limitations]. 1
(exome 1
("next-generation 1
sequencers", 1
NGS), 1
exome. 1
birth), 1
"strong" 1
oncogenetics, 1
(deletions, 1
(hemopathy 1
"druggable" 1
Bcr/Abl 1
rearrangement; 1
verumafemib 1
identfication 1
MagNA 1
RHD-positive 1
96.1 1
RhD-specific 1
positives; 1
(29/34) 1
(32/39) 1
(11/23) 1
myocyte. 1
cardiac-specific, 1
(hYAP) 1
2b). 1
(AAV1)/SERCA2a 1
peptide/BNP 1
(>1,200 1
time-to-recurrent 1
[all-cause 1
failure]) 1
[CUPID-2b]; 1
NCT01643330). 1
cardiomyoblasts. 1
supernate 1
survivin-transduced 1
survivin-conditioned 1
null-conditioned 1
Subsets 1
control- 1
empty-treated 1
survivin-treated 1
PP1β, 1
heart-failure-inducible 1
PP1β-inhibition 1
viral-9 1
emerald-green 1
(EmGFP) 1
(AAV9-BNP-EmGFP-PP1βshRNA 1
AAV9-BNP-EmGFP-NCshRNA) 1
(2×10(11) 1
GC/mouse) 1
(MLPKO), 1
EmGFP 1
PP1βshRNA 1
AAV9-BNP-EmGFP-PP1βshRNA 1
AAV9-BNP-EmGFP-NCshRNA 1
Resorting 1
stand? 1
miRNome 1
miRNome. 1
AAV9.SERCA2a, 1
subcutis 1
submucosa. 1
suffocation. 1
kinin-kallikrein 1
risk-minimization 1
Ecallantide, 1
(MSCS) 1
(TOS). 1
MSCS 1
TOSs 1
46.5; 1
20.0 1
58.9; 1
(MSCS 1
.028; 1
TOS, 1
.039). 1
(C1-INH), 1
fibrinolytic, 1
epsilon-aminocaproic 1
(HAE), 1
episodic, 1
cramping, 1
angioedema: 1
VIII: 1
virus-inactivated, 1
(C1-INH) 1
nanofiltered 1
Rhucin, 1
Icatibant, 1
(For 1
Angioedema 1
(BVT). 1
(R1047L) 1
parasystole. 1
Electrocardiograms 1
beats, 1
trigeminy 1
3n 1
3n-2 1
(p.Phe90Leu) 1
Phe90 1
Ca2+-sensing 1
(A1924T) 1
hH1 1
Ca2+/CaM, 1
(arrhythmia 1
free) 1
Non-viral 1
Oct4-EGFP, 1
NMRI 1
transposons&apos; 1
beauty, 1
11,169 1
coexist, 1
90's 1
aspirin) 1
(OAT) 1
preventable, 1
[Pharmacokinetics 1
rivaroxaban]. 1
later). 1
pk/pd 1
FXa. 1
aprox. 1
(Yale-Brown 1
Gambling) 1
Gambling, 1
34.0% 1
Axis. 1
Hypothalamic-pituitary-adrenal 1
(IHT), 1
misses 1
21-55), 1
18.6-34.2). 1
nalmefene: 1
25.2 1
70.3 1
microg/dl 1
IHT, 1
(crib-biting) 1
bites/min. 1
diprenorphine. 1
naloxone/kg, 1
naltrexone/kg, 1
nalmefene/kg, 1
diprenorphine/kg. 1
nalmefene/hr. 1
triexponential 1
Mowat-Wilson" 1
2q22). 1
Duhamel 1
0.3-7) 1
(rectosigmoid 1
HD). 1
stoma 1
(32.5 1
627 1
DiGeorge-like 1
(Petric 1
Biomed. 1
Inform. 1
42(2): 1
219-227, 1
Proving 1
Interactogeneous: 1
guilt-by-association 1
adjacencies 1
links) 1
(shortest 1
paths) 1
knowledge; 1
Interactogeneous. 1
Interactogeneous 1
intensive, 1
if-then-else 1
BioHEL's 1
pointwise 1
mouse-based 1
Ontology), 1
human-based 1
Ontology). 1
Vax1 1
Gdf6 1
Marcks 1
BSD 1
licence 1
http://code.google.com/p/phenomeblast/wiki/CAMP. 1
PhenomeNET 1
PhenomeBrowser 1
http://phenomebrowser.net. 1
boosting. 1
GP-MIDAS-VXEF 1
truest 1
resample 1
imputation: 1
non-ensemble 1
non-imputation 1
true/false 1
10-20%, 1
http://home.gwu.edu/~ylai/research/Missing. 1
ENDEAVOU 1
prioritizer 1
co-expression. 1
quantity, 1
(http://www.esat.kuleuven.be/endeavourweb; 1
Endeavour. 1
GPSy: 1
processes--application 1
GPSy's 1
server-based 1
http://gpsy.genouest.org. 1
networ 1
diseases-schizophrenia 1
category-specific 1
(core 1
http://bioinfo.mc.vanderbilt.edu/SZGR/. 1
bio-ontologies 1
free-text 1
repository. 1
multi-source 1
(http://www.genemania.org) 1
GEO, 1
BioGRID, 1
I2D, 1
analyze. 1
benchmarks. 1
(UBB, 1
GPR37 1
approaches--the 1
caveats. 1
(LDA) 1
LDA 1
(http://main.g2.bx.psu.edu/). 1
(APLN, 1
ZC4H2, 1
MAGED4, 1
MAGED4B, 1
RAP2C, 1
FAM156A, 1
FAM156B, 1
TBL1X, 1
UXT) 1
highly-ranked 1
motif-orientated 1
Génie: 1
http://cbdm.mdc-berlin.de/tools/genie/. 1
PINTA: 1
http://www.esat.kuleuven.be/pinta/; 1
Affymetrix) 1
browsed 1
http://www.esat.kuleuven.be/pinta/ 1
knowledge--such 1
individuals.To 1
Arnoldi 1
(Simple 1
Ranking). 1
Kernel 1
83.7%. 1
(review). 1
late‑onset 1
amyloid‑β 1
(Aβ)‑binding 1
(p75NTR) 1
calcium‑sensing 1
(VEGF)‑A 1
(Aβs), 1
Aβ‑ 1
NO‑producing 1
self‑sustaining 1
self‑reinforcing 1
pre‑MCI 1
ciliopathies: 1
(nonmotile) 1
Ift88, 1
Kif3a, 1
Bbs 1
disease--in 1
Rab8a, 1
cholangiocytes), 1
fibrocystin, 1
AC6, 1
osmo-, 1
chemo-sensory 1
ciliary-associated 1
cholangiociliopathies) 1
fibrocystin. 1
cholangiociliopathies, 1
Amniotes 1
(MIP-1α) 1
prostanoid, 1
(PPAR)-α, 1
PPAR-r 1
pretreat 1
ONO-1301 1
CAY 1
10449, 1
monocyte/CD4 1
(IL)-17A, 1
differentiation/expansion 1
(mDCs) 1
(IL)-10 1
iloprost-treated 1
I:C)-stimulated 1
I-prostanoid 1
E-prostanoid 1
adenyl 1
phospho-activating 1
(ATF)2 1
TNFA 1
(H3K4)-specific 1
(WD 1
Iloprost-treated 1
IP/EP2/EP4 1
receptors-cAMP 1
receptor-Ca(2+) 1
MAPK-p38-ATF2 1
NC). 1
2C8 1
3-sequence 1
combination/agent 1
0.972 1
(0.824-1.145) 1
1.030 1
(0.900, 1
1.1-9), 1
0.881 1
(0.804-0.966) 1
0.910 1
(0.876-0.946), 1
0.8-1.25. 1
NC) 1
half-life; 1
0.5-16 1
diolamine, 1
5244 1
20,4086 1
pg·hr-·mL- 1
1383 1
33588 1
CL/F 1
2·2-, 1
4·9- 1
7·6-fold, 1
nausea). 1
calories. 1
500-calorie 1
(WB500), 1
(WB250), 1
(HF250) 1
(Ensure®)] 1
AUC0-inf) 1
prostacyclin-related 1
reports). 1
Scleroderma 1
dual-center, 1
tolerated) 1
1,176 1
2,107 1
7,187 1
12,992 1
hr*pg/mL) 1
0.015 1
NCT00848939. 1
(prostanoids) 1
antithrombotic, 1
oral. 1
packs, 1
trerpostinil 1
Angiology 1
trerpostinil, 1
l/min/m2 1
16.26 1
4.48 1
WU. 1
(31.8%). 1
Ras-proximate 1
blood-derived, 1
CD49 1
CD29 1
Cell-matrix 1
treprostinil/cAMP-induced 1
A-independent 1
Rap 1
c-Raf 1
cAMP-Rap 1
CTD/overlap 1
(initiated 1
ng/kg/min, 1
upward) 1
ng/kg/min. 1
Six-minute 1
(6MW) 1
dyspnea-fatigue 1
m). 1
ng/kg/min 1
ng/kg/min). 1
treprostinil-treated 1
0.055); 1
systemic-to-pulmonary 1
(PPH) 1
(TRE), 1
NFkappaB.DNA 1
NFkappaB, 1
FP, 1
EP3 1
EP2, 1
EP3, 1
IP-receptor 1
polyethylenimine 1
(PEI) 1
(IP1) 1
2-4-fold 1
FLUO-BSA-TRP 1
(PEI-g-ILO) 1
(F(ILO) 1
(ILO:PEI) 1
(N/P 1
46-fold 1
14-fold 1
PEI. 1
aplasia/hypoplasia. 1
(length) 1
centiles, 1
2SD 1
syndrome--insights 1
MGS. 1
cheerful 1
naso-labial 1
breasts, 1
ears?⁻?. 1
Rothschild 1
[1959: 1
Helv 1
Paediatr 1
14:213-216] 1
[1975: 1
Miscellany, 1
39-50], 1
slender 1
[Boles 1
3:207-214]. 1
labyrinthine 1
Neuroradiographic 1
maloclussion 1
ears�{�. 1
marker-assisted 1
up]. 1
CCL18/PARC, 1
[French 1
(ceredase) 1
(cerezyme) 1
obviated 1
U/K 1
severely-ill 1
normalised: 1
respond, 1
Seroconversion 1
effective; 1
$US3.70 1
(1994 1
dollars); 1
70kg 1
$US404,040 1
$US147,000 1
$US75,000 1
$US49,000 1
areas.(ABSTRACT 1
"simple" 1
Gaucher-like 1
1( 1
MTX1) 1
convergently 1
MTX1, 1
628T-->C, 1
post-fixed 1
non-lamellar 1
immature-lamellar 1
Assay-by-Design 1
G2019S. 1
beta-glucosidase, 1
P289L 1
D409V) 1
5-30% 1
F216Y 1
S364T 1
V394L, 1
T323I, 1
V394L 1
glycon 1
(V394L, 1
R463C) 1
(L444P 1
T323I), 1
Substitutions 1
Asp-443 1
Asp-445 1
beta-glucosidase. 1
E.C.3.2.1.45). 1
nonneuronopathic; 1
neuronopathic; 1
230800, 1
230900, 1
231000). 1
(PLGD) 1
PLGD. 1
E.C.3.2.1.45) 1
(LIMP-2), 1
SCARB2. 1
(AMRF), 1
LIMP2/glucocerebrosidase 1
AMRF, 1
sparsely-tethered 1
GCase. 1
membrane-water 1
protiated 1
(AMRF) 1
AMRF 1
AMRF. 1
centralized, 1
teenagers: 1
visit) 1
(QCSI), 1
(ml/kg 1
1.1-12.2) 1
imiglucerase/miglustat 1
miglustat. 1
enzyme-replacement 1
t.i.d.) 1
786 1
ratio=6.98, 1
2.54-19.21; 1
P=0.00002) 1
(76/1130=6.7%) 1
(4/391=1.0%) 1
(8.4%) 1
c.1263del+RecTL 1
N370S/RecΔ55 1
mannose-terminated 1
Chimerism 1
(branching-enzyme 1
amylopectin, 1
donor-specific 1
anti-HLA 1
amylopectin 1
Polymerase-chain-reaction 1
allotransplantation 1
(CDDP)-based 1
(BCICs) 1
BCICs. 1
CD44+ 1
CD44- 1
17-DMAG 1
BCIC 1
17-(allylamino)-17-demethoxygeldanamycin 1
CDDP-based 1
17-AAG), 1
signalin 1
extraneurally. 1
tenderness, 1
radiographically. 1
extraneurally 1
p18(Ink4c), 1
(Ptc1) 1
(CDKN2C) 1
p18(INK4C) 1
(EGL) 1
survival/progression 1
nonglial 1
meningioma), 1
adenoma), 1
Entities, 1
ganglioglioma 1
Mn-enhanced 1
(Ptch1) 1
pretumoral 1
Ptch1-CKO 1
ESCCs. 1
(PTs) 1
(MLNs), 1
cancer-adjacent 1
PTs 1
2.157; 1
C-phycocyanin. 1
Spirulina, 1
colorants 1
nutraceutical, 1
pigments/colors. 1
flat-type 1
photobioreactor, 1
g/L/d 1
μmol/m(2)/s, 1
0.045 1
platenesis, 1
medicinal, 1
hepatoprotectant 1
(0.8, 1
LC50 1
C-PC. 1
HCl-denatured 1
MG-P 1
(bluish-green) 1
platenesis 1
cyanobacteria-- 1
Grev 1
C-phycocyanin, 1
alga), 1
(0.5-10 1
GMP-induced 1
Ser(157) 1
Mw 1
(P47), 1
phorbol-12,13-dibutyrate 1
microg/mL)-activated 1
GMP/VASP 1
Ser157 1
alga) 1
line-K562. 1
(K562). 1
14.11 1
20.93% 1
poly(ADP) 1
cosmetics. 1
Tedious 1
scaleable 1
adsorption, 1
B-PE-rich 1
B-PE, 1
DEAE-cellulose 1
5.5. 1
cellulose. 1
sulfate-poly-acrylamide 1
beta)(6)gamma 1
(UV-visible 1
accompanied. 1
(PAGE) 1
R-phycoerythrin, 1
499, 1
A565/A280, 1
3.2. 1
240,000 1
sulphate-PAGE 1
21,000, 1
(alphabeta)6gamma 1
PAGE. 1
Visible 1
TOTO-3 1
TO-PRO-3 1
milliwatts 1
Aglaothamnion 1
neglectum, 1
tetrapyrroles. 1
36-kDa 1
33-kDa 1
nitrogen-deficient 1
plastid-encoded 1
rhodophyta 1
cryptophyta. 1
blue-colored 1
phycobiliprotein; 1
phycocyanobilin 1
14000 1
17000, 1
21000, 1
phycoerythrobilin 1
(chromatic 1
adaptation). 1
Phycobilisomes 1
phycoerythrins, 1
bilins, 1
(Ong, 1
Glazer, 1
266, 1
9515-9527). 1
15-kilobase 1
protein-phosphotyrosine 1
violacea: 1
violacea 1
progenitor) 1
pluricellular 1
rhodophytan 1
rpeB. 1
cryptomonads. 1
rpe 1
cryptomonads 1
proteinaceous, 1
(PLKs) 1
(nonaggregated) 1
(PLK) 1
(PLK1, 1
PLK3) 1
(>95% 1
conversion). 1
gamma-syn 1
(PLK1 1
PLK-mediated 1
103-140) 1
alpha-syn, 1
(Ser(P)-129) 1
(cytoplasm, 1
membranes) 1
PLKs. 1
PLK-syn 1
brain-permeable 1
Potent, 1
brain-penetrant 1
Plk-2-inhibitor 1
kinome-wide 1
cornea--a 1
scleritis, 1
endophthalmitis. 1
Keratoconjunctivitis 1
keratic 1
precipitates. 1
hellem, 1
(M2, 1
M2A, 1
M5, 1
M7, 1
M7A, 1
M8 1
PTP1) 1
M7 1
PTP1 1
(M2A, 1
M7A 1
M8) 1
M5 1
microsporidia. 1
killer" 1
(Nematocida 1
parisii). 1
Sporanauta 1
(marine 1
roundworms) 1
Odontophora 1
rectangula. 1
intestines. 1
hypodermis, 1
rectangula 1
nematode-infecting 1
killers"; 1
anglerfish 1
Spraguea 1
24-78 1
15-60s, 1
Spores 1
anglerfish, 1
disinfect 1
utensils 1
Fungi: 1
Fungi. 1
(LPI) 1
Antonospora 1
locustae, 1
Enterocytozoon 1
bieneusi, 1
cuniculi, 1
bombycis, 1
Nematocida 1
parisii, 1
(0.985), 1
Microsporidia. 1
Microsporidial 1
KOG 1
(Eukaryotic 1
COG) 1
CONCLUSION/SIGNIFICANCE: 1
mexican 1
reign. 1
Immunocompromized 1
serum-negative 1
hygienic 1
deinfection. 1
reign 1
skinny 1
right-side 1
right-side, 1
Biopsied 1
Ser303Pro 1
AD-EDMD 1
AD-EDMD. 1
Amiodaron 1
dystrophy--a 1
character; 1
antihuman 1
nuclear-envelope 1
nerve-conduction 1
genes---NF-L 1
KIF1Bbeta---have 1
(AR-CMT2) 1
1q21.2-q21.3 1
(Zmax=4.14). 1
envelope) 1
nonmyelinated 1
axonopathies. 1
1A, 1
CMT2B1. 1
8-cM 1
1q11-q23 1
5,6), 1
Xq27-qter 1
red/green 1
RGCP 1
(lod 1
coagulant 1
6.39), 1
DXS115 1
4.94). 1
DXS15 1
(DX13) 1
(St14) 1
200:1 1
cen-DXS304-9cM-DXS15-3cM-DXS52-2 1
cM-(RGCP,EMD)-3cM-F8C-2cM-DXS115 1
120:1 1
F8C. 1
hyperchromaticity 1
[Proximal 1
course: 1
myodystrophy 1
electromyography. 1
rivaroxaban--an 1
inhibitor--compared 1
thrombin). 1
Rivaroxaban--the 1
inhibitor--is 1
oxazolidinone 1
pockets. 1
antithrombin) 1
prothrombinase 1
tissue-factor 1
XIa 1
Citrated 1
platelets-rich 1
H-Gly-Pro-Arg-Pro-OH-AcOH 1
polymerisation). 1
(Innovin; 1
1:1,000 1
1:1,500) 1
(nM) 1
(apixaban), 1
(argatroban). 1
BMS-262084 1
FXIa) 1
(FVIIa 1
FXa) 1
Heparins, 1
(UFH 1
LMWHs), 1
LMWHs 1
UFH 1
Direct, 1
antithrombin-independent 1
antithrombin-dependent 1
antithrombotics 1
acenocoumarol 1
unfilled 1
(UFH) 1
sought, 1
factor/factor 1
VIIa-dependent 1
(rTFPI), 1
(NAPc2), 1
site-blocked 1
(FVIIai) 1
IXa, 1
VIIIa 1
Va) 1
indraparinux, 1
antistatin 1
antithrombin-heparin 1
(ATH), 1
(TAP, 1
ANT 1
ATH) 1
(fondaparinux) 1
Bimodal 1
FIIa 1
idraparinux, 1
efficacy-safety 1
warfarin), 1
coagulation-dependent 1
citrated, 1
anticoagulated, 1
(IC2x); 1
(ETP), 1
(IC50). 1
0.089 1
apixaban; 1
0.070 1
ETP 1
Conventionally, 1
[DTIs] 1
dabigatran-including 1
CLN3-defective 1
(LAP/ACP2) 1
48-week-old 1
CLN3-deficient 1
H(+)-ATPase 1
(V-ATPase) 1
V(0) 1
BTN1 1
(btn1-Delta), 1
ceroid-lipofuscinosis 1
Batten/Spielmeyer-Vogt-Sjogren 1
#204200) 1
(CLN1-9). 1
anti-neuronal 1
(PANcreatic-DERived 1
disease-bearing 1
ATP-, 1
v-ATPase- 1
cationic-dependent. 1
461-677del, 1
JNCL, 1
[corrected], 1
JNCL. 1
COS-1-cells 1
transport/transmission. 1
cerevisiae: 1
PCR-targeted 1
(YHC3), 1
(P-1, 1
P0, 1
P8) 1
P30. 1
predifferentiation 1
antiapoptotic, 1
ln3 1
-glycosylated 1
non-hormone-binding 1
TRalpha2-/- 1
TRalpha2+/- 1
TRalpha1:TRalpha2 1
http://bioinformatics.biol.uoa.gr/HMMpTM 1
http://MetaTM.sbc.su.se 1
http://bioinf.cs.ucl.ac.uk/psipred/. 1
http://bioinf.cs.ucl.ac.uk/psipred/ 1
(http://www.psipred.net) 1
HMMs: 1
top-scoring 1
explicitly, 1
HMMs. 1
HMM's 1
misplaced. 1
http://bioinformatics.biol.uoa.gr/HMM-TM, 1
inadequate: 1
non-cytoplasmic 1
http://www.enzim.hu/hmmtop. 1
Sscrofa9 1
(LHGRs), 1
heterogeneities, 1
followings: 1
LHGRs; 1
LHGRs. 1
(50%-51% 1
54%-55%) 1
(BGC), 1
density) 1
carolinensis 1
nonavian 1
reptile. 1
Reptilia 1
∼275 1
Turtle 1
(birds 1
crocodilians) 1
thermostable, 1
archosaurs, 1
testudines 1
(turtles), 1
(lizards 1
snakes), 1
red-eared 1
slider 1
opossum), 1
(chicken 1
alligator), 1
(western 1
frog) 1
third-codon-position 1
re-determined 1
boundary; 1
(note 1
feature). 1
chimpanzee. 1
(>300 1
Mutational/neutralist 1
selectionist 1
fourfold-redundant 1
(GC4) 1
(GCi). 1
asserted 1
envisage 1
interiors. 1
unsafe. 1
(>>300 1
(isochores) 1
[glycine 1
merr]. 1
4,339 1
(LHGRs). 1
(Family 1
16-59% 1
GC-heterogeneity 1
taxon; 1
Crocodiles 1
Sarcopterygii 1
Actinopterygii, 1
Sauropsida 1
"GC 1
segmentation" 1
modification? 1
stereotypic. 1
p150(glued) 1
desensitization: 1
non-GPCR 1
stimulus-, 1
context-, 1
GRK2-HDAC6-mediated 1
cell-labeling 1
hues 1
tracing, 1
egulation 1
GF-β-induced 1
ranscription 1
(CSCs). 1
well-placed 1
macrophage-conditioned 1
(AMCM) 1
AMCM. 1
(GM6001), 1
AMCM 1
nflammatory 1
TbetaR 1
(TGF-alpha) 1
(16.5%) 1
TGF-alpha-stimulated 1
trans-differentiation, 1
(IGF-IR) 1
IGF-IR-overexpressing 1
cross-regulating 1
Smad4-deficient 1
BMP-7 1
Smad4-dependent, 1
TGF-beta-, 1
BMP-responsive 1
BMP. 1
ransforming 1
pp60c-src. 1
unequally 1
ferric-reductase 1
in-plate 1
pIRO1, 1
(IRO1) 1
IRO1. 1
CAI4, 1
Deltaura3, 1
IRO1, 1
YNB 1
CAI4 1
SC5314. 1
Iro1p 1
Nhp6a/b 1
(Cyc8) 1
iron-responsive, 1
N-half, 1
UAS. 1
N-half 1
Nhp6. 1
Nhp6/Ssn6 1
Aft1-mediated 1
nonsequence-specific 1
protein-facilitated 1
Nhp6-mediated 1
Ssn6. 1
glutaredoxin-3 1
glutaredoxin-4 1
CGFS 1
glutaredoxin 1
Gal-YAH1 1
Ferredoxin 1
Yah1p 1
Aft1p-targeted 1
Mössbauer, 1
EPR, 1
spectroscopies 1
nonmitochondrial 1
vacuolar. 1
Yah1p-deficent 1
Ftr1/Fet3-mediated 1
siderophore-mediated 1
transitorily 1
Cth2. 1
assimilation. 1
redirect 1
Ftr1/Fet3 1
(DCM)-related 1
screenings, 1
(putative) 1
DES, 1
SGCB 1
(homozygous), 1
1.4-3.0). 1
clues, 1
clues. 1
((8)TRSAIRR(14)) 1
Thr(8) 1
(ACTC), 1
(CAVI), 1
(LDB3), 1
(DES), 1
(SGCD), 1
(TNNTI3), 1
(TNNT2), 1
(TPMI), 1
(VCL). 1
Logarithm 1
2-point 1
PLN/SERCA2; 1
Chengdu 1
area]. 1
(PCR)-single 1
lectrophoresis, 1
(FDCM) 1
(MYH7 1
(TNNT2 1
metavinculin 1
(VCL 1
sporadic). 1
R141W 1
(I201T, 1
T412N, 1
A550V) 1
(T1019N, 1
R1193S, 1
E1426K, 1
R1634S) 1
(P<0.03), 1
(P<0.04). 1
VCL 1
Ca-ATPase-phospholamban 1
repeat's 1
(widely 1
low-hanging 1
earlobes 1
depression), 1
corpal 1
demeanor 1
wide-based 1
foot/ankle 1
errors; 1
plan/refine 1
interventions; 1
geneticist. 1
(rarely) 1
alteration; 1
MWS-causing 1
reproduce. 1
0.5-70 1
10,000. 1
(agenesis 1
callosum-ACC) 1
(dysgenesis 1
callosum-DCC) 1
DCC. 1
DCC, 1
/poised 1
CaMV 1
(35Senh) 1
BREVIPEDICELLUS 1
(H3K27me3 1
regulator's 1
non-sequence-specific 1
cobinding 1
Polycomb- 1
REST-associated 1
(REST) 1
REST-deficient 1
pro-neural 1
Signal-dependent 1
non-biased 1
Bach2, 1
BACH2. 1
'guardian' 1
decommissioned, 1
Rb1 1
three-point 1
retinoblastoma. 1
(Rb). 1
retinoblast 1
t(11;15)(q23;q15) 1
TP53+/+ 1
17p13.1. 1
11q23. 1
t(11;15)(q23;q15). 1
15q15 1
40: 1
myxofibrosarcoma 1
(p53(I166T)) 1
p53(I166T) 1
Pituitary-tumor 1
visual-field 1
adenomectomy. 1
38th 1
re-growth. 1
pituitary-tumor 1
9-17% 1
pathologic. 1
Macroadenomas 1
larger; 1
cabergoline. 1
Bromocriptine 1
(PRL 1
appendicectomy. 1
Eight-four 1
conceived, 1
husband. 1
aborted, 1
hachimijiogan, 1
[Sterility 1
amenorrhea]. 1
amenorrhoea-hyperprolactinemia-syndrome 1
infertility-patients. 1
microsurgically. 1
infertility-patients 1
inter-strand 1
G:T/U-specific 1
(MUG), 1
cis-diamminedichloroplatinum. 1
thymines 1
double-helix, 1
'widowed' 1
deoxyguanosines 1
N7 1
restack 1
T/U-specific 1
U/T 1
Thox2 1
Dehal 1
TAAR1. 1
(TAAR1). 1
TAAR1 1
Extracardiac 1
thyronamine-derived 1
neuromodulators. 1
sulfotransferases. 1
Sulfotransferases 1
(SULTs) 1
(iodothyronines). 1
Decarboxylation 1
(T0AM), 1
(T1AM), 1
3,5-diiodothyronamine 1
(T2AM), 1
3,5,3'-triiodothyronamine 1
(T3AM) 1
(n=3). 1
T1AM 1
T0AM 1
T3AM 1
T2AM. 1
(1A1, 1
1A2, 1
1A3, 1
1C2, 1
1E1, 1
2A1, 1
2B1a, 1
2B1b). 1
T0AM, 1
T3AM, 1
SULT1A1 1
T3AM. 1
particulary 1
anti-insulin-like 1
anti-heat 1
matuzumab: 1
(V(1)) 1
(V(2)), 1
(Michaelis-Menten 1
constant: 1
V(max): 1
fat-free 1
(FFM) 1
(RSEs) 1
<42% 1
RSEs 1
dataset). 1
(RSE 1
<29%). 1
'targeted' 1
ligand-linked 1
ZD6474. 1
radiotherapy) 1
FISH) 1
(MCRC). 1
MCRC 1
EKB 1
MCRC. 1
(monoclonal 1
MCRC, 1
carcinogenetic 1
non-small-lung 1
erlotinib/gefitinib-based 1
KGaA 1
(EGFR)-specific 1
EGFR-bearing 1
biofuel 1
(n=12, 1
10-days 1
mitochondrial-cellular 1
energetics/redox 1
perilipins, 1
GRAF1a, 1
GRAF1 1
(GRAF1 1
ARHGAP26), 1
oleic-acid-fed 1
GRAF1a-specific 1
membrane-binding 1
GRAF1-knockout 1
GRAF1(-/-) 1
GRAF1(+/+) 1
sculpting 1
droplets: 1
oxidizable 1
peroxidized 1
oxygen-containing 1
hydrophobic/hydrophilic 1
(phospho)lipid 1
monolayer-the 1
oxTAGs 1
TAGs 1
(CG-MD) 1
LD, 1
conversions, 1
progenitors' 1
(5-days 1
(R3 1
(Nearest 1
Model). 1
catabolism) 1
Mis-splicing 1
ets-1 1
dying. 1
ebselen. 1
neuroprotectants 1
III-type 1
Nitrone-based 1
lanthionines. 1
phenyl-tert-butylnitrone 1
(PBN) 1
astrocytoma/glioblastoma 1
nitrones, 1
Nitrone 1
nitrone's 1
α-phenyl-tert-butylnitrone, 1
APC(Min/+) 1
2,4-disulfophenyl-tert-butylnitrone, 1
OKN-007. 1
S-nitrosylation 1
OGD. 1
NXY-059. 1
preclinically, 1
"package" 1
within-drug 1
post-SAINT 1
(tPA). 1
microspheres/nanobubbles, 1
neuroserpin 1
CDP-choline) 1
Desmoteplase, 1
Desmodus 1
rotundus 1
vampire 1
tPA-induced 1
related-receptors 1
(LPR) 1
(AIS), 1
neuroprotectant. 1
5028 1
(n=2438) 1
(n=2456): 1
disability=1.02; 1
(P=0.682, 1
(16.7% 1
alteplase-associated 1
dichotomization 1
ECASS-II). 1
ECASS-II, 1
ECASS-II) 1
fringes, 1
wellness 1
cerovive: 1
post-NXY-059 1
interpretively 1
measure--a 1
score--and 1
shortcomings; 1
cogency 1
adhered; 1
agent--its 1
nonlipophilic 1
penetrability, 1
urged, 1
nihilistic 1
chasm 1
contends 1
desmopressin, 1
369.5 1
(125.0 1
seconds) 1
369.1 1
(136.0 1
bedbound, 1
1699 1
(P=0.038 1
nonserious 1
(NIHSS): 1
P=0.86). 1
(P=0.036). 1
NCT00119626.). 1
SNOWDROP 1
agonist/serotonin 1
468) 1
481) 1
(SSEs) 1
(FSFI) 1
(FSDS-R) 1
desire), 1
SSEs 1
(-0.8 1
(-8.3 1
[0.6] 1
-6.3 1
[0.6]), 1
[0.4] 1
[0.4]; 1
(28.0%) 1
bi-level 1
(solicitations, 1
hops 1
darts, 1
investigations), 1
lordosis, 1
copulatory 1
(intromissions 1
ejaculations) 1
(EB 1
P) 1
(EB-alone) 1
hormone-treatment 1
pairmates, 1
Adrenocorticotropic 1
(15mg/kg) 1
marmosets 1
(0.1mg/kg) 1
15-16weeks. 1
counterbalanced, 1
8-OH-DPAT-, 1
de-sensitization 1
anti-sexual 1
anti-social 1
flibanserin's 1
restraint-related 1
affiliative 1
Flibanserin: 1
(HAMD) 1
item. 1
(50mg 1
(20mg 1
(50-100mg 1
(20-40mg 1
77-80%. 1
HAMD 1
"Genital 1
Symptoms" 1
flibanserin- 1
(http://services.hon.ch/cgi-bin/QA10/qa.pl) 1
engines: 1
Scholar.Google), 1
MedQA, 1
Onelook, 1
X?") 1
N-bromoacetyl-iodothyronine 1
labels. 1
N-bromoacetyl-3,3',5-[125I]triiodothyronine 1
(BrAc[125I]T3) 1
(ID-I 1
ID-III). 1
BrAc[125I]T3 1
BrAc[125I]T3-labeled 1
ID-I, 1
(p32) 1
BrAcT3, 1
11.5) 1
BrAc[125I]T3, 1
3,3',5'-triiodothyronine 1
ID-III, 1
BrAc[125I]rT3. 1
BrAc[125I]rT3 1
respectively.(ABSTRACT 1
5'-deiodinases. 1
6-n-propyl-2-thiouracil 1
(PTU-insensitive) 1
noncompetitive. 1
enzyme/substrate 1
uncompetitive, 1
Deiodination 1
MRE11-RAD50-NBS1 1
RAD50 1
Mirin 1
MRE11-processed 1
MRN 1
FANCD2-disrupted 1
nontemplated 1
SCEs. 1
(40.86 1
8.97, 1
(25.85 1
3.57, 1
(35.86 1
5.38, 1
One-compartment 1
2-compartment 1
1-compartment 1
L/kg) 1
(CL, 1
0.078 1
L/h/kg), 1
0.054 1
CL, 1
posthypoxic 1
post-hypoxic 1
(0.175-0.333 1
(0.0275-0.0333 1
systems--each 1
grafting, 1
103/42) 1
serum: 1
64/36; 1
38/20). 1
(97%, 1
(95%, 1
1.98-7.94, 1
Blood-derived 1
serum-based 1
(CCS, 1
motor-incomplete 1
(iSCI, 1
motor-complete 1
(cSCI, 1
(HC, 1
n=67), 1
p=0.006 1
p=0.025 1
p=0.010). 1
(p=0.011) 1
(r=-0.53, 1
(r=-0.69, 1
3-12-month 1
r=-0.43, 1
p=0.026 1
r=-0.72, 1
(NFL-H) 1
(mTBI). 1
NFL-H 1
(pNFL-H) 1
hemorrhaging, 1
Parkland 1
(CT+ 1
CTgroups, 1
(82.5%) 1
1071 1
amyloid-β1-42 1
(NC2) 1
FTD-causing 1
[bvFTD], 1
nonfluent 1
[PNFA], 1
[SD]), 1
(CDRsb). 1
Voxel-based 1
NfL. 1
NC2 1
CDRsb 1
autopsy-verified 1
biomarker-enriched 1
oligodendrocyte, 1
(GFAp). 1
nonsymptomatic 1
(Rey 1
Osterrieth 1
Figure, 1
Word 1
memory), 1
(Trail 1
Making, 1
Time, 1
Tapping) 1
(NFL). 1
subconcussive 1
(neurofilament 1
(NfH)). 1
(CIS) 1
thaws) 1
CIS/MS, 1
ECL-NfH(SMI35) 1
CSF:albumin 1
607), 1
Sahlgrenska 1
0.77-0.90; 1
0.75-0.87; 1
0.77-0.89; 1
0.74-0.80; 1
0.030). 1
0.83-0.93; 1
β1-42 1
pathology) 1
CSF-biomarkers 1
boxing: 1
Sports-related 1
(amateur) 1
532±553 1
135±51 1
(496±238 1
247±147 1
(58±26 1
49±21 1
p<0.025) 1
(0.76±0.29 1
0.60±0.23 1
(402±434 1
(369±113 1
(RRMS, 1
(SPMS, 1
(EDSS). 1
(MSSS), 1
SPMS 1
eurofilament 1
beta-42 1
(Abeta42) 1
neurodegeneration-neurofilament 1
(GFAp)-in 1
Neuropsychiatric, 1
DSM-III-R-based 1
GFAp, 1
73.9+/-3.2 1
(13.1%) 1
laboratory-supported 1
(NfH) 1
(SVD), 1
(306 1
SVD, 1
MCI, 1
1.38. 1
(1.38) 1
(0.74). 1
amyloid-beta(1-42), 1
threonine-181. 1
(NfL, 1
t-NfH 1
P-NfH) 1
NfH. 1
(ILOCA) 1
(MSA-C) 1
(NFHp35) 1
(HVA), 1
5-hydroxyindoleaceticacid 1
NFHp35, 1
NFHp35 1
129.5 1
MHPG, 1
LOCA. 1
(HR=1.59, 1
CI=1.36-1.87, 1
(HR=1.00, 1
CI=0.37-2.69, 1
P=0.993). 1
non-nucleus 1
(HR=1.65, 1
CI=1.40-1.95, 1
(HR=3.06, 1
CI=2.15-4.37, 1
(HR=0.44, 1
CI=0.26-0.75, 1
(OR=1.45, 1
